-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
risk NN O O
is NN O O
discussed NN O O
elsewhere NN O O
in NN O O
the NN O O
labeling NN O O
: NN O O
* NN O O
Hypotension NN B-AdverseReaction B-AdverseReaction
and NN O O
Reflex NN B-AdverseReaction B-AdverseReaction
Tachycardia NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
Most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>2 NN O O
% NN O O
) NN O O
are NN O O
headache NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
and NN O O
vomiting NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
The NN O O
Medicines NN O O
Company NN O O
at NN O O
1 NN O O
- NN O O
888 NN O O
- NN O O
977-MDCO NN O O
( NN O O
6326 NN O O
) NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Cleviprex NN O O
clinical NN O O
development NN O O
included NN O O
19 NN O O
studies NN O O
, NN O O
with NN O O
99 NN O O
healthy NN O O
subjects NN O O
and NN O O
1307 NN O O
hypertensive NN O O
patients NN O O
who NN O O
received NN O O
at NN O O
least NN O O
one NN O O
dose NN O O
of NN O O
clevidipine NN O O
( NN O O
1406 NN O O
total NN O O
exposures NN O O
) NN O O
. NN O O
Clevidipine NN O O
was NN O O
evaluated NN O O
in NN O O
15 NN O O
studies NN O O
in NN O O
hypertensive NN O O
patients NN O O
: NN O O
1099 NN O O
patients NN O O
with NN O O
perioperative NN O O
hypertension NN O O
, NN O O
126 NN O O
with NN O O
severe NN O O
hypertension NN O O
and NN O O
82 NN O O
patients NN O O
with NN O O
essential NN O O
hypertension NN O O
. NN O O
The NN O O
desired NN O O
therapeutic NN O O
response NN O O
was NN O O
achieved NN O O
at NN O O
doses NN O O
of NN O O
4 NN O O
- NN O O
6 NN O O
mg/hour NN O O
. NN O O
Cleviprex NN O O
was NN O O
infused NN O O
for NN O O
< NN O O
24 NN O O
hours NN O O
in NN O O
the NN O O
majority NN O O
of NN O O
patients NN O O
( NN O O
n=1199 NN O O
) NN O O
; NN O O
it NN O O
was NN O O
infused NN O O
as NN O O
a NN O O
continuous NN O O
infusion NN O O
in NN O O
an NN O O
additional NN O O
93 NN O O
patients NN O O
for NN O O
durations NN O O
between NN O O
24 NN O O
and NN O O
72 NN O O
hours NN O O
. NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
Perioperative NN O O
Hypertension NN O O
The NN O O
placebo NN O O
- NN O O
controlled NN O O
experience NN O O
with NN O O
Cleviprex NN O O
in NN O O
the NN O O
perioperative NN O O
setting NN O O
was NN O O
both NN O O
small NN O O
and NN O O
brief NN O O
( NN O O
about NN O O
30 NN O O
minutes NN O O
) NN O O
. NN O O
Table NN O O
2 NN O O
shows NN O O
treatment NN O O
- NN O O
emergent NN O O
adverse NN O O
reactions NN O O
and NN O O
the NN O O
category NN O O
of NN O O
" NN O O
any NN O O
common NN O O
adverse NN O O
event NN O O
" NN O O
in NN O O
ESCAPE-1 NN O O
and NN O O
ESCAPE-2 NN O O
where NN O O
the NN O O
rate NN O O
on NN O O
Cleviprex NN O O
exceeded NN O O
the NN O O
rate NN O O
on NN O O
placebo NN O O
by NN O O
at NN O O
least NN O O
5 NN O O
% NN O O
( NN O O
common NN O O
adverse NN O O
reactions NN O O
) NN O O
. NN O O
Table NN O O
2 NN O O
. NN O O
Common NN O O
adverse NN O O
reactions NN O O
in NN O O
placebo NN O O
- NN O O
controlled NN O O
perioperative NN O O
studies NN O O
. NN O O
ESCAPE-1 NN O O
ESCAPE-2 NN O O
CLVN=53( NN O O
% NN O O
) NN O O
PBON=51( NN O O
% NN O O
) NN O O
CLVN=61( NN O O
% NN O O
) NN O O
PBON=49( NN O O
% NN O O
) NN O O
Any NN O O
common NN O O
adverse NN O O
event NN O O
27 NN O O
( NN O O
51 NN O O
% NN O O
) NN O O
21 NN O O
( NN O O
41 NN O O
% NN O O
) NN O O
32 NN O O
( NN O O
53 NN O O
% NN O O
) NN O O
24 NN O O
( NN O O
49 NN O O
% NN O O
) NN O O
Acute NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
5 NN O O
( NN O O
9 NN O O
% NN O O
) NN O O
1 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
-- NN O O
-- NN O O
Atrial NN B-AdverseReaction B-AdverseReaction
fibrillation NN I-AdverseReaction I-AdverseReaction
-- NN O O
-- NN O O
13 NN O O
( NN O O
21 NN O O
% NN O O
) NN O O
6 NN O O
( NN O O
12 NN O O
% NN O O
) NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
-- NN O O
-- NN O O
13 NN O O
( NN O O
21 NN O O
% NN O O
) NN O O
6 NN O O
( NN O O
12 NN O O
% NN O O
) NN O O
Three NN O O
randomized NN O O
, NN O O
parallel NN O O
, NN O O
open NN O O
- NN O O
label NN O O
studies NN O O
called NN O O
ECLIPSE NN O O
, NN O O
with NN O O
longer NN O O
exposure NN O O
in NN O O
cardiac NN O O
surgery NN O O
patients NN O O
define NN O O
the NN O O
adverse NN O O
reactions NN O O
for NN O O
patients NN O O
with NN O O
perioperative NN O O
hypertension NN O O
. NN O O
Each NN O O
ECLIPSE NN O O
study NN O O
compared NN O O
Cleviprex NN O O
( NN O O
n=752 NN O O
) NN O O
to NN O O
an NN O O
active NN O O
comparator NN O O
: NN O O
nitroglycerin NN O O
( NN O O
NTG NN O O
, NN O O
n=278 NN O O
) NN O O
, NN O O
sodium NN O O
nitroprusside NN O O
( NN O O
SNP NN O O
, NN O O
n=283 NN O O
) NN O O
, NN O O
or NN O O
nicardipine NN O O
( NN O O
NIC NN O O
, NN O O
n=193 NN O O
) NN O O
. NN O O
The NN O O
pooled NN O O
mean NN O O
maximum NN O O
dose NN O O
in NN O O
these NN O O
studies NN O O
was NN O O
10 NN O O
mg/hour NN O O
and NN O O
the NN O O
mean NN O O
duration NN O O
of NN O O
treatment NN O O
was NN O O
8 NN O O
hours NN O O
. NN O O
There NN O O
were NN O O
many NN O O
adverse NN O O
events NN O O
associated NN O O
with NN O O
the NN O O
operative NN O O
procedure NN O O
in NN O O
the NN O O
clinical NN O O
studies NN O O
of NN O O
Cleviprex NN O O
and NN O O
relatively NN O O
few NN O O
plausibly NN O O
related NN O O
to NN O O
the NN O O
drugs NN O O
used NN O O
to NN O O
lower NN O O
blood NN O O
pressure NN O O
. NN O O
Thus NN O O
, NN O O
the NN O O
ability NN O O
to NN O O
differentiate NN O O
the NN O O
adverse NN O O
event NN O O
profile NN O O
between NN O O
treatments NN O O
is NN O O
limited NN O O
. NN O O
The NN O O
adverse NN O O
events NN O O
observed NN O O
within NN O O
one NN O O
hour NN O O
of NN O O
the NN O O
end NN O O
of NN O O
the NN O O
infusion NN O O
were NN O O
similar NN O O
in NN O O
patients NN O O
who NN O O
received NN O O
Cleviprex NN O O
and NN O O
in NN O O
those NN O O
who NN O O
received NN O O
comparator NN O O
agents NN O O
. NN O O
There NN O O
was NN O O
no NN O O
adverse NN O O
reaction NN O O
that NN O O
was NN O O
more NN O O
than NN O O
2 NN O O
% NN O O
more NN O O
common NN O O
on NN O O
Cleviprex NN O O
than NN O O
on NN O O
the NN O O
average NN O O
of NN O O
all NN O O
comparators NN O O
. NN O O
Serious NN O O
Adverse NN O O
Events NN O O
and NN O O
Discontinuation NN O O
- NN O O
Perioperative NN O O
Hypertension NN O O
Studies NN O O
The NN O O
incidence NN O O
of NN O O
adverse NN O O
events NN O O
leading NN O O
to NN O O
study NN O O
drug NN O O
discontinuation NN O O
in NN O O
patients NN O O
with NN O O
perioperative NN O O
hypertension NN O O
receiving NN O O
Cleviprex NN O O
was NN O O
5.9 NN O O
% NN O O
versus NN O O
3.2 NN O O
% NN O O
for NN O O
all NN O O
active NN O O
comparators NN O O
. NN O O
For NN O O
patients NN O O
receiving NN O O
Cleviprex NN O O
and NN O O
all NN O O
active NN O O
comparators NN O O
the NN O O
incidence NN O O
of NN O O
serious NN O O
adverse NN O O
events NN O O
within NN O O
one NN O O
hour NN O O
of NN O O
drug NN O O
infusion NN O O
discontinuation NN O O
was NN O O
similar NN O O
. NN O O
Severe NN O O
Hypertension NN O O
The NN O O
adverse NN O O
events NN O O
for NN O O
patients NN O O
with NN O O
severe NN O O
hypertension NN O O
are NN O O
based NN O O
on NN O O
an NN O O
uncontrolled NN O O
study NN O O
in NN O O
patients NN O O
with NN O O
severe NN O O
hypertension NN O O
( NN O O
VELOCITY NN O O
, NN O O
n=126 NN O O
) NN O O
. NN O O
The NN O O
common NN O O
adverse NN O O
reactions NN O O
for NN O O
Cleviprex NN O O
in NN O O
severe NN O O
hypertension NN O O
included NN O O
headache NN B-AdverseReaction B-AdverseReaction
( NN O O
6.3 NN O O
% NN O O
) NN O O
, NN O O
nausea NN B-AdverseReaction B-AdverseReaction
( NN O O
4.8 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
vomiting NN B-AdverseReaction B-AdverseReaction
( NN O O
3.2 NN O O
% NN O O
) NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
adverse NN O O
events NN O O
leading NN O O
to NN O O
study NN O O
drug NN O O
discontinuation NN O O
for NN O O
Cleviprex NN O O
in NN O O
severe NN O O
hypertension NN O O
was NN O O
4.8 NN O O
% NN O O
. NN O O
Less NN O O
Common NN O O
Adverse NN O O
Reactions NN O O
in NN O O
Patients NN O O
with NN O O
Severe NN O O
or NN O O
Essential NN O O
Hypertension NN O O
Adverse NN O O
reactions NN O O
that NN O O
were NN O O
reported NN O O
in NN O O
< NN O O
1 NN O O
% NN O O
of NN O O
patients NN O O
with NN O O
severe NN O O
or NN O O
essential NN O O
hypertension NN O O
included:Cardiac NN O O
: NN O O
myocardial NN B-AdverseReaction B-AdverseReaction
infarction NN I-AdverseReaction I-AdverseReaction
cardiac NN B-AdverseReaction B-AdverseReaction
arrest NN I-AdverseReaction I-AdverseReaction
system NN O O
: NN O O
syncope NN B-AdverseReaction B-AdverseReaction
dyspnea NN B-AdverseReaction B-AdverseReaction
6.2 NN O O
Post NN O O
- NN O O
Marketing NN O O
and NN O O
Other NN O O
Clinical NN O O
Experience NN O O
Because NN O O
adverse NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
estimate NN O O
reliably NN O O
their NN O O
frequency NN O O
or NN O O
to NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
identified NN O O
during NN O O
post NN O O
- NN O O
approval NN O O
use NN O O
of NN O O
Cleviprex NN O O
: NN O O
increased NN B-AdverseReaction B-AdverseReaction
blood NN I-AdverseReaction I-AdverseReaction
triglycerides NN I-AdverseReaction I-AdverseReaction
ileus NN B-AdverseReaction B-AdverseReaction
hypersensitivity NN B-AdverseReaction B-AdverseReaction
hypotension NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
decreased NN B-AdverseReaction B-AdverseReaction
oxygen NN I-AdverseReaction I-AdverseReaction
saturation NN I-AdverseReaction I-AdverseReaction
( NN O O
possible NN O O
pulmonary NN B-AdverseReaction B-AdverseReaction
shunting NN I-AdverseReaction I-AdverseReaction
and NN O O
reflex NN B-AdverseReaction B-AdverseReaction
tachycardia NN I-AdverseReaction I-AdverseReaction
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Maintain NN O O
aseptic NN O O
technique NN O O
. NN O O
Discard NN O O
unused NN O O
portion NN O O
12 NN O O
hours NN O O
after NN O O
stopper NN O O
puncture NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Hypotension NN B-AdverseReaction B-AdverseReaction
and NN O O
reflex NN B-AdverseReaction B-AdverseReaction
tachycardia NN I-AdverseReaction I-AdverseReaction
are NN O O
potential NN B-Factor B-Factor
consequences NN O O
of NN O O
rapid NN O O
upward NN O O
titration NN O O
of NN O O
Cleviprex NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Dihydropyridine NN B-DrugClass B-DrugClass
calcium NN I-DrugClass I-DrugClass
channel NN I-DrugClass I-DrugClass
blockers NN I-DrugClass I-DrugClass
can NN O O
produce NN O O
negative NN B-AdverseReaction B-AdverseReaction
inotropic NN I-AdverseReaction I-AdverseReaction
effects NN I-AdverseReaction I-AdverseReaction
and NN O O
exacerbate NN B-AdverseReaction B-AdverseReaction
heart NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
heart NN O O
failure NN O O
patients NN O O
carefully NN O O
. NN O O
( NN O O
5.4 NN O O
) NN O O
* NN O O
Cleviprex NN O O
gives NN O O
no NN O O
protection NN O O
against NN O O
the NN O O
effects NN O O
of NN O O
abrupt NN O O
beta NN O O
- NN O O
blocker NN O O
withdrawal NN O O
. NN O O
( NN O O
5.5 NN O O
) NN O O
* NN O O
Patients NN O O
who NN O O
receive NN O O
prolonged NN O O
Cleviprex NN O O
infusions NN O O
and NN O O
are NN O O
not NN O O
transitioned NN O O
to NN O O
other NN O O
antihypertensive NN O O
therapies NN O O
should NN O O
be NN O O
monitored NN O O
for NN O O
the NN O O
possibility NN O O
of NN O O
rebound NN O O
hypertension NN O O
for NN O O
at NN O O
least NN O O
8 NN O O
hours NN O O
after NN O O
the NN O O
infusion NN O O
is NN O O
stopped NN O O
. NN O O
( NN O O
5.6 NN O O
) NN O O
5.1 NN O O
Need NN O O
for NN O O
Aseptic NN O O
Technique NN O O
Use NN O O
aseptic NN O O
technique NN O O
and NN O O
discard NN O O
any NN O O
unused NN O O
product NN O O
within NN O O
12 NN O O
hours NN O O
of NN O O
stopper NN O O
puncture NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
Hypotension NN O O
and NN O O
Reflex NN O O
Tachycardia NN O O
Cleviprex NN O O
may NN B-Factor B-Factor
produce NN O O
systemic NN B-AdverseReaction B-AdverseReaction
hypotension NN I-AdverseReaction I-AdverseReaction
and NN O O
reflex NN B-AdverseReaction B-AdverseReaction
tachycardia NN I-AdverseReaction I-AdverseReaction
If NN O O
either NN O O
occurs NN O O
, NN O O
decrease NN O O
the NN O O
dose NN O O
of NN O O
Cleviprex NN O O
. NN O O
There NN O O
is NN O O
limited NN O O
experience NN O O
with NN O O
short NN O O
- NN O O
duration NN O O
therapy NN O O
with NN O O
beta NN O O
- NN O O
blockers NN O O
as NN O O
a NN O O
treatment NN O O
for NN O O
Cleviprex NN O O
- NN O O
induced NN O O
tachycardia NN O O
. NN O O
Beta NN O O
- NN O O
blocker NN O O
use NN O O
for NN O O
this NN O O
purpose NN O O
is NN O O
not NN O O
recommended NN O O
. NN O O
5.3 NN O O
Lipid NN O O
Intake NN O O
Cleviprex NN O O
contains NN O O
approximately NN O O
0.2 NN O O
g NN O O
of NN O O
lipid NN O O
per NN O O
mL NN O O
( NN O O
2.0 NN O O
kcal NN O O
) NN O O
. NN O O
Lipid NN O O
intake NN O O
restrictions NN O O
may NN O O
be NN O O
necessary NN O O
for NN O O
patients NN O O
with NN O O
significant NN O O
disorders NN O O
of NN O O
lipid NN O O
metabolism NN O O
. NN O O
For NN O O
these NN O O
patients NN O O
, NN O O
a NN O O
reduction NN O O
in NN O O
the NN O O
quantity NN O O
of NN O O
concurrently NN O O
administered NN O O
lipids NN O O
may NN O O
be NN O O
necessary NN O O
to NN O O
compensate NN O O
for NN O O
the NN O O
amount NN O O
of NN O O
lipid NN O O
infused NN O O
as NN O O
part NN O O
of NN O O
the NN O O
Cleviprex NN O O
formulation NN O O
. NN O O
5.4 NN O O
Negative NN O O
Inotropy NN O O
Dihydropyridine NN B-DrugClass B-DrugClass
calcium NN I-DrugClass I-DrugClass
channel NN I-DrugClass I-DrugClass
blockers NN I-DrugClass I-DrugClass
can NN O O
produce NN O O
negative NN B-AdverseReaction B-AdverseReaction
inotropic NN I-AdverseReaction I-AdverseReaction
effects NN I-AdverseReaction I-AdverseReaction
and NN O O
exacerbate NN B-AdverseReaction B-AdverseReaction
heart NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
heart NN O O
failure NN O O
patients NN O O
carefully NN O O
. NN O O
5.5 NN O O
Beta NN O O
- NN O O
Blocker NN O O
Withdrawal NN O O
Cleviprex NN O O
is NN O O
not NN O O
a NN O O
beta NN O O
- NN O O
blocker NN O O
, NN O O
does NN O O
not NN O O
reduce NN O O
heart NN O O
rate NN O O
, NN O O
and NN O O
gives NN O O
no NN O O
protection NN O O
against NN O O
the NN O O
effects NN O O
of NN O O
abrupt NN O O
beta NN O O
- NN O O
blocker NN O O
withdrawal NN O O
. NN O O
Beta NN O O
- NN O O
blockers NN O O
should NN O O
be NN O O
withdrawn NN O O
only NN O O
after NN O O
a NN O O
gradual NN O O
reduction NN O O
in NN O O
dose NN O O
. NN O O
5.6 NN O O
Rebound NN O O
Hypertension NN O O
Patients NN O O
who NN O O
receive NN O O
prolonged NN O O
Cleviprex NN O O
infusions NN O O
and NN O O
are NN O O
not NN O O
transitioned NN O O
to NN O O
other NN O O
antihypertensive NN O O
therapies NN O O
should NN O O
be NN O O
monitored NN O O
for NN O O
the NN O O
possibility NN O O
of NN O O
rebound NN O O
hypertension NN O O
for NN O O
at NN O O
least NN O O
8 NN O O
hours NN O O
after NN O O
the NN O O
infusion NN O O
is NN O O
stopped NN O O
. NN O O
5.7 NN O O
Pheochromocytoma NN O O
There NN O O
is NN O O
no NN O O
information NN O O
to NN O O
guide NN O O
use NN O O
of NN O O
Cleviprex NN O O
in NN O O
treating NN O O
hypertension NN O O
associated NN O O
with NN O O
pheochromocytoma NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
are NN O O
discussed NN O O
in NN O O
more NN O O
detail NN O O
in NN O O
other NN O O
sections NN O O
of NN O O
the NN O O
labeling NN O O
: NN O O
* NN O O
Hemorrhage NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Infections NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
Cytopenias NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
* NN O O
Atrial NN B-AdverseReaction B-AdverseReaction
Fibrillation NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
* NN O O
Second NN B-AdverseReaction B-AdverseReaction
Primary NN I-AdverseReaction I-AdverseReaction
Malignancies NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
* NN O O
Tumor NN B-AdverseReaction B-AdverseReaction
Lysis NN I-AdverseReaction I-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.6 NN O O
) NN O O
] NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
variable NN O O
conditions NN O O
, NN O O
adverse NN O O
event NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
with NN O O
rates NN O O
of NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=25 NN O O
% NN O O
) NN O O
in NN O O
patients NN O O
with NN O O
B NN O O
- NN O O
cell NN O O
malignancies NN O O
( NN O O
MCL NN O O
, NN O O
CLL NN O O
, NN O O
WM NN O O
) NN O O
were NN O O
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
neutropenia NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
anemia NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
musculoskeletal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
bruising NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
and NN O O
rash NN B-AdverseReaction B-AdverseReaction
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Pharmacyclics NN O O
at NN O O
1 NN O O
- NN O O
877 NN O O
- NN O O
877 NN O O
- NN O O
3536 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Mantle NN O O
Cell NN O O
Lymphoma NN O O
The NN O O
data NN O O
described NN O O
below NN O O
reflect NN O O
exposure NN O O
to NN O O
IMBRUVICA NN O O
in NN O O
a NN O O
clinical NN O O
trial NN O O
that NN O O
included NN O O
111 NN O O
patients NN O O
with NN O O
previously NN O O
treated NN O O
MCL NN O O
treated NN O O
with NN O O
560 NN O O
mg NN O O
daily NN O O
with NN O O
a NN O O
median NN O O
treatment NN O O
duration NN O O
of NN O O
8.3 NN O O
months NN O O
. NN O O
The NN O O
most NN O O
commonly NN O O
occurring NN O O
adverse NN O O
reactions NN O O
( NN O O
>= NN O O
20 NN O O
% NN O O
) NN O O
were NN O O
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
neutropenia NN B-AdverseReaction B-AdverseReaction
anemia NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
musculoskeletal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
peripheral NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
bruising NN B-AdverseReaction B-AdverseReaction
dyspnea NN B-AdverseReaction B-AdverseReaction
constipation NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
and NN O O
decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
( NN O O
see NN O O
Tables NN O O
1 NN O O
and NN O O
2 NN O O
) NN O O
. NN O O
The NN O O
most NN O O
common NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
or NN O O
4 NN O O
non NN O O
- NN O O
hematological NN O O
adverse NN O O
reactions NN O O
( NN O O
>= NN O O
5 NN O O
% NN O O
) NN O O
were NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
atrial NN B-AdverseReaction B-AdverseReaction
fibrillation NN I-AdverseReaction I-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
and NN O O
skin NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
Fatal NN B-AdverseReaction B-AdverseReaction
and NN O O
serious NN B-Severity B-Severity
cases NN O O
of NN O O
renal NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
have NN O O
occurred NN O O
with NN O O
IMBRUVICA NN O O
therapy NN O O
. NN O O
Increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
1.5 NN B-Severity B-Severity
to NN I-Severity I-Severity
3 NN I-Severity I-Severity
times NN I-Severity I-Severity
the NN I-Severity I-Severity
upper NN I-Severity I-Severity
limit NN I-Severity I-Severity
of NN I-Severity I-Severity
normal NN I-Severity I-Severity
occurred NN O O
in NN O O
9 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
Adverse NN O O
reactions NN O O
from NN O O
the NN O O
MCL NN O O
trial NN O O
( NN O O
N=111 NN O O
) NN O O
using NN O O
single NN O O
agent NN O O
IMBRUVICA NN O O
560 NN O O
mg NN O O
daily NN O O
occurring NN O O
at NN O O
a NN O O
rate NN O O
of NN O O
>= NN O O
10 NN O O
% NN O O
are NN O O
presented NN O O
in NN O O
Table NN O O
1 NN O O
. NN O O
Table NN O O
1 NN O O
: NN O O
Non NN O O
- NN O O
Hematologic NN O O
Adverse NN O O
Reactions NN O O
in NN O O
>= NN O O
10 NN O O
% NN O O
of NN O O
Patients NN O O
with NN O O
MCL NN O O
( NN O O
N=111 NN O O
) NN O O
System NN O O
Organ NN O O
Class NN O O
Preferred NN O O
Term NN O O
All NN O O
Grades NN O O
( NN O O
% NN O O
) NN O O
Grade NN O O
3 NN O O
or NN O O
4 NN O O
( NN O O
% NN O O
) NN O O
Gastrointestinal NN O O
disorders NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
51 NN O O
5 NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
31 NN O O
0 NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
25 NN O O
0 NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
24 NN O O
5 NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
23 NN O O
0 NN O O
Stomatitis NN B-AdverseReaction B-AdverseReaction
17 NN O O
1 NN O O
Dyspepsia NN B-AdverseReaction B-AdverseReaction
11 NN O O
0 NN O O
Infections NN O O
and NN O O
infestations NN O O
Upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
34 NN O O
0 NN O O
Urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
14 NN O O
3 NN O O
Pneumonia NN B-AdverseReaction B-AdverseReaction
14 NN O O
7 NN O O
Skin NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
14 NN O O
5 NN O O
Sinusitis NN B-AdverseReaction B-AdverseReaction
13 NN O O
1 NN O O
General NN O O
disorders NN O O
and NN O O
administrative NN O O
site NN O O
conditions NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
41 NN O O
5 NN O O
Peripheral NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
35 NN O O
3 NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
18 NN O O
1 NN O O
Asthenia NN B-AdverseReaction B-AdverseReaction
14 NN O O
3 NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
Bruising NN B-AdverseReaction B-AdverseReaction
30 NN O O
0 NN O O
Rash NN B-AdverseReaction B-AdverseReaction
25 NN O O
3 NN O O
Petechiae NN B-AdverseReaction B-AdverseReaction
11 NN O O
0 NN O O
Musculoskeletal NN O O
and NN O O
connective NN O O
tissue NN O O
disorders NN O O
Musculoskeletal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
37 NN O O
1 NN O O
Muscle NN B-AdverseReaction B-AdverseReaction
spasms NN I-AdverseReaction I-AdverseReaction
14 NN O O
0 NN O O
Arthralgia NN B-AdverseReaction B-AdverseReaction
11 NN O O
0 NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
and NN O O
mediastinal NN O O
disorders NN O O
Dyspnea NN B-AdverseReaction B-AdverseReaction
27 NN O O
4 NN O O
Cough NN B-AdverseReaction B-AdverseReaction
19 NN O O
0 NN O O
Epistaxis NN B-AdverseReaction B-AdverseReaction
11 NN O O
0 NN O O
Metabolism NN O O
and NN O O
nutrition NN O O
disorders NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
21 NN O O
2 NN O O
Dehydration NN B-AdverseReaction B-AdverseReaction
12 NN O O
4 NN O O
Nervous NN O O
system NN O O
disorders NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
14 NN O O
0 NN O O
Headache NN B-AdverseReaction B-AdverseReaction
13 NN O O
0 NN O O
Table NN O O
2 NN O O
: NN O O
Treatment NN O O
- NN O O
EmergentBased NN O O
on NN O O
laboratory NN O O
measurements NN O O
and NN O O
adverse NN O O
reactions NN O O
Decrease NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
Hemoglobin NN I-AdverseReaction I-AdverseReaction
Platelets NN O O
, NN O O
or NN O O
Neutrophils NN O O
in NN O O
Patients NN O O
with NN O O
MCL NN O O
( NN O O
N=111 NN O O
) NN O O
Percent NN O O
of NN O O
Patients NN O O
( NN O O
N=111 NN O O
) NN O O
All NN O O
Grades NN O O
( NN O O
% NN O O
) NN O O
Grade NN O O
3 NN O O
or NN O O
4 NN O O
( NN O O
% NN O O
) NN O O
Platelets NN B-AdverseReaction B-AdverseReaction
Decreased NN I-AdverseReaction I-AdverseReaction
57 NN O O
17 NN O O
Neutrophils NN B-AdverseReaction B-AdverseReaction
Decreased NN I-AdverseReaction I-AdverseReaction
47 NN O O
29 NN O O
Hemoglobin NN B-AdverseReaction B-AdverseReaction
Decreased NN I-AdverseReaction I-AdverseReaction
41 NN O O
9 NN O O
Ten NN O O
patients NN O O
( NN O O
9 NN O O
% NN O O
) NN O O
discontinued NN O O
treatment NN O O
due NN O O
to NN O O
adverse NN O O
reactions NN O O
in NN O O
the NN O O
trial NN O O
( NN O O
N=111 NN O O
) NN O O
. NN O O
The NN O O
most NN O O
frequent NN O O
adverse NN O O
reaction NN O O
leading NN O O
to NN O O
treatment NN O O
discontinuation NN O O
was NN O O
subdural NN B-AdverseReaction B-AdverseReaction
hematoma NN I-AdverseReaction I-AdverseReaction
( NN O O
1.8 NN O O
% NN O O
) NN O O
. NN O O
Adverse NN O O
reactions NN O O
leading NN O O
to NN O O
dose NN O O
reduction NN O O
occurred NN O O
in NN O O
14 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
Patients NN O O
with NN O O
MCL NN O O
who NN O O
develop NN O O
lymphocytosis NN O O
greater NN O O
than NN O O
400,000/mcL NN O O
have NN O O
developed NN O O
intracranial NN O O
hemorrhage NN O O
, NN O O
lethargy NN O O
, NN O O
gait NN O O
instability NN O O
, NN O O
and NN O O
headache NN O O
. NN O O
However NN O O
, NN O O
some NN O O
of NN O O
these NN O O
cases NN O O
were NN O O
in NN O O
the NN O O
setting NN O O
of NN O O
disease NN O O
progression NN O O
. NN O O
Forty NN O O
percent NN O O
of NN O O
patients NN O O
had NN O O
elevated NN B-AdverseReaction B-AdverseReaction
uric NN I-AdverseReaction I-AdverseReaction
acid NN I-AdverseReaction I-AdverseReaction
levels NN I-AdverseReaction I-AdverseReaction
on NN O O
study NN O O
including NN O O
13 NN O O
% NN O O
with NN O O
values NN O O
above NN B-Severity B-Severity
10 NN I-Severity I-Severity
mg/dL NN I-Severity I-Severity
Adverse NN O O
reaction NN O O
of NN O O
hyperuricemia NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
for NN O O
15 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
Chronic NN O O
Lymphocytic NN O O
Leukemia NN O O
The NN O O
data NN O O
described NN O O
below NN O O
reflect NN O O
exposure NN O O
to NN O O
IMBRUVICA NN O O
in NN O O
an NN O O
open NN O O
label NN O O
clinical NN O O
trial NN O O
( NN O O
Study NN O O
1 NN O O
) NN O O
that NN O O
included NN O O
48 NN O O
patients NN O O
with NN O O
previously NN O O
treated NN O O
CLL NN O O
and NN O O
a NN O O
randomized NN O O
clinical NN O O
trial NN O O
( NN O O
Study NN O O
2 NN O O
) NN O O
that NN O O
included NN O O
391 NN O O
randomized NN O O
patients NN O O
with NN O O
previously NN O O
treated NN O O
CLL NN O O
or NN O O
SLL. NN O O
The NN O O
most NN O O
commonly NN O O
occurring NN O O
adverse NN O O
reactions NN O O
in NN O O
Study NN O O
1 NN O O
and NN O O
Study NN O O
2 NN O O
( NN O O
>= NN O O
20 NN O O
% NN O O
) NN O O
were NN O O
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
neutropenia NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
anemia NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
musculoskeletal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
and NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
Approximately NN O O
five NN O O
percent NN O O
of NN O O
patients NN O O
receiving NN O O
IMBRUVICA NN O O
in NN O O
Study NN O O
1 NN O O
and NN O O
Study NN O O
2 NN O O
discontinued NN O O
treatment NN O O
due NN O O
to NN O O
adverse NN O O
events NN O O
. NN O O
These NN O O
included NN O O
infections NN B-AdverseReaction B-AdverseReaction
subdural NN B-AdverseReaction B-AdverseReaction
hematomas NN I-AdverseReaction I-AdverseReaction
and NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
Adverse NN O O
events NN O O
leading NN O O
to NN O O
dose NN O O
reduction NN O O
occurred NN O O
in NN O O
approximately NN O O
6 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
Study NN O O
1 NN O O
Adverse NN O O
reactions NN O O
and NN O O
laboratory NN O O
abnormalities NN O O
from NN O O
the NN O O
CLL NN O O
trial NN O O
( NN O O
N=48 NN O O
) NN O O
using NN O O
single NN O O
agent NN O O
IMBRUVICA NN O O
420 NN O O
mg NN O O
daily NN O O
occurring NN O O
at NN O O
a NN O O
rate NN O O
of NN O O
>= NN O O
10 NN O O
% NN O O
are NN O O
presented NN O O
in NN O O
Tables NN O O
3 NN O O
and NN O O
4 NN O O
. NN O O
Table NN O O
3 NN O O
: NN O O
Non NN O O
- NN O O
Hematologic NN O O
Adverse NN O O
Reactions NN O O
in NN O O
>= NN O O
10 NN O O
% NN O O
of NN O O
Patients NN O O
with NN O O
CLL NN O O
( NN O O
N=48 NN O O
) NN O O
in NN O O
Study NN O O
1 NN O O
System NN O O
Organ NN O O
Class NN O O
Preferred NN O O
Term NN O O
All NN O O
Grades NN O O
( NN O O
% NN O O
) NN O O
Grade NN O O
3 NN O O
or NN O O
4 NN O O
( NN O O
% NN O O
) NN O O
Gastrointestinal NN O O
disorders NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
63 NN O O
4 NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
23 NN O O
2 NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
21 NN O O
2 NN O O
Stomatitis NN B-AdverseReaction B-AdverseReaction
21 NN O O
0 NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
19 NN O O
2 NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
15 NN O O
0 NN O O
Dyspepsia NN B-AdverseReaction B-AdverseReaction
13 NN O O
0 NN O O
Infections NN O O
and NN O O
infestations NN O O
Upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
48 NN O O
2 NN O O
Sinusitis NN B-AdverseReaction B-AdverseReaction
21 NN O O
6 NN O O
Skin NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
17 NN O O
6 NN O O
Pneumonia NN B-AdverseReaction B-AdverseReaction
10 NN O O
8 NN O O
Urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
10 NN O O
0 NN O O
General NN O O
disorders NN O O
and NN O O
administrative NN O O
site NN O O
conditions NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
31 NN O O
4 NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
25 NN O O
2 NN O O
Peripheral NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
23 NN O O
0 NN O O
Asthenia NN B-AdverseReaction B-AdverseReaction
13 NN O O
4 NN O O
Chills NN B-AdverseReaction B-AdverseReaction
13 NN O O
0 NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
Bruising NN B-AdverseReaction B-AdverseReaction
54 NN O O
2 NN O O
Rash NN B-AdverseReaction B-AdverseReaction
27 NN O O
0 NN O O
Petechiae NN B-AdverseReaction B-AdverseReaction
17 NN O O
0 NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
and NN O O
mediastinal NN O O
disorders NN O O
Cough NN B-AdverseReaction B-AdverseReaction
19 NN O O
0 NN O O
Oropharyngeal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
15 NN O O
0 NN O O
Dyspnea NN B-AdverseReaction B-AdverseReaction
10 NN O O
0 NN O O
Musculoskeletal NN O O
and NN O O
connective NN O O
tissue NN O O
disorders NN O O
Musculoskeletal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
27 NN O O
6 NN O O
Arthralgia NN B-AdverseReaction B-AdverseReaction
23 NN O O
0 NN O O
Muscle NN B-AdverseReaction B-AdverseReaction
spasms NN I-AdverseReaction I-AdverseReaction
19 NN O O
2 NN O O
Nervous NN O O
system NN O O
disorders NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
21 NN O O
0 NN O O
Headache NN B-AdverseReaction B-AdverseReaction
19 NN O O
2 NN O O
Peripheral NN B-AdverseReaction B-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
10 NN O O
0 NN O O
Metabolism NN O O
and NN O O
nutrition NN O O
disorders NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
17 NN O O
2 NN O O
Neoplasms NN O O
benign NN O O
, NN O O
malignant NN O O
, NN O O
unspecified NN O O
Second NN B-AdverseReaction B-AdverseReaction
malignancies NN I-AdverseReaction I-AdverseReaction
10 NN O O
0 NN O O
Injury NN O O
, NN O O
poisoning NN O O
and NN O O
procedural NN O O
complications NN O O
Laceration NN B-AdverseReaction B-AdverseReaction
10 NN O O
2 NN O O
Psychiatric NN O O
disorders NN O O
Anxiety NN B-AdverseReaction B-AdverseReaction
10 NN O O
0 NN O O
Insomnia NN B-AdverseReaction B-AdverseReaction
10 NN O O
0 NN O O
Vascular NN O O
disorders NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
17 NN O O
8 NN O O
Table NN O O
4 NN O O
: NN O O
Treatment NN O O
- NN O O
EmergentBased NN O O
on NN O O
laboratory NN O O
measurements NN O O
per NN O O
IWCLL NN O O
criteria NN O O
and NN O O
adverse NN O O
reactions NN O O
Decrease NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
Hemoglobin NN I-AdverseReaction I-AdverseReaction
Platelets NN O O
, NN O O
or NN O O
Neutrophils NN O O
in NN O O
Patients NN O O
with NN O O
CLL NN O O
( NN O O
N=48 NN O O
) NN O O
in NN O O
Study NN O O
1 NN O O
Percent NN O O
of NN O O
Patients NN O O
( NN O O
N=48 NN O O
) NN O O
All NN O O
Grades NN O O
( NN O O
% NN O O
) NN O O
Grade NN O O
3 NN O O
or NN O O
4 NN O O
( NN O O
% NN O O
) NN O O
Platelets NN B-AdverseReaction B-AdverseReaction
Decreased NN I-AdverseReaction I-AdverseReaction
71 NN O O
10 NN O O
Neutrophils NN B-AdverseReaction B-AdverseReaction
Decreased NN I-AdverseReaction I-AdverseReaction
54 NN O O
27 NN O O
Hemoglobin NN B-AdverseReaction B-AdverseReaction
Decreased NN I-AdverseReaction I-AdverseReaction
44 NN O O
0 NN O O
Study NN O O
2 NN O O
Adverse NN O O
reactions NN O O
and NN O O
laboratory NN O O
abnormalities NN O O
described NN O O
below NN O O
in NN O O
Tables NN O O
5 NN O O
and NN O O
6 NN O O
reflect NN O O
exposure NN O O
to NN O O
IMBRUVICA NN O O
with NN O O
a NN O O
median NN O O
duration NN O O
of NN O O
8.6 NN O O
months NN O O
and NN O O
exposure NN O O
to NN O O
ofatumumab NN O O
with NN O O
a NN O O
median NN O O
of NN O O
5.3 NN O O
months NN O O
in NN O O
Study NN O O
2 NN O O
. NN O O
Table NN O O
5 NN O O
: NN O O
Non NN O O
- NN O O
Hematologic NN O O
Adverse NN O O
Reactions NN O O
>= NN O O
10 NN O O
% NN O O
Reported NN O O
in NN O O
Study NN O O
2 NN O O
IMBRUVICA(N=195 NN O O
) NN O O
Ofatumumab(N=191 NN O O
) NN O O
System NN O O
Organ NN O O
Class NN O O
ADR NN O O
Term NN O O
All NN O O
Grades NN O O
( NN O O
% NN O O
) NN O O
Grade NN O O
3 NN O O
or NN O O
4 NN O O
( NN O O
% NN O O
) NN O O
All NN O O
Grades NN O O
( NN O O
% NN O O
) NN O O
Grade NN O O
3 NN O O
or NN O O
4 NN O O
( NN O O
% NN O O
) NN O O
Subjects NN O O
with NN O O
multiple NN O O
events NN O O
for NN O O
a NN O O
given NN O O
ADR NN O O
term NN O O
are NN O O
counted NN O O
once NN O O
only NN O O
for NN O O
each NN O O
ADR NN O O
term NN O O
. NN O O
The NN O O
system NN O O
organ NN O O
class NN O O
and NN O O
individual NN O O
ADR NN O O
terms NN O O
are NN O O
sorted NN O O
in NN O O
descending NN O O
frequency NN O O
order NN O O
in NN O O
the NN O O
IMBRUVICA NN O O
arm NN O O
. NN O O
Gastrointestinal NN O O
disorders NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
48 NN O O
4 NN O O
18 NN O O
2 NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
26 NN O O
2 NN O O
18 NN O O
0 NN O O
Stomatitis NN B-AdverseReaction B-AdverseReaction
17 NN O O
1 NN O O
6 NN O O
1 NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
15 NN O O
0 NN O O
9 NN O O
0 NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
14 NN O O
0 NN O O
6 NN O O
1 NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
28 NN O O
2 NN O O
30 NN O O
2 NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
24 NN O O
2 NN O O
15 NN O O
1 NN O O
Infections NN O O
and NN O O
infestations NN O O
Upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
16 NN O O
1 NN O O
11 NN O O
2 NN O O
Pneumonia NN B-AdverseReaction B-AdverseReaction
15 NN O O
10 NN O O
13 NN O O
9 NN O O
Sinusitis NN B-AdverseReaction B-AdverseReaction
11 NN O O
1 NN O O
6 NN O O
0 NN O O
Urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
10 NN O O
4 NN O O
5 NN O O
1 NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
Rash NN B-AdverseReaction B-AdverseReaction
24 NN O O
3 NN O O
13 NN O O
0 NN O O
Petechiae NN B-AdverseReaction B-AdverseReaction
14 NN O O
0 NN O O
1 NN O O
0 NN O O
Bruising NN B-AdverseReaction B-AdverseReaction
12 NN O O
0 NN O O
1 NN O O
0 NN O O
Musculoskeletal NN O O
and NN O O
connective NN O O
tissue NN O O
disorders NN O O
Musculoskeletal NN B-AdverseReaction B-AdverseReaction
Pain NN I-AdverseReaction I-AdverseReaction
28 NN O O
2 NN O O
18 NN O O
1 NN O O
Arthralgia NN B-AdverseReaction B-AdverseReaction
17 NN O O
1 NN O O
7 NN O O
0 NN O O
Nervous NN O O
system NN O O
disorders NN O O
Headache NN B-AdverseReaction B-AdverseReaction
14 NN O O
1 NN O O
6 NN O O
0 NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
11 NN O O
0 NN O O
5 NN O O
0 NN O O
Injury NN O O
, NN O O
poisoning NN O O
and NN O O
procedural NN O O
complications NN O O
Contusion NN B-AdverseReaction B-AdverseReaction
11 NN O O
0 NN O O
3 NN O O
0 NN O O
Eye NN O O
disorders NN O O
Vision NN B-AdverseReaction B-AdverseReaction
blurred NN I-AdverseReaction I-AdverseReaction
10 NN O O
0 NN O O
3 NN O O
0 NN O O
Table NN O O
6 NN O O
: NN O O
Treatment NN O O
- NN O O
EmergentBased NN O O
on NN O O
laboratory NN O O
measurements NN O O
per NN O O
IWCLL NN O O
criteria NN O O
Decrease NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
Hemoglobin NN I-AdverseReaction I-AdverseReaction
Platelets NN O O
, NN O O
or NN O O
Neutrophils NN O O
in NN O O
Study NN O O
2 NN O O
IMBRUVICA(N=195 NN O O
) NN O O
Ofatumumab(N=191 NN O O
) NN O O
All NN O O
Grades NN O O
( NN O O
% NN O O
) NN O O
Grade NN O O
3 NN O O
or NN O O
4 NN O O
( NN O O
% NN O O
) NN O O
All NN O O
Grades NN O O
( NN O O
% NN O O
) NN O O
Grade NN O O
3 NN O O
or NN O O
4 NN O O
( NN O O
% NN O O
) NN O O
Neutrophils NN B-AdverseReaction B-AdverseReaction
Decreased NN I-AdverseReaction I-AdverseReaction
51 NN O O
23 NN O O
57 NN O O
26 NN O O
Platelets NN B-AdverseReaction B-AdverseReaction
Decreased NN I-AdverseReaction I-AdverseReaction
52 NN O O
5 NN O O
45 NN O O
10 NN O O
Hemoglobin NN B-AdverseReaction B-AdverseReaction
Decreased NN I-AdverseReaction I-AdverseReaction
36 NN O O
0 NN O O
21 NN O O
0 NN O O
Waldenstrom NN O O
's NN O O
Macroglobulinemia NN O O
The NN O O
data NN O O
described NN O O
below NN O O
reflect NN O O
exposure NN O O
to NN O O
IMBRUVICA NN O O
in NN O O
an NN O O
open NN O O
label NN O O
clinical NN O O
trial NN O O
that NN O O
included NN O O
63 NN O O
patients NN O O
with NN O O
previously NN O O
treated NN O O
WM. NN O O
The NN O O
most NN O O
commonly NN O O
occurring NN O O
adverse NN O O
reactions NN O O
in NN O O
the NN O O
WM NN O O
trial NN O O
( NN O O
>= NN O O
20 NN O O
% NN O O
) NN O O
were NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
muscle NN B-AdverseReaction B-AdverseReaction
spasms NN I-AdverseReaction I-AdverseReaction
and NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
Six NN O O
percent NN O O
of NN O O
patients NN O O
receiving NN O O
IMBRUVICA NN O O
in NN O O
the NN O O
WM NN O O
trial NN O O
discontinued NN O O
treatment NN O O
due NN O O
to NN O O
adverse NN O O
events NN O O
. NN O O
Adverse NN O O
events NN O O
leading NN O O
to NN O O
dose NN O O
reduction NN O O
occurred NN O O
in NN O O
11 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
Adverse NN O O
reactions NN O O
and NN O O
laboratory NN O O
abnormalities NN O O
described NN O O
below NN O O
in NN O O
Tables NN O O
7 NN O O
and NN O O
8 NN O O
reflect NN O O
exposure NN O O
to NN O O
IMBRUVICA NN O O
with NN O O
a NN O O
median NN O O
duration NN O O
of NN O O
11.7 NN O O
months NN O O
in NN O O
the NN O O
WM NN O O
trial NN O O
. NN O O
Table NN O O
7 NN O O
: NN O O
Non NN O O
- NN O O
Hematologic NN O O
Adverse NN O O
Reactions NN O O
in NN O O
>= NN O O
10 NN O O
% NN O O
of NN O O
Patients NN O O
with NN O O
Waldenstrom NN O O
's NN O O
Macroglobulinemia NN O O
( NN O O
N=63 NN O O
) NN O O
System NN O O
Organ NN O O
Class NN O O
Preferred NN O O
Term NN O O
All NN O O
Grades NN O O
( NN O O
% NN O O
) NN O O
Grade NN O O
3 NN O O
or NN O O
4 NN O O
( NN O O
% NN O O
) NN O O
The NN O O
system NN O O
organ NN O O
class NN O O
and NN O O
individual NN O O
ADR NN O O
terms NN O O
are NN O O
sorted NN O O
in NN O O
descending NN O O
frequency NN O O
order NN O O
. NN O O
Gastrointestinal NN O O
disorders NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
37 NN O O
0 NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
21 NN O O
0 NN O O
Stomatitis NN B-AdverseReaction B-AdverseReaction
16 NN O O
0 NN O O
Gastroesophageal NN B-AdverseReaction B-AdverseReaction
reflux NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
13 NN O O
0 NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
Rash NN B-AdverseReaction B-AdverseReaction
22 NN O O
0 NN O O
Bruising NN B-AdverseReaction B-AdverseReaction
16 NN O O
0 NN O O
Pruritus NN B-AdverseReaction B-AdverseReaction
11 NN O O
0 NN O O
General NN O O
disorders NN O O
and NN O O
administrative NN O O
site NN O O
conditions NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
21 NN O O
0 NN O O
Musculoskeletal NN O O
and NN O O
connective NN O O
tissue NN O O
disorders NN O O
Muscle NN B-AdverseReaction B-AdverseReaction
spasms NN I-AdverseReaction I-AdverseReaction
21 NN O O
0 NN O O
Arthropathy NN B-AdverseReaction B-AdverseReaction
13 NN O O
0 NN O O
Infections NN O O
and NN O O
infestations NN O O
Upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
19 NN O O
0 NN O O
Sinusitis NN B-AdverseReaction B-AdverseReaction
19 NN O O
0 NN O O
Pneumonia NN B-AdverseReaction B-AdverseReaction
14 NN O O
6 NN O O
Skin NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
14 NN O O
2 NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
and NN O O
mediastinal NN O O
disorders NN O O
Epistaxis NN B-AdverseReaction B-AdverseReaction
19 NN O O
0 NN O O
Cough NN B-AdverseReaction B-AdverseReaction
13 NN O O
0 NN O O
Nervous NN O O
system NN O O
disorders NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
14 NN O O
0 NN O O
Headache NN B-AdverseReaction B-AdverseReaction
13 NN O O
0 NN O O
Neoplasms NN O O
benign NN O O
, NN O O
malignant NN O O
, NN O O
and NN O O
unspecified NN O O
( NN O O
including NN O O
cysts NN O O
and NN O O
polyps NN O O
) NN O O
Skin NN B-AdverseReaction B-AdverseReaction
cancer NN I-AdverseReaction I-AdverseReaction
11 NN O O
0 NN O O
Table NN O O
8 NN O O
: NN O O
Treatment NN O O
- NN O O
EmergentBased NN O O
on NN O O
laboratory NN O O
measurements NN O O
. NN O O
Decrease NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
Hemoglobin NN I-AdverseReaction I-AdverseReaction
Platelets NN O O
, NN O O
or NN O O
Neutrophils NN O O
in NN O O
Patients NN O O
with NN O O
WM NN O O
( NN O O
N=63 NN O O
) NN O O
Percent NN O O
of NN O O
Patients NN O O
( NN O O
N=63 NN O O
) NN O O
All NN O O
Grades NN O O
( NN O O
% NN O O
) NN O O
Grade NN O O
3 NN O O
or NN O O
4 NN O O
( NN O O
% NN O O
) NN O O
Platelets NN B-AdverseReaction B-AdverseReaction
Decreased NN I-AdverseReaction I-AdverseReaction
43 NN O O
13 NN O O
Neutrophils NN B-AdverseReaction B-AdverseReaction
Decreased NN I-AdverseReaction I-AdverseReaction
44 NN O O
19 NN O O
Hemoglobin NN B-AdverseReaction B-AdverseReaction
Decreased NN I-AdverseReaction I-AdverseReaction
13 NN O O
8 NN O O
6 NN O O
. NN O O
2 NN O O
Postmarketing NN O O
Experience NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
identified NN O O
during NN O O
post NN O O
- NN O O
approval NN O O
use NN O O
of NN O O
IMBRUVICA. NN O O
Because NN O O
these NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
anaphylactic NN B-AdverseReaction B-AdverseReaction
shock NN I-AdverseReaction I-AdverseReaction
( NN O O
fatal NN O O
) NN O O
, NN O O
urticaria NN B-AdverseReaction B-AdverseReaction
and NN O O
angioedema NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Hemorrhage NN B-AdverseReaction B-AdverseReaction
Monitor NN O O
for NN O O
bleeding NN O O
( NN O O
5.1 NN O O
) NN O O
. NN O O
* NN O O
Infections NN B-AdverseReaction B-AdverseReaction
Monitor NN O O
patients NN O O
for NN O O
fever NN O O
and NN O O
infections NN O O
and NN O O
evaluate NN O O
promptly NN O O
( NN O O
5.2 NN O O
) NN O O
. NN O O
* NN O O
Cytopenias NN B-AdverseReaction B-AdverseReaction
Check NN O O
complete NN O O
blood NN O O
counts NN O O
monthly NN O O
( NN O O
5.3 NN O O
) NN O O
. NN O O
* NN O O
Atrial NN B-AdverseReaction B-AdverseReaction
Fibrillation NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
patients NN O O
for NN O O
atrial NN O O
fibrillation NN O O
( NN O O
5.4 NN O O
) NN O O
. NN O O
* NN O O
Second NN B-AdverseReaction B-AdverseReaction
Primary NN I-AdverseReaction I-AdverseReaction
Malignancies NN I-AdverseReaction I-AdverseReaction
Other NN O O
malignancies NN B-AdverseReaction B-AdverseReaction
have NN O O
occurred NN O O
in NN O O
patients NN O O
, NN O O
including NN O O
skin NN B-AdverseReaction B-AdverseReaction
cancers NN I-AdverseReaction I-AdverseReaction
and NN O O
other NN O O
carcinomas NN B-AdverseReaction B-AdverseReaction
( NN O O
5.5 NN O O
) NN O O
. NN O O
* NN O O
Tumor NN B-AdverseReaction B-AdverseReaction
Lysis NN I-AdverseReaction I-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
TLS NN O O
) NN O O
: NN O O
Monitor NN O O
patients NN O O
at NN O O
risk NN O O
for NN O O
TLS NN O O
( NN O O
e.g. NN O O
high NN O O
tumor NN O O
burden NN O O
) NN O O
( NN O O
5.6 NN O O
) NN O O
. NN O O
* NN O O
Embryo NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Fetal NN I-AdverseReaction I-AdverseReaction
Toxicity NN I-AdverseReaction I-AdverseReaction
Can NN B-Factor B-Factor
cause NN O O
fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
Advise NN O O
women NN O O
of NN O O
the NN O O
potential NN O O
risk NN O O
to NN O O
a NN O O
fetus NN O O
and NN O O
to NN O O
avoid NN O O
pregnancy NN O O
while NN O O
taking NN O O
the NN O O
drug NN O O
( NN O O
5.7 NN O O
) NN O O
. NN O O
5.1 NN O O
Hemorrhage NN O O
Fatal NN B-AdverseReaction B-AdverseReaction
bleeding NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
have NN O O
occurred NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
IMBRUVICA. NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
or NN O O
higher NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
( NN O O
subdural NN O O
hematoma NN O O
, NN O O
gastrointestinal NN B-AdverseReaction B-AdverseReaction
bleeding NN I-AdverseReaction I-AdverseReaction
hematuria NN B-AdverseReaction B-AdverseReaction
and NN O O
post NN B-AdverseReaction B-AdverseReaction
procedural NN I-AdverseReaction I-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
have NN O O
occurred NN O O
in NN O O
up NN O O
to NN O O
6 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
Bleeding NN B-AdverseReaction B-AdverseReaction
events NN O O
of NN O O
any NN O O
grade NN O O
, NN O O
including NN O O
bruising NN B-AdverseReaction B-AdverseReaction
and NN O O
petechiae NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
approximately NN O O
half NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
IMBRUVICA. NN O O
The NN O O
mechanism NN O O
for NN O O
the NN O O
bleeding NN O O
events NN O O
is NN O O
not NN O O
well NN O O
understood NN O O
. NN O O
IMBRUVICA NN O O
may NN B-Factor B-Factor
increase NN O O
the NN O O
risk NN O O
of NN O O
hemorrhage NN B-AdverseReaction B-AdverseReaction
in NN O O
patients NN O O
receiving NN O O
antiplatelet NN O O
or NN O O
anticoagulant NN O O
therapies NN O O
. NN O O
Consider NN O O
the NN O O
benefit NN O O
- NN O O
risk NN O O
of NN O O
withholding NN O O
IMBRUVICA NN O O
for NN O O
at NN O O
least NN O O
3 NN O O
to NN O O
7 NN O O
days NN O O
pre NN O O
and NN O O
post NN O O
- NN O O
surgery NN O O
depending NN O O
upon NN O O
the NN O O
type NN O O
of NN O O
surgery NN O O
and NN O O
the NN O O
risk NN O O
of NN O O
bleeding NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
Infections NN O O
Fatal NN B-AdverseReaction B-AdverseReaction
and NN O O
non NN B-Severity B-Severity
- NN I-Severity I-Severity
fatal NN I-Severity I-Severity
infections NN B-AdverseReaction B-AdverseReaction
have NN O O
occurred NN O O
with NN O O
IMBRUVICA NN O O
therapy NN O O
. NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
or NN O O
greater NN O O
infections NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
14 NN O O
% NN O O
to NN O O
26 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
[ NN O O
See NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Cases NN O O
of NN O O
progressive NN B-AdverseReaction B-AdverseReaction
multifocal NN I-AdverseReaction I-AdverseReaction
leukoencephalopathy NN I-AdverseReaction I-AdverseReaction
( NN O O
PML NN O O
) NN O O
have NN O O
occurred NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
IMBRUVICA. NN O O
Monitor NN O O
patients NN O O
for NN O O
fever NN O O
and NN O O
infections NN O O
and NN O O
evaluate NN O O
promptly NN O O
. NN O O
5.3 NN O O
Cytopenias NN O O
Treatment NN O O
- NN O O
emergent NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
or NN O O
4 NN O O
cytopenias NN B-AdverseReaction B-AdverseReaction
including NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
( NN O O
range NN O O
, NN O O
19 NN O O
to NN O O
29 NN O O
% NN O O
) NN O O
, NN O O
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
( NN O O
range NN O O
, NN O O
5 NN O O
to NN O O
17 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
anemia NN B-AdverseReaction B-AdverseReaction
( NN O O
range NN O O
, NN O O
0 NN O O
to NN O O
9 NN O O
% NN O O
) NN O O
occurred NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
IMBRUVICA. NN O O
Monitor NN O O
complete NN O O
blood NN O O
counts NN O O
monthly NN O O
. NN O O
5.4 NN O O
Atrial NN O O
Fibrillation NN O O
Atrial NN B-AdverseReaction B-AdverseReaction
fibrillation NN I-AdverseReaction I-AdverseReaction
and NN O O
atrial NN B-AdverseReaction B-AdverseReaction
flutter NN I-AdverseReaction I-AdverseReaction
( NN O O
range NN O O
, NN O O
6 NN O O
to NN O O
9 NN O O
% NN O O
) NN O O
have NN O O
occurred NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
IMBRUVICA NN O O
, NN O O
particularly NN O O
in NN O O
patients NN O O
with NN O O
cardiac NN O O
risk NN O O
factors NN O O
, NN O O
acute NN O O
infections NN O O
, NN O O
and NN O O
a NN O O
previous NN O O
history NN O O
of NN O O
atrial NN O O
fibrillation NN O O
. NN O O
Periodically NN O O
monitor NN O O
patients NN O O
clinically NN O O
for NN O O
atrial NN O O
fibrillation NN O O
. NN O O
Patients NN O O
who NN O O
develop NN O O
arrhythmic NN O O
symptoms NN O O
( NN O O
e.g. NN O O
, NN O O
palpitations NN O O
, NN O O
lightheadedness NN O O
) NN O O
or NN O O
new NN O O
onset NN O O
dyspnea NN O O
should NN O O
have NN O O
an NN O O
ECG NN O O
performed NN O O
. NN O O
If NN O O
atrial NN O O
fibrillation NN O O
persists NN O O
, NN O O
consider NN O O
the NN O O
risks NN O O
and NN O O
benefits NN O O
of NN O O
IMBRUVICA NN O O
treatment NN O O
and NN O O
dose NN O O
modification NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
] NN O O
. NN O O
5.5 NN O O
Second NN O O
Primary NN O O
Malignancies NN O O
Other NN O O
malignancies NN B-AdverseReaction B-AdverseReaction
( NN O O
range NN O O
, NN O O
5 NN O O
to NN O O
14 NN O O
% NN O O
) NN O O
including NN O O
non NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
skin NN I-AdverseReaction I-AdverseReaction
carcinomas NN I-AdverseReaction I-AdverseReaction
( NN O O
range NN O O
, NN O O
1 NN O O
to NN O O
3 NN O O
% NN O O
) NN O O
have NN O O
occurred NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
IMBRUVICA. NN O O
The NN O O
most NN O O
frequent NN O O
second NN B-AdverseReaction B-AdverseReaction
primary NN I-AdverseReaction I-AdverseReaction
malignancy NN I-AdverseReaction I-AdverseReaction
was NN O O
non NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
melanoma NN I-AdverseReaction I-AdverseReaction
skin NN I-AdverseReaction I-AdverseReaction
cancer NN I-AdverseReaction I-AdverseReaction
( NN O O
range NN O O
, NN O O
4 NN O O
to NN O O
11 NN O O
% NN O O
) NN O O
. NN O O
5.6 NN O O
Tumor NN O O
Lysis NN O O
Syndrome NN O O
Tumor NN B-AdverseReaction B-AdverseReaction
lysis NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
has NN O O
been NN O O
reported NN O O
with NN O O
IMBRUVICA NN O O
therapy NN O O
. NN O O
Monitor NN O O
patients NN O O
closely NN O O
and NN O O
take NN O O
appropriate NN O O
precautions NN O O
in NN O O
patients NN O O
at NN O O
risk NN O O
for NN O O
tumor NN O O
lysis NN O O
syndrome NN O O
( NN O O
e.g. NN O O
high NN O O
tumor NN O O
burden NN O O
) NN O O
. NN O O
5.7 NN O O
Embryo NN O O
- NN O O
Fetal NN O O
Toxicity NN O O
Based NN O O
on NN O O
findings NN O O
in NN O O
animals NN B-Animal B-Animal
IMBRUVICA NN O O
can NN O O
cause NN O O
fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
when NN O O
administered NN O O
to NN O O
a NN O O
pregnant NN O O
woman NN O O
. NN O O
Ibrutinib NN O O
caused NN O O
malformations NN B-AdverseReaction B-AdverseReaction
in NN O O
rats NN B-Animal B-Animal
at NN O O
exposures NN O O
14 NN O O
times NN O O
those NN O O
reported NN O O
in NN O O
patients NN O O
with NN O O
MCL NN O O
and NN O O
20 NN O O
times NN O O
those NN O O
reported NN O O
in NN O O
patients NN O O
with NN O O
CLL NN O O
or NN O O
WM NN O O
, NN O O
receiving NN O O
the NN O O
ibrutinib NN O O
dose NN O O
of NN O O
560 NN O O
mg NN O O
per NN O O
day NN O O
and NN O O
420 NN O O
mg NN O O
per NN O O
day NN O O
, NN O O
respectively NN O O
. NN O O
Reduced NN B-AdverseReaction B-AdverseReaction
fetal NN I-AdverseReaction I-AdverseReaction
weights NN I-AdverseReaction I-AdverseReaction
were NN O O
observed NN O O
at NN O O
lower NN O O
exposures NN O O
. NN O O
Advise NN O O
women NN O O
to NN O O
avoid NN O O
becoming NN O O
pregnant NN O O
while NN O O
taking NN O O
IMBRUVICA. NN O O
If NN O O
this NN O O
drug NN O O
is NN O O
used NN O O
during NN O O
pregnancy NN O O
or NN O O
if NN O O
the NN O O
patient NN O O
becomes NN O O
pregnant NN O O
while NN O O
taking NN O O
this NN O O
drug NN O O
, NN O O
the NN O O
patient NN O O
should NN O O
be NN O O
apprised NN O O
of NN O O
the NN O O
potential NN O O
hazard NN O O
to NN O O
a NN O O
fetus NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.1 NN O O
) NN O O
] NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
Serious NN B-Severity B-Severity
allergic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
anaphylactic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
may NN B-Factor B-Factor
occur NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
incidence NN O O
>1 NN O O
% NN O O
) NN O O
with NN O O
VORAXAZE NN O O
are NN O O
paraesthesias NN B-AdverseReaction B-AdverseReaction
flushing NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
and/or NN O O
vomiting NN B-AdverseReaction B-AdverseReaction
hypotension NN B-AdverseReaction B-AdverseReaction
and NN O O
headache NN B-AdverseReaction B-AdverseReaction
EXCERPT NN O O
: NN O O
In NN O O
clinical NN O O
trials NN O O
, NN O O
the NN O O
most NN O O
common NN O O
related NN O O
adverse NN O O
events NN O O
( NN O O
occurring NN O O
in NN O O
>1 NN O O
% NN O O
of NN O O
patients NN O O
) NN O O
were NN O O
paraesthesia NN B-AdverseReaction B-AdverseReaction
flushing NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
and/or NN O O
vomiting NN B-AdverseReaction B-AdverseReaction
hypotension NN B-AdverseReaction B-AdverseReaction
and NN O O
headache NN B-AdverseReaction B-AdverseReaction
( NN O O
6 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
call NN O O
877 NN O O
- NN O O
377 NN O O
- NN O O
3784 NN O O
or NN O O
contact NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
controlled NN O O
but NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
trials NN O O
of NN O O
VORAXAZE NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
other NN O O
drugs NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
The NN O O
evaluation NN O O
of NN O O
adverse NN O O
reactions NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
VORAXAZE NN O O
is NN O O
confounded NN O O
by NN O O
the NN O O
population NN O O
in NN O O
which NN O O
it NN O O
was NN O O
studied NN O O
, NN O O
patients NN O O
with NN O O
toxic NN O O
plasma NN O O
methotrexate NN O O
levels NN O O
due NN O O
to NN O O
impaired NN O O
renal NN O O
function NN O O
. NN O O
Adverse NN O O
reactions NN O O
related NN O O
to NN O O
toxic NN O O
methotrexate NN O O
levels NN O O
due NN O O
to NN O O
prolonged NN O O
methotrexate NN O O
clearance NN O O
include NN O O
myelosuppression NN O O
, NN O O
mucositis NN O O
, NN O O
acute NN O O
hepatitis NN O O
, NN O O
and NN O O
renal NN O O
dysfunction NN O O
and NN O O
failure NN O O
. NN O O
The NN O O
safety NN O O
of NN O O
VORAXAZE NN O O
is NN O O
based NN O O
on NN O O
data NN O O
from NN O O
290 NN O O
patients NN O O
who NN O O
were NN O O
treated NN O O
in NN O O
2 NN O O
single NN O O
- NN O O
arm NN O O
, NN O O
open NN O O
- NN O O
label NN O O
, NN O O
multicenter NN O O
trials NN O O
enrolling NN O O
patients NN O O
who NN O O
had NN O O
markedly NN O O
delayed NN O O
methotrexate NN O O
clearance NN O O
secondary NN O O
to NN O O
renal NN O O
dysfunction NN O O
. NN O O
Patients NN O O
with NN O O
osteosarcoma NN O O
were NN O O
eligible NN O O
for NN O O
these NN O O
studies NN O O
if NN O O
the NN O O
plasma NN O O
methotrexate NN O O
concentration NN O O
was NN O O
greater NN O O
than NN O O
50 NN O O
mumol/L NN O O
at NN O O
24 NN O O
hours NN O O
, NN O O
greater NN O O
that NN O O
5 NN O O
mumol/L NN O O
at NN O O
48 NN O O
hours NN O O
, NN O O
or NN O O
greater NN O O
than NN O O
2 NN O O
standard NN O O
deviations NN O O
above NN O O
the NN O O
mean NN O O
methotrexate NN O O
elimination NN O O
curve NN O O
at NN O O
least NN O O
12 NN O O
hours NN O O
after NN O O
methotrexate NN O O
administration NN O O
and NN O O
there NN O O
was NN O O
a NN O O
2-fold NN O O
or NN O O
greater NN O O
increase NN O O
in NN O O
serum NN O O
creatinine NN O O
above NN O O
baseline NN O O
. NN O O
All NN O O
other NN O O
patients NN O O
were NN O O
eligible NN O O
for NN O O
these NN O O
studies NN O O
if NN O O
the NN O O
plasma NN O O
methotrexate NN O O
level NN O O
was NN O O
greater NN O O
than NN O O
10 NN O O
mumol/L NN O O
more NN O O
than NN O O
42 NN O O
hours NN O O
after NN O O
the NN O O
start NN O O
of NN O O
the NN O O
methotrexate NN O O
or NN O O
the NN O O
plasma NN O O
level NN O O
was NN O O
greater NN O O
than NN O O
2 NN O O
standard NN O O
deviations NN O O
above NN O O
the NN O O
mean NN O O
methotrexate NN O O
excretion NN O O
curve NN O O
at NN O O
least NN O O
12 NN O O
hours NN O O
following NN O O
methotrexate NN O O
and NN O O
the NN O O
serum NN O O
creatinine NN O O
was NN O O
greater NN O O
than NN O O
1.5 NN O O
times NN O O
the NN O O
upper NN O O
limit NN O O
of NN O O
normal NN O O
or NN O O
the NN O O
creatinine NN O O
clearance NN O O
was NN O O
less NN O O
than NN O O
60 NN O O
mL/min NN O O
at NN O O
least NN O O
12 NN O O
hours NN O O
following NN O O
methotrexate NN O O
administration NN O O
. NN O O
Study NN O O
1 NN O O
, NN O O
conducted NN O O
by NN O O
the NN O O
National NN O O
Cancer NN O O
Institute NN O O
( NN O O
NCI NN O O
) NN O O
, NN O O
enrolled NN O O
184 NN O O
patients NN O O
; NN O O
safety NN O O
information NN O O
is NN O O
available NN O O
for NN O O
149 NN O O
patients NN O O
. NN O O
VORAXAZE NN O O
was NN O O
given NN O O
at NN O O
a NN O O
dose NN O O
of NN O O
50 NN O O
Units/kg NN O O
as NN O O
an NN O O
intravenous NN O O
injection NN O O
over NN O O
5 NN O O
minutes NN O O
. NN O O
Patients NN O O
with NN O O
pre NN O O
- NN O O
VORAXAZE NN O O
methotrexate NN O O
concentrations NN O O
>100 NN O O
mumol/L NN O O
were NN O O
to NN O O
receive NN O O
a NN O O
second NN O O
dose NN O O
of NN O O
VORAXAZE NN O O
48 NN O O
hours NN O O
after NN O O
the NN O O
first NN O O
dose NN O O
. NN O O
The NN O O
protocol NN O O
specified NN O O
that NN O O
patients NN O O
continue NN O O
receiving NN O O
intravenous NN O O
hydration NN O O
, NN O O
urinary NN O O
alkalinization NN O O
and NN O O
leucovorin NN O O
, NN O O
and NN O O
that NN O O
leucovorin NN O O
administration NN O O
be NN O O
adjusted NN O O
to NN O O
ensure NN O O
that NN O O
it NN O O
was NN O O
not NN O O
administered NN O O
within NN O O
two NN O O
hours NN O O
before NN O O
or NN O O
after NN O O
VORAXAZE. NN O O
In NN O O
Study NN O O
1 NN O O
, NN O O
VORAXAZE NN O O
- NN O O
related NN O O
adverse NN O O
reactions NN O O
were NN O O
collected NN O O
on NN O O
a NN O O
flow NN O O
sheet NN O O
with NN O O
a NN O O
daily NN O O
log NN O O
of NN O O
adverse NN O O
reactions NN O O
characterized NN O O
as NN O O
" NN O O
glucarpidase NN O O
toxicity NN O O
. NN O O
" NN O O
Additional NN O O
safety NN O O
information NN O O
was NN O O
collected NN O O
from NN O O
clinical NN O O
records NN O O
submitted NN O O
by NN O O
treating NN O O
physicians NN O O
. NN O O
This NN O O
information NN O O
was NN O O
abstracted NN O O
and NN O O
categorized NN O O
using NN O O
the NN O O
National NN O O
Cancer NN O O
Institute NN O O
( NN O O
NCI NN O O
) NN O O
" NN O O
Common NN O O
Terminology NN O O
Criteria NN O O
for NN O O
Adverse NN O O
Events NN O O
" NN O O
( NN O O
CTCAE NN O O
) NN O O
version NN O O
3 NN O O
scale NN O O
. NN O O
The NN O O
Study NN O O
1 NN O O
population NN O O
enrolled NN O O
patients NN O O
with NN O O
a NN O O
median NN O O
age NN O O
of NN O O
18 NN O O
years NN O O
( NN O O
1 NN O O
month NN O O
to NN O O
85 NN O O
years NN O O
) NN O O
; NN O O
63 NN O O
% NN O O
were NN O O
male NN O O
, NN O O
and NN O O
the NN O O
underlying NN O O
malignancies NN O O
were NN O O
osteosarcoma/sarcomas NN O O
in NN O O
32 NN O O
% NN O O
, NN O O
and NN O O
leukemia NN O O
or NN O O
lymphoma NN O O
in NN O O
63 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
One NN O O
( NN O O
n=106 NN O O
) NN O O
or NN O O
2 NN O O
( NN O O
n= NN O O
30 NN O O
) NN O O
doses NN O O
of NN O O
VORAXAZE NN O O
were NN O O
administered NN O O
intravenously NN O O
; NN O O
the NN O O
number NN O O
of NN O O
doses NN O O
was NN O O
not NN O O
specified NN O O
in NN O O
13 NN O O
patients NN O O
. NN O O
Doses NN O O
ranged NN O O
from NN O O
18 NN O O
to NN O O
98 NN O O
Units/kg NN O O
, NN O O
with NN O O
a NN O O
median NN O O
dose NN O O
of NN O O
49 NN O O
Units/kg NN O O
. NN O O
Study NN O O
2 NN O O
is NN O O
an NN O O
ongoing NN O O
expanded NN O O
access NN O O
program NN O O
. NN O O
At NN O O
the NN O O
time NN O O
of NN O O
data NN O O
cut NN O O
- NN O O
off NN O O
, NN O O
243 NN O O
patients NN O O
were NN O O
enrolled NN O O
and NN O O
safety NN O O
data NN O O
was NN O O
available NN O O
for NN O O
141 NN O O
patients NN O O
. NN O O
VORAXAZE NN O O
was NN O O
given NN O O
at NN O O
a NN O O
dose NN O O
of NN O O
50 NN O O
Units/kg NN O O
as NN O O
an NN O O
intravenous NN O O
injection NN O O
over NN O O
5 NN O O
minutes NN O O
. NN O O
The NN O O
criterion NN O O
for NN O O
allowing NN O O
patients NN O O
to NN O O
receive NN O O
a NN O O
second NN O O
glucarpidase NN O O
dose NN O O
was NN O O
not NN O O
specified NN O O
in NN O O
the NN O O
protocol NN O O
. NN O O
The NN O O
protocol NN O O
specified NN O O
that NN O O
patients NN O O
continue NN O O
receiving NN O O
intravenous NN O O
hydration NN O O
, NN O O
urinary NN O O
alkalinization NN O O
and NN O O
leucovorin NN O O
, NN O O
and NN O O
that NN O O
leucovorin NN O O
administration NN O O
be NN O O
adjusted NN O O
to NN O O
ensure NN O O
that NN O O
it NN O O
was NN O O
not NN O O
administered NN O O
within NN O O
two NN O O
hours NN O O
before NN O O
or NN O O
after NN O O
VORAXAZE. NN O O
Study NN O O
2 NN O O
enrolled NN O O
patients NN O O
with NN O O
a NN O O
median NN O O
age NN O O
of NN O O
17 NN O O
years NN O O
( NN O O
6 NN O O
months NN O O
to NN O O
85 NN O O
years NN O O
) NN O O
; NN O O
64 NN O O
% NN O O
were NN O O
male NN O O
, NN O O
and NN O O
the NN O O
underlying NN O O
malignancies NN O O
were NN O O
osteogenic NN O O
sarcoma NN O O
in NN O O
32 NN O O
% NN O O
, NN O O
and NN O O
leukemia NN O O
or NN O O
lymphoma NN O O
in NN O O
62 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
One NN O O
( NN O O
n=122 NN O O
) NN O O
or NN O O
2 NN O O
( NN O O
n= NN O O
18 NN O O
) NN O O
doses NN O O
of NN O O
VORAXAZE NN O O
were NN O O
administered NN O O
intravenously NN O O
; NN O O
the NN O O
number NN O O
of NN O O
doses NN O O
was NN O O
not NN O O
specified NN O O
for NN O O
1 NN O O
patient NN O O
. NN O O
Doses NN O O
ranged NN O O
from NN O O
6 NN O O
to NN O O
189 NN O O
Units/kg NN O O
, NN O O
with NN O O
a NN O O
median NN O O
dose NN O O
of NN O O
50 NN O O
Units/kg NN O O
. NN O O
In NN O O
Study NN O O
2 NN O O
only NN O O
VORAXAZE NN O O
- NN O O
related NN O O
adverse NN O O
reactions NN O O
were NN O O
collected NN O O
and NN O O
severity NN O O
was NN O O
graded NN O O
according NN O O
to NN O O
NCI NN O O
CTCAE NN O O
version NN O O
3 NN O O
. NN O O
Among NN O O
the NN O O
290 NN O O
patients NN O O
included NN O O
in NN O O
the NN O O
safety NN O O
evaluation NN O O
of NN O O
VORAXAZE NN O O
, NN O O
there NN O O
were NN O O
8 NN O O
deaths NN B-AdverseReaction B-AdverseReaction
within NN O O
30 NN O O
days NN O O
of NN O O
VORAXAZE NN O O
exposure NN O O
that NN O O
were NN O O
not NN O O
related NN O O
to NN O O
progressive NN O O
disease NN O O
. NN O O
Twenty NN O O
- NN O O
one NN O O
of NN O O
290 NN O O
patients NN O O
( NN O O
7 NN O O
% NN O O
) NN O O
experienced NN O O
adverse NN O O
reactions NN O O
that NN O O
were NN O O
assessed NN O O
as NN O O
related NN O O
to NN O O
VORAXAZE. NN O O
Most NN O O
were NN O O
Grade NN O O
1 NN O O
or NN O O
2 NN O O
events NN O O
. NN O O
One NN O O
patient NN O O
experienced NN O O
related NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
flushing NN B-AdverseReaction B-AdverseReaction
The NN O O
most NN O O
common NN O O
related NN O O
adverse NN O O
reactions NN O O
that NN O O
were NN O O
not NN O O
hematologic NN O O
, NN O O
hepatic NN O O
or NN O O
renal NN O O
events NN O O
were NN O O
paresthesia NN B-AdverseReaction B-AdverseReaction
flushing NN B-AdverseReaction B-AdverseReaction
and NN O O
nausea NN B-AdverseReaction B-AdverseReaction
and/or NN O O
vomiting NN B-AdverseReaction B-AdverseReaction
which NN O O
each NN O O
occurred NN O O
in NN O O
2 NN O O
% NN O O
of NN O O
patients NN O O
( NN O O
Table NN O O
1 NN O O
) NN O O
. NN O O
Table NN O O
1 NN O O
: NN O O
Per NN O O
Patient NN O O
Incidence NN O O
of NN O O
Grade NN O O
1 NN O O
and NN O O
2 NN O O
Adverse NN O O
Reactions NN O O
Assessed NN O O
as NN O O
Possibly NN O O
, NN O O
Probably NN O O
, NN O O
or NN O O
Definitely NN O O
Related NN O O
to NN O O
VORAXAZE NN O O
Excluding NN O O
Hematologic NN O O
, NN O O
Hepatic NN O O
, NN O O
or NN O O
Renal NN O O
Adverse NN O O
Reactions NN O O
1 NN O O
This NN O O
incidence NN O O
includes NN O O
the NN O O
following NN O O
terms NN O O
: NN O O
flushing NN B-AdverseReaction B-AdverseReaction
feeling NN B-AdverseReaction B-AdverseReaction
hot NN I-AdverseReaction I-AdverseReaction
burning NN B-AdverseReaction B-AdverseReaction
sensation NN I-AdverseReaction I-AdverseReaction
2 NN O O
One NN O O
of NN O O
these NN O O
reactions NN O O
was NN O O
classified NN O O
as NN O O
Grade NN O O
3 NN O O
in NN O O
severity NN O O
. NN O O
Adverse NN O O
Reaction NN O O
N= NN O O
290n NN O O
( NN O O
% NN O O
) NN O O
Paresthesias NN B-AdverseReaction B-AdverseReaction
7 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
Flushing NN B-AdverseReaction B-AdverseReaction
1,2 NN O O
5 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
5 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
Headache NN B-AdverseReaction B-AdverseReaction
2 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
Hypotension NN B-AdverseReaction B-AdverseReaction
2 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
Blurred NN B-AdverseReaction B-AdverseReaction
Vision NN I-AdverseReaction I-AdverseReaction
1 NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
1 NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
1 NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
1 NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
Rash NN B-AdverseReaction B-AdverseReaction
1 NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
Throat NN B-AdverseReaction B-AdverseReaction
irritation NN I-AdverseReaction I-AdverseReaction
tightness NN O O
1 NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
Tremor NN B-AdverseReaction B-AdverseReaction
1 NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
6.2 NN O O
Immunogenicity NN O O
As NN O O
with NN O O
all NN O O
therapeutic NN O O
proteins NN O O
, NN O O
there NN O O
is NN O O
potential NN O O
for NN O O
immunogenicity NN O O
. NN O O
In NN O O
clinical NN O O
trials NN O O
, NN O O
121 NN O O
patients NN O O
who NN O O
received NN O O
one NN O O
( NN O O
n=99 NN O O
) NN O O
, NN O O
two NN O O
( NN O O
n=21 NN O O
) NN O O
, NN O O
or NN O O
three NN O O
( NN O O
n=1 NN O O
) NN O O
doses NN O O
of NN O O
VORAXAZE NN O O
were NN O O
evaluated NN O O
for NN O O
anti NN O O
- NN O O
glucarpidase NN O O
antibodies NN O O
. NN O O
Twenty NN O O
- NN O O
five NN O O
of NN O O
these NN O O
121 NN O O
patients NN O O
( NN O O
21 NN O O
% NN O O
) NN O O
had NN O O
detectable NN O O
anti NN O O
- NN O O
glucarpidase NN O O
antibodies NN O O
following NN O O
VORAXAZE NN O O
administration NN O O
, NN O O
of NN O O
which NN O O
19 NN O O
received NN O O
a NN O O
single NN O O
dose NN O O
of NN O O
VORAXAZE NN O O
and NN O O
6 NN O O
received NN O O
two NN O O
doses NN O O
of NN O O
VORAXAZE. NN O O
Antibody NN O O
titers NN O O
were NN O O
determined NN O O
using NN O O
a NN O O
bridging NN O O
enzyme NN O O
- NN O O
linked NN O O
immunosorbent NN O O
assay NN O O
( NN O O
ELISA NN O O
) NN O O
for NN O O
anti NN O O
- NN O O
glucarpidase NN O O
antibodies NN O O
. NN O O
Neutralizing NN O O
antibodies NN O O
were NN O O
detected NN O O
in NN O O
11 NN O O
of NN O O
the NN O O
25 NN O O
patients NN O O
who NN O O
tested NN O O
positive NN O O
for NN O O
anti NN O O
- NN O O
glucarpidase NN O O
binding NN O O
antibodies NN O O
. NN O O
Eight NN O O
of NN O O
these NN O O
11 NN O O
patients NN O O
had NN O O
received NN O O
a NN O O
single NN O O
dose NN O O
of NN O O
VORAXAZE. NN O O
However NN O O
, NN O O
the NN O O
development NN O O
of NN O O
neutralizing NN O O
antibodies NN O O
may NN O O
be NN O O
underreported NN O O
due NN O O
to NN O O
lack NN O O
of NN O O
assay NN O O
sensitivity NN O O
. NN O O
The NN O O
detection NN O O
of NN O O
antibody NN O O
formation NN O O
is NN O O
highly NN O O
dependent NN O O
on NN O O
the NN O O
sensitivity NN O O
and NN O O
specificity NN O O
of NN O O
the NN O O
assay NN O O
. NN O O
Additionally NN O O
, NN O O
the NN O O
observed NN O O
incidence NN O O
of NN O O
antibody NN O O
( NN O O
including NN O O
neutralizing NN O O
antibody NN O O
) NN O O
positivity NN O O
in NN O O
an NN O O
assay NN O O
may NN O O
be NN O O
influenced NN O O
by NN O O
several NN O O
factors NN O O
, NN O O
including NN O O
assay NN O O
methodology NN O O
, NN O O
sample NN O O
handling NN O O
, NN O O
timing NN O O
of NN O O
sample NN O O
collection NN O O
, NN O O
concomitant NN O O
medications NN O O
, NN O O
and NN O O
underlying NN O O
disease NN O O
. NN O O
For NN O O
these NN O O
reasons NN O O
, NN O O
comparison NN O O
of NN O O
incidence NN O O
of NN O O
antibodies NN O O
to NN O O
VORAXAZE NN O O
with NN O O
the NN O O
incidence NN O O
of NN O O
antibodies NN O O
to NN O O
other NN O O
products NN O O
may NN O O
be NN O O
misleading NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Serious NN B-Severity B-Severity
allergic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
anaphylactic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
may NN B-Factor B-Factor
occur NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Measurement NN O O
of NN O O
methotrexate NN O O
using NN O O
immunoassays NN O O
is NN O O
unreliable NN O O
for NN O O
samples NN O O
collected NN O O
within NN O O
48 NN O O
hours NN O O
following NN O O
VORAXAZE NN O O
administration NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Continue NN O O
therapy NN O O
with NN O O
leucovorin NN O O
until NN O O
the NN O O
methotrexate NN O O
concentration NN O O
has NN O O
been NN O O
maintained NN O O
below NN O O
the NN O O
leucovorin NN O O
treatment NN O O
threshold NN O O
for NN O O
a NN O O
minimum NN O O
of NN O O
3 NN O O
days NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Do NN O O
not NN O O
administer NN O O
leucovorin NN O O
within NN O O
2 NN O O
hours NN O O
before NN O O
or NN O O
after NN O O
a NN O O
dose NN O O
of NN O O
VORAXAZE. NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
For NN O O
48 NN O O
hours NN O O
after NN O O
VORAXAZE NN O O
administration NN O O
, NN O O
determine NN O O
the NN O O
leucovorin NN O O
dose NN O O
based NN O O
on NN O O
the NN O O
patient NN O O
's NN O O
pre NN O O
- NN O O
VORAXAZE NN O O
methotrexate NN O O
concentration NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Continue NN O O
hydration NN O O
and NN O O
alkalinization NN O O
of NN O O
the NN O O
urine NN O O
as NN O O
indicated NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
5.1 NN O O
Serious NN O O
Allergic NN O O
Reactions NN O O
Serious NN B-Severity B-Severity
allergic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
of NN O O
patients NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
Monitoring NN O O
Methotrexate NN O O
Concentration/Interference NN O O
with NN O O
Assay NN O O
Methotrexate NN O O
concentrations NN O O
within NN O O
48 NN O O
hours NN O O
following NN O O
administration NN O O
of NN O O
VORAXAZE NN O O
can NN O O
only NN O O
be NN O O
reliably NN O O
measured NN O O
by NN O O
a NN O O
chromatographic NN O O
method NN O O
. NN O O
DAMPA NN O O
( NN O O
4-deoxy-4-amino NN O O
- NN O O
N NN O O
10 NN O O
-methylpteroic NN O O
acid NN O O
) NN O O
is NN O O
an NN O O
inactive NN O O
metabolite NN O O
of NN O O
methotrexate NN O O
resulting NN O O
from NN O O
treatment NN O O
with NN O O
VORAXAZE. NN O O
DAMPA NN O O
interferes NN O O
with NN O O
the NN O O
measurement NN O O
of NN O O
methotrexate NN O O
concentration NN O O
using NN O O
immunoassays NN O O
resulting NN O O
in NN O O
an NN O O
erroneous NN O O
measurement NN O O
which NN O O
overestimates NN O O
the NN O O
methotrexate NN O O
concentration NN O O
. NN O O
Due NN O O
to NN O O
the NN O O
long NN O O
half NN O O
- NN O O
life NN O O
of NN O O
DAMPA NN O O
( NN O O
t1/2of NN O O
approximately NN O O
9 NN O O
hours NN O O
) NN O O
, NN O O
measurement NN O O
of NN O O
methotrexate NN O O
using NN O O
immunoassays NN O O
is NN O O
unreliable NN O O
for NN O O
samples NN O O
collected NN O O
within NN O O
48 NN O O
hours NN O O
following NN O O
VORAXAZE NN O O
administration NN O O
[ NN O O
see NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.1 NN O O
) NN O O
] NN O O
. NN O O
5.3 NN O O
Continuation NN O O
and NN O O
Timing NN O O
of NN O O
Leucovorin NN O O
Rescue NN O O
Continue NN O O
to NN O O
administer NN O O
leucovorin NN O O
after NN O O
VORAXAZE. NN O O
Do NN O O
not NN O O
administer NN O O
leucovorin NN O O
within NN O O
2 NN O O
hours NN O O
before NN O O
or NN O O
after NN O O
a NN O O
dose NN O O
of NN O O
VORAXAZE NN O O
because NN O O
leucovorin NN O O
is NN O O
a NN O O
substrate NN O O
for NN O O
VORAXAZE NN O O
[ NN O O
see NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.1 NN O O
) NN O O
] NN O O
. NN O O
For NN O O
the NN O O
first NN O O
48 NN O O
hours NN O O
after NN O O
VORAXAZE NN O O
, NN O O
administer NN O O
the NN O O
same NN O O
leucovorin NN O O
dose NN O O
as NN O O
given NN O O
prior NN O O
to NN O O
VORAXAZE NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
Beyond NN O O
48 NN O O
hours NN O O
after NN O O
VORAXAZE NN O O
, NN O O
administer NN O O
leucovorin NN O O
based NN O O
on NN O O
the NN O O
measured NN O O
methotrexate NN O O
concentration NN O O
. NN O O
Do NN O O
not NN O O
discontinue NN O O
therapy NN O O
with NN O O
leucovorin NN O O
based NN O O
on NN O O
the NN O O
determination NN O O
of NN O O
a NN O O
single NN O O
methotrexate NN O O
concentration NN O O
below NN O O
the NN O O
leucovorin NN O O
treatment NN O O
threshold NN O O
. NN O O
Therapy NN O O
with NN O O
leucovorin NN O O
should NN O O
be NN O O
continued NN O O
until NN O O
the NN O O
methotrexate NN O O
concentration NN O O
has NN O O
been NN O O
maintained NN O O
below NN O O
the NN O O
leucovorin NN O O
treatment NN O O
threshold NN O O
for NN O O
a NN O O
minimum NN O O
of NN O O
3 NN O O
days NN O O
. NN O O
Continue NN O O
hydration NN O O
and NN O O
alkalinization NN O O
of NN O O
the NN O O
urine NN O O
as NN O O
indicated NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
serious NN O O
adverse NN O O
reactions NN O O
are NN O O
discussed NN O O
in NN O O
greater NN O O
detail NN O O
in NN O O
another NN O O
section NN O O
of NN O O
the NN O O
label NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5 NN O O
) NN O O
] NN O O
: NN O O
* NN O O
Non NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
infectious NN I-AdverseReaction I-AdverseReaction
pneumonitis NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Infections NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Angioedema NN B-AdverseReaction B-AdverseReaction
with NN O O
concomitant NN O O
use NN O O
of NN O O
ACE NN O O
inhibitors NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Oral NN B-AdverseReaction B-AdverseReaction
ulceration NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Renal NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Impaired NN B-AdverseReaction B-AdverseReaction
wound NN I-AdverseReaction I-AdverseReaction
healing NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.6 NN O O
) NN O O
] NN O O
. NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
the NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
other NN O O
trials NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O
EXCERPT NN O O
: NN O O
Advanced NN O O
HR+ NN O O
BC NN O O
, NN O O
advanced NN O O
PNET NN O O
, NN O O
advanced NN O O
RCC NN O O
: NN O O
Most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
incidence NN O O
>=30 NN O O
% NN O O
) NN O O
include NN O O
stomatitis NN B-AdverseReaction B-AdverseReaction
infections NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
edema NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
fever NN B-AdverseReaction B-AdverseReaction
asthenia NN B-AdverseReaction B-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
and NN O O
decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
( NN O O
6.1 NN O O
, NN O O
6.2 NN O O
, NN O O
6.3 NN O O
) NN O O
Renal NN O O
angiomyolipoma NN O O
with NN O O
TSC NN O O
: NN O O
Most NN O O
common NN O O
adverse NN O O
reaction NN O O
( NN O O
incidence NN O O
>= NN O O
30 NN O O
% NN O O
) NN O O
is NN O O
stomatitis NN B-AdverseReaction B-AdverseReaction
( NN O O
6.4 NN O O
) NN O O
SEGA NN O O
with NN O O
TSC NN O O
: NN O O
Most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
incidence NN O O
>= NN O O
30 NN O O
% NN O O
) NN O O
are NN O O
stomatitis NN B-AdverseReaction B-AdverseReaction
and NN O O
respiratory NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
( NN O O
6.5 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Novartis NN O O
Pharmaceuticals NN O O
Corporation NN O O
at NN O O
1 NN O O
- NN O O
888 NN O O
- NN O O
669 NN O O
- NN O O
6682 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Study NN O O
Experience NN O O
in NN O O
Advanced NN O O
Hormone NN O O
Receptor NN O O
- NN O O
Positive NN O O
, NN O O
HER2-Negative NN O O
Breast NN O O
Cancer NN O O
The NN O O
efficacy NN O O
and NN O O
safety NN O O
of NN O O
AFINITOR NN O O
( NN O O
10 NN O O
mg/day NN O O
) NN O O
plus NN O O
exemestane NN O O
( NN O O
25 NN O O
mg/day NN O O
) NN O O
( NN O O
n=485 NN O O
) NN O O
versus NN O O
placebo NN O O
plus NN O O
exemestane NN O O
( NN O O
25 NN O O
mg/day NN O O
) NN O O
( NN O O
n=239 NN O O
) NN O O
was NN O O
evaluated NN O O
in NN O O
a NN O O
randomized NN O O
, NN O O
controlled NN O O
trial NN O O
in NN O O
patients NN O O
with NN O O
advanced NN O O
or NN O O
metastatic NN O O
hormone NN O O
receptor NN O O
- NN O O
positive NN O O
, NN O O
HER2-negative NN O O
breast NN O O
cancer NN O O
. NN O O
The NN O O
median NN O O
age NN O O
of NN O O
patients NN O O
was NN O O
61 NN O O
years NN O O
( NN O O
range NN O O
28 NN O O
- NN O O
93 NN O O
years NN O O
) NN O O
, NN O O
and NN O O
75 NN O O
% NN O O
were NN O O
Caucasian NN O O
. NN O O
Safety NN O O
results NN O O
are NN O O
based NN O O
on NN O O
a NN O O
median NN O O
follow NN O O
- NN O O
up NN O O
of NN O O
approximately NN O O
13 NN O O
months NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
incidence NN O O
>= NN O O
30 NN O O
% NN O O
) NN O O
were NN O O
stomatitis NN B-AdverseReaction B-AdverseReaction
infections NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
and NN O O
decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
The NN O O
most NN O O
common NN O O
Grade NN B-Severity B-Severity
3/ NN I-Severity I-Severity
adverse NN O O
reactions NN O O
( NN O O
incidence NN O O
>= NN O O
2 NN O O
% NN O O
) NN O O
were NN O O
stomatitis NN B-AdverseReaction B-AdverseReaction
infections NN B-AdverseReaction B-AdverseReaction
hyperglycemia NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
dyspnea NN B-AdverseReaction B-AdverseReaction
pneumonitis NN B-AdverseReaction B-AdverseReaction
and NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
The NN O O
most NN O O
common NN O O
laboratory NN O O
abnormalities NN O O
( NN O O
incidence NN O O
>= NN O O
50 NN O O
% NN O O
) NN O O
were NN O O
hypercholesterolemia NN B-AdverseReaction B-AdverseReaction
hyperglycemia NN B-AdverseReaction B-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
aspartate NN I-AdverseReaction I-AdverseReaction
transaminase NN I-AdverseReaction I-AdverseReaction
( NN O O
AST NN O O
) NN O O
, NN O O
anemia NN B-AdverseReaction B-AdverseReaction
leukopenia NN B-AdverseReaction B-AdverseReaction
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
lymphopenia NN B-AdverseReaction B-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
alanine NN I-AdverseReaction I-AdverseReaction
transaminase NN I-AdverseReaction I-AdverseReaction
( NN O O
ALT NN O O
) NN O O
, NN O O
and NN O O
hypertriglyceridemia NN B-AdverseReaction B-AdverseReaction
The NN O O
most NN O O
common NN O O
Grade NN O O
3/4 NN O O
laboratory NN O O
abnormalities NN O O
( NN O O
incidence NN O O
>= NN O O
3 NN O O
% NN O O
) NN O O
were NN O O
lymphopenia NN B-AdverseReaction B-AdverseReaction
hyperglycemia NN B-AdverseReaction B-AdverseReaction
anemia NN B-AdverseReaction B-AdverseReaction
decreased NN B-AdverseReaction B-AdverseReaction
potassium NN I-AdverseReaction I-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
AST NN I-AdverseReaction I-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
ALT NN I-AdverseReaction I-AdverseReaction
and NN O O
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
Fatal NN B-AdverseReaction B-AdverseReaction
adverse NN O O
reactions NN O O
occurred NN O O
more NN O O
frequently NN O O
in NN O O
patients NN O O
who NN O O
received NN O O
AFINITOR NN O O
plus NN O O
exemestane NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
compared NN O O
to NN O O
patients NN O O
on NN O O
the NN O O
placebo NN O O
plus NN O O
exemestane NN O O
arm NN O O
( NN O O
0.4 NN O O
% NN O O
) NN O O
. NN O O
The NN O O
rates NN O O
of NN O O
treatment NN O O
- NN O O
emergent NN O O
adverse NN O O
events NN O O
resulting NN O O
in NN O O
permanent NN O O
discontinuation NN O O
were NN O O
24 NN O O
% NN O O
and NN O O
5 NN O O
% NN O O
for NN O O
the NN O O
AFINITOR NN O O
plus NN O O
exemestane NN O O
and NN O O
placebo NN O O
plus NN O O
exemestane NN O O
treatment NN O O
groups NN O O
, NN O O
respectively NN O O
. NN O O
Dose NN O O
adjustments NN O O
( NN O O
interruptions NN O O
or NN O O
reductions NN O O
) NN O O
were NN O O
more NN O O
frequent NN O O
among NN O O
patients NN O O
in NN O O
the NN O O
AFINITOR NN O O
plus NN O O
exemestane NN O O
arm NN O O
than NN O O
in NN O O
the NN O O
placebo NN O O
plus NN O O
exemestane NN O O
arm NN O O
( NN O O
63 NN O O
% NN O O
versus NN O O
14 NN O O
% NN O O
) NN O O
. NN O O
Table NN O O
2 NN O O
compares NN O O
the NN O O
incidence NN O O
of NN O O
treatment NN O O
- NN O O
emergent NN O O
adverse NN O O
reactions NN O O
reported NN O O
with NN O O
an NN O O
incidence NN O O
of NN O O
>=10 NN O O
% NN O O
for NN O O
patients NN O O
receiving NN O O
AFINITOR NN O O
10 NN O O
mg NN O O
daily NN O O
versus NN O O
placebo NN O O
. NN O O
Table NN O O
2 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Reported NN O O
>= NN O O
10 NN O O
% NN O O
of NN O O
Patients NN O O
with NN O O
Advanced NN O O
HR+ NN O O
BC NN O O
* NN O O
Grading NN O O
according NN O O
to NN O O
CTCAE NN O O
Version NN O O
3.0 NN O O
* NN O O
160 NN O O
patients NN O O
( NN O O
33.2 NN O O
% NN O O
) NN O O
were NN O O
exposed NN O O
to NN O O
AFINITOR NN O O
therapy NN O O
for NN O O
a NN O O
period NN O O
of NN O O
>= NN O O
32 NN O O
weeks NN O O
a NN O O
Exemestane NN O O
( NN O O
25 NN O O
mg/day NN O O
) NN O O
b NN O O
Includes NN O O
stomatitis NN B-AdverseReaction B-AdverseReaction
mouth NN B-AdverseReaction B-AdverseReaction
ulceration NN I-AdverseReaction I-AdverseReaction
aphthous NN B-AdverseReaction B-AdverseReaction
stomatitis NN I-AdverseReaction I-AdverseReaction
glossodynia NN B-AdverseReaction B-AdverseReaction
gingival NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
glossitis NN B-AdverseReaction B-AdverseReaction
and NN O O
lip NN B-AdverseReaction B-AdverseReaction
ulceration NN I-AdverseReaction I-AdverseReaction
c NN O O
Includes NN O O
all NN O O
preferred NN O O
terms NN O O
within NN O O
the NN O O
' NN O O
infections NN O O
and NN O O
infestations NN O O
' NN O O
system NN O O
organ NN O O
class NN O O
, NN O O
the NN O O
most NN O O
common NN O O
being NN O O
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
( NN O O
10 NN O O
% NN O O
) NN O O
, NN O O
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
( NN O O
10 NN O O
% NN O O
) NN O O
, NN O O
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
( NN O O
5 NN O O
% NN O O
) NN O O
, NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
( NN O O
4 NN O O
% NN O O
) NN O O
, NN O O
bronchitis NN B-AdverseReaction B-AdverseReaction
( NN O O
4 NN O O
% NN O O
) NN O O
, NN O O
cystitis NN B-AdverseReaction B-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
, NN O O
sinusitis NN B-AdverseReaction B-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
also NN O O
including NN O O
candidiasis NN B-AdverseReaction B-AdverseReaction
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
sepsis NN B-AdverseReaction B-AdverseReaction
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
hepatitis NN B-AdverseReaction B-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
. NN O O
d NN O O
Includes NN O O
pneumonitis NN B-AdverseReaction B-AdverseReaction
interstitial NN B-AdverseReaction B-AdverseReaction
lung NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
lung NN B-AdverseReaction B-AdverseReaction
infiltration NN I-AdverseReaction I-AdverseReaction
and NN O O
pulmonary NN B-AdverseReaction B-AdverseReaction
fibrosis NN I-AdverseReaction I-AdverseReaction
e NN O O
Exposure NN O O
to NN O O
AFINITOR NN O O
or NN O O
placebo NN O O
AFINITOR NN O O
( NN O O
10 NN O O
mg/day NN O O
) NN O O
+ NN O O
exemestane NN O O
a NN O O
N=482 NN O O
Placebo NN O O
+ NN O O
exemestane NN O O
a NN O O
N=238 NN O O
All NN O O
grades NN O O
Grade NN O O
3 NN O O
Grade NN O O
4 NN O O
All NN O O
grades NN O O
Grade NN O O
3 NN O O
Grade NN O O
4 NN O O
% NN O O
% NN O O
% NN O O
% NN O O
% NN O O
% NN O O
Any NN O O
adverse NN O O
reaction NN O O
100 NN O O
41 NN O O
9 NN O O
90 NN O O
22 NN O O
5 NN O O
Gastrointestinal NN O O
disorders NN O O
Stomatitis NN B-AdverseReaction B-AdverseReaction
b NN O O
67 NN O O
8 NN O O
0 NN O O
11 NN O O
0.8 NN O O
0 NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
33 NN O O
2 NN O O
0.2 NN O O
18 NN O O
0.8 NN O O
0 NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
29 NN O O
0.2 NN O O
0.2 NN O O
28 NN O O
1 NN O O
0 NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
17 NN O O
0.8 NN O O
0.2 NN O O
12 NN O O
0.8 NN O O
0 NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
14 NN O O
0.4 NN O O
0 NN O O
13 NN O O
0.4 NN O O
0 NN O O
Dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
11 NN O O
0 NN O O
0 NN O O
7 NN O O
0 NN O O
0 NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
36 NN O O
4 NN O O
0.4 NN O O
27 NN O O
1 NN O O
0 NN O O
Edema NN B-AdverseReaction B-AdverseReaction
peripheral NN I-AdverseReaction I-AdverseReaction
19 NN O O
1 NN O O
0 NN O O
6 NN O O
0.4 NN O O
0 NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
15 NN O O
0.2 NN O O
0 NN O O
7 NN O O
0.4 NN O O
0 NN O O
Asthenia NN B-AdverseReaction B-AdverseReaction
13 NN O O
2 NN O O
0.2 NN O O
4 NN O O
0 NN O O
0 NN O O
Infections NN O O
and NN O O
infestations NN O O
Infections NN B-AdverseReaction B-AdverseReaction
c NN O O
50 NN O O
4 NN O O
1 NN O O
25 NN O O
2 NN O O
0 NN O O
Investigations NN O O
Weight NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
25 NN O O
1 NN O O
0 NN O O
6 NN O O
0 NN O O
0 NN O O
Metabolism NN O O
and NN O O
nutrition NN O O
disorders NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
30 NN O O
1 NN O O
0 NN O O
12 NN O O
0.4 NN O O
0 NN O O
Hyperglycemia NN B-AdverseReaction B-AdverseReaction
14 NN O O
5 NN O O
0.4 NN O O
2 NN O O
0.4 NN O O
0 NN O O
Musculoskeletal NN O O
and NN O O
connective NN O O
tissue NN O O
disorders NN O O
Arthralgia NN B-AdverseReaction B-AdverseReaction
20 NN O O
0.8 NN O O
0 NN O O
17 NN O O
0 NN O O
0 NN O O
Back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
14 NN O O
0.2 NN O O
0 NN O O
10 NN O O
0.8 NN O O
0 NN O O
Pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
9 NN O O
0.4 NN O O
0 NN O O
11 NN O O
2 NN O O
0 NN O O
Nervous NN O O
system NN O O
disorders NN O O
Dysgeusia NN B-AdverseReaction B-AdverseReaction
22 NN O O
0.2 NN O O
0 NN O O
6 NN O O
0 NN O O
0 NN O O
Headache NN B-AdverseReaction B-AdverseReaction
21 NN O O
0.4 NN O O
0 NN O O
14 NN O O
0 NN O O
0 NN O O
Psychiatric NN O O
disorders NN O O
Insomnia NN B-AdverseReaction B-AdverseReaction
13 NN O O
0.2 NN O O
0 NN O O
8 NN O O
0 NN O O
0 NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
and NN O O
mediastinal NN O O
disorders NN O O
Cough NN B-AdverseReaction B-AdverseReaction
24 NN O O
0.6 NN O O
0 NN O O
12 NN O O
0 NN O O
0 NN O O
Dyspnea NN B-AdverseReaction B-AdverseReaction
21 NN O O
4 NN O O
0.2 NN O O
11 NN O O
0.8 NN O O
0.4 NN O O
Epistaxis NN B-AdverseReaction B-AdverseReaction
17 NN O O
0 NN O O
0 NN O O
1 NN O O
0 NN O O
0 NN O O
Pneumonitis NN B-AdverseReaction B-AdverseReaction
d NN O O
19 NN O O
4 NN O O
0.2 NN O O
0.4 NN O O
0 NN O O
0 NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
Rash NN B-AdverseReaction B-AdverseReaction
39 NN O O
1 NN O O
0 NN O O
6 NN O O
0 NN O O
0 NN O O
Pruritus NN B-AdverseReaction B-AdverseReaction
13 NN O O
0.2 NN O O
0 NN O O
5 NN O O
0 NN O O
0 NN O O
Alopecia NN B-AdverseReaction B-AdverseReaction
10 NN O O
0 NN O O
0 NN O O
5 NN O O
0 NN O O
0 NN O O
Vascular NN O O
disorders NN O O
Hot NN B-AdverseReaction B-AdverseReaction
flush NN I-AdverseReaction I-AdverseReaction
6 NN O O
0 NN O O
0 NN O O
14 NN O O
0 NN O O
0 NN O O
Median NN O O
duration NN O O
of NN O O
treatment NN O O
e NN O O
23.9 NN O O
weeks NN O O
13.4 NN O O
weeks NN O O
Key NN O O
observed NN O O
laboratory NN O O
abnormalities NN O O
are NN O O
presented NN O O
in NN O O
Table NN O O
3 NN O O
. NN O O
Table NN O O
3 NN O O
: NN O O
Key NN O O
Laboratory NN O O
Abnormalities NN O O
Reported NN O O
in NN O O
>= NN O O
10 NN O O
% NN O O
of NN O O
Patients NN O O
with NN O O
Advanced NN O O
HR+ NN O O
BC NN O O
Grading NN O O
according NN O O
to NN O O
CTCAE NN O O
Version NN O O
3.0 NN O O
a NN O O
Exemestane NN O O
( NN O O
25 NN O O
mg/day NN O O
) NN O O
b NN O O
Reflects NN O O
corresponding NN O O
adverse NN O O
drug NN O O
reaction NN O O
reports NN O O
of NN O O
anemia NN B-AdverseReaction B-AdverseReaction
leukopenia NN B-AdverseReaction B-AdverseReaction
lymphopenia NN B-AdverseReaction B-AdverseReaction
neutropenia NN B-AdverseReaction B-AdverseReaction
and NN O O
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
( NN O O
collectively NN O O
as NN O O
pancytopenia NN B-AdverseReaction B-AdverseReaction
which NN O O
occurred NN O O
at NN O O
lower NN O O
frequency NN O O
. NN O O
Laboratory NN O O
parameter NN O O
AFINITOR NN O O
( NN O O
10 NN O O
mg/day NN O O
) NN O O
+ NN O O
exemestane NN O O
a NN O O
N=482 NN O O
Placebo NN O O
+ NN O O
exemestane NN O O
a NN O O
N=238 NN O O
All NN O O
grades NN O O
Grade NN O O
3 NN O O
Grade NN O O
4 NN O O
All NN O O
grades NN O O
Grade NN O O
3 NN O O
Grade NN O O
4 NN O O
% NN O O
% NN O O
% NN O O
% NN O O
% NN O O
% NN O O
Hematology NN O O
b NN O O
Hemoglobin NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
68 NN O O
6 NN O O
0.6 NN O O
40 NN O O
0.8 NN O O
0.4 NN O O
WBC NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
58 NN O O
1 NN O O
0 NN O O
28 NN O O
5 NN O O
0.8 NN O O
Platelets NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
54 NN O O
3 NN O O
0.2 NN O O
5 NN O O
0 NN O O
0.4 NN O O
Lymphocytes NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
54 NN O O
11 NN O O
0.6 NN O O
37 NN O O
5 NN O O
0.8 NN O O
Neutrophils NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
31 NN O O
2 NN O O
0 NN O O
11 NN O O
0.8 NN O O
0.8 NN O O
Clinical NN O O
chemistry NN O O
Glucose NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
69 NN O O
9 NN O O
0.4 NN O O
44 NN O O
0.8 NN O O
0.4 NN O O
Cholesterol NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
70 NN O O
0.6 NN O O
0.2 NN O O
38 NN O O
0.8 NN O O
0.8 NN O O
Aspartate NN O O
transaminase NN O O
( NN O O
AST NN O O
) NN O O
increased NN O O
69 NN O O
4 NN O O
0.2 NN O O
45 NN O O
3 NN O O
0.4 NN O O
Alanine NN O O
transaminase NN O O
( NN O O
ALT NN O O
) NN O O
increased NN O O
51 NN O O
4 NN O O
0.2 NN O O
29 NN O O
5 NN O O
0 NN O O
Triglycerides NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
50 NN O O
0.8 NN O O
0 NN O O
26 NN O O
0 NN O O
0 NN O O
Albumin NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
33 NN O O
0.8 NN O O
0 NN O O
16 NN O O
0.8 NN O O
0 NN O O
Potassium NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
29 NN O O
4 NN O O
0.2 NN O O
7 NN O O
1 NN O O
0 NN O O
Creatinine NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
24 NN O O
2 NN O O
0.2 NN O O
13 NN O O
0 NN O O
0 NN O O
6.2 NN O O
Clinical NN O O
Study NN O O
Experience NN O O
in NN O O
Advanced NN O O
Pancreatic NN O O
Neuroendocrine NN O O
Tumors NN O O
In NN O O
a NN O O
randomized NN O O
, NN O O
controlled NN O O
trial NN O O
of NN O O
AFINITOR NN O O
( NN O O
n=204 NN O O
) NN O O
versus NN O O
placebo NN O O
( NN O O
n=203 NN O O
) NN O O
in NN O O
patients NN O O
with NN O O
advanced NN O O
PNET NN O O
the NN O O
median NN O O
age NN O O
of NN O O
patients NN O O
was NN O O
58 NN O O
years NN O O
( NN O O
range NN O O
20 NN O O
- NN O O
87 NN O O
) NN O O
, NN O O
79 NN O O
% NN O O
were NN O O
Caucasian NN O O
, NN O O
and NN O O
55 NN O O
% NN O O
were NN O O
male NN O O
. NN O O
Patients NN O O
on NN O O
the NN O O
placebo NN O O
arm NN O O
could NN O O
cross NN O O
over NN O O
to NN O O
open NN O O
- NN O O
label NN O O
AFINITOR NN O O
upon NN O O
disease NN O O
progression NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
incidence NN O O
>= NN O O
30 NN O O
% NN O O
) NN O O
were NN O O
stomatitis NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
edema NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
fever NN B-AdverseReaction B-AdverseReaction
and NN O O
headache NN B-AdverseReaction B-AdverseReaction
The NN O O
most NN O O
common NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
- NN I-Severity I-Severity
4 NN I-Severity I-Severity
adverse NN O O
reactions NN O O
( NN O O
incidence NN O O
>= NN O O
5 NN O O
% NN O O
) NN O O
were NN O O
stomatitis NN B-AdverseReaction B-AdverseReaction
and NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
The NN O O
most NN O O
common NN O O
laboratory NN O O
abnormalities NN O O
( NN O O
incidence NN O O
>= NN O O
50 NN O O
% NN O O
) NN O O
were NN O O
decreased NN B-AdverseReaction B-AdverseReaction
hemoglobin NN I-AdverseReaction I-AdverseReaction
hyperglycemia NN B-AdverseReaction B-AdverseReaction
alkaline NN B-AdverseReaction B-AdverseReaction
phosphatase NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
hypercholesterolemia NN B-AdverseReaction B-AdverseReaction
bicarbonate NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
and NN O O
increased NN B-AdverseReaction B-AdverseReaction
aspartate NN I-AdverseReaction I-AdverseReaction
transaminase NN I-AdverseReaction I-AdverseReaction
( NN O O
AST NN O O
) NN O O
. NN O O
The NN O O
most NN O O
common NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
- NN I-Severity I-Severity
4 NN I-Severity I-Severity
laboratory NN O O
abnormalities NN O O
( NN O O
incidence NN O O
>= NN O O
3 NN O O
% NN O O
) NN O O
were NN O O
hyperglycemia NN B-AdverseReaction B-AdverseReaction
lymphopenia NN B-AdverseReaction B-AdverseReaction
decreased NN B-AdverseReaction B-AdverseReaction
hemoglobin NN I-AdverseReaction I-AdverseReaction
hypophosphatemia NN B-AdverseReaction B-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
alkaline NN I-AdverseReaction I-AdverseReaction
phosphatase NN I-AdverseReaction I-AdverseReaction
neutropenia NN B-AdverseReaction B-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
aspartate NN I-AdverseReaction I-AdverseReaction
transaminase NN I-AdverseReaction I-AdverseReaction
( NN O O
AST NN O O
) NN O O
, NN O O
potassium NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
and NN O O
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
Deaths NN B-AdverseReaction B-AdverseReaction
during NN O O
double NN O O
- NN O O
blind NN O O
treatment NN O O
where NN O O
an NN O O
adverse NN O O
event NN O O
was NN O O
the NN O O
primary NN O O
cause NN O O
occurred NN O O
in NN O O
seven NN O O
patients NN O O
on NN O O
AFINITOR NN O O
and NN O O
one NN O O
patient NN O O
on NN O O
placebo NN O O
. NN O O
Causes NN O O
of NN O O
death NN B-AdverseReaction B-AdverseReaction
on NN O O
the NN O O
AFINITOR NN O O
arm NN O O
included NN O O
one NN O O
case NN O O
of NN O O
each NN O O
of NN O O
the NN O O
following NN O O
: NN O O
acute NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
acute NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
distress NN I-AdverseReaction I-AdverseReaction
cardiac NN B-AdverseReaction B-AdverseReaction
arrest NN I-AdverseReaction I-AdverseReaction
death NN B-AdverseReaction B-AdverseReaction
( NN O O
cause NN O O
unknown NN O O
) NN O O
, NN O O
hepatic NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
pneumonia NN B-AdverseReaction B-AdverseReaction
and NN O O
sepsis NN B-AdverseReaction B-AdverseReaction
There NN O O
was NN O O
one NN O O
death NN B-AdverseReaction B-AdverseReaction
due NN O O
to NN O O
pulmonary NN B-AdverseReaction B-AdverseReaction
embolism NN I-AdverseReaction I-AdverseReaction
on NN O O
the NN O O
placebo NN B-Factor B-Factor
arm NN O O
. NN O O
After NN O O
cross NN O O
- NN O O
over NN O O
to NN O O
open NN O O
- NN O O
label NN O O
AFINITOR NN O O
, NN O O
there NN O O
were NN O O
three NN O O
additional NN O O
deaths NN B-AdverseReaction B-AdverseReaction
one NN O O
due NN O O
to NN O O
hypoglycemia NN B-AdverseReaction B-AdverseReaction
and NN O O
cardiac NN B-AdverseReaction B-AdverseReaction
arrest NN I-AdverseReaction I-AdverseReaction
in NN O O
a NN O O
patient NN O O
with NN O O
insulinoma NN O O
, NN O O
one NN O O
due NN O O
to NN O O
myocardial NN B-AdverseReaction B-AdverseReaction
infarction NN I-AdverseReaction I-AdverseReaction
with NN O O
congestive NN B-AdverseReaction B-AdverseReaction
heart NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
and NN O O
the NN O O
other NN O O
due NN O O
to NN O O
sudden NN B-AdverseReaction B-AdverseReaction
death NN I-AdverseReaction I-AdverseReaction
The NN O O
rates NN O O
of NN O O
treatment NN O O
- NN O O
emergent NN O O
adverse NN O O
events NN O O
resulting NN O O
in NN O O
permanent NN O O
discontinuation NN O O
were NN O O
20 NN O O
% NN O O
and NN O O
6 NN O O
% NN O O
for NN O O
the NN O O
AFINITOR NN O O
and NN O O
placebo NN O O
treatment NN O O
groups NN O O
, NN O O
respectively NN O O
. NN O O
Dose NN O O
delay NN O O
or NN O O
reduction NN O O
was NN O O
necessary NN O O
in NN O O
61 NN O O
% NN O O
of NN O O
everolimus NN O O
patients NN O O
and NN O O
29 NN O O
% NN O O
of NN O O
placebo NN O O
patients NN O O
. NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
renal NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
six NN O O
patients NN O O
in NN O O
the NN O O
everolimus NN O O
arm NN O O
and NN O O
three NN O O
patients NN O O
in NN O O
the NN O O
placebo NN O O
arm NN O O
. NN O O
Thrombotic NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
included NN O O
five NN O O
patients NN O O
with NN O O
pulmonary NN B-AdverseReaction B-AdverseReaction
embolus NN I-AdverseReaction I-AdverseReaction
in NN O O
the NN O O
everolimus NN O O
arm NN O O
and NN O O
one NN O O
in NN O O
the NN O O
placebo NN O O
arm NN O O
as NN O O
well NN O O
as NN O O
three NN O O
patients NN O O
with NN O O
thrombosis NN B-AdverseReaction B-AdverseReaction
in NN O O
the NN O O
everolimus NN O O
arm NN O O
and NN O O
two NN O O
in NN O O
the NN O O
placebo NN O O
arm NN O O
. NN O O
Table NN O O
4 NN O O
compares NN O O
the NN O O
incidence NN O O
of NN O O
treatment NN O O
- NN O O
emergent NN O O
adverse NN O O
reactions NN O O
reported NN O O
with NN O O
an NN O O
incidence NN O O
of NN O O
>= NN O O
10 NN O O
% NN O O
for NN O O
patients NN O O
receiving NN O O
AFINITOR NN O O
10 NN O O
mg NN O O
daily NN O O
versus NN O O
placebo NN O O
. NN O O
Table NN O O
4 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Reported NN O O
>= NN O O
10 NN O O
% NN O O
of NN O O
Patients NN O O
with NN O O
Advanced NN O O
PNET NN O O
Grading NN O O
according NN O O
to NN O O
CTCAE NN O O
Version NN O O
3.0 NN O O
a NN O O
Includes NN O O
stomatitis NN B-AdverseReaction B-AdverseReaction
aphthous NN B-AdverseReaction B-AdverseReaction
stomatitis NN I-AdverseReaction I-AdverseReaction
gingival NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
glossitis NN B-AdverseReaction B-AdverseReaction
glossodynia NN B-AdverseReaction B-AdverseReaction
lip NN B-AdverseReaction B-AdverseReaction
ulceration NN I-AdverseReaction I-AdverseReaction
mouth NN B-AdverseReaction B-AdverseReaction
ulceration NN I-AdverseReaction I-AdverseReaction
tongue NN B-AdverseReaction B-AdverseReaction
ulceration NN I-AdverseReaction I-AdverseReaction
and NN O O
mucosal NN B-AdverseReaction B-AdverseReaction
inflammation NN I-AdverseReaction I-AdverseReaction
b NN O O
Includes NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
enteritis NN B-AdverseReaction B-AdverseReaction
enterocolitis NN B-AdverseReaction B-AdverseReaction
colitis NN B-AdverseReaction B-AdverseReaction
defecation NN B-AdverseReaction B-AdverseReaction
urgency NN I-AdverseReaction I-AdverseReaction
and NN O O
steatorrhea NN B-AdverseReaction B-AdverseReaction
c NN O O
Includes NN O O
pneumonitis NN B-AdverseReaction B-AdverseReaction
interstitial NN B-AdverseReaction B-AdverseReaction
lung NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
pulmonary NN B-AdverseReaction B-AdverseReaction
fibrosis NN I-AdverseReaction I-AdverseReaction
and NN O O
restrictive NN B-AdverseReaction B-AdverseReaction
pulmonary NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
AFINITOR NN O O
N=204 NN O O
Placebo NN O O
N=203 NN O O
All NN O O
grades NN O O
Grade NN O O
3 NN O O
Grade NN O O
4 NN O O
All NN O O
grades NN O O
Grade NN O O
3 NN O O
Grade NN O O
4 NN O O
% NN O O
% NN O O
% NN O O
% NN O O
% NN O O
% NN O O
Any NN O O
adverse NN O O
reaction NN O O
100 NN O O
49 NN O O
13 NN O O
98 NN O O
32 NN O O
8 NN O O
Gastrointestinal NN O O
disorders NN O O
Stomatitis NN B-AdverseReaction B-AdverseReaction
a NN O O
70 NN O O
7 NN O O
0 NN O O
20 NN O O
0 NN O O
0 NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
b NN O O
50 NN O O
5 NN O O
0.5 NN O O
25 NN O O
3 NN O O
0 NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
36 NN O O
4 NN O O
0 NN O O
32 NN O O
6 NN O O
1 NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
32 NN O O
2 NN O O
0 NN O O
33 NN O O
2 NN O O
0 NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
29 NN O O
1 NN O O
0 NN O O
21 NN O O
2 NN O O
0 NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
14 NN O O
0 NN O O
0 NN O O
13 NN O O
0.5 NN O O
0 NN O O
Dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
11 NN O O
0 NN O O
0 NN O O
4 NN O O
0 NN O O
0 NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
45 NN O O
3 NN O O
0.5 NN O O
27 NN O O
2 NN O O
0.5 NN O O
Edema NN O O
( NN O O
general NN O O
and NN O O
peripheral NN O O
) NN O O
39 NN O O
1 NN O O
0.5 NN O O
12 NN O O
1 NN O O
0 NN O O
Fever NN B-AdverseReaction B-AdverseReaction
31 NN O O
0.5 NN O O
0.5 NN O O
13 NN O O
0.5 NN O O
0 NN O O
Asthenia NN B-AdverseReaction B-AdverseReaction
19 NN O O
3 NN O O
0 NN O O
20 NN O O
3 NN O O
0 NN O O
Infections NN O O
and NN O O
infestations NN O O
Nasopharyngitis NN B-AdverseReaction B-AdverseReaction
25 NN O O
0 NN O O
0 NN O O
13 NN O O
0 NN O O
0 NN O O
Urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
16 NN O O
0 NN O O
0 NN O O
6 NN O O
0.5 NN O O
0 NN O O
Investigations NN O O
Weight NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
28 NN O O
0.5 NN O O
0 NN O O
11 NN O O
0 NN O O
0 NN O O
Metabolism NN O O
and NN O O
nutrition NN O O
disorders NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
30 NN O O
1 NN O O
0 NN O O
18 NN O O
1 NN O O
0 NN O O
Diabetes NN B-AdverseReaction B-AdverseReaction
mellitus NN I-AdverseReaction I-AdverseReaction
10 NN O O
2 NN O O
0 NN O O
0.5 NN O O
0 NN O O
0 NN O O
Musculoskeletal NN O O
and NN O O
connective NN O O
tissue NN O O
disorders NN O O
Arthralgia NN B-AdverseReaction B-AdverseReaction
15 NN O O
1 NN O O
0.5 NN O O
7 NN O O
0.5 NN O O
0 NN O O
Back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
15 NN O O
1 NN O O
0 NN O O
11 NN O O
1 NN O O
0 NN O O
Pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
14 NN O O
0.5 NN O O
0 NN O O
6 NN O O
1 NN O O
0 NN O O
Muscle NN B-AdverseReaction B-AdverseReaction
spasms NN I-AdverseReaction I-AdverseReaction
10 NN O O
0 NN O O
0 NN O O
4 NN O O
0 NN O O
0 NN O O
Nervous NN O O
system NN O O
disorders NN O O
Headache NN B-AdverseReaction B-AdverseReaction
30 NN O O
0.5 NN O O
0 NN O O
15 NN O O
1 NN O O
0 NN O O
Dysgeusia NN B-AdverseReaction B-AdverseReaction
19 NN O O
0 NN O O
0 NN O O
5 NN O O
0 NN O O
0 NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
12 NN O O
0.5 NN O O
0 NN O O
7 NN O O
0 NN O O
0 NN O O
Psychiatric NN O O
disorders NN O O
Insomnia NN B-AdverseReaction B-AdverseReaction
14 NN O O
0 NN O O
0 NN O O
8 NN O O
0 NN O O
0 NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
and NN O O
mediastinal NN O O
disorders NN O O
Cough NN B-AdverseReaction B-AdverseReaction
cough NN O O
25 NN O O
0.5 NN O O
0 NN O O
13 NN O O
0 NN O O
0 NN O O
Epistaxis NN B-AdverseReaction B-AdverseReaction
22 NN O O
0 NN O O
0 NN O O
1 NN O O
0 NN O O
0 NN O O
Dyspnea NN B-AdverseReaction B-AdverseReaction
exertional NN O O
20 NN O O
2 NN O O
0.5 NN O O
7 NN O O
0.5 NN O O
0 NN O O
Pneumonitis NN B-AdverseReaction B-AdverseReaction
c NN O O
17 NN O O
3 NN O O
0.5 NN O O
0 NN O O
0 NN O O
0 NN O O
Oropharyngeal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
11 NN O O
0 NN O O
0 NN O O
6 NN O O
0 NN O O
0 NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
disorders NN O O
Rash NN B-AdverseReaction B-AdverseReaction
59 NN O O
0.5 NN O O
0 NN O O
19 NN O O
0 NN O O
0 NN O O
Nail NN B-AdverseReaction B-AdverseReaction
disorders NN I-AdverseReaction I-AdverseReaction
22 NN O O
0.5 NN O O
0 NN O O
2 NN O O
0 NN O O
0 NN O O
Pruritus NN B-AdverseReaction B-AdverseReaction
generalized NN O O
21 NN O O
0 NN O O
0 NN O O
13 NN O O
0 NN O O
0 NN O O
Dry NN B-AdverseReaction B-AdverseReaction
skin NN I-AdverseReaction I-AdverseReaction
13 NN O O
0 NN O O
0 NN O O
6 NN O O
0 NN O O
0 NN O O
Vascular NN O O
disorders NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
13 NN O O
1 NN O O
0 NN O O
6 NN O O
1 NN O O
0 NN O O
Median NN O O
duration NN O O
of NN O O
treatment NN O O
( NN O O
wks NN O O
) NN O O
37 NN O O
16 NN O O
In NN O O
female NN O O
patients NN O O
aged NN O O
18 NN O O
to NN O O
55 NN O O
years NN O O
, NN O O
irregular NN B-AdverseReaction B-AdverseReaction
menstruation NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
5 NN O O
of NN O O
46 NN O O
( NN O O
11 NN O O
% NN O O
) NN O O
AFINITOR NN O O
- NN O O
treated NN O O
females NN O O
and NN O O
none NN O O
of NN O O
the NN O O
33 NN O O
females NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
. NN O O
Key NN O O
observed NN O O
laboratory NN O O
abnormalities NN O O
are NN O O
presented NN O O
in NN O O
Table NN O O
5 NN O O
. NN O O
Table NN O O
5 NN O O
: NN O O
Key NN O O
Laboratory NN O O
Abnormalities NN O O
Reported NN O O
in NN O O
>= NN O O
10 NN O O
% NN O O
of NN O O
Patients NN O O
with NN O O
Advanced NN O O
PNET NN O O
Grading NN O O
according NN O O
to NN O O
CTCAE NN O O
Version NN O O
3.0 NN O O
Laboratory NN O O
parameter NN O O
AFINITOR NN O O
N=204 NN O O
Placebo NN O O
N=203 NN O O
All NN O O
grades NN O O
Grade NN O O
3 NN O O
- NN O O
4 NN O O
All NN O O
grades NN O O
Grade NN O O
3 NN O O
- NN O O
4 NN O O
% NN O O
% NN O O
% NN O O
% NN O O
Hematology NN O O
Hemoglobin NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
86 NN O O
15 NN O O
63 NN O O
1 NN O O
Lymphocytes NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
45 NN O O
16 NN O O
22 NN O O
4 NN O O
Platelets NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
45 NN O O
3 NN O O
11 NN O O
0 NN O O
WBC NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
43 NN O O
2 NN O O
13 NN O O
0 NN O O
Neutrophils NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
30 NN O O
4 NN O O
17 NN O O
2 NN O O
Clinical NN O O
chemistry NN O O
Alkaline NN B-AdverseReaction B-AdverseReaction
phosphatase NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
74 NN O O
8 NN O O
66 NN O O
8 NN O O
Glucose NN B-AdverseReaction B-AdverseReaction
( NN I-AdverseReaction I-AdverseReaction
fasting NN I-AdverseReaction I-AdverseReaction
) NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
75 NN O O
17 NN O O
53 NN O O
6 NN O O
Cholesterol NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
66 NN O O
0.5 NN O O
22 NN O O
0 NN O O
Bicarbonate NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
56 NN O O
0 NN O O
40 NN O O
0 NN O O
Aspartate NN O O
transaminase NN O O
( NN O O
AST NN O O
) NN O O
increased NN O O
56 NN O O
4 NN O O
41 NN O O
4 NN O O
Alanine NN O O
transaminase NN O O
( NN O O
ALT NN O O
) NN O O
increased NN O O
48 NN O O
2 NN O O
35 NN O O
2 NN O O
Phosphate NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
40 NN O O
10 NN O O
14 NN O O
3 NN O O
Triglycerides NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
39 NN O O
0 NN O O
10 NN O O
0 NN O O
Calcium NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
37 NN O O
0.5 NN O O
12 NN O O
0 NN O O
Potassium NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
23 NN O O
4 NN O O
5 NN O O
0 NN O O
Creatinine NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
19 NN O O
2 NN O O
14 NN O O
0 NN O O
Sodium NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
16 NN O O
1 NN O O
16 NN O O
1 NN O O
Albumin NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
13 NN O O
1 NN O O
8 NN O O
0 NN O O
Bilirubin NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
10 NN O O
1 NN O O
14 NN O O
2 NN O O
Potassium NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
7 NN O O
0 NN O O
10 NN O O
0.5 NN O O
6.3 NN O O
Clinical NN O O
Study NN O O
Experience NN O O
in NN O O
Advanced NN O O
Renal NN O O
Cell NN O O
Carcinoma NN O O
The NN O O
data NN O O
described NN O O
below NN O O
reflect NN O O
exposure NN O O
to NN O O
AFINITOR NN O O
( NN O O
n=274 NN O O
) NN O O
and NN O O
placebo NN O O
( NN O O
n=137 NN O O
) NN O O
in NN O O
a NN O O
randomized NN O O
, NN O O
controlled NN O O
trial NN O O
in NN O O
patients NN O O
with NN O O
metastatic NN O O
renal NN O O
cell NN O O
carcinoma NN O O
who NN O O
received NN O O
prior NN O O
treatment NN O O
with NN O O
sunitinib NN O O
and/or NN O O
sorafenib NN O O
. NN O O
The NN O O
median NN O O
age NN O O
of NN O O
patients NN O O
was NN O O
61 NN O O
years NN O O
( NN O O
range NN O O
27 NN O O
- NN O O
85 NN O O
) NN O O
, NN O O
88 NN O O
% NN O O
were NN O O
Caucasian NN O O
, NN O O
and NN O O
78 NN O O
% NN O O
were NN O O
male NN O O
. NN O O
The NN O O
median NN O O
duration NN O O
of NN O O
blinded NN O O
study NN O O
treatment NN O O
was NN O O
141 NN O O
days NN O O
( NN O O
range NN O O
19 NN O O
- NN O O
451 NN O O
days NN O O
) NN O O
for NN O O
patients NN O O
receiving NN O O
AFINITOR NN O O
and NN O O
60 NN O O
days NN O O
( NN O O
range NN O O
21 NN O O
- NN O O
295 NN O O
days NN O O
) NN O O
for NN O O
those NN O O
receiving NN O O
placebo NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
incidence NN O O
>= NN O O
30 NN O O
% NN O O
) NN O O
were NN O O
stomatitis NN B-AdverseReaction B-AdverseReaction
infections NN B-AdverseReaction B-AdverseReaction
asthenia NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
and NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
The NN O O
most NN O O
common NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
- NN I-Severity I-Severity
4 NN I-Severity I-Severity
adverse NN O O
reactions NN O O
( NN O O
incidence NN O O
>= NN O O
3 NN O O
% NN O O
) NN O O
were NN O O
infections NN B-AdverseReaction B-AdverseReaction
dyspnea NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
stomatitis NN B-AdverseReaction B-AdverseReaction
dehydration NN B-AdverseReaction B-AdverseReaction
pneumonitis NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
and NN O O
asthenia NN B-AdverseReaction B-AdverseReaction
The NN O O
most NN O O
common NN O O
laboratory NN O O
abnormalities NN O O
( NN O O
incidence NN O O
>= NN O O
50 NN O O
% NN O O
) NN O O
were NN O O
anemia NN B-AdverseReaction B-AdverseReaction
hypercholesterolemia NN B-AdverseReaction B-AdverseReaction
hypertriglyceridemia NN O O
, NN O O
hyperglycemia NN B-AdverseReaction B-AdverseReaction
lymphopenia NN B-AdverseReaction B-AdverseReaction
and NN O O
increased NN B-AdverseReaction B-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
The NN O O
most NN O O
common NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
- NN I-Severity I-Severity
4 NN I-Severity I-Severity
laboratory NN O O
abnormalities NN O O
( NN O O
incidence NN O O
>= NN O O
3 NN O O
% NN O O
) NN O O
were NN O O
lymphopenia NN B-AdverseReaction B-AdverseReaction
hyperglycemia NN B-AdverseReaction B-AdverseReaction
anemia NN B-AdverseReaction B-AdverseReaction
hypophosphatemia NN B-AdverseReaction B-AdverseReaction
and NN O O
hypercholesterolemia NN B-AdverseReaction B-AdverseReaction
Deaths NN B-AdverseReaction B-AdverseReaction
due NN O O
to NN O O
acute NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
( NN O O
0.7 NN O O
% NN O O
) NN O O
, NN O O
infection NN B-AdverseReaction B-AdverseReaction
( NN O O
0.7 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
acute NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
( NN O O
0.4 NN O O
% NN O O
) NN O O
were NN O O
observed NN O O
on NN O O
the NN O O
AFINITOR NN O O
arm NN O O
but NN O O
none NN O O
on NN O O
the NN O O
placebo NN O O
arm NN O O
. NN O O
The NN O O
rates NN O O
of NN O O
treatment NN O O
- NN O O
emergent NN O O
adverse NN O O
events NN O O
( NN O O
irrespective NN O O
of NN O O
causality NN O O
) NN O O
resulting NN O O
in NN O O
permanent NN O O
discontinuation NN O O
were NN O O
14 NN O O
% NN O O
and NN O O
3 NN O O
% NN O O
for NN O O
the NN O O
AFINITOR NN O O
and NN O O
placebo NN O O
treatment NN O O
groups NN O O
, NN O O
respectively NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
irrespective NN O O
of NN O O
causality NN O O
) NN O O
leading NN O O
to NN O O
treatment NN O O
discontinuation NN O O
were NN O O
pneumonitis NN B-AdverseReaction B-AdverseReaction
and NN O O
dyspnea NN B-AdverseReaction B-AdverseReaction
Infections NN B-AdverseReaction B-AdverseReaction
stomatitis NN B-AdverseReaction B-AdverseReaction
and NN O O
pneumonitis NN B-AdverseReaction B-AdverseReaction
were NN O O
the NN O O
most NN O O
common NN O O
reasons NN O O
for NN O O
treatment NN O O
delay NN O O
or NN O O
dose NN O O
reduction NN O O
. NN O O
The NN O O
most NN O O
common NN O O
medical NN O O
interventions NN O O
required NN O O
during NN O O
AFINITOR NN O O
treatment NN O O
were NN O O
for NN O O
infections NN B-AdverseReaction B-AdverseReaction
anemia NN B-AdverseReaction B-AdverseReaction
and NN O O
stomatitis NN B-AdverseReaction B-AdverseReaction
Table NN O O
6 NN O O
compares NN O O
the NN O O
incidence NN O O
of NN O O
treatment NN O O
- NN O O
emergent NN O O
adverse NN O O
reactions NN O O
reported NN O O
with NN O O
an NN O O
incidence NN O O
of NN O O
>= NN O O
10 NN O O
% NN O O
for NN O O
patients NN O O
receiving NN O O
AFINITOR NN O O
10 NN O O
mg NN O O
daily NN O O
versus NN O O
placebo NN O O
. NN O O
Within NN O O
each NN O O
MedDRA NN O O
system NN O O
organ NN O O
class NN O O
, NN O O
the NN O O
adverse NN O O
reactions NN O O
are NN O O
presented NN O O
in NN O O
order NN O O
of NN O O
decreasing NN O O
frequency NN O O
. NN O O
Table NN O O
6 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Reported NN O O
in NN O O
at NN O O
Least NN O O
10 NN O O
% NN O O
of NN O O
Patients NN O O
with NN O O
RCC NN O O
and NN O O
at NN O O
a NN O O
Higher NN O O
Rate NN O O
in NN O O
the NN O O
AFINITOR NN O O
Arm NN O O
than NN O O
in NN O O
the NN O O
Placebo NN O O
Arm NN O O
Grading NN O O
according NN O O
to NN O O
CTCAE NN O O
Version NN O O
3.0 NN O O
a NN O O
Stomatitis NN B-AdverseReaction B-AdverseReaction
( NN O O
including NN O O
aphthous NN B-AdverseReaction B-AdverseReaction
stomatitis NN I-AdverseReaction I-AdverseReaction
and NN O O
mouth NN O O
and NN O O
tongue NN B-AdverseReaction B-AdverseReaction
ulceration NN I-AdverseReaction I-AdverseReaction
b NN O O
Includes NN O O
all NN O O
preferred NN O O
terms NN O O
within NN O O
the NN O O
' NN O O
infections NN O O
and NN O O
infestations NN O O
' NN O O
system NN O O
organ NN O O
class NN O O
, NN O O
the NN O O
most NN O O
common NN O O
being NN O O
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
( NN O O
6 NN O O
% NN O O
) NN O O
, NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
( NN O O
6 NN O O
% NN O O
) NN O O
, NN O O
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
( NN O O
5 NN O O
% NN O O
) NN O O
, NN O O
bronchitis NN B-AdverseReaction B-AdverseReaction
( NN O O
4 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
sinusitis NN B-AdverseReaction B-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
also NN O O
including NN O O
aspergillosis NN B-AdverseReaction B-AdverseReaction
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
, NN O O
candidiasis NN B-AdverseReaction B-AdverseReaction
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
sepsis NN B-AdverseReaction B-AdverseReaction
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
. NN O O
c NN O O
Includes NN O O
pneumonitis NN B-AdverseReaction B-AdverseReaction
interstitial NN B-AdverseReaction B-AdverseReaction
lung NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
lung NN B-AdverseReaction B-AdverseReaction
infiltration NN I-AdverseReaction I-AdverseReaction
pulmonary NN B-AdverseReaction B-AdverseReaction
alveolar NN I-AdverseReaction I-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
pulmonary NN B-AdverseReaction B-AdverseReaction
toxicity NN I-AdverseReaction I-AdverseReaction
and NN O O
alveolitis NN B-AdverseReaction B-AdverseReaction
AFINITOR NN O O
10 NN O O
mg/day NN O O
N=274 NN O O
Placebo NN O O
N=137 NN O O
All NN O O
grades NN O O
Grade NN O O
3 NN O O
Grade NN O O
4 NN O O
All NN O O
grades NN O O
Grade NN O O
3 NN O O
Grade NN O O
4 NN O O
% NN O O
% NN O O
% NN O O
% NN O O
% NN O O
% NN O O
Any NN O O
a NN O O
dverse NN O O
r NN O O
eaction NN O O
97 NN O O
52 NN O O
13 NN O O
93 NN O O
23 NN O O
5 NN O O
Gastrointestinal NN O O
d NN O O
isorders NN O O
Stomatitis NN B-AdverseReaction B-AdverseReaction
a NN O O
44 NN O O
4 NN O O
< NN O O
1 NN O O
8 NN O O
0 NN O O
0 NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
30 NN O O
1 NN O O
0 NN O O
7 NN O O
0 NN O O
0 NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
26 NN O O
1 NN O O
0 NN O O
19 NN O O
0 NN O O
0 NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
20 NN O O
2 NN O O
0 NN O O
12 NN O O
0 NN O O
0 NN O O
Infections NN O O
and NN O O
i NN O O
nfestations NN O O
b NN O O
37 NN O O
7 NN O O
3 NN O O
18 NN O O
1 NN O O
0 NN O O
General NN O O
d NN O O
isorders NN O O
and NN O O
a NN O O
dministration NN O O
s NN O O
ite NN O O
c NN O O
onditions NN O O
Asthenia NN B-AdverseReaction B-AdverseReaction
33 NN O O
3 NN O O
< NN O O
1 NN O O
23 NN O O
4 NN O O
0 NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
31 NN O O
5 NN O O
0 NN O O
27 NN O O
3 NN O O
< NN O O
1 NN O O
Edema NN B-AdverseReaction B-AdverseReaction
peripheral NN I-AdverseReaction I-AdverseReaction
25 NN O O
< NN O O
1 NN O O
0 NN O O
8 NN O O
< NN O O
1 NN O O
0 NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
20 NN O O
< NN O O
1 NN O O
0 NN O O
9 NN O O
0 NN O O
0 NN O O
Mucosal NN B-AdverseReaction B-AdverseReaction
inflammation NN I-AdverseReaction I-AdverseReaction
19 NN O O
1 NN O O
0 NN O O
1 NN O O
0 NN O O
0 NN O O
Respiratory NN O O
, NN O O
t NN O O
horacic NN O O
and NN O O
m NN O O
ediastinal NN O O
d NN O O
isorders NN O O
Cough NN B-AdverseReaction B-AdverseReaction
30 NN O O
< NN O O
1 NN O O
0 NN O O
16 NN O O
0 NN O O
0 NN O O
Dyspnea NN B-AdverseReaction B-AdverseReaction
24 NN O O
6 NN O O
1 NN O O
15 NN O O
3 NN O O
0 NN O O
Epistaxis NN B-AdverseReaction B-AdverseReaction
18 NN O O
0 NN O O
0 NN O O
0 NN O O
0 NN O O
0 NN O O
Pneumonitis NN B-AdverseReaction B-AdverseReaction
c NN O O
14 NN O O
4 NN O O
0 NN O O
0 NN O O
0 NN O O
0 NN O O
Skin NN O O
and NN O O
s NN O O
ubcutaneous NN O O
t NN O O
issue NN O O
d NN O O
isorders NN O O
Rash NN B-AdverseReaction B-AdverseReaction
29 NN O O
1 NN O O
0 NN O O
7 NN O O
0 NN O O
0 NN O O
Pruritus NN B-AdverseReaction B-AdverseReaction
14 NN O O
< NN O O
1 NN O O
0 NN O O
7 NN O O
0 NN O O
0 NN O O
Dry NN B-AdverseReaction B-AdverseReaction
skin NN I-AdverseReaction I-AdverseReaction
13 NN O O
< NN O O
1 NN O O
0 NN O O
5 NN O O
0 NN O O
0 NN O O
Metabolism NN O O
and NN O O
n NN O O
utrition NN O O
d NN O O
isorders NN O O
Anorexia NN B-AdverseReaction B-AdverseReaction
25 NN O O
1 NN O O
0 NN O O
14 NN O O
< NN O O
1 NN O O
0 NN O O
Nervous NN O O
s NN O O
ystem NN O O
d NN O O
isorders NN O O
Headache NN B-AdverseReaction B-AdverseReaction
19 NN O O
< NN O O
1 NN O O
< NN O O
1 NN O O
9 NN O O
< NN O O
1 NN O O
0 NN O O
Dysgeusia NN B-AdverseReaction B-AdverseReaction
10 NN O O
0 NN O O
0 NN O O
2 NN O O
0 NN O O
0 NN O O
Musculoskeletal NN O O
and NN O O
c NN O O
onnective NN O O
t NN O O
issue NN O O
d NN O O
isorders NN O O
Pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
10 NN O O
1 NN O O
0 NN O O
7 NN O O
0 NN O O
0 NN O O
Medi NN O O
an NN O O
d NN O O
uration NN O O
of NN O O
t NN O O
reatment NN O O
( NN O O
d NN O O
) NN O O
141 NN O O
60 NN O O
Other NN O O
notable NN O O
adverse NN O O
reactions NN O O
occurring NN O O
more NN O O
frequently NN O O
with NN O O
AFINITOR NN O O
than NN O O
with NN O O
placebo NN O O
, NN O O
but NN O O
with NN O O
an NN O O
incidence NN O O
of NN O O
< NN O O
10 NN O O
% NN O O
include NN O O
: NN O O
Gastrointestinal NN O O
disorders NN O O
: NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
( NN O O
9 NN O O
% NN O O
) NN O O
, NN O O
dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
( NN O O
8 NN O O
% NN O O
) NN O O
, NN O O
hemorrhoids NN B-AdverseReaction B-AdverseReaction
( NN O O
5 NN O O
% NN O O
) NN O O
, NN O O
dysphagia NN B-AdverseReaction B-AdverseReaction
( NN O O
4 NN O O
% NN O O
) NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
: NN O O
Weight NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
( NN O O
9 NN O O
% NN O O
) NN O O
, NN O O
chest NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
( NN O O
5 NN O O
% NN O O
) NN O O
, NN O O
chills NN B-AdverseReaction B-AdverseReaction
( NN O O
4 NN O O
% NN O O
) NN O O
, NN O O
impaired NN B-AdverseReaction B-AdverseReaction
wound NN I-AdverseReaction I-AdverseReaction
healing NN I-AdverseReaction I-AdverseReaction
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
and NN O O
mediastinal NN O O
disorders NN O O
: NN O O
Pleural NN B-AdverseReaction B-AdverseReaction
effusion NN I-AdverseReaction I-AdverseReaction
( NN O O
7 NN O O
% NN O O
) NN O O
, NN O O
pharyngolaryngeal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
( NN O O
4 NN O O
% NN O O
) NN O O
, NN O O
rhinorrhea NN B-AdverseReaction B-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
: NN O O
Hand NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
foot NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
reported NN O O
as NN O O
palmar NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
plantar NN I-AdverseReaction I-AdverseReaction
erythrodysesthesia NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
5 NN O O
% NN O O
) NN O O
, NN O O
nail NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
( NN O O
5 NN O O
% NN O O
) NN O O
, NN O O
erythema NN B-AdverseReaction B-AdverseReaction
( NN O O
4 NN O O
% NN O O
) NN O O
, NN O O
onychoclasis NN B-AdverseReaction B-AdverseReaction
( NN O O
4 NN O O
% NN O O
) NN O O
, NN O O
skin NN B-AdverseReaction B-AdverseReaction
lesion NN I-AdverseReaction I-AdverseReaction
( NN O O
4 NN O O
% NN O O
) NN O O
, NN O O
acneiform NN B-AdverseReaction B-AdverseReaction
dermatitis NN I-AdverseReaction I-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
, NN O O
angioedema NN B-AdverseReaction B-AdverseReaction
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
Metabolism NN O O
and NN O O
nutrition NN O O
disorders NN O O
: NN O O
Exacerbation NN O O
of NN O O
pre NN O O
- NN O O
existing NN O O
diabetes NN O O
mellitus NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
, NN O O
new NN B-AdverseReaction B-AdverseReaction
onset NN I-AdverseReaction I-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
diabetes NN I-AdverseReaction I-AdverseReaction
mellitus NN I-AdverseReaction I-AdverseReaction
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
Psychiatric NN O O
disorders NN O O
: NN O O
Insomnia NN B-AdverseReaction B-AdverseReaction
( NN O O
9 NN O O
% NN O O
) NN O O
Nervous NN O O
system NN O O
disorders NN O O
: NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
( NN O O
7 NN O O
% NN O O
) NN O O
, NN O O
paresthesia NN B-AdverseReaction B-AdverseReaction
( NN O O
5 NN O O
% NN O O
) NN O O
Eye NN O O
disorders NN O O
: NN O O
Eyelid NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
( NN O O
4 NN O O
% NN O O
) NN O O
, NN O O
conjunctivitis NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
Vascular NN O O
disorders NN O O
: NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
( NN O O
4 NN O O
% NN O O
) NN O O
, NN O O
deep NN B-AdverseReaction B-AdverseReaction
vein NN I-AdverseReaction I-AdverseReaction
thrombosis NN I-AdverseReaction I-AdverseReaction
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
Renal NN O O
and NN O O
urinary NN O O
disorders NN O O
: NN O O
Renal NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
Cardiac NN O O
disorders NN O O
: NN O O
Tachycardia NN B-AdverseReaction B-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
, NN O O
congestive NN B-AdverseReaction B-AdverseReaction
cardiac NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
( NN O O
1 NN O O
% NN O O
) NN O O
Musculoskeletal NN O O
and NN O O
connective NN O O
tissue NN O O
disorders NN O O
: NN O O
Jaw NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
Hematologic NN O O
disorders NN O O
: NN O O
Hemorrhage NN B-AdverseReaction B-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
Key NN O O
laboratory NN O O
abnormalities NN O O
are NN O O
presented NN O O
in NN O O
Table NN O O
7 NN O O
. NN O O
Table NN O O
7 NN O O
: NN O O
Key NN O O
Laboratory NN O O
Abnormalities NN O O
Reported NN O O
in NN O O
Patients NN O O
with NN O O
RCC NN O O
at NN O O
a NN O O
Higher NN O O
Rate NN O O
in NN O O
the NN O O
AFINITOR NN O O
Arm NN O O
than NN O O
the NN O O
Placebo NN O O
Arm NN O O
Grading NN O O
according NN O O
to NN O O
CTCAE NN O O
Version NN O O
3.0 NN O O
a NN O O
Reflects NN O O
corresponding NN O O
adverse NN O O
drug NN O O
reaction NN O O
reports NN O O
of NN O O
anemia NN B-AdverseReaction B-AdverseReaction
leukopenia NN B-AdverseReaction B-AdverseReaction
lymphopenia NN B-AdverseReaction B-AdverseReaction
neutropenia NN B-AdverseReaction B-AdverseReaction
and NN O O
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
( NN O O
collectively NN O O
pancytopenia NN B-AdverseReaction B-AdverseReaction
which NN O O
occurred NN O O
at NN O O
lower NN O O
frequency NN O O
. NN O O
Laboratory NN O O
p NN O O
arameter NN O O
AFINITOR NN O O
10 NN O O
mg/day NN O O
N=274 NN O O
Placebo NN O O
N=137 NN O O
All NN O O
grades NN O O
Grade NN O O
3 NN O O
Grade NN O O
4 NN O O
All NN O O
grades NN O O
Grade NN O O
3 NN O O
Grade NN O O
4 NN O O
% NN O O
% NN O O
% NN O O
% NN O O
% NN O O
% NN O O
Hematology NN O O
a NN O O
Hemoglobin NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
92 NN O O
12 NN O O
1 NN O O
79 NN O O
5 NN O O
< NN O O
1 NN O O
Lymphocytes NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
51 NN O O
16 NN O O
2 NN O O
28 NN O O
5 NN O O
0 NN O O
Platelets NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
23 NN O O
1 NN O O
0 NN O O
2 NN O O
0 NN O O
< NN O O
1 NN O O
Neutrophils NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
14 NN O O
0 NN O O
< NN O O
1 NN O O
4 NN O O
0 NN O O
0 NN O O
Clinical NN O O
c NN O O
hemistry NN O O
Cholesterol NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
77 NN O O
4 NN O O
0 NN O O
35 NN O O
0 NN O O
0 NN O O
Triglycerides NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
73 NN O O
< NN O O
1 NN O O
0 NN O O
34 NN O O
0 NN O O
0 NN O O
Glucose NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
57 NN O O
15 NN O O
< NN O O
1 NN O O
25 NN O O
1 NN O O
0 NN O O
Creatinine NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
50 NN O O
1 NN O O
0 NN O O
34 NN O O
0 NN O O
0 NN O O
Phosphate NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
37 NN O O
6 NN O O
0 NN O O
8 NN O O
0 NN O O
0 NN O O
Aspartate NN O O
transaminase NN O O
( NN O O
AST NN O O
) NN O O
increased NN O O
25 NN O O
< NN O O
1 NN O O
< NN O O
1 NN O O
7 NN O O
0 NN O O
0 NN O O
Alanine NN O O
transaminase NN O O
( NN O O
ALT NN O O
) NN O O
increased NN O O
21 NN O O
1 NN O O
0 NN O O
4 NN O O
0 NN O O
0 NN O O
Bilirubin NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
3 NN O O
< NN O O
1 NN O O
< NN O O
1 NN O O
2 NN O O
0 NN O O
0 NN O O
6.4 NN O O
Clinical NN O O
Study NN O O
Experience NN O O
in NN O O
Renal NN O O
Angiomyolipoma NN O O
with NN O O
Tuberous NN O O
Sclerosis NN O O
Complex NN O O
The NN O O
data NN O O
described NN O O
below NN O O
are NN O O
based NN O O
on NN O O
a NN O O
randomized NN O O
( NN O O
2:1 NN O O
) NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
trial NN O O
of NN O O
AFINITOR NN O O
in NN O O
118 NN O O
patients NN O O
with NN O O
renal NN O O
angiomyolipoma NN O O
as NN O O
a NN O O
feature NN O O
of NN O O
TSC NN O O
( NN O O
n=113 NN O O
) NN O O
or NN O O
sporadic NN O O
lymphangioleiomyomatosis NN O O
( NN O O
n=5 NN O O
) NN O O
. NN O O
The NN O O
median NN O O
age NN O O
of NN O O
patients NN O O
was NN O O
31 NN O O
years NN O O
( NN O O
range NN O O
18 NN O O
to NN O O
61 NN O O
years NN O O
) NN O O
, NN O O
89 NN O O
% NN O O
were NN O O
Caucasian NN O O
, NN O O
and NN O O
34 NN O O
% NN O O
were NN O O
male NN O O
. NN O O
The NN O O
median NN O O
duration NN O O
of NN O O
blinded NN O O
study NN O O
treatment NN O O
was NN O O
48 NN O O
weeks NN O O
( NN O O
range NN O O
2 NN O O
to NN O O
115 NN O O
weeks NN O O
) NN O O
for NN O O
patients NN O O
receiving NN O O
AFINITOR NN O O
and NN O O
45 NN O O
weeks NN O O
( NN O O
range NN O O
9 NN O O
to NN O O
115 NN O O
weeks NN O O
) NN O O
for NN O O
those NN O O
receiving NN O O
placebo NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reaction NN O O
reported NN O O
for NN O O
AFINITOR NN O O
( NN O O
incidence NN O O
>= NN O O
30 NN O O
% NN O O
) NN O O
was NN O O
stomatitis NN B-AdverseReaction B-AdverseReaction
The NN O O
most NN O O
common NN O O
Grade NN O O
3 NN O O
- NN O O
4 NN O O
adverse NN O O
reactions NN O O
( NN O O
incidence NN O O
>= NN O O
2 NN O O
% NN O O
) NN O O
were NN O O
stomatitis NN B-AdverseReaction B-AdverseReaction
and NN O O
amenorrhea NN B-AdverseReaction B-AdverseReaction
The NN O O
most NN O O
common NN O O
laboratory NN O O
abnormalities NN O O
( NN O O
incidence NN O O
>= NN O O
50 NN O O
% NN O O
) NN O O
were NN O O
hypercholesterolemia NN B-AdverseReaction B-AdverseReaction
hypertriglyceridemia NN B-AdverseReaction B-AdverseReaction
and NN O O
anemia NN B-AdverseReaction B-AdverseReaction
The NN O O
most NN O O
common NN O O
Grade NN O O
3 NN O O
- NN O O
4 NN O O
laboratory NN O O
abnormality NN O O
( NN O O
incidence NN O O
>= NN O O
3 NN O O
% NN O O
) NN O O
was NN O O
hypophosphatemia NN B-AdverseReaction B-AdverseReaction
The NN O O
rate NN O O
of NN O O
adverse NN O O
reactions NN O O
resulting NN O O
in NN O O
permanent NN O O
discontinuation NN O O
was NN O O
3.8 NN O O
% NN O O
in NN O O
the NN O O
AFINITOR NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Adverse NN O O
reactions NN O O
leading NN O O
to NN O O
permanent NN O O
discontinuation NN O O
in NN O O
the NN O O
AFINITOR NN O O
arm NN O O
were NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
convulsion NN B-AdverseReaction B-AdverseReaction
and NN O O
hypophosphatemia NN B-AdverseReaction B-AdverseReaction
Dose NN O O
adjustments NN O O
( NN O O
interruptions NN O O
or NN O O
reductions NN O O
) NN O O
due NN O O
to NN O O
adverse NN O O
reactions NN O O
occurred NN O O
in NN O O
52 NN O O
% NN O O
of NN O O
AFINITOR NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reaction NN O O
leading NN O O
to NN O O
AFINITOR NN O O
dose NN O O
adjustment NN O O
was NN O O
stomatitis NN B-AdverseReaction B-AdverseReaction
Table NN O O
8 NN O O
compares NN O O
the NN O O
incidence NN O O
of NN O O
adverse NN O O
reactions NN O O
reported NN O O
with NN O O
an NN O O
incidence NN O O
of NN O O
>= NN O O
10 NN O O
% NN O O
for NN O O
patients NN O O
receiving NN O O
AFINITOR NN O O
and NN O O
occurring NN O O
more NN O O
frequently NN O O
with NN O O
AFINITOR NN O O
than NN O O
with NN O O
placebo NN O O
. NN O O
Laboratory NN O O
abnormalities NN O O
are NN O O
described NN O O
separately NN O O
in NN O O
Table NN O O
9 NN O O
. NN O O
Table NN O O
8 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Reported NN O O
in NN O O
>= NN O O
10 NN O O
% NN O O
of NN O O
AFINITOR NN O O
- NN O O
treated NN O O
Patients NN O O
with NN O O
Renal NN O O
Angiomyolipoma NN O O
Grading NN O O
according NN O O
to NN O O
CTCAE NN O O
Version NN O O
3.0 NN O O
a NN O O
Includes NN O O
stomatitis NN B-AdverseReaction B-AdverseReaction
aphthous NN B-AdverseReaction B-AdverseReaction
stomatitis NN I-AdverseReaction I-AdverseReaction
mouth NN B-AdverseReaction B-AdverseReaction
ulceration NN I-AdverseReaction I-AdverseReaction
gingival NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
glossitis NN B-AdverseReaction B-AdverseReaction
and NN O O
glossodynia NN B-AdverseReaction B-AdverseReaction
AFINITOR NN O O
N=79 NN O O
Placebo NN O O
N=39 NN O O
All NN O O
grades NN O O
% NN O O
Grade NN O O
3 NN O O
% NN O O
Grade NN O O
4 NN O O
% NN O O
All NN O O
grades NN O O
% NN O O
Grade NN O O
3 NN O O
% NN O O
Grade NN O O
4 NN O O
% NN O O
Any NN O O
adverse NN O O
reaction NN O O
100 NN O O
25 NN O O
5 NN O O
97 NN O O
8 NN O O
5 NN O O
Gastrointestinal NN O O
disorders NN O O
Stomatitis NN B-AdverseReaction B-AdverseReaction
a NN O O
78 NN O O
6 NN O O
0 NN O O
23 NN O O
0 NN O O
0 NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
15 NN O O
0 NN O O
0 NN O O
5 NN O O
0 NN O O
0 NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
14 NN O O
0 NN O O
0 NN O O
5 NN O O
0 NN O O
0 NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
Peripheral NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
13 NN O O
0 NN O O
0 NN O O
8 NN O O
0 NN O O
0 NN O O
Infections NN O O
and NN O O
infestations NN O O
Upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
11 NN O O
0 NN O O
0 NN O O
5 NN O O
0 NN O O
0 NN O O
Musculoskeletal NN O O
and NN O O
connective NN O O
tissue NN O O
disorders NN O O
Arthralgia NN B-AdverseReaction B-AdverseReaction
13 NN O O
0 NN O O
0 NN O O
5 NN O O
0 NN O O
0 NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
and NN O O
mediastinal NN O O
disorders NN O O
Cough NN B-AdverseReaction B-AdverseReaction
20 NN O O
0 NN O O
0 NN O O
13 NN O O
0 NN O O
0 NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
Acne NN B-AdverseReaction B-AdverseReaction
22 NN O O
0 NN O O
0 NN O O
5 NN O O
0 NN O O
0 NN O O
Amenorrhea NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
15 NN O O
% NN O O
of NN O O
AFINITOR NN O O
- NN O O
treated NN O O
females NN O O
( NN O O
8 NN O O
of NN O O
52 NN O O
) NN O O
and NN O O
4 NN O O
% NN O O
( NN O O
1 NN O O
of NN O O
26 NN O O
) NN O O
of NN O O
females NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
. NN O O
Other NN O O
adverse NN O O
reactions NN O O
involving NN O O
the NN O O
female NN O O
reproductive NN O O
system NN O O
were NN O O
menorrhagia NN B-AdverseReaction B-AdverseReaction
( NN O O
10 NN O O
% NN O O
) NN O O
, NN O O
menstrual NN B-AdverseReaction B-AdverseReaction
irregularities NN I-AdverseReaction I-AdverseReaction
( NN O O
10 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
vaginal NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
( NN O O
8 NN O O
% NN O O
) NN O O
. NN O O
The NN O O
following NN O O
additional NN O O
adverse NN O O
reactions NN O O
occurred NN O O
in NN O O
less NN O O
than NN O O
10 NN O O
% NN O O
of NN O O
AFINITOR NN O O
-treated NN O O
patients NN O O
: NN O O
epistaxis NN B-AdverseReaction B-AdverseReaction
( NN O O
9 NN O O
% NN O O
) NN O O
, NN O O
decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
( NN O O
6 NN O O
% NN O O
) NN O O
, NN O O
otitis NN B-AdverseReaction B-AdverseReaction
media NN I-AdverseReaction I-AdverseReaction
( NN O O
6 NN O O
% NN O O
) NN O O
, NN O O
depression NN B-AdverseReaction B-AdverseReaction
( NN O O
5 NN O O
% NN O O
) NN O O
, NN O O
abnormal NN B-AdverseReaction B-AdverseReaction
taste NN I-AdverseReaction I-AdverseReaction
( NN O O
5 NN O O
% NN O O
) NN O O
, NN O O
increased NN O O
blood NN O O
luteinizing NN O O
hormone NN O O
( NN O O
LH NN O O
) NN O O
levels NN O O
( NN O O
4 NN O O
% NN O O
) NN O O
, NN O O
increased NN O O
blood NN O O
follicle NN O O
stimulating NN O O
hormone NN O O
( NN O O
FSH NN O O
) NN O O
levels NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
, NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
, NN O O
ovarian NN B-AdverseReaction B-AdverseReaction
cyst NN I-AdverseReaction I-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
, NN O O
pneumonitis NN B-AdverseReaction B-AdverseReaction
( NN O O
1 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
angioedema NN B-AdverseReaction B-AdverseReaction
( NN O O
1 NN O O
% NN O O
) NN O O
. NN O O
Table NN O O
9 NN O O
: NN O O
Key NN O O
Laboratory NN O O
Abnormalities NN O O
Reported NN O O
in NN O O
AFINITOR NN O O
- NN O O
treated NN O O
Patients NN O O
with NN O O
Renal NN O O
Angiomyolipoma NN O O
Grading NN O O
according NN O O
to NN O O
CTCAE NN O O
Version NN O O
3.0 NN O O
AFINITOR NN O O
N=79 NN O O
Placebo NN O O
N=39 NN O O
All NN O O
grades NN O O
% NN O O
Grade NN O O
3 NN O O
% NN O O
Grade NN O O
4 NN O O
% NN O O
All NN O O
grades NN O O
% NN O O
Grade NN O O
3 NN O O
% NN O O
Grade NN O O
4 NN O O
% NN O O
Hematology NN O O
Anemia NN O O
61 NN O O
0 NN O O
0 NN O O
49 NN O O
0 NN O O
0 NN O O
Leucopenia NN B-AdverseReaction B-AdverseReaction
37 NN O O
0 NN O O
0 NN O O
21 NN O O
0 NN O O
0 NN O O
Neutropenia NN B-AdverseReaction B-AdverseReaction
25 NN O O
0 NN O O
1 NN O O
26 NN O O
0 NN O O
0 NN O O
Lymphopenia NN B-AdverseReaction B-AdverseReaction
20 NN O O
1 NN O O
0 NN O O
8 NN O O
0 NN O O
0 NN O O
Thrombocytopenia NN B-AdverseReaction B-AdverseReaction
19 NN O O
0 NN O O
0 NN O O
3 NN O O
0 NN O O
0 NN O O
Clinical NN O O
chemistry NN O O
Hypercholesterolemia NN B-AdverseReaction B-AdverseReaction
85 NN O O
1 NN O O
0 NN O O
46 NN O O
0 NN O O
0 NN O O
Hypertriglyceridemia NN B-AdverseReaction B-AdverseReaction
52 NN O O
0 NN O O
0 NN O O
10 NN O O
0 NN O O
0 NN O O
Hypophosphatemia NN B-AdverseReaction B-AdverseReaction
49 NN O O
5 NN O O
0 NN O O
15 NN O O
0 NN O O
0 NN O O
Alkaline NN B-AdverseReaction B-AdverseReaction
phosphatase NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
32 NN O O
1 NN O O
0 NN O O
10 NN O O
0 NN O O
0 NN O O
Elevated NN B-AdverseReaction B-AdverseReaction
aspartate NN I-AdverseReaction I-AdverseReaction
transaminase NN I-AdverseReaction I-AdverseReaction
( NN O O
AST NN O O
) NN O O
23 NN O O
1 NN O O
0 NN O O
8 NN O O
0 NN O O
0 NN O O
Elevated NN B-AdverseReaction B-AdverseReaction
alanine NN I-AdverseReaction I-AdverseReaction
transaminase NN I-AdverseReaction I-AdverseReaction
( NN O O
ALT NN O O
) NN O O
20 NN O O
1 NN O O
0 NN O O
15 NN O O
0 NN O O
0 NN O O
Fasting NN B-AdverseReaction B-AdverseReaction
hyperglycemia NN I-AdverseReaction I-AdverseReaction
14 NN O O
0 NN O O
0 NN O O
8 NN O O
0 NN O O
0 NN O O
6.5 NN O O
Clinical NN O O
Study NN O O
Experience NN O O
in NN O O
Subependymal NN O O
Giant NN O O
Cell NN O O
Astrocytoma NN O O
with NN O O
Tuberous NN O O
Sclerosis NN O O
Complex NN O O
The NN O O
data NN O O
described NN O O
below NN O O
are NN O O
based NN O O
on NN O O
a NN O O
randomized NN O O
( NN O O
2:1 NN O O
) NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
trial NN O O
( NN O O
Study NN O O
1 NN O O
) NN O O
of NN O O
AFINITOR NN O O
in NN O O
117 NN O O
patients NN O O
with NN O O
subependymal NN O O
giant NN O O
cell NN O O
astrocytoma NN O O
( NN O O
SEGA NN O O
) NN O O
and NN O O
tuberous NN O O
sclerosis NN O O
complex NN O O
( NN O O
TSC NN O O
) NN O O
. NN O O
The NN O O
median NN O O
age NN O O
of NN O O
patients NN O O
was NN O O
9.5 NN O O
years NN O O
( NN O O
range NN O O
0.8 NN O O
to NN O O
26 NN O O
years NN O O
) NN O O
, NN O O
93 NN O O
% NN O O
were NN O O
Caucasian NN O O
, NN O O
and NN O O
57 NN O O
% NN O O
were NN O O
male NN O O
. NN O O
The NN O O
median NN O O
duration NN O O
of NN O O
blinded NN O O
study NN O O
treatment NN O O
was NN O O
52 NN O O
weeks NN O O
( NN O O
range NN O O
24 NN O O
to NN O O
89 NN O O
weeks NN O O
) NN O O
for NN O O
patients NN O O
receiving NN O O
AFINITOR NN O O
and NN O O
47 NN O O
weeks NN O O
( NN O O
range NN O O
14 NN O O
to NN O O
88 NN O O
weeks NN O O
) NN O O
for NN O O
those NN O O
receiving NN O O
placebo NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
reported NN O O
for NN O O
AFINITOR NN O O
( NN O O
incidence NN O O
>= NN O O
30 NN O O
% NN O O
) NN O O
were NN O O
stomatitis NN B-AdverseReaction B-AdverseReaction
and NN O O
respiratory NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
The NN O O
most NN O O
common NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
- NN I-Severity I-Severity
4 NN I-Severity I-Severity
adverse NN O O
reactions NN O O
( NN O O
incidence NN O O
>= NN O O
2 NN O O
% NN O O
) NN O O
were NN O O
stomatitis NN B-AdverseReaction B-AdverseReaction
pyrexia NN B-AdverseReaction B-AdverseReaction
pneumonia NN B-AdverseReaction B-AdverseReaction
gastroenteritis NN B-AdverseReaction B-AdverseReaction
aggression NN B-AdverseReaction B-AdverseReaction
agitation NN B-AdverseReaction B-AdverseReaction
and NN O O
amenorrhea NN B-AdverseReaction B-AdverseReaction
The NN O O
most NN O O
common NN O O
key NN O O
laboratory NN O O
abnormalities NN O O
( NN O O
incidence NN O O
>= NN O O
50 NN O O
% NN O O
) NN O O
were NN O O
hypercholesterolemia NN B-AdverseReaction B-AdverseReaction
and NN O O
elevated NN B-AdverseReaction B-AdverseReaction
partial NN I-AdverseReaction I-AdverseReaction
thromboplastin NN I-AdverseReaction I-AdverseReaction
time NN I-AdverseReaction I-AdverseReaction
The NN O O
most NN O O
common NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
- NN I-Severity I-Severity
4 NN I-Severity I-Severity
laboratory NN O O
abnormality NN O O
( NN O O
incidence NN O O
>= NN O O
3 NN O O
% NN O O
) NN O O
was NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
There NN O O
were NN O O
no NN O O
adverse NN O O
reactions NN O O
resulting NN O O
in NN O O
permanent NN O O
discontinuation NN O O
. NN O O
Dose NN O O
adjustments NN O O
( NN O O
interruptions NN O O
or NN O O
reductions NN O O
) NN O O
due NN O O
to NN O O
adverse NN O O
reactions NN O O
occurred NN O O
in NN O O
55 NN O O
% NN O O
of NN O O
AFINITOR NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reaction NN O O
leading NN O O
to NN O O
AFINITOR NN O O
dose NN O O
adjustment NN O O
was NN O O
stomatitis NN B-AdverseReaction B-AdverseReaction
Table NN O O
10 NN O O
compares NN O O
the NN O O
incidence NN O O
of NN O O
adverse NN O O
reactions NN O O
reported NN O O
with NN O O
an NN O O
incidence NN O O
of NN O O
>= NN O O
10 NN O O
% NN O O
for NN O O
patients NN O O
receiving NN O O
AFINITOR NN O O
and NN O O
occurring NN O O
more NN O O
frequently NN O O
with NN O O
AFINITOR NN O O
than NN O O
with NN O O
placebo NN O O
. NN O O
Laboratory NN O O
abnormalities NN O O
are NN O O
described NN O O
separately NN O O
in NN O O
Table NN O O
11 NN O O
. NN O O
Table NN O O
10 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Reported NN O O
in NN O O
>=10 NN O O
% NN O O
of NN O O
AFINITOR NN O O
- NN O O
treated NN O O
Patients NN O O
with NN O O
SEGA NN O O
in NN O O
Study NN O O
1 NN O O
Grading NN O O
according NN O O
to NN O O
CTCAE NN O O
Version NN O O
3.0 NN O O
a NN O O
Includes NN O O
mouth NN B-AdverseReaction B-AdverseReaction
ulceration NN I-AdverseReaction I-AdverseReaction
stomatitis NN B-AdverseReaction B-AdverseReaction
and NN O O
lip NN B-AdverseReaction B-AdverseReaction
ulceration NN I-AdverseReaction I-AdverseReaction
b NN O O
Includes NN O O
respiratory NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
and NN O O
respiratory NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
viral NN I-AdverseReaction I-AdverseReaction
c NN O O
Includes NN O O
gastroenteritis NN B-AdverseReaction B-AdverseReaction
gastroenteritis NN B-AdverseReaction B-AdverseReaction
viral NN I-AdverseReaction I-AdverseReaction
and NN O O
gastrointestinal NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
d NN O O
Includes NN O O
agitation NN B-AdverseReaction B-AdverseReaction
anxiety NN B-AdverseReaction B-AdverseReaction
panic NN B-AdverseReaction B-AdverseReaction
attack NN I-AdverseReaction I-AdverseReaction
aggression NN B-AdverseReaction B-AdverseReaction
abnormal NN B-AdverseReaction B-AdverseReaction
behavior NN I-AdverseReaction I-AdverseReaction
and NN O O
obsessive NN B-AdverseReaction B-AdverseReaction
compulsive NN I-AdverseReaction I-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
e NN O O
Includes NN O O
rash NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
generalized NN I-AdverseReaction I-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
macular NN I-AdverseReaction I-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
maculo NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
papular NN I-AdverseReaction I-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
papular NN I-AdverseReaction I-AdverseReaction
dermatitis NN B-AdverseReaction B-AdverseReaction
allergic NN I-AdverseReaction I-AdverseReaction
and NN O O
urticaria NN B-AdverseReaction B-AdverseReaction
AFINITOR NN O O
N=78 NN O O
Placebo NN O O
N=39 NN O O
All NN O O
grades NN O O
% NN O O
Grade NN O O
3 NN O O
% NN O O
Grade NN O O
4 NN O O
% NN O O
All NN O O
grades NN O O
% NN O O
Grade NN O O
3 NN O O
% NN O O
Grade NN O O
4 NN O O
% NN O O
Any NN O O
adverse NN O O
reaction NN O O
97 NN O O
36 NN O O
3 NN O O
92 NN O O
23 NN O O
3 NN O O
Gastrointestinal NN O O
disorders NN O O
Stomatitis NN B-AdverseReaction B-AdverseReaction
a NN O O
62 NN O O
9 NN O O
0 NN O O
26 NN O O
3 NN O O
0 NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
22 NN O O
1 NN O O
0 NN O O
13 NN O O
0 NN O O
0 NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
17 NN O O
0 NN O O
0 NN O O
5 NN O O
0 NN O O
0 NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
10 NN O O
0 NN O O
0 NN O O
3 NN O O
0 NN O O
0 NN O O
Infections NN O O
and NN O O
infestations NN O O
Respiratory NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
b NN O O
31 NN O O
1 NN O O
1 NN O O
23 NN O O
0 NN O O
0 NN O O
Gastroenteritis NN B-AdverseReaction B-AdverseReaction
c NN O O
10 NN O O
4 NN O O
1 NN O O
3 NN O O
0 NN O O
0 NN O O
Pharyngitis NN O O
streptococcal NN O O
10 NN O O
0 NN O O
0 NN O O
3 NN O O
0 NN O O
0 NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
23 NN O O
6 NN O O
0 NN O O
18 NN O O
3 NN O O
0 NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
14 NN O O
0 NN O O
0 NN O O
3 NN O O
0 NN O O
0 NN O O
Psychiatric NN O O
disorders NN O O
Anxiety NN B-AdverseReaction B-AdverseReaction
aggression NN B-AdverseReaction B-AdverseReaction
or NN O O
other NN O O
behavioral NN B-AdverseReaction B-AdverseReaction
disturbance NN I-AdverseReaction I-AdverseReaction
d NN O O
21 NN O O
5 NN O O
0 NN O O
3 NN O O
0 NN O O
0 NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
Rash NN B-AdverseReaction B-AdverseReaction
e NN O O
21 NN O O
0 NN O O
0 NN O O
8 NN O O
0 NN O O
0 NN O O
Acne NN B-AdverseReaction B-AdverseReaction
10 NN O O
0 NN O O
0 NN O O
5 NN O O
0 NN O O
0 NN O O
Amenorrhea NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
17 NN O O
% NN O O
of NN O O
AFINITOR NN O O
- NN O O
treated NN O O
females NN O O
aged NN O O
10 NN O O
to NN O O
55 NN O O
years NN O O
( NN O O
3 NN O O
of NN O O
18 NN O O
) NN O O
and NN O O
none NN O O
of NN O O
the NN O O
females NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
. NN O O
For NN O O
this NN O O
same NN O O
group NN O O
of NN O O
AFINITOR NN O O
- NN O O
treated NN O O
females NN O O
, NN O O
the NN O O
following NN O O
menstrual NN B-AdverseReaction B-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
: NN O O
dysmenorrhea NN B-AdverseReaction B-AdverseReaction
( NN O O
6 NN O O
% NN O O
) NN O O
, NN O O
menorrhagia NN B-AdverseReaction B-AdverseReaction
( NN O O
6 NN O O
% NN O O
) NN O O
, NN O O
metrorrhagia NN B-AdverseReaction B-AdverseReaction
( NN O O
6 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
unspecified NN B-AdverseReaction B-AdverseReaction
menstrual NN I-AdverseReaction I-AdverseReaction
irregularity NN I-AdverseReaction I-AdverseReaction
( NN O O
6 NN O O
% NN O O
) NN O O
. NN O O
The NN O O
following NN O O
additional NN O O
adverse NN O O
reactions NN O O
occurred NN O O
in NN O O
less NN O O
than NN O O
10 NN O O
% NN O O
of NN O O
AFINITOR NN O O
- NN O O
treated NN O O
patients NN O O
: NN O O
nausea NN B-AdverseReaction B-AdverseReaction
( NN O O
8 NN O O
% NN O O
) NN O O
, NN O O
pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
( NN O O
8 NN O O
% NN O O
) NN O O
, NN O O
insomnia NN B-AdverseReaction B-AdverseReaction
( NN O O
6 NN O O
% NN O O
) NN O O
, NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
( NN O O
6 NN O O
% NN O O
) NN O O
, NN O O
epistaxis NN B-AdverseReaction B-AdverseReaction
( NN O O
5 NN O O
% NN O O
) NN O O
, NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
, NN O O
increased NN O O
blood NN O O
luteinizing NN O O
hormone NN O O
( NN O O
LH NN O O
) NN O O
levels NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
and NN O O
pneumonitis NN B-AdverseReaction B-AdverseReaction
( NN O O
1 NN O O
% NN O O
) NN O O
. NN O O
Table NN O O
11 NN O O
: NN O O
Key NN O O
Laboratory NN O O
Abnormalities NN O O
Reported NN O O
in NN O O
AFINITOR NN O O
- NN O O
treated NN O O
Patients NN O O
with NN O O
SEGA NN O O
in NN O O
Study NN O O
1 NN O O
Grading NN O O
according NN O O
to NN O O
CTCAE NN O O
Version NN O O
3.0 NN O O
AFINITOR NN O O
N=78 NN O O
Placebo NN O O
N=39 NN O O
All NN O O
grades NN O O
% NN O O
Grade NN O O
3 NN O O
% NN O O
Grade NN O O
4 NN O O
% NN O O
All NN O O
grades NN O O
% NN O O
Grade NN O O
3 NN O O
% NN O O
Grade NN O O
4 NN O O
% NN O O
Hematology NN O O
Elevated NN B-AdverseReaction B-AdverseReaction
partial NN I-AdverseReaction I-AdverseReaction
thromboplastin NN I-AdverseReaction I-AdverseReaction
time NN I-AdverseReaction I-AdverseReaction
72 NN O O
3 NN O O
0 NN O O
44 NN O O
5 NN O O
0 NN O O
Neutropenia NN B-AdverseReaction B-AdverseReaction
46 NN O O
9 NN O O
0 NN O O
41 NN O O
3 NN O O
0 NN O O
Anemia NN B-AdverseReaction B-AdverseReaction
41 NN O O
0 NN O O
0 NN O O
21 NN O O
0 NN O O
0 NN O O
Clinical NN O O
chemistry NN O O
Hypercholesterolemia NN B-AdverseReaction B-AdverseReaction
81 NN O O
0 NN O O
0 NN O O
39 NN O O
0 NN O O
0 NN O O
Elevated NN B-AdverseReaction B-AdverseReaction
aspartate NN I-AdverseReaction I-AdverseReaction
transaminase NN I-AdverseReaction I-AdverseReaction
( NN O O
AST NN O O
) NN O O
33 NN O O
0 NN O O
0 NN O O
0 NN O O
0 NN O O
0 NN O O
Hypertriglyceridemia NN B-AdverseReaction B-AdverseReaction
27 NN O O
0 NN O O
0 NN O O
15 NN O O
0 NN O O
0 NN O O
Elevated NN B-AdverseReaction B-AdverseReaction
alanine NN I-AdverseReaction I-AdverseReaction
transaminase NN I-AdverseReaction I-AdverseReaction
( NN O O
ALT NN O O
) NN O O
18 NN O O
0 NN O O
0 NN O O
3 NN O O
0 NN O O
0 NN O O
Hypophosphatemia NN B-AdverseReaction B-AdverseReaction
9 NN O O
1 NN O O
0 NN O O
3 NN O O
0 NN O O
0 NN O O
Longer NN O O
- NN O O
term NN O O
follow NN O O
- NN O O
up NN O O
of NN O O
34.2 NN O O
months NN O O
( NN O O
range NN O O
4.7 NN O O
to NN O O
47.1 NN O O
months NN O O
) NN O O
from NN O O
a NN O O
non NN O O
- NN O O
randomized NN O O
, NN O O
open NN O O
- NN O O
label NN O O
, NN O O
28-patient NN O O
trial NN O O
resulted NN O O
in NN O O
the NN O O
following NN O O
additional NN O O
notable NN O O
adverse NN O O
reactions NN O O
and NN O O
key NN O O
laboratory NN O O
abnormalities NN O O
: NN O O
cellulitis NN B-AdverseReaction B-AdverseReaction
( NN O O
29 NN O O
% NN O O
) NN O O
, NN O O
hyperglycemia NN B-AdverseReaction B-AdverseReaction
( NN O O
25 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
elevated NN B-AdverseReaction B-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
( NN O O
14 NN O O
% NN O O
) NN O O
. NN O O
6.6 NN O O
Postmarketing NN O O
Experience NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
identified NN O O
during NN O O
post NN O O
approval NN O O
use NN O O
of NN O O
AFINITOR. NN O O
Because NN O O
these NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
: NN O O
acute NN B-AdverseReaction B-AdverseReaction
pancreatitis NN I-AdverseReaction I-AdverseReaction
cholecystitis NN B-AdverseReaction B-AdverseReaction
cholelithiasis NN B-AdverseReaction B-AdverseReaction
arterial NN B-AdverseReaction B-AdverseReaction
thrombotic NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
and NN O O
reflex NN B-AdverseReaction B-AdverseReaction
sympathetic NN I-AdverseReaction I-AdverseReaction
dystrophy NN I-AdverseReaction I-AdverseReaction
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Non NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
infectious NN I-AdverseReaction I-AdverseReaction
pneumonitis NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
for NN O O
clinical NN O O
symptoms NN O O
or NN O O
radiological NN O O
changes NN O O
; NN O O
fatal NN B-AdverseReaction B-AdverseReaction
cases NN O O
have NN O O
occurred NN O O
. NN O O
Manage NN O O
by NN O O
dose NN O O
reduction NN O O
or NN O O
discontinuation NN O O
until NN O O
symptoms NN O O
resolve NN O O
, NN O O
and NN O O
consider NN O O
use NN O O
of NN O O
corticosteroids NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Infections NN B-AdverseReaction B-AdverseReaction
Increased NN O O
risk NN B-Factor B-Factor
of NN O O
infections NN B-AdverseReaction B-AdverseReaction
some NN O O
fatal NN B-AdverseReaction B-AdverseReaction
Monitor NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
, NN O O
and NN O O
treat NN O O
promptly NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Angioedema NN B-AdverseReaction B-AdverseReaction
Patients NN O O
taking NN O O
concomitant NN O O
ACE NN O O
inhibitor NN O O
therapy NN O O
may NN O O
be NN O O
at NN O O
increased NN O O
risk NN O O
for NN O O
angioedema NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Oral NN B-AdverseReaction B-AdverseReaction
ulceration NN I-AdverseReaction I-AdverseReaction
Mouth NN B-AdverseReaction B-AdverseReaction
ulcers NN I-AdverseReaction I-AdverseReaction
stomatitis NN B-AdverseReaction B-AdverseReaction
and NN O O
oral NN B-AdverseReaction B-AdverseReaction
mucositis NN I-AdverseReaction I-AdverseReaction
are NN O O
common NN O O
. NN O O
Management NN O O
includes NN O O
mouthwashes NN O O
and NN O O
topical NN O O
treatments NN O O
. NN O O
( NN O O
5.4 NN O O
) NN O O
* NN O O
Renal NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
Cases NN O O
of NN O O
renal NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
( NN O O
including NN O O
acute NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
some NN O O
with NN O O
a NN O O
fatal NN B-AdverseReaction B-AdverseReaction
outcome NN O O
, NN O O
have NN O O
been NN O O
observed NN O O
. NN O O
( NN O O
5.5 NN O O
) NN O O
* NN O O
Impaired NN B-AdverseReaction B-AdverseReaction
wound NN I-AdverseReaction I-AdverseReaction
healing NN I-AdverseReaction I-AdverseReaction
Increased NN O O
risk NN B-Factor B-Factor
of NN O O
wound NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
complications NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
signs NN O O
and NN O O
symptoms NN O O
. NN O O
Exercise NN O O
caution NN O O
in NN O O
the NN O O
peri NN O O
- NN O O
surgical NN O O
period NN O O
. NN O O
( NN O O
5.6 NN O O
) NN O O
* NN O O
Laboratory NN O O
test NN O O
alterations NN O O
: NN O O
Elevations NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
urinary NN O O
protein NN O O
, NN O O
blood NN O O
glucose NN O O
, NN O O
and NN O O
lipids NN O O
may NN O O
occur NN O O
. NN O O
Decreases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
hemoglobin NN I-AdverseReaction I-AdverseReaction
neutrophils NN O O
, NN O O
and NN O O
platelets NN O O
may NN B-Factor B-Factor
also NN O O
occur NN O O
. NN O O
Monitor NN O O
renal NN O O
function NN O O
, NN O O
blood NN O O
glucose NN O O
, NN O O
lipids NN O O
, NN O O
and NN O O
hematologic NN O O
parameters NN O O
prior NN O O
to NN O O
treatment NN O O
and NN O O
periodically NN O O
thereafter NN O O
. NN O O
( NN O O
5.8 NN O O
) NN O O
* NN O O
Vaccinations NN O O
: NN O O
Avoid NN O O
live NN O O
vaccines NN O O
and NN O O
close NN O O
contact NN O O
with NN O O
those NN O O
who NN O O
have NN O O
received NN O O
live NN O O
vaccines NN O O
. NN O O
( NN O O
5.11 NN O O
) NN O O
* NN O O
Embryo NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
fetal NN I-AdverseReaction I-AdverseReaction
toxicity NN I-AdverseReaction I-AdverseReaction
Fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
when NN O O
administered NN O O
to NN O O
a NN O O
pregnant NN O O
woman NN O O
. NN O O
Apprise NN O O
women NN O O
of NN O O
potential NN O O
harm NN O O
to NN O O
the NN O O
fetus NN O O
. NN O O
( NN O O
5.12 NN O O
, NN O O
8.1 NN O O
) NN O O
5.1 NN O O
Non NN O O
- NN O O
infectious NN O O
Pneumonitis NN O O
Non NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
infectious NN I-AdverseReaction I-AdverseReaction
pneumonitis NN I-AdverseReaction I-AdverseReaction
is NN O O
a NN O O
class NN O O
effect NN O O
of NN O O
rapamycin NN O O
derivatives NN O O
, NN O O
including NN O O
AFINITOR. NN O O
Non NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
infectious NN I-AdverseReaction I-AdverseReaction
pneumonitis NN I-AdverseReaction I-AdverseReaction
was NN O O
reported NN O O
in NN O O
up NN O O
to NN O O
19 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
AFINITOR NN O O
in NN O O
clinical NN O O
trials NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
Common NN O O
Terminology NN O O
Criteria NN O O
( NN O O
CTC NN O O
) NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
and NN O O
4 NN O O
non NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
infectious NN I-AdverseReaction I-AdverseReaction
pneumonitis NN I-AdverseReaction I-AdverseReaction
was NN O O
up NN O O
to NN O O
4.0 NN O O
% NN O O
and NN O O
up NN O O
to NN O O
0.2 NN O O
% NN O O
, NN O O
respectively NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
, NN O O
6.2 NN O O
, NN O O
6.3 NN O O
, NN O O
6.4 NN O O
, NN O O
6.5 NN O O
) NN O O
] NN O O
. NN O O
Fatal NN B-AdverseReaction B-AdverseReaction
outcomes NN O O
have NN O O
been NN O O
observed NN O O
. NN O O
Consider NN B-Factor B-Factor
a NN O O
diagnosis NN O O
of NN O O
non NN O O
- NN O O
infectious NN O O
pneumonitis NN O O
in NN O O
patients NN O O
presenting NN O O
with NN O O
non NN O O
- NN O O
specific NN O O
respiratory NN O O
signs NN O O
and NN O O
symptoms NN O O
such NN O O
as NN O O
hypoxia NN O O
, NN O O
pleural NN O O
effusion NN O O
, NN O O
cough NN O O
, NN O O
or NN O O
dyspnea NN O O
, NN O O
and NN O O
in NN O O
whom NN O O
infectious NN O O
, NN O O
neoplastic NN O O
, NN O O
and NN O O
other NN O O
causes NN O O
have NN O O
been NN O O
excluded NN O O
by NN O O
means NN O O
of NN O O
appropriate NN O O
investigations NN O O
. NN O O
Opportunistic NN O O
infections NN O O
such NN O O
as NN O O
pneumocystis NN O O
jiroveci NN O O
pneumonia NN O O
( NN O O
PJP NN O O
) NN O O
should NN O O
be NN O O
considered NN O O
in NN O O
the NN O O
differential NN O O
diagnosis NN O O
. NN O O
Advise NN O O
patients NN O O
to NN O O
report NN O O
promptly NN O O
any NN O O
new NN O O
or NN O O
worsening NN O O
respiratory NN O O
symptoms NN O O
. NN O O
Patients NN O O
who NN O O
develop NN O O
radiological NN O O
changes NN O O
suggestive NN O O
of NN O O
non NN O O
- NN O O
infectious NN O O
pneumonitis NN O O
and NN O O
have NN O O
few NN O O
or NN O O
no NN O O
symptoms NN O O
may NN O O
continue NN O O
AFINITOR NN O O
therapy NN O O
without NN O O
dose NN O O
alteration NN O O
. NN O O
Imaging NN O O
appears NN O O
to NN O O
overestimate NN O O
the NN O O
incidence NN O O
of NN O O
clinical NN O O
pneumonitis NN O O
. NN O O
If NN O O
symptoms NN O O
are NN O O
moderate NN O O
, NN O O
consider NN O O
interrupting NN O O
therapy NN O O
until NN O O
symptoms NN O O
improve NN O O
. NN O O
The NN O O
use NN O O
of NN O O
corticosteroids NN O O
may NN O O
be NN O O
indicated NN B-Factor B-Factor
AFINITOR NN O O
may NN O O
be NN O O
reintroduced NN O O
at NN O O
a NN O O
daily NN O O
dose NN O O
approximately NN O O
50 NN O O
% NN O O
lower NN O O
than NN O O
the NN O O
dose NN O O
previously NN O O
administered NN O O
[ NN O O
see NN O O
Table NN O O
1 NN O O
in NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
] NN O O
. NN O O
For NN O O
cases NN O O
of NN O O
Grade NN O O
3 NN O O
non NN O O
- NN O O
infectious NN O O
pneumonitis NN O O
interrupt NN O O
AFINITOR NN O O
until NN O O
resolution NN O O
to NN O O
less NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
Grade NN O O
1 NN O O
. NN O O
AFINITOR NN O O
may NN O O
be NN O O
re NN O O
- NN O O
introduced NN O O
at NN O O
a NN O O
daily NN O O
dose NN O O
approximately NN O O
50 NN O O
% NN O O
lower NN O O
than NN O O
the NN O O
dose NN O O
previously NN O O
administered NN O O
depending NN O O
on NN O O
the NN O O
individual NN O O
clinical NN O O
circumstances NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
] NN O O
. NN O O
If NN O O
toxicity NN O O
recurs NN O O
at NN O O
Grade NN O O
3 NN O O
, NN O O
consider NN O O
discontinuation NN O O
of NN O O
AFINITOR. NN O O
For NN O O
cases NN O O
of NN O O
Grade NN O O
4 NN O O
non NN O O
- NN O O
infectious NN O O
pneumonitis NN O O
, NN O O
discontinue NN O O
AFINITOR. NN O O
Corticosteroids NN O O
may NN O O
be NN O O
indicated NN O O
until NN O O
clinical NN O O
symptoms NN O O
resolve NN O O
. NN O O
For NN O O
patients NN O O
who NN O O
require NN O O
use NN O O
of NN O O
corticosteroids NN O O
for NN O O
treatment NN O O
of NN O O
non NN O O
- NN O O
infectious NN O O
pneumonitis NN O O
, NN O O
prophylaxis NN O O
for NN O O
PJP NN O O
may NN O O
be NN O O
considered NN O O
. NN O O
The NN O O
development NN O O
of NN O O
pneumonitis NN B-AdverseReaction B-AdverseReaction
has NN O O
been NN O O
reported NN O O
even NN O O
at NN O O
a NN O O
reduced NN O O
dose NN O O
. NN O O
5.2 NN O O
Infections NN O O
AFINITOR NN O O
has NN O O
immunosuppressive NN O O
properties NN O O
and NN O O
may NN B-Factor B-Factor
predispose NN O O
patients NN O O
to NN O O
bacterial NN O O
, NN O O
fungal NN O O
, NN O O
viral NN O O
, NN O O
or NN O O
protozoal NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
including NN O O
infections NN B-AdverseReaction B-AdverseReaction
with NN I-AdverseReaction I-AdverseReaction
opportunistic NN I-AdverseReaction I-AdverseReaction
pathogens NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
, NN O O
6.2 NN O O
, NN O O
6.3 NN O O
, NN O O
6.4 NN O O
, NN O O
6.5 NN O O
) NN O O
] NN O O
. NN O O
Localized NN O O
and NN O O
systemic NN O O
infections NN O O
, NN O O
including NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
mycobacterial NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
other NN O O
bacterial NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
invasive NN B-AdverseReaction B-AdverseReaction
fungal NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
such NN O O
as NN O O
aspergillosis NN B-AdverseReaction B-AdverseReaction
candidiasis NN B-AdverseReaction B-AdverseReaction
or NN O O
pneumocystis NN B-AdverseReaction B-AdverseReaction
jiroveci NN I-AdverseReaction I-AdverseReaction
pneumonia NN I-AdverseReaction I-AdverseReaction
( NN O O
PJP NN O O
) NN O O
and NN O O
viral NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
including NN O O
reactivation NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
hepatitis NN I-AdverseReaction I-AdverseReaction
B NN I-AdverseReaction I-AdverseReaction
virus NN I-AdverseReaction I-AdverseReaction
have NN O O
occurred NN O O
in NN O O
patients NN O O
taking NN O O
AFINITOR. NN O O
Some NN O O
of NN O O
these NN O O
infections NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
severe NN B-Severity B-Severity
( NN O O
e.g. NN O O
, NN O O
leading NN O O
to NN O O
sepsis NN B-AdverseReaction B-AdverseReaction
respiratory NN O O
or NN O O
hepatic NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
or NN O O
fatal NN B-AdverseReaction B-AdverseReaction
Physicians NN O O
and NN O O
patients NN O O
should NN O O
be NN O O
aware NN O O
of NN O O
the NN O O
increased NN O O
risk NN O O
of NN O O
infection NN O O
with NN O O
AFINITOR. NN O O
Complete NN O O
treatment NN O O
of NN O O
pre NN O O
- NN O O
existing NN O O
invasive NN O O
fungal NN O O
infections NN O O
prior NN O O
to NN O O
starting NN O O
treatment NN O O
with NN O O
AFINITOR. NN O O
While NN O O
taking NN O O
AFINITOR NN O O
, NN O O
be NN O O
vigilant NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
infection NN O O
; NN O O
if NN O O
a NN O O
diagnosis NN O O
of NN O O
an NN O O
infection NN O O
is NN O O
made NN O O
, NN O O
institute NN O O
appropriate NN O O
treatment NN O O
promptly NN O O
and NN O O
consider NN O O
interruption NN O O
or NN O O
discontinuation NN O O
of NN O O
AFINITOR. NN O O
If NN O O
a NN O O
diagnosis NN O O
of NN O O
invasive NN O O
systemic NN O O
fungal NN O O
infection NN O O
is NN O O
made NN O O
, NN O O
discontinue NN O O
AFINITOR NN O O
and NN O O
treat NN O O
with NN O O
appropriate NN O O
antifungal NN O O
therapy NN O O
. NN O O
Pneumocystis NN B-AdverseReaction B-AdverseReaction
jiroveci NN I-AdverseReaction I-AdverseReaction
pneumonia NN I-AdverseReaction I-AdverseReaction
some NN O O
with NN O O
a NN O O
fatal NN B-AdverseReaction B-AdverseReaction
outcome NN O O
, NN O O
has NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
who NN O O
received NN O O
everolimus NN O O
. NN O O
This NN O O
may NN O O
be NN O O
associated NN O O
with NN O O
concomitant NN O O
use NN O O
of NN O O
corticosteroids NN O O
or NN O O
other NN O O
immunosuppressive NN O O
agents NN O O
. NN O O
Prophylaxis NN O O
for NN O O
PJP NN O O
should NN O O
be NN O O
considered NN O O
when NN O O
concomitant NN O O
use NN O O
of NN O O
corticosteroids NN O O
or NN O O
other NN O O
immunosuppressive NN O O
agents NN O O
are NN O O
required NN O O
. NN O O
5.3 NN O O
Angioedema NN O O
with NN O O
Concomitant NN O O
Use NN O O
of NN O O
Angiotensin NN O O
- NN O O
Converting NN O O
Enzyme NN O O
( NN O O
ACE NN O O
) NN O O
Inhibitors NN O O
Patients NN O O
taking NN O O
concomitant NN O O
ACE NN O O
inhibitor NN O O
therapy NN O O
may NN O O
be NN O O
at NN O O
increased NN O O
risk NN B-Factor B-Factor
for NN O O
angioedema NN B-AdverseReaction B-AdverseReaction
( NN O O
e.g. NN O O
, NN O O
swelling NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
airways NN I-AdverseReaction I-AdverseReaction
or NN O O
tongue NN O O
, NN O O
with NN O O
or NN O O
without NN O O
respiratory NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
In NN O O
a NN O O
pooled NN O O
analysis NN O O
of NN O O
randomized NN O O
double NN O O
- NN O O
blind NN O O
oncology NN O O
clinical NN O O
trials NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
angioedema NN B-AdverseReaction B-AdverseReaction
in NN O O
patients NN O O
taking NN O O
everolimus NN O O
with NN O O
an NN O O
ACE NN O O
inhibitor NN O O
was NN O O
6.8 NN O O
% NN O O
compared NN O O
to NN O O
1.3 NN O O
% NN O O
in NN O O
the NN O O
control NN O O
arm NN O O
with NN O O
an NN O O
ACE NN O O
inhibitor NN O O
. NN O O
5.4 NN O O
Oral NN O O
Ulceration NN O O
Mouth NN B-AdverseReaction B-AdverseReaction
ulcers NN I-AdverseReaction I-AdverseReaction
stomatitis NN B-AdverseReaction B-AdverseReaction
and NN O O
oral NN B-AdverseReaction B-AdverseReaction
mucositis NN I-AdverseReaction I-AdverseReaction
have NN O O
occurred NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
AFINITOR NN O O
at NN O O
an NN O O
incidence NN O O
ranging NN O O
from NN O O
44%-78 NN O O
% NN O O
across NN O O
the NN O O
clinical NN O O
trial NN O O
experience NN O O
. NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
or NN O O
4 NN O O
stomatitis NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
4%-9 NN O O
% NN O O
of NN O O
patients NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
, NN O O
6.2 NN O O
, NN O O
6.3 NN O O
, NN O O
6.4 NN O O
, NN O O
6.5 NN O O
) NN O O
] NN O O
. NN O O
In NN O O
such NN O O
cases NN O O
, NN O O
topical NN O O
treatments NN O O
are NN O O
recommended NN O O
, NN O O
but NN O O
alcohol- NN O O
, NN O O
hydrogen NN O O
peroxide- NN O O
, NN O O
iodine- NN O O
, NN O O
or NN O O
thyme- NN O O
containing NN O O
mouthwashes NN O O
should NN O O
be NN O O
avoided NN O O
as NN O O
they NN O O
may NN O O
exacerbate NN O O
the NN O O
condition NN O O
. NN O O
Antifungal NN O O
agents NN O O
should NN O O
not NN O O
be NN O O
used NN O O
unless NN O O
fungal NN O O
infection NN O O
has NN O O
been NN O O
diagnosed NN O O
[ NN O O
see NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.1 NN O O
) NN O O
] NN O O
. NN O O
5.5 NN O O
Renal NN O O
Failure NN O O
Cases NN O O
of NN O O
renal NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
( NN O O
including NN O O
acute NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
some NN O O
with NN O O
a NN O O
fatal NN B-AdverseReaction B-AdverseReaction
outcome NN O O
, NN O O
have NN O O
been NN O O
observed NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
AFINITOR NN O O
[ NN O O
see NN O O
Laboratory NN O O
Tests NN O O
and NN O O
Monitoring NN O O
( NN O O
5.8 NN O O
) NN O O
] NN O O
. NN O O
5.6 NN O O
Impaired NN O O
Wound NN O O
Healing NN O O
Everolimus NN O O
delays NN B-AdverseReaction B-AdverseReaction
wound NN I-AdverseReaction I-AdverseReaction
healing NN I-AdverseReaction I-AdverseReaction
and NN O O
increases NN O O
the NN O O
occurrence NN O O
of NN O O
wound NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
complications NN I-AdverseReaction I-AdverseReaction
like NN O O
wound NN B-AdverseReaction B-AdverseReaction
dehiscence NN I-AdverseReaction I-AdverseReaction
wound NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
incisional NN B-AdverseReaction B-AdverseReaction
hernia NN I-AdverseReaction I-AdverseReaction
lymphocele NN B-AdverseReaction B-AdverseReaction
and NN O O
seroma NN B-AdverseReaction B-AdverseReaction
These NN O O
wound NN O O
- NN O O
related NN O O
complications NN O O
may NN O O
require NN O O
surgical NN O O
intervention NN O O
. NN O O
Exercise NN O O
caution NN O O
with NN O O
the NN O O
use NN O O
of NN O O
AFINITOR NN O O
in NN O O
the NN O O
peri NN O O
- NN O O
surgical NN O O
period NN O O
. NN O O
5.7 NN O O
Geriatric NN O O
Patients NN O O
In NN O O
the NN O O
randomized NN O O
advanced NN O O
hormone NN O O
receptor NN O O
- NN O O
positive NN O O
, NN O O
HER2-negative NN O O
breast NN O O
cancer NN O O
study NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
deaths NN B-AdverseReaction B-AdverseReaction
due NN O O
to NN O O
any NN O O
cause NN O O
within NN O O
28 NN O O
days NN O O
of NN O O
the NN O O
last NN O O
AFINITOR NN O O
dose NN O O
was NN O O
6 NN O O
% NN O O
in NN O O
patients NN O O
>= NN O O
65 NN O O
years NN O O
of NN O O
age NN O O
compared NN O O
to NN O O
2 NN O O
% NN O O
in NN O O
patients NN O O
< NN O O
65 NN O O
years NN O O
of NN O O
age NN O O
. NN O O
Adverse NN O O
reactions NN O O
leading NN O O
to NN O O
permanent NN O O
treatment NN O O
discontinuation NN O O
occurred NN O O
in NN O O
33 NN O O
% NN O O
of NN O O
patients NN O O
>= NN O O
65 NN O O
years NN O O
of NN O O
age NN O O
compared NN O O
to NN O O
17 NN O O
% NN O O
in NN O O
patients NN O O
< NN O O
65 NN O O
years NN O O
of NN O O
age NN O O
. NN O O
Careful NN O O
monitoring NN O O
and NN O O
appropriate NN O O
dose NN O O
adjustments NN O O
for NN O O
adverse NN O O
reactions NN O O
are NN O O
recommended NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
, NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.5 NN O O
) NN O O
] NN O O
. NN O O
5.8 NN O O
Laboratory NN O O
Tests NN O O
and NN O O
Monitoring NN O O
Renal NN O O
Function NN O O
Elevations NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
and NN O O
proteinuria NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
taking NN O O
AFINITOR NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
, NN O O
6.2 NN O O
, NN O O
6.3 NN O O
, NN O O
6.4 NN O O
, NN O O
6.5 NN O O
) NN O O
] NN O O
. NN O O
Monitoring NN O O
of NN O O
renal NN O O
function NN O O
, NN O O
including NN O O
measurement NN O O
of NN O O
blood NN O O
urea NN O O
nitrogen NN O O
( NN O O
BUN NN O O
) NN O O
, NN O O
urinary NN O O
protein NN O O
, NN O O
or NN O O
serum NN O O
creatinine NN O O
, NN O O
is NN O O
recommended NN O O
prior NN O O
to NN O O
the NN O O
start NN O O
of NN O O
AFINITOR NN O O
therapy NN O O
and NN O O
periodically NN O O
thereafter NN O O
. NN O O
Renal NN O O
function NN O O
of NN O O
patients NN O O
should NN O O
be NN O O
monitored NN O O
particularly NN O O
where NN O O
patients NN O O
have NN O O
additional NN O O
risk NN O O
factors NN O O
that NN O O
may NN O O
further NN O O
impair NN O O
renal NN O O
function NN O O
. NN O O
Blood NN O O
Glucose NN O O
and NN O O
Lipids NN O O
Hyperglycemia NN B-AdverseReaction B-AdverseReaction
hyperlipidemia NN B-AdverseReaction B-AdverseReaction
and NN O O
hypertriglyceridemia NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
taking NN O O
AFINITOR NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
, NN O O
6.2 NN O O
, NN O O
6.3 NN O O
, NN O O
6.4 NN O O
, NN O O
6.5 NN O O
) NN O O
] NN O O
. NN O O
Monitoring NN O O
of NN O O
fasting NN O O
serum NN O O
glucose NN O O
and NN O O
lipid NN O O
profile NN O O
is NN O O
recommended NN O O
prior NN O O
to NN O O
the NN O O
start NN O O
of NN O O
AFINITOR NN O O
therapy NN O O
and NN O O
periodically NN O O
thereafter NN O O
as NN O O
well NN O O
as NN O O
management NN O O
with NN O O
appropriate NN O O
medical NN O O
therapy NN O O
. NN O O
More NN O O
frequent NN O O
monitoring NN O O
is NN O O
recommended NN O O
when NN O O
AFINITOR NN O O
is NN O O
co NN O O
- NN O O
administered NN O O
with NN O O
other NN O O
drugs NN O O
that NN O O
may NN O O
induce NN O O
hyperglycemia NN O O
. NN O O
When NN O O
possible NN O O
, NN O O
optimal NN O O
glucose NN O O
and NN O O
lipid NN O O
control NN O O
should NN O O
be NN O O
achieved NN O O
before NN O O
starting NN O O
a NN O O
patient NN O O
on NN O O
AFINITOR. NN O O
Hematologic NN O O
Parameters NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
hemoglobin NN I-AdverseReaction I-AdverseReaction
lymphocytes NN O O
, NN O O
neutrophils NN O O
, NN O O
and NN O O
platelets NN O O
have NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
taking NN O O
AFINITOR NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
, NN O O
6.2 NN O O
, NN O O
6.3 NN O O
, NN O O
6.4 NN O O
, NN O O
6.5 NN O O
) NN O O
] NN O O
. NN O O
Monitoring NN O O
of NN O O
complete NN O O
blood NN O O
count NN O O
is NN O O
recommended NN O O
prior NN O O
to NN O O
the NN O O
start NN O O
of NN O O
AFINITOR NN O O
therapy NN O O
and NN O O
periodically NN O O
thereafter NN O O
. NN O O
5.9 NN O O
Drug NN O O
- NN O O
drug NN O O
Interactions NN O O
Due NN O O
to NN O O
significant NN O O
increases NN O O
in NN O O
exposure NN O O
of NN O O
everolimus NN O O
, NN O O
co NN O O
- NN O O
administration NN O O
with NN O O
strong NN O O
CYP3A4/PgP NN O O
inhibitors NN O O
should NN O O
be NN O O
avoided NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
, NN O O
2.5 NN O O
) NN O O
and NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.1 NN O O
) NN O O
] NN O O
. NN O O
A NN O O
reduction NN O O
of NN O O
the NN O O
AFINITOR NN O O
dose NN O O
is NN O O
recommended NN O O
when NN O O
co NN O O
- NN O O
administered NN O O
with NN O O
a NN O O
moderate NN O O
CYP3A4/PgP NN O O
inhibitor NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
, NN O O
2.5 NN O O
) NN O O
and NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.1 NN O O
) NN O O
] NN O O
. NN O O
An NN O O
increase NN O O
in NN O O
the NN O O
AFINITOR NN O O
dose NN O O
is NN O O
recommended NN O O
when NN O O
co NN O O
- NN O O
administered NN O O
with NN O O
a NN O O
strong NN O O
CYP3A4/PgP NN O O
inducer NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
, NN O O
2.5 NN O O
) NN O O
and NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.2 NN O O
) NN O O
] NN O O
. NN O O
5.10 NN O O
Hepatic NN O O
Impairment NN O O
Exposure NN O O
to NN O O
everolimus NN O O
was NN O O
increased NN O O
in NN O O
patients NN O O
with NN O O
hepatic NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.3 NN O O
) NN O O
] NN O O
. NN O O
For NN O O
advanced NN O O
HR+ NN O O
BC NN O O
, NN O O
advanced NN O O
PNET NN O O
, NN O O
advanced NN O O
RCC NN O O
, NN O O
and NN O O
renal NN O O
angiomyolipoma NN O O
with NN O O
TSC NN O O
patients NN O O
with NN O O
severe NN B-Severity B-Severity
hepatic NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
( NN O O
Child NN O O
- NN O O
Pugh NN O O
class NN O O
C NN O O
) NN O O
, NN O O
AFINITOR NN O O
may NN O O
be NN O O
used NN O O
at NN O O
a NN O O
reduced NN O O
dose NN O O
if NN O O
the NN O O
desired NN O O
benefit NN O O
outweighs NN O O
the NN O O
risk NN O O
. NN O O
For NN O O
patients NN O O
with NN O O
mild NN O O
( NN O O
Child NN O O
- NN O O
Pugh NN O O
class NN O O
A NN O O
) NN O O
or NN O O
moderate NN O O
( NN O O
Child NN O O
- NN O O
Pugh NN O O
class NN O O
B NN O O
) NN O O
hepatic NN O O
impairment NN O O
, NN O O
a NN O O
dose NN O O
reduction NN O O
is NN O O
recommended NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
and NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.3 NN O O
) NN O O
] NN O O
. NN O O
For NN O O
patients NN O O
with NN O O
SEGA NN O O
and NN O O
mild NN O O
or NN O O
moderate NN O O
hepatic NN O O
impairment NN O O
, NN O O
adjust NN O O
the NN O O
dose NN O O
of NN O O
AFINITOR NN O O
Tablets NN O O
or NN O O
AFINITOR NN O O
DISPERZ NN O O
based NN O O
on NN O O
therapeutic NN O O
drug NN O O
monitoring NN O O
. NN O O
For NN O O
patients NN O O
with NN O O
SEGA NN O O
and NN O O
severe NN O O
hepatic NN O O
impairment NN O O
, NN O O
reduce NN O O
the NN O O
starting NN O O
dose NN O O
of NN O O
AFINITOR NN O O
Tablets NN O O
or NN O O
AFINITOR NN O O
DISPERZ NN O O
by NN O O
approximately NN O O
50 NN O O
% NN O O
and NN O O
adjust NN O O
subsequent NN O O
doses NN O O
based NN O O
on NN O O
therapeutic NN O O
drug NN O O
monitoring NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.4 NN O O
, NN O O
2.5 NN O O
) NN O O
] NN O O
. NN O O
5.11 NN O O
Vaccinations NN O O
During NN O O
AFINITOR NN O O
treatment NN O O
, NN O O
avoid NN O O
the NN O O
use NN O O
of NN O O
live NN O O
vaccines NN O O
and NN O O
avoid NN O O
close NN O O
contact NN O O
with NN O O
individuals NN O O
who NN O O
have NN O O
received NN O O
live NN O O
vaccines NN O O
( NN O O
e.g. NN O O
, NN O O
intranasal NN O O
influenza NN O O
, NN O O
measles NN O O
, NN O O
mumps NN O O
, NN O O
rubella NN O O
, NN O O
oral NN O O
polio NN O O
, NN O O
BCG NN O O
, NN O O
yellow NN O O
fever NN O O
, NN O O
varicella NN O O
, NN O O
and NN O O
TY21a NN O O
typhoid NN O O
vaccines NN O O
) NN O O
. NN O O
For NN O O
pediatric NN O O
patients NN O O
with NN O O
SEGA NN O O
that NN O O
do NN O O
not NN O O
require NN O O
immediate NN O O
treatment NN O O
, NN O O
complete NN O O
the NN O O
recommended NN O O
childhood NN O O
series NN O O
of NN O O
live NN O O
virus NN O O
vaccinations NN O O
according NN O O
to NN O O
American NN O O
Council NN O O
on NN O O
Immunization NN O O
Practices NN O O
( NN O O
ACIP NN O O
) NN O O
guidelines NN O O
prior NN O O
to NN O O
the NN O O
start NN O O
of NN O O
therapy NN O O
. NN O O
An NN O O
accelerated NN O O
vaccination NN O O
schedule NN O O
may NN O O
be NN O O
appropriate NN O O
. NN O O
5.12 NN O O
Embryo NN O O
- NN O O
fetal NN O O
Toxicity NN O O
Based NN O O
on NN O O
the NN O O
mechanism NN O O
of NN O O
action NN O O
, NN O O
AFINITOR NN O O
can NN B-Factor B-Factor
cause NN O O
fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
Everolimus NN O O
caused NN O O
embryo NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
fetal NN I-AdverseReaction I-AdverseReaction
toxicities NN I-AdverseReaction I-AdverseReaction
in NN O O
animals NN B-Animal B-Animal
at NN O O
maternal NN O O
exposures NN O O
that NN O O
were NN O O
lower NN O O
than NN O O
human NN O O
exposures NN O O
. NN O O
If NN O O
this NN O O
drug NN O O
is NN O O
used NN O O
during NN O O
pregnancy NN O O
or NN O O
if NN O O
the NN O O
patient NN O O
becomes NN O O
pregnant NN O O
while NN O O
taking NN O O
this NN O O
drug NN O O
, NN O O
the NN O O
patient NN O O
should NN O O
be NN O O
apprised NN O O
of NN O O
the NN O O
potential NN O O
hazard NN O O
to NN O O
a NN O O
fetus NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.1 NN O O
) NN O O
] NN O O
. NN O O
Advise NN O O
female NN O O
patients NN O O
of NN O O
reproductive NN O O
potential NN O O
to NN O O
avoid NN O O
becoming NN O O
pregnant NN O O
and NN O O
to NN O O
use NN O O
highly NN O O
effective NN O O
contraception NN O O
while NN O O
using NN O O
AFINITOR NN O O
and NN O O
for NN O O
up NN O O
to NN O O
8 NN O O
weeks NN O O
after NN O O
ending NN O O
treatment NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.6 NN O O
) NN O O
] NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
in NN O O
adults NN O O
( NN O O
>30 NN O O
% NN O O
) NN O O
are NN O O
headache NN B-AdverseReaction B-AdverseReaction
anorexia NN B-AdverseReaction B-AdverseReaction
dizziness NN B-AdverseReaction B-AdverseReaction
asthenia NN B-AdverseReaction B-AdverseReaction
arthralgia NN B-AdverseReaction B-AdverseReaction
and NN O O
myalgia NN B-AdverseReaction B-AdverseReaction
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
in NN O O
children NN O O
( NN O O
>12 NN O O
% NN O O
) NN O O
are NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
anorexia NN B-AdverseReaction B-AdverseReaction
and NN O O
headache NN B-AdverseReaction B-AdverseReaction
( NN O O
6.2 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Novartis NN O O
Pharmaceuticals NN O O
Corporation NN O O
at NN O O
1 NN O O
- NN O O
888 NN O O
- NN O O
669 NN O O
- NN O O
6682 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
6.1 NN O O
Serious NN O O
Adverse NN O O
Reactions NN O O
The NN O O
following NN O O
serious NN O O
and NN O O
otherwise NN O O
important NN O O
adverse NN O O
reactions NN O O
are NN O O
discussed NN O O
in NN O O
greater NN O O
detail NN O O
in NN O O
other NN O O
sections NN O O
of NN O O
labeling NN O O
: NN O O
* NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
and NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.3 NN O O
) NN O O
] NN O O
. NN O O
6.2 NN O O
Clinical NN O O
Studies NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rate NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
The NN O O
data NN O O
described NN O O
below NN O O
reflect NN O O
exposure NN O O
to NN O O
a NN O O
6-dose NN O O
regimen NN O O
of NN O O
Coartem NN O O
Tablets NN O O
in NN O O
1,979 NN O O
patients NN O O
including NN O O
647 NN O O
adults NN O O
( NN O O
older NN O O
than NN O O
16 NN O O
years NN O O
) NN O O
and NN O O
1,332 NN O O
children NN O O
( NN O O
16 NN O O
years NN O O
and NN O O
younger NN O O
) NN O O
. NN O O
For NN O O
the NN O O
6-dose NN O O
regimen NN O O
, NN O O
Coartem NN O O
Tablets NN O O
was NN O O
studied NN O O
in NN O O
active NN O O
- NN O O
controlled NN O O
( NN O O
366 NN O O
patients NN O O
) NN O O
and NN O O
non NN O O
- NN O O
controlled NN O O
, NN O O
open NN O O
- NN O O
label NN O O
trials NN O O
( NN O O
1,613 NN O O
patients NN O O
) NN O O
. NN O O
The NN O O
6-dose NN O O
Coartem NN O O
Tablets NN O O
population NN O O
was NN O O
patients NN O O
with NN O O
malaria NN O O
between NN O O
ages NN O O
2 NN O O
months NN O O
and NN O O
71 NN O O
years NN O O
: NN O O
67 NN O O
% NN O O
( NN O O
1,332 NN O O
) NN O O
were NN O O
16 NN O O
years NN O O
and NN O O
younger NN O O
and NN O O
33 NN O O
% NN O O
( NN O O
647 NN O O
) NN O O
were NN O O
older NN O O
than NN O O
16 NN O O
years NN O O
. NN O O
Males NN O O
represented NN O O
73 NN O O
% NN O O
and NN O O
53 NN O O
% NN O O
of NN O O
the NN O O
adult NN O O
and NN O O
pediatric NN O O
populations NN O O
, NN O O
respectively NN O O
. NN O O
The NN O O
majority NN O O
of NN O O
adult NN O O
patients NN O O
were NN O O
enrolled NN O O
in NN O O
studies NN O O
in NN O O
Thailand NN O O
, NN O O
while NN O O
the NN O O
majority NN O O
of NN O O
pediatric NN O O
patients NN O O
were NN O O
enrolled NN O O
in NN O O
Africa NN O O
. NN O O
Tables NN O O
1 NN O O
and NN O O
2 NN O O
show NN O O
the NN O O
most NN O O
frequently NN O O
reported NN O O
adverse NN O O
reactions NN O O
( NN O O
>=3 NN O O
% NN O O
) NN O O
in NN O O
adults NN O O
and NN O O
children NN O O
respectively NN O O
who NN O O
received NN O O
the NN O O
6-dose NN O O
regimen NN O O
of NN O O
Coartem NN O O
Tablets NN O O
. NN O O
Adverse NN O O
reactions NN O O
collected NN O O
in NN O O
clinical NN O O
trials NN O O
included NN O O
signs NN O O
and NN O O
symptoms NN O O
at NN O O
baseline NN O O
but NN O O
only NN O O
treatment NN O O
emergent NN O O
adverse NN O O
events NN O O
, NN O O
defined NN O O
as NN O O
events NN O O
that NN O O
appeared NN O O
or NN O O
worsened NN O O
after NN O O
the NN O O
start NN O O
of NN O O
treatment NN O O
, NN O O
are NN O O
presented NN O O
below NN O O
. NN O O
In NN O O
adults NN O O
, NN O O
the NN O O
most NN O O
frequently NN O O
reported NN O O
adverse NN O O
reactions NN O O
were NN O O
headache NN B-AdverseReaction B-AdverseReaction
anorexia NN B-AdverseReaction B-AdverseReaction
dizziness NN B-AdverseReaction B-AdverseReaction
and NN O O
asthenia NN B-AdverseReaction B-AdverseReaction
In NN O O
children NN O O
, NN O O
the NN O O
adverse NN O O
reactions NN O O
were NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
anorexia NN B-AdverseReaction B-AdverseReaction
and NN O O
headache NN B-AdverseReaction B-AdverseReaction
Most NN O O
adverse NN O O
reactions NN O O
were NN O O
mild NN O O
, NN O O
did NN O O
not NN O O
lead NN O O
to NN O O
discontinuation NN O O
of NN O O
study NN O O
medication NN O O
, NN O O
and NN O O
resolved NN O O
. NN O O
In NN O O
limited NN O O
comparative NN O O
studies NN O O
, NN O O
the NN O O
adverse NN O O
reaction NN O O
profile NN O O
of NN O O
Coartem NN O O
Tablets NN O O
appeared NN O O
similar NN O O
to NN O O
that NN O O
of NN O O
another NN O O
antimalarial NN O O
regimen NN O O
. NN O O
Discontinuation NN O O
of NN O O
Coartem NN O O
Tablets NN O O
due NN O O
to NN O O
adverse NN O O
drug NN O O
reactions NN O O
occurred NN O O
in NN O O
1.1 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
the NN O O
6-dose NN O O
regimen NN O O
overall NN O O
: NN O O
0.2 NN O O
% NN O O
( NN O O
1/647 NN O O
) NN O O
in NN O O
adults NN O O
and NN O O
1.6 NN O O
% NN O O
( NN O O
21/1,332 NN O O
) NN O O
in NN O O
children NN O O
. NN O O
Table NN O O
1 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Occurring NN O O
in NN O O
3 NN O O
% NN O O
or NN O O
More NN O O
of NN O O
Adult NN O O
Patients NN O O
Treated NN O O
in NN O O
Clinical NN O O
Trials NN O O
with NN O O
the NN O O
6-dose NN O O
Regimen NN O O
of NN O O
Coartem NN O O
Tablets NN O O
System NN O O
Organ NN O O
Class NN O O
Preferred NN O O
Term NN O O
Adults NN O O
* NN O O
N=647 NN O O
( NN O O
% NN O O
) NN O O
Nervous NN O O
system NN O O
disorders NN O O
Headache NN B-AdverseReaction B-AdverseReaction
360 NN O O
( NN O O
56 NN O O
) NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
253 NN O O
( NN O O
39 NN O O
) NN O O
Metabolism NN O O
and NN O O
nutrition NN O O
disorders NN O O
Anorexia NN B-AdverseReaction B-AdverseReaction
260 NN O O
( NN O O
40 NN O O
) NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
Asthenia NN B-AdverseReaction B-AdverseReaction
243 NN O O
( NN O O
38 NN O O
) NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
159 NN O O
( NN O O
25 NN O O
) NN O O
Chills NN B-AdverseReaction B-AdverseReaction
147 NN O O
( NN O O
23 NN O O
) NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
111 NN O O
( NN O O
17 NN O O
) NN O O
Malaise NN B-AdverseReaction B-AdverseReaction
20 NN O O
( NN O O
3 NN O O
) NN O O
Musculoskeletal NN O O
and NN O O
connective NN O O
tissue NN O O
disorders NN O O
Arthralgia NN B-AdverseReaction B-AdverseReaction
219 NN O O
( NN O O
34 NN O O
) NN O O
Myalgia NN B-AdverseReaction B-AdverseReaction
206 NN O O
( NN O O
32 NN O O
) NN O O
Gastrointestinal NN O O
disorders NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
169 NN O O
( NN O O
26 NN O O
) NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
113 NN O O
( NN O O
17 NN O O
) NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
112 NN O O
( NN O O
17 NN O O
) NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
46 NN O O
( NN O O
7 NN O O
) NN O O
Psychiatric NN O O
disorders NN O O
Sleep NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
144 NN O O
( NN O O
22 NN O O
) NN O O
Insomnia NN B-AdverseReaction B-AdverseReaction
32 NN O O
( NN O O
5 NN O O
) NN O O
Cardiac NN O O
disorders NN O O
Palpitations NN B-AdverseReaction B-AdverseReaction
115 NN O O
( NN O O
18 NN O O
) NN O O
Hepatobiliary NN O O
disorders NN O O
Hepatomegaly NN B-AdverseReaction B-AdverseReaction
59 NN O O
( NN O O
9 NN O O
) NN O O
Blood NN O O
and NN O O
lymphatic NN O O
system NN O O
disorders NN O O
Splenomegaly NN B-AdverseReaction B-AdverseReaction
57 NN O O
( NN O O
9 NN O O
) NN O O
Anemia NN B-AdverseReaction B-AdverseReaction
23 NN O O
( NN O O
4 NN O O
) NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
and NN O O
mediastinal NN O O
disorders NN O O
Cough NN B-AdverseReaction B-AdverseReaction
37 NN O O
( NN O O
6 NN O O
) NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
Pruritus NN B-AdverseReaction B-AdverseReaction
24 NN O O
( NN O O
4 NN O O
) NN O O
Rash NN B-AdverseReaction B-AdverseReaction
21 NN O O
( NN O O
3 NN O O
) NN O O
Ear NN O O
and NN O O
labyrinth NN O O
disorders NN O O
Vertigo NN B-AdverseReaction B-AdverseReaction
21 NN O O
( NN O O
3 NN O O
) NN O O
Infections NN O O
and NN O O
infestations NN O O
Malaria NN B-AdverseReaction B-AdverseReaction
18 NN O O
( NN O O
3 NN O O
) NN O O
Nasopharyngitis NN B-AdverseReaction B-AdverseReaction
17 NN O O
( NN O O
3 NN O O
) NN O O
* NN O O
Adult NN O O
patients NN O O
defined NN O O
as NN O O
>16 NN O O
years NN O O
of NN O O
age NN O O
Table NN O O
2 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Occurring NN O O
in NN O O
3 NN O O
% NN O O
or NN O O
More NN O O
of NN O O
Pediatric NN O O
Patients NN O O
Treated NN O O
in NN O O
Clinical NN O O
Trials NN O O
with NN O O
the NN O O
6-dose NN O O
Regimen NN O O
of NN O O
Coartem NN O O
Tablets NN O O
System NN O O
Organ NN O O
Class NN O O
Preferred NN O O
Term NN O O
Children NN O O
* NN O O
N=1,332 NN O O
( NN O O
% NN O O
) NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
381 NN O O
( NN O O
29 NN O O
) NN O O
Chills NN B-AdverseReaction B-AdverseReaction
72 NN O O
( NN O O
5 NN O O
) NN O O
Asthenia NN B-AdverseReaction B-AdverseReaction
63 NN O O
( NN O O
5 NN O O
) NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
46 NN O O
( NN O O
3 NN O O
) NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
and NN O O
mediastinal NN O O
disorders NN O O
Cough NN B-AdverseReaction B-AdverseReaction
302 NN O O
( NN O O
23 NN O O
) NN O O
Gastrointestinal NN O O
disorders NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
242 NN O O
( NN O O
18 NN O O
) NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
112 NN O O
( NN O O
8 NN O O
) NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
100 NN O O
( NN O O
8 NN O O
) NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
61 NN O O
( NN O O
5 NN O O
) NN O O
Infections NN O O
and NN O O
infestations NN O O
Plasmodium NN B-AdverseReaction B-AdverseReaction
falciparum NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
224 NN O O
( NN O O
17 NN O O
) NN O O
Rhinitis NN B-AdverseReaction B-AdverseReaction
51 NN O O
( NN O O
4 NN O O
) NN O O
Metabolism NN O O
and NN O O
nutrition NN O O
disorders NN O O
Anorexia NN B-AdverseReaction B-AdverseReaction
175 NN O O
( NN O O
13 NN O O
) NN O O
Nervous NN O O
system NN O O
disorders NN O O
Headache NN B-AdverseReaction B-AdverseReaction
168 NN O O
( NN O O
13 NN O O
) NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
56 NN O O
( NN O O
4 NN O O
) NN O O
Blood NN O O
and NN O O
lymphatic NN O O
system NN O O
disorders NN O O
Splenomegaly NN B-AdverseReaction B-AdverseReaction
124 NN O O
( NN O O
9 NN O O
) NN O O
Anemia NN B-AdverseReaction B-AdverseReaction
115 NN O O
( NN O O
9 NN O O
) NN O O
Hepatobiliary NN O O
disorders NN O O
Hepatomegaly NN B-AdverseReaction B-AdverseReaction
75 NN O O
( NN O O
6 NN O O
) NN O O
Investigations NN O O
Aspartate NN B-AdverseReaction B-AdverseReaction
aminotransferase NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
51 NN O O
( NN O O
4 NN O O
) NN O O
Musculoskeletal NN O O
and NN O O
connective NN O O
tissue NN O O
disorders NN O O
Arthralgia NN B-AdverseReaction B-AdverseReaction
39 NN O O
( NN O O
3 NN O O
) NN O O
Myalgia NN B-AdverseReaction B-AdverseReaction
39 NN O O
( NN O O
3 NN O O
) NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
Rash NN B-AdverseReaction B-AdverseReaction
38 NN O O
( NN O O
3 NN O O
) NN O O
* NN O O
Children NN O O
defined NN O O
as NN O O
patients NN O O
< NN O O
=16 NN O O
years NN O O
of NN O O
age NN O O
Clinically NN O O
significant NN O O
adverse NN O O
reactions NN O O
reported NN O O
in NN O O
adults NN O O
and/or NN O O
children NN O O
treated NN O O
with NN O O
the NN O O
6-dose NN O O
regimen NN O O
of NN O O
Coartem NN O O
Tablets NN O O
which NN O O
occurred NN O O
in NN O O
clinical NN O O
studies NN O O
at NN O O
<3 NN O O
% NN O O
regardless NN O O
of NN O O
causality NN O O
are NN O O
listed NN O O
below NN O O
: NN O O
Blood NN O O
and NN O O
lymphatic NN O O
system NN O O
disorders NN O O
: NN O O
eosinophilia NN B-AdverseReaction B-AdverseReaction
Ear NN O O
and NN O O
labyrinth NN O O
disorders NN O O
: NN O O
tinnitus NN B-AdverseReaction B-AdverseReaction
Eye NN O O
disorders NN O O
: NN O O
conjunctivitis NN B-AdverseReaction B-AdverseReaction
Gastrointestinal NN O O
disorders NN O O
: NN O O
constipation NN B-AdverseReaction B-AdverseReaction
dyspepsia NN B-AdverseReaction B-AdverseReaction
dysphagia NN B-AdverseReaction B-AdverseReaction
peptic NN B-AdverseReaction B-AdverseReaction
ulcer NN I-AdverseReaction I-AdverseReaction
General NN O O
disorders NN O O
: NN O O
gait NN B-AdverseReaction B-AdverseReaction
disturbance NN I-AdverseReaction I-AdverseReaction
Infections NN O O
and NN O O
infestations NN O O
: NN O O
abscess NN B-AdverseReaction B-AdverseReaction
acrodermatitis NN B-AdverseReaction B-AdverseReaction
bronchitis NN B-AdverseReaction B-AdverseReaction
ear NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
gastroenteritis NN B-AdverseReaction B-AdverseReaction
helminthic NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
hookworm NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
impetigo NN B-AdverseReaction B-AdverseReaction
influenza NN B-AdverseReaction B-AdverseReaction
lower NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
malaria NN B-AdverseReaction B-AdverseReaction
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
oral NN B-AdverseReaction B-AdverseReaction
herpes NN I-AdverseReaction I-AdverseReaction
pneumonia NN B-AdverseReaction B-AdverseReaction
respiratory NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
subcutaneous NN B-AdverseReaction B-AdverseReaction
abscess NN I-AdverseReaction I-AdverseReaction
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
Investigations NN O O
: NN O O
alanine NN B-AdverseReaction B-AdverseReaction
aminotransferase NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
aspartate NN B-AdverseReaction B-AdverseReaction
aminotransferase NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
hematocrit NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
lymphocyte NN B-AdverseReaction B-AdverseReaction
morphology NN I-AdverseReaction I-AdverseReaction
abnormal NN I-AdverseReaction I-AdverseReaction
platelet NN B-AdverseReaction B-AdverseReaction
count NN I-AdverseReaction I-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
platelet NN B-AdverseReaction B-AdverseReaction
count NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
white NN B-AdverseReaction B-AdverseReaction
blood NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
count NN I-AdverseReaction I-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
white NN B-AdverseReaction B-AdverseReaction
blood NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
count NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
Metabolism NN O O
and NN O O
nutrition NN O O
disorders NN O O
: NN O O
hypokalemia NN B-AdverseReaction B-AdverseReaction
Musculoskeletal NN O O
and NN O O
connective NN O O
tissue NN O O
disorders NN O O
: NN O O
back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
Nervous NN O O
system NN O O
disorders NN O O
: NN O O
ataxia NN B-AdverseReaction B-AdverseReaction
clonus NN B-AdverseReaction B-AdverseReaction
fine NN B-AdverseReaction B-AdverseReaction
motor NN I-AdverseReaction I-AdverseReaction
delay NN I-AdverseReaction I-AdverseReaction
hyperreflexia NN B-AdverseReaction B-AdverseReaction
hypoesthesia NN B-AdverseReaction B-AdverseReaction
nystagmus NN B-AdverseReaction B-AdverseReaction
tremor NN B-AdverseReaction B-AdverseReaction
Psychiatric NN O O
disorders NN O O
: NN O O
agitation NN B-AdverseReaction B-AdverseReaction
mood NN B-AdverseReaction B-AdverseReaction
swings NN I-AdverseReaction I-AdverseReaction
Renal NN O O
and NN O O
urinary NN O O
disorders NN O O
: NN O O
hematuria NN B-AdverseReaction B-AdverseReaction
proteinuria NN B-AdverseReaction B-AdverseReaction
Respiratory NN O O
, NN O O
thoracic NN O O
and NN O O
mediastinal NN O O
disorders NN O O
: NN O O
asthma NN B-AdverseReaction B-AdverseReaction
pharyngo NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
laryngeal NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
: NN O O
urticaria NN B-AdverseReaction B-AdverseReaction
6.3 NN O O
Postmarketing NN O O
Experience NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
identified NN O O
during NN O O
post NN O O
- NN O O
approval NN O O
use NN O O
of NN O O
Coartem NN O O
Tablets NN O O
. NN O O
Because NN O O
these NN O O
events NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
* NN O O
Hypersensitivity NN O O
reactions NN O O
: NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
urticaria NN B-AdverseReaction B-AdverseReaction
angioedema NN B-AdverseReaction B-AdverseReaction
and NN O O
serious NN B-Severity B-Severity
skin NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
( NN O O
bullous NN O O
eruption NN O O
) NN O O
have NN O O
been NN O O
reported NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Avoid NN O O
use NN O O
in NN O O
patients NN O O
with NN O O
known NN O O
QT NN O O
prolongation NN O O
, NN O O
those NN O O
with NN O O
hypokalemia NN O O
or NN O O
hypomagnesemia NN O O
, NN O O
and NN O O
those NN O O
taking NN O O
other NN O O
drugs NN O O
that NN O O
prolong NN O O
the NN O O
QT NN O O
interval NN O O
. NN O O
( NN O O
5.1,12.6 NN O O
) NN O O
* NN O O
Halofantrine NN O O
and NN O O
Coartem NN O O
Tablets NN O O
should NN O O
not NN O O
be NN O O
administered NN O O
within NN O O
one NN O O
month NN O O
of NN O O
each NN O O
other NN O O
due NN O O
to NN O O
potential NN O O
additive NN O O
effects NN O O
on NN O O
the NN O O
QT NN O O
interval NN O O
. NN O O
( NN O O
5.1,5.2,12.3 NN O O
) NN O O
* NN O O
Antimalarials NN O O
should NN O O
not NN O O
be NN O O
given NN O O
concomitantly NN O O
, NN O O
unless NN O O
there NN O O
is NN O O
no NN O O
other NN O O
treatment NN O O
option NN O O
, NN O O
due NN O O
to NN O O
limited NN O O
safety NN O O
data NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
QT NN O O
prolonging NN O O
drugs NN O O
, NN O O
including NN O O
quinine NN O O
and NN O O
quinidine NN O O
, NN O O
should NN O O
be NN O O
used NN O O
cautiously NN O O
following NN O O
Coartem NN O O
Tablets NN O O
. NN O O
( NN O O
5.1,5.2,7.7,12.3 NN O O
) NN O O
* NN O O
Substrates NN O O
, NN O O
inhibitors NN O O
, NN O O
or NN O O
inducers NN O O
of NN O O
CYP3A4 NN O O
, NN O O
including NN O O
antiretroviral NN O O
medications NN O O
, NN O O
should NN O O
be NN O O
used NN O O
cautiously NN O O
with NN O O
Coartem NN O O
Tablets NN O O
, NN O O
due NN O O
to NN O O
a NN O O
potential NN O O
loss NN O O
of NN O O
efficacy NN O O
of NN O O
the NN O O
concomitant NN O O
drug NN O O
or NN O O
additive NN O O
QT NN O O
prolongation NN O O
. NN O O
( NN O O
5.3,7.2,7.3 NN O O
) NN O O
5.1 NN O O
Prolongation NN O O
of NN O O
the NN O O
QT NN O O
Interval NN O O
Some NN O O
antimalarials NN O O
( NN O O
e.g. NN O O
, NN O O
halofantrine NN O O
, NN O O
quinine NN O O
, NN O O
quinidine NN O O
) NN O O
including NN O O
Coartem NN O O
Tablets NN O O
have NN O O
been NN O O
associated NN O O
with NN O O
prolongation NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
QT NN I-AdverseReaction I-AdverseReaction
interval NN I-AdverseReaction I-AdverseReaction
on NN O O
the NN O O
electrocardiogram NN O O
. NN O O
Coartem NN O O
Tablets NN O O
should NN O O
be NN O O
avoided NN O O
in NN O O
patients NN O O
: NN O O
* NN O O
with NN O O
congenital NN O O
prolongation NN O O
of NN O O
the NN O O
QT NN O O
interval NN O O
( NN O O
e.g. NN O O
, NN O O
long NN O O
QT NN O O
syndrome NN O O
) NN O O
or NN O O
any NN O O
other NN O O
clinical NN O O
condition NN O O
known NN O O
to NN O O
prolong NN O O
the NN O O
QTc NN O O
interval NN O O
such NN O O
as NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
symptomatic NN O O
cardiac NN O O
arrhythmias NN O O
, NN O O
with NN O O
clinically NN O O
relevant NN O O
bradycardia NN O O
or NN O O
with NN O O
severe NN O O
cardiac NN O O
disease NN O O
. NN O O
* NN O O
with NN O O
a NN O O
family NN O O
history NN O O
of NN O O
congenital NN O O
prolongation NN O O
of NN O O
the NN O O
QT NN O O
interval NN O O
or NN O O
sudden NN O O
death NN O O
. NN O O
* NN O O
with NN O O
known NN O O
disturbances NN O O
of NN O O
electrolyte NN O O
balance NN O O
, NN O O
e.g. NN O O
, NN O O
hypokalemia NN O O
or NN O O
hypomagnesemia NN O O
. NN O O
* NN O O
receiving NN O O
other NN O O
medications NN O O
that NN O O
prolong NN O O
the NN O O
QT NN O O
interval NN O O
, NN O O
such NN O O
as NN O O
class NN O O
IA NN O O
( NN O O
quinidine NN O O
, NN O O
procainamide NN O O
, NN O O
disopyramide NN O O
) NN O O
, NN O O
or NN O O
class NN O O
III NN O O
( NN O O
amiodarone NN O O
, NN O O
sotalol NN O O
) NN O O
antiarrhythmic NN O O
agents NN O O
; NN O O
antipsychotics NN O O
( NN O O
pimozide NN O O
, NN O O
ziprasidone NN O O
) NN O O
; NN O O
antidepressants NN O O
; NN O O
certain NN O O
antibiotics NN O O
( NN O O
macrolide NN O O
antibiotics NN O O
, NN O O
fluoroquinolone NN O O
antibiotics NN O O
, NN O O
imidazole NN O O
, NN O O
and NN O O
triazole NN O O
antifungal NN O O
agents NN O O
) NN O O
[ NN O O
see NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.6 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
receiving NN O O
medications NN O O
that NN O O
are NN O O
metabolized NN O O
by NN O O
the NN O O
cytochrome NN O O
enzyme NN O O
CYP2D6 NN O O
which NN O O
also NN O O
have NN O O
cardiac NN O O
effects NN O O
( NN O O
e.g. NN O O
, NN O O
flecainide NN O O
, NN O O
imipramine NN O O
, NN O O
amitriptyline NN O O
, NN O O
clomipramine NN O O
) NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
, NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.6 NN O O
) NN O O
, NN O O
and NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.3 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
Use NN O O
of NN O O
QT NN O O
Prolonging NN O O
Drugs NN O O
and NN O O
Other NN O O
Antimalarials NN O O
Halofantrine NN O O
and NN O O
Coartem NN O O
Tablets NN O O
should NN O O
not NN O O
be NN O O
administered NN O O
within NN O O
1 NN O O
month NN O O
of NN O O
each NN O O
other NN O O
due NN O O
to NN O O
the NN O O
long NN O O
elimination NN O O
half NN O O
- NN O O
life NN O O
of NN O O
lumefantrine NN O O
( NN O O
3 NN O O
to NN O O
6 NN O O
days NN O O
) NN O O
and NN O O
potential NN O O
additive NN O O
effects NN O O
on NN O O
the NN O O
QT NN O O
interval NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
and NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.3 NN O O
) NN O O
] NN O O
. NN O O
Antimalarials NN O O
should NN O O
not NN O O
be NN O O
given NN O O
concomitantly NN O O
with NN O O
Coartem NN O O
Tablets NN O O
, NN O O
unless NN O O
there NN O O
is NN O O
no NN O O
other NN O O
treatment NN O O
option NN O O
, NN O O
due NN O O
to NN O O
limited NN O O
safety NN O O
data NN O O
. NN O O
Drugs NN O O
that NN O O
prolong NN O O
the NN O O
QT NN O O
interval NN O O
, NN O O
including NN O O
antimalarials NN O O
such NN O O
as NN O O
quinine NN O O
and NN O O
quinidine NN O O
, NN O O
should NN O O
be NN O O
used NN O O
cautiously NN O O
following NN O O
Coartem NN O O
Tablets NN O O
, NN O O
due NN O O
to NN O O
the NN O O
long NN O O
elimination NN O O
half NN O O
- NN O O
life NN O O
of NN O O
lumefantrine NN O O
( NN O O
3 NN O O
to NN O O
6 NN O O
days NN O O
) NN O O
and NN O O
the NN O O
potential NN O O
for NN O O
additive NN O O
effects NN O O
on NN O O
the NN O O
QT NN O O
interval NN O O
; NN O O
ECG NN O O
monitoring NN O O
is NN O O
advised NN O O
if NN O O
use NN O O
of NN O O
drugs NN O O
that NN O O
prolong NN O O
the NN O O
QT NN O O
interval NN O O
is NN O O
medically NN O O
required NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
, NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.7 NN O O
) NN O O
, NN O O
and NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.3 NN O O
) NN O O
] NN O O
. NN O O
If NN O O
mefloquine NN O O
is NN O O
administered NN O O
immediately NN O O
prior NN O O
to NN O O
Coartem NN O O
Tablets NN O O
there NN O O
may NN O O
be NN O O
a NN O O
decreased NN O O
exposure NN O O
to NN O O
lumefantrine NN O O
, NN O O
possibly NN O O
due NN O O
to NN O O
a NN O O
mefloquine NN O O
- NN O O
induced NN O O
decrease NN O O
in NN O O
bile NN O O
production NN O O
. NN O O
Therefore NN O O
, NN O O
patients NN O O
should NN O O
be NN O O
monitored NN O O
for NN O O
decreased NN O O
efficacy NN O O
and NN O O
food NN O O
consumption NN O O
should NN O O
be NN O O
encouraged NN O O
while NN O O
taking NN O O
Coartem NN O O
Tablets NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.1 NN O O
) NN O O
, NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.4 NN O O
) NN O O
, NN O O
and NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.3 NN O O
) NN O O
] NN O O
. NN O O
5.3 NN O O
Drug NN O O
Interactions NN O O
with NN O O
CYP3A4 NN O O
When NN O O
Coartem NN O O
Tablets NN O O
are NN O O
coadministered NN O O
with NN O O
substrates NN O O
of NN O O
CYP3A4 NN O O
it NN O O
may NN O O
result NN O O
in NN O O
decreased NN O O
concentrations NN O O
of NN O O
the NN O O
substrate NN O O
and NN O O
potential NN O O
loss NN O O
of NN O O
substrate NN O O
efficacy NN O O
. NN O O
When NN O O
Coartem NN O O
Tablets NN O O
are NN O O
coadministered NN O O
with NN O O
an NN O O
inhibitor NN O O
of NN O O
CYP3A4 NN O O
, NN O O
including NN O O
grapefruit NN O O
juice NN O O
it NN O O
may NN B-Factor B-Factor
result NN O O
in NN O O
increased NN O O
concentrations NN O O
of NN O O
artemether NN O O
and/or NN O O
lumefantrine NN O O
and NN O O
potentiate NN O O
QT NN B-AdverseReaction B-AdverseReaction
prolongation NN I-AdverseReaction I-AdverseReaction
When NN O O
Coartem NN O O
Tablets NN O O
are NN O O
coadministered NN O O
with NN O O
inducers NN O O
of NN O O
CYP3A4 NN O O
it NN O O
may NN O O
result NN O O
in NN O O
decreased NN O O
concentrations NN O O
of NN O O
artemether NN O O
and/or NN O O
lumefantrine NN O O
and NN O O
loss NN O O
of NN O O
antimalarial NN O O
efficacy NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
and NN O O
Drug NN O O
Interactions NN O O
( NN O O
7 NN O O
) NN O O
] NN O O
. NN O O
Drugs NN O O
that NN O O
have NN O O
a NN O O
mixed NN O O
effect NN O O
on NN O O
CYP3A4 NN O O
, NN O O
especially NN O O
antiretroviral NN O O
drugs NN O O
such NN O O
as NN O O
HIV NN O O
protease NN O O
inhibitors NN O O
and NN O O
non NN O O
- NN O O
nucleoside NN O O
reverse NN O O
transcriptase NN O O
inhibitors NN O O
, NN O O
and NN O O
those NN O O
that NN O O
have NN O O
an NN O O
effect NN O O
on NN O O
the NN O O
QT NN O O
interval NN O O
should NN O O
be NN O O
used NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
taking NN O O
Coartem NN O O
Tablets NN O O
[ NN O O
see NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.3 NN O O
, NN O O
7.7 NN O O
) NN O O
] NN O O
. NN O O
Coartem NN O O
Tablets NN O O
may NN O O
reduce NN O O
the NN O O
effectiveness NN O O
of NN O O
hormonal NN O O
contraceptives NN O O
. NN O O
Therefore NN O O
, NN O O
patients NN O O
using NN O O
oral NN O O
, NN O O
transdermal NN O O
patch NN O O
, NN O O
or NN O O
other NN O O
systemic NN O O
hormonal NN O O
contraceptives NN O O
should NN O O
be NN O O
advised NN O O
to NN O O
use NN O O
an NN O O
additional NN O O
non NN O O
- NN O O
hormonal NN O O
method NN O O
of NN O O
birth NN O O
control NN O O
[ NN O O
see NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.5 NN O O
) NN O O
] NN O O
. NN O O
5.4 NN O O
Drug NN O O
Interactions NN O O
with NN O O
CYP2D6 NN O O
Administration NN O O
of NN O O
Coartem NN O O
Tablets NN O O
with NN O O
drugs NN O O
that NN O O
are NN O O
metabolized NN O O
by NN O O
CYP2D6 NN O O
may NN O O
significantly NN O O
increase NN O O
plasma NN O O
concentrations NN O O
of NN O O
the NN O O
coadministered NN O O
drug NN O O
and NN O O
increase NN O O
the NN O O
risk NN O O
of NN O O
adverse NN O O
effects NN O O
. NN O O
Many NN O O
of NN O O
the NN O O
drugs NN O O
metabolized NN O O
by NN O O
CYP2D6 NN O O
can NN O O
prolong NN O O
the NN O O
QT NN O O
interval NN O O
and NN O O
should NN O O
not NN O O
be NN O O
administered NN O O
with NN O O
Coartem NN O O
Tablets NN O O
due NN O O
to NN O O
the NN O O
potential NN O O
additive NN O O
effect NN O O
on NN O O
the NN O O
QT NN O O
interval NN O O
( NN O O
e.g. NN O O
, NN O O
flecainide NN O O
, NN O O
imipramine NN O O
, NN O O
amitriptyline NN O O
, NN O O
clomipramine NN O O
) NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
, NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.6 NN O O
) NN O O
, NN O O
and NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.3 NN O O
) NN O O
] NN O O
. NN O O
5.5 NN O O
Recrudescence NN O O
Food NN O O
enhances NN O O
absorption NN O O
of NN O O
artemether NN O O
and NN O O
lumefantrine NN O O
following NN O O
administration NN O O
of NN O O
Coartem NN O O
Tablets NN O O
. NN O O
Patients NN O O
who NN O O
remain NN O O
averse NN O O
to NN O O
food NN O O
during NN O O
treatment NN O O
should NN O O
be NN O O
closely NN O O
monitored NN O O
as NN O O
the NN O O
risk NN O O
of NN O O
recrudescence NN O O
may NN O O
be NN O O
greater NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.1 NN O O
) NN O O
] NN O O
. NN O O
In NN O O
the NN O O
event NN O O
of NN O O
recrudescent NN O O
P. NN O O
falciparum NN O O
infection NN O O
after NN O O
treatment NN O O
with NN O O
Coartem NN O O
Tablets NN O O
, NN O O
patients NN O O
should NN O O
be NN O O
treated NN O O
with NN O O
a NN O O
different NN O O
antimalarial NN O O
drug NN O O
. NN O O
5.6 NN O O
Hepatic NN O O
and NN O O
Renal NN O O
Impairment NN O O
Coartem NN O O
Tablets NN O O
have NN O O
not NN O O
been NN O O
studied NN O O
for NN O O
efficacy NN O O
and NN O O
safety NN O O
in NN O O
patients NN O O
with NN O O
severe NN O O
hepatic NN O O
and/or NN O O
renal NN O O
impairment NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.4 NN O O
) NN O O
] NN O O
. NN O O
5.7 NN O O
Plasmodium NN O O
vivax NN O O
Infection NN O O
Coartem NN O O
Tablets NN O O
have NN O O
been NN O O
shown NN O O
in NN O O
limited NN O O
data NN O O
( NN O O
43 NN O O
patients NN O O
) NN O O
to NN O O
be NN O O
effective NN O O
in NN O O
treating NN O O
the NN O O
erythrocytic NN O O
stage NN O O
of NN O O
P. NN O O
vivax NN O O
infection NN O O
. NN O O
However NN O O
, NN O O
relapsing NN O O
malaria NN O O
caused NN O O
by NN O O
P. NN O O
vivax NN O O
requires NN O O
additional NN O O
treatment NN O O
with NN O O
other NN O O
antimalarial NN O O
agents NN O O
to NN O O
achieve NN O O
radical NN O O
cure NN O O
i.e. NN O O
, NN O O
eradicate NN O O
any NN O O
hypnozoites NN O O
forms NN O O
that NN O O
may NN O O
remain NN O O
dormant NN O O
in NN O O
the NN O O
liver NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
are NN O O
discussed NN O O
in NN O O
greater NN O O
detail NN O O
in NN O O
another NN O O
section NN O O
of NN O O
the NN O O
label NN O O
: NN O O
* NN O O
New NN O O
Primary NN B-AdverseReaction B-AdverseReaction
Malignancies NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Tumor NN B-AdverseReaction B-AdverseReaction
Promotion NN I-AdverseReaction I-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
BRAF NN I-AdverseReaction I-AdverseReaction
Wild NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Type NN I-AdverseReaction I-AdverseReaction
Melanoma NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
Hemorrhage NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
* NN O O
Venous NN B-AdverseReaction B-AdverseReaction
Thromboembolism NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
* NN O O
Cardiomyopathy NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
* NN O O
Ocular NN B-AdverseReaction B-AdverseReaction
Toxicities NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.6 NN O O
) NN O O
] NN O O
* NN O O
Serious NN B-Severity B-Severity
Febrile NN B-AdverseReaction B-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.7 NN O O
) NN O O
] NN O O
* NN O O
Serious NN B-Severity B-Severity
Skin NN B-AdverseReaction B-AdverseReaction
Toxicity NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.8 NN O O
) NN O O
] NN O O
* NN O O
Hyperglycemia NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.9 NN O O
) NN O O
] NN O O
* NN O O
Glucose-6-Phosphate NN B-AdverseReaction B-AdverseReaction
Dehydrogenase NN I-AdverseReaction I-AdverseReaction
Deficiency NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.10 NN O O
) NN O O
] NN O O
* NN O O
Most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=20 NN O O
% NN O O
) NN O O
for NN O O
TAFINLAR NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
are NN O O
hyperkeratosis NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
pyrexia NN B-AdverseReaction B-AdverseReaction
arthralgia NN B-AdverseReaction B-AdverseReaction
papilloma NN B-AdverseReaction B-AdverseReaction
alopecia NN B-AdverseReaction B-AdverseReaction
and NN O O
palmar NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
plantar NN I-AdverseReaction I-AdverseReaction
erythrodysesthesia NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
* NN O O
Most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=20 NN O O
% NN O O
) NN O O
for NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
are NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
chills NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
peripheral NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
arthralgia NN B-AdverseReaction B-AdverseReaction
night NN B-AdverseReaction B-AdverseReaction
sweats NN I-AdverseReaction I-AdverseReaction
decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
constipation NN B-AdverseReaction B-AdverseReaction
and NN O O
myalgia NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
EXCERPT NN O O
: NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
GlaxoSmithKline NN O O
at NN O O
1 NN O O
- NN O O
888 NN O O
- NN O O
825 NN O O
- NN O O
5249 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
The NN O O
data NN O O
described NN O O
in NN O O
the NN O O
Warnings NN O O
and NN O O
Precautions NN O O
section NN O O
and NN O O
below NN O O
reflect NN O O
exposure NN O O
to NN O O
TAFINLAR NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
and NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
. NN O O
BRAF NN O O
V600E NN O O
Unresectable NN O O
or NN O O
Metastatic NN O O
Melanoma NN O O
: NN O O
The NN O O
safety NN O O
of NN O O
TAFINLAR NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
was NN O O
evaluated NN O O
in NN O O
586 NN O O
patients NN O O
with NN O O
BRAF NN O O
V600 NN O O
mutation NN O O
- NN O O
positive NN O O
unresectable NN O O
or NN O O
metastatic NN O O
melanoma NN O O
, NN O O
previously NN O O
treated NN O O
or NN O O
untreated NN O O
, NN O O
who NN O O
received NN O O
TAFINLAR NN O O
150 NN O O
mg NN O O
orally NN O O
twice NN O O
daily NN O O
until NN O O
disease NN O O
progression NN O O
or NN O O
unacceptable NN O O
toxicity NN O O
, NN O O
including NN O O
181 NN O O
patients NN O O
treated NN O O
for NN O O
at NN O O
least NN O O
6 NN O O
months NN O O
and NN O O
86 NN O O
additional NN O O
patients NN O O
treated NN O O
for NN O O
more NN O O
than NN O O
12 NN O O
months NN O O
. NN O O
TAFINLAR NN O O
was NN O O
studied NN O O
in NN O O
open NN O O
- NN O O
label NN O O
, NN O O
single NN O O
- NN O O
arm NN O O
trials NN O O
and NN O O
in NN O O
an NN O O
open NN O O
- NN O O
label NN O O
, NN O O
randomized NN O O
, NN O O
active NN O O
- NN O O
controlled NN O O
trial NN O O
. NN O O
The NN O O
median NN O O
daily NN O O
dose NN O O
of NN O O
TAFINLAR NN O O
was NN O O
300 NN O O
mg NN O O
( NN O O
range NN O O
: NN O O
118 NN O O
to NN O O
300 NN O O
mg NN O O
) NN O O
. NN O O
Table NN O O
3 NN O O
and NN O O
Table NN O O
4 NN O O
present NN O O
adverse NN O O
drug NN O O
reactions NN O O
and NN O O
laboratory NN O O
abnormalities NN O O
identified NN O O
from NN O O
analyses NN O O
of NN O O
Trial NN O O
1 NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14.1 NN O O
) NN O O
] NN O O
. NN O O
Trial NN O O
1 NN O O
, NN O O
a NN O O
multicenter NN O O
, NN O O
international NN O O
, NN O O
open NN O O
- NN O O
label NN O O
, NN O O
randomized NN O O
( NN O O
3:1 NN O O
) NN O O
, NN O O
controlled NN O O
trial NN O O
allocated NN O O
250 NN O O
patients NN O O
with NN O O
unresectable NN O O
or NN O O
metastatic NN O O
BRAF NN O O
V600E NN O O
mutation NN O O
- NN O O
positive NN O O
melanoma NN O O
to NN O O
receive NN O O
TAFINLAR NN O O
150 NN O O
mg NN O O
orally NN O O
twice NN O O
daily NN O O
( NN O O
n NN O O
= NN O O
187 NN O O
) NN O O
or NN O O
dacarbazine NN O O
1,000 NN O O
mg/m NN O O
2 NN O O
intravenously NN O O
every NN O O
3 NN O O
weeks NN O O
( NN O O
n NN O O
= NN O O
63 NN O O
) NN O O
. NN O O
The NN O O
trial NN O O
excluded NN O O
patients NN O O
with NN O O
abnormal NN O O
left NN O O
ventricular NN O O
ejection NN O O
fraction NN O O
or NN O O
cardiac NN O O
valve NN O O
morphology NN O O
( NN O O
>=Grade NN O O
2 NN O O
) NN O O
, NN O O
corrected NN O O
QT NN O O
interval NN O O
>=480 NN O O
milliseconds NN O O
on NN O O
electrocardiogram NN O O
, NN O O
or NN O O
a NN O O
known NN O O
history NN O O
of NN O O
glucose-6-phosphate NN O O
dehydrogenase NN O O
deficiency NN O O
. NN O O
The NN O O
median NN O O
duration NN O O
on NN O O
treatment NN O O
was NN O O
4.9 NN O O
months NN O O
for NN O O
patients NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
and NN O O
2.8 NN O O
months NN O O
for NN O O
dacarbazine NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
The NN O O
population NN O O
exposed NN O O
to NN O O
TAFINLAR NN O O
was NN O O
60 NN O O
% NN O O
male NN O O
, NN O O
99 NN O O
% NN O O
white NN O O
, NN O O
and NN O O
had NN O O
a NN O O
median NN O O
age NN O O
of NN O O
53 NN O O
years NN O O
. NN O O
The NN O O
most NN O O
commonly NN O O
occurring NN O O
adverse NN O O
reactions NN O O
( NN O O
>=20 NN O O
% NN O O
) NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
were NN O O
, NN O O
in NN O O
order NN O O
of NN O O
decreasing NN O O
frequency NN O O
: NN O O
hyperkeratosis NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
pyrexia NN B-AdverseReaction B-AdverseReaction
arthralgia NN B-AdverseReaction B-AdverseReaction
papilloma NN B-AdverseReaction B-AdverseReaction
alopecia NN B-AdverseReaction B-AdverseReaction
and NN O O
palmar NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
plantar NN I-AdverseReaction I-AdverseReaction
erythrodysesthesia NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
PPES NN O O
) NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
adverse NN O O
events NN O O
resulting NN O O
in NN O O
permanent NN O O
discontinuation NN O O
of NN O O
study NN O O
medication NN O O
in NN O O
Trial NN O O
1 NN O O
was NN O O
3 NN O O
% NN O O
for NN O O
patients NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
and NN O O
3 NN O O
% NN O O
for NN O O
patients NN O O
treated NN O O
with NN O O
dacarbazine NN O O
. NN O O
The NN O O
most NN O O
frequent NN O O
( NN O O
>=2 NN O O
% NN O O
) NN O O
adverse NN O O
reactions NN O O
leading NN O O
to NN O O
dose NN O O
reduction NN O O
of NN O O
TAFINLAR NN O O
were NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
( NN O O
9 NN O O
% NN O O
) NN O O
, NN O O
PPES NN B-AdverseReaction B-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
, NN O O
chills NN B-AdverseReaction B-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
, NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
headache NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
. NN O O
Table NN O O
3 NN O O
. NN O O
Selected NN O O
Common NN O O
Adverse NN O O
Reactions NN O O
Occurring NN O O
in NN O O
>=10 NN O O
% NN O O
( NN O O
All NN O O
Grades NN O O
) NN O O
or NN O O
>=2 NN O O
% NN O O
( NN O O
Grades NN O O
3 NN O O
or NN O O
4 NN O O
) NN O O
of NN O O
Patients NN O O
Treated NN O O
With NN O O
TAFINLARa NN O O
TAFINLARN NN O O
= NN O O
187 NN O O
Dacarbazine NN O O
N NN O O
= NN O O
59 NN O O
Primary NN O O
System NN O O
Organ NN O O
Class NN O O
Preferred NN O O
Term NN O O
All NN O O
Grades NN O O
( NN O O
% NN O O
) NN O O
Grades NN O O
3 NN O O
and NN O O
4b NN O O
( NN O O
% NN O O
) NN O O
All NN O O
Grades NN O O
( NN O O
% NN O O
) NN O O
Grades NN O O
3 NN O O
and NN O O
4 NN O O
( NN O O
% NN O O
) NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
Hyperkeratosis NN B-AdverseReaction B-AdverseReaction
37 NN O O
1 NN O O
0 NN O O
0 NN O O
Alopecia NN B-AdverseReaction B-AdverseReaction
22 NN O O
NAf NN O O
2 NN O O
NAf NN O O
Palmar NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
plantar NN I-AdverseReaction I-AdverseReaction
erythrodysesthesia NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
20 NN O O
2 NN O O
2 NN O O
0 NN O O
Rash NN B-AdverseReaction B-AdverseReaction
17 NN O O
0 NN O O
0 NN O O
0 NN O O
Nervous NN O O
system NN O O
disorders NN O O
Headache NN B-AdverseReaction B-AdverseReaction
32 NN O O
0 NN O O
8 NN O O
0 NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
28 NN O O
3 NN O O
10 NN O O
0 NN O O
Musculoskeletal NN O O
and NN O O
connective NN O O
tissue NN O O
disorders NN O O
Arthralgia NN B-AdverseReaction B-AdverseReaction
27 NN O O
1 NN O O
2 NN O O
0 NN O O
Back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
12 NN O O
3 NN O O
7 NN O O
0 NN O O
Myalgia NN B-AdverseReaction B-AdverseReaction
11 NN O O
0 NN O O
0 NN O O
0 NN O O
Neoplasms NN O O
benign NN O O
, NN O O
malignant NN O O
, NN O O
and NN O O
unspecified NN O O
( NN O O
including NN O O
cysts NN O O
and NN O O
polyps NN O O
) NN O O
Papilloma NN B-AdverseReaction B-AdverseReaction
c NN O O
27 NN O O
0 NN O O
2 NN O O
0 NN O O
cuSCC NN B-AdverseReaction B-AdverseReaction
d NN O O
, NN O O
e NN O O
7 NN O O
4 NN O O
0 NN O O
0 NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
, NN O O
and NN O O
mediastinal NN O O
disorders NN O O
Cough NN B-AdverseReaction B-AdverseReaction
12 NN O O
0 NN O O
5 NN O O
0 NN O O
Gastrointestinal NN O O
disorders NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
11 NN O O
2 NN O O
14 NN O O
0 NN O O
Infections NN O O
and NN O O
infestations NN O O
Nasopharyngitis NN B-AdverseReaction B-AdverseReaction
10 NN O O
0 NN O O
3 NN O O
0 NN O O
a NN O O
Adverse NN O O
drug NN O O
reactions NN O O
, NN O O
reported NN O O
using NN O O
MedDRA NN O O
and NN O O
graded NN O O
using NN O O
CTCAE NN O O
version NN O O
4.0 NN O O
for NN O O
assessment NN O O
of NN O O
toxicity NN O O
. NN O O
b NN O O
Grade NN B-Severity B-Severity
4 NN I-Severity I-Severity
adverse NN O O
reactions NN O O
limited NN O O
to NN O O
hyperkeratosis NN B-AdverseReaction B-AdverseReaction
( NN O O
n NN O O
= NN O O
1 NN O O
) NN O O
and NN O O
constipation NN B-AdverseReaction B-AdverseReaction
( NN O O
n NN O O
= NN O O
1 NN O O
) NN O O
. NN O O
c NN O O
Includes NN O O
skin NN B-AdverseReaction B-AdverseReaction
papilloma NN I-AdverseReaction I-AdverseReaction
and NN O O
papilloma NN B-AdverseReaction B-AdverseReaction
d NN O O
Includes NN O O
squamous NN B-AdverseReaction B-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
carcinoma NN I-AdverseReaction I-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
skin NN I-AdverseReaction I-AdverseReaction
and NN O O
keratoacanthoma NN B-AdverseReaction B-AdverseReaction
e NN O O
Cases NN O O
of NN O O
cutaneous NN B-AdverseReaction B-AdverseReaction
squamous NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
carcinoma NN I-AdverseReaction I-AdverseReaction
were NN O O
required NN O O
to NN O O
be NN O O
reported NN O O
as NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
per NN O O
protocol NN O O
. NN O O
f NN O O
NA NN O O
= NN O O
not NN O O
applicable NN O O
. NN O O
Table NN O O
4 NN O O
. NN O O
Incidence NN O O
of NN O O
Laboratory NN O O
Abnormalities NN O O
Increased NN O O
From NN O O
Baseline NN O O
Occurring NN O O
at NN O O
a NN O O
Higher NN O O
Incidence NN O O
in NN O O
Patients NN O O
Treated NN O O
With NN O O
TAFINLAR NN O O
in NN O O
Trial NN O O
1 NN O O
[ NN O O
Between NN O O
- NN O O
Arm NN O O
Difference NN O O
of NN O O
>=5 NN O O
% NN O O
( NN O O
All NN O O
Grades NN O O
) NN O O
or NN O O
>=2 NN O O
% NN O O
( NN O O
Grades NN O O
3 NN O O
or NN O O
4 NN O O
) NN O O
] NN O O
Test NN O O
TAFINLAR NN O O
N NN O O
= NN O O
187 NN O O
DTIC NN O O
N NN O O
= NN O O
59 NN O O
All NN O O
Grades NN O O
( NN O O
% NN O O
) NN O O
Grades NN O O
3 NN O O
and NN O O
4 NN O O
( NN O O
% NN O O
) NN O O
All NN O O
Grades NN O O
( NN O O
% NN O O
) NN O O
Grades NN O O
3 NN O O
and NN O O
4 NN O O
( NN O O
% NN O O
) NN O O
Hyperglycemia NN B-AdverseReaction B-AdverseReaction
50 NN O O
6 NN O O
43 NN O O
0 NN O O
Hypophosphatemia NN B-AdverseReaction B-AdverseReaction
37 NN O O
6a NN O O
14 NN O O
2 NN O O
Increased NN B-AdverseReaction B-AdverseReaction
alkaline NN I-AdverseReaction I-AdverseReaction
phosphatase NN I-AdverseReaction I-AdverseReaction
19 NN O O
0 NN O O
14 NN O O
2 NN O O
Hyponatremia NN B-AdverseReaction B-AdverseReaction
8 NN O O
2 NN O O
3 NN O O
0 NN O O
a NN O O
Grade NN B-Severity B-Severity
4 NN I-Severity I-Severity
laboratory NN O O
abnormality NN O O
limited NN O O
to NN O O
hypophosphatemia NN B-AdverseReaction B-AdverseReaction
( NN O O
n NN O O
= NN O O
1 NN O O
) NN O O
. NN O O
Other NN O O
clinically NN O O
important NN O O
adverse NN O O
reactions NN O O
observed NN O O
in NN O O
< NN O O
10 NN O O
% NN O O
of NN O O
patients NN O O
( NN O O
N NN O O
= NN O O
586 NN O O
) NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
were NN O O
: NN O O
Gastrointestinal NN O O
Disorders NN O O
: NN O O
Pancreatitis NN B-AdverseReaction B-AdverseReaction
Immune NN O O
System NN O O
Disorders NN O O
: NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
manifesting NN O O
as NN O O
bullous NN B-AdverseReaction B-AdverseReaction
rash NN I-AdverseReaction I-AdverseReaction
Renal NN O O
and NN O O
Urinary NN O O
Disorders NN O O
: NN O O
Interstitial NN B-AdverseReaction B-AdverseReaction
nephritis NN I-AdverseReaction I-AdverseReaction
BRAF NN O O
V600E NN O O
or NN O O
V600K NN O O
Unresectable NN O O
or NN O O
Metastatic NN O O
Melanoma NN O O
: NN O O
The NN O O
safety NN O O
of NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
was NN O O
evaluated NN O O
in NN O O
Trial NN O O
2 NN O O
and NN O O
other NN O O
trials NN O O
consisting NN O O
of NN O O
a NN O O
total NN O O
of NN O O
202 NN O O
patients NN O O
with NN O O
BRAF NN O O
V600 NN O O
mutation NN O O
- NN O O
positive NN O O
unresectable NN O O
or NN O O
metastatic NN O O
melanoma NN O O
who NN O O
received NN O O
TAFINLAR NN O O
150 NN O O
mg NN O O
orally NN O O
twice NN O O
daily NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
2 NN O O
mg NN O O
orally NN O O
once NN O O
daily NN O O
until NN O O
disease NN O O
progression NN O O
or NN O O
unacceptable NN O O
toxicity NN O O
. NN O O
Among NN O O
these NN O O
202 NN O O
patients NN O O
, NN O O
66 NN O O
( NN O O
33 NN O O
% NN O O
) NN O O
were NN O O
exposed NN O O
to NN O O
TAFINLAR NN O O
and NN O O
68 NN O O
( NN O O
34 NN O O
% NN O O
) NN O O
were NN O O
exposed NN O O
to NN O O
trametinib NN O O
for NN O O
greater NN O O
than NN O O
6 NN O O
to NN O O
12 NN O O
months NN O O
while NN O O
40 NN O O
( NN O O
20 NN O O
% NN O O
) NN O O
were NN O O
exposed NN O O
to NN O O
TAFINLAR NN O O
and NN O O
36 NN O O
( NN O O
18 NN O O
% NN O O
) NN O O
were NN O O
exposed NN O O
to NN O O
trametinib NN O O
for NN O O
greater NN O O
than NN O O
one NN O O
year NN O O
. NN O O
The NN O O
median NN O O
age NN O O
was NN O O
54 NN O O
years NN O O
, NN O O
57 NN O O
% NN O O
were NN O O
male NN O O
, NN O O
and NN O O
>99 NN O O
% NN O O
were NN O O
white NN O O
. NN O O
Table NN O O
5 NN O O
presents NN O O
adverse NN O O
reactions NN O O
from NN O O
Trial NN O O
2 NN O O
, NN O O
a NN O O
multicenter NN O O
, NN O O
open NN O O
- NN O O
label NN O O
, NN O O
randomized NN O O
trial NN O O
of NN O O
162 NN O O
patients NN O O
with NN O O
BRAF NN O O
V600E NN O O
or NN O O
V600K NN O O
mutation NN O O
- NN O O
positive NN O O
melanoma NN O O
receiving NN O O
TAFINLAR NN O O
150 NN O O
mg NN O O
twice NN O O
daily NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
2 NN O O
mg NN O O
orally NN O O
once NN O O
daily NN O O
( NN O O
n NN O O
= NN O O
55 NN O O
) NN O O
, NN O O
TAFINLAR NN O O
150 NN O O
mg NN O O
orally NN O O
twice NN O O
daily NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
1 NN O O
mg NN O O
once NN O O
daily NN O O
( NN O O
n NN O O
= NN O O
54 NN O O
) NN O O
, NN O O
and NN O O
TAFINLAR NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
150 NN O O
mg NN O O
orally NN O O
twice NN O O
daily NN O O
( NN O O
n NN O O
= NN O O
53 NN O O
) NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14.2 NN O O
) NN O O
] NN O O
. NN O O
Patients NN O O
with NN O O
abnormal NN O O
LVEF NN O O
, NN O O
history NN O O
of NN O O
acute NN O O
coronary NN O O
syndrome NN O O
within NN O O
6 NN O O
months NN O O
, NN O O
current NN O O
evidence NN O O
of NN O O
Class NN O O
II NN O O
or NN O O
greater NN O O
congestive NN O O
heart NN O O
failure NN O O
( NN O O
New NN O O
York NN O O
Heart NN O O
Association NN O O
) NN O O
, NN O O
history NN O O
RVO NN O O
or NN O O
RPED NN O O
, NN O O
QTc NN O O
interval NN O O
>=480 NN O O
msec NN O O
, NN O O
treatment NN O O
refractory NN O O
hypertension NN O O
, NN O O
uncontrolled NN O O
arrhythmias NN O O
, NN O O
history NN O O
of NN O O
pneumonitis NN O O
or NN O O
interstitial NN O O
lung NN O O
disease NN O O
, NN O O
or NN O O
a NN O O
known NN O O
history NN O O
of NN O O
G6PD NN O O
deficiency NN O O
were NN O O
excluded NN O O
. NN O O
The NN O O
median NN O O
duration NN O O
of NN O O
treatment NN O O
was NN O O
10.9 NN O O
months NN O O
for NN O O
both NN O O
TAFINLAR NN O O
and NN O O
trametinib NN O O
( NN O O
2-mg NN O O
orally NN O O
once NN O O
- NN O O
daily NN O O
treatment NN O O
group NN O O
) NN O O
when NN O O
used NN O O
in NN O O
combination NN O O
, NN O O
10.6 NN O O
months NN O O
for NN O O
both NN O O
TAFINLAR NN O O
and NN O O
trametinib NN O O
( NN O O
1-mg NN O O
orally NN O O
once NN O O
- NN O O
daily NN O O
treatment NN O O
group NN O O
) NN O O
when NN O O
used NN O O
in NN O O
combination NN O O
, NN O O
and NN O O
6.1 NN O O
months NN O O
for NN O O
TAFINLAR NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
. NN O O
In NN O O
Trial NN O O
2 NN O O
, NN O O
13 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
experienced NN O O
adverse NN O O
reactions NN O O
resulting NN O O
in NN O O
permanent NN O O
discontinuation NN O O
of NN O O
trial NN O O
medication(s NN O O
) NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reaction NN O O
resulting NN O O
in NN O O
permanent NN O O
discontinuation NN O O
was NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
( NN O O
4 NN O O
% NN O O
) NN O O
. NN O O
Adverse NN O O
reactions NN O O
led NN O O
to NN O O
dose NN O O
reductions NN O O
in NN O O
49 NN O O
% NN O O
and NN O O
dose NN O O
interruptions NN O O
in NN O O
67 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
. NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
chills NN B-AdverseReaction B-AdverseReaction
and NN O O
nausea NN B-AdverseReaction B-AdverseReaction
were NN O O
the NN O O
most NN O O
common NN O O
reasons NN O O
cited NN O O
for NN O O
dose NN O O
reductions NN O O
and NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
chills NN B-AdverseReaction B-AdverseReaction
and NN O O
decreased NN B-AdverseReaction B-AdverseReaction
ejection NN I-AdverseReaction I-AdverseReaction
fraction NN I-AdverseReaction I-AdverseReaction
were NN O O
the NN O O
most NN O O
common NN O O
reasons NN O O
cited NN O O
for NN O O
dose NN O O
interruptions NN O O
of NN O O
TAFINLAR NN O O
and NN O O
trametinib NN O O
when NN O O
used NN O O
in NN O O
combination NN O O
. NN O O
Table NN O O
5 NN O O
. NN O O
Common NN O O
Adverse NN O O
Drug NN O O
Reactions NN O O
Occurring NN O O
in NN O O
>=10 NN O O
% NN O O
at NN O O
( NN O O
All NN O O
Grades NN O O
) NN O O
or NN O O
>=5 NN O O
% NN O O
( NN O O
Grades NN O O
3 NN O O
or NN O O
4 NN O O
) NN O O
of NN O O
Patients NN O O
Treated NN O O
With NN O O
TAFINLAR NN O O
in NN O O
Combination NN O O
With NN O O
Trametinib NN O O
in NN O O
Trial NN O O
2 NN O O
Adverse NN O O
Reactions NN O O
TAFINLAR NN O O
plus NN O O
Trametinib NN O O
2 NN O O
mg NN O O
N NN O O
= NN O O
55 NN O O
TAFINLAR NN O O
plus NN O O
Trametinib NN O O
1 NN O O
mg NN O O
N NN O O
= NN O O
54 NN O O
TAFINLAR NN O O
N NN O O
= NN O O
53 NN O O
All NN O O
Gradesa NN O O
Grades NN O O
3 NN O O
and NN O O
4 NN O O
All NN O O
Gradesa NN O O
Grades NN O O
3 NN O O
and NN O O
4 NN O O
All NN O O
Gradesa NN O O
Grades NN O O
3 NN O O
and NN O O
4 NN O O
General NN O O
disorders NN O O
and NN O O
administrative NN O O
site NN O O
conditions NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
71 NN O O
5 NN O O
69 NN O O
9 NN O O
26 NN O O
0 NN O O
Chills NN B-AdverseReaction B-AdverseReaction
58 NN O O
2 NN O O
50 NN O O
2 NN O O
17 NN O O
0 NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
53 NN O O
4 NN O O
57 NN O O
2 NN O O
40 NN O O
6 NN O O
Edema NN B-AdverseReaction B-AdverseReaction
peripheral NN I-AdverseReaction I-AdverseReaction
b NN O O
31 NN O O
0 NN O O
28 NN O O
0 NN O O
17 NN O O
0 NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
Rash NN B-AdverseReaction B-AdverseReaction
c NN O O
45 NN O O
0 NN O O
43 NN O O
2 NN O O
53 NN O O
0 NN O O
Night NN B-AdverseReaction B-AdverseReaction
Sweats NN I-AdverseReaction I-AdverseReaction
24 NN O O
0 NN O O
15 NN O O
0 NN O O
6 NN O O
0 NN O O
Dry NN B-AdverseReaction B-AdverseReaction
skin NN I-AdverseReaction I-AdverseReaction
18 NN O O
0 NN O O
9 NN O O
0 NN O O
6 NN O O
0 NN O O
Dermatitis NN B-AdverseReaction B-AdverseReaction
acneiform NN I-AdverseReaction I-AdverseReaction
16 NN O O
0 NN O O
11 NN O O
0 NN O O
4 NN O O
0 NN O O
Actinic NN B-AdverseReaction B-AdverseReaction
keratosis NN I-AdverseReaction I-AdverseReaction
15 NN O O
0 NN O O
7 NN O O
0 NN O O
9 NN O O
0 NN O O
Erythema NN B-AdverseReaction B-AdverseReaction
15 NN O O
0 NN O O
6 NN O O
0 NN O O
2 NN O O
0 NN O O
Pruritus NN B-AdverseReaction B-AdverseReaction
11 NN O O
0 NN O O
11 NN O O
0 NN O O
13 NN O O
0 NN O O
Gastrointestinal NN O O
disorders NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
44 NN O O
2 NN O O
46 NN O O
6 NN O O
21 NN O O
0 NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
40 NN O O
2 NN O O
43 NN O O
4 NN O O
15 NN O O
0 NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
36 NN O O
2 NN O O
26 NN O O
0 NN O O
28 NN O O
0 NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
d NN O O
33 NN O O
2 NN O O
24 NN O O
2 NN O O
21 NN O O
2 NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
22 NN O O
0 NN O O
17 NN O O
2 NN O O
11 NN O O
0 NN O O
Dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
11 NN O O
0 NN O O
11 NN O O
0 NN O O
6 NN O O
0 NN O O
Nervous NN O O
system NN O O
disorders NN O O
Headache NN B-AdverseReaction B-AdverseReaction
29 NN O O
0 NN O O
37 NN O O
2 NN O O
28 NN O O
0 NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
16 NN O O
0 NN O O
13 NN O O
0 NN O O
9 NN O O
0 NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
, NN O O
and NN O O
mediastinal NN O O
disorders NN O O
Cough NN B-AdverseReaction B-AdverseReaction
29 NN O O
0 NN O O
11 NN O O
0 NN O O
21 NN O O
0 NN O O
Oropharyngeal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
13 NN O O
0 NN O O
7 NN O O
0 NN O O
0 NN O O
0 NN O O
Musculoskeletal NN O O
, NN O O
connective NN O O
tissue NN O O
, NN O O
and NN O O
bone NN O O
disorders NN O O
Arthralgia NN B-AdverseReaction B-AdverseReaction
27 NN O O
0 NN O O
44 NN O O
0 NN O O
34 NN O O
0 NN O O
Myalgia NN B-AdverseReaction B-AdverseReaction
22 NN O O
2 NN O O
24 NN O O
0 NN O O
23 NN O O
2 NN O O
Back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
18 NN O O
5 NN O O
11 NN O O
0 NN O O
11 NN O O
2 NN O O
Muscle NN B-AdverseReaction B-AdverseReaction
spasms NN I-AdverseReaction I-AdverseReaction
16 NN O O
0 NN O O
2 NN O O
0 NN O O
4 NN O O
0 NN O O
Pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
16 NN O O
0 NN O O
11 NN O O
2 NN O O
19 NN O O
0 NN O O
Metabolism NN O O
and NN O O
nutritional NN O O
disorders NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
22 NN O O
0 NN O O
30 NN O O
0 NN O O
19 NN O O
0 NN O O
Dehydration NN B-AdverseReaction B-AdverseReaction
11 NN O O
0 NN O O
6 NN O O
2 NN O O
2 NN O O
0 NN O O
Psychiatric NN O O
Disorders NN O O
Insomnia NN B-AdverseReaction B-AdverseReaction
18 NN O O
0 NN O O
11 NN O O
0 NN O O
8 NN O O
2 NN O O
Vascular NN O O
disorders NN O O
Hemorrhage NN B-AdverseReaction B-AdverseReaction
e NN O O
16 NN O O
5 NN O O
11 NN O O
0 NN O O
2 NN O O
0 NN O O
Infections NN O O
and NN O O
infestations NN O O
Urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
13 NN O O
2 NN O O
6 NN O O
0 NN O O
9 NN O O
2 NN O O
Renal NN O O
and NN O O
urinary NN O O
disorders NN O O
Renal NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
f NN O O
7 NN O O
7 NN O O
2 NN O O
0 NN O O
0 NN O O
0 NN O O
a NN O O
National NN O O
Cancer NN O O
Institute NN O O
Common NN O O
Terminology NN O O
Criteria NN O O
for NN O O
Adverse NN O O
Events NN O O
, NN O O
version NN O O
4 NN O O
. NN O O
b NN O O
Includes NN O O
the NN O O
following NN O O
terms NN O O
: NN O O
peripheral NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
edema NN B-AdverseReaction B-AdverseReaction
and NN O O
lymphedema NN B-AdverseReaction B-AdverseReaction
c NN O O
Includes NN O O
the NN O O
following NN O O
terms NN O O
: NN O O
rash NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
generalized NN I-AdverseReaction I-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
pruritic NN I-AdverseReaction I-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
erythematous NN I-AdverseReaction I-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
papular NN I-AdverseReaction I-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
vesicular NN I-AdverseReaction I-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
macular NN I-AdverseReaction I-AdverseReaction
and NN O O
rash NN B-AdverseReaction B-AdverseReaction
maculo NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
papular NN I-AdverseReaction I-AdverseReaction
d NN O O
Includes NN O O
the NN O O
following NN O O
terms NN O O
: NN O O
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
upper NN I-AdverseReaction I-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
lower NN I-AdverseReaction I-AdverseReaction
and NN O O
abdominal NN B-AdverseReaction B-AdverseReaction
discomfort NN I-AdverseReaction I-AdverseReaction
e NN O O
Includes NN O O
the NN O O
following NN O O
terms NN O O
: NN O O
brain NN B-AdverseReaction B-AdverseReaction
stem NN I-AdverseReaction I-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
cerebral NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
gastric NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
epistaxis NN B-AdverseReaction B-AdverseReaction
gingival NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
hematuria NN B-AdverseReaction B-AdverseReaction
vaginal NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
hemorrhage NN B-AdverseReaction B-AdverseReaction
intracranial NN I-AdverseReaction I-AdverseReaction
eye NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
and NN O O
vitreous NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
f NN O O
Includes NN O O
the NN O O
following NN O O
terms NN O O
: NN O O
renal NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
and NN O O
renal NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
acute NN I-AdverseReaction I-AdverseReaction
Other NN O O
clinically NN O O
important NN O O
adverse NN O O
reactions NN O O
( NN O O
N NN O O
= NN O O
202 NN O O
) NN O O
observed NN O O
in NN O O
< NN O O
10 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
were NN O O
: NN O O
Eye NN O O
Disorders NN O O
: NN O O
Vision NN B-AdverseReaction B-AdverseReaction
blurred NN I-AdverseReaction I-AdverseReaction
transient NN B-AdverseReaction B-AdverseReaction
blindness NN I-AdverseReaction I-AdverseReaction
Gastrointestinal NN O O
Disorders NN O O
: NN O O
Stomatitis NN B-AdverseReaction B-AdverseReaction
pancreatitis NN B-AdverseReaction B-AdverseReaction
General NN O O
Disorders NN O O
and NN O O
Administration NN O O
Site NN O O
Conditions NN O O
: NN O O
Asthenia NN B-AdverseReaction B-AdverseReaction
Infections NN O O
and NN O O
Infestations NN O O
: NN O O
Cellulitis NN B-AdverseReaction B-AdverseReaction
folliculitis NN B-AdverseReaction B-AdverseReaction
paronychia NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
pustular NN I-AdverseReaction I-AdverseReaction
Neoplasms NN O O
Benign NN O O
, NN O O
Malignant NN O O
, NN O O
and NN O O
Unspecified NN O O
( NN O O
including NN O O
cysts NN O O
and NN O O
polyps NN O O
) NN O O
: NN O O
Skin NN B-AdverseReaction B-AdverseReaction
papilloma NN I-AdverseReaction I-AdverseReaction
Skin NN O O
and NN O O
Subcutaneous NN O O
Tissue NN O O
Disorders NN O O
: NN O O
Palmar NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
plantar NN I-AdverseReaction I-AdverseReaction
erythrodysesthesia NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
hyperkeratosis NN B-AdverseReaction B-AdverseReaction
hyperhidrosis NN B-AdverseReaction B-AdverseReaction
Vascular NN O O
Disorders NN O O
: NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
Table NN O O
6 NN O O
. NN O O
Treatment NN O O
- NN O O
Emergent NN O O
Laboratory NN O O
Abnormalities NN O O
Occurring NN O O
at NN O O
>=10 NN O O
% NN O O
( NN O O
All NN O O
Grades NN O O
) NN O O
or NN O O
>=2 NN O O
% NN O O
( NN O O
Grades NN O O
3 NN O O
or NN O O
4 NN O O
) NN O O
] NN O O
of NN O O
Patients NN O O
Treated NN O O
With NN O O
TAFINLAR NN O O
in NN O O
Combination NN O O
With NN O O
Trametinib NN O O
in NN O O
Trial NN O O
2 NN O O
Tests NN O O
TAFINLAR NN O O
plus NN O O
Trametinib NN O O
2 NN O O
mg NN O O
N NN O O
= NN O O
55 NN O O
TAFINLAR NN O O
plus NN O O
Trametinib NN O O
1 NN O O
mg NN O O
N NN O O
= NN O O
54 NN O O
TAFINLAR NN O O
N NN O O
= NN O O
53 NN O O
All NN O O
Grades NN O O
Grades NN O O
3 NN O O
and NN O O
4 NN O O
All NN O O
Grades NN O O
Grades NN O O
3 NN O O
and NN O O
4 NN O O
All NN O O
Grades NN O O
Grades NN O O
3 NN O O
and NN O O
4a NN O O
Hematology NN O O
Leukopenia NN B-AdverseReaction B-AdverseReaction
62 NN O O
5 NN O O
46 NN O O
4 NN O O
21 NN O O
0 NN O O
Lymphopenia NN B-AdverseReaction B-AdverseReaction
55 NN O O
22 NN O O
59 NN O O
19 NN O O
40 NN O O
6 NN O O
Neutropenia NN B-AdverseReaction B-AdverseReaction
55 NN O O
13 NN O O
37 NN O O
2 NN O O
9 NN O O
2 NN O O
Anemia NN B-AdverseReaction B-AdverseReaction
55 NN O O
4 NN O O
46 NN O O
7 NN O O
28 NN O O
0 NN O O
Thrombocytopenia NN B-AdverseReaction B-AdverseReaction
31 NN O O
4 NN O O
31 NN O O
2 NN O O
8 NN O O
0 NN O O
Liver NN O O
Function NN O O
Tests NN O O
Increased NN B-AdverseReaction B-AdverseReaction
AST NN I-AdverseReaction I-AdverseReaction
60 NN O O
5 NN O O
54 NN O O
0 NN O O
15 NN O O
0 NN O O
Increased NN B-AdverseReaction B-AdverseReaction
alkaline NN I-AdverseReaction I-AdverseReaction
phosphatase NN I-AdverseReaction I-AdverseReaction
60 NN O O
2 NN O O
67 NN O O
6 NN O O
26 NN O O
2 NN O O
Increased NN B-AdverseReaction B-AdverseReaction
ALT NN I-AdverseReaction I-AdverseReaction
42 NN O O
4 NN O O
35 NN O O
4 NN O O
11 NN O O
0 NN O O
Hyperbilirubinemia NN B-AdverseReaction B-AdverseReaction
15 NN O O
0 NN O O
7 NN O O
4 NN O O
0 NN O O
0 NN O O
Chemistry NN O O
Hyperglycemia NN B-AdverseReaction B-AdverseReaction
58 NN O O
5 NN O O
67 NN O O
6 NN O O
49 NN O O
2 NN O O
Increased NN B-AdverseReaction B-AdverseReaction
GGT NN I-AdverseReaction I-AdverseReaction
56 NN O O
11 NN O O
54 NN O O
17 NN O O
38 NN O O
2 NN O O
Hyponatremia NN B-AdverseReaction B-AdverseReaction
55 NN O O
11 NN O O
48 NN O O
15 NN O O
36 NN O O
2 NN O O
Hypoalbuminemia NN B-AdverseReaction B-AdverseReaction
53 NN O O
0 NN O O
43 NN O O
2 NN O O
23 NN O O
0 NN O O
Hypophosphatemia NN B-AdverseReaction B-AdverseReaction
47 NN O O
5 NN O O
41 NN O O
11 NN O O
40 NN O O
0 NN O O
Hypokalemia NN B-AdverseReaction B-AdverseReaction
29 NN O O
2 NN O O
15 NN O O
2 NN O O
23 NN O O
6 NN O O
Increased NN B-AdverseReaction B-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
24 NN O O
5 NN O O
20 NN O O
2 NN O O
9 NN O O
0 NN O O
Hypomagnesemia NN B-AdverseReaction B-AdverseReaction
18 NN O O
2 NN O O
2 NN O O
0 NN O O
6 NN O O
0 NN O O
Hyperkalemia NN B-AdverseReaction B-AdverseReaction
18 NN O O
0 NN O O
22 NN O O
0 NN O O
15 NN O O
4 NN O O
Hypercalcemia NN B-AdverseReaction B-AdverseReaction
15 NN O O
0 NN O O
19 NN O O
2 NN O O
4 NN O O
0 NN O O
Hypocalcemia NN B-AdverseReaction B-AdverseReaction
13 NN O O
0 NN O O
20 NN O O
0 NN O O
9 NN O O
0 NN O O
a NN O O
No NN O O
Grade NN O O
4 NN O O
events NN O O
were NN O O
reported NN O O
in NN O O
patients NN O O
receiving NN O O
TAFINLAR NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
. NN O O
ALT NN O O
= NN O O
Alanine NN O O
aminotransferase NN O O
; NN O O
AST NN O O
= NN O O
Aspartate NN O O
aminotransferase NN O O
; NN O O
GGT NN O O
= NN O O
Gamma NN O O
glutamyltransferase NN O O
. NN O O
QT NN O O
Prolongation NN O O
: NN O O
In NN O O
Trial NN O O
2 NN O O
, NN O O
QTcF NN B-AdverseReaction B-AdverseReaction
prolongation NN I-AdverseReaction I-AdverseReaction
to NN O O
>500 NN O O
msec NN O O
occurred NN O O
in NN O O
4 NN O O
% NN O O
( NN O O
2/55 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
and NN O O
in NN O O
2 NN O O
% NN O O
( NN O O
1/53 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
. NN O O
The NN O O
QTcF NN B-AdverseReaction B-AdverseReaction
was NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
more NN O O
than NN O O
60 NN B-Severity B-Severity
msec NN I-Severity I-Severity
from NN I-Severity I-Severity
baseline NN I-Severity I-Severity
in NN O O
13 NN O O
% NN O O
( NN O O
7/55 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
and NN O O
2 NN O O
% NN O O
( NN O O
1/53 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
Review NN O O
the NN O O
Full NN O O
Prescribing NN O O
Information NN O O
for NN O O
trametinib NN O O
prior NN O O
to NN O O
initiation NN O O
of NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
. NN O O
The NN O O
following NN O O
serious NN O O
adverse NN O O
reactions NN O O
of NN O O
trametinib NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
, NN O O
which NN O O
may NN O O
occur NN O O
when NN O O
TAFINLAR NN O O
is NN O O
used NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
, NN O O
are NN O O
not NN O O
described NN O O
in NN O O
the NN O O
Full NN O O
Prescribing NN O O
Information NN O O
for NN O O
TAFINLAR NN O O
: NN O O
* NN O O
Retinal NN B-AdverseReaction B-AdverseReaction
vein NN I-AdverseReaction I-AdverseReaction
occlusion NN I-AdverseReaction I-AdverseReaction
* NN O O
Interstitial NN B-AdverseReaction B-AdverseReaction
lung NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
* NN O O
New NN O O
primary NN B-AdverseReaction B-AdverseReaction
malignancies NN I-AdverseReaction I-AdverseReaction
, NN I-AdverseReaction I-AdverseReaction
cutaneous NN I-AdverseReaction I-AdverseReaction
and NN O O
non NN O O
- NN O O
cutaneous NN O O
, NN O O
can NN B-Factor B-Factor
occur NN O O
when NN O O
TAFINLAR NN O O
is NN O O
administered NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
or NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
. NN O O
Monitor NN O O
patients NN O O
for NN O O
new NN O O
malignancies NN O O
prior NN O O
to NN O O
initiation NN O O
of NN O O
therapy NN O O
, NN O O
while NN O O
on NN O O
therapy NN O O
, NN O O
and NN O O
following NN O O
discontinuation NN O O
of NN O O
TAFINLAR NN O O
or NN O O
the NN O O
combination NN O O
therapy NN O O
. NN O O
( NN O O
5.1 NN O O
, NN O O
2.3 NN O O
) NN O O
* NN O O
Tumor NN B-AdverseReaction B-AdverseReaction
Promotion NN I-AdverseReaction I-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
BRAF NN I-AdverseReaction I-AdverseReaction
Wild NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Type NN I-AdverseReaction I-AdverseReaction
Melanoma NN I-AdverseReaction I-AdverseReaction
Increased NN B-AdverseReaction B-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
proliferation NN I-AdverseReaction I-AdverseReaction
can NN O O
occur NN O O
with NN O O
BRAF NN B-DrugClass B-DrugClass
inhibitors NN I-DrugClass I-DrugClass
( NN O O
5.2 NN O O
) NN O O
* NN O O
Hemorrhage NN B-AdverseReaction B-AdverseReaction
Major NN B-Severity B-Severity
hemorrhagic NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
in NN O O
patients NN O O
receiving NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
. NN O O
Monitor NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
bleeding NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Venous NN B-AdverseReaction B-AdverseReaction
Thromboembolism NN I-AdverseReaction I-AdverseReaction
Deep NN B-AdverseReaction B-AdverseReaction
vein NN I-AdverseReaction I-AdverseReaction
thrombosis NN I-AdverseReaction I-AdverseReaction
and NN O O
pulmonary NN B-AdverseReaction B-AdverseReaction
embolism NN I-AdverseReaction I-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
in NN O O
patients NN O O
receiving NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
. NN O O
( NN O O
5.4 NN O O
, NN O O
2.3 NN O O
) NN O O
* NN O O
Cardiomyopathy NN B-AdverseReaction B-AdverseReaction
Assess NN O O
LVEF NN O O
before NN O O
treatment NN O O
with NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
, NN O O
after NN O O
one NN O O
month NN O O
of NN O O
treatment NN O O
, NN O O
then NN O O
every NN O O
2 NN O O
to NN O O
3 NN O O
months NN O O
thereafter NN O O
. NN O O
( NN O O
5.5 NN O O
, NN O O
2.3 NN O O
) NN O O
* NN O O
Ocular NN B-AdverseReaction B-AdverseReaction
Toxicities NN I-AdverseReaction I-AdverseReaction
Perform NN O O
ophthalmologic NN O O
evaluation NN O O
for NN O O
any NN O O
visual NN O O
disturbances NN O O
. NN O O
( NN O O
5.6 NN O O
, NN O O
2.3 NN O O
) NN O O
* NN O O
Serious NN B-Severity B-Severity
Febrile NN B-AdverseReaction B-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
Incidence NN O O
and NN O O
severity NN O O
of NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
are NN O O
increased NN O O
with NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
. NN O O
( NN O O
5.7 NN O O
, NN O O
2.3 NN O O
) NN O O
* NN O O
Serious NN B-Severity B-Severity
Skin NN B-AdverseReaction B-AdverseReaction
Toxicity NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
for NN O O
skin NN O O
toxicities NN O O
and NN O O
for NN O O
secondary NN O O
infections NN O O
. NN O O
Discontinue NN O O
for NN O O
intolerable NN O O
Grade NN O O
2 NN O O
, NN O O
or NN O O
Grade NN O O
3 NN O O
or NN O O
4 NN O O
rash NN O O
not NN O O
improving NN O O
within NN O O
3 NN O O
weeks NN O O
despite NN O O
interruption NN O O
of NN O O
TAFINLAR. NN O O
( NN O O
5.8 NN O O
, NN O O
2.3 NN O O
) NN O O
* NN O O
Hyperglycemia NN B-AdverseReaction B-AdverseReaction
Monitor NN O O
serum NN O O
glucose NN O O
levels NN O O
in NN O O
patients NN O O
with NN O O
pre NN O O
- NN O O
existing NN O O
diabetes NN O O
or NN O O
hyperglycemia NN O O
. NN O O
( NN O O
5.9 NN O O
) NN O O
* NN O O
Glucose-6-Phosphate NN B-AdverseReaction B-AdverseReaction
Dehydrogenase NN I-AdverseReaction I-AdverseReaction
Deficiency NN I-AdverseReaction I-AdverseReaction
Closely NN O O
monitor NN O O
for NN O O
hemolytic NN O O
anemia NN O O
. NN O O
( NN O O
5.10 NN O O
) NN O O
* NN O O
Embryofetal NN B-AdverseReaction B-AdverseReaction
Toxicity NN I-AdverseReaction I-AdverseReaction
Can NN B-Factor B-Factor
cause NN O O
fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
Advise NN O O
females NN O O
of NN O O
reproductive NN O O
potential NN O O
of NN O O
potential NN O O
risk NN O O
to NN O O
a NN O O
fetus NN O O
. NN O O
TAFINLAR NN O O
may NN O O
render NN O O
hormonal NN O O
contraceptives NN O O
less NN O O
effective NN O O
and NN O O
an NN O O
alternative NN O O
method NN O O
of NN O O
contraception NN O O
should NN O O
be NN O O
used NN O O
. NN O O
( NN O O
5.11 NN O O
, NN O O
8.1 NN O O
) NN O O
EXCERPT NN O O
: NN O O
5.1 NN O O
New NN O O
Primary NN O O
Malignancies NN O O
New NN O O
primary NN B-AdverseReaction B-AdverseReaction
malignancies NN I-AdverseReaction I-AdverseReaction
, NN I-AdverseReaction I-AdverseReaction
cutaneous NN I-AdverseReaction I-AdverseReaction
and NN O O
non NN O O
- NN O O
cutaneous NN O O
, NN O O
can NN B-Factor B-Factor
occur NN O O
when NN O O
TAFINLAR NN O O
is NN O O
administered NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
or NN O O
when NN O O
used NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
. NN O O
Cutaneous NN O O
Malignancies NN O O
: NN O O
TAFINLAR NN O O
results NN O O
in NN O O
an NN O O
increased NN O O
incidence NN O O
of NN O O
cutaneous NN B-AdverseReaction B-AdverseReaction
squamous NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
carcinoma NN I-AdverseReaction I-AdverseReaction
keratoacanthoma NN B-AdverseReaction B-AdverseReaction
and NN O O
melanoma NN B-AdverseReaction B-AdverseReaction
TAFINLAR NN O O
when NN O O
used NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
results NN O O
in NN O O
an NN O O
increased NN O O
incidence NN O O
of NN O O
basal NN B-AdverseReaction B-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
carcinoma NN I-AdverseReaction I-AdverseReaction
In NN O O
Trial NN O O
1 NN O O
, NN O O
cutaneous NN B-AdverseReaction B-AdverseReaction
squamous NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
carcinomas NN I-AdverseReaction I-AdverseReaction
and NN O O
keratoacanthomas NN B-AdverseReaction B-AdverseReaction
( NN O O
cuSCC NN O O
) NN O O
occurred NN O O
in NN O O
7 NN O O
% NN O O
( NN O O
14/187 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
and NN O O
in NN O O
none NN O O
of NN O O
the NN O O
patients NN O O
treated NN O O
with NN O O
dacarbazine NN O O
. NN O O
Across NN O O
clinical NN O O
trials NN O O
of NN O O
TAFINLAR NN O O
( NN O O
N NN O O
= NN O O
586 NN O O
) NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
cuSCC NN B-AdverseReaction B-AdverseReaction
was NN O O
11 NN O O
% NN O O
. NN O O
The NN O O
median NN O O
time NN O O
to NN O O
first NN O O
cuSCC NN B-AdverseReaction B-AdverseReaction
was NN O O
9 NN O O
weeks NN O O
( NN O O
range NN O O
: NN O O
1 NN O O
to NN O O
53 NN O O
weeks NN O O
) NN O O
. NN O O
Of NN O O
those NN O O
patients NN O O
who NN O O
developed NN O O
new NN O O
cuSCC NN B-AdverseReaction B-AdverseReaction
approximately NN O O
33 NN O O
% NN O O
developed NN O O
one NN O O
or NN O O
more NN O O
cuSCC NN B-AdverseReaction B-AdverseReaction
with NN O O
continued NN O O
administration NN O O
of NN O O
TAFINLAR. NN O O
The NN O O
median NN O O
time NN O O
between NN O O
diagnosis NN O O
of NN O O
the NN O O
first NN O O
cuSCC NN B-AdverseReaction B-AdverseReaction
and NN O O
the NN O O
second NN O O
cuSCC NN B-AdverseReaction B-AdverseReaction
was NN O O
6 NN O O
weeks NN O O
. NN O O
In NN O O
Trial NN O O
1 NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
new NN O O
primary NN B-AdverseReaction B-AdverseReaction
malignant NN I-AdverseReaction I-AdverseReaction
melanomas NN I-AdverseReaction I-AdverseReaction
was NN O O
2 NN O O
% NN O O
( NN O O
3/187 NN O O
) NN O O
for NN O O
patients NN O O
receiving NN O O
TAFINLAR NN O O
while NN O O
no NN O O
dacarbazine NN O O
- NN O O
treated NN O O
patient NN O O
was NN O O
diagnosed NN O O
with NN O O
new NN O O
primary NN O O
malignant NN O O
melanoma NN O O
. NN O O
In NN O O
Trial NN O O
2 NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
basal NN B-AdverseReaction B-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
carcinoma NN I-AdverseReaction I-AdverseReaction
was NN O O
increased NN O O
in NN O O
patients NN O O
receiving NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
: NN O O
9 NN O O
% NN O O
( NN O O
5/55 NN O O
) NN O O
of NN O O
patients NN O O
receiving NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
compared NN O O
with NN O O
2 NN O O
% NN O O
( NN O O
1/53 NN O O
) NN O O
of NN O O
patients NN O O
receiving NN O O
TAFINLAR NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
. NN O O
The NN O O
range NN O O
of NN O O
time NN O O
to NN O O
diagnosis NN O O
of NN O O
basal NN B-AdverseReaction B-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
carcinoma NN I-AdverseReaction I-AdverseReaction
was NN O O
28 NN O O
to NN O O
249 NN O O
days NN O O
in NN O O
patients NN O O
receiving NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
and NN O O
was NN O O
197 NN O O
days NN O O
for NN O O
the NN O O
patient NN O O
receiving NN O O
TAFINLAR NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
. NN O O
Cutaneous NN B-AdverseReaction B-AdverseReaction
squamous NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
carcinoma NN I-AdverseReaction I-AdverseReaction
( NN O O
SCC NN O O
) NN O O
, NN O O
including NN O O
keratoacanthoma NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
7 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
and NN O O
19 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
TAFINLAR NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
. NN O O
The NN O O
range NN O O
of NN O O
time NN O O
to NN O O
diagnosis NN O O
of NN O O
cuSCC NN B-AdverseReaction B-AdverseReaction
was NN O O
136 NN O O
to197 NN O O
days NN O O
in NN O O
the NN O O
combination NN O O
arm NN O O
and NN O O
was NN O O
9 NN O O
to NN O O
197 NN O O
days NN O O
in NN O O
the NN O O
arm NN O O
receiving NN O O
TAFINLAR NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
. NN O O
New NN O O
primary NN B-AdverseReaction B-AdverseReaction
melanoma NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
2 NN O O
% NN O O
( NN O O
1/53 NN O O
) NN O O
of NN O O
patients NN O O
receiving NN O O
TAFINLAR NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
and NN O O
in NN O O
none NN O O
of NN O O
the NN O O
55 NN O O
patients NN O O
receiving NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
. NN O O
Perform NN O O
dermatologic NN O O
evaluations NN O O
prior NN O O
to NN O O
initiation NN O O
of NN O O
TAFINLAR NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
or NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
, NN O O
every NN O O
2 NN O O
months NN O O
while NN O O
on NN O O
therapy NN O O
, NN O O
and NN O O
for NN O O
up NN O O
to NN O O
6 NN O O
months NN O O
following NN O O
discontinuation NN O O
of NN O O
TAFINLAR. NN O O
No NN O O
dose NN O O
modifications NN O O
of NN O O
TAFINLAR NN O O
or NN O O
trametinib NN O O
are NN O O
required NN O O
in NN O O
patients NN O O
who NN O O
develop NN O O
new NN O O
primary NN O O
cutaneous NN O O
malignancies NN O O
. NN O O
Non NN O O
- NN O O
cutaneous NN O O
Malignancies NN O O
: NN O O
Based NN O O
on NN O O
its NN O O
mechanism NN O O
of NN O O
action NN O O
, NN O O
TAFINLAR NN O O
may NN B-Factor B-Factor
promote NN O O
the NN O O
growth NN O O
and NN O O
development NN O O
of NN O O
malignancies NN B-AdverseReaction B-AdverseReaction
with NN O O
activation NN O O
of NN O O
RAS NN O O
through NN O O
mutation NN O O
or NN O O
other NN O O
mechanisms NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
In NN O O
patients NN O O
receiving NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
four NN O O
cases NN O O
of NN O O
non NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
cutaneous NN I-AdverseReaction I-AdverseReaction
malignancies NN I-AdverseReaction I-AdverseReaction
were NN O O
identified NN O O
: NN O O
KRAS NN B-AdverseReaction B-AdverseReaction
mutation NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
positive NN I-AdverseReaction I-AdverseReaction
pancreatic NN I-AdverseReaction I-AdverseReaction
adenocarcinoma NN I-AdverseReaction I-AdverseReaction
( NN O O
n NN O O
= NN O O
1 NN O O
) NN O O
, NN O O
recurrent NN B-AdverseReaction B-AdverseReaction
NRAS NN I-AdverseReaction I-AdverseReaction
mutation NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
positive NN I-AdverseReaction I-AdverseReaction
colorectal NN I-AdverseReaction I-AdverseReaction
carcinoma NN I-AdverseReaction I-AdverseReaction
( NN O O
n NN O O
= NN O O
1 NN O O
) NN O O
, NN O O
head NN B-AdverseReaction B-AdverseReaction
and NN I-AdverseReaction I-AdverseReaction
neck NN I-AdverseReaction I-AdverseReaction
carcinoma NN I-AdverseReaction I-AdverseReaction
( NN O O
n NN O O
= NN O O
1 NN O O
) NN O O
, NN O O
and NN O O
glioblastoma NN B-AdverseReaction B-AdverseReaction
( NN O O
n NN O O
= NN O O
1 NN O O
) NN O O
. NN O O
Monitor NN O O
patients NN O O
receiving NN O O
the NN O O
combination NN O O
closely NN O O
for NN O O
signs NN O O
or NN O O
symptoms NN O O
of NN O O
non NN O O
- NN O O
cutaneous NN O O
malignancies NN O O
. NN O O
Permanently NN O O
discontinue NN O O
TAFINLAR NN O O
for NN O O
RAS NN O O
mutation NN O O
- NN O O
positive NN O O
non NN O O
- NN O O
cutaneous NN O O
malignancies NN O O
. NN O O
If NN O O
used NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
, NN O O
no NN O O
dose NN O O
modification NN O O
of NN O O
trametinib NN O O
is NN O O
required NN O O
for NN O O
patients NN O O
who NN O O
develop NN O O
non NN O O
- NN O O
cutaneous NN O O
malignancies NN O O
. NN O O
5.2 NN O O
Tumor NN O O
Promotion NN O O
in NN O O
BRAF NN O O
Wild NN O O
- NN O O
Type NN O O
Melanoma NN O O
In NN O O
vitro NN O O
experiments NN O O
have NN O O
demonstrated NN O O
paradoxical NN O O
activation NN O O
of NN O O
MAP NN O O
- NN O O
kinase NN O O
signaling NN O O
and NN O O
increased NN B-AdverseReaction B-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
proliferation NN I-AdverseReaction I-AdverseReaction
in NN O O
BRAF NN O O
wild NN O O
- NN O O
type NN O O
cells NN O O
which NN O O
are NN O O
exposed NN O O
to NN O O
BRAF NN B-DrugClass B-DrugClass
inhibitors NN I-DrugClass I-DrugClass
Confirm NN O O
evidence NN O O
of NN O O
BRAF NN O O
V600E NN O O
or NN O O
V600K NN O O
mutation NN O O
status NN O O
prior NN O O
to NN O O
initiation NN O O
of NN O O
TAFINLAR NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
or NN O O
combination NN O O
therapy NN O O
[ NN O O
see NN O O
Indications NN O O
and NN O O
Usage NN O O
( NN O O
1 NN O O
) NN O O
, NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.1 NN O O
) NN O O
] NN O O
. NN O O
5.3 NN O O
Hemorrhage NN O O
Hemorrhages NN B-AdverseReaction B-AdverseReaction
including NN O O
major NN B-Severity B-Severity
hemorrhages NN B-AdverseReaction B-AdverseReaction
defined NN O O
as NN O O
symptomatic NN B-AdverseReaction B-AdverseReaction
bleeding NN I-AdverseReaction I-AdverseReaction
in NN O O
a NN O O
critical NN O O
area NN O O
or NN O O
organ NN O O
, NN O O
can NN B-Factor B-Factor
occur NN O O
when NN O O
TAFINLAR NN O O
is NN O O
used NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
. NN O O
In NN O O
Trial NN O O
2 NN O O
, NN O O
treatment NN O O
with NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
resulted NN O O
in NN O O
an NN O O
increased NN O O
incidence NN O O
and NN O O
severity NN O O
of NN O O
any NN O O
hemorrhagic NN B-AdverseReaction B-AdverseReaction
event NN I-AdverseReaction I-AdverseReaction
16 NN O O
% NN O O
( NN O O
9/55 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
compared NN O O
with NN O O
2 NN O O
% NN O O
( NN O O
1/53 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
. NN O O
The NN O O
major NN B-Severity B-Severity
hemorrhagic NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
of NN O O
intracranial NN O O
or NN O O
gastric NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
5 NN O O
% NN O O
( NN O O
3/55 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
compared NN O O
with NN O O
none NN O O
of NN O O
the NN O O
53 NN O O
patients NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
. NN O O
Intracranial NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
was NN O O
fatal NN B-AdverseReaction B-AdverseReaction
in NN O O
4 NN O O
% NN O O
( NN O O
2/55 NN O O
) NN O O
of NN O O
patients NN O O
receiving NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
. NN O O
Permanently NN O O
discontinue NN O O
TAFINLAR NN O O
and NN O O
trametinib NN O O
for NN O O
all NN O O
Grade NN O O
4 NN O O
hemorrhagic NN O O
events NN O O
and NN O O
for NN O O
any NN O O
Grade NN O O
3 NN O O
hemorrhagic NN O O
events NN O O
that NN O O
do NN O O
not NN O O
improve NN O O
. NN O O
Withhold NN O O
TAFINLAR NN O O
for NN O O
Grade NN O O
3 NN O O
hemorrhagic NN O O
events NN O O
; NN O O
if NN O O
improved NN O O
resume NN O O
at NN O O
a NN O O
lower NN O O
dose NN O O
level NN O O
. NN O O
Withhold NN O O
trametinib NN O O
for NN O O
up NN O O
to NN O O
3 NN O O
weeks NN O O
for NN O O
Grade NN O O
3 NN O O
hemorrhagic NN O O
events NN O O
; NN O O
if NN O O
improved NN O O
, NN O O
resume NN O O
at NN O O
a NN O O
lower NN O O
dose NN O O
level NN O O
. NN O O
5.4 NN O O
Venous NN O O
Thromboembolism NN O O
Venous NN B-AdverseReaction B-AdverseReaction
thromboembolism NN I-AdverseReaction I-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
when NN O O
TAFINLAR NN O O
is NN O O
used NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
. NN O O
In NN O O
Trial NN O O
2 NN O O
, NN O O
treatment NN O O
with NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
resulted NN O O
in NN O O
an NN O O
increased NN O O
incidence NN O O
of NN O O
deep NN B-AdverseReaction B-AdverseReaction
venous NN I-AdverseReaction I-AdverseReaction
thrombosis NN I-AdverseReaction I-AdverseReaction
( NN O O
DVT NN O O
) NN O O
and NN O O
pulmonary NN B-AdverseReaction B-AdverseReaction
embolism NN I-AdverseReaction I-AdverseReaction
( NN O O
PE NN O O
) NN O O
: NN O O
7 NN O O
% NN O O
( NN O O
4/55 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
compared NN O O
with NN O O
none NN O O
of NN O O
the NN O O
53 NN O O
patients NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
. NN O O
Pulmonary NN B-AdverseReaction B-AdverseReaction
embolism NN I-AdverseReaction I-AdverseReaction
was NN O O
fatal NN B-AdverseReaction B-AdverseReaction
in NN O O
2 NN O O
% NN O O
( NN O O
1/55 NN O O
) NN O O
of NN O O
patients NN O O
receiving NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
. NN O O
Advise NN O O
patients NN O O
to NN O O
immediately NN O O
seek NN O O
medical NN O O
care NN O O
if NN O O
they NN O O
develop NN O O
symptoms NN O O
of NN O O
DVT NN O O
or NN O O
PE NN O O
, NN O O
such NN O O
as NN O O
shortness NN O O
of NN O O
breath NN O O
, NN O O
chest NN O O
pain NN O O
, NN O O
or NN O O
arm NN O O
or NN O O
leg NN O O
swelling NN O O
. NN O O
Permanently NN O O
discontinue NN O O
TAFINLAR NN O O
and NN O O
trametinib NN O O
for NN O O
life NN O O
- NN O O
threatening NN O O
PE. NN O O
Withhold NN O O
trametinib NN O O
and NN O O
continue NN O O
TAFINLAR NN O O
at NN O O
the NN O O
same NN O O
dose NN O O
for NN O O
uncomplicated NN O O
DVT NN O O
or NN O O
PE NN O O
; NN O O
if NN O O
improved NN O O
within NN O O
3 NN O O
weeks NN O O
, NN O O
trametinib NN O O
may NN O O
be NN O O
resumed NN O O
at NN O O
a NN O O
lower NN O O
dose NN O O
level NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
] NN O O
. NN O O
5.5 NN O O
Cardiomyopathy NN O O
Cardiomyopathy NN B-AdverseReaction B-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
when NN O O
TAFINLAR NN O O
is NN O O
used NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
and NN O O
with NN O O
trametinib NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
[ NN O O
refer NN O O
to NN O O
Full NN O O
Prescribing NN O O
Information NN O O
for NN O O
trametinib NN O O
] NN O O
. NN O O
In NN O O
Trial NN O O
2 NN O O
, NN O O
cardiomyopathy NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
9 NN O O
% NN O O
( NN O O
5/55 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
and NN O O
in NN O O
none NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
. NN O O
The NN O O
median NN O O
time NN O O
to NN O O
onset NN O O
of NN O O
cardiomyopathy NN B-AdverseReaction B-AdverseReaction
in NN O O
patients NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
was NN O O
86 NN O O
days NN O O
( NN O O
range NN O O
: NN O O
27 NN O O
to NN O O
253 NN O O
days NN O O
) NN O O
. NN O O
Cardiomyopathy NN B-AdverseReaction B-AdverseReaction
was NN O O
identified NN O O
within NN O O
the NN O O
first NN O O
month NN O O
of NN O O
treatment NN O O
with NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
in NN O O
two NN O O
of NN O O
five NN O O
patients NN O O
. NN O O
Development NN O O
of NN O O
cardiomyopathy NN B-AdverseReaction B-AdverseReaction
resolved NN O O
in NN O O
all NN O O
five NN O O
patients NN O O
following NN O O
dose NN O O
reduction NN O O
( NN O O
4/55 NN O O
) NN O O
and/or NN O O
dose NN O O
interruption NN O O
( NN O O
1/55 NN O O
) NN O O
. NN O O
Across NN O O
clinical NN O O
trials NN O O
of NN O O
TAFINLAR NN O O
administered NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
( NN O O
N NN O O
= NN O O
202 NN O O
) NN O O
, NN O O
8 NN O O
% NN O O
of NN O O
patients NN O O
developed NN O O
evidence NN O O
of NN O O
cardiomyopathy NN B-AdverseReaction B-AdverseReaction
( NN O O
decrease NN O O
in NN O O
LVEF NN O O
below NN O O
institutional NN B-Severity B-Severity
lower NN I-Severity I-Severity
limits NN I-Severity I-Severity
of NN I-Severity I-Severity
normal NN I-Severity I-Severity
with NN O O
an NN O O
absolute NN B-AdverseReaction B-AdverseReaction
decrease NN I-AdverseReaction I-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
LVEF NN I-AdverseReaction I-AdverseReaction
>=10 NN O O
% NN O O
below NN O O
baseline NN O O
) NN O O
. NN O O
Two NN O O
percent NN O O
demonstrated NN O O
a NN O O
decrease NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
LVEF NN I-AdverseReaction I-AdverseReaction
below NN O O
institutional NN B-Severity B-Severity
lower NN I-Severity I-Severity
limits NN I-Severity I-Severity
of NN I-Severity I-Severity
normal NN I-Severity I-Severity
with NN O O
an NN O O
absolute NN B-AdverseReaction B-AdverseReaction
decrease NN I-AdverseReaction I-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
LVEF NN I-AdverseReaction I-AdverseReaction
of NN O O
>=20 NN O O
% NN O O
below NN O O
baseline NN O O
. NN O O
Assess NN O O
LVEF NN O O
by NN O O
echocardiogram NN O O
or NN O O
multigated NN O O
acquisition NN O O
( NN O O
MUGA NN O O
) NN O O
scan NN O O
before NN O O
initiation NN O O
of NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
, NN O O
one NN O O
month NN O O
after NN O O
initiation NN O O
, NN O O
and NN O O
then NN O O
at NN O O
2- NN O O
to NN O O
3-month NN O O
intervals NN O O
while NN O O
on NN O O
treatment NN O O
with NN O O
the NN O O
combination NN O O
. NN O O
Withhold NN O O
treatment NN O O
with NN O O
trametinib NN O O
and NN O O
continue NN O O
TAFINLAR NN O O
at NN O O
the NN O O
same NN O O
dose NN O O
if NN O O
absolute NN O O
LVEF NN O O
value NN O O
decreases NN O O
by NN O O
10 NN O O
% NN O O
from NN O O
pretreatment NN O O
values NN O O
and NN O O
is NN O O
less NN O O
than NN O O
the NN O O
lower NN O O
limit NN O O
of NN O O
normal NN O O
. NN O O
For NN O O
symptomatic NN O O
cardiomyopathy NN O O
or NN O O
persistent NN O O
, NN O O
asymptomatic NN O O
LV NN O O
dysfunction NN O O
that NN O O
does NN O O
not NN O O
resolve NN O O
within NN O O
4 NN O O
weeks NN O O
, NN O O
permanently NN O O
discontinue NN O O
trametinib NN O O
and NN O O
withhold NN O O
TAFINLAR. NN O O
Resume NN O O
TAFINLAR NN O O
at NN O O
the NN O O
same NN O O
dose NN O O
level NN O O
upon NN O O
recovery NN O O
of NN O O
cardiac NN O O
function NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
] NN O O
. NN O O
5.6 NN O O
Ocular NN O O
Toxicities NN O O
Retinal NN O O
Pigment NN O O
Epithelial NN O O
Detachment NN O O
( NN O O
RPED NN O O
) NN O O
: NN O O
Retinal NN B-AdverseReaction B-AdverseReaction
pigment NN I-AdverseReaction I-AdverseReaction
epithelial NN I-AdverseReaction I-AdverseReaction
detachments NN I-AdverseReaction I-AdverseReaction
( NN O O
RPED NN O O
) NN O O
can NN B-Factor B-Factor
occur NN O O
when NN O O
TAFINLAR NN O O
is NN O O
used NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
and NN O O
with NN O O
trametinib NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
[ NN O O
refer NN O O
to NN O O
Full NN O O
Prescribing NN O O
Information NN O O
for NN O O
trametinib NN O O
] NN O O
. NN O O
Retinal NN B-AdverseReaction B-AdverseReaction
detachments NN I-AdverseReaction I-AdverseReaction
resulting NN O O
from NN O O
trametinib NN O O
are NN O O
often NN O O
bilateral NN O O
and NN O O
multifocal NN O O
, NN O O
occurring NN O O
in NN O O
the NN O O
macular NN O O
region NN O O
of NN O O
the NN O O
retina NN O O
. NN O O
In NN O O
Trial NN O O
2 NN O O
, NN O O
ophthalmologic NN O O
examinations NN O O
including NN O O
retinal NN O O
evaluation NN O O
were NN O O
performed NN O O
pretreatment NN O O
and NN O O
at NN O O
regular NN O O
intervals NN O O
during NN O O
treatment NN O O
. NN O O
RPED NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
2 NN O O
% NN O O
( NN O O
1/55 NN O O
) NN O O
of NN O O
patients NN O O
receiving NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
. NN O O
Across NN O O
clinical NN O O
trials NN O O
of NN O O
TAFINLAR NN O O
administered NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
( NN O O
N NN O O
= NN O O
202 NN O O
) NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
RPED NN B-AdverseReaction B-AdverseReaction
was NN O O
1 NN O O
% NN O O
( NN O O
2/202 NN O O
) NN O O
. NN O O
Perform NN O O
ophthalmological NN O O
evaluation NN O O
at NN O O
any NN O O
time NN O O
a NN O O
patient NN O O
reports NN O O
visual NN O O
disturbances NN O O
and NN O O
compare NN O O
with NN O O
baseline NN O O
, NN O O
if NN O O
available NN O O
. NN O O
If NN O O
TAFINLAR NN O O
is NN O O
used NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
, NN O O
do NN O O
not NN O O
modify NN O O
the NN O O
dose NN O O
of NN O O
TAFINLAR. NN O O
Withhold NN O O
trametinib NN O O
if NN O O
RPED NN O O
is NN O O
diagnosed NN O O
. NN O O
If NN O O
resolution NN O O
of NN O O
the NN O O
RPED NN O O
is NN O O
documented NN O O
on NN O O
repeat NN O O
ophthalmological NN O O
evaluation NN O O
within NN O O
3 NN O O
weeks NN O O
, NN O O
resume NN O O
trametinib NN O O
at NN O O
a NN O O
lower NN O O
dose NN O O
level NN O O
. NN O O
Discontinue NN O O
trametinib NN O O
if NN O O
no NN O O
improvement NN O O
after NN O O
3 NN O O
weeks NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
] NN O O
. NN O O
Uveitis NN O O
and NN O O
Iritis NN O O
: NN O O
Uveitis NN B-AdverseReaction B-AdverseReaction
and NN O O
iritis NN B-AdverseReaction B-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
when NN O O
TAFINLAR NN O O
is NN O O
administered NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
or NN O O
when NN O O
used NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
. NN O O
Uveitis NN B-AdverseReaction B-AdverseReaction
( NN O O
including NN O O
iritis NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
1 NN O O
% NN O O
( NN O O
6/586 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
and NN O O
uveitis NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
1 NN O O
% NN O O
( NN O O
2/202 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
. NN O O
Symptomatic NN O O
treatment NN O O
employed NN O O
in NN O O
clinical NN O O
trials NN O O
included NN O O
steroid NN O O
and NN O O
mydriatic NN O O
ophthalmic NN O O
drops NN O O
. NN O O
Monitor NN O O
patients NN O O
for NN O O
visual NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
uveitis NN O O
( NN O O
e.g. NN O O
, NN O O
change NN O O
in NN O O
vision NN O O
, NN O O
photophobia NN O O
, NN O O
eye NN O O
pain NN O O
) NN O O
. NN O O
If NN O O
diagnosed NN O O
, NN O O
withhold NN O O
TAFINLAR NN O O
for NN O O
up NN O O
to NN O O
6 NN O O
weeks NN O O
until NN O O
uveitis/iritis NN O O
resolves NN O O
to NN O O
Grade NN O O
0 NN O O
- NN O O
1 NN O O
. NN O O
If NN O O
TAFINLAR NN O O
is NN O O
used NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
, NN O O
do NN O O
not NN O O
modify NN O O
the NN O O
dose NN O O
of NN O O
trametinib NN O O
. NN O O
5.7 NN O O
Serious NN O O
Febrile NN O O
Reactions NN O O
Serious NN B-Severity B-Severity
febrile NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
and NN O O
fever NN B-AdverseReaction B-AdverseReaction
of NN O O
any NN O O
severity NN O O
complicated NN O O
by NN O O
hypotension NN B-AdverseReaction B-AdverseReaction
rigors NN B-AdverseReaction B-AdverseReaction
or NN O O
chills NN B-AdverseReaction B-AdverseReaction
dehydration NN B-AdverseReaction B-AdverseReaction
or NN O O
renal NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
when NN O O
TAFINLAR NN O O
is NN O O
administered NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
or NN O O
when NN O O
used NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
. NN O O
The NN O O
incidence NN O O
and NN O O
severity NN O O
of NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
are NN O O
increased NN O O
when NN O O
TAFINLAR NN O O
is NN O O
used NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
compared NN O O
with NN O O
TAFINLAR NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
In NN O O
Trial NN O O
1 NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
fever NN B-AdverseReaction B-AdverseReaction
( NN O O
serious NN O O
and NN O O
non NN O O
- NN O O
serious NN O O
) NN O O
was NN O O
28 NN O O
% NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
and NN O O
10 NN O O
% NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
dacarbazine NN O O
. NN O O
In NN O O
patients NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
, NN O O
the NN O O
median NN O O
time NN O O
to NN O O
initial NN O O
onset NN O O
of NN O O
fever NN B-AdverseReaction B-AdverseReaction
( NN O O
any NN O O
severity NN O O
) NN O O
was NN O O
11 NN O O
days NN O O
( NN O O
range NN O O
: NN O O
1 NN O O
to NN O O
202 NN O O
days NN O O
) NN O O
and NN O O
the NN O O
median NN O O
duration NN O O
of NN O O
fever NN B-AdverseReaction B-AdverseReaction
was NN O O
3 NN O O
days NN O O
( NN O O
range NN O O
: NN O O
1 NN O O
to NN O O
129 NN O O
days NN O O
) NN O O
. NN O O
Serious NN B-Severity B-Severity
febrile NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
and NN O O
fever NN B-AdverseReaction B-AdverseReaction
of NN O O
any NN O O
severity NN O O
complicated NN O O
by NN O O
hypotension NN B-AdverseReaction B-AdverseReaction
rigors NN B-AdverseReaction B-AdverseReaction
or NN O O
chills NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
3.7 NN O O
% NN O O
( NN O O
7/187 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
and NN O O
in NN O O
none NN O O
of NN O O
the NN O O
59 NN O O
patients NN O O
treated NN O O
with NN O O
dacarbazine NN O O
. NN O O
In NN O O
Trial NN O O
2 NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
fever NN B-AdverseReaction B-AdverseReaction
( NN O O
serious NN O O
and NN O O
non NN O O
- NN O O
serious NN O O
) NN O O
was NN O O
71 NN O O
% NN O O
( NN O O
39/55 NN O O
) NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
and NN O O
26 NN O O
% NN O O
( NN O O
14/53 NN O O
) NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
. NN O O
Serious NN B-Severity B-Severity
febrile NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
and NN O O
fever NN B-AdverseReaction B-AdverseReaction
of NN O O
any NN O O
severity NN O O
complicated NN O O
by NN O O
hypotension NN B-AdverseReaction B-AdverseReaction
rigors NN B-AdverseReaction B-AdverseReaction
or NN O O
chills NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
25 NN O O
% NN O O
( NN O O
14/55 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
compared NN O O
with NN O O
2 NN O O
% NN O O
( NN O O
1/53 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
. NN O O
Fever NN B-AdverseReaction B-AdverseReaction
was NN O O
complicated NN O O
with NN O O
chills NN B-AdverseReaction B-AdverseReaction
in NN O O
51 NN O O
% NN O O
( NN O O
28/55 NN O O
) NN O O
, NN O O
dehydration NN B-AdverseReaction B-AdverseReaction
in NN O O
9 NN O O
% NN O O
( NN O O
5/55 NN O O
) NN O O
, NN O O
renal NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
in NN O O
4 NN O O
% NN O O
( NN O O
2/55 NN O O
) NN O O
, NN O O
and NN O O
syncope NN B-AdverseReaction B-AdverseReaction
in NN O O
4 NN O O
% NN O O
( NN O O
2/55 NN O O
) NN O O
of NN O O
patients NN O O
in NN O O
Trial NN O O
2 NN O O
. NN O O
In NN O O
patients NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
, NN O O
the NN O O
median NN O O
time NN O O
to NN O O
initial NN O O
onset NN O O
of NN O O
fever NN B-AdverseReaction B-AdverseReaction
was NN O O
30 NN O O
days NN O O
compared NN O O
with NN O O
19 NN O O
days NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
; NN O O
the NN O O
median NN O O
duration NN O O
of NN O O
fever NN B-AdverseReaction B-AdverseReaction
was NN O O
6 NN O O
days NN O O
with NN O O
the NN O O
combination NN O O
compared NN O O
with NN O O
4 NN O O
days NN O O
with NN O O
TAFINLAR NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
. NN O O
Across NN O O
clinical NN O O
trials NN O O
of NN O O
TAFINLAR NN O O
administered NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
( NN O O
N NN O O
= NN O O
202 NN O O
) NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
was NN O O
57 NN O O
% NN O O
( NN O O
116/202 NN O O
) NN O O
. NN O O
Withhold NN O O
TAFINLAR NN O O
for NN O O
fever NN O O
of NN O O
101.3oF NN O O
or NN O O
higher NN O O
. NN O O
Withhold NN O O
trametinib NN O O
for NN O O
any NN O O
fever NN O O
higher NN O O
than NN O O
104oF. NN O O
Withhold NN O O
TAFINLAR NN O O
, NN O O
and NN O O
trametinib NN O O
if NN O O
used NN O O
in NN O O
combination NN O O
, NN O O
for NN O O
any NN O O
serious NN O O
febrile NN O O
reaction NN O O
or NN O O
fever NN O O
complicated NN O O
by NN O O
hypotension NN O O
, NN O O
rigors NN O O
or NN O O
chills NN O O
, NN O O
dehydration NN O O
, NN O O
or NN O O
renal NN O O
failure NN O O
and NN O O
evaluate NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
infection NN O O
. NN O O
Refer NN O O
to NN O O
Table NN O O
2 NN O O
for NN O O
recommended NN O O
dose NN O O
modifications NN O O
for NN O O
adverse NN O O
reactions NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
] NN O O
. NN O O
Prophylaxis NN O O
with NN O O
antipyretics NN O O
may NN O O
be NN O O
required NN O O
when NN O O
resuming NN O O
TAFINLAR NN O O
or NN O O
trametinib NN O O
. NN O O
5.8 NN O O
Serious NN O O
Skin NN O O
Toxicity NN O O
Serious NN B-Severity B-Severity
skin NN B-AdverseReaction B-AdverseReaction
toxicity NN I-AdverseReaction I-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
when NN O O
TAFINLAR NN O O
is NN O O
used NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
and NN O O
with NN O O
trametinib NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
[ NN O O
refer NN O O
to NN O O
Full NN O O
Prescribing NN O O
Information NN O O
for NN O O
trametinib NN O O
] NN O O
. NN O O
In NN O O
Trial NN O O
2 NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
any NN O O
skin NN B-AdverseReaction B-AdverseReaction
toxicity NN I-AdverseReaction I-AdverseReaction
was NN O O
similar NN O O
for NN O O
patients NN O O
receiving NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
( NN O O
65 NN O O
% NN O O
[ NN O O
36/55 NN O O
] NN O O
) NN O O
compared NN O O
with NN O O
patients NN O O
receiving NN O O
TAFINLAR NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
( NN O O
68 NN O O
% NN O O
[ NN O O
36/53 NN O O
] NN O O
) NN O O
. NN O O
The NN O O
median NN O O
time NN O O
to NN O O
onset NN O O
of NN O O
skin NN B-AdverseReaction B-AdverseReaction
toxicity NN I-AdverseReaction I-AdverseReaction
in NN O O
patients NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
was NN O O
37 NN O O
days NN O O
( NN O O
range NN O O
: NN O O
1 NN O O
to NN O O
225 NN O O
days NN O O
) NN O O
and NN O O
median NN O O
time NN O O
to NN O O
resolution NN O O
of NN O O
skin NN B-AdverseReaction B-AdverseReaction
toxicity NN I-AdverseReaction I-AdverseReaction
was NN O O
33 NN O O
days NN O O
( NN O O
range NN O O
: NN O O
3 NN O O
to NN O O
421 NN O O
days NN O O
) NN O O
. NN O O
No NN O O
patient NN O O
required NN O O
dose NN O O
reduction NN O O
or NN O O
permanent NN O O
discontinuation NN O O
of NN O O
TAFINLAR NN O O
or NN O O
trametinib NN O O
for NN O O
skin NN O O
toxicity NN O O
. NN O O
Across NN O O
clinical NN O O
trials NN O O
of NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
( NN O O
N NN O O
= NN O O
202 NN O O
) NN O O
, NN O O
severe NN B-Severity B-Severity
skin NN B-AdverseReaction B-AdverseReaction
toxicity NN I-AdverseReaction I-AdverseReaction
and NN O O
secondary NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
skin NN I-AdverseReaction I-AdverseReaction
requiring NN O O
hospitalization NN O O
occurred NN O O
in NN O O
2.5 NN O O
% NN O O
( NN O O
5/202 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
. NN O O
Withhold NN O O
TAFINLAR NN O O
, NN O O
and NN O O
trametinib NN O O
if NN O O
used NN O O
in NN O O
combination NN O O
, NN O O
for NN O O
intolerable NN O O
or NN O O
severe NN O O
skin NN O O
toxicity NN O O
. NN O O
TAFINLAR NN O O
and NN O O
trametinib NN O O
may NN O O
be NN O O
resumed NN O O
at NN O O
lower NN O O
dose NN O O
levels NN O O
in NN O O
patients NN O O
with NN O O
improvement NN O O
or NN O O
recovery NN O O
from NN O O
skin NN O O
toxicity NN O O
within NN O O
3 NN O O
weeks NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
] NN O O
. NN O O
5.9 NN O O
Hyperglycemia NN O O
Hyperglycemia NN B-AdverseReaction B-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
when NN O O
TAFINLAR NN O O
is NN O O
administered NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
or NN O O
when NN O O
used NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
. NN O O
In NN O O
Trial NN O O
1 NN O O
, NN O O
5 NN O O
of NN O O
12 NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
diabetes NN O O
required NN O O
more NN O O
intensive NN O O
hypoglycemic NN O O
therapy NN O O
while NN O O
taking NN O O
TAFINLAR. NN O O
The NN O O
incidence NN O O
of NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
hyperglycemia NN B-AdverseReaction B-AdverseReaction
based NN O O
on NN O O
laboratory NN O O
values NN O O
was NN O O
6 NN O O
% NN O O
( NN O O
12/187 NN O O
) NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
compared NN O O
with NN O O
none NN O O
of NN O O
the NN O O
dacarbazine NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
In NN O O
Trial NN O O
2 NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
hyperglycemia NN B-AdverseReaction B-AdverseReaction
based NN O O
on NN O O
laboratory NN O O
values NN O O
was NN O O
5 NN O O
% NN O O
( NN O O
3/55 NN O O
) NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
compared NN O O
with NN O O
2 NN O O
% NN O O
( NN O O
1/53 NN O O
) NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
TAFINLAR NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
. NN O O
Monitor NN O O
serum NN O O
glucose NN O O
levels NN O O
as NN O O
clinically NN O O
appropriate NN O O
when NN O O
TAFINLAR NN O O
is NN O O
administered NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
or NN O O
when NN O O
used NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
in NN O O
patients NN O O
with NN O O
pre NN O O
- NN O O
existing NN O O
diabetes NN O O
or NN O O
hyperglycemia NN O O
. NN O O
Advise NN O O
patients NN O O
to NN O O
report NN O O
symptoms NN O O
of NN O O
severe NN O O
hyperglycemia NN O O
such NN O O
as NN O O
excessive NN O O
thirst NN O O
or NN O O
any NN O O
increase NN O O
in NN O O
the NN O O
volume NN O O
or NN O O
frequency NN O O
of NN O O
urination NN O O
. NN O O
5.10 NN O O
Glucose-6-Phosphate NN O O
Dehydrogenase NN O O
Deficiency NN O O
TAFINLAR NN O O
, NN O O
which NN O O
contains NN O O
a NN O O
sulfonamide NN O O
moiety NN O O
, NN O O
confers NN O O
a NN O O
potential NN O O
risk NN B-Factor B-Factor
of NN O O
hemolytic NN B-AdverseReaction B-AdverseReaction
anemia NN I-AdverseReaction I-AdverseReaction
in NN O O
patients NN O O
with NN O O
glucose-6-phosphate NN O O
dehydrogenase NN O O
( NN O O
G6PD NN O O
) NN O O
deficiency NN O O
. NN O O
Closely NN O O
observe NN O O
patients NN O O
with NN O O
G6PD NN O O
deficiency NN O O
for NN O O
signs NN O O
of NN O O
hemolytic NN O O
anemia NN O O
. NN O O
5.11 NN O O
Embryofetal NN O O
Toxicity NN O O
Based NN O O
on NN O O
its NN O O
mechanism NN O O
of NN O O
action NN O O
, NN O O
TAFINLAR NN O O
can NN B-Factor B-Factor
cause NN O O
fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
when NN O O
administered NN O O
to NN O O
a NN O O
pregnant NN O O
woman NN O O
. NN O O
Dabrafenib NN O O
was NN O O
teratogenic NN B-AdverseReaction B-AdverseReaction
and NN O O
embryotoxic NN B-AdverseReaction B-AdverseReaction
in NN O O
rats NN B-Animal B-Animal
at NN O O
doses NN O O
three NN O O
times NN O O
greater NN O O
than NN O O
the NN O O
human NN O O
exposure NN O O
at NN O O
the NN O O
recommended NN O O
clinical NN O O
dose NN O O
. NN O O
If NN O O
this NN O O
drug NN O O
is NN O O
used NN O O
during NN O O
pregnancy NN O O
or NN O O
if NN O O
the NN O O
patient NN O O
becomes NN O O
pregnant NN O O
while NN O O
taking NN O O
this NN O O
drug NN O O
, NN O O
the NN O O
patient NN O O
should NN O O
be NN O O
apprised NN O O
of NN O O
the NN O O
potential NN O O
hazard NN O O
to NN O O
a NN O O
fetus NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.1 NN O O
) NN O O
] NN O O
. NN O O
Advise NN O O
female NN O O
patients NN O O
of NN O O
reproductive NN O O
potential NN O O
to NN O O
use NN O O
a NN O O
highly NN O O
effective NN O O
non NN O O
- NN O O
hormonal NN O O
method NN O O
of NN O O
contraception NN O O
since NN O O
TAFINLAR NN O O
can NN O O
render NN O O
hormonal NN O O
contraceptives NN O O
ineffective NN O O
, NN O O
during NN O O
treatment NN O O
and NN O O
for NN O O
at NN O O
least NN O O
2 NN O O
weeks NN O O
after NN O O
treatment NN O O
with NN O O
TAFINLAR NN O O
or NN O O
for NN O O
4 NN O O
months NN O O
after NN O O
treatment NN O O
with NN O O
TAFINLAR NN O O
in NN O O
combination NN O O
with NN O O
trametinib NN O O
. NN O O
Advise NN O O
patients NN O O
to NN O O
contact NN O O
their NN O O
healthcare NN O O
provider NN O O
if NN O O
they NN O O
become NN O O
pregnant NN O O
, NN O O
or NN O O
if NN O O
pregnancy NN O O
is NN O O
suspected NN O O
, NN O O
while NN O O
taking NN O O
TAFINLAR NN O O
[ NN O O
see NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.2 NN O O
) NN O O
, NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.6 NN O O
) NN O O
] NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
A NN O O
total NN O O
of NN O O
696 NN O O
HIV NN O O
- NN O O
positive NN O O
patients NN O O
in NN O O
three NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
received NN O O
FULYZAQ NN O O
for NN O O
a NN O O
mean NN O O
duration NN O O
of NN O O
78 NN O O
days NN O O
. NN O O
Of NN O O
the NN O O
total NN O O
population NN O O
across NN O O
the NN O O
three NN O O
trials NN O O
, NN O O
229 NN O O
patients NN O O
received NN O O
a NN O O
dose NN O O
of NN O O
125 NN O O
mg NN O O
twice NN O O
a NN O O
day NN O O
for NN O O
a NN O O
mean NN O O
duration NN O O
of NN O O
141 NN O O
days NN O O
, NN O O
69 NN O O
patients NN O O
received NN O O
a NN O O
dose NN O O
of NN O O
250 NN O O
mg NN O O
twice NN O O
a NN O O
day NN O O
for NN O O
a NN O O
mean NN O O
duration NN O O
of NN O O
139 NN O O
days NN O O
, NN O O
102 NN O O
patients NN O O
received NN O O
a NN O O
dose NN O O
of NN O O
250 NN O O
mg NN O O
four NN O O
times NN O O
a NN O O
day NN O O
for NN O O
a NN O O
mean NN O O
duration NN O O
of NN O O
14 NN O O
days NN O O
, NN O O
54 NN O O
patients NN O O
received NN O O
a NN O O
dose NN O O
of NN O O
500 NN O O
mg NN O O
twice NN O O
a NN O O
day NN O O
for NN O O
a NN O O
mean NN O O
duration NN O O
of NN O O
146 NN O O
days NN O O
, NN O O
and NN O O
242 NN O O
patients NN O O
received NN O O
a NN O O
dose NN O O
of NN O O
500 NN O O
mg NN O O
four NN O O
times NN O O
a NN O O
day NN O O
for NN O O
a NN O O
mean NN O O
duration NN O O
of NN O O
14 NN O O
days NN O O
. NN O O
Adverse NN O O
reactions NN O O
for NN O O
FULYZAQ NN O O
that NN O O
occurred NN O O
in NN O O
at NN O O
least NN O O
2 NN O O
% NN O O
of NN O O
patients NN O O
and NN O O
at NN O O
a NN O O
higher NN O O
incidence NN O O
than NN O O
placebo NN O O
are NN O O
provided NN O O
in NN O O
Table NN O O
1 NN O O
. NN O O
Table NN O O
1 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Occurring NN O O
in NN O O
at NN O O
Least NN O O
2 NN O O
% NN O O
of NN O O
Patients NN O O
in NN O O
the NN O O
125 NN O O
mg NN O O
Twice NN O O
Daily NN O O
Group NN O O
Adverse NN O O
Reaction NN O O
Crofelemer NN O O
125 NN O O
mg NN O O
BID*N NN O O
= NN O O
229n NN O O
( NN O O
% NN O O
) NN O O
PlaceboN NN O O
= NN O O
274n NN O O
( NN O O
% NN O O
) NN O O
Upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
13 NN O O
( NN O O
5.7 NN O O
) NN O O
4 NN O O
( NN O O
1.5 NN O O
) NN O O
Bronchitis NN B-AdverseReaction B-AdverseReaction
9 NN O O
( NN O O
3.9 NN O O
) NN O O
0 NN O O
Cough NN B-AdverseReaction B-AdverseReaction
8 NN O O
( NN O O
3.5 NN O O
) NN O O
3 NN O O
( NN O O
1.1 NN O O
) NN O O
Flatulence NN B-AdverseReaction B-AdverseReaction
7 NN O O
( NN O O
3.1 NN O O
) NN O O
3 NN O O
( NN O O
1.1 NN O O
) NN O O
Increased NN B-AdverseReaction B-AdverseReaction
bilirubin NN I-AdverseReaction I-AdverseReaction
7 NN O O
( NN O O
3.1 NN O O
) NN O O
3 NN O O
( NN O O
1.1 NN O O
) NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
6 NN O O
( NN O O
2.6 NN O O
) NN O O
4 NN O O
( NN O O
1.5 NN O O
) NN O O
Back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
6 NN O O
( NN O O
2.6 NN O O
) NN O O
4 NN O O
( NN O O
1.5 NN O O
) NN O O
Arthralgia NN B-AdverseReaction B-AdverseReaction
6 NN O O
( NN O O
2.6 NN O O
) NN O O
0 NN O O
Urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
5 NN O O
( NN O O
2.2 NN O O
) NN O O
2 NN O O
( NN O O
0.7 NN O O
) NN O O
Nasopharyngitis NN B-AdverseReaction B-AdverseReaction
5 NN O O
( NN O O
2.2 NN O O
) NN O O
2 NN O O
( NN O O
0.7 NN O O
) NN O O
Musculoskeletal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
5 NN O O
( NN O O
2.2 NN O O
) NN O O
1 NN O O
( NN O O
0.4 NN O O
) NN O O
Hemorrhoids NN B-AdverseReaction B-AdverseReaction
5 NN O O
( NN O O
2.2 NN O O
) NN O O
0 NN O O
Giardiasis NN B-AdverseReaction B-AdverseReaction
5 NN O O
( NN O O
2.2 NN O O
) NN O O
0 NN O O
Anxiety NN B-AdverseReaction B-AdverseReaction
5 NN O O
( NN O O
2.2 NN O O
) NN O O
1 NN O O
( NN O O
0.4 NN O O
) NN O O
Increased NN B-AdverseReaction B-AdverseReaction
alanine NN I-AdverseReaction I-AdverseReaction
aminotransferase NN I-AdverseReaction I-AdverseReaction
5 NN O O
( NN O O
2.2 NN O O
) NN O O
3 NN O O
( NN O O
1.1 NN O O
) NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
distension NN I-AdverseReaction I-AdverseReaction
5 NN O O
( NN O O
2.2 NN O O
) NN O O
1 NN O O
( NN O O
0.4 NN O O
) NN O O
* NN O O
Twice NN O O
daily NN O O
Adverse NN O O
reactions NN O O
that NN O O
occurred NN O O
in NN O O
between NN O O
1 NN O O
% NN O O
and NN O O
2 NN O O
% NN O O
of NN O O
patients NN O O
taking NN O O
a NN O O
250 NN O O
mg NN O O
daily NN O O
dose NN O O
of NN O O
FULYZAQ NN O O
were NN O O
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
acne NN B-AdverseReaction B-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
aspartate NN I-AdverseReaction I-AdverseReaction
aminotransferase NN I-AdverseReaction I-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
conjugated NN I-AdverseReaction I-AdverseReaction
bilirubin NN I-AdverseReaction I-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
unconjugated NN I-AdverseReaction I-AdverseReaction
blood NN I-AdverseReaction I-AdverseReaction
bilirubin NN I-AdverseReaction I-AdverseReaction
constipation NN B-AdverseReaction B-AdverseReaction
depression NN B-AdverseReaction B-AdverseReaction
dermatitis NN B-AdverseReaction B-AdverseReaction
dizziness NN B-AdverseReaction B-AdverseReaction
dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
dyspepsia NN B-AdverseReaction B-AdverseReaction
gastroenteritis NN B-AdverseReaction B-AdverseReaction
herpes NN B-AdverseReaction B-AdverseReaction
zoster NN I-AdverseReaction I-AdverseReaction
nephrolithiasis NN B-AdverseReaction B-AdverseReaction
pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
pollakiuria NN B-AdverseReaction B-AdverseReaction
procedural NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
seasonal NN B-AdverseReaction B-AdverseReaction
allergy NN I-AdverseReaction I-AdverseReaction
sinusitis NN B-AdverseReaction B-AdverseReaction
and NN O O
decreased NN B-AdverseReaction B-AdverseReaction
white NN I-AdverseReaction I-AdverseReaction
blood NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
count NN I-AdverseReaction I-AdverseReaction
Adverse NN O O
reactions NN O O
were NN O O
similar NN O O
in NN O O
patients NN O O
who NN O O
received NN O O
doses NN O O
greater NN O O
than NN O O
250 NN O O
mg NN O O
daily NN O O
. NN O O
EXCERPT NN O O
: NN O O
Most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
incidence NN O O
>= NN O O
3 NN O O
% NN O O
) NN O O
are NN O O
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
bronchitis NN B-AdverseReaction B-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
flatulence NN B-AdverseReaction B-AdverseReaction
and NN O O
increased NN B-AdverseReaction B-AdverseReaction
bilirubin NN I-AdverseReaction I-AdverseReaction
( NN O O
6 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Salix NN O O
Pharmaceuticals NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
508 NN O O
- NN O O
0024 NN O O
or NN O O
www NN O O
. NN O O
Salix.com NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
5 NN O O
. NN O O
1 NN O O
Risks NN O O
of NN O O
Treatment NN O O
in NN O O
Patients NN O O
with NN O O
Infectious NN O O
Diarrhea NN O O
If NN O O
infectious NN O O
etiologies NN O O
are NN O O
not NN O O
considered NN O O
, NN O O
and NN O O
FULYZAQ NN O O
is NN O O
initiated NN O O
based NN O O
on NN O O
a NN O O
presumptive NN O O
diagnosis NN O O
of NN O O
non NN O O
- NN O O
infectious NN O O
diarrhea NN O O
, NN O O
then NN O O
there NN O O
is NN O O
a NN O O
risk NN O O
that NN O O
patients NN O O
with NN O O
infectious NN O O
etiologies NN O O
will NN O O
not NN O O
receive NN O O
the NN O O
appropriate NN O O
treatments NN O O
, NN O O
and NN O O
their NN O O
disease NN O O
may NN O O
worsen NN O O
. NN O O
Before NN O O
starting NN O O
FULYZAQ NN O O
, NN O O
rule NN O O
out NN O O
infectious NN O O
etiologies NN O O
of NN O O
diarrhea NN O O
. NN O O
FULYZAQ NN O O
is NN O O
not NN O O
indicated NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
infectious NN O O
diarrhea NN O O
. NN O O
EXCERPT NN O O
: NN O O
Rule NN O O
out NN O O
infectious NN O O
etiologies NN O O
of NN O O
diarrhea NN O O
before NN O O
starting NN O O
crofelemer NN O O
. NN O O
If NN O O
infectious NN O O
etiologies NN O O
are NN O O
not NN O O
considered NN O O
, NN O O
there NN O O
is NN O O
a NN O O
risk NN O O
that NN O O
patients NN O O
with NN O O
infectious NN O O
etiologies NN O O
will NN O O
not NN O O
receive NN O O
the NN O O
appropriate NN O O
therapy NN O O
and NN O O
their NN O O
disease NN O O
may NN O O
worsen NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O
The NN O O
safety NN O O
of NN O O
INLYTA NN O O
has NN O O
been NN O O
evaluated NN O O
in NN O O
715 NN O O
patients NN O O
in NN O O
monotherapy NN O O
studies NN O O
, NN O O
which NN O O
included NN O O
537 NN O O
patients NN O O
with NN O O
advanced NN O O
RCC. NN O O
The NN O O
data NN O O
described NN O O
[ NN O O
seeAdverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
reflect NN O O
exposure NN O O
to NN O O
INLYTA NN O O
in NN O O
359 NN O O
patients NN O O
with NN O O
advanced NN O O
RCC NN O O
who NN O O
participated NN O O
in NN O O
a NN O O
randomized NN O O
clinical NN O O
study NN O O
versus NN O O
sorafenib NN O O
[ NN O O
seeClinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
following NN O O
risks NN B-Factor B-Factor
including NN O O
appropriate NN O O
action NN O O
to NN O O
be NN O O
taken NN O O
, NN O O
are NN O O
discussed NN O O
in NN O O
greater NN O O
detail NN O O
in NN O O
other NN O O
sections NN O O
of NN O O
the NN O O
label NN O O
[ NN O O
seeWarnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
- NN O O
5.13 NN O O
) NN O O
] NN O O
: NN O O
hypertension NN B-AdverseReaction B-AdverseReaction
arterial NN B-AdverseReaction B-AdverseReaction
thromboembolic NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
venous NN B-AdverseReaction B-AdverseReaction
thromboembolic NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
hemorrhage NN B-AdverseReaction B-AdverseReaction
cardiac NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
gastrointestinal NN B-AdverseReaction B-AdverseReaction
perforation NN I-AdverseReaction I-AdverseReaction
and NN O O
fistula NN B-AdverseReaction B-AdverseReaction
formation NN I-AdverseReaction I-AdverseReaction
thyroid NN B-AdverseReaction B-AdverseReaction
dysfunction NN I-AdverseReaction I-AdverseReaction
wound NN B-AdverseReaction B-AdverseReaction
healing NN I-AdverseReaction I-AdverseReaction
complications NN I-AdverseReaction I-AdverseReaction
RPLS NN B-AdverseReaction B-AdverseReaction
proteinuria NN B-AdverseReaction B-AdverseReaction
elevation NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
liver NN I-AdverseReaction I-AdverseReaction
enzymes NN I-AdverseReaction I-AdverseReaction
hepatic NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
and NN O O
fetal NN O O
development NN O O
. NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
common NN O O
( NN O O
>=20 NN O O
% NN O O
) NN O O
adverse NN O O
reactions NN O O
are NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
hypertension NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
dysphonia NN B-AdverseReaction B-AdverseReaction
palmar NN O O
- NN O O
plantar NN O O
erythrodysesthesia NN O O
( NN O O
hand NN O O
- NN O O
foot NN O O
) NN O O
syndrome NN O O
, NN O O
weight NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
asthenia NN B-AdverseReaction B-AdverseReaction
and NN O O
constipation NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Pfizer NN O O
, NN O O
Inc NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
438 NN O O
- NN O O
1985 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
The NN O O
median NN O O
duration NN O O
of NN O O
treatment NN O O
was NN O O
6.4 NN O O
months NN O O
( NN O O
range NN O O
0.03 NN O O
to NN O O
22.0 NN O O
) NN O O
for NN O O
patients NN O O
who NN O O
received NN O O
INLYTA NN O O
and NN O O
5.0 NN O O
months NN O O
( NN O O
range NN O O
0.03 NN O O
to NN O O
20.1 NN O O
) NN O O
for NN O O
patients NN O O
who NN O O
received NN O O
sorafenib NN O O
. NN O O
Dose NN O O
modifications NN O O
or NN O O
temporary NN O O
delay NN O O
of NN O O
treatment NN O O
due NN O O
to NN O O
an NN O O
adverse NN O O
reaction NN O O
occurred NN O O
in NN O O
199/359 NN O O
patients NN O O
( NN O O
55 NN O O
% NN O O
) NN O O
receiving NN O O
INLYTA NN O O
and NN O O
220/355 NN O O
patients NN O O
( NN O O
62 NN O O
% NN O O
) NN O O
receiving NN O O
sorafenib NN O O
. NN O O
Permanent NN O O
discontinuation NN O O
due NN O O
to NN O O
an NN O O
adverse NN O O
reaction NN O O
occurred NN O O
in NN O O
34/359 NN O O
patients NN O O
( NN O O
9 NN O O
% NN O O
) NN O O
receiving NN O O
INLYTA NN O O
and NN O O
46/355 NN O O
patients NN O O
( NN O O
13 NN O O
% NN O O
) NN O O
receiving NN O O
sorafenib NN O O
. NN O O
The NN O O
most NN O O
common NN O O
( NN O O
>=20 NN O O
% NN O O
) NN O O
adverse NN O O
reactions NN O O
observed NN O O
following NN O O
treatment NN O O
with NN O O
INLYTA NN O O
were NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
hypertension NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
dysphonia NN B-AdverseReaction B-AdverseReaction
palmar NN O O
- NN O O
plantar NN O O
erythrodysesthesia NN O O
( NN O O
hand NN O O
- NN O O
foot NN O O
) NN O O
syndrome NN O O
, NN O O
weight NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
asthenia NN B-AdverseReaction B-AdverseReaction
and NN O O
constipation NN B-AdverseReaction B-AdverseReaction
Table NN O O
1 NN O O
presents NN O O
adverse NN O O
reactions NN O O
reported NN O O
in NN O O
>=10 NN O O
% NN O O
patients NN O O
who NN O O
received NN O O
INLYTA NN O O
or NN O O
sorafenib NN O O
. NN O O
Table NN O O
1 NN O O
. NN O O
Adverse NN O O
Reactions NN O O
Occurring NN O O
in NN O O
>=10 NN O O
% NN O O
of NN O O
Patients NN O O
Who NN O O
Received NN O O
INLYTA NN O O
or NN O O
Sorafenib NN O O
Adverse NN O O
Reaction NN O O
INLYTA NN O O
Sorafenib NN O O
( NN O O
N=359 NN O O
) NN O O
( NN O O
N=355 NN O O
) NN O O
All NN O O
Grades NN O O
Grade NN O O
3/4 NN O O
All NN O O
Grades NN O O
Grade NN O O
3/4 NN O O
% NN O O
% NN O O
% NN O O
% NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
55 NN O O
11 NN O O
53 NN O O
7 NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
40 NN O O
16 NN O O
29 NN O O
11 NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
39 NN O O
11 NN O O
32 NN O O
5 NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
34 NN O O
5 NN O O
29 NN O O
4 NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
32 NN O O
3 NN O O
22 NN O O
1 NN O O
Dysphonia NN B-AdverseReaction B-AdverseReaction
31 NN O O
0 NN O O
14 NN O O
0 NN O O
Palmar NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
plantar NN I-AdverseReaction I-AdverseReaction
erythrodysesthesia NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
27 NN O O
5 NN O O
51 NN O O
16 NN O O
Weight NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
25 NN O O
2 NN O O
21 NN O O
1 NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
24 NN O O
3 NN O O
17 NN O O
1 NN O O
Asthenia NN B-AdverseReaction B-AdverseReaction
21 NN O O
5 NN O O
14 NN O O
3 NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
20 NN O O
1 NN O O
20 NN O O
1 NN O O
Hypothyroidism NN B-AdverseReaction B-AdverseReaction
19 NN O O
< NN O O
1 NN O O
8 NN O O
0 NN O O
Cough NN B-AdverseReaction B-AdverseReaction
15 NN O O
1 NN O O
17 NN O O
1 NN O O
Mucosal NN B-AdverseReaction B-AdverseReaction
inflammation NN I-AdverseReaction I-AdverseReaction
15 NN O O
1 NN O O
12 NN O O
1 NN O O
Arthralgia NN B-AdverseReaction B-AdverseReaction
15 NN O O
2 NN O O
11 NN O O
1 NN O O
Stomatitis NN B-AdverseReaction B-AdverseReaction
15 NN O O
1 NN O O
12 NN O O
< NN O O
1 NN O O
Dyspnea NN B-AdverseReaction B-AdverseReaction
15 NN O O
3 NN O O
12 NN O O
3 NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
14 NN O O
2 NN O O
11 NN O O
1 NN O O
Headache NN B-AdverseReaction B-AdverseReaction
14 NN O O
1 NN O O
11 NN O O
0 NN O O
Pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
13 NN O O
1 NN O O
14 NN O O
1 NN O O
Rash NN B-AdverseReaction B-AdverseReaction
13 NN O O
< NN O O
1 NN O O
32 NN O O
4 NN O O
Proteinuria NN B-AdverseReaction B-AdverseReaction
11 NN O O
3 NN O O
7 NN O O
2 NN O O
Dysgeusia NN B-AdverseReaction B-AdverseReaction
11 NN O O
0 NN O O
8 NN O O
0 NN O O
Dry NN B-AdverseReaction B-AdverseReaction
skin NN I-AdverseReaction I-AdverseReaction
10 NN O O
0 NN O O
11 NN O O
0 NN O O
Dyspepsia NN B-AdverseReaction B-AdverseReaction
10 NN O O
0 NN O O
2 NN O O
0 NN O O
Pruritus NN B-AdverseReaction B-AdverseReaction
7 NN O O
0 NN O O
12 NN O O
0 NN O O
Alopecia NN B-AdverseReaction B-AdverseReaction
4 NN O O
0 NN O O
32 NN O O
0 NN O O
Erythema NN B-AdverseReaction B-AdverseReaction
2 NN O O
0 NN O O
10 NN O O
< NN O O
1 NN O O
Selected NN O O
adverse NN O O
reactions NN O O
( NN O O
all NN O O
grades NN O O
) NN O O
that NN O O
were NN O O
reported NN O O
in NN O O
< NN O O
10 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
INLYTA NN O O
included NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
( NN O O
9 NN O O
% NN O O
) NN O O
, NN O O
upper NN B-AdverseReaction B-AdverseReaction
abdominal NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
( NN O O
8 NN O O
% NN O O
) NN O O
, NN O O
myalgia NN B-AdverseReaction B-AdverseReaction
( NN O O
7 NN O O
% NN O O
) NN O O
, NN O O
dehydration NN B-AdverseReaction B-AdverseReaction
( NN O O
6 NN O O
% NN O O
) NN O O
, NN O O
epistaxis NN B-AdverseReaction B-AdverseReaction
( NN O O
6 NN O O
% NN O O
) NN O O
, NN O O
anemia NN B-AdverseReaction B-AdverseReaction
( NN O O
4 NN O O
% NN O O
) NN O O
, NN O O
hemorrhoids NN B-AdverseReaction B-AdverseReaction
( NN O O
4 NN O O
% NN O O
) NN O O
, NN O O
hematuria NN B-AdverseReaction B-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
, NN O O
tinnitus NN B-AdverseReaction B-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
, NN O O
lipase NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
, NN O O
glossodynia NN B-AdverseReaction B-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
, NN O O
pulmonary NN B-AdverseReaction B-AdverseReaction
embolism NN I-AdverseReaction I-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
, NN O O
rectal NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
, NN O O
hemoptysis NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
, NN O O
deep NN B-AdverseReaction B-AdverseReaction
vein NN I-AdverseReaction I-AdverseReaction
thrombosis NN I-AdverseReaction I-AdverseReaction
( NN O O
1 NN O O
% NN O O
) NN O O
, NN O O
retinal NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
vein NN I-AdverseReaction I-AdverseReaction
occlusion NN I-AdverseReaction I-AdverseReaction
( NN O O
1 NN O O
% NN O O
) NN O O
, NN O O
polycythemia NN B-AdverseReaction B-AdverseReaction
( NN O O
1 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
transient NN B-AdverseReaction B-AdverseReaction
ischemic NN I-AdverseReaction I-AdverseReaction
attack NN I-AdverseReaction I-AdverseReaction
( NN O O
1 NN O O
% NN O O
) NN O O
. NN O O
Table NN O O
2 NN O O
presents NN O O
the NN O O
most NN O O
common NN O O
laboratory NN O O
abnormalities NN O O
reported NN O O
in NN O O
>=10 NN O O
% NN O O
patients NN O O
who NN O O
received NN O O
INLYTA NN O O
or NN O O
sorafenib NN O O
. NN O O
Table NN O O
2 NN O O
. NN O O
Laboratory NN O O
Abnormalities NN O O
Occurring NN O O
in NN O O
>=10 NN O O
% NN O O
of NN O O
Patients NN O O
Who NN O O
Received NN O O
INLYTA NN O O
or NN O O
Sorafenib NN O O
Laboratory NN O O
Abnormality NN O O
N NN O O
INLYTA NN O O
N NN O O
Sorafenib NN O O
All NN O O
Grades NN O O
Grade NN O O
3/4 NN O O
All NN O O
Grades NN O O
Grade NN O O
3/4 NN O O
% NN O O
% NN O O
% NN O O
% NN O O
ALP NN O O
: NN O O
alkaline NN O O
phosphatase NN O O
; NN O O
ALT NN O O
: NN O O
alanine NN O O
aminotransferase NN O O
; NN O O
AST NN O O
: NN O O
aspartate NN O O
aminotransferase NN O O
Hematology NN O O
Hemoglobin NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
320 NN O O
35 NN O O
< NN O O
1 NN O O
316 NN O O
52 NN O O
4 NN O O
Lymphocytes NN B-AdverseReaction B-AdverseReaction
( NN I-AdverseReaction I-AdverseReaction
absolute NN I-AdverseReaction I-AdverseReaction
) NN I-AdverseReaction I-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
317 NN O O
33 NN O O
3 NN O O
309 NN O O
36 NN O O
4 NN O O
Platelets NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
312 NN O O
15 NN O O
< NN O O
1 NN O O
310 NN O O
14 NN O O
0 NN O O
White NN B-AdverseReaction B-AdverseReaction
blood NN I-AdverseReaction I-AdverseReaction
cells NN I-AdverseReaction I-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
320 NN O O
11 NN O O
0 NN O O
315 NN O O
16 NN O O
< NN O O
1 NN O O
Chemistry NN O O
Creatinine NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
336 NN O O
55 NN O O
0 NN O O
318 NN O O
41 NN O O
< NN O O
1 NN O O
Bicarbonate NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
314 NN O O
44 NN O O
< NN O O
1 NN O O
291 NN O O
43 NN O O
0 NN O O
Hypocalcemia NN B-AdverseReaction B-AdverseReaction
336 NN O O
39 NN O O
1 NN O O
319 NN O O
59 NN O O
2 NN O O
ALP NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
336 NN O O
30 NN O O
1 NN O O
319 NN O O
34 NN O O
1 NN O O
Hyperglycemia NN B-AdverseReaction B-AdverseReaction
336 NN O O
28 NN O O
2 NN O O
319 NN O O
23 NN O O
2 NN O O
Lipase NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
338 NN O O
27 NN O O
5 NN O O
319 NN O O
46 NN O O
15 NN O O
Amylase NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
338 NN O O
25 NN O O
2 NN O O
319 NN O O
33 NN O O
2 NN O O
ALT NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
331 NN O O
22 NN O O
< NN O O
1 NN O O
313 NN O O
22 NN O O
2 NN O O
AST NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
331 NN O O
20 NN O O
< NN O O
1 NN O O
311 NN O O
25 NN O O
1 NN O O
Hypernatremia NN B-AdverseReaction B-AdverseReaction
338 NN O O
17 NN O O
1 NN O O
319 NN O O
13 NN O O
1 NN O O
Hypoalbuminemia NN B-AdverseReaction B-AdverseReaction
337 NN O O
15 NN O O
< NN O O
1 NN O O
319 NN O O
18 NN O O
1 NN O O
Hyperkalemia NN B-AdverseReaction B-AdverseReaction
333 NN O O
15 NN O O
3 NN O O
314 NN O O
10 NN O O
3 NN O O
Hypoglycemia NN B-AdverseReaction B-AdverseReaction
336 NN O O
11 NN O O
< NN O O
1 NN O O
319 NN O O
8 NN O O
< NN O O
1 NN O O
Hyponatremia NN B-AdverseReaction B-AdverseReaction
338 NN O O
13 NN O O
4 NN O O
319 NN O O
11 NN O O
2 NN O O
Hypophosphatemia NN B-AdverseReaction B-AdverseReaction
336 NN O O
13 NN O O
2 NN O O
318 NN O O
49 NN O O
16 NN O O
Selected NN O O
laboratory NN O O
abnormalities NN O O
( NN O O
all NN O O
grades NN O O
) NN O O
that NN O O
were NN O O
reported NN O O
in NN O O
< NN O O
10 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
INLYTA NN O O
included NN O O
hemoglobin NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
( NN O O
above NN O O
the NN O O
upper NN O O
limit NN O O
of NN O O
normal NN O O
) NN O O
( NN O O
9 NN O O
% NN O O
for NN O O
INLYTA NN O O
versus NN O O
1 NN O O
% NN O O
for NN O O
sorafenib NN O O
) NN O O
and NN O O
hypercalcemia NN B-AdverseReaction B-AdverseReaction
( NN O O
6 NN O O
% NN O O
for NN O O
INLYTA NN O O
versus NN O O
2 NN O O
% NN O O
for NN O O
sorafenib NN O O
) NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
including NN O O
hypertensive NN B-AdverseReaction B-AdverseReaction
crisis NN I-AdverseReaction I-AdverseReaction
has NN O O
been NN O O
observed NN O O
. NN O O
Blood NN O O
pressure NN O O
should NN O O
be NN O O
well NN O O
- NN O O
controlled NN O O
prior NN O O
to NN O O
initiating NN O O
INLYTA. NN O O
Monitor NN O O
for NN O O
hypertension NN O O
and NN O O
treat NN O O
as NN O O
needed NN O O
. NN O O
For NN O O
persistent NN O O
hypertension NN O O
despite NN O O
use NN O O
of NN O O
anti NN O O
- NN O O
hypertensive NN O O
medications NN O O
, NN O O
reduce NN O O
the NN O O
INLYTA NN O O
dose NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Arterial NN O O
and NN O O
venous NN B-AdverseReaction B-AdverseReaction
thrombotic NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
observed NN O O
and NN O O
can NN B-Factor B-Factor
be NN O O
fatal NN B-AdverseReaction B-AdverseReaction
Use NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
who NN O O
are NN O O
at NN O O
increased NN O O
risk NN O O
for NN O O
these NN O O
events NN O O
. NN O O
( NN O O
5.2,5.3 NN O O
) NN O O
* NN O O
Hemorrhagic NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
including NN O O
fatal NN B-AdverseReaction B-AdverseReaction
events NN O O
, NN O O
have NN O O
been NN O O
reported NN O O
. NN O O
INLYTA NN O O
has NN O O
not NN O O
been NN O O
studied NN O O
in NN O O
patients NN O O
with NN O O
evidence NN O O
of NN O O
untreated NN O O
brain NN O O
metastasis NN O O
or NN O O
recent NN O O
active NN O O
gastrointestinal NN O O
bleeding NN O O
and NN O O
should NN O O
not NN O O
be NN O O
used NN O O
in NN O O
those NN O O
patients NN O O
. NN O O
( NN O O
5.4 NN O O
) NN O O
* NN O O
Cardiac NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
has NN O O
been NN O O
observed NN O O
and NN O O
can NN B-Factor B-Factor
be NN O O
fatal NN B-AdverseReaction B-AdverseReaction
Monitor NN O O
for NN O O
signs NN O O
or NN O O
symptoms NN O O
of NN O O
cardiac NN O O
failure NN O O
throughout NN O O
treatment NN O O
with NN O O
INLYTA. NN O O
( NN O O
5.5 NN O O
) NN O O
* NN O O
Gastrointestinal NN B-AdverseReaction B-AdverseReaction
perforation NN I-AdverseReaction I-AdverseReaction
and NN O O
fistula NN O O
, NN O O
including NN O O
death NN B-AdverseReaction B-AdverseReaction
have NN O O
occurred NN O O
. NN O O
Use NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
at NN O O
risk NN O O
for NN O O
gastrointestinal NN O O
perforation NN O O
or NN O O
fistula NN O O
. NN O O
( NN O O
5.6 NN O O
) NN O O
* NN O O
Hypothyroidism NN B-AdverseReaction B-AdverseReaction
requiring NN O O
thyroid NN O O
hormone NN O O
replacement NN O O
has NN O O
been NN O O
reported NN O O
. NN O O
Monitor NN O O
thyroid NN O O
function NN O O
before NN O O
initiation NN O O
of NN O O
, NN O O
and NN O O
periodically NN O O
throughout NN O O
, NN O O
treatment NN O O
with NN O O
INLYTA. NN O O
( NN O O
5.7 NN O O
) NN O O
* NN O O
Stop NN O O
INLYTA NN O O
at NN O O
least NN O O
24 NN O O
hours NN O O
prior NN O O
to NN O O
scheduled NN O O
surgery NN O O
. NN O O
( NN O O
5.8 NN O O
) NN O O
* NN O O
Reversible NN B-AdverseReaction B-AdverseReaction
Posterior NN I-AdverseReaction I-AdverseReaction
Leukoencephalopathy NN I-AdverseReaction I-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
RPLS NN O O
) NN O O
has NN O O
been NN O O
observed NN O O
. NN O O
Permanently NN O O
discontinue NN O O
INLYTA NN O O
if NN O O
signs NN O O
or NN O O
symptoms NN O O
of NN O O
RPLS NN O O
occur NN O O
. NN O O
( NN O O
5.9 NN O O
) NN O O
* NN O O
Monitor NN O O
for NN O O
proteinuria NN O O
before NN O O
initiation NN O O
of NN O O
, NN O O
and NN O O
periodically NN O O
throughout NN O O
, NN O O
treatment NN O O
with NN O O
INLYTA. NN O O
For NN O O
moderate NN O O
to NN O O
severe NN O O
proteinuria NN O O
, NN O O
reduce NN O O
the NN O O
dose NN O O
or NN O O
temporarily NN O O
interrupt NN O O
treatment NN O O
with NN O O
INLYTA. NN O O
( NN O O
5.10 NN O O
) NN O O
* NN O O
Liver NN B-AdverseReaction B-AdverseReaction
enzyme NN I-AdverseReaction I-AdverseReaction
elevation NN I-AdverseReaction I-AdverseReaction
has NN O O
been NN O O
observed NN O O
during NN O O
treatment NN O O
with NN O O
INLYTA. NN O O
Monitor NN O O
ALT NN O O
, NN O O
AST NN O O
and NN O O
bilirubin NN O O
before NN O O
initiation NN O O
of NN O O
, NN O O
and NN O O
periodically NN O O
throughout NN O O
, NN O O
treatment NN O O
with NN O O
INLYTA. NN O O
( NN O O
5.11 NN O O
) NN O O
* NN O O
The NN O O
starting NN O O
dose NN O O
of NN O O
INLYTA NN O O
should NN O O
be NN O O
decreased NN O O
if NN O O
used NN O O
in NN O O
patients NN O O
with NN O O
moderate NN O O
hepatic NN O O
impairment NN O O
. NN O O
INLYTA NN O O
has NN O O
not NN O O
been NN O O
studied NN O O
in NN O O
patients NN O O
with NN O O
severe NN O O
hepatic NN O O
impairment NN O O
. NN O O
( NN O O
2.2,5.12 NN O O
) NN O O
* NN O O
INLYTA NN O O
can NN B-Factor B-Factor
cause NN O O
fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
when NN O O
administered NN O O
to NN O O
a NN O O
pregnant NN O O
woman NN O O
based NN O O
on NN O O
its NN O O
mechanism NN O O
of NN O O
action NN O O
. NN O O
Women NN O O
of NN O O
childbearing NN O O
potential NN O O
should NN O O
be NN O O
advised NN O O
of NN O O
the NN O O
potential NN O O
hazard NN O O
to NN O O
the NN O O
fetus NN O O
and NN O O
to NN O O
avoid NN O O
becoming NN O O
pregnant NN O O
while NN O O
receiving NN O O
INLYTA. NN O O
( NN O O
5.13,8.1 NN O O
) NN O O
5.1 NN O O
Hypertension NN O O
and NN O O
Hypertensive NN O O
Crisis NN O O
In NN O O
a NN O O
controlled NN O O
clinical NN O O
study NN O O
with NN O O
INLYTA NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
patients NN O O
with NN O O
RCC NN O O
, NN O O
hypertension NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
145/359 NN O O
patients NN O O
( NN O O
40 NN O O
% NN O O
) NN O O
receiving NN O O
INLYTA NN O O
and NN O O
103/355 NN O O
patients NN O O
( NN O O
29 NN O O
% NN O O
) NN O O
receiving NN O O
sorafenib NN O O
. NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
hypertension NN B-AdverseReaction B-AdverseReaction
was NN O O
observed NN O O
in NN O O
56/359 NN O O
patients NN O O
( NN O O
16 NN O O
% NN O O
) NN O O
receiving NN O O
INLYTA NN O O
and NN O O
39/355 NN O O
patients NN O O
( NN O O
11 NN O O
% NN O O
) NN O O
receiving NN O O
sorafenib NN O O
. NN O O
Hypertensive NN B-AdverseReaction B-AdverseReaction
crisis NN I-AdverseReaction I-AdverseReaction
was NN O O
reported NN O O
in NN O O
2/359 NN O O
patients NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
receiving NN O O
INLYTA NN O O
and NN O O
none NN O O
of NN O O
the NN O O
patients NN O O
receiving NN O O
sorafenib NN O O
. NN O O
The NN O O
median NN O O
onset NN O O
time NN O O
for NN O O
hypertension NN B-AdverseReaction B-AdverseReaction
( NN O O
systolic NN O O
blood NN O O
pressure NN O O
>150 NN O O
mmHg NN O O
or NN O O
diastolic NN B-AdverseReaction B-AdverseReaction
blood NN I-AdverseReaction I-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
>100 NN I-AdverseReaction I-AdverseReaction
mmHg NN I-AdverseReaction I-AdverseReaction
was NN O O
within NN O O
the NN O O
first NN O O
month NN O O
of NN O O
the NN O O
start NN O O
of NN O O
INLYTA NN O O
treatment NN O O
and NN O O
blood NN B-AdverseReaction B-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
increases NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
observed NN O O
as NN O O
early NN O O
as NN O O
4 NN O O
days NN O O
after NN O O
starting NN O O
INLYTA. NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
was NN O O
managed NN O O
with NN O O
standard NN O O
antihypertensive NN O O
therapy NN O O
. NN O O
Discontinuation NN O O
of NN O O
INLYTA NN O O
treatment NN O O
due NN O O
to NN O O
hypertension NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
1/359 NN O O
patients NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
receiving NN O O
INLYTA NN O O
and NN O O
none NN O O
of NN O O
the NN O O
patients NN O O
receiving NN O O
sorafenib NN O O
[ NN O O
seeAdverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Blood NN O O
pressure NN O O
should NN O O
be NN O O
well NN O O
- NN O O
controlled NN O O
prior NN O O
to NN O O
initiating NN O O
INLYTA. NN O O
Patients NN O O
should NN O O
be NN O O
monitored NN O O
for NN O O
hypertension NN O O
and NN O O
treated NN O O
as NN O O
needed NN O O
with NN O O
standard NN O O
anti NN O O
- NN O O
hypertensive NN O O
therapy NN O O
. NN O O
In NN O O
the NN O O
case NN O O
of NN O O
persistent NN O O
hypertension NN O O
despite NN O O
use NN O O
of NN O O
anti NN O O
- NN O O
hypertensive NN O O
medications NN O O
, NN O O
reduce NN O O
the NN O O
INLYTA NN O O
dose NN O O
. NN O O
Discontinue NN O O
INLYTA NN O O
if NN O O
hypertension NN O O
is NN O O
severe NN O O
and NN O O
persistent NN O O
despite NN O O
anti NN O O
- NN O O
hypertensive NN O O
therapy NN O O
and NN O O
dose NN O O
reduction NN O O
of NN O O
INLYTA NN O O
, NN O O
and NN O O
discontinuation NN O O
should NN O O
be NN O O
considered NN O O
if NN O O
there NN O O
is NN O O
evidence NN O O
of NN O O
hypertensive NN O O
crisis NN O O
. NN O O
If NN O O
INLYTA NN O O
is NN O O
interrupted NN O O
, NN O O
patients NN O O
receiving NN O O
antihypertensive NN O O
medications NN O O
should NN O O
be NN O O
monitored NN O O
for NN O O
hypotension NN O O
[ NN O O
seeDosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
Arterial NN O O
Thromboembolic NN O O
Events NN O O
In NN O O
clinical NN O O
trials NN O O
, NN O O
arterial NN B-AdverseReaction B-AdverseReaction
thromboembolic NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
, NN O O
including NN O O
deaths NN B-AdverseReaction B-AdverseReaction
In NN O O
a NN O O
controlled NN O O
clinical NN O O
study NN O O
with NN O O
INLYTA NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
patients NN O O
with NN O O
RCC NN O O
, NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
arterial NN B-AdverseReaction B-AdverseReaction
thromboembolic NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
in NN O O
4/359 NN O O
patients NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
receiving NN O O
INLYTA NN O O
and NN O O
4/355 NN O O
patients NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
receiving NN O O
sorafenib NN O O
. NN O O
Fatal NN B-AdverseReaction B-AdverseReaction
cerebrovascular NN B-AdverseReaction B-AdverseReaction
accident NN I-AdverseReaction I-AdverseReaction
was NN O O
reported NN O O
in NN O O
1/359 NN O O
patients NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
receiving NN O O
INLYTA NN O O
and NN O O
none NN O O
of NN O O
the NN O O
patients NN O O
receiving NN O O
sorafenib NN O O
[ NN O O
seeAdverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
In NN O O
clinical NN O O
trials NN O O
with NN O O
INLYTA NN O O
, NN O O
arterial NN B-AdverseReaction B-AdverseReaction
thromboembolic NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
( NN O O
including NN O O
transient NN B-AdverseReaction B-AdverseReaction
ischemic NN I-AdverseReaction I-AdverseReaction
attack NN I-AdverseReaction I-AdverseReaction
cerebrovascular NN B-AdverseReaction B-AdverseReaction
accident NN I-AdverseReaction I-AdverseReaction
myocardial NN B-AdverseReaction B-AdverseReaction
infarction NN I-AdverseReaction I-AdverseReaction
and NN O O
retinal NN B-AdverseReaction B-AdverseReaction
artery NN I-AdverseReaction I-AdverseReaction
occlusion NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
in NN O O
17/715 NN O O
patients NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
, NN O O
with NN O O
two NN O O
deaths NN B-AdverseReaction B-AdverseReaction
secondary NN O O
to NN O O
cerebrovascular NN B-AdverseReaction B-AdverseReaction
accident NN I-AdverseReaction I-AdverseReaction
Use NN O O
INLYTA NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
who NN O O
are NN O O
at NN O O
risk NN O O
for NN O O
, NN O O
or NN O O
who NN O O
have NN O O
a NN O O
history NN O O
of NN O O
, NN O O
these NN O O
events NN O O
. NN O O
INLYTA NN O O
has NN O O
not NN O O
been NN O O
studied NN O O
in NN O O
patients NN O O
who NN O O
had NN O O
an NN O O
arterial NN O O
thromboembolic NN O O
event NN O O
within NN O O
the NN O O
previous NN O O
12 NN O O
months NN O O
. NN O O
5.3 NN O O
Venous NN O O
Thromboembolic NN O O
Events NN O O
In NN O O
clinical NN O O
trials NN O O
, NN O O
venous NN B-AdverseReaction B-AdverseReaction
thromboembolic NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
, NN O O
including NN O O
deaths NN B-AdverseReaction B-AdverseReaction
In NN O O
a NN O O
controlled NN O O
clinical NN O O
study NN O O
with NN O O
INLYTA NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
patients NN O O
with NN O O
RCC NN O O
, NN O O
venous NN B-AdverseReaction B-AdverseReaction
thromboembolic NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
in NN O O
11/359 NN O O
patients NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
receiving NN O O
INLYTA NN O O
and NN O O
2/355 NN O O
patients NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
receiving NN O O
sorafenib NN O O
. NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
venous NN B-AdverseReaction B-AdverseReaction
thromboembolic NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
in NN O O
9/359 NN O O
patients NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
receiving NN O O
INLYTA NN O O
( NN O O
including NN O O
pulmonary NN B-AdverseReaction B-AdverseReaction
embolism NN I-AdverseReaction I-AdverseReaction
deep NN B-AdverseReaction B-AdverseReaction
vein NN I-AdverseReaction I-AdverseReaction
thrombosis NN I-AdverseReaction I-AdverseReaction
retinal NN B-AdverseReaction B-AdverseReaction
vein NN I-AdverseReaction I-AdverseReaction
occlusion NN I-AdverseReaction I-AdverseReaction
and NN O O
retinal NN B-AdverseReaction B-AdverseReaction
vein NN I-AdverseReaction I-AdverseReaction
thrombosis NN I-AdverseReaction I-AdverseReaction
and NN O O
2/355 NN O O
patients NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
receiving NN O O
sorafenib NN O O
. NN O O
Fatal NN B-AdverseReaction B-AdverseReaction
pulmonary NN B-AdverseReaction B-AdverseReaction
embolism NN I-AdverseReaction I-AdverseReaction
was NN O O
reported NN O O
in NN O O
1/359 NN O O
patients NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
receiving NN O O
INLYTA NN O O
and NN O O
none NN O O
of NN O O
the NN O O
patients NN O O
receiving NN O O
sorafenib NN O O
. NN O O
In NN O O
clinical NN O O
trials NN O O
with NN O O
INLYTA NN O O
, NN O O
venous NN B-AdverseReaction B-AdverseReaction
thromboembolic NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
in NN O O
22/715 NN O O
patients NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
, NN O O
with NN O O
two NN O O
deaths NN B-AdverseReaction B-AdverseReaction
secondary NN O O
to NN O O
pulmonary NN B-AdverseReaction B-AdverseReaction
embolism NN I-AdverseReaction I-AdverseReaction
Use NN O O
INLYTA NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
who NN O O
are NN O O
at NN O O
risk NN O O
for NN O O
, NN O O
or NN O O
who NN O O
have NN O O
a NN O O
history NN O O
of NN O O
, NN O O
these NN O O
events NN O O
. NN O O
INLYTA NN O O
has NN O O
not NN O O
been NN O O
studied NN O O
in NN O O
patients NN O O
who NN O O
had NN O O
a NN O O
venous NN O O
thromboembolic NN O O
event NN O O
within NN O O
the NN O O
previous NN O O
6 NN O O
months NN O O
. NN O O
5.4 NN O O
Hemorrhage NN O O
In NN O O
a NN O O
controlled NN O O
clinical NN O O
study NN O O
with NN O O
INLYTA NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
patients NN O O
with NN O O
RCC NN O O
, NN O O
hemorrhagic NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
in NN O O
58/359 NN O O
patients NN O O
( NN O O
16 NN O O
% NN O O
) NN O O
receiving NN O O
INLYTA NN O O
and NN O O
64/355 NN O O
patients NN O O
( NN O O
18 NN O O
% NN O O
) NN O O
receiving NN O O
sorafenib NN O O
. NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
hemorrhagic NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
in NN O O
5/359 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
patients NN O O
receiving NN O O
INLYTA NN O O
( NN O O
including NN O O
cerebral NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
hematuria NN B-AdverseReaction B-AdverseReaction
hemoptysis NN B-AdverseReaction B-AdverseReaction
lower NN B-AdverseReaction B-AdverseReaction
gastrointestinal NN I-AdverseReaction I-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
and NN O O
melena NN B-AdverseReaction B-AdverseReaction
and NN O O
11/355 NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
patients NN O O
receiving NN O O
sorafenib NN O O
. NN O O
Fatal NN B-AdverseReaction B-AdverseReaction
hemorrhage NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
1/359 NN O O
patients NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
receiving NN O O
INLYTA NN O O
( NN O O
gastric NN O O
hemorrhage NN O O
) NN O O
and NN O O
3/355 NN O O
patients NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
receiving NN O O
sorafenib NN O O
. NN O O
INLYTA NN O O
has NN O O
not NN O O
been NN O O
studied NN O O
in NN O O
patients NN O O
who NN O O
have NN O O
evidence NN O O
of NN O O
untreated NN O O
brain NN O O
metastasis NN O O
or NN O O
recent NN O O
active NN O O
gastrointestinal NN O O
bleeding NN O O
and NN O O
should NN O O
not NN O O
be NN O O
used NN O O
in NN O O
those NN O O
patients NN O O
. NN O O
If NN O O
any NN O O
bleeding NN O O
requires NN O O
medical NN O O
intervention NN O O
, NN O O
temporarily NN O O
interrupt NN O O
the NN O O
INLYTA NN O O
dose NN O O
. NN O O
5.5 NN O O
Cardiac NN O O
Failure NN O O
In NN O O
a NN O O
controlled NN O O
clinical NN O O
study NN O O
with NN O O
INLYTA NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
patients NN O O
with NN O O
RCC NN O O
, NN O O
cardiac NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
was NN O O
reported NN O O
in NN O O
6/359 NN O O
patients NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
receiving NN O O
INLYTA NN O O
and NN O O
3/355 NN O O
patients NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
receiving NN O O
sorafenib NN O O
. NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
cardiac NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
was NN O O
observed NN O O
in NN O O
2/359 NN O O
patients NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
receiving NN O O
INLYTA NN O O
and NN O O
1/355 NN O O
patients NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
receiving NN O O
sorafenib NN O O
. NN O O
Fatal NN B-AdverseReaction B-AdverseReaction
cardiac NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
was NN O O
reported NN O O
in NN O O
2/359 NN O O
patients NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
receiving NN O O
INLYTA NN O O
and NN O O
1/355 NN O O
patients NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
receiving NN O O
sorafenib NN O O
. NN O O
Monitor NN O O
for NN O O
signs NN O O
or NN O O
symptoms NN O O
of NN O O
cardiac NN O O
failure NN O O
throughout NN O O
treatment NN O O
with NN O O
INLYTA. NN O O
Management NN O O
of NN O O
cardiac NN O O
failure NN O O
may NN O O
require NN O O
permanent NN O O
discontinuation NN O O
of NN O O
INLYTA. NN O O
5.6 NN O O
Gastrointestinal NN O O
Perforation NN O O
and NN O O
Fistula NN O O
Formation NN O O
In NN O O
a NN O O
controlled NN O O
clinical NN O O
study NN O O
with NN O O
INLYTA NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
patients NN O O
with NN O O
RCC NN O O
, NN O O
gastrointestinal NN B-AdverseReaction B-AdverseReaction
perforation NN I-AdverseReaction I-AdverseReaction
was NN O O
reported NN O O
in NN O O
1/359 NN O O
patients NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
receiving NN O O
INLYTA NN O O
and NN O O
none NN O O
of NN O O
the NN O O
patients NN O O
receiving NN O O
sorafenib NN O O
. NN O O
In NN O O
clinical NN O O
trials NN O O
with NN O O
INLYTA NN O O
, NN O O
gastrointestinal NN B-AdverseReaction B-AdverseReaction
perforation NN I-AdverseReaction I-AdverseReaction
was NN O O
reported NN O O
in NN O O
5/715 NN O O
patients NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
, NN O O
including NN O O
one NN O O
death NN B-AdverseReaction B-AdverseReaction
In NN O O
addition NN O O
to NN O O
cases NN O O
of NN O O
gastrointestinal NN B-AdverseReaction B-AdverseReaction
perforation NN I-AdverseReaction I-AdverseReaction
fistulas NN O O
were NN O O
reported NN O O
in NN O O
4/715 NN O O
patients NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
. NN O O
Monitor NN O O
for NN O O
symptoms NN O O
of NN O O
gastrointestinal NN O O
perforation NN O O
or NN O O
fistula NN O O
periodically NN O O
throughout NN O O
treatment NN O O
with NN O O
INLYTA. NN O O
5.7 NN O O
Thyroid NN O O
Dysfunction NN O O
In NN O O
a NN O O
controlled NN O O
clinical NN O O
study NN O O
with NN O O
INLYTA NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
patients NN O O
with NN O O
RCC NN O O
, NN O O
hypothyroidism NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
69/359 NN O O
patients NN O O
( NN O O
19 NN O O
% NN O O
) NN O O
receiving NN O O
INLYTA NN O O
and NN O O
29/355 NN O O
patients NN O O
( NN O O
8 NN O O
% NN O O
) NN O O
receiving NN O O
sorafenib NN O O
. NN O O
Hyperthyroidism NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
4/359 NN O O
patients NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
receiving NN O O
INLYTA NN O O
and NN O O
4/355 NN O O
patients NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
receiving NN O O
sorafenib NN O O
. NN O O
In NN O O
patients NN O O
who NN O O
had NN O O
thyroid NN O O
stimulating NN O O
hormone NN O O
( NN O O
TSH NN O O
) NN O O
< NN O O
5 NN O O
muU/mL NN O O
before NN O O
treatment NN O O
, NN O O
elevations NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
TSH NN I-AdverseReaction I-AdverseReaction
to NN O O
>=10 NN O O
muU/mL NN O O
occurred NN O O
in NN O O
79/245 NN O O
patients NN O O
( NN O O
32 NN O O
% NN O O
) NN O O
receiving NN O O
INLYTA NN O O
and NN O O
25/232 NN O O
patients NN O O
( NN O O
11 NN O O
% NN O O
) NN O O
receiving NN O O
sorafenib NN O O
[ NN O O
seeAdverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Monitor NN O O
thyroid NN O O
function NN O O
before NN O O
initiation NN O O
of NN O O
, NN O O
and NN O O
periodically NN O O
throughout NN O O
, NN O O
treatment NN O O
with NN O O
INLYTA. NN O O
Treat NN O O
hypothyroidism NN O O
and NN O O
hyperthyroidism NN O O
according NN O O
to NN O O
standard NN O O
medical NN O O
practice NN O O
to NN O O
maintain NN O O
euthyroid NN O O
state NN O O
. NN O O
5.8 NN O O
Wound NN O O
Healing NN O O
Complications NN O O
No NN O O
formal NN O O
studies NN O O
of NN O O
the NN O O
effect NN O O
of NN O O
INLYTA NN O O
on NN O O
wound NN O O
healing NN O O
have NN O O
been NN O O
conducted NN O O
. NN O O
Stop NN O O
treatment NN O O
with NN O O
INLYTA NN O O
at NN O O
least NN O O
24 NN O O
hours NN O O
prior NN O O
to NN O O
scheduled NN O O
surgery NN O O
. NN O O
The NN O O
decision NN O O
to NN O O
resume NN O O
INLYTA NN O O
therapy NN O O
after NN O O
surgery NN O O
should NN O O
be NN O O
based NN O O
on NN O O
clinical NN O O
judgment NN O O
of NN O O
adequate NN O O
wound NN O O
healing NN O O
. NN O O
5.9 NN O O
Reversible NN O O
Posterior NN O O
Leukoencephalopathy NN O O
Syndrome NN O O
In NN O O
a NN O O
controlled NN O O
clinical NN O O
study NN O O
with NN O O
INLYTA NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
patients NN O O
with NN O O
RCC NN O O
, NN O O
reversible NN B-AdverseReaction B-AdverseReaction
posterior NN I-AdverseReaction I-AdverseReaction
leukoencephalopathy NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
RPLS NN O O
) NN O O
was NN O O
reported NN O O
in NN O O
1/359 NN O O
patients NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
receiving NN O O
INLYTA NN O O
and NN O O
none NN O O
of NN O O
the NN O O
patients NN O O
receiving NN O O
sorafenib NN O O
[ NN O O
seeAdverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
There NN O O
were NN O O
two NN O O
additional NN O O
reports NN O O
of NN O O
RPLS NN B-AdverseReaction B-AdverseReaction
in NN O O
other NN O O
clinical NN O O
trials NN O O
with NN O O
INLYTA. NN O O
RPLS NN B-AdverseReaction B-AdverseReaction
is NN O O
a NN O O
neurological NN O O
disorder NN O O
which NN O O
can NN B-Factor B-Factor
present NN O O
with NN O O
headache NN B-AdverseReaction B-AdverseReaction
seizure NN B-AdverseReaction B-AdverseReaction
lethargy NN B-AdverseReaction B-AdverseReaction
confusion NN B-AdverseReaction B-AdverseReaction
blindness NN B-AdverseReaction B-AdverseReaction
and NN O O
other NN O O
visual NN O O
and NN O O
neurologic NN B-AdverseReaction B-AdverseReaction
disturbances NN I-AdverseReaction I-AdverseReaction
Mild NN B-Severity B-Severity
to NN I-Severity I-Severity
severe NN I-Severity I-Severity
hypertension NN B-AdverseReaction B-AdverseReaction
may NN B-Factor B-Factor
be NN O O
present NN O O
. NN O O
Magnetic NN O O
resonance NN O O
imaging NN O O
is NN O O
necessary NN O O
to NN O O
confirm NN O O
the NN O O
diagnosis NN O O
of NN O O
RPLS. NN O O
Discontinue NN O O
INLYTA NN O O
in NN O O
patients NN O O
developing NN O O
RPLS. NN O O
The NN O O
safety NN O O
of NN O O
reinitiating NN O O
INLYTA NN O O
therapy NN O O
in NN O O
patients NN O O
previously NN O O
experiencing NN O O
RPLS NN O O
is NN O O
not NN O O
known NN O O
. NN O O
5.10 NN O O
Proteinuria NN O O
In NN O O
a NN O O
controlled NN O O
clinical NN O O
study NN O O
with NN O O
INLYTA NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
patients NN O O
with NN O O
RCC NN O O
, NN O O
proteinuria NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
39/359 NN O O
patients NN O O
( NN O O
11 NN O O
% NN O O
) NN O O
receiving NN O O
INLYTA NN O O
and NN O O
26/355 NN O O
patients NN O O
( NN O O
7 NN O O
% NN O O
) NN O O
receiving NN O O
sorafenib NN O O
. NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
proteinuria NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
11/359 NN O O
patients NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
receiving NN O O
INLYTA NN O O
and NN O O
6/355 NN O O
patients NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
receiving NN O O
sorafenib NN O O
[ NN O O
seeAdverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Monitoring NN O O
for NN O O
proteinuria NN O O
before NN O O
initiation NN O O
of NN O O
, NN O O
and NN O O
periodically NN O O
throughout NN O O
, NN O O
treatment NN O O
with NN O O
INLYTA NN O O
is NN O O
recommended NN O O
. NN O O
For NN O O
patients NN O O
who NN O O
develop NN O O
moderate NN O O
to NN O O
severe NN O O
proteinuria NN O O
, NN O O
reduce NN O O
the NN O O
dose NN O O
or NN O O
temporarily NN O O
interrupt NN O O
INLYTA NN O O
treatment NN O O
. NN O O
5.11 NN O O
Elevation NN O O
of NN O O
Liver NN O O
Enzymes NN O O
In NN O O
a NN O O
controlled NN O O
clinical NN O O
study NN O O
with NN O O
INLYTA NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
patients NN O O
with NN O O
RCC NN O O
, NN O O
alanine NN O O
aminotransferase NN O O
( NN O O
ALT NN O O
) NN O O
elevations NN O O
of NN O O
all NN O O
grades NN O O
occurred NN O O
in NN O O
22 NN O O
% NN O O
of NN O O
patients NN O O
on NN O O
both NN O O
arms NN O O
, NN O O
with NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
events NN O O
in NN O O
< NN O O
1 NN O O
% NN O O
of NN O O
patients NN O O
on NN O O
the NN O O
INLYTA NN O O
arm NN O O
and NN O O
2 NN O O
% NN O O
of NN O O
patients NN O O
on NN O O
the NN O O
sorafenib NN O O
arm NN O O
. NN O O
Monitor NN O O
ALT NN O O
, NN O O
aspartate NN O O
aminotransferase NN O O
( NN O O
AST NN O O
) NN O O
and NN O O
bilirubin NN O O
before NN O O
initiation NN O O
of NN O O
and NN O O
periodically NN O O
throughout NN O O
treatment NN O O
with NN O O
INLYTA. NN O O
5.12 NN O O
Hepatic NN O O
Impairment NN O O
The NN O O
systemic NN O O
exposure NN O O
to NN O O
axitinib NN O O
was NN O O
higher NN O O
in NN O O
subjects NN O O
with NN O O
moderate NN O O
hepatic NN O O
impairment NN O O
( NN O O
Child NN O O
- NN O O
Pugh NN O O
class NN O O
B NN O O
) NN O O
compared NN O O
to NN O O
subjects NN O O
with NN O O
normal NN O O
hepatic NN O O
function NN O O
. NN O O
A NN O O
dose NN O O
decrease NN O O
is NN O O
recommended NN O O
when NN O O
administering NN O O
INLYTA NN O O
to NN O O
patients NN O O
with NN O O
moderate NN O O
hepatic NN O O
impairment NN O O
( NN O O
Child NN O O
- NN O O
Pugh NN O O
class NN O O
B NN O O
) NN O O
. NN O O
INLYTA NN O O
has NN O O
not NN O O
been NN O O
studied NN O O
in NN O O
patients NN O O
with NN O O
severe NN O O
hepatic NN O O
impairment NN O O
( NN O O
Child NN O O
- NN O O
Pugh NN O O
class NN O O
C NN O O
) NN O O
[ NN O O
seeDosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2),Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.6 NN O O
) NN O O
, NN O O
andClinical NN O O
Pharmacology NN O O
( NN O O
12.3 NN O O
) NN O O
] NN O O
. NN O O
5.13 NN O O
Pregnancy NN O O
INLYTA NN O O
can NN B-Factor B-Factor
cause NN O O
fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
when NN O O
administered NN O O
to NN O O
a NN O O
pregnant NN O O
woman NN O O
based NN O O
on NN O O
its NN O O
mechanism NN O O
of NN O O
action NN O O
. NN O O
There NN O O
are NN O O
no NN O O
adequate NN O O
and NN O O
well NN O O
- NN O O
controlled NN O O
studies NN O O
in NN O O
pregnant NN O O
women NN O O
using NN O O
INLYTA. NN O O
In NN O O
developmental NN O O
toxicity NN O O
studies NN O O
in NN O O
mice NN B-Animal B-Animal
axitinib NN O O
was NN O O
teratogenic NN B-AdverseReaction B-AdverseReaction
embryotoxic NN B-AdverseReaction B-AdverseReaction
and NN O O
fetotoxic NN B-AdverseReaction B-AdverseReaction
at NN O O
maternal NN O O
exposures NN O O
that NN O O
were NN O O
lower NN O O
than NN O O
human NN O O
exposures NN O O
at NN O O
the NN O O
recommended NN O O
clinical NN O O
dose NN O O
. NN O O
Women NN O O
of NN O O
childbearing NN O O
potential NN O O
should NN O O
be NN O O
advised NN O O
to NN O O
avoid NN O O
becoming NN O O
pregnant NN O O
while NN O O
receiving NN O O
INLYTA. NN O O
If NN O O
this NN O O
drug NN O O
is NN O O
used NN O O
during NN O O
pregnancy NN O O
, NN O O
or NN O O
if NN O O
a NN O O
patient NN O O
becomes NN O O
pregnant NN O O
while NN O O
receiving NN O O
this NN O O
drug NN O O
, NN O O
the NN O O
patient NN O O
should NN O O
be NN O O
apprised NN O O
of NN O O
the NN O O
potential NN O O
hazard NN O O
to NN O O
the NN O O
fetus NN O O
[ NN O O
seeUse NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.1 NN O O
) NN O O
] NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
are NN O O
described NN O O
in NN O O
greater NN O O
detail NN O O
in NN O O
other NN O O
sections NN O O
: NN O O
* NN O O
Severe NN B-Severity B-Severity
skin NN O O
and NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
drug NN O O
reactions NN O O
of NN O O
moderate NN B-Severity B-Severity
to NN I-Severity I-Severity
severe NN I-Severity I-Severity
intensity NN O O
( NN O O
at NN O O
least NN O O
2 NN O O
% NN O O
) NN O O
which NN O O
occurred NN O O
at NN O O
a NN O O
higher NN O O
rate NN O O
than NN O O
placebo NN O O
in NN O O
adults NN O O
are NN O O
rash NN B-AdverseReaction B-AdverseReaction
and NN O O
peripheral NN B-AdverseReaction B-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
drug NN O O
reactions NN O O
in NN O O
at NN O O
least NN O O
2 NN O O
% NN O O
of NN O O
pediatric NN O O
patients NN O O
are NN O O
rash NN B-AdverseReaction B-AdverseReaction
and NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
( NN O O
6.2 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Janssen NN O O
Products NN O O
, NN O O
LP NN O O
at NN O O
1 NN O O
- NN O O
800-JANSSEN NN O O
( NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
526 NN O O
- NN O O
7736 NN O O
) NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
: NN O O
Adults NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
The NN O O
safety NN O O
assessment NN O O
is NN O O
based NN O O
on NN O O
all NN O O
data NN O O
from NN O O
1203 NN O O
subjects NN O O
in NN O O
the NN O O
Phase NN O O
3 NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
, NN O O
TMC125-C206 NN O O
and NN O O
TMC125-C216 NN O O
, NN O O
conducted NN O O
in NN O O
antiretroviral NN O O
treatment NN O O
- NN O O
experienced NN O O
HIV-1-infected NN O O
adult NN O O
subjects NN O O
, NN O O
599 NN O O
of NN O O
whom NN O O
received NN O O
INTELENCE NN O O
( NN O O
r NN O O
) NN O O
( NN O O
200 NN O O
mg NN O O
twice NN O O
daily NN O O
) NN O O
. NN O O
In NN O O
these NN O O
pooled NN O O
trials NN O O
, NN O O
the NN O O
median NN O O
exposure NN O O
for NN O O
subjects NN O O
in NN O O
the NN O O
INTELENCE NN O O
( NN O O
r NN O O
) NN O O
arm NN O O
and NN O O
placebo NN O O
arm NN O O
was NN O O
52.3 NN O O
and NN O O
51.0 NN O O
weeks NN O O
, NN O O
respectively NN O O
. NN O O
Discontinuations NN O O
due NN O O
to NN O O
adverse NN O O
drug NN O O
reactions NN O O
( NN O O
ADRs NN O O
) NN O O
were NN O O
5.2 NN O O
% NN O O
in NN O O
the NN O O
INTELENCE NN O O
( NN O O
r NN O O
) NN O O
arm NN O O
and NN O O
2.6 NN O O
% NN O O
in NN O O
the NN O O
placebo NN O O
arm NN O O
. NN O O
The NN O O
most NN O O
frequently NN O O
reported NN O O
ADR NN O O
at NN O O
least NN O O
Grade NN B-Severity B-Severity
2 NN I-Severity I-Severity
in NN O O
severity NN O O
was NN O O
rash NN B-AdverseReaction B-AdverseReaction
( NN O O
10.0 NN O O
% NN O O
) NN O O
. NN O O
Stevens NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Johnson NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
drug NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reaction NN O O
and NN O O
erythema NN B-AdverseReaction B-AdverseReaction
multiforme NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
in NN O O
less NN O O
than NN O O
0.1 NN O O
% NN O O
of NN O O
subjects NN O O
during NN O O
clinical NN O O
development NN O O
with NN O O
INTELENCE NN O O
( NN O O
r NN O O
) NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
A NN O O
total NN O O
of NN O O
2.2 NN O O
% NN O O
of NN O O
HIV-1-infected NN O O
subjects NN O O
in NN O O
Phase NN O O
3 NN O O
trials NN O O
receiving NN O O
INTELENCE NN O O
( NN O O
r NN O O
) NN O O
discontinued NN O O
due NN O O
to NN O O
rash NN B-AdverseReaction B-AdverseReaction
In NN O O
general NN O O
, NN O O
in NN O O
clinical NN O O
trials NN O O
, NN O O
rash NN B-AdverseReaction B-AdverseReaction
was NN O O
mild NN B-Severity B-Severity
to NN I-Severity I-Severity
moderate NN I-Severity I-Severity
occurred NN O O
primarily NN O O
in NN O O
the NN O O
second NN O O
week NN O O
of NN O O
therapy NN O O
, NN O O
and NN O O
was NN O O
infrequent NN O O
after NN O O
Week NN O O
4 NN O O
. NN O O
Rash NN B-AdverseReaction B-AdverseReaction
generally NN O O
resolved NN O O
within NN O O
1 NN O O
to NN O O
2 NN O O
weeks NN O O
on NN O O
continued NN O O
therapy NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
rash NN B-AdverseReaction B-AdverseReaction
was NN O O
higher NN O O
in NN O O
women NN O O
compared NN O O
to NN O O
men NN O O
in NN O O
the NN O O
INTELENCE NN O O
( NN O O
r NN O O
) NN O O
arm NN O O
in NN O O
the NN O O
Phase NN O O
3 NN O O
trials NN O O
( NN O O
rash NN O O
>= NN O O
Grade NN B-Severity B-Severity
2 NN I-Severity I-Severity
was NN O O
reported NN O O
in NN O O
9/60 NN O O
[ NN O O
15.0 NN O O
% NN O O
] NN O O
women NN O O
versus NN O O
51/539 NN O O
[ NN O O
9.5 NN O O
% NN O O
] NN O O
men NN O O
; NN O O
discontinuations NN O O
due NN O O
to NN O O
rash NN B-AdverseReaction B-AdverseReaction
were NN O O
reported NN O O
in NN O O
3/60 NN O O
[ NN O O
5.0 NN O O
% NN O O
] NN O O
women NN O O
versus NN O O
10/539 NN O O
[ NN O O
1.9 NN O O
% NN O O
] NN O O
men NN O O
) NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
Patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
NNRTI NN B-DrugClass B-DrugClass
rash NN B-AdverseReaction B-AdverseReaction
did NN O O
not NN O O
appear NN O O
to NN O O
be NN O O
at NN O O
increased NN O O
risk NN O O
for NN O O
the NN O O
development NN O O
of NN O O
INTELENCE NN O O
( NN O O
r NN O O
) NN O O
-related NN O O
rash NN B-AdverseReaction B-AdverseReaction
compared NN O O
to NN O O
patients NN O O
without NN O O
a NN O O
history NN O O
of NN O O
NNRTI NN B-DrugClass B-DrugClass
rash NN B-AdverseReaction B-AdverseReaction
Common NN O O
Adverse NN O O
Reactions NN O O
Clinical NN O O
ADRs NN O O
of NN O O
moderate NN O O
intensity NN O O
or NN O O
greater NN O O
( NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
Grade NN O O
2 NN O O
) NN O O
and NN O O
reported NN O O
in NN O O
at NN O O
least NN O O
2 NN O O
% NN O O
of NN O O
subjects NN O O
treated NN O O
with NN O O
INTELENCE NN O O
( NN O O
r NN O O
) NN O O
and NN O O
occurring NN O O
at NN O O
a NN O O
higher NN O O
rate NN O O
compared NN O O
to NN O O
placebo NN O O
( NN O O
excess NN O O
of NN O O
1 NN O O
% NN O O
) NN O O
are NN O O
presented NN O O
in NN O O
Table NN O O
1 NN O O
. NN O O
Laboratory NN O O
abnormalities NN O O
considered NN O O
ADRs NN O O
are NN O O
included NN O O
in NN O O
Table NN O O
2 NN O O
. NN O O
Table NN O O
1 NN O O
: NN O O
Treatment NN O O
- NN O O
Emergent NN O O
Adverse NN O O
ReactionsIncludes NN O O
adverse NN O O
reactions NN O O
at NN O O
least NN O O
possibly NN O O
, NN O O
probably NN O O
, NN O O
or NN O O
very NN O O
likely NN O O
related NN O O
to NN O O
the NN O O
drug NN O O
. NN O O
of NN O O
at NN O O
least NN O O
Moderate NN O O
IntensityIntensities NN O O
are NN O O
defined NN O O
as NN O O
follows NN O O
: NN O O
Moderate NN O O
( NN O O
discomfort NN O O
enough NN O O
to NN O O
cause NN O O
interference NN O O
with NN O O
usual NN O O
activity NN O O
) NN O O
; NN O O
Severe NN O O
( NN O O
incapacitating NN O O
with NN O O
inability NN O O
to NN O O
work NN O O
or NN O O
do NN O O
usual NN O O
activity NN O O
) NN O O
. NN O O
( NN O O
Grades NN O O
2 NN O O
to NN O O
4 NN O O
) NN O O
in NN O O
at NN O O
least NN O O
2 NN O O
% NN O O
of NN O O
Adult NN O O
Subjects NN O O
in NN O O
the NN O O
INTELENCE(r NN O O
) NN O O
Treatment NN O O
Groups NN O O
and NN O O
at NN O O
a NN O O
higher NN O O
rate NN O O
compared NN O O
to NN O O
placebo NN O O
( NN O O
excess NN O O
of NN O O
1 NN O O
% NN O O
) NN O O
System NN O O
Organ NN O O
Class NN O O
, NN O O
Preferred NN O O
Term NN O O
, NN O O
% NN O O
Pooled NN O O
TMC125-C206 NN O O
and NN O O
TMC125-C216 NN O O
Trials NN O O
INTELENCE NN O O
( NN O O
r NN O O
) NN O O
+ NN O O
BRN=599 NN O O
Placebo NN O O
+ NN O O
BRN=604 NN O O
N=total NN O O
number NN O O
of NN O O
subjects NN O O
per NN O O
treatment NN O O
group NN O O
, NN O O
BR=background NN O O
regimen NN O O
Nervous NN O O
System NN O O
Disorders NN O O
Peripheral NN B-AdverseReaction B-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
4 NN O O
% NN O O
2 NN O O
% NN O O
Skin NN O O
and NN O O
Subcutaneous NN O O
Tissue NN O O
Disorders NN O O
Rash NN B-AdverseReaction B-AdverseReaction
10 NN O O
% NN O O
3 NN O O
% NN O O
Less NN O O
Common NN O O
Adverse NN O O
Reactions NN O O
Treatment NN O O
- NN O O
emergent NN O O
ADRs NN O O
occurring NN O O
in NN O O
less NN O O
than NN O O
2 NN O O
% NN O O
of NN O O
subjects NN O O
( NN O O
599 NN O O
subjects NN O O
) NN O O
receiving NN O O
INTELENCE NN O O
( NN O O
r NN O O
) NN O O
and NN O O
of NN O O
at NN O O
least NN O O
moderate NN O O
intensity NN O O
( NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
Grade NN O O
2 NN O O
) NN O O
are NN O O
listed NN O O
below NN O O
by NN O O
body NN O O
system NN O O
: NN O O
Cardiac NN O O
Disorders NN O O
: NN O O
myocardial NN B-AdverseReaction B-AdverseReaction
infarction NN I-AdverseReaction I-AdverseReaction
angina NN B-AdverseReaction B-AdverseReaction
pectoris NN I-AdverseReaction I-AdverseReaction
atrial NN B-AdverseReaction B-AdverseReaction
fibrillation NN I-AdverseReaction I-AdverseReaction
Ear NN O O
and NN O O
Labyrinth NN O O
Disorders NN O O
: NN O O
vertigo NN B-AdverseReaction B-AdverseReaction
Eye NN O O
Disorders NN O O
: NN O O
blurred NN B-AdverseReaction B-AdverseReaction
vision NN I-AdverseReaction I-AdverseReaction
Gastrointestinal NN O O
Disorders NN O O
: NN O O
gastroesophageal NN B-AdverseReaction B-AdverseReaction
reflux NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
flatulence NN B-AdverseReaction B-AdverseReaction
gastritis NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
distension NN I-AdverseReaction I-AdverseReaction
pancreatitis NN B-AdverseReaction B-AdverseReaction
constipation NN B-AdverseReaction B-AdverseReaction
dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
hematemesis NN B-AdverseReaction B-AdverseReaction
retching NN B-AdverseReaction B-AdverseReaction
stomatitis NN B-AdverseReaction B-AdverseReaction
General NN O O
Disorders NN O O
and NN O O
Administration NN O O
Site NN O O
Conditions NN O O
: NN O O
sluggishness NN B-AdverseReaction B-AdverseReaction
Hematologic NN O O
Disorders NN O O
: NN O O
hemolytic NN B-AdverseReaction B-AdverseReaction
anemia NN I-AdverseReaction I-AdverseReaction
Hepatobiliary NN O O
Disorders NN O O
: NN O O
hepatic NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
hepatomegaly NN B-AdverseReaction B-AdverseReaction
cytolytic NN B-AdverseReaction B-AdverseReaction
hepatitis NN I-AdverseReaction I-AdverseReaction
hepatic NN B-AdverseReaction B-AdverseReaction
steatosis NN I-AdverseReaction I-AdverseReaction
hepatitis NN B-AdverseReaction B-AdverseReaction
Immune NN O O
System NN O O
Disorders NN O O
: NN O O
drug NN B-AdverseReaction B-AdverseReaction
hypersensitivity NN I-AdverseReaction I-AdverseReaction
immune NN B-AdverseReaction B-AdverseReaction
reconstitution NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
Metabolism NN O O
and NN O O
Nutrition NN O O
Disorders NN O O
: NN O O
diabetes NN B-AdverseReaction B-AdverseReaction
mellitus NN I-AdverseReaction I-AdverseReaction
anorexia NN B-AdverseReaction B-AdverseReaction
dyslipidemia NN B-AdverseReaction B-AdverseReaction
Nervous NN O O
System NN O O
Disorders NN O O
: NN O O
paraesthesia NN B-AdverseReaction B-AdverseReaction
somnolence NN B-AdverseReaction B-AdverseReaction
convulsion NN B-AdverseReaction B-AdverseReaction
hypoesthesia NN B-AdverseReaction B-AdverseReaction
amnesia NN B-AdverseReaction B-AdverseReaction
syncope NN B-AdverseReaction B-AdverseReaction
disturbance NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
attention NN I-AdverseReaction I-AdverseReaction
hypersomnia NN B-AdverseReaction B-AdverseReaction
tremor NN B-AdverseReaction B-AdverseReaction
Psychiatric NN O O
Disorders NN O O
: NN O O
anxiety NN B-AdverseReaction B-AdverseReaction
sleep NN B-AdverseReaction B-AdverseReaction
disorders NN I-AdverseReaction I-AdverseReaction
abnormal NN B-AdverseReaction B-AdverseReaction
dreams NN I-AdverseReaction I-AdverseReaction
confusional NN B-AdverseReaction B-AdverseReaction
state NN I-AdverseReaction I-AdverseReaction
disorientation NN B-AdverseReaction B-AdverseReaction
nervousness NN B-AdverseReaction B-AdverseReaction
nightmares NN B-AdverseReaction B-AdverseReaction
Renal NN O O
and NN O O
Urinary NN O O
Disorders NN O O
: NN O O
acute NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
Reproductive NN O O
System NN O O
and NN O O
Breast NN O O
Disorders NN O O
: NN O O
gynecomastia NN B-AdverseReaction B-AdverseReaction
Respiratory NN O O
, NN O O
Thoracic NN O O
and NN O O
Mediastinal NN O O
Disorders NN O O
: NN O O
exertional NN B-AdverseReaction B-AdverseReaction
dyspnea NN I-AdverseReaction I-AdverseReaction
bronchospasm NN B-AdverseReaction B-AdverseReaction
Skin NN O O
and NN O O
Subcutaneous NN O O
Tissue NN O O
Disorders NN O O
: NN O O
night NN B-AdverseReaction B-AdverseReaction
sweats NN I-AdverseReaction I-AdverseReaction
lipohypertrophy NN B-AdverseReaction B-AdverseReaction
prurigo NN B-AdverseReaction B-AdverseReaction
hyperhidrosis NN B-AdverseReaction B-AdverseReaction
dry NN B-AdverseReaction B-AdverseReaction
skin NN I-AdverseReaction I-AdverseReaction
swelling NN B-AdverseReaction B-AdverseReaction
face NN I-AdverseReaction I-AdverseReaction
Additional NN O O
ADRs NN O O
of NN O O
at NN O O
least NN O O
moderate NN O O
intensity NN O O
observed NN O O
in NN O O
other NN O O
trials NN O O
were NN O O
acquired NN B-AdverseReaction B-AdverseReaction
lipodystrophy NN I-AdverseReaction I-AdverseReaction
angioneurotic NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
erythema NN B-AdverseReaction B-AdverseReaction
multiforme NN I-AdverseReaction I-AdverseReaction
and NN O O
haemorrhagic NN B-AdverseReaction B-AdverseReaction
stroke NN I-AdverseReaction I-AdverseReaction
each NN O O
reported NN O O
in NN O O
no NN O O
more NN O O
than NN O O
0.5 NN O O
% NN O O
of NN O O
subjects NN O O
. NN O O
Laboratory NN O O
Abnormalities NN O O
in NN O O
Treatment NN O O
- NN O O
Experienced NN O O
Patients NN O O
Selected NN O O
Grade NN O O
2 NN O O
to NN O O
Grade NN O O
4 NN O O
laboratory NN O O
abnormalities NN O O
that NN O O
represent NN O O
a NN O O
worsening NN O O
from NN O O
baseline NN O O
observed NN O O
in NN O O
adult NN O O
subjects NN O O
treated NN O O
with NN O O
INTELENCE NN O O
( NN O O
r NN O O
) NN O O
are NN O O
presented NN O O
in NN O O
Table NN O O
2 NN O O
. NN O O
Table NN O O
2 NN O O
: NN O O
Selected NN O O
Grade NN O O
2 NN O O
to NN O O
4 NN O O
Laboratory NN O O
Abnormalities NN O O
Observed NN O O
in NN O O
Treatment NN O O
- NN O O
Experienced NN O O
Subjects NN O O
Pooled NN O O
TMC125-C206 NN O O
and NN O O
TMC125-C216 NN O O
Trials NN O O
Laboratory NN O O
ParameterPreferred NN O O
Term NN O O
, NN O O
% NN O O
DAIDS NN O O
Toxicity NN O O
Range NN O O
INTELENCE NN O O
( NN O O
r NN O O
) NN O O
+ NN O O
BRN=599 NN O O
Placebo NN O O
+ NN O O
BRN=604 NN O O
ULN=Upper NN O O
Limit NN O O
of NN O O
Normal NN O O
, NN O O
BR=background NN O O
regimen NN O O
GENERAL NN O O
BIOCHEMISTRY NN O O
Pancreatic NN O O
amylase NN O O
Grade NN O O
2 NN O O
> NN O O
1.5 NN O O
- NN O O
2 NN O O
* NN O O
ULN NN O O
7 NN O O
% NN O O
8 NN O O
% NN O O
Grade NN O O
3 NN O O
> NN O O
2 NN O O
- NN O O
5 NN O O
* NN O O
ULN NN O O
7 NN O O
% NN O O
8 NN O O
% NN O O
Grade NN O O
4 NN O O
> NN O O
5 NN O O
* NN O O
ULN NN O O
2 NN O O
% NN O O
1 NN O O
% NN O O
Lipase NN O O
Grade NN O O
2 NN O O
> NN O O
1.5 NN O O
- NN O O
3 NN O O
* NN O O
ULN NN O O
4 NN O O
% NN O O
6 NN O O
% NN O O
Grade NN O O
3 NN O O
> NN O O
3 NN O O
- NN O O
5 NN O O
* NN O O
ULN NN O O
2 NN O O
% NN O O
2 NN O O
% NN O O
Grade NN O O
4 NN O O
> NN O O
5*ULN NN O O
1 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
Creatinine NN O O
Grade NN O O
2 NN O O
> NN O O
1.4 NN O O
- NN O O
1.8 NN O O
* NN O O
ULN NN O O
6 NN O O
% NN O O
5 NN O O
% NN O O
Grade NN O O
3 NN O O
> NN O O
1.9 NN O O
- NN O O
3.4 NN O O
* NN O O
ULN NN O O
2 NN O O
% NN O O
1 NN O O
% NN O O
Grade NN O O
4 NN O O
> NN O O
3.4 NN O O
* NN O O
ULN NN O O
0 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
HEMATOLOGY NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
hemoglobin NN I-AdverseReaction I-AdverseReaction
Grade NN O O
2 NN O O
90 NN O O
- NN O O
99 NN O O
g/L NN O O
2 NN O O
% NN O O
4 NN O O
% NN O O
Grade NN O O
3 NN O O
70 NN O O
- NN O O
89 NN O O
g/L NN O O
< NN O O
1 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
Grade NN O O
4 NN O O
< NN O O
70 NN O O
g/L NN O O
< NN O O
1 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
White NN O O
blood NN O O
cell NN O O
count NN O O
Grade NN O O
2 NN O O
1,500 NN O O
- NN O O
1,999/mm NN O O
3 NN O O
2 NN O O
% NN O O
3 NN O O
% NN O O
Grade NN O O
3 NN O O
1,000 NN O O
- NN O O
1,499/mm NN O O
3 NN O O
1 NN O O
% NN O O
4 NN O O
% NN O O
Grade NN O O
4 NN O O
< NN O O
1,000/mm NN O O
3 NN O O
1 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
Neutrophils NN O O
Grade NN O O
2 NN O O
750 NN O O
- NN O O
999/mm NN O O
3 NN O O
5 NN O O
% NN O O
6 NN O O
% NN O O
Grade NN O O
3 NN O O
500 NN O O
- NN O O
749/mm NN O O
3 NN O O
4 NN O O
% NN O O
4 NN O O
% NN O O
Grade NN O O
4 NN O O
< NN O O
500/mm NN O O
3 NN O O
2 NN O O
% NN O O
3 NN O O
% NN O O
Platelet NN O O
count NN O O
Grade NN O O
2 NN O O
50,000 NN O O
- NN O O
99,999/mm NN O O
3 NN O O
3 NN O O
% NN O O
5 NN O O
% NN O O
Grade NN O O
3 NN O O
25,000 NN O O
- NN O O
49,999/mm NN O O
3 NN O O
1 NN O O
% NN O O
1 NN O O
% NN O O
Grade NN O O
4 NN O O
< NN O O
25,000/mm NN O O
3 NN O O
< NN O O
1 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
LIPIDS NN O O
AND NN O O
GLUCOSE NN O O
Total NN O O
cholesterol NN O O
Grade NN O O
2 NN O O
> NN O O
6.20 NN O O
- NN O O
7.77 NN O O
mmol/L240 NN O O
- NN O O
300 NN O O
mg/dL NN O O
20 NN O O
% NN O O
17 NN O O
% NN O O
Grade NN O O
3 NN O O
> NN O O
7.77 NN O O
mmol/L NN O O
> NN O O
300 NN O O
mg/dL NN O O
8 NN O O
% NN O O
5 NN O O
% NN O O
Low NN O O
density NN O O
lipoprotein NN O O
Grade NN O O
2 NN O O
4.13 NN O O
- NN O O
4.9 NN O O
mmol/L160 NN O O
- NN O O
190 NN O O
mg/dL NN O O
13 NN O O
% NN O O
12 NN O O
% NN O O
Grade NN O O
3 NN O O
> NN O O
4.9 NN O O
mmol/L NN O O
> NN O O
190 NN O O
mg/dL NN O O
7 NN O O
% NN O O
7 NN O O
% NN O O
Triglycerides NN O O
Grade NN O O
2 NN O O
5.65 NN O O
- NN O O
8.48 NN O O
mmol/L500 NN O O
-750 NN O O
mg/dL NN O O
9 NN O O
% NN O O
7 NN O O
% NN O O
Grade NN O O
3 NN O O
8.49 NN O O
- NN O O
13.56 NN O O
mmol/L751 NN O O
- NN O O
1200 NN O O
mg/dL NN O O
6 NN O O
% NN O O
4 NN O O
% NN O O
Grade NN O O
4 NN O O
> NN O O
13.56 NN O O
mmol/L NN O O
> NN O O
1200 NN O O
mg/dL NN O O
4 NN O O
% NN O O
2 NN O O
% NN O O
Elevated NN B-AdverseReaction B-AdverseReaction
glucose NN I-AdverseReaction I-AdverseReaction
levels NN I-AdverseReaction I-AdverseReaction
Grade NN O O
2 NN O O
6.95 NN O O
- NN O O
13.88 NN O O
mmol/L161 NN O O
- NN O O
250 NN O O
mg/dL NN O O
15 NN O O
% NN O O
13 NN O O
% NN O O
Grade NN O O
3 NN O O
13.89 NN O O
- NN O O
27.75 NN O O
mmol/L251 NN O O
- NN O O
500 NN O O
mg/dL NN O O
4 NN O O
% NN O O
2 NN O O
% NN O O
Grade NN O O
4 NN O O
> NN O O
27.75 NN O O
mmol/L NN O O
> NN O O
500 NN O O
mg/dL NN O O
0 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
HEPATIC NN O O
PARAMETERS NN O O
Alanine NN O O
amino NN O O
transferase NN O O
Grade NN O O
2 NN O O
2.6 NN O O
- NN O O
5 NN O O
* NN O O
ULN NN O O
6 NN O O
% NN O O
5 NN O O
% NN O O
Grade NN O O
3 NN O O
5.1 NN O O
- NN O O
10 NN O O
* NN O O
ULN NN O O
3 NN O O
% NN O O
2 NN O O
% NN O O
Grade NN O O
4 NN O O
> NN O O
10 NN O O
* NN O O
ULN NN O O
1 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
Aspartate NN O O
amino NN O O
transferase NN O O
Grade NN O O
2 NN O O
2.6 NN O O
- NN O O
5 NN O O
* NN O O
ULN NN O O
6 NN O O
% NN O O
8 NN O O
% NN O O
Grade NN O O
3 NN O O
5.1 NN O O
- NN O O
10 NN O O
* NN O O
ULN NN O O
3 NN O O
% NN O O
2 NN O O
% NN O O
Grade NN O O
4 NN O O
> NN O O
10 NN O O
* NN O O
ULN NN O O
< NN O O
1 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
Patients NN O O
co NN O O
- NN O O
infected NN O O
with NN O O
hepatitis NN O O
B NN O O
and/or NN O O
hepatitis NN O O
C NN O O
virus NN O O
In NN O O
Phase NN O O
3 NN O O
trials NN O O
TMC125-C206 NN O O
and NN O O
TMC125-C216 NN O O
, NN O O
139 NN O O
subjects NN O O
( NN O O
12.3 NN O O
% NN O O
) NN O O
with NN O O
chronic NN O O
hepatitis NN O O
B NN O O
and/or NN O O
hepatitis NN O O
C NN O O
virus NN O O
co NN O O
- NN O O
infection NN O O
out NN O O
of NN O O
1129 NN O O
subjects NN O O
were NN O O
permitted NN O O
to NN O O
enroll NN O O
. NN O O
AST NN O O
and NN O O
ALT NN B-AdverseReaction B-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
occurred NN O O
more NN O O
frequently NN O O
in NN O O
hepatitis NN O O
B NN O O
and/or NN O O
hepatitis NN O O
C NN O O
virus NN O O
co NN O O
- NN O O
infected NN O O
subjects NN O O
for NN O O
both NN O O
treatment NN O O
groups NN O O
. NN O O
Grade NN B-Severity B-Severity
2 NN I-Severity I-Severity
or NN O O
higher NN O O
laboratory NN O O
abnormalities NN O O
that NN O O
represent NN O O
a NN O O
worsening NN O O
from NN O O
baseline NN O O
of NN O O
AST NN O O
, NN O O
ALT NN O O
or NN O O
total NN O O
bilirubin NN O O
occurred NN O O
in NN O O
27.8 NN O O
% NN O O
, NN O O
25.0 NN O O
% NN O O
and NN O O
7.1 NN O O
% NN O O
respectively NN O O
, NN O O
of NN O O
INTELENCE NN O O
( NN O O
r NN O O
) NN O O
-treated NN O O
co NN O O
- NN O O
infected NN O O
subjects NN O O
as NN O O
compared NN O O
to NN O O
6.7 NN O O
% NN O O
, NN O O
7.5 NN O O
% NN O O
and NN O O
1.8 NN O O
% NN O O
of NN O O
non NN O O
- NN O O
co NN O O
- NN O O
infected NN O O
INTELENCE NN O O
( NN O O
r NN O O
) NN O O
-treated NN O O
subjects NN O O
. NN O O
In NN O O
general NN O O
, NN O O
adverse NN O O
events NN O O
reported NN O O
by NN O O
INTELENCE NN O O
( NN O O
r NN O O
) NN O O
-treated NN O O
subjects NN O O
with NN O O
hepatitis NN O O
B NN O O
and/or NN O O
hepatitis NN O O
C NN O O
virus NN O O
co NN O O
- NN O O
infection NN O O
were NN O O
similar NN O O
to NN O O
INTELENCE NN O O
( NN O O
r NN O O
) NN O O
-treated NN O O
subjects NN O O
without NN O O
hepatitis NN O O
B NN O O
and/or NN O O
hepatitis NN O O
C NN O O
virus NN O O
co NN O O
- NN O O
infection NN O O
. NN O O
6.2 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
: NN O O
Pediatric NN O O
Subjects NN O O
( NN O O
6 NN O O
years NN O O
to NN O O
less NN O O
than NN O O
18 NN O O
years NN O O
of NN O O
age NN O O
) NN O O
The NN O O
safety NN O O
assessment NN O O
in NN O O
children NN O O
and NN O O
adolescents NN O O
is NN O O
based NN O O
on NN O O
the NN O O
Week NN O O
24 NN O O
analysis NN O O
of NN O O
the NN O O
single NN O O
- NN O O
arm NN O O
, NN O O
Phase NN O O
2 NN O O
trial NN O O
TMC125-C213 NN O O
in NN O O
which NN O O
101 NN O O
antiretroviral NN O O
treatment NN O O
- NN O O
experienced NN O O
HIV-1 NN O O
infected NN O O
subjects NN O O
6 NN O O
years NN O O
to NN O O
less NN O O
than NN O O
18 NN O O
years NN O O
of NN O O
age NN O O
and NN O O
weighing NN O O
at NN O O
least NN O O
16 NN O O
kg NN O O
received NN O O
INTELENCE NN O O
( NN O O
r NN O O
) NN O O
in NN O O
combination NN O O
with NN O O
other NN O O
antiretroviral NN O O
agents NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14.2 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
frequency NN O O
, NN O O
type NN O O
and NN O O
severity NN O O
of NN O O
adverse NN O O
drug NN O O
reactions NN O O
in NN O O
pediatric NN O O
subjects NN O O
were NN O O
comparable NN O O
to NN O O
those NN O O
observed NN O O
in NN O O
adult NN O O
subjects NN O O
, NN O O
except NN O O
for NN O O
rash NN B-AdverseReaction B-AdverseReaction
which NN O O
was NN O O
observed NN O O
more NN O O
frequently NN O O
in NN O O
pediatric NN O O
subjects NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
drug NN O O
reactions NN O O
in NN O O
at NN O O
least NN O O
2 NN O O
% NN O O
of NN O O
pediatric NN O O
subjects NN O O
were NN O O
rash NN B-AdverseReaction B-AdverseReaction
and NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
Rash NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
more NN O O
frequently NN O O
in NN O O
female NN O O
subjects NN O O
than NN O O
in NN O O
male NN O O
subjects NN O O
( NN O O
rash NN O O
>= NN O O
Grade NN B-Severity B-Severity
2 NN I-Severity I-Severity
was NN O O
reported NN O O
in NN O O
13/64 NN O O
[ NN O O
20.3 NN O O
% NN O O
] NN O O
females NN O O
versus NN O O
2/37 NN O O
[ NN O O
5.4 NN O O
% NN O O
] NN O O
males NN O O
; NN O O
discontinuations NN O O
due NN O O
to NN O O
rash NN B-AdverseReaction B-AdverseReaction
were NN O O
reported NN O O
in NN O O
4/64 NN O O
[ NN O O
6.3 NN O O
% NN O O
] NN O O
females NN O O
versus NN O O
0/37 NN O O
[ NN O O
0 NN O O
% NN O O
] NN O O
males NN O O
) NN O O
. NN O O
Rash NN B-AdverseReaction B-AdverseReaction
( NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
Grade NN B-Severity B-Severity
2 NN I-Severity I-Severity
occurred NN O O
in NN O O
15 NN O O
% NN O O
of NN O O
pediatric NN O O
subjects NN O O
. NN O O
In NN O O
the NN O O
majority NN O O
of NN O O
cases NN O O
, NN O O
rash NN B-AdverseReaction B-AdverseReaction
was NN O O
mild NN B-Severity B-Severity
to NN I-Severity I-Severity
moderate NN I-Severity I-Severity
of NN O O
macular/papular NN O O
type NN O O
, NN O O
and NN O O
occurred NN O O
in NN O O
the NN O O
second NN O O
week NN O O
of NN O O
therapy NN O O
. NN O O
Rash NN B-AdverseReaction B-AdverseReaction
was NN O O
self NN O O
- NN O O
limiting NN O O
and NN O O
generally NN O O
resolved NN O O
within NN O O
1 NN O O
week NN O O
on NN O O
continued NN O O
therapy NN O O
. NN O O
The NN O O
safety NN O O
profile NN O O
for NN O O
subjects NN O O
who NN O O
completed NN O O
48 NN O O
weeks NN O O
of NN O O
treatment NN O O
was NN O O
similar NN O O
to NN O O
the NN O O
safety NN O O
profile NN O O
for NN O O
subjects NN O O
who NN O O
completed NN O O
24 NN O O
weeks NN O O
of NN O O
treatment NN O O
. NN O O
6.3 NN O O
Postmarketing NN O O
Experience NN O O
The NN O O
following NN O O
events NN O O
have NN O O
been NN O O
identified NN O O
during NN O O
postmarketing NN O O
use NN O O
of NN O O
INTELENCE NN O O
( NN O O
r NN O O
) NN O O
. NN O O
Because NN O O
these NN O O
events NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
unknown NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
Immune NN O O
System NN O O
Disorders NN O O
: NN O O
Severe NN B-Severity B-Severity
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN O O
including NN O O
DRESS NN B-AdverseReaction B-AdverseReaction
and NN O O
cases NN O O
of NN O O
hepatic NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
Musculoskeletal NN O O
and NN O O
Connective NN O O
Tissue NN O O
Disorders NN O O
: NN O O
rhabdomyolysis NN B-AdverseReaction B-AdverseReaction
Skin NN O O
and NN O O
Subcutaneous NN O O
Tissue NN O O
Disorders NN O O
: NN O O
Fatal NN B-AdverseReaction B-AdverseReaction
cases NN O O
of NN O O
toxic NN B-AdverseReaction B-AdverseReaction
epidermal NN I-AdverseReaction I-AdverseReaction
necrolysis NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
Severe NN B-Severity B-Severity
potentially NN O O
life NN B-Severity B-Severity
threatening NN I-Severity I-Severity
and NN O O
fatal NN B-AdverseReaction B-AdverseReaction
skin NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
. NN O O
This NN O O
includes NN O O
cases NN O O
of NN O O
Stevens NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Johnson NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
toxic NN B-AdverseReaction B-AdverseReaction
epidermal NN I-AdverseReaction I-AdverseReaction
necrolysis NN I-AdverseReaction I-AdverseReaction
and NN O O
erythema NN B-AdverseReaction B-AdverseReaction
multiforme NN I-AdverseReaction I-AdverseReaction
Immediately NN O O
discontinue NN O O
treatment NN O O
if NN O O
severe NN O O
hypersensitivity NN O O
, NN O O
severe NN O O
rash NN O O
or NN O O
rash NN O O
with NN O O
systemic NN O O
symptoms NN O O
or NN O O
liver NN O O
transaminase NN O O
elevations NN O O
develops NN O O
and NN O O
monitor NN O O
clinical NN O O
status NN O O
, NN O O
including NN O O
liver NN O O
transaminases NN O O
closely NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
5.1 NN O O
Severe NN O O
Skin NN O O
and NN O O
Hypersensitivity NN O O
Reactions NN O O
Severe NN B-Severity B-Severity
potentially NN B-Factor B-Factor
life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
and NN O O
fatal NN B-AdverseReaction B-AdverseReaction
skin NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
. NN O O
These NN O O
include NN O O
cases NN O O
of NN O O
Stevens NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Johnson NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
toxic NN B-AdverseReaction B-AdverseReaction
epidermal NN I-AdverseReaction I-AdverseReaction
necrolysis NN I-AdverseReaction I-AdverseReaction
and NN O O
erythema NN B-AdverseReaction B-AdverseReaction
multiforme NN I-AdverseReaction I-AdverseReaction
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
Drug NN B-AdverseReaction B-AdverseReaction
Rash NN I-AdverseReaction I-AdverseReaction
with NN I-AdverseReaction I-AdverseReaction
Eosinophilia NN I-AdverseReaction I-AdverseReaction
and NN I-AdverseReaction I-AdverseReaction
Systemic NN I-AdverseReaction I-AdverseReaction
Symptoms NN I-AdverseReaction I-AdverseReaction
( NN O O
DRESS NN O O
) NN O O
have NN O O
also NN O O
been NN O O
reported NN O O
and NN O O
were NN O O
characterized NN O O
by NN O O
rash NN B-AdverseReaction B-AdverseReaction
constitutional NN O O
findings NN O O
, NN O O
and NN O O
sometimes NN O O
organ NN B-AdverseReaction B-AdverseReaction
dysfunction NN I-AdverseReaction I-AdverseReaction
including NN O O
hepatic NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
In NN O O
Phase NN O O
3 NN O O
clinical NN O O
trials NN O O
, NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
and NN O O
4 NN O O
rashes NN B-AdverseReaction B-AdverseReaction
were NN O O
reported NN O O
in NN O O
1.3 NN O O
% NN O O
of NN O O
subjects NN O O
receiving NN O O
INTELENCE NN O O
( NN O O
r NN O O
) NN O O
compared NN O O
to NN O O
0.2 NN O O
% NN O O
of NN O O
placebo NN O O
subjects NN O O
. NN O O
A NN O O
total NN O O
of NN O O
2.2 NN O O
% NN O O
of NN O O
HIV-1-infected NN O O
subjects NN O O
receiving NN O O
INTELENCE NN O O
( NN O O
r NN O O
) NN O O
discontinued NN O O
from NN O O
Phase NN O O
3 NN O O
trials NN O O
due NN O O
to NN O O
rash NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
] NN O O
. NN O O
Rash NN B-AdverseReaction B-AdverseReaction
occurred NN O O
most NN O O
commonly NN O O
during NN O O
the NN O O
first NN O O
6 NN O O
weeks NN O O
of NN O O
therapy NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
rash NN B-AdverseReaction B-AdverseReaction
was NN O O
higher NN O O
in NN O O
females NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
] NN O O
Discontinue NN O O
INTELENCE NN O O
( NN O O
r NN O O
) NN O O
immediately NN O O
if NN O O
signs NN O O
or NN O O
symptoms NN O O
of NN O O
severe NN O O
skin NN O O
reactions NN O O
or NN O O
hypersensitivity NN O O
reactions NN O O
develop NN O O
( NN O O
including NN O O
, NN O O
but NN O O
not NN O O
limited NN O O
to NN O O
, NN O O
severe NN O O
rash NN O O
or NN O O
rash NN O O
accompanied NN O O
by NN O O
fever NN O O
, NN O O
general NN O O
malaise NN O O
, NN O O
fatigue NN O O
, NN O O
muscle NN O O
or NN O O
joint NN O O
aches NN O O
, NN O O
blisters NN O O
, NN O O
oral NN O O
lesions NN O O
, NN O O
conjunctivitis NN O O
, NN O O
facial NN O O
edema NN O O
, NN O O
hepatitis NN O O
, NN O O
eosinophilia NN O O
, NN O O
angioedema NN O O
) NN O O
. NN O O
Clinical NN O O
status NN O O
including NN O O
liver NN O O
transaminases NN O O
should NN O O
be NN O O
monitored NN O O
and NN O O
appropriate NN O O
therapy NN O O
initiated NN O O
. NN O O
Delay NN O O
in NN O O
stopping NN O O
INTELENCE NN O O
( NN O O
r NN O O
) NN O O
treatment NN O O
after NN O O
the NN O O
onset NN O O
of NN O O
severe NN O O
rash NN O O
may NN O O
result NN O O
in NN O O
a NN O O
life NN O O
- NN O O
threatening NN O O
reaction NN O O
. NN O O
5.2 NN O O
Fat NN O O
Redistribution NN O O
Redistribution/accumulation NN O O
of NN O O
body NN O O
fat NN O O
, NN O O
including NN O O
central NN B-AdverseReaction B-AdverseReaction
obesity NN I-AdverseReaction I-AdverseReaction
dorsocervical NN B-AdverseReaction B-AdverseReaction
fat NN I-AdverseReaction I-AdverseReaction
enlargement NN I-AdverseReaction I-AdverseReaction
( NN O O
buffalo NN O O
hump NN O O
) NN O O
, NN O O
peripheral NN O O
wasting NN O O
, NN O O
facial NN B-AdverseReaction B-AdverseReaction
wasting NN I-AdverseReaction I-AdverseReaction
breast NN B-AdverseReaction B-AdverseReaction
enlargement NN I-AdverseReaction I-AdverseReaction
and NN O O
" NN O O
cushingoid NN O O
appearance NN O O
" NN O O
have NN O O
been NN O O
observed NN O O
in NN O O
patients NN O O
receiving NN O O
antiretroviral NN O O
therapy NN O O
. NN O O
The NN O O
mechanism NN O O
and NN O O
long NN O O
- NN O O
term NN O O
consequences NN O O
of NN O O
these NN O O
events NN O O
are NN O O
currently NN O O
unknown NN O O
. NN O O
A NN O O
causal NN O O
relationship NN O O
has NN O O
not NN O O
been NN O O
established NN O O
. NN O O
5.3 NN O O
Immune NN O O
Reconstitution NN O O
Syndrome NN O O
Immune NN B-AdverseReaction B-AdverseReaction
reconstitution NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
has NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
combination NN O O
antiretroviral NN B-DrugClass B-DrugClass
therapy NN O O
, NN O O
including NN O O
INTELENCE NN O O
( NN O O
r NN O O
) NN O O
. NN O O
During NN O O
the NN O O
initial NN O O
phase NN O O
of NN O O
combination NN O O
antiretroviral NN O O
treatment NN O O
, NN O O
patients NN O O
whose NN O O
immune NN O O
system NN O O
responds NN O O
may NN O O
develop NN O O
an NN O O
inflammatory NN B-AdverseReaction B-AdverseReaction
response NN I-AdverseReaction I-AdverseReaction
to NN O O
indolent NN O O
or NN O O
residual NN O O
opportunistic NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
( NN O O
such NN O O
as NN O O
Mycobacterium NN B-AdverseReaction B-AdverseReaction
avium NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
cytomegalovirus NN B-AdverseReaction B-AdverseReaction
Pneumocystis NN B-AdverseReaction B-AdverseReaction
jiroveci NN I-AdverseReaction I-AdverseReaction
pneumonia NN I-AdverseReaction I-AdverseReaction
( NN O O
PCP NN O O
) NN O O
or NN O O
tuberculosis NN B-AdverseReaction B-AdverseReaction
which NN O O
may NN O O
necessitate NN O O
further NN O O
evaluation NN O O
and NN O O
treatment NN O O
. NN O O
Autoimmune NN B-AdverseReaction B-AdverseReaction
disorders NN I-AdverseReaction I-AdverseReaction
( NN O O
such NN O O
as NN O O
Graves NN B-AdverseReaction B-AdverseReaction
' NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
polymyositis NN B-AdverseReaction B-AdverseReaction
and NN O O
Guillain NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Barre NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
have NN O O
also NN O O
been NN O O
reported NN O O
to NN O O
occur NN O O
in NN O O
the NN O O
setting NN O O
of NN O O
immune NN O O
reconstitution NN O O
; NN O O
however NN O O
, NN O O
the NN O O
time NN O O
to NN O O
onset NN O O
is NN O O
more NN O O
variable NN O O
, NN O O
and NN O O
can NN O O
occur NN O O
many NN O O
months NN O O
after NN O O
initiation NN O O
of NN O O
treatment NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
are NN O O
discussed NN O O
in NN O O
greater NN O O
detail NN O O
in NN O O
other NN O O
sections NN O O
of NN O O
the NN O O
label NN O O
. NN O O
* NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
] NN O O
* NN O O
Suicidal NN B-AdverseReaction B-AdverseReaction
Thoughts NN I-AdverseReaction I-AdverseReaction
and NN O O
Behaviors NN O O
in NN O O
Adolescents NN O O
and NN O O
Young NN O O
Adults NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Serotonin NN B-AdverseReaction B-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
Elevated NN B-AdverseReaction B-AdverseReaction
Blood NN I-AdverseReaction I-AdverseReaction
Pressure NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
* NN O O
Abnormal NN B-AdverseReaction B-AdverseReaction
Bleeding NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
* NN O O
Angle NN B-AdverseReaction B-AdverseReaction
Closure NN I-AdverseReaction I-AdverseReaction
Glaucoma NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
* NN O O
Activation NN O O
of NN O O
Mania NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.6 NN O O
) NN O O
] NN O O
* NN O O
Discontinuation NN B-AdverseReaction B-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.7 NN O O
) NN O O
] NN O O
* NN O O
Seizure NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.8 NN O O
) NN O O
] NN O O
* NN O O
Hyponatremia NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.9 NN O O
) NN O O
] NN O O
* NN O O
Interstitial NN B-AdverseReaction B-AdverseReaction
Lung NN I-AdverseReaction I-AdverseReaction
Disease NN I-AdverseReaction I-AdverseReaction
and NN O O
Eosinophilic NN B-AdverseReaction B-AdverseReaction
Pneumonia NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.10 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
Most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
incidence NN O O
>=5 NN O O
% NN O O
and NN O O
twice NN O O
the NN O O
rate NN O O
of NN O O
placebo NN O O
in NN O O
the NN O O
50 NN O O
or NN O O
100 NN O O
mg NN O O
dose NN O O
groups NN O O
) NN O O
were NN O O
: NN O O
nausea NN B-AdverseReaction B-AdverseReaction
dizziness NN B-AdverseReaction B-AdverseReaction
insomnia NN B-AdverseReaction B-AdverseReaction
hyperhidrosis NN B-AdverseReaction B-AdverseReaction
constipation NN B-AdverseReaction B-AdverseReaction
somnolence NN B-AdverseReaction B-AdverseReaction
decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
anxiety NN B-AdverseReaction B-AdverseReaction
and NN O O
specific NN O O
male NN B-AdverseReaction B-AdverseReaction
sexual NN I-AdverseReaction I-AdverseReaction
function NN I-AdverseReaction I-AdverseReaction
disorders NN I-AdverseReaction I-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
. NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Wyeth NN O O
Pharmaceuticals NN O O
Inc. NN O O
, NN O O
a NN O O
subsidiary NN O O
of NN O O
Pfizer NN O O
Inc. NN O O
, NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
438 NN O O
- NN O O
1985 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
6.1 NN O O
Clinical NN O O
Studies NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
studies NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O
Patient NN O O
exposure NN O O
PRISTIQ NN O O
was NN O O
evaluated NN O O
for NN O O
safety NN O O
in NN O O
8,394 NN O O
patients NN O O
diagnosed NN O O
with NN O O
major NN O O
depressive NN O O
disorder NN O O
who NN O O
participated NN O O
in NN O O
multiple NN O O
- NN O O
dose NN O O
pre NN O O
- NN O O
marketing NN O O
studies NN O O
, NN O O
representing NN O O
2,784 NN O O
patient NN O O
- NN O O
years NN O O
of NN O O
exposure NN O O
. NN O O
Of NN O O
the NN O O
total NN O O
8,394 NN O O
patients NN O O
exposed NN O O
to NN O O
at NN O O
least NN O O
one NN O O
dose NN O O
of NN O O
PRISTIQ NN O O
; NN O O
2,116 NN O O
were NN O O
exposed NN O O
to NN O O
PRISTIQ NN O O
for NN O O
6 NN O O
months NN O O
, NN O O
representing NN O O
1,658 NN O O
patient NN O O
- NN O O
years NN O O
of NN O O
exposure NN O O
, NN O O
and NN O O
421 NN O O
were NN O O
exposed NN O O
for NN O O
one NN O O
year NN O O
, NN O O
representing NN O O
416 NN O O
patient NN O O
- NN O O
years NN O O
of NN O O
exposure NN O O
. NN O O
Adverse NN O O
reactions NN O O
reported NN O O
as NN O O
reasons NN O O
for NN O O
discontinuation NN O O
of NN O O
treatment NN O O
In NN O O
the NN O O
pre NN O O
- NN O O
marketing NN O O
pooled NN O O
8-week NN O O
placebo NN O O
- NN O O
controlled NN O O
studies NN O O
in NN O O
patients NN O O
with NN O O
MDD NN O O
, NN O O
1,834 NN O O
patients NN O O
were NN O O
exposed NN O O
to NN O O
PRISTIQ NN O O
( NN O O
50 NN O O
to NN O O
400 NN O O
mg NN O O
) NN O O
. NN O O
Of NN O O
the NN O O
1,834 NN O O
patients NN O O
, NN O O
12 NN O O
% NN O O
discontinued NN O O
treatment NN O O
due NN O O
to NN O O
an NN O O
adverse NN O O
reaction NN O O
, NN O O
compared NN O O
with NN O O
3 NN O O
% NN O O
of NN O O
the NN O O
1,116 NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
At NN O O
the NN O O
recommended NN O O
dose NN O O
of NN O O
50 NN O O
mg NN O O
, NN O O
the NN O O
discontinuation NN O O
rate NN O O
due NN O O
to NN O O
an NN O O
adverse NN O O
reaction NN O O
for NN O O
PRISTIQ NN O O
( NN O O
4.1 NN O O
% NN O O
) NN O O
was NN O O
similar NN O O
to NN O O
the NN O O
rate NN O O
for NN O O
placebo NN O O
( NN O O
3.8 NN O O
% NN O O
) NN O O
. NN O O
For NN O O
the NN O O
100 NN O O
mg NN O O
dose NN O O
of NN O O
PRISTIQ NN O O
the NN O O
discontinuation NN O O
rate NN O O
due NN O O
to NN O O
an NN O O
adverse NN O O
reaction NN O O
was NN O O
8.7 NN O O
% NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
leading NN O O
to NN O O
discontinuation NN O O
in NN O O
at NN O O
least NN O O
2 NN O O
% NN O O
and NN O O
at NN O O
a NN O O
rate NN O O
greater NN O O
than NN O O
placebo NN O O
of NN O O
the NN O O
PRISTIQ NN O O
treated NN O O
patients NN O O
in NN O O
the NN O O
short NN O O
- NN O O
term NN O O
studies NN O O
, NN O O
up NN O O
to NN O O
8 NN O O
weeks NN O O
, NN O O
were NN O O
: NN O O
nausea NN B-AdverseReaction B-AdverseReaction
( NN O O
4 NN O O
% NN O O
) NN O O
; NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
and NN O O
vomiting NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
each NN O O
) NN O O
. NN O O
In NN O O
a NN O O
longer NN O O
- NN O O
term NN O O
study NN O O
, NN O O
up NN O O
to NN O O
9 NN O O
months NN O O
, NN O O
the NN O O
most NN O O
common NN O O
was NN O O
vomiting NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
. NN O O
Common NN O O
adverse NN O O
reactions NN O O
in NN O O
placebo NN O O
- NN O O
controlled NN O O
MDD NN O O
studies NN O O
The NN O O
most NN O O
commonly NN O O
observed NN O O
adverse NN O O
reactions NN O O
in NN O O
PRISTIQ NN O O
treated NN O O
MDD NN O O
patients NN O O
in NN O O
pre NN O O
- NN O O
marketing NN O O
pooled NN O O
8-week NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
, NN O O
fixed NN O O
- NN O O
dose NN O O
studies NN O O
( NN O O
incidence NN O O
>= NN O O
5 NN O O
% NN O O
and NN O O
at NN O O
least NN O O
twice NN O O
the NN O O
rate NN O O
of NN O O
placebo NN O O
in NN O O
the NN O O
50 NN O O
or NN O O
100 NN O O
mg NN O O
dose NN O O
groups NN O O
) NN O O
were NN O O
: NN O O
nausea NN B-AdverseReaction B-AdverseReaction
dizziness NN B-AdverseReaction B-AdverseReaction
insomnia NN B-AdverseReaction B-AdverseReaction
hyperhidrosis NN B-AdverseReaction B-AdverseReaction
constipation NN B-AdverseReaction B-AdverseReaction
somnolence NN B-AdverseReaction B-AdverseReaction
decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
anxiety NN B-AdverseReaction B-AdverseReaction
and NN O O
specific NN O O
male NN B-AdverseReaction B-AdverseReaction
sexual NN I-AdverseReaction I-AdverseReaction
function NN I-AdverseReaction I-AdverseReaction
disorders NN I-AdverseReaction I-AdverseReaction
Table NN O O
2 NN O O
shows NN O O
the NN O O
incidence NN O O
of NN O O
common NN O O
adverse NN O O
reactions NN O O
that NN O O
occurred NN O O
in NN O O
>= NN O O
2 NN O O
% NN O O
of NN O O
PRISTIQ NN O O
treated NN O O
MDD NN O O
patients NN O O
and NN O O
twice NN O O
the NN O O
rate NN O O
of NN O O
placebo NN O O
at NN O O
any NN O O
dose NN O O
in NN O O
the NN O O
pre NN O O
- NN O O
marketing NN O O
pooled NN O O
8-week NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
, NN O O
fixed NN O O
dose NN O O
clinical NN O O
studies NN O O
Table NN O O
2 NN O O
: NN O O
Common NN O O
Adverse NN O O
Reactions NN O O
( NN O O
>= NN O O
2 NN O O
% NN O O
in NN O O
any NN O O
Fixed NN O O
- NN O O
Dose NN O O
Group NN O O
and NN O O
Twice NN O O
the NN O O
Rate NN O O
of NN O O
Placebo NN O O
) NN O O
in NN O O
Pre NN O O
- NN O O
marketing NN O O
Pooled NN O O
MDD NN O O
8-Week NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Studies NN O O
Percentage NN O O
of NN O O
Patients NN O O
Reporting NN O O
Reaction NN O O
PRISTIQ NN O O
System NN O O
Organ NN O O
Class NN O O
Preferred NN O O
Term NN O O
Placebo NN O O
( NN O O
n=636 NN O O
) NN O O
50 NN O O
mg NN O O
( NN O O
n=317 NN O O
) NN O O
100 NN O O
mg NN O O
( NN O O
n=424 NN O O
) NN O O
200 NN O O
mg NN O O
( NN O O
n=307 NN O O
) NN O O
400 NN O O
mg NN O O
( NN O O
n=317 NN O O
) NN O O
Cardiac NN O O
disorders NN O O
Blood NN B-AdverseReaction B-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
1 NN O O
1 NN O O
1 NN O O
2 NN O O
2 NN O O
Gastrointestinal NN O O
disorders NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
10 NN O O
22 NN O O
26 NN O O
36 NN O O
41 NN O O
Dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
9 NN O O
11 NN O O
17 NN O O
21 NN O O
25 NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
4 NN O O
9 NN O O
9 NN O O
10 NN O O
14 NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
3 NN O O
3 NN O O
4 NN O O
6 NN O O
9 NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
4 NN O O
7 NN O O
7 NN O O
10 NN O O
11 NN O O
Chills NN B-AdverseReaction B-AdverseReaction
1 NN O O
1 NN O O
< NN O O
1 NN O O
3 NN O O
4 NN O O
Feeling NN B-AdverseReaction B-AdverseReaction
jittery NN I-AdverseReaction I-AdverseReaction
1 NN O O
1 NN O O
2 NN O O
3 NN O O
3 NN O O
Metabolism NN O O
and NN O O
nutrition NN O O
disorders NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
2 NN O O
5 NN O O
8 NN O O
10 NN O O
10 NN O O
Nervous NN O O
system NN O O
disorders NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
5 NN O O
13 NN O O
10 NN O O
15 NN O O
16 NN O O
Somnolence NN B-AdverseReaction B-AdverseReaction
4 NN O O
4 NN O O
9 NN O O
12 NN O O
12 NN O O
Tremor NN B-AdverseReaction B-AdverseReaction
2 NN O O
2 NN O O
3 NN O O
9 NN O O
9 NN O O
Disturbance NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
attention NN I-AdverseReaction I-AdverseReaction
< NN O O
1 NN O O
< NN O O
1 NN O O
1 NN O O
2 NN O O
1 NN O O
Psychiatric NN O O
disorders NN O O
Insomnia NN B-AdverseReaction B-AdverseReaction
6 NN O O
9 NN O O
12 NN O O
14 NN O O
15 NN O O
Anxiety NN B-AdverseReaction B-AdverseReaction
2 NN O O
3 NN O O
5 NN O O
4 NN O O
4 NN O O
Nervousness NN B-AdverseReaction B-AdverseReaction
1 NN O O
< NN O O
1 NN O O
1 NN O O
2 NN O O
2 NN O O
Abnormal NN B-AdverseReaction B-AdverseReaction
dreams NN I-AdverseReaction I-AdverseReaction
1 NN O O
2 NN O O
3 NN O O
2 NN O O
4 NN O O
Renal NN O O
and NN O O
urinary NN O O
disorders NN O O
Urinary NN B-AdverseReaction B-AdverseReaction
hesitation NN I-AdverseReaction I-AdverseReaction
0 NN O O
< NN O O
1 NN O O
1 NN O O
2 NN O O
2 NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
and NN O O
mediastinal NN O O
disorders NN O O
Yawning NN B-AdverseReaction B-AdverseReaction
< NN O O
1 NN O O
1 NN O O
1 NN O O
4 NN O O
3 NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
Hyperhidrosis NN B-AdverseReaction B-AdverseReaction
4 NN O O
10 NN O O
11 NN O O
18 NN O O
21 NN O O
Special NN O O
Senses NN O O
Vision NN B-AdverseReaction B-AdverseReaction
blurred NN I-AdverseReaction I-AdverseReaction
1 NN O O
3 NN O O
4 NN O O
4 NN O O
4 NN O O
Mydriasis NN B-AdverseReaction B-AdverseReaction
< NN O O
1 NN O O
2 NN O O
2 NN O O
6 NN O O
6 NN O O
Vertigo NN B-AdverseReaction B-AdverseReaction
1 NN O O
2 NN O O
1 NN O O
5 NN O O
3 NN O O
Tinnitus NN B-AdverseReaction B-AdverseReaction
1 NN O O
2 NN O O
1 NN O O
1 NN O O
2 NN O O
Dysgeusia NN B-AdverseReaction B-AdverseReaction
1 NN O O
1 NN O O
1 NN O O
1 NN O O
2 NN O O
Vascular NN O O
disorders NN O O
Hot NN B-AdverseReaction B-AdverseReaction
flush NN I-AdverseReaction I-AdverseReaction
< NN O O
1 NN O O
1 NN O O
1 NN O O
2 NN O O
2 NN O O
Sexual NN O O
function NN O O
adverse NN O O
reactions NN O O
Table NN O O
3 NN O O
shows NN O O
the NN O O
incidence NN O O
of NN O O
sexual NN B-AdverseReaction B-AdverseReaction
function NN I-AdverseReaction I-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
that NN O O
occurred NN O O
in NN O O
>= NN O O
2 NN O O
% NN O O
of NN O O
PRISTIQ NN O O
treated NN O O
MDD NN O O
patients NN O O
in NN O O
any NN O O
fixed NN O O
- NN O O
dose NN O O
group NN O O
( NN O O
pre NN O O
- NN O O
marketing NN O O
pooled NN O O
8-week NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
, NN O O
fixed NN O O
-dose NN O O
, NN O O
clinical NN O O
studies NN O O
) NN O O
. NN O O
Table NN O O
3 NN O O
: NN O O
Sexual NN B-AdverseReaction B-AdverseReaction
Function NN I-AdverseReaction I-AdverseReaction
Adverse NN I-AdverseReaction I-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
( NN O O
>= NN O O
2 NN O O
% NN O O
in NN O O
Men NN O O
or NN O O
Women NN O O
in NN O O
any NN O O
PRISTIQ NN O O
Group NN O O
) NN O O
During NN O O
the NN O O
On NN O O
- NN O O
Therapy NN O O
Period NN O O
PRISTIQ NN O O
Placebo(n=239 NN O O
) NN O O
50 NN O O
mg(n=108 NN O O
) NN O O
100 NN O O
mg(n=157 NN O O
) NN O O
200 NN O O
mg(n=131 NN O O
) NN O O
400 NN O O
mg(n=154 NN O O
) NN O O
Men NN O O
only NN O O
Anorgasmia NN B-AdverseReaction B-AdverseReaction
0 NN O O
0 NN O O
3 NN O O
5 NN O O
8 NN O O
Libido NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
1 NN O O
4 NN O O
5 NN O O
6 NN O O
3 NN O O
Orgasm NN B-AdverseReaction B-AdverseReaction
abnormal NN I-AdverseReaction I-AdverseReaction
0 NN O O
0 NN O O
1 NN O O
2 NN O O
3 NN O O
Ejaculation NN B-AdverseReaction B-AdverseReaction
delayed NN I-AdverseReaction I-AdverseReaction
< NN O O
1 NN O O
1 NN O O
5 NN O O
7 NN O O
6 NN O O
Erectile NN B-AdverseReaction B-AdverseReaction
dysfunction NN I-AdverseReaction I-AdverseReaction
1 NN O O
3 NN O O
6 NN O O
8 NN O O
11 NN O O
Ejaculation NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
0 NN O O
0 NN O O
1 NN O O
2 NN O O
5 NN O O
Ejaculation NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
0 NN O O
1 NN O O
0 NN O O
2 NN O O
2 NN O O
Sexual NN B-AdverseReaction B-AdverseReaction
dysfunction NN I-AdverseReaction I-AdverseReaction
0 NN O O
1 NN O O
0 NN O O
0 NN O O
2 NN O O
PRISTIQ NN O O
Placebo(n=397 NN O O
) NN O O
50 NN O O
mg(n=209 NN O O
) NN O O
100 NN O O
mg(n=267 NN O O
) NN O O
200 NN O O
mg(n=176 NN O O
) NN O O
400 NN O O
mg(n=163 NN O O
) NN O O
Women NN O O
only NN O O
Anorgasmia NN B-AdverseReaction B-AdverseReaction
0 NN O O
1 NN O O
1 NN O O
0 NN O O
3 NN O O
Other NN O O
adverse NN O O
reactions NN O O
observed NN O O
in NN O O
premarketing NN O O
and NN O O
postmarketing NN O O
clinical NN O O
studies NN O O
Other NN O O
infrequent NN O O
adverse NN O O
reactions NN O O
, NN O O
not NN O O
described NN O O
elsewhere NN O O
in NN O O
the NN O O
label NN O O
, NN O O
occurring NN O O
at NN O O
an NN O O
incidence NN O O
of NN O O
< NN O O
2 NN O O
% NN O O
in NN O O
MDD NN O O
patients NN O O
treated NN O O
with NN O O
PRISTIQ NN O O
were NN O O
: NN O O
Cardiac NN O O
disorders NN O O
- NN O O
Tachycardia NN B-AdverseReaction B-AdverseReaction
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
- NN O O
Asthenia NN B-AdverseReaction B-AdverseReaction
Investigations NN O O
- NN O O
Weight NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
liver NN B-AdverseReaction B-AdverseReaction
function NN I-AdverseReaction I-AdverseReaction
test NN I-AdverseReaction I-AdverseReaction
abnormal NN I-AdverseReaction I-AdverseReaction
blood NN B-AdverseReaction B-AdverseReaction
prolactin NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
Musculoskeletal NN O O
and NN O O
connective NN O O
tissue NN O O
disorders NN O O
- NN O O
Musculoskeletal NN B-AdverseReaction B-AdverseReaction
stiffness NN I-AdverseReaction I-AdverseReaction
Nervous NN O O
system NN O O
disorders NN O O
- NN O O
Syncope NN B-AdverseReaction B-AdverseReaction
convulsion NN B-AdverseReaction B-AdverseReaction
dystonia NN B-AdverseReaction B-AdverseReaction
Psychiatric NN O O
disorders NN O O
- NN O O
Depersonalization NN B-AdverseReaction B-AdverseReaction
bruxism NN B-AdverseReaction B-AdverseReaction
Renal NN O O
and NN O O
urinary NN O O
disorders NN O O
- NN O O
Urinary NN B-AdverseReaction B-AdverseReaction
retention NN I-AdverseReaction I-AdverseReaction
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
- NN O O
Rash NN B-AdverseReaction B-AdverseReaction
alopecia NN B-AdverseReaction B-AdverseReaction
photosensitivity NN B-AdverseReaction B-AdverseReaction
reaction NN O O
, NN O O
angioedema NN B-AdverseReaction B-AdverseReaction
In NN O O
clinical NN O O
studies NN O O
, NN O O
there NN O O
were NN O O
uncommon NN O O
reports NN O O
of NN O O
ischemic NN B-AdverseReaction B-AdverseReaction
cardiac NN I-AdverseReaction I-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
myocardial NN B-AdverseReaction B-AdverseReaction
ischemia NN I-AdverseReaction I-AdverseReaction
myocardial NN B-AdverseReaction B-AdverseReaction
infarction NN I-AdverseReaction I-AdverseReaction
and NN O O
coronary NN B-AdverseReaction B-AdverseReaction
occlusion NN I-AdverseReaction I-AdverseReaction
requiring NN O O
revascularization NN O O
; NN O O
these NN O O
patients NN O O
had NN O O
multiple NN O O
underlying NN O O
cardiac NN O O
risk NN O O
factors NN O O
. NN O O
More NN O O
patients NN O O
experienced NN O O
these NN O O
events NN O O
during NN O O
PRISTIQ NN O O
treatment NN O O
as NN O O
compared NN O O
to NN O O
placebo NN O O
. NN O O
Laboratory NN O O
, NN O O
ECG NN O O
and NN O O
vital NN O O
sign NN O O
changes NN O O
observed NN O O
in NN O O
MDD NN O O
clinical NN O O
studies NN O O
The NN O O
following NN O O
changes NN O O
were NN O O
observed NN O O
in NN O O
pre NN O O
- NN O O
marketing NN O O
placebo NN O O
- NN O O
controlled NN O O
, NN O O
short NN O O
- NN O O
term NN O O
MDD NN O O
studies NN O O
with NN O O
PRISTIQ. NN O O
Lipids NN O O
Elevations NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
fasting NN I-AdverseReaction I-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
total NN I-AdverseReaction I-AdverseReaction
cholesterol NN I-AdverseReaction I-AdverseReaction
LDL NN O O
( NN O O
low NN O O
density NN O O
lipoproteins NN O O
) NN O O
cholesterol NN O O
, NN O O
and NN O O
triglycerides NN O O
occurred NN O O
in NN O O
the NN O O
controlled NN O O
studies NN O O
. NN O O
Some NN O O
of NN O O
these NN O O
abnormalities NN O O
were NN O O
considered NN O O
potentially NN O O
clinically NN O O
significant NN O O
. NN O O
The NN O O
percentage NN O O
of NN O O
patients NN O O
who NN O O
exceeded NN O O
a NN O O
predetermined NN O O
threshold NN O O
value NN O O
is NN O O
shown NN O O
in NN O O
Table NN O O
4 NN O O
. NN O O
Table NN O O
4 NN O O
: NN O O
Incidence NN O O
( NN O O
% NN O O
) NN O O
of NN O O
Patients NN O O
With NN O O
Lipid NN B-AdverseReaction B-AdverseReaction
Abnormalities NN I-AdverseReaction I-AdverseReaction
of NN O O
Potential NN O O
Clinical NN O O
Significance NN O O
* NN O O
PRISTIQ NN O O
Placebo NN O O
50 NN O O
mg NN O O
100 NN O O
mg NN O O
200 NN O O
mg NN O O
400 NN O O
mg NN O O
Total NN O O
Cholesterol*(Increase NN O O
of NN O O
>= NN O O
50 NN O O
mg/dl NN O O
and NN O O
an NN O O
absolute NN O O
value NN O O
of NN O O
>= NN O O
261 NN O O
mg/dl NN O O
) NN O O
2 NN O O
3 NN O O
4 NN O O
4 NN O O
10 NN O O
LDL NN O O
Cholesterol*(Increase NN O O
>= NN O O
50 NN O O
mg/dl NN O O
and NN O O
an NN O O
absolute NN O O
value NN O O
of NN O O
>= NN O O
190 NN O O
mg/dl NN O O
) NN O O
0 NN O O
1 NN O O
0 NN O O
1 NN O O
2 NN O O
Triglycerides NN O O
, NN O O
fasting*(Fasting NN O O
: NN O O
>= NN O O
327 NN O O
mg/dl NN O O
) NN O O
3 NN O O
2 NN O O
1 NN O O
4 NN O O
6 NN O O
Proteinuria NN O O
Proteinuria NN B-AdverseReaction B-AdverseReaction
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
trace NN O O
, NN O O
was NN O O
observed NN O O
in NN O O
the NN O O
pre NN O O
- NN O O
marketing NN O O
fixed NN O O
- NN O O
dose NN O O
controlled NN O O
studies NN O O
( NN O O
see NN O O
Table NN O O
5 NN O O
) NN O O
. NN O O
This NN O O
proteinuria NN B-AdverseReaction B-AdverseReaction
was NN O O
not NN B-Negation B-Negation
associated NN O O
with NN O O
increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
BUN NN I-AdverseReaction I-AdverseReaction
or NN O O
creatinine NN O O
and NN O O
was NN O O
generally NN O O
transient NN B-Severity B-Severity
Table NN O O
5 NN O O
: NN O O
Incidence NN O O
( NN O O
% NN O O
) NN O O
of NN O O
Patients NN O O
with NN O O
Proteinuria NN B-AdverseReaction B-AdverseReaction
in NN O O
the NN O O
Fixed NN O O
- NN O O
dose NN O O
Clinical NN O O
Studies NN O O
PRISTIQ NN O O
Placebo NN O O
50 NN O O
mg NN O O
100 NN O O
mg NN O O
200 NN O O
mg NN O O
400 NN O O
mg NN O O
Proteinuria NN B-AdverseReaction B-AdverseReaction
4 NN O O
6 NN O O
8 NN O O
5 NN O O
7 NN O O
Vital NN O O
sign NN O O
changes NN O O
Table NN O O
6 NN O O
summarizes NN O O
the NN O O
changes NN O O
that NN O O
were NN O O
observed NN O O
in NN O O
placebo NN O O
- NN O O
controlled NN O O
, NN O O
short NN O O
- NN O O
term NN O O
, NN O O
pre NN O O
- NN O O
marketing NN O O
studies NN O O
with NN O O
PRISTIQ NN O O
in NN O O
patients NN O O
with NN O O
MDD NN O O
( NN O O
doses NN O O
50 NN O O
to NN O O
400 NN O O
mg NN O O
) NN O O
. NN O O
Table NN O O
6 NN O O
: NN O O
Mean NN O O
Changes NN O O
in NN O O
Vital NN O O
Signs NN O O
at NN O O
Final NN O O
on NN O O
Therapy NN O O
for NN O O
All NN O O
Short NN O O
- NN O O
term NN O O
, NN O O
Fixed NN O O
- NN O O
dose NN O O
Controlled NN O O
Studies NN O O
PRISTIQ NN O O
Placebo NN O O
50 NN O O
mg NN O O
100 NN O O
mg NN O O
200 NN O O
mg NN O O
400 NN O O
mg NN O O
Blood NN O O
pressure NN O O
Supine NN O O
systolic NN O O
bp NN O O
( NN O O
mm NN O O
Hg NN O O
) NN O O
-1.4 NN O O
1.2 NN O O
2.0 NN O O
2.5 NN O O
2.1 NN O O
Supine NN O O
diastolic NN O O
bp NN O O
( NN O O
mm NN O O
Hg NN O O
) NN O O
-0.6 NN O O
0.7 NN O O
0.8 NN O O
1.8 NN O O
2.3 NN O O
Pulse NN O O
rate NN O O
Supine NN O O
pulse NN O O
( NN O O
bpm NN O O
) NN O O
-0.3 NN O O
1.3 NN O O
1.3 NN O O
0.9 NN O O
4.1 NN O O
Weight NN O O
( NN O O
kg NN O O
) NN O O
0.0 NN O O
-0.4 NN O O
-0.6 NN O O
-0.9 NN O O
-1.1 NN O O
Treatment NN O O
with NN O O
PRISTIQ NN O O
at NN O O
all NN O O
doses NN O O
from NN O O
50 NN O O
mg NN O O
per NN O O
day NN O O
to NN O O
400 NN O O
mg NN O O
per NN O O
day NN O O
in NN O O
controlled NN O O
studies NN O O
was NN O O
associated NN O O
with NN O O
sustained NN B-Severity B-Severity
hypertension NN B-AdverseReaction B-AdverseReaction
defined NN O O
as NN O O
treatment NN O O
- NN O O
emergent NN O O
supine NN O O
diastolic NN O O
blood NN O O
pressure NN O O
( NN O O
SDBP NN O O
) NN O O
>=90 NN O O
mm NN O O
Hg NN O O
and NN O O
>=10 NN O O
mm NN O O
Hg NN O O
above NN O O
baseline NN O O
for NN O O
3 NN O O
consecutive NN O O
on NN O O
- NN O O
therapy NN O O
visits NN O O
( NN O O
see NN O O
Table NN O O
7 NN O O
) NN O O
. NN O O
Analyses NN O O
of NN O O
patients NN O O
in NN O O
PRISTIQ NN O O
pre NN O O
- NN O O
marketing NN O O
short NN O O
- NN O O
term NN O O
controlled NN O O
studies NN O O
who NN O O
met NN O O
criteria NN O O
for NN O O
sustained NN B-Severity B-Severity
hypertension NN B-AdverseReaction B-AdverseReaction
revealed NN O O
a NN O O
consistent NN O O
increase NN O O
in NN O O
the NN O O
proportion NN O O
of NN O O
patients NN O O
who NN O O
developed NN O O
sustained NN B-Severity B-Severity
hypertension NN B-AdverseReaction B-AdverseReaction
This NN O O
was NN O O
seen NN O O
at NN O O
all NN O O
doses NN O O
with NN O O
a NN O O
suggestion NN O O
of NN O O
a NN O O
higher NN O O
rate NN O O
at NN O O
400 NN O O
mg NN O O
per NN O O
day NN O O
. NN O O
Table NN O O
7 NN O O
: NN O O
Proportion NN O O
of NN O O
Patients NN O O
with NN O O
Sustained NN B-Severity B-Severity
Elevation NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
Supine NN I-AdverseReaction I-AdverseReaction
Diastolic NN I-AdverseReaction I-AdverseReaction
Blood NN I-AdverseReaction I-AdverseReaction
Pressure NN I-AdverseReaction I-AdverseReaction
Treatment NN O O
Group NN O O
Proportion NN O O
of NN O O
Patients NN O O
with NN O O
Sustained NN O O
Hypertension NN O O
Placebo NN O O
0.5 NN O O
% NN O O
PRISTIQ NN O O
50 NN O O
mg NN O O
per NN O O
day NN O O
1.3 NN O O
% NN O O
PRISTIQ NN O O
100 NN O O
mg NN O O
per NN O O
day NN O O
0.7 NN O O
% NN O O
PRISTIQ NN O O
200 NN O O
mg NN O O
per NN O O
day NN O O
1.1 NN O O
% NN O O
PRISTIQ NN O O
400 NN O O
mg NN O O
per NN O O
day NN O O
2.3 NN O O
% NN O O
Orthostatic NN O O
hypotension NN O O
In NN O O
the NN O O
pre NN O O
- NN O O
marketing NN O O
short NN O O
- NN O O
term NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
clinical NN O O
studies NN O O
with NN O O
doses NN O O
of NN O O
50 NN O O
to NN O O
400 NN O O
mg NN O O
, NN O O
systolic NN B-AdverseReaction B-AdverseReaction
orthostatic NN I-AdverseReaction I-AdverseReaction
hypotension NN I-AdverseReaction I-AdverseReaction
( NN O O
decrease NN O O
>=30 NN O O
mm NN O O
Hg NN O O
from NN O O
supine NN O O
to NN O O
standing NN O O
position NN O O
) NN O O
occurred NN O O
more NN O O
frequently NN O O
in NN O O
patients NN O O
>=65 NN O O
years NN O O
of NN O O
age NN O O
receiving NN O O
PRISTIQ NN O O
( NN O O
8 NN O O
% NN O O
, NN O O
7/87 NN O O
) NN O O
versus NN O O
placebo NN O O
( NN O O
2.5 NN O O
% NN O O
, NN O O
1/40 NN O O
) NN O O
, NN O O
compared NN O O
to NN O O
patients NN O O
< NN O O
65 NN O O
years NN O O
of NN O O
age NN O O
receiving NN O O
PRISTIQ NN O O
( NN O O
0.9 NN O O
% NN O O
, NN O O
18/1,937 NN O O
) NN O O
versus NN O O
placebo NN O O
( NN O O
0.7 NN O O
% NN O O
, NN O O
8/1,218 NN O O
) NN O O
. NN O O
6.2 NN O O
Postmarketing NN O O
Experience NN O O
The NN O O
following NN O O
adverse NN O O
reaction NN O O
has NN O O
been NN O O
identified NN O O
during NN O O
post NN O O
- NN O O
approval NN O O
use NN O O
of NN O O
PRISTIQ. NN O O
Because NN O O
these NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
: NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
- NN O O
Stevens NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Johnson NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
SUICIDAL NN B-AdverseReaction B-AdverseReaction
THOUGHTS NN I-AdverseReaction I-AdverseReaction
AND NN O O
BEHAVIORS NN O O
WARNING NN O O
: NN O O
SUICIDAL NN B-AdverseReaction B-AdverseReaction
THOUGHTS NN I-AdverseReaction I-AdverseReaction
AND NN O O
BEHAVIORS NN O O
Antidepressants NN B-DrugClass B-DrugClass
increased NN O O
the NN O O
risk NN O O
of NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
thoughts NN I-AdverseReaction I-AdverseReaction
and NN O O
behavior NN O O
in NN O O
children NN O O
, NN O O
adolescents NN O O
, NN O O
and NN O O
young NN O O
adults NN O O
in NN O O
short NN O O
- NN O O
term NN O O
studies NN O O
. NN O O
These NN O O
studies NN O O
did NN O O
not NN B-Negation B-Negation
show NN O O
an NN O O
increase NN O O
in NN O O
the NN O O
risk NN O O
of NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
thoughts NN I-AdverseReaction I-AdverseReaction
and NN O O
behavior NN O O
with NN O O
antidepressant NN O O
use NN O O
in NN O O
patients NN O O
over NN O O
age NN O O
24 NN O O
; NN O O
there NN O O
was NN O O
a NN O O
reduction NN O O
in NN O O
risk NN O O
with NN O O
antidepressant NN O O
use NN O O
in NN O O
patients NN O O
aged NN O O
65 NN O O
and NN O O
older NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
In NN O O
patients NN O O
of NN O O
all NN O O
ages NN O O
who NN O O
are NN O O
started NN O O
on NN O O
antidepressant NN O O
therapy NN O O
, NN O O
monitor NN O O
closely NN O O
for NN O O
worsening NN O O
, NN O O
and NN O O
for NN O O
emergence NN O O
of NN O O
suicidal NN O O
thoughts NN O O
and NN O O
behaviors NN O O
. NN O O
Advise NN O O
families NN O O
and NN O O
caregivers NN O O
of NN O O
the NN O O
need NN O O
for NN O O
close NN O O
observation NN O O
and NN O O
communication NN O O
with NN O O
the NN O O
prescriber NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
PRISTIQ NN O O
is NN O O
not NN O O
approved NN O O
for NN O O
use NN O O
in NN O O
pediatric NN O O
patients NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.4 NN O O
) NN O O
] NN O O
. NN O O
EXCERPT NN O O
: NN O O
WARNING NN O O
: NN O O
SUICIDAL NN B-AdverseReaction B-AdverseReaction
THOUGHTS NN I-AdverseReaction I-AdverseReaction
AND NN O O
BEHAVIORS NN O O
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
. NN O O
* NN O O
Increased NN O O
risk NN O O
of NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
thinking NN I-AdverseReaction I-AdverseReaction
and NN O O
behavior NN O O
in NN O O
children NN O O
, NN O O
adolescents NN O O
and NN O O
young NN O O
adults NN O O
taking NN O O
antidepressants NN B-DrugClass B-DrugClass
( NN O O
5.1 NN O O
) NN O O
. NN O O
* NN O O
Monitor NN O O
for NN O O
worsening NN O O
and NN O O
emergence NN O O
of NN O O
suicidal NN O O
thoughts NN O O
and NN O O
behaviors NN O O
( NN O O
5.1 NN O O
) NN O O
. NN O O
* NN O O
PRISTIQ NN O O
is NN O O
not NN O O
approved NN O O
for NN O O
use NN O O
in NN O O
pediatric NN O O
patients NN O O
( NN O O
8.4 NN O O
) NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Clinical NN B-AdverseReaction B-AdverseReaction
Worsening NN I-AdverseReaction I-AdverseReaction
Risk NN O O
: NN O O
Monitor NN O O
for NN O O
clinical NN O O
worsening NN O O
and NN O O
suicide NN O O
risk NN O O
( NN O O
5.1 NN O O
) NN O O
. NN O O
* NN O O
Serotonin NN B-AdverseReaction B-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
Serotonin NN B-AdverseReaction B-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
has NN O O
been NN O O
reported NN O O
with NN O O
SSRIs NN O O
and NN O O
SNRIs NN O O
, NN O O
including NN O O
with NN O O
PRISTIQ NN O O
, NN O O
both NN O O
when NN O O
taken NN O O
alone NN O O
, NN O O
but NN O O
especially NN O O
when NN O O
co NN O O
- NN O O
administered NN O O
with NN O O
other NN O O
serotonergic NN O O
agents NN O O
( NN O O
including NN O O
triptans NN O O
, NN O O
tricyclic NN O O
antidepressants NN O O
, NN O O
fentanyl NN O O
, NN O O
lithium NN O O
, NN O O
tramadol NN O O
, NN O O
tryptophan NN O O
, NN O O
buspirone NN O O
, NN O O
and NN O O
St. NN O O
John NN O O
's NN O O
Wort NN O O
) NN O O
. NN O O
If NN O O
such NN O O
symptoms NN O O
occur NN O O
, NN O O
discontinue NN O O
PRISTIQ NN O O
and NN O O
initiate NN O O
supportive NN O O
treatment NN O O
. NN O O
If NN O O
concomitant NN O O
use NN O O
of NN O O
PRISTIQ NN O O
with NN O O
other NN O O
serotonergic NN O O
drugs NN O O
is NN O O
clinically NN O O
warranted NN O O
, NN O O
patients NN O O
should NN O O
be NN O O
made NN O O
aware NN O O
of NN O O
a NN O O
potential NN O O
increased NN O O
risk NN O O
for NN O O
serotonin NN O O
syndrome NN O O
, NN O O
particularly NN O O
during NN O O
treatment NN O O
initiation NN O O
and NN O O
dose NN O O
increases NN O O
( NN O O
5.2 NN O O
) NN O O
. NN O O
* NN O O
Elevated NN B-AdverseReaction B-AdverseReaction
Blood NN I-AdverseReaction I-AdverseReaction
Pressure NN I-AdverseReaction I-AdverseReaction
Control NN O O
hypertension NN O O
before NN O O
initiating NN O O
treatment NN O O
. NN O O
Monitor NN O O
blood NN O O
pressure NN O O
regularly NN O O
during NN O O
treatment NN O O
( NN O O
5.3 NN O O
) NN O O
. NN O O
* NN O O
Abnormal NN B-AdverseReaction B-AdverseReaction
Bleeding NN I-AdverseReaction I-AdverseReaction
PRISTIQ NN O O
may NN B-Factor B-Factor
increase NN O O
risk NN O O
of NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
events NN O O
. NN O O
Caution NN O O
patients NN O O
about NN O O
risk NN O O
of NN O O
bleeding NN O O
associated NN O O
with NN O O
concomitant NN O O
use NN O O
of NN O O
PRISTIQ NN O O
and NN O O
NSAIDs NN O O
, NN O O
aspirin NN O O
, NN O O
or NN O O
other NN O O
drugs NN O O
that NN O O
affect NN O O
coagulation NN O O
( NN O O
5.4 NN O O
) NN O O
. NN O O
* NN O O
Angle NN B-AdverseReaction B-AdverseReaction
Closure NN I-AdverseReaction I-AdverseReaction
Glaucoma NN I-AdverseReaction I-AdverseReaction
Angle NN B-AdverseReaction B-AdverseReaction
closure NN I-AdverseReaction I-AdverseReaction
glaucoma NN I-AdverseReaction I-AdverseReaction
has NN O O
occurred NN O O
in NN O O
patients NN O O
with NN O O
untreated NN O O
anatomically NN O O
narrow NN O O
angles NN O O
treated NN O O
with NN O O
antidepressants NN B-DrugClass B-DrugClass
( NN O O
5.5 NN O O
) NN O O
* NN O O
Activation NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
Mania NN I-AdverseReaction I-AdverseReaction
Use NN O O
cautiously NN O O
in NN O O
patients NN O O
with NN O O
Bipolar NN O O
Disorder NN O O
. NN O O
Caution NN O O
patients NN O O
about NN O O
risk NN O O
of NN O O
activation NN O O
of NN O O
mania/hypomania NN O O
( NN O O
5.6 NN O O
) NN O O
. NN O O
* NN O O
Discontinuation NN B-AdverseReaction B-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
Taper NN O O
dose NN O O
when NN O O
possible NN O O
and NN O O
monitor NN O O
for NN O O
discontinuation NN O O
symptoms NN O O
( NN O O
5.7 NN O O
) NN O O
. NN O O
* NN O O
Seizure NN B-AdverseReaction B-AdverseReaction
Can NN O O
occur NN O O
. NN O O
Use NN O O
cautiously NN O O
in NN O O
patients NN O O
with NN O O
seizure NN O O
disorder NN O O
( NN O O
5.8 NN O O
) NN O O
. NN O O
* NN O O
Hyponatremia NN B-AdverseReaction B-AdverseReaction
Can NN O O
occur NN O O
in NN O O
association NN O O
with NN O O
SIADH NN O O
( NN O O
5.9 NN O O
) NN O O
. NN O O
* NN O O
Interstitial NN B-AdverseReaction B-AdverseReaction
Lung NN I-AdverseReaction I-AdverseReaction
Disease NN I-AdverseReaction I-AdverseReaction
and NN O O
Eosinophilic NN B-AdverseReaction B-AdverseReaction
Pneumonia NN I-AdverseReaction I-AdverseReaction
Can NN O O
occur NN O O
( NN O O
5.10 NN O O
) NN O O
. NN O O
5.1 NN O O
Suicidal NN O O
Thoughts NN O O
and NN O O
Behaviors NN O O
in NN O O
Children NN O O
, NN O O
Adolescents NN O O
and NN O O
Young NN O O
Adults NN O O
Patients NN O O
with NN O O
major NN O O
depressive NN O O
disorder NN O O
( NN O O
MDD NN O O
) NN O O
, NN O O
both NN O O
adult NN O O
and NN O O
pediatric NN O O
, NN O O
may NN O O
experience NN O O
worsening NN O O
of NN O O
their NN O O
depression NN O O
and/or NN O O
the NN O O
emergence NN O O
of NN O O
suicidal NN O O
ideation NN O O
and NN O O
behavior NN O O
( NN O O
suicidality NN O O
) NN O O
or NN O O
unusual NN O O
changes NN O O
in NN O O
behavior NN O O
, NN O O
whether NN O O
or NN O O
not NN O O
they NN O O
are NN O O
taking NN O O
antidepressant NN O O
medications NN O O
, NN O O
and NN O O
this NN O O
risk NN O O
may NN O O
persist NN O O
until NN O O
significant NN O O
remission NN O O
occurs NN O O
. NN O O
Suicide NN O O
is NN O O
a NN O O
known NN O O
risk NN O O
of NN O O
depression NN O O
and NN O O
certain NN O O
other NN O O
psychiatric NN O O
disorders NN O O
, NN O O
and NN O O
these NN O O
disorders NN O O
themselves NN O O
are NN O O
the NN O O
strongest NN O O
predictors NN O O
of NN O O
suicide NN O O
. NN O O
There NN O O
has NN O O
been NN O O
a NN O O
long NN O O
- NN O O
standing NN O O
concern NN O O
, NN O O
however NN O O
, NN O O
that NN O O
antidepressants NN B-DrugClass B-DrugClass
may NN O O
have NN O O
a NN O O
role NN O O
in NN O O
inducing NN O O
worsening NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
depression NN I-AdverseReaction I-AdverseReaction
and NN O O
the NN O O
emergence NN O O
of NN O O
suicidality NN B-AdverseReaction B-AdverseReaction
in NN O O
certain NN O O
patients NN O O
during NN O O
the NN O O
early NN O O
phases NN O O
of NN O O
treatment NN O O
. NN O O
Pooled NN O O
analyses NN O O
of NN O O
short NN O O
- NN O O
term NN O O
placebo NN O O
- NN O O
controlled NN O O
studies NN O O
of NN O O
antidepressant NN B-DrugClass B-DrugClass
drugs NN I-DrugClass I-DrugClass
( NN O O
SSRIs NN O O
and NN O O
others NN O O
) NN O O
showed NN O O
that NN O O
these NN O O
drugs NN O O
increase NN O O
the NN O O
risk NN O O
of NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
thinking NN I-AdverseReaction I-AdverseReaction
and NN O O
behavior NN O O
( NN O O
suicidality NN O O
) NN O O
in NN O O
children NN O O
, NN O O
adolescents NN O O
, NN O O
and NN O O
young NN O O
adults NN O O
( NN O O
ages NN O O
18 NN O O
to NN O O
24 NN O O
) NN O O
with NN O O
major NN O O
depressive NN O O
disorder NN O O
( NN O O
MDD NN O O
) NN O O
and NN O O
other NN O O
psychiatric NN O O
disorders NN O O
. NN O O
Short NN O O
- NN O O
term NN O O
studies NN O O
did NN O O
not NN B-Negation B-Negation
show NN O O
an NN O O
increase NN O O
in NN O O
the NN O O
risk NN O O
of NN O O
suicidality NN B-AdverseReaction B-AdverseReaction
with NN O O
antidepressants NN O O
compared NN O O
to NN O O
placebo NN O O
in NN O O
adults NN O O
beyond NN O O
age NN O O
24 NN O O
; NN O O
there NN O O
was NN O O
a NN O O
reduction NN O O
with NN O O
antidepressants NN O O
compared NN O O
to NN O O
placebo NN O O
in NN O O
adults NN O O
aged NN O O
65 NN O O
and NN O O
older NN O O
. NN O O
The NN O O
pooled NN O O
analyses NN O O
of NN O O
placebo NN O O
- NN O O
controlled NN O O
studies NN O O
in NN O O
children NN O O
and NN O O
adolescents NN O O
with NN O O
MDD NN O O
, NN O O
obsessive NN O O
compulsive NN O O
disorder NN O O
( NN O O
OCD NN O O
) NN O O
, NN O O
or NN O O
other NN O O
psychiatric NN O O
disorders NN O O
included NN O O
a NN O O
total NN O O
of NN O O
24 NN O O
short NN O O
- NN O O
term NN O O
studies NN O O
of NN O O
9 NN O O
antidepressant NN O O
drugs NN O O
in NN O O
over NN O O
4,400 NN O O
patients NN O O
. NN O O
The NN O O
pooled NN O O
analyses NN O O
of NN O O
placebo NN O O
- NN O O
controlled NN O O
studies NN O O
in NN O O
adults NN O O
with NN O O
MDD NN O O
or NN O O
other NN O O
psychiatric NN O O
disorders NN O O
included NN O O
a NN O O
total NN O O
of NN O O
295 NN O O
short NN O O
- NN O O
term NN O O
studies NN O O
( NN O O
median NN O O
duration NN O O
of NN O O
2 NN O O
months NN O O
) NN O O
of NN O O
11 NN O O
antidepressant NN O O
drugs NN O O
in NN O O
over NN O O
77,000 NN O O
patients NN O O
. NN O O
There NN O O
was NN O O
considerable NN O O
variation NN O O
in NN O O
risk NN O O
of NN O O
suicidality NN B-AdverseReaction B-AdverseReaction
among NN O O
drugs NN B-DrugClass B-DrugClass
but NN O O
a NN O O
tendency NN O O
toward NN O O
an NN O O
increase NN O O
in NN O O
the NN O O
younger NN O O
patients NN O O
for NN O O
almost NN O O
all NN O O
drugs NN O O
studied NN O O
. NN O O
There NN O O
were NN O O
differences NN O O
in NN O O
absolute NN O O
risk NN O O
of NN O O
suicidality NN B-AdverseReaction B-AdverseReaction
across NN O O
the NN O O
different NN O O
indications NN O O
, NN O O
with NN O O
the NN O O
highest NN O O
incidence NN O O
in NN O O
MDD. NN O O
The NN O O
risk NN O O
differences NN O O
( NN O O
drug NN O O
vs. NN O O
placebo NN O O
) NN O O
, NN O O
however NN O O
, NN O O
were NN O O
relatively NN O O
stable NN O O
within NN O O
age NN O O
strata NN O O
and NN O O
across NN O O
indications NN O O
. NN O O
These NN O O
risk NN O O
differences NN O O
( NN O O
drug NN O O
- NN O O
placebo NN O O
difference NN O O
in NN O O
the NN O O
number NN O O
of NN O O
cases NN O O
of NN O O
suicidality NN B-AdverseReaction B-AdverseReaction
per NN O O
1,000 NN O O
patients NN O O
treated NN O O
) NN O O
are NN O O
provided NN O O
in NN O O
Table NN O O
1 NN O O
. NN O O
Table NN O O
1 NN O O
Age NN O O
Range NN O O
Drug NN O O
- NN O O
Placebo NN O O
Difference NN O O
in NN O O
Number NN O O
of NN O O
Cases NN O O
of NN O O
Suicidality NN B-AdverseReaction B-AdverseReaction
per NN O O
1,000 NN O O
Patients NN O O
Treated NN O O
Increases NN O O
Compared NN O O
to NN O O
Placebo NN O O
< NN O O
18 NN O O
14 NN O O
additional NN O O
cases NN O O
18 NN O O
to NN O O
24 NN O O
5 NN O O
additional NN O O
cases NN O O
Decreases NN O O
Compared NN O O
to NN O O
Placebo NN O O
25 NN O O
to NN O O
64 NN O O
1 NN O O
fewer NN O O
case NN O O
>=65 NN O O
6 NN O O
fewer NN O O
cases NN O O
No NN B-Negation B-Negation
suicides NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
any NN O O
of NN O O
the NN O O
pediatric NN O O
studies NN O O
. NN O O
There NN O O
were NN O O
suicides NN B-AdverseReaction B-AdverseReaction
in NN O O
the NN O O
adult NN O O
studies NN O O
, NN O O
but NN O O
the NN O O
number NN O O
was NN O O
not NN O O
sufficient NN O O
to NN O O
reach NN O O
any NN O O
conclusion NN O O
about NN O O
drug NN O O
effect NN O O
on NN O O
suicide NN O O
. NN O O
It NN O O
is NN O O
unknown NN O O
whether NN O O
the NN O O
suicidality NN B-AdverseReaction B-AdverseReaction
risk NN B-Factor B-Factor
extends NN O O
to NN O O
longer NN O O
- NN O O
term NN O O
use NN O O
, NN O O
i.e. NN O O
, NN O O
beyond NN O O
several NN O O
months NN O O
. NN O O
However NN O O
, NN O O
there NN O O
is NN O O
substantial NN O O
evidence NN O O
from NN O O
placebo NN O O
- NN O O
controlled NN O O
maintenance NN O O
studies NN O O
in NN O O
adults NN O O
with NN O O
depression NN O O
that NN O O
the NN O O
use NN O O
of NN O O
antidepressants NN O O
can NN O O
delay NN O O
the NN O O
recurrence NN O O
of NN O O
depression NN O O
. NN O O
All NN O O
patients NN O O
being NN O O
treated NN O O
with NN O O
antidepressants NN O O
for NN O O
any NN O O
indication NN O O
should NN O O
be NN O O
monitored NN O O
appropriately NN O O
and NN O O
observed NN O O
closely NN O O
for NN O O
clinical NN O O
worsening NN O O
, NN O O
suicidality NN O O
, NN O O
and NN O O
unusual NN O O
changes NN O O
in NN O O
behavior NN O O
, NN O O
especially NN O O
during NN O O
the NN O O
initial NN O O
few NN O O
months NN O O
of NN O O
a NN O O
course NN O O
of NN O O
drug NN O O
therapy NN O O
, NN O O
or NN O O
at NN O O
times NN O O
of NN O O
dose NN O O
changes NN O O
, NN O O
either NN O O
increases NN O O
or NN O O
decreases NN O O
. NN O O
The NN O O
following NN O O
symptoms NN O O
, NN O O
anxiety NN B-AdverseReaction B-AdverseReaction
agitation NN B-AdverseReaction B-AdverseReaction
panic NN B-AdverseReaction B-AdverseReaction
attacks NN I-AdverseReaction I-AdverseReaction
insomnia NN B-AdverseReaction B-AdverseReaction
irritability NN B-AdverseReaction B-AdverseReaction
hostility NN B-AdverseReaction B-AdverseReaction
aggressiveness NN B-AdverseReaction B-AdverseReaction
impulsivity NN B-AdverseReaction B-AdverseReaction
akathisia NN B-AdverseReaction B-AdverseReaction
( NN O O
psychomotor NN O O
restlessness NN O O
) NN O O
, NN O O
hypomania NN B-AdverseReaction B-AdverseReaction
and NN O O
mania NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
adult NN O O
and NN O O
pediatric NN O O
patients NN O O
being NN O O
treated NN O O
with NN O O
antidepressants NN B-DrugClass B-DrugClass
for NN O O
major NN O O
depressive NN O O
disorder NN O O
as NN O O
well NN O O
as NN O O
for NN O O
other NN O O
indications NN O O
, NN O O
both NN O O
psychiatric NN O O
and NN O O
nonpsychiatric NN O O
. NN O O
Although NN O O
a NN O O
causal NN O O
link NN O O
between NN O O
the NN O O
emergence NN O O
of NN O O
such NN O O
symptoms NN O O
and NN O O
either NN O O
the NN O O
worsening NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
depression NN I-AdverseReaction I-AdverseReaction
and/or NN O O
the NN O O
emergence NN O O
of NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
impulses NN I-AdverseReaction I-AdverseReaction
has NN O O
not NN B-Negation B-Negation
been NN I-Negation I-Negation
established NN I-Negation I-Negation
there NN O O
is NN O O
concern NN O O
that NN O O
such NN O O
symptoms NN O O
may NN B-Factor B-Factor
represent NN O O
precursors NN O O
to NN O O
emerging NN O O
suicidality NN B-AdverseReaction B-AdverseReaction
Consideration NN O O
should NN O O
be NN O O
given NN O O
to NN O O
changing NN O O
the NN O O
therapeutic NN O O
regimen NN O O
, NN O O
including NN O O
possibly NN O O
discontinuing NN O O
the NN O O
medication NN O O
, NN O O
in NN O O
patients NN O O
whose NN O O
depression NN O O
is NN O O
persistently NN O O
worse NN O O
, NN O O
or NN O O
who NN O O
are NN O O
experiencing NN O O
emergent NN O O
suicidality NN O O
or NN O O
symptoms NN O O
that NN O O
might NN O O
be NN O O
precursors NN O O
to NN O O
worsening NN O O
depression NN O O
or NN O O
suicidality NN O O
, NN O O
especially NN O O
if NN O O
these NN O O
symptoms NN O O
are NN O O
severe NN O O
, NN O O
abrupt NN O O
in NN O O
onset NN O O
, NN O O
or NN O O
were NN O O
not NN O O
part NN O O
of NN O O
the NN O O
patient NN O O
's NN O O
presenting NN O O
symptoms NN O O
. NN O O
If NN O O
the NN O O
decision NN O O
has NN O O
been NN O O
made NN O O
to NN O O
discontinue NN O O
treatment NN O O
, NN O O
medication NN O O
should NN O O
be NN O O
tapered NN O O
, NN O O
as NN O O
rapidly NN O O
as NN O O
is NN O O
feasible NN O O
, NN O O
but NN O O
with NN O O
recognition NN O O
that NN O O
abrupt NN O O
discontinuation NN O O
can NN O O
be NN O O
associated NN O O
with NN O O
certain NN O O
symptoms NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.4 NN O O
) NN O O
and NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.7 NN O O
) NN O O
for NN O O
a NN O O
description NN O O
of NN O O
the NN O O
risks NN O O
of NN O O
discontinuation NN O O
of NN O O
PRISTIQ NN O O
] NN O O
. NN O O
Families NN O O
and NN O O
caregivers NN O O
of NN O O
patients NN O O
being NN O O
treated NN O O
with NN O O
antidepressants NN O O
for NN O O
major NN O O
depressive NN O O
disorder NN O O
or NN O O
other NN O O
indications NN O O
, NN O O
both NN O O
psychiatric NN O O
and NN O O
nonpsychiatric NN O O
, NN O O
should NN O O
be NN O O
alerted NN O O
about NN O O
the NN O O
need NN O O
to NN O O
monitor NN O O
patients NN O O
for NN O O
the NN O O
emergence NN O O
of NN O O
agitation NN O O
, NN O O
irritability NN O O
, NN O O
unusual NN O O
changes NN O O
in NN O O
behavior NN O O
, NN O O
and NN O O
the NN O O
other NN O O
symptoms NN O O
described NN O O
above NN O O
, NN O O
as NN O O
well NN O O
as NN O O
the NN O O
emergence NN O O
of NN O O
suicidality NN O O
, NN O O
and NN O O
to NN O O
report NN O O
such NN O O
symptoms NN O O
immediately NN O O
to NN O O
healthcare NN O O
providers NN O O
. NN O O
Such NN O O
monitoring NN O O
should NN O O
include NN O O
daily NN O O
observation NN O O
by NN O O
families NN O O
and NN O O
caregivers NN O O
. NN O O
Prescriptions NN O O
for NN O O
PRISTIQ NN O O
should NN O O
be NN O O
written NN O O
for NN O O
the NN O O
smallest NN O O
quantity NN O O
of NN O O
tablets NN O O
consistent NN O O
with NN O O
good NN O O
patient NN O O
management NN O O
, NN O O
in NN O O
order NN O O
to NN O O
reduce NN O O
the NN O O
risk NN O O
of NN O O
overdose NN O O
. NN O O
Screening NN O O
patients NN O O
for NN O O
bipolar NN O O
disorder NN O O
A NN O O
major NN O O
depressive NN O O
episode NN O O
may NN O O
be NN O O
the NN O O
initial NN O O
presentation NN O O
of NN O O
bipolar NN O O
disorder NN O O
. NN O O
It NN O O
is NN O O
generally NN O O
believed NN O O
( NN O O
though NN O O
not NN O O
established NN O O
in NN O O
controlled NN O O
studies NN O O
) NN O O
that NN O O
treating NN O O
such NN O O
an NN O O
episode NN O O
with NN O O
an NN O O
antidepressant NN B-DrugClass B-DrugClass
alone NN O O
may NN O O
increase NN O O
the NN O O
likelihood NN O O
of NN O O
precipitation NN O O
of NN O O
a NN O O
mixed/manic NN O O
episode NN O O
in NN O O
patients NN O O
at NN O O
risk NN O O
for NN O O
bipolar NN O O
disorder NN O O
. NN O O
Whether NN O O
any NN O O
of NN O O
the NN O O
symptoms NN O O
described NN O O
above NN O O
represent NN O O
such NN O O
a NN O O
conversion NN O O
is NN O O
unknown NN O O
. NN O O
However NN O O
, NN O O
prior NN O O
to NN O O
initiating NN O O
treatment NN O O
with NN O O
an NN O O
antidepressant NN O O
, NN O O
patients NN O O
with NN O O
depressive NN O O
symptoms NN O O
should NN O O
be NN O O
adequately NN O O
screened NN O O
to NN O O
determine NN O O
if NN O O
they NN O O
are NN O O
at NN O O
risk NN O O
for NN O O
bipolar NN O O
disorder NN O O
; NN O O
such NN O O
screening NN O O
should NN O O
include NN O O
a NN O O
detailed NN O O
psychiatric NN O O
history NN O O
, NN O O
including NN O O
a NN O O
family NN O O
history NN O O
of NN O O
suicide NN O O
, NN O O
bipolar NN O O
disorder NN O O
, NN O O
and NN O O
depression NN O O
. NN O O
It NN O O
should NN O O
be NN O O
noted NN O O
that NN O O
PRISTIQ NN O O
is NN O O
not NN O O
approved NN O O
for NN O O
use NN O O
in NN O O
treating NN O O
bipolar NN O O
depression NN O O
. NN O O
5.2 NN O O
Serotonin NN O O
Syndrome NN O O
The NN O O
development NN O O
of NN O O
a NN O O
potentially NN B-Factor B-Factor
life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
serotonin NN B-AdverseReaction B-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
has NN O O
been NN O O
reported NN O O
with NN O O
SNRIs NN O O
and NN O O
SSRIs NN O O
, NN O O
including NN O O
PRISTIQ NN O O
, NN O O
alone NN O O
but NN O O
particularly NN O O
with NN O O
concomitant NN O O
use NN O O
of NN O O
other NN O O
serotonergic NN O O
drugs NN O O
( NN O O
including NN O O
triptans NN O O
, NN O O
tricyclic NN O O
antidepressants NN O O
, NN O O
fentanyl NN O O
, NN O O
lithium NN O O
, NN O O
tramadol NN O O
, NN O O
tryptophan NN O O
, NN O O
buspirone NN O O
, NN O O
and NN O O
St. NN O O
John NN O O
's NN O O
Wort NN O O
) NN O O
, NN O O
and NN O O
with NN O O
drugs NN O O
that NN O O
impair NN O O
metabolism NN O O
of NN O O
serotonin NN O O
( NN O O
in NN O O
particular NN O O
, NN O O
MAOIs NN O O
, NN O O
both NN O O
those NN O O
intended NN O O
to NN O O
treat NN O O
psychiatric NN O O
disorders NN O O
and NN O O
also NN O O
others NN O O
, NN O O
such NN O O
as NN O O
linezolid NN O O
and NN O O
intravenous NN O O
methylene NN O O
blue NN O O
) NN O O
. NN O O
Serotonin NN B-AdverseReaction B-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
symptoms NN O O
may NN B-Factor B-Factor
include NN O O
mental NN B-AdverseReaction B-AdverseReaction
status NN I-AdverseReaction I-AdverseReaction
changes NN I-AdverseReaction I-AdverseReaction
( NN O O
e.g. NN O O
, NN O O
agitation NN B-AdverseReaction B-AdverseReaction
hallucinations NN B-AdverseReaction B-AdverseReaction
delirium NN B-AdverseReaction B-AdverseReaction
and NN O O
coma NN B-AdverseReaction B-AdverseReaction
autonomic NN B-AdverseReaction B-AdverseReaction
instability NN I-AdverseReaction I-AdverseReaction
( NN O O
e.g. NN O O
, NN O O
tachycardia NN B-AdverseReaction B-AdverseReaction
labile NN B-AdverseReaction B-AdverseReaction
blood NN I-AdverseReaction I-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
dizziness NN B-AdverseReaction B-AdverseReaction
diaphoresis NN B-AdverseReaction B-AdverseReaction
flushing NN B-AdverseReaction B-AdverseReaction
hyperthermia NN B-AdverseReaction B-AdverseReaction
neuromuscular NN B-AdverseReaction B-AdverseReaction
symptoms NN I-AdverseReaction I-AdverseReaction
( NN O O
e.g. NN O O
, NN O O
tremor NN B-AdverseReaction B-AdverseReaction
rigidity NN B-AdverseReaction B-AdverseReaction
myoclonus NN B-AdverseReaction B-AdverseReaction
hyperreflexia NN B-AdverseReaction B-AdverseReaction
incoordination NN B-AdverseReaction B-AdverseReaction
seizures NN B-AdverseReaction B-AdverseReaction
and/or NN O O
gastrointestinal NN B-AdverseReaction B-AdverseReaction
symptoms NN I-AdverseReaction I-AdverseReaction
( NN O O
e.g. NN O O
, NN O O
nausea NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
Patients NN O O
should NN O O
be NN O O
monitored NN O O
for NN O O
the NN O O
emergence NN O O
of NN O O
serotonin NN O O
syndrome NN O O
. NN O O
The NN O O
concomitant NN O O
use NN O O
of NN O O
PRISTIQ NN O O
with NN O O
MAOIs NN O O
intended NN O O
to NN O O
treat NN O O
psychiatric NN O O
disorders NN O O
is NN O O
contraindicated NN O O
. NN O O
PRISTIQ NN O O
should NN O O
also NN O O
not NN O O
be NN O O
started NN O O
in NN O O
a NN O O
patient NN O O
who NN O O
is NN O O
being NN O O
treated NN O O
with NN O O
MAOIs NN O O
such NN O O
as NN O O
linezolid NN O O
or NN O O
intravenous NN O O
methylene NN O O
blue NN O O
. NN O O
All NN O O
reports NN O O
with NN O O
methylene NN O O
blue NN O O
that NN O O
provided NN O O
information NN O O
on NN O O
the NN O O
route NN O O
of NN O O
administration NN O O
involved NN O O
intravenous NN O O
administration NN O O
in NN O O
the NN O O
dose NN O O
range NN O O
of NN O O
1 NN O O
mg/kg NN O O
to NN O O
8 NN O O
mg/kg NN O O
. NN O O
No NN O O
reports NN O O
involved NN O O
the NN O O
administration NN O O
of NN O O
methylene NN O O
blue NN O O
by NN O O
other NN O O
routes NN O O
( NN O O
such NN O O
as NN O O
oral NN O O
tablets NN O O
or NN O O
local NN O O
tissue NN O O
injection NN O O
) NN O O
or NN O O
at NN O O
lower NN O O
doses NN O O
. NN O O
There NN O O
may NN O O
be NN O O
circumstances NN O O
when NN O O
it NN O O
is NN O O
necessary NN O O
to NN O O
initiate NN O O
treatment NN O O
with NN O O
a NN O O
MAOI NN O O
such NN O O
as NN O O
linezolid NN O O
or NN O O
intravenous NN O O
methylene NN O O
blue NN O O
in NN O O
a NN O O
patient NN O O
taking NN O O
PRISTIQ. NN O O
PRISTIQ NN O O
should NN O O
be NN O O
discontinued NN O O
before NN O O
initiating NN O O
treatment NN O O
with NN O O
the NN O O
MAOI NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4.2 NN O O
) NN O O
and NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.6 NN O O
) NN O O
] NN O O
. NN O O
If NN O O
concomitant NN O O
use NN O O
of NN O O
PRISTIQ NN O O
with NN O O
other NN O O
serotonergic NN O O
drugs NN O O
, NN O O
including NN O O
triptans NN O O
, NN O O
tricyclic NN O O
antidepressants NN O O
, NN O O
fentanyl NN O O
, NN O O
lithium NN O O
, NN O O
tramadol NN O O
, NN O O
buspirone NN O O
, NN O O
tryptophan NN O O
, NN O O
and NN O O
St. NN O O
John NN O O
's NN O O
Wort NN O O
is NN O O
clinically NN O O
warranted NN O O
, NN O O
patients NN O O
should NN O O
be NN O O
made NN O O
aware NN O O
of NN O O
a NN O O
potential NN O O
increased NN O O
risk NN O O
for NN O O
serotonin NN O O
syndrome NN O O
, NN O O
particularly NN O O
during NN O O
treatment NN O O
initiation NN O O
and NN O O
dose NN O O
increases NN O O
. NN O O
Treatment NN O O
with NN O O
PRISTIQ NN O O
and NN O O
any NN O O
concomitant NN O O
serotonergic NN O O
agents NN O O
should NN O O
be NN O O
discontinued NN O O
immediately NN O O
if NN O O
the NN O O
above NN O O
events NN O O
occur NN O O
and NN O O
supportive NN O O
symptomatic NN O O
treatment NN O O
should NN O O
be NN O O
initiated NN O O
. NN O O
5.3 NN O O
Elevated NN O O
Blood NN O O
Pressure NN O O
Patients NN O O
receiving NN O O
PRISTIQ NN O O
should NN O O
have NN O O
regular NN O O
monitoring NN O O
of NN O O
blood NN O O
pressure NN O O
since NN O O
increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
blood NN I-AdverseReaction I-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
were NN O O
observed NN O O
in NN O O
clinical NN O O
studies NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Pre NN O O
- NN O O
existing NN O O
hypertension NN O O
should NN O O
be NN O O
controlled NN O O
before NN O O
initiating NN O O
treatment NN O O
with NN O O
PRISTIQ. NN O O
Caution NN O O
should NN O O
be NN O O
exercised NN O O
in NN O O
treating NN O O
patients NN O O
with NN O O
pre NN O O
- NN O O
existing NN O O
hypertension NN O O
, NN O O
cardiovascular NN O O
, NN O O
or NN O O
cerebrovascular NN O O
conditions NN O O
that NN O O
might NN O O
be NN O O
compromised NN O O
by NN O O
increases NN O O
in NN O O
blood NN O O
pressure NN O O
. NN O O
Cases NN O O
of NN O O
elevated NN B-AdverseReaction B-AdverseReaction
blood NN I-AdverseReaction I-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
requiring NN O O
immediate NN O O
treatment NN O O
have NN O O
been NN O O
reported NN O O
with NN O O
PRISTIQ. NN O O
Sustained NN B-Severity B-Severity
blood NN B-AdverseReaction B-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
increases NN I-AdverseReaction I-AdverseReaction
could NN O O
have NN O O
adverse NN O O
consequences NN O O
. NN O O
For NN O O
patients NN O O
who NN O O
experience NN O O
a NN O O
sustained NN O O
increase NN O O
in NN O O
blood NN O O
pressure NN O O
while NN O O
receiving NN O O
PRISTIQ NN O O
, NN O O
either NN O O
dose NN O O
reduction NN O O
or NN O O
discontinuation NN O O
should NN O O
be NN O O
considered NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
5.4 NN O O
Abnormal NN O O
Bleeding NN O O
SSRIs NN O O
and NN O O
SNRIs NN O O
, NN O O
including NN O O
PRISTIQ NN O O
, NN O O
may NN O O
increase NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
events NN O O
. NN O O
Concomitant NN O O
use NN O O
of NN O O
aspirin NN O O
, NN O O
nonsteroidal NN O O
anti NN O O
- NN O O
inflammatory NN O O
drugs NN O O
, NN O O
warfarin NN O O
, NN O O
and NN O O
other NN O O
anticoagulants NN O O
may NN O O
add NN O O
to NN O O
this NN O O
risk NN O O
. NN O O
Case NN O O
reports NN O O
and NN O O
epidemiological NN O O
studies NN O O
( NN O O
case NN O O
- NN O O
control NN O O
and NN O O
cohort NN O O
design NN O O
) NN O O
have NN O O
demonstrated NN O O
an NN O O
association NN O O
between NN O O
use NN O O
of NN O O
drugs NN B-DrugClass B-DrugClass
that NN I-DrugClass I-DrugClass
interfere NN I-DrugClass I-DrugClass
with NN I-DrugClass I-DrugClass
serotonin NN I-DrugClass I-DrugClass
reuptake NN I-DrugClass I-DrugClass
and NN O O
the NN O O
occurrence NN O O
of NN O O
gastrointestinal NN B-AdverseReaction B-AdverseReaction
bleeding NN I-AdverseReaction I-AdverseReaction
Bleeding NN B-AdverseReaction B-AdverseReaction
events NN O O
related NN O O
to NN O O
SSRIs NN O O
and NN O O
SNRIs NN B-DrugClass B-DrugClass
have NN O O
ranged NN O O
from NN O O
ecchymosis NN B-AdverseReaction B-AdverseReaction
hematoma NN B-AdverseReaction B-AdverseReaction
epistaxis NN B-AdverseReaction B-AdverseReaction
and NN O O
petechiae NN B-AdverseReaction B-AdverseReaction
to NN O O
life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
hemorrhages NN B-AdverseReaction B-AdverseReaction
Patients NN O O
should NN O O
be NN O O
cautioned NN O O
about NN O O
the NN O O
risk NN O O
of NN O O
bleeding NN O O
associated NN O O
with NN O O
the NN O O
concomitant NN O O
use NN O O
of NN O O
PRISTIQ NN O O
and NN O O
NSAIDs NN O O
, NN O O
aspirin NN O O
, NN O O
or NN O O
other NN O O
drugs NN O O
that NN O O
affect NN O O
coagulation NN O O
or NN O O
bleeding NN O O
. NN O O
5.5 NN O O
Angle NN O O
Closure NN O O
Glaucoma NN O O
Angle NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Closure NN I-AdverseReaction I-AdverseReaction
Glaucoma NN I-AdverseReaction I-AdverseReaction
The NN O O
pupillary NN O O
dilation NN O O
that NN O O
occurs NN O O
following NN O O
use NN O O
of NN O O
many NN O O
antidepressant NN O O
drugs NN O O
including NN O O
Pristiq NN O O
may NN B-Factor B-Factor
trigger NN O O
an NN O O
angle NN B-AdverseReaction B-AdverseReaction
closure NN I-AdverseReaction I-AdverseReaction
attack NN I-AdverseReaction I-AdverseReaction
in NN O O
a NN O O
patient NN O O
with NN O O
anatomically NN O O
narrow NN O O
angles NN O O
who NN O O
does NN O O
not NN O O
have NN O O
a NN O O
patent NN O O
iridectomy NN O O
. NN O O
5.6 NN O O
Activation NN O O
of NN O O
Mania/Hypomania NN O O
During NN O O
all NN O O
MDD NN O O
phase NN O O
2 NN O O
and NN O O
phase NN O O
3 NN O O
studies NN O O
, NN O O
mania NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
for NN O O
approximately NN O O
0.02 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
PRISTIQ. NN O O
Activation NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
mania NN I-AdverseReaction I-AdverseReaction
has NN O O
also NN O O
been NN O O
reported NN O O
in NN O O
a NN O O
small NN O O
proportion NN O O
of NN O O
patients NN O O
with NN O O
major NN O O
affective NN O O
disorder NN O O
who NN O O
were NN O O
treated NN O O
with NN O O
other NN O O
marketed NN O O
antidepressants NN B-DrugClass B-DrugClass
As NN O O
with NN O O
all NN O O
antidepressants NN O O
, NN O O
PRISTIQ NN O O
should NN O O
be NN O O
used NN O O
cautiously NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
or NN O O
family NN O O
history NN O O
of NN O O
mania NN O O
or NN O O
hypomania NN O O
. NN O O
5.7 NN O O
Discontinuation NN O O
Syndrome NN O O
Discontinuation NN O O
symptoms NN O O
have NN O O
been NN O O
systematically NN O O
and NN O O
prospectively NN O O
evaluated NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
PRISTIQ NN O O
during NN O O
clinical NN O O
studies NN O O
in NN O O
Major NN O O
Depressive NN O O
Disorder NN O O
. NN O O
Abrupt NN O O
discontinuation NN O O
or NN O O
dose NN O O
reduction NN O O
has NN O O
been NN O O
associated NN O O
with NN O O
the NN O O
appearance NN O O
of NN O O
new NN O O
symptoms NN O O
that NN O O
include NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
irritability NN B-AdverseReaction B-AdverseReaction
insomnia NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
anxiety NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
abnormal NN B-AdverseReaction B-AdverseReaction
dreams NN I-AdverseReaction I-AdverseReaction
and NN O O
hyperhidrosis NN B-AdverseReaction B-AdverseReaction
In NN O O
general NN O O
, NN O O
discontinuation NN O O
events NN O O
occurred NN O O
more NN O O
frequently NN O O
with NN O O
longer NN O O
duration NN O O
of NN O O
therapy NN O O
. NN O O
During NN O O
marketing NN O O
of NN O O
SNRIs NN O O
( NN O O
Serotonin NN O O
and NN O O
Norepinephrine NN O O
Reuptake NN O O
Inhibitors NN O O
) NN O O
, NN O O
and NN O O
SSRIs NN O O
( NN O O
Selective NN O O
Serotonin NN O O
Reuptake NN O O
Inhibitors NN O O
) NN O O
, NN O O
there NN O O
have NN O O
been NN O O
spontaneous NN O O
reports NN O O
of NN O O
adverse NN O O
events NN O O
occurring NN O O
upon NN O O
discontinuation NN O O
of NN O O
these NN O O
drugs NN O O
, NN O O
particularly NN O O
when NN O O
abrupt NN O O
, NN O O
including NN O O
the NN O O
following NN O O
: NN O O
dysphoric NN O O
mood NN O O
, NN O O
irritability NN O O
, NN O O
agitation NN O O
, NN O O
dizziness NN O O
, NN O O
sensory NN O O
disturbances NN O O
( NN O O
e.g. NN O O
, NN O O
paresthesia NN O O
, NN O O
such NN O O
as NN O O
electric NN O O
shock NN O O
sensations NN O O
) NN O O
, NN O O
anxiety NN O O
, NN O O
confusion NN O O
, NN O O
headache NN O O
, NN O O
lethargy NN O O
, NN O O
emotional NN O O
lability NN O O
, NN O O
insomnia NN O O
, NN O O
hypomania NN O O
, NN O O
tinnitus NN O O
, NN O O
and NN O O
seizures NN O O
. NN O O
While NN O O
these NN O O
events NN O O
are NN O O
generally NN O O
self NN O O
- NN O O
limiting NN O O
, NN O O
there NN O O
have NN O O
been NN O O
reports NN O O
of NN O O
serious NN O O
discontinuation NN O O
symptoms NN O O
. NN O O
Patients NN O O
should NN O O
be NN O O
monitored NN O O
for NN O O
these NN O O
symptoms NN O O
when NN O O
discontinuing NN O O
treatment NN O O
with NN O O
PRISTIQ. NN O O
A NN O O
gradual NN O O
reduction NN O O
in NN O O
the NN O O
dose NN O O
rather NN O O
than NN O O
abrupt NN O O
cessation NN O O
is NN O O
recommended NN O O
whenever NN O O
possible NN O O
. NN O O
If NN O O
intolerable NN O O
symptoms NN O O
occur NN O O
following NN O O
a NN O O
decrease NN O O
in NN O O
the NN O O
dose NN O O
or NN O O
upon NN O O
discontinuation NN O O
of NN O O
treatment NN O O
, NN O O
then NN O O
resuming NN O O
the NN O O
previously NN O O
prescribed NN O O
dose NN O O
may NN O O
be NN O O
considered NN O O
. NN O O
Subsequently NN O O
, NN O O
the NN O O
physician NN O O
may NN O O
continue NN O O
decreasing NN O O
the NN O O
dose NN O O
, NN O O
but NN O O
at NN O O
a NN O O
more NN O O
gradual NN O O
rate NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.4 NN O O
) NN O O
and NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
5.8 NN O O
Seizure NN O O
Cases NN O O
of NN O O
seizure NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
pre NN O O
- NN O O
marketing NN O O
clinical NN O O
studies NN O O
with NN O O
PRISTIQ. NN O O
PRISTIQ NN O O
has NN O O
not NN O O
been NN O O
systematically NN O O
evaluated NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
seizure NN O O
disorder NN O O
. NN O O
Patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
seizures NN O O
were NN O O
excluded NN O O
from NN O O
pre NN O O
- NN O O
marketing NN O O
clinical NN O O
studies NN O O
. NN O O
PRISTIQ NN O O
should NN O O
be NN O O
prescribed NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
seizure NN O O
disorder NN O O
. NN O O
5.9 NN O O
Hyponatremia NN O O
Hyponatremia NN B-AdverseReaction B-AdverseReaction
may NN B-Factor B-Factor
occur NN O O
as NN O O
a NN O O
result NN O O
of NN O O
treatment NN O O
with NN O O
SSRIs NN O O
and NN O O
SNRIs NN O O
, NN O O
including NN O O
PRISTIQ. NN O O
In NN O O
many NN O O
cases NN O O
, NN O O
this NN O O
hyponatremia NN B-AdverseReaction B-AdverseReaction
appears NN O O
to NN O O
be NN O O
the NN O O
result NN O O
of NN O O
the NN O O
syndrome NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
inappropriate NN I-AdverseReaction I-AdverseReaction
antidiuretic NN I-AdverseReaction I-AdverseReaction
hormone NN I-AdverseReaction I-AdverseReaction
secretion NN I-AdverseReaction I-AdverseReaction
( NN O O
SIADH NN O O
) NN O O
. NN O O
Cases NN O O
with NN O O
serum NN B-AdverseReaction B-AdverseReaction
sodium NN I-AdverseReaction I-AdverseReaction
lower NN I-AdverseReaction I-AdverseReaction
than NN I-AdverseReaction I-AdverseReaction
110 NN I-AdverseReaction I-AdverseReaction
mmol/L NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
. NN O O
Elderly NN O O
patients NN O O
may NN O O
be NN O O
at NN O O
greater NN O O
risk NN O O
of NN O O
developing NN O O
hyponatremia NN B-AdverseReaction B-AdverseReaction
with NN O O
SSRIs NN O O
and NN O O
SNRIs NN B-DrugClass B-DrugClass
Also NN O O
, NN O O
patients NN O O
taking NN O O
diuretics NN O O
or NN O O
who NN O O
are NN O O
otherwise NN O O
volume NN O O
depleted NN O O
can NN O O
be NN O O
at NN O O
greater NN O O
risk NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.5 NN O O
) NN O O
and NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.6 NN O O
) NN O O
] NN O O
. NN O O
Discontinuation NN O O
of NN O O
PRISTIQ NN O O
should NN O O
be NN O O
considered NN O O
in NN O O
patients NN O O
with NN O O
symptomatic NN O O
hyponatremia NN O O
and NN O O
appropriate NN O O
medical NN O O
intervention NN O O
should NN O O
be NN O O
instituted NN O O
. NN O O
Signs NN O O
and NN O O
symptoms NN O O
of NN O O
hyponatremia NN B-AdverseReaction B-AdverseReaction
include NN O O
headache NN B-AdverseReaction B-AdverseReaction
difficulty NN B-AdverseReaction B-AdverseReaction
concentrating NN I-AdverseReaction I-AdverseReaction
memory NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
confusion NN B-AdverseReaction B-AdverseReaction
weakness NN B-AdverseReaction B-AdverseReaction
and NN O O
unsteadiness NN B-AdverseReaction B-AdverseReaction
which NN O O
can NN B-Factor B-Factor
lead NN O O
to NN O O
falls NN B-AdverseReaction B-AdverseReaction
Signs NN O O
and NN O O
symptoms NN O O
associated NN O O
with NN O O
more NN O O
severe NN O O
and/or NN O O
acute NN O O
cases NN O O
have NN O O
included NN O O
hallucination NN B-AdverseReaction B-AdverseReaction
syncope NN B-AdverseReaction B-AdverseReaction
seizure NN B-AdverseReaction B-AdverseReaction
coma NN B-AdverseReaction B-AdverseReaction
respiratory NN B-AdverseReaction B-AdverseReaction
arrest NN I-AdverseReaction I-AdverseReaction
and NN O O
death NN B-AdverseReaction B-AdverseReaction
5.10 NN O O
Interstitial NN O O
Lung NN O O
Disease NN O O
and NN O O
Eosinophilic NN O O
Pneumonia NN O O
Interstitial NN B-AdverseReaction B-AdverseReaction
lung NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
and NN O O
eosinophilic NN B-AdverseReaction B-AdverseReaction
pneumonia NN I-AdverseReaction I-AdverseReaction
associated NN O O
with NN O O
venlafaxine NN B-DrugClass B-DrugClass
( NN O O
the NN O O
parent NN O O
drug NN O O
of NN O O
PRISTIQ NN O O
) NN O O
therapy NN O O
have NN O O
been NN O O
rarely NN O O
reported NN O O
. NN O O
The NN O O
possibility NN O O
of NN O O
these NN O O
adverse NN O O
events NN O O
should NN O O
be NN O O
considered NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
PRISTIQ NN O O
who NN O O
present NN O O
with NN O O
progressive NN O O
dyspnea NN O O
, NN O O
cough NN O O
, NN O O
or NN O O
chest NN O O
discomfort NN O O
. NN O O
Such NN O O
patients NN O O
should NN O O
undergo NN O O
a NN O O
prompt NN O O
medical NN O O
evaluation NN O O
, NN O O
and NN O O
discontinuation NN O O
of NN O O
PRISTIQ NN O O
should NN O O
be NN O O
considered NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
are NN O O
described NN O O
in NN O O
greater NN O O
detail NN O O
in NN O O
other NN O O
sections NN O O
: NN O O
* NN O O
Paradoxical NN B-AdverseReaction B-AdverseReaction
bronchospasm NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
Worsening NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
narrow NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
angle NN I-AdverseReaction I-AdverseReaction
glaucoma NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
* NN O O
Worsening NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
urinary NN I-AdverseReaction I-AdverseReaction
retention NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
* NN O O
Immediate NN B-AdverseReaction B-AdverseReaction
Hypersensitivity NN I-AdverseReaction I-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
Most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=3 NN O O
% NN O O
incidence NN O O
and NN O O
greater NN O O
than NN O O
placebo NN O O
) NN O O
are NN O O
headache NN B-AdverseReaction B-AdverseReaction
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
and NN O O
cough NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
Contact NN O O
AstraZeneca NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
236 NN O O
- NN O O
9933 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
3-Month NN O O
and NN O O
6-Month NN O O
Trials NN O O
TUDORZA NN O O
PRESSAIR NN O O
was NN O O
studied NN O O
in NN O O
two NN O O
3-month NN O O
( NN O O
Trials NN O O
B NN O O
and NN O O
C NN O O
) NN O O
and NN O O
one NN O O
6-month NN O O
( NN O O
Trial NN O O
D NN O O
) NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
in NN O O
patients NN O O
with NN O O
COPD. NN O O
In NN O O
these NN O O
trials NN O O
, NN O O
636 NN O O
patients NN O O
were NN O O
treated NN O O
with NN O O
TUDORZA NN O O
PRESSAIR NN O O
at NN O O
the NN O O
recommended NN O O
dose NN O O
of NN O O
400 NN O O
mcg NN O O
twice NN O O
daily NN O O
. NN O O
The NN O O
population NN O O
had NN O O
a NN O O
mean NN O O
age NN O O
of NN O O
64 NN O O
years NN O O
( NN O O
ranging NN O O
from NN O O
40 NN O O
to NN O O
89 NN O O
years NN O O
) NN O O
, NN O O
with NN O O
58 NN O O
% NN O O
males NN O O
, NN O O
94 NN O O
% NN O O
Caucasian NN O O
, NN O O
and NN O O
had NN O O
COPD NN O O
with NN O O
a NN O O
mean NN O O
pre NN O O
- NN O O
bronchodilator NN O O
forced NN O O
expiratory NN O O
volume NN O O
in NN O O
one NN O O
second NN O O
( NN O O
FEV1 NN O O
) NN O O
percent NN O O
predicted NN O O
of NN O O
48 NN O O
% NN O O
. NN O O
Patients NN O O
with NN O O
unstable NN O O
cardiac NN O O
disease NN O O
, NN O O
narrow NN O O
- NN O O
angle NN O O
glaucoma NN O O
, NN O O
or NN O O
symptomatic NN O O
prostatic NN O O
hypertrophy NN O O
or NN O O
bladder NN O O
outlet NN O O
obstruction NN O O
were NN O O
excluded NN O O
from NN O O
these NN O O
trials NN O O
. NN O O
Table NN O O
1shows NN O O
all NN O O
adverse NN O O
reactions NN O O
that NN O O
occurred NN O O
with NN O O
a NN O O
frequency NN O O
of NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
1 NN O O
% NN O O
in NN O O
the NN O O
TUDORZA NN O O
PRESSAIR NN O O
group NN O O
in NN O O
the NN O O
two NN O O
3-month NN O O
and NN O O
one NN O O
6-month NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
where NN O O
the NN O O
rates NN O O
in NN O O
the NN O O
TUDORZA NN O O
PRESSAIR NN O O
group NN O O
exceeded NN O O
placebo NN O O
. NN O O
Table NN O O
1 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
( NN O O
% NN O O
Patients NN O O
) NN O O
in NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Clinical NN O O
Trials NN O O
Treatment NN O O
Adverse NN O O
Reactions NN O O
TUDORZA NN O O
PRESSAIR NN O O
Placebo NN O O
Preferred NN O O
Term NN O O
( NN O O
N=636 NN O O
) NN O O
( NN O O
N=640 NN O O
) NN O O
n NN O O
( NN O O
% NN O O
) NN O O
n NN O O
( NN O O
% NN O O
) NN O O
Headache NN B-AdverseReaction B-AdverseReaction
42 NN O O
( NN O O
6.6 NN O O
) NN O O
32 NN O O
( NN O O
5.0 NN O O
) NN O O
Nasopharyngitis NN B-AdverseReaction B-AdverseReaction
35 NN O O
( NN O O
5.5 NN O O
) NN O O
25 NN O O
( NN O O
3.9 NN O O
) NN O O
Cough NN B-AdverseReaction B-AdverseReaction
19 NN O O
( NN O O
3.0 NN O O
) NN O O
14 NN O O
( NN O O
2.2 NN O O
) NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
17 NN O O
( NN O O
2.7 NN O O
) NN O O
9 NN O O
( NN O O
1.4 NN O O
) NN O O
Sinusitis NN B-AdverseReaction B-AdverseReaction
11 NN O O
( NN O O
1.7 NN O O
) NN O O
5 NN O O
( NN O O
0.8 NN O O
) NN O O
Rhinitis NN B-AdverseReaction B-AdverseReaction
10 NN O O
( NN O O
1.6 NN O O
) NN O O
8 NN O O
( NN O O
1.2 NN O O
) NN O O
Toothache NN B-AdverseReaction B-AdverseReaction
7 NN O O
( NN O O
1.1 NN O O
) NN O O
5 NN O O
( NN O O
0.8 NN O O
) NN O O
Fall NN B-AdverseReaction B-AdverseReaction
7 NN O O
( NN O O
1.1 NN O O
) NN O O
3 NN O O
( NN O O
0.5 NN O O
) NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
7 NN O O
( NN O O
1.1 NN O O
) NN O O
3 NN O O
( NN O O
0.5 NN O O
) NN O O
In NN O O
addition NN O O
, NN O O
among NN O O
the NN O O
adverse NN O O
reactions NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
with NN O O
an NN O O
incidence NN O O
of NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
were NN O O
diabetes NN B-AdverseReaction B-AdverseReaction
mellitus NN I-AdverseReaction I-AdverseReaction
dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
1st NN B-Severity B-Severity
degree NN I-Severity I-Severity
AV NN B-AdverseReaction B-AdverseReaction
block NN I-AdverseReaction I-AdverseReaction
osteoarthritis NN B-AdverseReaction B-AdverseReaction
cardiac NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
and NN O O
cardio NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
arrest NN I-AdverseReaction I-AdverseReaction
Long NN O O
- NN O O
term NN O O
Safety NN O O
Trials NN O O
TUDORZA NN O O
PRESSAIR NN O O
was NN O O
studied NN O O
in NN O O
three NN O O
long NN O O
term NN O O
safety NN O O
trials NN O O
, NN O O
two NN O O
double NN O O
blind NN O O
and NN O O
one NN O O
open NN O O
label NN O O
, NN O O
ranging NN O O
from NN O O
40 NN O O
to NN O O
52 NN O O
weeks NN O O
in NN O O
patients NN O O
with NN O O
moderate NN O O
to NN O O
severe NN O O
COPD. NN O O
Two NN O O
of NN O O
these NN O O
trials NN O O
were NN O O
extensions NN O O
of NN O O
the NN O O
3-month NN O O
trials NN O O
, NN O O
and NN O O
one NN O O
was NN O O
a NN O O
dedicated NN O O
long NN O O
term NN O O
safety NN O O
trial NN O O
. NN O O
In NN O O
these NN O O
trials NN O O
, NN O O
891 NN O O
patients NN O O
were NN O O
treated NN O O
with NN O O
TUDORZA NN O O
PRESSAIR NN O O
at NN O O
the NN O O
recommended NN O O
dose NN O O
of NN O O
400 NN O O
mcg NN O O
twice NN O O
daily NN O O
. NN O O
The NN O O
demographic NN O O
and NN O O
baseline NN O O
characteristics NN O O
of NN O O
the NN O O
long NN O O
term NN O O
safety NN O O
trials NN O O
were NN O O
similar NN O O
to NN O O
those NN O O
of NN O O
the NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
. NN O O
The NN O O
adverse NN O O
events NN O O
reported NN O O
in NN O O
the NN O O
long NN O O
term NN O O
safety NN O O
trials NN O O
were NN O O
similar NN O O
to NN O O
those NN O O
occurring NN O O
in NN O O
the NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
of NN O O
3 NN O O
to NN O O
6 NN O O
months NN O O
. NN O O
No NN O O
new NN O O
safety NN O O
findings NN O O
were NN O O
reported NN O O
compared NN O O
to NN O O
the NN O O
placebo NN O O
controlled NN O O
trials NN O O
. NN O O
6.2 NN O O
Postmarketing NN O O
Experience NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
identified NN O O
during NN O O
postapproval NN O O
use NN O O
of NN O O
drug NN O O
TUDORZA NN O O
PRESSAIR. NN O O
Because NN O O
these NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
In NN O O
postmarketing NN O O
experience NN O O
with NN O O
TUDORZA NN O O
PRESSAIR NN O O
, NN O O
immediate NN B-AdverseReaction B-AdverseReaction
hypersensitivity NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
angioedema NN B-AdverseReaction B-AdverseReaction
( NN O O
including NN O O
swelling NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
lips NN I-AdverseReaction I-AdverseReaction
tongue NN O O
, NN O O
or NN O O
throat NN O O
) NN O O
, NN O O
urticaria NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
bronchospasm NN B-AdverseReaction B-AdverseReaction
or NN O O
itching NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Not NN O O
for NN O O
acute NN O O
use NN O O
: NN O O
Not NN O O
for NN O O
use NN O O
as NN O O
a NN O O
rescue NN O O
medication NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Paradoxical NN B-AdverseReaction B-AdverseReaction
bronchospasm NN I-AdverseReaction I-AdverseReaction
Discontinue NN O O
TUDORZA NN O O
PRESSAIR NN O O
and NN O O
consider NN O O
other NN O O
treatments NN O O
if NN O O
paradoxical NN O O
bronchospasm NN O O
occurs NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Worsening NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
narrow NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
angle NN I-AdverseReaction I-AdverseReaction
glaucoma NN I-AdverseReaction I-AdverseReaction
may NN B-Factor B-Factor
occur NN O O
. NN O O
Use NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
with NN O O
narrow NN O O
- NN O O
angle NN O O
glaucoma NN O O
and NN O O
instruct NN O O
patients NN O O
to NN O O
consult NN O O
a NN O O
physician NN O O
immediately NN O O
if NN O O
this NN O O
occurs NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Worsening NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
urinary NN I-AdverseReaction I-AdverseReaction
retention NN I-AdverseReaction I-AdverseReaction
may NN B-Factor B-Factor
occur NN O O
. NN O O
Use NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
with NN O O
prostatic NN O O
hyperplasia NN O O
or NN O O
bladder NN O O
- NN O O
neck NN O O
obstruction NN O O
and NN O O
instruct NN O O
patients NN O O
to NN O O
consult NN O O
a NN O O
physician NN O O
immediately NN O O
if NN O O
this NN O O
occurs NN O O
. NN O O
( NN O O
5.4 NN O O
) NN O O
* NN O O
Immediate NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
Discontinue NN O O
TUDORZA NN O O
PRESSAIR NN O O
at NN O O
once NN O O
and NN O O
consider NN O O
alternatives NN O O
if NN O O
immediate NN O O
hypersensitivity NN O O
reactions NN O O
, NN O O
including NN O O
angioedema NN O O
, NN O O
bronchospasm NN O O
, NN O O
or NN O O
anaphylaxis NN O O
, NN O O
occur NN O O
. NN O O
Use NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
with NN O O
severe NN O O
hypersensitivity NN O O
to NN O O
milk NN O O
proteins NN O O
. NN O O
( NN O O
5.5 NN O O
) NN O O
5.1 NN O O
Not NN O O
for NN O O
Acute NN O O
Use NN O O
TUDORZA NN O O
PRESSAIR NN O O
is NN O O
intended NN O O
as NN O O
a NN O O
twice NN O O
- NN O O
daily NN O O
maintenance NN O O
treatment NN O O
for NN O O
COPD NN O O
and NN O O
is NN O O
not NN O O
indicated NN O O
for NN O O
the NN O O
initial NN O O
treatment NN O O
of NN O O
acute NN O O
episodes NN O O
of NN O O
bronchospasm NN O O
( NN O O
i.e. NN O O
, NN O O
rescue NN O O
therapy NN O O
) NN O O
. NN O O
5.2 NN O O
Paradoxical NN O O
Bronchospasm NN O O
Inhaled NN O O
medicines NN O O
, NN O O
including NN O O
TUDORZA NN O O
PRESSAIR NN O O
, NN O O
may NN B-Factor B-Factor
cause NN O O
paradoxical NN B-AdverseReaction B-AdverseReaction
bronchospasm NN I-AdverseReaction I-AdverseReaction
If NN O O
this NN O O
occurs NN O O
, NN O O
treatment NN O O
with NN O O
TUDORZA NN O O
PRESSAIR NN O O
should NN O O
be NN O O
stopped NN O O
and NN O O
other NN O O
treatments NN O O
considered NN O O
. NN O O
5.3 NN O O
Worsening NN O O
of NN O O
Narrow NN O O
- NN O O
Angle NN O O
Glaucoma NN O O
TUDORZA NN O O
PRESSAIR NN O O
should NN O O
be NN O O
used NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
with NN O O
narrow NN O O
- NN O O
angle NN O O
glaucoma NN O O
. NN O O
Prescribers NN O O
and NN O O
patients NN O O
should NN O O
be NN O O
alert NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
acute NN O O
narrow NN O O
- NN O O
angle NN O O
glaucoma NN O O
( NN O O
e.g. NN O O
, NN O O
eye NN O O
pain NN O O
or NN O O
discomfort NN O O
, NN O O
blurred NN O O
vision NN O O
, NN O O
visual NN O O
halos NN O O
or NN O O
colored NN O O
images NN O O
in NN O O
association NN O O
with NN O O
red NN O O
eyes NN O O
from NN O O
conjunctival NN O O
congestion NN O O
and NN O O
corneal NN O O
edema NN O O
) NN O O
. NN O O
Instruct NN O O
patients NN O O
to NN O O
consult NN O O
a NN O O
physician NN O O
immediately NN O O
should NN O O
any NN O O
of NN O O
these NN O O
signs NN O O
or NN O O
symptoms NN O O
develop NN O O
. NN O O
5.4 NN O O
Worsening NN O O
of NN O O
Urinary NN O O
Retention NN O O
TUDORZA NN O O
PRESSAIR NN O O
should NN O O
be NN O O
used NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
with NN O O
urinary NN O O
retention NN O O
. NN O O
Prescribers NN O O
and NN O O
patients NN O O
should NN O O
be NN O O
alert NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
prostatic NN O O
hyperplasia NN O O
or NN O O
bladder NN O O
- NN O O
neck NN O O
obstruction NN O O
( NN O O
e.g. NN O O
, NN O O
difficulty NN O O
passing NN O O
urine NN O O
, NN O O
painful NN O O
urination NN O O
) NN O O
. NN O O
Instruct NN O O
patients NN O O
to NN O O
consult NN O O
a NN O O
physician NN O O
immediately NN O O
should NN O O
any NN O O
of NN O O
these NN O O
signs NN O O
or NN O O
symptoms NN O O
develop NN O O
. NN O O
5.5 NN O O
Immediate NN O O
Hypersensitivity NN O O
Reactions NN O O
Immediate NN B-AdverseReaction B-AdverseReaction
hypersensitivity NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
angioedema NN B-AdverseReaction B-AdverseReaction
( NN O O
including NN O O
swelling NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
lips NN I-AdverseReaction I-AdverseReaction
tongue NN O O
, NN O O
or NN O O
throat NN O O
) NN O O
, NN O O
urticaria NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
bronchospasm NN B-AdverseReaction B-AdverseReaction
or NN O O
itching NN B-AdverseReaction B-AdverseReaction
have NN O O
occurred NN O O
after NN O O
administration NN O O
of NN O O
TUDORZA NN O O
PRESSAIR. NN O O
If NN O O
such NN O O
a NN O O
reaction NN O O
occurs NN O O
, NN O O
therapy NN O O
with NN O O
TUDORZA NN O O
PRESSAIR NN O O
should NN O O
be NN O O
stopped NN O O
at NN O O
once NN O O
and NN O O
alternative NN O O
treatments NN O O
should NN O O
be NN O O
considered NN O O
. NN O O
Given NN O O
the NN O O
similar NN O O
structural NN O O
formula NN O O
of NN O O
atropine NN O O
to NN O O
aclidinium NN O O
, NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
hypersensitivity NN O O
reactions NN O O
to NN O O
atropine NN O O
should NN O O
be NN O O
closely NN O O
monitored NN O O
for NN O O
similar NN O O
hypersensitivity NN O O
reactions NN O O
to NN O O
TUDORZA NN O O
PRESSAIR. NN O O
In NN O O
addition NN O O
, NN O O
TUDORZA NN O O
PRESSAIR NN O O
should NN O O
be NN O O
used NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
with NN O O
severe NN O O
hypersensitivity NN O O
to NN O O
milk NN O O
proteins NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN O O
, NN O O
including NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
have NN O O
occurred NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
KALBITOR NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
and NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
EXCERPT NN O O
: NN O O
* NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
occurring NN O O
in NN O O
>=3 NN O O
% NN O O
of NN O O
KALBITOR NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
greater NN O O
than NN O O
placebo NN O O
are NN O O
headache NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
pyrexia NN B-AdverseReaction B-AdverseReaction
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
and NN O O
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
( NN O O
6 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Dyax NN O O
Corp. NN O O
at NN O O
1 NN O O
- NN O O
888 NN O O
- NN O O
452 NN O O
- NN O O
5248 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
The NN O O
safety NN O O
data NN O O
described NN O O
below NN O O
reflect NN O O
exposure NN O O
to NN O O
KALBITOR NN O O
in NN O O
255 NN O O
patients NN O O
with NN O O
HAE NN O O
treated NN O O
with NN O O
either NN O O
intravenous NN O O
or NN O O
subcutaneous NN O O
KALBITOR. NN O O
Of NN O O
the NN O O
255 NN O O
patients NN O O
, NN O O
66 NN O O
% NN O O
of NN O O
patients NN O O
were NN O O
female NN O O
and NN O O
86 NN O O
% NN O O
were NN O O
Caucasian NN O O
. NN O O
Patients NN O O
treated NN O O
with NN O O
KALBITOR NN O O
were NN O O
between NN O O
the NN O O
ages NN O O
of NN O O
10 NN O O
and NN O O
78 NN O O
years NN O O
. NN O O
Overall NN O O
, NN O O
the NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
in NN O O
255 NN O O
patients NN O O
with NN O O
HAE NN O O
were NN O O
headache NN B-AdverseReaction B-AdverseReaction
( NN O O
16 NN O O
% NN O O
) NN O O
, NN O O
nausea NN B-AdverseReaction B-AdverseReaction
( NN O O
13 NN O O
% NN O O
) NN O O
, NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
( NN O O
12 NN O O
% NN O O
) NN O O
, NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
( NN O O
11 NN O O
% NN O O
) NN O O
, NN O O
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
( NN O O
8 NN O O
% NN O O
) NN O O
, NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
( NN O O
7 NN O O
% NN O O
) NN O O
, NN O O
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
( NN O O
6 NN O O
% NN O O
) NN O O
, NN O O
vomiting NN B-AdverseReaction B-AdverseReaction
( NN O O
6 NN O O
% NN O O
) NN O O
, NN O O
pruritus NN B-AdverseReaction B-AdverseReaction
( NN O O
5 NN O O
% NN O O
) NN O O
, NN O O
upper NN B-AdverseReaction B-AdverseReaction
abdominal NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
( NN O O
5 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
( NN O O
5 NN O O
% NN O O
) NN O O
. NN O O
Anaphylaxis NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
4 NN O O
% NN O O
of NN O O
patients NN O O
with NN O O
HAE. NN O O
Injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
were NN O O
characterized NN O O
by NN O O
local NN O O
pruritus NN O O
, NN O O
erythema NN O O
, NN O O
pain NN O O
, NN O O
irritation NN O O
, NN O O
urticaria NN O O
, NN O O
and/or NN O O
bruising NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
adverse NN O O
reactions NN O O
below NN O O
is NN O O
based NN O O
upon NN O O
2 NN O O
placebo NN O O
- NN O O
controlled NN O O
, NN O O
clinical NN O O
trials NN O O
( NN O O
EDEMA3 NN O O
( NN O O
r NN O O
) NN O O
and NN O O
EDEMA4 NN O O
( NN O O
r NN O O
) NN O O
) NN O O
in NN O O
a NN O O
total NN O O
of NN O O
143 NN O O
unique NN O O
patients NN O O
with NN O O
HAE. NN O O
Patients NN O O
were NN O O
treated NN O O
with NN O O
KALBITOR NN O O
30 NN O O
mg NN O O
subcutaneous NN O O
or NN O O
placebo NN O O
. NN O O
Patients NN O O
were NN O O
permitted NN O O
to NN O O
participate NN O O
sequentially NN O O
in NN O O
both NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
; NN O O
safety NN O O
data NN O O
collected NN O O
during NN O O
exposure NN O O
to NN O O
KALBITOR NN O O
was NN O O
attributed NN O O
to NN O O
treatment NN O O
with NN O O
KALBITOR NN O O
, NN O O
and NN O O
safety NN O O
data NN O O
collected NN O O
during NN O O
exposure NN O O
to NN O O
placebo NN O O
was NN O O
attributed NN O O
to NN O O
treatment NN O O
with NN O O
placebo NN O O
. NN O O
Table NN O O
1 NN O O
shows NN O O
adverse NN O O
reactions NN O O
occurring NN O O
in NN O O
>=3 NN O O
% NN O O
of NN O O
KALBITOR NN O O
- NN O O
treated NN O O
patients NN O O
that NN O O
also NN O O
occurred NN O O
at NN O O
a NN O O
higher NN O O
rate NN O O
than NN O O
in NN O O
the NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
in NN O O
the NN O O
two NN O O
controlled NN O O
trials NN O O
( NN O O
EDEMA3 NN O O
and NN O O
EDEMA4 NN O O
) NN O O
of NN O O
the NN O O
30 NN O O
mg NN O O
subcutaneous NN O O
dose NN O O
. NN O O
Table NN O O
1 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Occurring NN O O
at NN O O
>=3 NN O O
% NN O O
and NN O O
Higher NN O O
than NN O O
Placebo NN O O
in NN O O
2 NN O O
Placebo NN O O
Controlled NN O O
Clinical NN O O
Trials NN O O
in NN O O
Patients NN O O
with NN O O
HAE NN O O
Treated NN O O
with NN O O
KALBITOR NN O O
a NN O O
Patients NN O O
experiencing NN O O
more NN O O
than NN O O
1 NN O O
event NN O O
with NN O O
the NN O O
same NN O O
preferred NN O O
term NN O O
are NN O O
counted NN O O
only NN O O
once NN O O
for NN O O
that NN O O
preferred NN O O
term NN O O
. NN O O
KALIBITORN=100 NN O O
PlaceboN=81 NN O O
Adverse NN O O
Reactions NN O O
n NN O O
( NN O O
% NN O O
) NN O O
a NN O O
n NN O O
( NN O O
% NN O O
) NN O O
a NN O O
Headache NN B-AdverseReaction B-AdverseReaction
8 NN O O
( NN O O
8 NN O O
% NN O O
) NN O O
6 NN O O
( NN O O
7 NN O O
% NN O O
) NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
5 NN O O
( NN O O
5 NN O O
% NN O O
) NN O O
1 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
4 NN O O
( NN O O
4 NN O O
% NN O O
) NN O O
3 NN O O
( NN O O
4 NN O O
% NN O O
) NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
4 NN O O
( NN O O
4 NN O O
% NN O O
) NN O O
0 NN O O
Injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
3 NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
1 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
Nasopharyngitis NN B-AdverseReaction B-AdverseReaction
3 NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
0 NN O O
Some NN O O
patients NN O O
in NN O O
EDEMA3 NN O O
and NN O O
EDEMA4 NN O O
received NN O O
a NN O O
second NN O O
, NN O O
open NN O O
- NN O O
label NN O O
30 NN O O
mg NN O O
subcutaneous NN O O
dose NN O O
of NN O O
KALBITOR NN O O
within NN O O
24 NN O O
hours NN O O
following NN O O
the NN O O
initial NN O O
dose NN O O
. NN O O
Adverse NN O O
reactions NN O O
reported NN O O
by NN O O
these NN O O
patients NN O O
who NN O O
received NN O O
the NN O O
additional NN O O
30 NN O O
mg NN O O
subcutaneous NN O O
dose NN O O
of NN O O
KALBITOR NN O O
were NN O O
consistent NN O O
with NN O O
those NN O O
reported NN O O
in NN O O
the NN O O
patients NN O O
receiving NN O O
a NN O O
single NN O O
dose NN O O
. NN O O
6.2 NN O O
Immunogenicity NN O O
In NN O O
the NN O O
KALBITOR NN O O
HAE NN O O
program NN O O
, NN O O
patients NN O O
developed NN O O
antibodies NN O O
to NN O O
KALBITOR. NN O O
Rates NN O O
of NN O O
seroconversion NN O O
increased NN O O
with NN O O
exposure NN O O
to NN O O
KALBITOR NN O O
over NN O O
time NN O O
. NN O O
Overall NN O O
, NN O O
20.2 NN O O
% NN O O
of NN O O
patients NN O O
seroconverted NN O O
to NN O O
anti NN O O
- NN O O
ecallantide NN O O
antibodies NN O O
. NN O O
Neutralizing NN O O
antibodies NN O O
to NN O O
ecallantide NN O O
were NN O O
determined NN O O
in NN O O
vitro NN O O
to NN O O
be NN O O
present NN O O
in NN O O
8.8 NN O O
% NN O O
of NN O O
patients NN O O
and NN O O
were NN O O
not NN O O
associated NN O O
with NN O O
loss NN O O
of NN O O
efficacy NN O O
. NN O O
Anti NN O O
- NN O O
ecallantide NN O O
IgE NN O O
antibodies NN O O
were NN O O
detected NN O O
at NN O O
a NN O O
rate NN O O
of NN O O
4.7 NN O O
% NN O O
for NN O O
tested NN O O
patients NN O O
, NN O O
and NN O O
anti- NN O O
P. NN O O
pastoris NN O O
IgE NN O O
antibodies NN O O
were NN O O
also NN O O
detected NN O O
at NN O O
a NN O O
rate NN O O
of NN O O
20.2 NN O O
% NN O O
. NN O O
Patients NN O O
who NN O O
seroconvert NN O O
may NN O O
be NN O O
at NN O O
a NN O O
higher NN O O
risk NN O O
of NN O O
a NN O O
hypersensitivity NN O O
reaction NN O O
. NN O O
The NN O O
long NN O O
- NN O O
term NN O O
effects NN O O
of NN O O
antibodies NN O O
to NN O O
KALBITOR NN O O
are NN O O
not NN O O
known NN O O
. NN O O
The NN O O
test NN O O
results NN O O
for NN O O
the NN O O
ecallantide NN O O
program NN O O
were NN O O
determined NN O O
using NN O O
one NN O O
of NN O O
two NN O O
assay NN O O
formats NN O O
: NN O O
ELISA NN O O
and NN O O
bridging NN O O
electrochemiluminescence NN O O
( NN O O
ECL NN O O
) NN O O
. NN O O
As NN O O
with NN O O
all NN O O
therapeutic NN O O
proteins NN O O
, NN O O
there NN O O
is NN O O
a NN O O
potential NN O O
for NN O O
immunogenicity NN O O
with NN O O
the NN O O
use NN O O
of NN O O
KALBITOR. NN O O
The NN O O
incidence NN O O
of NN O O
antibody NN O O
formation NN O O
is NN O O
highly NN O O
dependent NN O O
on NN O O
the NN O O
sensitivity NN O O
and NN O O
specificity NN O O
of NN O O
the NN O O
assay NN O O
. NN O O
Additionally NN O O
, NN O O
the NN O O
observed NN O O
incidence NN O O
of NN O O
antibody NN O O
( NN O O
including NN O O
neutralizing NN O O
antibody NN O O
) NN O O
positivity NN O O
in NN O O
an NN O O
assay NN O O
may NN O O
be NN O O
influenced NN O O
by NN O O
several NN O O
factors NN O O
, NN O O
including NN O O
assay NN O O
methodology NN O O
, NN O O
sample NN O O
handling NN O O
, NN O O
timing NN O O
of NN O O
sample NN O O
collection NN O O
, NN O O
concomitant NN O O
medications NN O O
, NN O O
and NN O O
underlying NN O O
disease NN O O
. NN O O
For NN O O
these NN O O
reasons NN O O
, NN O O
comparison NN O O
of NN O O
the NN O O
incidence NN O O
of NN O O
antibodies NN O O
to NN O O
KALBITOR NN O O
with NN O O
the NN O O
incidence NN O O
of NN O O
antibodies NN O O
to NN O O
other NN O O
products NN O O
may NN O O
be NN O O
misleading NN O O
. NN O O
6.3 NN O O
Postmarketing NN O O
Experience NN O O
Similar NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
observed NN O O
postmarketing NN O O
as NN O O
described NN O O
for NN O O
clinical NN O O
trial NN O O
experience NN O O
. NN O O
Because NN O O
these NN O O
events NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
frequency NN O O
or NN O O
to NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
with NN O O
drug NN O O
exposure NN O O
. NN O O
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
ANAPHYLAXIS NN B-AdverseReaction B-AdverseReaction
WARNING NN O O
: NN O O
ANAPHYLAXIS NN B-AdverseReaction B-AdverseReaction
Anaphylaxis NN B-AdverseReaction B-AdverseReaction
has NN O O
been NN O O
reported NN O O
after NN O O
administration NN O O
of NN O O
KALBITOR. NN O O
Because NN O O
of NN O O
the NN O O
risk NN O O
of NN O O
anaphylaxis NN O O
, NN O O
KALBITOR NN O O
should NN O O
only NN O O
be NN O O
administered NN O O
by NN O O
a NN O O
healthcare NN O O
professional NN O O
with NN O O
appropriate NN O O
medical NN O O
support NN O O
to NN O O
manage NN O O
anaphylaxis NN O O
and NN O O
hereditary NN O O
angioedema NN O O
. NN O O
Healthcare NN O O
professionals NN O O
should NN O O
be NN O O
aware NN O O
of NN O O
the NN O O
similarity NN O O
of NN O O
symptoms NN O O
between NN O O
hypersensitivity NN O O
reactions NN O O
and NN O O
hereditary NN O O
angioedema NN O O
and NN O O
patients NN O O
should NN O O
be NN O O
monitored NN O O
closely NN O O
. NN O O
Do NN O O
not NN O O
administer NN O O
KALBITOR NN O O
to NN O O
patients NN O O
with NN O O
known NN O O
clinical NN O O
hypersensitivity NN O O
to NN O O
KALBITOR. NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
, NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
, NN O O
and NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
WARNING NN O O
: NN O O
ANAPHYLAXIS NN B-AdverseReaction B-AdverseReaction
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
Anaphylaxis NN B-AdverseReaction B-AdverseReaction
has NN O O
been NN O O
reported NN O O
after NN O O
administration NN O O
of NN O O
KALBITOR NN O O
( NN O O
r NN O O
) NN O O
. NN O O
Because NN O O
of NN O O
the NN O O
risk NN O O
of NN O O
anaphylaxis NN O O
, NN O O
KALBITOR NN O O
should NN O O
only NN O O
be NN O O
administered NN O O
by NN O O
a NN O O
healthcare NN O O
professional NN O O
with NN O O
appropriate NN O O
medical NN O O
support NN O O
to NN O O
manage NN O O
anaphylaxis NN O O
and NN O O
hereditary NN O O
angioedema NN O O
. NN O O
Healthcare NN O O
professionals NN O O
should NN O O
be NN O O
aware NN O O
of NN O O
the NN O O
similarity NN O O
of NN O O
symptoms NN O O
between NN O O
hypersensitivity NN O O
reactions NN O O
and NN O O
hereditary NN O O
angioedema NN O O
and NN O O
patients NN O O
should NN O O
be NN O O
monitored NN O O
closely NN O O
. NN O O
Do NN O O
not NN O O
administer NN O O
KALBITOR NN O O
to NN O O
patients NN O O
with NN O O
known NN O O
clinical NN O O
hypersensitivity NN O O
to NN O O
KALBITOR NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
, NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
, NN O O
and NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
] NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
Including NN O O
Anaphylaxis NN B-AdverseReaction B-AdverseReaction
Anaphylaxis NN B-AdverseReaction B-AdverseReaction
has NN O O
occurred NN O O
in NN O O
4 NN O O
% NN O O
of NN O O
treated NN O O
patients NN O O
. NN O O
Administer NN O O
KALBITOR NN O O
in NN O O
a NN O O
setting NN O O
equipped NN O O
to NN O O
manage NN O O
anaphylaxis NN O O
and NN O O
hereditary NN O O
angioedema NN O O
. NN O O
Given NN O O
the NN O O
similarity NN O O
in NN O O
hypersensitivity NN O O
symptoms NN O O
and NN O O
acute NN O O
HAE NN O O
symptoms NN O O
, NN O O
monitor NN O O
patients NN O O
closely NN O O
for NN O O
hypersensitivity NN O O
reactions NN O O
( NN O O
5 NN O O
) NN O O
. NN O O
5.1 NN O O
Hypersensitivity NN O O
Reactions NN O O
, NN O O
Including NN O O
Anaphylaxis NN O O
Potentially NN B-Factor B-Factor
serious NN B-Severity B-Severity
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN O O
, NN O O
including NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
have NN O O
occurred NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
KALBITOR. NN O O
In NN O O
255 NN O O
HAE NN O O
patients NN O O
treated NN O O
with NN O O
intravenous NN O O
or NN O O
subcutaneous NN O O
KALBITOR NN O O
in NN O O
clinical NN O O
studies NN O O
, NN O O
10 NN O O
patients NN O O
( NN O O
4 NN O O
% NN O O
) NN O O
experienced NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
For NN O O
the NN O O
subgroup NN O O
of NN O O
187 NN O O
patients NN O O
treated NN O O
with NN O O
subcutaneous NN O O
KALBITOR NN O O
, NN O O
5 NN O O
patients NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
experienced NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
Symptoms NN O O
associated NN O O
with NN O O
these NN O O
reactions NN O O
have NN O O
included NN O O
chest NN B-AdverseReaction B-AdverseReaction
discomfort NN I-AdverseReaction I-AdverseReaction
flushing NN B-AdverseReaction B-AdverseReaction
pharyngeal NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
pruritus NN B-AdverseReaction B-AdverseReaction
rhinorrhea NN B-AdverseReaction B-AdverseReaction
sneezing NN B-AdverseReaction B-AdverseReaction
nasal NN B-AdverseReaction B-AdverseReaction
congestion NN I-AdverseReaction I-AdverseReaction
throat NN B-AdverseReaction B-AdverseReaction
irritation NN I-AdverseReaction I-AdverseReaction
urticaria NN B-AdverseReaction B-AdverseReaction
wheezing NN B-AdverseReaction B-AdverseReaction
and NN O O
hypotension NN B-AdverseReaction B-AdverseReaction
These NN O O
reactions NN O O
occurred NN O O
within NN O O
the NN O O
first NN O O
hour NN O O
after NN O O
dosing NN O O
. NN O O
Other NN O O
adverse NN O O
reactions NN O O
indicative NN O O
of NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN O O
included NN O O
the NN O O
following NN O O
: NN O O
pruritus NN B-AdverseReaction B-AdverseReaction
( NN O O
5 NN O O
% NN O O
) NN O O
, NN O O
rash NN B-AdverseReaction B-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
urticaria NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
. NN O O
Patients NN O O
should NN O O
be NN O O
observed NN O O
for NN O O
an NN O O
appropriate NN O O
period NN O O
of NN O O
time NN O O
after NN O O
administration NN O O
of NN O O
KALBITOR NN O O
, NN O O
taking NN O O
into NN O O
account NN O O
the NN O O
time NN O O
to NN O O
onset NN O O
of NN O O
anaphylaxis NN O O
seen NN O O
in NN O O
clinical NN O O
trials NN O O
. NN O O
Given NN O O
the NN O O
similarity NN O O
in NN O O
hypersensitivity NN O O
symptoms NN O O
and NN O O
acute NN O O
HAE NN O O
symptoms NN O O
, NN O O
patients NN O O
should NN O O
be NN O O
monitored NN O O
closely NN O O
in NN O O
the NN O O
event NN O O
of NN O O
a NN O O
hypersensitivity NN O O
reaction NN O O
. NN O O
KALBITOR NN O O
should NN O O
not NN O O
be NN O O
administered NN O O
to NN O O
any NN O O
patients NN O O
with NN O O
known NN O O
clinical NN O O
hypersensitivity NN O O
to NN O O
KALBITOR NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
] NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
See NN O O
the NN O O
peginterferon NN O O
alfa NN O O
and NN O O
ribavirin NN O O
prescribing NN O O
information NN O O
for NN O O
description NN O O
of NN O O
adverse NN O O
reactions NN O O
associated NN O O
with NN O O
their NN O O
use NN O O
. NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
commonly NN O O
reported NN O O
adverse NN O O
reactions NN O O
( NN O O
greater NN O O
than NN O O
35 NN O O
% NN O O
of NN O O
subjects NN O O
) NN O O
in NN O O
clinical NN O O
trials NN O O
in NN O O
adult NN O O
subjects NN O O
receiving NN O O
the NN O O
combination NN O O
of NN O O
VICTRELIS NN O O
with NN O O
PegIntron NN O O
and NN O O
REBETOL NN O O
were NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
anemia NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
and NN O O
dysgeusia NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Merck NN O O
Sharp NN O O
& NN O O
Dohme NN O O
Corp. NN O O
, NN O O
a NN O O
subsidiary NN O O
of NN O O
Merck NN O O
& NN O O
Co. NN O O
, NN O O
Inc. NN O O
, NN O O
at NN O O
1 NN O O
- NN O O
877 NN O O
- NN O O
888 NN O O
- NN O O
4231 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
trials NN O O
of NN O O
VICTRELIS NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
The NN O O
following NN O O
serious NN O O
and NN O O
otherwise NN O O
important NN O O
adverse NN O O
drug NN O O
reactions NN O O
( NN O O
ADRs NN O O
) NN O O
are NN O O
discussed NN O O
in NN O O
detail NN O O
in NN O O
another NN O O
section NN O O
of NN O O
the NN O O
labeling NN O O
: NN O O
* NN O O
Anemia NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
Neutropenia NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
* NN O O
Pancytopenia NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
* NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
and NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
The NN O O
most NN O O
commonly NN O O
reported NN O O
adverse NN O O
reactions NN O O
( NN O O
more NN O O
than NN O O
35 NN O O
% NN O O
of NN O O
subjects NN O O
regardless NN O O
of NN O O
investigator NN O O
's NN O O
causality NN O O
assessment NN O O
) NN O O
in NN O O
adult NN O O
subjects NN O O
were NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
anemia NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
and NN O O
dysgeusia NN B-AdverseReaction B-AdverseReaction
when NN O O
VICTRELIS NN O O
was NN O O
used NN O O
in NN O O
combination NN O O
with NN O O
PegIntron NN O O
and NN O O
REBETOL. NN O O
The NN O O
safety NN O O
of NN O O
the NN O O
combination NN O O
of NN O O
VICTRELIS NN O O
800 NN O O
mg NN O O
three NN O O
times NN O O
daily NN O O
with NN O O
PegIntron/REBETOL NN O O
was NN O O
assessed NN O O
in NN O O
2095 NN O O
subjects NN O O
with NN O O
chronic NN O O
hepatitis NN O O
C NN O O
in NN O O
one NN O O
Phase NN O O
2 NN O O
, NN O O
open NN O O
- NN O O
label NN O O
trial NN O O
and NN O O
two NN O O
Phase NN O O
3 NN O O
, NN O O
randomized NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
clinical NN O O
trials NN O O
. NN O O
SPRINT-1 NN O O
( NN O O
subjects NN O O
who NN O O
were NN O O
previously NN O O
untreated NN O O
) NN O O
evaluated NN O O
the NN O O
use NN O O
of NN O O
VICTRELIS NN O O
in NN O O
combination NN O O
with NN O O
PegIntron/REBETOL NN O O
with NN O O
or NN O O
without NN O O
a NN O O
four NN O O
- NN O O
week NN O O
lead NN O O
- NN O O
in NN O O
period NN O O
with NN O O
PegIntron/REBETOL NN O O
compared NN O O
to NN O O
PegIntron/REBETOL NN O O
alone NN O O
. NN O O
SPRINT-2 NN O O
( NN O O
subjects NN O O
who NN O O
were NN O O
previously NN O O
untreated NN O O
) NN O O
and NN O O
RESPOND-2 NN O O
( NN O O
subjects NN O O
who NN O O
had NN O O
failed NN O O
previous NN O O
therapy NN O O
) NN O O
evaluated NN O O
the NN O O
use NN O O
of NN O O
VICTRELIS NN O O
800 NN O O
mg NN O O
three NN O O
times NN O O
daily NN O O
in NN O O
combination NN O O
with NN O O
PegIntron/REBETOL NN O O
with NN O O
a NN O O
four NN O O
- NN O O
week NN O O
lead NN O O
- NN O O
in NN O O
period NN O O
with NN O O
PegIntron/REBETOL NN O O
compared NN O O
to NN O O
PegIntron/REBETOL NN O O
alone NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
population NN O O
studied NN O O
had NN O O
a NN O O
mean NN O O
age NN O O
of NN O O
49 NN O O
years NN O O
( NN O O
3 NN O O
% NN O O
of NN O O
subjects NN O O
were NN O O
older NN O O
than NN O O
65 NN O O
years NN O O
of NN O O
age NN O O
) NN O O
, NN O O
39 NN O O
% NN O O
were NN O O
female NN O O
, NN O O
82 NN O O
% NN O O
were NN O O
white NN O O
and NN O O
15 NN O O
% NN O O
were NN O O
black NN O O
. NN O O
During NN O O
the NN O O
four NN O O
week NN O O
lead NN O O
- NN O O
in NN O O
period NN O O
with NN O O
PegIntron/REBETOL NN O O
in NN O O
subjects NN O O
treated NN O O
with NN O O
the NN O O
combination NN O O
of NN O O
VICTRELIS NN O O
with NN O O
PegIntron/REBETOL NN O O
, NN O O
28/1263 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
subjects NN O O
experienced NN O O
adverse NN O O
reactions NN O O
leading NN O O
to NN O O
discontinuation NN O O
of NN O O
treatment NN O O
. NN O O
During NN O O
the NN O O
entire NN O O
course NN O O
of NN O O
treatment NN O O
, NN O O
the NN O O
proportion NN O O
of NN O O
subjects NN O O
who NN O O
discontinued NN O O
treatment NN O O
due NN O O
to NN O O
adverse NN O O
reactions NN O O
was NN O O
13 NN O O
% NN O O
for NN O O
subjects NN O O
receiving NN O O
the NN O O
combination NN O O
of NN O O
VICTRELIS NN O O
with NN O O
PegIntron/REBETOL NN O O
and NN O O
12 NN O O
% NN O O
for NN O O
subjects NN O O
receiving NN O O
PegIntron/REBETOL NN O O
alone NN O O
. NN O O
Events NN O O
resulting NN O O
in NN O O
discontinuation NN O O
were NN O O
similar NN O O
to NN O O
those NN O O
seen NN O O
in NN O O
previous NN O O
studies NN O O
with NN O O
PegIntron/REBETOL. NN O O
Only NN O O
anemia NN B-AdverseReaction B-AdverseReaction
and NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
were NN O O
reported NN O O
as NN O O
events NN O O
that NN O O
led NN O O
to NN O O
discontinuation NN O O
in NN O O
more NN O O
than NN O O
1 NN O O
% NN O O
of NN O O
subjects NN O O
in NN O O
any NN O O
arm NN O O
. NN O O
Adverse NN O O
reactions NN O O
that NN O O
led NN O O
to NN O O
dose NN O O
modifications NN O O
of NN O O
any NN O O
drug NN O O
( NN O O
primarily NN O O
PegIntron NN O O
and NN O O
REBETOL NN O O
) NN O O
occurred NN O O
in NN O O
39 NN O O
% NN O O
of NN O O
subjects NN O O
receiving NN O O
the NN O O
combination NN O O
of NN O O
VICTRELIS NN O O
with NN O O
PegIntron/REBETOL NN O O
compared NN O O
to NN O O
24 NN O O
% NN O O
of NN O O
subjects NN O O
receiving NN O O
PegIntron/REBETOL NN O O
alone NN O O
. NN O O
The NN O O
most NN O O
common NN O O
reason NN O O
for NN O O
dose NN O O
reduction NN O O
was NN O O
anemia NN B-AdverseReaction B-AdverseReaction
which NN O O
occurred NN O O
more NN O O
frequently NN O O
in NN O O
subjects NN O O
receiving NN O O
the NN O O
combination NN O O
of NN O O
VICTRELIS NN O O
with NN O O
PegIntron/REBETOL NN O O
than NN O O
in NN O O
subjects NN O O
receiving NN O O
PegIntron/REBETOL NN O O
alone NN O O
. NN O O
Serious NN O O
adverse NN O O
events NN O O
were NN O O
reported NN O O
in NN O O
11 NN O O
% NN O O
of NN O O
subjects NN O O
receiving NN O O
the NN O O
combination NN O O
of NN O O
VICTRELIS NN O O
with NN O O
PegIntron/REBETOL NN O O
and NN O O
in NN O O
8 NN O O
% NN O O
of NN O O
subjects NN O O
receiving NN O O
PegIntron/REBETOL. NN O O
Adverse NN O O
events NN O O
( NN O O
regardless NN O O
of NN O O
investigator NN O O
's NN O O
causality NN O O
assessment NN O O
) NN O O
reported NN O O
in NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
10 NN O O
% NN O O
of NN O O
subjects NN O O
receiving NN O O
the NN O O
combination NN O O
of NN O O
VICTRELIS NN O O
with NN O O
PegIntron/REBETOL NN O O
and NN O O
reported NN O O
at NN O O
a NN O O
rate NN O O
of NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
5 NN O O
% NN O O
than NN O O
PegIntron/REBETOL NN O O
alone NN O O
in NN O O
SPRINT-1 NN O O
, NN O O
SPRINT-2 NN O O
, NN O O
and NN O O
RESPOND-2 NN O O
are NN O O
presented NN O O
in NN O O
Table NN O O
3 NN O O
. NN O O
Table NN O O
3 NN O O
Adverse NN O O
Events NN O O
Reported NN O O
in NN O O
>=10 NN O O
% NN O O
of NN O O
Subjects NN O O
Receiving NN O O
the NN O O
Combination NN O O
of NN O O
VICTRELIS NN O O
with NN O O
PegIntron/REBETOL NN O O
and NN O O
Reported NN O O
at NN O O
a NN O O
Rate NN O O
of NN O O
>=5 NN O O
% NN O O
than NN O O
PegIntron/REBETOL NN O O
alone NN O O
Adverse NN O O
Events NN O O
Previously NN O O
Untreated(SPRINT-1 NN O O
and NN O O
SPRINT-2 NN O O
) NN O O
Previous NN O O
Treatment NN O O
Failures(RESPOND-2 NN O O
) NN O O
Percentage NN O O
of NN O O
Subjects NN O O
Reporting NN O O
Adverse NN O O
Events NN O O
Percentage NN O O
of NN O O
Subjects NN O O
Reporting NN O O
Adverse NN O O
Events NN O O
Body NN O O
System NN O O
Organ NN O O
Class NN O O
VICTRELIS NN O O
+ NN O O
PegIntron NN O O
+ NN O O
REBETOL(n=1225 NN O O
) NN O O
PegIntron NN O O
+ NN O O
REBETOL(n=467 NN O O
) NN O O
VICTRELIS NN O O
+ NN O O
PegIntron NN O O
+ NN O O
REBETOL(n=323 NN O O
) NN O O
PegIntron NN O O
+ NN O O
REBETOL(n=80 NN O O
) NN O O
Median NN O O
Exposure NN O O
( NN O O
days NN O O
) NN O O
197 NN O O
216 NN O O
253 NN O O
104 NN O O
Blood NN O O
and NN O O
Lymphatic NN O O
System NN O O
Disorders NN O O
Anemia NN B-AdverseReaction B-AdverseReaction
50 NN O O
30 NN O O
45 NN O O
20 NN O O
Neutropenia NN B-AdverseReaction B-AdverseReaction
25 NN O O
19 NN O O
14 NN O O
10 NN O O
Gastrointestinal NN O O
Disorders NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
46 NN O O
42 NN O O
43 NN O O
38 NN O O
Dysgeusia NN B-AdverseReaction B-AdverseReaction
35 NN O O
16 NN O O
44 NN O O
11 NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
25 NN O O
22 NN O O
24 NN O O
16 NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
20 NN O O
13 NN O O
15 NN O O
8 NN O O
Dry NN B-AdverseReaction B-AdverseReaction
Mouth NN I-AdverseReaction I-AdverseReaction
11 NN O O
10 NN O O
15 NN O O
9 NN O O
General NN O O
Disorders NN O O
and NN O O
Administration NN O O
Site NN O O
Conditions NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
58 NN O O
59 NN O O
55 NN O O
50 NN O O
Chills NN B-AdverseReaction B-AdverseReaction
34 NN O O
29 NN O O
33 NN O O
30 NN O O
Asthenia NN B-AdverseReaction B-AdverseReaction
15 NN O O
18 NN O O
21 NN O O
16 NN O O
Metabolism NN O O
and NN O O
Nutrition NN O O
Disorders NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
Appetite NN I-AdverseReaction I-AdverseReaction
25 NN O O
24 NN O O
26 NN O O
16 NN O O
Musculoskeletal NN O O
and NN O O
Connective NN O O
Tissue NN O O
Disorders NN O O
Arthralgia NN B-AdverseReaction B-AdverseReaction
19 NN O O
19 NN O O
23 NN O O
16 NN O O
Nervous NN O O
System NN O O
Disorders NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
19 NN O O
16 NN O O
16 NN O O
10 NN O O
Psychiatric NN O O
Disorders NN O O
Insomnia NN B-AdverseReaction B-AdverseReaction
34 NN O O
34 NN O O
30 NN O O
24 NN O O
Irritability NN B-AdverseReaction B-AdverseReaction
22 NN O O
23 NN O O
21 NN O O
13 NN O O
Respiratory NN O O
, NN O O
Thoracic NN O O
, NN O O
and NN O O
Mediastinal NN O O
Disorders NN O O
Dyspnea NN B-AdverseReaction B-AdverseReaction
Exertional NN I-AdverseReaction I-AdverseReaction
8 NN O O
8 NN O O
11 NN O O
5 NN O O
Skin NN O O
and NN O O
Subcutaneous NN O O
Tissue NN O O
Disorders NN O O
Alopecia NN B-AdverseReaction B-AdverseReaction
27 NN O O
27 NN O O
22 NN O O
16 NN O O
Dry NN B-AdverseReaction B-AdverseReaction
Skin NN I-AdverseReaction I-AdverseReaction
18 NN O O
18 NN O O
22 NN O O
9 NN O O
Rash NN B-AdverseReaction B-AdverseReaction
17 NN O O
19 NN O O
16 NN O O
6 NN O O
Other NN O O
Important NN O O
Adverse NN O O
Reactions NN O O
Reported NN O O
in NN O O
Clinical NN O O
Trials NN O O
Among NN O O
subjects NN O O
( NN O O
previously NN O O
untreated NN O O
subjects NN O O
or NN O O
those NN O O
who NN O O
failed NN O O
previous NN O O
therapy NN O O
) NN O O
who NN O O
received NN O O
VICTRELIS NN O O
in NN O O
combination NN O O
with NN O O
peginterferon NN O O
alfa NN O O
and NN O O
ribavirin NN O O
, NN O O
the NN O O
following NN O O
adverse NN O O
drug NN O O
reactions NN O O
were NN O O
reported NN O O
. NN O O
These NN O O
events NN O O
are NN O O
notable NN O O
because NN O O
of NN O O
their NN O O
seriousness NN O O
, NN O O
severity NN O O
, NN O O
or NN O O
increased NN O O
frequency NN O O
in NN O O
subjects NN O O
who NN O O
received NN O O
VICTRELIS NN O O
in NN O O
combination NN O O
with NN O O
peginterferon NN O O
alfa NN O O
and NN O O
ribavirin NN O O
compared NN O O
with NN O O
subjects NN O O
who NN O O
received NN O O
only NN O O
peginterferon NN O O
alfa NN O O
and NN O O
ribavirin NN O O
. NN O O
Gastrointestinal NN O O
Disorders NN O O
Dysgeusia NN B-AdverseReaction B-AdverseReaction
( NN O O
alteration NN O O
of NN O O
taste NN O O
) NN O O
was NN O O
an NN O O
adverse NN O O
event NN O O
reported NN O O
at NN O O
an NN O O
increased NN O O
frequency NN O O
in NN O O
subjects NN O O
receiving NN O O
VICTRELIS NN O O
in NN O O
combination NN O O
with NN O O
peginterferon NN O O
alfa NN O O
and NN O O
ribavirin NN O O
compared NN O O
with NN O O
subjects NN O O
receiving NN O O
peginterferon NN O O
alfa NN O O
and NN O O
ribavirin NN O O
alone NN O O
( NN O O
Table NN O O
3 NN O O
) NN O O
. NN O O
Adverse NN O O
events NN O O
such NN O O
as NN O O
dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
and NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
were NN O O
also NN O O
reported NN O O
at NN O O
an NN O O
increased NN O O
frequency NN O O
in NN O O
subjects NN O O
receiving NN O O
VICTRELIS NN O O
in NN O O
combination NN O O
with NN O O
peginterferon NN O O
alfa NN O O
and NN O O
ribavirin NN O O
. NN O O
Laboratory NN O O
Values NN O O
Changes NN O O
in NN O O
selected NN O O
hematological NN O O
parameters NN O O
during NN O O
treatment NN O O
of NN O O
adult NN O O
subjects NN O O
with NN O O
the NN O O
combination NN O O
of NN O O
VICTRELIS NN O O
with NN O O
PegIntron NN O O
and NN O O
REBETOL NN O O
are NN O O
described NN O O
in NN O O
Table NN O O
4 NN O O
. NN O O
Hemoglobin NN O O
Decreases NN O O
in NN O O
hemoglobin NN O O
may NN O O
require NN O O
a NN O O
decrease NN O O
in NN O O
dosage NN O O
or NN O O
discontinuation NN O O
of NN O O
ribavirin NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
and NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
[ NN O O
see NN O O
prescribing NN O O
information NN O O
for NN O O
ribavirin NN O O
] NN O O
. NN O O
If NN O O
ribavirin NN O O
is NN O O
permanently NN O O
discontinued NN O O
, NN O O
then NN O O
peginterferon NN O O
alfa NN O O
and NN O O
VICTRELIS NN O O
must NN O O
also NN O O
be NN O O
discontinued NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
] NN O O
. NN O O
Neutrophils NN O O
and NN O O
Platelets NN O O
The NN O O
proportion NN O O
of NN O O
subjects NN O O
with NN O O
decreased NN O O
neutrophil NN O O
and NN O O
platelet NN O O
counts NN O O
was NN O O
higher NN O O
in NN O O
subjects NN O O
treated NN O O
with NN O O
VICTRELIS NN O O
in NN O O
combination NN O O
with NN O O
PegIntron/REBETOL NN O O
compared NN O O
to NN O O
subjects NN O O
receiving NN O O
PegIntron/REBETOL NN O O
alone NN O O
. NN O O
Three NN O O
percent NN O O
of NN O O
subjects NN O O
receiving NN O O
the NN O O
combination NN O O
of NN O O
VICTRELIS NN O O
with NN O O
PegIntron/REBETOL NN O O
had NN O O
platelet NN B-AdverseReaction B-AdverseReaction
counts NN I-AdverseReaction I-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
less NN I-AdverseReaction I-AdverseReaction
than NN I-AdverseReaction I-AdverseReaction
50 NN I-AdverseReaction I-AdverseReaction
* NN I-AdverseReaction I-AdverseReaction
10 NN I-AdverseReaction I-AdverseReaction
9 NN I-AdverseReaction I-AdverseReaction
per NN I-AdverseReaction I-AdverseReaction
L NN I-AdverseReaction I-AdverseReaction
compared NN O O
to NN O O
1 NN O O
% NN O O
of NN O O
subjects NN O O
receiving NN O O
PegIntron/REBETOL NN O O
alone NN O O
. NN O O
Decreases NN O O
in NN O O
neutrophils NN O O
or NN O O
platelets NN O O
may NN O O
require NN O O
a NN O O
decrease NN O O
in NN O O
dosage NN O O
or NN O O
interruption NN O O
of NN O O
peginterferon NN O O
alfa NN O O
, NN O O
or NN O O
discontinuation NN O O
of NN O O
therapy NN O O
[ NN O O
see NN O O
prescribing NN O O
information NN O O
for NN O O
peginterferon NN O O
alfa NN O O
and NN O O
ribavirin NN O O
] NN O O
. NN O O
If NN O O
peginterferon NN O O
alfa NN O O
is NN O O
permanently NN O O
discontinued NN O O
, NN O O
then NN O O
ribavirin NN O O
and NN O O
VICTRELIS NN O O
must NN O O
also NN O O
be NN O O
discontinued NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
] NN O O
. NN O O
Table NN O O
4 NN O O
Selected NN O O
Hematological NN O O
Parameters NN O O
Previously NN O O
Untreated(SPRINT-1 NN O O
and NN O O
SPRINT-2 NN O O
) NN O O
Previous NN O O
Treatment NN O O
Failures(RESPOND-2 NN O O
) NN O O
Percentage NN O O
of NN O O
Subjects NN O O
Reporting NN O O
Selected NN O O
Hematological NN O O
Parameters NN O O
Percentage NN O O
of NN O O
Subjects NN O O
Reporting NN O O
Selected NN O O
Hematological NN O O
Parameters NN O O
Hematological NN O O
Parameters NN O O
VICTRELIS NN O O
+ NN O O
PegIntron NN O O
+ NN O O
REBETOL(n=1225 NN O O
) NN O O
PegIntron NN O O
+ NN O O
REBETOL(n=467 NN O O
) NN O O
VICTRELIS NN O O
+ NN O O
PegIntron NN O O
+ NN O O
REBETOL(n=323 NN O O
) NN O O
PegIntron NN O O
+ NN O O
REBETOL(n=80 NN O O
) NN O O
Hemoglobin NN B-AdverseReaction B-AdverseReaction
( NN I-AdverseReaction I-AdverseReaction
g/dL NN I-AdverseReaction I-AdverseReaction
) NN I-AdverseReaction I-AdverseReaction
< NN I-AdverseReaction I-AdverseReaction
10 NN I-AdverseReaction I-AdverseReaction
49 NN O O
29 NN O O
49 NN O O
25 NN O O
< NN O O
8.5 NN O O
6 NN O O
3 NN O O
10 NN O O
1 NN O O
Neutrophils NN B-AdverseReaction B-AdverseReaction
( NN I-AdverseReaction I-AdverseReaction
* NN I-AdverseReaction I-AdverseReaction
10 NN I-AdverseReaction I-AdverseReaction
9 NN I-AdverseReaction I-AdverseReaction
/L NN I-AdverseReaction I-AdverseReaction
) NN I-AdverseReaction I-AdverseReaction
< NN I-AdverseReaction I-AdverseReaction
0.75 NN I-AdverseReaction I-AdverseReaction
31 NN O O
18 NN O O
26 NN O O
13 NN O O
< NN O O
0.5 NN O O
8 NN O O
4 NN O O
7 NN O O
4 NN O O
Platelets NN B-AdverseReaction B-AdverseReaction
( NN I-AdverseReaction I-AdverseReaction
* NN I-AdverseReaction I-AdverseReaction
10 NN I-AdverseReaction I-AdverseReaction
9 NN I-AdverseReaction I-AdverseReaction
/L NN I-AdverseReaction I-AdverseReaction
) NN I-AdverseReaction I-AdverseReaction
< NN I-AdverseReaction I-AdverseReaction
50 NN I-AdverseReaction I-AdverseReaction
3 NN O O
1 NN O O
4 NN O O
0 NN O O
< NN O O
25 NN O O
< NN O O
1 NN O O
0 NN O O
0 NN O O
0 NN O O
6.2 NN O O
Postmarketing NN O O
Experience NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
identified NN O O
during NN O O
post NN O O
- NN O O
approval NN O O
use NN O O
of NN O O
VICTRELIS NN O O
in NN O O
combination NN O O
with NN O O
peginterferon NN O O
alfa NN O O
and NN O O
ribavirin NN O O
. NN O O
Because NN O O
these NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
Blood NN O O
and NN O O
Lymphatic NN O O
System NN O O
Disorders NN O O
: NN O O
agranulocytosis NN B-AdverseReaction B-AdverseReaction
pancytopenia NN B-AdverseReaction B-AdverseReaction
, NN O O
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
Gastrointestinal NN O O
Disorders NN O O
: NN O O
mouth NN B-AdverseReaction B-AdverseReaction
ulceration NN I-AdverseReaction I-AdverseReaction
stomatitis NN B-AdverseReaction B-AdverseReaction
Infections NN O O
and NN O O
Infestations NN O O
: NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
sepsis NN B-AdverseReaction B-AdverseReaction
Skin NN O O
and NN O O
Subcutaneous NN O O
Tissue NN O O
Disorders NN O O
: NN O O
angioedema NN B-AdverseReaction B-AdverseReaction
urticaria NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
; NN O O
drug NN O O
rash NN O O
with NN O O
eosinophilia NN O O
and NN O O
systemic NN O O
symptoms NN O O
( NN O O
DRESS NN O O
) NN O O
syndrome NN O O
, NN O O
exfoliative NN B-AdverseReaction B-AdverseReaction
rash NN I-AdverseReaction I-AdverseReaction
exfoliative NN B-AdverseReaction B-AdverseReaction
dermatitis NN I-AdverseReaction I-AdverseReaction
Stevens NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Johnson NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
toxic NN B-AdverseReaction B-AdverseReaction
skin NN I-AdverseReaction I-AdverseReaction
eruption NN I-AdverseReaction I-AdverseReaction
toxicoderma NN B-AdverseReaction B-AdverseReaction
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
Use NN O O
of NN O O
VICTRELIS NN O O
with NN O O
Ribavirin NN O O
and NN O O
Peginterferon NN O O
alfa NN O O
: NN O O
* NN O O
Embryofetal NN B-AdverseReaction B-AdverseReaction
Toxicity NN I-AdverseReaction I-AdverseReaction
( NN O O
Use NN O O
with NN O O
Ribavirin NN O O
and NN O O
Peginterferon NN O O
Alfa NN O O
) NN O O
: NN O O
Ribavirin NN O O
may NN B-Factor B-Factor
cause NN O O
birth NN B-AdverseReaction B-AdverseReaction
defects NN I-AdverseReaction I-AdverseReaction
and NN O O
fetal NN B-AdverseReaction B-AdverseReaction
death NN I-AdverseReaction I-AdverseReaction
avoid NN O O
pregnancy NN O O
in NN O O
female NN O O
patients NN O O
and NN O O
female NN O O
partners NN O O
of NN O O
male NN O O
patients NN O O
. NN O O
Patients NN O O
must NN O O
have NN O O
a NN O O
negative NN O O
pregnancy NN O O
test NN O O
prior NN O O
to NN O O
therapy NN O O
; NN O O
use NN O O
two NN O O
or NN O O
more NN O O
forms NN O O
of NN O O
contraception NN O O
, NN O O
and NN O O
have NN O O
monthly NN O O
pregnancy NN O O
tests NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Anemia NN B-AdverseReaction B-AdverseReaction
- NN O O
The NN O O
addition NN O O
of NN O O
VICTRELIS NN O O
to NN O O
peginterferon NN O O
alfa NN O O
and NN O O
ribavirin NN O O
is NN O O
associated NN O O
with NN O O
an NN O O
additional NN O O
decrease NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
hemoglobin NN I-AdverseReaction I-AdverseReaction
concentrations NN I-AdverseReaction I-AdverseReaction
compared NN O O
with NN O O
peginterferon NN O O
alfa NN O O
and NN O O
ribavirin NN O O
alone NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Neutropenia NN B-AdverseReaction B-AdverseReaction
- NN O O
The NN O O
addition NN O O
of NN O O
VICTRELIS NN O O
to NN O O
peginterferon NN O O
alfa NN O O
and NN O O
ribavirin NN O O
may NN B-Factor B-Factor
result NN O O
in NN O O
worsening NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
neutropenia NN I-AdverseReaction I-AdverseReaction
associated NN O O
with NN O O
peginterferon NN O O
alfa NN O O
and NN O O
ribavirin NN O O
therapy NN O O
alone NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
- NN O O
Serious NN B-Severity B-Severity
acute NN B-AdverseReaction B-AdverseReaction
hypersensitivity NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
( NN O O
e.g. NN O O
, NN O O
urticaria NN B-AdverseReaction B-AdverseReaction
angioedema NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
observed NN O O
during NN O O
combination NN O O
therapy NN O O
with NN O O
VICTRELIS NN O O
, NN O O
peginterferon NN O O
alfa NN O O
and NN O O
ribavirin NN O O
. NN O O
( NN O O
5.5 NN O O
) NN O O
5.1 NN O O
Embryofetal NN O O
Toxicity NN O O
( NN O O
Use NN O O
with NN O O
Ribavirin NN O O
and NN O O
Peginterferon NN O O
Alfa NN O O
) NN O O
Ribavirin NN O O
may NN B-Factor B-Factor
cause NN O O
birth NN B-AdverseReaction B-AdverseReaction
defects NN I-AdverseReaction I-AdverseReaction
and/or NN O O
death NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
exposed NN I-AdverseReaction I-AdverseReaction
fetus NN I-AdverseReaction I-AdverseReaction
Extreme NN O O
care NN O O
must NN O O
be NN O O
taken NN O O
to NN O O
avoid NN O O
pregnancy NN O O
in NN O O
female NN O O
patients NN O O
and NN O O
in NN O O
female NN O O
partners NN O O
of NN O O
male NN O O
patients NN O O
. NN O O
Ribavirin NN O O
therapy NN O O
should NN O O
not NN O O
be NN O O
started NN O O
unless NN O O
a NN O O
report NN O O
of NN O O
a NN O O
negative NN O O
pregnancy NN O O
test NN O O
has NN O O
been NN O O
obtained NN O O
immediately NN O O
prior NN O O
to NN O O
initiation NN O O
of NN O O
therapy NN O O
. NN O O
Refer NN O O
to NN O O
the NN O O
prescribing NN O O
information NN O O
for NN O O
ribavirin NN O O
for NN O O
additional NN O O
information NN O O
. NN O O
Women NN O O
of NN O O
childbearing NN O O
potential NN O O
and NN O O
men NN O O
must NN O O
use NN O O
at NN O O
least NN O O
two NN O O
forms NN O O
of NN O O
effective NN O O
contraception NN O O
during NN O O
treatment NN O O
and NN O O
for NN O O
at NN O O
least NN O O
6 NN O O
months NN O O
after NN O O
treatment NN O O
has NN O O
concluded NN O O
. NN O O
One NN O O
of NN O O
these NN O O
forms NN O O
of NN O O
contraception NN O O
can NN O O
be NN O O
a NN O O
combined NN O O
oral NN O O
contraceptive NN O O
product NN O O
containing NN O O
at NN O O
least NN O O
1 NN O O
mg NN O O
of NN O O
norethindrone NN O O
. NN O O
Oral NN O O
contraceptives NN O O
containing NN O O
lower NN O O
doses NN O O
of NN O O
norethindrone NN O O
and NN O O
other NN O O
forms NN O O
of NN O O
hormonal NN O O
contraception NN O O
have NN O O
not NN O O
been NN O O
studied NN O O
or NN O O
are NN O O
contraindicated NN O O
. NN O O
Routine NN O O
monthly NN O O
pregnancy NN O O
tests NN O O
must NN O O
be NN O O
performed NN O O
during NN O O
this NN O O
time NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
and NN O O
Drug NN O O
Interactions NN O O
( NN O O
7 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
Anemia NN O O
( NN O O
Use NN O O
with NN O O
Ribavirin NN O O
and NN O O
Peginterferon NN O O
Alfa NN O O
) NN O O
Anemia NN B-AdverseReaction B-AdverseReaction
has NN O O
been NN O O
reported NN O O
with NN O O
peginterferon NN O O
alfa NN O O
and NN O O
ribavirin NN O O
therapy NN O O
. NN O O
The NN O O
addition NN O O
of NN O O
VICTRELIS NN O O
to NN O O
peginterferon NN O O
alfa NN O O
and NN O O
ribavirin NN O O
is NN O O
associated NN O O
with NN O O
an NN O O
additional NN B-AdverseReaction B-AdverseReaction
decrease NN I-AdverseReaction I-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
hemoglobin NN I-AdverseReaction I-AdverseReaction
concentrations NN I-AdverseReaction I-AdverseReaction
Complete NN O O
blood NN O O
counts NN O O
( NN O O
with NN O O
white NN O O
blood NN O O
cell NN O O
differential NN O O
counts NN O O
) NN O O
should NN O O
be NN O O
obtained NN O O
pretreatment NN O O
, NN O O
and NN O O
at NN O O
Treatment NN O O
Weeks NN O O
2 NN O O
, NN O O
4 NN O O
, NN O O
8 NN O O
, NN O O
and NN O O
12 NN O O
, NN O O
and NN O O
should NN O O
be NN O O
monitored NN O O
closely NN O O
at NN O O
other NN O O
time NN O O
points NN O O
, NN O O
as NN O O
clinically NN O O
appropriate NN O O
. NN O O
If NN O O
hemoglobin NN O O
is NN O O
less NN O O
than NN O O
10 NN O O
g NN O O
per NN O O
dL NN O O
, NN O O
a NN O O
decrease NN O O
in NN O O
dosage NN O O
of NN O O
ribavirin NN O O
is NN O O
recommended NN O O
; NN O O
and NN O O
if NN O O
hemoglobin NN O O
is NN O O
less NN O O
than NN O O
8.5 NN O O
g NN O O
per NN O O
dL NN O O
, NN O O
discontinuation NN O O
of NN O O
ribavirin NN O O
is NN O O
recommended NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
and NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
. NN O O
If NN O O
ribavirin NN O O
is NN O O
permanently NN O O
discontinued NN O O
for NN O O
management NN O O
of NN O O
anemia NN O O
, NN O O
then NN O O
peginterferon NN O O
alfa NN O O
and NN O O
VICTRELIS NN O O
must NN O O
also NN O O
be NN O O
discontinued NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
] NN O O
. NN O O
Refer NN O O
to NN O O
the NN O O
prescribing NN O O
information NN O O
for NN O O
ribavirin NN O O
for NN O O
additional NN O O
information NN O O
regarding NN O O
dose NN O O
reduction NN O O
and/or NN O O
discontinuation NN O O
. NN O O
In NN O O
clinical NN O O
trials NN O O
with NN O O
VICTRELIS NN O O
, NN O O
the NN O O
proportion NN O O
of NN O O
subjects NN O O
who NN O O
experienced NN O O
hemoglobin NN B-AdverseReaction B-AdverseReaction
values NN I-AdverseReaction I-AdverseReaction
less NN I-AdverseReaction I-AdverseReaction
than NN I-AdverseReaction I-AdverseReaction
10 NN I-AdverseReaction I-AdverseReaction
g NN I-AdverseReaction I-AdverseReaction
per NN I-AdverseReaction I-AdverseReaction
dL NN I-AdverseReaction I-AdverseReaction
and NN O O
less NN O O
than NN O O
8.5 NN O O
g NN O O
per NN O O
dL NN O O
was NN O O
higher NN O O
in NN O O
subjects NN O O
treated NN O O
with NN O O
the NN O O
combination NN O O
of NN O O
VICTRELIS NN O O
with NN O O
PegIntron NN O O
( NN O O
r NN O O
) NN O O
/REBETOL NN O O
( NN O O
r NN O O
) NN O O
than NN O O
in NN O O
those NN O O
treated NN O O
with NN O O
PegIntron/REBETOL NN O O
alone NN O O
( NN O O
see NN O O
Table NN O O
4 NN O O
) NN O O
. NN O O
With NN O O
the NN O O
interventions NN O O
used NN O O
for NN O O
anemia NN O O
management NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
, NN O O
the NN O O
average NN O O
additional NN O O
decrease NN O O
of NN O O
hemoglobin NN O O
was NN O O
approximately NN O O
1 NN O O
g NN O O
per NN O O
dL. NN O O
In NN O O
clinical NN O O
trials NN O O
, NN O O
the NN O O
median NN O O
time NN O O
to NN O O
onset NN O O
of NN O O
hemoglobin NN B-AdverseReaction B-AdverseReaction
less NN I-AdverseReaction I-AdverseReaction
than NN I-AdverseReaction I-AdverseReaction
10 NN I-AdverseReaction I-AdverseReaction
g NN I-AdverseReaction I-AdverseReaction
per NN I-AdverseReaction I-AdverseReaction
dL NN I-AdverseReaction I-AdverseReaction
from NN O O
the NN O O
initiation NN O O
of NN O O
therapy NN O O
was NN O O
similar NN O O
among NN O O
subjects NN O O
treated NN O O
with NN O O
the NN O O
combination NN O O
of NN O O
VICTRELIS NN O O
and NN O O
PegIntron/REBETOL NN O O
( NN O O
71 NN O O
days NN O O
with NN O O
a NN O O
range NN O O
of NN O O
15 NN O O
- NN O O
337 NN O O
days NN O O
) NN O O
, NN O O
compared NN O O
to NN O O
those NN O O
who NN O O
received NN O O
PegIntron/REBETOL NN O O
( NN O O
71 NN O O
days NN O O
with NN O O
a NN O O
range NN O O
of NN O O
8 NN O O
- NN O O
337 NN O O
days NN O O
) NN O O
. NN O O
Certain NN O O
adverse NN O O
reactions NN O O
consistent NN O O
with NN O O
symptoms NN O O
of NN O O
anemia NN B-AdverseReaction B-AdverseReaction
such NN O O
as NN O O
dyspnea NN B-AdverseReaction B-AdverseReaction
exertional NN B-AdverseReaction B-AdverseReaction
dyspnea NN I-AdverseReaction I-AdverseReaction
dizziness NN B-AdverseReaction B-AdverseReaction
and NN O O
syncope NN B-AdverseReaction B-AdverseReaction
were NN O O
reported NN O O
more NN O O
frequently NN O O
in NN O O
subjects NN O O
who NN O O
received NN O O
the NN O O
combination NN O O
of NN O O
VICTRELIS NN O O
with NN O O
PegIntron/REBETOL NN O O
than NN O O
in NN O O
those NN O O
treated NN O O
with NN O O
PegIntron/REBETOL NN O O
alone NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
In NN O O
clinical NN O O
trials NN O O
with NN O O
VICTRELIS NN O O
, NN O O
dose NN O O
modifications NN O O
( NN O O
generally NN O O
of NN O O
PegIntron/REBETOL NN O O
) NN O O
due NN O O
to NN O O
anemia NN B-AdverseReaction B-AdverseReaction
occurred NN O O
twice NN O O
as NN O O
often NN O O
in NN O O
subjects NN O O
treated NN O O
with NN O O
the NN O O
combination NN O O
of NN O O
VICTRELIS NN O O
with NN O O
PegIntron/REBETOL NN O O
( NN O O
26 NN O O
% NN O O
) NN O O
compared NN O O
to NN O O
PegIntron/REBETOL NN O O
( NN O O
13 NN O O
% NN O O
) NN O O
. NN O O
The NN O O
proportion NN O O
of NN O O
subjects NN O O
who NN O O
discontinued NN O O
study NN O O
drug NN O O
due NN O O
to NN O O
anemia NN B-AdverseReaction B-AdverseReaction
was NN O O
1 NN O O
% NN O O
in NN O O
subjects NN O O
treated NN O O
with NN O O
the NN O O
combination NN O O
of NN O O
VICTRELIS NN O O
with NN O O
PegIntron/REBETOL NN O O
and NN O O
1 NN O O
% NN O O
in NN O O
subjects NN O O
who NN O O
received NN O O
PegIntron/REBETOL. NN O O
The NN O O
use NN O O
of NN O O
erythropoiesis NN O O
stimulating NN O O
agents NN O O
( NN O O
ESAs NN O O
) NN O O
was NN O O
permitted NN O O
for NN O O
management NN O O
of NN O O
anemia NN O O
, NN O O
at NN O O
the NN O O
investigator NN O O
's NN O O
discretion NN O O
, NN O O
with NN O O
or NN O O
without NN O O
ribavirin NN O O
dose NN O O
reduction NN O O
in NN O O
the NN O O
Phase NN O O
2 NN O O
and NN O O
3 NN O O
clinical NN O O
trials NN O O
. NN O O
The NN O O
proportion NN O O
of NN O O
subjects NN O O
who NN O O
received NN O O
an NN O O
ESA NN O O
was NN O O
43 NN O O
% NN O O
in NN O O
those NN O O
treated NN O O
with NN O O
the NN O O
combination NN O O
of NN O O
VICTRELIS NN O O
with NN O O
PegIntron/REBETOL NN O O
compared NN O O
to NN O O
24 NN O O
% NN O O
in NN O O
those NN O O
treated NN O O
with NN O O
PegIntron/REBETOL NN O O
alone NN O O
. NN O O
The NN O O
proportion NN O O
of NN O O
subjects NN O O
who NN O O
received NN O O
a NN O O
transfusion NN O O
for NN O O
the NN O O
management NN O O
of NN O O
anemia NN O O
was NN O O
3 NN O O
% NN O O
of NN O O
subjects NN O O
treated NN O O
with NN O O
the NN O O
combination NN O O
of NN O O
VICTRELIS NN O O
with NN O O
PegIntron/REBETOL NN O O
compared NN O O
to NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
in NN O O
subjects NN O O
who NN O O
received NN O O
PegIntron/REBETOL NN O O
alone NN O O
. NN O O
Thromboembolic NN O O
events NN O O
have NN O O
been NN O O
associated NN O O
with NN O O
ESA NN O O
use NN O O
in NN O O
other NN O O
disease NN O O
states NN O O
; NN O O
and NN O O
have NN O O
also NN O O
been NN O O
reported NN O O
with NN O O
peginterferon NN O O
alfa NN O O
use NN O O
in NN O O
hepatitis NN O O
C NN O O
patients NN O O
. NN O O
Thromboembolic NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
in NN O O
clinical NN O O
trials NN O O
with NN O O
VICTRELIS NN O O
among NN O O
subjects NN O O
receiving NN O O
the NN O O
combination NN O O
of NN O O
VICTRELIS NN O O
with NN O O
PegIntron/REBETOL NN O O
, NN O O
and NN O O
among NN O O
those NN O O
receiving NN O O
PegIntron/REBETOL NN O O
alone NN O O
, NN O O
regardless NN O O
of NN O O
ESA NN O O
use NN O O
. NN O O
No NN O O
definite NN O O
causality NN O O
assessment NN O O
or NN O O
benefit NN O O
risk NN O O
assessment NN O O
could NN O O
be NN O O
made NN O O
for NN O O
these NN O O
events NN O O
due NN O O
to NN O O
the NN O O
presence NN O O
of NN O O
confounding NN O O
factors NN O O
and NN O O
lack NN O O
of NN O O
randomization NN O O
of NN O O
ESA NN O O
use NN O O
. NN O O
A NN O O
randomized NN O O
, NN O O
parallel NN O O
- NN O O
arm NN O O
, NN O O
open NN O O
- NN O O
label NN O O
clinical NN O O
trial NN O O
was NN O O
conducted NN O O
in NN O O
previously NN O O
untreated NN O O
CHC NN O O
subjects NN O O
with NN O O
genotype NN O O
1 NN O O
infection NN O O
to NN O O
compare NN O O
use NN O O
of NN O O
an NN O O
ESA NN O O
versus NN O O
ribavirin NN O O
dose NN O O
reduction NN O O
for NN O O
initial NN O O
management NN O O
of NN O O
anemia NN O O
during NN O O
therapy NN O O
with NN O O
VICTRELIS NN O O
in NN O O
combination NN O O
with NN O O
peginterferon NN O O
alfa-2b NN O O
and NN O O
ribavirin NN O O
. NN O O
Similar NN O O
SVR NN O O
rates NN O O
were NN O O
reported NN O O
in NN O O
subjects NN O O
who NN O O
were NN O O
randomized NN O O
to NN O O
receive NN O O
ribavirin NN O O
dose NN O O
reduction NN O O
compared NN O O
to NN O O
subjects NN O O
who NN O O
were NN O O
randomized NN O O
to NN O O
receive NN O O
an NN O O
ESA. NN O O
In NN O O
this NN O O
trial NN O O
, NN O O
use NN O O
of NN O O
ESAs NN O O
was NN O O
associated NN O O
with NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
thromboembolic NN O O
events NN O O
including NN O O
pulmonary NN O O
embolism NN O O
, NN O O
acute NN O O
myocardial NN O O
infarction NN O O
, NN O O
cerebrovascular NN O O
accident NN O O
, NN O O
and NN O O
deep NN O O
vein NN O O
thrombosis NN O O
compared NN O O
to NN O O
ribavirin NN O O
dose NN O O
reduction NN O O
alone NN O O
. NN O O
The NN O O
treatment NN O O
discontinuation NN O O
rate NN O O
due NN O O
to NN O O
anemia NN B-AdverseReaction B-AdverseReaction
was NN O O
similar NN O O
in NN O O
subjects NN O O
randomized NN O O
to NN O O
receive NN O O
ribavirin NN O O
dose NN O O
reduction NN O O
compared NN O O
to NN O O
subjects NN O O
randomized NN O O
to NN O O
receive NN O O
ESA NN O O
( NN O O
2 NN O O
% NN O O
in NN O O
each NN O O
group NN O O
) NN O O
. NN O O
The NN O O
transfusion NN O O
rate NN O O
was NN O O
4 NN O O
% NN O O
in NN O O
subjects NN O O
randomized NN O O
to NN O O
receive NN O O
ribavirin NN O O
dose NN O O
reduction NN O O
and NN O O
2 NN O O
% NN O O
in NN O O
subjects NN O O
randomized NN O O
to NN O O
receive NN O O
ESA. NN O O
Ribavirin NN O O
dose NN O O
reduction NN O O
is NN O O
recommended NN O O
for NN O O
the NN O O
initial NN O O
management NN O O
of NN O O
anemia NN O O
. NN O O
5.3 NN O O
Neutropenia NN O O
( NN O O
Use NN O O
with NN O O
Ribavirin NN O O
and NN O O
Peginterferon NN O O
Alfa NN O O
) NN O O
In NN O O
Phase NN O O
2 NN O O
and NN O O
3 NN O O
clinical NN O O
trials NN O O
, NN O O
seven NN O O
percent NN O O
of NN O O
subjects NN O O
receiving NN O O
the NN O O
combination NN O O
of NN O O
VICTRELIS NN O O
with NN O O
PegIntron/REBETOL NN O O
had NN O O
neutrophil NN B-AdverseReaction B-AdverseReaction
counts NN I-AdverseReaction I-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
less NN I-AdverseReaction I-AdverseReaction
than NN I-AdverseReaction I-AdverseReaction
0.5 NN I-AdverseReaction I-AdverseReaction
* NN I-AdverseReaction I-AdverseReaction
10 NN I-AdverseReaction I-AdverseReaction
9 NN I-AdverseReaction I-AdverseReaction
per NN I-AdverseReaction I-AdverseReaction
L NN I-AdverseReaction I-AdverseReaction
compared NN O O
to NN O O
4 NN O O
% NN O O
of NN O O
subjects NN O O
receiving NN O O
PegIntron/REBETOL NN O O
alone NN O O
( NN O O
see NN O O
Table NN O O
4 NN O O
) NN O O
. NN O O
Three NN O O
subjects NN O O
experienced NN O O
severe NN B-Severity B-Severity
or NN O O
life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
infections NN B-AdverseReaction B-AdverseReaction
associated NN O O
with NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
and NN O O
two NN O O
subjects NN O O
experienced NN O O
life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
neutropenia NN B-AdverseReaction B-AdverseReaction
while NN O O
receiving NN O O
the NN O O
combination NN O O
of NN O O
VICTRELIS NN O O
with NN O O
PegIntron/REBETOL. NN O O
Complete NN O O
blood NN O O
counts NN O O
( NN O O
with NN O O
white NN O O
blood NN O O
cell NN O O
differential NN O O
counts NN O O
) NN O O
should NN O O
be NN O O
obtained NN O O
at NN O O
pretreatment NN O O
, NN O O
and NN O O
at NN O O
Treatment NN O O
Weeks NN O O
2 NN O O
, NN O O
4 NN O O
, NN O O
8 NN O O
, NN O O
and NN O O
12 NN O O
, NN O O
and NN O O
should NN O O
be NN O O
monitored NN O O
closely NN O O
at NN O O
other NN O O
time NN O O
points NN O O
, NN O O
as NN O O
clinically NN O O
appropriate NN O O
. NN O O
Decreases NN O O
in NN O O
neutrophil NN O O
counts NN O O
may NN O O
require NN O O
dose NN O O
reduction NN O O
or NN O O
discontinuation NN O O
of NN O O
peginterferon NN O O
alfa NN O O
and NN O O
ribavirin NN O O
. NN O O
If NN O O
peginterferon NN O O
alfa NN O O
and NN O O
ribavirin NN O O
are NN O O
permanently NN O O
discontinued NN O O
, NN O O
then NN O O
VICTRELIS NN O O
must NN O O
also NN O O
be NN O O
discontinued NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
] NN O O
. NN O O
Refer NN O O
to NN O O
the NN O O
prescribing NN O O
information NN O O
for NN O O
peginterferon NN O O
alfa NN O O
and NN O O
ribavirin NN O O
for NN O O
additional NN O O
information NN O O
regarding NN O O
dose NN O O
reduction NN O O
or NN O O
discontinuation NN O O
. NN O O
5.4 NN O O
Pancytopenia NN O O
( NN O O
Use NN O O
with NN O O
Ribavirin NN O O
and NN O O
Peginterferon NN O O
Alfa NN O O
) NN O O
Serious NN B-Severity B-Severity
cases NN O O
of NN O O
pancytopenia NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
postmarketing NN O O
in NN O O
patients NN O O
receiving NN O O
VICTRELIS NN O O
in NN O O
combination NN O O
with NN O O
peginterferon NN O O
alfa NN O O
and NN O O
ribavirin NN O O
. NN O O
Complete NN O O
blood NN O O
counts NN O O
( NN O O
with NN O O
white NN O O
blood NN O O
cell NN O O
differential NN O O
counts NN O O
) NN O O
should NN O O
be NN O O
obtained NN O O
at NN O O
pretreatment NN O O
, NN O O
and NN O O
at NN O O
Treatment NN O O
Weeks NN O O
2 NN O O
, NN O O
4 NN O O
, NN O O
8 NN O O
, NN O O
and NN O O
12 NN O O
, NN O O
and NN O O
should NN O O
be NN O O
monitored NN O O
closely NN O O
at NN O O
other NN O O
time NN O O
points NN O O
, NN O O
as NN O O
clinically NN O O
appropriate NN O O
. NN O O
Refer NN O O
to NN O O
the NN O O
prescribing NN O O
information NN O O
for NN O O
ribavirin NN O O
and NN O O
peginterferon NN O O
alfa NN O O
for NN O O
guidelines NN O O
for NN O O
discontinuation NN O O
of NN O O
therapy NN O O
based NN O O
on NN O O
laboratory NN O O
parameters NN O O
. NN O O
5.5 NN O O
Hypersensitivity NN O O
Serious NN B-Severity B-Severity
acute NN B-AdverseReaction B-AdverseReaction
hypersensitivity NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
( NN O O
e.g. NN O O
, NN O O
urticaria NN B-AdverseReaction B-AdverseReaction
angioedema NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
observed NN O O
during NN O O
combination NN O O
therapy NN O O
with NN O O
VICTRELIS NN O O
, NN O O
peginterferon NN O O
alfa NN O O
and NN O O
ribavirin NN O O
. NN O O
If NN O O
such NN O O
an NN O O
acute NN O O
reaction NN O O
occurs NN O O
, NN O O
combination NN O O
therapy NN O O
should NN O O
be NN O O
discontinued NN O O
and NN O O
appropriate NN O O
medical NN O O
therapy NN O O
immediately NN O O
instituted NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
and NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.2 NN O O
) NN O O
] NN O O
. NN O O
5.6 NN O O
Drug NN O O
Interactions NN O O
See NN O O
Table NN O O
2 NN O O
for NN O O
a NN O O
listing NN O O
of NN O O
drugs NN O O
that NN O O
are NN O O
contraindicated NN O O
for NN O O
use NN O O
with NN O O
VICTRELIS NN O O
due NN O O
to NN O O
potentially NN O O
life NN O O
- NN O O
threatening NN O O
adverse NN O O
events NN O O
, NN O O
significant NN O O
drug NN O O
interactions NN O O
or NN O O
loss NN O O
of NN O O
virologic NN O O
activity NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
] NN O O
. NN O O
Please NN O O
refer NN O O
to NN O O
Table NN O O
5 NN O O
for NN O O
established NN O O
and NN O O
other NN O O
potentially NN O O
significant NN O O
drug NN O O
interactions NN O O
[ NN O O
see NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.3 NN O O
) NN O O
] NN O O
. NN O O
5.7 NN O O
Laboratory NN O O
Tests NN O O
HCV NN O O
- NN O O
RNA NN O O
levels NN O O
should NN O O
be NN O O
monitored NN O O
at NN O O
Treatment NN O O
Weeks NN O O
4 NN O O
, NN O O
8 NN O O
, NN O O
12 NN O O
, NN O O
and NN O O
24 NN O O
, NN O O
at NN O O
the NN O O
end NN O O
of NN O O
treatment NN O O
, NN O O
during NN O O
treatment NN O O
follow NN O O
- NN O O
up NN O O
, NN O O
and NN O O
for NN O O
other NN O O
time NN O O
points NN O O
as NN O O
clinically NN O O
indicated NN O O
. NN O O
Use NN O O
of NN O O
a NN O O
sensitive NN O O
real NN O O
- NN O O
time NN O O
reverse NN O O
- NN O O
transcription NN O O
polymerase NN O O
chain NN O O
reaction NN O O
( NN O O
RT NN O O
- NN O O
PCR NN O O
) NN O O
assay NN O O
for NN O O
monitoring NN O O
HCV NN O O
- NN O O
RNA NN O O
levels NN O O
during NN O O
treatment NN O O
is NN O O
recommended NN O O
. NN O O
The NN O O
assay NN O O
should NN O O
have NN O O
a NN O O
lower NN O O
limit NN O O
of NN O O
HCV NN O O
- NN O O
RNA NN O O
quantification NN O O
of NN O O
equal NN O O
to NN O O
or NN O O
less NN O O
than NN O O
25 NN O O
IU NN O O
per NN O O
mL NN O O
, NN O O
and NN O O
a NN O O
limit NN O O
of NN O O
HCV NN O O
- NN O O
RNA NN O O
detection NN O O
of NN O O
approximately NN O O
10 NN O O
to NN O O
15 NN O O
IU NN O O
per NN O O
mL. NN O O
For NN O O
the NN O O
purposes NN O O
of NN O O
assessing NN O O
Response NN O O
- NN O O
Guided NN O O
Therapy NN O O
milestones NN O O
, NN O O
a NN O O
confirmed NN O O
" NN O O
detectable NN O O
but NN O O
below NN O O
limit NN O O
of NN O O
quantification NN O O
" NN O O
HCV NN O O
- NN O O
RNA NN O O
result NN O O
should NN O O
not NN O O
be NN O O
considered NN O O
equivalent NN O O
to NN O O
an NN O O
" NN O O
undetectable NN O O
" NN O O
HCV NN O O
- NN O O
RNA NN O O
result NN O O
( NN O O
reported NN O O
as NN O O
" NN O O
Target NN O O
Not NN O O
Detected NN O O
" NN O O
or NN O O
" NN O O
HCV NN O O
- NN O O
RNA NN O O
Not NN O O
Detected NN O O
" NN O O
) NN O O
. NN O O
Complete NN O O
blood NN O O
count NN O O
( NN O O
with NN O O
white NN O O
blood NN O O
cell NN O O
differential NN O O
counts NN O O
) NN O O
should NN O O
be NN O O
obtained NN O O
at NN O O
pretreatment NN O O
, NN O O
and NN O O
at NN O O
Treatment NN O O
Weeks NN O O
2 NN O O
, NN O O
4 NN O O
, NN O O
8 NN O O
, NN O O
and NN O O
12 NN O O
, NN O O
and NN O O
should NN O O
be NN O O
monitored NN O O
closely NN O O
at NN O O
other NN O O
time NN O O
points NN O O
, NN O O
as NN O O
clinically NN O O
appropriate NN O O
. NN O O
Refer NN O O
to NN O O
the NN O O
prescribing NN O O
information NN O O
for NN O O
peginterferon NN O O
alfa NN O O
and NN O O
ribavirin NN O O
for NN O O
pre NN O O
- NN O O
treatment NN O O
, NN O O
on NN O O
- NN O O
treatment NN O O
and NN O O
post NN O O
- NN O O
treatment NN O O
laboratory NN O O
testing NN O O
recommendations NN O O
including NN O O
hematology NN O O
, NN O O
biochemistry NN O O
( NN O O
including NN O O
hepatic NN O O
function NN O O
tests NN O O
) NN O O
, NN O O
and NN O O
pregnancy NN O O
testing NN O O
requirements NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
EXCERPT NN O O
: NN O O
Serious NN B-Severity B-Severity
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
following NN O O
AdreView NN O O
administration NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
, NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
pruritis NN B-AdverseReaction B-AdverseReaction
flushing NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
and NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
< NN O O
1.3 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
( NN O O
6.1 NN O O
, NN O O
6.2 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
GE NN O O
Healthcare NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
654 NN O O
- NN O O
0118 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Study NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
During NN O O
clinical NN O O
development NN O O
1346 NN O O
patients NN O O
were NN O O
exposed NN O O
to NN O O
AdreView NN O O
, NN O O
251 NN O O
patients NN O O
with NN O O
known NN O O
or NN O O
suspected NN O O
pheochromocytoma NN O O
or NN O O
neuroblastoma NN O O
, NN O O
985 NN O O
patients NN O O
with NN O O
heart NN O O
failure NN O O
, NN O O
and NN O O
110 NN O O
control NN O O
patients NN O O
. NN O O
All NN O O
patients NN O O
were NN O O
monitored NN O O
for NN O O
adverse NN O O
reactions NN O O
over NN O O
a NN O O
24 NN O O
hour NN O O
period NN O O
following NN O O
AdreView NN O O
administration NN O O
. NN O O
Pheochromocytoma NN O O
and NN O O
Neuroblastoma NN O O
Serious NN O O
adverse NN O O
reactions NN O O
were NN O O
not NN O O
observed NN O O
in NN O O
the NN O O
AdreView NN O O
clinical NN O O
study NN O O
. NN O O
Adverse NN O O
reactions NN O O
were NN O O
all NN O O
mild NN B-Severity B-Severity
to NN O O
moderate NN B-Severity B-Severity
in NN O O
severity NN O O
and NN O O
were NN O O
predominantly NN O O
isolated NN O O
occurrences NN O O
( NN O O
< NN O O
= NN O O
2 NN O O
patients NN O O
) NN O O
of NN O O
one NN O O
of NN O O
the NN O O
following NN O O
reactions NN O O
: NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
pruritus NN B-AdverseReaction B-AdverseReaction
flushing NN B-AdverseReaction B-AdverseReaction
or NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
Congestive NN O O
Heart NN O O
Failure NN O O
No NN O O
serious NN O O
adverse NN O O
reactions NN O O
to NN O O
AdreView NN O O
were NN O O
observed NN O O
in NN O O
clinical NN O O
studies NN O O
. NN O O
Adverse NN O O
reactions NN O O
that NN O O
occurred NN O O
with NN O O
a NN O O
frequency NN O O
> NN O O
1 NN O O
% NN O O
were NN O O
associated NN O O
with NN O O
the NN O O
injection NN O O
site NN O O
( NN O O
1.3 NN O O
% NN O O
) NN O O
, NN O O
problems NN O O
such NN O O
as NN O O
hematoma NN O O
and NN O O
bruising NN O O
. NN O O
The NN O O
other NN O O
most NN O O
common NN O O
reactions NN O O
were NN O O
flushing NN B-AdverseReaction B-AdverseReaction
( NN O O
0.3 NN O O
% NN O O
) NN O O
and NN O O
headache NN B-AdverseReaction B-AdverseReaction
( NN O O
0.4 NN O O
% NN O O
) NN O O
. NN O O
The NN O O
adverse NN O O
reactions NN O O
were NN O O
predominantly NN O O
of NN O O
mild NN O O
to NN O O
moderate NN O O
intensity NN O O
. NN O O
6.2 NN O O
Postmarketing NN O O
Experience NN O O
Because NN O O
postmarketing NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
have NN O O
uncommonly NN O O
been NN O O
reported NN O O
during NN O O
the NN O O
postmarketing NN O O
use NN O O
of NN O O
AdreView NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
have NN O O
followed NN O O
AdreView NN O O
administration NN O O
. NN O O
Have NN O O
anaphylactic NN O O
and NN O O
hypersensitivity NN O O
treatment NN O O
measures NN O O
available NN O O
prior NN O O
to NN O O
AdreView NN O O
administration NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Drugs NN O O
which NN O O
block NN O O
norepinephrine NN O O
uptake NN O O
or NN O O
deplete NN O O
norepinephrine NN O O
stores NN O O
may NN O O
decrease NN O O
AdreView NN O O
uptake NN O O
. NN O O
When NN O O
medically NN O O
feasible NN O O
, NN O O
stop NN O O
these NN O O
drugs NN O O
before NN O O
AdreView NN O O
administration NN O O
and NN O O
monitor NN O O
patients NN O O
for NN O O
withdrawal NN O O
signs NN O O
and NN O O
symptoms NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
AdreView NN O O
contains NN O O
benzyl NN O O
alcohol NN O O
( NN O O
10.3 NN O O
mg/mL NN O O
) NN O O
which NN O O
may NN O O
cause NN O O
serious NN O O
reactions NN O O
in NN O O
premature NN O O
or NN O O
low NN O O
birth NN O O
- NN O O
weight NN O O
infants NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Patients NN O O
with NN O O
severe NN O O
renal NN O O
impairment NN O O
may NN O O
have NN O O
increased NN O O
radiation NN O O
exposure NN O O
and NN O O
decreased NN O O
quality NN O O
of NN O O
AdreView NN O O
images NN O O
. NN O O
( NN O O
5.4 NN O O
) NN O O
* NN O O
Failure NN O O
to NN O O
block NN O O
thyroid NN O O
iodine NN O O
uptake NN O O
may NN O O
result NN O O
in NN O O
iodine NN O O
123 NN O O
accumulation NN O O
in NN O O
the NN O O
thyroid NN O O
. NN O O
( NN O O
5.6 NN O O
) NN O O
5.1 NN O O
Hypersensitivity NN O O
Reactions NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
following NN O O
AdreView NN O O
administration NN O O
. NN O O
Prior NN O O
to NN O O
administration NN O O
, NN O O
question NN O O
the NN O O
patient NN O O
for NN O O
a NN O O
history NN O O
of NN O O
prior NN O O
reactions NN O O
to NN O O
iodine NN O O
, NN O O
an NN O O
iodine NN O O
- NN O O
containing NN O O
contrast NN O O
agent NN O O
or NN O O
other NN O O
products NN O O
containing NN O O
iodine NN O O
. NN O O
If NN O O
the NN O O
patient NN O O
is NN O O
known NN O O
or NN O O
strongly NN O O
suspected NN O O
to NN O O
have NN O O
hypersensitivity NN O O
to NN O O
iodine NN O O
, NN O O
an NN O O
iodine NN O O
- NN O O
containing NN O O
contrast NN O O
agent NN O O
or NN O O
other NN O O
products NN O O
containing NN O O
iodine NN O O
, NN O O
the NN O O
decision NN O O
to NN O O
administer NN O O
AdreView NN O O
should NN O O
be NN O O
based NN O O
upon NN O O
an NN O O
assessment NN O O
of NN O O
the NN O O
expected NN O O
benefits NN O O
compared NN O O
to NN O O
the NN O O
potential NN O O
hypersensitivity NN O O
risks NN O O
. NN O O
Have NN O O
anaphylactic NN O O
and NN O O
hypersensitivity NN O O
treatment NN O O
measures NN O O
available NN O O
prior NN O O
to NN O O
AdreView NN O O
administration NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.2 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
Imaging NN O O
Errors NN O O
due NN O O
to NN O O
Concomitant NN O O
Medications NN O O
and NN O O
Risks NN O O
Associated NN O O
with NN O O
Withdrawal NN O O
of NN O O
Medications NN O O
Many NN O O
medications NN O O
have NN O O
the NN O O
potential NN O O
to NN O O
interfere NN O O
with NN O O
AdreView NN O O
imaging NN O O
and NN O O
review NN O O
of NN O O
the NN O O
patient NN O O
's NN O O
medications NN O O
is NN O O
required NN O O
prior NN O O
to NN O O
AdreView NN O O
dosing NN O O
due NN O O
to NN O O
the NN O O
risk NN O O
for NN O O
unreliable NN O O
imaging NN O O
results NN O O
. NN O O
If NN O O
the NN O O
AdreView NN O O
imaging NN O O
information NN O O
is NN O O
essential NN O O
for NN O O
clinical NN O O
care NN O O
, NN O O
consider NN O O
the NN O O
withdrawal NN O O
of NN O O
the NN O O
following NN O O
categories NN O O
of NN O O
medications NN O O
if NN O O
the NN O O
withdrawal NN O O
can NN O O
be NN O O
accomplished NN O O
safely NN O O
: NN O O
antihypertensives NN O O
that NN O O
deplete NN O O
norepinephrine NN O O
stores NN O O
or NN O O
inhibit NN O O
reuptake NN O O
( NN O O
e.g. NN O O
, NN O O
reserpine NN O O
, NN O O
labetalol NN O O
) NN O O
, NN O O
antidepressants NN O O
that NN O O
inhibit NN O O
norepinephrine NN O O
transporter NN O O
function NN O O
( NN O O
e.g. NN O O
, NN O O
amitriptyline NN O O
and NN O O
derivatives NN O O
, NN O O
imipramine NN O O
and NN O O
derivatives NN O O
, NN O O
selective NN O O
serotonin NN O O
reuptake NN O O
inhibitors NN O O
) NN O O
, NN O O
and NN O O
sympathomimetic NN O O
amines NN O O
( NN O O
e.g. NN O O
, NN O O
phenylephrine NN O O
, NN O O
phenylpropanolamine NN O O
, NN O O
pseudoephedrine NN O O
and NN O O
ephedrine NN O O
) NN O O
. NN O O
The NN O O
period NN O O
of NN O O
time NN O O
necessary NN O O
to NN O O
discontinue NN O O
any NN O O
specific NN O O
medication NN O O
prior NN O O
to NN O O
AdreView NN O O
dosing NN O O
has NN O O
not NN O O
been NN O O
established NN O O
[ NN O O
see NN O O
Drug NN O O
Interactions NN O O
( NN O O
7 NN O O
) NN O O
] NN O O
. NN O O
Pheochromocytoma NN O O
and NN O O
Neuroblastoma NN O O
Drugs NN O O
which NN O O
interfere NN O O
with NN O O
norepinephrine NN O O
uptake NN O O
in NN O O
neuroendocrine NN O O
tumors NN O O
may NN O O
lead NN O O
to NN O O
false NN O O
negative NN O O
imaging NN O O
results NN O O
. NN O O
When NN O O
medically NN O O
feasible NN O O
, NN O O
stop NN O O
these NN O O
drugs NN O O
before NN O O
AdreView NN O O
administration NN O O
and NN O O
monitor NN O O
patients NN O O
for NN O O
the NN O O
occurrence NN O O
of NN O O
clinically NN O O
significant NN O O
withdrawal NN O O
symptoms NN O O
, NN O O
especially NN O O
patients NN O O
with NN O O
elevated NN O O
levels NN O O
of NN O O
circulating NN O O
catecholamines NN O O
and NN O O
their NN O O
metabolites NN O O
. NN O O
Congestive NN O O
Heart NN O O
Failure NN O O
Many NN O O
commonly NN O O
used NN O O
cardiovascular NN O O
, NN O O
pulmonary NN O O
, NN O O
and NN O O
neuropsychiatric NN O O
medications NN O O
interfere NN O O
with NN O O
AdreView NN O O
imaging NN O O
( NN O O
see NN O O
above NN O O
) NN O O
. NN O O
AdreView NN O O
imaging NN O O
should NN O O
not NN O O
be NN O O
performed NN O O
if NN O O
discontinuation NN O O
of NN O O
these NN O O
medications NN O O
would NN O O
involve NN O O
risks NN O O
which NN O O
outweigh NN O O
the NN O O
value NN O O
of NN O O
AdreView NN O O
imaging NN O O
. NN O O
In NN O O
clinical NN O O
trials NN O O
, NN O O
patients NN O O
were NN O O
not NN O O
eligible NN O O
for NN O O
AdreView NN O O
imaging NN O O
if NN O O
they NN O O
were NN O O
receiving NN O O
medications NN O O
in NN O O
the NN O O
above NN O O
categories NN O O
and NN O O
the NN O O
risks NN O O
for NN O O
medication NN O O
withdrawal NN O O
were NN O O
unacceptable NN O O
or NN O O
if NN O O
they NN O O
were NN O O
not NN O O
clinically NN O O
stable NN O O
( NN O O
e.g. NN O O
, NN O O
experiencing NN O O
continuing NN O O
chest NN O O
pain NN O O
, NN O O
hemodynamic NN O O
instability NN O O
, NN O O
or NN O O
clinically NN O O
significant NN O O
arrhythmia NN O O
) NN O O
. NN O O
5.3 NN O O
Risks NN O O
for NN O O
Benzyl NN O O
Alcohol NN O O
Toxicity NN O O
in NN O O
Infants NN O O
AdreView NN O O
contains NN O O
benzyl NN O O
alcohol NN O O
at NN O O
a NN O O
concentration NN O O
of NN O O
10.3 NN O O
mg/mL. NN O O
Benzyl NN O O
alcohol NN O O
has NN O O
been NN O O
associated NN O O
with NN O O
a NN O O
fatal NN B-AdverseReaction B-AdverseReaction
" NN O O
Gasping NN O O
Syndrome NN O O
" NN O O
in NN O O
premature NN O O
infants NN O O
and NN O O
infants NN O O
of NN O O
low NN O O
birth NN O O
weight NN O O
. NN O O
Exposure NN O O
to NN O O
excessive NN O O
amounts NN O O
of NN O O
benzyl NN O O
alcohol NN O O
has NN O O
been NN O O
associated NN O O
with NN O O
toxicity NN O O
( NN O O
hypotension NN O O
, NN O O
metabolic NN O O
acidosis NN O O
) NN O O
, NN O O
particularly NN O O
in NN O O
neonates NN O O
, NN O O
and NN O O
an NN O O
increased NN O O
incidence NN O O
of NN O O
kernicterus NN O O
, NN O O
particularly NN O O
in NN O O
small NN O O
preterm NN O O
infants NN O O
. NN O O
There NN O O
have NN O O
been NN O O
rare NN O O
reports NN O O
of NN O O
deaths NN O O
, NN O O
primarily NN O O
in NN O O
preterm NN O O
infants NN O O
, NN O O
associated NN O O
with NN O O
exposure NN O O
to NN O O
excessive NN O O
amounts NN O O
of NN O O
benzyl NN O O
alcohol NN O O
[ NN O O
see NN O O
Description NN O O
( NN O O
11 NN O O
) NN O O
] NN O O
. NN O O
Observe NN O O
infants NN O O
for NN O O
signs NN O O
or NN O O
symptoms NN O O
of NN O O
benzyl NN O O
alcohol NN O O
toxicity NN O O
following NN O O
AdreView NN O O
administration NN O O
. NN O O
AdreView NN O O
safety NN O O
and NN O O
effectiveness NN O O
have NN O O
not NN O O
been NN O O
established NN O O
in NN O O
neonates NN O O
( NN O O
pediatric NN O O
patients NN O O
below NN O O
the NN O O
age NN O O
of NN O O
1 NN O O
month NN O O
) NN O O
. NN O O
5.4 NN O O
Increased NN O O
Radiation NN O O
Exposure NN O O
in NN O O
Patients NN O O
with NN O O
Severe NN O O
Renal NN O O
Impairment NN O O
AdreView NN O O
is NN O O
cleared NN O O
by NN O O
glomerular NN O O
filtration NN O O
and NN O O
is NN O O
not NN O O
dialyzable NN O O
. NN O O
The NN O O
radiation NN O O
dose NN O O
to NN O O
patients NN O O
with NN O O
severe NN O O
renal NN O O
impairment NN O O
may NN O O
be NN O O
increased NN O O
due NN O O
to NN O O
the NN O O
delayed NN O O
elimination NN O O
of NN O O
the NN O O
drug NN O O
. NN O O
Delayed NN O O
AdreView NN O O
clearance NN O O
may NN O O
also NN O O
reduce NN O O
the NN O O
target NN O O
to NN O O
background NN O O
ratios NN O O
and NN O O
decrease NN O O
the NN O O
quality NN O O
of NN O O
scintigraphic NN O O
images NN O O
. NN O O
These NN O O
risks NN O O
importantly NN O O
may NN O O
limit NN O O
the NN O O
role NN O O
of NN O O
AdreView NN O O
in NN O O
the NN O O
diagnostic NN O O
evaluation NN O O
of NN O O
patients NN O O
with NN O O
severe NN O O
renal NN O O
impairment NN O O
. NN O O
AdreView NN O O
safety NN O O
and NN O O
efficacy NN O O
have NN O O
not NN O O
been NN O O
established NN O O
in NN O O
these NN O O
patients NN O O
[ NN O O
see NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.2 NN O O
) NN O O
] NN O O
. NN O O
5.5 NN O O
Imaging NN O O
Errors NN O O
due NN O O
to NN O O
Conditions NN O O
that NN O O
Affect NN O O
the NN O O
Sympathetic NN O O
Nervous NN O O
System NN O O
Individuals NN O O
with NN O O
conditions NN O O
that NN O O
affect NN O O
the NN O O
sympathetic NN O O
nervous NN O O
system NN O O
, NN O O
e.g. NN O O
, NN O O
Parkinsonian NN O O
syndromes NN O O
such NN O O
as NN O O
Parkinson NN O O
's NN O O
disease NN O O
or NN O O
multiple NN O O
system NN O O
atrophy NN O O
, NN O O
may NN O O
show NN O O
decreased NN O O
cardiac NN O O
uptake NN O O
of NN O O
AdreView NN O O
independent NN O O
of NN O O
heart NN O O
disease NN O O
. NN O O
5.6 NN O O
Thyroid NN O O
Accumulation NN O O
Failure NN O O
to NN O O
block NN O O
thyroid NN O O
uptake NN O O
of NN O O
iodine NN O O
123 NN O O
may NN O O
result NN O O
in NN O O
an NN O O
increased NN O O
long NN O O
term NN O O
risk NN O O
for NN O O
thyroid NN O O
neoplasia NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
] NN O O
. NN O O
5.7 NN O O
Hypertension NN O O
Assess NN O O
the NN O O
patient NN O O
's NN O O
pulse NN O O
and NN O O
blood NN O O
pressure NN O O
before NN O O
and NN O O
intermittently NN O O
for NN O O
30 NN O O
minutes NN O O
after NN O O
AdreView NN O O
administration NN O O
. NN O O
AdreView NN O O
may NN B-Factor B-Factor
increase NN O O
release NN O O
of NN O O
norepinephrine NN O O
from NN O O
chromaffin NN O O
granules NN O O
and NN O O
produce NN O O
a NN O O
transient NN B-AdverseReaction B-AdverseReaction
episode NN I-AdverseReaction I-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
hypertension NN I-AdverseReaction I-AdverseReaction
although NN O O
this NN O O
was NN O O
not NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
studies NN O O
. NN O O
Prior NN O O
to NN O O
AdreView NN O O
administration NN O O
, NN O O
ensure NN O O
emergency NN O O
cardiac NN O O
and NN O O
anti NN O O
- NN O O
hypertensive NN O O
treatments NN O O
are NN O O
readily NN O O
available NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
serious NN O O
adverse NN O O
reactions NN O O
are NN O O
discussed NN O O
in NN O O
greater NN O O
detail NN O O
in NN O O
other NN O O
sections NN O O
of NN O O
the NN O O
prescribing NN O O
information NN O O
: NN O O
* NN O O
Peripheral NN B-AdverseReaction B-AdverseReaction
Neuropathy NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Anaphylaxis NN B-AdverseReaction B-AdverseReaction
and NN O O
Infusion NN B-AdverseReaction B-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
Hematologic NN B-AdverseReaction B-AdverseReaction
Toxicities NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
* NN O O
Serious NN B-Severity B-Severity
Infections NN B-AdverseReaction B-AdverseReaction
and NN O O
Opportunistic NN B-AdverseReaction B-AdverseReaction
Infections NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
* NN O O
Tumor NN B-AdverseReaction B-AdverseReaction
Lysis NN I-AdverseReaction I-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
* NN O O
Increased NN B-AdverseReaction B-AdverseReaction
Toxicity NN I-AdverseReaction I-AdverseReaction
in NN O O
the NN O O
Presence NN O O
of NN O O
Severe NN O O
Renal NN O O
Impairment NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.6 NN O O
) NN O O
] NN O O
* NN O O
Increased NN B-AdverseReaction B-AdverseReaction
Toxicity NN I-AdverseReaction I-AdverseReaction
in NN O O
the NN O O
Presence NN O O
of NN O O
Moderate NN O O
or NN O O
Severe NN O O
Hepatic NN O O
Impairment NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.7 NN O O
) NN O O
] NN O O
* NN O O
Hepatotoxicity NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.8 NN O O
) NN O O
] NN O O
* NN O O
Progressive NN B-AdverseReaction B-AdverseReaction
Multifocal NN I-AdverseReaction I-AdverseReaction
Leukoencephalopathy NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.9 NN O O
) NN O O
] NN O O
* NN O O
Pulmonary NN B-AdverseReaction B-AdverseReaction
Toxicity NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.10 NN O O
) NN O O
] NN O O
* NN O O
Serious NN B-Severity B-Severity
Dermatologic NN B-AdverseReaction B-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.11 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=20 NN O O
% NN O O
) NN O O
were NN O O
: NN O O
* NN O O
Relapsed NN O O
classical NN O O
HL NN O O
and NN O O
relapsed NN O O
sALCL NN O O
: NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
peripheral NN B-AdverseReaction B-AdverseReaction
sensory NN I-AdverseReaction I-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
anemia NN B-AdverseReaction B-AdverseReaction
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
pyrexia NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
and NN O O
vomiting NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
. NN O O
* NN O O
Classical NN O O
HL NN O O
post NN O O
- NN O O
auto NN O O
- NN O O
HSCT NN O O
consolidation NN O O
: NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
peripheral NN B-AdverseReaction B-AdverseReaction
sensory NN I-AdverseReaction I-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
anemia NN B-AdverseReaction B-AdverseReaction
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
peripheral NN B-AdverseReaction B-AdverseReaction
motor NN I-AdverseReaction I-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
and NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
. NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Seattle NN O O
Genetics NN O O
, NN O O
Inc. NN O O
at NN O O
1 NN O O
- NN O O
855 NN O O
- NN O O
473 NN O O
- NN O O
2436 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trial NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
The NN O O
data NN O O
below NN O O
reflect NN O O
exposure NN O O
to NN O O
ADCETRIS NN O O
as NN O O
monotherapy NN O O
in NN O O
327 NN O O
patients NN O O
with NN O O
classical NN O O
Hodgkin NN O O
lymphoma NN O O
( NN O O
HL NN O O
) NN O O
and NN O O
systemic NN O O
anaplastic NN O O
large NN O O
cell NN O O
lymphoma NN O O
( NN O O
sALCL NN O O
) NN O O
, NN O O
including NN O O
160 NN O O
patients NN O O
in NN O O
two NN O O
uncontrolled NN O O
single NN O O
- NN O O
arm NN O O
trials NN O O
( NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
) NN O O
and NN O O
167 NN O O
patients NN O O
in NN O O
one NN O O
placebo NN O O
- NN O O
controlled NN O O
randomized NN O O
trial NN O O
( NN O O
Study NN O O
3 NN O O
) NN O O
. NN O O
In NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
, NN O O
the NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=20 NN O O
% NN O O
) NN O O
, NN O O
regardless NN O O
of NN O O
causality NN O O
, NN O O
were NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
peripheral NN B-AdverseReaction B-AdverseReaction
sensory NN I-AdverseReaction I-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
anemia NN B-AdverseReaction B-AdverseReaction
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
pyrexia NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
and NN O O
vomiting NN B-AdverseReaction B-AdverseReaction
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
occurring NN O O
in NN O O
at NN O O
least NN O O
10 NN O O
% NN O O
of NN O O
patients NN O O
in NN O O
either NN O O
Study NN O O
1 NN O O
or NN O O
2 NN O O
, NN O O
regardless NN O O
of NN O O
causality NN O O
, NN O O
using NN O O
the NN O O
NCI NN O O
Common NN O O
Toxicity NN O O
Criteria NN O O
( NN O O
CTC NN O O
) NN O O
Version NN O O
3.0 NN O O
, NN O O
are NN O O
shown NN O O
in NN O O
Table NN O O
2 NN O O
. NN O O
In NN O O
Study NN O O
3 NN O O
, NN O O
the NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=20 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
ADCETRIS NN O O
- NN O O
treatment NN O O
arm NN O O
, NN O O
regardless NN O O
of NN O O
causality NN O O
, NN O O
were NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
peripheral NN B-AdverseReaction B-AdverseReaction
sensory NN I-AdverseReaction I-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
anemia NN B-AdverseReaction B-AdverseReaction
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
peripheral NN B-AdverseReaction B-AdverseReaction
motor NN I-AdverseReaction I-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
and NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
occurring NN O O
in NN O O
at NN O O
least NN O O
10 NN O O
% NN O O
of NN O O
patients NN O O
, NN O O
using NN O O
the NN O O
NCI NN O O
CTC NN O O
Version NN O O
4 NN O O
, NN O O
are NN O O
shown NN O O
in NN O O
Table NN O O
3 NN O O
. NN O O
Experience NN O O
in NN O O
Classical NN O O
Hodgkin NN O O
Lymphoma NN O O
Summary NN O O
of NN O O
Clinical NN O O
Trial NN O O
Experience NN O O
in NN O O
Relapsed NN O O
Classical NN O O
HL NN O O
( NN O O
Study NN O O
1 NN O O
) NN O O
ADCETRIS NN O O
was NN O O
studied NN O O
in NN O O
102 NN O O
patients NN O O
with NN O O
classical NN O O
HL NN O O
in NN O O
a NN O O
single NN O O
arm NN O O
clinical NN O O
trial NN O O
in NN O O
which NN O O
the NN O O
recommended NN O O
starting NN O O
dose NN O O
and NN O O
schedule NN O O
was NN O O
1.8 NN O O
mg/kg NN O O
intravenously NN O O
every NN O O
3 NN O O
weeks NN O O
. NN O O
Median NN O O
duration NN O O
of NN O O
treatment NN O O
was NN O O
9 NN O O
cycles NN O O
( NN O O
range NN O O
, NN O O
1 NN O O
- NN O O
16 NN O O
) NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14.1 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=20 NN O O
% NN O O
) NN O O
, NN O O
regardless NN O O
of NN O O
causality NN O O
, NN O O
were NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
peripheral NN B-AdverseReaction B-AdverseReaction
sensory NN I-AdverseReaction I-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
anemia NN B-AdverseReaction B-AdverseReaction
pyrexia NN B-AdverseReaction B-AdverseReaction
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
and NN O O
vomiting NN B-AdverseReaction B-AdverseReaction
Summary NN O O
of NN O O
Clinical NN O O
Trial NN O O
Experience NN O O
in NN O O
Classical NN O O
HL NN O O
Post NN O O
- NN O O
auto NN O O
- NN O O
HSCT NN O O
Consolidation NN O O
( NN O O
Study NN O O
3 NN O O
) NN O O
ADCETRIS NN O O
was NN O O
studied NN O O
in NN O O
329 NN O O
patients NN O O
with NN O O
classical NN O O
HL NN O O
at NN O O
high NN O O
risk NN O O
of NN O O
relapse NN O O
or NN O O
progression NN O O
post NN O O
- NN O O
auto NN O O
- NN O O
HSCT NN O O
in NN O O
a NN O O
randomized NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
clinical NN O O
trial NN O O
in NN O O
which NN O O
the NN O O
recommended NN O O
starting NN O O
dose NN O O
and NN O O
schedule NN O O
was NN O O
1.8 NN O O
mg/kg NN O O
of NN O O
ADCETRIS NN O O
administered NN O O
intravenously NN O O
over NN O O
30 NN O O
minutes NN O O
every NN O O
3 NN O O
weeks NN O O
or NN O O
placebo NN O O
for NN O O
up NN O O
to NN O O
16 NN O O
cycles NN O O
. NN O O
Of NN O O
the NN O O
329 NN O O
enrolled NN O O
patients NN O O
, NN O O
327 NN O O
( NN O O
167 NN O O
brentuximab NN O O
vedotin NN O O
, NN O O
160 NN O O
placebo NN O O
) NN O O
received NN O O
at NN O O
least NN O O
one NN O O
dose NN O O
of NN O O
study NN O O
treatment NN O O
. NN O O
The NN O O
median NN O O
number NN O O
of NN O O
treatment NN O O
cycles NN O O
in NN O O
each NN O O
study NN O O
arm NN O O
was NN O O
15 NN O O
( NN O O
range NN O O
, NN O O
1 NN O O
- NN O O
16 NN O O
) NN O O
and NN O O
80 NN O O
patients NN O O
( NN O O
48 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
ADCETRIS NN O O
- NN O O
treatment NN O O
arm NN O O
received NN O O
16 NN O O
cycles NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14.1 NN O O
) NN O O
] NN O O
. NN O O
Standard NN O O
international NN O O
guidelines NN O O
were NN O O
followed NN O O
for NN O O
infection NN O O
prophylaxis NN O O
for NN O O
herpes NN O O
simplex NN O O
virus NN O O
( NN O O
HSV NN O O
) NN O O
, NN O O
varicella NN O O
- NN O O
zoster NN O O
virus NN O O
( NN O O
VZV NN O O
) NN O O
, NN O O
and NN O O
Pneumocystis NN O O
jiroveci NN O O
pneumonia NN O O
( NN O O
PCP NN O O
) NN O O
post NN O O
- NN O O
auto NN O O
- NN O O
HSCT. NN O O
Overall NN O O
, NN O O
312 NN O O
patients NN O O
( NN O O
95 NN O O
% NN O O
) NN O O
received NN O O
HSV NN O O
and NN O O
VZV NN O O
prophylaxis NN O O
with NN O O
a NN O O
median NN O O
duration NN O O
of NN O O
11.1 NN O O
months NN O O
( NN O O
range NN O O
, NN O O
0 NN O O
- NN O O
20 NN O O
) NN O O
and NN O O
319 NN O O
patients NN O O
( NN O O
98 NN O O
% NN O O
) NN O O
received NN O O
PCP NN O O
prophylaxis NN O O
with NN O O
a NN O O
median NN O O
duration NN O O
of NN O O
6.5 NN O O
months NN O O
( NN O O
range NN O O
, NN O O
0 NN O O
- NN O O
20 NN O O
) NN O O
. NN O O
Experience NN O O
in NN O O
Systemic NN O O
Anaplastic NN O O
Large NN O O
Cell NN O O
Lymphoma NN O O
Summary NN O O
of NN O O
Clinical NN O O
Trial NN O O
Experience NN O O
in NN O O
Relapsed NN O O
sALCL NN O O
( NN O O
Study NN O O
2 NN O O
) NN O O
ADCETRIS NN O O
was NN O O
studied NN O O
in NN O O
58 NN O O
patients NN O O
with NN O O
sALCL NN O O
in NN O O
a NN O O
single NN O O
arm NN O O
clinical NN O O
trial NN O O
in NN O O
which NN O O
the NN O O
recommended NN O O
starting NN O O
dose NN O O
and NN O O
schedule NN O O
was NN O O
1.8 NN O O
mg/kg NN O O
intravenously NN O O
every NN O O
3 NN O O
weeks NN O O
. NN O O
Median NN O O
duration NN O O
of NN O O
treatment NN O O
was NN O O
7 NN O O
cycles NN O O
( NN O O
range NN O O
, NN O O
1 NN O O
- NN O O
16 NN O O
) NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14.2 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=20 NN O O
% NN O O
) NN O O
, NN O O
regardless NN O O
of NN O O
causality NN O O
, NN O O
were NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
anemia NN B-AdverseReaction B-AdverseReaction
peripheral NN B-AdverseReaction B-AdverseReaction
sensory NN I-AdverseReaction I-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
pyrexia NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
and NN O O
pain NN B-AdverseReaction B-AdverseReaction
Table NN O O
2 NN O O
: NN O O
Most NN O O
Commonly NN O O
Reported NN O O
( NN O O
>=10 NN O O
% NN O O
) NN O O
Adverse NN O O
Reactions NN O O
in NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
Classical NN O O
HL NN O O
sALCL NN O O
Total NN O O
N NN O O
= NN O O
102 NN O O
% NN O O
of NN O O
patients NN O O
Total NN O O
N NN O O
= NN O O
58 NN O O
% NN O O
of NN O O
patients NN O O
Adverse NN O O
Reaction NN O O
AnyGrade NN O O
Grade3 NN O O
Grade4 NN O O
AnyGrade NN O O
Grade3 NN O O
Grade4 NN O O
Blood NN O O
and NN O O
lymphatic NN O O
system NN O O
disorders NN O O
Neutropenia NN B-AdverseReaction B-AdverseReaction
54 NN O O
15 NN O O
6 NN O O
55 NN O O
12 NN O O
9 NN O O
Anemia NN B-AdverseReaction B-AdverseReaction
33 NN O O
8 NN O O
2 NN O O
52 NN O O
2 NN O O
- NN O O
Thrombocytopenia NN B-AdverseReaction B-AdverseReaction
28 NN O O
7 NN O O
2 NN O O
16 NN O O
5 NN O O
5 NN O O
Lymphadenopathy NN B-AdverseReaction B-AdverseReaction
11 NN O O
- NN O O
- NN O O
10 NN O O
- NN O O
- NN O O
Nervous NN O O
system NN O O
disorders NN O O
Peripheral NN B-AdverseReaction B-AdverseReaction
sensory NN I-AdverseReaction I-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
52 NN O O
8 NN O O
- NN O O
53 NN O O
10 NN O O
- NN O O
Peripheral NN B-AdverseReaction B-AdverseReaction
motor NN I-AdverseReaction I-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
16 NN O O
4 NN O O
- NN O O
7 NN O O
3 NN O O
- NN O O
Headache NN B-AdverseReaction B-AdverseReaction
19 NN O O
- NN O O
- NN O O
16 NN O O
2 NN O O
- NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
11 NN O O
- NN O O
- NN O O
16 NN O O
- NN O O
- NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
49 NN O O
3 NN O O
- NN O O
41 NN O O
2 NN O O
2 NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
29 NN O O
2 NN O O
- NN O O
38 NN O O
2 NN O O
- NN O O
Chills NN B-AdverseReaction B-AdverseReaction
13 NN O O
- NN O O
- NN O O
12 NN O O
- NN O O
- NN O O
Pain NN B-AdverseReaction B-AdverseReaction
7 NN O O
- NN O O
- NN O O
28 NN O O
- NN O O
5 NN O O
Edema NN B-AdverseReaction B-AdverseReaction
peripheral NN I-AdverseReaction I-AdverseReaction
4 NN O O
- NN O O
- NN O O
16 NN O O
- NN O O
- NN O O
Infections NN O O
and NN O O
infestations NN O O
Upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
47 NN O O
- NN O O
- NN O O
12 NN O O
- NN O O
- NN O O
Gastrointestinal NN O O
disorders NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
42 NN O O
- NN O O
- NN O O
38 NN O O
2 NN O O
- NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
36 NN O O
1 NN O O
- NN O O
29 NN O O
3 NN O O
- NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
25 NN O O
2 NN O O
1 NN O O
9 NN O O
2 NN O O
- NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
22 NN O O
- NN O O
- NN O O
17 NN O O
3 NN O O
- NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
16 NN O O
- NN O O
- NN O O
19 NN O O
2 NN O O
- NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
Rash NN B-AdverseReaction B-AdverseReaction
27 NN O O
- NN O O
- NN O O
31 NN O O
- NN O O
- NN O O
Pruritus NN B-AdverseReaction B-AdverseReaction
17 NN O O
- NN O O
- NN O O
19 NN O O
- NN O O
- NN O O
Alopecia NN B-AdverseReaction B-AdverseReaction
13 NN O O
- NN O O
- NN O O
14 NN O O
- NN O O
- NN O O
Night NN B-AdverseReaction B-AdverseReaction
sweats NN I-AdverseReaction I-AdverseReaction
12 NN O O
- NN O O
- NN O O
9 NN O O
- NN O O
- NN O O
Dry NN B-AdverseReaction B-AdverseReaction
skin NN I-AdverseReaction I-AdverseReaction
4 NN O O
- NN O O
- NN O O
10 NN O O
- NN O O
- NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
and NN O O
mediastinal NN O O
disorders NN O O
Cough NN B-AdverseReaction B-AdverseReaction
25 NN O O
- NN O O
- NN O O
17 NN O O
- NN O O
- NN O O
Dyspnea NN B-AdverseReaction B-AdverseReaction
13 NN O O
1 NN O O
- NN O O
19 NN O O
2 NN O O
- NN O O
Oropharyngeal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
11 NN O O
- NN O O
- NN O O
9 NN O O
- NN O O
- NN O O
Musculoskeletal NN O O
and NN O O
connective NN O O
tissue NN O O
disorders NN O O
Arthralgia NN B-AdverseReaction B-AdverseReaction
19 NN O O
- NN O O
- NN O O
9 NN O O
- NN O O
- NN O O
Myalgia NN B-AdverseReaction B-AdverseReaction
17 NN O O
- NN O O
- NN O O
16 NN O O
2 NN O O
- NN O O
Back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
14 NN O O
- NN O O
- NN O O
10 NN O O
2 NN O O
- NN O O
Pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
10 NN O O
- NN O O
- NN O O
10 NN O O
2 NN O O
2 NN O O
Muscle NN B-AdverseReaction B-AdverseReaction
spasms NN I-AdverseReaction I-AdverseReaction
9 NN O O
- NN O O
- NN O O
10 NN O O
2 NN O O
- NN O O
Psychiatric NN O O
disorders NN O O
Insomnia NN B-AdverseReaction B-AdverseReaction
14 NN O O
- NN O O
- NN O O
16 NN O O
- NN O O
- NN O O
Anxiety NN B-AdverseReaction B-AdverseReaction
11 NN O O
2 NN O O
- NN O O
7 NN O O
- NN O O
- NN O O
Metabolism NN O O
and NN O O
nutrition NN O O
disorders NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
11 NN O O
- NN O O
- NN O O
16 NN O O
2 NN O O
- NN O O
Investigations NN O O
Weight NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
6 NN O O
- NN O O
- NN O O
12 NN O O
3 NN O O
- NN O O
Table NN O O
3 NN O O
: NN O O
Most NN O O
Commonly NN O O
Reported NN O O
( NN O O
>=10 NN O O
% NN O O
in NN O O
the NN O O
ADCETRIS NN O O
arm NN O O
) NN O O
Adverse NN O O
Reactions NN O O
in NN O O
Study NN O O
3 NN O O
ADCETRIS NN O O
Placebo NN O O
Total NN O O
N NN O O
= NN O O
167 NN O O
% NN O O
of NN O O
patients NN O O
Total NN O O
N NN O O
= NN O O
160 NN O O
% NN O O
of NN O O
patients NN O O
Adverse NN O O
Reaction NN O O
AnyGrade NN O O
Grade3 NN O O
Grade4 NN O O
AnyGrade NN O O
Grade3 NN O O
Grade4 NN O O
Blood NN O O
and NN O O
lymphatic NN O O
system NN O O
disorders NN O O
Neutropenia NN B-AdverseReaction B-AdverseReaction
78 NN O O
30 NN O O
9 NN O O
34 NN O O
6 NN O O
4 NN O O
Thrombocytopenia NN B-AdverseReaction B-AdverseReaction
41 NN O O
2 NN O O
4 NN O O
20 NN O O
3 NN O O
2 NN O O
Anemia NN B-AdverseReaction B-AdverseReaction
27 NN O O
4 NN O O
- NN O O
19 NN O O
2 NN O O
- NN O O
Nervous NN O O
system NN O O
disorders NN O O
Peripheral NN B-AdverseReaction B-AdverseReaction
sensory NN I-AdverseReaction I-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
56 NN O O
10 NN O O
- NN O O
16 NN O O
1 NN O O
- NN O O
Peripheral NN B-AdverseReaction B-AdverseReaction
motor NN I-AdverseReaction I-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
23 NN O O
6 NN O O
- NN O O
2 NN O O
1 NN O O
- NN O O
Headache NN B-AdverseReaction B-AdverseReaction
11 NN O O
2 NN O O
- NN O O
8 NN O O
1 NN O O
- NN O O
Infections NN O O
and NN O O
infestations NN O O
Upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
26 NN O O
- NN O O
- NN O O
23 NN O O
1 NN O O
- NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
24 NN O O
2 NN O O
- NN O O
18 NN O O
3 NN O O
- NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
19 NN O O
2 NN O O
- NN O O
16 NN O O
- NN O O
- NN O O
Chills NN B-AdverseReaction B-AdverseReaction
10 NN O O
- NN O O
- NN O O
5 NN O O
- NN O O
- NN O O
Gastrointestinal NN O O
disorders NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
22 NN O O
3 NN O O
- NN O O
8 NN O O
- NN O O
- NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
20 NN O O
2 NN O O
- NN O O
10 NN O O
1 NN O O
- NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
16 NN O O
2 NN O O
- NN O O
7 NN O O
- NN O O
- NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
14 NN O O
2 NN O O
- NN O O
3 NN O O
- NN O O
- NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
13 NN O O
2 NN O O
- NN O O
3 NN O O
- NN O O
- NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
and NN O O
mediastinal NN O O
disorders NN O O
Cough NN B-AdverseReaction B-AdverseReaction
21 NN O O
- NN O O
- NN O O
16 NN O O
- NN O O
- NN O O
Dyspnea NN B-AdverseReaction B-AdverseReaction
13 NN O O
- NN O O
- NN O O
6 NN O O
- NN O O
1 NN O O
Investigations NN O O
Weight NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
19 NN O O
1 NN O O
- NN O O
6 NN O O
- NN O O
- NN O O
Musculoskeletal NN O O
and NN O O
connective NN O O
tissue NN O O
disorders NN O O
Arthralgia NN B-AdverseReaction B-AdverseReaction
18 NN O O
1 NN O O
- NN O O
9 NN O O
- NN O O
- NN O O
Muscle NN B-AdverseReaction B-AdverseReaction
spasms NN I-AdverseReaction I-AdverseReaction
11 NN O O
- NN O O
- NN O O
6 NN O O
- NN O O
- NN O O
Myalgia NN B-AdverseReaction B-AdverseReaction
11 NN O O
1 NN O O
- NN O O
4 NN O O
- NN O O
- NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
Pruritus NN B-AdverseReaction B-AdverseReaction
12 NN O O
1 NN O O
- NN O O
8 NN O O
- NN O O
- NN O O
Metabolism NN O O
and NN O O
nutrition NN O O
disorders NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
12 NN O O
1 NN O O
- NN O O
6 NN O O
- NN O O
- NN O O
Additional NN O O
Important NN O O
Adverse NN O O
Reactions NN O O
Peripheral NN O O
neuropathy NN O O
In NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
, NN O O
54 NN O O
% NN O O
of NN O O
patients NN O O
experienced NN O O
any NN O O
grade NN O O
of NN O O
neuropathy NN B-AdverseReaction B-AdverseReaction
Of NN O O
these NN O O
patients NN O O
, NN O O
49 NN O O
% NN O O
had NN O O
complete NN O O
resolution NN O O
, NN O O
31 NN O O
% NN O O
had NN O O
partial NN O O
improvement NN O O
, NN O O
and NN O O
20 NN O O
% NN O O
had NN O O
no NN O O
improvement NN O O
. NN O O
Of NN O O
the NN O O
patients NN O O
who NN O O
reported NN O O
neuropathy NN B-AdverseReaction B-AdverseReaction
51 NN O O
% NN O O
had NN O O
residual NN B-AdverseReaction B-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
at NN O O
the NN O O
time NN O O
of NN O O
their NN O O
last NN O O
evaluation NN O O
. NN O O
In NN O O
Study NN O O
3 NN O O
, NN O O
67 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
ADCETRIS NN O O
experienced NN O O
any NN O O
grade NN O O
of NN O O
neuropathy NN B-AdverseReaction B-AdverseReaction
The NN O O
median NN O O
time NN O O
to NN O O
first NN O O
onset NN O O
of NN O O
any NN O O
grade NN O O
was NN O O
14 NN O O
weeks NN O O
( NN O O
range NN O O
, NN O O
0.1 NN O O
- NN O O
47 NN O O
) NN O O
, NN O O
of NN O O
Grade NN O O
2 NN O O
was NN O O
27 NN O O
weeks NN O O
( NN O O
range NN O O
, NN O O
0.4 NN O O
- NN O O
52 NN O O
) NN O O
and NN O O
of NN O O
Grade NN O O
3 NN O O
was NN O O
34 NN O O
weeks NN O O
( NN O O
range NN O O
, NN O O
7 NN O O
- NN O O
106 NN O O
) NN O O
. NN O O
The NN O O
median NN O O
time NN O O
from NN O O
onset NN O O
to NN O O
resolution NN O O
or NN O O
improvement NN O O
of NN O O
any NN O O
grade NN O O
was NN O O
23 NN O O
weeks NN O O
( NN O O
range NN O O
, NN O O
0.1 NN O O
- NN O O
138 NN O O
) NN O O
, NN O O
of NN O O
Grade NN O O
2 NN O O
was NN O O
24 NN O O
weeks NN O O
( NN O O
range NN O O
, NN O O
1 NN O O
- NN O O
108 NN O O
) NN O O
and NN O O
of NN O O
Grade NN O O
3 NN O O
was NN O O
25 NN O O
weeks NN O O
( NN O O
range NN O O
, NN O O
2 NN O O
- NN O O
98 NN O O
) NN O O
. NN O O
Of NN O O
the NN O O
patients NN O O
who NN O O
reported NN O O
neuropathy NN B-AdverseReaction B-AdverseReaction
59 NN O O
% NN O O
had NN O O
complete NN O O
resolution NN O O
and NN O O
41 NN O O
% NN O O
had NN O O
residual NN B-AdverseReaction B-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
( NN O O
26 NN O O
% NN O O
partial NN O O
improvement NN O O
, NN O O
15 NN O O
% NN O O
no NN O O
improvement NN O O
) NN O O
at NN O O
the NN O O
time NN O O
of NN O O
their NN O O
last NN O O
evaluation NN O O
. NN O O
Infusion NN O O
reactions NN O O
Two NN O O
cases NN O O
of NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
were NN O O
reported NN O O
in NN O O
the NN O O
dose NN O O
- NN O O
finding NN O O
trials NN O O
. NN O O
There NN O O
were NN O O
no NN B-Negation B-Negation
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
or NN O O
4 NN O O
infusion NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
reported NN O O
in NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
; NN O O
however NN O O
, NN O O
Grade NN B-Severity B-Severity
1 NN I-Severity I-Severity
or NN O O
2 NN O O
infusion NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
for NN O O
19 NN O O
patients NN O O
( NN O O
12 NN O O
% NN O O
) NN O O
. NN O O
In NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
, NN O O
the NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=2 NN O O
% NN O O
) NN O O
associated NN O O
with NN O O
infusion NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
were NN O O
chills NN B-AdverseReaction B-AdverseReaction
( NN O O
4 NN O O
% NN O O
) NN O O
, NN O O
nausea NN B-AdverseReaction B-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
, NN O O
dyspnea NN B-AdverseReaction B-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
, NN O O
pruritus NN B-AdverseReaction B-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
, NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
cough NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
. NN O O
In NN O O
Study NN O O
3 NN O O
, NN O O
infusion NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
in NN O O
25 NN O O
patients NN O O
( NN O O
15 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
ADCETRIS NN O O
- NN O O
treated NN O O
arm NN O O
and NN O O
3 NN O O
patients NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
placebo NN O O
arm NN O O
. NN O O
Grade NN O O
3 NN O O
events NN O O
were NN O O
reported NN O O
in NN O O
3 NN O O
of NN O O
the NN O O
25 NN O O
patients NN O O
treated NN O O
with NN O O
ADCETRIS NN O O
who NN O O
experienced NN O O
infusion NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
No NN B-Negation B-Negation
Grade NN B-Severity B-Severity
4 NN I-Severity I-Severity
infusion NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=2 NN O O
% NN O O
) NN O O
associated NN O O
with NN O O
infusion NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
were NN O O
nausea NN B-AdverseReaction B-AdverseReaction
( NN O O
4 NN O O
% NN O O
) NN O O
, NN O O
chills NN B-AdverseReaction B-AdverseReaction
( NN O O
4 NN O O
% NN O O
) NN O O
, NN O O
dyspnea NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
, NN O O
headache NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
, NN O O
pruritus NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
, NN O O
rash NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
, NN O O
back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
vomiting NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
. NN O O
Pulmonary NN O O
Toxicity NN O O
In NN O O
a NN O O
trial NN O O
in NN O O
patients NN O O
with NN O O
classical NN O O
HL NN O O
that NN O O
studied NN O O
ADCETRIS NN O O
with NN O O
bleomycin NN O O
as NN O O
part NN O O
of NN O O
a NN O O
combination NN O O
regimen NN O O
, NN O O
the NN O O
rate NN O O
of NN O O
non NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
infectious NN I-AdverseReaction I-AdverseReaction
pulmonary NN I-AdverseReaction I-AdverseReaction
toxicity NN I-AdverseReaction I-AdverseReaction
was NN O O
higher NN O O
than NN O O
the NN O O
historical NN O O
incidence NN O O
reported NN O O
with NN O O
ABVD NN O O
( NN O O
adriamycin NN O O
, NN O O
bleomycin NN O O
, NN O O
vinblastine NN O O
, NN O O
dacarbazine NN O O
) NN O O
. NN O O
Patients NN O O
typically NN O O
reported NN O O
cough NN B-AdverseReaction B-AdverseReaction
and NN O O
dyspnea NN B-AdverseReaction B-AdverseReaction
Interstitial NN O O
infiltration NN O O
and/or NN O O
inflammation NN O O
were NN O O
observed NN O O
on NN O O
radiographs NN O O
and NN O O
computed NN O O
tomographic NN O O
imaging NN O O
of NN O O
the NN O O
chest NN O O
. NN O O
Most NN O O
patients NN O O
responded NN O O
to NN O O
corticosteroids NN O O
. NN O O
The NN O O
concomitant NN O O
use NN O O
of NN O O
ADCETRIS NN O O
with NN O O
bleomycin NN O O
is NN O O
contraindicated NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
] NN O O
. NN O O
Cases NN O O
of NN O O
pulmonary NN B-AdverseReaction B-AdverseReaction
toxicity NN I-AdverseReaction I-AdverseReaction
have NN O O
also NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
receiving NN O O
ADCETRIS. NN O O
In NN O O
Study NN O O
3 NN O O
, NN O O
pulmonary NN B-AdverseReaction B-AdverseReaction
toxicity NN I-AdverseReaction I-AdverseReaction
was NN O O
reported NN O O
in NN O O
8 NN O O
patients NN O O
( NN O O
5 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
ADCETRIS NN O O
- NN O O
treated NN O O
arm NN O O
and NN O O
5 NN O O
patients NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
placebo NN O O
arm NN O O
. NN O O
A NN O O
causal NN O O
association NN O O
with NN O O
single NN O O
- NN O O
agent NN O O
ADCETRIS NN O O
has NN O O
not NN O O
been NN O O
established NN O O
. NN O O
Serious NN O O
adverse NN O O
reactions NN O O
In NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
, NN O O
serious NN O O
adverse NN O O
reactions NN O O
, NN O O
regardless NN O O
of NN O O
causality NN O O
, NN O O
were NN O O
reported NN O O
in NN O O
31 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
ADCETRIS. NN O O
The NN O O
most NN O O
common NN O O
serious NN O O
adverse NN O O
reactions NN O O
experienced NN O O
by NN O O
patients NN O O
with NN O O
classical NN O O
HL NN O O
include NN O O
peripheral NN B-AdverseReaction B-AdverseReaction
motor NN I-AdverseReaction I-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
( NN O O
4 NN O O
% NN O O
) NN O O
, NN O O
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
, NN O O
pulmonary NN B-AdverseReaction B-AdverseReaction
embolism NN I-AdverseReaction I-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
, NN O O
pneumonitis NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
, NN O O
pneumothorax NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
, NN O O
pyelonephritis NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
. NN O O
The NN O O
most NN O O
common NN O O
serious NN O O
adverse NN O O
reactions NN O O
experienced NN O O
by NN O O
patients NN O O
with NN O O
sALCL NN O O
were NN O O
septic NN B-AdverseReaction B-AdverseReaction
shock NN I-AdverseReaction I-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
, NN O O
supraventricular NN B-AdverseReaction B-AdverseReaction
arrhythmia NN I-AdverseReaction I-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
, NN O O
pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
. NN O O
Other NN O O
important NN O O
serious NN O O
adverse NN O O
reactions NN O O
reported NN O O
include NN O O
PML NN B-AdverseReaction B-AdverseReaction
Stevens NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Johnson NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
and NN O O
tumor NN B-AdverseReaction B-AdverseReaction
lysis NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
In NN O O
Study NN O O
3 NN O O
, NN O O
serious NN O O
adverse NN O O
reactions NN O O
, NN O O
regardless NN O O
of NN O O
causality NN O O
, NN O O
were NN O O
reported NN O O
in NN O O
25 NN O O
% NN O O
of NN O O
ADCETRIS NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
The NN O O
most NN O O
common NN O O
serious NN O O
adverse NN O O
reactions NN O O
were NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
( NN O O
4 NN O O
% NN O O
) NN O O
, NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
( NN O O
4 NN O O
% NN O O
) NN O O
, NN O O
vomiting NN B-AdverseReaction B-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
, NN O O
nausea NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
, NN O O
hepatotoxicity NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
and NN O O
peripheral NN B-AdverseReaction B-AdverseReaction
sensory NN I-AdverseReaction I-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
. NN O O
Dose NN O O
modifications NN O O
Adverse NN O O
reactions NN O O
that NN O O
led NN O O
to NN O O
dose NN O O
delays NN O O
in NN O O
more NN O O
than NN O O
5 NN O O
% NN O O
of NN O O
patients NN O O
in NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
were NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
( NN O O
14 NN O O
% NN O O
) NN O O
and NN O O
peripheral NN B-AdverseReaction B-AdverseReaction
sensory NN I-AdverseReaction I-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
( NN O O
11 NN O O
% NN O O
) NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
] NN O O
. NN O O
Adverse NN O O
reactions NN O O
that NN O O
led NN O O
to NN O O
dose NN O O
delays NN O O
in NN O O
more NN O O
than NN O O
5 NN O O
% NN O O
of NN O O
ADCETRIS NN O O
- NN O O
treated NN O O
patients NN O O
in NN O O
Study NN O O
3 NN O O
were NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
( NN O O
22 NN O O
% NN O O
) NN O O
, NN O O
peripheral NN B-AdverseReaction B-AdverseReaction
sensory NN I-AdverseReaction I-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
( NN O O
16 NN O O
% NN O O
) NN O O
, NN O O
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
( NN O O
6 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
peripheral NN B-AdverseReaction B-AdverseReaction
motor NN I-AdverseReaction I-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
( NN O O
6 NN O O
% NN O O
) NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
] NN O O
. NN O O
Discontinuations NN O O
Adverse NN O O
reactions NN O O
led NN O O
to NN O O
treatment NN O O
discontinuation NN O O
in NN O O
21 NN O O
% NN O O
of NN O O
patients NN O O
in NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
. NN O O
Adverse NN O O
reactions NN O O
that NN O O
led NN O O
to NN O O
treatment NN O O
discontinuation NN O O
in NN O O
2 NN O O
or NN O O
more NN O O
patients NN O O
with NN O O
classical NN O O
HL NN O O
or NN O O
sALCL NN O O
were NN O O
peripheral NN B-AdverseReaction B-AdverseReaction
sensory NN I-AdverseReaction I-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
( NN O O
8 NN O O
% NN O O
) NN O O
and NN O O
peripheral NN B-AdverseReaction B-AdverseReaction
motor NN I-AdverseReaction I-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
. NN O O
Adverse NN O O
reactions NN O O
led NN O O
to NN O O
treatment NN O O
discontinuation NN O O
in NN O O
32 NN O O
% NN O O
of NN O O
ADCETRIS NN O O
- NN O O
treated NN O O
patients NN O O
in NN O O
Study NN O O
3 NN O O
. NN O O
Adverse NN O O
reactions NN O O
that NN O O
led NN O O
to NN O O
treatment NN O O
discontinuation NN O O
in NN O O
2 NN O O
or NN O O
more NN O O
patients NN O O
were NN O O
peripheral NN B-AdverseReaction B-AdverseReaction
sensory NN I-AdverseReaction I-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
( NN O O
14 NN O O
% NN O O
) NN O O
, NN O O
peripheral NN B-AdverseReaction B-AdverseReaction
motor NN I-AdverseReaction I-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
( NN O O
7 NN O O
% NN O O
) NN O O
, NN O O
acute NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
distress NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
1 NN O O
% NN O O
) NN O O
, NN O O
paraesthesia NN B-AdverseReaction B-AdverseReaction
( NN O O
1 NN O O
% NN O O
) NN O O
and NN O O
vomiting NN B-AdverseReaction B-AdverseReaction
( NN O O
1 NN O O
% NN O O
) NN O O
. NN O O
6.2 NN O O
Post NN O O
Marketing NN O O
Experience NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
identified NN O O
during NN O O
post NN O O
- NN O O
approval NN O O
use NN O O
of NN O O
ADCETRIS. NN O O
Because NN O O
these NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
Blood NN O O
and NN O O
lymphatic NN O O
system NN O O
disorders NN O O
: NN O O
febrile NN B-AdverseReaction B-AdverseReaction
neutropenia NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
. NN O O
Hepatobiliary NN O O
disorders NN O O
: NN O O
hepatotoxicity NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.8 NN O O
) NN O O
] NN O O
. NN O O
Infections NN O O
: NN O O
PML NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Boxed NN O O
Warning NN O O
, NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.9 NN O O
) NN O O
] NN O O
, NN O O
serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
and NN O O
opportunistic NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
. NN O O
Metabolism NN O O
and NN O O
nutrition NN O O
disorders NN O O
: NN O O
hyperglycemia NN B-AdverseReaction B-AdverseReaction
Gastrointestinal NN O O
disorders NN O O
: NN O O
Pancreatitis NN B-AdverseReaction B-AdverseReaction
( NN O O
including NN O O
fatal NN B-AdverseReaction B-AdverseReaction
outcomes NN O O
) NN O O
. NN O O
Consider NN O O
the NN O O
diagnosis NN O O
of NN O O
pancreatitis NN O O
for NN O O
patients NN O O
presenting NN O O
with NN O O
severe NN O O
abdominal NN O O
pain NN O O
. NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
and NN O O
mediastinal NN O O
disorders NN O O
: NN O O
noninfectious NN B-AdverseReaction B-AdverseReaction
pulmonary NN I-AdverseReaction I-AdverseReaction
toxicity NN I-AdverseReaction I-AdverseReaction
including NN O O
pneumonitis NN B-AdverseReaction B-AdverseReaction
interstitial NN B-AdverseReaction B-AdverseReaction
lung NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
and NN O O
ARDS NN B-AdverseReaction B-AdverseReaction
( NN O O
some NN O O
with NN O O
fatal NN B-AdverseReaction B-AdverseReaction
outcomes NN O O
) NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.10 NN O O
) NN O O
and NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
: NN O O
Toxic NN B-AdverseReaction B-AdverseReaction
epidermal NN I-AdverseReaction I-AdverseReaction
necrolysis NN I-AdverseReaction I-AdverseReaction
including NN O O
fatal NN B-AdverseReaction B-AdverseReaction
outcomes NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.11 NN O O
) NN O O
] NN O O
. NN O O
6.3 NN O O
Immunogenicity NN O O
Patients NN O O
with NN O O
classical NN O O
HL NN O O
and NN O O
sALCL NN O O
in NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
were NN O O
tested NN O O
for NN O O
antibodies NN O O
to NN O O
brentuximab NN O O
vedotin NN O O
every NN O O
3 NN O O
weeks NN O O
using NN O O
a NN O O
sensitive NN O O
electrochemiluminescent NN O O
immunoassay NN O O
. NN O O
Approximately NN O O
7 NN O O
% NN O O
of NN O O
patients NN O O
in NN O O
these NN O O
trials NN O O
developed NN O O
persistently NN O O
positive NN O O
antibodies NN O O
( NN O O
positive NN O O
test NN O O
at NN O O
more NN O O
than NN O O
2 NN O O
timepoints NN O O
) NN O O
and NN O O
30 NN O O
% NN O O
developed NN O O
transiently NN O O
positive NN O O
antibodies NN O O
( NN O O
positive NN O O
in NN O O
1 NN O O
or NN O O
2 NN O O
post NN O O
- NN O O
baseline NN O O
timepoints NN O O
) NN O O
. NN O O
The NN O O
anti NN O O
- NN O O
brentuximab NN O O
antibodies NN O O
were NN O O
directed NN O O
against NN O O
the NN O O
antibody NN O O
component NN O O
of NN O O
brentuximab NN O O
vedotin NN O O
in NN O O
all NN O O
patients NN O O
with NN O O
transiently NN O O
or NN O O
persistently NN O O
positive NN O O
antibodies NN O O
. NN O O
Two NN O O
of NN O O
the NN O O
patients NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
with NN O O
persistently NN O O
positive NN O O
antibodies NN O O
experienced NN O O
adverse NN O O
reactions NN O O
consistent NN O O
with NN O O
infusion NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
that NN O O
led NN O O
to NN O O
discontinuation NN O O
of NN O O
treatment NN O O
. NN O O
Overall NN O O
, NN O O
a NN O O
higher NN O O
incidence NN O O
of NN O O
infusion NN B-AdverseReaction B-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
was NN O O
observed NN O O
in NN O O
patients NN O O
who NN O O
developed NN O O
persistently NN O O
positive NN O O
antibodies NN O O
. NN O O
A NN O O
total NN O O
of NN O O
58 NN O O
patient NN O O
samples NN O O
that NN O O
were NN O O
either NN O O
transiently NN O O
or NN O O
persistently NN O O
positive NN O O
for NN O O
anti NN O O
- NN O O
brentuximab NN O O
vedotin NN O O
antibodies NN O O
were NN O O
tested NN O O
for NN O O
the NN O O
presence NN O O
of NN O O
neutralizing NN O O
antibodies NN O O
. NN O O
Sixty NN O O
- NN O O
two NN O O
percent NN O O
of NN O O
these NN O O
patients NN O O
had NN O O
at NN O O
least NN O O
one NN O O
sample NN O O
that NN O O
was NN O O
positive NN O O
for NN O O
the NN O O
presence NN O O
of NN O O
neutralizing NN O O
antibodies NN O O
. NN O O
The NN O O
effect NN O O
of NN O O
anti NN O O
- NN O O
brentuximab NN O O
vedotin NN O O
antibodies NN O O
on NN O O
safety NN O O
and NN O O
efficacy NN O O
is NN O O
not NN O O
known NN O O
. NN O O
Immunogenicity NN O O
assay NN O O
results NN O O
are NN O O
highly NN O O
dependent NN O O
on NN O O
several NN O O
factors NN O O
including NN O O
assay NN O O
sensitivity NN O O
and NN O O
specificity NN O O
, NN O O
assay NN O O
methodology NN O O
, NN O O
sample NN O O
handling NN O O
, NN O O
timing NN O O
of NN O O
sample NN O O
collection NN O O
, NN O O
concomitant NN O O
medications NN O O
, NN O O
and NN O O
underlying NN O O
disease NN O O
. NN O O
For NN O O
these NN O O
reasons NN O O
, NN O O
comparison NN O O
of NN O O
incidence NN O O
of NN O O
antibodies NN O O
to NN O O
ADCETRIS NN O O
with NN O O
the NN O O
incidence NN O O
of NN O O
antibodies NN O O
to NN O O
other NN O O
products NN O O
may NN O O
be NN O O
misleading NN O O
. NN O O
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
PROGRESSIVE NN B-AdverseReaction B-AdverseReaction
MULTIFOCAL NN I-AdverseReaction I-AdverseReaction
LEUKOENCEPHALOPATHY NN I-AdverseReaction I-AdverseReaction
( NN O O
PML NN O O
) NN O O
WARNING NN O O
: NN O O
PROGRESSIVE NN B-AdverseReaction B-AdverseReaction
MULTIFOCAL NN I-AdverseReaction I-AdverseReaction
LEUKOENCEPHALOPATHY NN I-AdverseReaction I-AdverseReaction
( NN O O
PML NN O O
) NN O O
JC NN B-AdverseReaction B-AdverseReaction
virus NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
resulting NN O O
in NN O O
PML NN B-AdverseReaction B-AdverseReaction
and NN O O
death NN B-AdverseReaction B-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
in NN O O
patients NN O O
receiving NN O O
ADCETRIS NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.9 NN O O
) NN O O
, NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
WARNING NN O O
: NN O O
PROGRESSIVE NN B-AdverseReaction B-AdverseReaction
MULTIFOCAL NN I-AdverseReaction I-AdverseReaction
LEUKOENCEPHALOPATHY NN I-AdverseReaction I-AdverseReaction
( NN O O
PML NN O O
) NN O O
See NN O O
Full NN O O
Prescribing NN O O
Information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
. NN O O
JC NN B-AdverseReaction B-AdverseReaction
virus NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
resulting NN O O
in NN O O
PML NN B-AdverseReaction B-AdverseReaction
and NN O O
death NN B-AdverseReaction B-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
in NN O O
patients NN O O
receiving NN O O
ADCETRIS NN O O
( NN O O
5.9 NN O O
, NN O O
6.2 NN O O
) NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Peripheral NN B-AdverseReaction B-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
: NN O O
Monitor NN O O
patients NN O O
for NN O O
neuropathy NN O O
and NN O O
institute NN O O
dose NN O O
modifications NN O O
accordingly NN O O
( NN O O
5.1 NN O O
) NN O O
. NN O O
* NN O O
Anaphylaxis NN B-AdverseReaction B-AdverseReaction
and NN O O
infusion NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
: NN O O
If NN O O
an NN O O
infusion NN O O
reaction NN O O
occurs NN O O
, NN O O
interrupt NN O O
the NN O O
infusion NN O O
. NN O O
If NN O O
anaphylaxis NN O O
occurs NN O O
, NN O O
immediately NN O O
discontinue NN O O
the NN O O
infusion NN O O
( NN O O
5.2 NN O O
) NN O O
. NN O O
* NN O O
Hematologic NN B-AdverseReaction B-AdverseReaction
toxicities NN I-AdverseReaction I-AdverseReaction
: NN O O
Monitor NN O O
complete NN O O
blood NN O O
counts NN O O
prior NN O O
to NN O O
each NN O O
dose NN O O
of NN O O
ADCETRIS. NN O O
Closely NN O O
monitor NN O O
patients NN O O
for NN O O
fever NN O O
. NN O O
If NN O O
Grade NN O O
3 NN O O
or NN O O
4 NN O O
neutropenia NN O O
develops NN O O
, NN O O
consider NN O O
dose NN O O
delays NN O O
, NN O O
reductions NN O O
, NN O O
discontinuation NN O O
, NN O O
or NN O O
G NN O O
- NN O O
CSF NN O O
prophylaxis NN O O
with NN O O
subsequent NN O O
doses NN O O
( NN O O
5.3 NN O O
) NN O O
. NN O O
* NN O O
Serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
and NN O O
opportunistic NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
: NN O O
Closely NN O O
monitor NN O O
patients NN O O
for NN O O
the NN O O
emergence NN O O
of NN O O
bacterial NN O O
, NN O O
fungal NN O O
or NN O O
viral NN O O
infections NN O O
( NN O O
5.4 NN O O
) NN O O
. NN O O
* NN O O
Tumor NN B-AdverseReaction B-AdverseReaction
lysis NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
: NN O O
Closely NN O O
monitor NN O O
patients NN O O
with NN O O
rapidly NN O O
proliferating NN O O
tumor NN O O
or NN O O
high NN O O
tumor NN O O
burden NN O O
( NN O O
5.5 NN O O
) NN O O
. NN O O
* NN O O
Hepatotoxicity NN B-AdverseReaction B-AdverseReaction
: NN O O
Monitor NN O O
liver NN O O
enzymes NN O O
and NN O O
bilirubin NN O O
( NN O O
5.8 NN O O
) NN O O
. NN O O
* NN O O
Pulmonary NN B-AdverseReaction B-AdverseReaction
Toxicity NN I-AdverseReaction I-AdverseReaction
: NN O O
Monitor NN O O
patients NN O O
for NN O O
new NN O O
or NN O O
worsening NN O O
symptoms NN O O
( NN O O
5.10 NN O O
) NN O O
. NN O O
* NN O O
Serious NN B-Severity B-Severity
dermatologic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
: NN O O
Discontinue NN O O
if NN O O
Stevens NN O O
- NN O O
Johnson NN O O
syndrome NN O O
or NN O O
toxic NN O O
epidermal NN O O
necrolysis NN O O
occurs NN O O
( NN O O
5.10 NN O O
) NN O O
. NN O O
* NN O O
Embryo NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
fetal NN I-AdverseReaction I-AdverseReaction
toxicity NN I-AdverseReaction I-AdverseReaction
: NN O O
Fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
. NN O O
Advise NN O O
pregnant NN O O
women NN O O
of NN O O
the NN O O
potential NN O O
hazard NN O O
to NN O O
the NN O O
fetus NN O O
( NN O O
5.12 NN O O
) NN O O
. NN O O
5.1 NN O O
Peripheral NN O O
Neuropathy NN O O
ADCETRIS NN O O
treatment NN O O
causes NN O O
a NN O O
peripheral NN B-AdverseReaction B-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
that NN O O
is NN O O
predominantly NN O O
sensory NN O O
. NN O O
Cases NN O O
of NN O O
peripheral NN B-AdverseReaction B-AdverseReaction
motor NN I-AdverseReaction I-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
have NN O O
also NN O O
been NN O O
reported NN O O
. NN O O
ADCETRIS NN O O
- NN O O
induced NN O O
peripheral NN B-AdverseReaction B-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
is NN O O
cumulative NN O O
. NN O O
In NN O O
the NN O O
relapsed NN O O
classical NN O O
HL NN O O
and NN O O
sALCL NN O O
clinical NN O O
trials NN O O
, NN O O
54 NN O O
% NN O O
of NN O O
patients NN O O
experienced NN O O
any NN O O
grade NN O O
of NN O O
neuropathy NN B-AdverseReaction B-AdverseReaction
Of NN O O
these NN O O
patients NN O O
, NN O O
49 NN O O
% NN O O
had NN O O
complete NN O O
resolution NN O O
, NN O O
31 NN O O
% NN O O
had NN O O
partial NN O O
improvement NN O O
, NN O O
and NN O O
20 NN O O
% NN O O
had NN O O
no NN O O
improvement NN O O
. NN O O
Of NN O O
the NN O O
patients NN O O
who NN O O
reported NN O O
neuropathy NN B-AdverseReaction B-AdverseReaction
51 NN O O
% NN O O
had NN O O
residual NN B-AdverseReaction B-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
at NN O O
the NN O O
time NN O O
of NN O O
their NN O O
last NN O O
evaluation NN O O
. NN O O
Monitor NN O O
patients NN O O
for NN O O
symptoms NN O O
of NN O O
neuropathy NN O O
, NN O O
such NN O O
as NN O O
hypoesthesia NN O O
, NN O O
hyperesthesia NN O O
, NN O O
paresthesia NN O O
, NN O O
discomfort NN O O
, NN O O
a NN O O
burning NN O O
sensation NN O O
, NN O O
neuropathic NN O O
pain NN O O
, NN O O
or NN O O
weakness NN O O
. NN O O
Patients NN O O
experiencing NN O O
new NN O O
or NN O O
worsening NN O O
peripheral NN O O
neuropathy NN O O
may NN O O
require NN O O
a NN O O
delay NN O O
, NN O O
change NN O O
in NN O O
dose NN O O
, NN O O
or NN O O
discontinuation NN O O
of NN O O
ADCETRIS NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
and NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
Anaphylaxis NN O O
and NN O O
Infusion NN O O
Reactions NN O O
Infusion NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
have NN O O
occurred NN O O
with NN O O
ADCETRIS. NN O O
Monitor NN O O
patients NN O O
during NN O O
infusion NN O O
. NN O O
If NN O O
anaphylaxis NN O O
occurs NN O O
, NN O O
immediately NN O O
and NN O O
permanently NN O O
discontinue NN O O
administration NN O O
of NN O O
ADCETRIS NN O O
and NN O O
administer NN O O
appropriate NN O O
medical NN O O
therapy NN O O
. NN O O
If NN O O
an NN O O
infusion NN O O
- NN O O
related NN O O
reaction NN O O
occurs NN O O
, NN O O
the NN O O
infusion NN O O
should NN O O
be NN O O
interrupted NN O O
and NN O O
appropriate NN O O
medical NN O O
management NN O O
instituted NN O O
. NN O O
Patients NN O O
who NN O O
have NN O O
experienced NN O O
a NN O O
prior NN O O
infusion NN O O
- NN O O
related NN O O
reaction NN O O
should NN O O
be NN O O
premedicated NN O O
for NN O O
subsequent NN O O
infusions NN O O
. NN O O
Premedication NN O O
may NN O O
include NN O O
acetaminophen NN O O
, NN O O
an NN O O
antihistamine NN O O
, NN O O
and NN O O
a NN O O
corticosteroid NN O O
. NN O O
5.3 NN O O
Hematologic NN O O
Toxicities NN O O
Prolonged NN O O
( NN O O
>=1 NN O O
week NN O O
) NN O O
severe NN B-Severity B-Severity
neutropenia NN B-AdverseReaction B-AdverseReaction
and NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
or NN O O
Grade NN B-Severity B-Severity
4 NN I-Severity I-Severity
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
or NN O O
anemia NN B-AdverseReaction B-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
with NN O O
ADCETRIS. NN O O
Febrile NN B-AdverseReaction B-AdverseReaction
neutropenia NN I-AdverseReaction I-AdverseReaction
has NN O O
been NN O O
reported NN O O
with NN O O
treatment NN O O
with NN O O
ADCETRIS. NN O O
Complete NN O O
blood NN O O
counts NN O O
should NN O O
be NN O O
monitored NN O O
prior NN O O
to NN O O
each NN O O
dose NN O O
of NN O O
ADCETRIS NN O O
and NN O O
more NN O O
frequent NN O O
monitoring NN O O
should NN O O
be NN O O
considered NN O O
for NN O O
patients NN O O
with NN O O
Grade NN O O
3 NN O O
or NN O O
4 NN O O
neutropenia NN O O
. NN O O
Monitor NN O O
patients NN O O
for NN O O
fever NN O O
. NN O O
If NN O O
Grade NN O O
3 NN O O
or NN O O
4 NN O O
neutropenia NN O O
develops NN O O
, NN O O
consider NN O O
dose NN O O
delays NN O O
, NN O O
reductions NN O O
, NN O O
discontinuation NN O O
, NN O O
or NN O O
G NN O O
- NN O O
CSF NN O O
prophylaxis NN O O
with NN O O
subsequent NN O O
ADCETRIS NN O O
doses NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
] NN O O
. NN O O
5.4 NN O O
Serious NN O O
Infections NN O O
and NN O O
Opportunistic NN O O
Infections NN O O
Serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
and NN O O
opportunistic NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
such NN O O
as NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
bacteremia NN B-AdverseReaction B-AdverseReaction
and NN O O
sepsis NN B-AdverseReaction B-AdverseReaction
or NN O O
septic NN B-AdverseReaction B-AdverseReaction
shock NN I-AdverseReaction I-AdverseReaction
( NN O O
including NN O O
fatal NN B-AdverseReaction B-AdverseReaction
outcomes NN O O
) NN O O
have NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
ADCETRIS. NN O O
Patients NN O O
should NN O O
be NN O O
closely NN O O
monitored NN O O
during NN O O
treatment NN O O
for NN O O
the NN O O
emergence NN O O
of NN O O
possible NN O O
bacterial NN O O
, NN O O
fungal NN O O
, NN O O
or NN O O
viral NN O O
infections NN O O
. NN O O
5.5 NN O O
Tumor NN O O
Lysis NN O O
Syndrome NN O O
Patients NN O O
with NN O O
rapidly NN O O
proliferating NN O O
tumor NN O O
and NN O O
high NN O O
tumor NN O O
burden NN O O
may NN B-Factor B-Factor
be NN O O
at NN O O
increased NN O O
risk NN O O
of NN O O
tumor NN B-AdverseReaction B-AdverseReaction
lysis NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
closely NN O O
and NN O O
take NN O O
appropriate NN O O
measures NN O O
. NN O O
5.6 NN O O
Increased NN O O
Toxicity NN O O
in NN O O
the NN O O
Presence NN O O
of NN O O
Severe NN O O
Renal NN O O
Impairment NN O O
The NN O O
frequency NN O O
of NN O O
>=Grade NN O O
3 NN O O
adverse NN O O
reactions NN O O
and NN O O
deaths NN B-AdverseReaction B-AdverseReaction
was NN O O
greater NN O O
in NN O O
patients NN O O
with NN O O
severe NN O O
renal NN O O
impairment NN O O
compared NN O O
to NN O O
patients NN O O
with NN O O
normal NN O O
renal NN O O
function NN O O
. NN O O
Due NN O O
to NN O O
higher NN O O
MMAE NN O O
exposure NN O O
, NN O O
>=Grade NN O O
3 NN O O
adverse NN O O
reactions NN O O
may NN O O
be NN O O
more NN O O
frequent NN O O
in NN O O
patients NN O O
with NN O O
severe NN O O
renal NN O O
impairment NN O O
compared NN O O
to NN O O
patients NN O O
with NN O O
normal NN O O
renal NN O O
function NN O O
. NN O O
Avoid NN O O
the NN O O
use NN O O
of NN O O
ADCETRIS NN O O
in NN O O
patients NN O O
with NN O O
severe NN O O
renal NN O O
impairment NN O O
[ NN O O
creatinine NN O O
clearance NN O O
( NN O O
CLcr NN O O
) NN O O
< NN O O
30 NN O O
mL/min NN O O
] NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.6 NN O O
) NN O O
] NN O O
. NN O O
5.7 NN O O
Increased NN O O
Toxicity NN O O
in NN O O
the NN O O
Presence NN O O
of NN O O
Moderate NN O O
or NN O O
Severe NN O O
Hepatic NN O O
Impairment NN O O
The NN O O
frequency NN O O
of NN O O
>=Grade NN O O
3 NN O O
adverse NN O O
reactions NN O O
and NN O O
deaths NN B-AdverseReaction B-AdverseReaction
was NN O O
greater NN O O
in NN O O
patients NN O O
with NN O O
moderate NN O O
and NN O O
severe NN O O
hepatic NN O O
impairment NN O O
compared NN O O
to NN O O
patients NN O O
with NN O O
normal NN O O
hepatic NN O O
function NN O O
. NN O O
Avoid NN O O
the NN O O
use NN O O
of NN O O
ADCETRIS NN O O
in NN O O
patients NN O O
with NN O O
moderate NN O O
( NN O O
Child NN O O
- NN O O
Pugh NN O O
B NN O O
) NN O O
or NN O O
severe NN O O
( NN O O
Child NN O O
- NN O O
Pugh NN O O
C NN O O
) NN O O
hepatic NN O O
impairment NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.7 NN O O
) NN O O
] NN O O
. NN O O
5.8 NN O O
Hepatotoxicity NN O O
Serious NN B-Severity B-Severity
cases NN O O
of NN O O
hepatotoxicity NN B-AdverseReaction B-AdverseReaction
including NN O O
fatal NN B-AdverseReaction B-AdverseReaction
outcomes NN O O
, NN O O
have NN O O
occurred NN O O
in NN O O
patients NN O O
receiving NN O O
ADCETRIS. NN O O
Cases NN O O
were NN O O
consistent NN O O
with NN O O
hepatocellular NN B-AdverseReaction B-AdverseReaction
injury NN I-AdverseReaction I-AdverseReaction
including NN O O
elevations NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
transaminases NN I-AdverseReaction I-AdverseReaction
and/or NN O O
bilirubin NN O O
. NN O O
Cases NN O O
have NN O O
occurred NN O O
after NN O O
the NN O O
first NN O O
dose NN O O
of NN O O
ADCETRIS NN O O
or NN O O
after NN O O
ADCETRIS NN O O
rechallenge NN O O
. NN O O
Preexisting NN O O
liver NN O O
disease NN O O
, NN O O
elevated NN O O
baseline NN O O
liver NN O O
enzymes NN O O
, NN O O
and NN O O
concomitant NN O O
medications NN O O
may NN O O
also NN O O
increase NN O O
the NN O O
risk NN O O
. NN O O
Monitor NN O O
liver NN O O
enzymes NN O O
and NN O O
bilirubin NN O O
. NN O O
Patients NN O O
experiencing NN O O
new NN O O
, NN O O
worsening NN O O
, NN O O
or NN O O
recurrent NN O O
hepatotoxicity NN O O
may NN O O
require NN O O
a NN O O
delay NN O O
, NN O O
change NN O O
in NN O O
dose NN O O
, NN O O
or NN O O
discontinuation NN O O
of NN O O
ADCETRIS. NN O O
5.9 NN O O
Progressive NN O O
Multifocal NN O O
Leukoencephalopathy NN O O
JC NN B-AdverseReaction B-AdverseReaction
virus NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
resulting NN O O
in NN O O
PML NN B-AdverseReaction B-AdverseReaction
and NN O O
death NN B-AdverseReaction B-AdverseReaction
has NN O O
been NN O O
reported NN O O
in NN O O
ADCETRIS NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
First NN O O
onset NN O O
of NN O O
symptoms NN O O
occurred NN O O
at NN O O
various NN O O
times NN O O
from NN O O
initiation NN O O
of NN O O
ADCETRIS NN O O
therapy NN O O
, NN O O
with NN O O
some NN O O
cases NN O O
occurring NN O O
within NN O O
3 NN O O
months NN O O
of NN O O
initial NN O O
exposure NN O O
. NN O O
In NN O O
addition NN O O
to NN O O
ADCETRIS NN O O
therapy NN O O
, NN O O
other NN O O
possible NN O O
contributory NN O O
factors NN O O
include NN O O
prior NN O O
therapies NN O O
and NN O O
underlying NN O O
disease NN O O
that NN O O
may NN O O
cause NN O O
immunosuppression NN O O
. NN O O
Consider NN O O
the NN O O
diagnosis NN O O
of NN O O
PML NN O O
in NN O O
any NN O O
patient NN O O
presenting NN O O
with NN O O
new NN O O
- NN O O
onset NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
central NN O O
nervous NN O O
system NN O O
abnormalities NN O O
. NN O O
Hold NN O O
ADCETRIS NN O O
dosing NN O O
for NN O O
any NN O O
suspected NN O O
case NN O O
of NN O O
PML NN O O
and NN O O
discontinue NN O O
ADCETRIS NN O O
dosing NN O O
if NN O O
a NN O O
diagnosis NN O O
of NN O O
PML NN O O
is NN O O
confirmed NN O O
. NN O O
5.10 NN O O
Pulmonary NN O O
Toxicity NN O O
Events NN O O
of NN O O
noninfectious NN B-AdverseReaction B-AdverseReaction
pulmonary NN I-AdverseReaction I-AdverseReaction
toxicity NN I-AdverseReaction I-AdverseReaction
including NN O O
pneumonitis NN B-AdverseReaction B-AdverseReaction
interstitial NN B-AdverseReaction B-AdverseReaction
lung NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
and NN O O
acute NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
distress NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
ARDS NN O O
) NN O O
, NN O O
some NN O O
with NN O O
fatal NN B-AdverseReaction B-AdverseReaction
outcomes NN O O
, NN O O
have NN O O
been NN O O
reported NN O O
. NN O O
Monitor NN O O
patients NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
pulmonary NN O O
toxicity NN O O
, NN O O
including NN O O
cough NN O O
and NN O O
dyspnea NN O O
. NN O O
In NN O O
the NN O O
event NN O O
of NN O O
new NN O O
or NN O O
worsening NN O O
pulmonary NN O O
symptoms NN O O
, NN O O
hold NN O O
ADCETRIS NN O O
dosing NN O O
during NN O O
evaluation NN O O
and NN O O
until NN O O
symptomatic NN O O
improvement NN O O
. NN O O
5.11 NN O O
Serious NN O O
Dermatologic NN O O
Reactions NN O O
Stevens NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Johnson NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
SJS NN O O
) NN O O
and NN O O
toxic NN B-AdverseReaction B-AdverseReaction
epidermal NN I-AdverseReaction I-AdverseReaction
necrolysis NN I-AdverseReaction I-AdverseReaction
( NN O O
TEN NN O O
) NN O O
, NN O O
including NN O O
fatal NN B-AdverseReaction B-AdverseReaction
outcomes NN O O
, NN O O
have NN O O
been NN O O
reported NN O O
with NN O O
ADCETRIS. NN O O
If NN O O
SJS NN O O
or NN O O
TEN NN O O
occurs NN O O
, NN O O
discontinue NN O O
ADCETRIS NN O O
and NN O O
administer NN O O
appropriate NN O O
medical NN O O
therapy NN O O
. NN O O
5.12 NN O O
Embryo NN O O
- NN O O
Fetal NN O O
Toxicity NN O O
There NN O O
are NN O O
no NN O O
adequate NN O O
and NN O O
well NN O O
- NN O O
controlled NN O O
studies NN O O
of NN O O
ADCETRIS NN O O
in NN O O
pregnant NN O O
women NN O O
. NN O O
However NN O O
, NN O O
based NN O O
on NN O O
its NN O O
mechanism NN O O
of NN O O
action NN O O
and NN O O
findings NN O O
in NN O O
animals NN O O
, NN O O
ADCETRIS NN O O
can NN B-Factor B-Factor
cause NN O O
fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
when NN O O
administered NN O O
to NN O O
a NN O O
pregnant NN O O
woman NN O O
. NN O O
Brentuximab NN O O
vedotin NN O O
caused NN O O
embryo NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
fetal NN I-AdverseReaction I-AdverseReaction
toxicities NN I-AdverseReaction I-AdverseReaction
including NN O O
significantly NN B-Severity B-Severity
decreased NN B-AdverseReaction B-AdverseReaction
embryo NN I-AdverseReaction I-AdverseReaction
viability NN I-AdverseReaction I-AdverseReaction
and NN O O
fetal NN B-AdverseReaction B-AdverseReaction
malformations NN I-AdverseReaction I-AdverseReaction
in NN O O
animals NN B-Animal B-Animal
at NN O O
maternal NN O O
exposures NN O O
that NN O O
were NN O O
similar NN O O
to NN O O
human NN O O
exposures NN O O
at NN O O
the NN O O
recommended NN O O
doses NN O O
for NN O O
patients NN O O
with NN O O
classical NN O O
HL NN O O
and NN O O
sALCL. NN O O
If NN O O
this NN O O
drug NN O O
is NN O O
used NN O O
during NN O O
pregnancy NN O O
, NN O O
or NN O O
if NN O O
the NN O O
patient NN O O
becomes NN O O
pregnant NN O O
while NN O O
receiving NN O O
the NN O O
drug NN O O
, NN O O
the NN O O
patient NN O O
should NN O O
be NN O O
apprised NN O O
of NN O O
the NN O O
potential NN O O
hazard NN O O
to NN O O
the NN O O
fetus NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.1 NN O O
) NN O O
] NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
serious NN O O
adverse NN O O
reactions NN O O
are NN O O
discussed NN O O
in NN O O
more NN O O
detail NN O O
in NN O O
other NN O O
sections NN O O
of NN O O
the NN O O
labeling NN O O
: NN O O
* NN O O
Ophthalmic NN B-AdverseReaction B-AdverseReaction
Adverse NN I-AdverseReaction I-AdverseReaction
Reaction NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=2 NN O O
% NN O O
) NN O O
are NN O O
local NN B-AdverseReaction B-AdverseReaction
skin NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pruritus NN I-AdverseReaction I-AdverseReaction
application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
irritation NN I-AdverseReaction I-AdverseReaction
application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
periorbital NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
and NN O O
headache NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
LEO NN O O
Pharma NN O O
Inc. NN O O
at NN O O
1 NN O O
- NN O O
877 NN O O
- NN O O
494 NN O O
- NN O O
4536 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O
The NN O O
data NN O O
described NN O O
below NN O O
reflect NN O O
exposure NN O O
to NN O O
Picato NN O O
( NN O O
r NN O O
) NN O O
gel NN O O
in NN O O
499 NN O O
subjects NN O O
with NN O O
actinic NN O O
keratosis NN O O
, NN O O
including NN O O
274 NN O O
subjects NN O O
exposed NN O O
to NN O O
Picato NN O O
( NN O O
r NN O O
) NN O O
gel NN O O
field NN O O
treatment NN O O
( NN O O
skin NN O O
area NN O O
of NN O O
25 NN O O
cm NN O O
2 NN O O
in NN O O
the NN O O
face NN O O
or NN O O
scalp NN O O
regions NN O O
) NN O O
at NN O O
a NN O O
concentration NN O O
of NN O O
0.015 NN O O
% NN O O
once NN O O
daily NN O O
for NN O O
3 NN O O
consecutive NN O O
days NN O O
, NN O O
and NN O O
225 NN O O
subjects NN O O
exposed NN O O
to NN O O
Picato NN O O
( NN O O
r NN O O
) NN O O
gel NN O O
field NN O O
treatment NN O O
( NN O O
skin NN O O
area NN O O
of NN O O
25 NN O O
cm NN O O
2 NN O O
in NN O O
the NN O O
trunk NN O O
or NN O O
extremities NN O O
regions NN O O
) NN O O
at NN O O
a NN O O
concentration NN O O
of NN O O
0.05 NN O O
% NN O O
once NN O O
daily NN O O
for NN O O
2 NN O O
consecutive NN O O
days NN O O
. NN O O
Local NN B-AdverseReaction B-AdverseReaction
skin NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
erythema NN O O
, NN O O
flaking/scaling NN O O
, NN O O
crusting NN O O
, NN O O
swelling NN O O
, NN O O
vesiculation/pustulation NN O O
, NN O O
and NN O O
erosion/ulceration NN O O
were NN O O
assessed NN O O
within NN O O
the NN O O
selected NN O O
treatment NN O O
area NN O O
and NN O O
graded NN O O
by NN O O
the NN O O
investigator NN O O
on NN O O
a NN O O
scale NN O O
of NN O O
0 NN O O
to NN O O
4 NN O O
. NN O O
A NN O O
grade NN O O
of NN O O
0 NN O O
represented NN O O
no NN O O
reaction NN O O
present NN O O
in NN O O
the NN O O
treated NN O O
area NN O O
, NN O O
and NN O O
a NN O O
grade NN O O
of NN O O
4 NN O O
indicated NN O O
a NN O O
marked NN O O
and NN O O
severe NN O O
skin NN O O
reaction NN O O
that NN O O
extended NN O O
beyond NN O O
the NN O O
treated NN O O
area NN O O
. NN O O
Table NN O O
1 NN O O
Investigator NN O O
Assessment NN O O
of NN O O
Maximal NN O O
Local NN B-AdverseReaction B-AdverseReaction
Skin NN I-AdverseReaction I-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
in NN O O
the NN O O
Treatment NN O O
Area NN O O
during NN O O
the NN O O
57 NN O O
Days NN O O
Post NN O O
Treatment NN O O
Period NN O O
( NN O O
face/scalp NN O O
trials NN O O
) NN O O
Face NN O O
and NN O O
Scalp NN O O
( NN O O
n=545 NN O O
) NN O O
Picato(r NN O O
) NN O O
gel NN O O
, NN O O
0.015 NN O O
% NN O O
once NN O O
daily NN O O
for NN O O
3 NN O O
days NN O O
Skin NN O O
reactions NN O O
Any NN O O
Gradea NN O O
> NN O O
Baseline NN O O
Grade NN O O
4 NN O O
Picato(r NN O O
) NN O O
gel NN O O
( NN O O
n=274 NN O O
) NN O O
Vehicle NN O O
( NN O O
n=271 NN O O
) NN O O
Picato(r NN O O
) NN O O
gel NN O O
( NN O O
n=274 NN O O
) NN O O
Vehicle NN O O
( NN O O
n=271 NN O O
) NN O O
Erythema NN O O
258 NN O O
( NN O O
94 NN O O
% NN O O
) NN O O
69 NN O O
( NN O O
25 NN O O
% NN O O
) NN O O
66 NN O O
( NN O O
24 NN O O
% NN O O
) NN O O
0 NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
Flaking/Scaling NN O O
233 NN O O
( NN O O
85 NN O O
% NN O O
) NN O O
67 NN O O
( NN O O
25 NN O O
% NN O O
) NN O O
25 NN O O
( NN O O
9 NN O O
% NN O O
) NN O O
0 NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
Crusting NN O O
220 NN O O
( NN O O
80 NN O O
% NN O O
) NN O O
46 NN O O
( NN O O
17 NN O O
% NN O O
) NN O O
16 NN O O
( NN O O
6 NN O O
% NN O O
) NN O O
0 NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
Swelling NN O O
217 NN O O
( NN O O
79 NN O O
% NN O O
) NN O O
11 NN O O
( NN O O
4 NN O O
% NN O O
) NN O O
14 NN O O
( NN O O
5 NN O O
% NN O O
) NN O O
0 NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
Vesiculation/Pustulation NN O O
154 NN O O
( NN O O
56 NN O O
% NN O O
) NN O O
1 NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
15 NN O O
( NN O O
5 NN O O
% NN O O
) NN O O
0 NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
Erosion/Ulceration NN O O
87 NN O O
( NN O O
32 NN O O
% NN O O
) NN O O
3 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
1 NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
0 NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
a NN O O
Mild NN O O
( NN O O
grade NN O O
1 NN O O
) NN O O
, NN O O
Moderate NN O O
( NN O O
grade NN O O
2 NN O O
- NN O O
3 NN O O
) NN O O
or NN O O
Severe NN O O
( NN O O
grade NN O O
4 NN O O
) NN O O
. NN O O
Table NN O O
2 NN O O
Investigator NN O O
Assessment NN O O
of NN O O
Maximal NN O O
Local NN B-AdverseReaction B-AdverseReaction
Skin NN I-AdverseReaction I-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
in NN O O
the NN O O
Treatment NN O O
Area NN O O
during NN O O
the NN O O
57 NN O O
Days NN O O
Post NN O O
Treatment NN O O
Period NN O O
( NN O O
trunk/extremities NN O O
trials NN O O
) NN O O
Trunk NN O O
and NN O O
Extremities NN O O
( NN O O
n=457 NN O O
) NN O O
Picato(r NN O O
) NN O O
gel NN O O
, NN O O
0.05 NN O O
% NN O O
once NN O O
daily NN O O
for NN O O
2 NN O O
days NN O O
Skin NN O O
reactions NN O O
Any NN O O
Gradea NN O O
> NN O O
Baseline NN O O
Grade NN O O
4 NN O O
Picato(r NN O O
) NN O O
gel NN O O
( NN O O
n=225 NN O O
) NN O O
Vehicle NN O O
( NN O O
n=232 NN O O
) NN O O
Picato(r NN O O
) NN O O
gel NN O O
( NN O O
n=225 NN O O
) NN O O
Vehicle NN O O
( NN O O
n=232 NN O O
) NN O O
Erythema NN O O
207 NN O O
( NN O O
92 NN O O
% NN O O
) NN O O
43 NN O O
( NN O O
19 NN O O
% NN O O
) NN O O
34 NN O O
( NN O O
15 NN O O
% NN O O
) NN O O
0 NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
Flaking/Scaling NN O O
203 NN O O
( NN O O
90 NN O O
% NN O O
) NN O O
44 NN O O
( NN O O
19 NN O O
% NN O O
) NN O O
18 NN O O
( NN O O
8 NN O O
% NN O O
) NN O O
0 NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
Crusting NN O O
167 NN O O
( NN O O
74 NN O O
% NN O O
) NN O O
23 NN O O
( NN O O
10 NN O O
% NN O O
) NN O O
8 NN O O
( NN O O
4 NN O O
% NN O O
) NN O O
0 NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
Swelling NN O O
143 NN O O
( NN O O
64 NN O O
% NN O O
) NN O O
13 NN O O
( NN O O
6 NN O O
% NN O O
) NN O O
7 NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
0 NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
Vesiculation/Pustulation NN O O
98 NN O O
( NN O O
44 NN O O
% NN O O
) NN O O
2 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
3 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
0 NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
Erosion/Ulceration NN O O
58 NN O O
( NN O O
26 NN O O
% NN O O
) NN O O
6 NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
2 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
0 NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
a NN O O
Mild NN O O
( NN O O
grade NN O O
1 NN O O
) NN O O
, NN O O
Moderate NN O O
( NN O O
grade NN O O
2 NN O O
- NN O O
3 NN O O
) NN O O
or NN O O
Severe NN O O
( NN O O
grade NN O O
4 NN O O
) NN O O
. NN O O
Local NN B-AdverseReaction B-AdverseReaction
skin NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
typically NN O O
occurred NN O O
within NN O O
1 NN O O
day NN O O
of NN O O
treatment NN O O
initiation NN O O
, NN O O
peaked NN O O
in NN O O
intensity NN O O
up NN O O
to NN O O
1 NN O O
week NN O O
following NN O O
completion NN O O
of NN O O
treatment NN O O
, NN O O
and NN O O
resolved NN O O
within NN O O
2 NN O O
weeks NN O O
for NN O O
areas NN O O
treated NN O O
on NN O O
the NN O O
face NN O O
and NN O O
scalp NN O O
, NN O O
and NN O O
within NN O O
4 NN O O
weeks NN O O
for NN O O
areas NN O O
treated NN O O
on NN O O
the NN O O
trunk NN O O
and NN O O
extremities NN O O
. NN O O
Adverse NN O O
reactions NN O O
that NN O O
occurred NN O O
in NN O O
>=2 NN O O
% NN O O
of NN O O
subjects NN O O
treated NN O O
with NN O O
Picato NN O O
( NN O O
r NN O O
) NN O O
gel NN O O
and NN O O
at NN O O
a NN O O
higher NN O O
frequency NN O O
than NN O O
the NN O O
vehicle NN O O
are NN O O
presented NN O O
in NN O O
Table NN O O
3 NN O O
and NN O O
Table NN O O
4 NN O O
. NN O O
Table NN O O
3 NN O O
Adverse NN O O
reactions NN O O
occurring NN O O
in NN O O
>= NN O O
2 NN O O
% NN O O
of NN O O
subjects NN O O
treated NN O O
with NN O O
Picato NN O O
( NN O O
r NN O O
) NN O O
gel NN O O
and NN O O
at NN O O
higher NN O O
frequency NN O O
than NN O O
vehicle NN O O
( NN O O
face/scalp NN O O
trials NN O O
) NN O O
Face/Scalp NN O O
Adverse NN O O
Reactions NN O O
Picato(r NN O O
) NN O O
gel NN O O
, NN O O
0.015 NN O O
% NN O O
( NN O O
N=274 NN O O
) NN O O
Vehicle NN O O
( NN O O
N=271 NN O O
) NN O O
Application NN B-AdverseReaction B-AdverseReaction
Site NN I-AdverseReaction I-AdverseReaction
Pain NN I-AdverseReaction I-AdverseReaction
42 NN O O
( NN O O
15 NN O O
% NN O O
) NN O O
1 NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
Application NN B-AdverseReaction B-AdverseReaction
Site NN I-AdverseReaction I-AdverseReaction
Pruritus NN I-AdverseReaction I-AdverseReaction
22 NN O O
( NN O O
8 NN O O
% NN O O
) NN O O
3 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
Application NN B-AdverseReaction B-AdverseReaction
Site NN I-AdverseReaction I-AdverseReaction
Infection NN I-AdverseReaction I-AdverseReaction
7 NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
0 NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
Periorbital NN B-AdverseReaction B-AdverseReaction
Edema NN I-AdverseReaction I-AdverseReaction
7 NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
0 NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
Headache NN B-AdverseReaction B-AdverseReaction
6 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
3 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
Table NN O O
4 NN O O
Adverse NN O O
reactions NN O O
occurring NN O O
in NN O O
>= NN O O
2 NN O O
% NN O O
of NN O O
subjects NN O O
treated NN O O
with NN O O
Picato NN O O
( NN O O
r NN O O
) NN O O
gel NN O O
and NN O O
at NN O O
higher NN O O
frequency NN O O
than NN O O
vehicle NN O O
( NN O O
trunk/extremities NN O O
trials NN O O
) NN O O
Trunk/Extremities NN O O
Adverse NN O O
Reactions NN O O
Picato(r NN O O
) NN O O
gel NN O O
, NN O O
0.05 NN O O
% NN O O
( NN O O
N=225 NN O O
) NN O O
Vehicle NN O O
( NN O O
N=232 NN O O
) NN O O
Application NN B-AdverseReaction B-AdverseReaction
Site NN I-AdverseReaction I-AdverseReaction
Pruritus NN I-AdverseReaction I-AdverseReaction
18 NN O O
( NN O O
8 NN O O
% NN O O
) NN O O
0 NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
Application NN B-AdverseReaction B-AdverseReaction
Site NN I-AdverseReaction I-AdverseReaction
Irritation NN I-AdverseReaction I-AdverseReaction
8 NN O O
( NN O O
4 NN O O
% NN O O
) NN O O
1 NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
Nasopharyngitis NN B-AdverseReaction B-AdverseReaction
4 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
2 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
Application NN B-AdverseReaction B-AdverseReaction
Site NN I-AdverseReaction I-AdverseReaction
Pain NN I-AdverseReaction I-AdverseReaction
5 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
0 NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
Less NN O O
common NN O O
adverse NN O O
reactions NN O O
in NN O O
subjects NN O O
treated NN O O
with NN O O
Picato NN O O
( NN O O
r NN O O
) NN O O
included NN O O
: NN O O
eyelid NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
eye NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
conjunctivitis NN B-AdverseReaction B-AdverseReaction
A NN O O
total NN O O
of NN O O
108 NN O O
subjects NN O O
treated NN O O
with NN O O
Picato NN O O
( NN O O
r NN O O
) NN O O
gel NN O O
on NN O O
the NN O O
face/scalp NN O O
and NN O O
38 NN O O
subjects NN O O
treated NN O O
on NN O O
the NN O O
trunk/extremities NN O O
were NN O O
followed NN O O
for NN O O
12 NN O O
months NN O O
. NN O O
Results NN O O
from NN O O
these NN O O
studies NN O O
did NN O O
not NN O O
change NN O O
the NN O O
safety NN O O
profile NN O O
of NN O O
Picato NN O O
( NN O O
r NN O O
) NN O O
gel NN O O
. NN O O
6.2 NN O O
Postmarketing NN O O
Experience NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
identified NN O O
during NN O O
post NN O O
approval NN O O
use NN O O
of NN O O
Picato NN O O
( NN O O
r NN O O
) NN O O
( NN O O
ingenol NN O O
mebutate NN O O
) NN O O
gel NN O O
, NN O O
0.015 NN O O
% NN O O
and NN O O
0.05 NN O O
% NN O O
: NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
allergic NN B-AdverseReaction B-AdverseReaction
contact NN I-AdverseReaction I-AdverseReaction
dermatitis NN I-AdverseReaction I-AdverseReaction
herpes NN B-AdverseReaction B-AdverseReaction
zoster NN I-AdverseReaction I-AdverseReaction
chemical NN B-AdverseReaction B-AdverseReaction
conjunctivitis NN I-AdverseReaction I-AdverseReaction
and NN O O
corneal NN B-AdverseReaction B-AdverseReaction
burn NN I-AdverseReaction I-AdverseReaction
Because NN O O
these NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
Avoid NN O O
treatment NN O O
in NN O O
the NN O O
periocular NN O O
area NN O O
. NN O O
Eye NN B-AdverseReaction B-AdverseReaction
disorders NN I-AdverseReaction I-AdverseReaction
including NN O O
severe NN B-Severity B-Severity
eye NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
chemical NN B-AdverseReaction B-AdverseReaction
conjunctivitis NN I-AdverseReaction I-AdverseReaction
corneal NN B-AdverseReaction B-AdverseReaction
burn NN I-AdverseReaction I-AdverseReaction
eyelid NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
eyelid NN B-AdverseReaction B-AdverseReaction
ptosis NN I-AdverseReaction I-AdverseReaction
periorbital NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
after NN O O
exposure NN O O
. NN O O
Avoid NN O O
accidental NN O O
transfer NN O O
of NN O O
the NN O O
drug NN O O
into NN O O
the NN O O
eyes NN O O
and NN O O
to NN O O
the NN O O
periocular NN O O
area NN O O
. NN O O
If NN O O
accidental NN O O
exposure NN O O
occurs NN O O
, NN O O
flush NN O O
eyes NN O O
with NN O O
water NN O O
and NN O O
seek NN O O
medical NN O O
care NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
Local NN B-AdverseReaction B-AdverseReaction
skin NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
including NN O O
severe NN B-Severity B-Severity
reactions NN O O
( NN O O
e.g. NN O O
, NN O O
vesiculation/pustulation NN O O
, NN O O
erosion/ulceration NN O O
) NN O O
. NN O O
Administration NN O O
of NN O O
Picato NN O O
( NN O O
r NN O O
) NN O O
gel NN O O
is NN O O
not NN O O
recommended NN O O
until NN O O
skin NN O O
is NN O O
healed NN O O
from NN O O
any NN O O
previous NN O O
drug NN O O
or NN O O
surgical NN O O
treatment NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
5.1 NN O O
Ophthalmic NN O O
Adverse NN O O
Reactions NN O O
Avoid NN O O
treatment NN O O
in NN O O
the NN O O
periocular NN O O
area NN O O
. NN O O
Eye NN B-AdverseReaction B-AdverseReaction
disorders NN I-AdverseReaction I-AdverseReaction
including NN O O
severe NN B-Severity B-Severity
eye NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
chemical NN B-AdverseReaction B-AdverseReaction
conjunctivitis NN I-AdverseReaction I-AdverseReaction
corneal NN B-AdverseReaction B-AdverseReaction
burn NN I-AdverseReaction I-AdverseReaction
eyelid NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
eyelid NN B-AdverseReaction B-AdverseReaction
ptosis NN I-AdverseReaction I-AdverseReaction
periorbital NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
after NN O O
exposure NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
] NN O O
. NN O O
To NN O O
avoid NN O O
transfer NN O O
of NN O O
the NN O O
drug NN O O
into NN O O
the NN O O
eyes NN O O
and NN O O
to NN O O
the NN O O
periocular NN O O
area NN O O
during NN O O
and NN O O
after NN O O
application NN O O
, NN O O
patients NN O O
should NN O O
wash NN O O
hands NN O O
well NN O O
after NN O O
applying NN O O
Picato NN O O
( NN O O
r NN O O
) NN O O
gel NN O O
. NN O O
If NN O O
accidental NN O O
exposure NN O O
occurs NN O O
, NN O O
the NN O O
area NN O O
should NN O O
be NN O O
flushed NN O O
with NN O O
water NN O O
and NN O O
the NN O O
patient NN O O
should NN O O
seek NN O O
medical NN O O
care NN O O
as NN O O
soon NN O O
as NN O O
possible NN O O
. NN O O
5.2 NN O O
Hypersensitivity NN O O
Reactions NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
and NN O O
allergic NN B-AdverseReaction B-AdverseReaction
contact NN I-AdverseReaction I-AdverseReaction
dermatitis NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
post NN O O
- NN O O
marketing NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.2 NN O O
) NN O O
] NN O O
. NN O O
If NN O O
anaphylactic NN O O
or NN O O
other NN O O
clinically NN O O
significant NN O O
hypersensitivity NN O O
reactions NN O O
occur NN O O
, NN O O
discontinue NN O O
Picato NN O O
( NN O O
r NN O O
) NN O O
immediately NN O O
and NN O O
institute NN O O
appropriate NN O O
medical NN O O
therapy NN O O
. NN O O
5.3 NN O O
Local NN O O
Skin NN O O
Reactions NN O O
Severe NN B-Severity B-Severity
skin NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
treated NN I-AdverseReaction I-AdverseReaction
area NN I-AdverseReaction I-AdverseReaction
including NN O O
erythema NN O O
, NN O O
crusting NN O O
, NN O O
swelling NN O O
, NN O O
vesiculation/postulation NN O O
, NN O O
and NN O O
erosion/ulceration NN O O
, NN O O
can NN B-Factor B-Factor
occur NN O O
after NN O O
topical NN O O
application NN O O
of NN O O
Picato NN O O
( NN O O
r NN O O
) NN O O
gel NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
] NN O O
. NN O O
Administration NN O O
of NN O O
Picato NN O O
( NN O O
r NN O O
) NN O O
gel NN O O
is NN O O
not NN O O
recommended NN O O
until NN O O
the NN O O
skin NN O O
is NN O O
healed NN O O
from NN O O
any NN O O
previous NN O O
drug NN O O
or NN O O
surgical NN O O
treatment NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
safety NN O O
concerns NN O O
are NN O O
described NN O O
elsewhere NN O O
in NN O O
the NN O O
label NN O O
: NN O O
* NN O O
New NN O O
or NN O O
worsening NN B-AdverseReaction B-AdverseReaction
heart NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
* NN O O
Liver NN B-AdverseReaction B-AdverseReaction
Injury NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
* NN O O
Pulmonary NN B-AdverseReaction B-AdverseReaction
toxicity NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.6 NN O O
) NN O O
] NN O O
* NN O O
Hypokalemia NN B-AdverseReaction B-AdverseReaction
and NN O O
hypomagnesemia NN B-AdverseReaction B-AdverseReaction
with NN O O
potassium NN O O
- NN O O
depleting NN O O
diuretics NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.7 NN O O
) NN O O
] NN O O
* NN O O
QT NN B-AdverseReaction B-AdverseReaction
prolongation NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.8 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
Most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=2 NN O O
% NN O O
) NN O O
are NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
and NN O O
asthenia NN B-AdverseReaction B-AdverseReaction
( NN O O
6 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
sanofi NN O O
- NN O O
aventis NN O O
U.S. NN O O
LLC NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
633 NN O O
- NN O O
1610 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
The NN O O
safety NN O O
evaluation NN O O
of NN O O
dronedarone NN O O
400 NN O O
mg NN O O
twice NN O O
daily NN O O
in NN O O
patients NN O O
with NN O O
AF NN O O
or NN O O
AFL NN O O
is NN O O
based NN O O
on NN O O
5 NN O O
placebo NN O O
controlled NN O O
studies NN O O
, NN O O
ATHENA NN O O
, NN O O
EURIDIS NN O O
, NN O O
ADONIS NN O O
, NN O O
ERATO NN O O
and NN O O
DAFNE. NN O O
In NN O O
these NN O O
studies NN O O
, NN O O
a NN O O
total NN O O
of NN O O
6285 NN O O
patients NN O O
were NN O O
randomized NN O O
and NN O O
treated NN O O
, NN O O
3282 NN O O
patients NN O O
with NN O O
MULTAQ NN O O
400 NN O O
mg NN O O
twice NN O O
daily NN O O
, NN O O
and NN O O
2875 NN O O
with NN O O
placebo NN O O
. NN O O
The NN O O
mean NN O O
exposure NN O O
across NN O O
studies NN O O
was NN O O
12 NN O O
months NN O O
. NN O O
In NN O O
ATHENA NN O O
, NN O O
the NN O O
maximum NN O O
follow NN O O
- NN O O
up NN O O
was NN O O
30 NN O O
months NN O O
. NN O O
In NN O O
clinical NN O O
trials NN O O
, NN O O
premature NN O O
discontinuation NN O O
because NN O O
of NN O O
adverse NN O O
reactions NN O O
occurred NN O O
in NN O O
11.8 NN O O
% NN O O
of NN O O
the NN O O
dronedarone NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
in NN O O
7.7 NN O O
% NN O O
of NN O O
the NN O O
placebo NN O O
- NN O O
treated NN O O
group NN O O
. NN O O
The NN O O
most NN O O
common NN O O
reasons NN O O
for NN O O
discontinuation NN O O
of NN O O
therapy NN O O
with NN O O
MULTAQ NN O O
were NN O O
gastrointestinal NN B-AdverseReaction B-AdverseReaction
disorders NN I-AdverseReaction I-AdverseReaction
( NN O O
3.2 NN O O
% NN O O
versus NN O O
1.8 NN O O
% NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
) NN O O
and NN O O
QT NN B-AdverseReaction B-AdverseReaction
prolongation NN I-AdverseReaction I-AdverseReaction
( NN O O
1.5 NN O O
% NN O O
versus NN O O
0.5 NN O O
% NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
) NN O O
. NN O O
The NN O O
most NN O O
frequent NN O O
adverse NN O O
reactions NN O O
observed NN O O
with NN O O
MULTAQ NN O O
400 NN O O
mg NN O O
twice NN O O
daily NN O O
in NN O O
the NN O O
5 NN O O
studies NN O O
were NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
and NN O O
asthenia NN B-AdverseReaction B-AdverseReaction
Table NN O O
1 NN O O
displays NN O O
adverse NN O O
reactions NN O O
more NN O O
common NN O O
with NN O O
dronedarone NN O O
400 NN O O
mg NN O O
twice NN O O
daily NN O O
than NN O O
with NN O O
placebo NN O O
in NN O O
AF NN O O
or NN O O
AFL NN O O
patients NN O O
, NN O O
presented NN O O
by NN O O
system NN O O
organ NN O O
class NN O O
and NN O O
by NN O O
decreasing NN O O
order NN O O
of NN O O
frequency NN O O
. NN O O
Adverse NN O O
laboratory NN O O
and NN O O
ECG NN O O
effects NN O O
are NN O O
presented NN O O
separately NN O O
in NN O O
Table NN O O
2 NN O O
. NN O O
Table NN O O
1 NN O O
: NN O O
Adverse NN O O
Drug NN O O
Reactions NN O O
that NN O O
Occurred NN O O
in NN O O
at NN O O
Least NN O O
1 NN O O
% NN O O
of NN O O
Patients NN O O
and NN O O
Were NN O O
More NN O O
Frequent NN O O
than NN O O
Placebo NN O O
Placebo NN O O
Dronedarone NN O O
400 NN O O
mg NN O O
twice NN O O
daily NN O O
( NN O O
N=2875 NN O O
) NN O O
( NN O O
N=3282 NN O O
) NN O O
Gastrointestinal NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
6 NN O O
% NN O O
9 NN O O
% NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
3 NN O O
% NN O O
5 NN O O
% NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
3 NN O O
% NN O O
4 NN O O
% NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
1 NN O O
% NN O O
2 NN O O
% NN O O
Dyspeptic NN B-AdverseReaction B-AdverseReaction
signs NN I-AdverseReaction I-AdverseReaction
and NN I-AdverseReaction I-AdverseReaction
symptoms NN I-AdverseReaction I-AdverseReaction
1 NN O O
% NN O O
2 NN O O
% NN O O
General NN O O
Asthenic NN B-AdverseReaction B-AdverseReaction
conditions NN I-AdverseReaction I-AdverseReaction
5 NN O O
% NN O O
7 NN O O
% NN O O
Cardiac NN O O
Bradycardia NN B-AdverseReaction B-AdverseReaction
1 NN O O
% NN O O
3 NN O O
% NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
Including NN O O
rashes NN B-AdverseReaction B-AdverseReaction
( NN O O
generalized NN O O
, NN O O
macular NN O O
, NN O O
maculo NN O O
- NN O O
papular NN O O
, NN O O
erythematous NN O O
) NN O O
, NN O O
pruritus NN B-AdverseReaction B-AdverseReaction
eczema NN B-AdverseReaction B-AdverseReaction
dermatitis NN B-AdverseReaction B-AdverseReaction
dermatitis NN B-AdverseReaction B-AdverseReaction
allergic NN I-AdverseReaction I-AdverseReaction
3 NN O O
% NN O O
5 NN O O
% NN O O
Photosensitivity NN B-AdverseReaction B-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
and NN O O
dysgeusia NN B-AdverseReaction B-AdverseReaction
have NN O O
also NN O O
been NN O O
reported NN O O
at NN O O
an NN O O
incidence NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
MULTAQ. NN O O
The NN O O
following NN O O
laboratory NN O O
data/ECG NN O O
parameters NN O O
were NN O O
reported NN O O
with NN O O
MULTAQ NN O O
400 NN O O
mg NN O O
twice NN O O
daily NN O O
. NN O O
Table NN O O
2 NN O O
: NN O O
Laboratory NN O O
data/ECG NN O O
parameters NN O O
not NN O O
necessarily NN O O
reported NN O O
as NN O O
adverse NN O O
events NN O O
Placebo NN O O
MULTAQ NN O O
400 NN O O
mg NN O O
twice NN O O
daily NN O O
( NN O O
N=2875 NN O O
) NN O O
( NN O O
N=3282 NN O O
) NN O O
Early NN O O
increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
>=10 NN O O
% NN O O
21 NN O O
% NN O O
51 NN O O
% NN O O
( NN O O
N=2237 NN O O
) NN O O
( NN O O
N=2701 NN O O
) NN O O
QTc NN B-AdverseReaction B-AdverseReaction
prolonged NN I-AdverseReaction I-AdverseReaction
19 NN O O
% NN O O
28 NN O O
% NN O O
Assessment NN O O
of NN O O
demographic NN O O
factors NN O O
such NN O O
as NN O O
gender NN O O
or NN O O
age NN O O
on NN O O
the NN O O
incidence NN O O
of NN O O
treatment NN O O
- NN O O
emergent NN O O
adverse NN O O
events NN O O
did NN O O
not NN O O
suggest NN O O
an NN O O
excess NN O O
of NN O O
adverse NN O O
events NN O O
in NN O O
any NN O O
particular NN O O
sub NN O O
- NN O O
group NN O O
. NN O O
6.2 NN O O
Postmarketing NN O O
Experience NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
identified NN O O
during NN O O
post NN O O
- NN O O
approval NN O O
use NN O O
of NN O O
MULTAQ. NN O O
Because NN O O
these NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
an NN O O
unknown NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
Cardiac NN O O
: NN O O
New NN O O
or NN O O
worsening NN O O
heart NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
Atrial NN B-AdverseReaction B-AdverseReaction
flutter NN I-AdverseReaction I-AdverseReaction
with NN I-AdverseReaction I-AdverseReaction
1:1 NN I-AdverseReaction I-AdverseReaction
atrioventricular NN I-AdverseReaction I-AdverseReaction
conduction NN I-AdverseReaction I-AdverseReaction
has NN O O
been NN O O
reported NN O O
very NN O O
rarely NN O O
. NN O O
Hepatic NN O O
: NN O O
Liver NN B-AdverseReaction B-AdverseReaction
Injury NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
Respiratory NN O O
: NN O O
Interstitial NN B-AdverseReaction B-AdverseReaction
lung NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
including NN O O
pneumonitis NN B-AdverseReaction B-AdverseReaction
and NN O O
pulmonary NN B-AdverseReaction B-AdverseReaction
fibrosis NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.6 NN O O
) NN O O
] NN O O
Immune NN O O
: NN O O
Anaphylactic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
angioedema NN B-AdverseReaction B-AdverseReaction
Vascular NN O O
: NN O O
Vasculitis NN B-AdverseReaction B-AdverseReaction
including NN O O
leukocytoclastic NN B-AdverseReaction B-AdverseReaction
vasculitis NN I-AdverseReaction I-AdverseReaction
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
INCREASED NN O O
RISK NN B-Factor B-Factor
OF NN O O
DEATH NN B-AdverseReaction B-AdverseReaction
STROKE NN B-AdverseReaction B-AdverseReaction
AND NN O O
HEART NN B-AdverseReaction B-AdverseReaction
FAILURE NN I-AdverseReaction I-AdverseReaction
IN NN O O
PATIENTS NN O O
WITH NN O O
DECOMPENSATED NN O O
HEART NN O O
FAILURE NN O O
OR NN O O
PERMANENT NN O O
ATRIAL NN O O
FIBRILLATION NN O O
WARNING NN O O
: NN O O
INCREASED NN O O
RISK NN B-Factor B-Factor
OF NN O O
DEATH NN B-AdverseReaction B-AdverseReaction
STROKE NN B-AdverseReaction B-AdverseReaction
AND NN O O
HEART NN B-AdverseReaction B-AdverseReaction
FAILURE NN I-AdverseReaction I-AdverseReaction
IN NN O O
PATIENTS NN O O
WITH NN O O
DECOMPENSATED NN O O
HEART NN O O
FAILURE NN O O
OR NN O O
PERMANENT NN O O
ATRIAL NN O O
FIBRILLATION NN O O
In NN O O
patients NN O O
with NN O O
symptomatic NN O O
heart NN O O
failure NN O O
and NN O O
recent NN O O
decompensation NN O O
requiring NN O O
hospitalization NN O O
or NN O O
NYHA NN O O
Class NN O O
IV NN O O
heart NN O O
failure NN O O
; NN O O
MULTAQ NN O O
doubles NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
death NN B-AdverseReaction B-AdverseReaction
( NN O O
14.3 NN O O
) NN O O
MULTAQ NN O O
is NN O O
contraindicated NN O O
in NN O O
patients NN O O
with NN O O
symptomatic NN O O
heart NN O O
failure NN O O
with NN O O
recent NN O O
decompensation NN O O
requiring NN O O
hospitalization NN O O
or NN O O
NYHA NN O O
Class NN O O
IV NN O O
heart NN O O
failure NN O O
. NN O O
( NN O O
4 NN O O
, NN O O
5.1 NN O O
) NN O O
In NN O O
patients NN O O
with NN O O
permanent NN O O
atrial NN O O
fibrillation NN O O
, NN O O
MULTAQ NN O O
doubles NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
death NN B-AdverseReaction B-AdverseReaction
stroke NN B-AdverseReaction B-AdverseReaction
and NN O O
hospitalization NN O O
for NN O O
heart NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
( NN O O
14.4 NN O O
) NN O O
. NN O O
MULTAQ NN O O
is NN O O
contraindicated NN O O
in NN O O
patients NN O O
in NN O O
atrial NN O O
fibrillation NN O O
( NN O O
AF NN O O
) NN O O
who NN O O
will NN O O
not NN O O
or NN O O
can NN O O
not NN O O
be NN O O
cardioverted NN O O
into NN O O
normal NN O O
sinus NN O O
rhythm NN O O
. NN O O
( NN O O
4 NN O O
, NN O O
5.2 NN O O
) NN O O
EXCERPT NN O O
: NN O O
WARNING NN O O
: NN O O
INCREASED NN O O
RISK NN B-Factor B-Factor
OF NN O O
DEATH NN B-AdverseReaction B-AdverseReaction
STROKE NN B-AdverseReaction B-AdverseReaction
AND NN O O
HEART NN B-AdverseReaction B-AdverseReaction
FAILURE NN I-AdverseReaction I-AdverseReaction
IN NN O O
PATIENTS NN O O
WITH NN O O
DECOMPENSATED NN O O
HEART NN O O
FAILURE NN O O
OR NN O O
PERMANENT NN O O
ATRIAL NN O O
FIBRILLATION NN O O
MULTAQ NN O O
is NN O O
contraindicated NN O O
in NN O O
patients NN O O
with NN O O
symptomatic NN O O
heart NN O O
failure NN O O
with NN O O
recent NN O O
decompensation NN O O
requiring NN O O
hospitalization NN O O
or NN O O
NYHA NN O O
Class NN O O
IV NN O O
heart NN O O
failure NN O O
. NN O O
MULTAQ NN O O
doubles NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
death NN B-AdverseReaction B-AdverseReaction
in NN O O
these NN O O
patients NN O O
( NN O O
4 NN O O
, NN O O
5.1 NN O O
, NN O O
14.3 NN O O
) NN O O
. NN O O
MULTAQ NN O O
is NN O O
contraindicated NN O O
in NN O O
patients NN O O
in NN O O
atrial NN O O
fibrillation NN O O
( NN O O
AF NN O O
) NN O O
who NN O O
will NN O O
not NN O O
or NN O O
can NN O O
not NN O O
be NN O O
cardioverted NN O O
into NN O O
normal NN O O
sinus NN O O
rhythm NN O O
. NN O O
In NN O O
patients NN O O
with NN O O
permanent NN O O
AF NN O O
, NN O O
MULTAQ NN O O
doubles NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
death NN B-AdverseReaction B-AdverseReaction
stroke NN B-AdverseReaction B-AdverseReaction
and NN O O
hospitalization NN O O
for NN O O
heart NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
( NN O O
4 NN O O
, NN O O
5.2 NN O O
, NN O O
14.4 NN O O
) NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Determine NN O O
cardiac NN O O
rhythm NN O O
at NN O O
least NN O O
once NN O O
every NN O O
3 NN O O
months NN O O
. NN O O
If NN O O
AF NN O O
is NN O O
detected NN O O
discontinue NN O O
MULTAQ NN O O
or NN O O
cardiovert NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Ensure NN O O
appropriate NN O O
antithrombotic NN O O
therapy NN O O
prior NN O O
to NN O O
and NN O O
throughout NN O O
MULTAQ NN O O
use NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Liver NN B-AdverseReaction B-AdverseReaction
injury NN I-AdverseReaction I-AdverseReaction
if NN O O
hepatic NN O O
injury NN O O
is NN O O
suspected NN O O
, NN O O
discontinue NN O O
MULTAQ NN O O
( NN O O
5.5 NN O O
) NN O O
* NN O O
If NN O O
pulmonary NN O O
toxicity NN O O
is NN O O
confirmed NN O O
, NN O O
discontinue NN O O
treatment NN O O
( NN O O
5.6 NN O O
) NN O O
* NN O O
Hypokalemia NN B-AdverseReaction B-AdverseReaction
and NN O O
hypomagnesemia NN B-AdverseReaction B-AdverseReaction
Maintain NN O O
potassium NN O O
and NN O O
magnesium NN O O
levels NN O O
within NN O O
the NN O O
normal NN O O
range NN O O
( NN O O
5.7 NN O O
) NN O O
* NN O O
Renal NN B-AdverseReaction B-AdverseReaction
Impairment NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
renal NN O O
function NN O O
periodically NN O O
( NN O O
5.9 NN O O
) NN O O
* NN O O
Teratogen NN B-AdverseReaction B-AdverseReaction
Women NN O O
of NN O O
childbearing NN O O
potential NN O O
should NN O O
use NN O O
effective NN O O
contraception NN O O
while NN O O
using NN O O
MULTAQ NN O O
( NN O O
5.10 NN O O
) NN O O
5.1 NN O O
Cardiovascular NN O O
Death NN O O
in NN O O
NYHA NN O O
Class NN O O
IV NN O O
or NN O O
Decompensated NN O O
Heart NN O O
Failure NN O O
MULTAQ NN O O
is NN O O
contraindicated NN O O
in NN O O
patients NN O O
with NN O O
NYHA NN O O
Class NN O O
IV NN O O
heart NN O O
failure NN O O
or NN O O
symptomatic NN O O
heart NN O O
failure NN O O
with NN O O
recent NN O O
decompensation NN O O
requiring NN O O
hospitalization NN O O
because NN O O
it NN O O
doubles NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
death NN B-AdverseReaction B-AdverseReaction
5.2 NN O O
Cardiovascular NN O O
Death NN O O
and NN O O
Heart NN O O
Failure NN O O
in NN O O
Permanent NN O O
AF NN O O
MULTAQ NN O O
doubles NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
cardiovascular NN B-AdverseReaction B-AdverseReaction
death NN I-AdverseReaction I-AdverseReaction
( NN O O
largely NN O O
arrhythmic NN O O
) NN O O
and NN O O
heart NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
in NN O O
patients NN O O
with NN O O
permanent NN O O
AF. NN O O
Patients NN O O
treated NN O O
with NN O O
dronedarone NN O O
should NN O O
undergo NN O O
monitoring NN O O
of NN O O
cardiac NN O O
rhythm NN O O
no NN O O
less NN O O
often NN O O
than NN O O
every NN O O
3 NN O O
months NN O O
. NN O O
Cardiovert NN O O
patients NN O O
who NN O O
are NN O O
in NN O O
atrial NN O O
fibrillation NN O O
( NN O O
if NN O O
clinically NN O O
indicated NN O O
) NN O O
or NN O O
discontinue NN O O
MULTAQ. NN O O
MULTAQ NN O O
offers NN O O
no NN O O
benefit NN O O
in NN O O
subjects NN O O
in NN O O
permanent NN O O
AF. NN O O
5.3 NN O O
Increased NN O O
Risk NN O O
of NN O O
Stroke NN O O
in NN O O
Permanent NN O O
AF NN O O
In NN O O
a NN O O
placebo NN O O
- NN O O
controlled NN O O
study NN O O
in NN O O
patients NN O O
with NN O O
permanent NN O O
atrial NN O O
fibrillation NN O O
, NN O O
dronedarone NN O O
was NN O O
associated NN O O
with NN O O
an NN O O
increased NN O O
risk NN B-Factor B-Factor
of NN O O
stroke NN B-AdverseReaction B-AdverseReaction
particularly NN O O
in NN O O
the NN O O
first NN O O
two NN O O
weeks NN O O
of NN O O
therapy NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14.4 NN O O
) NN O O
] NN O O
. NN O O
MULTAQ NN O O
should NN O O
only NN O O
be NN O O
initiated NN O O
in NN O O
patients NN O O
in NN O O
sinus NN O O
rhythm NN O O
who NN O O
are NN O O
receiving NN O O
appropriate NN O O
antithrombotic NN O O
therapy NN O O
[ NN O O
see NN O O
Drug NN O O
interactions NN O O
( NN O O
7.3 NN O O
) NN O O
] NN O O
. NN O O
5.4 NN O O
New NN O O
Onset NN O O
or NN O O
Worsening NN O O
Heart NN O O
Failure NN O O
New NN O O
onset NN O O
or NN O O
worsening NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
heart NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
has NN O O
been NN O O
reported NN O O
during NN O O
treatment NN O O
with NN O O
MULTAQ NN O O
in NN O O
the NN O O
postmarketing NN O O
setting NN O O
. NN O O
In NN O O
a NN O O
placebo NN O O
controlled NN O O
study NN O O
in NN O O
patients NN O O
with NN O O
permanent NN O O
AF NN O O
increased NN O O
rates NN O O
of NN O O
heart NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
were NN O O
observed NN O O
in NN O O
patients NN O O
with NN O O
normal NN O O
left NN O O
ventricular NN O O
function NN O O
and NN O O
no NN O O
history NN O O
of NN O O
symptomatic NN O O
heart NN O O
failure NN O O
, NN O O
as NN O O
well NN O O
as NN O O
those NN O O
with NN O O
a NN O O
history NN O O
of NN O O
heart NN O O
failure NN O O
or NN O O
left NN O O
ventricular NN O O
dysfunction NN O O
. NN O O
Advise NN O O
patients NN O O
to NN O O
consult NN O O
a NN O O
physician NN O O
if NN O O
they NN O O
develop NN O O
signs NN O O
or NN O O
symptoms NN O O
of NN O O
heart NN O O
failure NN O O
, NN O O
such NN O O
as NN O O
weight NN O O
gain NN O O
, NN O O
dependent NN O O
edema NN O O
, NN O O
or NN O O
increasing NN O O
shortness NN O O
of NN O O
breath NN O O
. NN O O
If NN O O
heart NN O O
failure NN O O
develops NN O O
or NN O O
worsens NN O O
and NN O O
requires NN O O
hospitalization NN O O
, NN O O
discontinue NN O O
MULTAQ. NN O O
5.5 NN O O
Liver NN O O
Injury NN O O
* NN O O
Hepatocellular NN B-AdverseReaction B-AdverseReaction
liver NN I-AdverseReaction I-AdverseReaction
injury NN I-AdverseReaction I-AdverseReaction
including NN O O
acute NN B-AdverseReaction B-AdverseReaction
liver NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
requiring NN O O
transplant NN O O
, NN O O
has NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
MULTAQ NN O O
in NN O O
the NN O O
postmarketing NN O O
setting NN O O
. NN O O
Advise NN O O
patients NN O O
treated NN O O
with NN O O
MULTAQ NN O O
to NN O O
report NN O O
immediately NN O O
symptoms NN O O
suggesting NN O O
hepatic NN O O
injury NN O O
( NN O O
such NN O O
as NN O O
anorexia NN O O
, NN O O
nausea NN O O
, NN O O
vomiting NN O O
, NN O O
fever NN O O
, NN O O
malaise NN O O
, NN O O
fatigue NN O O
, NN O O
right NN O O
upper NN O O
quadrant NN O O
pain NN O O
, NN O O
jaundice NN O O
, NN O O
dark NN O O
urine NN O O
, NN O O
or NN O O
itching NN O O
) NN O O
. NN O O
Consider NN O O
obtaining NN O O
periodic NN O O
hepatic NN O O
serum NN O O
enzymes NN O O
, NN O O
especially NN O O
during NN O O
the NN O O
first NN O O
6 NN O O
months NN O O
of NN O O
treatment NN O O
, NN O O
but NN O O
it NN O O
is NN O O
not NN O O
known NN O O
whether NN O O
routine NN O O
periodic NN O O
monitoring NN O O
of NN O O
serum NN O O
enzymes NN O O
will NN O O
prevent NN O O
the NN O O
development NN O O
of NN O O
severe NN O O
liver NN O O
injury NN O O
. NN O O
If NN O O
hepatic NN O O
injury NN O O
is NN O O
suspected NN O O
, NN O O
promptly NN O O
discontinue NN O O
MULTAQ NN O O
and NN O O
test NN O O
serum NN O O
enzymes NN O O
, NN O O
aspartate NN O O
aminotransferase NN O O
( NN O O
AST NN O O
) NN O O
, NN O O
alanine NN O O
aminotransferase NN O O
( NN O O
ALT NN O O
) NN O O
and NN O O
alkaline NN O O
phosphatase NN O O
, NN O O
as NN O O
well NN O O
as NN O O
serum NN O O
bilirubin NN O O
, NN O O
to NN O O
establish NN O O
whether NN O O
there NN O O
is NN O O
liver NN O O
injury NN O O
. NN O O
If NN O O
liver NN O O
injury NN O O
is NN O O
found NN O O
, NN O O
institute NN O O
appropriate NN O O
treatment NN O O
and NN O O
investigate NN O O
the NN O O
probable NN O O
cause NN O O
. NN O O
Do NN O O
not NN O O
restart NN O O
MULTAQ NN O O
in NN O O
patients NN O O
without NN O O
another NN O O
explanation NN O O
for NN O O
the NN O O
observed NN O O
liver NN O O
injury NN O O
. NN O O
5.6 NN O O
Pulmonary NN O O
Toxicity NN O O
Cases NN O O
of NN O O
interstitial NN B-AdverseReaction B-AdverseReaction
lung NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
including NN O O
pneumonitis NN B-AdverseReaction B-AdverseReaction
and NN O O
pulmonary NN B-AdverseReaction B-AdverseReaction
fibrosis NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
MULTAQ NN O O
in NN O O
the NN O O
post NN O O
- NN O O
marketing NN O O
setting NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.2 NN O O
) NN O O
] NN O O
. NN O O
Onset NN O O
of NN O O
dyspnea NN O O
or NN O O
non NN O O
- NN O O
productive NN O O
cough NN O O
may NN O O
be NN O O
related NN O O
to NN O O
pulmonary NN O O
toxicity NN O O
and NN O O
patients NN O O
should NN O O
be NN O O
carefully NN O O
evaluated NN O O
clinically NN O O
. NN O O
If NN O O
pulmonary NN O O
toxicity NN O O
is NN O O
confirmed NN O O
, NN O O
MULTAQ NN O O
should NN O O
be NN O O
discontinued NN O O
. NN O O
5.7 NN O O
Hypokalemia NN O O
and NN O O
Hypomagnesemia NN O O
with NN O O
Potassium NN O O
- NN O O
Depleting NN O O
Diuretics NN O O
Hypokalemia NN B-AdverseReaction B-AdverseReaction
or NN O O
hypomagnesemia NN B-AdverseReaction B-AdverseReaction
may NN B-Factor B-Factor
occur NN O O
with NN O O
concomitant NN O O
administration NN O O
of NN O O
potassium NN O O
- NN O O
depleting NN O O
diuretics NN O O
. NN O O
Potassium NN O O
levels NN O O
should NN O O
be NN O O
within NN O O
the NN O O
normal NN O O
range NN O O
prior NN O O
to NN O O
administration NN O O
of NN O O
MULTAQ NN O O
and NN O O
maintained NN O O
in NN O O
the NN O O
normal NN O O
range NN O O
during NN O O
administration NN O O
of NN O O
MULTAQ. NN O O
5.8 NN O O
QT NN O O
Interval NN O O
Prolongation NN O O
Dronedarone NN O O
induces NN O O
a NN O O
moderate NN B-Severity B-Severity
( NN O O
average NN O O
of NN O O
about NN O O
10 NN O O
ms NN O O
but NN O O
much NN O O
greater NN O O
effects NN O O
have NN O O
been NN O O
observed NN O O
) NN O O
QTc NN O O
( NN O O
Bazett NN O O
) NN O O
prolongation NN O O
[ NN O O
see NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.2 NN O O
) NN O O
and NN O O
Clinical NN O O
Studies NN O O
( NN O O
14.1 NN O O
) NN O O
] NN O O
. NN O O
If NN O O
the NN O O
QTc NN O O
Bazett NN O O
interval NN O O
is NN O O
>=500 NN O O
ms NN O O
, NN O O
discontinue NN O O
MULTAQ NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
] NN O O
. NN O O
5.9 NN O O
Renal NN O O
Impairment NN O O
and NN O O
Failure NN O O
Marked NN O O
increase NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
pre NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
azotemia NN I-AdverseReaction I-AdverseReaction
and NN O O
acute NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
often NN O O
in NN O O
the NN O O
setting NN O O
of NN O O
heart NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
or NN O O
hypovolemia NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
taking NN O O
MULTAQ. NN O O
In NN O O
most NN O O
cases NN O O
, NN O O
these NN O O
effects NN O O
appear NN O O
to NN O O
be NN O O
reversible NN O O
upon NN O O
drug NN O O
discontinuation NN O O
and NN O O
with NN O O
appropriate NN O O
medical NN O O
treatment NN O O
. NN O O
Monitor NN O O
renal NN O O
function NN O O
periodically NN O O
. NN O O
Small NN O O
increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
levels NN I-AdverseReaction I-AdverseReaction
( NN O O
about NN O O
0.1 NN B-Severity B-Severity
mg/dL NN I-Severity I-Severity
following NN O O
dronedarone NN O O
treatment NN O O
initiation NN O O
have NN O O
been NN O O
shown NN O O
to NN O O
be NN O O
a NN O O
result NN O O
of NN O O
inhibition NN O O
of NN O O
creatinine NN O O
's NN O O
tubular NN O O
secretion NN O O
. NN O O
The NN O O
elevation NN O O
has NN O O
a NN O O
rapid NN O O
onset NN O O
, NN O O
reaches NN O O
a NN O O
plateau NN O O
after NN O O
7 NN O O
days NN O O
and NN O O
is NN O O
reversible NN O O
after NN O O
discontinuation NN O O
. NN O O
5.10 NN O O
Women NN O O
of NN O O
Childbearing NN O O
Potential NN O O
Premenopausal NN O O
women NN O O
who NN O O
have NN O O
not NN O O
undergone NN O O
a NN O O
hysterectomy NN O O
or NN O O
oophorectomy NN O O
must NN O O
use NN O O
effective NN O O
contraception NN O O
while NN O O
using NN O O
MULTAQ. NN O O
Dronedarone NN O O
caused NN O O
fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
in NN O O
animal NN B-Animal B-Animal
studies NN O O
at NN O O
doses NN O O
equivalent NN O O
to NN O O
recommended NN O O
human NN O O
doses NN O O
. NN O O
Counsel NN O O
women NN O O
of NN O O
childbearing NN O O
potential NN O O
regarding NN O O
appropriate NN O O
contraceptive NN O O
choices NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.1 NN O O
) NN O O
] NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
one NN O O
clinical NN O O
trial NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
with NN O O
the NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
the NN O O
same NN O O
or NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
The NN O O
data NN O O
described NN O O
below NN O O
reflect NN O O
exposure NN O O
to NN O O
Besivance NN O O
in NN O O
approximately NN O O
1,000 NN O O
patients NN O O
between NN O O
1 NN O O
and NN O O
98 NN O O
years NN O O
old NN O O
with NN O O
clinical NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
bacterial NN O O
conjunctivitis NN O O
. NN O O
The NN O O
most NN O O
frequently NN O O
reported NN O O
ocular NN B-AdverseReaction B-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
was NN O O
conjunctival NN B-AdverseReaction B-AdverseReaction
redness NN I-AdverseReaction I-AdverseReaction
reported NN O O
in NN O O
approximately NN O O
2 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
Other NN O O
adverse NN O O
reactions NN O O
reported NN O O
in NN O O
patients NN O O
receiving NN O O
Besivance NN O O
occurring NN O O
in NN O O
approximately NN O O
1 NN O O
- NN O O
2 NN O O
% NN O O
of NN O O
patients NN O O
included NN O O
: NN O O
blurred NN B-AdverseReaction B-AdverseReaction
vision NN I-AdverseReaction I-AdverseReaction
eye NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
eye NN B-AdverseReaction B-AdverseReaction
irritation NN I-AdverseReaction I-AdverseReaction
eye NN B-AdverseReaction B-AdverseReaction
pruritus NN I-AdverseReaction I-AdverseReaction
and NN O O
headache NN B-AdverseReaction B-AdverseReaction
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reaction NN O O
reported NN O O
in NN O O
2 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
Besivance NN O O
was NN O O
conjunctival NN B-AdverseReaction B-AdverseReaction
redness NN I-AdverseReaction I-AdverseReaction
( NN O O
6 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Bausch NN O O
& NN O O
Lomb NN O O
Incorporated NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
323 NN O O
- NN O O
0000 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
Topical NN O O
Ophthalmic NN O O
Use NN O O
Only NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
Growth NN O O
of NN O O
Resistant NN O O
Organisms NN O O
with NN O O
Prolonged NN O O
Use NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
Avoidance NN O O
of NN O O
Contact NN O O
Lenses NN O O
. NN O O
Patients NN O O
should NN O O
not NN O O
wear NN O O
contact NN O O
lenses NN O O
if NN O O
they NN O O
have NN O O
signs NN O O
or NN O O
symptoms NN O O
of NN O O
bacterial NN O O
conjunctivitis NN O O
or NN O O
during NN O O
the NN O O
course NN O O
of NN O O
therapy NN O O
with NN O O
Besivance NN O O
( NN O O
5.3 NN O O
) NN O O
5.1 NN O O
Topical NN O O
Ophthalmic NN O O
Use NN O O
Only NN O O
NOT NN O O
FOR NN O O
INJECTION NN O O
INTO NN O O
THE NN O O
EYE. NN O O
Besivance NN O O
is NN O O
for NN O O
topical NN O O
ophthalmic NN O O
use NN O O
only NN O O
, NN O O
and NN O O
should NN O O
not NN O O
be NN O O
injected NN O O
subconjunctivally NN O O
, NN O O
nor NN O O
should NN O O
it NN O O
be NN O O
introduced NN O O
directly NN O O
into NN O O
the NN O O
anterior NN O O
chamber NN O O
of NN O O
the NN O O
eye NN O O
. NN O O
5.2 NN O O
Growth NN O O
of NN O O
Resistant NN O O
Organisms NN O O
with NN O O
Prolonged NN O O
Use NN O O
As NN O O
with NN O O
other NN O O
anti NN O O
- NN O O
infectives NN O O
, NN O O
prolonged NN O O
use NN O O
of NN O O
Besivance NN O O
( NN O O
besifloxacin NN O O
ophthalmic NN O O
suspension NN O O
) NN O O
0.6 NN O O
% NN O O
may NN B-Factor B-Factor
result NN O O
in NN O O
overgrowth NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
non NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
susceptible NN I-AdverseReaction I-AdverseReaction
organisms NN I-AdverseReaction I-AdverseReaction
including NN O O
fungi NN O O
. NN O O
If NN O O
super NN O O
- NN O O
infection NN O O
occurs NN O O
, NN O O
discontinue NN O O
use NN O O
and NN O O
institute NN O O
alternative NN O O
therapy NN O O
. NN O O
Whenever NN O O
clinical NN O O
judgment NN O O
dictates NN O O
, NN O O
the NN O O
patient NN O O
should NN O O
be NN O O
examined NN O O
with NN O O
the NN O O
aid NN O O
of NN O O
magnification NN O O
, NN O O
such NN O O
as NN O O
slit NN O O
- NN O O
lamp NN O O
biomicroscopy NN O O
, NN O O
and NN O O
, NN O O
where NN O O
appropriate NN O O
, NN O O
fluorescein NN O O
staining NN O O
. NN O O
5.3 NN O O
Avoidance NN O O
of NN O O
Contact NN O O
Lenses NN O O
Patients NN O O
should NN O O
not NN O O
wear NN O O
contact NN O O
lenses NN O O
if NN O O
they NN O O
have NN O O
signs NN O O
or NN O O
symptoms NN O O
of NN O O
bacterial NN O O
conjunctivitis NN O O
or NN O O
during NN O O
the NN O O
course NN O O
of NN O O
therapy NN O O
with NN O O
Besivance NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
serious NN O O
adverse NN O O
reactions NN O O
are NN O O
discussed NN O O
elsewhere NN O O
in NN O O
the NN O O
labeling NN O O
: NN O O
Application NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Associated NN I-AdverseReaction I-AdverseReaction
Pain NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
Increase NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
Blood NN I-AdverseReaction I-AdverseReaction
Pressure NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>= NN O O
5 NN O O
% NN O O
and NN O O
greater NN O O
than NN O O
control NN O O
) NN O O
are NN O O
application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
erythema NN I-AdverseReaction I-AdverseReaction
application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pruritus NN I-AdverseReaction I-AdverseReaction
and NN O O
application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
papules NN I-AdverseReaction I-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Acorda NN O O
Therapeutics NN O O
at NN O O
1 NN O O
- NN O O
877 NN O O
- NN O O
900 NN O O
- NN O O
6479 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
other NN O O
drugs NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O
Across NN O O
all NN O O
controlled NN O O
and NN O O
uncontrolled NN O O
trials NN O O
, NN O O
more NN O O
than NN O O
1,600 NN O O
patients NN O O
have NN O O
received NN O O
Qutenza NN O O
. NN O O
A NN O O
total NN O O
of NN O O
394 NN O O
patients NN O O
received NN O O
more NN O O
than NN O O
one NN O O
treatment NN O O
application NN O O
and NN O O
274 NN O O
patients NN O O
were NN O O
followed NN O O
for NN O O
48 NN O O
weeks NN O O
or NN O O
longer NN O O
. NN O O
In NN O O
controlled NN O O
clinical NN O O
studies NN O O
, NN O O
98 NN O O
% NN O O
of NN O O
patients NN O O
completed NN O O
>= NN O O
90 NN O O
% NN O O
of NN O O
the NN O O
intended NN O O
patch NN O O
application NN O O
duration NN O O
. NN O O
Among NN O O
patients NN O O
treated NN O O
with NN O O
Qutenza NN O O
, NN O O
1 NN O O
% NN O O
discontinued NN O O
prematurely NN O O
due NN O O
to NN O O
an NN O O
adverse NN O O
event NN O O
. NN O O
Controlled NN O O
Clinical NN O O
Studies NN O O
Common NN O O
Adverse NN O O
Reactions NN O O
Adverse NN O O
reactions NN O O
occurring NN O O
in NN O O
>= NN O O
5 NN O O
% NN O O
of NN O O
patients NN O O
in NN O O
the NN O O
Qutenza NN O O
group NN O O
and NN O O
at NN O O
an NN O O
incidence NN O O
greater NN O O
than NN O O
in NN O O
the NN O O
control NN O O
group NN O O
were NN O O
application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
erythema NN I-AdverseReaction I-AdverseReaction
application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pruritus NN I-AdverseReaction I-AdverseReaction
and NN O O
application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
papules NN I-AdverseReaction I-AdverseReaction
Table NN O O
1 NN O O
summarizes NN O O
all NN O O
adverse NN O O
reactions NN O O
, NN O O
regardless NN O O
of NN O O
causality NN O O
, NN O O
occurring NN O O
in NN O O
>= NN O O
1 NN O O
% NN O O
of NN O O
patients NN O O
with NN O O
postherpetic NN O O
neuralgia NN O O
in NN O O
the NN O O
Qutenza NN O O
group NN O O
for NN O O
which NN O O
the NN O O
incidence NN O O
was NN O O
greater NN O O
than NN O O
in NN O O
the NN O O
control NN O O
group NN O O
. NN O O
The NN O O
majority NN O O
of NN O O
application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
were NN O O
transient NN B-Severity B-Severity
and NN O O
self NN O O
- NN O O
limited NN O O
. NN O O
Transient NN B-Severity B-Severity
increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
were NN O O
commonly NN O O
observed NN O O
on NN O O
the NN O O
day NN O O
of NN O O
treatment NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
Qutenza NN O O
. NN O O
Pain NN B-AdverseReaction B-AdverseReaction
increases NN I-AdverseReaction I-AdverseReaction
occurring NN O O
during NN O O
patch NN O O
application NN O O
usually NN O O
began NN O O
to NN O O
resolve NN O O
after NN O O
patch NN O O
removal NN O O
. NN O O
On NN O O
average NN O O
, NN O O
pain NN O O
scores NN O O
returned NN O O
to NN O O
baseline NN O O
by NN O O
the NN O O
end NN O O
of NN O O
the NN O O
treatment NN O O
day NN O O
and NN O O
then NN O O
remained NN O O
at NN O O
or NN O O
below NN O O
baseline NN O O
levels NN O O
. NN O O
A NN O O
majority NN O O
of NN O O
Qutenza NN O O
- NN O O
treated NN O O
patients NN O O
in NN O O
clinical NN O O
studies NN O O
had NN O O
adverse NN O O
reactions NN O O
with NN O O
a NN O O
maximum NN O O
intensity NN O O
of NN O O
" NN O O
mild NN O O
" NN O O
or NN O O
" NN O O
moderate NN O O
" NN O O
. NN O O
TABLE NN O O
1 NN O O
: NN O O
Treatment NN O O
- NN O O
emergent NN O O
adverse NN O O
reaction NN O O
incidence NN O O
( NN O O
% NN O O
) NN O O
in NN O O
controlled NN O O
trials NN O O
in NN O O
Postherpetic NN O O
Neuralgia NN O O
( NN O O
Events NN O O
in NN O O
>= NN O O
1 NN O O
% NN O O
of NN O O
Qutenza NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
at NN O O
least NN O O
1 NN O O
% NN O O
greater NN O O
in NN O O
the NN O O
Qutenza NN O O
group NN O O
than NN O O
in NN O O
the NN O O
Control NN O O
group NN O O
) NN O O
Body NN O O
SystemPreferred NN O O
Term NN O O
Qutenza60 NN O O
minutes(N NN O O
= NN O O
622 NN O O
) NN O O
% NN O O
Control60 NN O O
minutes(N NN O O
= NN O O
495 NN O O
) NN O O
% NN O O
General NN O O
Disorders NN O O
and NN O O
Administration NN O O
Site NN O O
Conditions NN O O
Application NN B-AdverseReaction B-AdverseReaction
Site NN I-AdverseReaction I-AdverseReaction
Erythema NN I-AdverseReaction I-AdverseReaction
63 NN O O
54 NN O O
Application NN B-AdverseReaction B-AdverseReaction
Site NN I-AdverseReaction I-AdverseReaction
Pain NN I-AdverseReaction I-AdverseReaction
42 NN O O
21 NN O O
Application NN B-AdverseReaction B-AdverseReaction
Site NN I-AdverseReaction I-AdverseReaction
Pruritus NN I-AdverseReaction I-AdverseReaction
6 NN O O
4 NN O O
Application NN B-AdverseReaction B-AdverseReaction
Site NN I-AdverseReaction I-AdverseReaction
Papules NN I-AdverseReaction I-AdverseReaction
6 NN O O
3 NN O O
Application NN B-AdverseReaction B-AdverseReaction
Site NN I-AdverseReaction I-AdverseReaction
Edema NN I-AdverseReaction I-AdverseReaction
4 NN O O
1 NN O O
Application NN B-AdverseReaction B-AdverseReaction
Site NN I-AdverseReaction I-AdverseReaction
Swelling NN I-AdverseReaction I-AdverseReaction
2 NN O O
1 NN O O
Application NN B-AdverseReaction B-AdverseReaction
Site NN I-AdverseReaction I-AdverseReaction
Dryness NN I-AdverseReaction I-AdverseReaction
2 NN O O
1 NN O O
Infections NN O O
and NN O O
Infestations NN O O
Nasopharyngitis NN B-AdverseReaction B-AdverseReaction
4 NN O O
2 NN O O
Bronchitis NN B-AdverseReaction B-AdverseReaction
2 NN O O
1 NN O O
Sinusitis NN B-AdverseReaction B-AdverseReaction
3 NN O O
1 NN O O
Gastrointestinal NN O O
Disorders NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
5 NN O O
2 NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
3 NN O O
1 NN O O
Skin NN O O
and NN O O
Subcutaneous NN O O
Tissue NN O O
Disorder NN O O
Pruritus NN B-AdverseReaction B-AdverseReaction
2 NN O O
< NN O O
1 NN O O
Vascular NN O O
Disorders NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
2 NN O O
1 NN O O
Other NN O O
Adverse NN O O
Reactions NN O O
Observed NN O O
During NN O O
the NN O O
Clinical NN O O
Studies NN O O
of NN O O
Qutenza NN O O
General NN O O
Disorders NN O O
and NN O O
Administration NN O O
Site NN O O
Conditions NN O O
: NN O O
Application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
urticaria NN I-AdverseReaction I-AdverseReaction
Application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
paresthesia NN I-AdverseReaction I-AdverseReaction
Application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
dermatitis NN I-AdverseReaction I-AdverseReaction
Application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
hyperesthesia NN I-AdverseReaction I-AdverseReaction
Application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
excoriation NN I-AdverseReaction I-AdverseReaction
Application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
warmth NN I-AdverseReaction I-AdverseReaction
Application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
anesthesia NN I-AdverseReaction I-AdverseReaction
Application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
bruising NN I-AdverseReaction I-AdverseReaction
Application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
inflammation NN I-AdverseReaction I-AdverseReaction
Application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
exfoliation NN I-AdverseReaction I-AdverseReaction
Peripheral NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
Nervous NN O O
System NN O O
Disorders NN O O
: NN O O
Headache NN B-AdverseReaction B-AdverseReaction
Burning NN B-AdverseReaction B-AdverseReaction
sensation NN I-AdverseReaction I-AdverseReaction
Peripheral NN B-AdverseReaction B-AdverseReaction
sensory NN I-AdverseReaction I-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
Dizziness NN B-AdverseReaction B-AdverseReaction
Dysgeusia NN B-AdverseReaction B-AdverseReaction
Hyperesthesia NN B-AdverseReaction B-AdverseReaction
Hypoesthesia NN B-AdverseReaction B-AdverseReaction
Respiratory NN O O
, NN O O
Thoracic NN O O
and NN O O
Mediastinal NN O O
Disorders NN O O
: NN O O
Cough NN B-AdverseReaction B-AdverseReaction
Throat NN B-AdverseReaction B-AdverseReaction
irritation NN I-AdverseReaction I-AdverseReaction
Skin NN O O
and NN O O
Subcutaneous NN O O
Tissue NN O O
Disorders NN O O
: NN O O
Abnormal NN B-AdverseReaction B-AdverseReaction
skin NN I-AdverseReaction I-AdverseReaction
odor NN I-AdverseReaction I-AdverseReaction
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Do NN O O
not NN O O
use NN O O
near NN O O
eyes NN O O
or NN O O
mucous NN O O
membranes NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Inhalation NN O O
of NN O O
airborne NN O O
capsaicin NN O O
can NN B-Factor B-Factor
result NN O O
in NN O O
coughing NN B-AdverseReaction B-AdverseReaction
or NN O O
sneezing NN B-AdverseReaction B-AdverseReaction
( NN O O
5.2 NN O O
) NN O O
* NN O O
If NN O O
irritation NN O O
of NN O O
eyes NN O O
or NN O O
airway NN O O
occurs NN O O
, NN O O
remove NN O O
the NN O O
affected NN O O
individual NN O O
from NN O O
the NN O O
vicinity NN O O
of NN O O
Qutenza NN O O
and NN O O
flush NN O O
the NN O O
mucous NN O O
membranes NN O O
or NN O O
eyes NN O O
with NN O O
water NN O O
. NN O O
If NN O O
skin NN O O
not NN O O
intended NN O O
to NN O O
be NN O O
treated NN O O
comes NN O O
into NN O O
contact NN O O
with NN O O
Qutenza NN O O
, NN O O
apply NN O O
Cleansing NN O O
Gel NN O O
and NN O O
then NN O O
wipe NN O O
off NN O O
with NN O O
dry NN O O
gauze NN O O
. NN O O
( NN O O
5.2 NN O O
, NN O O
5.3 NN O O
) NN O O
* NN O O
Transient NN B-Severity B-Severity
increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
blood NN I-AdverseReaction I-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
may NN B-Factor B-Factor
occur NN O O
in NN O O
patients NN O O
during NN O O
and NN O O
shortly NN O O
after NN O O
the NN O O
Qutenza NN O O
treatment NN O O
. NN O O
Monitor NN O O
blood NN O O
pressure NN O O
during NN O O
and NN O O
following NN O O
the NN O O
treatment NN O O
procedure NN O O
. NN O O
For NN O O
those NN O O
patients NN O O
who NN O O
require NN O O
the NN O O
use NN O O
of NN O O
opioids NN O O
to NN O O
treat NN O O
pain NN O O
during NN O O
or NN O O
following NN O O
the NN O O
procedure NN O O
, NN O O
their NN O O
ability NN O O
to NN O O
perform NN O O
potentially NN O O
hazardous NN O O
activities NN O O
such NN O O
as NN O O
driving NN O O
or NN O O
operating NN O O
machinery NN O O
may NN O O
be NN O O
affected NN O O
. NN O O
( NN O O
5.4 NN O O
, NN O O
5.5 NN O O
) NN O O
5.1 NN O O
Eye NN O O
and NN O O
Mucous NN O O
Membrane NN O O
Exposure NN O O
Do NN O O
not NN O O
apply NN O O
Qutenza NN O O
to NN O O
the NN O O
face NN O O
or NN O O
scalp NN O O
to NN O O
avoid NN O O
risk NN O O
of NN O O
exposure NN O O
to NN O O
the NN O O
eyes NN O O
or NN O O
mucous NN O O
membranes NN O O
. NN O O
5.2 NN O O
Aerosolization NN O O
of NN O O
Capsaicin NN O O
Aerosolization NN O O
of NN O O
capsaicin NN O O
can NN O O
occur NN O O
upon NN O O
rapid NN O O
removal NN O O
of NN O O
Qutenza NN O O
patches NN O O
. NN O O
Therefore NN O O
, NN O O
remove NN O O
Qutenza NN O O
patches NN O O
gently NN O O
and NN O O
slowly NN O O
by NN O O
rolling NN O O
the NN O O
adhesive NN O O
side NN O O
inward NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
] NN O O
. NN O O
If NN O O
irritation NN O O
of NN O O
eyes NN O O
or NN O O
airways NN O O
occurs NN O O
, NN O O
remove NN O O
the NN O O
affected NN O O
individual NN O O
from NN O O
the NN O O
vicinity NN O O
of NN O O
Qutenza NN O O
. NN O O
Flush NN O O
eyes NN O O
and NN O O
mucous NN O O
membranes NN O O
with NN O O
cool NN O O
water NN O O
. NN O O
Inhalation NN O O
of NN O O
airborne NN O O
capsaicin NN O O
can NN B-Factor B-Factor
result NN O O
in NN O O
coughing NN B-AdverseReaction B-AdverseReaction
or NN O O
sneezing NN B-AdverseReaction B-AdverseReaction
Provide NN O O
supportive NN O O
medical NN O O
care NN O O
if NN O O
shortness NN O O
of NN O O
breath NN O O
develops NN O O
. NN O O
5.3 NN O O
Unintended NN O O
Skin NN O O
Exposure NN O O
If NN O O
skin NN O O
not NN O O
intended NN O O
to NN O O
be NN O O
treated NN O O
comes NN O O
in NN O O
contact NN O O
with NN O O
Qutenza NN O O
, NN O O
apply NN O O
Cleansing NN O O
Gel NN O O
for NN O O
one NN O O
minute NN O O
and NN O O
wipe NN O O
off NN O O
with NN O O
dry NN O O
gauze NN O O
. NN O O
After NN O O
the NN O O
Cleansing NN O O
Gel NN O O
has NN O O
been NN O O
wiped NN O O
off NN O O
, NN O O
wash NN O O
the NN O O
area NN O O
with NN O O
soap NN O O
and NN O O
water NN O O
. NN O O
5.4 NN O O
Application NN O O
Associated NN O O
Pain NN O O
Even NN O O
following NN O O
use NN O O
of NN O O
a NN O O
local NN O O
anesthetic NN O O
prior NN O O
to NN O O
administration NN O O
of NN O O
Qutenza NN O O
, NN O O
patients NN O O
may NN B-Factor B-Factor
experience NN O O
substantial NN B-Severity B-Severity
procedural NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
Prepare NN O O
to NN O O
treat NN O O
acute NN O O
pain NN O O
during NN O O
and NN O O
following NN O O
the NN O O
application NN O O
procedure NN O O
with NN O O
local NN O O
cooling NN O O
( NN O O
such NN O O
as NN O O
an NN O O
ice NN O O
pack NN O O
) NN O O
and/or NN O O
appropriate NN O O
analgesic NN O O
medication NN O O
, NN O O
such NN O O
as NN O O
opioids NN O O
. NN O O
Opioids NN O O
may NN O O
affect NN O O
the NN O O
ability NN O O
to NN O O
perform NN O O
potentially NN O O
hazardous NN O O
activities NN O O
such NN O O
as NN O O
driving NN O O
or NN O O
operating NN O O
machinery NN O O
. NN O O
5.5 NN O O
Increase NN O O
in NN O O
Blood NN O O
Pressure NN O O
In NN O O
clinical NN O O
trials NN O O
, NN O O
increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
blood NN I-AdverseReaction I-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
occurred NN O O
during NN O O
or NN O O
shortly NN O O
after NN O O
exposure NN O O
to NN O O
Qutenza NN O O
. NN O O
The NN O O
changes NN O O
averaged NN O O
less NN O O
than NN O O
10 NN O O
mm NN O O
Hg NN O O
, NN O O
although NN O O
some NN O O
patients NN O O
had NN O O
greater NN O O
increases NN O O
and NN O O
these NN O O
changes NN O O
lasted NN O O
for NN O O
approximately NN O O
two NN O O
hours NN O O
after NN O O
patch NN O O
removal NN O O
. NN O O
Increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
blood NN I-AdverseReaction I-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
were NN O O
unrelated NN O O
to NN O O
the NN O O
pretreatment NN O O
blood NN O O
pressure NN O O
but NN O O
were NN O O
related NN O O
to NN O O
treatment NN O O
- NN O O
related NN O O
increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
blood NN O O
pressure NN O O
periodically NN O O
during NN O O
the NN O O
treatment NN O O
and NN O O
provide NN O O
adequate NN O O
support NN O O
for NN O O
treatment NN O O
related NN O O
pain NN O O
. NN O O
Patients NN O O
with NN O O
unstable NN O O
or NN O O
poorly NN O O
controlled NN O O
hypertension NN O O
, NN O O
a NN O O
recent NN O O
history NN O O
of NN O O
cardiovascular NN O O
or NN O O
cerebrovascular NN O O
events NN O O
may NN O O
be NN O O
at NN O O
an NN O O
increased NN O O
risk NN B-Factor B-Factor
of NN O O
adverse NN B-AdverseReaction B-AdverseReaction
cardiovascular NN I-AdverseReaction I-AdverseReaction
effects NN I-AdverseReaction I-AdverseReaction
Consider NN O O
these NN O O
factors NN O O
prior NN O O
to NN O O
initiating NN O O
Qutenza NN O O
treatment NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
. NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
are NN O O
discussed NN O O
in NN O O
greater NN O O
detail NN O O
in NN O O
other NN O O
sections NN O O
of NN O O
the NN O O
label NN O O
: NN O O
* NN O O
Cytokine NN B-AdverseReaction B-AdverseReaction
Release NN I-AdverseReaction I-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Neurological NN B-AdverseReaction B-AdverseReaction
Toxicities NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
Infections NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
* NN O O
Tumor NN B-AdverseReaction B-AdverseReaction
Lysis NN I-AdverseReaction I-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
* NN O O
Neutropenia NN B-AdverseReaction B-AdverseReaction
and NN O O
Febrile NN B-AdverseReaction B-AdverseReaction
Neutropenia NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
* NN O O
Effects NN B-AdverseReaction B-AdverseReaction
on NN I-AdverseReaction I-AdverseReaction
Ability NN I-AdverseReaction I-AdverseReaction
to NN I-AdverseReaction I-AdverseReaction
Drive NN I-AdverseReaction I-AdverseReaction
and NN O O
Use NN O O
Machines NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.6 NN O O
) NN O O
] NN O O
* NN O O
Elevated NN B-AdverseReaction B-AdverseReaction
Liver NN I-AdverseReaction I-AdverseReaction
Enzymes NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.7 NN O O
) NN O O
] NN O O
* NN O O
Leukoencephalopathy NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.8 NN O O
) NN O O
] NN O O
* NN O O
Preparation NN O O
and NN O O
Administration NN O O
Errors NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.9 NN O O
) NN O O
] NN O O
* NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>= NN O O
20 NN O O
% NN O O
) NN O O
were NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
peripheral NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
febrile NN B-AdverseReaction B-AdverseReaction
neutropenia NN I-AdverseReaction I-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
hypokalemia NN B-AdverseReaction B-AdverseReaction
tremor NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
and NN O O
constipation NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
EXCERPT NN O O
: NN O O
} NN O O
} NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Amgen NN O O
Inc. NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
77-AMGEN NN O O
( NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
772 NN O O
- NN O O
6436 NN O O
) NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
The NN O O
safety NN O O
data NN O O
described NN O O
in NN O O
this NN O O
section NN O O
reflect NN O O
exposure NN O O
to NN O O
BLINCYTO NN O O
in NN O O
clinical NN O O
trials NN O O
in NN O O
which NN O O
212 NN O O
patients NN O O
with NN O O
relapsed NN O O
or NN O O
refractory NN O O
ALL NN O O
received NN O O
up NN O O
to NN O O
28 NN O O
mcg/day NN O O
. NN O O
All NN O O
patients NN O O
received NN O O
at NN O O
least NN O O
one NN O O
dose NN O O
of NN O O
BLINCYTO. NN O O
The NN O O
median NN O O
age NN O O
of NN O O
the NN O O
study NN O O
population NN O O
was NN O O
37 NN O O
years NN O O
( NN O O
range NN O O
: NN O O
18 NN O O
to NN O O
79 NN O O
years NN O O
) NN O O
, NN O O
63 NN O O
% NN O O
were NN O O
male NN O O
, NN O O
79 NN O O
% NN O O
were NN O O
White NN O O
, NN O O
3 NN O O
% NN O O
were NN O O
Asian NN O O
, NN O O
and NN O O
3 NN O O
% NN O O
were NN O O
Black NN O O
or NN O O
African NN O O
American NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>= NN O O
20 NN O O
% NN O O
) NN O O
were NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
( NN O O
62 NN O O
% NN O O
) NN O O
, NN O O
headache NN B-AdverseReaction B-AdverseReaction
( NN O O
36 NN O O
% NN O O
) NN O O
, NN O O
peripheral NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
( NN O O
25 NN O O
% NN O O
) NN O O
, NN O O
febrile NN B-AdverseReaction B-AdverseReaction
neutropenia NN I-AdverseReaction I-AdverseReaction
( NN O O
25 NN O O
% NN O O
) NN O O
, NN O O
nausea NN B-AdverseReaction B-AdverseReaction
( NN O O
25 NN O O
% NN O O
) NN O O
, NN O O
hypokalemia NN B-AdverseReaction B-AdverseReaction
( NN O O
23 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
constipation NN B-AdverseReaction B-AdverseReaction
( NN O O
20 NN O O
% NN O O
) NN O O
. NN O O
Serious NN O O
adverse NN O O
reactions NN O O
were NN O O
reported NN O O
in NN O O
65 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
The NN O O
most NN O O
common NN O O
serious NN O O
adverse NN O O
reactions NN O O
( NN O O
>= NN O O
2 NN O O
% NN O O
) NN O O
included NN O O
febrile NN B-AdverseReaction B-AdverseReaction
neutropenia NN I-AdverseReaction I-AdverseReaction
pyrexia NN B-AdverseReaction B-AdverseReaction
pneumonia NN B-AdverseReaction B-AdverseReaction
sepsis NN B-AdverseReaction B-AdverseReaction
neutropenia NN B-AdverseReaction B-AdverseReaction
device NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
tremor NN B-AdverseReaction B-AdverseReaction
encephalopathy NN B-AdverseReaction B-AdverseReaction
infection NN B-AdverseReaction B-AdverseReaction
overdose NN B-AdverseReaction B-AdverseReaction
confusion NN B-AdverseReaction B-AdverseReaction
Staphylococcal NN B-AdverseReaction B-AdverseReaction
bacteremia NN I-AdverseReaction I-AdverseReaction
and NN O O
headache NN B-AdverseReaction B-AdverseReaction
Adverse NN O O
reactions NN O O
of NN O O
Grade NN O O
3 NN O O
or NN O O
higher NN O O
were NN O O
reported NN O O
in NN O O
80 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
Discontinuation NN O O
of NN O O
therapy NN O O
due NN O O
to NN O O
adverse NN O O
reactions NN O O
occurred NN O O
in NN O O
18 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
BLINCYTO. NN O O
The NN O O
adverse NN O O
reactions NN O O
reported NN O O
most NN O O
frequently NN O O
as NN O O
the NN O O
reason NN O O
for NN O O
discontinuation NN O O
of NN O O
treatment NN O O
included NN O O
encephalopathy NN B-AdverseReaction B-AdverseReaction
and NN O O
sepsis NN B-AdverseReaction B-AdverseReaction
Fatal NN B-AdverseReaction B-AdverseReaction
adverse NN O O
events NN O O
occurred NN O O
in NN O O
15 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
The NN O O
majority NN O O
of NN O O
these NN O O
events NN O O
were NN O O
infections NN B-AdverseReaction B-AdverseReaction
No NN B-Negation B-Negation
fatal NN B-AdverseReaction B-AdverseReaction
adverse NN O O
events NN O O
occurred NN O O
on NN O O
treatment NN O O
among NN O O
patients NN O O
in NN O O
remission NN O O
. NN O O
The NN O O
adverse NN O O
reactions NN O O
with NN O O
>= NN O O
10 NN O O
% NN O O
incidence NN O O
for NN O O
any NN O O
grade NN O O
or NN O O
>= NN O O
5 NN O O
% NN O O
incidence NN O O
for NN O O
Grade NN O O
3 NN O O
or NN O O
higher NN O O
are NN O O
summarized NN O O
in NN O O
Table NN O O
2 NN O O
. NN O O
Table NN O O
2 NN O O
. NN O O
Adverse NN O O
Reactions NN O O
With NN O O
>= NN O O
10 NN O O
% NN O O
Incidence NN O O
for NN O O
Any NN O O
Grade NN O O
or NN O O
>= NN O O
5 NN O O
% NN O O
Incidence NN O O
for NN O O
Grade NN O O
3 NN O O
or NN O O
Higher NN O O
( NN O O
N NN O O
= NN O O
212 NN O O
) NN O O
Adverse NN O O
Reaction NN O O
Any NN O O
GradeGrading NN O O
based NN O O
on NN O O
NCI NN O O
Common NN O O
Terminology NN O O
Criteria NN O O
for NN O O
Adverse NN O O
Events NN O O
( NN O O
CTCAE NN O O
) NN O O
version NN O O
4.0( NN O O
% NN O O
) NN O O
Grade NN O O
3 NN O O
or NN O O
Higher( NN O O
% NN O O
) NN O O
Blood NN O O
and NN O O
lymphatic NN O O
system NN O O
disorders NN O O
Febrile NN B-AdverseReaction B-AdverseReaction
neutropenia NN I-AdverseReaction I-AdverseReaction
Anemia NN B-AdverseReaction B-AdverseReaction
Neutropenia NN B-AdverseReaction B-AdverseReaction
Thrombocytopenia NN B-AdverseReaction B-AdverseReaction
Leukopenia NN B-AdverseReaction B-AdverseReaction
251816119 NN O O
23131588 NN O O
Gastrointestinal NN O O
disorders NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
Constipation NN B-AdverseReaction B-AdverseReaction
Diarrhea NN B-AdverseReaction B-AdverseReaction
includes NN O O
the NN O O
following NN O O
terms NN O O
: NN O O
colitis NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
enteritis NN B-AdverseReaction B-AdverseReaction
and NN O O
neutropenic NN B-AdverseReaction B-AdverseReaction
colitis NN I-AdverseReaction I-AdverseReaction
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
Vomiting NN B-AdverseReaction B-AdverseReaction
2520201513 NN O O
0< NN O O
1120 NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
Peripheral NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
Fatigue NN B-AdverseReaction B-AdverseReaction
Chills NN B-AdverseReaction B-AdverseReaction
Chest NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
6225171511 NN O O
7< NN O O
1101 NN O O
Immune NN O O
system NN O O
disorders NN O O
Cytokine NN B-AdverseReaction B-AdverseReaction
release NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
11 NN O O
1 NN O O
Infections NN O O
and NN O O
infestations NN O O
Other NN O O
pathogen NN O O
infections NN B-AdverseReaction B-AdverseReaction
Bacterial NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
Fungal NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
Viral NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
Pneumonia NN B-AdverseReaction B-AdverseReaction
Sepsis NN B-AdverseReaction B-AdverseReaction
4419151397 NN O O
25127486 NN O O
Investigations NN O O
Increased NN B-AdverseReaction B-AdverseReaction
alanine NN I-AdverseReaction I-AdverseReaction
aminotransferase NN I-AdverseReaction I-AdverseReaction
Increased NN B-AdverseReaction B-AdverseReaction
aspartate NN I-AdverseReaction I-AdverseReaction
aminotransferase NN I-AdverseReaction I-AdverseReaction
Increased NN B-AdverseReaction B-AdverseReaction
weight NN I-AdverseReaction I-AdverseReaction
121111 NN O O
640 NN O O
Metabolism NN O O
and NN O O
nutrition NN O O
disorders NN O O
Hypokalemia NN B-AdverseReaction B-AdverseReaction
Hypomagnesemia NN B-AdverseReaction B-AdverseReaction
Hyperglycemia NN B-AdverseReaction B-AdverseReaction
Decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
Hypophosphatemia NN B-AdverseReaction B-AdverseReaction
231211106 NN O O
60735 NN O O
Musculoskeletal NN O O
and NN O O
connective NN O O
tissue NN O O
disorders NN O O
Back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
Pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
Bone NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
Arthralgia NN B-AdverseReaction B-AdverseReaction
14121110 NN O O
2132 NN O O
Nervous NN O O
system NN O O
disorders NN O O
Headache NN B-AdverseReaction B-AdverseReaction
Tremor NN B-AdverseReaction B-AdverseReaction
includes NN O O
the NN O O
following NN O O
terms NN O O
: NN O O
resting NN B-AdverseReaction B-AdverseReaction
tremor NN I-AdverseReaction I-AdverseReaction
and NN O O
tremor NN B-AdverseReaction B-AdverseReaction
Dizziness NN B-AdverseReaction B-AdverseReaction
362014 NN O O
31< NN O O
1 NN O O
Psychiatric NN O O
disorders NN O O
Insomnia NN B-AdverseReaction B-AdverseReaction
15 NN O O
0 NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
, NN O O
and NN O O
mediastinal NN O O
disorders NN O O
Cough NN B-AdverseReaction B-AdverseReaction
Dyspnea NN B-AdverseReaction B-AdverseReaction
includes NN O O
the NN O O
following NN O O
terms NN O O
: NN O O
acute NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
bronchial NN B-AdverseReaction B-AdverseReaction
hyperactivity NN I-AdverseReaction I-AdverseReaction
bronchospasm NN B-AdverseReaction B-AdverseReaction
dyspnea NN B-AdverseReaction B-AdverseReaction
dyspnea NN B-AdverseReaction B-AdverseReaction
exertional NN I-AdverseReaction I-AdverseReaction
respiratory NN B-AdverseReaction B-AdverseReaction
distress NN I-AdverseReaction I-AdverseReaction
respiratory NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
and NN O O
wheezing NN B-AdverseReaction B-AdverseReaction
1915 NN O O
05 NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
Rash NN B-AdverseReaction B-AdverseReaction
includes NN O O
the NN O O
following NN O O
terms NN O O
: NN O O
erythema NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
erythematous NN B-AdverseReaction B-AdverseReaction
rash NN I-AdverseReaction I-AdverseReaction
generalized NN B-AdverseReaction B-AdverseReaction
rash NN I-AdverseReaction I-AdverseReaction
macular NN B-AdverseReaction B-AdverseReaction
rash NN I-AdverseReaction I-AdverseReaction
maculo NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
papular NN I-AdverseReaction I-AdverseReaction
rash NN I-AdverseReaction I-AdverseReaction
papular NN B-AdverseReaction B-AdverseReaction
rash NN I-AdverseReaction I-AdverseReaction
and NN O O
vesicular NN B-AdverseReaction B-AdverseReaction
rash NN I-AdverseReaction I-AdverseReaction
21 NN O O
2 NN O O
Vascular NN O O
disorders NN O O
Hypotension NN B-AdverseReaction B-AdverseReaction
Hypertension NN B-AdverseReaction B-AdverseReaction
118 NN O O
25 NN O O
Additional NN O O
important NN O O
adverse NN O O
reactions NN O O
that NN O O
did NN O O
not NN O O
meet NN O O
the NN O O
threshold NN O O
criteria NN O O
for NN O O
inclusion NN O O
in NN O O
Table NN O O
2 NN O O
were NN O O
: NN O O
Blood NN O O
and NN O O
lymphatic NN O O
system NN O O
disorders NN O O
: NN O O
leukocytosis NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
, NN O O
lymphopenia NN B-AdverseReaction B-AdverseReaction
( NN O O
1 NN O O
% NN O O
) NN O O
Cardiac NN O O
disorders NN O O
: NN O O
tachycardia NN B-AdverseReaction B-AdverseReaction
( NN O O
8 NN O O
% NN O O
) NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
: NN O O
edema NN B-AdverseReaction B-AdverseReaction
( NN O O
5 NN O O
% NN O O
) NN O O
Immune NN O O
system NN O O
disorders NN O O
: NN O O
cytokine NN B-AdverseReaction B-AdverseReaction
storm NN I-AdverseReaction I-AdverseReaction
( NN O O
1 NN O O
% NN O O
) NN O O
Investigations NN O O
: NN O O
decreased NN B-AdverseReaction B-AdverseReaction
immunoglobulins NN I-AdverseReaction I-AdverseReaction
( NN O O
9 NN O O
% NN O O
) NN O O
, NN O O
increased NN B-AdverseReaction B-AdverseReaction
blood NN I-AdverseReaction I-AdverseReaction
bilirubin NN I-AdverseReaction I-AdverseReaction
( NN O O
8 NN O O
% NN O O
) NN O O
, NN O O
increased NN B-AdverseReaction B-AdverseReaction
gamma NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
glutamyl NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
transferase NN I-AdverseReaction I-AdverseReaction
( NN O O
6 NN O O
% NN O O
) NN O O
, NN O O
increased NN B-AdverseReaction B-AdverseReaction
liver NN I-AdverseReaction I-AdverseReaction
enzymes NN I-AdverseReaction I-AdverseReaction
( NN O O
1 NN O O
% NN O O
) NN O O
Metabolism NN O O
and NN O O
nutrition NN O O
disorders NN O O
: NN O O
tumor NN B-AdverseReaction B-AdverseReaction
lysis NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
4 NN O O
% NN O O
) NN O O
, NN O O
hypoalbuminemia NN B-AdverseReaction B-AdverseReaction
( NN O O
4 NN O O
% NN O O
) NN O O
Nervous NN O O
system NN O O
disorders NN O O
: NN O O
encephalopathy NN B-AdverseReaction B-AdverseReaction
( NN O O
5 NN O O
% NN O O
) NN O O
, NN O O
paresthesia NN B-AdverseReaction B-AdverseReaction
( NN O O
5 NN O O
% NN O O
) NN O O
, NN O O
aphasia NN B-AdverseReaction B-AdverseReaction
( NN O O
4 NN O O
% NN O O
) NN O O
, NN O O
convulsion NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
, NN O O
memory NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
, NN O O
cognitive NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
( NN O O
1 NN O O
% NN O O
) NN O O
, NN O O
speech NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
Psychiatric NN O O
disorders NN O O
: NN O O
confusion NN B-AdverseReaction B-AdverseReaction
( NN O O
7 NN O O
% NN O O
) NN O O
, NN O O
disorientation NN B-AdverseReaction B-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
Vascular NN O O
disorders NN O O
: NN O O
capillary NN B-AdverseReaction B-AdverseReaction
leak NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
. NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
related NN O O
to NN O O
BLINCYTO NN O O
treatment NN O O
were NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
( NN O O
1 NN O O
% NN O O
) NN O O
and NN O O
bronchospasm NN B-AdverseReaction B-AdverseReaction
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
. NN O O
6.2 NN O O
Immunogenicity NN O O
As NN O O
with NN O O
all NN O O
therapeutic NN O O
proteins NN O O
, NN O O
there NN O O
is NN O O
potential NN O O
for NN O O
immunogenicity NN O O
. NN O O
The NN O O
immunogenicity NN O O
of NN O O
BLINCYTO NN O O
has NN O O
been NN O O
evaluated NN O O
using NN O O
either NN O O
an NN O O
electrochemiluminescence NN O O
detection NN O O
technology NN O O
( NN O O
ECL NN O O
) NN O O
or NN O O
an NN O O
enzyme NN O O
- NN O O
linked NN O O
immunosorbent NN O O
assay NN O O
( NN O O
ELISA NN O O
) NN O O
screening NN O O
immunoassay NN O O
for NN O O
the NN O O
detection NN O O
of NN O O
binding NN O O
anti NN O O
- NN O O
blinatumomab NN O O
antibodies NN O O
. NN O O
For NN O O
patients NN O O
whose NN O O
sera NN O O
tested NN O O
positive NN O O
in NN O O
the NN O O
screening NN O O
immunoassay NN O O
, NN O O
an NN O O
in NN O O
vitro NN O O
biological NN O O
assay NN O O
was NN O O
performed NN O O
to NN O O
detect NN O O
neutralizing NN O O
antibodies NN O O
. NN O O
In NN O O
clinical NN O O
studies NN O O
, NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
BLINCYTO NN O O
tested NN O O
positive NN O O
for NN O O
binding NN O O
anti NN O O
- NN O O
blinatumomab NN O O
antibodies NN O O
. NN O O
All NN O O
patients NN O O
who NN O O
tested NN O O
positive NN O O
for NN O O
binding NN O O
antibodies NN O O
also NN O O
tested NN O O
positive NN O O
for NN O O
neutralizing NN O O
anti NN O O
- NN O O
blinatumomab NN O O
antibodies NN O O
. NN O O
Anti NN O O
- NN O O
blinatumomab NN O O
antibody NN O O
formation NN O O
may NN O O
affect NN O O
pharmacokinetics NN O O
of NN O O
BLINCYTO. NN O O
No NN O O
association NN O O
was NN O O
seen NN O O
between NN O O
antibody NN O O
development NN O O
and NN O O
development NN O O
of NN O O
adverse NN O O
events NN O O
. NN O O
If NN O O
formation NN O O
of NN O O
anti NN O O
- NN O O
blinatumomab NN O O
antibodies NN O O
with NN O O
a NN O O
clinically NN O O
significant NN O O
effect NN O O
is NN O O
suspected NN O O
, NN O O
contact NN O O
Amgen NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
77-AMGEN NN O O
( NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
772 NN O O
- NN O O
6436 NN O O
) NN O O
to NN O O
discuss NN O O
antibody NN O O
testing NN O O
. NN O O
The NN O O
detection NN O O
of NN O O
anti NN O O
- NN O O
blinatumomab NN O O
antibody NN O O
formation NN O O
is NN O O
highly NN O O
dependent NN O O
on NN O O
the NN O O
sensitivity NN O O
and NN O O
specificity NN O O
of NN O O
the NN O O
assay NN O O
. NN O O
Additionally NN O O
, NN O O
the NN O O
observed NN O O
incidence NN O O
of NN O O
antibody NN O O
( NN O O
including NN O O
neutralizing NN O O
antibody NN O O
) NN O O
positivity NN O O
in NN O O
an NN O O
assay NN O O
may NN O O
be NN O O
influenced NN O O
by NN O O
several NN O O
factors NN O O
, NN O O
including NN O O
assay NN O O
methodology NN O O
, NN O O
sample NN O O
handling NN O O
, NN O O
timing NN O O
of NN O O
sample NN O O
collection NN O O
, NN O O
concomitant NN O O
medications NN O O
, NN O O
and NN O O
underlying NN O O
disease NN O O
. NN O O
For NN O O
these NN O O
reasons NN O O
, NN O O
comparison NN O O
of NN O O
the NN O O
incidence NN O O
of NN O O
antibodies NN O O
to NN O O
blinatumomab NN O O
with NN O O
the NN O O
incidence NN O O
of NN O O
antibodies NN O O
to NN O O
other NN O O
products NN O O
may NN O O
be NN O O
misleading NN O O
. NN O O
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
CYTOKINE NN B-AdverseReaction B-AdverseReaction
RELEASE NN I-AdverseReaction I-AdverseReaction
SYNDROME NN I-AdverseReaction I-AdverseReaction
and NN O O
NEUROLOGICAL NN B-AdverseReaction B-AdverseReaction
TOXICITIES NN I-AdverseReaction I-AdverseReaction
WARNING NN O O
: NN O O
CYTOKINE NN B-AdverseReaction B-AdverseReaction
RELEASE NN I-AdverseReaction I-AdverseReaction
SYNDROME NN I-AdverseReaction I-AdverseReaction
and NN O O
NEUROLOGICAL NN B-AdverseReaction B-AdverseReaction
TOXICITIES NN I-AdverseReaction I-AdverseReaction
* NN O O
Cytokine NN B-AdverseReaction B-AdverseReaction
Release NN I-AdverseReaction I-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
CRS NN O O
) NN O O
, NN O O
which NN O O
may NN B-Factor B-Factor
be NN O O
life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
or NN O O
fatal NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
patients NN O O
receiving NN O O
BLINCYTO. NN O O
Interrupt NN O O
or NN O O
discontinue NN O O
BLINCYTO NN O O
as NN O O
recommended NN O O
. NN O O
[ NN O O
See NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
, NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Neurological NN B-AdverseReaction B-AdverseReaction
toxicities NN I-AdverseReaction I-AdverseReaction
which NN O O
may NN B-Factor B-Factor
be NN O O
severe NN B-Severity B-Severity
life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
or NN O O
fatal NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
patients NN O O
receiving NN O O
BLINCYTO. NN O O
Interrupt NN O O
or NN O O
discontinue NN O O
BLINCYTO NN O O
as NN O O
recommended NN O O
. NN O O
[ NN O O
See NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
, NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
EXCERPT NN O O
: NN O O
WARNING NN O O
: NN O O
CYTOKINE NN B-AdverseReaction B-AdverseReaction
RELEASE NN I-AdverseReaction I-AdverseReaction
SYNDROME NN I-AdverseReaction I-AdverseReaction
and NN O O
NEUROLOGICAL NN B-AdverseReaction B-AdverseReaction
TOXICITIES NN I-AdverseReaction I-AdverseReaction
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
. NN O O
* NN O O
Cytokine NN B-AdverseReaction B-AdverseReaction
Release NN I-AdverseReaction I-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
CRS NN O O
) NN O O
, NN O O
which NN O O
may NN B-Factor B-Factor
be NN O O
life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
or NN O O
fatal NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
patients NN O O
receiving NN O O
BLINCYTO. NN O O
Interrupt NN O O
or NN O O
discontinue NN O O
BLINCYTO NN O O
as NN O O
recommended NN O O
. NN O O
( NN O O
2.3 NN O O
) NN O O
, NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Neurological NN B-AdverseReaction B-AdverseReaction
toxicities NN I-AdverseReaction I-AdverseReaction
which NN O O
may NN B-Factor B-Factor
be NN O O
severe NN B-Severity B-Severity
life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
or NN O O
fatal NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
patients NN O O
receiving NN O O
BLINCYTO. NN O O
Interrupt NN O O
or NN O O
discontinue NN O O
BLINCYTO NN O O
as NN O O
recommended NN O O
. NN O O
( NN O O
2.3 NN O O
) NN O O
, NN O O
( NN O O
5.2 NN O O
) NN O O
5 NN O O
. NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Infections NN B-AdverseReaction B-AdverseReaction
Monitor NN O O
patients NN O O
for NN O O
signs NN O O
or NN O O
symptoms NN O O
and NN O O
treat NN O O
appropriately NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Effects NN B-AdverseReaction B-AdverseReaction
on NN I-AdverseReaction I-AdverseReaction
Ability NN I-AdverseReaction I-AdverseReaction
to NN I-AdverseReaction I-AdverseReaction
Drive NN I-AdverseReaction I-AdverseReaction
and NN O O
Use NN O O
Machines NN O O
: NN O O
Advise NN O O
patients NN O O
to NN O O
refrain NN O O
from NN O O
driving NN O O
and NN O O
engaging NN O O
in NN O O
hazardous NN O O
occupations NN O O
or NN O O
activities NN O O
such NN O O
as NN O O
operating NN O O
heavy NN O O
or NN O O
potentially NN O O
dangerous NN O O
machinery NN O O
while NN O O
BLINCYTO NN O O
is NN O O
being NN O O
administered NN O O
. NN O O
( NN O O
5.6 NN O O
) NN O O
* NN O O
Preparation NN O O
and NN O O
Administration NN O O
Errors NN O O
: NN O O
Strictly NN O O
follow NN O O
instructions NN O O
for NN O O
preparation NN O O
( NN O O
including NN O O
admixing NN O O
) NN O O
and NN O O
administration NN O O
. NN O O
( NN O O
5.9 NN O O
) NN O O
5.1 NN O O
Cytokine NN O O
Release NN O O
Syndrome NN O O
Cytokine NN B-AdverseReaction B-AdverseReaction
Release NN I-AdverseReaction I-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
CRS NN O O
) NN O O
, NN O O
which NN O O
may NN B-Factor B-Factor
be NN O O
life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
or NN O O
fatal NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
patients NN O O
receiving NN O O
BLINCYTO. NN O O
Infusion NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
have NN O O
occurred NN O O
with NN O O
the NN O O
BLINCYTO NN O O
infusion NN O O
and NN O O
may NN O O
be NN O O
clinically NN O O
indistinguishable NN O O
from NN O O
manifestations NN O O
of NN O O
CRS NN O O
. NN O O
Serious NN O O
adverse NN O O
events NN O O
that NN O O
may NN O O
be NN O O
associated NN O O
with NN O O
CRS NN B-AdverseReaction B-AdverseReaction
included NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
asthenia NN B-AdverseReaction B-AdverseReaction
hypotension NN B-AdverseReaction B-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
alanine NN I-AdverseReaction I-AdverseReaction
aminotransferase NN I-AdverseReaction I-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
aspartate NN I-AdverseReaction I-AdverseReaction
aminotransferase NN I-AdverseReaction I-AdverseReaction
and NN O O
increased NN B-AdverseReaction B-AdverseReaction
total NN I-AdverseReaction I-AdverseReaction
bilirubin NN I-AdverseReaction I-AdverseReaction
these NN O O
events NN O O
infrequently NN O O
led NN O O
to NN O O
BLINCYTO NN O O
discontinuation NN O O
. NN O O
Life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
or NN O O
fatal NN B-AdverseReaction B-AdverseReaction
CRS NN B-AdverseReaction B-AdverseReaction
was NN O O
infrequently NN O O
reported NN O O
in NN O O
patients NN O O
receiving NN O O
BLINCYTO. NN O O
In NN O O
some NN O O
cases NN O O
, NN O O
disseminated NN B-AdverseReaction B-AdverseReaction
intravascular NN I-AdverseReaction I-AdverseReaction
coagulation NN I-AdverseReaction I-AdverseReaction
( NN O O
DIC NN O O
) NN O O
, NN O O
capillary NN B-AdverseReaction B-AdverseReaction
leak NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
CLS NN O O
) NN O O
, NN O O
and NN O O
hemophagocytic NN B-AdverseReaction B-AdverseReaction
lymphohistiocytosis NN I-AdverseReaction I-AdverseReaction
activation NN O O
syndrome NN O O
( NN O O
HLH/MAS NN O O
) NN O O
have NN O O
been NN O O
reported NN O O
in NN O O
the NN O O
setting NN O O
of NN O O
CRS NN B-AdverseReaction B-AdverseReaction
Patients NN O O
should NN O O
be NN O O
closely NN O O
monitored NN O O
for NN O O
signs NN O O
or NN O O
symptoms NN O O
of NN O O
these NN O O
events NN O O
. NN O O
Management NN O O
of NN O O
these NN O O
events NN O O
may NN O O
require NN O O
either NN O O
temporary NN O O
interruption NN O O
or NN O O
discontinuation NN O O
of NN O O
BLINCYTO NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
Neurological NN O O
Toxicities NN O O
In NN O O
patients NN O O
receiving NN O O
BLINCYTO NN O O
in NN O O
clinical NN O O
trials NN O O
, NN O O
neurological NN B-AdverseReaction B-AdverseReaction
toxicities NN I-AdverseReaction I-AdverseReaction
have NN O O
occurred NN O O
in NN O O
approximately NN O O
50 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
The NN O O
median NN O O
time NN O O
to NN O O
onset NN O O
of NN O O
any NN O O
neurological NN O O
toxicity NN O O
was NN O O
7 NN O O
days NN O O
. NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
or NN O O
higher NN O O
( NN O O
severe NN O O
, NN O O
life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
or NN O O
fatal NN B-AdverseReaction B-AdverseReaction
neurological NN B-AdverseReaction B-AdverseReaction
toxicities NN I-AdverseReaction I-AdverseReaction
following NN O O
initiation NN O O
of NN O O
BLINCYTO NN O O
administration NN O O
occurred NN O O
in NN O O
approximately NN O O
15 NN O O
% NN O O
of NN O O
patients NN O O
and NN O O
included NN O O
encephalopathy NN B-AdverseReaction B-AdverseReaction
convulsions NN B-AdverseReaction B-AdverseReaction
speech NN B-AdverseReaction B-AdverseReaction
disorders NN I-AdverseReaction I-AdverseReaction
disturbances NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
consciousness NN I-AdverseReaction I-AdverseReaction
confusion NN B-AdverseReaction B-AdverseReaction
and NN O O
disorientation NN B-AdverseReaction B-AdverseReaction
and NN O O
coordination NN O O
and NN O O
balance NN B-AdverseReaction B-AdverseReaction
disorders NN I-AdverseReaction I-AdverseReaction
The NN O O
majority NN O O
of NN O O
events NN O O
resolved NN O O
following NN O O
interruption NN O O
of NN O O
BLINCYTO NN O O
, NN O O
but NN O O
some NN O O
resulted NN O O
in NN O O
treatment NN O O
discontinuation NN O O
. NN O O
Monitor NN O O
patients NN O O
receiving NN O O
BLINCYTO NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
neurological NN O O
toxicities NN O O
, NN O O
and NN O O
interrupt NN O O
or NN O O
discontinue NN O O
BLINCYTO NN O O
as NN O O
recommended NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
] NN O O
. NN O O
5.3 NN O O
Infections NN O O
In NN O O
patients NN O O
receiving NN O O
BLINCYTO NN O O
in NN O O
clinical NN O O
trials NN O O
, NN O O
serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
such NN O O
as NN O O
sepsis NN B-AdverseReaction B-AdverseReaction
pneumonia NN B-AdverseReaction B-AdverseReaction
bacteremia NN B-AdverseReaction B-AdverseReaction
opportunistic NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
and NN O O
catheter NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
were NN O O
observed NN O O
in NN O O
approximately NN O O
25 NN O O
% NN O O
of NN O O
patients NN O O
, NN O O
some NN O O
of NN O O
which NN O O
were NN O O
life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
or NN O O
fatal NN B-AdverseReaction B-AdverseReaction
As NN O O
appropriate NN O O
, NN O O
administer NN O O
prophylactic NN O O
antibiotics NN O O
and NN O O
employ NN O O
surveillance NN O O
testing NN O O
during NN O O
treatment NN O O
with NN O O
BLINCYTO. NN O O
Monitor NN O O
patients NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
infection NN O O
and NN O O
treat NN O O
appropriately NN O O
. NN O O
5.4 NN O O
Tumor NN O O
Lysis NN O O
Syndrome NN O O
Tumor NN B-AdverseReaction B-AdverseReaction
lysis NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
TLS NN O O
) NN O O
, NN O O
which NN O O
may NN B-Factor B-Factor
be NN O O
life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
or NN O O
fatal NN B-AdverseReaction B-AdverseReaction
has NN O O
been NN O O
observed NN O O
in NN O O
patients NN O O
receiving NN O O
BLINCYTO. NN O O
Appropriate NN O O
prophylactic NN O O
measures NN O O
, NN O O
including NN O O
pretreatment NN O O
nontoxic NN O O
cytoreduction NN O O
and NN O O
on NN O O
- NN O O
treatment NN O O
hydration NN O O
, NN O O
should NN O O
be NN O O
used NN O O
for NN O O
the NN O O
prevention NN O O
of NN O O
TLS NN O O
during NN O O
BLINCYTO NN O O
treatment NN O O
. NN O O
Monitor NN O O
for NN O O
signs NN O O
or NN O O
symptoms NN O O
of NN O O
TLS. NN O O
Management NN O O
of NN O O
these NN O O
events NN O O
may NN O O
require NN O O
either NN O O
temporary NN O O
interruption NN O O
or NN O O
discontinuation NN O O
of NN O O
BLINCYTO NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
] NN O O
. NN O O
5.5 NN O O
Neutropenia NN O O
and NN O O
Febrile NN O O
Neutropenia NN O O
Neutropenia NN B-AdverseReaction B-AdverseReaction
and NN O O
febrile NN B-AdverseReaction B-AdverseReaction
neutropenia NN I-AdverseReaction I-AdverseReaction
including NN O O
life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
cases NN O O
, NN O O
have NN O O
been NN O O
observed NN O O
in NN O O
patients NN O O
receiving NN O O
BLINCYTO. NN O O
Monitor NN O O
laboratory NN O O
parameters NN O O
( NN O O
including NN O O
, NN O O
but NN O O
not NN O O
limited NN O O
to NN O O
, NN O O
white NN O O
blood NN O O
cell NN O O
count NN O O
and NN O O
absolute NN O O
neutrophil NN O O
count NN O O
) NN O O
during NN O O
BLINCYTO NN O O
infusion NN O O
. NN O O
Interrupt NN O O
BLINCYTO NN O O
if NN O O
prolonged NN O O
neutropenia NN O O
occurs NN O O
. NN O O
5.6 NN O O
Effects NN O O
on NN O O
Ability NN O O
to NN O O
Drive NN O O
and NN O O
Use NN O O
Machines NN O O
Due NN O O
to NN O O
the NN O O
potential NN B-Factor B-Factor
for NN O O
neurologic NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
including NN O O
seizures NN B-AdverseReaction B-AdverseReaction
patients NN O O
receiving NN O O
BLINCYTO NN O O
are NN O O
at NN O O
risk NN B-Factor B-Factor
for NN O O
loss NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
consciousness NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
Advise NN O O
patients NN O O
to NN O O
refrain NN O O
from NN O O
driving NN O O
and NN O O
engaging NN O O
in NN O O
hazardous NN O O
occupations NN O O
or NN O O
activities NN O O
such NN O O
as NN O O
operating NN O O
heavy NN O O
or NN O O
potentially NN O O
dangerous NN O O
machinery NN O O
while NN O O
BLINCYTO NN O O
is NN O O
being NN O O
administered NN O O
. NN O O
5.7 NN O O
Elevated NN O O
Liver NN O O
Enzymes NN O O
Treatment NN O O
with NN O O
BLINCYTO NN O O
was NN O O
associated NN O O
with NN O O
transient NN B-Severity B-Severity
elevations NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
liver NN I-AdverseReaction I-AdverseReaction
enzymes NN I-AdverseReaction I-AdverseReaction
Although NN O O
the NN O O
majority NN O O
of NN O O
these NN O O
events NN O O
were NN O O
observed NN O O
in NN O O
the NN O O
setting NN O O
of NN O O
CRS NN B-AdverseReaction B-AdverseReaction
some NN O O
were NN O O
observed NN O O
outside NN O O
of NN O O
this NN O O
setting NN O O
. NN O O
For NN O O
these NN O O
events NN O O
, NN O O
the NN O O
median NN O O
time NN O O
to NN O O
onset NN O O
was NN O O
15 NN O O
days NN O O
. NN O O
In NN O O
patients NN O O
receiving NN O O
BLINCYTO NN O O
in NN O O
clinical NN O O
trials NN O O
, NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
or NN O O
greater NN O O
elevations NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
liver NN I-AdverseReaction I-AdverseReaction
enzymes NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
approximately NN O O
6 NN O O
% NN O O
of NN O O
patients NN O O
outside NN B-Negation B-Negation
the NN O O
setting NN O O
of NN O O
CRS NN B-AdverseReaction B-AdverseReaction
and NN O O
resulted NN O O
in NN O O
treatment NN O O
discontinuation NN O O
in NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
Monitor NN O O
alanine NN O O
aminotransferase NN O O
( NN O O
ALT NN O O
) NN O O
, NN O O
aspartate NN O O
aminotransferase NN O O
( NN O O
AST NN O O
) NN O O
, NN O O
gamma NN O O
- NN O O
glutamyl NN O O
transferase NN O O
( NN O O
GGT NN O O
) NN O O
, NN O O
and NN O O
total NN O O
blood NN O O
bilirubin NN O O
prior NN O O
to NN O O
the NN O O
start NN O O
of NN O O
and NN O O
during NN O O
BLINCYTO NN O O
treatment NN O O
. NN O O
Interrupt NN O O
BLINCYTO NN O O
if NN O O
the NN O O
transaminases NN O O
rise NN O O
to NN O O
greater NN O O
than NN O O
5 NN O O
times NN O O
the NN O O
upper NN O O
limit NN O O
of NN O O
normal NN O O
or NN O O
if NN O O
bilirubin NN O O
rises NN O O
to NN O O
more NN O O
than NN O O
3 NN O O
times NN O O
the NN O O
upper NN O O
limit NN O O
of NN O O
normal NN O O
. NN O O
5.8 NN O O
Leukoencephalopathy NN O O
Cranial NN O O
magnetic NN O O
resonance NN O O
imaging NN O O
( NN O O
MRI NN O O
) NN O O
changes NN O O
showing NN O O
leukoencephalopathy NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
observed NN O O
in NN O O
patients NN O O
receiving NN O O
BLINCYTO NN O O
, NN O O
especially NN O O
in NN O O
patients NN O O
with NN O O
prior NN O O
treatment NN O O
with NN O O
cranial NN O O
irradiation NN O O
and NN O O
antileukemic NN O O
chemotherapy NN O O
( NN O O
including NN O O
systemic NN O O
high NN O O
- NN O O
dose NN O O
methotrexate NN O O
or NN O O
intrathecal NN O O
cytarabine NN O O
) NN O O
. NN O O
The NN O O
clinical NN O O
significance NN O O
of NN O O
these NN O O
imaging NN O O
changes NN O O
is NN O O
unknown NN O O
. NN O O
5.9 NN O O
Preparation NN O O
and NN O O
Administration NN O O
Errors NN O O
Preparation NN O O
and NN O O
administration NN O O
errors NN O O
have NN O O
occurred NN O O
with NN O O
BLINCYTO NN O O
treatment NN O O
. NN O O
Follow NN O O
instructions NN O O
for NN O O
preparation NN O O
( NN O O
including NN O O
admixing NN O O
) NN O O
and NN O O
administration NN O O
strictly NN O O
to NN O O
minimize NN O O
medication NN O O
errors NN O O
( NN O O
including NN O O
underdose NN O O
and NN O O
overdose NN O O
) NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
and NN O O
( NN O O
2.4 NN O O
) NN O O
] NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
serious NN O O
adverse NN O O
reactions NN O O
in NN O O
patients NN O O
with NN O O
Dupuytren NN O O
's NN O O
contracture NN O O
are NN O O
discussed NN O O
in NN O O
greater NN O O
detail NN O O
elsewhere NN O O
in NN O O
the NN O O
labeling NN O O
: NN O O
* NN O O
Tendon NN B-AdverseReaction B-AdverseReaction
ruptures NN I-AdverseReaction I-AdverseReaction
or NN O O
other NN O O
serious NN B-Severity B-Severity
injury NN B-AdverseReaction B-AdverseReaction
to NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
injected NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
The NN O O
following NN O O
serious NN O O
adverse NN O O
reactions NN O O
in NN O O
patients NN O O
with NN O O
Peyronie NN O O
's NN O O
disease NN O O
are NN O O
discussed NN O O
in NN O O
greater NN O O
detail NN O O
elsewhere NN O O
in NN O O
the NN O O
labeling NN O O
: NN O O
* NN O O
Corporal NN B-AdverseReaction B-AdverseReaction
rupture NN I-AdverseReaction I-AdverseReaction
( NN O O
penile NN O O
fracture NN O O
) NN O O
and NN O O
severe NN B-Severity B-Severity
penile NN B-AdverseReaction B-AdverseReaction
hematoma NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
In NN O O
other NN O O
XIAFLEX NN O O
- NN O O
treated NN O O
patients NN O O
, NN O O
a NN O O
combination NN O O
of NN O O
penile NN B-AdverseReaction B-AdverseReaction
ecchymoses NN I-AdverseReaction I-AdverseReaction
or NN O O
hematoma NN O O
, NN O O
sudden NN O O
penile NN B-AdverseReaction B-AdverseReaction
detumescence NN I-AdverseReaction I-AdverseReaction
and/or NN O O
a NN O O
penile NN B-AdverseReaction B-AdverseReaction
" NN I-AdverseReaction I-AdverseReaction
popping NN I-AdverseReaction I-AdverseReaction
" NN I-AdverseReaction I-AdverseReaction
sound NN I-AdverseReaction I-AdverseReaction
or NN O O
sensation NN O O
was NN O O
reported NN O O
, NN O O
and NN O O
in NN O O
these NN O O
cases NN O O
, NN O O
a NN O O
diagnosis NN O O
of NN O O
corporal NN B-AdverseReaction B-AdverseReaction
rupture NN I-AdverseReaction I-AdverseReaction
can NN B-Factor B-Factor
not NN I-Factor I-Factor
be NN I-Factor I-Factor
excluded NN I-Factor I-Factor
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
Dupuytren NN O O
's NN O O
Contracture NN O O
( NN O O
6.1 NN O O
) NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
reported NN O O
in NN O O
>= NN O O
25 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
XIAFLEX NN O O
and NN O O
at NN O O
an NN O O
incidence NN O O
greater NN O O
than NN O O
placebo NN O O
were NN O O
edema NN B-AdverseReaction B-AdverseReaction
peripheral NN I-AdverseReaction I-AdverseReaction
( NN O O
e.g. NN O O
, NN O O
swelling NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
injected NN I-AdverseReaction I-AdverseReaction
hand NN I-AdverseReaction I-AdverseReaction
contusion NN B-AdverseReaction B-AdverseReaction
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
and NN O O
pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
injected NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
Peyronie NN O O
's NN O O
Disease NN O O
( NN O O
6.2 NN O O
) NN O O
The NN O O
most NN O O
frequently NN O O
reported NN O O
adverse NN O O
drug NN O O
reactions NN O O
reported NN O O
with NN O O
>= NN O O
25 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
XIAFLEX NN O O
and NN O O
at NN O O
an NN O O
incidence NN O O
greater NN O O
than NN O O
placebo NN O O
were NN O O
penile NN B-AdverseReaction B-AdverseReaction
hematoma NN I-AdverseReaction I-AdverseReaction
penile NN B-AdverseReaction B-AdverseReaction
swelling NN I-AdverseReaction I-AdverseReaction
and NN O O
penile NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Auxilium NN O O
Pharmaceuticals NN O O
, NN O O
Inc. NN O O
at NN O O
1 NN O O
- NN O O
877 NN O O
- NN O O
663 NN O O
- NN O O
0412 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Studies NN O O
Experience NN O O
in NN O O
Patients NN O O
with NN O O
Dupuytren NN O O
's NN O O
Contracture NN O O
Because NN O O
clinical NN O O
studies NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
studies NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
studies NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
Out NN O O
of NN O O
1082 NN O O
patients NN O O
who NN O O
received NN O O
0.58 NN O O
mg NN O O
of NN O O
XIAFLEX NN O O
in NN O O
the NN O O
controlled NN O O
and NN O O
uncontrolled NN O O
portions NN O O
of NN O O
the NN O O
XIAFLEX NN O O
studies NN O O
( NN O O
2630 NN O O
XIAFLEX NN O O
injections NN O O
) NN O O
, NN O O
3 NN O O
( NN O O
0.3 NN O O
% NN O O
) NN O O
patients NN O O
had NN O O
a NN O O
flexor NN O O
tendon NN O O
rupture NN O O
of NN O O
the NN O O
treated NN O O
finger NN O O
within NN O O
7 NN O O
days NN O O
of NN O O
the NN O O
injection NN O O
. NN O O
The NN O O
data NN O O
described NN O O
below NN O O
are NN O O
based NN O O
on NN O O
two NN O O
pooled NN O O
randomized NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
through NN O O
Day NN O O
90 NN O O
in NN O O
patients NN O O
with NN O O
Dupuytren NN O O
's NN O O
contracture NN O O
( NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
) NN O O
. NN O O
In NN O O
these NN O O
trials NN O O
, NN O O
patients NN O O
were NN O O
treated NN O O
with NN O O
up NN O O
to NN O O
3 NN O O
injections NN O O
of NN O O
0.58 NN O O
mg NN O O
of NN O O
XIAFLEX NN O O
or NN O O
placebo NN O O
with NN O O
approximately NN O O
4-week NN O O
intervals NN O O
between NN O O
injections NN O O
and NN O O
the NN O O
patients NN O O
had NN O O
finger NN O O
extension NN O O
procedures NN O O
the NN O O
day NN O O
after NN O O
injection NN O O
, NN O O
if NN O O
needed NN O O
, NN O O
to NN O O
facilitate NN O O
disruption NN O O
of NN O O
the NN O O
cord NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
. NN O O
These NN O O
trials NN O O
were NN O O
comprised NN O O
of NN O O
374 NN O O
patients NN O O
of NN O O
whom NN O O
249 NN O O
and NN O O
125 NN O O
received NN O O
0.58 NN O O
mg NN O O
of NN O O
XIAFLEX NN O O
and NN O O
placebo NN O O
, NN O O
respectively NN O O
. NN O O
The NN O O
mean NN O O
age NN O O
was NN O O
63 NN O O
years NN O O
, NN O O
80 NN O O
% NN O O
were NN O O
male NN O O
and NN O O
20 NN O O
% NN O O
were NN O O
female NN O O
, NN O O
and NN O O
100 NN O O
% NN O O
were NN O O
white NN O O
. NN O O
In NN O O
the NN O O
placebo NN O O
- NN O O
controlled NN O O
portions NN O O
of NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
through NN O O
Day NN O O
90 NN O O
, NN O O
98 NN O O
% NN O O
and NN O O
51 NN O O
% NN O O
of NN O O
XIAFLEX NN O O
- NN O O
treated NN O O
and NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
had NN O O
an NN O O
adverse NN O O
reaction NN O O
after NN O O
up NN O O
to NN O O
3 NN O O
injections NN O O
, NN O O
respectively NN O O
. NN O O
Over NN O O
95 NN O O
% NN O O
of NN O O
XIAFLEX NN O O
- NN O O
treated NN O O
patients NN O O
had NN O O
an NN O O
adverse NN B-AdverseReaction B-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
injected NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
after NN O O
up NN O O
to NN O O
3 NN O O
injections NN O O
. NN O O
Approximately NN O O
81 NN O O
% NN O O
of NN O O
these NN O O
local NN O O
reactions NN O O
resolved NN O O
without NN O O
intervention NN O O
within NN O O
4 NN O O
weeks NN O O
of NN O O
XIAFLEX NN O O
injections NN O O
. NN O O
The NN O O
adverse NN O O
reaction NN O O
profile NN O O
was NN O O
similar NN O O
for NN O O
each NN O O
injection NN O O
, NN O O
regardless NN O O
of NN O O
the NN O O
number NN O O
of NN O O
injections NN O O
administered NN O O
. NN O O
However NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
pruritus NN B-AdverseReaction B-AdverseReaction
increased NN O O
with NN O O
more NN O O
injections NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
most NN O O
frequently NN O O
reported NN O O
adverse NN O O
drug NN O O
reactions NN O O
( NN O O
>= NN O O
25 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
XIAFLEX NN O O
clinical NN O O
trials NN O O
in NN O O
patients NN O O
with NN O O
Dupuytren NN O O
's NN O O
contracture NN O O
included NN O O
edema NN B-AdverseReaction B-AdverseReaction
peripheral NN I-AdverseReaction I-AdverseReaction
( NN O O
mostly NN O O
swelling NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
injected NN I-AdverseReaction I-AdverseReaction
hand NN I-AdverseReaction I-AdverseReaction
contusion NN B-AdverseReaction B-AdverseReaction
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
and NN O O
pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
treated NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
Table NN O O
3 NN O O
shows NN O O
the NN O O
incidence NN O O
of NN O O
adverse NN O O
reactions NN O O
that NN O O
were NN O O
reported NN O O
in NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
5 NN O O
% NN O O
of NN O O
XIAFLEX NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
at NN O O
a NN O O
frequency NN O O
greater NN O O
than NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
after NN O O
up NN O O
to NN O O
3 NN O O
injections NN O O
in NN O O
the NN O O
pooled NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
through NN O O
Day NN O O
90 NN O O
( NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
) NN O O
. NN O O
Table NN O O
3 NN O O
. NN O O
Adverse NN O O
Reactions NN O O
Occurring NN O O
in NN O O
>= NN O O
5 NN O O
% NN O O
of NN O O
XIAFLEX NN O O
- NN O O
Treated NN O O
Patients NN O O
with NN O O
Dupuytren NN O O
's NN O O
Contracture NN O O
and NN O O
at NN O O
a NN O O
Greater NN O O
Incidence NN O O
than NN O O
Placebo NN O O
in NN O O
the NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Trials NN O O
Through NN O O
Day NN O O
90 NN O O
After NN O O
Up NN O O
to NN O O
3 NN O O
Injections NN O O
a NN O O
Most NN O O
of NN O O
these NN O O
events NN O O
were NN O O
swelling NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
injected NN I-AdverseReaction I-AdverseReaction
hand NN I-AdverseReaction I-AdverseReaction
b NN O O
Includes NN O O
the NN O O
terms NN O O
: NN O O
contusion NN B-AdverseReaction B-AdverseReaction
( NN O O
any NN O O
body NN O O
system NN O O
) NN O O
and NN O O
ecchymosis NN B-AdverseReaction B-AdverseReaction
c NN O O
Includes NN O O
the NN O O
terms NN O O
: NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
erythema NN I-AdverseReaction I-AdverseReaction
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
inflammation NN I-AdverseReaction I-AdverseReaction
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
irritation NN I-AdverseReaction I-AdverseReaction
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
and NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
warmth NN I-AdverseReaction I-AdverseReaction
d NN O O
Includes NN O O
the NN O O
terms NN O O
: NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
swelling NN I-AdverseReaction I-AdverseReaction
and NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
e NN O O
Includes NN O O
the NN O O
terms NN O O
: NN O O
pruritus NN B-AdverseReaction B-AdverseReaction
and NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pruritus NN I-AdverseReaction I-AdverseReaction
f NN O O
Includes NN O O
the NN O O
terms NN O O
: NN O O
lymphadenopathy NN B-AdverseReaction B-AdverseReaction
and NN O O
axillary NN B-AdverseReaction B-AdverseReaction
mass NN I-AdverseReaction I-AdverseReaction
Adverse NN O O
Reaction NN O O
XIAFLEXN=249 NN O O
PlaceboN=125 NN O O
All NN O O
Adverse NN O O
Reactions NN O O
98 NN O O
% NN O O
51 NN O O
% NN O O
Edema NN B-AdverseReaction B-AdverseReaction
Peripheral NN I-AdverseReaction I-AdverseReaction
a NN O O
73 NN O O
% NN O O
5 NN O O
% NN O O
Contusion NN B-AdverseReaction B-AdverseReaction
b NN O O
70 NN O O
% NN O O
3 NN O O
% NN O O
Injection NN B-AdverseReaction B-AdverseReaction
Site NN I-AdverseReaction I-AdverseReaction
Hemorrhage NN I-AdverseReaction I-AdverseReaction
38 NN O O
% NN O O
3 NN O O
% NN O O
Injection NN B-AdverseReaction B-AdverseReaction
Site NN I-AdverseReaction I-AdverseReaction
Reaction NN I-AdverseReaction I-AdverseReaction
c NN O O
35 NN O O
% NN O O
6 NN O O
% NN O O
Pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
Extremity NN I-AdverseReaction I-AdverseReaction
35 NN O O
% NN O O
4 NN O O
% NN O O
Tenderness NN B-AdverseReaction B-AdverseReaction
24 NN O O
% NN O O
0 NN O O
% NN O O
Injection NN B-AdverseReaction B-AdverseReaction
Site NN I-AdverseReaction I-AdverseReaction
Swelling NN I-AdverseReaction I-AdverseReaction
d NN O O
24 NN O O
% NN O O
6 NN O O
% NN O O
Pruritus NN B-AdverseReaction B-AdverseReaction
e NN O O
15 NN O O
% NN O O
1 NN O O
% NN O O
Lymphadenopathy NN B-AdverseReaction B-AdverseReaction
f NN O O
13 NN O O
% NN O O
0 NN O O
% NN O O
Skin NN B-AdverseReaction B-AdverseReaction
Laceration NN I-AdverseReaction I-AdverseReaction
9 NN O O
% NN O O
0 NN O O
% NN O O
Lymph NN B-AdverseReaction B-AdverseReaction
Node NN I-AdverseReaction I-AdverseReaction
Pain NN I-AdverseReaction I-AdverseReaction
8 NN O O
% NN O O
0 NN O O
% NN O O
Erythema NN B-AdverseReaction B-AdverseReaction
6 NN O O
% NN O O
0 NN O O
% NN O O
Axillary NN B-AdverseReaction B-AdverseReaction
Pain NN I-AdverseReaction I-AdverseReaction
6 NN O O
% NN O O
0 NN O O
% NN O O
Some NN O O
patients NN O O
developed NN O O
vasovagal NN B-AdverseReaction B-AdverseReaction
syncope NN I-AdverseReaction I-AdverseReaction
after NN O O
finger NN O O
extension NN O O
procedures NN O O
. NN O O
The NN O O
safety NN O O
of NN O O
two NN O O
concurrent NN O O
injections NN O O
of NN O O
XIAFLEX NN O O
0.58 NN O O
mg NN O O
into NN O O
Dupuytren NN O O
's NN O O
cords NN O O
in NN O O
the NN O O
same NN O O
hand NN O O
was NN O O
evaluated NN O O
in NN O O
a NN O O
historically NN O O
- NN O O
controlled NN O O
, NN O O
open NN O O
- NN O O
label NN O O
multi NN O O
- NN O O
center NN O O
trial NN O O
in NN O O
715 NN O O
adult NN O O
subjects NN O O
with NN O O
Dupuytren NN O O
's NN O O
contracture NN O O
( NN O O
Study NN O O
3 NN O O
) NN O O
. NN O O
In NN O O
Study NN O O
3 NN O O
, NN O O
finger NN O O
extension NN O O
procedures NN O O
were NN O O
performed NN O O
approximately NN O O
24 NN O O
to NN O O
72 NN O O
hours NN O O
after NN O O
injection NN O O
. NN O O
The NN O O
patient NN O O
demographics NN O O
were NN O O
similar NN O O
to NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
. NN O O
Out NN O O
of NN O O
715 NN O O
patients NN O O
who NN O O
received NN O O
two NN O O
concurrent NN O O
injections NN O O
of NN O O
XIAFLEX NN O O
0.58 NN O O
mg NN O O
in NN O O
the NN O O
same NN O O
hand NN O O
( NN O O
1450 NN O O
XIAFLEX NN O O
injections NN O O
) NN O O
in NN O O
Study NN O O
3 NN O O
, NN O O
one NN O O
( NN O O
0.1 NN O O
% NN O O
) NN O O
patient NN O O
experienced NN O O
a NN O O
tendon NN O O
rupture NN O O
of NN O O
the NN O O
treated NN O O
finger NN O O
within NN O O
3 NN O O
days NN O O
of NN O O
the NN O O
injection NN O O
. NN O O
Table NN O O
4 NN O O
shows NN O O
the NN O O
incidence NN O O
of NN O O
adverse NN O O
reactions NN O O
that NN O O
were NN O O
reported NN O O
in NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
5 NN O O
% NN O O
of NN O O
XIAFLEX NN O O
- NN O O
treated NN O O
patients NN O O
after NN O O
two NN O O
concurrent NN O O
injections NN O O
of NN O O
XIAFLEX NN O O
in NN O O
the NN O O
same NN O O
hand NN O O
through NN O O
Day NN O O
60 NN O O
in NN O O
Study NN O O
3 NN O O
. NN O O
Table NN O O
4 NN O O
. NN O O
Adverse NN O O
Reactions NN O O
Occurring NN O O
in NN O O
>=5.0 NN O O
% NN O O
of NN O O
Subjects NN O O
Who NN O O
Received NN O O
Two NN O O
Concurrent NN O O
Injections NN O O
of NN O O
XIAFLEX NN O O
in NN O O
Study NN O O
3 NN O O
Adverse NN O O
Reaction NN O O
XIAFLEXN=715 NN O O
Subjects NN O O
with NN O O
>=1 NN O O
adverse NN O O
reaction NN O O
95 NN O O
% NN O O
Edema NN B-AdverseReaction B-AdverseReaction
peripheral NN I-AdverseReaction I-AdverseReaction
77 NN O O
% NN O O
Contusion NN B-AdverseReaction B-AdverseReaction
59 NN O O
% NN O O
Pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
51 NN O O
% NN O O
Laceration NN B-AdverseReaction B-AdverseReaction
22 NN O O
% NN O O
Pruritus NN B-AdverseReaction B-AdverseReaction
15 NN O O
% NN O O
Injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
14 NN O O
% NN O O
Lymphadenopathy NN B-AdverseReaction B-AdverseReaction
13 NN O O
% NN O O
Blood NN B-AdverseReaction B-AdverseReaction
blister NN I-AdverseReaction I-AdverseReaction
12 NN O O
% NN O O
Injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
hematoma NN I-AdverseReaction I-AdverseReaction
8 NN O O
% NN O O
Axillary NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
7 NN O O
% NN O O
Injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
6 NN O O
% NN O O
Injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
swelling NN I-AdverseReaction I-AdverseReaction
5 NN O O
% NN O O
Ecchymosis NN B-AdverseReaction B-AdverseReaction
5 NN O O
% NN O O
Safety NN O O
of NN O O
Retreatment NN O O
of NN O O
Recurrent NN O O
Contractures NN O O
An NN O O
observational NN O O
, NN O O
open NN O O
label NN O O
study NN O O
was NN O O
conducted NN O O
in NN O O
subjects NN O O
who NN O O
had NN O O
participated NN O O
in NN O O
XIAFLEX NN O O
clinical NN O O
trials NN O O
for NN O O
Dupuytren NN O O
's NN O O
contracture NN O O
( NN O O
Study NN O O
4 NN O O
) NN O O
. NN O O
A NN O O
subset NN O O
of NN O O
patients NN O O
who NN O O
had NN O O
recurrence NN O O
of NN O O
contracture NN O O
in NN O O
a NN O O
joint NN O O
that NN O O
was NN O O
previously NN O O
successfully NN O O
treated NN O O
with NN O O
XIAFLEX NN O O
in NN O O
Study NN O O
4 NN O O
were NN O O
retreated NN O O
( NN O O
Study NN O O
5 NN O O
) NN O O
. NN O O
No NN O O
new NN O O
safety NN O O
signals NN O O
were NN O O
identified NN O O
among NN O O
subjects NN O O
who NN O O
were NN O O
retreated NN O O
with NN O O
XIAFLEX. NN O O
6.2 NN O O
Clinical NN O O
Studies NN O O
Experience NN O O
in NN O O
Patients NN O O
with NN O O
Peyronie NN O O
's NN O O
Disease NN O O
Because NN O O
clinical NN O O
studies NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
studies NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
studies NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
In NN O O
the NN O O
controlled NN O O
and NN O O
uncontrolled NN O O
clinical NN O O
studies NN O O
of NN O O
XIAFLEX NN O O
in NN O O
Peyronie NN O O
's NN O O
disease NN O O
, NN O O
1044 NN O O
patients NN O O
received NN O O
a NN O O
total NN O O
of NN O O
7466 NN O O
XIAFLEX NN O O
injections NN O O
. NN O O
Corporal NN O O
Rupture NN O O
and NN O O
Other NN O O
Serious NN O O
Penile NN O O
Injury NN O O
* NN O O
Corporal NN B-AdverseReaction B-AdverseReaction
rupture NN I-AdverseReaction I-AdverseReaction
was NN O O
reported NN O O
as NN O O
an NN O O
adverse NN O O
reaction NN O O
after NN O O
XIAFLEX NN O O
injections NN O O
in NN O O
5 NN O O
of NN O O
1044 NN O O
( NN O O
0.5 NN O O
% NN O O
) NN O O
XIAFLEX NN O O
treated NN O O
patients NN O O
. NN O O
* NN O O
In NN O O
other NN O O
XIAFLEX NN O O
- NN O O
treated NN O O
patients NN O O
( NN O O
9 NN O O
of NN O O
1044 NN O O
; NN O O
0.9 NN O O
% NN O O
) NN O O
, NN O O
a NN O O
combination NN O O
of NN O O
penile NN B-AdverseReaction B-AdverseReaction
ecchymoses NN I-AdverseReaction I-AdverseReaction
or NN O O
hematoma NN O O
, NN O O
sudden NN O O
penile NN B-AdverseReaction B-AdverseReaction
detumescence NN I-AdverseReaction I-AdverseReaction
and/or NN O O
a NN O O
penile NN B-AdverseReaction B-AdverseReaction
" NN I-AdverseReaction I-AdverseReaction
popping NN I-AdverseReaction I-AdverseReaction
" NN I-AdverseReaction I-AdverseReaction
sound NN I-AdverseReaction I-AdverseReaction
or NN O O
sensation NN O O
was NN O O
reported NN O O
, NN O O
and NN O O
in NN O O
these NN O O
cases NN O O
, NN O O
a NN O O
diagnosis NN O O
of NN O O
corporal NN B-AdverseReaction B-AdverseReaction
rupture NN I-AdverseReaction I-AdverseReaction
can NN B-Factor B-Factor
not NN I-Factor I-Factor
be NN I-Factor I-Factor
excluded NN I-Factor I-Factor
These NN O O
patients NN O O
were NN O O
managed NN O O
without NN O O
surgical NN O O
intervention NN O O
, NN O O
but NN O O
the NN O O
long NN O O
- NN O O
term NN O O
consequences NN O O
are NN O O
unknown NN O O
. NN O O
* NN O O
Severe NN B-Severity B-Severity
penile NN B-AdverseReaction B-AdverseReaction
hematoma NN I-AdverseReaction I-AdverseReaction
was NN O O
also NN O O
reported NN O O
as NN O O
an NN O O
adverse NN O O
reaction NN O O
in NN O O
39 NN O O
of NN O O
1044 NN O O
patients NN O O
( NN O O
3.7 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
controlled NN O O
and NN O O
uncontrolled NN O O
clinical NN O O
trials NN O O
in NN O O
Peyronie NN O O
's NN O O
disease NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
data NN O O
described NN O O
below NN O O
are NN O O
based NN O O
on NN O O
two NN O O
identical NN O O
, NN O O
pooled NN O O
, NN O O
randomized NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
, NN O O
multi NN O O
- NN O O
center NN O O
trials NN O O
through NN O O
Day NN O O
365 NN O O
in NN O O
patients NN O O
with NN O O
Peyronie NN O O
's NN O O
disease NN O O
( NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
) NN O O
. NN O O
These NN O O
trials NN O O
included NN O O
832 NN O O
patients NN O O
of NN O O
whom NN O O
551 NN O O
and NN O O
281 NN O O
received NN O O
XIAFLEX NN O O
and NN O O
placebo NN O O
, NN O O
respectively NN O O
. NN O O
In NN O O
these NN O O
trials NN O O
, NN O O
patients NN O O
were NN O O
given NN O O
up NN O O
to NN O O
4 NN O O
treatment NN O O
cycles NN O O
of NN O O
XIAFLEX NN O O
or NN O O
placebo NN O O
. NN O O
In NN O O
each NN O O
cycle NN O O
, NN O O
two NN O O
injections NN O O
of NN O O
XIAFLEX NN O O
or NN O O
two NN O O
injections NN O O
of NN O O
placebo NN O O
were NN O O
administered NN O O
1 NN O O
to NN O O
3 NN O O
days NN O O
apart NN O O
. NN O O
A NN O O
penile NN O O
modeling NN O O
procedure NN O O
was NN O O
performed NN O O
at NN O O
the NN O O
study NN O O
site NN O O
on NN O O
patients NN O O
1 NN O O
to NN O O
3 NN O O
days NN O O
after NN O O
the NN O O
second NN O O
injection NN O O
of NN O O
the NN O O
cycle NN O O
. NN O O
The NN O O
treatment NN O O
cycle NN O O
was NN O O
repeated NN O O
at NN O O
approximately NN O O
6-week NN O O
intervals NN O O
up NN O O
to NN O O
three NN O O
additional NN O O
times NN O O
, NN O O
for NN O O
a NN O O
maximum NN O O
of NN O O
8 NN O O
total NN O O
injection NN O O
procedures NN O O
and NN O O
4 NN O O
total NN O O
modeling NN O O
procedures NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14.2 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
majority NN O O
of NN O O
Peyronie NN O O
's NN O O
patients NN O O
experienced NN O O
at NN O O
least NN O O
one NN O O
adverse NN O O
reaction NN O O
( NN O O
92 NN O O
% NN O O
XIAFLEX NN O O
- NN O O
treated NN O O
patients NN O O
, NN O O
61 NN O O
% NN O O
placebo NN O O
- NN O O
treated NN O O
) NN O O
. NN O O
Most NN O O
adverse NN O O
reactions NN O O
were NN O O
local NN O O
events NN O O
of NN O O
the NN O O
penis NN O O
and NN O O
groin NN O O
and NN O O
the NN O O
majority NN O O
of NN O O
these NN O O
events NN O O
were NN O O
of NN O O
mild NN B-Severity B-Severity
or NN O O
moderate NN B-Severity B-Severity
severity NN O O
, NN O O
and NN O O
most NN O O
( NN O O
79 NN O O
% NN O O
) NN O O
resolved NN O O
within NN O O
14 NN O O
days NN O O
of NN O O
the NN O O
injection NN O O
. NN O O
The NN O O
adverse NN O O
reaction NN O O
profile NN O O
was NN O O
similar NN O O
after NN O O
each NN O O
injection NN O O
, NN O O
regardless NN O O
of NN O O
the NN O O
number NN O O
of NN O O
injections NN O O
administered NN O O
. NN O O
The NN O O
most NN O O
frequently NN O O
reported NN O O
adverse NN O O
drug NN O O
reactions NN O O
( NN O O
>= NN O O
25 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
XIAFLEX NN O O
clinical NN O O
trials NN O O
in NN O O
patients NN O O
with NN O O
Peyronie NN O O
's NN O O
disease NN O O
were NN O O
penile NN B-AdverseReaction B-AdverseReaction
hematoma NN I-AdverseReaction I-AdverseReaction
penile NN B-AdverseReaction B-AdverseReaction
swelling NN I-AdverseReaction I-AdverseReaction
and NN O O
penile NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
Table NN O O
5 NN O O
shows NN O O
the NN O O
incidence NN O O
of NN O O
adverse NN O O
reactions NN O O
that NN O O
were NN O O
reported NN O O
in NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
1 NN O O
% NN O O
of NN O O
XIAFLEX NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
at NN O O
a NN O O
frequency NN O O
greater NN O O
than NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
after NN O O
up NN O O
to NN O O
8 NN O O
injections NN O O
in NN O O
the NN O O
pooled NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
through NN O O
Day NN O O
365 NN O O
. NN O O
Table NN O O
5 NN O O
. NN O O
Adverse NN O O
Reactions NN O O
Occurring NN O O
in NN O O
>= NN O O
1 NN O O
% NN O O
of NN O O
XIAFLEX NN O O
- NN O O
Treated NN O O
Patients NN O O
with NN O O
Peyronie NN O O
's NN O O
disease NN O O
and NN O O
at NN O O
a NN O O
Greater NN O O
Incidence NN O O
than NN O O
Placebo NN O O
After NN O O
Up NN O O
to NN O O
Four NN O O
Treatment NN O O
Cycles NN O O
in NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
Combined NN O O
a NN O O
Includes NN O O
: NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
hematoma NN I-AdverseReaction I-AdverseReaction
and NN O O
penile NN B-AdverseReaction B-AdverseReaction
hematoma NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
with NN O O
the NN O O
verbatim NN O O
term NN O O
of NN O O
penile NN B-AdverseReaction B-AdverseReaction
bruising NN I-AdverseReaction I-AdverseReaction
or NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
bruising NN I-AdverseReaction I-AdverseReaction
in NN O O
87 NN O O
% NN O O
of NN O O
subjects NN O O
. NN O O
b NN O O
Includes NN O O
: NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
swelling NN I-AdverseReaction I-AdverseReaction
penile NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
penile NN B-AdverseReaction B-AdverseReaction
swelling NN I-AdverseReaction I-AdverseReaction
local NN B-AdverseReaction B-AdverseReaction
swelling NN I-AdverseReaction I-AdverseReaction
scrotal NN B-AdverseReaction B-AdverseReaction
swelling NN I-AdverseReaction I-AdverseReaction
and NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
c NN O O
Includes NN O O
: NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
penile NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
and NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
discomfort NN I-AdverseReaction I-AdverseReaction
d NN O O
Includes NN O O
: NN O O
contusion NN B-AdverseReaction B-AdverseReaction
ecchymoses NN B-AdverseReaction B-AdverseReaction
penile NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
and NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
Adverse NN O O
Reaction NN O O
XIAFLEXN=551 NN O O
PlaceboN=281 NN O O
All NN O O
Adverse NN O O
Reactions NN O O
84.2 NN O O
% NN O O
36.3 NN O O
% NN O O
Penile NN B-AdverseReaction B-AdverseReaction
hematoma NN I-AdverseReaction I-AdverseReaction
a NN O O
65.5 NN O O
% NN O O
19.2 NN O O
% NN O O
Penile NN B-AdverseReaction B-AdverseReaction
swelling NN I-AdverseReaction I-AdverseReaction
b NN O O
55.0 NN O O
% NN O O
3.2 NN O O
% NN O O
Penile NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
c NN O O
45.4 NN O O
% NN O O
9.3 NN O O
% NN O O
Penile NN B-AdverseReaction B-AdverseReaction
ecchymoses NN I-AdverseReaction I-AdverseReaction
d NN O O
14.5 NN O O
% NN O O
6.8 NN O O
% NN O O
Blood NN B-AdverseReaction B-AdverseReaction
blister NN I-AdverseReaction I-AdverseReaction
4.5 NN O O
% NN O O
0 NN O O
Penile NN B-AdverseReaction B-AdverseReaction
blister NN I-AdverseReaction I-AdverseReaction
3.3 NN O O
% NN O O
0 NN O O
Pruritus NN B-AdverseReaction B-AdverseReaction
genital NN I-AdverseReaction I-AdverseReaction
3.1 NN O O
% NN O O
0 NN O O
Painful NN B-AdverseReaction B-AdverseReaction
erection NN I-AdverseReaction I-AdverseReaction
2.9 NN O O
% NN O O
0 NN O O
Erectile NN B-AdverseReaction B-AdverseReaction
dysfunction NN I-AdverseReaction I-AdverseReaction
1.8 NN O O
% NN O O
0.4 NN O O
% NN O O
Skin NN B-AdverseReaction B-AdverseReaction
discoloration NN I-AdverseReaction I-AdverseReaction
1.8 NN O O
% NN O O
0 NN O O
Procedural NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
1.6 NN O O
% NN O O
0.7 NN O O
% NN O O
Injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
vesicles NN I-AdverseReaction I-AdverseReaction
1.3 NN O O
% NN O O
0 NN O O
Localized NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
1.3 NN O O
% NN O O
0 NN O O
Dyspareunia NN B-AdverseReaction B-AdverseReaction
1.1 NN O O
% NN O O
0 NN O O
Injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pruritus NN I-AdverseReaction I-AdverseReaction
1.1 NN O O
% NN O O
0 NN O O
Nodule NN B-AdverseReaction B-AdverseReaction
1.1 NN O O
% NN O O
0 NN O O
Suprapubic NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
1.1 NN O O
% NN O O
0 NN O O
Severe NN B-Severity B-Severity
penile NN B-AdverseReaction B-AdverseReaction
hematoma NN I-AdverseReaction I-AdverseReaction
or NN O O
severe NN B-Severity B-Severity
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
hematoma NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
in NN O O
33/551 NN O O
( NN O O
6.0 NN O O
% NN O O
) NN O O
of NN O O
XIAFLEX NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
0/281 NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
of NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
, NN O O
in NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
combined NN O O
. NN O O
Reports NN O O
of NN O O
penile NN O O
" NN O O
popping NN O O
" NN O O
sounds NN O O
or NN O O
sensations NN O O
A NN O O
popping NN O O
noise NN O O
or NN O O
popping NN B-AdverseReaction B-AdverseReaction
sensation NN I-AdverseReaction I-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
penis NN I-AdverseReaction I-AdverseReaction
sometimes NN O O
described NN O O
as NN O O
" NN O O
snapping NN O O
" NN O O
or NN O O
" NN O O
cracking NN O O
" NN O O
, NN O O
and NN O O
sometimes NN O O
accompanied NN O O
by NN O O
detumescence NN B-AdverseReaction B-AdverseReaction
hematoma NN B-AdverseReaction B-AdverseReaction
and/or NN O O
pain NN B-AdverseReaction B-AdverseReaction
were NN O O
reported NN O O
in NN O O
73/551 NN O O
( NN O O
13.2 NN O O
% NN O O
) NN O O
XIAFLEX NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
1/281 NN O O
( NN O O
0.3 NN O O
% NN O O
) NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
There NN O O
were NN O O
no NN O O
clinically NN O O
meaningful NN O O
differences NN O O
in NN O O
the NN O O
incidence NN O O
of NN O O
adverse NN O O
events NN O O
following NN O O
treatment NN O O
with NN O O
XIAFLEX NN O O
based NN O O
on NN O O
the NN O O
severity NN O O
of NN O O
baseline NN O O
erectile NN O O
dysfunction NN O O
or NN O O
concomitant NN O O
phosphodiesterase NN O O
type NN O O
5 NN O O
( NN O O
PDE5 NN O O
) NN O O
inhibitor NN O O
use NN O O
. NN O O
XIAFLEX NN O O
was NN O O
not NN B-Negation B-Negation
associated NN O O
with NN O O
shortening NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
penile NN I-AdverseReaction I-AdverseReaction
length NN I-AdverseReaction I-AdverseReaction
in NN O O
clinical NN O O
trials NN O O
in NN O O
the NN O O
treatment NN O O
of NN O O
Peyronie NN O O
's NN O O
disease NN O O
. NN O O
6.3 NN O O
Immunogenicity NN O O
During NN O O
clinical NN O O
studies NN O O
in NN O O
Dupuytren NN O O
's NN O O
contracture NN O O
and NN O O
Peyronie NN O O
's NN O O
disease NN O O
, NN O O
patients NN O O
were NN O O
tested NN O O
at NN O O
multiple NN O O
time NN O O
points NN O O
for NN O O
antibodies NN O O
to NN O O
the NN O O
protein NN O O
components NN O O
of NN O O
XIAFLEX NN O O
( NN O O
AUX NN O O
- NN O O
I NN O O
and NN O O
AUX NN O O
- NN O O
II NN O O
) NN O O
. NN O O
In NN O O
the NN O O
Dupuytren NN O O
's NN O O
contracture NN O O
clinical NN O O
studies NN O O
( NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
) NN O O
, NN O O
at NN O O
30 NN O O
days NN O O
post NN O O
the NN O O
first NN O O
injection NN O O
of NN O O
XIAFLEX NN O O
0.58 NN O O
mg NN O O
, NN O O
92 NN O O
% NN O O
of NN O O
patients NN O O
had NN O O
antibodies NN O O
against NN O O
AUX NN O O
- NN O O
I NN O O
detected NN O O
and NN O O
86 NN O O
% NN O O
of NN O O
patients NN O O
had NN O O
antibodies NN O O
against NN O O
AUX NN O O
- NN O O
II NN O O
detected NN O O
. NN O O
After NN O O
the NN O O
fourth NN O O
injection NN O O
of NN O O
XIAFLEX NN O O
, NN O O
every NN O O
XIAFLEX NN O O
- NN O O
treated NN O O
patient NN O O
developed NN O O
high NN O O
titers NN O O
of NN O O
antibodies NN O O
to NN O O
both NN O O
AUX NN O O
- NN O O
I NN O O
and NN O O
AUX NN O O
- NN O O
II. NN O O
After NN O O
five NN O O
years NN O O
more NN O O
than NN O O
90 NN O O
percent NN O O
of NN O O
patients NN O O
remained NN O O
seropositive NN O O
for NN O O
anti NN O O
- NN O O
AUX NN O O
- NN O O
I NN O O
and NN O O
anti NN O O
- NN O O
AUX NN O O
- NN O O
II NN O O
antibody NN O O
( NN O O
Study NN O O
4 NN O O
) NN O O
. NN O O
Neutralizing NN O O
antibodies NN O O
were NN O O
assayed NN O O
for NN O O
all NN O O
patients NN O O
( NN O O
204 NN O O
) NN O O
in NN O O
Study NN O O
1 NN O O
. NN O O
Neutralizing NN O O
antibodies NN O O
to NN O O
AUX NN O O
- NN O O
I NN O O
or NN O O
AUX NN O O
- NN O O
II NN O O
, NN O O
were NN O O
detected NN O O
in NN O O
10 NN O O
% NN O O
and NN O O
21 NN O O
% NN O O
, NN O O
respectively NN O O
, NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
XIAFLEX. NN O O
Among NN O O
patients NN O O
in NN O O
Study NN O O
3 NN O O
who NN O O
reported NN O O
no NN O O
prior NN O O
exposure NN O O
to NN O O
XIAFLEX NN O O
, NN O O
97 NN O O
% NN O O
of NN O O
patients NN O O
had NN O O
antibodies NN O O
against NN O O
AUX NN O O
- NN O O
I NN O O
and NN O O
AUX NN O O
- NN O O
II NN O O
after NN O O
two NN O O
concurrent NN O O
doses NN O O
of NN O O
XIAFLEX NN O O
0.58 NN O O
mg NN O O
( NN O O
total NN O O
dose NN O O
of NN O O
1.16 NN O O
mg NN O O
) NN O O
in NN O O
the NN O O
same NN O O
hand NN O O
. NN O O
In NN O O
Study NN O O
5 NN O O
, NN O O
treatment NN O O
of NN O O
recurrent NN O O
contractures NN O O
with NN O O
XIAFLEX NN O O
resulted NN O O
in NN O O
similar NN O O
immunogenicity NN O O
results NN O O
as NN O O
seen NN O O
in NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
. NN O O
In NN O O
the NN O O
Peyronie NN O O
's NN O O
disease NN O O
clinical NN O O
studies NN O O
, NN O O
at NN O O
6 NN O O
weeks NN O O
after NN O O
the NN O O
first NN O O
treatment NN O O
cycle NN O O
of NN O O
XIAFLEX NN O O
0.58 NN O O
mg NN O O
, NN O O
approximately NN O O
75 NN O O
% NN O O
of NN O O
patients NN O O
had NN O O
antibodies NN O O
against NN O O
AUX NN O O
- NN O O
I NN O O
and NN O O
approximately NN O O
55 NN O O
% NN O O
of NN O O
patients NN O O
had NN O O
antibodies NN O O
against NN O O
AUX NN O O
- NN O O
II. NN O O
Six NN O O
weeks NN O O
after NN O O
the NN O O
eighth NN O O
injection NN O O
( NN O O
fourth NN O O
treatment NN O O
cycle NN O O
) NN O O
of NN O O
XIAFLEX NN O O
, NN O O
>99 NN O O
% NN O O
of NN O O
XIAFLEX NN O O
- NN O O
treated NN O O
patients NN O O
developed NN O O
high NN O O
titers NN O O
of NN O O
antibodies NN O O
to NN O O
both NN O O
AUX NN O O
- NN O O
I NN O O
and NN O O
AUX NN O O
- NN O O
II. NN O O
Neutralizing NN O O
antibodies NN O O
were NN O O
assayed NN O O
for NN O O
a NN O O
subset NN O O
of NN O O
70 NN O O
samples NN O O
selected NN O O
to NN O O
be NN O O
representative NN O O
of NN O O
high NN O O
and NN O O
low NN O O
titer NN O O
binding NN O O
antibody NN O O
responses NN O O
at NN O O
week NN O O
12 NN O O
of NN O O
treatment NN O O
. NN O O
For NN O O
each NN O O
subject NN O O
in NN O O
whom NN O O
a NN O O
Week NN O O
12 NN O O
sample NN O O
was NN O O
selected NN O O
, NN O O
the NN O O
corresponding NN O O
Week NN O O
6 NN O O
, NN O O
18 NN O O
, NN O O
24 NN O O
, NN O O
and NN O O
52 NN O O
samples NN O O
were NN O O
assayed NN O O
if NN O O
they NN O O
were NN O O
also NN O O
binding NN O O
antibody NN O O
positive NN O O
. NN O O
Neutralizing NN O O
antibodies NN O O
to NN O O
AUX NN O O
- NN O O
I NN O O
or NN O O
AUX NN O O
- NN O O
II NN O O
, NN O O
were NN O O
detected NN O O
in NN O O
60 NN O O
% NN O O
and NN O O
51.8 NN O O
% NN O O
, NN O O
respectively NN O O
, NN O O
of NN O O
patients NN O O
tested NN O O
. NN O O
In NN O O
patients NN O O
treated NN O O
for NN O O
these NN O O
two NN O O
indications NN O O
, NN O O
there NN O O
was NN O O
no NN O O
apparent NN O O
correlation NN O O
of NN O O
antibody NN O O
frequency NN O O
, NN O O
antibody NN O O
titers NN O O
, NN O O
or NN O O
neutralizing NN O O
status NN O O
to NN O O
clinical NN O O
response NN O O
or NN O O
adverse NN O O
reactions NN O O
. NN O O
Since NN O O
the NN O O
protein NN O O
components NN O O
in NN O O
XIAFLEX NN O O
( NN O O
AUX NN O O
- NN O O
I NN O O
and NN O O
AUX NN O O
- NN O O
II NN O O
) NN O O
have NN O O
some NN O O
sequence NN O O
homology NN O O
with NN O O
human NN O O
matrix NN O O
metalloproteinases NN O O
( NN O O
MMPs NN O O
) NN O O
, NN O O
anti NN O O
- NN O O
product NN O O
antibodies NN O O
could NN O O
theoretically NN O O
interfere NN O O
with NN O O
human NN O O
MMPs NN O O
. NN O O
In NN O O
vitro NN O O
studies NN O O
showed NN O O
no NN O O
evidence NN O O
of NN O O
cross NN O O
- NN O O
reactivity NN O O
between NN O O
anti NN O O
- NN O O
drug NN O O
- NN O O
antibody NN O O
positive NN O O
patient NN O O
sera NN O O
and NN O O
a NN O O
series NN O O
of NN O O
relevant NN O O
MMPs NN O O
. NN O O
In NN O O
addition NN O O
, NN O O
no NN O O
clinical NN O O
safety NN O O
concerns NN O O
related NN O O
to NN O O
the NN O O
inhibition NN O O
of NN O O
endogenous NN O O
MMPs NN O O
have NN O O
been NN O O
observed NN O O
. NN O O
Immunogenicity NN O O
assay NN O O
results NN O O
are NN O O
highly NN O O
dependent NN O O
on NN O O
the NN O O
sensitivity NN O O
and NN O O
specificity NN O O
of NN O O
the NN O O
assay NN O O
used NN O O
in NN O O
detection NN O O
and NN O O
may NN O O
be NN O O
influenced NN O O
by NN O O
several NN O O
factors NN O O
, NN O O
including NN O O
sample NN O O
handling NN O O
, NN O O
timing NN O O
of NN O O
sample NN O O
collection NN O O
, NN O O
concomitant NN O O
medications NN O O
, NN O O
and NN O O
underlying NN O O
disease NN O O
. NN O O
For NN O O
these NN O O
reasons NN O O
, NN O O
comparison NN O O
of NN O O
incidence NN O O
of NN O O
antibodies NN O O
to NN O O
collagenase NN O O
clostridium NN O O
histolyticum NN O O
with NN O O
the NN O O
incidence NN O O
of NN O O
antibodies NN O O
to NN O O
other NN O O
products NN O O
may NN O O
be NN O O
misleading NN O O
. NN O O
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
CORPORAL NN B-AdverseReaction B-AdverseReaction
RUPTURE NN I-AdverseReaction I-AdverseReaction
( NN O O
PENILE NN O O
FRACTURE NN O O
) NN O O
OR NN O O
OTHER NN O O
SERIOUS NN B-Severity B-Severity
PENILE NN B-AdverseReaction B-AdverseReaction
INJURY NN I-AdverseReaction I-AdverseReaction
IN NN O O
THE NN O O
TREATMENT NN O O
OF NN O O
PEYRONIE NN O O
'S NN O O
DISEASE NN O O
WARNING NN O O
: NN O O
CORPORAL NN B-AdverseReaction B-AdverseReaction
RUPTURE NN I-AdverseReaction I-AdverseReaction
( NN O O
PENILE NN O O
FRACTURE NN O O
) NN O O
OR NN O O
OTHER NN O O
SERIOUS NN B-Severity B-Severity
PENILE NN B-AdverseReaction B-AdverseReaction
INJURY NN I-AdverseReaction I-AdverseReaction
IN NN O O
THE NN O O
TREATMENT NN O O
OF NN O O
PEYRONIE NN O O
'S NN O O
DISEASE NN O O
Corporal NN B-AdverseReaction B-AdverseReaction
rupture NN I-AdverseReaction I-AdverseReaction
( NN O O
penile NN O O
fracture NN O O
) NN O O
was NN O O
reported NN O O
as NN O O
an NN O O
adverse NN O O
reaction NN O O
in NN O O
5 NN O O
of NN O O
1044 NN O O
( NN O O
0.5 NN O O
% NN O O
) NN O O
XIAFLEX NN O O
- NN O O
treated NN O O
patients NN O O
in NN O O
clinical NN O O
studies NN O O
. NN O O
In NN O O
other NN O O
XIAFLEX NN O O
- NN O O
treated NN O O
patients NN O O
( NN O O
9 NN O O
of NN O O
1044 NN O O
; NN O O
0.9 NN O O
% NN O O
) NN O O
, NN O O
a NN O O
combination NN O O
of NN O O
penile NN B-AdverseReaction B-AdverseReaction
ecchymoses NN I-AdverseReaction I-AdverseReaction
or NN O O
hematoma NN O O
, NN O O
sudden NN O O
penile NN B-AdverseReaction B-AdverseReaction
detumescence NN I-AdverseReaction I-AdverseReaction
and/or NN O O
a NN O O
penile NN B-AdverseReaction B-AdverseReaction
" NN I-AdverseReaction I-AdverseReaction
popping NN I-AdverseReaction I-AdverseReaction
" NN I-AdverseReaction I-AdverseReaction
sound NN I-AdverseReaction I-AdverseReaction
or NN O O
sensation NN O O
was NN O O
reported NN O O
, NN O O
and NN O O
in NN O O
these NN O O
cases NN O O
, NN O O
a NN O O
diagnosis NN O O
of NN O O
corporal NN B-AdverseReaction B-AdverseReaction
rupture NN I-AdverseReaction I-AdverseReaction
can NN B-Factor B-Factor
not NN I-Factor I-Factor
be NN I-Factor I-Factor
excluded NN I-Factor I-Factor
Severe NN B-Severity B-Severity
penile NN B-AdverseReaction B-AdverseReaction
hematoma NN I-AdverseReaction I-AdverseReaction
was NN O O
also NN O O
reported NN O O
as NN O O
an NN O O
adverse NN O O
reaction NN O O
in NN O O
39 NN O O
of NN O O
1044 NN O O
( NN O O
3.7 NN O O
% NN O O
) NN O O
XIAFLEX NN O O
- NN O O
treated NN O O
patients NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
Signs NN O O
or NN O O
symptoms NN O O
that NN O O
may NN O O
reflect NN O O
serious NN O O
penile NN O O
injury NN O O
should NN O O
be NN O O
promptly NN O O
evaluated NN O O
to NN O O
assess NN O O
for NN O O
corporal NN O O
rupture NN O O
or NN O O
severe NN O O
penile NN O O
hematoma NN O O
which NN O O
may NN O O
require NN O O
surgical NN O O
intervention NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
Because NN O O
of NN O O
the NN O O
risks NN B-Factor B-Factor
of NN O O
corporal NN B-AdverseReaction B-AdverseReaction
rupture NN I-AdverseReaction I-AdverseReaction
or NN O O
other NN O O
serious NN B-Severity B-Severity
penile NN B-AdverseReaction B-AdverseReaction
injury NN I-AdverseReaction I-AdverseReaction
XIAFLEX NN O O
is NN O O
available NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
Peyronie NN O O
's NN O O
disease NN O O
only NN O O
through NN O O
a NN O O
restricted NN O O
program NN O O
under NN O O
a NN O O
Risk NN O O
Evaluation NN O O
and NN O O
Mitigation NN O O
Strategy NN O O
( NN O O
REMS NN O O
) NN O O
called NN O O
the NN O O
XIAFLEX NN O O
REMS NN O O
Program NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
. NN O O
EXCERPT NN O O
: NN O O
WARNING NN O O
: NN O O
CORPORAL NN B-AdverseReaction B-AdverseReaction
RUPTURE NN I-AdverseReaction I-AdverseReaction
( NN O O
PENILE NN O O
FRACTURE NN O O
) NN O O
OR NN O O
OTHER NN O O
SERIOUS NN B-Severity B-Severity
PENILE NN B-AdverseReaction B-AdverseReaction
INJURY NN I-AdverseReaction I-AdverseReaction
IN NN O O
THE NN O O
TREATMENT NN O O
OF NN O O
PEYRONIE NN O O
'S NN O O
DISEASE NN O O
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
* NN O O
Corporal NN B-AdverseReaction B-AdverseReaction
rupture NN I-AdverseReaction I-AdverseReaction
( NN O O
penile NN O O
fracture NN O O
) NN O O
was NN O O
reported NN O O
as NN O O
an NN O O
adverse NN O O
reaction NN O O
in NN O O
5 NN O O
of NN O O
1044 NN O O
( NN O O
0.5 NN O O
% NN O O
) NN O O
XIAFLEX NN O O
- NN O O
treated NN O O
patients NN O O
in NN O O
clinical NN O O
studies NN O O
. NN O O
In NN O O
other NN O O
XIAFLEX NN O O
- NN O O
treated NN O O
patients NN O O
( NN O O
9 NN O O
of NN O O
1044 NN O O
; NN O O
0.9 NN O O
% NN O O
) NN O O
, NN O O
a NN O O
diagnosis NN O O
of NN O O
corporal NN B-AdverseReaction B-AdverseReaction
rupture NN I-AdverseReaction I-AdverseReaction
can NN B-Factor B-Factor
not NN I-Factor I-Factor
be NN I-Factor I-Factor
excluded NN I-Factor I-Factor
Severe NN B-Severity B-Severity
penile NN B-AdverseReaction B-AdverseReaction
hematoma NN I-AdverseReaction I-AdverseReaction
was NN O O
also NN O O
reported NN O O
as NN O O
an NN O O
adverse NN O O
reaction NN O O
in NN O O
39 NN O O
of NN O O
1044 NN O O
( NN O O
3.7 NN O O
% NN O O
) NN O O
XIAFLEX NN O O
- NN O O
treated NN O O
patients NN O O
( NN O O
5.2 NN O O
) NN O O
. NN O O
* NN O O
XIAFLEX NN O O
is NN O O
available NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
Peyronie NN O O
's NN O O
disease NN O O
only NN O O
through NN O O
a NN O O
restricted NN O O
program NN O O
called NN O O
the NN O O
XIAFLEX NN O O
REMS NN O O
Program NN O O
( NN O O
5.3 NN O O
) NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Tendon NN B-AdverseReaction B-AdverseReaction
rupture NN I-AdverseReaction I-AdverseReaction
or NN O O
serious NN B-Severity B-Severity
injury NN B-AdverseReaction B-AdverseReaction
to NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
injected NN I-AdverseReaction I-AdverseReaction
finger NN I-AdverseReaction I-AdverseReaction
Avoid NN O O
injecting NN O O
XIAFLEX NN O O
into NN O O
tendons NN O O
, NN O O
nerves NN O O
, NN O O
blood NN O O
vessels NN O O
, NN O O
or NN O O
other NN O O
collagen NN O O
- NN O O
containing NN O O
structure NN O O
of NN O O
the NN O O
hand NN O O
. NN O O
Injection NN O O
into NN O O
these NN O O
structures NN O O
may NN O O
result NN O O
in NN O O
possible NN O O
permanent NN O O
injury NN O O
, NN O O
such NN O O
as NN O O
tendon NN O O
rupture NN O O
or NN O O
ligament NN O O
damage NN O O
, NN O O
or NN O O
skin NN O O
laceration NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Corporal NN B-AdverseReaction B-AdverseReaction
rupture NN I-AdverseReaction I-AdverseReaction
( NN O O
penile NN O O
fracture NN O O
) NN O O
or NN O O
other NN O O
serious NN B-Severity B-Severity
injury NN B-AdverseReaction B-AdverseReaction
to NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
penis NN I-AdverseReaction I-AdverseReaction
Avoid NN O O
injecting NN O O
into NN O O
the NN O O
urethra NN O O
, NN O O
nerves NN O O
, NN O O
blood NN O O
vessels NN O O
, NN O O
corpora NN O O
cavernosa NN O O
or NN O O
other NN O O
collagen NN O O
- NN O O
containing NN O O
structures NN O O
of NN O O
the NN O O
penis NN O O
. NN O O
Injection NN O O
into NN O O
these NN O O
structures NN O O
may NN B-Factor B-Factor
result NN O O
in NN O O
possible NN O O
permanent NN B-AdverseReaction B-AdverseReaction
injury NN I-AdverseReaction I-AdverseReaction
such NN O O
as NN O O
corporal NN B-AdverseReaction B-AdverseReaction
rupture NN I-AdverseReaction I-AdverseReaction
( NN O O
penile NN O O
fracture NN O O
) NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
Healthcare NN O O
providers NN O O
should NN O O
be NN O O
prepared NN O O
to NN O O
address NN O O
hypersensitivity NN O O
reactions NN O O
, NN O O
including NN O O
anaphylaxis NN O O
, NN O O
following NN O O
XIAFLEX NN O O
injections NN O O
. NN O O
( NN O O
5.4 NN O O
) NN O O
* NN O O
Patients NN O O
with NN O O
abnormal NN O O
coagulation NN O O
: NN O O
Use NN O O
with NN O O
caution NN O O
, NN O O
including NN O O
in NN O O
patients NN O O
who NN O O
have NN O O
received NN O O
anticoagulant NN O O
medications NN O O
other NN O O
than NN O O
low NN O O
- NN O O
dose NN O O
aspirin NN O O
within NN O O
7 NN O O
days NN O O
of NN O O
the NN O O
injection NN O O
. NN O O
( NN O O
5.5 NN O O
) NN O O
5.1 NN O O
Tendon NN O O
Rupture NN O O
or NN O O
Other NN O O
Serious NN O O
Injury NN O O
to NN O O
the NN O O
Injected NN O O
Finger/Hand NN O O
in NN O O
the NN O O
Treatment NN O O
of NN O O
Dupuytren NN O O
's NN O O
Contracture NN O O
In NN O O
the NN O O
controlled NN O O
and NN O O
uncontrolled NN O O
portions NN O O
of NN O O
clinical NN O O
trials NN O O
in NN O O
Dupuytren NN O O
's NN O O
contracture NN O O
, NN O O
flexor NN B-AdverseReaction B-AdverseReaction
tendon NN I-AdverseReaction I-AdverseReaction
ruptures NN I-AdverseReaction I-AdverseReaction
occurred NN O O
after NN O O
XIAFLEX NN O O
injection NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Injection NN O O
of NN O O
XIAFLEX NN O O
into NN O O
collagen NN O O
- NN O O
containing NN O O
structures NN O O
such NN O O
as NN O O
tendons NN O O
or NN O O
ligaments NN O O
of NN O O
the NN O O
hand NN O O
may NN B-Factor B-Factor
result NN O O
in NN O O
damage NN O O
to NN O O
those NN O O
structures NN O O
and NN O O
possible NN B-Factor B-Factor
permanent NN B-AdverseReaction B-AdverseReaction
injury NN I-AdverseReaction I-AdverseReaction
such NN O O
as NN O O
tendon NN B-AdverseReaction B-AdverseReaction
rupture NN I-AdverseReaction I-AdverseReaction
or NN O O
ligament NN B-AdverseReaction B-AdverseReaction
damage NN I-AdverseReaction I-AdverseReaction
Therefore NN O O
, NN O O
XIAFLEX NN O O
should NN O O
be NN O O
injected NN O O
only NN O O
into NN O O
the NN O O
collagen NN O O
cord NN O O
with NN O O
a NN O O
MP NN O O
or NN O O
PIP NN O O
joint NN O O
contracture NN O O
, NN O O
and NN O O
care NN O O
should NN O O
be NN O O
taken NN O O
to NN O O
avoid NN O O
injecting NN O O
into NN O O
tendons NN O O
, NN O O
nerves NN O O
, NN O O
blood NN O O
vessels NN O O
, NN O O
or NN O O
other NN O O
collagen NN O O
- NN O O
containing NN O O
structures NN O O
of NN O O
the NN O O
hand NN O O
. NN O O
When NN O O
injecting NN O O
a NN O O
cord NN O O
affecting NN O O
a NN O O
PIP NN O O
joint NN O O
of NN O O
the NN O O
fifth NN O O
finger NN O O
, NN O O
the NN O O
needle NN O O
insertion NN O O
should NN O O
not NN O O
be NN O O
more NN O O
than NN O O
2 NN O O
to NN O O
3 NN O O
mm NN O O
in NN O O
depth NN O O
and NN O O
avoid NN O O
injecting NN O O
more NN O O
than NN O O
4 NN O O
mm NN O O
distal NN O O
to NN O O
the NN O O
palmar NN O O
digital NN O O
crease NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.1 NN O O
) NN O O
] NN O O
. NN O O
Other NN O O
XIAFLEX NN O O
- NN O O
associated NN O O
serious NN O O
local NN O O
adverse NN O O
reactions NN O O
included NN O O
pulley NN B-AdverseReaction B-AdverseReaction
rupture NN I-AdverseReaction I-AdverseReaction
ligament NN B-AdverseReaction B-AdverseReaction
injury NN I-AdverseReaction I-AdverseReaction
complex NN B-AdverseReaction B-AdverseReaction
regional NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
CRPS NN O O
) NN O O
, NN O O
sensory NN B-AdverseReaction B-AdverseReaction
abnormality NN I-AdverseReaction I-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
hand NN I-AdverseReaction I-AdverseReaction
and NN O O
skin NN B-AdverseReaction B-AdverseReaction
laceration NN I-AdverseReaction I-AdverseReaction
( NN O O
tear NN O O
) NN O O
. NN O O
In NN O O
a NN O O
historically NN O O
controlled NN O O
post NN O O
- NN O O
marketing NN O O
trial NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
skin NN B-AdverseReaction B-AdverseReaction
laceration NN I-AdverseReaction I-AdverseReaction
( NN O O
22 NN O O
% NN O O
) NN O O
was NN O O
higher NN O O
for NN O O
subjects NN O O
treated NN O O
with NN O O
two NN O O
concurrent NN O O
injections NN O O
of NN O O
XIAFLEX NN O O
compared NN O O
with NN O O
subjects NN O O
treated NN O O
with NN O O
up NN O O
to NN O O
three NN O O
single NN O O
injections NN O O
in NN O O
the NN O O
placebo NN O O
- NN O O
controlled NN O O
premarketing NN O O
trials NN O O
( NN O O
9 NN O O
% NN O O
) NN O O
. NN O O
Cases NN O O
of NN O O
skin NN B-AdverseReaction B-AdverseReaction
laceration NN I-AdverseReaction I-AdverseReaction
requiring NN O O
skin NN O O
graft NN O O
after NN O O
finger NN O O
extension NN O O
procedures NN O O
have NN O O
been NN O O
reported NN O O
post NN O O
- NN O O
marketing NN O O
. NN O O
Signs NN O O
or NN O O
symptoms NN O O
that NN O O
may NN O O
reflect NN O O
serious NN O O
injury NN O O
to NN O O
the NN O O
injected NN O O
finger/hand NN O O
should NN O O
be NN O O
promptly NN O O
evaluated NN O O
because NN O O
surgical NN O O
intervention NN O O
may NN O O
be NN O O
required NN O O
. NN O O
5.2 NN O O
Corporal NN O O
Rupture NN O O
( NN O O
Penile NN O O
Fracture NN O O
) NN O O
or NN O O
Other NN O O
Serious NN O O
Injury NN O O
to NN O O
the NN O O
Penis NN O O
in NN O O
the NN O O
Treatment NN O O
of NN O O
Peyronie NN O O
's NN O O
Disease NN O O
Corporal NN B-AdverseReaction B-AdverseReaction
rupture NN I-AdverseReaction I-AdverseReaction
was NN O O
reported NN O O
as NN O O
an NN O O
adverse NN O O
reaction NN O O
after NN O O
XIAFLEX NN O O
injections NN O O
in NN O O
5 NN O O
of NN O O
1044 NN O O
( NN O O
0.5 NN O O
% NN O O
) NN O O
XIAFLEX NN O O
treated NN O O
patients NN O O
in NN O O
the NN O O
controlled NN O O
and NN O O
uncontrolled NN O O
clinical NN O O
trials NN O O
in NN O O
Peyronie NN O O
's NN O O
disease NN O O
. NN O O
In NN O O
other NN O O
XIAFLEX NN O O
- NN O O
treated NN O O
patients NN O O
( NN O O
9 NN O O
of NN O O
1044 NN O O
; NN O O
0.9 NN O O
% NN O O
) NN O O
, NN O O
a NN O O
combination NN O O
of NN O O
penile NN B-AdverseReaction B-AdverseReaction
ecchymoses NN I-AdverseReaction I-AdverseReaction
or NN O O
hematoma NN O O
, NN O O
sudden NN O O
penile NN B-AdverseReaction B-AdverseReaction
detumescence NN I-AdverseReaction I-AdverseReaction
and/or NN O O
a NN O O
penile NN B-AdverseReaction B-AdverseReaction
" NN I-AdverseReaction I-AdverseReaction
popping NN I-AdverseReaction I-AdverseReaction
" NN I-AdverseReaction I-AdverseReaction
sound NN I-AdverseReaction I-AdverseReaction
or NN O O
sensation NN O O
was NN O O
reported NN O O
, NN O O
and NN O O
in NN O O
these NN O O
cases NN O O
, NN O O
a NN O O
diagnosis NN O O
of NN O O
corporal NN B-AdverseReaction B-AdverseReaction
rupture NN I-AdverseReaction I-AdverseReaction
can NN B-Factor B-Factor
not NN I-Factor I-Factor
be NN I-Factor I-Factor
excluded NN I-Factor I-Factor
These NN O O
patients NN O O
were NN O O
managed NN O O
without NN O O
surgical NN O O
intervention NN O O
, NN O O
but NN O O
the NN O O
long NN O O
- NN O O
term NN O O
consequences NN O O
are NN O O
unknown NN O O
. NN O O
Severe NN B-Severity B-Severity
penile NN B-AdverseReaction B-AdverseReaction
hematoma NN I-AdverseReaction I-AdverseReaction
was NN O O
also NN O O
reported NN O O
as NN O O
an NN O O
adverse NN O O
reaction NN O O
in NN O O
39 NN O O
of NN O O
1044 NN O O
patients NN O O
( NN O O
3.7 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
controlled NN O O
and NN O O
uncontrolled NN O O
clinical NN O O
trials NN O O
in NN O O
Peyronie NN O O
's NN O O
disease NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
] NN O O
. NN O O
Signs NN O O
or NN O O
symptoms NN O O
that NN O O
may NN O O
reflect NN O O
serious NN O O
injury NN O O
to NN O O
the NN O O
penis NN O O
should NN O O
be NN O O
promptly NN O O
evaluated NN O O
in NN O O
order NN O O
to NN O O
assess NN O O
for NN O O
corporal NN O O
rupture NN O O
or NN O O
severe NN O O
penile NN O O
hematoma NN O O
, NN O O
which NN O O
may NN O O
require NN O O
surgical NN O O
intervention NN O O
. NN O O
Injection NN O O
of NN O O
XIAFLEX NN O O
into NN O O
collagen NN O O
- NN O O
containing NN O O
structures NN O O
such NN O O
as NN O O
the NN O O
corpora NN O O
cavernosa NN O O
of NN O O
the NN O O
penis NN O O
may NN B-Factor B-Factor
result NN O O
in NN O O
damage NN O O
to NN O O
those NN O O
structures NN O O
and NN O O
possible NN B-Factor B-Factor
injury NN O O
such NN O O
as NN O O
corporal NN B-AdverseReaction B-AdverseReaction
rupture NN I-AdverseReaction I-AdverseReaction
( NN O O
penile NN O O
fracture NN O O
) NN O O
. NN O O
Therefore NN O O
, NN O O
XIAFLEX NN O O
should NN O O
be NN O O
injected NN O O
only NN O O
into NN O O
the NN O O
Peyronie NN O O
's NN O O
plaque NN O O
and NN O O
care NN O O
should NN O O
be NN O O
taken NN O O
to NN O O
avoid NN O O
injecting NN O O
into NN O O
the NN O O
urethra NN O O
, NN O O
nerves NN O O
, NN O O
blood NN O O
vessels NN O O
, NN O O
corpora NN O O
cavernosa NN O O
or NN O O
other NN O O
collagen NN O O
- NN O O
containing NN O O
structures NN O O
of NN O O
the NN O O
penis NN O O
. NN O O
5.3 NN O O
XIAFLEX NN O O
REMS NN O O
Program NN O O
Because NN O O
of NN O O
the NN O O
risks NN O O
of NN O O
corporal NN O O
rupture NN O O
( NN O O
penile NN O O
fracture NN O O
) NN O O
or NN O O
other NN O O
serious NN O O
penile NN O O
injury NN O O
in NN O O
the NN O O
treatment NN O O
of NN O O
Peyronie NN O O
's NN O O
disease NN O O
, NN O O
XIAFLEX NN O O
is NN O O
available NN O O
only NN O O
through NN O O
the NN O O
XIAFLEX NN O O
REMS NN O O
Program NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
Required NN O O
components NN O O
of NN O O
the NN O O
XIAFLEX NN O O
REMS NN O O
Program NN O O
include NN O O
the NN O O
following NN O O
: NN O O
* NN O O
Prescribers NN O O
must NN O O
be NN O O
certified NN O O
with NN O O
the NN O O
program NN O O
by NN O O
enrolling NN O O
and NN O O
completing NN O O
training NN O O
in NN O O
the NN O O
administration NN O O
of NN O O
XIAFLEX NN O O
treatment NN O O
for NN O O
Peyronie NN O O
's NN O O
disease NN O O
. NN O O
* NN O O
Healthcare NN O O
sites NN O O
must NN O O
be NN O O
certified NN O O
with NN O O
the NN O O
program NN O O
and NN O O
ensure NN O O
that NN O O
XIAFLEX NN O O
is NN O O
only NN O O
dispensed NN O O
for NN O O
use NN O O
by NN O O
certified NN O O
prescribers NN O O
. NN O O
Further NN O O
information NN O O
is NN O O
available NN O O
at NN O O
www NN O O
. NN O O
XIAFLEXREMS.com NN O O
or NN O O
1 NN O O
- NN O O
877 NN O O
- NN O O
313 NN O O
- NN O O
1235 NN O O
. NN O O
5.4 NN O O
Hypersensitivity NN O O
Reactions NN O O
, NN O O
Including NN O O
Anaphylaxis NN O O
In NN O O
the NN O O
controlled NN O O
portions NN O O
of NN O O
the NN O O
clinical NN O O
trials NN O O
in NN O O
Dupuytren NN O O
's NN O O
contracture NN O O
( NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
) NN O O
, NN O O
a NN O O
greater NN O O
proportion NN O O
of NN O O
XIAFLEX NN O O
- NN O O
treated NN O O
patients NN O O
( NN O O
15 NN O O
% NN O O
) NN O O
compared NN O O
to NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
had NN O O
mild NN B-Severity B-Severity
allergic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
( NN O O
pruritus NN O O
) NN O O
after NN O O
up NN O O
to NN O O
3 NN O O
injections NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
XIAFLEX NN O O
- NN O O
associated NN O O
pruritus NN B-AdverseReaction B-AdverseReaction
increased NN O O
after NN O O
more NN O O
XIAFLEX NN O O
injections NN O O
in NN O O
patients NN O O
with NN O O
Dupuytren NN O O
's NN O O
contracture NN O O
. NN O O
In NN O O
the NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
portions NN O O
of NN O O
the NN O O
clinical NN O O
trials NN O O
in NN O O
Peyronie NN O O
's NN O O
disease NN O O
( NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
) NN O O
, NN O O
a NN O O
greater NN O O
proportion NN O O
of NN O O
XIAFLEX NN O O
- NN O O
treated NN O O
patients NN O O
( NN O O
4 NN O O
% NN O O
) NN O O
compared NN O O
to NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
had NN O O
localized NN B-AdverseReaction B-AdverseReaction
pruritus NN I-AdverseReaction I-AdverseReaction
after NN O O
up NN O O
to NN O O
4 NN O O
treatment NN O O
cycles NN O O
( NN O O
involving NN O O
up NN O O
to NN O O
8 NN O O
XIAFLEX NN O O
injection NN O O
procedures NN O O
) NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
XIAFLEX NN O O
- NN O O
associated NN O O
pruritus NN B-AdverseReaction B-AdverseReaction
was NN O O
similar NN O O
after NN O O
each NN O O
injection NN O O
regardless NN O O
of NN O O
the NN O O
number NN O O
of NN O O
injections NN O O
administered NN O O
. NN O O
Because NN O O
XIAFLEX NN O O
contains NN O O
foreign NN O O
proteins NN O O
, NN O O
severe NN B-Severity B-Severity
allergic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
to NN O O
XIAFLEX NN O O
can NN B-Factor B-Factor
occur NN O O
. NN O O
Anaphylaxis NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
a NN O O
post NN O O
- NN O O
marketing NN O O
clinical NN O O
trial NN O O
( NN O O
Study NN O O
3 NN O O
) NN O O
in NN O O
one NN O O
patient NN O O
who NN O O
had NN O O
previous NN O O
exposure NN O O
to NN O O
XIAFLEX NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
Dupuytren NN O O
's NN O O
contracture NN O O
. NN O O
Some NN O O
patients NN O O
with NN O O
Dupuytren NN O O
's NN O O
contracture NN O O
developed NN O O
IgE NN O O
- NN O O
anti NN O O
- NN O O
drug NN O O
antibodies NN O O
in NN O O
greater NN O O
proportions NN O O
and NN O O
higher NN O O
titers NN O O
with NN O O
successive NN O O
XIAFLEX NN O O
injections NN O O
. NN O O
Healthcare NN O O
providers NN O O
should NN O O
be NN O O
prepared NN O O
to NN O O
address NN O O
severe NN O O
allergic NN O O
reactions NN O O
following NN O O
XIAFLEX NN O O
injections NN O O
. NN O O
5.5 NN O O
Risk NN O O
of NN O O
bleeding NN O O
in NN O O
Patients NN O O
with NN O O
Abnormal NN O O
Coagulation NN O O
In NN O O
the NN O O
XIAFLEX NN O O
trials NN O O
in NN O O
Dupuytren NN O O
's NN O O
contracture NN O O
( NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
) NN O O
, NN O O
70 NN O O
% NN O O
and NN O O
38 NN O O
% NN O O
of NN O O
XIAFLEX NN O O
- NN O O
treated NN O O
patients NN O O
developed NN O O
an NN O O
ecchymosis NN B-AdverseReaction B-AdverseReaction
or NN O O
an NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
respectively NN O O
( NN O O
see NN O O
Table NN O O
3 NN O O
) NN O O
. NN O O
In NN O O
the NN O O
XIAFLEX NN O O
controlled NN O O
trials NN O O
in NN O O
Peyronie NN O O
's NN O O
disease NN O O
( NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
) NN O O
, NN O O
65.5 NN O O
% NN O O
of NN O O
XIAFLEX NN O O
- NN O O
treated NN O O
patients NN O O
developed NN O O
penile NN B-AdverseReaction B-AdverseReaction
hematoma NN I-AdverseReaction I-AdverseReaction
and NN O O
14.5 NN O O
% NN O O
developed NN O O
penile NN B-AdverseReaction B-AdverseReaction
ecchymosis NN I-AdverseReaction I-AdverseReaction
( NN O O
see NN O O
Table NN O O
4 NN O O
) NN O O
. NN O O
Patients NN O O
with NN O O
abnormal NN O O
coagulation NN O O
( NN O O
except NN O O
for NN O O
patients NN O O
taking NN O O
low NN O O
- NN O O
dose NN O O
aspirin NN O O
, NN O O
e.g. NN O O
, NN O O
up NN O O
to NN O O
150 NN O O
mg NN O O
per NN O O
day NN O O
) NN O O
were NN O O
excluded NN O O
from NN O O
participating NN O O
in NN O O
these NN O O
studies NN O O
. NN O O
Therefore NN O O
, NN O O
the NN O O
efficacy NN O O
and NN O O
safety NN O O
of NN O O
XIAFLEX NN O O
in NN O O
patients NN O O
receiving NN O O
anticoagulant NN O O
medications NN O O
( NN O O
other NN O O
than NN O O
low NN O O
- NN O O
dose NN O O
aspirin NN O O
, NN O O
e.g. NN O O
, NN O O
up NN O O
to NN O O
150 NN O O
mg NN O O
per NN O O
day NN O O
) NN O O
within NN O O
7 NN O O
days NN O O
prior NN O O
to NN O O
XIAFLEX NN O O
administration NN O O
is NN O O
not NN O O
known NN O O
. NN O O
In NN O O
addition NN O O
, NN O O
it NN O O
is NN O O
recommended NN O O
to NN O O
avoid NN O O
use NN O O
of NN O O
XIAFLEX NN O O
in NN O O
patients NN O O
with NN O O
coagulation NN O O
disorders NN O O
, NN O O
including NN O O
patients NN O O
receiving NN O O
concomitant NN O O
anticoagulants NN O O
( NN O O
except NN O O
for NN O O
low NN O O
- NN O O
dose NN O O
aspirin NN O O
) NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
are NN O O
discussed NN O O
in NN O O
greater NN O O
detail NN O O
in NN O O
the NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5 NN O O
) NN O O
section NN O O
of NN O O
the NN O O
labeling NN O O
: NN O O
* NN O O
Endophthalmitis NN B-AdverseReaction B-AdverseReaction
and NN O O
retinal NN B-AdverseReaction B-AdverseReaction
detachments NN I-AdverseReaction I-AdverseReaction
* NN O O
Increased NN B-AdverseReaction B-AdverseReaction
intraocular NN I-AdverseReaction I-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
* NN O O
Thromboembolic NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=5 NN O O
% NN O O
) NN O O
reported NN O O
in NN O O
patients NN O O
receiving NN O O
EYLEA NN O O
were NN O O
conjunctival NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
eye NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
cataract NN B-AdverseReaction B-AdverseReaction
vitreous NN B-AdverseReaction B-AdverseReaction
floaters NN I-AdverseReaction I-AdverseReaction
intraocular NN B-AdverseReaction B-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
and NN O O
vitreous NN B-AdverseReaction B-AdverseReaction
detachment NN I-AdverseReaction I-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Regeneron NN O O
at NN O O
1 NN O O
- NN O O
855 NN O O
- NN O O
395 NN O O
- NN O O
3248 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
other NN O O
clinical NN O O
trials NN O O
of NN O O
the NN O O
same NN O O
or NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
A NN O O
total NN O O
of NN O O
2711 NN O O
patients NN O O
treated NN O O
with NN O O
EYLEA NN O O
constituted NN O O
the NN O O
safety NN O O
population NN O O
in NN O O
seven NN O O
phase NN O O
3 NN O O
studies NN O O
. NN O O
Among NN O O
those NN O O
, NN O O
2110 NN O O
patients NN O O
were NN O O
treated NN O O
with NN O O
the NN O O
recommended NN O O
dose NN O O
of NN O O
2 NN O O
mg NN O O
. NN O O
Serious NN O O
adverse NN O O
reactions NN O O
related NN O O
to NN O O
the NN O O
injection NN O O
procedure NN O O
have NN O O
occurred NN O O
in NN O O
< NN O O
0.1 NN O O
% NN O O
of NN O O
intravitreal NN O O
injections NN O O
with NN O O
EYLEA NN O O
including NN O O
endophthalmitis NN B-AdverseReaction B-AdverseReaction
and NN O O
retinal NN B-AdverseReaction B-AdverseReaction
detachment NN I-AdverseReaction I-AdverseReaction
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=5 NN O O
% NN O O
) NN O O
reported NN O O
in NN O O
patients NN O O
receiving NN O O
EYLEA NN O O
were NN O O
conjunctival NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
eye NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
cataract NN B-AdverseReaction B-AdverseReaction
vitreous NN B-AdverseReaction B-AdverseReaction
floaters NN I-AdverseReaction I-AdverseReaction
intraocular NN B-AdverseReaction B-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
and NN O O
vitreous NN B-AdverseReaction B-AdverseReaction
detachment NN I-AdverseReaction I-AdverseReaction
Neovascular NN O O
( NN O O
Wet NN O O
) NN O O
Age NN O O
- NN O O
Related NN O O
Macular NN O O
Degeneration NN O O
( NN O O
AMD NN O O
) NN O O
The NN O O
data NN O O
described NN O O
below NN O O
reflect NN O O
exposure NN O O
to NN O O
EYLEA NN O O
in NN O O
1824 NN O O
patients NN O O
with NN O O
wet NN O O
AMD NN O O
, NN O O
including NN O O
1223 NN O O
patients NN O O
treated NN O O
with NN O O
the NN O O
2-mg NN O O
dose NN O O
, NN O O
in NN O O
2 NN O O
double NN O O
- NN O O
masked NN O O
, NN O O
active NN O O
- NN O O
controlled NN O O
clinical NN O O
studies NN O O
( NN O O
VIEW1 NN O O
and NN O O
VIEW2 NN O O
) NN O O
for NN O O
12 NN O O
months NN O O
[ NN O O
seeClinical NN O O
Studies NN O O
( NN O O
14.1 NN O O
) NN O O
] NN O O
. NN O O
Table NN O O
1 NN O O
: NN O O
Most NN O O
Common NN O O
Adverse NN O O
Reactions NN O O
( NN O O
>=1 NN O O
% NN O O
) NN O O
in NN O O
Wet NN O O
AMD NN O O
Studies NN O O
Adverse NN O O
Reactions NN O O
EYLEA(N=1824 NN O O
) NN O O
Active NN O O
Control NN O O
( NN O O
ranibizumab)(N=595 NN O O
) NN O O
Conjunctival NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
25 NN O O
% NN O O
28 NN O O
% NN O O
Eye NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
9 NN O O
% NN O O
9 NN O O
% NN O O
Cataract NN B-AdverseReaction B-AdverseReaction
7 NN O O
% NN O O
7 NN O O
% NN O O
Vitreous NN B-AdverseReaction B-AdverseReaction
detachment NN I-AdverseReaction I-AdverseReaction
6 NN O O
% NN O O
6 NN O O
% NN O O
Vitreous NN B-AdverseReaction B-AdverseReaction
floaters NN I-AdverseReaction I-AdverseReaction
6 NN O O
% NN O O
7 NN O O
% NN O O
Intraocular NN B-AdverseReaction B-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
5 NN O O
% NN O O
7 NN O O
% NN O O
Ocular NN B-AdverseReaction B-AdverseReaction
hyperemia NN I-AdverseReaction I-AdverseReaction
4 NN O O
% NN O O
8 NN O O
% NN O O
Corneal NN B-AdverseReaction B-AdverseReaction
epithelium NN I-AdverseReaction I-AdverseReaction
defect NN I-AdverseReaction I-AdverseReaction
4 NN O O
% NN O O
5 NN O O
% NN O O
Detachment NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
retinal NN I-AdverseReaction I-AdverseReaction
pigment NN I-AdverseReaction I-AdverseReaction
epithelium NN I-AdverseReaction I-AdverseReaction
3 NN O O
% NN O O
3 NN O O
% NN O O
Injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
3 NN O O
% NN O O
3 NN O O
% NN O O
Foreign NN B-AdverseReaction B-AdverseReaction
body NN I-AdverseReaction I-AdverseReaction
sensation NN I-AdverseReaction I-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
eyes NN I-AdverseReaction I-AdverseReaction
3 NN O O
% NN O O
4 NN O O
% NN O O
Lacrimation NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
3 NN O O
% NN O O
1 NN O O
% NN O O
Vision NN B-AdverseReaction B-AdverseReaction
blurred NN I-AdverseReaction I-AdverseReaction
2 NN O O
% NN O O
2 NN O O
% NN O O
Intraocular NN B-AdverseReaction B-AdverseReaction
inflammation NN I-AdverseReaction I-AdverseReaction
2 NN O O
% NN O O
3 NN O O
% NN O O
Retinal NN B-AdverseReaction B-AdverseReaction
pigment NN I-AdverseReaction I-AdverseReaction
epithelium NN I-AdverseReaction I-AdverseReaction
tear NN I-AdverseReaction I-AdverseReaction
2 NN O O
% NN O O
1 NN O O
% NN O O
Injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
1 NN O O
% NN O O
2 NN O O
% NN O O
Eyelid NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
1 NN O O
% NN O O
2 NN O O
% NN O O
Corneal NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
1 NN O O
% NN O O
1 NN O O
% NN O O
Less NN O O
common NN O O
serious NN O O
adverse NN O O
reactions NN O O
reported NN O O
in NN O O
< NN O O
1 NN O O
% NN O O
of NN O O
the NN O O
patients NN O O
treated NN O O
with NN O O
EYLEA NN O O
were NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
retinal NN B-AdverseReaction B-AdverseReaction
detachment NN I-AdverseReaction I-AdverseReaction
retinal NN B-AdverseReaction B-AdverseReaction
tear NN I-AdverseReaction I-AdverseReaction
and NN O O
endophthalmitis NN B-AdverseReaction B-AdverseReaction
Macular NN O O
Edema NN O O
Following NN O O
Retinal NN O O
Vein NN O O
Occlusion NN O O
( NN O O
RVO NN O O
) NN O O
The NN O O
data NN O O
described NN O O
below NN O O
reflect NN O O
6 NN O O
months NN O O
exposure NN O O
to NN O O
EYLEA NN O O
with NN O O
a NN O O
monthly NN O O
2 NN O O
mg NN O O
dose NN O O
in NN O O
218 NN O O
patients NN O O
following NN O O
CRVO NN O O
in NN O O
2 NN O O
clinical NN O O
studies NN O O
( NN O O
COPERNICUS NN O O
and NN O O
GALILEO NN O O
) NN O O
and NN O O
91 NN O O
patients NN O O
following NN O O
BRVO NN O O
in NN O O
one NN O O
clinical NN O O
study NN O O
( NN O O
VIBRANT NN O O
) NN O O
[ NN O O
seeClinical NN O O
Studies NN O O
( NN O O
14.2),(14.3 NN O O
) NN O O
] NN O O
. NN O O
Table NN O O
2 NN O O
: NN O O
Most NN O O
Common NN O O
Adverse NN O O
Reactions NN O O
( NN O O
>=1 NN O O
% NN O O
) NN O O
in NN O O
RVO NN O O
Studies NN O O
Adverse NN O O
Reactions NN O O
CRVO NN O O
BRVO NN O O
EYLEA(N=218 NN O O
) NN O O
Control(N=142 NN O O
) NN O O
EYLEA(N=91 NN O O
) NN O O
Control(N=92 NN O O
) NN O O
Eye NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
13 NN O O
% NN O O
5 NN O O
% NN O O
4 NN O O
% NN O O
5 NN O O
% NN O O
Conjunctival NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
12 NN O O
% NN O O
11 NN O O
% NN O O
20 NN O O
% NN O O
4 NN O O
% NN O O
Intraocular NN B-AdverseReaction B-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
8 NN O O
% NN O O
6 NN O O
% NN O O
2 NN O O
% NN O O
0 NN O O
% NN O O
Corneal NN B-AdverseReaction B-AdverseReaction
epithelium NN I-AdverseReaction I-AdverseReaction
defect NN I-AdverseReaction I-AdverseReaction
5 NN O O
% NN O O
4 NN O O
% NN O O
2 NN O O
% NN O O
0 NN O O
% NN O O
Vitreous NN B-AdverseReaction B-AdverseReaction
floaters NN I-AdverseReaction I-AdverseReaction
5 NN O O
% NN O O
1 NN O O
% NN O O
1 NN O O
% NN O O
0 NN O O
% NN O O
Ocular NN B-AdverseReaction B-AdverseReaction
hyperemia NN I-AdverseReaction I-AdverseReaction
5 NN O O
% NN O O
3 NN O O
% NN O O
2 NN O O
% NN O O
2 NN O O
% NN O O
Foreign NN B-AdverseReaction B-AdverseReaction
body NN I-AdverseReaction I-AdverseReaction
sensation NN I-AdverseReaction I-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
eyes NN I-AdverseReaction I-AdverseReaction
3 NN O O
% NN O O
5 NN O O
% NN O O
3 NN O O
% NN O O
0 NN O O
% NN O O
Vitreous NN B-AdverseReaction B-AdverseReaction
detachment NN I-AdverseReaction I-AdverseReaction
3 NN O O
% NN O O
4 NN O O
% NN O O
2 NN O O
% NN O O
0 NN O O
% NN O O
Lacrimation NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
3 NN O O
% NN O O
4 NN O O
% NN O O
3 NN O O
% NN O O
0 NN O O
% NN O O
Injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
3 NN O O
% NN O O
1 NN O O
% NN O O
1 NN O O
% NN O O
0 NN O O
% NN O O
Vision NN B-AdverseReaction B-AdverseReaction
blurred NN I-AdverseReaction I-AdverseReaction
1 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
1 NN O O
% NN O O
1 NN O O
% NN O O
Intraocular NN B-AdverseReaction B-AdverseReaction
inflammation NN I-AdverseReaction I-AdverseReaction
1 NN O O
% NN O O
1 NN O O
% NN O O
0 NN O O
% NN O O
0 NN O O
% NN O O
Cataract NN B-AdverseReaction B-AdverseReaction
< NN O O
1 NN O O
% NN O O
1 NN O O
% NN O O
5 NN O O
% NN O O
0 NN O O
% NN O O
Eyelid NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
< NN O O
1 NN O O
% NN O O
1 NN O O
% NN O O
1 NN O O
% NN O O
0 NN O O
% NN O O
Less NN O O
common NN O O
adverse NN O O
reactions NN O O
reported NN O O
in NN O O
< NN O O
1 NN O O
% NN O O
of NN O O
the NN O O
patients NN O O
treated NN O O
with NN O O
EYLEA NN O O
in NN O O
the NN O O
CRVO NN O O
studies NN O O
were NN O O
corneal NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
retinal NN B-AdverseReaction B-AdverseReaction
tear NN I-AdverseReaction I-AdverseReaction
hypersensitivity NN B-AdverseReaction B-AdverseReaction
and NN O O
endophthalmitis NN B-AdverseReaction B-AdverseReaction
Diabetic NN O O
Macular NN O O
Edema NN O O
( NN O O
DME NN O O
) NN O O
The NN O O
data NN O O
described NN O O
below NN O O
reflect NN O O
exposure NN O O
to NN O O
EYLEA NN O O
in NN O O
578 NN O O
patients NN O O
with NN O O
DME NN O O
treated NN O O
with NN O O
the NN O O
2-mg NN O O
dose NN O O
in NN O O
2 NN O O
double NN O O
- NN O O
masked NN O O
, NN O O
controlled NN O O
clinical NN O O
studies NN O O
( NN O O
VIVID NN O O
and NN O O
VISTA NN O O
) NN O O
from NN O O
baseline NN O O
to NN O O
week NN O O
52 NN O O
and NN O O
from NN O O
baseline NN O O
to NN O O
week NN O O
100 NN O O
[ NN O O
seeClinical NN O O
Studies NN O O
( NN O O
14.4 NN O O
) NN O O
] NN O O
. NN O O
Table NN O O
3 NN O O
: NN O O
Most NN O O
Common NN O O
Adverse NN O O
Reactions NN O O
( NN O O
>=1 NN O O
% NN O O
) NN O O
in NN O O
DME NN O O
Studies NN O O
Adverse NN O O
Reactions NN O O
Baseline NN O O
to NN O O
Week NN O O
52 NN O O
Baseline NN O O
to NN O O
Week NN O O
100 NN O O
EYLEA(N=578 NN O O
) NN O O
Control(N=287 NN O O
) NN O O
EYLEA(N=578 NN O O
) NN O O
Control(N=287 NN O O
) NN O O
Conjunctival NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
28 NN O O
% NN O O
17 NN O O
% NN O O
31 NN O O
% NN O O
21 NN O O
% NN O O
Eye NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
9 NN O O
% NN O O
6 NN O O
% NN O O
11 NN O O
% NN O O
9 NN O O
% NN O O
Cataract NN B-AdverseReaction B-AdverseReaction
8 NN O O
% NN O O
9 NN O O
% NN O O
19 NN O O
% NN O O
17 NN O O
% NN O O
Vitreous NN B-AdverseReaction B-AdverseReaction
floaters NN I-AdverseReaction I-AdverseReaction
6 NN O O
% NN O O
3 NN O O
% NN O O
8 NN O O
% NN O O
6 NN O O
% NN O O
Corneal NN B-AdverseReaction B-AdverseReaction
epithelium NN I-AdverseReaction I-AdverseReaction
defect NN I-AdverseReaction I-AdverseReaction
5 NN O O
% NN O O
3 NN O O
% NN O O
7 NN O O
% NN O O
5 NN O O
% NN O O
Intraocular NN B-AdverseReaction B-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
5 NN O O
% NN O O
3 NN O O
% NN O O
9 NN O O
% NN O O
5 NN O O
% NN O O
Ocular NN B-AdverseReaction B-AdverseReaction
hyperemia NN I-AdverseReaction I-AdverseReaction
5 NN O O
% NN O O
6 NN O O
% NN O O
5 NN O O
% NN O O
6 NN O O
% NN O O
Vitreous NN B-AdverseReaction B-AdverseReaction
detachment NN I-AdverseReaction I-AdverseReaction
3 NN O O
% NN O O
3 NN O O
% NN O O
8 NN O O
% NN O O
6 NN O O
% NN O O
Foreign NN B-AdverseReaction B-AdverseReaction
body NN I-AdverseReaction I-AdverseReaction
sensation NN I-AdverseReaction I-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
eyes NN I-AdverseReaction I-AdverseReaction
3 NN O O
% NN O O
3 NN O O
% NN O O
3 NN O O
% NN O O
3 NN O O
% NN O O
Lacrimation NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
3 NN O O
% NN O O
2 NN O O
% NN O O
4 NN O O
% NN O O
2 NN O O
% NN O O
Vision NN B-AdverseReaction B-AdverseReaction
blurred NN I-AdverseReaction I-AdverseReaction
2 NN O O
% NN O O
2 NN O O
% NN O O
3 NN O O
% NN O O
4 NN O O
% NN O O
Intraocular NN B-AdverseReaction B-AdverseReaction
inflammation NN I-AdverseReaction I-AdverseReaction
2 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
3 NN O O
% NN O O
1 NN O O
% NN O O
Injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
2 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
2 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
Eyelid NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
< NN O O
1 NN O O
% NN O O
1 NN O O
% NN O O
2 NN O O
% NN O O
1 NN O O
% NN O O
Less NN O O
common NN O O
adverse NN O O
reactions NN O O
reported NN O O
in NN O O
< NN O O
1 NN O O
% NN O O
of NN O O
the NN O O
patients NN O O
treated NN O O
with NN O O
EYLEA NN O O
were NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
retinal NN B-AdverseReaction B-AdverseReaction
detachment NN I-AdverseReaction I-AdverseReaction
retinal NN B-AdverseReaction B-AdverseReaction
tear NN I-AdverseReaction I-AdverseReaction
corneal NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
and NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
6.2 NN O O
Immunogenicity NN O O
As NN O O
with NN O O
all NN O O
therapeutic NN O O
proteins NN O O
, NN O O
there NN O O
is NN O O
a NN O O
potential NN O O
for NN O O
an NN O O
immune NN O O
response NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
EYLEA. NN O O
The NN O O
immunogenicity NN O O
of NN O O
EYLEA NN O O
was NN O O
evaluated NN O O
in NN O O
serum NN O O
samples NN O O
. NN O O
The NN O O
immunogenicity NN O O
data NN O O
reflect NN O O
the NN O O
percentage NN O O
of NN O O
patients NN O O
whose NN O O
test NN O O
results NN O O
were NN O O
considered NN O O
positive NN O O
for NN O O
antibodies NN O O
to NN O O
EYLEA NN O O
in NN O O
immunoassays NN O O
. NN O O
The NN O O
detection NN O O
of NN O O
an NN O O
immune NN O O
response NN O O
is NN O O
highly NN O O
dependent NN O O
on NN O O
the NN O O
sensitivity NN O O
and NN O O
specificity NN O O
of NN O O
the NN O O
assays NN O O
used NN O O
, NN O O
sample NN O O
handling NN O O
, NN O O
timing NN O O
of NN O O
sample NN O O
collection NN O O
, NN O O
concomitant NN O O
medications NN O O
, NN O O
and NN O O
underlying NN O O
disease NN O O
. NN O O
For NN O O
these NN O O
reasons NN O O
, NN O O
comparison NN O O
of NN O O
the NN O O
incidence NN O O
of NN O O
antibodies NN O O
to NN O O
EYLEA NN O O
with NN O O
the NN O O
incidence NN O O
of NN O O
antibodies NN O O
to NN O O
other NN O O
products NN O O
may NN O O
be NN O O
misleading NN O O
. NN O O
In NN O O
the NN O O
wet NN O O
AMD NN O O
, NN O O
RVO NN O O
, NN O O
and NN O O
DME NN O O
studies NN O O
, NN O O
the NN O O
pre NN O O
- NN O O
treatment NN O O
incidence NN O O
of NN O O
immunoreactivity NN O O
to NN O O
EYLEA NN O O
was NN O O
approximately NN O O
1 NN O O
% NN O O
to NN O O
3 NN O O
% NN O O
across NN O O
treatment NN O O
groups NN O O
. NN O O
After NN O O
dosing NN O O
with NN O O
EYLEA NN O O
for NN O O
24 NN O O
- NN O O
100 NN O O
weeks NN O O
, NN O O
antibodies NN O O
to NN O O
EYLEA NN O O
were NN O O
detected NN O O
in NN O O
a NN O O
similar NN O O
percentage NN O O
range NN O O
of NN O O
patients NN O O
. NN O O
There NN O O
were NN O O
no NN O O
differences NN O O
in NN O O
efficacy NN O O
or NN O O
safety NN O O
between NN O O
patients NN O O
with NN O O
or NN O O
without NN O O
immunoreactivity NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Endophthalmitis NN B-AdverseReaction B-AdverseReaction
and NN O O
retinal NN B-AdverseReaction B-AdverseReaction
detachments NN I-AdverseReaction I-AdverseReaction
may NN B-Factor B-Factor
occur NN O O
following NN O O
intravitreal NN O O
injections NN O O
. NN O O
Patients NN O O
should NN O O
be NN O O
instructed NN O O
to NN O O
report NN O O
any NN O O
symptoms NN O O
suggestive NN O O
of NN O O
endophthalmitis NN O O
or NN O O
retinal NN O O
detachment NN O O
without NN O O
delay NN O O
and NN O O
should NN O O
be NN O O
managed NN O O
appropriately NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
intraocular NN I-AdverseReaction I-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
seen NN O O
within NN O O
60 NN O O
minutes NN O O
of NN O O
an NN O O
intravitreal NN O O
injection NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
There NN O O
is NN O O
a NN O O
potential NN O O
risk NN O O
of NN O O
arterial NN B-AdverseReaction B-AdverseReaction
thromboembolic NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
following NN O O
intravitreal NN O O
use NN O O
of NN O O
VEGF NN B-DrugClass B-DrugClass
inhibitors NN I-DrugClass I-DrugClass
( NN O O
5.3 NN O O
) NN O O
5.1 NN O O
Endophthalmitis NN O O
and NN O O
Retinal NN O O
Detachments NN O O
Intravitreal NN O O
injections NN O O
, NN O O
including NN O O
those NN O O
with NN O O
EYLEA NN O O
, NN O O
have NN O O
been NN O O
associated NN O O
with NN O O
endophthalmitis NN B-AdverseReaction B-AdverseReaction
and NN O O
retinal NN B-AdverseReaction B-AdverseReaction
detachments NN I-AdverseReaction I-AdverseReaction
[ NN O O
seeAdverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Proper NN O O
aseptic NN O O
injection NN O O
technique NN O O
must NN O O
always NN O O
be NN O O
used NN O O
when NN O O
administering NN O O
EYLEA. NN O O
Patients NN O O
should NN O O
be NN O O
instructed NN O O
to NN O O
report NN O O
any NN O O
symptoms NN O O
suggestive NN O O
of NN O O
endophthalmitis NN O O
or NN O O
retinal NN O O
detachment NN O O
without NN O O
delay NN O O
and NN O O
should NN O O
be NN O O
managed NN O O
appropriately NN O O
[ NN O O
seeDosage NN O O
and NN O O
Administration NN O O
( NN O O
2.7)andPatient NN O O
Counseling NN O O
Information NN O O
( NN O O
17 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
Increase NN O O
in NN O O
Intraocular NN O O
Pressure NN O O
Acute NN B-AdverseReaction B-AdverseReaction
increases NN I-AdverseReaction I-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
intraocular NN I-AdverseReaction I-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
seen NN O O
within NN O O
60 NN O O
minutes NN O O
of NN O O
intravitreal NN O O
injection NN O O
, NN O O
including NN O O
with NN O O
EYLEA NN O O
[ NN O O
seeAdverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Sustained NN B-AdverseReaction B-AdverseReaction
increases NN I-AdverseReaction I-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
intraocular NN I-AdverseReaction I-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
have NN O O
also NN O O
been NN O O
reported NN O O
after NN O O
repeated NN O O
intravitreal NN O O
dosing NN O O
with NN O O
vascular NN O O
endothelial NN O O
growth NN O O
factor NN O O
( NN O O
VEGF NN O O
) NN O O
inhibitors NN O O
. NN O O
Intraocular NN O O
pressure NN O O
and NN O O
the NN O O
perfusion NN O O
of NN O O
the NN O O
optic NN O O
nerve NN O O
head NN O O
should NN O O
be NN O O
monitored NN O O
and NN O O
managed NN O O
appropriately NN O O
[ NN O O
seeDosage NN O O
and NN O O
Administration NN O O
( NN O O
2.7 NN O O
) NN O O
] NN O O
. NN O O
5.3 NN O O
Thromboembolic NN O O
Events NN O O
There NN O O
is NN O O
a NN O O
potential NN O O
risk NN B-Factor B-Factor
of NN O O
arterial NN B-AdverseReaction B-AdverseReaction
thromboembolic NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
( NN O O
ATEs NN O O
) NN O O
following NN O O
intravitreal NN O O
use NN O O
of NN O O
VEGF NN O O
inhibitors NN O O
, NN O O
including NN O O
EYLEA. NN O O
ATEs NN O O
are NN O O
defined NN O O
as NN O O
nonfatal NN O O
stroke NN O O
, NN O O
nonfatal NN O O
myocardial NN O O
infarction NN O O
, NN O O
or NN O O
vascular NN O O
death NN O O
( NN O O
including NN O O
deaths NN O O
of NN O O
unknown NN O O
cause NN O O
) NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
reported NN O O
thromboembolic NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
in NN O O
wet NN O O
AMD NN O O
studies NN O O
during NN O O
the NN O O
first NN O O
year NN O O
was NN O O
1.8 NN O O
% NN O O
( NN O O
32 NN O O
out NN O O
of NN O O
1824 NN O O
) NN O O
in NN O O
the NN O O
combined NN O O
group NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
EYLEA. NN O O
The NN O O
incidence NN O O
in NN O O
the NN O O
DME NN O O
studies NN O O
from NN O O
baseline NN O O
to NN O O
week NN O O
52 NN O O
was NN O O
3.3 NN O O
% NN O O
( NN O O
19 NN O O
out NN O O
of NN O O
578 NN O O
) NN O O
in NN O O
the NN O O
combined NN O O
group NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
EYLEA NN O O
compared NN O O
with NN O O
2.8 NN O O
% NN O O
( NN O O
8 NN O O
out NN O O
of NN O O
287 NN O O
) NN O O
in NN O O
the NN O O
control NN O O
group NN O O
; NN O O
from NN O O
baseline NN O O
to NN O O
week NN O O
100 NN O O
, NN O O
the NN O O
incidence NN O O
was NN O O
6.4 NN O O
% NN O O
( NN O O
37 NN O O
out NN O O
of NN O O
578 NN O O
) NN O O
in NN O O
the NN O O
combined NN O O
group NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
EYLEA NN O O
compared NN O O
with NN O O
4.2 NN O O
% NN O O
( NN O O
12 NN O O
out NN O O
of NN O O
287 NN O O
) NN O O
in NN O O
the NN O O
control NN O O
group NN O O
. NN O O
There NN O O
were NN O O
no NN B-Negation B-Negation
reported NN O O
thromboembolic NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
in NN O O
the NN O O
patients NN O O
treated NN O O
with NN O O
EYLEA NN O O
in NN O O
the NN O O
first NN O O
six NN O O
months NN O O
of NN O O
the NN O O
RVO NN O O
studies NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
. NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
serious NN O O
adverse NN O O
reactions NN O O
are NN O O
described NN O O
in NN O O
greater NN O O
detail NN O O
in NN O O
the NN O O
Warnings NN O O
and NN O O
Precautions NN O O
section NN O O
* NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Clostridium NN B-AdverseReaction B-AdverseReaction
difficile NN I-AdverseReaction I-AdverseReaction
-Associated NN I-AdverseReaction I-AdverseReaction
diarrhea NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
Direct NN B-AdverseReaction B-AdverseReaction
Coombs NN I-AdverseReaction I-AdverseReaction
' NN I-AdverseReaction I-AdverseReaction
Test NN I-AdverseReaction I-AdverseReaction
Seroconversion NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
occurring NN O O
in NN O O
>2 NN O O
% NN O O
of NN O O
patients NN O O
are NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
and NN O O
rash NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Forest NN O O
Laboratories NN O O
, NN O O
LLC NN O O
, NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
678 NN O O
- NN O O
1605 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
compared NN O O
directly NN O O
to NN O O
rates NN O O
from NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
Teflaro NN O O
was NN O O
evaluated NN O O
in NN O O
four NN O O
controlled NN O O
comparative NN O O
Phase NN O O
3 NN O O
clinical NN O O
trials NN O O
( NN O O
two NN O O
in NN O O
ABSSSI NN O O
and NN O O
two NN O O
in NN O O
CABP NN O O
) NN O O
which NN O O
included NN O O
1300 NN O O
adult NN O O
patients NN O O
treated NN O O
with NN O O
Teflaro NN O O
( NN O O
600 NN O O
mg NN O O
administered NN O O
by NN O O
IV NN O O
over NN O O
1 NN O O
hour NN O O
every NN O O
12h NN O O
) NN O O
and NN O O
1297 NN O O
patients NN O O
treated NN O O
with NN O O
comparator NN O O
( NN O O
vancomycin NN O O
plus NN O O
aztreonam NN O O
or NN O O
ceftriaxone NN O O
) NN O O
for NN O O
a NN O O
treatment NN O O
period NN O O
up NN O O
to NN O O
21 NN O O
days NN O O
. NN O O
The NN O O
median NN O O
age NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
Teflaro NN O O
was NN O O
54 NN O O
years NN O O
, NN O O
ranging NN O O
between NN O O
18 NN O O
and NN O O
99 NN O O
years NN O O
old NN O O
. NN O O
Patients NN O O
treated NN O O
with NN O O
Teflaro NN O O
were NN O O
predominantly NN O O
male NN O O
( NN O O
63 NN O O
% NN O O
) NN O O
and NN O O
Caucasian NN O O
( NN O O
82 NN O O
% NN O O
) NN O O
. NN O O
Serious NN O O
Adverse NN O O
Reactions NN O O
and NN O O
Adverse NN O O
Reactions NN O O
Leading NN O O
to NN O O
Discontinuation NN O O
In NN O O
the NN O O
four NN O O
pooled NN O O
Phase NN O O
3 NN O O
clinical NN O O
trials NN O O
, NN O O
serious NN O O
adverse NN O O
reactions NN O O
( NN O O
SARs NN O O
) NN O O
occurred NN O O
in NN O O
98/1300 NN O O
( NN O O
7.5 NN O O
% NN O O
) NN O O
of NN O O
patients NN O O
receiving NN O O
Teflaro NN O O
and NN O O
100/1297 NN O O
( NN O O
7.7 NN O O
% NN O O
) NN O O
of NN O O
patients NN O O
receiving NN O O
comparator NN O O
drugs NN O O
. NN O O
Treatment NN O O
discontinuation NN O O
due NN O O
to NN O O
adverse NN O O
reactions NN O O
occurred NN O O
in NN O O
35/1300 NN O O
( NN O O
2.7 NN O O
% NN O O
) NN O O
of NN O O
patients NN O O
receiving NN O O
Teflaro NN O O
and NN O O
48/1297 NN O O
( NN O O
3.7 NN O O
% NN O O
) NN O O
of NN O O
patients NN O O
receiving NN O O
comparator NN O O
drugs NN O O
with NN O O
the NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
leading NN O O
to NN O O
discontinuation NN O O
being NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
for NN O O
both NN O O
treatment NN O O
groups NN O O
at NN O O
a NN O O
rate NN O O
of NN O O
0.3 NN O O
% NN O O
in NN O O
the NN O O
Teflaro NN O O
group NN O O
and NN O O
0.5 NN O O
% NN O O
in NN O O
comparator NN O O
group NN O O
. NN O O
Most NN O O
Common NN O O
Adverse NN O O
Reactions NN O O
No NN O O
adverse NN O O
reactions NN O O
occurred NN O O
in NN O O
greater NN O O
than NN O O
5 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
Teflaro NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
occurring NN O O
in NN O O
> NN O O
2 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
Teflaro NN O O
in NN O O
the NN O O
pooled NN O O
phase NN O O
3 NN O O
clinical NN O O
trials NN O O
were NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
and NN O O
rash NN B-AdverseReaction B-AdverseReaction
Table NN O O
4 NN O O
lists NN O O
adverse NN O O
reactions NN O O
occurring NN O O
in NN O O
>= NN O O
2 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
Teflaro NN O O
in NN O O
the NN O O
pooled NN O O
Phase NN O O
3 NN O O
clinical NN O O
trials NN O O
. NN O O
Table NN O O
4 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Occurring NN O O
in NN O O
>= NN O O
2 NN O O
% NN O O
of NN O O
Patients NN O O
Receiving NN O O
Teflaro NN O O
in NN O O
the NN O O
Pooled NN O O
Phase NN O O
3 NN O O
Clinical NN O O
Trials NN O O
a NN O O
Comparators NN O O
included NN O O
vancomycin NN O O
1 NN O O
gram NN O O
IV NN O O
every NN O O
12h NN O O
plus NN O O
aztreonam NN O O
1 NN O O
gram NN O O
IV NN O O
every NN O O
12h NN O O
in NN O O
the NN O O
Phase NN O O
3 NN O O
ABSSSI NN O O
trials NN O O
, NN O O
and NN O O
ceftriaxone NN O O
1 NN O O
gram NN O O
IV NN O O
every NN O O
24h NN O O
in NN O O
the NN O O
Phase NN O O
3 NN O O
CABP NN O O
trials NN O O
. NN O O
Adverse NN O O
Reactions NN O O
Pooled NN O O
Phase NN O O
3 NN O O
Clinical NN O O
Trials NN O O
( NN O O
four NN O O
trials NN O O
, NN O O
two NN O O
in NN O O
ABSSSI NN O O
and NN O O
two NN O O
in NN O O
CABP NN O O
) NN O O
Teflaro NN O O
( NN O O
N=1300 NN O O
) NN O O
Pooled NN O O
Comparators NN O O
a NN O O
( NN O O
N=1297 NN O O
) NN O O
Gastrointestinal NN O O
Disorders NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
5 NN O O
% NN O O
3 NN O O
% NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
4 NN O O
% NN O O
4 NN O O
% NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
2 NN O O
% NN O O
2 NN O O
% NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
2 NN O O
% NN O O
2 NN O O
% NN O O
Laboratory NN O O
Investigations NN O O
Increased NN B-AdverseReaction B-AdverseReaction
transaminases NN I-AdverseReaction I-AdverseReaction
2 NN O O
% NN O O
3 NN O O
% NN O O
Metabolism NN O O
and NN O O
Nutrition NN O O
disorders NN O O
Hypokalemia NN B-AdverseReaction B-AdverseReaction
2 NN O O
% NN O O
3 NN O O
% NN O O
Skin NN O O
and NN O O
Subcutaneous NN O O
Tissue NN O O
Disorders NN O O
Rash NN B-AdverseReaction B-AdverseReaction
3 NN O O
% NN O O
2 NN O O
% NN O O
Vascular NN O O
Disorders NN O O
Phlebitis NN B-AdverseReaction B-AdverseReaction
2 NN O O
% NN O O
1 NN O O
% NN O O
Other NN O O
Adverse NN O O
Reactions NN O O
Observed NN O O
During NN O O
Clinical NN O O
Trials NN O O
of NN O O
Teflaro NN O O
Following NN O O
is NN O O
a NN O O
list NN O O
of NN O O
additional NN O O
adverse NN O O
reactions NN O O
reported NN O O
by NN O O
the NN O O
1740 NN O O
patients NN O O
who NN O O
received NN O O
Teflaro NN O O
in NN O O
any NN O O
clinical NN O O
trial NN O O
with NN O O
incidences NN O O
less NN O O
than NN O O
2 NN O O
% NN O O
. NN O O
Blood NN O O
and NN O O
lymphatic NN O O
system NN O O
disorders NN O O
- NN O O
Anemia NN B-AdverseReaction B-AdverseReaction
Eosinophilia NN B-AdverseReaction B-AdverseReaction
Neutropenia NN B-AdverseReaction B-AdverseReaction
Thrombocytopenia NN B-AdverseReaction B-AdverseReaction
Cardiac NN O O
disorders NN O O
- NN O O
Bradycardia NN B-AdverseReaction B-AdverseReaction
Palpitations NN B-AdverseReaction B-AdverseReaction
Gastrointestinal NN O O
disorders NN O O
- NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
- NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
Hepatobiliary NN O O
disorders NN O O
- NN O O
Hepatitis NN B-AdverseReaction B-AdverseReaction
Immune NN O O
system NN O O
disorders NN O O
- NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
Anaphylaxis NN B-AdverseReaction B-AdverseReaction
Infections NN O O
and NN O O
infestations NN O O
- NN O O
Clostridium NN B-AdverseReaction B-AdverseReaction
difficile NN I-AdverseReaction I-AdverseReaction
colitis NN I-AdverseReaction I-AdverseReaction
Metabolism NN O O
and NN O O
nutrition NN O O
disorders NN O O
- NN O O
Hyperglycemia NN B-AdverseReaction B-AdverseReaction
Hyperkalemia NN B-AdverseReaction B-AdverseReaction
Nervous NN O O
system NN O O
disorders NN O O
- NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
Convulsion NN B-AdverseReaction B-AdverseReaction
Renal NN O O
and NN O O
urinary NN O O
disorders NN O O
- NN O O
Renal NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
- NN O O
Urticaria NN B-AdverseReaction B-AdverseReaction
6.2 NN O O
Postmarketing NN O O
Experience NN O O
The NN O O
following NN O O
adverse NN O O
reaction NN O O
has NN O O
been NN O O
identified NN O O
during NN O O
postapproval NN O O
use NN O O
of NN O O
Teflaro NN O O
. NN O O
Because NN O O
this NN O O
adverse NN O O
reaction NN O O
was NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
possible NN O O
to NN O O
estimate NN O O
its NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
Blood NN O O
and NN O O
lymphatic NN O O
system NN O O
disorders NN O O
: NN O O
Agranulocytosis NN B-AdverseReaction B-AdverseReaction
5 NN O O
. NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Serious NN B-Severity B-Severity
hypersensitivity NN O O
( NN O O
anaphylactic NN O O
) NN O O
reactions NN O O
have NN O O
been NN O O
reported NN O O
with NN O O
beta NN O O
- NN O O
lactam NN O O
antibacterial NN O O
drugs NN O O
, NN O O
including NN O O
Teflaro NN O O
. NN O O
If NN O O
a NN O O
hypersensitivity NN O O
reaction NN O O
occurs NN O O
, NN O O
discontinue NN O O
Teflaro NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Clostridium NN B-AdverseReaction B-AdverseReaction
difficile NN I-AdverseReaction I-AdverseReaction
-associated NN I-AdverseReaction I-AdverseReaction
diarrhea NN I-AdverseReaction I-AdverseReaction
( NN O O
CDAD NN O O
) NN O O
has NN O O
been NN O O
reported NN O O
with NN O O
nearly NN O O
all NN O O
systemic NN O O
antibacterial NN O O
agents NN O O
, NN O O
including NN O O
Teflaro NN O O
. NN O O
Evaluate NN O O
if NN O O
diarrhea NN O O
occurs NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Direct NN B-AdverseReaction B-AdverseReaction
Coombs NN I-AdverseReaction I-AdverseReaction
' NN I-AdverseReaction I-AdverseReaction
test NN I-AdverseReaction I-AdverseReaction
seroconversion NN I-AdverseReaction I-AdverseReaction
has NN O O
been NN O O
reported NN O O
with NN O O
Teflaro NN O O
. NN O O
If NN O O
anemia NN O O
develops NN O O
during NN O O
or NN O O
after NN O O
therapy NN O O
, NN O O
a NN O O
diagnostic NN O O
workup NN O O
for NN O O
drug NN O O
- NN O O
induced NN O O
hemolytic NN O O
anemia NN O O
should NN O O
be NN O O
performed NN O O
and NN O O
consideration NN O O
given NN O O
to NN O O
discontinuation NN O O
of NN O O
Teflaro NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
5.1 NN O O
Hypersensitivity NN O O
Reactions NN O O
Serious NN B-Severity B-Severity
and NN O O
occasionally NN O O
fatal NN B-AdverseReaction B-AdverseReaction
hypersensitivity NN O O
( NN O O
anaphylactic NN O O
) NN O O
reactions NN O O
and NN O O
serious NN B-Severity B-Severity
skin NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
receiving NN O O
beta NN B-DrugClass B-DrugClass
- NN I-DrugClass I-DrugClass
lactam NN I-DrugClass I-DrugClass
antibacterial NN I-DrugClass I-DrugClass
drugs NN I-DrugClass I-DrugClass
Before NN O O
therapy NN O O
with NN O O
Teflaro NN O O
is NN O O
instituted NN O O
, NN O O
careful NN O O
inquiry NN O O
about NN O O
previous NN O O
hypersensitivity NN O O
reactions NN O O
to NN O O
other NN O O
cephalosporins NN O O
, NN O O
penicillins NN O O
, NN O O
or NN O O
carbapenems NN O O
should NN O O
be NN O O
made NN O O
. NN O O
Maintain NN O O
clinical NN O O
supervision NN O O
if NN O O
this NN O O
product NN O O
is NN O O
to NN O O
be NN O O
given NN O O
to NN O O
a NN O O
penicillin- NN O O
or NN O O
other NN O O
beta NN O O
- NN O O
lactam NN O O
- NN O O
allergic NN O O
patient NN O O
, NN O O
because NN O O
cross NN O O
sensitivity NN O O
among NN O O
beta NN O O
- NN O O
lactam NN O O
antibacterial NN O O
agents NN O O
has NN O O
been NN O O
clearly NN O O
established NN O O
. NN O O
If NN O O
an NN O O
allergic NN O O
reaction NN O O
to NN O O
Teflaro NN O O
occurs NN O O
, NN O O
discontinue NN O O
Teflaro NN O O
and NN O O
institute NN O O
appropriate NN O O
treatment NN O O
and NN O O
supportive NN O O
measures NN O O
. NN O O
5.2 NN O O
Clostridium NN O O
difficile NN O O
- NN O O
Associated NN O O
Diarrhea NN O O
Clostridium NN B-AdverseReaction B-AdverseReaction
difficile NN I-AdverseReaction I-AdverseReaction
-associated NN I-AdverseReaction I-AdverseReaction
diarrhea NN I-AdverseReaction I-AdverseReaction
( NN O O
CDAD NN O O
) NN O O
has NN O O
been NN O O
reported NN O O
for NN O O
nearly NN O O
all NN O O
systemic NN O O
antibacterial NN O O
agents NN O O
, NN O O
including NN O O
Teflaro NN O O
, NN O O
and NN O O
may NN O O
range NN O O
in NN O O
severity NN O O
from NN O O
mild NN B-Severity B-Severity
diarrhea NN B-AdverseReaction B-AdverseReaction
to NN O O
fatal NN B-AdverseReaction B-AdverseReaction
colitis NN B-AdverseReaction B-AdverseReaction
Treatment NN O O
with NN O O
antibacterial NN O O
agents NN O O
alters NN O O
the NN O O
normal NN O O
flora NN O O
of NN O O
the NN O O
colon NN O O
and NN O O
may NN O O
permit NN O O
overgrowth NN O O
of NN O O
C. NN O O
difficile NN O O
. NN O O
C. NN O O
difficile NN O O
produces NN O O
toxins NN O O
A NN O O
and NN O O
B NN O O
which NN O O
contribute NN O O
to NN O O
the NN O O
development NN O O
of NN O O
CDAD. NN O O
Hypertoxin NN O O
- NN O O
producing NN O O
strains NN O O
of NN O O
C. NN O O
difficile NN O O
cause NN O O
increased NN O O
morbidity NN O O
and NN O O
mortality NN O O
, NN O O
as NN O O
these NN O O
infections NN O O
can NN O O
be NN O O
refractory NN O O
to NN O O
antimicrobial NN O O
therapy NN O O
and NN O O
may NN O O
require NN O O
colectomy NN O O
. NN O O
CDAD NN O O
must NN O O
be NN O O
considered NN O O
in NN O O
all NN O O
patients NN O O
who NN O O
present NN O O
with NN O O
diarrhea NN O O
following NN O O
antibiotic NN O O
use NN O O
. NN O O
Careful NN O O
medical NN O O
history NN O O
is NN O O
necessary NN O O
because NN O O
CDAD NN O O
has NN O O
been NN O O
reported NN O O
to NN O O
occur NN O O
more NN O O
than NN O O
2 NN O O
months NN O O
after NN O O
the NN O O
administration NN O O
of NN O O
antibacterial NN O O
agents NN O O
. NN O O
If NN O O
CDAD NN O O
is NN O O
suspected NN O O
or NN O O
confirmed NN O O
, NN O O
antibacterials NN O O
not NN O O
directed NN O O
against NN O O
C. NN O O
difficile NN O O
should NN O O
be NN O O
discontinued NN O O
, NN O O
if NN O O
possible NN O O
. NN O O
Appropriate NN O O
fluid NN O O
and NN O O
electrolyte NN O O
management NN O O
, NN O O
protein NN O O
supplementation NN O O
, NN O O
antibiotic NN O O
treatment NN O O
of NN O O
C. NN O O
difficile NN O O
, NN O O
and NN O O
surgical NN O O
evaluation NN O O
should NN O O
be NN O O
instituted NN O O
as NN O O
clinically NN O O
indicated NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
5.3 NN O O
Direct NN O O
Coombs NN O O
' NN O O
Test NN O O
Seroconversion NN O O
Seroconversion NN B-AdverseReaction B-AdverseReaction
from NN I-AdverseReaction I-AdverseReaction
a NN I-AdverseReaction I-AdverseReaction
negative NN I-AdverseReaction I-AdverseReaction
to NN I-AdverseReaction I-AdverseReaction
a NN I-AdverseReaction I-AdverseReaction
positive NN I-AdverseReaction I-AdverseReaction
direct NN I-AdverseReaction I-AdverseReaction
Coombs NN I-AdverseReaction I-AdverseReaction
' NN I-AdverseReaction I-AdverseReaction
test NN I-AdverseReaction I-AdverseReaction
result NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
120/1114 NN O O
( NN O O
10.8 NN O O
% NN O O
) NN O O
of NN O O
patients NN O O
receiving NN O O
Teflaro NN O O
and NN O O
49/1116 NN O O
( NN O O
4.4 NN O O
% NN O O
) NN O O
of NN O O
patients NN O O
receiving NN O O
comparator NN O O
drugs NN O O
in NN O O
the NN O O
four NN O O
pooled NN O O
Phase NN O O
3 NN O O
trials NN O O
. NN O O
In NN O O
the NN O O
pooled NN O O
Phase NN O O
3 NN O O
CABP NN O O
trials NN O O
, NN O O
51/520 NN O O
( NN O O
9.8 NN O O
% NN O O
) NN O O
of NN O O
Teflaro NN O O
- NN O O
treated NN O O
patients NN O O
compared NN O O
to NN O O
24/534 NN O O
( NN O O
4.5 NN O O
% NN O O
) NN O O
of NN O O
ceftriaxone NN O O
- NN O O
treated NN O O
patients NN O O
seroconverted NN B-AdverseReaction B-AdverseReaction
from NN I-AdverseReaction I-AdverseReaction
a NN I-AdverseReaction I-AdverseReaction
negative NN I-AdverseReaction I-AdverseReaction
to NN I-AdverseReaction I-AdverseReaction
a NN I-AdverseReaction I-AdverseReaction
positive NN I-AdverseReaction I-AdverseReaction
direct NN I-AdverseReaction I-AdverseReaction
Coombs NN I-AdverseReaction I-AdverseReaction
' NN I-AdverseReaction I-AdverseReaction
test NN I-AdverseReaction I-AdverseReaction
result NN I-AdverseReaction I-AdverseReaction
No NN B-Negation B-Negation
adverse NN O O
reactions NN O O
representing NN O O
hemolytic NN B-AdverseReaction B-AdverseReaction
anemia NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
in NN O O
any NN O O
treatment NN O O
group NN O O
. NN O O
If NN O O
anemia NN O O
develops NN O O
during NN O O
or NN O O
after NN O O
treatment NN O O
with NN O O
Teflaro NN O O
, NN O O
drug NN O O
- NN O O
induced NN O O
hemolytic NN O O
anemia NN O O
should NN O O
be NN O O
considered NN O O
. NN O O
Diagnostic NN O O
studies NN O O
including NN O O
a NN O O
direct NN O O
Coombs NN O O
' NN O O
test NN O O
, NN O O
should NN O O
be NN O O
performed NN O O
. NN O O
If NN O O
drug NN O O
- NN O O
induced NN O O
hemolytic NN O O
anemia NN O O
is NN O O
suspected NN O O
, NN O O
discontinuation NN O O
of NN O O
Teflaro NN O O
should NN O O
be NN O O
considered NN O O
and NN O O
supportive NN O O
care NN O O
should NN O O
be NN O O
administered NN O O
to NN O O
the NN O O
patient NN O O
( NN O O
i.e. NN O O
transfusion NN O O
) NN O O
if NN O O
clinically NN O O
indicated NN O O
. NN O O
5.4 NN O O
Development NN O O
of NN O O
Drug NN O O
- NN O O
Resistant NN O O
Bacteria NN O O
Prescribing NN O O
Teflaro NN O O
in NN O O
the NN O O
absence NN O O
of NN O O
a NN O O
proven NN O O
or NN O O
strongly NN O O
suspected NN O O
bacterial NN O O
infection NN O O
is NN O O
unlikely NN O O
to NN O O
provide NN O O
benefit NN O O
to NN O O
the NN O O
patient NN O O
and NN O O
increases NN O O
the NN O O
risk NN O O
of NN O O
the NN O O
development NN O O
of NN O O
drug NN O O
- NN O O
resistant NN O O
bacteria NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
adverse NN O O
drug NN O O
reactions NN O O
are NN O O
discussed NN O O
in NN O O
other NN O O
sections NN O O
of NN O O
the NN O O
labeling NN O O
: NN O O
* NN O O
Lactic NN B-AdverseReaction B-AdverseReaction
Acidosis NN I-AdverseReaction I-AdverseReaction
Hepatomegaly NN B-AdverseReaction B-AdverseReaction
with NN O O
Steatosis NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Boxed NN O O
Warning NN O O
, NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Severe NN B-Severity B-Severity
Acute NN B-AdverseReaction B-AdverseReaction
Exacerbations NN I-AdverseReaction I-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
Hepatitis NN I-AdverseReaction I-AdverseReaction
B NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Boxed NN O O
Warning NN O O
, NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
New NN O O
Onset NN O O
or NN O O
Worsening NN B-AdverseReaction B-AdverseReaction
Renal NN I-AdverseReaction I-AdverseReaction
Impairment NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Bone NN B-AdverseReaction B-AdverseReaction
Effects NN I-AdverseReaction I-AdverseReaction
of NN O O
Tenofovir NN O O
DF NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.6 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Immune NN B-AdverseReaction B-AdverseReaction
Reconstitution NN I-AdverseReaction I-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.8 NN O O
) NN O O
] NN O O
. NN O O
EXCERPT NN O O
: NN O O
Most NN O O
common NN O O
adverse NN O O
drug NN O O
reactions NN O O
to NN O O
STRIBILD NN O O
( NN O O
incidence NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
10 NN O O
% NN O O
, NN O O
all NN O O
grades NN O O
) NN O O
are NN O O
nausea NN B-AdverseReaction B-AdverseReaction
and NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Gilead NN O O
Sciences NN O O
, NN O O
Inc. NN O O
at NN O O
1 NN O O
- NN O O
800-GILEAD-5 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Adverse NN O O
Reactions NN O O
from NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
In NN O O
HIV-1-Infected NN O O
Subjects NN O O
With NN O O
No NN O O
Antiretroviral NN O O
Treatment NN O O
History NN O O
The NN O O
safety NN O O
assessment NN O O
of NN O O
STRIBILD NN O O
is NN O O
based NN O O
on NN O O
the NN O O
Week NN O O
144 NN O O
pooled NN O O
data NN O O
from NN O O
1408 NN O O
subjects NN O O
in NN O O
two NN O O
randomized NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
active NN O O
- NN O O
controlled NN O O
clinical NN O O
trials NN O O
, NN O O
Study NN O O
102 NN O O
and NN O O
Study NN O O
103 NN O O
, NN O O
in NN O O
antiretroviral NN O O
treatment NN O O
- NN O O
naive NN O O
HIV-1 NN O O
infected NN O O
adult NN O O
subjects NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
. NN O O
A NN O O
total NN O O
of NN O O
701 NN O O
subjects NN O O
received NN O O
STRIBILD NN O O
once NN O O
daily NN O O
in NN O O
these NN O O
two NN O O
studies NN O O
. NN O O
The NN O O
proportion NN O O
of NN O O
subjects NN O O
who NN O O
discontinued NN O O
treatment NN O O
with NN O O
STRIBILD NN O O
( NN O O
elvitegravir NN O O
150 NN O O
mg/cobicistat NN O O
150 NN O O
mg/emtricitabine NN O O
200 NN O O
mg/tenofovir NN O O
DF NN O O
300 NN O O
mg NN O O
) NN O O
; NN O O
ATRIPLA NN O O
( NN O O
efavirenz NN O O
600 NN O O
mg/emtricitabine NN O O
200 NN O O
mg/tenofovir NN O O
DF NN O O
300 NN O O
mg NN O O
) NN O O
; NN O O
or NN O O
atazanavir NN O O
( NN O O
ATV NN O O
) NN O O
+ NN O O
ritonavir NN O O
( NN O O
RTV NN O O
) NN O O
+ NN O O
TRUVADA NN O O
( NN O O
emtricitabine NN O O
200 NN O O
mg/tenofovir NN O O
DF NN O O
300 NN O O
mg NN O O
) NN O O
due NN O O
to NN O O
adverse NN O O
events NN O O
, NN O O
regardless NN O O
of NN O O
severity NN O O
, NN O O
was NN O O
6.0 NN O O
% NN O O
, NN O O
7.4 NN O O
% NN O O
and NN O O
8.5 NN O O
% NN O O
, NN O O
respectively NN O O
. NN O O
Table NN O O
2 NN O O
displays NN O O
the NN O O
frequency NN O O
of NN O O
adverse NN O O
drug NN O O
reactions NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
5 NN O O
% NN O O
of NN O O
subjects NN O O
in NN O O
any NN O O
treatment NN O O
arm NN O O
. NN O O
Table NN O O
2 NN O O
Adverse NN O O
Drug NN O O
ReactionsFrequencies NN O O
of NN O O
adverse NN O O
reactions NN O O
are NN O O
based NN O O
on NN O O
all NN O O
treatment NN O O
- NN O O
emergent NN O O
adverse NN O O
events NN O O
, NN O O
attributed NN O O
to NN O O
study NN O O
drugs NN O O
. NN O O
( NN O O
all NN O O
grades NN O O
) NN O O
Reported NN O O
in NN O O
>= NN O O
5 NN O O
% NN O O
of NN O O
Subjects NN O O
in NN O O
Any NN O O
Treatment NN O O
Arm NN O O
in NN O O
Studies NN O O
102 NN O O
and NN O O
103 NN O O
( NN O O
Week NN O O
144 NN O O
analysis NN O O
) NN O O
. NN O O
STRIBILDN=701 NN O O
ATRIPLAN=352 NN O O
ATV NN O O
+ NN O O
RTV NN O O
+ NN O O
TRUVADAN=355 NN O O
EYE NN O O
DISORDERS NN O O
Ocular NN B-AdverseReaction B-AdverseReaction
icterus NN I-AdverseReaction I-AdverseReaction
< NN O O
1 NN O O
% NN O O
0 NN O O
% NN O O
13 NN O O
% NN O O
GASTROINTESTINAL NN O O
DISORDERS NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
12 NN O O
% NN O O
11 NN O O
% NN O O
17 NN O O
% NN O O
Flatulence NN B-AdverseReaction B-AdverseReaction
2 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
8 NN O O
% NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
16 NN O O
% NN O O
9 NN O O
% NN O O
14 NN O O
% NN O O
GENERAL NN O O
DISORDERS NN O O
AND NN O O
ADMINISTRATION NN O O
SITE NN O O
CONDITIONS NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
4 NN O O
% NN O O
8 NN O O
% NN O O
6 NN O O
% NN O O
HEPATOBILIARY NN O O
DISORDERS NN O O
Jaundice NN B-AdverseReaction B-AdverseReaction
0 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
9 NN O O
% NN O O
NERVOUS NN O O
SYSTEM NN O O
DISORDERS NN O O
Somnolence NN B-AdverseReaction B-AdverseReaction
1 NN O O
% NN O O
7 NN O O
% NN O O
1 NN O O
% NN O O
Headache NN B-AdverseReaction B-AdverseReaction
7 NN O O
% NN O O
4 NN O O
% NN O O
6 NN O O
% NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
3 NN O O
% NN O O
21 NN O O
% NN O O
5 NN O O
% NN O O
PSYCHIATRIC NN O O
DISORDERS NN O O
Insomnia NN B-AdverseReaction B-AdverseReaction
3 NN O O
% NN O O
9 NN O O
% NN O O
1 NN O O
% NN O O
Abnormal NN B-AdverseReaction B-AdverseReaction
dreams NN I-AdverseReaction I-AdverseReaction
9 NN O O
% NN O O
27 NN O O
% NN O O
4 NN O O
% NN O O
SKIN NN O O
AND NN O O
SUBCUTANEOUS NN O O
TISSUE NN O O
DISORDERS NN O O
Rash NN B-AdverseReaction B-AdverseReaction
4 NN O O
% NN O O
15 NN O O
% NN O O
6 NN O O
% NN O O
See NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
, NN O O
for NN O O
a NN O O
discussion NN O O
of NN O O
renal NN B-AdverseReaction B-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
from NN O O
clinical NN O O
trials NN O O
experience NN O O
with NN O O
STRIBILD. NN O O
Additional NN O O
adverse NN O O
drug NN O O
reactions NN O O
observed NN O O
with NN O O
STRIBILD NN O O
included NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
ideation NN I-AdverseReaction I-AdverseReaction
and NN O O
suicide NN B-AdverseReaction B-AdverseReaction
attempt NN I-AdverseReaction I-AdverseReaction
( NN O O
0.3 NN O O
% NN O O
) NN O O
, NN O O
all NN O O
in NN O O
subjects NN O O
with NN O O
a NN O O
pre NN O O
- NN O O
existing NN O O
history NN O O
of NN O O
depression NN O O
or NN O O
psychiatric NN O O
illness NN O O
. NN O O
In NN O O
Virologically NN O O
- NN O O
Suppressed NN O O
HIV-1-Infected NN O O
Subjects NN O O
No NN O O
new NN O O
adverse NN O O
reactions NN O O
to NN O O
STRIBILD NN O O
through NN O O
Week NN O O
48 NN O O
were NN O O
identified NN O O
in NN O O
584 NN O O
virologically NN O O
stably NN O O
suppressed NN O O
subjects NN O O
switching NN O O
to NN O O
STRIBILD NN O O
from NN O O
a NN O O
regimen NN O O
containing NN O O
a NN O O
RTV NN O O
- NN O O
boosted NN O O
protease NN O O
inhibitor NN O O
( NN O O
PI NN O O
) NN O O
or NN O O
a NN O O
non NN O O
- NN O O
nucleoside NN O O
reverse NN O O
transcriptase NN O O
inhibitor NN O O
( NN O O
NNRTI NN O O
) NN O O
. NN O O
In NN O O
a NN O O
combined NN O O
analysis NN O O
of NN O O
Studies NN O O
115 NN O O
and NN O O
121 NN O O
, NN O O
the NN O O
frequency NN O O
of NN O O
adverse NN O O
reactions NN O O
( NN O O
all NN O O
grades NN O O
) NN O O
was NN O O
24 NN O O
% NN O O
in NN O O
subjects NN O O
switching NN O O
to NN O O
STRIBILD NN O O
compared NN O O
to NN O O
6 NN O O
% NN O O
of NN O O
subjects NN O O
in NN O O
either NN O O
group NN O O
who NN O O
stayed NN O O
on NN O O
their NN O O
baseline NN O O
antiretroviral NN O O
regimen NN O O
, NN O O
RTV NN O O
- NN O O
boosted NN O O
PI NN O O
+ NN O O
TRUVADA NN O O
or NN O O
NNRTI NN O O
+ NN O O
TRUVADA. NN O O
Common NN O O
adverse NN O O
reactions NN O O
that NN O O
occurred NN O O
in NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
2 NN O O
% NN O O
of NN O O
subjects NN O O
switching NN O O
to NN O O
STRIBILD NN O O
were NN O O
nausea NN B-AdverseReaction B-AdverseReaction
( NN O O
4 NN O O
% NN O O
) NN O O
, NN O O
flatulence NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
headache NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
. NN O O
The NN O O
proportion NN O O
of NN O O
subjects NN O O
who NN O O
discontinued NN O O
treatment NN O O
with NN O O
STRIBILD NN O O
, NN O O
the NN O O
RTV NN O O
- NN O O
boosted NN O O
PI NN O O
, NN O O
or NN O O
the NN O O
NNRTI NN O O
due NN O O
to NN O O
adverse NN O O
events NN O O
, NN O O
was NN O O
2 NN O O
% NN O O
, NN O O
3 NN O O
% NN O O
and NN O O
1 NN O O
% NN O O
, NN O O
respectively NN O O
. NN O O
Adverse NN O O
Reactions NN O O
from NN O O
Clinical NN O O
Trials NN O O
of NN O O
the NN O O
Components NN O O
of NN O O
STRIBILD NN O O
Emtricitabine NN O O
and NN O O
Tenofovir NN O O
Disoproxil NN O O
Fumarate NN O O
: NN O O
In NN O O
addition NN O O
to NN O O
the NN O O
adverse NN O O
reactions NN O O
observed NN O O
with NN O O
STRIBILD NN O O
, NN O O
the NN O O
following NN O O
adverse NN O O
reactions NN O O
occurred NN O O
in NN O O
at NN O O
least NN O O
5 NN O O
% NN O O
of NN O O
treatment NN O O
- NN O O
experienced NN O O
or NN O O
treatment NN O O
- NN O O
naive NN O O
subjects NN O O
receiving NN O O
emtricitabine NN O O
or NN O O
tenofovir NN O O
DF NN O O
with NN O O
other NN O O
antiretroviral NN O O
agents NN O O
in NN O O
other NN O O
clinical NN O O
trials NN O O
: NN O O
depression NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
dyspepsia NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
fever NN B-AdverseReaction B-AdverseReaction
pain NN B-AdverseReaction B-AdverseReaction
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
pneumonia NN B-AdverseReaction B-AdverseReaction
sinusitis NN B-AdverseReaction B-AdverseReaction
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
arthralgia NN B-AdverseReaction B-AdverseReaction
back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
myalgia NN B-AdverseReaction B-AdverseReaction
paresthesia NN B-AdverseReaction B-AdverseReaction
peripheral NN B-AdverseReaction B-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
( NN O O
including NN O O
peripheral NN B-AdverseReaction B-AdverseReaction
neuritis NN I-AdverseReaction I-AdverseReaction
and NN O O
neuropathy NN O O
) NN O O
, NN O O
anxiety NN B-AdverseReaction B-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
cough NN I-AdverseReaction I-AdverseReaction
and NN O O
rhinitis NN B-AdverseReaction B-AdverseReaction
Skin NN B-AdverseReaction B-AdverseReaction
discoloration NN I-AdverseReaction I-AdverseReaction
has NN O O
been NN O O
reported NN O O
with NN O O
higher NN O O
frequency NN O O
among NN O O
emtricitabine NN O O
- NN O O
treated NN O O
subjects NN O O
; NN O O
it NN O O
was NN O O
manifested NN O O
by NN O O
hyperpigmentation NN B-AdverseReaction B-AdverseReaction
on NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
palms NN I-AdverseReaction I-AdverseReaction
and/or NN O O
soles NN O O
and NN O O
was NN O O
generally NN O O
mild NN B-Severity B-Severity
and NN O O
asymptomatic NN O O
. NN O O
The NN O O
mechanism NN O O
and NN O O
clinical NN O O
significance NN O O
are NN O O
unknown NN O O
. NN O O
Laboratory NN O O
Abnormalities NN O O
The NN O O
frequency NN O O
of NN O O
laboratory NN O O
abnormalities NN O O
( NN O O
Grades NN O O
3 NN O O
- NN O O
4 NN O O
) NN O O
occurring NN O O
in NN O O
at NN O O
least NN O O
2 NN O O
% NN O O
of NN O O
subjects NN O O
receiving NN O O
STRIBILD NN O O
in NN O O
Studies NN O O
102 NN O O
and NN O O
103 NN O O
are NN O O
presented NN O O
in NN O O
Table NN O O
3 NN O O
. NN O O
Table NN O O
3 NN O O
Laboratory NN O O
Abnormalities NN O O
( NN O O
Grades NN O O
3 NN O O
- NN O O
4 NN O O
) NN O O
Reported NN O O
in NN O O
>= NN O O
2 NN O O
% NN O O
of NN O O
Subjects NN O O
Receiving NN O O
STRIBILD NN O O
in NN O O
Studies NN O O
102 NN O O
and NN O O
103 NN O O
( NN O O
Week NN O O
144 NN O O
analysis NN O O
) NN O O
STRIBILD NN O O
ATRIPLA NN O O
ATV NN O O
+ NN O O
RTV NN O O
+ NN O O
TRUVADA NN O O
Laboratory NN O O
Parameter NN O O
Abnormality NN O O
, NN O O
N=701 NN O O
N=352 NN O O
N=355 NN O O
AST NN O O
( NN O O
>5.0 NN O O
* NN O O
ULN NN O O
) NN O O
3 NN O O
% NN O O
6 NN O O
% NN O O
6 NN O O
% NN O O
ALT NN O O
( NN O O
>3.0 NN O O
* NN O O
ULN NN O O
) NN O O
2 NN O O
% NN O O
5 NN O O
% NN O O
4 NN O O
% NN O O
Amylase(>2.0 NN O O
* NN O O
ULN NN O O
) NN O O
3 NN O O
% NN O O
3 NN O O
% NN O O
5 NN O O
% NN O O
Creatine NN O O
Kinase NN O O
( NN O O
>= NN O O
10.0 NN O O
* NN O O
ULN NN O O
) NN O O
8 NN O O
% NN O O
15 NN O O
% NN O O
11 NN O O
% NN O O
Urine NN B-AdverseReaction B-AdverseReaction
RBC NN I-AdverseReaction I-AdverseReaction
( NN O O
Hematuria NN O O
) NN O O
( NN O O
> NN O O
75 NN O O
RBC/HPF NN O O
) NN O O
4 NN O O
% NN O O
2 NN O O
% NN O O
4 NN O O
% NN O O
In NN O O
Study NN O O
103 NN O O
, NN O O
BMD NN O O
was NN O O
assessed NN O O
by NN O O
DEXA NN O O
in NN O O
a NN O O
non NN O O
- NN O O
random NN O O
subset NN O O
of NN O O
120 NN O O
subjects NN O O
( NN O O
STRIBILD NN O O
group NN O O
N NN O O
= NN O O
54 NN O O
; NN O O
ATV NN O O
+ NN O O
RTV NN O O
+ NN O O
TRUVADA NN O O
group NN O O
N NN O O
= NN O O
66 NN O O
) NN O O
. NN O O
Mean NN O O
percentage NN O O
decreases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
BMD NN I-AdverseReaction I-AdverseReaction
from NN O O
baseline NN O O
to NN O O
Week NN O O
144 NN O O
in NN O O
the NN O O
STRIBILD NN O O
group NN O O
were NN O O
comparable NN O O
to NN O O
the NN O O
ATV NN O O
+ NN O O
RTV NN O O
+ NN O O
TRUVADA NN O O
group NN O O
at NN O O
the NN O O
lumbar NN O O
spine NN O O
( NN O O
-1.43 NN O O
% NN O O
versus NN O O
-3.68 NN O O
% NN O O
, NN O O
respectively NN O O
) NN O O
and NN O O
at NN O O
the NN O O
hip NN O O
( NN O O
-2.83 NN O O
% NN O O
versus NN O O
-3.77 NN O O
% NN O O
, NN O O
respectively NN O O
) NN O O
. NN O O
In NN O O
Studies NN O O
102 NN O O
and NN O O
103 NN O O
, NN O O
bone NN B-AdverseReaction B-AdverseReaction
fractures NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
27 NN O O
subjects NN O O
( NN O O
3.9 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
STRIBILD NN O O
group NN O O
, NN O O
8 NN O O
subjects NN O O
( NN O O
2.3 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
ATRIPLA NN O O
group NN O O
, NN O O
and NN O O
19 NN O O
subjects NN O O
( NN O O
5.4 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
ATV NN O O
+ NN O O
RTV NN O O
+ NN O O
TRUVADA NN O O
group NN O O
. NN O O
These NN O O
findings NN O O
were NN O O
consistent NN O O
with NN O O
data NN O O
from NN O O
an NN O O
earlier NN O O
144-week NN O O
trial NN O O
of NN O O
treatment NN O O
- NN O O
naive NN O O
subjects NN O O
receiving NN O O
tenofovir NN O O
DF NN O O
+ NN O O
lamivudine NN O O
+ NN O O
efavirenz NN O O
. NN O O
Proteinuria NN B-AdverseReaction B-AdverseReaction
( NN O O
all NN O O
grades NN O O
) NN O O
occurred NN O O
in NN O O
52 NN O O
% NN O O
of NN O O
subjects NN O O
receiving NN O O
STRIBILD NN O O
, NN O O
41 NN O O
% NN O O
of NN O O
subjects NN O O
receiving NN O O
ATRIPLA NN O O
, NN O O
and NN O O
42 NN O O
% NN O O
of NN O O
subjects NN O O
receiving NN O O
ATV NN O O
+ NN O O
RTV NN O O
+ NN O O
TRUVADA. NN O O
The NN O O
cobicistat NN O O
component NN O O
of NN O O
STRIBILD NN O O
has NN O O
been NN O O
shown NN O O
to NN O O
increase NN B-AdverseReaction B-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
and NN O O
decrease NN B-AdverseReaction B-AdverseReaction
estimated NN I-AdverseReaction I-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
clearance NN I-AdverseReaction I-AdverseReaction
due NN O O
to NN O O
inhibition NN O O
of NN O O
tubular NN O O
secretion NN O O
of NN O O
creatinine NN O O
without NN B-Negation B-Negation
affecting NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
glomerular NN I-AdverseReaction I-AdverseReaction
function NN I-AdverseReaction I-AdverseReaction
In NN O O
Studies NN O O
102 NN O O
and NN O O
103 NN O O
, NN O O
increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
and NN O O
decreases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
estimated NN I-AdverseReaction I-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
clearance NN I-AdverseReaction I-AdverseReaction
occurred NN O O
early NN O O
in NN O O
treatment NN O O
with NN O O
STRIBILD NN O O
, NN O O
after NN O O
which NN O O
they NN O O
stabilized NN O O
. NN O O
Table NN O O
4 NN O O
displays NN O O
the NN O O
mean NN O O
changes NN O O
in NN O O
serum NN O O
creatinine NN O O
and NN O O
eGFR NN O O
levels NN O O
at NN O O
Week NN O O
144 NN O O
and NN O O
the NN O O
percentage NN O O
of NN O O
subjects NN O O
with NN O O
elevations NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
( NN O O
All NN O O
Grades NN O O
) NN O O
. NN O O
Table NN O O
4 NN O O
Change NN O O
from NN O O
Baseline NN O O
in NN O O
Serum NN O O
Creatinine NN O O
and NN O O
eGFR NN O O
and NN O O
Incidence NN O O
of NN O O
Elevated NN B-AdverseReaction B-AdverseReaction
Serum NN I-AdverseReaction I-AdverseReaction
Creatinine NN I-AdverseReaction I-AdverseReaction
( NN O O
All NN O O
Grades NN O O
) NN O O
in NN O O
Studies NN O O
102 NN O O
and NN O O
103 NN O O
at NN O O
Week NN O O
144 NN O O
STRIBILD(N=701 NN O O
) NN O O
ATRIPLA(N=352 NN O O
) NN O O
ATV NN O O
+ NN O O
RTV NN O O
+ NN O O
TRUVADA(N=355 NN O O
) NN O O
Serum NN O O
Creatinine NN O O
( NN O O
mg/dL NN O O
) NN O O
0.14 NN O O
( NN O O
+/-0.14 NN O O
) NN O O
0.01 NN O O
( NN O O
+/-0.12 NN O O
) NN O O
0.09 NN O O
( NN O O
+/-0.15 NN O O
) NN O O
eGFR NN O O
by NN O O
Cockcroft NN O O
- NN O O
Gault NN O O
( NN O O
mL/minute NN O O
) NN O O
-14.0 NN O O
( NN O O
+/-16.6 NN O O
) NN O O
-1.9 NN O O
( NN O O
+/-17.9 NN O O
) NN O O
-9.8 NN O O
( NN O O
+/-19.4 NN O O
) NN O O
Subjects NN O O
with NN O O
Elevations NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
Serum NN I-AdverseReaction I-AdverseReaction
Creatinine NN I-AdverseReaction I-AdverseReaction
( NN O O
All NN O O
Grades)( NN O O
% NN O O
) NN O O
12 NN O O
2 NN O O
6 NN O O
Emtricitabine NN O O
or NN O O
Tenofovir NN O O
DF NN O O
: NN O O
In NN O O
addition NN O O
to NN O O
the NN O O
laboratory NN O O
abnormalities NN O O
observed NN O O
with NN O O
STRIBILD NN O O
, NN O O
the NN O O
following NN O O
laboratory NN O O
abnormalities NN O O
have NN O O
been NN O O
previously NN O O
reported NN O O
in NN O O
subjects NN O O
treated NN O O
with NN O O
emtricitabine NN O O
or NN O O
tenofovir NN O O
DF NN O O
with NN O O
other NN O O
antiretroviral NN O O
agents NN O O
in NN O O
other NN O O
clinical NN O O
trials NN O O
: NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
or NN O O
4 NN O O
laboratory NN O O
abnormalities NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
ALT NN I-AdverseReaction I-AdverseReaction
( NN O O
M NN O O
: NN O O
greater NN O O
than NN O O
215 NN B-Severity B-Severity
U NN I-Severity I-Severity
per NN I-Severity I-Severity
L NN I-Severity I-Severity
F NN O O
: NN O O
greater NN O O
than NN O O
170 NN B-Severity B-Severity
U NN I-Severity I-Severity
per NN I-Severity I-Severity
L NN I-Severity I-Severity
alkaline NN O O
phosphatase NN O O
( NN O O
greater NN O O
than NN O O
550 NN B-Severity B-Severity
U NN I-Severity I-Severity
per NN I-Severity I-Severity
L NN I-Severity I-Severity
bilirubin NN O O
( NN O O
greater NN O O
than NN O O
2.5 NN B-Severity B-Severity
* NN I-Severity I-Severity
ULN NN I-Severity I-Severity
serum NN O O
glucose NN O O
( NN O O
less NN O O
than NN O O
40 NN O O
or NN O O
greater NN O O
than NN O O
250 NN B-Severity B-Severity
mg NN I-Severity I-Severity
per NN I-Severity I-Severity
dL NN I-Severity I-Severity
glycosuria NN O O
( NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
3+ NN B-Severity B-Severity
neutrophils NN O O
( NN O O
less NN O O
than NN O O
750 NN B-Severity B-Severity
per NN I-Severity I-Severity
mm NN I-Severity I-Severity
3 NN I-Severity I-Severity
) NN O O
, NN O O
fasting NN O O
cholesterol NN O O
( NN O O
greater NN O O
than NN O O
240 NN B-Severity B-Severity
mg NN I-Severity I-Severity
per NN I-Severity I-Severity
dL NN I-Severity I-Severity
and NN O O
fasting NN O O
triglycerides NN O O
( NN O O
greater NN O O
than NN O O
750 NN B-Severity B-Severity
mg NN I-Severity I-Severity
per NN I-Severity I-Severity
dL NN I-Severity I-Severity
Serum NN O O
Lipids NN O O
: NN O O
In NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
STRIBILD NN O O
, NN O O
a NN O O
similar NN O O
percentage NN O O
of NN O O
subjects NN O O
receiving NN O O
STRIBILD NN O O
, NN O O
ATRIPLA NN O O
, NN O O
and NN O O
ATV NN O O
+ NN O O
RTV NN O O
+ NN O O
TRUVADA NN O O
were NN O O
on NN O O
lipid NN O O
lowering NN O O
agents NN O O
at NN O O
baseline NN O O
( NN O O
12 NN O O
% NN O O
, NN O O
12 NN O O
% NN O O
, NN O O
and NN O O
13 NN O O
% NN O O
, NN O O
respectively NN O O
) NN O O
. NN O O
While NN O O
receiving NN O O
study NN O O
drug NN O O
through NN O O
Week NN O O
144 NN O O
, NN O O
an NN O O
additional NN O O
11 NN O O
% NN O O
of NN O O
STRIBILD NN O O
subjects NN O O
were NN O O
started NN O O
on NN O O
lipid NN O O
lowering NN O O
agents NN O O
, NN O O
compared NN O O
to NN O O
13 NN O O
% NN O O
of NN O O
ATRIPLA NN O O
and NN O O
12 NN O O
% NN O O
of NN O O
ATV NN O O
+ NN O O
RTV NN O O
+ NN O O
TRUVADA NN O O
subjects NN O O
. NN O O
Changes NN O O
from NN O O
baseline NN O O
in NN O O
total NN O O
cholesterol NN O O
, NN O O
HDL NN O O
- NN O O
cholesterol NN O O
, NN O O
LDL NN O O
- NN O O
cholesterol NN O O
, NN O O
and NN O O
triglycerides NN O O
are NN O O
presented NN O O
in NN O O
Table NN O O
5 NN O O
. NN O O
Table NN O O
5 NN O O
Lipid NN O O
Values NN O O
, NN O O
Mean NN O O
Change NN O O
from NN O O
Baseline NN O O
at NN O O
Week NN O O
144 NN O O
in NN O O
Subjects NN O O
Receiving NN O O
STRIBILD NN O O
or NN O O
Comparator NN O O
in NN O O
Studies NN O O
102 NN O O
and NN O O
103 NN O O
STRIBILDN=701 NN O O
ATRIPLAN=352 NN O O
ATV NN O O
+ NN O O
RTV NN O O
+ NN O O
TRUVADAN=355 NN O O
Baseline NN O O
Week NN O O
144 NN O O
Baseline NN O O
Week NN O O
144 NN O O
Baseline NN O O
Week NN O O
144 NN O O
mg/dL NN O O
Change NN O O
mg/dL NN O O
Change NN O O
mg/dL NN O O
Change NN O O
Total NN O O
Cholesterol NN O O
( NN O O
fasted NN O O
) NN O O
166[N=675 NN O O
] NN O O
+17[N=535 NN O O
] NN O O
161[N=343 NN O O
] NN O O
+22[N=262 NN O O
] NN O O
168[N=337 NN O O
] NN O O
+16[N=243 NN O O
] NN O O
HDL NN O O
- NN O O
cholesterol NN O O
( NN O O
fasted NN O O
) NN O O
43[N=675 NN O O
] NN O O
+7[N=535 NN O O
] NN O O
43[N=343 NN O O
] NN O O
+9[N=262 NN O O
] NN O O
42[N=335 NN O O
] NN O O
+7[N=242 NN O O
] NN O O
LDL NN O O
- NN O O
cholesterol NN O O
( NN O O
fasted NN O O
) NN O O
100[N=675 NN O O
] NN O O
+15[N=535 NN O O
] NN O O
97[N=343 NN O O
] NN O O
+19[N=262 NN O O
] NN O O
101[N=337 NN O O
] NN O O
+18[N=242 NN O O
] NN O O
Triglycerides NN O O
( NN O O
fasted NN O O
) NN O O
122[N=675 NN O O
] NN O O
+12[N=535 NN O O
] NN O O
121[N=343 NN O O
] NN O O
+5[N=262 NN O O
] NN O O
132[N=337 NN O O
] NN O O
+22[N=242 NN O O
] NN O O
6.2 NN O O
Postmarketing NN O O
Experience NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
identified NN O O
during NN O O
post NN O O
approval NN O O
use NN O O
of NN O O
tenofovir NN O O
DF. NN O O
Because NN O O
postmarketing NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
No NN O O
additional NN O O
postmarketing NN O O
adverse NN O O
reactions NN O O
specific NN O O
for NN O O
emtricitabine NN O O
have NN O O
been NN O O
identified NN O O
. NN O O
Immune NN O O
System NN O O
Disorders NN O O
allergic NN B-AdverseReaction B-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
including NN O O
angioedema NN B-AdverseReaction B-AdverseReaction
Metabolism NN O O
and NN O O
Nutrition NN O O
Disorders NN O O
lactic NN B-AdverseReaction B-AdverseReaction
acidosis NN I-AdverseReaction I-AdverseReaction
hypokalemia NN B-AdverseReaction B-AdverseReaction
hypophosphatemia NN B-AdverseReaction B-AdverseReaction
Respiratory NN O O
, NN O O
Thoracic NN O O
, NN O O
and NN O O
Mediastinal NN O O
Disorders NN O O
dyspnea NN B-AdverseReaction B-AdverseReaction
Gastrointestinal NN O O
Disorders NN O O
pancreatitis NN B-AdverseReaction B-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
amylase NN I-AdverseReaction I-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
Hepatobiliary NN O O
Disorders NN O O
hepatic NN B-AdverseReaction B-AdverseReaction
steatosis NN I-AdverseReaction I-AdverseReaction
hepatitis NN B-AdverseReaction B-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
liver NN I-AdverseReaction I-AdverseReaction
enzymes NN I-AdverseReaction I-AdverseReaction
( NN O O
most NN O O
commonly NN O O
AST NN O O
, NN O O
ALT NN O O
gamma NN O O
GT NN O O
) NN O O
Skin NN O O
and NN O O
Subcutaneous NN O O
Tissue NN O O
Disorders NN O O
rash NN B-AdverseReaction B-AdverseReaction
Musculoskeletal NN O O
and NN O O
Connective NN O O
Tissue NN O O
Disorders NN O O
rhabdomyolysis NN B-AdverseReaction B-AdverseReaction
osteomalacia NN B-AdverseReaction B-AdverseReaction
( NN O O
manifested NN O O
as NN O O
bone NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
and NN O O
which NN O O
may NN O O
contribute NN O O
to NN O O
fractures NN B-AdverseReaction B-AdverseReaction
muscular NN B-AdverseReaction B-AdverseReaction
weakness NN I-AdverseReaction I-AdverseReaction
myopathy NN B-AdverseReaction B-AdverseReaction
Renal NN O O
and NN O O
Urinary NN O O
Disorders NN O O
acute NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
renal NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
acute NN B-AdverseReaction B-AdverseReaction
tubular NN I-AdverseReaction I-AdverseReaction
necrosis NN I-AdverseReaction I-AdverseReaction
Fanconi NN B-AdverseReaction B-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
proximal NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
tubulopathy NN I-AdverseReaction I-AdverseReaction
interstitial NN B-AdverseReaction B-AdverseReaction
nephritis NN I-AdverseReaction I-AdverseReaction
( NN O O
including NN O O
acute NN O O
cases NN O O
) NN O O
, NN O O
nephrogenic NN B-AdverseReaction B-AdverseReaction
diabetes NN I-AdverseReaction I-AdverseReaction
insipidus NN I-AdverseReaction I-AdverseReaction
renal NN B-AdverseReaction B-AdverseReaction
insufficiency NN I-AdverseReaction I-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
proteinuria NN B-AdverseReaction B-AdverseReaction
polyuria NN B-AdverseReaction B-AdverseReaction
General NN O O
Disorders NN O O
and NN O O
Administration NN O O
Site NN O O
Conditions NN O O
asthenia NN B-AdverseReaction B-AdverseReaction
The NN O O
following NN O O
adverse NN O O
reactions NN O O
, NN O O
listed NN O O
under NN O O
the NN O O
body NN O O
system NN O O
headings NN O O
above NN O O
, NN O O
may NN O O
occur NN O O
as NN O O
a NN O O
consequence NN O O
of NN O O
proximal NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
tubulopathy NN I-AdverseReaction I-AdverseReaction
rhabdomyolysis NN B-AdverseReaction B-AdverseReaction
osteomalacia NN B-AdverseReaction B-AdverseReaction
hypokalemia NN B-AdverseReaction B-AdverseReaction
muscular NN B-AdverseReaction B-AdverseReaction
weakness NN I-AdverseReaction I-AdverseReaction
myopathy NN B-AdverseReaction B-AdverseReaction
hypophosphatemia NN B-AdverseReaction B-AdverseReaction
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
LACTIC NN B-AdverseReaction B-AdverseReaction
ACIDOSIS NN I-AdverseReaction I-AdverseReaction
HEPATOMEGALY NN B-AdverseReaction B-AdverseReaction
WITH NN O O
STEATOSIS NN B-AdverseReaction B-AdverseReaction
and NN O O
POST NN O O
TREATMENT NN O O
ACUTE NN B-AdverseReaction B-AdverseReaction
EXACERBATION NN I-AdverseReaction I-AdverseReaction
OF NN I-AdverseReaction I-AdverseReaction
HEPATITIS NN I-AdverseReaction I-AdverseReaction
B NN I-AdverseReaction I-AdverseReaction
WARNING NN O O
: NN O O
LACTIC NN B-AdverseReaction B-AdverseReaction
ACIDOSIS NN I-AdverseReaction I-AdverseReaction
HEPATOMEGALY NN B-AdverseReaction B-AdverseReaction
WITH NN O O
STEATOSIS NN B-AdverseReaction B-AdverseReaction
and NN O O
POST NN O O
TREATMENT NN O O
ACUTE NN B-AdverseReaction B-AdverseReaction
EXACERBATION NN I-AdverseReaction I-AdverseReaction
OF NN I-AdverseReaction I-AdverseReaction
HEPATITIS NN I-AdverseReaction I-AdverseReaction
B NN I-AdverseReaction I-AdverseReaction
Lactic NN B-AdverseReaction B-AdverseReaction
acidosis NN I-AdverseReaction I-AdverseReaction
and NN O O
severe NN B-Severity B-Severity
hepatomegaly NN B-AdverseReaction B-AdverseReaction
with NN O O
steatosis NN B-AdverseReaction B-AdverseReaction
including NN O O
fatal NN B-AdverseReaction B-AdverseReaction
cases NN O O
, NN O O
have NN O O
been NN O O
reported NN O O
with NN O O
the NN O O
use NN O O
of NN O O
nucleoside NN O O
analogs NN O O
, NN O O
including NN O O
tenofovir NN O O
disoproxil NN O O
fumarate NN O O
, NN O O
a NN O O
component NN O O
of NN O O
STRIBILD NN O O
, NN O O
in NN O O
combination NN O O
with NN O O
other NN O O
antiretrovirals NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
STRIBILD NN O O
is NN O O
not NN O O
approved NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
chronic NN O O
hepatitis NN O O
B NN O O
virus NN O O
( NN O O
HBV NN O O
) NN O O
infection NN O O
and NN O O
the NN O O
safety NN O O
and NN O O
efficacy NN O O
of NN O O
STRIBILD NN O O
have NN O O
not NN O O
been NN O O
established NN O O
in NN O O
patients NN O O
coinfected NN O O
with NN O O
HBV NN O O
and NN O O
HIV-1 NN O O
. NN O O
Severe NN B-Severity B-Severity
acute NN B-AdverseReaction B-AdverseReaction
exacerbations NN I-AdverseReaction I-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
hepatitis NN I-AdverseReaction I-AdverseReaction
B NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
who NN O O
are NN O O
coinfected NN O O
with NN O O
HBV NN O O
and NN O O
human NN O O
immunodeficiency NN O O
virus-1 NN O O
( NN O O
HIV-1 NN O O
) NN O O
and NN O O
have NN O O
discontinued NN O O
EMTRIVA NN O O
or NN O O
VIREAD NN O O
, NN O O
which NN O O
are NN O O
components NN O O
of NN O O
STRIBILD. NN O O
Hepatic NN O O
function NN O O
should NN O O
be NN O O
monitored NN O O
closely NN O O
with NN O O
both NN O O
clinical NN O O
and NN O O
laboratory NN O O
follow NN O O
- NN O O
up NN O O
for NN O O
at NN O O
least NN O O
several NN O O
months NN O O
in NN O O
patients NN O O
who NN O O
are NN O O
coinfected NN O O
with NN O O
HIV-1 NN O O
and NN O O
HBV NN O O
and NN O O
discontinue NN O O
STRIBILD. NN O O
If NN O O
appropriate NN O O
, NN O O
initiation NN O O
of NN O O
anti NN O O
- NN O O
hepatitis NN O O
B NN O O
therapy NN O O
may NN O O
be NN O O
warranted NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
EXCERPT NN O O
: NN O O
WARNING NN O O
: NN O O
LACTIC NN B-AdverseReaction B-AdverseReaction
ACIDOSIS NN I-AdverseReaction I-AdverseReaction
HEPATOMEGALY NN B-AdverseReaction B-AdverseReaction
WITH NN O O
STEATOSIS NN B-AdverseReaction B-AdverseReaction
and NN O O
POST NN O O
TREATMENT NN O O
ACUTE NN B-AdverseReaction B-AdverseReaction
EXACERBATION NN I-AdverseReaction I-AdverseReaction
OF NN I-AdverseReaction I-AdverseReaction
HEPATITIS NN I-AdverseReaction I-AdverseReaction
B NN I-AdverseReaction I-AdverseReaction
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
. NN O O
* NN O O
Lactic NN B-AdverseReaction B-AdverseReaction
acidosis NN I-AdverseReaction I-AdverseReaction
and NN O O
severe NN B-Severity B-Severity
hepatomegaly NN B-AdverseReaction B-AdverseReaction
with NN O O
steatosis NN B-AdverseReaction B-AdverseReaction
including NN O O
fatal NN B-AdverseReaction B-AdverseReaction
cases NN O O
, NN O O
have NN O O
been NN O O
reported NN O O
with NN O O
the NN O O
use NN O O
of NN O O
nucleoside NN O O
analogs NN O O
, NN O O
including NN O O
tenofovir NN O O
disoproxil NN O O
fumarate NN O O
( NN O O
DF NN O O
) NN O O
, NN O O
a NN O O
component NN O O
of NN O O
STRIBILD. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
STRIBILD NN O O
is NN O O
not NN O O
approved NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
chronic NN O O
hepatitis NN O O
B NN O O
virus NN O O
( NN O O
HBV NN O O
) NN O O
infection NN O O
. NN O O
Severe NN B-Severity B-Severity
acute NN B-AdverseReaction B-AdverseReaction
exacerbations NN I-AdverseReaction I-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
hepatitis NN I-AdverseReaction I-AdverseReaction
B NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
coinfected NN O O
with NN O O
HIV-1 NN O O
and NN O O
HBV NN O O
who NN O O
have NN O O
discontinued NN O O
EMTRIVA NN O O
or NN O O
VIREAD NN O O
, NN O O
two NN O O
of NN O O
the NN O O
components NN O O
of NN O O
STRIBILD. NN O O
Hepatic NN O O
function NN O O
should NN O O
be NN O O
monitored NN O O
closely NN O O
in NN O O
these NN O O
patients NN O O
. NN O O
If NN O O
appropriate NN O O
, NN O O
initiation NN O O
of NN O O
anti NN O O
- NN O O
hepatitis NN O O
B NN O O
therapy NN O O
may NN O O
be NN O O
warranted NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
New NN O O
onset NN O O
or NN O O
worsening NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
Can NN B-Factor B-Factor
include NN O O
acute NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
and NN O O
Fanconi NN B-AdverseReaction B-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
Assess NN O O
creatinine NN O O
clearance NN O O
( NN O O
CLcr NN O O
) NN O O
, NN O O
urine NN O O
glucose NN O O
and NN O O
urine NN O O
protein NN O O
before NN O O
initiating NN O O
treatment NN O O
with NN O O
STRIBILD. NN O O
Monitor NN O O
CLcr NN O O
, NN O O
urine NN O O
glucose NN O O
, NN O O
and NN O O
urine NN O O
protein NN O O
in NN O O
all NN O O
patients NN O O
. NN O O
Monitor NN O O
serum NN O O
phosphorus NN O O
in NN O O
patients NN O O
at NN O O
risk NN O O
for NN O O
renal NN O O
impairment NN O O
. NN O O
Avoid NN O O
administering NN O O
STRIBILD NN O O
with NN O O
concurrent NN O O
or NN O O
recent NN O O
use NN O O
of NN O O
nephrotoxic NN O O
drugs NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Avoid NN O O
coadministration NN O O
with NN O O
other NN O O
anti NN O O
- NN O O
retroviral NN O O
products NN O O
: NN O O
Do NN O O
not NN O O
use NN O O
with NN O O
products NN O O
containing NN O O
any NN O O
of NN O O
the NN O O
components NN O O
of NN O O
STRIBILD NN O O
( NN O O
cobicistat NN O O
, NN O O
elvitegravir NN O O
, NN O O
emtricitabine NN O O
, NN O O
and NN O O
tenofovir NN O O
disoproxil NN O O
fumarate NN O O
) NN O O
, NN O O
including NN O O
ATRIPLA NN O O
, NN O O
COMPLERA NN O O
, NN O O
EMTRIVA NN O O
, NN O O
TRUVADA NN O O
, NN O O
TYBOST NN O O
, NN O O
VIREAD NN O O
, NN O O
or NN O O
VITEKTA NN O O
; NN O O
with NN O O
drugs NN O O
containing NN O O
lamivudine NN O O
; NN O O
or NN O O
with NN O O
drugs NN O O
or NN O O
regimens NN O O
containing NN O O
ritonavir NN O O
. NN O O
Do NN O O
not NN O O
administer NN O O
in NN O O
combination NN O O
with NN O O
HEPSERA. NN O O
( NN O O
5.4 NN O O
) NN O O
* NN O O
Risk NN O O
of NN O O
adverse NN O O
reactions NN O O
or NN O O
loss NN O O
of NN O O
virologic NN O O
response NN O O
due NN O O
to NN O O
drug NN O O
interactions NN O O
: NN O O
The NN O O
concomitant NN O O
use NN O O
of NN O O
STRIBILD NN O O
and NN O O
other NN O O
drugs NN O O
may NN O O
result NN O O
in NN O O
known NN O O
or NN O O
potentially NN O O
significant NN O O
drug NN O O
interactions NN O O
, NN O O
some NN O O
of NN O O
which NN O O
may NN O O
lead NN O O
to NN O O
loss NN O O
of NN O O
therapeutic NN O O
effect NN O O
of NN O O
STRIBILD NN O O
and NN O O
possible NN O O
development NN O O
of NN O O
resistance NN O O
; NN O O
and NN O O
possible NN O O
clinically NN O O
significant NN O O
adverse NN O O
reactions NN O O
from NN O O
greater NN O O
exposures NN O O
of NN O O
concomitant NN O O
drugs NN O O
. NN O O
( NN O O
5.5 NN O O
) NN O O
* NN O O
Decreases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
bone NN I-AdverseReaction I-AdverseReaction
mineral NN I-AdverseReaction I-AdverseReaction
density NN I-AdverseReaction I-AdverseReaction
( NN O O
BMD NN O O
) NN O O
: NN O O
Consider NN O O
monitoring NN O O
BMD NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
pathologic NN O O
fracture NN O O
or NN O O
other NN O O
risk NN O O
factors NN O O
of NN O O
osteoporosis NN O O
or NN O O
bone NN O O
loss NN O O
. NN O O
( NN O O
5.6 NN O O
) NN O O
* NN O O
Redistribution/accumulation NN O O
of NN O O
body NN O O
fat NN O O
: NN O O
Observed NN O O
in NN O O
patients NN O O
receiving NN O O
antiretroviral NN O O
therapy NN O O
. NN O O
( NN O O
5.7 NN O O
) NN O O
* NN O O
Immune NN B-AdverseReaction B-AdverseReaction
reconstitution NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
May NN O O
necessitate NN O O
further NN O O
evaluation NN O O
and NN O O
treatment NN O O
. NN O O
( NN O O
5.8 NN O O
) NN O O
5.1 NN O O
Lactic NN O O
Acidosis/Severe NN O O
Hepatomegaly NN O O
with NN O O
Steatosis NN O O
Lactic NN B-AdverseReaction B-AdverseReaction
acidosis NN I-AdverseReaction I-AdverseReaction
and NN O O
severe NN B-Severity B-Severity
hepatomegaly NN B-AdverseReaction B-AdverseReaction
with NN O O
steatosis NN B-AdverseReaction B-AdverseReaction
including NN O O
fatal NN B-AdverseReaction B-AdverseReaction
cases NN O O
, NN O O
have NN O O
been NN O O
reported NN O O
with NN O O
the NN O O
use NN O O
of NN O O
nucleoside NN O O
analogs NN O O
, NN O O
including NN O O
tenofovir NN O O
DF NN O O
, NN O O
a NN O O
component NN O O
of NN O O
STRIBILD NN O O
, NN O O
in NN O O
combination NN O O
with NN O O
other NN O O
antiretrovirals NN O O
. NN O O
A NN O O
majority NN O O
of NN O O
these NN O O
cases NN O O
have NN O O
been NN O O
in NN O O
women NN O O
. NN O O
Obesity NN O O
and NN O O
prolonged NN O O
nucleoside NN O O
exposure NN O O
may NN O O
be NN O O
risk NN O O
factors NN O O
. NN O O
Particular NN O O
caution NN O O
should NN O O
be NN O O
exercised NN O O
when NN O O
administering NN O O
nucleoside NN O O
analogs NN O O
to NN O O
any NN O O
patient NN O O
with NN O O
known NN O O
risk NN O O
factors NN O O
for NN O O
liver NN O O
disease NN O O
; NN O O
however NN O O
, NN O O
cases NN O O
have NN O O
also NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
with NN O O
no NN O O
known NN O O
risk NN O O
factors NN O O
. NN O O
Treatment NN O O
with NN O O
STRIBILD NN O O
should NN O O
be NN O O
suspended NN O O
in NN O O
any NN O O
patient NN O O
who NN O O
develops NN O O
clinical NN O O
or NN O O
laboratory NN O O
findings NN O O
suggestive NN O O
of NN O O
lactic NN O O
acidosis NN O O
or NN O O
pronounced NN O O
hepatotoxicity NN O O
( NN O O
which NN O O
may NN O O
include NN O O
hepatomegaly NN O O
and NN O O
steatosis NN O O
even NN O O
in NN O O
the NN O O
absence NN O O
of NN O O
marked NN O O
transaminase NN O O
elevations NN O O
) NN O O
. NN O O
5.2 NN O O
Patients NN O O
Coinfected NN O O
with NN O O
HIV-1 NN O O
and NN O O
HBV NN O O
It NN O O
is NN O O
recommended NN O O
that NN O O
all NN O O
patients NN O O
with NN O O
HIV-1 NN O O
be NN O O
tested NN O O
for NN O O
the NN O O
presence NN O O
of NN O O
chronic NN O O
hepatitis NN O O
B NN O O
virus NN O O
( NN O O
HBV NN O O
) NN O O
before NN O O
initiating NN O O
antiretroviral NN O O
therapy NN O O
. NN O O
STRIBILD NN O O
is NN O O
not NN O O
approved NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
chronic NN O O
HBV NN O O
infection NN O O
and NN O O
the NN O O
safety NN O O
and NN O O
efficacy NN O O
of NN O O
STRIBILD NN O O
have NN O O
not NN O O
been NN O O
established NN O O
in NN O O
patients NN O O
coinfected NN O O
with NN O O
HBV NN O O
and NN O O
HIV-1 NN O O
. NN O O
Severe NN O O
acute NN O O
exacerbations NN O O
of NN O O
hepatitis NN O O
B NN O O
have NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
who NN O O
are NN O O
coinfected NN O O
with NN O O
HBV NN O O
and NN O O
HIV-1 NN O O
and NN O O
have NN O O
discontinued NN O O
emtricitabine NN O O
or NN O O
tenofovir NN O O
DF NN O O
, NN O O
two NN O O
of NN O O
the NN O O
components NN O O
of NN O O
STRIBILD. NN O O
In NN O O
some NN O O
patients NN O O
infected NN O O
with NN O O
HBV NN O O
and NN O O
treated NN O O
with NN O O
EMTRIVA NN O O
, NN O O
the NN O O
exacerbations NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
hepatitis NN I-AdverseReaction I-AdverseReaction
B NN I-AdverseReaction I-AdverseReaction
were NN O O
associated NN O O
with NN O O
liver NN B-AdverseReaction B-AdverseReaction
decompensation NN I-AdverseReaction I-AdverseReaction
and NN O O
liver NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
Patients NN O O
who NN O O
are NN O O
coinfected NN O O
with NN O O
HIV-1 NN O O
and NN O O
HBV NN O O
should NN O O
be NN O O
closely NN O O
monitored NN O O
with NN O O
both NN O O
clinical NN O O
and NN O O
laboratory NN O O
follow NN O O
- NN O O
up NN O O
for NN O O
at NN O O
least NN O O
several NN O O
months NN O O
after NN O O
stopping NN O O
treatment NN O O
with NN O O
STRIBILD. NN O O
If NN O O
appropriate NN O O
, NN O O
initiation NN O O
of NN O O
anti NN O O
- NN O O
hepatitis NN O O
B NN O O
therapy NN O O
may NN O O
be NN O O
warranted NN O O
. NN O O
5.3 NN O O
New NN O O
Onset NN O O
or NN O O
Worsening NN O O
Renal NN O O
Impairment NN O O
Renal NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
including NN O O
cases NN O O
of NN O O
acute NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
and NN O O
Fanconi NN B-AdverseReaction B-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
renal NN O O
tubular NN O O
injury NN O O
with NN O O
severe NN B-Severity B-Severity
hypophosphatemia NN B-AdverseReaction B-AdverseReaction
has NN O O
been NN O O
reported NN O O
with NN O O
the NN O O
use NN O O
of NN O O
tenofovir NN O O
DF NN O O
, NN O O
a NN O O
component NN O O
of NN O O
STRIBILD NN O O
, NN O O
and NN O O
with NN O O
the NN O O
use NN O O
of NN O O
STRIBILD NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.2 NN O O
) NN O O
] NN O O
. NN O O
In NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
STRIBILD NN O O
over NN O O
144 NN O O
weeks NN O O
, NN O O
13 NN O O
( NN O O
1.9 NN O O
% NN O O
) NN O O
subjects NN O O
in NN O O
the NN O O
STRIBILD NN O O
group NN O O
( NN O O
N=701 NN O O
) NN O O
, NN O O
8 NN O O
( NN O O
2.3 NN O O
% NN O O
) NN O O
subjects NN O O
in NN O O
the NN O O
ATV NN O O
+ NN O O
RTV NN O O
+ NN O O
TRUVADA NN O O
group NN O O
( NN O O
N=355 NN O O
) NN O O
and NN O O
no NN O O
subjects NN O O
in NN O O
the NN O O
ATRIPLA NN O O
group NN O O
( NN O O
N NN O O
= NN O O
352 NN O O
) NN O O
discontinued NN O O
study NN O O
drug NN O O
due NN O O
to NN O O
a NN O O
renal NN B-AdverseReaction B-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
Of NN O O
these NN O O
discontinuations NN O O
, NN O O
8 NN O O
in NN O O
the NN O O
STRIBILD NN O O
group NN O O
and NN O O
1 NN O O
in NN O O
the NN O O
ATV NN O O
+ NN O O
RTV NN O O
+ NN O O
TRUVADA NN O O
group NN O O
occurred NN O O
during NN O O
the NN O O
first NN O O
48 NN O O
weeks NN O O
. NN O O
Four NN O O
( NN O O
0.6 NN O O
% NN O O
) NN O O
subjects NN O O
who NN O O
received NN O O
STRIBILD NN O O
developed NN O O
laboratory NN O O
findings NN O O
consistent NN O O
with NN O O
proximal NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
tubular NN I-AdverseReaction I-AdverseReaction
dysfunction NN I-AdverseReaction I-AdverseReaction
leading NN O O
to NN O O
discontinuation NN O O
of NN O O
STRIBILD NN O O
during NN O O
the NN O O
first NN O O
48 NN O O
weeks NN O O
of NN O O
treatment NN O O
. NN O O
Two NN O O
of NN O O
the NN O O
four NN O O
subjects NN O O
had NN O O
renal NN O O
impairment NN O O
( NN O O
i.e. NN O O
estimated NN O O
creatinine NN O O
clearance NN O O
less NN O O
than NN O O
70 NN O O
mL NN O O
per NN O O
minute NN O O
) NN O O
at NN O O
baseline NN O O
. NN O O
The NN O O
laboratory NN O O
findings NN O O
in NN O O
these NN O O
4 NN O O
subjects NN O O
improved NN O O
but NN O O
did NN O O
not NN O O
completely NN O O
resolve NN O O
in NN O O
all NN O O
subjects NN O O
upon NN O O
discontinuation NN O O
of NN O O
STRIBILD. NN O O
Renal NN O O
replacement NN O O
therapy NN O O
was NN O O
not NN O O
required NN O O
for NN O O
these NN O O
subjects NN O O
. NN O O
One NN O O
( NN O O
0.3 NN O O
% NN O O
) NN O O
subject NN O O
who NN O O
received NN O O
ATV NN O O
+ NN O O
RTV NN O O
+ NN O O
TRUVADA NN O O
developed NN O O
laboratory NN O O
findings NN O O
consistent NN O O
with NN O O
proximal NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
tubular NN I-AdverseReaction I-AdverseReaction
dysfunction NN I-AdverseReaction I-AdverseReaction
leading NN O O
to NN O O
discontinuation NN O O
of NN O O
ATV NN O O
+ NN O O
RTV NN O O
+ NN O O
TRUVADA NN O O
after NN O O
Week NN O O
96 NN O O
. NN O O
STRIBILD NN O O
should NN O O
be NN O O
avoided NN O O
with NN O O
concurrent NN O O
or NN O O
recent NN O O
use NN O O
of NN O O
a NN O O
nephrotoxic NN O O
agent NN O O
. NN O O
( NN O O
e.g. NN O O
, NN O O
high NN O O
- NN O O
dose NN O O
or NN O O
multiple NN O O
non NN O O
- NN O O
steroidal NN O O
anti NN O O
- NN O O
inflammatory NN O O
drugs NN O O
( NN O O
NSAIDs NN O O
) NN O O
) NN O O
[ NN O O
see NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.4 NN O O
) NN O O
] NN O O
. NN O O
Cases NN O O
of NN O O
acute NN O O
renal NN O O
failure NN O O
after NN O O
initiation NN O O
of NN O O
high NN O O
dose NN O O
or NN O O
multiple NN O O
NSAIDs NN O O
have NN O O
been NN O O
reported NN O O
in NN O O
HIV NN O O
- NN O O
infected NN O O
patients NN O O
with NN O O
risk NN O O
factors NN O O
for NN O O
renal NN O O
dysfunction NN O O
who NN O O
appeared NN O O
stable NN O O
on NN O O
tenofovir NN O O
DF. NN O O
Some NN O O
patients NN O O
required NN O O
hospitalization NN O O
and NN O O
renal NN O O
replacement NN O O
therapy NN O O
. NN O O
Alternatives NN O O
to NN O O
NSAIDs NN O O
should NN O O
be NN O O
considered NN O O
, NN O O
if NN O O
needed NN O O
, NN O O
in NN O O
patients NN O O
at NN O O
risk NN O O
for NN O O
renal NN O O
dysfunction NN O O
. NN O O
Persistent NN O O
or NN O O
worsening NN O O
bone NN O O
pain NN O O
, NN O O
pain NN O O
in NN O O
extremities NN O O
, NN O O
fractures NN O O
and/or NN O O
muscular NN O O
pain NN O O
or NN O O
weakness NN O O
may NN O O
be NN O O
manifestations NN O O
of NN O O
proximal NN O O
renal NN O O
tubulopathy NN O O
and NN O O
should NN O O
prompt NN O O
an NN O O
evaluation NN O O
of NN O O
renal NN O O
function NN O O
in NN O O
at NN O O
- NN O O
risk NN O O
patients NN O O
. NN O O
Estimated NN O O
creatinine NN O O
clearance NN O O
, NN O O
urine NN O O
glucose NN O O
and NN O O
urine NN O O
protein NN O O
should NN O O
be NN O O
documented NN O O
in NN O O
all NN O O
patients NN O O
prior NN O O
to NN O O
initiating NN O O
therapy NN O O
. NN O O
Initiation NN O O
of NN O O
STRIBILD NN O O
in NN O O
patients NN O O
with NN O O
estimated NN O O
creatinine NN O O
clearance NN O O
below NN O O
70 NN O O
mL NN O O
per NN O O
minute NN O O
is NN O O
not NN O O
recommended NN O O
. NN O O
Routine NN O O
monitoring NN O O
of NN O O
estimated NN O O
creatinine NN O O
clearance NN O O
, NN O O
urine NN O O
glucose NN O O
, NN O O
and NN O O
urine NN O O
protein NN O O
should NN O O
be NN O O
performed NN O O
during NN O O
STRIBILD NN O O
therapy NN O O
in NN O O
all NN O O
patients NN O O
. NN O O
Additionally NN O O
, NN O O
serum NN O O
phosphorus NN O O
should NN O O
be NN O O
measured NN O O
in NN O O
patients NN O O
at NN O O
risk NN O O
for NN O O
renal NN O O
impairment NN O O
. NN O O
Although NN O O
cobicistat NN O O
( NN O O
a NN O O
component NN O O
of NN O O
STRIBILD NN O O
) NN O O
may NN B-Factor B-Factor
cause NN O O
modest NN B-Severity B-Severity
increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
and NN O O
modest NN B-Severity B-Severity
declines NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
estimated NN I-AdverseReaction I-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
clearance NN I-AdverseReaction I-AdverseReaction
without NN O O
affecting NN O O
renal NN O O
glomerular NN O O
function NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
, NN O O
patients NN O O
who NN O O
experience NN O O
a NN O O
confirmed NN O O
increase NN O O
in NN O O
serum NN O O
creatinine NN O O
of NN O O
greater NN O O
than NN O O
0.4 NN O O
mg NN O O
per NN O O
dL NN O O
from NN O O
baseline NN O O
should NN O O
be NN O O
closely NN O O
monitored NN O O
for NN O O
renal NN O O
safety NN O O
. NN O O
The NN O O
emtricitabine NN O O
and NN O O
tenofovir NN O O
DF NN O O
components NN O O
of NN O O
STRIBILD NN O O
are NN O O
primarily NN O O
excreted NN O O
by NN O O
the NN O O
kidney NN O O
. NN O O
STRIBILD NN O O
should NN O O
be NN O O
discontinued NN O O
if NN O O
estimated NN O O
creatinine NN O O
clearance NN O O
declines NN O O
below NN O O
50 NN O O
mL NN O O
per NN O O
minute NN O O
as NN O O
dose NN O O
interval NN O O
adjustment NN O O
required NN O O
for NN O O
emtricitabine NN O O
and NN O O
tenofovir NN O O
DF NN O O
can NN O O
not NN O O
be NN O O
achieved NN O O
with NN O O
the NN O O
fixed NN O O
- NN O O
dose NN O O
combination NN O O
tablet NN O O
. NN O O
5.4 NN O O
Avoid NN O O
Use NN O O
with NN O O
Other NN O O
Antiretroviral NN O O
Products NN O O
STRIBILD NN O O
is NN O O
indicated NN O O
for NN O O
use NN O O
as NN O O
a NN O O
complete NN O O
regimen NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
HIV-1 NN O O
infection NN O O
and NN O O
coadministration NN O O
with NN O O
other NN O O
antiretroviral NN O O
products NN O O
is NN O O
not NN O O
recommended NN O O
. NN O O
STRIBILD NN O O
is NN O O
not NN O O
recommended NN O O
for NN O O
coadministration NN O O
with NN O O
the NN O O
following NN O O
: NN O O
* NN O O
cobicistat NN O O
( NN O O
TYBOST NN O O
) NN O O
; NN O O
* NN O O
elvitegravir NN O O
( NN O O
VITEKTA NN O O
) NN O O
; NN O O
* NN O O
products NN O O
containing NN O O
emtricitabine NN O O
or NN O O
tenofovir NN O O
DF NN O O
( NN O O
ATRIPLA NN O O
, NN O O
COMPLERA NN O O
, NN O O
EMTRIVA NN O O
, NN O O
TRUVADA NN O O
, NN O O
VIREAD NN O O
) NN O O
; NN O O
* NN O O
products NN O O
containing NN O O
lamivudine NN O O
( NN O O
COMBIVIR NN O O
, NN O O
EPIVIR NN O O
, NN O O
EPIVIR NN O O
- NN O O
HBV NN O O
, NN O O
EPZICOM NN O O
, NN O O
TRIUMEQ NN O O
, NN O O
TRIZIVIR NN O O
) NN O O
; NN O O
* NN O O
adefovir NN O O
dipivoxil NN O O
( NN O O
HEPSERA NN O O
) NN O O
; NN O O
* NN O O
products NN O O
containing NN O O
ritonavir NN O O
( NN O O
NORVIR NN O O
, NN O O
KALETRA NN O O
) NN O O
5.5 NN O O
Risk NN O O
of NN O O
Adverse NN O O
Reactions NN O O
or NN O O
Loss NN O O
of NN O O
Virologic NN O O
Response NN O O
Due NN O O
to NN O O
Drug NN O O
Interactions NN O O
The NN O O
concomitant NN O O
use NN O O
of NN O O
STRIBILD NN O O
and NN O O
other NN O O
drugs NN O O
may NN O O
result NN O O
in NN O O
known NN O O
or NN O O
potentially NN O O
significant NN O O
drug NN O O
interactions NN O O
, NN O O
some NN O O
of NN O O
which NN O O
may NN O O
lead NN O O
to NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
, NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.5 NN O O
) NN O O
] NN O O
: NN O O
* NN O O
Loss NN O O
of NN O O
therapeutic NN O O
effect NN O O
of NN O O
STRIBILD NN O O
and NN O O
possible NN O O
development NN O O
of NN O O
resistance NN O O
. NN O O
* NN O O
Possible NN O O
clinically NN O O
significant NN O O
adverse NN O O
reactions NN O O
from NN O O
greater NN O O
exposures NN O O
of NN O O
concomitant NN O O
drugs NN O O
. NN O O
See NN O O
Table NN O O
6 NN O O
for NN O O
steps NN O O
to NN O O
prevent NN O O
or NN O O
manage NN O O
these NN O O
possible NN O O
and NN O O
known NN O O
significant NN O O
drug NN O O
interactions NN O O
, NN O O
including NN O O
dosing NN O O
recommendations NN O O
[ NN O O
see NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.5 NN O O
) NN O O
] NN O O
. NN O O
Consider NN O O
the NN O O
potential NN O O
for NN O O
drug NN O O
interactions NN O O
prior NN O O
to NN O O
and NN O O
during NN O O
STRIBILD NN O O
therapy NN O O
; NN O O
review NN O O
concomitant NN O O
medications NN O O
during NN O O
STRIBILD NN O O
therapy NN O O
; NN O O
and NN O O
monitor NN O O
for NN O O
the NN O O
adverse NN O O
reactions NN O O
associated NN O O
with NN O O
the NN O O
concomitant NN O O
drugs NN O O
. NN O O
5.6 NN O O
Bone NN O O
Effects NN O O
of NN O O
Tenofovir NN O O
DF NN O O
Bone NN O O
Mineral NN O O
Density NN O O
: NN O O
In NN O O
clinical NN O O
trials NN O O
in NN O O
HIV-1 NN O O
infected NN O O
adults NN O O
, NN O O
tenofovir NN O O
DF NN O O
( NN O O
a NN O O
component NN O O
of NN O O
STRIBILD NN O O
) NN O O
was NN O O
associated NN O O
with NN O O
slightly NN O O
greater NN O O
decreases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
bone NN I-AdverseReaction I-AdverseReaction
mineral NN I-AdverseReaction I-AdverseReaction
density NN I-AdverseReaction I-AdverseReaction
( NN O O
BMD NN O O
) NN O O
and NN O O
increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
biochemical NN I-AdverseReaction I-AdverseReaction
markers NN I-AdverseReaction I-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
bone NN I-AdverseReaction I-AdverseReaction
metabolism NN I-AdverseReaction I-AdverseReaction
suggesting NN O O
increased NN B-AdverseReaction B-AdverseReaction
bone NN I-AdverseReaction I-AdverseReaction
turnover NN I-AdverseReaction I-AdverseReaction
relative NN O O
to NN O O
comparators NN O O
. NN O O
Serum NN O O
parathyroid NN O O
hormone NN O O
levels NN O O
and NN O O
1.25 NN O O
Vitamin NN O O
D NN O O
levels NN O O
were NN O O
also NN O O
higher NN O O
in NN O O
subjects NN O O
receiving NN O O
tenofovir NN O O
DF. NN O O
For NN O O
additional NN O O
information NN O O
, NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
and NN O O
consult NN O O
the NN O O
VIREAD NN O O
prescribing NN O O
information NN O O
. NN O O
The NN O O
effects NN O O
of NN O O
tenofovir NN O O
DF NN O O
- NN O O
associated NN O O
changes NN O O
in NN O O
BMD NN O O
and NN O O
biochemical NN O O
markers NN O O
on NN O O
long NN O O
- NN O O
term NN O O
bone NN O O
health NN O O
and NN O O
future NN O O
fracture NN O O
risk NN O O
are NN O O
unknown NN O O
. NN O O
Assessment NN O O
of NN O O
BMD NN O O
should NN O O
be NN O O
considered NN O O
for NN O O
HIV-1 NN O O
infected NN O O
patients NN O O
who NN O O
have NN O O
a NN O O
history NN O O
of NN O O
pathologic NN O O
bone NN O O
fracture NN O O
or NN O O
other NN O O
risk NN O O
factors NN O O
for NN O O
osteoporosis NN O O
or NN O O
bone NN O O
loss NN O O
. NN O O
Although NN O O
the NN O O
effect NN O O
of NN O O
supplementation NN O O
with NN O O
calcium NN O O
and NN O O
vitamin NN O O
D NN O O
was NN O O
not NN O O
studied NN O O
, NN O O
such NN O O
supplementation NN O O
may NN O O
be NN O O
beneficial NN O O
in NN O O
all NN O O
patients NN O O
. NN O O
If NN O O
bone NN O O
abnormalities NN O O
are NN O O
suspected NN O O
, NN O O
then NN O O
appropriate NN O O
consultation NN O O
should NN O O
be NN O O
obtained NN O O
. NN O O
Mineralization NN O O
Defects NN O O
: NN O O
Cases NN O O
of NN O O
osteomalacia NN B-AdverseReaction B-AdverseReaction
associated NN O O
with NN O O
proximal NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
tubulopathy NN I-AdverseReaction I-AdverseReaction
manifested NN O O
as NN O O
bone NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
or NN O O
pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremities NN I-AdverseReaction I-AdverseReaction
and NN O O
which NN O O
may NN B-Factor B-Factor
contribute NN O O
to NN O O
fractures NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
association NN O O
with NN O O
the NN O O
use NN O O
of NN O O
tenofovir NN O O
DF NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.2 NN O O
) NN O O
] NN O O
. NN O O
Arthralgias NN B-AdverseReaction B-AdverseReaction
and NN O O
muscle NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
or NN O O
weakness NN O O
have NN O O
also NN O O
been NN O O
reported NN O O
in NN O O
cases NN O O
of NN O O
proximal NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
tubulopathy NN I-AdverseReaction I-AdverseReaction
Hypophosphatemia NN O O
and NN O O
osteomalacia NN O O
secondary NN O O
to NN O O
proximal NN O O
renal NN O O
tubulopathy NN O O
should NN O O
be NN O O
considered NN O O
in NN O O
patients NN O O
at NN O O
risk NN O O
of NN O O
renal NN O O
dysfunction NN O O
who NN O O
present NN O O
with NN O O
persistent NN O O
or NN O O
worsening NN O O
bone NN O O
or NN O O
muscle NN O O
symptoms NN O O
while NN O O
receiving NN O O
products NN O O
containing NN O O
tenofovir NN O O
DF NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
. NN O O
5.7 NN O O
Fat NN O O
Redistribution NN O O
Redistribution/accumulation NN O O
of NN O O
body NN O O
fat NN O O
including NN O O
central NN B-AdverseReaction B-AdverseReaction
obesity NN I-AdverseReaction I-AdverseReaction
dorsocervical NN B-AdverseReaction B-AdverseReaction
fat NN I-AdverseReaction I-AdverseReaction
enlargement NN I-AdverseReaction I-AdverseReaction
( NN O O
buffalo NN O O
hump NN O O
) NN O O
, NN O O
peripheral NN O O
wasting NN O O
, NN O O
facial NN B-AdverseReaction B-AdverseReaction
wasting NN I-AdverseReaction I-AdverseReaction
breast NN B-AdverseReaction B-AdverseReaction
enlargement NN I-AdverseReaction I-AdverseReaction
and NN O O
" NN O O
cushingoid NN O O
appearance NN O O
" NN O O
have NN O O
been NN O O
observed NN O O
in NN O O
patients NN O O
receiving NN O O
antiretroviral NN O O
therapy NN O O
. NN O O
The NN O O
mechanism NN O O
and NN O O
long NN O O
- NN O O
term NN O O
consequences NN O O
of NN O O
these NN O O
events NN O O
are NN O O
currently NN O O
unknown NN O O
. NN O O
A NN O O
causal NN O O
relationship NN O O
has NN O O
not NN O O
been NN O O
established NN O O
. NN O O
5.8 NN O O
Immune NN O O
Reconstitution NN O O
Syndrome NN O O
Immune NN B-AdverseReaction B-AdverseReaction
reconstitution NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
has NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
combination NN O O
antiretroviral NN O O
therapy NN O O
, NN O O
including NN O O
STRIBILD. NN O O
During NN O O
the NN O O
initial NN O O
phase NN O O
of NN O O
combination NN O O
antiretroviral NN O O
treatment NN O O
, NN O O
patients NN O O
whose NN O O
immune NN O O
system NN O O
responds NN O O
may NN B-Factor B-Factor
develop NN O O
an NN O O
inflammatory NN O O
response NN O O
to NN O O
indolent NN O O
or NN O O
residual NN B-AdverseReaction B-AdverseReaction
opportunistic NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
[ NN O O
such NN O O
as NN O O
Mycobacterium NN B-AdverseReaction B-AdverseReaction
avium NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
cytomegalovirus NN B-AdverseReaction B-AdverseReaction
Pneumocystis NN B-AdverseReaction B-AdverseReaction
jirovecii NN I-AdverseReaction I-AdverseReaction
pneumonia NN I-AdverseReaction I-AdverseReaction
( NN O O
PCP NN O O
) NN O O
, NN O O
or NN O O
tuberculosis NN B-AdverseReaction B-AdverseReaction
which NN O O
may NN O O
necessitate NN O O
further NN O O
evaluation NN O O
and NN O O
treatment NN O O
. NN O O
Autoimmune NN B-AdverseReaction B-AdverseReaction
disorders NN I-AdverseReaction I-AdverseReaction
( NN O O
such NN O O
as NN O O
Graves NN B-AdverseReaction B-AdverseReaction
' NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
polymyositis NN B-AdverseReaction B-AdverseReaction
and NN O O
Guillain NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Barre NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
have NN O O
also NN O O
been NN O O
reported NN O O
to NN O O
occur NN O O
in NN O O
the NN O O
setting NN O O
of NN O O
immune NN O O
reconstitution NN O O
, NN O O
however NN O O
, NN O O
the NN O O
time NN O O
to NN O O
onset NN O O
is NN O O
more NN O O
variable NN O O
, NN O O
and NN O O
can NN O O
occur NN O O
many NN O O
months NN O O
after NN O O
initiation NN O O
of NN O O
treatment NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
serious NN O O
adverse NN O O
reactions NN O O
associated NN O O
with NN O O
PROMACTA NN O O
are NN O O
described NN O O
in NN O O
other NN O O
sections NN O O
. NN O O
* NN O O
Hepatic NN B-AdverseReaction B-AdverseReaction
Decompensation NN I-AdverseReaction I-AdverseReaction
in NN O O
Patients NN O O
with NN O O
Chronic NN O O
Hepatitis NN O O
C NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Hepatotoxicity NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
Thrombotic/Thromboembolic NN O O
Complications NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
* NN O O
Cataracts NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
* NN O O
In NN O O
adult NN O O
patients NN O O
with NN O O
ITP NN O O
, NN O O
the NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
5 NN O O
% NN O O
and NN O O
greater NN O O
than NN O O
placebo NN O O
) NN O O
were NN O O
: NN O O
nausea NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
ALT NN I-AdverseReaction I-AdverseReaction
myalgia NN B-AdverseReaction B-AdverseReaction
and NN O O
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
* NN O O
In NN O O
pediatric NN O O
patients NN O O
age NN O O
6 NN O O
years NN O O
and NN O O
older NN O O
with NN O O
ITP NN O O
, NN O O
the NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
10 NN O O
% NN O O
and NN O O
greater NN O O
than NN O O
placebo NN O O
) NN O O
were NN O O
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
and NN O O
rhinitis NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
* NN O O
In NN O O
patients NN O O
with NN O O
chronic NN O O
hepatitis NN O O
C NN O O
- NN O O
associated NN O O
thrombocytopenia NN O O
, NN O O
the NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
10 NN O O
% NN O O
and NN O O
greater NN O O
than NN O O
placebo NN O O
) NN O O
were NN O O
: NN O O
anemia NN B-AdverseReaction B-AdverseReaction
pyrexia NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
influenza NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
like NN I-AdverseReaction I-AdverseReaction
illness NN I-AdverseReaction I-AdverseReaction
asthenia NN B-AdverseReaction B-AdverseReaction
insomnia NN B-AdverseReaction B-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
pruritus NN B-AdverseReaction B-AdverseReaction
chills NN B-AdverseReaction B-AdverseReaction
myalgia NN B-AdverseReaction B-AdverseReaction
alopecia NN B-AdverseReaction B-AdverseReaction
and NN O O
peripheral NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
* NN O O
In NN O O
patients NN O O
with NN O O
severe NN O O
aplastic NN O O
anemia NN O O
, NN O O
the NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
20 NN O O
% NN O O
) NN O O
were NN O O
: NN O O
nausea NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
and NN O O
headache NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
EXCERPT NN O O
: NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
GlaxoSmithKline NN O O
at NN O O
1 NN O O
- NN O O
888 NN O O
- NN O O
825 NN O O
- NN O O
5249 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
with NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
Chronic NN O O
Immune NN O O
( NN O O
Idiopathic NN O O
) NN O O
Thrombocytopenia NN O O
: NN O O
Adults NN O O
: NN O O
In NN O O
clinical NN O O
trials NN O O
, NN O O
hemorrhage NN B-AdverseReaction B-AdverseReaction
was NN O O
the NN O O
most NN O O
common NN O O
serious NN O O
adverse NN O O
reaction NN O O
and NN O O
most NN O O
hemorrhagic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
followed NN O O
discontinuation NN O O
of NN O O
PROMACTA. NN O O
Other NN O O
serious NN O O
adverse NN O O
reactions NN O O
included NN O O
thrombotic/thromboembolic NN O O
complications NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
data NN O O
described NN O O
below NN O O
reflect NN O O
exposure NN O O
of NN O O
PROMACTA NN O O
to NN O O
446 NN O O
patients NN O O
with NN O O
chronic NN O O
ITP NN O O
aged NN O O
18 NN O O
to NN O O
85 NN O O
years NN O O
, NN O O
of NN O O
whom NN O O
65 NN O O
% NN O O
were NN O O
female NN O O
, NN O O
across NN O O
the NN O O
ITP NN O O
clinical NN O O
development NN O O
program NN O O
including NN O O
three NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
. NN O O
PROMACTA NN O O
was NN O O
administered NN O O
to NN O O
277 NN O O
patients NN O O
for NN O O
at NN O O
least NN O O
6 NN O O
months NN O O
and NN O O
202 NN O O
patients NN O O
for NN O O
at NN O O
least NN O O
1 NN O O
year NN O O
. NN O O
Table NN O O
4 NN O O
presents NN O O
the NN O O
most NN O O
common NN O O
adverse NN O O
drug NN O O
reactions NN O O
( NN O O
experienced NN O O
by NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
3 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
PROMACTA NN O O
) NN O O
from NN O O
the NN O O
three NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
, NN O O
with NN O O
a NN O O
higher NN O O
incidence NN O O
in NN O O
PROMACTA NN O O
versus NN O O
placebo NN O O
. NN O O
Table NN O O
4 NN O O
. NN O O
Adverse NN O O
Reactions NN O O
( NN O O
>=3 NN O O
% NN O O
) NN O O
from NN O O
Three NN O O
Placebo NN O O
- NN O O
controlled NN O O
Trials NN O O
in NN O O
Adults NN O O
with NN O O
Chronic NN O O
Immune NN O O
( NN O O
Idiopathic NN O O
) NN O O
Thrombocytopenia NN O O
Adverse NN O O
Reaction NN O O
PROMACTA NN O O
50 NN O O
mg NN O O
n NN O O
= NN O O
241 NN O O
( NN O O
% NN O O
) NN O O
Placebo NN O O
n NN O O
= NN O O
128 NN O O
( NN O O
% NN O O
) NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
9 NN O O
3 NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
9 NN O O
7 NN O O
Upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
7 NN O O
6 NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
6 NN O O
< NN O O
1 NN O O
Increased NN B-AdverseReaction B-AdverseReaction
ALT NN I-AdverseReaction I-AdverseReaction
5 NN O O
3 NN O O
Myalgia NN B-AdverseReaction B-AdverseReaction
5 NN O O
2 NN O O
Urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
5 NN O O
3 NN O O
Oropharyngeal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
4 NN O O
3 NN O O
Increased NN B-AdverseReaction B-AdverseReaction
AST NN I-AdverseReaction I-AdverseReaction
4 NN O O
2 NN O O
Pharyngitis NN B-AdverseReaction B-AdverseReaction
4 NN O O
2 NN O O
Back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
3 NN O O
2 NN O O
Influenza NN B-AdverseReaction B-AdverseReaction
3 NN O O
2 NN O O
Paresthesia NN B-AdverseReaction B-AdverseReaction
3 NN O O
2 NN O O
Rash NN B-AdverseReaction B-AdverseReaction
3 NN O O
2 NN O O
In NN O O
the NN O O
three NN O O
controlled NN O O
clinical NN O O
chronic NN O O
ITP NN O O
trials NN O O
, NN O O
alopecia NN B-AdverseReaction B-AdverseReaction
musculoskeletal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
blood NN B-AdverseReaction B-AdverseReaction
alkaline NN I-AdverseReaction I-AdverseReaction
phosphatase NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
and NN O O
dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
were NN O O
the NN O O
adverse NN O O
reactions NN O O
reported NN O O
in NN O O
2 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
PROMACTA NN O O
and NN O O
in NN O O
no NN O O
patients NN O O
who NN O O
received NN O O
placebo NN O O
. NN O O
Among NN O O
299 NN O O
patients NN O O
with NN O O
chronic NN O O
ITP NN O O
who NN O O
received NN O O
PROMACTA NN O O
in NN O O
the NN O O
single NN O O
- NN O O
arm NN O O
extension NN O O
trial NN O O
, NN O O
the NN O O
adverse NN O O
reactions NN O O
occurred NN O O
in NN O O
a NN O O
pattern NN O O
similar NN O O
to NN O O
that NN O O
seen NN O O
in NN O O
the NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
. NN O O
Table NN O O
5 NN O O
presents NN O O
the NN O O
most NN O O
common NN O O
treatment NN O O
- NN O O
related NN O O
adverse NN O O
reactions NN O O
( NN O O
experienced NN O O
by NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
3 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
PROMACTA NN O O
) NN O O
from NN O O
the NN O O
extension NN O O
trial NN O O
. NN O O
Table NN O O
5 NN O O
. NN O O
Treatment NN O O
- NN O O
related NN O O
Adverse NN O O
Reactions NN O O
( NN O O
>=3 NN O O
% NN O O
) NN O O
from NN O O
Extension NN O O
Trial NN O O
in NN O O
Adults NN O O
with NN O O
Chronic NN O O
Immune NN O O
( NN O O
Idiopathic NN O O
) NN O O
Thrombocytopenia NN O O
Adverse NN O O
Reaction NN O O
PROMACTA NN O O
50 NN O O
mg NN O O
n NN O O
= NN O O
299 NN O O
( NN O O
% NN O O
) NN O O
Headache NN B-AdverseReaction B-AdverseReaction
10 NN O O
Hyperbilirubinemia NN B-AdverseReaction B-AdverseReaction
6 NN O O
ALT NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
6 NN O O
Cataract NN B-AdverseReaction B-AdverseReaction
5 NN O O
AST NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
4 NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
4 NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
4 NN O O
In NN O O
the NN O O
three NN O O
controlled NN O O
chronic NN O O
ITP NN O O
trials NN O O
, NN O O
serum NN B-AdverseReaction B-AdverseReaction
liver NN I-AdverseReaction I-AdverseReaction
test NN I-AdverseReaction I-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
( NN O O
predominantly NN O O
Grade NN B-Severity B-Severity
2 NN I-Severity I-Severity
or NN O O
less NN O O
in NN O O
severity NN O O
) NN O O
were NN O O
reported NN O O
in NN O O
11 NN O O
% NN O O
and NN O O
7 NN O O
% NN O O
of NN O O
patients NN O O
for NN O O
PROMACTA NN O O
and NN O O
placebo NN O O
, NN O O
respectively NN O O
. NN O O
Four NN O O
patients NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
treated NN O O
with NN O O
PROMACTA NN O O
and NN O O
three NN O O
patients NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
discontinued NN O O
treatment NN O O
due NN O O
to NN O O
hepatobiliary NN B-AdverseReaction B-AdverseReaction
laboratory NN I-AdverseReaction I-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
Seven NN O O
of NN O O
the NN O O
patients NN O O
treated NN O O
with NN O O
PROMACTA NN O O
in NN O O
the NN O O
controlled NN O O
trials NN O O
with NN O O
hepatobiliary NN B-AdverseReaction B-AdverseReaction
laboratory NN I-AdverseReaction I-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
were NN O O
re NN O O
- NN O O
exposed NN O O
to NN O O
PROMACTA NN O O
in NN O O
the NN O O
extension NN O O
trial NN O O
. NN O O
Six NN O O
of NN O O
these NN O O
patients NN O O
again NN O O
experienced NN O O
liver NN B-AdverseReaction B-AdverseReaction
test NN I-AdverseReaction I-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
( NN O O
predominantly NN O O
Grade NN B-Severity B-Severity
1 NN I-Severity I-Severity
resulting NN O O
in NN O O
discontinuation NN O O
of NN O O
PROMACTA NN O O
in NN O O
one NN O O
patient NN O O
. NN O O
In NN O O
the NN O O
extension NN O O
chronic NN O O
ITP NN O O
trial NN O O
, NN O O
one NN O O
additional NN O O
patient NN O O
had NN O O
PROMACTA NN O O
discontinued NN O O
due NN O O
to NN O O
liver NN B-AdverseReaction B-AdverseReaction
test NN I-AdverseReaction I-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
( NN O O
less NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
In NN O O
a NN O O
placebo NN O O
- NN O O
controlled NN O O
trial NN O O
of NN O O
PROMACTA NN O O
in NN O O
patients NN O O
with NN O O
chronic NN O O
liver NN O O
diseaseand NN O O
thrombocytopenia NN O O
not NN O O
related NN O O
to NN O O
ITP NN O O
, NN O O
six NN O O
patients NN O O
treated NN O O
with NN O O
PROMACTA NN O O
and NN O O
one NN O O
patient NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
developed NN O O
portal NN B-AdverseReaction B-AdverseReaction
vein NN I-AdverseReaction I-AdverseReaction
thromboses NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
. NN O O
Pediatric NN O O
Patients NN O O
: NN O O
The NN O O
data NN O O
described NN O O
below NN O O
reflect NN O O
median NN O O
exposure NN O O
to NN O O
PROMACTA NN O O
of NN O O
91 NN O O
days NN O O
for NN O O
82 NN O O
pediatric NN O O
patients NN O O
( NN O O
aged NN O O
6 NN O O
to NN O O
17 NN O O
years NN O O
) NN O O
with NN O O
chronic NN O O
ITP NN O O
, NN O O
of NN O O
whom NN O O
52 NN O O
% NN O O
were NN O O
female NN O O
, NN O O
across NN O O
the NN O O
randomized NN O O
phase NN O O
of NN O O
two NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
. NN O O
Table NN O O
6 NN O O
presents NN O O
the NN O O
most NN O O
common NN O O
adverse NN O O
drug NN O O
reactions NN O O
( NN O O
experienced NN O O
by NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
3 NN O O
% NN O O
of NN O O
pediatric NN O O
patients NN O O
6 NN O O
years NN O O
and NN O O
older NN O O
receiving NN O O
PROMACTA NN O O
) NN O O
across NN O O
the NN O O
two NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
, NN O O
with NN O O
a NN O O
higher NN O O
incidence NN O O
for NN O O
PROMACTA NN O O
versus NN O O
placebo NN O O
. NN O O
Table NN O O
6 NN O O
. NN O O
Adverse NN O O
Reactions NN O O
( NN O O
>=3 NN O O
% NN O O
) NN O O
with NN O O
a NN O O
Higher NN O O
Incidence NN O O
for NN O O
PROMACTA NN O O
versus NN O O
Placebo NN O O
from NN O O
Two NN O O
Placebo NN O O
- NN O O
controlled NN O O
Trials NN O O
in NN O O
Pediatric NN O O
Patients NN O O
6 NN O O
Years NN O O
and NN O O
Older NN O O
with NN O O
Chronic NN O O
Immune NN O O
( NN O O
Idiopathic NN O O
) NN O O
Thrombocytopenia NN O O
PROMACTA NN O O
Placebo NN O O
n NN O O
= NN O O
82 NN O O
n NN O O
= NN O O
40 NN O O
Adverse NN O O
Reaction NN O O
( NN O O
% NN O O
) NN O O
( NN O O
% NN O O
) NN O O
Upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
16 NN O O
5 NN O O
Nasopharyngitis NN B-AdverseReaction B-AdverseReaction
12 NN O O
5 NN O O
Rhinitis NN B-AdverseReaction B-AdverseReaction
11 NN O O
8 NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
9 NN O O
5 NN O O
Cough NN B-AdverseReaction B-AdverseReaction
9 NN O O
0 NN O O
Oropharyngeal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
9 NN O O
3 NN O O
Toothache NN B-AdverseReaction B-AdverseReaction
6 NN O O
0 NN O O
AST NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
5 NN O O
0 NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
5 NN O O
3 NN O O
Rash NN B-AdverseReaction B-AdverseReaction
5 NN O O
3 NN O O
ALT NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
6 NN O O
0 NN O O
Vitamin NN B-AdverseReaction B-AdverseReaction
D NN I-AdverseReaction I-AdverseReaction
deficiency NN I-AdverseReaction I-AdverseReaction
4 NN O O
0 NN O O
* NN O O
a NN O O
Includes NN O O
adverse NN O O
reactions NN O O
or NN O O
laboratory NN O O
abnormalities NN O O
>3 NN O O
x NN O O
ULN. NN O O
Chronic NN O O
Hepatitis NN O O
C NN O O
- NN O O
associated NN O O
Thrombocytopenia NN O O
: NN O O
In NN O O
the NN O O
two NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
, NN O O
955 NN O O
patients NN O O
with NN O O
chronic NN O O
hepatitis NN O O
C NN O O
- NN O O
associated NN O O
thrombocytopenia NN O O
received NN O O
PROMACTA. NN O O
Table NN O O
7 NN O O
presents NN O O
the NN O O
most NN O O
common NN O O
adverse NN O O
drug NN O O
reactions NN O O
( NN O O
experienced NN O O
by NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
10 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
PROMACTA NN O O
compared NN O O
with NN O O
placebo NN O O
) NN O O
. NN O O
Table NN O O
7 NN O O
. NN O O
Adverse NN O O
Reactions NN O O
( NN O O
>=10 NN O O
% NN O O
and NN O O
Greater NN O O
than NN O O
Placebo NN O O
) NN O O
from NN O O
Two NN O O
Placebo NN O O
- NN O O
controlled NN O O
Trials NN O O
in NN O O
Adults NN O O
with NN O O
Chronic NN O O
Hepatitis NN O O
C NN O O
Adverse NN O O
Reaction NN O O
PROMACTA NN O O
+ NN O O
Peginterferon/Ribavirin NN O O
n NN O O
= NN O O
955 NN O O
( NN O O
% NN O O
) NN O O
Placebo NN O O
+ NN O O
Peginterferon/Ribavirin NN O O
n NN O O
= NN O O
484 NN O O
( NN O O
% NN O O
) NN O O
Anemia NN B-AdverseReaction B-AdverseReaction
40 NN O O
35 NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
30 NN O O
24 NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
28 NN O O
23 NN O O
Headache NN B-AdverseReaction B-AdverseReaction
21 NN O O
20 NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
19 NN O O
14 NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
19 NN O O
11 NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
18 NN O O
14 NN O O
Influenza NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
like NN I-AdverseReaction I-AdverseReaction
illness NN I-AdverseReaction I-AdverseReaction
18 NN O O
16 NN O O
Asthenia NN B-AdverseReaction B-AdverseReaction
16 NN O O
13 NN O O
Insomnia NN B-AdverseReaction B-AdverseReaction
16 NN O O
15 NN O O
Cough NN B-AdverseReaction B-AdverseReaction
15 NN O O
12 NN O O
Pruritus NN B-AdverseReaction B-AdverseReaction
15 NN O O
13 NN O O
Chills NN B-AdverseReaction B-AdverseReaction
14 NN O O
9 NN O O
Myalgia NN B-AdverseReaction B-AdverseReaction
12 NN O O
10 NN O O
Alopecia NN B-AdverseReaction B-AdverseReaction
10 NN O O
6 NN O O
Peripheral NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
10 NN O O
5 NN O O
In NN O O
the NN O O
two NN O O
controlled NN O O
clinical NN O O
trials NN O O
in NN O O
patients NN O O
with NN O O
chronic NN O O
hepatitis NN O O
C NN O O
, NN O O
hyperbilirubinemia NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
8 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
PROMACTA NN O O
compared NN O O
with NN O O
3 NN O O
% NN O O
for NN O O
placebo NN O O
. NN O O
Total NN B-AdverseReaction B-AdverseReaction
bilirubin NN I-AdverseReaction I-AdverseReaction
greater NN I-AdverseReaction I-AdverseReaction
than NN I-AdverseReaction I-AdverseReaction
or NN I-AdverseReaction I-AdverseReaction
equal NN I-AdverseReaction I-AdverseReaction
to NN I-AdverseReaction I-AdverseReaction
1.5 NN I-AdverseReaction I-AdverseReaction
x NN I-AdverseReaction I-AdverseReaction
ULN NN I-AdverseReaction I-AdverseReaction
was NN O O
reported NN O O
in NN O O
76 NN O O
% NN O O
and NN O O
50 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
PROMACTA NN O O
and NN O O
placebo NN O O
, NN O O
respectively NN O O
. NN O O
ALT NN O O
or NN O O
AST NN B-AdverseReaction B-AdverseReaction
greater NN I-AdverseReaction I-AdverseReaction
than NN I-AdverseReaction I-AdverseReaction
or NN I-AdverseReaction I-AdverseReaction
equal NN I-AdverseReaction I-AdverseReaction
to NN I-AdverseReaction I-AdverseReaction
3 NN I-AdverseReaction I-AdverseReaction
x NN I-AdverseReaction I-AdverseReaction
ULN NN I-AdverseReaction I-AdverseReaction
was NN O O
reported NN O O
in NN O O
34 NN O O
% NN O O
and NN O O
38 NN O O
% NN O O
of NN O O
patients NN O O
for NN O O
PROMACTA NN O O
and NN O O
placebo NN O O
, NN O O
respectively NN O O
. NN O O
Severe NN O O
Aplastic NN O O
Anemia NN O O
: NN O O
In NN O O
the NN O O
single NN O O
- NN O O
arm NN O O
, NN O O
open NN O O
- NN O O
label NN O O
trial NN O O
, NN O O
43 NN O O
patients NN O O
with NN O O
severe NN O O
aplastic NN O O
anemia NN O O
received NN O O
PROMACTA. NN O O
Eleven NN O O
patients NN O O
( NN O O
26 NN O O
% NN O O
) NN O O
were NN O O
treated NN O O
for NN O O
greater NN O O
than NN O O
6 NN O O
months NN O O
and NN O O
7 NN O O
patients NN O O
( NN O O
16 NN O O
% NN O O
) NN O O
were NN O O
treated NN O O
for NN O O
greater NN O O
than NN O O
1 NN O O
year NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
20 NN O O
% NN O O
) NN O O
were NN O O
nausea NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
and NN O O
headache NN B-AdverseReaction B-AdverseReaction
Table NN O O
8 NN O O
. NN O O
Adverse NN O O
Reactions NN O O
( NN O O
>=10 NN O O
% NN O O
) NN O O
from NN O O
One NN O O
Open NN O O
- NN O O
label NN O O
Trial NN O O
in NN O O
Adults NN O O
with NN O O
Severe NN O O
Aplastic NN O O
Anemia NN O O
Adverse NN O O
Reaction NN O O
PROMACTA NN O O
( NN O O
n NN O O
= NN O O
43 NN O O
) NN O O
( NN O O
% NN O O
) NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
33 NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
28 NN O O
Cough NN B-AdverseReaction B-AdverseReaction
23 NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
21 NN O O
Headache NN B-AdverseReaction B-AdverseReaction
21 NN O O
Pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
19 NN O O
Dyspnea NN B-AdverseReaction B-AdverseReaction
14 NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
14 NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
14 NN O O
Oropharyngeal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
14 NN O O
Febrile NN B-AdverseReaction B-AdverseReaction
neutropenia NN I-AdverseReaction I-AdverseReaction
14 NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
12 NN O O
Ecchymosis NN B-AdverseReaction B-AdverseReaction
12 NN O O
Muscle NN B-AdverseReaction B-AdverseReaction
spasms NN I-AdverseReaction I-AdverseReaction
12 NN O O
Transaminases NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
12 NN O O
Arthralgia NN B-AdverseReaction B-AdverseReaction
12 NN O O
Rhinorrhea NN B-AdverseReaction B-AdverseReaction
12 NN O O
In NN O O
this NN O O
trial NN O O
, NN O O
patients NN O O
had NN O O
bone NN O O
marrow NN O O
aspirates NN O O
evaluated NN O O
for NN O O
cytogenetic NN O O
abnormalities NN O O
. NN O O
Eight NN O O
patients NN O O
had NN O O
a NN O O
new NN O O
cytogenetic NN B-AdverseReaction B-AdverseReaction
abnormality NN I-AdverseReaction I-AdverseReaction
reported NN O O
on NN O O
therapy NN O O
, NN O O
including NN O O
5 NN O O
patients NN O O
who NN O O
had NN O O
complex NN O O
changes NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
chromosome NN I-AdverseReaction I-AdverseReaction
7 NN I-AdverseReaction I-AdverseReaction
6.2 NN O O
Postmarketing NN O O
Experience NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
identified NN O O
during NN O O
post NN O O
approval NN O O
use NN O O
of NN O O
PROMACTA. NN O O
Because NN O O
these NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
the NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
Vascular NN O O
Disorders NN O O
: NN O O
Thrombotic NN B-AdverseReaction B-AdverseReaction
microangiopathy NN I-AdverseReaction I-AdverseReaction
with NN O O
acute NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
RISK NN B-Factor B-Factor
FOR NN O O
HEPATIC NN B-AdverseReaction B-AdverseReaction
DECOMPENSATION NN I-AdverseReaction I-AdverseReaction
IN NN O O
PATIENTS NN O O
WITH NN O O
CHRONIC NN O O
HEPATITIS NN O O
C NN O O
WARNING NN O O
: NN O O
RISK NN B-Factor B-Factor
FOR NN O O
HEPATIC NN B-AdverseReaction B-AdverseReaction
DECOMPENSATION NN I-AdverseReaction I-AdverseReaction
IN NN O O
PATIENTS NN O O
WITH NN O O
CHRONIC NN O O
HEPATITIS NN O O
C NN O O
In NN O O
patients NN O O
with NN O O
chronic NN O O
hepatitis NN O O
C NN O O
, NN O O
PROMACTA NN O O
( NN O O
r NN O O
) NN O O
in NN O O
combination NN O O
with NN O O
interferon NN O O
and NN O O
ribavirin NN O O
may NN O O
increase NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
hepatic NN B-AdverseReaction B-AdverseReaction
decompensation NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
EXCERPT NN O O
: NN O O
WARNING NN O O
: NN O O
RISK NN B-Factor B-Factor
FOR NN O O
HEPATIC NN B-AdverseReaction B-AdverseReaction
DECOMPENSATION NN I-AdverseReaction I-AdverseReaction
IN NN O O
PATIENTS NN O O
WITH NN O O
CHRONIC NN O O
HEPATITIS NN O O
C NN O O
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
. NN O O
In NN O O
patients NN O O
with NN O O
chronic NN O O
hepatitis NN O O
C NN O O
, NN O O
PROMACTA NN O O
in NN O O
combination NN O O
with NN O O
interferon NN O O
and NN O O
ribavirin NN O O
may NN O O
increase NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
hepatic NN B-AdverseReaction B-AdverseReaction
decompensation NN I-AdverseReaction I-AdverseReaction
( NN O O
5.1 NN O O
) NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Hepatotoxicity NN B-AdverseReaction B-AdverseReaction
Monitor NN O O
liver NN O O
function NN O O
before NN O O
and NN O O
during NN O O
therapy NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Thrombotic/Thromboembolic NN O O
Complications NN O O
: NN O O
Portal NN B-AdverseReaction B-AdverseReaction
vein NN I-AdverseReaction I-AdverseReaction
thrombosis NN I-AdverseReaction I-AdverseReaction
has NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
with NN O O
chronic NN O O
liver NN O O
disease NN O O
receiving NN O O
PROMACTA. NN O O
Monitor NN O O
platelet NN O O
counts NN O O
regularly NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
5.1 NN O O
Hepatic NN O O
Decompensation NN O O
in NN O O
Patients NN O O
with NN O O
Chronic NN O O
Hepatitis NN O O
C NN O O
In NN O O
patients NN O O
with NN O O
chronic NN O O
hepatitis NN O O
C NN O O
, NN O O
PROMACTA NN O O
in NN O O
combination NN O O
with NN O O
interferon NN O O
and NN O O
ribavirin NN O O
may NN O O
increase NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
hepatic NN B-AdverseReaction B-AdverseReaction
decompensation NN I-AdverseReaction I-AdverseReaction
In NN O O
two NN O O
controlled NN O O
clinical NN O O
trials NN O O
in NN O O
patients NN O O
with NN O O
chronic NN O O
hepatitis NN O O
C NN O O
and NN O O
thrombocytopenia NN O O
, NN O O
ascites NN B-AdverseReaction B-AdverseReaction
and NN O O
encephalopathy NN B-AdverseReaction B-AdverseReaction
occurred NN O O
more NN O O
frequently NN O O
on NN O O
the NN O O
arm NN O O
receiving NN O O
treatment NN O O
with NN O O
PROMACTA NN O O
plus NN O O
antivirals NN O O
( NN O O
7 NN O O
% NN O O
) NN O O
than NN O O
the NN O O
placebo NN O O
plus NN O O
antivirals NN O O
arm NN O O
( NN O O
4 NN O O
% NN O O
) NN O O
. NN O O
Patients NN O O
with NN O O
low NN O O
albumin NN O O
levels NN O O
( NN O O
less NN O O
than NN O O
3.5 NN O O
g/dL NN O O
) NN O O
or NN O O
Model NN O O
for NN O O
End NN O O
- NN O O
Stage NN O O
Liver NN O O
Disease NN O O
( NN O O
MELD NN O O
) NN O O
score NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
10 NN O O
at NN O O
baseline NN O O
had NN O O
a NN O O
greater NN O O
risk NN B-Factor B-Factor
for NN O O
hepatic NN B-AdverseReaction B-AdverseReaction
decompensation NN I-AdverseReaction I-AdverseReaction
on NN O O
the NN O O
arm NN O O
receiving NN O O
treatment NN O O
with NN O O
PROMACTA NN O O
plus NN O O
antivirals NN O O
. NN O O
Discontinue NN O O
PROMACTA NN O O
if NN O O
antiviral NN O O
therapy NN O O
is NN O O
discontinued NN O O
. NN O O
5.2 NN O O
Hepatotoxicity NN O O
PROMACTA NN O O
can NN B-Factor B-Factor
cause NN O O
liver NN B-AdverseReaction B-AdverseReaction
enzyme NN I-AdverseReaction I-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Measure NN O O
serum NN O O
ALT NN O O
, NN O O
AST NN O O
, NN O O
and NN O O
bilirubin NN O O
prior NN O O
to NN O O
initiation NN O O
of NN O O
PROMACTA NN O O
, NN O O
every NN O O
2 NN O O
weeks NN O O
during NN O O
the NN O O
dose NN O O
adjustment NN O O
phase NN O O
, NN O O
and NN O O
monthly NN O O
following NN O O
establishment NN O O
of NN O O
a NN O O
stable NN O O
dose NN O O
. NN O O
PROMACTA NN O O
inhibits NN O O
UDP NN O O
- NN O O
glucuronosyltransferase NN O O
( NN O O
UGT)1A1 NN O O
and NN O O
organic NN O O
anion NN O O
- NN O O
transporting NN O O
polypeptide NN O O
( NN O O
OATP)1B1 NN O O
, NN O O
which NN O O
may NN B-Factor B-Factor
lead NN O O
to NN O O
indirect NN B-AdverseReaction B-AdverseReaction
hyperbilirubinemia NN I-AdverseReaction I-AdverseReaction
If NN O O
bilirubin NN O O
is NN O O
elevated NN O O
, NN O O
perform NN O O
fractionation NN O O
. NN O O
Evaluate NN O O
abnormal NN O O
serum NN O O
liver NN O O
tests NN O O
with NN O O
repeat NN O O
testing NN O O
within NN O O
3 NN O O
to NN O O
5 NN O O
days NN O O
. NN O O
If NN O O
the NN O O
abnormalities NN O O
are NN O O
confirmed NN O O
, NN O O
monitor NN O O
serum NN O O
liver NN O O
tests NN O O
weekly NN O O
until NN O O
resolved NN O O
or NN O O
stabilized NN O O
. NN O O
Discontinue NN O O
PROMACTA NN O O
if NN O O
ALT NN O O
levels NN O O
increase NN O O
to NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
3 NN O O
x NN O O
ULN NN O O
in NN O O
patients NN O O
with NN O O
normal NN O O
liver NN O O
function NN O O
or NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
3 NN O O
x NN O O
baseline NN O O
in NN O O
patients NN O O
with NN O O
pre NN O O
- NN O O
treatment NN O O
elevations NN O O
in NN O O
transaminases NN O O
and NN O O
are NN O O
: NN O O
* NN O O
progressively NN O O
increasing NN O O
, NN O O
or NN O O
* NN O O
persistent NN O O
for NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
4 NN O O
weeks NN O O
, NN O O
or NN O O
* NN O O
accompanied NN O O
by NN O O
increased NN O O
direct NN O O
bilirubin NN O O
, NN O O
or NN O O
* NN O O
accompanied NN O O
by NN O O
clinical NN O O
symptoms NN O O
of NN O O
liver NN O O
injury NN O O
or NN O O
evidence NN O O
for NN O O
hepatic NN O O
decompensation NN O O
. NN O O
If NN O O
the NN O O
potential NN O O
benefit NN O O
for NN O O
reinitiating NN O O
treatment NN O O
with NN O O
PROMACTA NN O O
is NN O O
considered NN O O
to NN O O
outweigh NN O O
the NN O O
risk NN O O
for NN O O
hepatotoxicity NN O O
, NN O O
then NN O O
consider NN O O
cautiously NN O O
reintroducing NN O O
PROMACTA NN O O
and NN O O
measure NN O O
serum NN O O
liver NN O O
tests NN O O
weekly NN O O
during NN O O
the NN O O
dose NN O O
adjustment NN O O
phase NN O O
. NN O O
Hepatotoxicity NN B-AdverseReaction B-AdverseReaction
may NN B-Factor B-Factor
reoccur NN O O
if NN O O
PROMACTA NN O O
is NN O O
reinitiated NN O O
. NN O O
If NN O O
liver NN O O
test NN O O
abnormalities NN O O
persist NN O O
, NN O O
worsen NN O O
or NN O O
recur NN O O
, NN O O
then NN O O
permanently NN O O
discontinue NN O O
PROMACTA. NN O O
5.3 NN O O
Thrombotic/Thromboembolic NN O O
Complications NN O O
In NN O O
two NN O O
controlled NN O O
clinical NN O O
trials NN O O
in NN O O
patients NN O O
with NN O O
chronic NN O O
hepatitis NN O O
C NN O O
and NN O O
thrombocytopenia NN O O
, NN O O
3 NN O O
% NN O O
( NN O O
31/955 NN O O
) NN O O
treated NN O O
with NN O O
PROMACTA NN O O
experienced NN O O
a NN O O
thrombotic NN B-AdverseReaction B-AdverseReaction
event NN I-AdverseReaction I-AdverseReaction
compared NN O O
with NN O O
1 NN O O
% NN O O
( NN O O
5/484 NN O O
) NN O O
on NN O O
placebo NN O O
. NN O O
The NN O O
majority NN O O
of NN O O
events NN O O
were NN O O
of NN O O
the NN O O
portal NN O O
venous NN O O
system NN O O
( NN O O
1 NN O O
% NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
PROMACTA NN O O
versus NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
for NN O O
placebo NN O O
) NN O O
. NN O O
Thrombotic/thromboembolic NN O O
complications NN O O
may NN B-Factor B-Factor
result NN O O
from NN O O
increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
platelet NN I-AdverseReaction I-AdverseReaction
counts NN I-AdverseReaction I-AdverseReaction
with NN O O
PROMACTA. NN O O
Reported NN O O
thrombotic/thromboembolic NN O O
complications NN O O
included NN O O
both NN O O
venous NN O O
and NN O O
arterial NN O O
events NN O O
and NN O O
were NN O O
observed NN O O
at NN O O
low NN O O
and NN O O
at NN O O
normal NN O O
platelet NN O O
counts NN O O
. NN O O
Consider NN O O
the NN O O
potential NN O O
for NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
thromboembolism NN O O
when NN O O
administering NN O O
PROMACTA NN O O
to NN O O
patients NN O O
with NN O O
known NN O O
risk NN O O
factors NN O O
for NN O O
thromboembolism NN O O
( NN O O
e.g. NN O O
, NN O O
Factor NN O O
V NN O O
Leiden NN O O
, NN O O
ATIII NN O O
deficiency NN O O
, NN O O
antiphospholipid NN O O
syndrome NN O O
, NN O O
chronic NN O O
liver NN O O
disease NN O O
) NN O O
. NN O O
To NN O O
minimize NN O O
the NN O O
risk NN O O
for NN O O
thrombotic/thromboembolic NN O O
complications NN O O
, NN O O
do NN O O
not NN O O
use NN O O
PROMACTA NN O O
in NN O O
an NN O O
attempt NN O O
to NN O O
normalize NN O O
platelet NN O O
counts NN O O
. NN O O
Follow NN O O
the NN O O
dose NN O O
adjustment NN O O
guidelines NN O O
to NN O O
achieve NN O O
and NN O O
maintain NN O O
target NN O O
platelet NN O O
counts NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.1 NN O O
, NN O O
2.2 NN O O
, NN O O
2.3 NN O O
) NN O O
] NN O O
. NN O O
In NN O O
a NN O O
controlled NN O O
trial NN O O
in NN O O
patients NN O O
with NN O O
chronic NN O O
liver NN O O
disease NN O O
and NN O O
thrombocytopenia NN O O
not NN O O
related NN O O
to NN O O
ITP NN O O
undergoing NN O O
elective NN O O
invasive NN O O
procedures NN O O
( NN O O
N NN O O
= NN O O
292 NN O O
) NN O O
, NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
thrombotic NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
was NN O O
increased NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
75 NN O O
mg NN O O
of NN O O
PROMACTA NN O O
once NN O O
daily NN O O
. NN O O
Seven NN O O
thrombotic NN B-AdverseReaction B-AdverseReaction
complications NN I-AdverseReaction I-AdverseReaction
( NN O O
six NN O O
patients NN O O
) NN O O
were NN O O
reported NN O O
in NN O O
the NN O O
group NN O O
that NN O O
received NN O O
PROMACTA NN O O
and NN O O
three NN O O
thrombotic NN B-AdverseReaction B-AdverseReaction
complications NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
in NN O O
the NN O O
placebo NN B-Factor B-Factor
group NN O O
( NN O O
two NN O O
patients NN O O
) NN O O
. NN O O
All NN O O
of NN O O
the NN O O
thrombotic NN B-AdverseReaction B-AdverseReaction
complications NN I-AdverseReaction I-AdverseReaction
reported NN O O
in NN O O
the NN O O
group NN O O
that NN O O
received NN O O
PROMACTA NN O O
were NN O O
portal NN B-AdverseReaction B-AdverseReaction
vein NN I-AdverseReaction I-AdverseReaction
thrombosis NN I-AdverseReaction I-AdverseReaction
( NN O O
PVT NN O O
) NN O O
. NN O O
Symptoms NN O O
of NN O O
PVT NN B-AdverseReaction B-AdverseReaction
included NN O O
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
and NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
Five NN O O
of NN O O
the NN O O
six NN O O
patients NN O O
in NN O O
the NN O O
group NN O O
that NN O O
received NN O O
PROMACTA NN O O
experienced NN O O
a NN O O
thrombotic NN B-AdverseReaction B-AdverseReaction
complication NN I-AdverseReaction I-AdverseReaction
within NN O O
30 NN O O
days NN O O
of NN O O
completing NN O O
treatment NN O O
with NN O O
PROMACTA NN O O
and NN O O
at NN O O
a NN O O
platelet NN O O
count NN O O
above NN O O
200 NN O O
x NN O O
10 NN O O
9 NN O O
/L. NN O O
The NN O O
risk NN B-Factor B-Factor
of NN O O
portal NN B-AdverseReaction B-AdverseReaction
venous NN I-AdverseReaction I-AdverseReaction
thrombosis NN I-AdverseReaction I-AdverseReaction
was NN O O
increased NN O O
in NN O O
thrombocytopenic NN O O
patients NN O O
with NN O O
chronic NN O O
liver NN O O
disease NN O O
treated NN O O
with NN O O
75 NN O O
mg NN O O
of NN O O
PROMACTA NN O O
once NN O O
daily NN O O
for NN O O
2 NN O O
weeks NN O O
in NN O O
preparation NN O O
for NN O O
invasive NN O O
procedures NN O O
. NN O O
5.4 NN O O
Cataracts NN O O
In NN O O
the NN O O
three NN O O
controlled NN O O
clinical NN O O
trials NN O O
in NN O O
adults NN O O
with NN O O
chronic NN O O
ITP NN O O
, NN O O
cataracts NN B-AdverseReaction B-AdverseReaction
developed NN O O
or NN O O
worsened NN O O
in NN O O
15 NN O O
( NN O O
7 NN O O
% NN O O
) NN O O
patients NN O O
who NN O O
received NN O O
50 NN O O
mg NN O O
of NN O O
PROMACTA NN O O
daily NN O O
and NN O O
8 NN O O
( NN O O
7 NN O O
% NN O O
) NN O O
placebo NN O O
- NN O O
group NN O O
patients NN O O
. NN O O
In NN O O
the NN O O
extension NN O O
trial NN O O
, NN O O
cataracts NN B-AdverseReaction B-AdverseReaction
developed NN O O
or NN O O
worsened NN O O
in NN O O
4 NN O O
% NN O O
of NN O O
patients NN O O
who NN O O
underwent NN O O
ocular NN O O
examination NN O O
prior NN O O
to NN O O
therapy NN O O
with NN O O
PROMACTA. NN O O
In NN O O
the NN O O
two NN O O
controlled NN O O
clinical NN O O
trials NN O O
in NN O O
patients NN O O
with NN O O
chronic NN O O
hepatitis NN O O
C NN O O
and NN O O
thrombocytopenia NN O O
, NN O O
cataracts NN B-AdverseReaction B-AdverseReaction
developed NN O O
or NN O O
worsened NN O O
in NN O O
8 NN O O
% NN O O
patients NN O O
treated NN O O
with NN O O
PROMACTA NN O O
and NN O O
5 NN O O
% NN O O
patients NN O O
treated NN O O
with NN O O
placebo NN O O
. NN O O
Cataracts NN B-AdverseReaction B-AdverseReaction
were NN O O
observed NN O O
in NN O O
toxicology NN O O
studies NN O O
of NN O O
eltrombopag NN O O
in NN O O
rodents NN B-Animal B-Animal
[ NN O O
see NN O O
Nonclinical NN O O
Toxicology NN O O
( NN O O
13.2 NN O O
) NN O O
] NN O O
. NN O O
Perform NN O O
a NN O O
baseline NN O O
ocular NN O O
examination NN O O
prior NN O O
to NN O O
administration NN O O
of NN O O
PROMACTA NN O O
and NN O O
, NN O O
during NN O O
therapy NN O O
with NN O O
PROMACTA NN O O
, NN O O
regularly NN O O
monitor NN O O
patients NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
cataracts NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
serious NN O O
adverse NN O O
reactions NN O O
are NN O O
discussed NN O O
below NN O O
and NN O O
elsewhere NN O O
in NN O O
labeling NN O O
: NN O O
* NN O O
Distant NN B-AdverseReaction B-AdverseReaction
Spread NN I-AdverseReaction I-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
Toxin NN I-AdverseReaction I-AdverseReaction
Effect NN I-AdverseReaction I-AdverseReaction
[ NN O O
seeBoxed NN O O
Warning NN O O
] NN O O
* NN O O
Lack NN O O
of NN O O
Interchangeability NN O O
between NN O O
Botulinum NN O O
Toxin NN O O
Products NN O O
[ NN O O
seeWarnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Spread NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
Effects NN I-AdverseReaction I-AdverseReaction
from NN I-AdverseReaction I-AdverseReaction
Toxin NN I-AdverseReaction I-AdverseReaction
[ NN O O
seeWarnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
Dysphagia NN B-AdverseReaction B-AdverseReaction
and NN O O
Breathing NN B-AdverseReaction B-AdverseReaction
Difficulties NN I-AdverseReaction I-AdverseReaction
[ NN O O
seeWarnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
* NN O O
Facial NN O O
Anatomy NN O O
in NN O O
the NN O O
Treatment NN O O
of NN O O
Glabellar NN O O
Lines NN O O
[ NN O O
seeWarnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
* NN O O
Pre NN O O
- NN O O
existing NN O O
Neuromuscular NN O O
Disorders NN O O
[ NN O O
seeWarnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
* NN O O
Human NN O O
Albumin NN O O
[ NN O O
seeWarnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.6 NN O O
) NN O O
] NN O O
* NN O O
Intradermal NN B-AdverseReaction B-AdverseReaction
Immune NN I-AdverseReaction I-AdverseReaction
Reaction NN I-AdverseReaction I-AdverseReaction
[ NN O O
seeWarnings NN O O
and NN O O
Precautions NN O O
( NN O O
5 NN O O
. NN O O
7 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
Cervical NN O O
Dystonia NN O O
Most NN O O
commonly NN O O
observed NN O O
adverse NN O O
reactions NN O O
( NN O O
> NN O O
5 NN O O
% NN O O
of NN O O
patients NN O O
) NN O O
are NN O O
: NN O O
muscular NN B-AdverseReaction B-AdverseReaction
weakness NN I-AdverseReaction I-AdverseReaction
dysphagia NN B-AdverseReaction B-AdverseReaction
dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
discomfort NN I-AdverseReaction I-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
neck NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
musculoskeletal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
dysphonia NN B-AdverseReaction B-AdverseReaction
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
and NN O O
eye NN B-AdverseReaction B-AdverseReaction
disorders NN I-AdverseReaction I-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
Glabellar NN O O
Lines NN O O
The NN O O
most NN O O
frequently NN O O
reported NN O O
adverse NN O O
reactions NN O O
( NN O O
>=2 NN O O
% NN O O
) NN O O
are NN O O
: NN O O
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
eyelid NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
eyelid NN B-AdverseReaction B-AdverseReaction
ptosis NN I-AdverseReaction I-AdverseReaction
sinusitis NN B-AdverseReaction B-AdverseReaction
and NN O O
nausea NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
Upper NN O O
Limb NN O O
Spasticity NN O O
The NN O O
most NN O O
frequently NN O O
reported NN O O
adverse NN O O
reactions NN O O
( NN O O
>=2 NN O O
% NN O O
) NN O O
are NN O O
: NN O O
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
muscular NN B-AdverseReaction B-AdverseReaction
weakness NN I-AdverseReaction I-AdverseReaction
musculoskeletal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
dizziness NN B-AdverseReaction B-AdverseReaction
fall NN B-AdverseReaction B-AdverseReaction
and NN O O
depression NN B-AdverseReaction B-AdverseReaction
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Ipsen NN O O
Biopharmaceuticals NN O O
, NN O O
Inc. NN O O
at NN O O
877 NN O O
- NN O O
397 NN O O
- NN O O
7671 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
Cervical NN O O
Dystonia NN O O
The NN O O
data NN O O
described NN O O
below NN O O
reflect NN O O
exposure NN O O
to NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
in NN O O
357 NN O O
cervical NN O O
dystonia NN O O
patients NN O O
in NN O O
6 NN O O
studies NN O O
. NN O O
Of NN O O
these NN O O
, NN O O
two NN O O
studies NN O O
were NN O O
randomized NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
single NN O O
treatment NN O O
, NN O O
placebo NN O O
controlled NN O O
studies NN O O
with NN O O
subsequent NN O O
optional NN O O
open NN O O
label NN O O
treatment NN O O
in NN O O
which NN O O
dose NN O O
optimization NN O O
( NN O O
250 NN O O
to NN O O
1000 NN O O
Units NN O O
per NN O O
treatment NN O O
) NN O O
over NN O O
the NN O O
course NN O O
of NN O O
5 NN O O
treatment NN O O
cycles NN O O
was NN O O
allowed NN O O
. NN O O
The NN O O
population NN O O
was NN O O
almost NN O O
entirely NN O O
Caucasian NN O O
( NN O O
99 NN O O
% NN O O
) NN O O
with NN O O
a NN O O
median NN O O
age NN O O
of NN O O
51 NN O O
years NN O O
( NN O O
range NN O O
18 NN O O
- NN O O
82 NN O O
years NN O O
) NN O O
. NN O O
Most NN O O
patients NN O O
( NN O O
87 NN O O
% NN O O
) NN O O
were NN O O
less NN O O
than NN O O
65 NN O O
years NN O O
of NN O O
age NN O O
; NN O O
58.4 NN O O
% NN O O
were NN O O
women NN O O
. NN O O
Common NN O O
Adverse NN O O
Reactions NN O O
The NN O O
most NN O O
commonly NN O O
reported NN O O
adverse NN O O
reactions NN O O
( NN O O
occurring NN O O
in NN O O
more NN O O
than NN O O
5 NN O O
% NN O O
of NN O O
patients NN O O
who NN O O
received NN O O
500 NN O O
Units NN O O
of NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
in NN O O
the NN O O
placebo NN O O
controlled NN O O
clinical NN O O
trials NN O O
) NN O O
in NN O O
cervical NN O O
dystonia NN O O
patients NN O O
were NN O O
: NN O O
muscular NN B-AdverseReaction B-AdverseReaction
weakness NN I-AdverseReaction I-AdverseReaction
dysphagia NN B-AdverseReaction B-AdverseReaction
dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
discomfort NN I-AdverseReaction I-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
neck NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
musculoskeletal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
dysphonia NN B-AdverseReaction B-AdverseReaction
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
and NN O O
eye NN B-AdverseReaction B-AdverseReaction
disorders NN I-AdverseReaction I-AdverseReaction
( NN O O
consisting NN O O
of NN O O
blurred NN B-AdverseReaction B-AdverseReaction
vision NN I-AdverseReaction I-AdverseReaction
diplopia NN B-AdverseReaction B-AdverseReaction
and NN O O
reduced NN B-AdverseReaction B-AdverseReaction
visual NN I-AdverseReaction I-AdverseReaction
acuity NN I-AdverseReaction I-AdverseReaction
and NN O O
accommodation NN O O
) NN O O
. NN O O
Other NN O O
than NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
most NN O O
adverse NN O O
reactions NN O O
became NN O O
noticeable NN O O
about NN O O
one NN O O
week NN O O
after NN O O
treatment NN O O
and NN O O
lasted NN O O
several NN O O
weeks NN O O
. NN O O
The NN O O
rates NN O O
of NN O O
adverse NN O O
reactions NN O O
were NN O O
higher NN O O
in NN O O
the NN O O
combined NN O O
controlled NN O O
and NN O O
open NN O O
- NN O O
label NN O O
experience NN O O
than NN O O
in NN O O
the NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
. NN O O
During NN O O
the NN O O
clinical NN O O
studies NN O O
, NN O O
two NN O O
patients NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
experienced NN O O
adverse NN O O
reactions NN O O
leading NN O O
to NN O O
withdrawal NN O O
. NN O O
One NN O O
patient NN O O
experienced NN O O
disturbance NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
attention NN I-AdverseReaction I-AdverseReaction
eyelid NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
feeling NN B-AdverseReaction B-AdverseReaction
abnormal NN I-AdverseReaction I-AdverseReaction
and NN O O
headache NN B-AdverseReaction B-AdverseReaction
and NN O O
one NN O O
patient NN O O
experienced NN O O
dysphagia NN B-AdverseReaction B-AdverseReaction
Table NN O O
3 NN O O
compares NN O O
the NN O O
incidence NN O O
of NN O O
the NN O O
most NN O O
frequent NN O O
adverse NN O O
reactions NN O O
from NN O O
a NN O O
single NN O O
treatment NN O O
cycle NN O O
of NN O O
500 NN O O
Units NN O O
of NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
compared NN O O
to NN O O
placebo NN O O
[ NN O O
seeClinical NN O O
Studies NN O O
( NN O O
14.1 NN O O
) NN O O
] NN O O
. NN O O
Table NN O O
3 NN O O
: NN O O
Most NN O O
Common NN O O
Adverse NN O O
Reactions NN O O
( NN O O
>5 NN O O
% NN O O
) NN O O
and NN O O
Greater NN O O
than NN O O
Placebo NN O O
in NN O O
the NN O O
Pooled NN O O
, NN O O
Double NN O O
- NN O O
blind NN O O
Phase NN O O
of NN O O
Clinical NN O O
Trials NN O O
in NN O O
Patients NN O O
with NN O O
Cervical NN O O
Dystonia NN O O
Adverse NN O O
Reaction NN O O
Preferred NN O O
Term NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
500 NN O O
Units(N=173 NN O O
) NN O O
Placebo(N=182 NN O O
) NN O O
% NN O O
% NN O O
Any NN O O
Adverse NN O O
Reaction NN O O
61 NN O O
51 NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
30 NN O O
23 NN O O
Injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
discomfort NN I-AdverseReaction I-AdverseReaction
13 NN O O
8 NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
12 NN O O
10 NN O O
Injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
5 NN O O
4 NN O O
Musculoskeletal NN O O
and NN O O
connective NN O O
tissue NN O O
disorders NN O O
30 NN O O
18 NN O O
Muscular NN B-AdverseReaction B-AdverseReaction
weakness NN I-AdverseReaction I-AdverseReaction
16 NN O O
4 NN O O
Musculoskeletal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
7 NN O O
3 NN O O
Gastrointestinal NN O O
disorders NN O O
28 NN O O
15 NN O O
Dysphagia NN B-AdverseReaction B-AdverseReaction
15 NN O O
4 NN O O
Dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
13 NN O O
7 NN O O
Nervous NN O O
system NN O O
disorders NN O O
16 NN O O
13 NN O O
Headache NN B-AdverseReaction B-AdverseReaction
11 NN O O
9 NN O O
Infections NN O O
and NN O O
infestations NN O O
13 NN O O
9 NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
and NN O O
mediastinal NN O O
disorders NN O O
12 NN O O
8 NN O O
Dysphonia NN B-AdverseReaction B-AdverseReaction
6 NN O O
2 NN O O
Eye NN O O
Disorders NN O O
7 NN O O
2 NN O O
Dose NN O O
- NN O O
response NN O O
relationships NN O O
for NN O O
common NN O O
adverse NN O O
reactions NN O O
in NN O O
a NN O O
randomized NN O O
multiple NN O O
fixed NN O O
- NN O O
dose NN O O
study NN O O
in NN O O
which NN O O
the NN O O
total NN O O
dose NN O O
was NN O O
divided NN O O
between NN O O
two NN O O
muscles NN O O
( NN O O
the NN O O
sternocleidomastoid NN O O
and NN O O
splenius NN O O
capitis NN O O
) NN O O
are NN O O
shown NN O O
in NN O O
Table NN O O
4 NN O O
. NN O O
Table NN O O
4 NN O O
: NN O O
Common NN O O
Adverse NN O O
Reactions NN O O
by NN O O
Dose NN O O
in NN O O
Fixed NN O O
- NN O O
dose NN O O
Study NN O O
in NN O O
Patients NN O O
with NN O O
Cervical NN O O
Dystonia NN O O
Adverse NN O O
Reaction NN O O
Preferred NN O O
Term NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
Dose NN O O
Placebo NN O O
250 NN O O
Units NN O O
500 NN O O
Units NN O O
1000 NN O O
Units NN O O
Any NN O O
Adverse NN O O
Event NN O O
30 NN O O
% NN O O
37 NN O O
% NN O O
65 NN O O
% NN O O
83 NN O O
% NN O O
Dysphagia NN B-AdverseReaction B-AdverseReaction
5 NN O O
% NN O O
21 NN O O
% NN O O
29 NN O O
% NN O O
39 NN O O
% NN O O
Dry NN B-AdverseReaction B-AdverseReaction
Mouth NN I-AdverseReaction I-AdverseReaction
10 NN O O
% NN O O
21 NN O O
% NN O O
18 NN O O
% NN O O
39 NN O O
% NN O O
Muscular NN B-AdverseReaction B-AdverseReaction
Weakness NN I-AdverseReaction I-AdverseReaction
0 NN O O
% NN O O
11 NN O O
% NN O O
12 NN O O
% NN O O
56 NN O O
% NN O O
Injection NN B-AdverseReaction B-AdverseReaction
Site NN I-AdverseReaction I-AdverseReaction
Discomfort NN I-AdverseReaction I-AdverseReaction
10 NN O O
% NN O O
5 NN O O
% NN O O
18 NN O O
% NN O O
22 NN O O
% NN O O
Dysphonia NN B-AdverseReaction B-AdverseReaction
0 NN O O
% NN O O
0 NN O O
% NN O O
18 NN O O
% NN O O
28 NN O O
% NN O O
Facial NN B-AdverseReaction B-AdverseReaction
Paresis NN I-AdverseReaction I-AdverseReaction
0 NN O O
% NN O O
5 NN O O
% NN O O
0 NN O O
% NN O O
11 NN O O
% NN O O
Eye NN O O
Disorders NN O O
0 NN O O
% NN O O
0 NN O O
% NN O O
6 NN O O
% NN O O
17 NN O O
% NN O O
Injection NN O O
Site NN O O
Reactions NN O O
Injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
discomfort NN I-AdverseReaction I-AdverseReaction
and NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
were NN O O
common NN O O
adverse NN O O
reactions NN O O
following NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
administration NN O O
. NN O O
Less NN O O
Common NN O O
Adverse NN O O
Reactions NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
were NN O O
reported NN O O
less NN O O
frequently NN O O
( NN O O
< NN O O
5 NN O O
% NN O O
) NN O O
. NN O O
Breathing NN O O
Difficulty NN O O
Breathing NN B-AdverseReaction B-AdverseReaction
difficulties NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
by NN O O
approximately NN O O
3 NN O O
% NN O O
of NN O O
patients NN O O
following NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
administration NN O O
and NN O O
in NN O O
1 NN O O
% NN O O
of NN O O
placebo NN O O
patients NN O O
in NN O O
clinical NN O O
trials NN O O
during NN O O
the NN O O
double NN O O
- NN O O
blind NN O O
phase NN O O
. NN O O
These NN O O
consisted NN O O
mainly NN O O
of NN O O
dyspnea NN B-AdverseReaction B-AdverseReaction
The NN O O
median NN O O
time NN O O
to NN O O
onset NN O O
from NN O O
last NN O O
dose NN O O
of NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
was NN O O
approximately NN O O
one NN O O
week NN O O
, NN O O
and NN O O
the NN O O
median NN O O
duration NN O O
was NN O O
approximately NN O O
three NN O O
weeks NN O O
. NN O O
Other NN O O
adverse NN O O
reactions NN O O
with NN O O
incidences NN O O
of NN O O
less NN O O
than NN O O
5 NN O O
% NN O O
in NN O O
the NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
500 NN O O
Units NN O O
group NN O O
in NN O O
the NN O O
double NN O O
- NN O O
blind NN O O
phase NN O O
of NN O O
clinical NN O O
trials NN O O
included NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
in NN O O
3.5 NN O O
% NN O O
of NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
-treated NN O O
patients NN O O
and NN O O
1 NN O O
% NN O O
of NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
, NN O O
and NN O O
muscle NN B-AdverseReaction B-AdverseReaction
atrophy NN I-AdverseReaction I-AdverseReaction
in NN O O
1 NN O O
% NN O O
of NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
-treated NN O O
patients NN O O
and NN O O
in NN O O
none NN O O
of NN O O
the NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Laboratory NN O O
Findings NN O O
Patients NN O O
treated NN O O
with NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
exhibited NN O O
a NN O O
small NN B-Severity B-Severity
increase NN O O
from NN O O
baseline NN O O
( NN O O
0.23 NN O O
mol/L NN O O
) NN O O
in NN O O
mean NN O O
blood NN O O
glucose NN O O
relative NN O O
to NN O O
placebo- NN O O
treated NN O O
patients NN O O
. NN O O
This NN O O
was NN O O
not NN O O
clinically NN O O
significant NN O O
among NN O O
patients NN O O
in NN O O
the NN O O
development NN O O
program NN O O
but NN O O
could NN O O
be NN O O
a NN O O
factor NN O O
in NN O O
patients NN O O
whose NN O O
diabetes NN O O
is NN O O
difficult NN O O
to NN O O
control NN O O
. NN O O
Electrocardiographic NN O O
Findings NN O O
ECG NN O O
measurements NN O O
were NN O O
only NN O O
recorded NN O O
in NN O O
a NN O O
limited NN O O
number NN O O
of NN O O
patients NN O O
in NN O O
an NN O O
open NN O O
- NN O O
label NN O O
study NN O O
without NN O O
a NN O O
placebo NN O O
or NN O O
active NN O O
control NN O O
. NN O O
This NN O O
study NN O O
showed NN O O
a NN O O
statistically NN O O
significant NN O O
reduction NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
heart NN I-AdverseReaction I-AdverseReaction
rate NN I-AdverseReaction I-AdverseReaction
compared NN O O
to NN O O
baseline NN O O
, NN O O
averaging NN O O
about NN O O
three NN O O
beats NN O O
per NN O O
minute NN O O
, NN O O
observed NN O O
thirty NN O O
minutes NN O O
after NN O O
injection NN O O
. NN O O
Glabellar NN O O
Lines NN O O
In NN O O
placebo NN O O
- NN O O
controlled NN O O
clinical NN O O
trials NN O O
of NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
, NN O O
the NN O O
most NN O O
common NN O O
adverse NN O O
reactions(>=2 NN O O
% NN O O
) NN O O
following NN O O
injection NN O O
of NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
were NN O O
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
eyelid NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
eyelid NN B-AdverseReaction B-AdverseReaction
ptosis NN I-AdverseReaction I-AdverseReaction
sinusitis NN B-AdverseReaction B-AdverseReaction
and NN O O
nausea NN B-AdverseReaction B-AdverseReaction
Table NN O O
5 NN O O
reflects NN O O
exposure NN O O
to NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
in NN O O
398 NN O O
patients NN O O
19 NN O O
to NN O O
75 NN O O
years NN O O
of NN O O
age NN O O
who NN O O
were NN O O
evaluated NN O O
in NN O O
the NN O O
randomized NN O O
, NN O O
placebo- NN O O
controlled NN O O
clinical NN O O
studies NN O O
that NN O O
assessed NN O O
the NN O O
use NN O O
of NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
for NN O O
the NN O O
temporary NN O O
improvement NN O O
in NN O O
the NN O O
appearance NN O O
of NN O O
glabellar NN O O
lines NN O O
[ NN O O
seeClinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
. NN O O
Adverse NN O O
reactions NN O O
of NN O O
any NN O O
cause NN O O
occurred NN O O
in NN O O
48 NN O O
% NN O O
of NN O O
the NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
-treated NN O O
patients NN O O
and NN O O
33 NN O O
% NN O O
of NN O O
the NN O O
placebo- NN O O
treated NN O O
patients NN O O
. NN O O
Table NN O O
5 NN O O
: NN O O
Most NN O O
Common NN O O
Adverse NN O O
Reactions NN O O
with NN O O
> NN O O
1 NN O O
% NN O O
Incidence NN O O
in NN O O
Pooled NN O O
, NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Trials NN O O
for NN O O
Glabellar NN O O
Lines NN O O
Adverse NN O O
Reactions NN O O
by NN O O
Body NN O O
System NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
n=398 NN O O
( NN O O
% NN O O
) NN O O
Placebon=496 NN O O
( NN O O
% NN O O
) NN O O
Any NN O O
Adverse NN O O
Reaction NN O O
48 NN O O
33 NN O O
Eye NN O O
Disorders NN O O
Eyelid NN B-AdverseReaction B-AdverseReaction
Edema NN I-AdverseReaction I-AdverseReaction
2 NN O O
0 NN O O
Eyelid NN B-AdverseReaction B-AdverseReaction
Ptosis NN I-AdverseReaction I-AdverseReaction
2 NN O O
< NN O O
1 NN O O
Gastrointestinal NN O O
Disorders NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
2 NN O O
1 NN O O
General NN O O
Disorders NN O O
and NN O O
Administration NN O O
Site NN O O
Conditions NN O O
Injection NN B-AdverseReaction B-AdverseReaction
Site NN I-AdverseReaction I-AdverseReaction
Pain NN I-AdverseReaction I-AdverseReaction
3 NN O O
2 NN O O
Injection NN B-AdverseReaction B-AdverseReaction
Site NN I-AdverseReaction I-AdverseReaction
Reaction NN I-AdverseReaction I-AdverseReaction
3 NN O O
< NN O O
1 NN O O
Infections NN O O
and NN O O
Infestations NN O O
Nasopharyngitis NN B-AdverseReaction B-AdverseReaction
10 NN O O
4 NN O O
Upper NN B-AdverseReaction B-AdverseReaction
Respiratory NN I-AdverseReaction I-AdverseReaction
Tract NN I-AdverseReaction I-AdverseReaction
Infection NN I-AdverseReaction I-AdverseReaction
3 NN O O
2 NN O O
Sinusitis NN B-AdverseReaction B-AdverseReaction
2 NN O O
1 NN O O
Investigations NN O O
Blood NN B-AdverseReaction B-AdverseReaction
Present NN I-AdverseReaction I-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
Urine NN I-AdverseReaction I-AdverseReaction
2 NN O O
< NN O O
1 NN O O
Nervous NN O O
System NN O O
Disorders NN O O
Headache NN B-AdverseReaction B-AdverseReaction
9 NN O O
5 NN O O
In NN O O
the NN O O
overall NN O O
safety NN O O
database NN O O
, NN O O
where NN O O
some NN O O
patients NN O O
received NN O O
up NN O O
to NN O O
twelve NN O O
treatments NN O O
with NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
, NN O O
adverse NN O O
reactions NN O O
were NN O O
reported NN O O
for NN O O
57 NN O O
% NN O O
( NN O O
1425/2491 NN O O
) NN O O
of NN O O
patients NN O O
. NN O O
The NN O O
most NN O O
frequently NN O O
reported NN O O
of NN O O
these NN O O
adverse NN O O
reactions NN O O
were NN O O
headache NN B-AdverseReaction B-AdverseReaction
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
sinusitis NN B-AdverseReaction B-AdverseReaction
URI NN B-AdverseReaction B-AdverseReaction
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
bruising NN I-AdverseReaction I-AdverseReaction
and NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
( NN O O
numbness NN O O
, NN O O
discomfort NN O O
, NN O O
erythema NN O O
, NN O O
tenderness NN O O
, NN O O
tingling NN O O
, NN O O
itching NN O O
, NN O O
stinging NN O O
, NN O O
warmth NN O O
, NN O O
irritation NN O O
, NN O O
tightness NN O O
, NN O O
swelling NN O O
) NN O O
. NN O O
Adverse NN O O
reactions NN O O
that NN O O
occurred NN O O
after NN O O
repeated NN O O
injections NN O O
in NN O O
2 NN O O
- NN O O
3 NN O O
% NN O O
of NN O O
the NN O O
population NN O O
included NN O O
bronchitis NN B-AdverseReaction B-AdverseReaction
influenza NN B-AdverseReaction B-AdverseReaction
pharyngolaryngeal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
contact NN B-AdverseReaction B-AdverseReaction
dermatitis NN I-AdverseReaction I-AdverseReaction
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
swelling NN I-AdverseReaction I-AdverseReaction
and NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
discomfort NN I-AdverseReaction I-AdverseReaction
The NN O O
incidence NN O O
of NN O O
eyelid NN B-AdverseReaction B-AdverseReaction
ptosis NN I-AdverseReaction I-AdverseReaction
did NN O O
not NN O O
increase NN O O
in NN O O
the NN O O
long NN O O
- NN O O
term NN O O
safety NN O O
studies NN O O
with NN O O
multiple NN O O
re NN O O
- NN O O
treatments NN O O
at NN O O
intervals NN O O
>= NN O O
three NN O O
months NN O O
. NN O O
The NN O O
majority NN O O
of NN O O
the NN O O
reports NN O O
of NN O O
eyelid NN B-AdverseReaction B-AdverseReaction
ptosis NN I-AdverseReaction I-AdverseReaction
were NN O O
mild NN B-Severity B-Severity
to NN O O
moderate NN B-Severity B-Severity
in NN O O
severity NN O O
and NN O O
resolved NN O O
over NN O O
several NN O O
weeks NN O O
. NN O O
[ NN O O
seeDosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
] NN O O
. NN O O
Upper NN O O
Limb NN O O
Spasticity NN O O
Table NN O O
6 NN O O
lists NN O O
the NN O O
most NN O O
frequently NN O O
reported NN O O
adverse NN O O
reactions NN O O
( NN O O
>=2 NN O O
% NN O O
) NN O O
in NN O O
any NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
dose NN O O
group NN O O
and NN O O
more NN O O
frequent NN O O
than NN O O
placebo NN O O
in NN O O
double NN O O
blind NN O O
studies NN O O
evaluating NN O O
the NN O O
treatment NN O O
of NN O O
upper NN O O
limb NN O O
spasticity NN O O
in NN O O
adults NN O O
with NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
. NN O O
Table NN O O
6 NN O O
: NN O O
Most NN O O
Common NN O O
Adverse NN O O
Reactions NN O O
Observed NN O O
in NN O O
at NN O O
Least NN O O
2 NN O O
% NN O O
of NN O O
Patients NN O O
Treated NN O O
in NN O O
Pooled NN O O
, NN O O
Double NN O O
- NN O O
Blind NN O O
Trials NN O O
of NN O O
Patients NN O O
with NN O O
Upper NN O O
Limb NN O O
Spasticity NN O O
Reported NN O O
More NN O O
Frequently NN O O
than NN O O
with NN O O
Placebo NN O O
Adverse NN O O
Reaction NN O O
Preferred NN O O
Term NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
Placebo NN O O
500 NN O O
Units(N=197 NN O O
) NN O O
% NN O O
1000 NN O O
Units(N=194 NN O O
) NN O O
% NN O O
( NN O O
N=279 NN O O
) NN O O
% NN O O
Infections NN O O
and NN O O
infestations NN O O
Nasopharyngitis NN B-AdverseReaction B-AdverseReaction
4 NN O O
1 NN O O
1 NN O O
Urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
3 NN O O
1 NN O O
2 NN O O
Influenza NN B-AdverseReaction B-AdverseReaction
1 NN O O
2 NN O O
1 NN O O
Infection NN B-AdverseReaction B-AdverseReaction
1 NN O O
2 NN O O
1 NN O O
Musculoskeletal NN O O
and NN O O
connective NN O O
tissue NN O O
disorders NN O O
Muscular NN B-AdverseReaction B-AdverseReaction
weakness NN I-AdverseReaction I-AdverseReaction
2 NN O O
4 NN O O
1 NN O O
Pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
0 NN O O
2 NN O O
1 NN O O
Musculoskeletal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
3 NN O O
2 NN O O
2 NN O O
Back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
1 NN O O
2 NN O O
1 NN O O
Nervous NN O O
system NN O O
disorders NN O O
Headache NN B-AdverseReaction B-AdverseReaction
1 NN O O
2 NN O O
1 NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
3 NN O O
1 NN O O
1 NN O O
Convulsion NN B-AdverseReaction B-AdverseReaction
2 NN O O
2 NN O O
1 NN O O
Syncope NN B-AdverseReaction B-AdverseReaction
1 NN O O
2 NN O O
0 NN O O
Hypoaesthesia NN B-AdverseReaction B-AdverseReaction
0 NN O O
2 NN O O
< NN O O
1 NN O O
Partial NN B-AdverseReaction B-AdverseReaction
seizures NN I-AdverseReaction I-AdverseReaction
0 NN O O
2 NN O O
0 NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
2 NN O O
2 NN O O
0 NN O O
Asthenia NN B-AdverseReaction B-AdverseReaction
2 NN O O
1 NN O O
< NN O O
1 NN O O
Injury NN O O
, NN O O
poisoning NN O O
and NN O O
procedural NN O O
complications NN O O
Fall NN B-AdverseReaction B-AdverseReaction
2 NN O O
3 NN O O
2 NN O O
Injury NN B-AdverseReaction B-AdverseReaction
2 NN O O
2 NN O O
1 NN O O
Contusion NN B-AdverseReaction B-AdverseReaction
1 NN O O
2 NN O O
< NN O O
1 NN O O
Gastrointestinal NN O O
disorders NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
1 NN O O
2 NN O O
< NN O O
1 NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
2 NN O O
1 NN O O
1 NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
0 NN O O
2 NN O O
1 NN O O
Investigation NN O O
Blood NN B-AdverseReaction B-AdverseReaction
triglycerides NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
2 NN O O
1 NN O O
0 NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
and NN O O
mediastinal NN O O
disorders NN O O
Cough NN B-AdverseReaction B-AdverseReaction
1 NN O O
2 NN O O
1 NN O O
Vascular NN O O
disorders NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
1 NN O O
2 NN O O
< NN O O
1 NN O O
Psychiatric NN O O
disorders NN O O
Depression NN B-AdverseReaction B-AdverseReaction
2 NN O O
3 NN O O
1 NN O O
Injection NN O O
Site NN O O
Reactions NN O O
Injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
( NN O O
e.g. NN O O
pain NN O O
, NN O O
bruising NN O O
, NN O O
haemorrhage NN O O
, NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
erythema NN I-AdverseReaction I-AdverseReaction
etc NN O O
. NN O O
) NN O O
have NN O O
occurred NN O O
following NN O O
administration NN O O
of NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
. NN O O
Less NN O O
Common NN O O
Adverse NN O O
Reactions NN O O
In NN O O
a NN O O
pooled NN O O
analysis NN O O
of NN O O
clinical NN O O
studies NN O O
, NN O O
adverse NN O O
reactions NN O O
with NN O O
an NN O O
incidence NN O O
of NN O O
less NN O O
than NN O O
2 NN O O
% NN O O
reported NN O O
in NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
treatment NN O O
groups NN O O
included NN O O
dysphagia NN B-AdverseReaction B-AdverseReaction
0.5 NN O O
% NN O O
, NN O O
gait NN B-AdverseReaction B-AdverseReaction
disturbance NN I-AdverseReaction I-AdverseReaction
0.5 NN O O
% NN O O
, NN O O
hypertonia NN B-AdverseReaction B-AdverseReaction
0.5 NN O O
% NN O O
, NN O O
and NN O O
sensation NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
heaviness NN I-AdverseReaction I-AdverseReaction
0.3 NN O O
% NN O O
. NN O O
6.2 NN O O
Postmarketing NN O O
Experience NN O O
Because NN O O
adverse NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
identified NN O O
during NN O O
post NN O O
- NN O O
approval NN O O
use NN O O
of NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
: NN O O
vertigo NN B-AdverseReaction B-AdverseReaction
photophobia NN B-AdverseReaction B-AdverseReaction
influenza NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
like NN I-AdverseReaction I-AdverseReaction
illness NN I-AdverseReaction I-AdverseReaction
amyotrophy NN B-AdverseReaction B-AdverseReaction
burning NN B-AdverseReaction B-AdverseReaction
sensation NN I-AdverseReaction I-AdverseReaction
facial NN B-AdverseReaction B-AdverseReaction
paresis NN I-AdverseReaction I-AdverseReaction
hypoesthesia NN B-AdverseReaction B-AdverseReaction
erythema NN B-AdverseReaction B-AdverseReaction
and NN O O
excessive NN B-AdverseReaction B-AdverseReaction
granulation NN I-AdverseReaction I-AdverseReaction
tissue NN I-AdverseReaction I-AdverseReaction
6.3 NN O O
Immunogenicity NN O O
As NN O O
with NN O O
all NN O O
therapeutic NN O O
proteins NN O O
, NN O O
there NN O O
is NN O O
a NN O O
potential NN O O
for NN O O
immunogenicity NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
antibody NN O O
formation NN O O
is NN O O
highly NN O O
dependent NN O O
on NN O O
the NN O O
sensitivity NN O O
and NN O O
specificity NN O O
of NN O O
the NN O O
assay NN O O
. NN O O
In NN O O
addition NN O O
, NN O O
the NN O O
observed NN O O
incidence NN O O
of NN O O
antibody NN O O
positivity NN O O
in NN O O
an NN O O
assay NN O O
may NN O O
be NN O O
influenced NN O O
by NN O O
several NN O O
factors NN O O
including NN O O
assay NN O O
methodology NN O O
, NN O O
sample NN O O
handling NN O O
, NN O O
timing NN O O
of NN O O
sample NN O O
collection NN O O
, NN O O
concomitant NN O O
medications NN O O
, NN O O
and NN O O
underlying NN O O
disease NN O O
. NN O O
For NN O O
these NN O O
reasons NN O O
, NN O O
comparison NN O O
of NN O O
the NN O O
incidence NN O O
of NN O O
antibodies NN O O
across NN O O
products NN O O
in NN O O
this NN O O
class NN O O
may NN O O
be NN O O
misleading NN O O
. NN O O
Cervical NN O O
Dystonia NN O O
About NN O O
3 NN O O
% NN O O
of NN O O
subjects NN O O
developed NN O O
antibodies NN O O
( NN O O
binding NN O O
or NN O O
neutralizing NN O O
) NN O O
over NN O O
time NN O O
with NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
treatment NN O O
. NN O O
Glabellar NN O O
Lines NN O O
Testing NN O O
for NN O O
antibodies NN O O
to NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
was NN O O
performed NN O O
for NN O O
1554 NN O O
subjects NN O O
who NN O O
had NN O O
up NN O O
to NN O O
nine NN O O
cycles NN O O
of NN O O
treatment NN O O
. NN O O
Two NN O O
subjects NN O O
( NN O O
0.13 NN O O
% NN O O
) NN O O
tested NN O O
positive NN O O
for NN O O
binding NN O O
antibodies NN O O
at NN O O
baseline NN O O
. NN O O
Three NN O O
additional NN O O
subjects NN O O
tested NN O O
positive NN O O
for NN O O
binding NN O O
antibodies NN O O
after NN O O
receiving NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
treatment NN O O
. NN O O
None NN O O
of NN O O
the NN O O
subjects NN O O
tested NN O O
positive NN O O
for NN O O
neutralizing NN O O
antibodies NN O O
. NN O O
Upper NN O O
Limb NN O O
Spasticity NN O O
From NN O O
230 NN O O
subjects NN O O
treated NN O O
with NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
and NN O O
tested NN O O
for NN O O
the NN O O
presence NN O O
of NN O O
binding NN O O
antibodies NN O O
, NN O O
5 NN O O
subjects NN O O
were NN O O
positive NN O O
at NN O O
baseline NN O O
and NN O O
17 NN O O
developed NN O O
antibodies NN O O
after NN O O
treatment NN O O
. NN O O
Among NN O O
those NN O O
17 NN O O
subjects NN O O
, NN O O
10 NN O O
subjects NN O O
developed NN O O
neutralizing NN O O
antibodies NN O O
. NN O O
An NN O O
additional NN O O
51 NN O O
subjects NN O O
from NN O O
a NN O O
separate NN O O
repeat NN O O
dose NN O O
study NN O O
were NN O O
tested NN O O
for NN O O
the NN O O
presence NN O O
of NN O O
neutralizing NN O O
antibodies NN O O
only NN O O
. NN O O
None NN O O
of NN O O
the NN O O
subjects NN O O
tested NN O O
positive NN O O
. NN O O
In NN O O
total NN O O
, NN O O
from NN O O
the NN O O
281 NN O O
subjects NN O O
treated NN O O
in NN O O
the NN O O
long NN O O
- NN O O
term NN O O
studies NN O O
and NN O O
tested NN O O
for NN O O
the NN O O
presence NN O O
of NN O O
neutralizing NN O O
antibodies NN O O
, NN O O
3.6 NN O O
% NN O O
developed NN O O
neutralizing NN O O
antibodies NN O O
after NN O O
treatment NN O O
. NN O O
In NN O O
the NN O O
presence NN O O
of NN O O
binding NN O O
and NN O O
neutralizing NN O O
antibodies NN O O
to NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
some NN O O
patients NN O O
continue NN O O
to NN O O
experience NN O O
clinical NN O O
benefit NN O O
. NN O O
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
DISTANT NN B-AdverseReaction B-AdverseReaction
SPREAD NN I-AdverseReaction I-AdverseReaction
OF NN I-AdverseReaction I-AdverseReaction
TOXIN NN I-AdverseReaction I-AdverseReaction
EFFECT NN I-AdverseReaction I-AdverseReaction
WARNING NN O O
: NN O O
DISTANT NN B-AdverseReaction B-AdverseReaction
SPREAD NN I-AdverseReaction I-AdverseReaction
OF NN I-AdverseReaction I-AdverseReaction
TOXIN NN I-AdverseReaction I-AdverseReaction
EFFECT NN I-AdverseReaction I-AdverseReaction
Postmarketing NN O O
reports NN O O
indicate NN O O
that NN O O
the NN O O
effects NN O O
of NN O O
DYSPORT(r NN O O
) NN O O
and NN O O
all NN O O
botulinum NN O O
toxin NN O O
products NN O O
may NN B-Factor B-Factor
spread NN O O
from NN O O
the NN O O
area NN O O
of NN O O
injection NN O O
to NN O O
produce NN O O
symptoms NN O O
consistent NN O O
with NN O O
botulinum NN O O
toxin NN O O
effects NN O O
. NN O O
These NN O O
may NN B-Factor B-Factor
include NN O O
asthenia NN B-AdverseReaction B-AdverseReaction
generalized NN B-AdverseReaction B-AdverseReaction
muscle NN I-AdverseReaction I-AdverseReaction
weakness NN I-AdverseReaction I-AdverseReaction
diplopia NN B-AdverseReaction B-AdverseReaction
blurred NN B-AdverseReaction B-AdverseReaction
vision NN I-AdverseReaction I-AdverseReaction
ptosis NN B-AdverseReaction B-AdverseReaction
dysphagia NN B-AdverseReaction B-AdverseReaction
dysphonia NN B-AdverseReaction B-AdverseReaction
dysarthria NN B-AdverseReaction B-AdverseReaction
urinary NN B-AdverseReaction B-AdverseReaction
incontinence NN I-AdverseReaction I-AdverseReaction
and NN O O
breathing NN B-AdverseReaction B-AdverseReaction
difficulties NN I-AdverseReaction I-AdverseReaction
These NN O O
symptoms NN O O
have NN O O
been NN O O
reported NN O O
hours NN O O
to NN O O
weeks NN O O
after NN O O
injection NN O O
. NN O O
Swallowing NN O O
and NN O O
breathing NN B-AdverseReaction B-AdverseReaction
difficulties NN I-AdverseReaction I-AdverseReaction
can NN O O
be NN O O
life NN O O
threatening NN O O
and NN O O
there NN O O
have NN O O
been NN O O
reports NN O O
of NN O O
death NN B-AdverseReaction B-AdverseReaction
The NN O O
risk NN O O
of NN O O
symptoms NN O O
is NN O O
probably NN O O
greatest NN O O
in NN O O
children NN O O
treated NN O O
for NN O O
spasticity NN O O
but NN O O
symptoms NN O O
can NN O O
also NN O O
occur NN O O
in NN O O
adults NN O O
treated NN O O
for NN O O
spasticity NN O O
and NN O O
other NN O O
conditions NN O O
, NN O O
particularly NN O O
in NN O O
those NN O O
patients NN O O
who NN O O
have NN O O
underlying NN O O
conditions NN O O
that NN O O
would NN O O
predispose NN O O
them NN O O
to NN O O
these NN O O
symptoms NN O O
. NN O O
In NN O O
unapproved NN O O
uses NN O O
, NN O O
including NN O O
spasticity NN O O
in NN O O
children NN O O
, NN O O
and NN O O
in NN O O
approved NN O O
indications NN O O
, NN O O
cases NN O O
of NN O O
spread NN O O
of NN O O
effect NN O O
have NN O O
been NN O O
reported NN O O
at NN O O
doses NN O O
comparable NN O O
to NN O O
or NN O O
lower NN O O
than NN O O
the NN O O
maximum NN O O
recommended NN O O
total NN O O
dose NN O O
. NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
WARNING NN O O
: NN O O
DISTANT NN B-AdverseReaction B-AdverseReaction
SPREAD NN I-AdverseReaction I-AdverseReaction
OF NN I-AdverseReaction I-AdverseReaction
TOXIN NN I-AdverseReaction I-AdverseReaction
EFFECT NN I-AdverseReaction I-AdverseReaction
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
The NN O O
effects NN O O
of NN O O
DYSPORT(r NN O O
) NN O O
and NN O O
all NN O O
botulinum NN O O
toxin NN O O
products NN O O
may NN B-Factor B-Factor
spread NN O O
from NN O O
the NN O O
area NN O O
of NN O O
injection NN O O
to NN O O
produce NN O O
symptoms NN O O
consistent NN O O
with NN O O
botulinum NN O O
toxin NN O O
effects NN O O
. NN O O
These NN O O
symptoms NN O O
have NN O O
been NN O O
reported NN O O
hours NN O O
to NN O O
weeks NN O O
after NN O O
injection NN O O
. NN O O
Swallowing NN O O
and NN O O
breathing NN B-AdverseReaction B-AdverseReaction
difficulties NN I-AdverseReaction I-AdverseReaction
can NN O O
be NN O O
life NN O O
threatening NN O O
and NN O O
there NN O O
have NN O O
been NN O O
reports NN O O
of NN O O
death NN B-AdverseReaction B-AdverseReaction
The NN O O
risk NN O O
of NN O O
symptoms NN O O
is NN O O
probably NN O O
greatest NN O O
in NN O O
children NN O O
treated NN O O
for NN O O
spasticity NN O O
but NN O O
symptoms NN O O
can NN O O
also NN O O
occur NN O O
in NN O O
adults NN O O
, NN O O
particularly NN O O
in NN O O
those NN O O
patients NN O O
who NN O O
have NN O O
underlying NN O O
conditions NN O O
that NN O O
would NN O O
predispose NN O O
them NN O O
to NN O O
these NN O O
symptoms NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
The NN O O
potency NN O O
Units NN O O
of NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
are NN O O
not NN O O
interchangeable NN O O
with NN O O
other NN O O
preparations NN O O
of NN O O
botulinum NN O O
toxin NN O O
products NN O O
and NN O O
, NN O O
therefore NN O O
, NN O O
units NN O O
of NN O O
biological NN O O
activity NN O O
of NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
can NN O O
not NN O O
be NN O O
compared NN O O
to NN O O
or NN O O
converted NN O O
into NN O O
units NN O O
of NN O O
any NN O O
other NN O O
botulinum NN O O
toxin NN O O
products NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Recommended NN O O
dose NN O O
and NN O O
frequency NN O O
of NN O O
administration NN O O
should NN O O
not NN O O
be NN O O
exceeded NN O O
( NN O O
5.4 NN O O
) NN O O
* NN O O
Immediate NN O O
medical NN O O
attention NN O O
may NN O O
be NN O O
required NN O O
in NN O O
cases NN O O
of NN O O
respiratory NN O O
, NN O O
speech NN O O
or NN O O
swallowing NN B-AdverseReaction B-AdverseReaction
difficulties NN I-AdverseReaction I-AdverseReaction
( NN O O
5.3 NN O O
) NN O O
* NN O O
Concomitant NN O O
neuromuscular NN O O
disorder NN O O
may NN O O
exacerbate NN O O
clinical NN O O
effects NN O O
of NN O O
treatment NN O O
( NN O O
5.5 NN O O
) NN O O
* NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
contains NN O O
human NN O O
albumin NN O O
. NN O O
There NN O O
is NN O O
a NN O O
risk NN B-Factor B-Factor
for NN O O
transmission NN O O
of NN O O
Creutzfeldt NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Jakob NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
( NN O O
CJD NN O O
) NN O O
however NN O O
, NN O O
no NN O O
cases NN O O
of NN O O
transmission NN O O
of NN O O
viral NN B-AdverseReaction B-AdverseReaction
diseases NN I-AdverseReaction I-AdverseReaction
or NN O O
CJD NN B-AdverseReaction B-AdverseReaction
have NN O O
ever NN O O
been NN O O
identified NN O O
for NN O O
albumin NN O O
( NN O O
5.6 NN O O
) NN O O
5.1 NN O O
Lack NN O O
of NN O O
Interchangeability NN O O
between NN O O
Botulinum NN O O
Toxin NN O O
Products NN O O
The NN O O
potency NN O O
Units NN O O
of NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
are NN O O
specific NN O O
to NN O O
the NN O O
preparation NN O O
and NN O O
assay NN O O
method NN O O
utilized NN O O
. NN O O
They NN O O
are NN O O
not NN O O
interchangeable NN O O
with NN O O
other NN O O
preparations NN O O
of NN O O
botulinum NN O O
toxin NN O O
products NN O O
and NN O O
, NN O O
therefore NN O O
, NN O O
units NN O O
of NN O O
biological NN O O
activity NN O O
of NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
can NN O O
not NN O O
be NN O O
compared NN O O
to NN O O
or NN O O
converted NN O O
into NN O O
units NN O O
of NN O O
any NN O O
other NN O O
botulinum NN O O
toxin NN O O
products NN O O
assessed NN O O
with NN O O
any NN O O
other NN O O
specific NN O O
assay NN O O
method NN O O
[ NN O O
seeDescription NN O O
( NN O O
11 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
Spread NN O O
of NN O O
Toxin NN O O
Effect NN O O
Post NN O O
- NN O O
marketing NN O O
safety NN O O
data NN O O
from NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
and NN O O
other NN O O
approved NN O O
botulinum NN O O
toxins NN O O
suggest NN O O
that NN O O
botulinum NN O O
toxin NN O O
effects NN O O
may NN B-Factor B-Factor
in NN O O
some NN O O
cases NN O O
, NN O O
be NN O O
observed NN O O
beyond NN O O
the NN O O
site NN O O
of NN O O
local NN O O
injection NN O O
. NN O O
The NN O O
symptoms NN O O
are NN O O
consistent NN O O
with NN O O
the NN O O
mechanism NN O O
of NN O O
action NN O O
of NN O O
botulinum NN O O
toxin NN O O
and NN O O
may NN B-Factor B-Factor
include NN O O
asthenia NN B-AdverseReaction B-AdverseReaction
generalized NN B-AdverseReaction B-AdverseReaction
muscle NN I-AdverseReaction I-AdverseReaction
weakness NN I-AdverseReaction I-AdverseReaction
diplopia NN B-AdverseReaction B-AdverseReaction
blurred NN B-AdverseReaction B-AdverseReaction
vision NN I-AdverseReaction I-AdverseReaction
ptosis NN B-AdverseReaction B-AdverseReaction
dysphagia NN B-AdverseReaction B-AdverseReaction
dysphonia NN B-AdverseReaction B-AdverseReaction
dysarthria NN B-AdverseReaction B-AdverseReaction
urinary NN B-AdverseReaction B-AdverseReaction
incontinence NN I-AdverseReaction I-AdverseReaction
and NN O O
breathing NN B-AdverseReaction B-AdverseReaction
difficulties NN I-AdverseReaction I-AdverseReaction
These NN O O
symptoms NN O O
have NN O O
been NN O O
reported NN O O
hours NN O O
to NN O O
weeks NN O O
after NN O O
injection NN O O
. NN O O
Swallowing NN O O
and NN O O
breathing NN B-AdverseReaction B-AdverseReaction
difficulties NN I-AdverseReaction I-AdverseReaction
can NN O O
be NN O O
life NN O O
threatening NN O O
and NN O O
there NN O O
have NN O O
been NN O O
reports NN O O
of NN O O
death NN B-AdverseReaction B-AdverseReaction
related NN O O
to NN O O
spread NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
toxin NN I-AdverseReaction I-AdverseReaction
effects NN I-AdverseReaction I-AdverseReaction
The NN O O
risk NN O O
of NN O O
the NN O O
symptoms NN O O
is NN O O
probably NN O O
greatest NN O O
in NN O O
children NN O O
treated NN O O
for NN O O
spasticity NN O O
but NN O O
symptoms NN O O
can NN O O
also NN O O
occur NN O O
in NN O O
adults NN O O
treated NN O O
for NN O O
spasticity NN O O
and NN O O
other NN O O
conditions NN O O
, NN O O
and NN O O
particularly NN O O
in NN O O
those NN O O
patients NN O O
who NN O O
have NN O O
underlying NN O O
conditions NN O O
that NN O O
would NN O O
predispose NN O O
them NN O O
to NN O O
these NN O O
symptoms NN O O
. NN O O
In NN O O
unapproved NN O O
uses NN O O
, NN O O
including NN O O
spasticity NN O O
in NN O O
children NN O O
and NN O O
in NN O O
approved NN O O
indications NN O O
, NN O O
symptoms NN O O
consistent NN O O
with NN O O
spread NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
toxin NN I-AdverseReaction I-AdverseReaction
effect NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
at NN O O
doses NN O O
comparable NN O O
to NN O O
or NN O O
lower NN O O
than NN O O
the NN O O
maximum NN O O
recommended NN O O
total NN O O
dose NN O O
. NN O O
5.3 NN O O
Dysphagia NN O O
and NN O O
Breathing NN O O
Difficulties NN O O
Treatment NN O O
with NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
and NN O O
other NN O O
botulinum NN O O
toxin NN O O
products NN O O
can NN B-Factor B-Factor
result NN O O
in NN O O
swallowing NN O O
or NN O O
breathing NN B-AdverseReaction B-AdverseReaction
difficulties NN I-AdverseReaction I-AdverseReaction
Patients NN O O
with NN O O
pre- NN O O
existing NN O O
swallowing NN O O
or NN O O
breathing NN O O
difficulties NN O O
may NN O O
be NN O O
more NN O O
susceptible NN O O
to NN O O
these NN O O
complications NN O O
. NN O O
In NN O O
most NN O O
cases NN O O
, NN O O
this NN O O
is NN O O
a NN O O
consequence NN O O
of NN O O
weakening NN O O
of NN O O
muscles NN O O
in NN O O
the NN O O
area NN O O
of NN O O
injection NN O O
that NN O O
are NN O O
involved NN O O
in NN O O
breathing NN O O
or NN O O
swallowing NN O O
. NN O O
When NN O O
distant NN O O
effects NN O O
occur NN O O
, NN O O
additional NN O O
respiratory NN O O
muscles NN O O
may NN O O
be NN O O
involved NN O O
[ NN O O
seeWarnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
Deaths NN B-AdverseReaction B-AdverseReaction
as NN O O
a NN O O
complication NN O O
of NN O O
severe NN B-Severity B-Severity
dysphagia NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
after NN O O
treatment NN O O
with NN O O
botulinum NN O O
toxin NN O O
. NN O O
Dysphagia NN B-AdverseReaction B-AdverseReaction
may NN O O
persist NN O O
for NN O O
several NN O O
weeks NN O O
, NN O O
and NN O O
require NN O O
use NN O O
of NN O O
a NN O O
feeding NN O O
tube NN O O
to NN O O
maintain NN O O
adequate NN O O
nutrition NN O O
and NN O O
hydration NN O O
. NN O O
Aspiration NN B-AdverseReaction B-AdverseReaction
may NN B-Factor B-Factor
result NN O O
from NN O O
severe NN B-Severity B-Severity
dysphagia NN B-AdverseReaction B-AdverseReaction
and NN O O
is NN O O
a NN O O
particular NN O O
risk NN O O
when NN O O
treating NN O O
patients NN O O
in NN O O
whom NN O O
swallowing NN O O
or NN O O
respiratory NN O O
function NN O O
is NN O O
already NN O O
compromised NN O O
. NN O O
Treatment NN O O
of NN O O
cervical NN O O
dystonia NN O O
with NN O O
botulinum NN O O
toxins NN O O
may NN B-Factor B-Factor
weaken NN B-AdverseReaction B-AdverseReaction
neck NN I-AdverseReaction I-AdverseReaction
muscles NN I-AdverseReaction I-AdverseReaction
that NN O O
serve NN O O
as NN O O
accessory NN O O
muscles NN O O
of NN O O
ventilation NN O O
. NN O O
This NN O O
may NN B-Factor B-Factor
result NN O O
in NN O O
a NN O O
critical NN B-Severity B-Severity
loss NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
breathing NN I-AdverseReaction I-AdverseReaction
capacity NN I-AdverseReaction I-AdverseReaction
in NN O O
patients NN O O
with NN O O
respiratory NN O O
disorders NN O O
who NN O O
may NN O O
have NN O O
become NN O O
dependent NN O O
upon NN O O
these NN O O
accessory NN O O
muscles NN O O
. NN O O
There NN O O
have NN O O
been NN O O
post NN O O
- NN O O
marketing NN O O
reports NN O O
of NN O O
serious NN B-Severity B-Severity
breathing NN B-AdverseReaction B-AdverseReaction
difficulties NN I-AdverseReaction I-AdverseReaction
including NN O O
respiratory NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
Patients NN B-Factor B-Factor
treated NN O O
with NN O O
botulinum NN O O
toxin NN O O
may NN O O
require NN O O
immediate NN O O
medical NN O O
attention NN O O
should NN O O
they NN O O
develop NN O O
problems NN O O
with NN O O
swallowing NN O O
, NN O O
speech NN O O
or NN O O
respiratory NN O O
disorders NN O O
. NN O O
These NN O O
reactions NN O O
can NN O O
occur NN O O
within NN O O
hours NN O O
to NN O O
weeks NN O O
after NN O O
injection NN O O
with NN O O
botulinum NN O O
toxin NN O O
[ NN O O
seeWarnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2),Adverse NN O O
Reactions NN O O
( NN O O
6.1),Clinical NN O O
Pharmacology NN O O
( NN O O
12.2 NN O O
) NN O O
] NN O O
. NN O O
5.4 NN O O
Facial NN O O
Anatomy NN O O
in NN O O
the NN O O
Treatment NN O O
of NN O O
Glabellar NN O O
Lines NN O O
Caution NN O O
should NN O O
be NN O O
exercised NN O O
when NN O O
administering NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
to NN O O
patients NN O O
with NN O O
surgical NN O O
alterations NN O O
to NN O O
the NN O O
facial NN O O
anatomy NN O O
, NN O O
excessive NN O O
weakness NN O O
or NN O O
atrophy NN O O
in NN O O
the NN O O
target NN O O
muscle(s NN O O
) NN O O
, NN O O
marked NN O O
facial NN O O
asymmetry NN O O
, NN O O
inflammation NN O O
at NN O O
the NN O O
injection NN O O
site(s NN O O
) NN O O
, NN O O
ptosis NN O O
, NN O O
excessive NN O O
dermatochalasis NN O O
, NN O O
deep NN O O
dermal NN O O
scarring NN O O
, NN O O
thick NN O O
sebaceous NN O O
skin NN O O
[ NN O O
seeDosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
] NN O O
or NN O O
the NN O O
inability NN O O
to NN O O
substantially NN O O
lessen NN O O
glabellar NN O O
lines NN O O
by NN O O
physically NN O O
spreading NN O O
them NN O O
apart NN O O
[ NN O O
seeClinical NN O O
Studies NN O O
( NN O O
14.2 NN O O
) NN O O
] NN O O
. NN O O
Do NN O O
not NN O O
exceed NN O O
the NN O O
recommended NN O O
dosage NN O O
and NN O O
frequency NN O O
of NN O O
administration NN O O
of NN O O
DYSPORT NN B-Factor B-Factor
( NN O O
r NN O O
) NN O O
. NN O O
In NN O O
clinical NN O O
trials NN O O
, NN O O
subjects NN O O
who NN O O
received NN O O
a NN O O
higher NN O O
dose NN O O
of NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
had NN O O
an NN O O
increased NN O O
incidence NN O O
of NN O O
eyelid NN B-AdverseReaction B-AdverseReaction
ptosis NN I-AdverseReaction I-AdverseReaction
5.5 NN O O
Pre NN O O
- NN O O
existing NN O O
Neuromuscular NN O O
Disorders NN O O
Individuals NN O O
with NN O O
peripheral NN O O
motor NN O O
neuropathic NN O O
diseases NN O O
, NN O O
amyotrophic NN O O
lateral NN O O
sclerosis NN O O
or NN O O
neuromuscular NN O O
junction NN O O
disorders NN O O
( NN O O
e.g. NN O O
, NN O O
myasthenia NN O O
gravis NN O O
or NN O O
Lambert NN O O
- NN O O
Eaton NN O O
syndrome NN O O
) NN O O
should NN O O
be NN O O
monitored NN O O
particularly NN O O
closely NN O O
when NN O O
given NN O O
botulinum NN O O
toxin NN O O
. NN O O
Patients NN O O
with NN O O
neuromuscular NN O O
disorders NN O O
may NN O O
be NN O O
at NN O O
increased NN O O
risk NN B-Factor B-Factor
of NN O O
clinically NN O O
significant NN O O
effects NN O O
including NN O O
severe NN B-Severity B-Severity
dysphagia NN B-AdverseReaction B-AdverseReaction
and NN O O
respiratory NN B-AdverseReaction B-AdverseReaction
compromise NN I-AdverseReaction I-AdverseReaction
from NN O O
typical NN O O
doses NN O O
of NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
[ NN O O
seeAdverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
5.6 NN O O
Human NN O O
Albumin NN O O
This NN O O
product NN O O
contains NN O O
albumin NN O O
, NN O O
a NN O O
derivative NN O O
of NN O O
human NN O O
blood NN O O
. NN O O
Based NN O O
on NN O O
effective NN O O
donor NN O O
screening NN O O
and NN O O
product NN O O
manufacturing NN O O
processes NN O O
, NN O O
it NN O O
carries NN O O
an NN O O
extremely NN O O
remote NN O O
risk NN B-Factor B-Factor
for NN O O
transmission NN O O
of NN O O
viral NN B-AdverseReaction B-AdverseReaction
diseases NN I-AdverseReaction I-AdverseReaction
A NN O O
theoretical NN O O
risk NN B-Factor B-Factor
for NN O O
transmission NN O O
of NN O O
Creutzfeldt NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Jakob NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
( NN O O
CJD NN O O
) NN O O
is NN O O
also NN O O
considered NN O O
extremely NN O O
remote NN O O
. NN O O
No NN O O
cases NN O O
of NN O O
transmission NN O O
of NN O O
viral NN B-AdverseReaction B-AdverseReaction
diseases NN I-AdverseReaction I-AdverseReaction
or NN O O
CJD NN B-AdverseReaction B-AdverseReaction
have NN O O
ever NN O O
been NN O O
reported NN O O
for NN O O
albumin NN O O
. NN O O
5.7 NN O O
Intradermal NN O O
Immune NN O O
Reaction NN O O
The NN O O
possibility NN O O
of NN O O
an NN O O
immune NN O O
reaction NN O O
when NN O O
injected NN O O
intradermally NN O O
is NN O O
unknown NN O O
. NN O O
The NN O O
safety NN O O
of NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
hyperhidrosis NN O O
has NN O O
not NN O O
been NN O O
established NN O O
. NN O O
DYSPORT NN O O
( NN O O
r NN O O
) NN O O
is NN O O
approved NN O O
only NN O O
for NN O O
intramuscular NN O O
injection NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
EXCERPT NN O O
: NN O O
Common NN O O
adverse NN O O
reactions NN O O
( NN O O
reported NN O O
in NN O O
>=4 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
NESINA NN O O
25 NN O O
mg NN O O
and NN O O
more NN O O
frequently NN O O
than NN O O
in NN O O
patients NN O O
who NN O O
received NN O O
placebo NN O O
) NN O O
are NN O O
: NN O O
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
and NN O O
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Takeda NN O O
Pharmaceuticals NN O O
at NN O O
1 NN O O
- NN O O
877-TAKEDA-7 NN O O
( NN O O
1 NN O O
- NN O O
877 NN O O
- NN O O
825 NN O O
- NN O O
3327 NN O O
) NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Studies NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O
Approximately NN O O
8500 NN O O
patients NN O O
with NN O O
type NN O O
2 NN O O
diabetes NN O O
have NN O O
been NN O O
treated NN O O
with NN O O
NESINA NN O O
in NN O O
14 NN O O
randomized NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
controlled NN O O
clinical NN O O
trials NN O O
with NN O O
approximately NN O O
2900 NN O O
subjects NN O O
randomized NN O O
to NN O O
placebo NN O O
and NN O O
approximately NN O O
2200 NN O O
to NN O O
an NN O O
active NN O O
comparator NN O O
. NN O O
The NN O O
mean NN O O
exposure NN O O
to NN O O
NESINA NN O O
was NN O O
40 NN O O
weeks NN O O
with NN O O
more NN O O
than NN O O
2400 NN O O
subjects NN O O
treated NN O O
for NN O O
more NN O O
than NN O O
one NN O O
year NN O O
. NN O O
Among NN O O
these NN O O
patients NN O O
, NN O O
63 NN O O
% NN O O
had NN O O
a NN O O
history NN O O
of NN O O
hypertension NN O O
, NN O O
51 NN O O
% NN O O
had NN O O
a NN O O
history NN O O
of NN O O
dyslipidemia NN O O
, NN O O
25 NN O O
% NN O O
had NN O O
a NN O O
history NN O O
of NN O O
myocardial NN O O
infarction NN O O
, NN O O
8 NN O O
% NN O O
had NN O O
a NN O O
history NN O O
of NN O O
unstable NN O O
angina NN O O
and NN O O
7 NN O O
% NN O O
had NN O O
a NN O O
history NN O O
of NN O O
congestive NN O O
heart NN O O
failure NN O O
. NN O O
The NN O O
mean NN O O
duration NN O O
of NN O O
diabetes NN O O
was NN O O
seven NN O O
years NN O O
, NN O O
the NN O O
mean NN O O
body NN O O
mass NN O O
index NN O O
( NN O O
BMI NN O O
) NN O O
was NN O O
31 NN O O
kg/m NN O O
2 NN O O
( NN O O
51 NN O O
% NN O O
of NN O O
patients NN O O
had NN O O
a NN O O
BMI NN O O
>=30 NN O O
kg/m NN O O
2 NN O O
) NN O O
, NN O O
and NN O O
the NN O O
mean NN O O
age NN O O
was NN O O
57 NN O O
years NN O O
( NN O O
24 NN O O
% NN O O
of NN O O
patients NN O O
>=65 NN O O
years NN O O
of NN O O
age NN O O
) NN O O
. NN O O
Two NN O O
placebo NN O O
- NN O O
controlled NN O O
monotherapy NN O O
trials NN O O
of NN O O
12 NN O O
and NN O O
26 NN O O
weeks NN O O
of NN O O
duration NN O O
were NN O O
conducted NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
NESINA NN O O
12.5 NN O O
mg NN O O
daily NN O O
, NN O O
NESINA NN O O
25 NN O O
mg NN O O
daily NN O O
and NN O O
placebo NN O O
. NN O O
Four NN O O
placebo NN O O
- NN O O
controlled NN O O
add NN O O
- NN O O
on NN O O
combination NN O O
therapy NN O O
trials NN O O
of NN O O
26 NN O O
weeks NN O O
duration NN O O
were NN O O
also NN O O
conducted NN O O
: NN O O
with NN O O
metformin NN O O
, NN O O
with NN O O
a NN O O
sulfonylurea NN O O
, NN O O
with NN O O
a NN O O
thiazolidinedione NN O O
and NN O O
with NN O O
insulin NN O O
. NN O O
Four NN O O
placebo NN O O
- NN O O
controlled NN O O
and NN O O
one NN O O
active NN O O
- NN O O
controlled NN O O
trials NN O O
of NN O O
16 NN O O
weeks NN O O
up NN O O
through NN O O
two NN O O
years NN O O
in NN O O
duration NN O O
were NN O O
conducted NN O O
in NN O O
combination NN O O
with NN O O
metformin NN O O
, NN O O
in NN O O
combination NN O O
with NN O O
pioglitazone NN O O
and NN O O
with NN O O
pioglitazone NN O O
added NN O O
to NN O O
a NN O O
background NN O O
of NN O O
metformin NN O O
therapy NN O O
. NN O O
Three NN O O
active NN O O
- NN O O
controlled NN O O
trials NN O O
of NN O O
52 NN O O
weeks NN O O
in NN O O
duration NN O O
were NN O O
conducted NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
pioglitazone NN O O
and NN O O
metformin NN O O
, NN O O
in NN O O
combination NN O O
with NN O O
metformin NN O O
and NN O O
as NN O O
monotherapy NN O O
compared NN O O
to NN O O
glipizide NN O O
. NN O O
In NN O O
a NN O O
pooled NN O O
analysis NN O O
of NN O O
these NN O O
14 NN O O
controlled NN O O
clinical NN O O
trials NN O O
, NN O O
the NN O O
overall NN O O
incidence NN O O
of NN O O
adverse NN O O
events NN O O
was NN O O
66 NN O O
% NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
NESINA NN O O
25 NN O O
mg NN O O
compared NN O O
to NN O O
62 NN O O
% NN O O
with NN O O
placebo NN O O
and NN O O
70 NN O O
% NN O O
with NN O O
active NN O O
comparator NN O O
. NN O O
Overall NN O O
discontinuation NN O O
of NN O O
therapy NN O O
due NN O O
to NN O O
adverse NN O O
events NN O O
was NN O O
4.7 NN O O
% NN O O
with NN O O
NESINA NN O O
25 NN O O
mg NN O O
compared NN O O
to NN O O
4.5 NN O O
% NN O O
with NN O O
placebo NN O O
or NN O O
6.2 NN O O
% NN O O
with NN O O
active NN O O
comparator NN O O
. NN O O
Adverse NN O O
reactions NN O O
reported NN O O
in NN O O
>=4 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
NESINA NN O O
25 NN O O
mg NN O O
and NN O O
more NN O O
frequently NN O O
than NN O O
in NN O O
patients NN O O
who NN O O
received NN O O
placebo NN O O
are NN O O
summarized NN O O
in NN O O
Table NN O O
1 NN O O
. NN O O
Table NN O O
1 NN O O
. NN O O
Adverse NN O O
Reactions NN O O
Reported NN O O
in NN O O
>=4 NN O O
% NN O O
Patients NN O O
Treated NN O O
with NN O O
NESINA NN O O
25 NN O O
mg NN O O
and NN O O
More NN O O
Frequently NN O O
Than NN O O
in NN O O
Patients NN O O
Given NN O O
Placebo NN O O
in NN O O
Pooled NN O O
Studies NN O O
Number NN O O
of NN O O
Patients NN O O
( NN O O
% NN O O
) NN O O
NESINA25 NN O O
mg NN O O
Placebo NN O O
Active NN O O
Comparator NN O O
N=5902 NN O O
N=2926 NN O O
N=2257 NN O O
Nasopharyngitis NN B-AdverseReaction B-AdverseReaction
257 NN O O
( NN O O
4.4 NN O O
) NN O O
89 NN O O
( NN O O
3.0 NN O O
) NN O O
113 NN O O
( NN O O
5.0 NN O O
) NN O O
Headache NN B-AdverseReaction B-AdverseReaction
247 NN O O
( NN O O
4.2 NN O O
) NN O O
72 NN O O
( NN O O
2.5 NN O O
) NN O O
121 NN O O
( NN O O
5.4 NN O O
) NN O O
Upper NN B-AdverseReaction B-AdverseReaction
Respiratory NN I-AdverseReaction I-AdverseReaction
Tract NN I-AdverseReaction I-AdverseReaction
Infection NN I-AdverseReaction I-AdverseReaction
247 NN O O
( NN O O
4.2 NN O O
) NN O O
61 NN O O
( NN O O
2.1 NN O O
) NN O O
113 NN O O
( NN O O
5.0 NN O O
) NN O O
Pancreatitis NN O O
In NN O O
the NN O O
clinical NN O O
trial NN O O
program NN O O
, NN O O
pancreatitis NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
11 NN O O
of NN O O
5902 NN O O
( NN O O
0.2 NN O O
% NN O O
) NN O O
patients NN O O
receiving NN O O
NESINA NN O O
25 NN O O
mg NN O O
daily NN O O
compared NN O O
to NN O O
five NN O O
of NN O O
5183 NN O O
( NN O O
< NN O O
0.1 NN O O
% NN O O
) NN O O
patients NN O O
receiving NN O O
all NN O O
comparators NN O O
. NN O O
Hypersensitivity NN O O
Reactions NN O O
In NN O O
a NN O O
pooled NN O O
analysis NN O O
, NN O O
the NN O O
overall NN O O
incidence NN O O
of NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
was NN O O
0.6 NN O O
% NN O O
with NN O O
NESINA NN O O
25 NN O O
mg NN O O
compared NN O O
to NN O O
0.8 NN O O
% NN O O
with NN O O
all NN O O
comparators NN O O
. NN O O
A NN O O
single NN O O
event NN O O
of NN O O
serum NN B-AdverseReaction B-AdverseReaction
sickness NN I-AdverseReaction I-AdverseReaction
was NN O O
reported NN O O
in NN O O
a NN O O
patient NN O O
treated NN O O
with NN O O
NESINA NN O O
25 NN O O
mg NN O O
. NN O O
Hypoglycemia NN O O
Hypoglycemic NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
were NN O O
documented NN O O
based NN O O
upon NN O O
a NN O O
blood NN O O
glucose NN O O
value NN O O
and/or NN O O
clinical NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
hypoglycemia NN B-AdverseReaction B-AdverseReaction
In NN O O
the NN O O
monotherapy NN O O
study NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
hypoglycemia NN B-AdverseReaction B-AdverseReaction
was NN O O
1.5 NN O O
% NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
NESINA NN O O
compared NN O O
to NN O O
1.6 NN O O
% NN O O
with NN O O
placebo NN O O
. NN O O
The NN O O
use NN O O
of NN O O
NESINA NN O O
as NN O O
add NN O O
- NN O O
on NN O O
therapy NN O O
to NN O O
glyburide NN O O
or NN O O
insulin NN O O
did NN O O
not NN O O
increase NN O O
the NN O O
incidence NN O O
of NN O O
hypoglycemia NN B-AdverseReaction B-AdverseReaction
compared NN O O
to NN O O
placebo NN O O
. NN O O
In NN O O
a NN O O
monotherapy NN O O
study NN O O
comparing NN O O
NESINA NN O O
to NN O O
a NN O O
sulfonylurea NN O O
in NN O O
elderly NN O O
patients NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
hypoglycemia NN B-AdverseReaction B-AdverseReaction
was NN O O
5.4 NN O O
% NN O O
with NN O O
NESINA NN O O
compared NN O O
to NN O O
26 NN O O
% NN O O
with NN O O
glipizide NN O O
( NN O O
Table NN O O
2 NN O O
) NN O O
. NN O O
Table NN O O
2 NN O O
. NN O O
Incidence NN O O
and NN O O
Rate NN O O
of NN O O
Hypoglycemia NN B-AdverseReaction B-AdverseReaction
reactions NN O O
of NN O O
hypoglycemia NN B-AdverseReaction B-AdverseReaction
were NN O O
based NN O O
on NN O O
all NN O O
reports NN O O
of NN O O
symptomatic NN B-Severity B-Severity
and NN O O
asymptomatic NN O O
hypoglycemia NN B-AdverseReaction B-AdverseReaction
a NN O O
concurrent NN O O
glucose NN O O
measurement NN O O
was NN O O
not NN O O
required NN O O
; NN O O
intent NN O O
- NN O O
to NN O O
- NN O O
treat NN O O
population NN O O
. NN O O
in NN O O
Placebo NN O O
and NN O O
Active NN O O
- NN O O
Controlled NN O O
Studies NN O O
when NN O O
NESINA NN O O
Was NN O O
Used NN O O
as NN O O
Add NN O O
- NN O O
On NN O O
Therapy NN O O
to NN O O
Glyburide NN O O
, NN O O
Insulin NN O O
, NN O O
Metformin NN O O
, NN O O
Pioglitazone NN O O
or NN O O
Compared NN O O
to NN O O
Glipizide NN O O
Add NN O O
- NN O O
On NN O O
to NN O O
Glyburide(26 NN O O
Weeks NN O O
) NN O O
NESINA NN O O
25 NN O O
mg+ NN O O
Glyburide NN O O
Placebo+ NN O O
Glyburide NN O O
N=198 NN O O
N=99 NN O O
Overall NN O O
( NN O O
% NN O O
) NN O O
19 NN O O
( NN O O
9.6 NN O O
) NN O O
11 NN O O
( NN O O
11.1 NN O O
) NN O O
Severe NN O O
( NN O O
%)Severe NN O O
events NN O O
of NN O O
hypoglycemia NN B-AdverseReaction B-AdverseReaction
were NN O O
defined NN O O
as NN O O
those NN O O
events NN O O
requiring NN O O
medical NN O O
assistance NN O O
or NN O O
exhibiting NN O O
depressed NN O O
level NN O O
or NN O O
loss NN O O
of NN O O
consciousness NN O O
or NN O O
seizure NN O O
. NN O O
0 NN O O
1 NN O O
( NN O O
1 NN O O
) NN O O
Add NN O O
- NN O O
On NN O O
to NN O O
Insulin NN O O
( NN O O
+/- NN O O
Metformin)(26 NN O O
Weeks NN O O
) NN O O
NESINA NN O O
25 NN O O
mg+ NN O O
Insulin NN O O
( NN O O
+/- NN O O
Metformin NN O O
) NN O O
Placebo+ NN O O
Insulin NN O O
( NN O O
+/- NN O O
Metformin NN O O
) NN O O
N=129 NN O O
N=129 NN O O
Overall NN O O
( NN O O
% NN O O
) NN O O
35 NN O O
( NN O O
27 NN O O
) NN O O
31 NN O O
( NN O O
24 NN O O
) NN O O
Severe NN O O
( NN O O
% NN O O
) NN O O
1 NN O O
( NN O O
0.8 NN O O
) NN O O
2 NN O O
( NN O O
1.6 NN O O
) NN O O
Add NN O O
- NN O O
On NN O O
to NN O O
Metformin(26 NN O O
Weeks NN O O
) NN O O
NESINA NN O O
25 NN O O
mg+ NN O O
Metformin NN O O
Placebo+ NN O O
Metformin NN O O
N=207 NN O O
N=104 NN O O
Overall NN O O
( NN O O
% NN O O
) NN O O
0 NN O O
3 NN O O
( NN O O
2.9 NN O O
) NN O O
Severe NN O O
( NN O O
% NN O O
) NN O O
0 NN O O
0 NN O O
Add NN O O
- NN O O
On NN O O
to NN O O
Pioglitazone(+/- NN O O
Metformin NN O O
or NN O O
Sulfonylurea)(26 NN O O
Weeks NN O O
) NN O O
NESINA NN O O
25 NN O O
mg+ NN O O
Pioglitazone NN O O
Placebo+ NN O O
Pioglitazone NN O O
N=199 NN O O
N=97 NN O O
Overall NN O O
( NN O O
% NN O O
) NN O O
14 NN O O
( NN O O
7.0 NN O O
) NN O O
5 NN O O
( NN O O
5.2 NN O O
) NN O O
Severe NN O O
( NN O O
% NN O O
) NN O O
0 NN O O
1 NN O O
( NN O O
1 NN O O
) NN O O
Compared NN O O
to NN O O
Glipizide(52 NN O O
Weeks NN O O
) NN O O
NESINA NN O O
25 NN O O
mg NN O O
Glipizide NN O O
N=222 NN O O
N=219 NN O O
Overall NN O O
( NN O O
% NN O O
) NN O O
12 NN O O
( NN O O
5.4 NN O O
) NN O O
57 NN O O
( NN O O
26 NN O O
) NN O O
Severe NN O O
( NN O O
% NN O O
) NN O O
0 NN O O
3 NN O O
( NN O O
1.4 NN O O
) NN O O
Add NN O O
- NN O O
On NN O O
to NN O O
Metformin(26 NN O O
Weeks NN O O
) NN O O
NESINA NN O O
25 NN O O
mg NN O O
Metformin NN O O
500 NN O O
mg NN O O
twice NN O O
daily NN O O
N=112 NN O O
N=109 NN O O
Overall NN O O
( NN O O
% NN O O
) NN O O
2 NN O O
( NN O O
1.8 NN O O
) NN O O
2 NN O O
( NN O O
1.8 NN O O
) NN O O
Severe NN O O
( NN O O
% NN O O
) NN O O
0 NN O O
0 NN O O
Add NN O O
- NN O O
On NN O O
to NN O O
Metformin NN O O
Compared NN O O
to NN O O
Glipizide(52 NN O O
Weeks NN O O
) NN O O
NESINA NN O O
25 NN O O
mg+ NN O O
Metformin NN O O
Glipizide NN O O
+ NN O O
Metformin NN O O
N=877 NN O O
N=869 NN O O
Overall NN O O
( NN O O
% NN O O
) NN O O
12 NN O O
( NN O O
1.4 NN O O
) NN O O
207 NN O O
( NN O O
23.8 NN O O
) NN O O
Severe NN O O
( NN O O
% NN O O
) NN O O
0 NN O O
4 NN O O
( NN O O
0.5 NN O O
) NN O O
Vital NN O O
Signs NN O O
No NN B-Negation B-Negation
clinically NN O O
meaningful NN O O
changes NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
vital NN I-AdverseReaction I-AdverseReaction
signs NN I-AdverseReaction I-AdverseReaction
or NN O O
in NN O O
electrocardiograms NN O O
were NN O O
observed NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
NESINA. NN O O
Laboratory NN O O
Tests NN O O
No NN O O
clinically NN O O
meaningful NN O O
changes NN O O
in NN O O
hematology NN O O
, NN O O
serum NN O O
chemistry NN O O
or NN O O
urinalysis NN O O
were NN O O
observed NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
NESINA. NN O O
6.2 NN O O
Postmarketing NN O O
Experience NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
identified NN O O
during NN O O
the NN O O
postmarketing NN O O
use NN O O
of NN O O
NESINA. NN O O
Because NN O O
these NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
angioedema NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
urticaria NN B-AdverseReaction B-AdverseReaction
and NN O O
severe NN B-Severity B-Severity
cutaneous NN B-AdverseReaction B-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
Stevens NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Johnson NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
hepatic NN B-AdverseReaction B-AdverseReaction
enzyme NN I-AdverseReaction I-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
fulminant NN B-AdverseReaction B-AdverseReaction
hepatic NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
severe NN B-Severity B-Severity
and NN O O
disabling NN B-Severity B-Severity
arthralgia NN B-AdverseReaction B-AdverseReaction
and NN O O
acute NN B-AdverseReaction B-AdverseReaction
pancreatitis NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1,5.2,5.3,5.5 NN O O
) NN O O
] NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Acute NN B-AdverseReaction B-AdverseReaction
pancreatitis NN I-AdverseReaction I-AdverseReaction
There NN O O
have NN O O
been NN O O
postmarketing NN O O
reports NN O O
of NN O O
acute NN B-AdverseReaction B-AdverseReaction
pancreatitis NN I-AdverseReaction I-AdverseReaction
If NN O O
pancreatitis NN O O
is NN O O
suspected NN O O
, NN O O
promptly NN O O
discontinue NN O O
NESINA. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
There NN O O
have NN O O
been NN O O
postmarketing NN O O
reports NN O O
of NN O O
serious NN B-Severity B-Severity
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
in NN O O
patients NN O O
treated NN O O
with NN O O
NESINA NN O O
such NN O O
as NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
angioedema NN B-AdverseReaction B-AdverseReaction
and NN O O
severe NN B-Severity B-Severity
cutaneous NN B-AdverseReaction B-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
In NN O O
such NN O O
cases NN O O
, NN O O
promptly NN O O
discontinue NN O O
NESINA NN O O
, NN O O
assess NN O O
for NN O O
other NN O O
potential NN O O
causes NN O O
, NN O O
institute NN O O
appropriate NN O O
monitoring NN O O
and NN O O
treatment NN O O
and NN O O
initiate NN O O
alternative NN O O
treatment NN O O
for NN O O
diabetes NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Hepatic NN B-AdverseReaction B-AdverseReaction
effects NN I-AdverseReaction I-AdverseReaction
Postmarketing NN O O
reports NN O O
of NN O O
hepatic NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
sometimes NN O O
fatal NN B-AdverseReaction B-AdverseReaction
Causality NN O O
can NN O O
not NN O O
be NN O O
excluded NN O O
. NN O O
If NN O O
liver NN O O
injury NN O O
is NN O O
detected NN O O
, NN O O
promptly NN O O
interrupt NN O O
NESINA NN O O
and NN O O
assess NN O O
patient NN O O
for NN O O
probable NN O O
cause NN O O
, NN O O
then NN O O
treat NN O O
cause NN O O
if NN O O
possible NN O O
, NN O O
to NN O O
resolution NN O O
or NN O O
stabilization NN O O
. NN O O
Do NN O O
not NN O O
restart NN O O
NESINA NN O O
if NN O O
liver NN O O
injury NN O O
is NN O O
confirmed NN O O
and NN O O
no NN O O
alternative NN O O
etiology NN O O
can NN O O
be NN O O
found NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Hypoglycemia NN B-AdverseReaction B-AdverseReaction
When NN O O
an NN O O
insulin NN O O
secretagogue NN O O
( NN O O
e.g. NN O O
, NN O O
sulfonylurea NN O O
) NN O O
or NN O O
insulin NN O O
is NN O O
used NN O O
in NN O O
combination NN O O
with NN O O
NESINA NN O O
, NN O O
a NN O O
lower NN O O
dose NN O O
of NN O O
the NN O O
insulin NN O O
secretagogue NN O O
or NN O O
insulin NN O O
may NN O O
be NN O O
required NN O O
to NN O O
minimize NN O O
the NN O O
risk NN O O
of NN O O
hypoglycemia NN O O
. NN O O
( NN O O
5.4 NN O O
) NN O O
* NN O O
Arthralgia NN B-AdverseReaction B-AdverseReaction
Severe NN B-Severity B-Severity
and NN O O
disabling NN B-Severity B-Severity
arthralgia NN B-AdverseReaction B-AdverseReaction
has NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
taking NN O O
DPP-4 NN B-DrugClass B-DrugClass
inhibitors NN I-DrugClass I-DrugClass
Consider NN O O
as NN O O
a NN O O
possible NN O O
cause NN O O
for NN O O
severe NN O O
joint NN O O
pain NN O O
and NN O O
discontinue NN O O
drug NN O O
if NN O O
appropriate NN O O
. NN O O
( NN O O
5.5 NN O O
) NN O O
* NN O O
Macrovascular NN O O
outcomes NN O O
: NN O O
There NN O O
have NN O O
been NN O O
no NN O O
clinical NN O O
studies NN O O
establishing NN O O
conclusive NN O O
evidence NN O O
of NN O O
macrovascular NN O O
risk NN O O
reduction NN O O
with NN O O
NESINA NN O O
or NN O O
any NN O O
other NN O O
antidiabetic NN O O
drug NN O O
. NN O O
( NN O O
5.6 NN O O
) NN O O
5.1 NN O O
Pancreatitis NN O O
There NN O O
have NN O O
been NN O O
postmarketing NN O O
reports NN O O
of NN O O
acute NN B-AdverseReaction B-AdverseReaction
pancreatitis NN I-AdverseReaction I-AdverseReaction
in NN O O
patients NN O O
taking NN O O
NESINA. NN O O
After NN O O
initiation NN O O
of NN O O
NESINA NN O O
, NN O O
patients NN O O
should NN O O
be NN O O
observed NN O O
carefully NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
pancreatitis NN O O
. NN O O
If NN O O
pancreatitis NN O O
is NN O O
suspected NN O O
, NN O O
NESINA NN O O
should NN O O
promptly NN O O
be NN O O
discontinued NN O O
and NN O O
appropriate NN O O
management NN O O
should NN O O
be NN O O
initiated NN O O
. NN O O
It NN O O
is NN O O
unknown NN O O
whether NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
pancreatitis NN O O
are NN O O
at NN O O
increased NN O O
risk NN O O
for NN O O
the NN O O
development NN O O
of NN O O
pancreatitis NN O O
while NN O O
using NN O O
NESINA. NN O O
5.2 NN O O
Hypersensitivity NN O O
Reactions NN O O
There NN O O
have NN O O
been NN O O
postmarketing NN O O
reports NN O O
of NN O O
serious NN B-Severity B-Severity
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
in NN O O
patients NN O O
treated NN O O
with NN O O
NESINA. NN O O
These NN O O
reactions NN O O
include NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
angioedema NN B-AdverseReaction B-AdverseReaction
and NN O O
severe NN B-Severity B-Severity
cutaneous NN B-AdverseReaction B-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
Stevens NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Johnson NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
If NN O O
a NN O O
serious NN O O
hypersensitivity NN O O
reaction NN O O
is NN O O
suspected NN O O
, NN O O
discontinue NN O O
NESINA NN O O
, NN O O
assess NN O O
for NN O O
other NN O O
potential NN O O
causes NN O O
for NN O O
the NN O O
event NN O O
and NN O O
institute NN O O
alternative NN O O
treatment NN O O
for NN O O
diabetes NN O O
[ NN O O
seeAdverse NN O O
Reactions NN O O
( NN O O
6.2 NN O O
) NN O O
] NN O O
. NN O O
Use NN O O
caution NN O O
in NN O O
a NN O O
patient NN O O
with NN O O
a NN O O
history NN O O
of NN O O
angioedema NN O O
with NN O O
another NN O O
DPP-4 NN O O
inhibitor NN O O
because NN O O
it NN O O
is NN O O
unknown NN O O
whether NN O O
such NN O O
patients NN O O
will NN O O
be NN O O
predisposed NN O O
to NN O O
angioedema NN O O
with NN O O
NESINA. NN O O
5.3 NN O O
Hepatic NN O O
Effects NN O O
There NN O O
have NN O O
been NN O O
postmarketing NN O O
reports NN O O
of NN O O
fatal NN B-AdverseReaction B-AdverseReaction
and NN O O
nonfatal NN B-Severity B-Severity
hepatic NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
in NN O O
patients NN O O
taking NN O O
NESINA NN O O
, NN O O
although NN O O
some NN O O
of NN O O
the NN O O
reports NN O O
contain NN O O
insufficient NN O O
information NN O O
necessary NN O O
to NN O O
establish NN O O
the NN O O
probable NN O O
cause NN O O
[ NN O O
seeAdverse NN O O
Reactions NN O O
( NN O O
6.2 NN O O
) NN O O
] NN O O
. NN O O
In NN O O
randomized NN O O
controlled NN O O
studies NN O O
, NN O O
serum NN O O
alanine NN O O
aminotransferase NN O O
( NN O O
ALT NN O O
) NN O O
elevations NN O O
greater NN O O
than NN O O
three NN B-Severity B-Severity
times NN I-Severity I-Severity
the NN I-Severity I-Severity
upper NN I-Severity I-Severity
limit NN I-Severity I-Severity
of NN I-Severity I-Severity
normal NN I-Severity I-Severity
( NN I-Severity I-Severity
ULN NN I-Severity I-Severity
) NN I-Severity I-Severity
were NN O O
observed NN O O
: NN O O
1.3 NN O O
% NN O O
in NN O O
alogliptin NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
1.5 NN O O
% NN O O
in NN O O
all NN O O
comparator NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Patients NN O O
with NN O O
type NN O O
2 NN O O
diabetes NN O O
may NN O O
have NN O O
fatty NN O O
liver NN O O
disease NN O O
, NN O O
which NN O O
may NN O O
cause NN O O
liver NN O O
test NN O O
abnormalities NN O O
, NN O O
and NN O O
they NN O O
may NN O O
also NN O O
have NN O O
other NN O O
forms NN O O
of NN O O
liver NN O O
disease NN O O
, NN O O
many NN O O
of NN O O
which NN O O
can NN O O
be NN O O
treated NN O O
or NN O O
managed NN O O
. NN O O
Therefore NN O O
, NN O O
obtaining NN O O
a NN O O
liver NN O O
test NN O O
panel NN O O
and NN O O
assessing NN O O
the NN O O
patient NN O O
before NN O O
initiating NN O O
NESINA NN O O
therapy NN O O
is NN O O
recommended NN O O
. NN O O
In NN O O
patients NN O O
with NN O O
abnormal NN O O
liver NN O O
tests NN O O
, NN O O
NESINA NN O O
should NN O O
be NN O O
initiated NN O O
with NN O O
caution NN O O
. NN O O
Measure NN O O
liver NN O O
tests NN O O
promptly NN O O
in NN O O
patients NN O O
who NN O O
report NN O O
symptoms NN O O
that NN O O
may NN O O
indicate NN O O
liver NN O O
injury NN O O
, NN O O
including NN O O
fatigue NN O O
, NN O O
anorexia NN O O
, NN O O
right NN O O
upper NN O O
abdominal NN O O
discomfort NN O O
, NN O O
dark NN O O
urine NN O O
or NN O O
jaundice NN O O
. NN O O
In NN O O
this NN O O
clinical NN O O
context NN O O
, NN O O
if NN O O
the NN O O
patient NN O O
is NN O O
found NN O O
to NN O O
have NN O O
clinically NN O O
significant NN O O
liver NN O O
enzyme NN O O
elevations NN O O
and NN O O
if NN O O
abnormal NN O O
liver NN O O
tests NN O O
persist NN O O
or NN O O
worsen NN O O
, NN O O
NESINA NN O O
should NN O O
be NN O O
interrupted NN O O
and NN O O
investigation NN O O
done NN O O
to NN O O
establish NN O O
the NN O O
probable NN O O
cause NN O O
. NN O O
NESINA NN O O
should NN O O
not NN O O
be NN O O
restarted NN O O
in NN O O
these NN O O
patients NN O O
without NN O O
another NN O O
explanation NN O O
for NN O O
the NN O O
liver NN O O
test NN O O
abnormalities NN O O
. NN O O
5.4 NN O O
Use NN O O
with NN O O
Medications NN O O
Known NN O O
to NN O O
Cause NN O O
Hypoglycemia NN O O
Insulin NN O O
and NN O O
insulin NN O O
secretagogues NN O O
, NN O O
such NN O O
as NN O O
sulfonylureas NN O O
, NN O O
are NN O O
known NN O O
to NN O O
cause NN O O
hypoglycemia NN O O
. NN O O
Therefore NN O O
, NN O O
a NN O O
lower NN O O
dose NN O O
of NN O O
insulin NN O O
or NN O O
insulin NN O O
secretagogue NN O O
may NN O O
be NN O O
required NN O O
to NN O O
minimize NN O O
the NN O O
risk NN O O
of NN O O
hypoglycemia NN O O
when NN O O
used NN O O
in NN O O
combination NN O O
with NN O O
NESINA. NN O O
5.5 NN O O
Severe NN O O
and NN O O
Disabling NN O O
Arthralgia NN O O
There NN O O
have NN O O
been NN O O
postmarketing NN O O
reports NN O O
of NN O O
severe NN B-Severity B-Severity
and NN O O
disabling NN B-Severity B-Severity
arthralgia NN B-AdverseReaction B-AdverseReaction
in NN O O
patients NN O O
taking NN O O
DPP-4 NN B-DrugClass B-DrugClass
inhibitors NN I-DrugClass I-DrugClass
The NN O O
time NN O O
to NN O O
onset NN O O
of NN O O
symptoms NN O O
following NN O O
initiation NN O O
of NN O O
drug NN O O
therapy NN O O
varied NN O O
from NN O O
one NN O O
day NN O O
to NN O O
years NN O O
. NN O O
Patients NN O O
experienced NN O O
relief NN O O
of NN O O
symptoms NN O O
upon NN O O
discontinuation NN O O
of NN O O
the NN O O
medication NN O O
. NN O O
A NN O O
subset NN O O
of NN O O
patients NN O O
experienced NN O O
a NN O O
recurrence NN O O
of NN O O
symptoms NN O O
when NN O O
restarting NN O O
the NN O O
same NN O O
drug NN O O
or NN O O
a NN O O
different NN O O
DPP-4 NN O O
inhibitor NN O O
. NN O O
Consider NN O O
DPP-4 NN O O
inhibitors NN O O
as NN O O
a NN O O
possible NN O O
cause NN O O
for NN O O
severe NN O O
joint NN O O
pain NN O O
and NN O O
discontinue NN O O
drug NN O O
if NN O O
appropriate NN O O
. NN O O
5.6 NN O O
Macrovascular NN O O
Outcomes NN O O
There NN O O
have NN O O
been NN O O
no NN O O
clinical NN O O
studies NN O O
establishing NN O O
conclusive NN O O
evidence NN O O
of NN O O
macrovascular NN O O
risk NN O O
reduction NN O O
with NN O O
NESINA NN O O
or NN O O
any NN O O
other NN O O
antidiabetic NN O O
drug NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
EXCERPT NN O O
: NN O O
Most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
> NN O O
1 NN O O
% NN O O
and NN O O
more NN O O
common NN O O
than NN O O
with NN O O
placebo NN O O
) NN O O
: NN O O
ocular NN B-AdverseReaction B-AdverseReaction
irritation NN I-AdverseReaction I-AdverseReaction
application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
irritation NN I-AdverseReaction I-AdverseReaction
and NN O O
application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
anesthesia NN I-AdverseReaction I-AdverseReaction
and NN O O
hypoesthesia NN O O
. NN O O
( NN O O
6 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Zylera NN O O
Pharmaceuticals NN O O
, NN O O
LLC. NN O O
at NN O O
1 NN O O
- NN O O
866 NN O O
- NN O O
416 NN O O
- NN O O
9637 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O
The NN O O
rates NN O O
of NN O O
adverse NN O O
reactions NN O O
below NN O O
were NN O O
derived NN O O
from NN O O
two NN O O
randomized NN O O
, NN O O
multi NN O O
- NN O O
center NN O O
, NN O O
vehicle NN O O
- NN O O
controlled NN O O
clinical NN O O
trials NN O O
and NN O O
one NN O O
open NN O O
- NN O O
label NN O O
study NN O O
in NN O O
subjects NN O O
with NN O O
head NN O O
lice NN O O
infestation NN O O
. NN O O
Skin NN O O
, NN O O
scalp NN O O
, NN O O
and NN O O
ocular NN O O
irritation NN O O
were NN O O
monitored NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
. NN O O
All NN O O
subjects NN O O
were NN O O
queried NN O O
about NN O O
the NN O O
presence NN O O
of NN O O
skin NN O O
and NN O O
scalp NN O O
symptoms NN O O
; NN O O
the NN O O
results NN O O
are NN O O
presented NN O O
in NN O O
Table NN O O
2 NN O O
. NN O O
Table NN O O
2 NN O O
: NN O O
Monitored NN O O
Adverse NN O O
Reactions NN O O
- NN O O
Application NN O O
Site NN O O
Symptoms NN O O
Event NN O O
ULESFIA NN O O
( NN O O
r NN O O
) NN O O
Lotion NN O O
Vehicle NN O O
Application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
Irritation NN I-AdverseReaction I-AdverseReaction
2 NN O O
% NN O O
( NN O O
11/478 NN O O
) NN O O
1 NN O O
% NN O O
( NN O O
2/336 NN O O
) NN O O
Application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
anesthesia NN I-AdverseReaction I-AdverseReaction
&hypoesthesia NN O O
2 NN O O
% NN O O
( NN O O
10/478 NN O O
) NN O O
0 NN O O
% NN O O
( NN O O
0/336 NN O O
) NN O O
Pain NN B-AdverseReaction B-AdverseReaction
1 NN O O
% NN O O
( NN O O
5/478 NN O O
) NN O O
0 NN O O
% NN O O
( NN O O
1/336 NN O O
) NN O O
The NN O O
subset NN O O
of NN O O
subjects NN O O
who NN O O
did NN O O
not NN O O
have NN O O
pruritus NN O O
, NN O O
erythema NN O O
, NN O O
edema NN O O
or NN O O
pyoderma NN O O
of NN O O
skin NN O O
and NN O O
scalp NN O O
, NN O O
or NN O O
ocular NN O O
irritation NN O O
prior NN O O
to NN O O
treatment NN O O
were NN O O
assessed NN O O
for NN O O
these NN O O
signs NN O O
and NN O O
symptoms NN O O
after NN O O
treatment NN O O
; NN O O
the NN O O
results NN O O
are NN O O
presented NN O O
in NN O O
Table NN O O
3 NN O O
. NN O O
Table NN O O
3 NN O O
: NN O O
Monitored NN O O
Adverse NN O O
Reactions NN O O
- NN O O
Pruritus NN B-AdverseReaction B-AdverseReaction
Erythema NN B-AdverseReaction B-AdverseReaction
Pyoderma NN B-AdverseReaction B-AdverseReaction
and NN O O
Ocular NN B-AdverseReaction B-AdverseReaction
Irritation NN I-AdverseReaction I-AdverseReaction
with NN O O
Onset NN O O
After NN O O
Treatment NN O O
Signs/Symptoms NN O O
ULESFIA NN O O
( NN O O
r NN O O
) NN O O
Lotion NN O O
Vehicle NN O O
Pruritus NN B-AdverseReaction B-AdverseReaction
12 NN O O
% NN O O
( NN O O
14/116 NN O O
) NN O O
4 NN O O
% NN O O
( NN O O
3/67 NN O O
) NN O O
Erythema NN B-AdverseReaction B-AdverseReaction
10 NN O O
% NN O O
( NN O O
32/309 NN O O
) NN O O
9 NN O O
% NN O O
( NN O O
19/217 NN O O
) NN O O
Pyoderma NN B-AdverseReaction B-AdverseReaction
7 NN O O
% NN O O
( NN O O
22/308 NN O O
) NN O O
4 NN O O
% NN O O
( NN O O
10/230 NN O O
) NN O O
Ocular NN B-AdverseReaction B-AdverseReaction
irritation NN I-AdverseReaction I-AdverseReaction
6 NN O O
% NN O O
( NN O O
26/428 NN O O
) NN O O
1 NN O O
% NN O O
( NN O O
3/313 NN O O
) NN O O
Other NN O O
less NN O O
common NN O O
reactions NN O O
( NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
but NN O O
more NN O O
than NN O O
0.1 NN O O
% NN O O
) NN O O
were NN O O
, NN O O
in NN O O
decreasing NN O O
order NN O O
of NN O O
incidence NN O O
: NN O O
application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
dryness NN I-AdverseReaction I-AdverseReaction
application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
excoriation NN I-AdverseReaction I-AdverseReaction
paraesthesia NN B-AdverseReaction B-AdverseReaction
application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
dermatitis NN I-AdverseReaction I-AdverseReaction
excoriation NN B-AdverseReaction B-AdverseReaction
thermal NN B-AdverseReaction B-AdverseReaction
burn NN I-AdverseReaction I-AdverseReaction
dandruff NN B-AdverseReaction B-AdverseReaction
erythema NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
and NN O O
skin NN B-AdverseReaction B-AdverseReaction
exfoliation NN I-AdverseReaction I-AdverseReaction
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Neonatal NN B-AdverseReaction B-AdverseReaction
toxicity NN I-AdverseReaction I-AdverseReaction
Risk NN B-Factor B-Factor
of NN O O
gasping NN B-AdverseReaction B-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
if NN O O
benzyl NN O O
alcohol NN O O
is NN O O
used NN O O
in NN O O
neonates NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Eye NN B-AdverseReaction B-AdverseReaction
irritation NN I-AdverseReaction I-AdverseReaction
Avoid NN O O
eye NN O O
exposure NN O O
. NN O O
Flush NN O O
immediately NN O O
with NN O O
water NN O O
if NN O O
ULESFIA NN O O
( NN O O
r NN O O
) NN O O
Lotion NN O O
comes NN O O
into NN O O
contact NN O O
with NN O O
eyes NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Contact NN B-AdverseReaction B-AdverseReaction
dermatitis NN I-AdverseReaction I-AdverseReaction
May NN B-Factor B-Factor
occur NN O O
with NN O O
ULESFIA NN O O
( NN O O
r NN O O
) NN O O
Lotion NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Use NN O O
in NN O O
children NN O O
: NN O O
ULESFIA NN O O
( NN O O
r NN O O
) NN O O
Lotion NN O O
should NN O O
only NN O O
be NN O O
used NN O O
on NN O O
children NN O O
under NN O O
the NN O O
direct NN O O
supervision NN O O
of NN O O
an NN O O
adult NN O O
. NN O O
Keep NN O O
out NN O O
of NN O O
reach NN O O
of NN O O
children NN O O
. NN O O
( NN O O
5.4 NN O O
) NN O O
5 NN O O
. NN O O
1 NN O O
Neonatal NN O O
Toxicity NN O O
Intravenous NN O O
administration NN O O
of NN O O
products NN O O
containing NN O O
benzyl NN O O
alcohol NN O O
has NN O O
been NN O O
associated NN O O
with NN O O
neonatal NN B-AdverseReaction B-AdverseReaction
gasping NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
consisting NN O O
of NN O O
severe NN B-Severity B-Severity
metabolic NN B-AdverseReaction B-AdverseReaction
acidosis NN I-AdverseReaction I-AdverseReaction
gasping NN B-AdverseReaction B-AdverseReaction
respirations NN I-AdverseReaction I-AdverseReaction
progressive NN B-AdverseReaction B-AdverseReaction
hypotension NN I-AdverseReaction I-AdverseReaction
seizures NN B-AdverseReaction B-AdverseReaction
central NN B-AdverseReaction B-AdverseReaction
nervous NN I-AdverseReaction I-AdverseReaction
system NN I-AdverseReaction I-AdverseReaction
depression NN I-AdverseReaction I-AdverseReaction
intraventricular NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
and NN O O
death NN B-AdverseReaction B-AdverseReaction
in NN O O
preterm NN O O
, NN O O
low NN O O
birth NN O O
weight NN O O
infants NN O O
. NN O O
Neonates NN O O
( NN O O
i.e. NN O O
patients NN O O
less NN O O
than NN O O
1 NN O O
month NN O O
of NN O O
age NN O O
or NN O O
preterm NN O O
infants NN O O
with NN O O
a NN O O
corrected NN O O
age NN O O
of NN O O
less NN O O
than NN O O
44 NN O O
weeks NN O O
) NN O O
could NN O O
be NN O O
at NN O O
risk NN B-Factor B-Factor
for NN O O
gasping NN B-AdverseReaction B-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
if NN O O
treated NN O O
with NN O O
ULESFIA NN O O
( NN O O
r NN O O
) NN O O
Lotion NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.4 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
Eye NN O O
Irritation NN O O
Avoid NN O O
eye NN O O
exposure NN O O
. NN O O
ULESFIA NN O O
( NN O O
r NN O O
) NN O O
Lotion NN O O
may NN B-Factor B-Factor
cause NN O O
eye NN B-AdverseReaction B-AdverseReaction
irritation NN I-AdverseReaction I-AdverseReaction
If NN O O
ULESFIA NN O O
( NN O O
r NN O O
) NN O O
Lotion NN O O
comes NN O O
in NN O O
contact NN O O
with NN O O
the NN O O
eyes NN O O
, NN O O
flush NN O O
them NN O O
immediately NN O O
with NN O O
water NN O O
. NN O O
If NN O O
irritation NN O O
persists NN O O
, NN O O
consult NN O O
a NN O O
physician NN O O
. NN O O
5 NN O O
. NN O O
3 NN O O
Contact NN O O
Dermatitis NN O O
ULESFIA NN O O
( NN O O
r NN O O
) NN O O
Lotion NN O O
may NN B-Factor B-Factor
cause NN O O
allergic NN O O
or NN O O
irritant NN B-AdverseReaction B-AdverseReaction
dermatitis NN I-AdverseReaction I-AdverseReaction
5.4 NN O O
Use NN O O
in NN O O
Children NN O O
ULESFIA NN O O
( NN O O
r NN O O
) NN O O
Lotion NN O O
should NN O O
only NN O O
be NN O O
used NN O O
on NN O O
children NN O O
( NN O O
6 NN O O
months NN O O
of NN O O
age NN O O
and NN O O
older NN O O
) NN O O
under NN O O
the NN O O
direct NN O O
supervision NN O O
of NN O O
an NN O O
adult NN O O
. NN O O
Keep NN O O
out NN O O
of NN O O
reach NN O O
of NN O O
children NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
trials NN O O
of NN O O
DALVANCE NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
DALVANCE NN O O
were NN O O
nausea NN B-AdverseReaction B-AdverseReaction
( NN O O
5.5 NN O O
% NN O O
) NN O O
, NN O O
headache NN B-AdverseReaction B-AdverseReaction
( NN O O
4.7 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
( NN O O
4.4 NN O O
% NN O O
) NN O O
. NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Durata NN O O
Therapeutics NN O O
, NN O O
Inc. NN O O
at NN O O
1 NN O O
- NN O O
855 NN O O
- NN O O
387 NN O O
- NN O O
2825 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov NN O O
/medwatch NN O O
. NN O O
6.1 NN O O
Adverse NN O O
Reactions NN O O
in NN O O
Clinical NN O O
Trials NN O O
Adverse NN O O
reactions NN O O
were NN O O
evaluated NN O O
for NN O O
1778 NN O O
patients NN O O
treated NN O O
with NN O O
DALVANCE NN O O
and NN O O
1224 NN O O
patients NN O O
treated NN O O
with NN O O
comparator NN O O
antibacterial NN O O
drugs NN O O
in NN O O
seven NN O O
Phase NN O O
2 NN O O
and NN O O
Phase NN O O
3 NN O O
clinical NN O O
trials NN O O
. NN O O
A NN O O
causal NN O O
relationship NN O O
between NN O O
study NN O O
drug NN O O
and NN O O
adverse NN O O
reactions NN O O
was NN O O
not NN O O
always NN O O
established NN O O
. NN O O
The NN O O
median NN O O
age NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
DALVANCE NN O O
was NN O O
47 NN O O
years NN O O
, NN O O
ranging NN O O
between NN O O
16 NN O O
and NN O O
93 NN O O
years NN O O
old NN O O
. NN O O
Patients NN O O
treated NN O O
with NN O O
DALVANCE NN O O
were NN O O
predominantly NN O O
male NN O O
( NN O O
60 NN O O
% NN O O
) NN O O
and NN O O
Caucasian NN O O
( NN O O
78 NN O O
% NN O O
) NN O O
. NN O O
Serious NN O O
Adverse NN O O
Reactions NN O O
and NN O O
Adverse NN O O
Reactions NN O O
Leading NN O O
to NN O O
Discontinuation NN O O
Serious NN O O
adverse NN O O
reactions NN O O
occurred NN O O
in NN O O
109/1778 NN O O
( NN O O
6.1 NN O O
% NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
DALVANCE NN O O
and NN O O
in NN O O
80/1224 NN O O
( NN O O
6.5 NN O O
% NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
comparator NN O O
. NN O O
DALVANCE NN O O
was NN O O
discontinued NN O O
due NN O O
to NN O O
an NN O O
adverse NN O O
reaction NN O O
in NN O O
53/1778 NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
patients NN O O
and NN O O
the NN O O
comparator NN O O
was NN O O
discontinued NN O O
due NN O O
to NN O O
an NN O O
adverse NN O O
reaction NN O O
in NN O O
35/1224 NN O O
( NN O O
2.8 NN O O
% NN O O
) NN O O
patients NN O O
. NN O O
Most NN O O
Common NN O O
Adverse NN O O
Reactions NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
DALVANCE NN O O
were NN O O
nausea NN B-AdverseReaction B-AdverseReaction
( NN O O
5.5 NN O O
% NN O O
) NN O O
, NN O O
headache NN B-AdverseReaction B-AdverseReaction
( NN O O
4.7 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
( NN O O
4.4 NN O O
% NN O O
) NN O O
. NN O O
The NN O O
median NN O O
duration NN O O
of NN O O
adverse NN O O
reactions NN O O
was NN O O
4.0 NN O O
days NN O O
in NN O O
both NN O O
treatment NN O O
groups NN O O
. NN O O
Table NN O O
1 NN O O
lists NN O O
selected NN O O
adverse NN O O
reactions NN O O
occurring NN O O
in NN O O
more NN O O
than NN O O
2 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
DALVANCE NN O O
in NN O O
clinical NN O O
trials NN O O
. NN O O
Table1 NN O O
. NN O O
Selected NN O O
Adverse NN O O
Reactions NN O O
in NN O O
Phase NN O O
2/3 NN O O
Trials NN O O
( NN O O
Number NN O O
( NN O O
% NN O O
) NN O O
of NN O O
Patients NN O O
) NN O O
Dalbavancin NN O O
Comparator NN O O
* NN O O
( NN O O
N NN O O
= NN O O
1778 NN O O
) NN O O
( NN O O
N NN O O
= NN O O
1224 NN O O
) NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
98 NN O O
( NN O O
5.5 NN O O
) NN O O
78 NN O O
( NN O O
6.4 NN O O
) NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
50 NN O O
( NN O O
2.8 NN O O
) NN O O
37 NN O O
( NN O O
3 NN O O
) NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
79 NN O O
( NN O O
4.4 NN O O
) NN O O
72 NN O O
( NN O O
5.9 NN O O
) NN O O
Headache NN B-AdverseReaction B-AdverseReaction
83 NN O O
( NN O O
4.7 NN O O
) NN O O
59 NN O O
( NN O O
4.8 NN O O
) NN O O
Rash NN B-AdverseReaction B-AdverseReaction
48 NN O O
( NN O O
2.7 NN O O
) NN O O
30 NN O O
( NN O O
2.4 NN O O
) NN O O
Pruritus NN B-AdverseReaction B-AdverseReaction
38 NN O O
( NN O O
2.1 NN O O
) NN O O
41 NN O O
( NN O O
3.3 NN O O
) NN O O
* NN O O
Comparators NN O O
included NN O O
linezolid NN O O
, NN O O
cefazolin NN O O
, NN O O
cephalexin NN O O
, NN O O
and NN O O
vancomycin NN O O
. NN O O
The NN O O
following NN O O
selected NN O O
adverse NN O O
reactions NN O O
were NN O O
reported NN O O
in NN O O
DALVANCE NN O O
treated NN O O
patients NN O O
at NN O O
a NN O O
rate NN O O
of NN O O
less NN O O
than NN O O
2 NN O O
% NN O O
in NN O O
these NN O O
clinical NN O O
trials NN O O
: NN O O
Blood NN O O
and NN O O
lymphatic NN O O
system NN O O
disorders NN O O
: NN O O
anemia NN B-AdverseReaction B-AdverseReaction
hemorrhagic NN B-AdverseReaction B-AdverseReaction
anemia NN I-AdverseReaction I-AdverseReaction
leucopenia NN B-AdverseReaction B-AdverseReaction
neutropenia NN B-AdverseReaction B-AdverseReaction
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
petechiae NN B-AdverseReaction B-AdverseReaction
eosinophilia NN B-AdverseReaction B-AdverseReaction
thrombocytosis NN B-AdverseReaction B-AdverseReaction
Gastrointestinal NN O O
disorders NN O O
: NN O O
gastrointestinal NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
melena NN B-AdverseReaction B-AdverseReaction
hematochezia NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
: NN O O
infusion NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
Hepatobiliary NN O O
disorders NN O O
: NN O O
hepatotoxicity NN B-AdverseReaction B-AdverseReaction
Immune NN O O
system NN O O
disorders NN O O
: NN O O
anaphylactoid NN B-AdverseReaction B-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
Infections NN O O
and NN O O
infestations NN O O
: NN O O
Clostridium NN B-AdverseReaction B-AdverseReaction
difficile NN I-AdverseReaction I-AdverseReaction
colitis NN I-AdverseReaction I-AdverseReaction
oral NN B-AdverseReaction B-AdverseReaction
candidiasis NN I-AdverseReaction I-AdverseReaction
vulvovaginal NN B-AdverseReaction B-AdverseReaction
mycotic NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
Investigations NN O O
: NN O O
hepatic NN B-AdverseReaction B-AdverseReaction
transaminases NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
blood NN B-AdverseReaction B-AdverseReaction
alkaline NN I-AdverseReaction I-AdverseReaction
phosphatase NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
international NN B-AdverseReaction B-AdverseReaction
normalized NN I-AdverseReaction I-AdverseReaction
ratio NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
Metabolism NN O O
and NN O O
nutrition NN O O
disorders NN O O
: NN O O
hypoglycemia NN B-AdverseReaction B-AdverseReaction
Nervous NN O O
System NN O O
disorders NN O O
: NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
Respiratory NN O O
, NN O O
thoracic NN O O
and NN O O
mediastinal NN O O
disorders NN O O
: NN O O
bronchospasm NN B-AdverseReaction B-AdverseReaction
Skin NN O O
and NN O O
Subcutaneous NN O O
Tissue NN O O
disorders NN O O
: NN O O
urticaria NN B-AdverseReaction B-AdverseReaction
Vascular NN O O
disorders NN O O
: NN O O
flushing NN B-AdverseReaction B-AdverseReaction
phlebitis NN B-AdverseReaction B-AdverseReaction
wound NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
spontaneous NN B-AdverseReaction B-AdverseReaction
hematoma NN I-AdverseReaction I-AdverseReaction
Alanine NN O O
Aminotransferase NN O O
( NN O O
ALT NN O O
) NN O O
Elevations NN O O
Among NN O O
patients NN O O
with NN O O
normal NN O O
baseline NN O O
ALT NN O O
levels NN O O
, NN O O
more NN O O
DALVANCE- NN O O
than NN O O
comparator NN O O
- NN O O
treated NN O O
patients NN O O
had NN O O
post NN O O
- NN O O
baseline NN O O
ALT NN B-AdverseReaction B-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
greater NN O O
than NN O O
3 NN B-Severity B-Severity
times NN I-Severity I-Severity
the NN I-Severity I-Severity
upper NN I-Severity I-Severity
limit NN I-Severity I-Severity
of NN I-Severity I-Severity
normal NN I-Severity I-Severity
( NN O O
ULN NN O O
) NN O O
, NN O O
12 NN O O
( NN O O
0.8 NN O O
% NN O O
) NN O O
vs. NN O O
2 NN O O
( NN O O
0.2 NN O O
% NN O O
) NN O O
, NN O O
respectively NN O O
including NN O O
three NN O O
subjects NN O O
with NN O O
post NN O O
- NN O O
baseline NN O O
ALT NN B-AdverseReaction B-AdverseReaction
values NN I-AdverseReaction I-AdverseReaction
greater NN I-AdverseReaction I-AdverseReaction
than NN I-AdverseReaction I-AdverseReaction
10 NN I-AdverseReaction I-AdverseReaction
times NN I-AdverseReaction I-AdverseReaction
ULN NN I-AdverseReaction I-AdverseReaction
Eight NN O O
of NN O O
12 NN O O
patients NN O O
treated NN O O
with NN O O
DALVANCE NN O O
and NN O O
one NN O O
comparator NN O O
patient NN O O
had NN O O
underlying NN O O
conditions NN O O
which NN O O
could NN O O
affect NN O O
liver NN O O
enzymes NN O O
, NN O O
including NN O O
chronic NN O O
viral NN O O
hepatitis NN O O
and NN O O
a NN O O
history NN O O
of NN O O
alcohol NN O O
abuse NN O O
. NN O O
In NN O O
addition NN O O
, NN O O
one NN O O
DALVANCE NN O O
- NN O O
treated NN O O
subject NN O O
in NN O O
a NN O O
Phase NN O O
1 NN O O
trial NN O O
had NN O O
post NN O O
- NN O O
baseline NN O O
ALT NN B-AdverseReaction B-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
greater NN O O
than NN O O
20 NN B-Severity B-Severity
times NN I-Severity I-Severity
ULN NN I-Severity I-Severity
ALT NN B-AdverseReaction B-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
were NN O O
reversible NN O O
in NN O O
all NN O O
subjects NN O O
. NN O O
No NN B-Negation B-Negation
comparator NN O O
- NN O O
treated NN O O
subject NN O O
with NN O O
normal NN O O
baseline NN O O
transaminases NN O O
had NN O O
post NN O O
- NN O O
baseline NN O O
ALT NN B-AdverseReaction B-AdverseReaction
elevation NN I-AdverseReaction I-AdverseReaction
greater NN O O
than NN O O
10 NN B-Severity B-Severity
times NN I-Severity I-Severity
ULN NN I-Severity I-Severity
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Serious NN B-Severity B-Severity
hypersensitivity NN O O
( NN O O
anaphylactic NN O O
) NN O O
and NN O O
skin NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
with NN O O
glycopeptide NN O O
antibacterial NN O O
agents NN O O
, NN O O
including NN O O
DALVANCE NN O O
; NN O O
exercise NN O O
caution NN O O
in NN O O
patients NN O O
with NN O O
known NN O O
hypersensitivity NN O O
to NN O O
glycopeptides NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Rapid NN O O
intravenous NN O O
infusion NN O O
of NN O O
glycopeptide NN O O
antibacterial NN O O
agents NN O O
can NN B-Factor B-Factor
cause NN O O
reactions NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
ALT NN B-AdverseReaction B-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
with NN O O
DALVANCE NN O O
treatment NN O O
were NN O O
reported NN O O
in NN O O
clinical NN O O
trials NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Clostridium NN B-AdverseReaction B-AdverseReaction
difficile NN I-AdverseReaction I-AdverseReaction
-associated NN I-AdverseReaction I-AdverseReaction
diarrhea NN I-AdverseReaction I-AdverseReaction
( NN O O
CDAD NN O O
) NN O O
has NN O O
been NN O O
reported NN O O
with NN O O
nearly NN O O
all NN O O
systemic NN O O
antibacterial NN O O
agents NN O O
, NN O O
including NN O O
DALVANCE. NN O O
Evaluate NN O O
if NN O O
diarrhea NN O O
occurs NN O O
. NN O O
( NN O O
5.4 NN O O
) NN O O
5.1 NN O O
Hypersensitivity NN O O
Reactions NN O O
Serious NN B-Severity B-Severity
hypersensitivity NN O O
( NN O O
anaphylactic NN O O
) NN O O
and NN O O
skin NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
DALVANCE. NN O O
If NN O O
an NN O O
allergic NN O O
reaction NN O O
occurs NN O O
, NN O O
treatment NN O O
with NN O O
DALVANCE NN O O
should NN O O
be NN O O
discontinued NN O O
. NN O O
Before NN O O
using NN O O
DALVANCE NN O O
, NN O O
inquire NN O O
carefully NN O O
about NN O O
previous NN O O
hypersensitivity NN O O
reactions NN O O
to NN O O
glycopeptides NN O O
, NN O O
and NN O O
due NN O O
to NN O O
the NN O O
possibility NN O O
of NN O O
cross NN O O
- NN O O
sensitivity NN O O
, NN O O
exercise NN O O
caution NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
glycopeptide NN O O
allergy NN O O
[ NN O O
see NN O O
Patient NN O O
Counseling NN O O
Information NN O O
( NN O O
17 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
Infusion NN O O
- NN O O
Related NN O O
Reactions NN O O
DALVANCE NN O O
is NN O O
administered NN O O
via NN O O
intravenous NN O O
infusion NN O O
, NN O O
using NN O O
a NN O O
total NN O O
infusion NN O O
time NN O O
of NN O O
30 NN O O
minutes NN O O
to NN O O
minimize NN O O
the NN O O
risk NN O O
of NN O O
infusion NN O O
- NN O O
related NN O O
reactions NN O O
. NN O O
Rapid NN O O
intravenous NN O O
infusions NN O O
of NN O O
DALVANCE NN O O
can NN B-Factor B-Factor
cause NN O O
reactions NN O O
that NN O O
resemble NN O O
" NN O O
Red NN O O
- NN O O
Man NN O O
Syndrome NN O O
, NN O O
" NN O O
including NN O O
flushing NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
upper NN I-AdverseReaction I-AdverseReaction
body NN I-AdverseReaction I-AdverseReaction
urticaria NN B-AdverseReaction B-AdverseReaction
pruritus NN B-AdverseReaction B-AdverseReaction
and/or NN O O
rash NN B-AdverseReaction B-AdverseReaction
Stopping NN O O
or NN O O
slowing NN O O
the NN O O
infusion NN O O
may NN O O
result NN O O
in NN O O
cessation NN O O
of NN O O
these NN O O
reactions NN O O
. NN O O
5.3 NN O O
Hepatic NN O O
Effects NN O O
In NN O O
Phase NN O O
2 NN O O
and NN O O
3 NN O O
clinical NN O O
trials NN O O
, NN O O
more NN O O
DALVANCE- NN O O
than NN O O
comparator NN O O
- NN O O
treated NN O O
subjects NN O O
with NN O O
normal NN O O
baseline NN O O
transaminase NN O O
levels NN O O
had NN O O
post NN O O
- NN O O
baseline NN O O
alanine NN O O
aminotransferase NN O O
( NN O O
ALT NN O O
) NN O O
elevation NN O O
greater NN O O
than NN O O
3 NN B-Severity B-Severity
times NN I-Severity I-Severity
the NN I-Severity I-Severity
upper NN I-Severity I-Severity
limit NN I-Severity I-Severity
of NN I-Severity I-Severity
normal NN I-Severity I-Severity
( NN O O
ULN NN O O
) NN O O
. NN O O
Overall NN O O
, NN O O
abnormalities NN O O
in NN O O
liver NN O O
tests NN O O
( NN O O
ALT NN O O
, NN O O
AST NN O O
, NN O O
bilirubin NN O O
) NN O O
were NN O O
reported NN O O
with NN O O
similar NN O O
frequency NN O O
in NN O O
the NN O O
DALVANCE NN O O
and NN O O
comparator NN O O
arms NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
5.4 NN O O
Clostridium NN O O
difficile NN O O
- NN O O
Associated NN O O
Diarrhea NN O O
Clostridium NN B-AdverseReaction B-AdverseReaction
difficile NN I-AdverseReaction I-AdverseReaction
-associated NN I-AdverseReaction I-AdverseReaction
diarrhea NN I-AdverseReaction I-AdverseReaction
( NN O O
CDAD NN O O
) NN O O
has NN O O
been NN O O
reported NN O O
in NN O O
users NN O O
of NN O O
nearly NN O O
all NN O O
systemic NN O O
antibacterial NN O O
drugs NN O O
, NN O O
including NN O O
DALVANCE NN O O
, NN O O
with NN O O
severity NN O O
ranging NN O O
from NN O O
mild NN B-Severity B-Severity
diarrhea NN B-AdverseReaction B-AdverseReaction
to NN O O
fatal NN B-AdverseReaction B-AdverseReaction
colitis NN B-AdverseReaction B-AdverseReaction
Treatment NN O O
with NN O O
antibacterial NN O O
agents NN O O
can NN O O
alter NN O O
the NN O O
normal NN O O
flora NN O O
of NN O O
the NN O O
colon NN O O
, NN O O
and NN O O
may NN O O
permit NN O O
overgrowth NN O O
of NN O O
C. NN O O
difficile NN O O
. NN O O
C. NN O O
difficile NN O O
produces NN O O
toxins NN O O
A NN O O
and NN O O
B NN O O
which NN O O
contribute NN O O
to NN O O
the NN O O
development NN O O
of NN O O
CDAD. NN O O
Hypertoxin NN O O
- NN O O
producing NN O O
strains NN O O
of NN O O
C. NN O O
difficile NN O O
cause NN O O
increased NN O O
morbidity NN O O
and NN O O
mortality NN O O
, NN O O
as NN O O
these NN O O
infections NN O O
can NN O O
be NN O O
refractory NN O O
to NN O O
antibacterial NN O O
therapy NN O O
and NN O O
may NN O O
require NN O O
colectomy NN O O
. NN O O
CDAD NN O O
must NN O O
be NN O O
considered NN O O
in NN O O
all NN O O
patients NN O O
who NN O O
present NN O O
with NN O O
diarrhea NN O O
following NN O O
antibacterial NN O O
use NN O O
. NN O O
Careful NN O O
medical NN O O
history NN O O
is NN O O
necessary NN O O
because NN O O
CDAD NN O O
has NN O O
been NN O O
reported NN O O
to NN O O
occur NN O O
more NN O O
than NN O O
2 NN O O
months NN O O
after NN O O
the NN O O
administration NN O O
of NN O O
antibacterial NN O O
agents NN O O
. NN O O
If NN O O
CDAD NN O O
is NN O O
suspected NN O O
or NN O O
confirmed NN O O
, NN O O
ongoing NN O O
antibacterial NN O O
use NN O O
not NN O O
directed NN O O
against NN O O
C. NN O O
difficile NN O O
should NN O O
be NN O O
discontinued NN O O
, NN O O
if NN O O
possible NN O O
. NN O O
Appropriate NN O O
measures NN O O
such NN O O
as NN O O
fluid NN O O
and NN O O
electrolyte NN O O
management NN O O
, NN O O
protein NN O O
supplementation NN O O
, NN O O
antibacterial NN O O
treatment NN O O
of NN O O
C. NN O O
difficile NN O O
, NN O O
and NN O O
surgical NN O O
evaluation NN O O
should NN O O
be NN O O
instituted NN O O
as NN O O
clinically NN O O
indicated NN O O
. NN O O
5.5 NN O O
Development NN O O
of NN O O
Drug NN O O
- NN O O
Resistant NN O O
Bacteria NN O O
Prescribing NN O O
DALVANCE NN O O
in NN O O
the NN O O
absence NN O O
of NN O O
a NN O O
proven NN O O
or NN O O
strongly NN O O
suspected NN O O
bacterial NN O O
infection NN O O
is NN O O
unlikely NN O O
to NN O O
provide NN O O
benefit NN O O
to NN O O
the NN O O
patient NN O O
and NN O O
increases NN O O
the NN O O
risk NN O O
of NN O O
the NN O O
development NN O O
of NN O O
drug NN O O
- NN O O
resistant NN O O
bacteria NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
adverse NN O O
drug NN O O
reactions NN O O
( NN O O
adverse NN O O
events NN O O
assessed NN O O
as NN O O
causally NN O O
related NN O O
by NN O O
the NN O O
investigator NN O O
or NN O O
ADRs NN O O
) NN O O
are NN O O
discussed NN O O
in NN O O
other NN O O
sections NN O O
of NN O O
the NN O O
labeling NN O O
: NN O O
* NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Effects NN O O
on NN O O
serum NN O O
liver NN O O
biochemistries NN O O
in NN O O
patients NN O O
with NN O O
hepatitis NN O O
B NN O O
or NN O O
C NN O O
co NN O O
- NN O O
infection NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Fat NN B-AdverseReaction B-AdverseReaction
Redistribution NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Immune NN B-AdverseReaction B-AdverseReaction
Reconstitution NN I-AdverseReaction I-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
. NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
with NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
of NN O O
moderate NN B-Severity B-Severity
to NN O O
severe NN B-Severity B-Severity
intensity NN O O
and NN O O
incidence NN O O
at NN O O
least NN O O
2 NN O O
% NN O O
( NN O O
in NN O O
those NN O O
receiving NN O O
TIVICAY NN O O
in NN O O
any NN O O
one NN O O
adult NN O O
trial NN O O
) NN O O
are NN O O
insomnia NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
and NN O O
headache NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
ViiV NN O O
Healthcare NN O O
at NN O O
1 NN O O
- NN O O
877 NN O O
- NN O O
844 NN O O
- NN O O
8872 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
in NN O O
Adult NN O O
Subjects NN O O
Treatment NN O O
- NN O O
emergent NN O O
Adverse NN O O
Drug NN O O
Reactions NN O O
( NN O O
ADRs NN O O
) NN O O
Treatment NN O O
- NN O O
naive NN O O
Subjects NN O O
: NN O O
The NN O O
safety NN O O
assessment NN O O
of NN O O
TIVICAY NN O O
in NN O O
HIV-1-infected NN O O
treatment NN O O
- NN O O
naive NN O O
subjects NN O O
is NN O O
based NN O O
on NN O O
the NN O O
analyses NN O O
of NN O O
96-week NN O O
data NN O O
from NN O O
2 NN O O
international NN O O
, NN O O
multicenter NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
trials NN O O
, NN O O
SPRING-2 NN O O
( NN O O
ING113086 NN O O
) NN O O
and NN O O
SINGLE NN O O
( NN O O
ING114467 NN O O
) NN O O
and NN O O
48-week NN O O
data NN O O
from NN O O
the NN O O
international NN O O
, NN O O
multicenter NN O O
, NN O O
open NN O O
- NN O O
label NN O O
FLAMINGO NN O O
( NN O O
ING114915 NN O O
) NN O O
trial NN O O
. NN O O
In NN O O
SPRING-2 NN O O
, NN O O
822 NN O O
subjects NN O O
were NN O O
randomized NN O O
and NN O O
received NN O O
at NN O O
least NN O O
1 NN O O
dose NN O O
of NN O O
either NN O O
TIVICAY NN O O
50 NN O O
mg NN O O
once NN O O
daily NN O O
or NN O O
raltegravir NN O O
400 NN O O
mg NN O O
twice NN O O
daily NN O O
, NN O O
both NN O O
in NN O O
combination NN O O
with NN O O
fixed NN O O
- NN O O
dose NN O O
dual NN O O
nucleoside NN O O
reverse NN O O
transcriptase NN O O
inhibitor NN O O
( NN O O
NRTI NN O O
) NN O O
treatment NN O O
( NN O O
either NN O O
abacavir NN O O
sulfate NN O O
and NN O O
lamivudine NN O O
[ NN O O
EPZICOM NN O O
( NN O O
r NN O O
) NN O O
] NN O O
or NN O O
emtricitabine/tenofovir NN O O
[ NN O O
TRUVADA NN O O
( NN O O
r NN O O
) NN O O
] NN O O
) NN O O
. NN O O
There NN O O
were NN O O
808 NN O O
subjects NN O O
included NN O O
in NN O O
the NN O O
efficacy NN O O
and NN O O
safety NN O O
analyses NN O O
. NN O O
Through NN O O
96 NN O O
weeks NN O O
, NN O O
the NN O O
rate NN O O
of NN O O
adverse NN O O
events NN O O
leading NN O O
to NN O O
discontinuation NN O O
was NN O O
2 NN O O
% NN O O
in NN O O
both NN O O
treatment NN O O
arms NN O O
. NN O O
In NN O O
SINGLE NN O O
, NN O O
833 NN O O
subjects NN O O
were NN O O
randomized NN O O
and NN O O
received NN O O
at NN O O
least NN O O
1 NN O O
dose NN O O
of NN O O
either NN O O
TIVICAY NN O O
50 NN O O
mg NN O O
with NN O O
fixed NN O O
- NN O O
dose NN O O
abacavir NN O O
sulfate NN O O
and NN O O
lamivudine NN O O
( NN O O
EPZICOM NN O O
) NN O O
once NN O O
daily NN O O
or NN O O
fixed NN O O
- NN O O
dose NN O O
efavirenz/emtricitabine/tenofovir NN O O
( NN O O
ATRIPLA NN O O
( NN O O
r NN O O
) NN O O
) NN O O
once NN O O
daily NN O O
. NN O O
Through NN O O
96 NN O O
weeks NN O O
, NN O O
the NN O O
rates NN O O
of NN O O
adverse NN O O
events NN O O
leading NN O O
to NN O O
discontinuation NN O O
were NN O O
3 NN O O
% NN O O
in NN O O
subjects NN O O
receiving NN O O
TIVICAY NN O O
50 NN O O
mg NN O O
once NN O O
daily NN O O
+ NN O O
EPZICOM NN O O
and NN O O
12 NN O O
% NN O O
in NN O O
subjects NN O O
receiving NN O O
ATRIPLA NN O O
once NN O O
daily NN O O
. NN O O
Treatment NN O O
- NN O O
emergent NN O O
ADRs NN O O
of NN O O
moderate NN O O
to NN O O
severe NN O O
intensity NN O O
observed NN O O
in NN O O
at NN O O
least NN O O
2 NN O O
% NN O O
of NN O O
subjects NN O O
in NN O O
either NN O O
treatment NN O O
arm NN O O
in NN O O
SPRING-2 NN O O
and NN O O
SINGLE NN O O
trials NN O O
are NN O O
provided NN O O
in NN O O
Table NN O O
2 NN O O
. NN O O
Side NN O O
- NN O O
by NN O O
- NN O O
side NN O O
tabulation NN O O
is NN O O
to NN O O
simplify NN O O
presentation NN O O
; NN O O
direct NN O O
comparisons NN O O
across NN O O
trials NN O O
should NN O O
not NN O O
be NN O O
made NN O O
due NN O O
to NN O O
differing NN O O
trial NN O O
designs NN O O
. NN O O
Table NN O O
2 NN O O
. NN O O
Treatment NN O O
- NN O O
emergent NN O O
Adverse NN O O
Drug NN O O
Reactions NN O O
of NN O O
at NN O O
Least NN O O
Moderate NN O O
Intensity NN O O
( NN O O
Grades NN O O
2 NN O O
to NN O O
4 NN O O
) NN O O
and NN O O
at NN O O
Least NN O O
2 NN O O
% NN O O
Frequency NN O O
in NN O O
Treatment NN O O
- NN O O
naive NN O O
Subjects NN O O
in NN O O
SPRING-2 NN O O
and NN O O
SINGLE NN O O
Trials NN O O
( NN O O
Week NN O O
96 NN O O
Analysis NN O O
) NN O O
System NN O O
Organ NN O O
Class/ NN O O
Preferred NN O O
Term NN O O
SPRING-2 NN O O
SINGLE NN O O
TIVICAY NN O O
50 NN O O
mg NN O O
Once NN O O
Daily NN O O
+ NN O O
2 NN O O
NRTIs NN O O
( NN O O
n NN O O
= NN O O
403 NN O O
) NN O O
Raltegravir NN O O
400 NN O O
mg NN O O
Twice NN O O
Daily NN O O
+ NN O O
2 NN O O
NRTIs(n NN O O
= NN O O
405 NN O O
) NN O O
TIVICAY NN O O
50 NN O O
mg NN O O
+ NN O O
EPZICOM NN O O
Once NN O O
Daily(n NN O O
= NN O O
414 NN O O
) NN O O
ATRIPLA NN O O
Once NN O O
Daily(n NN O O
= NN O O
419 NN O O
) NN O O
Psychiatric NN O O
Insomnia NN B-AdverseReaction B-AdverseReaction
< NN O O
1 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
3 NN O O
% NN O O
2 NN O O
% NN O O
Depression NN B-AdverseReaction B-AdverseReaction
< NN O O
1 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
1 NN O O
% NN O O
2 NN O O
% NN O O
Abnormal NN B-AdverseReaction B-AdverseReaction
dreams NN I-AdverseReaction I-AdverseReaction
< NN O O
1 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
2 NN O O
% NN O O
Nervous NN O O
System NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
< NN O O
1 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
5 NN O O
% NN O O
Headache NN B-AdverseReaction B-AdverseReaction
< NN O O
1 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
2 NN O O
% NN O O
2 NN O O
% NN O O
Gastrointestinal NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
1 NN O O
% NN O O
1 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
3 NN O O
% NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
< NN O O
1 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
2 NN O O
% NN O O
Skin NN O O
and NN O O
Subcutaneous NN O O
Tissue NN O O
Rash NN B-AdverseReaction B-AdverseReaction
0 NN O O
< NN O O
1 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
6 NN O O
% NN O O
General NN O O
Disorders NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
< NN O O
1 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
2 NN O O
% NN O O
2 NN O O
% NN O O
Ear NN O O
and NN O O
Labyrinth NN O O
Vertigo NN B-AdverseReaction B-AdverseReaction
0 NN O O
< NN O O
1 NN O O
% NN O O
0 NN O O
2 NN O O
% NN O O
a NN O O
Includes NN O O
pooled NN O O
terms NN O O
: NN O O
rash NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
generalized NN I-AdverseReaction I-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
macular NN I-AdverseReaction I-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
maculo NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
papular NN I-AdverseReaction I-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
pruritic NN I-AdverseReaction I-AdverseReaction
and NN O O
drug NN B-AdverseReaction B-AdverseReaction
eruption NN I-AdverseReaction I-AdverseReaction
In NN O O
addition NN O O
, NN O O
Grade NN B-Severity B-Severity
1 NN I-Severity I-Severity
insomnia NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
by NN O O
1 NN O O
% NN O O
and NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
of NN O O
subjects NN O O
receiving NN O O
TIVICAY NN O O
and NN O O
raltegravir NN O O
, NN O O
respectively NN O O
, NN O O
in NN O O
SPRING-2 NN O O
; NN O O
whereas NN O O
in NN O O
SINGLE NN O O
the NN O O
rates NN O O
were NN O O
7 NN O O
% NN O O
and NN O O
4 NN O O
% NN O O
for NN O O
TIVICAY NN O O
and NN O O
ATRIPLA NN O O
, NN O O
respectively NN O O
. NN O O
These NN O O
events NN O O
were NN O O
not NN O O
treatment NN O O
limiting NN O O
. NN O O
In NN O O
a NN O O
multicenter NN O O
, NN O O
open NN O O
- NN O O
label NN O O
trial NN O O
( NN O O
FLAMINGO NN O O
) NN O O
, NN O O
243 NN O O
subjects NN O O
received NN O O
TIVICAY NN O O
50 NN O O
mg NN O O
once NN O O
daily NN O O
versus NN O O
242 NN O O
subjects NN O O
who NN O O
received NN O O
darunavir NN O O
800 NN O O
mg/ritonavir NN O O
100 NN O O
mg NN O O
once NN O O
daily NN O O
, NN O O
both NN O O
in NN O O
combination NN O O
with NN O O
investigator NN O O
- NN O O
selected NN O O
NRTI NN O O
background NN O O
regimen NN O O
( NN O O
either NN O O
EPZICOM NN O O
or NN O O
TRUVADA NN O O
) NN O O
. NN O O
There NN O O
were NN O O
484 NN O O
subjects NN O O
included NN O O
in NN O O
the NN O O
efficacy NN O O
and NN O O
safety NN O O
analyses NN O O
. NN O O
Through NN O O
48 NN O O
weeks NN O O
, NN O O
the NN O O
rates NN O O
of NN O O
adverse NN O O
events NN O O
leading NN O O
to NN O O
discontinuation NN O O
were NN O O
2 NN O O
% NN O O
in NN O O
subjects NN O O
receiving NN O O
TIVICAY NN O O
and NN O O
4 NN O O
% NN O O
in NN O O
subjects NN O O
receiving NN O O
darunavir/ritonavir NN O O
. NN O O
The NN O O
ADRs NN O O
observed NN O O
in NN O O
FLAMINGO NN O O
were NN O O
generally NN O O
consistent NN O O
with NN O O
those NN O O
seen NN O O
in NN O O
SPRING-2 NN O O
and NN O O
SINGLE. NN O O
Treatment NN O O
- NN O O
experienced NN O O
, NN O O
Integrase NN O O
Strand NN O O
Transfer NN O O
Inhibitor NN O O
- NN O O
naive NN O O
Subjects NN O O
: NN O O
In NN O O
an NN O O
international NN O O
, NN O O
multicenter NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
trial NN O O
( NN O O
ING111762 NN O O
, NN O O
SAILING NN O O
) NN O O
, NN O O
719 NN O O
HIV-1-infected NN O O
, NN O O
antiretroviral NN O O
treatment NN O O
- NN O O
experienced NN O O
adults NN O O
were NN O O
randomized NN O O
and NN O O
received NN O O
either NN O O
TIVICAY NN O O
50 NN O O
mg NN O O
once NN O O
daily NN O O
or NN O O
raltegravir NN O O
400 NN O O
mg NN O O
twice NN O O
daily NN O O
with NN O O
investigator NN O O
- NN O O
selected NN O O
background NN O O
regimen NN O O
consisting NN O O
of NN O O
up NN O O
to NN O O
2 NN O O
agents NN O O
, NN O O
including NN O O
at NN O O
least NN O O
one NN O O
fully NN O O
active NN O O
agent NN O O
. NN O O
At NN O O
48 NN O O
weeks NN O O
, NN O O
the NN O O
rates NN O O
of NN O O
adverse NN O O
events NN O O
leading NN O O
to NN O O
discontinuation NN O O
were NN O O
3 NN O O
% NN O O
in NN O O
subjects NN O O
receiving NN O O
TIVICAY NN O O
50 NN O O
mg NN O O
once NN O O
daily NN O O
+ NN O O
background NN O O
regimen NN O O
and NN O O
4 NN O O
% NN O O
in NN O O
subjects NN O O
receiving NN O O
raltegravir NN O O
400 NN O O
mg NN O O
twice NN O O
daily NN O O
+ NN O O
background NN O O
regimen NN O O
. NN O O
The NN O O
only NN O O
treatment NN O O
- NN O O
emergent NN O O
ADR NN O O
of NN O O
moderate NN B-Severity B-Severity
to NN O O
severe NN B-Severity B-Severity
intensity NN O O
with NN O O
at NN O O
least NN O O
2 NN O O
% NN O O
frequency NN O O
in NN O O
either NN O O
treatment NN O O
group NN O O
was NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
2 NN O O
% NN O O
( NN O O
6 NN O O
of NN O O
354 NN O O
) NN O O
in NN O O
subjects NN O O
receiving NN O O
TIVICAY NN O O
50 NN O O
mg NN O O
once NN O O
daily NN O O
+ NN O O
background NN O O
regimen NN O O
and NN O O
1 NN O O
% NN O O
( NN O O
5 NN O O
of NN O O
361 NN O O
) NN O O
in NN O O
subjects NN O O
receiving NN O O
raltegravir NN O O
400 NN O O
mg NN O O
twice NN O O
daily NN O O
+ NN O O
background NN O O
regimen NN O O
. NN O O
Treatment NN O O
- NN O O
experienced NN O O
, NN O O
Integrase NN O O
Strand NN O O
Transfer NN O O
Inhibitor NN O O
- NN O O
experienced NN O O
Subjects NN O O
: NN O O
In NN O O
a NN O O
multicenter NN O O
, NN O O
open NN O O
- NN O O
label NN O O
, NN O O
single NN O O
- NN O O
arm NN O O
trial NN O O
( NN O O
ING112574 NN O O
, NN O O
VIKING-3 NN O O
) NN O O
, NN O O
183 NN O O
HIV-1-infected NN O O
, NN O O
antiretroviral NN O O
treatment NN O O
- NN O O
experienced NN O O
adults NN O O
with NN O O
virological NN O O
failure NN O O
and NN O O
current NN O O
or NN O O
historical NN O O
evidence NN O O
of NN O O
raltegravir NN O O
and/or NN O O
elvitegravir NN O O
resistance NN O O
received NN O O
TIVICAY NN O O
50 NN O O
mg NN O O
twice NN O O
daily NN O O
with NN O O
the NN O O
current NN O O
failing NN O O
background NN O O
regimen NN O O
for NN O O
7 NN O O
days NN O O
and NN O O
with NN O O
optimized NN O O
background NN O O
therapy NN O O
from NN O O
Day NN O O
8 NN O O
. NN O O
The NN O O
rate NN O O
of NN O O
adverse NN O O
events NN O O
leading NN O O
to NN O O
discontinuation NN O O
was NN O O
4 NN O O
% NN O O
of NN O O
subjects NN O O
at NN O O
Week NN O O
48 NN O O
. NN O O
Treatment NN O O
- NN O O
emergent NN O O
ADRs NN O O
in NN O O
VIKING-3 NN O O
were NN O O
generally NN O O
similar NN O O
compared NN O O
with NN O O
observations NN O O
with NN O O
the NN O O
50-mg NN O O
once NN O O
- NN O O
daily NN O O
dose NN O O
in NN O O
adult NN O O
Phase NN O O
3 NN O O
trials NN O O
. NN O O
Less NN O O
Common NN O O
Adverse NN O O
Reactions NN O O
Observed NN O O
in NN O O
Treatment NN O O
- NN O O
naive NN O O
and NN O O
Treatment NN O O
- NN O O
experienced NN O O
Trials NN O O
The NN O O
following NN O O
ADRs NN O O
occurred NN O O
in NN O O
less NN O O
than NN O O
2 NN O O
% NN O O
of NN O O
treatment NN O O
- NN O O
naive NN O O
or NN O O
treatment NN O O
- NN O O
experienced NN O O
subjects NN O O
receiving NN O O
TIVICAY NN O O
in NN O O
a NN O O
combination NN O O
regimen NN O O
in NN O O
any NN O O
one NN O O
trial NN O O
. NN O O
These NN O O
events NN O O
have NN O O
been NN O O
included NN O O
because NN O O
of NN O O
their NN O O
seriousness NN O O
and NN O O
assessment NN O O
of NN O O
potential NN O O
causal NN O O
relationship NN O O
. NN O O
Gastrointestinal NN O O
Disorders NN O O
: NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
discomfort NN I-AdverseReaction I-AdverseReaction
flatulence NN B-AdverseReaction B-AdverseReaction
upper NN B-AdverseReaction B-AdverseReaction
abdominal NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
Hepatobiliary NN O O
Disorders NN O O
: NN O O
Hepatitis NN B-AdverseReaction B-AdverseReaction
Musculoskeletal NN O O
Disorders NN O O
: NN O O
Myositis NN B-AdverseReaction B-AdverseReaction
Psychiatric NN O O
Disorders NN O O
: NN O O
Suicidal NN B-AdverseReaction B-AdverseReaction
ideation NN I-AdverseReaction I-AdverseReaction
attempt NN O O
, NN O O
behavior NN O O
, NN O O
or NN O O
completion NN O O
. NN O O
These NN O O
events NN O O
were NN O O
observed NN O O
primarily NN O O
in NN O O
subjects NN O O
with NN O O
a NN O O
pre NN O O
- NN O O
existing NN O O
history NN O O
of NN O O
depression NN O O
or NN O O
other NN O O
psychiatric NN O O
illness NN O O
. NN O O
Renal NN O O
and NN O O
Urinary NN O O
Disorders NN O O
: NN O O
Renal NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
Skin NN O O
and NN O O
Subcutaneous NN O O
Tissue NN O O
Disorders NN O O
: NN O O
Pruritus NN B-AdverseReaction B-AdverseReaction
Laboratory NN O O
Abnormalities NN O O
Treatment NN O O
- NN O O
naive NN O O
Subjects NN O O
: NN O O
Selected NN O O
laboratory NN O O
abnormalities NN O O
( NN O O
Grades NN O O
2 NN O O
to NN O O
4 NN O O
) NN O O
with NN O O
a NN O O
worsening NN O O
grade NN O O
from NN O O
baseline NN O O
and NN O O
representing NN O O
the NN O O
worst NN O O
- NN O O
grade NN O O
toxicity NN O O
in NN O O
at NN O O
least NN O O
2 NN O O
% NN O O
of NN O O
subjects NN O O
are NN O O
presented NN O O
in NN O O
Table NN O O
3 NN O O
. NN O O
The NN O O
mean NN O O
change NN O O
from NN O O
baseline NN O O
observed NN O O
for NN O O
selected NN O O
lipid NN O O
values NN O O
is NN O O
presented NN O O
in NN O O
Table NN O O
4 NN O O
. NN O O
Side NN O O
- NN O O
by NN O O
- NN O O
side NN O O
tabulation NN O O
is NN O O
to NN O O
simplify NN O O
presentation NN O O
; NN O O
direct NN O O
comparisons NN O O
across NN O O
trials NN O O
should NN O O
not NN O O
be NN O O
made NN O O
due NN O O
to NN O O
differing NN O O
trial NN O O
designs NN O O
. NN O O
Table NN O O
3 NN O O
. NN O O
Selected NN O O
Laboratory NN O O
Abnormalities NN O O
( NN O O
Grades NN O O
2 NN O O
to NN O O
4 NN O O
) NN O O
in NN O O
Treatment NN O O
- NN O O
naive NN O O
Subjects NN O O
in NN O O
SPRING-2 NN O O
and NN O O
SINGLE NN O O
Trials NN O O
( NN O O
Week NN O O
96 NN O O
Analysis NN O O
) NN O O
Laboratory NN O O
Parameter NN O O
Preferred NN O O
Term NN O O
SPRING-2 NN O O
SINGLE NN O O
TIVICAY NN O O
50 NN O O
mg NN O O
Once NN O O
Daily NN O O
+ NN O O
2 NN O O
NRTIs NN O O
( NN O O
n NN O O
= NN O O
403 NN O O
) NN O O
Raltegravir NN O O
400 NN O O
mg NN O O
Twice NN O O
Daily NN O O
+ NN O O
2 NN O O
NRTIs NN O O
( NN O O
n NN O O
= NN O O
405 NN O O
) NN O O
TIVICAY NN O O
50 NN O O
mg NN O O
+ NN O O
EPZICOM NN O O
Once NN O O
Daily NN O O
( NN O O
n NN O O
= NN O O
414 NN O O
) NN O O
ATRIPLA NN O O
Once NN O O
Daily NN O O
( NN O O
n NN O O
= NN O O
419 NN O O
) NN O O
ALT NN O O
4 NN O O
% NN O O
4 NN O O
% NN O O
2 NN O O
% NN O O
5 NN O O
% NN O O
2 NN O O
% NN O O
2 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
AST NN O O
5 NN O O
% NN O O
3 NN O O
% NN O O
3 NN O O
% NN O O
3 NN O O
% NN O O
3 NN O O
% NN O O
2 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
3 NN O O
% NN O O
3 NN O O
% NN O O
2 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
0 NN O O
< NN O O
1 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
0 NN O O
Creatine NN O O
kinase NN O O
2 NN O O
% NN O O
5 NN O O
% NN O O
4 NN O O
% NN O O
1 NN O O
% NN O O
7 NN O O
% NN O O
4 NN O O
% NN O O
5 NN O O
% NN O O
7 NN O O
% NN O O
Hyperglycemia NN B-AdverseReaction B-AdverseReaction
6 NN O O
% NN O O
6 NN O O
% NN O O
7 NN O O
% NN O O
5 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
2 NN O O
% NN O O
2 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
Lipase NN O O
7 NN O O
% NN O O
7 NN O O
% NN O O
9 NN O O
% NN O O
9 NN O O
% NN O O
2 NN O O
% NN O O
5 NN O O
% NN O O
4 NN O O
% NN O O
3 NN O O
% NN O O
Total NN O O
neutrophils NN O O
4 NN O O
% NN O O
3 NN O O
% NN O O
3 NN O O
% NN O O
5 NN O O
% NN O O
2 NN O O
% NN O O
2 NN O O
% NN O O
2 NN O O
% NN O O
3 NN O O
% NN O O
ULN NN O O
= NN O O
Upper NN O O
limit NN O O
of NN O O
normal NN O O
. NN O O
Table NN O O
4 NN O O
. NN O O
Mean NN O O
Change NN O O
from NN O O
Baseline NN O O
in NN O O
Fasted NN O O
Lipid NN O O
Values NN O O
in NN O O
Treatment NN O O
- NN O O
naive NN O O
Subjects NN O O
in NN O O
SPRING-2 NN O O
and NN O O
SINGLE NN O O
Trials NN O O
( NN O O
Week NN O O
96 NN O O
Analysisa NN O O
) NN O O
Laboratory NN O O
Parameter NN O O
Preferred NN O O
Term NN O O
SPRING-2 NN O O
SINGLE NN O O
TIVICAY NN O O
50 NN O O
mg NN O O
Once NN O O
Daily NN O O
+ NN O O
2 NN O O
NRTIs NN O O
( NN O O
n NN O O
= NN O O
403 NN O O
) NN O O
Raltegravir NN O O
400 NN O O
mg NN O O
Twice NN O O
Daily NN O O
+ NN O O
2 NN O O
NRTIs NN O O
( NN O O
n NN O O
= NN O O
405 NN O O
) NN O O
TIVICAY NN O O
50 NN O O
mg NN O O
+ NN O O
EPZICOM NN O O
Once NN O O
Daily NN O O
( NN O O
n NN O O
= NN O O
414 NN O O
) NN O O
ATRIPLA NN O O
Once NN O O
Daily NN O O
( NN O O
n NN O O
= NN O O
419 NN O O
) NN O O
Cholesterol NN O O
( NN O O
mg/dL NN O O
) NN O O
8.1 NN O O
10.1 NN O O
23.2 NN O O
28.0 NN O O
HDL NN O O
cholesterol NN O O
( NN O O
mg/dL NN O O
) NN O O
2.0 NN O O
2.3 NN O O
5.2 NN O O
7.4 NN O O
LDL NN O O
cholesterol NN O O
( NN O O
mg/dL NN O O
) NN O O
5.1 NN O O
6.1 NN O O
14.5 NN O O
18.0 NN O O
Triglycerides NN O O
( NN O O
mg/dL NN O O
) NN O O
6.7 NN O O
6.6 NN O O
17.2 NN O O
17.4 NN O O
a NN O O
Subjects NN O O
on NN O O
lipid NN O O
- NN O O
lowering NN O O
agents NN O O
at NN O O
baseline NN O O
were NN O O
excluded NN O O
from NN O O
these NN O O
analyses NN O O
( NN O O
19 NN O O
subjects NN O O
in NN O O
each NN O O
arm NN O O
in NN O O
SPRING-2 NN O O
, NN O O
and NN O O
in NN O O
SINGLE NN O O
: NN O O
TIVICAY NN O O
n NN O O
= NN O O
30 NN O O
and NN O O
ATRIPLA NN O O
n NN O O
= NN O O
27 NN O O
) NN O O
. NN O O
Seventy NN O O
- NN O O
seven NN O O
subjects NN O O
initiated NN O O
a NN O O
lipid NN O O
- NN O O
lowering NN O O
agent NN O O
post NN O O
- NN O O
baseline NN O O
; NN O O
their NN O O
last NN O O
fasted NN O O
on NN O O
- NN O O
treatment NN O O
values NN O O
( NN O O
prior NN O O
to NN O O
starting NN O O
the NN O O
agent NN O O
) NN O O
were NN O O
used NN O O
regardless NN O O
if NN O O
they NN O O
discontinued NN O O
the NN O O
agent NN O O
( NN O O
SPRING-2 NN O O
: NN O O
TIVICAY NN O O
n NN O O
= NN O O
9 NN O O
, NN O O
raltegravir NN O O
n NN O O
= NN O O
13 NN O O
; NN O O
SINGLE NN O O
: NN O O
TIVICAY NN O O
n NN O O
= NN O O
25 NN O O
and NN O O
ATRIPLA NN O O
: NN O O
n NN O O
= NN O O
30 NN O O
) NN O O
. NN O O
Laboratory NN O O
abnormalities NN O O
observed NN O O
in NN O O
the NN O O
FLAMINGO NN O O
trial NN O O
were NN O O
generally NN O O
consistent NN O O
with NN O O
observations NN O O
in NN O O
SPRING-2 NN O O
and NN O O
SINGLE. NN O O
Treatment NN O O
- NN O O
experienced NN O O
, NN O O
Integrase NN O O
Strand NN O O
Transfer NN O O
Inhibitor NN O O
- NN O O
naive NN O O
Subjects NN O O
: NN O O
Laboratory NN O O
abnormalities NN O O
observed NN O O
in NN O O
SAILING NN O O
were NN O O
generally NN O O
similar NN O O
compared NN O O
with NN O O
observations NN O O
seen NN O O
in NN O O
the NN O O
treatment NN O O
- NN O O
naive NN O O
( NN O O
SPRING-2 NN O O
and NN O O
SINGLE NN O O
) NN O O
trials NN O O
. NN O O
Treatment NN O O
- NN O O
experienced NN O O
, NN O O
Integrase NN O O
Strand NN O O
Transfer NN O O
Inhibitor NN O O
- NN O O
experienced NN O O
Subjects NN O O
: NN O O
The NN O O
most NN O O
common NN O O
treatment NN O O
- NN O O
emergent NN O O
laboratory NN O O
abnormalities NN O O
( NN O O
greater NN O O
than NN O O
5 NN O O
% NN O O
for NN O O
Grades NN O O
2 NN O O
to NN O O
4 NN O O
combined NN O O
) NN O O
observed NN O O
in NN O O
VIKING-3 NN O O
at NN O O
Week NN O O
48 NN O O
were NN O O
elevated NN B-AdverseReaction B-AdverseReaction
ALT NN I-AdverseReaction I-AdverseReaction
( NN O O
9 NN O O
% NN O O
) NN O O
, NN O O
AST NN O O
( NN O O
8 NN O O
% NN O O
) NN O O
, NN O O
cholesterol NN O O
( NN O O
10 NN O O
% NN O O
) NN O O
, NN O O
creatine NN O O
kinase NN O O
( NN O O
6 NN O O
% NN O O
) NN O O
, NN O O
hyperglycemia NN B-AdverseReaction B-AdverseReaction
( NN O O
14 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
lipase NN O O
( NN O O
10 NN O O
% NN O O
) NN O O
. NN O O
Two NN O O
percent NN O O
( NN O O
4 NN O O
of NN O O
183 NN O O
) NN O O
of NN O O
subjects NN O O
had NN O O
a NN O O
Grade NN O O
3 NN O O
to NN O O
4 NN O O
treatment NN O O
- NN O O
emergent NN O O
hematology NN O O
laboratory NN O O
abnormality NN O O
, NN O O
with NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
[ NN O O
3 NN O O
of NN O O
183 NN O O
] NN O O
) NN O O
being NN O O
the NN O O
most NN O O
frequently NN O O
reported NN O O
. NN O O
Hepatitis NN O O
B NN O O
and/or NN O O
Hepatitis NN O O
C NN O O
Virus NN O O
Co NN O O
- NN O O
infection NN O O
: NN O O
In NN O O
Phase NN O O
3 NN O O
trials NN O O
, NN O O
subjects NN O O
with NN O O
hepatitis NN O O
B NN O O
and/or NN O O
C NN O O
virus NN O O
co NN O O
- NN O O
infection NN O O
were NN O O
permitted NN O O
to NN O O
enroll NN O O
provided NN O O
that NN O O
baseline NN O O
liver NN O O
chemistry NN O O
tests NN O O
did NN O O
not NN O O
exceed NN O O
5 NN O O
times NN O O
the NN O O
upper NN O O
limit NN O O
of NN O O
normal NN O O
. NN O O
Overall NN O O
, NN O O
the NN O O
safety NN O O
profile NN O O
in NN O O
subjects NN O O
with NN O O
hepatitis NN O O
B NN O O
and/or NN O O
C NN O O
virus NN O O
co NN O O
- NN O O
infection NN O O
was NN O O
similar NN O O
to NN O O
that NN O O
observed NN O O
in NN O O
subjects NN O O
without NN O O
hepatitis NN O O
B NN O O
or NN O O
C NN O O
co NN O O
- NN O O
infection NN O O
, NN O O
although NN O O
the NN O O
rates NN O O
of NN O O
AST NN O O
and NN O O
ALT NN B-AdverseReaction B-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
were NN O O
higher NN O O
in NN O O
the NN O O
subgroup NN O O
with NN O O
hepatitis NN O O
B NN O O
and/or NN O O
C NN O O
virus NN O O
co NN O O
- NN O O
infection NN O O
for NN O O
all NN O O
treatment NN O O
groups NN O O
. NN O O
Grades NN B-Severity B-Severity
2 NN I-Severity I-Severity
to NN I-Severity I-Severity
4 NN I-Severity I-Severity
ALT NN B-AdverseReaction B-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
in NN O O
hepatitis NN O O
B NN O O
and/or NN O O
C NN O O
co NN O O
- NN O O
infected NN O O
compared NN O O
with NN O O
HIV NN O O
mono NN O O
- NN O O
infected NN O O
subjects NN O O
receiving NN O O
TIVICAY NN O O
were NN O O
observed NN O O
in NN O O
18 NN O O
% NN O O
vs. NN O O
3 NN O O
% NN O O
with NN O O
the NN O O
50-mg NN O O
once NN O O
- NN O O
daily NN O O
dose NN O O
and NN O O
13 NN O O
% NN O O
vs. NN O O
8 NN O O
% NN O O
with NN O O
the NN O O
50-mg NN O O
twice NN O O
- NN O O
daily NN O O
dose NN O O
. NN O O
Liver NN B-AdverseReaction B-AdverseReaction
chemistry NN I-AdverseReaction I-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
consistent NN O O
with NN O O
immune NN B-AdverseReaction B-AdverseReaction
reconstitution NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
were NN O O
observed NN O O
in NN O O
some NN O O
subjects NN O O
with NN O O
hepatitis NN O O
B NN O O
and/or NN O O
C NN O O
at NN O O
the NN O O
start NN O O
of NN O O
therapy NN O O
with NN O O
TIVICAY NN O O
, NN O O
particularly NN O O
in NN O O
the NN O O
setting NN O O
where NN O O
anti NN O O
- NN O O
hepatitis NN O O
therapy NN O O
was NN O O
withdrawn NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
Changes NN O O
in NN O O
Serum NN O O
Creatinine NN O O
Dolutegravir NN O O
has NN O O
been NN O O
shown NN O O
to NN O O
increase NN B-AdverseReaction B-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
due NN O O
to NN O O
inhibition NN O O
of NN O O
tubular NN O O
secretion NN O O
of NN O O
creatinine NN O O
without NN O O
affecting NN O O
renal NN O O
glomerular NN O O
function NN O O
[ NN O O
see NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.2 NN O O
) NN O O
] NN O O
. NN O O
Increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
occurred NN O O
within NN O O
the NN O O
first NN O O
4 NN O O
weeks NN O O
of NN O O
treatment NN O O
and NN O O
remained NN O O
stable NN O O
through NN O O
48 NN O O
to NN O O
96 NN O O
weeks NN O O
. NN O O
In NN O O
treatment NN O O
- NN O O
naive NN O O
subjects NN O O
, NN O O
a NN O O
mean NN O O
change NN O O
from NN O O
baseline NN O O
of NN O O
0.15 NN O O
mg NN O O
per NN O O
dL NN O O
( NN O O
range NN O O
: NN O O
-0.32 NN O O
mg NN O O
per NN O O
dL NN O O
to NN O O
0.65 NN O O
mg NN O O
per NN O O
dL NN O O
) NN O O
was NN O O
observed NN O O
after NN O O
96 NN O O
weeks NN O O
of NN O O
treatment NN O O
. NN O O
Creatinine NN B-AdverseReaction B-AdverseReaction
increases NN I-AdverseReaction I-AdverseReaction
were NN O O
comparable NN O O
by NN O O
background NN O O
NRTIs NN O O
and NN O O
were NN O O
similar NN O O
in NN O O
treatment NN O O
- NN O O
experienced NN O O
subjects NN O O
. NN O O
6.2 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
in NN O O
Pediatric NN O O
Subjects NN O O
IMPAACT NN O O
P1093 NN O O
is NN O O
an NN O O
ongoing NN O O
multicenter NN O O
, NN O O
open NN O O
- NN O O
label NN O O
, NN O O
non NN O O
- NN O O
comparative NN O O
trial NN O O
of NN O O
approximately NN O O
160 NN O O
HIV-1-infected NN O O
pediatric NN O O
subjects NN O O
aged NN O O
6 NN O O
weeks NN O O
to NN O O
less NN O O
than NN O O
18 NN O O
years NN O O
, NN O O
of NN O O
which NN O O
23 NN O O
treatment NN O O
- NN O O
experienced NN O O
, NN O O
INSTI NN O O
- NN O O
naive NN O O
subjects NN O O
aged NN O O
12 NN O O
to NN O O
less NN O O
than NN O O
18 NN O O
years NN O O
were NN O O
enrolled NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.4 NN O O
) NN O O
, NN O O
Clinical NN O O
Studies NN O O
( NN O O
14.2 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
adverse NN O O
reaction NN O O
profile NN O O
was NN O O
similar NN O O
to NN O O
that NN O O
for NN O O
adults NN O O
. NN O O
Grade NN B-Severity B-Severity
2 NN I-Severity I-Severity
ADRs NN O O
reported NN O O
in NN O O
at NN O O
least NN O O
1 NN O O
subject NN O O
were NN O O
rash NN B-AdverseReaction B-AdverseReaction
( NN O O
n NN O O
= NN O O
1 NN O O
) NN O O
, NN O O
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
( NN O O
n NN O O
= NN O O
1 NN O O
) NN O O
, NN O O
and NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
( NN O O
n NN O O
= NN O O
1 NN O O
) NN O O
. NN O O
No NN O O
Grade NN O O
3 NN O O
or NN O O
4 NN O O
ADRs NN O O
were NN O O
reported NN O O
. NN O O
The NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
laboratory NN O O
abnormalities NN O O
were NN O O
elevated NN B-AdverseReaction B-AdverseReaction
total NN I-AdverseReaction I-AdverseReaction
bilirubin NN I-AdverseReaction I-AdverseReaction
and NN O O
lipase NN O O
reported NN O O
in NN O O
1 NN O O
subject NN O O
each NN O O
. NN O O
No NN O O
Grade NN O O
4 NN O O
laboratory NN O O
abnormalities NN O O
were NN O O
reported NN O O
. NN O O
The NN O O
changes NN O O
in NN O O
mean NN O O
serum NN O O
creatinine NN O O
were NN O O
similar NN O O
to NN O O
those NN O O
observed NN O O
in NN O O
adults NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
characterized NN O O
by NN O O
rash NN B-AdverseReaction B-AdverseReaction
constitutional NN O O
findings NN O O
, NN O O
and NN O O
sometimes NN O O
organ NN B-AdverseReaction B-AdverseReaction
dysfunction NN I-AdverseReaction I-AdverseReaction
including NN O O
liver NN B-AdverseReaction B-AdverseReaction
injury NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
. NN O O
Discontinue NN O O
TIVICAY NN O O
and NN O O
other NN O O
suspect NN O O
agents NN O O
immediately NN O O
if NN O O
signs NN O O
or NN O O
symptoms NN O O
of NN O O
hypersensitivity NN O O
reactions NN O O
develop NN O O
, NN O O
as NN O O
a NN O O
delay NN O O
in NN O O
stopping NN O O
treatment NN O O
may NN O O
result NN O O
in NN O O
a NN O O
life NN O O
- NN O O
threatening NN O O
reaction NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Patients NN O O
with NN O O
underlying NN O O
hepatitis NN O O
B NN O O
or NN O O
C NN O O
may NN O O
be NN O O
at NN O O
increased NN O O
risk NN B-Factor B-Factor
for NN O O
worsening NN O O
or NN O O
development NN O O
of NN O O
transaminase NN B-AdverseReaction B-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
with NN O O
use NN O O
of NN O O
TIVICAY. NN O O
Appropriate NN O O
laboratory NN O O
testing NN O O
prior NN O O
to NN O O
initiating NN O O
therapy NN O O
and NN O O
monitoring NN O O
for NN O O
hepatotoxicity NN O O
during NN O O
therapy NN O O
with NN O O
TIVICAY NN O O
is NN O O
recommended NN O O
in NN O O
patients NN O O
with NN O O
underlying NN O O
hepatic NN O O
disease NN O O
such NN O O
as NN O O
hepatitis NN O O
B NN O O
or NN O O
C. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Redistribution/accumulation NN O O
of NN O O
body NN O O
fat NN O O
and NN O O
immune NN B-AdverseReaction B-AdverseReaction
reconstitution NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
combination NN B-DrugClass B-DrugClass
antiretroviral NN I-DrugClass I-DrugClass
therapy NN I-DrugClass I-DrugClass
( NN O O
5.3 NN O O
, NN O O
5.4 NN O O
) NN O O
5.1 NN O O
Hypersensitivity NN O O
Reactions NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN O O
have NN O O
been NN O O
reported NN O O
and NN O O
were NN O O
characterized NN O O
by NN O O
rash NN B-AdverseReaction B-AdverseReaction
constitutional NN O O
findings NN O O
, NN O O
and NN O O
sometimes NN O O
organ NN B-AdverseReaction B-AdverseReaction
dysfunction NN I-AdverseReaction I-AdverseReaction
including NN O O
liver NN B-AdverseReaction B-AdverseReaction
injury NN I-AdverseReaction I-AdverseReaction
The NN O O
events NN O O
were NN O O
reported NN O O
in NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
of NN O O
subjects NN O O
receiving NN O O
TIVICAY NN O O
in NN O O
Phase NN O O
3 NN O O
clinical NN O O
trials NN O O
. NN O O
Discontinue NN O O
TIVICAY NN O O
and NN O O
other NN O O
suspect NN O O
agents NN O O
immediately NN O O
if NN O O
signs NN O O
or NN O O
symptoms NN O O
of NN O O
hypersensitivity NN O O
reactions NN O O
develop NN O O
( NN O O
including NN O O
, NN O O
but NN O O
not NN O O
limited NN O O
to NN O O
, NN O O
severe NN O O
rash NN O O
or NN O O
rash NN O O
accompanied NN O O
by NN O O
fever NN O O
, NN O O
general NN O O
malaise NN O O
, NN O O
fatigue NN O O
, NN O O
muscle NN O O
or NN O O
joint NN O O
aches NN O O
, NN O O
blisters NN O O
or NN O O
peeling NN O O
of NN O O
the NN O O
skin NN O O
, NN O O
oral NN O O
blisters NN O O
or NN O O
lesions NN O O
, NN O O
conjunctivitis NN O O
, NN O O
facial NN O O
edema NN O O
, NN O O
hepatitis NN O O
, NN O O
eosinophilia NN O O
, NN O O
angioedema NN O O
, NN O O
difficulty NN O O
breathing NN O O
) NN O O
. NN O O
Clinical NN O O
status NN O O
, NN O O
including NN O O
liver NN O O
aminotransferases NN O O
, NN O O
should NN O O
be NN O O
monitored NN O O
and NN O O
appropriate NN O O
therapy NN O O
initiated NN O O
. NN O O
Delay NN O O
in NN O O
stopping NN O O
treatment NN O O
with NN O O
TIVICAY NN O O
or NN O O
other NN O O
suspect NN O O
agents NN O O
after NN O O
the NN O O
onset NN O O
of NN O O
hypersensitivity NN O O
may NN O O
result NN O O
in NN O O
a NN O O
life NN O O
- NN O O
threatening NN O O
reaction NN O O
. NN O O
TIVICAY NN O O
is NN O O
contraindicated NN O O
in NN O O
patients NN O O
who NN O O
have NN O O
experienced NN O O
a NN O O
previous NN O O
hypersensitivity NN O O
reaction NN O O
to NN O O
dolutegravir NN O O
. NN O O
5.2 NN O O
Effects NN O O
on NN O O
Serum NN O O
Liver NN O O
Biochemistries NN O O
in NN O O
Patients NN O O
with NN O O
Hepatitis NN O O
B NN O O
or NN O O
C NN O O
Co NN O O
- NN O O
infection NN O O
Patients NN O O
with NN O O
underlying NN O O
hepatitis NN O O
B NN O O
or NN O O
C NN O O
may NN O O
be NN O O
at NN O O
increased NN O O
risk NN B-Factor B-Factor
for NN O O
worsening NN O O
or NN O O
development NN O O
of NN O O
transaminase NN B-AdverseReaction B-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
with NN O O
use NN O O
of NN O O
TIVICAY NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
In NN O O
some NN O O
cases NN O O
the NN O O
elevations NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
transaminases NN I-AdverseReaction I-AdverseReaction
were NN O O
consistent NN O O
with NN O O
immune NN B-AdverseReaction B-AdverseReaction
reconstitution NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
or NN O O
hepatitis NN B-AdverseReaction B-AdverseReaction
B NN I-AdverseReaction I-AdverseReaction
reactivation NN I-AdverseReaction I-AdverseReaction
particularly NN O O
in NN O O
the NN O O
setting NN O O
where NN O O
anti NN O O
- NN O O
hepatitis NN O O
therapy NN O O
was NN O O
withdrawn NN O O
. NN O O
Appropriate NN O O
laboratory NN O O
testing NN O O
prior NN O O
to NN O O
initiating NN O O
therapy NN O O
and NN O O
monitoring NN O O
for NN O O
hepatotoxicity NN O O
during NN O O
therapy NN O O
with NN O O
TIVICAY NN O O
are NN O O
recommended NN O O
in NN O O
patients NN O O
with NN O O
underlying NN O O
hepatic NN O O
disease NN O O
such NN O O
as NN O O
hepatitis NN O O
B NN O O
or NN O O
C. NN O O
5.3 NN O O
Fat NN O O
Redistribution NN O O
Redistribution/accumulation NN O O
of NN O O
body NN O O
fat NN O O
, NN O O
including NN O O
central NN B-AdverseReaction B-AdverseReaction
obesity NN I-AdverseReaction I-AdverseReaction
dorsocervical NN B-AdverseReaction B-AdverseReaction
fat NN I-AdverseReaction I-AdverseReaction
enlargement NN I-AdverseReaction I-AdverseReaction
( NN O O
buffalo NN O O
hump NN O O
) NN O O
, NN O O
peripheral NN O O
wasting NN O O
, NN O O
facial NN B-AdverseReaction B-AdverseReaction
wasting NN I-AdverseReaction I-AdverseReaction
breast NN B-AdverseReaction B-AdverseReaction
enlargement NN I-AdverseReaction I-AdverseReaction
and NN O O
" NN O O
cushingoid NN O O
appearance NN O O
" NN O O
have NN O O
been NN O O
observed NN O O
in NN O O
patients NN O O
receiving NN O O
antiretroviral NN B-DrugClass B-DrugClass
therapy NN I-DrugClass I-DrugClass
The NN O O
mechanism NN O O
and NN O O
long NN O O
- NN O O
term NN O O
consequences NN O O
of NN O O
these NN O O
events NN O O
are NN O O
currently NN O O
unknown NN O O
. NN O O
A NN O O
causal NN O O
relationship NN O O
has NN O O
not NN O O
been NN O O
established NN O O
. NN O O
5.4 NN O O
Immune NN O O
Reconstitution NN O O
Syndrome NN O O
Immune NN B-AdverseReaction B-AdverseReaction
reconstitution NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
has NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
combination NN O O
antiretroviral NN O O
therapy NN O O
, NN O O
including NN O O
TIVICAY. NN O O
During NN O O
the NN O O
initial NN O O
phase NN O O
of NN O O
combination NN O O
antiretroviral NN O O
treatment NN O O
, NN O O
patients NN O O
whose NN O O
immune NN O O
systems NN O O
respond NN O O
may NN B-Factor B-Factor
develop NN O O
an NN O O
inflammatory NN B-AdverseReaction B-AdverseReaction
response NN I-AdverseReaction I-AdverseReaction
to NN O O
indolent NN O O
or NN O O
residual NN B-AdverseReaction B-AdverseReaction
opportunistic NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
( NN O O
such NN O O
as NN O O
Mycobacterium NN B-AdverseReaction B-AdverseReaction
avium NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
cytomegalovirus NN B-AdverseReaction B-AdverseReaction
Pneumocystis NN B-AdverseReaction B-AdverseReaction
jirovecii NN I-AdverseReaction I-AdverseReaction
pneumonia NN I-AdverseReaction I-AdverseReaction
[ NN O O
PCP NN O O
] NN O O
, NN O O
or NN O O
tuberculosis NN B-AdverseReaction B-AdverseReaction
which NN O O
may NN O O
necessitate NN O O
further NN O O
evaluation NN O O
and NN O O
treatment NN O O
. NN O O
Autoimmune NN B-AdverseReaction B-AdverseReaction
disorders NN I-AdverseReaction I-AdverseReaction
( NN O O
such NN O O
as NN O O
Graves NN B-AdverseReaction B-AdverseReaction
' NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
polymyositis NN B-AdverseReaction B-AdverseReaction
and NN O O
Guillain NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Barre NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
have NN O O
also NN O O
been NN O O
reported NN O O
to NN O O
occur NN O O
in NN O O
the NN O O
setting NN O O
of NN O O
immune NN O O
reconstitution NN O O
; NN O O
however NN O O
, NN O O
the NN O O
time NN O O
to NN O O
onset NN O O
is NN O O
more NN O O
variable NN O O
and NN O O
can NN O O
occur NN O O
many NN O O
months NN O O
after NN O O
initiation NN O O
of NN O O
treatment NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
are NN O O
discussed NN O O
in NN O O
greater NN O O
detail NN O O
in NN O O
other NN O O
sections NN O O
of NN O O
the NN O O
labeling NN O O
: NN O O
* NN O O
Cardiac NN B-AdverseReaction B-AdverseReaction
Toxicities NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Acute NN B-AdverseReaction B-AdverseReaction
Renal NN I-AdverseReaction I-AdverseReaction
Failure NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
Tumor NN B-AdverseReaction B-AdverseReaction
Lysis NN I-AdverseReaction I-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
* NN O O
Pulmonary NN B-AdverseReaction B-AdverseReaction
Toxicity NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
* NN O O
Pulmonary NN B-AdverseReaction B-AdverseReaction
Hypertension NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
* NN O O
Dyspnea NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.6 NN O O
) NN O O
] NN O O
* NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.7 NN O O
) NN O O
] NN O O
* NN O O
Venous NN B-AdverseReaction B-AdverseReaction
Thrombosis NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.8 NN O O
) NN O O
] NN O O
* NN O O
Infusion NN B-AdverseReaction B-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.9 NN O O
) NN O O
] NN O O
* NN O O
Thrombocytopenia NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.10 NN O O
) NN O O
] NN O O
* NN O O
Hepatic NN B-AdverseReaction B-AdverseReaction
Toxicity NN I-AdverseReaction I-AdverseReaction
and NN O O
Hepatic NN B-AdverseReaction B-AdverseReaction
Failure NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.11 NN O O
) NN O O
] NN O O
* NN O O
Thrombotic NN B-AdverseReaction B-AdverseReaction
Thrombocytopenic NN I-AdverseReaction I-AdverseReaction
Purpura NN I-AdverseReaction I-AdverseReaction
Uremic NN O O
Syndrome NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.12 NN O O
) NN O O
] NN O O
* NN O O
Posterior NN B-AdverseReaction B-AdverseReaction
Reversible NN I-AdverseReaction I-AdverseReaction
Encephalopathy NN I-AdverseReaction I-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
PRES NN O O
) NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.13 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
events NN O O
occurring NN O O
in NN O O
at NN O O
least NN O O
20 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
Kyprolis NN O O
in NN O O
monotherapy NN O O
trials NN O O
: NN O O
anemia NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
pyrexia NN B-AdverseReaction B-AdverseReaction
decreased NN B-AdverseReaction B-AdverseReaction
platelets NN I-AdverseReaction I-AdverseReaction
dyspnea NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
decreased NN B-AdverseReaction B-AdverseReaction
lymphocyte NN I-AdverseReaction I-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
decreased NN B-AdverseReaction B-AdverseReaction
hemoglobin NN I-AdverseReaction I-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
edema NN B-AdverseReaction B-AdverseReaction
peripheral NN I-AdverseReaction I-AdverseReaction
( NN O O
6 NN O O
) NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
events NN O O
occurring NN O O
in NN O O
at NN O O
least NN O O
20 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
Kyprolis NN O O
in NN O O
the NN O O
combination NN O O
therapy NN O O
trial NN O O
: NN O O
decreased NN B-AdverseReaction B-AdverseReaction
lymphocytes NN I-AdverseReaction I-AdverseReaction
decreased NN B-AdverseReaction B-AdverseReaction
absolute NN I-AdverseReaction I-AdverseReaction
neutrophil NN I-AdverseReaction I-AdverseReaction
count NN I-AdverseReaction I-AdverseReaction
decreased NN B-AdverseReaction B-AdverseReaction
phosphorus NN I-AdverseReaction I-AdverseReaction
anemia NN B-AdverseReaction B-AdverseReaction
neutropenia NN B-AdverseReaction B-AdverseReaction
decreased NN B-AdverseReaction B-AdverseReaction
total NN I-AdverseReaction I-AdverseReaction
white NN I-AdverseReaction I-AdverseReaction
blood NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
count NN I-AdverseReaction I-AdverseReaction
decreased NN B-AdverseReaction B-AdverseReaction
platelets NN I-AdverseReaction I-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
pyrexia NN B-AdverseReaction B-AdverseReaction
muscle NN B-AdverseReaction B-AdverseReaction
spasm NN I-AdverseReaction I-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
decreased NN B-AdverseReaction B-AdverseReaction
hemoglobin NN I-AdverseReaction I-AdverseReaction
hypokalemia NN B-AdverseReaction B-AdverseReaction
( NN O O
6 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Amgen NN O O
Medical NN O O
Information NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
77-AMGEN NN O O
( NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
772 NN O O
- NN O O
6436 NN O O
) NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
with NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
, NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
medical NN O O
practice NN O O
. NN O O
6.1.1 NN O O
Safety NN O O
Experience NN O O
with NN O O
Kyprolis NN O O
in NN O O
Combination NN O O
with NN O O
Lenalidomide NN O O
and NN O O
Dexamethasone NN O O
in NN O O
Patients NN O O
with NN O O
Multiple NN O O
Myeloma NN O O
The NN O O
safety NN O O
of NN O O
Kyprolis NN O O
in NN O O
combination NN O O
with NN O O
lenalidomide NN O O
and NN O O
dexamethasone NN O O
( NN O O
KRd NN O O
) NN O O
was NN O O
evaluated NN O O
in NN O O
an NN O O
open NN O O
- NN O O
label NN O O
randomized NN O O
study NN O O
in NN O O
patients NN O O
with NN O O
relapsed NN O O
multiple NN O O
myeloma NN O O
. NN O O
Details NN O O
of NN O O
the NN O O
study NN O O
treatment NN O O
are NN O O
described NN O O
in NN O O
Section NN O O
14.1 NN O O
. NN O O
The NN O O
median NN O O
number NN O O
of NN O O
cycles NN O O
initiated NN O O
was NN O O
22 NN O O
cycles NN O O
for NN O O
the NN O O
KRd NN O O
arm NN O O
and NN O O
14 NN O O
cycles NN O O
for NN O O
the NN O O
Rd NN O O
arm NN O O
. NN O O
Deaths NN B-AdverseReaction B-AdverseReaction
due NN O O
to NN O O
adverse NN O O
events NN O O
within NN O O
30 NN O O
days NN O O
of NN O O
the NN O O
last NN O O
dose NN O O
of NN O O
any NN O O
therapy NN O O
in NN O O
the NN O O
KRd NN O O
arm NN O O
occurred NN O O
in NN O O
27/392 NN O O
( NN O O
7 NN O O
% NN O O
) NN O O
patients NN O O
compared NN O O
with NN O O
27/389 NN O O
( NN O O
7 NN O O
% NN O O
) NN O O
patients NN O O
who NN O O
died NN B-AdverseReaction B-AdverseReaction
due NN O O
to NN O O
adverse NN O O
events NN O O
within NN O O
30 NN O O
days NN O O
of NN O O
the NN O O
last NN O O
dose NN O O
of NN O O
any NN O O
Rd NN O O
therapy NN O O
. NN O O
The NN O O
most NN O O
common NN O O
cause NN O O
of NN O O
deaths NN B-AdverseReaction B-AdverseReaction
occurring NN O O
in NN O O
patients NN O O
( NN O O
% NN O O
) NN O O
in NN O O
the NN O O
two NN O O
arms NN O O
( NN O O
KRd NN O O
versus NN O O
Rd NN O O
) NN O O
included NN O O
cardiac NN O O
10 NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
versus NN O O
7 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
, NN O O
infection NN O O
9 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
versus NN O O
10 NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
, NN O O
renal NN O O
0 NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
versus NN O O
1 NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
other NN O O
adverse NN O O
events NN O O
9 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
versus NN O O
10 NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
. NN O O
Serious NN O O
adverse NN O O
events NN O O
were NN O O
reported NN O O
in NN O O
60 NN O O
% NN O O
of NN O O
the NN O O
patients NN O O
in NN O O
the NN O O
KRd NN O O
arm NN O O
and NN O O
54 NN O O
% NN O O
of NN O O
the NN O O
patients NN O O
in NN O O
the NN O O
Rd NN O O
arm NN O O
. NN O O
The NN O O
most NN O O
common NN O O
serious NN O O
adverse NN O O
events NN O O
reported NN O O
in NN O O
the NN O O
KRd NN O O
arm NN O O
as NN O O
compared NN O O
with NN O O
the NN O O
Rd NN O O
arm NN O O
were NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
( NN O O
14 NN O O
% NN O O
versus NN O O
11 NN O O
% NN O O
) NN O O
, NN O O
respiratory NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
( NN O O
4 NN O O
% NN O O
versus NN O O
1.5 NN O O
% NN O O
) NN O O
, NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
( NN O O
4 NN O O
% NN O O
versus NN O O
2 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
pulmonary NN B-AdverseReaction B-AdverseReaction
embolism NN I-AdverseReaction I-AdverseReaction
( NN O O
3 NN O O
% NN O O
versus NN O O
2 NN O O
% NN O O
) NN O O
. NN O O
Discontinuation NN O O
due NN O O
to NN O O
any NN O O
adverse NN O O
event NN O O
occurred NN O O
in NN O O
26 NN O O
% NN O O
in NN O O
the NN O O
KRd NN O O
arm NN O O
versus NN O O
25 NN O O
% NN O O
in NN O O
the NN O O
Rd NN O O
arm NN O O
. NN O O
Adverse NN O O
events NN O O
leading NN O O
to NN O O
discontinuation NN O O
of NN O O
Kyprolis NN O O
occurred NN O O
in NN O O
12 NN O O
% NN O O
of NN O O
patients NN O O
and NN O O
the NN O O
most NN O O
common NN O O
events NN O O
included NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
( NN O O
1 NN O O
% NN O O
) NN O O
, NN O O
myocardial NN B-AdverseReaction B-AdverseReaction
infarction NN I-AdverseReaction I-AdverseReaction
( NN O O
0.8 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
( NN O O
0.8 NN O O
% NN O O
) NN O O
. NN O O
Common NN O O
Adverse NN O O
Events NN O O
( NN O O
>= NN O O
10 NN O O
% NN O O
) NN O O
The NN O O
adverse NN O O
events NN O O
in NN O O
the NN O O
first NN O O
12 NN O O
cycles NN O O
of NN O O
therapy NN O O
that NN O O
occurred NN O O
at NN O O
a NN O O
rate NN O O
of NN O O
10 NN O O
% NN O O
or NN O O
greater NN O O
in NN O O
the NN O O
KRd NN O O
arm NN O O
are NN O O
presented NN O O
in NN O O
Table NN O O
5 NN O O
. NN O O
Table NN O O
5 NN O O
: NN O O
Common NN O O
Adverse NN O O
Events NN O O
( NN O O
>= NN O O
10 NN O O
% NN O O
in NN O O
the NN O O
KRd NN O O
Arm NN O O
) NN O O
Occurring NN O O
in NN O O
Cycles NN O O
1 NN O O
- NN O O
12 NN O O
( NN O O
Combination NN O O
Therapy NN O O
) NN O O
KRd NN O O
= NN O O
Kyprolis NN O O
, NN O O
lenalidomide NN O O
, NN O O
and NN O O
low NN O O
- NN O O
dose NN O O
dexamethasone NN O O
; NN O O
Rd NN O O
= NN O O
lenalidomide NN O O
and NN O O
low NN O O
- NN O O
dose NN O O
dexamethasone NN O O
a NN O O
Pneumonia NN B-AdverseReaction B-AdverseReaction
includes NN O O
preferred NN O O
terms NN O O
of NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
bronchopneumonia NN B-AdverseReaction B-AdverseReaction
b NN O O
Peripheral NN B-AdverseReaction B-AdverseReaction
neuropathies NN I-AdverseReaction I-AdverseReaction
NEC NN I-AdverseReaction I-AdverseReaction
includes NN O O
preferred NN O O
terms NN O O
under NN O O
HLT NN O O
peripheral NN B-AdverseReaction B-AdverseReaction
neuropathies NN I-AdverseReaction I-AdverseReaction
NEC NN I-AdverseReaction I-AdverseReaction
c NN O O
Dyspnea NN B-AdverseReaction B-AdverseReaction
includes NN O O
preferred NN O O
terms NN O O
of NN O O
dyspnea NN B-AdverseReaction B-AdverseReaction
dyspnea NN B-AdverseReaction B-AdverseReaction
exertional NN I-AdverseReaction I-AdverseReaction
d NN O O
Embolic NN B-AdverseReaction B-AdverseReaction
and NN I-AdverseReaction I-AdverseReaction
thrombotic NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
, NN I-AdverseReaction I-AdverseReaction
venous NN I-AdverseReaction I-AdverseReaction
include NN O O
preferred NN O O
terms NN O O
in NN O O
MedDRA NN O O
SMQ NN O O
narrow NN O O
scope NN O O
search NN O O
of NN O O
embolic NN B-AdverseReaction B-AdverseReaction
and NN I-AdverseReaction I-AdverseReaction
thrombotic NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
, NN I-AdverseReaction I-AdverseReaction
venous NN I-AdverseReaction I-AdverseReaction
e NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
includes NN O O
preferred NN O O
terms NN O O
of NN O O
hypertension NN B-AdverseReaction B-AdverseReaction
hypertensive NN B-AdverseReaction B-AdverseReaction
crisis NN I-AdverseReaction I-AdverseReaction
hypertensive NN B-AdverseReaction B-AdverseReaction
emergency NN I-AdverseReaction I-AdverseReaction
System NN O O
Organ NN O O
Class NN O O
KRd NN O O
Arm(N NN O O
= NN O O
392 NN O O
) NN O O
Rd NN O O
Arm(N NN O O
= NN O O
389 NN O O
) NN O O
Preferred NN O O
Term NN O O
Any NN O O
Grade NN O O
>= NN O O
Grade NN O O
3 NN O O
Any NN O O
Grade NN O O
>= NN O O
Grade NN O O
3 NN O O
Blood NN O O
and NN O O
Lymphatic NN O O
System NN O O
Disorders NN O O
Anemia NN B-AdverseReaction B-AdverseReaction
138 NN O O
( NN O O
35 NN O O
% NN O O
) NN O O
53 NN O O
( NN O O
14 NN O O
% NN O O
) NN O O
127 NN O O
( NN O O
33 NN O O
% NN O O
) NN O O
47 NN O O
( NN O O
12 NN O O
% NN O O
) NN O O
Neutropenia NN B-AdverseReaction B-AdverseReaction
124 NN O O
( NN O O
32 NN O O
% NN O O
) NN O O
104 NN O O
( NN O O
27 NN O O
% NN O O
) NN O O
115 NN O O
( NN O O
30 NN O O
% NN O O
) NN O O
89 NN O O
( NN O O
23 NN O O
% NN O O
) NN O O
Thrombocytopenia NN B-AdverseReaction B-AdverseReaction
100 NN O O
( NN O O
26 NN O O
% NN O O
) NN O O
58 NN O O
( NN O O
15 NN O O
% NN O O
) NN O O
75 NN O O
( NN O O
19 NN O O
% NN O O
) NN O O
39 NN O O
( NN O O
10 NN O O
% NN O O
) NN O O
Gastrointestinal NN O O
Disorders NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
115 NN O O
( NN O O
29 NN O O
% NN O O
) NN O O
7 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
105 NN O O
( NN O O
27 NN O O
% NN O O
) NN O O
12 NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
68 NN O O
( NN O O
17 NN O O
% NN O O
) NN O O
0 NN O O
53 NN O O
( NN O O
14 NN O O
% NN O O
) NN O O
1 NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
60 NN O O
( NN O O
15 NN O O
% NN O O
) NN O O
1 NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
39 NN O O
( NN O O
10 NN O O
% NN O O
) NN O O
3 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
General NN O O
Disorders NN O O
and NN O O
Administration NN O O
Site NN O O
Conditions NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
109 NN O O
( NN O O
28 NN O O
% NN O O
) NN O O
21 NN O O
( NN O O
5 NN O O
% NN O O
) NN O O
104 NN O O
( NN O O
27 NN O O
% NN O O
) NN O O
20 NN O O
( NN O O
5 NN O O
% NN O O
) NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
93 NN O O
( NN O O
24 NN O O
% NN O O
) NN O O
5 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
64 NN O O
( NN O O
17 NN O O
% NN O O
) NN O O
1 NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
Edema NN B-AdverseReaction B-AdverseReaction
Peripheral NN I-AdverseReaction I-AdverseReaction
63 NN O O
( NN O O
16 NN O O
% NN O O
) NN O O
2 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
57 NN O O
( NN O O
15 NN O O
% NN O O
) NN O O
2 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
Asthenia NN B-AdverseReaction B-AdverseReaction
53 NN O O
( NN O O
14 NN O O
% NN O O
) NN O O
11 NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
46 NN O O
( NN O O
12 NN O O
% NN O O
) NN O O
7 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
Infections NN O O
and NN O O
Infestations NN O O
Upper NN B-AdverseReaction B-AdverseReaction
Respiratory NN I-AdverseReaction I-AdverseReaction
Tract NN I-AdverseReaction I-AdverseReaction
Infection NN I-AdverseReaction I-AdverseReaction
85 NN O O
( NN O O
22 NN O O
% NN O O
) NN O O
7 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
52 NN O O
( NN O O
13 NN O O
% NN O O
) NN O O
3 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
Nasopharyngitis NN B-AdverseReaction B-AdverseReaction
63 NN O O
( NN O O
16 NN O O
% NN O O
) NN O O
0 NN O O
43 NN O O
( NN O O
11 NN O O
% NN O O
) NN O O
0 NN O O
Bronchitis NN B-AdverseReaction B-AdverseReaction
54 NN O O
( NN O O
14 NN O O
% NN O O
) NN O O
5 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
39 NN O O
( NN O O
10 NN O O
% NN O O
) NN O O
2 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
Pneumonia NN B-AdverseReaction B-AdverseReaction
54 NN O O
( NN O O
14 NN O O
% NN O O
) NN O O
35 NN O O
( NN O O
9 NN O O
% NN O O
) NN O O
43 NN O O
( NN O O
11 NN O O
% NN O O
) NN O O
27 NN O O
( NN O O
7 NN O O
% NN O O
) NN O O
Metabolism NN O O
and NN O O
Nutrition NN O O
Disorders NN O O
Hypokalemia NN B-AdverseReaction B-AdverseReaction
78 NN O O
( NN O O
20 NN O O
% NN O O
) NN O O
22 NN O O
( NN O O
6 NN O O
% NN O O
) NN O O
35 NN O O
( NN O O
9 NN O O
% NN O O
) NN O O
12 NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
Hypocalcemia NN B-AdverseReaction B-AdverseReaction
55 NN O O
( NN O O
14 NN O O
% NN O O
) NN O O
10 NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
39 NN O O
( NN O O
10 NN O O
% NN O O
) NN O O
5 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
Hyperglycemia NN B-AdverseReaction B-AdverseReaction
43 NN O O
( NN O O
11 NN O O
% NN O O
) NN O O
18 NN O O
( NN O O
5 NN O O
% NN O O
) NN O O
33 NN O O
( NN O O
9 NN O O
% NN O O
) NN O O
15 NN O O
( NN O O
4 NN O O
% NN O O
) NN O O
Musculoskeletal NN O O
and NN O O
Connective NN O O
Tissue NN O O
Disorders NN O O
Muscle NN B-AdverseReaction B-AdverseReaction
Spasms NN I-AdverseReaction I-AdverseReaction
88 NN O O
( NN O O
22 NN O O
% NN O O
) NN O O
3 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
73 NN O O
( NN O O
19 NN O O
% NN O O
) NN O O
3 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
Nervous NN O O
System NN O O
Disorders NN O O
Peripheral NN B-AdverseReaction B-AdverseReaction
Neuropathies NN I-AdverseReaction I-AdverseReaction
NEC NN I-AdverseReaction I-AdverseReaction
43 NN O O
( NN O O
11 NN O O
% NN O O
) NN O O
7 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
37 NN O O
( NN O O
10 NN O O
% NN O O
) NN O O
4 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
Psychiatric NN O O
Disorders NN O O
Insomnia NN B-AdverseReaction B-AdverseReaction
63 NN O O
( NN O O
16 NN O O
% NN O O
) NN O O
6 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
50 NN O O
( NN O O
13 NN O O
% NN O O
) NN O O
8 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
Respiratory NN O O
, NN O O
Thoracic NN O O
, NN O O
and NN O O
Mediastinal NN O O
Disorders NN O O
Cough NN B-AdverseReaction B-AdverseReaction
85 NN O O
( NN O O
22 NN O O
% NN O O
) NN O O
1 NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
46 NN O O
( NN O O
12 NN O O
% NN O O
) NN O O
0 NN O O
Dyspnea NN B-AdverseReaction B-AdverseReaction
70 NN O O
( NN O O
18 NN O O
% NN O O
) NN O O
9 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
58 NN O O
( NN O O
15 NN O O
% NN O O
) NN O O
6 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
Skin NN O O
and NN O O
Subcutaneous NN O O
Tissue NN O O
Disorders NN O O
Rash NN B-AdverseReaction B-AdverseReaction
45 NN O O
( NN O O
12 NN O O
% NN O O
) NN O O
5 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
53 NN O O
( NN O O
14 NN O O
% NN O O
) NN O O
5 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
Vascular NN O O
Disorders NN O O
Embolic NN B-AdverseReaction B-AdverseReaction
and NN I-AdverseReaction I-AdverseReaction
Thrombotic NN I-AdverseReaction I-AdverseReaction
Events NN I-AdverseReaction I-AdverseReaction
, NN I-AdverseReaction I-AdverseReaction
Venous NN I-AdverseReaction I-AdverseReaction
49 NN O O
( NN O O
13 NN O O
% NN O O
) NN O O
16 NN O O
( NN O O
4 NN O O
% NN O O
) NN O O
22 NN O O
( NN O O
6 NN O O
% NN O O
) NN O O
9 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
41 NN O O
( NN O O
11 NN O O
% NN O O
) NN O O
12 NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
15 NN O O
( NN O O
4 NN O O
% NN O O
) NN O O
4 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
There NN O O
were NN O O
274 NN O O
( NN O O
70 NN O O
% NN O O
) NN O O
patients NN O O
in NN O O
the NN O O
KRd NN O O
arm NN O O
who NN O O
received NN O O
treatment NN O O
beyond NN O O
Cycle NN O O
12 NN O O
. NN O O
There NN O O
were NN O O
no NN O O
new NN O O
clinically NN O O
relevant NN O O
AEs NN O O
that NN O O
emerged NN O O
in NN O O
the NN O O
later NN O O
treatment NN O O
cycles NN O O
. NN O O
Adverse NN O O
Reactions NN O O
Occurring NN O O
at NN O O
a NN O O
Frequency NN O O
of NN O O
< NN O O
10 NN O O
% NN O O
* NN O O
Blood NN O O
and NN O O
lymphatic NN O O
system NN O O
disorders NN O O
: NN O O
febrile NN B-AdverseReaction B-AdverseReaction
neutropenia NN I-AdverseReaction I-AdverseReaction
lymphopenia NN B-AdverseReaction B-AdverseReaction
* NN O O
Cardiac NN O O
disorders NN O O
: NN O O
cardiac NN B-AdverseReaction B-AdverseReaction
arrest NN I-AdverseReaction I-AdverseReaction
cardiac NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
cardiac NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
congestive NN I-AdverseReaction I-AdverseReaction
myocardial NN B-AdverseReaction B-AdverseReaction
infarction NN I-AdverseReaction I-AdverseReaction
myocardial NN B-AdverseReaction B-AdverseReaction
ischemia NN I-AdverseReaction I-AdverseReaction
* NN O O
Eye NN O O
disorders NN O O
: NN O O
cataract NN B-AdverseReaction B-AdverseReaction
vision NN B-AdverseReaction B-AdverseReaction
blurred NN I-AdverseReaction I-AdverseReaction
* NN O O
Gastrointestinal NN O O
disorders NN O O
: NN O O
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
upper NN I-AdverseReaction I-AdverseReaction
dyspepsia NN B-AdverseReaction B-AdverseReaction
toothache NN B-AdverseReaction B-AdverseReaction
* NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
: NN O O
chills NN B-AdverseReaction B-AdverseReaction
infusion NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
multi NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
organ NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
pain NN B-AdverseReaction B-AdverseReaction
* NN O O
Infections NN O O
and NN O O
infestations NN O O
: NN O O
influenza NN B-AdverseReaction B-AdverseReaction
sepsis NN B-AdverseReaction B-AdverseReaction
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
viral NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
* NN O O
Metabolism NN O O
and NN O O
nutrition NN O O
disorders NN O O
: NN O O
dehydration NN B-AdverseReaction B-AdverseReaction
hyperkalemia NN B-AdverseReaction B-AdverseReaction
hyperuricemia NN B-AdverseReaction B-AdverseReaction
hypoalbuminemia NN B-AdverseReaction B-AdverseReaction
hyponatremia NN B-AdverseReaction B-AdverseReaction
tumor NN B-AdverseReaction B-AdverseReaction
lysis NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
* NN O O
Musculoskeletal NN O O
and NN O O
connective NN O O
tissue NN O O
disorders NN O O
: NN O O
muscular NN B-AdverseReaction B-AdverseReaction
weakness NN I-AdverseReaction I-AdverseReaction
myalgia NN B-AdverseReaction B-AdverseReaction
* NN O O
Nervous NN O O
system NN O O
disorders NN O O
: NN O O
hypoesthesia NN B-AdverseReaction B-AdverseReaction
paresthesia NN B-AdverseReaction B-AdverseReaction
deafness NN B-AdverseReaction B-AdverseReaction
* NN O O
Psychiatric NN O O
disorders NN O O
: NN O O
anxiety NN B-AdverseReaction B-AdverseReaction
delirium NN B-AdverseReaction B-AdverseReaction
* NN O O
Renal NN O O
and NN O O
urinary NN O O
disorders NN O O
: NN O O
renal NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
renal NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
acute NN I-AdverseReaction I-AdverseReaction
renal NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
* NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
and NN O O
mediastinal NN O O
disorders NN O O
: NN O O
dysphonia NN B-AdverseReaction B-AdverseReaction
epistaxis NN B-AdverseReaction B-AdverseReaction
oropharyngeal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
pulmonary NN B-AdverseReaction B-AdverseReaction
embolism NN I-AdverseReaction I-AdverseReaction
pulmonary NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
* NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
: NN O O
erythema NN B-AdverseReaction B-AdverseReaction
hyperhidrosis NN B-AdverseReaction B-AdverseReaction
pruritus NN B-AdverseReaction B-AdverseReaction
* NN O O
Vascular NN O O
disorders NN O O
: NN O O
deep NN B-AdverseReaction B-AdverseReaction
vein NN I-AdverseReaction I-AdverseReaction
thrombosis NN I-AdverseReaction I-AdverseReaction
hypotension NN B-AdverseReaction B-AdverseReaction
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
and NN O O
higher NN O O
adverse NN O O
reactions NN O O
that NN O O
occurred NN O O
during NN O O
Cycles NN O O
1 NN O O
- NN O O
12 NN O O
with NN O O
a NN O O
substantial NN O O
difference NN O O
( NN O O
>= NN O O
2 NN O O
% NN O O
) NN O O
between NN O O
the NN O O
two NN O O
arms NN O O
were NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
hypokalemia NN B-AdverseReaction B-AdverseReaction
and NN O O
hypophosphatemia NN B-AdverseReaction B-AdverseReaction
Laboratory NN O O
Abnormalities NN O O
Table NN O O
6 NN O O
describes NN O O
Grade NN O O
3 NN O O
- NN O O
4 NN O O
laboratory NN O O
abnormalities NN O O
reported NN O O
at NN O O
a NN O O
rate NN O O
of NN O O
>=10 NN O O
% NN O O
in NN O O
the NN O O
KRd NN O O
arm NN O O
for NN O O
patients NN O O
who NN O O
received NN O O
combination NN O O
therapy NN O O
. NN O O
Table NN O O
6 NN O O
: NN O O
Grade NN O O
3 NN O O
- NN O O
4 NN O O
Laboratory NN O O
Abnormalities NN O O
( NN O O
>= NN O O
10 NN O O
% NN O O
) NN O O
in NN O O
Cycles NN O O
1 NN O O
- NN O O
12 NN O O
( NN O O
Combination NN O O
Therapy NN O O
) NN O O
KRd NN O O
= NN O O
Kyprolis NN O O
, NN O O
lenalidomide NN O O
, NN O O
and NN O O
low NN O O
- NN O O
dose NN O O
dexamethasone NN O O
; NN O O
Rd NN O O
= NN O O
lenalidomide NN O O
and NN O O
low NN O O
- NN O O
dose NN O O
dexamethasone NN O O
Laboratory NN O O
Abnormality NN O O
KRd NN O O
( NN O O
N NN O O
= NN O O
392 NN O O
) NN O O
Rd(N NN O O
= NN O O
389 NN O O
) NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
Lymphocytes NN I-AdverseReaction I-AdverseReaction
182 NN O O
( NN O O
46 NN O O
% NN O O
) NN O O
119 NN O O
( NN O O
31 NN O O
% NN O O
) NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
Absolute NN I-AdverseReaction I-AdverseReaction
Neutrophil NN I-AdverseReaction I-AdverseReaction
Count NN I-AdverseReaction I-AdverseReaction
152 NN O O
( NN O O
39 NN O O
% NN O O
) NN O O
140 NN O O
( NN O O
36 NN O O
% NN O O
) NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
Phosphorus NN I-AdverseReaction I-AdverseReaction
122 NN O O
( NN O O
31 NN O O
% NN O O
) NN O O
106 NN O O
( NN O O
27 NN O O
% NN O O
) NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
Platelets NN I-AdverseReaction I-AdverseReaction
101 NN O O
( NN O O
26 NN O O
% NN O O
) NN O O
59 NN O O
( NN O O
15 NN O O
% NN O O
) NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
Total NN I-AdverseReaction I-AdverseReaction
White NN I-AdverseReaction I-AdverseReaction
Blood NN I-AdverseReaction I-AdverseReaction
Cell NN I-AdverseReaction I-AdverseReaction
Count NN I-AdverseReaction I-AdverseReaction
97 NN O O
( NN O O
25 NN O O
% NN O O
) NN O O
71 NN O O
( NN O O
18 NN O O
% NN O O
) NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
Hemoglobin NN I-AdverseReaction I-AdverseReaction
58 NN O O
( NN O O
15 NN O O
% NN O O
) NN O O
68 NN O O
( NN O O
18 NN O O
% NN O O
) NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
Potassium NN I-AdverseReaction I-AdverseReaction
41 NN O O
( NN O O
11 NN O O
% NN O O
) NN O O
23 NN O O
( NN O O
6 NN O O
% NN O O
) NN O O
6.1.2 NN O O
Safety NN O O
Experience NN O O
with NN O O
Kyprolis NN O O
in NN O O
Patients NN O O
with NN O O
Multiple NN O O
Myeloma NN O O
who NN O O
Received NN O O
Monotherapy NN O O
The NN O O
safety NN O O
of NN O O
Kyprolis NN O O
was NN O O
evaluated NN O O
in NN O O
clinical NN O O
trials NN O O
in NN O O
which NN O O
598 NN O O
patients NN O O
with NN O O
relapsed NN O O
and/or NN O O
refractory NN O O
myeloma NN O O
received NN O O
Kyprolis NN O O
monotherapy NN O O
starting NN O O
with NN O O
the NN O O
20 NN O O
mg/m NN O O
2 NN O O
dose NN O O
in NN O O
Cycle NN O O
1 NN O O
Day NN O O
1 NN O O
and NN O O
escalating NN O O
to NN O O
27 NN O O
mg/m NN O O
2 NN O O
on NN O O
Cycle NN O O
1 NN O O
Day NN O O
8 NN O O
or NN O O
Cycle NN O O
2 NN O O
Day NN O O
1 NN O O
. NN O O
The NN O O
median NN O O
age NN O O
of NN O O
these NN O O
patients NN O O
was NN O O
64 NN O O
years NN O O
( NN O O
range NN O O
32 NN O O
- NN O O
87 NN O O
) NN O O
. NN O O
The NN O O
patients NN O O
received NN O O
a NN O O
median NN O O
of NN O O
5 NN O O
( NN O O
range NN O O
1 NN O O
- NN O O
20 NN O O
) NN O O
prior NN O O
regimens NN O O
. NN O O
Approximately NN O O
57 NN O O
% NN O O
of NN O O
the NN O O
patients NN O O
were NN O O
male NN O O
. NN O O
The NN O O
median NN O O
number NN O O
of NN O O
cycles NN O O
initiated NN O O
was NN O O
4 NN O O
( NN O O
range NN O O
1 NN O O
- NN O O
35 NN O O
) NN O O
. NN O O
Serious NN O O
adverse NN O O
events NN O O
were NN O O
reported NN O O
, NN O O
regardless NN O O
of NN O O
causality NN O O
, NN O O
in NN O O
50 NN O O
% NN O O
of NN O O
patients NN O O
in NN O O
the NN O O
pooled NN O O
Kyprolis NN O O
monotherapy NN O O
studies NN O O
( NN O O
n NN O O
= NN O O
598 NN O O
) NN O O
. NN O O
The NN O O
most NN O O
common NN O O
serious NN O O
adverse NN O O
events NN O O
were NN O O
: NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
( NN O O
8 NN O O
% NN O O
) NN O O
, NN O O
acute NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
( NN O O
5 NN O O
% NN O O
) NN O O
, NN O O
disease NN B-AdverseReaction B-AdverseReaction
progression NN I-AdverseReaction I-AdverseReaction
( NN O O
4 NN O O
% NN O O
) NN O O
, NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
, NN O O
hypercalcemia NN B-AdverseReaction B-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
, NN O O
congestive NN B-AdverseReaction B-AdverseReaction
heart NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
, NN O O
multiple NN B-AdverseReaction B-AdverseReaction
myeloma NN I-AdverseReaction I-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
, NN O O
anemia NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
dyspnea NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
. NN O O
In NN O O
patients NN O O
treated NN O O
with NN O O
Kyprolis NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
serious NN O O
adverse NN O O
events NN O O
was NN O O
higher NN O O
in NN O O
those NN O O
>= NN O O
65 NN O O
years NN O O
old NN O O
and NN O O
in NN O O
those NN O O
>= NN O O
75 NN O O
years NN O O
old NN O O
[ NN O O
see NN O O
Geriatric NN O O
Use NN O O
( NN O O
8.5 NN O O
) NN O O
] NN O O
. NN O O
Deaths NN B-AdverseReaction B-AdverseReaction
due NN O O
to NN O O
adverse NN O O
events NN O O
within NN O O
30 NN O O
days NN O O
of NN O O
the NN O O
last NN O O
dose NN O O
of NN O O
Kyprolis NN O O
occurred NN O O
in NN O O
30/598 NN O O
( NN O O
5 NN O O
% NN O O
) NN O O
patients NN O O
receiving NN O O
Kyprolis NN O O
monotherapy NN O O
. NN O O
These NN O O
adverse NN O O
events NN O O
were NN O O
related NN O O
to NN O O
cardiac NN B-AdverseReaction B-AdverseReaction
disorders NN I-AdverseReaction I-AdverseReaction
in NN O O
10 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
patients NN O O
, NN O O
infections NN B-AdverseReaction B-AdverseReaction
in NN O O
8 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
patients NN O O
, NN O O
renal NN B-AdverseReaction B-AdverseReaction
disorders NN I-AdverseReaction I-AdverseReaction
in NN O O
4 NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
patients NN O O
, NN O O
and NN O O
other NN O O
adverse NN O O
events NN O O
in NN O O
8 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
patients NN O O
. NN O O
In NN O O
a NN O O
randomized NN O O
trial NN O O
comparing NN O O
Kyprolis NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
versus NN O O
corticosteroids NN O O
with NN O O
optional NN O O
oral NN O O
cyclophosphamide NN O O
for NN O O
patients NN O O
with NN O O
relapsed NN O O
and NN O O
refractory NN O O
multiple NN O O
myeloma NN O O
, NN O O
mortality NN B-AdverseReaction B-AdverseReaction
was NN O O
higher NN O O
in NN O O
the NN O O
patients NN O O
treated NN O O
with NN O O
Kyprolis NN O O
in NN O O
comparison NN O O
to NN O O
the NN O O
control NN O O
arm NN O O
in NN O O
the NN O O
subgroup NN O O
of NN O O
48 NN O O
patients NN O O
>=75 NN O O
years NN O O
of NN O O
age NN O O
. NN O O
The NN O O
most NN O O
common NN O O
cause NN O O
of NN O O
discontinuation NN O O
due NN O O
to NN O O
an NN O O
adverse NN O O
event NN O O
was NN O O
acute NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
. NN O O
The NN O O
common NN O O
adverse NN O O
events NN O O
occurring NN O O
at NN O O
a NN O O
rate NN O O
of NN O O
10 NN O O
% NN O O
or NN O O
greater NN O O
with NN O O
Kyprolis NN O O
monotherapy NN O O
are NN O O
presented NN O O
in NN O O
Table NN O O
7 NN O O
. NN O O
Table NN O O
7 NN O O
: NN O O
Most NN O O
Commonly NN O O
Reported NN O O
Adverse NN O O
Events NN O O
( NN O O
>= NN O O
10 NN O O
% NN O O
) NN O O
with NN O O
Kyprolis NN O O
Monotherapy NN O O
a NN O O
Pneumonia NN B-AdverseReaction B-AdverseReaction
includes NN O O
the NN O O
preferred NN O O
terms NN O O
of NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
bronchopneumonia NN B-AdverseReaction B-AdverseReaction
b NN O O
Peripheral NN B-AdverseReaction B-AdverseReaction
neuropathies NN I-AdverseReaction I-AdverseReaction
NEC NN I-AdverseReaction I-AdverseReaction
includes NN O O
the NN O O
preferred NN O O
terms NN O O
under NN O O
HLT NN O O
peripheral NN B-AdverseReaction B-AdverseReaction
neuropathies NN I-AdverseReaction I-AdverseReaction
NEC NN I-AdverseReaction I-AdverseReaction
c NN O O
Dyspnea NN B-AdverseReaction B-AdverseReaction
includes NN O O
the NN O O
preferred NN O O
terms NN O O
of NN O O
dyspnea NN B-AdverseReaction B-AdverseReaction
dyspnea NN B-AdverseReaction B-AdverseReaction
exertional NN I-AdverseReaction I-AdverseReaction
d NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
includes NN O O
the NN O O
preferred NN O O
terms NN O O
of NN O O
hypertension NN B-AdverseReaction B-AdverseReaction
hypertensive NN B-AdverseReaction B-AdverseReaction
crisis NN I-AdverseReaction I-AdverseReaction
and NN O O
hypertensive NN B-AdverseReaction B-AdverseReaction
emergency NN I-AdverseReaction I-AdverseReaction
Kyprolis NN O O
Monotherapy20/27 NN O O
mg/m2 NN O O
( NN O O
N NN O O
= NN O O
598 NN O O
) NN O O
System NN O O
Organ NN O O
Class NN O O
Any NN O O
Grade NN O O
>= NN O O
Grade3 NN O O
Blood NN O O
and NN O O
Lymphatic NN O O
System NN O O
Disorders NN O O
Anemia NN B-AdverseReaction B-AdverseReaction
291 NN O O
( NN O O
49 NN O O
% NN O O
) NN O O
141 NN O O
( NN O O
24 NN O O
% NN O O
) NN O O
Thrombocytopenia NN B-AdverseReaction B-AdverseReaction
220 NN O O
( NN O O
37 NN O O
% NN O O
) NN O O
152 NN O O
( NN O O
25 NN O O
% NN O O
) NN O O
Neutropenia NN B-AdverseReaction B-AdverseReaction
113 NN O O
( NN O O
19 NN O O
% NN O O
) NN O O
63 NN O O
( NN O O
11 NN O O
% NN O O
) NN O O
Lymphopenia NN B-AdverseReaction B-AdverseReaction
85 NN O O
( NN O O
14 NN O O
% NN O O
) NN O O
73 NN O O
( NN O O
12 NN O O
% NN O O
) NN O O
Leukopenia NN B-AdverseReaction B-AdverseReaction
61 NN O O
( NN O O
10 NN O O
% NN O O
) NN O O
26 NN O O
( NN O O
4 NN O O
% NN O O
) NN O O
Gastrointestinal NN O O
Disorders NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
211 NN O O
( NN O O
35 NN O O
% NN O O
) NN O O
7 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
160 NN O O
( NN O O
27 NN O O
% NN O O
) NN O O
8 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
104 NN O O
( NN O O
17 NN O O
% NN O O
) NN O O
4 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
90 NN O O
( NN O O
15 NN O O
% NN O O
) NN O O
1 NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
General NN O O
Disorders NN O O
and NN O O
Administration NN O O
Site NN O O
Conditions NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
238 NN O O
( NN O O
40 NN O O
% NN O O
) NN O O
25 NN O O
( NN O O
4 NN O O
% NN O O
) NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
177 NN O O
( NN O O
30 NN O O
% NN O O
) NN O O
11 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
Edema NN B-AdverseReaction B-AdverseReaction
Peripheral NN I-AdverseReaction I-AdverseReaction
118 NN O O
( NN O O
20 NN O O
% NN O O
) NN O O
1 NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
Chills NN B-AdverseReaction B-AdverseReaction
73 NN O O
( NN O O
12 NN O O
% NN O O
) NN O O
1 NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
Asthenia NN B-AdverseReaction B-AdverseReaction
71 NN O O
( NN O O
12 NN O O
% NN O O
) NN O O
9 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
Infections NN O O
and NN O O
Infestations NN O O
Upper NN B-AdverseReaction B-AdverseReaction
Respiratory NN I-AdverseReaction I-AdverseReaction
Tract NN I-AdverseReaction I-AdverseReaction
Infection NN I-AdverseReaction I-AdverseReaction
112 NN O O
( NN O O
19 NN O O
% NN O O
) NN O O
15 NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
Pneumonia NN B-AdverseReaction B-AdverseReaction
71 NN O O
( NN O O
12 NN O O
% NN O O
) NN O O
54 NN O O
( NN O O
9 NN O O
% NN O O
) NN O O
Metabolism NN O O
and NN O O
Nutrition NN O O
Disorders NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
Appetite NN I-AdverseReaction I-AdverseReaction
89 NN O O
( NN O O
15 NN O O
% NN O O
) NN O O
2 NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
Hypercalcemia NN B-AdverseReaction B-AdverseReaction
68 NN O O
( NN O O
11 NN O O
% NN O O
) NN O O
26 NN O O
( NN O O
4 NN O O
% NN O O
) NN O O
Hypokalemia NN B-AdverseReaction B-AdverseReaction
61 NN O O
( NN O O
10 NN O O
% NN O O
) NN O O
17 NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
Musculoskeletal NN O O
and NN O O
Connective NN O O
Tissue NN O O
Disorders NN O O
Back NN B-AdverseReaction B-AdverseReaction
Pain NN I-AdverseReaction I-AdverseReaction
115 NN O O
( NN O O
19 NN O O
% NN O O
) NN O O
19 NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
Arthralgia NN B-AdverseReaction B-AdverseReaction
83 NN O O
( NN O O
14 NN O O
% NN O O
) NN O O
5 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
Pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
Extremity NN I-AdverseReaction I-AdverseReaction
69 NN O O
( NN O O
12 NN O O
% NN O O
) NN O O
7 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
Muscle NN B-AdverseReaction B-AdverseReaction
Spasms NN I-AdverseReaction I-AdverseReaction
62 NN O O
( NN O O
10 NN O O
% NN O O
) NN O O
2 NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
Musculoskeletal NN B-AdverseReaction B-AdverseReaction
Pain NN I-AdverseReaction I-AdverseReaction
60 NN O O
( NN O O
10 NN O O
% NN O O
) NN O O
12 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
Nervous NN O O
System NN O O
Disorders NN O O
Headache NN B-AdverseReaction B-AdverseReaction
141 NN O O
( NN O O
24 NN O O
% NN O O
) NN O O
7 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
64 NN O O
( NN O O
11 NN O O
% NN O O
) NN O O
5 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
Peripheral NN B-AdverseReaction B-AdverseReaction
Neuropathies NN I-AdverseReaction I-AdverseReaction
NEC NN I-AdverseReaction I-AdverseReaction
62 NN O O
( NN O O
10 NN O O
% NN O O
) NN O O
5 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
Psychiatric NN O O
Disorders NN O O
Insomnia NN B-AdverseReaction B-AdverseReaction
75 NN O O
( NN O O
13 NN O O
% NN O O
) NN O O
0 NN O O
Respiratory NN O O
, NN O O
Thoracic NN O O
, NN O O
and NN O O
Mediastinal NN O O
Disorders NN O O
Dyspnea NN B-AdverseReaction B-AdverseReaction
202 NN O O
( NN O O
34 NN O O
% NN O O
) NN O O
21 NN O O
( NN O O
4 NN O O
% NN O O
) NN O O
Cough NN B-AdverseReaction B-AdverseReaction
120 NN O O
( NN O O
20 NN O O
% NN O O
) NN O O
2 NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
Epistaxis NN B-AdverseReaction B-AdverseReaction
60 NN O O
( NN O O
10 NN O O
% NN O O
) NN O O
5 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
Renal NN O O
Disorders NN O O
Renal NN B-AdverseReaction B-AdverseReaction
Failure NN I-AdverseReaction I-AdverseReaction
76 NN O O
( NN O O
13 NN O O
% NN O O
) NN O O
49 NN O O
( NN O O
8 NN O O
% NN O O
) NN O O
Vascular NN O O
Disorders NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
90 NN O O
( NN O O
15 NN O O
% NN O O
) NN O O
22 NN O O
( NN O O
4 NN O O
% NN O O
) NN O O
Adverse NN O O
Reactions NN O O
Occurring NN O O
at NN O O
a NN O O
Frequency NN O O
of NN O O
< NN O O
10 NN O O
% NN O O
* NN O O
Blood NN O O
and NN O O
lymphatic NN O O
system NN O O
disorders NN O O
: NN O O
febrile NN B-AdverseReaction B-AdverseReaction
neutropenia NN I-AdverseReaction I-AdverseReaction
* NN O O
Cardiac NN O O
disorders NN O O
: NN O O
cardiac NN B-AdverseReaction B-AdverseReaction
arrest NN I-AdverseReaction I-AdverseReaction
cardiac NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
congestive NN I-AdverseReaction I-AdverseReaction
myocardial NN B-AdverseReaction B-AdverseReaction
infarction NN I-AdverseReaction I-AdverseReaction
myocardial NN B-AdverseReaction B-AdverseReaction
ischemia NN I-AdverseReaction I-AdverseReaction
* NN O O
Eye NN O O
disorders NN O O
: NN O O
cataract NN B-AdverseReaction B-AdverseReaction
blurred NN B-AdverseReaction B-AdverseReaction
vision NN I-AdverseReaction I-AdverseReaction
* NN O O
Gastrointestinal NN O O
disorders NN O O
: NN O O
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
upper NN I-AdverseReaction I-AdverseReaction
dyspepsia NN B-AdverseReaction B-AdverseReaction
toothache NN B-AdverseReaction B-AdverseReaction
* NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
: NN O O
infusion NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
multi NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
organ NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
pain NN B-AdverseReaction B-AdverseReaction
* NN O O
Hepatobiliary NN O O
disorders NN O O
: NN O O
hepatic NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
* NN O O
Infections NN O O
and NN O O
infestations NN O O
: NN O O
bronchitis NN B-AdverseReaction B-AdverseReaction
influenza NN B-AdverseReaction B-AdverseReaction
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
respiratory NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
sepsis NN B-AdverseReaction B-AdverseReaction
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
* NN O O
Metabolism NN O O
and NN O O
nutrition NN O O
disorders NN O O
: NN O O
hyperglycemia NN B-AdverseReaction B-AdverseReaction
hyperkalemia NN B-AdverseReaction B-AdverseReaction
hyperuricemia NN B-AdverseReaction B-AdverseReaction
hypoalbuminemia NN B-AdverseReaction B-AdverseReaction
hypocalcemia NN B-AdverseReaction B-AdverseReaction
hypomagnesemia NN B-AdverseReaction B-AdverseReaction
hyponatremia NN B-AdverseReaction B-AdverseReaction
hypophosphatemia NN B-AdverseReaction B-AdverseReaction
tumor NN B-AdverseReaction B-AdverseReaction
lysis NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
* NN O O
Musculoskeletal NN O O
and NN O O
connective NN O O
tissue NN O O
disorders NN O O
: NN O O
musculoskeletal NN B-AdverseReaction B-AdverseReaction
chest NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
myalgia NN B-AdverseReaction B-AdverseReaction
* NN O O
Nervous NN O O
system NN O O
disorders NN O O
: NN O O
hypoesthesia NN B-AdverseReaction B-AdverseReaction
paresthesia NN B-AdverseReaction B-AdverseReaction
* NN O O
Psychiatric NN O O
disorders NN O O
: NN O O
anxiety NN B-AdverseReaction B-AdverseReaction
* NN O O
Renal NN O O
and NN O O
urinary NN O O
disorders NN O O
: NN O O
renal NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
* NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
and NN O O
mediastinal NN O O
disorders NN O O
: NN O O
dysphonia NN B-AdverseReaction B-AdverseReaction
oropharyngeal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
pulmonary NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
* NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
: NN O O
erythema NN B-AdverseReaction B-AdverseReaction
hyperhidrosis NN B-AdverseReaction B-AdverseReaction
pruritus NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
* NN O O
Vascular NN O O
disorders NN O O
: NN O O
embolic NN B-AdverseReaction B-AdverseReaction
and NN I-AdverseReaction I-AdverseReaction
thrombotic NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
, NN I-AdverseReaction I-AdverseReaction
venous NN I-AdverseReaction I-AdverseReaction
( NN O O
including NN O O
deep NN B-AdverseReaction B-AdverseReaction
vein NN I-AdverseReaction I-AdverseReaction
thrombosis NN I-AdverseReaction I-AdverseReaction
and NN O O
pulmonary NN B-AdverseReaction B-AdverseReaction
embolism NN I-AdverseReaction I-AdverseReaction
hypotension NN B-AdverseReaction B-AdverseReaction
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
and NN O O
higher NN O O
adverse NN O O
reactions NN O O
occurring NN O O
at NN O O
an NN O O
incidence NN O O
of NN O O
>1 NN O O
% NN O O
include NN O O
febrile NN B-AdverseReaction B-AdverseReaction
neutropenia NN I-AdverseReaction I-AdverseReaction
cardiac NN B-AdverseReaction B-AdverseReaction
arrest NN I-AdverseReaction I-AdverseReaction
cardiac NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
congestive NN I-AdverseReaction I-AdverseReaction
pain NN B-AdverseReaction B-AdverseReaction
sepsis NN B-AdverseReaction B-AdverseReaction
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
hyperglycemia NN B-AdverseReaction B-AdverseReaction
hyperkalemia NN B-AdverseReaction B-AdverseReaction
hyperuricemia NN B-AdverseReaction B-AdverseReaction
hypoalbuminemia NN B-AdverseReaction B-AdverseReaction
hypocalcemia NN B-AdverseReaction B-AdverseReaction
hyponatremia NN B-AdverseReaction B-AdverseReaction
hypophosphatemia NN B-AdverseReaction B-AdverseReaction
renal NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
renal NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
acute NN I-AdverseReaction I-AdverseReaction
renal NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
pulmonary NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
and NN O O
hypotension NN B-AdverseReaction B-AdverseReaction
Laboratory NN O O
Abnormalities NN O O
Table NN O O
8 NN O O
describes NN O O
Grade NN O O
3 NN O O
- NN O O
4 NN O O
laboratory NN O O
abnormalities NN O O
reported NN O O
at NN O O
a NN O O
rate NN O O
of NN O O
> NN O O
10 NN O O
% NN O O
for NN O O
patients NN O O
who NN O O
received NN O O
Kyprolis NN O O
monotherapy NN O O
. NN O O
Table NN O O
8 NN O O
: NN O O
Grade NN O O
3 NN O O
- NN O O
4 NN O O
Laboratory NN O O
Abnormalities NN O O
( NN O O
> NN O O
10 NN O O
% NN O O
) NN O O
( NN O O
Monotherapy NN O O
) NN O O
Adverse NN O O
Reaction NN O O
Kyprolis(N NN O O
= NN O O
598 NN O O
) NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
Platelets NN I-AdverseReaction I-AdverseReaction
184 NN O O
( NN O O
31 NN O O
% NN O O
) NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
Lymphocytes NN I-AdverseReaction I-AdverseReaction
151 NN O O
( NN O O
25 NN O O
% NN O O
) NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
Hemoglobin NN I-AdverseReaction I-AdverseReaction
132 NN O O
( NN O O
22 NN O O
% NN O O
) NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
Total NN I-AdverseReaction I-AdverseReaction
White NN I-AdverseReaction I-AdverseReaction
Blood NN I-AdverseReaction I-AdverseReaction
Cell NN I-AdverseReaction I-AdverseReaction
Count NN I-AdverseReaction I-AdverseReaction
71 NN O O
( NN O O
12 NN O O
% NN O O
) NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
Sodium NN I-AdverseReaction I-AdverseReaction
69 NN O O
( NN O O
12 NN O O
% NN O O
) NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
Absolute NN I-AdverseReaction I-AdverseReaction
Neutrophil NN I-AdverseReaction I-AdverseReaction
Count NN I-AdverseReaction I-AdverseReaction
67 NN O O
( NN O O
11 NN O O
% NN O O
) NN O O
6.2 NN O O
Post NN O O
- NN O O
marketing NN O O
Experience NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
were NN O O
reported NN O O
in NN O O
the NN O O
post NN O O
- NN O O
marketing NN O O
experience NN O O
with NN O O
Kyprolis NN O O
. NN O O
Because NN O O
these NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
: NN O O
dehydration NN B-AdverseReaction B-AdverseReaction
thrombotic NN B-AdverseReaction B-AdverseReaction
thrombocytopenic NN I-AdverseReaction I-AdverseReaction
purpura NN I-AdverseReaction I-AdverseReaction
uremic NN O O
syndrome NN O O
( NN O O
TTP/HUS NN O O
) NN O O
, NN O O
tumor NN B-AdverseReaction B-AdverseReaction
lysis NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
including NN O O
fatal NN B-AdverseReaction B-AdverseReaction
outcomes NN O O
, NN O O
and NN O O
posterior NN B-AdverseReaction B-AdverseReaction
reversible NN I-AdverseReaction I-AdverseReaction
encephalopathy NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
PRES NN O O
) NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Cardiac NN B-AdverseReaction B-AdverseReaction
toxicities NN I-AdverseReaction I-AdverseReaction
include NN O O
cardiac NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
and NN O O
myocardial NN B-AdverseReaction B-AdverseReaction
infarction NN I-AdverseReaction I-AdverseReaction
with NN O O
fatal NN B-AdverseReaction B-AdverseReaction
outcome NN O O
, NN O O
and NN O O
myocardial NN B-AdverseReaction B-AdverseReaction
ischemia NN I-AdverseReaction I-AdverseReaction
Withhold NN O O
Kyprolis NN O O
and NN O O
evaluate NN O O
promptly NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Acute NN B-AdverseReaction B-AdverseReaction
Renal NN I-AdverseReaction I-AdverseReaction
Failure NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
serum NN O O
creatinine NN O O
regularly NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Tumor NN B-AdverseReaction B-AdverseReaction
Lysis NN I-AdverseReaction I-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
TLS NN O O
) NN O O
: NN O O
Administer NN O O
pre NN O O
- NN O O
treatment NN O O
hydration NN O O
. NN O O
( NN O O
2.1 NN O O
) NN O O
Monitor NN O O
for NN O O
TLS NN O O
, NN O O
including NN O O
uric NN O O
acid NN O O
levels NN O O
and NN O O
treat NN O O
promptly NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Pulmonary NN B-AdverseReaction B-AdverseReaction
Toxicity NN I-AdverseReaction I-AdverseReaction
including NN O O
Acute NN B-AdverseReaction B-AdverseReaction
Respiratory NN I-AdverseReaction I-AdverseReaction
Distress NN I-AdverseReaction I-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
acute NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
and NN O O
acute NN B-AdverseReaction B-AdverseReaction
diffuse NN I-AdverseReaction I-AdverseReaction
infiltrative NN I-AdverseReaction I-AdverseReaction
pulmonary NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
Withhold NN O O
Kyprolis NN O O
and NN O O
evaluate NN O O
promptly NN O O
( NN O O
5.4 NN O O
) NN O O
* NN O O
Pulmonary NN B-AdverseReaction B-AdverseReaction
Hypertension NN I-AdverseReaction I-AdverseReaction
Withhold NN O O
Kyprolis NN O O
and NN O O
evaluate NN O O
( NN O O
5.5 NN O O
) NN O O
* NN O O
Dyspnea NN B-AdverseReaction B-AdverseReaction
For NN O O
severe NN O O
or NN O O
life NN O O
threatening NN O O
dyspnea NN O O
, NN O O
withhold NN O O
Kyprolis NN O O
and NN O O
evaluate NN O O
. NN O O
( NN O O
5.6 NN O O
) NN O O
* NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
including NN O O
hypertensive NN B-AdverseReaction B-AdverseReaction
crisis NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
blood NN O O
pressure NN O O
regularly NN O O
. NN O O
If NN O O
hypertension NN O O
can NN O O
not NN O O
be NN O O
adequately NN O O
controlled NN O O
, NN O O
a NN O O
risk NN O O
- NN O O
benefit NN O O
decision NN O O
on NN O O
continued NN O O
Kyprolis NN O O
therapy NN O O
is NN O O
needed NN O O
. NN O O
( NN O O
5.7 NN O O
) NN O O
* NN O O
Venous NN B-AdverseReaction B-AdverseReaction
Thrombosis NN I-AdverseReaction I-AdverseReaction
Thromboprophylaxis NN O O
is NN O O
recommended NN O O
. NN O O
( NN O O
5.8 NN O O
) NN O O
* NN O O
Infusion NN B-AdverseReaction B-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
Pre NN O O
- NN O O
medicate NN O O
with NN O O
dexamethasone NN O O
. NN O O
( NN O O
2.1 NN O O
, NN O O
5.9 NN O O
) NN O O
* NN O O
Thrombocytopenia NN B-AdverseReaction B-AdverseReaction
Monitor NN O O
platelet NN O O
counts NN O O
; NN O O
interrupt NN O O
or NN O O
reduce NN O O
Kyprolis NN O O
dosing NN O O
as NN O O
clinically NN O O
indicated NN O O
. NN O O
( NN O O
2.4 NN O O
, NN O O
5.10 NN O O
) NN O O
* NN O O
Hepatic NN B-AdverseReaction B-AdverseReaction
Toxicity NN I-AdverseReaction I-AdverseReaction
and NN O O
Hepatic NN B-AdverseReaction B-AdverseReaction
Failure NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
liver NN O O
enzymes NN O O
. NN O O
Withhold NN O O
Kyprolis NN O O
if NN O O
suspected NN O O
. NN O O
( NN O O
5.11 NN O O
) NN O O
* NN O O
Thrombotic NN B-AdverseReaction B-AdverseReaction
thrombocytopenic NN I-AdverseReaction I-AdverseReaction
purpura NN I-AdverseReaction I-AdverseReaction
uremic NN O O
syndrome NN O O
( NN O O
TTP/HUS NN O O
) NN O O
. NN O O
Monitor NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
TTP/HUS. NN O O
Discontinue NN O O
Kyprolis NN O O
if NN O O
suspected NN O O
. NN O O
( NN O O
5.12 NN O O
) NN O O
* NN O O
Posterior NN B-AdverseReaction B-AdverseReaction
reversible NN I-AdverseReaction I-AdverseReaction
encephalopathy NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
PRES NN O O
) NN O O
: NN O O
Consider NN O O
neuro NN O O
- NN O O
radiological NN O O
imaging NN O O
( NN O O
MRI NN O O
) NN O O
for NN O O
onset NN O O
of NN O O
visual NN O O
or NN O O
neurological NN O O
symptoms NN O O
; NN O O
discontinue NN O O
Kyprolis NN O O
if NN O O
suspected NN O O
. NN O O
( NN O O
5.13 NN O O
) NN O O
* NN O O
Embryo NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
fetal NN I-AdverseReaction I-AdverseReaction
Toxicity NN I-AdverseReaction I-AdverseReaction
Kyprolis NN O O
can NN B-Factor B-Factor
cause NN O O
fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
Females NN O O
of NN O O
reproductive NN O O
potential NN O O
should NN O O
avoid NN O O
becoming NN O O
pregnant NN O O
while NN O O
being NN O O
treated NN O O
. NN O O
( NN O O
5.14 NN O O
, NN O O
8.1 NN O O
) NN O O
5.1 NN O O
Cardiac NN O O
Toxicities NN O O
New NN O O
onset NN O O
or NN O O
worsening NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
pre NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
existing NN I-AdverseReaction I-AdverseReaction
cardiac NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
( NN O O
e.g. NN O O
, NN O O
congestive NN B-AdverseReaction B-AdverseReaction
heart NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
pulmonary NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
decreased NN B-AdverseReaction B-AdverseReaction
ejection NN I-AdverseReaction I-AdverseReaction
fraction NN I-AdverseReaction I-AdverseReaction
restrictive NN B-AdverseReaction B-AdverseReaction
cardiomyopathy NN I-AdverseReaction I-AdverseReaction
myocardial NN B-AdverseReaction B-AdverseReaction
ischemia NN I-AdverseReaction I-AdverseReaction
and NN O O
myocardial NN B-AdverseReaction B-AdverseReaction
infarction NN I-AdverseReaction I-AdverseReaction
including NN O O
fatalities NN B-AdverseReaction B-AdverseReaction
have NN O O
occurred NN O O
following NN O O
administration NN O O
of NN O O
Kyprolis NN O O
. NN O O
In NN O O
clinical NN O O
studies NN O O
with NN O O
Kyprolis NN O O
, NN O O
these NN O O
events NN O O
typically NN O O
occurred NN O O
early NN O O
in NN O O
the NN O O
course NN O O
of NN O O
Kyprolis NN O O
therapy NN O O
( NN O O
< NN O O
5 NN O O
cycles NN O O
) NN O O
. NN O O
Death NN B-AdverseReaction B-AdverseReaction
due NN O O
to NN O O
cardiac NN B-AdverseReaction B-AdverseReaction
arrest NN I-AdverseReaction I-AdverseReaction
has NN O O
occurred NN O O
within NN O O
a NN O O
day NN O O
of NN O O
Kyprolis NN O O
administration NN O O
. NN O O
Withhold NN O O
Kyprolis NN O O
for NN O O
Grade NN O O
3 NN O O
or NN O O
4 NN O O
cardiac NN O O
adverse NN O O
events NN O O
until NN O O
recovery NN O O
, NN O O
and NN O O
consider NN O O
whether NN O O
to NN O O
restart NN O O
Kyprolis NN O O
at NN O O
1 NN O O
dose NN O O
level NN O O
reduction NN O O
based NN O O
on NN O O
a NN O O
benefit/risk NN O O
assessment NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2 NN O O
) NN O O
] NN O O
. NN O O
While NN O O
adequate NN O O
hydration NN O O
is NN O O
required NN O O
prior NN O O
to NN O O
each NN O O
dose NN O O
in NN O O
Cycle NN O O
1 NN O O
, NN O O
all NN O O
patients NN O O
should NN O O
also NN O O
be NN O O
monitored NN O O
for NN O O
evidence NN O O
of NN O O
volume NN O O
overload NN O O
, NN O O
especially NN O O
patients NN O O
at NN O O
risk NN O O
for NN O O
cardiac NN O O
failure NN O O
. NN O O
Adjust NN O O
total NN O O
fluid NN O O
intake NN O O
as NN O O
clinically NN O O
appropriate NN O O
in NN O O
patients NN O O
with NN O O
baseline NN O O
cardiac NN O O
failure NN O O
or NN O O
who NN O O
are NN O O
at NN O O
risk NN O O
for NN O O
cardiac NN O O
failure NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2 NN O O
) NN O O
] NN O O
. NN O O
In NN O O
patients NN O O
>= NN O O
75 NN O O
years NN O O
of NN O O
age NN O O
, NN O O
the NN O O
risk NN O O
of NN O O
cardiac NN O O
failure NN O O
is NN O O
increased NN O O
. NN O O
Patients NN O O
with NN O O
New NN O O
York NN O O
Heart NN O O
Association NN O O
Class NN O O
III NN O O
and NN O O
IV NN O O
heart NN O O
failure NN O O
, NN O O
recent NN O O
myocardial NN O O
infarction NN O O
, NN O O
and NN O O
conduction NN O O
abnormalities NN O O
uncontrolled NN O O
by NN O O
medications NN O O
were NN O O
not NN O O
eligible NN O O
for NN O O
the NN O O
clinical NN O O
trials NN O O
. NN O O
These NN O O
patients NN O O
may NN O O
be NN O O
at NN O O
greater NN O O
risk NN O O
for NN O O
cardiac NN O O
complications NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
Acute NN O O
Renal NN O O
Failure NN O O
Cases NN O O
of NN O O
acute NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
have NN O O
occurred NN O O
in NN O O
patients NN O O
receiving NN O O
Kyprolis NN O O
. NN O O
Renal NN B-AdverseReaction B-AdverseReaction
insufficiency NN I-AdverseReaction I-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
( NN O O
renal NN O O
impairment NN O O
, NN O O
acute NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
renal NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
have NN O O
occurred NN O O
with NN O O
an NN O O
incidence NN O O
of NN O O
approximately NN O O
8 NN O O
% NN O O
in NN O O
a NN O O
randomized NN O O
controlled NN O O
trial NN O O
. NN O O
Acute NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
was NN O O
reported NN O O
more NN O O
frequently NN O O
in NN O O
patients NN O O
with NN O O
advanced NN O O
relapsed NN O O
and NN O O
refractory NN O O
multiple NN O O
myeloma NN O O
who NN O O
received NN O O
Kyprolis NN O O
monotherapy NN O O
. NN O O
This NN O O
risk NN O O
was NN O O
greater NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
baseline NN O O
reduced NN O O
estimated NN O O
creatinine NN O O
clearance NN O O
( NN O O
calculated NN O O
using NN O O
Cockcroft NN O O
and NN O O
Gault NN O O
equation NN O O
) NN O O
. NN O O
Monitor NN O O
renal NN O O
function NN O O
with NN O O
regular NN O O
measurement NN O O
of NN O O
the NN O O
serum NN O O
creatinine NN O O
and/or NN O O
estimated NN O O
creatinine NN O O
clearance NN O O
. NN O O
Reduce NN O O
or NN O O
withhold NN O O
dose NN O O
as NN O O
appropriate NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2 NN O O
) NN O O
] NN O O
. NN O O
5.3 NN O O
Tumor NN O O
Lysis NN O O
Syndrome NN O O
Cases NN O O
of NN O O
tumor NN B-AdverseReaction B-AdverseReaction
lysis NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
TLS NN O O
) NN O O
, NN O O
including NN O O
fatal NN B-AdverseReaction B-AdverseReaction
outcomes NN O O
, NN O O
have NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
who NN O O
received NN O O
Kyprolis NN O O
. NN O O
Patients NN O O
with NN O O
multiple NN O O
myeloma NN O O
and NN O O
a NN O O
high NN O O
tumor NN O O
burden NN O O
should NN O O
be NN O O
considered NN O O
to NN O O
be NN O O
at NN O O
greater NN O O
risk NN O O
for NN O O
TLS. NN O O
Ensure NN O O
that NN O O
patients NN O O
are NN O O
well NN O O
hydrated NN O O
before NN O O
administration NN O O
of NN O O
Kyprolis NN O O
in NN O O
Cycle NN O O
1 NN O O
, NN O O
and NN O O
in NN O O
subsequent NN O O
cycles NN O O
as NN O O
needed NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2 NN O O
) NN O O
] NN O O
. NN O O
Consider NN O O
uric NN O O
acid NN O O
lowering NN O O
drugs NN O O
in NN O O
patients NN O O
at NN O O
risk NN O O
for NN O O
TLS. NN O O
Monitor NN O O
for NN O O
evidence NN O O
of NN O O
TLS NN O O
during NN O O
treatment NN O O
and NN O O
manage NN O O
promptly NN O O
including NN O O
interruption NN O O
of NN O O
Kyprolis NN O O
until NN O O
TLS NN O O
is NN O O
resolved NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2 NN O O
) NN O O
] NN O O
. NN O O
5.4 NN O O
Pulmonary NN O O
Toxicity NN O O
Acute NN B-AdverseReaction B-AdverseReaction
Respiratory NN I-AdverseReaction I-AdverseReaction
Distress NN I-AdverseReaction I-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
ARDS NN O O
) NN O O
, NN O O
acute NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
and NN O O
acute NN B-AdverseReaction B-AdverseReaction
diffuse NN I-AdverseReaction I-AdverseReaction
infiltrative NN I-AdverseReaction I-AdverseReaction
pulmonary NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
such NN O O
as NN O O
pneumonitis NN B-AdverseReaction B-AdverseReaction
and NN O O
interstitial NN B-AdverseReaction B-AdverseReaction
lung NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
have NN O O
occurred NN O O
in NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
Kyprolis NN O O
. NN O O
Some NN O O
events NN O O
have NN O O
been NN O O
fatal NN B-AdverseReaction B-AdverseReaction
In NN O O
the NN O O
event NN O O
of NN O O
drug NN O O
- NN O O
induced NN O O
pulmonary NN O O
toxicity NN O O
, NN O O
discontinue NN O O
Kyprolis NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2 NN O O
) NN O O
] NN O O
. NN O O
5.5 NN O O
Pulmonary NN O O
Hypertension NN O O
Pulmonary NN B-AdverseReaction B-AdverseReaction
arterial NN I-AdverseReaction I-AdverseReaction
hypertension NN I-AdverseReaction I-AdverseReaction
( NN O O
PAH NN O O
) NN O O
was NN O O
reported NN O O
in NN O O
approximately NN O O
1 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
Kyprolis NN O O
and NN O O
was NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
or NN O O
greater NN O O
in NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
Evaluate NN O O
with NN O O
cardiac NN O O
imaging NN O O
and/or NN O O
other NN O O
tests NN O O
as NN O O
indicated NN O O
. NN O O
Withhold NN O O
Kyprolis NN O O
for NN O O
pulmonary NN O O
hypertension NN O O
until NN O O
resolved NN O O
or NN O O
returned NN O O
to NN O O
baseline NN O O
and NN O O
consider NN O O
whether NN O O
to NN O O
restart NN O O
Kyprolis NN O O
based NN O O
on NN O O
a NN O O
benefit/risk NN O O
assessment NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2 NN O O
) NN O O
] NN O O
. NN O O
5.6 NN O O
Dyspnea NN O O
Dyspnea NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
28 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
Kyprolis NN O O
and NN O O
was NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
or NN O O
greater NN O O
in NN O O
4 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
Evaluate NN O O
dyspnea NN O O
to NN O O
exclude NN O O
cardiopulmonary NN O O
conditions NN O O
including NN O O
cardiac NN O O
failure NN O O
and NN O O
pulmonary NN O O
syndromes NN O O
. NN O O
Stop NN O O
Kyprolis NN O O
for NN O O
Grade NN O O
3 NN O O
or NN O O
4 NN O O
dyspnea NN O O
until NN O O
resolved NN O O
or NN O O
returned NN O O
to NN O O
baseline NN O O
. NN O O
Consider NN O O
whether NN O O
to NN O O
restart NN O O
Kyprolis NN O O
based NN O O
on NN O O
a NN O O
benefit/risk NN O O
assessment NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
, NN O O
Warnings NN O O
and NN O O
Precautions NN O O
- NN O O
Cardiac NN O O
Toxicities NN O O
( NN O O
5.1 NN O O
) NN O O
, NN O O
Pulmonary NN O O
Toxicity NN O O
( NN O O
5.4 NN O O
) NN O O
, NN O O
and NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
] NN O O
. NN O O
5.7 NN O O
Hypertension NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
including NN O O
hypertensive NN B-AdverseReaction B-AdverseReaction
crisis NN I-AdverseReaction I-AdverseReaction
and NN O O
hypertensive NN B-AdverseReaction B-AdverseReaction
emergency NN I-AdverseReaction I-AdverseReaction
has NN O O
been NN O O
observed NN O O
with NN O O
Kyprolis NN O O
. NN O O
Some NN O O
of NN O O
these NN O O
events NN O O
have NN O O
been NN O O
fatal NN B-AdverseReaction B-AdverseReaction
Monitor NN O O
blood NN O O
pressure NN O O
regularly NN O O
in NN O O
all NN O O
patients NN O O
. NN O O
If NN O O
hypertension NN O O
can NN O O
not NN O O
be NN O O
adequately NN O O
controlled NN O O
, NN O O
withhold NN O O
Kyprolis NN O O
and NN O O
evaluate NN O O
. NN O O
Consider NN O O
whether NN O O
to NN O O
restart NN O O
Kyprolis NN O O
based NN O O
on NN O O
a NN O O
benefit/risk NN O O
assessment NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2 NN O O
) NN O O
] NN O O
. NN O O
5.8 NN O O
Venous NN O O
Thrombosis NN O O
Venous NN B-AdverseReaction B-AdverseReaction
thromboembolic NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
( NN O O
including NN O O
deep NN B-AdverseReaction B-AdverseReaction
venous NN I-AdverseReaction I-AdverseReaction
thrombosis NN I-AdverseReaction I-AdverseReaction
and NN O O
pulmonary NN B-AdverseReaction B-AdverseReaction
embolism NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
observed NN O O
with NN O O
Kyprolis NN O O
. NN O O
In NN O O
the NN O O
combination NN O O
study NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
venous NN B-AdverseReaction B-AdverseReaction
thromboembolic NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
in NN O O
the NN O O
first NN O O
12 NN O O
cycles NN O O
was NN O O
13 NN O O
% NN O O
in NN O O
the NN O O
Kyprolis NN O O
combination NN O O
arm NN O O
versus NN O O
6 NN O O
% NN O O
in NN O O
the NN O O
control NN O O
arm NN O O
. NN O O
With NN O O
Kyprolis NN O O
monotherapy NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
venous NN B-AdverseReaction B-AdverseReaction
thromboembolic NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
was NN O O
2 NN O O
% NN O O
. NN O O
Thromboprophylaxis NN O O
is NN O O
recommended NN O O
and NN O O
should NN O O
be NN O O
based NN O O
on NN O O
an NN O O
assessment NN O O
of NN O O
the NN O O
patient NN O O
's NN O O
underlying NN O O
risks NN O O
, NN O O
treatment NN O O
regimen NN O O
, NN O O
and NN O O
clinical NN O O
status NN O O
. NN O O
5.9 NN O O
Infusion NN O O
Reactions NN O O
Infusion NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
reactions NN O O
, NN O O
have NN O O
occurred NN O O
in NN O O
patients NN O O
receiving NN O O
Kyprolis NN O O
. NN O O
Symptoms NN O O
include NN O O
fever NN B-AdverseReaction B-AdverseReaction
chills NN B-AdverseReaction B-AdverseReaction
arthralgia NN B-AdverseReaction B-AdverseReaction
myalgia NN B-AdverseReaction B-AdverseReaction
facial NN B-AdverseReaction B-AdverseReaction
flushing NN I-AdverseReaction I-AdverseReaction
facial NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
weakness NN B-AdverseReaction B-AdverseReaction
shortness NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
breath NN I-AdverseReaction I-AdverseReaction
hypotension NN B-AdverseReaction B-AdverseReaction
syncope NN B-AdverseReaction B-AdverseReaction
chest NN B-AdverseReaction B-AdverseReaction
tightness NN I-AdverseReaction I-AdverseReaction
or NN O O
angina NN B-AdverseReaction B-AdverseReaction
These NN O O
reactions NN O O
can NN O O
occur NN O O
immediately NN O O
following NN O O
or NN O O
up NN O O
to NN O O
24 NN O O
hours NN O O
after NN O O
administration NN O O
of NN O O
Kyprolis NN O O
. NN O O
Administer NN O O
dexamethasone NN O O
prior NN O O
to NN O O
Kyprolis NN O O
to NN O O
reduce NN O O
the NN O O
incidence NN O O
and NN O O
severity NN O O
of NN O O
infusion NN O O
reactions NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2 NN O O
) NN O O
] NN O O
. NN O O
Inform NN O O
patients NN O O
of NN O O
the NN O O
risk NN O O
and NN O O
of NN O O
symptoms NN O O
and NN O O
to NN O O
contact NN O O
a NN O O
physician NN O O
immediately NN O O
if NN O O
symptoms NN O O
of NN O O
an NN O O
infusion NN O O
reaction NN O O
occur NN O O
[ NN O O
see NN O O
Patient NN O O
Counseling NN O O
Information NN O O
( NN O O
17 NN O O
) NN O O
] NN O O
. NN O O
5.10 NN O O
Thrombocytopenia NN O O
Kyprolis NN O O
causes NN O O
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
with NN O O
platelet NN B-AdverseReaction B-AdverseReaction
nadirs NN I-AdverseReaction I-AdverseReaction
observed NN O O
between NN O O
Day NN O O
8 NN O O
and NN O O
Day NN O O
15 NN O O
of NN O O
each NN O O
28-day NN O O
cycle NN O O
with NN O O
recovery NN O O
to NN O O
baseline NN O O
platelet NN O O
count NN O O
usually NN O O
by NN O O
the NN O O
start NN O O
of NN O O
the NN O O
next NN O O
cycle NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
] NN O O
. NN O O
Thrombocytopenia NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
approximately NN O O
40 NN O O
% NN O O
of NN O O
patients NN O O
in NN O O
clinical NN O O
trials NN O O
with NN O O
Kyprolis NN O O
. NN O O
Monitor NN O O
platelet NN O O
counts NN O O
frequently NN O O
during NN O O
treatment NN O O
with NN O O
Kyprolis NN O O
. NN O O
Reduce NN O O
or NN O O
withhold NN O O
dose NN O O
as NN O O
appropriate NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2 NN O O
) NN O O
] NN O O
. NN O O
5.11 NN O O
Hepatic NN O O
Toxicity NN O O
and NN O O
Hepatic NN O O
Failure NN O O
Cases NN O O
of NN O O
hepatic NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
including NN O O
fatal NN B-AdverseReaction B-AdverseReaction
cases NN O O
, NN O O
have NN O O
been NN O O
reported NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
during NN O O
treatment NN O O
with NN O O
Kyprolis NN O O
. NN O O
Kyprolis NN O O
can NN B-Factor B-Factor
cause NN O O
increased NN B-AdverseReaction B-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
transaminases NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
liver NN O O
enzymes NN O O
regularly NN O O
. NN O O
Reduce NN O O
or NN O O
withhold NN O O
dose NN O O
as NN O O
appropriate NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2 NN O O
) NN O O
and NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
] NN O O
. NN O O
5.12 NN O O
Thrombotic NN O O
Thrombocytopenic NN O O
Purpura/Hemolytic NN O O
Uremic NN O O
Syndrome NN O O
Cases NN O O
of NN O O
thrombotic NN B-AdverseReaction B-AdverseReaction
thrombocytopenic NN I-AdverseReaction I-AdverseReaction
purpura NN I-AdverseReaction I-AdverseReaction
uremic NN O O
syndrome NN O O
( NN O O
TTP/HUS NN O O
) NN O O
including NN O O
fatal NN B-AdverseReaction B-AdverseReaction
outcome NN O O
have NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
who NN O O
received NN O O
Kyprolis NN O O
. NN O O
Monitor NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
TTP/HUS. NN O O
If NN O O
the NN O O
diagnosis NN O O
is NN O O
suspected NN O O
, NN O O
stop NN O O
Kyprolis NN O O
and NN O O
evaluate NN O O
. NN O O
If NN O O
the NN O O
diagnosis NN O O
of NN O O
TTP/HUS NN O O
is NN O O
excluded NN O O
, NN O O
Kyprolis NN O O
may NN O O
be NN O O
restarted NN O O
. NN O O
The NN O O
safety NN O O
of NN O O
reinitiating NN O O
Kyprolis NN O O
therapy NN O O
in NN O O
patients NN O O
previously NN O O
experiencing NN O O
TTP/HUS NN O O
is NN O O
not NN O O
known NN O O
. NN O O
5.13 NN O O
Posterior NN O O
Reversible NN O O
Encephalopathy NN O O
Syndrome NN O O
( NN O O
PRES NN O O
) NN O O
Cases NN O O
of NN O O
PRES NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
receiving NN O O
Kyprolis NN O O
. NN O O
Posterior NN O O
reversible NN O O
encephalopathy NN O O
syndrome NN O O
( NN O O
PRES NN O O
) NN O O
, NN O O
formerly NN O O
termed NN O O
Reversible NN O O
Posterior NN O O
Leukoencephalopathy NN O O
Syndrome NN O O
( NN O O
RPLS NN O O
) NN O O
, NN O O
is NN O O
a NN O O
neurological NN O O
disorder NN O O
which NN O O
can NN O O
present NN O O
with NN O O
seizure NN O O
, NN O O
headache NN O O
, NN O O
lethargy NN O O
, NN O O
confusion NN O O
, NN O O
blindness NN O O
, NN O O
altered NN O O
consciousness NN O O
, NN O O
and NN O O
other NN O O
visual NN O O
and NN O O
neurological NN O O
disturbances NN O O
, NN O O
along NN O O
with NN O O
hypertension NN O O
, NN O O
and NN O O
the NN O O
diagnosis NN O O
is NN O O
confirmed NN O O
by NN O O
neuro NN O O
- NN O O
radiological NN O O
imaging NN O O
( NN O O
MRI NN O O
) NN O O
. NN O O
Discontinue NN O O
Kyprolis NN O O
if NN O O
PRES NN O O
is NN O O
suspected NN O O
and NN O O
evaluate NN O O
. NN O O
The NN O O
safety NN O O
of NN O O
reinitiating NN O O
Kyprolis NN O O
therapy NN O O
in NN O O
patients NN O O
previously NN O O
experiencing NN O O
PRES NN O O
is NN O O
not NN O O
known NN O O
. NN O O
5.14 NN O O
Embryo NN O O
- NN O O
fetal NN O O
Toxicity NN O O
Kyprolis NN O O
can NN B-Factor B-Factor
cause NN O O
fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
when NN O O
administered NN O O
to NN O O
a NN O O
pregnant NN O O
woman NN O O
based NN O O
on NN O O
its NN O O
mechanism NN O O
of NN O O
action NN O O
and NN O O
findings NN O O
in NN O O
animals NN O O
. NN O O
There NN O O
are NN O O
no NN O O
adequate NN O O
and NN O O
well NN O O
- NN O O
controlled NN O O
studies NN O O
in NN O O
pregnant NN O O
women NN O O
using NN O O
Kyprolis NN O O
. NN O O
Carfilzomib NN O O
caused NN O O
embryo NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
fetal NN I-AdverseReaction I-AdverseReaction
toxicity NN I-AdverseReaction I-AdverseReaction
in NN O O
pregnant NN O O
rabbits NN B-Animal B-Animal
at NN O O
doses NN O O
that NN O O
were NN O O
lower NN O O
than NN O O
in NN O O
patients NN O O
receiving NN O O
the NN O O
recommended NN O O
dose NN O O
. NN O O
Females NN O O
of NN O O
reproductive NN O O
potential NN O O
should NN O O
be NN O O
advised NN O O
to NN O O
avoid NN O O
becoming NN O O
pregnant NN O O
while NN O O
being NN O O
treated NN O O
with NN O O
Kyprolis NN O O
. NN O O
If NN O O
this NN O O
drug NN O O
is NN O O
used NN O O
during NN O O
pregnancy NN O O
, NN O O
or NN O O
if NN O O
the NN O O
patient NN O O
becomes NN O O
pregnant NN O O
while NN O O
taking NN O O
this NN O O
drug NN O O
, NN O O
the NN O O
patient NN O O
should NN O O
be NN O O
apprised NN O O
of NN O O
the NN O O
potential NN O O
hazard NN O O
to NN O O
the NN O O
fetus NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.1 NN O O
) NN O O
] NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
are NN O O
nausea NN B-AdverseReaction B-AdverseReaction
( NN O O
11 NN O O
% NN O O
) NN O O
, NN O O
vomiting NN B-AdverseReaction B-AdverseReaction
( NN O O
7 NN O O
% NN O O
) NN O O
, NN O O
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
( NN O O
6 NN O O
% NN O O
) NN O O
, NN O O
gastrointestinal NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
( NN O O
4 NN O O
% NN O O
) NN O O
, NN O O
anemia NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
( NN O O
6 NN O O
) NN O O
. NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Cubist NN O O
Pharmaceuticals NN O O
at NN O O
1 NN O O
- NN O O
877-CUBIST-6 NN O O
( NN O O
1 NN O O
- NN O O
877 NN O O
- NN O O
282 NN O O
- NN O O
4786 NN O O
) NN O O
or NN O O
FDA NN O O
at NN O O
( NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
) NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
event NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
any NN O O
other NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
The NN O O
safety NN O O
of NN O O
DIFICID NN O O
200 NN O O
mg NN O O
tablets NN O O
taken NN O O
twice NN O O
a NN O O
day NN O O
for NN O O
10 NN O O
days NN O O
was NN O O
evaluated NN O O
in NN O O
564 NN O O
patients NN O O
with NN O O
CDAD NN O O
in NN O O
two NN O O
active NN O O
- NN O O
comparator NN O O
controlled NN O O
trials NN O O
with NN O O
86.7 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
a NN O O
full NN O O
course NN O O
of NN O O
treatment NN O O
. NN O O
Thirty NN O O
- NN O O
three NN O O
patients NN O O
receiving NN O O
DIFICID NN O O
( NN O O
5.9 NN O O
% NN O O
) NN O O
withdrew NN O O
from NN O O
trials NN O O
as NN O O
a NN O O
result NN O O
of NN O O
adverse NN O O
reactions NN O O
( NN O O
AR NN O O
) NN O O
. NN O O
The NN O O
types NN O O
of NN O O
AR NN O O
resulting NN O O
in NN O O
withdrawal NN O O
from NN O O
the NN O O
study NN O O
varied NN O O
considerably NN O O
. NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
was NN O O
the NN O O
primary NN O O
adverse NN O O
reaction NN O O
leading NN O O
to NN O O
discontinuation NN O O
of NN O O
dosing NN O O
; NN O O
this NN O O
occurred NN O O
at NN O O
an NN O O
incidence NN O O
of NN O O
0.5 NN O O
% NN O O
in NN O O
both NN O O
the NN O O
fidaxomicin NN O O
and NN O O
vancomycin NN O O
patients NN O O
in NN O O
Phase NN O O
3 NN O O
studies NN O O
. NN O O
Table NN O O
1 NN O O
. NN O O
Selected NN O O
Adverse NN O O
Reactions NN O O
with NN O O
an NN O O
Incidence NN O O
of NN O O
>=2 NN O O
% NN O O
Reported NN O O
in NN O O
DIFICID NN O O
Patients NN O O
in NN O O
Controlled NN O O
Trials NN O O
DIFICID NN O O
( NN O O
N=564 NN O O
) NN O O
Vancomycin NN O O
( NN O O
N=583 NN O O
) NN O O
System NN O O
Organ NN O O
Class NN O O
Preferred NN O O
Term NN O O
n NN O O
( NN O O
% NN O O
) NN O O
n NN O O
( NN O O
% NN O O
) NN O O
Blood NN O O
and NN O O
Lymphatic NN O O
System NN O O
Disorders NN O O
Anemia NN B-AdverseReaction B-AdverseReaction
14 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
12 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
Neutropenia NN B-AdverseReaction B-AdverseReaction
14 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
6 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
Gastrointestinal NN O O
Disorders NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
62 NN O O
( NN O O
11 NN O O
% NN O O
) NN O O
66 NN O O
( NN O O
11 NN O O
% NN O O
) NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
41 NN O O
( NN O O
7 NN O O
% NN O O
) NN O O
37 NN O O
( NN O O
6 NN O O
% NN O O
) NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
Pain NN I-AdverseReaction I-AdverseReaction
33 NN O O
( NN O O
6 NN O O
% NN O O
) NN O O
23 NN O O
( NN O O
4 NN O O
% NN O O
) NN O O
Gastrointestinal NN B-AdverseReaction B-AdverseReaction
Hemorrhage NN I-AdverseReaction I-AdverseReaction
20 NN O O
( NN O O
4 NN O O
% NN O O
) NN O O
12 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
were NN O O
reported NN O O
in NN O O
< NN O O
2 NN O O
% NN O O
of NN O O
patients NN O O
taking NN O O
DIFICID NN O O
tablets NN O O
in NN O O
controlled NN O O
trials NN O O
: NN O O
Gastrointestinal NN O O
Disorders NN O O
: NN O O
abdominal NN B-AdverseReaction B-AdverseReaction
distension NN I-AdverseReaction I-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
tenderness NN I-AdverseReaction I-AdverseReaction
dyspepsia NN B-AdverseReaction B-AdverseReaction
dysphagia NN B-AdverseReaction B-AdverseReaction
flatulence NN B-AdverseReaction B-AdverseReaction
intestinal NN B-AdverseReaction B-AdverseReaction
obstruction NN I-AdverseReaction I-AdverseReaction
megacolon NN B-AdverseReaction B-AdverseReaction
Investigations NN O O
: NN O O
increased NN B-AdverseReaction B-AdverseReaction
blood NN I-AdverseReaction I-AdverseReaction
alkaline NN I-AdverseReaction I-AdverseReaction
phosphatase NN I-AdverseReaction I-AdverseReaction
decreased NN B-AdverseReaction B-AdverseReaction
blood NN I-AdverseReaction I-AdverseReaction
bicarbonate NN I-AdverseReaction I-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
hepatic NN I-AdverseReaction I-AdverseReaction
enzymes NN I-AdverseReaction I-AdverseReaction
decreased NN B-AdverseReaction B-AdverseReaction
platelet NN I-AdverseReaction I-AdverseReaction
count NN I-AdverseReaction I-AdverseReaction
Metabolism NN O O
and NN O O
Nutrition NN O O
Disorders NN O O
: NN O O
hyperglycemia NN B-AdverseReaction B-AdverseReaction
metabolic NN B-AdverseReaction B-AdverseReaction
acidosis NN I-AdverseReaction I-AdverseReaction
Skin NN O O
and NN O O
Subcutaneous NN O O
Tissue NN O O
Disorders NN O O
: NN O O
drug NN B-AdverseReaction B-AdverseReaction
eruption NN I-AdverseReaction I-AdverseReaction
pruritus NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
6.2 NN O O
Post NN O O
Marketing NN O O
Experience NN O O
Adverse NN O O
reactions NN O O
reported NN O O
in NN O O
the NN O O
post NN O O
marketing NN O O
setting NN O O
arise NN O O
from NN O O
a NN O O
population NN O O
of NN O O
unknown NN O O
size NN O O
and NN O O
are NN O O
voluntary NN O O
in NN O O
nature NN O O
. NN O O
As NN O O
such NN O O
, NN O O
reliability NN O O
in NN O O
estimating NN O O
their NN O O
frequency NN O O
or NN O O
in NN O O
establishing NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
. NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
( NN O O
dyspnea NN O O
, NN O O
angioedema NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
and NN O O
pruritus NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
DIFICID NN O O
should NN O O
not NN O O
be NN O O
used NN O O
for NN O O
systemic NN O O
infections NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Acute NN B-AdverseReaction B-AdverseReaction
hypersensitivity NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
( NN O O
angioedema NN O O
, NN O O
dyspnea NN B-AdverseReaction B-AdverseReaction
pruritus NN B-AdverseReaction B-AdverseReaction
and NN O O
rash NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
. NN O O
In NN O O
the NN O O
event NN O O
of NN O O
a NN O O
severe NN O O
reaction NN O O
, NN O O
discontinue NN O O
DIFICID. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Development NN O O
of NN O O
drug NN O O
- NN O O
resistant NN O O
bacteria NN O O
: NN O O
Only NN O O
use NN O O
DIFICID NN O O
for NN O O
infection NN O O
proven NN O O
or NN O O
strongly NN O O
suspected NN O O
to NN O O
be NN O O
caused NN O O
by NN O O
C. NN O O
difficile NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
5.1 NN O O
Not NN O O
for NN O O
Systemic NN O O
Infections NN O O
Since NN O O
there NN O O
is NN O O
minimal NN O O
systemic NN O O
absorption NN O O
of NN O O
fidaxomicin NN O O
, NN O O
DIFICID NN O O
is NN O O
not NN O O
effective NN O O
for NN O O
treatment NN O O
of NN O O
systemic NN O O
infections NN O O
. NN O O
5.2 NN O O
Hypersensitivity NN O O
Reactions NN O O
Acute NN B-AdverseReaction B-AdverseReaction
hypersensitivity NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
dyspnea NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
pruritus NN B-AdverseReaction B-AdverseReaction
and NN O O
angioedema NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
throat NN O O
, NN O O
and NN O O
face NN O O
have NN O O
been NN O O
reported NN O O
with NN O O
fidaxomicin NN O O
. NN O O
If NN O O
a NN O O
severe NN O O
hypersensitivity NN O O
reaction NN O O
occurs NN O O
, NN O O
DIFICID NN O O
( NN O O
r NN O O
) NN O O
should NN O O
be NN O O
discontinued NN O O
and NN O O
appropriate NN O O
therapy NN O O
should NN O O
be NN O O
instituted NN O O
. NN O O
Some NN O O
patients NN O O
with NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
also NN O O
reported NN O O
a NN O O
history NN O O
of NN O O
allergy NN O O
to NN O O
other NN O O
macrolides NN O O
. NN O O
Physicians NN O O
prescribing NN O O
DIFICID NN O O
to NN O O
patients NN O O
with NN O O
a NN O O
known NN O O
macrolide NN O O
allergy NN O O
should NN O O
be NN O O
aware NN O O
of NN O O
the NN O O
possibility NN O O
of NN O O
hypersensitivity NN O O
reactions NN O O
. NN O O
5.3 NN O O
Development NN O O
of NN O O
Drug NN O O
- NN O O
Resistant NN O O
Bacteria NN O O
Prescribing NN O O
DIFICID NN O O
in NN O O
the NN O O
absence NN O O
of NN O O
a NN O O
proven NN O O
or NN O O
strongly NN O O
suspected NN O O
C. NN O O
difficile NN O O
infection NN O O
is NN O O
unlikely NN O O
to NN O O
provide NN O O
benefit NN O O
to NN O O
the NN O O
patient NN O O
and NN O O
increases NN O O
the NN O O
risk NN O O
of NN O O
the NN O O
development NN O O
of NN O O
drug NN O O
- NN O O
resistant NN O O
bacteria NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
are NN O O
discussed NN O O
in NN O O
greater NN O O
detail NN O O
in NN O O
other NN O O
sections NN O O
of NN O O
the NN O O
labeling NN O O
: NN O O
* NN O O
Severe NN B-Severity B-Severity
or NN O O
Persistent NN B-Severity B-Severity
Gastrointestinal NN B-AdverseReaction B-AdverseReaction
Toxicity NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Hepatotoxicity NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
Interstitial NN B-AdverseReaction B-AdverseReaction
Lung NN I-AdverseReaction I-AdverseReaction
Disease NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
* NN O O
QT NN B-AdverseReaction B-AdverseReaction
Interval NN I-AdverseReaction I-AdverseReaction
Prolongation NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
and NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.2 NN O O
) NN O O
] NN O O
* NN O O
Hyperglycemia NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
* NN O O
Bradycardia NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.6 NN O O
) NN O O
and NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.2 NN O O
) NN O O
] NN O O
* NN O O
Pancreatitis NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.7 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
incidence NN O O
of NN O O
at NN O O
least NN O O
25 NN O O
% NN O O
) NN O O
are NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
elevated NN B-AdverseReaction B-AdverseReaction
transaminases NN I-AdverseReaction I-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
and NN O O
constipation NN B-AdverseReaction B-AdverseReaction
( NN O O
6 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Novartis NN O O
Pharmaceuticals NN O O
Corporation NN O O
at NN O O
1 NN O O
- NN O O
888 NN O O
- NN O O
669 NN O O
- NN O O
6682 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
The NN O O
safety NN O O
evaluation NN O O
of NN O O
ZYKADIA NN O O
is NN O O
based NN O O
on NN O O
255 NN O O
ALK NN O O
- NN O O
positive NN O O
patients NN O O
in NN O O
Study NN O O
1 NN O O
( NN O O
246 NN O O
patients NN O O
with NN O O
NSCLC NN O O
and NN O O
9 NN O O
patients NN O O
with NN O O
other NN O O
cancers NN O O
who NN O O
received NN O O
ZYKADIA NN O O
at NN O O
a NN O O
dose NN O O
of NN O O
750 NN O O
mg NN O O
daily NN O O
) NN O O
. NN O O
The NN O O
median NN O O
duration NN O O
of NN O O
exposure NN O O
to NN O O
ZYKADIA NN O O
was NN O O
6 NN O O
months NN O O
. NN O O
The NN O O
study NN O O
population NN O O
characteristics NN O O
were NN O O
: NN O O
median NN O O
age NN O O
53 NN O O
years NN O O
, NN O O
age NN O O
less NN O O
than NN O O
65 NN O O
( NN O O
84 NN O O
% NN O O
) NN O O
, NN O O
female NN O O
( NN O O
53 NN O O
% NN O O
) NN O O
, NN O O
Caucasian NN O O
( NN O O
63 NN O O
% NN O O
) NN O O
, NN O O
Asian NN O O
( NN O O
34 NN O O
% NN O O
) NN O O
, NN O O
NSCLC NN O O
adenocarcinoma NN O O
histology NN O O
( NN O O
90 NN O O
% NN O O
) NN O O
, NN O O
never NN O O
or NN O O
former NN O O
smoker NN O O
( NN O O
97 NN O O
% NN O O
) NN O O
, NN O O
ECOG NN O O
PS NN O O
0 NN O O
or NN O O
1 NN O O
( NN O O
89 NN O O
% NN O O
) NN O O
, NN O O
brain NN O O
metastasis NN O O
( NN O O
49 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
number NN O O
of NN O O
prior NN O O
therapies NN O O
2 NN O O
or NN O O
more NN O O
( NN O O
67 NN O O
% NN O O
) NN O O
. NN O O
Dose NN O O
reductions NN O O
due NN O O
to NN O O
adverse NN O O
reactions NN O O
occurred NN O O
in NN O O
59 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
ZYKADIA. NN O O
The NN O O
most NN O O
frequent NN O O
adverse NN O O
reactions NN O O
, NN O O
reported NN O O
in NN O O
at NN O O
least NN O O
10 NN O O
% NN O O
of NN O O
patients NN O O
, NN O O
that NN O O
led NN O O
to NN O O
dose NN O O
reductions NN O O
or NN O O
interruptions NN O O
were NN O O
: NN O O
increased NN B-AdverseReaction B-AdverseReaction
ALT NN I-AdverseReaction I-AdverseReaction
( NN O O
29 NN O O
% NN O O
) NN O O
, NN O O
nausea NN B-AdverseReaction B-AdverseReaction
( NN O O
20 NN O O
% NN O O
) NN O O
, NN O O
increased NN B-AdverseReaction B-AdverseReaction
AST NN I-AdverseReaction I-AdverseReaction
( NN O O
16 NN O O
% NN O O
) NN O O
, NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
( NN O O
16 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
vomiting NN B-AdverseReaction B-AdverseReaction
( NN O O
16 NN O O
% NN O O
) NN O O
. NN O O
Serious NN O O
adverse NN O O
drug NN O O
reactions NN O O
reported NN O O
in NN O O
2 NN O O
% NN O O
or NN O O
more NN O O
of NN O O
patients NN O O
in NN O O
Study NN O O
1 NN O O
were NN O O
convulsion NN B-AdverseReaction B-AdverseReaction
pneumonia NN B-AdverseReaction B-AdverseReaction
ILD NN B-AdverseReaction B-AdverseReaction
dyspnea NN B-AdverseReaction B-AdverseReaction
dehydration NN B-AdverseReaction B-AdverseReaction
hyperglycemia NN B-AdverseReaction B-AdverseReaction
and NN O O
nausea NN B-AdverseReaction B-AdverseReaction
Fatal NN B-AdverseReaction B-AdverseReaction
adverse NN O O
reactions NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
ZYKADIA NN O O
occurred NN O O
in NN O O
5 NN O O
% NN O O
of NN O O
patients NN O O
, NN O O
consisting NN O O
of NN O O
: NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
( NN O O
4 NN O O
patients NN O O
) NN O O
, NN O O
respiratory NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
ILD NN B-AdverseReaction B-AdverseReaction
pneumothorax NN B-AdverseReaction B-AdverseReaction
gastric NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
general NN B-AdverseReaction B-AdverseReaction
physical NN I-AdverseReaction I-AdverseReaction
health NN I-AdverseReaction I-AdverseReaction
deterioration NN I-AdverseReaction I-AdverseReaction
pulmonary NN B-AdverseReaction B-AdverseReaction
tuberculosis NN I-AdverseReaction I-AdverseReaction
cardiac NN B-AdverseReaction B-AdverseReaction
tamponade NN I-AdverseReaction I-AdverseReaction
and NN O O
sepsis NN B-AdverseReaction B-AdverseReaction
( NN O O
1 NN O O
patient NN O O
each NN O O
) NN O O
. NN O O
Discontinuation NN O O
of NN O O
therapy NN O O
due NN O O
to NN O O
adverse NN O O
reactions NN O O
occurred NN O O
in NN O O
10 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
ZYKADIA. NN O O
The NN O O
most NN O O
frequent NN O O
adverse NN O O
drug NN O O
reactions NN O O
that NN O O
led NN O O
to NN O O
discontinuation NN O O
in NN O O
1 NN O O
% NN O O
or NN O O
more NN O O
of NN O O
patients NN O O
in NN O O
Study NN O O
1 NN O O
were NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
ILD NN B-AdverseReaction B-AdverseReaction
and NN O O
decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
Tables NN O O
2 NN O O
and NN O O
3 NN O O
summarize NN O O
the NN O O
common NN O O
adverse NN O O
reactions NN O O
and NN O O
laboratory NN O O
abnormalities NN O O
observed NN O O
in NN O O
ZYKADIA NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Table NN O O
2 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
( NN O O
>10 NN O O
% NN O O
for NN O O
All NN O O
NCI NN O O
CTCAE NN O O
* NN O O
Grades NN O O
or NN O O
>=2 NN O O
% NN O O
for NN O O
Grades NN O O
3 NN O O
- NN O O
4 NN O O
) NN O O
in NN O O
ALK NN O O
- NN O O
Positive NN O O
Patients NN O O
Treated NN O O
with NN O O
ZYKADIA NN O O
in NN O O
Study NN O O
1 NN O O
* NN O O
National NN O O
Cancer NN O O
Institute NN O O
Common NN O O
Terminology NN O O
Criteria NN O O
for NN O O
Adverse NN O O
Events NN O O
( NN O O
version NN O O
4.03 NN O O
) NN O O
a NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
( NN O O
abdominal NN O O
pain NN O O
, NN O O
upper NN B-AdverseReaction B-AdverseReaction
abdominal NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
discomfort NN I-AdverseReaction I-AdverseReaction
epigastric NN B-AdverseReaction B-AdverseReaction
discomfort NN I-AdverseReaction I-AdverseReaction
b NN O O
Esophageal NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
( NN O O
dyspepsia NN O O
, NN O O
gastroesophageal NN B-AdverseReaction B-AdverseReaction
reflux NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
dysphagia NN B-AdverseReaction B-AdverseReaction
c NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
( NN O O
fatigue NN O O
, NN O O
asthenia NN B-AdverseReaction B-AdverseReaction
d NN O O
Rash NN B-AdverseReaction B-AdverseReaction
( NN O O
rash NN O O
, NN O O
maculopapular NN B-AdverseReaction B-AdverseReaction
rash NN I-AdverseReaction I-AdverseReaction
acneiform NN B-AdverseReaction B-AdverseReaction
dermatitis NN I-AdverseReaction I-AdverseReaction
ZYKADIAN=255 NN O O
All NN O O
Grades NN O O
Grade NN O O
3 NN O O
- NN O O
4 NN O O
% NN O O
% NN O O
Gastrointestinal NN O O
disorders NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
86 NN O O
6 NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
80 NN O O
4 NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
60 NN O O
4 NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
a NN O O
54 NN O O
2 NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
29 NN O O
0 NN O O
Esophageal NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
b NN O O
16 NN O O
1 NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
c NN O O
52 NN O O
5 NN O O
Metabolism NN O O
and NN O O
nutrition NN O O
disorders NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
34 NN O O
1 NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
Rash NN B-AdverseReaction B-AdverseReaction
d NN O O
16 NN O O
0 NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
and NN O O
mediastinal NN O O
disorders NN O O
Interstitial NN B-AdverseReaction B-AdverseReaction
lung NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
4 NN O O
3 NN O O
Additional NN O O
clinically NN O O
significant NN O O
adverse NN O O
reactions NN O O
occurring NN O O
in NN O O
2 NN O O
% NN O O
or NN O O
more NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
ZYKADIA NN O O
included NN O O
neuropathy NN B-AdverseReaction B-AdverseReaction
( NN O O
17 NN O O
% NN O O
; NN O O
comprised NN O O
of NN O O
paresthesia NN B-AdverseReaction B-AdverseReaction
muscular NN B-AdverseReaction B-AdverseReaction
weakness NN I-AdverseReaction I-AdverseReaction
gait NN B-AdverseReaction B-AdverseReaction
disturbance NN I-AdverseReaction I-AdverseReaction
peripheral NN B-AdverseReaction B-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
hypoesthesia NN B-AdverseReaction B-AdverseReaction
peripheral NN B-AdverseReaction B-AdverseReaction
sensory NN I-AdverseReaction I-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
dysesthesia NN B-AdverseReaction B-AdverseReaction
neuralgia NN B-AdverseReaction B-AdverseReaction
peripheral NN B-AdverseReaction B-AdverseReaction
motor NN I-AdverseReaction I-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
hypotonia NN B-AdverseReaction B-AdverseReaction
or NN O O
polyneuropathy NN B-AdverseReaction B-AdverseReaction
vision NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
( NN O O
9 NN O O
% NN O O
; NN O O
comprised NN O O
of NN O O
vision NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
blurred NN B-AdverseReaction B-AdverseReaction
vision NN I-AdverseReaction I-AdverseReaction
photopsia NN B-AdverseReaction B-AdverseReaction
accommodation NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
presbyopia NN B-AdverseReaction B-AdverseReaction
or NN O O
reduced NN B-AdverseReaction B-AdverseReaction
visual NN I-AdverseReaction I-AdverseReaction
acuity NN I-AdverseReaction I-AdverseReaction
prolonged NN B-AdverseReaction B-AdverseReaction
QT NN I-AdverseReaction I-AdverseReaction
interval NN I-AdverseReaction I-AdverseReaction
( NN O O
4 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
bradycardia NN B-AdverseReaction B-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
. NN O O
Table NN O O
3 NN O O
: NN O O
Key NN O O
Laboratory NN O O
Abnormalities NN O O
Occurring NN O O
in NN O O
>10 NN O O
% NN O O
( NN O O
All NN O O
NCI NN O O
CTCAE NN O O
Grades NN O O
) NN O O
of NN O O
ALK NN O O
- NN O O
Positive NN O O
Patients NN O O
Treated NN O O
with NN O O
ZYKADIA NN O O
in NN O O
Study NN O O
1 NN O O
ZYKADIAN=255 NN O O
All NN O O
Grades NN O O
Grade NN O O
3 NN O O
- NN O O
4 NN O O
% NN O O
% NN O O
Hemoglobin NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
84 NN O O
5 NN O O
Alanine NN O O
transaminase NN O O
( NN O O
ALT NN O O
) NN O O
increased NN O O
80 NN O O
27 NN O O
Aspartate NN O O
transaminase NN O O
( NN O O
AST NN O O
) NN O O
increased NN O O
75 NN O O
13 NN O O
Creatinine NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
58 NN O O
2 NN O O
Glucose NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
49 NN O O
13 NN O O
Phosphate NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
36 NN O O
7 NN O O
Lipase NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
28 NN O O
10 NN O O
Bilirubin NN O O
( NN O O
total NN O O
) NN O O
increased NN O O
15 NN O O
1 NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Severe NN O O
or NN O O
Persistent NN O O
Gastrointestinal NN O O
Toxicity NN O O
: NN O O
Dose NN O O
modification NN O O
due NN O O
to NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
or NN O O
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
38 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
Withhold NN O O
if NN O O
not NN O O
responsive NN O O
to NN O O
anti NN O O
- NN O O
emetics NN O O
or NN O O
anti NN O O
- NN O O
diarrheals NN O O
, NN O O
then NN O O
dose NN O O
reduce NN O O
ZYKADIA. NN O O
( NN O O
2.2 NN O O
, NN O O
5.1 NN O O
) NN O O
* NN O O
Hepatotoxicity NN B-AdverseReaction B-AdverseReaction
: NN O O
ZYKADIA NN O O
can NN B-Factor B-Factor
cause NN O O
hepatotoxicity NN B-AdverseReaction B-AdverseReaction
Monitor NN O O
liver NN O O
laboratory NN O O
tests NN O O
at NN O O
least NN O O
monthly NN O O
. NN O O
Withhold NN O O
then NN O O
dose NN O O
reduce NN O O
, NN O O
or NN O O
permanently NN O O
discontinue NN O O
ZYKADIA. NN O O
( NN O O
2.2 NN O O
, NN O O
5.2 NN O O
) NN O O
* NN O O
Interstitial NN B-AdverseReaction B-AdverseReaction
Lung NN I-AdverseReaction I-AdverseReaction
Disease NN I-AdverseReaction I-AdverseReaction
( NN O O
ILD)/Pneumonitis NN O O
: NN O O
Occurred NN O O
in NN O O
4 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
Permanently NN O O
discontinue NN O O
ZYKADIA NN O O
in NN O O
patients NN O O
diagnosed NN O O
with NN O O
treatment NN O O
- NN O O
related NN O O
ILD/pneumonitis NN O O
. NN O O
( NN O O
2.2 NN O O
, NN O O
5.3 NN O O
) NN O O
* NN O O
QT NN B-AdverseReaction B-AdverseReaction
Interval NN I-AdverseReaction I-AdverseReaction
Prolongation NN I-AdverseReaction I-AdverseReaction
: NN O O
ZYKADIA NN O O
can NN B-Factor B-Factor
cause NN O O
QTc NN B-AdverseReaction B-AdverseReaction
interval NN I-AdverseReaction I-AdverseReaction
prolongation NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
electrocardiograms NN O O
and NN O O
electrolytes NN O O
in NN O O
patients NN O O
with NN O O
congestive NN O O
heart NN O O
failure NN O O
, NN O O
bradyarrhythmias NN O O
, NN O O
electrolyte NN O O
abnormalities NN O O
, NN O O
or NN O O
those NN O O
who NN O O
are NN O O
taking NN O O
medications NN O O
that NN O O
are NN O O
known NN O O
to NN O O
prolong NN O O
the NN O O
QTc NN O O
interval NN O O
. NN O O
Withhold NN O O
then NN O O
dose NN O O
reduce NN O O
, NN O O
or NN O O
permanently NN O O
discontinue NN O O
ZYKADIA. NN O O
( NN O O
2.2 NN O O
, NN O O
5.4 NN O O
) NN O O
* NN O O
Hyperglycemia NN B-AdverseReaction B-AdverseReaction
: NN O O
ZYKADIA NN O O
can NN B-Factor B-Factor
cause NN O O
hyperglycemia NN B-AdverseReaction B-AdverseReaction
Monitor NN O O
fasting NN O O
glucose NN O O
prior NN O O
to NN O O
treatment NN O O
and NN O O
periodically NN O O
thereafter NN O O
as NN O O
clinically NN O O
indicated NN O O
. NN O O
Initiate NN O O
or NN O O
optimize NN O O
anti NN O O
- NN O O
hyperglycemic NN O O
medications NN O O
as NN O O
indicated NN O O
. NN O O
Withhold NN O O
then NN O O
dose NN O O
reduce NN O O
, NN O O
or NN O O
permanently NN O O
discontinue NN O O
ZYKADIA. NN O O
( NN O O
2.2 NN O O
, NN O O
5.5 NN O O
) NN O O
* NN O O
Bradycardia NN B-AdverseReaction B-AdverseReaction
: NN O O
ZYKADIA NN O O
can NN B-Factor B-Factor
cause NN O O
bradycardia NN B-AdverseReaction B-AdverseReaction
Monitor NN O O
heart NN O O
rate NN O O
and NN O O
blood NN O O
pressure NN O O
regularly NN O O
. NN O O
Withhold NN O O
then NN O O
dose NN O O
reduce NN O O
, NN O O
or NN O O
permanently NN O O
discontinue NN O O
ZYKADIA. NN O O
( NN O O
2.2 NN O O
, NN O O
5.6 NN O O
) NN O O
* NN O O
Pancreatitis NN B-AdverseReaction B-AdverseReaction
: NN O O
Elevations NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
lipase NN I-AdverseReaction I-AdverseReaction
and/or NN O O
amylase NN O O
and NN O O
pancreatitis NN B-AdverseReaction B-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
. NN O O
Monitor NN O O
lipase NN O O
and NN O O
amylase NN O O
prior NN O O
to NN O O
treatment NN O O
and NN O O
periodically NN O O
thereafter NN O O
as NN O O
clinically NN O O
indicated NN O O
. NN O O
( NN O O
2.2 NN O O
, NN O O
5.7 NN O O
) NN O O
* NN O O
Embryofetal NN B-AdverseReaction B-AdverseReaction
Toxicity NN I-AdverseReaction I-AdverseReaction
: NN O O
ZYKADIA NN O O
may NN B-Factor B-Factor
cause NN O O
fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
Advise NN O O
females NN O O
of NN O O
reproductive NN O O
potential NN O O
of NN O O
the NN O O
potential NN O O
risk NN O O
to NN O O
a NN O O
fetus NN O O
. NN O O
( NN O O
5.8 NN O O
, NN O O
8.1 NN O O
, NN O O
8.7 NN O O
) NN O O
5.1 NN O O
Severe NN O O
or NN O O
Persistent NN O O
Gastrointestinal NN O O
Toxicity NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
or NN O O
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
96 NN O O
% NN O O
of NN O O
255 NN O O
patients NN O O
including NN O O
severe NN B-Severity B-Severity
cases NN O O
in NN O O
14 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
ZYKADIA NN O O
in NN O O
Study NN O O
1 NN O O
. NN O O
Dose NN O O
modification NN O O
due NN O O
to NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
or NN O O
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
38 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
Monitor NN O O
and NN O O
manage NN O O
patients NN O O
using NN O O
standards NN O O
of NN O O
care NN O O
, NN O O
including NN O O
anti NN O O
- NN O O
diarrheals NN O O
, NN O O
anti NN O O
- NN O O
emetics NN O O
, NN O O
or NN O O
fluid NN O O
replacement NN O O
, NN O O
as NN O O
indicated NN O O
. NN O O
Based NN O O
on NN O O
the NN O O
severity NN O O
of NN O O
the NN O O
adverse NN O O
drug NN O O
reaction NN O O
, NN O O
withhold NN O O
ZYKADIA NN O O
with NN O O
resumption NN O O
at NN O O
a NN O O
reduced NN O O
dose NN O O
as NN O O
described NN O O
in NN O O
Table NN O O
1 NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
and NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
Hepatotoxicity NN O O
Drug NN O O
- NN O O
induced NN O O
hepatotoxicity NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
ZYKADIA. NN O O
Elevations NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
alanine NN I-AdverseReaction I-AdverseReaction
aminotransferase NN I-AdverseReaction I-AdverseReaction
( NN O O
ALT NN O O
) NN O O
greater NN O O
than NN O O
5 NN B-Severity B-Severity
times NN I-Severity I-Severity
the NN I-Severity I-Severity
upper NN I-Severity I-Severity
limit NN I-Severity I-Severity
of NN I-Severity I-Severity
normal NN I-Severity I-Severity
( NN O O
ULN NN O O
) NN O O
occurred NN O O
in NN O O
27 NN O O
% NN O O
of NN O O
255 NN O O
patients NN O O
in NN O O
Study NN O O
1 NN O O
. NN O O
One NN O O
patient NN O O
( NN O O
0.4 NN O O
% NN O O
) NN O O
required NN O O
permanent NN O O
discontinuation NN O O
due NN O O
to NN O O
elevated NN B-AdverseReaction B-AdverseReaction
transaminases NN I-AdverseReaction I-AdverseReaction
and NN O O
jaundice NN B-AdverseReaction B-AdverseReaction
Concurrent NN O O
elevations NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
ALT NN I-AdverseReaction I-AdverseReaction
greater NN O O
than NN O O
3 NN B-Severity B-Severity
times NN I-Severity I-Severity
the NN I-Severity I-Severity
ULN NN I-Severity I-Severity
and NN O O
total NN O O
bilirubin NN O O
greater NN O O
than NN O O
2 NN O O
times NN O O
the NN O O
ULN NN O O
, NN O O
with NN O O
normal NN O O
alkaline NN O O
phosphatase NN O O
, NN O O
occurred NN O O
in NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
of NN O O
patients NN O O
in NN O O
clinical NN O O
studies NN O O
. NN O O
Monitor NN O O
with NN O O
liver NN O O
laboratory NN O O
tests NN O O
including NN O O
ALT NN O O
, NN O O
aspartate NN O O
aminotransferase NN O O
( NN O O
AST NN O O
) NN O O
, NN O O
and NN O O
total NN O O
bilirubin NN O O
once NN O O
a NN O O
month NN O O
and NN O O
as NN O O
clinically NN O O
indicated NN O O
, NN O O
with NN O O
more NN O O
frequent NN O O
testing NN O O
in NN O O
patients NN O O
who NN O O
develop NN O O
transaminase NN O O
elevations NN O O
. NN O O
Based NN O O
on NN O O
the NN O O
severity NN O O
of NN O O
the NN O O
adverse NN O O
drug NN O O
reaction NN O O
, NN O O
withhold NN O O
ZYKADIA NN O O
with NN O O
resumption NN O O
at NN O O
a NN O O
reduced NN O O
dose NN O O
, NN O O
or NN O O
permanently NN O O
discontinue NN O O
ZYKADIA NN O O
as NN O O
described NN O O
in NN O O
Table NN O O
1 NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
and NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
] NN O O
. NN O O
5.3 NN O O
Interstitial NN O O
Lung NN O O
Disease NN O O
( NN O O
ILD)/Pneumonitis NN O O
Severe NN B-Severity B-Severity
life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
or NN O O
fatal NN B-AdverseReaction B-AdverseReaction
ILD NN B-AdverseReaction B-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
ZYKADIA. NN O O
In NN O O
Study NN O O
1 NN O O
, NN O O
pneumonitis NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
4 NN O O
% NN O O
of NN O O
255 NN O O
patients NN O O
treated NN O O
with NN O O
ZYKADIA. NN O O
CTCAE NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
or NN O O
4 NN O O
ILD NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
3 NN O O
% NN O O
of NN O O
patients NN O O
, NN O O
and NN O O
fatal NN B-AdverseReaction B-AdverseReaction
ILD NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
1 NN O O
patient NN O O
( NN O O
0.4 NN O O
% NN O O
) NN O O
in NN O O
Study NN O O
1 NN O O
. NN O O
One NN O O
percent NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
of NN O O
patients NN O O
discontinued NN O O
ZYKADIA NN O O
in NN O O
Study NN O O
1 NN O O
due NN O O
to NN O O
ILD NN B-AdverseReaction B-AdverseReaction
Monitor NN O O
patients NN O O
for NN O O
pulmonary NN O O
symptoms NN O O
indicative NN O O
of NN O O
ILD/pneumonitis NN O O
. NN O O
Exclude NN O O
other NN O O
potential NN O O
causes NN O O
of NN O O
ILD/pneumonitis NN O O
, NN O O
and NN O O
permanently NN O O
discontinue NN O O
ZYKADIA NN O O
in NN O O
patients NN O O
diagnosed NN O O
with NN O O
treatment NN O O
- NN O O
related NN O O
ILD/pneumonitis NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
and NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
] NN O O
. NN O O
5.4 NN O O
QT NN O O
Interval NN O O
Prolongation NN O O
QTc NN B-AdverseReaction B-AdverseReaction
interval NN I-AdverseReaction I-AdverseReaction
prolongation NN I-AdverseReaction I-AdverseReaction
which NN O O
may NN O O
lead NN O O
to NN O O
an NN O O
increased NN O O
risk NN B-Factor B-Factor
for NN O O
ventricular NN B-AdverseReaction B-AdverseReaction
tachyarrhythmias NN I-AdverseReaction I-AdverseReaction
( NN O O
e.g. NN O O
, NN O O
Torsade NN B-AdverseReaction B-AdverseReaction
de NN I-AdverseReaction I-AdverseReaction
pointes NN I-AdverseReaction I-AdverseReaction
or NN O O
sudden NN B-AdverseReaction B-AdverseReaction
death NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
ZYKADIA NN O O
in NN O O
clinical NN O O
trials NN O O
. NN O O
Three NN O O
percent NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
of NN O O
255 NN O O
patients NN O O
experienced NN O O
a NN O O
QTc NN B-AdverseReaction B-AdverseReaction
interval NN I-AdverseReaction I-AdverseReaction
increase NN I-AdverseReaction I-AdverseReaction
over NN O O
baseline NN O O
greater NN O O
than NN O O
60 NN B-Severity B-Severity
msec NN I-Severity I-Severity
in NN O O
Study NN O O
1 NN O O
. NN O O
Across NN O O
the NN O O
development NN O O
program NN O O
of NN O O
ZYKADIA NN O O
, NN O O
one NN O O
of NN O O
304 NN O O
patients NN O O
( NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
) NN O O
treated NN O O
with NN O O
ZYKADIA NN O O
doses NN O O
ranging NN O O
from NN O O
50 NN O O
to NN O O
750 NN O O
mg NN O O
was NN O O
found NN O O
to NN O O
have NN O O
a NN O O
QTc NN B-AdverseReaction B-AdverseReaction
greater NN I-AdverseReaction I-AdverseReaction
than NN I-AdverseReaction I-AdverseReaction
500 NN I-AdverseReaction I-AdverseReaction
msec NN I-AdverseReaction I-AdverseReaction
and NN O O
3 NN O O
% NN O O
of NN O O
patients NN O O
had NN O O
an NN O O
increase NN B-AdverseReaction B-AdverseReaction
from NN I-AdverseReaction I-AdverseReaction
baseline NN I-AdverseReaction I-AdverseReaction
QTc NN I-AdverseReaction I-AdverseReaction
greater NN O O
than NN O O
60 NN B-Severity B-Severity
msec NN I-Severity I-Severity
A NN O O
pharmacokinetic NN O O
analysis NN O O
suggested NN B-Factor B-Factor
that NN O O
ZYKADIA NN O O
causes NN O O
concentration NN O O
- NN O O
dependent NN O O
increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
QTc NN I-AdverseReaction I-AdverseReaction
interval NN I-AdverseReaction I-AdverseReaction
When NN O O
possible NN O O
, NN O O
avoid NN O O
use NN O O
of NN O O
ZYKADIA NN O O
in NN O O
patients NN O O
with NN O O
congenital NN O O
long NN O O
QT NN O O
syndrome NN O O
. NN O O
Conduct NN O O
periodic NN O O
monitoring NN O O
with NN O O
electrocardiograms NN O O
( NN O O
ECGs NN O O
) NN O O
and NN O O
electrolytes NN O O
in NN O O
patients NN O O
with NN O O
congestive NN O O
heart NN O O
failure NN O O
, NN O O
bradyarrhythmias NN O O
, NN O O
electrolyte NN O O
abnormalities NN O O
, NN O O
or NN O O
those NN O O
who NN O O
are NN O O
taking NN O O
medications NN O O
that NN O O
are NN O O
known NN O O
to NN O O
prolong NN O O
the NN O O
QTc NN O O
interval NN O O
. NN O O
Withhold NN O O
ZYKADIA NN O O
in NN O O
patients NN O O
who NN O O
develop NN O O
a NN O O
QTc NN O O
interval NN O O
greater NN O O
than NN O O
500 NN O O
msec NN O O
on NN O O
at NN O O
least NN O O
2 NN O O
separate NN O O
ECGs NN O O
until NN O O
the NN O O
QTc NN O O
interval NN O O
is NN O O
less NN O O
than NN O O
481 NN O O
msec NN O O
or NN O O
recovery NN O O
to NN O O
baseline NN O O
if NN O O
the NN O O
QTc NN O O
interval NN O O
is NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
481 NN O O
msec NN O O
, NN O O
then NN O O
resume NN O O
ZYKADIA NN O O
at NN O O
a NN O O
reduced NN O O
dose NN O O
as NN O O
described NN O O
in NN O O
Table NN O O
1 NN O O
. NN O O
Permanently NN O O
discontinue NN O O
ZYKADIA NN O O
in NN O O
patients NN O O
who NN O O
develop NN O O
QTc NN O O
interval NN O O
prolongation NN O O
in NN O O
combination NN O O
with NN O O
Torsade NN O O
de NN O O
pointes NN O O
or NN O O
polymorphic NN O O
ventricular NN O O
tachycardia NN O O
or NN O O
signs/symptoms NN O O
of NN O O
serious NN O O
arrhythmia NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
and NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.2 NN O O
) NN O O
] NN O O
. NN O O
5.5 NN O O
Hyperglycemia NN O O
Hyperglycemia NN B-AdverseReaction B-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
in NN O O
patients NN O O
receiving NN O O
ZYKADIA. NN O O
In NN O O
Study NN O O
1 NN O O
, NN O O
CTCAE NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
- NN I-Severity I-Severity
4 NN I-Severity I-Severity
hyperglycemia NN B-AdverseReaction B-AdverseReaction
based NN O O
on NN O O
laboratory NN O O
values NN O O
, NN O O
occurred NN O O
in NN O O
13 NN O O
% NN O O
of NN O O
255 NN O O
patients NN O O
. NN O O
There NN O O
was NN O O
a NN O O
6-fold NN O O
increase NN O O
in NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
CTCAE NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
- NN I-Severity I-Severity
4 NN I-Severity I-Severity
hyperglycemia NN B-AdverseReaction B-AdverseReaction
in NN O O
patients NN O O
with NN O O
diabetes NN O O
or NN O O
glucose NN O O
intolerance NN O O
and NN O O
a NN O O
2-fold NN O O
increase NN O O
in NN O O
patients NN O O
taking NN O O
corticosteroids NN O O
. NN O O
Monitor NN O O
fasting NN O O
serum NN O O
glucose NN O O
prior NN O O
to NN O O
the NN O O
start NN O O
of NN O O
ZYKADIA NN O O
treatment NN O O
and NN O O
periodically NN O O
thereafter NN O O
as NN O O
clinically NN O O
indicated NN O O
. NN O O
Initiate NN O O
or NN O O
optimize NN O O
anti NN O O
- NN O O
hyperglycemic NN O O
medications NN O O
as NN O O
indicated NN O O
. NN O O
Based NN O O
on NN O O
the NN O O
severity NN O O
of NN O O
the NN O O
adverse NN O O
drug NN O O
reaction NN O O
, NN O O
withhold NN O O
ZYKADIA NN O O
until NN O O
hyperglycemia NN O O
is NN O O
adequately NN O O
controlled NN O O
, NN O O
then NN O O
resume NN O O
ZYKADIA NN O O
at NN O O
a NN O O
reduced NN O O
dose NN O O
as NN O O
described NN O O
in NN O O
Table NN O O
1 NN O O
. NN O O
If NN O O
adequate NN O O
hyperglycemic NN O O
control NN O O
can NN O O
not NN O O
be NN O O
achieved NN O O
with NN O O
optimal NN O O
medical NN O O
management NN O O
, NN O O
permanently NN O O
discontinue NN O O
ZYKADIA NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
and NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
] NN O O
. NN O O
5.6 NN O O
Bradycardia NN O O
Bradycardia NN B-AdverseReaction B-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
in NN O O
patients NN O O
receiving NN O O
ZYKADIA. NN O O
In NN O O
Study NN O O
1 NN O O
, NN O O
sinus NN B-AdverseReaction B-AdverseReaction
bradycardia NN I-AdverseReaction I-AdverseReaction
defined NN O O
as NN O O
a NN O O
heart NN B-AdverseReaction B-AdverseReaction
rate NN I-AdverseReaction I-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
less NN I-AdverseReaction I-AdverseReaction
than NN I-AdverseReaction I-AdverseReaction
50 NN I-AdverseReaction I-AdverseReaction
beats NN I-AdverseReaction I-AdverseReaction
per NN I-AdverseReaction I-AdverseReaction
minute NN I-AdverseReaction I-AdverseReaction
was NN O O
noted NN O O
as NN O O
a NN O O
new NN O O
finding NN O O
in NN O O
1 NN O O
% NN O O
of NN O O
255 NN O O
patients NN O O
. NN O O
Bradycardia NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
as NN O O
an NN O O
adverse NN O O
drug NN O O
reaction NN O O
in NN O O
3 NN O O
% NN O O
of NN O O
patients NN O O
in NN O O
Study NN O O
1 NN O O
. NN O O
Avoid NN O O
using NN O O
ZYKADIA NN O O
in NN O O
combination NN O O
with NN O O
other NN O O
agents NN O O
known NN O O
to NN O O
cause NN O O
bradycardia NN O O
( NN O O
e.g. NN O O
, NN O O
beta NN O O
- NN O O
blockers NN O O
, NN O O
non NN O O
- NN O O
dihydropyridine NN O O
calcium NN O O
channel NN O O
blockers NN O O
, NN O O
clonidine NN O O
, NN O O
and NN O O
digoxin NN O O
) NN O O
to NN O O
the NN O O
extent NN O O
possible NN O O
. NN O O
Monitor NN O O
heart NN O O
rate NN O O
and NN O O
blood NN O O
pressure NN O O
regularly NN O O
. NN O O
In NN O O
cases NN O O
of NN O O
symptomatic NN O O
bradycardia NN O O
that NN O O
is NN O O
not NN O O
life NN O O
- NN O O
threatening NN O O
, NN O O
withhold NN O O
ZYKADIA NN O O
until NN O O
recovery NN O O
to NN O O
asymptomatic NN O O
bradycardia NN O O
or NN O O
to NN O O
a NN O O
heart NN O O
rate NN O O
of NN O O
60 NN O O
bpm NN O O
or NN O O
above NN O O
, NN O O
evaluate NN O O
the NN O O
use NN O O
of NN O O
concomitant NN O O
medications NN O O
, NN O O
and NN O O
adjust NN O O
the NN O O
dose NN O O
of NN O O
ZYKADIA. NN O O
Permanently NN O O
discontinue NN O O
ZYKADIA NN O O
for NN O O
life NN O O
- NN O O
threatening NN O O
bradycardia NN O O
if NN O O
no NN O O
contributing NN O O
concomitant NN O O
medication NN O O
is NN O O
identified NN O O
; NN O O
however NN O O
, NN O O
if NN O O
associated NN O O
with NN O O
a NN O O
concomitant NN O O
medication NN O O
known NN O O
to NN O O
cause NN O O
bradycardia NN O O
or NN O O
hypotension NN O O
, NN O O
withhold NN O O
ZYKADIA NN O O
until NN O O
recovery NN O O
to NN O O
asymptomatic NN O O
bradycardia NN O O
or NN O O
to NN O O
a NN O O
heart NN O O
rate NN O O
of NN O O
60 NN O O
bpm NN O O
or NN O O
above NN O O
, NN O O
and NN O O
if NN O O
the NN O O
concomitant NN O O
medication NN O O
can NN O O
be NN O O
adjusted NN O O
or NN O O
discontinued NN O O
, NN O O
resume NN O O
ZYKADIA NN O O
at NN O O
a NN O O
reduced NN O O
dose NN O O
as NN O O
described NN O O
in NN O O
Table NN O O
1 NN O O
upon NN O O
recovery NN O O
to NN O O
asymptomatic NN O O
bradycardia NN O O
or NN O O
to NN O O
a NN O O
heart NN O O
rate NN O O
of NN O O
60 NN O O
bpm NN O O
or NN O O
above NN O O
, NN O O
with NN O O
frequent NN O O
monitoring NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
and NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
] NN O O
. NN O O
5.7 NN O O
Pancreatitis NN O O
Pancreatitis NN B-AdverseReaction B-AdverseReaction
including NN O O
one NN O O
fatality NN B-AdverseReaction B-AdverseReaction
has NN O O
been NN O O
reported NN O O
in NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
ZYKADIA NN O O
in NN O O
clinical NN O O
trials NN O O
. NN O O
CTCAE NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
- NN I-Severity I-Severity
4 NN I-Severity I-Severity
elevations NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
lipase NN I-AdverseReaction I-AdverseReaction
and/or NN O O
amylase NN O O
occurred NN O O
in NN O O
15 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
ZYKADIA NN O O
in NN O O
Study NN O O
1 NN O O
. NN O O
Monitor NN O O
lipase NN O O
and NN O O
amylase NN O O
prior NN O O
to NN O O
the NN O O
start NN O O
of NN O O
ZYKADIA NN O O
treatment NN O O
and NN O O
periodically NN O O
thereafter NN O O
as NN O O
clinically NN O O
indicated NN O O
. NN O O
Based NN O O
on NN O O
the NN O O
severity NN O O
of NN O O
the NN O O
laboratory NN O O
abnormalities NN O O
, NN O O
withhold NN O O
ZYKADIA NN O O
with NN O O
resumption NN O O
at NN O O
a NN O O
reduced NN O O
dose NN O O
as NN O O
described NN O O
in NN O O
Table NN O O
1 NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
and NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
] NN O O
. NN O O
5.8 NN O O
Embryofetal NN O O
Toxicity NN O O
Based NN O O
on NN O O
its NN O O
mechanism NN O O
of NN O O
action NN O O
, NN O O
ZYKADIA NN O O
may NN B-Factor B-Factor
cause NN O O
fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
when NN O O
administered NN O O
to NN O O
a NN O O
pregnant NN O O
woman NN O O
. NN O O
In NN O O
animal NN O O
studies NN O O
, NN O O
administration NN O O
of NN O O
ceritinib NN O O
to NN O O
rats NN O O
and NN O O
rabbits NN O O
during NN O O
organogenesis NN O O
at NN O O
maternal NN O O
plasma NN O O
exposures NN O O
below NN O O
the NN O O
recommended NN O O
human NN O O
dose NN O O
of NN O O
750 NN O O
mg NN O O
daily NN O O
caused NN O O
increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
skeletal NN I-AdverseReaction I-AdverseReaction
anomalies NN I-AdverseReaction I-AdverseReaction
in NN O O
rats NN B-Animal B-Animal
and NN O O
rabbits NN B-Animal B-Animal
Apprise NN O O
women NN O O
of NN O O
reproductive NN O O
potential NN O O
of NN O O
the NN O O
potential NN O O
hazard NN O O
to NN O O
a NN O O
fetus NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.1 NN O O
) NN O O
] NN O O
. NN O O
Advise NN O O
females NN O O
of NN O O
reproductive NN O O
potential NN O O
to NN O O
use NN O O
effective NN O O
contraception NN O O
during NN O O
treatment NN O O
with NN O O
ZYKADIA NN O O
and NN O O
for NN O O
at NN O O
least NN O O
2 NN O O
weeks NN O O
following NN O O
completion NN O O
of NN O O
therapy NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.7 NN O O
) NN O O
] NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
serious NN O O
reactions NN O O
are NN O O
described NN O O
below NN O O
or NN O O
elsewhere NN O O
in NN O O
the NN O O
prescribing NN O O
information NN O O
: NN O O
* NN O O
Risk NN B-Factor B-Factor
of NN O O
Thyroid NN B-AdverseReaction B-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
Tumors NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Pancreatitis NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
Hypoglycemia NN B-AdverseReaction B-AdverseReaction
with NN O O
Concomitant NN O O
Use NN O O
of NN O O
Insulin NN O O
Secretagogues NN O O
or NN O O
Insulin NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
* NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
* NN O O
Renal NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
* NN O O
Severe NN B-Severity B-Severity
Gastrointestinal NN B-AdverseReaction B-AdverseReaction
Disease NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.6 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
, NN O O
reported NN O O
in NN O O
>=5 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
TRULICITY NN O O
are NN O O
: NN O O
nausea NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
and NN O O
decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
. NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Eli NN O O
Lilly NN O O
and NN O O
Company NN O O
at NN O O
1 NN O O
- NN O O
800-LillyRx NN O O
( NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
545 NN O O
- NN O O
5979 NN O O
) NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Studies NN O O
Experience NN O O
Because NN O O
clinical NN O O
studies NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
studies NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
studies NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
Pool NN O O
of NN O O
Placebo NN O O
- NN O O
controlled NN O O
Trials NN O O
The NN O O
data NN O O
in NN O O
Table NN O O
1 NN O O
are NN O O
derived NN O O
from NN O O
the NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
. NN O O
These NN O O
data NN O O
reflect NN O O
exposure NN O O
of NN O O
1670 NN O O
patients NN O O
to NN O O
TRULICITY NN O O
and NN O O
a NN O O
mean NN O O
duration NN O O
of NN O O
exposure NN O O
to NN O O
TRULICITY NN O O
of NN O O
23.8 NN O O
weeks NN O O
. NN O O
Across NN O O
the NN O O
treatment NN O O
arms NN O O
, NN O O
the NN O O
mean NN O O
age NN O O
of NN O O
patients NN O O
was NN O O
56 NN O O
years NN O O
, NN O O
1 NN O O
% NN O O
were NN O O
75 NN O O
years NN O O
or NN O O
older NN O O
and NN O O
53 NN O O
% NN O O
were NN O O
male NN O O
. NN O O
The NN O O
population NN O O
in NN O O
these NN O O
studies NN O O
was NN O O
69 NN O O
% NN O O
White NN O O
, NN O O
7 NN O O
% NN O O
Black NN O O
or NN O O
African NN O O
American NN O O
, NN O O
13 NN O O
% NN O O
Asian NN O O
; NN O O
30 NN O O
% NN O O
were NN O O
of NN O O
Hispanic NN O O
or NN O O
Latino NN O O
ethnicity NN O O
. NN O O
At NN O O
baseline NN O O
, NN O O
the NN O O
population NN O O
had NN O O
diabetes NN O O
for NN O O
an NN O O
average NN O O
of NN O O
8.0 NN O O
years NN O O
and NN O O
had NN O O
a NN O O
mean NN O O
HbA1c NN O O
of NN O O
8.0 NN O O
% NN O O
. NN O O
At NN O O
baseline NN O O
, NN O O
2.5 NN O O
% NN O O
of NN O O
the NN O O
population NN O O
reported NN O O
retinopathy NN O O
. NN O O
Baseline NN O O
estimated NN O O
renal NN O O
function NN O O
was NN O O
normal NN O O
or NN O O
mildly NN O O
impaired NN O O
( NN O O
eGFR NN O O
>=60mL/min/1.73 NN O O
m NN O O
2 NN O O
) NN O O
in NN O O
96.0 NN O O
% NN O O
of NN O O
the NN O O
pooled NN O O
study NN O O
populations NN O O
. NN O O
Table NN O O
1 NN O O
shows NN O O
common NN O O
adverse NN O O
reactions NN O O
, NN O O
excluding NN O O
hypoglycemia NN B-AdverseReaction B-AdverseReaction
associated NN O O
with NN O O
the NN O O
use NN O O
of NN O O
TRULICITY NN O O
in NN O O
the NN O O
pool NN O O
of NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
. NN O O
These NN O O
adverse NN O O
reactions NN O O
were NN O O
not NN O O
present NN O O
at NN O O
baseline NN O O
, NN O O
occurred NN O O
more NN O O
commonly NN O O
on NN O O
TRULICITY NN O O
than NN O O
on NN O O
placebo NN O O
, NN O O
and NN O O
occurred NN O O
in NN O O
at NN O O
least NN O O
5 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
TRULICITY. NN O O
Table NN O O
1 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
in NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Trials NN O O
Reported NN O O
in NN O O
>=5 NN O O
% NN O O
of NN O O
TRULICITY NN O O
- NN O O
Treated NN O O
Patients NN O O
a NN O O
Includes NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
fecal NN B-AdverseReaction B-AdverseReaction
volume NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
frequent NN B-AdverseReaction B-AdverseReaction
bowel NN I-AdverseReaction I-AdverseReaction
movements NN I-AdverseReaction I-AdverseReaction
b NN O O
Includes NN O O
retching NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
projectile NN I-AdverseReaction I-AdverseReaction
c NN O O
Includes NN O O
abdominal NN B-AdverseReaction B-AdverseReaction
discomfort NN I-AdverseReaction I-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
lower NN I-AdverseReaction I-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
upper NN I-AdverseReaction I-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
tenderness NN I-AdverseReaction I-AdverseReaction
gastrointestinal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
d NN O O
Includes NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
asthenia NN B-AdverseReaction B-AdverseReaction
malaise NN B-AdverseReaction B-AdverseReaction
Note NN O O
: NN O O
Percentages NN O O
reflect NN O O
the NN O O
number NN O O
of NN O O
patients NN O O
that NN O O
reported NN O O
at NN O O
least NN O O
1 NN O O
treatment- NN O O
emergent NN O O
occurrence NN O O
of NN O O
the NN O O
adverse NN O O
reaction NN O O
. NN O O
Adverse NN O O
Reaction NN O O
Placebo NN O O
( NN O O
N=568 NN O O
) NN O O
% NN O O
Trulicity NN O O
0.75 NN O O
mg NN O O
( NN O O
N=836 NN O O
) NN O O
% NN O O
Trulicity NN O O
1.5 NN O O
mg NN O O
( NN O O
N=834 NN O O
) NN O O
% NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
5.3 NN O O
12.4 NN O O
21.1 NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
a NN O O
6.7 NN O O
8.9 NN O O
12.6 NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
b NN O O
2.3 NN O O
6.0 NN O O
12.7 NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
Pain NN I-AdverseReaction I-AdverseReaction
c NN O O
4.9 NN O O
6.5 NN O O
9.4 NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
Appetite NN I-AdverseReaction I-AdverseReaction
1.6 NN O O
4.9 NN O O
8.6 NN O O
Dyspepsia NN B-AdverseReaction B-AdverseReaction
2.3 NN O O
4.1 NN O O
5.8 NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
d NN O O
2.6 NN O O
4.2 NN O O
5.6 NN O O
Gastrointestinal NN O O
Adverse NN O O
Reactions NN O O
In NN O O
the NN O O
pool NN O O
of NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
, NN O O
gastrointestinal NN B-AdverseReaction B-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
occurred NN O O
more NN O O
frequently NN O O
among NN O O
patients NN O O
receiving NN O O
TRULICITY NN O O
than NN O O
placebo NN O O
( NN O O
placebo NN O O
21.3 NN O O
% NN O O
, NN O O
0.75 NN O O
mg NN O O
31.6 NN O O
% NN O O
, NN O O
1.5 NN O O
mg NN O O
41.0 NN O O
% NN O O
) NN O O
. NN O O
More NN O O
patients NN O O
receiving NN O O
TRULICITY NN O O
0.75 NN O O
mg NN O O
( NN O O
1.3 NN O O
% NN O O
) NN O O
and NN O O
TRULICITY NN O O
1.5 NN O O
mg NN O O
( NN O O
3.5 NN O O
% NN O O
) NN O O
discontinued NN O O
treatment NN O O
due NN O O
to NN O O
gastrointestinal NN B-AdverseReaction B-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
than NN O O
patients NN O O
receiving NN O O
placebo NN O O
( NN O O
0.2 NN O O
% NN O O
) NN O O
. NN O O
Investigators NN O O
graded NN O O
the NN O O
severity NN O O
of NN O O
gastrointestinal NN B-AdverseReaction B-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
occurring NN O O
on NN O O
0.75 NN O O
mg NN O O
and NN O O
1.5 NN O O
mg NN O O
of NN O O
TRULICITY NN O O
as NN O O
" NN O O
mild NN O O
" NN O O
in NN O O
58 NN O O
% NN O O
and NN O O
48 NN O O
% NN O O
of NN O O
cases NN O O
, NN O O
respectively NN O O
, NN O O
" NN O O
moderate NN O O
" NN O O
in NN O O
35 NN O O
% NN O O
and NN O O
42 NN O O
% NN O O
of NN O O
cases NN O O
, NN O O
respectively NN O O
, NN O O
or NN O O
" NN O O
severe NN O O
" NN O O
in NN O O
7 NN O O
% NN O O
and NN O O
11 NN O O
% NN O O
of NN O O
cases NN O O
, NN O O
respectively NN O O
. NN O O
In NN O O
addition NN O O
to NN O O
the NN O O
reactions NN O O
in NN O O
Table NN O O
1 NN O O
, NN O O
the NN O O
following NN O O
adverse NN O O
reactions NN O O
were NN O O
reported NN O O
more NN O O
frequently NN O O
in NN O O
TRULICITY NN O O
- NN O O
treated NN O O
patients NN O O
than NN O O
placebo NN O O
( NN O O
frequencies NN O O
listed NN O O
, NN O O
respectively NN O O
, NN O O
as NN O O
: NN O O
placebo NN O O
; NN O O
0.75 NN O O
mg NN O O
; NN O O
1.5 NN O O
mg NN O O
) NN O O
: NN O O
constipation NN B-AdverseReaction B-AdverseReaction
( NN O O
0.7 NN O O
% NN O O
, NN O O
3.9 NN O O
% NN O O
, NN O O
3.7 NN O O
% NN O O
) NN O O
, NN O O
flatulence NN B-AdverseReaction B-AdverseReaction
( NN O O
1.4 NN O O
% NN O O
, NN O O
1.4 NN O O
% NN O O
, NN O O
3.4 NN O O
% NN O O
) NN O O
, NN O O
abdominal NN B-AdverseReaction B-AdverseReaction
distension NN I-AdverseReaction I-AdverseReaction
( NN O O
0.7 NN O O
% NN O O
, NN O O
2.9 NN O O
% NN O O
, NN O O
2.3 NN O O
% NN O O
) NN O O
, NN O O
gastroesophageal NN B-AdverseReaction B-AdverseReaction
reflux NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
( NN O O
0.5 NN O O
% NN O O
, NN O O
1.7 NN O O
% NN O O
, NN O O
2.0 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
eructation NN B-AdverseReaction B-AdverseReaction
( NN O O
0.2 NN O O
% NN O O
, NN O O
0.6 NN O O
% NN O O
, NN O O
1.6 NN O O
% NN O O
) NN O O
. NN O O
Pool NN O O
of NN O O
Placebo- NN O O
and NN O O
Active NN O O
- NN O O
Controlled NN O O
Trials NN O O
The NN O O
occurrence NN O O
of NN O O
adverse NN O O
reactions NN O O
was NN O O
also NN O O
evaluated NN O O
in NN O O
a NN O O
larger NN O O
pool NN O O
of NN O O
patients NN O O
with NN O O
type NN O O
2 NN O O
diabetes NN O O
participating NN O O
in NN O O
6 NN O O
placebo- NN O O
and NN O O
active NN O O
- NN O O
controlled NN O O
trials NN O O
evaluating NN O O
the NN O O
use NN O O
of NN O O
TRULICITY NN O O
as NN O O
monotherapy NN O O
and NN O O
add NN O O
- NN O O
on NN O O
therapy NN O O
to NN O O
oral NN O O
medications NN O O
or NN O O
insulin NN O O
. NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
. NN O O
In NN O O
this NN O O
pool NN O O
, NN O O
a NN O O
total NN O O
of NN O O
3342 NN O O
patients NN O O
with NN O O
type NN O O
2 NN O O
diabetes NN O O
were NN O O
treated NN O O
with NN O O
TRULICITY NN O O
for NN O O
a NN O O
mean NN O O
duration NN O O
of NN O O
52 NN O O
weeks NN O O
. NN O O
The NN O O
mean NN O O
age NN O O
of NN O O
patients NN O O
was NN O O
56 NN O O
years NN O O
, NN O O
2 NN O O
% NN O O
were NN O O
75 NN O O
years NN O O
or NN O O
older NN O O
and NN O O
51 NN O O
% NN O O
were NN O O
male NN O O
. NN O O
The NN O O
population NN O O
in NN O O
these NN O O
studies NN O O
was NN O O
71 NN O O
% NN O O
White NN O O
, NN O O
7 NN O O
% NN O O
Black NN O O
or NN O O
African NN O O
American NN O O
, NN O O
11 NN O O
% NN O O
Asian NN O O
; NN O O
32 NN O O
% NN O O
were NN O O
of NN O O
Hispanic NN O O
or NN O O
Latino NN O O
ethnicity NN O O
. NN O O
At NN O O
baseline NN O O
, NN O O
the NN O O
population NN O O
had NN O O
diabetes NN O O
for NN O O
an NN O O
average NN O O
of NN O O
8.2 NN O O
years NN O O
and NN O O
had NN O O
a NN O O
mean NN O O
HbA1c NN O O
of NN O O
7.6 NN O O
- NN O O
8.5 NN O O
% NN O O
. NN O O
At NN O O
baseline NN O O
, NN O O
5.2 NN O O
% NN O O
of NN O O
the NN O O
population NN O O
reported NN O O
retinopathy NN O O
. NN O O
Baseline NN O O
estimated NN O O
renal NN O O
function NN O O
was NN O O
normal NN O O
or NN O O
mildly NN O O
impaired NN O O
( NN O O
eGFR NN O O
>=60 NN O O
ml/min/1.73 NN O O
m2 NN O O
) NN O O
in NN O O
95.7 NN O O
% NN O O
of NN O O
the NN O O
TRULICITY NN O O
population NN O O
. NN O O
In NN O O
the NN O O
pool NN O O
of NN O O
placebo- NN O O
and NN O O
active NN O O
- NN O O
controlled NN O O
trials NN O O
, NN O O
the NN O O
types NN O O
and NN O O
frequency NN O O
of NN O O
common NN O O
adverse NN O O
reactions NN O O
, NN O O
excluding NN O O
hypoglycemia NN B-AdverseReaction B-AdverseReaction
were NN O O
similar NN O O
to NN O O
those NN O O
listed NN O O
in NN O O
Table NN O O
1 NN O O
. NN O O
Other NN O O
Adverse NN O O
Reactions NN O O
Hypoglycemia NN O O
Table NN O O
2 NN O O
summarizes NN O O
the NN O O
incidence NN O O
of NN O O
documented NN O O
symptomatic NN O O
( NN O O
< NN O O
=70 NN O O
mg/dL NN O O
glucose NN O O
threshold NN O O
) NN O O
and NN O O
severe NN B-Severity B-Severity
hypoglycemia NN B-AdverseReaction B-AdverseReaction
in NN O O
the NN O O
placebo NN O O
- NN O O
controlled NN O O
clinical NN O O
studies NN O O
. NN O O
Table NN O O
2 NN O O
: NN O O
Incidence NN O O
( NN O O
% NN O O
) NN O O
of NN O O
Documented NN O O
Symptomatic NN O O
and NN O O
Severe NN B-Severity B-Severity
Hypoglycemia NN B-AdverseReaction B-AdverseReaction
Adverse NN O O
Reactions NN O O
in NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Trials NN O O
Placebo NN O O
TRULICITY NN O O
0.75 NN O O
mg NN O O
TRULICITY NN O O
1.5 NN O O
mg NN O O
Add NN O O
- NN O O
on NN O O
to NN O O
Metformin NN O O
( NN O O
26 NN O O
weeks NN O O
) NN O O
N=177 NN O O
N=302 NN O O
N=304 NN O O
Documented NN O O
symptomatic NN O O
1.1 NN O O
% NN O O
2.6 NN O O
% NN O O
5.6 NN O O
% NN O O
Severe NN O O
0 NN O O
0 NN O O
0 NN O O
Add NN O O
- NN O O
on NN O O
to NN O O
Metformin NN O O
+ NN O O
Pioglitazone NN O O
( NN O O
26 NN O O
weeks NN O O
) NN O O
N=141 NN O O
N=280 NN O O
N=279 NN O O
Documented NN O O
symptomatic NN O O
1.4 NN O O
% NN O O
4.6 NN O O
% NN O O
5.0 NN O O
% NN O O
Severe NN O O
0 NN O O
0 NN O O
0 NN O O
Hypoglycemia NN B-AdverseReaction B-AdverseReaction
was NN O O
more NN O O
frequent NN O O
when NN O O
TRULICITY NN O O
was NN O O
used NN O O
in NN O O
combination NN O O
with NN O O
a NN O O
sulfonylurea NN O O
or NN O O
insulin NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
. NN O O
Documented NN O O
symptomatic NN B-AdverseReaction B-AdverseReaction
hypoglycemia NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
39 NN O O
% NN O O
and NN O O
40 NN O O
% NN O O
of NN O O
patients NN O O
when NN O O
TRULICITY NN O O
0.75 NN O O
mg NN O O
and NN O O
1.5 NN O O
mg NN O O
, NN O O
respectively NN O O
, NN O O
was NN O O
co NN O O
- NN O O
administered NN O O
with NN O O
a NN O O
sulfonylurea NN O O
. NN O O
Severe NN B-Severity B-Severity
hypoglycemia NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
0 NN O O
% NN O O
and NN O O
0.7 NN O O
% NN O O
of NN O O
patients NN O O
when NN O O
TRULICITY NN O O
0.75 NN O O
mg NN O O
and NN O O
1.5 NN O O
mg NN O O
, NN O O
respectively NN O O
, NN O O
was NN O O
co NN O O
- NN O O
administered NN O O
with NN O O
a NN O O
sulfonylurea NN O O
. NN O O
Documented NN O O
symptomatic NN B-AdverseReaction B-AdverseReaction
hypoglycemia NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
85 NN O O
% NN O O
and NN O O
80 NN O O
% NN O O
of NN O O
patients NN O O
when NN O O
TRULICITY NN O O
0.75 NN O O
mg NN O O
and NN O O
1.5 NN O O
mg NN O O
, NN O O
respectively NN O O
, NN O O
was NN O O
co NN O O
- NN O O
administered NN O O
with NN O O
prandial NN O O
insulin NN O O
. NN O O
Severe NN B-Severity B-Severity
hypoglycemia NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
2.4 NN O O
% NN O O
and NN O O
3.4 NN O O
% NN O O
of NN O O
patients NN O O
when NN O O
TRULICITY NN O O
0.75 NN O O
mg NN O O
and NN O O
1.5 NN O O
mg NN O O
, NN O O
respectively NN O O
, NN O O
was NN O O
co NN O O
- NN O O
administered NN O O
with NN O O
prandial NN O O
insulin NN O O
. NN O O
Heart NN O O
Rate NN O O
Increase NN O O
and NN O O
Tachycardia NN O O
Related NN O O
Adverse NN O O
Reactions NN O O
. NN O O
TRULICITY NN O O
0.75 NN O O
mg NN O O
and NN O O
1.5 NN O O
mg NN O O
resulted NN O O
in NN O O
a NN O O
mean NN O O
increase NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
heart NN I-AdverseReaction I-AdverseReaction
rate NN I-AdverseReaction I-AdverseReaction
( NN O O
HR NN O O
) NN O O
of NN O O
2 NN O O
- NN O O
4 NN O O
beats NN O O
per NN O O
minute NN O O
( NN O O
bpm NN O O
) NN O O
. NN O O
The NN O O
long NN O O
- NN O O
term NN O O
clinical NN O O
effects NN O O
of NN O O
the NN O O
increase NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
HR NN I-AdverseReaction I-AdverseReaction
have NN O O
not NN O O
been NN O O
established NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.7 NN O O
) NN O O
] NN O O
. NN O O
Adverse NN O O
reactions NN O O
of NN O O
sinus NN B-AdverseReaction B-AdverseReaction
tachycardia NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
more NN O O
frequently NN O O
in NN O O
patients NN O O
exposed NN O O
to NN O O
TRULICITY. NN O O
Sinus NN B-AdverseReaction B-AdverseReaction
tachycardia NN I-AdverseReaction I-AdverseReaction
was NN O O
reported NN O O
in NN O O
3.0 NN O O
% NN O O
, NN O O
2.8 NN O O
% NN O O
, NN O O
and NN O O
5.6 NN O O
% NN O O
of NN O O
patient NN O O
treated NN O O
with NN O O
placebo NN O O
, NN O O
TRULICITY NN O O
0.75 NN O O
mg NN O O
and NN O O
TRULICITY NN O O
1.5 NN O O
mg NN O O
, NN O O
respectively NN O O
. NN O O
Persistence NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
sinus NN I-AdverseReaction I-AdverseReaction
tachycardia NN I-AdverseReaction I-AdverseReaction
( NN O O
reported NN O O
at NN O O
more NN O O
than NN O O
2 NN O O
visits NN O O
) NN O O
was NN O O
reported NN O O
in NN O O
0.2 NN O O
% NN O O
, NN O O
0.4 NN O O
% NN O O
and NN O O
1.6 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
placebo NN O O
, NN O O
TRULICITY NN O O
0.75 NN O O
mg NN O O
and NN O O
TRULICITY NN O O
1.5 NN O O
mg NN O O
, NN O O
respectively NN O O
. NN O O
Episodes NN O O
of NN O O
sinus NN B-AdverseReaction B-AdverseReaction
tachycardia NN I-AdverseReaction I-AdverseReaction
associated NN O O
with NN O O
a NN O O
concomitant NN O O
increase NN O O
from NN O O
baseline NN O O
in NN O O
heart NN O O
rate NN O O
of NN O O
>=15 NN O O
beats NN O O
per NN O O
minute NN O O
, NN O O
were NN O O
reported NN O O
in NN O O
0.7 NN O O
% NN O O
, NN O O
1.3 NN O O
% NN O O
and NN O O
2.2 NN O O
% NN O O
of NN O O
patient NN O O
treated NN O O
with NN O O
placebo NN O O
, NN O O
TRULICITY NN O O
0.75 NN O O
mg NN O O
and NN O O
TRULICITY NN O O
1.5 NN O O
mg NN O O
, NN O O
respectively NN O O
. NN O O
Immunogenicity NN O O
Across NN O O
four NN O O
Phase NN O O
2 NN O O
and NN O O
five NN O O
Phase NN O O
3 NN O O
clinical NN O O
studies NN O O
, NN O O
64 NN O O
( NN O O
1.6 NN O O
% NN O O
) NN O O
TRULICITY NN O O
treated NN O O
patients NN O O
developed NN O O
anti NN O O
- NN O O
drug NN O O
antibodies NN O O
( NN O O
ADAs NN O O
) NN O O
to NN O O
the NN O O
active NN O O
ingredient NN O O
in NN O O
TRULICITY NN O O
( NN O O
i.e. NN O O
, NN O O
dulaglutide NN O O
) NN O O
. NN O O
Of NN O O
the NN O O
64 NN O O
dulaglutide NN O O
- NN O O
treated NN O O
patients NN O O
that NN O O
developed NN O O
dulaglutide NN O O
ADAs NN O O
, NN O O
34 NN O O
patients NN O O
( NN O O
0.9 NN O O
% NN O O
of NN O O
the NN O O
overall NN O O
population NN O O
) NN O O
had NN O O
dulaglutide NN O O
- NN O O
neutralizing NN O O
antibodies NN O O
, NN O O
and NN O O
36 NN O O
patients NN O O
( NN O O
0.9 NN O O
% NN O O
of NN O O
the NN O O
overall NN O O
population NN O O
) NN O O
developed NN O O
antibodies NN O O
against NN O O
native NN O O
GLP-1 NN O O
. NN O O
The NN O O
detection NN O O
of NN O O
antibody NN O O
formation NN O O
is NN O O
highly NN O O
dependent NN O O
on NN O O
the NN O O
sensitivity NN O O
and NN O O
specificity NN O O
of NN O O
the NN O O
assay NN O O
. NN O O
Additionally NN O O
, NN O O
the NN O O
observed NN O O
incidence NN O O
of NN O O
antibody NN O O
( NN O O
including NN O O
neutralizing NN O O
antibody NN O O
) NN O O
positivity NN O O
in NN O O
an NN O O
assay NN O O
may NN O O
be NN O O
influenced NN O O
by NN O O
several NN O O
factors NN O O
including NN O O
assay NN O O
methodology NN O O
, NN O O
sample NN O O
handling NN O O
, NN O O
timing NN O O
of NN O O
sample NN O O
collection NN O O
, NN O O
concomitant NN O O
medications NN O O
, NN O O
and NN O O
underlying NN O O
disease NN O O
. NN O O
For NN O O
these NN O O
reasons NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
antibodies NN O O
to NN O O
dulaglutide NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
with NN O O
the NN O O
incidence NN O O
of NN O O
antibodies NN O O
of NN O O
other NN O O
products NN O O
. NN O O
Hypersensitivity NN O O
Systemic NN B-AdverseReaction B-AdverseReaction
hypersensitivity NN I-AdverseReaction I-AdverseReaction
adverse NN O O
reactions NN O O
sometimes NN O O
severe NN B-Severity B-Severity
( NN O O
e.g. NN O O
, NN O O
severe NN B-Severity B-Severity
urticaria NN B-AdverseReaction B-AdverseReaction
systemic NN B-AdverseReaction B-AdverseReaction
rash NN I-AdverseReaction I-AdverseReaction
facial NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
lip NN B-AdverseReaction B-AdverseReaction
swelling NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
0.5 NN O O
% NN O O
of NN O O
patients NN O O
on NN O O
TRULICITY NN O O
in NN O O
the NN O O
four NN O O
Phase NN O O
2 NN O O
and NN O O
five NN O O
Phase NN O O
3 NN O O
studies NN O O
. NN O O
Injection NN O O
- NN O O
site NN O O
Reactions NN O O
In NN O O
the NN O O
placebo NN O O
- NN O O
controlled NN O O
studies NN O O
, NN O O
injection NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
( NN O O
e.g. NN O O
, NN O O
injection NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
rash NN I-AdverseReaction I-AdverseReaction
erythema NN O O
) NN O O
were NN O O
reported NN O O
in NN O O
0.5 NN O O
% NN O O
of NN O O
TRULICITY NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
in NN O O
0.0 NN O O
% NN O O
of NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
PR NN O O
Interval NN O O
Prolongation NN O O
and NN O O
Adverse NN O O
Reactions NN O O
of NN O O
First NN O O
Degree NN O O
Atrioventricular NN O O
( NN O O
AV NN O O
) NN O O
Block NN O O
A NN O O
mean NN O O
increase NN O O
from NN O O
baseline NN O O
in NN O O
PR NN O O
interval NN O O
of NN O O
2 NN O O
- NN O O
3 NN O O
milliseconds NN O O
was NN O O
observed NN O O
in NN O O
TRULICITY NN O O
- NN O O
treated NN O O
patients NN O O
in NN O O
contrast NN O O
to NN O O
a NN O O
mean NN O O
decrease NN O O
of NN O O
0.9 NN O O
millisecond NN O O
in NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
The NN O O
adverse NN O O
reaction NN O O
of NN O O
first NN B-AdverseReaction B-AdverseReaction
degree NN I-AdverseReaction I-AdverseReaction
AV NN I-AdverseReaction I-AdverseReaction
block NN I-AdverseReaction I-AdverseReaction
occurred NN O O
more NN O O
frequently NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
TRULICITY NN O O
than NN O O
placebo NN O O
( NN O O
0.9 NN O O
% NN O O
, NN O O
1.7 NN O O
% NN O O
and NN O O
2.3 NN O O
% NN O O
for NN O O
placebo NN O O
, NN O O
TRULICITY NN O O
0.75 NN O O
mg NN O O
and NN O O
TRULICITY NN O O
1.5 NN O O
mg NN O O
, NN O O
respectively NN O O
) NN O O
. NN O O
On NN O O
electrocardiograms NN O O
, NN O O
a NN O O
PR NN B-AdverseReaction B-AdverseReaction
interval NN I-AdverseReaction I-AdverseReaction
increase NN I-AdverseReaction I-AdverseReaction
to NN O O
at NN O O
least NN O O
220 NN O O
milliseconds NN O O
was NN O O
observed NN O O
in NN O O
0.7 NN O O
% NN O O
, NN O O
2.5 NN O O
% NN O O
and NN O O
3.2 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
placebo NN O O
, NN O O
TRULICITY NN O O
0.75 NN O O
mg NN O O
and NN O O
TRULICITY NN O O
1.5 NN O O
mg NN O O
, NN O O
respectively NN O O
. NN O O
Amylase NN O O
and NN O O
Lipase NN O O
Increase NN O O
Patients NN O O
exposed NN O O
to NN O O
TRULICITY NN O O
had NN O O
mean NN O O
increases NN O O
from NN O O
baseline NN O O
in NN O O
lipase NN O O
and/or NN O O
pancreatic NN O O
amylase NN O O
of NN O O
14 NN O O
% NN O O
to NN O O
20 NN O O
% NN O O
, NN O O
while NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
had NN O O
mean NN O O
increases NN O O
of NN O O
up NN O O
to NN O O
3 NN O O
% NN O O
. NN O O
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
RISK NN B-Factor B-Factor
OF NN O O
THYROID NN B-AdverseReaction B-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
CELL NN I-AdverseReaction I-AdverseReaction
TUMORS NN I-AdverseReaction I-AdverseReaction
WARNING NN O O
: NN O O
RISK NN B-Factor B-Factor
OF NN O O
THYROID NN B-AdverseReaction B-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
CELL NN I-AdverseReaction I-AdverseReaction
TUMORS NN I-AdverseReaction I-AdverseReaction
* NN O O
In NN O O
male NN O O
and NN O O
female NN O O
rats NN B-Animal B-Animal
dulaglutide NN O O
causes NN O O
a NN O O
dose NN O O
- NN O O
related NN O O
and NN O O
treatment NN O O
- NN O O
duration NN O O
- NN O O
dependent NN O O
increase NN O O
in NN O O
the NN O O
incidence NN O O
of NN O O
thyroid NN B-AdverseReaction B-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
tumors NN I-AdverseReaction I-AdverseReaction
( NN O O
adenomas NN O O
and NN O O
carcinomas NN O O
) NN O O
after NN O O
lifetime NN O O
exposure NN O O
. NN O O
It NN O O
is NN O O
unknown NN B-Factor B-Factor
whether NN O O
TRULICITY NN O O
causes NN O O
thyroid NN B-AdverseReaction B-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
tumors NN I-AdverseReaction I-AdverseReaction
including NN O O
medullary NN B-AdverseReaction B-AdverseReaction
thyroid NN I-AdverseReaction I-AdverseReaction
carcinoma NN I-AdverseReaction I-AdverseReaction
( NN O O
MTC NN O O
) NN O O
, NN O O
in NN O O
humans NN O O
as NN O O
human NN O O
relevance NN O O
of NN O O
dulaglutide NN O O
- NN O O
induced NN O O
rodent NN B-Animal B-Animal
thyroid NN B-AdverseReaction B-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
tumors NN I-AdverseReaction I-AdverseReaction
has NN O O
not NN O O
been NN O O
determined NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
, NN O O
and NN O O
Nonclinical NN O O
Toxicology NN O O
( NN O O
13.1 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
TRULICITY NN O O
is NN O O
contraindicated NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
personal NN O O
or NN O O
family NN O O
history NN O O
of NN O O
MTC NN O O
and NN O O
in NN O O
patients NN O O
with NN O O
Multiple NN O O
Endocrine NN O O
Neoplasia NN O O
syndrome NN O O
type NN O O
2 NN O O
( NN O O
MEN NN O O
2 NN O O
) NN O O
. NN O O
Counsel NN O O
patients NN O O
regarding NN O O
the NN O O
potential NN O O
risk NN O O
of NN O O
MTC NN O O
with NN O O
use NN O O
of NN O O
TRULICITY NN O O
and NN O O
inform NN O O
them NN O O
of NN O O
symptoms NN O O
of NN O O
thyroid NN O O
tumors NN O O
( NN O O
e.g. NN O O
, NN O O
mass NN O O
in NN O O
the NN O O
neck NN O O
, NN O O
dysphagia NN O O
, NN O O
dyspnea NN O O
, NN O O
persistent NN O O
hoarseness NN O O
) NN O O
. NN O O
Routine NN O O
monitoring NN O O
of NN O O
serum NN O O
calcitonin NN O O
or NN O O
using NN O O
thyroid NN O O
ultrasound NN O O
is NN O O
of NN O O
uncertain NN O O
value NN O O
for NN O O
early NN O O
detection NN O O
of NN O O
MTC NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
TRULICITY NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4.1 NN O O
) NN O O
and NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
EXCERPT NN O O
: NN O O
WARNING NN O O
: NN O O
RISK NN B-Factor B-Factor
OF NN O O
THYROID NN B-AdverseReaction B-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
CELL NN I-AdverseReaction I-AdverseReaction
TUMORS NN I-AdverseReaction I-AdverseReaction
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
. NN O O
* NN O O
Dulaglutide NN O O
causes NN O O
thyroid NN B-AdverseReaction B-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
tumors NN I-AdverseReaction I-AdverseReaction
in NN O O
rats NN B-Animal B-Animal
It NN O O
is NN O O
unknown NN B-Factor B-Factor
whether NN O O
TRULICITY NN O O
causes NN O O
thyroid NN B-AdverseReaction B-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
tumors NN I-AdverseReaction I-AdverseReaction
including NN O O
medullary NN B-AdverseReaction B-AdverseReaction
thyroid NN I-AdverseReaction I-AdverseReaction
carcinoma NN I-AdverseReaction I-AdverseReaction
( NN O O
MTC NN O O
) NN O O
, NN O O
in NN O O
humans NN O O
as NN O O
the NN O O
human NN O O
relevance NN O O
of NN O O
dulaglutide NN O O
- NN O O
induced NN O O
rodent NN B-Animal B-Animal
thyroid NN B-AdverseReaction B-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
tumors NN I-AdverseReaction I-AdverseReaction
has NN O O
not NN O O
been NN O O
determined NN O O
( NN O O
5.1 NN O O
, NN O O
13.1 NN O O
) NN O O
. NN O O
* NN O O
TRULICITY NN O O
is NN O O
contraindicated NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
personal NN O O
or NN O O
family NN O O
history NN O O
of NN O O
MTC NN O O
and NN O O
in NN O O
patients NN O O
with NN O O
Multiple NN O O
Endocrine NN O O
Neoplasia NN O O
syndrome NN O O
type NN O O
2 NN O O
( NN O O
MEN NN O O
2 NN O O
) NN O O
. NN O O
Counsel NN O O
patients NN O O
regarding NN O O
the NN O O
potential NN O O
risk NN O O
of NN O O
MTC NN O O
and NN O O
symptoms NN O O
of NN O O
thyroid NN O O
tumors NN O O
( NN O O
4.1 NN O O
, NN O O
5.1 NN O O
) NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Thyroid NN B-AdverseReaction B-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
Tumors NN I-AdverseReaction I-AdverseReaction
See NN O O
Boxed NN O O
Warning NN O O
( NN O O
5.1 NN O O
) NN O O
. NN O O
* NN O O
Pancreatitis NN B-AdverseReaction B-AdverseReaction
Has NN O O
been NN O O
reported NN O O
in NN O O
clinical NN O O
trials NN O O
. NN O O
Discontinue NN O O
promptly NN O O
if NN O O
pancreatitis NN O O
is NN O O
suspected NN O O
. NN O O
Do NN O O
not NN O O
restart NN O O
if NN O O
pancreatitis NN O O
is NN O O
confirmed NN O O
. NN O O
Consider NN O O
other NN O O
antidiabetic NN O O
therapies NN O O
in NN O O
patients NN O O
with NN O O
history NN O O
of NN O O
pancreatitis NN O O
( NN O O
5.2 NN O O
) NN O O
. NN O O
* NN O O
Hypoglycemia NN B-AdverseReaction B-AdverseReaction
When NN O O
TRULICITY NN O O
is NN O O
used NN O O
with NN O O
an NN O O
insulin NN O O
secretagogue NN O O
( NN O O
e.g. NN O O
, NN O O
a NN O O
sulfonylurea NN O O
) NN O O
or NN O O
insulin NN O O
, NN O O
consider NN O O
lowering NN O O
the NN O O
dose NN O O
of NN O O
the NN O O
sulfonylurea NN O O
or NN O O
insulin NN O O
to NN O O
reduce NN O O
the NN O O
risk NN O O
of NN O O
hypoglycemia NN O O
( NN O O
5.3 NN O O
) NN O O
. NN O O
* NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
Reactions NN O O
: NN O O
Discontinue NN O O
TRULICITY NN O O
if NN O O
suspected NN O O
. NN O O
Monitor NN O O
and NN O O
treat NN O O
promptly NN O O
per NN O O
standard NN O O
of NN O O
care NN O O
until NN O O
signs NN O O
and NN O O
symptoms NN O O
resolve NN O O
( NN O O
5.4 NN O O
) NN O O
. NN O O
* NN O O
Renal NN B-AdverseReaction B-AdverseReaction
Impairment NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
renal NN O O
function NN O O
in NN O O
patients NN O O
with NN O O
renal NN O O
impairment NN O O
reporting NN O O
severe NN O O
adverse NN O O
gastrointestinal NN O O
reactions NN O O
( NN O O
5.5 NN O O
) NN O O
. NN O O
* NN O O
Macrovascular NN O O
outcomes NN O O
: NN O O
There NN O O
have NN O O
been NN O O
no NN O O
studies NN O O
establishing NN O O
conclusive NN O O
evidence NN O O
of NN O O
macrovascular NN O O
risk NN O O
reduction NN O O
with NN O O
TRULICITY NN O O
or NN O O
any NN O O
other NN O O
antidiabetic NN O O
drug NN O O
( NN O O
5.7 NN O O
) NN O O
. NN O O
5.1 NN O O
Risk NN O O
of NN O O
Thyroid NN O O
C NN O O
- NN O O
cell NN O O
Tumors NN O O
In NN O O
male NN O O
and NN O O
female NN O O
rats NN B-Animal B-Animal
dulaglutide NN O O
causes NN O O
a NN O O
dose NN O O
- NN O O
related NN O O
and NN O O
treatment NN O O
- NN O O
duration NN O O
- NN O O
dependent NN O O
increase NN O O
in NN O O
the NN O O
incidence NN O O
of NN O O
thyroid NN B-AdverseReaction B-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
tumors NN I-AdverseReaction I-AdverseReaction
( NN O O
adenomas NN O O
and NN O O
carcinomas NN O O
) NN O O
after NN O O
lifetime NN O O
exposure NN O O
[ NN O O
see NN O O
Nonclinical NN O O
Toxicology NN O O
( NN O O
13.1 NN O O
) NN O O
] NN O O
. NN O O
Glucagon NN O O
- NN O O
like NN O O
peptide NN O O
( NN O O
GLP-1 NN O O
) NN O O
receptor NN O O
agonists NN O O
have NN O O
induced NN O O
thyroid NN B-AdverseReaction B-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
adenomas NN I-AdverseReaction I-AdverseReaction
and NN O O
carcinomas NN O O
in NN O O
mice NN B-Animal B-Animal
and NN O O
rats NN B-Animal B-Animal
at NN O O
clinically NN O O
relevant NN O O
exposures NN O O
. NN O O
It NN O O
is NN O O
unknown NN B-Factor B-Factor
whether NN O O
TRULICITY NN O O
will NN O O
cause NN O O
thyroid NN B-AdverseReaction B-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
tumors NN I-AdverseReaction I-AdverseReaction
including NN O O
medullary NN B-AdverseReaction B-AdverseReaction
thyroid NN I-AdverseReaction I-AdverseReaction
carcinoma NN I-AdverseReaction I-AdverseReaction
( NN O O
MTC NN O O
) NN O O
, NN O O
in NN O O
humans NN O O
, NN O O
as NN O O
the NN O O
human NN O O
relevance NN O O
of NN O O
dulaglutide NN O O
- NN O O
induced NN O O
rodent NN B-Animal B-Animal
thyroid NN B-AdverseReaction B-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
tumors NN I-AdverseReaction I-AdverseReaction
has NN O O
not NN O O
been NN O O
determined NN O O
. NN O O
One NN O O
case NN O O
of NN O O
MTC NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
a NN O O
patient NN O O
treated NN O O
with NN O O
TRULICITY. NN O O
This NN O O
patient NN O O
had NN O O
pretreatment NN O O
calcitonin NN O O
levels NN O O
approximately NN O O
8 NN O O
times NN O O
the NN O O
upper NN O O
limit NN O O
of NN O O
normal NN O O
( NN O O
ULN NN O O
) NN O O
. NN O O
Cases NN O O
of NN O O
MTC NN B-AdverseReaction B-AdverseReaction
in NN O O
patients NN O O
treated NN O O
with NN O O
liraglutide NN O O
, NN O O
another NN O O
GLP-1 NN B-DrugClass B-DrugClass
receptor NN I-DrugClass I-DrugClass
agonist NN I-DrugClass I-DrugClass
have NN O O
been NN O O
reported NN O O
in NN O O
the NN O O
postmarketing NN O O
period NN O O
; NN O O
the NN O O
data NN O O
in NN O O
these NN O O
reports NN O O
are NN O O
insufficient NN O O
to NN O O
establish NN O O
or NN O O
exclude NN O O
a NN O O
causal NN O O
relationship NN O O
between NN O O
MTC NN B-AdverseReaction B-AdverseReaction
and NN O O
GLP-1 NN O O
receptor NN O O
agonist NN O O
use NN O O
in NN O O
humans NN O O
. NN O O
TRULICITY NN O O
is NN O O
contraindicated NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
personal NN O O
or NN O O
family NN O O
history NN O O
of NN O O
MTC NN O O
or NN O O
in NN O O
patients NN O O
with NN O O
MEN NN O O
2 NN O O
. NN O O
Counsel NN O O
patients NN O O
regarding NN O O
the NN O O
potential NN O O
risk NN O O
for NN O O
MTC NN O O
with NN O O
the NN O O
use NN O O
of NN O O
TRULICITY NN O O
and NN O O
inform NN O O
them NN O O
of NN O O
symptoms NN O O
of NN O O
thyroid NN O O
tumors NN O O
( NN O O
e.g. NN O O
a NN O O
mass NN O O
in NN O O
the NN O O
neck NN O O
, NN O O
dysphagia NN O O
, NN O O
dyspnea NN O O
, NN O O
persistent NN O O
hoarseness NN O O
) NN O O
. NN O O
Routine NN O O
monitoring NN O O
of NN O O
serum NN O O
calcitonin NN O O
or NN O O
using NN O O
thyroid NN O O
ultrasound NN O O
is NN O O
of NN O O
uncertain NN O O
value NN O O
for NN O O
early NN O O
detection NN O O
of NN O O
MTC NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
TRULICITY. NN O O
Such NN O O
monitoring NN O O
may NN O O
increase NN O O
the NN O O
risk NN O O
of NN O O
unnecessary NN O O
procedures NN O O
, NN O O
due NN O O
to NN O O
the NN O O
low NN O O
test NN O O
specificity NN O O
for NN O O
serum NN O O
calcitonin NN O O
and NN O O
a NN O O
high NN O O
background NN O O
incidence NN O O
of NN O O
thyroid NN O O
disease NN O O
. NN O O
Significantly NN O O
elevated NN O O
serum NN O O
calcitonin NN O O
value NN O O
may NN O O
indicate NN O O
MTC NN O O
and NN O O
patients NN O O
with NN O O
MTC NN O O
usually NN O O
have NN O O
calcitonin NN O O
values NN O O
>50 NN O O
ng/L. NN O O
If NN O O
serum NN O O
calcitonin NN O O
is NN O O
measured NN O O
and NN O O
found NN O O
to NN O O
be NN O O
elevated NN O O
, NN O O
the NN O O
patient NN O O
should NN O O
be NN O O
further NN O O
evaluated NN O O
. NN O O
Patients NN O O
with NN O O
thyroid NN O O
nodules NN O O
noted NN O O
on NN O O
physical NN O O
examination NN O O
or NN O O
neck NN O O
imaging NN O O
should NN O O
also NN O O
be NN O O
further NN O O
evaluated NN O O
. NN O O
5.2 NN O O
Pancreatitis NN O O
In NN O O
Phase NN O O
2 NN O O
and NN O O
Phase NN O O
3 NN O O
clinical NN O O
studies NN O O
, NN O O
12 NN O O
( NN O O
3.4 NN O O
cases NN O O
per NN O O
1000 NN O O
patient NN O O
years NN O O
) NN O O
pancreatitis NN B-AdverseReaction B-AdverseReaction
related NN O O
adverse NN O O
reactions NN O O
were NN O O
reported NN O O
in NN O O
patients NN O O
exposed NN O O
to NN O O
TRULICITY NN O O
versus NN O O
3 NN O O
in NN O O
non NN O O
- NN O O
incretin NN O O
comparators NN O O
( NN O O
2.7 NN O O
cases NN O O
per NN O O
1000 NN O O
patient NN O O
years NN O O
) NN O O
. NN O O
An NN O O
analyses NN O O
of NN O O
adjudicated NN O O
events NN O O
revealed NN O O
5 NN O O
cases NN O O
of NN O O
confirmed NN O O
pancreatitis NN B-AdverseReaction B-AdverseReaction
in NN O O
patients NN O O
exposed NN O O
to NN O O
TRULICITY NN O O
( NN O O
1.4 NN O O
cases NN O O
per NN O O
1000 NN O O
patient NN O O
years NN O O
) NN O O
versus NN O O
1 NN O O
case NN O O
in NN O O
non NN O O
- NN O O
incretin NN O O
comparators NN O O
( NN O O
0.88 NN O O
cases NN O O
per NN O O
1000 NN O O
patient NN O O
years NN O O
) NN O O
. NN O O
After NN O O
initiation NN O O
of NN O O
TRULICITY NN O O
, NN O O
observe NN O O
patients NN O O
carefully NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
pancreatitis NN O O
, NN O O
including NN O O
persistent NN O O
severe NN O O
abdominal NN O O
pain NN O O
. NN O O
If NN O O
pancreatitis NN O O
is NN O O
suspected NN O O
, NN O O
promptly NN O O
discontinue NN O O
TRULICITY. NN O O
If NN O O
pancreatitis NN O O
is NN O O
confirmed NN O O
, NN O O
TRULICITY NN O O
should NN O O
not NN O O
be NN O O
restarted NN O O
. NN O O
TRULICITY NN O O
has NN O O
not NN O O
been NN O O
evaluated NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
prior NN O O
history NN O O
of NN O O
pancreatitis NN O O
. NN O O
Consider NN O O
other NN O O
antidiabetic NN O O
therapies NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
pancreatitis NN O O
. NN O O
5.3 NN O O
Hypoglycemia NN O O
with NN O O
Concomitant NN O O
Use NN O O
of NN O O
Insulin NN O O
Secretagogues NN O O
or NN O O
Insulin NN O O
The NN O O
risk NN B-Factor B-Factor
of NN O O
hypoglycemia NN B-AdverseReaction B-AdverseReaction
is NN O O
increased NN O O
when NN O O
TRULICITY NN O O
is NN O O
used NN O O
in NN O O
combination NN O O
with NN O O
insulin NN O O
secretagogues NN O O
( NN O O
e.g. NN O O
, NN O O
sulfonylureas NN O O
) NN O O
or NN O O
insulin NN O O
. NN O O
Patients NN O O
may NN O O
require NN O O
a NN O O
lower NN O O
dose NN O O
of NN O O
sulfonylurea NN O O
or NN O O
insulin NN O O
to NN O O
reduce NN O O
the NN O O
risk NN O O
of NN O O
hypoglycemia NN O O
in NN O O
this NN O O
setting NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
5.4 NN O O
Hypersensitivity NN O O
Reactions NN O O
Systemic NN B-AdverseReaction B-AdverseReaction
hypersensitivity NN I-AdverseReaction I-AdverseReaction
reactions NN O O
were NN O O
observed NN O O
in NN O O
patients NN O O
receiving NN O O
TRULICITY NN O O
in NN O O
clinical NN O O
trials NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
If NN O O
a NN O O
hypersensitivity NN O O
reaction NN O O
occurs NN O O
, NN O O
the NN O O
patient NN O O
should NN O O
discontinue NN O O
TRULICITY NN O O
and NN O O
promptly NN O O
seek NN O O
medical NN O O
advice NN O O
. NN O O
5.5 NN O O
Renal NN O O
Impairment NN O O
In NN O O
patients NN O O
treated NN O O
with NN O O
GLP-1 NN B-DrugClass B-DrugClass
receptor NN I-DrugClass I-DrugClass
agonists NN I-DrugClass I-DrugClass
there NN O O
have NN O O
been NN O O
postmarketing NN O O
reports NN O O
of NN O O
acute NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
and NN O O
worsening NN O O
of NN O O
chronic NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
which NN O O
may NN O O
sometimes NN O O
require NN O O
hemodialysis NN O O
. NN O O
Some NN O O
of NN O O
these NN O O
events NN O O
were NN O O
reported NN O O
in NN O O
patients NN O O
without NN O O
known NN O O
underlying NN O O
renal NN O O
disease NN O O
. NN O O
A NN O O
majority NN O O
of NN O O
reported NN O O
events NN O O
occurred NN O O
in NN O O
patients NN O O
who NN O O
had NN O O
experienced NN O O
nausea NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
or NN O O
dehydration NN B-AdverseReaction B-AdverseReaction
Because NN O O
these NN O O
reactions NN O O
may NN O O
worsen NN O O
renal NN O O
function NN O O
, NN O O
use NN O O
caution NN O O
when NN O O
initiating NN O O
or NN O O
escalating NN O O
doses NN O O
of NN O O
TRULICITY NN O O
in NN O O
patients NN O O
with NN O O
renal NN O O
impairment NN O O
. NN O O
Monitor NN O O
renal NN O O
function NN O O
in NN O O
patients NN O O
with NN O O
renal NN O O
impairment NN O O
reporting NN O O
severe NN O O
adverse NN O O
gastrointestinal NN O O
reactions NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
, NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.7 NN O O
) NN O O
] NN O O
. NN O O
5.6 NN O O
Severe NN O O
Gastrointestinal NN O O
Disease NN O O
Use NN O O
of NN O O
TRULICITY NN O O
may NN O O
be NN O O
associated NN O O
with NN O O
gastrointestinal NN B-AdverseReaction B-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
sometimes NN O O
severe NN B-Severity B-Severity
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
TRULICITY NN O O
has NN O O
not NN O O
been NN O O
studied NN O O
in NN O O
patients NN O O
with NN O O
severe NN O O
gastrointestinal NN O O
disease NN O O
, NN O O
including NN O O
severe NN O O
gastroparesis NN O O
, NN O O
and NN O O
is NN O O
therefore NN O O
not NN O O
recommended NN O O
in NN O O
these NN O O
patients NN O O
. NN O O
5.7 NN O O
Macrovascular NN O O
Outcomes NN O O
There NN O O
have NN O O
been NN O O
no NN O O
clinical NN O O
studies NN O O
establishing NN O O
conclusive NN O O
evidence NN O O
of NN O O
macrovascular NN O O
risk NN O O
reduction NN O O
with NN O O
TRULICITY NN O O
or NN O O
any NN O O
other NN O O
antidiabetic NN O O
drug NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
Exclusive NN O O
of NN O O
an NN O O
uncommon NN O O
, NN O O
mild NN B-Severity B-Severity
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
no NN O O
adverse NN O O
reactions NN O O
to NN O O
11 NN O O
C NN O O
- NN O O
choline NN O O
have NN O O
been NN O O
reported NN O O
. NN O O
EXCERPT NN O O
: NN O O
Exclusive NN O O
of NN O O
an NN O O
uncommon NN O O
, NN O O
mild NN B-Severity B-Severity
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
no NN O O
other NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
reported NN O O
( NN O O
6 NN O O
) NN O O
. NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Division NN O O
of NN O O
Nuclear NN O O
Medicine NN O O
, NN O O
Department NN O O
of NN O O
Radiology NN O O
, NN O O
Mayo NN O O
Clinic NN O O
at NN O O
507 NN O O
- NN O O
284 NN O O
- NN O O
2511 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Imaging NN O O
errors NN O O
have NN O O
been NN O O
reported NN O O
; NN O O
blood NN O O
PSA NN O O
levels NN O O
< NN O O
2 NN O O
ng/mL NN O O
have NN O O
been NN O O
associated NN O O
with NN O O
poor NN O O
imaging NN O O
performance NN O O
( NN O O
5.1 NN O O
) NN O O
. NN O O
* NN O O
Allergic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
have NN O O
emergency NN O O
resuscitation NN O O
equipment NN O O
and NN O O
personnel NN O O
readily NN O O
available NN O O
( NN O O
5.2 NN O O
) NN O O
. NN O O
* NN O O
Radiation NN B-AdverseReaction B-AdverseReaction
risk NN I-AdverseReaction I-AdverseReaction
Choline NN O O
C NN O O
11 NN O O
Injection NN O O
contributes NN O O
to NN O O
a NN O O
patient NN O O
's NN O O
long NN O O
- NN O O
term NN O O
cumulative NN O O
radiation NN O O
exposure NN O O
. NN O O
Ensure NN O O
safe NN O O
handling NN O O
to NN O O
protect NN O O
the NN O O
patient NN O O
and NN O O
health NN O O
care NN O O
worker NN O O
( NN O O
5.3 NN O O
) NN O O
. NN O O
5.1 NN O O
Imaging NN O O
Errors NN O O
Imaging NN O O
errors NN O O
have NN O O
been NN O O
reported NN O O
with NN O O
11 NN O O
C NN O O
- NN O O
choline NN O O
PET NN O O
and NN O O
PET/CT NN O O
imaging NN O O
. NN O O
A NN O O
negative NN O O
image NN O O
does NN O O
not NN O O
rule NN O O
out NN O O
the NN O O
presence NN O O
of NN O O
recurrent NN O O
prostate NN O O
cancer NN O O
and NN O O
a NN O O
positive NN O O
image NN O O
does NN O O
not NN O O
confirm NN O O
the NN O O
presence NN O O
of NN O O
recurrent NN O O
cancer NN O O
. NN O O
11 NN O O
C NN O O
- NN O O
choline NN O O
uptake NN O O
is NN O O
not NN O O
specific NN O O
for NN O O
prostate NN O O
cancer NN O O
and NN O O
may NN O O
occur NN O O
with NN O O
other NN O O
types NN O O
of NN O O
cancer NN O O
( NN O O
such NN O O
as NN O O
lung NN O O
carcinoma NN O O
and NN O O
brain NN O O
tumors NN O O
) NN O O
. NN O O
Clinical NN O O
correlation NN O O
, NN O O
including NN O O
histopathological NN O O
evaluation NN O O
of NN O O
the NN O O
suspected NN O O
recurrence NN O O
site NN O O
, NN O O
is NN O O
essential NN O O
to NN O O
proper NN O O
use NN O O
of NN O O
the NN O O
PET NN O O
imaging NN O O
information NN O O
. NN O O
* NN O O
Blood NN O O
PSA NN O O
levels NN O O
< NN O O
2 NN O O
ng/mL NN O O
have NN O O
been NN O O
associated NN O O
with NN O O
poor NN O O
performance NN O O
of NN O O
11 NN O O
C NN O O
- NN O O
choline NN O O
PET NN O O
imaging NN O O
( NN O O
higher NN O O
numbers NN O O
of NN O O
false NN O O
positive NN O O
and NN O O
false NN O O
negative NN O O
results NN O O
) NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Tissue NN O O
inflammation NN O O
as NN O O
well NN O O
as NN O O
prostatic NN O O
hyperplasia NN O O
have NN O O
been NN O O
associated NN O O
with NN O O
false NN O O
positive NN O O
11 NN O O
C NN O O
- NN O O
choline NN O O
PET NN O O
images NN O O
. NN O O
* NN O O
Concomitant NN O O
colchicine NN O O
or NN O O
androgen NN O O
- NN O O
deprivation NN O O
therapeutic NN O O
drugs NN O O
( NN O O
such NN O O
as NN O O
luteinizing NN O O
hormone NN O O
- NN O O
releasing NN O O
analogs NN O O
and NN O O
anti NN O O
- NN O O
androgen NN O O
drugs NN O O
) NN O O
may NN O O
interfere NN O O
with NN O O
11 NN O O
C NN O O
- NN O O
choline NN O O
PET NN O O
imaging NN O O
. NN O O
One NN O O
published NN O O
report NN O O
of NN O O
18 NN O O
F NN O O
- NN O O
methylcholine NN O O
PET NN O O
imaging NN O O
indicated NN O O
that NN O O
discontinuation NN O O
of NN O O
colchicine NN O O
for NN O O
two NN O O
weeks NN O O
resolved NN O O
the NN O O
colchicine NN O O
effect NN O O
. NN O O
The NN O O
impact NN O O
of NN O O
discontinuation NN O O
of NN O O
androgen NN O O
- NN O O
deprivation NN O O
therapy NN O O
upon NN O O
11 NN O O
C NN O O
- NN O O
choline NN O O
PET NN O O
imaging NN O O
has NN O O
not NN O O
been NN O O
established NN O O
[ NN O O
see NN O O
Drug NN O O
Interactions NN O O
( NN O O
7 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
Allergic NN O O
Reactions NN O O
As NN O O
with NN O O
any NN O O
injectable NN O O
drug NN O O
product NN O O
, NN O O
allergic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
and NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
may NN B-Factor B-Factor
occur NN O O
. NN O O
Emergency NN O O
resuscitation NN O O
equipment NN O O
and NN O O
personnel NN O O
should NN O O
be NN O O
immediately NN O O
available NN O O
. NN O O
5.3 NN O O
Radiation NN O O
Risks NN O O
Choline NN O O
C NN O O
11 NN O O
Injection NN O O
contributes NN O O
to NN O O
a NN O O
patient NN O O
's NN O O
overall NN O O
long NN O O
- NN O O
term NN O O
cumulative NN O O
radiation NN O O
exposure NN O O
. NN O O
Long NN O O
- NN O O
term NN O O
cumulative NN O O
radiation NN O O
exposure NN O O
is NN O O
associated NN O O
with NN O O
an NN O O
increased NN O O
risk NN B-Factor B-Factor
for NN O O
cancer NN B-AdverseReaction B-AdverseReaction
Safe NN O O
handling NN O O
should NN O O
be NN O O
ensured NN O O
to NN O O
minimize NN O O
radiation NN O O
exposure NN O O
to NN O O
the NN O O
patient NN O O
and NN O O
health NN O O
care NN O O
workers NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2 NN O O
. NN O O
1 NN O O
) NN O O
] NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
common NN O O
reported NN O O
adverse NN O O
reaction NN O O
was NN O O
headache NN B-AdverseReaction B-AdverseReaction
occurring NN O O
in NN O O
2 NN O O
% NN O O
of NN O O
patients NN O O
, NN O O
followed NN O O
by NN O O
musculoskeletal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
blood NN B-AdverseReaction B-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
and NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
all NN O O
occurring NN O O
in NN O O
< NN O O
1 NN O O
% NN O O
of NN O O
patients NN O O
( NN O O
6 NN O O
) NN O O
. NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Eli NN O O
Lilly NN O O
and NN O O
Company NN O O
at NN O O
1 NN O O
- NN O O
800-LillyRx NN O O
( NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
545 NN O O
- NN O O
5979 NN O O
) NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O
In NN O O
clinical NN O O
studies NN O O
, NN O O
555 NN O O
patients NN O O
were NN O O
exposed NN O O
to NN O O
Amyvid NN O O
. NN O O
Amyvid NN O O
caused NN O O
no NN O O
serious NN O O
adverse NN O O
reactions NN O O
in NN O O
the NN O O
studies NN O O
and NN O O
the NN O O
reported NN O O
adverse NN O O
reactions NN O O
were NN O O
predominantly NN O O
mild NN O O
to NN O O
moderate NN O O
in NN O O
severity NN O O
. NN O O
The NN O O
adverse NN O O
reactions NN O O
reported NN O O
in NN O O
more NN O O
than NN O O
one NN O O
subject NN O O
within NN O O
the NN O O
studies NN O O
are NN O O
shown NN O O
in NN O O
Table NN O O
2 NN O O
. NN O O
Table NN O O
2 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Reported NN O O
in NN O O
Clinical NN O O
Trials NN O O
( NN O O
N=555 NN O O
patients NN O O
) NN O O
a NN O O
Includes NN O O
the NN O O
terms NN O O
blood NN B-AdverseReaction B-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
and NN O O
hypertension NN B-AdverseReaction B-AdverseReaction
b NN O O
Includes NN O O
the NN O O
terms NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
haemorrhage NN I-AdverseReaction I-AdverseReaction
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
irritation NN I-AdverseReaction I-AdverseReaction
and NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
c NN O O
Includes NN O O
the NN O O
terms NN O O
feeling NN B-AdverseReaction B-AdverseReaction
cold NN I-AdverseReaction I-AdverseReaction
and NN O O
chills NN B-AdverseReaction B-AdverseReaction
Adverse NN O O
Reactions NN O O
N NN O O
( NN O O
Percent NN O O
of NN O O
patients NN O O
) NN O O
Headache NN B-AdverseReaction B-AdverseReaction
10 NN O O
( NN O O
1.8 NN O O
% NN O O
) NN O O
Musculoskeletal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
4 NN O O
( NN O O
0.7 NN O O
% NN O O
) NN O O
Blood NN B-AdverseReaction B-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
a NN O O
4 NN O O
( NN O O
0.7 NN O O
% NN O O
) NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
4 NN O O
( NN O O
0.7 NN O O
% NN O O
) NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
3 NN O O
( NN O O
0.5 NN O O
% NN O O
) NN O O
Injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
b NN O O
3 NN O O
( NN O O
0.5 NN O O
% NN O O
) NN O O
Anxiety NN B-AdverseReaction B-AdverseReaction
2 NN O O
( NN O O
0.4 NN O O
% NN O O
) NN O O
Back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
2 NN O O
( NN O O
0.4 NN O O
% NN O O
) NN O O
Claustrophobia NN B-AdverseReaction B-AdverseReaction
2 NN O O
( NN O O
0.4 NN O O
% NN O O
) NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
2 NN O O
( NN O O
0.4 NN O O
% NN O O
) NN O O
Feeling NN B-AdverseReaction B-AdverseReaction
cold NN I-AdverseReaction I-AdverseReaction
c NN O O
2 NN O O
( NN O O
0.4 NN O O
% NN O O
) NN O O
Insomnia NN B-AdverseReaction B-AdverseReaction
2 NN O O
( NN O O
0.4 NN O O
% NN O O
) NN O O
Neck NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
2 NN O O
( NN O O
0.4 NN O O
% NN O O
) NN O O
Other NN O O
adverse NN O O
reactions NN O O
occurred NN O O
at NN O O
lower NN O O
frequencies NN O O
and NN O O
included NN O O
infusion NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
rash NN I-AdverseReaction I-AdverseReaction
dysgeusia NN B-AdverseReaction B-AdverseReaction
pruritis NN B-AdverseReaction B-AdverseReaction
urticaria NN B-AdverseReaction B-AdverseReaction
and NN O O
flushing NN B-AdverseReaction B-AdverseReaction
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Image NN O O
interpretation NN O O
errors NN O O
( NN O O
especially NN O O
false NN O O
negatives NN O O
) NN O O
have NN O O
been NN O O
observed NN O O
( NN O O
5.1 NN O O
) NN O O
. NN O O
* NN O O
Radiation NN B-AdverseReaction B-AdverseReaction
risk NN I-AdverseReaction I-AdverseReaction
Amyvid NN O O
, NN O O
similar NN O O
to NN O O
all NN O O
radiopharmaceuticals NN O O
, NN O O
contributes NN O O
to NN O O
a NN O O
patient NN O O
's NN O O
long NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
term NN I-AdverseReaction I-AdverseReaction
cumulative NN I-AdverseReaction I-AdverseReaction
radiation NN I-AdverseReaction I-AdverseReaction
exposure NN I-AdverseReaction I-AdverseReaction
Ensure NN O O
safe NN O O
handling NN O O
to NN O O
protect NN O O
patients NN O O
and NN O O
health NN O O
care NN O O
workers NN O O
from NN O O
unintentional NN O O
radiation NN O O
exposure NN O O
( NN O O
2.1 NN O O
, NN O O
5.2 NN O O
) NN O O
. NN O O
5.1 NN O O
Risk NN O O
for NN O O
Image NN O O
Misinterpretation NN O O
and NN O O
other NN O O
Errors NN O O
Errors NN O O
may NN O O
occur NN O O
in NN O O
the NN O O
Amyvid NN O O
estimation NN O O
of NN O O
brain NN O O
neuritic NN O O
plaque NN O O
density NN O O
during NN O O
image NN O O
interpretation NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
. NN O O
Image NN O O
interpretation NN O O
should NN O O
be NN O O
performed NN O O
independently NN O O
of NN O O
the NN O O
patient NN O O
's NN O O
clinical NN O O
information NN O O
. NN O O
The NN O O
use NN O O
of NN O O
clinical NN O O
information NN O O
in NN O O
the NN O O
interpretation NN O O
of NN O O
Amyvid NN O O
images NN O O
has NN O O
not NN O O
been NN O O
evaluated NN O O
and NN O O
may NN O O
lead NN O O
to NN O O
errors NN O O
. NN O O
Other NN O O
errors NN O O
may NN O O
be NN O O
due NN O O
to NN O O
extensive NN O O
brain NN O O
atrophy NN O O
that NN O O
limits NN O O
the NN O O
ability NN O O
to NN O O
distinguish NN O O
gray NN O O
and NN O O
white NN O O
matter NN O O
on NN O O
the NN O O
Amyvid NN O O
scan NN O O
as NN O O
well NN O O
as NN O O
motion NN O O
artifacts NN O O
that NN O O
distort NN O O
the NN O O
image NN O O
. NN O O
Amyvid NN O O
scan NN O O
results NN O O
are NN O O
indicative NN O O
of NN O O
the NN O O
brain NN O O
neuritic NN O O
amyloid NN O O
plaque NN O O
content NN O O
only NN O O
at NN O O
the NN O O
time NN O O
of NN O O
image NN O O
acquisition NN O O
and NN O O
a NN O O
negative NN O O
scan NN O O
result NN O O
does NN O O
not NN O O
preclude NN O O
the NN O O
development NN O O
of NN O O
brain NN O O
amyloid NN O O
in NN O O
the NN O O
future NN O O
. NN O O
5.2 NN O O
Radiation NN O O
Risk NN O O
Amyvid NN O O
, NN O O
similar NN O O
to NN O O
other NN O O
radiopharmaceuticals NN O O
, NN O O
contributes NN O O
to NN O O
a NN O O
patient NN O O
's NN O O
overall NN O O
long NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
term NN I-AdverseReaction I-AdverseReaction
cumulative NN I-AdverseReaction I-AdverseReaction
radiation NN I-AdverseReaction I-AdverseReaction
exposure NN I-AdverseReaction I-AdverseReaction
Long NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
term NN I-AdverseReaction I-AdverseReaction
cumulative NN I-AdverseReaction I-AdverseReaction
radiation NN I-AdverseReaction I-AdverseReaction
exposure NN I-AdverseReaction I-AdverseReaction
is NN O O
associated NN O O
with NN O O
an NN O O
increased NN O O
risk NN B-Factor B-Factor
of NN O O
cancer NN B-AdverseReaction B-AdverseReaction
Ensure NN O O
safe NN O O
handling NN O O
to NN O O
protect NN O O
patients NN O O
and NN O O
health NN O O
care NN O O
workers NN O O
from NN O O
unintentional NN O O
radiation NN O O
exposure NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.1 NN O O
) NN O O
] NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
serious NN O O
adverse NN O O
reactions NN O O
are NN O O
discussed NN O O
elsewhere NN O O
in NN O O
the NN O O
label NN O O
: NN O O
* NN O O
Perforations NN B-AdverseReaction B-AdverseReaction
and NN O O
Fistula NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Boxed NN O O
Warning NN O O
, NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Hemorrhage NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Boxed NN O O
Warning NN O O
, NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
Thromboembolic NN B-AdverseReaction B-AdverseReaction
Events NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
* NN O O
Wound NN B-AdverseReaction B-AdverseReaction
Complications NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
* NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
* NN O O
Osteonecrosis NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
Jaw NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.6 NN O O
) NN O O
] NN O O
* NN O O
Palmar NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
plantar NN I-AdverseReaction I-AdverseReaction
erythrodysesthesia NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.7 NN O O
) NN O O
] NN O O
* NN O O
Proteinuria NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.8 NN O O
) NN O O
] NN O O
* NN O O
Reversible NN B-AdverseReaction B-AdverseReaction
Posterior NN I-AdverseReaction I-AdverseReaction
Leukoencephalopathy NN I-AdverseReaction I-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.9 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
commonly NN O O
reported NN O O
adverse NN O O
drug NN O O
reactions NN O O
( NN O O
>=25 NN O O
% NN O O
) NN O O
are NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
stomatitis NN B-AdverseReaction B-AdverseReaction
palmar NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
plantar NN I-AdverseReaction I-AdverseReaction
erythrodysesthesia NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
PPES NN O O
) NN O O
, NN O O
decreased NN B-AdverseReaction B-AdverseReaction
weight NN I-AdverseReaction I-AdverseReaction
decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
oral NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
hair NN B-AdverseReaction B-AdverseReaction
color NN I-AdverseReaction I-AdverseReaction
changes NN I-AdverseReaction I-AdverseReaction
dysgeusia NN B-AdverseReaction B-AdverseReaction
hypertension NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
and NN O O
constipation NN B-AdverseReaction B-AdverseReaction
The NN O O
most NN O O
common NN O O
laboratory NN O O
abnormalities NN O O
( NN O O
>=25 NN O O
% NN O O
) NN O O
are NN O O
increased NN B-AdverseReaction B-AdverseReaction
AST NN I-AdverseReaction I-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
ALT NN I-AdverseReaction I-AdverseReaction
lymphopenia NN B-AdverseReaction B-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
alkaline NN I-AdverseReaction I-AdverseReaction
phosphatase NN I-AdverseReaction I-AdverseReaction
hypocalcemia NN B-AdverseReaction B-AdverseReaction
neutropenia NN B-AdverseReaction B-AdverseReaction
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
hypophosphatemia NN B-AdverseReaction B-AdverseReaction
and NN O O
hyperbilirubinemia NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Exelixis NN O O
, NN O O
Inc. NN O O
at NN O O
1 NN O O
- NN O O
855 NN O O
- NN O O
500 NN O O
- NN O O
3935 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trial NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
The NN O O
safety NN O O
of NN O O
COMETRIQ NN O O
was NN O O
evaluated NN O O
in NN O O
330 NN O O
patients NN O O
with NN O O
progressive NN O O
metastatic NN O O
medullary NN O O
thyroid NN O O
cancer NN O O
randomized NN O O
to NN O O
receive NN O O
140 NN O O
mg NN O O
COMETRIQ NN O O
( NN O O
n NN O O
= NN O O
214 NN O O
) NN O O
or NN O O
placebo NN O O
( NN O O
n NN O O
= NN O O
109 NN O O
) NN O O
administered NN O O
daily NN O O
until NN O O
disease NN O O
progression NN O O
or NN O O
intolerable NN O O
toxicity NN O O
in NN O O
a NN O O
randomized NN O O
, NN O O
doubleblind NN O O
, NN O O
controlled NN O O
trial NN O O
. NN O O
[ NN O O
See NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
. NN O O
] NN O O
The NN O O
data NN O O
described NN O O
below NN O O
reflect NN O O
a NN O O
median NN O O
exposure NN O O
to NN O O
COMETRIQ NN O O
for NN O O
204 NN O O
days NN O O
. NN O O
The NN O O
population NN O O
exposed NN O O
to NN O O
COMETRIQ NN O O
was NN O O
70 NN O O
% NN O O
male NN O O
, NN O O
90 NN O O
% NN O O
white NN O O
, NN O O
and NN O O
had NN O O
a NN O O
median NN O O
age NN O O
of NN O O
55 NN O O
years NN O O
. NN O O
Adverse NN O O
reactions NN O O
which NN O O
occurred NN O O
in NN O O
>= NN O O
25 NN O O
% NN O O
of NN O O
COMETRIQ NN O O
- NN O O
treated NN O O
patients NN O O
occurring NN O O
more NN O O
frequently NN O O
in NN O O
the NN O O
COMETRIQ NN O O
arm NN O O
with NN O O
a NN O O
between NN O O
- NN O O
arm NN O O
difference NN O O
of NN O O
>= NN O O
5 NN O O
% NN O O
included NN O O
, NN O O
in NN O O
order NN O O
of NN O O
decreasing NN O O
frequency NN O O
: NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
stomatitis NN B-AdverseReaction B-AdverseReaction
palmar NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
plantar NN I-AdverseReaction I-AdverseReaction
erythrodysesthesia NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
PPES NN O O
) NN O O
, NN O O
decreased NN B-AdverseReaction B-AdverseReaction
weight NN I-AdverseReaction I-AdverseReaction
decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
oral NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
hair NN B-AdverseReaction B-AdverseReaction
color NN I-AdverseReaction I-AdverseReaction
changes NN I-AdverseReaction I-AdverseReaction
dysgeusia NN B-AdverseReaction B-AdverseReaction
hypertension NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
and NN O O
constipation NN B-AdverseReaction B-AdverseReaction
The NN O O
most NN O O
common NN O O
laboratory NN O O
abnormalities NN O O
( NN O O
>25 NN O O
% NN O O
) NN O O
were NN O O
increased NN B-AdverseReaction B-AdverseReaction
AST NN I-AdverseReaction I-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
ALT NN I-AdverseReaction I-AdverseReaction
lymphopenia NN B-AdverseReaction B-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
ALP NN I-AdverseReaction I-AdverseReaction
hypocalcemia NN B-AdverseReaction B-AdverseReaction
neutropenia NN B-AdverseReaction B-AdverseReaction
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
hypophosphatemia NN B-AdverseReaction B-AdverseReaction
and NN O O
hyperbilirubinemia NN B-AdverseReaction B-AdverseReaction
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
- NN I-Severity I-Severity
4 NN I-Severity I-Severity
adverse NN O O
reactions NN O O
and NN O O
laboratory NN O O
abnormalities NN O O
which NN O O
occurred NN O O
in NN O O
>= NN O O
5 NN O O
% NN O O
of NN O O
COMETRIQ NN O O
- NN O O
treated NN O O
patients NN O O
occurring NN O O
more NN O O
frequently NN O O
in NN O O
the NN O O
COMETRIQ NN O O
arm NN O O
with NN O O
a NN O O
between NN O O
- NN O O
arm NN O O
difference NN O O
of NN O O
>= NN O O
2 NN O O
% NN O O
included NN O O
, NN O O
in NN O O
order NN O O
of NN O O
decreasing NN O O
frequency NN O O
; NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
PPES NN B-AdverseReaction B-AdverseReaction
lymphopenia NN B-AdverseReaction B-AdverseReaction
hypocalcemia NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
hypertension NN B-AdverseReaction B-AdverseReaction
asthenia NN B-AdverseReaction B-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
ALT NN I-AdverseReaction I-AdverseReaction
decreased NN B-AdverseReaction B-AdverseReaction
weight NN I-AdverseReaction I-AdverseReaction
stomatitis NN B-AdverseReaction B-AdverseReaction
and NN O O
decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
( NN O O
see NN O O
Table NN O O
1 NN O O
, NN O O
Table NN O O
2 NN O O
) NN O O
. NN O O
Fatal NN B-AdverseReaction B-AdverseReaction
adverse NN O O
reactions NN O O
occurred NN O O
in NN O O
6 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
COMETRIQ NN O O
and NN O O
resulted NN O O
from NN O O
hemorrhage NN B-AdverseReaction B-AdverseReaction
pneumonia NN B-AdverseReaction B-AdverseReaction
septicemia NN B-AdverseReaction B-AdverseReaction
fistulas NN B-AdverseReaction B-AdverseReaction
cardiac NN B-AdverseReaction B-AdverseReaction
arrest NN I-AdverseReaction I-AdverseReaction
respiratory NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
and NN O O
unspecified NN O O
death NN B-AdverseReaction B-AdverseReaction
Fatal NN B-AdverseReaction B-AdverseReaction
adverse NN O O
reactions NN O O
occurred NN O O
in NN O O
5 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
placebo NN B-Factor B-Factor
and NN O O
resulted NN O O
from NN O O
septicemia NN B-AdverseReaction B-AdverseReaction
pneumonia NN B-AdverseReaction B-AdverseReaction
and NN O O
general NN B-AdverseReaction B-AdverseReaction
deterioration NN I-AdverseReaction I-AdverseReaction
The NN O O
dose NN O O
was NN O O
reduced NN O O
in NN O O
79 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
COMETRIQ NN O O
compared NN O O
to NN O O
9 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
placebo NN O O
. NN O O
The NN O O
median NN O O
number NN O O
of NN O O
dosing NN O O
delays NN O O
was NN O O
one NN O O
in NN O O
patients NN O O
receiving NN O O
COMETRIQ NN O O
compared NN O O
to NN O O
none NN O O
in NN O O
patients NN O O
receiving NN O O
placebo NN O O
. NN O O
Adverse NN O O
reactions NN O O
led NN O O
to NN O O
study NN O O
treatment NN O O
discontinuation NN O O
in NN O O
16 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
COMETRIQ NN O O
and NN O O
in NN O O
8 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
placebo NN O O
. NN O O
The NN O O
most NN O O
frequent NN O O
adverse NN O O
reactions NN O O
leading NN O O
to NN O O
permanent NN O O
discontinuation NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
COMETRIQ NN O O
were NN O O
: NN O O
hypocalcemia NN B-AdverseReaction B-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
lipase NN I-AdverseReaction I-AdverseReaction
PPES NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
hypertension NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
pancreatitis NN B-AdverseReaction B-AdverseReaction
tracheal NN B-AdverseReaction B-AdverseReaction
fistula NN I-AdverseReaction I-AdverseReaction
formation NN I-AdverseReaction I-AdverseReaction
and NN O O
vomiting NN B-AdverseReaction B-AdverseReaction
Increased NN B-AdverseReaction B-AdverseReaction
levels NN I-AdverseReaction I-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
thyroid NN I-AdverseReaction I-AdverseReaction
stimulating NN I-AdverseReaction I-AdverseReaction
hormone NN I-AdverseReaction I-AdverseReaction
( NN O O
TSH NN O O
) NN O O
were NN O O
observed NN O O
in NN O O
57 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
COMETRIQ NN O O
after NN O O
the NN O O
first NN O O
dose NN O O
compared NN O O
to NN O O
19 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
placebo NN O O
( NN O O
regardless NN O O
of NN O O
baseline NN O O
value NN O O
) NN O O
. NN O O
Ninety NN O O
- NN O O
two NN O O
percent NN O O
( NN O O
92 NN O O
% NN O O
) NN O O
of NN O O
patients NN O O
on NN O O
the NN O O
COMETRIQ NN O O
arm NN O O
had NN O O
a NN O O
prior NN O O
thyroidectomy NN O O
, NN O O
and NN O O
89 NN O O
% NN O O
were NN O O
taking NN O O
thyroid NN O O
hormone NN O O
replacement NN O O
prior NN O O
to NN O O
the NN O O
first NN O O
dose NN O O
. NN O O
Table NN O O
1 NN O O
Per NN O O
- NN O O
Patient NN O O
Incidence NN O O
of NN O O
Selected NN O O
Adverse NN O O
Reactions NN O O
in NN O O
Protocol NN O O
XL184 NN O O
- NN O O
301 NN O O
Occurring NN O O
at NN O O
a NN O O
Higher NN O O
Incidence NN O O
in NN O O
COMETRIQ NN O O
- NN O O
Treated NN O O
Patients NN O O
[ NN O O
Between NN O O
Arm NN O O
Difference NN O O
of NN O O
>= NN O O
5 NN O O
% NN O O
( NN O O
All NN O O
Grades)National NN O O
Cancer NN O O
Institute NN O O
Common NN O O
Terminology NN O O
Criteria NN O O
for NN O O
Adverse NN O O
Events NN O O
Version NN O O
3.0 NN O O
or NN O O
>= NN O O
2 NN O O
% NN O O
( NN O O
Grades NN O O
3 NN O O
- NN O O
4 NN O O
) NN O O
] NN O O
MedDRA NN O O
System NN O O
Organ NN O O
Class/Preferred NN O O
Terms NN O O
COMETRIQ(n=214 NN O O
) NN O O
Placebo(n=109 NN O O
) NN O O
AllGrades NN O O
Grades3 NN O O
- NN O O
4 NN O O
AllGrades NN O O
Grades3 NN O O
- NN O O
4 NN O O
GASTROINTESTINAL NN O O
DISORDERS NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
63 NN O O
16 NN O O
33 NN O O
2 NN O O
Stomatitis NN B-AdverseReaction B-AdverseReaction
51 NN O O
5 NN O O
6 NN O O
0 NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
43 NN O O
1 NN O O
21 NN O O
0 NN O O
Oral NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
36 NN O O
2 NN O O
6 NN O O
0 NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
27 NN O O
0 NN O O
6 NN O O
0 NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
27 NN O O
3 NN O O
13 NN O O
1 NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
24 NN O O
2 NN O O
2 NN O O
1 NN O O
Dysphagia NN B-AdverseReaction B-AdverseReaction
13 NN O O
4 NN O O
6 NN O O
1 NN O O
Dyspepsia NN B-AdverseReaction B-AdverseReaction
11 NN O O
0 NN O O
0 NN O O
0 NN O O
Hemorrhoids NN B-AdverseReaction B-AdverseReaction
9 NN O O
0 NN O O
3 NN O O
0 NN O O
GENERAL NN O O
DISORDERS NN O O
AND NN O O
ADMINISTRATION NN O O
SITE NN O O
CONDITIONS NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
41 NN O O
9 NN O O
28 NN O O
3 NN O O
Asthenia NN B-AdverseReaction B-AdverseReaction
21 NN O O
6 NN O O
15 NN O O
1 NN O O
INVESTIGATIONS NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
weight NN I-AdverseReaction I-AdverseReaction
48 NN O O
5 NN O O
10 NN O O
0 NN O O
METABOLISM NN O O
AND NN O O
NUTRITION NN O O
DISORDERS NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
46 NN O O
5 NN O O
16 NN O O
1 NN O O
Dehydration NN B-AdverseReaction B-AdverseReaction
7 NN O O
2 NN O O
2 NN O O
1 NN O O
MUSCULOSKELETAL NN O O
AND NN O O
CONNECTIVE NN O O
TISSUE NN O O
DISORDERS NN O O
Arthralgia NN B-AdverseReaction B-AdverseReaction
14 NN O O
1 NN O O
7 NN O O
0 NN O O
Muscle NN B-AdverseReaction B-AdverseReaction
spasms NN I-AdverseReaction I-AdverseReaction
12 NN O O
0 NN O O
5 NN O O
0 NN O O
Musculoskeletal NN B-AdverseReaction B-AdverseReaction
chest NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
9 NN O O
1 NN O O
4 NN O O
0 NN O O
NERVOUS NN O O
SYSTEM NN O O
DISORDERS NN O O
Dysgeusia NN B-AdverseReaction B-AdverseReaction
34 NN O O
0 NN O O
6 NN O O
0 NN O O
Headache NN B-AdverseReaction B-AdverseReaction
18 NN O O
0 NN O O
8 NN O O
0 NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
14 NN O O
0 NN O O
7 NN O O
0 NN O O
Paresthesia NN B-AdverseReaction B-AdverseReaction
7 NN O O
0 NN O O
2 NN O O
0 NN O O
Peripheral NN B-AdverseReaction B-AdverseReaction
sensory NN I-AdverseReaction I-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
7 NN O O
0 NN O O
0 NN O O
0 NN O O
Peripheral NN B-AdverseReaction B-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
5 NN O O
0 NN O O
0 NN O O
0 NN O O
PSYCHIATRIC NN O O
DISORDERS NN O O
Anxiety NN B-AdverseReaction B-AdverseReaction
9 NN O O
0 NN O O
2 NN O O
0 NN O O
RESPIRATORY NN O O
, NN O O
THORACIC NN O O
AND NN O O
MEDIASTINAL NN O O
DISORDERS NN O O
Dysphonia NN B-AdverseReaction B-AdverseReaction
20 NN O O
0 NN O O
9 NN O O
0 NN O O
SKIN NN O O
AND NN O O
SUBCUTANEOUS NN O O
TISSUE NN O O
DISORDERS NN O O
PPES NN B-AdverseReaction B-AdverseReaction
50 NN O O
13 NN O O
2 NN O O
0 NN O O
Hair NN B-AdverseReaction B-AdverseReaction
color NN I-AdverseReaction I-AdverseReaction
changes NN I-AdverseReaction I-AdverseReaction
depigmentation NN O O
, NN O O
graying NN O O
34 NN O O
0 NN O O
1 NN O O
0 NN O O
Rash NN B-AdverseReaction B-AdverseReaction
19 NN O O
1 NN O O
10 NN O O
0 NN O O
Dry NN B-AdverseReaction B-AdverseReaction
skin NN I-AdverseReaction I-AdverseReaction
19 NN O O
0 NN O O
3 NN O O
0 NN O O
Alopecia NN B-AdverseReaction B-AdverseReaction
16 NN O O
0 NN O O
2 NN O O
0 NN O O
Erythema NN B-AdverseReaction B-AdverseReaction
11 NN O O
1 NN O O
2 NN O O
0 NN O O
Hyperkeratosis NN B-AdverseReaction B-AdverseReaction
7 NN O O
0 NN O O
0 NN O O
0 NN O O
VASCULAR NN O O
DISORDERS NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
33 NN O O
8 NN O O
4 NN O O
0 NN O O
Hypotension NN B-AdverseReaction B-AdverseReaction
7 NN O O
1 NN O O
0 NN O O
0 NN O O
Table NN O O
2 NN O O
Percent NN O O
- NN O O
Patient NN O O
Incidence NN O O
of NN O O
Laboratory NN O O
Abnormalities NN O O
Occurring NN O O
at NN O O
a NN O O
Higher NN O O
Incidence NN O O
in NN O O
COMETRIQ NN O O
- NN O O
Treated NN O O
Patients NN O O
in NN O O
Protocol NN O O
XL184 NN O O
- NN O O
301 NN O O
[ NN O O
Between NN O O
Arm NN O O
Difference NN O O
of NN O O
>= NN O O
5 NN O O
% NN O O
( NN O O
All NN O O
Grades NN O O
) NN O O
or NN O O
>= NN O O
2 NN O O
% NN O O
( NN O O
Grades NN O O
3 NN O O
- NN O O
4 NN O O
) NN O O
] NN O O
Adverse NN O O
Event NN O O
COMETRIQ(n=214 NN O O
) NN O O
Placebo(N=109 NN O O
) NN O O
AllGrades NN O O
Grade3 NN O O
- NN O O
4 NN O O
AllGrades NN O O
Grade3 NN O O
- NN O O
4 NN O O
Chemistries NN O O
Increased NN B-AdverseReaction B-AdverseReaction
AST NN I-AdverseReaction I-AdverseReaction
86 NN O O
3 NN O O
35 NN O O
2 NN O O
Increased NN B-AdverseReaction B-AdverseReaction
ALT NN I-AdverseReaction I-AdverseReaction
86 NN O O
6 NN O O
41 NN O O
2 NN O O
Increased NN B-AdverseReaction B-AdverseReaction
ALP NN I-AdverseReaction I-AdverseReaction
52 NN O O
3 NN O O
35 NN O O
3 NN O O
Hypocalcemia NN B-AdverseReaction B-AdverseReaction
52 NN O O
12 NN O O
27 NN O O
3 NN O O
Hypophosphatemia NN B-AdverseReaction B-AdverseReaction
28 NN O O
3 NN O O
10 NN O O
1 NN O O
Hyperbilirubinemia NN B-AdverseReaction B-AdverseReaction
25 NN O O
2 NN O O
14 NN O O
5 NN O O
Hypomagnesemia NN B-AdverseReaction B-AdverseReaction
19 NN O O
1 NN O O
4 NN O O
0 NN O O
Hypokalemia NN B-AdverseReaction B-AdverseReaction
18 NN O O
4 NN O O
9 NN O O
3 NN O O
Hyponatremia NN B-AdverseReaction B-AdverseReaction
10 NN O O
2 NN O O
5 NN O O
0 NN O O
Hematologic NN O O
Lymphopenia NN B-AdverseReaction B-AdverseReaction
53 NN O O
16 NN O O
51 NN O O
11 NN O O
Neutropenia NN B-AdverseReaction B-AdverseReaction
35 NN O O
3 NN O O
15 NN O O
2 NN O O
Thrombocytopenia NN B-AdverseReaction B-AdverseReaction
35 NN O O
0 NN O O
4 NN O O
3 NN O O
ALT NN O O
, NN O O
alanine NN O O
aminotransferase NN O O
; NN O O
ALP NN O O
, NN O O
alkaline NN O O
phosphatase NN O O
; NN O O
AST NN O O
, NN O O
aspartate NN O O
aminotransferase NN O O
Nearly NN O O
all NN O O
COMETRIQ NN O O
- NN O O
treated NN O O
patients NN O O
( NN O O
96 NN O O
% NN O O
vs. NN O O
84 NN O O
% NN O O
placebo NN O O
) NN O O
experienced NN O O
elevated NN B-AdverseReaction B-AdverseReaction
blood NN I-AdverseReaction I-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
and NN O O
there NN O O
was NN O O
a NN O O
doubling NN O O
in NN O O
the NN O O
incidence NN O O
of NN O O
overt NN O O
hypertension NN B-AdverseReaction B-AdverseReaction
in NN O O
COMETRIQ NN O O
- NN O O
treated NN O O
patients NN O O
over NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
( NN O O
61 NN O O
% NN O O
vs. NN O O
30 NN O O
% NN O O
) NN O O
according NN O O
to NN O O
modified NN O O
Joint NN O O
National NN O O
Committee NN O O
on NN O O
Prevention NN O O
, NN O O
Detection NN O O
, NN O O
Evaluation NN O O
, NN O O
and NN O O
Treatment NN O O
of NN O O
High NN O O
Blood NN O O
Pressure NN O O
( NN O O
JNC NN O O
) NN O O
staging NN O O
criteria NN O O
. NN O O
No NN B-Negation B-Negation
patients NN O O
developed NN O O
malignant NN B-AdverseReaction B-AdverseReaction
hypertension NN I-AdverseReaction I-AdverseReaction
Table NN O O
3 NN O O
Per NN O O
- NN O O
Patient NN O O
Incidence NN O O
of NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
in NN O O
Protocol NN O O
XL184 NN O O
- NN O O
301 NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
JNCStage NN O O
COMETRIQN=211( NN O O
% NN O O
) NN O O
PlaceboN=107( NN O O
% NN O O
) NN O O
Normal NN O O
: NN O O
Grade NN O O
0 NN O O
: NN O O
Systolic NN O O
< NN O O
120 NN O O
mmHg NN O O
and NN O O
Diastolic NN O O
< NN O O
80 NN O O
mmHg NN O O
4 NN O O
15 NN O O
Pre NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
hypertension NN I-AdverseReaction I-AdverseReaction
Systolic NN O O
>= NN O O
120 NN O O
mmHg NN O O
or NN O O
Diastolic NN O O
>= NN O O
80 NN O O
mmHg NN O O
34 NN O O
54 NN O O
Stage NN O O
1 NN O O
: NN O O
Systolic NN O O
>= NN O O
140 NN O O
mmHg NN O O
or NN O O
Diastolic NN O O
>= NN O O
90 NN O O
mmHg NN O O
46 NN O O
25 NN O O
Stage NN O O
2 NN O O
: NN O O
Systolic NN O O
>= NN O O
160 NN O O
mmHg NN O O
or NN O O
Diastolic NN O O
>= NN O O
100 NN O O
mmHg NN O O
15 NN O O
5 NN O O
Malignant NN O O
: NN O O
Diastolic NN O O
>= NN O O
120 NN O O
mmHg NN O O
0 NN O O
0 NN O O
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
PERFORATIONS NN B-AdverseReaction B-AdverseReaction
AND NN O O
FISTULAS NN B-AdverseReaction B-AdverseReaction
and NN O O
HEMORRHAGE NN B-AdverseReaction B-AdverseReaction
WARNING NN O O
: NN O O
PERFORATIONS NN B-AdverseReaction B-AdverseReaction
AND NN O O
FISTULAS NN B-AdverseReaction B-AdverseReaction
and NN O O
HEMORRHAGE NN B-AdverseReaction B-AdverseReaction
Perforations NN B-AdverseReaction B-AdverseReaction
and NN O O
fistulas NN B-AdverseReaction B-AdverseReaction
Gastrointestinal NN B-AdverseReaction B-AdverseReaction
perforations NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
3 NN O O
% NN O O
and NN O O
fistula NN B-AdverseReaction B-AdverseReaction
formation NN I-AdverseReaction I-AdverseReaction
in NN O O
1 NN O O
% NN O O
of NN O O
COMETRIQTM NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Discontinue NN O O
COMETRIQ NN O O
for NN O O
perforation NN O O
or NN O O
for NN O O
fistula NN O O
formation NN O O
[ NN O O
See NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
Hemorrhage NN B-AdverseReaction B-AdverseReaction
Severe NN B-Severity B-Severity
sometimes NN O O
fatal NN B-AdverseReaction B-AdverseReaction
hemorrhage NN B-AdverseReaction B-AdverseReaction
including NN O O
hemoptysis NN B-AdverseReaction B-AdverseReaction
and NN O O
gastrointestinal NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
3 NN O O
% NN O O
of NN O O
COMETRIQ NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Monitor NN O O
patients NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
bleeding NN O O
. NN O O
Do NN O O
not NN O O
administer NN O O
COMETRIQ NN O O
to NN O O
patients NN O O
with NN O O
severe NN O O
hemorrhage NN O O
[ NN O O
See NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
EXCERPT NN O O
: NN O O
WARNING NN O O
: NN O O
PERFORATIONS NN B-AdverseReaction B-AdverseReaction
AND NN O O
FISTULAS NN B-AdverseReaction B-AdverseReaction
andHEMORRHAGE NN O O
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
. NN O O
* NN O O
Perforations NN B-AdverseReaction B-AdverseReaction
and NN O O
Fistulas NN B-AdverseReaction B-AdverseReaction
Gastrointestinal NN B-AdverseReaction B-AdverseReaction
perforations NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
3 NN O O
% NN O O
and NN O O
fistula NN B-AdverseReaction B-AdverseReaction
formation NN I-AdverseReaction I-AdverseReaction
in NN O O
1 NN O O
% NN O O
of NN O O
COMETRIQ NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Discontinue NN O O
COMETRIQ NN O O
in NN O O
patients NN O O
with NN O O
perforation NN O O
or NN O O
fistula NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Hemorrhage NN B-AdverseReaction B-AdverseReaction
Severe NN B-Severity B-Severity
sometimes NN O O
fatal NN B-AdverseReaction B-AdverseReaction
hemorrhage NN B-AdverseReaction B-AdverseReaction
including NN O O
hemoptysis NN B-AdverseReaction B-AdverseReaction
and NN O O
gastrointestinal NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
3 NN O O
% NN O O
of NN O O
COMETRIQ NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Monitor NN O O
patients NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
bleeding NN O O
. NN O O
Do NN O O
not NN O O
administer NN O O
COMETRIQ NN O O
to NN O O
patients NN O O
with NN O O
severe NN O O
hemorrhage NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Thrombotic NN B-AdverseReaction B-AdverseReaction
Events NN I-AdverseReaction I-AdverseReaction
Discontinue NN O O
COMETRIQ NN O O
for NN O O
myocardial NN O O
infarction NN O O
, NN O O
cerebral NN O O
infarction NN O O
, NN O O
or NN O O
other NN O O
serious NN O O
arterial NN O O
thromboembolic NN O O
events NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Wound NN B-AdverseReaction B-AdverseReaction
Complications NN I-AdverseReaction I-AdverseReaction
Withhold NN O O
COMETRIQ NN O O
for NN O O
dehiscence NN O O
or NN O O
complications NN O O
requiring NN O O
medical NN O O
intervention NN O O
. NN O O
( NN O O
5.4 NN O O
) NN O O
* NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
Monitor NN O O
blood NN O O
pressure NN O O
regularly NN O O
. NN O O
Discontinue NN O O
COMETRIQ NN O O
for NN O O
hypertensive NN O O
crisis NN O O
. NN O O
( NN O O
5.5 NN O O
) NN O O
* NN O O
Osteonecrosis NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
jaw NN I-AdverseReaction I-AdverseReaction
Discontinue NN O O
COMETRIQ. NN O O
( NN O O
5.6 NN O O
) NN O O
. NN O O
* NN O O
Palmar NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
plantar NN I-AdverseReaction I-AdverseReaction
Erythrodysesthesia NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
PPES NN O O
) NN O O
: NN O O
Interrupt NN O O
COMETRIQ NN O O
, NN O O
decrease NN O O
dose NN O O
. NN O O
( NN O O
5.7 NN O O
) NN O O
* NN O O
Proteinuria NN B-AdverseReaction B-AdverseReaction
Monitor NN O O
urine NN O O
protein NN O O
. NN O O
Discontinue NN O O
for NN O O
nephrotic NN O O
syndrome NN O O
. NN O O
( NN O O
5.8 NN O O
) NN O O
* NN O O
Reversible NN B-AdverseReaction B-AdverseReaction
posterior NN I-AdverseReaction I-AdverseReaction
leukoencephalopathy NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
RPLS NN O O
) NN O O
: NN O O
Discontinue NN O O
COMETRIQ. NN O O
( NN O O
5.9 NN O O
) NN O O
* NN O O
Embryofetal NN B-AdverseReaction B-AdverseReaction
toxicity NN I-AdverseReaction I-AdverseReaction
Can NN B-Factor B-Factor
cause NN O O
fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
Advise NN O O
women NN O O
of NN O O
potential NN O O
risk NN O O
to NN O O
a NN O O
fetus NN O O
. NN O O
( NN O O
5.11 NN O O
, NN O O
8.1 NN O O
) NN O O
5.1 NN O O
Perforations NN O O
and NN O O
Fistulas NN O O
Gastrointestinal NN O O
( NN O O
GI NN O O
) NN O O
perforations NN O O
and NN O O
fistulas NN O O
were NN O O
reported NN O O
in NN O O
3 NN O O
% NN O O
and NN O O
1 NN O O
% NN O O
of NN O O
COMETRIQ NN O O
- NN O O
treated NN O O
patients NN O O
, NN O O
respectively NN O O
. NN O O
All NN O O
were NN O O
serious NN B-Severity B-Severity
and NN O O
one NN O O
GI NN B-AdverseReaction B-AdverseReaction
fistula NN I-AdverseReaction I-AdverseReaction
was NN O O
fatal NN B-AdverseReaction B-AdverseReaction
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
. NN O O
Non NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
GI NN I-AdverseReaction I-AdverseReaction
fistulas NN I-AdverseReaction I-AdverseReaction
including NN O O
tracheal/esophageal NN O O
were NN O O
reported NN O O
in NN O O
4 NN O O
% NN O O
of NN O O
COMETRIQ NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Two NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
of NN O O
these NN O O
were NN O O
fatal NN B-AdverseReaction B-AdverseReaction
Monitor NN O O
patients NN O O
for NN O O
symptoms NN O O
of NN O O
perforations NN O O
and NN O O
fistulas NN O O
. NN O O
Discontinue NN O O
COMETRIQ NN O O
in NN O O
patients NN O O
who NN O O
experience NN O O
a NN O O
perforation NN O O
or NN O O
a NN O O
fistula NN O O
. NN O O
5.2 NN O O
Hemorrhage NN O O
Serious NN B-Severity B-Severity
and NN O O
sometimes NN O O
fatal NN B-AdverseReaction B-AdverseReaction
hemorrhage NN B-AdverseReaction B-AdverseReaction
occurred NN O O
with NN O O
COMETRIQ. NN O O
The NN O O
incidence NN O O
of NN O O
Grade NN O O
>=3 NN O O
hemorrhagic NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
was NN O O
higher NN O O
in NN O O
COMETRIQ NN O O
- NN O O
treated NN O O
patients NN O O
compared NN O O
with NN O O
placebo NN O O
( NN O O
3 NN O O
% NN O O
vs. NN O O
1 NN O O
% NN O O
) NN O O
. NN O O
Do NN O O
not NN O O
administer NN O O
COMETRIQ NN O O
to NN O O
patients NN O O
with NN O O
a NN O O
recent NN O O
history NN O O
of NN O O
hemorrhage NN O O
or NN O O
hemoptysis NN O O
. NN O O
5.3 NN O O
Thrombotic NN O O
Events NN O O
COMETRIQ NN O O
treatment NN O O
results NN O O
in NN O O
an NN O O
increased NN O O
incidence NN O O
of NN O O
thrombotic NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
( NN O O
venous NN O O
thromboembolism NN O O
: NN O O
6 NN O O
% NN O O
vs. NN O O
3 NN O O
% NN O O
and NN O O
arterial NN B-AdverseReaction B-AdverseReaction
thromboembolism NN I-AdverseReaction I-AdverseReaction
2 NN O O
% NN O O
vs. NN O O
0 NN O O
% NN O O
in NN O O
COMETRIQ NN O O
- NN O O
treated NN O O
and NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
, NN O O
respectively NN O O
) NN O O
. NN O O
Discontinue NN O O
COMETRIQ NN O O
in NN O O
patients NN O O
who NN O O
develop NN O O
an NN O O
acute NN O O
myocardial NN O O
infarction NN O O
or NN O O
any NN O O
other NN O O
clinically NN O O
significant NN O O
arterial NN O O
thromboembolic NN O O
complication NN O O
. NN O O
5.4 NN O O
Wound NN O O
Complications NN O O
Wound NN B-AdverseReaction B-AdverseReaction
complications NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
with NN O O
COMETRIQ. NN O O
Stop NN O O
treatment NN O O
with NN O O
COMETRIQ NN O O
at NN O O
least NN O O
28 NN O O
days NN O O
prior NN O O
to NN O O
scheduled NN O O
surgery NN O O
. NN O O
Resume NN O O
COMETRIQ NN O O
therapy NN O O
after NN O O
surgery NN O O
based NN O O
on NN O O
clinical NN O O
judgment NN O O
of NN O O
adequate NN O O
wound NN O O
healing NN O O
. NN O O
Withhold NN O O
COMETRIQ NN O O
in NN O O
patients NN O O
with NN O O
dehiscence NN O O
or NN O O
wound NN O O
healing NN O O
complications NN O O
requiring NN O O
medical NN O O
intervention NN O O
. NN O O
5.5 NN O O
Hypertension NN O O
COMETRIQ NN O O
treatment NN O O
results NN O O
in NN O O
an NN O O
increased NN O O
incidence NN O O
of NN O O
treatment NN O O
- NN O O
emergent NN O O
hypertension NN B-AdverseReaction B-AdverseReaction
with NN O O
Joint NN O O
National NN O O
Committee NN O O
on NN O O
Prevention NN O O
, NN O O
Detection NN O O
, NN O O
Evaluation NN O O
, NN O O
and NN O O
Treatment NN O O
of NN O O
High NN O O
Blood NN O O
Pressure NN O O
( NN O O
modified NN O O
JNC NN O O
criteria NN O O
) NN O O
stage NN B-Severity B-Severity
1 NN I-Severity I-Severity
or NN O O
2 NN O O
hypertension NN B-AdverseReaction B-AdverseReaction
identified NN O O
in NN O O
61 NN O O
% NN O O
in NN O O
COMETRIQ NN O O
- NN O O
treated NN O O
patients NN O O
compared NN O O
with NN O O
30 NN O O
% NN O O
of NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
in NN O O
the NN O O
randomized NN O O
trial NN O O
. NN O O
Monitor NN O O
blood NN O O
pressure NN O O
prior NN O O
to NN O O
initiation NN O O
and NN O O
regularly NN O O
during NN O O
COMETRIQ NN O O
treatment NN O O
. NN O O
Withhold NN O O
COMETRIQ NN O O
for NN O O
hypertension NN O O
that NN O O
is NN O O
not NN O O
adequately NN O O
controlled NN O O
with NN O O
medical NN O O
management NN O O
; NN O O
when NN O O
controlled NN O O
, NN O O
resume NN O O
COMETRIQ NN O O
at NN O O
a NN O O
reduced NN O O
dose NN O O
. NN O O
Discontinue NN O O
COMETRIQ NN O O
for NN O O
severe NN O O
hypertension NN O O
that NN O O
can NN O O
not NN O O
be NN O O
controlled NN O O
with NN O O
anti NN O O
- NN O O
hypertensive NN O O
therapy NN O O
. NN O O
5.6 NN O O
Osteonecrosis NN O O
of NN O O
the NN O O
Jaw NN O O
Osteonecrosis NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
jaw NN I-AdverseReaction I-AdverseReaction
( NN O O
ONJ NN O O
) NN O O
occurred NN O O
in NN O O
1 NN O O
% NN O O
of NN O O
COMETRIQ NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
ONJ NN B-AdverseReaction B-AdverseReaction
can NN B-Factor B-Factor
manifest NN O O
as NN O O
jaw NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
osteomyelitis NN B-AdverseReaction B-AdverseReaction
osteitis NN B-AdverseReaction B-AdverseReaction
bone NN B-AdverseReaction B-AdverseReaction
erosion NN I-AdverseReaction I-AdverseReaction
tooth NN O O
or NN O O
periodontal NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
toothache NN B-AdverseReaction B-AdverseReaction
gingival NN B-AdverseReaction B-AdverseReaction
ulceration NN I-AdverseReaction I-AdverseReaction
or NN O O
erosion NN O O
, NN O O
persistent NN B-AdverseReaction B-AdverseReaction
jaw NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
or NN O O
slow NN O O
healing NN O O
of NN O O
the NN O O
mouth NN O O
or NN O O
jaw NN O O
after NN O O
dental NN O O
surgery NN O O
. NN O O
Perform NN O O
an NN O O
oral NN O O
examination NN O O
prior NN O O
to NN O O
initiation NN O O
of NN O O
COMETRIQ NN O O
and NN O O
periodically NN O O
during NN O O
COMETRIQ NN O O
therapy NN O O
. NN O O
Advise NN O O
patients NN O O
regarding NN O O
good NN O O
oral NN O O
hygiene NN O O
practices NN O O
. NN O O
For NN O O
invasive NN O O
dental NN O O
procedures NN O O
, NN O O
withhold NN O O
COMETRIQ NN O O
treatment NN O O
for NN O O
at NN O O
least NN O O
28 NN O O
days NN O O
prior NN O O
to NN O O
scheduled NN O O
surgery NN O O
, NN O O
if NN O O
possible NN O O
. NN O O
5.7 NN O O
Palmar NN O O
- NN O O
Plantar NN O O
Erythrodysesthesia NN O O
Syndrome NN O O
Palmar NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
plantar NN I-AdverseReaction I-AdverseReaction
erythrodysesthesia NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
PPES NN O O
) NN O O
occurred NN O O
in NN O O
50 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
COMETRIQ NN O O
and NN O O
was NN O O
severe NN B-Severity B-Severity
( NN O O
>= NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
in NN O O
13 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
Withhold NN O O
COMETRIQ NN O O
in NN O O
patients NN O O
who NN O O
develop NN O O
intolerable NN O O
Grade NN O O
2 NN O O
PPES NN O O
or NN O O
Grade NN O O
3 NN O O
- NN O O
4 NN O O
PPES NN O O
until NN O O
improvement NN O O
to NN O O
Grade NN O O
1 NN O O
; NN O O
resume NN O O
COMETRIQ NN O O
at NN O O
a NN O O
reduced NN O O
dose NN O O
. NN O O
5.8 NN O O
Proteinuria NN O O
Proteinuria NN B-AdverseReaction B-AdverseReaction
was NN O O
observed NN O O
in NN O O
4 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
of NN O O
patients NN O O
receiving NN O O
COMETRIQ NN O O
, NN O O
including NN O O
one NN O O
with NN O O
nephrotic NN B-AdverseReaction B-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
as NN O O
compared NN O O
to NN O O
none NN O O
of NN O O
the NN O O
patients NN O O
receiving NN O O
placebo NN O O
. NN O O
Monitor NN O O
urine NN O O
protein NN O O
regularly NN O O
during NN O O
COMETRIQ NN O O
treatment NN O O
. NN O O
Discontinue NN O O
COMETRIQ NN O O
in NN O O
patients NN O O
who NN O O
develop NN O O
nephrotic NN O O
syndrome NN O O
. NN O O
5.9 NN O O
Reversible NN O O
Posterior NN O O
Leukoencephalopathy NN O O
Syndrome NN O O
Reversible NN B-AdverseReaction B-AdverseReaction
Posterior NN I-AdverseReaction I-AdverseReaction
Leukoencephalopathy NN I-AdverseReaction I-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
RPLS NN O O
) NN O O
, NN O O
a NN O O
syndrome NN O O
of NN O O
subcortical NN B-AdverseReaction B-AdverseReaction
vasogenic NN I-AdverseReaction I-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
diagnosed NN O O
by NN O O
characteristic NN O O
finding NN O O
on NN O O
MRI NN O O
, NN O O
occurred NN O O
in NN O O
one NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
patient NN O O
. NN O O
Perform NN O O
an NN O O
evaluation NN O O
for NN O O
RPLS NN O O
in NN O O
any NN O O
patient NN O O
presenting NN O O
with NN O O
seizures NN O O
, NN O O
headache NN O O
, NN O O
visual NN O O
disturbances NN O O
, NN O O
confusion NN O O
or NN O O
altered NN O O
mental NN O O
function NN O O
. NN O O
Discontinue NN O O
COMETRIQ NN O O
in NN O O
patients NN O O
who NN O O
develop NN O O
RPLS. NN O O
5.10 NN O O
Drug NN O O
Interactions NN O O
Avoid NN O O
administration NN O O
of NN O O
COMETRIQ NN O O
with NN O O
agents NN O O
that NN O O
are NN O O
strong NN O O
CYP3A4 NN O O
inducers NN O O
or NN O O
inhibitors NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.1 NN O O
) NN O O
and NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.1 NN O O
, NN O O
7.2 NN O O
) NN O O
] NN O O
. NN O O
5.11 NN O O
Hepatic NN O O
Impairment NN O O
COMETRIQ NN O O
is NN O O
not NN O O
recommended NN O O
for NN O O
use NN O O
in NN O O
patients NN O O
with NN O O
moderate NN O O
or NN O O
severe NN O O
hepatic NN O O
impairment NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.6 NN O O
) NN O O
] NN O O
. NN O O
5.12 NN O O
Embryo NN O O
- NN O O
fetal NN O O
Toxicity NN O O
COMETRIQ NN O O
can NN B-Factor B-Factor
cause NN O O
fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
when NN O O
administered NN O O
to NN O O
a NN O O
pregnant NN O O
woman NN O O
. NN O O
Cabozantinib NN O O
was NN O O
embryolethal NN B-AdverseReaction B-AdverseReaction
in NN O O
rats NN B-Animal B-Animal
at NN O O
exposures NN O O
below NN O O
the NN O O
recommended NN O O
human NN O O
dose NN O O
, NN O O
with NN O O
increased NN O O
incidences NN O O
of NN O O
skeletal NN B-AdverseReaction B-AdverseReaction
variations NN I-AdverseReaction I-AdverseReaction
in NN O O
rats NN B-Animal B-Animal
and NN O O
visceral NN B-AdverseReaction B-AdverseReaction
variations NN I-AdverseReaction I-AdverseReaction
and NN O O
malformations NN O O
in NN O O
rabbits NN B-Animal B-Animal
If NN O O
this NN O O
drug NN O O
is NN O O
used NN O O
during NN O O
pregnancy NN O O
, NN O O
or NN O O
if NN O O
the NN O O
patient NN O O
becomes NN O O
pregnant NN O O
while NN O O
taking NN O O
this NN O O
drug NN O O
, NN O O
the NN O O
patient NN O O
should NN O O
be NN O O
apprised NN O O
of NN O O
the NN O O
potential NN O O
hazard NN O O
to NN O O
the NN O O
fetus NN O O
[ NN O O
See NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.1 NN O O
) NN O O
] NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
are NN O O
discussed NN O O
in NN O O
greater NN O O
detail NN O O
in NN O O
other NN O O
sections NN O O
of NN O O
the NN O O
labeling NN O O
: NN O O
* NN O O
Hepatotoxicity NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Interstitial NN B-AdverseReaction B-AdverseReaction
Lung NN I-AdverseReaction I-AdverseReaction
Disease NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
QT NN B-AdverseReaction B-AdverseReaction
Interval NN I-AdverseReaction I-AdverseReaction
Prolongation NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
* NN O O
Bradycardia NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
* NN O O
Severe NN B-Severity B-Severity
Visual NN B-AdverseReaction B-AdverseReaction
Loss NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=25 NN O O
% NN O O
) NN O O
are NN O O
vision NN B-AdverseReaction B-AdverseReaction
disorders NN I-AdverseReaction I-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
constipation NN B-AdverseReaction B-AdverseReaction
edema NN B-AdverseReaction B-AdverseReaction
elevated NN B-AdverseReaction B-AdverseReaction
transaminases NN I-AdverseReaction I-AdverseReaction
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
and NN O O
dysgeusia NN B-AdverseReaction B-AdverseReaction
( NN O O
6 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Pfizer NN O O
Inc. NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
438 NN O O
- NN O O
1985 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O
The NN O O
safety NN O O
of NN O O
XALKORI NN O O
is NN O O
based NN O O
primarily NN O O
on NN O O
343 NN O O
patients NN O O
with NN O O
ALK NN O O
- NN O O
positive NN O O
metastatic NN O O
NSCLC NN O O
who NN O O
received NN O O
XALKORI NN O O
250 NN O O
mg NN O O
twice NN O O
daily NN O O
in NN O O
two NN O O
open NN O O
- NN O O
label NN O O
, NN O O
randomized NN O O
, NN O O
active NN O O
- NN O O
controlled NN O O
trials NN O O
( NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
) NN O O
. NN O O
This NN O O
is NN O O
supplemented NN O O
with NN O O
information NN O O
on NN O O
adverse NN O O
drug NN O O
reactions NN O O
in NN O O
1326 NN O O
patients NN O O
with NN O O
ALK NN O O
- NN O O
positive NN O O
metastatic NN O O
NSCLC NN O O
who NN O O
received NN O O
XALKORI NN O O
250 NN O O
mg NN O O
twice NN O O
daily NN O O
across NN O O
clinical NN O O
trials NN O O
, NN O O
for NN O O
a NN O O
total NN O O
of NN O O
1669 NN O O
patients NN O O
across NN O O
all NN O O
clinical NN O O
studies NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=25 NN O O
% NN O O
) NN O O
of NN O O
XALKORI NN O O
in NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
are NN O O
vision NN B-AdverseReaction B-AdverseReaction
disorders NN I-AdverseReaction I-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
constipation NN B-AdverseReaction B-AdverseReaction
edema NN B-AdverseReaction B-AdverseReaction
elevated NN B-AdverseReaction B-AdverseReaction
transaminases NN I-AdverseReaction I-AdverseReaction
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
and NN O O
dysgeusia NN B-AdverseReaction B-AdverseReaction
Previously NN O O
Untreated NN O O
ALK NN O O
- NN O O
Positive NN O O
Metastatic NN O O
NSCLC NN O O
- NN O O
Study NN O O
1 NN O O
The NN O O
data NN O O
in NN O O
Table NN O O
3 NN O O
are NN O O
derived NN O O
from NN O O
340 NN O O
patients NN O O
with NN O O
ALK NN O O
- NN O O
positive NN O O
metastatic NN O O
NSCLC NN O O
who NN O O
had NN O O
not NN O O
received NN O O
previous NN O O
systemic NN O O
treatment NN O O
for NN O O
advanced NN O O
disease NN O O
who NN O O
received NN O O
treatment NN O O
in NN O O
a NN O O
randomized NN O O
, NN O O
multicenter NN O O
, NN O O
open NN O O
- NN O O
label NN O O
, NN O O
active NN O O
- NN O O
controlled NN O O
trial NN O O
( NN O O
Study NN O O
1 NN O O
) NN O O
. NN O O
Patients NN O O
in NN O O
the NN O O
XALKORI NN O O
arm NN O O
( NN O O
n=171 NN O O
) NN O O
received NN O O
XALKORI NN O O
250 NN O O
mg NN O O
orally NN O O
twice NN O O
daily NN O O
until NN O O
documented NN O O
disease NN O O
progression NN O O
, NN O O
intolerance NN O O
to NN O O
therapy NN O O
, NN O O
or NN O O
the NN O O
investigator NN O O
determined NN O O
that NN O O
the NN O O
patient NN O O
was NN O O
no NN O O
longer NN O O
experiencing NN O O
clinical NN O O
benefit NN O O
. NN O O
A NN O O
total NN O O
of NN O O
169 NN O O
patients NN O O
in NN O O
the NN O O
chemotherapy NN O O
arm NN O O
received NN O O
pemetrexed NN O O
500 NN O O
mg/m NN O O
2 NN O O
in NN O O
combination NN O O
with NN O O
cisplatin NN O O
75 NN O O
mg/m NN O O
2 NN O O
( NN O O
n=91 NN O O
) NN O O
or NN O O
carboplatin NN O O
at NN O O
a NN O O
dose NN O O
calculated NN O O
to NN O O
produce NN O O
an NN O O
area NN O O
under NN O O
the NN O O
concentration NN O O
- NN O O
time NN O O
curve NN O O
( NN O O
AUC NN O O
) NN O O
of NN O O
5 NN O O
or NN O O
6 NN O O
mg?min/mL NN O O
( NN O O
n=78 NN O O
) NN O O
. NN O O
Chemotherapy NN O O
was NN O O
given NN O O
by NN O O
intravenous NN O O
infusion NN O O
every NN O O
3 NN O O
weeks NN O O
for NN O O
up NN O O
to NN O O
6 NN O O
cycles NN O O
, NN O O
in NN O O
the NN O O
absence NN O O
of NN O O
dose NN O O
- NN O O
limiting NN O O
chemotherapy NN O O
- NN O O
related NN O O
toxicities NN O O
. NN O O
After NN O O
6 NN O O
cycles NN O O
, NN O O
patients NN O O
remained NN O O
on NN O O
study NN O O
with NN O O
no NN O O
additional NN O O
anticancer NN O O
treatment NN O O
, NN O O
and NN O O
tumor NN O O
assessments NN O O
continued NN O O
until NN O O
documented NN O O
disease NN O O
progression NN O O
. NN O O
The NN O O
median NN O O
duration NN O O
of NN O O
study NN O O
treatment NN O O
was NN O O
10.9 NN O O
months NN O O
for NN O O
patients NN O O
in NN O O
the NN O O
XALKORI NN O O
arm NN O O
and NN O O
4.1 NN O O
months NN O O
for NN O O
patients NN O O
in NN O O
the NN O O
chemotherapy NN O O
arm NN O O
. NN O O
Median NN O O
duration NN O O
of NN O O
treatment NN O O
was NN O O
5.2 NN O O
months NN O O
for NN O O
patients NN O O
who NN O O
received NN O O
XALKORI NN O O
after NN O O
cross NN O O
over NN O O
from NN O O
chemotherapy NN O O
. NN O O
Across NN O O
the NN O O
340 NN O O
patients NN O O
who NN O O
were NN O O
treated NN O O
in NN O O
Study NN O O
1 NN O O
, NN O O
the NN O O
median NN O O
age NN O O
was NN O O
53 NN O O
years NN O O
; NN O O
16 NN O O
% NN O O
of NN O O
patients NN O O
were NN O O
older NN O O
than NN O O
65 NN O O
years NN O O
. NN O O
A NN O O
total NN O O
of NN O O
62 NN O O
% NN O O
of NN O O
patients NN O O
were NN O O
female NN O O
and NN O O
46 NN O O
% NN O O
were NN O O
Asian NN O O
. NN O O
Serious NN O O
adverse NN O O
events NN O O
were NN O O
reported NN O O
in NN O O
58 NN O O
patients NN O O
( NN O O
34 NN O O
% NN O O
) NN O O
treated NN O O
with NN O O
XALKORI. NN O O
The NN O O
most NN O O
frequent NN O O
serious NN O O
adverse NN O O
events NN O O
reported NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
XALKORI NN O O
were NN O O
dyspnea NN B-AdverseReaction B-AdverseReaction
( NN O O
4.1 NN O O
% NN O O
) NN O O
and NN O O
pulmonary NN B-AdverseReaction B-AdverseReaction
embolism NN I-AdverseReaction I-AdverseReaction
( NN O O
2.9 NN O O
% NN O O
) NN O O
. NN O O
Fatal NN B-AdverseReaction B-AdverseReaction
adverse NN O O
events NN O O
in NN O O
XALKORI NN O O
- NN O O
treated NN O O
patients NN O O
occurred NN O O
in NN O O
2.3 NN O O
% NN O O
patients NN O O
, NN O O
consisting NN O O
of NN O O
septic NN B-AdverseReaction B-AdverseReaction
shock NN I-AdverseReaction I-AdverseReaction
acute NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
and NN O O
diabetic NN B-AdverseReaction B-AdverseReaction
ketoacidosis NN I-AdverseReaction I-AdverseReaction
Dose NN O O
reductions NN O O
due NN O O
to NN O O
adverse NN O O
reactions NN O O
were NN O O
required NN O O
in NN O O
6.4 NN O O
% NN O O
of NN O O
XALKORI NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
The NN O O
most NN O O
frequent NN O O
adverse NN O O
reactions NN O O
that NN O O
led NN O O
to NN O O
dose NN O O
reduction NN O O
in NN O O
these NN O O
patients NN O O
were NN O O
nausea NN B-AdverseReaction B-AdverseReaction
( NN O O
1.8 NN O O
% NN O O
) NN O O
and NN O O
elevated NN B-AdverseReaction B-AdverseReaction
transaminases NN I-AdverseReaction I-AdverseReaction
( NN O O
1.8 NN O O
% NN O O
) NN O O
. NN O O
Permanent NN O O
discontinuation NN O O
of NN O O
XALKORI NN O O
treatment NN O O
for NN O O
adverse NN O O
reactions NN O O
was NN O O
8.2 NN O O
% NN O O
. NN O O
The NN O O
most NN O O
frequent NN O O
adverse NN O O
reactions NN O O
that NN O O
led NN O O
to NN O O
permanent NN O O
discontinuation NN O O
in NN O O
XALKORI NN O O
- NN O O
treated NN O O
patients NN O O
were NN O O
elevated NN B-AdverseReaction B-AdverseReaction
transaminases NN I-AdverseReaction I-AdverseReaction
( NN O O
1.2 NN O O
% NN O O
) NN O O
, NN O O
hepatotoxicity NN B-AdverseReaction B-AdverseReaction
( NN O O
1.2 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
ILD NN B-AdverseReaction B-AdverseReaction
( NN O O
1.2 NN O O
% NN O O
) NN O O
. NN O O
Tables NN O O
3 NN O O
and NN O O
4 NN O O
summarize NN O O
common NN O O
adverse NN O O
reactions NN O O
and NN O O
laboratory NN O O
abnormalities NN O O
in NN O O
XALKORI NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Table NN O O
3 NN O O
. NN O O
Adverse NN O O
Reactions NN O O
Reported NN O O
at NN O O
a NN O O
Higher NN O O
Incidence NN O O
( NN O O
>=5 NN O O
% NN O O
Higher NN O O
for NN O O
All NN O O
Grades NN O O
or NN O O
>=2 NN O O
% NN O O
Higher NN O O
for NN O O
Grades NN O O
3/4 NN O O
) NN O O
with NN O O
XALKORI NN O O
than NN O O
Chemotherapy NN O O
in NN O O
Study NN O O
1 NN O O
Adverse NN O O
Reaction NN O O
XALKORI(N=171 NN O O
) NN O O
Chemotherapy NN O O
( NN O O
Pemetrexed/Cisplatin NN O O
or NN O O
Pemetrexed/Carboplatin)(N=169 NN O O
) NN O O
All NN O O
Grades( NN O O
% NN O O
) NN O O
Grade NN O O
3/4( NN O O
% NN O O
) NN O O
All NN O O
Grades( NN O O
% NN O O
) NN O O
Grade NN O O
3/4( NN O O
% NN O O
) NN O O
Includes NN O O
cases NN O O
reported NN O O
within NN O O
the NN O O
clustered NN O O
terms NN O O
: NN O O
Cardiac NN O O
Disorders NN O O
Electrocardiogram NN B-AdverseReaction B-AdverseReaction
QT NN I-AdverseReaction I-AdverseReaction
prolonged NN I-AdverseReaction I-AdverseReaction
6 NN O O
2 NN O O
2 NN O O
0 NN O O
Bradycardia NN B-AdverseReaction B-AdverseReaction
14 NN O O
1 NN O O
1 NN O O
0 NN O O
Eye NN O O
Disorders NN O O
Vision NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
71 NN O O
1 NN O O
10 NN O O
0 NN O O
Gastrointestinal NN O O
Disorders NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
46 NN O O
2 NN O O
36 NN O O
3 NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
61 NN O O
2 NN O O
13 NN O O
1 NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
43 NN O O
2 NN O O
30 NN O O
0 NN O O
Dyspepsia NN B-AdverseReaction B-AdverseReaction
14 NN O O
0 NN O O
2 NN O O
0 NN O O
Dysphagia NN B-AdverseReaction B-AdverseReaction
10 NN O O
1 NN O O
2 NN O O
1 NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
26 NN O O
0 NN O O
12 NN O O
0 NN O O
General NN O O
Disorders NN O O
and NN O O
Administration NN O O
Site NN O O
Conditions NN O O
Edema NN B-AdverseReaction B-AdverseReaction
49 NN O O
1 NN O O
12 NN O O
1 NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
19 NN O O
0 NN O O
11 NN O O
1 NN O O
Infections NN O O
and NN O O
Infestations NN O O
Upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
32 NN O O
0 NN O O
12 NN O O
1 NN O O
Investigations NN O O
Weight NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
8 NN O O
1 NN O O
2 NN O O
0 NN O O
Musculoskeletal NN O O
and NN O O
Connective NN O O
Tissue NN O O
Disorders NN O O
Pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
16 NN O O
0 NN O O
7 NN O O
0 NN O O
Muscle NN B-AdverseReaction B-AdverseReaction
spasm NN I-AdverseReaction I-AdverseReaction
8 NN O O
0 NN O O
2 NN O O
1 NN O O
Nervous NN O O
System NN O O
Disorder NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
18 NN O O
0 NN O O
10 NN O O
1 NN O O
Dysgeusia NN B-AdverseReaction B-AdverseReaction
26 NN O O
0 NN O O
5 NN O O
0 NN O O
Headache NN B-AdverseReaction B-AdverseReaction
22 NN O O
1 NN O O
15 NN O O
0 NN O O
Additional NN O O
adverse NN O O
reactions NN O O
occurring NN O O
at NN O O
an NN O O
overall NN O O
incidence NN O O
between NN O O
1 NN O O
% NN O O
and NN O O
60 NN O O
% NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
XALKORI NN O O
included NN O O
nausea NN B-AdverseReaction B-AdverseReaction
( NN O O
56 NN O O
% NN O O
) NN O O
, NN O O
decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
( NN O O
30 NN O O
% NN O O
) NN O O
, NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
( NN O O
29 NN O O
% NN O O
) NN O O
, NN O O
neuropathy NN B-AdverseReaction B-AdverseReaction
( NN O O
21 NN O O
% NN O O
; NN O O
which NN O O
included NN O O
gait NN B-AdverseReaction B-AdverseReaction
disturbance NN I-AdverseReaction I-AdverseReaction
hypoaesthesia NN B-AdverseReaction B-AdverseReaction
muscular NN B-AdverseReaction B-AdverseReaction
weakness NN I-AdverseReaction I-AdverseReaction
neuralgia NN B-AdverseReaction B-AdverseReaction
neuropathy NN B-AdverseReaction B-AdverseReaction
peripheral NN I-AdverseReaction I-AdverseReaction
paraesthesia NN B-AdverseReaction B-AdverseReaction
peripheral NN B-AdverseReaction B-AdverseReaction
sensory NN I-AdverseReaction I-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
polyneuropathy NN B-AdverseReaction B-AdverseReaction
sensory NN B-AdverseReaction B-AdverseReaction
disturbance NN I-AdverseReaction I-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
( NN O O
11 NN O O
% NN O O
) NN O O
, NN O O
renal NN B-AdverseReaction B-AdverseReaction
cyst NN I-AdverseReaction I-AdverseReaction
( NN O O
5 NN O O
% NN O O
) NN O O
, NN O O
ILD NN B-AdverseReaction B-AdverseReaction
( NN O O
1 NN O O
% NN O O
; NN O O
ILD NN B-AdverseReaction B-AdverseReaction
pneumonitis NN B-AdverseReaction B-AdverseReaction
and NN O O
syncope NN B-AdverseReaction B-AdverseReaction
( NN O O
1 NN O O
% NN O O
) NN O O
. NN O O
Table NN O O
4 NN O O
. NN O O
Summary NN O O
of NN O O
Treatment NN O O
- NN O O
Emergent NN O O
Laboratory NN O O
Abnormalities NN O O
with NN O O
Grade NN O O
3 NN O O
or NN O O
4 NN O O
Incidence NN O O
of NN O O
>=4 NN O O
% NN O O
in NN O O
XALKORI NN O O
- NN O O
Treated NN O O
Patients NN O O
in NN O O
Study NN O O
1 NN O O
Laboratory NN O O
Abnormality NN O O
XALKORI NN O O
Chemotherapy NN O O
Any NN O O
Grade( NN O O
% NN O O
) NN O O
Grade NN O O
3/4( NN O O
% NN O O
) NN O O
Any NN O O
Grade( NN O O
% NN O O
) NN O O
Grade NN O O
3/4( NN O O
% NN O O
) NN O O
Hematology NN O O
Neutropenia NN B-AdverseReaction B-AdverseReaction
52 NN O O
11 NN O O
59 NN O O
16 NN O O
Lymphopenia NN B-AdverseReaction B-AdverseReaction
48 NN O O
7 NN O O
53 NN O O
13 NN O O
Chemistry NN O O
ALT NN B-AdverseReaction B-AdverseReaction
elevation NN I-AdverseReaction I-AdverseReaction
79 NN O O
15 NN O O
33 NN O O
2 NN O O
AST NN B-AdverseReaction B-AdverseReaction
elevation NN I-AdverseReaction I-AdverseReaction
66 NN O O
8 NN O O
28 NN O O
1 NN O O
Hypophosphatemia NN B-AdverseReaction B-AdverseReaction
32 NN O O
10 NN O O
21 NN O O
6 NN O O
Previously NN O O
Treated NN O O
ALK NN O O
- NN O O
Positive NN O O
Metastatic NN O O
NSCLC NN O O
- NN O O
Study NN O O
2 NN O O
The NN O O
data NN O O
in NN O O
Table NN O O
5 NN O O
are NN O O
derived NN O O
from NN O O
343 NN O O
patients NN O O
with NN O O
ALK NN O O
- NN O O
positive NN O O
metastatic NN O O
NSCLC NN O O
enrolled NN O O
in NN O O
a NN O O
randomized NN O O
, NN O O
multicenter NN O O
, NN O O
active NN O O
- NN O O
controlled NN O O
, NN O O
open NN O O
- NN O O
label NN O O
trial NN O O
( NN O O
Study NN O O
2 NN O O
) NN O O
. NN O O
Patients NN O O
in NN O O
the NN O O
XALKORI NN O O
arm NN O O
( NN O O
n=172 NN O O
) NN O O
received NN O O
XALKORI NN O O
250 NN O O
mg NN O O
orally NN O O
twice NN O O
daily NN O O
until NN O O
documented NN O O
disease NN O O
progression NN O O
, NN O O
intolerance NN O O
to NN O O
therapy NN O O
, NN O O
or NN O O
the NN O O
investigator NN O O
determined NN O O
that NN O O
the NN O O
patient NN O O
was NN O O
no NN O O
longer NN O O
experiencing NN O O
clinical NN O O
benefit NN O O
. NN O O
A NN O O
total NN O O
of NN O O
171 NN O O
patients NN O O
in NN O O
the NN O O
chemotherapy NN O O
arm NN O O
received NN O O
pemetrexed NN O O
500 NN O O
mg/m NN O O
2 NN O O
( NN O O
n=99 NN O O
) NN O O
or NN O O
docetaxel NN O O
75 NN O O
mg/m NN O O
2 NN O O
( NN O O
n=72 NN O O
) NN O O
by NN O O
intravenous NN O O
infusion NN O O
every NN O O
three NN O O
weeks NN O O
until NN O O
documented NN O O
disease NN O O
progression NN O O
, NN O O
intolerance NN O O
to NN O O
therapy NN O O
, NN O O
or NN O O
the NN O O
investigator NN O O
determined NN O O
that NN O O
the NN O O
patient NN O O
was NN O O
no NN O O
longer NN O O
experiencing NN O O
clinical NN O O
benefit NN O O
. NN O O
Patients NN O O
in NN O O
the NN O O
chemotherapy NN O O
arm NN O O
received NN O O
pemetrexed NN O O
unless NN O O
they NN O O
had NN O O
received NN O O
pemetrexed NN O O
as NN O O
part NN O O
of NN O O
first NN O O
- NN O O
line NN O O
or NN O O
maintenance NN O O
treatment NN O O
. NN O O
The NN O O
median NN O O
duration NN O O
of NN O O
study NN O O
treatment NN O O
was NN O O
7.1 NN O O
months NN O O
for NN O O
patients NN O O
who NN O O
received NN O O
XALKORI NN O O
and NN O O
2.8 NN O O
months NN O O
for NN O O
patients NN O O
who NN O O
received NN O O
chemotherapy NN O O
. NN O O
Across NN O O
the NN O O
347 NN O O
patients NN O O
who NN O O
were NN O O
randomized NN O O
to NN O O
study NN O O
treatment NN O O
( NN O O
343 NN O O
received NN O O
at NN O O
least NN O O
one NN O O
dose NN O O
of NN O O
study NN O O
treatment NN O O
) NN O O
, NN O O
the NN O O
median NN O O
age NN O O
was NN O O
50 NN O O
years NN O O
; NN O O
14 NN O O
% NN O O
of NN O O
patients NN O O
were NN O O
older NN O O
than NN O O
65 NN O O
years NN O O
. NN O O
A NN O O
total NN O O
of NN O O
56 NN O O
% NN O O
of NN O O
patients NN O O
were NN O O
female NN O O
and NN O O
45 NN O O
% NN O O
of NN O O
patients NN O O
were NN O O
Asian NN O O
. NN O O
Serious NN O O
adverse NN O O
reactions NN O O
were NN O O
reported NN O O
in NN O O
64 NN O O
patients NN O O
( NN O O
37.2 NN O O
% NN O O
) NN O O
treated NN O O
with NN O O
XALKORI NN O O
and NN O O
40 NN O O
patients NN O O
( NN O O
23.4 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
chemotherapy NN O O
arm NN O O
. NN O O
The NN O O
most NN O O
frequent NN O O
serious NN O O
adverse NN O O
reactions NN O O
reported NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
XALKORI NN O O
were NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
( NN O O
4.1 NN O O
% NN O O
) NN O O
, NN O O
pulmonary NN B-AdverseReaction B-AdverseReaction
embolism NN I-AdverseReaction I-AdverseReaction
( NN O O
3.5 NN O O
% NN O O
) NN O O
, NN O O
dyspnea NN B-AdverseReaction B-AdverseReaction
( NN O O
2.3 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
ILD NN B-AdverseReaction B-AdverseReaction
( NN O O
2.9 NN O O
% NN O O
) NN O O
. NN O O
Fatal NN B-AdverseReaction B-AdverseReaction
adverse NN O O
reactions NN O O
in NN O O
XALKORI NN O O
- NN O O
treated NN O O
patients NN O O
in NN O O
Study NN O O
2 NN O O
occurred NN O O
in NN O O
9 NN O O
( NN O O
5 NN O O
% NN O O
) NN O O
patients NN O O
, NN O O
consisting NN O O
of NN O O
: NN O O
acute NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
distress NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
arrhythmia NN B-AdverseReaction B-AdverseReaction
dyspnea NN B-AdverseReaction B-AdverseReaction
pneumonia NN B-AdverseReaction B-AdverseReaction
pneumonitis NN B-AdverseReaction B-AdverseReaction
pulmonary NN B-AdverseReaction B-AdverseReaction
embolism NN I-AdverseReaction I-AdverseReaction
ILD NN B-AdverseReaction B-AdverseReaction
respiratory NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
and NN O O
sepsis NN B-AdverseReaction B-AdverseReaction
Dose NN O O
reductions NN O O
due NN O O
to NN O O
adverse NN O O
reactions NN O O
were NN O O
required NN O O
in NN O O
16 NN O O
% NN O O
of NN O O
XALKORI NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
The NN O O
most NN O O
frequent NN O O
adverse NN O O
reactions NN O O
that NN O O
led NN O O
to NN O O
dose NN O O
reduction NN O O
in NN O O
the NN O O
patients NN O O
treated NN O O
with NN O O
XALKORI NN O O
were NN O O
alanine NN O O
aminotransferase NN O O
( NN O O
ALT NN O O
) NN O O
elevation NN O O
( NN O O
7.6 NN O O
% NN O O
) NN O O
including NN O O
some NN O O
patients NN O O
with NN O O
concurrent NN O O
aspartate NN O O
aminotransferase NN O O
( NN O O
AST NN O O
) NN O O
elevation NN O O
, NN O O
QTc NN B-AdverseReaction B-AdverseReaction
prolongation NN I-AdverseReaction I-AdverseReaction
( NN O O
2.9 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
( NN O O
2.3 NN O O
% NN O O
) NN O O
. NN O O
XALKORI NN O O
was NN O O
discontinued NN O O
for NN O O
adverse NN O O
reactions NN O O
in NN O O
15 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
The NN O O
most NN O O
frequent NN O O
adverse NN O O
reactions NN O O
that NN O O
led NN O O
to NN O O
discontinuation NN O O
of NN O O
XALKORI NN O O
were NN O O
ILD NN B-AdverseReaction B-AdverseReaction
( NN O O
1.7 NN O O
% NN O O
) NN O O
, NN O O
ALT NN O O
and NN O O
AST NN B-AdverseReaction B-AdverseReaction
elevation NN I-AdverseReaction I-AdverseReaction
( NN O O
1.2 NN O O
% NN O O
) NN O O
, NN O O
dyspnea NN B-AdverseReaction B-AdverseReaction
( NN O O
1.2 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
pulmonary NN B-AdverseReaction B-AdverseReaction
embolism NN I-AdverseReaction I-AdverseReaction
( NN O O
1.2 NN O O
% NN O O
) NN O O
. NN O O
Tables NN O O
5 NN O O
and NN O O
6 NN O O
summarize NN O O
common NN O O
adverse NN O O
reactions NN O O
and NN O O
laboratory NN O O
abnormalities NN O O
in NN O O
XALKORI NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Table NN O O
5 NN O O
. NN O O
Adverse NN O O
Reactions NN O O
Reported NN O O
at NN O O
a NN O O
Higher NN O O
Incidence NN O O
( NN O O
>=5 NN O O
% NN O O
Higher NN O O
for NN O O
All NN O O
Grades NN O O
or NN O O
>=2 NN O O
% NN O O
Higher NN O O
for NN O O
Grades NN O O
3/4 NN O O
) NN O O
with NN O O
XALKORI NN O O
than NN O O
Chemotherapy NN O O
in NN O O
Study NN O O
2 NN O O
Adverse NN O O
Reaction NN O O
XALKORI(N=172 NN O O
) NN O O
Chemotherapy NN O O
( NN O O
Pemetrexed NN O O
or NN O O
Docetaxel)(N=171 NN O O
) NN O O
All NN O O
Grades( NN O O
% NN O O
) NN O O
Grade NN O O
3/4( NN O O
% NN O O
) NN O O
All NN O O
Grades( NN O O
% NN O O
) NN O O
Grade NN O O
3/4( NN O O
% NN O O
) NN O O
Includes NN O O
cases NN O O
reported NN O O
within NN O O
the NN O O
clustered NN O O
terms NN O O
: NN O O
Nervous NN O O
System NN O O
Disorder NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
22 NN O O
1 NN O O
8 NN O O
0 NN O O
Dysgeusia NN B-AdverseReaction B-AdverseReaction
26 NN O O
0 NN O O
9 NN O O
0 NN O O
Syncope NN B-AdverseReaction B-AdverseReaction
3 NN O O
3 NN O O
0 NN O O
0 NN O O
Eye NN O O
Disorders NN O O
Vision NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
60 NN O O
0 NN O O
9 NN O O
0 NN O O
Cardiac NN O O
Disorders NN O O
Electrocardiogram NN B-AdverseReaction B-AdverseReaction
QT NN I-AdverseReaction I-AdverseReaction
prolonged NN I-AdverseReaction I-AdverseReaction
5 NN O O
3 NN O O
0 NN O O
0 NN O O
Bradycardia NN B-AdverseReaction B-AdverseReaction
5 NN O O
0 NN O O
0 NN O O
0 NN O O
Investigations NN O O
Weight NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
10 NN O O
1 NN O O
4 NN O O
0 NN O O
Gastrointestinal NN O O
Disorders NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
47 NN O O
1 NN O O
18 NN O O
0 NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
55 NN O O
1 NN O O
37 NN O O
1 NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
60 NN O O
0 NN O O
19 NN O O
1 NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
42 NN O O
2 NN O O
23 NN O O
0 NN O O
Dyspepsia NN B-AdverseReaction B-AdverseReaction
8 NN O O
0 NN O O
3 NN O O
0 NN O O
Infections NN O O
and NN O O
Infestations NN O O
Upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
26 NN O O
0 NN O O
13 NN O O
1 NN O O
Respiratory NN O O
, NN O O
Thoracic NN O O
and NN O O
Mediastinal NN O O
Disorders NN O O
Pulmonary NN B-AdverseReaction B-AdverseReaction
embolism NN I-AdverseReaction I-AdverseReaction
6 NN O O
5 NN O O
2 NN O O
2 NN O O
General NN O O
Disorders NN O O
and NN O O
Administration NN O O
Site NN O O
Conditions NN O O
Edema NN B-AdverseReaction B-AdverseReaction
31 NN O O
0 NN O O
16 NN O O
0 NN O O
Additional NN O O
adverse NN O O
reactions NN O O
occurring NN O O
at NN O O
an NN O O
overall NN O O
incidence NN O O
between NN O O
1 NN O O
% NN O O
and NN O O
30 NN O O
% NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
XALKORI NN O O
included NN O O
( NN O O
% NN O O
) NN O O
, NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
( NN O O
27 NN O O
% NN O O
) NN O O
, NN O O
neuropathy NN B-AdverseReaction B-AdverseReaction
( NN O O
19 NN O O
% NN O O
; NN O O
dysesthesia NN B-AdverseReaction B-AdverseReaction
gait NN B-AdverseReaction B-AdverseReaction
disturbance NN I-AdverseReaction I-AdverseReaction
hypoesthesia NN B-AdverseReaction B-AdverseReaction
muscular NN B-AdverseReaction B-AdverseReaction
weakness NN I-AdverseReaction I-AdverseReaction
neuralgia NN B-AdverseReaction B-AdverseReaction
peripheral NN B-AdverseReaction B-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
parasthesia NN B-AdverseReaction B-AdverseReaction
peripheral NN B-AdverseReaction B-AdverseReaction
sensory NN I-AdverseReaction I-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
polyneuropathy NN B-AdverseReaction B-AdverseReaction
burning NN B-AdverseReaction B-AdverseReaction
sensation NN I-AdverseReaction I-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
skin NN I-AdverseReaction I-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
( NN O O
9 NN O O
% NN O O
) NN O O
, NN O O
ILD NN B-AdverseReaction B-AdverseReaction
( NN O O
4 NN O O
% NN O O
; NN O O
acute NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
distress NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
ILD NN B-AdverseReaction B-AdverseReaction
pneumonitis NN B-AdverseReaction B-AdverseReaction
renal NN B-AdverseReaction B-AdverseReaction
cyst NN I-AdverseReaction I-AdverseReaction
( NN O O
4 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
hepatic NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
( NN O O
1 NN O O
% NN O O
) NN O O
. NN O O
Table NN O O
6 NN O O
. NN O O
Summary NN O O
of NN O O
Treatment NN O O
- NN O O
Emergent NN O O
Laboratory NN O O
Abnormalities NN O O
with NN O O
Grade NN O O
3 NN O O
or NN O O
4 NN O O
Incidence NN O O
of NN O O
>=4 NN O O
% NN O O
in NN O O
XALKORI NN O O
- NN O O
Treated NN O O
Patients NN O O
in NN O O
Study NN O O
2 NN O O
Laboratory NN O O
Abnormality NN O O
XALKORI NN O O
Chemotherapy NN O O
Any NN O O
Grade( NN O O
% NN O O
) NN O O
Grade NN O O
3/4( NN O O
% NN O O
) NN O O
Any NN O O
Grade( NN O O
% NN O O
) NN O O
Grade NN O O
3/4( NN O O
% NN O O
) NN O O
Hematology NN O O
Neutropenia NN B-AdverseReaction B-AdverseReaction
49 NN O O
12 NN O O
28 NN O O
12 NN O O
Lymphopenia NN B-AdverseReaction B-AdverseReaction
51 NN O O
9 NN O O
60 NN O O
25 NN O O
Chemistry NN O O
ALT NN B-AdverseReaction B-AdverseReaction
elevation NN I-AdverseReaction I-AdverseReaction
76 NN O O
17 NN O O
38 NN O O
4 NN O O
AST NN B-AdverseReaction B-AdverseReaction
elevation NN I-AdverseReaction I-AdverseReaction
61 NN O O
9 NN O O
33 NN O O
0 NN O O
Hypokalemia NN B-AdverseReaction B-AdverseReaction
18 NN O O
4 NN O O
10 NN O O
1 NN O O
Hypophosphatemia NN B-AdverseReaction B-AdverseReaction
28 NN O O
5 NN O O
25 NN O O
6 NN O O
Description NN O O
of NN O O
Selected NN O O
Adverse NN O O
Drug NN O O
Reactions NN O O
Vision NN O O
disorders NN O O
Vision NN B-AdverseReaction B-AdverseReaction
disorders NN I-AdverseReaction I-AdverseReaction
most NN O O
commonly NN O O
visual NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
photopsia NN B-AdverseReaction B-AdverseReaction
blurred NN B-AdverseReaction B-AdverseReaction
vision NN I-AdverseReaction I-AdverseReaction
or NN O O
vitreous NN B-AdverseReaction B-AdverseReaction
floaters NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
1038 NN O O
( NN O O
62 NN O O
% NN O O
) NN O O
of NN O O
1669 NN O O
patients NN O O
. NN O O
The NN O O
majority NN O O
( NN O O
95 NN O O
% NN O O
) NN O O
of NN O O
these NN O O
patients NN O O
had NN O O
Grade NN B-Severity B-Severity
1 NN I-Severity I-Severity
visual NN B-AdverseReaction B-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
There NN O O
were NN O O
13 NN O O
( NN O O
0.8 NN O O
% NN O O
) NN O O
patients NN O O
with NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
and NN O O
4 NN O O
( NN O O
0.2 NN O O
% NN O O
) NN O O
patients NN O O
with NN O O
Grade NN B-Severity B-Severity
4 NN I-Severity I-Severity
visual NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
Based NN O O
on NN O O
the NN O O
Visual NN O O
Symptom NN O O
Assessment NN O O
Questionnaire NN O O
( NN O O
VSAQ NN O O
- NN O O
ALK NN O O
) NN O O
, NN O O
patients NN O O
treated NN O O
with NN O O
XALKORI NN O O
in NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
reported NN O O
a NN O O
higher NN O O
incidence NN O O
of NN O O
visual NN B-AdverseReaction B-AdverseReaction
disturbances NN I-AdverseReaction I-AdverseReaction
compared NN O O
to NN O O
patients NN O O
treated NN O O
with NN O O
chemotherapy NN O O
. NN O O
The NN O O
onset NN O O
of NN O O
vision NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
generally NN O O
was NN O O
within NN O O
the NN O O
first NN O O
week NN O O
of NN O O
drug NN O O
administration NN O O
. NN O O
The NN O O
majority NN O O
of NN O O
patients NN O O
on NN O O
the NN O O
XALKORI NN O O
arms NN O O
in NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
( NN O O
>50 NN O O
% NN O O
) NN O O
reported NN O O
visual NN B-AdverseReaction B-AdverseReaction
disturbances NN I-AdverseReaction I-AdverseReaction
which NN O O
occurred NN O O
at NN O O
a NN O O
frequency NN O O
of NN O O
4 NN O O
- NN O O
7 NN O O
days NN O O
each NN O O
week NN O O
, NN O O
lasted NN O O
up NN O O
to NN O O
1 NN O O
minute NN O O
, NN O O
and NN O O
had NN O O
mild NN O O
or NN O O
no NN O O
impact NN O O
( NN O O
scores NN O O
0 NN O O
to NN O O
3 NN O O
out NN O O
of NN O O
a NN O O
maximum NN O O
score NN O O
of NN O O
10 NN O O
) NN O O
on NN O O
daily NN O O
activities NN O O
as NN O O
captured NN O O
in NN O O
the NN O O
VSAQ NN O O
- NN O O
ALK NN O O
questionnaire NN O O
. NN O O
Neuropathy NN O O
Neuropathy NN B-AdverseReaction B-AdverseReaction
most NN O O
commonly NN O O
sensory NN O O
in NN O O
nature NN O O
, NN O O
occurred NN O O
in NN O O
419 NN O O
( NN O O
25 NN O O
% NN O O
) NN O O
of NN O O
1669 NN O O
patients NN O O
. NN O O
Most NN O O
events NN O O
( NN O O
95 NN O O
% NN O O
) NN O O
were NN O O
Grade NN O O
1 NN O O
or NN O O
Grade NN O O
2 NN O O
in NN O O
severity NN O O
. NN O O
Renal NN O O
Cysts NN O O
Renal NN B-AdverseReaction B-AdverseReaction
cysts NN I-AdverseReaction I-AdverseReaction
were NN O O
experienced NN O O
by NN O O
50 NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
of NN O O
1669 NN O O
patients NN O O
. NN O O
Renal NN B-AdverseReaction B-AdverseReaction
cysts NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
8 NN O O
( NN O O
5 NN O O
% NN O O
) NN O O
patients NN O O
treated NN O O
with NN O O
XALKORI NN O O
and NN O O
1 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
patient NN O O
treated NN O O
with NN O O
chemotherapy NN O O
in NN O O
Study NN O O
1 NN O O
. NN O O
Renal NN B-AdverseReaction B-AdverseReaction
cysts NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
8 NN O O
( NN O O
5 NN O O
% NN O O
) NN O O
patients NN O O
treated NN O O
with NN O O
XALKORI NN O O
and NN O O
1 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
patient NN O O
treated NN O O
with NN O O
chemotherapy NN O O
in NN O O
Study NN O O
2 NN O O
. NN O O
The NN O O
majority NN O O
of NN O O
renal NN B-AdverseReaction B-AdverseReaction
cysts NN I-AdverseReaction I-AdverseReaction
in NN O O
XALKORI NN O O
- NN O O
treated NN O O
patients NN O O
were NN O O
complex NN O O
. NN O O
Local NN B-AdverseReaction B-AdverseReaction
cystic NN I-AdverseReaction I-AdverseReaction
invasion NN I-AdverseReaction I-AdverseReaction
beyond NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
kidney NN I-AdverseReaction I-AdverseReaction
occurred NN O O
, NN O O
in NN O O
some NN O O
cases NN O O
with NN O O
imaging NN O O
characteristics NN O O
suggestive NN B-Factor B-Factor
of NN O O
abscess NN B-AdverseReaction B-AdverseReaction
formation NN O O
. NN O O
However NN O O
, NN O O
across NN O O
clinical NN O O
trials NN O O
no NN B-Negation B-Negation
renal NN B-AdverseReaction B-AdverseReaction
abscesses NN I-AdverseReaction I-AdverseReaction
were NN O O
confirmed NN O O
by NN O O
microbiology NN O O
tests NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Hepatotoxicity NN B-AdverseReaction B-AdverseReaction
Fatal NN B-AdverseReaction B-AdverseReaction
hepatotoxicity NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
0.1 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
Monitor NN O O
with NN O O
periodic NN O O
liver NN O O
testing NN O O
. NN O O
Temporarily NN O O
suspend NN O O
, NN O O
dose NN O O
reduce NN O O
, NN O O
or NN O O
permanently NN O O
discontinue NN O O
XALKORI. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Interstitial NN B-AdverseReaction B-AdverseReaction
Lung NN I-AdverseReaction I-AdverseReaction
Disease NN I-AdverseReaction I-AdverseReaction
( NN O O
ILD)/Pneumonitis NN O O
: NN O O
Occurred NN O O
in NN O O
2.9 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
Permanently NN O O
discontinue NN O O
in NN O O
patients NN O O
with NN O O
ILD/pneumonitis NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
QT NN B-AdverseReaction B-AdverseReaction
Interval NN I-AdverseReaction I-AdverseReaction
Prolongation NN I-AdverseReaction I-AdverseReaction
Occurred NN O O
in NN O O
2.1 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
Monitor NN O O
with NN O O
electrocardiograms NN O O
and NN O O
electrolytes NN O O
in NN O O
patients NN O O
who NN O O
have NN O O
a NN O O
history NN O O
of NN O O
or NN O O
predisposition NN O O
for NN O O
QTc NN O O
prolongation NN O O
, NN O O
or NN O O
who NN O O
are NN O O
taking NN O O
medications NN O O
that NN O O
prolong NN O O
QT. NN O O
Temporarily NN O O
suspend NN O O
, NN O O
dose NN O O
reduce NN O O
, NN O O
or NN O O
permanently NN O O
discontinue NN O O
XALKORI. NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Bradycardia NN B-AdverseReaction B-AdverseReaction
XALKORI NN O O
can NN B-Factor B-Factor
cause NN O O
bradycardia NN B-AdverseReaction B-AdverseReaction
Monitor NN O O
heart NN O O
rate NN O O
and NN O O
blood NN O O
pressure NN O O
regularly NN O O
. NN O O
Temporarily NN O O
suspend NN O O
, NN O O
dose NN O O
reduce NN O O
, NN O O
or NN O O
permanently NN O O
discontinue NN O O
XALKORI. NN O O
( NN O O
5.4 NN O O
) NN O O
* NN O O
Severe NN B-Severity B-Severity
Visual NN B-AdverseReaction B-AdverseReaction
Loss NN I-AdverseReaction I-AdverseReaction
Reported NN O O
in NN O O
0.2 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
Discontinue NN O O
XALKORI NN O O
in NN O O
patients NN O O
with NN O O
severe NN O O
visual NN O O
loss NN O O
. NN O O
Perform NN O O
an NN O O
ophthalmological NN O O
evaluation NN O O
. NN O O
( NN O O
5.5 NN O O
) NN O O
* NN O O
Embryofetal NN B-AdverseReaction B-AdverseReaction
Toxicity NN I-AdverseReaction I-AdverseReaction
Can NN B-Factor B-Factor
cause NN O O
fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
Advise NN O O
females NN O O
of NN O O
reproductive NN O O
potential NN O O
of NN O O
the NN O O
potential NN O O
risk NN O O
to NN O O
a NN O O
fetus NN O O
and NN O O
use NN O O
of NN O O
effective NN O O
contraception NN O O
. NN O O
( NN O O
5.6 NN O O
, NN O O
8.1 NN O O
, NN O O
8.3 NN O O
) NN O O
5.1 NN O O
Hepatotoxicity NN O O
Drug NN O O
- NN O O
induced NN O O
hepatotoxicity NN B-AdverseReaction B-AdverseReaction
with NN O O
fatal NN B-AdverseReaction B-AdverseReaction
outcome NN O O
occurred NN O O
in NN O O
2 NN O O
( NN O O
0.1 NN O O
% NN O O
) NN O O
of NN O O
the NN O O
1669 NN O O
patients NN O O
treated NN O O
with NN O O
XALKORI NN O O
across NN O O
clinical NN O O
trials NN O O
in NN O O
patients NN O O
with NN O O
NSCLC. NN O O
Concurrent NN O O
elevations NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
alanine NN I-AdverseReaction I-AdverseReaction
aminotransferase NN I-AdverseReaction I-AdverseReaction
( NN O O
ALT NN O O
) NN O O
or NN O O
aspartate NN O O
aminotransferase NN O O
( NN O O
AST NN O O
) NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
three NN B-Severity B-Severity
times NN I-Severity I-Severity
the NN I-Severity I-Severity
upper NN I-Severity I-Severity
limit NN I-Severity I-Severity
of NN I-Severity I-Severity
normal NN I-Severity I-Severity
( NN I-Severity I-Severity
ULN NN I-Severity I-Severity
) NN I-Severity I-Severity
and NN O O
total NN O O
bilirubin NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
two NN O O
times NN O O
the NN O O
ULN NN O O
, NN O O
with NN O O
normal NN O O
alkaline NN O O
phosphatase NN O O
, NN O O
occurred NN O O
in NN O O
10 NN O O
patients NN O O
( NN O O
0.6 NN O O
% NN O O
) NN O O
treated NN O O
with NN O O
XALKORI. NN O O
Additionally NN O O
, NN O O
elevations NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
ALT NN I-AdverseReaction I-AdverseReaction
or NN O O
AST NN O O
greater NN O O
than NN O O
five NN B-Severity B-Severity
times NN I-Severity I-Severity
the NN I-Severity I-Severity
ULN NN I-Severity I-Severity
occurred NN O O
in NN O O
184 NN O O
( NN O O
11 NN O O
% NN O O
) NN O O
and NN O O
93 NN O O
( NN O O
5.7 NN O O
% NN O O
) NN O O
patients NN O O
, NN O O
respectively NN O O
. NN O O
Seventeen NN O O
patients NN O O
( NN O O
1.0 NN O O
% NN O O
) NN O O
required NN O O
permanent NN O O
discontinuation NN O O
due NN O O
to NN O O
elevated NN B-AdverseReaction B-AdverseReaction
transaminases NN I-AdverseReaction I-AdverseReaction
Transaminase NN B-AdverseReaction B-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
generally NN O O
occurred NN O O
within NN O O
the NN O O
first NN O O
2 NN O O
months NN O O
of NN O O
treatment NN O O
. NN O O
Monitor NN O O
with NN O O
liver NN O O
function NN O O
tests NN O O
including NN O O
ALT NN O O
and NN O O
total NN O O
bilirubin NN O O
every NN O O
2 NN O O
weeks NN O O
during NN O O
the NN O O
first NN O O
2 NN O O
months NN O O
of NN O O
treatment NN O O
, NN O O
then NN O O
once NN O O
a NN O O
month NN O O
and NN O O
as NN O O
clinically NN O O
indicated NN O O
, NN O O
with NN O O
more NN O O
frequent NN O O
repeat NN O O
testing NN O O
for NN O O
increased NN O O
liver NN O O
transaminases NN O O
, NN O O
alkaline NN O O
phosphatase NN O O
, NN O O
or NN O O
total NN O O
bilirubin NN O O
in NN O O
patients NN O O
who NN O O
develop NN O O
transaminase NN O O
elevations NN O O
. NN O O
Temporarily NN O O
suspend NN O O
, NN O O
dose NN O O
reduce NN O O
, NN O O
or NN O O
permanently NN O O
discontinue NN O O
XALKORI NN O O
as NN O O
described NN O O
in NN O O
Table NN O O
2 NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
and NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
Interstitial NN O O
Lung NN O O
Disease NN O O
( NN O O
Pneumonitis NN O O
) NN O O
Severe NN B-Severity B-Severity
life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
or NN O O
fatal NN B-AdverseReaction B-AdverseReaction
interstitial NN B-AdverseReaction B-AdverseReaction
lung NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
( NN O O
ILD)/pneumonitis NN O O
can NN B-Factor B-Factor
occur NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
XALKORI. NN O O
Across NN O O
clinical NN O O
trials NN O O
( NN O O
n=1669 NN O O
) NN O O
, NN O O
49 NN O O
XALKORI NN O O
- NN O O
treated NN O O
patients NN O O
( NN O O
2.9 NN O O
% NN O O
) NN O O
had NN O O
ILD NN B-AdverseReaction B-AdverseReaction
of NN O O
any NN O O
grade NN O O
, NN O O
18 NN O O
patients NN O O
( NN O O
1.1 NN O O
% NN O O
) NN O O
had NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
or NN O O
4 NN O O
ILD NN B-AdverseReaction B-AdverseReaction
and NN O O
8 NN O O
patients NN O O
( NN O O
0.5 NN O O
% NN O O
) NN O O
had NN O O
fatal NN B-AdverseReaction B-AdverseReaction
ILD NN B-AdverseReaction B-AdverseReaction
These NN O O
cases NN O O
generally NN O O
occurred NN O O
within NN O O
3 NN O O
months NN O O
after NN O O
the NN O O
initiation NN O O
of NN O O
XALKORI. NN O O
Monitor NN O O
patients NN O O
for NN O O
pulmonary NN O O
symptoms NN O O
indicative NN O O
of NN O O
ILD/pneumonitis NN O O
. NN O O
Exclude NN O O
other NN O O
potential NN O O
causes NN O O
of NN O O
ILD/pneumonitis NN O O
, NN O O
and NN O O
permanently NN O O
discontinue NN O O
XALKORI NN O O
in NN O O
patients NN O O
diagnosed NN O O
with NN O O
drug NN O O
- NN O O
related NN O O
ILD/pneumonitis NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
and NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
] NN O O
. NN O O
5.3 NN O O
QT NN O O
Interval NN O O
Prolongation NN O O
QTc NN B-AdverseReaction B-AdverseReaction
prolongation NN I-AdverseReaction I-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
XALKORI. NN O O
Across NN O O
clinical NN O O
trials NN O O
, NN O O
32 NN O O
of NN O O
1560 NN O O
patients NN O O
( NN O O
2.1 NN O O
% NN O O
) NN O O
had NN O O
QTcF NN O O
( NN O O
corrected NN O O
QT NN O O
by NN O O
the NN O O
Fridericia NN O O
method NN O O
) NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
500 NN O O
ms NN O O
and NN O O
76 NN O O
of NN O O
1520 NN O O
patients NN O O
( NN O O
5.0 NN O O
% NN O O
) NN O O
had NN O O
an NN O O
increase NN O O
from NN O O
baseline NN O O
QTcF NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
60 NN B-Severity B-Severity
ms NN I-Severity I-Severity
by NN O O
automated NN O O
machine NN O O
- NN O O
read NN O O
evaluation NN O O
of NN O O
ECG. NN O O
Avoid NN O O
use NN O O
of NN O O
XALKORI NN O O
in NN O O
patients NN O O
with NN O O
congenital NN O O
long NN O O
QT NN O O
syndrome NN O O
. NN O O
Consider NN O O
periodic NN O O
monitoring NN O O
with NN O O
electrocardiograms NN O O
( NN O O
ECGs NN O O
) NN O O
and NN O O
electrolytes NN O O
in NN O O
patients NN O O
with NN O O
congestive NN O O
heart NN O O
failure NN O O
, NN O O
bradyarrhythmias NN O O
, NN O O
electrolyte NN O O
abnormalities NN O O
, NN O O
or NN O O
who NN O O
are NN O O
taking NN O O
medications NN O O
that NN O O
are NN O O
known NN O O
to NN O O
prolong NN O O
the NN O O
QT NN O O
interval NN O O
. NN O O
Permanently NN O O
discontinue NN O O
XALKORI NN O O
in NN O O
patients NN O O
who NN O O
develop NN O O
QTc NN O O
greater NN O O
than NN O O
500 NN O O
ms NN O O
or NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
60 NN O O
ms NN O O
change NN O O
from NN O O
baseline NN O O
with NN O O
Torsade NN O O
de NN O O
pointes NN O O
or NN O O
polymorphic NN O O
ventricular NN O O
tachycardia NN O O
or NN O O
signs/symptoms NN O O
of NN O O
serious NN O O
arrhythmia NN O O
. NN O O
Withhold NN O O
XALKORI NN O O
in NN O O
patients NN O O
who NN O O
develop NN O O
QTc NN O O
greater NN O O
than NN O O
500 NN O O
ms NN O O
on NN O O
at NN O O
least NN O O
2 NN O O
separate NN O O
ECGs NN O O
until NN O O
recovery NN O O
to NN O O
a NN O O
QTc NN O O
less NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
480 NN O O
ms NN O O
, NN O O
then NN O O
resume NN O O
XALKORI NN O O
at NN O O
a NN O O
reduced NN O O
dose NN O O
as NN O O
described NN O O
in NN O O
Table NN O O
2 NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
and NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.2 NN O O
) NN O O
] NN O O
. NN O O
5.4 NN O O
Bradycardia NN O O
Symptomatic NN B-AdverseReaction B-AdverseReaction
bradycardia NN I-AdverseReaction I-AdverseReaction
can NN O O
occur NN O O
in NN O O
patients NN O O
receiving NN O O
XALKORI. NN O O
Across NN O O
clinical NN O O
trials NN O O
, NN O O
bradycardia NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
205 NN O O
( NN O O
12.3 NN O O
% NN O O
) NN O O
of NN O O
1669 NN O O
patients NN O O
treated NN O O
with NN O O
XALKORI. NN O O
A NN O O
total NN O O
of NN O O
242 NN O O
( NN O O
14.9 NN O O
% NN O O
) NN O O
patients NN O O
had NN O O
a NN O O
heart NN B-AdverseReaction B-AdverseReaction
rate NN I-AdverseReaction I-AdverseReaction
less NN I-AdverseReaction I-AdverseReaction
than NN I-AdverseReaction I-AdverseReaction
50 NN I-AdverseReaction I-AdverseReaction
beats NN I-AdverseReaction I-AdverseReaction
per NN I-AdverseReaction I-AdverseReaction
minute NN I-AdverseReaction I-AdverseReaction
In NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
, NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
syncope NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
2.0 NN O O
% NN O O
of NN O O
XALKORI NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
in NN O O
0.6 NN O O
% NN O O
of NN O O
the NN O O
chemotherapy NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Avoid NN O O
using NN O O
XALKORI NN O O
in NN O O
combination NN O O
with NN O O
other NN O O
agents NN O O
known NN O O
to NN O O
cause NN O O
bradycardia NN O O
( NN O O
e.g. NN O O
, NN O O
beta NN O O
- NN O O
blockers NN O O
, NN O O
non NN O O
- NN O O
dihydropyridine NN O O
calcium NN O O
channel NN O O
blockers NN O O
, NN O O
clonidine NN O O
and NN O O
digoxin NN O O
) NN O O
to NN O O
the NN O O
extent NN O O
possible NN O O
. NN O O
Monitor NN O O
heart NN O O
rate NN O O
and NN O O
blood NN O O
pressure NN O O
regularly NN O O
. NN O O
In NN O O
cases NN O O
of NN O O
symptomatic NN O O
bradycardia NN O O
that NN O O
is NN O O
not NN O O
life NN O O
- NN O O
threatening NN O O
, NN O O
hold NN O O
XALKORI NN O O
until NN O O
recovery NN O O
to NN O O
asymptomatic NN O O
bradycardia NN O O
or NN O O
to NN O O
a NN O O
heart NN O O
rate NN O O
of NN O O
60 NN O O
bpm NN O O
or NN O O
above NN O O
, NN O O
re NN O O
- NN O O
evaluate NN O O
the NN O O
use NN O O
of NN O O
concomitant NN O O
medications NN O O
, NN O O
and NN O O
adjust NN O O
the NN O O
dose NN O O
of NN O O
XALKORI. NN O O
Permanently NN O O
discontinue NN O O
for NN O O
life NN O O
- NN O O
threatening NN O O
bradycardia NN O O
due NN O O
to NN O O
XALKORI NN O O
; NN O O
however NN O O
, NN O O
if NN O O
associated NN O O
with NN O O
concomitant NN O O
medications NN O O
known NN O O
to NN O O
cause NN O O
bradycardia NN O O
or NN O O
hypotension NN O O
, NN O O
hold NN O O
XALKORI NN O O
until NN O O
recovery NN O O
to NN O O
asymptomatic NN O O
bradycardia NN O O
or NN O O
to NN O O
a NN O O
heart NN O O
rate NN O O
of NN O O
60 NN O O
bpm NN O O
or NN O O
above NN O O
, NN O O
and NN O O
if NN O O
concomitant NN O O
medications NN O O
can NN O O
be NN O O
adjusted NN O O
or NN O O
discontinued NN O O
, NN O O
restart NN O O
XALKORI NN O O
at NN O O
250 NN O O
mg NN O O
once NN O O
daily NN O O
with NN O O
frequent NN O O
monitoring NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
and NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
] NN O O
. NN O O
5.5 NN O O
Severe NN O O
Visual NN O O
Loss NN O O
Across NN O O
all NN O O
clinical NN O O
trials NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
Grade NN B-Severity B-Severity
4 NN I-Severity I-Severity
visual NN B-AdverseReaction B-AdverseReaction
field NN I-AdverseReaction I-AdverseReaction
defect NN I-AdverseReaction I-AdverseReaction
with NN O O
vision NN B-AdverseReaction B-AdverseReaction
loss NN I-AdverseReaction I-AdverseReaction
was NN O O
0.2 NN O O
% NN O O
( NN O O
4/1669 NN O O
) NN O O
. NN O O
Optic NN B-AdverseReaction B-AdverseReaction
atrophy NN I-AdverseReaction I-AdverseReaction
and NN O O
optic NN B-AdverseReaction B-AdverseReaction
nerve NN I-AdverseReaction I-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
as NN O O
potential NN B-Factor B-Factor
causes NN O O
of NN O O
vision NN B-AdverseReaction B-AdverseReaction
loss NN I-AdverseReaction I-AdverseReaction
Discontinue NN O O
XALKORI NN O O
in NN O O
patients NN O O
with NN O O
new NN O O
onset NN O O
of NN O O
severe NN O O
visual NN O O
loss NN O O
( NN O O
best NN O O
corrected NN O O
vision NN O O
less NN O O
than NN O O
20/200 NN O O
in NN O O
one NN O O
or NN O O
both NN O O
eyes NN O O
) NN O O
. NN O O
Perform NN O O
an NN O O
ophthalmological NN O O
evaluation NN O O
consisting NN O O
of NN O O
best NN O O
corrected NN O O
visual NN O O
acuity NN O O
, NN O O
retinal NN O O
photographs NN O O
, NN O O
visual NN O O
fields NN O O
, NN O O
optical NN O O
coherence NN O O
tomography NN O O
( NN O O
OCT NN O O
) NN O O
and NN O O
other NN O O
evaluations NN O O
as NN O O
appropriate NN O O
for NN O O
new NN O O
onset NN O O
of NN O O
severe NN O O
visual NN O O
loss NN O O
. NN O O
There NN O O
is NN O O
insufficient NN O O
information NN O O
to NN O O
characterize NN O O
the NN O O
risks NN O O
of NN O O
resumption NN O O
of NN O O
XALKORI NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
severe NN O O
visual NN O O
loss NN O O
; NN O O
a NN O O
decision NN O O
to NN O O
resume NN O O
XALKORI NN O O
should NN O O
consider NN O O
the NN O O
potential NN O O
benefits NN O O
to NN O O
the NN O O
patient NN O O
. NN O O
5.6 NN O O
Embryofetal NN O O
Toxicity NN O O
Based NN O O
on NN O O
its NN O O
mechanism NN O O
of NN O O
action NN O O
, NN O O
XALKORI NN O O
can NN B-Factor B-Factor
cause NN O O
fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
when NN O O
administered NN O O
to NN O O
a NN O O
pregnant NN O O
woman NN O O
. NN O O
In NN O O
animal NN O O
reproduction NN O O
studies NN O O
, NN O O
oral NN O O
administration NN O O
of NN O O
crizotinib NN O O
in NN O O
pregnant NN O O
rats NN B-Animal B-Animal
during NN O O
organogenesis NN O O
at NN O O
exposures NN O O
similar NN O O
to NN O O
those NN O O
observed NN O O
with NN O O
the NN O O
maximum NN O O
recommended NN O O
human NN O O
dose NN O O
resulted NN O O
in NN O O
embryotoxicity NN B-AdverseReaction B-AdverseReaction
and NN O O
fetotoxicity NN B-AdverseReaction B-AdverseReaction
Advise NN O O
pregnant NN O O
women NN O O
of NN O O
the NN O O
potential NN O O
risk NN O O
to NN O O
a NN O O
fetus NN O O
. NN O O
Advise NN O O
females NN O O
of NN O O
reproductive NN O O
potential NN O O
to NN O O
use NN O O
effective NN O O
contraception NN O O
during NN O O
treatment NN O O
with NN O O
XALKORI NN O O
and NN O O
for NN O O
at NN O O
least NN O O
45 NN O O
days NN O O
following NN O O
the NN O O
final NN O O
dose NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.1 NN O O
, NN O O
8.3 NN O O
) NN O O
] NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
with NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
The NN O O
following NN O O
have NN O O
been NN O O
observed NN O O
with NN O O
BENLYSTA NN O O
and NN O O
are NN O O
discussed NN O O
in NN O O
detail NN O O
in NN O O
the NN O O
Warnings NN O O
and NN O O
Precautions NN O O
section NN O O
: NN O O
* NN O O
Mortality NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Serious NN B-Severity B-Severity
Infections NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
Malignancy NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
* NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
Anaphylaxis NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
* NN O O
Infusion NN B-AdverseReaction B-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
* NN O O
Depression NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.6 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
Common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=5 NN O O
% NN O O
) NN O O
in NN O O
clinical NN O O
trials NN O O
were NN O O
: NN O O
nausea NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
pyrexia NN B-AdverseReaction B-AdverseReaction
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
bronchitis NN B-AdverseReaction B-AdverseReaction
insomnia NN B-AdverseReaction B-AdverseReaction
pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
depression NN B-AdverseReaction B-AdverseReaction
migraine NN B-AdverseReaction B-AdverseReaction
and NN O O
pharyngitis NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
GlaxoSmithKline NN O O
at NN O O
1 NN O O
- NN O O
877 NN O O
- NN O O
423 NN O O
- NN O O
6597 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
The NN O O
data NN O O
described NN O O
below NN O O
reflect NN O O
exposure NN O O
to NN O O
BENLYSTA NN O O
plus NN O O
standard NN O O
of NN O O
care NN O O
compared NN O O
with NN O O
placebo NN O O
plus NN O O
standard NN O O
of NN O O
care NN O O
in NN O O
2,133 NN O O
patients NN O O
in NN O O
3 NN O O
controlled NN O O
trials NN O O
. NN O O
Patients NN O O
received NN O O
BENLYSTA NN O O
at NN O O
doses NN O O
of NN O O
1 NN O O
mg/kg NN O O
( NN O O
N NN O O
= NN O O
673 NN O O
) NN O O
, NN O O
4 NN O O
mg/kg NN O O
( NN O O
N NN O O
= NN O O
111 NN O O
; NN O O
Trial NN O O
1 NN O O
only NN O O
) NN O O
, NN O O
or NN O O
10 NN O O
mg/kg NN O O
( NN O O
N NN O O
= NN O O
674 NN O O
) NN O O
or NN O O
placebo NN O O
( NN O O
N NN O O
= NN O O
675 NN O O
) NN O O
intravenously NN O O
over NN O O
a NN O O
1-hour NN O O
period NN O O
on NN O O
Days NN O O
0 NN O O
, NN O O
14 NN O O
, NN O O
28 NN O O
, NN O O
and NN O O
then NN O O
every NN O O
28 NN O O
days NN O O
. NN O O
In NN O O
2 NN O O
of NN O O
the NN O O
trials NN O O
( NN O O
Trial NN O O
1 NN O O
and NN O O
Trial NN O O
3 NN O O
) NN O O
, NN O O
treatment NN O O
was NN O O
given NN O O
for NN O O
48 NN O O
weeks NN O O
, NN O O
while NN O O
in NN O O
the NN O O
other NN O O
trial NN O O
( NN O O
Trial NN O O
2 NN O O
) NN O O
treatment NN O O
was NN O O
given NN O O
for NN O O
72 NN O O
weeks NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
. NN O O
Because NN O O
there NN O O
was NN O O
no NN O O
apparent NN O O
dose NN O O
- NN O O
related NN O O
increase NN O O
in NN O O
the NN O O
majority NN O O
of NN O O
adverse NN O O
events NN O O
observed NN O O
with NN O O
BENLYSTA NN O O
, NN O O
the NN O O
safety NN O O
data NN O O
summarized NN O O
below NN O O
are NN O O
presented NN O O
for NN O O
the NN O O
3 NN O O
doses NN O O
pooled NN O O
, NN O O
unless NN O O
otherwise NN O O
indicated NN O O
; NN O O
the NN O O
adverse NN O O
reaction NN O O
table NN O O
displays NN O O
the NN O O
results NN O O
for NN O O
the NN O O
recommended NN O O
dose NN O O
of NN O O
10 NN O O
mg/kg NN O O
compared NN O O
with NN O O
placebo NN O O
. NN O O
The NN O O
population NN O O
had NN O O
a NN O O
mean NN O O
age NN O O
of NN O O
39 NN O O
( NN O O
range NN O O
: NN O O
18 NN O O
to NN O O
75 NN O O
) NN O O
, NN O O
94 NN O O
% NN O O
were NN O O
female NN O O
, NN O O
and NN O O
52 NN O O
% NN O O
were NN O O
Caucasian NN O O
. NN O O
In NN O O
these NN O O
trials NN O O
, NN O O
93 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
BENLYSTA NN O O
reported NN O O
an NN O O
adverse NN O O
reaction NN O O
compared NN O O
with NN O O
92 NN O O
% NN O O
treated NN O O
with NN O O
placebo NN O O
. NN O O
The NN O O
most NN O O
common NN O O
serious NN O O
adverse NN O O
reactions NN O O
were NN O O
serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
( NN O O
6.0 NN O O
% NN O O
and NN O O
5.2 NN O O
% NN O O
in NN O O
the NN O O
groups NN O O
receiving NN O O
BENLYSTA NN O O
and NN O O
placebo NN O O
, NN O O
respectively NN O O
) NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
most NN O O
commonly NN O O
- NN O O
reported NN O O
adverse NN O O
reactions NN O O
, NN O O
occurring NN O O
in NN O O
>=5 NN O O
% NN O O
of NN O O
patients NN O O
in NN O O
clinical NN O O
trials NN O O
were NN O O
nausea NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
pyrexia NN B-AdverseReaction B-AdverseReaction
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
bronchitis NN B-AdverseReaction B-AdverseReaction
insomnia NN B-AdverseReaction B-AdverseReaction
pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
depression NN B-AdverseReaction B-AdverseReaction
migraine NN B-AdverseReaction B-AdverseReaction
and NN O O
pharyngitis NN B-AdverseReaction B-AdverseReaction
The NN O O
proportion NN O O
of NN O O
patients NN O O
who NN O O
discontinued NN O O
treatment NN O O
due NN O O
to NN O O
any NN O O
adverse NN O O
reaction NN O O
during NN O O
the NN O O
controlled NN O O
clinical NN O O
trials NN O O
was NN O O
6.2 NN O O
% NN O O
for NN O O
patients NN O O
receiving NN O O
BENLYSTA NN O O
and NN O O
7.1 NN O O
% NN O O
for NN O O
patients NN O O
receiving NN O O
placebo NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
resulting NN O O
in NN O O
discontinuation NN O O
of NN O O
treatment NN O O
( NN O O
>=1 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
BENLYSTA NN O O
or NN O O
placebo NN O O
) NN O O
were NN O O
infusion NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
( NN O O
1.6 NN O O
% NN O O
BENLYSTA NN O O
and NN O O
0.9 NN O O
% NN O O
placebo NN O O
) NN O O
, NN O O
lupus NN B-AdverseReaction B-AdverseReaction
nephritis NN I-AdverseReaction I-AdverseReaction
( NN O O
0.7 NN O O
% NN O O
BENLYSTA NN O O
and NN O O
1.2 NN O O
% NN O O
placebo NN O O
) NN O O
, NN O O
and NN O O
infections NN B-AdverseReaction B-AdverseReaction
( NN O O
0.7 NN O O
% NN O O
BENLYSTA NN O O
and NN O O
1.0 NN O O
% NN O O
placebo NN O O
) NN O O
. NN O O
Table NN O O
1 NN O O
lists NN O O
adverse NN O O
reactions NN O O
, NN O O
regardless NN O O
of NN O O
causality NN O O
, NN O O
occurring NN O O
in NN O O
at NN O O
least NN O O
3 NN O O
% NN O O
of NN O O
patients NN O O
with NN O O
SLE NN O O
who NN O O
received NN O O
BENLYSTA NN O O
10 NN O O
mg/kg NN O O
and NN O O
at NN O O
an NN O O
incidence NN O O
at NN O O
least NN O O
1 NN O O
% NN O O
greater NN O O
than NN O O
that NN O O
observed NN O O
with NN O O
placebo NN O O
in NN O O
the NN O O
3 NN O O
controlled NN O O
studies NN O O
. NN O O
Table NN O O
1 NN O O
. NN O O
Incidence NN O O
of NN O O
Adverse NN O O
Reactions NN O O
occurring NN O O
in NN O O
at NN O O
Least NN O O
3 NN O O
% NN O O
of NN O O
Patients NN O O
Treated NN O O
with NN O O
BENLYSTA NN O O
10 NN O O
mg/kg NN O O
plus NN O O
Standard NN O O
of NN O O
Care NN O O
and NN O O
at NN O O
Least NN O O
1 NN O O
% NN O O
More NN O O
Frequently NN O O
than NN O O
in NN O O
Patients NN O O
receiving NN O O
Placebo NN O O
plus NN O O
Standard NN O O
of NN O O
Care NN O O
in NN O O
3 NN O O
Controlled NN O O
SLE NN O O
Studies NN O O
Preferred NN O O
Term NN O O
BENLYSTA NN O O
10 NN O O
mg/kg NN O O
+ NN O O
Standard NN O O
of NN O O
Care(n NN O O
= NN O O
674 NN O O
) NN O O
% NN O O
Placebo NN O O
+ NN O O
Standard NN O O
of NN O O
Care(n NN O O
= NN O O
675 NN O O
) NN O O
% NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
15 NN O O
12 NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
12 NN O O
9 NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
10 NN O O
8 NN O O
Nasopharyngitis NN B-AdverseReaction B-AdverseReaction
9 NN O O
7 NN O O
Bronchitis NN B-AdverseReaction B-AdverseReaction
9 NN O O
5 NN O O
Insomnia NN B-AdverseReaction B-AdverseReaction
7 NN O O
5 NN O O
Pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
6 NN O O
4 NN O O
Depression NN B-AdverseReaction B-AdverseReaction
5 NN O O
4 NN O O
Migraine NN B-AdverseReaction B-AdverseReaction
5 NN O O
4 NN O O
Pharyngitis NN B-AdverseReaction B-AdverseReaction
5 NN O O
3 NN O O
Cystitis NN B-AdverseReaction B-AdverseReaction
4 NN O O
3 NN O O
Leukopenia NN B-AdverseReaction B-AdverseReaction
4 NN O O
2 NN O O
Gastroenteritis NN B-AdverseReaction B-AdverseReaction
viral NN I-AdverseReaction I-AdverseReaction
3 NN O O
1 NN O O
6.2 NN O O
Immunogenicity NN O O
In NN O O
Trials NN O O
2 NN O O
and NN O O
3 NN O O
, NN O O
anti NN O O
- NN O O
belimumab NN O O
antibodies NN O O
were NN O O
detected NN O O
in NN O O
4 NN O O
of NN O O
563 NN O O
( NN O O
0.7 NN O O
% NN O O
) NN O O
patients NN O O
receiving NN O O
BENLYSTA NN O O
10 NN O O
mg/kg NN O O
and NN O O
in NN O O
27 NN O O
of NN O O
559 NN O O
( NN O O
4.8 NN O O
% NN O O
) NN O O
patients NN O O
receiving NN O O
BENLYSTA NN O O
1 NN O O
mg/kg NN O O
. NN O O
The NN O O
reported NN O O
frequency NN O O
for NN O O
the NN O O
group NN O O
receiving NN O O
10 NN O O
mg/kg NN O O
may NN O O
underestimate NN O O
the NN O O
actual NN O O
frequency NN O O
due NN O O
to NN O O
lower NN O O
assay NN O O
sensitivity NN O O
in NN O O
the NN O O
presence NN O O
of NN O O
high NN O O
drug NN O O
concentrations NN O O
. NN O O
Neutralizing NN O O
antibodies NN O O
were NN O O
detected NN O O
in NN O O
3 NN O O
patients NN O O
receiving NN O O
BENLYSTA NN O O
1 NN O O
mg/kg NN O O
. NN O O
Three NN O O
patients NN O O
with NN O O
anti NN O O
- NN O O
belimumab NN O O
antibodies NN O O
experienced NN O O
mild NN B-Severity B-Severity
infusion NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
of NN O O
nausea NN B-AdverseReaction B-AdverseReaction
erythematous NN B-AdverseReaction B-AdverseReaction
rash NN I-AdverseReaction I-AdverseReaction
pruritus NN B-AdverseReaction B-AdverseReaction
eyelid NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
and NN O O
dyspnea NN B-AdverseReaction B-AdverseReaction
none NN O O
of NN O O
the NN O O
reactions NN O O
was NN O O
life NN O O
- NN O O
threatening NN O O
. NN O O
The NN O O
clinical NN O O
relevance NN O O
of NN O O
the NN O O
presence NN O O
of NN O O
anti NN O O
- NN O O
belimumab NN O O
antibodies NN O O
is NN O O
not NN O O
known NN O O
. NN O O
The NN O O
data NN O O
reflect NN O O
the NN O O
percentage NN O O
of NN O O
patients NN O O
whose NN O O
test NN O O
results NN O O
were NN O O
positive NN O O
for NN O O
antibodies NN O O
to NN O O
belimumab NN O O
in NN O O
specific NN O O
assays NN O O
. NN O O
The NN O O
observed NN O O
incidence NN O O
of NN O O
antibody NN O O
positivity NN O O
in NN O O
an NN O O
assay NN O O
is NN O O
highly NN O O
dependent NN O O
on NN O O
several NN O O
factors NN O O
, NN O O
including NN O O
assay NN O O
sensitivity NN O O
and NN O O
specificity NN O O
, NN O O
assay NN O O
methodology NN O O
, NN O O
sample NN O O
handling NN O O
, NN O O
timing NN O O
of NN O O
sample NN O O
collection NN O O
, NN O O
concomitant NN O O
medications NN O O
, NN O O
and NN O O
underlying NN O O
disease NN O O
. NN O O
For NN O O
these NN O O
reasons NN O O
, NN O O
comparison NN O O
of NN O O
the NN O O
incidence NN O O
of NN O O
antibodies NN O O
to NN O O
belimumab NN O O
with NN O O
the NN O O
incidence NN O O
of NN O O
antibodies NN O O
to NN O O
other NN O O
products NN O O
may NN O O
be NN O O
misleading NN O O
. NN O O
6.3 NN O O
Postmarketing NN O O
Experience NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
identified NN O O
during NN O O
postapproval NN O O
use NN O O
of NN O O
BENLYSTA. NN O O
Because NN O O
these NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
* NN O O
Fatal NN B-AdverseReaction B-AdverseReaction
anaphylaxis NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Mortality NN B-AdverseReaction B-AdverseReaction
There NN O O
were NN O O
more NN O O
deaths NN B-AdverseReaction B-AdverseReaction
reported NN O O
with NN O O
BENLYSTA NN O O
than NN O O
with NN O O
placebo NN O O
during NN O O
the NN O O
controlled NN O O
period NN O O
of NN O O
clinical NN O O
trials NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Serious NN B-Severity B-Severity
Infections NN B-AdverseReaction B-AdverseReaction
Serious NN B-Severity B-Severity
and NN O O
sometimes NN O O
fatal NN B-AdverseReaction B-AdverseReaction
infections NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
receiving NN O O
immunosuppressive NN O O
agents NN O O
, NN O O
including NN O O
BENLYSTA. NN O O
Use NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
with NN O O
chronic NN O O
infections NN O O
. NN O O
Consider NN O O
interrupting NN O O
therapy NN O O
with NN O O
BENLYSTA NN O O
if NN O O
patients NN O O
develop NN O O
a NN O O
new NN O O
infection NN O O
during NN O O
treatment NN O O
with NN O O
BENLYSTA. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Progressive NN B-AdverseReaction B-AdverseReaction
Multifocal NN I-AdverseReaction I-AdverseReaction
Leukoencephalopathy NN I-AdverseReaction I-AdverseReaction
( NN O O
PML NN O O
) NN O O
: NN O O
Patients NN O O
presenting NN O O
with NN O O
new NN O O
- NN O O
onset NN O O
or NN O O
deteriorating NN O O
neurological NN O O
signs NN O O
and NN O O
symptoms NN O O
should NN O O
be NN O O
evaluated NN O O
for NN O O
PML NN O O
by NN O O
an NN O O
appropriate NN O O
specialist NN O O
. NN O O
If NN O O
PML NN O O
is NN O O
confirmed NN O O
, NN O O
consider NN O O
discontinuation NN O O
of NN O O
immunosuppressant NN O O
therapy NN O O
, NN O O
including NN O O
BENLYSTA. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
Anaphylaxis NN B-AdverseReaction B-AdverseReaction
Serious NN B-Severity B-Severity
and NN O O
fatal NN B-AdverseReaction B-AdverseReaction
reactions NN O O
have NN O O
been NN O O
reported NN O O
. NN O O
BENLYSTA NN O O
should NN O O
be NN O O
administered NN O O
by NN O O
healthcare NN O O
providers NN O O
prepared NN O O
to NN O O
manage NN O O
anaphylaxis NN O O
. NN O O
Monitor NN O O
patients NN O O
during NN O O
and NN O O
for NN O O
an NN O O
appropriate NN O O
period NN O O
of NN O O
time NN O O
after NN O O
administration NN O O
of NN O O
BENLYSTA. NN O O
( NN O O
2.2 NN O O
, NN O O
5.4 NN O O
) NN O O
* NN O O
Depression NN B-AdverseReaction B-AdverseReaction
Depression NN B-AdverseReaction B-AdverseReaction
and NN O O
suicidality NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
trials NN O O
with NN O O
BENLYSTA. NN O O
Patients NN O O
should NN O O
be NN O O
instructed NN O O
to NN O O
contact NN O O
their NN O O
healthcare NN O O
provider NN O O
if NN O O
they NN O O
experience NN O O
new NN O O
or NN O O
worsening NN O O
depression NN O O
, NN O O
suicidal NN O O
thoughts NN O O
or NN O O
other NN O O
mood NN O O
changes NN O O
. NN O O
( NN O O
5.6 NN O O
) NN O O
* NN O O
Immunization NN O O
: NN O O
Live NN O O
vaccines NN O O
should NN O O
not NN O O
be NN O O
given NN O O
concurrently NN O O
with NN O O
BENLYSTA. NN O O
( NN O O
5.7 NN O O
) NN O O
5.1 NN O O
Mortality NN O O
There NN O O
were NN O O
more NN O O
deaths NN B-AdverseReaction B-AdverseReaction
reported NN O O
with NN O O
BENLYSTA NN O O
than NN O O
with NN O O
placebo NN O O
during NN O O
the NN O O
controlled NN O O
period NN O O
of NN O O
the NN O O
clinical NN O O
trials NN O O
. NN O O
Out NN O O
of NN O O
2,133 NN O O
patients NN O O
in NN O O
3 NN O O
clinical NN O O
trials NN O O
, NN O O
a NN O O
total NN O O
of NN O O
14 NN O O
deaths NN B-AdverseReaction B-AdverseReaction
occurred NN O O
during NN O O
the NN O O
placebo NN O O
- NN O O
controlled NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
treatment NN O O
periods NN O O
: NN O O
3/675 NN O O
( NN O O
0.4 NN O O
% NN O O
) NN O O
, NN O O
5/673 NN O O
( NN O O
0.7 NN O O
% NN O O
) NN O O
, NN O O
0/111 NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
6/674 NN O O
( NN O O
0.9 NN O O
% NN O O
) NN O O
deaths NN B-AdverseReaction B-AdverseReaction
in NN O O
the NN O O
groups NN O O
receiving NN O O
placebo NN O O
, NN O O
BENLYSTA NN O O
1 NN O O
mg/kg NN O O
, NN O O
BENLYSTA NN O O
4 NN O O
mg/kg NN O O
, NN O O
and NN O O
BENLYSTA NN O O
10 NN O O
mg/kg NN O O
, NN O O
respectively NN O O
. NN O O
No NN O O
single NN O O
cause NN O O
of NN O O
death NN B-AdverseReaction B-AdverseReaction
predominated NN O O
. NN O O
Etiologies NN O O
included NN O O
infection NN B-AdverseReaction B-AdverseReaction
cardiovascular NN B-AdverseReaction B-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
and NN O O
suicide NN B-AdverseReaction B-AdverseReaction
5.2 NN O O
Serious NN O O
Infections NN O O
Serious NN B-Severity B-Severity
and NN O O
sometimes NN O O
fatal NN B-AdverseReaction B-AdverseReaction
infections NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
receiving NN O O
immunosuppressive NN O O
agents NN O O
, NN O O
including NN O O
BENLYSTA. NN O O
Physicians NN O O
should NN O O
exercise NN O O
caution NN O O
when NN O O
considering NN O O
the NN O O
use NN O O
of NN O O
BENLYSTA NN O O
in NN O O
patients NN O O
with NN O O
chronic NN O O
infections NN O O
. NN O O
Patients NN O O
receiving NN O O
any NN O O
therapy NN O O
for NN O O
chronic NN O O
infection NN O O
should NN O O
not NN O O
begin NN O O
therapy NN O O
with NN O O
BENLYSTA. NN O O
Consider NN O O
interrupting NN O O
therapy NN O O
with NN O O
BENLYSTA NN O O
in NN O O
patients NN O O
who NN O O
develop NN O O
a NN O O
new NN O O
infection NN O O
while NN O O
undergoing NN O O
treatment NN O O
with NN O O
BENLYSTA NN O O
and NN O O
monitor NN O O
these NN O O
patients NN O O
closely NN O O
. NN O O
In NN O O
the NN O O
controlled NN O O
clinical NN O O
trials NN O O
, NN O O
the NN O O
overall NN O O
incidence NN O O
of NN O O
infections NN B-AdverseReaction B-AdverseReaction
was NN O O
71 NN O O
% NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
BENLYSTA NN O O
compared NN O O
with NN O O
67 NN O O
% NN O O
in NN O O
patients NN O O
who NN O O
received NN O O
placebo NN O O
. NN O O
The NN O O
most NN O O
frequent NN O O
infections NN B-AdverseReaction B-AdverseReaction
( NN O O
>5 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
BENLYSTA NN O O
) NN O O
were NN O O
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
sinusitis NN B-AdverseReaction B-AdverseReaction
bronchitis NN B-AdverseReaction B-AdverseReaction
and NN O O
influenza NN B-AdverseReaction B-AdverseReaction
Serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
6.0 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
BENLYSTA NN O O
and NN O O
in NN O O
5.2 NN O O
% NN O O
of NN O O
patients NN O O
who NN O O
received NN O O
placebo NN O O
. NN O O
The NN O O
most NN O O
frequent NN O O
serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
included NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
cellulitis NN B-AdverseReaction B-AdverseReaction
and NN O O
bronchitis NN B-AdverseReaction B-AdverseReaction
Infections NN B-AdverseReaction B-AdverseReaction
leading NN O O
to NN O O
discontinuation NN O O
of NN O O
treatment NN O O
occurred NN O O
in NN O O
0.7 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
BENLYSTA NN O O
and NN O O
1.0 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
placebo NN O O
. NN O O
Infections NN B-AdverseReaction B-AdverseReaction
resulting NN O O
in NN O O
death NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
0.3 NN O O
% NN O O
( NN O O
4/1,458 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
BENLYSTA NN O O
and NN O O
in NN O O
0.1 NN O O
% NN O O
( NN O O
1/675 NN O O
) NN O O
of NN O O
patients NN O O
receiving NN O O
placebo NN O O
. NN O O
Progressive NN O O
Multifocal NN O O
Leukoencephalopathy NN O O
( NN O O
PML NN O O
) NN O O
Cases NN O O
of NN O O
JC NN B-AdverseReaction B-AdverseReaction
virus NN I-AdverseReaction I-AdverseReaction
PML NN B-AdverseReaction B-AdverseReaction
resulting NN O O
in NN O O
neurological NN B-AdverseReaction B-AdverseReaction
deficits NN I-AdverseReaction I-AdverseReaction
including NN O O
fatal NN B-AdverseReaction B-AdverseReaction
cases NN O O
, NN O O
have NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
with NN O O
SLE NN O O
receiving NN O O
immunosuppressants NN O O
, NN O O
including NN O O
BENLYSTA. NN O O
Risk NN O O
factors NN O O
for NN O O
PML NN O O
include NN O O
treatment NN O O
with NN O O
immunosuppressant NN O O
therapies NN O O
and NN O O
impairment NN O O
of NN O O
immune NN O O
function NN O O
. NN O O
Consider NN O O
the NN O O
diagnosis NN O O
of NN O O
PML NN O O
in NN O O
any NN O O
patient NN O O
presenting NN O O
with NN O O
new NN O O
- NN O O
onset NN O O
or NN O O
deteriorating NN O O
neurological NN O O
signs NN O O
and NN O O
symptoms NN O O
and NN O O
consult NN O O
with NN O O
a NN O O
neurologist NN O O
or NN O O
other NN O O
appropriate NN O O
specialist NN O O
as NN O O
clinically NN O O
indicated NN O O
. NN O O
In NN O O
patients NN O O
with NN O O
confirmed NN O O
PML NN O O
, NN O O
consider NN O O
stopping NN O O
immunosuppressant NN O O
therapy NN O O
, NN O O
including NN O O
BENLYSTA. NN O O
5.3 NN O O
Malignancy NN O O
The NN O O
impact NN O O
of NN O O
treatment NN O O
with NN O O
BENLYSTA NN O O
on NN O O
the NN O O
development NN O O
of NN O O
malignancies NN B-AdverseReaction B-AdverseReaction
is NN O O
not NN B-Factor B-Factor
known NN I-Factor I-Factor
In NN O O
the NN O O
controlled NN O O
clinical NN O O
trials NN O O
, NN O O
malignancies NN B-AdverseReaction B-AdverseReaction
( NN O O
including NN O O
non NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
melanoma NN I-AdverseReaction I-AdverseReaction
skin NN I-AdverseReaction I-AdverseReaction
cancers NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
in NN O O
0.4 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
BENLYSTA NN O O
and NN O O
0.4 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
placebo NN O O
. NN O O
In NN O O
the NN O O
controlled NN O O
clinical NN O O
trials NN O O
, NN O O
malignancies NN B-AdverseReaction B-AdverseReaction
excluding NN O O
non NN O O
- NN O O
melanoma NN O O
skin NN O O
cancers NN O O
, NN O O
were NN O O
observed NN O O
in NN O O
0.2 NN O O
% NN O O
( NN O O
3/1,458 NN O O
) NN O O
and NN O O
0.3 NN O O
% NN O O
( NN O O
2/675 NN O O
) NN O O
of NN O O
patients NN O O
receiving NN O O
BENLYSTA NN O O
and NN O O
placebo NN O O
, NN O O
respectively NN O O
. NN O O
The NN O O
mechanism NN O O
of NN O O
action NN O O
of NN O O
BENLYSTA NN O O
could NN O O
increase NN O O
the NN O O
risk NN B-Factor B-Factor
for NN O O
the NN O O
development NN O O
of NN O O
malignancies NN B-AdverseReaction B-AdverseReaction
5.4 NN O O
Hypersensitivity NN O O
Reactions NN O O
, NN O O
including NN O O
Anaphylaxis NN O O
Acute NN B-AdverseReaction B-AdverseReaction
hypersensitivity NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
and NN O O
death NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
association NN O O
with NN O O
BENLYSTA. NN O O
These NN O O
events NN O O
generally NN O O
occurred NN O O
within NN O O
hours NN O O
of NN O O
the NN O O
infusion NN O O
; NN O O
however NN O O
, NN O O
they NN O O
may NN O O
occur NN O O
later NN O O
. NN O O
Non NN O O
- NN O O
acute NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
rash NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
myalgia NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
and NN O O
facial NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
and NN O O
typically NN O O
occurred NN O O
up NN O O
to NN O O
a NN O O
week NN O O
following NN O O
the NN O O
most NN O O
recent NN O O
infusion NN O O
. NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
including NN O O
serious NN B-Severity B-Severity
reactions NN O O
, NN O O
has NN O O
occurred NN O O
in NN O O
patients NN O O
who NN O O
have NN O O
previously NN O O
tolerated NN O O
infusions NN O O
of NN O O
BENLYSTA. NN O O
Limited NN O O
data NN O O
suggest NN O O
that NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
multiple NN O O
drug NN O O
allergies NN O O
or NN O O
significant NN O O
hypersensitivity NN O O
may NN O O
be NN O O
at NN O O
increased NN O O
risk NN O O
. NN O O
In NN O O
the NN O O
controlled NN O O
clinical NN O O
trials NN O O
, NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
( NN O O
occurring NN O O
on NN O O
the NN O O
same NN O O
day NN O O
of NN O O
infusion NN O O
) NN O O
were NN O O
reported NN O O
in NN O O
13 NN O O
% NN O O
( NN O O
191/1,458 NN O O
) NN O O
of NN O O
patients NN O O
receiving NN O O
BENLYSTA NN O O
and NN O O
11 NN O O
% NN O O
( NN O O
76/675 NN O O
) NN O O
of NN O O
patients NN O O
receiving NN O O
placebo NN O O
. NN O O
Anaphylaxis NN B-AdverseReaction B-AdverseReaction
was NN O O
observed NN O O
in NN O O
0.6 NN O O
% NN O O
( NN O O
9/1,458 NN O O
) NN O O
of NN O O
patients NN O O
receiving NN O O
BENLYSTA NN O O
and NN O O
0.4 NN O O
% NN O O
( NN O O
3/675 NN O O
) NN O O
of NN O O
patients NN O O
receiving NN O O
placebo NN O O
. NN O O
Manifestations NN O O
included NN O O
hypotension NN B-AdverseReaction B-AdverseReaction
angioedema NN B-AdverseReaction B-AdverseReaction
urticaria NN B-AdverseReaction B-AdverseReaction
or NN O O
other NN O O
rash NN B-AdverseReaction B-AdverseReaction
pruritus NN B-AdverseReaction B-AdverseReaction
and NN O O
dyspnea NN B-AdverseReaction B-AdverseReaction
Due NN O O
to NN O O
overlap NN O O
in NN O O
signs NN O O
and NN O O
symptoms NN O O
, NN O O
it NN O O
was NN O O
not NN O O
possible NN O O
to NN O O
distinguish NN O O
between NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
and NN O O
infusion NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
in NN O O
all NN O O
cases NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
. NN O O
Some NN O O
patients NN O O
( NN O O
13 NN O O
% NN O O
) NN O O
received NN O O
premedication NN O O
, NN O O
which NN O O
may NN O O
have NN O O
mitigated NN O O
or NN O O
masked NN O O
a NN O O
hypersensitivity NN O O
response NN O O
; NN O O
however NN O O
, NN O O
there NN O O
is NN O O
insufficient NN O O
evidence NN O O
to NN O O
determine NN O O
whether NN O O
premedication NN O O
diminishes NN O O
the NN O O
frequency NN O O
or NN O O
severity NN O O
of NN O O
hypersensitivity NN O O
reactions NN O O
. NN O O
BENLYSTA NN O O
should NN O O
be NN O O
administered NN O O
by NN O O
healthcare NN O O
providers NN O O
prepared NN O O
to NN O O
manage NN O O
anaphylaxis NN O O
. NN O O
In NN O O
the NN O O
event NN O O
of NN O O
a NN O O
serious NN O O
reaction NN O O
, NN O O
administration NN O O
of NN O O
BENLYSTA NN O O
must NN O O
be NN O O
discontinued NN O O
immediately NN O O
and NN O O
appropriate NN O O
medical NN O O
therapy NN O O
administered NN O O
. NN O O
Patients NN O O
should NN O O
be NN O O
monitored NN O O
during NN O O
and NN O O
for NN O O
an NN O O
appropriate NN O O
period NN O O
of NN O O
time NN O O
after NN O O
administration NN O O
of NN O O
BENLYSTA. NN O O
Patients NN O O
should NN O O
be NN O O
informed NN O O
of NN O O
the NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
an NN O O
acute NN O O
hypersensitivity NN O O
reaction NN O O
and NN O O
be NN O O
instructed NN O O
to NN O O
seek NN O O
immediate NN O O
medical NN O O
care NN O O
should NN O O
a NN O O
reaction NN O O
occur NN O O
. NN O O
5.5 NN O O
Infusion NN O O
Reactions NN O O
In NN O O
the NN O O
controlled NN O O
clinical NN O O
trials NN O O
, NN O O
adverse NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
associated NN I-AdverseReaction I-AdverseReaction
with NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
infusion NN I-AdverseReaction I-AdverseReaction
( NN O O
occurring NN O O
on NN O O
the NN O O
same NN O O
day NN O O
of NN O O
the NN O O
infusion NN O O
) NN O O
were NN O O
reported NN O O
in NN O O
17 NN O O
% NN O O
( NN O O
251/1,458 NN O O
) NN O O
of NN O O
patients NN O O
receiving NN O O
BENLYSTA NN O O
and NN O O
15 NN O O
% NN O O
( NN O O
99/675 NN O O
) NN O O
of NN O O
patients NN O O
receiving NN O O
placebo NN O O
. NN O O
Serious NN B-Severity B-Severity
infusion NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
( NN O O
excluding NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
in NN O O
0.5 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
BENLYSTA NN O O
and NN O O
0.4 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
placebo NN O O
and NN O O
included NN O O
bradycardia NN B-AdverseReaction B-AdverseReaction
myalgia NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
urticaria NN B-AdverseReaction B-AdverseReaction
and NN O O
hypotension NN B-AdverseReaction B-AdverseReaction
The NN O O
most NN O O
common NN O O
infusion NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
( NN O O
>=3 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
BENLYSTA NN O O
) NN O O
were NN O O
headache NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
and NN O O
skin NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
Due NN O O
to NN O O
overlap NN O O
in NN O O
signs NN O O
and NN O O
symptoms NN O O
, NN O O
it NN O O
was NN O O
not NN O O
possible NN O O
to NN O O
distinguish NN O O
between NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
and NN O O
infusion NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
in NN O O
all NN O O
cases NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
. NN O O
Some NN O O
patients NN O O
( NN O O
13 NN O O
% NN O O
) NN O O
received NN O O
premedication NN O O
, NN O O
which NN O O
may NN O O
have NN O O
mitigated NN O O
or NN O O
masked NN O O
an NN O O
infusion NN O O
reaction NN O O
; NN O O
however NN O O
, NN O O
there NN O O
is NN O O
insufficient NN O O
evidence NN O O
to NN O O
determine NN O O
whether NN O O
premedication NN O O
diminishes NN O O
the NN O O
frequency NN O O
or NN O O
severity NN O O
of NN O O
infusion NN O O
reactions NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
BENLYSTA NN O O
should NN O O
be NN O O
administered NN O O
by NN O O
healthcare NN O O
providers NN O O
prepared NN O O
to NN O O
manage NN O O
infusion NN O O
reactions NN O O
. NN O O
The NN O O
infusion NN O O
rate NN O O
may NN O O
be NN O O
slowed NN O O
or NN O O
interrupted NN O O
if NN O O
the NN O O
patient NN O O
develops NN O O
an NN O O
infusion NN O O
reaction NN O O
. NN O O
Healthcare NN O O
providers NN O O
should NN O O
be NN O O
aware NN O O
of NN O O
the NN O O
risk NN O O
of NN O O
hypersensitivity NN O O
reactions NN O O
, NN O O
which NN O O
may NN O O
present NN O O
as NN O O
infusion NN O O
reactions NN O O
, NN O O
and NN O O
monitor NN O O
patients NN O O
closely NN O O
. NN O O
5.6 NN O O
Depression NN O O
In NN O O
the NN O O
controlled NN O O
clinical NN O O
trials NN O O
, NN O O
psychiatric NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
more NN O O
frequently NN O O
with NN O O
BENLYSTA NN O O
( NN O O
16 NN O O
% NN O O
) NN O O
than NN O O
with NN O O
placebo NN O O
( NN O O
12 NN O O
% NN O O
) NN O O
, NN O O
related NN O O
primarily NN O O
to NN O O
depression NN B-AdverseReaction B-AdverseReaction
events NN O O
( NN O O
6.3 NN O O
% NN O O
BENLYSTA NN O O
and NN O O
4.7 NN O O
% NN O O
placebo NN O O
) NN O O
, NN O O
insomnia NN B-AdverseReaction B-AdverseReaction
( NN O O
6.0 NN O O
% NN O O
BENLYSTA NN O O
and NN O O
5.3 NN O O
% NN O O
placebo NN O O
) NN O O
, NN O O
and NN O O
anxiety NN B-AdverseReaction B-AdverseReaction
( NN O O
3.9 NN O O
% NN O O
BENLYSTA NN O O
and NN O O
2.8 NN O O
% NN O O
placebo NN O O
) NN O O
. NN O O
Serious NN B-Severity B-Severity
psychiatric NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
in NN O O
0.8 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
BENLYSTA NN O O
( NN O O
0.6 NN O O
% NN O O
and NN O O
1.2 NN O O
% NN O O
with NN O O
1 NN O O
and NN O O
10 NN O O
mg/kg NN O O
, NN O O
respectively NN O O
) NN O O
and NN O O
0.4 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
placebo NN O O
. NN O O
Serious NN B-Severity B-Severity
depression NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
0.4 NN O O
% NN O O
( NN O O
6/1,458 NN O O
) NN O O
of NN O O
patients NN O O
receiving NN O O
BENLYSTA NN O O
and NN O O
0.1 NN O O
% NN O O
( NN O O
1/675 NN O O
) NN O O
of NN O O
patients NN O O
receiving NN O O
placebo NN O O
. NN O O
Two NN O O
suicides NN B-AdverseReaction B-AdverseReaction
( NN O O
0.1 NN O O
% NN O O
) NN O O
were NN O O
reported NN O O
in NN O O
patients NN O O
receiving NN O O
BENLYSTA. NN O O
The NN O O
majority NN O O
of NN O O
patients NN O O
who NN O O
reported NN O O
serious NN B-Severity B-Severity
depression NN B-AdverseReaction B-AdverseReaction
or NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
behavior NN I-AdverseReaction I-AdverseReaction
had NN O O
a NN O O
history NN O O
of NN O O
depression NN O O
or NN O O
other NN O O
serious NN O O
psychiatric NN O O
disorders NN O O
and NN O O
most NN O O
were NN O O
receiving NN O O
psychoactive NN O O
medications NN O O
. NN O O
It NN O O
is NN O O
unknown NN O O
if NN O O
treatment NN O O
with NN O O
BENLYSTA NN O O
is NN O O
associated NN O O
with NN O O
increased NN O O
risk NN O O
for NN O O
these NN O O
events NN O O
. NN O O
Patients NN O O
receiving NN O O
BENLYSTA NN O O
should NN O O
be NN O O
instructed NN O O
to NN O O
contact NN O O
their NN O O
healthcare NN O O
provider NN O O
if NN O O
they NN O O
experience NN O O
new NN O O
or NN O O
worsening NN O O
depression NN O O
, NN O O
suicidal NN O O
thoughts NN O O
, NN O O
or NN O O
other NN O O
mood NN O O
changes NN O O
. NN O O
5.7 NN O O
Immunization NN O O
Live NN O O
vaccines NN O O
should NN O O
not NN O O
be NN O O
given NN O O
for NN O O
30 NN O O
days NN O O
before NN O O
or NN O O
concurrently NN O O
with NN O O
BENLYSTA NN O O
as NN O O
clinical NN O O
safety NN O O
has NN O O
not NN O O
been NN O O
established NN O O
. NN O O
No NN O O
data NN O O
are NN O O
available NN O O
on NN O O
the NN O O
secondary NN O O
transmission NN O O
of NN O O
infection NN O O
from NN O O
persons NN O O
receiving NN O O
live NN O O
vaccines NN O O
to NN O O
patients NN O O
receiving NN O O
BENLYSTA NN O O
or NN O O
the NN O O
effect NN O O
of NN O O
BENLYSTA NN O O
on NN O O
new NN O O
immunizations NN O O
. NN O O
Because NN O O
of NN O O
its NN O O
mechanism NN O O
of NN O O
action NN O O
, NN O O
BENLYSTA NN O O
may NN O O
interfere NN O O
with NN O O
the NN O O
response NN O O
to NN O O
immunizations NN O O
. NN O O
5.8 NN O O
Concomitant NN O O
Use NN O O
with NN O O
Other NN O O
Biologic NN O O
Therapies NN O O
or NN O O
Intravenous NN O O
Cyclophosphamide NN O O
BENLYSTA NN O O
has NN O O
not NN O O
been NN O O
studied NN O O
in NN O O
combination NN O O
with NN O O
other NN O O
biologic NN O O
therapies NN O O
, NN O O
including NN O O
B NN O O
- NN O O
cell NN O O
targeted NN O O
therapies NN O O
, NN O O
or NN O O
intravenous NN O O
cyclophosphamide NN O O
. NN O O
Therefore NN O O
, NN O O
use NN O O
of NN O O
BENLYSTA NN O O
is NN O O
not NN O O
recommended NN O O
in NN O O
combination NN O O
with NN O O
biologic NN O O
therapies NN O O
or NN O O
intravenous NN O O
cyclophosphamide NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
serious NN O O
adverse NN O O
reactions NN O O
are NN O O
discussed NN O O
in NN O O
greater NN O O
detail NN O O
in NN O O
another NN O O
section NN O O
of NN O O
the NN O O
label NN O O
: NN O O
* NN O O
Bone NN B-AdverseReaction B-AdverseReaction
Marrow NN I-AdverseReaction I-AdverseReaction
Suppression NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Gastrointestinal NN B-AdverseReaction B-AdverseReaction
Adverse NN I-AdverseReaction I-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Renal NN B-AdverseReaction B-AdverseReaction
Failure NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Use NN O O
in NN O O
Elderly NN O O
Patients NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Use NN O O
in NN O O
Patients NN O O
with NN O O
Hepatic NN O O
Impairment NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.6 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Embryo NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Fetal NN I-AdverseReaction I-AdverseReaction
Toxicity NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.7 NN O O
) NN O O
] NN O O
. NN O O
EXCERPT NN O O
: NN O O
Most NN O O
common NN O O
all NN O O
grades NN O O
adverse NN O O
reactions NN O O
( NN O O
>=10 NN O O
% NN O O
) NN O O
are NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
anemia NN B-AdverseReaction B-AdverseReaction
leukopenia NN B-AdverseReaction B-AdverseReaction
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
constipation NN B-AdverseReaction B-AdverseReaction
asthenia NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
hematuria NN B-AdverseReaction B-AdverseReaction
back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
anorexia NN B-AdverseReaction B-AdverseReaction
peripheral NN B-AdverseReaction B-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
pyrexia NN B-AdverseReaction B-AdverseReaction
dyspnea NN B-AdverseReaction B-AdverseReaction
dysgeusia NN B-AdverseReaction B-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
arthralgia NN B-AdverseReaction B-AdverseReaction
and NN O O
alopecia NN B-AdverseReaction B-AdverseReaction
( NN O O
6 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
sanofi NN O O
- NN O O
aventis NN O O
U.S. NN O O
LLC NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
633 NN O O
- NN O O
1610 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trial NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
the NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
other NN O O
trials NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O
The NN O O
safety NN O O
of NN O O
JEVTANA NN O O
in NN O O
combination NN O O
with NN O O
prednisone NN O O
was NN O O
evaluated NN O O
in NN O O
371 NN O O
patients NN O O
with NN O O
hormone NN O O
- NN O O
refractory NN O O
metastatic NN O O
prostate NN O O
cancer NN O O
treated NN O O
in NN O O
a NN O O
single NN O O
randomized NN O O
trial NN O O
, NN O O
compared NN O O
to NN O O
mitoxantrone NN O O
plus NN O O
prednisone NN O O
. NN O O
Deaths NN B-AdverseReaction B-AdverseReaction
due NN O O
to NN O O
causes NN O O
other NN O O
than NN O O
disease NN O O
progression NN O O
within NN O O
30 NN O O
days NN O O
of NN O O
last NN O O
study NN O O
drug NN O O
dose NN O O
were NN O O
reported NN O O
in NN O O
18 NN O O
( NN O O
5 NN O O
% NN O O
) NN O O
JEVTANA NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
3 NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
mitoxantrone NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
The NN O O
most NN O O
common NN O O
fatal NN B-AdverseReaction B-AdverseReaction
adverse NN O O
reactions NN O O
in NN O O
JEVTANA NN O O
- NN O O
treated NN O O
patients NN O O
were NN O O
infections NN B-AdverseReaction B-AdverseReaction
( NN O O
n=5 NN O O
) NN O O
and NN O O
renal NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
( NN O O
n=4 NN O O
) NN O O
. NN O O
The NN O O
majority NN O O
( NN O O
4 NN O O
of NN O O
5 NN O O
patients NN O O
) NN O O
of NN O O
fatal NN B-AdverseReaction B-AdverseReaction
infection NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
occurred NN O O
after NN O O
a NN O O
single NN O O
dose NN O O
of NN O O
JEVTANA. NN O O
Other NN O O
fatal NN B-AdverseReaction B-AdverseReaction
adverse NN O O
reactions NN O O
in NN O O
JEVTANA NN O O
- NN O O
treated NN O O
patients NN O O
included NN O O
ventricular NN B-AdverseReaction B-AdverseReaction
fibrillation NN I-AdverseReaction I-AdverseReaction
cerebral NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
and NN O O
dyspnea NN B-AdverseReaction B-AdverseReaction
The NN O O
most NN O O
common NN O O
( NN O O
>= NN O O
10 NN O O
% NN O O
) NN O O
grade NN B-Severity B-Severity
1 NN I-Severity I-Severity
- NN I-Severity I-Severity
4 NN I-Severity I-Severity
adverse NN O O
reactions NN O O
were NN O O
anemia NN B-AdverseReaction B-AdverseReaction
leukopenia NN B-AdverseReaction B-AdverseReaction
neutropenia NN B-AdverseReaction B-AdverseReaction
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
constipation NN B-AdverseReaction B-AdverseReaction
asthenia NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
hematuria NN B-AdverseReaction B-AdverseReaction
back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
anorexia NN B-AdverseReaction B-AdverseReaction
peripheral NN B-AdverseReaction B-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
pyrexia NN B-AdverseReaction B-AdverseReaction
dyspnea NN B-AdverseReaction B-AdverseReaction
dysguesia NN B-AdverseReaction B-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
arthralgia NN B-AdverseReaction B-AdverseReaction
and NN O O
alopecia NN B-AdverseReaction B-AdverseReaction
The NN O O
most NN O O
common NN O O
( NN O O
>= NN O O
5 NN O O
% NN O O
) NN O O
grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
- NN I-Severity I-Severity
4 NN I-Severity I-Severity
adverse NN O O
reactions NN O O
in NN O O
patients NN O O
who NN O O
received NN O O
JEVTANA NN O O
were NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
leukopenia NN B-AdverseReaction B-AdverseReaction
anemia NN B-AdverseReaction B-AdverseReaction
febrile NN B-AdverseReaction B-AdverseReaction
neutropenia NN I-AdverseReaction I-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
and NN O O
asthenia NN B-AdverseReaction B-AdverseReaction
Treatment NN O O
discontinuations NN O O
due NN O O
to NN O O
adverse NN O O
drug NN O O
reactions NN O O
occurred NN O O
in NN O O
18 NN O O
% NN O O
of NN O O
patients NN O O
who NN O O
received NN O O
JEVTANA NN O O
and NN O O
8 NN O O
% NN O O
of NN O O
patients NN O O
who NN O O
received NN O O
mitoxantrone NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
leading NN O O
to NN O O
treatment NN O O
discontinuation NN O O
in NN O O
the NN O O
JEVTANA NN O O
group NN O O
were NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
and NN O O
renal NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
Dose NN O O
reductions NN O O
were NN O O
reported NN O O
in NN O O
12 NN O O
% NN O O
of NN O O
JEVTANA NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
4 NN O O
% NN O O
of NN O O
mitoxantrone NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Dose NN O O
delays NN O O
were NN O O
reported NN O O
in NN O O
28 NN O O
% NN O O
of NN O O
JEVTANA NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
15 NN O O
% NN O O
of NN O O
mitoxantrone NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Table NN O O
2 NN O O
- NN O O
Incidence NN O O
of NN O O
Reported NN O O
Adverse NN O O
ReactionsGraded NN O O
using NN O O
NCI NN O O
CTCAE NN O O
version NN O O
3 NN O O
and NN O O
Hematologic NN B-AdverseReaction B-AdverseReaction
Abnormalities NN I-AdverseReaction I-AdverseReaction
in NN O O
>= NN O O
5 NN O O
% NN O O
of NN O O
Patients NN O O
Receiving NN O O
JEVTANA NN O O
in NN O O
Combination NN O O
with NN O O
Prednisone NN O O
or NN O O
Mitoxantrone NN O O
in NN O O
Combination NN O O
with NN O O
Prednisone NN O O
JEVTANA NN O O
25 NN O O
mg/m NN O O
2 NN O O
every NN O O
3 NN O O
weeks NN O O
with NN O O
prednisone NN O O
10 NN O O
mg NN O O
dailyn=371 NN O O
Mitoxantrone NN O O
12 NN O O
mg/m NN O O
2 NN O O
every NN O O
3 NN O O
weeks NN O O
with NN O O
prednisone NN O O
10 NN O O
mg NN O O
dailyn=371 NN O O
Grade NN O O
1 NN O O
- NN O O
4n NN O O
( NN O O
% NN O O
) NN O O
Grade NN O O
3 NN O O
- NN O O
4n NN O O
( NN O O
% NN O O
) NN O O
Grade NN O O
1 NN O O
- NN O O
4n NN O O
( NN O O
% NN O O
) NN O O
Grade NN O O
3 NN O O
- NN O O
4n NN O O
( NN O O
% NN O O
) NN O O
Any NN O O
Adverse NN O O
Reaction NN O O
Blood NN O O
and NN O O
Lymphatic NN O O
System NN O O
Disorders NN O O
Neutropenia NN B-AdverseReaction B-AdverseReaction
347 NN O O
( NN O O
94 NN O O
% NN O O
) NN O O
303 NN O O
( NN O O
82 NN O O
% NN O O
) NN O O
325 NN O O
( NN O O
87 NN O O
% NN O O
) NN O O
215 NN O O
( NN O O
58 NN O O
% NN O O
) NN O O
Febrile NN B-AdverseReaction B-AdverseReaction
Neutropenia NN I-AdverseReaction I-AdverseReaction
27 NN O O
( NN O O
7 NN O O
% NN O O
) NN O O
27 NN O O
( NN O O
7 NN O O
% NN O O
) NN O O
5 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
5 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
Anemia NN B-AdverseReaction B-AdverseReaction
361 NN O O
( NN O O
98 NN O O
% NN O O
) NN O O
39 NN O O
( NN O O
11 NN O O
% NN O O
) NN O O
302 NN O O
( NN O O
82 NN O O
% NN O O
) NN O O
18 NN O O
( NN O O
5 NN O O
% NN O O
) NN O O
Leukopenia NN B-AdverseReaction B-AdverseReaction
355 NN O O
( NN O O
96 NN O O
% NN O O
) NN O O
253 NN O O
( NN O O
69 NN O O
% NN O O
) NN O O
343 NN O O
( NN O O
93 NN O O
% NN O O
) NN O O
157 NN O O
( NN O O
42 NN O O
% NN O O
) NN O O
Thrombocytopenia NN B-AdverseReaction B-AdverseReaction
176 NN O O
( NN O O
48 NN O O
% NN O O
) NN O O
15 NN O O
( NN O O
4 NN O O
% NN O O
) NN O O
160 NN O O
( NN O O
43 NN O O
% NN O O
) NN O O
6 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
Cardiac NN O O
Disorders NN O O
Arrhythmia NN B-AdverseReaction B-AdverseReaction
18 NN O O
( NN O O
5 NN O O
% NN O O
) NN O O
4 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
6 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
1 NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
Gastrointestinal NN O O
Disorders NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
173 NN O O
( NN O O
47 NN O O
% NN O O
) NN O O
23 NN O O
( NN O O
6 NN O O
% NN O O
) NN O O
39 NN O O
( NN O O
11 NN O O
% NN O O
) NN O O
1 NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
127 NN O O
( NN O O
34 NN O O
% NN O O
) NN O O
7 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
85 NN O O
( NN O O
23 NN O O
% NN O O
) NN O O
1 NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
83 NN O O
( NN O O
22 NN O O
% NN O O
) NN O O
6 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
38 NN O O
( NN O O
10 NN O O
% NN O O
) NN O O
0 NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
76 NN O O
( NN O O
20 NN O O
% NN O O
) NN O O
4 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
57 NN O O
( NN O O
15 NN O O
% NN O O
) NN O O
2 NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
Pain NN I-AdverseReaction I-AdverseReaction
64 NN O O
( NN O O
17 NN O O
% NN O O
) NN O O
7 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
23 NN O O
( NN O O
6 NN O O
% NN O O
) NN O O
0 NN O O
Dyspepsia NN B-AdverseReaction B-AdverseReaction
36 NN O O
( NN O O
10 NN O O
% NN O O
) NN O O
0 NN O O
9 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
0 NN O O
General NN O O
Disorders NN O O
and NN O O
Administration NN O O
Site NN O O
Conditions NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
136 NN O O
( NN O O
37 NN O O
% NN O O
) NN O O
18 NN O O
( NN O O
5 NN O O
% NN O O
) NN O O
102 NN O O
( NN O O
27 NN O O
% NN O O
) NN O O
11 NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
Asthenia NN B-AdverseReaction B-AdverseReaction
76 NN O O
( NN O O
20 NN O O
% NN O O
) NN O O
17 NN O O
( NN O O
5 NN O O
% NN O O
) NN O O
46 NN O O
( NN O O
12 NN O O
% NN O O
) NN O O
9 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
45 NN O O
( NN O O
12 NN O O
% NN O O
) NN O O
4 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
23 NN O O
( NN O O
6 NN O O
% NN O O
) NN O O
1 NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
Peripheral NN B-AdverseReaction B-AdverseReaction
Edema NN I-AdverseReaction I-AdverseReaction
34 NN O O
( NN O O
9 NN O O
% NN O O
) NN O O
2 NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
34 NN O O
( NN O O
9 NN O O
% NN O O
) NN O O
2 NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
Mucosal NN B-AdverseReaction B-AdverseReaction
Inflammation NN I-AdverseReaction I-AdverseReaction
22 NN O O
( NN O O
6 NN O O
% NN O O
) NN O O
1 NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
10 NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
1 NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
Pain NN B-AdverseReaction B-AdverseReaction
20 NN O O
( NN O O
5 NN O O
% NN O O
) NN O O
4 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
18 NN O O
( NN O O
5 NN O O
% NN O O
) NN O O
7 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
Infections NN O O
and NN O O
Infestations NN O O
Urinary NN B-AdverseReaction B-AdverseReaction
Tract NN I-AdverseReaction I-AdverseReaction
Infection NN I-AdverseReaction I-AdverseReaction
29 NN O O
( NN O O
8 NN O O
% NN O O
) NN O O
6 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
12 NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
4 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
Investigations NN O O
Weight NN B-AdverseReaction B-AdverseReaction
Decreased NN I-AdverseReaction I-AdverseReaction
32 NN O O
( NN O O
9 NN O O
% NN O O
) NN O O
0 NN O O
28 NN O O
( NN O O
8 NN O O
% NN O O
) NN O O
1 NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
Metabolism NN O O
and NN O O
Nutrition NN O O
Disorders NN O O
Anorexia NN B-AdverseReaction B-AdverseReaction
59 NN O O
( NN O O
16 NN O O
% NN O O
) NN O O
3 NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
39 NN O O
( NN O O
11 NN O O
% NN O O
) NN O O
3 NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
Dehydration NN B-AdverseReaction B-AdverseReaction
18 NN O O
( NN O O
5 NN O O
% NN O O
) NN O O
8 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
10 NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
3 NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
Musculoskeletal NN O O
and NN O O
Connective NN O O
Tissue NN O O
Disorders NN O O
Back NN B-AdverseReaction B-AdverseReaction
Pain NN I-AdverseReaction I-AdverseReaction
60 NN O O
( NN O O
16 NN O O
% NN O O
) NN O O
14 NN O O
( NN O O
4 NN O O
% NN O O
) NN O O
45 NN O O
( NN O O
12 NN O O
% NN O O
) NN O O
11 NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
Arthralgia NN B-AdverseReaction B-AdverseReaction
39 NN O O
( NN O O
11 NN O O
% NN O O
) NN O O
4 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
31 NN O O
( NN O O
8 NN O O
% NN O O
) NN O O
4 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
Muscle NN B-AdverseReaction B-AdverseReaction
Spasms NN I-AdverseReaction I-AdverseReaction
27 NN O O
( NN O O
7 NN O O
% NN O O
) NN O O
0 NN O O
10 NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
0 NN O O
Nervous NN O O
System NN O O
Disorders NN O O
Peripheral NN B-AdverseReaction B-AdverseReaction
Neuropathy NN I-AdverseReaction I-AdverseReaction
50 NN O O
( NN O O
13 NN O O
% NN O O
) NN O O
3 NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
12 NN O O
( NN O O
3.2 NN O O
% NN O O
) NN O O
3 NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
Dysgeusia NN B-AdverseReaction B-AdverseReaction
41 NN O O
( NN O O
11 NN O O
% NN O O
) NN O O
0 NN O O
15 NN O O
( NN O O
4 NN O O
% NN O O
) NN O O
0 NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
30 NN O O
( NN O O
8 NN O O
% NN O O
) NN O O
0 NN O O
21 NN O O
( NN O O
6 NN O O
% NN O O
) NN O O
2 NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
Headache NN B-AdverseReaction B-AdverseReaction
28 NN O O
( NN O O
8 NN O O
% NN O O
) NN O O
0 NN O O
19 NN O O
( NN O O
5 NN O O
% NN O O
) NN O O
0 NN O O
Renal NN O O
and NN O O
Urinary NN O O
Tract NN O O
Disorders NN O O
Hematuria NN B-AdverseReaction B-AdverseReaction
62 NN O O
( NN O O
17 NN O O
% NN O O
) NN O O
7 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
13 NN O O
( NN O O
4 NN O O
% NN O O
) NN O O
1 NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
Dysuria NN B-AdverseReaction B-AdverseReaction
25 NN O O
( NN O O
7 NN O O
% NN O O
) NN O O
0 NN O O
5 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
0 NN O O
Respiratory NN O O
, NN O O
Thoracic NN O O
and NN O O
Mediastinal NN O O
Disorders NN O O
Dyspnea NN B-AdverseReaction B-AdverseReaction
43 NN O O
( NN O O
12 NN O O
% NN O O
) NN O O
4 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
16 NN O O
( NN O O
4 NN O O
% NN O O
) NN O O
2 NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
Cough NN B-AdverseReaction B-AdverseReaction
40 NN O O
( NN O O
11 NN O O
% NN O O
) NN O O
0 NN O O
22 NN O O
( NN O O
6 NN O O
% NN O O
) NN O O
0 NN O O
Skin NN O O
and NN O O
Subcutaneous NN O O
Tissue NN O O
Disorders NN O O
Alopecia NN B-AdverseReaction B-AdverseReaction
37 NN O O
( NN O O
10 NN O O
% NN O O
) NN O O
0 NN O O
18 NN O O
( NN O O
5 NN O O
% NN O O
) NN O O
0 NN O O
Vascular NN O O
Disorders NN O O
Hypotension NN B-AdverseReaction B-AdverseReaction
20 NN O O
( NN O O
5 NN O O
% NN O O
) NN O O
2 NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
9 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
1 NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
Median NN O O
Duration NN O O
of NN O O
Treatment NN O O
6 NN O O
cycles NN O O
4 NN O O
cycles NN O O
Neutropenia NN O O
and NN O O
Associated NN O O
Clinical NN O O
Events NN O O
: NN O O
Five NN O O
patients NN O O
experienced NN O O
fatal NN B-AdverseReaction B-AdverseReaction
infectious NN B-AdverseReaction B-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
( NN O O
sepsis NN O O
or NN O O
septic NN B-AdverseReaction B-AdverseReaction
shock NN I-AdverseReaction I-AdverseReaction
All NN O O
had NN O O
grade NN B-Severity B-Severity
4 NN I-Severity I-Severity
neutropenia NN B-AdverseReaction B-AdverseReaction
and NN O O
one NN O O
had NN O O
febrile NN B-AdverseReaction B-AdverseReaction
neutropenia NN I-AdverseReaction I-AdverseReaction
One NN O O
additional NN O O
patient NN O O
's NN O O
death NN B-AdverseReaction B-AdverseReaction
was NN O O
attributed NN O O
to NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
without NN B-Negation B-Negation
a NN O O
documented NN O O
infection NN B-AdverseReaction B-AdverseReaction
Twenty NN O O
- NN O O
two NN O O
( NN O O
6 NN O O
% NN O O
) NN O O
patients NN O O
discontinued NN O O
JEVTANA NN O O
treatment NN O O
due NN O O
to NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
febrile NN B-AdverseReaction B-AdverseReaction
neutropenia NN I-AdverseReaction I-AdverseReaction
infection NN B-AdverseReaction B-AdverseReaction
or NN O O
sepsis NN B-AdverseReaction B-AdverseReaction
The NN O O
most NN O O
common NN O O
adverse NN O O
reaction NN O O
leading NN O O
to NN O O
treatment NN O O
discontinuation NN O O
in NN O O
the NN O O
JEVTANA NN O O
group NN O O
was NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
. NN O O
Hematuria NN O O
: NN O O
Adverse NN O O
events NN O O
of NN O O
hematuria NN B-AdverseReaction B-AdverseReaction
including NN O O
those NN O O
requiring NN O O
medical NN O O
intervention NN O O
, NN O O
were NN O O
more NN O O
common NN O O
in NN O O
JEVTANA NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
grade NN O O
>= NN O O
2 NN O O
hematuria NN B-AdverseReaction B-AdverseReaction
was NN O O
6 NN O O
% NN O O
in NN O O
JEVTANA NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
2 NN O O
% NN O O
in NN O O
mitoxantrone NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Other NN O O
factors NN O O
associated NN O O
with NN O O
hematuria NN B-AdverseReaction B-AdverseReaction
were NN O O
well NN O O
- NN O O
balanced NN O O
between NN O O
arms NN O O
and NN O O
do NN O O
not NN O O
account NN O O
for NN O O
the NN O O
increased NN O O
rate NN O O
of NN O O
hematuria NN B-AdverseReaction B-AdverseReaction
on NN O O
the NN O O
JEVTANA NN O O
arm NN O O
. NN O O
Hepatic NN O O
Laboratory NN O O
Abnormalities NN O O
: NN O O
The NN O O
incidences NN O O
of NN O O
grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
- NN I-Severity I-Severity
4 NN I-Severity I-Severity
increased NN B-AdverseReaction B-AdverseReaction
AST NN I-AdverseReaction I-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
ALT NN I-AdverseReaction I-AdverseReaction
and NN O O
increased NN B-AdverseReaction B-AdverseReaction
bilirubin NN I-AdverseReaction I-AdverseReaction
were NN O O
each NN O O
< NN O O
= NN O O
1 NN O O
% NN O O
. NN O O
Elderly NN O O
Population NN O O
: NN O O
The NN O O
following NN O O
grade NN B-Severity B-Severity
1 NN I-Severity I-Severity
- NN I-Severity I-Severity
4 NN I-Severity I-Severity
adverse NN O O
reactions NN O O
were NN O O
reported NN O O
at NN O O
rates NN O O
>= NN O O
5 NN O O
% NN O O
higher NN O O
in NN O O
patients NN O O
65 NN O O
years NN O O
of NN O O
age NN O O
or NN O O
greater NN O O
compared NN O O
to NN O O
younger NN O O
patients NN O O
: NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
( NN O O
40 NN O O
% NN O O
vs. NN O O
30 NN O O
% NN O O
) NN O O
, NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
( NN O O
97 NN O O
% NN O O
vs. NN O O
89 NN O O
% NN O O
) NN O O
, NN O O
asthenia NN B-AdverseReaction B-AdverseReaction
( NN O O
24 NN O O
% NN O O
vs. NN O O
15 NN O O
% NN O O
) NN O O
, NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
( NN O O
15 NN O O
% NN O O
vs. NN O O
8 NN O O
% NN O O
) NN O O
, NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
( NN O O
10 NN O O
% NN O O
vs. NN O O
5 NN O O
% NN O O
) NN O O
, NN O O
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
( NN O O
10 NN O O
% NN O O
vs. NN O O
3 NN O O
% NN O O
) NN O O
and NN O O
dehydration NN B-AdverseReaction B-AdverseReaction
( NN O O
7 NN O O
% NN O O
vs. NN O O
2 NN O O
% NN O O
) NN O O
, NN O O
respectively NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
the NN O O
following NN O O
grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
- NN I-Severity I-Severity
4 NN I-Severity I-Severity
adverse NN O O
reactions NN O O
were NN O O
higher NN O O
in NN O O
patients NN O O
>= NN O O
65 NN O O
years NN O O
of NN O O
age NN O O
compared NN O O
to NN O O
younger NN O O
patients NN O O
; NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
( NN O O
87 NN O O
% NN O O
vs. NN O O
74 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
febrile NN B-AdverseReaction B-AdverseReaction
neutropenia NN I-AdverseReaction I-AdverseReaction
( NN O O
8 NN O O
% NN O O
vs. NN O O
6 NN O O
% NN O O
) NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.5 NN O O
) NN O O
] NN O O
. NN O O
6.2 NN O O
Postmarketing NN O O
Experience NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
identified NN O O
from NN O O
clinical NN O O
trials NN O O
and/or NN O O
post NN O O
- NN O O
marketing NN O O
surveillance NN O O
. NN O O
Because NN O O
they NN O O
are NN O O
reported NN O O
from NN O O
a NN O O
population NN O O
of NN O O
unknown NN O O
size NN O O
, NN O O
precise NN O O
estimates NN O O
of NN O O
frequency NN O O
can NN O O
not NN O O
be NN O O
made NN O O
. NN O O
Gastrointestinal NN O O
: NN O O
Gastritis NN B-AdverseReaction B-AdverseReaction
intestinal NN B-AdverseReaction B-AdverseReaction
obstruction NN I-AdverseReaction I-AdverseReaction
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
NEUTROPENIA NN B-AdverseReaction B-AdverseReaction
AND NN O O
HYPERSENSITIVITY NN B-AdverseReaction B-AdverseReaction
WARNING NN O O
: NN O O
NEUTROPENIA NN B-AdverseReaction B-AdverseReaction
AND NN O O
HYPERSENSITIVITY NN B-AdverseReaction B-AdverseReaction
EXCERPT NN O O
: NN O O
WARNING NN O O
: NN O O
NEUTROPENIA NN B-AdverseReaction B-AdverseReaction
AND NN O O
HYPERSENSITIVITY NN B-AdverseReaction B-AdverseReaction
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
. NN O O
* NN O O
Neutropenic NN B-AdverseReaction B-AdverseReaction
deaths NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
. NN O O
Obtain NN O O
frequent NN O O
blood NN O O
counts NN O O
to NN O O
monitor NN O O
for NN O O
neutropenia NN O O
. NN O O
Do NN O O
not NN O O
give NN O O
JEVTANA NN O O
if NN O O
neutrophil NN O O
counts NN O O
are NN O O
< NN O O
=1,500 NN O O
cells/mm3 NN O O
. NN O O
( NN O O
2.2)(4 NN O O
) NN O O
* NN O O
Severe NN B-Severity B-Severity
hypersensitivity NN B-AdverseReaction B-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
and NN O O
may NN B-Factor B-Factor
include NN O O
generalized NN B-AdverseReaction B-AdverseReaction
rash NN I-AdverseReaction I-AdverseReaction
hypotension NN B-AdverseReaction B-AdverseReaction
and NN O O
bronchospasm NN B-AdverseReaction B-AdverseReaction
Discontinue NN O O
JEVTANA NN O O
immediately NN O O
if NN O O
severe NN O O
reactions NN O O
occur NN O O
and NN O O
administer NN O O
appropriate NN O O
therapy NN O O
. NN O O
( NN O O
2.1)(5.2 NN O O
) NN O O
* NN O O
Contraindicated NN O O
if NN O O
history NN O O
of NN O O
severe NN O O
hypersensitivity NN O O
reactions NN O O
to NN O O
JEVTANA NN O O
or NN O O
to NN O O
drugs NN O O
formulated NN O O
with NN O O
polysorbate NN O O
80 NN O O
. NN O O
( NN O O
4 NN O O
) NN O O
Neutropenia NN O O
: NN O O
Neutropenic NN B-AdverseReaction B-AdverseReaction
deaths NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
. NN O O
In NN O O
order NN O O
to NN O O
monitor NN O O
the NN O O
occurrence NN O O
of NN O O
neutropenia NN O O
, NN O O
frequent NN O O
blood NN O O
cell NN O O
counts NN O O
should NN O O
be NN O O
performed NN O O
on NN O O
all NN O O
patients NN O O
receiving NN O O
JEVTANA. NN O O
JEVTANA NN O O
is NN O O
contraindicated NN O O
in NN O O
patients NN O O
with NN O O
neutrophil NN O O
counts NN O O
of NN O O
< NN O O
=1,500 NN O O
cells/mm NN O O
3 NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
and NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
Severe NN O O
hypersensitivity NN O O
: NN O O
Severe NN B-Severity B-Severity
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
and NN O O
may NN B-Factor B-Factor
include NN O O
generalized NN B-AdverseReaction B-AdverseReaction
rash NN I-AdverseReaction I-AdverseReaction
hypotension NN B-AdverseReaction B-AdverseReaction
and NN O O
bronchospasm NN B-AdverseReaction B-AdverseReaction
Severe NN B-Severity B-Severity
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
require NN O O
immediate NN O O
discontinuation NN O O
of NN O O
the NN O O
JEVTANA NN O O
infusion NN O O
and NN O O
administration NN O O
of NN O O
appropriate NN O O
therapy NN O O
. NN O O
Patients NN O O
should NN O O
receive NN O O
premedication NN O O
. NN O O
JEVTANA NN O O
is NN O O
contraindicated NN O O
in NN O O
patients NN O O
who NN O O
have NN O O
a NN O O
history NN O O
of NN O O
severe NN O O
hypersensitivity NN O O
reactions NN O O
to NN O O
cabazitaxel NN O O
or NN O O
to NN O O
other NN O O
drugs NN O O
formulated NN O O
with NN O O
polysorbate NN O O
80 NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.1 NN O O
) NN O O
, NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
, NN O O
and NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Bone NN B-AdverseReaction B-AdverseReaction
marrow NN I-AdverseReaction I-AdverseReaction
suppression NN I-AdverseReaction I-AdverseReaction
( NN O O
particularly NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
and NN O O
its NN O O
clinical NN O O
consequences NN O O
( NN O O
febrile NN O O
neutropenia NN O O
, NN O O
neutropenic NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
blood NN O O
counts NN O O
frequently NN O O
to NN O O
determine NN O O
if NN O O
dosage NN O O
modification NN O O
or NN O O
initiation NN O O
of NN O O
G NN O O
- NN O O
CSF NN O O
is NN O O
needed NN O O
. NN O O
Primary NN O O
prophylaxis NN O O
with NN O O
G NN O O
- NN O O
CSF NN O O
should NN O O
be NN O O
considered NN O O
in NN O O
patients NN O O
with NN O O
high NN O O
- NN O O
risk NN O O
clinical NN O O
features NN O O
. NN O O
Use NN O O
caution NN O O
in NN O O
patients NN O O
with NN O O
hemoglobin NN O O
< NN O O
10 NN O O
g/dL. NN O O
( NN O O
2.2 NN O O
)( NN O O
4 NN O O
)( NN O O
5.1 NN O O
) NN O O
* NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
Severe NN B-Severity B-Severity
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
. NN O O
Premedicate NN O O
with NN O O
corticosteroids NN O O
and NN O O
H2 NN O O
antagonists NN O O
. NN O O
Discontinue NN O O
infusion NN O O
immediately NN O O
if NN O O
hypersensitivity NN O O
is NN O O
observed NN O O
and NN O O
treat NN O O
as NN O O
indicated NN O O
. NN O O
( NN O O
4 NN O O
)( NN O O
5.2 NN O O
) NN O O
* NN O O
Gastrointestinal NN B-AdverseReaction B-AdverseReaction
disorders NN I-AdverseReaction I-AdverseReaction
Nausea NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
and NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
may NN B-Factor B-Factor
occur NN O O
. NN O O
Mortality NN B-AdverseReaction B-AdverseReaction
related NN O O
to NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
has NN O O
been NN O O
reported NN O O
. NN O O
Rehydrate NN O O
and NN O O
treat NN O O
with NN O O
anti NN O O
- NN O O
emetics NN O O
and NN O O
anti NN O O
- NN O O
diarrheals NN O O
as NN O O
needed NN O O
. NN O O
If NN O O
experiencing NN O O
Grade NN O O
>= NN O O
3 NN O O
diarrhea NN O O
, NN O O
dosage NN O O
should NN O O
be NN O O
modified NN O O
. NN O O
( NN O O
2.2 NN O O
) NN O O
Deaths NN B-AdverseReaction B-AdverseReaction
have NN O O
occurred NN O O
due NN O O
to NN O O
gastrointestinal NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
perforation NN O O
and NN O O
neutropenic NN B-AdverseReaction B-AdverseReaction
enterocolitis NN I-AdverseReaction I-AdverseReaction
Delay NN O O
or NN O O
discontinue NN O O
JEVTANA. NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Renal NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
including NN O O
cases NN O O
with NN O O
fatal NN B-AdverseReaction B-AdverseReaction
outcomes NN O O
, NN O O
has NN O O
been NN O O
reported NN O O
. NN O O
Identify NN O O
cause NN O O
and NN O O
manage NN O O
aggressively NN O O
. NN O O
( NN O O
5.4 NN O O
) NN O O
* NN O O
Elderly NN O O
patients NN O O
: NN O O
Patients NN O O
>= NN O O
65 NN O O
years NN O O
of NN O O
age NN O O
were NN O O
more NN O O
likely NN O O
to NN O O
experience NN O O
fatal NN B-AdverseReaction B-AdverseReaction
outcomes NN O O
not NN O O
related NN O O
to NN O O
disease NN O O
progression NN O O
and NN O O
certain NN O O
adverse NN O O
reactions NN O O
, NN O O
including NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
and NN O O
febrile NN B-AdverseReaction B-AdverseReaction
neutropenia NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
closely NN O O
. NN O O
( NN O O
5.5 NN O O
)( NN O O
6 NN O O
)( NN O O
8.5 NN O O
) NN O O
* NN O O
Hepatic NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
Reduce NN O O
the NN O O
JEVTANA NN O O
dose NN O O
to NN O O
20 NN O O
mg/m NN O O
2 NN O O
in NN O O
patients NN O O
with NN O O
mild NN O O
hepatic NN O O
impairment NN O O
and NN O O
to NN O O
15 NN O O
mg/m NN O O
2 NN O O
in NN O O
patients NN O O
with NN O O
moderate NN O O
hepatic NN O O
impairment NN O O
. NN O O
( NN O O
2.3 NN O O
) NN O O
* NN O O
JEVTANA NN O O
can NN B-Factor B-Factor
cause NN O O
fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
when NN O O
administered NN O O
to NN O O
a NN O O
pregnant NN O O
woman NN O O
. NN O O
( NN O O
5.7 NN O O
)( NN O O
8.1 NN O O
) NN O O
5.1 NN O O
Bone NN O O
Marrow NN O O
Suppression NN O O
Bone NN B-AdverseReaction B-AdverseReaction
marrow NN I-AdverseReaction I-AdverseReaction
suppression NN I-AdverseReaction I-AdverseReaction
manifested NN O O
as NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
anemia NN B-AdverseReaction B-AdverseReaction
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
and/or NN O O
pancytopenia NN B-AdverseReaction B-AdverseReaction
may NN B-Factor B-Factor
occur NN O O
. NN O O
Neutropenic NN B-AdverseReaction B-AdverseReaction
deaths NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
. NN O O
In NN O O
the NN O O
randomized NN O O
trial NN O O
, NN O O
five NN O O
patients NN O O
( NN O O
1.3 NN O O
% NN O O
) NN O O
experienced NN O O
fatal NN B-AdverseReaction B-AdverseReaction
infectious NN B-AdverseReaction B-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
( NN O O
sepsis NN O O
or NN O O
septic NN B-AdverseReaction B-AdverseReaction
shock NN I-AdverseReaction I-AdverseReaction
All NN O O
had NN O O
grade NN B-Severity B-Severity
4 NN I-Severity I-Severity
neutropenia NN B-AdverseReaction B-AdverseReaction
and NN O O
one NN O O
had NN O O
febrile NN B-AdverseReaction B-AdverseReaction
neutropenia NN I-AdverseReaction I-AdverseReaction
One NN O O
additional NN O O
patient NN O O
's NN O O
death NN B-AdverseReaction B-AdverseReaction
was NN O O
attributed NN O O
to NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
without NN B-Negation B-Negation
a NN O O
documented NN O O
infection NN B-AdverseReaction B-AdverseReaction
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
- NN I-Severity I-Severity
4 NN I-Severity I-Severity
neutropenia NN B-AdverseReaction B-AdverseReaction
has NN O O
been NN O O
observed NN O O
in NN O O
82 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
JEVTANA NN O O
in NN O O
the NN O O
randomized NN O O
trial NN O O
. NN O O
G NN O O
- NN O O
CSF NN O O
may NN O O
be NN O O
administered NN O O
to NN O O
reduce NN O O
the NN O O
risks NN O O
of NN O O
neutropenia NN O O
complications NN O O
associated NN O O
with NN O O
JEVTANA NN O O
use NN O O
. NN O O
Primary NN O O
prophylaxis NN O O
with NN O O
G NN O O
- NN O O
CSF NN O O
should NN O O
be NN O O
considered NN O O
in NN O O
patients NN O O
with NN O O
high NN O O
- NN O O
risk NN O O
clinical NN O O
features NN O O
( NN O O
age NN O O
> NN O O
65 NN O O
years NN O O
, NN O O
poor NN O O
performance NN O O
status NN O O
, NN O O
previous NN O O
episodes NN O O
of NN O O
febrile NN O O
neutropenia NN O O
, NN O O
extensive NN O O
prior NN O O
radiation NN O O
ports NN O O
, NN O O
poor NN O O
nutritional NN O O
status NN O O
, NN O O
or NN O O
other NN O O
serious NN O O
comorbidities NN O O
) NN O O
that NN O O
predispose NN O O
them NN O O
to NN O O
increased NN O O
complications NN O O
from NN O O
prolonged NN O O
neutropenia NN O O
. NN O O
Therapeutic NN O O
use NN O O
of NN O O
G NN O O
- NN O O
CSF NN O O
and NN O O
secondary NN O O
prophylaxis NN O O
should NN O O
be NN O O
considered NN O O
in NN O O
all NN O O
patients NN O O
considered NN O O
to NN O O
be NN O O
at NN O O
increased NN O O
risk NN O O
for NN O O
neutropenia NN O O
complications NN O O
. NN O O
Monitoring NN O O
of NN O O
complete NN O O
blood NN O O
counts NN O O
is NN O O
essential NN O O
on NN O O
a NN O O
weekly NN O O
basis NN O O
during NN O O
cycle NN O O
1 NN O O
and NN O O
before NN O O
each NN O O
treatment NN O O
cycle NN O O
thereafter NN O O
so NN O O
that NN O O
the NN O O
dose NN O O
can NN O O
be NN O O
adjusted NN O O
, NN O O
if NN O O
needed NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
] NN O O
. NN O O
JEVTANA NN O O
is NN O O
contraindicated NN O O
in NN O O
patients NN O O
with NN O O
neutrophils NN O O
< NN O O
= NN O O
1,500/mm NN O O
3 NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
] NN O O
. NN O O
Caution NN O O
is NN O O
recommended NN O O
in NN O O
patients NN O O
with NN O O
hemoglobin NN O O
< NN O O
10 NN O O
g/dl NN O O
. NN O O
5.2 NN O O
Hypersensitivity NN O O
Reactions NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
may NN B-Factor B-Factor
occur NN O O
within NN O O
a NN O O
few NN O O
minutes NN O O
following NN O O
the NN O O
initiation NN O O
of NN O O
the NN O O
infusion NN O O
of NN O O
JEVTANA NN O O
, NN O O
thus NN O O
facilities NN O O
and NN O O
equipment NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
hypotension NN O O
and NN O O
bronchospasm NN O O
should NN O O
be NN O O
available NN O O
. NN O O
Severe NN B-Severity B-Severity
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
and NN O O
may NN B-Factor B-Factor
include NN O O
generalized NN B-AdverseReaction B-AdverseReaction
rash NN I-AdverseReaction I-AdverseReaction
hypotension NN B-AdverseReaction B-AdverseReaction
and NN O O
bronchospasm NN B-AdverseReaction B-AdverseReaction
Premedicate NN O O
all NN O O
patients NN O O
prior NN O O
to NN O O
the NN O O
initiation NN O O
of NN O O
the NN O O
infusion NN O O
of NN O O
JEVTANA NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.1 NN O O
) NN O O
] NN O O
. NN O O
Observe NN O O
patients NN O O
closely NN O O
for NN O O
hypersensitivity NN O O
reactions NN O O
, NN O O
especially NN O O
during NN O O
the NN O O
first NN O O
and NN O O
second NN O O
infusions NN O O
. NN O O
Severe NN B-Severity B-Severity
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
require NN O O
immediate NN O O
discontinuation NN O O
of NN O O
the NN O O
JEVTANA NN O O
infusion NN O O
and NN O O
appropriate NN O O
therapy NN O O
. NN O O
JEVTANA NN O O
is NN O O
contraindicated NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
severe NN O O
hypersensitivity NN O O
reactions NN O O
to NN O O
cabazitaxel NN O O
or NN O O
to NN O O
other NN O O
drugs NN O O
formulated NN O O
with NN O O
polysorbate NN O O
80 NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
] NN O O
. NN O O
5.3 NN O O
Gastrointestinal NN O O
Adverse NN O O
Reactions NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
and NN O O
severe NN B-Severity B-Severity
diarrhea NN B-AdverseReaction B-AdverseReaction
at NN O O
times NN O O
, NN O O
may NN B-Factor B-Factor
occur NN O O
. NN O O
Death NN B-AdverseReaction B-AdverseReaction
related NN O O
to NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
and NN O O
electrolyte NN B-AdverseReaction B-AdverseReaction
imbalance NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
the NN O O
randomized NN O O
clinical NN O O
trial NN O O
. NN O O
Intensive NN O O
measures NN O O
may NN O O
be NN O O
required NN O O
for NN O O
severe NN O O
diarrhea NN O O
and NN O O
electrolyte NN O O
imbalance NN O O
. NN O O
Antiemetic NN O O
prophylaxis NN O O
is NN O O
recommended NN O O
. NN O O
Treat NN O O
patients NN O O
with NN O O
rehydration NN O O
, NN O O
anti NN O O
- NN O O
diarrheal NN O O
or NN O O
anti NN O O
- NN O O
emetic NN O O
medications NN O O
as NN O O
needed NN O O
. NN O O
Treatment NN O O
delay NN O O
or NN O O
dosage NN O O
reduction NN O O
may NN O O
be NN O O
necessary NN O O
if NN O O
patients NN O O
experience NN O O
Grade NN O O
>= NN O O
3 NN O O
diarrhea NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
] NN O O
. NN O O
Gastrointestinal NN O O
( NN O O
GI NN O O
) NN O O
hemorrhage NN O O
and NN O O
perforation NN O O
, NN O O
ileus NN B-AdverseReaction B-AdverseReaction
enterocolitis NN B-AdverseReaction B-AdverseReaction
neutropenic NN B-AdverseReaction B-AdverseReaction
enterocolitis NN I-AdverseReaction I-AdverseReaction
including NN O O
fatal NN B-AdverseReaction B-AdverseReaction
outcome NN O O
, NN O O
have NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
JEVTANA NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.2 NN O O
) NN O O
] NN O O
. NN O O
Risk NN O O
may NN O O
be NN O O
increased NN O O
with NN O O
neutropenia NN O O
, NN O O
age NN O O
, NN O O
steroid NN O O
use NN O O
, NN O O
concomitant NN O O
use NN O O
of NN O O
NSAIDs NN O O
, NN O O
anti NN O O
- NN O O
platelet NN O O
therapy NN O O
or NN O O
anti NN O O
- NN O O
coagulants NN O O
, NN O O
and NN O O
patients NN O O
with NN O O
a NN O O
prior NN O O
history NN O O
of NN O O
pelvic NN O O
radiotherapy NN O O
, NN O O
adhesions NN O O
, NN O O
ulceration NN O O
and NN O O
GI NN O O
bleeding NN O O
. NN O O
Abdominal NN O O
pain NN O O
and NN O O
tenderness NN O O
, NN O O
fever NN O O
, NN O O
persistent NN O O
constipation NN O O
, NN O O
diarrhea NN O O
, NN O O
with NN O O
or NN O O
without NN O O
neutropenia NN O O
, NN O O
may NN O O
be NN O O
early NN O O
manifestations NN O O
of NN O O
serious NN O O
gastrointestinal NN O O
toxicity NN O O
and NN O O
should NN O O
be NN O O
evaluated NN O O
and NN O O
treated NN O O
promptly NN O O
. NN O O
JEVTANA NN O O
treatment NN O O
delay NN O O
or NN O O
discontinuation NN O O
may NN O O
be NN O O
necessary NN O O
. NN O O
5.4 NN O O
Renal NN O O
Failure NN O O
In NN O O
the NN O O
randomized NN O O
clinical NN O O
trial NN O O
, NN O O
renal NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
of NN O O
any NN O O
grade NN O O
occurred NN O O
in NN O O
4 NN O O
% NN O O
of NN O O
the NN O O
patients NN O O
being NN O O
treated NN O O
with NN O O
JEVTANA NN O O
, NN O O
including NN O O
four NN O O
cases NN O O
with NN O O
fatal NN B-AdverseReaction B-AdverseReaction
outcome NN O O
. NN O O
Most NN O O
cases NN O O
occurred NN O O
in NN O O
association NN O O
with NN O O
sepsis NN B-AdverseReaction B-AdverseReaction
dehydration NN B-AdverseReaction B-AdverseReaction
or NN O O
obstructive NN B-AdverseReaction B-AdverseReaction
uropathy NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Some NN O O
deaths NN B-AdverseReaction B-AdverseReaction
due NN O O
to NN O O
renal NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
did NN O O
not NN O O
have NN O O
a NN O O
clear NN O O
etiology NN O O
. NN O O
Appropriate NN O O
measures NN O O
should NN O O
be NN O O
taken NN O O
to NN O O
identify NN O O
causes NN O O
of NN O O
renal NN O O
failure NN O O
and NN O O
treat NN O O
aggressively NN O O
. NN O O
5.5 NN O O
Use NN O O
in NN O O
Elderly NN O O
Patients NN O O
In NN O O
the NN O O
randomized NN O O
clinical NN O O
trial NN O O
, NN O O
3 NN O O
of NN O O
131 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
patients NN O O
< NN O O
65 NN O O
years NN O O
of NN O O
age NN O O
and NN O O
15 NN O O
of NN O O
240 NN O O
( NN O O
6 NN O O
% NN O O
) NN O O
>= NN O O
65 NN O O
years NN O O
of NN O O
age NN O O
died NN B-AdverseReaction B-AdverseReaction
of NN O O
causes NN O O
other NN O O
than NN O O
disease NN O O
progression NN O O
within NN O O
30 NN O O
days NN O O
of NN O O
the NN O O
last NN O O
cabazitaxel NN O O
dose NN O O
. NN O O
Patients NN O O
>= NN O O
65 NN O O
years NN O O
of NN O O
age NN O O
are NN O O
more NN O O
likely NN O O
to NN O O
experience NN O O
certain NN O O
adverse NN O O
reactions NN O O
, NN O O
including NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
and NN O O
febrile NN B-AdverseReaction B-AdverseReaction
neutropenia NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
and NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.5 NN O O
) NN O O
] NN O O
. NN O O
5.6 NN O O
Use NN O O
in NN O O
Patients NN O O
with NN O O
Hepatic NN O O
Impairment NN O O
Cabazitaxel NN O O
is NN O O
extensively NN O O
metabolized NN O O
in NN O O
the NN O O
liver NN O O
. NN O O
JEVTANA NN O O
is NN O O
contraindicated NN O O
in NN O O
patients NN O O
with NN O O
severe NN O O
hepatic NN O O
impairment NN O O
( NN O O
total NN O O
bilirubin NN O O
> NN O O
3 NN O O
* NN O O
ULN NN O O
) NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
] NN O O
. NN O O
Dose NN O O
should NN O O
be NN O O
reduced NN O O
for NN O O
patients NN O O
with NN O O
mild NN O O
( NN O O
total NN O O
bilirubin NN O O
> NN O O
1 NN O O
to NN O O
< NN O O
= NN O O
1.5 NN O O
* NN O O
ULN NN O O
or NN O O
AST NN O O
> NN O O
1.5 NN O O
* NN O O
ULN NN O O
) NN O O
and NN O O
moderate NN O O
( NN O O
total NN O O
bilirubin NN O O
> NN O O
1.5 NN O O
to NN O O
< NN O O
= NN O O
3.0 NN O O
* NN O O
ULN NN O O
and NN O O
any NN O O
AST NN O O
) NN O O
hepatic NN O O
impairment NN O O
, NN O O
based NN O O
on NN O O
tolerability NN O O
data NN O O
in NN O O
these NN O O
patients NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
and NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.7 NN O O
) NN O O
] NN O O
. NN O O
Administration NN O O
of NN O O
cabazitaxel NN O O
to NN O O
patients NN O O
with NN O O
mild NN O O
and NN O O
moderate NN O O
hepatic NN O O
impairment NN O O
should NN O O
be NN O O
undertaken NN O O
with NN O O
caution NN O O
and NN O O
close NN O O
monitoring NN O O
of NN O O
safety NN O O
. NN O O
5.7 NN O O
Embryo NN O O
- NN O O
Fetal NN O O
Toxicity NN O O
JEVTANA NN O O
is NN O O
not NN O O
indicated NN O O
for NN O O
use NN O O
in NN O O
female NN O O
patients NN O O
. NN O O
JEVTANA NN O O
can NN B-Factor B-Factor
cause NN O O
fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
when NN O O
administered NN O O
to NN O O
a NN O O
pregnant NN O O
woman NN O O
. NN O O
In NN O O
non NN O O
- NN O O
clinical NN O O
studies NN O O
in NN O O
rats NN B-Animal B-Animal
and NN O O
rabbits NN B-Animal B-Animal
cabazitaxel NN O O
was NN O O
embryotoxic NN B-AdverseReaction B-AdverseReaction
fetotoxic NN B-AdverseReaction B-AdverseReaction
and NN O O
abortifacient NN B-AdverseReaction B-AdverseReaction
at NN O O
exposures NN O O
significantly NN O O
lower NN O O
than NN O O
those NN O O
expected NN O O
at NN O O
the NN O O
recommended NN O O
human NN O O
dose NN O O
level NN O O
. NN O O
There NN O O
are NN O O
no NN O O
adequate NN O O
and NN O O
well NN O O
- NN O O
controlled NN O O
studies NN O O
in NN O O
pregnant NN O O
women NN O O
using NN O O
JEVTANA. NN O O
If NN O O
this NN O O
drug NN O O
is NN O O
used NN O O
during NN O O
pregnancy NN O O
, NN O O
or NN O O
if NN O O
the NN O O
patient NN O O
becomes NN O O
pregnant NN O O
while NN O O
taking NN O O
this NN O O
drug NN O O
, NN O O
the NN O O
patient NN O O
should NN O O
be NN O O
apprised NN O O
of NN O O
the NN O O
potential NN O O
hazard NN O O
to NN O O
the NN O O
fetus NN O O
. NN O O
Females NN O O
of NN O O
childbearing NN O O
potential NN O O
should NN O O
be NN O O
advised NN O O
to NN O O
avoid NN O O
becoming NN O O
pregnant NN O O
during NN O O
treatment NN O O
with NN O O
JEVTANA NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.1 NN O O
) NN O O
] NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
commonly NN O O
reported NN O O
adverse NN O O
reactions NN O O
were NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
which NN O O
occurred NN O O
in NN O O
almost NN O O
all NN O O
patients NN O O
( NN O O
97 NN O O
% NN O O
) NN O O
in NN O O
clinical NN O O
trials NN O O
. NN O O
Other NN O O
common NN O O
adverse NN O O
reactions NN O O
occurring NN O O
in NN O O
greater NN O O
than NN O O
1 NN O O
% NN O O
of NN O O
patients NN O O
included NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
transaminase NN B-AdverseReaction B-AdverseReaction
increase NN I-AdverseReaction I-AdverseReaction
dizziness NN B-AdverseReaction B-AdverseReaction
and NN O O
rash NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Shire NN O O
Human NN O O
Genetic NN O O
Therapies NN O O
at NN O O
the NN O O
OnePath NN O O
( NN O O
r NN O O
) NN O O
phone NN O O
# NN O O
1 NN O O
- NN O O
866 NN O O
- NN O O
888 NN O O
- NN O O
0660 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
The NN O O
safety NN O O
of NN O O
icatibant NN O O
was NN O O
evaluated NN O O
in NN O O
three NN O O
controlled NN O O
trials NN O O
that NN O O
included NN O O
223 NN O O
patients NN O O
who NN O O
received NN O O
FIRAZYR NN O O
30 NN O O
mg NN O O
( NN O O
n=113 NN O O
) NN O O
, NN O O
placebo NN O O
( NN O O
n=75 NN O O
) NN O O
, NN O O
or NN O O
comparator NN O O
( NN O O
n=38 NN O O
) NN O O
. NN O O
The NN O O
mean NN O O
age NN O O
at NN O O
study NN O O
entry NN O O
was NN O O
38 NN O O
years NN O O
( NN O O
range NN O O
18 NN O O
to NN O O
83 NN O O
years NN O O
) NN O O
, NN O O
64 NN O O
% NN O O
were NN O O
female NN O O
, NN O O
and NN O O
95 NN O O
% NN O O
were NN O O
white NN O O
. NN O O
The NN O O
data NN O O
described NN O O
below NN O O
represent NN O O
adverse NN O O
reactions NN O O
observed NN O O
from NN O O
the NN O O
two NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
, NN O O
consisting NN O O
of NN O O
77 NN O O
patients NN O O
who NN O O
received NN O O
FIRAZYR NN O O
at NN O O
a NN O O
dose NN O O
of NN O O
30 NN O O
mg NN O O
SC NN O O
, NN O O
and NN O O
75 NN O O
who NN O O
received NN O O
placebo NN O O
. NN O O
The NN O O
most NN O O
frequently NN O O
reported NN O O
adverse NN O O
reactions NN O O
( NN O O
occurring NN O O
in NN O O
greater NN O O
than NN O O
1 NN O O
% NN O O
of NN O O
patients NN O O
and NN O O
at NN O O
a NN O O
higher NN O O
rate NN O O
with NN O O
FIRAZYR NN O O
versus NN O O
placebo NN O O
) NN O O
are NN O O
shown NN O O
in NN O O
Table NN O O
1 NN O O
. NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
Table NN O O
1 NN O O
Adverse NN O O
reactions NN O O
observed NN O O
in NN O O
>1 NN O O
% NN O O
of NN O O
patients NN O O
with NN O O
acute NN O O
attacks NN O O
of NN O O
HAE NN O O
and NN O O
at NN O O
a NN O O
higher NN O O
rate NN O O
with NN O O
FIRAZYR NN O O
versus NN O O
placebo NN O O
in NN O O
the NN O O
placebo NN O O
- NN O O
controlled NN O O
trialsEvents NN O O
occurring NN O O
within NN O O
14 NN O O
days NN O O
of NN O O
study NN O O
drug NN O O
administration NN O O
FIRAZYR(N NN O O
=77 NN O O
) NN O O
Placebo(N NN O O
= NN O O
75 NN O O
) NN O O
System NN O O
Organ NN O O
ClassPreferred NN O O
Term NN O O
Subjects NN O O
( NN O O
% NN O O
) NN O O
Subjects NN O O
( NN O O
% NN O O
) NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
Injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
75 NN O O
( NN O O
97 NN O O
) NN O O
25 NN O O
( NN O O
33 NN O O
) NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
3 NN O O
( NN O O
4 NN O O
) NN O O
0 NN O O
Investigations NN O O
Transaminase NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
3 NN O O
( NN O O
4 NN O O
) NN O O
0 NN O O
Nervous NN O O
system NN O O
disorders NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
2 NN O O
( NN O O
3 NN O O
) NN O O
1 NN O O
( NN O O
1 NN O O
) NN O O
The NN O O
third NN O O
trial NN O O
was NN O O
active NN O O
- NN O O
controlled NN O O
and NN O O
was NN O O
comprised NN O O
of NN O O
35 NN O O
patients NN O O
who NN O O
received NN O O
FIRAZYR NN O O
30 NN O O
mg NN O O
and NN O O
38 NN O O
patients NN O O
who NN O O
received NN O O
the NN O O
comparator NN O O
. NN O O
Adverse NN O O
reactions NN O O
for NN O O
FIRAZYR NN O O
were NN O O
similar NN O O
in NN O O
nature NN O O
and NN O O
frequency NN O O
to NN O O
those NN O O
reported NN O O
in NN O O
Table NN O O
1 NN O O
. NN O O
In NN O O
all NN O O
three NN O O
controlled NN O O
trials NN O O
, NN O O
patients NN O O
were NN O O
eligible NN O O
for NN O O
treatment NN O O
of NN O O
subsequent NN O O
attacks NN O O
in NN O O
an NN O O
open NN O O
- NN O O
label NN O O
extension NN O O
. NN O O
Patients NN O O
were NN O O
treated NN O O
with NN O O
FIRAZYR NN O O
30 NN O O
mg NN O O
and NN O O
could NN O O
receive NN O O
up NN O O
to NN O O
3 NN O O
doses NN O O
of NN O O
FIRAZYR NN O O
30 NN O O
mg NN O O
administered NN O O
at NN O O
least NN O O
6 NN O O
hours NN O O
apart NN O O
for NN O O
each NN O O
attack NN O O
. NN O O
A NN O O
total NN O O
of NN O O
225 NN O O
patients NN O O
were NN O O
treated NN O O
with NN O O
1,076 NN O O
doses NN O O
of NN O O
30 NN O O
mg NN O O
FIRAZYR NN O O
for NN O O
987 NN O O
attacks NN O O
of NN O O
acute NN O O
HAE. NN O O
Adverse NN O O
reactions NN O O
similar NN O O
in NN O O
nature NN O O
and NN O O
frequency NN O O
were NN O O
observed NN O O
to NN O O
those NN O O
seen NN O O
in NN O O
the NN O O
controlled NN O O
phase NN O O
of NN O O
the NN O O
trials NN O O
. NN O O
Other NN O O
adverse NN O O
reactions NN O O
reported NN O O
included NN O O
rash NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
and NN O O
headache NN B-AdverseReaction B-AdverseReaction
in NN O O
patients NN O O
exposed NN O O
to NN O O
FIRAZYR. NN O O
The NN O O
safety NN O O
of NN O O
self NN O O
- NN O O
administration NN O O
was NN O O
evaluated NN O O
in NN O O
a NN O O
separate NN O O
, NN O O
open NN O O
- NN O O
label NN O O
trial NN O O
in NN O O
56 NN O O
patients NN O O
with NN O O
HAE. NN O O
In NN O O
this NN O O
trial NN O O
, NN O O
the NN O O
safety NN O O
profile NN O O
of NN O O
FIRAZYR NN O O
in NN O O
patients NN O O
who NN O O
self NN O O
- NN O O
administered NN O O
FIRAZYR NN O O
was NN O O
similar NN O O
in NN O O
nature NN O O
and NN O O
frequency NN O O
to NN O O
that NN O O
of NN O O
patients NN O O
whose NN O O
therapy NN O O
was NN O O
administered NN O O
by NN O O
healthcare NN O O
professionals NN O O
. NN O O
6.2 NN O O
Immunogenicity NN O O
Across NN O O
repeated NN O O
treatment NN O O
in NN O O
the NN O O
controlled NN O O
trials NN O O
, NN O O
4 NN O O
patients NN O O
tested NN O O
positive NN O O
for NN O O
anti NN O O
- NN O O
icatibant NN O O
antibodies NN O O
. NN O O
Three NN O O
of NN O O
these NN O O
patients NN O O
had NN O O
subsequent NN O O
tests NN O O
which NN O O
were NN O O
negative NN O O
. NN O O
No NN B-Negation B-Negation
hypersensitivity NN B-AdverseReaction B-AdverseReaction
or NN O O
anaphylactic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
with NN O O
FIRAZYR. NN O O
No NN O O
association NN O O
between NN O O
anti NN O O
- NN O O
icatibant NN O O
antibodies NN O O
and NN O O
efficacy NN O O
was NN O O
observed NN O O
. NN O O
6.3 NN O O
Postmarketing NN O O
Experience NN O O
Similar NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
observed NN O O
in NN O O
postmarketing NN O O
use NN O O
as NN O O
compared NN O O
to NN O O
the NN O O
clinical NN O O
trials NN O O
. NN O O
Because NN O O
these NN O O
events NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Laryngeal NN O O
attacks NN O O
: NN O O
Following NN O O
treatment NN O O
of NN O O
laryngeal NN O O
attacks NN O O
with NN O O
FIRAZYR NN O O
, NN O O
advise NN O O
patients NN O O
to NN O O
seek NN O O
immediate NN O O
medical NN O O
attention NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
5.1 NN O O
Laryngeal NN O O
Attacks NN O O
Given NN O O
the NN O O
potential NN O O
for NN O O
airway NN O O
obstruction NN O O
during NN O O
acute NN O O
laryngeal NN O O
HAE NN O O
attacks NN O O
, NN O O
patients NN O O
should NN O O
be NN O O
advised NN O O
to NN O O
seek NN O O
medical NN O O
attention NN O O
in NN O O
an NN O O
appropriate NN O O
healthcare NN O O
facility NN O O
immediately NN O O
in NN O O
addition NN O O
to NN O O
treatment NN O O
with NN O O
FIRAZYR. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
Three NN O O
hundred NN O O
ninety NN O O
- NN O O
five NN O O
patients NN O O
, NN O O
including NN O O
approximately NN O O
250 NN O O
children NN O O
( NN O O
aged NN O O
2 NN O O
to NN O O
17 NN O O
years NN O O
) NN O O
have NN O O
been NN O O
treated NN O O
with NN O O
ILARIS NN O O
in NN O O
interventional NN O O
trials NN O O
in NN O O
CAPS NN O O
or NN O O
SJIA. NN O O
The NN O O
most NN O O
frequently NN O O
reported NN O O
adverse NN O O
drug NN O O
reactions NN O O
were NN O O
infections NN B-AdverseReaction B-AdverseReaction
predominantly NN O O
of NN O O
the NN O O
upper NN O O
respiratory NN O O
tract NN O O
. NN O O
The NN O O
majority NN O O
of NN O O
the NN O O
events NN O O
were NN O O
mild NN B-Severity B-Severity
to NN I-Severity I-Severity
moderate NN I-Severity I-Severity
although NN O O
serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
were NN O O
observed NN O O
. NN O O
The NN O O
type NN O O
and NN O O
frequency NN O O
of NN O O
adverse NN O O
drug NN O O
reactions NN O O
appeared NN O O
to NN O O
be NN O O
consistent NN O O
over NN O O
time NN O O
. NN O O
Opportunistic NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
have NN O O
also NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
ILARIS NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
EXCERPT NN O O
: NN O O
CAPS NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
greater NN O O
than NN O O
10 NN O O
% NN O O
reported NN O O
by NN O O
patients NN O O
with NN O O
CAPS NN O O
treated NN O O
with NN O O
ILARIS NN O O
are NN O O
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
influenza NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
and NN O O
nausea NN B-AdverseReaction B-AdverseReaction
( NN O O
6 NN O O
) NN O O
SJIA NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
drug NN O O
reactions NN O O
greater NN O O
than NN O O
10 NN O O
% NN O O
reported NN O O
by NN O O
patients NN O O
with NN O O
SJIA NN O O
treated NN O O
with NN O O
ILARIS NN O O
are NN O O
infections NN B-AdverseReaction B-AdverseReaction
( NN O O
nasopharyngitis NN O O
and NN O O
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
and NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
( NN O O
6 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Novartis NN O O
Pharmaceuticals NN O O
Corporation NN O O
at NN O O
1 NN O O
- NN O O
888 NN O O
- NN O O
669 NN O O
- NN O O
6682 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
6.1 NN O O
Clinical NN O O
Trial NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
Treatment NN O O
of NN O O
CAPS NN O O
The NN O O
data NN O O
described NN O O
herein NN O O
reflect NN O O
exposure NN O O
to NN O O
ILARIS NN O O
in NN O O
104 NN O O
adult NN O O
and NN O O
pediatric NN O O
CAPS NN O O
patients NN O O
, NN O O
including NN O O
20 NN O O
FCAS NN O O
, NN O O
72 NN O O
MWS NN O O
, NN O O
10 NN O O
MWS/NOMID NN O O
( NN O O
Neonatal NN O O
Onset NN O O
Multisystem NN O O
Inflammatory NN O O
Disorder NN O O
) NN O O
overlap NN O O
, NN O O
1 NN O O
non NN O O
- NN O O
FCAS NN O O
non NN O O
- NN O O
MWS NN O O
, NN O O
and NN O O
1 NN O O
misdiagnosed NN O O
in NN O O
placebo NN O O
- NN O O
controlled NN O O
( NN O O
35 NN O O
patients NN O O
) NN O O
and NN O O
uncontrolled NN O O
trials NN O O
. NN O O
Sixty NN O O
- NN O O
two NN O O
patients NN O O
were NN O O
exposed NN O O
to NN O O
ILARIS NN O O
for NN O O
at NN O O
least NN O O
6 NN O O
months NN O O
, NN O O
56 NN O O
for NN O O
at NN O O
least NN O O
1 NN O O
year NN O O
and NN O O
4 NN O O
for NN O O
at NN O O
least NN O O
3 NN O O
years NN O O
. NN O O
A NN O O
total NN O O
of NN O O
9 NN O O
serious NN O O
adverse NN O O
reactions NN O O
were NN O O
reported NN O O
for NN O O
CAPS NN O O
patients NN O O
. NN O O
Among NN O O
these NN O O
were NN O O
vertigo NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
patients NN O O
) NN O O
, NN O O
infections NN B-AdverseReaction B-AdverseReaction
( NN O O
3 NN O O
patients NN O O
) NN O O
, NN O O
including NN O O
intra NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
abdominal NN I-AdverseReaction I-AdverseReaction
abscess NN I-AdverseReaction I-AdverseReaction
following NN O O
appendectomy NN O O
( NN O O
1 NN O O
patient NN O O
) NN O O
. NN O O
The NN O O
most NN O O
commonly NN O O
reported NN O O
adverse NN O O
reactions NN O O
associated NN O O
with NN O O
ILARIS NN O O
treatment NN O O
in NN O O
the NN O O
CAPS NN O O
patients NN O O
were NN O O
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
influenza NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
and NN O O
nausea NN B-AdverseReaction B-AdverseReaction
One NN O O
patient NN O O
discontinued NN O O
treatment NN O O
due NN O O
to NN O O
potential NN B-Factor B-Factor
infection NN B-AdverseReaction B-AdverseReaction
CAPS NN O O
Study NN O O
1 NN O O
investigated NN O O
the NN O O
safety NN O O
of NN O O
ILARIS NN O O
in NN O O
an NN O O
8-week NN O O
, NN O O
open NN O O
- NN O O
label NN O O
period NN O O
( NN O O
Part NN O O
1 NN O O
) NN O O
, NN O O
followed NN O O
by NN O O
a NN O O
24-week NN O O
, NN O O
randomized NN O O
withdrawal NN O O
period NN O O
( NN O O
Part NN O O
2 NN O O
) NN O O
, NN O O
followed NN O O
by NN O O
a NN O O
16-week NN O O
, NN O O
open NN O O
- NN O O
label NN O O
period NN O O
( NN O O
Part NN O O
3 NN O O
) NN O O
. NN O O
All NN O O
patients NN O O
were NN O O
treated NN O O
with NN O O
ILARIS NN O O
150 NN O O
mg NN O O
subcutaneously NN O O
or NN O O
2 NN O O
mg/kg NN O O
if NN O O
body NN O O
weight NN O O
was NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
15 NN O O
kg NN O O
and NN O O
less NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
40 NN O O
kg NN O O
( NN O O
see NN O O
Table NN O O
1 NN O O
) NN O O
. NN O O
Since NN O O
all NN O O
CAPS NN O O
patients NN O O
received NN O O
ILARIS NN O O
in NN O O
Part NN O O
1 NN O O
, NN O O
there NN O O
are NN O O
no NN O O
controlled NN O O
data NN O O
on NN O O
adverse NN O O
events NN O O
( NN O O
AEs NN O O
) NN O O
. NN O O
Data NN O O
in NN O O
Table NN O O
1 NN O O
are NN O O
for NN O O
all NN O O
AEs NN O O
for NN O O
all NN O O
CAPS NN O O
patients NN O O
receiving NN O O
canakinumab NN O O
. NN O O
In NN O O
CAPS NN O O
Study NN O O
1 NN O O
, NN O O
no NN O O
pattern NN O O
was NN O O
observed NN O O
for NN O O
any NN O O
type NN O O
or NN O O
frequency NN O O
of NN O O
adverse NN O O
events NN O O
throughout NN O O
the NN O O
three NN O O
study NN O O
periods NN O O
. NN O O
Table NN O O
1 NN O O
Number NN O O
( NN O O
% NN O O
) NN O O
of NN O O
Patients NN O O
with NN O O
AEs NN O O
by NN O O
Preferred NN O O
Terms NN O O
, NN O O
in NN O O
>10 NN O O
% NN O O
of NN O O
Patients NN O O
in NN O O
Parts NN O O
1 NN O O
to NN O O
3 NN O O
of NN O O
the NN O O
Phase NN O O
3 NN O O
Trial NN O O
for NN O O
CAPS NN O O
Patients NN O O
Preferred NN O O
Term NN O O
ILARISN=35n NN O O
( NN O O
% NN O O
) NN O O
n NN O O
% NN O O
of NN O O
Patients NN O O
with NN O O
Adverse NN O O
Events NN O O
35 NN O O
( NN O O
100 NN O O
) NN O O
Nasopharyngitis NN B-AdverseReaction B-AdverseReaction
12 NN O O
( NN O O
34 NN O O
) NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
7 NN O O
( NN O O
20 NN O O
) NN O O
Influenza NN B-AdverseReaction B-AdverseReaction
6 NN O O
( NN O O
17 NN O O
) NN O O
Rhinitis NN B-AdverseReaction B-AdverseReaction
6 NN O O
( NN O O
17 NN O O
) NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
5 NN O O
( NN O O
14 NN O O
) NN O O
Headache NN B-AdverseReaction B-AdverseReaction
5 NN O O
( NN O O
14 NN O O
) NN O O
Bronchitis NN B-AdverseReaction B-AdverseReaction
4 NN O O
( NN O O
11 NN O O
) NN O O
Gastroenteritis NN B-AdverseReaction B-AdverseReaction
4 NN O O
( NN O O
11 NN O O
) NN O O
Pharyngitis NN B-AdverseReaction B-AdverseReaction
4 NN O O
( NN O O
11 NN O O
) NN O O
Weight NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
4 NN O O
( NN O O
11 NN O O
) NN O O
Musculoskeletal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
4 NN O O
( NN O O
11 NN O O
) NN O O
Vertigo NN B-AdverseReaction B-AdverseReaction
4 NN O O
( NN O O
11 NN O O
) NN O O
Vertigo NN O O
Vertigo NN B-AdverseReaction B-AdverseReaction
has NN O O
been NN O O
reported NN O O
in NN O O
9 NN O O
% NN O O
to NN O O
14 NN O O
% NN O O
of NN O O
patients NN O O
in NN O O
CAPS NN O O
studies NN O O
, NN O O
exclusively NN O O
in NN O O
MWS NN O O
patients NN O O
, NN O O
and NN O O
reported NN O O
as NN O O
a NN O O
serious NN B-Severity B-Severity
adverse NN O O
event NN O O
in NN O O
two NN O O
cases NN O O
. NN O O
All NN O O
events NN O O
resolved NN O O
with NN O O
continued NN O O
treatment NN O O
with NN O O
ILARIS. NN O O
Injection NN O O
Site NN O O
Reactions NN O O
In NN O O
CAPS NN O O
Study NN O O
1 NN O O
, NN O O
subcutaneous NN B-AdverseReaction B-AdverseReaction
injection NN I-AdverseReaction I-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
were NN O O
observed NN O O
in NN O O
9 NN O O
% NN O O
of NN O O
patients NN O O
in NN O O
Part NN O O
1 NN O O
with NN O O
mild NN O O
tolerability NN O O
reactions NN O O
; NN O O
in NN O O
Part NN O O
2 NN O O
, NN O O
one NN O O
patient NN O O
each NN O O
( NN O O
7 NN O O
% NN O O
) NN O O
had NN O O
a NN O O
mild NN O O
or NN O O
a NN O O
moderate NN O O
tolerability NN O O
reaction NN O O
and NN O O
, NN O O
in NN O O
Part NN O O
3 NN O O
, NN O O
one NN O O
patient NN O O
had NN O O
a NN O O
mild NN B-Severity B-Severity
local NN B-AdverseReaction B-AdverseReaction
tolerability NN I-AdverseReaction I-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
No NN B-Negation B-Negation
severe NN B-Severity B-Severity
injection NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
and NN O O
none NN O O
led NN O O
to NN O O
discontinuation NN O O
of NN O O
treatment NN O O
. NN O O
Treatment NN O O
of NN O O
SJIA NN O O
A NN O O
total NN O O
of NN O O
201 NN O O
SJIA NN O O
patients NN O O
aged NN O O
2 NN O O
to NN O O
less NN O O
than NN O O
20 NN O O
years NN O O
have NN O O
received NN O O
ILARIS NN O O
in NN O O
clinical NN O O
trials NN O O
. NN O O
The NN O O
safety NN O O
of NN O O
ILARIS NN O O
compared NN O O
to NN O O
placebo NN O O
was NN O O
investigated NN O O
in NN O O
two NN O O
phase NN O O
3 NN O O
studies NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14.2 NN O O
) NN O O
] NN O O
. NN O O
Patients NN O O
in NN O O
SJIA NN O O
Study NN O O
1 NN O O
received NN O O
a NN O O
single NN O O
dose NN O O
of NN O O
ILARIS NN O O
4 NN O O
mg/kg NN O O
( NN O O
n=43 NN O O
) NN O O
or NN O O
placebo NN O O
( NN O O
n=41 NN O O
) NN O O
via NN O O
subcutaneous NN O O
injection NN O O
and NN O O
were NN O O
assessed NN O O
at NN O O
Day NN O O
15 NN O O
for NN O O
the NN O O
efficacy NN O O
endpoints NN O O
and NN O O
had NN O O
a NN O O
safety NN O O
analysis NN O O
up NN O O
to NN O O
Day NN O O
29 NN O O
. NN O O
SJIA NN O O
Study NN O O
2 NN O O
was NN O O
a NN O O
two NN O O
- NN O O
part NN O O
study NN O O
with NN O O
an NN O O
open NN O O
- NN O O
label NN O O
, NN O O
single NN O O
- NN O O
arm NN O O
active NN O O
treatment NN O O
period NN O O
( NN O O
Part NN O O
I NN O O
) NN O O
followed NN O O
by NN O O
a NN O O
randomized NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
, NN O O
event NN O O
- NN O O
driven NN O O
withdrawal NN O O
design NN O O
( NN O O
Part NN O O
II NN O O
) NN O O
. NN O O
Overall NN O O
, NN O O
177 NN O O
patients NN O O
were NN O O
enrolled NN O O
into NN O O
the NN O O
study NN O O
and NN O O
received NN O O
ILARIS NN O O
4 NN O O
mg/kg NN O O
( NN O O
up NN O O
to NN O O
300 NN O O
mg NN O O
maximum NN O O
) NN O O
in NN O O
Part NN O O
I NN O O
, NN O O
and NN O O
100 NN O O
patients NN O O
received NN O O
ILARIS NN O O
4 NN O O
mg/kg NN O O
( NN O O
up NN O O
to NN O O
300 NN O O
mg NN O O
maximum NN O O
) NN O O
every NN O O
4 NN O O
weeks NN O O
or NN O O
placebo NN O O
in NN O O
Part NN O O
II. NN O O
Adverse NN O O
drug NN O O
reactions NN O O
listed NN O O
in NN O O
Table NN O O
2 NN O O
showed NN O O
higher NN O O
rates NN O O
than NN O O
placebo NN O O
from NN O O
both NN O O
trials NN O O
. NN O O
The NN O O
adverse NN O O
drug NN O O
reactions NN O O
associated NN O O
with NN O O
ILARIS NN O O
treatment NN O O
in NN O O
SJIA NN O O
patients NN O O
were NN O O
infections NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
and NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
Serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
( NN O O
e.g. NN O O
, NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
varicella NN B-AdverseReaction B-AdverseReaction
gastroenteritis NN B-AdverseReaction B-AdverseReaction
measles NN B-AdverseReaction B-AdverseReaction
sepsis NN B-AdverseReaction B-AdverseReaction
otitis NN B-AdverseReaction B-AdverseReaction
media NN I-AdverseReaction I-AdverseReaction
sinusitis NN B-AdverseReaction B-AdverseReaction
adenovirus NN B-AdverseReaction B-AdverseReaction
lymph NN B-AdverseReaction B-AdverseReaction
node NN I-AdverseReaction I-AdverseReaction
abscess NN I-AdverseReaction I-AdverseReaction
pharyngitis NN B-AdverseReaction B-AdverseReaction
were NN O O
observed NN O O
in NN O O
approximately NN O O
4 NN O O
% NN O O
to NN O O
5 NN O O
% NN O O
( NN O O
0.02 NN O O
to NN O O
0.17 NN O O
per NN O O
100 NN O O
patient NN O O
- NN O O
days NN O O
) NN O O
of NN O O
patients NN O O
receiving NN O O
ILARIS NN O O
in NN O O
both NN O O
studies NN O O
. NN O O
Adverse NN O O
reactions NN O O
are NN O O
listed NN O O
according NN O O
to NN O O
MedDRA NN O O
version NN O O
15.0 NN O O
system NN O O
organ NN O O
class NN O O
. NN O O
Table NN O O
2 NN O O
Tabulated NN O O
Summary NN O O
of NN O O
Adverse NN O O
Drug NN O O
Reactions NN O O
from NN O O
Pivotal NN O O
SJIA NN O O
Clinical NN O O
Trials NN O O
n= NN O O
number NN O O
of NN O O
patients^ NN O O
IR=Exposure NN O O
adjusted NN O O
incidence NN O O
rate NN O O
per NN O O
100 NN O O
patient NN O O
- NN O O
days NN O O
* NN O O
No NN O O
injection NN O O
site NN O O
reaction NN O O
led NN O O
to NN O O
study NN O O
discontinuation NN O O
SJIA NN O O
Study NN O O
2 NN O O
SJIA NN O O
Study NN O O
1 NN O O
Part NN O O
I NN O O
Part NN O O
II NN O O
ILARISN=177n NN O O
( NN O O
%)(IR)^ NN O O
ILARISN=50n NN O O
( NN O O
%)(IR NN O O
) NN O O
PlaceboN=50n NN O O
( NN O O
%)(IR NN O O
) NN O O
ILARISN=43n NN O O
( NN O O
%)(IR NN O O
) NN O O
PlaceboN=41n NN O O
( NN O O
%)(IR NN O O
) NN O O
Infections NN O O
and NN O O
infestations NN O O
All NN O O
Infections NN B-AdverseReaction B-AdverseReaction
( NN O O
e.g. NN O O
, NN O O
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
( NN O O
viral NN O O
) NN O O
upper NN O O
respiratory NN O O
tract NN O O
infection NN O O
, NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
rhinitis NN B-AdverseReaction B-AdverseReaction
pharyngitis NN B-AdverseReaction B-AdverseReaction
tonsillitis NN B-AdverseReaction B-AdverseReaction
sinusitis NN B-AdverseReaction B-AdverseReaction
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
gastroenteritis NN B-AdverseReaction B-AdverseReaction
viral NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
97 NN O O
( NN O O
54.8%)(0.91 NN O O
) NN O O
27 NN O O
( NN O O
54%)(0.59 NN O O
) NN O O
19 NN O O
( NN O O
38%)(0.63 NN O O
) NN O O
13 NN O O
( NN O O
30.2%)(1.26 NN O O
) NN O O
5 NN O O
( NN O O
12.2%)(1.37 NN O O
) NN O O
Gastrointestinal NN O O
disorders NN O O
Abdominal NN O O
pain NN O O
( NN O O
upper NN O O
) NN O O
25 NN O O
( NN O O
14.1%)(0.16 NN O O
) NN O O
8 NN O O
( NN O O
16%)(0.15 NN O O
) NN O O
6 NN O O
( NN O O
12%)(0.08 NN O O
) NN O O
3 NN O O
( NN O O
7%)(0.25 NN O O
) NN O O
1 NN O O
( NN O O
2.4%)(0.23 NN O O
) NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
Injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
mild NN O O
19 NN O O
( NN O O
10.7 NN O O
% NN O O
) NN O O
6 NN O O
( NN O O
12.0 NN O O
% NN O O
) NN O O
2 NN O O
( NN O O
4.0 NN O O
% NN O O
) NN O O
0 NN O O
3 NN O O
( NN O O
7.3 NN O O
% NN O O
) NN O O
moderate NN O O
2 NN O O
( NN O O
1.1 NN O O
% NN O O
) NN O O
1 NN O O
( NN O O
2.0 NN O O
% NN O O
) NN O O
0 NN O O
0 NN O O
0 NN O O
6.2 NN O O
Hypersensitivity NN O O
During NN O O
clinical NN O O
trials NN O O
, NN O O
no NN B-Negation B-Negation
anaphylactic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
. NN O O
In NN O O
CAPS NN O O
trials NN O O
one NN O O
patient NN O O
discontinued NN O O
and NN O O
in NN O O
SJIA NN O O
trials NN O O
no NN O O
patients NN O O
discontinued NN O O
due NN O O
to NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
ILARIS NN O O
should NN O O
not NN O O
be NN O O
administered NN O O
to NN O O
any NN O O
patients NN O O
with NN O O
known NN O O
clinical NN O O
hypersensitivity NN O O
to NN O O
ILARIS NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
and NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
. NN O O
6.3 NN O O
Immunogenicity NN O O
A NN O O
biosensor NN O O
binding NN O O
assay NN O O
or NN O O
a NN O O
bridging NN O O
immunoassay NN O O
was NN O O
used NN O O
to NN O O
detect NN O O
antibodies NN O O
directed NN O O
against NN O O
canakinumab NN O O
in NN O O
patients NN O O
who NN O O
received NN O O
ILARIS. NN O O
Antibodies NN O O
against NN O O
ILARIS NN O O
were NN O O
observed NN O O
in NN O O
approximately NN O O
1.5 NN O O
% NN O O
and NN O O
3.1 NN O O
% NN O O
of NN O O
the NN O O
patients NN O O
treated NN O O
with NN O O
ILARIS NN O O
for NN O O
CAPS NN O O
and NN O O
SJIA NN O O
, NN O O
respectively NN O O
. NN O O
No NN O O
neutralizing NN O O
antibodies NN O O
were NN O O
detected NN O O
. NN O O
No NN O O
apparent NN O O
correlation NN O O
of NN O O
antibody NN O O
development NN O O
to NN O O
clinical NN O O
response NN O O
or NN O O
adverse NN O O
events NN O O
was NN O O
observed NN O O
. NN O O
The NN O O
CAPS NN O O
clinical NN O O
studies NN O O
employed NN O O
the NN O O
biosensor NN O O
binding NN O O
assay NN O O
, NN O O
and NN O O
most NN O O
of NN O O
the NN O O
SJIA NN O O
clinical NN O O
studies NN O O
employed NN O O
the NN O O
bridging NN O O
assay NN O O
. NN O O
The NN O O
data NN O O
obtained NN O O
in NN O O
an NN O O
assay NN O O
are NN O O
highly NN O O
dependent NN O O
on NN O O
several NN O O
factors NN O O
including NN O O
assay NN O O
sensitivity NN O O
and NN O O
specificity NN O O
, NN O O
assay NN O O
methodology NN O O
, NN O O
sample NN O O
handling NN O O
, NN O O
timing NN O O
of NN O O
sample NN O O
collection NN O O
, NN O O
concomitant NN O O
medications NN O O
, NN O O
underlying NN O O
disease NN O O
, NN O O
and NN O O
the NN O O
number NN O O
of NN O O
patients NN O O
tested NN O O
. NN O O
For NN O O
these NN O O
reasons NN O O
, NN O O
comparison NN O O
of NN O O
the NN O O
incidence NN O O
of NN O O
antibodies NN O O
to NN O O
canakinumab NN O O
between NN O O
the NN O O
CAPS NN O O
and NN O O
SJIA NN O O
clinical NN O O
studies NN O O
or NN O O
with NN O O
the NN O O
incidence NN O O
of NN O O
antibodies NN O O
to NN O O
other NN O O
products NN O O
may NN O O
be NN O O
misleading NN O O
. NN O O
6.4 NN O O
Laboratory NN O O
Findings NN O O
Hematology NN O O
During NN O O
clinical NN O O
trials NN O O
with NN O O
ILARIS NN O O
, NN O O
mean NN O O
values NN O O
decreased NN O O
for NN O O
white NN O O
blood NN O O
cells NN O O
, NN O O
neutrophils NN O O
and NN O O
platelets NN O O
. NN O O
In NN O O
the NN O O
randomized NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
portion NN O O
of NN O O
SJIA NN O O
Study NN O O
2 NN O O
decreased NN B-AdverseReaction B-AdverseReaction
white NN I-AdverseReaction I-AdverseReaction
blood NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
counts NN I-AdverseReaction I-AdverseReaction
( NN O O
WBC NN O O
) NN O O
less NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
0.8 NN B-Severity B-Severity
times NN I-Severity I-Severity
lower NN I-Severity I-Severity
limit NN I-Severity I-Severity
of NN I-Severity I-Severity
normal NN I-Severity I-Severity
( NN O O
LLN NN O O
) NN O O
were NN O O
reported NN O O
in NN O O
5 NN O O
patients NN O O
( NN O O
10.4%)in NN O O
the NN O O
ILARIS NN O O
group NN O O
compared NN O O
to NN O O
2 NN O O
( NN O O
4.0 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
. NN O O
Transient NN B-Severity B-Severity
decreases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
absolute NN I-AdverseReaction I-AdverseReaction
neutrophil NN I-AdverseReaction I-AdverseReaction
count NN I-AdverseReaction I-AdverseReaction
( NN O O
ANC NN O O
) NN O O
to NN O O
less NN O O
than NN O O
1x10 NN B-Severity B-Severity
9 NN I-Severity I-Severity
/L NN I-Severity I-Severity
were NN O O
reported NN O O
in NN O O
3 NN O O
patients NN O O
( NN O O
6.0 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
ILARIS NN O O
group NN O O
compared NN O O
to1 NN O O
patient NN O O
( NN O O
2.0 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
. NN O O
One NN O O
case NN O O
of NN O O
ANC NN B-AdverseReaction B-AdverseReaction
less NN I-AdverseReaction I-AdverseReaction
than NN I-AdverseReaction I-AdverseReaction
0.5x10 NN I-AdverseReaction I-AdverseReaction
9 NN I-AdverseReaction I-AdverseReaction
/L NN I-AdverseReaction I-AdverseReaction
was NN O O
observed NN O O
in NN O O
the NN O O
ILARIS NN O O
group NN O O
and NN O O
none NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
. NN O O
Mild NN B-Severity B-Severity
( NN O O
less NN O O
than NN O O
LLN NN B-Severity B-Severity
and NN O O
greater NN O O
than NN O O
75x10 NN B-Severity B-Severity
9 NN I-Severity I-Severity
/L NN I-Severity I-Severity
and NN O O
transient NN B-Severity B-Severity
decreases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
platelet NN I-AdverseReaction I-AdverseReaction
counts NN I-AdverseReaction I-AdverseReaction
were NN O O
observed NN O O
in NN O O
3 NN O O
( NN O O
6.3 NN O O
% NN O O
) NN O O
ILARIS NN O O
treated NN O O
patients NN O O
versus NN O O
1 NN O O
( NN O O
2.0 NN O O
% NN O O
) NN O O
placebo NN O O
- NN O O
treated NN O O
patient NN O O
. NN O O
Hepatic NN O O
Transaminases NN O O
Elevations NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
transaminases NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
observed NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
ILARIS. NN O O
In NN O O
the NN O O
randomized NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
portion NN O O
of NN O O
SJIA NN O O
Study NN O O
2 NN O O
, NN O O
high NN B-AdverseReaction B-AdverseReaction
ALT NN I-AdverseReaction I-AdverseReaction
and/or NN O O
AST NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
3 NN B-Severity B-Severity
times NN I-Severity I-Severity
upper NN I-Severity I-Severity
limit NN I-Severity I-Severity
of NN I-Severity I-Severity
normal NN I-Severity I-Severity
( NN O O
ULN NN O O
) NN O O
were NN O O
reported NN O O
in NN O O
2 NN O O
( NN O O
4.1 NN O O
% NN O O
) NN O O
ILARIS NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
1 NN O O
( NN O O
2.0 NN O O
% NN O O
) NN O O
placebo NN O O
patient NN O O
. NN O O
All NN O O
patients NN O O
had NN O O
normal NN O O
values NN O O
at NN O O
the NN O O
next NN O O
visit NN O O
. NN O O
Bilirubin NN O O
Asymptomatic NN O O
and NN O O
mild NN B-Severity B-Severity
elevations NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
bilirubin NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
observed NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
ILARIS NN O O
without NN B-Negation B-Negation
concomitant NN O O
elevations NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
transaminases NN I-AdverseReaction I-AdverseReaction
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Interleukin-1 NN O O
blockade NN O O
may NN O O
interfere NN O O
with NN O O
immune NN O O
response NN O O
to NN O O
infections NN O O
. NN O O
Treatment NN O O
with NN O O
medications NN B-DrugClass B-DrugClass
that NN I-DrugClass I-DrugClass
work NN I-DrugClass I-DrugClass
through NN I-DrugClass I-DrugClass
inhibition NN I-DrugClass I-DrugClass
of NN I-DrugClass I-DrugClass
IL-1 NN I-DrugClass I-DrugClass
has NN O O
been NN O O
associated NN O O
with NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
ILARIS NN O O
has NN O O
been NN O O
associated NN O O
with NN O O
an NN O O
increased NN O O
incidence NN O O
of NN O O
serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
Physicians NN O O
should NN O O
exercise NN O O
caution NN O O
when NN O O
administering NN O O
ILARIS NN O O
to NN O O
patients NN O O
with NN O O
infections NN O O
, NN O O
a NN O O
history NN O O
of NN O O
recurring NN O O
infections NN O O
or NN O O
underlying NN O O
conditions NN O O
which NN O O
may NN O O
predispose NN O O
them NN O O
to NN O O
infections NN O O
. NN O O
Discontinue NN O O
treatment NN O O
with NN O O
ILARIS NN O O
if NN O O
a NN O O
patient NN O O
develops NN O O
a NN O O
serious NN O O
infection NN O O
. NN O O
Do NN O O
not NN O O
administer NN O O
ILARIS NN O O
to NN O O
patients NN O O
during NN O O
an NN O O
active NN O O
infection NN O O
requiring NN O O
medical NN O O
intervention NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Live NN O O
vaccines NN O O
should NN O O
not NN O O
be NN O O
given NN O O
concurrently NN O O
with NN O O
ILARIS. NN O O
Prior NN O O
to NN O O
initiation NN O O
of NN O O
therapy NN O O
with NN O O
ILARIS NN O O
, NN O O
patients NN O O
should NN O O
receive NN O O
all NN O O
recommended NN O O
vaccinations NN O O
. NN O O
( NN O O
5.4 NN O O
) NN O O
5.1 NN O O
Serious NN O O
Infections NN O O
ILARIS NN O O
has NN O O
been NN O O
associated NN O O
with NN O O
an NN O O
increased NN O O
risk NN B-Factor B-Factor
of NN O O
serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
Physicians NN O O
should NN O O
exercise NN O O
caution NN O O
when NN O O
administering NN O O
ILARIS NN O O
to NN O O
patients NN O O
with NN O O
infections NN O O
, NN O O
a NN O O
history NN O O
of NN O O
recurring NN O O
infections NN O O
or NN O O
underlying NN O O
conditions NN O O
which NN O O
may NN O O
predispose NN O O
them NN O O
to NN O O
infections NN O O
. NN O O
ILARIS NN O O
should NN O O
not NN O O
be NN O O
administered NN O O
to NN O O
patients NN O O
during NN O O
an NN O O
active NN O O
infection NN O O
requiring NN O O
medical NN O O
intervention NN O O
. NN O O
Administration NN O O
of NN O O
ILARIS NN O O
should NN O O
be NN O O
discontinued NN O O
if NN O O
a NN O O
patient NN O O
develops NN O O
a NN O O
serious NN O O
infection NN O O
. NN O O
Infections NN B-AdverseReaction B-AdverseReaction
predominantly NN O O
of NN O O
the NN O O
upper NN O O
respiratory NN O O
tract NN O O
, NN O O
in NN O O
some NN O O
instances NN O O
serious NN B-Severity B-Severity
have NN O O
been NN O O
reported NN O O
with NN O O
ILARIS. NN O O
Generally NN O O
, NN O O
the NN O O
observed NN O O
infections NN B-AdverseReaction B-AdverseReaction
responded NN O O
to NN O O
standard NN O O
therapy NN O O
. NN O O
Isolated NN O O
cases NN O O
of NN O O
unusual NN O O
or NN O O
opportunistic NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
( NN O O
e.g. NN O O
, NN O O
aspergillosis NN B-AdverseReaction B-AdverseReaction
atypical NN B-AdverseReaction B-AdverseReaction
mycobacterial NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
cytomegalovirus NN O O
, NN O O
herpes NN B-AdverseReaction B-AdverseReaction
zoster NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
during NN O O
ILARIS NN O O
treatment NN O O
. NN O O
A NN O O
causal NN O O
relationship NN O O
of NN O O
ILARIS NN O O
to NN O O
these NN O O
events NN O O
can NN O O
not NN O O
be NN O O
excluded NN O O
. NN O O
In NN O O
clinical NN O O
trials NN O O
, NN O O
ILARIS NN O O
has NN O O
not NN O O
been NN O O
administered NN O O
concomitantly NN O O
with NN O O
tumor NN O O
necrosis NN O O
factor NN O O
( NN O O
TNF NN O O
) NN O O
inhibitors NN O O
. NN O O
An NN O O
increased NN O O
incidence NN O O
of NN O O
serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
has NN O O
been NN O O
associated NN O O
with NN O O
administration NN O O
of NN O O
another NN O O
IL-1 NN B-DrugClass B-DrugClass
blocker NN I-DrugClass I-DrugClass
in NN O O
combination NN O O
with NN O O
TNF NN O O
inhibitors NN O O
. NN O O
Coadministration NN O O
of NN O O
ILARIS NN O O
with NN O O
TNF NN O O
inhibitors NN O O
is NN O O
not NN O O
recommended NN O O
because NN O O
this NN O O
may NN O O
increase NN O O
the NN O O
risk NN O O
of NN O O
serious NN O O
infections NN O O
[ NN O O
see NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.1 NN O O
) NN O O
] NN O O
. NN O O
Drugs NN O O
that NN O O
affect NN O O
the NN O O
immune NN O O
system NN O O
by NN O O
blocking NN O O
TNF NN O O
have NN O O
been NN O O
associated NN O O
with NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
new NN O O
tuberculosis NN O O
and NN O O
reactivation NN O O
of NN O O
latent NN O O
tuberculosis NN O O
( NN O O
TB NN O O
) NN O O
. NN O O
It NN O O
is NN O O
possible NN O O
that NN O O
use NN O O
of NN O O
IL-1 NN O O
inhibitors NN O O
such NN O O
as NN O O
ILARIS NN O O
increases NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
reactivation NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
tuberculosis NN I-AdverseReaction I-AdverseReaction
or NN O O
of NN O O
opportunistic NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
Prior NN O O
to NN O O
initiating NN O O
immunomodulatory NN O O
therapies NN O O
, NN O O
including NN O O
ILARIS NN O O
, NN O O
patients NN O O
should NN O O
be NN O O
evaluated NN O O
for NN O O
active NN O O
and NN O O
latent NN O O
tuberculosis NN O O
infection NN O O
. NN O O
Appropriate NN O O
screening NN O O
tests NN O O
should NN O O
be NN O O
performed NN O O
in NN O O
all NN O O
patients NN O O
. NN O O
ILARIS NN O O
has NN O O
not NN O O
been NN O O
studied NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
positive NN O O
tuberculosis NN O O
screen NN O O
, NN O O
and NN O O
the NN O O
safety NN O O
of NN O O
ILARIS NN O O
in NN O O
individuals NN O O
with NN O O
latent NN O O
tuberculosis NN O O
infection NN O O
is NN O O
unknown NN O O
. NN O O
Patients NN O O
testing NN O O
positive NN O O
in NN O O
tuberculosis NN O O
screening NN O O
should NN O O
be NN O O
treated NN O O
according NN O O
to NN O O
standard NN O O
medical NN O O
practice NN O O
prior NN O O
to NN O O
therapy NN O O
with NN O O
ILARIS. NN O O
All NN O O
patients NN O O
should NN O O
be NN O O
instructed NN O O
to NN O O
seek NN O O
medical NN O O
advice NN O O
if NN O O
signs NN O O
, NN O O
symptoms NN O O
, NN O O
or NN O O
high NN O O
risk NN O O
exposure NN O O
suggestive NN O O
of NN O O
tuberculosis NN O O
( NN O O
e.g. NN O O
, NN O O
persistent NN O O
cough NN O O
, NN O O
weight NN O O
loss NN O O
, NN O O
subfebrile NN O O
temperature NN O O
) NN O O
appear NN O O
during NN O O
or NN O O
after NN O O
ILARIS NN O O
therapy NN O O
. NN O O
Healthcare NN O O
providers NN O O
should NN O O
follow NN O O
current NN O O
CDC NN O O
guidelines NN O O
both NN O O
to NN O O
evaluate NN O O
for NN O O
and NN O O
to NN O O
treat NN O O
possible NN O O
latent NN O O
tuberculosis NN O O
infections NN O O
before NN O O
initiating NN O O
therapy NN O O
with NN O O
ILARIS. NN O O
5.2 NN O O
Immunosuppression NN O O
The NN O O
impact NN O O
of NN O O
treatment NN O O
with NN O O
anti NN O O
- NN O O
interleukin-1 NN O O
( NN O O
IL-1 NN O O
) NN O O
therapy NN O O
on NN O O
the NN O O
development NN O O
of NN O O
malignancies NN O O
is NN O O
not NN O O
known NN O O
. NN O O
However NN O O
, NN O O
treatment NN O O
with NN O O
immunosuppressants NN O O
, NN O O
including NN O O
ILARIS NN O O
, NN O O
may NN O O
result NN O O
in NN O O
an NN O O
increase NN O O
in NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
malignancies NN B-AdverseReaction B-AdverseReaction
5.3 NN O O
Hypersensitivity NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
with NN O O
ILARIS NN O O
therapy NN O O
. NN O O
During NN O O
clinical NN O O
trials NN O O
, NN O O
no NN B-Negation B-Negation
anaphylactic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
. NN O O
It NN O O
should NN O O
be NN O O
recognized NN O O
that NN O O
symptoms NN O O
of NN O O
the NN O O
underlying NN O O
disease NN O O
being NN O O
treated NN O O
may NN O O
be NN O O
similar NN O O
to NN O O
symptoms NN O O
of NN O O
hypersensitivity NN O O
. NN O O
ILARIS NN O O
should NN O O
not NN O O
be NN O O
administered NN O O
to NN O O
any NN O O
patients NN O O
with NN O O
known NN O O
clinical NN O O
hypersensitivity NN O O
to NN O O
ILARIS NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
and NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.2 NN O O
) NN O O
] NN O O
. NN O O
5.4 NN O O
Immunizations NN O O
Live NN O O
vaccines NN O O
should NN O O
not NN O O
be NN O O
given NN O O
concurrently NN O O
with NN O O
ILARIS NN O O
[ NN O O
see NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.2 NN O O
) NN O O
] NN O O
. NN O O
Since NN O O
no NN O O
data NN O O
are NN O O
available NN O O
on NN O O
either NN O O
the NN O O
efficacy NN O O
or NN O O
on NN O O
the NN O O
risks NN O O
of NN O O
secondary NN O O
transmission NN O O
of NN O O
infection NN O O
by NN O O
live NN O O
vaccines NN O O
in NN O O
patients NN O O
receiving NN O O
ILARIS NN O O
, NN O O
live NN O O
vaccines NN O O
should NN O O
not NN O O
be NN O O
given NN O O
concurrently NN O O
with NN O O
ILARIS. NN O O
In NN O O
addition NN O O
, NN O O
because NN O O
ILARIS NN O O
may NN B-Factor B-Factor
interfere NN B-AdverseReaction B-AdverseReaction
with NN I-AdverseReaction I-AdverseReaction
normal NN I-AdverseReaction I-AdverseReaction
immune NN I-AdverseReaction I-AdverseReaction
response NN I-AdverseReaction I-AdverseReaction
to NN O O
new NN O O
antigens NN O O
, NN O O
vaccinations NN O O
may NN O O
not NN O O
be NN O O
effective NN O O
in NN O O
patients NN O O
receiving NN O O
ILARIS. NN O O
No NN O O
data NN O O
are NN O O
available NN O O
on NN O O
the NN O O
effectiveness NN O O
of NN O O
vaccinations NN O O
with NN O O
inactivated NN O O
( NN O O
killed NN O O
) NN O O
antigens NN O O
in NN O O
patients NN O O
receiving NN O O
ILARIS NN O O
[ NN O O
see NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.2 NN O O
) NN O O
] NN O O
. NN O O
Because NN O O
IL-1 NN O O
blockade NN O O
may NN O O
interfere NN O O
with NN O O
immune NN O O
response NN O O
to NN O O
infections NN O O
, NN O O
it NN O O
is NN O O
recommended NN O O
that NN O O
prior NN O O
to NN O O
initiation NN O O
of NN O O
therapy NN O O
with NN O O
ILARIS NN O O
, NN O O
adult NN O O
and NN O O
pediatric NN O O
patients NN O O
receive NN O O
all NN O O
recommended NN O O
vaccinations NN O O
, NN O O
as NN O O
appropriate NN O O
, NN O O
including NN O O
pneumococcal NN O O
vaccine NN O O
and NN O O
inactivated NN O O
influenza NN O O
vaccine NN O O
. NN O O
( NN O O
See NN O O
current NN O O
recommended NN O O
immunization NN O O
schedules NN O O
at NN O O
the NN O O
website NN O O
of NN O O
the NN O O
Centers NN O O
for NN O O
Disease NN O O
Control NN O O
, NN O O
http://www.cdc.gov/vaccines/schedules/index.html NN O O
) NN O O
. NN O O
5.5 NN O O
Macrophage NN O O
Activation NN O O
Syndrome NN O O
Macrophage NN O O
activation NN O O
syndrome NN O O
( NN O O
MAS NN O O
) NN O O
is NN O O
a NN O O
known NN O O
, NN O O
life NN O O
- NN O O
threatening NN O O
disorder NN O O
that NN O O
may NN O O
develop NN O O
in NN O O
patients NN O O
with NN O O
rheumatic NN O O
conditions NN O O
, NN O O
in NN O O
particular NN O O
SJIA NN O O
, NN O O
and NN O O
should NN O O
be NN O O
aggressively NN O O
treated NN O O
. NN O O
Physicians NN O O
should NN O O
be NN O O
attentive NN O O
to NN O O
symptoms NN O O
of NN O O
infection NN O O
or NN O O
worsening NN O O
of NN O O
SJIA NN O O
, NN O O
as NN O O
these NN O O
are NN O O
known NN O O
triggers NN O O
for NN O O
MAS. NN O O
Eleven NN O O
cases NN O O
of NN O O
MAS NN B-AdverseReaction B-AdverseReaction
were NN O O
observed NN O O
in NN O O
201 NN O O
SJIA NN O O
patients NN O O
treated NN O O
with NN O O
canakinumab NN O O
in NN O O
clinical NN O O
trials NN O O
. NN O O
Based NN O O
on NN O O
the NN O O
clinical NN O O
trial NN O O
experience NN O O
, NN O O
ILARIS NN O O
does NN O O
not NN O O
appear NN O O
to NN O O
increase NN O O
the NN O O
incidence NN O O
of NN O O
MAS NN B-AdverseReaction B-AdverseReaction
in NN O O
SJIA NN O O
patients NN O O
, NN O O
but NN O O
no NN B-Factor B-Factor
definitive NN I-Factor I-Factor
conclusion NN I-Factor I-Factor
can NN O O
be NN O O
made NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
serious NN O O
adverse NN O O
reactions NN O O
are NN O O
discussed NN O O
elsewhere NN O O
in NN O O
the NN O O
labeling NN O O
: NN O O
* NN O O
Increased NN B-AdverseReaction B-AdverseReaction
mortality NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
QT NN B-AdverseReaction B-AdverseReaction
Prolongation NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
and NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.2 NN O O
) NN O O
] NN O O
* NN O O
Hepatotoxicity NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
* NN O O
Drug NN O O
Interactions NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
* NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
reported NN O O
in NN O O
10 NN O O
% NN O O
or NN O O
more NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
SIRTURO NN O O
were NN O O
nausea NN B-AdverseReaction B-AdverseReaction
arthralgia NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
hemoptysis NN B-AdverseReaction B-AdverseReaction
and NN O O
chest NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
EXCERPT NN O O
: NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Janssen NN O O
Therapeutics NN O O
, NN O O
Division NN O O
of NN O O
Janssen NN O O
Products NN O O
, NN O O
LP NN O O
at NN O O
1 NN O O
- NN O O
800-JANSSEN NN O O
( NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
526 NN O O
- NN O O
7736 NN O O
) NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Studies NN O O
Experience NN O O
Because NN O O
clinical NN O O
studies NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
studies NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
the NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
studies NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O
Adverse NN O O
drug NN O O
reactions NN O O
for NN O O
SIRTURO NN O O
were NN O O
identified NN O O
from NN O O
the NN O O
pooled NN O O
safety NN O O
data NN O O
from NN O O
335 NN O O
SIRTURO NN O O
- NN O O
exposed NN O O
patients NN O O
who NN O O
received NN O O
8 NN O O
weeks NN O O
( NN O O
Study NN O O
2 NN O O
) NN O O
and NN O O
24 NN O O
weeks NN O O
( NN O O
Studies NN O O
1 NN O O
and NN O O
3 NN O O
) NN O O
at NN O O
the NN O O
proposed NN O O
dose NN O O
. NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
were NN O O
randomized NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
trial NN O O
in NN O O
newly NN O O
diagnosed NN O O
patients NN O O
with NN O O
pulmonary NN O O
MDR NN O O
- NN O O
TB. NN O O
In NN O O
both NN O O
treatment NN O O
arms NN O O
, NN O O
patients NN O O
received NN O O
SIRTURO NN O O
or NN O O
placebo NN O O
in NN O O
combination NN O O
with NN O O
other NN O O
drugs NN O O
used NN O O
to NN O O
treat NN O O
MDR NN O O
- NN O O
TB. NN O O
Study NN O O
3 NN O O
was NN O O
an NN O O
open NN O O
- NN O O
label NN O O
, NN O O
noncomparative NN O O
study NN O O
with NN O O
SIRTURO NN O O
administered NN O O
as NN O O
part NN O O
of NN O O
an NN O O
individualized NN O O
pulmonary NN O O
MDR NN O O
- NN O O
TB NN O O
treatment NN O O
regimen NN O O
in NN O O
previously NN O O
treated NN O O
patients NN O O
. NN O O
In NN O O
Study NN O O
1 NN O O
, NN O O
35 NN O O
% NN O O
were NN O O
Black NN O O
, NN O O
17.5 NN O O
% NN O O
were NN O O
Hispanic NN O O
, NN O O
12.5 NN O O
% NN O O
were NN O O
White NN O O
, NN O O
9.4 NN O O
% NN O O
were NN O O
Asian NN O O
, NN O O
and NN O O
25.6 NN O O
% NN O O
were NN O O
of NN O O
another NN O O
race NN O O
. NN O O
Eight NN O O
of NN O O
79 NN O O
( NN O O
10.1 NN O O
% NN O O
) NN O O
patients NN O O
in NN O O
the NN O O
SIRTURO NN O O
group NN O O
and NN O O
16 NN O O
of NN O O
81 NN O O
( NN O O
19.8 NN O O
% NN O O
) NN O O
patients NN O O
in NN O O
the NN O O
placebo NN O O
treatment NN O O
group NN O O
were NN O O
HIV NN O O
- NN O O
infected NN O O
. NN O O
Seven NN O O
( NN O O
8.9 NN O O
% NN O O
) NN O O
SIRTURO NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
six NN O O
( NN O O
7.4 NN O O
% NN O O
) NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
discontinued NN O O
Study NN O O
1 NN O O
because NN O O
of NN O O
an NN O O
adverse NN O O
reaction NN O O
. NN O O
Table NN O O
1 NN O O
: NN O O
Select NN O O
Adverse NN O O
Reactions NN O O
from NN O O
Study NN O O
1 NN O O
That NN O O
Occurred NN O O
More NN O O
Frequently NN O O
Than NN O O
Placebo NN O O
During NN O O
Treatment NN O O
with NN O O
SIRTURO NN O O
Adverse NN O O
Reactions NN O O
SIRTURO NN O O
Treatment NN O O
GroupN=79n NN O O
( NN O O
% NN O O
) NN O O
Placebo NN O O
Treatment NN O O
GroupN=81n NN O O
( NN O O
% NN O O
) NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
30 NN O O
( NN O O
38 NN O O
) NN O O
26 NN O O
( NN O O
32 NN O O
) NN O O
Arthralgia NN B-AdverseReaction B-AdverseReaction
26 NN O O
( NN O O
33 NN O O
) NN O O
18 NN O O
( NN O O
22 NN O O
) NN O O
Headache NN B-AdverseReaction B-AdverseReaction
22 NN O O
( NN O O
28 NN O O
) NN O O
10 NN O O
( NN O O
12 NN O O
) NN O O
Hemoptysis NN B-AdverseReaction B-AdverseReaction
14 NN O O
( NN O O
18 NN O O
) NN O O
9 NN O O
( NN O O
11 NN O O
) NN O O
Chest NN B-AdverseReaction B-AdverseReaction
Pain NN I-AdverseReaction I-AdverseReaction
9 NN O O
( NN O O
11 NN O O
) NN O O
6 NN O O
( NN O O
7 NN O O
) NN O O
Anorexia NN B-AdverseReaction B-AdverseReaction
7 NN O O
( NN O O
9 NN O O
) NN O O
3 NN O O
( NN O O
4 NN O O
) NN O O
Transaminases NN B-AdverseReaction B-AdverseReaction
Increased NN I-AdverseReaction I-AdverseReaction
7 NN O O
( NN O O
9 NN O O
) NN O O
1 NN O O
( NN O O
1 NN O O
) NN O O
Rash NN B-AdverseReaction B-AdverseReaction
6 NN O O
( NN O O
8 NN O O
) NN O O
3 NN O O
( NN O O
4 NN O O
) NN O O
Blood NN B-AdverseReaction B-AdverseReaction
Amylase NN I-AdverseReaction I-AdverseReaction
Increased NN I-AdverseReaction I-AdverseReaction
2 NN O O
( NN O O
3 NN O O
) NN O O
1 NN O O
( NN O O
1 NN O O
) NN O O
No NN O O
additional NN O O
unique NN O O
Adverse NN O O
Reactions NN O O
were NN O O
identified NN O O
from NN O O
the NN O O
uncontrolled NN O O
Study NN O O
3 NN O O
. NN O O
In NN O O
both NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
, NN O O
aminotransferase NN B-AdverseReaction B-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
of NN O O
at NN O O
least NN O O
3 NN B-Severity B-Severity
times NN I-Severity I-Severity
the NN I-Severity I-Severity
upper NN I-Severity I-Severity
limit NN I-Severity I-Severity
of NN I-Severity I-Severity
normal NN I-Severity I-Severity
developed NN O O
more NN O O
frequently NN O O
in NN O O
the NN O O
SIRTURO NN O O
treatment NN O O
group NN O O
( NN O O
11/102 NN O O
[ NN O O
10.8 NN O O
% NN O O
] NN O O
vs NN O O
6/105 NN O O
[ NN O O
5.7 NN O O
% NN O O
] NN O O
) NN O O
than NN O O
in NN O O
the NN O O
placebo NN O O
treatment NN O O
group NN O O
. NN O O
In NN O O
Study NN O O
3 NN O O
, NN O O
22/230 NN O O
( NN O O
9.6 NN O O
% NN O O
) NN O O
patients NN O O
had NN O O
alanine NN O O
aminotransferase NN O O
or NN O O
aspartate NN O O
aminotransferase NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
3 NN O O
times NN O O
the NN O O
upper NN O O
limit NN O O
of NN O O
normal NN O O
during NN O O
the NN O O
overall NN O O
treatment NN O O
period NN O O
. NN O O
Increased NN O O
Mortality NN O O
In NN O O
Study NN O O
1 NN O O
, NN O O
there NN O O
was NN O O
a NN O O
statistically NN O O
significant NN O O
increased NN B-AdverseReaction B-AdverseReaction
mortality NN I-AdverseReaction I-AdverseReaction
risk NN B-Factor B-Factor
by NN O O
Week NN O O
120 NN O O
in NN O O
the NN O O
SIRTURO NN O O
treatment NN O O
group NN O O
compared NN O O
to NN O O
the NN O O
placebo NN O O
treatment NN O O
group NN O O
( NN O O
9/79 NN O O
( NN O O
11.4 NN O O
% NN O O
) NN O O
versus NN O O
2/81 NN O O
( NN O O
2.5 NN O O
% NN O O
) NN O O
, NN O O
p NN O O
- NN O O
value=0.03 NN O O
, NN O O
an NN O O
exact NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
of NN O O
the NN O O
difference NN O O
[ NN O O
1.1 NN O O
% NN O O
, NN O O
18.2 NN O O
% NN O O
] NN O O
) NN O O
. NN O O
Five NN O O
of NN O O
the NN O O
9 NN O O
SIRTURO NN O O
deaths NN B-AdverseReaction B-AdverseReaction
and NN O O
the NN O O
2 NN O O
placebo NN B-Factor B-Factor
deaths NN B-AdverseReaction B-AdverseReaction
were NN O O
tuberculosis NN O O
- NN O O
related NN O O
. NN O O
One NN O O
death NN B-AdverseReaction B-AdverseReaction
occurred NN O O
during NN O O
the NN O O
24-week NN O O
SIRTURO NN O O
treatment NN O O
period NN O O
. NN O O
The NN O O
median NN O O
time NN O O
to NN O O
death NN B-AdverseReaction B-AdverseReaction
for NN O O
the NN O O
remaining NN O O
eight NN O O
subjects NN O O
in NN O O
the NN O O
SIRTURO NN O O
treatment NN O O
group NN O O
was NN O O
329 NN O O
days NN O O
after NN O O
last NN O O
intake NN O O
of NN O O
SIRTURO. NN O O
The NN O O
imbalance NN O O
in NN O O
deaths NN B-AdverseReaction B-AdverseReaction
is NN O O
unexplained NN O O
; NN O O
no NN O O
discernible NN O O
pattern NN O O
between NN O O
death NN B-AdverseReaction B-AdverseReaction
and NN O O
sputum NN O O
conversion NN O O
, NN O O
relapse NN O O
, NN O O
sensitivity NN O O
to NN O O
other NN O O
drugs NN O O
used NN O O
to NN O O
treat NN O O
tuberculosis NN O O
, NN O O
HIV NN O O
status NN O O
, NN O O
and NN O O
severity NN O O
of NN O O
disease NN O O
was NN O O
observed NN O O
. NN O O
In NN O O
the NN O O
open NN O O
- NN O O
label NN O O
Study NN O O
3 NN O O
, NN O O
6.9 NN O O
% NN O O
( NN O O
16/233 NN O O
) NN O O
subjects NN O O
died NN B-AdverseReaction B-AdverseReaction
The NN O O
most NN O O
common NN O O
cause NN O O
of NN O O
death NN B-AdverseReaction B-AdverseReaction
as NN O O
reported NN O O
by NN O O
the NN O O
investigator NN O O
was NN O O
TB NN O O
( NN O O
9 NN O O
subjects NN O O
) NN O O
. NN O O
All NN O O
but NN O O
one NN O O
subject NN O O
who NN O O
died NN B-AdverseReaction B-AdverseReaction
of NN O O
TB NN O O
had NN O O
not NN O O
converted NN O O
or NN O O
had NN O O
relapsed NN O O
. NN O O
The NN O O
causes NN O O
of NN O O
death NN B-AdverseReaction B-AdverseReaction
in NN O O
the NN O O
remaining NN O O
subjects NN O O
varied NN O O
. NN O O
BOXED NN O O
WARNING NN O O
: NN O O
WARNINGS NN O O
: NN O O
INCREASED NN B-AdverseReaction B-AdverseReaction
MORTALITY NN I-AdverseReaction I-AdverseReaction
QT NN B-AdverseReaction B-AdverseReaction
PROLONGATION NN I-AdverseReaction I-AdverseReaction
WARNINGS NN O O
: NN O O
INCREASED NN B-AdverseReaction B-AdverseReaction
MORTALITY NN I-AdverseReaction I-AdverseReaction
QT NN B-AdverseReaction B-AdverseReaction
PROLONGATION NN I-AdverseReaction I-AdverseReaction
EXCERPT NN O O
: NN O O
WARNINGS NN O O
: NN O O
INCREASED NN B-AdverseReaction B-AdverseReaction
MORTALITY NN I-AdverseReaction I-AdverseReaction
QT NN B-AdverseReaction B-AdverseReaction
PROLONGATION NN I-AdverseReaction I-AdverseReaction
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
. NN O O
Increased NN O O
Mortality NN O O
* NN O O
An NN O O
increased NN O O
risk NN B-Factor B-Factor
of NN O O
death NN B-AdverseReaction B-AdverseReaction
was NN O O
seen NN O O
in NN O O
the NN O O
SIRTURO NN O O
treatment NN O O
group NN O O
( NN O O
9/79 NN O O
, NN O O
11.4 NN O O
% NN O O
) NN O O
compared NN O O
to NN O O
the NN O O
placebo NN O O
treatment NN O O
group NN O O
( NN O O
2/81 NN O O
, NN O O
2.5 NN O O
% NN O O
) NN O O
in NN O O
one NN O O
placebo NN O O
- NN O O
controlled NN O O
trial NN O O
. NN O O
Only NN O O
use NN O O
SIRTURO NN O O
when NN O O
an NN O O
effective NN O O
treatment NN O O
regimen NN O O
can NN O O
not NN O O
otherwise NN O O
be NN O O
provided NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
QT NN O O
Prolongation NN O O
* NN O O
QT NN B-AdverseReaction B-AdverseReaction
prolongation NN I-AdverseReaction I-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
with NN O O
SIRTURO. NN O O
Use NN O O
with NN O O
drugs NN O O
that NN O O
prolong NN O O
the NN O O
QT NN O O
interval NN O O
may NN B-Factor B-Factor
cause NN O O
additive NN O O
QT NN B-AdverseReaction B-AdverseReaction
prolongation NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
ECGs NN O O
. NN O O
Discontinue NN O O
SIRTURO NN O O
if NN O O
significant NN O O
ventricular NN O O
arrhythmia NN O O
or NN O O
QTcF NN O O
interval NN O O
>500 NN O O
ms NN O O
develops NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
Increased NN O O
Mortality NN O O
* NN O O
An NN O O
increased NN O O
risk NN B-Factor B-Factor
of NN O O
death NN B-AdverseReaction B-AdverseReaction
was NN O O
seen NN O O
in NN O O
the NN O O
SIRTURO NN O O
treatment NN O O
group NN O O
( NN O O
9/79 NN O O
, NN O O
11.4 NN O O
% NN O O
) NN O O
compared NN O O
to NN O O
the NN O O
placebo NN O O
treatment NN O O
group NN O O
( NN O O
2/81 NN O O
, NN O O
2.5 NN O O
% NN O O
) NN O O
in NN O O
one NN O O
placebo NN O O
- NN O O
controlled NN O O
trial NN O O
. NN O O
Only NN O O
use NN O O
SIRTURO NN O O
when NN O O
an NN O O
effective NN O O
treatment NN O O
regimen NN O O
can NN O O
not NN O O
otherwise NN O O
be NN O O
provided NN O O
[ NN O O
see NN O O
Indications NN O O
and NN O O
Usage NN O O
( NN O O
1 NN O O
) NN O O
and NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
QT NN O O
Prolongation NN O O
* NN O O
QT NN B-AdverseReaction B-AdverseReaction
prolongation NN I-AdverseReaction I-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
with NN O O
SIRTURO. NN O O
Use NN O O
with NN O O
drugs NN O O
that NN O O
prolong NN O O
the NN O O
QT NN O O
interval NN O O
may NN B-Factor B-Factor
cause NN O O
additive NN B-AdverseReaction B-AdverseReaction
QT NN I-AdverseReaction I-AdverseReaction
prolongation NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
ECGs NN O O
. NN O O
Discontinue NN O O
SIRTURO NN O O
if NN O O
significant NN O O
ventricular NN O O
arrhythmia NN O O
or NN O O
if NN O O
QTcF NN O O
interval NN O O
prolongation NN O O
of NN O O
greater NN O O
than NN O O
500 NN O O
ms NN O O
develops NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
QT NN B-AdverseReaction B-AdverseReaction
prolongation NN I-AdverseReaction I-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
with NN O O
SIRTURO. NN O O
Monitor NN O O
ECGs NN O O
and NN O O
discontinue NN O O
SIRTURO NN O O
if NN O O
significant NN O O
ventricular NN O O
arrhythmia NN O O
or NN O O
QTcF NN O O
interval NN O O
> NN O O
500 NN O O
ms NN O O
develops NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Hepatotoxicity NN B-AdverseReaction B-AdverseReaction
may NN B-Factor B-Factor
occur NN O O
with NN O O
use NN O O
of NN O O
SIRTURO. NN O O
Monitor NN O O
liver NN O O
- NN O O
related NN O O
laboratory NN O O
tests NN O O
. NN O O
Discontinue NN O O
if NN O O
evidence NN O O
of NN O O
liver NN O O
injury NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
5.1 NN O O
Increased NN O O
Mortality NN O O
An NN O O
increased NN O O
risk NN B-Factor B-Factor
of NN O O
death NN B-AdverseReaction B-AdverseReaction
was NN O O
seen NN O O
in NN O O
the NN O O
SIRTURO NN O O
treatment NN O O
group NN O O
( NN O O
9/79 NN O O
, NN O O
11.4 NN O O
% NN O O
) NN O O
compared NN O O
to NN O O
the NN O O
placebo NN O O
treatment NN O O
group NN O O
( NN O O
2/81 NN O O
, NN O O
2.5 NN O O
% NN O O
) NN O O
in NN O O
one NN O O
placebo NN O O
- NN O O
controlled NN O O
trial NN O O
( NN O O
based NN O O
on NN O O
the NN O O
120-week NN O O
visit NN O O
window NN O O
) NN O O
. NN O O
One NN O O
death NN B-AdverseReaction B-AdverseReaction
occurred NN O O
during NN O O
the NN O O
24 NN O O
weeks NN O O
of NN O O
administration NN O O
of NN O O
SIRTURO. NN O O
The NN O O
imbalance NN O O
in NN O O
deaths NN B-AdverseReaction B-AdverseReaction
is NN O O
unexplained NN O O
. NN O O
No NN O O
discernible NN O O
pattern NN O O
between NN O O
death NN B-AdverseReaction B-AdverseReaction
and NN O O
sputum NN O O
culture NN O O
conversion NN O O
, NN O O
relapse NN O O
, NN O O
sensitivity NN O O
to NN O O
other NN O O
drugs NN O O
used NN O O
to NN O O
treat NN O O
tuberculosis NN O O
, NN O O
HIV NN O O
status NN O O
, NN O O
or NN O O
severity NN O O
of NN O O
disease NN O O
could NN O O
be NN O O
observed NN O O
. NN O O
Only NN O O
use NN O O
SIRTURO NN O O
when NN O O
an NN O O
effective NN O O
treatment NN O O
regimen NN O O
can NN O O
not NN O O
otherwise NN O O
be NN O O
provided NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
QT NN O O
Prolongation NN O O
SIRTURO NN O O
prolongs NN B-AdverseReaction B-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
QT NN I-AdverseReaction I-AdverseReaction
interval NN I-AdverseReaction I-AdverseReaction
Obtain NN O O
an NN O O
ECG NN O O
before NN O O
initiation NN O O
of NN O O
treatment NN O O
, NN O O
and NN O O
at NN O O
least NN O O
2 NN O O
, NN O O
12 NN O O
, NN O O
and NN O O
24 NN O O
weeks NN O O
after NN O O
starting NN O O
treatment NN O O
with NN O O
SIRTURO. NN O O
Obtain NN O O
serum NN O O
potassium NN O O
, NN O O
calcium NN O O
, NN O O
and NN O O
magnesium NN O O
at NN O O
baseline NN O O
and NN O O
correct NN O O
if NN O O
abnormal NN O O
. NN O O
Monitor NN O O
electrolytes NN O O
if NN O O
QT NN O O
prolongation NN O O
is NN O O
detected NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
and NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.4 NN O O
) NN O O
] NN O O
. NN O O
SIRTURO NN O O
has NN O O
not NN O O
been NN O O
studied NN O O
in NN O O
patients NN O O
with NN O O
ventricular NN O O
arrhythmias NN O O
or NN O O
recent NN O O
myocardial NN O O
infarction NN O O
. NN O O
The NN O O
following NN O O
may NN O O
increase NN O O
the NN O O
risk NN B-Factor B-Factor
for NN O O
QT NN B-AdverseReaction B-AdverseReaction
prolongation NN I-AdverseReaction I-AdverseReaction
when NN O O
patients NN O O
are NN O O
receiving NN O O
SIRTURO NN O O
: NN O O
* NN O O
use NN O O
with NN O O
other NN O O
QT NN O O
prolonging NN O O
drugs NN O O
including NN O O
fluoroquinolones NN O O
and NN O O
macrolide NN O O
antibacterial NN O O
drugs NN O O
and NN O O
the NN O O
antimycobacterial NN O O
drug NN O O
, NN O O
clofazimine NN O O
* NN O O
a NN O O
history NN O O
of NN O O
Torsade NN O O
de NN O O
Pointes NN O O
* NN O O
a NN O O
history NN O O
of NN O O
congenital NN O O
long NN O O
QT NN O O
syndrome NN O O
* NN O O
a NN O O
history NN O O
of NN O O
or NN O O
ongoing NN O O
hypothyroidism NN O O
* NN O O
a NN O O
history NN O O
of NN O O
or NN O O
ongoing NN O O
bradyarrhythmias NN O O
* NN O O
a NN O O
history NN O O
of NN O O
uncompensated NN O O
heart NN O O
failure NN O O
* NN O O
serum NN O O
calcium NN O O
, NN O O
magnesium NN O O
, NN O O
or NN O O
potassium NN O O
levels NN O O
below NN O O
the NN O O
lower NN O O
limits NN O O
of NN O O
normal NN O O
If NN O O
necessary NN O O
, NN O O
bedaquiline NN O O
treatment NN O O
initiation NN O O
could NN O O
be NN O O
considered NN O O
in NN O O
these NN O O
patients NN O O
after NN O O
a NN O O
favorable NN O O
benefit NN O O
risk NN O O
assessment NN O O
and NN O O
with NN O O
frequent NN O O
ECG NN O O
monitoring NN O O
. NN O O
Discontinue NN O O
SIRTURO NN O O
and NN O O
all NN O O
other NN O O
QT NN O O
prolonging NN O O
drugs NN O O
if NN O O
the NN O O
patient NN O O
develops NN O O
: NN O O
* NN O O
Clinically NN O O
significant NN O O
ventricular NN O O
arrhythmia NN O O
* NN O O
A NN O O
QTcF NN O O
interval NN O O
of NN O O
greater NN O O
than NN O O
500 NN O O
ms NN O O
( NN O O
confirmed NN O O
by NN O O
repeat NN O O
ECG NN O O
) NN O O
If NN O O
syncope NN O O
occurs NN O O
, NN O O
obtain NN O O
an NN O O
ECG NN O O
to NN O O
detect NN O O
QT NN O O
prolongation NN O O
. NN O O
5.3 NN O O
Hepatotoxicity NN O O
More NN O O
hepatic NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
with NN O O
the NN O O
use NN O O
of NN O O
SIRTURO NN O O
plus NN O O
other NN O O
drugs NN O O
used NN O O
to NN O O
treat NN O O
tuberculosis NN O O
compared NN O O
to NN O O
other NN O O
drugs NN O O
used NN O O
to NN O O
treat NN O O
tuberculosis NN O O
without NN O O
the NN O O
addition NN O O
of NN O O
SIRTURO. NN O O
Alcohol NN O O
and NN O O
other NN O O
hepatotoxic NN O O
drugs NN O O
should NN O O
be NN O O
avoided NN O O
while NN O O
on NN O O
SIRTURO NN O O
, NN O O
especially NN O O
in NN O O
patients NN O O
with NN O O
impaired NN O O
hepatic NN O O
function NN O O
. NN O O
Monitor NN O O
symptoms NN O O
( NN O O
such NN O O
as NN O O
fatigue NN O O
, NN O O
anorexia NN O O
, NN O O
nausea NN O O
, NN O O
jaundice NN O O
, NN O O
dark NN O O
urine NN O O
, NN O O
liver NN O O
tenderness NN O O
and NN O O
hepatomegaly NN O O
) NN O O
and NN O O
laboratory NN O O
tests NN O O
( NN O O
ALT NN O O
, NN O O
AST NN O O
, NN O O
alkaline NN O O
phosphatase NN O O
, NN O O
and NN O O
bilirubin NN O O
) NN O O
at NN O O
baseline NN O O
, NN O O
monthly NN O O
while NN O O
on NN O O
treatment NN O O
, NN O O
and NN O O
as NN O O
needed NN O O
. NN O O
Test NN O O
for NN O O
viral NN O O
hepatitis NN O O
and NN O O
discontinue NN O O
other NN O O
hepatotoxic NN O O
medications NN O O
if NN O O
evidence NN O O
of NN O O
new NN O O
or NN O O
worsening NN O O
liver NN O O
dysfunction NN O O
occurs NN O O
. NN O O
Discontinue NN O O
SIRTURO NN O O
if NN O O
: NN O O
* NN O O
aminotransferase NN O O
elevations NN O O
are NN O O
accompanied NN O O
by NN O O
total NN O O
bilirubin NN O O
elevation NN O O
greater NN O O
than NN O O
two NN O O
times NN O O
the NN O O
upper NN O O
limit NN O O
of NN O O
normal NN O O
* NN O O
aminotransferase NN O O
elevations NN O O
are NN O O
greater NN O O
than NN O O
eight NN O O
times NN O O
the NN O O
upper NN O O
limit NN O O
of NN O O
normal NN O O
* NN O O
aminotransferase NN O O
elevations NN O O
are NN O O
greater NN O O
than NN O O
five NN O O
times NN O O
the NN O O
upper NN O O
limit NN O O
of NN O O
normal NN O O
and NN O O
persist NN O O
beyond NN O O
two NN O O
weeks NN O O
5.4 NN O O
Drug NN O O
Interactions NN O O
CYP3A4 NN O O
inducers/inhibitors NN O O
Bedaquiline NN O O
is NN O O
metabolized NN O O
by NN O O
CYP3A4 NN O O
and NN O O
its NN O O
systemic NN O O
exposure NN O O
and NN O O
therapeutic NN O O
effect NN O O
may NN O O
therefore NN O O
be NN O O
reduced NN O O
during NN O O
co NN O O
- NN O O
administration NN O O
with NN O O
inducers NN O O
of NN O O
CYP3A4 NN O O
. NN O O
Avoid NN O O
co NN O O
- NN O O
administration NN O O
of NN O O
strong NN O O
CYP3A4 NN O O
inducers NN O O
, NN O O
such NN O O
as NN O O
rifamycins NN O O
( NN O O
i.e. NN O O
, NN O O
rifampin NN O O
, NN O O
rifapentine NN O O
and NN O O
rifabutin NN O O
) NN O O
, NN O O
or NN O O
moderate NN O O
CYP3A4 NN O O
inducers NN O O
, NN O O
such NN O O
as NN O O
efavirenz NN O O
, NN O O
during NN O O
treatment NN O O
with NN O O
SIRTURO NN O O
[ NN O O
see NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.1 NN O O
) NN O O
] NN O O
. NN O O
Co NN O O
- NN O O
administration NN O O
of NN O O
SIRTURO NN O O
with NN O O
strong NN O O
CYP3A4 NN O O
inhibitors NN O O
may NN O O
increase NN O O
the NN O O
systemic NN O O
exposure NN O O
to NN O O
bedaquiline NN O O
, NN O O
which NN O O
could NN O O
potentially NN O O
increase NN O O
the NN O O
risk NN O O
of NN O O
adverse NN O O
reactions NN O O
. NN O O
Therefore NN O O
, NN O O
avoid NN O O
the NN O O
use NN O O
of NN O O
strong NN O O
CYP3A4 NN O O
inhibitors NN O O
for NN O O
more NN O O
than NN O O
14 NN O O
consecutive NN O O
days NN O O
while NN O O
on NN O O
SIRTURO NN O O
, NN O O
unless NN O O
the NN O O
benefit NN O O
of NN O O
treatment NN O O
with NN O O
the NN O O
drug NN O O
combination NN O O
outweighs NN O O
the NN O O
risk NN O O
[ NN O O
see NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.1 NN O O
) NN O O
] NN O O
. NN O O
Appropriate NN O O
clinical NN O O
monitoring NN O O
for NN O O
SIRTURO NN O O
- NN O O
related NN O O
adverse NN O O
reactions NN O O
is NN O O
recommended NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
important NN O O
adverse NN O O
reactions NN O O
are NN O O
described NN O O
below NN O O
and NN O O
elsewhere NN O O
in NN O O
the NN O O
labeling NN O O
: NN O O
* NN O O
Hypotension NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Impairment NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
Renal NN I-AdverseReaction I-AdverseReaction
Function NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
Hypoglycemia NN B-AdverseReaction B-AdverseReaction
with NN O O
Concomitant NN O O
Use NN O O
with NN O O
Insulin NN O O
and NN O O
Insulin NN O O
Secretagogues NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
* NN O O
Genital NN B-AdverseReaction B-AdverseReaction
Mycotic NN I-AdverseReaction I-AdverseReaction
Infections NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
* NN O O
Urinary NN B-AdverseReaction B-AdverseReaction
Tract NN I-AdverseReaction I-AdverseReaction
Infections NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
* NN O O
Increased NN B-AdverseReaction B-AdverseReaction
Low NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Density NN I-AdverseReaction I-AdverseReaction
Lipoprotein NN I-AdverseReaction I-AdverseReaction
Cholesterol NN I-AdverseReaction I-AdverseReaction
( NN O O
LDL NN O O
- NN O O
C NN O O
) NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.6 NN O O
) NN O O
] NN O O
* NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
associated NN O O
with NN O O
JARDIANCE NN O O
( NN O O
5 NN O O
% NN O O
or NN O O
greater NN O O
incidence NN O O
) NN O O
were NN O O
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
and NN O O
female NN O O
genital NN B-AdverseReaction B-AdverseReaction
mycotic NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
EXCERPT NN O O
: NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Boehringer NN O O
Ingelheim NN O O
Pharmaceuticals NN O O
, NN O O
Inc. NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
542 NN O O
- NN O O
6257 NN O O
or NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
459 NN O O
- NN O O
9906 NN O O
TTY NN O O
, NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
Pool NN O O
of NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Trials NN O O
evaluating NN O O
JARDIANCE NN O O
10 NN O O
and NN O O
25 NN O O
mg NN O O
The NN O O
data NN O O
in NN O O
Table NN O O
1 NN O O
are NN O O
derived NN O O
from NN O O
a NN O O
pool NN O O
of NN O O
four NN O O
24-week NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
and NN O O
18-week NN O O
data NN O O
from NN O O
a NN O O
placebo NN O O
- NN O O
controlled NN O O
trial NN O O
with NN O O
insulin NN O O
. NN O O
JARDIANCE NN O O
was NN O O
used NN O O
as NN O O
monotherapy NN O O
in NN O O
one NN O O
trial NN O O
and NN O O
as NN O O
add NN O O
- NN O O
on NN O O
therapy NN O O
in NN O O
four NN O O
trials NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
. NN O O
These NN O O
data NN O O
reflect NN O O
exposure NN O O
of NN O O
1976 NN O O
patients NN O O
to NN O O
JARDIANCE NN O O
with NN O O
a NN O O
mean NN O O
exposure NN O O
duration NN O O
of NN O O
approximately NN O O
23 NN O O
weeks NN O O
. NN O O
Patients NN O O
received NN O O
placebo NN O O
( NN O O
N=995 NN O O
) NN O O
, NN O O
JARDIANCE NN O O
10 NN O O
mg NN O O
( NN O O
N=999 NN O O
) NN O O
, NN O O
or NN O O
JARDIANCE NN O O
25 NN O O
mg NN O O
( NN O O
N=977 NN O O
) NN O O
once NN O O
daily NN O O
. NN O O
The NN O O
mean NN O O
age NN O O
of NN O O
the NN O O
population NN O O
was NN O O
56 NN O O
years NN O O
and NN O O
3 NN O O
% NN O O
were NN O O
older NN O O
than NN O O
75 NN O O
years NN O O
of NN O O
age NN O O
. NN O O
More NN O O
than NN O O
half NN O O
( NN O O
55 NN O O
% NN O O
) NN O O
of NN O O
the NN O O
population NN O O
was NN O O
male NN O O
; NN O O
46 NN O O
% NN O O
were NN O O
White NN O O
, NN O O
50 NN O O
% NN O O
were NN O O
Asian NN O O
, NN O O
and NN O O
3 NN O O
% NN O O
were NN O O
Black NN O O
or NN O O
African NN O O
American NN O O
. NN O O
At NN O O
baseline NN O O
, NN O O
57 NN O O
% NN O O
of NN O O
the NN O O
population NN O O
had NN O O
diabetes NN O O
more NN O O
than NN O O
5 NN O O
years NN O O
and NN O O
had NN O O
a NN O O
mean NN O O
hemoglobin NN O O
A1c NN O O
( NN O O
HbA1c NN O O
) NN O O
of NN O O
8 NN O O
% NN O O
. NN O O
Established NN O O
microvascular NN O O
complications NN O O
of NN O O
diabetes NN O O
at NN O O
baseline NN O O
included NN O O
diabetic NN O O
nephropathy NN O O
( NN O O
7 NN O O
% NN O O
) NN O O
, NN O O
retinopathy NN O O
( NN O O
8 NN O O
% NN O O
) NN O O
, NN O O
or NN O O
neuropathy NN O O
( NN O O
16 NN O O
% NN O O
) NN O O
. NN O O
Baseline NN O O
renal NN O O
function NN O O
was NN O O
normal NN O O
or NN O O
mildly NN O O
impaired NN O O
in NN O O
91 NN O O
% NN O O
of NN O O
patients NN O O
and NN O O
moderately NN O O
impaired NN O O
in NN O O
9 NN O O
% NN O O
of NN O O
patients NN O O
( NN O O
mean NN O O
eGFR NN O O
86.8 NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
) NN O O
. NN O O
Table NN O O
1 NN O O
shows NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
excluding NN O O
hypoglycemia NN B-AdverseReaction B-AdverseReaction
associated NN O O
with NN O O
the NN O O
use NN O O
of NN O O
JARDIANCE. NN O O
The NN O O
adverse NN O O
reactions NN O O
were NN O O
not NN O O
present NN O O
at NN O O
baseline NN O O
, NN O O
occurred NN O O
more NN O O
commonly NN O O
on NN O O
JARDIANCE NN O O
than NN O O
on NN O O
placebo NN O O
and NN O O
occurred NN O O
in NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
2 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
JARDIANCE NN O O
10 NN O O
mg NN O O
or NN O O
JARDIANCE NN O O
25 NN O O
mg NN O O
. NN O O
Table NN O O
1 NN O O
Adverse NN O O
Reactions NN O O
Reported NN O O
in NN O O
>=2 NN O O
% NN O O
of NN O O
Patients NN O O
Treated NN O O
with NN O O
JARDIANCE NN O O
and NN O O
Greater NN O O
than NN O O
Placebo NN O O
in NN O O
Pooled NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Clinical NN O O
Studies NN O O
of NN O O
JARDIANCE NN O O
Monotherapy NN O O
or NN O O
Combination NN O O
Therapy NN O O
a NN O O
Predefined NN O O
adverse NN O O
event NN O O
grouping NN O O
, NN O O
including NN O O
, NN O O
but NN O O
not NN O O
limited NN O O
to NN O O
, NN O O
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
asymptomatic NN B-AdverseReaction B-AdverseReaction
bacteriuria NN I-AdverseReaction I-AdverseReaction
cystitis NN B-AdverseReaction B-AdverseReaction
b NN O O
Female NN B-AdverseReaction B-AdverseReaction
genital NN I-AdverseReaction I-AdverseReaction
mycotic NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
include NN O O
the NN O O
following NN O O
adverse NN O O
reactions NN O O
: NN O O
vulvovaginal NN B-AdverseReaction B-AdverseReaction
mycotic NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
vaginal NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
vulvitis NN B-AdverseReaction B-AdverseReaction
vulvovaginal NN B-AdverseReaction B-AdverseReaction
candidiasis NN I-AdverseReaction I-AdverseReaction
genital NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
genital NN B-AdverseReaction B-AdverseReaction
candidiasis NN I-AdverseReaction I-AdverseReaction
genital NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
fungal NN I-AdverseReaction I-AdverseReaction
genitourinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
vulvovaginitis NN B-AdverseReaction B-AdverseReaction
cervicitis NN B-AdverseReaction B-AdverseReaction
urogenital NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
fungal NN I-AdverseReaction I-AdverseReaction
vaginitis NN B-AdverseReaction B-AdverseReaction
bacterial NN I-AdverseReaction I-AdverseReaction
Percentages NN O O
calculated NN O O
with NN O O
the NN O O
number NN O O
of NN O O
female NN O O
subjects NN O O
in NN O O
each NN O O
group NN O O
as NN O O
denominator NN O O
: NN O O
placebo NN O O
( NN O O
N=481 NN O O
) NN O O
, NN O O
JARDIANCE NN O O
10 NN O O
mg NN O O
( NN O O
N=443 NN O O
) NN O O
, NN O O
JARDIANCE NN O O
25 NN O O
mg NN O O
( NN O O
N=420 NN O O
) NN O O
. NN O O
c NN O O
Predefined NN O O
adverse NN O O
event NN O O
grouping NN O O
, NN O O
including NN O O
, NN O O
but NN O O
not NN O O
limited NN O O
to NN O O
, NN O O
polyuria NN B-AdverseReaction B-AdverseReaction
pollakiuria NN B-AdverseReaction B-AdverseReaction
and NN O O
nocturia NN B-AdverseReaction B-AdverseReaction
d NN O O
Male NN O O
genital NN O O
mycotic NN O O
infections NN O O
include NN O O
the NN O O
following NN O O
adverse NN O O
reactions NN O O
: NN O O
balanoposthitis NN B-AdverseReaction B-AdverseReaction
balanitis NN B-AdverseReaction B-AdverseReaction
genital NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
fungal NN I-AdverseReaction I-AdverseReaction
genitourinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
balanitis NN B-AdverseReaction B-AdverseReaction
candida NN I-AdverseReaction I-AdverseReaction
scrotal NN B-AdverseReaction B-AdverseReaction
abscess NN I-AdverseReaction I-AdverseReaction
penile NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
Percentages NN O O
calculated NN O O
with NN O O
the NN O O
number NN O O
of NN O O
male NN O O
subjects NN O O
in NN O O
each NN O O
group NN O O
as NN O O
denominator NN O O
: NN O O
placebo NN O O
( NN O O
N=514 NN O O
) NN O O
, NN O O
JARDIANCE NN O O
10 NN O O
mg NN O O
( NN O O
N=556 NN O O
) NN O O
, NN O O
JARDIANCE NN O O
25 NN O O
mg NN O O
( NN O O
N=557 NN O O
) NN O O
. NN O O
Number NN O O
( NN O O
% NN O O
) NN O O
of NN O O
Patients NN O O
PlaceboN=995 NN O O
JARDIANCE NN O O
10 NN O O
mgN=999 NN O O
JARDIANCE NN O O
25 NN O O
mgN=977 NN O O
Urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
a NN O O
7.6 NN O O
% NN O O
9.3 NN O O
% NN O O
7.6 NN O O
% NN O O
Female NN B-AdverseReaction B-AdverseReaction
genital NN I-AdverseReaction I-AdverseReaction
mycotic NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
b NN O O
1.5 NN O O
% NN O O
5.4 NN O O
% NN O O
6.4 NN O O
% NN O O
Upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
3.8 NN O O
% NN O O
3.1 NN O O
% NN O O
4.0 NN O O
% NN O O
Increased NN B-AdverseReaction B-AdverseReaction
urination NN I-AdverseReaction I-AdverseReaction
c NN O O
1.0 NN O O
% NN O O
3.4 NN O O
% NN O O
3.2 NN O O
% NN O O
Dyslipidemia NN B-AdverseReaction B-AdverseReaction
3.4 NN O O
% NN O O
3.9 NN O O
% NN O O
2.9 NN O O
% NN O O
Arthralgia NN B-AdverseReaction B-AdverseReaction
2.2 NN O O
% NN O O
2.4 NN O O
% NN O O
2.3 NN O O
% NN O O
Male NN B-AdverseReaction B-AdverseReaction
genital NN I-AdverseReaction I-AdverseReaction
mycotic NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
d NN O O
0.4 NN O O
% NN O O
3.1 NN O O
% NN O O
1.6 NN O O
% NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
1.4 NN O O
% NN O O
2.3 NN O O
% NN O O
1.1 NN O O
% NN O O
Thirst NN B-AdverseReaction B-AdverseReaction
( NN O O
including NN O O
polydipsia NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
0 NN O O
% NN O O
, NN O O
1.7 NN O O
% NN O O
, NN O O
and NN O O
1.5 NN O O
% NN O O
for NN O O
placebo NN O O
, NN O O
JARDIANCE NN O O
10 NN O O
mg NN O O
, NN O O
and NN O O
JARDIANCE NN O O
25 NN O O
mg NN O O
, NN O O
respectively NN O O
. NN O O
Volume NN O O
Depletion NN O O
JARDIANCE NN O O
causes NN O O
an NN O O
osmotic NN B-AdverseReaction B-AdverseReaction
diuresis NN I-AdverseReaction I-AdverseReaction
which NN O O
may NN B-Factor B-Factor
lead NN O O
to NN O O
intravascular NN B-AdverseReaction B-AdverseReaction
volume NN I-AdverseReaction I-AdverseReaction
contraction NN I-AdverseReaction I-AdverseReaction
and NN O O
adverse NN O O
reactions NN O O
related NN O O
to NN O O
volume NN B-AdverseReaction B-AdverseReaction
depletion NN I-AdverseReaction I-AdverseReaction
In NN O O
the NN O O
pool NN O O
of NN O O
five NN O O
placebo NN O O
- NN O O
controlled NN O O
clinical NN O O
trials NN O O
, NN O O
adverse NN O O
reactions NN O O
related NN O O
to NN O O
volume NN B-AdverseReaction B-AdverseReaction
depletion NN I-AdverseReaction I-AdverseReaction
( NN O O
e.g. NN O O
, NN O O
blood NN O O
pressure NN O O
( NN O O
ambulatory NN O O
) NN O O
decreased NN O O
, NN O O
blood NN B-AdverseReaction B-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
systolic NN I-AdverseReaction I-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
dehydration NN B-AdverseReaction B-AdverseReaction
hypotension NN B-AdverseReaction B-AdverseReaction
hypovolemia NN B-AdverseReaction B-AdverseReaction
orthostatic NN B-AdverseReaction B-AdverseReaction
hypotension NN I-AdverseReaction I-AdverseReaction
and NN O O
syncope NN B-AdverseReaction B-AdverseReaction
were NN O O
reported NN O O
by NN O O
0.3 NN O O
% NN O O
, NN O O
0.5 NN O O
% NN O O
, NN O O
and NN O O
0.3 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
placebo NN O O
, NN O O
JARDIANCE NN O O
10 NN O O
mg NN O O
, NN O O
and NN O O
JARDIANCE NN O O
25 NN O O
mg NN O O
respectively NN O O
. NN O O
JARDIANCE NN O O
may NN O O
increase NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
hypotension NN B-AdverseReaction B-AdverseReaction
in NN O O
patients NN O O
at NN O O
risk NN O O
for NN O O
volume NN O O
contraction NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
and NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.5 NN O O
, NN O O
8.6 NN O O
) NN O O
] NN O O
. NN O O
Increased NN B-AdverseReaction B-AdverseReaction
Urination NN I-AdverseReaction I-AdverseReaction
In NN O O
the NN O O
pool NN O O
of NN O O
five NN O O
placebo NN O O
- NN O O
controlled NN O O
clinical NN O O
trials NN O O
, NN O O
adverse NN O O
reactions NN O O
of NN O O
increased NN B-AdverseReaction B-AdverseReaction
urination NN I-AdverseReaction I-AdverseReaction
( NN O O
e.g. NN O O
, NN O O
polyuria NN B-AdverseReaction B-AdverseReaction
pollakiuria NN B-AdverseReaction B-AdverseReaction
and NN O O
nocturia NN B-AdverseReaction B-AdverseReaction
occurred NN O O
more NN O O
frequently NN O O
on NN O O
JARDIANCE NN O O
than NN O O
on NN O O
placebo NN O O
( NN O O
see NN O O
Table NN O O
1 NN O O
) NN O O
. NN O O
Specifically NN O O
, NN O O
nocturia NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
by NN O O
0.4 NN O O
% NN O O
, NN O O
0.3 NN O O
% NN O O
, NN O O
and NN O O
0.8 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
placebo NN O O
, NN O O
JARDIANCE NN O O
10 NN O O
mg NN O O
, NN O O
and NN O O
JARDIANCE NN O O
25 NN O O
mg NN O O
, NN O O
respectively NN O O
. NN O O
Impairment NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
Renal NN I-AdverseReaction I-AdverseReaction
Function NN I-AdverseReaction I-AdverseReaction
Use NN O O
of NN O O
JARDIANCE NN O O
was NN O O
associated NN O O
with NN O O
increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
and NN O O
decreases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
eGFR NN I-AdverseReaction I-AdverseReaction
( NN O O
see NN O O
Table NN O O
2 NN O O
) NN O O
. NN O O
Patients NN O O
with NN O O
moderate NN O O
renal NN O O
impairment NN O O
at NN O O
baseline NN O O
had NN O O
larger NN O O
mean NN O O
changes NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
and NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.5 NN O O
, NN O O
8.6 NN O O
) NN O O
] NN O O
. NN O O
Table NN O O
2 NN O O
Changes NN O O
from NN O O
Baseline NN O O
in NN O O
Serum NN O O
Creatinine NN O O
and NN O O
eGFR NN O O
in NN O O
the NN O O
Pool NN O O
of NN O O
Four NN O O
24-week NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Studies NN O O
and NN O O
Renal NN O O
Impairment NN O O
Study NN O O
a NN O O
Subset NN O O
of NN O O
patients NN O O
from NN O O
renal NN O O
impairment NN O O
study NN O O
with NN O O
eGFR NN B-AdverseReaction B-AdverseReaction
30 NN I-AdverseReaction I-AdverseReaction
to NN I-AdverseReaction I-AdverseReaction
less NN I-AdverseReaction I-AdverseReaction
than NN I-AdverseReaction I-AdverseReaction
60 NN I-AdverseReaction I-AdverseReaction
mL/min/1.73 NN I-AdverseReaction I-AdverseReaction
m NN I-AdverseReaction I-AdverseReaction
2 NN I-AdverseReaction I-AdverseReaction
Pool NN O O
of NN O O
24-Week NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Studies NN O O
Placebo NN O O
JARDIANCE NN O O
10 NN O O
mg NN O O
JARDIANCE NN O O
25 NN O O
mg NN O O
Baseline NN O O
Mean NN O O
N NN O O
825 NN O O
830 NN O O
822 NN O O
Creatinine NN O O
( NN O O
mg/dL NN O O
) NN O O
0.84 NN O O
0.85 NN O O
0.85 NN O O
eGFR NN O O
( NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
) NN O O
87.3 NN O O
87.1 NN O O
87.8 NN O O
Week NN O O
12 NN O O
Change NN O O
N NN O O
771 NN O O
797 NN O O
783 NN O O
Creatinine NN O O
( NN O O
mg/dL NN O O
) NN O O
0.00 NN O O
0.02 NN O O
0.01 NN O O
eGFR NN O O
( NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
) NN O O
-0.3 NN O O
-1.3 NN O O
-1.4 NN O O
Week NN O O
24 NN O O
Change NN O O
N NN O O
708 NN O O
769 NN O O
754 NN O O
Creatinine NN O O
( NN O O
mg/dL NN O O
) NN O O
0.00 NN O O
0.01 NN O O
0.01 NN O O
eGFR NN O O
( NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
) NN O O
-0.3 NN O O
-0.6 NN O O
-1.4 NN O O
Moderate NN O O
Renal NN O O
Impairment NN O O
a NN O O
Placebo NN O O
JARDIANCE NN O O
25 NN O O
mg NN O O
Baseline NN O O
N NN O O
187 NN O O
-- NN O O
187 NN O O
Creatinine NN O O
( NN O O
mg/dL NN O O
) NN O O
1.49 NN O O
-- NN O O
1.46 NN O O
eGFR NN O O
( NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
) NN O O
44.3 NN O O
-- NN O O
45.4 NN O O
Week NN O O
12 NN O O
Change NN O O
N NN O O
176 NN O O
-- NN O O
179 NN O O
Creatinine NN O O
( NN O O
mg/dL NN O O
) NN O O
0.01 NN O O
-- NN O O
0.12 NN O O
eGFR NN O O
( NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
) NN O O
0.1 NN O O
-- NN O O
-3.8 NN O O
Week NN O O
24 NN O O
Change NN O O
N NN O O
170 NN O O
-- NN O O
171 NN O O
Creatinine NN O O
( NN O O
mg/dL NN O O
) NN O O
0.01 NN O O
-- NN O O
0.10 NN O O
eGFR NN O O
( NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
) NN O O
0.2 NN O O
-- NN O O
-3.2 NN O O
Week NN O O
52 NN O O
Change NN O O
N NN O O
164 NN O O
-- NN O O
162 NN O O
Creatinine NN O O
( NN O O
mg/dL NN O O
) NN O O
0.02 NN O O
-- NN O O
0.11 NN O O
eGFR NN O O
( NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
) NN O O
-0.3 NN O O
-- NN O O
-2.8 NN O O
Hypoglycemia NN B-AdverseReaction B-AdverseReaction
The NN O O
incidence NN O O
of NN O O
hypoglycemia NN B-AdverseReaction B-AdverseReaction
by NN O O
study NN O O
is NN O O
shown NN O O
in NN O O
Table NN O O
3 NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
hypoglycemia NN B-AdverseReaction B-AdverseReaction
increased NN O O
when NN O O
JARDIANCE NN O O
was NN O O
administered NN O O
with NN O O
insulin NN O O
or NN O O
sulfonylurea NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
. NN O O
Table NN O O
3 NN O O
Incidence NN O O
of NN O O
Overalla NN O O
and NN O O
Severe NN B-Severity B-Severity
Hypoglycemic NN B-AdverseReaction B-AdverseReaction
Events NN I-AdverseReaction I-AdverseReaction
in NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Clinical NN O O
Studies NN O O
a NN O O
Overall NN O O
hypoglycemic NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
plasma NN O O
or NN O O
capillary NN B-AdverseReaction B-AdverseReaction
glucose NN I-AdverseReaction I-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
less NN I-AdverseReaction I-AdverseReaction
than NN I-AdverseReaction I-AdverseReaction
or NN I-AdverseReaction I-AdverseReaction
equal NN I-AdverseReaction I-AdverseReaction
to NN I-AdverseReaction I-AdverseReaction
70 NN I-AdverseReaction I-AdverseReaction
mg/dL NN I-AdverseReaction I-AdverseReaction
b NN O O
Severe NN B-Severity B-Severity
hypoglycemic NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
requiring NN O O
assistance NN O O
regardless NN O O
of NN O O
blood NN O O
glucose NN O O
c NN O O
Insulin NN O O
dose NN O O
could NN O O
not NN O O
be NN O O
adjusted NN O O
during NN O O
the NN O O
initial NN O O
18 NN O O
week NN O O
treatment NN O O
period NN O O
Monotherapy(24 NN O O
weeks NN O O
) NN O O
Placebo(n=229 NN O O
) NN O O
JARDIANCE NN O O
10 NN O O
mg(n=224 NN O O
) NN O O
JARDIANCE NN O O
25 NN O O
mg(n=223 NN O O
) NN O O
Overall NN O O
( NN O O
% NN O O
) NN O O
0.4 NN O O
% NN O O
0.4 NN O O
% NN O O
0.4 NN O O
% NN O O
Severe NN O O
( NN O O
% NN O O
) NN O O
0 NN O O
% NN O O
0 NN O O
% NN O O
0 NN O O
% NN O O
In NN O O
Combination NN O O
withMetformin(24 NN O O
weeks NN O O
) NN O O
Placebo NN O O
+ NN O O
Metformin(n=206 NN O O
) NN O O
JARDIANCE NN O O
10 NN O O
mg NN O O
+ NN O O
Metformin(n=217 NN O O
) NN O O
JARDIANCE NN O O
25 NN O O
mg NN O O
+ NN O O
Metformin(n=214 NN O O
) NN O O
Overall NN O O
( NN O O
% NN O O
) NN O O
0.5 NN O O
% NN O O
1.8 NN O O
% NN O O
1.4 NN O O
% NN O O
Severe NN O O
( NN O O
% NN O O
) NN O O
0 NN O O
% NN O O
0 NN O O
% NN O O
0 NN O O
% NN O O
In NN O O
Combination NN O O
withMetformin NN O O
+ NN O O
Sulfonylurea(24 NN O O
weeks NN O O
) NN O O
Placebo(n=225 NN O O
) NN O O
JARDIANCE NN O O
10 NN O O
mg NN O O
+ NN O O
Metformin NN O O
+ NN O O
Sulfonylurea(n=224 NN O O
) NN O O
JARDIANCE NN O O
25 NN O O
mg NN O O
+ NN O O
Metformin NN O O
+ NN O O
Sulfonylurea(n=217 NN O O
) NN O O
Overall NN O O
( NN O O
% NN O O
) NN O O
8.4 NN O O
% NN O O
16.1 NN O O
% NN O O
11.5 NN O O
% NN O O
Severe NN O O
( NN O O
% NN O O
) NN O O
0 NN O O
% NN O O
0 NN O O
% NN O O
0 NN O O
% NN O O
In NN O O
Combination NN O O
withPioglitazone NN O O
+/- NN O O
Metformin(24 NN O O
weeks NN O O
) NN O O
Placebo(n=165 NN O O
) NN O O
JARDIANCE NN O O
10 NN O O
mg NN O O
+ NN O O
Pioglitazone NN O O
+/- NN O O
Metformin(n=165 NN O O
) NN O O
JARDIANCE NN O O
25 NN O O
mg NN O O
+ NN O O
Pioglitazone NN O O
+/- NN O O
Metformin(n=168 NN O O
) NN O O
Overall NN O O
( NN O O
% NN O O
) NN O O
1.8 NN O O
% NN O O
1.2 NN O O
% NN O O
2.4 NN O O
% NN O O
Severe NN O O
( NN O O
% NN O O
) NN O O
0 NN O O
% NN O O
0 NN O O
% NN O O
0 NN O O
% NN O O
In NN O O
Combination NN O O
with NN O O
Basal NN O O
Insulin(18 NN O O
weeks NN O O
c NN O O
) NN O O
Placebo(n=170 NN O O
) NN O O
JARDIANCE NN O O
10 NN O O
mg(n=169 NN O O
) NN O O
JARDIANCE NN O O
25 NN O O
mg(n=155 NN O O
) NN O O
Overall NN O O
( NN O O
% NN O O
) NN O O
20.6 NN O O
% NN O O
19.5 NN O O
% NN O O
28.4 NN O O
% NN O O
Severe NN O O
( NN O O
% NN O O
) NN O O
0 NN O O
% NN O O
0 NN O O
% NN O O
1.3 NN O O
% NN O O
In NN O O
Combination NN O O
with NN O O
MDI NN O O
Insulin NN O O
+/- NN O O
Metformin(18 NN O O
weeks NN O O
c NN O O
) NN O O
Placebo(n=188 NN O O
) NN O O
JARDIANCE NN O O
10 NN O O
mg(n=186 NN O O
) NN O O
JARDIANCE NN O O
25 NN O O
mg(n=189 NN O O
) NN O O
Overall NN O O
( NN O O
% NN O O
) NN O O
37.2 NN O O
% NN O O
39.8 NN O O
% NN O O
41.3 NN O O
% NN O O
Severe NN O O
( NN O O
% NN O O
) NN O O
0.5 NN O O
% NN O O
0.5 NN O O
% NN O O
0.5 NN O O
% NN O O
Genital NN B-AdverseReaction B-AdverseReaction
Mycotic NN I-AdverseReaction I-AdverseReaction
Infections NN I-AdverseReaction I-AdverseReaction
In NN O O
the NN O O
pool NN O O
of NN O O
five NN O O
placebo NN O O
- NN O O
controlled NN O O
clinical NN O O
trials NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
genital NN B-AdverseReaction B-AdverseReaction
mycotic NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
( NN O O
e.g. NN O O
, NN O O
vaginal NN B-AdverseReaction B-AdverseReaction
mycotic NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
vaginal NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
genital NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
fungal NN I-AdverseReaction I-AdverseReaction
vulvovaginal NN B-AdverseReaction B-AdverseReaction
candidiasis NN I-AdverseReaction I-AdverseReaction
and NN O O
vulvitis NN B-AdverseReaction B-AdverseReaction
was NN O O
increased NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
JARDIANCE NN O O
compared NN O O
to NN O O
placebo NN O O
, NN O O
occurring NN O O
in NN O O
0.9 NN O O
% NN O O
, NN O O
4.1 NN O O
% NN O O
, NN O O
and NN O O
3.7 NN O O
% NN O O
of NN O O
patients NN O O
randomized NN O O
to NN O O
placebo NN O O
, NN O O
JARDIANCE NN O O
10 NN O O
mg NN O O
, NN O O
and NN O O
JARDIANCE NN O O
25 NN O O
mg NN O O
, NN O O
respectively NN O O
. NN O O
Discontinuation NN O O
from NN O O
study NN O O
due NN O O
to NN O O
genital NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
0 NN O O
% NN O O
of NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
0.2 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
either NN O O
JARDIANCE NN O O
10 NN O O
or NN O O
25 NN O O
mg NN O O
. NN O O
Genital NN B-AdverseReaction B-AdverseReaction
mycotic NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
occurred NN O O
more NN O O
frequently NN O O
in NN O O
female NN O O
than NN O O
male NN O O
patients NN O O
( NN O O
see NN O O
Table NN O O
1 NN O O
) NN O O
. NN O O
Phimosis NN B-AdverseReaction B-AdverseReaction
occurred NN O O
more NN O O
frequently NN O O
in NN O O
male NN O O
patients NN O O
treated NN O O
with NN O O
JARDIANCE NN O O
10 NN O O
mg NN O O
( NN O O
less NN O O
than NN O O
0.1 NN O O
% NN O O
) NN O O
and NN O O
JARDIANCE NN O O
25 NN O O
mg NN O O
( NN O O
0.1 NN O O
% NN O O
) NN O O
than NN O O
placebo NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
. NN O O
Urinary NN B-AdverseReaction B-AdverseReaction
Tract NN I-AdverseReaction I-AdverseReaction
Infections NN I-AdverseReaction I-AdverseReaction
In NN O O
the NN O O
pool NN O O
of NN O O
five NN O O
placebo NN O O
- NN O O
controlled NN O O
clinical NN O O
trials NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
( NN O O
e.g. NN O O
, NN O O
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
asymptomatic NN B-AdverseReaction B-AdverseReaction
bacteriuria NN I-AdverseReaction I-AdverseReaction
and NN O O
cystitis NN B-AdverseReaction B-AdverseReaction
was NN O O
increased NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
JARDIANCE NN O O
compared NN O O
to NN O O
placebo NN O O
( NN O O
see NN O O
Table NN O O
1 NN O O
) NN O O
. NN O O
Patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
chronic NN O O
or NN O O
recurrent NN O O
urinary NN O O
tract NN O O
infections NN O O
were NN O O
more NN O O
likely NN O O
to NN O O
experience NN O O
a NN O O
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
The NN O O
rate NN O O
of NN O O
treatment NN O O
discontinuation NN O O
due NN O O
to NN O O
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
was NN O O
0.1 NN O O
% NN O O
, NN O O
0.2 NN O O
% NN O O
, NN O O
and NN O O
0.1 NN O O
% NN O O
for NN O O
placebo NN O O
, NN O O
JARDIANCE NN O O
10 NN O O
mg NN O O
, NN O O
and NN O O
JARDIANCE NN O O
25 NN O O
mg NN O O
, NN O O
respectively NN O O
. NN O O
Urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
occurred NN O O
more NN O O
frequently NN O O
in NN O O
female NN O O
patients NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
in NN O O
female NN O O
patients NN O O
randomized NN O O
to NN O O
placebo NN O O
, NN O O
JARDIANCE NN O O
10 NN O O
mg NN O O
, NN O O
and NN O O
JARDIANCE NN O O
25 NN O O
mg NN O O
was NN O O
16.6 NN O O
% NN O O
, NN O O
18.4 NN O O
% NN O O
, NN O O
and NN O O
17.0 NN O O
% NN O O
, NN O O
respectively NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
in NN O O
male NN O O
patients NN O O
randomized NN O O
to NN O O
placebo NN O O
, NN O O
JARDIANCE NN O O
10 NN O O
mg NN O O
, NN O O
and NN O O
JARDIANCE NN O O
25 NN O O
mg NN O O
was NN O O
3.2 NN O O
% NN O O
, NN O O
3.6 NN O O
% NN O O
, NN O O
and NN O O
4.1 NN O O
% NN O O
, NN O O
respectively NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
and NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.5 NN O O
) NN O O
] NN O O
. NN O O
Laboratory NN O O
Tests NN O O
Increase NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
Low NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Density NN I-AdverseReaction I-AdverseReaction
Lipoprotein NN I-AdverseReaction I-AdverseReaction
Cholesterol NN I-AdverseReaction I-AdverseReaction
( NN O O
LDL NN O O
- NN O O
C NN O O
) NN O O
Dose NN O O
- NN O O
related NN O O
increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
low NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
density NN I-AdverseReaction I-AdverseReaction
lipoprotein NN I-AdverseReaction I-AdverseReaction
cholesterol NN I-AdverseReaction I-AdverseReaction
( NN O O
LDL NN O O
- NN O O
C NN O O
) NN O O
were NN O O
observed NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
JARDIANCE. NN O O
LDL NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
by NN O O
2.3 NN O O
% NN O O
, NN O O
4.6 NN O O
% NN O O
, NN O O
and NN O O
6.5 NN O O
% NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
placebo NN O O
, NN O O
JARDIANCE NN O O
10 NN O O
mg NN O O
, NN O O
and NN O O
JARDIANCE NN O O
25 NN O O
mg NN O O
, NN O O
respectively NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.6 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
range NN O O
of NN O O
mean NN O O
baseline NN O O
LDL NN O O
- NN O O
C NN O O
levels NN O O
was NN O O
90.3 NN O O
to NN O O
90.6 NN O O
mg/dL NN O O
across NN O O
treatment NN O O
groups NN O O
. NN O O
Increase NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
Hematocrit NN I-AdverseReaction I-AdverseReaction
In NN O O
a NN O O
pool NN O O
of NN O O
four NN O O
placebo NN O O
- NN O O
controlled NN O O
studies NN O O
, NN O O
median NN O O
hematocrit NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
by NN O O
1.3 NN O O
% NN O O
in NN O O
placebo NN B-Factor B-Factor
and NN O O
increased NN O O
by NN O O
2.8 NN O O
% NN O O
in NN O O
JARDIANCE NN O O
10 NN O O
mg NN O O
and NN O O
2.8 NN O O
% NN O O
in NN O O
JARDIANCE NN O O
25 NN O O
mg NN O O
treated NN O O
patients NN O O
. NN O O
At NN O O
the NN O O
end NN O O
of NN O O
treatment NN O O
, NN O O
0.6 NN O O
% NN O O
, NN O O
2.7 NN O O
% NN O O
, NN O O
and NN O O
3.5 NN O O
% NN O O
of NN O O
patients NN O O
with NN O O
hematocrits NN O O
initially NN O O
within NN O O
the NN O O
reference NN O O
range NN O O
had NN O O
values NN O O
above NN O O
the NN O O
upper NN O O
limit NN O O
of NN O O
the NN O O
reference NN O O
range NN O O
with NN O O
placebo NN O O
, NN O O
JARDIANCE NN O O
10 NN O O
mg NN O O
, NN O O
and NN O O
JARDIANCE NN O O
25 NN O O
mg NN O O
, NN O O
respectively NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Hypotension NN B-AdverseReaction B-AdverseReaction
Before NN O O
initiating NN O O
JARDIANCE NN O O
assess NN O O
and NN O O
correct NN O O
volume NN O O
status NN O O
in NN O O
patients NN O O
with NN O O
renal NN O O
impairment NN O O
, NN O O
the NN O O
elderly NN O O
, NN O O
in NN O O
patients NN O O
with NN O O
low NN O O
systolic NN O O
blood NN O O
pressure NN O O
, NN O O
and NN O O
in NN O O
patients NN O O
on NN O O
diuretics NN O O
. NN O O
Monitor NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
during NN O O
therapy NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Impairment NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
function NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
renal NN O O
function NN O O
during NN O O
therapy NN O O
. NN O O
More NN O O
frequent NN O O
monitoring NN O O
is NN O O
recommended NN O O
in NN O O
patients NN O O
with NN O O
eGFR NN O O
below NN O O
60 NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Hypoglycemia NN B-AdverseReaction B-AdverseReaction
Consider NN O O
lowering NN O O
the NN O O
dose NN O O
of NN O O
insulin NN O O
secretagogue NN O O
or NN O O
insulin NN O O
to NN O O
reduce NN O O
the NN O O
risk NN O O
of NN O O
hypoglycemia NN O O
when NN O O
initiating NN O O
JARDIANCE NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Genital NN B-AdverseReaction B-AdverseReaction
mycotic NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
and NN O O
treat NN O O
as NN O O
appropriate NN O O
( NN O O
5.4 NN O O
) NN O O
* NN O O
Urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
and NN O O
treat NN O O
as NN O O
appropriate NN O O
( NN O O
5.5 NN O O
) NN O O
* NN O O
Increased NN B-AdverseReaction B-AdverseReaction
LDL NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
and NN O O
treat NN O O
as NN O O
appropriate NN O O
( NN O O
5.6 NN O O
) NN O O
* NN O O
Macrovascular NN O O
outcomes NN O O
: NN O O
There NN O O
have NN O O
been NN O O
no NN O O
clinical NN O O
studies NN O O
establishing NN O O
conclusive NN O O
evidence NN O O
of NN O O
macrovascular NN O O
risk NN O O
reduction NN O O
with NN O O
JARDIANCE NN O O
( NN O O
5.7 NN O O
) NN O O
5.1 NN O O
Hypotension NN O O
JARDIANCE NN O O
causes NN O O
intravascular NN B-AdverseReaction B-AdverseReaction
volume NN I-AdverseReaction I-AdverseReaction
contraction NN I-AdverseReaction I-AdverseReaction
Symptomatic NN B-AdverseReaction B-AdverseReaction
hypotension NN I-AdverseReaction I-AdverseReaction
may NN B-Factor B-Factor
occur NN O O
after NN O O
initiating NN O O
JARDIANCE NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
particularly NN O O
in NN O O
patients NN O O
with NN O O
renal NN O O
impairment NN O O
, NN O O
the NN O O
elderly NN O O
, NN O O
in NN O O
patients NN O O
with NN O O
low NN O O
systolic NN O O
blood NN O O
pressure NN O O
, NN O O
and NN O O
in NN O O
patients NN O O
on NN O O
diuretics NN O O
. NN O O
Before NN O O
initiating NN O O
JARDIANCE NN O O
, NN O O
assess NN O O
for NN O O
volume NN O O
contraction NN O O
and NN O O
correct NN O O
volume NN O O
status NN O O
if NN O O
indicated NN O O
. NN O O
Monitor NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
hypotension NN O O
after NN O O
initiating NN O O
therapy NN O O
and NN O O
increase NN O O
monitoring NN O O
in NN O O
clinical NN O O
situations NN O O
where NN O O
volume NN O O
contraction NN O O
is NN O O
expected NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.5 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
Impairment NN O O
in NN O O
Renal NN O O
Function NN O O
JARDIANCE NN O O
increases NN B-AdverseReaction B-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
and NN O O
decreases NN B-AdverseReaction B-AdverseReaction
eGFR NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
risk NN B-Factor B-Factor
of NN O O
impaired NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
function NN I-AdverseReaction I-AdverseReaction
with NN O O
JARDIANCE NN O O
is NN O O
increased NN O O
in NN O O
elderly NN O O
patients NN O O
and NN O O
patients NN O O
with NN O O
moderate NN O O
renal NN O O
impairment NN O O
. NN O O
More NN O O
frequent NN O O
monitoring NN O O
of NN O O
renal NN O O
function NN O O
is NN O O
recommended NN O O
in NN O O
these NN O O
patients NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.5 NN O O
, NN O O
8.6 NN O O
) NN O O
] NN O O
. NN O O
Renal NN O O
function NN O O
should NN O O
be NN O O
evaluated NN O O
prior NN O O
to NN O O
initiating NN O O
JARDIANCE NN O O
and NN O O
periodically NN O O
thereafter NN O O
. NN O O
5.3 NN O O
Hypoglycemia NN O O
with NN O O
Concomitant NN O O
Use NN O O
with NN O O
Insulin NN O O
and NN O O
Insulin NN O O
Secretagogues NN O O
Insulin NN O O
and NN O O
insulin NN O O
secretagogues NN O O
are NN O O
known NN O O
to NN O O
cause NN O O
hypoglycemia NN O O
. NN O O
The NN O O
risk NN B-Factor B-Factor
of NN O O
hypoglycemia NN B-AdverseReaction B-AdverseReaction
is NN O O
increased NN O O
when NN O O
JARDIANCE NN O O
is NN O O
used NN O O
in NN O O
combination NN O O
with NN O O
insulin NN O O
secretagogues NN O O
( NN O O
e.g. NN O O
, NN O O
sulfonylurea NN O O
) NN O O
or NN O O
insulin NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Therefore NN O O
, NN O O
a NN O O
lower NN O O
dose NN O O
of NN O O
the NN O O
insulin NN O O
secretagogue NN O O
or NN O O
insulin NN O O
may NN O O
be NN O O
required NN O O
to NN O O
reduce NN O O
the NN O O
risk NN O O
of NN O O
hypoglycemia NN O O
when NN O O
used NN O O
in NN O O
combination NN O O
with NN O O
JARDIANCE. NN O O
5.4 NN O O
Genital NN O O
Mycotic NN O O
Infections NN O O
JARDIANCE NN O O
increases NN O O
the NN O O
risk NN B-Factor B-Factor
for NN O O
genital NN B-AdverseReaction B-AdverseReaction
mycotic NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
chronic NN O O
or NN O O
recurrent NN O O
genital NN O O
mycotic NN O O
infections NN O O
were NN O O
more NN O O
likely NN O O
to NN O O
develop NN O O
mycotic NN B-AdverseReaction B-AdverseReaction
genital NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
and NN O O
treat NN O O
as NN O O
appropriate NN O O
. NN O O
5.5 NN O O
Urinary NN O O
Tract NN O O
Infections NN O O
JARDIANCE NN O O
increases NN O O
the NN O O
risk NN B-Factor B-Factor
for NN O O
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Monitor NN O O
and NN O O
treat NN O O
as NN O O
appropriate NN O O
. NN O O
5.6 NN O O
Increased NN O O
Low NN O O
- NN O O
Density NN O O
Lipoprotein NN O O
Cholesterol NN O O
( NN O O
LDL NN O O
- NN O O
C NN O O
) NN O O
Increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
LDL NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
with NN O O
JARDIANCE NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Monitor NN O O
and NN O O
treat NN O O
as NN O O
appropriate NN O O
. NN O O
5.7 NN O O
Macrovascular NN O O
Outcomes NN O O
There NN O O
have NN O O
been NN O O
no NN O O
clinical NN O O
studies NN O O
establishing NN O O
conclusive NN O O
evidence NN O O
of NN O O
macrovascular NN O O
risk NN O O
reduction NN O O
with NN O O
JARDIANCE NN O O
or NN O O
any NN O O
other NN O O
antidiabetic NN O O
drug NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
EXCERPT NN O O
: NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
and NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
following NN O O
DaTscan NN O O
administration NN O O
. NN O O
( NN O O
6.2 NN O O
) NN O O
In NN O O
clinical NN O O
trials NN O O
, NN O O
the NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
, NN O O
headache NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
vertigo NN B-AdverseReaction B-AdverseReaction
dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
or NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
< NN O O
1 NN O O
% NN O O
of NN O O
subjects NN O O
. NN O O
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
GE NN O O
Healthcare NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
654 NN O O
- NN O O
0118 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Study NN O O
Experience NN O O
The NN O O
data NN O O
from NN O O
clinical NN O O
studies NN O O
reflect NN O O
exposure NN O O
to NN O O
DaTscan NN O O
in NN O O
942 NN O O
subjects NN O O
with NN O O
a NN O O
mean NN O O
age NN O O
of NN O O
66 NN O O
years NN O O
( NN O O
range NN O O
25 NN O O
to NN O O
90 NN O O
years NN O O
) NN O O
. NN O O
Among NN O O
these NN O O
subjects NN O O
, NN O O
42 NN O O
% NN O O
were NN O O
women NN O O
and NN O O
99 NN O O
% NN O O
Caucasian NN O O
. NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
DaTscan NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
In NN O O
clinical NN O O
trials NN O O
, NN O O
no NN O O
serious NN O O
adverse NN O O
reactions NN O O
were NN O O
reported NN O O
. NN O O
Other NN O O
adverse NN O O
reactions NN O O
occurred NN O O
at NN O O
a NN O O
rate NN O O
of NN O O
1 NN O O
% NN O O
or NN O O
less NN O O
and NN O O
the NN O O
reported NN O O
events NN O O
consisted NN O O
of NN O O
headache NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
vertigo NN B-AdverseReaction B-AdverseReaction
dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
or NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
These NN O O
reactions NN O O
were NN O O
of NN O O
mild NN O O
to NN O O
moderate NN O O
severity NN O O
. NN O O
6.2 NN O O
Postmarketing NN O O
Experience NN O O
Because NN O O
postmarketing NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
In NN O O
the NN O O
postmarketing NN O O
experience NN O O
, NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
. NN O O
The NN O O
reactions NN O O
generally NN O O
related NN O O
to NN O O
rash NN B-AdverseReaction B-AdverseReaction
and NN O O
pruritis NN B-AdverseReaction B-AdverseReaction
within NN O O
minutes NN O O
of NN O O
DaTscan NN O O
administration NN O O
. NN O O
The NN O O
reactions NN O O
either NN O O
resolved NN O O
spontaneously NN O O
or NN O O
following NN O O
the NN O O
administration NN O O
of NN O O
corticosteroids NN O O
and NN O O
antihistamines NN O O
. NN O O
Injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
has NN O O
also NN O O
been NN O O
reported NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
following NN O O
DaTscan NN O O
administration NN O O
. NN O O
Have NN O O
anaphylactic NN O O
and NN O O
hypersensitivity NN O O
treatment NN O O
measures NN O O
available NN O O
prior NN O O
to NN O O
DaTscan NN O O
administration NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Administer NN O O
a NN O O
thyroid NN O O
- NN O O
blocking NN O O
agent NN O O
before NN O O
DaTscan NN O O
administration NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
5.1 NN O O
Hypersensitivity NN O O
Reactions NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
following NN O O
DaTscan NN O O
administration NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.2 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
reactions NN O O
have NN O O
generally NN O O
consisted NN O O
of NN O O
skin NN B-AdverseReaction B-AdverseReaction
erythema NN I-AdverseReaction I-AdverseReaction
and NN O O
pruritis NN B-AdverseReaction B-AdverseReaction
and NN O O
have NN O O
either NN O O
resolved NN O O
spontaneously NN O O
or NN O O
following NN O O
the NN O O
administration NN O O
of NN O O
corticosteroids NN O O
and NN O O
anti NN O O
- NN O O
histamines NN O O
. NN O O
Prior NN O O
to NN O O
administration NN O O
, NN O O
question NN O O
the NN O O
patient NN O O
for NN O O
a NN O O
history NN O O
of NN O O
prior NN O O
reactions NN O O
to NN O O
DaTscan NN O O
. NN O O
If NN O O
the NN O O
patient NN O O
is NN O O
known NN O O
or NN O O
strongly NN O O
suspected NN O O
of NN O O
having NN O O
had NN O O
a NN O O
hypersensitivity NN O O
reaction NN O O
to NN O O
DaTscan NN O O
, NN O O
the NN O O
decision NN O O
to NN O O
administer NN O O
DaTscan NN O O
should NN O O
be NN O O
based NN O O
upon NN O O
an NN O O
assessment NN O O
of NN O O
the NN O O
expected NN O O
benefits NN O O
compared NN O O
to NN O O
the NN O O
potential NN O O
hypersensitivity NN O O
risks NN O O
. NN O O
Have NN O O
anaphylactic NN O O
and NN O O
hypersensitivity NN O O
treatment NN O O
measures NN O O
available NN O O
prior NN O O
to NN O O
DaTscan NN O O
administration NN O O
and NN O O
, NN O O
following NN O O
administration NN O O
, NN O O
observe NN O O
patients NN O O
for NN O O
symptoms NN O O
or NN O O
signs NN O O
of NN O O
a NN O O
hypersensitivity NN O O
reaction NN O O
. NN O O
5.2 NN O O
Thyroid NN O O
Accumulation NN O O
The NN O O
DaTscan NN O O
injection NN O O
may NN O O
contain NN O O
up NN O O
to NN O O
6 NN O O
% NN O O
of NN O O
free NN O O
iodide NN O O
( NN O O
iodine NN O O
123 NN O O
) NN O O
. NN O O
To NN O O
decrease NN O O
thyroid NN O O
accumulation NN O O
of NN O O
iodine NN O O
123 NN O O
, NN O O
block NN O O
the NN O O
thyroid NN O O
gland NN O O
before NN O O
administration NN O O
of NN O O
DaTscan NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
] NN O O
. NN O O
Avoid NN O O
the NN O O
use NN O O
of NN O O
Potassium NN O O
Iodide NN O O
Oral NN O O
Solution NN O O
or NN O O
Lugol NN O O
's NN O O
Solution NN O O
in NN O O
patients NN O O
who NN O O
are NN O O
sensitive NN O O
to NN O O
such NN O O
products NN O O
. NN O O
Failure NN O O
to NN O O
block NN O O
thyroid NN O O
uptake NN O O
of NN O O
iodine NN O O
123 NN O O
may NN O O
result NN O O
in NN O O
an NN O O
increased NN O O
long NN O O
term NN O O
risk NN O O
for NN O O
thyroid NN O O
neoplasia NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
are NN O O
discussed NN O O
in NN O O
greater NN O O
detail NN O O
in NN O O
other NN O O
sections NN O O
of NN O O
the NN O O
labeling NN O O
. NN O O
* NN O O
? NN O O
Immune NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
mediated NN I-AdverseReaction I-AdverseReaction
enterocolitis NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
? NN O O
Immune NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
mediated NN I-AdverseReaction I-AdverseReaction
hepatitis NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
? NN O O
Immune NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
mediated NN I-AdverseReaction I-AdverseReaction
dermatitis NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
? NN O O
Immune NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
mediated NN I-AdverseReaction I-AdverseReaction
neuropathies NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
? NN O O
Immune NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
mediated NN I-AdverseReaction I-AdverseReaction
endocrinopathies NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
? NN O O
Other NN O O
immune NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
mediated NN I-AdverseReaction I-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
ocular NN B-AdverseReaction B-AdverseReaction
manifestations NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.6 NN O O
) NN O O
] NN O O
. NN O O
EXCERPT NN O O
: NN O O
Most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=5 NN O O
% NN O O
) NN O O
are NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
pruritus NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
and NN O O
colitis NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Bristol NN O O
- NN O O
Myers NN O O
Squibb NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
721 NN O O
- NN O O
5072 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
the NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
with NN O O
rates NN O O
in NN O O
other NN O O
clinical NN O O
trials NN O O
or NN O O
experience NN O O
with NN O O
therapeutics NN O O
in NN O O
the NN O O
same NN O O
class NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O
The NN O O
clinical NN O O
development NN O O
program NN O O
excluded NN O O
patients NN O O
with NN O O
active NN O O
autoimmune NN O O
disease NN O O
or NN O O
those NN O O
receiving NN O O
systemic NN O O
immunosuppression NN O O
for NN O O
organ NN O O
transplantation NN O O
. NN O O
Exposure NN O O
to NN O O
YERVOY NN O O
3 NN O O
mg/kg NN O O
for NN O O
4 NN O O
doses NN O O
given NN O O
by NN O O
intravenous NN O O
infusion NN O O
in NN O O
previously NN O O
treated NN O O
patients NN O O
with NN O O
unresectable NN O O
or NN O O
metastatic NN O O
melanoma NN O O
was NN O O
assessed NN O O
in NN O O
a NN O O
randomized NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
clinical NN O O
study NN O O
( NN O O
Study NN O O
1 NN O O
) NN O O
. NN O O
[ NN O O
See NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
. NN O O
] NN O O
One NN O O
hundred NN O O
thirty NN O O
- NN O O
one NN O O
patients NN O O
( NN O O
median NN O O
age NN O O
57 NN O O
years NN O O
, NN O O
60 NN O O
% NN O O
male NN O O
) NN O O
received NN O O
YERVOY NN O O
as NN O O
a NN O O
single NN O O
agent NN O O
, NN O O
380 NN O O
patients NN O O
( NN O O
median NN O O
age NN O O
56 NN O O
years NN O O
, NN O O
61 NN O O
% NN O O
male NN O O
) NN O O
received NN O O
YERVOY NN O O
with NN O O
an NN O O
investigational NN O O
gp100 NN O O
peptide NN O O
vaccine NN O O
( NN O O
gp100 NN O O
) NN O O
, NN O O
and NN O O
132 NN O O
patients NN O O
( NN O O
median NN O O
age NN O O
57 NN O O
years NN O O
, NN O O
54 NN O O
% NN O O
male NN O O
) NN O O
received NN O O
gp100 NN O O
peptide NN O O
vaccine NN O O
alone NN O O
. NN O O
Patients NN O O
in NN O O
the NN O O
study NN O O
received NN O O
a NN O O
median NN O O
of NN O O
4 NN O O
doses NN O O
( NN O O
range NN O O
: NN O O
1 NN O O
- NN O O
4 NN O O
doses NN O O
) NN O O
. NN O O
YERVOY NN O O
was NN O O
discontinued NN O O
for NN O O
adverse NN O O
reactions NN O O
in NN O O
10 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=5 NN O O
% NN O O
) NN O O
in NN O O
patients NN O O
who NN O O
received NN O O
YERVOY NN O O
at NN O O
3 NN O O
mg/kg NN O O
were NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
pruritus NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
and NN O O
colitis NN B-AdverseReaction B-AdverseReaction
Table NN O O
1 NN O O
presents NN O O
selected NN O O
adverse NN O O
reactions NN O O
from NN O O
Study NN O O
1 NN O O
, NN O O
which NN O O
occurred NN O O
in NN O O
at NN O O
least NN O O
5 NN O O
% NN O O
of NN O O
patients NN O O
in NN O O
the NN O O
YERVOY NN O O
- NN O O
containing NN O O
arms NN O O
and NN O O
with NN O O
at NN O O
least NN O O
5 NN O O
% NN O O
increased NN O O
incidence NN O O
over NN O O
the NN O O
control NN O O
gp100 NN O O
arm NN O O
for NN O O
all NN O O
- NN O O
grade NN O O
events NN O O
and NN O O
at NN O O
least NN O O
1 NN O O
% NN O O
incidence NN O O
over NN O O
the NN O O
control NN O O
group NN O O
for NN O O
Grade NN O O
3 NN O O
- NN O O
5 NN O O
events NN O O
. NN O O
Table NN O O
1 NN O O
: NN O O
Selected NN O O
Adverse NN O O
Reactions NN O O
in NN O O
Study NN O O
1 NN O O
a NN O O
Incidences NN O O
presented NN O O
in NN O O
this NN O O
table NN O O
are NN O O
based NN O O
on NN O O
reports NN O O
of NN O O
adverse NN O O
events NN O O
regardless NN O O
of NN O O
causality NN O O
. NN O O
Percentage NN O O
( NN O O
% NN O O
) NN O O
of NN O O
Patientsa NN O O
YERVOY3 NN O O
mg/kgn=131 NN O O
YERVOY3 NN O O
mg/kg+gp100n=380 NN O O
gp100n=132 NN O O
System NN O O
Organ NN O O
Class/Preferred NN O O
Term NN O O
AnyGrade NN O O
Grade3 NN O O
- NN O O
5 NN O O
AnyGrade NN O O
Grade3 NN O O
- NN O O
5 NN O O
AnyGrade NN O O
Grade3 NN O O
- NN O O
5 NN O O
Gastrointestinal NN O O
Disorders NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
32 NN O O
5 NN O O
37 NN O O
4 NN O O
20 NN O O
1 NN O O
Colitis NN B-AdverseReaction B-AdverseReaction
8 NN O O
5 NN O O
5 NN O O
3 NN O O
2 NN O O
0 NN O O
Skin NN O O
and NN O O
Subcutaneous NN O O
Tissue NN O O
Disorders NN O O
Pruritus NN B-AdverseReaction B-AdverseReaction
31 NN O O
0 NN O O
21 NN O O
< NN O O
1 NN O O
11 NN O O
0 NN O O
Rash NN B-AdverseReaction B-AdverseReaction
29 NN O O
2 NN O O
25 NN O O
2 NN O O
8 NN O O
0 NN O O
General NN O O
Disorders NN O O
and NN O O
Administration NN O O
Site NN O O
Conditions NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
41 NN O O
7 NN O O
34 NN O O
5 NN O O
31 NN O O
3 NN O O
Table NN O O
2 NN O O
presents NN O O
the NN O O
per NN O O
- NN O O
patient NN O O
incidence NN O O
of NN O O
severe NN B-Severity B-Severity
life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
or NN O O
fatal NN B-AdverseReaction B-AdverseReaction
immune NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
mediated NN I-AdverseReaction I-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
from NN O O
Study NN O O
1 NN O O
. NN O O
Table NN O O
2 NN O O
: NN O O
Severe NN B-Severity B-Severity
to NN O O
Fatal NN B-AdverseReaction B-AdverseReaction
Immune NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
mediated NN I-AdverseReaction I-AdverseReaction
Adverse NN I-AdverseReaction I-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
in NN O O
Study NN O O
1 NN O O
a NN O O
Including NN O O
fatal NN B-AdverseReaction B-AdverseReaction
outcome NN O O
. NN O O
b NN O O
Including NN O O
intestinal NN B-AdverseReaction B-AdverseReaction
perforation NN I-AdverseReaction I-AdverseReaction
c NN O O
Underlying NN O O
etiology NN O O
not NN O O
established NN O O
. NN O O
Percentage NN O O
( NN O O
% NN O O
) NN O O
of NN O O
Patients NN O O
YERVOY3 NN O O
mg/kgn=131 NN O O
YERVOY3 NN O O
mg/kg+gp100n=380 NN O O
Any NN O O
Immune NN O O
- NN O O
mediated NN O O
Adverse NN O O
Reaction NN O O
15 NN O O
12 NN O O
Enterocolitis NN B-AdverseReaction B-AdverseReaction
7 NN O O
7 NN O O
Hepatotoxicity NN B-AdverseReaction B-AdverseReaction
1 NN O O
2 NN O O
Dermatitis NN B-AdverseReaction B-AdverseReaction
2 NN O O
3 NN O O
Neuropathy NN B-AdverseReaction B-AdverseReaction
1 NN O O
< NN O O
1 NN O O
Endocrinopathy NN B-AdverseReaction B-AdverseReaction
4 NN O O
1 NN O O
Hypopituitarism NN B-AdverseReaction B-AdverseReaction
4 NN O O
1 NN O O
Adrenal NN B-AdverseReaction B-AdverseReaction
insufficiency NN I-AdverseReaction I-AdverseReaction
0 NN O O
1 NN O O
Other NN O O
Pneumonitis NN B-AdverseReaction B-AdverseReaction
0 NN O O
< NN O O
1 NN O O
Meningitis NN B-AdverseReaction B-AdverseReaction
0 NN O O
< NN O O
1 NN O O
Nephritis NN B-AdverseReaction B-AdverseReaction
1 NN O O
0 NN O O
Eosinophilia NN B-AdverseReaction B-AdverseReaction
1 NN O O
0 NN O O
Pericarditis NN B-AdverseReaction B-AdverseReaction
0 NN O O
< NN O O
1 NN O O
Across NN O O
clinical NN O O
studies NN O O
that NN O O
utilized NN O O
YERVOY NN O O
doses NN O O
ranging NN O O
from NN O O
0.3 NN O O
to NN O O
10 NN O O
mg/kg NN O O
, NN O O
the NN O O
following NN O O
adverse NN O O
reactions NN O O
were NN O O
also NN O O
reported NN O O
( NN O O
incidence NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
unless NN O O
otherwise NN O O
noted NN O O
) NN O O
: NN O O
urticaria NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
, NN O O
large NN B-AdverseReaction B-AdverseReaction
intestinal NN I-AdverseReaction I-AdverseReaction
ulcer NN I-AdverseReaction I-AdverseReaction
esophagitis NN B-AdverseReaction B-AdverseReaction
acute NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
distress NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
renal NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
and NN O O
infusion NN B-AdverseReaction B-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
Based NN O O
on NN O O
the NN O O
experience NN O O
in NN O O
the NN O O
entire NN O O
clinical NN O O
program NN O O
for NN O O
melanoma NN O O
, NN O O
the NN O O
incidence NN O O
and NN O O
severity NN O O
of NN O O
enterocolitis NN B-AdverseReaction B-AdverseReaction
and NN O O
hepatitis NN B-AdverseReaction B-AdverseReaction
appear NN O O
to NN O O
be NN O O
dose NN O O
dependent NN O O
. NN O O
6.2 NN O O
Postmarketing NN O O
Experience NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
identified NN O O
during NN O O
postapproval NN O O
use NN O O
of NN O O
YERVOY. NN O O
Because NN O O
these NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
Skin NN O O
and NN O O
Subcutaneous NN O O
Tissue NN O O
Disorders NN O O
: NN O O
Drug NN B-AdverseReaction B-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
with NN I-AdverseReaction I-AdverseReaction
eosinophilia NN I-AdverseReaction I-AdverseReaction
and NN I-AdverseReaction I-AdverseReaction
systemic NN I-AdverseReaction I-AdverseReaction
symptoms NN I-AdverseReaction I-AdverseReaction
( NN O O
DRESS NN O O
syndrome NN O O
) NN O O
6.3 NN O O
Immunogenicity NN O O
In NN O O
clinical NN O O
studies NN O O
, NN O O
1.1 NN O O
% NN O O
of NN O O
1024 NN O O
evaluable NN O O
patients NN O O
tested NN O O
positive NN O O
for NN O O
binding NN O O
antibodies NN O O
against NN O O
ipilimumab NN O O
in NN O O
an NN O O
electrochemiluminescent NN O O
( NN O O
ECL NN O O
) NN O O
based NN O O
assay NN O O
. NN O O
This NN O O
assay NN O O
has NN O O
substantial NN O O
limitations NN O O
in NN O O
detecting NN O O
anti NN O O
- NN O O
ipilimumab NN O O
antibodies NN O O
in NN O O
the NN O O
presence NN O O
of NN O O
ipilimumab NN O O
. NN O O
Infusion NN O O
- NN O O
related NN O O
or NN O O
peri NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
infusional NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
consistent NN O O
with NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
or NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
were NN O O
not NN B-Negation B-Negation
reported NN O O
in NN O O
these NN O O
11 NN O O
patients NN O O
nor NN O O
were NN O O
neutralizing NN O O
antibodies NN O O
against NN O O
ipilimumab NN O O
detected NN O O
. NN O O
Because NN O O
trough NN O O
levels NN O O
of NN O O
ipilimumab NN O O
interfere NN O O
with NN O O
the NN O O
ECL NN O O
assay NN O O
results NN O O
, NN O O
a NN O O
subset NN O O
analysis NN O O
was NN O O
performed NN O O
in NN O O
the NN O O
dose NN O O
cohort NN O O
with NN O O
the NN O O
lowest NN O O
trough NN O O
levels NN O O
. NN O O
In NN O O
this NN O O
analysis NN O O
, NN O O
6.9 NN O O
% NN O O
of NN O O
58 NN O O
evaluable NN O O
patients NN O O
, NN O O
who NN O O
were NN O O
treated NN O O
with NN O O
0.3 NN O O
mg/kg NN O O
dose NN O O
, NN O O
tested NN O O
positive NN O O
for NN O O
binding NN O O
antibodies NN O O
against NN O O
ipilimumab NN O O
. NN O O
Immunogenicity NN O O
assay NN O O
results NN O O
are NN O O
highly NN O O
dependent NN O O
on NN O O
several NN O O
factors NN O O
including NN O O
assay NN O O
sensitivity NN O O
and NN O O
specificity NN O O
, NN O O
assay NN O O
methodology NN O O
, NN O O
sample NN O O
handling NN O O
, NN O O
timing NN O O
of NN O O
sample NN O O
collection NN O O
, NN O O
concomitant NN O O
medications NN O O
, NN O O
and NN O O
underlying NN O O
disease NN O O
. NN O O
For NN O O
these NN O O
reasons NN O O
, NN O O
comparison NN O O
of NN O O
incidence NN O O
of NN O O
antibodies NN O O
to NN O O
YERVOY NN O O
with NN O O
the NN O O
incidences NN O O
of NN O O
antibodies NN O O
to NN O O
other NN O O
products NN O O
may NN O O
be NN O O
misleading NN O O
. NN O O
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
IMMUNE NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
MEDIATED NN I-AdverseReaction I-AdverseReaction
ADVERSE NN I-AdverseReaction I-AdverseReaction
REACTIONS NN I-AdverseReaction I-AdverseReaction
WARNING NN O O
: NN O O
IMMUNE NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
MEDIATED NN I-AdverseReaction I-AdverseReaction
ADVERSE NN I-AdverseReaction I-AdverseReaction
REACTIONS NN I-AdverseReaction I-AdverseReaction
YERVOY NN O O
can NN B-Factor B-Factor
result NN O O
in NN O O
severe NN B-Severity B-Severity
and NN O O
fatal NN B-AdverseReaction B-AdverseReaction
immune NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
mediated NN I-AdverseReaction I-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
due NN O O
to NN O O
T NN O O
- NN O O
cell NN O O
activation NN O O
and NN O O
proliferation NN O O
. NN O O
These NN O O
immune NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
mediated NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
may NN B-Factor B-Factor
involve NN O O
any NN O O
organ NN O O
system NN O O
; NN O O
however NN O O
, NN O O
the NN O O
most NN O O
common NN O O
severe NN B-Severity B-Severity
immune NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
mediated NN I-AdverseReaction I-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
are NN O O
enterocolitis NN B-AdverseReaction B-AdverseReaction
hepatitis NN B-AdverseReaction B-AdverseReaction
dermatitis NN B-AdverseReaction B-AdverseReaction
( NN O O
including NN O O
toxic NN B-AdverseReaction B-AdverseReaction
epidermal NN I-AdverseReaction I-AdverseReaction
necrolysis NN I-AdverseReaction I-AdverseReaction
neuropathy NN B-AdverseReaction B-AdverseReaction
and NN O O
endocrinopathy NN B-AdverseReaction B-AdverseReaction
The NN O O
majority NN O O
of NN O O
these NN O O
immune NN O O
- NN O O
mediated NN O O
reactions NN O O
initially NN O O
manifested NN O O
during NN O O
treatment NN O O
; NN O O
however NN O O
, NN O O
a NN O O
minority NN O O
occurred NN O O
weeks NN O O
to NN O O
months NN O O
after NN O O
discontinuation NN O O
of NN O O
YERVOY. NN O O
Permanently NN O O
discontinue NN O O
YERVOY NN O O
and NN O O
initiate NN O O
systemic NN O O
high NN O O
- NN O O
dose NN O O
corticosteroid NN O O
therapy NN O O
for NN O O
severe NN O O
immune NN O O
- NN O O
mediated NN O O
reactions NN O O
. NN O O
[ NN O O
See NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
. NN O O
] NN O O
Assess NN O O
patients NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
enterocolitis NN O O
, NN O O
dermatitis NN O O
, NN O O
neuropathy NN O O
, NN O O
and NN O O
endocrinopathy NN O O
and NN O O
evaluate NN O O
clinical NN O O
chemistries NN O O
including NN O O
liver NN O O
function NN O O
tests NN O O
and NN O O
thyroid NN O O
function NN O O
tests NN O O
at NN O O
baseline NN O O
and NN O O
before NN O O
each NN O O
dose NN O O
. NN O O
[ NN O O
See NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
, NN O O
5.2 NN O O
, NN O O
5.3 NN O O
, NN O O
5.4 NN O O
, NN O O
5.5 NN O O
) NN O O
. NN O O
] NN O O
EXCERPT NN O O
: NN O O
WARNING NN O O
: NN O O
IMMUNE NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
MEDIATED NN I-AdverseReaction I-AdverseReaction
ADVERSE NN I-AdverseReaction I-AdverseReaction
REACTIONS NN I-AdverseReaction I-AdverseReaction
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
. NN O O
YERVOY NN O O
can NN B-Factor B-Factor
result NN O O
in NN O O
severe NN B-Severity B-Severity
and NN O O
fatal NN B-AdverseReaction B-AdverseReaction
immune NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
mediated NN I-AdverseReaction I-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
due NN O O
to NN O O
T NN O O
- NN O O
cell NN O O
activation NN O O
and NN O O
proliferation NN O O
. NN O O
These NN O O
immune NN O O
- NN O O
mediated NN O O
reactions NN O O
may NN B-Factor B-Factor
involve NN O O
any NN O O
organ NN O O
system NN O O
; NN O O
however NN O O
, NN O O
the NN O O
most NN O O
common NN O O
severe NN B-Severity B-Severity
immune NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
mediated NN I-AdverseReaction I-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
are NN O O
enterocolitis NN B-AdverseReaction B-AdverseReaction
hepatitis NN B-AdverseReaction B-AdverseReaction
dermatitis NN B-AdverseReaction B-AdverseReaction
( NN O O
including NN O O
toxic NN B-AdverseReaction B-AdverseReaction
epidermal NN I-AdverseReaction I-AdverseReaction
necrolysis NN I-AdverseReaction I-AdverseReaction
neuropathy NN B-AdverseReaction B-AdverseReaction
and NN O O
endocrinopathy NN B-AdverseReaction B-AdverseReaction
The NN O O
majority NN O O
of NN O O
these NN O O
immune NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
mediated NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
initially NN O O
manifested NN O O
during NN O O
treatment NN O O
; NN O O
however NN O O
, NN O O
a NN O O
minority NN O O
occurred NN O O
weeks NN O O
to NN O O
months NN O O
after NN O O
discontinuation NN O O
of NN O O
YERVOY. NN O O
Permanently NN O O
discontinue NN O O
YERVOY NN O O
and NN O O
initiate NN O O
systemic NN O O
high NN O O
- NN O O
dose NN O O
corticosteroid NN O O
therapy NN O O
for NN O O
severe NN O O
immune NN O O
- NN O O
mediated NN O O
reactions NN O O
. NN O O
( NN O O
2.2 NN O O
) NN O O
Assess NN O O
patients NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
enterocolitis NN O O
, NN O O
dermatitis NN O O
, NN O O
neuropathy NN O O
, NN O O
and NN O O
endocrinopathy NN O O
and NN O O
evaluate NN O O
clinical NN O O
chemistries NN O O
including NN O O
liver NN O O
function NN O O
tests NN O O
and NN O O
thyroid NN O O
function NN O O
tests NN O O
at NN O O
baseline NN O O
and NN O O
before NN O O
each NN O O
dose NN O O
. NN O O
( NN O O
5.1 NN O O
, NN O O
5.2 NN O O
, NN O O
5.3 NN O O
, NN O O
5.4 NN O O
, NN O O
5.5 NN O O
) NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
YERVOY NN O O
can NN B-Factor B-Factor
result NN O O
in NN O O
severe NN B-Severity B-Severity
and NN O O
fatal NN B-AdverseReaction B-AdverseReaction
immune NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
mediated NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
due NN O O
to NN O O
T NN O O
- NN O O
cell NN O O
activation NN O O
and NN O O
proliferation NN O O
. NN O O
[ NN O O
See NN O O
Boxed NN O O
Warning NN O O
. NN O O
] NN O O
EXCERPT NN O O
: NN O O
Immune NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
mediated NN I-AdverseReaction I-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
Permanently NN O O
discontinue NN O O
for NN O O
severe NN O O
reactions NN O O
. NN O O
Withhold NN O O
dose NN O O
for NN O O
moderate NN O O
immune NN O O
- NN O O
mediated NN O O
adverse NN O O
reactions NN O O
until NN O O
return NN O O
to NN O O
baseline NN O O
, NN O O
improvement NN O O
to NN O O
mild NN O O
severity NN O O
, NN O O
or NN O O
complete NN O O
resolution NN O O
, NN O O
and NN O O
patient NN O O
is NN O O
receiving NN O O
less NN O O
than NN O O
7.5 NN O O
mg NN O O
prednisone NN O O
or NN O O
equivalent NN O O
per NN O O
day NN O O
. NN O O
Administer NN O O
systemic NN O O
high NN O O
- NN O O
dose NN O O
corticosteroids NN O O
for NN O O
severe NN O O
, NN O O
persistent NN O O
, NN O O
or NN O O
recurring NN O O
immune NN O O
- NN O O
mediated NN O O
reactions NN O O
. NN O O
( NN O O
5.1 NN O O
, NN O O
5.2 NN O O
, NN O O
5.3 NN O O
, NN O O
5.4 NN O O
, NN O O
5.5 NN O O
) NN O O
* NN O O
? NN O O
Immune NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
mediated NN I-AdverseReaction I-AdverseReaction
hepatitis NN I-AdverseReaction I-AdverseReaction
Evaluate NN O O
liver NN O O
function NN O O
tests NN O O
before NN O O
each NN O O
dose NN O O
of NN O O
YERVOY. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
? NN O O
Immune NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
mediated NN I-AdverseReaction I-AdverseReaction
endocrinopathies NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
thyroid NN O O
function NN O O
tests NN O O
and NN O O
clinical NN O O
chemistries NN O O
prior NN O O
to NN O O
each NN O O
dose NN O O
. NN O O
Evaluate NN O O
at NN O O
each NN O O
visit NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
endocrinopathy NN O O
. NN O O
Institute NN O O
hormone NN O O
replacement NN O O
therapy NN O O
as NN O O
needed NN O O
. NN O O
( NN O O
5.5 NN O O
) NN O O
5.1 NN O O
Immune NN O O
- NN O O
mediated NN O O
Enterocolitis NN O O
In NN O O
Study NN O O
1 NN O O
, NN O O
severe NN B-Severity B-Severity
life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
or NN O O
fatal NN B-AdverseReaction B-AdverseReaction
( NN O O
diarrhea NN O O
of NN O O
7 NN B-Severity B-Severity
or NN I-Severity I-Severity
more NN I-Severity I-Severity
stools NN I-Severity I-Severity
above NN I-Severity I-Severity
baseline NN I-Severity I-Severity
fever NN B-AdverseReaction B-AdverseReaction
ileus NN B-AdverseReaction B-AdverseReaction
peritoneal NN B-AdverseReaction B-AdverseReaction
signs NN I-AdverseReaction I-AdverseReaction
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
- NN I-Severity I-Severity
5 NN I-Severity I-Severity
immune NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
mediated NN I-AdverseReaction I-AdverseReaction
enterocolitis NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
34 NN O O
( NN O O
7 NN O O
% NN O O
) NN O O
YERVOY NN O O
- NN O O
treated NN O O
patients NN O O
, NN O O
and NN O O
moderate NN B-Severity B-Severity
( NN O O
diarrhea NN O O
with NN O O
up NN B-Severity B-Severity
to NN I-Severity I-Severity
6 NN I-Severity I-Severity
stools NN I-Severity I-Severity
above NN I-Severity I-Severity
baseline NN I-Severity I-Severity
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
mucus NN O O
or NN O O
blood NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
stool NN I-AdverseReaction I-AdverseReaction
Grade NN B-Severity B-Severity
2 NN I-Severity I-Severity
enterocolitis NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
28 NN O O
( NN O O
5 NN O O
% NN O O
) NN O O
YERVOY NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Across NN O O
all NN O O
YERVOY NN O O
- NN O O
treated NN O O
patients NN O O
( NN O O
n=511 NN O O
) NN O O
, NN O O
5 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
patients NN O O
developed NN O O
intestinal NN B-AdverseReaction B-AdverseReaction
perforation NN I-AdverseReaction I-AdverseReaction
4 NN O O
( NN O O
0.8 NN O O
% NN O O
) NN O O
patients NN O O
died NN B-AdverseReaction B-AdverseReaction
as NN O O
a NN O O
result NN O O
of NN O O
complications NN O O
, NN O O
and NN O O
26 NN O O
( NN O O
5 NN O O
% NN O O
) NN O O
patients NN O O
were NN O O
hospitalized NN O O
for NN O O
severe NN B-Severity B-Severity
enterocolitis NN B-AdverseReaction B-AdverseReaction
The NN O O
median NN O O
time NN O O
to NN O O
onset NN O O
was NN O O
7.4 NN O O
weeks NN O O
( NN O O
range NN O O
: NN O O
1.6 NN O O
- NN O O
13.4 NN O O
) NN O O
and NN O O
6.3 NN O O
weeks NN O O
( NN O O
range NN O O
: NN O O
0.3 NN O O
- NN O O
18.9 NN O O
) NN O O
after NN O O
the NN O O
initiation NN O O
of NN O O
YERVOY NN O O
for NN O O
patients NN O O
with NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
- NN I-Severity I-Severity
5 NN I-Severity I-Severity
enterocolitis NN B-AdverseReaction B-AdverseReaction
and NN O O
with NN O O
Grade NN B-Severity B-Severity
2 NN I-Severity I-Severity
enterocolitis NN B-AdverseReaction B-AdverseReaction
respectively NN O O
. NN O O
Twenty NN O O
- NN O O
nine NN O O
patients NN O O
( NN O O
85 NN O O
% NN O O
) NN O O
with NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
- NN I-Severity I-Severity
5 NN I-Severity I-Severity
enterocolitis NN B-AdverseReaction B-AdverseReaction
were NN O O
treated NN O O
with NN O O
high NN O O
- NN O O
dose NN O O
( NN O O
>=40 NN O O
mg NN O O
prednisone NN O O
equivalent NN O O
per NN O O
day NN O O
) NN O O
corticosteroids NN O O
, NN O O
with NN O O
a NN O O
median NN O O
dose NN O O
of NN O O
80 NN O O
mg/day NN O O
of NN O O
prednisone NN O O
or NN O O
equivalent NN O O
; NN O O
the NN O O
median NN O O
duration NN O O
of NN O O
treatment NN O O
was NN O O
2.3 NN O O
weeks NN O O
( NN O O
ranging NN O O
up NN O O
to NN O O
13.9 NN O O
weeks NN O O
) NN O O
followed NN O O
by NN O O
corticosteroid NN O O
taper NN O O
. NN O O
Of NN O O
the NN O O
28 NN O O
patients NN O O
with NN O O
moderate NN B-Severity B-Severity
enterocolitis NN B-AdverseReaction B-AdverseReaction
46 NN O O
% NN O O
were NN O O
not NN O O
treated NN O O
with NN O O
systemic NN O O
corticosteroids NN O O
, NN O O
29 NN O O
% NN O O
were NN O O
treated NN O O
with NN O O
< NN O O
40 NN O O
mg NN O O
prednisone NN O O
or NN O O
equivalent NN O O
per NN O O
day NN O O
for NN O O
a NN O O
median NN O O
duration NN O O
of NN O O
5.1 NN O O
weeks NN O O
, NN O O
and NN O O
25 NN O O
% NN O O
were NN O O
treated NN O O
with NN O O
high NN O O
- NN O O
dose NN O O
corticosteroids NN O O
for NN O O
a NN O O
median NN O O
duration NN O O
of NN O O
10 NN O O
days NN O O
prior NN O O
to NN O O
corticosteroid NN O O
taper NN O O
. NN O O
Infliximab NN O O
was NN O O
administered NN O O
to NN O O
5 NN O O
of NN O O
the NN O O
62 NN O O
patients NN O O
( NN O O
8 NN O O
% NN O O
) NN O O
with NN O O
moderate NN B-Severity B-Severity
severe NN B-Severity B-Severity
or NN O O
life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
immune NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
mediated NN I-AdverseReaction I-AdverseReaction
enterocolitis NN I-AdverseReaction I-AdverseReaction
following NN O O
inadequate NN O O
response NN O O
to NN O O
corticosteroids NN O O
. NN O O
Of NN O O
the NN O O
34 NN O O
patients NN O O
with NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
- NN I-Severity I-Severity
5 NN I-Severity I-Severity
enterocolitis NN B-AdverseReaction B-AdverseReaction
74 NN O O
% NN O O
experienced NN O O
complete NN O O
resolution NN O O
, NN O O
3 NN O O
% NN O O
experienced NN O O
improvement NN O O
to NN O O
Grade NN O O
2 NN O O
severity NN O O
, NN O O
and NN O O
24 NN O O
% NN O O
did NN O O
not NN O O
improve NN O O
. NN O O
Among NN O O
the NN O O
28 NN O O
patients NN O O
with NN O O
Grade NN B-Severity B-Severity
2 NN I-Severity I-Severity
enterocolitis NN B-AdverseReaction B-AdverseReaction
79 NN O O
% NN O O
experienced NN O O
complete NN O O
resolution NN O O
, NN O O
11 NN O O
% NN O O
improved NN O O
, NN O O
and NN O O
11 NN O O
% NN O O
did NN O O
not NN O O
improve NN O O
. NN O O
Monitor NN O O
patients NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
enterocolitis NN O O
( NN O O
such NN O O
as NN O O
diarrhea NN O O
, NN O O
abdominal NN O O
pain NN O O
, NN O O
mucus NN O O
or NN O O
blood NN O O
in NN O O
stool NN O O
, NN O O
with NN O O
or NN O O
without NN O O
fever NN O O
) NN O O
and NN O O
of NN O O
bowel NN O O
perforation NN O O
( NN O O
such NN O O
as NN O O
peritoneal NN O O
signs NN O O
and NN O O
ileus NN O O
) NN O O
. NN O O
In NN O O
symptomatic NN O O
patients NN O O
, NN O O
rule NN O O
out NN O O
infectious NN O O
etiologies NN O O
and NN O O
consider NN O O
endoscopic NN O O
evaluation NN O O
for NN O O
persistent NN O O
or NN O O
severe NN O O
symptoms NN O O
. NN O O
Permanently NN O O
discontinue NN O O
YERVOY NN O O
in NN O O
patients NN O O
with NN O O
severe NN O O
enterocolitis NN O O
and NN O O
initiate NN O O
systemic NN O O
corticosteroids NN O O
at NN O O
a NN O O
dose NN O O
of NN O O
1 NN O O
to NN O O
2 NN O O
mg/kg/day NN O O
of NN O O
prednisone NN O O
or NN O O
equivalent NN O O
. NN O O
Upon NN O O
improvement NN O O
to NN O O
Grade NN O O
1 NN O O
or NN O O
less NN O O
, NN O O
initiate NN O O
corticosteroid NN O O
taper NN O O
and NN O O
continue NN O O
to NN O O
taper NN O O
over NN O O
at NN O O
least NN O O
1 NN O O
month NN O O
. NN O O
In NN O O
clinical NN O O
trials NN O O
, NN O O
rapid NN O O
corticosteroid NN O O
tapering NN O O
resulted NN O O
in NN O O
recurrence NN O O
or NN O O
worsening NN O O
symptoms NN O O
of NN O O
enterocolitis NN O O
in NN O O
some NN O O
patients NN O O
. NN O O
Withhold NN O O
YERVOY NN O O
dosing NN O O
for NN O O
moderate NN O O
enterocolitis NN O O
; NN O O
administer NN O O
anti NN O O
- NN O O
diarrheal NN O O
treatment NN O O
and NN O O
, NN O O
if NN O O
persistent NN O O
for NN O O
more NN O O
than NN O O
1 NN O O
week NN O O
, NN O O
initiate NN O O
systemic NN O O
corticosteroids NN O O
at NN O O
a NN O O
dose NN O O
of NN O O
0.5 NN O O
mg/kg/day NN O O
prednisone NN O O
or NN O O
equivalent NN O O
. NN O O
[ NN O O
See NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
. NN O O
] NN O O
5.2 NN O O
Immune NN O O
- NN O O
mediated NN O O
Hepatitis NN O O
In NN O O
Study NN O O
1 NN O O
, NN O O
severe NN B-Severity B-Severity
life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
or NN O O
fatal NN B-AdverseReaction B-AdverseReaction
hepatotoxicity NN B-AdverseReaction B-AdverseReaction
( NN O O
AST NN O O
or NN O O
ALT NN B-AdverseReaction B-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
of NN O O
more NN O O
than NN O O
5 NN B-Severity B-Severity
times NN I-Severity I-Severity
the NN I-Severity I-Severity
upper NN I-Severity I-Severity
limit NN I-Severity I-Severity
of NN I-Severity I-Severity
normal NN I-Severity I-Severity
or NN O O
total NN B-AdverseReaction B-AdverseReaction
bilirubin NN I-AdverseReaction I-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
more NN O O
than NN O O
3 NN B-Severity B-Severity
times NN I-Severity I-Severity
the NN I-Severity I-Severity
upper NN I-Severity I-Severity
limit NN I-Severity I-Severity
of NN I-Severity I-Severity
normal NN I-Severity I-Severity
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
- NN I-Severity I-Severity
5 NN I-Severity I-Severity
occurred NN O O
in NN O O
8 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
YERVOY NN O O
- NN O O
treated NN O O
patients NN O O
, NN O O
with NN O O
fatal NN B-AdverseReaction B-AdverseReaction
hepatic NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
in NN O O
0.2 NN O O
% NN O O
and NN O O
hospitalization NN O O
in NN O O
0.4 NN O O
% NN O O
of NN O O
YERVOY NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
An NN O O
additional NN O O
13 NN O O
( NN O O
2.5 NN O O
% NN O O
) NN O O
patients NN O O
experienced NN O O
moderate NN B-Severity B-Severity
hepatotoxicity NN B-AdverseReaction B-AdverseReaction
manifested NN O O
by NN O O
liver NN B-AdverseReaction B-AdverseReaction
function NN I-AdverseReaction I-AdverseReaction
test NN I-AdverseReaction I-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
( NN O O
AST NN O O
or NN O O
ALT NN B-AdverseReaction B-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
of NN O O
more NN O O
than NN O O
2.5 NN B-Severity B-Severity
times NN I-Severity I-Severity
but NN I-Severity I-Severity
not NN I-Severity I-Severity
more NN I-Severity I-Severity
than NN I-Severity I-Severity
5 NN I-Severity I-Severity
times NN I-Severity I-Severity
the NN I-Severity I-Severity
upper NN I-Severity I-Severity
limit NN I-Severity I-Severity
of NN I-Severity I-Severity
normal NN I-Severity I-Severity
or NN O O
total NN B-AdverseReaction B-AdverseReaction
bilirubin NN I-AdverseReaction I-AdverseReaction
elevation NN I-AdverseReaction I-AdverseReaction
of NN O O
more NN O O
than NN O O
1.5 NN B-Severity B-Severity
times NN I-Severity I-Severity
but NN I-Severity I-Severity
not NN I-Severity I-Severity
more NN I-Severity I-Severity
than NN I-Severity I-Severity
3 NN I-Severity I-Severity
times NN I-Severity I-Severity
the NN I-Severity I-Severity
upper NN I-Severity I-Severity
limit NN I-Severity I-Severity
of NN I-Severity I-Severity
normal NN I-Severity I-Severity
Grade NN B-Severity B-Severity
2 NN I-Severity I-Severity
The NN O O
underlying NN O O
pathology NN O O
was NN O O
not NN O O
ascertained NN O O
in NN O O
all NN O O
patients NN O O
but NN O O
in NN O O
some NN O O
instances NN O O
included NN O O
immune NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
mediated NN I-AdverseReaction I-AdverseReaction
hepatitis NN I-AdverseReaction I-AdverseReaction
There NN O O
were NN O O
insufficient NN O O
numbers NN O O
of NN O O
patients NN O O
with NN O O
biopsy NN O O
- NN O O
proven NN O O
hepatitis NN O O
to NN O O
characterize NN O O
the NN O O
clinical NN O O
course NN O O
of NN O O
this NN O O
event NN O O
. NN O O
Monitor NN O O
liver NN O O
function NN O O
tests NN O O
( NN O O
hepatic NN O O
transaminase NN O O
and NN O O
bilirubin NN O O
levels NN O O
) NN O O
and NN O O
assess NN O O
patients NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
hepatotoxicity NN O O
before NN O O
each NN O O
dose NN O O
of NN O O
YERVOY. NN O O
In NN O O
patients NN O O
with NN O O
hepatotoxicity NN O O
, NN O O
rule NN O O
out NN O O
infectious NN O O
or NN O O
malignant NN O O
causes NN O O
and NN O O
increase NN O O
frequency NN O O
of NN O O
liver NN O O
function NN O O
test NN O O
monitoring NN O O
until NN O O
resolution NN O O
. NN O O
Permanently NN O O
discontinue NN O O
YERVOY NN O O
in NN O O
patients NN O O
with NN O O
Grade NN O O
3 NN O O
- NN O O
5 NN O O
hepatotoxicity NN O O
and NN O O
administer NN O O
systemic NN O O
corticosteroids NN O O
at NN O O
a NN O O
dose NN O O
of NN O O
1 NN O O
to NN O O
2 NN O O
mg/kg/day NN O O
of NN O O
prednisone NN O O
or NN O O
equivalent NN O O
. NN O O
When NN O O
liver NN O O
function NN O O
tests NN O O
show NN O O
sustained NN O O
improvement NN O O
or NN O O
return NN O O
to NN O O
baseline NN O O
, NN O O
initiate NN O O
corticosteroid NN O O
tapering NN O O
and NN O O
continue NN O O
to NN O O
taper NN O O
over NN O O
1 NN O O
month NN O O
. NN O O
Across NN O O
the NN O O
clinical NN O O
development NN O O
program NN O O
for NN O O
YERVOY NN O O
, NN O O
mycophenolate NN O O
treatment NN O O
has NN O O
been NN O O
administered NN O O
in NN O O
patients NN O O
who NN O O
have NN O O
persistent NN O O
severe NN O O
hepatitis NN O O
despite NN O O
high NN O O
- NN O O
dose NN O O
corticosteroids NN O O
. NN O O
Withhold NN O O
YERVOY NN O O
in NN O O
patients NN O O
with NN O O
Grade NN O O
2 NN O O
hepatotoxicity NN O O
. NN O O
[ NN O O
See NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
. NN O O
] NN O O
Concurrent NN O O
Administration NN O O
with NN O O
Vemurafenib NN O O
In NN O O
a NN O O
dose NN O O
- NN O O
finding NN O O
trial NN O O
, NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
transaminases NN I-AdverseReaction I-AdverseReaction
with NN O O
or NN O O
without NN O O
concomitant NN O O
increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
total NN I-AdverseReaction I-AdverseReaction
bilirubin NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
6 NN O O
of NN O O
10 NN O O
patients NN O O
who NN O O
received NN O O
concurrent NN O O
YERVOY NN O O
( NN O O
3 NN O O
mg/kg NN O O
) NN O O
and NN O O
vemurafenib NN O O
( NN O O
960 NN O O
mg NN O O
BID NN O O
or NN O O
720 NN O O
mg NN O O
BID NN O O
) NN O O
. NN O O
5.3 NN O O
Immune NN O O
- NN O O
mediated NN O O
Dermatitis NN O O
In NN O O
Study NN O O
1 NN O O
, NN O O
severe NN B-Severity B-Severity
life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
or NN O O
fatal NN B-AdverseReaction B-AdverseReaction
immune NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
mediated NN I-AdverseReaction I-AdverseReaction
dermatitis NN I-AdverseReaction I-AdverseReaction
( NN O O
eg NN O O
, NN O O
Stevens NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Johnson NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
toxic NN B-AdverseReaction B-AdverseReaction
epidermal NN I-AdverseReaction I-AdverseReaction
necrolysis NN I-AdverseReaction I-AdverseReaction
or NN O O
rash NN B-AdverseReaction B-AdverseReaction
complicated NN O O
by NN O O
full NN O O
thickness NN O O
dermal NN B-AdverseReaction B-AdverseReaction
ulceration NN I-AdverseReaction I-AdverseReaction
or NN O O
necrotic NN O O
, NN O O
bullous NN O O
, NN O O
or NN O O
hemorrhagic NN O O
manifestations NN O O
; NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
- NN I-Severity I-Severity
5 NN I-Severity I-Severity
occurred NN O O
in NN O O
13 NN O O
( NN O O
2.5 NN O O
% NN O O
) NN O O
YERVOY NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
One NN O O
( NN O O
0.2 NN O O
% NN O O
) NN O O
patient NN O O
died NN B-AdverseReaction B-AdverseReaction
as NN O O
a NN O O
result NN O O
of NN O O
toxic NN B-AdverseReaction B-AdverseReaction
epidermal NN I-AdverseReaction I-AdverseReaction
necrolysis NN I-AdverseReaction I-AdverseReaction
and NN O O
one NN O O
additional NN O O
patient NN O O
required NN O O
hospitalization NN O O
for NN O O
severe NN B-Severity B-Severity
dermatitis NN B-AdverseReaction B-AdverseReaction
There NN O O
were NN O O
63 NN O O
( NN O O
12 NN O O
% NN O O
) NN O O
patients NN O O
with NN O O
moderate NN B-Severity B-Severity
( NN O O
Grade NN O O
2 NN O O
) NN O O
dermatitis NN B-AdverseReaction B-AdverseReaction
The NN O O
median NN O O
time NN O O
to NN O O
onset NN O O
of NN O O
moderate NN B-Severity B-Severity
severe NN B-Severity B-Severity
or NN O O
life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
immune NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
mediated NN I-AdverseReaction I-AdverseReaction
dermatitis NN I-AdverseReaction I-AdverseReaction
was NN O O
3.1 NN O O
weeks NN O O
and NN O O
ranged NN O O
up NN O O
to NN O O
17.3 NN O O
weeks NN O O
from NN O O
the NN O O
initiation NN O O
of NN O O
YERVOY. NN O O
Seven NN O O
( NN O O
54 NN O O
% NN O O
) NN O O
YERVOY NN O O
- NN O O
treated NN O O
patients NN O O
with NN O O
severe NN B-Severity B-Severity
dermatitis NN B-AdverseReaction B-AdverseReaction
received NN O O
high NN O O
- NN O O
dose NN O O
corticosteroids NN O O
( NN O O
median NN O O
dose NN O O
60 NN O O
mg NN O O
prednisone/day NN O O
or NN O O
equivalent NN O O
) NN O O
for NN O O
up NN O O
to NN O O
14.9 NN O O
weeks NN O O
followed NN O O
by NN O O
corticosteroid NN O O
taper NN O O
. NN O O
Of NN O O
these NN O O
7 NN O O
patients NN O O
, NN O O
6 NN O O
had NN O O
complete NN O O
resolution NN O O
; NN O O
time NN O O
to NN O O
resolution NN O O
ranged NN O O
up NN O O
to NN O O
15.6 NN O O
weeks NN O O
. NN O O
Of NN O O
the NN O O
63 NN O O
patients NN O O
with NN O O
moderate NN B-Severity B-Severity
dermatitis NN B-AdverseReaction B-AdverseReaction
25 NN O O
( NN O O
40 NN O O
% NN O O
) NN O O
were NN O O
treated NN O O
with NN O O
systemic NN O O
corticosteroids NN O O
( NN O O
median NN O O
of NN O O
60 NN O O
mg/day NN O O
of NN O O
prednisone NN O O
or NN O O
equivalent NN O O
) NN O O
for NN O O
a NN O O
median NN O O
of NN O O
2.1 NN O O
weeks NN O O
, NN O O
7 NN O O
( NN O O
11 NN O O
% NN O O
) NN O O
were NN O O
treated NN O O
with NN O O
only NN O O
topical NN O O
corticosteroids NN O O
, NN O O
and NN O O
31 NN O O
( NN O O
49 NN O O
% NN O O
) NN O O
did NN O O
not NN O O
receive NN O O
systemic NN O O
or NN O O
topical NN O O
corticosteroids NN O O
. NN O O
Forty NN O O
- NN O O
four NN O O
( NN O O
70 NN O O
% NN O O
) NN O O
patients NN O O
with NN O O
moderate NN B-Severity B-Severity
dermatitis NN B-AdverseReaction B-AdverseReaction
were NN O O
reported NN O O
to NN O O
have NN O O
complete NN O O
resolution NN O O
, NN O O
7 NN O O
( NN O O
11 NN O O
% NN O O
) NN O O
improved NN O O
to NN O O
mild NN O O
( NN O O
Grade NN O O
1 NN O O
) NN O O
severity NN O O
, NN O O
and NN O O
12 NN O O
( NN O O
19 NN O O
% NN O O
) NN O O
had NN O O
no NN O O
reported NN O O
improvement NN O O
. NN O O
Monitor NN O O
patients NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
dermatitis NN O O
such NN O O
as NN O O
rash NN O O
and NN O O
pruritus NN O O
. NN O O
Unless NN O O
an NN O O
alternate NN O O
etiology NN O O
has NN O O
been NN O O
identified NN O O
, NN O O
signs NN O O
or NN O O
symptoms NN O O
of NN O O
dermatitis NN O O
should NN O O
be NN O O
considered NN O O
immune NN O O
- NN O O
mediated NN O O
. NN O O
Permanently NN O O
discontinue NN O O
YERVOY NN O O
in NN O O
patients NN O O
with NN O O
Stevens NN O O
- NN O O
Johnson NN O O
syndrome NN O O
, NN O O
toxic NN O O
epidermal NN O O
necrolysis NN O O
, NN O O
or NN O O
rash NN O O
complicated NN O O
by NN O O
full NN O O
thickness NN O O
dermal NN O O
ulceration NN O O
, NN O O
or NN O O
necrotic NN O O
, NN O O
bullous NN O O
, NN O O
or NN O O
hemorrhagic NN O O
manifestations NN O O
. NN O O
Administer NN O O
systemic NN O O
corticosteroids NN O O
at NN O O
a NN O O
dose NN O O
of NN O O
1 NN O O
to NN O O
2 NN O O
mg/kg/day NN O O
of NN O O
prednisone NN O O
or NN O O
equivalent NN O O
. NN O O
When NN O O
dermatitis NN O O
is NN O O
controlled NN O O
, NN O O
corticosteroid NN O O
tapering NN O O
should NN O O
occur NN O O
over NN O O
a NN O O
period NN O O
of NN O O
at NN O O
least NN O O
1 NN O O
month NN O O
. NN O O
Withhold NN O O
YERVOY NN O O
dosing NN O O
in NN O O
patients NN O O
with NN O O
moderate NN O O
to NN O O
severe NN O O
signs NN O O
and NN O O
symptoms NN O O
. NN O O
[ NN O O
See NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
. NN O O
] NN O O
For NN O O
mild NN O O
to NN O O
moderate NN O O
dermatitis NN O O
, NN O O
such NN O O
as NN O O
localized NN O O
rash NN O O
and NN O O
pruritus NN O O
, NN O O
treat NN O O
symptomatically NN O O
. NN O O
Administer NN O O
topical NN O O
or NN O O
systemic NN O O
corticosteroids NN O O
if NN O O
there NN O O
is NN O O
no NN O O
improvement NN O O
of NN O O
symptoms NN O O
within NN O O
1 NN O O
week NN O O
. NN O O
5.4 NN O O
Immune NN O O
- NN O O
mediated NN O O
Neuropathies NN O O
In NN O O
Study NN O O
1 NN O O
, NN O O
1 NN O O
case NN O O
of NN O O
fatal NN B-AdverseReaction B-AdverseReaction
Guillain NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Barre NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
and NN O O
1 NN O O
case NN O O
of NN O O
severe NN B-Severity B-Severity
( NN O O
Grade NN O O
3 NN O O
) NN O O
peripheral NN B-AdverseReaction B-AdverseReaction
motor NN I-AdverseReaction I-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
. NN O O
Across NN O O
the NN O O
clinical NN O O
development NN O O
program NN O O
of NN O O
YERVOY NN O O
, NN O O
myasthenia NN B-AdverseReaction B-AdverseReaction
gravis NN I-AdverseReaction I-AdverseReaction
and NN O O
additional NN O O
cases NN O O
of NN O O
Guillain NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Barre NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
. NN O O
Monitor NN O O
for NN O O
symptoms NN O O
of NN O O
motor NN O O
or NN O O
sensory NN O O
neuropathy NN O O
such NN O O
as NN O O
unilateral NN O O
or NN O O
bilateral NN O O
weakness NN O O
, NN O O
sensory NN O O
alterations NN O O
, NN O O
or NN O O
paresthesia NN O O
. NN O O
Permanently NN O O
discontinue NN O O
YERVOY NN O O
in NN O O
patients NN O O
with NN O O
severe NN O O
neuropathy NN O O
( NN O O
interfering NN O O
with NN O O
daily NN O O
activities NN O O
) NN O O
such NN O O
as NN O O
Guillain NN O O
- NN O O
Barre NN O O
- NN O O
like NN O O
syndromes NN O O
. NN O O
Institute NN O O
medical NN O O
intervention NN O O
as NN O O
appropriate NN O O
for NN O O
management NN O O
of NN O O
severe NN O O
neuropathy NN O O
. NN O O
Consider NN O O
initiation NN O O
of NN O O
systemic NN O O
corticosteroids NN O O
at NN O O
a NN O O
dose NN O O
of NN O O
1 NN O O
to NN O O
2 NN O O
mg/kg/day NN O O
prednisone NN O O
or NN O O
equivalent NN O O
for NN O O
severe NN O O
neuropathies NN O O
. NN O O
Withhold NN O O
YERVOY NN O O
dosing NN O O
in NN O O
patients NN O O
with NN O O
moderate NN O O
neuropathy NN O O
( NN O O
not NN O O
interfering NN O O
with NN O O
daily NN O O
activities NN O O
) NN O O
. NN O O
[ NN O O
See NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
. NN O O
] NN O O
5.5 NN O O
Immune NN O O
- NN O O
mediated NN O O
Endocrinopathies NN O O
In NN O O
Study NN O O
1 NN O O
, NN O O
severe NN B-Severity B-Severity
to NN O O
life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
immune NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
mediated NN I-AdverseReaction I-AdverseReaction
endocrinopathies NN I-AdverseReaction I-AdverseReaction
( NN O O
requiring NN O O
hospitalization NN O O
, NN O O
urgent NN O O
medical NN O O
intervention NN O O
, NN O O
or NN O O
interfering NN O O
with NN O O
activities NN O O
of NN O O
daily NN O O
living NN O O
; NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
- NN I-Severity I-Severity
4 NN I-Severity I-Severity
occurred NN O O
in NN O O
9 NN O O
( NN O O
1.8 NN O O
% NN O O
) NN O O
YERVOY NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
All NN O O
9 NN O O
patients NN O O
had NN O O
hypopituitarism NN B-AdverseReaction B-AdverseReaction
and NN O O
some NN O O
had NN O O
additional NN O O
concomitant NN O O
endocrinopathies NN B-AdverseReaction B-AdverseReaction
such NN O O
as NN O O
adrenal NN B-AdverseReaction B-AdverseReaction
insufficiency NN I-AdverseReaction I-AdverseReaction
hypogonadism NN B-AdverseReaction B-AdverseReaction
and NN O O
hypothyroidism NN B-AdverseReaction B-AdverseReaction
Six NN O O
of NN O O
the NN O O
9 NN O O
patients NN O O
were NN O O
hospitalized NN O O
for NN O O
severe NN B-Severity B-Severity
endocrinopathies NN B-AdverseReaction B-AdverseReaction
Moderate NN B-Severity B-Severity
endocrinopathy NN B-AdverseReaction B-AdverseReaction
( NN O O
requiring NN O O
hormone NN O O
replacement NN O O
or NN O O
medical NN O O
intervention NN O O
; NN O O
Grade NN B-Severity B-Severity
2 NN I-Severity I-Severity
occurred NN O O
in NN O O
12 NN O O
( NN O O
2.3 NN O O
% NN O O
) NN O O
patients NN O O
and NN O O
consisted NN O O
of NN O O
hypothyroidism NN B-AdverseReaction B-AdverseReaction
adrenal NN B-AdverseReaction B-AdverseReaction
insufficiency NN I-AdverseReaction I-AdverseReaction
hypopituitarism NN B-AdverseReaction B-AdverseReaction
and NN O O
1 NN O O
case NN O O
each NN O O
of NN O O
hyperthyroidism NN B-AdverseReaction B-AdverseReaction
and NN O O
Cushing NN B-AdverseReaction B-AdverseReaction
's NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
The NN O O
median NN O O
time NN O O
to NN O O
onset NN O O
of NN O O
moderate NN B-Severity B-Severity
to NN O O
severe NN B-Severity B-Severity
immune NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
mediated NN I-AdverseReaction I-AdverseReaction
endocrinopathy NN I-AdverseReaction I-AdverseReaction
was NN O O
11 NN O O
weeks NN O O
and NN O O
ranged NN O O
up NN O O
to NN O O
19.3 NN O O
weeks NN O O
after NN O O
the NN O O
initiation NN O O
of NN O O
YERVOY. NN O O
Of NN O O
the NN O O
21 NN O O
patients NN O O
with NN O O
moderate NN B-Severity B-Severity
to NN O O
life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
endocrinopathy NN B-AdverseReaction B-AdverseReaction
17 NN O O
patients NN O O
required NN O O
long NN O O
- NN O O
term NN O O
hormone NN O O
replacement NN O O
therapy NN O O
including NN O O
, NN O O
most NN O O
commonly NN O O
, NN O O
adrenal NN O O
hormones NN O O
( NN O O
n=10 NN O O
) NN O O
and NN O O
thyroid NN O O
hormones NN O O
( NN O O
n=13 NN O O
) NN O O
. NN O O
Monitor NN O O
patients NN O O
for NN O O
clinical NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
hypophysitis NN O O
, NN O O
adrenal NN O O
insufficiency NN O O
( NN O O
including NN O O
adrenal NN O O
crisis NN O O
) NN O O
, NN O O
and NN O O
hyper- NN O O
or NN O O
hypothyroidism NN O O
. NN O O
Patients NN O O
may NN O O
present NN O O
with NN O O
fatigue NN O O
, NN O O
headache NN O O
, NN O O
mental NN O O
status NN O O
changes NN O O
, NN O O
abdominal NN O O
pain NN O O
, NN O O
unusual NN O O
bowel NN O O
habits NN O O
, NN O O
and NN O O
hypotension NN O O
, NN O O
or NN O O
nonspecific NN O O
symptoms NN O O
which NN O O
may NN O O
resemble NN O O
other NN O O
causes NN O O
such NN O O
as NN O O
brain NN O O
metastasis NN O O
or NN O O
underlying NN O O
disease NN O O
. NN O O
Unless NN O O
an NN O O
alternate NN O O
etiology NN O O
has NN O O
been NN O O
identified NN O O
, NN O O
signs NN O O
or NN O O
symptoms NN O O
of NN O O
endocrinopathies NN O O
should NN O O
be NN O O
considered NN O O
immune NN O O
- NN O O
mediated NN O O
. NN O O
Monitor NN O O
thyroid NN O O
function NN O O
tests NN O O
and NN O O
clinical NN O O
chemistries NN O O
at NN O O
the NN O O
start NN O O
of NN O O
treatment NN O O
, NN O O
before NN O O
each NN O O
dose NN O O
, NN O O
and NN O O
as NN O O
clinically NN O O
indicated NN O O
based NN O O
on NN O O
symptoms NN O O
. NN O O
In NN O O
a NN O O
limited NN O O
number NN O O
of NN O O
patients NN O O
, NN O O
hypophysitis NN B-AdverseReaction B-AdverseReaction
was NN O O
diagnosed NN O O
by NN O O
imaging NN O O
studies NN O O
through NN O O
enlargement NN O O
of NN O O
the NN O O
pituitary NN O O
gland NN O O
. NN O O
Withhold NN O O
YERVOY NN O O
dosing NN O O
in NN O O
symptomatic NN O O
patients NN O O
. NN O O
Initiate NN O O
systemic NN O O
corticosteroids NN O O
at NN O O
a NN O O
dose NN O O
of NN O O
1 NN O O
to NN O O
2 NN O O
mg/kg/day NN O O
of NN O O
prednisone NN O O
or NN O O
equivalent NN O O
, NN O O
and NN O O
initiate NN O O
appropriate NN O O
hormone NN O O
replacement NN O O
therapy NN O O
. NN O O
[ NN O O
See NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
. NN O O
] NN O O
5.6 NN O O
Other NN O O
Immune NN O O
- NN O O
mediated NN O O
Adverse NN O O
Reactions NN O O
, NN O O
Including NN O O
Ocular NN O O
Manifestations NN O O
The NN O O
following NN O O
clinically NN O O
significant NN O O
immune NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
mediated NN I-AdverseReaction I-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
were NN O O
seen NN O O
in NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
of NN O O
YERVOY NN O O
- NN O O
treated NN O O
patients NN O O
in NN O O
Study NN O O
1 NN O O
: NN O O
nephritis NN B-AdverseReaction B-AdverseReaction
pneumonitis NN B-AdverseReaction B-AdverseReaction
meningitis NN B-AdverseReaction B-AdverseReaction
pericarditis NN B-AdverseReaction B-AdverseReaction
uveitis NN B-AdverseReaction B-AdverseReaction
iritis NN B-AdverseReaction B-AdverseReaction
and NN O O
hemolytic NN B-AdverseReaction B-AdverseReaction
anemia NN I-AdverseReaction I-AdverseReaction
Across NN O O
the NN O O
clinical NN O O
development NN O O
program NN O O
for NN O O
YERVOY NN O O
, NN O O
the NN O O
following NN O O
likely NN O O
immune NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
mediated NN I-AdverseReaction I-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
were NN O O
also NN O O
reported NN O O
with NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
incidence NN O O
: NN O O
myocarditis NN B-AdverseReaction B-AdverseReaction
angiopathy NN B-AdverseReaction B-AdverseReaction
temporal NN B-AdverseReaction B-AdverseReaction
arteritis NN I-AdverseReaction I-AdverseReaction
vasculitis NN B-AdverseReaction B-AdverseReaction
polymyalgia NN B-AdverseReaction B-AdverseReaction
rheumatica NN I-AdverseReaction I-AdverseReaction
conjunctivitis NN B-AdverseReaction B-AdverseReaction
blepharitis NN B-AdverseReaction B-AdverseReaction
episcleritis NN B-AdverseReaction B-AdverseReaction
scleritis NN B-AdverseReaction B-AdverseReaction
leukocytoclastic NN B-AdverseReaction B-AdverseReaction
vasculitis NN I-AdverseReaction I-AdverseReaction
erythema NN B-AdverseReaction B-AdverseReaction
multiforme NN I-AdverseReaction I-AdverseReaction
psoriasis NN B-AdverseReaction B-AdverseReaction
pancreatitis NN B-AdverseReaction B-AdverseReaction
arthritis NN B-AdverseReaction B-AdverseReaction
autoimmune NN B-AdverseReaction B-AdverseReaction
thyroiditis NN I-AdverseReaction I-AdverseReaction
sarcoidosis NN B-AdverseReaction B-AdverseReaction
neurosensory NN B-AdverseReaction B-AdverseReaction
hypoacusis NN I-AdverseReaction I-AdverseReaction
autoimmune NN B-AdverseReaction B-AdverseReaction
central NN I-AdverseReaction I-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
( NN O O
encephalitis NN O O
) NN O O
, NN O O
myositis NN B-AdverseReaction B-AdverseReaction
polymyositis NN B-AdverseReaction B-AdverseReaction
and NN O O
ocular NN B-AdverseReaction B-AdverseReaction
myositis NN I-AdverseReaction I-AdverseReaction
Permanently NN O O
discontinue NN O O
YERVOY NN O O
for NN O O
clinically NN O O
significant NN O O
or NN O O
severe NN O O
immune NN O O
- NN O O
mediated NN O O
adverse NN O O
reactions NN O O
. NN O O
Initiate NN O O
systemic NN O O
corticosteroids NN O O
at NN O O
a NN O O
dose NN O O
of NN O O
1 NN O O
to NN O O
2 NN O O
mg/kg/day NN O O
prednisone NN O O
or NN O O
equivalent NN O O
for NN O O
severe NN O O
immune NN O O
- NN O O
mediated NN O O
adverse NN O O
reactions NN O O
. NN O O
Administer NN O O
corticosteroid NN O O
eye NN O O
drops NN O O
to NN O O
patients NN O O
who NN O O
develop NN O O
uveitis NN O O
, NN O O
iritis NN O O
, NN O O
or NN O O
episcleritis NN O O
. NN O O
Permanently NN O O
discontinue NN O O
YERVOY NN O O
for NN O O
immune NN O O
- NN O O
mediated NN O O
ocular NN O O
disease NN O O
that NN O O
is NN O O
unresponsive NN O O
to NN O O
local NN O O
immunosuppressive NN O O
therapy NN O O
. NN O O
[ NN O O
See NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
. NN O O
] NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
Because NN O O
clinical NN O O
studies NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
studies NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
studies NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
are NN O O
described NN O O
in NN O O
more NN O O
detail NN O O
in NN O O
the NN O O
Warnings NN O O
and NN O O
Precautions NN O O
section NN O O
of NN O O
the NN O O
label NN O O
: NN O O
Seizures NN B-AdverseReaction B-AdverseReaction
Anaphylaxis NN B-AdverseReaction B-AdverseReaction
and NN O O
Urinary NN B-AdverseReaction B-AdverseReaction
Tract NN I-AdverseReaction I-AdverseReaction
Infections NN I-AdverseReaction I-AdverseReaction
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
events NN O O
( NN O O
incidence NN O O
>=2 NN O O
% NN O O
and NN O O
at NN O O
a NN O O
rate NN O O
greater NN O O
than NN O O
the NN O O
placebo NN O O
rate NN O O
) NN O O
for NN O O
AMPYRA NN O O
were NN O O
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
insomnia NN B-AdverseReaction B-AdverseReaction
dizziness NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
asthenia NN B-AdverseReaction B-AdverseReaction
back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
balance NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
multiple NN B-AdverseReaction B-AdverseReaction
sclerosis NN I-AdverseReaction I-AdverseReaction
relapse NN I-AdverseReaction I-AdverseReaction
paresthesia NN B-AdverseReaction B-AdverseReaction
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
constipation NN B-AdverseReaction B-AdverseReaction
dyspepsia NN B-AdverseReaction B-AdverseReaction
and NN O O
pharyngolaryngeal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
. NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Acorda NN O O
Therapeutics NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
367 NN O O
- NN O O
5109 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Controlled NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
In NN O O
three NN O O
placebo NN O O
- NN O O
controlled NN O O
clinical NN O O
trials NN O O
of NN O O
up NN O O
to NN O O
14 NN O O
weeks NN O O
duration NN O O
, NN O O
4 NN O O
% NN O O
( NN O O
15/400 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
AMPYRA NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
experienced NN O O
one NN O O
or NN O O
more NN O O
treatment NN O O
emergent NN O O
adverse NN O O
events NN O O
leading NN O O
to NN O O
discontinuation NN O O
, NN O O
compared NN O O
to NN O O
2 NN O O
% NN O O
( NN O O
5/238 NN O O
) NN O O
of NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
The NN O O
treatment NN O O
emergent NN O O
adverse NN O O
events NN O O
leading NN O O
to NN O O
discontinuation NN O O
of NN O O
at NN O O
least NN O O
2 NN O O
patients NN O O
treated NN O O
with NN O O
AMPYRA NN O O
and NN O O
that NN O O
led NN O O
to NN O O
discontinuation NN O O
more NN O O
frequently NN O O
compared NN O O
to NN O O
placebo NN O O
were NN O O
headache NN B-AdverseReaction B-AdverseReaction
( NN O O
AMPYRA NN O O
0.5 NN O O
% NN O O
, NN O O
placebo NN O O
0 NN O O
% NN O O
) NN O O
, NN O O
balance NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
( NN O O
AMPYRA NN O O
0.5 NN O O
% NN O O
, NN O O
placebo NN O O
0 NN O O
% NN O O
) NN O O
, NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
( NN O O
AMPYRA NN O O
0.5 NN O O
% NN O O
, NN O O
placebo NN O O
0 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
confusional NN B-AdverseReaction B-AdverseReaction
state NN I-AdverseReaction I-AdverseReaction
( NN O O
AMPYRA NN O O
0.3 NN O O
% NN O O
, NN O O
placebo NN O O
0 NN O O
% NN O O
) NN O O
. NN O O
Table NN O O
1 NN O O
lists NN O O
adverse NN O O
reactions NN O O
that NN O O
occurred NN O O
in NN O O
>=2 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
AMPYRA NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
, NN O O
and NN O O
more NN O O
frequently NN O O
than NN O O
in NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
, NN O O
in NN O O
controlled NN O O
clinical NN O O
trials NN O O
. NN O O
Table NN O O
1 NN O O
: NN O O
Adverse NN O O
reactions NN O O
with NN O O
an NN O O
incidence NN O O
>=2 NN O O
% NN O O
of NN O O
AMPYRA NN O O
treated NN O O
MS NN O O
patients NN O O
, NN O O
and NN O O
more NN O O
frequent NN O O
with NN O O
AMPYRA NN O O
compared NN O O
to NN O O
placebo NN O O
in NN O O
controlled NN O O
clinical NN O O
trials NN O O
Adverse NN O O
Reaction NN O O
Placebo(N=238 NN O O
) NN O O
AMPYRA10 NN O O
mg NN O O
twice NN O O
daily(N=400 NN O O
) NN O O
Urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
8 NN O O
% NN O O
12 NN O O
% NN O O
Insomnia NN B-AdverseReaction B-AdverseReaction
4 NN O O
% NN O O
9 NN O O
% NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
4 NN O O
% NN O O
7 NN O O
% NN O O
Headache NN B-AdverseReaction B-AdverseReaction
4 NN O O
% NN O O
7 NN O O
% NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
3 NN O O
% NN O O
7 NN O O
% NN O O
Asthenia NN B-AdverseReaction B-AdverseReaction
4 NN O O
% NN O O
7 NN O O
% NN O O
Back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
2 NN O O
% NN O O
5 NN O O
% NN O O
Balance NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
1 NN O O
% NN O O
5 NN O O
% NN O O
Multiple NN B-AdverseReaction B-AdverseReaction
sclerosis NN I-AdverseReaction I-AdverseReaction
relapse NN I-AdverseReaction I-AdverseReaction
3 NN O O
% NN O O
4 NN O O
% NN O O
Paresthesia NN B-AdverseReaction B-AdverseReaction
3 NN O O
% NN O O
4 NN O O
% NN O O
Nasopharyngitis NN B-AdverseReaction B-AdverseReaction
2 NN O O
% NN O O
4 NN O O
% NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
2 NN O O
% NN O O
3 NN O O
% NN O O
Dyspepsia NN B-AdverseReaction B-AdverseReaction
1 NN O O
% NN O O
2 NN O O
% NN O O
Pharyngolaryngeal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
1 NN O O
% NN O O
2 NN O O
% NN O O
6.2 NN O O
Other NN O O
Adverse NN O O
Reactions NN O O
AMPYRA NN O O
has NN O O
been NN O O
evaluated NN O O
in NN O O
a NN O O
total NN O O
of NN O O
1,952 NN O O
subjects NN O O
, NN O O
including NN O O
917 NN O O
MS NN O O
patients NN O O
. NN O O
A NN O O
total NN O O
of NN O O
741 NN O O
patients NN O O
have NN O O
been NN O O
treated NN O O
with NN O O
AMPYRA NN O O
for NN O O
over NN O O
six NN O O
months NN O O
, NN O O
501 NN O O
for NN O O
over NN O O
one NN O O
year NN O O
and NN O O
352 NN O O
for NN O O
over NN O O
two NN O O
years NN O O
. NN O O
The NN O O
experience NN O O
in NN O O
open NN O O
- NN O O
label NN O O
clinical NN O O
trials NN O O
is NN O O
consistent NN O O
with NN O O
the NN O O
safety NN O O
profile NN O O
observed NN O O
in NN O O
the NN O O
placebo NN O O
- NN O O
controlled NN O O
clinical NN O O
trials NN O O
. NN O O
As NN O O
in NN O O
controlled NN O O
clinical NN O O
trials NN O O
, NN O O
a NN O O
dose NN O O
- NN O O
dependent NN O O
increase NN O O
in NN O O
the NN O O
incidence NN O O
of NN O O
seizures NN B-AdverseReaction B-AdverseReaction
has NN O O
been NN O O
observed NN O O
in NN O O
open NN O O
- NN O O
label NN O O
clinical NN O O
trials NN O O
with NN O O
AMPYRA NN O O
in NN O O
patients NN O O
with NN O O
MS NN O O
as NN O O
follows NN O O
: NN O O
AMPYRA NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
0.41 NN O O
per NN O O
100 NN O O
person NN O O
- NN O O
years NN O O
( NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
0.13 NN O O
- NN O O
0.96 NN O O
) NN O O
; NN O O
dalfampridine NN O O
15 NN O O
mg NN O O
twice NN O O
daily NN O O
1.7 NN O O
per NN O O
100 NN O O
person NN O O
- NN O O
years NN O O
( NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
0.21 NN O O
- NN O O
6.28 NN O O
) NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
AMPYRA NN O O
can NN B-Factor B-Factor
cause NN O O
seizures NN B-AdverseReaction B-AdverseReaction
the NN O O
risk NN B-Factor B-Factor
of NN O O
seizures NN B-AdverseReaction B-AdverseReaction
increases NN O O
with NN O O
increasing NN O O
AMPYRA NN O O
doses NN O O
; NN O O
discontinue NN O O
AMPYRA NN O O
and NN O O
do NN O O
not NN O O
restart NN O O
if NN O O
a NN O O
seizure NN O O
occurs NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
AMPYRA NN O O
should NN O O
not NN O O
be NN O O
taken NN O O
with NN O O
other NN O O
forms NN O O
of NN O O
4-aminopyridine NN O O
( NN O O
4-AP NN O O
, NN O O
fampridine NN O O
) NN O O
, NN O O
since NN O O
the NN O O
active NN O O
ingredient NN O O
is NN O O
the NN O O
same NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
AMPYRA NN O O
can NN B-Factor B-Factor
cause NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
Discontinue NN O O
and NN O O
do NN O O
not NN O O
restart NN O O
AMPYRA NN O O
if NN O O
this NN O O
occurs NN O O
( NN O O
5.4 NN O O
) NN O O
5.1 NN O O
Seizures NN O O
AMPYRA NN O O
can NN B-Factor B-Factor
cause NN O O
seizures NN B-AdverseReaction B-AdverseReaction
Increased NN O O
incidence NN O O
of NN O O
seizures NN B-AdverseReaction B-AdverseReaction
has NN O O
been NN O O
observed NN O O
at NN O O
20 NN O O
mg NN O O
twice NN O O
daily NN O O
in NN O O
controlled NN O O
clinical NN O O
studies NN O O
of NN O O
9 NN O O
- NN O O
14 NN O O
weeks NN O O
duration NN O O
with NN O O
dalfampridine NN O O
in NN O O
patients NN O O
with NN O O
MS. NN O O
In NN O O
open NN O O
label NN O O
extension NN O O
trials NN O O
in NN O O
MS NN O O
patients NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
seizures NN B-AdverseReaction B-AdverseReaction
during NN O O
treatment NN O O
with NN O O
dalfampridine NN O O
15 NN O O
mg NN O O
twice NN O O
daily NN O O
( NN O O
1.7/100PY NN O O
) NN O O
was NN O O
over NN O O
4 NN O O
times NN O O
higher NN O O
than NN O O
the NN O O
incidence NN O O
during NN O O
treatment NN O O
with NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
( NN O O
0.4/100PY NN O O
) NN O O
. NN O O
In NN O O
the NN O O
post NN O O
- NN O O
marketing NN O O
period NN O O
seizures NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
. NN O O
The NN O O
majority NN O O
of NN O O
seizures NN B-AdverseReaction B-AdverseReaction
occurred NN O O
at NN O O
the NN O O
recommended NN O O
dose NN O O
and NN O O
in NN O O
patients NN O O
without NN O O
a NN O O
history NN O O
of NN O O
seizures NN O O
, NN O O
and NN O O
generally NN O O
within NN O O
days NN O O
to NN O O
weeks NN O O
of NN O O
starting NN O O
therapy NN O O
. NN O O
AMPYRA NN O O
has NN O O
not NN O O
been NN O O
evaluated NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
seizures NN O O
or NN O O
with NN O O
evidence NN O O
of NN O O
epileptiform NN O O
activity NN O O
on NN O O
an NN O O
EEG NN O O
, NN O O
as NN O O
these NN O O
patients NN O O
were NN O O
excluded NN O O
from NN O O
clinical NN O O
trials NN O O
. NN O O
The NN O O
risk NN O O
of NN O O
seizures NN O O
in NN O O
patients NN O O
with NN O O
epileptiform NN O O
activity NN O O
on NN O O
an NN O O
EEG NN O O
is NN O O
unknown NN O O
, NN O O
and NN O O
could NN O O
be NN O O
substantially NN O O
higher NN O O
than NN O O
that NN O O
observed NN O O
in NN O O
AMPYRA NN O O
clinical NN O O
studies NN O O
. NN O O
AMPYRA NN O O
should NN O O
be NN O O
discontinued NN O O
and NN O O
not NN O O
restarted NN O O
in NN O O
patients NN O O
who NN O O
experience NN O O
a NN O O
seizure NN O O
while NN O O
on NN O O
treatment NN O O
. NN O O
AMPYRA NN O O
is NN O O
contraindicated NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
seizures NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
Renal NN O O
Impairment NN O O
AMPYRA NN O O
is NN O O
eliminated NN O O
through NN O O
the NN O O
kidneys NN O O
primarily NN O O
as NN O O
unchanged NN O O
drug NN O O
[ NN O O
see NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.4 NN O O
) NN O O
] NN O O
. NN O O
Because NN O O
patients NN O O
with NN O O
moderate NN O O
to NN O O
severe NN O O
renal NN O O
impairment NN O O
( NN O O
CrCl NN O O
< NN O O
=50mL/min NN O O
) NN O O
would NN O O
require NN O O
a NN O O
dose NN O O
lower NN O O
than NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
and NN O O
no NN O O
strength NN O O
smaller NN O O
than NN O O
10 NN O O
mg NN O O
is NN O O
available NN O O
, NN O O
AMPYRA NN O O
is NN O O
contraindicated NN O O
in NN O O
these NN O O
patients NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
] NN O O
. NN O O
In NN O O
patients NN O O
with NN O O
mild NN O O
renal NN O O
impairment NN O O
( NN O O
CrCl NN O O
51 NN O O
- NN O O
80 NN O O
mL/min NN O O
) NN O O
, NN O O
AMPYRA NN O O
plasma NN O O
levels NN O O
may NN O O
approach NN O O
those NN O O
seen NN O O
at NN O O
a NN O O
dose NN O O
of NN O O
15 NN O O
mg NN O O
twice NN O O
daily NN O O
, NN O O
a NN O O
dose NN O O
that NN O O
may NN B-Factor B-Factor
be NN O O
associated NN O O
with NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
seizures NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
5.3 NN O O
Concurrent NN O O
Treatment NN O O
with NN O O
Other NN O O
Forms NN O O
of NN O O
4-Aminopyridine NN O O
AMPYRA NN O O
should NN O O
not NN O O
be NN O O
taken NN O O
with NN O O
other NN O O
forms NN O O
of NN O O
4-aminopyridine NN O O
( NN O O
4-AP NN O O
, NN O O
fampridine NN O O
) NN O O
since NN O O
the NN O O
active NN O O
ingredient NN O O
is NN O O
the NN O O
same NN O O
. NN O O
Patients NN O O
should NN O O
discontinue NN O O
use NN O O
of NN O O
any NN O O
product NN O O
containing NN O O
4-aminopyridine NN O O
prior NN O O
to NN O O
initiating NN O O
treatment NN O O
with NN O O
AMPYRA NN O O
in NN O O
order NN O O
to NN O O
reduce NN O O
the NN O O
potential NN O O
for NN O O
dose NN O O
- NN O O
related NN O O
adverse NN O O
reactions NN O O
. NN O O
5.4 NN O O
Anaphylaxis NN O O
AMPYRA NN O O
can NN B-Factor B-Factor
cause NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
and NN O O
severe NN B-Severity B-Severity
allergic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
Signs NN O O
and NN O O
symptoms NN O O
have NN O O
included NN O O
respiratory NN B-AdverseReaction B-AdverseReaction
compromise NN I-AdverseReaction I-AdverseReaction
urticaria NN B-AdverseReaction B-AdverseReaction
and NN O O
angioedema NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
throat NN I-AdverseReaction I-AdverseReaction
and NN O O
or NN O O
tongue NN O O
. NN O O
Patients NN O O
should NN O O
be NN O O
informed NN O O
of NN O O
the NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
anaphylaxis NN O O
and NN O O
instructed NN O O
to NN O O
discontinue NN O O
AMPYRA NN O O
and NN O O
seek NN O O
immediate NN O O
medical NN O O
care NN O O
should NN O O
these NN O O
signs NN O O
and NN O O
symptoms NN O O
occur NN O O
( NN O O
17.3 NN O O
) NN O O
. NN O O
5.5 NN O O
Urinary NN O O
Tract NN O O
Infections NN O O
Urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
( NN O O
UTIs NN O O
) NN O O
were NN O O
reported NN O O
more NN O O
frequently NN O O
as NN O O
adverse NN O O
reactions NN O O
in NN O O
controlled NN O O
studies NN O O
in NN O O
patients NN O O
receiving NN O O
AMPYRA NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
( NN O O
12 NN O O
% NN O O
) NN O O
as NN O O
compared NN O O
to NN O O
placebo NN O O
( NN O O
8 NN O O
% NN O O
) NN O O
. NN O O
UTIs NN O O
in NN O O
AMPYRA NN O O
- NN O O
treated NN O O
patients NN O O
should NN O O
be NN O O
evaluated NN O O
and NN O O
treated NN O O
as NN O O
clinically NN O O
indicated NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
are NN O O
described NN O O
in NN O O
more NN O O
detail NN O O
in NN O O
the NN O O
Warnings NN O O
and NN O O
Precautions NN O O
section NN O O
of NN O O
the NN O O
label NN O O
: NN O O
* NN O O
Retinal NN B-AdverseReaction B-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
and NN O O
potential NN B-Factor B-Factor
vision NN B-AdverseReaction B-AdverseReaction
loss NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Urinary NN B-AdverseReaction B-AdverseReaction
retention NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
Skin NN B-AdverseReaction B-AdverseReaction
discoloration NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
* NN O O
Neuropsychiatric NN B-AdverseReaction B-AdverseReaction
symptoms NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
* NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
and NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
* NN O O
QT NN B-AdverseReaction B-AdverseReaction
interval NN I-AdverseReaction I-AdverseReaction
effect NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.6 NN O O
) NN O O
] NN O O
* NN O O
Suicidal NN B-AdverseReaction B-AdverseReaction
behavior NN I-AdverseReaction I-AdverseReaction
and NN O O
ideation NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.7 NN O O
) NN O O
] NN O O
* NN O O
Withdrawal NN B-AdverseReaction B-AdverseReaction
seizures NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.8 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
Most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
incidence NN O O
>=4 NN O O
% NN O O
and NN O O
twice NN O O
placebo NN O O
) NN O O
were NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
somnolence NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
confusional NN B-AdverseReaction B-AdverseReaction
state NN I-AdverseReaction I-AdverseReaction
vertigo NN B-AdverseReaction B-AdverseReaction
tremor NN B-AdverseReaction B-AdverseReaction
abnormal NN B-AdverseReaction B-AdverseReaction
coordination NN I-AdverseReaction I-AdverseReaction
diplopia NN B-AdverseReaction B-AdverseReaction
disturbance NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
attention NN I-AdverseReaction I-AdverseReaction
memory NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
asthenia NN B-AdverseReaction B-AdverseReaction
blurred NN B-AdverseReaction B-AdverseReaction
vision NN I-AdverseReaction I-AdverseReaction
gait NN B-AdverseReaction B-AdverseReaction
disturbance NN I-AdverseReaction I-AdverseReaction
aphasia NN B-AdverseReaction B-AdverseReaction
dysarthria NN B-AdverseReaction B-AdverseReaction
and NN O O
balance NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
GlaxoSmithKline NN O O
at NN O O
1 NN O O
- NN O O
888 NN O O
- NN O O
825 NN O O
- NN O O
5249 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
with NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
POTIGA NN O O
was NN O O
administered NN O O
as NN O O
adjunctive NN O O
therapy NN O O
to NN O O
1,365 NN O O
patients NN O O
with NN O O
epilepsy NN O O
in NN O O
all NN O O
controlled NN O O
and NN O O
uncontrolled NN O O
clinical NN O O
studies NN O O
during NN O O
the NN O O
premarketing NN O O
development NN O O
. NN O O
A NN O O
total NN O O
of NN O O
801 NN O O
patients NN O O
were NN O O
treated NN O O
for NN O O
at NN O O
least NN O O
6 NN O O
months NN O O
, NN O O
585 NN O O
patients NN O O
were NN O O
treated NN O O
for NN O O
1 NN O O
year NN O O
or NN O O
longer NN O O
, NN O O
and NN O O
311 NN O O
patients NN O O
were NN O O
treated NN O O
for NN O O
at NN O O
least NN O O
2 NN O O
years NN O O
. NN O O
Adverse NN O O
Reactions NN O O
Leading NN O O
to NN O O
Discontinuation NN O O
in NN O O
All NN O O
Controlled NN O O
Clinical NN O O
Studies NN O O
In NN O O
the NN O O
3 NN O O
randomized NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
studies NN O O
, NN O O
199 NN O O
of NN O O
813 NN O O
patients NN O O
( NN O O
25 NN O O
% NN O O
) NN O O
receiving NN O O
POTIGA NN O O
and NN O O
45 NN O O
of NN O O
427 NN O O
patients NN O O
( NN O O
11 NN O O
% NN O O
) NN O O
receiving NN O O
placebo NN O O
discontinued NN O O
treatment NN O O
because NN O O
of NN O O
adverse NN O O
reactions NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
leading NN O O
to NN O O
withdrawal NN O O
in NN O O
patients NN O O
receiving NN O O
POTIGA NN O O
were NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
( NN O O
6 NN O O
% NN O O
) NN O O
, NN O O
confusional NN B-AdverseReaction B-AdverseReaction
state NN I-AdverseReaction I-AdverseReaction
( NN O O
4 NN O O
% NN O O
) NN O O
, NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
. NN O O
Common NN O O
Adverse NN O O
Reactions NN O O
in NN O O
All NN O O
Controlled NN O O
Clinical NN O O
Studies NN O O
Overall NN O O
, NN O O
the NN O O
most NN O O
frequently NN O O
reported NN O O
adverse NN O O
reactions NN O O
in NN O O
patients NN O O
receiving NN O O
POTIGA NN O O
( NN O O
>=4 NN O O
% NN O O
and NN O O
occurring NN O O
approximately NN O O
twice NN O O
the NN O O
placebo NN O O
rate NN O O
) NN O O
were NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
( NN O O
23 NN O O
% NN O O
) NN O O
, NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
( NN O O
22 NN O O
% NN O O
) NN O O
, NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
( NN O O
15 NN O O
% NN O O
) NN O O
, NN O O
confusional NN B-AdverseReaction B-AdverseReaction
state NN I-AdverseReaction I-AdverseReaction
( NN O O
9 NN O O
% NN O O
) NN O O
, NN O O
vertigo NN B-AdverseReaction B-AdverseReaction
( NN O O
8 NN O O
% NN O O
) NN O O
, NN O O
tremor NN B-AdverseReaction B-AdverseReaction
( NN O O
8 NN O O
% NN O O
) NN O O
, NN O O
abnormal NN B-AdverseReaction B-AdverseReaction
coordination NN I-AdverseReaction I-AdverseReaction
( NN O O
7 NN O O
% NN O O
) NN O O
, NN O O
diplopia NN B-AdverseReaction B-AdverseReaction
( NN O O
7 NN O O
% NN O O
) NN O O
, NN O O
disturbance NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
attention NN I-AdverseReaction I-AdverseReaction
( NN O O
6 NN O O
% NN O O
) NN O O
, NN O O
memory NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
( NN O O
6 NN O O
% NN O O
) NN O O
, NN O O
asthenia NN B-AdverseReaction B-AdverseReaction
( NN O O
5 NN O O
% NN O O
) NN O O
, NN O O
blurred NN B-AdverseReaction B-AdverseReaction
vision NN I-AdverseReaction I-AdverseReaction
( NN O O
5 NN O O
% NN O O
) NN O O
, NN O O
gait NN B-AdverseReaction B-AdverseReaction
disturbance NN I-AdverseReaction I-AdverseReaction
( NN O O
4 NN O O
% NN O O
) NN O O
, NN O O
aphasia NN B-AdverseReaction B-AdverseReaction
( NN O O
4 NN O O
% NN O O
) NN O O
, NN O O
dysarthria NN B-AdverseReaction B-AdverseReaction
( NN O O
4 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
balance NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
( NN O O
4 NN O O
% NN O O
) NN O O
( NN O O
see NN O O
Table NN O O
4 NN O O
) NN O O
. NN O O
In NN O O
most NN O O
cases NN O O
the NN O O
reactions NN O O
were NN O O
of NN O O
mild NN O O
or NN O O
moderate NN O O
intensity NN O O
. NN O O
Table NN O O
4 NN O O
. NN O O
Adverse NN O O
Reactions NN O O
Incidence NN O O
in NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Adjunctive NN O O
Trials NN O O
in NN O O
Adult NN O O
Patients NN O O
with NN O O
Partial NN O O
- NN O O
Onset NN O O
Seizures NN O O
( NN O O
Adverse NN O O
reactions NN O O
in NN O O
at NN O O
least NN O O
2 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
POTIGA NN O O
in NN O O
any NN O O
treatment NN O O
group NN O O
and NN O O
numerically NN O O
more NN O O
frequent NN O O
than NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
. NN O O
) NN O O
Body NN O O
System/Adverse NN O O
Reaction NN O O
Placebo NN O O
POTIGA NN O O
600 NN O O
mg/day NN O O
900 NN O O
mg/day NN O O
1,200 NN O O
mg/day NN O O
All NN O O
( NN O O
N NN O O
= NN O O
427 NN O O
) NN O O
% NN O O
( NN O O
n NN O O
= NN O O
281 NN O O
) NN O O
% NN O O
( NN O O
n NN O O
= NN O O
273 NN O O
) NN O O
% NN O O
( NN O O
n NN O O
= NN O O
259 NN O O
) NN O O
% NN O O
( NN O O
N NN O O
= NN O O
813 NN O O
) NN O O
% NN O O
Eye NN O O
Diplopia NN B-AdverseReaction B-AdverseReaction
2 NN O O
8 NN O O
6 NN O O
7 NN O O
7 NN O O
Blurred NN B-AdverseReaction B-AdverseReaction
vision NN I-AdverseReaction I-AdverseReaction
2 NN O O
2 NN O O
4 NN O O
10 NN O O
5 NN O O
Gastrointestinal NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
5 NN O O
6 NN O O
6 NN O O
9 NN O O
7 NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
1 NN O O
1 NN O O
4 NN O O
5 NN O O
3 NN O O
Dyspepsia NN B-AdverseReaction B-AdverseReaction
2 NN O O
3 NN O O
2 NN O O
3 NN O O
2 NN O O
General NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
6 NN O O
16 NN O O
15 NN O O
13 NN O O
15 NN O O
Asthenia NN B-AdverseReaction B-AdverseReaction
2 NN O O
4 NN O O
6 NN O O
4 NN O O
5 NN O O
Infections NN O O
and NN O O
infestations NN O O
Influenza NN B-AdverseReaction B-AdverseReaction
2 NN O O
4 NN O O
1 NN O O
5 NN O O
3 NN O O
Investigations NN O O
Weight NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
1 NN O O
2 NN O O
3 NN O O
3 NN O O
3 NN O O
Nervous NN O O
system NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
9 NN O O
15 NN O O
23 NN O O
32 NN O O
23 NN O O
Somnolence NN B-AdverseReaction B-AdverseReaction
12 NN O O
15 NN O O
25 NN O O
27 NN O O
22 NN O O
Memory NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
3 NN O O
3 NN O O
6 NN O O
9 NN O O
6 NN O O
Tremor NN B-AdverseReaction B-AdverseReaction
3 NN O O
3 NN O O
10 NN O O
12 NN O O
8 NN O O
Vertigo NN B-AdverseReaction B-AdverseReaction
2 NN O O
8 NN O O
8 NN O O
9 NN O O
8 NN O O
Abnormal NN B-AdverseReaction B-AdverseReaction
coordination NN I-AdverseReaction I-AdverseReaction
3 NN O O
5 NN O O
5 NN O O
12 NN O O
7 NN O O
Disturbance NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
attention NN I-AdverseReaction I-AdverseReaction
< NN O O
1 NN O O
6 NN O O
6 NN O O
7 NN O O
6 NN O O
Gait NN B-AdverseReaction B-AdverseReaction
disturbance NN I-AdverseReaction I-AdverseReaction
1 NN O O
2 NN O O
5 NN O O
6 NN O O
4 NN O O
Aphasia NN B-AdverseReaction B-AdverseReaction
< NN O O
1 NN O O
1 NN O O
3 NN O O
7 NN O O
4 NN O O
Dysarthria NN B-AdverseReaction B-AdverseReaction
< NN O O
1 NN O O
4 NN O O
2 NN O O
8 NN O O
4 NN O O
Balance NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
< NN O O
1 NN O O
3 NN O O
3 NN O O
5 NN O O
4 NN O O
Paresthesia NN B-AdverseReaction B-AdverseReaction
2 NN O O
3 NN O O
2 NN O O
5 NN O O
3 NN O O
Amnesia NN B-AdverseReaction B-AdverseReaction
< NN O O
1 NN O O
< NN O O
1 NN O O
3 NN O O
3 NN O O
2 NN O O
Dysphasia NN B-AdverseReaction B-AdverseReaction
< NN O O
1 NN O O
1 NN O O
1 NN O O
3 NN O O
2 NN O O
Psychiatric NN O O
Confusional NN B-AdverseReaction B-AdverseReaction
state NN I-AdverseReaction I-AdverseReaction
3 NN O O
4 NN O O
8 NN O O
16 NN O O
9 NN O O
Anxiety NN B-AdverseReaction B-AdverseReaction
2 NN O O
3 NN O O
2 NN O O
5 NN O O
3 NN O O
Disorientation NN B-AdverseReaction B-AdverseReaction
< NN O O
1 NN O O
< NN O O
1 NN O O
< NN O O
1 NN O O
5 NN O O
2 NN O O
Psychotic NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
0 NN O O
0 NN O O
< NN O O
1 NN O O
2 NN O O
< NN O O
1 NN O O
Renal NN O O
and NN O O
urinary NN O O
Dysuria NN B-AdverseReaction B-AdverseReaction
< NN O O
1 NN O O
1 NN O O
2 NN O O
4 NN O O
2 NN O O
Urinary NN B-AdverseReaction B-AdverseReaction
hesitation NN I-AdverseReaction I-AdverseReaction
< NN O O
1 NN O O
2 NN O O
1 NN O O
4 NN O O
2 NN O O
Hematuria NN B-AdverseReaction B-AdverseReaction
< NN O O
1 NN O O
2 NN O O
1 NN O O
2 NN O O
2 NN O O
Chromaturia NN B-AdverseReaction B-AdverseReaction
< NN O O
1 NN O O
< NN O O
1 NN O O
2 NN O O
3 NN O O
2 NN O O
Other NN O O
adverse NN O O
reactions NN O O
reported NN O O
in NN O O
these NN O O
3 NN O O
studies NN O O
in NN O O
< NN O O
2 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
POTIGA NN O O
and NN O O
numerically NN O O
greater NN O O
than NN O O
placebo NN O O
were NN O O
increased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
hallucinations NN B-AdverseReaction B-AdverseReaction
myoclonus NN B-AdverseReaction B-AdverseReaction
peripheral NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
hypokinesia NN B-AdverseReaction B-AdverseReaction
dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
dysphagia NN B-AdverseReaction B-AdverseReaction
hyperhydrosis NN B-AdverseReaction B-AdverseReaction
urinary NN B-AdverseReaction B-AdverseReaction
retention NN I-AdverseReaction I-AdverseReaction
malaise NN B-AdverseReaction B-AdverseReaction
and NN O O
increased NN B-AdverseReaction B-AdverseReaction
liver NN I-AdverseReaction I-AdverseReaction
enzymes NN I-AdverseReaction I-AdverseReaction
Most NN O O
of NN O O
the NN O O
adverse NN O O
reactions NN O O
appear NN O O
to NN O O
be NN O O
dose NN O O
related NN O O
( NN O O
especially NN O O
those NN O O
classified NN O O
as NN O O
psychiatric NN O O
and NN O O
nervous NN O O
system NN O O
symptoms NN O O
) NN O O
, NN O O
including NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
somnolence NN B-AdverseReaction B-AdverseReaction
confusional NN B-AdverseReaction B-AdverseReaction
state NN I-AdverseReaction I-AdverseReaction
tremor NN B-AdverseReaction B-AdverseReaction
abnormal NN B-AdverseReaction B-AdverseReaction
coordination NN I-AdverseReaction I-AdverseReaction
memory NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
blurred NN B-AdverseReaction B-AdverseReaction
vision NN I-AdverseReaction I-AdverseReaction
gait NN B-AdverseReaction B-AdverseReaction
disturbance NN I-AdverseReaction I-AdverseReaction
aphasia NN B-AdverseReaction B-AdverseReaction
balance NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
constipation NN B-AdverseReaction B-AdverseReaction
dysuria NN B-AdverseReaction B-AdverseReaction
and NN O O
chromaturia NN B-AdverseReaction B-AdverseReaction
POTIGA NN O O
was NN O O
associated NN O O
with NN O O
dose NN O O
- NN O O
related NN O O
weight NN B-AdverseReaction B-AdverseReaction
gain NN I-AdverseReaction I-AdverseReaction
with NN O O
mean NN O O
weight NN B-AdverseReaction B-AdverseReaction
increasing NN I-AdverseReaction I-AdverseReaction
by NN O O
0.2 NN O O
kg NN O O
, NN O O
1.2 NN O O
kg NN O O
, NN O O
1.6 NN O O
kg NN O O
, NN O O
and NN O O
2.7 NN O O
kg NN O O
in NN O O
the NN O O
placebo NN O O
, NN O O
600 NN O O
mg NN O O
per NN O O
day NN O O
, NN O O
900 NN O O
mg NN O O
per NN O O
day NN O O
, NN O O
and NN O O
1,200 NN O O
mg NN O O
per NN O O
day NN O O
groups NN O O
, NN O O
respectively NN O O
. NN O O
Additional NN O O
Adverse NN O O
Reactions NN O O
Observed NN O O
during NN O O
All NN O O
Phase NN O O
2 NN O O
and NN O O
3 NN O O
Clinical NN O O
Trials NN O O
Following NN O O
is NN O O
a NN O O
list NN O O
of NN O O
adverse NN O O
reactions NN O O
reported NN O O
by NN O O
patients NN O O
treated NN O O
with NN O O
POTIGA NN O O
during NN O O
all NN O O
clinical NN O O
trials NN O O
: NN O O
rash NN B-AdverseReaction B-AdverseReaction
nystagmus NN B-AdverseReaction B-AdverseReaction
dyspnea NN B-AdverseReaction B-AdverseReaction
leukopenia NN B-AdverseReaction B-AdverseReaction
muscle NN B-AdverseReaction B-AdverseReaction
spasms NN I-AdverseReaction I-AdverseReaction
alopecia NN B-AdverseReaction B-AdverseReaction
nephrolithiasis NN B-AdverseReaction B-AdverseReaction
syncope NN B-AdverseReaction B-AdverseReaction
neutropenia NN B-AdverseReaction B-AdverseReaction
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
euphoric NN B-AdverseReaction B-AdverseReaction
mood NN I-AdverseReaction I-AdverseReaction
renal NN B-AdverseReaction B-AdverseReaction
colic NN I-AdverseReaction I-AdverseReaction
coma NN B-AdverseReaction B-AdverseReaction
encephalopathy NN B-AdverseReaction B-AdverseReaction
Comparison NN O O
of NN O O
Gender NN O O
, NN O O
Age NN O O
, NN O O
and NN O O
Race NN O O
The NN O O
overall NN O O
adverse NN O O
reaction NN O O
profile NN O O
of NN O O
POTIGA NN O O
was NN O O
similar NN O O
for NN O O
females NN O O
and NN O O
males NN O O
. NN O O
There NN O O
are NN O O
insufficient NN O O
data NN O O
to NN O O
support NN O O
meaningful NN O O
analyses NN O O
of NN O O
adverse NN O O
reactions NN O O
by NN O O
age NN O O
or NN O O
race NN O O
. NN O O
Approximately NN O O
86 NN O O
% NN O O
of NN O O
the NN O O
population NN O O
studied NN O O
was NN O O
Caucasian NN O O
, NN O O
and NN O O
0.8 NN O O
% NN O O
of NN O O
the NN O O
population NN O O
was NN O O
aged NN O O
65 NN O O
years NN O O
or NN O O
older NN O O
. NN O O
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
RETINAL NN B-AdverseReaction B-AdverseReaction
ABNORMALITIES NN I-AdverseReaction I-AdverseReaction
AND NN O O
POTENTIAL NN B-Factor B-Factor
VISION NN B-AdverseReaction B-AdverseReaction
LOSS NN I-AdverseReaction I-AdverseReaction
WARNING NN O O
: NN O O
RETINAL NN B-AdverseReaction B-AdverseReaction
ABNORMALITIES NN I-AdverseReaction I-AdverseReaction
AND NN O O
POTENTIAL NN B-Factor B-Factor
VISION NN B-AdverseReaction B-AdverseReaction
LOSS NN I-AdverseReaction I-AdverseReaction
POTIGA NN O O
can NN B-Factor B-Factor
cause NN O O
retinal NN B-AdverseReaction B-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
with NN O O
funduscopic NN O O
features NN O O
similar NN O O
to NN O O
those NN O O
seen NN O O
in NN O O
retinal NN O O
pigment NN O O
dystrophies NN O O
, NN O O
which NN O O
are NN O O
known NN O O
to NN O O
result NN O O
in NN O O
damage NN B-AdverseReaction B-AdverseReaction
to NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
photoreceptors NN I-AdverseReaction I-AdverseReaction
and NN O O
vision NN B-AdverseReaction B-AdverseReaction
loss NN I-AdverseReaction I-AdverseReaction
Some NN O O
patients NN O O
with NN O O
retinal NN B-AdverseReaction B-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
found NN O O
to NN O O
have NN O O
abnormal NN B-AdverseReaction B-AdverseReaction
visual NN I-AdverseReaction I-AdverseReaction
acuity NN I-AdverseReaction I-AdverseReaction
It NN O O
is NN O O
not NN B-Factor B-Factor
possible NN I-Factor I-Factor
to NN I-Factor I-Factor
determine NN I-Factor I-Factor
whether NN O O
POTIGA NN O O
caused NN O O
this NN O O
decreased NN B-AdverseReaction B-AdverseReaction
visual NN I-AdverseReaction I-AdverseReaction
acuity NN I-AdverseReaction I-AdverseReaction
as NN O O
baseline NN O O
assessments NN O O
are NN O O
not NN O O
available NN O O
for NN O O
these NN O O
patients NN O O
. NN O O
Approximately NN O O
one NN O O
third NN O O
of NN O O
the NN O O
patients NN O O
who NN O O
had NN O O
eye NN O O
examinations NN O O
performed NN O O
after NN O O
approximately NN O O
4 NN O O
years NN O O
of NN O O
treatment NN O O
were NN O O
found NN O O
to NN O O
have NN O O
retinal NN B-AdverseReaction B-AdverseReaction
pigmentary NN I-AdverseReaction I-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
An NN O O
earlier NN O O
onset NN O O
can NN O O
not NN O O
be NN O O
ruled NN O O
out NN O O
, NN O O
and NN O O
it NN O O
is NN O O
possible NN O O
that NN O O
retinal NN B-AdverseReaction B-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
were NN O O
present NN O O
earlier NN O O
in NN O O
the NN O O
course NN O O
of NN O O
exposure NN O O
to NN O O
POTIGA. NN O O
The NN O O
rate NN O O
of NN O O
progression NN O O
of NN O O
retinal NN B-AdverseReaction B-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
and NN O O
their NN O O
reversibility NN O O
are NN O O
unknown NN O O
. NN O O
POTIGA NN O O
should NN O O
only NN O O
be NN O O
used NN O O
in NN O O
patients NN O O
who NN O O
have NN O O
responded NN O O
inadequately NN O O
to NN O O
several NN O O
alternative NN O O
treatments NN O O
and NN O O
for NN O O
whom NN O O
the NN O O
benefits NN O O
outweigh NN O O
the NN O O
potential NN O O
risk NN O O
of NN O O
vision NN O O
loss NN O O
. NN O O
Patients NN O O
who NN O O
fail NN O O
to NN O O
show NN O O
substantial NN O O
clinical NN O O
benefit NN O O
after NN O O
adequate NN O O
titration NN O O
should NN O O
be NN O O
discontinued NN O O
from NN O O
POTIGA. NN O O
All NN O O
patients NN O O
taking NN O O
POTIGA NN O O
should NN O O
have NN O O
baseline NN O O
and NN O O
periodic NN O O
( NN O O
every NN O O
6 NN O O
months NN O O
) NN O O
systematic NN O O
visual NN O O
monitoring NN O O
by NN O O
an NN O O
ophthalmic NN O O
professional NN O O
. NN O O
Testing NN O O
should NN O O
include NN O O
visual NN O O
acuity NN O O
and NN O O
dilated NN O O
fundus NN O O
photography NN O O
. NN O O
Additional NN O O
testing NN O O
may NN O O
include NN O O
fluorescein NN O O
angiograms NN O O
( NN O O
FA NN O O
) NN O O
, NN O O
optical NN O O
coherence NN O O
tomography NN O O
( NN O O
OCT NN O O
) NN O O
, NN O O
perimetry NN O O
, NN O O
and NN O O
electroretinograms NN O O
( NN O O
ERG NN O O
) NN O O
. NN O O
If NN O O
retinal NN O O
pigmentary NN O O
abnormalities NN O O
or NN O O
vision NN O O
changes NN O O
are NN O O
detected NN O O
, NN O O
POTIGA NN O O
should NN O O
be NN O O
discontinued NN O O
unless NN O O
no NN O O
other NN O O
suitable NN O O
treatment NN O O
options NN O O
are NN O O
available NN O O
and NN O O
the NN O O
benefits NN O O
of NN O O
treatment NN O O
outweigh NN O O
the NN O O
potential NN O O
risk NN O O
of NN O O
vision NN O O
loss NN O O
. NN O O
EXCERPT NN O O
: NN O O
WARNING NN O O
: NN O O
RETINAL NN B-AdverseReaction B-AdverseReaction
ABNORMALITIES NN I-AdverseReaction I-AdverseReaction
AND NN O O
POTENTIAL NN B-Factor B-Factor
VISION NN B-AdverseReaction B-AdverseReaction
LOSS NN I-AdverseReaction I-AdverseReaction
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
. NN O O
* NN O O
POTIGA NN O O
can NN O O
cause NN O O
retinal NN B-AdverseReaction B-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
with NN O O
funduscopic NN O O
features NN O O
similar NN O O
to NN O O
those NN O O
seen NN O O
in NN O O
retinal NN O O
pigment NN O O
dystrophies NN O O
, NN O O
which NN O O
are NN O O
known NN O O
to NN O O
result NN O O
in NN O O
damage NN B-AdverseReaction B-AdverseReaction
to NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
photoreceptors NN I-AdverseReaction I-AdverseReaction
and NN O O
vision NN B-AdverseReaction B-AdverseReaction
loss NN I-AdverseReaction I-AdverseReaction
( NN O O
5.1 NN O O
) NN O O
* NN O O
Some NN O O
patients NN O O
with NN O O
retinal NN O O
abnormalities NN O O
have NN O O
been NN O O
found NN O O
to NN O O
have NN O O
abnormal NN O O
visual NN O O
acuity NN O O
. NN O O
It NN O O
is NN O O
not NN B-Factor B-Factor
possible NN I-Factor I-Factor
to NN I-Factor I-Factor
determine NN I-Factor I-Factor
whether NN O O
POTIGA NN O O
caused NN O O
this NN O O
decreased NN B-AdverseReaction B-AdverseReaction
visual NN I-AdverseReaction I-AdverseReaction
acuity NN I-AdverseReaction I-AdverseReaction
( NN O O
5.1 NN O O
) NN O O
* NN O O
The NN O O
rate NN O O
of NN O O
progression NN O O
of NN O O
retinal NN O O
abnormalities NN O O
and NN O O
their NN O O
reversibility NN O O
are NN O O
unknown NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Patients NN O O
who NN O O
fail NN O O
to NN O O
show NN O O
substantial NN O O
clinical NN O O
benefit NN O O
after NN O O
adequate NN O O
titration NN O O
should NN O O
be NN O O
discontinued NN O O
from NN O O
POTIGA. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
All NN O O
patients NN O O
taking NN O O
POTIGA NN O O
should NN O O
have NN O O
baseline NN O O
and NN O O
periodic NN O O
( NN O O
every NN O O
6 NN O O
months NN O O
) NN O O
systematic NN O O
visual NN O O
monitoring NN O O
by NN O O
an NN O O
ophthalmic NN O O
professional NN O O
. NN O O
Testing NN O O
should NN O O
include NN O O
visual NN O O
acuity NN O O
and NN O O
dilated NN O O
fundus NN O O
photography NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
If NN O O
retinal NN O O
pigmentary NN O O
abnormalities NN O O
or NN O O
vision NN O O
changes NN O O
are NN O O
detected NN O O
, NN O O
POTIGA NN O O
should NN O O
be NN O O
discontinued NN O O
unless NN O O
no NN O O
other NN O O
suitable NN O O
treatment NN O O
options NN O O
are NN O O
available NN O O
and NN O O
the NN O O
benefits NN O O
of NN O O
treatment NN O O
outweigh NN O O
the NN O O
potential NN O O
risk NN O O
of NN O O
vision NN O O
loss NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Urinary NN B-AdverseReaction B-AdverseReaction
retention NN I-AdverseReaction I-AdverseReaction
Patients NN O O
should NN O O
be NN O O
carefully NN O O
monitored NN O O
for NN O O
urologic NN O O
symptoms NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
POTIGA NN O O
can NN B-Factor B-Factor
cause NN O O
skin NN B-AdverseReaction B-AdverseReaction
discoloration NN I-AdverseReaction I-AdverseReaction
If NN O O
a NN O O
patient NN O O
develops NN O O
skin NN O O
discoloration NN O O
, NN O O
serious NN O O
consideration NN O O
should NN O O
be NN O O
given NN O O
to NN O O
an NN O O
alternative NN O O
treatment NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Neuropsychiatric NN B-AdverseReaction B-AdverseReaction
symptoms NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
for NN O O
confusional NN O O
state NN O O
, NN O O
psychotic NN O O
symptoms NN O O
, NN O O
and NN O O
hallucinations NN O O
. NN O O
( NN O O
5.4 NN O O
) NN O O
* NN O O
Monitor NN O O
for NN O O
dizziness NN O O
and NN O O
somnolence NN O O
. NN O O
( NN O O
5.5 NN O O
) NN O O
* NN O O
QT NN B-AdverseReaction B-AdverseReaction
prolongation NN I-AdverseReaction I-AdverseReaction
QT NN O O
interval NN O O
should NN O O
be NN O O
monitored NN O O
in NN O O
patients NN O O
taking NN O O
concomitant NN O O
medications NN O O
known NN O O
to NN O O
increase NN O O
the NN O O
QT NN O O
interval NN O O
or NN O O
with NN O O
certain NN O O
heart NN O O
conditions NN O O
. NN O O
( NN O O
5.6 NN O O
) NN O O
* NN O O
Monitor NN O O
for NN O O
suicidal NN O O
thoughts NN O O
or NN O O
behaviors NN O O
. NN O O
( NN O O
5.7 NN O O
) NN O O
5.1 NN O O
Retinal NN O O
Abnormalities NN O O
and NN O O
Potential NN O O
Vision NN O O
Loss NN O O
POTIGA NN O O
can NN B-Factor B-Factor
cause NN O O
abnormalities NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
retina NN I-AdverseReaction I-AdverseReaction
The NN O O
abnormalities NN O O
seen NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
POTIGA NN O O
have NN O O
funduscopic NN O O
features NN O O
similar NN O O
to NN O O
those NN O O
seen NN O O
in NN O O
retinal NN O O
pigment NN O O
dystrophies NN O O
that NN O O
are NN O O
known NN O O
to NN O O
result NN O O
in NN O O
damage NN B-AdverseReaction B-AdverseReaction
to NN I-AdverseReaction I-AdverseReaction
photoreceptors NN I-AdverseReaction I-AdverseReaction
and NN O O
vision NN B-AdverseReaction B-AdverseReaction
loss NN I-AdverseReaction I-AdverseReaction
The NN O O
retinal NN B-AdverseReaction B-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
observed NN O O
with NN O O
POTIGA NN O O
have NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
who NN O O
were NN O O
originally NN O O
enrolled NN O O
in NN O O
clinical NN O O
trials NN O O
with NN O O
POTIGA NN O O
and NN O O
who NN O O
have NN O O
generally NN O O
taken NN O O
the NN O O
drug NN O O
for NN O O
a NN O O
long NN O O
period NN O O
of NN O O
time NN O O
in NN O O
2 NN O O
ongoing NN O O
extension NN O O
trials NN O O
. NN O O
Approximately NN O O
one NN O O
third NN O O
of NN O O
the NN O O
patients NN O O
who NN O O
had NN O O
eye NN O O
examinations NN O O
performed NN O O
after NN O O
approximately NN O O
4 NN O O
years NN O O
of NN O O
treatment NN O O
were NN O O
found NN O O
to NN O O
have NN O O
retinal NN B-AdverseReaction B-AdverseReaction
pigmentary NN I-AdverseReaction I-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
However NN O O
, NN O O
an NN O O
earlier NN O O
onset NN O O
can NN O O
not NN O O
be NN O O
ruled NN O O
out NN O O
, NN O O
and NN O O
it NN O O
is NN O O
possible NN O O
that NN O O
retinal NN B-AdverseReaction B-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
were NN O O
present NN O O
earlier NN O O
in NN O O
the NN O O
course NN O O
of NN O O
exposure NN O O
to NN O O
POTIGA. NN O O
POTIGA NN O O
causes NN O O
skin NN O O
, NN O O
scleral NN O O
, NN O O
nail NN O O
, NN O O
and NN O O
mucous NN B-AdverseReaction B-AdverseReaction
membrane NN I-AdverseReaction I-AdverseReaction
discoloration NN I-AdverseReaction I-AdverseReaction
and NN O O
it NN O O
is NN O O
not NN O O
clear NN O O
whether NN O O
this NN O O
discoloration NN B-AdverseReaction B-AdverseReaction
is NN O O
related NN O O
to NN O O
retinal NN B-AdverseReaction B-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
. NN O O
Approximately NN O O
15 NN O O
% NN O O
of NN O O
patients NN O O
with NN O O
retinal NN B-AdverseReaction B-AdverseReaction
pigmentary NN I-AdverseReaction I-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
had NN O O
no NN B-Negation B-Negation
such NN O O
discoloration NN B-AdverseReaction B-AdverseReaction
Funduscopic NN B-AdverseReaction B-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
have NN O O
most NN O O
commonly NN O O
been NN O O
described NN O O
as NN O O
perivascular NN O O
pigmentation NN O O
( NN O O
bone NN O O
spicule NN O O
pattern NN O O
) NN O O
in NN O O
the NN O O
retinal NN O O
periphery NN O O
and/or NN O O
as NN O O
areas NN O O
of NN O O
focal NN B-AdverseReaction B-AdverseReaction
retinal NN I-AdverseReaction I-AdverseReaction
pigment NN I-AdverseReaction I-AdverseReaction
epithelium NN I-AdverseReaction I-AdverseReaction
clumping NN I-AdverseReaction I-AdverseReaction
Although NN O O
some NN O O
of NN O O
the NN O O
patients NN O O
with NN O O
retinal NN B-AdverseReaction B-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
found NN O O
to NN O O
have NN O O
abnormal NN B-AdverseReaction B-AdverseReaction
visual NN I-AdverseReaction I-AdverseReaction
acuity NN I-AdverseReaction I-AdverseReaction
it NN O O
is NN O O
not NN O O
possible NN O O
to NN O O
assess NN O O
whether NN B-Factor B-Factor
POTIGA NN O O
caused NN O O
their NN O O
decreased NN B-AdverseReaction B-AdverseReaction
visual NN I-AdverseReaction I-AdverseReaction
acuity NN I-AdverseReaction I-AdverseReaction
as NN O O
baseline NN O O
assessments NN O O
are NN O O
not NN O O
available NN O O
for NN O O
these NN O O
patients NN O O
. NN O O
Two NN O O
patients NN O O
with NN O O
retinal NN B-AdverseReaction B-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
have NN O O
had NN O O
more NN O O
extensive NN O O
diagnostic NN O O
retinal NN O O
evaluations NN O O
. NN O O
The NN O O
results NN O O
of NN O O
these NN O O
evaluations NN O O
were NN O O
consistent NN O O
with NN O O
a NN O O
retinal NN B-AdverseReaction B-AdverseReaction
dystrophy NN I-AdverseReaction I-AdverseReaction
including NN O O
abnormalities NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
electroretinogram NN I-AdverseReaction I-AdverseReaction
and NN O O
electrooculogram NN O O
of NN O O
both NN O O
patients NN O O
, NN O O
with NN O O
abnormal NN B-AdverseReaction B-AdverseReaction
fluorescein NN I-AdverseReaction I-AdverseReaction
angiography NN I-AdverseReaction I-AdverseReaction
and NN O O
diminished NN B-AdverseReaction B-AdverseReaction
sensitivity NN I-AdverseReaction I-AdverseReaction
on NN I-AdverseReaction I-AdverseReaction
visual NN I-AdverseReaction I-AdverseReaction
field NN I-AdverseReaction I-AdverseReaction
testing NN O O
in NN O O
one NN O O
patient NN O O
. NN O O
The NN O O
rate NN O O
of NN O O
progression NN O O
of NN O O
retinal NN B-AdverseReaction B-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
and NN O O
the NN O O
reversibility NN O O
after NN O O
drug NN O O
discontinuation NN O O
are NN O O
unknown NN O O
. NN O O
Because NN B-Factor B-Factor
of NN O O
the NN O O
observed NN O O
ophthalmologic NN O O
adverse NN O O
reactions NN O O
, NN O O
POTIGA NN O O
should NN O O
only NN O O
be NN O O
used NN O O
in NN O O
patients NN O O
who NN O O
have NN O O
responded NN O O
inadequately NN O O
to NN O O
several NN O O
alternative NN O O
treatments NN O O
and NN O O
for NN O O
whom NN O O
the NN O O
benefits NN O O
outweigh NN O O
the NN O O
risk NN O O
of NN O O
retinal NN O O
abnormalities NN O O
and NN O O
potential NN O O
vision NN O O
loss NN O O
. NN O O
Patients NN O O
who NN O O
fail NN O O
to NN O O
show NN O O
substantial NN O O
clinical NN O O
benefit NN O O
after NN O O
adequate NN O O
titration NN O O
should NN O O
be NN O O
discontinued NN O O
from NN O O
POTIGA. NN O O
Patients NN O O
should NN O O
have NN O O
baseline NN O O
ophthalmologic NN O O
testing NN O O
by NN O O
an NN O O
ophthalmic NN O O
professional NN O O
and NN O O
follow NN O O
- NN O O
up NN O O
testing NN O O
every NN O O
6 NN O O
months NN O O
. NN O O
The NN O O
best NN O O
method NN O O
of NN O O
detection NN O O
of NN O O
these NN O O
abnormalities NN O O
and NN O O
the NN O O
optimal NN O O
frequency NN O O
of NN O O
periodic NN O O
ophthalmologic NN O O
monitoring NN O O
are NN O O
unknown NN O O
. NN O O
Patients NN O O
who NN O O
can NN O O
not NN O O
be NN O O
monitored NN O O
should NN O O
usually NN O O
not NN O O
be NN O O
treated NN O O
with NN O O
POTIGA. NN O O
The NN O O
ophthalmologic NN O O
monitoring NN O O
program NN O O
should NN O O
include NN O O
visual NN O O
acuity NN O O
testing NN O O
and NN O O
dilated NN O O
fundus NN O O
photography NN O O
. NN O O
Additional NN O O
testing NN O O
may NN O O
include NN O O
fluorescein NN O O
angiograms NN O O
( NN O O
FA NN O O
) NN O O
, NN O O
optical NN O O
coherence NN O O
tomography NN O O
( NN O O
OCT NN O O
) NN O O
, NN O O
perimetry NN O O
, NN O O
and NN O O
electroretinograms NN O O
( NN O O
ERG NN O O
) NN O O
. NN O O
If NN O O
retinal NN O O
pigmentary NN O O
abnormalities NN O O
or NN O O
vision NN O O
changes NN O O
are NN O O
detected NN O O
, NN O O
POTIGA NN O O
should NN O O
be NN O O
discontinued NN O O
unless NN O O
no NN O O
other NN O O
suitable NN O O
treatment NN O O
options NN O O
are NN O O
available NN O O
and NN O O
the NN O O
benefits NN O O
of NN O O
treatment NN O O
outweigh NN O O
the NN O O
potential NN O O
risk NN O O
of NN O O
vision NN O O
loss NN B-Factor B-Factor
5.2 NN O O
Urinary NN O O
Retention NN O O
POTIGA NN O O
caused NN O O
urinary NN B-AdverseReaction B-AdverseReaction
retention NN I-AdverseReaction I-AdverseReaction
in NN O O
clinical NN O O
trials NN O O
. NN O O
Urinary NN B-AdverseReaction B-AdverseReaction
retention NN I-AdverseReaction I-AdverseReaction
was NN O O
generally NN O O
reported NN O O
within NN O O
the NN O O
first NN O O
6 NN O O
months NN O O
of NN O O
treatment NN O O
, NN O O
but NN O O
was NN O O
also NN O O
observed NN O O
later NN O O
. NN O O
Urinary NN B-AdverseReaction B-AdverseReaction
retention NN I-AdverseReaction I-AdverseReaction
was NN O O
reported NN O O
as NN O O
an NN O O
adverse NN O O
event NN O O
in NN O O
29 NN O O
of NN O O
1,365 NN O O
( NN O O
approximately NN O O
2 NN O O
% NN O O
) NN O O
patients NN O O
treated NN O O
with NN O O
POTIGA NN O O
in NN O O
the NN O O
open NN O O
- NN O O
label NN O O
and NN O O
placebo NN O O
- NN O O
controlled NN O O
epilepsy NN O O
database NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
. NN O O
Of NN O O
these NN O O
29 NN O O
patients NN O O
, NN O O
5 NN O O
( NN O O
17 NN O O
% NN O O
) NN O O
required NN O O
catheterization NN O O
, NN O O
with NN O O
post NN O O
- NN O O
voiding NN O O
residuals NN O O
of NN O O
up NN O O
to NN O O
1,500 NN O O
mL. NN O O
POTIGA NN O O
was NN O O
discontinued NN O O
in NN O O
3 NN O O
of NN O O
the NN O O
5 NN O O
patients NN O O
who NN O O
required NN O O
catheterization NN O O
, NN O O
and NN O O
all NN O O
were NN O O
able NN O O
to NN O O
void NN O O
spontaneously NN O O
; NN O O
however NN O O
, NN O O
1 NN O O
of NN O O
the NN O O
3 NN O O
patients NN O O
continued NN O O
intermittent NN O O
self NN O O
- NN O O
catheterization NN O O
. NN O O
Two NN O O
patients NN O O
continued NN O O
treatment NN O O
with NN O O
POTIGA NN O O
and NN O O
were NN O O
able NN O O
to NN O O
void NN O O
spontaneously NN O O
after NN O O
catheter NN O O
removal NN O O
. NN O O
Hydronephrosis NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
2 NN O O
patients NN O O
, NN O O
one NN O O
of NN O O
whom NN O O
had NN O O
associated NN O O
renal NN B-AdverseReaction B-AdverseReaction
function NN I-AdverseReaction I-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
that NN O O
resolved NN O O
upon NN O O
discontinuation NN O O
of NN O O
POTIGA. NN O O
Hydronephrosis NN B-AdverseReaction B-AdverseReaction
was NN O O
not NN B-Negation B-Negation
reported NN O O
in NN O O
placebo NN B-Factor B-Factor
patients NN O O
. NN O O
In NN O O
the NN O O
placebo NN O O
- NN O O
controlled NN O O
epilepsy NN O O
trials NN O O
, NN O O
" NN O O
urinary NN O O
retention NN O O
, NN O O
" NN O O
" NN O O
urinary NN O O
hesitation NN O O
, NN O O
" NN O O
and NN O O
" NN O O
dysuria NN O O
" NN O O
were NN O O
reported NN O O
in NN O O
0.9 NN O O
% NN O O
, NN O O
2.2 NN O O
% NN O O
, NN O O
and NN O O
2.3 NN O O
% NN O O
of NN O O
patients NN O O
on NN O O
POTIGA NN O O
, NN O O
respectively NN O O
, NN O O
and NN O O
in NN O O
0.5 NN O O
% NN O O
, NN O O
0.9 NN O O
% NN O O
, NN O O
and NN O O
0.7 NN O O
% NN O O
of NN O O
patients NN O O
on NN O O
placebo NN O O
, NN O O
respectively NN O O
. NN O O
Because NN B-Factor B-Factor
of NN O O
the NN O O
increased NN O O
risk NN O O
of NN O O
urinary NN O O
retention NN O O
on NN O O
POTIGA NN O O
, NN O O
urologic NN O O
symptoms NN O O
should NN O O
be NN O O
carefully NN O O
monitored NN O O
. NN O O
Closer NN O O
monitoring NN O O
is NN O O
recommended NN O O
for NN O O
patients NN O O
who NN O O
have NN O O
other NN O O
risk NN O O
factors NN O O
for NN O O
urinary NN O O
retention NN O O
( NN O O
e.g. NN O O
, NN O O
benign NN O O
prostatic NN O O
hyperplasia NN O O
[ NN O O
BPH NN O O
] NN O O
) NN O O
, NN O O
patients NN O O
who NN O O
are NN O O
unable NN O O
to NN O O
communicate NN O O
clinical NN O O
symptoms NN O O
( NN O O
e.g. NN O O
, NN O O
cognitively NN O O
impaired NN O O
patients NN O O
) NN O O
, NN O O
or NN O O
patients NN O O
who NN O O
use NN O O
concomitant NN O O
medications NN O O
that NN O O
may NN O O
affect NN O O
voiding NN O O
( NN O O
e.g. NN O O
, NN O O
anticholinergics NN O O
) NN O O
. NN O O
In NN O O
these NN O O
patients NN O O
, NN O O
a NN O O
comprehensive NN O O
evaluation NN O O
of NN O O
urologic NN O O
symptoms NN O O
prior NN O O
to NN O O
and NN O O
during NN O O
treatment NN O O
with NN O O
POTIGA NN O O
may NN O O
be NN O O
appropriate NN B-Factor B-Factor
5.3 NN O O
Skin NN O O
Discoloration NN O O
POTIGA NN O O
can NN B-Factor B-Factor
cause NN O O
skin NN B-AdverseReaction B-AdverseReaction
discoloration NN I-AdverseReaction I-AdverseReaction
The NN O O
skin NN B-AdverseReaction B-AdverseReaction
discoloration NN I-AdverseReaction I-AdverseReaction
is NN O O
generally NN O O
described NN O O
as NN O O
blue NN O O
, NN O O
but NN O O
has NN O O
also NN O O
been NN O O
described NN O O
as NN O O
grey NN O O
- NN O O
blue NN O O
or NN O O
brown NN O O
. NN O O
It NN O O
is NN O O
predominantly NN O O
on NN O O
or NN O O
around NN O O
the NN O O
lips NN O O
or NN O O
in NN O O
the NN O O
nail NN O O
beds NN O O
of NN O O
the NN O O
fingers NN O O
or NN O O
toes NN O O
, NN O O
but NN O O
more NN O O
widespread NN O O
involvement NN O O
of NN O O
the NN O O
face NN O O
and NN O O
legs NN O O
has NN O O
also NN O O
been NN O O
reported NN O O
. NN O O
Discoloration NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
palate NN I-AdverseReaction I-AdverseReaction
sclera NN O O
, NN O O
and NN O O
conjunctiva NN O O
has NN O O
also NN O O
been NN O O
reported NN O O
. NN O O
Approximately NN O O
10 NN O O
% NN O O
of NN O O
patients NN O O
in NN O O
long NN O O
- NN O O
term NN O O
clinical NN O O
trials NN O O
developed NN O O
skin NN B-AdverseReaction B-AdverseReaction
discoloration NN I-AdverseReaction I-AdverseReaction
generally NN O O
after NN O O
2 NN O O
or NN O O
more NN O O
years NN O O
of NN O O
treatment NN O O
and NN O O
at NN O O
higher NN O O
doses NN O O
( NN O O
900 NN O O
mg NN O O
or NN O O
greater NN O O
) NN O O
of NN O O
POTIGA. NN O O
Among NN O O
patients NN O O
in NN O O
whom NN O O
the NN O O
status NN O O
of NN O O
both NN O O
skin NN O O
, NN O O
nail NN O O
, NN O O
lip NN O O
, NN O O
or NN O O
mucous NN B-AdverseReaction B-AdverseReaction
membrane NN I-AdverseReaction I-AdverseReaction
discoloration NN I-AdverseReaction I-AdverseReaction
and NN O O
retinal NN B-AdverseReaction B-AdverseReaction
pigmentary NN I-AdverseReaction I-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
are NN O O
reported NN O O
, NN O O
approximately NN O O
a NN O O
quarter NN O O
of NN O O
those NN O O
with NN O O
skin NN O O
, NN O O
nail NN O O
, NN O O
lip NN O O
, NN O O
or NN O O
mucous NN B-AdverseReaction B-AdverseReaction
membrane NN I-AdverseReaction I-AdverseReaction
discoloration NN I-AdverseReaction I-AdverseReaction
had NN O O
concurrent NN O O
retinal NN B-AdverseReaction B-AdverseReaction
pigmentary NN I-AdverseReaction I-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
Information NN O O
on NN O O
the NN O O
consequences NN O O
, NN O O
reversibility NN O O
, NN O O
time NN O O
to NN O O
onset NN O O
, NN O O
and NN O O
pathophysiology NN O O
of NN O O
the NN O O
skin NN B-AdverseReaction B-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
remains NN O O
incomplete NN O O
. NN O O
The NN O O
possibility NN O O
of NN O O
more NN O O
extensive NN O O
systemic NN O O
involvement NN O O
has NN O O
not NN O O
been NN O O
excluded NN O O
. NN O O
If NN O O
a NN O O
patient NN O O
develops NN O O
skin NN O O
discoloration NN O O
, NN O O
serious NN O O
consideration NN O O
should NN O O
be NN O O
given NN O O
to NN O O
changing NN O O
to NN O O
an NN O O
alternate NN O O
medication NN O O
. NN O O
5.4 NN O O
Neuropsychiatric NN O O
Symptoms NN O O
Confusional NN B-AdverseReaction B-AdverseReaction
state NN I-AdverseReaction I-AdverseReaction
psychotic NN B-AdverseReaction B-AdverseReaction
symptoms NN I-AdverseReaction I-AdverseReaction
and NN O O
hallucinations NN B-AdverseReaction B-AdverseReaction
were NN O O
reported NN O O
more NN O O
frequently NN O O
as NN O O
adverse NN O O
reactions NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
POTIGA NN O O
than NN O O
in NN O O
those NN O O
treated NN O O
with NN O O
placebo NN O O
in NN O O
placebo NN O O
- NN O O
controlled NN O O
epilepsy NN O O
trials NN O O
( NN O O
see NN O O
Table NN O O
2 NN O O
) NN O O
. NN O O
Discontinuations NN O O
resulting NN O O
from NN O O
these NN O O
reactions NN O O
were NN O O
more NN O O
common NN O O
in NN O O
the NN O O
drug NN O O
- NN O O
treated NN O O
group NN O O
( NN O O
see NN O O
Table NN O O
2 NN O O
) NN O O
. NN O O
These NN O O
effects NN O O
were NN O O
dose NN O O
- NN O O
related NN O O
and NN O O
generally NN O O
appeared NN O O
within NN O O
the NN O O
first NN O O
8 NN O O
weeks NN O O
of NN O O
treatment NN O O
. NN O O
Half NN O O
of NN O O
the NN O O
patients NN O O
in NN O O
the NN O O
controlled NN O O
trials NN O O
who NN O O
discontinued NN O O
POTIGA NN O O
due NN O O
to NN O O
hallucinations NN B-AdverseReaction B-AdverseReaction
or NN O O
psychosis NN B-AdverseReaction B-AdverseReaction
required NN O O
hospitalization NN O O
. NN O O
Approximately NN O O
two NN O O
- NN O O
thirds NN O O
of NN O O
patients NN O O
with NN O O
psychosis NN B-AdverseReaction B-AdverseReaction
in NN O O
controlled NN O O
trials NN O O
had NN O O
no NN O O
prior NN O O
psychiatric NN O O
history NN O O
. NN O O
The NN O O
psychiatric NN B-AdverseReaction B-AdverseReaction
symptoms NN I-AdverseReaction I-AdverseReaction
in NN O O
the NN O O
vast NN O O
majority NN O O
of NN O O
patients NN O O
in NN O O
both NN O O
controlled NN O O
and NN O O
open NN O O
- NN O O
label NN O O
trials NN O O
resolved NN O O
within NN O O
7 NN O O
days NN O O
of NN O O
discontinuation NN O O
of NN O O
POTIGA. NN O O
Rapid NN O O
titration NN O O
at NN O O
greater NN O O
than NN O O
the NN O O
recommended NN O O
doses NN O O
appeared NN O O
to NN O O
increase NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
psychosis NN B-AdverseReaction B-AdverseReaction
and NN O O
hallucinations NN B-AdverseReaction B-AdverseReaction
Table NN O O
2 NN O O
. NN O O
Major NN O O
Neuropsychiatric NN B-AdverseReaction B-AdverseReaction
Symptoms NN I-AdverseReaction I-AdverseReaction
in NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Epilepsy NN O O
Trials NN O O
Adverse NN O O
Reaction NN O O
Number NN O O
( NN O O
% NN O O
) NN O O
with NN O O
Adverse NN O O
Reaction NN O O
Number NN O O
( NN O O
% NN O O
) NN O O
Discontinuing NN O O
POTIGA NN O O
( NN O O
n NN O O
= NN O O
813 NN O O
) NN O O
Placebo NN O O
( NN O O
n NN O O
= NN O O
427 NN O O
) NN O O
POTIGA NN O O
( NN O O
n NN O O
= NN O O
813 NN O O
) NN O O
Placebo NN O O
( NN O O
n NN O O
= NN O O
427 NN O O
) NN O O
Confusional NN B-AdverseReaction B-AdverseReaction
state NN I-AdverseReaction I-AdverseReaction
75 NN O O
( NN O O
9 NN O O
% NN O O
) NN O O
11 NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
32 NN O O
( NN O O
4 NN O O
% NN O O
) NN O O
4 NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
Psychosis NN B-AdverseReaction B-AdverseReaction
9 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
0 NN O O
6 NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
0 NN O O
Hallucinations NN B-AdverseReaction B-AdverseReaction
14 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
2 NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
6 NN O O
( NN O O
< NN O O
1 NN O O
% NN O O
) NN O O
0 NN O O
a NN O O
Hallucinations NN B-AdverseReaction B-AdverseReaction
includes NN O O
visual NN O O
, NN O O
auditory NN O O
, NN O O
and NN O O
mixed NN B-AdverseReaction B-AdverseReaction
hallucinations NN I-AdverseReaction I-AdverseReaction
5.5 NN O O
Dizziness NN O O
and NN O O
Somnolence NN O O
POTIGA NN O O
causes NN O O
dose NN O O
- NN O O
related NN O O
increases NN O O
in NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
and NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
In NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
in NN O O
patients NN O O
with NN O O
epilepsy NN O O
, NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
23 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
POTIGA NN O O
and NN O O
9 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
placebo NN O O
. NN O O
Somnolence NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
22 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
POTIGA NN O O
and NN O O
12 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
placebo NN O O
. NN O O
In NN O O
these NN O O
trials NN O O
6 NN O O
% NN O O
of NN O O
patients NN O O
on NN O O
POTIGA NN O O
and NN O O
1.2 NN O O
% NN O O
on NN O O
placebo NN O O
discontinued NN O O
treatment NN O O
because NN O O
of NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
3 NN O O
% NN O O
of NN O O
patients NN O O
on NN O O
POTIGA NN O O
and NN O O
< NN O O
1.0 NN O O
% NN O O
on NN O O
placebo NN O O
discontinued NN O O
because NN O O
of NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
Most NN O O
of NN O O
these NN O O
adverse NN O O
reactions NN O O
were NN O O
mild NN O O
to NN O O
moderate NN O O
in NN O O
intensity NN O O
and NN O O
occurred NN O O
during NN O O
the NN O O
titration NN O O
phase NN O O
. NN O O
For NN O O
those NN O O
patients NN O O
continued NN O O
on NN O O
POTIGA NN O O
, NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
and NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
appeared NN O O
to NN O O
diminish NN O O
with NN O O
continued NN O O
use NN O O
. NN O O
5.6 NN O O
QT NN O O
Interval NN O O
Effect NN O O
A NN O O
study NN O O
of NN O O
cardiac NN O O
conduction NN O O
showed NN O O
that NN O O
POTIGA NN O O
produced NN O O
a NN O O
mean NN O O
7.7-msec NN B-Severity B-Severity
QT NN B-AdverseReaction B-AdverseReaction
prolongation NN I-AdverseReaction I-AdverseReaction
in NN O O
healthy NN O O
volunteers NN O O
titrated NN O O
to NN O O
400 NN O O
mg NN O O
3 NN O O
times NN O O
daily NN O O
. NN O O
The NN O O
QT NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
prolonging NN I-AdverseReaction I-AdverseReaction
effect NN O O
occurred NN O O
within NN O O
3 NN O O
hours NN O O
. NN O O
The NN O O
QT NN O O
interval NN O O
should NN O O
be NN O O
monitored NN O O
when NN O O
POTIGA NN O O
is NN O O
prescribed NN O O
with NN O O
medicines NN O O
known NN O O
to NN O O
increase NN O O
QT NN O O
interval NN O O
and NN O O
in NN O O
patients NN O O
with NN O O
known NN O O
prolonged NN O O
QT NN O O
interval NN O O
, NN O O
congestive NN O O
heart NN O O
failure NN O O
, NN O O
ventricular NN O O
hypertrophy NN O O
, NN O O
hypokalemia NN O O
, NN O O
or NN O O
hypomagnesemia NN O O
[ NN O O
see NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.2 NN O O
) NN O O
] NN O O
. NN O O
5.7 NN O O
Suicidal NN O O
Behavior NN O O
and NN O O
Ideation NN O O
Antiepileptic NN O O
drugs NN O O
( NN O O
AEDs NN O O
) NN O O
, NN O O
including NN O O
POTIGA NN O O
, NN O O
increase NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
thoughts NN I-AdverseReaction I-AdverseReaction
or NN O O
behavior NN O O
in NN O O
patients NN O O
taking NN O O
these NN O O
drugs NN O O
for NN O O
any NN O O
indication NN O O
. NN O O
Patients NN O O
treated NN O O
with NN O O
any NN O O
AED NN O O
for NN O O
any NN O O
indication NN O O
should NN O O
be NN O O
monitored NN O O
for NN O O
the NN O O
emergence NN O O
or NN O O
worsening NN O O
of NN O O
depression NN O O
, NN O O
suicidal NN O O
thoughts NN O O
or NN O O
behavior NN O O
, NN O O
and/or NN O O
any NN O O
unusual NN O O
changes NN O O
in NN O O
mood NN O O
or NN O O
behavior NN O O
. NN O O
Pooled NN O O
analyses NN O O
of NN O O
199 NN O O
placebo NN O O
- NN O O
controlled NN O O
clinical NN O O
trials NN O O
( NN O O
mono- NN O O
and NN O O
adjunctive NN O O
- NN O O
therapy NN O O
) NN O O
of NN O O
11 NN O O
different NN O O
AEDs NN O O
showed NN O O
that NN O O
patients NN O O
randomized NN O O
to NN O O
one NN O O
of NN O O
the NN O O
AEDs NN O O
had NN O O
approximately NN O O
twice NN O O
the NN O O
risk NN B-Factor B-Factor
( NN O O
adjusted NN O O
relative NN O O
risk NN O O
1.8 NN O O
, NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
[ NN O O
CI NN O O
] NN O O
: NN O O
1.2 NN O O
, NN O O
2.7 NN O O
) NN O O
of NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
thinking NN I-AdverseReaction I-AdverseReaction
or NN O O
behavior NN O O
compared NN O O
with NN O O
patients NN O O
randomized NN O O
to NN O O
placebo NN O O
. NN O O
In NN O O
these NN O O
trials NN O O
, NN O O
which NN O O
had NN O O
a NN O O
median NN O O
treatment NN O O
duration NN O O
of NN O O
12 NN O O
weeks NN O O
, NN O O
the NN O O
estimated NN O O
incidence NN O O
of NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
behavior NN I-AdverseReaction I-AdverseReaction
or NN O O
ideation NN O O
among NN O O
27,863 NN O O
AED NN O O
- NN O O
treated NN O O
patients NN O O
was NN O O
0.43 NN O O
% NN O O
compared NN O O
with NN O O
0.24 NN O O
% NN O O
among NN O O
16,029 NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
, NN O O
representing NN O O
an NN O O
increase NN O O
of NN O O
approximately NN O O
1 NN O O
case NN O O
of NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
thinking NN I-AdverseReaction I-AdverseReaction
or NN O O
behavior NN O O
for NN O O
every NN O O
530 NN O O
patients NN O O
treated NN O O
. NN O O
There NN O O
were NN O O
4 NN O O
suicides NN B-AdverseReaction B-AdverseReaction
in NN O O
drug NN O O
- NN O O
treated NN O O
patients NN O O
in NN O O
the NN O O
trials NN O O
and NN O O
none NN O O
in NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
, NN O O
but NN O O
the NN O O
number NN B-Factor B-Factor
is NN I-Factor I-Factor
too NN I-Factor I-Factor
small NN I-Factor I-Factor
to NN O O
allow NN O O
any NN O O
conclusion NN O O
about NN O O
drug NN O O
effect NN O O
on NN O O
suicide NN B-AdverseReaction B-AdverseReaction
The NN O O
increased NN O O
risk NN O O
of NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
thoughts NN I-AdverseReaction I-AdverseReaction
or NN O O
behavior NN O O
with NN O O
AEDs NN B-DrugClass B-DrugClass
was NN O O
observed NN O O
as NN O O
early NN O O
as NN O O
1 NN O O
week NN O O
after NN O O
starting NN O O
treatment NN O O
with NN O O
AEDs NN O O
and NN O O
persisted NN O O
for NN O O
the NN O O
duration NN O O
of NN O O
treatment NN O O
assessed NN O O
. NN O O
Because NN O O
most NN O O
trials NN O O
included NN O O
in NN O O
the NN O O
analysis NN O O
did NN O O
not NN O O
extend NN O O
beyond NN O O
24 NN O O
weeks NN O O
, NN O O
the NN O O
risk NN O O
of NN O O
suicidal NN O O
thoughts NN O O
or NN O O
behavior NN O O
beyond NN O O
24 NN O O
weeks NN O O
could NN O O
not NN O O
be NN O O
assessed NN O O
. NN O O
The NN O O
risk NN B-Factor B-Factor
of NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
thoughts NN I-AdverseReaction I-AdverseReaction
or NN O O
behavior NN O O
was NN O O
generally NN O O
consistent NN O O
among NN O O
drugs NN O O
in NN O O
the NN O O
data NN O O
analyzed NN O O
. NN O O
The NN O O
finding NN O O
of NN O O
increased NN O O
risk NN O O
with NN O O
AEDs NN O O
of NN O O
varying NN O O
mechanism NN O O
of NN O O
action NN O O
and NN O O
across NN O O
a NN O O
range NN O O
of NN O O
indications NN O O
suggests NN O O
that NN O O
the NN O O
risk NN O O
applies NN O O
to NN O O
all NN O O
AEDs NN O O
used NN O O
for NN O O
any NN O O
indication NN O O
. NN O O
The NN O O
risk NN O O
did NN O O
not NN O O
vary NN O O
substantially NN O O
by NN O O
age NN O O
( NN O O
5 NN O O
to NN O O
100 NN O O
years NN O O
) NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
analyzed NN O O
. NN O O
Table NN O O
3 NN O O
shows NN O O
absolute NN O O
and NN O O
relative NN O O
risk NN O O
by NN O O
indication NN O O
for NN O O
all NN O O
evaluated NN O O
AEDs NN O O
. NN O O
Table NN O O
3 NN O O
. NN O O
Risk NN B-Factor B-Factor
of NN O O
Suicidal NN B-AdverseReaction B-AdverseReaction
Thoughts NN I-AdverseReaction I-AdverseReaction
or NN O O
Behaviors NN O O
by NN O O
Indication NN O O
for NN O O
Antiepileptic NN O O
Drugs NN O O
in NN O O
the NN O O
Pooled NN O O
Analysis NN O O
Indication NN O O
Placebo NN O O
Patients NN O O
with NN O O
Events NN O O
per NN O O
1,000 NN O O
Patients NN O O
Drug NN O O
Patients NN O O
with NN O O
Events NN O O
per NN O O
1,000 NN O O
Patients NN O O
Relative NN O O
Risk NN O O
: NN O O
Incidence NN O O
of NN O O
Events NN O O
in NN O O
Drug NN O O
Patients/Incidence NN O O
in NN O O
Placebo NN O O
Patients NN O O
Risk NN O O
Difference NN O O
: NN O O
Additional NN O O
Drug NN O O
Patients NN O O
with NN O O
Events NN O O
per NN O O
1,000 NN O O
Patients NN O O
Epilepsy NN O O
1.0 NN O O
3.4 NN O O
3.5 NN O O
2.4 NN O O
Psychiatric NN O O
5.7 NN O O
8.5 NN O O
1.5 NN O O
2.9 NN O O
Other NN O O
1.0 NN O O
1.8 NN O O
1.9 NN O O
0.9 NN O O
Total NN O O
2.4 NN O O
4.3 NN O O
1.8 NN O O
1.9 NN O O
The NN O O
relative NN O O
risk NN B-Factor B-Factor
for NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
thoughts NN I-AdverseReaction I-AdverseReaction
or NN O O
behavior NN O O
was NN O O
higher NN O O
in NN O O
clinical NN O O
trials NN O O
in NN O O
patients NN O O
with NN O O
epilepsy NN O O
than NN O O
in NN O O
clinical NN O O
trials NN O O
in NN O O
patients NN O O
with NN O O
psychiatric NN O O
or NN O O
other NN O O
conditions NN O O
, NN O O
but NN O O
the NN O O
absolute NN O O
risk NN O O
differences NN O O
were NN O O
similar NN O O
for NN O O
epilepsy NN O O
and NN O O
psychiatric NN O O
indications NN O O
. NN O O
Anyone NN O O
considering NN O O
prescribing NN O O
POTIGA NN O O
or NN O O
any NN O O
other NN O O
AED NN O O
must NN O O
balance NN O O
this NN O O
risk NN O O
with NN O O
the NN O O
risk NN O O
of NN O O
untreated NN O O
illness NN O O
. NN O O
Epilepsy NN O O
and NN O O
many NN O O
other NN O O
illnesses NN O O
for NN O O
which NN O O
AEDs NN O O
are NN O O
prescribed NN O O
are NN O O
themselves NN O O
associated NN O O
with NN O O
morbidity NN O O
and NN O O
mortality NN O O
and NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
suicidal NN O O
thoughts NN O O
and NN O O
behavior NN O O
. NN O O
Should NN O O
suicidal NN O O
thoughts NN O O
and NN O O
behavior NN O O
emerge NN O O
during NN O O
treatment NN O O
, NN O O
the NN O O
prescriber NN O O
needs NN O O
to NN O O
consider NN O O
whether NN O O
the NN O O
emergence NN O O
of NN O O
these NN O O
symptoms NN O O
in NN O O
any NN O O
given NN O O
patient NN O O
may NN O O
be NN O O
related NN O O
to NN O O
the NN O O
illness NN O O
being NN O O
treated NN O O
. NN O O
Patients NN O O
, NN O O
their NN O O
caregivers NN O O
, NN O O
and NN O O
families NN O O
should NN O O
be NN O O
informed NN O O
that NN O O
AEDs NN O O
increase NN O O
the NN O O
risk NN O O
of NN O O
suicidal NN O O
thoughts NN O O
and NN O O
behavior NN O O
and NN O O
should NN O O
be NN O O
advised NN O O
of NN O O
the NN O O
need NN O O
to NN O O
be NN O O
alert NN O O
for NN O O
the NN O O
emergence NN O O
or NN O O
worsening NN O O
of NN O O
the NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
depression NN O O
; NN O O
any NN O O
unusual NN O O
changes NN O O
in NN O O
mood NN O O
or NN O O
behavior NN O O
; NN O O
or NN O O
the NN O O
emergence NN O O
of NN O O
suicidal NN O O
thoughts NN O O
, NN O O
behavior NN O O
, NN O O
or NN O O
thoughts NN O O
about NN O O
self NN O O
- NN O O
harm NN O O
. NN O O
Behaviors NN O O
of NN O O
concern NN O O
should NN O O
be NN O O
reported NN O O
immediately NN O O
to NN O O
healthcare NN O O
providers NN O O
. NN O O
5.8 NN O O
Withdrawal NN O O
Seizures NN O O
As NN O O
with NN O O
all NN O O
AEDs NN O O
, NN O O
when NN O O
POTIGA NN O O
is NN O O
discontinued NN O O
, NN O O
it NN O O
should NN O O
be NN O O
withdrawn NN O O
gradually NN O O
when NN O O
possible NN O O
to NN O O
minimize NN O O
the NN O O
potential NN O O
of NN O O
increased NN O O
seizure NN O O
frequency NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.1 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
dosage NN O O
of NN O O
POTIGA NN O O
should NN O O
be NN O O
reduced NN O O
over NN O O
a NN O O
period NN O O
of NN O O
at NN O O
least NN O O
3 NN O O
weeks NN O O
, NN O O
unless NN O O
safety NN O O
concerns NN O O
require NN O O
abrupt NN O O
withdrawal NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
serious NN O O
adverse NN O O
reactions NN O O
are NN O O
discussed NN O O
below NN O O
and NN O O
also NN O O
elsewhere NN O O
in NN O O
the NN O O
labeling NN O O
: NN O O
* NN O O
Hypocalcemia NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
* NN O O
Serious NN B-Severity B-Severity
Infections NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.6 NN O O
) NN O O
] NN O O
* NN O O
Dermatologic NN B-AdverseReaction B-AdverseReaction
Adverse NN I-AdverseReaction I-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.7 NN O O
) NN O O
] NN O O
* NN O O
Osteonecrosis NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
Jaw NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
* NN O O
Atypical NN O O
Subtrochanteric NN O O
and NN O O
Diaphyseal NN O O
Femoral NN O O
Fractures NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
reported NN O O
with NN O O
Prolia NN O O
in NN O O
patients NN O O
with NN O O
postmenopausal NN O O
osteoporosis NN O O
are NN O O
back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
musculoskeletal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
hypercholesterolemia NN B-AdverseReaction B-AdverseReaction
and NN O O
cystitis NN B-AdverseReaction B-AdverseReaction
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
reported NN O O
with NN O O
Prolia NN O O
in NN O O
men NN O O
with NN O O
osteoporosis NN O O
are NN O O
back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
arthralgia NN B-AdverseReaction B-AdverseReaction
and NN O O
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
The NN O O
most NN O O
common NN O O
( NN O O
per NN O O
patient NN O O
incidence NN O O
>= NN O O
10 NN O O
% NN O O
) NN O O
adverse NN O O
reactions NN O O
reported NN O O
with NN O O
Prolia NN O O
in NN O O
patients NN O O
with NN O O
bone NN O O
loss NN O O
receiving NN O O
androgen NN O O
deprivation NN O O
therapy NN O O
for NN O O
prostate NN O O
cancer NN O O
or NN O O
adjuvant NN O O
aromatase NN O O
inhibitor NN O O
therapy NN O O
for NN O O
breast NN O O
cancer NN O O
are NN O O
arthralgia NN B-AdverseReaction B-AdverseReaction
and NN O O
back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
Pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
and NN O O
musculoskeletal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
have NN O O
also NN O O
been NN O O
reported NN O O
in NN O O
clinical NN O O
trials NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
leading NN O O
to NN O O
discontinuation NN O O
of NN O O
Prolia NN O O
in NN O O
patients NN O O
with NN O O
postmenopausal NN O O
osteoporosis NN O O
are NN O O
back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
and NN O O
constipation NN B-AdverseReaction B-AdverseReaction
The NN O O
Prolia NN O O
Postmarketing NN O O
Active NN O O
Safety NN O O
Surveillance NN O O
Program NN O O
is NN O O
available NN O O
to NN O O
collect NN O O
information NN O O
from NN O O
prescribers NN O O
on NN O O
specific NN O O
adverse NN O O
events NN O O
. NN O O
Please NN O O
see NN O O
www.proliasafety.com NN O O
or NN O O
call NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
772 NN O O
- NN O O
6436 NN O O
for NN O O
more NN O O
information NN O O
about NN O O
this NN O O
program NN O O
. NN O O
EXCERPT NN O O
: NN O O
* NN O O
Postmenopausal NN O O
osteoporosis NN O O
: NN O O
Most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
> NN O O
5 NN O O
% NN O O
and NN O O
more NN O O
common NN O O
than NN O O
placebo NN O O
) NN O O
were NN O O
: NN O O
back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
hypercholesterolemia NN B-AdverseReaction B-AdverseReaction
musculoskeletal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
and NN O O
cystitis NN B-AdverseReaction B-AdverseReaction
Pancreatitis NN B-AdverseReaction B-AdverseReaction
has NN O O
been NN O O
reported NN O O
in NN O O
clinical NN O O
trials NN O O
( NN O O
6.1 NN O O
) NN O O
* NN O O
Male NN O O
Osteoporosis NN O O
: NN O O
Most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
> NN O O
5 NN O O
% NN O O
and NN O O
more NN O O
common NN O O
than NN O O
placebo NN O O
) NN O O
were NN O O
: NN O O
back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
arthralgia NN B-AdverseReaction B-AdverseReaction
and NN O O
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
* NN O O
Bone NN O O
loss NN O O
due NN O O
to NN O O
hormone NN O O
ablation NN O O
for NN O O
cancer NN O O
: NN O O
Most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>= NN O O
10 NN O O
% NN O O
and NN O O
more NN O O
common NN O O
than NN O O
placebo NN O O
) NN O O
were NN O O
: NN O O
arthralgia NN B-AdverseReaction B-AdverseReaction
and NN O O
back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
Pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
and NN O O
musculoskeletal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
have NN O O
also NN O O
been NN O O
reported NN O O
in NN O O
clinical NN O O
trials NN O O
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Amgen NN O O
Inc. NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
77-AMGEN NN O O
( NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
772 NN O O
- NN O O
6436 NN O O
) NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
studies NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
studies NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
studies NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O
Treatment NN O O
of NN O O
Postmenopausal NN O O
Women NN O O
with NN O O
Osteoporosis NN O O
The NN O O
safety NN O O
of NN O O
Prolia NN O O
in NN O O
the NN O O
treatment NN O O
of NN O O
postmenopausal NN O O
osteoporosis NN O O
was NN O O
assessed NN O O
in NN O O
a NN O O
3-year NN O O
, NN O O
randomized NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
, NN O O
multinational NN O O
study NN O O
of NN O O
7808 NN O O
postmenopausal NN O O
women NN O O
aged NN O O
60 NN O O
to NN O O
91 NN O O
years NN O O
. NN O O
A NN O O
total NN O O
of NN O O
3876 NN O O
women NN O O
were NN O O
exposed NN O O
to NN O O
placebo NN O O
and NN O O
3886 NN O O
women NN O O
were NN O O
exposed NN O O
to NN O O
Prolia NN O O
administered NN O O
subcutaneously NN O O
once NN O O
every NN O O
6 NN O O
months NN O O
as NN O O
a NN O O
single NN O O
60 NN O O
mg NN O O
dose NN O O
. NN O O
All NN O O
women NN O O
were NN O O
instructed NN O O
to NN O O
take NN O O
at NN O O
least NN O O
1000 NN O O
mg NN O O
of NN O O
calcium NN O O
and NN O O
400 NN O O
IU NN O O
of NN O O
vitamin NN O O
D NN O O
supplementation NN O O
per NN O O
day NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
all NN O O
- NN O O
cause NN O O
mortality NN B-AdverseReaction B-AdverseReaction
was NN O O
2.3 NN O O
% NN O O
( NN O O
n NN O O
= NN O O
90 NN O O
) NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
and NN O O
1.8 NN O O
% NN O O
( NN O O
n NN O O
= NN O O
70 NN O O
) NN O O
in NN O O
the NN O O
Prolia NN O O
group NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
nonfatal NN O O
serious NN O O
adverse NN O O
events NN O O
was NN O O
24.2 NN O O
% NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
and NN O O
25.0 NN O O
% NN O O
in NN O O
the NN O O
Prolia NN O O
group NN O O
. NN O O
The NN O O
percentage NN O O
of NN O O
patients NN O O
who NN O O
withdrew NN O O
from NN O O
the NN O O
study NN O O
due NN O O
to NN O O
adverse NN O O
events NN O O
was NN O O
2.1 NN O O
% NN O O
and NN O O
2.4 NN O O
% NN O O
for NN O O
the NN O O
placebo NN O O
and NN O O
Prolia NN O O
groups NN O O
, NN O O
respectively NN O O
. NN O O
Adverse NN O O
reactions NN O O
reported NN O O
in NN O O
>= NN O O
2 NN O O
% NN O O
of NN O O
postmenopausal NN O O
women NN O O
with NN O O
osteoporosis NN O O
and NN O O
more NN O O
frequently NN O O
in NN O O
the NN O O
Prolia NN O O
- NN O O
treated NN O O
women NN O O
than NN O O
in NN O O
the NN O O
placebo NN O O
- NN O O
treated NN O O
women NN O O
are NN O O
shown NN O O
in NN O O
the NN O O
table NN O O
below NN O O
. NN O O
Table NN O O
1 NN O O
. NN O O
Adverse NN O O
Reactions NN O O
Occurring NN O O
in NN O O
>= NN O O
2 NN O O
% NN O O
of NN O O
Patients NN O O
with NN O O
Osteoporosis NN O O
and NN O O
More NN O O
Frequently NN O O
than NN O O
in NN O O
Placebo NN O O
- NN O O
treated NN O O
Patients NN O O
SYSTEM NN O O
ORGAN NN O O
CLASS NN O O
Preferred NN O O
Term NN O O
Prolia(N NN O O
= NN O O
3886)n NN O O
( NN O O
% NN O O
) NN O O
Placebo(N NN O O
= NN O O
3876)n NN O O
( NN O O
% NN O O
) NN O O
BLOOD NN O O
AND NN O O
LYMPHATIC NN O O
SYSTEM NN O O
DISORDERS NN O O
Anemia NN B-AdverseReaction B-AdverseReaction
129 NN O O
( NN O O
3.3 NN O O
) NN O O
107 NN O O
( NN O O
2.8 NN O O
) NN O O
CARDIAC NN O O
DISORDERS NN O O
Angina NN B-AdverseReaction B-AdverseReaction
pectoris NN I-AdverseReaction I-AdverseReaction
101 NN O O
( NN O O
2.6 NN O O
) NN O O
87 NN O O
( NN O O
2.2 NN O O
) NN O O
Atrial NN B-AdverseReaction B-AdverseReaction
fibrillation NN I-AdverseReaction I-AdverseReaction
79 NN O O
( NN O O
2.0 NN O O
) NN O O
77 NN O O
( NN O O
2.0 NN O O
) NN O O
EAR NN O O
AND NN O O
LABYRINTH NN O O
DISORDERS NN O O
Vertigo NN B-AdverseReaction B-AdverseReaction
195 NN O O
( NN O O
5.0 NN O O
) NN O O
187 NN O O
( NN O O
4.8 NN O O
) NN O O
GASTROINTESTINAL NN O O
DISORDERS NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
upper NN I-AdverseReaction I-AdverseReaction
129 NN O O
( NN O O
3.3 NN O O
) NN O O
111 NN O O
( NN O O
2.9 NN O O
) NN O O
Flatulence NN B-AdverseReaction B-AdverseReaction
84 NN O O
( NN O O
2.2 NN O O
) NN O O
53 NN O O
( NN O O
1.4 NN O O
) NN O O
Gastroesophageal NN B-AdverseReaction B-AdverseReaction
reflux NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
80 NN O O
( NN O O
2.1 NN O O
) NN O O
66 NN O O
( NN O O
1.7 NN O O
) NN O O
GENERAL NN O O
DISORDERS NN O O
AND NN O O
ADMINISTRATION NN O O
SITE NN O O
CONDITIONS NN O O
Edema NN B-AdverseReaction B-AdverseReaction
peripheral NN I-AdverseReaction I-AdverseReaction
189 NN O O
( NN O O
4.9 NN O O
) NN O O
155 NN O O
( NN O O
4.0 NN O O
) NN O O
Asthenia NN B-AdverseReaction B-AdverseReaction
90 NN O O
( NN O O
2.3 NN O O
) NN O O
73 NN O O
( NN O O
1.9 NN O O
) NN O O
INFECTIONS NN O O
AND NN O O
INFESTATIONS NN O O
Cystitis NN B-AdverseReaction B-AdverseReaction
228 NN O O
( NN O O
5.9 NN O O
) NN O O
225 NN O O
( NN O O
5.8 NN O O
) NN O O
Upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
190 NN O O
( NN O O
4.9 NN O O
) NN O O
167 NN O O
( NN O O
4.3 NN O O
) NN O O
Pneumonia NN B-AdverseReaction B-AdverseReaction
152 NN O O
( NN O O
3.9 NN O O
) NN O O
150 NN O O
( NN O O
3.9 NN O O
) NN O O
Pharyngitis NN B-AdverseReaction B-AdverseReaction
91 NN O O
( NN O O
2.3 NN O O
) NN O O
78 NN O O
( NN O O
2.0 NN O O
) NN O O
Herpes NN B-AdverseReaction B-AdverseReaction
zoster NN I-AdverseReaction I-AdverseReaction
79 NN O O
( NN O O
2.0 NN O O
) NN O O
72 NN O O
( NN O O
1.9 NN O O
) NN O O
METABOLISM NN O O
AND NN O O
NUTRITION NN O O
DISORDERS NN O O
Hypercholesterolemia NN B-AdverseReaction B-AdverseReaction
280 NN O O
( NN O O
7.2 NN O O
) NN O O
236 NN O O
( NN O O
6.1 NN O O
) NN O O
MUSCULOSKELETAL NN O O
AND NN O O
CONNECTIVE NN O O
TISSUE NN O O
DISORDERS NN O O
Back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
1347 NN O O
( NN O O
34.7 NN O O
) NN O O
1340 NN O O
( NN O O
34.6 NN O O
) NN O O
Pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
453 NN O O
( NN O O
11.7 NN O O
) NN O O
430 NN O O
( NN O O
11.1 NN O O
) NN O O
Musculoskeletal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
297 NN O O
( NN O O
7.6 NN O O
) NN O O
291 NN O O
( NN O O
7.5 NN O O
) NN O O
Bone NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
142 NN O O
( NN O O
3.7 NN O O
) NN O O
117 NN O O
( NN O O
3.0 NN O O
) NN O O
Myalgia NN B-AdverseReaction B-AdverseReaction
114 NN O O
( NN O O
2.9 NN O O
) NN O O
94 NN O O
( NN O O
2.4 NN O O
) NN O O
Spinal NN B-AdverseReaction B-AdverseReaction
osteoarthritis NN I-AdverseReaction I-AdverseReaction
82 NN O O
( NN O O
2.1 NN O O
) NN O O
64 NN O O
( NN O O
1.7 NN O O
) NN O O
NERVOUS NN O O
SYSTEM NN O O
DISORDERS NN O O
Sciatica NN B-AdverseReaction B-AdverseReaction
178 NN O O
( NN O O
4.6 NN O O
) NN O O
149 NN O O
( NN O O
3.8 NN O O
) NN O O
PSYCHIATRIC NN O O
DISORDERS NN O O
Insomnia NN B-AdverseReaction B-AdverseReaction
126 NN O O
( NN O O
3.2 NN O O
) NN O O
122 NN O O
( NN O O
3.1 NN O O
) NN O O
SKIN NN O O
AND NN O O
SUBCUTANEOUS NN O O
TISSUE NN O O
DISORDERS NN O O
Rash NN B-AdverseReaction B-AdverseReaction
96 NN O O
( NN O O
2.5 NN O O
) NN O O
79 NN O O
( NN O O
2.0 NN O O
) NN O O
Pruritus NN B-AdverseReaction B-AdverseReaction
87 NN O O
( NN O O
2.2 NN O O
) NN O O
82 NN O O
( NN O O
2.1 NN O O
) NN O O
Hypocalcemia NN B-AdverseReaction B-AdverseReaction
Decreases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
calcium NN I-AdverseReaction I-AdverseReaction
levels NN I-AdverseReaction I-AdverseReaction
to NN O O
less NN O O
than NN O O
8.5 NN O O
mg/dL NN O O
at NN O O
any NN O O
visit NN O O
were NN O O
reported NN O O
in NN O O
0.4 NN O O
% NN O O
women NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
and NN O O
1.7 NN O O
% NN O O
women NN O O
in NN O O
the NN O O
Prolia NN O O
group NN O O
. NN O O
The NN O O
nadir NN O O
in NN O O
serum NN O O
calcium NN O O
level NN O O
occurs NN O O
at NN O O
approximately NN O O
day NN O O
10 NN O O
after NN O O
Prolia NN O O
dosing NN O O
in NN O O
subjects NN O O
with NN O O
normal NN O O
renal NN O O
function NN O O
. NN O O
In NN O O
clinical NN O O
studies NN O O
, NN O O
subjects NN O O
with NN O O
impaired NN O O
renal NN O O
function NN O O
were NN O O
more NN O O
likely NN O O
to NN O O
have NN O O
greater NN O O
reductions NN O O
in NN O O
serum NN O O
calcium NN O O
levels NN O O
compared NN O O
to NN O O
subjects NN O O
with NN O O
normal NN O O
renal NN O O
function NN O O
. NN O O
In NN O O
a NN O O
study NN O O
of NN O O
55 NN O O
subjects NN O O
with NN O O
varying NN O O
degrees NN O O
of NN O O
renal NN O O
function NN O O
, NN O O
serum NN O O
calcium NN O O
levels NN O O
< NN O O
7.5 NN O O
mg/dL NN O O
or NN O O
symptomatic NN B-AdverseReaction B-AdverseReaction
hypocalcemia NN I-AdverseReaction I-AdverseReaction
were NN O O
observed NN O O
in NN O O
5 NN O O
subjects NN O O
. NN O O
These NN O O
included NN O O
no NN O O
subjects NN O O
in NN O O
the NN O O
normal NN O O
renal NN O O
function NN O O
group NN O O
, NN O O
10 NN O O
% NN O O
of NN O O
subjects NN O O
in NN O O
the NN O O
creatinine NN O O
clearance NN O O
50 NN O O
to NN O O
80 NN O O
mL/min NN O O
group NN O O
, NN O O
29 NN O O
% NN O O
of NN O O
subjects NN O O
in NN O O
the NN O O
creatinine NN O O
clearance NN O O
< NN O O
30 NN O O
mL/min NN O O
group NN O O
, NN O O
and NN O O
29 NN O O
% NN O O
of NN O O
subjects NN O O
in NN O O
the NN O O
hemodialysis NN O O
group NN O O
. NN O O
These NN O O
subjects NN O O
did NN O O
not NN O O
receive NN O O
calcium NN O O
and NN O O
vitamin NN O O
D NN O O
supplementation NN O O
. NN O O
In NN O O
a NN O O
study NN O O
of NN O O
4550 NN O O
postmenopausal NN O O
women NN O O
with NN O O
osteoporosis NN O O
, NN O O
the NN O O
mean NN O O
change NN O O
from NN O O
baseline NN O O
in NN O O
serum NN O O
calcium NN O O
level NN O O
10 NN O O
days NN O O
after NN O O
Prolia NN O O
dosing NN O O
was NN O O
-5.5 NN O O
% NN O O
in NN O O
subjects NN O O
with NN O O
creatinine NN O O
clearance NN O O
< NN O O
30 NN O O
mL/min NN O O
vs. NN O O
-3.1 NN O O
% NN O O
in NN O O
subjects NN O O
with NN O O
creatinine NN O O
clearance NN O O
>= NN O O
30 NN O O
mL/min NN O O
. NN O O
Serious NN O O
Infections NN O O
Receptor NN O O
activator NN O O
of NN O O
nuclear NN O O
factor NN O O
kappa NN O O
- NN O O
B NN O O
ligand NN O O
( NN O O
RANKL NN O O
) NN O O
is NN O O
expressed NN O O
on NN O O
activated NN O O
T NN O O
and NN O O
B NN O O
lymphocytes NN O O
and NN O O
in NN O O
lymph NN O O
nodes NN O O
. NN O O
Therefore NN O O
, NN O O
a NN O O
RANKL NN O O
inhibitor NN O O
such NN O O
as NN O O
Prolia NN O O
may NN O O
increase NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
infection NN B-AdverseReaction B-AdverseReaction
In NN O O
the NN O O
clinical NN O O
study NN O O
of NN O O
7808 NN O O
postmenopausal NN O O
women NN O O
with NN O O
osteoporosis NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
infections NN B-AdverseReaction B-AdverseReaction
resulting NN O O
in NN O O
death NN B-AdverseReaction B-AdverseReaction
was NN O O
0.2 NN O O
% NN O O
in NN O O
both NN O O
placebo NN O O
and NN O O
Prolia NN O O
treatment NN O O
groups NN O O
. NN O O
However NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
nonfatal NN O O
serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
was NN O O
3.3 NN O O
% NN O O
in NN O O
the NN O O
placebo NN O O
and NN O O
4.0 NN O O
% NN O O
in NN O O
the NN O O
Prolia NN O O
groups NN O O
. NN O O
Hospitalizations NN O O
due NN O O
to NN O O
serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
abdomen NN I-AdverseReaction I-AdverseReaction
( NN O O
0.7 NN O O
% NN O O
placebo NN O O
vs. NN O O
0.9 NN O O
% NN O O
Prolia NN O O
) NN O O
, NN O O
urinary NN O O
tract NN O O
( NN O O
0.5 NN O O
% NN O O
placebo NN O O
vs. NN O O
0.7 NN O O
% NN O O
Prolia NN O O
) NN O O
, NN O O
and NN O O
ear NN O O
( NN O O
0.0 NN O O
% NN O O
placebo NN O O
vs. NN O O
0.1 NN O O
% NN O O
Prolia NN O O
) NN O O
were NN O O
reported NN O O
. NN O O
Endocarditis NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
no NN O O
placebo NN O O
patients NN O O
and NN O O
3 NN O O
patients NN O O
receiving NN O O
Prolia NN O O
. NN O O
Skin NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
including NN O O
erysipelas NN B-AdverseReaction B-AdverseReaction
and NN O O
cellulitis NN B-AdverseReaction B-AdverseReaction
leading NN O O
to NN O O
hospitalization NN O O
were NN O O
reported NN O O
more NN O O
frequently NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
Prolia NN O O
( NN O O
< NN O O
0.1 NN O O
% NN O O
placebo NN O O
vs. NN O O
0.4 NN O O
% NN O O
Prolia NN O O
) NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
opportunistic NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
was NN O O
similar NN O O
to NN O O
that NN O O
reported NN O O
with NN O O
placebo NN O O
. NN O O
Dermatologic NN O O
Reactions NN O O
A NN O O
significantly NN O O
higher NN O O
number NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
Prolia NN O O
developed NN O O
epidermal NN O O
and NN O O
dermal NN B-AdverseReaction B-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
( NN O O
such NN O O
as NN O O
dermatitis NN B-AdverseReaction B-AdverseReaction
eczema NN B-AdverseReaction B-AdverseReaction
and NN O O
rashes NN B-AdverseReaction B-AdverseReaction
with NN O O
these NN O O
events NN O O
reported NN O O
in NN O O
8.2 NN O O
% NN O O
of NN O O
the NN O O
placebo NN O O
and NN O O
10.8 NN O O
% NN O O
of NN O O
the NN O O
Prolia NN O O
groups NN O O
( NN O O
p NN O O
< NN O O
0.0001 NN O O
) NN O O
. NN O O
Most NN O O
of NN O O
these NN O O
events NN O O
were NN O O
not NN O O
specific NN O O
to NN O O
the NN O O
injection NN O O
site NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.7 NN O O
) NN O O
] NN O O
. NN O O
Osteonecrosis NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
Jaw NN I-AdverseReaction I-AdverseReaction
ONJ NN B-AdverseReaction B-AdverseReaction
has NN O O
been NN O O
reported NN O O
in NN O O
the NN O O
osteoporosis NN O O
clinical NN O O
trial NN O O
program NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
Prolia NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
. NN O O
Atypical NN O O
Subtrochanteric NN O O
and NN O O
Diaphyseal NN O O
Fractures NN O O
In NN O O
the NN O O
osteoporosis NN O O
clinical NN O O
trial NN O O
program NN O O
, NN O O
atypical NN B-AdverseReaction B-AdverseReaction
femoral NN I-AdverseReaction I-AdverseReaction
fractures NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
Prolia NN O O
. NN O O
The NN O O
duration NN O O
of NN O O
Prolia NN O O
exposure NN O O
to NN O O
time NN O O
of NN O O
atypical NN B-AdverseReaction B-AdverseReaction
femoral NN I-AdverseReaction I-AdverseReaction
fracture NN I-AdverseReaction I-AdverseReaction
diagnosis NN O O
was NN O O
as NN O O
early NN O O
as NN O O
21/2 NN O O
years NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
. NN O O
Pancreatitis NN O O
Pancreatitis NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
4 NN O O
patients NN O O
( NN O O
0.1 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
placebo NN O O
and NN O O
8 NN O O
patients NN O O
( NN O O
0.2 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
Prolia NN O O
groups NN O O
. NN O O
Of NN O O
these NN O O
reports NN O O
, NN O O
1 NN O O
patient NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
and NN O O
all NN O O
8 NN O O
patients NN O O
in NN O O
the NN O O
Prolia NN O O
group NN O O
had NN O O
serious NN O O
events NN O O
, NN O O
including NN O O
one NN O O
death NN B-AdverseReaction B-AdverseReaction
in NN O O
the NN O O
Prolia NN O O
group NN O O
. NN O O
Several NN O O
patients NN O O
had NN O O
a NN O O
prior NN O O
history NN O O
of NN O O
pancreatitis NN O O
. NN O O
The NN O O
time NN O O
from NN O O
product NN O O
administration NN O O
to NN O O
event NN O O
occurrence NN O O
was NN O O
variable NN O O
. NN O O
New NN O O
Malignancies NN O O
The NN O O
overall NN O O
incidence NN O O
of NN O O
new NN O O
malignancies NN B-AdverseReaction B-AdverseReaction
was NN O O
4.3 NN O O
% NN O O
in NN O O
the NN O O
placebo NN O O
and NN O O
4.8 NN O O
% NN O O
in NN O O
the NN O O
Prolia NN O O
groups NN O O
. NN O O
New NN O O
malignancies NN O O
related NN O O
to NN O O
the NN O O
breast NN O O
( NN O O
0.7 NN O O
% NN O O
placebo NN O O
vs. NN O O
0.9 NN O O
% NN O O
Prolia NN O O
) NN O O
, NN O O
reproductive NN O O
system NN O O
( NN O O
0.2 NN O O
% NN O O
placebo NN O O
vs. NN O O
0.5 NN O O
% NN O O
Prolia NN O O
) NN O O
, NN O O
and NN O O
gastrointestinal NN O O
system NN O O
( NN O O
0.6 NN O O
% NN O O
placebo NN O O
vs. NN O O
0.9 NN O O
% NN O O
Prolia NN O O
) NN O O
were NN O O
reported NN O O
. NN O O
A NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
has NN O O
not NN O O
been NN O O
established NN O O
. NN O O
Treatment NN O O
to NN O O
Increase NN O O
Bone NN O O
Mass NN O O
in NN O O
Men NN O O
with NN O O
Osteoporosis NN O O
The NN O O
safety NN O O
of NN O O
Prolia NN O O
in NN O O
the NN O O
treatment NN O O
of NN O O
men NN O O
with NN O O
osteoporosis NN O O
was NN O O
assessed NN O O
in NN O O
a NN O O
1-year NN O O
randomized NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
study NN O O
. NN O O
A NN O O
total NN O O
of NN O O
120 NN O O
men NN O O
were NN O O
exposed NN O O
to NN O O
placebo NN O O
and NN O O
120 NN O O
men NN O O
were NN O O
exposed NN O O
to NN O O
Prolia NN O O
administered NN O O
subcutaneously NN O O
once NN O O
every NN O O
6 NN O O
months NN O O
as NN O O
a NN O O
single NN O O
60 NN O O
mg NN O O
dose NN O O
. NN O O
All NN O O
men NN O O
were NN O O
instructed NN O O
to NN O O
take NN O O
at NN O O
least NN O O
1000 NN O O
mg NN O O
of NN O O
calcium NN O O
and NN O O
800 NN O O
IU NN O O
of NN O O
vitamin NN O O
D NN O O
supplementation NN O O
per NN O O
day NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
all NN O O
- NN O O
cause NN O O
mortality NN B-AdverseReaction B-AdverseReaction
was NN O O
0.8 NN O O
% NN O O
( NN O O
n NN O O
= NN O O
1 NN O O
) NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
and NN O O
0.8 NN O O
% NN O O
( NN O O
n NN O O
= NN O O
1 NN O O
) NN O O
in NN O O
the NN O O
Prolia NN O O
group NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
nonfatal NN O O
serious NN O O
adverse NN O O
events NN O O
was NN O O
7.5 NN O O
% NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
and NN O O
8.3 NN O O
% NN O O
in NN O O
the NN O O
Prolia NN O O
group NN O O
. NN O O
The NN O O
percentage NN O O
of NN O O
patients NN O O
who NN O O
withdrew NN O O
from NN O O
the NN O O
study NN O O
due NN O O
to NN O O
adverse NN O O
events NN O O
was NN O O
0 NN O O
% NN O O
and NN O O
2.5 NN O O
% NN O O
for NN O O
the NN O O
placebo NN O O
and NN O O
Prolia NN O O
groups NN O O
, NN O O
respectively NN O O
. NN O O
Adverse NN O O
reactions NN O O
reported NN O O
in NN O O
>= NN O O
5 NN O O
% NN O O
of NN O O
men NN O O
with NN O O
osteoporosis NN O O
and NN O O
more NN O O
frequently NN O O
with NN O O
Prolia NN O O
than NN O O
in NN O O
the NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
were NN O O
: NN O O
back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
( NN O O
6.7 NN O O
% NN O O
placebo NN O O
vs. NN O O
8.3 NN O O
% NN O O
Prolia NN O O
) NN O O
, NN O O
arthralgia NN B-AdverseReaction B-AdverseReaction
( NN O O
5.8 NN O O
% NN O O
placebo NN O O
vs. NN O O
6.7 NN O O
% NN O O
Prolia NN O O
) NN O O
, NN O O
and NN O O
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
( NN O O
5.8 NN O O
% NN O O
placebo NN O O
vs. NN O O
6.7 NN O O
% NN O O
Prolia NN O O
) NN O O
. NN O O
Serious NN O O
Infections NN O O
S NN B-Severity B-Severity
erious NN I-Severity I-Severity
infection NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
1 NN O O
patient NN O O
( NN O O
0.8 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
and NN O O
no NN B-Negation B-Negation
patients NN O O
in NN O O
the NN O O
Prolia NN O O
group NN O O
. NN O O
Dermatologic NN O O
Reactions NN O O
Epidermal NN O O
and NN O O
dermal NN B-AdverseReaction B-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
( NN O O
such NN O O
as NN O O
dermatitis NN B-AdverseReaction B-AdverseReaction
eczema NN B-AdverseReaction B-AdverseReaction
and NN O O
rashes NN B-AdverseReaction B-AdverseReaction
were NN O O
reported NN O O
in NN O O
4 NN O O
patients NN O O
( NN O O
3.3 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
and NN O O
5 NN O O
patients NN O O
( NN O O
4.2 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
Prolia NN O O
group NN O O
. NN O O
Osteonecrosis NN O O
of NN O O
the NN O O
Jaw NN O O
No NN B-Negation B-Negation
cases NN O O
of NN O O
ONJ NN B-AdverseReaction B-AdverseReaction
were NN O O
reported NN O O
. NN O O
Pancreatitis NN O O
Pancreatitis NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
1 NN O O
patient NN O O
( NN O O
0.8 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
and NN O O
1 NN O O
patient NN O O
( NN O O
0.8 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
Prolia NN O O
group NN O O
. NN O O
New NN O O
Malignancies NN O O
New NN O O
malignancies NN B-AdverseReaction B-AdverseReaction
were NN O O
reported NN O O
in NN O O
no NN O O
patients NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
and NN O O
4 NN O O
( NN O O
3.3 NN O O
% NN O O
) NN O O
patients NN O O
( NN O O
3 NN O O
prostate NN B-AdverseReaction B-AdverseReaction
cancers NN I-AdverseReaction I-AdverseReaction
1 NN O O
basal NN B-AdverseReaction B-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
carcinoma NN I-AdverseReaction I-AdverseReaction
in NN O O
the NN O O
Prolia NN O O
group NN O O
. NN O O
Treatment NN O O
of NN O O
Bone NN O O
Loss NN O O
in NN O O
Patients NN O O
Receiving NN O O
Androgen NN O O
Deprivation NN O O
Therapy NN O O
for NN O O
Prostate NN O O
Cancer NN O O
or NN O O
Adjuvant NN O O
Aromatase NN O O
Inhibitor NN O O
Therapy NN O O
for NN O O
Breast NN O O
Cancer NN O O
The NN O O
safety NN O O
of NN O O
Prolia NN O O
in NN O O
the NN O O
treatment NN O O
of NN O O
bone NN O O
loss NN O O
in NN O O
men NN O O
with NN O O
nonmetastatic NN O O
prostate NN O O
cancer NN O O
receiving NN O O
androgen NN O O
deprivation NN O O
therapy NN O O
( NN O O
ADT NN O O
) NN O O
was NN O O
assessed NN O O
in NN O O
a NN O O
3-year NN O O
, NN O O
randomized NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
, NN O O
multinational NN O O
study NN O O
of NN O O
1468 NN O O
men NN O O
aged NN O O
48 NN O O
to NN O O
97 NN O O
years NN O O
. NN O O
A NN O O
total NN O O
of NN O O
725 NN O O
men NN O O
were NN O O
exposed NN O O
to NN O O
placebo NN O O
and NN O O
731 NN O O
men NN O O
were NN O O
exposed NN O O
to NN O O
Prolia NN O O
administered NN O O
once NN O O
every NN O O
6 NN O O
months NN O O
as NN O O
a NN O O
single NN O O
60 NN O O
mg NN O O
subcutaneous NN O O
dose NN O O
. NN O O
All NN O O
men NN O O
were NN O O
instructed NN O O
to NN O O
take NN O O
at NN O O
least NN O O
1000 NN O O
mg NN O O
of NN O O
calcium NN O O
and NN O O
400 NN O O
IU NN O O
of NN O O
vitamin NN O O
D NN O O
supplementation NN O O
per NN O O
day NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
serious NN O O
adverse NN O O
events NN O O
was NN O O
30.6 NN O O
% NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
and NN O O
34.6 NN O O
% NN O O
in NN O O
the NN O O
Prolia NN O O
group NN O O
. NN O O
The NN O O
percentage NN O O
of NN O O
patients NN O O
who NN O O
withdrew NN O O
from NN O O
the NN O O
study NN O O
due NN O O
to NN O O
adverse NN O O
events NN O O
was NN O O
6.1 NN O O
% NN O O
and NN O O
7.0 NN O O
% NN O O
for NN O O
the NN O O
placebo NN O O
and NN O O
Prolia NN O O
groups NN O O
, NN O O
respectively NN O O
. NN O O
The NN O O
safety NN O O
of NN O O
Prolia NN O O
in NN O O
the NN O O
treatment NN O O
of NN O O
bone NN O O
loss NN O O
in NN O O
women NN O O
with NN O O
nonmetastatic NN O O
breast NN O O
cancer NN O O
receiving NN O O
aromatase NN O O
inhibitor NN O O
( NN O O
AI NN O O
) NN O O
therapy NN O O
was NN O O
assessed NN O O
in NN O O
a NN O O
2-year NN O O
, NN O O
randomized NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
, NN O O
multinational NN O O
study NN O O
of NN O O
252 NN O O
postmenopausal NN O O
women NN O O
aged NN O O
35 NN O O
to NN O O
84 NN O O
years NN O O
. NN O O
A NN O O
total NN O O
of NN O O
120 NN O O
women NN O O
were NN O O
exposed NN O O
to NN O O
placebo NN O O
and NN O O
129 NN O O
women NN O O
were NN O O
exposed NN O O
to NN O O
Prolia NN O O
administered NN O O
once NN O O
every NN O O
6 NN O O
months NN O O
as NN O O
a NN O O
single NN O O
60 NN O O
mg NN O O
subcutaneous NN O O
dose NN O O
. NN O O
All NN O O
women NN O O
were NN O O
instructed NN O O
to NN O O
take NN O O
at NN O O
least NN O O
1000 NN O O
mg NN O O
of NN O O
calcium NN O O
and NN O O
400 NN O O
IU NN O O
of NN O O
vitamin NN O O
D NN O O
supplementation NN O O
per NN O O
day NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
serious NN O O
adverse NN O O
events NN O O
was NN O O
9.2 NN O O
% NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
and NN O O
14.7 NN O O
% NN O O
in NN O O
the NN O O
Prolia NN O O
group NN O O
. NN O O
The NN O O
percentage NN O O
of NN O O
patients NN O O
who NN O O
withdrew NN O O
from NN O O
the NN O O
study NN O O
due NN O O
to NN O O
adverse NN O O
events NN O O
was NN O O
4.2 NN O O
% NN O O
and NN O O
0.8 NN O O
% NN O O
for NN O O
the NN O O
placebo NN O O
and NN O O
Prolia NN O O
groups NN O O
, NN O O
respectively NN O O
. NN O O
Adverse NN O O
reactions NN O O
reported NN O O
in NN O O
>= NN O O
10 NN O O
% NN O O
of NN O O
Prolia NN O O
- NN O O
treated NN O O
patients NN O O
receiving NN O O
ADT NN O O
for NN O O
prostate NN O O
cancer NN O O
or NN O O
adjuvant NN O O
AI NN O O
therapy NN O O
for NN O O
breast NN O O
cancer NN O O
, NN O O
and NN O O
more NN O O
frequently NN O O
than NN O O
in NN O O
the NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
were NN O O
: NN O O
arthralgia NN B-AdverseReaction B-AdverseReaction
( NN O O
13.0 NN O O
% NN O O
placebo NN O O
vs. NN O O
14.3 NN O O
% NN O O
Prolia NN O O
) NN O O
and NN O O
back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
( NN O O
10.5 NN O O
% NN O O
placebo NN O O
vs. NN O O
11.5 NN O O
% NN O O
Prolia NN O O
) NN O O
. NN O O
Pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
( NN O O
7.7 NN O O
% NN O O
placebo NN O O
vs. NN O O
9.9 NN O O
% NN O O
Prolia NN O O
) NN O O
and NN O O
musculoskeletal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
( NN O O
3.8 NN O O
% NN O O
placebo NN O O
vs. NN O O
6.0 NN O O
% NN O O
Prolia NN O O
) NN O O
have NN O O
also NN O O
been NN O O
reported NN O O
in NN O O
clinical NN O O
trials NN O O
. NN O O
Additionally NN O O
in NN O O
Prolia NN O O
- NN O O
treated NN O O
men NN O O
with NN O O
nonmetastatic NN O O
prostate NN O O
cancer NN O O
receiving NN O O
ADT NN O O
, NN O O
a NN O O
greater NN O O
incidence NN O O
of NN O O
cataracts NN B-AdverseReaction B-AdverseReaction
was NN O O
observed NN O O
( NN O O
1.2 NN O O
% NN O O
placebo NN O O
vs. NN O O
4.7 NN O O
% NN O O
Prolia NN O O
) NN O O
. NN O O
Hypocalcemia NN B-AdverseReaction B-AdverseReaction
( NN O O
serum NN O O
calcium NN O O
< NN O O
8.4 NN O O
mg/dL NN O O
) NN O O
was NN O O
reported NN O O
only NN O O
in NN O O
Prolia NN O O
- NN O O
treated NN O O
patients NN O O
( NN O O
2.4 NN O O
% NN O O
vs. NN O O
0 NN O O
% NN O O
) NN O O
at NN O O
the NN O O
month NN O O
1 NN O O
visit NN O O
. NN O O
6.2 NN O O
Postmarketing NN O O
Experience NN O O
Because NN O O
postmarketing NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
identified NN O O
during NN O O
post NN O O
approval NN O O
use NN O O
of NN O O
Prolia NN O O
: NN O O
* NN O O
Drug NN O O
- NN O O
related NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
anaphylaxis NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
urticaria NN B-AdverseReaction B-AdverseReaction
facial NN B-AdverseReaction B-AdverseReaction
swelling NN I-AdverseReaction I-AdverseReaction
and NN O O
erythema NN B-AdverseReaction B-AdverseReaction
* NN O O
Hypocalcemia NN B-AdverseReaction B-AdverseReaction
severe NN B-Severity B-Severity
symptomatic NN B-AdverseReaction B-AdverseReaction
hypocalcemia NN I-AdverseReaction I-AdverseReaction
* NN O O
Musculoskeletal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
including NN O O
severe NN B-Severity B-Severity
cases NN O O
* NN O O
Parathyroid NN O O
Hormone NN O O
( NN O O
PTH NN O O
) NN O O
: NN O O
Marked NN B-Severity B-Severity
elevation NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
PTH NN I-AdverseReaction I-AdverseReaction
in NN O O
patients NN O O
with NN O O
severe NN O O
renal NN O O
impairment NN O O
( NN O O
creatinine NN O O
clearance NN O O
< NN O O
30 NN O O
mL/min NN O O
) NN O O
or NN O O
receiving NN O O
dialysis NN O O
. NN O O
6.3 NN O O
Immunogenicity NN O O
Denosumab NN O O
is NN O O
a NN O O
human NN O O
monoclonal NN O O
antibody NN O O
. NN O O
As NN O O
with NN O O
all NN O O
therapeutic NN O O
proteins NN O O
, NN O O
there NN O O
is NN O O
potential NN O O
for NN O O
immunogenicity NN O O
. NN O O
Using NN O O
an NN O O
electrochemiluminescent NN O O
bridging NN O O
immunoassay NN O O
, NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
( NN O O
55 NN O O
out NN O O
of NN O O
8113 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
Prolia NN O O
for NN O O
up NN O O
to NN O O
5 NN O O
years NN O O
tested NN O O
positive NN O O
for NN O O
binding NN O O
antibodies NN O O
( NN O O
including NN O O
pre NN O O
- NN O O
existing NN O O
, NN O O
transient NN O O
, NN O O
and NN O O
developing NN O O
antibodies NN O O
) NN O O
. NN O O
None NN O O
of NN O O
the NN O O
patients NN O O
tested NN O O
positive NN O O
for NN O O
neutralizing NN O O
antibodies NN O O
, NN O O
as NN O O
was NN O O
assessed NN O O
using NN O O
a NN O O
chemiluminescent NN O O
cell NN O O
- NN O O
based NN O O
in NN O O
vitro NN O O
biological NN O O
assay NN O O
. NN O O
No NN B-Negation B-Negation
evidence NN O O
of NN O O
altered NN O O
pharmacokinetic NN O O
profile NN O O
, NN O O
toxicity NN B-AdverseReaction B-AdverseReaction
profile NN O O
, NN O O
or NN O O
clinical NN O O
response NN O O
was NN O O
associated NN O O
with NN O O
binding NN O O
antibody NN O O
development NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
antibody NN O O
formation NN O O
is NN O O
highly NN O O
dependent NN O O
on NN O O
the NN O O
sensitivity NN O O
and NN O O
specificity NN O O
of NN O O
the NN O O
assay NN O O
. NN O O
Additionally NN O O
, NN O O
the NN O O
observed NN O O
incidence NN O O
of NN O O
a NN O O
positive NN O O
antibody NN O O
( NN O O
including NN O O
neutralizing NN O O
antibody NN O O
) NN O O
test NN O O
result NN O O
may NN O O
be NN O O
influenced NN O O
by NN O O
several NN O O
factors NN O O
, NN O O
including NN O O
assay NN O O
methodology NN O O
, NN O O
sample NN O O
handling NN O O
, NN O O
timing NN O O
of NN O O
sample NN O O
collection NN O O
, NN O O
concomitant NN O O
medications NN O O
, NN O O
and NN O O
underlying NN O O
disease NN O O
. NN O O
For NN O O
these NN O O
reasons NN O O
, NN O O
comparison NN O O
of NN O O
antibodies NN O O
to NN O O
denosumab NN O O
with NN O O
the NN O O
incidence NN O O
of NN O O
antibodies NN O O
to NN O O
other NN O O
products NN O O
may NN O O
be NN O O
misleading NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Same NN O O
Active NN O O
Ingredient NN O O
: NN O O
Patients NN O O
receiving NN O O
Prolia NN O O
should NN O O
not NN O O
receive NN O O
XGEVA NN O O
( NN O O
r NN O O
) NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
including NN O O
anaphylactic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
may NN O O
occur NN O O
. NN O O
Discontinue NN O O
permanently NN O O
if NN O O
a NN O O
clinically NN O O
significant NN O O
reaction NN O O
occurs NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Hypocalcemia NN B-AdverseReaction B-AdverseReaction
Must NN O O
be NN O O
corrected NN O O
before NN O O
initiating NN O O
Prolia NN O O
. NN O O
May NN O O
worsen NN O O
, NN O O
especially NN O O
in NN O O
patients NN O O
with NN O O
renal NN O O
impairment NN O O
. NN O O
Adequately NN O O
supplement NN O O
patients NN O O
with NN O O
calcium NN O O
and NN O O
vitamin NN O O
D NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Osteonecrosis NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
jaw NN I-AdverseReaction I-AdverseReaction
Has NN O O
been NN O O
reported NN O O
with NN O O
Prolia NN O O
. NN O O
Monitor NN O O
for NN O O
symptoms NN O O
( NN O O
5.4 NN O O
) NN O O
* NN O O
Atypical NN B-AdverseReaction B-AdverseReaction
femoral NN I-AdverseReaction I-AdverseReaction
fractures NN I-AdverseReaction I-AdverseReaction
Have NN O O
been NN O O
reported NN O O
. NN O O
Evaluate NN O O
patients NN O O
with NN O O
thigh NN O O
or NN O O
groin NN O O
pain NN O O
to NN O O
rule NN O O
out NN O O
a NN O O
femoral NN O O
fracture NN O O
( NN O O
5.5 NN O O
) NN O O
* NN O O
Serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
including NN O O
skin NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
May NN O O
occur NN O O
, NN O O
including NN O O
those NN O O
leading NN O O
to NN O O
hospitalization NN O O
. NN O O
Advise NN O O
patients NN O O
to NN O O
seek NN O O
prompt NN O O
medical NN O O
attention NN O O
if NN O O
they NN O O
develop NN O O
signs NN O O
or NN O O
symptoms NN O O
of NN O O
infection NN O O
, NN O O
including NN O O
cellulitis NN O O
( NN O O
5.6 NN O O
) NN O O
* NN O O
Dermatologic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
Dermatitis NN B-AdverseReaction B-AdverseReaction
rashes NN B-AdverseReaction B-AdverseReaction
and NN O O
eczema NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
. NN O O
Consider NN O O
discontinuing NN O O
Prolia NN O O
if NN O O
severe NN O O
symptoms NN O O
develop NN O O
( NN O O
5.7 NN O O
) NN O O
* NN O O
Severe NN B-Severity B-Severity
Bone NN O O
, NN O O
Joint NN O O
, NN O O
Muscle NN B-AdverseReaction B-AdverseReaction
Pain NN I-AdverseReaction I-AdverseReaction
may NN O O
occur NN O O
. NN O O
Discontinue NN O O
use NN O O
if NN O O
severe NN O O
symptoms NN O O
develop NN O O
( NN O O
5.8 NN O O
) NN O O
* NN O O
Suppression NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
bone NN I-AdverseReaction I-AdverseReaction
turnover NN I-AdverseReaction I-AdverseReaction
Significant NN O O
suppression NN O O
has NN O O
been NN O O
demonstrated NN O O
. NN O O
Monitor NN O O
for NN O O
consequences NN O O
of NN O O
bone NN O O
oversuppression NN O O
( NN O O
5.9 NN O O
) NN O O
5.1 NN O O
Drug NN O O
Products NN O O
with NN O O
Same NN O O
Active NN O O
Ingredient NN O O
Prolia NN O O
contains NN O O
the NN O O
same NN O O
active NN O O
ingredient NN O O
( NN O O
denosumab NN O O
) NN O O
found NN O O
in NN O O
Xgeva NN O O
. NN O O
Patients NN O O
receiving NN O O
Prolia NN O O
should NN O O
not NN O O
receive NN O O
Xgeva NN O O
. NN O O
5.2 NN O O
Hypersensitivity NN O O
Clinically NN O O
significant NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
including NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
has NN O O
been NN O O
reported NN O O
with NN O O
Prolia NN O O
. NN O O
Symptoms NN O O
have NN O O
included NN O O
hypotension NN B-AdverseReaction B-AdverseReaction
dyspnea NN B-AdverseReaction B-AdverseReaction
throat NN B-AdverseReaction B-AdverseReaction
tightness NN I-AdverseReaction I-AdverseReaction
facial NN O O
and NN O O
upper NN B-AdverseReaction B-AdverseReaction
airway NN I-AdverseReaction I-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
pruritus NN B-AdverseReaction B-AdverseReaction
and NN O O
urticaria NN B-AdverseReaction B-AdverseReaction
If NN O O
an NN O O
anaphylactic NN O O
or NN O O
other NN O O
clinically NN O O
significant NN O O
allergic NN O O
reaction NN O O
occurs NN O O
, NN O O
initiate NN O O
appropriate NN O O
therapy NN O O
and NN O O
discontinue NN O O
further NN O O
use NN O O
of NN O O
Prolia NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4.3 NN O O
) NN O O
, NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.2 NN O O
) NN O O
] NN O O
. NN O O
5.3 NN O O
Hypocalcemia NN O O
and NN O O
Mineral NN O O
Metabolism NN O O
Hypocalcemia NN O O
may NN B-Factor B-Factor
be NN O O
exacerbated NN O O
by NN O O
the NN O O
use NN O O
of NN O O
Prolia NN O O
. NN O O
Pre NN O O
- NN O O
existing NN O O
hypocalcemia NN O O
must NN O O
be NN O O
corrected NN O O
prior NN O O
to NN O O
initiating NN O O
therapy NN O O
with NN O O
Prolia NN O O
. NN O O
In NN O O
patients NN O O
predisposed NN O O
to NN O O
hypocalcemia NN O O
and NN O O
disturbances NN O O
of NN O O
mineral NN O O
metabolism NN O O
( NN O O
e.g. NN O O
history NN O O
of NN O O
hypoparathyroidism NN O O
, NN O O
thyroid NN O O
surgery NN O O
, NN O O
parathyroid NN O O
surgery NN O O
, NN O O
malabsorption NN O O
syndromes NN O O
, NN O O
excision NN O O
of NN O O
small NN O O
intestine NN O O
, NN O O
severe NN O O
renal NN O O
impairment NN O O
[ NN O O
creatinine NN O O
clearance NN O O
< NN O O
30 NN O O
mL/min NN O O
] NN O O
or NN O O
receiving NN O O
dialysis NN O O
) NN O O
, NN O O
clinical NN O O
monitoring NN O O
of NN O O
calcium NN O O
and NN O O
mineral NN O O
levels NN O O
( NN O O
phosphorus NN O O
and NN O O
magnesium NN O O
) NN O O
is NN O O
highly NN O O
recommended NN O O
within NN O O
14 NN O O
days NN O O
of NN O O
Prolia NN O O
injection NN O O
. NN O O
In NN O O
some NN O O
postmarketing NN O O
cases NN O O
, NN O O
hypocalcemia NN B-AdverseReaction B-AdverseReaction
persisted NN O O
for NN O O
weeks NN O O
or NN O O
months NN O O
and NN O O
required NN O O
frequent NN O O
monitoring NN O O
and NN O O
intravenous NN O O
and/or NN O O
oral NN O O
calcium NN O O
replacement NN O O
, NN O O
with NN O O
or NN O O
without NN O O
vitamin NN O O
D. NN O O
Hypocalcemia NN B-AdverseReaction B-AdverseReaction
following NN O O
Prolia NN O O
administration NN O O
is NN O O
a NN O O
significant NN O O
risk NN O O
in NN O O
patients NN O O
with NN O O
severe NN O O
renal NN O O
impairment NN O O
[ NN O O
creatinine NN O O
clearance NN O O
< NN O O
30 NN O O
mL/min NN O O
] NN O O
or NN O O
receiving NN O O
dialysis NN O O
. NN O O
These NN O O
patients NN O O
may NN B-Factor B-Factor
also NN O O
develop NN O O
marked NN B-Severity B-Severity
elevations NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
parathyroid NN I-AdverseReaction I-AdverseReaction
hormone NN I-AdverseReaction I-AdverseReaction
( NN O O
PTH NN O O
) NN O O
. NN O O
Instruct NN O O
all NN O O
patients NN O O
with NN O O
severe NN O O
renal NN O O
impairment NN O O
, NN O O
including NN O O
those NN O O
receiving NN O O
dialysis NN O O
, NN O O
about NN O O
the NN O O
symptoms NN O O
of NN O O
hypocalcemia NN O O
and NN O O
the NN O O
importance NN O O
of NN O O
maintaining NN O O
calcium NN O O
levels NN O O
with NN O O
adequate NN O O
calcium NN O O
and NN O O
vitamin NN O O
D NN O O
supplementation NN O O
. NN O O
Adequately NN O O
supplement NN O O
all NN O O
patients NN O O
with NN O O
calcium NN O O
and NN O O
vitamin NN O O
D NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.1 NN O O
) NN O O
, NN O O
Contraindications NN O O
( NN O O
4.1 NN O O
) NN O O
, NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
, NN O O
and NN O O
Patient NN O O
Counseling NN O O
Information NN O O
( NN O O
17.3 NN O O
) NN O O
] NN O O
. NN O O
5.4 NN O O
Osteonecrosis NN O O
of NN O O
the NN O O
Jaw NN O O
Osteonecrosis NN O O
of NN O O
the NN O O
jaw NN O O
( NN O O
ONJ NN O O
) NN O O
, NN O O
which NN O O
can NN O O
occur NN O O
spontaneously NN O O
, NN O O
is NN O O
generally NN O O
associated NN O O
with NN O O
tooth NN O O
extraction NN O O
and/or NN O O
local NN O O
infection NN O O
with NN O O
delayed NN O O
healing NN O O
. NN O O
ONJ NN B-AdverseReaction B-AdverseReaction
has NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
receiving NN O O
denosumab NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
A NN O O
routine NN O O
oral NN O O
exam NN O O
should NN O O
be NN O O
performed NN O O
by NN O O
the NN O O
prescriber NN O O
prior NN O O
to NN O O
initiation NN O O
of NN O O
Prolia NN O O
treatment NN O O
. NN O O
A NN O O
dental NN O O
examination NN O O
with NN O O
appropriate NN O O
preventive NN O O
dentistry NN O O
is NN O O
recommended NN O O
prior NN O O
to NN O O
treatment NN O O
with NN O O
Prolia NN O O
in NN O O
patients NN O O
with NN O O
risk NN O O
factors NN O O
for NN O O
ONJ NN O O
such NN O O
as NN O O
invasive NN O O
dental NN O O
procedures NN O O
( NN O O
e.g. NN O O
tooth NN O O
extraction NN O O
, NN O O
dental NN O O
implants NN O O
, NN O O
oral NN O O
surgery NN O O
) NN O O
, NN O O
diagnosis NN O O
of NN O O
cancer NN O O
, NN O O
concomitant NN O O
therapies NN O O
( NN O O
e.g. NN O O
chemotherapy NN O O
, NN O O
corticosteroids NN O O
, NN O O
angiogenesis NN O O
inhibitors NN O O
) NN O O
, NN O O
poor NN O O
oral NN O O
hygiene NN O O
, NN O O
and NN O O
co NN O O
- NN O O
morbid NN O O
disorders NN O O
( NN O O
e.g. NN O O
periodontal NN O O
and/or NN O O
other NN O O
pre NN O O
- NN O O
existing NN O O
dental NN O O
disease NN O O
, NN O O
anemia NN O O
, NN O O
coagulopathy NN O O
, NN O O
infection NN O O
, NN O O
ill NN O O
- NN O O
fitting NN O O
dentures NN O O
) NN O O
. NN O O
Good NN O O
oral NN O O
hygiene NN O O
practices NN O O
should NN O O
be NN O O
maintained NN O O
during NN O O
treatment NN O O
with NN O O
Prolia NN O O
. NN O O
Concomitant NN O O
administration NN O O
of NN O O
drugs NN O O
associated NN O O
with NN O O
ONJ NN O O
may NN O O
increase NN O O
the NN O O
risk NN O O
of NN O O
developing NN O O
ONJ. NN O O
For NN O O
patients NN O O
requiring NN O O
invasive NN O O
dental NN O O
procedures NN O O
, NN O O
clinical NN O O
judgment NN O O
of NN O O
the NN O O
treating NN O O
physician NN O O
and/or NN O O
oral NN O O
surgeon NN O O
should NN O O
guide NN O O
the NN O O
management NN O O
plan NN O O
of NN O O
each NN O O
patient NN O O
based NN O O
on NN O O
individual NN O O
benefit NN O O
- NN O O
risk NN O O
assessment NN O O
. NN O O
Patients NN O O
who NN O O
are NN O O
suspected NN O O
of NN O O
having NN O O
or NN O O
who NN O O
develop NN O O
ONJ NN O O
while NN O O
on NN O O
Prolia NN O O
should NN O O
receive NN O O
care NN O O
by NN O O
a NN O O
dentist NN O O
or NN O O
an NN O O
oral NN O O
surgeon NN O O
. NN O O
In NN O O
these NN O O
patients NN O O
, NN O O
extensive NN O O
dental NN O O
surgery NN O O
to NN O O
treat NN O O
ONJ NN O O
may NN O O
exacerbate NN O O
the NN O O
condition NN O O
. NN O O
Discontinuation NN O O
of NN O O
Prolia NN O O
therapy NN O O
should NN O O
be NN O O
considered NN O O
based NN O O
on NN O O
individual NN O O
benefit NN O O
- NN O O
risk NN O O
assessment NN O O
. NN O O
5.5 NN O O
Atypical NN O O
Subtrochanteric NN O O
and NN O O
Diaphyseal NN O O
Femoral NN O O
Fractures NN O O
Atypical NN O O
low NN O O
- NN O O
energy NN O O
or NN O O
low NN O O
trauma NN O O
fractures NN O O
of NN O O
the NN O O
shaft NN O O
have NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
receiving NN O O
Prolia NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
These NN O O
fractures NN O O
can NN O O
occur NN O O
anywhere NN O O
in NN O O
the NN O O
femoral NN O O
shaft NN O O
from NN O O
just NN O O
below NN O O
the NN O O
lesser NN O O
trochanter NN O O
to NN O O
above NN O O
the NN O O
supracondylar NN O O
flare NN O O
and NN O O
are NN O O
transverse NN O O
or NN O O
short NN O O
oblique NN O O
in NN O O
orientation NN O O
without NN O O
evidence NN O O
of NN O O
comminution NN O O
. NN O O
Causality NN O O
has NN O O
not NN O O
been NN O O
established NN O O
as NN O O
these NN O O
fractures NN O O
also NN O O
occur NN O O
in NN O O
osteoporotic NN O O
patients NN O O
who NN O O
have NN O O
not NN O O
been NN O O
treated NN O O
with NN O O
anti NN O O
- NN O O
resorptive NN O O
agents NN O O
. NN O O
Atypical NN B-AdverseReaction B-AdverseReaction
femoral NN I-AdverseReaction I-AdverseReaction
fractures NN I-AdverseReaction I-AdverseReaction
most NN O O
commonly NN O O
occur NN O O
with NN O O
minimal NN O O
or NN O O
no NN O O
trauma NN O O
to NN O O
the NN O O
affected NN O O
area NN O O
. NN O O
They NN O O
may NN O O
be NN O O
bilateral NN O O
and NN O O
many NN O O
patients NN O O
report NN O O
prodromal NN O O
pain NN O O
in NN O O
the NN O O
affected NN O O
area NN O O
, NN O O
usually NN O O
presenting NN O O
as NN O O
dull NN O O
, NN O O
aching NN O O
thigh NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
weeks NN O O
to NN O O
months NN O O
before NN O O
a NN O O
complete NN O O
fracture NN O O
occurs NN O O
. NN O O
A NN O O
number NN O O
of NN O O
reports NN O O
note NN O O
that NN O O
patients NN O O
were NN O O
also NN O O
receiving NN O O
treatment NN O O
with NN O O
glucocorticoids NN O O
( NN O O
e.g. NN O O
prednisone NN O O
) NN O O
at NN O O
the NN O O
time NN O O
of NN O O
fracture NN O O
. NN O O
During NN O O
Prolia NN O O
treatment NN O O
, NN O O
patients NN O O
should NN O O
be NN O O
advised NN O O
to NN O O
report NN O O
new NN O O
or NN O O
unusual NN O O
thigh NN O O
, NN O O
hip NN O O
, NN O O
or NN O O
groin NN O O
pain NN O O
. NN O O
Any NN O O
patient NN O O
who NN O O
presents NN O O
with NN O O
thigh NN O O
or NN O O
groin NN O O
pain NN O O
should NN O O
be NN O O
suspected NN O O
of NN O O
having NN O O
an NN O O
atypical NN O O
fracture NN O O
and NN O O
should NN O O
be NN O O
evaluated NN O O
to NN O O
rule NN O O
out NN O O
an NN O O
incomplete NN O O
femur NN O O
fracture NN O O
. NN O O
Patient NN O O
presenting NN O O
with NN O O
an NN O O
atypical NN O O
femur NN O O
fracture NN O O
should NN O O
also NN O O
be NN O O
assessed NN O O
for NN O O
symptoms NN O O
and NN O O
signs NN O O
of NN O O
fracture NN O O
in NN O O
the NN O O
contralateral NN O O
limb NN O O
. NN O O
Interruption NN O O
of NN O O
Prolia NN O O
therapy NN O O
should NN O O
be NN O O
considered NN O O
, NN O O
pending NN O O
a NN O O
risk/benefit NN O O
assessment NN O O
, NN O O
on NN O O
an NN O O
individual NN O O
basis NN O O
. NN O O
5.6 NN O O
Serious NN O O
Infections NN O O
In NN O O
a NN O O
clinical NN O O
trial NN O O
of NN O O
over NN O O
7800 NN O O
women NN O O
with NN O O
postmenopausal NN O O
osteoporosis NN O O
, NN O O
serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
leading NN O O
to NN O O
hospitalization NN O O
were NN O O
reported NN O O
more NN O O
frequently NN O O
in NN O O
the NN O O
Prolia NN O O
group NN O O
than NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Serious NN B-Severity B-Severity
skin NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
as NN O O
well NN O O
as NN O O
infections NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
abdomen NN I-AdverseReaction I-AdverseReaction
urinary NN O O
tract NN O O
, NN O O
and NN O O
ear NN O O
, NN O O
were NN O O
more NN O O
frequent NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
Prolia NN O O
. NN O O
Endocarditis NN B-AdverseReaction B-AdverseReaction
was NN O O
also NN O O
reported NN O O
more NN O O
frequently NN O O
in NN O O
Prolia NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
opportunistic NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
was NN O O
similar NN O O
between NN O O
placebo NN O O
and NN O O
Prolia NN O O
groups NN O O
, NN O O
and NN O O
the NN O O
overall NN O O
incidence NN O O
of NN O O
infections NN B-AdverseReaction B-AdverseReaction
was NN O O
similar NN O O
between NN O O
the NN O O
treatment NN O O
groups NN O O
. NN O O
Advise NN O O
patients NN O O
to NN O O
seek NN O O
prompt NN O O
medical NN O O
attention NN O O
if NN O O
they NN O O
develop NN O O
signs NN O O
or NN O O
symptoms NN O O
of NN O O
severe NN O O
infection NN O O
, NN O O
including NN O O
cellulitis NN O O
. NN O O
Patients NN O O
on NN O O
concomitant NN O O
immunosuppressant NN O O
agents NN O O
or NN O O
with NN O O
impaired NN O O
immune NN O O
systems NN O O
may NN B-Factor B-Factor
be NN O O
at NN O O
increased NN O O
risk NN O O
for NN O O
serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
Consider NN O O
the NN O O
benefit NN O O
- NN O O
risk NN O O
profile NN O O
in NN O O
such NN O O
patients NN O O
before NN O O
treating NN O O
with NN O O
Prolia NN O O
. NN O O
In NN O O
patients NN O O
who NN O O
develop NN O O
serious NN O O
infections NN O O
while NN O O
on NN O O
Prolia NN O O
, NN O O
prescribers NN O O
should NN O O
assess NN O O
the NN O O
need NN O O
for NN O O
continued NN O O
Prolia NN O O
therapy NN O O
. NN O O
5.7 NN O O
Dermatologic NN O O
Adverse NN O O
Reactions NN O O
In NN O O
a NN O O
large NN O O
clinical NN O O
trial NN O O
of NN O O
over NN O O
7800 NN O O
women NN O O
with NN O O
postmenopausal NN O O
osteoporosis NN O O
, NN O O
epidermal NN O O
and NN O O
dermal NN B-AdverseReaction B-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
such NN O O
as NN O O
dermatitis NN B-AdverseReaction B-AdverseReaction
eczema NN B-AdverseReaction B-AdverseReaction
and NN O O
rashes NN B-AdverseReaction B-AdverseReaction
occurred NN O O
at NN O O
a NN O O
significantly NN O O
higher NN O O
rate NN O O
in NN O O
the NN O O
Prolia NN O O
group NN O O
compared NN O O
to NN O O
the NN O O
placebo NN O O
group NN O O
. NN O O
Most NN O O
of NN O O
these NN O O
events NN O O
were NN O O
not NN O O
specific NN O O
to NN O O
the NN O O
injection NN O O
site NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Consider NN O O
discontinuing NN O O
Prolia NN O O
if NN O O
severe NN O O
symptoms NN O O
develop NN O O
. NN O O
5.8 NN O O
Musculoskeletal NN O O
Pain NN O O
In NN O O
post NN O O
- NN O O
marketing NN O O
experience NN O O
, NN O O
severe NN B-Severity B-Severity
and NN O O
occasionally NN O O
incapacitating NN B-Severity B-Severity
bone NN O O
, NN O O
joint NN O O
, NN O O
and/or NN O O
muscle NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
has NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
taking NN O O
Prolia NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.2 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
time NN O O
to NN O O
onset NN O O
of NN O O
symptoms NN O O
varied NN O O
from NN O O
one NN O O
day NN O O
to NN O O
several NN O O
months NN O O
after NN O O
starting NN O O
Prolia NN O O
. NN O O
Consider NN O O
discontinuing NN O O
use NN O O
if NN O O
severe NN O O
symptoms NN O O
develop NN O O
[ NN O O
see NN O O
Patient NN O O
Counseling NN O O
Information NN O O
( NN O O
17.8 NN O O
) NN O O
] NN O O
. NN O O
5.9 NN O O
Suppression NN O O
of NN O O
Bone NN O O
Turnover NN O O
In NN O O
clinical NN O O
trials NN O O
in NN O O
women NN O O
with NN O O
postmenopausal NN O O
osteoporosis NN O O
, NN O O
treatment NN O O
with NN O O
Prolia NN O O
resulted NN O O
in NN O O
significant NN O O
suppression NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
bone NN I-AdverseReaction I-AdverseReaction
remodeling NN I-AdverseReaction I-AdverseReaction
as NN O O
evidenced NN O O
by NN O O
markers NN O O
of NN O O
bone NN O O
turnover NN O O
and NN O O
bone NN O O
histomorphometry NN O O
[ NN O O
see NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.2 NN O O
) NN O O
and NN O O
Clinical NN O O
Studies NN O O
( NN O O
14.1 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
significance NN O O
of NN O O
these NN O O
findings NN O O
and NN O O
the NN O O
effect NN O O
of NN O O
long NN O O
- NN O O
term NN O O
treatment NN O O
with NN O O
Prolia NN O O
are NN O O
unknown NN O O
. NN O O
The NN O O
long NN O O
- NN O O
term NN O O
consequences NN O O
of NN O O
the NN O O
degree NN O O
of NN O O
suppression NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
bone NN I-AdverseReaction I-AdverseReaction
remodeling NN I-AdverseReaction I-AdverseReaction
observed NN O O
with NN O O
Prolia NN O O
may NN B-Factor B-Factor
contribute NN O O
to NN O O
adverse NN O O
outcomes NN O O
such NN O O
as NN O O
osteonecrosis NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
jaw NN I-AdverseReaction I-AdverseReaction
atypical NN B-AdverseReaction B-AdverseReaction
fractures NN I-AdverseReaction I-AdverseReaction
and NN O O
delayed NN B-AdverseReaction B-AdverseReaction
fracture NN I-AdverseReaction I-AdverseReaction
healing NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
patients NN O O
for NN O O
these NN O O
consequences NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
incidence NN O O
>=7 NN O O
% NN O O
and NN O O
higher NN O O
than NN O O
placebo NN O O
) NN O O
: NN O O
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
and NN O O
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
UCB NN O O
, NN O O
Inc. NN O O
at NN O O
1 NN O O
- NN O O
866 NN O O
- NN O O
822 NN O O
- NN O O
0068 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
The NN O O
most NN O O
serious NN O O
adverse NN O O
reactions NN O O
were NN O O
: NN O O
* NN O O
Serious NN B-Severity B-Severity
Infections NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Malignancies NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
Heart NN B-AdverseReaction B-AdverseReaction
Failure NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
Because NN O O
clinical NN O O
studies NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
and NN O O
controlled NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
studies NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
studies NN O O
of NN O O
another NN O O
drug NN O O
, NN O O
and NN O O
may NN O O
not NN O O
predict NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
a NN O O
broader NN O O
patient NN O O
population NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O
In NN O O
premarketing NN O O
controlled NN O O
trials NN O O
of NN O O
all NN O O
patient NN O O
populations NN O O
combined NN O O
the NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>= NN O O
8 NN O O
% NN O O
) NN O O
were NN O O
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
( NN O O
18 NN O O
% NN O O
) NN O O
, NN O O
rash NN B-AdverseReaction B-AdverseReaction
( NN O O
9 NN O O
% NN O O
) NN O O
and NN O O
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
( NN O O
8 NN O O
% NN O O
) NN O O
. NN O O
Adverse NN O O
Reactions NN O O
Most NN O O
Commonly NN O O
Leading NN O O
to NN O O
Discontinuation NN O O
of NN O O
Treatment NN O O
in NN O O
Premarketing NN O O
Controlled NN O O
Trials NN O O
The NN O O
proportion NN O O
of NN O O
patients NN O O
with NN O O
Crohn NN O O
's NN O O
disease NN O O
who NN O O
discontinued NN O O
treatment NN O O
due NN O O
to NN O O
adverse NN O O
reactions NN O O
in NN O O
the NN O O
controlled NN O O
clinical NN O O
studies NN O O
was NN O O
8 NN O O
% NN O O
for NN O O
CIMZIA NN O O
and NN O O
7 NN O O
% NN O O
for NN O O
placebo NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
leading NN O O
to NN O O
the NN O O
discontinuation NN O O
of NN O O
CIMZIA NN O O
( NN O O
for NN O O
at NN O O
least NN O O
2 NN O O
patients NN O O
and NN O O
with NN O O
a NN O O
higher NN O O
incidence NN O O
than NN O O
placebo NN O O
) NN O O
were NN O O
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
( NN O O
0.4 NN O O
% NN O O
CIMZIA NN O O
, NN O O
0.2 NN O O
% NN O O
placebo NN O O
) NN O O
, NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
( NN O O
0.4 NN O O
% NN O O
CIMZIA NN O O
, NN O O
0 NN O O
% NN O O
placebo NN O O
) NN O O
, NN O O
and NN O O
intestinal NN B-AdverseReaction B-AdverseReaction
obstruction NN I-AdverseReaction I-AdverseReaction
( NN O O
0.4 NN O O
% NN O O
CIMZIA NN O O
, NN O O
0 NN O O
% NN O O
placebo NN O O
) NN O O
. NN O O
The NN O O
proportion NN O O
of NN O O
patients NN O O
with NN O O
rheumatoid NN O O
arthritis NN O O
who NN O O
discontinued NN O O
treatment NN O O
due NN O O
to NN O O
adverse NN O O
reactions NN O O
in NN O O
the NN O O
controlled NN O O
clinical NN O O
studies NN O O
was NN O O
5 NN O O
% NN O O
for NN O O
CIMZIA NN O O
and NN O O
2.5 NN O O
% NN O O
for NN O O
placebo NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
leading NN O O
to NN O O
discontinuation NN O O
of NN O O
CIMZIA NN O O
were NN O O
tuberculosis NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
( NN O O
0.5 NN O O
% NN O O
) NN O O
; NN O O
and NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
urticaria NN B-AdverseReaction B-AdverseReaction
pneumonia NN B-AdverseReaction B-AdverseReaction
and NN O O
rash NN B-AdverseReaction B-AdverseReaction
( NN O O
0.3 NN O O
% NN O O
) NN O O
. NN O O
Controlled NN O O
Studies NN O O
with NN O O
Crohn NN O O
's NN O O
Disease NN O O
The NN O O
data NN O O
described NN O O
below NN O O
reflect NN O O
exposure NN O O
to NN O O
CIMZIA NN O O
at NN O O
400 NN O O
mg NN O O
subcutaneous NN O O
dosing NN O O
in NN O O
studies NN O O
of NN O O
patients NN O O
with NN O O
Crohn NN O O
's NN O O
disease NN O O
. NN O O
In NN O O
the NN O O
safety NN O O
population NN O O
in NN O O
controlled NN O O
studies NN O O
, NN O O
a NN O O
total NN O O
of NN O O
620 NN O O
patients NN O O
with NN O O
Crohn NN O O
's NN O O
disease NN O O
received NN O O
CIMZIA NN O O
at NN O O
a NN O O
dose NN O O
of NN O O
400 NN O O
mg NN O O
, NN O O
and NN O O
614 NN O O
subjects NN O O
received NN O O
placebo NN O O
( NN O O
including NN O O
subjects NN O O
randomized NN O O
to NN O O
placebo NN O O
in NN O O
Study NN O O
CD2 NN O O
following NN O O
open NN O O
label NN O O
dosing NN O O
of NN O O
CIMZIA NN O O
at NN O O
Weeks NN O O
0 NN O O
, NN O O
2 NN O O
, NN O O
4 NN O O
) NN O O
. NN O O
In NN O O
controlled NN O O
and NN O O
uncontrolled NN O O
studies NN O O
, NN O O
1,564 NN O O
patients NN O O
received NN O O
CIMZIA NN O O
at NN O O
some NN O O
dose NN O O
level NN O O
, NN O O
of NN O O
whom NN O O
1,350 NN O O
patients NN O O
received NN O O
400 NN O O
mg NN O O
CIMZIA. NN O O
Approximately NN O O
55 NN O O
% NN O O
of NN O O
subjects NN O O
were NN O O
female NN O O
, NN O O
45 NN O O
% NN O O
were NN O O
male NN O O
, NN O O
and NN O O
94 NN O O
% NN O O
were NN O O
Caucasian NN O O
. NN O O
The NN O O
majority NN O O
of NN O O
patients NN O O
in NN O O
the NN O O
active NN O O
group NN O O
were NN O O
between NN O O
the NN O O
ages NN O O
of NN O O
18 NN O O
and NN O O
64 NN O O
. NN O O
During NN O O
controlled NN O O
clinical NN O O
studies NN O O
, NN O O
the NN O O
proportion NN O O
of NN O O
patients NN O O
with NN O O
serious NN O O
adverse NN O O
reactions NN O O
was NN O O
10 NN O O
% NN O O
for NN O O
CIMZIA NN O O
and NN O O
9 NN O O
% NN O O
for NN O O
placebo NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
occurring NN O O
in NN O O
>= NN O O
5 NN O O
% NN O O
of NN O O
CIMZIA NN O O
- NN O O
treated NN O O
patients NN O O
, NN O O
and NN O O
with NN O O
a NN O O
higher NN O O
incidence NN O O
compared NN O O
to NN O O
placebo NN O O
) NN O O
in NN O O
controlled NN O O
clinical NN O O
studies NN O O
with NN O O
CIMZIA NN O O
were NN O O
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
( NN O O
e.g. NN O O
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
laryngitis NN B-AdverseReaction B-AdverseReaction
viral NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
in NN O O
20 NN O O
% NN O O
of NN O O
CIMZIA NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
13 NN O O
% NN O O
of NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
, NN O O
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
( NN O O
e.g. NN O O
bladder NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
bacteriuria NN B-AdverseReaction B-AdverseReaction
cystitis NN B-AdverseReaction B-AdverseReaction
in NN O O
7 NN O O
% NN O O
of NN O O
CIMZIA NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
in NN O O
6 NN O O
% NN O O
of NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
, NN O O
and NN O O
arthralgia NN B-AdverseReaction B-AdverseReaction
( NN O O
6 NN O O
% NN O O
CIMZIA NN O O
, NN O O
4 NN O O
% NN O O
placebo NN O O
) NN O O
. NN O O
Other NN O O
Adverse NN O O
Reactions NN O O
The NN O O
most NN O O
commonly NN O O
occurring NN O O
adverse NN O O
reactions NN O O
in NN O O
controlled NN O O
trials NN O O
of NN O O
Crohn NN O O
's NN O O
disease NN O O
were NN O O
described NN O O
above NN O O
. NN O O
Other NN O O
serious NN O O
or NN O O
significant NN O O
adverse NN O O
reactions NN O O
reported NN O O
in NN O O
controlled NN O O
and NN O O
uncontrolled NN O O
studies NN O O
in NN O O
Crohn NN O O
's NN O O
disease NN O O
and NN O O
other NN O O
diseases NN O O
, NN O O
occurring NN O O
in NN O O
patients NN O O
receiving NN O O
CIMZIA NN O O
at NN O O
doses NN O O
of NN O O
400 NN O O
mg NN O O
or NN O O
other NN O O
doses NN O O
include NN O O
: NN O O
Blood NN O O
and NN O O
lymphatic NN O O
system NN O O
disorders NN O O
: NN O O
Anemia NN B-AdverseReaction B-AdverseReaction
leukopenia NN B-AdverseReaction B-AdverseReaction
lymphadenopathy NN B-AdverseReaction B-AdverseReaction
pancytopenia NN B-AdverseReaction B-AdverseReaction
and NN O O
thrombophilia NN B-AdverseReaction B-AdverseReaction
Cardiac NN O O
disorders NN O O
: NN O O
Angina NN B-AdverseReaction B-AdverseReaction
pectoris NN I-AdverseReaction I-AdverseReaction
arrhythmias NN B-AdverseReaction B-AdverseReaction
atrial NN B-AdverseReaction B-AdverseReaction
fibrillation NN I-AdverseReaction I-AdverseReaction
cardiac NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
hypertensive NN B-AdverseReaction B-AdverseReaction
heart NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
myocardial NN B-AdverseReaction B-AdverseReaction
infarction NN I-AdverseReaction I-AdverseReaction
myocardial NN B-AdverseReaction B-AdverseReaction
ischemia NN I-AdverseReaction I-AdverseReaction
pericardial NN B-AdverseReaction B-AdverseReaction
effusion NN I-AdverseReaction I-AdverseReaction
pericarditis NN B-AdverseReaction B-AdverseReaction
stroke NN B-AdverseReaction B-AdverseReaction
and NN O O
transient NN B-AdverseReaction B-AdverseReaction
ischemic NN I-AdverseReaction I-AdverseReaction
attack NN I-AdverseReaction I-AdverseReaction
Eye NN O O
disorders NN O O
: NN O O
Optic NN B-AdverseReaction B-AdverseReaction
neuritis NN I-AdverseReaction I-AdverseReaction
retinal NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
and NN O O
uveitis NN B-AdverseReaction B-AdverseReaction
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
: NN O O
Bleeding NN B-AdverseReaction B-AdverseReaction
and NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
Hepatobiliary NN O O
disorders NN O O
: NN O O
Elevated NN B-AdverseReaction B-AdverseReaction
liver NN I-AdverseReaction I-AdverseReaction
enzymes NN I-AdverseReaction I-AdverseReaction
and NN O O
hepatitis NN B-AdverseReaction B-AdverseReaction
Immune NN O O
system NN O O
disorders NN O O
: NN O O
Alopecia NN B-AdverseReaction B-AdverseReaction
totalis NN I-AdverseReaction I-AdverseReaction
Psychiatric NN O O
disorders NN O O
: NN O O
Anxiety NN B-AdverseReaction B-AdverseReaction
bipolar NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
and NN O O
suicide NN B-AdverseReaction B-AdverseReaction
attempt NN I-AdverseReaction I-AdverseReaction
Renal NN O O
and NN O O
urinary NN O O
disorders NN O O
: NN O O
Nephrotic NN B-AdverseReaction B-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
and NN O O
renal NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
Reproductive NN O O
system NN O O
and NN O O
breast NN O O
disorders NN O O
: NN O O
Menstrual NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
: NN O O
Dermatitis NN B-AdverseReaction B-AdverseReaction
erythema NN B-AdverseReaction B-AdverseReaction
nodosum NN I-AdverseReaction I-AdverseReaction
and NN O O
urticaria NN B-AdverseReaction B-AdverseReaction
Vascular NN O O
disorders NN O O
: NN O O
Thrombophlebitis NN B-AdverseReaction B-AdverseReaction
vasculitis NN B-AdverseReaction B-AdverseReaction
Controlled NN O O
Studies NN O O
with NN O O
Rheumatoid NN O O
Arthritis NN O O
CIMZIA NN O O
was NN O O
studied NN O O
primarily NN O O
in NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
and NN O O
in NN O O
long NN O O
- NN O O
term NN O O
follow NN O O
- NN O O
up NN O O
studies NN O O
. NN O O
The NN O O
data NN O O
described NN O O
below NN O O
reflect NN O O
the NN O O
exposure NN O O
to NN O O
CIMZIA NN O O
in NN O O
2,367 NN O O
RA NN O O
patients NN O O
, NN O O
including NN O O
2,030 NN O O
exposed NN O O
for NN O O
at NN O O
least NN O O
6 NN O O
months NN O O
, NN O O
1,663 NN O O
exposed NN O O
for NN O O
at NN O O
least NN O O
one NN O O
year NN O O
and NN O O
282 NN O O
for NN O O
at NN O O
least NN O O
2 NN O O
years NN O O
; NN O O
and NN O O
1,774 NN O O
in NN O O
adequate NN O O
and NN O O
well NN O O
- NN O O
controlled NN O O
studies NN O O
. NN O O
In NN O O
placebo NN O O
- NN O O
controlled NN O O
studies NN O O
, NN O O
the NN O O
population NN O O
had NN O O
a NN O O
median NN O O
age NN O O
of NN O O
53 NN O O
years NN O O
at NN O O
entry NN O O
; NN O O
approximately NN O O
80 NN O O
% NN O O
were NN O O
females NN O O
, NN O O
93 NN O O
% NN O O
were NN O O
Caucasian NN O O
and NN O O
all NN O O
patients NN O O
were NN O O
suffering NN O O
from NN O O
active NN O O
rheumatoid NN O O
arthritis NN O O
, NN O O
with NN O O
a NN O O
median NN O O
disease NN O O
duration NN O O
of NN O O
6.2 NN O O
years NN O O
. NN O O
Most NN O O
patients NN O O
received NN O O
the NN O O
recommended NN O O
dose NN O O
of NN O O
CIMZIA NN O O
or NN O O
higher NN O O
. NN O O
Table NN O O
1 NN O O
summarizes NN O O
the NN O O
reactions NN O O
reported NN O O
at NN O O
a NN O O
rate NN O O
of NN O O
at NN O O
least NN O O
3 NN O O
% NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
CIMZIA NN O O
200 NN O O
mg NN O O
every NN O O
other NN O O
week NN O O
compared NN O O
to NN O O
placebo NN O O
( NN O O
saline NN O O
formulation NN O O
) NN O O
, NN O O
given NN O O
concomitantly NN O O
with NN O O
methotrexate NN O O
. NN O O
Table NN O O
1 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Reported NN O O
by NN O O
>=3 NN O O
% NN O O
of NN O O
Patients NN O O
Treated NN O O
with NN O O
CIMZIA NN O O
Dosed NN O O
Every NN O O
Other NN O O
Week NN O O
during NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Period NN O O
of NN O O
Rheumatoid NN O O
Arthritis NN O O
Studies NN O O
, NN O O
with NN O O
Concomitant NN O O
Methotrexate NN O O
. NN O O
Adverse NN O O
Reaction(Preferred NN O O
Term NN O O
) NN O O
Placebo+ NN O O
MTX(%)N NN O O
=324 NN O O
CIMZIA NN O O
200 NN O O
mg NN O O
EOW NN O O
+ NN O O
MTX(%)N NN O O
=640 NN O O
Upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
2 NN O O
6 NN O O
Headache NN B-AdverseReaction B-AdverseReaction
4 NN O O
5 NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
2 NN O O
5 NN O O
Nasopharyngitis NN B-AdverseReaction B-AdverseReaction
1 NN O O
5 NN O O
Back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
1 NN O O
4 NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
2 NN O O
3 NN O O
Pharyngitis NN B-AdverseReaction B-AdverseReaction
1 NN O O
3 NN O O
Rash NN B-AdverseReaction B-AdverseReaction
1 NN O O
3 NN O O
Acute NN B-AdverseReaction B-AdverseReaction
bronchitis NN I-AdverseReaction I-AdverseReaction
1 NN O O
3 NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
2 NN O O
3 NN O O
Hypertensive NN B-AdverseReaction B-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
were NN O O
observed NN O O
more NN O O
frequently NN O O
in NN O O
patients NN O O
receiving NN O O
CIMZIA NN O O
than NN O O
in NN O O
controls NN O O
. NN O O
These NN O O
adverse NN O O
reactions NN O O
occurred NN O O
more NN O O
frequently NN O O
among NN O O
patients NN O O
with NN O O
a NN O O
baseline NN O O
history NN O O
of NN O O
hypertension NN O O
and NN O O
among NN O O
patients NN O O
receiving NN O O
concomitant NN O O
corticosteroids NN O O
and NN O O
non NN O O
- NN O O
steroidal NN O O
anti NN O O
- NN O O
inflammatory NN O O
drugs NN O O
. NN O O
Patients NN O O
receiving NN O O
CIMZIA NN O O
400 NN O O
mg NN O O
as NN O O
monotherapy NN O O
every NN O O
4 NN O O
weeks NN O O
in NN O O
rheumatoid NN O O
arthritis NN O O
controlled NN O O
clinical NN O O
trials NN O O
had NN O O
similar NN O O
adverse NN O O
reactions NN O O
to NN O O
those NN O O
patients NN O O
receiving NN O O
CIMZIA NN O O
200 NN O O
mg NN O O
every NN O O
other NN O O
week NN O O
. NN O O
Other NN O O
Adverse NN O O
Reactions NN O O
Other NN O O
infrequent NN O O
adverse NN O O
reactions NN O O
( NN O O
occurring NN O O
in NN O O
less NN O O
than NN O O
3 NN O O
% NN O O
of NN O O
RA NN O O
patients NN O O
) NN O O
were NN O O
similar NN O O
to NN O O
those NN O O
seen NN O O
in NN O O
Crohn NN O O
's NN O O
disease NN O O
patients NN O O
. NN O O
Psoriatic NN O O
Arthritis NN O O
Clinical NN O O
Study NN O O
CIMZIA NN O O
has NN O O
been NN O O
studied NN O O
in NN O O
409 NN O O
patients NN O O
with NN O O
psoriatic NN O O
arthritis NN O O
( NN O O
PsA NN O O
) NN O O
in NN O O
a NN O O
placebo NN O O
- NN O O
controlled NN O O
trial NN O O
. NN O O
The NN O O
safety NN O O
profile NN O O
for NN O O
patients NN O O
with NN O O
PsA NN O O
treated NN O O
with NN O O
CIMZIA NN O O
was NN O O
similar NN O O
to NN O O
the NN O O
safety NN O O
profile NN O O
seen NN O O
in NN O O
patients NN O O
with NN O O
RA NN O O
and NN O O
previous NN O O
experience NN O O
with NN O O
CIMZIA NN O O
. NN O O
Ankylosing NN O O
Spondylitis NN O O
Clinical NN O O
Study NN O O
CIMZIA NN O O
has NN O O
been NN O O
studied NN O O
in NN O O
325 NN O O
patients NN O O
with NN O O
axial NN O O
spondyloarthritis NN O O
of NN O O
whom NN O O
the NN O O
majority NN O O
had NN O O
ankylosing NN O O
spondylitis NN O O
( NN O O
AS NN O O
) NN O O
in NN O O
a NN O O
placebo NN O O
- NN O O
controlled NN O O
study NN O O
( NN O O
AS-1 NN O O
) NN O O
. NN O O
The NN O O
safety NN O O
profile NN O O
for NN O O
patients NN O O
in NN O O
study NN O O
AS-1 NN O O
treated NN O O
with NN O O
CIMZIA NN O O
was NN O O
similar NN O O
to NN O O
the NN O O
safety NN O O
profile NN O O
seen NN O O
in NN O O
patients NN O O
with NN O O
RA. NN O O
Infections NN O O
The NN O O
incidence NN O O
of NN O O
infections NN B-AdverseReaction B-AdverseReaction
in NN O O
controlled NN O O
studies NN O O
in NN O O
Crohn NN O O
's NN O O
disease NN O O
was NN O O
38 NN O O
% NN O O
for NN O O
CIMZIA NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
30 NN O O
% NN O O
for NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
The NN O O
infections NN B-AdverseReaction B-AdverseReaction
consisted NN O O
primarily NN O O
of NN O O
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
( NN O O
20 NN O O
% NN O O
for NN O O
CIMZIA NN O O
, NN O O
13 NN O O
% NN O O
for NN O O
placebo NN O O
) NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
during NN O O
the NN O O
controlled NN O O
clinical NN O O
studies NN O O
was NN O O
3 NN O O
% NN O O
per NN O O
patient NN O O
- NN O O
year NN O O
for NN O O
CIMZIA NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
1 NN O O
% NN O O
for NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
observed NN O O
included NN O O
bacterial NN O O
and NN O O
viral NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
pneumonia NN B-AdverseReaction B-AdverseReaction
and NN O O
pyelonephritis NN B-AdverseReaction B-AdverseReaction
The NN O O
incidence NN O O
of NN O O
new NN O O
cases NN O O
of NN O O
infections NN B-AdverseReaction B-AdverseReaction
in NN O O
controlled NN O O
clinical NN O O
studies NN O O
in NN O O
rheumatoid NN O O
arthritis NN O O
was NN O O
0.91 NN O O
per NN O O
patient NN O O
- NN O O
year NN O O
for NN O O
all NN O O
CIMZIA NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
0.72 NN O O
per NN O O
patient NN O O
- NN O O
year NN O O
for NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
The NN O O
infections NN B-AdverseReaction B-AdverseReaction
consisted NN O O
primarily NN O O
of NN O O
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
herpes NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
and NN O O
lower NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
In NN O O
the NN O O
controlled NN O O
rheumatoid NN O O
arthritis NN O O
studies NN O O
, NN O O
there NN O O
were NN O O
more NN O O
new NN O O
cases NN O O
of NN O O
serious NN B-Severity B-Severity
infection NN B-AdverseReaction B-AdverseReaction
adverse NN O O
reactions NN O O
in NN O O
the NN O O
CIMZIA NN O O
treatment NN O O
groups NN O O
, NN O O
compared NN O O
to NN O O
the NN O O
placebo NN O O
groups NN O O
( NN O O
0.06 NN O O
per NN O O
patient NN O O
- NN O O
year NN O O
for NN O O
all NN O O
CIMZIA NN O O
doses NN O O
vs. NN O O
0.02 NN O O
per NN O O
patient NN O O
- NN O O
year NN O O
for NN O O
placebo NN O O
) NN O O
. NN O O
Rates NN O O
of NN O O
serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
in NN O O
the NN O O
200 NN O O
mg NN O O
every NN O O
other NN O O
week NN O O
dose NN O O
group NN O O
were NN O O
0.06 NN O O
per NN O O
patient NN O O
- NN O O
year NN O O
and NN O O
in NN O O
the NN O O
400 NN O O
mg NN O O
every NN O O
4 NN O O
weeks NN O O
dose NN O O
group NN O O
were NN O O
0.04 NN O O
per NN O O
patient NN O O
- NN O O
year NN O O
. NN O O
Serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
included NN O O
tuberculosis NN B-AdverseReaction B-AdverseReaction
pneumonia NN B-AdverseReaction B-AdverseReaction
cellulitis NN B-AdverseReaction B-AdverseReaction
and NN O O
pyelonephritis NN B-AdverseReaction B-AdverseReaction
In NN O O
the NN O O
placebo NN B-Factor B-Factor
group NN O O
, NN O O
no NN O O
serious NN B-Severity B-Severity
infection NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
more NN O O
than NN O O
one NN O O
subject NN O O
. NN O O
There NN O O
is NN O O
no NN O O
evidence NN O O
of NN O O
increased NN O O
risk NN O O
of NN O O
infections NN O O
with NN O O
continued NN O O
exposure NN O O
over NN O O
time NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
Tuberculosis NN O O
and NN O O
Opportunistic NN O O
Infections NN O O
In NN O O
completed NN O O
and NN O O
ongoing NN O O
global NN O O
clinical NN O O
studies NN O O
in NN O O
all NN O O
indications NN O O
including NN O O
5,118 NN O O
CIMZIA NN O O
- NN O O
treated NN O O
patients NN O O
, NN O O
the NN O O
overall NN O O
rate NN O O
of NN O O
tuberculosis NN B-AdverseReaction B-AdverseReaction
is NN O O
approximately NN O O
0.61 NN O O
per NN O O
100 NN O O
patient NN O O
- NN O O
years NN O O
across NN O O
all NN O O
indications NN O O
. NN O O
The NN O O
majority NN O O
of NN O O
cases NN O O
occurred NN O O
in NN O O
countries NN O O
with NN O O
high NN O O
endemic NN O O
rates NN O O
of NN O O
TB NN B-AdverseReaction B-AdverseReaction
Reports NN O O
include NN O O
cases NN O O
of NN O O
miliary NN O O
, NN O O
lymphatic NN O O
, NN O O
peritoneal NN O O
, NN O O
as NN O O
well NN O O
as NN O O
pulmonary NN B-AdverseReaction B-AdverseReaction
TB NN I-AdverseReaction I-AdverseReaction
The NN O O
median NN O O
time NN O O
to NN O O
onset NN O O
of NN O O
TB NN B-AdverseReaction B-AdverseReaction
for NN O O
all NN O O
patients NN O O
exposed NN O O
to NN O O
CIMZIA NN O O
across NN O O
all NN O O
indications NN O O
was NN O O
345 NN O O
days NN O O
. NN O O
In NN O O
the NN O O
studies NN O O
with NN O O
CIMZIA NN O O
in NN O O
RA NN O O
, NN O O
there NN O O
were NN O O
36 NN O O
cases NN O O
of NN O O
TB NN B-AdverseReaction B-AdverseReaction
among NN O O
2,367 NN O O
exposed NN O O
patients NN O O
, NN O O
including NN O O
some NN O O
fatal NN B-AdverseReaction B-AdverseReaction
cases NN O O
. NN O O
Rare NN O O
cases NN O O
of NN O O
opportunistic NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
have NN O O
also NN O O
been NN O O
reported NN O O
in NN O O
these NN O O
clinical NN O O
trials NN O O
. NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
Malignancies NN O O
In NN O O
clinical NN O O
studies NN O O
of NN O O
CIMZIA NN O O
, NN O O
the NN O O
overall NN O O
incidence NN O O
rate NN O O
of NN O O
malignancies NN B-AdverseReaction B-AdverseReaction
was NN O O
similar NN O O
for NN O O
CIMZIA NN O O
- NN O O
treated NN O O
and NN O O
control NN O O
patients NN O O
. NN O O
For NN O O
some NN O O
TNF NN O O
blockers NN O O
, NN O O
more NN O O
cases NN O O
of NN O O
malignancies NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
observed NN O O
among NN O O
patients NN O O
receiving NN O O
those NN O O
TNF NN B-DrugClass B-DrugClass
blockers NN I-DrugClass I-DrugClass
compared NN O O
to NN O O
control NN O O
patients NN O O
. NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
Heart NN O O
Failure NN O O
In NN O O
placebo NN O O
- NN O O
controlled NN O O
and NN O O
open NN O O
- NN O O
label NN O O
rheumatoid NN O O
arthritis NN O O
studies NN O O
, NN O O
cases NN O O
of NN O O
new NN O O
or NN O O
worsening NN B-AdverseReaction B-AdverseReaction
heart NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
for NN O O
CIMZIA NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
The NN O O
majority NN O O
of NN O O
these NN O O
cases NN O O
were NN O O
mild NN O O
to NN O O
moderate NN O O
and NN O O
occurred NN O O
during NN O O
the NN O O
first NN O O
year NN O O
of NN O O
exposure NN O O
. NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
. NN O O
Autoantibodies NN O O
In NN O O
clinical NN O O
studies NN O O
in NN O O
Crohn NN O O
's NN O O
disease NN O O
, NN O O
4 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
CIMZIA NN O O
and NN O O
2 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
placebo NN O O
that NN O O
had NN O O
negative NN O O
baseline NN O O
ANA NN O O
titers NN O O
developed NN O O
positive NN O O
titers NN O O
during NN O O
the NN O O
studies NN O O
. NN O O
One NN O O
of NN O O
the NN O O
1,564 NN O O
Crohn NN O O
's NN O O
disease NN O O
patients NN O O
treated NN O O
with NN O O
CIMZIA NN O O
developed NN O O
symptoms NN O O
of NN O O
a NN O O
lupus NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
like NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
In NN O O
clinical NN O O
trials NN O O
of NN O O
TNF NN O O
blockers NN O O
, NN O O
including NN O O
CIMZIA NN O O
, NN O O
in NN O O
patients NN O O
with NN O O
RA NN O O
, NN O O
some NN O O
patients NN O O
have NN O O
developed NN O O
ANA NN B-AdverseReaction B-AdverseReaction
Four NN O O
patients NN O O
out NN O O
of NN O O
2,367 NN O O
patients NN O O
treated NN O O
with NN O O
CIMZIA NN O O
in NN O O
RA NN O O
clinical NN O O
studies NN O O
developed NN O O
clinical NN O O
signs NN O O
suggestive NN O O
of NN O O
a NN O O
lupus NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
like NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
The NN O O
impact NN O O
of NN O O
long NN O O
- NN O O
term NN O O
treatment NN O O
with NN O O
CIMZIA NN O O
on NN O O
the NN O O
development NN O O
of NN O O
autoimmune NN O O
diseases NN O O
is NN O O
unknown NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.9 NN O O
) NN O O
] NN O O
. NN O O
Immunogenicity NN O O
Patients NN O O
were NN O O
tested NN O O
at NN O O
multiple NN O O
time NN O O
points NN O O
for NN O O
antibodies NN O O
to NN O O
certolizumab NN O O
pegol NN O O
during NN O O
Studies NN O O
CD1 NN O O
and NN O O
CD2 NN O O
. NN O O
The NN O O
overall NN O O
percentage NN O O
of NN O O
antibody NN O O
positive NN O O
patients NN O O
was NN O O
8 NN O O
% NN O O
in NN O O
patients NN O O
continuously NN O O
exposed NN O O
to NN O O
CIMZIA NN O O
, NN O O
approximately NN O O
6 NN O O
% NN O O
were NN O O
neutralizing NN O O
in NN O O
vitro NN O O
. NN O O
No NN O O
apparent NN O O
correlation NN O O
of NN O O
antibody NN O O
development NN O O
to NN O O
adverse NN O O
events NN O O
or NN O O
efficacy NN O O
was NN O O
observed NN O O
. NN O O
Patients NN O O
treated NN O O
with NN O O
concomitant NN O O
immunosuppressants NN O O
had NN O O
a NN O O
lower NN O O
rate NN O O
of NN O O
antibody NN O O
development NN O O
than NN O O
patients NN O O
not NN O O
taking NN O O
immunosuppressants NN O O
at NN O O
baseline NN O O
( NN O O
3 NN O O
% NN O O
and NN O O
11 NN O O
% NN O O
, NN O O
respectively NN O O
) NN O O
. NN O O
The NN O O
following NN O O
adverse NN O O
events NN O O
were NN O O
reported NN O O
in NN O O
Crohn NN O O
's NN O O
disease NN O O
patients NN O O
who NN O O
were NN O O
antibody NN O O
- NN O O
positive NN O O
( NN O O
N NN O O
= NN O O
100 NN O O
) NN O O
at NN O O
an NN O O
incidence NN O O
at NN O O
least NN O O
3 NN O O
% NN O O
higher NN O O
compared NN O O
to NN O O
antibody NN O O
- NN O O
negative NN O O
patients NN O O
( NN O O
N NN O O
= NN O O
1,242 NN O O
) NN O O
: NN O O
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
arthralgia NN B-AdverseReaction B-AdverseReaction
edema NN B-AdverseReaction B-AdverseReaction
peripheral NN I-AdverseReaction I-AdverseReaction
erythema NN B-AdverseReaction B-AdverseReaction
nodosum NN I-AdverseReaction I-AdverseReaction
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
erythema NN I-AdverseReaction I-AdverseReaction
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
and NN O O
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
The NN O O
overall NN O O
percentage NN O O
of NN O O
patients NN O O
with NN O O
antibodies NN O O
to NN O O
certolizumab NN O O
pegol NN O O
detectable NN O O
on NN O O
at NN O O
least NN O O
one NN O O
occasion NN O O
was NN O O
7 NN O O
% NN O O
( NN O O
105 NN O O
of NN O O
1,509 NN O O
) NN O O
in NN O O
the NN O O
rheumatoid NN O O
arthritis NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
. NN O O
Approximately NN O O
one NN O O
third NN O O
( NN O O
3 NN O O
% NN O O
, NN O O
39 NN O O
of NN O O
1,509 NN O O
) NN O O
of NN O O
these NN O O
patients NN O O
had NN O O
antibodies NN O O
with NN O O
neutralizing NN O O
activity NN O O
in NN O O
vitro NN O O
. NN O O
Patients NN O O
treated NN O O
with NN O O
concomitant NN O O
immunosuppressants NN O O
( NN O O
MTX NN O O
) NN O O
had NN O O
a NN O O
lower NN O O
rate NN O O
of NN O O
antibody NN O O
development NN O O
than NN O O
patients NN O O
not NN O O
taking NN O O
immunosuppressants NN O O
at NN O O
baseline NN O O
. NN O O
Patients NN O O
treated NN O O
with NN O O
concomitant NN O O
immunosuppressant NN O O
therapy NN O O
( NN O O
MTX NN O O
) NN O O
in NN O O
RA NN O O
- NN O O
I NN O O
, NN O O
RA NN O O
- NN O O
II NN O O
, NN O O
RA NN O O
- NN O O
III NN O O
had NN O O
a NN O O
lower NN O O
rate NN O O
of NN O O
neutralizing NN O O
antibody NN O O
formation NN O O
overall NN O O
than NN O O
patients NN O O
treated NN O O
with NN O O
CIMZIA NN O O
monotherapy NN O O
in NN O O
RA NN O O
- NN O O
IV NN O O
( NN O O
2 NN O O
% NN O O
vs. NN O O
8 NN O O
% NN O O
) NN O O
. NN O O
Both NN O O
the NN O O
loading NN O O
dose NN O O
of NN O O
400 NN O O
mg NN O O
every NN O O
other NN O O
week NN O O
at NN O O
Weeks NN O O
0 NN O O
, NN O O
2 NN O O
and NN O O
4 NN O O
and NN O O
concomitant NN O O
use NN O O
of NN O O
MTX NN O O
were NN O O
associated NN O O
with NN O O
reduced NN O O
immunogenicity NN O O
. NN O O
Antibody NN O O
formation NN O O
was NN O O
associated NN O O
with NN O O
lowered NN O O
drug NN O O
plasma NN O O
concentration NN O O
and NN O O
reduced NN O O
efficacy NN O O
. NN O O
In NN O O
patients NN O O
receiving NN O O
the NN O O
recommended NN O O
CIMZIA NN O O
dosage NN O O
of NN O O
200 NN O O
mg NN O O
every NN O O
other NN O O
week NN O O
with NN O O
concomitant NN O O
MTX NN O O
, NN O O
the NN O O
ACR20 NN O O
response NN O O
was NN O O
lower NN O O
among NN O O
antibody NN O O
positive NN O O
patients NN O O
than NN O O
among NN O O
antibody NN O O
- NN O O
negative NN O O
patients NN O O
( NN O O
Study NN O O
RA NN O O
- NN O O
I NN O O
, NN O O
48 NN O O
% NN O O
versus NN O O
60 NN O O
% NN O O
; NN O O
Study NN O O
RA NN O O
- NN O O
II NN O O
35 NN O O
% NN O O
versus NN O O
59 NN O O
% NN O O
, NN O O
respectively NN O O
) NN O O
. NN O O
In NN O O
Study NN O O
RA NN O O
- NN O O
III NN O O
, NN O O
too NN O O
few NN O O
patients NN O O
developed NN O O
antibodies NN O O
to NN O O
allow NN O O
for NN O O
meaningful NN O O
analysis NN O O
of NN O O
ACR20 NN O O
response NN O O
by NN O O
antibody NN O O
status NN O O
. NN O O
In NN O O
Study NN O O
RA NN O O
- NN O O
IV NN O O
( NN O O
monotherapy NN O O
) NN O O
, NN O O
the NN O O
ACR20 NN O O
response NN O O
was NN O O
33 NN O O
% NN O O
versus NN O O
56 NN O O
% NN O O
, NN O O
antibody NN O O
- NN O O
positive NN O O
versus NN O O
antibody NN O O
- NN O O
negative NN O O
status NN O O
, NN O O
respectively NN O O
. NN O O
[ NN O O
see NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.3 NN O O
) NN O O
] NN O O
. NN O O
No NN O O
association NN O O
was NN O O
seen NN O O
between NN O O
antibody NN O O
development NN O O
and NN O O
the NN O O
development NN O O
of NN O O
adverse NN O O
events NN O O
. NN O O
The NN O O
data NN O O
reflect NN O O
the NN O O
percentage NN O O
of NN O O
patients NN O O
whose NN O O
test NN O O
results NN O O
were NN O O
considered NN O O
positive NN O O
for NN O O
antibodies NN O O
to NN O O
certolizumab NN O O
pegol NN O O
in NN O O
an NN O O
ELISA NN O O
, NN O O
and NN O O
are NN O O
highly NN O O
dependent NN O O
on NN O O
the NN O O
sensitivity NN O O
and NN O O
specificity NN O O
of NN O O
the NN O O
assay NN O O
. NN O O
The NN O O
observed NN O O
incidence NN O O
of NN O O
antibody NN O O
( NN O O
including NN O O
neutralizing NN O O
antibody NN O O
) NN O O
positivity NN O O
in NN O O
an NN O O
assay NN O O
is NN O O
highly NN O O
dependent NN O O
on NN O O
several NN O O
factors NN O O
, NN O O
including NN O O
assay NN O O
sensitivity NN O O
and NN O O
specificity NN O O
, NN O O
assay NN O O
methodology NN O O
, NN O O
sample NN O O
handling NN O O
, NN O O
timing NN O O
of NN O O
sample NN O O
collection NN O O
, NN O O
concomitant NN O O
medications NN O O
, NN O O
and NN O O
underlying NN O O
disease NN O O
. NN O O
For NN O O
these NN O O
reasons NN O O
, NN O O
comparison NN O O
of NN O O
the NN O O
incidence NN O O
of NN O O
antibodies NN O O
to NN O O
certolizumab NN O O
pegol NN O O
with NN O O
the NN O O
incidence NN O O
of NN O O
antibodies NN O O
to NN O O
other NN O O
products NN O O
may NN O O
be NN O O
misleading NN O O
. NN O O
Hypersensitivity NN O O
Reactions NN O O
The NN O O
following NN O O
symptoms NN O O
that NN O O
could NN O O
be NN O O
compatible NN O O
with NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
rarely NN O O
following NN O O
CIMZIA NN O O
administration NN O O
to NN O O
patients NN O O
: NN O O
angioedema NN B-AdverseReaction B-AdverseReaction
dermatitis NN B-AdverseReaction B-AdverseReaction
allergic NN I-AdverseReaction I-AdverseReaction
dizziness NN O O
( NN O O
postural NN O O
) NN O O
, NN O O
dyspnea NN B-AdverseReaction B-AdverseReaction
hot NN B-AdverseReaction B-AdverseReaction
flush NN I-AdverseReaction I-AdverseReaction
hypotension NN B-AdverseReaction B-AdverseReaction
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
malaise NN B-AdverseReaction B-AdverseReaction
pyrexia NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
serum NN B-AdverseReaction B-AdverseReaction
sickness NN I-AdverseReaction I-AdverseReaction
and NN O O
( NN O O
vasovagal NN O O
) NN O O
syncope NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
. NN O O
6.2 NN O O
Postmarketing NN O O
Experience NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
identified NN O O
during NN O O
post NN O O
- NN O O
approval NN O O
use NN O O
of NN O O
CIMZIA. NN O O
Because NN O O
these NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
estimate NN O O
reliably NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
Vascular NN O O
disorder NN O O
: NN O O
systemic NN B-AdverseReaction B-AdverseReaction
vasculitis NN I-AdverseReaction I-AdverseReaction
has NN O O
been NN O O
identified NN O O
during NN O O
post NN O O
- NN O O
approval NN O O
use NN O O
of NN O O
TNF NN B-DrugClass B-DrugClass
blockers NN I-DrugClass I-DrugClass
Skin NN O O
: NN O O
case NN O O
of NN O O
severe NN B-Severity B-Severity
skin NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
Stevens NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Johnson NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
toxic NN B-AdverseReaction B-AdverseReaction
epidermal NN I-AdverseReaction I-AdverseReaction
necrolysis NN I-AdverseReaction I-AdverseReaction
erythema NN B-AdverseReaction B-AdverseReaction
multiforme NN I-AdverseReaction I-AdverseReaction
and NN O O
new NN O O
or NN O O
worsening NN O O
psoriasis NN B-AdverseReaction B-AdverseReaction
( NN O O
all NN O O
sub NN O O
- NN O O
types NN O O
including NN O O
pustular NN O O
and NN O O
palmoplantar NN O O
) NN O O
have NN O O
been NN O O
identified NN O O
during NN O O
post NN O O
- NN O O
approval NN O O
use NN O O
of NN O O
TNF NN B-DrugClass B-DrugClass
blockers NN I-DrugClass I-DrugClass
Immune NN O O
System NN O O
Disorders NN O O
: NN O O
sarcoidosis NN B-AdverseReaction B-AdverseReaction
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
SERIOUS NN B-Severity B-Severity
INFECTIONS NN B-AdverseReaction B-AdverseReaction
AND NN O O
MALIGNANCY NN B-AdverseReaction B-AdverseReaction
WARNING NN O O
: NN O O
SERIOUS NN B-Severity B-Severity
INFECTIONS NN B-AdverseReaction B-AdverseReaction
AND NN O O
MALIGNANCY NN B-AdverseReaction B-AdverseReaction
SERIOUS NN O O
INFECTIONS NN O O
Patients NN O O
treated NN O O
with NN O O
CIMZIA NN O O
are NN O O
at NN O O
increased NN O O
risk NN B-Factor B-Factor
for NN O O
developing NN O O
serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
that NN O O
may NN B-Factor B-Factor
lead NN O O
to NN O O
hospitalization NN O O
or NN O O
death NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
and NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Most NN O O
patients NN O O
who NN O O
developed NN O O
these NN O O
infections NN B-AdverseReaction B-AdverseReaction
were NN O O
taking NN O O
concomitant NN O O
immunosuppressants NN O O
such NN O O
as NN O O
methotrexate NN O O
or NN O O
corticosteroids NN O O
. NN O O
CIMZIA NN O O
should NN O O
be NN O O
discontinued NN O O
if NN O O
a NN O O
patient NN O O
develops NN O O
a NN O O
serious NN O O
infection NN O O
or NN O O
sepsis NN O O
. NN O O
Reported NN O O
infections NN O O
include NN O O
: NN O O
* NN O O
Active NN B-AdverseReaction B-AdverseReaction
tuberculosis NN I-AdverseReaction I-AdverseReaction
including NN O O
reactivation NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
latent NN I-AdverseReaction I-AdverseReaction
tuberculosis NN I-AdverseReaction I-AdverseReaction
Patients NN O O
with NN O O
tuberculosis NN O O
have NN O O
frequently NN O O
presented NN O O
with NN O O
disseminated NN O O
or NN O O
extrapulmonary NN O O
disease NN O O
. NN O O
Patients NN O O
should NN O O
be NN O O
tested NN O O
for NN O O
latent NN O O
tuberculosis NN O O
before NN O O
CIMZIA NN O O
use NN O O
and NN O O
during NN O O
therapy NN O O
. NN O O
Treatment NN O O
for NN O O
latent NN O O
infection NN O O
should NN O O
be NN O O
initiated NN O O
prior NN O O
to NN O O
CIMZIA NN O O
use NN O O
. NN O O
* NN O O
Invasive NN B-AdverseReaction B-AdverseReaction
fungal NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
including NN O O
histoplasmosis NN B-AdverseReaction B-AdverseReaction
coccidioidomycosis NN B-AdverseReaction B-AdverseReaction
candidiasis NN B-AdverseReaction B-AdverseReaction
aspergillosis NN B-AdverseReaction B-AdverseReaction
blastomycosis NN B-AdverseReaction B-AdverseReaction
and NN O O
pneumocystosis NN B-AdverseReaction B-AdverseReaction
Patients NN O O
with NN O O
histoplasmosis NN B-AdverseReaction B-AdverseReaction
or NN O O
other NN O O
invasive NN B-AdverseReaction B-AdverseReaction
fungal NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
may NN B-Factor B-Factor
present NN O O
with NN O O
disseminated NN O O
, NN O O
rather NN O O
than NN O O
localized NN O O
disease NN O O
. NN O O
Antigen NN O O
and NN O O
antibody NN O O
testing NN O O
for NN O O
histoplasmosis NN O O
may NN O O
be NN O O
negative NN O O
in NN O O
some NN O O
patients NN O O
with NN O O
active NN O O
infection NN O O
. NN O O
Empiric NN O O
anti NN O O
- NN O O
fungal NN O O
therapy NN O O
should NN O O
be NN O O
considered NN O O
in NN O O
patients NN O O
at NN O O
risk NN O O
for NN O O
invasive NN O O
fungal NN O O
infections NN O O
who NN O O
develop NN O O
severe NN O O
systemic NN O O
illness NN O O
. NN O O
* NN O O
Bacterial NN O O
, NN O O
viral NN O O
and NN O O
other NN O O
infections NN O O
due NN O O
to NN O O
opportunistic NN O O
pathogens NN O O
, NN O O
including NN O O
Legionella NN O O
and NN O O
Listeria NN O O
. NN O O
The NN O O
risks NN O O
and NN O O
benefits NN O O
of NN O O
treatment NN O O
with NN O O
CIMZIA NN O O
should NN O O
be NN O O
carefully NN O O
considered NN O O
prior NN O O
to NN O O
initiating NN O O
therapy NN O O
in NN O O
patients NN O O
with NN O O
chronic NN O O
or NN O O
recurrent NN O O
infection NN O O
. NN O O
Patients NN O O
should NN O O
be NN O O
closely NN O O
monitored NN O O
for NN O O
the NN O O
development NN O O
of NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
infection NN O O
during NN O O
and NN O O
after NN O O
treatment NN O O
with NN O O
CIMZIA NN O O
, NN O O
including NN O O
the NN O O
possible NN O O
development NN O O
of NN O O
tuberculosis NN O O
in NN O O
patients NN O O
who NN O O
tested NN O O
negative NN O O
for NN O O
latent NN O O
tuberculosis NN O O
infection NN O O
prior NN O O
to NN O O
initiating NN O O
therapy NN O O
. NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
and NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
MALIGNANCY NN O O
Lymphoma NN B-AdverseReaction B-AdverseReaction
and NN O O
other NN O O
malignancies NN B-AdverseReaction B-AdverseReaction
some NN O O
fatal NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
children NN O O
and NN O O
adolescent NN O O
patients NN O O
treated NN O O
with NN O O
TNF NN B-DrugClass B-DrugClass
blockers NN I-DrugClass I-DrugClass
of NN O O
which NN O O
CIMZIA NN O O
is NN O O
a NN O O
member NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
CIMZIA NN O O
is NN O O
not NN O O
indicated NN O O
for NN O O
use NN O O
in NN O O
pediatric NN O O
patients NN O O
. NN O O
EXCERPT NN O O
: NN O O
WARNING NN O O
: NN O O
SERIOUS NN B-Severity B-Severity
INFECTIONS NN B-AdverseReaction B-AdverseReaction
AND NN O O
MALIGNANCY NN B-AdverseReaction B-AdverseReaction
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
. NN O O
* NN O O
Increased NN O O
risk NN B-Factor B-Factor
of NN O O
serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
leading NN O O
to NN O O
hospitalization NN O O
or NN O O
death NN B-AdverseReaction B-AdverseReaction
including NN O O
tuberculosis NN B-AdverseReaction B-AdverseReaction
( NN O O
TB NN O O
) NN O O
, NN O O
bacterial NN B-AdverseReaction B-AdverseReaction
sepsis NN I-AdverseReaction I-AdverseReaction
invasive NN B-AdverseReaction B-AdverseReaction
fungal NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
( NN O O
such NN O O
as NN O O
histoplasmosis NN B-AdverseReaction B-AdverseReaction
and NN O O
infections NN B-AdverseReaction B-AdverseReaction
due NN I-AdverseReaction I-AdverseReaction
to NN I-AdverseReaction I-AdverseReaction
other NN I-AdverseReaction I-AdverseReaction
opportunistic NN I-AdverseReaction I-AdverseReaction
pathogens NN I-AdverseReaction I-AdverseReaction
( NN O O
5.1 NN O O
) NN O O
. NN O O
* NN O O
CIMZIA NN O O
should NN O O
be NN O O
discontinued NN O O
if NN O O
a NN O O
patient NN O O
develops NN O O
a NN O O
serious NN O O
infection NN O O
or NN O O
sepsis NN O O
( NN O O
5.1 NN O O
) NN O O
. NN O O
* NN O O
Perform NN O O
test NN O O
for NN O O
latent NN O O
TB NN O O
; NN O O
if NN O O
positive NN O O
, NN O O
start NN O O
treatment NN O O
for NN O O
TB NN O O
prior NN O O
to NN O O
starting NN O O
CIMZIA NN O O
( NN O O
5.1 NN O O
) NN O O
. NN O O
* NN O O
Monitor NN O O
all NN O O
patients NN O O
for NN O O
active NN O O
TB NN O O
during NN O O
treatment NN O O
, NN O O
even NN O O
if NN O O
initial NN O O
latent NN O O
TB NN O O
test NN O O
is NN O O
negative NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Lymphoma NN B-AdverseReaction B-AdverseReaction
and NN O O
other NN O O
malignancies NN B-AdverseReaction B-AdverseReaction
some NN O O
fatal NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
children NN O O
and NN O O
adolescent NN O O
patients NN O O
treated NN O O
with NN O O
TNF NN B-DrugClass B-DrugClass
blockers NN I-DrugClass I-DrugClass
of NN O O
which NN O O
CIMZIA NN O O
is NN O O
a NN O O
member NN O O
( NN O O
5.2 NN O O
) NN O O
. NN O O
CIMZIA NN O O
is NN O O
not NN O O
indicated NN O O
for NN O O
use NN O O
in NN O O
pediatric NN O O
patients NN O O
. NN O O
( NN O O
8.4 NN O O
) NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
- NN O O
do NN O O
not NN O O
start NN O O
CIMZIA NN O O
during NN O O
an NN O O
active NN O O
infection NN O O
. NN O O
If NN O O
an NN O O
infection NN O O
develops NN O O
, NN O O
monitor NN O O
carefully NN O O
, NN O O
and NN O O
stop NN O O
CIMZIA NN O O
if NN O O
infection NN O O
becomes NN O O
serious NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Invasive NN B-AdverseReaction B-AdverseReaction
fungal NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
- NN O O
for NN O O
patients NN O O
who NN O O
develop NN O O
a NN O O
systemic NN O O
illness NN O O
on NN O O
CIMZIA NN O O
, NN O O
consider NN O O
empiric NN O O
antifungal NN O O
therapy NN O O
for NN O O
those NN O O
who NN O O
reside NN O O
or NN O O
travel NN O O
to NN O O
regions NN O O
where NN O O
mycoses NN O O
are NN O O
endemic NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Cases NN O O
of NN O O
lymphoma NN B-AdverseReaction B-AdverseReaction
and NN O O
other NN O O
malignancies NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
observed NN O O
among NN O O
patients NN O O
receiving NN O O
TNF NN B-DrugClass B-DrugClass
blockers NN I-DrugClass I-DrugClass
( NN O O
5.2 NN O O
) NN O O
* NN O O
Heart NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
, NN I-AdverseReaction I-AdverseReaction
worsening NN I-AdverseReaction I-AdverseReaction
or NN O O
new NN O O
onset NN O O
may NN B-Factor B-Factor
occur NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Anaphylaxis NN B-AdverseReaction B-AdverseReaction
or NN O O
serious NN B-Severity B-Severity
allergic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
may NN B-Factor B-Factor
occur NN O O
( NN O O
5.4 NN O O
) NN O O
* NN O O
Hepatitis NN B-AdverseReaction B-AdverseReaction
B NN I-AdverseReaction I-AdverseReaction
virus NN I-AdverseReaction I-AdverseReaction
reactivation NN I-AdverseReaction I-AdverseReaction
- NN O O
test NN O O
for NN O O
HBV NN O O
infection NN O O
before NN O O
starting NN O O
CIMZIA. NN O O
Monitor NN O O
HBV NN O O
carriers NN O O
during NN O O
and NN O O
several NN O O
months NN O O
after NN O O
therapy NN O O
. NN O O
If NN O O
reactivation NN O O
occurs NN O O
, NN O O
stop NN O O
CIMZIA NN O O
and NN O O
begin NN O O
anti NN O O
- NN O O
viral NN O O
therapy NN O O
( NN O O
5.5 NN O O
) NN O O
* NN O O
Demyelinating NN B-AdverseReaction B-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
exacerbation NN O O
or NN O O
new NN O O
onset NN O O
, NN O O
may NN B-Factor B-Factor
occur NN O O
( NN O O
5.6 NN O O
) NN O O
* NN O O
Cytopenias NN B-AdverseReaction B-AdverseReaction
pancytopenia NN B-AdverseReaction B-AdverseReaction
- NN O O
advise NN O O
patients NN O O
to NN O O
seek NN O O
immediate NN O O
medical NN O O
attention NN O O
if NN O O
symptoms NN O O
develop NN O O
, NN O O
and NN O O
consider NN O O
stopping NN O O
CIMZIA NN O O
( NN O O
5.7 NN O O
) NN O O
* NN O O
Lupus NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
like NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
- NN O O
stop NN O O
CIMZIA NN O O
if NN O O
syndrome NN O O
develops NN O O
( NN O O
5.9 NN O O
) NN O O
5.1 NN O O
Risk NN O O
of NN O O
Serious NN O O
Infections NN O O
[ NN O O
see NN O O
Boxed NN O O
Warning NN O O
] NN O O
Patients NN O O
treated NN O O
with NN O O
CIMZIA NN O O
are NN O O
at NN O O
an NN O O
increased NN O O
risk NN B-Factor B-Factor
for NN O O
developing NN O O
serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
involving NN O O
various NN O O
organ NN O O
systems NN O O
and NN O O
sites NN O O
that NN O O
may NN B-Factor B-Factor
lead NN O O
to NN O O
hospitalization NN O O
or NN O O
death NN B-AdverseReaction B-AdverseReaction
Opportunistic NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
due NN O O
to NN O O
bacterial NN O O
, NN O O
mycobacterial NN O O
, NN O O
invasive NN O O
fungal NN O O
, NN O O
viral NN O O
, NN O O
parasitic NN O O
, NN O O
or NN O O
other NN O O
opportunistic NN O O
pathogens NN O O
including NN O O
aspergillosis NN B-AdverseReaction B-AdverseReaction
blastomycosis NN B-AdverseReaction B-AdverseReaction
candidiasis NN B-AdverseReaction B-AdverseReaction
coccidioidomycosis NN B-AdverseReaction B-AdverseReaction
histoplasmosis NN B-AdverseReaction B-AdverseReaction
legionellosis NN B-AdverseReaction B-AdverseReaction
listeriosis NN B-AdverseReaction B-AdverseReaction
pneumocystosis NN B-AdverseReaction B-AdverseReaction
and NN O O
tuberculosis NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
with NN O O
TNF NN B-DrugClass B-DrugClass
blockers NN I-DrugClass I-DrugClass
Patients NN O O
have NN O O
frequently NN O O
presented NN O O
with NN O O
disseminated NN O O
rather NN O O
than NN O O
localized NN O O
disease NN O O
. NN O O
Treatment NN O O
with NN O O
CIMZIA NN O O
should NN O O
not NN O O
be NN O O
initiated NN O O
in NN O O
patients NN O O
with NN O O
an NN O O
active NN O O
infection NN O O
, NN O O
including NN O O
clinically NN O O
important NN O O
localized NN O O
infections NN O O
. NN O O
Patients NN O O
greater NN O O
than NN O O
65 NN O O
years NN O O
of NN O O
age NN O O
, NN O O
patients NN O O
with NN O O
co NN O O
- NN O O
morbid NN O O
conditions NN O O
, NN O O
and/or NN O O
patients NN O O
taking NN O O
concomitant NN O O
immunosuppressants NN O O
( NN O O
e.g. NN O O
corticosteroids NN O O
or NN O O
methotrexate NN O O
) NN O O
may NN O O
be NN O O
at NN O O
a NN O O
greater NN O O
risk NN B-Factor B-Factor
of NN O O
infection NN B-AdverseReaction B-AdverseReaction
The NN O O
risks NN O O
and NN O O
benefits NN O O
of NN O O
treatment NN O O
should NN O O
be NN O O
considered NN O O
prior NN O O
to NN O O
initiating NN O O
therapy NN O O
in NN O O
patients NN O O
: NN O O
* NN O O
with NN O O
chronic NN O O
or NN O O
recurrent NN O O
infection NN O O
* NN O O
who NN O O
have NN O O
been NN O O
exposed NN O O
to NN O O
tuberculosis NN O O
* NN O O
with NN O O
a NN O O
history NN O O
of NN O O
an NN O O
opportunistic NN O O
infection NN O O
* NN O O
who NN O O
have NN O O
resided NN O O
or NN O O
traveled NN O O
in NN O O
areas NN O O
of NN O O
endemic NN O O
tuberculosis NN O O
or NN O O
endemic NN O O
mycoses NN O O
, NN O O
such NN O O
as NN O O
histoplasmosis NN O O
, NN O O
coccidioidomycosis NN O O
, NN O O
or NN O O
blastomycosis NN O O
* NN O O
with NN O O
underlying NN O O
conditions NN O O
that NN O O
may NN O O
predispose NN O O
them NN O O
to NN O O
infection NN O O
Tuberculosis NN O O
Cases NN O O
of NN O O
reactivation NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
tuberculosis NN I-AdverseReaction I-AdverseReaction
or NN O O
new NN O O
tuberculosis NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
observed NN O O
in NN O O
patients NN O O
receiving NN O O
CIMZIA NN O O
, NN O O
including NN O O
patients NN O O
who NN O O
have NN O O
previously NN O O
received NN O O
treatment NN O O
for NN O O
latent NN O O
or NN O O
active NN O O
tuberculosis NN O O
. NN O O
Patients NN O O
should NN O O
be NN O O
evaluated NN O O
for NN O O
tuberculosis NN O O
risk NN O O
factors NN O O
and NN O O
tested NN O O
for NN O O
latent NN O O
infection NN O O
prior NN O O
to NN O O
initiating NN O O
CIMZIA NN O O
and NN O O
periodically NN O O
during NN O O
therapy NN O O
. NN O O
Treatment NN O O
of NN O O
latent NN O O
tuberculosis NN O O
infection NN O O
prior NN O O
to NN O O
therapy NN O O
with NN O O
TNF NN O O
- NN O O
blocking NN O O
agents NN O O
has NN O O
been NN O O
shown NN O O
to NN O O
reduce NN O O
the NN O O
risk NN O O
of NN O O
tuberculosis NN O O
reactivation NN O O
during NN O O
therapy NN O O
. NN O O
Induration NN O O
of NN O O
5 NN O O
mm NN O O
or NN O O
greater NN O O
with NN O O
tuberculin NN O O
skin NN O O
testing NN O O
should NN O O
be NN O O
considered NN O O
a NN O O
positive NN O O
test NN O O
result NN O O
when NN O O
assessing NN O O
if NN O O
treatment NN O O
for NN O O
latent NN O O
tuberculosis NN O O
is NN O O
needed NN O O
prior NN O O
to NN O O
initiating NN O O
CIMZIA NN O O
, NN O O
even NN O O
for NN O O
patients NN O O
previously NN O O
vaccinated NN O O
with NN O O
Bacille NN O O
Calmette NN O O
- NN O O
Guerin NN O O
( NN O O
BCG NN O O
) NN O O
. NN O O
Anti NN O O
- NN O O
tuberculosis NN O O
therapy NN O O
should NN O O
also NN O O
be NN O O
considered NN O O
prior NN O O
to NN O O
initiation NN O O
of NN O O
CIMZIA NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
past NN O O
history NN O O
of NN O O
latent NN O O
or NN O O
active NN O O
tuberculosis NN O O
in NN O O
whom NN O O
an NN O O
adequate NN O O
course NN O O
of NN O O
treatment NN O O
can NN O O
not NN O O
be NN O O
confirmed NN O O
, NN O O
and NN O O
for NN O O
patients NN O O
with NN O O
a NN O O
negative NN O O
test NN O O
for NN O O
latent NN O O
tuberculosis NN O O
but NN O O
having NN O O
risk NN O O
factors NN O O
for NN O O
tuberculosis NN O O
infection NN O O
. NN O O
Consultation NN O O
with NN O O
a NN O O
physician NN O O
with NN O O
expertise NN O O
in NN O O
the NN O O
treatment NN O O
of NN O O
tuberculosis NN O O
is NN O O
recommended NN O O
to NN O O
aid NN O O
in NN O O
the NN O O
decision NN O O
of NN O O
whether NN O O
initiating NN O O
anti NN O O
- NN O O
tuberculosis NN O O
therapy NN O O
is NN O O
appropriate NN O O
for NN O O
an NN O O
individual NN O O
patient NN O O
. NN O O
Tuberculosis NN O O
should NN O O
be NN O O
strongly NN O O
considered NN O O
in NN O O
patients NN O O
who NN O O
develop NN O O
a NN O O
new NN O O
infection NN O O
during NN O O
CIMZIA NN O O
treatment NN O O
, NN O O
especially NN O O
in NN O O
patients NN O O
who NN O O
have NN O O
previously NN O O
or NN O O
recently NN O O
traveled NN O O
to NN O O
countries NN O O
with NN O O
a NN O O
high NN O O
prevalence NN O O
of NN O O
tuberculosis NN O O
, NN O O
or NN O O
who NN O O
have NN O O
had NN O O
close NN O O
contact NN O O
with NN O O
a NN O O
person NN O O
with NN O O
active NN O O
tuberculosis NN O O
. NN O O
Monitoring NN O O
Patients NN O O
should NN O O
be NN O O
closely NN O O
monitored NN O O
for NN O O
the NN O O
development NN O O
of NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
infection NN O O
during NN O O
and NN O O
after NN O O
treatment NN O O
with NN O O
CIMZIA NN O O
, NN O O
including NN O O
the NN O O
development NN O O
of NN O O
tuberculosis NN O O
in NN O O
patients NN O O
who NN O O
tested NN O O
negative NN O O
for NN O O
latent NN O O
tuberculosis NN O O
infection NN O O
prior NN O O
to NN O O
initiating NN O O
therapy NN O O
. NN O O
Tests NN O O
for NN O O
latent NN O O
tuberculosis NN O O
infection NN O O
may NN O O
also NN O O
be NN O O
falsely NN O O
negative NN O O
while NN O O
on NN O O
therapy NN O O
with NN O O
CIMZIA. NN O O
CIMZIA NN O O
should NN O O
be NN O O
discontinued NN O O
if NN O O
a NN O O
patient NN O O
develops NN O O
a NN O O
serious NN O O
infection NN O O
or NN O O
sepsis NN O O
. NN O O
A NN O O
patient NN O O
who NN O O
develops NN O O
a NN O O
new NN O O
infection NN O O
during NN O O
treatment NN O O
with NN O O
CIMZIA NN O O
should NN O O
be NN O O
closely NN O O
monitored NN O O
, NN O O
undergo NN O O
a NN O O
prompt NN O O
and NN O O
complete NN O O
diagnostic NN O O
workup NN O O
appropriate NN O O
for NN O O
an NN O O
immunocompromised NN O O
patient NN O O
, NN O O
and NN O O
appropriate NN O O
antimicrobial NN O O
therapy NN O O
should NN O O
be NN O O
initiated NN O O
. NN O O
Invasive NN O O
Fungal NN O O
Infections NN O O
For NN O O
patients NN O O
who NN O O
reside NN O O
or NN O O
travel NN O O
in NN O O
regions NN O O
where NN O O
mycoses NN O O
are NN O O
endemic NN O O
, NN O O
invasive NN O O
fungal NN O O
infection NN O O
should NN O O
be NN O O
suspected NN O O
if NN O O
they NN O O
develop NN O O
a NN O O
serious NN O O
systemic NN O O
illness NN O O
. NN O O
Appropriate NN O O
empiric NN O O
antifungal NN O O
therapy NN O O
should NN O O
be NN O O
considered NN O O
while NN O O
a NN O O
diagnostic NN O O
workup NN O O
is NN O O
being NN O O
performed NN O O
. NN O O
Antigen NN O O
and NN O O
antibody NN O O
testing NN O O
for NN O O
histoplasmosis NN O O
may NN O O
be NN O O
negative NN O O
in NN O O
some NN O O
patients NN O O
with NN O O
active NN O O
infection NN O O
. NN O O
When NN O O
feasible NN O O
, NN O O
the NN O O
decision NN O O
to NN O O
administer NN O O
empiric NN O O
antifungal NN O O
therapy NN O O
in NN O O
these NN O O
patients NN O O
should NN O O
be NN O O
made NN O O
in NN O O
consultation NN O O
with NN O O
a NN O O
physician NN O O
with NN O O
expertise NN O O
in NN O O
the NN O O
diagnosis NN O O
and NN O O
treatment NN O O
of NN O O
invasive NN O O
fungal NN O O
infections NN O O
and NN O O
should NN O O
take NN O O
into NN O O
account NN O O
both NN O O
the NN O O
risk NN O O
for NN O O
severe NN O O
fungal NN O O
infection NN O O
and NN O O
risks NN O O
of NN O O
antifungal NN O O
therapy NN O O
. NN O O
5.2 NN O O
Malignancies NN O O
In NN O O
the NN O O
controlled NN O O
portions NN O O
of NN O O
clinical NN O O
studies NN O O
of NN O O
some NN O O
TNF NN O O
blockers NN O O
, NN O O
more NN O O
cases NN O O
of NN O O
malignancies NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
observed NN O O
among NN O O
patients NN O O
receiving NN O O
TNF NN B-DrugClass B-DrugClass
blockers NN I-DrugClass I-DrugClass
compared NN O O
to NN O O
control NN O O
patients NN O O
. NN O O
During NN O O
controlled NN O O
and NN O O
open NN O O
- NN O O
labeled NN O O
portions NN O O
of NN O O
CIMZIA NN O O
studies NN O O
of NN O O
Crohn NN O O
's NN O O
disease NN O O
and NN O O
other NN O O
diseases NN O O
, NN O O
malignancies NN B-AdverseReaction B-AdverseReaction
( NN O O
excluding NN O O
non NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
melanoma NN I-AdverseReaction I-AdverseReaction
skin NN I-AdverseReaction I-AdverseReaction
cancer NN I-AdverseReaction I-AdverseReaction
were NN O O
observed NN O O
at NN O O
a NN O O
rate NN O O
( NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
) NN O O
of NN O O
0.5 NN O O
( NN O O
0.4 NN O O
, NN O O
0.7 NN O O
) NN O O
per NN O O
100 NN O O
patient NN O O
- NN O O
years NN O O
among NN O O
4,650 NN O O
CIMZIA NN O O
- NN O O
treated NN O O
patients NN O O
versus NN O O
a NN O O
rate NN O O
of NN O O
0.6 NN O O
( NN O O
0.1 NN O O
, NN O O
1.7 NN O O
) NN O O
per NN O O
100 NN O O
patient NN O O
- NN O O
years NN O O
among NN O O
1,319 NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
The NN O O
size NN O O
of NN O O
the NN O O
control NN O O
group NN O O
and NN O O
limited NN O O
duration NN O O
of NN O O
the NN O O
controlled NN O O
portions NN O O
of NN O O
the NN O O
studies NN O O
precludes NN O O
the NN O O
ability NN O O
to NN O O
draw NN O O
firm NN O O
conclusions NN O O
. NN O O
Malignancies NN B-AdverseReaction B-AdverseReaction
some NN O O
fatal NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
among NN O O
children NN O O
, NN O O
adolescents NN O O
, NN O O
and NN O O
young NN O O
adults NN O O
who NN O O
received NN O O
treatment NN O O
with NN O O
TNF NN B-DrugClass B-DrugClass
- NN I-DrugClass I-DrugClass
blocking NN I-DrugClass I-DrugClass
agents NN I-DrugClass I-DrugClass
( NN O O
initiation NN O O
of NN O O
therapy NN O O
< NN O O
= NN O O
18 NN O O
years NN O O
of NN O O
age NN O O
) NN O O
, NN O O
of NN O O
which NN O O
CIMZIA NN O O
is NN O O
a NN O O
member NN O O
. NN O O
Approximately NN O O
half NN O O
the NN O O
cases NN O O
were NN O O
lymphomas NN B-AdverseReaction B-AdverseReaction
including NN O O
Hodgkin NN O O
's NN O O
and NN O O
non NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Hodgkin NN I-AdverseReaction I-AdverseReaction
's NN I-AdverseReaction I-AdverseReaction
lymphoma NN I-AdverseReaction I-AdverseReaction
The NN O O
other NN O O
cases NN O O
represented NN O O
a NN O O
variety NN O O
of NN O O
different NN O O
malignancies NN B-AdverseReaction B-AdverseReaction
and NN O O
included NN O O
rare NN B-AdverseReaction B-AdverseReaction
malignancies NN I-AdverseReaction I-AdverseReaction
usually NN O O
associated NN O O
with NN O O
immunosuppression NN O O
and NN O O
malignancies NN B-AdverseReaction B-AdverseReaction
that NN O O
are NN O O
not NN O O
usually NN O O
observed NN O O
in NN O O
children NN O O
and NN O O
adolescents NN O O
. NN O O
The NN O O
malignancies NN B-AdverseReaction B-AdverseReaction
occurred NN O O
after NN O O
a NN O O
median NN O O
of NN O O
30 NN O O
months NN O O
of NN O O
therapy NN O O
( NN O O
range NN O O
1 NN O O
to NN O O
84 NN O O
months NN O O
) NN O O
. NN O O
Most NN O O
of NN O O
the NN O O
patients NN O O
were NN O O
receiving NN O O
concomitant NN O O
immunosuppressants NN O O
. NN O O
These NN O O
cases NN O O
were NN O O
reported NN O O
post NN O O
- NN O O
marketing NN O O
and NN O O
are NN O O
derived NN O O
from NN O O
a NN O O
variety NN O O
of NN O O
sources NN O O
including NN O O
registries NN O O
and NN O O
spontaneous NN O O
post NN O O
- NN O O
marketing NN O O
reports NN O O
. NN O O
CIMZIA NN O O
is NN O O
not NN O O
indicated NN O O
for NN O O
use NN O O
in NN O O
pediatric NN O O
patients NN O O
. NN O O
In NN O O
the NN O O
controlled NN O O
portions NN O O
of NN O O
clinical NN O O
trials NN O O
of NN O O
all NN O O
the NN O O
TNF NN O O
blockers NN O O
, NN O O
more NN O O
cases NN O O
of NN O O
lymphoma NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
observed NN O O
among NN O O
patients NN O O
receiving NN O O
TNF NN B-DrugClass B-DrugClass
blockers NN I-DrugClass I-DrugClass
compared NN O O
to NN O O
control NN O O
patients NN O O
. NN O O
In NN O O
controlled NN O O
studies NN O O
of NN O O
CIMZIA NN O O
for NN O O
Crohn NN O O
's NN O O
disease NN O O
and NN O O
other NN O O
investigational NN O O
uses NN O O
, NN O O
there NN O O
was NN O O
one NN O O
case NN O O
of NN O O
lymphoma NN B-AdverseReaction B-AdverseReaction
among NN O O
2,657 NN O O
Cimzia NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
one NN O O
case NN O O
of NN O O
Hodgkin NN B-AdverseReaction B-AdverseReaction
's NN I-AdverseReaction I-AdverseReaction
lymphoma NN I-AdverseReaction I-AdverseReaction
among NN O O
1,319 NN O O
placebo NN B-Factor B-Factor
patients NN O O
. NN O O
In NN O O
the NN O O
CIMZIA NN O O
RA NN O O
clinical NN O O
trials NN O O
( NN O O
placebo NN O O
- NN O O
controlled NN O O
and NN O O
open NN O O
label NN O O
) NN O O
a NN O O
total NN O O
of NN O O
three NN O O
cases NN O O
of NN O O
lymphoma NN B-AdverseReaction B-AdverseReaction
were NN O O
observed NN O O
among NN O O
2,367 NN O O
patients NN O O
. NN O O
This NN O O
is NN O O
approximately NN O O
2-fold NN O O
higher NN O O
than NN O O
expected NN O O
in NN O O
the NN O O
general NN O O
population NN O O
. NN O O
Patients NN O O
with NN O O
RA NN O O
, NN O O
particularly NN O O
those NN O O
with NN O O
highly NN O O
active NN O O
disease NN O O
, NN O O
are NN O O
at NN O O
a NN O O
higher NN O O
risk NN O O
for NN O O
the NN O O
development NN O O
of NN O O
lymphoma NN O O
. NN O O
Rates NN O O
in NN O O
clinical NN O O
studies NN O O
for NN O O
CIMZIA NN O O
can NN O O
not NN O O
be NN O O
compared NN O O
to NN O O
the NN O O
rates NN O O
of NN O O
clinical NN O O
trials NN O O
of NN O O
other NN O O
TNF NN O O
blockers NN O O
and NN O O
may NN O O
not NN O O
predict NN O O
the NN O O
rates NN O O
observed NN O O
when NN O O
CIMZIA NN O O
is NN O O
used NN O O
in NN O O
a NN O O
broader NN O O
patient NN O O
population NN O O
. NN O O
Patients NN O O
with NN O O
Crohn NN O O
's NN O O
disease NN O O
that NN O O
require NN O O
chronic NN O O
exposure NN O O
to NN O O
immunosuppressant NN B-DrugClass B-DrugClass
therapies NN I-DrugClass I-DrugClass
may NN O O
be NN O O
at NN O O
higher NN O O
risk NN O O
than NN O O
the NN O O
general NN O O
population NN O O
for NN O O
the NN O O
development NN O O
of NN O O
lymphoma NN B-AdverseReaction B-AdverseReaction
even NN O O
in NN O O
the NN O O
absence NN O O
of NN O O
TNF NN O O
blocker NN O O
therapy NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
potential NN O O
role NN O O
of NN O O
TNF NN O O
blocker NN O O
therapy NN O O
in NN O O
the NN O O
development NN O O
of NN O O
malignancies NN O O
in NN O O
adults NN O O
is NN O O
not NN O O
known NN O O
. NN O O
Postmarketing NN O O
cases NN O O
of NN O O
hepatosplenic NN B-AdverseReaction B-AdverseReaction
T NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
lymphoma NN I-AdverseReaction I-AdverseReaction
( NN O O
HSTCL NN O O
) NN O O
, NN O O
a NN O O
rare NN O O
type NN O O
of NN O O
T NN O O
- NN O O
cell NN O O
lymphoma NN O O
that NN O O
has NN O O
a NN O O
very NN O O
aggressive NN O O
disease NN O O
course NN O O
and NN O O
is NN O O
usually NN O O
fatal NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
TNF NN O O
blockers NN O O
, NN O O
including NN O O
CIMZIA. NN O O
The NN O O
majority NN O O
of NN O O
reported NN O O
TNF NN O O
blocker NN O O
cases NN O O
occurred NN O O
in NN O O
adolescent NN O O
and NN O O
young NN O O
adult NN O O
males NN O O
with NN O O
Crohn NN O O
's NN O O
disease NN O O
or NN O O
ulcerative NN O O
colitis NN O O
. NN O O
Almost NN O O
all NN O O
of NN O O
these NN O O
patients NN O O
had NN O O
received NN O O
treatment NN O O
with NN O O
the NN O O
immunosuppressants NN O O
azathioprine NN O O
and/or NN O O
6-mercaptopurine NN O O
( NN O O
6-MP NN O O
) NN O O
concomitantly NN O O
with NN O O
a NN O O
TNF NN O O
blocker NN O O
at NN O O
or NN O O
prior NN O O
to NN O O
diagnosis NN O O
. NN O O
It NN O O
is NN O O
uncertain NN O O
whether NN O O
the NN O O
occurrence NN O O
of NN O O
HSTCL NN O O
is NN O O
related NN O O
to NN O O
use NN O O
of NN O O
a NN O O
TNF NN O O
blocker NN O O
or NN O O
a NN O O
TNF NN O O
blocker NN O O
in NN O O
combination NN O O
with NN O O
these NN O O
other NN O O
immunosuppressants NN O O
. NN O O
The NN O O
potential NN O O
risk NN O O
of NN O O
using NN O O
a NN O O
TNF NN O O
blocker NN O O
in NN O O
combination NN O O
with NN O O
azathioprine NN O O
or NN O O
6-MP NN O O
should NN O O
be NN O O
carefully NN O O
considered NN O O
. NN O O
Cases NN O O
of NN O O
acute NN O O
and NN O O
chronic NN B-AdverseReaction B-AdverseReaction
leukemia NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
association NN O O
with NN O O
post NN O O
- NN O O
marketing NN O O
TNF NN B-DrugClass B-DrugClass
- NN I-DrugClass I-DrugClass
blocker NN I-DrugClass I-DrugClass
use NN O O
in NN O O
RA NN O O
and NN O O
other NN O O
indications NN O O
. NN O O
Even NN O O
in NN O O
the NN O O
absence NN O O
of NN O O
TNF NN O O
- NN O O
blocker NN O O
therapy NN O O
, NN O O
patients NN O O
with NN O O
RA NN O O
may NN O O
be NN O O
at NN O O
a NN O O
higher NN O O
risk NN O O
( NN O O
approximately NN O O
2-fold NN O O
) NN O O
than NN O O
the NN O O
general NN O O
population NN O O
for NN O O
the NN O O
development NN O O
of NN O O
leukemia NN O O
. NN O O
Periodic NN O O
skin NN O O
examinations NN O O
are NN O O
recommended NN O O
for NN O O
all NN O O
patients NN O O
, NN O O
particularly NN O O
those NN O O
with NN O O
risk NN O O
factors NN O O
for NN O O
skin NN O O
cancer NN O O
. NN O O
5.3 NN O O
Heart NN O O
Failure NN O O
Cases NN O O
of NN O O
worsening NN B-AdverseReaction B-AdverseReaction
congestive NN I-AdverseReaction I-AdverseReaction
heart NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
( NN O O
CHF NN O O
) NN O O
and NN O O
new NN B-AdverseReaction B-AdverseReaction
onset NN I-AdverseReaction I-AdverseReaction
CHF NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
with NN O O
TNF NN O O
blockers NN O O
, NN O O
including NN O O
CIMZIA. NN O O
CIMZIA NN O O
has NN O O
not NN O O
been NN O O
formally NN O O
studied NN O O
in NN O O
patients NN O O
with NN O O
CHF NN O O
; NN O O
however NN O O
, NN O O
in NN O O
clinical NN O O
studies NN O O
in NN O O
patients NN O O
with NN O O
CHF NN O O
with NN O O
another NN O O
TNF NN B-DrugClass B-DrugClass
blocker NN I-DrugClass I-DrugClass
worsening NN B-AdverseReaction B-AdverseReaction
congestive NN I-AdverseReaction I-AdverseReaction
heart NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
( NN O O
CHF NN O O
) NN O O
and NN O O
increased NN B-AdverseReaction B-AdverseReaction
mortality NN I-AdverseReaction I-AdverseReaction
due NN O O
to NN O O
CHF NN B-AdverseReaction B-AdverseReaction
were NN O O
observed NN O O
. NN O O
Exercise NN O O
caution NN O O
in NN O O
patients NN O O
with NN O O
heart NN O O
failure NN O O
and NN O O
monitor NN O O
them NN O O
carefully NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
5.4 NN O O
Hypersensitivity NN O O
Reactions NN O O
The NN O O
following NN O O
symptoms NN O O
that NN O O
could NN B-Factor B-Factor
be NN O O
compatible NN O O
with NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
rarely NN O O
following NN O O
CIMZIA NN O O
administration NN O O
to NN O O
patients NN O O
: NN O O
angioedema NN B-AdverseReaction B-AdverseReaction
dyspnea NN B-AdverseReaction B-AdverseReaction
hypotension NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
serum NN B-AdverseReaction B-AdverseReaction
sickness NN I-AdverseReaction I-AdverseReaction
and NN O O
urticaria NN B-AdverseReaction B-AdverseReaction
Some NN O O
of NN O O
these NN O O
reactions NN O O
occurred NN O O
after NN O O
the NN O O
first NN O O
administration NN O O
of NN O O
CIMZIA. NN O O
If NN O O
such NN O O
reactions NN O O
occur NN O O
, NN O O
discontinue NN O O
further NN O O
administration NN O O
of NN O O
CIMZIA NN O O
and NN O O
institute NN O O
appropriate NN O O
therapy NN O O
. NN O O
There NN O O
are NN O O
no NN O O
data NN O O
on NN O O
the NN O O
risks NN O O
of NN O O
using NN O O
CIMZIA NN O O
in NN O O
patients NN O O
who NN O O
have NN O O
experienced NN O O
a NN O O
severe NN O O
hypersensitivity NN O O
reaction NN O O
towards NN O O
another NN O O
TNF NN O O
blocker NN O O
; NN O O
in NN O O
these NN O O
patients NN O O
caution NN O O
is NN O O
needed NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
5.5 NN O O
Hepatitis NN O O
B NN O O
Virus NN O O
Reactivation NN O O
Use NN O O
of NN O O
TNF NN O O
blockers NN O O
, NN O O
including NN O O
CIMZIA NN O O
, NN O O
has NN O O
been NN O O
associated NN O O
with NN O O
reactivation NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
hepatitis NN I-AdverseReaction I-AdverseReaction
B NN I-AdverseReaction I-AdverseReaction
virus NN I-AdverseReaction I-AdverseReaction
( NN O O
HBV NN O O
) NN O O
in NN O O
patients NN O O
who NN O O
are NN O O
chronic NN O O
carriers NN O O
of NN O O
this NN O O
virus NN O O
. NN O O
In NN O O
some NN O O
instances NN O O
, NN O O
HBV NN B-AdverseReaction B-AdverseReaction
reactivation NN I-AdverseReaction I-AdverseReaction
occurring NN O O
in NN O O
conjunction NN O O
with NN O O
TNF NN B-DrugClass B-DrugClass
blocker NN I-DrugClass I-DrugClass
therapy NN O O
has NN O O
been NN O O
fatal NN B-AdverseReaction B-AdverseReaction
The NN O O
majority NN O O
of NN O O
reports NN O O
have NN O O
occurred NN O O
in NN O O
patients NN O O
concomitantly NN O O
receiving NN O O
other NN O O
medications NN O O
that NN O O
suppress NN O O
the NN O O
immune NN O O
system NN O O
, NN O O
which NN O O
may NN O O
also NN O O
contribute NN O O
to NN O O
HBV NN B-AdverseReaction B-AdverseReaction
reactivation NN I-AdverseReaction I-AdverseReaction
Test NN O O
patients NN O O
for NN O O
HBV NN O O
infection NN O O
before NN O O
initiating NN O O
treatment NN O O
with NN O O
CIMZIA. NN O O
For NN O O
patients NN O O
who NN O O
test NN O O
positive NN O O
for NN O O
HBV NN O O
infection NN O O
, NN O O
consultation NN O O
with NN O O
a NN O O
physician NN O O
with NN O O
expertise NN O O
in NN O O
the NN O O
treatment NN O O
of NN O O
hepatitis NN O O
B NN O O
is NN O O
recommended NN O O
. NN O O
Adequate NN O O
data NN O O
are NN O O
not NN O O
available NN O O
on NN O O
the NN O O
safety NN O O
or NN O O
efficacy NN O O
of NN O O
treating NN O O
patients NN O O
who NN O O
are NN O O
carriers NN O O
of NN O O
HBV NN O O
with NN O O
anti NN O O
- NN O O
viral NN O O
therapy NN O O
in NN O O
conjunction NN O O
with NN O O
TNF NN O O
blocker NN O O
therapy NN O O
to NN O O
prevent NN O O
HBV NN O O
reactivation NN O O
. NN O O
Patients NN O O
who NN O O
are NN O O
carriers NN O O
of NN O O
HBV NN O O
and NN O O
require NN O O
treatment NN O O
with NN O O
CIMZIA NN O O
should NN O O
be NN O O
closely NN O O
monitored NN O O
for NN O O
clinical NN O O
and NN O O
laboratory NN O O
signs NN O O
of NN O O
active NN O O
HBV NN O O
infection NN O O
throughout NN O O
therapy NN O O
and NN O O
for NN O O
several NN O O
months NN O O
following NN O O
termination NN O O
of NN O O
therapy NN O O
. NN O O
In NN O O
patients NN O O
who NN O O
develop NN O O
HBV NN O O
reactivation NN O O
, NN O O
discontinue NN O O
CIMZIA NN O O
and NN O O
initiate NN O O
effective NN O O
anti NN O O
- NN O O
viral NN O O
therapy NN O O
with NN O O
appropriate NN O O
supportive NN O O
treatment NN O O
. NN O O
The NN O O
safety NN O O
of NN O O
resuming NN O O
TNF NN O O
blocker NN O O
therapy NN O O
after NN O O
HBV NN O O
reactivation NN O O
is NN O O
controlled NN O O
is NN O O
not NN O O
known NN O O
. NN O O
Therefore NN O O
, NN O O
exercise NN O O
caution NN O O
when NN O O
considering NN O O
resumption NN O O
of NN O O
CIMZIA NN O O
therapy NN O O
in NN O O
this NN O O
situation NN O O
and NN O O
monitor NN O O
patients NN O O
closely NN O O
. NN O O
5.6 NN O O
Neurologic NN O O
Reactions NN O O
Use NN O O
of NN O O
TNF NN B-DrugClass B-DrugClass
blockers NN I-DrugClass I-DrugClass
of NN O O
which NN O O
CIMZIA NN O O
is NN O O
a NN O O
member NN O O
, NN O O
has NN O O
been NN O O
associated NN O O
with NN O O
rare NN O O
cases NN O O
of NN O O
new NN O O
onset NN O O
or NN O O
exacerbation NN O O
of NN O O
clinical NN O O
symptoms NN O O
and/or NN O O
radiographic NN O O
evidence NN O O
of NN O O
central NN B-AdverseReaction B-AdverseReaction
nervous NN I-AdverseReaction I-AdverseReaction
system NN I-AdverseReaction I-AdverseReaction
demyelinating NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
including NN O O
multiple NN B-AdverseReaction B-AdverseReaction
sclerosis NN I-AdverseReaction I-AdverseReaction
and NN O O
with NN O O
peripheral NN B-AdverseReaction B-AdverseReaction
demyelinating NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
including NN O O
Guillain NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Barre NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
. NN O O
Exercise NN O O
caution NN O O
in NN O O
considering NN O O
the NN O O
use NN O O
of NN O O
CIMZIA NN O O
in NN O O
patients NN O O
with NN O O
pre NN O O
- NN O O
existing NN O O
or NN O O
recent NN O O
- NN O O
onset NN O O
central NN O O
or NN O O
peripheral NN O O
nervous NN O O
system NN O O
demyelinating NN O O
disorders NN O O
. NN O O
Rare NN O O
cases NN O O
of NN O O
neurological NN B-AdverseReaction B-AdverseReaction
disorders NN I-AdverseReaction I-AdverseReaction
including NN O O
seizure NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
optic NN B-AdverseReaction B-AdverseReaction
neuritis NN I-AdverseReaction I-AdverseReaction
and NN O O
peripheral NN B-AdverseReaction B-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
CIMZIA NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
5.7 NN O O
Hematological NN O O
Reactions NN O O
Rare NN O O
reports NN O O
of NN O O
pancytopenia NN B-AdverseReaction B-AdverseReaction
including NN O O
aplastic NN B-AdverseReaction B-AdverseReaction
anemia NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
with NN O O
TNF NN B-DrugClass B-DrugClass
blockers NN I-DrugClass I-DrugClass
Adverse NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
hematologic NN I-AdverseReaction I-AdverseReaction
system NN I-AdverseReaction I-AdverseReaction
including NN O O
medically NN B-Severity B-Severity
significant NN I-Severity I-Severity
cytopenia NN B-AdverseReaction B-AdverseReaction
( NN O O
e.g. NN O O
, NN O O
leukopenia NN B-AdverseReaction B-AdverseReaction
pancytopenia NN B-AdverseReaction B-AdverseReaction
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
infrequently NN O O
reported NN O O
with NN O O
CIMZIA NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
causal NN O O
relationship NN O O
of NN O O
these NN O O
events NN O O
to NN O O
CIMZIA NN O O
remains NN O O
unclear NN O O
. NN O O
Although NN O O
no NN O O
high NN O O
risk NN O O
group NN O O
has NN O O
been NN O O
identified NN O O
, NN O O
exercise NN O O
caution NN O O
in NN O O
patients NN O O
being NN O O
treated NN O O
with NN O O
CIMZIA NN O O
who NN O O
have NN O O
ongoing NN O O
, NN O O
or NN O O
a NN O O
history NN O O
of NN O O
, NN O O
significant NN O O
hematologic NN O O
abnormalities NN O O
. NN O O
Advise NN O O
all NN O O
patients NN O O
to NN O O
seek NN O O
immediate NN O O
medical NN O O
attention NN O O
if NN O O
they NN O O
develop NN O O
signs NN O O
and NN O O
symptoms NN O O
suggestive NN O O
of NN O O
blood NN O O
dyscrasias NN O O
or NN O O
infection NN O O
( NN O O
e.g. NN O O
, NN O O
persistent NN O O
fever NN O O
, NN O O
bruising NN O O
, NN O O
bleeding NN O O
, NN O O
pallor NN O O
) NN O O
while NN O O
on NN O O
CIMZIA. NN O O
Consider NN O O
discontinuation NN O O
of NN O O
CIMZIA NN O O
therapy NN O O
in NN O O
patients NN O O
with NN O O
confirmed NN O O
significant NN O O
hematologic NN O O
abnormalities NN O O
. NN O O
5.8 NN O O
Use NN O O
with NN O O
Biological NN O O
Disease NN O O
- NN O O
Modifying NN O O
Antirheumatic NN O O
Drugs NN O O
( NN O O
Biological NN O O
DMARDs NN O O
) NN O O
Serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
were NN O O
seen NN O O
in NN O O
clinical NN O O
studies NN O O
with NN O O
concurrent NN O O
use NN O O
of NN O O
anakinra NN O O
( NN O O
an NN O O
interleukin-1 NN O O
antagonist NN O O
) NN O O
and NN O O
another NN O O
TNF NN O O
blocker NN O O
, NN O O
etanercept NN B-DrugClass B-DrugClass
with NN O O
no NN O O
added NN O O
benefit NN O O
compared NN O O
to NN O O
etanercept NN O O
alone NN O O
. NN O O
A NN O O
higher NN O O
risk NN B-Factor B-Factor
of NN O O
serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
was NN O O
also NN O O
observed NN O O
in NN O O
combination NN O O
use NN O O
of NN O O
TNF NN B-DrugClass B-DrugClass
blockers NN I-DrugClass I-DrugClass
with NN O O
abatacept NN O O
and NN O O
rituximab NN O O
. NN O O
Because NN O O
of NN O O
the NN O O
nature NN O O
of NN O O
the NN O O
adverse NN O O
events NN O O
seen NN O O
with NN O O
this NN O O
combination NN O O
therapy NN O O
, NN O O
similar NN O O
toxicities NN O O
may NN O O
also NN O O
result NN O O
from NN O O
the NN O O
use NN O O
of NN O O
CIMZIA NN O O
in NN O O
this NN O O
combination NN O O
. NN O O
Therefore NN O O
, NN O O
the NN O O
use NN O O
of NN O O
CIMZIA NN O O
in NN O O
combination NN O O
with NN O O
other NN O O
biological NN O O
DMARDs NN O O
is NN O O
not NN O O
recommended NN O O
[ NN O O
see NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.1 NN O O
) NN O O
] NN O O
. NN O O
5.9 NN O O
Autoimmunity NN O O
Treatment NN O O
with NN O O
CIMZIA NN O O
may NN B-Factor B-Factor
result NN O O
in NN O O
the NN O O
formation NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
autoantibodies NN I-AdverseReaction I-AdverseReaction
and NN O O
rarely NN O O
, NN O O
in NN O O
the NN O O
development NN O O
of NN O O
a NN O O
lupus NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
like NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
If NN O O
a NN O O
patient NN O O
develops NN O O
symptoms NN O O
suggestive NN O O
of NN O O
a NN O O
lupus NN O O
- NN O O
like NN O O
syndrome NN O O
following NN O O
treatment NN O O
with NN O O
CIMZIA NN O O
, NN O O
discontinue NN O O
treatment NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
5.10 NN O O
Immunizations NN O O
Patients NN O O
treated NN O O
with NN O O
CIMZIA NN O O
may NN O O
receive NN O O
vaccinations NN O O
, NN O O
except NN O O
for NN O O
live NN O O
or NN O O
live NN O O
attenuated NN O O
vaccines NN O O
. NN O O
No NN O O
data NN O O
are NN O O
available NN O O
on NN O O
the NN O O
response NN O O
to NN O O
live NN O O
vaccinations NN O O
or NN O O
the NN O O
secondary NN O O
transmission NN O O
of NN O O
infection NN O O
by NN O O
live NN O O
vaccines NN O O
in NN O O
patients NN O O
receiving NN O O
CIMZIA. NN O O
In NN O O
a NN O O
placebo NN O O
- NN O O
controlled NN O O
clinical NN O O
trial NN O O
of NN O O
patients NN O O
with NN O O
rheumatoid NN O O
arthritis NN O O
, NN O O
no NN O O
difference NN O O
was NN O O
detected NN O O
in NN O O
antibody NN O O
response NN O O
to NN O O
vaccine NN O O
between NN O O
CIMZIA NN O O
and NN O O
placebo NN O O
treatment NN O O
groups NN O O
when NN O O
the NN O O
pneumococcal NN O O
polysaccharide NN O O
vaccine NN O O
and NN O O
influenza NN O O
vaccine NN O O
were NN O O
administered NN O O
concurrently NN O O
with NN O O
CIMZIA. NN O O
Similar NN O O
proportions NN O O
of NN O O
patients NN O O
developed NN O O
protective NN O O
levels NN O O
of NN O O
anti NN O O
- NN O O
vaccine NN O O
antibodies NN O O
between NN O O
CIMZIA NN O O
and NN O O
placebo NN O O
treatment NN O O
groups NN O O
; NN O O
however NN O O
patients NN O O
receiving NN O O
CIMZIA NN O O
and NN O O
concomitant NN O O
methotrexate NN O O
had NN O O
a NN O O
lower NN O O
humoral NN O O
response NN O O
compared NN O O
with NN O O
patients NN O O
receiving NN O O
CIMZIA NN O O
alone NN O O
. NN O O
The NN O O
clinical NN O O
significance NN O O
of NN O O
this NN O O
is NN O O
unknown NN O O
. NN O O
5.11 NN O O
Immunosuppression NN O O
Since NN O O
TNF NN O O
mediates NN O O
inflammation NN O O
and NN O O
modulates NN O O
cellular NN O O
immune NN O O
responses NN O O
, NN O O
the NN O O
possibility NN O O
exists NN O O
for NN O O
TNF NN O O
blockers NN O O
, NN O O
including NN O O
CIMZIA NN O O
, NN O O
to NN O O
affect NN O O
host NN O O
defenses NN O O
against NN O O
infections NN O O
and NN O O
malignancies NN O O
. NN O O
The NN O O
impact NN O O
of NN O O
treatment NN O O
with NN O O
CIMZIA NN O O
on NN O O
the NN O O
development NN O O
and NN O O
course NN O O
of NN O O
malignancies NN O O
, NN O O
as NN O O
well NN O O
as NN O O
active NN O O
and/or NN O O
chronic NN O O
infections NN O O
, NN O O
is NN O O
not NN O O
fully NN O O
understood NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
, NN O O
5.2 NN O O
, NN O O
5.5 NN O O
) NN O O
and NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
safety NN O O
and NN O O
efficacy NN O O
of NN O O
CIMZIA NN O O
in NN O O
patients NN O O
with NN O O
immunosuppression NN O O
has NN O O
not NN O O
been NN O O
formally NN O O
evaluated NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
frequently NN O O
reported NN O O
adverse NN O O
events NN O O
( NN O O
>=4 NN O O
% NN O O
) NN O O
for NN O O
Toviaz NN O O
were NN O O
: NN O O
dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
( NN O O
placebo NN O O
, NN O O
7 NN O O
% NN O O
; NN O O
Toviaz NN O O
4 NN O O
mg NN O O
, NN O O
19 NN O O
% NN O O
; NN O O
Toviaz NN O O
8 NN O O
mg NN O O
, NN O O
35 NN O O
% NN O O
) NN O O
and NN O O
constipation NN B-AdverseReaction B-AdverseReaction
( NN O O
placebo NN O O
, NN O O
2 NN O O
% NN O O
; NN O O
Toviaz NN O O
4 NN O O
mg NN O O
, NN O O
4 NN O O
% NN O O
; NN O O
Toviaz NN O O
8 NN O O
mg NN O O
, NN O O
6 NN O O
% NN O O
) NN O O
. NN O O
( NN O O
6 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Pfizer NN O O
Inc NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
438 NN O O
- NN O O
1985 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
The NN O O
safety NN O O
of NN O O
Toviaz NN O O
was NN O O
evaluated NN O O
in NN O O
Phase NN O O
2 NN O O
and NN O O
3 NN O O
controlled NN O O
trials NN O O
in NN O O
a NN O O
total NN O O
of NN O O
2859 NN O O
patients NN O O
with NN O O
overactive NN O O
bladder NN O O
, NN O O
of NN O O
which NN O O
2288 NN O O
were NN O O
treated NN O O
with NN O O
fesoterodine NN O O
. NN O O
Of NN O O
this NN O O
total NN O O
, NN O O
782 NN O O
received NN O O
Toviaz NN O O
4 NN O O
mg/day NN O O
, NN O O
and NN O O
785 NN O O
received NN O O
Toviaz NN O O
8 NN O O
mg/day NN O O
in NN O O
Phase NN O O
2 NN O O
or NN O O
3 NN O O
studies NN O O
with NN O O
treatment NN O O
periods NN O O
of NN O O
8 NN O O
or NN O O
12 NN O O
weeks NN O O
. NN O O
Approximately NN O O
80 NN O O
% NN O O
of NN O O
these NN O O
patients NN O O
had NN O O
>10 NN O O
weeks NN O O
exposure NN O O
to NN O O
Toviaz NN O O
in NN O O
these NN O O
trials NN O O
. NN O O
A NN O O
total NN O O
of NN O O
1964 NN O O
patients NN O O
participated NN O O
in NN O O
two NN O O
12-week NN O O
, NN O O
Phase NN O O
3 NN O O
efficacy NN O O
and NN O O
safety NN O O
studies NN O O
and NN O O
subsequent NN O O
open NN O O
- NN O O
label NN O O
extension NN O O
studies NN O O
. NN O O
In NN O O
these NN O O
two NN O O
studies NN O O
combined NN O O
, NN O O
554 NN O O
patients NN O O
received NN O O
Toviaz NN O O
4 NN O O
mg/day NN O O
and NN O O
566 NN O O
patients NN O O
received NN O O
Toviaz NN O O
8 NN O O
mg/day NN O O
. NN O O
In NN O O
Phase NN O O
2 NN O O
and NN O O
3 NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
combined NN O O
, NN O O
the NN O O
incidences NN O O
of NN O O
serious NN O O
adverse NN O O
events NN O O
in NN O O
patients NN O O
receiving NN O O
placebo NN O O
, NN O O
Toviaz NN O O
4 NN O O
mg NN O O
, NN O O
and NN O O
Toviaz NN O O
8 NN O O
mg NN O O
were NN O O
1.9 NN O O
% NN O O
, NN O O
3.5 NN O O
% NN O O
, NN O O
and NN O O
2.9 NN O O
% NN O O
, NN O O
respectively NN O O
. NN O O
All NN O O
serious NN O O
adverse NN O O
events NN O O
were NN O O
judged NN O O
to NN O O
be NN O O
not NN O O
related NN O O
or NN O O
unlikely NN O O
to NN O O
be NN O O
related NN O O
to NN O O
study NN O O
medication NN O O
by NN O O
the NN O O
investigator NN O O
, NN O O
except NN O O
for NN O O
four NN O O
patients NN O O
receiving NN O O
Toviaz NN O O
who NN O O
reported NN O O
one NN O O
serious NN O O
adverse NN O O
event NN O O
each NN O O
: NN O O
angina NN B-AdverseReaction B-AdverseReaction
chest NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
gastroenteritis NN B-AdverseReaction B-AdverseReaction
and NN O O
QT NN B-AdverseReaction B-AdverseReaction
prolongation NN I-AdverseReaction I-AdverseReaction
on NN O O
ECG. NN O O
The NN O O
most NN O O
commonly NN O O
reported NN O O
adverse NN O O
event NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
Toviaz NN O O
was NN O O
dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
The NN O O
incidence NN O O
of NN O O
dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
was NN O O
higher NN O O
in NN O O
those NN O O
taking NN O O
8 NN O O
mg/day NN O O
( NN O O
35 NN O O
% NN O O
) NN O O
and NN O O
in NN O O
those NN O O
taking NN O O
4 NN O O
mg/day NN O O
( NN O O
19 NN O O
% NN O O
) NN O O
, NN O O
as NN O O
compared NN O O
to NN O O
placebo NN O O
( NN O O
7 NN O O
% NN O O
) NN O O
. NN O O
Dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
led NN O O
to NN O O
discontinuation NN O O
in NN O O
0.4 NN O O
% NN O O
, NN O O
0.4 NN O O
% NN O O
, NN O O
and NN O O
0.8 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
placebo NN O O
, NN O O
Toviaz NN O O
4 NN O O
mg NN O O
, NN O O
and NN O O
Toviaz NN O O
8 NN O O
mg NN O O
, NN O O
respectively NN O O
. NN O O
For NN O O
those NN O O
patients NN O O
who NN O O
reported NN O O
dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
most NN O O
had NN O O
their NN O O
first NN O O
occurrence NN O O
of NN O O
the NN O O
event NN O O
within NN O O
the NN O O
first NN O O
month NN O O
of NN O O
treatment NN O O
. NN O O
The NN O O
second NN O O
most NN O O
commonly NN O O
reported NN O O
adverse NN O O
event NN O O
was NN O O
constipation NN B-AdverseReaction B-AdverseReaction
The NN O O
incidence NN O O
of NN O O
constipation NN B-AdverseReaction B-AdverseReaction
was NN O O
2 NN O O
% NN O O
in NN O O
those NN O O
taking NN O O
placebo NN O O
, NN O O
4 NN O O
% NN O O
in NN O O
those NN O O
taking NN O O
4 NN O O
mg/day NN O O
, NN O O
and NN O O
6 NN O O
% NN O O
in NN O O
those NN O O
taking NN O O
8 NN O O
mg/day NN O O
. NN O O
Table NN O O
1 NN O O
lists NN O O
adverse NN O O
events NN O O
, NN O O
regardless NN O O
of NN O O
causality NN O O
, NN O O
that NN O O
were NN O O
reported NN O O
in NN O O
the NN O O
combined NN O O
Phase NN O O
3 NN O O
, NN O O
randomized NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
at NN O O
an NN O O
incidence NN O O
greater NN O O
than NN O O
placebo NN O O
and NN O O
in NN O O
1 NN O O
% NN O O
or NN O O
more NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
Toviaz NN O O
4 NN O O
or NN O O
8 NN O O
mg NN O O
once NN O O
daily NN O O
for NN O O
up NN O O
to NN O O
12 NN O O
weeks NN O O
. NN O O
Table NN O O
1 NN O O
: NN O O
Adverse NN O O
events NN O O
with NN O O
an NN O O
incidence NN O O
exceeding NN O O
the NN O O
placebo NN O O
rate NN O O
and NN O O
reported NN O O
by NN O O
>=1 NN O O
% NN O O
of NN O O
patients NN O O
from NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
Phase NN O O
3 NN O O
trials NN O O
of NN O O
12 NN O O
weeks NN O O
treatment NN O O
duration NN O O
System NN O O
organ NN O O
class/Preferred NN O O
term NN O O
Placebo NN O O
N=554 NN O O
% NN O O
Toviaz NN O O
4 NN O O
mg/day NN O O
N=554 NN O O
% NN O O
Toviaz NN O O
8 NN O O
mg/day NN O O
N=566 NN O O
% NN O O
ALT NN O O
= NN O O
alanine NN O O
aminotransferase NN O O
; NN O O
GGT NN O O
= NN O O
gamma NN O O
glutamyltransferase NN O O
Gastrointestinal NN O O
disorders NN O O
Dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
7.0 NN O O
18.8 NN O O
34.6 NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
2.0 NN O O
4.2 NN O O
6.0 NN O O
Dyspepsia NN B-AdverseReaction B-AdverseReaction
0.5 NN O O
1.6 NN O O
2.3 NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
1.3 NN O O
0.7 NN O O
1.9 NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
upper NN I-AdverseReaction I-AdverseReaction
0.5 NN O O
1.1 NN O O
0.5 NN O O
Infections NN O O
Urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
3.1 NN O O
3.2 NN O O
4.2 NN O O
Upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
2.2 NN O O
2.5 NN O O
1.8 NN O O
Eye NN O O
disorders NN O O
Dry NN B-AdverseReaction B-AdverseReaction
eyes NN I-AdverseReaction I-AdverseReaction
0 NN O O
1.4 NN O O
3.7 NN O O
Renal NN O O
and NN O O
urinary NN O O
disorders NN O O
Dysuria NN B-AdverseReaction B-AdverseReaction
0.7 NN O O
1.3 NN O O
1.6 NN O O
Urinary NN B-AdverseReaction B-AdverseReaction
retention NN I-AdverseReaction I-AdverseReaction
0.2 NN O O
1.1 NN O O
1.4 NN O O
Respiratory NN O O
disorders NN O O
Cough NN B-AdverseReaction B-AdverseReaction
0.5 NN O O
1.6 NN O O
0.9 NN O O
Dry NN B-AdverseReaction B-AdverseReaction
throat NN I-AdverseReaction I-AdverseReaction
0.4 NN O O
0.9 NN O O
2.3 NN O O
General NN O O
disorders NN O O
Edema NN B-AdverseReaction B-AdverseReaction
peripheral NN I-AdverseReaction I-AdverseReaction
0.7 NN O O
0.7 NN O O
1.2 NN O O
Musculoskeletal NN O O
disorders NN O O
Back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
0.4 NN O O
2.0 NN O O
0.9 NN O O
Psychiatric NN O O
disorders NN O O
Insomnia NN B-AdverseReaction B-AdverseReaction
0.5 NN O O
1.3 NN O O
0.4 NN O O
Investigations NN O O
ALT NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
0.9 NN O O
0.5 NN O O
1.2 NN O O
GGT NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
0.4 NN O O
0.4 NN O O
1.2 NN O O
Skin NN O O
disorders NN O O
Rash NN B-AdverseReaction B-AdverseReaction
0.5 NN O O
0.7 NN O O
1.1 NN O O
Patients NN O O
also NN O O
received NN O O
Toviaz NN O O
for NN O O
up NN O O
to NN O O
three NN O O
years NN O O
in NN O O
open NN O O
- NN O O
label NN O O
extension NN O O
phases NN O O
of NN O O
one NN O O
Phase NN O O
2 NN O O
and NN O O
two NN O O
Phase NN O O
3 NN O O
controlled NN O O
trials NN O O
. NN O O
In NN O O
all NN O O
open NN O O
- NN O O
label NN O O
trials NN O O
combined NN O O
, NN O O
857 NN O O
, NN O O
701 NN O O
, NN O O
529 NN O O
, NN O O
and NN O O
105 NN O O
patients NN O O
received NN O O
Toviaz NN O O
for NN O O
at NN O O
least NN O O
6 NN O O
months NN O O
, NN O O
1 NN O O
year NN O O
, NN O O
2 NN O O
years NN O O
, NN O O
and NN O O
3 NN O O
years NN O O
, NN O O
respectively NN O O
. NN O O
The NN O O
adverse NN O O
events NN O O
observed NN O O
during NN O O
long NN O O
- NN O O
term NN O O
, NN O O
open NN O O
- NN O O
label NN O O
studies NN O O
were NN O O
similar NN O O
to NN O O
those NN O O
observed NN O O
in NN O O
the NN O O
12-week NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
studies NN O O
, NN O O
and NN O O
included NN O O
dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
constipation NN B-AdverseReaction B-AdverseReaction
dry NN B-AdverseReaction B-AdverseReaction
eyes NN I-AdverseReaction I-AdverseReaction
dyspepsia NN B-AdverseReaction B-AdverseReaction
and NN O O
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
Similar NN O O
to NN O O
the NN O O
controlled NN O O
studies NN O O
, NN O O
most NN O O
adverse NN O O
events NN O O
of NN O O
dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
and NN O O
constipation NN B-AdverseReaction B-AdverseReaction
were NN O O
mild NN B-Severity B-Severity
to NN I-Severity I-Severity
moderate NN I-Severity I-Severity
in NN O O
intensity NN O O
. NN O O
Serious NN O O
adverse NN O O
events NN O O
, NN O O
judged NN O O
to NN O O
be NN O O
at NN O O
least NN O O
possibly NN O O
related NN O O
to NN O O
study NN O O
medication NN O O
by NN O O
the NN O O
investigator NN O O
and NN O O
reported NN O O
more NN O O
than NN O O
once NN O O
during NN O O
the NN O O
open NN O O
- NN O O
label NN O O
treatment NN O O
period NN O O
of NN O O
up NN O O
to NN O O
3 NN O O
years NN O O
, NN O O
included NN O O
urinary NN B-AdverseReaction B-AdverseReaction
retention NN I-AdverseReaction I-AdverseReaction
( NN O O
3 NN O O
cases NN O O
) NN O O
, NN O O
diverticulitis NN B-AdverseReaction B-AdverseReaction
( NN O O
3 NN O O
cases NN O O
) NN O O
, NN O O
constipation NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
cases NN O O
) NN O O
, NN O O
irritable NN B-AdverseReaction B-AdverseReaction
bowel NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
2 NN O O
cases NN O O
) NN O O
, NN O O
and NN O O
electrocardiogram NN O O
QT NN B-AdverseReaction B-AdverseReaction
corrected NN I-AdverseReaction I-AdverseReaction
interval NN I-AdverseReaction I-AdverseReaction
prolongation NN I-AdverseReaction I-AdverseReaction
( NN O O
2 NN O O
cases NN O O
) NN O O
. NN O O
6.2 NN O O
Post NN O O
- NN O O
marketing NN O O
Experience NN O O
The NN O O
following NN O O
events NN O O
have NN O O
been NN O O
reported NN O O
in NN O O
association NN O O
with NN O O
fesoterodine NN O O
use NN O O
in NN O O
worldwide NN O O
post NN O O
- NN O O
marketing NN O O
experience NN O O
: NN O O
Eye NN O O
disorders NN O O
: NN O O
Blurred NN B-AdverseReaction B-AdverseReaction
vision NN I-AdverseReaction I-AdverseReaction
Cardiac NN O O
disorders NN O O
: NN O O
Palpitations NN B-AdverseReaction B-AdverseReaction
General NN O O
disorders NN O O
and NN O O
administrative NN O O
site NN O O
conditions NN O O
: NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
angioedema NN B-AdverseReaction B-AdverseReaction
with NN O O
airway NN B-AdverseReaction B-AdverseReaction
obstruction NN I-AdverseReaction I-AdverseReaction
face NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
Central NN O O
nervous NN O O
system NN O O
disorders NN O O
: NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
somnolence NN B-AdverseReaction B-AdverseReaction
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
: NN O O
Urticaria NN B-AdverseReaction B-AdverseReaction
pruritus NN B-AdverseReaction B-AdverseReaction
Because NN O O
these NN O O
spontaneously NN O O
reported NN O O
events NN O O
are NN O O
from NN O O
the NN O O
worldwide NN O O
post NN O O
- NN O O
marketing NN O O
experience NN O O
, NN O O
the NN O O
frequency NN O O
of NN O O
events NN O O
and NN O O
the NN O O
role NN O O
of NN O O
fesoterodine NN O O
in NN O O
their NN O O
causation NN O O
can NN O O
not NN O O
be NN O O
reliably NN O O
determined NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Angioedema NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
face NN I-AdverseReaction I-AdverseReaction
lips NN O O
, NN O O
tongue NN O O
, NN O O
and/or NN O O
larynx NN O O
has NN O O
been NN O O
reported NN O O
with NN O O
fesoterodine NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
. NN O O
* NN O O
Toviaz NN O O
should NN O O
be NN O O
administered NN O O
with NN O O
caution NN O O
to NN O O
patients NN O O
with NN O O
clinically NN O O
significant NN O O
bladder NN O O
outlet NN O O
obstruction NN O O
because NN O O
of NN O O
the NN O O
risk NN O O
of NN O O
urinary NN O O
retention NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Toviaz NN O O
, NN O O
like NN O O
other NN O O
antimuscarinic NN O O
drugs NN O O
, NN O O
should NN O O
be NN O O
used NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
with NN O O
decreased NN O O
gastrointestinal NN O O
motility NN O O
, NN O O
such NN O O
as NN O O
those NN O O
with NN O O
severe NN O O
constipation NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Toviaz NN O O
should NN O O
be NN O O
used NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
being NN O O
treated NN O O
for NN O O
narrow NN O O
- NN O O
angle NN O O
glaucoma NN O O
, NN O O
and NN O O
only NN O O
where NN O O
the NN O O
potential NN O O
benefits NN O O
outweigh NN O O
the NN O O
risks NN O O
( NN O O
5.4 NN O O
) NN O O
* NN O O
Central NN B-AdverseReaction B-AdverseReaction
Nervous NN I-AdverseReaction I-AdverseReaction
System NN I-AdverseReaction I-AdverseReaction
Effects NN I-AdverseReaction I-AdverseReaction
Somnolence NN B-AdverseReaction B-AdverseReaction
has NN O O
been NN O O
reported NN O O
with NN O O
Toviaz NN O O
. NN O O
Advise NN O O
patients NN O O
not NN O O
to NN O O
drive NN O O
or NN O O
operate NN O O
heavy NN O O
machinery NN O O
until NN O O
they NN O O
know NN O O
how NN O O
Toviaz NN O O
affects NN O O
them NN O O
( NN O O
5.5 NN O O
) NN O O
* NN O O
Toviaz NN O O
should NN O O
be NN O O
used NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
with NN O O
myasthenia NN O O
gravis NN O O
, NN O O
a NN O O
disease NN O O
characterized NN O O
by NN O O
decreased NN O O
cholinergic NN O O
activity NN O O
at NN O O
the NN O O
neuromuscular NN O O
junction NN O O
. NN O O
( NN O O
5.9 NN O O
) NN O O
5.1 NN O O
Angioedema NN O O
Angioedema NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
face NN I-AdverseReaction I-AdverseReaction
lips NN O O
, NN O O
tongue NN O O
, NN O O
and/or NN O O
larynx NN O O
has NN O O
been NN O O
reported NN O O
with NN O O
fesoterodine NN O O
. NN O O
In NN O O
some NN O O
cases NN O O
angioedema NN O O
occurred NN O O
after NN O O
the NN O O
first NN O O
dose NN O O
. NN O O
Angioedema NN B-AdverseReaction B-AdverseReaction
associated NN O O
with NN O O
upper NN B-AdverseReaction B-AdverseReaction
airway NN I-AdverseReaction I-AdverseReaction
swelling NN I-AdverseReaction I-AdverseReaction
may NN B-Factor B-Factor
be NN O O
life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
If NN O O
involvement NN O O
of NN O O
the NN O O
tongue NN O O
, NN O O
hypopharynx NN O O
, NN O O
or NN O O
larynx NN O O
occurs NN O O
, NN O O
fesoterodine NN O O
should NN O O
be NN O O
promptly NN O O
discontinued NN O O
and NN O O
appropriate NN O O
therapy NN O O
and/or NN O O
measures NN O O
to NN O O
ensure NN O O
a NN O O
patent NN O O
airway NN O O
should NN O O
be NN O O
promptly NN O O
provided NN O O
. NN O O
5.2 NN O O
Bladder NN O O
Outlet NN O O
Obstruction NN O O
Toviaz NN O O
should NN O O
be NN O O
administered NN O O
with NN O O
caution NN O O
to NN O O
patients NN O O
with NN O O
clinically NN O O
significant NN O O
bladder NN O O
outlet NN O O
obstruction NN O O
because NN O O
of NN O O
the NN O O
risk NN O O
of NN O O
urinary NN O O
retention NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
] NN O O
. NN O O
5.3 NN O O
Decreased NN O O
Gastrointestinal NN O O
Motility NN O O
Toviaz NN O O
, NN O O
like NN O O
other NN O O
antimuscarinic NN O O
drugs NN O O
, NN O O
should NN O O
be NN O O
used NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
with NN O O
decreased NN O O
gastrointestinal NN O O
motility NN O O
, NN O O
such NN O O
as NN O O
those NN O O
with NN O O
severe NN O O
constipation NN O O
. NN O O
5.4 NN O O
Controlled NN O O
Narrow NN O O
- NN O O
Angle NN O O
Glaucoma NN O O
Toviaz NN O O
should NN O O
be NN O O
used NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
being NN O O
treated NN O O
for NN O O
narrow NN O O
- NN O O
angle NN O O
glaucoma NN O O
, NN O O
and NN O O
only NN O O
where NN O O
the NN O O
potential NN O O
benefits NN O O
outweigh NN O O
the NN O O
risks NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
] NN O O
. NN O O
5.5 NN O O
Central NN O O
Nervous NN O O
System NN O O
Effects NN O O
Toviaz NN O O
is NN O O
associated NN O O
with NN O O
anticholinergic NN O O
central NN O O
nervous NN O O
sytem NN O O
( NN O O
CNS NN O O
) NN O O
effects NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.2 NN O O
) NN O O
] NN O O
. NN O O
A NN O O
variety NN O O
of NN O O
CNS NN B-AdverseReaction B-AdverseReaction
anticholinergic NN I-AdverseReaction I-AdverseReaction
effects NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
, NN O O
including NN O O
headache NN B-AdverseReaction B-AdverseReaction
dizziness NN B-AdverseReaction B-AdverseReaction
and NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
Patients NN O O
should NN O O
be NN O O
monitored NN O O
for NN O O
signs NN O O
of NN O O
anticholinergic NN O O
CNS NN O O
effects NN O O
, NN O O
particularly NN O O
after NN O O
beginning NN O O
treatment NN O O
or NN O O
increasing NN O O
the NN O O
dose NN O O
. NN O O
Advise NN O O
patients NN O O
not NN O O
to NN O O
drive NN O O
or NN O O
operate NN O O
heavy NN O O
machinery NN O O
until NN O O
they NN O O
know NN O O
how NN O O
Toviaz NN O O
affects NN O O
them NN O O
. NN O O
If NN O O
a NN O O
patient NN O O
experiences NN O O
anticholinergic NN O O
CNS NN O O
effects NN O O
, NN O O
dose NN O O
reduction NN O O
or NN O O
drug NN O O
discontinuation NN O O
should NN O O
be NN O O
considered NN O O
. NN O O
5.6 NN O O
Hepatic NN O O
Impairment NN O O
Toviaz NN O O
has NN O O
not NN O O
been NN O O
studied NN O O
in NN O O
patients NN O O
with NN O O
severe NN O O
hepatic NN O O
impairment NN O O
and NN O O
therefore NN O O
is NN O O
not NN O O
recommended NN O O
for NN O O
use NN O O
in NN O O
this NN O O
patient NN O O
population NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.7 NN O O
) NN O O
and NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2 NN O O
) NN O O
] NN O O
. NN O O
5.7 NN O O
Renal NN O O
Impairment NN O O
Doses NN O O
of NN O O
Toviaz NN O O
greater NN O O
than NN O O
4 NN O O
mg NN O O
are NN O O
not NN O O
recommended NN O O
in NN O O
patients NN O O
with NN O O
severe NN O O
renal NN O O
impairment NN O O
[ NN O O
see NN O O
Use NN O O
In NN O O
Specific NN O O
Populations NN O O
( NN O O
8.6 NN O O
) NN O O
and NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2 NN O O
) NN O O
] NN O O
. NN O O
5.8 NN O O
Concomitant NN O O
Administration NN O O
with NN O O
CYP3A4 NN O O
Inhibitors NN O O
* NN O O
Doses NN O O
of NN O O
Toviaz NN O O
greater NN O O
than NN O O
4 NN O O
mg NN O O
are NN O O
not NN O O
recommended NN O O
in NN O O
patients NN O O
taking NN O O
a NN O O
potent NN O O
CYP3A4 NN O O
inhibitor NN O O
( NN O O
e.g. NN O O
, NN O O
ketoconazole NN O O
, NN O O
itraconazole NN O O
, NN O O
clarithromycin NN O O
) NN O O
. NN O O
* NN O O
No NN O O
dosing NN O O
adjustments NN O O
are NN O O
recommended NN O O
in NN O O
the NN O O
presence NN O O
of NN O O
moderate NN O O
CYP3A4 NN O O
inhibitors NN O O
( NN O O
e.g. NN O O
, NN O O
erythromycin NN O O
, NN O O
fluconazole NN O O
, NN O O
diltiazem NN O O
, NN O O
verapamil NN O O
and NN O O
grapefruit NN O O
juice NN O O
) NN O O
. NN O O
* NN O O
While NN O O
the NN O O
effect NN O O
of NN O O
weak NN O O
CYP3A4 NN O O
inhibitors NN O O
( NN O O
e.g. NN O O
cimetidine NN O O
) NN O O
was NN O O
not NN O O
examined NN O O
by NN O O
clinical NN O O
study NN O O
, NN O O
some NN O O
pharmacokinetic NN O O
interaction NN O O
is NN O O
expected NN O O
, NN O O
albeit NN O O
less NN O O
than NN O O
that NN O O
observed NN O O
with NN O O
moderate NN O O
CYP3A4 NN O O
inhibitors NN O O
[ NN O O
see NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.2 NN O O
) NN O O
and NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2 NN O O
) NN O O
] NN O O
. NN O O
5.9 NN O O
Myasthenia NN O O
Gravis NN O O
Toviaz NN O O
should NN O O
be NN O O
used NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
with NN O O
myasthenia NN O O
gravis NN O O
, NN O O
a NN O O
disease NN O O
characterized NN O O
by NN O O
decreased NN O O
cholinergic NN O O
activity NN O O
at NN O O
the NN O O
neuromuscular NN O O
junction NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
* NN O O
The NN O O
following NN O O
serious NN O O
adverse NN O O
reactions NN O O
are NN O O
discussed NN O O
elsewhere NN O O
in NN O O
labeling NN O O
: NN O O
* NN O O
Nephrogenic NN B-AdverseReaction B-AdverseReaction
Systemic NN I-AdverseReaction I-AdverseReaction
Fibrosis NN I-AdverseReaction I-AdverseReaction
( NN O O
NSF NN O O
) NN O O
[ NN O O
see NN O O
Boxed NN O O
Warning NN O O
and NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
and NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
EXCERPT NN O O
: NN O O
* NN O O
Most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
incidence NN O O
>= NN O O
0.5 NN O O
% NN O O
) NN O O
are NN O O
headache NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
and NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Bayer NN O O
HealthCare NN O O
Pharmaceuticals NN O O
Inc. NN O O
at NN O O
1 NN O O
- NN O O
888 NN O O
- NN O O
842 NN O O
- NN O O
2937 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O
The NN O O
adverse NN O O
reactions NN O O
described NN O O
in NN O O
this NN O O
section NN O O
reflect NN O O
Gadavist NN O O
exposure NN O O
in NN O O
6,330 NN O O
subjects NN O O
( NN O O
including NN O O
184 NN O O
pediatric NN O O
patients NN O O
, NN O O
ages NN O O
0 NN O O
to NN O O
17 NN O O
years NN O O
) NN O O
with NN O O
the NN O O
majority NN O O
receiving NN O O
the NN O O
recommended NN O O
dose NN O O
. NN O O
Approximately NN O O
50 NN O O
% NN O O
of NN O O
the NN O O
subjects NN O O
were NN O O
male NN O O
and NN O O
the NN O O
ethnic NN O O
distribution NN O O
was NN O O
60 NN O O
% NN O O
Caucasian NN O O
, NN O O
30 NN O O
% NN O O
Asian NN O O
, NN O O
6 NN O O
% NN O O
Hispanic NN O O
, NN O O
2 NN O O
% NN O O
Black NN O O
, NN O O
and NN O O
3 NN O O
% NN O O
patients NN O O
of NN O O
other NN O O
ethnic NN O O
groups NN O O
. NN O O
The NN O O
average NN O O
age NN O O
was NN O O
55 NN O O
years NN O O
( NN O O
range NN O O
from1 NN O O
week NN O O
to NN O O
93 NN O O
years NN O O
) NN O O
. NN O O
Overall NN O O
, NN O O
approximately NN O O
4 NN O O
% NN O O
of NN O O
subjects NN O O
reported NN O O
one NN O O
or NN O O
more NN O O
adverse NN O O
reactions NN O O
during NN O O
a NN O O
follow NN O O
- NN O O
up NN O O
period NN O O
that NN O O
ranged NN O O
from NN O O
24 NN O O
hours NN O O
to NN O O
7 NN O O
days NN O O
after NN O O
Gadavist NN O O
administration NN O O
. NN O O
Adverse NN O O
reactions NN O O
associated NN O O
with NN O O
the NN O O
use NN O O
of NN O O
Gadavist NN O O
were NN O O
usually NN O O
mild NN O O
to NN O O
moderate NN O O
in NN O O
severity NN O O
and NN O O
transient NN O O
in NN O O
nature NN O O
. NN O O
Table NN O O
2 NN O O
lists NN O O
adverse NN O O
reactions NN O O
that NN O O
occurred NN O O
in NN O O
>= NN O O
0.1 NN O O
% NN O O
subjects NN O O
who NN O O
received NN O O
Gadavist NN O O
. NN O O
Table NN O O
2 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Reaction NN O O
Rate NN O O
( NN O O
% NN O O
) NN O O
n=6330 NN O O
Headache NN B-AdverseReaction B-AdverseReaction
1.5 NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
1.2 NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
0.5 NN O O
Dysgeusia NN B-AdverseReaction B-AdverseReaction
0.4 NN O O
Feeling NN B-AdverseReaction B-AdverseReaction
Hot NN I-AdverseReaction I-AdverseReaction
0.4 NN O O
Injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
0.4 NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
0.4 NN O O
Rash NN B-AdverseReaction B-AdverseReaction
( NN O O
includes NN O O
generalized NN O O
, NN O O
macular NN O O
, NN O O
papular NN O O
, NN O O
pruritic NN O O
) NN O O
0.3 NN O O
Pruritus NN B-AdverseReaction B-AdverseReaction
( NN O O
includes NN O O
generalized NN O O
) NN O O
0.2 NN O O
Erythema NN B-AdverseReaction B-AdverseReaction
0.2 NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
0.1 NN O O
Dyspnea NN B-AdverseReaction B-AdverseReaction
0.1 NN O O
Paresthesia NN B-AdverseReaction B-AdverseReaction
0.1 NN O O
* NN O O
Hypersensitivity/anaphylactoid NN O O
reaction NN O O
may NN O O
occur NN O O
with NN O O
one NN O O
or NN O O
more NN O O
of NN O O
the NN O O
following NN O O
adverse NN O O
reactions NN O O
: NN O O
for NN O O
example NN O O
, NN O O
hypotension NN B-AdverseReaction B-AdverseReaction
urticaria NN B-AdverseReaction B-AdverseReaction
face NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
eyelid NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
flushing NN B-AdverseReaction B-AdverseReaction
Adverse NN O O
reactions NN O O
that NN O O
occurred NN O O
with NN O O
a NN O O
frequency NN O O
of NN O O
< NN O O
0.1 NN O O
% NN O O
in NN O O
subjects NN O O
who NN O O
received NN O O
Gadavist NN O O
include NN O O
: NN O O
loss NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
consciousness NN I-AdverseReaction I-AdverseReaction
convulsion NN B-AdverseReaction B-AdverseReaction
parosmia NN B-AdverseReaction B-AdverseReaction
tachycardia NN B-AdverseReaction B-AdverseReaction
palpitation NN B-AdverseReaction B-AdverseReaction
dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
malaise NN B-AdverseReaction B-AdverseReaction
and NN O O
feeling NN B-AdverseReaction B-AdverseReaction
cold NN I-AdverseReaction I-AdverseReaction
6.2 NN O O
Postmarketing NN O O
Experience NN O O
The NN O O
following NN O O
additional NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
reported NN O O
during NN O O
postmarketing NN O O
use NN O O
of NN O O
Gadavist NN O O
. NN O O
Because NN O O
these NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
* NN O O
Cardiac NN B-AdverseReaction B-AdverseReaction
arrest NN I-AdverseReaction I-AdverseReaction
* NN O O
Nephrogenic NN B-AdverseReaction B-AdverseReaction
Systemic NN I-AdverseReaction I-AdverseReaction
Fibrosis NN I-AdverseReaction I-AdverseReaction
( NN O O
NSF NN O O
) NN O O
* NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
( NN O O
anaphylactic NN O O
shock NN O O
, NN O O
circulatory NN B-AdverseReaction B-AdverseReaction
collapse NN I-AdverseReaction I-AdverseReaction
respiratory NN B-AdverseReaction B-AdverseReaction
arrest NN I-AdverseReaction I-AdverseReaction
pulmonary NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
bronchospasm NN B-AdverseReaction B-AdverseReaction
cyanosis NN B-AdverseReaction B-AdverseReaction
oropharyngeal NN B-AdverseReaction B-AdverseReaction
swelling NN I-AdverseReaction I-AdverseReaction
laryngeal NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
blood NN B-AdverseReaction B-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
chest NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
angioedema NN B-AdverseReaction B-AdverseReaction
conjunctivitis NN B-AdverseReaction B-AdverseReaction
hyperhidrosis NN B-AdverseReaction B-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
sneezing NN B-AdverseReaction B-AdverseReaction
burning NN B-AdverseReaction B-AdverseReaction
sensation NN I-AdverseReaction I-AdverseReaction
and NN O O
pallor NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
NEPHROGENIC NN B-AdverseReaction B-AdverseReaction
SYSTEMIC NN I-AdverseReaction I-AdverseReaction
FIBROSIS NN I-AdverseReaction I-AdverseReaction
WARNING NN O O
: NN O O
NEPHROGENIC NN B-AdverseReaction B-AdverseReaction
SYSTEMIC NN I-AdverseReaction I-AdverseReaction
FIBROSIS NN I-AdverseReaction I-AdverseReaction
Gadolinium NN B-DrugClass B-DrugClass
- NN I-DrugClass I-DrugClass
based NN I-DrugClass I-DrugClass
contrast NN I-DrugClass I-DrugClass
agents NN I-DrugClass I-DrugClass
( NN O O
GBCAs NN O O
) NN O O
increase NN O O
the NN O O
risk NN B-Factor B-Factor
for NN O O
NSF NN B-AdverseReaction B-AdverseReaction
among NN O O
patients NN O O
with NN O O
impaired NN O O
elimination NN O O
of NN O O
the NN O O
drugs NN O O
. NN O O
Avoid NN O O
use NN O O
of NN O O
GBCAs NN O O
in NN O O
these NN O O
patients NN O O
unless NN O O
the NN O O
diagnostic NN O O
information NN O O
is NN O O
essential NN O O
and NN O O
not NN O O
available NN O O
with NN O O
non NN O O
- NN O O
contrasted NN O O
MRI NN O O
or NN O O
other NN O O
modalities NN O O
. NN O O
NSF NN B-AdverseReaction B-AdverseReaction
may NN B-Factor B-Factor
result NN O O
in NN O O
fatal NN B-AdverseReaction B-AdverseReaction
or NN O O
debilitating NN B-Severity B-Severity
fibrosis NN B-AdverseReaction B-AdverseReaction
affecting NN O O
the NN O O
skin NN O O
, NN O O
muscle NN O O
and NN O O
internal NN O O
organs NN O O
. NN O O
* NN O O
The NN O O
risk NN B-Factor B-Factor
for NN O O
NSF NN B-AdverseReaction B-AdverseReaction
appears NN O O
highest NN O O
among NN O O
patients NN O O
with:Chronic NN O O
, NN O O
severe NN O O
kidney NN O O
disease NN O O
( NN O O
GFR NN O O
< NN O O
30 NN O O
mL/min/1.73m2 NN O O
) NN O O
, NN O O
orAcute NN O O
kidney NN O O
injury NN O O
. NN O O
* NN O O
Screen NN O O
patients NN O O
for NN O O
acute NN O O
kidney NN O O
injury NN O O
and NN O O
other NN O O
conditions NN O O
that NN O O
may NN O O
reduce NN O O
renal NN O O
function NN O O
. NN O O
For NN O O
patients NN O O
at NN O O
risk NN O O
for NN O O
chronically NN O O
reduced NN O O
renal NN O O
function NN O O
( NN O O
for NN O O
example NN O O
, NN O O
age NN O O
> NN O O
60 NN O O
years NN O O
, NN O O
hypertension NN O O
or NN O O
diabetes NN O O
) NN O O
, NN O O
estimate NN O O
the NN O O
glomerular NN O O
filtration NN O O
rate NN O O
( NN O O
GFR NN O O
) NN O O
through NN O O
laboratory NN O O
testing NN O O
. NN O O
* NN O O
For NN O O
patients NN O O
at NN O O
highest NN O O
risk NN O O
for NN O O
NSF NN O O
, NN O O
do NN O O
not NN O O
exceed NN O O
the NN O O
recommended NN O O
Gadavist NN O O
dose NN O O
and NN O O
allow NN O O
a NN O O
sufficient NN O O
period NN O O
of NN O O
time NN O O
for NN O O
elimination NN O O
of NN O O
the NN O O
drug NN O O
from NN O O
the NN O O
body NN O O
prior NN O O
to NN O O
any NN O O
re NN O O
- NN O O
administration NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
EXCERPT NN O O
: NN O O
WARNING NN O O
: NN O O
NEPHROGENIC NN B-AdverseReaction B-AdverseReaction
SYSTEMIC NN I-AdverseReaction I-AdverseReaction
FIBROSIS NN I-AdverseReaction I-AdverseReaction
( NN O O
NSF NN O O
) NN O O
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
Gadolinium NN B-DrugClass B-DrugClass
- NN I-DrugClass I-DrugClass
based NN I-DrugClass I-DrugClass
contrast NN I-DrugClass I-DrugClass
agents NN I-DrugClass I-DrugClass
( NN O O
GBCAs NN O O
) NN O O
increase NN O O
the NN O O
risk NN O O
for NN O O
NSF NN B-AdverseReaction B-AdverseReaction
among NN O O
patients NN O O
with NN O O
impaired NN O O
elimination NN O O
of NN O O
the NN O O
drugs NN O O
. NN O O
Avoid NN O O
use NN O O
of NN O O
GBCAs NN O O
in NN O O
these NN O O
patients NN O O
unless NN O O
the NN O O
diagnostic NN O O
information NN O O
is NN O O
essential NN O O
and NN O O
not NN O O
available NN O O
with NN O O
non NN O O
- NN O O
contrasted NN O O
MRI NN O O
or NN O O
other NN O O
modalities NN O O
. NN O O
* NN O O
The NN O O
risk NN B-Factor B-Factor
for NN O O
NSF NN B-AdverseReaction B-AdverseReaction
appears NN O O
highest NN O O
among NN O O
patients NN O O
with:Chronic NN O O
, NN O O
severe NN O O
kidney NN O O
disease NN O O
( NN O O
GFR NN O O
< NN O O
30 NN O O
mL/min/1.73m2 NN O O
) NN O O
, NN O O
orAcute NN O O
kidney NN O O
injury NN O O
. NN O O
* NN O O
Screen NN O O
patients NN O O
for NN O O
acute NN O O
kidney NN O O
injury NN O O
and NN O O
other NN O O
conditions NN O O
that NN O O
may NN O O
reduce NN O O
renal NN O O
function NN O O
. NN O O
For NN O O
patients NN O O
at NN O O
risk NN O O
for NN O O
chronically NN O O
reduced NN O O
renal NN O O
function NN O O
( NN O O
for NN O O
example NN O O
, NN O O
age NN O O
>60 NN O O
years NN O O
, NN O O
hypertension NN O O
or NN O O
diabetes NN O O
) NN O O
, NN O O
estimate NN O O
the NN O O
glomerular NN O O
filtration NN O O
rate NN O O
( NN O O
GFR NN O O
) NN O O
through NN O O
laboratory NN O O
testing NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Nephrogenic NN B-AdverseReaction B-AdverseReaction
Systemic NN I-AdverseReaction I-AdverseReaction
Fibrosis NN I-AdverseReaction I-AdverseReaction
has NN O O
occurred NN O O
in NN O O
patients NN O O
with NN O O
impaired NN O O
elimination NN O O
of NN O O
GBCAs NN O O
. NN O O
Higher NN O O
than NN O O
recommended NN O O
dosing NN O O
or NN O O
repeated NN O O
dosing NN O O
appears NN O O
to NN O O
increase NN O O
the NN O O
risk NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Anaphylactic NN O O
and NN O O
other NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
with NN O O
cardiovascular NN O O
, NN O O
respiratory NN O O
or NN O O
cutaneous NN B-AdverseReaction B-AdverseReaction
manifestations NN I-AdverseReaction I-AdverseReaction
ranging NN O O
from NN O O
mild NN B-Severity B-Severity
to NN O O
severe NN B-Severity B-Severity
including NN O O
death NN B-AdverseReaction B-AdverseReaction
have NN O O
occurred NN O O
. NN O O
Monitor NN O O
patients NN O O
closely NN O O
during NN O O
and NN O O
after NN O O
administration NN O O
of NN O O
Gadavist NN O O
( NN O O
5.2 NN O O
) NN O O
5.1 NN O O
Nephrogenic NN O O
Systemic NN O O
Fibrosis NN O O
Gadolinium NN B-DrugClass B-DrugClass
- NN I-DrugClass I-DrugClass
based NN I-DrugClass I-DrugClass
contrast NN I-DrugClass I-DrugClass
agents NN I-DrugClass I-DrugClass
( NN O O
GBCAs NN O O
) NN O O
increase NN O O
the NN O O
risk NN O O
for NN O O
nephrogenic NN B-AdverseReaction B-AdverseReaction
systemic NN I-AdverseReaction I-AdverseReaction
fibrosis NN I-AdverseReaction I-AdverseReaction
( NN O O
NSF NN O O
) NN O O
among NN O O
patients NN O O
with NN O O
impaired NN O O
elimination NN O O
of NN O O
the NN O O
drugs NN O O
. NN O O
Avoid NN O O
use NN O O
of NN O O
GBCAs NN O O
among NN O O
these NN O O
patients NN O O
unless NN O O
the NN O O
diagnostic NN O O
information NN O O
is NN O O
essential NN O O
and NN O O
not NN O O
available NN O O
with NN O O
non NN O O
- NN O O
contrast NN O O
MRI NN O O
or NN O O
other NN O O
modalities NN O O
. NN O O
The NN O O
GBCA NN B-DrugClass B-DrugClass
NSF NN B-AdverseReaction B-AdverseReaction
risk NN O O
appears NN O O
highest NN O O
for NN O O
patients NN O O
with NN O O
chronic NN O O
, NN O O
severe NN O O
kidney NN O O
disease NN O O
( NN O O
GFR NN O O
< NN O O
30 NN O O
mL/min/1.73m NN O O
2 NN O O
) NN O O
as NN O O
well NN O O
as NN O O
patients NN O O
with NN O O
acute NN O O
kidney NN O O
injury NN O O
. NN O O
The NN O O
risk NN O O
appears NN O O
lower NN O O
for NN O O
patients NN O O
with NN O O
chronic NN O O
, NN O O
moderate NN O O
kidney NN O O
disease NN O O
( NN O O
GFR NN O O
30 NN O O
to NN O O
59 NN O O
mL/min/1.73m NN O O
2 NN O O
) NN O O
and NN O O
little NN O O
, NN O O
if NN O O
any NN O O
, NN O O
for NN O O
patients NN O O
with NN O O
chronic NN O O
, NN O O
mild NN O O
kidney NN O O
disease NN O O
( NN O O
GFR NN O O
60 NN O O
to NN O O
89 NN O O
mL/min/1.73m NN O O
2 NN O O
) NN O O
. NN O O
NSF NN B-AdverseReaction B-AdverseReaction
may NN B-Factor B-Factor
result NN O O
in NN O O
fatal NN B-AdverseReaction B-AdverseReaction
or NN O O
debilitating NN B-Severity B-Severity
fibrosis NN B-AdverseReaction B-AdverseReaction
affecting NN O O
the NN O O
skin NN O O
, NN O O
muscle NN O O
and NN O O
internal NN O O
organs NN O O
. NN O O
Report NN O O
any NN O O
diagnosis NN O O
of NN O O
NSF NN O O
following NN O O
Gadavist NN O O
administration NN O O
to NN O O
Bayer NN O O
Healthcare NN O O
( NN O O
1 NN O O
- NN O O
888 NN O O
- NN O O
842 NN O O
- NN O O
2937 NN O O
) NN O O
or NN O O
FDA NN O O
( NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
) NN O O
. NN O O
Screen NN O O
patients NN O O
for NN O O
acute NN O O
kidney NN O O
injury NN O O
and NN O O
other NN O O
conditions NN O O
that NN O O
may NN O O
reduce NN O O
renal NN O O
function NN O O
. NN O O
Features NN O O
of NN O O
acute NN O O
kidney NN O O
injury NN O O
consist NN O O
of NN O O
rapid NN O O
( NN O O
over NN O O
hours NN O O
to NN O O
days NN O O
) NN O O
and NN O O
usually NN O O
reversible NN O O
decrease NN O O
in NN O O
kidney NN O O
function NN O O
, NN O O
commonly NN O O
in NN O O
the NN O O
setting NN O O
of NN O O
surgery NN O O
, NN O O
severe NN O O
infection NN O O
, NN O O
injury NN O O
or NN O O
drug NN O O
- NN O O
induced NN O O
kidney NN O O
toxicity NN O O
. NN O O
Serum NN O O
creatinine NN O O
levels NN O O
and NN O O
estimated NN O O
GFR NN O O
may NN O O
not NN O O
reliably NN O O
assess NN O O
renal NN O O
function NN O O
in NN O O
the NN O O
setting NN O O
of NN O O
acute NN O O
kidney NN O O
injury NN O O
. NN O O
For NN O O
patients NN O O
at NN O O
risk NN O O
for NN O O
chronically NN O O
reduced NN O O
renal NN O O
function NN O O
( NN O O
for NN O O
example NN O O
, NN O O
age NN O O
> NN O O
60 NN O O
years NN O O
, NN O O
diabetes NN O O
mellitus NN O O
or NN O O
chronic NN O O
hypertension NN O O
) NN O O
, NN O O
estimate NN O O
the NN O O
GFR NN O O
through NN O O
laboratory NN O O
testing NN O O
. NN O O
Among NN O O
the NN O O
factors NN O O
that NN O O
may NN O O
increase NN O O
the NN O O
risk NN O O
for NN O O
NSF NN O O
are NN O O
repeated NN O O
or NN O O
higher NN O O
than NN O O
recommended NN O O
doses NN O O
of NN O O
a NN O O
GBCA NN O O
and NN O O
degree NN O O
of NN O O
renal NN O O
impairment NN O O
at NN O O
the NN O O
time NN O O
of NN O O
exposure NN O O
. NN O O
Record NN O O
the NN O O
specific NN O O
GBCA NN O O
and NN O O
the NN O O
dose NN O O
administered NN O O
to NN O O
a NN O O
patient NN O O
. NN O O
For NN O O
patients NN O O
at NN O O
highest NN O O
risk NN O O
for NN O O
NSF NN O O
, NN O O
do NN O O
not NN O O
exceed NN O O
the NN O O
recommended NN O O
Gadavist NN O O
dose NN O O
and NN O O
allow NN O O
a NN O O
sufficient NN O O
period NN O O
of NN O O
time NN O O
for NN O O
elimination NN O O
of NN O O
the NN O O
drug NN O O
prior NN O O
to NN O O
re NN O O
- NN O O
administration NN O O
. NN O O
For NN O O
patients NN O O
receiving NN O O
hemodialysis NN O O
, NN O O
consider NN O O
the NN O O
prompt NN O O
initiation NN O O
of NN O O
hemodialysis NN O O
following NN O O
the NN O O
administration NN O O
of NN O O
a NN O O
GBCA NN O O
in NN O O
order NN O O
to NN O O
enhance NN O O
the NN O O
contrast NN O O
agent NN O O
's NN O O
elimination NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.6 NN O O
) NN O O
and NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.3 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
usefulness NN O O
of NN O O
hemodialysis NN O O
in NN O O
the NN O O
prevention NN O O
of NN O O
NSF NN O O
is NN O O
unknown NN O O
[ NN O O
see NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.3 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
Hypersensitivity NN O O
Reactions NN O O
Anaphylactic NN O O
and NN O O
other NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
with NN O O
cardiovascular NN O O
, NN O O
respiratory NN O O
or NN O O
cutaneous NN O O
manifestations NN O O
, NN O O
ranging NN O O
from NN O O
mild NN B-Severity B-Severity
to NN O O
severe NN B-Severity B-Severity
including NN O O
death NN B-AdverseReaction B-AdverseReaction
have NN O O
uncommonly NN O O
occurred NN O O
following NN O O
Gadavist NN O O
administration NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Before NN O O
Gadavist NN O O
administration NN O O
, NN O O
assess NN O O
all NN O O
patients NN O O
for NN O O
any NN O O
history NN O O
of NN O O
a NN O O
reaction NN O O
to NN O O
contrast NN O O
media NN O O
, NN O O
bronchial NN O O
asthma NN O O
and/or NN O O
allergic NN O O
disorders NN O O
. NN O O
These NN O O
patients NN O O
may NN O O
have NN O O
an NN O O
increased NN O O
risk NN O O
for NN O O
a NN O O
hypersensitivity NN O O
reaction NN O O
to NN O O
Gadavist NN O O
. NN O O
* NN O O
Administer NN O O
Gadavist NN O O
only NN O O
in NN O O
situations NN O O
where NN O O
trained NN O O
personnel NN O O
and NN O O
therapies NN O O
are NN O O
promptly NN O O
available NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
hypersensitivity NN O O
reactions NN O O
, NN O O
including NN O O
personnel NN O O
trained NN O O
in NN O O
resuscitation NN O O
. NN O O
Most NN O O
hypersensitivity NN O O
reactions NN O O
to NN O O
Gadavist NN O O
have NN O O
occurred NN O O
within NN O O
half NN O O
an NN O O
hour NN O O
after NN O O
administration NN O O
. NN O O
Delayed NN O O
reactions NN O O
can NN O O
occur NN O O
up NN O O
to NN O O
several NN O O
days NN O O
after NN O O
administration NN O O
. NN O O
Observe NN O O
patients NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
hypersensitivity NN O O
reactions NN O O
during NN O O
and NN O O
following NN O O
Gadavist NN O O
administration NN O O
. NN O O
5.3 NN O O
Acute NN O O
Kidney NN O O
Injury NN O O
In NN O O
patients NN O O
with NN O O
chronic NN O O
renal NN O O
impairment NN O O
, NN O O
acute NN B-AdverseReaction B-AdverseReaction
kidney NN I-AdverseReaction I-AdverseReaction
injury NN I-AdverseReaction I-AdverseReaction
sometimes NN O O
requiring NN O O
dialysis NN O O
has NN O O
been NN O O
observed NN O O
with NN O O
the NN O O
use NN O O
of NN O O
some NN O O
GBCAs NN B-DrugClass B-DrugClass
Do NN O O
not NN O O
exceed NN O O
the NN O O
recommended NN O O
dose NN O O
; NN O O
the NN O O
risk NN O O
of NN O O
acute NN O O
kidney NN O O
injury NN O O
may NN O O
increase NN O O
with NN O O
higher NN O O
than NN O O
recommended NN O O
doses NN O O
. NN O O
5.4 NN O O
Extravasation NN O O
and NN O O
Injection NN O O
Site NN O O
Reactions NN O O
Ensure NN O O
catheter NN O O
and NN O O
venous NN O O
patency NN O O
before NN O O
the NN O O
injection NN O O
of NN O O
Gadavist NN O O
. NN O O
Extravasation NN O O
into NN O O
tissues NN O O
during NN O O
Gadavist NN O O
administration NN O O
may NN B-Factor B-Factor
result NN O O
in NN O O
moderate NN B-Severity B-Severity
irritation NN O O
[ NN O O
see NN O O
Nonclinical NN O O
Toxicology NN O O
( NN O O
13.2 NN O O
) NN O O
] NN O O
. NN O O
5.5 NN O O
Overestimation NN O O
of NN O O
Extent NN O O
of NN O O
Malignant NN O O
Disease NN O O
in NN O O
MRI NN O O
of NN O O
the NN O O
Breast NN O O
Gadavist NN O O
MRI NN O O
of NN O O
the NN O O
breast NN O O
overestimated NN O O
the NN O O
histologically NN O O
confirmed NN O O
extent NN O O
of NN O O
malignancy NN O O
in NN O O
the NN O O
diseased NN O O
breast NN O O
in NN O O
up NN O O
to NN O O
50 NN O O
% NN O O
of NN O O
the NN O O
patients NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14.2 NN O O
) NN O O
] NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reaction NN O O
( NN O O
incidence NN O O
>=1.5 NN O O
% NN O O
) NN O O
occurring NN O O
with NN O O
a NN O O
higher NN O O
frequency NN O O
than NN O O
placebo NN O O
among NN O O
ENTEREG NN O O
- NN O O
treated NN O O
patients NN O O
undergoing NN O O
surgeries NN O O
that NN O O
included NN O O
a NN O O
bowel NN O O
resection NN O O
was NN O O
dyspepsia NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Merck NN O O
Sharp NN O O
& NN O O
Dohme NN O O
Corp. NN O O
, NN O O
a NN O O
subsidiary NN O O
of NN O O
Merck NN O O
& NN O O
Co. NN O O
, NN O O
Inc. NN O O
, NN O O
at NN O O
1 NN O O
- NN O O
877 NN O O
- NN O O
888 NN O O
- NN O O
4231 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
compared NN O O
directly NN O O
with NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O
The NN O O
adverse NN O O
event NN O O
information NN O O
from NN O O
clinical NN O O
trials NN O O
does NN O O
, NN O O
however NN O O
, NN O O
provide NN O O
a NN O O
basis NN O O
for NN O O
identifying NN O O
the NN O O
adverse NN O O
events NN O O
that NN O O
appear NN O O
to NN O O
be NN O O
related NN O O
to NN O O
drug NN O O
use NN O O
and NN O O
for NN O O
approximating NN O O
rates NN O O
. NN O O
The NN O O
data NN O O
described NN O O
below NN O O
reflect NN O O
exposure NN O O
to NN O O
ENTEREG NN O O
12 NN O O
mg NN O O
in NN O O
1,793 NN O O
patients NN O O
in NN O O
10 NN O O
placebo NN O O
- NN O O
controlled NN O O
studies NN O O
. NN O O
The NN O O
population NN O O
was NN O O
19 NN O O
to NN O O
97 NN O O
years NN O O
old NN O O
, NN O O
64 NN O O
% NN O O
were NN O O
female NN O O
, NN O O
and NN O O
84 NN O O
% NN O O
were NN O O
Caucasian NN O O
; NN O O
64 NN O O
% NN O O
were NN O O
undergoing NN O O
a NN O O
surgery NN O O
that NN O O
included NN O O
bowel NN O O
resection NN O O
. NN O O
The NN O O
first NN O O
dose NN O O
of NN O O
ENTEREG NN O O
was NN O O
administered NN O O
30 NN O O
minutes NN O O
to NN O O
5 NN O O
hours NN O O
before NN O O
the NN O O
scheduled NN O O
start NN O O
of NN O O
surgery NN O O
and NN O O
then NN O O
twice NN O O
daily NN O O
until NN O O
hospital NN O O
discharge NN O O
( NN O O
or NN O O
for NN O O
a NN O O
maximum NN O O
of NN O O
7 NN O O
days NN O O
of NN O O
postoperative NN O O
treatment NN O O
) NN O O
. NN O O
Among NN O O
ENTEREG NN O O
- NN O O
treated NN O O
patients NN O O
undergoing NN O O
surgeries NN O O
that NN O O
included NN O O
a NN O O
bowel NN O O
resection NN O O
, NN O O
the NN O O
most NN O O
common NN O O
adverse NN O O
reaction NN O O
( NN O O
incidence NN O O
>=1.5 NN O O
% NN O O
) NN O O
occurring NN O O
with NN O O
a NN O O
higher NN O O
frequency NN O O
than NN O O
placebo NN O O
was NN O O
dyspepsia NN B-AdverseReaction B-AdverseReaction
( NN O O
ENTEREG NN O O
, NN O O
1.5 NN O O
% NN O O
; NN O O
placebo NN O O
, NN O O
0.8 NN O O
% NN O O
) NN O O
. NN O O
Adverse NN O O
reactions NN O O
are NN O O
events NN O O
that NN O O
occurred NN O O
after NN O O
the NN O O
first NN O O
dose NN O O
of NN O O
study NN O O
medication NN O O
treatment NN O O
and NN O O
within NN O O
7 NN O O
days NN O O
of NN O O
the NN O O
last NN O O
dose NN O O
of NN O O
study NN O O
medication NN O O
or NN O O
events NN O O
present NN O O
at NN O O
baseline NN O O
that NN O O
increased NN O O
in NN O O
severity NN O O
after NN O O
the NN O O
start NN O O
of NN O O
study NN O O
medication NN O O
treatment NN O O
. NN O O
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
POTENTIAL NN O O
RISK NN B-Factor B-Factor
OF NN O O
MYOCARDIAL NN B-AdverseReaction B-AdverseReaction
INFARCTION NN I-AdverseReaction I-AdverseReaction
WITH NN O O
LONG NN O O
- NN O O
TERM NN O O
USE NN O O
: NN O O
FOR NN O O
SHORT NN O O
- NN O O
TERM NN O O
HOSPITAL NN O O
USE NN O O
ONLY NN O O
WARNING NN O O
: NN O O
POTENTIAL NN O O
RISK NN B-Factor B-Factor
OF NN O O
MYOCARDIAL NN B-AdverseReaction B-AdverseReaction
INFARCTION NN I-AdverseReaction I-AdverseReaction
WITH NN O O
LONG NN O O
- NN O O
TERM NN O O
USE NN O O
: NN O O
FOR NN O O
SHORT NN O O
- NN O O
TERM NN O O
HOSPITAL NN O O
USE NN O O
ONLY NN O O
There NN O O
was NN O O
a NN O O
greater NN O O
incidence NN O O
of NN O O
myocardial NN B-AdverseReaction B-AdverseReaction
infarction NN I-AdverseReaction I-AdverseReaction
in NN O O
alvimopan NN O O
- NN O O
treated NN O O
patients NN O O
compared NN O O
to NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
in NN O O
a NN O O
12-month NN O O
clinical NN O O
trial NN O O
, NN O O
although NN O O
a NN O O
causal NN O O
relationship NN O O
has NN O O
not NN O O
been NN O O
established NN O O
. NN O O
In NN O O
short NN O O
- NN O O
term NN O O
trials NN O O
with NN O O
ENTEREG(r NN O O
) NN O O
, NN O O
no NN B-Negation B-Negation
increased NN O O
risk NN O O
of NN O O
myocardial NN B-AdverseReaction B-AdverseReaction
infarction NN I-AdverseReaction I-AdverseReaction
was NN O O
observed NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
Because NN O O
of NN O O
the NN O O
potential NN O O
risk NN O O
of NN O O
myocardial NN O O
infarction NN O O
with NN O O
long NN O O
- NN O O
term NN O O
use NN O O
, NN O O
ENTEREG NN O O
is NN O O
available NN O O
only NN O O
through NN O O
a NN O O
restricted NN O O
program NN O O
for NN O O
short NN O O
- NN O O
term NN O O
use NN O O
( NN O O
15 NN O O
doses NN O O
) NN O O
under NN O O
a NN O O
Risk NN O O
Evaluation NN O O
and NN O O
Mitigation NN O O
Strategy NN O O
( NN O O
REMS NN O O
) NN O O
called NN O O
the NN O O
ENTEREG NN O O
Access NN O O
Support NN O O
and NN O O
Education NN O O
( NN O O
E.A.S.E.(r NN O O
) NN O O
) NN O O
Program NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
and NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
WARNING NN O O
: NN O O
POTENTIAL NN O O
RISK NN B-Factor B-Factor
OF NN O O
MYOCARDIAL NN B-AdverseReaction B-AdverseReaction
INFARCTION NN I-AdverseReaction I-AdverseReaction
WITH NN O O
LONG NN O O
- NN O O
TERM NN O O
USE NN O O
: NN O O
FOR NN O O
SHORT NN O O
- NN O O
TERM NN O O
HOSPITAL NN O O
USE NN O O
ONLY NN O O
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
. NN O O
* NN O O
Increased NN O O
incidence NN O O
of NN O O
myocardial NN B-AdverseReaction B-AdverseReaction
infarction NN I-AdverseReaction I-AdverseReaction
was NN O O
seen NN O O
in NN O O
a NN O O
clinical NN O O
trial NN O O
of NN O O
patients NN O O
taking NN O O
alvimopan NN O O
for NN O O
long NN O O
- NN O O
term NN O O
use NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
ENTEREG NN O O
is NN O O
available NN O O
only NN O O
through NN O O
a NN O O
restricted NN O O
program NN O O
for NN O O
short NN O O
- NN O O
term NN O O
use NN O O
( NN O O
15 NN O O
doses NN O O
) NN O O
called NN O O
the NN O O
ENTEREG NN O O
Access NN O O
Support NN O O
and NN O O
Education NN O O
( NN O O
E.A.S.E.(r NN O O
) NN O O
) NN O O
Program NN O O
. NN O O
( NN O O
5.1 NN O O
, NN O O
5.2 NN O O
) NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
A NN O O
higher NN O O
number NN O O
of NN O O
myocardial NN B-AdverseReaction B-AdverseReaction
infarctions NN I-AdverseReaction I-AdverseReaction
was NN O O
reported NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
alvimopan NN O O
0.5 NN O O
mg NN O O
twice NN O O
daily NN O O
compared NN O O
with NN O O
placebo NN O O
in NN O O
a NN O O
12-month NN O O
study NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
opioids NN O O
for NN O O
chronic NN O O
non NN O O
- NN O O
cancer NN O O
pain NN O O
, NN O O
although NN O O
a NN O O
causal NN O O
relationship NN O O
with NN O O
long NN O O
- NN O O
term NN O O
use NN O O
has NN O O
not NN O O
been NN O O
established NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Patients NN O O
recently NN O O
exposed NN O O
to NN O O
opioids NN O O
are NN O O
expected NN O O
to NN O O
be NN O O
more NN O O
sensitive NN O O
to NN O O
the NN O O
effects NN O O
of NN O O
ENTEREG NN O O
and NN O O
therefore NN O O
may NN B-Factor B-Factor
experience NN O O
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
and NN O O
vomiting NN B-AdverseReaction B-AdverseReaction
and NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
( NN O O
5.3 NN O O
) NN O O
* NN O O
Not NN O O
recommended NN O O
in NN O O
patients NN O O
with NN O O
severe NN O O
hepatic NN O O
impairment NN O O
. NN O O
( NN O O
5.4 NN O O
) NN O O
* NN O O
Not NN O O
recommended NN O O
in NN O O
patients NN O O
with NN O O
end NN O O
- NN O O
stage NN O O
renal NN O O
disease NN O O
. NN O O
( NN O O
5.5 NN O O
) NN O O
* NN O O
Not NN O O
recommended NN O O
in NN O O
patients NN O O
with NN O O
complete NN O O
gastrointestinal NN O O
obstruction NN O O
or NN O O
in NN O O
patients NN O O
who NN O O
have NN O O
surgery NN O O
for NN O O
correction NN O O
of NN O O
complete NN O O
bowel NN O O
obstruction NN O O
. NN O O
( NN O O
5.6 NN O O
) NN O O
* NN O O
Not NN O O
recommended NN O O
in NN O O
pancreatic NN O O
or NN O O
gastric NN O O
anastomosis NN O O
. NN O O
( NN O O
5.7 NN O O
) NN O O
5.1 NN O O
Potential NN O O
Risk NN O O
of NN O O
Myocardial NN O O
Infarction NN O O
with NN O O
Long NN O O
- NN O O
term NN O O
Use NN O O
There NN O O
were NN O O
more NN O O
reports NN O O
of NN O O
myocardial NN B-AdverseReaction B-AdverseReaction
infarctions NN I-AdverseReaction I-AdverseReaction
in NN O O
patients NN O O
treated NN O O
with NN O O
alvimopan NN O O
0.5 NN O O
mg NN O O
twice NN O O
daily NN O O
compared NN O O
with NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
in NN O O
a NN O O
12-month NN O O
study NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
opioids NN O O
for NN O O
chronic NN O O
non NN O O
- NN O O
cancer NN O O
pain NN O O
( NN O O
alvimopan NN O O
0.5 NN O O
mg NN O O
, NN O O
n NN O O
= NN O O
538 NN O O
; NN O O
placebo NN O O
, NN O O
n NN O O
= NN O O
267 NN O O
) NN O O
. NN O O
In NN O O
this NN O O
study NN O O
, NN O O
the NN O O
majority NN O O
of NN O O
myocardial NN B-AdverseReaction B-AdverseReaction
infarctions NN I-AdverseReaction I-AdverseReaction
occurred NN O O
between NN O O
1 NN O O
and NN O O
4 NN O O
months NN O O
after NN O O
initiation NN O O
of NN O O
treatment NN O O
. NN O O
This NN O O
imbalance NN O O
has NN O O
not NN O O
been NN O O
observed NN O O
in NN O O
other NN O O
studies NN O O
of NN O O
ENTEREG NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
opioids NN O O
for NN O O
chronic NN O O
pain NN O O
, NN O O
nor NN O O
in NN O O
patients NN O O
treated NN O O
within NN O O
the NN O O
surgical NN O O
setting NN O O
, NN O O
including NN O O
patients NN O O
undergoing NN O O
surgeries NN O O
that NN O O
included NN O O
bowel NN O O
resection NN O O
who NN O O
received NN O O
ENTEREG NN O O
12 NN O O
mg NN O O
twice NN O O
daily NN O O
for NN O O
up NN O O
to NN O O
7 NN O O
days NN O O
( NN O O
the NN O O
indicated NN O O
dose NN O O
and NN O O
patient NN O O
population NN O O
; NN O O
ENTEREG NN O O
12 NN O O
mg NN O O
, NN O O
n NN O O
= NN O O
1,142 NN O O
; NN O O
placebo NN O O
, NN O O
n NN O O
= NN O O
1,120 NN O O
) NN O O
. NN O O
A NN O O
causal NN O O
relationship NN O O
with NN O O
alvimopan NN O O
with NN O O
long NN O O
- NN O O
term NN O O
use NN O O
has NN O O
not NN O O
been NN O O
established NN O O
. NN O O
ENTEREG NN O O
is NN O O
available NN O O
only NN O O
through NN O O
a NN O O
program NN O O
under NN O O
a NN O O
REMS NN O O
that NN O O
restricts NN O O
use NN O O
to NN O O
enrolled NN O O
hospitals NN O O
[ NN O O
seeWarnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
E.A.S.E. NN O O
ENTEREG NN O O
REMS NN O O
Program NN O O
ENTEREG NN O O
is NN O O
available NN O O
only NN O O
through NN O O
a NN O O
program NN O O
called NN O O
the NN O O
ENTEREG NN O O
Access NN O O
Support NN O O
and NN O O
Education NN O O
( NN O O
E.A.S.E. NN O O
) NN O O
ENTEREG NN O O
REMS NN O O
Program NN O O
that NN O O
restricts NN O O
use NN O O
to NN O O
enrolled NN O O
hospitals NN O O
because NN O O
of NN O O
the NN O O
potential NN O O
risk NN O O
of NN O O
myocardial NN O O
infarction NN O O
with NN O O
long NN O O
- NN O O
term NN O O
use NN O O
of NN O O
ENTEREG NN O O
[ NN O O
seeWarnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
Notable NN O O
requirements NN O O
of NN O O
the NN O O
E.A.S.E. NN O O
Program NN O O
include NN O O
the NN O O
following NN O O
: NN O O
ENTEREG NN O O
is NN O O
available NN O O
only NN O O
for NN O O
short NN O O
- NN O O
term NN O O
( NN O O
15 NN O O
doses NN O O
) NN O O
use NN O O
in NN O O
hospitalized NN O O
patients NN O O
. NN O O
Only NN O O
hospitals NN O O
that NN O O
have NN O O
enrolled NN O O
in NN O O
and NN O O
met NN O O
all NN O O
of NN O O
the NN O O
requirements NN O O
for NN O O
the NN O O
E.A.S.E. NN O O
program NN O O
may NN O O
use NN O O
ENTEREG. NN O O
To NN O O
enroll NN O O
in NN O O
the NN O O
E.A.S.E. NN O O
Program NN O O
, NN O O
an NN O O
authorized NN O O
hospital NN O O
representative NN O O
must NN O O
acknowledge NN O O
that NN O O
: NN O O
* NN O O
hospital NN O O
staff NN O O
who NN O O
prescribe NN O O
, NN O O
dispense NN O O
, NN O O
or NN O O
administer NN O O
ENTEREG NN O O
have NN O O
been NN O O
provided NN O O
the NN O O
educational NN O O
materials NN O O
on NN O O
the NN O O
need NN O O
to NN O O
limit NN O O
use NN O O
of NN O O
ENTEREG NN O O
to NN O O
short NN O O
- NN O O
term NN O O
, NN O O
inpatient NN O O
use NN O O
; NN O O
* NN O O
patients NN O O
will NN O O
not NN O O
receive NN O O
more NN O O
than NN O O
15 NN O O
doses NN O O
of NN O O
ENTEREG NN O O
; NN O O
and NN O O
* NN O O
ENTEREG NN O O
will NN O O
not NN O O
be NN O O
dispensed NN O O
to NN O O
patients NN O O
after NN O O
they NN O O
have NN O O
been NN O O
discharged NN O O
from NN O O
the NN O O
hospital NN O O
. NN O O
Further NN O O
information NN O O
is NN O O
available NN O O
at NN O O
www NN O O
. NN O O
ENTEREGREMS.com NN O O
or NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
278 NN O O
- NN O O
0340 NN O O
. NN O O
5.3 NN O O
Gastrointestinal NN O O
- NN O O
Related NN O O
Adverse NN O O
Reactions NN O O
in NN O O
Opioid NN O O
- NN O O
Tolerant NN O O
Patients NN O O
Patients NN O O
recently NN O O
exposed NN O O
to NN O O
opioids NN O O
are NN O O
expected NN O O
to NN O O
be NN O O
more NN O O
sensitive NN O O
to NN O O
the NN O O
effects NN O O
of NN O O
mu NN O O
- NN O O
opioid NN O O
receptor NN O O
antagonists NN O O
, NN O O
such NN O O
as NN O O
ENTEREG. NN O O
Since NN O O
ENTEREG NN O O
acts NN O O
peripherally NN O O
, NN O O
clinical NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
increased NN O O
sensitivity NN O O
would NN O O
be NN O O
related NN O O
to NN O O
the NN O O
gastrointestinal NN O O
tract NN O O
( NN O O
e.g. NN O O
, NN O O
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
and NN O O
vomiting NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
Patients NN O O
receiving NN O O
more NN O O
than NN O O
3 NN O O
doses NN O O
of NN O O
an NN O O
opioid NN O O
within NN O O
the NN O O
week NN O O
prior NN O O
to NN O O
surgery NN O O
were NN O O
not NN O O
studied NN O O
in NN O O
the NN O O
postoperative NN O O
ileus NN O O
clinical NN O O
trials NN O O
. NN O O
Therefore NN O O
, NN O O
if NN O O
ENTEREG NN O O
is NN O O
administered NN O O
to NN O O
these NN O O
patients NN O O
, NN O O
they NN O O
should NN O O
be NN O O
monitored NN O O
for NN O O
gastrointestinal NN O O
adverse NN O O
reactions NN O O
. NN O O
ENTEREG NN O O
is NN O O
contraindicated NN O O
in NN O O
patients NN O O
who NN O O
have NN O O
taken NN O O
therapeutic NN O O
doses NN O O
of NN O O
opioids NN O O
for NN O O
more NN O O
than NN O O
7 NN O O
consecutive NN O O
days NN O O
immediately NN O O
prior NN O O
to NN O O
taking NN O O
ENTEREG. NN O O
5.4 NN O O
Risk NN O O
of NN O O
Serious NN O O
Adverse NN O O
Reactions NN O O
in NN O O
Patients NN O O
with NN O O
Severe NN O O
Hepatic NN O O
Impairment NN O O
Patients NN O O
with NN O O
severe NN O O
hepatic NN O O
impairment NN O O
may NN O O
be NN O O
at NN O O
higher NN O O
risk NN O O
of NN O O
serious NN O O
adverse NN O O
reactions NN O O
( NN O O
including NN O O
dose NN O O
- NN O O
related NN O O
serious NN O O
adverse NN O O
reactions NN O O
) NN O O
because NN O O
up NN O O
to NN O O
10-fold NN O O
higher NN O O
plasma NN O O
levels NN O O
of NN O O
drug NN O O
have NN O O
been NN O O
observed NN O O
in NN O O
such NN O O
patients NN O O
compared NN O O
with NN O O
patients NN O O
with NN O O
normal NN O O
hepatic NN O O
function NN O O
. NN O O
Therefore NN O O
, NN O O
the NN O O
use NN O O
of NN O O
ENTEREG NN O O
is NN O O
not NN O O
recommended NN O O
in NN O O
this NN O O
population NN O O
. NN O O
5.5 NN O O
End NN O O
- NN O O
Stage NN O O
Renal NN O O
Disease NN O O
No NN O O
studies NN O O
have NN O O
been NN O O
conducted NN O O
in NN O O
patients NN O O
with NN O O
end NN O O
- NN O O
stage NN O O
renal NN O O
disease NN O O
. NN O O
ENTEREG NN O O
is NN O O
not NN O O
recommended NN O O
for NN O O
use NN O O
in NN O O
these NN O O
patients NN O O
. NN O O
5.6 NN O O
Risk NN O O
of NN O O
Serious NN O O
Adverse NN O O
Reactions NN O O
in NN O O
Patients NN O O
with NN O O
Complete NN O O
Gastrointestinal NN O O
Obstruction NN O O
No NN O O
studies NN O O
have NN O O
been NN O O
conducted NN O O
in NN O O
patients NN O O
with NN O O
complete NN O O
gastrointestinal NN O O
obstruction NN O O
or NN O O
in NN O O
patients NN O O
who NN O O
have NN O O
surgery NN O O
for NN O O
correction NN O O
of NN O O
complete NN O O
bowel NN O O
obstruction NN O O
. NN O O
ENTEREG NN O O
is NN O O
not NN O O
recommended NN O O
for NN O O
use NN O O
in NN O O
these NN O O
patients NN O O
. NN O O
5.7 NN O O
Risk NN O O
of NN O O
Serious NN O O
Adverse NN O O
Reactions NN O O
in NN O O
Pancreatic NN O O
and NN O O
Gastric NN O O
Anastomoses NN O O
ENTEREG NN O O
has NN O O
not NN O O
been NN O O
studied NN O O
in NN O O
patients NN O O
having NN O O
pancreatic NN O O
or NN O O
gastric NN O O
anastomosis NN O O
. NN O O
Therefore NN O O
, NN O O
ENTEREG NN O O
is NN O O
not NN O O
recommended NN O O
for NN O O
use NN O O
in NN O O
these NN O O
patients NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=10 NN O O
% NN O O
) NN O O
are NN O O
: NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremities NN I-AdverseReaction I-AdverseReaction
and NN O O
upper NN B-AdverseReaction B-AdverseReaction
abdominal NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Genzyme NN O O
Corporation NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
745 NN O O
- NN O O
4447 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
to NN O O
CERDELGA NN O O
( NN O O
occurring NN O O
in NN O O
>=10 NN O O
% NN O O
of NN O O
the NN O O
126 NN O O
GD1 NN O O
patients NN O O
treated NN O O
with NN O O
CERDELGA NN O O
across NN O O
Trials NN O O
1 NN O O
and NN O O
2 NN O O
) NN O O
were NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremities NN I-AdverseReaction I-AdverseReaction
and NN O O
upper NN B-AdverseReaction B-AdverseReaction
abdominal NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
The NN O O
adverse NN O O
reaction NN O O
profile NN O O
of NN O O
CERDELGA NN O O
is NN O O
based NN O O
on NN O O
two NN O O
controlled NN O O
studies NN O O
, NN O O
Trials NN O O
1 NN O O
and NN O O
2 NN O O
. NN O O
Table NN O O
1 NN O O
presents NN O O
the NN O O
profile NN O O
from NN O O
the NN O O
9-month NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
randomized NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
trial NN O O
of NN O O
40 NN O O
treatment NN O O
- NN O O
naive NN O O
patients NN O O
( NN O O
Trial NN O O
1 NN O O
) NN O O
. NN O O
Patients NN O O
were NN O O
between NN O O
the NN O O
ages NN O O
of NN O O
16 NN O O
and NN O O
63 NN O O
on NN O O
the NN O O
date NN O O
of NN O O
the NN O O
first NN O O
dose NN O O
of NN O O
study NN O O
drug NN O O
, NN O O
and NN O O
included NN O O
20 NN O O
males NN O O
and NN O O
20 NN O O
females NN O O
. NN O O
Table NN O O
1 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Occurring NN O O
in NN O O
>=10 NN O O
% NN O O
of NN O O
Treatment NN O O
- NN O O
Naive NN O O
GD1 NN O O
Patients NN O O
and NN O O
More NN O O
Frequently NN O O
than NN O O
Placebo NN O O
( NN O O
Trial NN O O
1 NN O O
) NN O O
CERDELGA(N=20 NN O O
) NN O O
Placebo(N=20 NN O O
) NN O O
Adverse NN O O
Reaction NN O O
Patientsn NN O O
( NN O O
% NN O O
) NN O O
Patientsn NN O O
( NN O O
% NN O O
) NN O O
Arthralgia NN B-AdverseReaction B-AdverseReaction
9 NN O O
( NN O O
45 NN O O
) NN O O
2 NN O O
( NN O O
10 NN O O
) NN O O
Headache NN B-AdverseReaction B-AdverseReaction
8 NN O O
( NN O O
40 NN O O
) NN O O
6 NN O O
( NN O O
30 NN O O
) NN O O
Migraine NN B-AdverseReaction B-AdverseReaction
2 NN O O
( NN O O
10 NN O O
) NN O O
0 NN O O
( NN O O
0 NN O O
) NN O O
Flatulence NN B-AdverseReaction B-AdverseReaction
2 NN O O
( NN O O
10 NN O O
) NN O O
1 NN O O
( NN O O
5 NN O O
) NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
2 NN O O
( NN O O
10 NN O O
) NN O O
1 NN O O
( NN O O
5 NN O O
) NN O O
Oropharyngeal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
2 NN O O
( NN O O
10 NN O O
) NN O O
1 NN O O
( NN O O
5 NN O O
) NN O O
Table NN O O
2 NN O O
presents NN O O
the NN O O
profile NN O O
from NN O O
the NN O O
12-month NN O O
open NN O O
- NN O O
label NN O O
, NN O O
randomized NN O O
, NN O O
imiglucerase NN O O
- NN O O
controlled NN O O
trial NN O O
of NN O O
159 NN O O
treated NN O O
patients NN O O
switching NN O O
from NN O O
enzyme NN O O
replacement NN O O
therapy NN O O
( NN O O
ERT NN O O
) NN O O
( NN O O
Trial NN O O
2 NN O O
) NN O O
. NN O O
Patients NN O O
were NN O O
between NN O O
the NN O O
ages NN O O
of NN O O
18 NN O O
and NN O O
69 NN O O
on NN O O
the NN O O
date NN O O
of NN O O
the NN O O
first NN O O
dose NN O O
of NN O O
CERDELGA NN O O
, NN O O
and NN O O
included NN O O
87 NN O O
females NN O O
and NN O O
72 NN O O
males NN O O
. NN O O
Table NN O O
2 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Occurring NN O O
in NN O O
>=5 NN O O
% NN O O
of NN O O
GD1 NN O O
Patients NN O O
Switching NN O O
from NN O O
Enzyme NN O O
Replacement NN O O
Therapy NN O O
to NN O O
CERDELGA NN O O
and NN O O
More NN O O
Frequently NN O O
than NN O O
Imiglucerase NN O O
( NN O O
Trial NN O O
2)Trial NN O O
2 NN O O
was NN O O
not NN O O
designed NN O O
to NN O O
support NN O O
comparative NN O O
claims NN O O
for NN O O
CERDELGA NN O O
for NN O O
the NN O O
adverse NN O O
reactions NN O O
reported NN O O
in NN O O
this NN O O
table NN O O
. NN O O
CERDELGA(N=106 NN O O
) NN O O
Imiglucerase(N=53 NN O O
) NN O O
Adverse NN O O
Reaction NN O O
Patientsn NN O O
( NN O O
% NN O O
) NN O O
Patientsn NN O O
( NN O O
% NN O O
) NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
15 NN O O
( NN O O
14 NN O O
) NN O O
1 NN O O
( NN O O
2 NN O O
) NN O O
Headache NN B-AdverseReaction B-AdverseReaction
14 NN O O
( NN O O
13 NN O O
) NN O O
1 NN O O
( NN O O
2 NN O O
) NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
13 NN O O
( NN O O
12 NN O O
) NN O O
0 NN O O
( NN O O
0 NN O O
) NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
13 NN O O
( NN O O
12 NN O O
) NN O O
2 NN O O
( NN O O
4 NN O O
) NN O O
Back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
13 NN O O
( NN O O
12 NN O O
) NN O O
3 NN O O
( NN O O
6 NN O O
) NN O O
Pain NN O O
in NN O O
extremity NN O O
12 NN O O
( NN O O
11 NN O O
) NN O O
1 NN O O
( NN O O
2 NN O O
) NN O O
Upper NN B-AdverseReaction B-AdverseReaction
abdominal NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
11 NN O O
( NN O O
10 NN O O
) NN O O
0 NN O O
( NN O O
0 NN O O
) NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
9 NN O O
( NN O O
8 NN O O
) NN O O
0 NN O O
( NN O O
0 NN O O
) NN O O
Asthenia NN B-AdverseReaction B-AdverseReaction
9 NN O O
( NN O O
8 NN O O
) NN O O
0 NN O O
( NN O O
0 NN O O
) NN O O
Cough NN B-AdverseReaction B-AdverseReaction
7 NN O O
( NN O O
7 NN O O
) NN O O
2 NN O O
( NN O O
4 NN O O
) NN O O
Dyspepsia NN B-AdverseReaction B-AdverseReaction
7 NN O O
( NN O O
7 NN O O
) NN O O
1 NN O O
( NN O O
2 NN O O
) NN O O
Gastroesophageal NN B-AdverseReaction B-AdverseReaction
reflux NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
7 NN O O
( NN O O
7 NN O O
) NN O O
0 NN O O
( NN O O
0 NN O O
) NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
5 NN O O
( NN O O
5 NN O O
) NN O O
0 NN O O
( NN O O
0 NN O O
) NN O O
Palpitations NN B-AdverseReaction B-AdverseReaction
5 NN O O
( NN O O
5 NN O O
) NN O O
0 NN O O
( NN O O
0 NN O O
) NN O O
Rash NN B-AdverseReaction B-AdverseReaction
5 NN O O
( NN O O
5 NN O O
) NN O O
0 NN O O
( NN O O
0 NN O O
) NN O O
In NN O O
an NN O O
uncontrolled NN O O
study NN O O
, NN O O
with NN O O
up NN O O
to NN O O
4 NN O O
years NN O O
of NN O O
treatment NN O O
, NN O O
in NN O O
26 NN O O
patients NN O O
, NN O O
the NN O O
types NN O O
and NN O O
incidences NN O O
of NN O O
adverse NN O O
reactions NN O O
were NN O O
similar NN O O
to NN O O
Trials NN O O
1 NN O O
and NN O O
2 NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
ECG NN B-AdverseReaction B-AdverseReaction
Changes NN I-AdverseReaction I-AdverseReaction
and NN O O
Potential NN B-Factor B-Factor
for NN O O
Cardiac NN B-AdverseReaction B-AdverseReaction
Arrhythmias NN I-AdverseReaction I-AdverseReaction
Not NN O O
recommended NN O O
in NN O O
patients NN O O
with NN O O
pre NN O O
- NN O O
existing NN O O
cardiac NN O O
disease NN O O
, NN O O
long NN O O
QT NN O O
syndrome NN O O
, NN O O
and NN O O
concomitant NN O O
use NN O O
of NN O O
Class NN O O
IA NN O O
and NN O O
Class NN O O
III NN O O
antiarrhythmics NN O O
( NN O O
5.2 NN O O
) NN O O
5.1 NN O O
Drug NN O O
- NN O O
Drug NN O O
Interactions NN O O
Eliglustat NN O O
is NN O O
a NN O O
CYP2D6 NN O O
and NN O O
CYP3A NN O O
substrate NN O O
. NN O O
Drugs NN O O
that NN O O
inhibit NN O O
CYP2D6 NN O O
and NN O O
CYP3A NN O O
metabolism NN O O
pathways NN O O
may NN O O
significantly NN O O
increase NN O O
the NN O O
exposure NN O O
to NN O O
eliglustat NN O O
and NN O O
result NN O O
in NN O O
prolongation NN O O
of NN O O
the NN O O
PR NN O O
, NN O O
QTc NN O O
, NN O O
and/or NN O O
QRS NN O O
cardiac NN O O
intervals NN O O
that NN O O
could NN B-Factor B-Factor
result NN O O
in NN O O
cardiac NN B-AdverseReaction B-AdverseReaction
arrhythmias NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.2 NN O O
) NN O O
] NN O O
. NN O O
Some NN O O
drugs NN O O
that NN O O
are NN O O
inhibitors NN O O
of NN O O
CYP2D6 NN O O
and NN O O
CYP3A NN O O
are NN O O
contraindicated NN O O
with NN O O
CERDELGA NN O O
depending NN O O
on NN O O
the NN O O
patient NN O O
's NN O O
CYP2D6 NN O O
metabolizer NN O O
status NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
] NN O O
. NN O O
See NN O O
Table NN O O
3 NN O O
and NN O O
Table NN O O
4 NN O O
for NN O O
other NN O O
potentially NN O O
significant NN O O
drug NN O O
interactions NN O O
[ NN O O
see NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.1 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
ECG NN O O
Changes NN O O
and NN O O
Potential NN O O
for NN O O
Cardiac NN O O
Arrhythmias NN O O
Use NN O O
of NN O O
CERDELGA NN O O
in NN O O
patients NN O O
with NN O O
pre NN O O
- NN O O
existing NN O O
cardiac NN O O
conditions NN O O
has NN O O
not NN O O
been NN O O
studied NN O O
during NN O O
clinical NN O O
trials NN O O
. NN O O
Because NN O O
CERDELGA NN O O
is NN O O
predicted NN O O
to NN O O
cause NN O O
increases NN O O
in NN O O
ECG NN O O
intervals NN O O
( NN O O
PR NN O O
, NN O O
QTc NN O O
, NN O O
and NN O O
QRS NN O O
) NN O O
at NN O O
substantially NN O O
elevated NN O O
eliglustat NN O O
plasma NN O O
concentrations NN O O
, NN O O
use NN O O
of NN O O
CERDELGA NN O O
is NN O O
not NN O O
recommended NN O O
in NN O O
patients NN O O
with NN O O
pre NN O O
- NN O O
existing NN O O
cardiac NN O O
disease NN O O
( NN O O
congestive NN O O
heart NN O O
failure NN O O
, NN O O
recent NN O O
acute NN O O
myocardial NN O O
infarction NN O O
, NN O O
bradycardia NN O O
, NN O O
heart NN O O
block NN O O
, NN O O
ventricular NN O O
arrhythmia NN O O
) NN O O
, NN O O
long NN O O
QT NN O O
syndrome NN O O
, NN O O
and NN O O
in NN O O
combination NN O O
with NN O O
Class NN O O
IA NN O O
( NN O O
e.g. NN O O
, NN O O
quinidine NN O O
, NN O O
procainamide NN O O
) NN O O
and NN O O
Class NN O O
III NN O O
( NN O O
e.g. NN O O
, NN O O
amiodarone NN O O
, NN O O
sotalol NN O O
) NN O O
antiarrhythmic NN O O
medications NN O O
[ NN O O
see NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.2 NN O O
) NN O O
] NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
serious NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
associated NN O O
with NN O O
TREANDA NN O O
in NN O O
clinical NN O O
trials NN O O
and NN O O
are NN O O
discussed NN O O
in NN O O
greater NN O O
detail NN O O
in NN O O
other NN O O
sections NN O O
of NN O O
the NN O O
label NN O O
. NN O O
* NN O O
Myelosuppression NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Infections NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
Anaphylaxis NN B-AdverseReaction B-AdverseReaction
and NN O O
Infusion NN B-AdverseReaction B-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
* NN O O
Tumor NN B-AdverseReaction B-AdverseReaction
Lysis NN I-AdverseReaction I-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
* NN O O
Skin NN B-AdverseReaction B-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
* NN O O
Other NN O O
Malignancies NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.6 NN O O
) NN O O
] NN O O
* NN O O
Extravasation NN B-AdverseReaction B-AdverseReaction
injury NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.7 NN O O
) NN O O
] NN O O
* NN O O
* NN O O
Most NN O O
common NN O O
non NN O O
- NN O O
hematologic NN O O
adverse NN O O
reactions NN O O
for NN O O
CLL NN O O
( NN O O
frequency NN O O
>= NN O O
15 NN O O
% NN O O
) NN O O
are NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
and NN O O
vomiting NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
* NN O O
Most NN O O
common NN O O
non NN O O
- NN O O
hematologic NN O O
adverse NN O O
reactions NN O O
for NN O O
NHL NN O O
( NN O O
frequency NN O O
>= NN O O
15 NN O O
% NN O O
) NN O O
are NN O O
nausea NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
pyrexia NN B-AdverseReaction B-AdverseReaction
constipation NN B-AdverseReaction B-AdverseReaction
anorexia NN B-AdverseReaction B-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
weight NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
dyspnea NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
and NN O O
stomatitis NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
* NN O O
Most NN O O
common NN O O
hematologic NN B-AdverseReaction B-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
for NN O O
both NN O O
indications NN O O
( NN O O
frequency NN O O
>= NN O O
15 NN O O
% NN O O
) NN O O
are NN O O
lymphopenia NN B-AdverseReaction B-AdverseReaction
anemia NN B-AdverseReaction B-AdverseReaction
leukopenia NN B-AdverseReaction B-AdverseReaction
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
and NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
EXCERPT NN O O
: NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Teva NN O O
Pharmaceuticals NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
896 NN O O
- NN O O
5855 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
Chronic NN O O
Lymphocytic NN O O
Leukemia NN O O
The NN O O
data NN O O
described NN O O
below NN O O
reflect NN O O
exposure NN O O
to NN O O
TREANDA NN O O
in NN O O
153 NN O O
patients NN O O
with NN O O
CLL NN O O
studied NN O O
in NN O O
an NN O O
active NN O O
- NN O O
controlled NN O O
, NN O O
randomized NN O O
trial NN O O
. NN O O
The NN O O
population NN O O
was NN O O
45 NN O O
- NN O O
77 NN O O
years NN O O
of NN O O
age NN O O
, NN O O
63 NN O O
% NN O O
male NN O O
, NN O O
100 NN O O
% NN O O
white NN O O
, NN O O
and NN O O
were NN O O
treatment NN O O
naive NN O O
. NN O O
All NN O O
patients NN O O
started NN O O
the NN O O
study NN O O
at NN O O
a NN O O
dose NN O O
of NN O O
100 NN O O
mg/m NN O O
2 NN O O
intravenously NN O O
over NN O O
30 NN O O
minutes NN O O
on NN O O
Days NN O O
1 NN O O
and NN O O
2 NN O O
every NN O O
28 NN O O
days NN O O
. NN O O
Adverse NN O O
reactions NN O O
were NN O O
reported NN O O
according NN O O
to NN O O
NCI NN O O
CTC NN O O
v.2.0 NN O O
. NN O O
Non NN O O
- NN O O
hematologic NN O O
adverse NN O O
reactions NN O O
( NN O O
any NN O O
grade NN O O
) NN O O
in NN O O
the NN O O
TREANDA NN O O
group NN O O
that NN O O
occurred NN O O
with NN O O
a NN O O
frequency NN O O
greater NN O O
than NN O O
15 NN O O
% NN O O
were NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
( NN O O
24 NN O O
% NN O O
) NN O O
, NN O O
nausea NN B-AdverseReaction B-AdverseReaction
( NN O O
20 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
vomiting NN B-AdverseReaction B-AdverseReaction
( NN O O
16 NN O O
% NN O O
) NN O O
. NN O O
Other NN O O
adverse NN O O
reactions NN O O
seen NN O O
frequently NN O O
in NN O O
one NN O O
or NN O O
more NN O O
studies NN O O
included NN O O
asthenia NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
malaise NN B-AdverseReaction B-AdverseReaction
and NN O O
weakness NN B-AdverseReaction B-AdverseReaction
dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
somnolence NN B-AdverseReaction B-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
constipation NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
mucosal NN B-AdverseReaction B-AdverseReaction
inflammation NN I-AdverseReaction I-AdverseReaction
and NN O O
stomatitis NN B-AdverseReaction B-AdverseReaction
Worsening NN B-AdverseReaction B-AdverseReaction
hypertension NN I-AdverseReaction I-AdverseReaction
was NN O O
reported NN O O
in NN O O
4 NN O O
patients NN O O
treated NN O O
with NN O O
TREANDA NN O O
in NN O O
the NN O O
CLL NN O O
trial NN O O
and NN O O
in NN O O
none NN O O
treated NN O O
with NN O O
chlorambucil NN O O
. NN O O
Three NN O O
of NN O O
these NN O O
4 NN O O
adverse NN O O
reactions NN O O
were NN O O
described NN O O
as NN O O
a NN O O
hypertensive NN B-AdverseReaction B-AdverseReaction
crisis NN I-AdverseReaction I-AdverseReaction
and NN O O
were NN O O
managed NN O O
with NN O O
oral NN O O
medications NN O O
and NN O O
resolved NN O O
. NN O O
The NN O O
most NN O O
frequent NN O O
adverse NN O O
reactions NN O O
leading NN O O
to NN O O
study NN O O
withdrawal NN O O
for NN O O
patients NN O O
receiving NN O O
TREANDA NN O O
were NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
and NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
( NN O O
1 NN O O
% NN O O
) NN O O
. NN O O
Table NN O O
1 NN O O
contains NN O O
the NN O O
treatment NN O O
emergent NN O O
adverse NN O O
reactions NN O O
, NN O O
regardless NN O O
of NN O O
attribution NN O O
, NN O O
that NN O O
were NN O O
reported NN O O
in NN O O
>= NN O O
5 NN O O
% NN O O
of NN O O
patients NN O O
in NN O O
either NN O O
treatment NN O O
group NN O O
in NN O O
the NN O O
randomized NN O O
CLL NN O O
clinical NN O O
study NN O O
. NN O O
Table NN O O
1 NN O O
: NN O O
Non NN O O
- NN O O
Hematologic NN O O
Adverse NN O O
Reactions NN O O
Occurring NN O O
in NN O O
Randomized NN O O
CLL NN O O
Clinical NN O O
Study NN O O
in NN O O
at NN O O
Least NN O O
5 NN O O
% NN O O
of NN O O
Patients NN O O
Number NN O O
( NN O O
% NN O O
) NN O O
of NN O O
patients NN O O
TREANDA(N=153 NN O O
) NN O O
Chlorambucil(N=143 NN O O
) NN O O
System NN O O
organ NN O O
class NN O O
Preferred NN O O
term NN O O
All NN O O
Grades NN O O
Grade NN O O
3/4 NN O O
All NN O O
Grades NN O O
Grade NN O O
3/4 NN O O
Total NN O O
number NN O O
of NN O O
patients NN O O
with NN O O
at NN O O
least NN O O
1 NN O O
adverse NN O O
reaction NN O O
121 NN O O
( NN O O
79 NN O O
) NN O O
52 NN O O
( NN O O
34 NN O O
) NN O O
96 NN O O
( NN O O
67 NN O O
) NN O O
25 NN O O
( NN O O
17 NN O O
) NN O O
Gastrointestinal NN O O
disorders NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
31 NN O O
( NN O O
20 NN O O
) NN O O
1 NN O O
( NN O O
< NN O O
1 NN O O
) NN O O
21 NN O O
( NN O O
15 NN O O
) NN O O
1 NN O O
( NN O O
< NN O O
1 NN O O
) NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
24 NN O O
( NN O O
16 NN O O
) NN O O
1 NN O O
( NN O O
< NN O O
1 NN O O
) NN O O
9 NN O O
( NN O O
6 NN O O
) NN O O
0 NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
14 NN O O
( NN O O
9 NN O O
) NN O O
2 NN O O
( NN O O
1 NN O O
) NN O O
5 NN O O
( NN O O
3 NN O O
) NN O O
0 NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
36 NN O O
( NN O O
24 NN O O
) NN O O
6 NN O O
( NN O O
4 NN O O
) NN O O
8 NN O O
( NN O O
6 NN O O
) NN O O
2 NN O O
( NN O O
1 NN O O
) NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
14 NN O O
( NN O O
9 NN O O
) NN O O
2 NN O O
( NN O O
1 NN O O
) NN O O
8 NN O O
( NN O O
6 NN O O
) NN O O
0 NN O O
Asthenia NN B-AdverseReaction B-AdverseReaction
13 NN O O
( NN O O
8 NN O O
) NN O O
0 NN O O
6 NN O O
( NN O O
4 NN O O
) NN O O
0 NN O O
Chills NN B-AdverseReaction B-AdverseReaction
9 NN O O
( NN O O
6 NN O O
) NN O O
0 NN O O
1 NN O O
( NN O O
< NN O O
1 NN O O
) NN O O
0 NN O O
Immune NN O O
system NN O O
disorders NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
7 NN O O
( NN O O
5 NN O O
) NN O O
2 NN O O
( NN O O
1 NN O O
) NN O O
3 NN O O
( NN O O
2 NN O O
) NN O O
0 NN O O
Infections NN O O
and NN O O
infestations NN O O
Nasopharyngitis NN B-AdverseReaction B-AdverseReaction
10 NN O O
( NN O O
7 NN O O
) NN O O
0 NN O O
12 NN O O
( NN O O
8 NN O O
) NN O O
0 NN O O
Infection NN B-AdverseReaction B-AdverseReaction
9 NN O O
( NN O O
6 NN O O
) NN O O
3 NN O O
( NN O O
2 NN O O
) NN O O
1 NN O O
( NN O O
< NN O O
1 NN O O
) NN O O
1 NN O O
( NN O O
< NN O O
1 NN O O
) NN O O
Herpes NN B-AdverseReaction B-AdverseReaction
simplex NN I-AdverseReaction I-AdverseReaction
5 NN O O
( NN O O
3 NN O O
) NN O O
0 NN O O
7 NN O O
( NN O O
5 NN O O
) NN O O
0 NN O O
Investigations NN O O
Weight NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
11 NN O O
( NN O O
7 NN O O
) NN O O
0 NN O O
5 NN O O
( NN O O
3 NN O O
) NN O O
0 NN O O
Metabolism NN O O
and NN O O
nutrition NN O O
disorders NN O O
Hyperuricemia NN B-AdverseReaction B-AdverseReaction
11 NN O O
( NN O O
7 NN O O
) NN O O
3 NN O O
( NN O O
2 NN O O
) NN O O
2 NN O O
( NN O O
1 NN O O
) NN O O
0 NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
and NN O O
mediastinal NN O O
disorders NN O O
Cough NN B-AdverseReaction B-AdverseReaction
6 NN O O
( NN O O
4 NN O O
) NN O O
1 NN O O
( NN O O
< NN O O
1 NN O O
) NN O O
7 NN O O
( NN O O
5 NN O O
) NN O O
1 NN O O
( NN O O
< NN O O
1 NN O O
) NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
Rash NN B-AdverseReaction B-AdverseReaction
12 NN O O
( NN O O
8 NN O O
) NN O O
4 NN O O
( NN O O
3 NN O O
) NN O O
7 NN O O
( NN O O
5 NN O O
) NN O O
3 NN O O
( NN O O
2 NN O O
) NN O O
Pruritus NN B-AdverseReaction B-AdverseReaction
8 NN O O
( NN O O
5 NN O O
) NN O O
0 NN O O
2 NN O O
( NN O O
1 NN O O
) NN O O
0 NN O O
The NN O O
Grade NN O O
3 NN O O
and NN O O
4 NN O O
hematology NN O O
laboratory NN O O
test NN O O
values NN O O
by NN O O
treatment NN O O
group NN O O
in NN O O
the NN O O
randomized NN O O
CLL NN O O
clinical NN O O
study NN O O
are NN O O
described NN O O
in NN O O
Table NN O O
2 NN O O
. NN O O
These NN O O
findings NN O O
confirm NN O O
the NN O O
myelosuppressive NN B-AdverseReaction B-AdverseReaction
effects NN I-AdverseReaction I-AdverseReaction
seen NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
TREANDA. NN O O
Red NN O O
blood NN O O
cell NN O O
transfusions NN O O
were NN O O
administered NN O O
to NN O O
20 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
TREANDA NN O O
compared NN O O
with NN O O
6 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
chlorambucil NN O O
. NN O O
Table NN O O
2 NN O O
: NN O O
Incidence NN O O
of NN O O
Hematology NN O O
Laboratory NN O O
Abnormalities NN O O
in NN O O
Patients NN O O
Who NN O O
Received NN O O
TREANDA NN O O
or NN O O
Chlorambucil NN O O
in NN O O
the NN O O
Randomized NN O O
CLL NN O O
Clinical NN O O
Study NN O O
TREANDA NN O O
N=150 NN O O
ChlorambucilN=141 NN O O
Laboratory NN O O
Abnormality NN O O
All NN O O
Gradesn NN O O
( NN O O
% NN O O
) NN O O
Grade NN O O
3/4n NN O O
( NN O O
% NN O O
) NN O O
All NN O O
Gradesn NN O O
( NN O O
% NN O O
) NN O O
Grade NN O O
3/4n NN O O
( NN O O
% NN O O
) NN O O
Hemoglobin NN B-AdverseReaction B-AdverseReaction
Decreased NN I-AdverseReaction I-AdverseReaction
134 NN O O
( NN O O
89 NN O O
) NN O O
20 NN O O
( NN O O
13 NN O O
) NN O O
115 NN O O
( NN O O
82 NN O O
) NN O O
12 NN O O
( NN O O
9 NN O O
) NN O O
Platelets NN B-AdverseReaction B-AdverseReaction
Decreased NN I-AdverseReaction I-AdverseReaction
116 NN O O
( NN O O
77 NN O O
) NN O O
16 NN O O
( NN O O
11 NN O O
) NN O O
110 NN O O
( NN O O
78 NN O O
) NN O O
14 NN O O
( NN O O
10 NN O O
) NN O O
Leukocytes NN B-AdverseReaction B-AdverseReaction
Decreased NN I-AdverseReaction I-AdverseReaction
92 NN O O
( NN O O
61 NN O O
) NN O O
42 NN O O
( NN O O
28 NN O O
) NN O O
26 NN O O
( NN O O
18 NN O O
) NN O O
4 NN O O
( NN O O
3 NN O O
) NN O O
Lymphocytes NN B-AdverseReaction B-AdverseReaction
Decreased NN I-AdverseReaction I-AdverseReaction
102 NN O O
( NN O O
68 NN O O
) NN O O
70 NN O O
( NN O O
47 NN O O
) NN O O
27 NN O O
( NN O O
19 NN O O
) NN O O
6 NN O O
( NN O O
4 NN O O
) NN O O
Neutrophils NN B-AdverseReaction B-AdverseReaction
Decreased NN I-AdverseReaction I-AdverseReaction
113 NN O O
( NN O O
75 NN O O
) NN O O
65 NN O O
( NN O O
43 NN O O
) NN O O
86 NN O O
( NN O O
61 NN O O
) NN O O
30 NN O O
( NN O O
21 NN O O
) NN O O
In NN O O
the NN O O
CLL NN O O
trial NN O O
, NN O O
34 NN O O
% NN O O
of NN O O
patients NN O O
had NN O O
bilirubin NN B-AdverseReaction B-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
some NN O O
without NN B-Negation B-Negation
associated NN O O
significant NN B-Severity B-Severity
elevations NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
AST NN I-AdverseReaction I-AdverseReaction
and NN O O
ALT. NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
or NN O O
4 NN O O
increased NN B-AdverseReaction B-AdverseReaction
bilirubin NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
3 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
Increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
AST NN I-AdverseReaction I-AdverseReaction
and NN O O
ALT NN O O
of NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
or NN O O
4 NN O O
were NN O O
limited NN O O
to NN O O
1 NN O O
% NN O O
and NN O O
3 NN O O
% NN O O
of NN O O
patients NN O O
, NN O O
respectively NN O O
. NN O O
Patients NN O O
treated NN O O
with NN O O
TREANDA NN O O
may NN B-Factor B-Factor
also NN O O
have NN O O
changes NN O O
in NN O O
their NN O O
creatinine NN O O
levels NN O O
. NN O O
If NN O O
abnormalities NN O O
are NN O O
detected NN O O
, NN O O
monitoring NN O O
of NN O O
these NN O O
parameters NN O O
should NN O O
be NN O O
continued NN O O
to NN O O
ensure NN O O
that NN O O
further NN O O
deterioration NN O O
does NN O O
not NN O O
occur NN O O
. NN O O
Non NN O O
- NN O O
Hodgkin NN O O
Lymphoma NN O O
The NN O O
data NN O O
described NN O O
below NN O O
reflect NN O O
exposure NN O O
to NN O O
TREANDA NN O O
in NN O O
176 NN O O
patients NN O O
with NN O O
indolent NN O O
B NN O O
- NN O O
cell NN O O
NHL NN O O
treated NN O O
in NN O O
two NN O O
single NN O O
- NN O O
arm NN O O
studies NN O O
. NN O O
The NN O O
population NN O O
was NN O O
31 NN O O
- NN O O
84 NN O O
years NN O O
of NN O O
age NN O O
, NN O O
60 NN O O
% NN O O
male NN O O
, NN O O
and NN O O
40 NN O O
% NN O O
female NN O O
. NN O O
The NN O O
race NN O O
distribution NN O O
was NN O O
89 NN O O
% NN O O
White NN O O
, NN O O
7 NN O O
% NN O O
Black NN O O
, NN O O
3 NN O O
% NN O O
Hispanic NN O O
, NN O O
1 NN O O
% NN O O
other NN O O
, NN O O
and NN O O
< NN O O
1 NN O O
% NN O O
Asian NN O O
. NN O O
These NN O O
patients NN O O
received NN O O
TREANDA NN O O
at NN O O
a NN O O
dose NN O O
of NN O O
120 NN O O
mg/m NN O O
2 NN O O
intravenously NN O O
on NN O O
Days NN O O
1 NN O O
and NN O O
2 NN O O
for NN O O
up NN O O
to NN O O
eight NN O O
21-day NN O O
cycles NN O O
. NN O O
The NN O O
adverse NN O O
reactions NN O O
occurring NN O O
in NN O O
at NN O O
least NN O O
5 NN O O
% NN O O
of NN O O
the NN O O
NHL NN O O
patients NN O O
, NN O O
regardless NN O O
of NN O O
severity NN O O
, NN O O
are NN O O
shown NN O O
in NN O O
Table NN O O
3 NN O O
. NN O O
The NN O O
most NN O O
common NN O O
non NN O O
- NN O O
hematologic NN O O
adverse NN O O
reactions NN O O
( NN O O
>=30 NN O O
% NN O O
) NN O O
were NN O O
nausea NN B-AdverseReaction B-AdverseReaction
( NN O O
75 NN O O
% NN O O
) NN O O
, NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
( NN O O
57 NN O O
% NN O O
) NN O O
, NN O O
vomiting NN B-AdverseReaction B-AdverseReaction
( NN O O
40 NN O O
% NN O O
) NN O O
, NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
( NN O O
37 NN O O
% NN O O
) NN O O
and NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
( NN O O
34 NN O O
% NN O O
) NN O O
. NN O O
The NN O O
most NN O O
common NN O O
non NN O O
- NN O O
hematologic NN O O
Grade NN O O
3 NN O O
or NN O O
4 NN O O
adverse NN O O
reactions NN O O
( NN O O
>=5 NN O O
% NN O O
) NN O O
were NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
( NN O O
11 NN O O
% NN O O
) NN O O
, NN O O
febrile NN B-AdverseReaction B-AdverseReaction
neutropenia NN I-AdverseReaction I-AdverseReaction
( NN O O
6 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
hypokalemia NN B-AdverseReaction B-AdverseReaction
and NN O O
dehydration NN B-AdverseReaction B-AdverseReaction
each NN O O
reported NN O O
in NN O O
5 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
Table NN O O
3 NN O O
: NN O O
Non NN O O
- NN O O
Hematologic NN O O
Adverse NN O O
Reactions NN O O
Occurring NN O O
in NN O O
at NN O O
Least NN O O
5 NN O O
% NN O O
of NN O O
NHL NN O O
Patients NN O O
Treated NN O O
with NN O O
TREANDA NN O O
by NN O O
System NN O O
Organ NN O O
Class NN O O
and NN O O
Preferred NN O O
Term NN O O
( NN O O
N=176 NN O O
) NN O O
System NN O O
organ NN O O
class NN O O
Number NN O O
( NN O O
% NN O O
) NN O O
of NN O O
patients NN O O
* NN O O
Preferred NN O O
term NN O O
All NN O O
Grades NN O O
Grade NN O O
3/4 NN O O
Total NN O O
number NN O O
of NN O O
patients NN O O
with NN O O
at NN O O
least NN O O
1 NN O O
adverse NN O O
reaction NN O O
176 NN O O
( NN O O
100 NN O O
) NN O O
94 NN O O
( NN O O
53 NN O O
) NN O O
Cardiac NN O O
disorders NN O O
Tachycardia NN B-AdverseReaction B-AdverseReaction
13 NN O O
( NN O O
7 NN O O
) NN O O
0 NN O O
Gastrointestinal NN O O
disorders NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
132 NN O O
( NN O O
75 NN O O
) NN O O
7 NN O O
( NN O O
4 NN O O
) NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
71 NN O O
( NN O O
40 NN O O
) NN O O
5 NN O O
( NN O O
3 NN O O
) NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
65 NN O O
( NN O O
37 NN O O
) NN O O
6 NN O O
( NN O O
3 NN O O
) NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
51 NN O O
( NN O O
29 NN O O
) NN O O
1 NN O O
( NN O O
< NN O O
1 NN O O
) NN O O
Stomatitis NN B-AdverseReaction B-AdverseReaction
27 NN O O
( NN O O
15 NN O O
) NN O O
1 NN O O
( NN O O
< NN O O
1 NN O O
) NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
22 NN O O
( NN O O
13 NN O O
) NN O O
2 NN O O
( NN O O
1 NN O O
) NN O O
Dyspepsia NN B-AdverseReaction B-AdverseReaction
20 NN O O
( NN O O
11 NN O O
) NN O O
0 NN O O
Gastroesophageal NN B-AdverseReaction B-AdverseReaction
reflux NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
18 NN O O
( NN O O
10 NN O O
) NN O O
0 NN O O
Dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
15 NN O O
( NN O O
9 NN O O
) NN O O
1 NN O O
( NN O O
< NN O O
1 NN O O
) NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
upper NN I-AdverseReaction I-AdverseReaction
8 NN O O
( NN O O
5 NN O O
) NN O O
0 NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
distension NN I-AdverseReaction I-AdverseReaction
8 NN O O
( NN O O
5 NN O O
) NN O O
0 NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
101 NN O O
( NN O O
57 NN O O
) NN O O
19 NN O O
( NN O O
11 NN O O
) NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
59 NN O O
( NN O O
34 NN O O
) NN O O
3 NN O O
( NN O O
2 NN O O
) NN O O
Chills NN B-AdverseReaction B-AdverseReaction
24 NN O O
( NN O O
14 NN O O
) NN O O
0 NN O O
Edema NN B-AdverseReaction B-AdverseReaction
peripheral NN I-AdverseReaction I-AdverseReaction
23 NN O O
( NN O O
13 NN O O
) NN O O
1 NN O O
( NN O O
< NN O O
1 NN O O
) NN O O
Asthenia NN B-AdverseReaction B-AdverseReaction
19 NN O O
( NN O O
11 NN O O
) NN O O
4 NN O O
( NN O O
2 NN O O
) NN O O
Chest NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
11 NN O O
( NN O O
6 NN O O
) NN O O
1 NN O O
( NN O O
< NN O O
1 NN O O
) NN O O
Infusion NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
11 NN O O
( NN O O
6 NN O O
) NN O O
0 NN O O
Pain NN B-AdverseReaction B-AdverseReaction
10 NN O O
( NN O O
6 NN O O
) NN O O
0 NN O O
Catheter NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
8 NN O O
( NN O O
5 NN O O
) NN O O
0 NN O O
Infections NN O O
and NN O O
infestations NN O O
Herpes NN B-AdverseReaction B-AdverseReaction
zoster NN I-AdverseReaction I-AdverseReaction
18 NN O O
( NN O O
10 NN O O
) NN O O
5 NN O O
( NN O O
3 NN O O
) NN O O
Upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
18 NN O O
( NN O O
10 NN O O
) NN O O
0 NN O O
Urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
17 NN O O
( NN O O
10 NN O O
) NN O O
4 NN O O
( NN O O
2 NN O O
) NN O O
Sinusitis NN B-AdverseReaction B-AdverseReaction
15 NN O O
( NN O O
9 NN O O
) NN O O
0 NN O O
Pneumonia NN B-AdverseReaction B-AdverseReaction
14 NN O O
( NN O O
8 NN O O
) NN O O
9 NN O O
( NN O O
5 NN O O
) NN O O
Febrile NN B-AdverseReaction B-AdverseReaction
neutropenia NN I-AdverseReaction I-AdverseReaction
11 NN O O
( NN O O
6 NN O O
) NN O O
11 NN O O
( NN O O
6 NN O O
) NN O O
Oral NN B-AdverseReaction B-AdverseReaction
candidiasis NN I-AdverseReaction I-AdverseReaction
11 NN O O
( NN O O
6 NN O O
) NN O O
2 NN O O
( NN O O
1 NN O O
) NN O O
Nasopharyngitis NN B-AdverseReaction B-AdverseReaction
11 NN O O
( NN O O
6 NN O O
) NN O O
0 NN O O
Investigations NN O O
Weight NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
31 NN O O
( NN O O
18 NN O O
) NN O O
3 NN O O
( NN O O
2 NN O O
) NN O O
Metabolism NN O O
and NN O O
nutrition NN O O
disorders NN O O
Anorexia NN B-AdverseReaction B-AdverseReaction
40 NN O O
( NN O O
23 NN O O
) NN O O
3 NN O O
( NN O O
2 NN O O
) NN O O
Dehydration NN B-AdverseReaction B-AdverseReaction
24 NN O O
( NN O O
14 NN O O
) NN O O
8 NN O O
( NN O O
5 NN O O
) NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
22 NN O O
( NN O O
13 NN O O
) NN O O
1 NN O O
( NN O O
< NN O O
1 NN O O
) NN O O
Hypokalemia NN B-AdverseReaction B-AdverseReaction
15 NN O O
( NN O O
9 NN O O
) NN O O
9 NN O O
( NN O O
5 NN O O
) NN O O
Musculoskeletal NN O O
and NN O O
connective NN O O
tissue NN O O
disorders NN O O
Back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
25 NN O O
( NN O O
14 NN O O
) NN O O
5 NN O O
( NN O O
3 NN O O
) NN O O
Arthralgia NN B-AdverseReaction B-AdverseReaction
11 NN O O
( NN O O
6 NN O O
) NN O O
0 NN O O
Pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
8 NN O O
( NN O O
5 NN O O
) NN O O
2 NN O O
( NN O O
1 NN O O
) NN O O
Bone NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
8 NN O O
( NN O O
5 NN O O
) NN O O
0 NN O O
Nervous NN O O
system NN O O
disorders NN O O
Headache NN B-AdverseReaction B-AdverseReaction
36 NN O O
( NN O O
21 NN O O
) NN O O
0 NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
25 NN O O
( NN O O
14 NN O O
) NN O O
0 NN O O
Dysgeusia NN B-AdverseReaction B-AdverseReaction
13 NN O O
( NN O O
7 NN O O
) NN O O
0 NN O O
Psychiatric NN O O
disorders NN O O
Insomnia NN B-AdverseReaction B-AdverseReaction
23 NN O O
( NN O O
13 NN O O
) NN O O
0 NN O O
Anxiety NN B-AdverseReaction B-AdverseReaction
14 NN O O
( NN O O
8 NN O O
) NN O O
1 NN O O
( NN O O
< NN O O
1 NN O O
) NN O O
Depression NN B-AdverseReaction B-AdverseReaction
10 NN O O
( NN O O
6 NN O O
) NN O O
0 NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
and NN O O
mediastinal NN O O
disorders NN O O
Cough NN B-AdverseReaction B-AdverseReaction
38 NN O O
( NN O O
22 NN O O
) NN O O
1 NN O O
( NN O O
< NN O O
1 NN O O
) NN O O
Dyspnea NN B-AdverseReaction B-AdverseReaction
28 NN O O
( NN O O
16 NN O O
) NN O O
3 NN O O
( NN O O
2 NN O O
) NN O O
Pharyngolaryngeal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
14 NN O O
( NN O O
8 NN O O
) NN O O
1 NN O O
( NN O O
< NN O O
1 NN O O
) NN O O
Wheezing NN B-AdverseReaction B-AdverseReaction
8 NN O O
( NN O O
5 NN O O
) NN O O
0 NN O O
Nasal NN B-AdverseReaction B-AdverseReaction
congestion NN I-AdverseReaction I-AdverseReaction
8 NN O O
( NN O O
5 NN O O
) NN O O
0 NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
Rash NN B-AdverseReaction B-AdverseReaction
28 NN O O
( NN O O
16 NN O O
) NN O O
1 NN O O
( NN O O
< NN O O
1 NN O O
) NN O O
Pruritus NN B-AdverseReaction B-AdverseReaction
11 NN O O
( NN O O
6 NN O O
) NN O O
0 NN O O
Dry NN B-AdverseReaction B-AdverseReaction
skin NN I-AdverseReaction I-AdverseReaction
9 NN O O
( NN O O
5 NN O O
) NN O O
0 NN O O
Night NN B-AdverseReaction B-AdverseReaction
sweats NN I-AdverseReaction I-AdverseReaction
9 NN O O
( NN O O
5 NN O O
) NN O O
0 NN O O
Hyperhidrosis NN B-AdverseReaction B-AdverseReaction
8 NN O O
( NN O O
5 NN O O
) NN O O
0 NN O O
Vascular NN O O
disorders NN O O
Hypotension NN B-AdverseReaction B-AdverseReaction
10 NN O O
( NN O O
6 NN O O
) NN O O
2 NN O O
( NN O O
1 NN O O
) NN O O
* NN O O
Patients NN O O
may NN O O
have NN O O
reported NN O O
more NN O O
than NN O O
1 NN O O
adverse NN O O
reaction NN O O
. NN O O
NOTE NN O O
: NN O O
Patients NN O O
counted NN O O
only NN O O
once NN O O
in NN O O
each NN O O
preferred NN O O
term NN O O
category NN O O
and NN O O
once NN O O
in NN O O
each NN O O
system NN O O
organ NN O O
class NN O O
category NN O O
. NN O O
Hematologic NN B-AdverseReaction B-AdverseReaction
toxicities NN I-AdverseReaction I-AdverseReaction
based NN O O
on NN O O
laboratory NN O O
values NN O O
and NN O O
CTC NN O O
grade NN O O
, NN O O
in NN O O
NHL NN O O
patients NN O O
treated NN O O
in NN O O
both NN O O
single NN O O
arm NN O O
studies NN O O
combined NN O O
are NN O O
described NN O O
in NN O O
Table NN O O
4 NN O O
. NN O O
Clinically NN O O
important NN O O
chemistry NN O O
laboratory NN O O
values NN O O
that NN O O
were NN O O
new NN O O
or NN O O
worsened NN O O
from NN O O
baseline NN O O
and NN O O
occurred NN O O
in NN O O
>1 NN O O
% NN O O
of NN O O
patients NN O O
at NN O O
Grade NN O O
3 NN O O
or NN O O
4 NN O O
, NN O O
in NN O O
NHL NN O O
patients NN O O
treated NN O O
in NN O O
both NN O O
single NN O O
arm NN O O
studies NN O O
combined NN O O
were NN O O
hyperglycemia NN B-AdverseReaction B-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
, NN O O
elevated NN B-AdverseReaction B-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
, NN O O
hyponatremia NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
hypocalcemia NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
. NN O O
Table NN O O
4 NN O O
: NN O O
Incidence NN O O
of NN O O
Hematology NN O O
Laboratory NN O O
Abnormalities NN O O
in NN O O
Patients NN O O
Who NN O O
Received NN O O
TREANDA NN O O
in NN O O
the NN O O
NHL NN O O
Studies NN O O
Percent NN O O
of NN O O
patients NN O O
Hematology NN O O
variable NN O O
All NN O O
Grades NN O O
Grades NN O O
3/4 NN O O
Lymphocytes NN B-AdverseReaction B-AdverseReaction
Decreased NN I-AdverseReaction I-AdverseReaction
99 NN O O
94 NN O O
Leukocytes NN B-AdverseReaction B-AdverseReaction
Decreased NN I-AdverseReaction I-AdverseReaction
94 NN O O
56 NN O O
Hemoglobin NN B-AdverseReaction B-AdverseReaction
Decreased NN I-AdverseReaction I-AdverseReaction
88 NN O O
11 NN O O
Neutrophils NN B-AdverseReaction B-AdverseReaction
Decreased NN I-AdverseReaction I-AdverseReaction
86 NN O O
60 NN O O
Platelets NN B-AdverseReaction B-AdverseReaction
Decreased NN I-AdverseReaction I-AdverseReaction
86 NN O O
25 NN O O
In NN O O
both NN O O
studies NN O O
, NN O O
serious NN O O
adverse NN O O
reactions NN O O
, NN O O
regardless NN O O
of NN O O
causality NN O O
, NN O O
were NN O O
reported NN O O
in NN O O
37 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
TREANDA. NN O O
The NN O O
most NN O O
common NN O O
serious NN O O
adverse NN O O
reactions NN O O
occurring NN O O
in NN O O
>=5 NN O O
% NN O O
of NN O O
patients NN O O
were NN O O
febrile NN B-AdverseReaction B-AdverseReaction
neutropenia NN I-AdverseReaction I-AdverseReaction
and NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
Other NN O O
important NN O O
serious NN O O
adverse NN O O
reactions NN O O
reported NN O O
in NN O O
clinical NN O O
trials NN O O
and/or NN O O
postmarketing NN O O
experience NN O O
were NN O O
acute NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
cardiac NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
hypersensitivity NN B-AdverseReaction B-AdverseReaction
skin NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
pulmonary NN B-AdverseReaction B-AdverseReaction
fibrosis NN I-AdverseReaction I-AdverseReaction
and NN O O
myelodysplastic NN B-AdverseReaction B-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
Serious NN O O
drug NN O O
- NN O O
related NN O O
adverse NN O O
reactions NN O O
reported NN O O
in NN O O
clinical NN O O
trials NN O O
included NN O O
myelosuppression NN B-AdverseReaction B-AdverseReaction
infection NN B-AdverseReaction B-AdverseReaction
pneumonia NN B-AdverseReaction B-AdverseReaction
tumor NN B-AdverseReaction B-AdverseReaction
lysis NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
and NN O O
infusion NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5 NN O O
) NN O O
] NN O O
. NN O O
Adverse NN O O
reactions NN O O
occurring NN O O
less NN O O
frequently NN O O
but NN O O
possibly NN B-Factor B-Factor
related NN O O
to NN O O
TREANDA NN O O
treatment NN O O
were NN O O
hemolysis NN B-AdverseReaction B-AdverseReaction
dysgeusia NN B-AdverseReaction B-AdverseReaction
disorder NN O O
, NN O O
atypical NN B-AdverseReaction B-AdverseReaction
pneumonia NN I-AdverseReaction I-AdverseReaction
sepsis NN B-AdverseReaction B-AdverseReaction
herpes NN B-AdverseReaction B-AdverseReaction
zoster NN I-AdverseReaction I-AdverseReaction
erythema NN B-AdverseReaction B-AdverseReaction
dermatitis NN B-AdverseReaction B-AdverseReaction
and NN O O
skin NN B-AdverseReaction B-AdverseReaction
necrosis NN I-AdverseReaction I-AdverseReaction
6.2 NN O O
Postmarketing NN O O
Experience NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
identified NN O O
during NN O O
post NN O O
- NN O O
approval NN O O
use NN O O
of NN O O
TREANDA. NN O O
Because NN O O
these NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
: NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
and NN O O
injection NN O O
or NN O O
infusion NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
phlebitis NN O O
, NN O O
pruritus NN O O
, NN O O
irritation NN O O
, NN O O
pain NN O O
, NN O O
and NN O O
swelling NN O O
; NN O O
pneumocystis NN B-AdverseReaction B-AdverseReaction
jiroveci NN I-AdverseReaction I-AdverseReaction
pneumonia NN I-AdverseReaction I-AdverseReaction
and NN O O
pneumonitis NN B-AdverseReaction B-AdverseReaction
Skin NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
SJS NN B-AdverseReaction B-AdverseReaction
and NN O O
TEN NN B-AdverseReaction B-AdverseReaction
have NN O O
occurred NN O O
when NN O O
TREANDA NN O O
was NN O O
administered NN O O
concomitantly NN O O
with NN O O
allopurinol NN O O
and NN O O
other NN O O
medications NN O O
known NN O O
to NN O O
cause NN O O
these NN O O
syndromes NN O O
. NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Myelosuppression NN B-AdverseReaction B-AdverseReaction
Delay NN O O
or NN O O
reduce NN O O
dose NN O O
. NN O O
Restart NN O O
treatment NN O O
based NN O O
on NN O O
ANC NN O O
and NN O O
platelet NN O O
count NN O O
recovery NN O O
. NN O O
( NN O O
2.2 NN O O
) NN O O
Complications NN O O
of NN O O
myelosuppression NN B-AdverseReaction B-AdverseReaction
may NN B-Factor B-Factor
lead NN O O
to NN O O
death NN B-AdverseReaction B-AdverseReaction
( NN O O
5.1 NN O O
) NN O O
* NN O O
Infections NN B-AdverseReaction B-AdverseReaction
Monitor NN O O
for NN O O
fever NN O O
and NN O O
other NN O O
signs NN O O
of NN O O
infection NN O O
and NN O O
treat NN O O
promptly NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Anaphylaxis NN B-AdverseReaction B-AdverseReaction
and NN O O
Infusion NN B-AdverseReaction B-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
Severe NN O O
and NN O O
anaphylactic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
have NN O O
occurred NN O O
; NN O O
monitor NN O O
clinically NN O O
and NN O O
discontinue NN O O
TREANDA. NN O O
Pre NN O O
- NN O O
medicate NN O O
in NN O O
subsequent NN O O
cycles NN O O
for NN O O
milder NN O O
reactions NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Tumor NN B-AdverseReaction B-AdverseReaction
Lysis NN I-AdverseReaction I-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
Acute NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
and NN O O
death NN B-AdverseReaction B-AdverseReaction
anticipate NN O O
and NN O O
use NN O O
supportive NN O O
measures NN O O
. NN O O
( NN O O
5.4 NN O O
) NN O O
* NN O O
Skin NN B-AdverseReaction B-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
Discontinue NN O O
for NN O O
severe NN O O
skin NN O O
reactions NN O O
. NN O O
Cases NN O O
of NN O O
SJS NN B-AdverseReaction B-AdverseReaction
and NN O O
TEN NN B-AdverseReaction B-AdverseReaction
some NN O O
fatal NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
when NN O O
TREANDA NN O O
was NN O O
administered NN O O
concomitantly NN O O
with NN O O
allopurinol NN O O
and NN O O
other NN O O
medications NN O O
known NN O O
to NN O O
cause NN O O
these NN O O
syndromes NN O O
. NN O O
( NN O O
5.5 NN O O
) NN O O
* NN O O
Other NN O O
Malignancies NN B-AdverseReaction B-AdverseReaction
Pre NN O O
- NN O O
malignant NN O O
and NN O O
malignant NN B-AdverseReaction B-AdverseReaction
diseases NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
. NN O O
( NN O O
5.6 NN O O
) NN O O
* NN O O
Extravasation NN B-AdverseReaction B-AdverseReaction
Assure NN O O
good NN O O
venous NN O O
access NN O O
and NN O O
monitor NN O O
infusion NN O O
site NN O O
during NN O O
and NN O O
after NN O O
administration NN O O
. NN O O
( NN O O
5.7 NN O O
) NN O O
* NN O O
Embryo NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
fetal NN I-AdverseReaction I-AdverseReaction
toxicity NN I-AdverseReaction I-AdverseReaction
Fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
when NN O O
administered NN O O
to NN O O
a NN O O
pregnant NN O O
woman NN O O
. NN O O
Women NN O O
should NN O O
be NN O O
advised NN O O
to NN O O
avoid NN O O
becoming NN O O
pregnant NN O O
when NN O O
receiving NN O O
TREANDA. NN O O
( NN O O
5.8 NN O O
, NN O O
8.1 NN O O
) NN O O
5.1 NN O O
Myelosuppression NN O O
TREANDA NN O O
caused NN O O
severe NN B-Severity B-Severity
myelosuppression NN B-AdverseReaction B-AdverseReaction
( NN O O
Grade NN O O
3 NN O O
- NN O O
4 NN O O
) NN O O
in NN O O
98 NN O O
% NN O O
of NN O O
patients NN O O
in NN O O
the NN O O
two NN O O
NHL NN O O
studies NN O O
( NN O O
see NN O O
Table NN O O
4 NN O O
) NN O O
. NN O O
Three NN O O
patients NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
died NN B-AdverseReaction B-AdverseReaction
from NN O O
myelosuppression NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
one NN O O
each NN O O
from NN O O
neutropenic NN B-AdverseReaction B-AdverseReaction
sepsis NN I-AdverseReaction I-AdverseReaction
diffuse NN B-AdverseReaction B-AdverseReaction
alveolar NN I-AdverseReaction I-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
with NN O O
Grade NN B-Severity B-Severity
3 NN O O
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
and NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
from NN O O
an NN O O
opportunistic NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
( NN O O
CMV NN O O
) NN O O
. NN O O
In NN O O
the NN O O
event NN O O
of NN O O
treatment NN O O
- NN O O
related NN O O
myelosuppression NN O O
, NN O O
monitor NN O O
leukocytes NN O O
, NN O O
platelets NN O O
, NN O O
hemoglobin NN O O
( NN O O
Hgb NN O O
) NN O O
, NN O O
and NN O O
neutrophils NN O O
frequently NN O O
. NN O O
In NN O O
the NN O O
clinical NN O O
trials NN O O
, NN O O
blood NN O O
counts NN O O
were NN O O
monitored NN O O
every NN O O
week NN O O
initially NN O O
. NN O O
Hematologic NN O O
nadirs NN O O
were NN O O
observed NN O O
predominantly NN O O
in NN O O
the NN O O
third NN O O
week NN O O
of NN O O
therapy NN O O
. NN O O
Myelosuppression NN O O
may NN O O
require NN O O
dose NN O O
delays NN O O
and/or NN O O
subsequent NN O O
dose NN O O
reductions NN O O
if NN O O
recovery NN O O
to NN O O
the NN O O
recommended NN O O
values NN O O
has NN O O
not NN O O
occurred NN O O
by NN O O
the NN O O
first NN O O
day NN O O
of NN O O
the NN O O
next NN O O
scheduled NN O O
cycle NN O O
. NN O O
Prior NN O O
to NN O O
the NN O O
initiation NN O O
of NN O O
the NN O O
next NN O O
cycle NN O O
of NN O O
therapy NN O O
, NN O O
the NN O O
ANC NN O O
should NN O O
be NN O O
>= NN O O
1 NN O O
x NN O O
10 NN O O
9 NN O O
/L NN O O
and NN O O
the NN O O
platelet NN O O
count NN O O
should NN O O
be NN O O
>= NN O O
75 NN O O
x NN O O
10 NN O O
9 NN O O
/L. NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
and NN O O
( NN O O
2.3 NN O O
) NN O O
] NN O O
5.2 NN O O
Infections NN O O
Infection NN B-AdverseReaction B-AdverseReaction
including NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
sepsis NN B-AdverseReaction B-AdverseReaction
septic NN B-AdverseReaction B-AdverseReaction
shock NN I-AdverseReaction I-AdverseReaction
and NN O O
death NN B-AdverseReaction B-AdverseReaction
have NN O O
occurred NN O O
in NN O O
adult NN O O
and NN O O
pediatric NN O O
patients NN O O
in NN O O
clinical NN O O
trials NN O O
and NN O O
in NN O O
postmarketing NN O O
reports NN O O
. NN O O
Patients NN O O
with NN O O
myelosuppression NN B-AdverseReaction B-AdverseReaction
following NN O O
treatment NN O O
with NN O O
TREANDA NN O O
are NN O O
more NN O O
susceptible NN B-Factor B-Factor
to NN O O
infections NN B-AdverseReaction B-AdverseReaction
Advise NN O O
patients NN O O
with NN O O
myelosuppression NN O O
following NN O O
TREANDA NN O O
treatment NN O O
to NN O O
contact NN O O
a NN O O
physician NN O O
if NN O O
they NN O O
have NN O O
symptoms NN O O
or NN O O
signs NN O O
of NN O O
infection NN O O
. NN O O
5.3 NN O O
Anaphylaxis NN O O
and NN O O
Infusion NN O O
Reactions NN O O
Infusion NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
to NN O O
TREANDA NN O O
have NN O O
occurred NN O O
commonly NN O O
in NN O O
clinical NN O O
trials NN O O
. NN O O
Symptoms NN O O
include NN O O
fever NN B-AdverseReaction B-AdverseReaction
chills NN B-AdverseReaction B-AdverseReaction
pruritus NN B-AdverseReaction B-AdverseReaction
and NN O O
rash NN B-AdverseReaction B-AdverseReaction
In NN O O
rare NN O O
instances NN O O
severe NN B-Severity B-Severity
anaphylactic NN O O
and NN O O
anaphylactoid NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
have NN O O
occurred NN O O
, NN O O
particularly NN O O
in NN O O
the NN O O
second NN O O
and NN O O
subsequent NN O O
cycles NN O O
of NN O O
therapy NN O O
. NN O O
Monitor NN O O
clinically NN O O
and NN O O
discontinue NN O O
drug NN O O
for NN O O
severe NN O O
reactions NN O O
. NN O O
Ask NN O O
patients NN O O
about NN O O
symptoms NN O O
suggestive NN O O
of NN O O
infusion NN O O
reactions NN O O
after NN O O
their NN O O
first NN O O
cycle NN O O
of NN O O
therapy NN O O
. NN O O
Patients NN O O
who NN O O
experience NN O O
Grade NN O O
3 NN O O
or NN O O
worse NN O O
allergic NN O O
- NN O O
type NN O O
reactions NN O O
should NN O O
not NN O O
be NN O O
rechallenged NN O O
. NN O O
Consider NN O O
measures NN O O
to NN O O
prevent NN O O
severe NN O O
reactions NN O O
, NN O O
including NN O O
antihistamines NN O O
, NN O O
antipyretics NN O O
and NN O O
corticosteroids NN O O
in NN O O
subsequent NN O O
cycles NN O O
in NN O O
patients NN O O
who NN O O
have NN O O
experienced NN O O
Grade NN O O
1 NN O O
or NN O O
2 NN O O
infusion NN O O
reactions NN O O
. NN O O
Discontinue NN O O
TREANDA NN O O
for NN O O
patients NN O O
with NN O O
Grade NN O O
4 NN O O
infusion NN O O
reactions NN O O
. NN O O
Consider NN O O
discontinuation NN O O
for NN O O
Grade NN O O
3 NN O O
infusions NN O O
reactions NN O O
as NN O O
clinically NN O O
appropriate NN O O
considering NN O O
individual NN O O
benefits NN O O
, NN O O
risks NN O O
, NN O O
and NN O O
supportive NN O O
care NN O O
. NN O O
5.4 NN O O
Tumor NN O O
Lysis NN O O
Syndrome NN O O
Tumor NN B-AdverseReaction B-AdverseReaction
lysis NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
associated NN O O
with NN O O
TREANDA NN O O
treatment NN O O
has NN O O
occurred NN O O
in NN O O
patients NN O O
in NN O O
clinical NN O O
trials NN O O
and NN O O
in NN O O
postmarketing NN O O
reports NN O O
. NN O O
The NN O O
onset NN O O
tends NN O O
to NN O O
be NN O O
within NN O O
the NN O O
first NN O O
treatment NN O O
cycle NN O O
of NN O O
TREANDA NN O O
and NN O O
, NN O O
without NN O O
intervention NN O O
, NN O O
may NN B-Factor B-Factor
lead NN O O
to NN O O
acute NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
and NN O O
death NN B-AdverseReaction B-AdverseReaction
Preventive NN O O
measures NN O O
include NN O O
vigorous NN O O
hydration NN O O
and NN O O
close NN O O
monitoring NN O O
of NN O O
blood NN O O
chemistry NN O O
, NN O O
particularly NN O O
potassium NN O O
and NN O O
uric NN O O
acid NN O O
levels NN O O
. NN O O
Allopurinol NN O O
has NN O O
also NN O O
been NN O O
used NN O O
during NN O O
the NN O O
beginning NN O O
of NN O O
TREANDA NN O O
therapy NN O O
. NN O O
However NN O O
, NN O O
there NN O O
may NN O O
be NN O O
an NN O O
increased NN O O
risk NN B-Factor B-Factor
of NN O O
severe NN B-Severity B-Severity
skin NN B-AdverseReaction B-AdverseReaction
toxicity NN I-AdverseReaction I-AdverseReaction
when NN O O
TREANDA NN O O
and NN O O
allopurinol NN O O
are NN O O
administered NN O O
concomitantly NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
. NN O O
5.5 NN O O
Skin NN O O
Reactions NN O O
Skin NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
with NN O O
TREANDA NN O O
treatment NN O O
in NN O O
clinical NN O O
trials NN O O
and NN O O
postmarketing NN O O
safety NN O O
reports NN O O
, NN O O
including NN O O
rash NN B-AdverseReaction B-AdverseReaction
toxic NN B-AdverseReaction B-AdverseReaction
skin NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
and NN O O
bullous NN B-AdverseReaction B-AdverseReaction
exanthema NN I-AdverseReaction I-AdverseReaction
Some NN O O
events NN O O
occurred NN O O
when NN O O
TREANDA NN O O
was NN O O
given NN O O
in NN O O
combination NN O O
with NN O O
other NN O O
anticancer NN O O
agents NN O O
. NN O O
In NN O O
a NN O O
study NN O O
of NN O O
TREANDA NN O O
( NN O O
90 NN O O
mg/m NN O O
2 NN O O
) NN O O
in NN O O
combination NN O O
with NN O O
rituximab NN O O
, NN O O
one NN O O
case NN O O
of NN O O
toxic NN B-AdverseReaction B-AdverseReaction
epidermal NN I-AdverseReaction I-AdverseReaction
necrolysis NN I-AdverseReaction I-AdverseReaction
( NN O O
TEN NN O O
) NN O O
occurred NN O O
. NN O O
TEN NN O O
has NN O O
been NN O O
reported NN O O
for NN O O
rituximab NN O O
( NN O O
see NN O O
rituximab NN O O
package NN O O
insert NN O O
) NN O O
. NN O O
Cases NN O O
of NN O O
Stevens NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Johnson NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
SJS NN O O
) NN O O
and NN O O
TEN NN B-AdverseReaction B-AdverseReaction
some NN O O
fatal NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
when NN O O
TREANDA NN O O
was NN O O
administered NN O O
concomitantly NN O O
with NN O O
allopurinol NN O O
and NN O O
other NN O O
medications NN O O
known NN O O
to NN O O
cause NN O O
these NN O O
syndromes NN O O
. NN O O
The NN O O
relationship NN O O
to NN O O
TREANDA NN O O
can NN O O
not NN O O
be NN O O
determined NN O O
. NN O O
Where NN O O
skin NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
occur NN O O
, NN O O
they NN O O
may NN O O
be NN O O
progressive NN O O
and NN O O
increase NN O O
in NN O O
severity NN O O
with NN O O
further NN O O
treatment NN O O
. NN O O
Monitor NN O O
patients NN O O
with NN O O
skin NN O O
reactions NN O O
closely NN O O
. NN O O
If NN O O
skin NN O O
reactions NN O O
are NN O O
severe NN O O
or NN O O
progressive NN O O
, NN O O
withhold NN O O
or NN O O
discontinue NN O O
TREANDA. NN O O
5.6 NN O O
Other NN O O
Malignancies NN O O
There NN O O
are NN O O
reports NN O O
of NN O O
pre NN O O
- NN O O
malignant NN O O
and NN O O
malignant NN B-AdverseReaction B-AdverseReaction
diseases NN I-AdverseReaction I-AdverseReaction
that NN O O
have NN O O
developed NN O O
in NN O O
patients NN O O
who NN O O
have NN O O
been NN O O
treated NN O O
with NN O O
TREANDA NN O O
, NN O O
including NN O O
myelodysplastic NN B-AdverseReaction B-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
myeloproliferative NN B-AdverseReaction B-AdverseReaction
disorders NN I-AdverseReaction I-AdverseReaction
acute NN B-AdverseReaction B-AdverseReaction
myeloid NN I-AdverseReaction I-AdverseReaction
leukemia NN I-AdverseReaction I-AdverseReaction
and NN O O
bronchial NN B-AdverseReaction B-AdverseReaction
carcinoma NN I-AdverseReaction I-AdverseReaction
The NN O O
association NN O O
with NN O O
TREANDA NN O O
therapy NN O O
has NN O O
not NN O O
been NN O O
determined NN O O
. NN O O
5.7 NN O O
Extravasation NN O O
Injury NN O O
TREANDA NN O O
extravasations NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
post NN O O
marketing NN O O
resulting NN O O
in NN O O
hospitalizations NN O O
from NN O O
erythema NN B-AdverseReaction B-AdverseReaction
marked NN B-Severity B-Severity
swelling NN B-AdverseReaction B-AdverseReaction
and NN O O
pain NN B-AdverseReaction B-AdverseReaction
Assure NN O O
good NN O O
venous NN O O
access NN O O
prior NN O O
to NN O O
starting NN O O
TREANDA NN O O
infusion NN O O
and NN O O
monitor NN O O
the NN O O
intravenous NN O O
infusion NN O O
site NN O O
for NN O O
redness NN O O
, NN O O
swelling NN O O
, NN O O
pain NN O O
, NN O O
infection NN O O
, NN O O
and NN O O
necrosis NN O O
during NN O O
and NN O O
after NN O O
administration NN O O
of NN O O
TREANDA. NN O O
5.8 NN O O
Embryo NN O O
- NN O O
fetal NN O O
Toxicity NN O O
TREANDA NN O O
can NN B-Factor B-Factor
cause NN O O
fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
when NN O O
administered NN O O
to NN O O
a NN O O
pregnant NN O O
woman NN O O
. NN O O
Single NN O O
intraperitoneal NN O O
doses NN O O
of NN O O
bendamustine NN O O
in NN O O
mice NN B-Animal B-Animal
and NN O O
rats NN B-Animal B-Animal
administered NN O O
during NN O O
organogenesis NN O O
caused NN O O
an NN O O
increase NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
resorptions NN I-AdverseReaction I-AdverseReaction
skeletal NN O O
and NN O O
visceral NN B-AdverseReaction B-AdverseReaction
malformations NN I-AdverseReaction I-AdverseReaction
and NN O O
decreased NN B-AdverseReaction B-AdverseReaction
fetal NN I-AdverseReaction I-AdverseReaction
body NN I-AdverseReaction I-AdverseReaction
weights NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.1 NN O O
) NN O O
] NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
are NN O O
discussed NN O O
in NN O O
more NN O O
detail NN O O
in NN O O
other NN O O
sections NN O O
of NN O O
the NN O O
labeling NN O O
: NN O O
* NN O O
Use NN O O
in NN O O
Elderly NN O O
Patients NN O O
with NN O O
Dementia NN O O
- NN O O
Related NN O O
Psychosis NN O O
[ NN O O
seeBoxed NN O O
Warningand NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1and5.2 NN O O
) NN O O
] NN O O
* NN O O
Neuroleptic NN B-AdverseReaction B-AdverseReaction
Malignant NN I-AdverseReaction I-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
* NN O O
Tardive NN B-AdverseReaction B-AdverseReaction
Dyskinesia NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
* NN O O
Metabolic NN B-AdverseReaction B-AdverseReaction
Changes NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
* NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Contraindications NN O O
, NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.6 NN O O
) NN O O
and NN O O
Patient NN O O
Counseling NN O O
Information NN O O
( NN O O
17 NN O O
) NN O O
] NN O O
* NN O O
Application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
oral NN O O
ulcers NN O O
, NN O O
blisters NN O O
, NN O O
peeling/sloughing NN O O
and NN O O
inflammation NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.2 NN O O
) NN O O
] NN O O
* NN O O
Orthostatic NN B-AdverseReaction B-AdverseReaction
Hypotension NN I-AdverseReaction I-AdverseReaction
Syncope NN B-AdverseReaction B-AdverseReaction
and NN O O
other NN O O
Hemodynamic NN B-AdverseReaction B-AdverseReaction
Effects NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.7 NN O O
) NN O O
] NN O O
* NN O O
Leukopenia NN B-AdverseReaction B-AdverseReaction
Neutropenia NN B-AdverseReaction B-AdverseReaction
and NN O O
Agranulocytosis NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.8 NN O O
) NN O O
] NN O O
* NN O O
QT NN B-AdverseReaction B-AdverseReaction
Interval NN I-AdverseReaction I-AdverseReaction
Prolongation NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.9 NN O O
) NN O O
] NN O O
* NN O O
Hyperprolactinemia NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.10 NN O O
) NN O O
] NN O O
* NN O O
Seizures NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.11 NN O O
) NN O O
] NN O O
* NN O O
Potential NN B-Factor B-Factor
for NN O O
Cognitive NN O O
and NN O O
Motor NN B-AdverseReaction B-AdverseReaction
Impairment NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.12 NN O O
) NN O O
] NN O O
* NN O O
Body NN O O
Temperature NN O O
Regulation NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.13 NN O O
) NN O O
] NN O O
* NN O O
Suicide NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.14 NN O O
) NN O O
] NN O O
* NN O O
Dysphagia NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.15 NN O O
) NN O O
] NN O O
* NN O O
Use NN O O
in NN O O
Patients NN O O
with NN O O
Concomitant NN O O
Illness NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.16 NN O O
) NN O O
] NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=5 NN O O
% NN O O
and NN O O
at NN O O
least NN O O
twice NN O O
the NN O O
rate NN O O
of NN O O
placebo NN O O
) NN O O
reported NN O O
with NN O O
acute NN O O
treatment NN O O
in NN O O
adults NN O O
with NN O O
schizophrenia NN O O
were NN O O
akathisia NN B-AdverseReaction B-AdverseReaction
oral NN B-AdverseReaction B-AdverseReaction
hypoesthesia NN I-AdverseReaction I-AdverseReaction
and NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
The NN O O
safety NN O O
profile NN O O
of NN O O
SAPHRIS NN O O
in NN O O
the NN O O
maintenance NN O O
treatment NN O O
of NN O O
schizophrenia NN O O
in NN O O
adults NN O O
was NN O O
similar NN O O
to NN O O
that NN O O
seen NN O O
with NN O O
acute NN O O
treatment NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=5 NN O O
% NN O O
and NN O O
at NN O O
least NN O O
twice NN O O
the NN O O
rate NN O O
of NN O O
placebo NN O O
) NN O O
reported NN O O
with NN O O
acute NN O O
monotherapy NN O O
treatment NN O O
of NN O O
manic NN O O
or NN O O
mixed NN O O
episodes NN O O
associated NN O O
with NN O O
bipolar NN O O
I NN O O
disorder NN O O
in NN O O
adults NN O O
were NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
dizziness NN B-AdverseReaction B-AdverseReaction
extrapyramidal NN B-AdverseReaction B-AdverseReaction
symptoms NN I-AdverseReaction I-AdverseReaction
other NN B-Factor B-Factor
than NN I-Factor I-Factor
akathisia NN B-AdverseReaction B-AdverseReaction
and NN O O
increased NN B-AdverseReaction B-AdverseReaction
weight NN I-AdverseReaction I-AdverseReaction
and NN O O
during NN O O
the NN O O
adjunctive NN O O
therapy NN O O
trial NN O O
in NN O O
bipolar NN O O
I NN O O
disorder NN O O
in NN O O
adults NN O O
were NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
and NN O O
oral NN B-AdverseReaction B-AdverseReaction
hypoesthesia NN I-AdverseReaction I-AdverseReaction
The NN O O
adult NN O O
information NN O O
below NN O O
is NN O O
derived NN O O
from NN O O
a NN O O
clinical NN O O
trial NN O O
database NN O O
for NN O O
SAPHRIS NN O O
consisting NN O O
of NN O O
over NN O O
4565 NN O O
patients NN O O
and/or NN O O
healthy NN O O
subjects NN O O
exposed NN O O
to NN O O
one NN O O
or NN O O
more NN O O
sublingual NN O O
doses NN O O
of NN O O
SAPHRIS. NN O O
A NN O O
total NN O O
of NN O O
1314 NN O O
SAPHRIS NN O O
- NN O O
treated NN O O
patients NN O O
were NN O O
treated NN O O
for NN O O
at NN O O
least NN O O
24 NN O O
weeks NN O O
and NN O O
785 NN O O
SAPHRIS NN O O
- NN O O
treated NN O O
patients NN O O
had NN O O
at NN O O
least NN O O
52 NN O O
weeks NN O O
of NN O O
exposure NN O O
at NN O O
therapeutic NN O O
doses NN O O
. NN O O
In NN O O
a NN O O
3-week NN O O
monotherapy NN O O
trial NN O O
, NN O O
the NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=5 NN O O
% NN O O
and NN O O
at NN O O
least NN O O
twice NN O O
the NN O O
rate NN O O
of NN O O
placebo NN O O
) NN O O
reported NN O O
in NN O O
pediatric NN O O
patients NN O O
with NN O O
bipolar NN O O
I NN O O
disorder NN O O
treated NN O O
with NN O O
SAPHRIS NN O O
were NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
dizziness NN B-AdverseReaction B-AdverseReaction
dysgeusia NN B-AdverseReaction B-AdverseReaction
oral NN B-AdverseReaction B-AdverseReaction
paresthesia NN I-AdverseReaction I-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
and NN O O
increased NN B-AdverseReaction B-AdverseReaction
weight NN I-AdverseReaction I-AdverseReaction
No NN O O
new NN O O
major NN O O
safety NN O O
findings NN O O
were NN O O
reported NN O O
from NN O O
a NN O O
50-week NN O O
, NN O O
open NN O O
- NN O O
label NN O O
, NN O O
uncontrolled NN O O
safety NN O O
trial NN O O
. NN O O
A NN O O
total NN O O
of NN O O
651 NN O O
pediatric NN O O
patients NN O O
were NN O O
treated NN O O
with NN O O
SAPHRIS. NN O O
Of NN O O
these NN O O
patients NN O O
, NN O O
352 NN O O
pediatric NN O O
patients NN O O
were NN O O
treated NN O O
with NN O O
SAPHRIS NN O O
for NN O O
at NN O O
least NN O O
180 NN O O
days NN O O
and NN O O
58 NN O O
pediatric NN O O
patients NN O O
treated NN O O
with NN O O
SAPHRIS NN O O
had NN O O
at NN O O
least NN O O
1 NN O O
year NN O O
of NN O O
exposure NN O O
. NN O O
The NN O O
safety NN O O
of NN O O
SAPHRIS NN O O
was NN O O
evaluated NN O O
in NN O O
403 NN O O
pediatric NN O O
patients NN O O
with NN O O
bipolar NN O O
I NN O O
disorder NN O O
who NN O O
participated NN O O
in NN O O
a NN O O
3-week NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
trial NN O O
, NN O O
of NN O O
whom NN O O
302 NN O O
patients NN O O
received NN O O
SAPHRIS NN O O
at NN O O
fixed NN O O
doses NN O O
ranging NN O O
from NN O O
2.5 NN O O
mg NN O O
to NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
. NN O O
The NN O O
stated NN O O
frequencies NN O O
of NN O O
adverse NN O O
reactions NN O O
represent NN O O
the NN O O
proportion NN O O
of NN O O
individuals NN O O
who NN O O
experienced NN O O
a NN O O
treatment NN O O
- NN O O
emergent NN O O
adverse NN O O
event NN O O
of NN O O
the NN O O
type NN O O
listed NN O O
. NN O O
A NN O O
reaction NN O O
was NN O O
considered NN O O
treatment NN O O
emergent NN O O
if NN O O
it NN O O
occurred NN O O
for NN O O
the NN O O
first NN O O
time NN O O
or NN O O
worsened NN O O
while NN O O
receiving NN O O
therapy NN O O
following NN O O
baseline NN O O
evaluation NN O O
. NN O O
EXCERPT NN O O
: NN O O
Commonly NN O O
observed NN O O
adverse NN O O
reactions NN O O
( NN O O
incidence NN O O
>=5 NN O O
% NN O O
and NN O O
at NN O O
least NN O O
twice NN O O
that NN O O
for NN O O
placebo NN O O
) NN O O
were NN O O
( NN O O
6.1 NN O O
) NN O O
: NN O O
* NN O O
Schizophrenia NN O O
Adults NN O O
: NN O O
akathisia NN B-AdverseReaction B-AdverseReaction
oral NN B-AdverseReaction B-AdverseReaction
hypoesthesia NN I-AdverseReaction I-AdverseReaction
somnolence NN B-AdverseReaction B-AdverseReaction
* NN O O
Bipolar NN O O
Disorder NN O O
Adults NN O O
( NN O O
Monotherapy NN O O
) NN O O
: NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
dizziness NN B-AdverseReaction B-AdverseReaction
extrapyramidal NN B-AdverseReaction B-AdverseReaction
symptoms NN I-AdverseReaction I-AdverseReaction
other NN B-Factor B-Factor
than NN I-Factor I-Factor
akathisia NN B-AdverseReaction B-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
weight NN I-AdverseReaction I-AdverseReaction
* NN O O
Bipolar NN O O
Disorder NN O O
Pediatric NN O O
Patients NN O O
( NN O O
Monotherapy NN O O
) NN O O
: NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
dizziness NN B-AdverseReaction B-AdverseReaction
dysgeusia NN B-AdverseReaction B-AdverseReaction
oral NN B-AdverseReaction B-AdverseReaction
paresthesia NN I-AdverseReaction I-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
weight NN I-AdverseReaction I-AdverseReaction
* NN O O
Bipolar NN O O
Disorder NN O O
Adults NN O O
( NN O O
Adjunctive NN O O
) NN O O
: NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
oral NN B-AdverseReaction B-AdverseReaction
hypoesthesia NN I-AdverseReaction I-AdverseReaction
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Forest NN O O
Laboratories NN O O
, NN O O
LLC. NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
678 NN O O
- NN O O
1605 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
Adult NN O O
Patients NN O O
with NN O O
Schizophrenia NN O O
: NN O O
The NN O O
following NN O O
findings NN O O
are NN O O
based NN O O
on NN O O
the NN O O
short NN O O
- NN O O
term NN O O
placebo NN O O
- NN O O
controlled NN O O
pre NN O O
- NN O O
marketing NN O O
trials NN O O
for NN O O
schizophrenia NN O O
( NN O O
a NN O O
pool NN O O
of NN O O
three NN O O
6-week NN O O
fixed NN O O
- NN O O
dose NN O O
trials NN O O
and NN O O
one NN O O
6-week NN O O
flexible NN O O
- NN O O
dose NN O O
trial NN O O
) NN O O
in NN O O
which NN O O
sublingual NN O O
SAPHRIS NN O O
was NN O O
administered NN O O
in NN O O
doses NN O O
ranging NN O O
from NN O O
5 NN O O
to NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
. NN O O
Adverse NN O O
Reactions NN O O
Associated NN O O
with NN O O
Discontinuation NN O O
of NN O O
Treatment NN O O
: NN O O
A NN O O
total NN O O
of NN O O
9 NN O O
% NN O O
of NN O O
SAPHRIS NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
10 NN O O
% NN O O
of NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
discontinued NN O O
due NN O O
to NN O O
adverse NN O O
reactions NN O O
. NN O O
There NN O O
were NN O O
no NN O O
drug NN O O
- NN O O
related NN O O
adverse NN O O
reactions NN O O
associated NN O O
with NN O O
discontinuation NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
SAPHRIS NN O O
at NN O O
the NN O O
rate NN O O
of NN O O
at NN O O
least NN O O
1 NN O O
% NN O O
and NN O O
at NN O O
least NN O O
twice NN O O
the NN O O
placebo NN O O
rate NN O O
. NN O O
Adverse NN O O
Reactions NN O O
Occurring NN O O
at NN O O
an NN O O
Incidence NN O O
of NN O O
2 NN O O
% NN O O
or NN O O
More NN O O
in NN O O
SAPHRIS NN O O
- NN O O
Treated NN O O
Patients NN O O
with NN O O
Schizophrenia NN O O
: NN O O
Adverse NN O O
reactions NN O O
associated NN O O
with NN O O
the NN O O
use NN O O
of NN O O
SAPHRIS NN O O
( NN O O
incidence NN O O
of NN O O
2 NN O O
% NN O O
or NN O O
greater NN O O
, NN O O
rounded NN O O
to NN O O
the NN O O
nearest NN O O
percent NN O O
, NN O O
and NN O O
SAPHRIS NN O O
incidence NN O O
greater NN O O
than NN O O
placebo NN O O
) NN O O
that NN O O
occurred NN O O
during NN O O
acute NN O O
therapy NN O O
( NN O O
up NN O O
to NN O O
6-weeks NN O O
in NN O O
patients NN O O
with NN O O
schizophrenia NN O O
) NN O O
are NN O O
shown NN O O
in NN O O
Table NN O O
8 NN O O
. NN O O
Table NN O O
8 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Reported NN O O
in NN O O
2 NN O O
% NN O O
or NN O O
More NN O O
of NN O O
Adult NN O O
Patients NN O O
in NN O O
Any NN O O
SAPHRIS NN O O
Dose NN O O
Group NN O O
and NN O O
Which NN O O
Occurred NN O O
at NN O O
Greater NN O O
Incidence NN O O
Than NN O O
in NN O O
the NN O O
Placebo NN O O
Group NN O O
in NN O O
6-Week NN O O
Schizophrenia NN O O
Trials NN O O
* NN O O
Akathisia NN B-AdverseReaction B-AdverseReaction
includes NN O O
: NN O O
akathisia NN B-AdverseReaction B-AdverseReaction
and NN O O
hyperkinesia NN B-AdverseReaction B-AdverseReaction
Extrapyramidal NN B-AdverseReaction B-AdverseReaction
symptoms NN I-AdverseReaction I-AdverseReaction
included NN O O
dystonia NN B-AdverseReaction B-AdverseReaction
oculogyration NN B-AdverseReaction B-AdverseReaction
dyskinesia NN B-AdverseReaction B-AdverseReaction
tardive NN B-AdverseReaction B-AdverseReaction
dyskinesia NN I-AdverseReaction I-AdverseReaction
muscle NN B-AdverseReaction B-AdverseReaction
rigidity NN I-AdverseReaction I-AdverseReaction
parkinsonism NN B-AdverseReaction B-AdverseReaction
tremor NN B-AdverseReaction B-AdverseReaction
and NN O O
extrapyramidal NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
( NN O O
excluding NN O O
akathisia NN B-AdverseReaction B-AdverseReaction
? NN O O
Somnolence NN B-AdverseReaction B-AdverseReaction
includes NN O O
the NN O O
following NN O O
events NN O O
: NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
sedation NN B-AdverseReaction B-AdverseReaction
and NN O O
hypersomnia NN B-AdverseReaction B-AdverseReaction
S NN O O
Also NN O O
includes NN O O
the NN O O
Flexible NN O O
- NN O O
dose NN O O
trial NN O O
( NN O O
N=90 NN O O
) NN O O
. NN O O
System NN O O
Organ NN O O
Class/ NN O O
Preferred NN O O
Term NN O O
Placebo NN O O
N=378 NN O O
% NN O O
SAPHRIS NN O O
5 NN O O
mg NN O O
twice NN O O
daily NN O O
N=274 NN O O
% NN O O
SAPHRIS NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
N=208 NN O O
% NN O O
All NN O O
SAPHRIS NN O O
S NN O O
5 NN O O
mg NN O O
or NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
N=572 NN O O
% NN O O
Gastrointestinal NN O O
disorders NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
6 NN O O
7 NN O O
4 NN O O
5 NN O O
Dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
1 NN O O
3 NN O O
1 NN O O
2 NN O O
Oral NN B-AdverseReaction B-AdverseReaction
hypoesthesia NN I-AdverseReaction I-AdverseReaction
1 NN O O
6 NN O O
7 NN O O
5 NN O O
Salivary NN B-AdverseReaction B-AdverseReaction
hypersecretion NN I-AdverseReaction I-AdverseReaction
0 NN O O
< NN O O
1 NN O O
4 NN O O
2 NN O O
Stomach NN B-AdverseReaction B-AdverseReaction
discomfort NN I-AdverseReaction I-AdverseReaction
1 NN O O
< NN O O
1 NN O O
3 NN O O
2 NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
5 NN O O
4 NN O O
7 NN O O
5 NN O O
General NN O O
disorders NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
3 NN O O
4 NN O O
3 NN O O
3 NN O O
Irritability NN B-AdverseReaction B-AdverseReaction
< NN O O
1 NN O O
2 NN O O
1 NN O O
2 NN O O
Investigations NN O O
Increased NN B-AdverseReaction B-AdverseReaction
weight NN I-AdverseReaction I-AdverseReaction
< NN O O
1 NN O O
2 NN O O
2 NN O O
3 NN O O
Metabolism NN O O
disorders NN O O
Increased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
< NN O O
1 NN O O
3 NN O O
0 NN O O
2 NN O O
Nervous NN O O
system NN O O
disorders NN O O
Akathisia NN B-AdverseReaction B-AdverseReaction
3 NN O O
4 NN O O
11 NN O O
6 NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
4 NN O O
7 NN O O
3 NN O O
5 NN O O
Extrapyramidal NN B-AdverseReaction B-AdverseReaction
symptoms NN I-AdverseReaction I-AdverseReaction
( NN O O
excluding NN O O
akathisia NN B-AdverseReaction B-AdverseReaction
7 NN O O
9 NN O O
12 NN O O
10 NN O O
Somnolence NN B-AdverseReaction B-AdverseReaction
? NN O O
7 NN O O
15 NN O O
13 NN O O
13 NN O O
Psychiatric NN O O
disorders NN O O
Insomnia NN B-AdverseReaction B-AdverseReaction
13 NN O O
16 NN O O
15 NN O O
15 NN O O
Vascular NN O O
disorders NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
2 NN O O
2 NN O O
3 NN O O
2 NN O O
Dose NN O O
- NN O O
Related NN O O
Adverse NN O O
Reactions NN O O
: NN O O
In NN O O
the NN O O
short NN O O
term NN O O
schizophrenia NN O O
trials NN O O
the NN O O
incidence NN O O
of NN O O
akathisia NN B-AdverseReaction B-AdverseReaction
appeared NN O O
to NN O O
be NN O O
dose NN O O
- NN O O
related NN O O
( NN O O
seeTable NN O O
8 NN O O
) NN O O
. NN O O
Monotherapy NN O O
in NN O O
Adult NN O O
Patients NN O O
with NN O O
Bipolar NN O O
Mania NN O O
: NN O O
The NN O O
following NN O O
findings NN O O
are NN O O
based NN O O
on NN O O
the NN O O
short NN O O
- NN O O
term NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
for NN O O
bipolar NN O O
mania NN O O
( NN O O
a NN O O
pool NN O O
of NN O O
two NN O O
3-week NN O O
flexible NN O O
- NN O O
dose NN O O
trials NN O O
) NN O O
in NN O O
which NN O O
sublingual NN O O
SAPHRIS NN O O
was NN O O
administered NN O O
in NN O O
doses NN O O
of NN O O
5 NN O O
mg NN O O
or NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
. NN O O
Adverse NN O O
Reactions NN O O
Associated NN O O
with NN O O
Discontinuation NN O O
of NN O O
Treatment NN O O
: NN O O
Approximately NN O O
10 NN O O
% NN O O
( NN O O
38/379 NN O O
) NN O O
of NN O O
SAPHRIS NN O O
- NN O O
treated NN O O
patients NN O O
in NN O O
short NN O O
- NN O O
term NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
discontinued NN O O
treatment NN O O
due NN O O
to NN O O
an NN O O
adverse NN O O
reaction NN O O
, NN O O
compared NN O O
with NN O O
about NN O O
6 NN O O
% NN O O
( NN O O
12/203 NN O O
) NN O O
on NN O O
placebo NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
associated NN O O
with NN O O
discontinuation NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
SAPHRIS NN O O
( NN O O
rates NN O O
at NN O O
least NN O O
1 NN O O
% NN O O
and NN O O
at NN O O
least NN O O
twice NN O O
the NN O O
placebo NN O O
rate NN O O
) NN O O
were NN O O
anxiety NN B-AdverseReaction B-AdverseReaction
( NN O O
1.1 NN O O
% NN O O
) NN O O
and NN O O
oral NN B-AdverseReaction B-AdverseReaction
hypoesthesia NN I-AdverseReaction I-AdverseReaction
( NN O O
1.1 NN O O
% NN O O
) NN O O
compared NN O O
to NN O O
placebo NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
. NN O O
Adverse NN O O
Reactions NN O O
Occurring NN O O
at NN O O
an NN O O
Incidence NN O O
of NN O O
2 NN O O
% NN O O
or NN O O
More NN O O
Among NN O O
SAPHRIS NN O O
- NN O O
Treated NN O O
( NN O O
Monotherapy NN O O
) NN O O
patients NN O O
with NN O O
Bipolar NN O O
I NN O O
Disorder NN O O
: NN O O
Adverse NN O O
reactions NN O O
associated NN O O
with NN O O
the NN O O
use NN O O
of NN O O
SAPHRIS NN O O
( NN O O
incidence NN O O
of NN O O
2 NN O O
% NN O O
or NN O O
greater NN O O
, NN O O
rounded NN O O
to NN O O
the NN O O
nearest NN O O
percent NN O O
, NN O O
and NN O O
SAPHRIS NN O O
incidence NN O O
greater NN O O
than NN O O
placebo NN O O
) NN O O
that NN O O
occurred NN O O
during NN O O
acute NN O O
monotherapy NN O O
( NN O O
up NN O O
to NN O O
3-weeks NN O O
in NN O O
patients NN O O
with NN O O
bipolar NN O O
mania NN O O
) NN O O
are NN O O
shown NN O O
in NN O O
Table NN O O
9 NN O O
. NN O O
Table NN O O
9 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Reported NN O O
in NN O O
2 NN O O
% NN O O
or NN O O
More NN O O
of NN O O
Adult NN O O
Patients NN O O
in NN O O
Any NN O O
SAPHRIS NN O O
Dose NN O O
Group NN O O
and NN O O
Which NN O O
Occurred NN O O
at NN O O
Greater NN O O
Incidence NN O O
Than NN O O
in NN O O
the NN O O
Placebo NN O O
Group NN O O
in NN O O
3-Week NN O O
Bipolar NN O O
Mania NN O O
Trials NN O O
* NN O O
SAPHRIS NN O O
5 NN O O
mg NN O O
to NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
with NN O O
flexible NN O O
dosing NN O O
. NN O O
Extrapyramidal NN B-AdverseReaction B-AdverseReaction
symptoms NN I-AdverseReaction I-AdverseReaction
included NN O O
: NN O O
dystonia NN B-AdverseReaction B-AdverseReaction
blepharospasm NN B-AdverseReaction B-AdverseReaction
torticollis NN B-AdverseReaction B-AdverseReaction
dyskinesia NN B-AdverseReaction B-AdverseReaction
tardive NN B-AdverseReaction B-AdverseReaction
dyskinesia NN I-AdverseReaction I-AdverseReaction
muscle NN B-AdverseReaction B-AdverseReaction
rigidity NN I-AdverseReaction I-AdverseReaction
parkinsonism NN B-AdverseReaction B-AdverseReaction
gait NN B-AdverseReaction B-AdverseReaction
disturbance NN I-AdverseReaction I-AdverseReaction
masked NN B-AdverseReaction B-AdverseReaction
facies NN I-AdverseReaction I-AdverseReaction
and NN O O
tremor NN B-AdverseReaction B-AdverseReaction
( NN O O
excluding NN O O
akathisia NN B-AdverseReaction B-AdverseReaction
? NN O O
Somnolence NN B-AdverseReaction B-AdverseReaction
includes NN O O
the NN O O
following NN O O
events NN O O
: NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
sedation NN B-AdverseReaction B-AdverseReaction
and NN O O
hypersomnia NN B-AdverseReaction B-AdverseReaction
System NN O O
Organ NN O O
Class/Preferred NN O O
Term NN O O
Placebo NN O O
N=203 NN O O
% NN O O
SAPHRIS NN O O
5 NN O O
mg NN O O
or NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
* NN O O
N=379 NN O O
% NN O O
Gastrointestinal NN O O
disorders NN O O
Dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
1 NN O O
3 NN O O
Dyspepsia NN B-AdverseReaction B-AdverseReaction
2 NN O O
4 NN O O
Oral NN B-AdverseReaction B-AdverseReaction
hypoesthesia NN I-AdverseReaction I-AdverseReaction
< NN O O
1 NN O O
4 NN O O
Toothache NN B-AdverseReaction B-AdverseReaction
2 NN O O
3 NN O O
General NN O O
disorders NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
2 NN O O
4 NN O O
Investigations NN O O
Increased NN B-AdverseReaction B-AdverseReaction
weight NN I-AdverseReaction I-AdverseReaction
< NN O O
1 NN O O
5 NN O O
Metabolism NN O O
disorders NN O O
Increased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
1 NN O O
4 NN O O
Musculoskeletal NN O O
and NN O O
connective NN O O
tissue NN O O
disorders NN O O
Arthralgia NN B-AdverseReaction B-AdverseReaction
1 NN O O
3 NN O O
Pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
< NN O O
1 NN O O
2 NN O O
Nervous NN O O
system NN O O
disorders NN O O
Akathisia NN B-AdverseReaction B-AdverseReaction
2 NN O O
4 NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
3 NN O O
11 NN O O
Dysgeusia NN B-AdverseReaction B-AdverseReaction
< NN O O
1 NN O O
3 NN O O
Headache NN B-AdverseReaction B-AdverseReaction
11 NN O O
12 NN O O
Other NN O O
extrapyramidal NN B-AdverseReaction B-AdverseReaction
symptoms NN I-AdverseReaction I-AdverseReaction
( NN O O
excluding NN O O
akathisia NN B-AdverseReaction B-AdverseReaction
2 NN O O
7 NN O O
Somnolence NN B-AdverseReaction B-AdverseReaction
? NN O O
6 NN O O
24 NN O O
Psychiatric NN O O
disorders NN O O
Anxiety NN B-AdverseReaction B-AdverseReaction
2 NN O O
4 NN O O
Depression NN B-AdverseReaction B-AdverseReaction
1 NN O O
2 NN O O
Insomnia NN B-AdverseReaction B-AdverseReaction
5 NN O O
6 NN O O
Monotherapy NN O O
in NN O O
Pediatric NN O O
Patients NN O O
with NN O O
Bipolar NN O O
Mania NN O O
: NN O O
The NN O O
following NN O O
findings NN O O
are NN O O
based NN O O
on NN O O
a NN O O
3-week NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
trial NN O O
for NN O O
bipolar NN O O
mania NN O O
in NN O O
which NN O O
SAPHRIS NN O O
was NN O O
administered NN O O
at NN O O
doses NN O O
of NN O O
2.5 NN O O
mg NN O O
, NN O O
5 NN O O
mg NN O O
, NN O O
or NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
. NN O O
Adverse NN O O
Reactions NN O O
Leading NN O O
to NN O O
Discontinuation NN O O
of NN O O
Treatment NN O O
: NN O O
A NN O O
total NN O O
of NN O O
6.7 NN O O
% NN O O
( NN O O
7/104 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
SAPHRIS NN O O
2.5 NN O O
mg NN O O
twice NN O O
daily NN O O
, NN O O
5.1 NN O O
% NN O O
( NN O O
5/99 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
SAPHRIS NN O O
5 NN O O
mg NN O O
twice NN O O
daily NN O O
, NN O O
and NN O O
5.1 NN O O
% NN O O
( NN O O
5/99 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
SAPHRIS NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
discontinued NN O O
treatment NN O O
due NN O O
to NN O O
adverse NN O O
reactions NN O O
compared NN O O
to NN O O
4 NN O O
% NN O O
( NN O O
4/101 NN O O
) NN O O
on NN O O
placebo NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
that NN O O
led NN O O
to NN O O
discontinuation NN O O
in NN O O
pediatric NN O O
patients NN O O
treated NN O O
with NN O O
SAPHRIS NN O O
( NN O O
rates NN O O
at NN O O
least NN O O
2 NN O O
% NN O O
in NN O O
any NN O O
SAPHRIS NN O O
arm NN O O
and NN O O
at NN O O
least NN O O
twice NN O O
the NN O O
placebo NN O O
rate NN O O
) NN O O
were NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
( NN O O
3 NN O O
% NN O O
in NN O O
the NN O O
2.5mg NN O O
twice NN O O
daily NN O O
group NN O O
, NN O O
1 NN O O
% NN O O
in NN O O
the NN O O
5mg NN O O
twice NN O O
daily NN O O
group NN O O
, NN O O
and NN O O
2 NN O O
% NN O O
in NN O O
the NN O O
10mg NN O O
twice NN O O
daily NN O O
group NN O O
) NN O O
, NN O O
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
( NN O O
2 NN O O
% NN O O
in NN O O
the NN O O
10mg NN O O
twice NN O O
daily NN O O
group NN O O
) NN O O
, NN O O
and NN O O
nausea NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
in NN O O
the NN O O
10mg NN O O
twice NN O O
daily NN O O
group NN O O
) NN O O
No NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
dropped NN O O
out NN O O
for NN O O
these NN O O
events NN O O
. NN O O
Adverse NN O O
Reactions NN O O
Occurring NN O O
with NN O O
SAPHRIS NN O O
at NN O O
an NN O O
Incidence NN O O
of NN O O
2 NN O O
% NN O O
or NN O O
More NN O O
in NN O O
SAPHRIS NN O O
- NN O O
treated NN O O
Bipolar NN O O
Patients NN O O
: NN O O
Adverse NN O O
reactions NN O O
associated NN O O
with NN O O
the NN O O
use NN O O
of NN O O
SAPHRIS NN O O
( NN O O
incidence NN O O
of NN O O
>=2 NN O O
% NN O O
in NN O O
any NN O O
SAPHRIS NN O O
dose NN O O
group NN O O
and NN O O
greater NN O O
than NN O O
placebo NN O O
) NN O O
that NN O O
occurred NN O O
during NN O O
acute NN O O
therapy NN O O
are NN O O
shown NN O O
in NN O O
Table NN O O
10 NN O O
. NN O O
Table NN O O
10 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Reported NN O O
in NN O O
2 NN O O
% NN O O
or NN O O
More NN O O
of NN O O
Pediatric NN O O
Patients NN O O
( NN O O
Ages NN O O
10 NN O O
to NN O O
17 NN O O
Years NN O O
) NN O O
in NN O O
Any NN O O
SAPHRIS NN O O
Dose NN O O
Group NN O O
and NN O O
Which NN O O
Occurred NN O O
at NN O O
Greater NN O O
Incidence NN O O
Than NN O O
in NN O O
the NN O O
Placebo NN O O
Group NN O O
in NN O O
a NN O O
3-Week NN O O
Bipolar NN O O
Mania NN O O
Trial NN O O
1Includes NN O O
the NN O O
preferred NN O O
terms NN O O
tachycardia NN B-AdverseReaction B-AdverseReaction
and NN O O
heart NN B-AdverseReaction B-AdverseReaction
rate NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
2Includes NN O O
the NN O O
preferred NN O O
terms NN O O
oral NN B-AdverseReaction B-AdverseReaction
hypoesthesia NN I-AdverseReaction I-AdverseReaction
oral NN B-AdverseReaction B-AdverseReaction
paresthesia NN I-AdverseReaction I-AdverseReaction
and NN O O
oral NN B-AdverseReaction B-AdverseReaction
dysesthesia NN I-AdverseReaction I-AdverseReaction
3Includes NN O O
the NN O O
preferred NN O O
terms NN O O
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
upper NN I-AdverseReaction I-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
lower NN I-AdverseReaction I-AdverseReaction
and NN O O
abdominal NN B-AdverseReaction B-AdverseReaction
discomfort NN I-AdverseReaction I-AdverseReaction
4Includes NN O O
the NN O O
preferred NN O O
terms NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
and NN O O
lethargy NN B-AdverseReaction B-AdverseReaction
5Includes NN O O
the NN O O
preferred NN O O
terms NN O O
hyperinsulinemia NN B-AdverseReaction B-AdverseReaction
and NN O O
blood NN B-AdverseReaction B-AdverseReaction
insulin NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
6Includes NN O O
the NN O O
preferred NN O O
terms NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
sedation NN B-AdverseReaction B-AdverseReaction
and NN O O
hypersomnia NN B-AdverseReaction B-AdverseReaction
System NN O O
Organ NN O O
Class/ NN O O
AE NN O O
Preferred NN O O
Term NN O O
Placebo NN O O
N=101 NN O O
Placebo NN O O
SAPHRIS NN O O
2.5 NN O O
mg NN O O
twice NN O O
daily NN O O
N=104 NN O O
2.5mg NN O O
SAPHRIS NN O O
5 NN O O
mg NN O O
twice NN O O
daily NN O O
N=99 NN O O
5mg NN O O
SAPHRIS NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
N=99 NN O O
10mg NN O O
All NN O O
SAPHRIS NN O O
2.5 NN O O
, NN O O
5 NN O O
, NN O O
and NN O O
10 NN O O
mg NN O O
N=101 NN O O
% NN O O
N=104 NN O O
% NN O O
N=99 NN O O
% NN O O
N=99 NN O O
% NN O O
N=302 NN O O
% NN O O
Cardiac NN O O
Disorders NN O O
Tachycardia NN B-AdverseReaction B-AdverseReaction
1 NN O O
0 NN O O
3 NN O O
0 NN O O
1 NN O O
1 NN O O
Gastrointestinal NN O O
Disorders NN O O
Oral NN B-AdverseReaction B-AdverseReaction
paraesthesia NN I-AdverseReaction I-AdverseReaction
2 NN O O
4 NN O O
25 NN O O
25 NN O O
30 NN O O
27 NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
3 NN O O
6 NN O O
6 NN O O
6 NN O O
6 NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
3 NN O O
4 NN O O
4 NN O O
4 NN O O
4 NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
3 NN O O
7 NN O O
9 NN O O
3 NN O O
5 NN O O
6 NN O O
Glossodynia NN B-AdverseReaction B-AdverseReaction
0 NN O O
0 NN O O
2 NN O O
0 NN O O
1 NN O O
General NN O O
Disorders NN O O
and NN O O
Administrative NN O O
Site NN O O
Disorders NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
4 NN O O
5 NN O O
4 NN O O
8 NN O O
14 NN O O
9 NN O O
Irritability NN B-AdverseReaction B-AdverseReaction
1 NN O O
1 NN O O
1 NN O O
2 NN O O
1 NN O O
Injury NN O O
, NN O O
Poisoning NN O O
, NN O O
and NN O O
Procedural NN O O
Complications NN O O
Muscle NN B-AdverseReaction B-AdverseReaction
strain NN I-AdverseReaction I-AdverseReaction
0 NN O O
0 NN O O
0 NN O O
2 NN O O
1 NN O O
Investigations NN O O
Increased NN B-AdverseReaction B-AdverseReaction
weight NN I-AdverseReaction I-AdverseReaction
0 NN O O
6 NN O O
2 NN O O
2 NN O O
3 NN O O
Hyperinsulinemia NN B-AdverseReaction B-AdverseReaction
5 NN O O
0 NN O O
1 NN O O
3 NN O O
1 NN O O
2 NN O O
ALT NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
0 NN O O
0 NN O O
0 NN O O
2 NN O O
1 NN O O
AST NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
0 NN O O
0 NN O O
0 NN O O
2 NN O O
1 NN O O
Metabolism NN O O
and NN O O
Nutrition NN O O
Disorders NN O O
Increased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
2 NN O O
10 NN O O
9 NN O O
6 NN O O
8 NN O O
Dehydration NN B-AdverseReaction B-AdverseReaction
1 NN O O
0 NN O O
2 NN O O
0 NN O O
1 NN O O
Musculoskeletal NN O O
and NN O O
Connective NN O O
Tissue NN O O
Disorders NN O O
Myalgia NN B-AdverseReaction B-AdverseReaction
0 NN O O
0 NN O O
2 NN O O
1 NN O O
1 NN O O
Nervous NN O O
System NN O O
Disorders NN O O
Somnolence NN B-AdverseReaction B-AdverseReaction
6 NN O O
12 NN O O
46 NN O O
53 NN O O
49 NN O O
49 NN O O
Headache NN B-AdverseReaction B-AdverseReaction
6 NN O O
8 NN O O
11 NN O O
9 NN O O
9 NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
3 NN O O
6 NN O O
10 NN O O
5 NN O O
7 NN O O
Dysgeusia NN B-AdverseReaction B-AdverseReaction
2 NN O O
4 NN O O
5 NN O O
9 NN O O
6 NN O O
Akathisia NN B-AdverseReaction B-AdverseReaction
0 NN O O
2 NN O O
2 NN O O
1 NN O O
2 NN O O
Parkinsonism NN B-AdverseReaction B-AdverseReaction
0 NN O O
1 NN O O
0 NN O O
2 NN O O
1 NN O O
Psychiatric NN O O
Disorders NN O O
Insomnia NN B-AdverseReaction B-AdverseReaction
3 NN O O
3 NN O O
4 NN O O
3 NN O O
3 NN O O
Suicidal NN B-AdverseReaction B-AdverseReaction
ideation NN I-AdverseReaction I-AdverseReaction
1 NN O O
4 NN O O
1 NN O O
3 NN O O
3 NN O O
Anger NN B-AdverseReaction B-AdverseReaction
0 NN O O
0 NN O O
0 NN O O
2 NN O O
1 NN O O
Reproductive NN O O
System NN O O
and NN O O
Breast NN O O
Disorders NN O O
Dysmenorrhea NN B-AdverseReaction B-AdverseReaction
1 NN O O
0 NN O O
2 NN O O
0 NN O O
1 NN O O
Respiratory NN O O
, NN O O
Thoracic NN O O
, NN O O
and NN O O
Mediastinal NN O O
Disorders NN O O
Oropharyngeal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
2 NN O O
0 NN O O
3 NN O O
1 NN O O
1 NN O O
Nasal NN B-AdverseReaction B-AdverseReaction
congestion NN I-AdverseReaction I-AdverseReaction
1 NN O O
0 NN O O
2 NN O O
0 NN O O
1 NN O O
Dyspnea NN B-AdverseReaction B-AdverseReaction
0 NN O O
0 NN O O
2 NN O O
0 NN O O
1 NN O O
Skin NN O O
and NN O O
Subcutaneous NN O O
Tissue NN O O
Disorders NN O O
Rash NN B-AdverseReaction B-AdverseReaction
1 NN O O
0 NN O O
1 NN O O
2 NN O O
1 NN O O
Dose NN O O
- NN O O
Related NN O O
Adverse NN O O
Reactions NN O O
: NN O O
In NN O O
the NN O O
short NN O O
term NN O O
pediatric NN O O
bipolar NN O O
trials NN O O
the NN O O
incidence NN O O
of NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
appeared NN O O
to NN O O
be NN O O
dose NN O O
- NN O O
related NN O O
( NN O O
see NN O O
Table NN O O
10 NN O O
) NN O O
Adjunctive NN O O
Therapy NN O O
in NN O O
Adult NN O O
Patients NN O O
with NN O O
Bipolar NN O O
Mania NN O O
: NN O O
The NN O O
following NN O O
findings NN O O
are NN O O
based NN O O
on NN O O
a NN O O
12 NN O O
week NN O O
placebo NN O O
- NN O O
controlled NN O O
trial NN O O
( NN O O
with NN O O
a NN O O
3 NN O O
week NN O O
efficacy NN O O
endpoint NN O O
) NN O O
in NN O O
adult NN O O
patients NN O O
with NN O O
bipolar NN O O
mania NN O O
in NN O O
which NN O O
sublingual NN O O
SAPHRIS NN O O
was NN O O
administered NN O O
in NN O O
doses NN O O
of NN O O
5 NN O O
mg NN O O
or NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
as NN O O
adjunctive NN O O
therapy NN O O
with NN O O
lithium NN O O
or NN O O
valproate NN O O
. NN O O
Adverse NN O O
Reactions NN O O
Associated NN O O
with NN O O
Discontinuation NN O O
of NN O O
Treatment NN O O
: NN O O
Approximately NN O O
16 NN O O
% NN O O
( NN O O
25/158 NN O O
) NN O O
of NN O O
SAPHRIS NN O O
- NN O O
treated NN O O
patients NN O O
discontinued NN O O
treatment NN O O
due NN O O
to NN O O
an NN O O
adverse NN O O
reaction NN O O
, NN O O
compared NN O O
with NN O O
about NN O O
11 NN O O
% NN O O
( NN O O
18/166 NN O O
) NN O O
on NN O O
placebo NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
associated NN O O
with NN O O
discontinuation NN O O
in NN O O
subjects NN O O
treated NN O O
with NN O O
SAPHRIS NN O O
( NN O O
rates NN O O
at NN O O
least NN O O
1 NN O O
% NN O O
and NN O O
at NN O O
least NN O O
twice NN O O
the NN O O
placebo NN O O
rate NN O O
) NN O O
were NN O O
depression NN B-AdverseReaction B-AdverseReaction
( NN O O
2.5 NN O O
% NN O O
) NN O O
, NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
ideation NN I-AdverseReaction I-AdverseReaction
( NN O O
2.5 NN O O
% NN O O
) NN O O
, NN O O
bipolar NN B-AdverseReaction B-AdverseReaction
I NN I-AdverseReaction I-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
( NN O O
1.9 NN O O
% NN O O
) NN O O
, NN O O
insomnia NN B-AdverseReaction B-AdverseReaction
( NN O O
1.9 NN O O
% NN O O
) NN O O
and NN O O
depressive NN B-AdverseReaction B-AdverseReaction
symptoms NN I-AdverseReaction I-AdverseReaction
( NN O O
1.3 NN O O
% NN O O
) NN O O
. NN O O
Adverse NN O O
Reactions NN O O
Occurring NN O O
at NN O O
an NN O O
Incidence NN O O
of NN O O
2 NN O O
% NN O O
or NN O O
More NN O O
Among NN O O
SAPHRIS NN O O
- NN O O
Treated NN O O
( NN O O
Adjunctive NN O O
) NN O O
Bipolar NN O O
Patients NN O O
: NN O O
Adverse NN O O
reactions NN O O
associated NN O O
with NN O O
the NN O O
use NN O O
of NN O O
SAPHRIS NN O O
( NN O O
incidence NN O O
of NN O O
2 NN O O
% NN O O
or NN O O
greater NN O O
, NN O O
rounded NN O O
to NN O O
the NN O O
nearest NN O O
percent NN O O
, NN O O
and NN O O
SAPHRIS NN O O
incidence NN O O
greater NN O O
than NN O O
placebo NN O O
) NN O O
that NN O O
occurred NN O O
during NN O O
acute NN O O
adjunctive NN O O
therapy NN O O
at NN O O
3 NN O O
weeks NN O O
, NN O O
a NN O O
time NN O O
when NN O O
most NN O O
of NN O O
the NN O O
patients NN O O
were NN O O
still NN O O
participating NN O O
in NN O O
the NN O O
trial NN O O
, NN O O
are NN O O
shown NN O O
in NN O O
Table NN O O
11 NN O O
. NN O O
Table NN O O
11 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Reported NN O O
in NN O O
2 NN O O
% NN O O
or NN O O
More NN O O
of NN O O
Adult NN O O
Patients NN O O
In NN O O
Any NN O O
SAPHRIS NN O O
- NN O O
Dose NN O O
Group NN O O
and NN O O
Which NN O O
Occurred NN O O
at NN O O
Greater NN O O
Incidence NN O O
Than NN O O
in NN O O
the NN O O
Placebo NN O O
Group NN O O
at NN O O
3 NN O O
Weeks NN O O
in NN O O
Adjunctive NN O O
Bipolar NN O O
Mania NN O O
Trials NN O O
* NN O O
SAPHRIS NN O O
5 NN O O
mg NN O O
to NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
with NN O O
flexible NN O O
dosing NN O O
. NN O O
Extrapyramidal NN B-AdverseReaction B-AdverseReaction
symptoms NN I-AdverseReaction I-AdverseReaction
included NN O O
: NN O O
dystonia NN B-AdverseReaction B-AdverseReaction
parkinsonism NN B-AdverseReaction B-AdverseReaction
oculogyration NN B-AdverseReaction B-AdverseReaction
and NN O O
tremor NN B-AdverseReaction B-AdverseReaction
( NN O O
excluding NN O O
akathisia NN B-AdverseReaction B-AdverseReaction
? NN O O
Somnolence NN B-AdverseReaction B-AdverseReaction
includes NN O O
the NN O O
following NN O O
events NN O O
: NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
and NN O O
sedation NN B-AdverseReaction B-AdverseReaction
System NN O O
Organ NN O O
Class/Preferred NN O O
Term NN O O
Placebo NN O O
N=166 NN O O
% NN O O
SAPHRIS NN O O
5 NN O O
mg NN O O
or NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
* NN O O
N=158 NN O O
% NN O O
Gastrointestinal NN O O
disorders NN O O
Dyspepsia NN B-AdverseReaction B-AdverseReaction
2 NN O O
3 NN O O
Oral NN B-AdverseReaction B-AdverseReaction
hypoesthesia NN I-AdverseReaction I-AdverseReaction
0 NN O O
5 NN O O
General NN O O
disorders NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
2 NN O O
4 NN O O
Edema NN B-AdverseReaction B-AdverseReaction
peripheral NN I-AdverseReaction I-AdverseReaction
< NN O O
1 NN O O
3 NN O O
Investigations NN O O
Increased NN B-AdverseReaction B-AdverseReaction
weight NN I-AdverseReaction I-AdverseReaction
0 NN O O
3 NN O O
Nervous NN O O
system NN O O
disorders NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
2 NN O O
4 NN O O
Other NN O O
extrapyramidal NN B-AdverseReaction B-AdverseReaction
symptoms NN I-AdverseReaction I-AdverseReaction
( NN O O
excluding NN O O
akathisia NN B-AdverseReaction B-AdverseReaction
5 NN O O
6 NN O O
Somnolence NN B-AdverseReaction B-AdverseReaction
? NN O O
10 NN O O
22 NN O O
Psychiatric NN O O
disorders NN O O
Insomnia NN B-AdverseReaction B-AdverseReaction
8 NN O O
10 NN O O
Vascular NN O O
disorders NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
< NN O O
1 NN O O
3 NN O O
Dystonia NN O O
: NN O O
Symptoms NN O O
of NN O O
dystonia NN B-AdverseReaction B-AdverseReaction
prolonged NN B-AdverseReaction B-AdverseReaction
abnormal NN I-AdverseReaction I-AdverseReaction
contractions NN I-AdverseReaction I-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
muscle NN I-AdverseReaction I-AdverseReaction
groups NN I-AdverseReaction I-AdverseReaction
may NN B-Factor B-Factor
occur NN O O
in NN O O
susceptible NN O O
individuals NN O O
during NN O O
the NN O O
first NN O O
few NN O O
days NN O O
of NN O O
treatment NN O O
. NN O O
Dystonic NN B-AdverseReaction B-AdverseReaction
symptoms NN I-AdverseReaction I-AdverseReaction
include NN O O
: NN O O
spasm NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
neck NN I-AdverseReaction I-AdverseReaction
muscles NN I-AdverseReaction I-AdverseReaction
sometimes NN O O
progressing NN O O
to NN O O
tightness NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
throat NN I-AdverseReaction I-AdverseReaction
swallowing NN B-AdverseReaction B-AdverseReaction
difficulty NN I-AdverseReaction I-AdverseReaction
difficulty NN B-AdverseReaction B-AdverseReaction
breathing NN I-AdverseReaction I-AdverseReaction
and/or NN O O
protrusion NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
tongue NN I-AdverseReaction I-AdverseReaction
While NN O O
these NN O O
symptoms NN O O
can NN O O
occur NN O O
at NN O O
low NN O O
doses NN O O
, NN O O
they NN O O
occur NN O O
more NN O O
frequently NN O O
and NN O O
with NN O O
greater NN O O
severity NN O O
with NN O O
high NN O O
potency NN O O
and NN O O
at NN O O
higher NN O O
doses NN O O
of NN O O
first NN O O
generation NN O O
antipsychotic NN O O
drugs NN O O
. NN O O
An NN O O
elevated NN O O
risk NN B-Factor B-Factor
of NN O O
acute NN B-AdverseReaction B-AdverseReaction
dystonia NN I-AdverseReaction I-AdverseReaction
is NN O O
observed NN O O
in NN O O
males NN O O
and NN O O
younger NN O O
age NN O O
groups NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
, NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.4 NN O O
) NN O O
, NN O O
and NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.3 NN O O
) NN O O
] NN O O
. NN O O
Extrapyramidal NN O O
Symptoms NN O O
: NN O O
In NN O O
the NN O O
short NN O O
- NN O O
term NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
schizophrenia NN O O
and NN O O
bipolar NN O O
mania NN O O
adult NN O O
trials NN O O
, NN O O
data NN O O
was NN O O
objectively NN O O
collected NN O O
on NN O O
the NN O O
Simpson NN O O
Angus NN O O
Rating NN O O
Scale NN O O
for NN O O
extrapyramidal NN B-AdverseReaction B-AdverseReaction
symptoms NN I-AdverseReaction I-AdverseReaction
( NN O O
EPS NN O O
) NN O O
, NN O O
the NN O O
Barnes NN O O
Akathisia NN O O
Scale NN O O
( NN O O
for NN O O
akathisia NN B-AdverseReaction B-AdverseReaction
and NN O O
the NN O O
Assessments NN O O
of NN O O
Involuntary NN O O
Movement NN O O
Scales NN O O
( NN O O
for NN O O
dyskinesias NN B-AdverseReaction B-AdverseReaction
The NN O O
mean NN O O
change NN O O
from NN O O
baseline NN O O
for NN O O
the NN O O
all NN O O
- NN O O
SAPHRIS NN O O
5 NN O O
mg NN O O
or NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
treated NN O O
group NN O O
was NN O O
comparable NN O O
to NN O O
placebo NN O O
in NN O O
each NN O O
of NN O O
the NN O O
rating NN O O
scale NN O O
scores NN O O
. NN O O
In NN O O
the NN O O
short NN O O
- NN O O
term NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
schizophrenia NN O O
adult NN O O
trials NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
reported NN O O
EPS NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
excluding NN B-Negation B-Negation
events NN O O
related NN O O
to NN O O
akathisia NN B-AdverseReaction B-AdverseReaction
for NN O O
SAPHRIS NN O O
- NN O O
treated NN O O
patients NN O O
was NN O O
10 NN O O
% NN O O
versus NN O O
7 NN O O
% NN O O
for NN O O
placebo NN O O
; NN O O
and NN O O
the NN O O
incidence NN O O
of NN O O
akathisia NN B-AdverseReaction B-AdverseReaction
events NN O O
for NN O O
SAPHRIS NN O O
- NN O O
treated NN O O
patients NN O O
was NN O O
6 NN O O
% NN O O
versus NN O O
3 NN O O
% NN O O
for NN O O
placebo NN O O
. NN O O
In NN O O
short NN O O
- NN O O
term NN O O
placebo NN O O
- NN O O
controlled NN O O
bipolar NN O O
mania NN O O
adult NN O O
trials NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
EPS NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
excluding NN B-Negation B-Negation
events NN O O
related NN O O
to NN O O
akathisia NN B-AdverseReaction B-AdverseReaction
for NN O O
SAPHRIS NN O O
- NN O O
treated NN O O
patients NN O O
was NN O O
7 NN O O
% NN O O
versus NN O O
2 NN O O
% NN O O
for NN O O
placebo NN O O
; NN O O
and NN O O
the NN O O
incidence NN O O
of NN O O
akathisia NN B-AdverseReaction B-AdverseReaction
events NN O O
for NN O O
SAPHRIS NN O O
- NN O O
treated NN O O
patients NN O O
was NN O O
4 NN O O
% NN O O
versus NN O O
2 NN O O
% NN O O
for NN O O
placebo NN O O
. NN O O
In NN O O
a NN O O
3-week NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
pediatric NN O O
trial NN O O
with NN O O
bipolar NN O O
I NN O O
disorder NN O O
, NN O O
the NN O O
incidences NN O O
of NN O O
EPS NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
excluding NN B-Negation B-Negation
events NN O O
related NN O O
to NN O O
akathisia NN B-AdverseReaction B-AdverseReaction
were NN O O
4 NN O O
% NN O O
, NN O O
3 NN O O
% NN O O
, NN O O
and NN O O
5 NN O O
% NN O O
for NN O O
patients NN O O
treated NN O O
with NN O O
SAPHRIS NN O O
2.5 NN O O
mg NN O O
, NN O O
5 NN O O
mg NN O O
, NN O O
and NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
, NN O O
respectively NN O O
, NN O O
as NN O O
compared NN O O
to NN O O
3 NN O O
% NN O O
for NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
EPS NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
include NN O O
: NN O O
bradykinesia NN B-AdverseReaction B-AdverseReaction
dyskinesia NN B-AdverseReaction B-AdverseReaction
dystonia NN B-AdverseReaction B-AdverseReaction
oromandibular NN B-AdverseReaction B-AdverseReaction
dystonia NN I-AdverseReaction I-AdverseReaction
muscle NN B-AdverseReaction B-AdverseReaction
contractions NN I-AdverseReaction I-AdverseReaction
involuntary NN I-AdverseReaction I-AdverseReaction
muscle NN B-AdverseReaction B-AdverseReaction
twitching NN I-AdverseReaction I-AdverseReaction
musculoskeletal NN B-AdverseReaction B-AdverseReaction
stiffness NN I-AdverseReaction I-AdverseReaction
parkinsonism NN B-AdverseReaction B-AdverseReaction
protrusion NN B-AdverseReaction B-AdverseReaction
tongue NN I-AdverseReaction I-AdverseReaction
resting NN B-AdverseReaction B-AdverseReaction
tremor NN I-AdverseReaction I-AdverseReaction
and NN O O
tremor NN B-AdverseReaction B-AdverseReaction
For NN O O
events NN O O
of NN O O
akathisia NN B-AdverseReaction B-AdverseReaction
incidences NN O O
were NN O O
2 NN O O
% NN O O
, NN O O
2 NN O O
% NN O O
, NN O O
and NN O O
1 NN O O
% NN O O
for NN O O
patients NN O O
treated NN O O
with NN O O
SAPHRIS NN O O
2.5 NN O O
mg NN O O
, NN O O
5 NN O O
mg NN O O
, NN O O
and NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
, NN O O
respectively NN O O
, NN O O
as NN O O
compared NN O O
to NN O O
0 NN O O
% NN O O
for NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Other NN O O
Findings NN O O
: NN O O
Oral NN B-AdverseReaction B-AdverseReaction
hypoesthesia NN I-AdverseReaction I-AdverseReaction
and/or NN O O
oral NN B-AdverseReaction B-AdverseReaction
paresthesia NN I-AdverseReaction I-AdverseReaction
may NN O O
occur NN O O
directly NN O O
after NN O O
administration NN O O
of NN O O
SAPHRIS NN O O
and NN O O
usually NN O O
resolves NN O O
within NN O O
1 NN O O
hour NN O O
. NN O O
Laboratory NN O O
Test NN O O
Abnormalities NN O O
: NN O O
Transaminases NN O O
: NN O O
Transient NN O O
elevations NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
transaminases NN I-AdverseReaction I-AdverseReaction
( NN O O
primarily NN O O
ALT NN O O
) NN O O
in NN O O
the NN O O
short NN O O
- NN O O
term NN O O
schizophrenia NN O O
and NN O O
bipolar NN O O
mania NN O O
adult NN O O
trials NN O O
were NN O O
more NN O O
common NN O O
in NN O O
treated NN O O
patients NN O O
. NN O O
In NN O O
short NN O O
- NN O O
term NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
schizophrenia NN O O
adult NN O O
trials NN O O
, NN O O
the NN O O
mean NN O O
increase NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
transaminase NN I-AdverseReaction I-AdverseReaction
levels NN I-AdverseReaction I-AdverseReaction
for NN O O
SAPHRIS NN O O
- NN O O
treated NN O O
patients NN O O
was NN O O
1.6 NN O O
units/L NN O O
compared NN O O
to NN O O
a NN O O
decrease NN O O
of NN O O
0.4 NN O O
units/L NN O O
for NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
The NN O O
proportion NN O O
of NN O O
patients NN O O
with NN O O
transaminase NN B-AdverseReaction B-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
>=3 NN O O
times NN O O
ULN NN O O
( NN O O
at NN O O
Endpoint NN O O
) NN O O
was NN O O
0.9 NN O O
% NN O O
for NN O O
SAPHRIS NN O O
- NN O O
treated NN O O
patients NN O O
versus NN O O
1.3 NN O O
% NN O O
for NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
In NN O O
short NN O O
- NN O O
term NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
bipolar NN O O
adult NN O O
mania NN O O
trials NN O O
, NN O O
the NN O O
mean NN O O
increase NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
transaminase NN I-AdverseReaction I-AdverseReaction
levels NN I-AdverseReaction I-AdverseReaction
for NN O O
SAPHRIS NN O O
- NN O O
treated NN O O
patients NN O O
was NN O O
8.9 NN O O
units/L NN O O
compared NN O O
to NN O O
a NN O O
decrease NN O O
of NN O O
4.9 NN O O
units/L NN O O
in NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
The NN O O
proportion NN O O
of NN O O
patients NN O O
with NN O O
transaminase NN B-AdverseReaction B-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
>=3 NN O O
times NN O O
upper NN O O
limit NN O O
of NN O O
normal NN O O
( NN O O
ULN NN O O
) NN O O
( NN O O
at NN O O
Endpoint NN O O
) NN O O
was NN O O
2.5 NN O O
% NN O O
for NN O O
SAPHRIS NN O O
- NN O O
treated NN O O
patients NN O O
versus NN O O
0.6 NN O O
% NN O O
for NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
In NN O O
a NN O O
52-week NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
comparator NN O O
- NN O O
controlled NN O O
trial NN O O
that NN O O
included NN O O
primarily NN O O
adult NN O O
patients NN O O
with NN O O
schizophrenia NN O O
, NN O O
the NN O O
mean NN O O
increase NN O O
from NN O O
baseline NN O O
of NN O O
ALT NN O O
was NN O O
1.7 NN B-Severity B-Severity
units/L NN I-Severity I-Severity
In NN O O
a NN O O
3-week NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
pediatric NN O O
trial NN O O
with NN O O
bipolar NN O O
I NN O O
disorder NN O O
, NN O O
transient NN O O
elevations NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
transaminases NN I-AdverseReaction I-AdverseReaction
( NN O O
primarily NN O O
ALT NN O O
) NN O O
were NN O O
more NN O O
common NN O O
in NN O O
treated NN O O
patients NN O O
. NN O O
The NN O O
proportion NN O O
of NN O O
pediatric NN O O
patients NN O O
with NN O O
ALT NN B-AdverseReaction B-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
>=3 NN O O
times NN O O
upper NN O O
limit NN O O
of NN O O
normal NN O O
( NN O O
ULN NN O O
) NN O O
was NN O O
2.4 NN O O
% NN O O
for NN O O
patients NN O O
treated NN O O
with NN O O
SAPHRIS NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
versus NN O O
none NN O O
for NN O O
the NN O O
other NN O O
SAPHRIS NN O O
dose NN O O
groups NN O O
and NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Prolactin NN O O
: NN O O
In NN O O
short NN O O
- NN O O
term NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
adult NN O O
schizophrenia NN O O
trials NN O O
, NN O O
the NN O O
mean NN O O
decreases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
prolactin NN I-AdverseReaction I-AdverseReaction
levels NN I-AdverseReaction I-AdverseReaction
were NN O O
6.5 NN O O
ng/mL NN O O
for NN O O
SAPHRIS NN O O
- NN O O
treated NN O O
patients NN O O
compared NN O O
to NN O O
10.7 NN O O
ng/mL NN O O
for NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
The NN O O
proportion NN O O
of NN O O
patients NN O O
with NN O O
prolactin NN B-AdverseReaction B-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
>=4 NN O O
times NN O O
ULN NN O O
( NN O O
at NN O O
Endpoint NN O O
) NN O O
were NN O O
2.6 NN O O
% NN O O
for NN O O
SAPHRIS NN O O
- NN O O
treated NN O O
patients NN O O
versus NN O O
0.6 NN O O
% NN O O
for NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
In NN O O
short NN O O
- NN O O
term NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
bipolar NN O O
mania NN O O
adult NN O O
trials NN O O
, NN O O
the NN O O
mean NN O O
increase NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
prolactin NN I-AdverseReaction I-AdverseReaction
levels NN I-AdverseReaction I-AdverseReaction
was NN O O
4.9 NN O O
ng/mL NN O O
for NN O O
SAPHRIS NN O O
- NN O O
treated NN O O
patients NN O O
compared NN O O
to NN O O
a NN O O
decrease NN O O
of NN O O
0.2 NN O O
ng/mL NN O O
for NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
The NN O O
proportion NN O O
of NN O O
patients NN O O
with NN O O
prolactin NN B-AdverseReaction B-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
>=4 NN O O
times NN O O
ULN NN O O
( NN O O
at NN O O
Endpoint NN O O
) NN O O
were NN O O
2.3 NN O O
% NN O O
for NN O O
SAPHRIS NN O O
- NN O O
treated NN O O
patients NN O O
versus NN O O
0.7 NN O O
% NN O O
for NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
In NN O O
a NN O O
long NN O O
- NN O O
term NN O O
( NN O O
52-week NN O O
) NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
comparator NN O O
- NN O O
controlled NN O O
adult NN O O
trial NN O O
that NN O O
included NN O O
primarily NN O O
patients NN O O
with NN O O
schizophrenia NN O O
, NN O O
the NN O O
mean NN O O
decrease NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
prolactin NN I-AdverseReaction I-AdverseReaction
from NN O O
baseline NN O O
for NN O O
SAPHRIS NN O O
- NN O O
treated NN O O
patients NN O O
was NN O O
26.9 NN O O
ng/mL. NN O O
In NN O O
a NN O O
3-week NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
pediatric NN O O
trial NN O O
with NN O O
bipolar NN O O
I NN O O
disorder NN O O
, NN O O
the NN O O
mean NN O O
increases NN O O
( NN O O
at NN O O
Endpoint NN O O
) NN O O
in NN O O
prolactin NN O O
levels NN O O
were NN O O
3.2 NN O O
ng/mL NN O O
for NN O O
patients NN O O
treated NN O O
with NN O O
SAPHRIS NN O O
2.5 NN O O
mg NN O O
twice NN O O
daily NN O O
, NN O O
2.1 NN O O
ng/mL NN O O
for NN O O
patients NN O O
treated NN O O
with NN O O
SAPHRIS NN O O
5 NN O O
mg NN O O
twice NN O O
daily NN O O
, NN O O
and NN O O
6.4 NN O O
ng/mL NN O O
for NN O O
patients NN O O
treated NN O O
with NN O O
SAPHRIS NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
compared NN O O
to NN O O
an NN O O
increase NN O O
of NN O O
2.5 NN O O
ng/mL NN O O
for NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
There NN O O
were NN O O
no NN B-Negation B-Negation
reports NN O O
of NN O O
prolactin NN B-AdverseReaction B-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
>=4 NN O O
times NN O O
ULN NN O O
( NN O O
at NN O O
Endpoint NN O O
) NN O O
for NN O O
patients NN O O
treated NN O O
with NN O O
SAPHRIS NN O O
or NN O O
placebo NN O O
. NN O O
Galactorrhea NN B-AdverseReaction B-AdverseReaction
or NN O O
dysmenorrhea NN B-AdverseReaction B-AdverseReaction
were NN O O
reported NN O O
in NN O O
0 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
SAPHRIS NN O O
2.5 NN O O
mg NN O O
twice NN O O
daily NN O O
, NN O O
2 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
SAPHRIS NN O O
5 NN O O
mg NN O O
twice NN O O
daily NN O O
, NN O O
and NN O O
1 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
SAPHRIS NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
compared NN O O
to NN O O
1 NN O O
% NN O O
of NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
There NN O O
were NN O O
no NN B-Negation B-Negation
reports NN O O
of NN O O
gynecomastia NN B-AdverseReaction B-AdverseReaction
in NN O O
this NN O O
trial NN O O
. NN O O
Creatine NN O O
Kinase NN O O
( NN O O
CK NN O O
) NN O O
: NN O O
The NN O O
proportion NN O O
of NN O O
adult NN O O
patients NN O O
with NN O O
CK NN B-AdverseReaction B-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
>3 NN O O
times NN O O
ULN NN O O
at NN O O
any NN O O
time NN O O
were NN O O
6.4 NN O O
% NN O O
and NN O O
11.1 NN O O
% NN O O
for NN O O
patients NN O O
treated NN O O
with NN O O
SAPHRIS NN O O
5 NN O O
mg NN O O
twice NN O O
daily NN O O
and NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
, NN O O
respectively NN O O
, NN O O
as NN O O
compared NN O O
to NN O O
6.7 NN O O
% NN O O
for NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
in NN O O
short NN O O
- NN O O
term NN O O
, NN O O
fixed NN O O
- NN O O
dose NN O O
trials NN O O
in NN O O
schizophrenia NN O O
and NN O O
bipolar NN O O
mania NN O O
. NN O O
The NN O O
clinical NN O O
relevance NN O O
of NN O O
this NN O O
finding NN O O
is NN O O
unknown NN O O
. NN O O
The NN O O
proportion NN O O
of NN O O
patients NN O O
with NN O O
CK NN B-AdverseReaction B-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
>=3 NN O O
times NN O O
ULN NN O O
during NN O O
a NN O O
3-week NN O O
trial NN O O
in NN O O
pediatric NN O O
bipolar NN O O
I NN O O
disorder NN O O
at NN O O
any NN O O
time NN O O
were NN O O
1 NN O O
% NN O O
, NN O O
0 NN O O
% NN O O
, NN O O
and NN O O
1 NN O O
% NN O O
for NN O O
patients NN O O
treated NN O O
with NN O O
SAPHRIS NN O O
2.5 NN O O
mg NN O O
, NN O O
5 NN O O
mg NN O O
, NN O O
and NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
, NN O O
respectively NN O O
, NN O O
versus NN O O
3 NN O O
% NN O O
for NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Other NN O O
Adverse NN O O
Reactions NN O O
Observed NN O O
During NN O O
the NN O O
Premarketing NN O O
Evaluation NN O O
of NN O O
SAPHRIS NN O O
: NN O O
Following NN O O
is NN O O
a NN O O
list NN O O
of NN O O
MedDRA NN O O
terms NN O O
that NN O O
reflect NN O O
adverse NN O O
reactions NN O O
reported NN O O
by NN O O
patients NN O O
treated NN O O
with NN O O
sublingual NN O O
SAPHRIS NN O O
at NN O O
multiple NN O O
doses NN O O
of NN O O
>=5 NN O O
mg NN O O
twice NN O O
daily NN O O
during NN O O
any NN O O
phase NN O O
of NN O O
a NN O O
trial NN O O
within NN O O
the NN O O
database NN O O
of NN O O
adult NN O O
patients NN O O
. NN O O
The NN O O
reactions NN O O
listed NN O O
are NN O O
those NN O O
that NN O O
could NN O O
be NN O O
of NN O O
clinical NN O O
importance NN O O
, NN O O
as NN O O
well NN O O
as NN O O
reactions NN O O
that NN O O
are NN O O
plausibly NN O O
drug NN O O
- NN O O
related NN O O
on NN O O
pharmacologic NN O O
or NN O O
other NN O O
grounds NN O O
. NN O O
Reactions NN O O
already NN O O
listed NN O O
for NN O O
either NN O O
adults NN O O
or NN O O
pediatric NN O O
patients NN O O
in NN O O
other NN O O
parts NN O O
of NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
, NN O O
or NN O O
those NN O O
considered NN O O
in NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
, NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5 NN O O
) NN O O
or NN O O
Overdosage NN O O
( NN O O
10 NN O O
) NN O O
are NN O O
not NN O O
included NN O O
. NN O O
Reactions NN O O
are NN O O
further NN O O
categorized NN O O
by NN O O
MedDRA NN O O
system NN O O
organ NN O O
class NN O O
and NN O O
listed NN O O
in NN O O
order NN O O
of NN O O
decreasing NN O O
frequency NN O O
according NN O O
to NN O O
the NN O O
following NN O O
definitions NN O O
: NN O O
those NN O O
occurring NN O O
in NN O O
at NN O O
least NN O O
1/100 NN O O
patients NN O O
( NN O O
frequent NN O O
) NN O O
( NN O O
only NN O O
those NN O O
not NN O O
already NN O O
listed NN O O
in NN O O
the NN O O
tabulated NN O O
results NN O O
from NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
appear NN O O
in NN O O
this NN O O
listing NN O O
) NN O O
; NN O O
those NN O O
occurring NN O O
in NN O O
1/100 NN O O
to NN O O
1/1000 NN O O
patients NN O O
( NN O O
infrequent NN O O
) NN O O
; NN O O
and NN O O
those NN O O
occurring NN O O
in NN O O
fewer NN O O
than NN O O
1/1000 NN O O
patients NN O O
( NN O O
rare NN O O
) NN O O
. NN O O
* NN O O
Blood NN O O
and NN O O
lymphatic NN O O
disorders NN O O
: NN O O
infrequent NN O O
: NN O O
anemia NN B-AdverseReaction B-AdverseReaction
rare NN O O
: NN O O
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
* NN O O
Cardiac NN O O
disorders NN O O
: NN O O
infrequent NN O O
: NN O O
temporary NN B-AdverseReaction B-AdverseReaction
bundle NN I-AdverseReaction I-AdverseReaction
branch NN I-AdverseReaction I-AdverseReaction
block NN I-AdverseReaction I-AdverseReaction
* NN O O
Eye NN O O
disorders NN O O
: NN O O
infrequent NN O O
: NN O O
accommodation NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
* NN O O
Gastrointestinal NN O O
disorders NN O O
: NN O O
infrequent NN O O
: NN O O
swollen NN B-AdverseReaction B-AdverseReaction
tongue NN I-AdverseReaction I-AdverseReaction
* NN O O
General NN O O
disorders NN O O
: NN O O
rare NN O O
: NN O O
idiosyncratic NN B-AdverseReaction B-AdverseReaction
drug NN I-AdverseReaction I-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
* NN O O
Investigations NN O O
: NN O O
infrequent NN O O
: NN O O
hyponatremia NN B-AdverseReaction B-AdverseReaction
* NN O O
Nervous NN O O
system NN O O
disorders NN O O
: NN O O
infrequent NN O O
: NN O O
dysarthria NN B-AdverseReaction B-AdverseReaction
Following NN O O
is NN O O
a NN O O
list NN O O
of NN O O
MedDRA NN O O
terms NN O O
not NN O O
already NN O O
listed NN O O
either NN O O
for NN O O
adults NN O O
or NN O O
pediatric NN O O
patients NN O O
in NN O O
other NN O O
parts NN O O
of NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
, NN O O
or NN O O
those NN O O
considered NN O O
in NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
, NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5 NN O O
) NN O O
or NN O O
Overdosage NN O O
( NN O O
10 NN O O
) NN O O
that NN O O
reflect NN O O
adverse NN O O
reactions NN O O
reported NN O O
by NN O O
pediatric NN O O
patients NN O O
( NN O O
Ages NN O O
10 NN O O
to NN O O
17 NN O O
years NN O O
) NN O O
treated NN O O
with NN O O
sublingual NN O O
SAPHRIS NN O O
at NN O O
doses NN O O
of NN O O
2.5 NN O O
mg NN O O
, NN O O
5 NN O O
mg NN O O
, NN O O
or NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
during NN O O
any NN O O
phase NN O O
of NN O O
a NN O O
trial NN O O
within NN O O
the NN O O
database NN O O
of NN O O
pediatric NN O O
patients NN O O
. NN O O
* NN O O
Eye NN O O
disorders NN O O
: NN O O
infrequent NN O O
: NN O O
diplopia NN B-AdverseReaction B-AdverseReaction
vision NN B-AdverseReaction B-AdverseReaction
blurred NN I-AdverseReaction I-AdverseReaction
* NN O O
Gastrointestinal NN O O
disorders NN O O
: NN O O
infrequent NN O O
: NN O O
gastroesophageal NN B-AdverseReaction B-AdverseReaction
reflux NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
* NN O O
Injury NN O O
, NN O O
Poisoning NN O O
, NN O O
and NN O O
Procedural NN O O
Complications NN O O
: NN O O
infrequent NN O O
: NN O O
fall NN B-AdverseReaction B-AdverseReaction
* NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
: NN O O
infrequent NN O O
: NN O O
photosensitivity NN B-AdverseReaction B-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
* NN O O
Renal NN O O
and NN O O
urinary NN O O
disorders NN O O
: NN O O
infrequent NN O O
: NN O O
enuresis NN B-AdverseReaction B-AdverseReaction
6.2 NN O O
Postmarketing NN O O
Experience NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
identified NN O O
during NN O O
post NN O O
- NN O O
approval NN O O
use NN O O
of NN O O
SAPHRIS. NN O O
Because NN O O
these NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
In NN O O
many NN O O
cases NN O O
, NN O O
the NN O O
occurrence NN O O
of NN O O
these NN O O
adverse NN O O
reactions NN O O
led NN O O
to NN O O
discontinuation NN O O
of NN O O
therapy NN O O
. NN O O
* NN O O
Application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
primarily NN O O
in NN O O
the NN O O
sublingual NN O O
area NN O O
, NN O O
have NN O O
been NN O O
reported NN O O
. NN O O
These NN O O
application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
included NN O O
oral NN O O
ulcers NN O O
, NN O O
blisters NN O O
, NN O O
peeling/sloughing NN O O
, NN O O
and NN O O
inflammation NN O O
. NN O O
* NN O O
Choking NN B-AdverseReaction B-AdverseReaction
has NN O O
been NN O O
reported NN O O
by NN O O
patients NN O O
, NN O O
some NN O O
of NN O O
whom NN O O
may NN B-Factor B-Factor
have NN O O
also NN O O
experienced NN O O
oropharyngeal NN B-AdverseReaction B-AdverseReaction
muscular NN I-AdverseReaction I-AdverseReaction
dysfunction NN I-AdverseReaction I-AdverseReaction
or NN O O
hypoesthesia NN B-AdverseReaction B-AdverseReaction
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
INCREASED NN B-AdverseReaction B-AdverseReaction
MORTALITY NN I-AdverseReaction I-AdverseReaction
IN NN O O
ELDERLY NN O O
PATIENTS NN O O
WITH NN O O
DEMENTIA NN O O
- NN O O
RELATED NN O O
PSYCHOSIS NN O O
WARNING NN O O
: NN O O
INCREASED NN B-AdverseReaction B-AdverseReaction
MORTALITY NN I-AdverseReaction I-AdverseReaction
IN NN O O
ELDERLY NN O O
PATIENTS NN O O
WITH NN O O
DEMENTIA NN O O
- NN O O
RELATED NN O O
PSYCHOSIS NN O O
Elderly NN O O
patients NN O O
with NN O O
dementia NN O O
- NN O O
related NN O O
psychosis NN O O
treated NN O O
with NN O O
antipsychotic NN B-DrugClass B-DrugClass
drugs NN I-DrugClass I-DrugClass
are NN O O
at NN O O
an NN O O
increased NN O O
risk NN B-Factor B-Factor
of NN O O
death NN B-AdverseReaction B-AdverseReaction
SAPHRIS NN O O
( NN O O
r NN O O
) NN O O
( NN O O
asenapine NN O O
) NN O O
is NN O O
not NN O O
approved NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
patients NN O O
with NN O O
dementia NN O O
- NN O O
related NN O O
psychosis NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
, NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
WARNING NN O O
: NN O O
INCREASED NN B-AdverseReaction B-AdverseReaction
MORTALITY NN I-AdverseReaction I-AdverseReaction
IN NN O O
ELDERLY NN O O
PATIENTS NN O O
WITH NN O O
DEMENTIA NN O O
- NN O O
RELATED NN O O
PSYCHOSIS NN O O
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
. NN O O
Elderly NN O O
patients NN O O
with NN O O
dementia NN O O
- NN O O
related NN O O
psychosis NN O O
treated NN O O
with NN O O
antipsychotic NN B-DrugClass B-DrugClass
drugs NN I-DrugClass I-DrugClass
are NN O O
at NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
death NN B-AdverseReaction B-AdverseReaction
SAPHRIS NN O O
is NN O O
not NN O O
approved NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
patients NN O O
with NN O O
dementia NN O O
- NN O O
related NN O O
psychosis NN O O
. NN O O
( NN O O
5.1 NN O O
, NN O O
5.2 NN O O
) NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Cerebrovascular NN B-AdverseReaction B-AdverseReaction
Adverse NN I-AdverseReaction I-AdverseReaction
Events NN I-AdverseReaction I-AdverseReaction
An NN O O
increased NN O O
incidence NN O O
of NN O O
cerebrovascular NN B-AdverseReaction B-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
( NN O O
e.g. NN O O
, NN O O
stroke NN B-AdverseReaction B-AdverseReaction
transient NN B-AdverseReaction B-AdverseReaction
ischemic NN I-AdverseReaction I-AdverseReaction
attack NN I-AdverseReaction I-AdverseReaction
has NN O O
been NN O O
seen NN O O
in NN O O
elderly NN O O
patients NN O O
with NN O O
dementia NN O O
- NN O O
related NN O O
psychoses NN O O
treated NN O O
with NN O O
atypical NN B-DrugClass B-DrugClass
antipsychotic NN I-DrugClass I-DrugClass
drugs NN I-DrugClass I-DrugClass
( NN O O
5.2 NN O O
) NN O O
* NN O O
Neuroleptic NN B-AdverseReaction B-AdverseReaction
Malignant NN I-AdverseReaction I-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
Manage NN O O
with NN O O
immediate NN O O
discontinuation NN O O
and NN O O
close NN O O
monitoring NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Tardive NN B-AdverseReaction B-AdverseReaction
Dyskinesia NN I-AdverseReaction I-AdverseReaction
Discontinue NN O O
if NN O O
clinically NN O O
appropriate NN O O
. NN O O
( NN O O
5.4 NN O O
) NN O O
* NN O O
dispatch NN O O
: NN O O
unexpected NN O O
key NN O O
: NN O O
list NN O O
in NN O O
dispatch NN O O
table NN O O
: NN O O
{ NN O O
' NN O O
caption NN O O
' NN O O
: NN O O
< NN O O
function NN O O
print_caption NN O O
at NN O O
0x1c6c8c0 NN O O
> NN O O
, NN O O
' NN O O
text NN O O
' NN O O
: NN O O
< NN O O
function NN O O
print_text NN O O
at NN O O
0x1c6c500 NN O O
> NN O O
} NN O O
Metabolic NN B-AdverseReaction B-AdverseReaction
Changes NN I-AdverseReaction I-AdverseReaction
Atypical NN B-DrugClass B-DrugClass
antipsychotic NN I-DrugClass I-DrugClass
drugs NN I-DrugClass I-DrugClass
have NN O O
been NN O O
associated NN O O
with NN O O
metabolic NN B-AdverseReaction B-AdverseReaction
changes NN I-AdverseReaction I-AdverseReaction
that NN O O
may NN O O
increase NN O O
cardiovascular/cerebrovascular NN O O
risk NN O O
. NN O O
These NN O O
metabolic NN B-AdverseReaction B-AdverseReaction
changes NN I-AdverseReaction I-AdverseReaction
include NN O O
hyperglycemia NN B-AdverseReaction B-AdverseReaction
dyslipidemia NN B-AdverseReaction B-AdverseReaction
and NN O O
weight NN B-AdverseReaction B-AdverseReaction
gain NN I-AdverseReaction I-AdverseReaction
( NN O O
5.5 NN O O
) NN O O
* NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
and NN O O
angioedema NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
observed NN O O
. NN O O
( NN O O
5.6 NN O O
) NN O O
* NN O O
Orthostatic NN B-AdverseReaction B-AdverseReaction
Hypotension NN I-AdverseReaction I-AdverseReaction
Syncope NN B-AdverseReaction B-AdverseReaction
and NN O O
Other NN O O
Hemodynamic NN B-AdverseReaction B-AdverseReaction
Effects NN I-AdverseReaction I-AdverseReaction
Dizziness NN B-AdverseReaction B-AdverseReaction
tachycardia NN B-AdverseReaction B-AdverseReaction
or NN O O
bradycardia NN B-AdverseReaction B-AdverseReaction
and NN O O
syncope NN B-AdverseReaction B-AdverseReaction
may NN B-Factor B-Factor
occur NN O O
, NN O O
especially NN O O
early NN O O
in NN O O
treatment NN O O
. NN O O
Use NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
with NN O O
known NN O O
cardiovascular NN O O
or NN O O
cerebrovascular NN O O
disease NN O O
, NN O O
and NN O O
in NN O O
antipsychotic NN O O
- NN O O
naive NN O O
patients NN O O
. NN O O
( NN O O
5.7 NN O O
) NN O O
* NN O O
Leukopenia NN B-AdverseReaction B-AdverseReaction
Neutropenia NN B-AdverseReaction B-AdverseReaction
and NN O O
Agranulocytosis NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
with NN O O
antipsychotics NN B-DrugClass B-DrugClass
Patients NN O O
with NN O O
a NN O O
pre NN O O
- NN O O
existing NN O O
low NN O O
white NN O O
blood NN O O
cell NN O O
count NN O O
( NN O O
WBC NN O O
) NN O O
or NN O O
a NN O O
history NN O O
of NN O O
leukopenia/neutropenia NN O O
should NN O O
have NN O O
their NN O O
complete NN O O
blood NN O O
count NN O O
( NN O O
CBC NN O O
) NN O O
monitored NN O O
frequently NN O O
during NN O O
the NN O O
first NN O O
few NN O O
months NN O O
of NN O O
therapy NN O O
and NN O O
SAPHRIS NN O O
should NN O O
be NN O O
discontinued NN O O
at NN O O
the NN O O
first NN O O
sign NN O O
of NN O O
a NN O O
decline NN O O
in NN O O
WBC NN O O
in NN O O
the NN O O
absence NN O O
of NN O O
other NN O O
causative NN O O
factors NN O O
. NN O O
( NN O O
5.8 NN O O
) NN O O
* NN O O
QT NN B-AdverseReaction B-AdverseReaction
Prolongation NN I-AdverseReaction I-AdverseReaction
Increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
QT NN I-AdverseReaction I-AdverseReaction
interval NN I-AdverseReaction I-AdverseReaction
avoid NN O O
use NN O O
with NN O O
drugs NN O O
that NN O O
also NN O O
increase NN O O
the NN O O
QT NN O O
interval NN O O
and NN O O
in NN O O
patients NN O O
with NN O O
risk NN O O
factors NN O O
for NN O O
prolonged NN O O
QT NN O O
interval NN O O
. NN O O
( NN O O
5.9 NN O O
) NN O O
* NN O O
Seizures NN B-AdverseReaction B-AdverseReaction
Use NN O O
cautiously NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
seizures NN O O
or NN O O
with NN O O
conditions NN O O
that NN O O
lower NN O O
the NN O O
seizure NN O O
threshold NN O O
. NN O O
( NN O O
5.11 NN O O
) NN O O
* NN O O
Potential NN B-Factor B-Factor
for NN O O
Cognitive NN O O
and NN O O
Motor NN B-AdverseReaction B-AdverseReaction
Impairment NN I-AdverseReaction I-AdverseReaction
Use NN O O
caution NN O O
when NN O O
operating NN O O
machinery NN O O
. NN O O
( NN O O
5.12 NN O O
) NN O O
* NN O O
Suicide NN B-AdverseReaction B-AdverseReaction
The NN O O
possibility NN O O
of NN O O
a NN O O
suicide NN O O
attempt NN O O
is NN O O
inherent NN O O
in NN O O
schizophrenia NN O O
and NN O O
bipolar NN O O
disorder NN O O
. NN O O
Closely NN O O
supervise NN O O
high NN O O
- NN O O
risk NN O O
patients NN O O
. NN O O
( NN O O
5.14 NN O O
) NN O O
5.1 NN O O
Increased NN O O
Mortality NN O O
in NN O O
Elderly NN O O
Patients NN O O
with NN O O
Dementia NN O O
- NN O O
Related NN O O
Psychosis NN O O
Elderly NN O O
patients NN O O
with NN O O
dementia NN O O
- NN O O
related NN O O
psychosis NN O O
treated NN O O
with NN O O
antipsychotic NN B-DrugClass B-DrugClass
drugs NN I-DrugClass I-DrugClass
are NN O O
at NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
death NN B-AdverseReaction B-AdverseReaction
Analyses NN O O
of NN O O
17 NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
( NN O O
modal NN O O
duration NN O O
of NN O O
10 NN O O
weeks NN O O
) NN O O
, NN O O
largely NN O O
in NN O O
patients NN O O
taking NN O O
atypical NN B-DrugClass B-DrugClass
antipsychotic NN I-DrugClass I-DrugClass
drugs NN I-DrugClass I-DrugClass
revealed NN O O
a NN O O
risk NN O O
of NN O O
death NN B-AdverseReaction B-AdverseReaction
in NN O O
the NN O O
drug NN O O
- NN O O
treated NN O O
patients NN O O
of NN O O
between NN O O
1.6 NN O O
to NN O O
1.7 NN O O
times NN O O
that NN O O
seen NN O O
in NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Over NN O O
the NN O O
course NN O O
of NN O O
a NN O O
typical NN O O
10-week NN O O
controlled NN O O
trial NN O O
, NN O O
the NN O O
rate NN O O
of NN O O
death NN B-AdverseReaction B-AdverseReaction
in NN O O
drug NN O O
- NN O O
treated NN O O
patients NN O O
was NN O O
about NN O O
4.5 NN O O
% NN O O
, NN O O
compared NN O O
to NN O O
a NN O O
rate NN O O
of NN O O
about NN O O
2.6 NN O O
% NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
. NN O O
Although NN O O
the NN O O
causes NN O O
of NN O O
death NN B-AdverseReaction B-AdverseReaction
were NN O O
varied NN O O
, NN O O
most NN O O
of NN O O
the NN O O
deaths NN B-AdverseReaction B-AdverseReaction
appeared NN O O
to NN O O
be NN O O
either NN O O
cardiovascular NN O O
( NN O O
e.g. NN O O
, NN O O
heart NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
sudden NN B-AdverseReaction B-AdverseReaction
death NN I-AdverseReaction I-AdverseReaction
or NN O O
infectious NN O O
( NN O O
e.g. NN O O
, NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
in NN O O
nature NN O O
. NN O O
Observational NN O O
studies NN O O
suggest NN O O
that NN O O
, NN O O
similar NN O O
to NN O O
atypical NN O O
antipsychotic NN O O
drugs NN O O
, NN O O
treatment NN O O
with NN O O
conventional NN O O
antipsychotic NN O O
drugs NN O O
may NN O O
increase NN O O
mortality NN O O
. NN O O
The NN O O
extent NN O O
to NN O O
which NN O O
the NN O O
findings NN O O
of NN O O
increased NN B-AdverseReaction B-AdverseReaction
mortality NN I-AdverseReaction I-AdverseReaction
in NN O O
observational NN O O
studies NN O O
may NN O O
be NN O O
attributed NN O O
to NN O O
the NN O O
antipsychotic NN B-DrugClass B-DrugClass
drug NN I-DrugClass I-DrugClass
as NN O O
opposed NN O O
to NN O O
some NN O O
characteristic(s NN O O
) NN O O
of NN O O
the NN O O
patients NN O O
is NN O O
not NN O O
clear NN O O
. NN O O
SAPHRIS NN O O
is NN O O
not NN O O
approved NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
patients NN O O
with NN O O
dementia NN O O
- NN O O
related NN O O
psychosis NN O O
[ NN O O
seeBoxed NN O O
Warningand NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
Cerebrovascular NN O O
Adverse NN O O
Events NN O O
, NN O O
Including NN O O
Stroke NN O O
, NN O O
In NN O O
Elderly NN O O
Patients NN O O
with NN O O
Dementia NN O O
- NN O O
Related NN O O
Psychosis NN O O
In NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
with NN O O
risperidone NN B-DrugClass B-DrugClass
aripiprazole NN B-DrugClass B-DrugClass
and NN O O
olanzapine NN B-DrugClass B-DrugClass
in NN O O
elderly NN O O
subjects NN O O
with NN O O
dementia NN O O
, NN O O
there NN O O
was NN O O
a NN O O
higher NN O O
incidence NN O O
of NN O O
cerebrovascular NN B-AdverseReaction B-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
( NN O O
cerebrovascular NN O O
accidents NN O O
and NN O O
transient NN B-AdverseReaction B-AdverseReaction
ischemic NN I-AdverseReaction I-AdverseReaction
attacks NN I-AdverseReaction I-AdverseReaction
including NN O O
fatalities NN B-AdverseReaction B-AdverseReaction
compared NN O O
to NN O O
placebo NN O O
- NN O O
treated NN O O
subjects NN O O
. NN O O
SAPHRIS NN O O
is NN O O
not NN O O
approved NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
patients NN O O
with NN O O
dementia NN O O
- NN O O
related NN O O
psychosis NN O O
[ NN O O
see NN O O
alsoBoxed NN O O
Warningand NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
5.3 NN O O
Neuroleptic NN O O
Malignant NN O O
Syndrome NN O O
A NN O O
potentially NN B-Factor B-Factor
fatal NN B-AdverseReaction B-AdverseReaction
symptom NN O O
complex NN O O
sometimes NN O O
referred NN O O
to NN O O
as NN O O
Neuroleptic NN B-AdverseReaction B-AdverseReaction
Malignant NN I-AdverseReaction I-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
NMS NN O O
) NN O O
has NN O O
been NN O O
reported NN O O
in NN O O
association NN O O
with NN O O
administration NN O O
of NN O O
antipsychotic NN O O
drugs NN O O
, NN O O
including NN O O
SAPHRIS. NN O O
Clinical NN O O
manifestations NN O O
of NN O O
NMS NN B-AdverseReaction B-AdverseReaction
are NN O O
hyperpyrexia NN B-AdverseReaction B-AdverseReaction
muscle NN B-AdverseReaction B-AdverseReaction
rigidity NN I-AdverseReaction I-AdverseReaction
altered NN B-AdverseReaction B-AdverseReaction
mental NN I-AdverseReaction I-AdverseReaction
status NN I-AdverseReaction I-AdverseReaction
and NN O O
evidence NN O O
of NN O O
autonomic NN B-AdverseReaction B-AdverseReaction
instability NN I-AdverseReaction I-AdverseReaction
( NN O O
irregular NN O O
pulse NN O O
or NN O O
blood NN O O
pressure NN O O
, NN O O
tachycardia NN B-AdverseReaction B-AdverseReaction
diaphoresis NN B-AdverseReaction B-AdverseReaction
and NN O O
cardiac NN B-AdverseReaction B-AdverseReaction
dysrhythmia NN I-AdverseReaction I-AdverseReaction
Additional NN O O
signs NN O O
may NN B-Factor B-Factor
include NN O O
elevated NN B-AdverseReaction B-AdverseReaction
creatine NN I-AdverseReaction I-AdverseReaction
phosphokinase NN I-AdverseReaction I-AdverseReaction
myoglobinuria NN B-AdverseReaction B-AdverseReaction
( NN O O
rhabdomyolysis NN O O
) NN O O
, NN O O
and NN O O
acute NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
The NN O O
diagnostic NN O O
evaluation NN O O
of NN O O
patients NN O O
with NN O O
this NN O O
syndrome NN O O
is NN O O
complicated NN O O
. NN O O
It NN O O
is NN O O
important NN O O
to NN O O
exclude NN O O
cases NN O O
where NN O O
the NN O O
clinical NN O O
presentation NN O O
includes NN O O
both NN O O
serious NN O O
medical NN O O
illness NN O O
( NN O O
e.g. NN O O
pneumonia NN O O
, NN O O
systemic NN O O
infection NN O O
) NN O O
and NN O O
untreated NN O O
or NN O O
inadequately NN O O
treated NN O O
extrapyramidal NN O O
signs NN O O
and NN O O
symptoms NN O O
( NN O O
EPS NN O O
) NN O O
. NN O O
Other NN O O
important NN O O
considerations NN O O
in NN O O
the NN O O
differential NN O O
diagnosis NN O O
include NN O O
central NN O O
anticholinergic NN O O
toxicity NN O O
, NN O O
heat NN O O
stroke NN O O
, NN O O
drug NN O O
fever NN O O
, NN O O
and NN O O
primary NN O O
central NN O O
nervous NN O O
system NN O O
pathology NN O O
. NN O O
The NN O O
management NN O O
of NN O O
NMS NN O O
should NN O O
include NN O O
: NN O O
1 NN O O
) NN O O
immediate NN O O
discontinuation NN O O
of NN O O
antipsychotic NN O O
drugs NN O O
and NN O O
other NN O O
drugs NN O O
not NN O O
essential NN O O
to NN O O
concurrent NN O O
therapy NN O O
; NN O O
2 NN O O
) NN O O
intensive NN O O
symptomatic NN O O
treatment NN O O
and NN O O
medical NN O O
monitoring NN O O
; NN O O
and NN O O
3 NN O O
) NN O O
treatment NN O O
of NN O O
any NN O O
concomitant NN O O
serious NN O O
medical NN O O
problems NN O O
for NN O O
which NN O O
specific NN O O
treatments NN O O
are NN O O
available NN O O
. NN O O
There NN O O
is NN O O
no NN O O
general NN O O
agreement NN O O
about NN O O
specific NN O O
pharmacological NN O O
treatment NN O O
regimens NN O O
for NN O O
NMS. NN O O
If NN O O
a NN O O
patient NN O O
requires NN O O
antipsychotic NN O O
drug NN O O
treatment NN O O
after NN O O
recovery NN O O
from NN O O
NMS NN O O
, NN O O
the NN O O
potential NN O O
reintroduction NN O O
of NN O O
drug NN O O
therapy NN O O
should NN O O
be NN O O
carefully NN O O
considered NN O O
. NN O O
The NN O O
patient NN O O
should NN O O
be NN O O
carefully NN O O
monitored NN O O
, NN O O
since NN O O
recurrences NN O O
of NN O O
NMS NN O O
have NN O O
been NN O O
reported NN O O
. NN O O
5.4 NN O O
Tardive NN O O
Dyskinesia NN O O
A NN O O
syndrome NN O O
of NN O O
potentially NN B-Severity B-Severity
irreversible NN I-Severity I-Severity
involuntary NN B-AdverseReaction B-AdverseReaction
, NN I-AdverseReaction I-AdverseReaction
dyskinetic NN I-AdverseReaction I-AdverseReaction
movements NN I-AdverseReaction I-AdverseReaction
can NN O O
develop NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
antipsychotic NN B-DrugClass B-DrugClass
drugs NN I-DrugClass I-DrugClass
Although NN O O
the NN O O
prevalence NN O O
of NN O O
the NN O O
syndrome NN O O
appears NN O O
to NN O O
be NN O O
highest NN O O
among NN O O
the NN O O
elderly NN O O
, NN O O
especially NN O O
elderly NN O O
women NN O O
, NN O O
it NN O O
is NN O O
impossible NN O O
to NN O O
rely NN O O
upon NN O O
prevalence NN O O
estimates NN O O
to NN O O
predict NN O O
, NN O O
at NN O O
the NN O O
inception NN O O
of NN O O
antipsychotic NN O O
treatment NN O O
, NN O O
which NN O O
patients NN O O
are NN O O
likely NN O O
to NN O O
develop NN O O
the NN O O
syndrome NN O O
. NN O O
Whether NN O O
antipsychotic NN B-DrugClass B-DrugClass
drug NN I-DrugClass I-DrugClass
products NN O O
differ NN O O
in NN O O
their NN O O
potential NN O O
to NN O O
cause NN O O
Tardive NN B-AdverseReaction B-AdverseReaction
Dyskinesia NN I-AdverseReaction I-AdverseReaction
( NN O O
TD NN O O
) NN O O
is NN O O
unknown NN O O
. NN O O
The NN O O
risk NN O O
of NN O O
developing NN O O
TD NN B-AdverseReaction B-AdverseReaction
and NN O O
the NN O O
likelihood NN O O
that NN O O
it NN O O
will NN O O
become NN O O
irreversible NN B-Severity B-Severity
are NN O O
believed NN O O
to NN O O
increase NN O O
as NN O O
the NN O O
duration NN O O
of NN O O
treatment NN O O
and NN O O
the NN O O
total NN O O
cumulative NN O O
dose NN O O
of NN O O
antipsychotic NN B-DrugClass B-DrugClass
drugs NN I-DrugClass I-DrugClass
administered NN O O
to NN O O
the NN O O
patient NN O O
increase NN O O
. NN O O
However NN O O
, NN O O
the NN O O
syndrome NN O O
can NN O O
develop NN O O
, NN O O
although NN O O
much NN O O
less NN O O
commonly NN O O
, NN O O
after NN O O
relatively NN O O
brief NN O O
treatment NN O O
periods NN O O
at NN O O
low NN O O
doses NN O O
. NN O O
There NN O O
is NN O O
no NN O O
known NN O O
treatment NN O O
for NN O O
established NN O O
cases NN O O
of NN O O
TD NN O O
, NN O O
although NN O O
the NN O O
syndrome NN O O
may NN O O
remit NN O O
, NN O O
partially NN O O
or NN O O
completely NN O O
, NN O O
if NN O O
antipsychotic NN O O
treatment NN O O
is NN O O
withdrawn NN O O
. NN O O
Antipsychotic NN O O
treatment NN O O
, NN O O
itself NN O O
, NN O O
however NN O O
, NN O O
may NN O O
suppress NN O O
( NN O O
or NN O O
partially NN O O
suppress NN O O
) NN O O
the NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
the NN O O
syndrome NN O O
and NN O O
thereby NN O O
may NN O O
possibly NN O O
mask NN O O
the NN O O
underlying NN O O
process NN O O
. NN O O
The NN O O
effect NN O O
that NN O O
symptomatic NN O O
suppression NN O O
has NN O O
upon NN O O
the NN O O
long NN O O
- NN O O
term NN O O
course NN O O
of NN O O
the NN O O
syndrome NN O O
is NN O O
unknown NN O O
. NN O O
Given NN O O
these NN O O
considerations NN O O
, NN O O
SAPHRIS NN O O
should NN O O
be NN O O
prescribed NN O O
in NN O O
a NN O O
manner NN O O
that NN O O
is NN O O
most NN O O
likely NN O O
to NN O O
minimize NN O O
the NN O O
occurrence NN O O
of NN O O
TD. NN O O
Chronic NN O O
antipsychotic NN O O
treatment NN O O
should NN O O
generally NN O O
be NN O O
reserved NN O O
for NN O O
patients NN O O
who NN O O
suffer NN O O
from NN O O
a NN O O
chronic NN O O
illness NN O O
that NN O O
( NN O O
1 NN O O
) NN O O
is NN O O
known NN O O
to NN O O
respond NN O O
to NN O O
antipsychotic NN O O
drugs NN O O
, NN O O
and NN O O
( NN O O
2 NN O O
) NN O O
for NN O O
whom NN O O
alternative NN O O
, NN O O
equally NN O O
effective NN O O
, NN O O
but NN O O
potentially NN O O
less NN O O
harmful NN O O
treatments NN O O
are NN O O
not NN O O
available NN O O
or NN O O
appropriate NN O O
. NN O O
In NN O O
patients NN O O
who NN O O
do NN O O
require NN O O
chronic NN O O
treatment NN O O
, NN O O
the NN O O
smallest NN O O
dose NN O O
and NN O O
the NN O O
shortest NN O O
duration NN O O
of NN O O
treatment NN O O
producing NN O O
a NN O O
satisfactory NN O O
clinical NN O O
response NN O O
should NN O O
be NN O O
sought NN O O
. NN O O
The NN O O
need NN O O
for NN O O
continued NN O O
treatment NN O O
should NN O O
be NN O O
reassessed NN O O
periodically NN O O
. NN O O
If NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
TD NN O O
appear NN O O
in NN O O
a NN O O
patient NN O O
on NN O O
SAPHRIS NN O O
, NN O O
drug NN O O
discontinuation NN O O
should NN O O
be NN O O
considered NN O O
. NN O O
However NN O O
, NN O O
some NN O O
patients NN O O
may NN O O
require NN O O
treatment NN O O
with NN O O
SAPHRIS NN O O
despite NN O O
the NN O O
presence NN O O
of NN O O
the NN O O
syndrome NN O O
. NN O O
5.5 NN O O
Metabolic NN O O
Changes NN O O
Atypical NN B-DrugClass B-DrugClass
antipsychotic NN I-DrugClass I-DrugClass
drugs NN I-DrugClass I-DrugClass
have NN O O
been NN O O
associated NN O O
with NN O O
metabolic NN B-AdverseReaction B-AdverseReaction
changes NN I-AdverseReaction I-AdverseReaction
that NN O O
may NN O O
increase NN O O
cardiovascular/cerebrovascular NN O O
risk NN O O
. NN O O
These NN O O
metabolic NN B-AdverseReaction B-AdverseReaction
changes NN I-AdverseReaction I-AdverseReaction
include NN O O
hyperglycemia NN B-AdverseReaction B-AdverseReaction
dyslipidemia NN B-AdverseReaction B-AdverseReaction
and NN O O
body NN B-AdverseReaction B-AdverseReaction
weight NN I-AdverseReaction I-AdverseReaction
gain NN I-AdverseReaction I-AdverseReaction
While NN O O
all NN O O
of NN O O
the NN O O
drugs NN B-DrugClass B-DrugClass
in NN I-DrugClass I-DrugClass
the NN I-DrugClass I-DrugClass
class NN I-DrugClass I-DrugClass
have NN O O
been NN O O
shown NN O O
to NN O O
produce NN O O
some NN O O
metabolic NN B-AdverseReaction B-AdverseReaction
changes NN I-AdverseReaction I-AdverseReaction
each NN O O
drug NN O O
has NN O O
its NN O O
own NN O O
specific NN O O
risk NN O O
profile NN O O
. NN O O
Hyperglycemia NN O O
and NN O O
Diabetes NN O O
Mellitus NN O O
Hyperglycemia NN B-AdverseReaction B-AdverseReaction
in NN O O
some NN O O
cases NN O O
extreme NN B-Severity B-Severity
and NN O O
associated NN O O
with NN O O
ketoacidosis NN B-AdverseReaction B-AdverseReaction
or NN O O
hyperosmolar NN B-AdverseReaction B-AdverseReaction
coma NN I-AdverseReaction I-AdverseReaction
or NN O O
death NN B-AdverseReaction B-AdverseReaction
has NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
atypical NN B-DrugClass B-DrugClass
antipsychotics NN I-DrugClass I-DrugClass
Assessment NN O O
of NN O O
the NN O O
relationship NN O O
between NN O O
atypical NN O O
antipsychotic NN O O
use NN O O
and NN O O
glucose NN O O
abnormalities NN O O
is NN O O
complicated NN O O
by NN O O
the NN O O
possibility NN O O
of NN O O
an NN O O
increased NN O O
background NN O O
risk NN O O
of NN O O
diabetes NN O O
mellitus NN O O
in NN O O
patients NN O O
with NN O O
schizophrenia NN O O
and NN O O
the NN O O
increasing NN O O
incidence NN O O
of NN O O
diabetes NN O O
mellitus NN O O
in NN O O
the NN O O
general NN O O
population NN O O
. NN O O
Given NN O O
these NN O O
confounders NN O O
, NN O O
the NN O O
relationship NN O O
between NN O O
atypical NN B-DrugClass B-DrugClass
antipsychotic NN I-DrugClass I-DrugClass
use NN O O
and NN O O
hyperglycemia NN B-AdverseReaction B-AdverseReaction
adverse NN O O
reactions NN O O
is NN O O
not NN O O
completely NN O O
understood NN O O
. NN O O
However NN O O
, NN O O
epidemiological NN O O
studies NN O O
suggest NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
treatment NN O O
- NN O O
emergent NN O O
hyperglycemia NN B-AdverseReaction B-AdverseReaction
adverse NN O O
events NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
the NN O O
atypical NN B-DrugClass B-DrugClass
antipsychotics NN I-DrugClass I-DrugClass
included NN O O
in NN O O
these NN O O
studies NN O O
. NN O O
Precise NN O O
risk NN O O
estimates NN O O
for NN O O
hyperglycemia NN B-AdverseReaction B-AdverseReaction
adverse NN O O
events NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
atypical NN B-DrugClass B-DrugClass
antipsychotics NN I-DrugClass I-DrugClass
are NN O O
not NN O O
available NN O O
. NN O O
Patients NN O O
with NN O O
an NN O O
established NN O O
diagnosis NN O O
of NN O O
diabetes NN O O
mellitus NN O O
who NN O O
are NN O O
started NN O O
on NN O O
atypical NN O O
antipsychotics NN O O
should NN O O
be NN O O
monitored NN O O
regularly NN O O
for NN O O
worsening NN O O
of NN O O
glucose NN O O
control NN O O
. NN O O
Patients NN O O
with NN O O
risk NN O O
factors NN O O
for NN O O
diabetes NN O O
mellitus NN O O
( NN O O
e.g. NN O O
, NN O O
obesity NN O O
, NN O O
family NN O O
history NN O O
of NN O O
diabetes NN O O
) NN O O
who NN O O
are NN O O
starting NN O O
treatment NN O O
with NN O O
atypical NN O O
antipsychotics NN O O
should NN O O
undergo NN O O
fasting NN O O
blood NN O O
glucose NN O O
testing NN O O
at NN O O
the NN O O
beginning NN O O
of NN O O
treatment NN O O
and NN O O
periodically NN O O
during NN O O
treatment NN O O
. NN O O
Any NN O O
patient NN O O
treated NN O O
with NN O O
atypical NN O O
antipsychotics NN O O
should NN O O
be NN O O
monitored NN O O
for NN O O
symptoms NN O O
of NN O O
hyperglycemia NN O O
including NN O O
polydipsia NN O O
, NN O O
polyuria NN O O
, NN O O
polyphagia NN O O
, NN O O
and NN O O
weakness NN O O
. NN O O
Patients NN O O
who NN O O
develop NN O O
symptoms NN O O
of NN O O
hyperglycemia NN O O
during NN O O
treatment NN O O
with NN O O
atypical NN O O
antipsychotics NN O O
should NN O O
undergo NN O O
fasting NN O O
blood NN O O
glucose NN O O
testing NN O O
. NN O O
In NN O O
some NN O O
cases NN O O
, NN O O
hyperglycemia NN O O
has NN O O
resolved NN O O
when NN O O
the NN O O
atypical NN O O
antipsychotic NN O O
was NN O O
discontinued NN O O
; NN O O
however NN O O
, NN O O
some NN O O
patients NN O O
required NN O O
continuation NN O O
of NN O O
anti NN O O
- NN O O
diabetic NN O O
treatment NN O O
despite NN O O
discontinuation NN O O
of NN O O
the NN O O
antipsychotic NN O O
drug NN O O
. NN O O
Adult NN O O
Patients NN O O
: NN O O
Pooled NN O O
data NN O O
from NN O O
the NN O O
short NN O O
- NN O O
term NN O O
placebo NN O O
- NN O O
controlled NN O O
schizophrenia NN O O
and NN O O
bipolar NN O O
mania NN O O
trials NN O O
are NN O O
presented NN O O
in NN O O
Table NN O O
1 NN O O
. NN O O
TABLE NN O O
1 NN O O
: NN O O
Changes NN O O
in NN O O
Fasting NN O O
Glucose NN O O
in NN O O
Adult NN O O
Patients NN O O
N NN O O
* NN O O
= NN O O
Number NN O O
of NN O O
patients NN O O
who NN O O
had NN O O
assessments NN O O
at NN O O
both NN O O
Baseline NN O O
and NN O O
Endpoint NN O O
. NN O O
N NN O O
* NN O O
* NN O O
= NN O O
Number NN O O
of NN O O
patients NN O O
at NN O O
risk NN O O
at NN O O
Baseline NN O O
with NN O O
assessments NN O O
at NN O O
both NN O O
Baseline NN O O
and NN O O
Endpoint NN O O
. NN O O
S NN O O
Includes NN O O
patients NN O O
treated NN O O
with NN O O
flexible NN O O
dose NN O O
of NN O O
SAPHRIS NN O O
5 NN O O
or NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
( NN O O
N=90 NN O O
) NN O O
. NN O O
SAPHRIS NN O O
5 NN O O
mg NN O O
or NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
with NN O O
flexible NN O O
dosing NN O O
. NN O O
Schizophrenia NN O O
( NN O O
6-weeks NN O O
) NN O O
Bipolar NN O O
( NN O O
3-weeks NN O O
) NN O O
Placebo NN O O
SAPHRIS NN O O
Placebo NN O O
SAPHRIS5 NN O O
or NN O O
10 NN O O
mgtwice NN O O
daily NN O O
5 NN O O
mgtwice NN O O
daily NN O O
10 NN O O
mgtwice NN O O
daily NN O O
5 NN O O
or NN O O
10 NN O O
mgtwice NN O O
daily NN O O
S NN O O
Mean NN O O
Change NN O O
from NN O O
Baseline NN O O
in NN O O
Fasting NN O O
Glucose NN O O
at NN O O
Endpoint NN O O
Change NN O O
from NN O O
Baseline NN O O
( NN O O
mg/dL NN O O
) NN O O
( NN O O
N NN O O
* NN O O
) NN O O
-0.2(232 NN O O
) NN O O
3.8(158 NN O O
) NN O O
1.1(153 NN O O
) NN O O
3.2(377 NN O O
) NN O O
-0.6(89 NN O O
) NN O O
-0.6(156 NN O O
) NN O O
Proportion NN O O
of NN O O
Patients NN O O
with NN O O
Shifts NN O O
from NN O O
Baseline NN O O
to NN O O
Endpoint NN O O
Normal NN O O
to NN O O
High<100 NN O O
to NN O O
>=126 NN O O
mg/dL NN O O
4.1 NN O O
% NN O O
4.5 NN O O
% NN O O
4.5 NN O O
% NN O O
5.0 NN O O
% NN O O
3.3 NN O O
% NN O O
2.7 NN O O
% NN O O
( NN O O
n/N NN O O
* NN O O
* NN O O
) NN O O
( NN O O
7/170 NN O O
) NN O O
( NN O O
5/111 NN O O
) NN O O
( NN O O
5/111 NN O O
) NN O O
( NN O O
13/262 NN O O
) NN O O
( NN O O
2/61 NN O O
) NN O O
( NN O O
3/111 NN O O
) NN O O
Borderline NN O O
to NN O O
High>=100 NN O O
and NN O O
< NN O O
126to NN O O
>=126 NN O O
mg/dL NN O O
5.9 NN O O
% NN O O
6.8 NN O O
% NN O O
6.3 NN O O
% NN O O
10.5 NN O O
% NN O O
0.0 NN O O
% NN O O
11.4 NN O O
% NN O O
( NN O O
n/N NN O O
* NN O O
* NN O O
) NN O O
( NN O O
3/51 NN O O
) NN O O
( NN O O
3/44 NN O O
) NN O O
( NN O O
2/32 NN O O
) NN O O
( NN O O
10/95 NN O O
) NN O O
( NN O O
0/23 NN O O
) NN O O
( NN O O
4/35 NN O O
) NN O O
In NN O O
a NN O O
52-week NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
comparator NN O O
- NN O O
controlled NN O O
trial NN O O
that NN O O
included NN O O
primarily NN O O
patients NN O O
with NN O O
schizophrenia NN O O
, NN O O
the NN O O
mean NN O O
increase NN O O
from NN O O
baseline NN O O
of NN O O
fasting NN O O
glucose NN O O
was NN O O
2.4 NN O O
mg/dL. NN O O
Pediatric NN O O
Patients NN O O
: NN O O
Data NN O O
from NN O O
the NN O O
short NN O O
- NN O O
term NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
trial NN O O
in NN O O
pediatric NN O O
patients NN O O
with NN O O
bipolar NN O O
I NN O O
disorder NN O O
are NN O O
shown NN O O
in NN O O
Table NN O O
2 NN O O
. NN O O
TABLE NN O O
2 NN O O
: NN O O
Changes NN O O
in NN O O
Fasting NN O O
Glucose NN O O
in NN O O
Pediatric NN O O
Subjects NN O O
Bipolar NN O O
I NN O O
Disorder NN O O
( NN O O
3-weeks NN O O
) NN O O
Placebo NN O O
SAPHRIS2.5 NN O O
mgtwice NN O O
daily NN O O
SAPHRIS5 NN O O
mgtwice NN O O
daily NN O O
SAPHRIS10 NN O O
mgtwice NN O O
daily NN O O
Mean NN O O
Change NN O O
from NN O O
Baseline NN O O
in NN O O
Fasting NN O O
Glucose NN O O
at NN O O
Endpoint NN O O
Change NN O O
from NN O O
Baseline NN O O
( NN O O
mg/dL NN O O
) NN O O
( NN O O
N NN O O
* NN O O
) NN O O
-2.24(56 NN O O
) NN O O
1.43(51 NN O O
) NN O O
-0.45(57 NN O O
) NN O O
0.34(52 NN O O
) NN O O
Proportion NN O O
of NN O O
Subjects NN O O
with NN O O
Shifts NN O O
from NN O O
Baseline NN O O
to NN O O
Endpoint NN O O
Normal NN O O
to NN O O
High>45 NN O O
& NN O O
< NN O O
100 NN O O
to NN O O
>=126 NN O O
mg/dL NN O O
0 NN O O
% NN O O
0 NN O O
% NN O O
1.8 NN O O
% NN O O
0 NN O O
% NN O O
( NN O O
n/N NN O O
* NN O O
) NN O O
( NN O O
0/56 NN O O
) NN O O
( NN O O
0/51 NN O O
) NN O O
( NN O O
1/57 NN O O
) NN O O
( NN O O
0/52 NN O O
) NN O O
Dyslipidemia NN B-AdverseReaction B-AdverseReaction
Undesirable NN B-AdverseReaction B-AdverseReaction
alterations NN I-AdverseReaction I-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
lipids NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
observed NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
atypical NN B-DrugClass B-DrugClass
antipsychotics NN I-DrugClass I-DrugClass
Adult NN O O
Patients NN O O
: NN O O
Pooled NN O O
data NN O O
from NN O O
the NN O O
short NN O O
- NN O O
term NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
schizophrenia NN O O
and NN O O
bipolar NN O O
mania NN O O
trials NN O O
are NN O O
presented NN O O
in NN O O
Table NN O O
3 NN O O
. NN O O
TABLE NN O O
3 NN O O
: NN O O
Changes NN O O
in NN O O
Lipids NN O O
in NN O O
Adult NN O O
Patients NN O O
N NN O O
* NN O O
= NN O O
Number NN O O
of NN O O
subjects NN O O
who NN O O
had NN O O
assessments NN O O
at NN O O
both NN O O
Baseline NN O O
and NN O O
Endpoint NN O O
. NN O O
S NN O O
Includes NN O O
subjects NN O O
treated NN O O
with NN O O
flexible NN O O
dose NN O O
of NN O O
SAPHRIS NN O O
5 NN O O
or NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
( NN O O
N=90 NN O O
) NN O O
. NN O O
SAPHRIS NN O O
5 NN O O
mg NN O O
or NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
with NN O O
flexible NN O O
dosing NN O O
. NN O O
Schizophrenia NN O O
( NN O O
6-weeks NN O O
) NN O O
Bipolar NN O O
( NN O O
3-weeks NN O O
) NN O O
Placebo NN O O
SAPHRIS NN O O
Placebo NN O O
SAPHRIS5 NN O O
or NN O O
10 NN O O
mgtwice NN O O
daily NN O O
5 NN O O
mgtwice NN O O
daily NN O O
10 NN O O
mgtwice NN O O
daily NN O O
5 NN O O
or NN O O
10 NN O O
mgtwice NN O O
daily NN O O
S NN O O
Mean NN O O
Change NN O O
from NN O O
Baseline NN O O
( NN O O
mg/dL NN O O
) NN O O
Total NN O O
cholesterol(N NN O O
* NN O O
) NN O O
-2.2(351 NN O O
) NN O O
-2.4(258 NN O O
) NN O O
3.3(199 NN O O
) NN O O
0.4(539 NN O O
) NN O O
-1.5(163 NN O O
) NN O O
1.1(322 NN O O
) NN O O
LDL NN O O
( NN O O
N NN O O
* NN O O
) NN O O
0.1(285 NN O O
) NN O O
-0.2(195 NN O O
) NN O O
2.6(195 NN O O
) NN O O
1.3(465 NN O O
) NN O O
1.9(158 NN O O
) NN O O
1.6(304 NN O O
) NN O O
HDL NN O O
( NN O O
N NN O O
* NN O O
) NN O O
0.5(290 NN O O
) NN O O
0.4(199 NN O O
) NN O O
1.0(199 NN O O
) NN O O
0.5(480 NN O O
) NN O O
0.0(163 NN O O
) NN O O
0.9(322 NN O O
) NN O O
Fasting NN O O
triglycerides NN O O
( NN O O
N NN O O
* NN O O
) NN O O
-7.6(233 NN O O
) NN O O
-1.9(159 NN O O
) NN O O
0.1(154 NN O O
) NN O O
3.8(380 NN O O
) NN O O
-17.9(129 NN O O
) NN O O
-3.5(237 NN O O
) NN O O
Proportion NN O O
of NN O O
Patients NN O O
with NN O O
Shifts NN O O
from NN O O
Baseline NN O O
to NN O O
Endpoint NN O O
Total NN O O
cholesterolNormal NN O O
to NN O O
High<200 NN O O
to NN O O
>=240(mg/dL NN O O
) NN O O
( NN O O
n/N NN O O
* NN O O
) NN O O
1.3%(3/225 NN O O
) NN O O
0.6%(1/161 NN O O
) NN O O
2.2%(3/134 NN O O
) NN O O
1.7%(6/343 NN O O
) NN O O
1.1%(1/95 NN O O
) NN O O
2.5%(5/204 NN O O
) NN O O
LDLNormal NN O O
to NN O O
High<100 NN O O
to NN O O
>=160(mg/dL NN O O
) NN O O
( NN O O
n/N NN O O
* NN O O
) NN O O
1.7%(2/117 NN O O
) NN O O
0.0%(0/80 NN O O
) NN O O
1.2%(1/86 NN O O
) NN O O
1.0%(2/196 NN O O
) NN O O
1.9%(1/53 NN O O
) NN O O
0.0%(0/141 NN O O
) NN O O
HDLNormal NN O O
to NN O O
Low>=40 NN O O
to NN O O
< NN O O
40 NN O O
( NN O O
mg/dL NN O O
) NN O O
( NN O O
n/N NN O O
* NN O O
) NN O O
10.7%(21/196 NN O O
) NN O O
13.3%(18/135 NN O O
) NN O O
14.7%(20/136 NN O O
) NN O O
14.0%(45/322 NN O O
) NN O O
7.4%(9/122 NN O O
) NN O O
8.7%(21/242 NN O O
) NN O O
Fasting NN O O
triglyceridesNormal NN O O
to NN O O
High<150 NN O O
to NN O O
>=200 NN O O
( NN O O
mg/dL NN O O
) NN O O
( NN O O
n/N NN O O
* NN O O
) NN O O
2.4%(4/167 NN O O
) NN O O
7.0%(8/115 NN O O
) NN O O
8.3%(9/108 NN O O
) NN O O
7.7%(20/260 NN O O
) NN O O
5.1%(4/78 NN O O
) NN O O
7.4%(11/148 NN O O
) NN O O
In NN O O
short NN O O
- NN O O
term NN O O
schizophrenia NN O O
trials NN O O
, NN O O
the NN O O
proportion NN O O
of NN O O
patients NN O O
with NN O O
total NN B-AdverseReaction B-AdverseReaction
cholesterol NN I-AdverseReaction I-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
>=240 NN O O
mg/dL NN O O
( NN O O
at NN O O
Endpoint NN O O
) NN O O
was NN O O
8.3 NN O O
% NN O O
for NN O O
SAPHRIS NN O O
- NN O O
treated NN O O
patients NN O O
versus NN O O
7 NN O O
% NN O O
for NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
The NN O O
proportion NN O O
of NN O O
patients NN O O
with NN O O
elevations NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
triglycerides NN I-AdverseReaction I-AdverseReaction
>=200 NN O O
mg/dL NN O O
( NN O O
at NN O O
Endpoint NN O O
) NN O O
was NN O O
13.2 NN O O
% NN O O
for NN O O
SAPHRIS NN O O
- NN O O
treated NN O O
patients NN O O
versus NN O O
10.5 NN O O
% NN O O
for NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
In NN O O
short NN O O
- NN O O
term NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
bipolar NN O O
mania NN O O
trials NN O O
, NN O O
the NN O O
proportion NN O O
of NN O O
patients NN O O
with NN O O
total NN B-AdverseReaction B-AdverseReaction
cholesterol NN I-AdverseReaction I-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
>=240 NN O O
mg/dL NN O O
( NN O O
at NN O O
Endpoint NN O O
) NN O O
was NN O O
8.7 NN O O
% NN O O
for NN O O
SAPHRIS NN O O
- NN O O
treated NN O O
patients NN O O
versus NN O O
8.6 NN O O
% NN O O
for NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
The NN O O
proportion NN O O
of NN O O
patients NN O O
with NN O O
elevations NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
triglycerides NN I-AdverseReaction I-AdverseReaction
>=200 NN O O
mg/dL NN O O
( NN O O
at NN O O
Endpoint NN O O
) NN O O
was NN O O
15.2 NN O O
% NN O O
for NN O O
SAPHRIS NN O O
- NN O O
treated NN O O
patients NN O O
versus NN O O
11.4 NN O O
% NN O O
for NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
In NN O O
a NN O O
52-week NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
comparator NN O O
- NN O O
controlled NN O O
trial NN O O
that NN O O
included NN O O
primarily NN O O
patients NN O O
with NN O O
schizophrenia NN O O
, NN O O
the NN O O
mean NN O O
decrease NN O O
from NN O O
baseline NN O O
of NN O O
total NN O O
cholesterol NN O O
was NN O O
6 NN O O
mg/dL NN O O
and NN O O
the NN O O
mean NN O O
decrease NN O O
from NN O O
baseline NN O O
of NN O O
fasting NN O O
triglycerides NN O O
was NN O O
9.8 NN O O
mg/dL. NN O O
Pediatric NN O O
Patients NN O O
: NN O O
Data NN O O
from NN O O
the NN O O
short NN O O
- NN O O
term NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
bipolar NN O O
mania NN O O
trial NN O O
are NN O O
presented NN O O
in NN O O
Table NN O O
4 NN O O
. NN O O
TABLE NN O O
4 NN O O
: NN O O
Changes NN O O
in NN O O
Fasting NN O O
Lipids NN O O
in NN O O
Pediatric NN O O
Subjects NN O O
N NN O O
* NN O O
= NN O O
Number NN O O
of NN O O
patients NN O O
who NN O O
had NN O O
assessments NN O O
at NN O O
both NN O O
Baseline NN O O
and NN O O
Endpoint NN O O
Bipolar NN O O
I NN O O
Disorder NN O O
( NN O O
3-weeks NN O O
) NN O O
Placebo NN O O
SAPHRIS2.5 NN O O
mgtwice NN O O
daily NN O O
SAPHRIS5 NN O O
mgtwice NN O O
daily NN O O
SAPHRIS10 NN O O
mgtwice NN O O
daily NN O O
Mean NN O O
Change NN O O
from NN O O
Baseline NN O O
( NN O O
mg/dL NN O O
) NN O O
Total NN O O
fasting NN O O
cholesterol NN O O
( NN O O
N NN O O
* NN O O
) NN O O
-2.3(57 NN O O
) NN O O
3.7(50 NN O O
) NN O O
7.2(57 NN O O
) NN O O
9.3(52 NN O O
) NN O O
Fasting NN O O
LDL(N NN O O
* NN O O
) NN O O
-2.5(57 NN O O
) NN O O
-0.2(50 NN O O
) NN O O
3.0(57 NN O O
) NN O O
4.9(51 NN O O
) NN O O
Fasting NN O O
HDL(N NN O O
* NN O O
) NN O O
1.6(57 NN O O
) NN O O
2.3(50 NN O O
) NN O O
1.5(57 NN O O
) NN O O
1.7(52 NN O O
) NN O O
Fasting NN O O
triglycerides NN O O
( NN O O
N NN O O
* NN O O
) NN O O
-6.6(57 NN O O
) NN O O
8.7(50 NN O O
) NN O O
13.4(57 NN O O
) NN O O
14.7(52 NN O O
) NN O O
Proportion NN O O
of NN O O
Subjects NN O O
with NN O O
Shifts NN O O
from NN O O
Baseline NN O O
to NN O O
Endpoint NN O O
Total NN O O
fasting NN O O
cholesterolNormal NN O O
to NN O O
High<170 NN O O
to NN O O
>=200(mg/dL)(n/N NN O O
* NN O O
) NN O O
1.8%(1/57 NN O O
) NN O O
0%(0/50 NN O O
) NN O O
1.8%(1/57 NN O O
) NN O O
0%(0/52 NN O O
) NN O O
Fasting NN O O
LDLNormal NN O O
to NN O O
High<110 NN O O
to NN O O
>=130(n/N NN O O
* NN O O
) NN O O
1.8%(1/57 NN O O
) NN O O
2.0%(1/50 NN O O
) NN O O
1.8%(1/57 NN O O
) NN O O
0%(0/51 NN O O
) NN O O
Fasting NN O O
HDLNormal NN O O
to NN O O
Low>=40 NN O O
to NN O O
< NN O O
40 NN O O
( NN O O
mg/dL)(n/N NN O O
* NN O O
) NN O O
3.5%(2/57 NN O O
) NN O O
6.0%(3/50 NN O O
) NN O O
3.5%(2/57 NN O O
) NN O O
9.6%(5/52 NN O O
) NN O O
Fasting NN O O
triglyceridesNormal NN O O
to NN O O
High<150 NN O O
to NN O O
>=200 NN O O
( NN O O
mg/dL)(n/N NN O O
* NN O O
) NN O O
0%(0/57 NN O O
) NN O O
4.0%(2/50 NN O O
) NN O O
3.5%(2/57 NN O O
) NN O O
1.9%(1/52 NN O O
) NN O O
Weight NN O O
Gain NN O O
Increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
weight NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
observed NN O O
in NN O O
pre NN O O
- NN O O
marketing NN O O
clinical NN O O
trials NN O O
with NN O O
SAPHRIS. NN O O
Patients NN O O
receiving NN O O
SAPHRIS NN O O
should NN O O
receive NN O O
regular NN O O
monitoring NN O O
of NN O O
weight NN O O
[ NN O O
see NN O O
Patient NN O O
Counseling NN O O
Information NN O O
( NN O O
17 NN O O
) NN O O
] NN O O
. NN O O
Adult NN O O
Patients NN O O
: NN O O
Pooled NN O O
data NN O O
on NN O O
mean NN O O
changes NN O O
in NN O O
body NN O O
weight NN O O
and NN O O
the NN O O
proportion NN O O
of NN O O
subjects NN O O
meeting NN O O
a NN O O
weight NN B-AdverseReaction B-AdverseReaction
gain NN I-AdverseReaction I-AdverseReaction
criterion NN O O
of NN O O
>=7 NN O O
% NN O O
of NN O O
body NN O O
weight NN O O
from NN O O
the NN O O
short NN O O
- NN O O
term NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
schizophrenia NN O O
and NN O O
bipolar NN O O
mania NN O O
trials NN O O
are NN O O
presented NN O O
in NN O O
Table NN O O
5 NN O O
. NN O O
Table NN O O
5 NN O O
: NN O O
Change NN O O
in NN O O
Body NN O O
Weight NN O O
in NN O O
Adult NN O O
Patients NN O O
from NN O O
Baseline NN O O
N NN O O
* NN O O
= NN O O
Number NN O O
of NN O O
subjects NN O O
who NN O O
had NN O O
assessments NN O O
at NN O O
both NN O O
Baseline NN O O
and NN O O
Endpoint NN O O
. NN O O
S NN O O
Includes NN O O
subjects NN O O
treated NN O O
with NN O O
flexible NN O O
dose NN O O
of NN O O
SAPHRIS NN O O
5 NN O O
or NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
( NN O O
N=90 NN O O
) NN O O
. NN O O
SAPHRIS NN O O
5 NN O O
mg NN O O
or NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
with NN O O
flexible NN O O
dosing NN O O
. NN O O
Schizophrenia NN O O
( NN O O
6-weeks NN O O
) NN O O
Bipolar NN O O
( NN O O
3-weeks NN O O
) NN O O
Placebo NN O O
SAPHRIS NN O O
Placebo NN O O
SAPHRIS5 NN O O
or NN O O
10 NN O O
mgtwice NN O O
daily NN O O
5 NN O O
mgtwice NN O O
daily NN O O
10 NN O O
mgtwice NN O O
daily NN O O
5 NN O O
or NN O O
10 NN O O
mgtwice NN O O
daily NN O O
S NN O O
Change NN O O
from NN O O
Baseline NN O O
( NN O O
kg NN O O
) NN O O
( NN O O
N NN O O
* NN O O
) NN O O
0.0(348 NN O O
) NN O O
1.0(251 NN O O
) NN O O
0.9(200 NN O O
) NN O O
1.1(532 NN O O
) NN O O
0.2(171 NN O O
) NN O O
1.3(336 NN O O
) NN O O
Proportion NN O O
of NN O O
Patients NN O O
with NN O O
a NN O O
>=7 NN O O
% NN O O
Increase NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
Body NN I-AdverseReaction I-AdverseReaction
Weight NN I-AdverseReaction I-AdverseReaction
% NN O O
with NN O O
>=7 NN O O
% NN O O
increase NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
body NN I-AdverseReaction I-AdverseReaction
weight NN I-AdverseReaction I-AdverseReaction
1.6 NN O O
% NN O O
4.4 NN O O
% NN O O
4.8 NN O O
% NN O O
4.9 NN O O
% NN O O
0.5 NN O O
% NN O O
5.8 NN O O
% NN O O
Adult NN O O
Patients NN O O
: NN O O
In NN O O
a NN O O
52-week NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
comparator NN O O
- NN O O
controlled NN O O
adult NN O O
trial NN O O
that NN O O
included NN O O
primarily NN O O
patients NN O O
with NN O O
schizophrenia NN O O
, NN O O
the NN O O
mean NN O O
weight NN B-AdverseReaction B-AdverseReaction
gain NN I-AdverseReaction I-AdverseReaction
from NN O O
baseline NN O O
was NN O O
0.9 NN O O
kg NN O O
. NN O O
The NN O O
proportion NN O O
of NN O O
patients NN O O
with NN O O
a NN O O
>=7 NN O O
% NN O O
increase NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
body NN I-AdverseReaction I-AdverseReaction
weight NN I-AdverseReaction I-AdverseReaction
( NN O O
at NN O O
Endpoint NN O O
) NN O O
was NN O O
14.7%.Table NN O O
5provides NN O O
the NN O O
mean NN O O
weight NN B-AdverseReaction B-AdverseReaction
change NN I-AdverseReaction I-AdverseReaction
from NN O O
baseline NN O O
and NN O O
the NN O O
proportion NN O O
of NN O O
patients NN O O
with NN O O
a NN O O
weight NN B-AdverseReaction B-AdverseReaction
gain NN I-AdverseReaction I-AdverseReaction
of NN O O
>=7 NN O O
% NN O O
categorized NN O O
by NN O O
Body NN O O
Mass NN O O
Index NN O O
( NN O O
BMI NN O O
) NN O O
at NN O O
baseline NN O O
. NN O O
Table NN O O
6 NN O O
: NN O O
Weight NN O O
Change NN O O
Results NN O O
Categorized NN O O
by NN O O
BMI NN O O
at NN O O
Baseline NN O O
: NN O O
Comparator NN O O
- NN O O
Controlled NN O O
52-Week NN O O
Study NN O O
in NN O O
Adults NN O O
with NN O O
Schizophrenia NN O O
BMI NN O O
< NN O O
23 NN O O
SAPHRIS NN O O
N=295 NN O O
BMI NN O O
23 NN O O
- NN O O
< NN O O
=27 NN O O
SAPHRIS NN O O
N=290 NN O O
BMI NN O O
>27 NN O O
SAPHRIS NN O O
N=302 NN O O
Mean NN O O
change NN O O
from NN O O
Baseline NN O O
( NN O O
kg NN O O
) NN O O
1.7 NN O O
1 NN O O
0 NN O O
% NN O O
with NN O O
>=7 NN O O
% NN O O
increase NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
body NN I-AdverseReaction I-AdverseReaction
weight NN I-AdverseReaction I-AdverseReaction
22 NN O O
% NN O O
13 NN O O
% NN O O
9 NN O O
% NN O O
Pediatric NN O O
Patients NN O O
: NN O O
Data NN O O
on NN O O
mean NN O O
changes NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
body NN I-AdverseReaction I-AdverseReaction
weight NN I-AdverseReaction I-AdverseReaction
and NN O O
the NN O O
proportion NN O O
of NN O O
pediatric NN O O
patients NN O O
meeting NN O O
a NN O O
weight NN B-AdverseReaction B-AdverseReaction
gain NN I-AdverseReaction I-AdverseReaction
criterion NN O O
of NN O O
>=7 NN O O
% NN O O
of NN O O
body NN O O
weight NN O O
from NN O O
the NN O O
short NN O O
- NN O O
term NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
bipolar NN O O
mania NN O O
trial NN O O
are NN O O
presented NN O O
in NN O O
Table NN O O
7 NN O O
. NN O O
To NN O O
adjust NN O O
for NN O O
normal NN O O
growth NN O O
, NN O O
z NN O O
- NN O O
scores NN O O
were NN O O
derived NN O O
( NN O O
measured NN O O
in NN O O
standard NN O O
deviations NN O O
[ NN O O
SD NN O O
] NN O O
) NN O O
, NN O O
which NN O O
normalize NN O O
for NN O O
the NN O O
natural NN O O
growth NN O O
of NN O O
pediatric NN O O
patients NN O O
by NN O O
comparisons NN O O
to NN O O
age- NN O O
and NN O O
sex NN O O
- NN O O
matched NN O O
population NN O O
standards NN O O
. NN O O
The NN O O
distance NN O O
of NN O O
a NN O O
z NN O O
- NN O O
score NN O O
from NN O O
0 NN O O
represents NN O O
the NN O O
distance NN O O
of NN O O
a NN O O
percentile NN O O
from NN O O
the NN O O
median NN O O
, NN O O
measured NN O O
in NN O O
standard NN O O
deviations NN O O
( NN O O
SD NN O O
) NN O O
. NN O O
After NN O O
adjusting NN O O
for NN O O
age NN O O
and NN O O
sex NN O O
, NN O O
the NN O O
mean NN O O
change NN O O
from NN O O
baseline NN O O
to NN O O
endpoint NN O O
in NN O O
weight NN O O
z NN O O
- NN O O
score NN O O
for NN O O
SAPHRS NN O O
2.5 NN O O
mg NN O O
, NN O O
5 NN O O
mg NN O O
, NN O O
and NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
, NN O O
was NN O O
0.11 NN O O
, NN O O
0.08 NN O O
and NN O O
0.09 NN O O
SD NN O O
versus NN O O
0.02 NN O O
SD NN O O
for NN O O
placebo NN O O
, NN O O
respectively NN O O
. NN O O
When NN O O
treating NN O O
pediatric NN O O
patients NN O O
, NN O O
weight NN O O
gain NN O O
should NN O O
be NN O O
monitored NN O O
and NN O O
assessed NN O O
against NN O O
that NN O O
expected NN O O
for NN O O
normal NN O O
growth NN O O
. NN O O
Table NN O O
7 NN O O
: NN O O
Change NN O O
in NN O O
Body NN O O
Weight NN O O
in NN O O
Pediatric NN O O
Subjects NN O O
from NN O O
Baseline NN O O
N NN O O
* NN O O
= NN O O
Number NN O O
of NN O O
subjects NN O O
who NN O O
had NN O O
assessments NN O O
at NN O O
both NN O O
Baseline NN O O
and NN O O
Endpoint NN O O
. NN O O
Bipolar NN O O
I NN O O
Disorder NN O O
( NN O O
3-weeks NN O O
) NN O O
Placebo NN O O
SAPHRIS2.5 NN O O
mgtwice NN O O
daily NN O O
SAPHRIS5 NN O O
mgtwice NN O O
daily NN O O
SAPHRIS10 NN O O
mgtwice NN O O
daily NN O O
Change NN O O
from NN O O
Baseline NN O O
( NN O O
kg NN O O
) NN O O
( NN O O
N NN O O
* NN O O
) NN O O
0.5(89 NN O O
) NN O O
1.7(92 NN O O
) NN O O
1.6(90 NN O O
) NN O O
1.4(87 NN O O
) NN O O
Proportion NN O O
of NN O O
Subjects NN O O
with NN O O
a NN O O
>=7 NN O O
% NN O O
Increase NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
Body NN I-AdverseReaction I-AdverseReaction
Weight NN I-AdverseReaction I-AdverseReaction
% NN O O
with NN O O
>=7 NN O O
% NN O O
increase NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
body NN I-AdverseReaction I-AdverseReaction
weight NN I-AdverseReaction I-AdverseReaction
1.1 NN O O
% NN O O
12.0 NN O O
% NN O O
8.9 NN O O
% NN O O
8.0 NN O O
% NN O O
5.6 NN O O
Hypersensitivity NN O O
Reactions NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
observed NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
SAPHRIS. NN O O
In NN O O
several NN O O
cases NN O O
, NN O O
these NN O O
reactions NN O O
occurred NN O O
after NN O O
the NN O O
first NN O O
dose NN O O
. NN O O
These NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
included NN O O
: NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
angioedema NN B-AdverseReaction B-AdverseReaction
hypotension NN B-AdverseReaction B-AdverseReaction
tachycardia NN B-AdverseReaction B-AdverseReaction
swollen NN B-AdverseReaction B-AdverseReaction
tongue NN I-AdverseReaction I-AdverseReaction
dyspnea NN B-AdverseReaction B-AdverseReaction
wheezing NN B-AdverseReaction B-AdverseReaction
and NN O O
rash NN B-AdverseReaction B-AdverseReaction
5.7 NN O O
Orthostatic NN O O
Hypotension NN O O
, NN O O
Syncope NN O O
, NN O O
and NN O O
Other NN O O
Hemodynamic NN O O
Effects NN O O
SAPHRIS NN O O
may NN B-Factor B-Factor
induce NN O O
orthostatic NN B-AdverseReaction B-AdverseReaction
hypotension NN I-AdverseReaction I-AdverseReaction
and NN O O
syncope NN B-AdverseReaction B-AdverseReaction
in NN O O
some NN O O
patients NN O O
, NN O O
especially NN O O
early NN O O
in NN O O
treatment NN O O
, NN O O
because NN O O
of NN O O
its NN O O
alpha1-adrenergic NN O O
antagonist NN O O
activity NN O O
. NN O O
In NN O O
short NN O O
- NN O O
term NN O O
schizophrenia NN O O
adult NN O O
trials NN O O
, NN O O
syncope NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
0.2 NN O O
% NN O O
( NN O O
1/572 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
therapeutic NN O O
doses NN O O
( NN O O
5 NN O O
mg NN O O
or NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
) NN O O
of NN O O
SAPHRIS NN O O
, NN O O
compared NN O O
to NN O O
0.3 NN O O
% NN O O
( NN O O
1/378 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
placebo NN O O
. NN O O
In NN O O
short NN O O
- NN O O
term NN O O
bipolar NN O O
mania NN O O
adult NN O O
trials NN O O
, NN O O
syncope NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
0.3 NN O O
% NN O O
( NN O O
1/379 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
therapeutic NN O O
doses NN O O
( NN O O
5 NN O O
mg NN O O
or NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
) NN O O
of NN O O
SAPHRIS NN O O
, NN O O
compared NN O O
to NN O O
0 NN O O
% NN O O
( NN O O
0/203 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
placebo NN O O
. NN O O
During NN O O
adult NN O O
pre NN O O
- NN O O
marketing NN O O
clinical NN O O
trials NN O O
with NN O O
SAPHRIS NN O O
, NN O O
including NN O O
long NN O O
- NN O O
term NN O O
trials NN O O
without NN O O
comparison NN O O
to NN O O
placebo NN O O
, NN O O
syncope NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
0.6 NN O O
% NN O O
( NN O O
11/1953 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
SAPHRIS. NN O O
In NN O O
a NN O O
3-week NN O O
, NN O O
bipolar NN O O
mania NN O O
pediatric NN O O
trial NN O O
, NN O O
syncope NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
1 NN O O
% NN O O
( NN O O
1/104 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
SAPHRIS NN O O
2.5 NN O O
mg NN O O
twice NN O O
daily NN O O
, NN O O
1 NN O O
% NN O O
( NN O O
1/99 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
SAPHRIS NN O O
5 NN O O
mg NN O O
twice NN O O
daily NN O O
, NN O O
and NN O O
0 NN O O
% NN O O
( NN O O
0/99 NN O O
) NN O O
for NN O O
patients NN O O
treated NN O O
with NN O O
SAPHRIS NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
compared NN O O
to NN O O
0 NN O O
% NN O O
( NN O O
0/101 NN O O
) NN O O
for NN O O
patients NN O O
treated NN O O
with NN O O
placebo NN O O
. NN O O
Patients NN O O
should NN O O
be NN O O
instructed NN O O
about NN O O
non NN O O
- NN O O
pharmacologic NN O O
interventions NN O O
that NN O O
help NN O O
to NN O O
reduce NN O O
the NN O O
occurrence NN O O
of NN O O
orthostatic NN O O
hypotension NN O O
( NN O O
e.g. NN O O
, NN O O
sitting NN O O
on NN O O
the NN O O
edge NN O O
of NN O O
the NN O O
bed NN O O
for NN O O
several NN O O
minutes NN O O
before NN O O
attempting NN O O
to NN O O
stand NN O O
in NN O O
the NN O O
morning NN O O
and NN O O
slowly NN O O
rising NN O O
from NN O O
a NN O O
seated NN O O
position NN O O
) NN O O
. NN O O
SAPHRIS NN O O
should NN O O
be NN O O
used NN O O
with NN O O
caution NN O O
in NN O O
( NN O O
1 NN O O
) NN O O
patients NN O O
with NN O O
known NN O O
cardiovascular NN O O
disease NN O O
( NN O O
history NN O O
of NN O O
myocardial NN O O
infarction NN O O
or NN O O
ischemic NN O O
heart NN O O
disease NN O O
, NN O O
heart NN O O
failure NN O O
or NN O O
conduction NN O O
abnormalities NN O O
) NN O O
, NN O O
cerebrovascular NN O O
disease NN O O
, NN O O
or NN O O
conditions NN O O
which NN O O
would NN O O
predispose NN O O
patients NN O O
to NN O O
hypotension NN O O
( NN O O
dehydration NN O O
, NN O O
hypovolemia NN O O
, NN O O
and NN O O
treatment NN O O
with NN O O
antihypertensive NN O O
medications NN O O
) NN O O
; NN O O
and NN O O
( NN O O
2 NN O O
) NN O O
in NN O O
the NN O O
elderly NN O O
. NN O O
SAPHRIS NN O O
should NN O O
be NN O O
used NN O O
cautiously NN O O
when NN O O
treating NN O O
patients NN O O
who NN O O
receive NN O O
treatment NN O O
with NN O O
other NN O O
drugs NN O O
that NN O O
can NN O O
induce NN O O
hypotension NN O O
, NN O O
bradycardia NN O O
, NN O O
respiratory NN O O
or NN O O
central NN O O
nervous NN O O
system NN O O
depression NN O O
[ NN O O
see NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.1 NN O O
) NN O O
] NN O O
. NN O O
Monitoring NN O O
of NN O O
orthostatic NN O O
vital NN O O
signs NN O O
should NN O O
be NN O O
considered NN O O
in NN O O
all NN O O
such NN O O
patients NN O O
, NN O O
and NN O O
a NN O O
dose NN O O
reduction NN O O
should NN O O
be NN O O
considered NN O O
if NN O O
hypotension NN O O
occurs NN O O
. NN O O
5.8 NN O O
Leukopenia NN O O
, NN O O
Neutropenia NN O O
, NN O O
and NN O O
Agranulocytosis NN O O
In NN O O
clinical NN O O
trial NN O O
and NN O O
postmarketing NN O O
experience NN O O
, NN O O
leukopenia NN B-AdverseReaction B-AdverseReaction
and NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
temporally NN O O
related NN O O
to NN O O
antipsychotic NN O O
agents NN O O
, NN O O
including NN O O
SAPHRIS. NN O O
Agranulocytosis NN B-AdverseReaction B-AdverseReaction
( NN O O
including NN O O
fatal NN B-AdverseReaction B-AdverseReaction
cases NN O O
) NN O O
has NN O O
been NN O O
reported NN O O
with NN O O
other NN B-DrugClass B-DrugClass
agents NN I-DrugClass I-DrugClass
in NN I-DrugClass I-DrugClass
the NN I-DrugClass I-DrugClass
class NN I-DrugClass I-DrugClass
Possible NN O O
risk NN O O
factors NN O O
for NN O O
leukopenia/neutropenia NN O O
include NN O O
pre NN O O
- NN O O
existing NN O O
low NN O O
white NN O O
blood NN O O
cell NN O O
count NN O O
( NN O O
WBC)/absolute NN O O
neutrophil NN O O
count NN O O
( NN O O
ANC NN O O
) NN O O
and NN O O
history NN O O
of NN O O
drug NN O O
induced NN O O
leukopenia/neutropenia NN O O
. NN O O
In NN O O
patients NN O O
with NN O O
a NN O O
pre NN O O
- NN O O
existing NN O O
low NN O O
WBC/ANC NN O O
or NN O O
drug NN O O
- NN O O
induced NN O O
leukopenia/neutropenia NN O O
, NN O O
perform NN O O
a NN O O
complete NN O O
blood NN O O
count NN O O
( NN O O
CBC NN O O
) NN O O
frequently NN O O
during NN O O
the NN O O
first NN O O
few NN O O
months NN O O
of NN O O
therapy NN O O
. NN O O
In NN O O
such NN O O
patients NN O O
, NN O O
consider NN O O
discontinuation NN O O
of NN O O
SAPHRIS NN O O
at NN O O
the NN O O
first NN O O
sign NN O O
of NN O O
a NN O O
clinically NN O O
significant NN O O
decline NN O O
in NN O O
WBC NN O O
in NN O O
the NN O O
absence NN O O
of NN O O
other NN O O
causative NN O O
factors NN O O
. NN O O
Monitor NN O O
patients NN O O
with NN O O
clinically NN O O
significant NN O O
neutropenia NN O O
for NN O O
fever NN O O
or NN O O
other NN O O
symptoms NN O O
or NN O O
signs NN O O
of NN O O
infection NN O O
and NN O O
treat NN O O
promptly NN O O
if NN O O
such NN O O
symptoms NN O O
or NN O O
signs NN O O
occur NN O O
. NN O O
Discontinue NN O O
SAPHRIS NN O O
in NN O O
patients NN O O
with NN O O
severe NN O O
neutropenia NN O O
( NN O O
absolute NN O O
neutrophil NN O O
count NN O O
< NN O O
1000/mm NN O O
3 NN O O
) NN O O
and NN O O
follow NN O O
their NN O O
WBC NN O O
until NN O O
recovery NN O O
. NN O O
5.9 NN O O
QT NN O O
Prolongation NN O O
The NN O O
effects NN O O
of NN O O
SAPHRIS NN O O
on NN O O
the NN O O
QT/QTc NN O O
interval NN O O
were NN O O
evaluated NN O O
in NN O O
a NN O O
dedicated NN O O
adult NN O O
QT NN O O
study NN O O
. NN O O
This NN O O
trial NN O O
involved NN O O
SAPHRIS NN O O
doses NN O O
of NN O O
5 NN O O
mg NN O O
, NN O O
10 NN O O
mg NN O O
, NN O O
15 NN O O
mg NN O O
, NN O O
and NN O O
20 NN O O
mg NN O O
twice NN O O
daily NN O O
, NN O O
and NN O O
placebo NN O O
, NN O O
and NN O O
was NN O O
conducted NN O O
in NN O O
151 NN O O
clinically NN O O
stable NN O O
patients NN O O
with NN O O
schizophrenia NN O O
, NN O O
with NN O O
electrocardiographic NN O O
assessments NN O O
throughout NN O O
the NN O O
dosing NN O O
interval NN O O
at NN O O
baseline NN O O
and NN O O
steady NN O O
state NN O O
. NN O O
At NN O O
these NN O O
doses NN O O
, NN O O
SAPHRIS NN O O
was NN O O
associated NN O O
with NN O O
increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
QTc NN I-AdverseReaction I-AdverseReaction
interval NN I-AdverseReaction I-AdverseReaction
ranging NN O O
from NN O O
2 NN B-Severity B-Severity
to NN I-Severity I-Severity
5 NN I-Severity I-Severity
msec NN I-Severity I-Severity
compared NN O O
to NN O O
placebo NN O O
. NN O O
No NN B-Negation B-Negation
patients NN O O
treated NN O O
with NN O O
SAPHRIS NN O O
experienced NN O O
QTc NN B-AdverseReaction B-AdverseReaction
increases NN I-AdverseReaction I-AdverseReaction
>=60 NN O O
msec NN O O
from NN O O
baseline NN O O
measurements NN O O
, NN O O
nor NN B-Negation B-Negation
did NN O O
any NN O O
patient NN O O
experience NN O O
a NN O O
QTc NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
>=500 NN I-AdverseReaction I-AdverseReaction
msec NN I-AdverseReaction I-AdverseReaction
Electrocardiogram NN O O
( NN O O
ECG NN O O
) NN O O
measurements NN O O
were NN O O
taken NN O O
at NN O O
various NN O O
time NN O O
points NN O O
during NN O O
the NN O O
SAPHRIS NN O O
clinical NN O O
trial NN O O
program NN O O
( NN O O
5 NN O O
mg NN O O
or NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
doses NN O O
) NN O O
. NN O O
Post NN O O
- NN O O
baseline NN O O
QT NN B-AdverseReaction B-AdverseReaction
prolongations NN I-AdverseReaction I-AdverseReaction
exceeding NN O O
500 NN B-Severity B-Severity
msec NN I-Severity I-Severity
were NN O O
reported NN O O
at NN O O
comparable NN O O
rates NN O O
for NN O O
SAPHRIS NN O O
and NN O O
placebo NN O O
in NN O O
these NN O O
short NN O O
- NN O O
term NN O O
trials NN O O
. NN O O
There NN O O
were NN O O
no NN B-Negation B-Negation
reports NN O O
of NN O O
Torsade NN B-AdverseReaction B-AdverseReaction
de NN I-AdverseReaction I-AdverseReaction
Pointes NN I-AdverseReaction I-AdverseReaction
or NN O O
any NN O O
other NN O O
adverse NN O O
reactions NN O O
associated NN O O
with NN O O
delayed NN B-AdverseReaction B-AdverseReaction
ventricular NN I-AdverseReaction I-AdverseReaction
repolarization NN I-AdverseReaction I-AdverseReaction
The NN O O
use NN O O
of NN O O
SAPHRIS NN O O
should NN O O
be NN O O
avoided NN O O
in NN O O
combination NN O O
with NN O O
other NN O O
drugs NN O O
known NN O O
to NN O O
prolong NN O O
QTc NN O O
including NN O O
Class NN O O
1A NN O O
antiarrhythmics NN O O
( NN O O
e.g. NN O O
, NN O O
quinidine NN O O
, NN O O
procainamide NN O O
) NN O O
or NN O O
Class NN O O
3 NN O O
antiarrhythmics NN O O
( NN O O
e.g. NN O O
, NN O O
amiodarone NN O O
, NN O O
sotalol NN O O
) NN O O
, NN O O
antipsychotic NN O O
medications NN O O
( NN O O
e.g. NN O O
, NN O O
ziprasidone NN O O
, NN O O
chlorpromazine NN O O
, NN O O
thioridazine NN O O
) NN O O
, NN O O
and NN O O
antibiotics NN O O
( NN O O
e.g. NN O O
, NN O O
gatifloxacin NN O O
, NN O O
moxifloxacin NN O O
) NN O O
. NN O O
SAPHRIS NN O O
should NN O O
also NN O O
be NN O O
avoided NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
cardiac NN O O
arrhythmias NN O O
and NN O O
in NN O O
other NN O O
circumstances NN O O
that NN O O
may NN O O
increase NN O O
the NN O O
risk NN O O
of NN O O
the NN O O
occurrence NN O O
of NN O O
torsade NN O O
de NN O O
pointes NN O O
and/or NN O O
sudden NN O O
death NN O O
in NN O O
association NN O O
with NN O O
the NN O O
use NN O O
of NN O O
drugs NN O O
that NN O O
prolong NN O O
the NN O O
QTc NN O O
interval NN O O
, NN O O
including NN O O
bradycardia NN O O
; NN O O
hypokalemia NN O O
or NN O O
hypomagnesemia NN O O
; NN O O
and NN O O
presence NN O O
of NN O O
congenital NN O O
prolongation NN O O
of NN O O
the NN O O
QT NN O O
interval NN O O
. NN O O
5.10 NN O O
Hyperprolactinemia NN O O
Like NN O O
other NN O O
drugs NN O O
that NN O O
antagonize NN O O
dopamine NN O O
D2receptors NN O O
, NN O O
SAPHRIS NN O O
can NN B-Factor B-Factor
elevate NN B-AdverseReaction B-AdverseReaction
prolactin NN I-AdverseReaction I-AdverseReaction
levels NN I-AdverseReaction I-AdverseReaction
and NN O O
the NN O O
elevation NN O O
can NN O O
persist NN O O
during NN O O
chronic NN O O
administration NN O O
. NN O O
Hyperprolactinemia NN B-AdverseReaction B-AdverseReaction
may NN B-Factor B-Factor
suppress NN B-AdverseReaction B-AdverseReaction
hypothalamic NN I-AdverseReaction I-AdverseReaction
GnRH NN I-AdverseReaction I-AdverseReaction
resulting NN O O
in NN O O
reduced NN B-AdverseReaction B-AdverseReaction
pituitary NN I-AdverseReaction I-AdverseReaction
gonadotropin NN I-AdverseReaction I-AdverseReaction
secretion NN I-AdverseReaction I-AdverseReaction
This NN O O
, NN O O
in NN O O
turn NN O O
, NN O O
may NN B-Factor B-Factor
inhibit NN B-AdverseReaction B-AdverseReaction
reproductive NN I-AdverseReaction I-AdverseReaction
function NN I-AdverseReaction I-AdverseReaction
by NN O O
impairing NN B-AdverseReaction B-AdverseReaction
gonadal NN I-AdverseReaction I-AdverseReaction
steroidogenesis NN I-AdverseReaction I-AdverseReaction
in NN O O
both NN O O
female NN O O
and NN O O
male NN O O
patients NN O O
. NN O O
Galactorrhea NN B-AdverseReaction B-AdverseReaction
amenorrhea NN B-AdverseReaction B-AdverseReaction
gynecomastia NN B-AdverseReaction B-AdverseReaction
and NN O O
impotence NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
receiving NN O O
prolactin NN B-DrugClass B-DrugClass
- NN I-DrugClass I-DrugClass
elevating NN I-DrugClass I-DrugClass
compounds NN I-DrugClass I-DrugClass
Long NN O O
- NN O O
standing NN O O
hyperprolactinemia NN B-AdverseReaction B-AdverseReaction
when NN O O
associated NN O O
with NN O O
hypogonadism NN B-AdverseReaction B-AdverseReaction
may NN B-Factor B-Factor
lead NN O O
to NN O O
decreased NN B-AdverseReaction B-AdverseReaction
bone NN I-AdverseReaction I-AdverseReaction
density NN I-AdverseReaction I-AdverseReaction
in NN O O
both NN O O
female NN O O
and NN O O
male NN O O
subjects NN O O
. NN O O
In NN O O
SAPHRIS NN O O
adult NN O O
clinical NN O O
trials NN O O
, NN O O
the NN O O
incidences NN O O
of NN O O
adverse NN O O
events NN O O
related NN O O
to NN O O
abnormal NN B-AdverseReaction B-AdverseReaction
prolactin NN I-AdverseReaction I-AdverseReaction
levels NN I-AdverseReaction I-AdverseReaction
were NN O O
0.4 NN O O
% NN O O
versus NN O O
0 NN O O
% NN O O
for NN O O
placebo NN O O
. NN O O
In NN O O
a NN O O
3-week NN O O
, NN O O
bipolar NN O O
mania NN O O
pediatric NN O O
trial NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
adverse NN O O
events NN O O
related NN O O
to NN O O
abnormal NN B-AdverseReaction B-AdverseReaction
prolactin NN I-AdverseReaction I-AdverseReaction
levels NN I-AdverseReaction I-AdverseReaction
were NN O O
0 NN O O
% NN O O
in NN O O
the NN O O
SAPHRIS NN O O
2.5 NN O O
mg NN O O
twice NN O O
daily NN O O
treatment NN O O
group NN O O
, NN O O
2 NN O O
% NN O O
in NN O O
the NN O O
SAPHRIS NN O O
5 NN O O
mg NN O O
twice NN O O
daily NN O O
treatment NN O O
group NN O O
, NN O O
and NN O O
1 NN O O
% NN O O
in NN O O
the NN O O
SAPHRIS NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
treatment NN O O
group NN O O
versus NN O O
to NN O O
1 NN O O
% NN O O
for NN O O
patients NN O O
treated NN O O
with NN O O
placebo NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Tissue NN O O
culture NN O O
experiments NN O O
indicate NN O O
that NN O O
approximately NN O O
one NN O O
- NN O O
third NN O O
of NN O O
human NN O O
breast NN O O
cancers NN O O
are NN O O
prolactin NN O O
- NN O O
dependent NN O O
in NN O O
vitro NN O O
, NN O O
a NN O O
factor NN O O
of NN O O
potential NN O O
importance NN O O
if NN O O
the NN O O
prescription NN O O
of NN O O
these NN O O
drugs NN O O
is NN O O
considered NN O O
in NN O O
a NN O O
patient NN O O
with NN O O
previously NN O O
- NN O O
detected NN O O
breast NN O O
cancer NN O O
. NN O O
Neither NN O O
clinical NN O O
studies NN O O
nor NN O O
epidemiologic NN O O
studies NN O O
conducted NN O O
to NN O O
date NN O O
have NN O O
shown NN O O
an NN O O
association NN O O
between NN O O
chronic NN O O
administration NN O O
of NN O O
this NN O O
class NN O O
of NN O O
drugs NN O O
and NN O O
tumorigenesis NN B-AdverseReaction B-AdverseReaction
in NN O O
humans NN O O
, NN O O
but NN O O
the NN O O
available NN O O
evidence NN O O
is NN O O
too NN O O
limited NN O O
to NN O O
be NN O O
conclusive NN O O
. NN O O
5.11 NN O O
Seizures NN O O
Seizures NN B-AdverseReaction B-AdverseReaction
were NN O O
reported NN O O
in NN O O
0 NN O O
% NN O O
and NN O O
0.3 NN O O
% NN O O
( NN O O
0/572 NN O O
, NN O O
1/379 NN O O
) NN O O
of NN O O
adult NN O O
patients NN O O
treated NN O O
with NN O O
doses NN O O
of NN O O
5 NN O O
mg NN O O
and NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
of NN O O
SAPHRIS NN O O
, NN O O
respectively NN O O
, NN O O
compared NN O O
to NN O O
0 NN O O
% NN O O
( NN O O
0/503 NN O O
, NN O O
0/203 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
placebo NN O O
in NN O O
short NN O O
- NN O O
term NN O O
schizophrenia NN O O
and NN O O
bipolar NN O O
mania NN O O
trials NN O O
, NN O O
respectively NN O O
. NN O O
During NN O O
adult NN O O
pre NN O O
- NN O O
marketing NN O O
clinical NN O O
trials NN O O
with NN O O
SAPHRIS NN O O
, NN O O
including NN O O
long NN O O
- NN O O
term NN O O
trials NN O O
without NN O O
comparison NN O O
to NN O O
placebo NN O O
, NN O O
seizures NN B-AdverseReaction B-AdverseReaction
were NN O O
reported NN O O
in NN O O
0.3 NN O O
% NN O O
( NN O O
5/1953 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
SAPHRIS. NN O O
There NN O O
were NN O O
no NN B-Negation B-Negation
reports NN O O
of NN O O
seizures NN B-AdverseReaction B-AdverseReaction
in NN O O
pediatric NN O O
patients NN O O
treated NN O O
with NN O O
SAPHRIS NN O O
in NN O O
a NN O O
3-week NN O O
- NN O O
term NN O O
, NN O O
bipolar NN O O
mania NN O O
trial NN O O
. NN O O
As NN O O
with NN O O
other NN O O
antipsychotic NN O O
drugs NN O O
, NN O O
SAPHRIS NN O O
should NN O O
be NN O O
used NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
seizures NN O O
or NN O O
with NN O O
conditions NN O O
that NN O O
potentially NN O O
lower NN O O
the NN O O
seizure NN O O
threshold NN O O
. NN O O
Conditions NN O O
that NN O O
lower NN O O
the NN O O
seizure NN O O
threshold NN O O
may NN O O
be NN O O
more NN O O
prevalent NN O O
in NN O O
patients NN O O
65 NN O O
years NN O O
or NN O O
older NN O O
. NN O O
5.12 NN O O
Potential NN O O
for NN O O
Cognitive NN O O
and NN O O
Motor NN O O
Impairment NN O O
Somnolence NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
SAPHRIS. NN O O
It NN O O
was NN O O
usually NN O O
transient NN O O
with NN O O
the NN O O
highest NN O O
incidence NN O O
reported NN O O
during NN O O
the NN O O
first NN O O
week NN O O
of NN O O
treatment NN O O
. NN O O
In NN O O
short NN O O
- NN O O
term NN O O
, NN O O
fixed NN O O
- NN O O
dose NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
schizophrenia NN O O
adult NN O O
trials NN O O
, NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
15 NN O O
% NN O O
( NN O O
41/274 NN O O
) NN O O
of NN O O
patients NN O O
on NN O O
SAPHRIS NN O O
5 NN O O
mg NN O O
twice NN O O
daily NN O O
and NN O O
in NN O O
13 NN O O
% NN O O
( NN O O
26/208 NN O O
) NN O O
of NN O O
patients NN O O
on NN O O
SAPHRIS NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
compared NN O O
to NN O O
7 NN O O
% NN O O
( NN O O
26/378 NN O O
) NN O O
of NN O O
placebo NN O O
patients NN O O
. NN O O
In NN O O
short NN O O
- NN O O
term NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
bipolar NN O O
mania NN O O
adult NN O O
trials NN O O
of NN O O
therapeutic NN O O
doses NN O O
( NN O O
5 NN O O
- NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
) NN O O
, NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
24 NN O O
% NN O O
( NN O O
90/379 NN O O
) NN O O
of NN O O
patients NN O O
on NN O O
SAPHRIS NN O O
compared NN O O
to NN O O
6 NN O O
% NN O O
( NN O O
13/203 NN O O
) NN O O
of NN O O
placebo NN O O
patients NN O O
. NN O O
During NN O O
adult NN O O
pre NN O O
- NN O O
marketing NN O O
clinical NN O O
trials NN O O
with NN O O
SAPHRIS NN O O
, NN O O
including NN O O
long NN O O
- NN O O
term NN O O
trials NN O O
without NN O O
comparison NN O O
to NN O O
placebo NN O O
, NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
18 NN O O
% NN O O
( NN O O
358/1953 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
SAPHRIS. NN O O
Somnolence NN B-AdverseReaction B-AdverseReaction
( NN O O
including NN O O
sedation NN B-AdverseReaction B-AdverseReaction
led NN O O
to NN O O
discontinuation NN O O
in NN O O
0.6 NN O O
% NN O O
( NN O O
12/1953 NN O O
) NN O O
of NN O O
patients NN O O
in NN O O
short NN O O
- NN O O
term NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
. NN O O
In NN O O
a NN O O
3-week NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
, NN O O
bipolar NN O O
I NN O O
pediatric NN O O
trial NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
( NN O O
including NN O O
sedation NN B-AdverseReaction B-AdverseReaction
and NN O O
hypersomnia NN B-AdverseReaction B-AdverseReaction
for NN O O
placebo NN O O
, NN O O
SAPHRIS NN O O
2.5 NN O O
mg NN O O
twice NN O O
daily NN O O
, NN O O
5 NN O O
mg NN O O
twice NN O O
daily NN O O
, NN O O
and NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
, NN O O
was NN O O
12 NN O O
% NN O O
( NN O O
12/101 NN O O
) NN O O
, NN O O
46 NN O O
% NN O O
( NN O O
48/104 NN O O
) NN O O
, NN O O
53 NN O O
% NN O O
( NN O O
52/99 NN O O
) NN O O
, NN O O
and NN O O
49 NN O O
% NN O O
( NN O O
49/99 NN O O
) NN O O
, NN O O
respectively NN O O
. NN O O
Somnolence NN B-AdverseReaction B-AdverseReaction
led NN O O
to NN O O
discontinuation NN O O
in NN O O
0 NN O O
% NN O O
, NN O O
3 NN O O
% NN O O
, NN O O
1 NN O O
% NN O O
, NN O O
and NN O O
2 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
placebo NN O O
, NN O O
and NN O O
SAPHRIS NN O O
2.5 NN O O
mg NN O O
twice NN O O
daily NN O O
, NN O O
5 NN O O
mg NN O O
twice NN O O
daily NN O O
, NN O O
and NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
, NN O O
respectively NN O O
. NN O O
Patients NN O O
should NN O O
be NN O O
cautioned NN O O
about NN O O
performing NN O O
activities NN O O
requiring NN O O
mental NN O O
alertness NN O O
, NN O O
such NN O O
as NN O O
operating NN O O
hazardous NN O O
machinery NN O O
or NN O O
operating NN O O
a NN O O
motor NN O O
vehicle NN O O
, NN O O
until NN O O
they NN O O
are NN O O
reasonably NN O O
certain NN O O
that NN O O
SAPHRIS NN O O
therapy NN O O
does NN O O
not NN O O
affect NN O O
them NN O O
adversely NN O O
. NN O O
5.13 NN O O
Body NN O O
Temperature NN O O
Regulation NN O O
Disruption NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
body NN I-AdverseReaction I-AdverseReaction
's NN I-AdverseReaction I-AdverseReaction
ability NN I-AdverseReaction I-AdverseReaction
to NN I-AdverseReaction I-AdverseReaction
reduce NN I-AdverseReaction I-AdverseReaction
core NN I-AdverseReaction I-AdverseReaction
body NN I-AdverseReaction I-AdverseReaction
temperature NN I-AdverseReaction I-AdverseReaction
has NN O O
been NN O O
attributed NN O O
to NN O O
antipsychotic NN B-DrugClass B-DrugClass
agents NN I-DrugClass I-DrugClass
In NN O O
the NN O O
short NN O O
- NN O O
term NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
for NN O O
both NN O O
schizophrenia NN O O
and NN O O
acute NN O O
bipolar NN O O
disorder NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
adverse NN O O
reactions NN O O
suggestive NN O O
of NN O O
body NN B-AdverseReaction B-AdverseReaction
temperature NN I-AdverseReaction I-AdverseReaction
increases NN I-AdverseReaction I-AdverseReaction
was NN O O
low NN O O
( NN O O
< NN O O
=1 NN O O
% NN O O
) NN O O
and NN O O
comparable NN O O
to NN O O
placebo NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
. NN O O
During NN O O
clinical NN O O
trials NN O O
with NN O O
SAPHRIS NN O O
, NN O O
including NN O O
long NN O O
- NN O O
term NN O O
trials NN O O
without NN O O
comparison NN O O
to NN O O
placebo NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
adverse NN O O
reactions NN O O
suggestive NN O O
of NN O O
body NN B-AdverseReaction B-AdverseReaction
temperature NN I-AdverseReaction I-AdverseReaction
increases NN I-AdverseReaction I-AdverseReaction
( NN O O
pyrexia NN O O
and NN O O
feeling NN B-AdverseReaction B-AdverseReaction
hot NN I-AdverseReaction I-AdverseReaction
was NN O O
< NN O O
=1 NN O O
% NN O O
. NN O O
Appropriate NN O O
care NN O O
is NN O O
advised NN O O
when NN O O
prescribing NN O O
SAPHRIS NN O O
for NN O O
patients NN O O
who NN O O
will NN O O
be NN O O
experiencing NN O O
conditions NN O O
that NN O O
may NN O O
contribute NN O O
to NN O O
an NN O O
elevation NN O O
in NN O O
core NN O O
body NN O O
temperature NN O O
, NN O O
e.g. NN O O
, NN O O
exercising NN O O
strenuously NN O O
, NN O O
exposure NN O O
to NN O O
extreme NN O O
heat NN O O
, NN O O
receiving NN O O
concomitant NN O O
medication NN O O
with NN O O
anticholinergic NN O O
activity NN O O
, NN O O
or NN O O
being NN O O
subject NN O O
to NN O O
dehydration NN O O
. NN O O
5.14 NN O O
Suicide NN O O
The NN O O
possibility NN O O
of NN O O
a NN O O
suicide NN O O
attempt NN O O
is NN O O
inherent NN O O
in NN O O
psychotic NN O O
illnesses NN O O
and NN O O
bipolar NN O O
disorder NN O O
, NN O O
and NN O O
close NN O O
supervision NN O O
of NN O O
high NN O O
- NN O O
risk NN O O
patients NN O O
should NN O O
accompany NN O O
drug NN O O
therapy NN O O
. NN O O
Prescriptions NN O O
for NN O O
SAPHRIS NN O O
should NN O O
be NN O O
written NN O O
for NN O O
the NN O O
smallest NN O O
quantity NN O O
of NN O O
tablets NN O O
consistent NN O O
with NN O O
good NN O O
patient NN O O
management NN O O
in NN O O
order NN O O
to NN O O
reduce NN O O
the NN O O
risk NN O O
of NN O O
overdose NN O O
. NN O O
5.15 NN O O
Dysphagia NN O O
Esophageal NN B-AdverseReaction B-AdverseReaction
dysmotility NN I-AdverseReaction I-AdverseReaction
and NN O O
aspiration NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
associated NN O O
with NN O O
antipsychotic NN B-DrugClass B-DrugClass
drug NN I-DrugClass I-DrugClass
use NN O O
. NN O O
Dysphagia NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
0.2 NN O O
% NN O O
and NN O O
0 NN O O
% NN O O
( NN O O
1/572 NN O O
, NN O O
0/379 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
therapeutic NN O O
doses NN O O
( NN O O
5 NN O O
- NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
) NN O O
of NN O O
SAPHRIS NN O O
as NN O O
compared NN O O
to NN O O
0 NN O O
% NN O O
( NN O O
0/378 NN O O
, NN O O
0/203 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
placebo NN O O
in NN O O
short NN O O
- NN O O
term NN O O
schizophrenia NN O O
and NN O O
bipolar NN O O
mania NN O O
adult NN O O
trials NN O O
, NN O O
respectively NN O O
. NN O O
During NN O O
adult NN O O
pre NN O O
- NN O O
marketing NN O O
clinical NN O O
trials NN O O
with NN O O
SAPHRIS NN O O
, NN O O
including NN O O
long NN O O
- NN O O
term NN O O
trials NN O O
without NN O O
comparison NN O O
to NN O O
placebo NN O O
, NN O O
dysphagia NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
0.1 NN O O
% NN O O
( NN O O
2/1953 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
SAPHRIS. NN O O
Aspiration NN O O
pneumonia NN O O
is NN O O
a NN O O
common NN O O
cause NN O O
of NN O O
morbidity NN O O
and NN O O
mortality NN O O
in NN O O
elderly NN O O
patients NN O O
, NN O O
in NN O O
particular NN O O
those NN O O
with NN O O
advanced NN O O
Alzheimer NN O O
's NN O O
dementia NN O O
. NN O O
SAPHRIS NN O O
is NN O O
not NN O O
indicated NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
dementia NN O O
- NN O O
related NN O O
psychosis NN O O
, NN O O
and NN O O
should NN O O
not NN O O
be NN O O
used NN O O
in NN O O
patients NN O O
at NN O O
risk NN O O
for NN O O
aspiration NN O O
pneumonia NN O O
[ NN O O
see NN O O
also NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
5.16 NN O O
Use NN O O
in NN O O
Patients NN O O
with NN O O
Concomitant NN O O
Illness NN O O
Clinical NN O O
experience NN O O
with NN O O
SAPHRIS NN O O
in NN O O
patients NN O O
with NN O O
certain NN O O
concomitant NN O O
systemic NN O O
illnesses NN O O
is NN O O
limited NN O O
[ NN O O
see NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.3 NN O O
) NN O O
] NN O O
. NN O O
SAPHRIS NN O O
has NN O O
not NN O O
been NN O O
evaluated NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
recent NN O O
history NN O O
of NN O O
myocardial NN O O
infarction NN O O
or NN O O
unstable NN O O
heart NN O O
disease NN O O
. NN O O
Patients NN O O
with NN O O
these NN O O
diagnoses NN O O
were NN O O
excluded NN O O
from NN O O
pre NN O O
- NN O O
marketing NN O O
clinical NN O O
trials NN O O
. NN O O
Because NN O O
of NN O O
the NN O O
risk NN O O
of NN O O
orthostatic NN O O
hypotension NN O O
with NN O O
SAPHRIS NN O O
, NN O O
caution NN O O
should NN O O
be NN O O
observed NN O O
in NN O O
cardiac NN O O
patients NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.7 NN O O
) NN O O
] NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
EXCERPT NN O O
: NN O O
Adverse NN O O
reactions NN O O
occurring NN O O
in NN O O
at NN O O
least NN O O
1 NN O O
% NN O O
of NN O O
ULORIC NN O O
- NN O O
treated NN O O
patients NN O O
, NN O O
and NN O O
at NN O O
least NN O O
0.5 NN O O
% NN O O
greater NN O O
than NN O O
placebo NN O O
, NN O O
are NN O O
liver NN B-AdverseReaction B-AdverseReaction
function NN I-AdverseReaction I-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
arthralgia NN B-AdverseReaction B-AdverseReaction
and NN O O
rash NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Takeda NN O O
Pharmaceuticals NN O O
at NN O O
1 NN O O
- NN O O
877-TAKEDA-7 NN O O
( NN O O
1 NN O O
- NN O O
877 NN O O
- NN O O
825 NN O O
- NN O O
3327 NN O O
) NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
A NN O O
total NN O O
of NN O O
2757 NN O O
subjects NN O O
with NN O O
hyperuricemia NN O O
and NN O O
gout NN O O
were NN O O
treated NN O O
with NN O O
ULORIC NN O O
40 NN O O
mg NN O O
or NN O O
80 NN O O
mg NN O O
daily NN O O
in NN O O
clinical NN O O
studies NN O O
. NN O O
For NN O O
ULORIC NN O O
40 NN O O
mg NN O O
, NN O O
559 NN O O
patients NN O O
were NN O O
treated NN O O
for NN O O
>=6 NN O O
months NN O O
. NN O O
For NN O O
ULORIC NN O O
80 NN O O
mg NN O O
, NN O O
1377 NN O O
subjects NN O O
were NN O O
treated NN O O
for NN O O
>=6 NN O O
months NN O O
, NN O O
674 NN O O
patients NN O O
were NN O O
treated NN O O
for NN O O
>=1 NN O O
year NN O O
and NN O O
515 NN O O
patients NN O O
were NN O O
treated NN O O
for NN O O
>=2 NN O O
years NN O O
. NN O O
Most NN O O
Common NN O O
Adverse NN O O
Reactions NN O O
In NN O O
three NN O O
randomized NN O O
, NN O O
controlled NN O O
clinical NN O O
studies NN O O
( NN O O
Studies NN O O
1 NN O O
, NN O O
2 NN O O
and NN O O
3 NN O O
) NN O O
, NN O O
which NN O O
were NN O O
six NN O O
to NN O O
12 NN O O
months NN O O
in NN O O
duration NN O O
, NN O O
the NN O O
following NN O O
adverse NN O O
reactions NN O O
were NN O O
reported NN O O
by NN O O
the NN O O
treating NN O O
physician NN O O
as NN O O
related NN O O
to NN O O
study NN O O
drug NN O O
. NN O O
Table NN O O
1 NN O O
summarizes NN O O
adverse NN O O
reactions NN O O
reported NN O O
at NN O O
a NN O O
rate NN O O
of NN O O
at NN O O
least NN O O
1 NN O O
% NN O O
in NN O O
ULORIC NN O O
treatment NN O O
groups NN O O
and NN O O
at NN O O
least NN O O
0.5 NN O O
% NN O O
greater NN O O
than NN O O
placebo NN O O
. NN O O
Table NN O O
1 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Occurring NN O O
in NN O O
>=1 NN O O
% NN O O
of NN O O
ULORIC NN O O
- NN O O
Treated NN O O
Patients NN O O
and NN O O
at NN O O
Least NN O O
0.5%Greater NN O O
than NN O O
Seen NN O O
in NN O O
Patients NN O O
Receiving NN O O
Placebo NN O O
in NN O O
Controlled NN O O
Studies NN O O
Adverse NN O O
Reactions NN O O
Placebo NN O O
ULORIC NN O O
allopurinolOf NN O O
the NN O O
subjects NN O O
who NN O O
received NN O O
allopurinol NN O O
, NN O O
10 NN O O
received NN O O
100 NN O O
mg NN O O
, NN O O
145 NN O O
received NN O O
200 NN O O
mg NN O O
, NN O O
and NN O O
1122 NN O O
received NN O O
300 NN O O
mg NN O O
, NN O O
based NN O O
on NN O O
level NN O O
of NN O O
renal NN O O
impairment NN O O
. NN O O
( NN O O
N=134 NN O O
) NN O O
40 NN O O
mg NN O O
daily(N=757 NN O O
) NN O O
80 NN O O
mg NN O O
daily(N=1279 NN O O
) NN O O
( NN O O
N=1277 NN O O
) NN O O
Liver NN B-AdverseReaction B-AdverseReaction
Function NN I-AdverseReaction I-AdverseReaction
Abnormalities NN I-AdverseReaction I-AdverseReaction
0.7 NN O O
% NN O O
6.6 NN O O
% NN O O
4.6 NN O O
% NN O O
4.2 NN O O
% NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
0.7 NN O O
% NN O O
1.1 NN O O
% NN O O
1.3 NN O O
% NN O O
0.8 NN O O
% NN O O
Arthralgia NN B-AdverseReaction B-AdverseReaction
0 NN O O
% NN O O
1.1 NN O O
% NN O O
0.7 NN O O
% NN O O
0.7 NN O O
% NN O O
Rash NN B-AdverseReaction B-AdverseReaction
0.7 NN O O
% NN O O
0.5 NN O O
% NN O O
1.6 NN O O
% NN O O
1.6 NN O O
% NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reaction NN O O
leading NN O O
to NN O O
discontinuation NN O O
from NN O O
therapy NN O O
was NN O O
liver NN B-AdverseReaction B-AdverseReaction
function NN I-AdverseReaction I-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
in NN O O
1.8 NN O O
% NN O O
of NN O O
ULORIC NN O O
40 NN O O
mg NN O O
, NN O O
1.2 NN O O
% NN O O
of NN O O
ULORIC NN O O
80 NN O O
mg NN O O
, NN O O
and NN O O
in NN O O
0.9 NN O O
% NN O O
of NN O O
allopurinol NN O O
- NN O O
treated NN O O
subjects NN O O
. NN O O
In NN O O
addition NN O O
to NN O O
the NN O O
adverse NN O O
reactions NN O O
presented NN O O
in NN O O
Table NN O O
1 NN O O
, NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
more NN O O
than NN O O
1 NN O O
% NN O O
of NN O O
ULORIC NN O O
- NN O O
treated NN O O
subjects NN O O
although NN O O
not NN O O
at NN O O
a NN O O
rate NN O O
more NN O O
than NN O O
0.5 NN O O
% NN O O
greater NN O O
than NN O O
placebo NN O O
. NN O O
Less NN O O
Common NN O O
Adverse NN O O
Reactions NN O O
In NN O O
Phase NN O O
2 NN O O
and NN O O
3 NN O O
clinical NN O O
studies NN O O
the NN O O
following NN O O
adverse NN O O
reactions NN O O
occurred NN O O
in NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
of NN O O
subjects NN O O
and NN O O
in NN O O
more NN O O
than NN O O
one NN O O
subject NN O O
treated NN O O
with NN O O
doses NN O O
ranging NN O O
from NN O O
40 NN O O
mg NN O O
to NN O O
240 NN O O
mg NN O O
of NN O O
ULORIC. NN O O
This NN O O
list NN O O
also NN O O
includes NN O O
adverse NN O O
reactions NN O O
( NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
of NN O O
subjects NN O O
) NN O O
associated NN O O
with NN O O
organ NN O O
systems NN O O
from NN O O
Warnings NN O O
and NN O O
Precautions NN O O
. NN O O
Blood NN O O
and NN O O
Lymphatic NN O O
System NN O O
Disorders NN O O
: NN O O
anemia NN B-AdverseReaction B-AdverseReaction
idiopathic NN B-AdverseReaction B-AdverseReaction
thrombocytopenic NN I-AdverseReaction I-AdverseReaction
purpura NN I-AdverseReaction I-AdverseReaction
leukocytosis NN B-AdverseReaction B-AdverseReaction
neutropenia NN B-AdverseReaction B-AdverseReaction
pancytopenia NN B-AdverseReaction B-AdverseReaction
splenomegaly NN B-AdverseReaction B-AdverseReaction
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
Cardiac NN O O
Disorders NN O O
: NN O O
angina NN B-AdverseReaction B-AdverseReaction
pectoris NN I-AdverseReaction I-AdverseReaction
atrial NN B-AdverseReaction B-AdverseReaction
fibrillation NN I-AdverseReaction I-AdverseReaction
cardiac NN B-AdverseReaction B-AdverseReaction
murmur NN I-AdverseReaction I-AdverseReaction
ECG NN B-AdverseReaction B-AdverseReaction
abnormal NN I-AdverseReaction I-AdverseReaction
palpitations NN B-AdverseReaction B-AdverseReaction
sinus NN B-AdverseReaction B-AdverseReaction
bradycardia NN I-AdverseReaction I-AdverseReaction
tachycardia NN B-AdverseReaction B-AdverseReaction
Ear NN O O
and NN O O
Labyrinth NN O O
Disorders NN O O
: NN O O
deafness NN B-AdverseReaction B-AdverseReaction
tinnitus NN B-AdverseReaction B-AdverseReaction
vertigo NN B-AdverseReaction B-AdverseReaction
Eye NN O O
Disorders NN O O
: NN O O
vision NN B-AdverseReaction B-AdverseReaction
blurred NN I-AdverseReaction I-AdverseReaction
Gastrointestinal NN O O
Disorders NN O O
: NN O O
abdominal NN B-AdverseReaction B-AdverseReaction
distention NN I-AdverseReaction I-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
constipation NN B-AdverseReaction B-AdverseReaction
dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
dyspepsia NN B-AdverseReaction B-AdverseReaction
flatulence NN B-AdverseReaction B-AdverseReaction
frequent NN B-AdverseReaction B-AdverseReaction
stools NN I-AdverseReaction I-AdverseReaction
gastritis NN B-AdverseReaction B-AdverseReaction
gastroesophageal NN B-AdverseReaction B-AdverseReaction
reflux NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
gastrointestinal NN B-AdverseReaction B-AdverseReaction
discomfort NN I-AdverseReaction I-AdverseReaction
gingival NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
haematemesis NN B-AdverseReaction B-AdverseReaction
hyperchlorhydria NN B-AdverseReaction B-AdverseReaction
hematochezia NN B-AdverseReaction B-AdverseReaction
mouth NN B-AdverseReaction B-AdverseReaction
ulceration NN I-AdverseReaction I-AdverseReaction
pancreatitis NN B-AdverseReaction B-AdverseReaction
peptic NN B-AdverseReaction B-AdverseReaction
ulcer NN I-AdverseReaction I-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
General NN O O
Disorders NN O O
and NN O O
Administration NN O O
Site NN O O
Conditions NN O O
: NN O O
asthenia NN B-AdverseReaction B-AdverseReaction
chest NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
edema NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
feeling NN B-AdverseReaction B-AdverseReaction
abnormal NN I-AdverseReaction I-AdverseReaction
gait NN B-AdverseReaction B-AdverseReaction
disturbance NN I-AdverseReaction I-AdverseReaction
influenza NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
like NN I-AdverseReaction I-AdverseReaction
symptoms NN I-AdverseReaction I-AdverseReaction
mass NN B-AdverseReaction B-AdverseReaction
pain NN B-AdverseReaction B-AdverseReaction
thirst NN B-AdverseReaction B-AdverseReaction
Hepatobiliary NN O O
Disorders NN O O
: NN O O
cholelithiasis NN B-AdverseReaction B-AdverseReaction
hepatic NN B-AdverseReaction B-AdverseReaction
steatosis NN I-AdverseReaction I-AdverseReaction
hepatitis NN B-AdverseReaction B-AdverseReaction
hepatomegaly NN B-AdverseReaction B-AdverseReaction
Immune NN O O
System NN O O
Disorder NN O O
: NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
Infections NN O O
and NN O O
Infestations NN O O
: NN O O
herpes NN B-AdverseReaction B-AdverseReaction
zoster NN I-AdverseReaction I-AdverseReaction
Procedural NN O O
Complications NN O O
: NN O O
contusion NN B-AdverseReaction B-AdverseReaction
Metabolism NN O O
and NN O O
Nutrition NN O O
Disorders NN O O
: NN O O
anorexia NN B-AdverseReaction B-AdverseReaction
appetite NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
dehydration NN B-AdverseReaction B-AdverseReaction
diabetes NN B-AdverseReaction B-AdverseReaction
mellitus NN I-AdverseReaction I-AdverseReaction
hypercholesterolemia NN B-AdverseReaction B-AdverseReaction
hyperglycemia NN B-AdverseReaction B-AdverseReaction
hyperlipidemia NN B-AdverseReaction B-AdverseReaction
hypertriglyceridemia NN B-AdverseReaction B-AdverseReaction
hypokalemia NN B-AdverseReaction B-AdverseReaction
weight NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
Musculoskeletal NN O O
and NN O O
Connective NN O O
Tissue NN O O
Disorders NN O O
: NN O O
arthritis NN B-AdverseReaction B-AdverseReaction
joint NN B-AdverseReaction B-AdverseReaction
stiffness NN I-AdverseReaction I-AdverseReaction
joint NN B-AdverseReaction B-AdverseReaction
swelling NN I-AdverseReaction I-AdverseReaction
muscle NN B-AdverseReaction B-AdverseReaction
spasms NN I-AdverseReaction I-AdverseReaction
musculoskeletal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
myalgia NN B-AdverseReaction B-AdverseReaction
Nervous NN O O
System NN O O
Disorders NN O O
: NN O O
altered NN B-AdverseReaction B-AdverseReaction
taste NN I-AdverseReaction I-AdverseReaction
balance NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
cerebrovascular NN B-AdverseReaction B-AdverseReaction
accident NN I-AdverseReaction I-AdverseReaction
Guillain NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Barre NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
hemiparesis NN B-AdverseReaction B-AdverseReaction
hypoesthesia NN B-AdverseReaction B-AdverseReaction
hyposmia NN B-AdverseReaction B-AdverseReaction
lacunar NN B-AdverseReaction B-AdverseReaction
infarction NN I-AdverseReaction I-AdverseReaction
lethargy NN B-AdverseReaction B-AdverseReaction
mental NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
migraine NN B-AdverseReaction B-AdverseReaction
paresthesia NN B-AdverseReaction B-AdverseReaction
somnolence NN B-AdverseReaction B-AdverseReaction
transient NN B-AdverseReaction B-AdverseReaction
ischemic NN I-AdverseReaction I-AdverseReaction
attack NN I-AdverseReaction I-AdverseReaction
tremor NN B-AdverseReaction B-AdverseReaction
Psychiatric NN O O
Disorders NN O O
: NN O O
agitation NN B-AdverseReaction B-AdverseReaction
anxiety NN B-AdverseReaction B-AdverseReaction
depression NN B-AdverseReaction B-AdverseReaction
insomnia NN B-AdverseReaction B-AdverseReaction
irritability NN B-AdverseReaction B-AdverseReaction
libido NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
nervousness NN B-AdverseReaction B-AdverseReaction
panic NN B-AdverseReaction B-AdverseReaction
attack NN I-AdverseReaction I-AdverseReaction
personality NN B-AdverseReaction B-AdverseReaction
change NN I-AdverseReaction I-AdverseReaction
Renal NN O O
and NN O O
Urinary NN O O
Disorders NN O O
: NN O O
hematuria NN B-AdverseReaction B-AdverseReaction
nephrolithiasis NN B-AdverseReaction B-AdverseReaction
pollakiuria NN B-AdverseReaction B-AdverseReaction
proteinuria NN B-AdverseReaction B-AdverseReaction
renal NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
renal NN B-AdverseReaction B-AdverseReaction
insufficiency NN I-AdverseReaction I-AdverseReaction
urgency NN O O
, NN O O
incontinence NN O O
. NN O O
Reproductive NN O O
System NN O O
and NN O O
Breast NN O O
Changes NN O O
: NN O O
breast NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
erectile NN B-AdverseReaction B-AdverseReaction
dysfunction NN I-AdverseReaction I-AdverseReaction
gynecomastia NN B-AdverseReaction B-AdverseReaction
Respiratory NN O O
, NN O O
Thoracic NN O O
and NN O O
Mediastinal NN O O
Disorders NN O O
: NN O O
bronchitis NN B-AdverseReaction B-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
dyspnea NN B-AdverseReaction B-AdverseReaction
epistaxis NN B-AdverseReaction B-AdverseReaction
nasal NN B-AdverseReaction B-AdverseReaction
dryness NN I-AdverseReaction I-AdverseReaction
paranasal NN B-AdverseReaction B-AdverseReaction
sinus NN I-AdverseReaction I-AdverseReaction
hypersecretion NN I-AdverseReaction I-AdverseReaction
pharyngeal NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
respiratory NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
congestion NN I-AdverseReaction I-AdverseReaction
sneezing NN B-AdverseReaction B-AdverseReaction
throat NN B-AdverseReaction B-AdverseReaction
irritation NN I-AdverseReaction I-AdverseReaction
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
Skin NN O O
and NN O O
Subcutaneous NN O O
Tissue NN O O
Disorders NN O O
: NN O O
alopecia NN B-AdverseReaction B-AdverseReaction
angio NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
dermatitis NN B-AdverseReaction B-AdverseReaction
dermographism NN B-AdverseReaction B-AdverseReaction
ecchymosis NN B-AdverseReaction B-AdverseReaction
eczema NN B-AdverseReaction B-AdverseReaction
hair NN B-AdverseReaction B-AdverseReaction
color NN I-AdverseReaction I-AdverseReaction
changes NN I-AdverseReaction I-AdverseReaction
hair NN B-AdverseReaction B-AdverseReaction
growth NN I-AdverseReaction I-AdverseReaction
abnormal NN I-AdverseReaction I-AdverseReaction
hyperhidrosis NN B-AdverseReaction B-AdverseReaction
, NN O O
peeling NN B-AdverseReaction B-AdverseReaction
skin NN I-AdverseReaction I-AdverseReaction
petechiae NN B-AdverseReaction B-AdverseReaction
photosensitivity NN B-AdverseReaction B-AdverseReaction
pruritus NN B-AdverseReaction B-AdverseReaction
purpura NN B-AdverseReaction B-AdverseReaction
skin NN B-AdverseReaction B-AdverseReaction
discoloration NN I-AdverseReaction I-AdverseReaction
pigmentation NN O O
, NN O O
skin NN B-AdverseReaction B-AdverseReaction
lesion NN I-AdverseReaction I-AdverseReaction
skin NN B-AdverseReaction B-AdverseReaction
odor NN I-AdverseReaction I-AdverseReaction
abnormal NN I-AdverseReaction I-AdverseReaction
urticaria NN B-AdverseReaction B-AdverseReaction
Vascular NN O O
Disorders NN O O
: NN O O
flushing NN B-AdverseReaction B-AdverseReaction
hot NN B-AdverseReaction B-AdverseReaction
flush NN I-AdverseReaction I-AdverseReaction
hypertension NN B-AdverseReaction B-AdverseReaction
hypotension NN B-AdverseReaction B-AdverseReaction
Laboratory NN O O
Parameters NN O O
: NN O O
activated NN B-AdverseReaction B-AdverseReaction
partial NN I-AdverseReaction I-AdverseReaction
thromboplastin NN I-AdverseReaction I-AdverseReaction
time NN I-AdverseReaction I-AdverseReaction
prolonged NN I-AdverseReaction I-AdverseReaction
creatine NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
bicarbonate NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
sodium NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
EEG NN B-AdverseReaction B-AdverseReaction
abnormal NN I-AdverseReaction I-AdverseReaction
glucose NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
cholesterol NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
triglycerides NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
amylase NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
potassium NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
TSH NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
platelet NN B-AdverseReaction B-AdverseReaction
count NN I-AdverseReaction I-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
hematocrit NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
hemoglobin NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
MCV NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
RBC NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
creatinine NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
blood NN B-AdverseReaction B-AdverseReaction
urea NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
BUN/creatinine NN B-AdverseReaction B-AdverseReaction
ratio NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
creatine NN O O
phosphokinase NN O O
( NN O O
CPK NN O O
) NN O O
increased NN O O
, NN O O
alkaline NN B-AdverseReaction B-AdverseReaction
phosphatase NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
LDH NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
PSA NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
urine NN B-AdverseReaction B-AdverseReaction
output NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
lymphocyte NN B-AdverseReaction B-AdverseReaction
count NN I-AdverseReaction I-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
neutrophil NN B-AdverseReaction B-AdverseReaction
count NN I-AdverseReaction I-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
WBC NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
coagulation NN B-AdverseReaction B-AdverseReaction
test NN I-AdverseReaction I-AdverseReaction
abnormal NN I-AdverseReaction I-AdverseReaction
low NN O O
density NN O O
lipoprotein NN O O
( NN O O
LDL NN O O
) NN O O
increased NN O O
, NN O O
prothrombin NN B-AdverseReaction B-AdverseReaction
time NN I-AdverseReaction I-AdverseReaction
prolonged NN I-AdverseReaction I-AdverseReaction
urinary NN B-AdverseReaction B-AdverseReaction
casts NN I-AdverseReaction I-AdverseReaction
urine NN B-AdverseReaction B-AdverseReaction
positive NN I-AdverseReaction I-AdverseReaction
for NN I-AdverseReaction I-AdverseReaction
white NN I-AdverseReaction I-AdverseReaction
blood NN I-AdverseReaction I-AdverseReaction
cells NN I-AdverseReaction I-AdverseReaction
and NN O O
protein NN O O
. NN O O
Cardiovascular NN O O
Safety NN O O
Cardiovascular NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
and NN O O
deaths NN B-AdverseReaction B-AdverseReaction
were NN O O
adjudicated NN O O
to NN O O
one NN O O
of NN O O
the NN O O
pre NN O O
- NN O O
defined NN O O
endpoints NN O O
from NN O O
the NN O O
Anti NN O O
- NN O O
Platelet NN O O
Trialists NN O O
' NN O O
Collaborations NN O O
( NN O O
APTC NN O O
) NN O O
( NN O O
cardiovascular NN O O
death NN O O
, NN O O
non NN B-Severity B-Severity
- NN I-Severity I-Severity
fatal NN I-Severity I-Severity
myocardial NN B-AdverseReaction B-AdverseReaction
infarction NN I-AdverseReaction I-AdverseReaction
and NN O O
non NN B-Severity B-Severity
- NN I-Severity I-Severity
fatal NN I-Severity I-Severity
stroke NN B-AdverseReaction B-AdverseReaction
in NN O O
the NN O O
randomized NN O O
controlled NN O O
and NN O O
long NN O O
- NN O O
term NN O O
extension NN O O
studies NN O O
. NN O O
In NN O O
the NN O O
Phase NN O O
3 NN O O
randomized NN O O
controlled NN O O
studies NN O O
, NN O O
the NN O O
incidences NN O O
of NN O O
adjudicated NN O O
APTC NN O O
events NN O O
per NN O O
100 NN O O
patient NN O O
- NN O O
years NN O O
of NN O O
exposure NN O O
were NN O O
: NN O O
Placebo NN O O
0 NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
0.00 NN O O
- NN O O
6.16 NN O O
) NN O O
, NN O O
ULORIC NN O O
40 NN O O
mg NN O O
0 NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
0.00 NN O O
- NN O O
1.08 NN O O
) NN O O
, NN O O
ULORIC NN O O
80 NN O O
mg NN O O
1.09 NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
0.44 NN O O
- NN O O
2.24 NN O O
) NN O O
, NN O O
and NN O O
allopurinol NN O O
0.60 NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
0.16 NN O O
- NN O O
1.53 NN O O
) NN O O
. NN O O
In NN O O
the NN O O
long NN O O
- NN O O
term NN O O
extension NN O O
studies NN O O
, NN O O
the NN O O
incidences NN O O
of NN O O
adjudicated NN O O
APTC NN O O
events NN O O
were NN O O
: NN O O
ULORIC NN O O
80 NN O O
mg NN O O
0.97 NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
0.57 NN O O
- NN O O
1.56 NN O O
) NN O O
, NN O O
and NN O O
allopurinol NN O O
0.58 NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
0.02 NN O O
- NN O O
3.24 NN O O
) NN O O
. NN O O
Overall NN O O
, NN O O
a NN O O
higher NN O O
rate NN O O
of NN O O
APTC NN O O
events NN O O
was NN O O
observed NN O O
in NN O O
ULORIC NN O O
than NN O O
in NN O O
allopurinol NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
A NN O O
causal NN O O
relationship NN O O
with NN O O
ULORIC NN O O
has NN O O
not NN O O
been NN O O
established NN O O
. NN O O
Monitor NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
MI NN O O
and NN O O
stroke NN O O
. NN O O
6.2 NN O O
Postmarketing NN O O
Experience NN O O
Adverse NN O O
reactions NN O O
have NN O O
been NN O O
identified NN O O
during NN O O
postapproval NN O O
use NN O O
of NN O O
ULORIC. NN O O
Because NN O O
these NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
. NN O O
Hepatobiliary NN O O
Disorders NN O O
: NN O O
hepatic NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
( NN O O
some NN O O
fatal NN B-AdverseReaction B-AdverseReaction
jaundice NN B-AdverseReaction B-AdverseReaction
serious NN B-Severity B-Severity
cases NN O O
of NN O O
abnormal NN B-AdverseReaction B-AdverseReaction
liver NN I-AdverseReaction I-AdverseReaction
function NN I-AdverseReaction I-AdverseReaction
test NN O O
results NN O O
, NN O O
liver NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
Immune NN O O
System NN O O
Disorders NN O O
: NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
anaphylactic NN B-AdverseReaction B-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
Musculoskeletal NN O O
and NN O O
Connective NN O O
Tissue NN O O
Disorders NN O O
: NN O O
rhabdomyolysis NN B-AdverseReaction B-AdverseReaction
Psychiatric NN O O
Disorders NN O O
: NN O O
psychotic NN B-AdverseReaction B-AdverseReaction
behavior NN I-AdverseReaction I-AdverseReaction
including NN O O
aggressive NN B-AdverseReaction B-AdverseReaction
thoughts NN I-AdverseReaction I-AdverseReaction
Renal NN O O
and NN O O
Urinary NN O O
Disorders NN O O
: NN O O
tubulointerstitial NN B-AdverseReaction B-AdverseReaction
nephritis NN I-AdverseReaction I-AdverseReaction
Skin NN O O
and NN O O
Subcutaneous NN O O
Tissue NN O O
Disorders NN O O
: NN O O
generalized NN B-AdverseReaction B-AdverseReaction
rash NN I-AdverseReaction I-AdverseReaction
Stevens NN B-AdverseReaction B-AdverseReaction
Johnson NN I-AdverseReaction I-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
hypersensitivity NN B-AdverseReaction B-AdverseReaction
skin NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Gout NN B-AdverseReaction B-AdverseReaction
Flare NN I-AdverseReaction I-AdverseReaction
: NN O O
An NN O O
increase NN O O
in NN O O
gout NN B-AdverseReaction B-AdverseReaction
flares NN I-AdverseReaction I-AdverseReaction
is NN O O
frequently NN O O
observed NN O O
during NN O O
initiation NN O O
of NN O O
anti NN O O
- NN O O
hyperuricemic NN O O
agents NN O O
, NN O O
including NN O O
ULORIC. NN O O
If NN O O
a NN O O
gout NN O O
flare NN O O
occurs NN O O
during NN O O
treatment NN O O
, NN O O
ULORIC NN O O
need NN O O
not NN O O
be NN O O
discontinued NN O O
. NN O O
Prophylactic NN O O
therapy NN O O
( NN O O
i.e. NN O O
, NN O O
non NN O O
- NN O O
steroidal NN O O
anti NN O O
- NN O O
inflammatory NN O O
drug NN O O
[ NN O O
NSAID NN O O
] NN O O
or NN O O
colchicine NN O O
upon NN O O
initiation NN O O
of NN O O
treatment NN O O
) NN O O
may NN O O
be NN O O
beneficial NN O O
for NN O O
up NN O O
to NN O O
six NN O O
months NN O O
. NN O O
( NN O O
2.4 NN O O
, NN O O
5.1 NN O O
) NN O O
* NN O O
Cardiovascular NN B-AdverseReaction B-AdverseReaction
Events NN I-AdverseReaction I-AdverseReaction
: NN O O
A NN O O
higher NN O O
rate NN O O
of NN O O
cardiovascular NN B-AdverseReaction B-AdverseReaction
thromboembolic NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
was NN O O
observed NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
ULORIC NN O O
than NN O O
allopurinol NN O O
in NN O O
clinical NN O O
trials NN O O
. NN O O
Monitor NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
MI NN O O
and NN O O
stroke NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Hepatic NN B-AdverseReaction B-AdverseReaction
Effects NN I-AdverseReaction I-AdverseReaction
Postmarketing NN O O
reports NN O O
of NN O O
hepatic NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
sometimes NN O O
fatal NN B-AdverseReaction B-AdverseReaction
Causality NN O O
can NN O O
not NN O O
be NN O O
excluded NN O O
. NN O O
If NN O O
liver NN O O
injury NN O O
is NN O O
detected NN O O
, NN O O
promptly NN O O
interrupt NN O O
ULORIC NN O O
and NN O O
assess NN O O
patient NN O O
for NN O O
probable NN O O
cause NN O O
, NN O O
then NN O O
treat NN O O
cause NN O O
if NN O O
possible NN O O
, NN O O
to NN O O
resolution NN O O
or NN O O
stabilization NN O O
. NN O O
Do NN O O
not NN O O
restart NN O O
ULORIC NN O O
if NN O O
liver NN O O
injury NN O O
is NN O O
confirmed NN O O
and NN O O
no NN O O
alternate NN O O
etiology NN O O
can NN O O
be NN O O
found NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
5.1 NN O O
Gout NN O O
Flare NN O O
After NN O O
initiation NN O O
of NN O O
ULORIC NN O O
, NN O O
an NN O O
increase NN O O
in NN O O
gout NN B-AdverseReaction B-AdverseReaction
flares NN I-AdverseReaction I-AdverseReaction
is NN O O
frequently NN O O
observed NN O O
. NN O O
This NN O O
increase NN O O
is NN O O
due NN O O
to NN O O
reduction NN O O
in NN O O
serum NN O O
uric NN O O
acid NN O O
levels NN O O
, NN O O
resulting NN O O
in NN O O
mobilization NN O O
of NN O O
urate NN O O
from NN O O
tissue NN O O
deposits NN O O
. NN O O
In NN O O
order NN O O
to NN O O
prevent NN O O
gout NN O O
flares NN O O
when NN O O
ULORIC NN O O
is NN O O
initiated NN O O
, NN O O
concurrent NN O O
prophylactic NN O O
treatment NN O O
with NN O O
an NN O O
NSAID NN O O
or NN O O
colchicine NN O O
is NN O O
recommended NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.4 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
Cardiovascular NN O O
Events NN O O
In NN O O
the NN O O
randomized NN O O
controlled NN O O
studies NN O O
, NN O O
there NN O O
was NN O O
a NN O O
higher NN O O
rate NN O O
of NN O O
cardiovascular NN B-AdverseReaction B-AdverseReaction
thromboembolic NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
( NN O O
cardiovascular NN O O
deaths NN O O
, NN O O
non NN B-Severity B-Severity
- NN I-Severity I-Severity
fatal NN I-Severity I-Severity
myocardial NN B-AdverseReaction B-AdverseReaction
infarctions NN I-AdverseReaction I-AdverseReaction
and NN O O
non NN B-Severity B-Severity
- NN I-Severity I-Severity
fatal NN I-Severity I-Severity
strokes NN B-AdverseReaction B-AdverseReaction
in NN O O
patients NN O O
treated NN O O
with NN O O
ULORIC NN O O
( NN O O
0.74 NN O O
per NN O O
100 NN O O
P NN O O
- NN O O
Y NN O O
[ NN O O
95 NN O O
% NN O O
Confidence NN O O
Interval NN O O
( NN O O
CI NN O O
) NN O O
0.36 NN O O
- NN O O
1.37 NN O O
] NN O O
) NN O O
than NN O O
allopurinol NN O O
( NN O O
0.60 NN O O
per NN O O
100 NN O O
P NN O O
- NN O O
Y NN O O
[ NN O O
95 NN O O
% NN O O
CI NN O O
0.16 NN O O
- NN O O
1.53 NN O O
] NN O O
) NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
A NN O O
causal NN O O
relationship NN O O
with NN O O
ULORIC NN O O
has NN O O
not NN O O
been NN O O
established NN O O
. NN O O
Monitor NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
myocardial NN O O
infarction NN O O
( NN O O
MI NN O O
) NN O O
and NN O O
stroke NN O O
. NN O O
5.3 NN O O
Hepatic NN O O
Effects NN O O
There NN O O
have NN O O
been NN O O
postmarketing NN O O
reports NN O O
of NN O O
fatal NN B-AdverseReaction B-AdverseReaction
and NN O O
non NN O O
- NN O O
fatal NN O O
hepatic NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
in NN O O
patients NN O O
taking NN O O
ULORIC NN O O
, NN O O
although NN O O
the NN O O
reports NN O O
contain NN O O
insufficient NN O O
information NN O O
necessary NN O O
to NN O O
establish NN O O
the NN O O
probable NN O O
cause NN O O
. NN O O
During NN O O
randomized NN O O
controlled NN O O
studies NN O O
, NN O O
transaminase NN B-AdverseReaction B-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
greater NN O O
than NN O O
three NN B-Severity B-Severity
times NN I-Severity I-Severity
the NN I-Severity I-Severity
upper NN I-Severity I-Severity
limit NN I-Severity I-Severity
of NN I-Severity I-Severity
normal NN I-Severity I-Severity
( NN O O
ULN NN O O
) NN O O
were NN O O
observed NN O O
( NN O O
AST NN O O
: NN O O
2 NN O O
% NN O O
, NN O O
2 NN O O
% NN O O
, NN O O
and NN O O
ALT NN O O
: NN O O
3 NN O O
% NN O O
, NN O O
2 NN O O
% NN O O
in NN O O
ULORIC NN O O
and NN O O
allopurinol NN O O
- NN O O
treated NN O O
patients NN O O
, NN O O
respectively NN O O
) NN O O
. NN O O
No NN O O
dose NN O O
- NN O O
effect NN O O
relationship NN O O
for NN O O
these NN O O
transaminase NN O O
elevations NN O O
was NN O O
noted NN O O
[ NN O O
see NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.3 NN O O
) NN O O
] NN O O
. NN O O
Obtain NN O O
a NN O O
liver NN O O
test NN O O
panel NN O O
( NN O O
serum NN O O
alanine NN O O
aminotransferase NN O O
[ NN O O
ALT NN O O
] NN O O
, NN O O
aspartate NN O O
aminotransferase NN O O
[ NN O O
AST NN O O
] NN O O
, NN O O
alkaline NN O O
phosphatase NN O O
, NN O O
and NN O O
total NN O O
bilirubin NN O O
) NN O O
as NN O O
a NN O O
baseline NN O O
before NN O O
initiating NN O O
ULORIC. NN O O
Measure NN O O
liver NN O O
tests NN O O
promptly NN O O
in NN O O
patients NN O O
who NN O O
report NN O O
symptoms NN O O
that NN O O
may NN O O
indicate NN O O
liver NN O O
injury NN O O
, NN O O
including NN O O
fatigue NN O O
, NN O O
anorexia NN O O
, NN O O
right NN O O
upper NN O O
abdominal NN O O
discomfort NN O O
, NN O O
dark NN O O
urine NN O O
or NN O O
jaundice NN O O
. NN O O
In NN O O
this NN O O
clinical NN O O
context NN O O
, NN O O
if NN O O
the NN O O
patient NN O O
is NN O O
found NN O O
to NN O O
have NN O O
abnormal NN O O
liver NN O O
tests NN O O
( NN O O
ALT NN O O
greater NN O O
than NN O O
three NN O O
times NN O O
the NN O O
upper NN O O
limit NN O O
of NN O O
the NN O O
reference NN O O
range NN O O
) NN O O
, NN O O
ULORIC NN O O
treatment NN O O
should NN O O
be NN O O
interrupted NN O O
and NN O O
investigation NN O O
done NN O O
to NN O O
establish NN O O
the NN O O
probable NN O O
cause NN O O
. NN O O
ULORIC NN O O
should NN O O
not NN O O
be NN O O
restarted NN O O
in NN O O
these NN O O
patients NN O O
without NN O O
another NN O O
explanation NN O O
for NN O O
the NN O O
liver NN O O
test NN O O
abnormalities NN O O
. NN O O
Patients NN O O
who NN O O
have NN O O
serum NN O O
ALT NN O O
greater NN O O
than NN O O
three NN O O
times NN O O
the NN O O
reference NN O O
range NN O O
with NN O O
serum NN O O
total NN O O
bilirubin NN O O
greater NN O O
than NN O O
two NN O O
times NN O O
the NN O O
reference NN O O
range NN O O
without NN O O
alternative NN O O
etiologies NN O O
are NN O O
at NN O O
risk NN O O
for NN O O
severe NN O O
drug NN O O
- NN O O
induced NN O O
liver NN O O
injury NN O O
and NN O O
should NN O O
not NN O O
be NN O O
restarted NN O O
on NN O O
ULORIC. NN O O
For NN O O
patients NN O O
with NN O O
lesser NN O O
elevations NN O O
of NN O O
serum NN O O
ALT NN O O
or NN O O
bilirubin NN O O
and NN O O
with NN O O
an NN O O
alternate NN O O
probable NN O O
cause NN O O
, NN O O
treatment NN O O
with NN O O
ULORIC NN O O
can NN O O
be NN O O
used NN O O
with NN O O
caution NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reaction NN O O
in NN O O
adults NN O O
was NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
. NN O O
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Arbor NN O O
Pharmaceuticals NN O O
, NN O O
LLC NN O O
at NN O O
1 NN O O
- NN O O
866 NN O O
- NN O O
516 NN O O
- NN O O
4950 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
A NN O O
total NN O O
of NN O O
4814 NN O O
patients NN O O
were NN O O
evaluated NN O O
for NN O O
safety NN O O
when NN O O
treated NN O O
with NN O O
Edarbi NN O O
at NN O O
doses NN O O
of NN O O
20 NN O O
, NN O O
40 NN O O
, NN O O
or NN O O
80 NN O O
mg NN O O
in NN O O
clinical NN O O
trials NN O O
. NN O O
This NN O O
includes NN O O
1704 NN O O
patients NN O O
treated NN O O
for NN O O
at NN O O
least NN O O
six NN O O
months NN O O
; NN O O
of NN O O
these NN O O
, NN O O
588 NN O O
were NN O O
treated NN O O
for NN O O
at NN O O
least NN O O
one NN O O
year NN O O
. NN O O
Treatment NN O O
with NN O O
Edarbi NN O O
was NN O O
well NN O O
- NN O O
tolerated NN O O
with NN O O
an NN O O
overall NN O O
incidence NN O O
of NN O O
adverse NN O O
reactions NN O O
similar NN O O
to NN O O
placebo NN O O
. NN O O
The NN O O
rate NN O O
of NN O O
withdrawals NN O O
due NN O O
to NN O O
adverse NN O O
events NN O O
in NN O O
placebo NN O O
- NN O O
controlled NN O O
monotherapy NN O O
and NN O O
combination NN O O
therapy NN O O
trials NN O O
was NN O O
2.4 NN O O
% NN O O
( NN O O
19/801 NN O O
) NN O O
for NN O O
placebo NN O O
, NN O O
2.2 NN O O
% NN O O
( NN O O
24/1072 NN O O
) NN O O
for NN O O
Edarbi NN O O
40 NN O O
mg NN O O
, NN O O
and NN O O
2.7 NN O O
% NN O O
( NN O O
29/1074 NN O O
) NN O O
for NN O O
Edarbi NN O O
80 NN O O
mg NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
event NN O O
leading NN O O
to NN O O
discontinuation NN O O
, NN O O
hypotension NN B-AdverseReaction B-AdverseReaction
hypotension NN O O
, NN O O
was NN O O
reported NN O O
by NN O O
0.4 NN O O
% NN O O
( NN O O
8/2146 NN O O
) NN O O
patients NN O O
randomized NN O O
to NN O O
Edarbi NN O O
40 NN O O
mg NN O O
or NN O O
80 NN O O
mg NN O O
compared NN O O
to NN O O
0 NN O O
% NN O O
( NN O O
0/801 NN O O
) NN O O
patients NN O O
randomized NN O O
to NN O O
placebo NN O O
. NN O O
Generally NN O O
, NN O O
adverse NN O O
reactions NN O O
were NN O O
mild NN O O
, NN O O
not NN O O
dose NN O O
related NN O O
, NN O O
and NN O O
similar NN O O
regardless NN O O
of NN O O
age NN O O
, NN O O
gender NN O O
, NN O O
and NN O O
race NN O O
. NN O O
In NN O O
placebo NN O O
- NN O O
controlled NN O O
monotherapy NN O O
trials NN O O
, NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
up NN O O
to NN O O
2 NN O O
% NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
Edarbi NN O O
80 NN O O
mg NN O O
daily NN O O
compared NN O O
with NN O O
0.5 NN O O
% NN O O
of NN O O
patients NN O O
on NN O O
placebo NN O O
. NN O O
Other NN O O
adverse NN O O
reactions NN O O
with NN O O
a NN O O
plausible NN O O
relationship NN O O
to NN O O
treatment NN O O
that NN O O
have NN O O
been NN O O
reported NN O O
with NN O O
an NN O O
incidence NN O O
of NN O O
>=0.3 NN O O
% NN O O
and NN O O
greater NN O O
than NN O O
placebo NN O O
in NN O O
more NN O O
than NN O O
3300 NN O O
patients NN O O
treated NN O O
with NN O O
Edarbi NN O O
in NN O O
controlled NN O O
trials NN O O
are NN O O
listed NN O O
below NN O O
: NN O O
Gastrointestinal NN O O
Disorders NN O O
: NN O O
nausea NN B-AdverseReaction B-AdverseReaction
General NN O O
Disorders NN O O
and NN O O
Administration NN O O
Site NN O O
Conditions NN O O
: NN O O
asthenia NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
Musculoskeletal NN O O
and NN O O
Connective NN O O
Tissue NN O O
Disorders NN O O
: NN O O
muscle NN B-AdverseReaction B-AdverseReaction
spasm NN I-AdverseReaction I-AdverseReaction
Nervous NN O O
System NN O O
Disorders NN O O
: NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
dizziness NN B-AdverseReaction B-AdverseReaction
postural NN I-AdverseReaction I-AdverseReaction
Respiratory NN O O
, NN O O
Thoracic NN O O
, NN O O
and NN O O
Mediastinal NN O O
Disorders NN O O
: NN O O
cough NN B-AdverseReaction B-AdverseReaction
6.2 NN O O
Clinical NN O O
Laboratory NN O O
Findings NN O O
In NN O O
controlled NN O O
clinical NN O O
trials NN O O
, NN O O
clinically NN O O
relevant NN O O
changes NN O O
in NN O O
standard NN O O
laboratory NN O O
parameters NN O O
were NN O O
uncommon NN O O
with NN O O
administration NN O O
of NN O O
Edarbi NN O O
. NN O O
Serum NN O O
creatinine NN O O
Small NN B-Severity B-Severity
reversible NN B-Severity B-Severity
increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
are NN O O
seen NN O O
in NN O O
patients NN O O
receiving NN O O
80 NN O O
mg NN O O
of NN O O
Edarbi NN O O
. NN O O
The NN O O
increase NN O O
may NN O O
be NN O O
larger NN O O
when NN O O
coadministered NN O O
with NN O O
chlorthalidone NN O O
or NN O O
hydrochlorothiazide NN O O
. NN O O
In NN O O
addition NN O O
, NN O O
patients NN O O
taking NN O O
Edarbi NN O O
who NN O O
had NN O O
moderate NN O O
to NN O O
severe NN O O
renal NN O O
impairment NN O O
at NN O O
baseline NN O O
or NN O O
who NN O O
were NN O O
>75 NN O O
years NN O O
of NN O O
age NN O O
were NN O O
more NN O O
likely NN O O
to NN O O
report NN O O
serum NN B-AdverseReaction B-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
increases NN I-AdverseReaction I-AdverseReaction
Hemoglobin/Hematocrit NN O O
Low NN B-AdverseReaction B-AdverseReaction
hemoglobin NN I-AdverseReaction I-AdverseReaction
hematocrit NN O O
, NN O O
and NN O O
RBC NN O O
counts NN O O
were NN O O
observed NN O O
in NN O O
0.2 NN O O
% NN O O
, NN O O
0.4 NN O O
% NN O O
, NN O O
and NN O O
0.3 NN O O
% NN O O
of NN O O
Edarbi NN O O
- NN O O
treated NN O O
subjects NN O O
, NN O O
respectively NN O O
. NN O O
None NN O O
of NN O O
these NN O O
abnormalities NN O O
were NN O O
reported NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
. NN O O
Low NN O O
and NN O O
high NN O O
markedly NN B-Severity B-Severity
abnormal NN O O
platelet NN O O
and NN O O
WBC NN O O
counts NN O O
were NN O O
observed NN O O
in NN O O
< NN O O
0.1 NN O O
% NN O O
of NN O O
subjects NN O O
. NN O O
6.3 NN O O
Postmarketing NN O O
Experience NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
identified NN O O
during NN O O
the NN O O
postmarketing NN O O
use NN O O
of NN O O
EDARBI. NN O O
Because NN O O
these NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
* NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
* NN O O
Muscle NN B-AdverseReaction B-AdverseReaction
spasms NN I-AdverseReaction I-AdverseReaction
* NN O O
Rash NN B-AdverseReaction B-AdverseReaction
* NN O O
Pruritus NN B-AdverseReaction B-AdverseReaction
* NN O O
Angioedema NN B-AdverseReaction B-AdverseReaction
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
FETAL NN B-AdverseReaction B-AdverseReaction
TOXICITY NN I-AdverseReaction I-AdverseReaction
WARNING NN O O
: NN O O
FETAL NN B-AdverseReaction B-AdverseReaction
TOXICITY NN I-AdverseReaction I-AdverseReaction
* NN O O
When NN O O
pregnancy NN O O
is NN O O
detected NN O O
, NN O O
discontinue NN O O
Edarbi NN O O
as NN O O
soon NN O O
as NN O O
possible NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Drugs NN B-DrugClass B-DrugClass
that NN I-DrugClass I-DrugClass
act NN I-DrugClass I-DrugClass
directly NN I-DrugClass I-DrugClass
on NN I-DrugClass I-DrugClass
the NN I-DrugClass I-DrugClass
renin NN I-DrugClass I-DrugClass
- NN I-DrugClass I-DrugClass
angiotensin NN I-DrugClass I-DrugClass
system NN I-DrugClass I-DrugClass
can NN O O
cause NN O O
injury NN O O
and NN O O
death NN B-AdverseReaction B-AdverseReaction
to NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
developing NN I-AdverseReaction I-AdverseReaction
fetus NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
WARNING NN O O
: NN O O
FETAL NN B-AdverseReaction B-AdverseReaction
TOXICITY NN I-AdverseReaction I-AdverseReaction
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
. NN O O
* NN O O
When NN O O
pregnancy NN O O
is NN O O
detected NN O O
, NN O O
discontinue NN O O
Edarbi NN O O
as NN O O
soon NN O O
as NN O O
possible NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Drugs NN B-DrugClass B-DrugClass
that NN I-DrugClass I-DrugClass
act NN I-DrugClass I-DrugClass
directly NN I-DrugClass I-DrugClass
on NN I-DrugClass I-DrugClass
the NN I-DrugClass I-DrugClass
renin NN I-DrugClass I-DrugClass
- NN I-DrugClass I-DrugClass
angiotensin NN I-DrugClass I-DrugClass
system NN I-DrugClass I-DrugClass
can NN O O
cause NN O O
injury NN O O
and NN O O
death NN B-AdverseReaction B-AdverseReaction
to NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
developing NN I-AdverseReaction I-AdverseReaction
fetus NN I-AdverseReaction I-AdverseReaction
( NN O O
5.1 NN O O
) NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Correct NN O O
volume NN O O
or NN O O
salt NN O O
depletion NN O O
prior NN O O
to NN O O
administration NN O O
of NN O O
Edarbi NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Monitor NN O O
for NN O O
worsening NN O O
renal NN O O
function NN O O
in NN O O
patients NN O O
with NN O O
renal NN O O
impairment NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
5.1 NN O O
Fetal NN O O
Toxicity NN O O
Use NN O O
of NN O O
drugs NN B-DrugClass B-DrugClass
that NN I-DrugClass I-DrugClass
act NN I-DrugClass I-DrugClass
on NN I-DrugClass I-DrugClass
the NN I-DrugClass I-DrugClass
renin NN I-DrugClass I-DrugClass
- NN I-DrugClass I-DrugClass
angiotensin NN I-DrugClass I-DrugClass
system NN I-DrugClass I-DrugClass
during NN O O
the NN O O
second NN O O
and NN O O
third NN O O
trimesters NN O O
of NN O O
pregnancy NN O O
reduces NN B-AdverseReaction B-AdverseReaction
fetal NN I-AdverseReaction I-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
function NN I-AdverseReaction I-AdverseReaction
and NN O O
increases NN O O
fetal NN O O
and NN O O
neonatal NN B-AdverseReaction B-AdverseReaction
morbidity NN I-AdverseReaction I-AdverseReaction
and NN O O
death NN O O
. NN O O
Resulting NN O O
oligohydramnios NN B-AdverseReaction B-AdverseReaction
can NN B-Factor B-Factor
be NN O O
associated NN O O
with NN O O
fetal NN B-AdverseReaction B-AdverseReaction
lung NN I-AdverseReaction I-AdverseReaction
hypoplasia NN I-AdverseReaction I-AdverseReaction
and NN O O
skeletal NN O O
deformations NN O O
. NN O O
Potential NN B-Factor B-Factor
neonatal NN B-AdverseReaction B-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
effects NN I-AdverseReaction I-AdverseReaction
include NN O O
skull NN O O
hypoplasia NN O O
, NN O O
anuria NN O O
, NN O O
hypotension NN O O
, NN O O
renal NN O O
failure NN O O
, NN O O
and NN O O
death NN O O
. NN O O
When NN O O
pregnancy NN O O
is NN O O
detected NN O O
, NN O O
discontinue NN O O
Edarbi NN O O
as NN O O
soon NN O O
as NN O O
possible NN O O
[ NN O O
seeUse NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.1 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
Hypotension NN O O
in NN O O
Volume- NN O O
or NN O O
Salt NN O O
- NN O O
Depleted NN O O
Patients NN O O
In NN O O
patients NN O O
with NN O O
an NN O O
activated NN O O
renin NN O O
- NN O O
angiotensin NN O O
system NN O O
, NN O O
such NN O O
as NN O O
volume- NN O O
and/or NN O O
salt NN O O
- NN O O
depleted NN O O
patients NN O O
( NN O O
e.g. NN O O
, NN O O
those NN O O
being NN O O
treated NN O O
with NN O O
high NN O O
doses NN O O
of NN O O
diuretics NN O O
) NN O O
, NN O O
symptomatic NN B-AdverseReaction B-AdverseReaction
hypotension NN I-AdverseReaction I-AdverseReaction
may NN B-Factor B-Factor
occur NN O O
after NN O O
initiation NN O O
of NN O O
treatment NN O O
with NN O O
Edarbi NN O O
. NN O O
Correct NN O O
volume NN O O
or NN O O
salt NN O O
depletion NN O O
prior NN O O
to NN O O
administration NN O O
of NN O O
Edarbi NN O O
, NN O O
or NN O O
start NN O O
treatment NN O O
at NN O O
40 NN O O
mg NN O O
. NN O O
If NN O O
hypotension NN O O
does NN O O
occur NN O O
, NN O O
the NN O O
patient NN O O
should NN O O
be NN O O
placed NN O O
in NN O O
the NN O O
supine NN O O
position NN O O
and NN O O
, NN O O
if NN O O
necessary NN O O
, NN O O
given NN O O
an NN O O
intravenous NN O O
infusion NN O O
of NN O O
normal NN O O
saline NN O O
. NN O O
A NN O O
transient NN O O
hypotensive NN O O
response NN O O
is NN O O
not NN O O
a NN O O
contraindication NN O O
to NN O O
further NN O O
treatment NN O O
, NN O O
which NN O O
usually NN O O
can NN O O
be NN O O
continued NN O O
without NN O O
difficulty NN O O
once NN O O
the NN O O
blood NN O O
pressure NN O O
has NN O O
stabilized NN O O
. NN O O
5.3 NN O O
Impaired NN O O
Renal NN O O
Function NN O O
As NN O O
a NN O O
consequence NN O O
of NN O O
inhibiting NN O O
the NN O O
renin NN O O
- NN O O
angiotensin NN O O
system NN O O
, NN O O
changes NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
function NN I-AdverseReaction I-AdverseReaction
may NN B-Factor B-Factor
be NN O O
anticipated NN O O
in NN O O
susceptible NN O O
individuals NN O O
treated NN O O
with NN O O
Edarbi NN O O
. NN O O
In NN O O
patients NN O O
whose NN O O
renal NN O O
function NN O O
may NN O O
depend NN O O
on NN O O
the NN O O
activity NN O O
of NN O O
the NN O O
renin NN O O
- NN O O
angiotensin NN O O
system NN O O
( NN O O
e.g. NN O O
, NN O O
patients NN O O
with NN O O
severe NN O O
congestive NN O O
heart NN O O
failure NN O O
, NN O O
renal NN O O
artery NN O O
stenosis NN O O
, NN O O
or NN O O
volume NN O O
depletion NN O O
) NN O O
, NN O O
treatment NN O O
with NN O O
angiotensin NN B-DrugClass B-DrugClass
- NN I-DrugClass I-DrugClass
converting NN I-DrugClass I-DrugClass
enzyme NN I-DrugClass I-DrugClass
inhibitors NN I-DrugClass I-DrugClass
and NN O O
angiotensin NN B-DrugClass B-DrugClass
receptor NN I-DrugClass I-DrugClass
blockers NN I-DrugClass I-DrugClass
has NN O O
been NN O O
associated NN O O
with NN O O
oliguria NN B-AdverseReaction B-AdverseReaction
or NN O O
progressive NN B-AdverseReaction B-AdverseReaction
azotemia NN I-AdverseReaction I-AdverseReaction
and NN O O
rarely NN O O
with NN O O
acute NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
and NN O O
death NN B-AdverseReaction B-AdverseReaction
Similar NN O O
results NN O O
may NN O O
be NN O O
anticipated NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
Edarbi NN O O
[ NN O O
seeDrug NN O O
Interactions NN O O
( NN O O
7),Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.6 NN O O
) NN O O
, NN O O
andClinical NN O O
Pharmacology NN O O
( NN O O
12.3 NN O O
) NN O O
] NN O O
. NN O O
In NN O O
studies NN O O
of NN O O
ACE NN B-DrugClass B-DrugClass
inhibitors NN I-DrugClass I-DrugClass
in NN O O
patients NN O O
with NN O O
unilateral NN O O
or NN O O
bilateral NN O O
renal NN O O
artery NN O O
stenosis NN O O
, NN O O
increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
or NN O O
blood NN O O
urea NN O O
nitrogen NN O O
have NN O O
been NN O O
reported NN O O
. NN O O
There NN O O
has NN O O
been NN O O
no NN O O
long NN O O
- NN O O
term NN O O
use NN O O
of NN O O
Edarbi NN O O
in NN O O
patients NN O O
with NN O O
unilateral NN O O
or NN O O
bilateral NN O O
renal NN O O
artery NN O O
stenosis NN O O
, NN O O
but NN O O
similar NN O O
results NN O O
may NN O O
be NN O O
expected NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
important NN O O
adverse NN O O
reactions NN O O
are NN O O
described NN O O
below NN O O
and NN O O
elsewhere NN O O
in NN O O
the NN O O
labeling NN O O
: NN O O
* NN O O
Hypotension NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Impairment NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
Renal NN I-AdverseReaction I-AdverseReaction
Function NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
Hypoglycemia NN B-AdverseReaction B-AdverseReaction
with NN O O
Concomitant NN O O
Use NN O O
with NN O O
Insulin NN O O
and NN O O
Insulin NN O O
Secretagogues NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
* NN O O
Genital NN B-AdverseReaction B-AdverseReaction
Mycotic NN I-AdverseReaction I-AdverseReaction
Infections NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
* NN O O
Increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
Low NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Density NN I-AdverseReaction I-AdverseReaction
Lipoprotein NN I-AdverseReaction I-AdverseReaction
Cholesterol NN I-AdverseReaction I-AdverseReaction
( NN O O
LDL NN O O
- NN O O
C NN O O
) NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
* NN O O
Bladder NN B-AdverseReaction B-AdverseReaction
Cancer NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.6 NN O O
) NN O O
] NN O O
* NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
associated NN O O
with NN O O
FARXIGA NN O O
( NN O O
5 NN O O
% NN O O
or NN O O
greater NN O O
incidence NN O O
) NN O O
were NN O O
female NN B-AdverseReaction B-AdverseReaction
genital NN I-AdverseReaction I-AdverseReaction
mycotic NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
and NN O O
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
EXCERPT NN O O
: NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
AstraZeneca NN O O
at NN O O
1 NN O O
- NN O O
800- NN O O
236 NN O O
- NN O O
9933 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O
Pool NN O O
of NN O O
12 NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Studies NN O O
for NN O O
FARXIGA NN O O
5 NN O O
and NN O O
10 NN O O
mg NN O O
The NN O O
data NN O O
in NN O O
Table NN O O
1 NN O O
is NN O O
derived NN O O
from NN O O
12 NN O O
placebo NN O O
- NN O O
controlled NN O O
studies NN O O
ranging NN O O
from NN O O
12 NN O O
to NN O O
24 NN O O
weeks NN O O
. NN O O
In NN O O
4 NN O O
studies NN O O
FARXIGA NN O O
was NN O O
used NN O O
as NN O O
monotherapy NN O O
, NN O O
and NN O O
in NN O O
8 NN O O
studies NN O O
FARXIGA NN O O
was NN O O
used NN O O
as NN O O
add NN O O
- NN O O
on NN O O
to NN O O
background NN O O
antidiabetic NN O O
therapy NN O O
or NN O O
as NN O O
combination NN O O
therapy NN O O
with NN O O
metformin NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
. NN O O
These NN O O
data NN O O
reflect NN O O
exposure NN O O
of NN O O
2338 NN O O
patients NN O O
to NN O O
FARXIGA NN O O
with NN O O
a NN O O
mean NN O O
exposure NN O O
duration NN O O
of NN O O
21 NN O O
weeks NN O O
. NN O O
Patients NN O O
received NN O O
placebo NN O O
( NN O O
N=1393 NN O O
) NN O O
, NN O O
FARXIGA NN O O
5 NN O O
mg NN O O
( NN O O
N=1145 NN O O
) NN O O
, NN O O
or NN O O
FARXIGA NN O O
10 NN O O
mg NN O O
( NN O O
N=1193 NN O O
) NN O O
once NN O O
daily NN O O
. NN O O
The NN O O
mean NN O O
age NN O O
of NN O O
the NN O O
population NN O O
was NN O O
55 NN O O
years NN O O
and NN O O
2 NN O O
% NN O O
were NN O O
older NN O O
than NN O O
75 NN O O
years NN O O
of NN O O
age NN O O
. NN O O
Fifty NN O O
percent NN O O
( NN O O
50 NN O O
% NN O O
) NN O O
of NN O O
the NN O O
population NN O O
were NN O O
male NN O O
; NN O O
81 NN O O
% NN O O
were NN O O
White NN O O
, NN O O
14 NN O O
% NN O O
were NN O O
Asian NN O O
, NN O O
and NN O O
3 NN O O
% NN O O
were NN O O
Black NN O O
or NN O O
African NN O O
American NN O O
. NN O O
At NN O O
baseline NN O O
, NN O O
the NN O O
population NN O O
had NN O O
diabetes NN O O
for NN O O
an NN O O
average NN O O
of NN O O
6 NN O O
years NN O O
, NN O O
had NN O O
a NN O O
mean NN O O
hemoglobin NN O O
A1c NN O O
( NN O O
HbA1c NN O O
) NN O O
of NN O O
8.3 NN O O
% NN O O
, NN O O
and NN O O
21 NN O O
% NN O O
had NN O O
established NN O O
microvascular NN O O
complications NN O O
of NN O O
diabetes NN O O
. NN O O
Baseline NN O O
renal NN O O
function NN O O
was NN O O
normal NN O O
or NN O O
mildly NN O O
impaired NN O O
in NN O O
92 NN O O
% NN O O
of NN O O
patients NN O O
and NN O O
moderately NN O O
impaired NN O O
in NN O O
8 NN O O
% NN O O
of NN O O
patients NN O O
( NN O O
mean NN O O
eGFR NN O O
86 NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
) NN O O
. NN O O
Table NN O O
1 NN O O
shows NN O O
common NN O O
adverse NN O O
reactions NN O O
associated NN O O
with NN O O
the NN O O
use NN O O
of NN O O
FARXIGA. NN O O
These NN O O
adverse NN O O
reactions NN O O
were NN O O
not NN O O
present NN O O
at NN O O
baseline NN O O
, NN O O
occurred NN O O
more NN O O
commonly NN O O
on NN O O
FARXIGA NN O O
than NN O O
on NN O O
placebo NN O O
, NN O O
and NN O O
occurred NN O O
in NN O O
at NN O O
least NN O O
2 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
either NN O O
FARXIGA NN O O
5 NN O O
mg NN O O
or NN O O
FARXIGA NN O O
10 NN O O
mg NN O O
. NN O O
Table NN O O
1 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
in NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Studies NN O O
Reported NN O O
in NN O O
>=2 NN O O
% NN O O
of NN O O
Patients NN O O
Treated NN O O
with NN O O
FARXIGA NN O O
Adverse NN O O
Reaction NN O O
% NN O O
of NN O O
Patients NN O O
Pool NN O O
of NN O O
12 NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Studies NN O O
Placebo NN O O
N=1393 NN O O
FARXIGA NN O O
5 NN O O
mg NN O O
N=1145 NN O O
FARXIGA NN O O
10 NN O O
mg NN O O
N=1193 NN O O
Female NN O O
genital NN O O
mycotic NN O O
infectionsGenital NN O O
mycotic NN O O
infections NN O O
include NN O O
the NN O O
following NN O O
adverse NN O O
reactions NN O O
, NN O O
listed NN O O
in NN O O
order NN O O
of NN O O
frequency NN O O
reported NN O O
for NN O O
females NN O O
: NN O O
vulvovaginal NN B-AdverseReaction B-AdverseReaction
mycotic NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
vaginal NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
vulvovaginal NN B-AdverseReaction B-AdverseReaction
candidiasis NN I-AdverseReaction I-AdverseReaction
vulvovaginitis NN B-AdverseReaction B-AdverseReaction
genital NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
genital NN B-AdverseReaction B-AdverseReaction
candidiasis NN I-AdverseReaction I-AdverseReaction
fungal NN B-AdverseReaction B-AdverseReaction
genital NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
vulvitis NN B-AdverseReaction B-AdverseReaction
genitourinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
vulval NN B-AdverseReaction B-AdverseReaction
abscess NN I-AdverseReaction I-AdverseReaction
and NN O O
vaginitis NN B-AdverseReaction B-AdverseReaction
bacterial NN I-AdverseReaction I-AdverseReaction
( NN O O
N NN O O
for NN O O
females NN O O
: NN O O
Placebo=677 NN O O
, NN O O
FARXIGA NN O O
5 NN O O
mg=581 NN O O
, NN O O
FARXIGA NN O O
10 NN O O
mg=598 NN O O
) NN O O
. NN O O
1.5 NN O O
8.4 NN O O
6.9 NN O O
Nasopharyngitis NN B-AdverseReaction B-AdverseReaction
6.2 NN O O
6.6 NN O O
6.3 NN O O
Urinary NN O O
tract NN O O
infectionsUrinary NN O O
tract NN O O
infections NN O O
include NN O O
the NN O O
following NN O O
adverse NN O O
reactions NN O O
, NN O O
listed NN O O
in NN O O
order NN O O
of NN O O
frequency NN O O
reported NN O O
: NN O O
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
cystitis NN B-AdverseReaction B-AdverseReaction
Escherichia NN B-AdverseReaction B-AdverseReaction
urinary NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
genitourinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
pyelonephritis NN B-AdverseReaction B-AdverseReaction
trigonitis NN B-AdverseReaction B-AdverseReaction
urethritis NN B-AdverseReaction B-AdverseReaction
kidney NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
and NN O O
prostatitis NN B-AdverseReaction B-AdverseReaction
3.7 NN O O
5.7 NN O O
4.3 NN O O
Back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
3.2 NN O O
3.1 NN O O
4.2 NN O O
Increased NN O O
urinationIncreased NN O O
urination NN O O
includes NN O O
the NN O O
following NN O O
adverse NN O O
reactions NN O O
, NN O O
listed NN O O
in NN O O
order NN O O
of NN O O
frequency NN O O
reported NN O O
: NN O O
pollakiuria NN B-AdverseReaction B-AdverseReaction
polyuria NN B-AdverseReaction B-AdverseReaction
and NN O O
urine NN B-AdverseReaction B-AdverseReaction
output NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
1.7 NN O O
2.9 NN O O
3.8 NN O O
Male NN O O
genital NN O O
mycotic NN O O
infectionsGenital NN O O
mycotic NN O O
infections NN O O
include NN O O
the NN O O
following NN O O
adverse NN O O
reactions NN O O
, NN O O
listed NN O O
in NN O O
order NN O O
of NN O O
frequency NN O O
reported NN O O
for NN O O
males NN O O
: NN O O
balanitis NN B-AdverseReaction B-AdverseReaction
fungal NN B-AdverseReaction B-AdverseReaction
genital NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
balanitis NN B-AdverseReaction B-AdverseReaction
candida NN I-AdverseReaction I-AdverseReaction
genital NN B-AdverseReaction B-AdverseReaction
candidiasis NN I-AdverseReaction I-AdverseReaction
genital NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
male NN I-AdverseReaction I-AdverseReaction
penile NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
balanoposthitis NN B-AdverseReaction B-AdverseReaction
balanoposthitis NN B-AdverseReaction B-AdverseReaction
infective NN I-AdverseReaction I-AdverseReaction
genital NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
posthitis NN B-AdverseReaction B-AdverseReaction
( NN O O
N NN O O
for NN O O
males NN O O
: NN O O
Placebo=716 NN O O
, NN O O
FARXIGA NN O O
5 NN O O
mg=564 NN O O
, NN O O
FARXIGA NN O O
10 NN O O
mg=595 NN O O
) NN O O
. NN O O
0.3 NN O O
2.8 NN O O
2.7 NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
2.4 NN O O
2.8 NN O O
2.5 NN O O
Influenza NN B-AdverseReaction B-AdverseReaction
2.3 NN O O
2.7 NN O O
2.3 NN O O
Dyslipidemia NN B-AdverseReaction B-AdverseReaction
1.5 NN O O
2.1 NN O O
2.5 NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
1.5 NN O O
2.2 NN O O
1.9 NN O O
Discomfort NN B-AdverseReaction B-AdverseReaction
with NN I-AdverseReaction I-AdverseReaction
urination NN I-AdverseReaction I-AdverseReaction
0.7 NN O O
1.6 NN O O
2.1 NN O O
Pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
1.4 NN O O
2.0 NN O O
1.7 NN O O
Pool NN O O
of NN O O
13 NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Studies NN O O
for NN O O
FARXIGA NN O O
10 NN O O
mg NN O O
The NN O O
safety NN O O
and NN O O
tolerability NN O O
of NN O O
FARXIGA NN O O
10 NN O O
mg NN O O
was NN O O
also NN O O
evaluated NN O O
in NN O O
a NN O O
larger NN O O
placebo NN O O
- NN O O
controlled NN O O
study NN O O
pool NN O O
. NN O O
This NN O O
pool NN O O
combined NN O O
13 NN O O
placebo NN O O
- NN O O
controlled NN O O
studies NN O O
, NN O O
including NN O O
3 NN O O
monotherapy NN O O
studies NN O O
, NN O O
9 NN O O
add NN O O
- NN O O
on NN O O
to NN O O
background NN O O
antidiabetic NN O O
therapy NN O O
studies NN O O
, NN O O
and NN O O
an NN O O
initial NN O O
combination NN O O
with NN O O
metformin NN O O
study NN O O
. NN O O
Across NN O O
these NN O O
13 NN O O
studies NN O O
, NN O O
2360 NN O O
patients NN O O
were NN O O
treated NN O O
once NN O O
daily NN O O
with NN O O
FARXIGA NN O O
10 NN O O
mg NN O O
for NN O O
a NN O O
mean NN O O
duration NN O O
of NN O O
exposure NN O O
of NN O O
22 NN O O
weeks NN O O
. NN O O
The NN O O
mean NN O O
age NN O O
of NN O O
the NN O O
population NN O O
was NN O O
59 NN O O
years NN O O
and NN O O
4 NN O O
% NN O O
were NN O O
older NN O O
than NN O O
75 NN O O
years NN O O
. NN O O
Fifty NN O O
- NN O O
eight NN O O
percent NN O O
( NN O O
58 NN O O
% NN O O
) NN O O
of NN O O
the NN O O
population NN O O
were NN O O
male NN O O
; NN O O
84 NN O O
% NN O O
were NN O O
White NN O O
, NN O O
9 NN O O
% NN O O
were NN O O
Asian NN O O
, NN O O
and NN O O
3 NN O O
% NN O O
were NN O O
Black NN O O
or NN O O
African NN O O
American NN O O
. NN O O
At NN O O
baseline NN O O
, NN O O
the NN O O
population NN O O
had NN O O
diabetes NN O O
for NN O O
an NN O O
average NN O O
of NN O O
9 NN O O
years NN O O
, NN O O
had NN O O
a NN O O
mean NN O O
HbA1c NN O O
of NN O O
8.2 NN O O
% NN O O
, NN O O
and NN O O
30 NN O O
% NN O O
had NN O O
established NN O O
microvascular NN O O
disease NN O O
. NN O O
Baseline NN O O
renal NN O O
function NN O O
was NN O O
normal NN O O
or NN O O
mildly NN O O
impaired NN O O
in NN O O
88 NN O O
% NN O O
of NN O O
patients NN O O
and NN O O
moderately NN O O
impaired NN O O
in NN O O
11 NN O O
% NN O O
of NN O O
patients NN O O
( NN O O
mean NN O O
eGFR NN O O
82 NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
) NN O O
. NN O O
Volume NN O O
Depletion NN O O
FARXIGA NN O O
causes NN O O
an NN O O
osmotic NN B-AdverseReaction B-AdverseReaction
diuresis NN I-AdverseReaction I-AdverseReaction
which NN O O
may NN B-Factor B-Factor
lead NN O O
to NN O O
reductions NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
intravascular NN I-AdverseReaction I-AdverseReaction
volume NN I-AdverseReaction I-AdverseReaction
Adverse NN O O
reactions NN O O
related NN O O
to NN O O
volume NN B-AdverseReaction B-AdverseReaction
depletion NN I-AdverseReaction I-AdverseReaction
( NN O O
including NN O O
reports NN O O
of NN O O
dehydration NN B-AdverseReaction B-AdverseReaction
hypovolemia NN B-AdverseReaction B-AdverseReaction
orthostatic NN B-AdverseReaction B-AdverseReaction
hypotension NN I-AdverseReaction I-AdverseReaction
or NN O O
hypotension NN B-AdverseReaction B-AdverseReaction
are NN O O
shown NN O O
in NN O O
Table NN O O
2 NN O O
for NN O O
the NN O O
12-study NN O O
and NN O O
13-study NN O O
, NN O O
short NN O O
- NN O O
term NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
pools NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
Table NN O O
2 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
of NN O O
Volume NN B-AdverseReaction B-AdverseReaction
Depletion NN I-AdverseReaction I-AdverseReaction
depletion NN O O
includes NN O O
reports NN O O
of NN O O
dehydration NN B-AdverseReaction B-AdverseReaction
hypovolemia NN B-AdverseReaction B-AdverseReaction
orthostatic NN B-AdverseReaction B-AdverseReaction
hypotension NN I-AdverseReaction I-AdverseReaction
or NN O O
hypotension NN B-AdverseReaction B-AdverseReaction
in NN O O
Clinical NN O O
Studies NN O O
with NN O O
FARXIGA NN O O
Pool NN O O
of NN O O
12 NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Studies NN O O
Pool NN O O
of NN O O
13 NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Studies NN O O
Placebo NN O O
FARXIGA NN O O
5 NN O O
mg NN O O
FARXIGA NN O O
10 NN O O
mg NN O O
Placebo NN O O
FARXIGA NN O O
10 NN O O
mg NN O O
Overall NN O O
population NN O O
N NN O O
( NN O O
% NN O O
) NN O O
N=1393 NN O O
5 NN O O
( NN O O
0.4 NN O O
% NN O O
) NN O O
N=1145 NN O O
7 NN O O
( NN O O
0.6 NN O O
% NN O O
) NN O O
N=1193 NN O O
9 NN O O
( NN O O
0.8 NN O O
% NN O O
) NN O O
N=2295 NN O O
17 NN O O
( NN O O
0.7 NN O O
% NN O O
) NN O O
N=2360 NN O O
27 NN O O
( NN O O
1.1 NN O O
% NN O O
) NN O O
Patient NN O O
Subgroup NN O O
n NN O O
( NN O O
% NN O O
) NN O O
Patients NN O O
on NN O O
loop NN O O
diuretics NN O O
n=551 NN O O
( NN O O
1.8 NN O O
% NN O O
) NN O O
n=400 NN O O
n=313 NN O O
( NN O O
9.7 NN O O
% NN O O
) NN O O
n=2674 NN O O
( NN O O
1.5 NN O O
% NN O O
) NN O O
n=2366 NN O O
( NN O O
2.5 NN O O
% NN O O
) NN O O
Patients NN O O
with NN O O
moderate NN O O
renal NN O O
impairment NN O O
with NN O O
eGFR NN O O
>=30 NN O O
and NN O O
< NN O O
60 NN O O
mL/min/1.73 NN O O
m2 NN O O
n=1072 NN O O
( NN O O
1.9 NN O O
% NN O O
) NN O O
n=1071 NN O O
( NN O O
0.9 NN O O
% NN O O
) NN O O
n=891 NN O O
( NN O O
1.1 NN O O
% NN O O
) NN O O
n=2684 NN O O
( NN O O
1.5 NN O O
% NN O O
) NN O O
n=2655 NN O O
( NN O O
1.9 NN O O
% NN O O
) NN O O
Patients NN O O
>=65 NN O O
years NN O O
of NN O O
age NN O O
n=2761 NN O O
( NN O O
0.4 NN O O
% NN O O
) NN O O
n=2161 NN O O
( NN O O
0.5 NN O O
% NN O O
) NN O O
n=2043 NN O O
( NN O O
1.5 NN O O
% NN O O
) NN O O
n=7116 NN O O
( NN O O
0.8 NN O O
% NN O O
) NN O O
n=66511 NN O O
( NN O O
1.7 NN O O
% NN O O
) NN O O
Impairment NN O O
of NN O O
Renal NN O O
Function NN O O
Use NN O O
of NN O O
FARXIGA NN O O
was NN O O
associated NN O O
with NN O O
increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
and NN O O
decreases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
eGFR NN I-AdverseReaction I-AdverseReaction
( NN O O
see NN O O
Table NN O O
3 NN O O
) NN O O
. NN O O
In NN O O
patients NN O O
with NN O O
normal NN O O
or NN O O
mildly NN O O
impaired NN O O
renal NN O O
function NN O O
at NN O O
baseline NN O O
, NN O O
serum NN O O
creatinine NN O O
and NN O O
eGFR NN O O
returned NN O O
to NN O O
baseline NN O O
values NN O O
at NN O O
Week NN O O
24 NN O O
. NN O O
Renal NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
renal NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
and NN O O
blood NN B-AdverseReaction B-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
increase NN I-AdverseReaction I-AdverseReaction
were NN O O
more NN O O
frequent NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
FARXIGA NN O O
( NN O O
see NN O O
Table NN O O
4 NN O O
) NN O O
. NN O O
Elderly NN O O
patients NN O O
and NN O O
patients NN O O
with NN O O
impaired NN O O
renal NN O O
function NN O O
were NN O O
more NN O O
susceptible NN O O
to NN O O
these NN O O
adverse NN O O
reactions NN O O
( NN O O
see NN O O
Table NN O O
4 NN O O
) NN O O
. NN O O
Sustained NN O O
decreases NN O O
in NN O O
eGFR NN O O
were NN O O
seen NN O O
in NN O O
patients NN O O
with NN O O
moderate NN O O
renal NN O O
impairment NN O O
( NN O O
eGFR NN O O
30 NN O O
to NN O O
less NN O O
than NN O O
60 NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
) NN O O
. NN O O
Table NN O O
3 NN O O
: NN O O
Changes NN O O
in NN O O
Serum NN O O
Creatinine NN O O
and NN O O
eGFR NN O O
Associated NN O O
with NN O O
FARXIGA NN O O
in NN O O
the NN O O
Pool NN O O
of NN O O
12 NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Studies NN O O
and NN O O
Moderate NN O O
Renal NN O O
Impairment NN O O
Study NN O O
Pool NN O O
of NN O O
12 NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Studies NN O O
PlaceboN=1393 NN O O
FARXIGA NN O O
5 NN O O
mgN=1145 NN O O
FARXIGA NN O O
10 NN O O
mgN=1193 NN O O
Baseline NN O O
Mean NN O O
Serum NN O O
Creatinine NN O O
( NN O O
mg/dL NN O O
) NN O O
0.853 NN O O
0.860 NN O O
0.847 NN O O
eGFR NN O O
( NN O O
mL/min/1.73 NN O O
m2 NN O O
) NN O O
86.0 NN O O
85.3 NN O O
86.7 NN O O
Week NN O O
1 NN O O
Change NN O O
Serum NN O O
Creatinine NN O O
( NN O O
mg/dL NN O O
) NN O O
-0.003 NN O O
0.029 NN O O
0.041 NN O O
eGFR NN O O
( NN O O
mL/min/1.73 NN O O
m2 NN O O
) NN O O
0.4 NN O O
-2.9 NN O O
-4.1 NN O O
Week NN O O
24 NN O O
Change NN O O
Serum NN O O
Creatinine NN O O
( NN O O
mg/dL NN O O
) NN O O
-0.005 NN O O
-0.001 NN O O
0.001 NN O O
eGFR NN O O
( NN O O
mL/min/1.73 NN O O
m2 NN O O
) NN O O
0.8 NN O O
0.8 NN O O
0.3 NN O O
Moderate NN O O
Renal NN O O
Impairment NN O O
Study NN O O
PlaceboN=84 NN O O
FARXIGA NN O O
5 NN O O
mgN=83 NN O O
FARXIGA NN O O
10 NN O O
mgN=85 NN O O
Baseline NN O O
Mean NN O O
Serum NN O O
Creatinine NN O O
( NN O O
mg/dL NN O O
) NN O O
1.46 NN O O
1.53 NN O O
1.52 NN O O
eGFR NN O O
( NN O O
mL/min/1.73 NN O O
m2 NN O O
) NN O O
45.6 NN O O
44.2 NN O O
43.9 NN O O
Week NN O O
1 NN O O
Change NN O O
Serum NN O O
Creatinine NN O O
( NN O O
mg/dL NN O O
) NN O O
0.01 NN O O
0.13 NN O O
0.18 NN O O
eGFR NN O O
( NN O O
mL/min/1.73 NN O O
m2 NN O O
) NN O O
0.5 NN O O
-3.8 NN O O
-5.5 NN O O
Week NN O O
24 NN O O
Change NN O O
Serum NN O O
Creatinine NN O O
( NN O O
mg/dL NN O O
) NN O O
0.02 NN O O
0.08 NN O O
0.16 NN O O
eGFR NN O O
( NN O O
mL/min/1.73 NN O O
m2 NN O O
) NN O O
0.03 NN O O
-4.0 NN O O
-7.4 NN O O
Week NN O O
52 NN O O
Change NN O O
Serum NN O O
Creatinine NN O O
( NN O O
mg/dL NN O O
) NN O O
0.10 NN O O
0.06 NN O O
0.15 NN O O
eGFR NN O O
( NN O O
mL/min/1.73 NN O O
m2 NN O O
) NN O O
-2.6 NN O O
-4.2 NN O O
-7.3 NN O O
Table NN O O
4 NN O O
: NN O O
Proportion NN O O
of NN O O
Patients NN O O
with NN O O
at NN O O
Least NN O O
One NN O O
Renal NN B-AdverseReaction B-AdverseReaction
Impairment NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Related NN I-AdverseReaction I-AdverseReaction
Adverse NN I-AdverseReaction I-AdverseReaction
Reaction NN I-AdverseReaction I-AdverseReaction
Pool NN O O
of NN O O
6 NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Studies NN O O
( NN O O
up NN O O
to NN O O
104 NN O O
weeks NN O O
) NN O O
Pool NN O O
of NN O O
9 NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Studies NN O O
( NN O O
up NN O O
to NN O O
104 NN O O
weeks NN O O
) NN O O
Baseline NN O O
Characteristic NN O O
Placebo NN O O
FARXIGA NN O O
5 NN O O
mg NN O O
FARXIGA NN O O
10 NN O O
mg NN O O
Placebo NN O O
FARXIGA NN O O
10 NN O O
mg NN O O
Overall NN O O
populationPatients NN O O
( NN O O
% NN O O
) NN O O
with NN O O
at NN O O
least NN O O
one NN O O
event NN O O
n=78513 NN O O
( NN O O
1.7 NN O O
% NN O O
) NN O O
n=76714 NN O O
( NN O O
1.8 NN O O
% NN O O
) NN O O
n=85916 NN O O
( NN O O
1.9 NN O O
% NN O O
) NN O O
n=195682 NN O O
( NN O O
4.2 NN O O
% NN O O
) NN O O
n=2026136 NN O O
( NN O O
6.7 NN O O
% NN O O
) NN O O
65 NN O O
years NN O O
of NN O O
age NN O O
and NN O O
older NN O O
Patients NN O O
( NN O O
% NN O O
) NN O O
with NN O O
at NN O O
least NN O O
one NN O O
event NN O O
n=1904 NN O O
( NN O O
2.1 NN O O
% NN O O
) NN O O
n=1625 NN O O
( NN O O
3.1 NN O O
% NN O O
) NN O O
n=1596 NN O O
( NN O O
3.8 NN O O
% NN O O
) NN O O
n=65552 NN O O
( NN O O
7.9 NN O O
% NN O O
) NN O O
n=62087 NN O O
( NN O O
14.0 NN O O
% NN O O
) NN O O
eGFR NN O O
>=30 NN O O
and NN O O
< NN O O
60 NN O O
mL/min/1.73 NN O O
m2Patients NN O O
( NN O O
% NN O O
) NN O O
with NN O O
at NN O O
least NN O O
one NN O O
event NN O O
n=775 NN O O
( NN O O
6.5 NN O O
% NN O O
) NN O O
n=887 NN O O
( NN O O
8.0 NN O O
% NN O O
) NN O O
n=75 NN O O
9 NN O O
( NN O O
12.0 NN O O
% NN O O
) NN O O
n=24940 NN O O
( NN O O
16.1 NN O O
% NN O O
) NN O O
n=25171 NN O O
( NN O O
28.3 NN O O
% NN O O
) NN O O
65 NN O O
years NN O O
of NN O O
age NN O O
and NN O O
older NN O O
and NN O O
eGFR NN O O
>=30 NN O O
and NN O O
< NN O O
60 NN O O
mL/min/1.73 NN O O
m2Patients NN O O
( NN O O
% NN O O
) NN O O
with NN O O
at NN O O
least NN O O
one NN O O
event NN O O
n=412 NN O O
( NN O O
4.9 NN O O
% NN O O
) NN O O
n=433 NN O O
( NN O O
7.0 NN O O
% NN O O
) NN O O
n=354 NN O O
( NN O O
11.4 NN O O
% NN O O
) NN O O
n=14127 NN O O
( NN O O
19.1 NN O O
% NN O O
) NN O O
n=13447 NN O O
( NN O O
35.1 NN O O
% NN O O
) NN O O
The NN O O
safety NN O O
of NN O O
FARXIGA NN O O
was NN O O
evaluated NN O O
in NN O O
a NN O O
study NN O O
of NN O O
patients NN O O
with NN O O
moderate NN O O
renal NN O O
impairment NN O O
( NN O O
eGFR NN O O
30 NN O O
to NN O O
less NN O O
than NN O O
60 NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
) NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
. NN O O
In NN O O
this NN O O
study NN O O
13 NN O O
patients NN O O
experienced NN O O
bone NN B-AdverseReaction B-AdverseReaction
fractures NN I-AdverseReaction I-AdverseReaction
for NN O O
treatment NN O O
durations NN O O
up NN O O
to NN O O
104 NN O O
weeks NN O O
. NN O O
No NN O O
fractures NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
, NN O O
5 NN O O
occurred NN O O
in NN O O
the NN O O
FARXIGA NN O O
5 NN O O
mg NN O O
group NN O O
, NN O O
and NN O O
8 NN O O
occurred NN O O
in NN O O
the NN O O
FARXIGA NN O O
10 NN O O
mg NN O O
group NN O O
. NN O O
Eight NN O O
of NN O O
these NN O O
13 NN O O
fractures NN B-AdverseReaction B-AdverseReaction
were NN O O
in NN O O
patients NN O O
who NN O O
had NN O O
a NN O O
baseline NN O O
eGFR NN O O
of NN O O
30 NN O O
to NN O O
45 NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
. NN O O
Eleven NN O O
of NN O O
the NN O O
13 NN O O
fractures NN B-AdverseReaction B-AdverseReaction
were NN O O
reported NN O O
within NN O O
the NN O O
first NN O O
52 NN O O
weeks NN O O
. NN O O
There NN O O
was NN O O
no NN O O
apparent NN O O
pattern NN O O
with NN O O
respect NN O O
to NN O O
the NN O O
anatomic NN O O
site NN O O
of NN O O
fracture NN B-AdverseReaction B-AdverseReaction
Hypoglycemia NN O O
The NN O O
frequency NN O O
of NN O O
hypoglycemia NN B-AdverseReaction B-AdverseReaction
by NN O O
study NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
is NN O O
shown NN O O
in NN O O
Table NN O O
5 NN O O
. NN O O
Hypoglycemia NN B-AdverseReaction B-AdverseReaction
was NN O O
more NN O O
frequent NN O O
when NN O O
FARXIGA NN O O
was NN O O
added NN O O
to NN O O
sulfonylurea NN O O
or NN O O
insulin NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
. NN O O
Table NN O O
5 NN O O
: NN O O
Incidence NN O O
of NN O O
MajorMajor NN O O
episodes NN O O
of NN O O
hypoglycemia NN B-AdverseReaction B-AdverseReaction
were NN O O
defined NN O O
as NN O O
symptomatic NN O O
episodes NN O O
requiring NN O O
external NN O O
( NN O O
third NN O O
party NN O O
) NN O O
assistance NN O O
due NN O O
to NN O O
severe NN B-Severity B-Severity
impairment NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
consciousness NN I-AdverseReaction I-AdverseReaction
or NN O O
behavior NN O O
with NN O O
a NN O O
capillary NN O O
or NN O O
plasma NN B-AdverseReaction B-AdverseReaction
glucose NN I-AdverseReaction I-AdverseReaction
value NN I-AdverseReaction I-AdverseReaction
< NN I-AdverseReaction I-AdverseReaction
54 NN I-AdverseReaction I-AdverseReaction
mg/dL NN I-AdverseReaction I-AdverseReaction
and NN O O
prompt NN O O
recovery NN O O
after NN O O
glucose NN O O
or NN O O
glucagon NN O O
administration NN O O
. NN O O
and NN O O
MinorMinor NN O O
episodes NN O O
of NN O O
hypoglycemia NN B-AdverseReaction B-AdverseReaction
were NN O O
defined NN O O
as NN O O
either NN O O
a NN O O
symptomatic NN O O
episode NN O O
with NN O O
a NN O O
capillary NN O O
or NN O O
plasma NN B-AdverseReaction B-AdverseReaction
glucose NN I-AdverseReaction I-AdverseReaction
measurement NN I-AdverseReaction I-AdverseReaction
< NN I-AdverseReaction I-AdverseReaction
63 NN I-AdverseReaction I-AdverseReaction
mg/dL NN I-AdverseReaction I-AdverseReaction
regardless NN O O
of NN O O
need NN O O
for NN O O
external NN O O
assistance NN O O
, NN O O
or NN O O
an NN O O
asymptomatic NN O O
capillary NN O O
or NN O O
plasma NN B-AdverseReaction B-AdverseReaction
glucose NN I-AdverseReaction I-AdverseReaction
measurement NN I-AdverseReaction I-AdverseReaction
< NN I-AdverseReaction I-AdverseReaction
63 NN I-AdverseReaction I-AdverseReaction
mg/dL NN I-AdverseReaction I-AdverseReaction
that NN O O
does NN O O
not NN O O
qualify NN O O
as NN O O
a NN O O
major NN O O
episode NN O O
. NN O O
Hypoglycemia NN B-AdverseReaction B-AdverseReaction
in NN O O
Controlled NN O O
Clinical NN O O
Studies NN O O
Placebo/Active NN O O
Control NN O O
FARXIGA NN O O
5 NN O O
mg NN O O
FARXIGA NN O O
10 NN O O
mg NN O O
Monotherapy NN O O
( NN O O
24 NN O O
weeks NN O O
) NN O O
N=75 NN O O
N=64 NN O O
N=70 NN O O
Major NN O O
[ NN O O
n NN O O
( NN O O
% NN O O
) NN O O
] NN O O
0 NN O O
0 NN O O
0 NN O O
Minor NN O O
[ NN O O
n NN O O
( NN O O
% NN O O
) NN O O
] NN O O
0 NN O O
0 NN O O
0 NN O O
Add NN O O
- NN O O
on NN O O
to NN O O
Metformin NN O O
( NN O O
24 NN O O
weeks NN O O
) NN O O
N=137 NN O O
N=137 NN O O
N=135 NN O O
Major NN O O
[ NN O O
n NN O O
( NN O O
% NN O O
) NN O O
] NN O O
0 NN O O
0 NN O O
0 NN O O
Minor NN O O
[ NN O O
n NN O O
( NN O O
% NN O O
) NN O O
] NN O O
0 NN O O
2 NN O O
( NN O O
1.5 NN O O
) NN O O
1 NN O O
( NN O O
0.7 NN O O
) NN O O
Active NN O O
Control NN O O
Add NN O O
- NN O O
on NN O O
to NN O O
Metformin NN O O
versus NN O O
Glipizide NN O O
( NN O O
52 NN O O
weeks NN O O
) NN O O
N=408 NN O O
- NN O O
N=406 NN O O
Major NN O O
[ NN O O
n NN O O
( NN O O
% NN O O
) NN O O
] NN O O
3 NN O O
( NN O O
0.7 NN O O
) NN O O
- NN O O
0 NN O O
Minor NN O O
[ NN O O
n NN O O
( NN O O
% NN O O
) NN O O
] NN O O
147 NN O O
( NN O O
36.0 NN O O
) NN O O
- NN O O
7 NN O O
( NN O O
1.7 NN O O
) NN O O
Add NN O O
- NN O O
on NN O O
to NN O O
Glimepiride NN O O
( NN O O
24 NN O O
weeks NN O O
) NN O O
N=146 NN O O
N=145 NN O O
N=151 NN O O
Major NN O O
[ NN O O
n NN O O
( NN O O
% NN O O
) NN O O
] NN O O
0 NN O O
0 NN O O
0 NN O O
Minor NN O O
[ NN O O
n NN O O
( NN O O
% NN O O
) NN O O
] NN O O
3 NN O O
( NN O O
2.1 NN O O
) NN O O
8 NN O O
( NN O O
5.5 NN O O
) NN O O
9 NN O O
( NN O O
6.0 NN O O
) NN O O
Add NN O O
- NN O O
on NN O O
to NN O O
Metformin NN O O
and NN O O
a NN O O
Sulfonylurea NN O O
( NN O O
24 NN O O
Weeks NN O O
) NN O O
N=109 NN O O
- NN O O
N=109 NN O O
Major NN O O
[ NN O O
n NN O O
( NN O O
% NN O O
) NN O O
] NN O O
0 NN O O
- NN O O
0 NN O O
Minor NN O O
[ NN O O
n NN O O
( NN O O
% NN O O
) NN O O
] NN O O
4 NN O O
( NN O O
3.7 NN O O
) NN O O
- NN O O
14 NN O O
( NN O O
12.8 NN O O
) NN O O
Add NN O O
- NN O O
on NN O O
to NN O O
Pioglitazone NN O O
( NN O O
24 NN O O
weeks NN O O
) NN O O
N=139 NN O O
N=141 NN O O
N=140 NN O O
Major NN O O
[ NN O O
n NN O O
( NN O O
% NN O O
) NN O O
] NN O O
0 NN O O
0 NN O O
0 NN O O
Minor NN O O
[ NN O O
n NN O O
( NN O O
% NN O O
) NN O O
] NN O O
0 NN O O
3 NN O O
( NN O O
2.1 NN O O
) NN O O
0 NN O O
Add NN O O
- NN O O
on NN O O
to NN O O
DPP4 NN O O
inhibitor NN O O
( NN O O
24 NN O O
weeks NN O O
) NN O O
N=226 NN O O
- NN O O
N=225 NN O O
Major NN O O
[ NN O O
n NN O O
( NN O O
% NN O O
) NN O O
] NN O O
0 NN O O
- NN O O
1 NN O O
( NN O O
0.4 NN O O
) NN O O
Minor NN O O
[ NN O O
n NN O O
( NN O O
% NN O O
) NN O O
] NN O O
3 NN O O
( NN O O
1.3 NN O O
) NN O O
- NN O O
4 NN O O
( NN O O
1.8 NN O O
) NN O O
Add NN O O
- NN O O
on NN O O
to NN O O
Insulin NN O O
with NN O O
or NN O O
without NN O O
other NN O O
OADsOAD NN O O
= NN O O
oral NN O O
antidiabetic NN O O
therapy NN O O
. NN O O
( NN O O
24 NN O O
weeks NN O O
) NN O O
N=197 NN O O
N=212 NN O O
N=196 NN O O
Major NN O O
[ NN O O
n NN O O
( NN O O
% NN O O
) NN O O
] NN O O
1 NN O O
( NN O O
0.5 NN O O
) NN O O
1 NN O O
( NN O O
0.5 NN O O
) NN O O
1 NN O O
( NN O O
0.5 NN O O
) NN O O
Minor NN O O
[ NN O O
n NN O O
( NN O O
% NN O O
) NN O O
] NN O O
67 NN O O
( NN O O
34.0 NN O O
) NN O O
92 NN O O
( NN O O
43.4 NN O O
) NN O O
79 NN O O
( NN O O
40.3 NN O O
) NN O O
Genital NN O O
Mycotic NN O O
Infections NN O O
Genital NN B-AdverseReaction B-AdverseReaction
mycotic NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
were NN O O
more NN O O
frequent NN O O
with NN O O
FARXIGA NN O O
treatment NN O O
. NN O O
Genital NN B-AdverseReaction B-AdverseReaction
mycotic NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
in NN O O
0.9 NN O O
% NN O O
of NN O O
patients NN O O
on NN O O
placebo NN O O
, NN O O
5.7 NN O O
% NN O O
on NN O O
FARXIGA NN O O
5 NN O O
mg NN O O
, NN O O
and NN O O
4.8 NN O O
% NN O O
on NN O O
FARXIGA NN O O
10 NN O O
mg NN O O
, NN O O
in NN O O
the NN O O
12-study NN O O
placebo NN O O
- NN O O
controlled NN O O
pool NN O O
. NN O O
Discontinuation NN O O
from NN O O
study NN O O
due NN O O
to NN O O
genital NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
0 NN O O
% NN O O
of NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
0.2 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
FARXIGA NN O O
10 NN O O
mg NN O O
. NN O O
Infections NN B-AdverseReaction B-AdverseReaction
were NN O O
more NN O O
frequently NN O O
reported NN O O
in NN O O
females NN O O
than NN O O
in NN O O
males NN O O
( NN O O
see NN O O
Table NN O O
1 NN O O
) NN O O
. NN O O
The NN O O
most NN O O
frequently NN O O
reported NN O O
genital NN B-AdverseReaction B-AdverseReaction
mycotic NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
were NN O O
vulvovaginal NN B-AdverseReaction B-AdverseReaction
mycotic NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
in NN O O
females NN O O
and NN O O
balanitis NN B-AdverseReaction B-AdverseReaction
in NN O O
males NN O O
. NN O O
Patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
genital NN O O
mycotic NN O O
infections NN O O
were NN O O
more NN O O
likely NN O O
to NN O O
have NN O O
a NN O O
genital NN B-AdverseReaction B-AdverseReaction
mycotic NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
during NN O O
the NN O O
study NN O O
than NN O O
those NN O O
with NN O O
no NN O O
prior NN O O
history NN O O
( NN O O
10.0 NN O O
% NN O O
, NN O O
23.1 NN O O
% NN O O
, NN O O
and NN O O
25.0 NN O O
% NN O O
versus NN O O
0.8 NN O O
% NN O O
, NN O O
5.9 NN O O
% NN O O
, NN O O
and NN O O
5.0 NN O O
% NN O O
on NN O O
placebo NN O O
, NN O O
FARXIGA NN O O
5 NN O O
mg NN O O
, NN O O
and NN O O
FARXIGA NN O O
10 NN O O
mg NN O O
, NN O O
respectively NN O O
) NN O O
. NN O O
Hypersensitivity NN O O
Reactions NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
( NN O O
e.g. NN O O
, NN O O
angioedema NN B-AdverseReaction B-AdverseReaction
urticaria NN B-AdverseReaction B-AdverseReaction
hypersensitivity NN B-AdverseReaction B-AdverseReaction
were NN O O
reported NN O O
with NN O O
FARXIGA NN O O
treatment NN O O
. NN O O
Across NN O O
the NN O O
clinical NN O O
program NN O O
, NN O O
serious NN B-Severity B-Severity
anaphylactic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
and NN O O
severe NN B-Severity B-Severity
cutaneous NN B-AdverseReaction B-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
and NN O O
angioedema NN B-AdverseReaction B-AdverseReaction
were NN O O
reported NN O O
in NN O O
0.2 NN O O
% NN O O
of NN O O
comparator NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
0.3 NN O O
% NN O O
of NN O O
FARXIGA NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
If NN O O
hypersensitivity NN O O
reactions NN O O
occur NN O O
, NN O O
discontinue NN O O
use NN O O
of NN O O
FARXIGA NN O O
; NN O O
treat NN O O
per NN O O
standard NN O O
of NN O O
care NN O O
and NN O O
monitor NN O O
until NN O O
signs NN O O
and NN O O
symptoms NN O O
resolve NN O O
. NN O O
Laboratory NN O O
Tests NN O O
Increase NN O O
in NN O O
Hematocrit NN O O
In NN O O
the NN O O
pool NN O O
of NN O O
13 NN O O
placebo NN O O
- NN O O
controlled NN O O
studies NN O O
, NN O O
increases NN O O
from NN O O
baseline NN O O
in NN O O
mean NN O O
hematocrit NN O O
values NN O O
were NN O O
observed NN O O
in NN O O
FARXIGA NN O O
- NN O O
treated NN O O
patients NN O O
starting NN O O
at NN O O
Week NN O O
1 NN O O
and NN O O
continuing NN O O
up NN O O
to NN O O
Week NN O O
16 NN O O
, NN O O
when NN O O
the NN O O
maximum NN O O
mean NN O O
difference NN O O
from NN O O
baseline NN O O
was NN O O
observed NN O O
. NN O O
At NN O O
Week NN O O
24 NN O O
, NN O O
the NN O O
mean NN O O
changes NN O O
from NN O O
baseline NN O O
in NN O O
hematocrit NN O O
were NN O O
-0.33 NN O O
% NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
and NN O O
2.30 NN O O
% NN O O
in NN O O
the NN O O
FARXIGA NN O O
10 NN O O
mg NN O O
group NN O O
. NN O O
By NN O O
Week NN O O
24 NN O O
, NN O O
hematocrit NN B-AdverseReaction B-AdverseReaction
values NN I-AdverseReaction I-AdverseReaction
>55 NN I-AdverseReaction I-AdverseReaction
% NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
in NN O O
0.4 NN O O
% NN O O
of NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
1.3 NN O O
% NN O O
of NN O O
FARXIGA NN O O
10 NN O O
mg NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Increase NN O O
in NN O O
Serum NN O O
Inorganic NN O O
Phosphorus NN O O
In NN O O
the NN O O
pool NN O O
of NN O O
13 NN O O
placebo NN O O
- NN O O
controlled NN O O
studies NN O O
, NN O O
increases NN O O
from NN O O
baseline NN O O
in NN O O
mean NN O O
serum NN O O
phosphorus NN O O
levels NN O O
were NN O O
reported NN O O
at NN O O
Week NN O O
24 NN O O
in NN O O
FARXIGA NN O O
- NN O O
treated NN O O
patients NN O O
compared NN O O
with NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
( NN O O
mean NN O O
increase NN O O
of NN O O
0.13 NN O O
versus NN O O
-0.04 NN O O
mg/dL NN O O
, NN O O
respectively NN O O
) NN O O
. NN O O
Higher NN O O
proportions NN O O
of NN O O
patients NN O O
with NN O O
marked NN O O
laboratory NN O O
abnormalities NN O O
of NN O O
hyperphosphatemia NN B-AdverseReaction B-AdverseReaction
( NN O O
>=5.6 NN O O
mg/dL NN O O
for NN O O
age NN O O
17 NN O O
- NN O O
65 NN O O
years NN O O
or NN O O
>=5.1 NN O O
mg/dL NN O O
for NN O O
age NN O O
>=66 NN O O
years NN O O
) NN O O
were NN O O
reported NN O O
on NN O O
FARXIGA NN O O
at NN O O
Week NN O O
24 NN O O
( NN O O
0.9 NN O O
% NN O O
versus NN O O
1.7 NN O O
% NN O O
for NN O O
placebo NN O O
and NN O O
FARXIGA NN O O
10 NN O O
mg NN O O
, NN O O
respectively NN O O
) NN O O
. NN O O
Increase NN O O
in NN O O
Low NN O O
- NN O O
Density NN O O
Lipoprotein NN O O
Cholesterol NN O O
In NN O O
the NN O O
pool NN O O
of NN O O
13 NN O O
placebo NN O O
- NN O O
controlled NN O O
studies NN O O
, NN O O
changes NN O O
from NN O O
baseline NN O O
in NN O O
mean NN O O
lipid NN O O
values NN O O
were NN O O
reported NN O O
in NN O O
FARXIGA NN O O
- NN O O
treated NN O O
patients NN O O
compared NN O O
to NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Mean NN O O
percent NN O O
changes NN O O
from NN O O
baseline NN O O
at NN O O
Week NN O O
24 NN O O
, NN O O
were NN O O
0.0 NN O O
% NN O O
versus NN O O
2.5 NN O O
% NN O O
for NN O O
total NN O O
cholesterol NN O O
and NN O O
-1.0 NN O O
% NN O O
versus NN O O
2.9 NN O O
% NN O O
for NN O O
LDL NN O O
cholesterol NN O O
, NN O O
in NN O O
the NN O O
placebo NN O O
and NN O O
FARXIGA NN O O
10 NN O O
mg NN O O
groups NN O O
, NN O O
respectively NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Hypotension NN B-AdverseReaction B-AdverseReaction
Before NN O O
initiating NN O O
FARXIGA NN O O
, NN O O
assess NN O O
volume NN O O
status NN O O
and NN O O
correct NN O O
hypovolemia NN O O
in NN O O
the NN O O
elderly NN O O
, NN O O
in NN O O
patients NN O O
with NN O O
renal NN O O
impairment NN O O
or NN O O
low NN O O
systolic NN O O
blood NN O O
pressure NN O O
, NN O O
and NN O O
in NN O O
patients NN O O
on NN O O
diuretics NN O O
. NN O O
Monitor NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
during NN O O
therapy NN O O
. NN O O
( NN O O
5.1 NN O O
, NN O O
6.1 NN O O
) NN O O
* NN O O
Impairment NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
function NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
renal NN O O
function NN O O
during NN O O
therapy NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Hypoglycemia NN B-AdverseReaction B-AdverseReaction
In NN O O
patients NN O O
taking NN O O
insulin NN O O
or NN O O
an NN O O
insulin NN O O
secretagogue NN O O
with NN O O
FARXIGA NN O O
, NN O O
consider NN O O
a NN O O
lower NN O O
dose NN O O
of NN O O
insulin NN O O
or NN O O
the NN O O
insulin NN O O
secretagogue NN O O
to NN O O
reduce NN O O
the NN O O
risk NN O O
of NN O O
hypoglycemia NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Genital NN B-AdverseReaction B-AdverseReaction
mycotic NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
and NN O O
treat NN O O
if NN O O
indicated NN O O
. NN O O
( NN O O
5.4 NN O O
) NN O O
* NN O O
Increased NN B-AdverseReaction B-AdverseReaction
LDL NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
and NN O O
treat NN O O
per NN O O
standard NN O O
of NN O O
care NN O O
. NN O O
( NN O O
5.5 NN O O
) NN O O
* NN O O
Bladder NN B-AdverseReaction B-AdverseReaction
Cancer NN I-AdverseReaction I-AdverseReaction
An NN O O
imbalance NN O O
in NN O O
bladder NN B-AdverseReaction B-AdverseReaction
cancers NN I-AdverseReaction I-AdverseReaction
was NN O O
observed NN O O
in NN O O
clinical NN O O
trials NN O O
. NN O O
FARXIGA NN O O
should NN O O
not NN O O
be NN O O
used NN O O
in NN O O
patients NN O O
with NN O O
active NN O O
bladder NN O O
cancer NN O O
and NN O O
should NN O O
be NN O O
used NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
prior NN O O
history NN O O
of NN O O
bladder NN O O
cancer NN O O
. NN O O
( NN O O
5.6 NN O O
) NN O O
* NN O O
Macrovascular NN O O
outcomes NN O O
: NN O O
There NN O O
have NN O O
been NN O O
no NN O O
clinical NN O O
studies NN O O
establishing NN O O
conclusive NN O O
evidence NN O O
of NN O O
macrovascular NN O O
risk NN O O
reduction NN O O
with NN O O
FARXIGA NN O O
or NN O O
any NN O O
other NN O O
antidiabetic NN O O
drug NN O O
. NN O O
( NN O O
5.7 NN O O
) NN O O
5.1 NN O O
Hypotension NN O O
FARXIGA NN O O
causes NN O O
intravascular NN B-AdverseReaction B-AdverseReaction
volume NN I-AdverseReaction I-AdverseReaction
contraction NN I-AdverseReaction I-AdverseReaction
Symptomatic NN B-AdverseReaction B-AdverseReaction
hypotension NN I-AdverseReaction I-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
after NN O O
initiating NN O O
FARXIGA NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
particularly NN O O
in NN O O
patients NN O O
with NN O O
impaired NN O O
renal NN O O
function NN O O
( NN O O
eGFR NN O O
less NN O O
than NN O O
60 NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
) NN O O
, NN O O
elderly NN O O
patients NN O O
, NN O O
or NN O O
patients NN O O
on NN O O
loop NN O O
diuretics NN O O
. NN O O
Before NN O O
initiating NN O O
FARXIGA NN O O
in NN O O
patients NN O O
with NN O O
one NN O O
or NN O O
more NN O O
of NN O O
these NN O O
characteristics NN O O
, NN O O
volume NN O O
status NN O O
should NN O O
be NN O O
assessed NN O O
and NN O O
corrected NN O O
. NN O O
Monitor NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
hypotension NN O O
after NN O O
initiating NN O O
therapy NN O O
. NN O O
5.2 NN O O
Impairment NN O O
in NN O O
Renal NN O O
Function NN O O
FARXIGA NN O O
increases NN B-AdverseReaction B-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
and NN O O
decreases NN B-AdverseReaction B-AdverseReaction
eGFR NN I-AdverseReaction I-AdverseReaction
Elderly NN O O
patients NN O O
and NN O O
patients NN O O
with NN O O
impaired NN O O
renal NN O O
function NN O O
may NN O O
be NN O O
more NN O O
susceptible NN O O
to NN O O
these NN O O
changes NN O O
. NN O O
Adverse NN O O
reactions NN O O
related NN O O
to NN O O
renal NN O O
function NN O O
can NN B-Factor B-Factor
occur NN O O
after NN O O
initiating NN O O
FARXIGA NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Renal NN O O
function NN O O
should NN O O
be NN O O
evaluated NN O O
prior NN O O
to NN O O
initiation NN O O
of NN O O
FARXIGA NN O O
and NN O O
monitored NN O O
periodically NN O O
thereafter NN O O
. NN O O
5.3 NN O O
Hypoglycemia NN O O
with NN O O
Concomitant NN O O
Use NN O O
with NN O O
Insulin NN O O
and NN O O
Insulin NN O O
Secretagogues NN O O
Insulin NN O O
and NN O O
insulin NN O O
secretagogues NN O O
are NN O O
known NN O O
to NN O O
cause NN O O
hypoglycemia NN O O
. NN O O
FARXIGA NN O O
can NN B-Factor B-Factor
increase NN O O
the NN O O
risk NN O O
of NN O O
hypoglycemia NN B-AdverseReaction B-AdverseReaction
when NN O O
combined NN O O
with NN O O
insulin NN O O
or NN O O
an NN O O
insulin NN O O
secretagogue NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Therefore NN O O
, NN O O
a NN O O
lower NN O O
dose NN O O
of NN O O
insulin NN O O
or NN O O
insulin NN O O
secretagogue NN O O
may NN O O
be NN O O
required NN O O
to NN O O
minimize NN O O
the NN O O
risk NN O O
of NN O O
hypoglycemia NN O O
when NN O O
these NN O O
agents NN O O
are NN O O
used NN O O
in NN O O
combination NN O O
with NN O O
FARXIGA. NN O O
5.4 NN O O
Genital NN O O
Mycotic NN O O
Infections NN O O
FARXIGA NN O O
increases NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
genital NN B-AdverseReaction B-AdverseReaction
mycotic NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
Patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
genital NN O O
mycotic NN O O
infections NN O O
were NN O O
more NN O O
likely NN O O
to NN O O
develop NN O O
genital NN B-AdverseReaction B-AdverseReaction
mycotic NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Monitor NN O O
and NN O O
treat NN O O
appropriately NN O O
. NN O O
5.5 NN O O
Increases NN O O
in NN O O
Low NN O O
- NN O O
Density NN O O
Lipoprotein NN O O
Cholesterol NN O O
( NN O O
LDL NN O O
- NN O O
C NN O O
) NN O O
Increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
LDL NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
occur NN O O
with NN O O
FARXIGA NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Monitor NN O O
LDL NN O O
- NN O O
C NN O O
and NN O O
treat NN O O
per NN O O
standard NN O O
of NN O O
care NN O O
after NN O O
initiating NN O O
FARXIGA. NN O O
5.6 NN O O
Bladder NN O O
Cancer NN O O
Across NN O O
22 NN O O
clinical NN O O
studies NN O O
, NN O O
newly NN O O
diagnosed NN O O
cases NN O O
of NN O O
bladder NN B-AdverseReaction B-AdverseReaction
cancer NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
in NN O O
10/6045 NN O O
patients NN O O
( NN O O
0.17 NN O O
% NN O O
) NN O O
treated NN O O
with NN O O
FARXIGA NN O O
and NN O O
1/3512 NN O O
patient NN O O
( NN O O
0.03 NN O O
% NN O O
) NN O O
treated NN O O
with NN O O
placebo/comparator NN O O
. NN O O
After NN O O
excluding NN O O
patients NN O O
in NN O O
whom NN O O
exposure NN O O
to NN O O
study NN O O
drug NN O O
was NN O O
less NN O O
than NN O O
one NN O O
year NN O O
at NN O O
the NN O O
time NN O O
of NN O O
diagnosis NN O O
of NN O O
bladder NN B-AdverseReaction B-AdverseReaction
cancer NN I-AdverseReaction I-AdverseReaction
there NN O O
were NN O O
4 NN O O
cases NN O O
with NN O O
FARXIGA NN O O
and NN O O
no NN O O
cases NN O O
with NN O O
placebo/comparator NN O O
. NN O O
Bladder NN O O
cancer NN O O
risk NN O O
factors NN O O
and NN O O
hematuria NN O O
( NN O O
a NN O O
potential NN O O
indicator NN O O
of NN O O
pre NN O O
- NN O O
existing NN O O
tumors NN O O
) NN O O
were NN O O
balanced NN O O
between NN O O
treatment NN O O
arms NN O O
at NN O O
baseline NN O O
. NN O O
There NN O O
were NN O O
too NN O O
few NN O O
cases NN O O
to NN O O
determine NN O O
whether NN O O
the NN O O
emergence NN O O
of NN O O
these NN O O
events NN O O
is NN O O
related NN O O
to NN O O
FARXIGA. NN O O
There NN O O
are NN O O
insufficient NN O O
data NN O O
to NN O O
determine NN O O
whether NN O O
FARXIGA NN O O
has NN O O
an NN O O
effect NN O O
on NN O O
pre NN O O
- NN O O
existing NN O O
bladder NN O O
tumors NN O O
. NN O O
Consequently NN O O
, NN O O
FARXIGA NN O O
should NN O O
not NN O O
be NN O O
used NN O O
in NN O O
patients NN O O
with NN O O
active NN O O
bladder NN O O
cancer NN O O
. NN O O
In NN O O
patients NN O O
with NN O O
prior NN O O
history NN O O
of NN O O
bladder NN O O
cancer NN O O
, NN O O
the NN O O
benefits NN O O
of NN O O
glycemic NN O O
control NN O O
versus NN O O
unknown NN O O
risks NN O O
for NN O O
cancer NN O O
recurrence NN O O
with NN O O
FARXIGA NN O O
should NN O O
be NN O O
considered NN O O
. NN O O
5.7 NN O O
Macrovascular NN O O
Outcomes NN O O
There NN O O
have NN O O
been NN O O
no NN O O
clinical NN O O
studies NN O O
establishing NN O O
conclusive NN O O
evidence NN O O
of NN O O
macrovascular NN O O
risk NN O O
reduction NN O O
with NN O O
FARXIGA NN O O
or NN O O
any NN O O
other NN O O
antidiabetic NN O O
drug NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
commonly NN O O
reported NN O O
adverse NN O O
reactions NN O O
were NN O O
: NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
consisting NN O O
of NN O O
erythema NN O O
( NN O O
1.7 NN O O
% NN O O
) NN O O
, NN O O
irritation NN O O
( NN O O
1.2 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
pain NN O O
( NN O O
3.9 NN O O
% NN O O
) NN O O
. NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Piramal NN O O
at NN O O
1 NN O O
- NN O O
855 NN O O
- NN O O
545 NN O O
- NN O O
5245 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rate NN O O
observed NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O
The NN O O
overall NN O O
safety NN O O
profile NN O O
of NN O O
Neuraceq NN O O
is NN O O
based NN O O
on NN O O
data NN O O
from NN O O
978 NN O O
administrations NN O O
of NN O O
Neuraceq NN O O
to NN O O
872 NN O O
subjects NN O O
and NN O O
12 NN O O
subjects NN O O
who NN O O
received NN O O
vehicle NN O O
only NN O O
. NN O O
No NN O O
serious NN O O
adverse NN O O
reactions NN O O
related NN O O
to NN O O
Neuraceq NN O O
administration NN O O
have NN O O
been NN O O
reported NN O O
. NN O O
The NN O O
most NN O O
frequently NN O O
observed NN O O
adverse NN O O
drug NN O O
reactions NN O O
in NN O O
subjects NN O O
receiving NN O O
Neuraceq NN O O
were NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
consisting NN O O
of NN O O
erythema NN O O
, NN O O
irritation NN O O
and NN O O
pain NN O O
. NN O O
All NN O O
adverse NN O O
reactions NN O O
were NN O O
mild NN O O
to NN O O
moderate NN O O
in NN O O
severity NN O O
and NN O O
of NN O O
short NN O O
duration NN O O
. NN O O
The NN O O
most NN O O
commonly NN O O
reported NN O O
adverse NN O O
reactions NN O O
( NN O O
occurring NN O O
in NN O O
at NN O O
least NN O O
0.5 NN O O
% NN O O
of NN O O
subjects NN O O
) NN O O
during NN O O
Neuraceq NN O O
clinical NN O O
trials NN O O
are NN O O
shown NN O O
in NN O O
Table NN O O
2 NN O O
. NN O O
Table NN O O
2 NN O O
Adverse NN O O
Reactions NN O O
with NN O O
a NN O O
Frequency NN O O
>=0.5 NN O O
% NN O O
Reported NN O O
in NN O O
Clinical NN O O
Trials NN O O
( NN O O
n NN O O
= NN O O
978 NN O O
Administrations NN O O
in NN O O
872 NN O O
Subjects NN O O
) NN O O
Adverse NN O O
drug NN O O
reaction NN O O
n NN O O
( NN O O
% NN O O
) NN O O
Injection NN O O
/ NN O O
application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
erythema NN I-AdverseReaction I-AdverseReaction
17 NN O O
( NN O O
1.7 NN O O
) NN O O
Injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
irritation NN I-AdverseReaction I-AdverseReaction
12 NN O O
( NN O O
1.2 NN O O
) NN O O
Injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
38 NN O O
( NN O O
3.9 NN O O
) NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
Image NN O O
interpretation NN O O
errors NN O O
( NN O O
especially NN O O
false NN O O
positives NN O O
) NN O O
have NN O O
been NN O O
observed NN O O
( NN O O
5.1 NN O O
) NN O O
. NN O O
Neuraceq NN O O
, NN O O
like NN O O
all NN O O
radiopharmaceuticals NN O O
, NN O O
contributes NN O O
to NN O O
a NN O O
patient NN O O
's NN O O
long NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
term NN I-AdverseReaction I-AdverseReaction
cumulative NN I-AdverseReaction I-AdverseReaction
radiation NN I-AdverseReaction I-AdverseReaction
exposure NN I-AdverseReaction I-AdverseReaction
Ensure NN O O
safe NN O O
handling NN O O
to NN O O
protect NN O O
patients NN O O
and NN O O
health NN O O
care NN O O
workers NN O O
from NN O O
unintentional NN O O
radiation NN O O
exposure NN O O
( NN O O
5.2 NN O O
) NN O O
. NN O O
5.1 NN O O
Risk NN O O
for NN O O
Image NN O O
Misinterpretation NN O O
and NN O O
Other NN O O
Errors NN O O
Errors NN O O
may NN O O
occur NN O O
in NN O O
the NN O O
Neuraceq NN O O
estimation NN O O
of NN O O
brain NN O O
neuritic NN O O
beta NN O O
- NN O O
amyloid NN O O
plaque NN O O
density NN O O
during NN O O
image NN O O
interpretation NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
. NN O O
Image NN O O
interpretation NN O O
should NN O O
be NN O O
performed NN O O
independently NN O O
of NN O O
the NN O O
patient NN O O
's NN O O
clinical NN O O
information NN O O
. NN O O
The NN O O
use NN O O
of NN O O
clinical NN O O
information NN O O
in NN O O
the NN O O
interpretation NN O O
of NN O O
Neuraceq NN O O
images NN O O
has NN O O
not NN O O
been NN O O
evaluated NN O O
and NN O O
may NN O O
lead NN O O
to NN O O
errors NN O O
. NN O O
Errors NN O O
may NN O O
also NN O O
occur NN O O
in NN O O
cases NN O O
with NN O O
severe NN O O
brain NN O O
atrophy NN O O
that NN O O
limits NN O O
the NN O O
ability NN O O
to NN O O
distinguish NN O O
gray NN O O
and NN O O
white NN O O
matter NN O O
on NN O O
the NN O O
Neuraceq NN O O
scan NN O O
. NN O O
Errors NN O O
may NN O O
also NN O O
occur NN O O
due NN O O
to NN O O
motion NN O O
artifacts NN O O
that NN O O
result NN O O
in NN O O
image NN O O
distortion NN O O
. NN O O
Neuraceq NN O O
scan NN O O
results NN O O
are NN O O
indicative NN O O
of NN O O
the NN O O
presence NN O O
of NN O O
brain NN O O
neuritic NN O O
beta NN O O
- NN O O
amyloid NN O O
plaques NN O O
only NN O O
at NN O O
the NN O O
time NN O O
of NN O O
image NN O O
acquisition NN O O
and NN O O
a NN O O
negative NN O O
scan NN O O
result NN O O
does NN O O
not NN O O
preclude NN O O
the NN O O
development NN O O
of NN O O
brain NN O O
neuritic NN O O
beta NN O O
- NN O O
amyloid NN O O
plaques NN O O
in NN O O
the NN O O
future NN O O
. NN O O
5.2 NN O O
Radiation NN O O
Risk NN O O
Neuraceq NN O O
, NN O O
similar NN O O
to NN O O
other NN O O
radiopharmaceuticals NN O O
, NN O O
contributes NN O O
to NN O O
a NN O O
patient NN O O
's NN O O
overall NN O O
long NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
term NN I-AdverseReaction I-AdverseReaction
cumulative NN I-AdverseReaction I-AdverseReaction
radiation NN I-AdverseReaction I-AdverseReaction
exposure NN I-AdverseReaction I-AdverseReaction
Long NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
term NN I-AdverseReaction I-AdverseReaction
cumulative NN I-AdverseReaction I-AdverseReaction
radiation NN I-AdverseReaction I-AdverseReaction
exposure NN I-AdverseReaction I-AdverseReaction
is NN O O
associated NN O O
with NN O O
an NN O O
increased NN O O
risk NN B-Factor B-Factor
of NN O O
cancer NN B-AdverseReaction B-AdverseReaction
Ensure NN O O
safe NN O O
handling NN O O
to NN O O
protect NN O O
patients NN O O
and NN O O
health NN O O
care NN O O
workers NN O O
from NN O O
unintentional NN O O
radiation NN O O
exposure NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.1 NN O O
) NN O O
] NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
most NN O O
serious NN O O
adverse NN O O
reactions NN O O
reported NN O O
with NN O O
NULOJIX NN O O
are NN O O
: NN O O
* NN O O
PTLD NN B-AdverseReaction B-AdverseReaction
predominantly NN O O
CNS NN B-AdverseReaction B-AdverseReaction
PTLD NN I-AdverseReaction I-AdverseReaction
and NN O O
other NN O O
malignancies NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Boxed NN O O
Warning NN O O
and NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
, NN O O
5.3 NN O O
) NN O O
] NN O O
* NN O O
Serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
including NN O O
JC NN B-AdverseReaction B-AdverseReaction
virus NN I-AdverseReaction I-AdverseReaction
PML NN B-AdverseReaction B-AdverseReaction
and NN O O
polyoma NN B-AdverseReaction B-AdverseReaction
virus NN I-AdverseReaction I-AdverseReaction
nephropathy NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
, NN O O
5.5 NN O O
, NN O O
5.6 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
Most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=20 NN O O
% NN O O
on NN O O
NULOJIX NN O O
treatment NN O O
) NN O O
are NN O O
anemia NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
peripheral NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
constipation NN B-AdverseReaction B-AdverseReaction
hypertension NN B-AdverseReaction B-AdverseReaction
pyrexia NN B-AdverseReaction B-AdverseReaction
graft NN B-AdverseReaction B-AdverseReaction
dysfunction NN I-AdverseReaction I-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
hypokalemia NN B-AdverseReaction B-AdverseReaction
hyperkalemia NN B-AdverseReaction B-AdverseReaction
and NN O O
leukopenia NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Bristol NN O O
- NN O O
Myers NN O O
Squibb NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
721 NN O O
- NN O O
5072 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Studies NN O O
Experience NN O O
The NN O O
data NN O O
described NN O O
below NN O O
primarily NN O O
derive NN O O
from NN O O
two NN O O
randomized NN O O
, NN O O
active NN O O
- NN O O
controlled NN O O
three NN O O
- NN O O
year NN O O
trials NN O O
of NN O O
NULOJIX NN O O
in NN O O
de NN O O
novo NN O O
kidney NN O O
transplant NN O O
patients NN O O
. NN O O
In NN O O
Study NN O O
1 NN O O
and NN O O
Study NN O O
2 NN O O
, NN O O
NULOJIX NN O O
was NN O O
studied NN O O
at NN O O
the NN O O
recommended NN O O
dose NN O O
and NN O O
frequency NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.1 NN O O
) NN O O
] NN O O
in NN O O
a NN O O
total NN O O
of NN O O
401 NN O O
patients NN O O
compared NN O O
to NN O O
a NN O O
cyclosporine NN O O
control NN O O
regimen NN O O
in NN O O
a NN O O
total NN O O
of NN O O
405 NN O O
patients NN O O
. NN O O
These NN O O
two NN O O
trials NN O O
also NN O O
included NN O O
a NN O O
total NN O O
of NN O O
403 NN O O
patients NN O O
treated NN O O
with NN O O
a NN O O
NULOJIX NN O O
regimen NN O O
of NN O O
higher NN O O
cumulative NN O O
dose NN O O
and NN O O
more NN O O
frequent NN O O
dosing NN O O
than NN O O
recommended NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14.1 NN O O
) NN O O
] NN O O
. NN O O
All NN O O
patients NN O O
also NN O O
received NN O O
basiliximab NN O O
induction NN O O
, NN O O
mycophenolate NN O O
mofetil NN O O
, NN O O
and NN O O
corticosteroids NN O O
. NN O O
Patients NN O O
were NN O O
treated NN O O
and NN O O
followed NN O O
for NN O O
3 NN O O
years NN O O
. NN O O
CNS NN B-AdverseReaction B-AdverseReaction
PTLD NN I-AdverseReaction I-AdverseReaction
PML NN B-AdverseReaction B-AdverseReaction
and NN O O
other NN O O
CNS NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
were NN O O
more NN O O
frequently NN O O
observed NN O O
in NN O O
association NN O O
with NN O O
a NN O O
NULOJIX NN O O
regimen NN O O
of NN O O
higher NN O O
cumulative NN O O
dose NN O O
and NN O O
more NN O O
frequent NN O O
dosing NN O O
compared NN O O
to NN O O
the NN O O
recommended NN O O
regimen NN O O
; NN O O
therefore NN O O
, NN O O
administration NN O O
of NN O O
higher NN O O
than NN O O
the NN O O
recommended NN O O
doses NN O O
and/or NN O O
more NN O O
frequent NN O O
dosing NN O O
of NN O O
NULOJIX NN O O
is NN O O
not NN O O
recommended NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.1 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
average NN O O
age NN O O
of NN O O
patients NN O O
in NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
in NN O O
the NN O O
NULOJIX NN O O
recommended NN O O
dose NN O O
and NN O O
cyclosporine NN O O
control NN O O
regimens NN O O
was NN O O
49 NN O O
years NN O O
, NN O O
ranging NN O O
from NN O O
18 NN O O
to NN O O
79 NN O O
years NN O O
. NN O O
Approximately NN O O
70 NN O O
% NN O O
of NN O O
patients NN O O
were NN O O
male NN O O
; NN O O
67 NN O O
% NN O O
were NN O O
white NN O O
, NN O O
11 NN O O
% NN O O
were NN O O
black NN O O
, NN O O
and NN O O
22 NN O O
% NN O O
other NN O O
races NN O O
. NN O O
About NN O O
25 NN O O
% NN O O
of NN O O
patients NN O O
were NN O O
from NN O O
the NN O O
United NN O O
States NN O O
and NN O O
75 NN O O
% NN O O
from NN O O
other NN O O
countries NN O O
. NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
the NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
other NN O O
trials NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O
The NN O O
most NN O O
commonly NN O O
reported NN O O
adverse NN O O
reactions NN O O
occurring NN O O
in NN O O
>=20 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
the NN O O
recommended NN O O
dose NN O O
and NN O O
frequency NN O O
of NN O O
NULOJIX NN O O
were NN O O
anemia NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
peripheral NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
constipation NN B-AdverseReaction B-AdverseReaction
hypertension NN B-AdverseReaction B-AdverseReaction
pyrexia NN B-AdverseReaction B-AdverseReaction
graft NN B-AdverseReaction B-AdverseReaction
dysfunction NN I-AdverseReaction I-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
hypokalemia NN B-AdverseReaction B-AdverseReaction
hyperkalemia NN B-AdverseReaction B-AdverseReaction
and NN O O
leukopenia NN B-AdverseReaction B-AdverseReaction
The NN O O
proportion NN O O
of NN O O
patients NN O O
who NN O O
discontinued NN O O
treatment NN O O
due NN O O
to NN O O
adverse NN O O
reactions NN O O
was NN O O
13 NN O O
% NN O O
for NN O O
the NN O O
recommended NN O O
NULOJIX NN O O
regimen NN O O
and NN O O
19 NN O O
% NN O O
for NN O O
the NN O O
cyclosporine NN O O
control NN O O
arm NN O O
through NN O O
three NN O O
years NN O O
of NN O O
treatment NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
leading NN O O
to NN O O
discontinuation NN O O
in NN O O
NULOJIX NN O O
- NN O O
treated NN O O
patients NN O O
were NN O O
cytomegalovirus NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
( NN O O
1.5 NN O O
% NN O O
) NN O O
and NN O O
complications NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
transplanted NN I-AdverseReaction I-AdverseReaction
kidney NN I-AdverseReaction I-AdverseReaction
( NN O O
1.5 NN O O
% NN O O
) NN O O
. NN O O
Information NN O O
on NN O O
selected NN O O
significant NN O O
adverse NN O O
reactions NN O O
observed NN O O
during NN O O
clinical NN O O
trials NN O O
is NN O O
summarized NN O O
below NN O O
. NN O O
Post NN O O
- NN O O
Transplant NN O O
Lymphoproliferative NN O O
Disorder NN O O
Reported NN O O
cases NN O O
of NN O O
post NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
transplant NN I-AdverseReaction I-AdverseReaction
lymphoproliferative NN I-AdverseReaction I-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
( NN O O
PTLD NN O O
) NN O O
up NN O O
to NN O O
36 NN O O
months NN O O
post NN O O
transplant NN O O
were NN O O
obtained NN O O
for NN O O
NULOJIX NN O O
by NN O O
pooling NN O O
both NN O O
dosage NN O O
regimens NN O O
of NN O O
NULOJIX NN O O
in NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
( NN O O
804 NN O O
patients NN O O
) NN O O
with NN O O
data NN O O
from NN O O
a NN O O
third NN O O
study NN O O
in NN O O
kidney NN O O
transplantation NN O O
( NN O O
Study NN O O
3 NN O O
, NN O O
145 NN O O
patients NN O O
) NN O O
which NN O O
evaluated NN O O
two NN O O
NULOJIX NN O O
dosage NN O O
regimens NN O O
similar NN O O
, NN O O
but NN O O
slightly NN O O
different NN O O
, NN O O
from NN O O
those NN O O
of NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
( NN O O
see NN O O
Table NN O O
2 NN O O
) NN O O
. NN O O
The NN O O
total NN O O
number NN O O
of NN O O
NULOJIX NN O O
patients NN O O
from NN O O
these NN O O
three NN O O
studies NN O O
( NN O O
949 NN O O
) NN O O
was NN O O
compared NN O O
to NN O O
the NN O O
pooled NN O O
cyclosporine NN O O
control NN O O
groups NN O O
from NN O O
all NN O O
three NN O O
studies NN O O
( NN O O
476 NN O O
patients NN O O
) NN O O
. NN O O
Among NN O O
401 NN O O
patients NN O O
in NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
treated NN O O
with NN O O
the NN O O
recommended NN O O
regimen NN O O
of NN O O
NULOJIX NN O O
and NN O O
the NN O O
71 NN O O
patients NN O O
in NN O O
Study NN O O
3 NN O O
treated NN O O
with NN O O
a NN O O
very NN O O
similar NN O O
( NN O O
but NN O O
non NN O O
- NN O O
identical NN O O
) NN O O
NULOJIX NN O O
regimen NN O O
, NN O O
there NN O O
were NN O O
5 NN O O
cases NN O O
of NN O O
PTLD NN B-AdverseReaction B-AdverseReaction
3 NN O O
in NN O O
EBV NN O O
seropositive NN O O
patients NN O O
and NN O O
2 NN O O
in NN O O
EBV NN O O
seronegative NN O O
patients NN O O
. NN O O
Two NN O O
of NN O O
the NN O O
5 NN O O
cases NN O O
presented NN O O
with NN O O
CNS NN O O
involvement NN O O
. NN O O
Among NN O O
the NN O O
477 NN O O
patients NN O O
in NN O O
Studies NN O O
1 NN O O
, NN O O
2 NN O O
, NN O O
and NN O O
3 NN O O
treated NN O O
with NN O O
the NN O O
NULOJIX NN O O
regimen NN O O
of NN O O
higher NN O O
cumulative NN O O
dose NN O O
and NN O O
more NN O O
frequent NN O O
dosing NN O O
than NN O O
recommended NN O O
, NN O O
there NN O O
were NN O O
8 NN O O
cases NN O O
of NN O O
PTLD NN B-AdverseReaction B-AdverseReaction
2 NN O O
in NN O O
EBV NN O O
seropositive NN O O
patients NN O O
and NN O O
6 NN O O
in NN O O
EBV NN O O
seronegative NN O O
or NN O O
serostatus NN O O
unknown NN O O
patients NN O O
. NN O O
Six NN O O
of NN O O
the NN O O
8 NN O O
cases NN O O
presented NN O O
with NN O O
CNS NN O O
involvement NN O O
. NN O O
Therefore NN O O
, NN O O
administration NN O O
of NN O O
higher NN O O
than NN O O
the NN O O
recommended NN O O
doses NN O O
or NN O O
more NN O O
frequent NN O O
dosing NN O O
of NN O O
NULOJIX NN O O
is NN O O
not NN O O
recommended NN O O
. NN O O
[ NN O O
See NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.1 NN O O
) NN O O
and NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
. NN O O
] NN O O
One NN O O
of NN O O
the NN O O
476 NN O O
patients NN O O
treated NN O O
with NN O O
cyclosporine NN O O
developed NN O O
PTLD NN B-AdverseReaction B-AdverseReaction
without NN O O
CNS NN O O
involvement NN O O
. NN O O
All NN O O
cases NN O O
of NN O O
PTLD NN B-AdverseReaction B-AdverseReaction
reported NN O O
up NN O O
to NN O O
36 NN O O
months NN O O
post NN O O
transplant NN O O
in NN O O
NULOJIX- NN O O
or NN O O
cyclosporine NN O O
- NN O O
treated NN O O
patients NN O O
presented NN O O
within NN O O
18 NN O O
months NN O O
of NN O O
transplantation NN O O
. NN O O
Overall NN O O
, NN O O
the NN O O
rate NN O O
of NN O O
PTLD NN B-AdverseReaction B-AdverseReaction
in NN O O
949 NN O O
patients NN O O
treated NN O O
with NN O O
any NN O O
of NN O O
the NN O O
NULOJIX NN O O
regimens NN O O
was NN O O
9-fold NN O O
higher NN O O
in NN O O
those NN O O
who NN O O
were NN O O
EBV NN O O
seronegative NN O O
or NN O O
EBV NN O O
serostatus NN O O
unknown NN O O
( NN O O
8/139 NN O O
) NN O O
compared NN O O
to NN O O
those NN O O
who NN O O
were NN O O
EBV NN O O
seropositive NN O O
( NN O O
5/810 NN O O
patients NN O O
) NN O O
. NN O O
Therefore NN O O
NULOJIX NN O O
is NN O O
recommended NN O O
for NN O O
use NN O O
only NN O O
in NN O O
patients NN O O
who NN O O
are NN O O
EBV NN O O
seropositive NN O O
[ NN O O
see NN O O
Boxed NN O O
Warning NN O O
and NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
] NN O O
. NN O O
Table NN O O
2 NN O O
: NN O O
Summary NN O O
of NN O O
PTLD NN B-AdverseReaction B-AdverseReaction
Reported NN O O
in NN O O
Studies NN O O
1 NN O O
, NN O O
2 NN O O
, NN O O
and NN O O
3 NN O O
Through NN O O
Three NN O O
Years NN O O
of NN O O
Treatment NN O O
NULOJIX NN O O
Non NN O O
- NN O O
Recommended NN O O
Regimen NN O O
* NN O O
( NN O O
N=477 NN O O
) NN O O
NULOJIX NN O O
Recommended NN O O
Regimen NN O O
( NN O O
N=472 NN O O
) NN O O
Cyclosporine NN O O
( NN O O
N=476 NN O O
) NN O O
Trial NN O O
EBV NN O O
Positive NN O O
( NN O O
n=406 NN O O
) NN O O
EBV NN O O
Negative NN O O
( NN O O
n=43 NN O O
) NN O O
EBV NN O O
Unknown NN O O
( NN O O
n=28 NN O O
) NN O O
EBV NN O O
Positive NN O O
( NN O O
n=404 NN O O
) NN O O
EBV NN O O
Negative NN O O
( NN O O
n=48 NN O O
) NN O O
EBV NN O O
Unknown NN O O
( NN O O
n=20 NN O O
) NN O O
EBV NN O O
Positive NN O O
( NN O O
n=399 NN O O
) NN O O
EBV NN O O
Negative NN O O
( NN O O
n=57 NN O O
) NN O O
EBV NN O O
Unknown NN O O
( NN O O
n=20 NN O O
) NN O O
* NN O O
Regimen NN O O
with NN O O
higher NN O O
cumulative NN O O
dose NN O O
and NN O O
more NN O O
frequent NN O O
dosing NN O O
than NN O O
the NN O O
recommended NN O O
NULOJIX NN O O
regimen NN O O
. NN O O
In NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
the NN O O
NULOJIX NN O O
regimen NN O O
is NN O O
identical NN O O
to NN O O
the NN O O
recommended NN O O
regimen NN O O
, NN O O
but NN O O
is NN O O
slightly NN O O
different NN O O
in NN O O
Study NN O O
3 NN O O
. NN O O
Study NN O O
1 NN O O
CNS NN B-AdverseReaction B-AdverseReaction
PTLD NN I-AdverseReaction I-AdverseReaction
1 NN O O
1 NN O O
Non NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
CNSPTLD NN I-AdverseReaction I-AdverseReaction
1 NN O O
2 NN O O
1 NN O O
Study NN O O
2 NN O O
CNS NN B-AdverseReaction B-AdverseReaction
PTLD NN I-AdverseReaction I-AdverseReaction
1 NN O O
1 NN O O
1 NN O O
1 NN O O
Non NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
CNSPTLD NN I-AdverseReaction I-AdverseReaction
1 NN O O
Study NN O O
3 NN O O
CNS NN B-AdverseReaction B-AdverseReaction
PTLD NN I-AdverseReaction I-AdverseReaction
2 NN O O
Non NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
CNSPTLD NN I-AdverseReaction I-AdverseReaction
1 NN O O
Total NN O O
( NN O O
% NN O O
) NN O O
2 NN O O
( NN O O
0.5 NN O O
) NN O O
5 NN O O
( NN O O
11.6 NN O O
) NN O O
1 NN O O
( NN O O
3.6 NN O O
) NN O O
3 NN O O
( NN O O
0.7 NN O O
) NN O O
2 NN O O
( NN O O
4.1 NN O O
) NN O O
0 NN O O
0 NN O O
1 NN O O
( NN O O
1.8 NN O O
) NN O O
0 NN O O
EBV NN O O
Seropositive NN O O
Subpopulation NN O O
Among NN O O
the NN O O
806 NN O O
EBV NN O O
seropositive NN O O
patients NN O O
with NN O O
known NN O O
CMV NN O O
serostatus NN O O
treated NN O O
with NN O O
either NN O O
NULOJIX NN O O
regimen NN O O
in NN O O
Studies NN O O
1 NN O O
, NN O O
2 NN O O
, NN O O
and NN O O
3 NN O O
, NN O O
two NN O O
percent NN O O
( NN O O
2 NN O O
% NN O O
; NN O O
4/210 NN O O
) NN O O
of NN O O
CMV NN O O
seronegative NN O O
patients NN O O
developed NN O O
PTLD NN B-AdverseReaction B-AdverseReaction
compared NN O O
to NN O O
0.2 NN O O
% NN O O
( NN O O
1/596 NN O O
) NN O O
of NN O O
CMV NN O O
seropositive NN O O
patients NN O O
. NN O O
Among NN O O
the NN O O
404 NN O O
EBV NN O O
seropositive NN O O
recipients NN O O
treated NN O O
with NN O O
the NN O O
recommended NN O O
dosage NN O O
regimen NN O O
of NN O O
NULOJIX NN O O
, NN O O
three NN O O
PTLD NN B-AdverseReaction B-AdverseReaction
cases NN O O
were NN O O
detected NN O O
among NN O O
99 NN O O
CMV NN O O
seronegative NN O O
patients NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
and NN O O
there NN O O
was NN O O
no NN O O
case NN O O
detected NN O O
among NN O O
303 NN O O
CMV NN O O
seropositive NN O O
patients NN O O
. NN O O
The NN O O
clinical NN O O
significance NN O O
of NN O O
CMV NN O O
serology NN O O
as NN O O
a NN O O
risk NN O O
factor NN O O
for NN O O
PTLD NN B-AdverseReaction B-AdverseReaction
remains NN O O
to NN O O
be NN O O
determined NN O O
; NN O O
however NN O O
, NN O O
these NN O O
findings NN O O
should NN O O
be NN O O
considered NN O O
when NN O O
prescribing NN O O
NULOJIX NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
Other NN O O
Malignancies NN O O
Malignancies NN B-AdverseReaction B-AdverseReaction
excluding NN B-Negation B-Negation
non NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
melanoma NN I-AdverseReaction I-AdverseReaction
skin NN I-AdverseReaction I-AdverseReaction
cancer NN I-AdverseReaction I-AdverseReaction
and NN O O
PTLD NN B-AdverseReaction B-AdverseReaction
were NN O O
reported NN O O
in NN O O
Study NN O O
1 NN O O
and NN O O
Study NN O O
2 NN O O
in NN O O
3.5 NN O O
% NN O O
( NN O O
14/401 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
the NN O O
recommended NN O O
NULOJIX NN O O
regimen NN O O
and NN O O
3.7 NN O O
% NN O O
( NN O O
15/405 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
the NN O O
cyclosporine NN O O
control NN O O
regimen NN O O
. NN O O
Non NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
melanoma NN I-AdverseReaction I-AdverseReaction
skin NN I-AdverseReaction I-AdverseReaction
cancer NN I-AdverseReaction I-AdverseReaction
was NN O O
reported NN O O
in NN O O
1.5 NN O O
% NN O O
( NN O O
6/401 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
the NN O O
recommended NN O O
NULOJIX NN O O
regimen NN O O
and NN O O
in NN O O
3.7 NN O O
% NN O O
( NN O O
15/405 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
cyclosporine NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
. NN O O
Progressive NN O O
Multifocal NN O O
Leukoencephalopathy NN O O
Two NN O O
fatal NN B-AdverseReaction B-AdverseReaction
cases NN O O
of NN O O
progressive NN B-AdverseReaction B-AdverseReaction
multifocal NN I-AdverseReaction I-AdverseReaction
leukoencephalopathy NN I-AdverseReaction I-AdverseReaction
( NN O O
PML NN O O
) NN O O
have NN O O
been NN O O
reported NN O O
among NN O O
1096 NN O O
patients NN O O
treated NN O O
with NN O O
a NN O O
NULOJIX NN O O
- NN O O
containing NN O O
regimen NN O O
: NN O O
one NN O O
patient NN O O
in NN O O
clinical NN O O
trials NN O O
of NN O O
kidney NN O O
transplant NN O O
( NN O O
Studies NN O O
1 NN O O
, NN O O
2 NN O O
, NN O O
and NN O O
3 NN O O
described NN O O
above NN O O
) NN O O
and NN O O
one NN O O
patient NN O O
in NN O O
a NN O O
trial NN O O
of NN O O
liver NN O O
transplant NN O O
( NN O O
trial NN O O
of NN O O
250 NN O O
patients NN O O
) NN O O
. NN O O
No NN B-Negation B-Negation
cases NN O O
of NN O O
PML NN B-AdverseReaction B-AdverseReaction
were NN O O
reported NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
the NN O O
recommended NN O O
NULOJIX NN O O
regimen NN O O
or NN O O
the NN O O
control NN O O
regimen NN O O
in NN O O
these NN O O
trials NN O O
. NN O O
The NN O O
kidney NN O O
transplant NN O O
recipient NN O O
was NN O O
treated NN O O
with NN O O
the NN O O
NULOJIX NN O O
regimen NN O O
of NN O O
higher NN O O
cumulative NN O O
dose NN O O
and NN O O
more NN O O
frequent NN O O
dosing NN O O
than NN O O
recommended NN O O
, NN O O
mycophenolate NN O O
mofetil NN O O
( NN O O
MMF NN O O
) NN O O
, NN O O
and NN O O
corticosteroids NN O O
for NN O O
2 NN O O
years NN O O
. NN O O
The NN O O
liver NN O O
transplant NN O O
recipient NN O O
was NN O O
treated NN O O
with NN O O
6 NN O O
months NN O O
of NN O O
a NN O O
NULOJIX NN O O
dosage NN O O
regimen NN O O
that NN O O
was NN O O
more NN O O
intensive NN O O
than NN O O
that NN O O
studied NN O O
in NN O O
kidney NN O O
transplant NN O O
recipients NN O O
, NN O O
MMF NN O O
at NN O O
doses NN O O
higher NN O O
than NN O O
the NN O O
recommended NN O O
dose NN O O
, NN O O
and NN O O
corticosteroids NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
. NN O O
Bacterial NN O O
, NN O O
Mycobacterial NN O O
, NN O O
Viral NN O O
, NN O O
and NN O O
Fungal NN O O
Infections NN O O
Adverse NN O O
reactions NN O O
of NN O O
infectious NN B-AdverseReaction B-AdverseReaction
etiology NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
based NN O O
on NN O O
clinical NN O O
assessment NN O O
by NN O O
physicians NN O O
. NN O O
The NN O O
causative NN O O
organisms NN O O
for NN O O
these NN O O
reactions NN O O
are NN O O
identified NN O O
when NN O O
provided NN O O
by NN O O
the NN O O
physician NN O O
. NN O O
The NN O O
overall NN O O
number NN O O
of NN O O
infections NN B-AdverseReaction B-AdverseReaction
serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
and NN O O
select NN O O
infections NN B-AdverseReaction B-AdverseReaction
with NN O O
identified NN O O
etiology NN O O
reported NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
the NN O O
NULOJIX NN O O
recommended NN O O
regimen NN O O
or NN O O
the NN O O
cyclosporine NN O O
control NN O O
in NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
are NN O O
shown NN O O
in NN O O
Table NN O O
3 NN O O
. NN O O
Fungal NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
in NN O O
18 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
NULOJIX NN O O
compared NN O O
to NN O O
22 NN O O
% NN O O
receiving NN O O
cyclosporine NN O O
, NN O O
primarily NN O O
due NN O O
to NN O O
skin NN O O
and NN O O
mucocutaneous NN B-AdverseReaction B-AdverseReaction
fungal NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
Tuberculosis NN B-AdverseReaction B-AdverseReaction
and NN O O
herpes NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
more NN O O
frequently NN O O
in NN O O
patients NN O O
receiving NN O O
NULOJIX NN O O
than NN O O
cyclosporine NN O O
. NN O O
Of NN O O
the NN O O
patients NN O O
who NN O O
developed NN O O
tuberculosis NN B-AdverseReaction B-AdverseReaction
through NN O O
3 NN O O
years NN O O
, NN O O
all NN O O
but NN O O
one NN O O
NULOJIX NN O O
patient NN O O
lived NN O O
in NN O O
countries NN O O
with NN O O
a NN O O
high NN O O
prevalence NN O O
of NN O O
tuberculosis NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
. NN O O
Table NN O O
3 NN O O
: NN O O
Overall NN O O
Infections NN B-AdverseReaction B-AdverseReaction
and NN O O
Select NN O O
Infections NN B-AdverseReaction B-AdverseReaction
with NN O O
Identified NN O O
Etiology NN O O
by NN O O
Treatment NN O O
Group NN O O
following NN O O
One NN O O
and NN O O
Three NN O O
Years NN O O
of NN O O
Treatment NN O O
in NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
* NN O O
Up NN O O
to NN O O
Year NN O O
1 NN O O
Up NN O O
to NN O O
Year NN O O
3 NN O O
NULOJIX NN O O
Recommended NN O O
Regimen NN O O
N=401 NN O O
n NN O O
( NN O O
% NN O O
) NN O O
Cyclosporine NN O O
N=405 NN O O
n NN O O
( NN O O
% NN O O
) NN O O
NULOJIX NN O O
Recommended NN O O
Regimen NN O O
N=401 NN O O
n NN O O
( NN O O
% NN O O
) NN O O
Cyclosporine NN O O
N=405 NN O O
n NN O O
( NN O O
% NN O O
) NN O O
* NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
were NN O O
not NN O O
designed NN O O
to NN O O
support NN O O
comparative NN O O
claims NN O O
for NN O O
NULOJIX NN O O
for NN O O
the NN O O
adverse NN O O
reactions NN O O
reported NN O O
in NN O O
this NN O O
table NN O O
. NN O O
Median NN O O
exposure NN O O
in NN O O
days NN O O
for NN O O
pooled NN O O
studies NN O O
: NN O O
1203 NN O O
for NN O O
NULOJIX NN O O
recommended NN O O
regimen NN O O
and NN O O
1163 NN O O
for NN O O
cyclosporine NN O O
in NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
. NN O O
? NN O O
All NN O O
infections NN B-AdverseReaction B-AdverseReaction
include NN O O
bacterial NN O O
, NN O O
viral NN O O
, NN O O
fungal NN O O
, NN O O
and NN O O
other NN O O
organisms NN O O
. NN O O
For NN O O
infectious NN B-AdverseReaction B-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
the NN O O
causative NN O O
organism NN O O
is NN O O
reported NN O O
if NN O O
specified NN O O
by NN O O
the NN O O
physician NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
. NN O O
S NN O O
A NN O O
medically NN O O
important NN O O
event NN O O
that NN O O
may NN O O
be NN O O
life NN O O
- NN O O
threatening NN O O
or NN O O
result NN O O
in NN O O
death NN B-AdverseReaction B-AdverseReaction
or NN O O
hospitalization NN O O
or NN O O
prolongation NN O O
of NN O O
existing NN O O
hospitalization NN O O
. NN O O
Infections NN B-AdverseReaction B-AdverseReaction
not NN O O
meeting NN O O
these NN O O
criteria NN O O
are NN O O
considered NN O O
non NN O O
- NN O O
serious NN O O
. NN O O
BK NN B-AdverseReaction B-AdverseReaction
virus NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
associated NN I-AdverseReaction I-AdverseReaction
nephropathy NN I-AdverseReaction I-AdverseReaction
was NN O O
reported NN O O
in NN O O
6 NN O O
NULOJIX NN O O
patients NN O O
( NN O O
4 NN O O
of NN O O
which NN O O
resulted NN O O
in NN O O
graft NN O O
loss NN O O
) NN O O
and NN O O
6 NN O O
cyclosporine NN O O
patients NN O O
( NN O O
none NN O O
of NN O O
which NN O O
resulted NN O O
in NN O O
graft NN O O
loss NN O O
) NN O O
by NN O O
Year NN O O
3 NN O O
. NN O O
# NN O O
Most NN O O
herpes NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
were NN O O
non NN B-Severity B-Severity
- NN I-Severity I-Severity
serious NN I-Severity I-Severity
and NN O O
1 NN O O
led NN O O
to NN O O
treatment NN O O
discontinuation NN O O
. NN O O
All NN O O
infections NN B-AdverseReaction B-AdverseReaction
287 NN O O
( NN O O
72 NN O O
) NN O O
299 NN O O
( NN O O
74 NN O O
) NN O O
329 NN O O
( NN O O
82 NN O O
) NN O O
327 NN O O
( NN O O
81 NN O O
) NN O O
Serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
98 NN O O
( NN O O
24 NN O O
) NN O O
113 NN O O
( NN O O
28 NN O O
) NN O O
144 NN O O
( NN O O
36 NN O O
) NN O O
157 NN O O
( NN O O
39 NN O O
) NN O O
CMV NN O O
44 NN O O
( NN O O
11 NN O O
) NN O O
52 NN O O
( NN O O
13 NN O O
) NN O O
53 NN O O
( NN O O
13 NN O O
) NN O O
56 NN O O
( NN O O
14 NN O O
) NN O O
Polyoma NN O O
virus NN O O
10 NN O O
( NN O O
3 NN O O
) NN O O
23 NN O O
( NN O O
6 NN O O
) NN O O
17 NN O O
( NN O O
4 NN O O
) NN O O
27 NN O O
( NN O O
7 NN O O
) NN O O
Herpes# NN O O
27 NN O O
( NN O O
7 NN O O
) NN O O
26 NN O O
( NN O O
6 NN O O
) NN O O
55 NN O O
( NN O O
14 NN O O
) NN O O
46 NN O O
( NN O O
11 NN O O
) NN O O
Tuberculosis NN B-AdverseReaction B-AdverseReaction
2 NN O O
( NN O O
1 NN O O
) NN O O
1 NN O O
( NN O O
< NN O O
1 NN O O
) NN O O
6 NN O O
( NN O O
2 NN O O
) NN O O
1 NN O O
( NN O O
< NN O O
1 NN O O
) NN O O
Infections NN O O
Reported NN O O
in NN O O
the NN O O
CNS NN O O
Following NN O O
three NN O O
years NN O O
of NN O O
treatment NN O O
in NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
, NN O O
cryptococcal NN B-AdverseReaction B-AdverseReaction
meningitis NN I-AdverseReaction I-AdverseReaction
was NN O O
reported NN O O
in NN O O
one NN O O
patient NN O O
out NN O O
of NN O O
401 NN O O
patients NN O O
treated NN O O
with NN O O
the NN O O
NULOJIX NN O O
recommended NN O O
regimen NN O O
( NN O O
0.2 NN O O
% NN O O
) NN O O
and NN O O
one NN O O
patient NN O O
out NN O O
of NN O O
the NN O O
405 NN O O
treated NN O O
with NN O O
the NN O O
cyclosporine NN O O
control NN O O
( NN O O
0.2 NN O O
% NN O O
) NN O O
. NN O O
Six NN O O
patients NN O O
out NN O O
of NN O O
the NN O O
403 NN O O
who NN O O
were NN O O
treated NN O O
with NN O O
the NN O O
NULOJIX NN O O
regimen NN O O
of NN O O
higher NN O O
cumulative NN O O
dose NN O O
and NN O O
more NN O O
frequent NN O O
dosing NN O O
than NN O O
recommended NN O O
in NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
( NN O O
1.5 NN O O
% NN O O
) NN O O
were NN O O
reported NN O O
to NN O O
have NN O O
developed NN O O
CNS NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
including NN O O
2 NN O O
cases NN O O
of NN O O
cryptococcal NN B-AdverseReaction B-AdverseReaction
meningitis NN I-AdverseReaction I-AdverseReaction
one NN O O
case NN O O
of NN O O
Chagas NN B-AdverseReaction B-AdverseReaction
encephalitis NN I-AdverseReaction I-AdverseReaction
with NN O O
cryptococcal NN B-AdverseReaction B-AdverseReaction
meningitis NN I-AdverseReaction I-AdverseReaction
one NN O O
case NN O O
of NN O O
cerebral NN B-AdverseReaction B-AdverseReaction
aspergillosis NN I-AdverseReaction I-AdverseReaction
one NN O O
case NN O O
of NN O O
West NN B-AdverseReaction B-AdverseReaction
Nile NN I-AdverseReaction I-AdverseReaction
encephalitis NN I-AdverseReaction I-AdverseReaction
and NN O O
one NN O O
case NN O O
of NN O O
PML NN B-AdverseReaction B-AdverseReaction
( NN O O
discussed NN O O
above NN O O
) NN O O
. NN O O
Infusion NN O O
Reactions NN O O
There NN O O
were NN O O
no NN B-Negation B-Negation
reports NN O O
of NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
or NN O O
drug NN B-AdverseReaction B-AdverseReaction
hypersensitivity NN I-AdverseReaction I-AdverseReaction
in NN O O
patients NN O O
treated NN O O
with NN O O
NULOJIX NN O O
in NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
through NN O O
three NN O O
years NN O O
. NN O O
Infusion NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
within NN O O
one NN O O
hour NN O O
of NN O O
infusion NN O O
were NN O O
reported NN O O
in NN O O
5 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
the NN O O
recommended NN O O
dose NN O O
of NN O O
NULOJIX NN O O
, NN O O
similar NN O O
to NN O O
the NN O O
placebo NN O O
rate NN O O
. NN O O
No NN O O
serious NN O O
events NN O O
were NN O O
reported NN O O
through NN O O
Year NN O O
3 NN O O
. NN O O
The NN O O
most NN O O
frequent NN O O
reactions NN O O
were NN O O
hypotension NN B-AdverseReaction B-AdverseReaction
and NN O O
hypertension NN B-AdverseReaction B-AdverseReaction
Proteinuria NN O O
At NN O O
Month NN O O
1 NN O O
after NN O O
transplantation NN O O
in NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
, NN O O
the NN O O
frequency NN O O
of NN O O
2 NN B-Severity B-Severity
proteinuria NN B-AdverseReaction B-AdverseReaction
on NN O O
urine NN O O
dipstick NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
the NN O O
NULOJIX NN O O
recommended NN O O
regimen NN O O
was NN O O
33 NN O O
% NN O O
( NN O O
130/390 NN O O
) NN O O
and NN O O
28 NN O O
% NN O O
( NN O O
107/384 NN O O
) NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
the NN O O
cyclosporine NN O O
control NN O O
regimen NN O O
. NN O O
The NN O O
frequency NN O O
of NN O O
2 NN B-Severity B-Severity
proteinuria NN B-AdverseReaction B-AdverseReaction
was NN O O
similar NN O O
between NN O O
the NN O O
two NN O O
treatment NN O O
groups NN O O
between NN O O
one NN O O
and NN O O
three NN O O
years NN O O
after NN O O
transplantation NN O O
( NN O O
< NN O O
10 NN O O
% NN O O
in NN O O
both NN O O
studies NN O O
) NN O O
. NN O O
There NN O O
were NN O O
no NN O O
differences NN O O
in NN O O
the NN O O
occurrence NN O O
of NN O O
3 NN B-Severity B-Severity
proteinuria NN B-AdverseReaction B-AdverseReaction
( NN O O
< NN O O
4 NN O O
% NN O O
in NN O O
both NN O O
studies NN O O
) NN O O
at NN O O
any NN O O
time NN O O
point NN O O
, NN O O
and NN O O
no NN B-Negation B-Negation
patients NN O O
experienced NN O O
4 NN B-Severity B-Severity
proteinuria NN B-AdverseReaction B-AdverseReaction
The NN O O
clinical NN O O
significance NN O O
of NN O O
this NN O O
increase NN O O
in NN O O
early NN B-AdverseReaction B-AdverseReaction
proteinuria NN I-AdverseReaction I-AdverseReaction
is NN O O
unknown NN O O
. NN O O
Immunogenicity NN O O
Antibodies NN O O
directed NN O O
against NN O O
the NN O O
belatacept NN O O
molecule NN O O
were NN O O
assessed NN O O
in NN O O
398 NN O O
patients NN O O
treated NN O O
with NN O O
the NN O O
NULOJIX NN O O
recommended NN O O
regimen NN O O
in NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
( NN O O
212 NN O O
of NN O O
these NN O O
patients NN O O
were NN O O
treated NN O O
for NN O O
at NN O O
least NN O O
2 NN O O
years NN O O
) NN O O
. NN O O
Of NN O O
the NN O O
372 NN O O
patients NN O O
with NN O O
immunogenicity NN O O
assessment NN O O
at NN O O
baseline NN O O
( NN O O
prior NN O O
to NN O O
receiving NN O O
belatacept NN O O
treatment NN O O
) NN O O
, NN O O
29 NN O O
patients NN O O
tested NN O O
positive NN O O
for NN O O
anti NN O O
- NN O O
belatacept NN O O
antibodies NN O O
; NN O O
13 NN O O
of NN O O
these NN O O
patients NN O O
had NN O O
antibodies NN O O
to NN O O
the NN O O
modified NN O O
cytotoxic NN O O
T NN O O
- NN O O
lymphocyte NN O O
- NN O O
associated NN O O
antigen NN O O
4 NN O O
( NN O O
CTLA-4 NN O O
) NN O O
. NN O O
Anti NN O O
- NN O O
belatacept NN O O
antibody NN O O
titers NN O O
did NN O O
not NN O O
increase NN O O
during NN O O
treatment NN O O
in NN O O
these NN O O
29 NN O O
patients NN O O
. NN O O
Eight NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
patients NN O O
developed NN O O
antibodies NN O O
during NN O O
treatment NN O O
with NN O O
the NN O O
NULOJIX NN O O
recommended NN O O
regimen NN O O
. NN O O
In NN O O
the NN O O
patients NN O O
who NN O O
developed NN O O
antibodies NN O O
during NN O O
treatment NN O O
, NN O O
the NN O O
median NN O O
titer NN O O
( NN O O
by NN O O
dilution NN O O
method NN O O
) NN O O
was NN O O
8 NN O O
, NN O O
with NN O O
a NN O O
range NN O O
of NN O O
5 NN O O
to NN O O
80 NN O O
. NN O O
Of NN O O
56 NN O O
patients NN O O
who NN O O
tested NN O O
negative NN O O
for NN O O
antibodies NN O O
during NN O O
treatment NN O O
and NN O O
reassessed NN O O
approximately NN O O
7 NN O O
half NN O O
- NN O O
lives NN O O
after NN O O
discontinuation NN O O
of NN O O
NULOJIX NN O O
, NN O O
1 NN O O
tested NN O O
antibody NN O O
positive NN O O
. NN O O
Anti NN O O
- NN O O
belatacept NN O O
antibody NN O O
development NN O O
was NN O O
not NN O O
associated NN O O
with NN O O
altered NN O O
clearance NN O O
of NN O O
belatacept NN O O
. NN O O
Samples NN O O
from NN O O
6 NN O O
patients NN O O
with NN O O
confirmed NN O O
binding NN O O
activity NN O O
to NN O O
the NN O O
modified NN O O
cytotoxic NN O O
T NN O O
- NN O O
lymphocyte NN O O
- NN O O
associated NN O O
antigen NN O O
4 NN O O
( NN O O
CTLA-4 NN O O
) NN O O
region NN O O
of NN O O
the NN O O
belatacept NN O O
molecule NN O O
were NN O O
assessed NN O O
by NN O O
an NN O O
in NN O O
vitro NN O O
bioassay NN O O
for NN O O
the NN O O
presence NN O O
of NN O O
neutralizing NN O O
antibodies NN O O
. NN O O
Three NN O O
of NN O O
these NN O O
6 NN O O
patients NN O O
tested NN O O
positive NN O O
for NN O O
neutralizing NN O O
antibodies NN O O
. NN O O
However NN O O
, NN O O
the NN O O
development NN O O
of NN O O
neutralizing NN O O
antibodies NN O O
may NN O O
be NN O O
underreported NN O O
due NN O O
to NN O O
lack NN O O
of NN O O
assay NN O O
sensitivity NN O O
. NN O O
The NN O O
clinical NN O O
impact NN O O
of NN O O
anti NN O O
- NN O O
belatacept NN O O
antibodies NN O O
( NN O O
including NN O O
neutralizing NN O O
anti NN O O
- NN O O
belatacept NN O O
antibodies NN O O
) NN O O
could NN O O
not NN O O
be NN O O
determined NN O O
in NN O O
the NN O O
studies NN O O
. NN O O
The NN O O
data NN O O
reflect NN O O
the NN O O
percentage NN O O
of NN O O
patients NN O O
whose NN O O
test NN O O
results NN O O
were NN O O
positive NN O O
for NN O O
antibodies NN O O
to NN O O
belatacept NN O O
in NN O O
specific NN O O
assays NN O O
. NN O O
The NN O O
observed NN O O
incidence NN O O
of NN O O
antibody NN O O
( NN O O
including NN O O
neutralizing NN O O
antibody NN O O
) NN O O
positivity NN O O
in NN O O
an NN O O
assay NN O O
may NN O O
be NN O O
influenced NN O O
by NN O O
several NN O O
factors NN O O
including NN O O
assay NN O O
sensitivity NN O O
and NN O O
specificity NN O O
, NN O O
assay NN O O
methodology NN O O
, NN O O
sample NN O O
handling NN O O
, NN O O
timing NN O O
of NN O O
sample NN O O
collection NN O O
, NN O O
concomitant NN O O
medications NN O O
, NN O O
and NN O O
underlying NN O O
disease NN O O
. NN O O
For NN O O
these NN O O
reasons NN O O
, NN O O
comparison NN O O
of NN O O
the NN O O
incidence NN O O
of NN O O
antibodies NN O O
to NN O O
belatacept NN O O
with NN O O
the NN O O
incidence NN O O
of NN O O
antibodies NN O O
to NN O O
other NN O O
products NN O O
may NN O O
be NN O O
misleading NN O O
. NN O O
New NN O O
- NN O O
Onset NN O O
Diabetes NN O O
After NN O O
Transplantation NN O O
The NN O O
incidence NN O O
of NN O O
new NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
onset NN I-AdverseReaction I-AdverseReaction
diabetes NN I-AdverseReaction I-AdverseReaction
after NN I-AdverseReaction I-AdverseReaction
transplantation NN I-AdverseReaction I-AdverseReaction
( NN O O
NODAT NN O O
) NN O O
was NN O O
defined NN O O
in NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
as NN O O
use NN O O
of NN O O
an NN O O
antidiabetic NN O O
agent NN O O
for NN O O
>=30 NN O O
days NN O O
or NN O O
>=2 NN O O
fasting NN O O
plasma NN O O
glucose NN O O
values NN O O
>=126 NN O O
mg/dL NN O O
( NN O O
7.0 NN O O
mmol/L NN O O
) NN O O
post NN O O
- NN O O
transplantation NN O O
. NN O O
Of NN O O
the NN O O
patients NN O O
treated NN O O
with NN O O
the NN O O
NULOJIX NN O O
recommended NN O O
regimen NN O O
, NN O O
5 NN O O
% NN O O
( NN O O
14/304 NN O O
) NN O O
developed NN O O
NODAT NN B-AdverseReaction B-AdverseReaction
by NN O O
the NN O O
end NN O O
of NN O O
one NN O O
year NN O O
compared NN O O
to NN O O
10 NN O O
% NN O O
( NN O O
27/280 NN O O
) NN O O
of NN O O
patients NN O O
on NN O O
the NN O O
cyclosporine NN O O
control NN O O
regimen NN O O
. NN O O
However NN O O
, NN O O
by NN O O
the NN O O
end NN O O
of NN O O
the NN O O
third NN O O
year NN O O
, NN O O
the NN O O
cumulative NN O O
incidence NN O O
of NN O O
NODAT NN B-AdverseReaction B-AdverseReaction
was NN O O
8 NN O O
% NN O O
( NN O O
24/304 NN O O
) NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
the NN O O
NULOJIX NN O O
recommended NN O O
regimen NN O O
and NN O O
10 NN O O
% NN O O
( NN O O
29/280 NN O O
) NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
the NN O O
cyclosporine NN O O
regimen NN O O
. NN O O
Hypertension NN O O
Blood NN O O
pressure NN O O
and NN O O
use NN O O
of NN O O
antihypertensive NN O O
medications NN O O
were NN O O
reported NN O O
in NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
. NN O O
By NN O O
Year NN O O
3 NN O O
, NN O O
one NN O O
or NN O O
more NN O O
antihypertensive NN O O
medications NN O O
were NN O O
used NN O O
in NN O O
85 NN O O
% NN O O
of NN O O
NULOJIX NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
92 NN O O
% NN O O
of NN O O
cyclosporine NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
At NN O O
one NN O O
year NN O O
after NN O O
transplantation NN O O
, NN O O
systolic NN O O
blood NN O O
pressures NN O O
were NN O O
8 NN O O
mmHg NN O O
lower NN O O
and NN O O
diastolic NN O O
blood NN O O
pressures NN O O
were NN O O
3 NN O O
mmHg NN O O
lower NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
the NN O O
NULOJIX NN O O
recommended NN O O
regimen NN O O
compared NN O O
to NN O O
the NN O O
cyclosporine NN O O
control NN O O
regimen NN O O
. NN O O
At NN O O
three NN O O
years NN O O
after NN O O
transplantation NN O O
, NN O O
systolic NN O O
blood NN O O
pressures NN O O
were NN O O
6 NN O O
mmHg NN O O
lower NN O O
and NN O O
diastolic NN O O
blood NN O O
pressures NN O O
were NN O O
3 NN O O
mmHg NN O O
lower NN O O
in NN O O
NULOJIX NN O O
- NN O O
treated NN O O
patients NN O O
compared NN O O
to NN O O
cyclosporine NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
as NN O O
an NN O O
adverse NN O O
reaction NN O O
in NN O O
32 NN O O
% NN O O
of NN O O
NULOJIX NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
37 NN O O
% NN O O
of NN O O
cyclosporine NN O O
- NN O O
treated NN O O
patients NN O O
( NN O O
see NN O O
Table NN O O
4 NN O O
) NN O O
. NN O O
Dyslipidemia NN O O
Mean NN O O
values NN O O
of NN O O
total NN O O
cholesterol NN O O
, NN O O
HDL NN O O
, NN O O
LDL NN O O
, NN O O
and NN O O
triglycerides NN O O
were NN O O
reported NN O O
in NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
. NN O O
At NN O O
one NN O O
year NN O O
after NN O O
transplantation NN O O
these NN O O
values NN O O
were NN O O
183 NN O O
mg/dL NN O O
, NN O O
50 NN O O
mg/dL NN O O
, NN O O
102 NN O O
mg/dL NN O O
, NN O O
and NN O O
151 NN O O
mg/dL NN O O
, NN O O
respectively NN O O
, NN O O
in NN O O
401 NN O O
patients NN O O
treated NN O O
with NN O O
the NN O O
NULOJIX NN O O
recommended NN O O
regimen NN O O
and NN O O
196 NN O O
mg/dL NN O O
, NN O O
48 NN O O
mg/dL NN O O
, NN O O
108 NN O O
mg/dL NN O O
, NN O O
and NN O O
195 NN O O
mg/dL NN O O
, NN O O
respectively NN O O
, NN O O
in NN O O
405 NN O O
patients NN O O
treated NN O O
with NN O O
the NN O O
cyclosporine NN O O
control NN O O
regimen NN O O
. NN O O
At NN O O
three NN O O
years NN O O
after NN O O
transplantation NN O O
, NN O O
the NN O O
total NN O O
cholesterol NN O O
, NN O O
HDL NN O O
, NN O O
LDL NN O O
, NN O O
and NN O O
triglycerides NN O O
were NN O O
176 NN O O
mg/dL NN O O
, NN O O
49 NN O O
mg/dL NN O O
, NN O O
100 NN O O
mg/dL NN O O
, NN O O
and NN O O
141 NN O O
mg/dL NN O O
, NN O O
respectively NN O O
, NN O O
in NN O O
NULOJIX NN O O
- NN O O
treated NN O O
patients NN O O
compared NN O O
to NN O O
193 NN O O
mg/dL NN O O
, NN O O
48 NN O O
mg/dL NN O O
, NN O O
106 NN O O
mg/dL NN O O
, NN O O
and NN O O
180 NN O O
mg/dL NN O O
in NN O O
cyclosporine NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
The NN O O
clinical NN O O
significance NN O O
of NN O O
the NN O O
lower NN O O
mean NN O O
triglyceride NN O O
values NN O O
in NN O O
NULOJIX NN O O
- NN O O
treated NN O O
patients NN O O
at NN O O
one NN O O
and NN O O
three NN O O
years NN O O
is NN O O
unknown NN O O
. NN O O
Other NN O O
Adverse NN O O
Reactions NN O O
Adverse NN O O
reactions NN O O
that NN O O
occurred NN O O
at NN O O
a NN O O
frequency NN O O
of NN O O
>=10 NN O O
% NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
the NN O O
NULOJIX NN O O
recommended NN O O
regimen NN O O
or NN O O
cyclosporine NN O O
control NN O O
regimen NN O O
in NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
through NN O O
three NN O O
years NN O O
are NN O O
summarized NN O O
by NN O O
preferred NN O O
term NN O O
in NN O O
decreasing NN O O
order NN O O
of NN O O
frequency NN O O
within NN O O
Table NN O O
4 NN O O
. NN O O
Table NN O O
4 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Reported NN O O
by NN O O
>=10 NN O O
% NN O O
of NN O O
Patients NN O O
Treated NN O O
with NN O O
Either NN O O
the NN O O
NULOJIX NN O O
Recommended NN O O
Regimen NN O O
or NN O O
Control NN O O
in NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
Through NN O O
Three NN O O
Years NN O O
* NN O O
, NN O O
Adverse NN O O
Reaction NN O O
NULOJIX NN O O
Recommended NN O O
Regimen NN O O
N=401 NN O O
% NN O O
Cyclosporine NN O O
N=405 NN O O
% NN O O
* NN O O
All NN O O
randomized NN O O
and NN O O
transplanted NN O O
patients NN O O
in NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
. NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
were NN O O
not NN O O
designed NN O O
to NN O O
support NN O O
comparative NN O O
claims NN O O
for NN O O
NULOJIX NN O O
for NN O O
the NN O O
adverse NN O O
reactions NN O O
reported NN O O
in NN O O
this NN O O
table NN O O
. NN O O
Infections NN O O
and NN O O
Infestations NN O O
Urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
37 NN O O
36 NN O O
Upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
15 NN O O
16 NN O O
Nasopharyngitis NN B-AdverseReaction B-AdverseReaction
13 NN O O
16 NN O O
Cytomegalovirus NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
12 NN O O
12 NN O O
Influenza NN B-AdverseReaction B-AdverseReaction
11 NN O O
8 NN O O
Bronchitis NN B-AdverseReaction B-AdverseReaction
10 NN O O
7 NN O O
Gastrointestinal NN O O
Disorders NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
39 NN O O
36 NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
33 NN O O
35 NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
24 NN O O
27 NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
22 NN O O
20 NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
19 NN O O
16 NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
upper NN I-AdverseReaction I-AdverseReaction
9 NN O O
10 NN O O
Metabolism NN O O
and NN O O
Nutrition NN O O
Disorders NN O O
Hyperkalemia NN B-AdverseReaction B-AdverseReaction
20 NN O O
20 NN O O
Hypokalemia NN B-AdverseReaction B-AdverseReaction
21 NN O O
14 NN O O
Hypophosphatemia NN B-AdverseReaction B-AdverseReaction
19 NN O O
13 NN O O
Dyslipidemia NN B-AdverseReaction B-AdverseReaction
19 NN O O
24 NN O O
Hyperglycemia NN B-AdverseReaction B-AdverseReaction
16 NN O O
17 NN O O
Hypocalcemia NN B-AdverseReaction B-AdverseReaction
13 NN O O
11 NN O O
Hypercholesterolemia NN B-AdverseReaction B-AdverseReaction
11 NN O O
11 NN O O
Hypomagnesemia NN B-AdverseReaction B-AdverseReaction
7 NN O O
10 NN O O
Hyperuricemia NN B-AdverseReaction B-AdverseReaction
5 NN O O
12 NN O O
Procedural NN O O
Complications NN O O
Graft NN B-AdverseReaction B-AdverseReaction
dysfunction NN I-AdverseReaction I-AdverseReaction
25 NN O O
34 NN O O
General NN O O
Disorders NN O O
Peripheral NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
34 NN O O
42 NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
28 NN O O
26 NN O O
Blood NN O O
and NN O O
Lymphatic NN O O
System NN O O
Disorders NN O O
Anemia NN B-AdverseReaction B-AdverseReaction
45 NN O O
44 NN O O
Leukopenia NN B-AdverseReaction B-AdverseReaction
20 NN O O
23 NN O O
Renal NN O O
and NN O O
Urinary NN O O
Disorders NN O O
Hematuria NN B-AdverseReaction B-AdverseReaction
16 NN O O
18 NN O O
Proteinuria NN B-AdverseReaction B-AdverseReaction
16 NN O O
12 NN O O
Dysuria NN B-AdverseReaction B-AdverseReaction
11 NN O O
11 NN O O
Renal NN B-AdverseReaction B-AdverseReaction
tubular NN I-AdverseReaction I-AdverseReaction
necrosis NN I-AdverseReaction I-AdverseReaction
9 NN O O
13 NN O O
Vascular NN O O
Disorders NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
32 NN O O
37 NN O O
Hypotension NN B-AdverseReaction B-AdverseReaction
18 NN O O
12 NN O O
Respiratory NN O O
, NN O O
Thoracic NN O O
, NN O O
and NN O O
Mediastinal NN O O
Disorders NN O O
Cough NN B-AdverseReaction B-AdverseReaction
24 NN O O
18 NN O O
Dyspnea NN B-AdverseReaction B-AdverseReaction
12 NN O O
15 NN O O
Investigations NN O O
Blood NN B-AdverseReaction B-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
15 NN O O
20 NN O O
Musculoskeletal NN O O
and NN O O
Connective NN O O
Tissue NN O O
Disorders NN O O
Arthralgia NN B-AdverseReaction B-AdverseReaction
17 NN O O
13 NN O O
Back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
13 NN O O
13 NN O O
Nervous NN O O
System NN O O
Disorders NN O O
Headache NN B-AdverseReaction B-AdverseReaction
21 NN O O
18 NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
9 NN O O
10 NN O O
Tremor NN B-AdverseReaction B-AdverseReaction
8 NN O O
17 NN O O
Skin NN O O
and NN O O
Subcutaneous NN O O
Tissue NN O O
Disorders NN O O
Acne NN B-AdverseReaction B-AdverseReaction
8 NN O O
11 NN O O
Psychiatric NN O O
Disorders NN O O
Insomnia NN B-AdverseReaction B-AdverseReaction
15 NN O O
18 NN O O
Anxiety NN B-AdverseReaction B-AdverseReaction
10 NN O O
11 NN O O
Selected NN O O
adverse NN O O
reactions NN O O
occurring NN O O
in NN O O
< NN O O
10 NN O O
% NN O O
from NN O O
NULOJIX NN O O
- NN O O
treated NN O O
patients NN O O
in NN O O
either NN O O
regimen NN O O
through NN O O
three NN O O
years NN O O
in NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
are NN O O
listed NN O O
below NN O O
: NN O O
Immune NN O O
System NN O O
Disorders NN O O
: NN O O
Guillain NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Barre NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
Infections NN O O
and NN O O
Infestations NN O O
: NN O O
see NN O O
Table NN O O
3 NN O O
Gastrointestinal NN O O
Disorders NN O O
: NN O O
stomatitis NN B-AdverseReaction B-AdverseReaction
including NN O O
aphthous NN B-AdverseReaction B-AdverseReaction
stomatitis NN I-AdverseReaction I-AdverseReaction
Injury NN O O
, NN O O
Poisoning NN O O
, NN O O
and NN O O
Procedural NN O O
Complications NN O O
: NN O O
chronic NN B-AdverseReaction B-AdverseReaction
allograft NN I-AdverseReaction I-AdverseReaction
nephropathy NN I-AdverseReaction I-AdverseReaction
complications NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
transplanted NN I-AdverseReaction I-AdverseReaction
kidney NN I-AdverseReaction I-AdverseReaction
including NN O O
wound NN B-AdverseReaction B-AdverseReaction
dehiscence NN I-AdverseReaction I-AdverseReaction
arteriovenous NN B-AdverseReaction B-AdverseReaction
fistula NN I-AdverseReaction I-AdverseReaction
thrombosis NN I-AdverseReaction I-AdverseReaction
Blood NN O O
and NN O O
Lymphatic NN O O
System NN O O
Disorders NN O O
: NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
Renal NN O O
and NN O O
Urinary NN O O
Disorders NN O O
: NN O O
renal NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
including NN O O
acute NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
renal NN B-AdverseReaction B-AdverseReaction
artery NN I-AdverseReaction I-AdverseReaction
stenosis NN I-AdverseReaction I-AdverseReaction
urinary NN B-AdverseReaction B-AdverseReaction
incontinence NN I-AdverseReaction I-AdverseReaction
hydronephrosis NN B-AdverseReaction B-AdverseReaction
Vascular NN O O
Disorders NN O O
: NN O O
hematoma NN B-AdverseReaction B-AdverseReaction
lymphocele NN B-AdverseReaction B-AdverseReaction
Musculoskeletal NN O O
and NN O O
Connective NN O O
Tissue NN O O
Disorders NN O O
: NN O O
musculoskeletal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
Skin NN O O
and NN O O
Subcutaneous NN O O
Tissue NN O O
Disorders NN O O
: NN O O
alopecia NN B-AdverseReaction B-AdverseReaction
hyperhidrosis NN B-AdverseReaction B-AdverseReaction
Cardiac NN O O
Disorders NN O O
: NN O O
atrial NN B-AdverseReaction B-AdverseReaction
fibrillation NN I-AdverseReaction I-AdverseReaction
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
POST NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
TRANSPLANT NN I-AdverseReaction I-AdverseReaction
LYMPHOPROLIFERATIVE NN I-AdverseReaction I-AdverseReaction
DISORDER NN I-AdverseReaction I-AdverseReaction
OTHER NN O O
MALIGNANCIES NN B-AdverseReaction B-AdverseReaction
AND NN O O
SERIOUS NN B-Severity B-Severity
INFECTIONS NN B-AdverseReaction B-AdverseReaction
WARNING NN O O
: NN O O
POST NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
TRANSPLANT NN I-AdverseReaction I-AdverseReaction
LYMPHOPROLIFERATIVE NN I-AdverseReaction I-AdverseReaction
DISORDER NN I-AdverseReaction I-AdverseReaction
OTHER NN O O
MALIGNANCIES NN B-AdverseReaction B-AdverseReaction
AND NN O O
SERIOUS NN B-Severity B-Severity
INFECTIONS NN B-AdverseReaction B-AdverseReaction
Increased NN O O
risk NN B-Factor B-Factor
for NN O O
developing NN O O
post NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
transplant NN I-AdverseReaction I-AdverseReaction
lymphoproliferative NN I-AdverseReaction I-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
( NN O O
PTLD NN O O
) NN O O
, NN O O
predominantly NN O O
involving NN O O
the NN O O
central NN O O
nervous NN O O
system NN O O
( NN O O
CNS NN O O
) NN O O
. NN O O
Recipients NN O O
without NN O O
immunity NN O O
to NN O O
Epstein NN O O
- NN O O
Barr NN O O
virus NN O O
( NN O O
EBV NN O O
) NN O O
are NN O O
at NN O O
a NN O O
particularly NN O O
increased NN O O
risk NN O O
; NN O O
therefore NN O O
, NN O O
use NN O O
in NN O O
EBV NN O O
seropositive NN O O
patients NN O O
only NN O O
. NN O O
Do NN O O
not NN O O
use NN O O
NULOJIX NN O O
in NN O O
transplant NN O O
recipients NN O O
who NN O O
are NN O O
EBV NN O O
seronegative NN O O
or NN O O
with NN O O
unknown NN O O
EBV NN O O
serostatus NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
and NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
Only NN O O
physicians NN O O
experienced NN O O
in NN O O
immunosuppressive NN O O
therapy NN O O
and NN O O
management NN O O
of NN O O
kidney NN O O
transplant NN O O
patients NN O O
should NN O O
prescribe NN O O
NULOJIX. NN O O
Patients NN O O
receiving NN O O
the NN O O
drug NN O O
should NN O O
be NN O O
managed NN O O
in NN O O
facilities NN O O
equipped NN O O
and NN O O
staffed NN O O
with NN O O
adequate NN O O
laboratory NN O O
and NN O O
supportive NN O O
medical NN O O
resources NN O O
. NN O O
The NN O O
physician NN O O
responsible NN O O
for NN O O
maintenance NN O O
therapy NN O O
should NN O O
have NN O O
complete NN O O
information NN O O
requisite NN O O
for NN O O
the NN O O
follow NN O O
- NN O O
up NN O O
of NN O O
the NN O O
patient NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
Increased NN B-AdverseReaction B-AdverseReaction
susceptibility NN I-AdverseReaction I-AdverseReaction
to NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
and NN O O
the NN O O
possible NN O O
development NN O O
of NN O O
malignancies NN B-AdverseReaction B-AdverseReaction
may NN B-Factor B-Factor
result NN O O
from NN O O
immunosuppression NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
, NN O O
5.3 NN O O
, NN O O
5.4 NN O O
, NN O O
5.5 NN O O
) NN O O
] NN O O
. NN O O
Use NN O O
in NN O O
liver NN O O
transplant NN O O
patients NN O O
is NN O O
not NN O O
recommended NN O O
due NN O O
to NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
graft NN O O
loss NN O O
and NN O O
death NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.6 NN O O
) NN O O
] NN O O
. NN O O
EXCERPT NN O O
: NN O O
WARNING NN O O
: NN O O
POST NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
TRANSPLANT NN I-AdverseReaction I-AdverseReaction
LYMPHOPROLIFERATIVE NN I-AdverseReaction I-AdverseReaction
DISORDER NN I-AdverseReaction I-AdverseReaction
OTHER NN O O
MALIGNANCIES NN B-AdverseReaction B-AdverseReaction
AND NN O O
SERIOUS NN B-Severity B-Severity
INFECTIONS NN B-AdverseReaction B-AdverseReaction
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
. NN O O
* NN O O
Increased NN O O
risk NN B-Factor B-Factor
for NN O O
developing NN O O
post NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
transplant NN I-AdverseReaction I-AdverseReaction
lymphoproliferative NN I-AdverseReaction I-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
( NN O O
PTLD NN O O
) NN O O
, NN O O
predominantly NN O O
involving NN O O
the NN O O
central NN O O
nervous NN O O
system NN O O
( NN O O
CNS NN O O
) NN O O
. NN O O
Recipients NN O O
without NN O O
immunity NN O O
to NN O O
Epstein NN O O
- NN O O
Barr NN O O
virus NN O O
( NN O O
EBV NN O O
) NN O O
are NN O O
at NN O O
a NN O O
particularly NN O O
increased NN O O
risk NN O O
; NN O O
therefore NN O O
, NN O O
use NN O O
in NN O O
EBV NN O O
seropositive NN O O
patients NN O O
only NN O O
. NN O O
Do NN O O
not NN O O
use NN O O
NULOJIX NN O O
in NN O O
transplant NN O O
recipients NN O O
who NN O O
are NN O O
EBV NN O O
seronegative NN O O
or NN O O
with NN O O
unknown NN O O
serostatus NN O O
. NN O O
( NN O O
4 NN O O
, NN O O
5.1 NN O O
) NN O O
* NN O O
Only NN O O
physicians NN O O
experienced NN O O
in NN O O
immunosuppressive NN O O
therapy NN O O
and NN O O
management NN O O
of NN O O
kidney NN O O
transplant NN O O
patients NN O O
should NN O O
prescribe NN O O
NULOJIX. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Increased NN B-AdverseReaction B-AdverseReaction
susceptibility NN I-AdverseReaction I-AdverseReaction
to NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
and NN O O
the NN O O
possible NN O O
development NN O O
of NN O O
malignancies NN B-AdverseReaction B-AdverseReaction
may NN B-Factor B-Factor
result NN O O
from NN O O
immunosuppression NN O O
. NN O O
( NN O O
5.1 NN O O
, NN O O
5.3 NN O O
, NN O O
5.4 NN O O
, NN O O
5.5 NN O O
) NN O O
* NN O O
Use NN O O
in NN O O
liver NN O O
transplant NN O O
patients NN O O
is NN O O
not NN O O
recommended NN O O
due NN O O
to NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
graft NN O O
loss NN O O
and NN O O
death NN O O
. NN O O
( NN O O
5.6 NN O O
) NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Post NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Transplant NN I-AdverseReaction I-AdverseReaction
Lymphoproliferative NN I-AdverseReaction I-AdverseReaction
Disorder NN I-AdverseReaction I-AdverseReaction
( NN O O
PTLD NN O O
) NN O O
: NN O O
increased NN O O
risk NN B-Factor B-Factor
predominantly NN O O
involving NN O O
the NN O O
CNS NN O O
; NN O O
monitor NN O O
for NN O O
new NN O O
or NN O O
worsening NN O O
neurological NN O O
, NN O O
cognitive NN O O
, NN O O
or NN O O
behavioral NN O O
signs NN O O
and NN O O
symptoms NN O O
. NN O O
( NN O O
Boxed NN O O
Warning NN O O
, NN O O
4 NN O O
, NN O O
5.1 NN O O
, NN O O
5.6 NN O O
) NN O O
* NN O O
Other NN O O
malignancies NN B-AdverseReaction B-AdverseReaction
: NN O O
increased NN O O
risk NN O O
with NN O O
all NN O O
immunosuppressants NN B-DrugClass B-DrugClass
appears NN O O
related NN O O
to NN O O
intensity NN O O
and NN O O
duration NN O O
of NN O O
use NN O O
. NN O O
Avoid NN O O
prolonged NN O O
exposure NN O O
to NN O O
UV NN O O
light NN O O
and NN O O
sunlight NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Progressive NN B-AdverseReaction B-AdverseReaction
Multifocal NN I-AdverseReaction I-AdverseReaction
Leukoencephalopathy NN I-AdverseReaction I-AdverseReaction
( NN O O
PML NN O O
) NN O O
: NN O O
increased NN O O
risk NN B-Factor B-Factor
consider NN O O
in NN O O
the NN O O
diagnosis NN O O
of NN O O
patients NN O O
reporting NN O O
new NN O O
or NN O O
worsening NN O O
neurological NN O O
, NN O O
cognitive NN O O
, NN O O
or NN O O
behavioral NN O O
signs NN O O
and NN O O
symptoms NN O O
. NN O O
Recommended NN O O
doses NN O O
of NN O O
immunosuppressants NN O O
should NN O O
not NN O O
be NN O O
exceeded NN O O
. NN O O
( NN O O
5.4 NN O O
) NN O O
* NN O O
Other NN O O
serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
: NN O O
increased NN O O
risk NN B-Factor B-Factor
of NN O O
bacterial NN O O
, NN O O
viral NN O O
, NN O O
fungal NN O O
, NN O O
and NN O O
protozoal NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
including NN O O
opportunistic NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
and NN O O
tuberculosis NN B-AdverseReaction B-AdverseReaction
Some NN O O
infections NN B-AdverseReaction B-AdverseReaction
were NN O O
fatal NN B-AdverseReaction B-AdverseReaction
Polyoma NN B-AdverseReaction B-AdverseReaction
virus NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
associated NN I-AdverseReaction I-AdverseReaction
nephropathy NN I-AdverseReaction I-AdverseReaction
can NN B-Factor B-Factor
lead NN O O
to NN O O
kidney NN B-AdverseReaction B-AdverseReaction
graft NN I-AdverseReaction I-AdverseReaction
loss NN I-AdverseReaction I-AdverseReaction
consider NN O O
reduction NN O O
in NN O O
immunosuppression NN O O
. NN O O
Evaluate NN O O
for NN O O
tuberculosis NN O O
and NN O O
initiate NN O O
treatment NN O O
for NN O O
latent NN O O
infection NN O O
prior NN O O
to NN O O
NULOJIX NN O O
use NN O O
. NN O O
Cytomegalovirus NN O O
and NN O O
pneumocystis NN O O
prophylaxis NN O O
are NN O O
recommended NN O O
after NN O O
transplantation NN O O
. NN O O
( NN O O
5.1 NN O O
, NN O O
5.4 NN O O
, NN O O
5.5 NN O O
) NN O O
* NN O O
Liver NN O O
transplant NN O O
: NN O O
use NN O O
is NN O O
not NN O O
recommended NN O O
. NN O O
( NN O O
5.6 NN O O
) NN O O
* NN O O
Acute NN O O
Rejection NN O O
and NN O O
Graft NN B-AdverseReaction B-AdverseReaction
Loss NN I-AdverseReaction I-AdverseReaction
with NN O O
Corticosteroid NN O O
Minimization NN O O
: NN O O
corticosteroid NN O O
utilization NN O O
should NN O O
be NN O O
consistent NN O O
with NN O O
the NN O O
NULOJIX NN O O
clinical NN O O
trial NN O O
experience NN O O
. NN O O
( NN O O
2.1 NN O O
, NN O O
5.7 NN O O
, NN O O
14.1 NN O O
) NN O O
* NN O O
Immunizations NN O O
: NN O O
avoid NN O O
use NN O O
of NN O O
live NN O O
vaccines NN O O
during NN O O
treatment NN O O
. NN O O
( NN O O
5.8 NN O O
) NN O O
5.1 NN O O
Post NN O O
- NN O O
Transplant NN O O
Lymphoproliferative NN O O
Disorder NN O O
NULOJIX NN O O
- NN O O
treated NN O O
patients NN O O
have NN O O
an NN O O
increased NN O O
risk NN B-Factor B-Factor
for NN O O
developing NN O O
post NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
transplant NN I-AdverseReaction I-AdverseReaction
lymphoproliferative NN I-AdverseReaction I-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
( NN O O
PTLD NN O O
) NN O O
, NN O O
predominantly NN O O
involving NN O O
the NN O O
CNS NN O O
, NN O O
compared NN O O
to NN O O
patients NN O O
on NN O O
a NN O O
cyclosporine NN O O
- NN O O
based NN O O
regimen NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
and NN O O
Table NN O O
2 NN O O
] NN O O
. NN O O
As NN O O
the NN O O
total NN O O
burden NN O O
of NN O O
immunosuppression NN O O
is NN O O
a NN O O
risk NN O O
factor NN O O
for NN O O
PTLD NN O O
, NN O O
higher NN O O
than NN O O
the NN O O
recommended NN O O
doses NN O O
or NN O O
more NN O O
frequent NN O O
dosing NN O O
of NN O O
NULOJIX NN O O
and NN O O
higher NN O O
than NN O O
recommended NN O O
doses NN O O
of NN O O
concomitant NN O O
immunosuppressive NN O O
agents NN O O
are NN O O
not NN O O
recommended NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.1 NN O O
) NN O O
and NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.6 NN O O
) NN O O
] NN O O
. NN O O
Physicians NN O O
should NN O O
consider NN O O
PTLD NN O O
in NN O O
patients NN O O
reporting NN O O
new NN O O
or NN O O
worsening NN O O
neurological NN O O
, NN O O
cognitive NN O O
, NN O O
or NN O O
behavioral NN O O
signs NN O O
or NN O O
symptoms NN O O
. NN O O
EBV NN O O
Serostatus NN O O
The NN O O
risk NN B-Factor B-Factor
of NN O O
PTLD NN B-AdverseReaction B-AdverseReaction
was NN O O
higher NN O O
in NN O O
EBV NN O O
seronegative NN O O
patients NN O O
compared NN O O
to NN O O
EBV NN O O
seropositive NN O O
patients NN O O
. NN O O
EBV NN O O
seropositive NN O O
patients NN O O
are NN O O
defined NN O O
as NN O O
having NN O O
evidence NN O O
of NN O O
acquired NN O O
immunity NN O O
shown NN O O
by NN O O
the NN O O
presence NN O O
of NN O O
IgG NN O O
antibodies NN O O
to NN O O
viral NN O O
capsid NN O O
antigen NN O O
( NN O O
VCA NN O O
) NN O O
and NN O O
EBV NN O O
nuclear NN O O
antigen NN O O
( NN O O
EBNA NN O O
) NN O O
. NN O O
Epstein NN O O
- NN O O
Barr NN O O
virus NN O O
serology NN O O
should NN O O
be NN O O
ascertained NN O O
before NN O O
starting NN O O
administration NN O O
of NN O O
NULOJIX NN O O
, NN O O
and NN O O
only NN O O
patients NN O O
who NN O O
are NN O O
EBV NN O O
seropositive NN O O
should NN O O
receive NN O O
NULOJIX. NN O O
Transplant NN O O
recipients NN O O
who NN O O
are NN O O
EBV NN O O
seronegative NN O O
, NN O O
or NN O O
with NN O O
unknown NN O O
serostatus NN O O
, NN O O
should NN O O
not NN O O
receive NN O O
NULOJIX NN O O
[ NN O O
see NN O O
Boxed NN O O
Warning NN O O
and NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
] NN O O
. NN O O
Other NN O O
Risk NN O O
Factors NN O O
Other NN O O
known NN O O
risk NN O O
factors NN O O
for NN O O
PTLD NN O O
include NN O O
cytomegalovirus NN O O
( NN O O
CMV NN O O
) NN O O
infection NN O O
and NN O O
T NN O O
- NN O O
cell NN O O
- NN O O
depleting NN O O
therapy NN O O
. NN O O
T NN O O
- NN O O
cell NN O O
- NN O O
depleting NN O O
therapies NN O O
to NN O O
treat NN O O
acute NN O O
rejection NN O O
should NN O O
be NN O O
used NN O O
cautiously NN O O
. NN O O
CMV NN O O
prophylaxis NN O O
is NN O O
recommended NN O O
for NN O O
at NN O O
least NN O O
3 NN O O
months NN O O
after NN O O
transplantation NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
. NN O O
Patients NN O O
who NN O O
are NN O O
EBV NN O O
seropositive NN O O
and NN O O
CMV NN O O
seronegative NN O O
may NN O O
be NN O O
at NN O O
increased NN O O
risk NN O O
for NN O O
PTLD NN O O
compared NN O O
to NN O O
patients NN O O
who NN O O
are NN O O
EBV NN O O
seropositive NN O O
and NN O O
CMV NN O O
seropositive NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Since NN O O
CMV NN O O
seronegative NN O O
patients NN O O
are NN O O
at NN O O
increased NN O O
risk NN O O
for NN O O
CMV NN O O
disease NN O O
( NN O O
a NN O O
known NN O O
risk NN O O
factor NN O O
for NN O O
PTLD NN O O
) NN O O
, NN O O
the NN O O
clinical NN O O
significance NN O O
of NN O O
CMV NN O O
serology NN O O
for NN O O
PTLD NN O O
remains NN O O
to NN O O
be NN O O
determined NN O O
; NN O O
however NN O O
, NN O O
these NN O O
findings NN O O
should NN O O
be NN O O
considered NN O O
when NN O O
prescribing NN O O
NULOJIX. NN O O
5.2 NN O O
Management NN O O
of NN O O
Immunosuppression NN O O
Only NN O O
physicians NN O O
experienced NN O O
in NN O O
management NN O O
of NN O O
systemic NN O O
immunosuppressant NN O O
therapy NN O O
in NN O O
transplantation NN O O
should NN O O
prescribe NN O O
NULOJIX. NN O O
Patients NN O O
receiving NN O O
the NN O O
drug NN O O
should NN O O
be NN O O
managed NN O O
in NN O O
facilities NN O O
equipped NN O O
and NN O O
staffed NN O O
with NN O O
adequate NN O O
laboratory NN O O
and NN O O
supportive NN O O
medical NN O O
resources NN O O
. NN O O
The NN O O
physician NN O O
responsible NN O O
for NN O O
the NN O O
maintenance NN O O
therapy NN O O
should NN O O
have NN O O
complete NN O O
information NN O O
requisite NN O O
for NN O O
the NN O O
follow NN O O
- NN O O
up NN O O
of NN O O
the NN O O
patient NN O O
[ NN O O
see NN O O
Boxed NN O O
Warning NN O O
] NN O O
. NN O O
5.3 NN O O
Other NN O O
Malignancies NN O O
Patients NN O O
receiving NN O O
immunosuppressants NN O O
, NN O O
including NN O O
NULOJIX NN O O
, NN O O
are NN O O
at NN O O
increased NN O O
risk NN O O
of NN O O
developing NN O O
malignancies NN B-AdverseReaction B-AdverseReaction
in NN O O
addition NN O O
to NN O O
PTLD NN B-AdverseReaction B-AdverseReaction
including NN O O
the NN O O
skin NN O O
[ NN O O
see NN O O
Boxed NN O O
Warning NN O O
and NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
Exposure NN O O
to NN O O
sunlight NN O O
and NN O O
ultraviolet NN O O
( NN O O
UV NN O O
) NN O O
light NN O O
should NN O O
be NN O O
limited NN O O
by NN O O
wearing NN O O
protective NN O O
clothing NN O O
and NN O O
using NN O O
a NN O O
sunscreen NN O O
with NN O O
a NN O O
high NN O O
protection NN O O
factor NN O O
. NN O O
5.4 NN O O
Progressive NN O O
Multifocal NN O O
Leukoencephalopathy NN O O
Progressive NN O O
multifocal NN O O
leukoencephalopathy NN O O
( NN O O
PML NN O O
) NN O O
is NN O O
an NN O O
often NN O O
rapidly NN O O
progressive NN O O
and NN O O
fatal NN O O
opportunistic NN O O
infection NN O O
of NN O O
the NN O O
CNS NN O O
that NN O O
is NN O O
caused NN O O
by NN O O
the NN O O
JC NN O O
virus NN O O
, NN O O
a NN O O
human NN O O
polyoma NN O O
virus NN O O
. NN O O
In NN O O
clinical NN O O
trials NN O O
with NN O O
NULOJIX NN O O
, NN O O
two NN O O
cases NN O O
of NN O O
PML NN B-AdverseReaction B-AdverseReaction
were NN O O
reported NN O O
in NN O O
patients NN O O
receiving NN O O
NULOJIX NN O O
at NN O O
higher NN O O
cumulative NN O O
doses NN O O
and NN O O
more NN O O
frequently NN O O
than NN O O
the NN O O
recommended NN O O
regimen NN O O
, NN O O
along NN O O
with NN O O
mycophenolate NN O O
mofetil NN O O
( NN O O
MMF NN O O
) NN O O
and NN O O
corticosteroids NN O O
; NN O O
one NN O O
case NN O O
occurred NN O O
in NN O O
a NN O O
kidney NN O O
transplant NN O O
recipient NN O O
and NN O O
the NN O O
second NN O O
case NN O O
occurred NN O O
in NN O O
a NN O O
liver NN O O
transplant NN O O
recipient NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.6 NN O O
) NN O O
] NN O O
. NN O O
As NN O O
PML NN O O
has NN O O
been NN O O
associated NN O O
with NN O O
high NN O O
levels NN O O
of NN O O
overall NN O O
immunosuppression NN O O
, NN O O
the NN O O
recommended NN O O
doses NN O O
and NN O O
frequency NN O O
of NN O O
NULOJIX NN O O
and NN O O
concomitant NN O O
immunosuppressives NN O O
, NN O O
including NN O O
MMF NN O O
, NN O O
should NN O O
not NN O O
be NN O O
exceeded NN O O
. NN O O
Physicians NN O O
should NN O O
consider NN O O
PML NN O O
in NN O O
the NN O O
differential NN O O
diagnosis NN O O
in NN O O
patients NN O O
with NN O O
new NN O O
or NN O O
worsening NN O O
neurological NN O O
, NN O O
cognitive NN O O
, NN O O
or NN O O
behavioral NN O O
signs NN O O
or NN O O
symptoms NN O O
. NN O O
PML NN O O
is NN O O
usually NN O O
diagnosed NN O O
by NN O O
brain NN O O
imaging NN O O
, NN O O
cerebrospinal NN O O
fluid NN O O
( NN O O
CSF NN O O
) NN O O
testing NN O O
for NN O O
JC NN O O
viral NN O O
DNA NN O O
by NN O O
polymerase NN O O
chain NN O O
reaction NN O O
( NN O O
PCR NN O O
) NN O O
, NN O O
and/or NN O O
brain NN O O
biopsy NN O O
. NN O O
Consultation NN O O
with NN O O
a NN O O
specialist NN O O
( NN O O
e.g. NN O O
, NN O O
neurologist NN O O
and/or NN O O
infectious NN O O
disease NN O O
) NN O O
should NN O O
be NN O O
considered NN O O
for NN O O
any NN O O
suspected NN O O
or NN O O
confirmed NN O O
cases NN O O
of NN O O
PML. NN O O
If NN O O
PML NN O O
is NN O O
diagnosed NN O O
, NN O O
consideration NN O O
should NN O O
be NN O O
given NN O O
to NN O O
reduction NN O O
or NN O O
withdrawal NN O O
of NN O O
immunosuppression NN O O
taking NN O O
into NN O O
account NN O O
the NN O O
risk NN O O
to NN O O
the NN O O
allograft NN O O
. NN O O
5.5 NN O O
Other NN O O
Serious NN O O
Infections NN O O
Patients NN O O
receiving NN O O
immunosuppressants NN O O
, NN O O
including NN O O
NULOJIX NN O O
, NN O O
are NN O O
at NN O O
increased NN O O
risk NN B-Factor B-Factor
of NN O O
developing NN O O
bacterial NN O O
, NN O O
viral NN O O
( NN O O
cytomegalovirus NN O O
[ NN O O
CMV NN O O
] NN O O
and NN O O
herpes NN O O
) NN O O
, NN O O
fungal NN O O
, NN O O
and NN O O
protozoal NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
including NN O O
opportunistic NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
These NN O O
infections NN B-AdverseReaction B-AdverseReaction
may NN O O
lead NN O O
to NN O O
serious NN B-Severity B-Severity
including NN O O
fatal NN B-AdverseReaction B-AdverseReaction
outcomes NN O O
[ NN O O
see NN O O
Boxed NN O O
Warning NN O O
and NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Prophylaxis NN O O
for NN O O
cytomegalovirus NN O O
is NN O O
recommended NN O O
for NN O O
at NN O O
least NN O O
3 NN O O
months NN O O
after NN O O
transplantation NN O O
. NN O O
Prophylaxis NN O O
for NN O O
Pneumocystis NN O O
jiroveci NN O O
is NN O O
recommended NN O O
after NN O O
transplantation NN O O
. NN O O
Tuberculosis NN O O
Tuberculosis NN B-AdverseReaction B-AdverseReaction
was NN O O
more NN O O
frequently NN O O
observed NN O O
in NN O O
patients NN O O
receiving NN O O
NULOJIX NN O O
than NN O O
cyclosporine NN O O
in NN O O
clinical NN O O
trials NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Patients NN O O
should NN O O
be NN O O
evaluated NN O O
for NN O O
tuberculosis NN O O
and NN O O
tested NN O O
for NN O O
latent NN O O
infection NN O O
prior NN O O
to NN O O
initiating NN O O
NULOJIX. NN O O
Treatment NN O O
of NN O O
latent NN O O
tuberculosis NN O O
infection NN O O
should NN O O
be NN O O
initiated NN O O
prior NN O O
to NN O O
NULOJIX NN O O
use NN O O
. NN O O
Polyoma NN O O
Virus NN O O
Nephropathy NN O O
In NN O O
addition NN O O
to NN O O
cases NN O O
of NN O O
JC NN B-AdverseReaction B-AdverseReaction
virus NN I-AdverseReaction I-AdverseReaction
PML NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
, NN O O
cases NN O O
of NN O O
polyoma NN B-AdverseReaction B-AdverseReaction
virus NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
associated NN I-AdverseReaction I-AdverseReaction
nephropathy NN I-AdverseReaction I-AdverseReaction
( NN O O
PVAN NN O O
) NN O O
, NN O O
mostly NN O O
due NN O O
to NN O O
BK NN B-AdverseReaction B-AdverseReaction
virus NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
. NN O O
PVAN NN B-AdverseReaction B-AdverseReaction
is NN O O
associated NN O O
with NN O O
serious NN O O
outcomes NN O O
; NN O O
including NN O O
deteriorating NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
function NN I-AdverseReaction I-AdverseReaction
and NN O O
kidney NN B-AdverseReaction B-AdverseReaction
graft NN I-AdverseReaction I-AdverseReaction
loss NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Patient NN O O
monitoring NN O O
may NN O O
help NN O O
detect NN O O
patients NN O O
at NN O O
risk NN O O
for NN O O
PVAN. NN O O
Reductions NN O O
in NN O O
immunosuppression NN O O
should NN O O
be NN O O
considered NN O O
for NN O O
patients NN O O
who NN O O
develop NN O O
evidence NN O O
of NN O O
PVAN. NN O O
Physicians NN O O
should NN O O
also NN O O
consider NN O O
the NN O O
risk NN O O
that NN O O
reduced NN O O
immunosuppression NN O O
represents NN O O
to NN O O
the NN O O
functioning NN O O
allograft NN O O
. NN O O
5.6 NN O O
Liver NN O O
Transplant NN O O
Use NN O O
of NN O O
NULOJIX NN O O
in NN O O
liver NN O O
transplant NN O O
patients NN O O
is NN O O
not NN O O
recommended NN O O
[ NN O O
see NN O O
Boxed NN O O
Warning NN O O
] NN O O
. NN O O
In NN O O
a NN O O
clinical NN O O
trial NN O O
of NN O O
liver NN O O
transplant NN O O
patients NN O O
, NN O O
use NN O O
of NN O O
NULOJIX NN O O
regimens NN O O
with NN O O
more NN O O
frequent NN O O
administration NN O O
of NN O O
belatacept NN O O
than NN O O
any NN O O
of NN O O
those NN O O
studied NN O O
in NN O O
kidney NN O O
transplant NN O O
, NN O O
along NN O O
with NN O O
mycophenolate NN O O
mofetil NN O O
( NN O O
MMF NN O O
) NN O O
and NN O O
corticosteroids NN O O
, NN O O
was NN O O
associated NN O O
with NN O O
a NN O O
higher NN O O
rate NN O O
of NN O O
graft NN B-AdverseReaction B-AdverseReaction
loss NN I-AdverseReaction I-AdverseReaction
and NN O O
death NN B-AdverseReaction B-AdverseReaction
compared NN O O
to NN O O
the NN O O
tacrolimus NN O O
control NN O O
arms NN O O
. NN O O
In NN O O
addition NN O O
, NN O O
two NN O O
cases NN O O
of NN O O
PTLD NN B-AdverseReaction B-AdverseReaction
involving NN O O
the NN O O
liver NN O O
allograft NN O O
( NN O O
one NN O O
fatal NN B-AdverseReaction B-AdverseReaction
and NN O O
one NN O O
fatal NN B-AdverseReaction B-AdverseReaction
case NN O O
of NN O O
PML NN B-AdverseReaction B-AdverseReaction
were NN O O
observed NN O O
among NN O O
the NN O O
147 NN O O
patients NN O O
randomized NN O O
to NN O O
NULOJIX. NN O O
The NN O O
two NN O O
cases NN O O
of NN O O
PTLD NN B-AdverseReaction B-AdverseReaction
were NN O O
reported NN O O
among NN O O
the NN O O
140 NN O O
EBV NN O O
seropositive NN O O
patients NN O O
( NN O O
1.4 NN O O
% NN O O
) NN O O
. NN O O
The NN O O
fatal NN B-AdverseReaction B-AdverseReaction
case NN O O
of NN O O
PML NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
a NN O O
patient NN O O
receiving NN O O
higher NN O O
than NN O O
recommended NN O O
doses NN O O
of NN O O
NULOJIX NN O O
and NN O O
MMF NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
. NN O O
5.7 NN O O
Acute NN O O
Rejection NN O O
and NN O O
Graft NN O O
Loss NN O O
with NN O O
Corticosteroid NN O O
Minimization NN O O
In NN O O
postmarketing NN O O
experience NN O O
, NN O O
use NN O O
of NN O O
NULOJIX NN O O
in NN O O
conjunction NN O O
with NN O O
basiliximab NN O O
induction NN O O
, NN O O
MMF NN O O
, NN O O
and NN O O
corticosteroid NN O O
minimization NN O O
to NN O O
5 NN O O
mg NN O O
per NN O O
day NN O O
between NN O O
Day NN O O
3 NN O O
and NN O O
Week NN O O
6 NN O O
post NN O O
- NN O O
transplant NN O O
was NN O O
associated NN O O
with NN O O
an NN O O
increased NN O O
rate NN O O
and NN O O
grade NN O O
of NN O O
acute NN O O
rejection NN O O
, NN O O
particularly NN O O
Grade NN B-Severity B-Severity
III NN I-Severity I-Severity
rejection NN O O
. NN O O
These NN O O
Grade NN B-Severity B-Severity
III NN I-Severity I-Severity
rejections NN O O
occurred NN O O
in NN O O
patients NN O O
with NN O O
4 NN O O
to NN O O
6 NN O O
HLA NN O O
mismatches NN O O
. NN O O
Graft NN B-AdverseReaction B-AdverseReaction
loss NN I-AdverseReaction I-AdverseReaction
was NN O O
a NN O O
consequence NN O O
of NN O O
Grade NN B-Severity B-Severity
III NN I-Severity I-Severity
rejection NN O O
in NN O O
some NN O O
patients NN O O
. NN O O
Corticosteroid NN O O
utilization NN O O
should NN O O
be NN O O
consistent NN O O
with NN O O
the NN O O
NULOJIX NN O O
clinical NN O O
trial NN O O
experience NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.1 NN O O
) NN O O
and NN O O
Clinical NN O O
Studies NN O O
( NN O O
14.1 NN O O
) NN O O
] NN O O
. NN O O
5.8 NN O O
Immunizations NN O O
The NN O O
use NN O O
of NN O O
live NN O O
vaccines NN O O
should NN O O
be NN O O
avoided NN O O
during NN O O
treatment NN O O
with NN O O
NULOJIX NN O O
, NN O O
including NN O O
but NN O O
not NN O O
limited NN O O
to NN O O
the NN O O
following NN O O
: NN O O
intranasal NN O O
influenza NN O O
, NN O O
measles NN O O
, NN O O
mumps NN O O
, NN O O
rubella NN O O
, NN O O
oral NN O O
polio NN O O
, NN O O
BCG NN O O
, NN O O
yellow NN O O
fever NN O O
, NN O O
varicella NN O O
, NN O O
and NN O O
TY21a NN O O
typhoid NN O O
vaccines NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
L NN O O
ong NN O O
- NN O O
acting NN O O
beta NN O O
2 NN O O
-adrenergic NN O O
agonists NN O O
, NN O O
such NN O O
as NN O O
A NN O O
RCAPTA NN O O
NEOHALER NN O O
, NN O O
increase NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
asthma NN B-AdverseReaction B-AdverseReaction
death NN B-AdverseReaction B-AdverseReaction
. NN O O
ARCAPTA NN O O
NEOHALER NN O O
is NN O O
not NN O O
indicated NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
asthma NN O O
[ NN O O
See NN O O
B NN O O
oxed NN O O
Warning NN O O
and NN O O
W NN O O
arning NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
EXCERPT NN O O
: NN O O
Most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>2 NN O O
% NN O O
and NN O O
more NN O O
common NN O O
than NN O O
placebo NN O O
) NN O O
are NN O O
cough NN B-AdverseReaction B-AdverseReaction
oropharyngeal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
and NN O O
nausea NN B-AdverseReaction B-AdverseReaction
( NN O O
6 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Novartis NN O O
Pharmaceuticals NN O O
Corporation NN O O
at NN O O
1 NN O O
- NN O O
888 NN O O
- NN O O
669 NN O O
- NN O O
6682 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
in NN O O
Chronic NN O O
Obstructive NN O O
Pulmonary NN O O
Disease NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
The NN O O
ARCAPTA NN O O
NEOHALER NN O O
safety NN O O
database NN O O
reflects NN O O
exposure NN O O
of NN O O
2516 NN O O
patients NN O O
to NN O O
ARCAPTA NN O O
NEOHALER NN O O
at NN O O
doses NN O O
of NN O O
75 NN O O
mcg NN O O
or NN O O
greater NN O O
for NN O O
at NN O O
least NN O O
12 NN O O
weeks NN O O
in NN O O
six NN O O
confirmatory NN O O
randomized NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
placebo NN O O
and NN O O
active NN O O
- NN O O
controlled NN O O
clinical NN O O
trials NN O O
( NN O O
see NN O O
Section NN O O
14 NN O O
) NN O O
. NN O O
In NN O O
these NN O O
trials NN O O
, NN O O
449 NN O O
patients NN O O
were NN O O
exposed NN O O
to NN O O
the NN O O
recommended NN O O
dose NN O O
of NN O O
75 NN O O
mcg NN O O
for NN O O
up NN O O
to NN O O
3 NN O O
months NN O O
, NN O O
and NN O O
144 NN O O
, NN O O
583 NN O O
and NN O O
425 NN O O
COPD NN O O
patients NN O O
were NN O O
exposed NN O O
to NN O O
a NN O O
dose NN O O
of NN O O
150 NN O O
, NN O O
300 NN O O
or NN O O
600 NN O O
mcg NN O O
for NN O O
one NN O O
year NN O O
, NN O O
respectively NN O O
. NN O O
Overall NN O O
, NN O O
patients NN O O
had NN O O
a NN O O
mean NN O O
pre NN O O
- NN O O
bronchodilator NN O O
forced NN O O
expiratory NN O O
volume NN O O
in NN O O
one NN O O
second NN O O
( NN O O
FEV1 NN O O
) NN O O
percent NN O O
predicted NN O O
of NN O O
54 NN O O
% NN O O
. NN O O
The NN O O
mean NN O O
age NN O O
of NN O O
patients NN O O
was NN O O
64 NN O O
years NN O O
, NN O O
with NN O O
47 NN O O
% NN O O
of NN O O
patients NN O O
aged NN O O
65 NN O O
years NN O O
or NN O O
older NN O O
, NN O O
and NN O O
the NN O O
majority NN O O
( NN O O
88 NN O O
% NN O O
) NN O O
was NN O O
Caucasian NN O O
. NN O O
In NN O O
these NN O O
six NN O O
clinical NN O O
trials NN O O
, NN O O
48 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
any NN O O
dose NN O O
of NN O O
ARCAPTA NN O O
NEOHALER NN O O
reported NN O O
an NN O O
adverse NN O O
reaction NN O O
compared NN O O
with NN O O
43 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
placebo NN O O
. NN O O
The NN O O
proportion NN O O
of NN O O
patients NN O O
who NN O O
discontinued NN O O
treatment NN O O
due NN O O
to NN O O
adverse NN O O
reaction NN O O
was NN O O
5 NN O O
% NN O O
for NN O O
ARCAPTA NN O O
NEOHALER NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
5 NN O O
% NN O O
for NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
that NN O O
lead NN O O
to NN O O
discontinuation NN O O
of NN O O
ARCAPTA NN O O
NEOHALER NN O O
were NN O O
COPD NN B-AdverseReaction B-AdverseReaction
and NN O O
dyspnea NN B-AdverseReaction B-AdverseReaction
The NN O O
most NN O O
common NN O O
serious NN O O
adverse NN O O
reactions NN O O
were NN O O
COPD NN B-AdverseReaction B-AdverseReaction
exacerbation NN I-AdverseReaction I-AdverseReaction
pneumonia NN B-AdverseReaction B-AdverseReaction
angina NN B-AdverseReaction B-AdverseReaction
pectoris NN I-AdverseReaction I-AdverseReaction
and NN O O
atrial NN B-AdverseReaction B-AdverseReaction
fibrillation NN I-AdverseReaction I-AdverseReaction
which NN O O
occurred NN O O
at NN O O
similar NN O O
rates NN O O
across NN O O
treatment NN O O
groups NN O O
. NN O O
Table NN O O
1 NN O O
displays NN O O
adverse NN O O
drug NN O O
reactions NN O O
reported NN O O
by NN O O
at NN O O
least NN O O
2 NN O O
% NN O O
of NN O O
patients NN O O
( NN O O
and NN O O
higher NN O O
than NN O O
placebo NN O O
) NN O O
during NN O O
a NN O O
3 NN O O
month NN O O
exposure NN O O
at NN O O
the NN O O
recommended NN O O
75 NN O O
mcg NN O O
once NN O O
daily NN O O
dose NN O O
. NN O O
Adverse NN O O
drug NN O O
reactions NN O O
are NN O O
listed NN O O
according NN O O
to NN O O
MedDRA NN O O
( NN O O
version NN O O
13.0 NN O O
) NN O O
system NN O O
organ NN O O
class NN O O
and NN O O
sorted NN O O
in NN O O
descending NN O O
order NN O O
of NN O O
frequency NN O O
. NN O O
Table NN O O
1 NN O O
: NN O O
Number NN O O
and NN O O
frequency NN O O
of NN O O
adverse NN O O
drug NN O O
reactions NN O O
greater NN O O
than NN O O
2 NN O O
% NN O O
( NN O O
and NN O O
higher NN O O
than NN O O
placebo NN O O
) NN O O
in NN O O
COPD NN O O
patients NN O O
exposed NN O O
to NN O O
ARCAPTA NN O O
NEOHALER NN O O
75 NN O O
mcg NN O O
for NN O O
up NN O O
to NN O O
3 NN O O
months NN O O
in NN O O
multiple NN O O
dose NN O O
, NN O O
controlled NN O O
trials NN O O
Indacaterol NN O O
75 NN O O
mcg NN O O
once NN O O
daily NN O O
Placebo NN O O
n=449 NN O O
n= NN O O
445 NN O O
n NN O O
( NN O O
% NN O O
) NN O O
n NN O O
( NN O O
% NN O O
) NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
and NN O O
mediastinal NN O O
disorders NN O O
- NN O O
Cough NN B-AdverseReaction B-AdverseReaction
29 NN O O
( NN O O
6.5 NN O O
) NN O O
20 NN O O
( NN O O
4.5 NN O O
) NN O O
- NN O O
Oropharyngeal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
10 NN O O
( NN O O
2.2 NN O O
) NN O O
3 NN O O
( NN O O
0.7 NN O O
) NN O O
Infections NN O O
and NN O O
infestations NN O O
- NN O O
Nasopharyngitis NN B-AdverseReaction B-AdverseReaction
24 NN O O
( NN O O
5.3 NN O O
) NN O O
12 NN O O
( NN O O
2.7 NN O O
) NN O O
Nervous NN O O
system NN O O
disorders NN O O
- NN O O
Headache NN B-AdverseReaction B-AdverseReaction
23 NN O O
( NN O O
5.1 NN O O
) NN O O
11 NN O O
( NN O O
2.5 NN O O
) NN O O
Gastrointestinal NN O O
disorders NN O O
- NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
11 NN O O
( NN O O
2.4 NN O O
) NN O O
4 NN O O
( NN O O
0.9 NN O O
) NN O O
In NN O O
these NN O O
trials NN O O
the NN O O
overall NN O O
frequency NN O O
of NN O O
all NN O O
cardiovascular NN B-AdverseReaction B-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
was NN O O
2.5 NN O O
% NN O O
for NN O O
ARCAPTA NN O O
NEOHALER NN O O
75 NN O O
mcg NN O O
and NN O O
1.6 NN O O
% NN O O
for NN O O
placebo NN O O
during NN O O
a NN O O
3 NN O O
month NN O O
exposure NN O O
. NN O O
There NN O O
were NN O O
no NN O O
frequently NN O O
occurring NN O O
specific NN O O
cardiovascular NN O O
adverse NN O O
reactions NN O O
for NN O O
ARCAPTA NN O O
NEOHALER NN O O
75 NN O O
mcg NN O O
( NN O O
frequency NN O O
at NN O O
least NN O O
1 NN O O
% NN O O
and NN O O
greater NN O O
than NN O O
placebo NN O O
) NN O O
. NN O O
Additional NN O O
adverse NN O O
drug NN O O
reactions NN O O
reported NN O O
in NN O O
greater NN O O
than NN O O
2 NN O O
% NN O O
( NN O O
and NN O O
higher NN O O
than NN O O
on NN O O
placebo NN O O
) NN O O
in NN O O
patients NN O O
dosed NN O O
with NN O O
150 NN O O
, NN O O
300 NN O O
or NN O O
600 NN O O
mcg NN O O
for NN O O
up NN O O
to NN O O
12 NN O O
months NN O O
were NN O O
as NN O O
follows NN O O
: NN O O
* NN O O
Musculoskeletal NN O O
and NN O O
connective NN O O
tissue NN O O
disorders NN O O
: NN O O
muscle NN B-AdverseReaction B-AdverseReaction
spasm NN I-AdverseReaction I-AdverseReaction
musculoskeletal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
* NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
: NN O O
edema NN B-AdverseReaction B-AdverseReaction
peripheral NN I-AdverseReaction I-AdverseReaction
* NN O O
Metabolism NN O O
and NN O O
nutrition NN O O
disorder NN O O
: NN O O
diabetes NN B-AdverseReaction B-AdverseReaction
mellitus NN I-AdverseReaction I-AdverseReaction
hyperglycemia NN B-AdverseReaction B-AdverseReaction
* NN O O
Infections NN O O
and NN O O
infestations NN O O
: NN O O
sinusitis NN B-AdverseReaction B-AdverseReaction
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
C NN O O
ough NN O O
experienced NN O O
p NN O O
ost NN O O
- NN O O
inhalation NN O O
In NN O O
the NN O O
clinical NN O O
trials NN O O
, NN O O
health NN O O
care NN O O
providers NN O O
observed NN O O
during NN O O
clinic NN O O
visits NN O O
that NN O O
an NN O O
average NN O O
of NN O O
24 NN O O
% NN O O
of NN O O
patients NN O O
experienced NN O O
a NN O O
cough NN B-AdverseReaction B-AdverseReaction
on NN O O
at NN O O
least NN O O
20 NN O O
% NN O O
of NN O O
visits NN O O
following NN O O
inhalation NN O O
of NN O O
the NN O O
recommended NN O O
75 NN O O
mcg NN O O
dose NN O O
of NN O O
ARCAPTA NN O O
NEOHALER NN O O
compared NN O O
to NN O O
7 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
placebo NN O O
. NN O O
The NN O O
cough NN B-AdverseReaction B-AdverseReaction
usually NN O O
occurred NN O O
within NN O O
15 NN O O
seconds NN O O
following NN O O
inhalation NN O O
and NN O O
lasted NN O O
for NN O O
no NN O O
more NN O O
than NN O O
15 NN O O
seconds NN O O
. NN O O
Cough NN B-AdverseReaction B-AdverseReaction
following NN O O
inhalation NN O O
in NN O O
clinical NN O O
trials NN O O
was NN O O
not NN B-Negation B-Negation
associated NN O O
with NN O O
bronchospasm NN B-AdverseReaction B-AdverseReaction
exacerbations NN O O
, NN O O
deteriorations NN O O
of NN O O
disease NN O O
or NN O O
loss NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
efficacy NN I-AdverseReaction I-AdverseReaction
6.2 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
in NN O O
Asthma NN O O
In NN O O
a NN O O
6-month NN O O
randomized NN O O
, NN O O
active NN O O
controlled NN O O
asthma NN O O
safety NN O O
trial NN O O
, NN O O
805 NN O O
adult NN O O
patients NN O O
with NN O O
moderate NN O O
to NN O O
severe NN O O
persistent NN O O
asthma NN O O
were NN O O
treated NN O O
with NN O O
ARCAPTA NN O O
NEOHALER NN O O
300 NN O O
mcg NN O O
( NN O O
n=268 NN O O
) NN O O
, NN O O
ARCAPTA NN O O
NEOHALER NN O O
600 NN O O
mcg NN O O
( NN O O
n=268 NN O O
) NN O O
, NN O O
and NN O O
salmeterol NN O O
( NN O O
n=269 NN O O
) NN O O
, NN O O
all NN O O
concomitant NN O O
with NN O O
inhaled NN O O
corticosteroids NN O O
, NN O O
which NN O O
were NN O O
not NN O O
co NN O O
- NN O O
randomized NN O O
. NN O O
Of NN O O
these NN O O
patients NN O O
, NN O O
there NN O O
were NN O O
2 NN O O
respiratory NN O O
- NN O O
related NN O O
deaths NN B-AdverseReaction B-AdverseReaction
in NN O O
the NN O O
ARCAPTA NN O O
NEOHALER NN O O
300 NN O O
mcg NN O O
dose NN O O
group NN O O
. NN O O
There NN O O
were NN O O
no NN B-Negation B-Negation
deaths NN B-AdverseReaction B-AdverseReaction
in NN O O
the NN O O
ARCAPTA NN O O
NEOHALER NN O O
600 NN O O
mcg NN O O
dose NN O O
group NN O O
or NN O O
in NN O O
the NN O O
salmeterol NN O O
active NN O O
control NN O O
group NN O O
. NN O O
Serious NN O O
adverse NN O O
reactions NN O O
related NN O O
to NN O O
asthma NN B-AdverseReaction B-AdverseReaction
exacerbation NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
for NN O O
2 NN O O
patients NN O O
in NN O O
the NN O O
indacaterol NN O O
300 NN O O
mcg NN O O
group NN O O
, NN O O
3 NN O O
patients NN O O
in NN O O
the NN O O
indacaterol NN O O
600 NN O O
mcg NN O O
group NN O O
, NN O O
and NN O O
no NN O O
patients NN O O
in NN O O
the NN O O
salmeterol NN O O
active NN O O
control NN O O
group NN O O
. NN O O
In NN O O
addition NN O O
, NN O O
a NN O O
two NN O O
- NN O O
week NN O O
dose NN O O
- NN O O
ranging NN O O
trial NN O O
was NN O O
conducted NN O O
in NN O O
511 NN O O
adult NN O O
patients NN O O
with NN O O
mild NN O O
persistent NN O O
asthma NN O O
taking NN O O
inhaled NN O O
corticosteroids NN O O
. NN O O
No NN B-Negation B-Negation
deaths NN B-AdverseReaction B-AdverseReaction
intubations NN O O
, NN O O
or NN O O
serious NN O O
adverse NN O O
reactions NN O O
related NN O O
to NN O O
asthma NN B-AdverseReaction B-AdverseReaction
exacerbation NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
in NN O O
this NN O O
trial NN O O
. NN O O
6.3 NN O O
Postmarketing NN O O
Experience NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
identified NN O O
during NN O O
worldwide NN O O
post NN O O
- NN O O
approval NN O O
use NN O O
of NN O O
indacaterol NN O O
, NN O O
the NN O O
active NN O O
ingredient NN O O
in NN O O
ARCAPTA NN O O
NEOHALER. NN O O
Because NN O O
these NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
These NN O O
adverse NN O O
reactions NN O O
are NN O O
: NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
paradoxical NN B-AdverseReaction B-AdverseReaction
bronchospasm NN I-AdverseReaction I-AdverseReaction
tachycardia NN B-AdverseReaction B-AdverseReaction
rate NN O O
increase/palpitations NN O O
, NN O O
pruritus NN B-AdverseReaction B-AdverseReaction
and NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
ASTHMA NN O O
- NN O O
RELATED NN O O
DEATH NN B-AdverseReaction B-AdverseReaction
WARNING NN O O
: NN O O
ASTHMA NN O O
- NN O O
RELATED NN O O
DEATH NN B-AdverseReaction B-AdverseReaction
L NN B-DrugClass B-DrugClass
ong NN I-DrugClass I-DrugClass
- NN I-DrugClass I-DrugClass
acting NN I-DrugClass I-DrugClass
beta NN I-DrugClass I-DrugClass
2 NN I-DrugClass I-DrugClass
-adrenergic NN I-DrugClass I-DrugClass
agonist NN I-DrugClass I-DrugClass
s NN I-DrugClass I-DrugClass
( NN O O
LABA NN O O
) NN O O
increase NN O O
the NN O O
risk NN O O
of NN O O
asthma NN O O
- NN O O
related NN O O
death NN B-AdverseReaction B-AdverseReaction
Data NN O O
from NN O O
a NN O O
large NN O O
placebo NN O O
- NN O O
controlled NN O O
US NN O O
study NN O O
that NN O O
compared NN O O
the NN O O
safety NN O O
of NN O O
another NN O O
long NN B-DrugClass B-DrugClass
- NN I-DrugClass I-DrugClass
acting NN I-DrugClass I-DrugClass
beta NN I-DrugClass I-DrugClass
2 NN I-DrugClass I-DrugClass
-adrenergic NN I-DrugClass I-DrugClass
agonist NN I-DrugClass I-DrugClass
( NN O O
salmeterol NN O O
) NN O O
or NN O O
placebo NN O O
added NN O O
to NN O O
usual NN O O
asthma NN O O
therapy NN O O
showed NN O O
an NN O O
increase NN O O
in NN O O
asthma NN O O
- NN O O
related NN O O
deaths NN B-AdverseReaction B-AdverseReaction
in NN O O
patients NN O O
receiving NN O O
salmeterol NN O O
. NN O O
This NN O O
finding NN O O
with NN O O
salmeterol NN O O
is NN O O
considered NN O O
a NN O O
class NN O O
effect NN O O
of NN O O
LABA NN O O
, NN O O
including NN O O
indacaterol NN O O
, NN O O
the NN O O
active NN O O
ingredient NN O O
in NN O O
ARCAPTA NN O O
NEOHALER NN O O
. NN O O
The NN O O
safety NN O O
and NN O O
efficacy NN O O
of NN O O
ARCAPTA NN O O
NEOHALER NN O O
in NN O O
patients NN O O
with NN O O
asthma NN O O
have NN O O
not NN O O
been NN O O
established NN O O
. NN O O
A NN O O
RCAPTA NN O O
NEOHALER NN O O
is NN O O
not NN O O
indicated NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
asthma NN O O
. NN O O
[ NN O O
See NN O O
C NN O O
ontraindications NN O O
( NN O O
4 NN O O
) NN O O
, NN O O
W NN O O
arnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
EXCERPT NN O O
: NN O O
WARNING NN O O
: NN O O
ASTHMA NN O O
- NN O O
RELATED NN O O
DEATH NN B-AdverseReaction B-AdverseReaction
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
* NN O O
Long NN B-DrugClass B-DrugClass
- NN I-DrugClass I-DrugClass
acting NN I-DrugClass I-DrugClass
beta2-adrenergic NN I-DrugClass I-DrugClass
agonists NN I-DrugClass I-DrugClass
( NN O O
LABA NN O O
) NN O O
increase NN O O
the NN O O
risk NN O O
of NN O O
asthma NN O O
- NN O O
related NN O O
death NN B-AdverseReaction B-AdverseReaction
( NN O O
5.1 NN O O
) NN O O
. NN O O
* NN O O
A NN O O
placebo NN O O
- NN O O
controlled NN O O
study NN O O
with NN O O
another NN O O
long NN B-DrugClass B-DrugClass
- NN I-DrugClass I-DrugClass
acting NN I-DrugClass I-DrugClass
beta2-adrenergic NN I-DrugClass I-DrugClass
agonist NN I-DrugClass I-DrugClass
( NN O O
salmeterol NN O O
) NN O O
showed NN O O
an NN O O
increase NN O O
in NN O O
asthma NN O O
- NN O O
related NN O O
deaths NN B-AdverseReaction B-AdverseReaction
in NN O O
patients NN O O
receiving NN O O
salmeterol NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
This NN O O
finding NN O O
of NN O O
an NN O O
increased NN O O
risk NN B-Factor B-Factor
of NN O O
asthma NN O O
- NN O O
related NN O O
death NN B-AdverseReaction B-AdverseReaction
with NN O O
salmeterol NN O O
is NN O O
considered NN O O
a NN O O
class NN O O
effect NN O O
of NN O O
LABA NN O O
, NN O O
including NN O O
indacaterol NN O O
, NN O O
the NN O O
active NN O O
ingredient NN O O
in NN O O
ARCAPTA NN O O
NEOHALER. NN O O
The NN O O
safety NN O O
and NN O O
efficacy NN O O
of NN O O
ARCAPTA NN O O
NEOHALER NN O O
in NN O O
patients NN O O
with NN O O
asthma NN O O
have NN O O
not NN O O
been NN O O
established NN O O
. NN O O
ARCAPTA NN O O
NEOHALER NN O O
is NN O O
not NN O O
indicated NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
asthma NN O O
. NN O O
( NN O O
4 NN O O
, NN O O
5.1 NN O O
) NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Do NN O O
not NN O O
initiate NN O O
in NN O O
acutely NN O O
deteriorating NN O O
COPD NN O O
patients NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Do NN O O
not NN O O
use NN O O
for NN O O
relief NN O O
of NN O O
acute NN O O
symptoms NN O O
. NN O O
Concomitant NN O O
short NN O O
- NN O O
acting NN O O
beta2-agonists NN O O
can NN O O
be NN O O
used NN O O
as NN O O
needed NN O O
for NN O O
acute NN O O
relief NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Do NN O O
not NN O O
exceed NN O O
the NN O O
recommended NN O O
dose NN O O
. NN O O
Excessive NN O O
use NN O O
or NN O O
use NN O O
in NN O O
conjunction NN O O
with NN O O
other NN O O
medications NN O O
containing NN O O
LABA NN B-DrugClass B-DrugClass
can NN O O
result NN O O
in NN O O
clinically NN O O
significant NN B-Severity B-Severity
cardiovascular NN B-AdverseReaction B-AdverseReaction
effects NN I-AdverseReaction I-AdverseReaction
and NN O O
may NN O O
be NN O O
fatal NN B-AdverseReaction B-AdverseReaction
( NN O O
5.3 NN O O
) NN O O
* NN O O
Immediate NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
may NN B-Factor B-Factor
occur NN O O
. NN O O
Discontinue NN O O
immediately NN O O
. NN O O
( NN O O
5.4 NN O O
) NN O O
* NN O O
Life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
paradoxical NN B-AdverseReaction B-AdverseReaction
bronchospasm NN I-AdverseReaction I-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
. NN O O
Discontinue NN O O
immediately NN O O
. NN O O
( NN O O
5.5 NN O O
) NN O O
* NN O O
Use NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
with NN O O
cardiovascular NN O O
or NN O O
convulsive NN O O
disorders NN O O
, NN O O
thyrotoxicosis NN O O
or NN O O
sensitivity NN O O
to NN O O
sympathomimetic NN O O
drugs NN O O
. NN O O
( NN O O
5.6 NN O O
, NN O O
5.7 NN O O
) NN O O
5.1 NN O O
Asthma NN O O
- NN O O
Related NN O O
Death NN O O
[ NN O O
See NN O O
Boxed NN O O
Warning NN O O
] NN O O
* NN O O
Data NN O O
from NN O O
a NN O O
large NN O O
placebo NN O O
- NN O O
controlled NN O O
study NN O O
in NN O O
asthma NN O O
patients NN O O
showed NN O O
that NN O O
long NN B-DrugClass B-DrugClass
- NN I-DrugClass I-DrugClass
acting NN I-DrugClass I-DrugClass
beta NN I-DrugClass I-DrugClass
2 NN I-DrugClass I-DrugClass
-adrenergic NN I-DrugClass I-DrugClass
agonists NN I-DrugClass I-DrugClass
may NN O O
increase NN O O
the NN O O
risk NN O O
of NN O O
asthma NN O O
- NN O O
related NN O O
death NN B-AdverseReaction B-AdverseReaction
Data NN O O
are NN O O
not NN O O
available NN O O
to NN O O
determine NN O O
whether NN O O
the NN O O
rate NN O O
of NN O O
death NN O O
in NN O O
patients NN O O
with NN O O
COPD NN O O
is NN O O
increased NN O O
by NN O O
long NN O O
- NN O O
acting NN O O
beta NN O O
2 NN O O
-adrenergic NN O O
agonists NN O O
. NN O O
* NN O O
A NN O O
28-week NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
US NN O O
study NN O O
comparing NN O O
the NN O O
safety NN O O
of NN O O
another NN O O
long NN B-DrugClass B-DrugClass
- NN I-DrugClass I-DrugClass
acting NN I-DrugClass I-DrugClass
beta NN I-DrugClass I-DrugClass
2 NN I-DrugClass I-DrugClass
-adrenergic NN I-DrugClass I-DrugClass
agonist NN I-DrugClass I-DrugClass
( NN O O
salmeterol NN O O
) NN O O
with NN O O
placebo NN O O
, NN O O
each NN O O
added NN O O
to NN O O
usual NN O O
asthma NN O O
therapy NN O O
, NN O O
showed NN O O
an NN O O
increase NN O O
in NN O O
asthma NN O O
- NN O O
related NN O O
deaths NN B-AdverseReaction B-AdverseReaction
in NN O O
patients NN O O
receiving NN O O
salmeterol NN O O
( NN O O
13/13,176 NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
salmeterol NN O O
vs. NN O O
3/13,179 NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
placebo NN O O
; NN O O
RR NN O O
4.37 NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
1.25 NN O O
, NN O O
15.34 NN O O
) NN O O
. NN O O
The NN O O
increased NN O O
risk NN B-Factor B-Factor
of NN O O
asthma NN O O
- NN O O
related NN O O
death NN B-AdverseReaction B-AdverseReaction
is NN O O
considered NN O O
a NN O O
class NN O O
effect NN O O
of NN O O
the NN O O
long NN O O
- NN O O
acting NN O O
beta NN O O
2 NN O O
-adrenergic NN O O
agonists NN O O
, NN O O
including NN O O
ARCAPTA NN O O
NEOHALER NN O O
. NN O O
No NN O O
study NN O O
adequate NN O O
to NN O O
determine NN O O
whether NN O O
the NN O O
rate NN O O
of NN O O
asthma NN O O
- NN O O
related NN O O
death NN O O
is NN O O
increased NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
ARCAPTA NN O O
NEOHALER NN O O
has NN O O
been NN O O
conducted NN O O
. NN O O
The NN O O
safety NN O O
and NN O O
efficacy NN O O
of NN O O
ARCAPTA NN O O
NEOHALER NN O O
in NN O O
patients NN O O
with NN O O
asthma NN O O
have NN O O
not NN O O
been NN O O
established NN O O
. NN O O
ARCAPTA NN O O
NEOHALER NN O O
is NN O O
not NN O O
indicated NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
asthma NN O O
. NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Serious NN O O
asthma NN O O
- NN O O
related NN O O
events NN O O
, NN O O
including NN O O
death NN B-AdverseReaction B-AdverseReaction
were NN O O
reported NN O O
in NN O O
clinical NN O O
studies NN O O
with NN O O
ARCAPTA NN O O
NEOHALER. NN O O
The NN O O
sizes NN O O
of NN O O
these NN O O
studies NN O O
were NN O O
not NN O O
adequate NN O O
to NN O O
precisely NN O O
quantify NN O O
the NN O O
differences NN O O
in NN O O
serious NN O O
asthma NN O O
exacerbation NN O O
rates NN O O
between NN O O
treatment NN O O
groups NN O O
. NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.2 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
Deterioration NN O O
of NN O O
Disease NN O O
and NN O O
Acute NN O O
Episodes NN O O
ARCAPTA NN O O
NEOHALER NN O O
should NN O O
not NN O O
be NN O O
initiated NN O O
in NN O O
patients NN O O
with NN O O
acutely NN O O
deteriorating NN O O
COPD NN O O
, NN O O
which NN O O
may NN O O
be NN O O
a NN O O
life NN O O
- NN O O
threatening NN O O
condition NN O O
. NN O O
ARCAPTA NN O O
NEOHALER NN O O
has NN O O
not NN O O
been NN O O
studied NN O O
in NN O O
patients NN O O
with NN O O
acutely NN O O
deteriorating NN O O
COPD. NN O O
The NN O O
use NN O O
of NN O O
ARCAPTA NN O O
NEOHALER NN O O
in NN O O
this NN O O
setting NN O O
is NN O O
inappropriate NN O O
. NN O O
ARCAPTA NN O O
NEOHALER NN O O
should NN O O
not NN O O
be NN O O
used NN O O
for NN O O
the NN O O
relief NN O O
of NN O O
acute NN O O
symptoms NN O O
, NN O O
i.e. NN O O
as NN O O
rescue NN O O
therapy NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
acute NN O O
episodes NN O O
of NN O O
bronchospasm NN O O
. NN O O
ARCAPTA NN O O
NEOHALER NN O O
has NN O O
not NN O O
been NN O O
studied NN O O
in NN O O
the NN O O
relief NN O O
of NN O O
acute NN O O
symptoms NN O O
and NN O O
extra NN O O
doses NN O O
should NN O O
not NN O O
be NN O O
used NN O O
for NN O O
that NN O O
purpose NN O O
. NN O O
Acute NN O O
symptoms NN O O
should NN O O
be NN O O
treated NN O O
with NN O O
an NN O O
inhaled NN O O
short NN O O
- NN O O
acting NN O O
beta2-agonist NN O O
. NN O O
When NN O O
beginning NN O O
ARCAPTA NN O O
NEOHALER NN O O
, NN O O
patients NN O O
who NN O O
have NN O O
been NN O O
taking NN O O
inhaled NN O O
, NN O O
short NN O O
- NN O O
acting NN O O
beta2-agonists NN O O
on NN O O
a NN O O
regular NN O O
basis NN O O
( NN O O
e.g. NN O O
, NN O O
four NN O O
times NN O O
a NN O O
day NN O O
) NN O O
should NN O O
be NN O O
instructed NN O O
to NN O O
discontinue NN O O
the NN O O
regular NN O O
use NN O O
of NN O O
these NN O O
drugs NN O O
and NN O O
use NN O O
them NN O O
only NN O O
for NN O O
symptomatic NN O O
relief NN O O
of NN O O
acute NN O O
respiratory NN O O
symptoms NN O O
. NN O O
When NN O O
prescribing NN O O
ARCAPTA NN O O
NEOHALER NN O O
, NN O O
the NN O O
healthcare NN O O
provider NN O O
should NN O O
also NN O O
prescribe NN O O
an NN O O
inhaled NN O O
, NN O O
short NN O O
- NN O O
acting NN O O
beta2- NN O O
agonist NN O O
and NN O O
instruct NN O O
the NN O O
patient NN O O
on NN O O
how NN O O
it NN O O
should NN O O
be NN O O
used NN O O
. NN O O
Increasing NN O O
inhaled NN O O
beta2-agonist NN O O
use NN O O
is NN O O
a NN O O
signal NN O O
of NN O O
deteriorating NN O O
disease NN O O
for NN O O
which NN O O
prompt NN O O
medical NN O O
attention NN O O
is NN O O
indicated NN O O
. NN O O
COPD NN O O
may NN O O
deteriorate NN O O
acutely NN O O
over NN O O
a NN O O
period NN O O
of NN O O
hours NN O O
or NN O O
chronically NN O O
over NN O O
several NN O O
days NN O O
or NN O O
longer NN O O
. NN O O
If NN O O
ARCAPTA NN O O
NEOHALER NN O O
no NN O O
longer NN O O
controls NN O O
the NN O O
symptoms NN O O
of NN O O
bronchoconstriction NN O O
, NN O O
or NN O O
the NN O O
patient NN O O
's NN O O
inhaled NN O O
, NN O O
short NN O O
- NN O O
acting NN O O
beta2-agonist NN O O
becomes NN O O
less NN O O
effective NN O O
or NN O O
the NN O O
patient NN O O
needs NN O O
more NN O O
inhalation NN O O
of NN O O
short NN O O
- NN O O
acting NN O O
beta2-agonist NN O O
than NN O O
usual NN O O
, NN O O
these NN O O
may NN O O
be NN O O
markers NN O O
of NN O O
deterioration NN O O
of NN O O
disease NN O O
. NN O O
In NN O O
this NN O O
setting NN O O
, NN O O
a NN O O
re NN O O
- NN O O
evaluation NN O O
of NN O O
the NN O O
patient NN O O
and NN O O
the NN O O
COPD NN O O
treatment NN O O
regimen NN O O
should NN O O
be NN O O
undertaken NN O O
at NN O O
once NN O O
. NN O O
Increasing NN O O
the NN O O
daily NN O O
dosage NN O O
of NN O O
ARCAPTA NN O O
NEOHALER NN O O
beyond NN O O
the NN O O
recommended NN O O
dose NN O O
is NN O O
not NN O O
appropriate NN O O
in NN O O
this NN O O
situation NN O O
. NN O O
5.3 NN O O
Excessive NN O O
Use NN O O
of NN O O
ARCAPTA NN O O
NEOHALER NN O O
and NN O O
Use NN O O
with NN O O
Other NN O O
Long NN O O
- NN O O
Acting NN O O
Beta2-Agonists NN O O
As NN O O
with NN O O
other NN O O
inhaled NN O O
beta2-adrenergic NN O O
drugs NN O O
, NN O O
ARCAPTA NN O O
NEOHALER NN O O
should NN O O
not NN O O
be NN O O
used NN O O
more NN O O
often NN O O
, NN O O
at NN O O
higher NN O O
doses NN O O
than NN O O
recommended NN O O
, NN O O
or NN O O
in NN O O
conjunction NN O O
with NN O O
other NN O O
medications NN O O
containing NN O O
long NN O O
- NN O O
acting NN O O
beta2-agonists NN O O
, NN O O
as NN O O
an NN O O
overdose NN O O
may NN O O
result NN O O
. NN O O
Clinically NN O O
significant NN O O
cardiovascular NN O O
effects NN O O
and NN O O
fatalities NN O O
have NN O O
been NN O O
reported NN O O
in NN O O
association NN O O
with NN O O
excessive NN O O
use NN O O
of NN O O
inhaled NN O O
sympathomimetic NN O O
drugs NN O O
. NN O O
5.4 NN O O
Immediate NN O O
Hypersensitivity NN O O
Reactions NN O O
Immediate NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
may NN B-Factor B-Factor
occur NN O O
after NN O O
administration NN O O
of NN O O
ARCAPTA NN O O
NEOHALER. NN O O
If NN O O
signs NN O O
suggesting NN O O
allergic NN O O
reactions NN O O
( NN O O
in NN O O
particular NN O O
, NN O O
difficulties NN O O
in NN O O
breathing NN O O
or NN O O
swallowing NN O O
, NN O O
swelling NN O O
of NN O O
tongue NN O O
, NN O O
lips NN O O
and NN O O
face NN O O
, NN O O
urticaria NN O O
, NN O O
skin NN O O
rash NN O O
) NN O O
occur NN O O
, NN O O
ARCAPTA NN O O
NEOHALER NN O O
should NN O O
be NN O O
discontinued NN O O
immediately NN O O
and NN O O
alternative NN O O
therapy NN O O
instituted NN O O
. NN O O
5.5 NN O O
Paradoxical NN O O
Bronchospasm NN O O
As NN O O
with NN O O
other NN O O
inhaled NN O O
beta2-agonists NN O O
, NN O O
ARCAPTA NN O O
NEOHALER NN O O
may NN B-Factor B-Factor
produce NN O O
paradoxical NN B-AdverseReaction B-AdverseReaction
bronchospasm NN I-AdverseReaction I-AdverseReaction
that NN O O
may NN O O
be NN O O
life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
If NN O O
paradoxical NN O O
bronchospasm NN O O
occurs NN O O
, NN O O
ARCAPTA NN O O
NEOHALER NN O O
should NN O O
be NN O O
discontinued NN O O
immediately NN O O
and NN O O
alternative NN O O
therapy NN O O
instituted NN O O
. NN O O
5.6 NN O O
Cardiovascular NN O O
Effects NN O O
ARCAPTA NN O O
NEOHALER NN O O
, NN O O
like NN O O
other NN O O
beta2-agonists NN O O
, NN O O
can NN B-Factor B-Factor
produce NN O O
a NN O O
clinically NN O O
significant NN B-Severity B-Severity
cardiovascular NN B-AdverseReaction B-AdverseReaction
effect NN I-AdverseReaction I-AdverseReaction
in NN O O
some NN O O
patients NN O O
as NN O O
measured NN O O
by NN O O
increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
pulse NN I-AdverseReaction I-AdverseReaction
rate NN I-AdverseReaction I-AdverseReaction
systolic NN O O
or NN O O
diastolic NN O O
blood NN O O
pressure NN O O
, NN O O
or NN O O
symptoms NN O O
. NN O O
If NN O O
such NN O O
effects NN O O
occur NN O O
, NN O O
ARCAPTA NN O O
NEOHALER NN O O
may NN O O
need NN O O
to NN O O
be NN O O
discontinued NN O O
. NN O O
In NN O O
addition NN O O
, NN O O
beta NN B-DrugClass B-DrugClass
- NN I-DrugClass I-DrugClass
agonists NN I-DrugClass I-DrugClass
have NN O O
been NN O O
reported NN O O
to NN O O
produce NN O O
ECG NN B-AdverseReaction B-AdverseReaction
changes NN I-AdverseReaction I-AdverseReaction
such NN O O
as NN O O
flattening NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
T NN I-AdverseReaction I-AdverseReaction
wave NN I-AdverseReaction I-AdverseReaction
prolongation NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
QTc NN I-AdverseReaction I-AdverseReaction
interval NN I-AdverseReaction I-AdverseReaction
and NN O O
ST NN B-AdverseReaction B-AdverseReaction
segment NN I-AdverseReaction I-AdverseReaction
depression NN I-AdverseReaction I-AdverseReaction
although NN O O
the NN O O
clinical NN O O
significance NN O O
of NN O O
these NN O O
findings NN O O
is NN O O
unknown NN O O
. NN O O
Therefore NN O O
, NN O O
ARCAPTA NN O O
NEOHALER NN O O
, NN O O
like NN O O
other NN O O
sympathomimetic NN O O
amines NN O O
, NN O O
should NN O O
be NN O O
used NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
with NN O O
cardiovascular NN O O
disorders NN O O
, NN O O
especially NN O O
coronary NN O O
insufficiency NN O O
, NN O O
cardiac NN O O
arrhythmias NN O O
, NN O O
and NN O O
hypertension NN O O
. NN O O
5.7 NN O O
Coexisting NN O O
Conditions NN O O
ARCAPTA NN O O
NEOHALER NN O O
, NN O O
like NN O O
other NN O O
sympathomimetic NN O O
amines NN O O
, NN O O
should NN O O
be NN O O
used NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
with NN O O
convulsive NN O O
disorders NN O O
or NN O O
thyrotoxicosis NN O O
, NN O O
and NN O O
in NN O O
patients NN O O
who NN O O
are NN O O
unusually NN O O
responsive NN O O
to NN O O
sympathomimetic NN O O
amines NN O O
. NN O O
Doses NN O O
of NN O O
the NN O O
related NN O O
beta2-agonist NN B-DrugClass B-DrugClass
albuterol NN O O
, NN O O
when NN O O
administered NN O O
intravenously NN O O
, NN O O
have NN O O
been NN O O
reported NN O O
to NN O O
aggravate NN B-AdverseReaction B-AdverseReaction
pre NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
existing NN I-AdverseReaction I-AdverseReaction
diabetes NN I-AdverseReaction I-AdverseReaction
mellitus NN I-AdverseReaction I-AdverseReaction
and NN O O
ketoacidosis NN O O
. NN O O
5.8 NN O O
Hypokalemia NN O O
and NN O O
Hyperglycemia NN O O
Beta2-agonist NN B-DrugClass B-DrugClass
medications NN O O
may NN O O
produce NN O O
significant NN B-Severity B-Severity
hypokalemia NN B-AdverseReaction B-AdverseReaction
in NN O O
some NN O O
patients NN O O
, NN O O
possibly NN O O
through NN O O
intracellular NN O O
shunting NN O O
, NN O O
which NN O O
has NN O O
the NN O O
potential NN O O
to NN O O
produce NN O O
adverse NN B-AdverseReaction B-AdverseReaction
cardiovascular NN I-AdverseReaction I-AdverseReaction
effects NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.2 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
decrease NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
potassium NN I-AdverseReaction I-AdverseReaction
is NN O O
usually NN O O
transient NN O O
, NN O O
not NN O O
requiring NN O O
supplementation NN O O
. NN O O
Inhalation NN O O
of NN O O
high NN O O
doses NN O O
of NN O O
beta2-adrenergic NN B-DrugClass B-DrugClass
agonists NN I-DrugClass I-DrugClass
may NN O O
produce NN O O
increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
plasma NN I-AdverseReaction I-AdverseReaction
glucose NN I-AdverseReaction I-AdverseReaction
Clinically NN O O
notable NN O O
decreases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
potassium NN I-AdverseReaction I-AdverseReaction
or NN O O
changes NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
blood NN I-AdverseReaction I-AdverseReaction
glucose NN I-AdverseReaction I-AdverseReaction
were NN O O
infrequent NN O O
during NN O O
clinical NN O O
studies NN O O
with NN O O
long NN O O
- NN O O
term NN O O
administration NN O O
of NN O O
ARCAPTA NN O O
NEOHALER NN O O
with NN O O
the NN O O
rates NN O O
similar NN O O
to NN O O
those NN O O
for NN O O
placebo NN O O
controls NN O O
. NN O O
ARCAPTA NN O O
NEOHALER NN O O
has NN O O
not NN O O
been NN O O
investigated NN O O
in NN O O
patients NN O O
whose NN O O
diabetes NN O O
mellitus NN O O
is NN O O
not NN O O
well NN O O
controlled NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
adverse NN O O
reaction NN O O
is NN O O
discussed NN O O
in NN O O
greater NN O O
detail NN O O
in NN O O
other NN O O
sections NN O O
of NN O O
the NN O O
label NN O O
: NN O O
* NN O O
Transaminase NN B-AdverseReaction B-AdverseReaction
Elevations NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
drug NN O O
reactions NN O O
to NN O O
KALYDECO NN O O
( NN O O
occurring NN O O
in NN O O
>=8 NN O O
% NN O O
of NN O O
patients NN O O
with NN O O
CF NN O O
who NN O O
have NN O O
a NN O O
G551D NN O O
mutation NN O O
in NN O O
the NN O O
CFTR NN O O
gene NN O O
) NN O O
were NN O O
headache NN B-AdverseReaction B-AdverseReaction
oropharyngeal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
nasal NN B-AdverseReaction B-AdverseReaction
congestion NN I-AdverseReaction I-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
and NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Vertex NN O O
Pharmaceuticals NN O O
Incorporated NN O O
at NN O O
1 NN O O
- NN O O
877 NN O O
- NN O O
634 NN O O
- NN O O
8789 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O
The NN O O
overall NN O O
safety NN O O
profile NN O O
of NN O O
KALYDECO NN O O
is NN O O
based NN O O
on NN O O
pooled NN O O
data NN O O
from NN O O
three NN O O
placebo NN O O
- NN O O
controlled NN O O
clinical NN O O
trials NN O O
conducted NN O O
in NN O O
353 NN O O
patients NN O O
6 NN O O
years NN O O
of NN O O
age NN O O
and NN O O
older NN O O
with NN O O
CF NN O O
who NN O O
had NN O O
a NN O O
G551D NN O O
mutation NN O O
in NN O O
the NN O O
CFTR NN O O
gene NN O O
( NN O O
Trials NN O O
1 NN O O
and NN O O
2 NN O O
) NN O O
or NN O O
were NN O O
homozygous NN O O
for NN O O
the NN O O
F508del NN O O
mutation NN O O
( NN O O
Trial NN O O
3 NN O O
) NN O O
. NN O O
In NN O O
addition NN O O
, NN O O
the NN O O
following NN O O
clinical NN O O
trials NN O O
have NN O O
also NN O O
been NN O O
conducted NN O O
[ NN O O
see NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12 NN O O
) NN O O
and NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
: NN O O
* NN O O
An NN O O
8-week NN O O
crossover NN O O
design NN O O
trial NN O O
( NN O O
Trial NN O O
4 NN O O
) NN O O
involving NN O O
39 NN O O
patients NN O O
between NN O O
the NN O O
ages NN O O
of NN O O
6 NN O O
and NN O O
57 NN O O
years NN O O
with NN O O
a NN O O
G1244E NN O O
, NN O O
G1349D NN O O
, NN O O
G178R NN O O
, NN O O
G551S NN O O
, NN O O
G970R NN O O
, NN O O
S1251N NN O O
, NN O O
S1255P NN O O
, NN O O
S549N NN O O
, NN O O
or NN O O
S549R NN O O
mutation NN O O
in NN O O
the NN O O
CFTR NN O O
gene NN O O
. NN O O
* NN O O
A NN O O
24-week NN O O
placebo NN O O
- NN O O
controlled NN O O
trial NN O O
( NN O O
Trial NN O O
5 NN O O
) NN O O
involving NN O O
69 NN O O
patients NN O O
between NN O O
the NN O O
ages NN O O
of NN O O
6 NN O O
and NN O O
68 NN O O
years NN O O
with NN O O
an NN O O
R117H NN O O
mutation NN O O
in NN O O
the NN O O
CFTR NN O O
gene NN O O
. NN O O
* NN O O
A NN O O
24-week NN O O
open NN O O
- NN O O
label NN O O
trial NN O O
( NN O O
Trial NN O O
6 NN O O
) NN O O
in NN O O
34 NN O O
patients NN O O
2 NN O O
to NN O O
less NN O O
than NN O O
6 NN O O
years NN O O
of NN O O
age NN O O
. NN O O
Patients NN O O
eligible NN O O
for NN O O
Trial NN O O
6 NN O O
were NN O O
those NN O O
with NN O O
the NN O O
G551D NN O O
, NN O O
G1244E NN O O
, NN O O
G1349D NN O O
, NN O O
G178R NN O O
, NN O O
G551S NN O O
, NN O O
G970R NN O O
, NN O O
S1251N NN O O
, NN O O
S1255P NN O O
, NN O O
S549N NN O O
, NN O O
or NN O O
S549R NN O O
mutation NN O O
in NN O O
the NN O O
CFTR NN O O
gene NN O O
. NN O O
Of NN O O
34 NN O O
patients NN O O
enrolled NN O O
, NN O O
32 NN O O
had NN O O
the NN O O
G551D NN O O
mutation NN O O
and NN O O
2 NN O O
had NN O O
the NN O O
S549N NN O O
mutation NN O O
. NN O O
Of NN O O
the NN O O
353 NN O O
patients NN O O
included NN O O
in NN O O
the NN O O
pooled NN O O
analyses NN O O
of NN O O
patients NN O O
with NN O O
CF NN O O
who NN O O
had NN O O
either NN O O
a NN O O
G551D NN O O
mutation NN O O
or NN O O
were NN O O
homozygous NN O O
for NN O O
the NN O O
F508del NN O O
mutation NN O O
in NN O O
the NN O O
CFTR NN O O
gene NN O O
, NN O O
50 NN O O
% NN O O
of NN O O
patients NN O O
were NN O O
female NN O O
and NN O O
97 NN O O
% NN O O
were NN O O
Caucasian NN O O
; NN O O
221 NN O O
received NN O O
KALYDECO NN O O
, NN O O
and NN O O
132 NN O O
received NN O O
placebo NN O O
from NN O O
16 NN O O
to NN O O
48 NN O O
weeks NN O O
. NN O O
The NN O O
proportion NN O O
of NN O O
patients NN O O
who NN O O
prematurely NN O O
discontinued NN O O
study NN O O
drug NN O O
due NN O O
to NN O O
adverse NN O O
reactions NN O O
was NN O O
2 NN O O
% NN O O
for NN O O
KALYDECO NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
5 NN O O
% NN O O
for NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Serious NN O O
adverse NN O O
reactions NN O O
, NN O O
whether NN O O
considered NN O O
drug NN O O
- NN O O
related NN O O
or NN O O
not NN O O
by NN O O
the NN O O
investigators NN O O
, NN O O
that NN O O
occurred NN O O
more NN O O
frequently NN O O
in NN O O
KALYDECO NN O O
- NN O O
treated NN O O
patients NN O O
included NN O O
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
hepatic NN I-AdverseReaction I-AdverseReaction
enzymes NN I-AdverseReaction I-AdverseReaction
and NN O O
hypoglycemia NN B-AdverseReaction B-AdverseReaction
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
in NN O O
the NN O O
221 NN O O
patients NN O O
treated NN O O
with NN O O
KALYDECO NN O O
were NN O O
headache NN B-AdverseReaction B-AdverseReaction
( NN O O
17 NN O O
% NN O O
) NN O O
, NN O O
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
( NN O O
16 NN O O
% NN O O
) NN O O
, NN O O
nasal NN B-AdverseReaction B-AdverseReaction
congestion NN I-AdverseReaction I-AdverseReaction
( NN O O
16 NN O O
% NN O O
) NN O O
, NN O O
nausea NN B-AdverseReaction B-AdverseReaction
( NN O O
10 NN O O
% NN O O
) NN O O
, NN O O
rash NN B-AdverseReaction B-AdverseReaction
( NN O O
10 NN O O
% NN O O
) NN O O
, NN O O
rhinitis NN B-AdverseReaction B-AdverseReaction
( NN O O
6 NN O O
% NN O O
) NN O O
, NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
( NN O O
5 NN O O
% NN O O
) NN O O
, NN O O
arthralgia NN B-AdverseReaction B-AdverseReaction
( NN O O
5 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
bacteria NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
sputum NN I-AdverseReaction I-AdverseReaction
( NN O O
5 NN O O
% NN O O
) NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
adverse NN O O
reactions NN O O
below NN O O
is NN O O
based NN O O
upon NN O O
two NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
, NN O O
48-week NN O O
clinical NN O O
trials NN O O
( NN O O
Trials NN O O
1 NN O O
and NN O O
2 NN O O
) NN O O
in NN O O
a NN O O
total NN O O
of NN O O
213 NN O O
patients NN O O
with NN O O
CF NN O O
ages NN O O
6 NN O O
to NN O O
53 NN O O
who NN O O
have NN O O
a NN O O
G551D NN O O
mutation NN O O
in NN O O
the NN O O
CFTR NN O O
gene NN O O
and NN O O
who NN O O
were NN O O
treated NN O O
with NN O O
KALYDECO NN O O
150 NN O O
mg NN O O
orally NN O O
or NN O O
placebo NN O O
twice NN O O
daily NN O O
. NN O O
Table NN O O
2 NN O O
shows NN O O
adverse NN O O
reactions NN O O
occurring NN O O
in NN O O
>=8 NN O O
% NN O O
of NN O O
KALYDECO NN O O
- NN O O
treated NN O O
patients NN O O
with NN O O
CF NN O O
who NN O O
have NN O O
a NN O O
G551D NN O O
mutation NN O O
in NN O O
the NN O O
CFTR NN O O
gene NN O O
that NN O O
also NN O O
occurred NN O O
at NN O O
a NN O O
higher NN O O
rate NN O O
than NN O O
in NN O O
the NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
in NN O O
the NN O O
two NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
. NN O O
Table NN O O
2 NN O O
: NN O O
Incidence NN O O
of NN O O
Adverse NN O O
Drug NN O O
Reactions NN O O
in NN O O
>=8 NN O O
% NN O O
of NN O O
KALYDECO NN O O
- NN O O
Treated NN O O
Patients NN O O
with NN O O
a NN O O
G551D NN O O
Mutation NN O O
in NN O O
the NN O O
CFTR NN O O
Gene NN O O
and NN O O
Greater NN O O
than NN O O
Placebo NN O O
in NN O O
2 NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Phase NN O O
3 NN O O
Clinical NN O O
Trials NN O O
of NN O O
48 NN O O
Weeks NN O O
Duration NN O O
Adverse NN O O
Reaction(Preferred NN O O
Term NN O O
) NN O O
Incidence NN O O
: NN O O
Pooled NN O O
48-Week NN O O
Trials NN O O
KALYDECON=109n NN O O
( NN O O
% NN O O
) NN O O
PlaceboN=104n NN O O
( NN O O
% NN O O
) NN O O
Headache NN B-AdverseReaction B-AdverseReaction
26 NN O O
( NN O O
24 NN O O
) NN O O
17 NN O O
( NN O O
16 NN O O
) NN O O
Oropharyngeal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
24 NN O O
( NN O O
22 NN O O
) NN O O
19 NN O O
( NN O O
18 NN O O
) NN O O
Upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
24 NN O O
( NN O O
22 NN O O
) NN O O
14 NN O O
( NN O O
14 NN O O
) NN O O
Nasal NN B-AdverseReaction B-AdverseReaction
congestion NN I-AdverseReaction I-AdverseReaction
22 NN O O
( NN O O
20 NN O O
) NN O O
16 NN O O
( NN O O
15 NN O O
) NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
17 NN O O
( NN O O
16 NN O O
) NN O O
13 NN O O
( NN O O
13 NN O O
) NN O O
Nasopharyngitis NN B-AdverseReaction B-AdverseReaction
16 NN O O
( NN O O
15 NN O O
) NN O O
12 NN O O
( NN O O
12 NN O O
) NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
14 NN O O
( NN O O
13 NN O O
) NN O O
10 NN O O
( NN O O
10 NN O O
) NN O O
Rash NN B-AdverseReaction B-AdverseReaction
14 NN O O
( NN O O
13 NN O O
) NN O O
7 NN O O
( NN O O
7 NN O O
) NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
13 NN O O
( NN O O
12 NN O O
) NN O O
11 NN O O
( NN O O
11 NN O O
) NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
10 NN O O
( NN O O
9 NN O O
) NN O O
1 NN O O
( NN O O
1 NN O O
) NN O O
Adverse NN O O
reactions NN O O
in NN O O
the NN O O
48-week NN O O
clinical NN O O
trials NN O O
that NN O O
occurred NN O O
in NN O O
the NN O O
KALYDECO NN O O
group NN O O
at NN O O
a NN O O
frequency NN O O
of NN O O
4 NN O O
to NN O O
7 NN O O
% NN O O
where NN O O
rates NN O O
exceeded NN O O
that NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
include NN O O
: NN O O
* NN O O
Infections NN O O
and NN O O
infestations NN O O
: NN O O
rhinitis NN B-AdverseReaction B-AdverseReaction
* NN O O
Investigations NN O O
: NN O O
aspartate NN B-AdverseReaction B-AdverseReaction
aminotransferase NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
bacteria NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
sputum NN I-AdverseReaction I-AdverseReaction
blood NN B-AdverseReaction B-AdverseReaction
glucose NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
hepatic NN B-AdverseReaction B-AdverseReaction
enzyme NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
* NN O O
Musculoskeletal NN O O
and NN O O
connective NN O O
tissue NN O O
disorders NN O O
: NN O O
arthralgia NN B-AdverseReaction B-AdverseReaction
musculoskeletal NN B-AdverseReaction B-AdverseReaction
chest NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
myalgia NN B-AdverseReaction B-AdverseReaction
* NN O O
Nervous NN O O
system NN O O
disorders NN O O
: NN O O
sinus NN B-AdverseReaction B-AdverseReaction
headache NN I-AdverseReaction I-AdverseReaction
* NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
and NN O O
mediastinal NN O O
disorders NN O O
: NN O O
pharyngeal NN B-AdverseReaction B-AdverseReaction
erythema NN I-AdverseReaction I-AdverseReaction
pleuritic NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
sinus NN B-AdverseReaction B-AdverseReaction
congestion NN I-AdverseReaction I-AdverseReaction
wheezing NN B-AdverseReaction B-AdverseReaction
* NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
: NN O O
acne NN B-AdverseReaction B-AdverseReaction
The NN O O
safety NN O O
profile NN O O
for NN O O
the NN O O
CF NN O O
patients NN O O
enrolled NN O O
in NN O O
the NN O O
other NN O O
clinical NN O O
trials NN O O
( NN O O
Trials NN O O
3 NN O O
- NN O O
6 NN O O
) NN O O
was NN O O
similar NN O O
to NN O O
that NN O O
observed NN O O
in NN O O
the NN O O
48-week NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
( NN O O
Trials NN O O
1 NN O O
and NN O O
2 NN O O
) NN O O
. NN O O
Laboratory NN O O
Abnormalities NN O O
Transaminase NN O O
Elevations NN O O
: NN O O
In NN O O
Trials NN O O
1 NN O O
, NN O O
2 NN O O
, NN O O
and NN O O
3 NN O O
the NN O O
incidence NN O O
of NN O O
maximum NN O O
transaminase NN O O
( NN O O
ALT NN O O
or NN O O
AST NN O O
) NN O O
>8 NN O O
, NN O O
>5 NN O O
, NN O O
or NN O O
>3 NN O O
* NN O O
ULN NN O O
was NN O O
2 NN O O
% NN O O
, NN O O
2 NN O O
% NN O O
, NN O O
and NN O O
6 NN O O
% NN O O
in NN O O
KALYDECO NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
2 NN O O
% NN O O
, NN O O
2 NN O O
% NN O O
, NN O O
and NN O O
8 NN O O
% NN O O
in NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
, NN O O
respectively NN O O
. NN O O
Two NN O O
patients NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
on NN O O
placebo NN O O
and NN O O
1 NN O O
patient NN O O
( NN O O
0.5 NN O O
% NN O O
) NN O O
on NN O O
KALYDECO NN O O
permanently NN O O
discontinued NN O O
treatment NN O O
for NN O O
elevated NN B-AdverseReaction B-AdverseReaction
transaminases NN I-AdverseReaction I-AdverseReaction
all NN O O
>8 NN B-Severity B-Severity
* NN I-Severity I-Severity
ULN NN I-Severity I-Severity
Two NN O O
patients NN O O
treated NN O O
with NN O O
KALYDECO NN O O
were NN O O
reported NN O O
to NN O O
have NN O O
serious NN B-Severity B-Severity
adverse NN O O
reactions NN O O
of NN O O
elevated NN B-AdverseReaction B-AdverseReaction
liver NN I-AdverseReaction I-AdverseReaction
transaminases NN I-AdverseReaction I-AdverseReaction
compared NN O O
to NN O O
none NN O O
on NN O O
placebo NN O O
. NN O O
Transaminase NN O O
elevations NN O O
were NN O O
more NN O O
common NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
transaminase NN O O
elevations NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
During NN O O
the NN O O
24-week NN O O
, NN O O
open NN O O
- NN O O
label NN O O
, NN O O
clinical NN O O
trial NN O O
in NN O O
34 NN O O
patients NN O O
ages NN O O
2 NN O O
to NN O O
less NN O O
than NN O O
6 NN O O
years NN O O
( NN O O
Trial NN O O
6 NN O O
) NN O O
, NN O O
where NN O O
patients NN O O
received NN O O
either NN O O
50 NN O O
mg NN O O
( NN O O
less NN O O
than NN O O
14 NN O O
kg NN O O
) NN O O
or NN O O
75 NN O O
mg NN O O
( NN O O
14 NN O O
kg NN O O
or NN O O
greater NN O O
) NN O O
ivacaftor NN O O
granules NN O O
twice NN O O
daily NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
patients NN O O
experiencing NN O O
transaminase NN B-AdverseReaction B-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
( NN O O
ALT NN O O
or NN O O
AST NN O O
) NN O O
>3 NN B-Severity B-Severity
* NN I-Severity I-Severity
ULN NN I-Severity I-Severity
was NN O O
14.7 NN O O
% NN O O
( NN O O
5/34 NN O O
) NN O O
. NN O O
All NN O O
5 NN O O
patients NN O O
had NN O O
maximum NN O O
ALT NN O O
or NN O O
AST NN B-AdverseReaction B-AdverseReaction
levels NN I-AdverseReaction I-AdverseReaction
>8 NN I-AdverseReaction I-AdverseReaction
* NN I-AdverseReaction I-AdverseReaction
ULN NN I-AdverseReaction I-AdverseReaction
which NN O O
returned NN O O
to NN O O
baseline NN O O
levels NN O O
following NN O O
interruption NN O O
of NN O O
KALYDECO NN O O
dosing NN O O
. NN O O
Transaminase NN O O
elevations NN O O
were NN O O
more NN O O
common NN O O
in NN O O
patients NN O O
who NN O O
had NN O O
abnormal NN O O
transaminases NN O O
at NN O O
baseline NN O O
. NN O O
KALYDECO NN O O
was NN O O
permanently NN O O
discontinued NN O O
in NN O O
one NN O O
patient NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Elevated NN B-AdverseReaction B-AdverseReaction
transaminases NN I-AdverseReaction I-AdverseReaction
( NN O O
ALT NN O O
or NN O O
AST NN O O
) NN O O
: NN O O
Transaminases NN O O
( NN O O
ALT NN O O
and NN O O
AST NN O O
) NN O O
should NN O O
be NN O O
assessed NN O O
prior NN O O
to NN O O
initiating NN O O
KALYDECO NN O O
, NN O O
every NN O O
3 NN O O
months NN O O
during NN O O
the NN O O
first NN O O
year NN O O
of NN O O
treatment NN O O
, NN O O
and NN O O
annually NN O O
thereafter NN O O
. NN O O
In NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
transaminase NN O O
elevations NN O O
, NN O O
more NN O O
frequent NN O O
monitoring NN O O
of NN O O
liver NN O O
function NN O O
tests NN O O
should NN O O
be NN O O
considered NN O O
. NN O O
Patients NN O O
who NN O O
develop NN O O
increased NN O O
transaminase NN O O
levels NN O O
should NN O O
be NN O O
closely NN O O
monitored NN O O
until NN O O
the NN O O
abnormalities NN O O
resolve NN O O
. NN O O
Dosing NN O O
should NN O O
be NN O O
interrupted NN O O
in NN O O
patients NN O O
with NN O O
ALT NN O O
or NN O O
AST NN O O
of NN O O
greater NN O O
than NN O O
5 NN O O
times NN O O
the NN O O
upper NN O O
limit NN O O
of NN O O
normal NN O O
( NN O O
ULN NN O O
) NN O O
. NN O O
Following NN O O
resolution NN O O
of NN O O
transaminase NN O O
elevations NN O O
, NN O O
consider NN O O
the NN O O
benefits NN O O
and NN O O
risks NN O O
of NN O O
resuming NN O O
KALYDECO NN O O
dosing NN O O
. NN O O
( NN O O
5.1 NN O O
, NN O O
6 NN O O
) NN O O
* NN O O
Use NN O O
with NN O O
CYP3A NN O O
inducers NN O O
: NN O O
Concomitant NN O O
use NN O O
with NN O O
strong NN O O
CYP3A NN O O
inducers NN O O
( NN O O
e.g. NN O O
, NN O O
rifampin NN O O
, NN O O
St. NN O O
John NN O O
's NN O O
wort NN O O
) NN O O
substantially NN O O
decreases NN O O
exposure NN O O
of NN O O
ivacaftor NN O O
, NN O O
which NN O O
may NN O O
diminish NN O O
effectiveness NN O O
. NN O O
Therefore NN O O
, NN O O
co NN O O
- NN O O
administration NN O O
is NN O O
not NN O O
recommended NN O O
. NN O O
( NN O O
5.2 NN O O
, NN O O
7.2 NN O O
, NN O O
12.3 NN O O
) NN O O
* NN O O
Cataracts NN B-AdverseReaction B-AdverseReaction
Non NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
congenital NN I-AdverseReaction I-AdverseReaction
lens NN I-AdverseReaction I-AdverseReaction
opacities NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
pediatric NN O O
patients NN O O
treated NN O O
with NN O O
KALYDECO. NN O O
Baseline NN O O
and NN O O
follow NN O O
- NN O O
up NN O O
examinations NN O O
are NN O O
recommended NN O O
in NN O O
pediatric NN O O
patients NN O O
initiating NN O O
KALYDECO NN O O
treatment NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
5.1 NN O O
Transaminase NN O O
( NN O O
ALT NN O O
or NN O O
AST NN O O
) NN O O
Elevations NN O O
Elevated NN B-AdverseReaction B-AdverseReaction
transaminases NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
with NN O O
CF NN O O
receiving NN O O
KALYDECO. NN O O
It NN O O
is NN O O
recommended NN O O
that NN O O
ALT NN O O
and NN O O
AST NN O O
be NN O O
assessed NN O O
prior NN O O
to NN O O
initiating NN O O
KALYDECO NN O O
, NN O O
every NN O O
3 NN O O
months NN O O
during NN O O
the NN O O
first NN O O
year NN O O
of NN O O
treatment NN O O
, NN O O
and NN O O
annually NN O O
thereafter NN O O
. NN O O
For NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
transaminase NN O O
elevations NN O O
, NN O O
more NN O O
frequent NN O O
monitoring NN O O
of NN O O
liver NN O O
function NN O O
tests NN O O
should NN O O
be NN O O
considered NN O O
. NN O O
Patients NN O O
who NN O O
develop NN O O
increased NN O O
transaminase NN O O
levels NN O O
should NN O O
be NN O O
closely NN O O
monitored NN O O
until NN O O
the NN O O
abnormalities NN O O
resolve NN O O
. NN O O
Dosing NN O O
should NN O O
be NN O O
interrupted NN O O
in NN O O
patients NN O O
with NN O O
ALT NN O O
or NN O O
AST NN O O
of NN O O
greater NN O O
than NN O O
5 NN O O
times NN O O
the NN O O
upper NN O O
limit NN O O
of NN O O
normal NN O O
( NN O O
ULN NN O O
) NN O O
. NN O O
Following NN O O
resolution NN O O
of NN O O
transaminase NN O O
elevations NN O O
, NN O O
consider NN O O
the NN O O
benefits NN O O
and NN O O
risks NN O O
of NN O O
resuming NN O O
KALYDECO NN O O
dosing NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
and NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.6 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
Concomitant NN O O
Use NN O O
with NN O O
CYP3A NN O O
Inducers NN O O
Use NN O O
of NN O O
KALYDECO NN O O
with NN O O
strong NN O O
CYP3A NN O O
inducers NN O O
, NN O O
such NN O O
as NN O O
rifampin NN O O
, NN O O
substantially NN O O
decreases NN O O
the NN O O
exposure NN O O
of NN O O
ivacaftor NN O O
, NN O O
which NN O O
may NN O O
reduce NN O O
the NN O O
therapeutic NN O O
effectiveness NN O O
of NN O O
KALYDECO. NN O O
Therefore NN O O
, NN O O
co NN O O
- NN O O
administration NN O O
of NN O O
KALYDECO NN O O
with NN O O
strong NN O O
CYP3A NN O O
inducers NN O O
( NN O O
e.g. NN O O
, NN O O
rifampin NN O O
, NN O O
St. NN O O
John NN O O
's NN O O
wort NN O O
) NN O O
is NN O O
not NN O O
recommended NN O O
[ NN O O
see NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.2 NN O O
) NN O O
and NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.3 NN O O
) NN O O
] NN O O
. NN O O
5.3 NN O O
Cataracts NN O O
Cases NN O O
of NN O O
non NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
congenital NN I-AdverseReaction I-AdverseReaction
lens NN I-AdverseReaction I-AdverseReaction
opacities NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
pediatric NN O O
patients NN O O
treated NN O O
with NN O O
KALYDECO. NN O O
Although NN O O
other NN O O
risk NN O O
factors NN O O
were NN O O
present NN O O
in NN O O
some NN O O
cases NN O O
( NN O O
such NN O O
as NN O O
corticosteroid NN O O
use NN O O
and/or NN O O
exposure NN O O
to NN O O
radiation NN O O
) NN O O
, NN O O
a NN O O
possible NN O O
risk NN O O
attributable NN O O
to NN O O
KALYDECO NN O O
can NN O O
not NN O O
be NN O O
excluded NN O O
. NN O O
Baseline NN O O
and NN O O
follow NN O O
- NN O O
up NN O O
ophthalmological NN O O
examinations NN O O
are NN O O
recommended NN O O
in NN O O
pediatric NN O O
patients NN O O
initiating NN O O
KALYDECO NN O O
treatment NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
are NN O O
( NN O O
incidence NN O O
>= NN O O
5 NN O O
% NN O O
) NN O O
chromaturia NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
and NN O O
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
alanine NN B-AdverseReaction B-AdverseReaction
aminotransferase NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
arthralgia NN B-AdverseReaction B-AdverseReaction
and NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
( NN O O
5.1 NN O O
, NN O O
6 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
ApoPharma NN O O
Inc. NN O O
at NN O O
: NN O O
Telephone NN O O
: NN O O
1 NN O O
- NN O O
866 NN O O
- NN O O
949 NN O O
- NN O O
0995 NN O O
Email NN O O
: NN O O
medicalsafety@apopharma.com NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
} NN O O
} NN O O
6.1 NN O O
Clinical NN O O
Trial NN O O
Experience NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
are NN O O
also NN O O
discussed NN O O
in NN O O
other NN O O
sections NN O O
of NN O O
the NN O O
labeling NN O O
: NN O O
Agranulocytosis NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
Elevated NN B-AdverseReaction B-AdverseReaction
ALT NN I-AdverseReaction I-AdverseReaction
( NN O O
5.3 NN O O
) NN O O
, NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
plasma NN I-AdverseReaction I-AdverseReaction
zinc NN I-AdverseReaction I-AdverseReaction
concentrations NN I-AdverseReaction I-AdverseReaction
( NN O O
5.3 NN O O
) NN O O
. NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
Adverse NN O O
reaction NN O O
information NN O O
for NN O O
Ferriprox NN O O
represents NN O O
the NN O O
pooled NN O O
data NN O O
collected NN O O
from NN O O
642 NN O O
patients NN O O
who NN O O
participated NN O O
in NN O O
single NN O O
arm NN O O
or NN O O
active NN O O
- NN O O
controlled NN O O
clinical NN O O
studies NN O O
. NN O O
The NN O O
most NN O O
serious NN O O
adverse NN O O
reaction NN O O
reported NN O O
in NN O O
clinical NN O O
trials NN O O
with NN O O
Ferriprox NN O O
was NN O O
agranulocytosis NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
reported NN O O
during NN O O
clinical NN O O
trials NN O O
were NN O O
chromaturia NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
alanine NN B-AdverseReaction B-AdverseReaction
aminotransferase NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
arthralgia NN B-AdverseReaction B-AdverseReaction
and NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
The NN O O
table NN O O
below NN O O
lists NN O O
the NN O O
adverse NN O O
drug NN O O
reactions NN O O
that NN O O
occurred NN O O
in NN O O
at NN O O
least NN O O
1 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
Ferriprox NN O O
in NN O O
clinical NN O O
trials NN O O
. NN O O
Table NN O O
2 NN O O
: NN O O
Adverse NN O O
drug NN O O
reactions NN O O
occurring NN O O
in NN O O
>= NN O O
1 NN O O
% NN O O
of NN O O
642 NN O O
Ferriprox NN O O
- NN O O
treated NN O O
patients NN O O
Body NN O O
System NN O O
% NN O O
Subjects NN O O
Preferred NN O O
Term NN O O
BLOOD NN O O
AND NN O O
LYMPHATIC NN O O
SYSTEM NN O O
DISORDERS NN O O
Neutropenia NN B-AdverseReaction B-AdverseReaction
6.2 NN O O
Agranulocytosis NN B-AdverseReaction B-AdverseReaction
1.7 NN O O
GASTROINTESTINAL NN O O
DISORDERS NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
12.6 NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
10.4 NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
9.8 NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
3.0 NN O O
Dyspepsia NN B-AdverseReaction B-AdverseReaction
2.0 NN O O
INVESTIGATIONS NN O O
Alanine NN B-AdverseReaction B-AdverseReaction
Aminotransferase NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
7.5 NN O O
Neutrophil NN B-AdverseReaction B-AdverseReaction
count NN I-AdverseReaction I-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
7.3 NN O O
Weight NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
1.9 NN O O
Aspartate NN B-AdverseReaction B-AdverseReaction
Aminotransferase NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
1.2 NN O O
METABOLISM NN O O
AND NN O O
NUTRITION NN O O
DISORDERS NN O O
Increased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
4.0 NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
1.1 NN O O
MUSCULOSKELETAL NN O O
AND NN O O
CONNECTIVE NN O O
TISSUE NN O O
DISORDERS NN O O
Arthralgia NN B-AdverseReaction B-AdverseReaction
9.8 NN O O
Back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
2.0 NN O O
Pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
1.9 NN O O
Arthropathy NN B-AdverseReaction B-AdverseReaction
1.4 NN O O
NERVOUS NN O O
SYSTEM NN O O
DISORDERS NN O O
Headache NN B-AdverseReaction B-AdverseReaction
2.5 NN O O
URINARY NN O O
DISORDERS NN O O
Chromaturia NN B-AdverseReaction B-AdverseReaction
14.6 NN O O
Gastrointestinal NN O O
symptoms NN O O
such NN O O
as NN O O
nausea NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
and NN O O
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
were NN O O
the NN O O
most NN O O
frequent NN O O
adverse NN O O
reactions NN O O
reported NN O O
by NN O O
patients NN O O
participating NN O O
in NN O O
clinical NN O O
trials NN O O
and NN O O
led NN O O
to NN O O
the NN O O
discontinuation NN O O
of NN O O
Ferriprox NN O O
therapy NN O O
in NN O O
1.6 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
Chromaturia NN B-AdverseReaction B-AdverseReaction
( NN O O
reddish/brown NN O O
discoloration NN O O
of NN O O
the NN O O
urine NN O O
) NN O O
is NN O O
a NN O O
result NN O O
of NN O O
the NN O O
excretion NN O O
of NN O O
the NN O O
iron NN O O
in NN O O
the NN O O
urine NN O O
. NN O O
6.2 NN O O
Postmarketing NN O O
Experience NN O O
The NN O O
following NN O O
additional NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
receiving NN O O
Ferriprox NN O O
. NN O O
Because NN O O
these NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
to NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
Blood NN O O
and NN O O
lymphatic NN O O
system NN O O
disorders NN O O
: NN O O
thrombocytosis NN B-AdverseReaction B-AdverseReaction
pancytopenia NN B-AdverseReaction B-AdverseReaction
Cardiac NN O O
disorders NN O O
: NN O O
atrial NN B-AdverseReaction B-AdverseReaction
fibrillation NN I-AdverseReaction I-AdverseReaction
cardiac NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
Congenital NN O O
, NN O O
familial NN O O
and NN O O
genetic NN O O
disorders NN O O
: NN O O
hypospadias NN B-AdverseReaction B-AdverseReaction
Eye NN O O
disorders NN O O
: NN O O
diplopia NN B-AdverseReaction B-AdverseReaction
papilledema NN B-AdverseReaction B-AdverseReaction
retinal NN B-AdverseReaction B-AdverseReaction
toxicity NN I-AdverseReaction I-AdverseReaction
Gastrointestinal NN O O
disorders NN O O
: NN O O
enterocolitis NN B-AdverseReaction B-AdverseReaction
rectal NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
gastric NN B-AdverseReaction B-AdverseReaction
ulcer NN I-AdverseReaction I-AdverseReaction
pancreatitis NN B-AdverseReaction B-AdverseReaction
parotid NN B-AdverseReaction B-AdverseReaction
gland NN I-AdverseReaction I-AdverseReaction
enlargement NN I-AdverseReaction I-AdverseReaction
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
: NN O O
chills NN B-AdverseReaction B-AdverseReaction
pyrexia NN B-AdverseReaction B-AdverseReaction
edema NN B-AdverseReaction B-AdverseReaction
peripheral NN I-AdverseReaction I-AdverseReaction
multi NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
organ NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
Hepatobiliary NN O O
disorders NN O O
: NN O O
jaundice NN B-AdverseReaction B-AdverseReaction
hepatomegaly NN B-AdverseReaction B-AdverseReaction
Immune NN O O
system NN O O
disorders NN O O
: NN O O
anaphylactic NN B-AdverseReaction B-AdverseReaction
shock NN I-AdverseReaction I-AdverseReaction
hypersensitivity NN B-AdverseReaction B-AdverseReaction
I NN O O
nfections NN O O
and NN O O
infestations NN O O
: NN O O
cryptococcal NN B-AdverseReaction B-AdverseReaction
cutaneous NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
enteroviral NN B-AdverseReaction B-AdverseReaction
encephalitis NN I-AdverseReaction I-AdverseReaction
pharyngitis NN B-AdverseReaction B-AdverseReaction
pneumonia NN B-AdverseReaction B-AdverseReaction
sepsis NN B-AdverseReaction B-AdverseReaction
furuncle NN B-AdverseReaction B-AdverseReaction
infectious NN B-AdverseReaction B-AdverseReaction
hepatitis NN I-AdverseReaction I-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
pustular NN I-AdverseReaction I-AdverseReaction
subcutaneous NN B-AdverseReaction B-AdverseReaction
abscess NN I-AdverseReaction I-AdverseReaction
Investigations NN O O
: NN O O
blood NN B-AdverseReaction B-AdverseReaction
bilirubin NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
blood NN B-AdverseReaction B-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
phosphokinase NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
Metabolism NN O O
and NN O O
nutrition NN O O
disorders NN O O
: NN O O
metabolic NN B-AdverseReaction B-AdverseReaction
acidosis NN I-AdverseReaction I-AdverseReaction
dehydration NN B-AdverseReaction B-AdverseReaction
Musculoskeletal NN O O
and NN O O
connective NN O O
tissue NN O O
disorders NN O O
: NN O O
myositis NN B-AdverseReaction B-AdverseReaction
chondropathy NN B-AdverseReaction B-AdverseReaction
trismus NN B-AdverseReaction B-AdverseReaction
Nervous NN O O
system NN O O
disorders NN O O
: NN O O
cerebellar NN B-AdverseReaction B-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
cerebral NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
convulsion NN B-AdverseReaction B-AdverseReaction
gait NN B-AdverseReaction B-AdverseReaction
disturbance NN I-AdverseReaction I-AdverseReaction
intracranial NN B-AdverseReaction B-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
psychomotor NN B-AdverseReaction B-AdverseReaction
skills NN I-AdverseReaction I-AdverseReaction
impaired NN I-AdverseReaction I-AdverseReaction
pyramidal NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
somnolence NN B-AdverseReaction B-AdverseReaction
Psychiatric NN O O
disorders NN O O
: NN O O
bruxism NN B-AdverseReaction B-AdverseReaction
depression NN B-AdverseReaction B-AdverseReaction
obsessive NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
compulsive NN I-AdverseReaction I-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
Renal NN O O
disorders NN O O
: NN O O
glycosuria NN B-AdverseReaction B-AdverseReaction
hemoglobinuria NN B-AdverseReaction B-AdverseReaction
Respiratory NN O O
, NN O O
thoracic NN O O
and NN O O
mediastinal NN O O
disorders NN O O
: NN O O
acute NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
distress NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
epistaxis NN B-AdverseReaction B-AdverseReaction
hemoptysis NN B-AdverseReaction B-AdverseReaction
pulmonary NN B-AdverseReaction B-AdverseReaction
embolism NN I-AdverseReaction I-AdverseReaction
Skin NN O O
, NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
: NN O O
hyperhidrosis NN B-AdverseReaction B-AdverseReaction
periorbital NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
photosensitivity NN B-AdverseReaction B-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
pruritis NN B-AdverseReaction B-AdverseReaction
urticaria NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
Henoch NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Schonlein NN I-AdverseReaction I-AdverseReaction
purpura NN I-AdverseReaction I-AdverseReaction
Vascular NN O O
disorders NN O O
: NN O O
hypotension NN B-AdverseReaction B-AdverseReaction
hypertension NN B-AdverseReaction B-AdverseReaction
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
AGRANULOCYTOSIS NN B-AdverseReaction B-AdverseReaction
WARNING NN O O
: NN O O
AGRANULOCYTOSIS NN B-AdverseReaction B-AdverseReaction
* NN O O
Ferriprox NN O O
can NN B-Factor B-Factor
cause NN O O
agranulocytosis NN B-AdverseReaction B-AdverseReaction
that NN O O
can NN B-Factor B-Factor
lead NN O O
to NN O O
serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
and NN O O
death NN B-AdverseReaction B-AdverseReaction
Neutropenia NN B-AdverseReaction B-AdverseReaction
may NN B-Factor B-Factor
precede NN O O
the NN O O
development NN O O
of NN O O
agranulocytosis NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Measure NN O O
the NN O O
absolute NN O O
neutrophil NN O O
count NN O O
( NN O O
ANC NN O O
) NN O O
before NN O O
starting NN O O
Ferriprox NN O O
therapy NN O O
and NN O O
monitor NN O O
the NN O O
ANC NN O O
weekly NN O O
on NN O O
therapy NN O O
. NN O O
Interrupt NN O O
Ferriprox NN O O
therapy NN O O
if NN O O
neutropenia NN O O
develops NN O O
. NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Interrupt NN O O
Ferriprox NN O O
if NN O O
infection NN O O
develops NN O O
, NN O O
and NN O O
monitor NN O O
the NN O O
ANC NN O O
more NN O O
frequently NN O O
. NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Advise NN O O
patients NN O O
taking NN O O
Ferriprox NN O O
to NN O O
report NN O O
immediately NN O O
any NN O O
symptoms NN O O
indicative NN O O
of NN O O
infection NN O O
. NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
WARNING NN O O
: NN O O
AGRANULOCYTOSIS NN B-AdverseReaction B-AdverseReaction
/NEUTROPENIA NN O O
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
. NN O O
* NN O O
Ferriprox NN O O
can NN B-Factor B-Factor
cause NN O O
agranulocytosis NN B-AdverseReaction B-AdverseReaction
that NN O O
can NN B-Factor B-Factor
lead NN O O
to NN O O
serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
and NN O O
death NN B-AdverseReaction B-AdverseReaction
Neutropenia NN B-AdverseReaction B-AdverseReaction
may NN B-Factor B-Factor
precede NN O O
the NN O O
development NN O O
of NN O O
agranulocytosis NN B-AdverseReaction B-AdverseReaction
( NN O O
5.1 NN O O
) NN O O
* NN O O
Measure NN O O
the NN O O
absolute NN O O
neutrophil NN O O
count NN O O
( NN O O
ANC NN O O
) NN O O
before NN O O
starting NN O O
Ferriprox NN O O
and NN O O
monitor NN O O
the NN O O
ANC NN O O
weekly NN O O
on NN O O
therapy NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Interrupt NN O O
Ferriprox NN O O
if NN O O
infection NN O O
develops NN O O
and NN O O
monitor NN O O
the NN O O
ANC NN O O
more NN O O
frequently NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Advise NN O O
patients NN O O
taking NN O O
Ferriprox NN O O
to NN O O
report NN O O
immediately NN O O
any NN O O
symptoms NN O O
indicative NN O O
of NN O O
infection NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
If NN O O
infection NN O O
occurs NN O O
while NN O O
on NN O O
Ferriprox NN O O
, NN O O
interrupt NN O O
therapy NN O O
and NN O O
monitor NN O O
the NN O O
ANC NN O O
more NN O O
frequently NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Ferriprox NN O O
can NN B-Factor B-Factor
cause NN O O
fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
Women NN O O
should NN O O
be NN O O
advised NN O O
of NN O O
the NN O O
potential NN O O
hazard NN O O
to NN O O
the NN O O
fetus NN O O
and NN O O
to NN O O
avoid NN O O
pregnancy NN O O
while NN O O
on NN O O
this NN O O
drug NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
5.1 NN O O
Agranulocytosis/Neutropenia NN O O
Fatal NN B-AdverseReaction B-AdverseReaction
agranulocytosis NN B-AdverseReaction B-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
with NN O O
Ferriprox NN O O
use NN O O
. NN O O
Ferriprox NN O O
can NN B-Factor B-Factor
also NN O O
cause NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
which NN O O
may NN B-Factor B-Factor
foreshadow NN O O
agranulocytosis NN B-AdverseReaction B-AdverseReaction
Measure NN O O
the NN O O
absolute NN O O
neutrophil NN O O
count NN O O
( NN O O
ANC NN O O
) NN O O
before NN O O
starting NN O O
Ferriprox NN O O
therapy NN O O
and NN O O
monitor NN O O
the NN O O
ANC NN O O
weekly NN O O
on NN O O
therapy NN O O
. NN O O
Interrupt NN O O
Ferriprox NN O O
therapy NN O O
if NN O O
neutropenia NN O O
develops NN O O
( NN O O
ANC NN O O
< NN O O
1.5 NN O O
x NN O O
10 NN O O
9 NN O O
/L NN O O
) NN O O
. NN O O
Interrupt NN O O
Ferriprox NN O O
if NN O O
infection NN O O
develops NN O O
, NN O O
and NN O O
monitor NN O O
the NN O O
ANC NN O O
more NN O O
frequently NN O O
. NN O O
Advise NN O O
patients NN O O
taking NN O O
Ferriprox NN O O
to NN O O
immediately NN O O
interrupt NN O O
therapy NN O O
and NN O O
report NN O O
to NN O O
their NN O O
physician NN O O
if NN O O
they NN O O
experience NN O O
any NN O O
symptoms NN O O
indicative NN O O
of NN O O
infection NN O O
. NN O O
In NN O O
pooled NN O O
clinical NN O O
trials NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
agranulocytosis NN B-AdverseReaction B-AdverseReaction
was NN O O
1.7 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
The NN O O
mechanism NN O O
of NN O O
Ferriprox NN O O
- NN O O
associated NN O O
agranulocytosis NN B-AdverseReaction B-AdverseReaction
is NN O O
unknown NN O O
. NN O O
Agranulocytosis NN B-AdverseReaction B-AdverseReaction
and NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
usually NN O O
resolve NN O O
upon NN O O
discontinuation NN O O
of NN O O
Ferriprox NN O O
, NN O O
but NN O O
there NN O O
have NN O O
been NN O O
reports NN O O
of NN O O
agranulocytosis NN B-AdverseReaction B-AdverseReaction
leading NN O O
to NN O O
death NN B-AdverseReaction B-AdverseReaction
Implement NN O O
a NN O O
plan NN O O
to NN O O
monitor NN O O
for NN O O
and NN O O
to NN O O
manage NN O O
agranulocytosis/neutropenia NN O O
prior NN O O
to NN O O
initiating NN O O
Ferriprox NN O O
treatment NN O O
. NN O O
For NN O O
neutropenia NN O O
( NN O O
ANC NN O O
< NN O O
1.5 NN O O
x NN O O
10 NN O O
9 NN O O
/L NN O O
and NN O O
> NN O O
0.5 NN O O
x NN O O
10 NN O O
9 NN O O
/L NN O O
) NN O O
: NN O O
Instruct NN O O
the NN O O
patient NN O O
to NN O O
immediately NN O O
discontinue NN O O
Ferriprox NN O O
and NN O O
all NN O O
other NN O O
medications NN O O
with NN O O
a NN O O
potential NN O O
to NN O O
cause NN O O
neutropenia NN O O
. NN O O
Obtain NN O O
a NN O O
complete NN O O
blood NN O O
cell NN O O
( NN O O
CBC NN O O
) NN O O
count NN O O
, NN O O
including NN O O
a NN O O
white NN O O
blood NN O O
cell NN O O
( NN O O
WBC NN O O
) NN O O
count NN O O
corrected NN O O
for NN O O
the NN O O
presence NN O O
of NN O O
nucleated NN O O
red NN O O
blood NN O O
cells NN O O
, NN O O
an NN O O
absolute NN O O
neutrophil NN O O
count NN O O
( NN O O
ANC NN O O
) NN O O
, NN O O
and NN O O
a NN O O
platelet NN O O
count NN O O
daily NN O O
until NN O O
recovery NN O O
( NN O O
ANC NN O O
>= NN O O
1.5 NN O O
x NN O O
10 NN O O
9 NN O O
/L NN O O
) NN O O
. NN O O
For NN O O
agranulocytosis NN O O
( NN O O
ANC NN O O
< NN O O
0.5 NN O O
x NN O O
10 NN O O
9 NN O O
/L NN O O
) NN O O
: NN O O
Consider NN O O
hospitalization NN O O
and NN O O
other NN O O
management NN O O
as NN O O
clinically NN O O
appropriate NN O O
. NN O O
Do NN O O
not NN O O
resume NN O O
Ferriprox NN O O
in NN O O
patients NN O O
who NN O O
have NN O O
developed NN O O
agranulocytosis NN O O
unless NN O O
potential NN O O
benefits NN O O
outweigh NN O O
potential NN O O
risks NN O O
. NN O O
Do NN O O
not NN O O
rechallenge NN O O
patients NN O O
who NN O O
develop NN O O
neutropenia NN O O
with NN O O
Ferriprox NN O O
unless NN O O
potential NN O O
benefits NN O O
outweigh NN O O
potential NN O O
risks NN O O
. NN O O
5.2 NN O O
Embryofetal NN O O
Toxicity NN O O
Based NN O O
on NN O O
evidence NN O O
of NN O O
genotoxicity NN B-AdverseReaction B-AdverseReaction
and NN O O
developmental NN O O
toxicity NN O O
in NN O O
animal NN B-Animal B-Animal
studies NN O O
, NN O O
Ferriprox NN O O
can NN B-Factor B-Factor
cause NN O O
fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
when NN O O
administered NN O O
to NN O O
a NN O O
pregnant NN O O
woman NN O O
. NN O O
In NN O O
animal NN B-Animal B-Animal
studies NN O O
, NN O O
administration NN O O
of NN O O
deferiprone NN O O
during NN O O
the NN O O
period NN O O
of NN O O
organogenesis NN O O
resulted NN O O
in NN O O
embryofetal NN B-AdverseReaction B-AdverseReaction
death NN I-AdverseReaction I-AdverseReaction
and NN O O
malformations NN O O
at NN O O
doses NN O O
lower NN O O
than NN O O
equivalent NN O O
human NN O O
clinical NN O O
doses NN O O
. NN O O
If NN O O
Ferriprox NN O O
is NN O O
used NN O O
during NN O O
pregnancy NN O O
or NN O O
if NN O O
the NN O O
patient NN O O
becomes NN O O
pregnant NN O O
while NN O O
taking NN O O
Ferriprox NN O O
, NN O O
the NN O O
patient NN O O
should NN O O
be NN O O
apprised NN O O
of NN O O
the NN O O
potential NN O O
hazard NN O O
to NN O O
the NN O O
fetus NN O O
. NN O O
Women NN O O
of NN O O
reproductive NN O O
potential NN O O
should NN O O
be NN O O
advised NN O O
to NN O O
avoid NN O O
pregnancy NN O O
when NN O O
taking NN O O
Ferriprox NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.1 NN O O
) NN O O
and NN O O
Nonclinical NN O O
Toxicology NN O O
( NN O O
13.1 NN O O
) NN O O
] NN O O
. NN O O
5.3 NN O O
Laboratory NN O O
Tests NN O O
Serum NN O O
Liver NN O O
Enzyme NN O O
Activities NN O O
In NN O O
clinical NN O O
studies NN O O
, NN O O
7.5 NN O O
% NN O O
of NN O O
642 NN O O
subjects NN O O
treated NN O O
with NN O O
Ferriprox NN O O
developed NN O O
increased NN B-AdverseReaction B-AdverseReaction
ALT NN I-AdverseReaction I-AdverseReaction
values NN I-AdverseReaction I-AdverseReaction
Four NN O O
( NN O O
0.62 NN O O
% NN O O
) NN O O
Ferriprox NN O O
- NN O O
treated NN O O
subjects NN O O
discontinued NN O O
the NN O O
drug NN O O
due NN O O
to NN O O
increased NN B-AdverseReaction B-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
ALT NN I-AdverseReaction I-AdverseReaction
levels NN O O
and NN O O
1 NN O O
( NN O O
0.16 NN O O
% NN O O
) NN O O
due NN O O
to NN O O
an NN O O
increase NN O O
in NN O O
both NN O O
ALT NN O O
and NN O O
AST. NN O O
Monitor NN O O
serum NN O O
ALT NN O O
values NN O O
monthly NN O O
during NN O O
therapy NN O O
with NN O O
Ferriprox NN O O
, NN O O
and NN O O
consider NN O O
interruption NN O O
of NN O O
therapy NN O O
if NN O O
there NN O O
is NN O O
a NN O O
persistent NN O O
increase NN O O
in NN O O
the NN O O
serum NN O O
transaminase NN O O
levels NN O O
. NN O O
Plasma NN O O
Zinc NN O O
Concentration NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
plasma NN I-AdverseReaction I-AdverseReaction
zinc NN I-AdverseReaction I-AdverseReaction
concentrations NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
observed NN O O
on NN O O
Ferriprox NN O O
therapy NN O O
. NN O O
Monitor NN O O
plasma NN O O
zinc NN O O
, NN O O
and NN O O
supplement NN O O
in NN O O
the NN O O
event NN O O
of NN O O
a NN O O
deficiency NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
serious NN O O
adverse NN O O
reactions NN O O
are NN O O
discussed NN O O
in NN O O
greater NN O O
detail NN O O
in NN O O
other NN O O
sections NN O O
of NN O O
the NN O O
prescribing NN O O
information NN O O
. NN O O
* NN O O
? NN O O
Increased NN O O
risk NN B-Factor B-Factor
of NN O O
thrombotic NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
after NN O O
premature NN O O
discontinuation NN O O
[ NN O O
seeWarnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
? NN O O
Bleeding NN B-AdverseReaction B-AdverseReaction
[ NN O O
seeWarnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
? NN O O
Spinal/epidural NN O O
anesthesia NN O O
or NN O O
puncture NN O O
[ NN O O
seeWarnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
Most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>1 NN O O
% NN O O
) NN O O
are NN O O
related NN O O
to NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Bristol NN O O
- NN O O
Myers NN O O
Squibb NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
721 NN O O
- NN O O
5072 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
Reduction NN O O
of NN O O
Risk NN O O
of NN O O
Stroke NN O O
and NN O O
Systemic NN O O
Embolism NN O O
in NN O O
Patients NN O O
with NN O O
Nonvalvular NN O O
Atrial NN O O
Fibrillation NN O O
The NN O O
safety NN O O
of NN O O
ELIQUIS NN O O
was NN O O
evaluated NN O O
in NN O O
the NN O O
ARISTOTLE NN O O
and NN O O
AVERROES NN O O
studies NN O O
[ NN O O
seeClinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
, NN O O
including NN O O
11,284 NN O O
patients NN O O
exposed NN O O
to NN O O
ELIQUIS NN O O
5 NN O O
mg NN O O
twice NN O O
daily NN O O
and NN O O
602 NN O O
patients NN O O
exposed NN O O
to NN O O
ELIQUIS NN O O
2.5 NN O O
mg NN O O
twice NN O O
daily NN O O
. NN O O
The NN O O
duration NN O O
of NN O O
ELIQUIS NN O O
exposure NN O O
was NN O O
>=12 NN O O
months NN O O
for NN O O
9375 NN O O
patients NN O O
and NN O O
>=24 NN O O
months NN O O
for NN O O
3369 NN O O
patients NN O O
in NN O O
the NN O O
two NN O O
studies NN O O
. NN O O
In NN O O
ARISTOTLE NN O O
, NN O O
the NN O O
mean NN O O
duration NN O O
of NN O O
exposure NN O O
was NN O O
89 NN O O
weeks NN O O
( NN O O
>15,000 NN O O
patient NN O O
- NN O O
years NN O O
) NN O O
. NN O O
In NN O O
AVERROES NN O O
, NN O O
the NN O O
mean NN O O
duration NN O O
of NN O O
exposure NN O O
was NN O O
approximately NN O O
59 NN O O
weeks NN O O
( NN O O
>3000 NN O O
patient NN O O
- NN O O
years NN O O
) NN O O
. NN O O
The NN O O
most NN O O
common NN O O
reason NN O O
for NN O O
treatment NN O O
discontinuation NN O O
in NN O O
both NN O O
studies NN O O
was NN O O
for NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
in NN O O
ARISTOTLE NN O O
this NN O O
occurred NN O O
in NN O O
1.7 NN O O
% NN O O
and NN O O
2.5 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
ELIQUIS NN O O
and NN O O
warfarin NN O O
, NN O O
respectively NN O O
, NN O O
and NN O O
in NN O O
AVERROES NN O O
, NN O O
in NN O O
1.5 NN O O
% NN O O
and NN O O
1.3 NN O O
% NN O O
on NN O O
ELIQUIS NN O O
and NN O O
aspirin NN O O
, NN O O
respectively NN O O
. NN O O
Bleeding NN O O
in NN O O
Patients NN O O
with NN O O
Nonvalvular NN O O
Atrial NN O O
Fibrillation NN O O
in NN O O
ARISTOTLE NN O O
and NN O O
AVERROES NN O O
Tables NN O O
1 NN O O
and NN O O
2 NN O O
show NN O O
the NN O O
number NN O O
of NN O O
patients NN O O
experiencing NN O O
major NN B-Severity B-Severity
bleeding NN B-AdverseReaction B-AdverseReaction
during NN O O
the NN O O
treatment NN O O
period NN O O
and NN O O
the NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
rate NN O O
( NN O O
percentage NN O O
of NN O O
subjects NN O O
with NN O O
at NN O O
least NN O O
one NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
event NN O O
per NN O O
100 NN O O
patient NN O O
- NN O O
years NN O O
) NN O O
in NN O O
ARISTOTLE NN O O
and NN O O
AVERROES. NN O O
Table NN O O
1 NN O O
: NN O O
Bleeding NN B-AdverseReaction B-AdverseReaction
Events NN O O
in NN O O
Patients NN O O
with NN O O
Nonvalvular NN O O
Atrial NN O O
Fibrillation NN O O
in NN O O
ARISTOTLE NN O O
* NN O O
ELIQUISN=9088n NN O O
( NN O O
per NN O O
100 NN O O
pt NN O O
- NN O O
year NN O O
) NN O O
WarfarinN=9052n NN O O
( NN O O
per NN O O
100 NN O O
pt NN O O
- NN O O
year NN O O
) NN O O
Hazard NN O O
Ratio(95 NN O O
% NN O O
CI NN O O
) NN O O
P NN O O
- NN O O
value NN O O
* NN O O
Bleeding NN B-AdverseReaction B-AdverseReaction
events NN O O
within NN O O
each NN O O
subcategory NN O O
were NN O O
counted NN O O
once NN O O
per NN O O
subject NN O O
, NN O O
but NN O O
subjects NN O O
may NN O O
have NN O O
contributed NN O O
events NN O O
to NN O O
multiple NN O O
endpoints NN O O
. NN O O
Bleeding NN B-AdverseReaction B-AdverseReaction
events NN O O
were NN O O
counted NN O O
during NN O O
treatment NN O O
or NN O O
within NN O O
2 NN O O
days NN O O
of NN O O
stopping NN O O
study NN O O
treatment NN O O
( NN O O
on NN O O
- NN O O
treatment NN O O
period NN O O
) NN O O
. NN O O
Defined NN O O
as NN O O
clinically NN O O
overt NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
accompanied NN O O
by NN O O
one NN O O
or NN O O
more NN O O
of NN O O
the NN O O
following NN O O
: NN O O
a NN O O
decrease NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
hemoglobin NN I-AdverseReaction I-AdverseReaction
of NN O O
>=2 NN O O
g/dL NN O O
, NN O O
a NN O O
transfusion NN O O
of NN O O
2 NN O O
or NN O O
more NN O O
units NN O O
of NN O O
packed NN O O
red NN O O
blood NN O O
cells NN O O
, NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
at NN I-AdverseReaction I-AdverseReaction
a NN I-AdverseReaction I-AdverseReaction
critical NN I-AdverseReaction I-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
intracranial NN O O
, NN O O
intraspinal NN O O
, NN O O
intraocular NN O O
, NN O O
pericardial NN O O
, NN O O
intra NN O O
- NN O O
articular NN O O
, NN O O
intramuscular NN O O
with NN O O
compartment NN B-AdverseReaction B-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
retroperitoneal NN O O
or NN O O
with NN O O
fatal NN B-AdverseReaction B-AdverseReaction
outcome NN I-AdverseReaction I-AdverseReaction
? NN O O
Intracranial NN B-AdverseReaction B-AdverseReaction
bleed NN I-AdverseReaction I-AdverseReaction
includes NN O O
intracerebral NN O O
, NN O O
intraventricular NN O O
, NN O O
subdural NN O O
, NN O O
and NN O O
subarachnoid NN B-AdverseReaction B-AdverseReaction
bleeding NN I-AdverseReaction I-AdverseReaction
Any NN O O
type NN O O
of NN O O
hemorrhagic NN B-AdverseReaction B-AdverseReaction
stroke NN I-AdverseReaction I-AdverseReaction
was NN O O
adjudicated NN O O
and NN O O
counted NN O O
as NN O O
an NN O O
intracranial NN O O
major NN B-Severity B-Severity
bleed NN O O
. NN O O
S NN O O
On NN O O
- NN O O
treatment NN O O
analysis NN O O
based NN O O
on NN O O
the NN O O
safety NN O O
population NN O O
, NN O O
compared NN O O
to NN O O
ITT NN O O
analysis NN O O
presented NN O O
in NN O O
Section NN O O
14 NN O O
. NN O O
GI NN B-AdverseReaction B-AdverseReaction
bleed NN I-AdverseReaction I-AdverseReaction
includes NN O O
upper NN O O
GI NN O O
, NN O O
lower NN O O
GI NN O O
, NN O O
and NN O O
rectal NN B-AdverseReaction B-AdverseReaction
bleeding NN I-AdverseReaction I-AdverseReaction
Fatal NN B-AdverseReaction B-AdverseReaction
bleeding NN B-AdverseReaction B-AdverseReaction
is NN O O
an NN O O
adjudicated NN O O
death NN B-AdverseReaction B-AdverseReaction
with NN O O
the NN O O
primary NN O O
cause NN O O
of NN O O
death NN B-AdverseReaction B-AdverseReaction
as NN O O
intracranial NN B-AdverseReaction B-AdverseReaction
bleeding NN I-AdverseReaction I-AdverseReaction
or NN O O
non NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
intracranial NN I-AdverseReaction I-AdverseReaction
bleeding NN I-AdverseReaction I-AdverseReaction
during NN O O
the NN O O
on NN O O
- NN O O
treatment NN O O
period NN O O
. NN O O
Major NN O O
327 NN O O
( NN O O
2.13 NN O O
) NN O O
462 NN O O
( NN O O
3.09 NN O O
) NN O O
0.69 NN O O
( NN O O
0.60 NN O O
, NN O O
0.80 NN O O
) NN O O
< NN O O
0.0001 NN O O
Intracranial NN O O
( NN O O
ICH NN O O
) NN O O
? NN O O
52 NN O O
( NN O O
0.33 NN O O
) NN O O
125 NN O O
( NN O O
0.82 NN O O
) NN O O
0.41 NN O O
( NN O O
0.30 NN O O
, NN O O
0.57 NN O O
) NN O O
- NN O O
Hemorrhagic NN B-AdverseReaction B-AdverseReaction
stroke NN I-AdverseReaction I-AdverseReaction
38 NN O O
( NN O O
0.24 NN O O
) NN O O
74 NN O O
( NN O O
0.49 NN O O
) NN O O
0.51 NN O O
( NN O O
0.34 NN O O
, NN O O
0.75 NN O O
) NN O O
- NN O O
Other NN O O
ICH NN B-AdverseReaction B-AdverseReaction
15 NN O O
( NN O O
0.10 NN O O
) NN O O
51 NN O O
( NN O O
0.34 NN O O
) NN O O
0.29 NN O O
( NN O O
0.16 NN O O
, NN O O
0.51 NN O O
) NN O O
- NN O O
Gastrointestinal NN O O
( NN O O
GI NN O O
) NN O O
128 NN O O
( NN O O
0.83 NN O O
) NN O O
141 NN O O
( NN O O
0.93 NN O O
) NN O O
0.89 NN O O
( NN O O
0.70 NN O O
, NN O O
1.14 NN O O
) NN O O
- NN O O
Fatal NN B-AdverseReaction B-AdverseReaction
10 NN O O
( NN O O
0.06 NN O O
) NN O O
37 NN O O
( NN O O
0.24 NN O O
) NN O O
0.27 NN O O
( NN O O
0.13 NN O O
, NN O O
0.53 NN O O
) NN O O
- NN O O
Intracranial NN O O
4 NN O O
( NN O O
0.03 NN O O
) NN O O
30 NN O O
( NN O O
0.20 NN O O
) NN O O
0.13 NN O O
( NN O O
0.05 NN O O
, NN O O
0.37 NN O O
) NN O O
- NN O O
Non NN O O
- NN O O
intracranial NN O O
6 NN O O
( NN O O
0.04 NN O O
) NN O O
7 NN O O
( NN O O
0.05 NN O O
) NN O O
0.84 NN O O
( NN O O
0.28 NN O O
, NN O O
2.15 NN O O
) NN O O
- NN O O
In NN O O
ARISTOTLE NN O O
, NN O O
the NN O O
results NN O O
for NN O O
major NN B-Severity B-Severity
bleeding NN B-AdverseReaction B-AdverseReaction
were NN O O
generally NN O O
consistent NN O O
across NN O O
most NN O O
major NN O O
subgroups NN O O
including NN O O
age NN O O
, NN O O
weight NN O O
, NN O O
CHADS2score NN O O
( NN O O
a NN O O
scale NN O O
from NN O O
0 NN O O
to NN O O
6 NN O O
used NN O O
to NN O O
estimate NN O O
risk NN O O
of NN O O
stroke NN O O
, NN O O
with NN O O
higher NN O O
scores NN O O
predicting NN O O
greater NN O O
risk NN O O
) NN O O
, NN O O
prior NN O O
warfarin NN O O
use NN O O
, NN O O
geographic NN O O
region NN O O
, NN O O
and NN O O
aspirin NN O O
use NN O O
at NN O O
randomization NN O O
( NN O O
Figure NN O O
1 NN O O
) NN O O
. NN O O
Subjects NN O O
treated NN O O
with NN O O
apixaban NN O O
with NN O O
diabetes NN O O
bled NN B-AdverseReaction B-AdverseReaction
more NN O O
( NN O O
3.0 NN O O
% NN O O
per NN O O
year NN O O
) NN O O
than NN O O
did NN O O
subjects NN O O
without NN O O
diabetes NN O O
( NN O O
1.9 NN O O
% NN O O
per NN O O
year NN O O
) NN O O
. NN O O
Figure NN O O
1 NN O O
: NN O O
Major NN B-Severity B-Severity
Bleeding NN B-AdverseReaction B-AdverseReaction
Hazard NN O O
Ratios NN O O
by NN O O
Baseline NN O O
Characteristics NN O O
- NN O O
ARISTOTLE NN O O
Study NN O O
Note NN O O
: NN O O
The NN O O
figure NN O O
above NN O O
presents NN O O
effects NN O O
in NN O O
various NN O O
subgroups NN O O
, NN O O
all NN O O
of NN O O
which NN O O
are NN O O
baseline NN O O
characteristics NN O O
and NN O O
all NN O O
of NN O O
which NN O O
were NN O O
pre NN O O
- NN O O
specified NN O O
, NN O O
if NN O O
not NN O O
the NN O O
groupings NN O O
. NN O O
The NN O O
95 NN O O
% NN O O
confidence NN O O
limits NN O O
that NN O O
are NN O O
shown NN O O
do NN O O
not NN O O
take NN O O
into NN O O
account NN O O
how NN O O
many NN O O
comparisons NN O O
were NN O O
made NN O O
, NN O O
nor NN O O
do NN O O
they NN O O
reflect NN O O
the NN O O
effect NN O O
of NN O O
a NN O O
particular NN O O
factor NN O O
after NN O O
adjustment NN O O
for NN O O
all NN O O
other NN O O
factors NN O O
. NN O O
Apparent NN O O
homogeneity NN O O
or NN O O
heterogeneity NN O O
among NN O O
groups NN O O
should NN O O
not NN O O
be NN O O
over NN O O
- NN O O
interpreted NN O O
. NN O O
Table NN O O
2 NN O O
: NN O O
Bleeding NN B-AdverseReaction B-AdverseReaction
Events NN O O
in NN O O
Patients NN O O
with NN O O
Nonvalvular NN O O
Atrial NN O O
Fibrillation NN O O
in NN O O
AVERROES NN O O
ELIQUISN=2798n NN O O
( NN O O
%/year NN O O
) NN O O
AspirinN=2780n NN O O
( NN O O
%/year NN O O
) NN O O
Hazard NN O O
Ratio(95 NN O O
% NN O O
CI NN O O
) NN O O
P NN O O
- NN O O
value NN O O
Events NN O O
associated NN O O
with NN O O
each NN O O
endpoint NN O O
were NN O O
counted NN O O
once NN O O
per NN O O
subject NN O O
, NN O O
but NN O O
subjects NN O O
may NN O O
have NN O O
contributed NN O O
events NN O O
to NN O O
multiple NN O O
endpoints NN O O
. NN O O
Major NN O O
45 NN O O
( NN O O
1.41 NN O O
) NN O O
29 NN O O
( NN O O
0.92 NN O O
) NN O O
1.54 NN O O
( NN O O
0.96 NN O O
, NN O O
2.45 NN O O
) NN O O
0.07 NN O O
Fatal NN B-AdverseReaction B-AdverseReaction
5 NN O O
( NN O O
0.16 NN O O
) NN O O
5 NN O O
( NN O O
0.16 NN O O
) NN O O
0.99 NN O O
( NN O O
0.23 NN O O
, NN O O
4.29 NN O O
) NN O O
- NN O O
Intracranial NN O O
11 NN O O
( NN O O
0.34 NN O O
) NN O O
11 NN O O
( NN O O
0.35 NN O O
) NN O O
0.99 NN O O
( NN O O
0.39 NN O O
, NN O O
2.51 NN O O
) NN O O
- NN O O
ARISTOTLE NN O O
Major NN B-Severity B-Severity
Bleeding NN B-AdverseReaction B-AdverseReaction
Forest NN O O
Plot NN O O
Other NN O O
Adverse NN O O
Reactions NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
( NN O O
including NN O O
drug NN B-AdverseReaction B-AdverseReaction
hypersensitivity NN I-AdverseReaction I-AdverseReaction
such NN O O
as NN O O
skin NN B-AdverseReaction B-AdverseReaction
rash NN I-AdverseReaction I-AdverseReaction
and NN O O
anaphylactic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
such NN O O
as NN O O
allergic NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
and NN O O
syncope NN B-AdverseReaction B-AdverseReaction
were NN O O
reported NN O O
in NN O O
< NN O O
1 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
ELIQUIS. NN O O
Prophylaxis NN O O
of NN O O
Deep NN O O
Vein NN O O
Thrombosis NN O O
Following NN O O
Hip NN O O
or NN O O
Knee NN O O
Replacement NN O O
Surgery NN O O
The NN O O
safety NN O O
of NN O O
ELIQUIS NN O O
has NN O O
been NN O O
evaluated NN O O
in NN O O
1 NN O O
Phase NN O O
II NN O O
and NN O O
3 NN O O
Phase NN O O
III NN O O
studies NN O O
including NN O O
5924 NN O O
patients NN O O
exposed NN O O
to NN O O
ELIQUIS NN O O
2.5 NN O O
mg NN O O
twice NN O O
daily NN O O
undergoing NN O O
major NN O O
orthopedic NN O O
surgery NN O O
of NN O O
the NN O O
lower NN O O
limbs NN O O
( NN O O
elective NN O O
hip NN O O
replacement NN O O
or NN O O
elective NN O O
knee NN O O
replacement NN O O
) NN O O
treated NN O O
for NN O O
up NN O O
to NN O O
38 NN O O
days NN O O
. NN O O
In NN O O
total NN O O
, NN O O
11 NN O O
% NN O O
of NN O O
the NN O O
patients NN O O
treated NN O O
with NN O O
ELIQUIS NN O O
2.5 NN O O
mg NN O O
twice NN O O
daily NN O O
experienced NN O O
adverse NN O O
reactions NN O O
. NN O O
Bleeding NN B-AdverseReaction B-AdverseReaction
results NN O O
during NN O O
the NN O O
treatment NN O O
period NN O O
in NN O O
the NN O O
Phase NN O O
III NN O O
studies NN O O
are NN O O
shown NN O O
in NN O O
Table NN O O
3 NN O O
. NN O O
Bleeding NN B-AdverseReaction B-AdverseReaction
was NN O O
assessed NN O O
in NN O O
each NN O O
study NN O O
beginning NN O O
with NN O O
the NN O O
first NN O O
dose NN O O
of NN O O
double NN O O
- NN O O
blind NN O O
study NN O O
drug NN O O
. NN O O
Table NN O O
3 NN O O
: NN O O
Bleeding NN B-AdverseReaction B-AdverseReaction
During NN O O
the NN O O
Treatment NN O O
Period NN O O
in NN O O
Patients NN O O
Undergoing NN O O
Elective NN O O
Hip NN O O
or NN O O
Knee NN O O
Replacement NN O O
Surgery NN O O
Bleeding NN O O
Endpoint NN O O
* NN O O
ADVANCE-3Hip NN O O
Replacement NN O O
Surgery NN O O
ADVANCE-2Knee NN O O
Replacement NN O O
Surgery NN O O
ADVANCE-1Knee NN O O
Replacement NN O O
Surgery NN O O
* NN O O
All NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
criteria NN O O
included NN O O
surgical NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
bleeding NN I-AdverseReaction I-AdverseReaction
Includes NN O O
13 NN O O
subjects NN O O
with NN O O
major NN B-Severity B-Severity
bleeding NN B-AdverseReaction B-AdverseReaction
events NN O O
that NN O O
occurred NN O O
before NN B-Negation B-Negation
the NN I-Negation I-Negation
first NN I-Negation I-Negation
dose NN I-Negation I-Negation
of NN O O
apixaban NN O O
( NN O O
administered NN O O
12 NN O O
to NN O O
24 NN O O
hours NN O O
post NN O O
surgery NN O O
) NN O O
. NN O O
? NN O O
Includes NN O O
5 NN O O
subjects NN O O
with NN O O
major NN B-Severity B-Severity
bleeding NN B-AdverseReaction B-AdverseReaction
events NN O O
that NN O O
occurred NN O O
before NN B-Negation B-Negation
the NN I-Negation I-Negation
first NN I-Negation I-Negation
dose NN I-Negation I-Negation
of NN O O
apixaban NN O O
( NN O O
administered NN O O
12 NN O O
to NN O O
24 NN O O
hours NN O O
post NN O O
surgery NN O O
) NN O O
. NN O O
S NN O O
Intracranial NN O O
, NN O O
intraspinal NN O O
, NN O O
intraocular NN O O
, NN O O
pericardial NN O O
, NN O O
an NN O O
operated NN O O
joint NN O O
requiring NN O O
re NN O O
- NN O O
operation NN O O
or NN O O
intervention NN O O
, NN O O
intramuscular NN O O
with NN O O
compartment NN O O
syndrome NN O O
, NN O O
or NN O O
retroperitoneal NN O O
. NN O O
Bleeding NN B-AdverseReaction B-AdverseReaction
into NN I-AdverseReaction I-AdverseReaction
an NN I-AdverseReaction I-AdverseReaction
operated NN I-AdverseReaction I-AdverseReaction
joint NN I-AdverseReaction I-AdverseReaction
requiring NN O O
re NN O O
- NN O O
operation NN O O
or NN O O
intervention NN O O
was NN O O
present NN O O
in NN O O
all NN O O
patients NN O O
with NN O O
this NN O O
category NN O O
of NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
Events NN O O
and NN O O
event NN O O
rates NN O O
include NN O O
one NN O O
enoxaparin NN O O
- NN O O
treated NN O O
patient NN O O
in NN O O
ADVANCE-1 NN O O
who NN O O
also NN O O
had NN O O
intracranial NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
CRNM NN O O
= NN O O
clinically NN O O
relevant NN O O
nonmajor NN O O
. NN O O
ELIQUIS2.5 NN O O
mg NN O O
po NN O O
bid35+/-3 NN O O
days NN O O
Enoxaparin NN O O
40 NN O O
mg NN O O
sc NN O O
qd NN O O
35+/-3 NN O O
days NN O O
ELIQUIS NN O O
2.5 NN O O
mg NN O O
po NN O O
bid NN O O
12+/-2 NN O O
days NN O O
Enoxaparin NN O O
40 NN O O
mg NN O O
sc NN O O
qd NN O O
12+/-2 NN O O
days NN O O
ELIQUIS NN O O
2.5 NN O O
mg NN O O
po NN O O
bid NN O O
12+/-2 NN O O
days NN O O
Enoxaparin NN O O
30 NN O O
mg NN O O
sc NN O O
q12h NN O O
12+/-2 NN O O
days NN O O
First NN O O
dose NN O O
12 NN O O
to NN O O
24 NN O O
hours NN O O
post NN O O
surgery NN O O
First NN O O
dose NN O O
9 NN O O
to NN O O
15 NN O O
hours NN O O
prior NN O O
to NN O O
surgery NN O O
First NN O O
dose NN O O
12 NN O O
to NN O O
24 NN O O
hours NN O O
post NN O O
surgery NN O O
First NN O O
dose NN O O
9 NN O O
to NN O O
15 NN O O
hours NN O O
prior NN O O
to NN O O
surgery NN O O
First NN O O
dose NN O O
12 NN O O
to NN O O
24 NN O O
hours NN O O
post NN O O
surgery NN O O
First NN O O
dose NN O O
12 NN O O
to NN O O
24 NN O O
hours NN O O
post NN O O
surgery NN O O
All NN O O
treated NN O O
N=2673 NN O O
N=2659 NN O O
N=1501 NN O O
N=1508 NN O O
N=1596 NN O O
N=1588 NN O O
Major NN O O
( NN O O
including NN O O
surgical NN O O
site NN O O
) NN O O
22 NN O O
( NN O O
0.82 NN O O
% NN O O
) NN O O
18 NN O O
( NN O O
0.68 NN O O
% NN O O
) NN O O
9 NN O O
( NN O O
0.60 NN O O
% NN O O
) NN O O
? NN O O
14 NN O O
( NN O O
0.93 NN O O
% NN O O
) NN O O
11 NN O O
( NN O O
0.69 NN O O
% NN O O
) NN O O
22 NN O O
( NN O O
1.39 NN O O
% NN O O
) NN O O
Fatal NN B-AdverseReaction B-AdverseReaction
0 NN O O
0 NN O O
0 NN O O
0 NN O O
0 NN O O
1 NN O O
( NN O O
0.06 NN O O
% NN O O
) NN O O
Hgb NN B-AdverseReaction B-AdverseReaction
decrease NN I-AdverseReaction I-AdverseReaction
>=2 NN O O
g/dL NN O O
13 NN O O
( NN O O
0.49 NN O O
% NN O O
) NN O O
10 NN O O
( NN O O
0.38 NN O O
% NN O O
) NN O O
8 NN O O
( NN O O
0.53 NN O O
% NN O O
) NN O O
9 NN O O
( NN O O
0.60 NN O O
% NN O O
) NN O O
10 NN O O
( NN O O
0.63 NN O O
% NN O O
) NN O O
16 NN O O
( NN O O
1.01 NN O O
% NN O O
) NN O O
Transfusion NN O O
of NN O O
>=2 NN O O
units NN O O
RBC NN O O
16 NN O O
( NN O O
0.60 NN O O
% NN O O
) NN O O
14 NN O O
( NN O O
0.53 NN O O
% NN O O
) NN O O
5 NN O O
( NN O O
0.33 NN O O
% NN O O
) NN O O
9 NN O O
( NN O O
0.60 NN O O
% NN O O
) NN O O
9 NN O O
( NN O O
0.56 NN O O
% NN O O
) NN O O
18 NN O O
( NN O O
1.13 NN O O
% NN O O
) NN O O
Bleed NN B-AdverseReaction B-AdverseReaction
at NN I-AdverseReaction I-AdverseReaction
critical NN I-AdverseReaction I-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
1 NN O O
( NN O O
0.04 NN O O
% NN O O
) NN O O
1 NN O O
( NN O O
0.04 NN O O
% NN O O
) NN O O
1 NN O O
( NN O O
0.07 NN O O
% NN O O
) NN O O
2 NN O O
( NN O O
0.13 NN O O
% NN O O
) NN O O
1 NN O O
( NN O O
0.06 NN O O
% NN O O
) NN O O
4 NN O O
( NN O O
0.25 NN O O
% NN O O
) NN O O
Major+ NN O O
CRNM NN O O
129 NN O O
( NN O O
4.83 NN O O
% NN O O
) NN O O
134 NN O O
( NN O O
5.04 NN O O
% NN O O
) NN O O
53 NN O O
( NN O O
3.53 NN O O
% NN O O
) NN O O
72 NN O O
( NN O O
4.77 NN O O
% NN O O
) NN O O
46 NN O O
( NN O O
2.88 NN O O
% NN O O
) NN O O
68 NN O O
( NN O O
4.28 NN O O
% NN O O
) NN O O
All NN O O
313 NN O O
( NN O O
11.71 NN O O
% NN O O
) NN O O
334 NN O O
( NN O O
12.56 NN O O
% NN O O
) NN O O
104 NN O O
( NN O O
6.93 NN O O
% NN O O
) NN O O
126 NN O O
( NN O O
8.36 NN O O
% NN O O
) NN O O
85 NN O O
( NN O O
5.33 NN O O
% NN O O
) NN O O
108 NN O O
( NN O O
6.80 NN O O
% NN O O
) NN O O
Adverse NN O O
reactions NN O O
occurring NN O O
in NN O O
>=1 NN O O
% NN O O
of NN O O
patients NN O O
undergoing NN O O
hip NN O O
or NN O O
knee NN O O
replacement NN O O
surgery NN O O
in NN O O
the NN O O
1 NN O O
Phase NN O O
II NN O O
study NN O O
and NN O O
the NN O O
3 NN O O
Phase NN O O
III NN O O
studies NN O O
are NN O O
listed NN O O
in NN O O
Table NN O O
4 NN O O
. NN O O
Table NN O O
4 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Occurring NN O O
in NN O O
>=1 NN O O
% NN O O
of NN O O
Patients NN O O
in NN O O
Either NN O O
Group NN O O
Undergoing NN O O
Hip NN O O
or NN O O
Knee NN O O
Replacement NN O O
Surgery NN O O
ELIQUIS NN O O
, NN O O
n NN O O
( NN O O
%)2.5 NN O O
mg NN O O
po NN O O
bidN=5924 NN O O
Enoxaparin NN O O
, NN O O
n NN O O
( NN O O
%)40 NN O O
mg NN O O
sc NN O O
qd NN O O
or30 NN O O
mg NN O O
sc NN O O
q12hN=5904 NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
153 NN O O
( NN O O
2.6 NN O O
) NN O O
159 NN O O
( NN O O
2.7 NN O O
) NN O O
Anemia NN B-AdverseReaction B-AdverseReaction
( NN O O
including NN O O
postoperative NN O O
and NN O O
hemorrhagic NN B-AdverseReaction B-AdverseReaction
anemia NN I-AdverseReaction I-AdverseReaction
and NN O O
respective NN O O
laboratory NN O O
parameters NN O O
) NN O O
153 NN O O
( NN O O
2.6 NN O O
) NN O O
178 NN O O
( NN O O
3.0 NN O O
) NN O O
Contusion NN B-AdverseReaction B-AdverseReaction
83 NN O O
( NN O O
1.4 NN O O
) NN O O
115 NN O O
( NN O O
1.9 NN O O
) NN O O
Hemorrhage NN B-AdverseReaction B-AdverseReaction
( NN O O
including NN O O
hematoma NN B-AdverseReaction B-AdverseReaction
and NN O O
vaginal NN O O
and NN O O
urethral NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
67 NN O O
( NN O O
1.1 NN O O
) NN O O
81 NN O O
( NN O O
1.4 NN O O
) NN O O
Postprocedural NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
( NN O O
including NN O O
postprocedural NN B-AdverseReaction B-AdverseReaction
hematoma NN I-AdverseReaction I-AdverseReaction
wound NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
vessel NN B-AdverseReaction B-AdverseReaction
puncture NN I-AdverseReaction I-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
hematoma NN I-AdverseReaction I-AdverseReaction
and NN O O
catheter NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
54 NN O O
( NN O O
0.9 NN O O
) NN O O
60 NN O O
( NN O O
1.0 NN O O
) NN O O
Transaminases NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
( NN O O
including NN O O
alanine NN B-AdverseReaction B-AdverseReaction
aminotransferase NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
and NN O O
alanine NN B-AdverseReaction B-AdverseReaction
aminotransferase NN I-AdverseReaction I-AdverseReaction
abnormal NN I-AdverseReaction I-AdverseReaction
50 NN O O
( NN O O
0.8 NN O O
) NN O O
71 NN O O
( NN O O
1.2 NN O O
) NN O O
Aspartate NN B-AdverseReaction B-AdverseReaction
aminotransferase NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
47 NN O O
( NN O O
0.8 NN O O
) NN O O
69 NN O O
( NN O O
1.2 NN O O
) NN O O
Gamma NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
glutamyltransferase NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
38 NN O O
( NN O O
0.6 NN O O
) NN O O
65 NN O O
( NN O O
1.1 NN O O
) NN O O
Less NN O O
common NN O O
adverse NN O O
reactions NN O O
in NN O O
apixaban NN O O
- NN O O
treated NN O O
patients NN O O
undergoing NN O O
hip NN O O
or NN O O
knee NN O O
replacement NN O O
surgery NN O O
occurring NN O O
at NN O O
a NN O O
frequency NN O O
of NN O O
>=0.1 NN O O
% NN O O
to NN O O
< NN O O
1 NN O O
% NN O O
: NN O O
Blood NN O O
and NN O O
lymphatic NN O O
system NN O O
disorders NN O O
: NN O O
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
( NN O O
including NN O O
platelet NN B-AdverseReaction B-AdverseReaction
count NN I-AdverseReaction I-AdverseReaction
decreases NN I-AdverseReaction I-AdverseReaction
Vascular NN O O
disorders NN O O
: NN O O
hypotension NN B-AdverseReaction B-AdverseReaction
( NN O O
including NN O O
procedural NN B-AdverseReaction B-AdverseReaction
hypotension NN I-AdverseReaction I-AdverseReaction
Respiratory NN O O
, NN O O
thoracic NN O O
, NN O O
and NN O O
mediastinal NN O O
disorders NN O O
: NN O O
epistaxis NN B-AdverseReaction B-AdverseReaction
Gastrointestinal NN O O
disorders NN O O
: NN O O
gastrointestinal NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
( NN O O
including NN O O
hematemesis NN B-AdverseReaction B-AdverseReaction
and NN O O
melena NN B-AdverseReaction B-AdverseReaction
hematochezia NN B-AdverseReaction B-AdverseReaction
Hepatobiliary NN O O
disorders NN O O
: NN O O
liver NN B-AdverseReaction B-AdverseReaction
function NN I-AdverseReaction I-AdverseReaction
test NN I-AdverseReaction I-AdverseReaction
abnormal NN I-AdverseReaction I-AdverseReaction
blood NN B-AdverseReaction B-AdverseReaction
alkaline NN I-AdverseReaction I-AdverseReaction
phosphatase NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
blood NN B-AdverseReaction B-AdverseReaction
bilirubin NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
Renal NN O O
and NN O O
urinary NN O O
disorders NN O O
: NN O O
hematuria NN B-AdverseReaction B-AdverseReaction
( NN O O
including NN O O
respective NN O O
laboratory NN O O
parameters NN O O
) NN O O
Injury NN O O
, NN O O
poisoning NN O O
, NN O O
and NN O O
procedural NN O O
complications NN O O
: NN O O
wound NN B-AdverseReaction B-AdverseReaction
secretion NN I-AdverseReaction I-AdverseReaction
incision NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
( NN O O
including NN O O
incision NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
hematoma NN I-AdverseReaction I-AdverseReaction
operative NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
Less NN O O
common NN O O
adverse NN O O
reactions NN O O
in NN O O
apixaban NN O O
- NN O O
treated NN O O
patients NN O O
undergoing NN O O
hip NN O O
or NN O O
knee NN O O
replacement NN O O
surgery NN O O
occurring NN O O
at NN O O
a NN O O
frequency NN O O
of NN O O
< NN O O
0.1 NN O O
% NN O O
: NN O O
Gingival NN B-AdverseReaction B-AdverseReaction
bleeding NN I-AdverseReaction I-AdverseReaction
hemoptysis NN B-AdverseReaction B-AdverseReaction
hypersensitivity NN B-AdverseReaction B-AdverseReaction
muscle NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
ocular NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
( NN O O
including NN O O
conjunctival NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
rectal NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
Treatment NN O O
of NN O O
DVT NN O O
and NN O O
PE NN O O
and NN O O
Reduction NN O O
in NN O O
the NN O O
Risk NN O O
of NN O O
Recurrence NN O O
of NN O O
DVT NN O O
or NN O O
PE NN O O
The NN O O
safety NN O O
of NN O O
ELIQUIS NN O O
has NN O O
been NN O O
evaluated NN O O
in NN O O
the NN O O
AMPLIFY NN O O
and NN O O
AMPLIFY NN O O
- NN O O
EXT NN O O
studies NN O O
, NN O O
including NN O O
2676 NN O O
patients NN O O
exposed NN O O
to NN O O
ELIQUIS NN O O
10 NN O O
mg NN O O
twice NN O O
daily NN O O
, NN O O
3359 NN O O
patients NN O O
exposed NN O O
to NN O O
ELIQUIS NN O O
5 NN O O
mg NN O O
twice NN O O
daily NN O O
, NN O O
and NN O O
840 NN O O
patients NN O O
exposed NN O O
to NN O O
ELIQUIS NN O O
2.5 NN O O
mg NN O O
twice NN O O
daily NN O O
. NN O O
Common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=1 NN O O
% NN O O
) NN O O
were NN O O
gingival NN B-AdverseReaction B-AdverseReaction
bleeding NN I-AdverseReaction I-AdverseReaction
epistaxis NN B-AdverseReaction B-AdverseReaction
contusion NN B-AdverseReaction B-AdverseReaction
hematuria NN B-AdverseReaction B-AdverseReaction
rectal NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
hematoma NN B-AdverseReaction B-AdverseReaction
menorrhagia NN B-AdverseReaction B-AdverseReaction
and NN O O
hemoptysis NN B-AdverseReaction B-AdverseReaction
AMPLIFY NN O O
Study NN O O
The NN O O
mean NN O O
duration NN O O
of NN O O
exposure NN O O
to NN O O
ELIQUIS NN O O
was NN O O
154 NN O O
days NN O O
and NN O O
to NN O O
enoxaparin/warfarin NN O O
was NN O O
152 NN O O
days NN O O
in NN O O
the NN O O
AMPLIFY NN O O
study NN O O
. NN O O
Adverse NN O O
reactions NN O O
related NN O O
to NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
417 NN O O
( NN O O
15.6 NN O O
% NN O O
) NN O O
ELIQUIS NN O O
- NN O O
treated NN O O
patients NN O O
compared NN O O
to NN O O
661 NN O O
( NN O O
24.6 NN O O
% NN O O
) NN O O
enoxaparin/warfarin NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
The NN O O
discontinuation NN O O
rate NN O O
due NN O O
to NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
events NN O O
was NN O O
0.7 NN O O
% NN O O
in NN O O
the NN O O
ELIQUIS NN O O
- NN O O
treated NN O O
patients NN O O
compared NN O O
to NN O O
1.7 NN O O
% NN O O
in NN O O
enoxaparin/warfarin NN O O
- NN O O
treated NN O O
patients NN O O
in NN O O
the NN O O
AMPLIFY NN O O
study NN O O
. NN O O
In NN O O
the NN O O
AMPLIFY NN O O
study NN O O
, NN O O
ELIQUIS NN O O
was NN O O
statistically NN O O
superior NN O O
to NN O O
enoxaparin/warfarin NN O O
in NN O O
the NN O O
primary NN O O
safety NN O O
endpoint NN O O
of NN O O
major NN B-Severity B-Severity
bleeding NN B-AdverseReaction B-AdverseReaction
( NN O O
relative NN O O
risk NN O O
0.31 NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
[ NN O O
0.17 NN O O
, NN O O
0.55 NN O O
] NN O O
, NN O O
P NN O O
- NN O O
value NN O O
< NN O O
0.0001 NN O O
) NN O O
. NN O O
Bleeding NN B-AdverseReaction B-AdverseReaction
results NN O O
from NN O O
the NN O O
AMPLIFY NN O O
study NN O O
are NN O O
summarized NN O O
in NN O O
Table NN O O
5 NN O O
. NN O O
Table NN O O
5 NN O O
: NN O O
Bleeding NN B-AdverseReaction B-AdverseReaction
Results NN O O
in NN O O
the NN O O
AMPLIFY NN O O
Study NN O O
ELIQUISN=2676n NN O O
( NN O O
% NN O O
) NN O O
Enoxaparin/WarfarinN=2689n NN O O
( NN O O
% NN O O
) NN O O
Relative NN O O
Risk NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
) NN O O
* NN O O
CRNM NN B-AdverseReaction B-AdverseReaction
= NN O O
clinically NN B-AdverseReaction B-AdverseReaction
relevant NN I-AdverseReaction I-AdverseReaction
nonmajor NN I-AdverseReaction I-AdverseReaction
bleeding NN I-AdverseReaction I-AdverseReaction
associated NN O O
with NN O O
each NN O O
endpoint NN O O
were NN O O
counted NN O O
once NN O O
per NN O O
subject NN O O
, NN O O
but NN O O
subjects NN O O
may NN O O
have NN O O
contributed NN O O
events NN O O
to NN O O
multiple NN O O
endpoints NN O O
. NN O O
Major NN O O
15 NN O O
( NN O O
0.6 NN O O
) NN O O
49 NN O O
( NN O O
1.8 NN O O
) NN O O
0.31 NN O O
( NN O O
0.17 NN O O
, NN O O
0.55)p<0.0001 NN O O
CRNM NN B-AdverseReaction B-AdverseReaction
103 NN O O
( NN O O
3.9 NN O O
) NN O O
215 NN O O
( NN O O
8.0 NN O O
) NN O O
Major NN O O
+ NN O O
CRNM NN B-AdverseReaction B-AdverseReaction
115 NN O O
( NN O O
4.3 NN O O
) NN O O
261 NN O O
( NN O O
9.7 NN O O
) NN O O
Minor NN O O
313 NN O O
( NN O O
11.7 NN O O
) NN O O
505 NN O O
( NN O O
18.8 NN O O
) NN O O
All NN O O
402 NN O O
( NN O O
15.0 NN O O
) NN O O
676 NN O O
( NN O O
25.1 NN O O
) NN O O
Adverse NN O O
reactions NN O O
occurring NN O O
in NN O O
>=1 NN O O
% NN O O
of NN O O
patients NN O O
in NN O O
the NN O O
AMPLIFY NN O O
study NN O O
are NN O O
listed NN O O
in NN O O
Table NN O O
6 NN O O
. NN O O
Table NN O O
6 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Occurring NN O O
in NN O O
>=1 NN O O
% NN O O
of NN O O
Patients NN O O
Treated NN O O
for NN O O
DVT NN O O
and NN O O
PE NN O O
in NN O O
the NN O O
AMPLIFY NN O O
Study NN O O
ELIQUISN=2676n NN O O
( NN O O
% NN O O
) NN O O
Enoxaparin/WarfarinN=2689n NN O O
( NN O O
% NN O O
) NN O O
Epistaxis NN B-AdverseReaction B-AdverseReaction
77 NN O O
( NN O O
2.9 NN O O
) NN O O
146 NN O O
( NN O O
5.4 NN O O
) NN O O
Contusion NN B-AdverseReaction B-AdverseReaction
49 NN O O
( NN O O
1.8 NN O O
) NN O O
97 NN O O
( NN O O
3.6 NN O O
) NN O O
Hematuria NN B-AdverseReaction B-AdverseReaction
46 NN O O
( NN O O
1.7 NN O O
) NN O O
102 NN O O
( NN O O
3.8 NN O O
) NN O O
Menorrhagia NN B-AdverseReaction B-AdverseReaction
38 NN O O
( NN O O
1.4 NN O O
) NN O O
30 NN O O
( NN O O
1.1 NN O O
) NN O O
Hematoma NN B-AdverseReaction B-AdverseReaction
35 NN O O
( NN O O
1.3 NN O O
) NN O O
76 NN O O
( NN O O
2.8 NN O O
) NN O O
Hemoptysis NN B-AdverseReaction B-AdverseReaction
32 NN O O
( NN O O
1.2 NN O O
) NN O O
31 NN O O
( NN O O
1.2 NN O O
) NN O O
Rectal NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
26 NN O O
( NN O O
1.0 NN O O
) NN O O
39 NN O O
( NN O O
1.5 NN O O
) NN O O
Gingival NN B-AdverseReaction B-AdverseReaction
bleeding NN I-AdverseReaction I-AdverseReaction
26 NN O O
( NN O O
1.0 NN O O
) NN O O
50 NN O O
( NN O O
1.9 NN O O
) NN O O
AMPLIFY NN O O
- NN O O
EXT NN O O
Study NN O O
The NN O O
mean NN O O
duration NN O O
of NN O O
exposure NN O O
to NN O O
ELIQUIS NN O O
was NN O O
approximately NN O O
330 NN O O
days NN O O
and NN O O
to NN O O
placebo NN O O
was NN O O
312 NN O O
days NN O O
in NN O O
the NN O O
AMPLIFY NN O O
- NN O O
EXT NN O O
study NN O O
. NN O O
Adverse NN O O
reactions NN O O
related NN O O
to NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
219 NN O O
( NN O O
13.3 NN O O
% NN O O
) NN O O
ELIQUIS NN O O
- NN O O
treated NN O O
patients NN O O
compared NN O O
to NN O O
72 NN O O
( NN O O
8.7 NN O O
% NN O O
) NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
The NN O O
discontinuation NN O O
rate NN O O
due NN O O
to NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
events NN O O
was NN O O
approximately NN O O
1 NN O O
% NN O O
in NN O O
the NN O O
ELIQUIS NN O O
- NN O O
treated NN O O
patients NN O O
compared NN O O
to NN O O
0.4 NN O O
% NN O O
in NN O O
those NN O O
patients NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
in NN O O
the NN O O
AMPLIFY NN O O
- NN O O
EXT NN O O
study NN O O
. NN O O
Bleeding NN B-AdverseReaction B-AdverseReaction
results NN O O
from NN O O
the NN O O
AMPLIFY NN O O
- NN O O
EXT NN O O
study NN O O
are NN O O
summarized NN O O
in NN O O
Table NN O O
7 NN O O
. NN O O
Table NN O O
7 NN O O
: NN O O
Bleeding NN B-AdverseReaction B-AdverseReaction
Results NN O O
in NN O O
the NN O O
AMPLIFY NN O O
- NN O O
EXT NN O O
Study NN O O
ELIQUIS NN O O
2.5 NN O O
mg NN O O
bidN=840n NN O O
( NN O O
% NN O O
) NN O O
ELIQUIS NN O O
5 NN O O
mg NN O O
bidN=811n NN O O
( NN O O
% NN O O
) NN O O
PlaceboN=826n NN O O
( NN O O
% NN O O
) NN O O
* NN O O
CRNM NN B-AdverseReaction B-AdverseReaction
= NN O O
clinically NN B-AdverseReaction B-AdverseReaction
relevant NN I-AdverseReaction I-AdverseReaction
nonmajor NN I-AdverseReaction I-AdverseReaction
bleeding NN I-AdverseReaction I-AdverseReaction
associated NN O O
with NN O O
each NN O O
endpoint NN O O
were NN O O
counted NN O O
once NN O O
per NN O O
subject NN O O
, NN O O
but NN O O
subjects NN O O
may NN O O
have NN O O
contributed NN O O
events NN O O
to NN O O
multiple NN O O
endpoints NN O O
. NN O O
Major NN O O
2 NN O O
( NN O O
0.2 NN O O
) NN O O
1 NN O O
( NN O O
0.1 NN O O
) NN O O
4 NN O O
( NN O O
0.5 NN O O
) NN O O
CRNM NN B-AdverseReaction B-AdverseReaction
25 NN O O
( NN O O
3.0 NN O O
) NN O O
34 NN O O
( NN O O
4.2 NN O O
) NN O O
19 NN O O
( NN O O
2.3 NN O O
) NN O O
Major NN O O
+ NN O O
CRNM NN B-AdverseReaction B-AdverseReaction
27 NN O O
( NN O O
3.2 NN O O
) NN O O
35 NN O O
( NN O O
4.3 NN O O
) NN O O
22 NN O O
( NN O O
2.7 NN O O
) NN O O
Minor NN O O
75 NN O O
( NN O O
8.9 NN O O
) NN O O
98 NN O O
( NN O O
12.1 NN O O
) NN O O
58 NN O O
( NN O O
7.0 NN O O
) NN O O
All NN O O
94 NN O O
( NN O O
11.2 NN O O
) NN O O
121 NN O O
( NN O O
14.9 NN O O
) NN O O
74 NN O O
( NN O O
9.0 NN O O
) NN O O
Adverse NN O O
reactions NN O O
occurring NN O O
in NN O O
>=1 NN O O
% NN O O
of NN O O
patients NN O O
in NN O O
the NN O O
AMPLIFY NN O O
- NN O O
EXT NN O O
study NN O O
are NN O O
listed NN O O
in NN O O
Table NN O O
8 NN O O
. NN O O
Table NN O O
8 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Occurring NN O O
in NN O O
>=1 NN O O
% NN O O
of NN O O
Patients NN O O
Undergoing NN O O
Extended NN O O
Treatment NN O O
for NN O O
DVT NN O O
and NN O O
PE NN O O
in NN O O
the NN O O
AMPLIFY NN O O
- NN O O
EXT NN O O
Study NN O O
ELIQUIS NN O O
2.5 NN O O
mg NN O O
bidN=840n NN O O
( NN O O
% NN O O
) NN O O
ELIQUIS NN O O
5 NN O O
mg NN O O
bidN=811n NN O O
( NN O O
% NN O O
) NN O O
PlaceboN=826n NN O O
( NN O O
% NN O O
) NN O O
Epistaxis NN B-AdverseReaction B-AdverseReaction
13 NN O O
( NN O O
1.5 NN O O
) NN O O
29 NN O O
( NN O O
3.6 NN O O
) NN O O
9 NN O O
( NN O O
1.1 NN O O
) NN O O
Hematuria NN B-AdverseReaction B-AdverseReaction
12 NN O O
( NN O O
1.4 NN O O
) NN O O
17 NN O O
( NN O O
2.1 NN O O
) NN O O
9 NN O O
( NN O O
1.1 NN O O
) NN O O
Hematoma NN B-AdverseReaction B-AdverseReaction
13 NN O O
( NN O O
1.5 NN O O
) NN O O
16 NN O O
( NN O O
2.0 NN O O
) NN O O
10 NN O O
( NN O O
1.2 NN O O
) NN O O
Contusion NN B-AdverseReaction B-AdverseReaction
18 NN O O
( NN O O
2.1 NN O O
) NN O O
18 NN O O
( NN O O
2.2 NN O O
) NN O O
18 NN O O
( NN O O
2.2 NN O O
) NN O O
Gingival NN B-AdverseReaction B-AdverseReaction
bleeding NN I-AdverseReaction I-AdverseReaction
12 NN O O
( NN O O
1.4 NN O O
) NN O O
9 NN O O
( NN O O
1.1 NN O O
) NN O O
3 NN O O
( NN O O
0.4 NN O O
) NN O O
Other NN O O
Adverse NN O O
Reactions NN O O
Less NN O O
common NN O O
adverse NN O O
reactions NN O O
in NN O O
ELIQUIS NN O O
- NN O O
treated NN O O
patients NN O O
in NN O O
the NN O O
AMPLIFY NN O O
or NN O O
AMPLIFY NN O O
- NN O O
EXT NN O O
studies NN O O
occurring NN O O
at NN O O
a NN O O
frequency NN O O
of NN O O
>=0.1 NN O O
% NN O O
to NN O O
< NN O O
1 NN O O
% NN O O
: NN O O
Blood NN O O
and NN O O
lymphatic NN O O
system NN O O
disorders NN O O
: NN O O
hemorrhagic NN B-AdverseReaction B-AdverseReaction
anemia NN I-AdverseReaction I-AdverseReaction
Gastrointestinal NN O O
disorders NN O O
: NN O O
hematochezia NN B-AdverseReaction B-AdverseReaction
hemorrhoidal NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
gastrointestinal NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
hematemesis NN B-AdverseReaction B-AdverseReaction
melena NN B-AdverseReaction B-AdverseReaction
anal NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
Injury NN O O
, NN O O
poisoning NN O O
, NN O O
and NN O O
procedural NN O O
complications NN O O
: NN O O
wound NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
postprocedural NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
traumatic NN B-AdverseReaction B-AdverseReaction
hematoma NN I-AdverseReaction I-AdverseReaction
periorbital NN B-AdverseReaction B-AdverseReaction
hematoma NN I-AdverseReaction I-AdverseReaction
Musculoskeletal NN O O
and NN O O
connective NN O O
tissue NN O O
disorders NN O O
: NN O O
muscle NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
Reproductive NN O O
system NN O O
and NN O O
breast NN O O
disorders NN O O
: NN O O
vaginal NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
metrorrhagia NN B-AdverseReaction B-AdverseReaction
menometrorrhagia NN B-AdverseReaction B-AdverseReaction
genital NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
Vascular NN O O
disorders NN O O
: NN O O
hemorrhage NN B-AdverseReaction B-AdverseReaction
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
: NN O O
ecchymosis NN B-AdverseReaction B-AdverseReaction
skin NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
petechiae NN B-AdverseReaction B-AdverseReaction
Eye NN O O
disorders NN O O
: NN O O
conjunctival NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
retinal NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
eye NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
Investigations NN O O
: NN O O
blood NN B-AdverseReaction B-AdverseReaction
urine NN I-AdverseReaction I-AdverseReaction
present NN I-AdverseReaction I-AdverseReaction
occult NN B-AdverseReaction B-AdverseReaction
blood NN I-AdverseReaction I-AdverseReaction
positive NN I-AdverseReaction I-AdverseReaction
occult NN B-AdverseReaction B-AdverseReaction
blood NN I-AdverseReaction I-AdverseReaction
red NN B-AdverseReaction B-AdverseReaction
blood NN I-AdverseReaction I-AdverseReaction
cells NN I-AdverseReaction I-AdverseReaction
urine NN I-AdverseReaction I-AdverseReaction
positive NN I-AdverseReaction I-AdverseReaction
General NN O O
disorders NN O O
and NN O O
administration NN O O
- NN O O
site NN O O
conditions NN O O
: NN O O
injection NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
hematoma NN I-AdverseReaction I-AdverseReaction
vessel NN B-AdverseReaction B-AdverseReaction
puncture NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
hematoma NN I-AdverseReaction I-AdverseReaction
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
( NN O O
A NN O O
) NN O O
PREMATURE NN O O
DISCONTINUATION NN O O
OF NN O O
ELIQUIS NN O O
INCREASES NN O O
THE NN O O
RISK NN B-Factor B-Factor
OF NN O O
THROMBOTIC NN B-AdverseReaction B-AdverseReaction
EVENTS NN I-AdverseReaction I-AdverseReaction
SPINAL/EPIDURAL NN O O
HEMATOMA NN O O
WARNING NN O O
: NN O O
( NN O O
A NN O O
) NN O O
PREMATURE NN O O
DISCONTINUATION NN O O
OF NN O O
ELIQUIS NN O O
INCREASES NN O O
THE NN O O
RISK NN B-Factor B-Factor
OF NN O O
THROMBOTIC NN B-AdverseReaction B-AdverseReaction
EVENTS NN I-AdverseReaction I-AdverseReaction
SPINAL/EPIDURAL NN O O
HEMATOMA NN O O
( NN O O
A NN O O
) NN O O
PREMATURE NN O O
DISCONTINUATION NN O O
OF NN O O
ELIQUIS NN O O
INCREASES NN O O
THE NN O O
RISK NN B-Factor B-Factor
OF NN O O
THROMBOTIC NN B-AdverseReaction B-AdverseReaction
EVENTS NN I-AdverseReaction I-AdverseReaction
Premature NN O O
discontinuation NN O O
of NN O O
any NN O O
oral NN O O
anticoagulant NN O O
, NN O O
including NN O O
ELIQUIS NN O O
, NN O O
increases NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
thrombotic NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
If NN O O
anticoagulation NN O O
with NN O O
ELIQUIS NN O O
is NN O O
discontinued NN O O
for NN O O
a NN O O
reason NN O O
other NN O O
than NN O O
pathological NN O O
bleeding NN O O
or NN O O
completion NN O O
of NN O O
a NN O O
course NN O O
of NN O O
therapy NN O O
, NN O O
consider NN O O
coverage NN O O
with NN O O
another NN O O
anticoagulant NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.4 NN O O
) NN O O
, NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
, NN O O
and NN O O
Clinical NN O O
Studies NN O O
( NN O O
14.1 NN O O
) NN O O
] NN O O
. NN O O
( NN O O
B NN O O
) NN O O
SPINAL/EPIDURAL NN O O
HEMATOMA NN O O
Epidural NN O O
or NN O O
spinal NN B-AdverseReaction B-AdverseReaction
hematomas NN I-AdverseReaction I-AdverseReaction
may NN B-Factor B-Factor
occur NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
ELIQUIS NN O O
who NN O O
are NN O O
receiving NN O O
neuraxial NN O O
anesthesia NN O O
or NN O O
undergoing NN O O
spinal NN O O
puncture NN O O
. NN O O
These NN O O
hematomas NN B-AdverseReaction B-AdverseReaction
may NN B-Factor B-Factor
result NN O O
in NN O O
long NN O O
- NN O O
term NN O O
or NN O O
permanent NN B-AdverseReaction B-AdverseReaction
paralysis NN I-AdverseReaction I-AdverseReaction
Consider NN O O
these NN O O
risks NN O O
when NN O O
scheduling NN O O
patients NN O O
for NN O O
spinal NN O O
procedures NN O O
. NN O O
Factors NN O O
that NN O O
can NN O O
increase NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
developing NN O O
epidural NN O O
or NN O O
spinal NN B-AdverseReaction B-AdverseReaction
hematomas NN I-AdverseReaction I-AdverseReaction
in NN O O
these NN O O
patients NN O O
include NN O O
: NN O O
* NN O O
?use NN O O
of NN O O
indwelling NN O O
epidural NN O O
catheters NN O O
* NN O O
?concomitant NN O O
use NN O O
of NN O O
other NN O O
drugs NN O O
that NN O O
affect NN O O
hemostasis NN O O
, NN O O
such NN O O
as NN O O
nonsteroidal NN O O
anti NN O O
- NN O O
inflammatory NN O O
drugs NN O O
( NN O O
NSAIDs NN O O
) NN O O
, NN O O
platelet NN O O
inhibitors NN O O
, NN O O
other NN O O
anticoagulants NN O O
* NN O O
?a NN O O
history NN O O
of NN O O
traumatic NN O O
or NN O O
repeated NN O O
epidural NN O O
or NN O O
spinal NN O O
punctures NN O O
* NN O O
?a NN O O
history NN O O
of NN O O
spinal NN O O
deformity NN O O
or NN O O
spinal NN O O
surgery NN O O
* NN O O
?optimal NN O O
timing NN O O
between NN O O
the NN O O
administration NN O O
of NN O O
ELIQUIS NN O O
and NN O O
neuraxial NN O O
procedures NN O O
is NN O O
not NN O O
known NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
Monitor NN O O
patients NN O O
frequently NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
neurological NN O O
impairment NN O O
. NN O O
If NN O O
neurological NN O O
compromise NN O O
is NN O O
noted NN O O
, NN O O
urgent NN O O
treatment NN O O
is NN O O
necessary NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
. NN O O
Consider NN O O
the NN O O
benefits NN O O
and NN O O
risks NN O O
before NN O O
neuraxial NN O O
intervention NN O O
in NN O O
patients NN O O
anticoagulated NN O O
or NN O O
to NN O O
be NN O O
anticoagulated NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
. NN O O
WARNING NN O O
: NN O O
( NN O O
A NN O O
) NN O O
PREMATURE NN O O
DISCONTINUATION NN O O
OF NN O O
ELIQUIS NN O O
INCREASES NN O O
THE NN O O
RISK NN B-Factor B-Factor
OF NN O O
THROMBOTIC NN B-AdverseReaction B-AdverseReaction
EVENTS NN I-AdverseReaction I-AdverseReaction
SPINAL/EPIDURAL NN O O
HEMATOMA NN O O
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
. NN O O
( NN O O
A NN O O
) NN O O
PREMATURE NN O O
DISCONTINUATION NN O O
OF NN O O
ELIQUIS NN O O
INCREASES NN O O
THE NN O O
RISK NN B-Factor B-Factor
OF NN O O
THROMBOTIC NN B-AdverseReaction B-AdverseReaction
EVENTS NN I-AdverseReaction I-AdverseReaction
Premature NN O O
discontinuation NN O O
of NN O O
any NN O O
oral NN O O
anticoagulant NN O O
, NN O O
including NN O O
ELIQUIS NN O O
, NN O O
increases NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
thrombotic NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
To NN O O
reduce NN O O
this NN O O
risk NN O O
, NN O O
consider NN O O
coverage NN O O
with NN O O
another NN O O
anticoagulant NN O O
if NN O O
ELIQUIS NN O O
is NN O O
discontinued NN O O
for NN O O
a NN O O
reason NN O O
other NN O O
than NN O O
pathological NN O O
bleeding NN O O
or NN O O
completion NN O O
of NN O O
a NN O O
course NN O O
of NN O O
therapy NN O O
. NN O O
( NN O O
2.4 NN O O
, NN O O
5.1 NN O O
, NN O O
14.1 NN O O
) NN O O
( NN O O
B NN O O
) NN O O
SPINAL/EPIDURAL NN O O
HEMATOMA NN O O
: NN O O
Epidural NN O O
or NN O O
spinal NN B-AdverseReaction B-AdverseReaction
hematomas NN I-AdverseReaction I-AdverseReaction
may NN B-Factor B-Factor
occur NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
ELIQUIS NN O O
who NN O O
are NN O O
receiving NN O O
neuraxial NN O O
anesthesia NN O O
or NN O O
undergoing NN O O
spinal NN O O
puncture NN O O
. NN O O
These NN O O
hematomas NN B-AdverseReaction B-AdverseReaction
may NN B-Factor B-Factor
result NN O O
in NN O O
long NN O O
- NN O O
term NN O O
or NN O O
permanent NN B-AdverseReaction B-AdverseReaction
paralysis NN I-AdverseReaction I-AdverseReaction
Consider NN O O
these NN O O
risks NN O O
when NN O O
scheduling NN O O
patients NN O O
for NN O O
spinal NN O O
procedures NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
? NN O O
ELIQUIS NN O O
can NN B-Factor B-Factor
cause NN O O
serious NN B-Severity B-Severity
potentially NN B-Factor B-Factor
fatal NN B-AdverseReaction B-AdverseReaction
bleeding NN B-AdverseReaction B-AdverseReaction
Promptly NN O O
evaluate NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
blood NN O O
loss.(5.2 NN O O
) NN O O
* NN O O
? NN O O
Prosthetic NN O O
heart NN O O
valves NN O O
: NN O O
ELIQUIS NN O O
use NN O O
not NN O O
recommended.(5.4 NN O O
) NN O O
5.1 NN O O
Increased NN O O
Risk NN O O
of NN O O
Thrombotic NN O O
Events NN O O
after NN O O
Premature NN O O
Discontinuation NN O O
Premature NN O O
discontinuation NN O O
of NN O O
any NN O O
oral NN O O
anticoagulant NN O O
, NN O O
including NN O O
ELIQUIS NN O O
, NN O O
in NN O O
the NN O O
absence NN O O
of NN O O
adequate NN O O
alternative NN O O
anticoagulation NN O O
increases NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
thrombotic NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
An NN O O
increased NN O O
rate NN O O
of NN O O
stroke NN B-AdverseReaction B-AdverseReaction
was NN O O
observed NN O O
during NN O O
the NN O O
transition NN O O
from NN O O
ELIQUIS NN O O
to NN O O
warfarin NN O O
in NN O O
clinical NN O O
trials NN O O
in NN O O
atrial NN O O
fibrillation NN O O
patients NN O O
. NN O O
If NN O O
ELIQUIS NN O O
is NN O O
discontinued NN O O
for NN O O
a NN O O
reason NN O O
other NN O O
than NN O O
pathological NN O O
bleeding NN O O
or NN O O
completion NN O O
of NN O O
a NN O O
course NN O O
of NN O O
therapy NN O O
, NN O O
consider NN O O
coverage NN O O
with NN O O
another NN O O
anticoagulant NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.4 NN O O
) NN O O
andClinical NN O O
Studies NN O O
( NN O O
14.1 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
Bleeding NN O O
ELIQUIS NN O O
increases NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
and NN O O
can NN B-Factor B-Factor
cause NN O O
serious NN B-Severity B-Severity
potentially NN B-Factor B-Factor
fatal NN B-AdverseReaction B-AdverseReaction
bleeding NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.1 NN O O
) NN O O
andAdverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Concomitant NN O O
use NN O O
of NN O O
drugs NN O O
affecting NN O O
hemostasis NN O O
increases NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
These NN O O
include NN O O
aspirin NN O O
and NN O O
other NN O O
antiplatelet NN O O
agents NN O O
, NN O O
other NN O O
anticoagulants NN O O
, NN O O
heparin NN O O
, NN O O
thrombolytic NN O O
agents NN O O
, NN O O
selective NN O O
serotonin NN O O
reuptake NN O O
inhibitors NN O O
, NN O O
serotonin NN O O
norepinephrine NN O O
reuptake NN O O
inhibitors NN O O
, NN O O
and NN O O
nonsteroidal NN O O
anti NN O O
- NN O O
inflammatory NN O O
drugs NN O O
( NN O O
NSAIDs NN O O
) NN O O
[ NN O O
seeDrug NN O O
Interactions NN O O
( NN O O
7.3 NN O O
) NN O O
] NN O O
. NN O O
Advise NN O O
patients NN O O
of NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
blood NN O O
loss NN O O
and NN O O
to NN O O
report NN O O
them NN O O
immediately NN O O
or NN O O
go NN O O
to NN O O
an NN O O
emergency NN O O
room NN O O
. NN O O
Discontinue NN O O
ELIQUIS NN O O
in NN O O
patients NN O O
with NN O O
active NN O O
pathological NN O O
hemorrhage NN O O
. NN O O
There NN O O
is NN O O
no NN O O
established NN O O
way NN O O
to NN O O
reverse NN O O
the NN O O
anticoagulant NN O O
effect NN O O
of NN O O
apixaban NN O O
, NN O O
which NN O O
can NN O O
be NN O O
expected NN O O
to NN O O
persist NN O O
for NN O O
at NN O O
least NN O O
24 NN O O
hours NN O O
after NN O O
the NN O O
last NN O O
dose NN O O
, NN O O
i.e. NN O O
, NN O O
for NN O O
about NN O O
two NN O O
drug NN O O
half NN O O
- NN O O
lives NN O O
. NN O O
A NN O O
specific NN O O
antidote NN O O
for NN O O
ELIQUIS NN O O
is NN O O
not NN O O
available NN O O
. NN O O
Hemodialysis NN O O
does NN O O
not NN O O
appear NN O O
to NN O O
have NN O O
a NN O O
substantial NN O O
impact NN O O
on NN O O
apixaban NN O O
exposure NN O O
[ NN O O
seeClinical NN O O
Pharmacology NN O O
( NN O O
12.3 NN O O
) NN O O
] NN O O
. NN O O
Protamine NN O O
sulfate NN O O
and NN O O
vitamin NN O O
K NN O O
are NN O O
not NN O O
expected NN O O
to NN O O
affect NN O O
the NN O O
anticoagulant NN O O
activity NN O O
of NN O O
apixaban NN O O
. NN O O
There NN O O
is NN O O
no NN O O
experience NN O O
with NN O O
antifibrinolytic NN O O
agents NN O O
( NN O O
tranexamic NN O O
acid NN O O
, NN O O
aminocaproic NN O O
acid NN O O
) NN O O
in NN O O
individuals NN O O
receiving NN O O
apixaban NN O O
. NN O O
There NN O O
is NN O O
neither NN O O
scientific NN O O
rationale NN O O
for NN O O
reversal NN O O
nor NN O O
experience NN O O
with NN O O
systemic NN O O
hemostatics NN O O
( NN O O
desmopressin NN O O
and NN O O
aprotinin NN O O
) NN O O
in NN O O
individuals NN O O
receiving NN O O
apixaban NN O O
. NN O O
Use NN O O
of NN O O
procoagulant NN O O
reversal NN O O
agents NN O O
such NN O O
as NN O O
prothrombin NN O O
complex NN O O
concentrate NN O O
, NN O O
activated NN O O
prothrombin NN O O
complex NN O O
concentrate NN O O
, NN O O
or NN O O
recombinant NN O O
factor NN O O
VIIa NN O O
may NN O O
be NN O O
considered NN O O
but NN O O
has NN O O
not NN O O
been NN O O
evaluated NN O O
in NN O O
clinical NN O O
studies NN O O
. NN O O
Activated NN O O
oral NN O O
charcoal NN O O
reduces NN O O
absorption NN O O
of NN O O
apixaban NN O O
, NN O O
thereby NN O O
lowering NN O O
apixaban NN O O
plasma NN O O
concentration NN O O
[ NN O O
seeOverdosage NN O O
( NN O O
10 NN O O
) NN O O
] NN O O
. NN O O
5.3 NN O O
Spinal/Epidural NN O O
Anesthesia NN O O
or NN O O
Puncture NN O O
When NN O O
neuraxial NN O O
anesthesia NN O O
( NN O O
spinal/epidural NN O O
anesthesia NN O O
) NN O O
or NN O O
spinal/epidural NN O O
puncture NN O O
is NN O O
employed NN O O
, NN O O
patients NN O O
treated NN O O
with NN O O
antithrombotic NN O O
agents NN O O
for NN O O
prevention NN O O
of NN O O
thromboembolic NN O O
complications NN O O
are NN O O
at NN O O
risk NN B-Factor B-Factor
of NN O O
developing NN O O
an NN O O
epidural NN O O
or NN O O
spinal NN B-AdverseReaction B-AdverseReaction
hematoma NN I-AdverseReaction I-AdverseReaction
which NN O O
can NN B-Factor B-Factor
result NN O O
in NN O O
long NN O O
- NN O O
term NN O O
or NN O O
permanent NN B-AdverseReaction B-AdverseReaction
paralysis NN I-AdverseReaction I-AdverseReaction
The NN O O
risk NN O O
of NN O O
these NN O O
events NN O O
may NN O O
be NN O O
increased NN O O
by NN O O
the NN O O
postoperative NN O O
use NN O O
of NN O O
indwelling NN O O
epidural NN O O
catheters NN O O
or NN O O
the NN O O
concomitant NN O O
use NN O O
of NN O O
medicinal NN O O
products NN O O
affecting NN O O
hemostasis NN O O
. NN O O
Indwelling NN O O
epidural NN O O
or NN O O
intrathecal NN O O
catheters NN O O
should NN O O
not NN O O
be NN O O
removed NN O O
earlier NN O O
than NN O O
24 NN O O
hours NN O O
after NN O O
the NN O O
last NN O O
administration NN O O
of NN O O
ELIQUIS. NN O O
The NN O O
next NN O O
dose NN O O
of NN O O
ELIQUIS NN O O
should NN O O
not NN O O
be NN O O
administered NN O O
earlier NN O O
than NN O O
5 NN O O
hours NN O O
after NN O O
the NN O O
removal NN O O
of NN O O
the NN O O
catheter NN O O
. NN O O
The NN O O
risk NN O O
may NN O O
also NN O O
be NN O O
increased NN O O
by NN O O
traumatic NN O O
or NN O O
repeated NN O O
epidural NN O O
or NN O O
spinal NN O O
puncture NN O O
. NN O O
If NN O O
traumatic NN O O
puncture NN O O
occurs NN O O
, NN O O
delay NN O O
the NN O O
administration NN O O
of NN O O
ELIQUIS NN O O
for NN O O
48 NN O O
hours NN O O
. NN O O
Monitor NN O O
patients NN O O
frequently NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
neurological NN O O
impairment NN O O
( NN O O
e.g. NN O O
, NN O O
numbness NN O O
or NN O O
weakness NN O O
of NN O O
the NN O O
legs NN O O
, NN O O
bowel NN O O
, NN O O
or NN O O
bladder NN O O
dysfunction NN O O
) NN O O
. NN O O
If NN O O
neurological NN O O
compromise NN O O
is NN O O
noted NN O O
, NN O O
urgent NN O O
diagnosis NN O O
and NN O O
treatment NN O O
is NN O O
necessary NN O O
. NN O O
Prior NN O O
to NN O O
neuraxial NN O O
intervention NN O O
the NN O O
physician NN O O
should NN O O
consider NN O O
the NN O O
potential NN O O
benefit NN O O
versus NN O O
the NN O O
risk NN O O
in NN O O
anticoagulated NN O O
patients NN O O
or NN O O
in NN O O
patients NN O O
to NN O O
be NN O O
anticoagulated NN O O
for NN O O
thromboprophylaxis NN O O
. NN O O
5.4 NN O O
Patients NN O O
with NN O O
Prosthetic NN O O
Heart NN O O
Valves NN O O
The NN O O
safety NN O O
and NN O O
efficacy NN O O
of NN O O
ELIQUIS NN O O
have NN O O
not NN O O
been NN O O
studied NN O O
in NN O O
patients NN O O
with NN O O
prosthetic NN O O
heart NN O O
valves NN O O
. NN O O
Therefore NN O O
, NN O O
use NN O O
of NN O O
ELIQUIS NN O O
is NN O O
not NN O O
recommended NN O O
in NN O O
these NN O O
patients NN O O
. NN O O
5.5 NN O O
Acute NN O O
PE NN O O
in NN O O
Hemodynamically NN O O
Unstable NN O O
Patients NN O O
or NN O O
Patients NN O O
who NN O O
Require NN O O
Thrombolysis NN O O
or NN O O
Pulmonary NN O O
Embolectomy NN O O
Initiation NN O O
of NN O O
ELIQUIS NN O O
is NN O O
not NN O O
recommended NN O O
as NN O O
an NN O O
alternative NN O O
to NN O O
unfractionated NN O O
heparin NN O O
for NN O O
the NN O O
initial NN O O
treatment NN O O
of NN O O
patients NN O O
with NN O O
PE NN O O
who NN O O
present NN O O
with NN O O
hemodynamic NN O O
instability NN O O
or NN O O
who NN O O
may NN O O
receive NN O O
thrombolysis NN O O
or NN O O
pulmonary NN O O
embolectomy NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
The NN O O
following NN O O
serious NN O O
adverse NN O O
reactions NN O O
are NN O O
described NN O O
below NN O O
and NN O O
elsewhere NN O O
in NN O O
the NN O O
labeling NN O O
: NN O O
. NN O O
Anaphylaxis NN B-AdverseReaction B-AdverseReaction
and NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=10 NN O O
% NN O O
) NN O O
observed NN O O
across NN O O
pre NN O O
- NN O O
marketing NN O O
clinical NN O O
trials NN O O
were NN O O
similar NN O O
in NN O O
type NN O O
and NN O O
frequency NN O O
as NN O O
those NN O O
observed NN O O
in NN O O
the NN O O
placebo NN O O
- NN O O
controlled NN O O
trial NN O O
( NN O O
see NN O O
Table1 NN O O
) NN O O
. NN O O
The NN O O
acute NN O O
reactions NN O O
requiring NN O O
intervention NN O O
were NN O O
managed NN O O
by NN O O
either NN O O
temporarily NN O O
interrupting NN O O
or NN O O
discontinuing NN O O
infusion NN O O
, NN O O
and NN O O
administering NN O O
additional NN O O
antihistamine NN O O
, NN O O
antipyretics NN O O
, NN O O
or NN O O
corticosteroids NN O O
. NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=10 NN O O
% NN O O
in NN O O
Vimizim NN O O
patients NN O O
and NN O O
occurring NN O O
at NN O O
a NN O O
higher NN O O
incidence NN O O
than NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
) NN O O
were NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
chills NN B-AdverseReaction B-AdverseReaction
and NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
. NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
BioMarin NN O O
at NN O O
1 NN O O
- NN O O
866 NN O O
- NN O O
906 NN O O
- NN O O
6100 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
A NN O O
24-week NN O O
, NN O O
randomized NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
clinical NN O O
trial NN O O
of NN O O
Vimizim NN O O
was NN O O
conducted NN O O
in NN O O
176 NN O O
patients NN O O
with NN O O
MPS NN O O
IVA NN O O
, NN O O
ages NN O O
5 NN O O
to NN O O
57 NN O O
years NN O O
old NN O O
. NN O O
Approximately NN O O
half NN O O
of NN O O
the NN O O
patients NN O O
( NN O O
49 NN O O
% NN O O
) NN O O
were NN O O
male NN O O
. NN O O
Of NN O O
the NN O O
176 NN O O
patients NN O O
, NN O O
65 NN O O
% NN O O
were NN O O
White NN O O
, NN O O
23 NN O O
% NN O O
Asian NN O O
, NN O O
3 NN O O
% NN O O
Black NN O O
, NN O O
and NN O O
10 NN O O
% NN O O
Other NN O O
race NN O O
. NN O O
The NN O O
majority NN O O
of NN O O
patients NN O O
( NN O O
78 NN O O
% NN O O
) NN O O
were NN O O
non NN O O
- NN O O
Hispanic NN O O
. NN O O
Patients NN O O
were NN O O
randomized NN O O
to NN O O
three NN O O
treatment NN O O
groups NN O O
: NN O O
Vimizim NN O O
2 NN O O
mg/kg NN O O
once NN O O
per NN O O
week NN O O
( NN O O
n=58 NN O O
) NN O O
, NN O O
Vimizim NN O O
2 NN O O
mg/kg NN O O
once NN O O
every NN O O
other NN O O
week NN O O
( NN O O
n=59 NN O O
) NN O O
, NN O O
or NN O O
placebo NN O O
( NN O O
n=59 NN O O
) NN O O
. NN O O
All NN O O
patients NN O O
were NN O O
treated NN O O
with NN O O
antihistamines NN O O
prior NN O O
to NN O O
each NN O O
infusion NN O O
. NN O O
Table NN O O
1 NN O O
summarizes NN O O
the NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
that NN O O
occurred NN O O
in NN O O
the NN O O
placebo NN O O
- NN O O
controlled NN O O
trial NN O O
with NN O O
an NN O O
incidence NN O O
of NN O O
>= NN O O
10 NN O O
% NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
Vimizim NN O O
2 NN O O
mg/kg NN O O
once NN O O
per NN O O
week NN O O
and NN O O
with NN O O
a NN O O
higher NN O O
incidence NN O O
than NN O O
in NN O O
the NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Table NN O O
1 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
That NN O O
Occurred NN O O
in NN O O
the NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Trial NN O O
in NN O O
At NN O O
Least NN O O
10 NN O O
% NN O O
of NN O O
Patients NN O O
in NN O O
the NN O O
Vimizim NN O O
2 NN O O
mg/kg NN O O
Once NN O O
Per NN O O
Week NN O O
Group NN O O
and NN O O
with NN O O
a NN O O
Higher NN O O
Incidence NN O O
than NN O O
in NN O O
the NN O O
Placebo NN O O
Group NN O O
Adverse NN O O
Reaction NN O O
Vimizim NN O O
2 NN O O
mg/kg NN O O
once NN O O
per NN O O
week NN O O
Placebo NN O O
N= NN O O
58n NN O O
( NN O O
% NN O O
) NN O O
N= NN O O
59 NN O O
n NN O O
( NN O O
% NN O O
) NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
19 NN O O
( NN O O
33 NN O O
% NN O O
) NN O O
8 NN O O
( NN O O
14 NN O O
% NN O O
) NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
18 NN O O
( NN O O
31 NN O O
% NN O O
) NN O O
4 NN O O
( NN O O
7 NN O O
% NN O O
) NN O O
Headache NN B-AdverseReaction B-AdverseReaction
15 NN O O
( NN O O
26 NN O O
% NN O O
) NN O O
9 NN O O
( NN O O
15 NN O O
% NN O O
) NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
14 NN O O
( NN O O
24 NN O O
% NN O O
) NN O O
4 NN O O
( NN O O
7 NN O O
% NN O O
) NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
12 NN O O
( NN O O
21 NN O O
% NN O O
) NN O O
1 NN O O
( NN O O
1.7 NN O O
% NN O O
) NN O O
Chills NN B-AdverseReaction B-AdverseReaction
6 NN O O
( NN O O
10.3 NN O O
% NN O O
) NN O O
1 NN O O
( NN O O
1.7 NN O O
% NN O O
) NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
6 NN O O
( NN O O
10.3 NN O O
% NN O O
) NN O O
2 NN O O
( NN O O
3.4 NN O O
% NN O O
) NN O O
Extension NN O O
Trial NN O O
An NN O O
open NN O O
- NN O O
label NN O O
extension NN O O
trial NN O O
was NN O O
conducted NN O O
in NN O O
173 NN O O
patients NN O O
who NN O O
completed NN O O
the NN O O
placebo NN O O
- NN O O
controlled NN O O
trial NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
. NN O O
No NN O O
new NN O O
adverse NN O O
reactions NN O O
were NN O O
reported NN O O
. NN O O
6.2 NN O O
Immunogenicity NN O O
As NN O O
with NN O O
all NN O O
therapeutic NN O O
proteins NN O O
, NN O O
there NN O O
is NN O O
potential NN O O
for NN O O
immunogenicity NN O O
. NN O O
All NN O O
patients NN O O
treated NN O O
with NN O O
Vimizim NN O O
2 NN O O
mg/kg NN O O
once NN O O
per NN O O
week NN O O
in NN O O
the NN O O
placebo NN O O
- NN O O
controlled NN O O
trial NN O O
developed NN O O
anti NN O O
- NN O O
drug NN O O
antibodies NN O O
by NN O O
Week NN O O
4 NN O O
. NN O O
Anti NN O O
- NN O O
drug NN O O
antibody NN O O
titers NN O O
were NN O O
sustained NN O O
or NN O O
increased NN O O
for NN O O
the NN O O
duration NN O O
of NN O O
Vimizim NN O O
treatment NN O O
. NN O O
Because NN O O
all NN O O
patients NN O O
developed NN O O
anti NN O O
- NN O O
drug NN O O
antibodies NN O O
, NN O O
associations NN O O
between NN O O
antibody NN O O
titers NN O O
and NN O O
reductions NN O O
in NN O O
treatment NN O O
effect NN O O
or NN O O
the NN O O
occurrence NN O O
of NN O O
anaphylaxis NN O O
or NN O O
other NN O O
hypersensitivity NN O O
reactions NN O O
could NN O O
not NN O O
be NN O O
determined NN O O
. NN O O
All NN O O
patients NN O O
treated NN O O
with NN O O
Vimizim NN O O
2 NN O O
mg/kg NN O O
once NN O O
per NN O O
week NN O O
tested NN O O
positive NN O O
for NN O O
neutralizing NN O O
antibodies NN O O
capable NN O O
of NN O O
inhibiting NN O O
the NN O O
drug NN O O
from NN O O
binding NN O O
to NN O O
the NN O O
mannose-6-phosphate NN O O
receptor NN O O
at NN O O
least NN O O
once NN O O
during NN O O
the NN O O
trial NN O O
. NN O O
Binding NN O O
to NN O O
this NN O O
receptor NN O O
is NN O O
required NN O O
for NN O O
Vimizim NN O O
to NN O O
be NN O O
taken NN O O
into NN O O
cells NN O O
where NN O O
it NN O O
is NN O O
active NN O O
. NN O O
Neutralizing NN O O
antibody NN O O
titers NN O O
were NN O O
not NN O O
determined NN O O
in NN O O
the NN O O
patients NN O O
. NN O O
Therefore NN O O
, NN O O
the NN O O
possibility NN O O
of NN O O
an NN O O
association NN O O
between NN O O
neutralizing NN O O
antibody NN O O
titer NN O O
and NN O O
treatment NN O O
effect NN O O
can NN O O
not NN O O
be NN O O
assessed NN O O
. NN O O
Assessment NN O O
of NN O O
the NN O O
incidence NN O O
of NN O O
antibody NN O O
formation NN O O
is NN O O
highly NN O O
dependent NN O O
on NN O O
the NN O O
sensitivity NN O O
and NN O O
specificity NN O O
of NN O O
the NN O O
assay NN O O
. NN O O
Additionally NN O O
, NN O O
the NN O O
observed NN O O
incidence NN O O
of NN O O
antibody NN O O
( NN O O
including NN O O
neutralizing NN O O
antibody NN O O
) NN O O
positivity NN O O
in NN O O
an NN O O
assay NN O O
may NN O O
be NN O O
influenced NN O O
by NN O O
several NN O O
factors NN O O
including NN O O
assay NN O O
methodology NN O O
, NN O O
sample NN O O
handling NN O O
, NN O O
timing NN O O
of NN O O
sample NN O O
collection NN O O
, NN O O
concomitant NN O O
medications NN O O
, NN O O
and NN O O
underlying NN O O
disease NN O O
. NN O O
For NN O O
these NN O O
reasons NN O O
, NN O O
comparison NN O O
of NN O O
the NN O O
incidence NN O O
of NN O O
antibodies NN O O
to NN O O
Vimizim NN O O
with NN O O
the NN O O
incidence NN O O
of NN O O
antibodies NN O O
to NN O O
other NN O O
products NN O O
may NN O O
be NN O O
misleading NN O O
. NN O O
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
RISK NN B-Factor B-Factor
OF NN O O
ANAPHYLAXIS NN B-AdverseReaction B-AdverseReaction
WARNING NN O O
: NN O O
RISK NN B-Factor B-Factor
OF NN O O
ANAPHYLAXIS NN B-AdverseReaction B-AdverseReaction
Life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
anaphylactic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
have NN O O
occurred NN O O
in NN O O
some NN O O
patients NN O O
during NN O O
Vimizim NN O O
infusions NN O O
. NN O O
Anaphylaxis NN B-AdverseReaction B-AdverseReaction
presenting NN O O
as NN O O
cough NN B-AdverseReaction B-AdverseReaction
erythema NN B-AdverseReaction B-AdverseReaction
throat NN B-AdverseReaction B-AdverseReaction
tightness NN I-AdverseReaction I-AdverseReaction
urticaria NN B-AdverseReaction B-AdverseReaction
flushing NN B-AdverseReaction B-AdverseReaction
cyanosis NN B-AdverseReaction B-AdverseReaction
hypotension NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
dyspnea NN B-AdverseReaction B-AdverseReaction
chest NN B-AdverseReaction B-AdverseReaction
discomfort NN I-AdverseReaction I-AdverseReaction
and NN O O
gastrointestinal NN B-AdverseReaction B-AdverseReaction
symptoms NN I-AdverseReaction I-AdverseReaction
( NN O O
e.g. NN O O
, NN O O
nausea NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
retching NN B-AdverseReaction B-AdverseReaction
and NN O O
vomiting NN B-AdverseReaction B-AdverseReaction
in NN O O
conjunction NN O O
with NN O O
urticaria NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
to NN O O
occur NN O O
during NN O O
Vimizim NN O O
infusions NN O O
, NN O O
regardless NN O O
of NN O O
duration NN O O
of NN O O
the NN O O
course NN O O
of NN O O
treatment NN O O
. NN O O
Closely NN O O
observe NN O O
patients NN O O
during NN O O
and NN O O
after NN O O
Vimizim NN O O
administration NN O O
and NN O O
be NN O O
prepared NN O O
to NN O O
manage NN O O
anaphylaxis NN O O
. NN O O
Inform NN O O
patients NN O O
of NN O O
the NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
anaphylaxis NN O O
and NN O O
have NN O O
them NN O O
seek NN O O
immediate NN O O
medical NN O O
care NN O O
should NN O O
symptoms NN O O
occur NN O O
. NN O O
Patients NN O O
with NN O O
acute NN O O
respiratory NN O O
illness NN O O
may NN O O
be NN O O
at NN O O
risk NN O O
of NN O O
serious NN O O
acute NN O O
exacerbation NN O O
of NN O O
their NN O O
respiratory NN O O
compromise NN O O
due NN O O
to NN O O
hypersensitivity NN O O
reactions NN O O
, NN O O
and NN O O
require NN O O
additional NN O O
monitoring NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
, NN O O
5.2 NN O O
) NN O O
and NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
] NN O O
. NN O O
EXCERPT NN O O
: NN O O
WARNING NN O O
: NN O O
RISK NN B-Factor B-Factor
OF NN O O
ANAPHYLAXIS NN B-AdverseReaction B-AdverseReaction
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
. NN O O
Life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
anaphylactic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
have NN O O
occurred NN O O
in NN O O
some NN O O
patients NN O O
during NN O O
Vimizim NN O O
infusions NN O O
. NN O O
Anaphylaxis NN B-AdverseReaction B-AdverseReaction
presenting NN O O
as NN O O
cough NN B-AdverseReaction B-AdverseReaction
erythema NN B-AdverseReaction B-AdverseReaction
throat NN B-AdverseReaction B-AdverseReaction
tightness NN I-AdverseReaction I-AdverseReaction
urticaria NN B-AdverseReaction B-AdverseReaction
flushing NN B-AdverseReaction B-AdverseReaction
cyanosis NN B-AdverseReaction B-AdverseReaction
hypotension NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
dyspnea NN B-AdverseReaction B-AdverseReaction
chest NN B-AdverseReaction B-AdverseReaction
discomfort NN I-AdverseReaction I-AdverseReaction
and NN O O
gastrointestinal NN B-AdverseReaction B-AdverseReaction
symptoms NN I-AdverseReaction I-AdverseReaction
in NN O O
conjunction NN O O
with NN O O
urticaria NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
to NN O O
occur NN O O
during NN O O
infusions NN O O
, NN O O
regardless NN O O
of NN O O
duration NN O O
of NN O O
the NN O O
course NN O O
of NN O O
treatment NN O O
. NN O O
Closely NN O O
observe NN O O
patients NN O O
during NN O O
and NN O O
after NN O O
Vimizim NN O O
administration NN O O
and NN O O
be NN O O
prepared NN O O
to NN O O
manage NN O O
anaphylaxis NN O O
. NN O O
Inform NN O O
patients NN O O
of NN O O
the NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
anaphylaxis NN O O
and NN O O
have NN O O
them NN O O
seek NN O O
immediate NN O O
medical NN O O
care NN O O
should NN O O
symptoms NN O O
occur NN O O
. NN O O
Patients NN O O
with NN O O
acute NN O O
respiratory NN O O
illness NN O O
may NN O O
be NN O O
at NN O O
risk NN O O
of NN O O
serious NN O O
acute NN O O
exacerbation NN O O
of NN O O
their NN O O
respiratory NN O O
compromise NN O O
due NN O O
to NN O O
hypersensitivity NN O O
reactions NN O O
, NN O O
and NN O O
require NN O O
additional NN O O
monitoring NN O O
( NN O O
5.1 NN O O
, NN O O
5.2 NN O O
, NN O O
6 NN O O
) NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
. NN O O
Anaphylaxis NN B-AdverseReaction B-AdverseReaction
and NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
Life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
anaphylaxis NN B-AdverseReaction B-AdverseReaction
and NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN O O
have NN O O
been NN O O
observed NN O O
in NN O O
some NN O O
patients NN O O
during NN O O
treatment NN O O
with NN O O
Vimizim NN O O
. NN O O
If NN O O
anaphylaxis NN O O
or NN O O
severe NN O O
hypersensitivity NN O O
reactions NN O O
occur NN O O
, NN O O
immediately NN O O
stop NN O O
the NN O O
infusion NN O O
and NN O O
initiate NN O O
appropriate NN O O
medical NN O O
treatment NN O O
. NN O O
Pre NN O O
- NN O O
treatment NN O O
with NN O O
antihistamines NN O O
with NN O O
or NN O O
without NN O O
antipyretics NN O O
is NN O O
recommended NN O O
prior NN O O
to NN O O
the NN O O
start NN O O
of NN O O
infusion NN O O
( NN O O
5.1 NN O O
) NN O O
. NN O O
. NN O O
Risk NN B-Factor B-Factor
of NN O O
Acute NN B-AdverseReaction B-AdverseReaction
Respiratory NN I-AdverseReaction I-AdverseReaction
Complications NN I-AdverseReaction I-AdverseReaction
Patients NN O O
with NN O O
acute NN O O
febrile NN O O
or NN O O
respiratory NN O O
illness NN O O
may NN O O
be NN O O
at NN O O
higher NN O O
risk NN O O
of NN O O
life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
complications NN O O
from NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
Careful NN O O
consideration NN O O
should NN O O
be NN O O
given NN O O
to NN O O
the NN O O
patient NN O O
's NN O O
clinical NN O O
status NN O O
prior NN O O
to NN O O
administration NN O O
of NN O O
Vimizim NN O O
and NN O O
consider NN O O
delaying NN O O
the NN O O
Vimizim NN O O
infusion NN O O
( NN O O
5.2 NN O O
) NN O O
. NN O O
5.1 NN O O
Anaphylaxis NN O O
and NN O O
Hypersensitivity NN O O
Reactions NN O O
Anaphylaxis NN B-AdverseReaction B-AdverseReaction
and NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN O O
have NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
Vimizim NN O O
. NN O O
In NN O O
premarketing NN O O
clinical NN O O
trials NN O O
, NN O O
18 NN O O
of NN O O
235 NN O O
( NN O O
7.7 NN O O
% NN O O
) NN O O
patients NN O O
treated NN O O
with NN O O
Vimizim NN O O
experienced NN O O
signs NN O O
and NN O O
symptoms NN O O
consistent NN O O
with NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
These NN O O
18 NN O O
patients NN O O
experienced NN O O
26 NN O O
anaphylactic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
during NN O O
infusion NN O O
with NN O O
signs NN O O
and NN O O
symptoms NN O O
including NN O O
cough NN B-AdverseReaction B-AdverseReaction
erythema NN B-AdverseReaction B-AdverseReaction
throat NN B-AdverseReaction B-AdverseReaction
tightness NN I-AdverseReaction I-AdverseReaction
urticaria NN B-AdverseReaction B-AdverseReaction
flushing NN B-AdverseReaction B-AdverseReaction
cyanosis NN B-AdverseReaction B-AdverseReaction
hypotension NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
dyspnea NN B-AdverseReaction B-AdverseReaction
chest NN B-AdverseReaction B-AdverseReaction
discomfort NN I-AdverseReaction I-AdverseReaction
and NN O O
gastrointestinal NN B-AdverseReaction B-AdverseReaction
symptoms NN I-AdverseReaction I-AdverseReaction
( NN O O
e.g. NN O O
, NN O O
nausea NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
retching NN B-AdverseReaction B-AdverseReaction
and NN O O
vomiting NN B-AdverseReaction B-AdverseReaction
in NN O O
conjunction NN O O
with NN O O
urticaria NN B-AdverseReaction B-AdverseReaction
These NN O O
cases NN O O
of NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
occurred NN O O
as NN O O
early NN O O
as NN O O
30 NN O O
minutes NN O O
from NN O O
the NN O O
start NN O O
of NN O O
infusion NN O O
and NN O O
up NN O O
to NN O O
three NN O O
hours NN O O
after NN O O
infusion NN O O
. NN O O
Anaphylaxis NN B-AdverseReaction B-AdverseReaction
occurred NN O O
as NN O O
late NN O O
into NN O O
treatment NN O O
as NN O O
the NN O O
47 NN O O
th NN O O
infusion NN O O
. NN O O
In NN O O
clinical NN O O
trials NN O O
with NN O O
Vimizim NN O O
, NN O O
44 NN O O
of NN O O
235 NN O O
( NN O O
18.7 NN O O
% NN O O
) NN O O
patients NN O O
experienced NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN O O
, NN O O
including NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN O O
have NN O O
occurred NN O O
as NN O O
early NN O O
as NN O O
30 NN O O
minutes NN O O
from NN O O
the NN O O
start NN O O
of NN O O
infusion NN O O
but NN O O
as NN O O
late NN O O
as NN O O
six NN O O
days NN O O
after NN O O
infusion NN O O
. NN O O
Frequent NN O O
symptoms NN O O
of NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN O O
( NN O O
occurring NN O O
in NN O O
more NN O O
than NN O O
2 NN O O
patients NN O O
) NN O O
included NN O O
anaphylactic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
urticaria NN B-AdverseReaction B-AdverseReaction
peripheral NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
dyspnea NN B-AdverseReaction B-AdverseReaction
and NN O O
flushing NN B-AdverseReaction B-AdverseReaction
Due NN O O
to NN O O
the NN O O
potential NN O O
for NN O O
anaphylaxis NN O O
, NN O O
appropriate NN O O
medical NN O O
support NN O O
should NN O O
be NN O O
readily NN O O
available NN O O
when NN O O
Vimizim NN O O
is NN O O
administered NN O O
. NN O O
Observe NN O O
patients NN O O
closely NN O O
for NN O O
an NN O O
appropriate NN O O
period NN O O
of NN O O
time NN O O
after NN O O
administration NN O O
of NN O O
Vimizim NN O O
, NN O O
taking NN O O
into NN O O
account NN O O
the NN O O
time NN O O
to NN O O
onset NN O O
of NN O O
anaphylaxis NN O O
seen NN O O
in NN O O
premarketing NN O O
clinical NN O O
trials NN O O
. NN O O
Inform NN O O
patients NN O O
of NN O O
the NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
anaphylaxis NN O O
, NN O O
and NN O O
instruct NN O O
them NN O O
to NN O O
seek NN O O
immediate NN O O
medical NN O O
care NN O O
should NN O O
signs NN O O
and NN O O
symptoms NN O O
occur NN O O
. NN O O
Because NN O O
of NN O O
the NN O O
potential NN O O
for NN O O
hypersensitivity NN O O
reactions NN O O
, NN O O
administer NN O O
antihistamines NN O O
with NN O O
or NN O O
without NN O O
antipyretics NN O O
prior NN O O
to NN O O
infusion NN O O
. NN O O
Management NN O O
of NN O O
hypersensitivity NN O O
reactions NN O O
should NN O O
be NN O O
based NN O O
on NN O O
the NN O O
severity NN O O
of NN O O
the NN O O
reaction NN O O
and NN O O
include NN O O
slowing NN O O
or NN O O
temporary NN O O
interruption NN O O
of NN O O
the NN O O
infusion NN O O
and/or NN O O
administration NN O O
of NN O O
additional NN O O
antihistamines NN O O
, NN O O
antipyretics NN O O
, NN O O
and/or NN O O
corticosteroids NN O O
for NN O O
mild NN O O
reactions NN O O
. NN O O
However NN O O
, NN O O
if NN O O
severe NN O O
hypersensitivity NN O O
reactions NN O O
occur NN O O
, NN O O
immediately NN O O
stop NN O O
the NN O O
infusion NN O O
of NN O O
Vimizim NN O O
and NN O O
initiate NN O O
appropriate NN O O
treatment NN O O
. NN O O
Consider NN O O
the NN O O
risks NN O O
and NN O O
benefits NN O O
of NN O O
re NN O O
- NN O O
administering NN O O
Vimizim NN O O
following NN O O
a NN O O
severe NN O O
reaction NN O O
. NN O O
5.2 NN O O
Risk NN O O
of NN O O
Acute NN O O
Respiratory NN O O
Complications NN O O
Patients NN O O
with NN O O
acute NN O O
febrile NN O O
or NN O O
respiratory NN O O
illness NN O O
at NN O O
the NN O O
time NN O O
of NN O O
Vimizim NN O O
infusion NN O O
may NN O O
be NN O O
at NN O O
higher NN O O
risk NN B-Factor B-Factor
of NN O O
life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
complications NN O O
from NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
Careful NN O O
consideration NN O O
should NN O O
be NN O O
given NN O O
to NN O O
the NN O O
patient NN O O
's NN O O
clinical NN O O
status NN O O
prior NN O O
to NN O O
administration NN O O
of NN O O
Vimizim NN O O
and NN O O
consider NN O O
delaying NN O O
the NN O O
Vimizim NN O O
infusion NN O O
. NN O O
Sleep NN O O
apnea NN O O
is NN O O
common NN O O
in NN O O
MPS NN O O
IVA NN O O
patients NN O O
. NN O O
Evaluation NN O O
of NN O O
airway NN O O
patency NN O O
should NN O O
be NN O O
considered NN O O
prior NN O O
to NN O O
initiation NN O O
of NN O O
treatment NN O O
with NN O O
Vimizim NN O O
. NN O O
Patients NN O O
using NN O O
supplemental NN O O
oxygen NN O O
or NN O O
continuous NN O O
positive NN O O
airway NN O O
pressure NN O O
( NN O O
CPAP NN O O
) NN O O
during NN O O
sleep NN O O
should NN O O
have NN O O
these NN O O
treatments NN O O
readily NN O O
available NN O O
during NN O O
infusion NN O O
in NN O O
the NN O O
event NN O O
of NN O O
an NN O O
acute NN O O
reaction NN O O
, NN O O
or NN O O
extreme NN O O
drowsiness/sleep NN O O
induced NN O O
by NN O O
antihistamine NN O O
use NN O O
. NN O O
5.3 NN O O
Spinal NN O O
or NN O O
Cervical NN O O
Cord NN O O
Compression NN O O
Spinal NN O O
or NN O O
cervical NN O O
cord NN O O
compression NN O O
( NN O O
SCC NN O O
) NN O O
is NN O O
a NN O O
known NN O O
and NN O O
serious NN O O
complication NN O O
of NN O O
MPS NN O O
IVA NN O O
and NN O O
may NN O O
occur NN O O
as NN O O
part NN O O
of NN O O
the NN O O
natural NN O O
history NN O O
of NN O O
the NN O O
disease NN O O
. NN O O
In NN O O
clinical NN O O
trials NN O O
, NN O O
SCC NN O O
was NN O O
observed NN O O
both NN O O
in NN O O
patients NN O O
receiving NN O O
Vimizim NN O O
and NN O O
patients NN O O
receiving NN O O
placebo NN O O
. NN O O
Patients NN O O
with NN O O
MPS NN O O
IVA NN O O
should NN O O
be NN O O
monitored NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
SCC NN O O
( NN O O
including NN O O
back NN O O
pain NN O O
, NN O O
paralysis NN O O
of NN O O
limbs NN O O
below NN O O
the NN O O
level NN O O
of NN O O
compression NN O O
, NN O O
urinary NN O O
and NN O O
fecal NN O O
incontinence NN O O
) NN O O
and NN O O
given NN O O
appropriate NN O O
clinical NN O O
care NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
incidence NN O O
>1 NN O O
% NN O O
) NN O O
were NN O O
ingrown NN B-AdverseReaction B-AdverseReaction
toenails NN I-AdverseReaction I-AdverseReaction
application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
dermatitis NN I-AdverseReaction I-AdverseReaction
application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
vesicles NN I-AdverseReaction I-AdverseReaction
and NN O O
application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Valeant NN O O
Pharmaceuticals NN O O
North NN O O
America NN O O
LLC NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
321 NN O O
- NN O O
4576 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
In NN O O
two NN O O
clinical NN O O
trials NN O O
, NN O O
1227 NN O O
subjects NN O O
were NN O O
treated NN O O
with NN O O
JUBLIA NN O O
, NN O O
1161 NN O O
for NN O O
at NN O O
least NN O O
24 NN O O
weeks NN O O
and NN O O
780 NN O O
for NN O O
48 NN O O
weeks NN O O
. NN O O
Adverse NN O O
reactions NN O O
reported NN O O
within NN O O
48 NN O O
weeks NN O O
of NN O O
treatment NN O O
and NN O O
in NN O O
at NN O O
least NN O O
1 NN O O
% NN O O
of NN O O
subjects NN O O
treated NN O O
with NN O O
JUBLIA NN O O
and NN O O
those NN O O
reported NN O O
in NN O O
subjects NN O O
treated NN O O
with NN O O
the NN O O
vehicle NN O O
are NN O O
presented NN O O
in NN O O
Table NN O O
1 NN O O
. NN O O
Table NN O O
1 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Reported NN O O
by NN O O
at NN O O
Least NN O O
1 NN O O
% NN O O
of NN O O
Subjects NN O O
Treated NN O O
for NN O O
up NN O O
to NN O O
48 NN O O
Weeks NN O O
Adverse NN O O
Event NN O O
, NN O O
n NN O O
( NN O O
% NN O O
) NN O O
JUBLIAN NN O O
= NN O O
1227 NN O O
VehicleN NN O O
= NN O O
413 NN O O
Ingrown NN B-AdverseReaction B-AdverseReaction
toenail NN I-AdverseReaction I-AdverseReaction
28 NN O O
( NN O O
2.3 NN O O
% NN O O
) NN O O
3 NN O O
( NN O O
0.7 NN O O
% NN O O
) NN O O
Application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
dermatitis NN I-AdverseReaction I-AdverseReaction
27 NN O O
( NN O O
2.2 NN O O
% NN O O
) NN O O
1 NN O O
( NN O O
0.2 NN O O
% NN O O
) NN O O
Application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
vesicles NN I-AdverseReaction I-AdverseReaction
20 NN O O
( NN O O
1.6 NN O O
% NN O O
) NN O O
0 NN O O
( NN O O
0.0 NN O O
% NN O O
) NN O O
Application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
13 NN O O
( NN O O
1.1 NN O O
% NN O O
) NN O O
1 NN O O
( NN O O
0.2 NN O O
% NN O O
) NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
are NN O O
discussed NN O O
in NN O O
more NN O O
detail NN O O
in NN O O
other NN O O
sections NN O O
of NN O O
the NN O O
labeling NN O O
: NN O O
* NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
Hypokalemia NN B-AdverseReaction B-AdverseReaction
and NN O O
Fluid NN B-AdverseReaction B-AdverseReaction
Retention NN I-AdverseReaction I-AdverseReaction
due NN O O
to NN O O
Mineralocorticoid NN B-AdverseReaction B-AdverseReaction
Excess NN I-AdverseReaction I-AdverseReaction
[ NN O O
seeWarnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Adrenocortical NN B-AdverseReaction B-AdverseReaction
Insufficiency NN I-AdverseReaction I-AdverseReaction
[ NN O O
seeWarnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Hepatotoxicity NN B-AdverseReaction B-AdverseReaction
[ NN O O
seeWarnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
. NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=10 NN O O
% NN O O
) NN O O
are NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
joint NN B-AdverseReaction B-AdverseReaction
swelling NN I-AdverseReaction I-AdverseReaction
or NN O O
discomfort NN O O
, NN O O
edema NN B-AdverseReaction B-AdverseReaction
hot NN B-AdverseReaction B-AdverseReaction
flush NN I-AdverseReaction I-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
hypertension NN B-AdverseReaction B-AdverseReaction
dyspnea NN B-AdverseReaction B-AdverseReaction
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
and NN O O
contusion NN B-AdverseReaction B-AdverseReaction
The NN O O
most NN O O
common NN O O
laboratory NN O O
abnormalities NN O O
( NN O O
>20 NN O O
% NN O O
) NN O O
are NN O O
anemia NN B-AdverseReaction B-AdverseReaction
elevated NN B-AdverseReaction B-AdverseReaction
alkaline NN I-AdverseReaction I-AdverseReaction
phosphatase NN I-AdverseReaction I-AdverseReaction
hypertriglyceridemia NN B-AdverseReaction B-AdverseReaction
lymphopenia NN B-AdverseReaction B-AdverseReaction
hypercholesterolemia NN B-AdverseReaction B-AdverseReaction
hyperglycemia NN B-AdverseReaction B-AdverseReaction
elevated NN B-AdverseReaction B-AdverseReaction
AST NN I-AdverseReaction I-AdverseReaction
hypophosphatemia NN B-AdverseReaction B-AdverseReaction
elevated NN B-AdverseReaction B-AdverseReaction
ALT NN I-AdverseReaction I-AdverseReaction
and NN O O
hypokalemia NN B-AdverseReaction B-AdverseReaction
( NN O O
6 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Janssen NN O O
Biotech NN O O
, NN O O
Inc. NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
526 NN O O
- NN O O
7736 NN O O
( NN O O
1 NN O O
- NN O O
800-JANSSEN NN O O
) NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trial NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O
Two NN O O
randomized NN O O
placebo NN O O
- NN O O
controlled NN O O
, NN O O
multicenter NN O O
clinical NN O O
trials NN O O
enrolled NN O O
patients NN O O
who NN O O
had NN O O
metastatic NN O O
castration NN O O
- NN O O
resistant NN O O
prostate NN O O
cancer NN O O
who NN O O
were NN O O
using NN O O
a NN O O
gonadotropin NN O O
- NN O O
releasing NN O O
hormone NN O O
( NN O O
GnRH NN O O
) NN O O
agonist NN O O
or NN O O
were NN O O
previously NN O O
treated NN O O
with NN O O
orchiectomy NN O O
. NN O O
In NN O O
both NN O O
Study NN O O
1 NN O O
and NN O O
Study NN O O
2 NN O O
ZYTIGA NN O O
was NN O O
administered NN O O
at NN O O
a NN O O
dose NN O O
of NN O O
1,000 NN O O
mg NN O O
daily NN O O
in NN O O
combination NN O O
with NN O O
prednisone NN O O
5 NN O O
mg NN O O
twice NN O O
daily NN O O
in NN O O
the NN O O
active NN O O
treatment NN O O
arms NN O O
. NN O O
Placebo NN O O
plus NN O O
prednisone NN O O
5 NN O O
mg NN O O
twice NN O O
daily NN O O
was NN O O
given NN O O
to NN O O
control NN O O
patients NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
drug NN O O
reactions NN O O
( NN O O
>=10 NN O O
% NN O O
) NN O O
reported NN O O
in NN O O
the NN O O
two NN O O
randomized NN O O
clinical NN O O
trials NN O O
that NN O O
occurred NN O O
more NN O O
commonly NN O O
( NN O O
>2 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
abiraterone NN O O
acetate NN O O
arm NN O O
were NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
joint NN B-AdverseReaction B-AdverseReaction
swelling NN I-AdverseReaction I-AdverseReaction
or NN O O
discomfort NN O O
, NN O O
edema NN B-AdverseReaction B-AdverseReaction
hot NN B-AdverseReaction B-AdverseReaction
flush NN I-AdverseReaction I-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
hypertension NN B-AdverseReaction B-AdverseReaction
dyspnea NN B-AdverseReaction B-AdverseReaction
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
and NN O O
contusion NN B-AdverseReaction B-AdverseReaction
The NN O O
most NN O O
common NN O O
laboratory NN O O
abnormalities NN O O
( NN O O
>20 NN O O
% NN O O
) NN O O
reported NN O O
in NN O O
the NN O O
two NN O O
randomized NN O O
clinical NN O O
trials NN O O
that NN O O
occurred NN O O
more NN O O
commonly NN O O
( NN O O
>=2 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
abiraterone NN O O
acetate NN O O
arm NN O O
were NN O O
anemia NN B-AdverseReaction B-AdverseReaction
elevated NN B-AdverseReaction B-AdverseReaction
alkaline NN I-AdverseReaction I-AdverseReaction
phosphatase NN I-AdverseReaction I-AdverseReaction
hypertriglyceridemia NN B-AdverseReaction B-AdverseReaction
lymphopenia NN B-AdverseReaction B-AdverseReaction
hypercholesterolemia NN B-AdverseReaction B-AdverseReaction
hyperglycemia NN B-AdverseReaction B-AdverseReaction
elevated NN B-AdverseReaction B-AdverseReaction
AST NN I-AdverseReaction I-AdverseReaction
hypophosphatemia NN B-AdverseReaction B-AdverseReaction
elevated NN B-AdverseReaction B-AdverseReaction
ALT NN I-AdverseReaction I-AdverseReaction
and NN O O
hypokalemia NN B-AdverseReaction B-AdverseReaction
Study NN O O
1 NN O O
: NN O O
Metastatic NN O O
CRPC NN O O
Following NN O O
Chemotherapy NN O O
Study NN O O
1 NN O O
enrolled NN O O
1195 NN O O
patients NN O O
with NN O O
metastatic NN O O
CRPC NN O O
who NN O O
had NN O O
received NN O O
prior NN O O
docetaxel NN O O
chemotherapy NN O O
. NN O O
Patients NN O O
were NN O O
not NN O O
eligible NN O O
if NN O O
AST NN O O
and/or NN O O
ALT NN O O
>=2.5 NN O O
* NN O O
ULN NN O O
in NN O O
the NN O O
absence NN O O
of NN O O
liver NN O O
metastases NN O O
. NN O O
Patients NN O O
with NN O O
liver NN O O
metastases NN O O
were NN O O
excluded NN O O
if NN O O
AST NN O O
and/or NN O O
ALT NN O O
>5 NN O O
* NN O O
ULN. NN O O
Table NN O O
1 NN O O
shows NN O O
adverse NN O O
reactions NN O O
on NN O O
the NN O O
ZYTIGA NN O O
arm NN O O
in NN O O
Study NN O O
1 NN O O
that NN O O
occurred NN O O
with NN O O
a NN O O
>=2 NN O O
% NN O O
absolute NN O O
increase NN O O
in NN O O
frequency NN O O
compared NN O O
to NN O O
placebo NN O O
or NN O O
were NN O O
events NN O O
of NN O O
special NN O O
interest NN O O
. NN O O
The NN O O
median NN O O
duration NN O O
of NN O O
treatment NN O O
with NN O O
ZYTIGA NN O O
was NN O O
8 NN O O
months NN O O
. NN O O
Table NN O O
1 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
due NN O O
to NN O O
ZYTIGA NN O O
in NN O O
Study NN O O
1 NN O O
ZYTIGA NN O O
with NN O O
Prednisone(N=791 NN O O
) NN O O
Placebo NN O O
with NN O O
Prednisone(N=394 NN O O
) NN O O
System/Organ NN O O
Class NN O O
Adverse NN O O
reaction NN O O
All NN O O
Grades NN O O
% NN O O
Grade NN O O
3 NN O O
- NN O O
4 NN O O
% NN O O
All NN O O
Grades NN O O
% NN O O
Grade NN O O
3 NN O O
- NN O O
4 NN O O
% NN O O
Musculoskeletal NN O O
and NN O O
connective NN O O
tissue NN O O
disorders NN O O
Joint NN B-AdverseReaction B-AdverseReaction
swelling NN I-AdverseReaction I-AdverseReaction
29.5 NN O O
4.2 NN O O
23.4 NN O O
4.1 NN O O
Muscle NN B-AdverseReaction B-AdverseReaction
discomfort NN I-AdverseReaction I-AdverseReaction
26.2 NN O O
3.0 NN O O
23.1 NN O O
2.3 NN O O
General NN O O
disorders NN O O
Edema NN B-AdverseReaction B-AdverseReaction
26.7 NN O O
1.9 NN O O
18.3 NN O O
0.8 NN O O
Vascular NN O O
disorders NN O O
Hot NN B-AdverseReaction B-AdverseReaction
flush NN I-AdverseReaction I-AdverseReaction
19.0 NN O O
0.3 NN O O
16.8 NN O O
0.3 NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
8.5 NN O O
1.3 NN O O
6.9 NN O O
0.3 NN O O
Gastrointestinal NN O O
disorders NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
17.6 NN O O
0.6 NN O O
13.5 NN O O
1.3 NN O O
Dyspepsia NN B-AdverseReaction B-AdverseReaction
6.1 NN O O
0 NN O O
3.3 NN O O
0 NN O O
Infections NN O O
and NN O O
infestations NN O O
Urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
11.5 NN O O
2.1 NN O O
7.1 NN O O
0.5 NN O O
Upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
5.4 NN O O
0 NN O O
2.5 NN O O
0 NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
and NN O O
mediastinal NN O O
disorders NN O O
Cough NN B-AdverseReaction B-AdverseReaction
10.6 NN O O
0 NN O O
7.6 NN O O
0 NN O O
Renal NN O O
and NN O O
urinary NN O O
disorders NN O O
Urinary NN B-AdverseReaction B-AdverseReaction
frequency NN I-AdverseReaction I-AdverseReaction
7.2 NN O O
0.3 NN O O
5.1 NN O O
0.3 NN O O
Nocturia NN B-AdverseReaction B-AdverseReaction
6.2 NN O O
0 NN O O
4.1 NN O O
0 NN O O
Injury NN O O
, NN O O
poisoning NN O O
and NN O O
procedural NN O O
complications NN O O
Fractures NN B-AdverseReaction B-AdverseReaction
5.9 NN O O
1.4 NN O O
2.3 NN O O
0 NN O O
Cardiac NN O O
disorders NN O O
Arrhythmia NN B-AdverseReaction B-AdverseReaction
7.2 NN O O
1.1 NN O O
4.6 NN O O
1.0 NN O O
Chest NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
or NN O O
chest NN B-AdverseReaction B-AdverseReaction
discomfort NN I-AdverseReaction I-AdverseReaction
3.8 NN O O
0.5 NN O O
2.8 NN O O
0 NN O O
Cardiac NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
2.3 NN O O
1.9 NN O O
1.0 NN O O
0.3 NN O O
Table NN O O
2 NN O O
shows NN O O
laboratory NN O O
abnormalities NN O O
of NN O O
interest NN O O
from NN O O
Study NN O O
1 NN O O
. NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
- NN I-Severity I-Severity
4 NN I-Severity I-Severity
low NN B-AdverseReaction B-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
phosphorus NN I-AdverseReaction I-AdverseReaction
( NN O O
7 NN O O
% NN O O
) NN O O
and NN O O
low NN B-AdverseReaction B-AdverseReaction
potassium NN I-AdverseReaction I-AdverseReaction
( NN O O
5 NN O O
% NN O O
) NN O O
occurred NN O O
at NN O O
a NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
5 NN O O
% NN O O
rate NN O O
in NN O O
the NN O O
ZYTIGA NN O O
arm NN O O
. NN O O
Table NN O O
2 NN O O
: NN O O
Laboratory NN O O
Abnormalities NN O O
of NN O O
Interest NN O O
in NN O O
Study NN O O
1 NN O O
Abiraterone NN O O
( NN O O
N=791 NN O O
) NN O O
Placebo NN O O
( NN O O
N=394 NN O O
) NN O O
Laboratory NN O O
Abnormality NN O O
All NN O O
Grades NN O O
( NN O O
% NN O O
) NN O O
Grade NN O O
3 NN O O
- NN O O
4 NN O O
( NN O O
% NN O O
) NN O O
All NN O O
Grades NN O O
( NN O O
% NN O O
) NN O O
Grade NN O O
3 NN O O
- NN O O
4 NN O O
( NN O O
% NN O O
) NN O O
Hypertriglyceridemia NN B-AdverseReaction B-AdverseReaction
62.5 NN O O
0.4 NN O O
53.0 NN O O
0 NN O O
High NN B-AdverseReaction B-AdverseReaction
AST NN I-AdverseReaction I-AdverseReaction
30.6 NN O O
2.1 NN O O
36.3 NN O O
1.5 NN O O
Hypokalemia NN B-AdverseReaction B-AdverseReaction
28.3 NN O O
5.3 NN O O
19.8 NN O O
1.0 NN O O
Hypophosphatemia NN B-AdverseReaction B-AdverseReaction
23.8 NN O O
7.2 NN O O
15.7 NN O O
5.8 NN O O
High NN B-AdverseReaction B-AdverseReaction
ALT NN I-AdverseReaction I-AdverseReaction
11.1 NN O O
1.4 NN O O
10.4 NN O O
0.8 NN O O
High NN B-AdverseReaction B-AdverseReaction
Total NN I-AdverseReaction I-AdverseReaction
Bilirubin NN I-AdverseReaction I-AdverseReaction
6.6 NN O O
0.1 NN O O
4.6 NN O O
0 NN O O
Study NN O O
2 NN O O
: NN O O
Metastatic NN O O
CRPC NN O O
Prior NN O O
to NN O O
Chemotherapy NN O O
Study NN O O
2 NN O O
enrolled NN O O
1088 NN O O
patients NN O O
with NN O O
metastatic NN O O
CRPC NN O O
who NN O O
had NN O O
not NN O O
received NN O O
prior NN O O
cytotoxic NN O O
chemotherapy NN O O
. NN O O
Patients NN O O
were NN O O
ineligible NN O O
if NN O O
AST NN O O
and/or NN O O
ALT NN O O
>=2.5 NN O O
* NN O O
ULN NN O O
and NN O O
patients NN O O
were NN O O
excluded NN O O
if NN O O
they NN O O
had NN O O
liver NN O O
metastases NN O O
. NN O O
Table NN O O
3 NN O O
shows NN O O
adverse NN O O
reactions NN O O
on NN O O
the NN O O
ZYTIGA NN O O
arm NN O O
in NN O O
Study NN O O
2 NN O O
that NN O O
occurred NN O O
with NN O O
a NN O O
>=2 NN O O
% NN O O
absolute NN O O
increase NN O O
in NN O O
frequency NN O O
compared NN O O
to NN O O
placebo NN O O
. NN O O
The NN O O
median NN O O
duration NN O O
of NN O O
treatment NN O O
with NN O O
ZYTIGA NN O O
was NN O O
13.8 NN O O
months NN O O
. NN O O
Table NN O O
3 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
in NN O O
>=5 NN O O
% NN O O
of NN O O
Patients NN O O
on NN O O
the NN O O
ZYTIGA NN O O
Arm NN O O
in NN O O
Study NN O O
2 NN O O
ZYTIGA NN O O
with NN O O
Prednisone NN O O
( NN O O
N=542 NN O O
) NN O O
Placebo NN O O
with NN O O
Prednisone NN O O
( NN O O
N=540 NN O O
) NN O O
System/Organ NN O O
Class NN O O
Adverse NN O O
reaction NN O O
All NN O O
Grades NN O O
% NN O O
Grade NN O O
3 NN O O
- NN O O
4 NN O O
% NN O O
All NN O O
Grades NN O O
% NN O O
Grade NN O O
3 NN O O
- NN O O
4 NN O O
% NN O O
General NN O O
disorders NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
39.1 NN O O
2.2 NN O O
34.3 NN O O
1.7 NN O O
Edema NN B-AdverseReaction B-AdverseReaction
25.1 NN O O
0.4 NN O O
20.7 NN O O
1.1 NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
8.7 NN O O
0.6 NN O O
5.9 NN O O
0.2 NN O O
Musculoskeletal NN O O
and NN O O
connective NN O O
tissue NN O O
disorders NN O O
Joint NN B-AdverseReaction B-AdverseReaction
swelling NN I-AdverseReaction I-AdverseReaction
30.3 NN O O
2.0 NN O O
25.2 NN O O
2.0 NN O O
Groin NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
6.6 NN O O
0.4 NN O O
4.1 NN O O
0.7 NN O O
Gastrointestinal NN O O
disorders NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
23.1 NN O O
0.4 NN O O
19.1 NN O O
0.6 NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
21.6 NN O O
0.9 NN O O
17.8 NN O O
0.9 NN O O
Dyspepsia NN B-AdverseReaction B-AdverseReaction
11.1 NN O O
0.0 NN O O
5.0 NN O O
0.2 NN O O
Vascular NN O O
disorders NN O O
Hot NN B-AdverseReaction B-AdverseReaction
flush NN I-AdverseReaction I-AdverseReaction
22.3 NN O O
0.2 NN O O
18.1 NN O O
0.0 NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
21.6 NN O O
3.9 NN O O
13.1 NN O O
3.0 NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
and NN O O
mediastinal NN O O
disorders NN O O
Cough NN B-AdverseReaction B-AdverseReaction
17.3 NN O O
0.0 NN O O
13.5 NN O O
0.2 NN O O
Dyspnea NN B-AdverseReaction B-AdverseReaction
11.8 NN O O
2.4 NN O O
9.6 NN O O
0.9 NN O O
Psychiatric NN O O
disorders NN O O
Insomnia NN B-AdverseReaction B-AdverseReaction
13.5 NN O O
0.2 NN O O
11.3 NN O O
0.0 NN O O
Injury NN O O
, NN O O
poisoning NN O O
and NN O O
procedural NN O O
complications NN O O
Contusion NN B-AdverseReaction B-AdverseReaction
13.3 NN O O
0.0 NN O O
9.1 NN O O
0.0 NN O O
Falls NN B-AdverseReaction B-AdverseReaction
5.9 NN O O
0.0 NN O O
3.3 NN O O
0.0 NN O O
Infections NN O O
and NN O O
infestations NN O O
Upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
12.7 NN O O
0.0 NN O O
8.0 NN O O
0.0 NN O O
Nasopharyngitis NN B-AdverseReaction B-AdverseReaction
10.7 NN O O
0.0 NN O O
8.1 NN O O
0.0 NN O O
Renal NN O O
and NN O O
urinary NN O O
disorders NN O O
Hematuria NN B-AdverseReaction B-AdverseReaction
10.3 NN O O
1.3 NN O O
5.6 NN O O
0.6 NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
Rash NN B-AdverseReaction B-AdverseReaction
8.1 NN O O
0.0 NN O O
3.7 NN O O
0.0 NN O O
Table NN O O
4 NN O O
shows NN O O
laboratory NN O O
abnormalities NN O O
that NN O O
occurred NN O O
in NN O O
greater NN O O
than NN O O
15 NN O O
% NN O O
of NN O O
patients NN O O
, NN O O
and NN O O
more NN O O
frequently NN O O
( NN O O
>5 NN O O
% NN O O
) NN O O
in NN O O
the NN O O
ZYTIGA NN O O
arm NN O O
compared NN O O
to NN O O
placebo NN O O
in NN O O
Study NN O O
2 NN O O
. NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
- NN I-Severity I-Severity
4 NN I-Severity I-Severity
lymphopenia NN B-AdverseReaction B-AdverseReaction
( NN O O
9 NN O O
% NN O O
) NN O O
, NN O O
hyperglycemia NN B-AdverseReaction B-AdverseReaction
( NN O O
7 NN O O
% NN O O
) NN O O
and NN O O
high NN B-AdverseReaction B-AdverseReaction
alanine NN I-AdverseReaction I-AdverseReaction
aminotransferase NN I-AdverseReaction I-AdverseReaction
( NN O O
6 NN O O
% NN O O
) NN O O
occurred NN O O
at NN O O
a NN O O
greater NN O O
than NN O O
5 NN O O
% NN O O
rate NN O O
in NN O O
the NN O O
ZYTIGA NN O O
arm NN O O
. NN O O
Table NN O O
4 NN O O
: NN O O
Laboratory NN O O
Abnormalities NN O O
in NN O O
>15 NN O O
% NN O O
of NN O O
Patients NN O O
in NN O O
the NN O O
ZYTIGA NN O O
Arm NN O O
of NN O O
Study NN O O
2 NN O O
Abiraterone NN O O
( NN O O
N=542 NN O O
) NN O O
Placebo NN O O
( NN O O
N=540 NN O O
) NN O O
Laboratory NN O O
Abnormality NN O O
Grade NN O O
1 NN O O
- NN O O
4 NN O O
% NN O O
Grade NN O O
3 NN O O
- NN O O
4 NN O O
% NN O O
Grade NN O O
1 NN O O
- NN O O
4 NN O O
% NN O O
Grade NN O O
3 NN O O
- NN O O
4 NN O O
% NN O O
Hematology NN O O
Lymphopenia NN B-AdverseReaction B-AdverseReaction
38.2 NN O O
8.7 NN O O
31.7 NN O O
7.4 NN O O
Chemistry NN O O
Hyperglycemia NN B-AdverseReaction B-AdverseReaction
56.6 NN O O
6.5 NN O O
50.9 NN O O
5.2 NN O O
High NN B-AdverseReaction B-AdverseReaction
ALT NN I-AdverseReaction I-AdverseReaction
41.9 NN O O
6.1 NN O O
29.1 NN O O
0.7 NN O O
High NN B-AdverseReaction B-AdverseReaction
AST NN I-AdverseReaction I-AdverseReaction
37.3 NN O O
3.1 NN O O
28.7 NN O O
1.1 NN O O
Hypernatremia NN B-AdverseReaction B-AdverseReaction
32.8 NN O O
0.4 NN O O
25.0 NN O O
0.2 NN O O
Hypokalemia NN B-AdverseReaction B-AdverseReaction
17.2 NN O O
2.8 NN O O
10.2 NN O O
1.7 NN O O
Cardiovascular NN O O
Adverse NN O O
Reactions NN O O
: NN O O
In NN O O
the NN O O
combined NN O O
data NN O O
for NN O O
studies NN O O
1 NN O O
and NN O O
2 NN O O
, NN O O
cardiac NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
occurred NN O O
more NN O O
commonly NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
ZYTIGA NN O O
compared NN O O
to NN O O
patients NN O O
on NN O O
the NN O O
placebo NN O O
arm NN O O
( NN O O
2.1 NN O O
% NN O O
versus NN O O
0.7 NN O O
% NN O O
) NN O O
. NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
- NN I-Severity I-Severity
4 NN I-Severity I-Severity
cardiac NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
1.6 NN O O
% NN O O
of NN O O
patients NN O O
taking NN O O
ZYTIGA NN O O
and NN O O
led NN O O
to NN O O
5 NN O O
treatment NN O O
discontinuations NN O O
and NN O O
2 NN O O
deaths NN B-AdverseReaction B-AdverseReaction
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
- NN I-Severity I-Severity
4 NN I-Severity I-Severity
cardiac NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
0.2 NN O O
% NN O O
of NN O O
patients NN O O
taking NN O O
placebo NN B-Factor B-Factor
There NN O O
were NN O O
no NN O O
treatment NN O O
discontinuations NN O O
and NN O O
one NN O O
death NN B-AdverseReaction B-AdverseReaction
due NN O O
to NN O O
cardiac NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
in NN O O
the NN O O
placebo NN B-Factor B-Factor
group NN O O
. NN O O
In NN O O
Study NN O O
1 NN O O
and NN O O
2 NN O O
, NN O O
the NN O O
majority NN O O
of NN O O
arrhythmias NN B-AdverseReaction B-AdverseReaction
were NN O O
grade NN B-Severity B-Severity
1 NN I-Severity I-Severity
or NN O O
2 NN O O
. NN O O
There NN O O
was NN O O
one NN O O
death NN B-AdverseReaction B-AdverseReaction
associated NN O O
with NN O O
arrhythmia NN B-AdverseReaction B-AdverseReaction
and NN O O
one NN O O
patient NN O O
with NN O O
sudden NN B-AdverseReaction B-AdverseReaction
death NN I-AdverseReaction I-AdverseReaction
in NN O O
the NN O O
ZYTIGA NN O O
arms NN O O
and NN O O
no NN B-Negation B-Negation
deaths NN B-AdverseReaction B-AdverseReaction
in NN O O
the NN O O
placebo NN B-Factor B-Factor
arms NN O O
. NN O O
There NN O O
were NN O O
7 NN O O
( NN O O
0.5 NN O O
% NN O O
) NN O O
deaths NN B-AdverseReaction B-AdverseReaction
due NN O O
to NN O O
cardiorespiratory NN B-AdverseReaction B-AdverseReaction
arrest NN I-AdverseReaction I-AdverseReaction
in NN O O
the NN O O
ZYTIGA NN O O
arms NN O O
and NN O O
3 NN O O
( NN O O
0.3 NN O O
% NN O O
) NN O O
deaths NN B-AdverseReaction B-AdverseReaction
in NN O O
the NN O O
placebo NN B-Factor B-Factor
arms NN O O
. NN O O
Myocardial NN B-AdverseReaction B-AdverseReaction
ischemia NN I-AdverseReaction I-AdverseReaction
or NN O O
myocardial NN B-AdverseReaction B-AdverseReaction
infarction NN I-AdverseReaction I-AdverseReaction
led NN O O
to NN O O
death NN B-AdverseReaction B-AdverseReaction
in NN O O
3 NN O O
patients NN O O
in NN O O
the NN O O
placebo NN B-Factor B-Factor
arms NN O O
and NN O O
2 NN O O
deaths NN B-AdverseReaction B-AdverseReaction
in NN O O
the NN O O
ZYTIGA NN O O
arms NN O O
. NN O O
6.2 NN O O
Post NN O O
Marketing NN O O
Experience NN O O
The NN O O
following NN O O
additional NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
identified NN O O
during NN O O
post NN O O
approval NN O O
use NN O O
of NN O O
ZYTIGA. NN O O
Because NN O O
these NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
Respiratory NN O O
, NN O O
Thoracic NN O O
and NN O O
Mediastinal NN O O
Disorders NN O O
: NN O O
non NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
infectious NN I-AdverseReaction I-AdverseReaction
pneumonitis NN I-AdverseReaction I-AdverseReaction
Musculoskeletal NN O O
and NN O O
Connective NN O O
Tissue NN O O
Disorders NN O O
: NN O O
myopathy NN B-AdverseReaction B-AdverseReaction
including NN O O
rhabdomyolysis NN B-AdverseReaction B-AdverseReaction
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Mineralocorticoid NN B-AdverseReaction B-AdverseReaction
excess NN I-AdverseReaction I-AdverseReaction
Use NN O O
ZYTIGA NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
cardiovascular NN O O
disease NN O O
. NN O O
The NN O O
safety NN O O
of NN O O
ZYTIGA NN O O
in NN O O
patients NN O O
with NN O O
LVEF NN O O
< NN O O
50 NN O O
% NN O O
or NN O O
NYHA NN O O
Class NN O O
III NN O O
or NN O O
IV NN O O
heart NN O O
failure NN O O
in NN O O
Study NN O O
1 NN O O
or NN O O
LVEF NN O O
< NN O O
50 NN O O
% NN O O
or NN O O
NYHA NN O O
Class NN O O
II NN O O
to NN O O
IV NN O O
heart NN O O
failure NN O O
in NN O O
Study NN O O
2 NN O O
was NN O O
not NN O O
established NN O O
. NN O O
Control NN O O
hypertension NN O O
and NN O O
correct NN O O
hypokalemia NN O O
before NN O O
treatment NN O O
. NN O O
Monitor NN O O
blood NN O O
pressure NN O O
, NN O O
serum NN O O
potassium NN O O
and NN O O
symptoms NN O O
of NN O O
fluid NN O O
retention NN O O
at NN O O
least NN O O
monthly NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Adrenocortical NN B-AdverseReaction B-AdverseReaction
insufficiency NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
for NN O O
symptoms NN O O
and NN O O
signs NN O O
of NN O O
adrenocortical NN O O
insufficiency NN O O
. NN O O
Increased NN O O
dosage NN O O
of NN O O
corticosteroids NN O O
may NN O O
be NN O O
indicated NN O O
before NN O O
, NN O O
during NN O O
and NN O O
after NN O O
stressful NN O O
situations NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Hepatotoxicity NN B-AdverseReaction B-AdverseReaction
Increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
liver NN I-AdverseReaction I-AdverseReaction
enzymes NN I-AdverseReaction I-AdverseReaction
have NN O O
led NN O O
to NN O O
drug NN O O
interruption NN O O
, NN O O
dose NN O O
modification NN O O
and/or NN O O
discontinuation NN O O
. NN O O
Monitor NN O O
liver NN O O
function NN O O
and NN O O
modify NN O O
, NN O O
interrupt NN O O
, NN O O
or NN O O
discontinue NN O O
ZYTIGA NN O O
dosing NN O O
as NN O O
recommended NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
5.1 NN O O
Hypertension NN O O
, NN O O
Hypokalemia NN O O
and NN O O
Fluid NN O O
Retention NN O O
Due NN O O
to NN O O
Mineralocorticoid NN O O
Excess NN O O
ZYTIGA NN O O
may NN B-Factor B-Factor
cause NN O O
hypertension NN B-AdverseReaction B-AdverseReaction
hypokalemia NN B-AdverseReaction B-AdverseReaction
and NN O O
fluid NN B-AdverseReaction B-AdverseReaction
retention NN I-AdverseReaction I-AdverseReaction
as NN O O
a NN O O
consequence NN O O
of NN O O
increased NN B-AdverseReaction B-AdverseReaction
mineralocorticoid NN I-AdverseReaction I-AdverseReaction
levels NN I-AdverseReaction I-AdverseReaction
resulting NN O O
from NN O O
CYP17 NN O O
inhibition NN O O
[ NN O O
seeClinical NN O O
Pharmacology NN O O
( NN O O
12.1 NN O O
) NN O O
] NN O O
. NN O O
In NN O O
the NN O O
two NN O O
randomized NN O O
clinical NN O O
trials NN O O
, NN O O
grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
to NN I-Severity I-Severity
4 NN I-Severity I-Severity
hypertension NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
2 NN O O
% NN O O
of NN O O
patients NN O O
, NN O O
grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
to NN I-Severity I-Severity
4 NN I-Severity I-Severity
hypokalemia NN B-AdverseReaction B-AdverseReaction
in NN O O
4 NN O O
% NN O O
of NN O O
patients NN O O
, NN O O
and NN O O
grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
to NN I-Severity I-Severity
4 NN I-Severity I-Severity
edema NN B-AdverseReaction B-AdverseReaction
in NN O O
1 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
ZYTIGA NN O O
[ NN O O
seeAdverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
] NN O O
. NN O O
Co NN O O
- NN O O
administration NN O O
of NN O O
a NN O O
corticosteroid NN O O
suppresses NN O O
adrenocorticotropic NN O O
hormone NN O O
( NN O O
ACTH NN O O
) NN O O
drive NN O O
, NN O O
resulting NN O O
in NN O O
a NN O O
reduction NN O O
in NN O O
the NN O O
incidence NN O O
and NN O O
severity NN O O
of NN O O
these NN O O
adverse NN O O
reactions NN O O
. NN O O
Use NN O O
caution NN O O
when NN O O
treating NN O O
patients NN O O
whose NN O O
underlying NN O O
medical NN O O
conditions NN O O
might NN O O
be NN O O
compromised NN O O
by NN O O
increases NN O O
in NN O O
blood NN O O
pressure NN O O
, NN O O
hypokalemia NN O O
or NN O O
fluid NN O O
retention NN O O
, NN O O
e.g. NN O O
, NN O O
those NN O O
with NN O O
heart NN O O
failure NN O O
, NN O O
recent NN O O
myocardial NN O O
infarction NN O O
or NN O O
ventricular NN O O
arrhythmia NN O O
. NN O O
Use NN O O
ZYTIGA NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
cardiovascular NN O O
disease NN O O
. NN O O
The NN O O
safety NN O O
of NN O O
ZYTIGA NN O O
in NN O O
patients NN O O
with NN O O
left NN O O
ventricular NN O O
ejection NN O O
fraction NN O O
< NN O O
50 NN O O
% NN O O
or NN O O
New NN O O
York NN O O
Heart NN O O
Association NN O O
( NN O O
NYHA NN O O
) NN O O
Class NN O O
III NN O O
or NN O O
IV NN O O
heart NN O O
failure NN O O
( NN O O
in NN O O
Study NN O O
1 NN O O
) NN O O
or NN O O
NYHA NN O O
Class NN O O
II NN O O
to NN O O
IV NN O O
heart NN O O
failure NN O O
( NN O O
in NN O O
Study NN O O
2 NN O O
) NN O O
was NN O O
not NN O O
established NN O O
because NN O O
these NN O O
patients NN O O
were NN O O
excluded NN O O
from NN O O
these NN O O
randomized NN O O
clinical NN O O
trials NN O O
[ NN O O
seeClinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
. NN O O
Monitor NN O O
patients NN O O
for NN O O
hypertension NN O O
, NN O O
hypokalemia NN O O
, NN O O
and NN O O
fluid NN O O
retention NN O O
at NN O O
least NN O O
once NN O O
a NN O O
month NN O O
. NN O O
Control NN O O
hypertension NN O O
and NN O O
correct NN O O
hypokalemia NN O O
before NN O O
and NN O O
during NN O O
treatment NN O O
with NN O O
ZYTIGA. NN O O
5.2 NN O O
Adrenocortical NN O O
Insufficiency NN O O
Adrenal NN B-AdverseReaction B-AdverseReaction
insufficiency NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
the NN O O
two NN O O
randomized NN O O
clinical NN O O
studies NN O O
in NN O O
0.5 NN O O
% NN O O
of NN O O
patients NN O O
taking NN O O
ZYTIGA NN O O
and NN O O
in NN O O
0.2 NN O O
% NN O O
of NN O O
patients NN O O
taking NN O O
placebo NN O O
. NN O O
Adrenocortical NN B-AdverseReaction B-AdverseReaction
insufficiency NN I-AdverseReaction I-AdverseReaction
was NN O O
reported NN O O
in NN O O
patients NN O O
receiving NN O O
ZYTIGA NN O O
in NN O O
combination NN O O
with NN O O
prednisone NN O O
, NN O O
following NN O O
interruption NN O O
of NN O O
daily NN O O
steroids NN O O
and/or NN O O
with NN O O
concurrent NN O O
infection NN O O
or NN O O
stress NN O O
. NN O O
Use NN O O
caution NN O O
and NN O O
monitor NN O O
for NN O O
symptoms NN O O
and NN O O
signs NN O O
of NN O O
adrenocortical NN O O
insufficiency NN O O
, NN O O
particularly NN O O
if NN O O
patients NN O O
are NN O O
withdrawn NN O O
from NN O O
prednisone NN O O
, NN O O
have NN O O
prednisone NN O O
dose NN O O
reductions NN O O
, NN O O
or NN O O
experience NN O O
unusual NN O O
stress NN O O
. NN O O
Symptoms NN O O
and NN O O
signs NN O O
of NN O O
adrenocortical NN B-AdverseReaction B-AdverseReaction
insufficiency NN I-AdverseReaction I-AdverseReaction
may NN O O
be NN O O
masked NN O O
by NN O O
adverse NN O O
reactions NN O O
associated NN O O
with NN O O
mineralocorticoid NN B-AdverseReaction B-AdverseReaction
excess NN I-AdverseReaction I-AdverseReaction
seen NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
ZYTIGA. NN O O
If NN O O
clinically NN O O
indicated NN O O
, NN O O
perform NN O O
appropriate NN O O
tests NN O O
to NN O O
confirm NN O O
the NN O O
diagnosis NN O O
of NN O O
adrenocortical NN O O
insufficiency NN O O
. NN O O
Increased NN O O
dosage NN O O
of NN O O
corticosteroids NN O O
may NN O O
be NN O O
indicated NN O O
before NN O O
, NN O O
during NN O O
and NN O O
after NN O O
stressful NN O O
situations NN O O
[ NN O O
seeWarnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
5.3 NN O O
Hepatotoxicity NN O O
In NN O O
the NN O O
two NN O O
randomized NN O O
clinical NN O O
trials NN O O
, NN O O
grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
or NN O O
4 NN O O
ALT NN O O
or NN O O
AST NN B-AdverseReaction B-AdverseReaction
increases NN I-AdverseReaction I-AdverseReaction
( NN O O
at NN O O
least NN O O
5 NN O O
* NN O O
ULN NN O O
) NN O O
were NN O O
reported NN O O
in NN O O
4 NN O O
% NN O O
of NN O O
patients NN O O
who NN O O
received NN O O
ZYTIGA NN O O
, NN O O
typically NN O O
during NN O O
the NN O O
first NN O O
3 NN O O
months NN O O
after NN O O
starting NN O O
treatment NN O O
. NN O O
Patients NN O O
whose NN O O
baseline NN O O
ALT NN O O
or NN O O
AST NN O O
were NN O O
elevated NN O O
were NN O O
more NN O O
likely NN O O
to NN O O
experience NN O O
liver NN B-AdverseReaction B-AdverseReaction
test NN I-AdverseReaction I-AdverseReaction
elevation NN I-AdverseReaction I-AdverseReaction
than NN O O
those NN O O
beginning NN O O
with NN O O
normal NN O O
values NN O O
. NN O O
Treatment NN O O
discontinuation NN O O
due NN O O
to NN O O
liver NN B-AdverseReaction B-AdverseReaction
enzyme NN I-AdverseReaction I-AdverseReaction
increases NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
1 NN O O
% NN O O
of NN O O
patients NN O O
taking NN O O
ZYTIGA. NN O O
No NN B-Negation B-Negation
deaths NN B-AdverseReaction B-AdverseReaction
clearly NN O O
related NN O O
to NN O O
ZYTIGA NN O O
were NN O O
reported NN O O
due NN O O
to NN O O
hepatotoxicity NN B-AdverseReaction B-AdverseReaction
events NN O O
. NN O O
Measure NN O O
serum NN O O
transaminases NN O O
( NN O O
ALT NN O O
and NN O O
AST NN O O
) NN O O
and NN O O
bilirubin NN O O
levels NN O O
prior NN O O
to NN O O
starting NN O O
treatment NN O O
with NN O O
ZYTIGA NN O O
, NN O O
every NN O O
two NN O O
weeks NN O O
for NN O O
the NN O O
first NN O O
three NN O O
months NN O O
of NN O O
treatment NN O O
and NN O O
monthly NN O O
thereafter NN O O
. NN O O
In NN O O
patients NN O O
with NN O O
baseline NN O O
moderate NN O O
hepatic NN O O
impairment NN O O
receiving NN O O
a NN O O
reduced NN O O
ZYTIGA NN O O
dose NN O O
of NN O O
250 NN O O
mg NN O O
, NN O O
measure NN O O
ALT NN O O
, NN O O
AST NN O O
, NN O O
and NN O O
bilirubin NN O O
prior NN O O
to NN O O
the NN O O
start NN O O
of NN O O
treatment NN O O
, NN O O
every NN O O
week NN O O
for NN O O
the NN O O
first NN O O
month NN O O
, NN O O
every NN O O
two NN O O
weeks NN O O
for NN O O
the NN O O
following NN O O
two NN O O
months NN O O
of NN O O
treatment NN O O
and NN O O
monthly NN O O
thereafter NN O O
. NN O O
Promptly NN O O
measure NN O O
serum NN O O
total NN O O
bilirubin NN O O
, NN O O
AST NN O O
, NN O O
and NN O O
ALT NN O O
if NN O O
clinical NN O O
symptoms NN O O
or NN O O
signs NN O O
suggestive NN O O
of NN O O
hepatotoxicity NN O O
develop NN O O
. NN O O
Elevations NN O O
of NN O O
AST NN O O
, NN O O
ALT NN O O
, NN O O
or NN O O
bilirubin NN O O
from NN O O
the NN O O
patient NN O O
's NN O O
baseline NN O O
should NN O O
prompt NN O O
more NN O O
frequent NN O O
monitoring NN O O
. NN O O
If NN O O
at NN O O
any NN O O
time NN O O
AST NN O O
or NN O O
ALT NN O O
rise NN O O
above NN O O
five NN O O
times NN O O
the NN O O
ULN NN O O
, NN O O
or NN O O
the NN O O
bilirubin NN O O
rises NN O O
above NN O O
three NN O O
times NN O O
the NN O O
ULN NN O O
, NN O O
interrupt NN O O
ZYTIGA NN O O
treatment NN O O
and NN O O
closely NN O O
monitor NN O O
liver NN O O
function NN O O
. NN O O
Re NN O O
- NN O O
treatment NN O O
with NN O O
ZYTIGA NN O O
at NN O O
a NN O O
reduced NN O O
dose NN O O
level NN O O
may NN O O
take NN O O
place NN O O
only NN O O
after NN O O
return NN O O
of NN O O
liver NN O O
function NN O O
tests NN O O
to NN O O
the NN O O
patient NN O O
's NN O O
baseline NN O O
or NN O O
to NN O O
AST NN O O
and NN O O
ALT NN O O
less NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
2.5 NN O O
* NN O O
ULN NN O O
and NN O O
total NN O O
bilirubin NN O O
less NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
1.5 NN O O
* NN O O
ULN NN O O
[ NN O O
seeDosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
safety NN O O
of NN O O
ZYTIGA NN O O
re NN O O
- NN O O
treatment NN O O
of NN O O
patients NN O O
who NN O O
develop NN O O
AST NN O O
or NN O O
ALT NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
20 NN O O
* NN O O
ULN NN O O
and/or NN O O
bilirubin NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
10 NN O O
* NN O O
ULN NN O O
is NN O O
unknown NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
are NN O O
described NN O O
in NN O O
more NN O O
detail NN O O
in NN O O
the NN O O
Warnings NN O O
and NN O O
Precautions NN O O
section NN O O
of NN O O
the NN O O
label NN O O
: NN O O
* NN O O
Suicidal NN B-AdverseReaction B-AdverseReaction
Behavior NN I-AdverseReaction I-AdverseReaction
and NN O O
Ideation NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Serious NN B-Severity B-Severity
Dermatologic NN B-AdverseReaction B-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
Drug NN B-AdverseReaction B-AdverseReaction
Reaction NN I-AdverseReaction I-AdverseReaction
with NN I-AdverseReaction I-AdverseReaction
Eosinophilia NN I-AdverseReaction I-AdverseReaction
and NN I-AdverseReaction I-AdverseReaction
Systemic NN I-AdverseReaction I-AdverseReaction
Symptoms NN I-AdverseReaction I-AdverseReaction
( NN O O
DRESS)/Multiorgan NN O O
Hypersensitivity NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
* NN O O
Anaphylactic NN B-AdverseReaction B-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
and NN O O
Angioedema NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
* NN O O
Hyponatremia NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
* NN O O
Neurological NN B-AdverseReaction B-AdverseReaction
Adverse NN I-AdverseReaction I-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.6 NN O O
) NN O O
] NN O O
* NN O O
Drug NN B-AdverseReaction B-AdverseReaction
Induced NN I-AdverseReaction I-AdverseReaction
Liver NN I-AdverseReaction I-AdverseReaction
Injury NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.8 NN O O
) NN O O
] NN O O
* NN O O
Abnormal NN B-AdverseReaction B-AdverseReaction
Thyroid NN I-AdverseReaction I-AdverseReaction
Function NN I-AdverseReaction I-AdverseReaction
Tests NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.9 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
Most NN O O
common NN O O
adverse NN O O
reactions NN O O
in NN O O
patients NN O O
receiving NN O O
APTIOM NN O O
( NN O O
>=4 NN O O
% NN O O
and NN O O
>=2 NN O O
% NN O O
greater NN O O
than NN O O
placebo NN O O
) NN O O
: NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
somnolence NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
diplopia NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
vertigo NN B-AdverseReaction B-AdverseReaction
ataxia NN B-AdverseReaction B-AdverseReaction
blurred NN B-AdverseReaction B-AdverseReaction
vision NN I-AdverseReaction I-AdverseReaction
and NN O O
tremor NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Sunovion NN O O
at NN O O
1 NN O O
- NN O O
877 NN O O
- NN O O
737 NN O O
- NN O O
7226 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
In NN O O
monotherapy NN O O
trials NN O O
in NN O O
patients NN O O
with NN O O
partial NN O O
- NN O O
onset NN O O
seizures NN O O
[ NN O O
Study NN O O
1 NN O O
and NN O O
Study NN O O
2 NN O O
, NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14.1 NN O O
) NN O O
] NN O O
, NN O O
365 NN O O
patients NN O O
received NN O O
APTIOM NN O O
, NN O O
of NN O O
whom NN O O
225 NN O O
were NN O O
treated NN O O
for NN O O
longer NN O O
than NN O O
12 NN O O
months NN O O
and NN O O
134 NN O O
for NN O O
longer NN O O
than NN O O
24 NN O O
months NN O O
. NN O O
Of NN O O
the NN O O
patients NN O O
in NN O O
those NN O O
trials NN O O
, NN O O
95 NN O O
% NN O O
were NN O O
between NN O O
18 NN O O
and NN O O
65 NN O O
years NN O O
old NN O O
; NN O O
48 NN O O
% NN O O
were NN O O
male NN O O
, NN O O
and NN O O
84 NN O O
% NN O O
were NN O O
Caucasian NN O O
. NN O O
Across NN O O
controlled NN O O
and NN O O
uncontrolled NN O O
trials NN O O
in NN O O
patients NN O O
receiving NN O O
adjunctive NN O O
therapy NN O O
for NN O O
partial NN O O
- NN O O
onset NN O O
seizures NN O O
, NN O O
1195 NN O O
patients NN O O
received NN O O
APTIOM NN O O
, NN O O
of NN O O
whom NN O O
586 NN O O
were NN O O
treated NN O O
for NN O O
longer NN O O
than NN O O
6 NN O O
months NN O O
and NN O O
462 NN O O
for NN O O
longer NN O O
than NN O O
12 NN O O
months NN O O
. NN O O
In NN O O
the NN O O
placebo NN O O
controlled NN O O
adjunctive NN O O
therapy NN O O
trials NN O O
in NN O O
patients NN O O
with NN O O
partial NN O O
- NN O O
onset NN O O
seizures NN O O
( NN O O
Study NN O O
3 NN O O
, NN O O
Study NN O O
4 NN O O
and NN O O
Study NN O O
5 NN O O
) NN O O
, NN O O
1021 NN O O
patients NN O O
received NN O O
APTIOM. NN O O
Of NN O O
the NN O O
patients NN O O
in NN O O
those NN O O
trials NN O O
, NN O O
approximately NN O O
95 NN O O
% NN O O
were NN O O
between NN O O
18 NN O O
and NN O O
60 NN O O
years NN O O
old NN O O
, NN O O
approximately NN O O
50 NN O O
% NN O O
were NN O O
male NN O O
, NN O O
and NN O O
approximately NN O O
80 NN O O
% NN O O
were NN O O
Caucasian NN O O
. NN O O
Monotherapy NN O O
Historical NN O O
Control NN O O
Trials NN O O
In NN O O
the NN O O
monotherapy NN O O
epilepsy NN O O
trials NN O O
( NN O O
Study NN O O
1 NN O O
and NN O O
Study NN O O
2 NN O O
) NN O O
, NN O O
13 NN O O
% NN O O
of NN O O
patients NN O O
randomized NN O O
to NN O O
receive NN O O
APTIOM NN O O
at NN O O
the NN O O
recommended NN O O
doses NN O O
of NN O O
1200 NN O O
mg NN O O
and NN O O
1600 NN O O
mg NN O O
once NN O O
daily NN O O
discontinued NN O O
from NN O O
the NN O O
trials NN O O
as NN O O
a NN O O
result NN O O
of NN O O
an NN O O
adverse NN O O
event NN O O
. NN O O
The NN O O
adverse NN O O
reaction NN O O
most NN O O
commonly NN O O
( NN O O
>=1 NN O O
% NN O O
on NN O O
APTIOM NN O O
) NN O O
leading NN O O
to NN O O
discontinuation NN O O
was NN O O
hyponatremia NN B-AdverseReaction B-AdverseReaction
Adverse NN O O
reactions NN O O
observed NN O O
in NN O O
these NN O O
studies NN O O
were NN O O
generally NN O O
similar NN O O
to NN O O
those NN O O
observed NN O O
and NN O O
attributed NN O O
to NN O O
drug NN O O
in NN O O
adjunctive NN O O
placebo NN O O
- NN O O
controlled NN O O
studies NN O O
. NN O O
Because NN O O
these NN O O
studies NN O O
did NN O O
not NN O O
include NN O O
a NN O O
placebo NN O O
control NN O O
group NN O O
, NN O O
causality NN O O
could NN O O
not NN O O
be NN O O
established NN O O
. NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
somnolence NN B-AdverseReaction B-AdverseReaction
and NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
were NN O O
all NN O O
reported NN O O
at NN O O
lower NN O O
incidences NN O O
during NN O O
the NN O O
AED NN O O
Withdrawal NN O O
Phase NN O O
and NN O O
Monotherapy NN O O
Phase NN O O
compared NN O O
with NN O O
the NN O O
Titration NN O O
Phase NN O O
. NN O O
Adjunctive NN O O
Therapy NN O O
Controlled NN O O
Trials NN O O
In NN O O
the NN O O
controlled NN O O
adjunctive NN O O
therapy NN O O
epilepsy NN O O
trials NN O O
( NN O O
Study NN O O
3 NN O O
, NN O O
Study NN O O
4 NN O O
, NN O O
and NN O O
Study NN O O
5 NN O O
) NN O O
, NN O O
the NN O O
rate NN O O
of NN O O
discontinuation NN O O
as NN O O
a NN O O
result NN O O
of NN O O
any NN O O
adverse NN O O
reaction NN O O
was NN O O
14 NN O O
% NN O O
for NN O O
the NN O O
800 NN O O
mg NN O O
dose NN O O
, NN O O
25 NN O O
% NN O O
for NN O O
the NN O O
1200 NN O O
mg NN O O
dose NN O O
, NN O O
and NN O O
7 NN O O
% NN O O
in NN O O
subjects NN O O
randomized NN O O
to NN O O
placebo NN O O
. NN O O
The NN O O
adverse NN O O
reactions NN O O
most NN O O
commonly NN O O
( NN O O
>=1 NN O O
% NN O O
in NN O O
any NN O O
APTIOM NN O O
treatment NN O O
group NN O O
, NN O O
and NN O O
greater NN O O
than NN O O
placebo NN O O
) NN O O
leading NN O O
to NN O O
discontinuation NN O O
, NN O O
in NN O O
descending NN O O
order NN O O
of NN O O
frequency NN O O
, NN O O
were NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
ataxia NN B-AdverseReaction B-AdverseReaction
diplopia NN B-AdverseReaction B-AdverseReaction
somnolence NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
blurred NN B-AdverseReaction B-AdverseReaction
vision NN I-AdverseReaction I-AdverseReaction
vertigo NN B-AdverseReaction B-AdverseReaction
asthenia NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
dysarthria NN B-AdverseReaction B-AdverseReaction
and NN O O
tremor NN B-AdverseReaction B-AdverseReaction
The NN O O
most NN O O
frequently NN O O
reported NN O O
adverse NN O O
reactions NN O O
in NN O O
patients NN O O
receiving NN O O
APTIOM NN O O
at NN O O
doses NN O O
of NN O O
800 NN O O
mg NN O O
or NN O O
1200 NN O O
mg NN O O
( NN O O
>=4 NN O O
% NN O O
and NN O O
>=2 NN O O
% NN O O
greater NN O O
than NN O O
placebo NN O O
) NN O O
were NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
somnolence NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
diplopia NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
vertigo NN B-AdverseReaction B-AdverseReaction
ataxia NN B-AdverseReaction B-AdverseReaction
blurred NN B-AdverseReaction B-AdverseReaction
vision NN I-AdverseReaction I-AdverseReaction
and NN O O
tremor NN B-AdverseReaction B-AdverseReaction
Table NN O O
3 NN O O
gives NN O O
the NN O O
incidence NN O O
of NN O O
adverse NN O O
reactions NN O O
that NN O O
occurred NN O O
in NN O O
>=2 NN O O
% NN O O
of NN O O
subjects NN O O
with NN O O
partial NN O O
- NN O O
onset NN O O
seizures NN O O
in NN O O
any NN O O
APTIOM NN O O
treatment NN O O
group NN O O
and NN O O
for NN O O
which NN O O
the NN O O
incidence NN O O
was NN O O
greater NN O O
than NN O O
placebo NN O O
during NN O O
the NN O O
controlled NN O O
clinical NN O O
trials NN O O
. NN O O
Adverse NN O O
reactions NN O O
during NN O O
titration NN O O
were NN O O
less NN O O
frequent NN O O
for NN O O
patients NN O O
who NN O O
began NN O O
therapy NN O O
at NN O O
an NN O O
initial NN O O
dose NN O O
of NN O O
400 NN O O
mg NN O O
for NN O O
1 NN O O
week NN O O
and NN O O
then NN O O
increased NN O O
to NN O O
800 NN O O
mg NN O O
compared NN O O
to NN O O
patients NN O O
who NN O O
initiated NN O O
therapy NN O O
at NN O O
800 NN O O
mg NN O O
. NN O O
Table NN O O
3 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Incidence NN O O
in NN O O
Pooled NN O O
Controlled NN O O
Clinical NN O O
Trials NN O O
of NN O O
Adjunctive NN O O
Therapy NN O O
in NN O O
Adults NN O O
( NN O O
Events NN O O
>=2 NN O O
% NN O O
of NN O O
Patients NN O O
in NN O O
the NN O O
APTIOM NN O O
800 NN O O
mg NN O O
or NN O O
1200 NN O O
mg NN O O
Dose NN O O
Group NN O O
and NN O O
More NN O O
Frequent NN O O
Than NN O O
in NN O O
the NN O O
Placebo NN O O
Group NN O O
) NN O O
Placebo NN O O
APTIOM NN O O
800 NN O O
mg NN O O
1200 NN O O
mg NN O O
( NN O O
N=426 NN O O
) NN O O
% NN O O
( NN O O
N=415 NN O O
) NN O O
% NN O O
( NN O O
N=410 NN O O
) NN O O
% NN O O
Ear NN O O
and NN O O
labyrinth NN O O
disorders NN O O
Vertigo NN B-AdverseReaction B-AdverseReaction
< NN O O
1 NN O O
2 NN O O
6 NN O O
Eye NN O O
disorders NN O O
Diplopia NN B-AdverseReaction B-AdverseReaction
Blurred NN B-AdverseReaction B-AdverseReaction
vision NN I-AdverseReaction I-AdverseReaction
Visual NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
211 NN O O
962 NN O O
1151 NN O O
Gastrointestinal NN O O
disorders NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
Vomiting NN B-AdverseReaction B-AdverseReaction
Diarrhea NN B-AdverseReaction B-AdverseReaction
Constipation NN B-AdverseReaction B-AdverseReaction
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
Gastritis NN B-AdverseReaction B-AdverseReaction
53311<1 NN O O
1064222 NN O O
1610222<1 NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
Asthenia NN B-AdverseReaction B-AdverseReaction
Gait NN B-AdverseReaction B-AdverseReaction
disturbance NN I-AdverseReaction I-AdverseReaction
Peripheral NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
42<11 NN O O
4222 NN O O
7321 NN O O
Infections NN O O
and NN O O
Infestations NN O O
Urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
1 NN O O
2 NN O O
2 NN O O
Injury NN O O
, NN O O
poisoning NN O O
and NN O O
procedural NN O O
complications NN O O
Fall NN B-AdverseReaction B-AdverseReaction
1 NN O O
3 NN O O
1 NN O O
Metabolism NN O O
and NN O O
nutrition NN O O
disorders NN O O
Hyponatremia NN B-AdverseReaction B-AdverseReaction
< NN O O
1 NN O O
2 NN O O
2 NN O O
Nervous NN O O
system NN O O
disorders NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
Somnolence NN B-AdverseReaction B-AdverseReaction
Headache NN B-AdverseReaction B-AdverseReaction
Ataxia NN B-AdverseReaction B-AdverseReaction
Balance NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
Tremor NN B-AdverseReaction B-AdverseReaction
Dysarthria NN B-AdverseReaction B-AdverseReaction
Memory NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
Nystagmus NN B-AdverseReaction B-AdverseReaction
9892<110<1<1 NN O O
201113432111 NN O O
281815634222 NN O O
Psychiatric NN O O
disorders NN O O
Depression NN B-AdverseReaction B-AdverseReaction
Insomnia NN B-AdverseReaction B-AdverseReaction
21 NN O O
12 NN O O
32 NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
and NN O O
mediastinal NN O O
disorders NN O O
Cough NN B-AdverseReaction B-AdverseReaction
1 NN O O
2 NN O O
1 NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
Rash NN B-AdverseReaction B-AdverseReaction
1 NN O O
1 NN O O
3 NN O O
Vascular NN O O
disorders NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
1 NN O O
1 NN O O
2 NN O O
Other NN O O
Adverse NN O O
Reactions NN O O
with NN O O
APTIOM NN O O
Use NN O O
Compared NN O O
to NN O O
placebo NN O O
, NN O O
APTIOM NN O O
use NN O O
was NN O O
associated NN O O
with NN O O
slightly NN O O
higher NN O O
frequencies NN O O
of NN O O
decreases NN O O
in NN O O
hemoglobin NN O O
and NN O O
hematocrit NN O O
, NN O O
increases NN O O
in NN O O
total NN O O
cholesterol NN O O
, NN O O
triglycerides NN O O
, NN O O
and NN O O
LDL NN O O
, NN O O
and NN O O
increases NN O O
in NN O O
creatine NN O O
phosphokinase NN O O
. NN O O
Adverse NN O O
Reactions NN O O
Based NN O O
on NN O O
Gender NN O O
and NN O O
Race NN O O
No NN O O
significant NN O O
gender NN O O
differences NN O O
were NN O O
noted NN O O
in NN O O
the NN O O
incidence NN O O
of NN O O
adverse NN O O
reactions NN O O
. NN O O
Although NN O O
there NN O O
were NN O O
few NN O O
non NN O O
- NN O O
Caucasian NN O O
patients NN O O
, NN O O
no NN O O
differences NN O O
in NN O O
the NN O O
incidences NN O O
of NN O O
adverse NN O O
reactions NN O O
compared NN O O
to NN O O
Caucasian NN O O
patients NN O O
were NN O O
observed NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Suicidal NN B-AdverseReaction B-AdverseReaction
Behavior NN I-AdverseReaction I-AdverseReaction
and NN O O
Ideation NN O O
: NN O O
Monitor NN O O
for NN O O
suicidal NN O O
thoughts NN O O
or NN O O
behavior NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Serious NN B-Severity B-Severity
Dermatologic NN B-AdverseReaction B-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
Drug NN B-AdverseReaction B-AdverseReaction
Reaction NN I-AdverseReaction I-AdverseReaction
with NN I-AdverseReaction I-AdverseReaction
Eosinophilia NN I-AdverseReaction I-AdverseReaction
and NN I-AdverseReaction I-AdverseReaction
Systemic NN I-AdverseReaction I-AdverseReaction
Symptoms NN I-AdverseReaction I-AdverseReaction
( NN O O
DRESS NN O O
) NN O O
, NN O O
Anaphylactic NN B-AdverseReaction B-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
and NN O O
Angioedema NN B-AdverseReaction B-AdverseReaction
Monitor NN O O
and NN O O
discontinue NN O O
if NN O O
another NN O O
cause NN O O
can NN O O
not NN O O
be NN O O
established NN O O
. NN O O
( NN O O
5.2 NN O O
, NN O O
5.3 NN O O
, NN O O
5.4 NN O O
) NN O O
* NN O O
Hyponatremia NN B-AdverseReaction B-AdverseReaction
Monitor NN O O
sodium NN O O
levels NN O O
in NN O O
patients NN O O
at NN O O
risk NN O O
or NN O O
patients NN O O
experiencing NN O O
hyponatremia NN O O
symptoms NN O O
. NN O O
( NN O O
5.5 NN O O
) NN O O
* NN O O
Neurological NN B-AdverseReaction B-AdverseReaction
Adverse NN I-AdverseReaction I-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
for NN O O
dizziness NN O O
, NN O O
disturbance NN O O
in NN O O
gait NN O O
and NN O O
coordination NN O O
, NN O O
somnolence NN O O
, NN O O
fatigue NN O O
, NN O O
cognitive NN O O
dysfunction NN O O
, NN O O
and NN O O
visual NN O O
changes NN O O
. NN O O
Use NN O O
caution NN O O
when NN O O
driving NN O O
or NN O O
operating NN O O
machinery NN O O
. NN O O
( NN O O
5.6 NN O O
) NN O O
* NN O O
Withdrawal NN O O
of NN O O
APTIOM NN O O
: NN O O
Withdraw NN O O
APTIOM NN O O
gradually NN O O
to NN O O
minimize NN O O
the NN O O
risk NN O O
of NN O O
increased NN O O
seizure NN O O
frequency NN O O
and NN O O
status NN O O
epilepticus NN O O
. NN O O
( NN O O
2.6 NN O O
, NN O O
5.7 NN O O
) NN O O
* NN O O
Drug NN B-AdverseReaction B-AdverseReaction
Induced NN I-AdverseReaction I-AdverseReaction
Liver NN I-AdverseReaction I-AdverseReaction
Injury NN I-AdverseReaction I-AdverseReaction
Discontinue NN O O
APTIOM NN O O
in NN O O
patients NN O O
with NN O O
jaundice NN O O
or NN O O
evidence NN O O
of NN O O
significant NN O O
liver NN O O
injury NN O O
. NN O O
( NN O O
5.8 NN O O
) NN O O
5.1 NN O O
Suicidal NN O O
Behavior NN O O
and NN O O
Ideation NN O O
Antiepileptic NN O O
drugs NN O O
( NN O O
AEDs NN O O
) NN O O
, NN O O
including NN O O
APTIOM NN O O
, NN O O
increase NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
thoughts NN I-AdverseReaction I-AdverseReaction
or NN O O
behavior NN O O
in NN O O
patients NN O O
taking NN O O
these NN O O
drugs NN O O
for NN O O
any NN O O
indication NN O O
. NN O O
Patients NN O O
treated NN O O
with NN O O
any NN O O
AED NN O O
for NN O O
any NN O O
indication NN O O
should NN O O
be NN O O
monitored NN O O
for NN O O
the NN O O
emergence NN O O
or NN O O
worsening NN O O
of NN O O
depression NN O O
, NN O O
suicidal NN O O
thoughts NN O O
or NN O O
behavior NN O O
, NN O O
and/or NN O O
any NN O O
unusual NN O O
changes NN O O
in NN O O
mood NN O O
or NN O O
behavior NN O O
. NN O O
Pooled NN O O
analyses NN O O
of NN O O
199 NN O O
placebo NN O O
- NN O O
controlled NN O O
clinical NN O O
trials NN O O
( NN O O
mono- NN O O
and NN O O
adjunctive NN O O
therapy NN O O
) NN O O
of NN O O
11 NN O O
different NN O O
AEDs NN O O
showed NN O O
that NN O O
patients NN O O
randomized NN O O
to NN O O
one NN O O
of NN O O
the NN O O
AEDs NN O O
had NN O O
approximately NN O O
twice NN O O
the NN O O
risk NN O O
( NN O O
adjusted NN O O
Relative NN O O
Risk NN O O
1.8 NN O O
, NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
[ NN O O
CI NN O O
] NN O O
: NN O O
1.2 NN O O
, NN O O
2.7 NN O O
) NN O O
of NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
thinking NN I-AdverseReaction I-AdverseReaction
or NN O O
behavior NN O O
compared NN O O
to NN O O
patients NN O O
randomized NN O O
to NN O O
placebo NN O O
. NN O O
In NN O O
these NN O O
trials NN O O
, NN O O
which NN O O
had NN O O
a NN O O
median NN O O
treatment NN O O
duration NN O O
of NN O O
12 NN O O
weeks NN O O
, NN O O
the NN O O
estimated NN O O
incidence NN O O
of NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
behavior NN I-AdverseReaction I-AdverseReaction
or NN O O
ideation NN O O
among NN O O
27,863 NN O O
AED NN O O
- NN O O
treated NN O O
patients NN O O
was NN O O
0.43 NN O O
% NN O O
, NN O O
compared NN O O
to NN O O
0.24 NN O O
% NN O O
among NN O O
16,029 NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
, NN O O
representing NN O O
an NN O O
increase NN O O
of NN O O
approximately NN O O
one NN O O
case NN O O
of NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
thinking NN I-AdverseReaction I-AdverseReaction
or NN O O
behavior NN O O
for NN O O
every NN O O
530 NN O O
patients NN O O
treated NN O O
. NN O O
There NN O O
were NN O O
four NN O O
suicides NN B-AdverseReaction B-AdverseReaction
in NN O O
drug NN O O
- NN O O
treated NN O O
patients NN O O
in NN O O
the NN O O
trials NN O O
and NN O O
none NN O O
in NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
, NN O O
but NN O O
the NN O O
number NN B-Factor B-Factor
of NN I-Factor I-Factor
events NN I-Factor I-Factor
is NN I-Factor I-Factor
too NN I-Factor I-Factor
small NN I-Factor I-Factor
to NN I-Factor I-Factor
allow NN I-Factor I-Factor
any NN I-Factor I-Factor
conclusion NN I-Factor I-Factor
about NN O O
drug NN O O
effect NN O O
on NN O O
suicide NN B-AdverseReaction B-AdverseReaction
The NN O O
increased NN O O
risk NN B-Factor B-Factor
of NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
thoughts NN I-AdverseReaction I-AdverseReaction
or NN O O
behavior NN O O
with NN O O
AEDs NN O O
was NN O O
observed NN O O
as NN O O
early NN O O
as NN O O
one NN O O
week NN O O
after NN O O
starting NN O O
treatment NN O O
with NN O O
AEDs NN O O
and NN O O
persisted NN O O
for NN O O
the NN O O
duration NN O O
of NN O O
treatment NN O O
assessed NN O O
. NN O O
Because NN O O
most NN O O
trials NN O O
included NN O O
in NN O O
the NN O O
analysis NN O O
did NN O O
not NN O O
extend NN O O
beyond NN O O
24 NN O O
weeks NN O O
, NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
thoughts NN I-AdverseReaction I-AdverseReaction
or NN O O
behavior NN O O
beyond NN O O
24 NN O O
weeks NN O O
could NN O O
not NN O O
be NN O O
assessed NN O O
. NN O O
The NN O O
risk NN B-Factor B-Factor
of NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
thoughts NN I-AdverseReaction I-AdverseReaction
or NN O O
behavior NN O O
was NN O O
generally NN O O
consistent NN O O
among NN O O
drugs NN O O
in NN O O
the NN O O
data NN O O
analyzed NN O O
. NN O O
The NN O O
finding NN O O
of NN O O
increased NN O O
risk NN O O
with NN O O
AEDs NN O O
of NN O O
varying NN O O
mechanisms NN O O
of NN O O
action NN O O
and NN O O
across NN O O
a NN O O
range NN O O
of NN O O
indications NN O O
suggests NN O O
that NN O O
the NN O O
risk NN O O
applies NN O O
to NN O O
all NN O O
AEDs NN O O
used NN O O
for NN O O
any NN O O
indication NN O O
. NN O O
The NN O O
risk NN O O
did NN O O
not NN O O
vary NN O O
substantially NN O O
by NN O O
age NN O O
( NN O O
5 NN O O
- NN O O
100 NN O O
years NN O O
) NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
analyzed NN O O
. NN O O
Table NN O O
2 NN O O
shows NN O O
absolute NN O O
and NN O O
relative NN O O
risk NN O O
by NN O O
indication NN O O
for NN O O
all NN O O
evaluated NN O O
AEDs NN O O
. NN O O
Table NN O O
2 NN O O
: NN O O
Risk NN B-Factor B-Factor
of NN O O
Suicidal NN B-AdverseReaction B-AdverseReaction
Thoughts NN I-AdverseReaction I-AdverseReaction
or NN O O
Behaviors NN O O
by NN O O
Indication NN O O
for NN O O
Antiepileptic NN O O
Drugs NN O O
in NN O O
the NN O O
Pooled NN O O
Analysis NN O O
Indication NN O O
Placebo NN O O
Patients NN O O
with NN O O
Events NN O O
Per NN O O
1000 NN O O
Patients NN O O
Drug NN O O
Patients NN O O
with NN O O
Events NN O O
Per NN O O
1000 NN O O
Patients NN O O
Relative NN O O
Risk NN O O
: NN O O
Incidence NN O O
of NN O O
Events NN O O
in NN O O
Drug NN O O
Patients/Incidence NN O O
in NN O O
Placebo NN O O
Patients NN O O
Risk NN O O
Differences NN O O
: NN O O
Additional NN O O
Drug NN O O
Patients NN O O
with NN O O
Events NN O O
Per NN O O
1000 NN O O
Patients NN O O
Epilepsy NN O O
1.0 NN O O
3.4 NN O O
3.5 NN O O
2.4 NN O O
Psychiatric NN O O
5.7 NN O O
8.5 NN O O
1.5 NN O O
2.9 NN O O
Other NN O O
1.0 NN O O
1.8 NN O O
1.9 NN O O
0.9 NN O O
Total NN O O
2.4 NN O O
4.3 NN O O
1.8 NN O O
1.9 NN O O
The NN O O
relative NN O O
risk NN O O
for NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
thoughts NN I-AdverseReaction I-AdverseReaction
or NN O O
behavior NN O O
was NN O O
higher NN O O
in NN O O
clinical NN O O
trials NN O O
in NN O O
patients NN O O
with NN O O
epilepsy NN O O
than NN O O
in NN O O
clinical NN O O
trials NN O O
in NN O O
patients NN O O
with NN O O
psychiatric NN O O
or NN O O
other NN O O
conditions NN O O
, NN O O
but NN O O
the NN O O
absolute NN O O
risk NN O O
differences NN O O
were NN O O
similar NN O O
for NN O O
epilepsy NN O O
and NN O O
psychiatric NN O O
indications NN O O
. NN O O
Anyone NN O O
considering NN O O
prescribing NN O O
APTIOM NN O O
or NN O O
any NN O O
other NN O O
AED NN O O
must NN O O
balance NN O O
this NN O O
risk NN O O
with NN O O
the NN O O
risk NN O O
of NN O O
untreated NN O O
illness NN O O
. NN O O
Epilepsy NN O O
and NN O O
many NN O O
other NN O O
illnesses NN B-Negation B-Negation
for NN I-Negation I-Negation
which NN I-Negation I-Negation
AEDs NN I-Negation I-Negation
are NN I-Negation I-Negation
prescribed NN I-Negation I-Negation
are NN O O
themselves NN O O
associated NN O O
with NN O O
morbidity NN B-AdverseReaction B-AdverseReaction
and NN O O
mortality NN B-AdverseReaction B-AdverseReaction
and NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
thoughts NN I-AdverseReaction I-AdverseReaction
and NN O O
behavior NN O O
. NN O O
Should NN O O
suicidal NN O O
thoughts NN O O
and NN O O
behavior NN O O
emerge NN O O
during NN O O
treatment NN O O
, NN O O
the NN O O
prescriber NN O O
needs NN O O
to NN O O
consider NN O O
whether NN O O
the NN O O
emergence NN O O
of NN O O
these NN O O
symptoms NN O O
in NN O O
any NN O O
given NN O O
patient NN O O
may NN O O
be NN O O
related NN O O
to NN O O
the NN O O
illness NN O O
being NN O O
treated NN O O
. NN O O
Patients NN O O
, NN O O
their NN O O
caregivers NN O O
, NN O O
and NN O O
families NN O O
should NN O O
be NN O O
informed NN O O
that NN O O
AEDs NN O O
increase NN O O
the NN O O
risk NN O O
of NN O O
suicidal NN O O
thoughts NN O O
and NN O O
behavior NN O O
and NN O O
should NN O O
be NN O O
advised NN O O
of NN O O
the NN O O
need NN O O
to NN O O
be NN O O
alert NN O O
for NN O O
the NN O O
emergence NN O O
or NN O O
worsening NN O O
of NN O O
the NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
depression NN O O
; NN O O
any NN O O
unusual NN O O
changes NN O O
in NN O O
mood NN O O
or NN O O
behavior NN O O
; NN O O
or NN O O
the NN O O
emergence NN O O
of NN O O
suicidal NN O O
thoughts NN O O
, NN O O
behavior NN O O
, NN O O
or NN O O
thoughts NN O O
about NN O O
self NN O O
- NN O O
harm NN O O
. NN O O
Behaviors NN O O
of NN O O
concern NN O O
should NN O O
be NN O O
reported NN O O
immediately NN O O
to NN O O
healthcare NN O O
providers NN O O
. NN O O
5.2 NN O O
Serious NN O O
Dermatologic NN O O
Reactions NN O O
Serious NN O O
dermatologic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
Stevens NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Johnson NN I-AdverseReaction I-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
SJS NN O O
) NN O O
have NN O O
been NN O O
reported NN O O
in NN O O
association NN O O
with NN O O
APTIOM NN O O
use NN O O
. NN O O
Serious NN B-Severity B-Severity
and NN O O
sometimes NN O O
fatal NN B-AdverseReaction B-AdverseReaction
dermatologic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
toxic NN B-AdverseReaction B-AdverseReaction
epidermal NN I-AdverseReaction I-AdverseReaction
necrolysis NN I-AdverseReaction I-AdverseReaction
( NN O O
TEN NN O O
) NN O O
and NN O O
SJS NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
using NN O O
oxcarbazepine NN B-DrugClass B-DrugClass
or NN O O
carbamazepine NN O O
which NN O O
are NN O O
chemically NN O O
related NN O O
to NN O O
APTIOM. NN O O
The NN O O
reporting NN O O
rate NN O O
of NN O O
these NN O O
reactions NN O O
associated NN O O
with NN O O
oxcarbazepine NN O O
use NN O O
exceeds NN O O
the NN O O
background NN O O
incidence NN O O
rate NN O O
estimates NN O O
by NN O O
a NN O O
factor NN O O
of NN O O
3- NN O O
to NN O O
10-fold NN O O
. NN O O
Risk NN O O
factors NN O O
for NN O O
development NN O O
of NN O O
serious NN B-Severity B-Severity
dermatologic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
with NN O O
APTIOM NN O O
use NN O O
have NN O O
not NN B-Negation B-Negation
been NN O O
identified NN O O
. NN O O
If NN O O
a NN O O
patient NN O O
develops NN O O
a NN O O
dermatologic NN O O
reaction NN O O
while NN O O
taking NN O O
APTIOM NN O O
, NN O O
discontinue NN O O
APTIOM NN O O
use NN O O
, NN O O
unless NN O O
the NN O O
reaction NN O O
is NN O O
clearly NN O O
not NN O O
drug NN O O
- NN O O
related NN O O
. NN O O
Patients NN O O
with NN O O
a NN O O
prior NN O O
dermatologic NN O O
reaction NN O O
with NN O O
either NN O O
oxcarbazepine NN O O
or NN O O
APTIOM NN O O
should NN O O
not NN O O
be NN O O
treated NN O O
with NN O O
APTIOM NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
] NN O O
. NN O O
5.3 NN O O
Drug NN O O
Reaction NN O O
with NN O O
Eosinophilia NN O O
and NN O O
Systemic NN O O
Symptoms NN O O
( NN O O
DRESS)/Multiorgan NN O O
Hypersensitivity NN O O
Drug NN B-AdverseReaction B-AdverseReaction
Reaction NN I-AdverseReaction I-AdverseReaction
with NN I-AdverseReaction I-AdverseReaction
Eosinophilia NN I-AdverseReaction I-AdverseReaction
and NN I-AdverseReaction I-AdverseReaction
Systemic NN I-AdverseReaction I-AdverseReaction
Symptoms NN I-AdverseReaction I-AdverseReaction
( NN O O
DRESS NN O O
) NN O O
, NN O O
also NN O O
known NN O O
as NN O O
Multiorgan NN B-AdverseReaction B-AdverseReaction
Hypersensitivity NN I-AdverseReaction I-AdverseReaction
has NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
taking NN O O
APTIOM. NN O O
DRESS NN B-AdverseReaction B-AdverseReaction
may NN O O
be NN O O
fatal NN B-AdverseReaction B-AdverseReaction
or NN O O
life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
DRESS NN B-AdverseReaction B-AdverseReaction
typically NN O O
, NN O O
although NN O O
not NN O O
exclusively NN O O
, NN O O
presents NN O O
with NN O O
fever NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
and/or NN O O
lymphadenopathy NN B-AdverseReaction B-AdverseReaction
in NN O O
association NN O O
with NN O O
other NN O O
organ NN O O
system NN O O
involvement NN O O
, NN O O
such NN O O
as NN O O
hepatitis NN B-AdverseReaction B-AdverseReaction
nephritis NN B-AdverseReaction B-AdverseReaction
hematological NN B-AdverseReaction B-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
myocarditis NN B-AdverseReaction B-AdverseReaction
or NN O O
myositis NN B-AdverseReaction B-AdverseReaction
sometimes NN O O
resembling NN O O
an NN O O
acute NN O O
viral NN O O
infection NN O O
. NN O O
Eosinophilia NN B-AdverseReaction B-AdverseReaction
is NN O O
often NN O O
present NN O O
. NN O O
Because NN O O
this NN O O
disorder NN O O
is NN O O
variable NN O O
in NN O O
its NN O O
expression NN O O
, NN O O
other NN O O
organ NN O O
systems NN O O
not NN O O
noted NN O O
here NN O O
may NN O O
be NN O O
involved NN O O
. NN O O
It NN O O
is NN O O
important NN O O
to NN O O
note NN O O
that NN O O
early NN O O
manifestations NN O O
of NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
such NN O O
as NN O O
fever NN B-AdverseReaction B-AdverseReaction
or NN O O
lymphadenopathy NN B-AdverseReaction B-AdverseReaction
may NN O O
be NN O O
present NN O O
even NN O O
though NN O O
rash NN B-AdverseReaction B-AdverseReaction
is NN O O
not NN B-Negation B-Negation
evident NN I-Negation I-Negation
If NN O O
such NN O O
signs NN O O
or NN O O
symptoms NN O O
are NN O O
present NN O O
, NN O O
the NN O O
patient NN O O
should NN O O
be NN O O
evaluated NN O O
immediately NN O O
. NN O O
APTIOM NN O O
should NN O O
be NN O O
discontinued NN O O
and NN O O
not NN O O
be NN O O
resumed NN O O
if NN O O
an NN O O
alternative NN O O
etiology NN O O
for NN O O
the NN O O
signs NN O O
or NN O O
symptoms NN O O
can NN O O
not NN O O
be NN O O
established NN O O
. NN O O
Patients NN O O
with NN O O
a NN O O
prior NN O O
DRESS NN O O
reaction NN O O
with NN O O
either NN O O
oxcarbazepine NN O O
or NN O O
APTIOM NN O O
should NN O O
not NN O O
be NN O O
treated NN O O
with NN O O
APTIOM NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
] NN O O
. NN O O
5.4 NN O O
Anaphylactic NN O O
Reactions NN O O
and NN O O
Angioedema NN O O
Rare NN O O
cases NN O O
of NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
and NN O O
angioedema NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
taking NN O O
APTIOM. NN O O
Anaphylaxis NN B-AdverseReaction B-AdverseReaction
and NN O O
angioedema NN B-AdverseReaction B-AdverseReaction
associated NN O O
with NN O O
laryngeal NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
can NN B-Factor B-Factor
be NN O O
fatal NN B-AdverseReaction B-AdverseReaction
If NN O O
a NN O O
patient NN O O
develops NN O O
any NN O O
of NN O O
these NN O O
reactions NN O O
after NN O O
treatment NN O O
with NN O O
APTIOM NN O O
, NN O O
the NN O O
drug NN O O
should NN O O
be NN O O
discontinued NN O O
. NN O O
Patients NN O O
with NN O O
a NN O O
prior NN O O
anaphylactic NN O O
- NN O O
type NN O O
reaction NN O O
with NN O O
either NN O O
oxcarbazepine NN O O
or NN O O
APTIOM NN O O
should NN O O
not NN O O
be NN O O
treated NN O O
with NN O O
APTIOM NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
] NN O O
. NN O O
5.5 NN O O
Hyponatremia NN O O
Clinically NN O O
significant NN O O
hyponatremia NN B-AdverseReaction B-AdverseReaction
( NN O O
sodium NN O O
< NN O O
125 NN O O
mEq/L NN O O
) NN O O
can NN O O
develop NN O O
in NN O O
patients NN O O
taking NN O O
APTIOM. NN O O
In NN O O
the NN O O
controlled NN O O
adjunctive NN O O
epilepsy NN O O
trials NN O O
, NN O O
4/415 NN O O
patients NN O O
( NN O O
1.0 NN O O
% NN O O
) NN O O
treated NN O O
with NN O O
800 NN O O
mg NN O O
and NN O O
6/410 NN O O
( NN O O
1.5 NN O O
% NN O O
) NN O O
patients NN O O
treated NN O O
with NN O O
1200 NN O O
mg NN O O
of NN O O
APTIOM NN O O
had NN O O
at NN O O
least NN O O
one NN O O
serum NN O O
sodium NN O O
value NN O O
less NN O O
than NN O O
125 NN O O
mEq/L NN O O
, NN O O
compared NN O O
to NN O O
none NN O O
of NN O O
the NN O O
patients NN O O
assigned NN O O
to NN O O
placebo NN O O
. NN O O
A NN O O
higher NN O O
percentage NN O O
of NN O O
APTIOM NN O O
- NN O O
treated NN O O
patients NN O O
( NN O O
5.1 NN O O
% NN O O
) NN O O
than NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
( NN O O
0.7 NN O O
% NN O O
) NN O O
experienced NN O O
decreases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
sodium NN I-AdverseReaction I-AdverseReaction
values NN I-AdverseReaction I-AdverseReaction
of NN O O
more NN O O
than NN O O
10 NN B-Severity B-Severity
mEq/L NN I-Severity I-Severity
These NN O O
effects NN O O
were NN O O
dose NN O O
- NN O O
related NN O O
and NN O O
generally NN O O
appeared NN O O
within NN O O
the NN O O
first NN O O
8 NN O O
weeks NN O O
of NN O O
treatment NN O O
( NN O O
as NN O O
early NN O O
as NN O O
after NN O O
3 NN O O
days NN O O
) NN O O
. NN O O
Serious NN O O
, NN O O
life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
complications NN O O
were NN O O
reported NN O O
with NN O O
APTIOM NN O O
- NN O O
associated NN O O
hyponatremia NN B-AdverseReaction B-AdverseReaction
( NN O O
as NN O O
low NN O O
as NN O O
112 NN B-Severity B-Severity
mEq/L NN I-Severity I-Severity
including NN O O
seizures NN B-AdverseReaction B-AdverseReaction
severe NN B-Severity B-Severity
nausea NN B-AdverseReaction B-AdverseReaction
leading NN O O
to NN O O
dehydration NN B-AdverseReaction B-AdverseReaction
severe NN B-Severity B-Severity
gait NN B-AdverseReaction B-AdverseReaction
instability NN I-AdverseReaction I-AdverseReaction
and NN O O
injury NN B-AdverseReaction B-AdverseReaction
Some NN O O
patients NN O O
required NN O O
hospitalization NN O O
and NN O O
discontinuation NN O O
of NN O O
APTIOM. NN O O
Concurrent NN O O
hypochloremia NN B-AdverseReaction B-AdverseReaction
was NN O O
also NN O O
present NN O O
in NN O O
patients NN O O
with NN O O
hyponatremia NN B-AdverseReaction B-AdverseReaction
Depending NN O O
on NN O O
the NN O O
severity NN O O
of NN O O
hyponatremia NN O O
, NN O O
the NN O O
dose NN O O
of NN O O
APTIOM NN O O
may NN O O
need NN O O
to NN O O
be NN O O
reduced NN O O
or NN O O
discontinued NN O O
. NN O O
Hyponatremia NN B-AdverseReaction B-AdverseReaction
was NN O O
also NN O O
observed NN O O
in NN O O
monotherapy NN O O
trials NN O O
. NN O O
Measurement NN O O
of NN O O
serum NN O O
sodium NN O O
and NN O O
chloride NN O O
levels NN O O
should NN O O
be NN O O
considered NN O O
during NN O O
maintenance NN O O
treatment NN O O
with NN O O
APTIOM NN O O
, NN O O
particularly NN O O
if NN O O
the NN O O
patient NN O O
is NN O O
receiving NN O O
other NN O O
medications NN O O
known NN O O
to NN O O
decrease NN O O
serum NN O O
sodium NN O O
levels NN O O
and NN O O
should NN O O
be NN O O
performed NN O O
if NN O O
symptoms NN O O
of NN O O
hyponatremia NN O O
develop NN O O
( NN O O
e.g. NN O O
, NN O O
nausea/vomiting NN O O
, NN O O
malaise NN O O
, NN O O
headache NN O O
, NN O O
lethargy NN O O
, NN O O
confusion NN O O
, NN O O
irritability NN O O
, NN O O
muscle NN O O
weakness/spasms NN O O
, NN O O
obtundation NN O O
, NN O O
or NN O O
increase NN O O
in NN O O
seizure NN O O
frequency NN O O
or NN O O
severity NN O O
) NN O O
. NN O O
5.6 NN O O
Neurological NN O O
Adverse NN O O
Reactions NN O O
Dizziness NN O O
and NN O O
Disturbance NN O O
in NN O O
Gait NN O O
and NN O O
Coordination NN O O
APTIOM NN O O
causes NN O O
dose NN O O
- NN O O
related NN O O
increases NN O O
in NN O O
adverse NN O O
reactions NN O O
related NN O O
to NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
and NN O O
disturbance NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
gait NN I-AdverseReaction I-AdverseReaction
and NN O O
coordination NN O O
( NN O O
dizziness NN O O
, NN O O
ataxia NN B-AdverseReaction B-AdverseReaction
vertigo NN B-AdverseReaction B-AdverseReaction
balance NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
gait NN B-AdverseReaction B-AdverseReaction
disturbance NN I-AdverseReaction I-AdverseReaction
nystagmus NN B-AdverseReaction B-AdverseReaction
and NN O O
abnormal NN B-AdverseReaction B-AdverseReaction
coordination NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
In NN O O
controlled NN O O
adjunctive NN O O
epilepsy NN O O
trials NN O O
, NN O O
these NN O O
events NN O O
were NN O O
reported NN O O
in NN O O
26 NN O O
% NN O O
and NN O O
38 NN O O
% NN O O
of NN O O
patients NN O O
randomized NN O O
to NN O O
receive NN O O
APTIOM NN O O
at NN O O
doses NN O O
of NN O O
800 NN O O
mg NN O O
and NN O O
1200 NN O O
mg/day NN O O
, NN O O
respectively NN O O
, NN O O
compared NN O O
to NN O O
12 NN O O
% NN O O
of NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Events NN O O
related NN O O
to NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
and NN O O
disturbance NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
gait NN I-AdverseReaction I-AdverseReaction
and NN O O
coordination NN O O
were NN O O
more NN O O
often NN O O
serious NN O O
in NN O O
APTIOM NN O O
- NN O O
treated NN O O
patients NN O O
than NN O O
in NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
( NN O O
2 NN O O
% NN O O
vs. NN O O
0 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
more NN O O
often NN O O
led NN O O
to NN O O
study NN O O
withdrawal NN O O
in NN O O
APTIOM NN O O
- NN O O
treated NN O O
patients NN O O
than NN O O
in NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
( NN O O
9 NN O O
% NN O O
vs. NN O O
0.7 NN O O
% NN O O
) NN O O
. NN O O
There NN O O
was NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
these NN O O
adverse NN O O
reactions NN O O
during NN O O
the NN O O
titration NN O O
period NN O O
( NN O O
compared NN O O
to NN O O
the NN O O
maintenance NN O O
period NN O O
) NN O O
and NN O O
there NN O O
also NN O O
may NN O O
be NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
these NN O O
adverse NN O O
reactions NN O O
in NN O O
patients NN O O
60 NN O O
years NN O O
of NN O O
age NN O O
and NN O O
older NN O O
compared NN O O
to NN O O
younger NN O O
adults NN O O
. NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
and NN O O
vomiting NN B-AdverseReaction B-AdverseReaction
also NN O O
occurred NN O O
with NN O O
these NN O O
events NN O O
. NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
and NN O O
disturbance NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
gait NN I-AdverseReaction I-AdverseReaction
and NN O O
coordination NN O O
were NN O O
also NN O O
observed NN O O
in NN O O
monotherapy NN O O
trials NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
was NN O O
greater NN O O
with NN O O
the NN O O
concomitant NN O O
use NN O O
of NN O O
APTIOM NN O O
and NN O O
carbamazepine NN O O
compared NN O O
to NN O O
the NN O O
use NN O O
of NN O O
APTIOM NN O O
without NN O O
carbamazepine NN O O
( NN O O
up NN O O
to NN O O
37 NN O O
% NN O O
vs. NN O O
19 NN O O
% NN O O
, NN O O
respectively NN O O
) NN O O
. NN O O
Therefore NN O O
, NN O O
consider NN O O
dosage NN O O
modifications NN O O
of NN O O
both NN O O
APTIOM NN O O
and NN O O
carbamazepine NN O O
if NN O O
these NN O O
drugs NN O O
are NN O O
used NN O O
concomitantly NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
] NN O O
. NN O O
Somnolence NN O O
and NN O O
Fatigue NN O O
APTIOM NN O O
causes NN O O
dose NN O O
- NN O O
dependent NN O O
increases NN O O
in NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
and NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
adverse NN O O
reactions NN O O
( NN O O
fatigue NN O O
, NN O O
asthenia NN B-AdverseReaction B-AdverseReaction
malaise NN B-AdverseReaction B-AdverseReaction
hypersomnia NN B-AdverseReaction B-AdverseReaction
sedation NN B-AdverseReaction B-AdverseReaction
and NN O O
lethargy NN B-AdverseReaction B-AdverseReaction
In NN O O
the NN O O
controlled NN O O
adjunctive NN O O
epilepsy NN O O
trials NN O O
, NN O O
these NN O O
events NN O O
were NN O O
reported NN O O
in NN O O
13 NN O O
% NN O O
of NN O O
placebo NN O O
patients NN O O
, NN O O
16 NN O O
% NN O O
of NN O O
patients NN O O
randomized NN O O
to NN O O
receive NN O O
800 NN O O
mg/day NN O O
APTIOM NN O O
, NN O O
and NN O O
28 NN O O
% NN O O
of NN O O
patients NN O O
randomized NN O O
to NN O O
receive NN O O
1200 NN O O
mg/day NN O O
APTIOM. NN O O
Somnolence NN B-AdverseReaction B-AdverseReaction
and NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
were NN O O
serious NN O O
in NN O O
0.3 NN O O
% NN O O
of NN O O
APTIOM NN O O
- NN O O
treated NN O O
patients NN O O
( NN O O
and NN O O
0 NN O O
placebo NN O O
patients NN O O
) NN O O
and NN O O
led NN O O
to NN O O
discontinuation NN O O
in NN O O
3 NN O O
% NN O O
of NN O O
APTIOM NN O O
- NN O O
treated NN O O
patients NN O O
( NN O O
and NN O O
0.7 NN O O
% NN O O
of NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
) NN O O
. NN O O
Somnolence NN B-AdverseReaction B-AdverseReaction
and NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
were NN O O
also NN O O
observed NN O O
in NN O O
monotherapy NN O O
trials NN O O
. NN O O
Cognitive NN O O
Dysfunction NN O O
APTIOM NN O O
causes NN O O
dose NN O O
- NN O O
dependent NN O O
increases NN O O
in NN O O
cognitive NN B-AdverseReaction B-AdverseReaction
dysfunction NN I-AdverseReaction I-AdverseReaction
events NN O O
( NN O O
memory NN O O
impairment NN O O
, NN O O
disturbance NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
attention NN I-AdverseReaction I-AdverseReaction
amnesia NN B-AdverseReaction B-AdverseReaction
confusional NN B-AdverseReaction B-AdverseReaction
state NN I-AdverseReaction I-AdverseReaction
aphasia NN B-AdverseReaction B-AdverseReaction
speech NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
slowness NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
thought NN I-AdverseReaction I-AdverseReaction
disorientation NN B-AdverseReaction B-AdverseReaction
and NN O O
psychomotor NN B-AdverseReaction B-AdverseReaction
retardation NN I-AdverseReaction I-AdverseReaction
In NN O O
the NN O O
controlled NN O O
adjunctive NN O O
epilepsy NN O O
trials NN O O
, NN O O
these NN O O
events NN O O
were NN O O
reported NN O O
in NN O O
1 NN O O
% NN O O
of NN O O
placebo NN O O
patients NN O O
, NN O O
4 NN O O
% NN O O
of NN O O
patients NN O O
randomized NN O O
to NN O O
receive NN O O
800 NN O O
mg/day NN O O
APTIOM NN O O
, NN O O
and NN O O
7 NN O O
% NN O O
of NN O O
patients NN O O
randomized NN O O
to NN O O
receive NN O O
1200 NN O O
mg/day NN O O
APTIOM. NN O O
Cognitive NN B-AdverseReaction B-AdverseReaction
dysfunction NN I-AdverseReaction I-AdverseReaction
events NN O O
were NN O O
serious NN B-Severity B-Severity
in NN O O
0.2 NN O O
% NN O O
of NN O O
APTIOM NN O O
- NN O O
treated NN O O
patients NN O O
( NN O O
and NN O O
0.2 NN O O
% NN O O
of NN O O
placebo NN O O
patients NN O O
) NN O O
and NN O O
led NN O O
to NN O O
discontinuation NN O O
in NN O O
1 NN O O
% NN O O
of NN O O
APTIOM NN O O
- NN O O
treated NN O O
patients NN O O
( NN O O
and NN O O
0.5 NN O O
% NN O O
of NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
) NN O O
. NN O O
Cognitive NN B-AdverseReaction B-AdverseReaction
dysfunction NN I-AdverseReaction I-AdverseReaction
events NN O O
were NN O O
also NN O O
observed NN O O
in NN O O
monotherapy NN O O
trials NN O O
. NN O O
Visual NN O O
Changes NN O O
APTIOM NN O O
causes NN O O
dose NN O O
- NN O O
dependent NN O O
increases NN O O
in NN O O
events NN O O
related NN O O
to NN O O
visual NN B-AdverseReaction B-AdverseReaction
changes NN I-AdverseReaction I-AdverseReaction
including NN O O
diplopia NN B-AdverseReaction B-AdverseReaction
blurred NN B-AdverseReaction B-AdverseReaction
vision NN I-AdverseReaction I-AdverseReaction
and NN O O
impaired NN B-AdverseReaction B-AdverseReaction
vision NN I-AdverseReaction I-AdverseReaction
In NN O O
the NN O O
controlled NN O O
adjunctive NN O O
epilepsy NN O O
trials NN O O
, NN O O
these NN O O
events NN O O
were NN O O
reported NN O O
in NN O O
16 NN O O
% NN O O
of NN O O
patients NN O O
randomized NN O O
to NN O O
receive NN O O
APTIOM NN O O
compared NN O O
to NN O O
6 NN O O
% NN O O
of NN O O
placebo NN O O
patients NN O O
. NN O O
Eye NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
were NN O O
serious NN B-Severity B-Severity
in NN O O
0.7 NN O O
% NN O O
of NN O O
APTIOM NN O O
- NN O O
treated NN O O
patients NN O O
( NN O O
and NN O O
0 NN O O
placebo NN O O
patients NN O O
) NN O O
and NN O O
led NN O O
to NN O O
discontinuation NN O O
in NN O O
4 NN O O
% NN O O
of NN O O
APTIOM NN O O
- NN O O
treated NN O O
patients NN O O
( NN O O
and NN O O
0.2 NN O O
% NN O O
of NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
) NN O O
. NN O O
There NN O O
was NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
these NN O O
adverse NN O O
reactions NN O O
during NN O O
the NN O O
titration NN O O
period NN O O
( NN O O
compared NN O O
to NN O O
the NN O O
maintenance NN O O
period NN O O
) NN O O
and NN O O
also NN O O
in NN O O
patients NN O O
60 NN O O
years NN O O
of NN O O
age NN O O
and NN O O
older NN O O
( NN O O
compared NN O O
to NN O O
younger NN O O
adults NN O O
) NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
diplopia NN B-AdverseReaction B-AdverseReaction
was NN O O
greater NN O O
with NN O O
the NN O O
concomitant NN O O
use NN O O
of NN O O
APTIOM NN O O
and NN O O
carbamazepine NN O O
compared NN O O
to NN O O
the NN O O
use NN O O
of NN O O
APTIOM NN O O
without NN O O
carbamazepine NN O O
( NN O O
up NN O O
to NN O O
16 NN O O
% NN O O
vs. NN O O
6 NN O O
% NN O O
, NN O O
respectively NN O O
) NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
] NN O O
. NN O O
Events NN O O
related NN O O
to NN O O
visual NN B-AdverseReaction B-AdverseReaction
changes NN I-AdverseReaction I-AdverseReaction
were NN O O
also NN O O
observed NN O O
in NN O O
monotherapy NN O O
trials NN O O
. NN O O
Hazardous NN O O
Activities NN O O
Prescribers NN O O
should NN O O
advise NN O O
patients NN O O
against NN O O
engaging NN O O
in NN O O
hazardous NN O O
activities NN O O
requiring NN O O
mental NN O O
alertness NN O O
, NN O O
such NN O O
as NN O O
operating NN O O
motor NN O O
vehicles NN O O
or NN O O
dangerous NN O O
machinery NN O O
, NN O O
until NN O O
the NN O O
effect NN O O
of NN O O
APTIOM NN O O
is NN O O
known NN O O
. NN O O
5.7 NN O O
Withdrawal NN O O
of NN O O
AEDs NN O O
As NN O O
with NN O O
all NN O O
antiepileptic NN O O
drugs NN O O
, NN O O
APTIOM NN O O
should NN O O
be NN O O
withdrawn NN O O
gradually NN O O
because NN O O
of NN O O
the NN O O
risk NN O O
of NN O O
increased NN O O
seizure NN O O
frequency NN O O
and NN O O
status NN O O
epilepticus NN O O
. NN O O
5.8 NN O O
Drug NN O O
Induced NN O O
Liver NN O O
Injury NN O O
Hepatic NN O O
effects NN O O
, NN O O
ranging NN O O
from NN O O
mild NN B-Severity B-Severity
to NN I-Severity I-Severity
moderate NN I-Severity I-Severity
elevations NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
transaminases NN I-AdverseReaction I-AdverseReaction
( NN O O
>3 NN O O
times NN O O
the NN O O
upper NN O O
limit NN O O
of NN O O
normal NN O O
) NN O O
to NN O O
rare NN O O
cases NN O O
with NN O O
concomitant NN O O
elevations NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
total NN I-AdverseReaction I-AdverseReaction
bilirubin NN I-AdverseReaction I-AdverseReaction
( NN O O
>2 NN O O
times NN O O
the NN O O
upper NN O O
limit NN O O
of NN O O
normal NN O O
) NN O O
have NN O O
been NN O O
reported NN O O
with NN O O
APTIOM NN O O
use NN O O
. NN O O
Baseline NN O O
evaluations NN O O
of NN O O
liver NN O O
laboratory NN O O
tests NN O O
are NN O O
recommended NN O O
. NN O O
The NN O O
combination NN O O
of NN O O
transaminase NN B-AdverseReaction B-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
and NN O O
elevated NN B-AdverseReaction B-AdverseReaction
bilirubin NN I-AdverseReaction I-AdverseReaction
without NN O O
evidence NN O O
of NN O O
obstruction NN O O
is NN O O
generally NN O O
recognized NN O O
as NN O O
an NN O O
important NN O O
predictor NN O O
of NN O O
severe NN B-Severity B-Severity
liver NN B-AdverseReaction B-AdverseReaction
injury NN I-AdverseReaction I-AdverseReaction
APTIOM NN O O
should NN O O
be NN O O
discontinued NN O O
in NN O O
patients NN O O
with NN O O
jaundice NN O O
or NN O O
other NN O O
evidence NN O O
of NN O O
significant NN O O
liver NN O O
injury NN O O
( NN O O
e.g. NN O O
, NN O O
laboratory NN O O
evidence NN O O
) NN O O
. NN O O
5.9 NN O O
Abnormal NN O O
Thyroid NN O O
Function NN O O
Tests NN O O
Dose NN O O
- NN O O
dependent NN O O
decreases NN O O
in NN O O
serum NN O O
T3 NN O O
and NN O O
T4 NN O O
( NN O O
free NN O O
and NN O O
total NN O O
) NN O O
values NN O O
have NN O O
been NN O O
observed NN O O
in NN O O
patients NN O O
taking NN O O
APTIOM. NN O O
These NN O O
changes NN O O
were NN O O
not NN B-Negation B-Negation
associated NN O O
with NN O O
other NN O O
abnormal NN B-AdverseReaction B-AdverseReaction
thyroid NN I-AdverseReaction I-AdverseReaction
function NN I-AdverseReaction I-AdverseReaction
tests NN O O
suggesting NN O O
hypothyroidism NN B-AdverseReaction B-AdverseReaction
Abnormal NN O O
thyroid NN O O
function NN O O
tests NN O O
should NN O O
be NN O O
clinically NN O O
evaluated NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
are NN O O
described NN O O
in NN O O
more NN O O
detail NN O O
in NN O O
the NN O O
Warnings NN O O
and NN O O
Precautions NN O O
section NN O O
of NN O O
the NN O O
label NN O O
: NN O O
* NN O O
Somnolence NN B-AdverseReaction B-AdverseReaction
and NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
RLS NN O O
: NN O O
Most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=10 NN O O
% NN O O
and NN O O
at NN O O
least NN O O
2 NN O O
times NN O O
the NN O O
rate NN O O
of NN O O
placebo NN O O
) NN O O
were NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
and NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
* NN O O
PHN NN O O
: NN O O
Most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=10 NN O O
% NN O O
and NN O O
greater NN O O
than NN O O
placebo NN O O
) NN O O
were NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
somnolence NN B-AdverseReaction B-AdverseReaction
and NN O O
headache NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
EXCERPT NN O O
: NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
XenoPort NN O O
at NN O O
1 NN O O
- NN O O
877-XENOPRT NN O O
( NN O O
1 NN O O
- NN O O
877 NN O O
- NN O O
936 NN O O
- NN O O
6778 NN O O
) NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
with NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
In NN O O
all NN O O
controlled NN O O
and NN O O
uncontrolled NN O O
trials NN O O
across NN O O
various NN O O
patient NN O O
populations NN O O
, NN O O
more NN O O
than NN O O
2,300 NN O O
patients NN O O
have NN O O
received NN O O
HORIZANT NN O O
orally NN O O
in NN O O
daily NN O O
doses NN O O
ranging NN O O
from NN O O
600 NN O O
to NN O O
3,600 NN O O
mg NN O O
. NN O O
Restless NN O O
Legs NN O O
Syndrome NN O O
: NN O O
The NN O O
exposure NN O O
to NN O O
HORIZANT NN O O
in NN O O
1,201 NN O O
patients NN O O
with NN O O
RLS NN O O
included NN O O
613 NN O O
exposed NN O O
for NN O O
at NN O O
least NN O O
6 NN O O
months NN O O
and NN O O
371 NN O O
exposed NN O O
for NN O O
at NN O O
least NN O O
1 NN O O
year NN O O
. NN O O
HORIZANT NN O O
in NN O O
the NN O O
treatment NN O O
of NN O O
RLS NN O O
was NN O O
studied NN O O
primarily NN O O
in NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
( NN O O
n NN O O
= NN O O
642 NN O O
) NN O O
, NN O O
and NN O O
in NN O O
long NN O O
- NN O O
term NN O O
follow NN O O
- NN O O
up NN O O
studies NN O O
. NN O O
The NN O O
population NN O O
with NN O O
RLS NN O O
ranged NN O O
from NN O O
18 NN O O
to NN O O
82 NN O O
years NN O O
of NN O O
age NN O O
, NN O O
with NN O O
60 NN O O
% NN O O
being NN O O
female NN O O
and NN O O
95 NN O O
% NN O O
being NN O O
Caucasian NN O O
. NN O O
The NN O O
safety NN O O
of NN O O
HORIZANT NN O O
in NN O O
doses NN O O
ranging NN O O
from NN O O
600 NN O O
to NN O O
2,400 NN O O
mg NN O O
has NN O O
been NN O O
evaluated NN O O
in NN O O
515 NN O O
patients NN O O
with NN O O
RLS NN O O
in NN O O
3 NN O O
double NN O O
blind NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
, NN O O
12 NN O O
week NN O O
clinical NN O O
trials NN O O
. NN O O
The NN O O
600-mg NN O O
dose NN O O
was NN O O
studied NN O O
in NN O O
2 NN O O
of NN O O
the NN O O
3 NN O O
studies NN O O
. NN O O
Eleven NN O O
out NN O O
of NN O O
163 NN O O
( NN O O
7 NN O O
% NN O O
) NN O O
patients NN O O
treated NN O O
with NN O O
600 NN O O
mg NN O O
of NN O O
HORIZANT NN O O
discontinued NN O O
treatment NN O O
due NN O O
to NN O O
adverse NN O O
reactions NN O O
compared NN O O
with NN O O
10 NN O O
of NN O O
the NN O O
245 NN O O
( NN O O
4 NN O O
% NN O O
) NN O O
patients NN O O
who NN O O
received NN O O
placebo NN O O
. NN O O
The NN O O
most NN O O
commonly NN O O
observed NN O O
adverse NN O O
reactions NN O O
( NN O O
>=5 NN O O
% NN O O
and NN O O
at NN O O
least NN O O
2 NN O O
times NN O O
the NN O O
rate NN O O
of NN O O
placebo NN O O
) NN O O
in NN O O
these NN O O
trials NN O O
for NN O O
the NN O O
600 NN O O
mg NN O O
dose NN O O
of NN O O
HORIZANT NN O O
were NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
and NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
( NN O O
see NN O O
Table NN O O
4 NN O O
) NN O O
. NN O O
Table NN O O
4 NN O O
lists NN O O
treatment NN O O
- NN O O
emergent NN O O
adverse NN O O
reactions NN O O
that NN O O
occurred NN O O
in NN O O
>=2 NN O O
% NN O O
of NN O O
patients NN O O
with NN O O
RLS NN O O
treated NN O O
with NN O O
HORIZANT NN O O
and NN O O
numerically NN O O
greater NN O O
than NN O O
placebo NN O O
. NN O O
Table NN O O
4 NN O O
. NN O O
Incidence NN O O
of NN O O
Adverse NN O O
Reactions NN O O
in NN O O
12 NN O O
Week NN O O
RLS NN O O
Studies NN O O
Reported NN O O
in NN O O
>=2 NN O O
% NN O O
of NN O O
Patients NN O O
Treated NN O O
With NN O O
600 NN O O
or NN O O
1,200 NN O O
mg NN O O
of NN O O
HORIZANT NN O O
and NN O O
Numerically NN O O
Greater NN O O
Than NN O O
Placebo NN O O
Body NN O O
System/Adverse NN O O
Reaction NN O O
Placebo NN O O
a NN O O
( NN O O
N NN O O
= NN O O
245 NN O O
) NN O O
% NN O O
HORIZANT600 NN O O
mg/day NN O O
b NN O O
( NN O O
N NN O O
= NN O O
163 NN O O
) NN O O
% NN O O
HORIZANT1,200 NN O O
mg/day NN O O
c NN O O
( NN O O
N NN O O
= NN O O
269 NN O O
) NN O O
% NN O O
Nervous NN O O
system NN O O
disorders NN O O
Somnolence NN B-AdverseReaction B-AdverseReaction
6 NN O O
20 NN O O
27 NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
4 NN O O
13 NN O O
22 NN O O
Headache NN B-AdverseReaction B-AdverseReaction
11 NN O O
12 NN O O
15 NN O O
Gastrointestinal NN O O
disorders NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
5 NN O O
6 NN O O
7 NN O O
Dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
2 NN O O
3 NN O O
4 NN O O
Flatulence NN B-AdverseReaction B-AdverseReaction
< NN O O
1 NN O O
3 NN O O
2 NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
4 NN O O
6 NN O O
7 NN O O
Irritability NN B-AdverseReaction B-AdverseReaction
1 NN O O
4 NN O O
4 NN O O
Feeling NN B-AdverseReaction B-AdverseReaction
drunk NN I-AdverseReaction I-AdverseReaction
0 NN O O
1 NN O O
3 NN O O
Feeling NN B-AdverseReaction B-AdverseReaction
abnormal NN I-AdverseReaction I-AdverseReaction
< NN O O
1 NN O O
< NN O O
1 NN O O
3 NN O O
Peripheral NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
1 NN O O
< NN O O
1 NN O O
3 NN O O
Metabolism NN O O
and NN O O
nutritional NN O O
disorders NN O O
Weight NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
2 NN O O
2 NN O O
3 NN O O
Increased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
< NN O O
1 NN O O
2 NN O O
2 NN O O
Ear NN O O
and NN O O
labyrinth NN O O
disorders NN O O
Vertigo NN B-AdverseReaction B-AdverseReaction
0 NN O O
1 NN O O
3 NN O O
Psychiatric NN O O
disorders NN O O
Depression NN B-AdverseReaction B-AdverseReaction
< NN O O
1 NN O O
< NN O O
1 NN O O
3 NN O O
Libido NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
< NN O O
1 NN O O
< NN O O
1 NN O O
2 NN O O
a NN O O
Placebo NN O O
was NN O O
a NN O O
treatment NN O O
arm NN O O
in NN O O
each NN O O
of NN O O
the NN O O
3 NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
, NN O O
12-week NN O O
clinical NN O O
trials NN O O
. NN O O
b NN O O
The NN O O
600-mg NN O O
dose NN O O
of NN O O
HORIZANT NN O O
was NN O O
a NN O O
treatment NN O O
arm NN O O
in NN O O
2 NN O O
of NN O O
the NN O O
3 NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
, NN O O
12-week NN O O
clinical NN O O
trials NN O O
. NN O O
c NN O O
The NN O O
1,200-mg NN O O
dose NN O O
of NN O O
HORIZANT NN O O
was NN O O
a NN O O
treatment NN O O
arm NN O O
in NN O O
each NN O O
of NN O O
the NN O O
3 NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
, NN O O
12-week NN O O
clinical NN O O
trials NN O O
. NN O O
Adverse NN O O
reactions NN O O
reported NN O O
in NN O O
these NN O O
three NN O O
12 NN O O
week NN O O
studies NN O O
in NN O O
< NN O O
2 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
600 NN O O
mg NN O O
of NN O O
HORIZANT NN O O
and NN O O
numerically NN O O
greater NN O O
than NN O O
placebo NN O O
were NN O O
balance NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
blurred NN B-AdverseReaction B-AdverseReaction
vision NN I-AdverseReaction I-AdverseReaction
disorientation NN B-AdverseReaction B-AdverseReaction
feeling NN B-AdverseReaction B-AdverseReaction
drunk NN I-AdverseReaction I-AdverseReaction
lethargy NN B-AdverseReaction B-AdverseReaction
and NN O O
vertigo NN B-AdverseReaction B-AdverseReaction
The NN O O
following NN O O
adverse NN O O
reactions NN O O
were NN O O
dose NN O O
- NN O O
related NN O O
: NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
dizziness NN B-AdverseReaction B-AdverseReaction
feeling NN B-AdverseReaction B-AdverseReaction
drunk NN I-AdverseReaction I-AdverseReaction
libido NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
depression NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
peripheral NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
and NN O O
vertigo NN B-AdverseReaction B-AdverseReaction
Postherpetic NN O O
Neuralgia NN O O
: NN O O
The NN O O
exposure NN O O
to NN O O
HORIZANT NN O O
in NN O O
417 NN O O
patients NN O O
with NN O O
PHN NN O O
included NN O O
207 NN O O
patients NN O O
exposed NN O O
for NN O O
at NN O O
least NN O O
3 NN O O
months NN O O
. NN O O
Overall NN O O
, NN O O
the NN O O
mean NN O O
age NN O O
of NN O O
patients NN O O
in NN O O
the NN O O
PHN NN O O
studies NN O O
ranged NN O O
from NN O O
61 NN O O
to NN O O
64 NN O O
years NN O O
of NN O O
age NN O O
across NN O O
dose NN O O
groups NN O O
; NN O O
the NN O O
majority NN O O
of NN O O
patients NN O O
were NN O O
male NN O O
( NN O O
45 NN O O
% NN O O
to NN O O
61 NN O O
% NN O O
) NN O O
and NN O O
Caucasian NN O O
( NN O O
80 NN O O
% NN O O
to NN O O
98 NN O O
% NN O O
) NN O O
. NN O O
The NN O O
safety NN O O
of NN O O
HORIZANT NN O O
in NN O O
doses NN O O
ranging NN O O
from NN O O
1,200 NN O O
to NN O O
3,600 NN O O
mg NN O O
has NN O O
been NN O O
evaluated NN O O
in NN O O
417 NN O O
patients NN O O
with NN O O
PHN NN O O
in NN O O
3 NN O O
clinical NN O O
studies NN O O
. NN O O
The NN O O
principal NN O O
efficacy NN O O
study NN O O
evaluating NN O O
the NN O O
efficacy NN O O
and NN O O
safety NN O O
of NN O O
HORIZANT NN O O
in NN O O
the NN O O
management NN O O
of NN O O
PHN NN O O
was NN O O
a NN O O
12-week NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
multicenter NN O O
study NN O O
comparing NN O O
1,200 NN O O
mg/day NN O O
, NN O O
2,400 NN O O
mg/day NN O O
and NN O O
3,600 NN O O
mg/day NN O O
to NN O O
placebo NN O O
. NN O O
Six NN O O
out NN O O
of NN O O
107 NN O O
( NN O O
6 NN O O
% NN O O
) NN O O
patients NN O O
treated NN O O
with NN O O
1,200 NN O O
mg NN O O
of NN O O
HORIZANT NN O O
discontinued NN O O
treatment NN O O
due NN O O
to NN O O
adverse NN O O
events NN O O
compared NN O O
with NN O O
12 NN O O
of NN O O
the NN O O
95 NN O O
( NN O O
13 NN O O
% NN O O
) NN O O
patients NN O O
who NN O O
received NN O O
placebo NN O O
. NN O O
The NN O O
most NN O O
commonly NN O O
observed NN O O
adverse NN O O
reactions NN O O
( NN O O
>=10 NN O O
% NN O O
and NN O O
greater NN O O
than NN O O
placebo NN O O
) NN O O
in NN O O
this NN O O
trial NN O O
for NN O O
the NN O O
1,200 NN O O
mg NN O O
dose NN O O
of NN O O
HORIZANT NN O O
were NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
somnolence NN B-AdverseReaction B-AdverseReaction
and NN O O
headache NN B-AdverseReaction B-AdverseReaction
( NN O O
see NN O O
Table NN O O
5 NN O O
) NN O O
. NN O O
Table NN O O
5 NN O O
lists NN O O
treatment NN O O
- NN O O
emergent NN O O
adverse NN O O
reactions NN O O
that NN O O
occurred NN O O
in NN O O
>=2 NN O O
% NN O O
of NN O O
patients NN O O
with NN O O
PHN NN O O
treated NN O O
with NN O O
HORIZANT NN O O
1,200 NN O O
mg/day NN O O
and NN O O
numerically NN O O
greater NN O O
than NN O O
placebo NN O O
. NN O O
Table NN O O
5 NN O O
. NN O O
Incidence NN O O
of NN O O
Adverse NN O O
Reactions NN O O
( NN O O
in NN O O
At NN O O
Least NN O O
2 NN O O
% NN O O
of NN O O
Patients NN O O
Treated NN O O
With NN O O
1,200 NN O O
mg/day NN O O
of NN O O
HORIZANT NN O O
and NN O O
Numerically NN O O
Greater NN O O
Than NN O O
the NN O O
Placebo NN O O
Rate NN O O
) NN O O
Reported NN O O
in NN O O
All NN O O
Patients NN O O
in NN O O
the NN O O
12-Week NN O O
PHN NN O O
Study NN O O
Body NN O O
System/Adverse NN O O
Reaction NN O O
Placebo(N NN O O
= NN O O
95 NN O O
) NN O O
% NN O O
HORIZANT1,200 NN O O
mg/day(N NN O O
= NN O O
107 NN O O
) NN O O
% NN O O
HORIZANT2,400 NN O O
mg/day(N NN O O
= NN O O
82 NN O O
) NN O O
% NN O O
HORIZANT3,600 NN O O
mg/day(N NN O O
= NN O O
87 NN O O
) NN O O
% NN O O
Nervous NN O O
System NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
15 NN O O
17 NN O O
26 NN O O
30 NN O O
Somnolence NN B-AdverseReaction B-AdverseReaction
8 NN O O
10 NN O O
11 NN O O
14 NN O O
Headache NN B-AdverseReaction B-AdverseReaction
9 NN O O
10 NN O O
10 NN O O
7 NN O O
Gastrointestinal NN O O
disorders NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
5 NN O O
8 NN O O
4 NN O O
9 NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
1 NN O O
6 NN O O
4 NN O O
10 NN O O
Peripheral NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
0 NN O O
6 NN O O
7 NN O O
6 NN O O
Psychiatric NN O O
disorders NN O O
Insomnia NN B-AdverseReaction B-AdverseReaction
2 NN O O
3 NN O O
5 NN O O
7 NN O O
Metabolism NN O O
and NN O O
nutritional NN O O
disorders NN O O
Weight NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
1 NN O O
3 NN O O
5 NN O O
5 NN O O
Eye NN O O
disorders NN O O
Blurred NN B-AdverseReaction B-AdverseReaction
vision NN I-AdverseReaction I-AdverseReaction
0 NN O O
2 NN O O
5 NN O O
2 NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
were NN O O
also NN O O
reported NN O O
as NN O O
>=2 NN O O
% NN O O
at NN O O
2,400 NN O O
mg/day NN O O
and/or NN O O
3,600 NN O O
mg/day NN O O
and NN O O
appeared NN O O
to NN O O
be NN O O
dose NN O O
- NN O O
related NN O O
but NN O O
were NN O O
< NN O O
2 NN O O
% NN O O
at NN O O
1,200 NN O O
mg/day NN O O
: NN O O
balance NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
confusional NN B-AdverseReaction B-AdverseReaction
state NN I-AdverseReaction I-AdverseReaction
depression NN B-AdverseReaction B-AdverseReaction
dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
flatulence NN B-AdverseReaction B-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
irritability NN B-AdverseReaction B-AdverseReaction
and NN O O
vertigo NN B-AdverseReaction B-AdverseReaction
Dizziness NN B-AdverseReaction B-AdverseReaction
somnolence NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
and NN O O
insomnia NN B-AdverseReaction B-AdverseReaction
appeared NN O O
to NN O O
show NN O O
a NN O O
dose NN O O
relationship NN O O
. NN O O
6.2 NN O O
Adverse NN O O
Events NN O O
Associated NN O O
With NN O O
Gabapentin NN O O
The NN O O
following NN O O
adverse NN O O
events NN O O
have NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
receiving NN O O
gabapentin NN O O
, NN O O
either NN O O
in NN O O
clinical NN O O
trials NN O O
or NN O O
postmarketing NN O O
: NN O O
breast NN B-AdverseReaction B-AdverseReaction
enlargement NN I-AdverseReaction I-AdverseReaction
gynecomastia NN B-AdverseReaction B-AdverseReaction
and NN O O
elevated NN B-AdverseReaction B-AdverseReaction
creatine NN I-AdverseReaction I-AdverseReaction
kinase NN I-AdverseReaction I-AdverseReaction
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Driving NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
Warn NN O O
patients NN O O
not NN O O
to NN O O
drive NN O O
until NN O O
they NN O O
have NN O O
gained NN O O
sufficient NN O O
experience NN O O
with NN O O
HORIZANT NN O O
to NN O O
assess NN O O
whether NN O O
it NN O O
will NN O O
impair NN O O
their NN O O
ability NN O O
to NN O O
drive NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Somnolence NN B-AdverseReaction B-AdverseReaction
and NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
May NN B-Factor B-Factor
impair NN O O
the NN O O
patient NN O O
's NN O O
ability NN O O
to NN O O
operate NN O O
complex NN O O
machinery NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
HORIZANT NN O O
is NN O O
not NN O O
interchangeable NN O O
with NN O O
other NN O O
gabapentin NN O O
products NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Suicidal NN B-AdverseReaction B-AdverseReaction
thoughts NN I-AdverseReaction I-AdverseReaction
or NN O O
behaviors NN O O
: NN O O
HORIZANT NN O O
is NN O O
a NN O O
prodrug NN O O
of NN O O
gabapentin NN O O
, NN O O
an NN O O
antiepileptic NN O O
drug NN O O
( NN O O
AED NN O O
) NN O O
. NN O O
AEDs NN B-DrugClass B-DrugClass
increase NN O O
the NN O O
risk NN O O
of NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
thoughts NN I-AdverseReaction I-AdverseReaction
or NN O O
behaviors NN O O
. NN O O
Monitor NN O O
for NN O O
suicidal NN O O
thoughts NN O O
or NN O O
behaviors NN O O
. NN O O
( NN O O
5.4 NN O O
) NN O O
5.1 NN O O
Effects NN O O
on NN O O
Driving NN O O
HORIZANT NN O O
may NN B-Factor B-Factor
cause NN O O
significant NN B-Severity B-Severity
driving NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14.3 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
duration NN O O
of NN O O
driving NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
after NN O O
starting NN O O
therapy NN O O
with NN O O
HORIZANT NN O O
is NN O O
unknown NN O O
. NN O O
Patients NN O O
taking NN O O
HORIZANT NN O O
should NN O O
not NN O O
drive NN O O
until NN O O
they NN O O
have NN O O
gained NN O O
sufficient NN O O
experience NN O O
to NN O O
assess NN O O
whether NN O O
HORIZANT NN O O
impairs NN O O
their NN O O
ability NN O O
to NN O O
drive NN O O
. NN O O
However NN O O
, NN O O
prescribers NN O O
and NN O O
patients NN O O
should NN O O
be NN O O
aware NN O O
that NN O O
patients NN O O
' NN O O
ability NN O O
to NN O O
assess NN O O
their NN O O
own NN O O
driving NN O O
competence NN O O
, NN O O
as NN O O
well NN O O
as NN O O
their NN O O
ability NN O O
to NN O O
assess NN O O
the NN O O
degree NN O O
of NN O O
somnolence NN O O
caused NN O O
by NN O O
HORIZANT NN O O
, NN O O
can NN O O
be NN O O
imperfect NN O O
. NN O O
Whether NN O O
the NN O O
impairment NN O O
is NN O O
related NN O O
to NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
or NN O O
other NN O O
effects NN O O
of NN O O
HORIZANT NN O O
is NN O O
unknown NN O O
. NN O O
5.2 NN O O
Somnolence/Sedation NN O O
and NN O O
Dizziness NN O O
HORIZANT NN O O
causes NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
and NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
( NN O O
see NN O O
Tables NN O O
4 NN O O
and NN O O
5 NN O O
) NN O O
. NN O O
Patients NN O O
should NN O O
be NN O O
advised NN O O
not NN O O
to NN O O
drive NN O O
a NN O O
car NN O O
or NN O O
operate NN O O
other NN O O
complex NN O O
machinery NN O O
until NN O O
they NN O O
have NN O O
gained NN O O
sufficient NN O O
experience NN O O
on NN O O
HORIZANT NN O O
to NN O O
assess NN O O
whether NN O O
HORIZANT NN O O
impairs NN O O
their NN O O
ability NN O O
to NN O O
perform NN O O
these NN O O
tasks NN O O
. NN O O
During NN O O
the NN O O
controlled NN O O
trials NN O O
in NN O O
patients NN O O
with NN O O
RLS NN O O
, NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
20 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
600 NN O O
mg NN O O
of NN O O
HORIZANT NN O O
per NN O O
day NN O O
compared NN O O
with NN O O
6 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
placebo NN O O
. NN O O
In NN O O
those NN O O
patients NN O O
treated NN O O
with NN O O
HORIZANT NN O O
who NN O O
reported NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
the NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
persisted NN O O
during NN O O
treatment NN O O
in NN O O
about NN O O
30 NN O O
% NN O O
. NN O O
In NN O O
the NN O O
remaining NN O O
patients NN O O
, NN O O
symptoms NN O O
resolved NN O O
within NN O O
3 NN O O
to NN O O
4 NN O O
weeks NN O O
. NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
13 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
600 NN O O
mg NN O O
of NN O O
HORIZANT NN O O
per NN O O
day NN O O
compared NN O O
with NN O O
4 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
placebo NN O O
. NN O O
In NN O O
those NN O O
patients NN O O
treated NN O O
with NN O O
HORIZANT NN O O
who NN O O
reported NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
symptoms NN O O
persisted NN O O
during NN O O
treatment NN O O
in NN O O
about NN O O
20 NN O O
% NN O O
. NN O O
Somnolence NN B-AdverseReaction B-AdverseReaction
led NN O O
to NN O O
withdrawal NN O O
in NN O O
2 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
600 NN O O
mg NN O O
of NN O O
HORIZANT NN O O
per NN O O
day NN O O
. NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
led NN O O
to NN O O
withdrawal NN O O
in NN O O
1 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
600 NN O O
mg NN O O
of NN O O
HORIZANT NN O O
per NN O O
day NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
these NN O O
adverse NN O O
reactions NN O O
was NN O O
greater NN O O
in NN O O
the NN O O
patients NN O O
receiving NN O O
1,200 NN O O
mg NN O O
per NN O O
day NN O O
. NN O O
During NN O O
the NN O O
12-week NN O O
, NN O O
controlled NN O O
study NN O O
in NN O O
patients NN O O
with NN O O
PHN NN O O
, NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
10 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
1,200 NN O O
mg NN O O
of NN O O
HORIZANT NN O O
per NN O O
day NN O O
compared NN O O
with NN O O
8 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
placebo NN O O
. NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
6 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
1,200 NN O O
mg NN O O
of NN O O
HORIZANT NN O O
per NN O O
day NN O O
compared NN O O
with NN O O
1 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
placebo NN O O
. NN O O
In NN O O
those NN O O
patients NN O O
treated NN O O
with NN O O
1,200 NN O O
mg NN O O
of NN O O
HORIZANT NN O O
per NN O O
day NN O O
who NN O O
reported NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
( NN O O
10 NN O O
% NN O O
) NN O O
, NN O O
the NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
persisted NN O O
during NN O O
treatment NN O O
in NN O O
about NN O O
27 NN O O
% NN O O
. NN O O
In NN O O
the NN O O
remaining NN O O
patients NN O O
, NN O O
symptoms NN O O
resolved NN O O
within NN O O
4 NN O O
to NN O O
5 NN O O
weeks NN O O
. NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
17 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
1,200 NN O O
mg NN O O
of NN O O
HORIZANT NN O O
per NN O O
day NN O O
compared NN O O
with NN O O
15 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
placebo NN O O
. NN O O
In NN O O
those NN O O
patients NN O O
treated NN O O
with NN O O
1,200 NN O O
mg NN O O
of NN O O
HORIZANT NN O O
per NN O O
day NN O O
who NN O O
reported NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
symptoms NN O O
persisted NN O O
during NN O O
treatment NN O O
in NN O O
about NN O O
6 NN O O
% NN O O
. NN O O
Somnolence NN B-AdverseReaction B-AdverseReaction
led NN O O
to NN O O
withdrawal NN O O
in NN O O
< NN O O
1 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
1,200 NN O O
mg NN O O
of NN O O
HORIZANT NN O O
per NN O O
day NN O O
compared NN O O
with NN O O
2 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
placebo NN O O
. NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
led NN O O
to NN O O
withdrawal NN O O
in NN O O
2 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
1,200 NN O O
mg NN O O
of NN O O
HORIZANT NN O O
per NN O O
day NN O O
compared NN O O
with NN O O
3 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
placebo NN O O
. NN O O
5.3 NN O O
Lack NN O O
of NN O O
Interchangeability NN O O
With NN O O
Gabapentin NN O O
HORIZANT NN O O
is NN O O
not NN O O
interchangeable NN O O
with NN O O
other NN O O
gabapentin NN O O
products NN O O
because NN O O
of NN O O
differing NN O O
pharmacokinetic NN O O
profiles NN O O
. NN O O
The NN O O
same NN O O
dose NN O O
of NN O O
HORIZANT NN O O
results NN O O
in NN O O
different NN O O
plasma NN O O
concentrations NN O O
of NN O O
gabapentin NN O O
relative NN O O
to NN O O
other NN O O
gabapentin NN O O
products NN O O
. NN O O
[ NN O O
See NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.3 NN O O
) NN O O
. NN O O
] NN O O
The NN O O
safety NN O O
and NN O O
effectiveness NN O O
of NN O O
HORIZANT NN O O
in NN O O
patients NN O O
with NN O O
epilepsy NN O O
have NN O O
not NN O O
been NN O O
studied NN O O
. NN O O
5.4 NN O O
Suicidal NN O O
Behavior NN O O
and NN O O
Ideation NN O O
HORIZANT NN O O
( NN O O
gabapentin NN O O
enacarbil NN O O
) NN O O
is NN O O
a NN O O
prodrug NN O O
of NN O O
gabapentin NN O O
, NN O O
an NN O O
antiepileptic NN O O
drug NN O O
( NN O O
AED NN O O
) NN O O
. NN O O
AEDs NN B-DrugClass B-DrugClass
increase NN O O
the NN O O
risk NN O O
of NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
thoughts NN I-AdverseReaction I-AdverseReaction
or NN O O
behavior NN O O
in NN O O
patients NN O O
taking NN O O
these NN O O
drugs NN O O
for NN O O
any NN O O
indication NN O O
. NN O O
Because NN O O
HORIZANT NN O O
is NN O O
a NN O O
prodrug NN O O
of NN O O
gabapentin NN O O
, NN O O
HORIZANT NN O O
also NN O O
increases NN O O
this NN O O
risk NN O O
. NN O O
Patients NN O O
treated NN O O
with NN O O
any NN O O
AED NN O O
for NN O O
any NN O O
indication NN O O
should NN O O
be NN O O
monitored NN O O
for NN O O
the NN O O
emergence NN O O
or NN O O
worsening NN O O
of NN O O
depression NN O O
, NN O O
suicidal NN O O
thoughts NN O O
or NN O O
behavior NN O O
, NN O O
and/or NN O O
any NN O O
unusual NN O O
changes NN O O
in NN O O
mood NN O O
or NN O O
behavior NN O O
. NN O O
Pooled NN O O
analyses NN O O
of NN O O
199 NN O O
placebo NN O O
- NN O O
controlled NN O O
clinical NN O O
trials NN O O
( NN O O
monotherapy NN O O
and NN O O
adjunctive NN O O
therapy NN O O
) NN O O
of NN O O
11 NN O O
different NN O O
AEDs NN O O
showed NN O O
that NN O O
patients NN O O
randomized NN O O
to NN O O
1 NN O O
of NN O O
the NN O O
AEDs NN B-DrugClass B-DrugClass
had NN O O
approximately NN O O
twice NN O O
the NN O O
risk NN O O
[ NN O O
adjusted NN O O
relative NN O O
risk NN O O
1.8 NN O O
, NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
( NN O O
CI NN O O
) NN O O
: NN O O
1.2 NN O O
, NN O O
2.7 NN O O
] NN O O
of NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
thinking NN I-AdverseReaction I-AdverseReaction
or NN O O
behavior NN O O
compared NN O O
with NN O O
patients NN O O
randomized NN O O
to NN O O
placebo NN O O
. NN O O
In NN O O
these NN O O
trials NN O O
, NN O O
which NN O O
had NN O O
a NN O O
median NN O O
treatment NN O O
duration NN O O
of NN O O
12 NN O O
weeks NN O O
, NN O O
the NN O O
estimated NN O O
incidence NN O O
rate NN O O
of NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
behavior NN I-AdverseReaction I-AdverseReaction
or NN O O
ideation NN O O
among NN O O
27,863 NN O O
AED NN O O
- NN O O
treated NN O O
patients NN O O
was NN O O
0.43 NN O O
% NN O O
, NN O O
compared NN O O
with NN O O
0.24 NN O O
% NN O O
among NN O O
16,029 NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
, NN O O
representing NN O O
an NN O O
increase NN O O
of NN O O
approximately NN O O
1 NN O O
case NN O O
of NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
thinking NN I-AdverseReaction I-AdverseReaction
or NN O O
behavior NN O O
for NN O O
every NN O O
530 NN O O
patients NN O O
treated NN O O
. NN O O
There NN O O
were NN O O
4 NN O O
suicides NN B-AdverseReaction B-AdverseReaction
in NN O O
drug NN O O
- NN O O
treated NN O O
patients NN O O
in NN O O
the NN O O
trials NN O O
and NN O O
none NN O O
in NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
, NN O O
but NN O O
the NN O O
number NN B-Factor B-Factor
is NN I-Factor I-Factor
too NN I-Factor I-Factor
small NN I-Factor I-Factor
to NN O O
allow NN O O
any NN O O
conclusion NN O O
about NN O O
drug NN O O
effect NN O O
on NN O O
suicide NN B-AdverseReaction B-AdverseReaction
The NN O O
increased NN O O
risk NN O O
of NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
thoughts NN I-AdverseReaction I-AdverseReaction
or NN O O
behavior NN O O
with NN O O
AEDs NN B-DrugClass B-DrugClass
was NN O O
observed NN O O
as NN O O
early NN O O
as NN O O
1 NN O O
week NN O O
after NN O O
starting NN O O
drug NN O O
treatment NN O O
with NN O O
AEDs NN O O
and NN O O
persisted NN O O
for NN O O
the NN O O
duration NN O O
of NN O O
treatment NN O O
assessed NN O O
. NN O O
Because NN O O
most NN O O
trials NN O O
included NN O O
in NN O O
the NN O O
analysis NN O O
did NN O O
not NN O O
extend NN O O
beyond NN O O
24 NN O O
weeks NN O O
, NN O O
the NN O O
risk NN O O
of NN O O
suicidal NN O O
thoughts NN O O
or NN O O
behavior NN O O
beyond NN O O
24 NN O O
weeks NN O O
could NN O O
not NN O O
be NN O O
assessed NN O O
. NN O O
The NN O O
risk NN B-Factor B-Factor
of NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
thoughts NN I-AdverseReaction I-AdverseReaction
or NN O O
behavior NN O O
was NN O O
generally NN O O
consistent NN O O
among NN O O
drugs NN O O
in NN O O
the NN O O
data NN O O
analyzed NN O O
. NN O O
The NN O O
finding NN O O
of NN O O
increased NN O O
risk NN O O
with NN O O
AEDs NN O O
of NN O O
varying NN O O
mechanisms NN O O
of NN O O
action NN O O
and NN O O
across NN O O
a NN O O
range NN O O
of NN O O
indications NN O O
suggests NN O O
that NN O O
the NN O O
risk NN O O
applies NN O O
to NN O O
all NN O O
AEDs NN O O
used NN O O
for NN O O
any NN O O
indication NN O O
. NN O O
The NN O O
risk NN O O
did NN O O
not NN O O
vary NN O O
substantially NN O O
by NN O O
age NN O O
( NN O O
5 NN O O
to NN O O
100 NN O O
years NN O O
) NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
analyzed NN O O
. NN O O
Table NN O O
3 NN O O
shows NN O O
absolute NN O O
and NN O O
relative NN O O
risk NN O O
by NN O O
indication NN O O
for NN O O
all NN O O
evaluated NN O O
AEDs NN O O
. NN O O
Table NN O O
3 NN O O
. NN O O
Risk NN O O
by NN O O
Indication NN O O
for NN O O
Antiepileptic NN O O
Drugs NN O O
in NN O O
the NN O O
Pooled NN O O
Analysis NN O O
Indication NN O O
PlaceboPatients NN O O
WithEvents NN O O
Per1,000 NN O O
Patients NN O O
Drug NN O O
PatientsWith NN O O
Events NN O O
Per1,000 NN O O
Patients NN O O
Relative NN O O
Risk:Incidence NN O O
of NN O O
Eventsin NN O O
DrugPatients/Incidencein NN O O
Placebo NN O O
Patients NN O O
Risk NN O O
Difference:Additional NN O O
DrugPatients NN O O
WithEvents NN O O
Per NN O O
1,000Patients NN O O
Epilepsy NN O O
1.0 NN O O
3.4 NN O O
3.5 NN O O
2.4 NN O O
Psychiatric NN O O
5.7 NN O O
8.5 NN O O
1.5 NN O O
2.9 NN O O
Other NN O O
1.0 NN O O
1.8 NN O O
1.9 NN O O
0.9 NN O O
Total NN O O
2.4 NN O O
4.3 NN O O
1.8 NN O O
1.9 NN O O
The NN O O
relative NN O O
risk NN B-Factor B-Factor
for NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
thoughts NN I-AdverseReaction I-AdverseReaction
or NN O O
behavior NN O O
was NN O O
higher NN O O
in NN O O
clinical NN O O
trials NN O O
for NN O O
epilepsy NN O O
than NN O O
in NN O O
clinical NN O O
trials NN O O
for NN O O
psychiatric NN O O
or NN O O
other NN O O
conditions NN O O
, NN O O
but NN O O
the NN O O
absolute NN O O
risk NN O O
differences NN O O
were NN O O
similar NN O O
for NN O O
the NN O O
epilepsy NN O O
and NN O O
psychiatric NN O O
indications NN O O
. NN O O
Anyone NN O O
considering NN O O
prescribing NN O O
HORIZANT NN O O
must NN O O
balance NN O O
the NN O O
risk NN O O
of NN O O
suicidal NN O O
thoughts NN O O
or NN O O
behavior NN O O
with NN O O
the NN O O
risk NN O O
of NN O O
untreated NN O O
illness NN O O
. NN O O
Epilepsy NN O O
and NN O O
many NN O O
other NN O O
illnesses NN O O
for NN O O
which NN O O
AEDs NN O O
are NN O O
prescribed NN O O
are NN O O
themselves NN O O
associated NN O O
with NN O O
morbidity NN O O
and NN O O
mortality NN O O
and NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
suicidal NN O O
thoughts NN O O
and NN O O
behavior NN O O
. NN O O
Should NN O O
suicidal NN O O
thoughts NN O O
and NN O O
behavior NN O O
emerge NN O O
during NN O O
treatment NN O O
, NN O O
the NN O O
prescriber NN O O
needs NN O O
to NN O O
consider NN O O
whether NN O O
the NN O O
emergence NN O O
of NN O O
these NN O O
symptoms NN O O
in NN O O
any NN O O
given NN O O
patient NN O O
may NN O O
be NN O O
related NN O O
to NN O O
the NN O O
illness NN O O
being NN O O
treated NN O O
. NN O O
Patients NN O O
, NN O O
their NN O O
caregivers NN O O
, NN O O
and NN O O
families NN O O
should NN O O
be NN O O
informed NN O O
that NN O O
HORIZANT NN O O
increases NN O O
the NN O O
risk NN O O
of NN O O
suicidal NN O O
thoughts NN O O
and NN O O
behavior NN O O
and NN O O
should NN O O
be NN O O
advised NN O O
of NN O O
the NN O O
need NN O O
to NN O O
be NN O O
alert NN O O
for NN O O
the NN O O
emergence NN O O
or NN O O
worsening NN O O
of NN O O
the NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
depression NN O O
, NN O O
any NN O O
unusual NN O O
changes NN O O
in NN O O
mood NN O O
or NN O O
behavior NN O O
, NN O O
or NN O O
the NN O O
emergence NN O O
of NN O O
suicidal NN O O
thoughts NN O O
, NN O O
behavior NN O O
, NN O O
or NN O O
thoughts NN O O
about NN O O
self NN O O
- NN O O
harm NN O O
. NN O O
Behaviors NN O O
of NN O O
concern NN O O
should NN O O
be NN O O
reported NN O O
immediately NN O O
to NN O O
healthcare NN O O
providers NN O O
. NN O O
5.5 NN O O
Drug NN O O
Reaction NN O O
With NN O O
Eosinophilia NN O O
and NN O O
Systemic NN O O
Symptoms NN O O
( NN O O
DRESS)/Multiorgan NN O O
Hypersensitivity NN O O
Drug NN B-AdverseReaction B-AdverseReaction
Reaction NN I-AdverseReaction I-AdverseReaction
with NN I-AdverseReaction I-AdverseReaction
Eosinophilia NN I-AdverseReaction I-AdverseReaction
and NN I-AdverseReaction I-AdverseReaction
Systemic NN I-AdverseReaction I-AdverseReaction
Symptoms NN I-AdverseReaction I-AdverseReaction
( NN O O
DRESS NN O O
) NN O O
, NN O O
also NN O O
known NN O O
as NN O O
multiorgan NN B-AdverseReaction B-AdverseReaction
hypersensitivity NN I-AdverseReaction I-AdverseReaction
has NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
taking NN O O
antiepileptic NN B-DrugClass B-DrugClass
drugs NN I-DrugClass I-DrugClass
including NN O O
gabapentin NN O O
. NN O O
HORIZANT NN O O
is NN O O
a NN O O
prodrug NN O O
of NN O O
gabapentin NN O O
. NN O O
Some NN O O
of NN O O
these NN O O
events NN O O
have NN O O
been NN O O
fatal NN B-AdverseReaction B-AdverseReaction
or NN O O
life NN O O
- NN O O
threatening NN O O
. NN O O
DRESS NN B-AdverseReaction B-AdverseReaction
typically NN O O
, NN O O
although NN O O
not NN O O
exclusively NN O O
, NN O O
presents NN O O
with NN O O
fever NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
and/or NN O O
lymphadenopathy NN B-AdverseReaction B-AdverseReaction
in NN O O
association NN O O
with NN O O
other NN O O
organ NN O O
system NN O O
involvement NN O O
, NN O O
such NN O O
as NN O O
hepatitis NN B-AdverseReaction B-AdverseReaction
nephritis NN B-AdverseReaction B-AdverseReaction
hematological NN B-AdverseReaction B-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
myocarditis NN B-AdverseReaction B-AdverseReaction
or NN O O
myositis NN B-AdverseReaction B-AdverseReaction
sometimes NN O O
resembling NN O O
an NN O O
acute NN O O
viral NN O O
infection NN O O
. NN O O
Eosinophilia NN B-AdverseReaction B-AdverseReaction
is NN O O
often NN O O
present NN O O
. NN O O
Because NN O O
this NN O O
disorder NN O O
is NN O O
variable NN O O
in NN O O
its NN O O
expression NN O O
, NN O O
other NN O O
organ NN O O
systems NN O O
not NN O O
noted NN O O
here NN O O
may NN O O
be NN O O
involved NN O O
. NN O O
It NN O O
is NN O O
important NN O O
to NN O O
note NN O O
that NN O O
early NN O O
manifestations NN O O
of NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
such NN O O
as NN O O
fever NN B-AdverseReaction B-AdverseReaction
or NN O O
lymphadenopathy NN B-AdverseReaction B-AdverseReaction
may NN B-Factor B-Factor
be NN O O
present NN O O
even NN O O
though NN O O
rash NN B-AdverseReaction B-AdverseReaction
is NN O O
not NN B-Negation B-Negation
evident NN I-Negation I-Negation
If NN O O
such NN O O
signs NN O O
or NN O O
symptoms NN O O
are NN O O
present NN O O
, NN O O
the NN O O
patient NN O O
should NN O O
be NN O O
evaluated NN O O
immediately NN O O
. NN O O
HORIZANT NN O O
should NN O O
be NN O O
discontinued NN O O
if NN O O
an NN O O
alternative NN O O
etiology NN O O
for NN O O
the NN O O
signs NN O O
or NN O O
symptoms NN O O
can NN O O
not NN O O
be NN O O
established NN O O
. NN O O
5.6 NN O O
Discontinuation NN O O
of NN O O
HORIZANT NN O O
When NN O O
discontinuing NN O O
HORIZANT NN O O
, NN O O
patients NN O O
with NN O O
RLS NN O O
receiving NN O O
600 NN O O
mg NN O O
or NN O O
less NN O O
once NN O O
daily NN O O
can NN O O
discontinue NN O O
the NN O O
drug NN O O
without NN O O
tapering NN O O
. NN O O
If NN O O
the NN O O
recommended NN O O
dose NN O O
is NN O O
exceeded NN O O
, NN O O
the NN O O
dose NN O O
should NN O O
be NN O O
reduced NN O O
to NN O O
600 NN O O
mg NN O O
daily NN O O
for NN O O
1 NN O O
week NN O O
prior NN O O
to NN O O
discontinuation NN O O
to NN O O
minimize NN O O
the NN O O
potential NN O O
of NN O O
withdrawal NN O O
seizure NN O O
. NN O O
In NN O O
patients NN O O
with NN O O
PHN NN O O
receiving NN O O
HORIZANT NN O O
twice NN O O
daily NN O O
, NN O O
the NN O O
dose NN O O
should NN O O
be NN O O
reduced NN O O
to NN O O
once NN O O
daily NN O O
for NN O O
1 NN O O
week NN O O
prior NN O O
to NN O O
discontinuation NN O O
to NN O O
minimize NN O O
the NN O O
potential NN O O
of NN O O
withdrawal NN O O
seizure NN O O
, NN O O
see NN O O
Table NN O O
2 NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
] NN O O
. NN O O
5.7 NN O O
Tumorigenic NN O O
Potential NN O O
In NN O O
an NN O O
oral NN O O
carcinogenicity NN O O
study NN O O
, NN O O
gabapentin NN O O
enacarbil NN O O
increased NN O O
the NN O O
incidence NN O O
of NN O O
pancreatic NN B-AdverseReaction B-AdverseReaction
acinar NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
adenoma NN I-AdverseReaction I-AdverseReaction
and NN O O
carcinoma NN O O
in NN O O
male NN O O
and NN O O
female NN O O
rats NN B-Animal B-Animal
[ NN O O
see NN O O
Nonclinical NN O O
Toxicology NN O O
( NN O O
13.1 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
clinical NN O O
significance NN O O
of NN O O
this NN O O
finding NN O O
is NN O O
unknown NN O O
. NN O O
In NN O O
clinical NN O O
studies NN O O
of NN O O
gabapentin NN O O
as NN O O
adjunctive NN O O
therapy NN O O
in NN O O
epilepsy NN O O
comprising NN O O
2,085 NN O O
patient NN O O
- NN O O
years NN O O
of NN O O
exposure NN O O
in NN O O
patients NN O O
>12 NN O O
years NN O O
of NN O O
age NN O O
, NN O O
new NN O O
tumors NN B-AdverseReaction B-AdverseReaction
were NN O O
reported NN O O
in NN O O
10 NN O O
patients NN O O
( NN O O
2 NN O O
breast NN O O
, NN O O
3 NN O O
brain NN O O
, NN O O
2 NN O O
lung NN O O
, NN O O
1 NN O O
adrenal NN O O
, NN O O
1 NN O O
non NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Hodgkin NN I-AdverseReaction I-AdverseReaction
's NN I-AdverseReaction I-AdverseReaction
lymphoma NN I-AdverseReaction I-AdverseReaction
1 NN O O
endometrial NN B-AdverseReaction B-AdverseReaction
carcinoma NN I-AdverseReaction I-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
situ NN I-AdverseReaction I-AdverseReaction
and NN O O
preexisting NN O O
tumors NN O O
worsened NN O O
in NN O O
11 NN O O
patients NN O O
( NN O O
9 NN O O
brain NN O O
, NN O O
1 NN O O
breast NN O O
, NN O O
1 NN O O
prostate NN O O
) NN O O
during NN O O
or NN O O
up NN O O
to NN O O
2 NN O O
years NN O O
following NN O O
discontinuation NN O O
of NN O O
gabapentin NN O O
. NN O O
Without NN O O
knowledge NN O O
of NN O O
the NN O O
background NN O O
incidence NN O O
and NN O O
recurrence NN O O
in NN O O
a NN O O
similar NN O O
population NN O O
not NN O O
treated NN O O
with NN O O
gabapentin NN O O
, NN O O
it NN O O
is NN O O
impossible NN O O
to NN O O
know NN O O
whether NN O O
the NN O O
incidence NN O O
reported NN O O
in NN O O
this NN O O
cohort NN O O
is NN O O
or NN O O
is NN O O
not NN O O
affected NN O O
by NN O O
treatment NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
with NN O O
NORTHERA NN O O
are NN O O
included NN O O
in NN O O
more NN O O
detail NN O O
in NN O O
the NN O O
Warnings NN O O
and NN O O
Precautions NN O O
section NN O O
of NN O O
the NN O O
label NN O O
: NN O O
* NN O O
Supine NN B-AdverseReaction B-AdverseReaction
Hypertension NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Hyperpyrexia NN B-AdverseReaction B-AdverseReaction
and NN O O
Confusion NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
May NN B-Factor B-Factor
exacerbate NN O O
existing NN O O
ischemic NN O O
heart NN O O
disease NN O O
, NN O O
arrhythmias NN O O
, NN O O
and NN O O
congestive NN O O
heart NN O O
failure NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
Headache NN B-AdverseReaction B-AdverseReaction
dizziness NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
hypertension NN B-AdverseReaction B-AdverseReaction
and NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
( NN O O
greater NN O O
than NN O O
5 NN O O
% NN O O
) NN O O
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Lundbeck NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
455 NN O O
- NN O O
1141 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O
The NN O O
safety NN O O
evaluation NN O O
of NN O O
NORTHERA NN O O
is NN O O
based NN O O
on NN O O
two NN O O
placebo NN O O
- NN O O
controlled NN O O
studies NN O O
1 NN O O
to NN O O
2 NN O O
weeks NN O O
in NN O O
duration NN O O
( NN O O
Studies NN O O
301 NN O O
and NN O O
302 NN O O
) NN O O
, NN O O
one NN O O
8-week NN O O
placebo NN O O
- NN O O
controlled NN O O
study NN O O
( NN O O
Study NN O O
306 NN O O
) NN O O
, NN O O
and NN O O
two NN O O
long NN O O
- NN O O
term NN O O
, NN O O
open NN O O
- NN O O
label NN O O
extension NN O O
studies NN O O
( NN O O
Studies NN O O
303 NN O O
and NN O O
304 NN O O
) NN O O
. NN O O
In NN O O
the NN O O
placebo NN O O
- NN O O
controlled NN O O
studies NN O O
, NN O O
a NN O O
total NN O O
of NN O O
485 NN O O
patients NN O O
with NN O O
Parkinson NN O O
's NN O O
disease NN O O
, NN O O
multiple NN O O
system NN O O
atrophy NN O O
, NN O O
pure NN O O
autonomic NN O O
failure NN O O
, NN O O
dopamine NN O O
beta NN O O
- NN O O
hydroxylase NN O O
deficiency NN O O
, NN O O
or NN O O
non NN O O
- NN O O
diabetic NN O O
autonomic NN O O
neuropathy NN O O
were NN O O
randomized NN O O
and NN O O
treated NN O O
, NN O O
245 NN O O
with NN O O
NORTHERA NN O O
and NN O O
240 NN O O
with NN O O
placebo NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
. NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Experience NN O O
The NN O O
most NN O O
commonly NN O O
observed NN O O
adverse NN O O
reactions NN O O
( NN O O
those NN O O
occurring NN O O
at NN O O
an NN O O
incidence NN O O
of NN O O
greater NN O O
than NN O O
5 NN O O
% NN O O
in NN O O
the NN O O
NORTHERA NN O O
group NN O O
and NN O O
with NN O O
at NN O O
least NN O O
a NN O O
3 NN O O
% NN O O
greater NN O O
incidence NN O O
in NN O O
the NN O O
NORTHERA NN O O
group NN O O
than NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
) NN O O
in NN O O
NORTHERA NN O O
- NN O O
treated NN O O
patients NN O O
during NN O O
the NN O O
three NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
were NN O O
headache NN B-AdverseReaction B-AdverseReaction
dizziness NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
hypertension NN B-AdverseReaction B-AdverseReaction
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
leading NN O O
to NN O O
discontinuation NN O O
from NN O O
NORTHERA NN O O
were NN O O
hypertension NN B-AdverseReaction B-AdverseReaction
or NN O O
increased NN B-AdverseReaction B-AdverseReaction
blood NN I-AdverseReaction I-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
and NN O O
nausea NN B-AdverseReaction B-AdverseReaction
Table NN O O
1 NN O O
. NN O O
Most NN O O
Common NN O O
Adverse NN O O
Reactions NN O O
Occurring NN O O
More NN O O
Frequently NN O O
in NN O O
the NN O O
NORTHERA NN O O
Group NN O O
Study NN O O
301 NN O O
and NN O O
Study NN O O
302 NN O O
( NN O O
1 NN O O
to NN O O
2 NN O O
Weeks NN O O
Randomized NN O O
Treatment NN O O
) NN O O
Study NN O O
306 NN O O
( NN O O
8 NN O O
to NN O O
10 NN O O
Weeks NN O O
Randomized NN O O
Treatment NN O O
) NN O O
Placebo NN O O
( NN O O
N=132 NN O O
) NN O O
n NN O O
( NN O O
% NN O O
) NN O O
NORTHERA NN O O
( NN O O
N=131 NN O O
) NN O O
n NN O O
( NN O O
% NN O O
) NN O O
Placebo NN O O
( NN O O
N=108 NN O O
) NN O O
n NN O O
( NN O O
% NN O O
) NN O O
NORTHERA NN O O
( NN O O
N=114 NN O O
) NN O O
n NN O O
( NN O O
% NN O O
) NN O O
Headache NN B-AdverseReaction B-AdverseReaction
4 NN O O
( NN O O
3.0 NN O O
) NN O O
8 NN O O
( NN O O
6.1 NN O O
) NN O O
8 NN O O
( NN O O
7.4 NN O O
) NN O O
15 NN O O
( NN O O
13.2 NN O O
) NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
2 NN O O
( NN O O
1.5 NN O O
) NN O O
5 NN O O
( NN O O
3.8 NN O O
) NN O O
5 NN O O
( NN O O
4.6 NN O O
) NN O O
11 NN O O
( NN O O
9.6 NN O O
) NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
2 NN O O
( NN O O
1.5 NN O O
) NN O O
2 NN O O
( NN O O
1.5 NN O O
) NN O O
5 NN O O
( NN O O
4.6 NN O O
) NN O O
10 NN O O
( NN O O
8.8 NN O O
) NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
0 NN O O
2 NN O O
( NN O O
1.5 NN O O
) NN O O
1 NN O O
( NN O O
0.9 NN O O
) NN O O
8 NN O O
( NN O O
7.0 NN O O
) NN O O
Note NN O O
: NN O O
n=number NN O O
of NN O O
patients NN O O
. NN O O
Table NN O O
displays NN O O
adverse NN O O
reactions NN O O
that NN O O
were NN O O
reported NN O O
in NN O O
greater NN O O
than NN O O
5 NN O O
% NN O O
of NN O O
patients NN O O
in NN O O
the NN O O
NORTHERA NN O O
group NN O O
and NN O O
with NN O O
at NN O O
least NN O O
a NN O O
3 NN O O
% NN O O
greater NN O O
incidence NN O O
in NN O O
the NN O O
NORTHERA NN O O
group NN O O
than NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
. NN O O
Long NN O O
- NN O O
Term NN O O
, NN O O
Open NN O O
- NN O O
Label NN O O
Trials NN O O
with NN O O
NORTHERA NN O O
In NN O O
the NN O O
long NN O O
- NN O O
term NN O O
, NN O O
open NN O O
- NN O O
label NN O O
extension NN O O
studies NN O O
, NN O O
a NN O O
total NN O O
of NN O O
422 NN O O
patients NN O O
, NN O O
mean NN O O
age NN O O
65 NN O O
years NN O O
, NN O O
were NN O O
treated NN O O
with NN O O
NORTHERA NN O O
for NN O O
a NN O O
mean NN O O
total NN O O
exposure NN O O
of NN O O
approximately NN O O
one NN O O
year NN O O
. NN O O
The NN O O
commonly NN O O
reported NN O O
adverse NN O O
events NN O O
were NN O O
falls NN B-AdverseReaction B-AdverseReaction
( NN O O
24 NN O O
% NN O O
) NN O O
, NN O O
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
( NN O O
15 NN O O
% NN O O
) NN O O
, NN O O
headache NN B-AdverseReaction B-AdverseReaction
( NN O O
13 NN O O
% NN O O
) NN O O
, NN O O
syncope NN B-AdverseReaction B-AdverseReaction
( NN O O
13 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
( NN O O
10 NN O O
% NN O O
) NN O O
. NN O O
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
SUPINE NN B-AdverseReaction B-AdverseReaction
HYPERTENSION NN I-AdverseReaction I-AdverseReaction
WARNING NN O O
: NN O O
SUPINE NN B-AdverseReaction B-AdverseReaction
HYPERTENSION NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
supine NN O O
blood NN O O
pressure NN O O
prior NN O O
to NN O O
and NN O O
during NN O O
treatment NN O O
and NN O O
more NN O O
frequently NN O O
when NN O O
increasing NN O O
doses NN O O
. NN O O
Elevating NN O O
the NN O O
head NN O O
of NN O O
the NN O O
bed NN O O
lessens NN O O
the NN O O
risk NN O O
of NN O O
supine NN O O
hypertension NN O O
, NN O O
and NN O O
blood NN O O
pressure NN O O
should NN O O
be NN O O
measured NN O O
in NN O O
this NN O O
position NN O O
. NN O O
If NN O O
supine NN O O
hypertension NN O O
can NN O O
not NN O O
be NN O O
managed NN O O
by NN O O
elevation NN O O
of NN O O
the NN O O
head NN O O
of NN O O
the NN O O
bed NN O O
, NN O O
reduce NN O O
or NN O O
discontinue NN O O
NORTHERA NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
EXCERPT NN O O
: NN O O
WARNING NN O O
: NN O O
SUPINE NN B-AdverseReaction B-AdverseReaction
HYPERTENSION NN I-AdverseReaction I-AdverseReaction
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
. NN O O
Monitor NN O O
supine NN O O
blood NN O O
pressure NN O O
prior NN O O
to NN O O
and NN O O
during NN O O
treatment NN O O
and NN O O
more NN O O
frequently NN O O
when NN O O
increasing NN O O
doses NN O O
. NN O O
Elevating NN O O
the NN O O
head NN O O
of NN O O
the NN O O
bed NN O O
lessens NN O O
the NN O O
risk NN O O
of NN O O
supine NN O O
hypertension NN O O
, NN O O
and NN O O
blood NN O O
pressure NN O O
should NN O O
be NN O O
measured NN O O
in NN O O
this NN O O
position NN O O
. NN O O
If NN O O
supine NN O O
hypertension NN O O
can NN O O
not NN O O
be NN O O
managed NN O O
by NN O O
elevation NN O O
of NN O O
the NN O O
head NN O O
of NN O O
the NN O O
bed NN O O
, NN O O
reduce NN O O
or NN O O
discontinue NN O O
NORTHERA NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
NORTHERA NN O O
can NN B-Factor B-Factor
cause NN O O
supine NN B-AdverseReaction B-AdverseReaction
hypertension NN I-AdverseReaction I-AdverseReaction
and NN O O
may NN B-Factor B-Factor
increase NN O O
cardiovascular NN B-AdverseReaction B-AdverseReaction
risk NN I-AdverseReaction I-AdverseReaction
if NN O O
supine NN B-AdverseReaction B-AdverseReaction
hypertension NN I-AdverseReaction I-AdverseReaction
is NN O O
not NN O O
well NN O O
- NN O O
managed NN O O
( NN O O
5.1 NN O O
) NN O O
. NN O O
* NN O O
Hyperpyrexia NN B-AdverseReaction B-AdverseReaction
and NN O O
confusion NN B-AdverseReaction B-AdverseReaction
( NN O O
5.2 NN O O
) NN O O
* NN O O
May NN B-Factor B-Factor
exacerbate NN O O
symptoms NN O O
in NN O O
patients NN O O
with NN O O
existing NN O O
ischemic NN O O
heart NN O O
disease NN O O
, NN O O
arrhythmias NN O O
, NN O O
and NN O O
congestive NN O O
heart NN O O
failure NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Allergic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
( NN O O
5.4 NN O O
) NN O O
5.1 NN O O
Supine NN O O
Hypertension NN O O
NORTHERA NN O O
therapy NN O O
may NN B-Factor B-Factor
cause NN O O
or NN O O
exacerbate NN O O
supine NN B-AdverseReaction B-AdverseReaction
hypertension NN I-AdverseReaction I-AdverseReaction
in NN O O
patients NN O O
with NN O O
NOH. NN O O
Patients NN O O
should NN O O
be NN O O
advised NN O O
to NN O O
elevate NN O O
the NN O O
head NN O O
of NN O O
the NN O O
bed NN O O
when NN O O
resting NN O O
or NN O O
sleeping NN O O
. NN O O
Monitor NN O O
blood NN O O
pressure NN O O
, NN O O
both NN O O
in NN O O
the NN O O
supine NN O O
position NN O O
and NN O O
in NN O O
the NN O O
recommended NN O O
head NN O O
- NN O O
elevated NN O O
sleeping NN O O
position NN O O
. NN O O
Reduce NN O O
or NN O O
discontinue NN O O
NORTHERA NN O O
if NN O O
supine NN O O
hypertension NN O O
persists NN O O
. NN O O
If NN O O
supine NN O O
hypertension NN O O
is NN O O
not NN O O
well NN O O
- NN O O
managed NN O O
, NN O O
NORTHERA NN O O
may NN O O
increase NN O O
the NN O O
risk NN O O
of NN O O
cardiovascular NN O O
events NN O O
. NN O O
5.2 NN O O
Hyperpyrexia NN O O
and NN O O
Confusion NN O O
Post NN O O
- NN O O
marketing NN O O
cases NN O O
of NN O O
a NN O O
symptom NN O O
complex NN O O
resembling NN O O
neuroleptic NN B-AdverseReaction B-AdverseReaction
malignant NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
NMS NN O O
) NN O O
have NN O O
been NN O O
reported NN O O
with NN O O
NORTHERA NN O O
use NN O O
during NN O O
post NN O O
- NN O O
marketing NN O O
surveillance NN O O
in NN O O
Japan NN O O
. NN O O
Observe NN O O
patients NN O O
carefully NN O O
when NN O O
the NN O O
dosage NN O O
of NN O O
NORTHERA NN O O
is NN O O
changed NN O O
or NN O O
when NN O O
concomitant NN O O
levodopa NN O O
is NN O O
reduced NN O O
abruptly NN O O
or NN O O
discontinued NN O O
, NN O O
especially NN O O
if NN O O
the NN O O
patient NN O O
is NN O O
receiving NN O O
neuroleptics NN O O
. NN O O
NMS NN B-AdverseReaction B-AdverseReaction
is NN O O
an NN O O
uncommon NN O O
but NN O O
life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
syndrome NN O O
characterized NN O O
by NN O O
fever NN B-AdverseReaction B-AdverseReaction
or NN O O
hyperthermia NN B-AdverseReaction B-AdverseReaction
muscle NN B-AdverseReaction B-AdverseReaction
rigidity NN I-AdverseReaction I-AdverseReaction
involuntary NN B-AdverseReaction B-AdverseReaction
movements NN I-AdverseReaction I-AdverseReaction
altered NN B-AdverseReaction B-AdverseReaction
consciousness NN I-AdverseReaction I-AdverseReaction
and NN O O
mental NN B-AdverseReaction B-AdverseReaction
status NN I-AdverseReaction I-AdverseReaction
changes NN I-AdverseReaction I-AdverseReaction
The NN O O
early NN O O
diagnosis NN O O
of NN O O
this NN O O
condition NN O O
is NN O O
important NN O O
for NN O O
the NN O O
appropriate NN O O
management NN O O
of NN O O
these NN O O
patients NN O O
. NN O O
5.3 NN O O
Ischemic NN O O
Heart NN O O
Disease NN O O
, NN O O
Arrhythmias NN O O
, NN O O
and NN O O
Congestive NN O O
Heart NN O O
Failure NN O O
NORTHERA NN O O
may NN B-Factor B-Factor
exacerbate NN O O
existing NN O O
ischemic NN O O
heart NN O O
disease NN O O
, NN O O
arrhythmias NN O O
, NN O O
and NN O O
congestive NN O O
heart NN O O
failure NN O O
. NN O O
Careful NN O O
consideration NN O O
should NN O O
be NN O O
given NN O O
to NN O O
this NN O O
potential NN O O
risk NN O O
prior NN O O
to NN O O
initiating NN O O
therapy NN O O
in NN O O
patients NN O O
with NN O O
these NN O O
conditions NN O O
. NN O O
5.4 NN O O
Allergic NN O O
Reactions NN O O
This NN O O
product NN O O
contains NN O O
FD&C NN O O
Yellow NN O O
No NN O O
. NN O O
5 NN O O
( NN O O
tartrazine NN O O
) NN O O
which NN O O
may NN B-Factor B-Factor
cause NN O O
allergic NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
type NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
( NN O O
including NN O O
bronchial NN B-AdverseReaction B-AdverseReaction
asthma NN I-AdverseReaction I-AdverseReaction
in NN O O
certain NN O O
susceptible NN O O
persons NN O O
. NN O O
Although NN O O
the NN O O
overall NN O O
incidence NN O O
of NN O O
FD&C NN O O
Yellow NN O O
No NN O O
. NN O O
5 NN O O
( NN O O
tartrazine NN O O
) NN O O
sensitivity NN O O
in NN O O
the NN O O
general NN O O
population NN O O
is NN O O
low NN O O
, NN O O
it NN O O
is NN O O
frequently NN O O
seen NN O O
in NN O O
patients NN O O
who NN O O
also NN O O
have NN O O
aspirin NN O O
hypersensitivity NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
The NN O O
most NN O O
frequently NN O O
reported NN O O
adverse NN O O
reactions NN O O
( NN O O
>= NN O O
5 NN O O
% NN O O
) NN O O
in NN O O
clinical NN O O
trials NN O O
were NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
and NN O O
included NN O O
: NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
pyrexia NN B-AdverseReaction B-AdverseReaction
flushing NN B-AdverseReaction B-AdverseReaction
hot NN O O
, NN O O
urticaria NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
hyperhidrosis NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
decreased NN B-AdverseReaction B-AdverseReaction
oxygen NN I-AdverseReaction I-AdverseReaction
saturation NN I-AdverseReaction I-AdverseReaction
tachycardia NN B-AdverseReaction B-AdverseReaction
tachypnea NN B-AdverseReaction B-AdverseReaction
chest NN B-AdverseReaction B-AdverseReaction
discomfort NN I-AdverseReaction I-AdverseReaction
dizziness NN B-AdverseReaction B-AdverseReaction
muscle NN B-AdverseReaction B-AdverseReaction
twitching NN I-AdverseReaction I-AdverseReaction
agitation NN B-AdverseReaction B-AdverseReaction
cyanosis NN B-AdverseReaction B-AdverseReaction
erythema NN B-AdverseReaction B-AdverseReaction
hypertension NN B-AdverseReaction B-AdverseReaction
blood NN O O
pressure NN O O
, NN O O
pallor NN B-AdverseReaction B-AdverseReaction
rigors NN B-AdverseReaction B-AdverseReaction
tremor NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
and NN O O
myalgia NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
. NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Genzyme NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
745 NN O O
- NN O O
4447 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O
The NN O O
following NN O O
serious NN O O
adverse NN O O
reactions NN O O
are NN O O
described NN O O
below NN O O
and NN O O
elsewhere NN O O
in NN O O
the NN O O
labeling NN O O
: NN O O
* NN O O
Anaphylaxis NN O O
and NN O O
hypersensitivity NN O O
reactions NN O O
[ NN O O
seeWarnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
In NN O O
clinical NN O O
trials NN O O
, NN O O
the NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>= NN O O
5 NN O O
% NN O O
) NN O O
following NN O O
alglucosidase NN O O
alfa NN O O
treatment NN O O
were NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
and NN O O
included NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
pyrexia NN B-AdverseReaction B-AdverseReaction
flushing NN B-AdverseReaction B-AdverseReaction
hot NN O O
, NN O O
urticaria NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
hyperhidrosis NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
decreased NN B-AdverseReaction B-AdverseReaction
oxygen NN I-AdverseReaction I-AdverseReaction
saturation NN I-AdverseReaction I-AdverseReaction
tachycardia NN B-AdverseReaction B-AdverseReaction
tachypnea NN B-AdverseReaction B-AdverseReaction
chest NN B-AdverseReaction B-AdverseReaction
discomfort NN I-AdverseReaction I-AdverseReaction
dizziness NN B-AdverseReaction B-AdverseReaction
muscle NN B-AdverseReaction B-AdverseReaction
twitching NN I-AdverseReaction I-AdverseReaction
agitation NN B-AdverseReaction B-AdverseReaction
cyanosis NN B-AdverseReaction B-AdverseReaction
erythema NN B-AdverseReaction B-AdverseReaction
hypertension NN B-AdverseReaction B-AdverseReaction
blood NN O O
pressure NN O O
, NN O O
pallor NN B-AdverseReaction B-AdverseReaction
rigors NN B-AdverseReaction B-AdverseReaction
tremor NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
and NN O O
myalgia NN B-AdverseReaction B-AdverseReaction
Clinical NN O O
Trials NN O O
in NN O O
Infantile NN O O
- NN O O
Onset NN O O
and NN O O
Juvenile NN O O
- NN O O
Onset NN O O
Pompe NN O O
Disease NN O O
Two NN O O
multicenter NN O O
, NN O O
open NN O O
- NN O O
label NN O O
clinical NN O O
trials NN O O
were NN O O
conducted NN O O
in NN O O
39 NN O O
infantile NN O O
- NN O O
onset NN O O
Pompe NN O O
disease NN O O
patients NN O O
, NN O O
ages NN O O
1 NN O O
month NN O O
to NN O O
3.5 NN O O
years NN O O
old NN O O
. NN O O
Approximately NN O O
half NN O O
of NN O O
the NN O O
patients NN O O
( NN O O
54 NN O O
% NN O O
) NN O O
were NN O O
male NN O O
. NN O O
Patients NN O O
were NN O O
treated NN O O
with NN O O
alglucosidase NN O O
alfa NN O O
20 NN O O
or NN O O
40 NN O O
mg/kg NN O O
every NN O O
other NN O O
week NN O O
for NN O O
periods NN O O
ranging NN O O
from NN O O
1 NN O O
to NN O O
106 NN O O
weeks NN O O
( NN O O
mean NN O O
: NN O O
61 NN O O
weeks NN O O
) NN O O
. NN O O
The NN O O
most NN O O
serious NN O O
adverse NN O O
reactions NN O O
reported NN O O
with NN O O
alglucosidase NN O O
alfa NN O O
treatment NN O O
included NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
and NN O O
acute NN B-AdverseReaction B-AdverseReaction
cardiorespiratory NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
requiring NN O O
intervention NN O O
in NN O O
clinical NN O O
trials NN O O
were NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
occurring NN O O
in NN O O
20 NN O O
of NN O O
39 NN O O
( NN O O
51 NN O O
% NN O O
) NN O O
patients NN O O
treated NN O O
with NN O O
alglucosidase NN O O
alfa NN O O
, NN O O
and NN O O
included NN O O
rash NN B-AdverseReaction B-AdverseReaction
pyrexia NN B-AdverseReaction B-AdverseReaction
urticaria NN B-AdverseReaction B-AdverseReaction
flushing NN B-AdverseReaction B-AdverseReaction
decreased NN B-AdverseReaction B-AdverseReaction
oxygen NN I-AdverseReaction I-AdverseReaction
saturation NN I-AdverseReaction I-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
tachypnea NN B-AdverseReaction B-AdverseReaction
tachycardia NN B-AdverseReaction B-AdverseReaction
hypertension NN B-AdverseReaction B-AdverseReaction
blood NN O O
pressure NN O O
, NN O O
pallor NN B-AdverseReaction B-AdverseReaction
rigors NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
cyanosis NN B-AdverseReaction B-AdverseReaction
agitation NN B-AdverseReaction B-AdverseReaction
and NN O O
tremor NN B-AdverseReaction B-AdverseReaction
These NN O O
reactions NN O O
were NN O O
more NN O O
likely NN O O
to NN O O
occur NN O O
with NN O O
higher NN O O
infusion NN O O
rates NN O O
. NN O O
Some NN O O
patients NN O O
who NN O O
were NN O O
pre NN O O
- NN O O
treated NN O O
with NN O O
antihistamines NN O O
, NN O O
antipyretics NN O O
and/or NN O O
corticosteroids NN O O
still NN O O
experienced NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
Table NN O O
2 NN O O
summarizes NN O O
all NN O O
adverse NN O O
reactions NN O O
occurring NN O O
in NN O O
>= NN O O
5 NN O O
% NN O O
of NN O O
patients NN O O
( NN O O
2 NN O O
or NN O O
more NN O O
patients NN O O
) NN O O
treated NN O O
with NN O O
alglucosidase NN O O
alfa NN O O
in NN O O
clinical NN O O
trials NN O O
described NN O O
above NN O O
. NN O O
Table NN O O
2 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
that NN O O
Occurred NN O O
in NN O O
At NN O O
Least NN O O
5 NN O O
% NN O O
of NN O O
Infantile NN O O
- NN O O
Onset NN O O
Patients NN O O
Treated NN O O
with NN O O
Alglucosidase NN O O
Alfa NN O O
in NN O O
Clinical NN O O
Trials NN O O
Number NN O O
of NN O O
Patients(N=39)n NN O O
( NN O O
% NN O O
) NN O O
Adverse NN O O
Reaction NN O O
20 NN O O
( NN O O
51 NN O O
) NN O O
Rash NN B-AdverseReaction B-AdverseReaction
( NN O O
including NN O O
rash NN B-AdverseReaction B-AdverseReaction
erythematous NN I-AdverseReaction I-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
macular NN I-AdverseReaction I-AdverseReaction
and NN O O
maculo NN O O
- NN O O
papular NN O O
) NN O O
7 NN O O
( NN O O
18 NN O O
) NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
6 NN O O
( NN O O
15 NN O O
) NN O O
Urticaria NN B-AdverseReaction B-AdverseReaction
5 NN O O
( NN O O
13 NN O O
) NN O O
Flushing NN B-AdverseReaction B-AdverseReaction
5 NN O O
( NN O O
13 NN O O
) NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
Blood NN O O
Pressure NN O O
4 NN O O
( NN O O
10 NN O O
) NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
Oxygen NN I-AdverseReaction I-AdverseReaction
Saturation NN I-AdverseReaction I-AdverseReaction
3 NN O O
( NN O O
8 NN O O
) NN O O
Cough NN B-AdverseReaction B-AdverseReaction
3 NN O O
( NN O O
8 NN O O
) NN O O
Tachypnea NN B-AdverseReaction B-AdverseReaction
3 NN O O
( NN O O
8 NN O O
) NN O O
Tachycardia NN B-AdverseReaction B-AdverseReaction
3 NN O O
( NN O O
8 NN O O
) NN O O
Erythema NN B-AdverseReaction B-AdverseReaction
2 NN O O
( NN O O
5 NN O O
) NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
2 NN O O
( NN O O
5 NN O O
) NN O O
Rigors NN B-AdverseReaction B-AdverseReaction
2 NN O O
( NN O O
5 NN O O
) NN O O
Pallor NN B-AdverseReaction B-AdverseReaction
2 NN O O
( NN O O
5 NN O O
) NN O O
Cyanosis NN B-AdverseReaction B-AdverseReaction
2 NN O O
( NN O O
5 NN O O
) NN O O
Agitation NN B-AdverseReaction B-AdverseReaction
2 NN O O
( NN O O
5 NN O O
) NN O O
Tremor NN B-AdverseReaction B-AdverseReaction
2 NN O O
( NN O O
5 NN O O
) NN O O
An NN O O
open NN O O
- NN O O
label NN O O
, NN O O
single NN O O
- NN O O
center NN O O
trial NN O O
was NN O O
conducted NN O O
in NN O O
18 NN O O
treatment NN O O
- NN O O
naive NN O O
infantile NN O O
- NN O O
onset NN O O
Pompe NN O O
disease NN O O
patients NN O O
who NN O O
were NN O O
treated NN O O
exclusively NN O O
with NN O O
alglucosidase NN O O
alfa NN O O
. NN O O
Adverse NN O O
reactions NN O O
observed NN O O
in NN O O
these NN O O
patients NN O O
were NN O O
similar NN O O
to NN O O
infantile NN O O
- NN O O
onset NN O O
Pompe NN O O
disease NN O O
patients NN O O
who NN O O
received NN O O
alglucosidase NN O O
alfa NN O O
in NN O O
other NN O O
clinical NN O O
trials NN O O
. NN O O
Additional NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
observed NN O O
in NN O O
infantile NN O O
- NN O O
onset NN O O
Pompe NN O O
disease NN O O
patients NN O O
treated NN O O
in NN O O
other NN O O
clinical NN O O
trials NN O O
and NN O O
expanded NN O O
access NN O O
programs NN O O
with NN O O
alglucosidase NN O O
alfa NN O O
included NN O O
livedo NN B-AdverseReaction B-AdverseReaction
reticularis NN I-AdverseReaction I-AdverseReaction
irritability NN B-AdverseReaction B-AdverseReaction
retching NN B-AdverseReaction B-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
lacrimation NN I-AdverseReaction I-AdverseReaction
ventricular NN B-AdverseReaction B-AdverseReaction
extrasystoles NN I-AdverseReaction I-AdverseReaction
nodal NN B-AdverseReaction B-AdverseReaction
rhythm NN I-AdverseReaction I-AdverseReaction
rales NN B-AdverseReaction B-AdverseReaction
respiratory NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
irritation NN I-AdverseReaction I-AdverseReaction
and NN O O
cold NN B-AdverseReaction B-AdverseReaction
sweat NN I-AdverseReaction I-AdverseReaction
Safety NN O O
was NN O O
also NN O O
evaluated NN O O
in NN O O
99 NN O O
patients NN O O
( NN O O
51 NN O O
male NN O O
, NN O O
48 NN O O
females NN O O
) NN O O
with NN O O
Pompe NN O O
disease NN O O
in NN O O
an NN O O
ongoing NN O O
, NN O O
open NN O O
- NN O O
label NN O O
, NN O O
prospective NN O O
study NN O O
in NN O O
patients NN O O
12 NN O O
months NN O O
of NN O O
age NN O O
and NN O O
older NN O O
who NN O O
were NN O O
previously NN O O
treated NN O O
with NN O O
the NN O O
160 NN O O
L NN O O
scale NN O O
of NN O O
alglucosidase NN O O
alfa NN O O
and NN O O
switched NN O O
to NN O O
the NN O O
4000 NN O O
L NN O O
scale NN O O
of NN O O
alglucosidase NN O O
alfa NN O O
. NN O O
Patients NN O O
were NN O O
aged NN O O
1 NN O O
to NN O O
18 NN O O
years NN O O
with NN O O
a NN O O
median NN O O
duration NN O O
of NN O O
treatment NN O O
of NN O O
437 NN O O
days NN O O
( NN O O
range NN O O
13 NN O O
to NN O O
466 NN O O
days NN O O
) NN O O
. NN O O
No NN O O
new NN O O
safety NN O O
findings NN O O
were NN O O
observed NN O O
following NN O O
the NN O O
switch NN O O
to NN O O
4000 NN O O
L NN O O
scale NN O O
of NN O O
alglucosidase NN O O
alfa NN O O
. NN O O
Clinical NN O O
Trials NN O O
in NN O O
Late NN O O
- NN O O
Onset NN O O
Pompe NN O O
Disease NN O O
Assessment NN O O
of NN O O
adverse NN O O
reactions NN O O
in NN O O
patients NN O O
with NN O O
late NN O O
- NN O O
onset NN O O
Pompe NN O O
disease NN O O
is NN O O
based NN O O
on NN O O
the NN O O
exposure NN O O
of NN O O
90 NN O O
patients NN O O
( NN O O
45 NN O O
male NN O O
, NN O O
45 NN O O
female NN O O
) NN O O
, NN O O
aged NN O O
10 NN O O
to NN O O
70 NN O O
years NN O O
, NN O O
to NN O O
20 NN O O
mg/kg NN O O
alglucosidase NN O O
alfa NN O O
or NN O O
placebo NN O O
in NN O O
a NN O O
randomized NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
trial NN O O
. NN O O
The NN O O
youngest NN O O
alglucosidase NN O O
alfa NN O O
- NN O O
treated NN O O
patient NN O O
was NN O O
16 NN O O
years NN O O
of NN O O
age NN O O
, NN O O
and NN O O
the NN O O
youngest NN O O
placebo NN O O
- NN O O
treated NN O O
patient NN O O
was NN O O
10 NN O O
years NN O O
of NN O O
age NN O O
. NN O O
All NN O O
patients NN O O
were NN O O
naive NN O O
to NN O O
enzyme NN O O
replacement NN O O
therapy NN O O
. NN O O
Patients NN O O
were NN O O
randomized NN O O
in NN O O
a NN O O
2:1 NN O O
ratio NN O O
and NN O O
received NN O O
alglucosidase NN O O
alfa NN O O
or NN O O
placebo NN O O
every NN O O
other NN O O
week NN O O
for NN O O
78 NN O O
weeks NN O O
( NN O O
18 NN O O
months NN O O
) NN O O
. NN O O
The NN O O
study NN O O
population NN O O
included NN O O
34 NN O O
males NN O O
and NN O O
26 NN O O
females NN O O
( NN O O
n=60 NN O O
) NN O O
in NN O O
the NN O O
alglucosidase NN O O
alfa NN O O
group NN O O
and NN O O
11 NN O O
males NN O O
and NN O O
19 NN O O
females NN O O
( NN O O
n=30 NN O O
) NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
. NN O O
Two NN O O
patients NN O O
receiving NN O O
alglucosidase NN O O
alfa NN O O
discontinued NN O O
the NN O O
trial NN O O
due NN O O
to NN O O
anaphylactic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
Serious NN O O
adverse NN O O
reactions NN O O
reported NN O O
with NN O O
alglucosidase NN O O
alfa NN O O
included NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
which NN O O
presented NN O O
as NN O O
angioedema NN B-AdverseReaction B-AdverseReaction
throat NN B-AdverseReaction B-AdverseReaction
tightness NN I-AdverseReaction I-AdverseReaction
and NN O O
chest NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
One NN O O
patient NN O O
with NN O O
a NN O O
history NN O O
of NN O O
Wolff NN O O
- NN O O
Parkinson NN O O
- NN O O
White NN O O
syndrome NN O O
experienced NN O O
a NN O O
serious NN O O
adverse NN O O
reaction NN O O
of NN O O
supraventricular NN B-AdverseReaction B-AdverseReaction
tachycardia NN I-AdverseReaction I-AdverseReaction
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>= NN O O
3 NN O O
% NN O O
; NN O O
2 NN O O
or NN O O
more NN O O
patients NN O O
) NN O O
observed NN O O
in NN O O
alglucosidase NN O O
alfa NN O O
- NN O O
treated NN O O
patients NN O O
were NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
and NN O O
included NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
urticaria NN B-AdverseReaction B-AdverseReaction
dizziness NN B-AdverseReaction B-AdverseReaction
chest NN B-AdverseReaction B-AdverseReaction
discomfort NN I-AdverseReaction I-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
hyperhidrosis NN B-AdverseReaction B-AdverseReaction
flushing NN B-AdverseReaction B-AdverseReaction
hot NN O O
, NN O O
increased NN B-AdverseReaction B-AdverseReaction
blood NN I-AdverseReaction I-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
paresthesia NN B-AdverseReaction B-AdverseReaction
pyrexia NN B-AdverseReaction B-AdverseReaction
local NN B-AdverseReaction B-AdverseReaction
swelling NN I-AdverseReaction I-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
pruritus NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
and NN O O
throat NN B-AdverseReaction B-AdverseReaction
tightness NN I-AdverseReaction I-AdverseReaction
Delayed NN O O
- NN O O
onset NN O O
reactions NN O O
, NN O O
defined NN O O
as NN O O
adverse NN O O
reactions NN O O
occurring NN O O
2 NN O O
- NN O O
48 NN O O
hours NN O O
after NN O O
completion NN O O
of NN O O
alglucosidase NN O O
alfa NN O O
infusion NN O O
, NN O O
that NN O O
were NN O O
observed NN O O
in NN O O
>= NN O O
3 NN O O
% NN O O
more NN O O
patients NN O O
in NN O O
the NN O O
alglucosidase NN O O
alfa NN O O
- NN O O
treated NN O O
group NN O O
compared NN O O
to NN O O
patients NN O O
in NN O O
the NN O O
placebo NN O O
- NN O O
treated NN O O
group NN O O
in NN O O
the NN O O
controlled NN O O
trial NN O O
, NN O O
included NN O O
hyperhidrosis NN B-AdverseReaction B-AdverseReaction
Additional NN O O
delayed NN O O
- NN O O
onset NN O O
reactions NN O O
occurring NN O O
in NN O O
alglucosidase NN O O
alfa NN O O
- NN O O
treated NN O O
patients NN O O
included NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
myalgia NN B-AdverseReaction B-AdverseReaction
and NN O O
nausea NN B-AdverseReaction B-AdverseReaction
Patients NN O O
should NN O O
be NN O O
counseled NN O O
about NN O O
the NN O O
possibility NN O O
of NN O O
delayed NN O O
- NN O O
onset NN O O
hypersensitivity NN O O
reactions NN O O
and NN O O
given NN O O
proper NN O O
follow NN O O
- NN O O
up NN O O
instructions NN O O
. NN O O
Table NN O O
3 NN O O
summarizes NN O O
the NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
that NN O O
occurred NN O O
in NN O O
at NN O O
least NN O O
3 NN O O
% NN O O
of NN O O
alglucosidase NN O O
alfa NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
with NN O O
a NN O O
higher NN O O
incidence NN O O
than NN O O
the NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
during NN O O
the NN O O
randomized NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
study NN O O
described NN O O
above NN O O
. NN O O
Table NN O O
3 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Occurring NN O O
in NN O O
at NN O O
Least NN O O
3 NN O O
% NN O O
of NN O O
Alglucosidase NN O O
Alfa NN O O
- NN O O
Treated NN O O
Late NN O O
- NN O O
Onset NN O O
Patients NN O O
and NN O O
with NN O O
a NN O O
Higher NN O O
Incidence NN O O
than NN O O
the NN O O
Placebo NN O O
- NN O O
Treated NN O O
Patients NN O O
Adverse NN O O
Reaction NN O O
Alglucosidase NN O O
Alfan=60N NN O O
( NN O O
% NN O O
) NN O O
Placebon=30N NN O O
( NN O O
% NN O O
) NN O O
Hyperhidrosis NN B-AdverseReaction B-AdverseReaction
5 NN O O
( NN O O
8.3 NN O O
) NN O O
0 NN O O
( NN O O
0 NN O O
) NN O O
Urticaria NN B-AdverseReaction B-AdverseReaction
5 NN O O
( NN O O
8.3 NN O O
) NN O O
0 NN O O
( NN O O
0 NN O O
) NN O O
Anaphylaxis NN B-AdverseReaction B-AdverseReaction
4 NN O O
( NN O O
6.7 NN O O
) NN O O
0 NN O O
( NN O O
0 NN O O
) NN O O
Chest NN B-AdverseReaction B-AdverseReaction
Discomfort NN I-AdverseReaction I-AdverseReaction
4 NN O O
( NN O O
6.7 NN O O
) NN O O
1 NN O O
( NN O O
3.3 NN O O
) NN O O
Muscle NN B-AdverseReaction B-AdverseReaction
Twitching NN I-AdverseReaction I-AdverseReaction
4 NN O O
( NN O O
6.7 NN O O
) NN O O
1 NN O O
( NN O O
3.3 NN O O
) NN O O
Myalgia NN B-AdverseReaction B-AdverseReaction
3 NN O O
( NN O O
5.0 NN O O
) NN O O
1 NN O O
( NN O O
3.3 NN O O
) NN O O
Flushing NN B-AdverseReaction B-AdverseReaction
Hot NN O O
3 NN O O
( NN O O
5.0 NN O O
) NN O O
0 NN O O
( NN O O
0 NN O O
) NN O O
Increased NN B-AdverseReaction B-AdverseReaction
Blood NN I-AdverseReaction I-AdverseReaction
Pressure NN I-AdverseReaction I-AdverseReaction
3 NN O O
( NN O O
5.0 NN O O
) NN O O
0 NN O O
( NN O O
0 NN O O
) NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
3 NN O O
( NN O O
5.0 NN O O
) NN O O
0 NN O O
( NN O O
0 NN O O
) NN O O
Edema NN B-AdverseReaction B-AdverseReaction
, NN I-AdverseReaction I-AdverseReaction
Peripheral NN I-AdverseReaction I-AdverseReaction
2 NN O O
( NN O O
3.3 NN O O
) NN O O
0 NN O O
( NN O O
0 NN O O
) NN O O
Pruritus NN B-AdverseReaction B-AdverseReaction
2 NN O O
( NN O O
3.3 NN O O
) NN O O
0 NN O O
( NN O O
0 NN O O
) NN O O
Rash NN B-AdverseReaction B-AdverseReaction
Papular NN I-AdverseReaction I-AdverseReaction
2 NN O O
( NN O O
3.3 NN O O
) NN O O
0 NN O O
( NN O O
0 NN O O
) NN O O
Throat NN B-AdverseReaction B-AdverseReaction
Tightness NN I-AdverseReaction I-AdverseReaction
2 NN O O
( NN O O
3.3 NN O O
) NN O O
0 NN O O
( NN O O
0 NN O O
) NN O O
In NN O O
clinical NN O O
trials NN O O
, NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
and NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
were NN O O
managed NN O O
with NN O O
infusion NN O O
interruption NN O O
, NN O O
decreased NN O O
infusion NN O O
rate NN O O
, NN O O
administration NN O O
of NN O O
antihistamines NN O O
, NN O O
corticosteroids NN O O
, NN O O
intravenous NN O O
fluids NN O O
, NN O O
and/or NN O O
oxygen NN O O
, NN O O
when NN O O
clinically NN O O
indicated NN O O
. NN O O
In NN O O
some NN O O
cases NN O O
of NN O O
anaphylactic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
epinephrine NN O O
was NN O O
administered NN O O
. NN O O
Patients NN O O
who NN O O
have NN O O
experienced NN O O
anaphylaxis NN O O
or NN O O
hypersensitivity NN O O
reactions NN O O
should NN O O
be NN O O
treated NN O O
with NN O O
caution NN O O
when NN O O
they NN O O
are NN O O
re NN O O
- NN O O
administered NN O O
alglucosidase NN O O
alfa NN O O
. NN O O
6.2 NN O O
Immunogenicity NN O O
As NN O O
with NN O O
all NN O O
therapeutic NN O O
proteins NN O O
, NN O O
there NN O O
is NN O O
potential NN O O
for NN O O
immunogenicity NN O O
. NN O O
The NN O O
data NN O O
reflect NN O O
the NN O O
percentage NN O O
of NN O O
patients NN O O
whose NN O O
test NN O O
results NN O O
were NN O O
considered NN O O
positive NN O O
for NN O O
antibodies NN O O
to NN O O
alglucosidase NN O O
alfa NN O O
using NN O O
an NN O O
enzyme NN O O
- NN O O
linked NN O O
immunosorbent NN O O
assay NN O O
( NN O O
ELISA NN O O
) NN O O
and NN O O
confirmed NN O O
by NN O O
a NN O O
radioimmunoprecipitation NN O O
( NN O O
RIP NN O O
) NN O O
assay NN O O
for NN O O
alglucosidase NN O O
alfa NN O O
- NN O O
specific NN O O
IgG NN O O
antibodies NN O O
. NN O O
In NN O O
the NN O O
two NN O O
clinical NN O O
trials NN O O
in NN O O
infantile NN O O
- NN O O
onset NN O O
patients NN O O
, NN O O
the NN O O
majority NN O O
of NN O O
patients NN O O
( NN O O
34 NN O O
of NN O O
38 NN O O
; NN O O
89 NN O O
% NN O O
) NN O O
tested NN O O
positive NN O O
for NN O O
IgG NN O O
antibodies NN O O
to NN O O
alglucosidase NN O O
alfa NN O O
. NN O O
There NN O O
is NN O O
evidence NN O O
to NN O O
suggest NN O O
that NN O O
some NN O O
patients NN O O
who NN O O
develop NN O O
high NN O O
sustained NN O O
titers NN O O
of NN O O
anti NN O O
- NN O O
alglucosidase NN O O
alfa NN O O
antibodies NN O O
may NN O O
experience NN O O
reduced NN O O
clinical NN O O
efficacy NN O O
to NN O O
alglucosidase NN O O
alfa NN O O
treatment NN O O
[ NN O O
seeWarnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
. NN O O
Some NN O O
IgG NN O O
- NN O O
positive NN O O
patients NN O O
in NN O O
clinical NN O O
trials NN O O
who NN O O
were NN O O
retrospectively NN O O
evaluated NN O O
for NN O O
the NN O O
presence NN O O
of NN O O
inhibitory NN O O
antibodies NN O O
tested NN O O
positive NN O O
for NN O O
inhibition NN O O
of NN O O
enzyme NN O O
activity NN O O
and/or NN O O
uptake NN O O
in NN O O
in NN O O
vitro NN O O
assays NN O O
. NN O O
Furthermore NN O O
, NN O O
CRIM NN O O
- NN O O
negative NN O O
infants NN O O
have NN O O
shown NN O O
reduced NN O O
clinical NN O O
effect NN O O
in NN O O
the NN O O
presence NN O O
of NN O O
high NN B-Severity B-Severity
sustained NN I-Severity I-Severity
IgG NN B-AdverseReaction B-AdverseReaction
antibody NN I-AdverseReaction I-AdverseReaction
titers NN I-AdverseReaction I-AdverseReaction
with NN I-AdverseReaction I-AdverseReaction
inhibitory NN I-AdverseReaction I-AdverseReaction
activity NN I-AdverseReaction I-AdverseReaction
Alglucosidase NN O O
alfa NN O O
- NN O O
treated NN O O
patients NN O O
who NN O O
experience NN O O
a NN O O
decrease NN O O
in NN O O
motor NN O O
function NN O O
should NN O O
be NN O O
tested NN O O
for NN O O
the NN O O
presence NN O O
of NN O O
inhibitory NN O O
antibodies NN O O
that NN O O
neutralize NN O O
enzyme NN O O
uptake NN O O
or NN O O
activity NN O O
. NN O O
In NN O O
the NN O O
randomized NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
trial NN O O
in NN O O
late NN O O
- NN O O
onset NN O O
patients NN O O
, NN O O
all NN O O
alglucosidase NN O O
alfa NN O O
- NN O O
treated NN O O
patients NN O O
with NN O O
available NN O O
samples NN O O
( NN O O
N=59 NN O O
, NN O O
100 NN O O
% NN O O
) NN O O
developed NN O O
IgG NN O O
antibodies NN O O
to NN O O
alglucosidase NN O O
alfa NN O O
. NN O O
Most NN O O
patients NN O O
who NN O O
developed NN O O
IgG NN O O
antibodies NN O O
did NN O O
so NN O O
within NN O O
the NN O O
first NN O O
3 NN O O
months NN O O
of NN O O
exposure NN O O
( NN O O
median NN O O
time NN O O
to NN O O
seroconversion NN O O
was NN O O
4 NN O O
weeks NN O O
) NN O O
. NN O O
There NN O O
was NN O O
no NN O O
apparent NN O O
association NN O O
between NN O O
mean NN O O
or NN O O
peak NN O O
IgG NN O O
antibody NN O O
titers NN O O
and NN O O
the NN O O
occurrence NN O O
of NN O O
adverse NN O O
reactions NN O O
. NN O O
None NN O O
of NN O O
the NN O O
59 NN O O
evaluable NN O O
patients NN O O
tested NN O O
positive NN O O
for NN O O
inhibition NN O O
of NN O O
enzyme NN O O
activity NN O O
. NN O O
Antibody NN O O
titers NN O O
for NN O O
cellular NN O O
uptake NN O O
inhibition NN O O
were NN O O
present NN O O
in NN O O
18 NN O O
of NN O O
59 NN O O
( NN O O
31 NN O O
% NN O O
) NN O O
patients NN O O
by NN O O
Week NN O O
78 NN O O
. NN O O
All NN O O
other NN O O
patients NN O O
tested NN O O
negative NN O O
for NN O O
inhibition NN O O
of NN O O
cellular NN O O
uptake NN O O
. NN O O
Patients NN O O
who NN O O
tested NN O O
positive NN O O
for NN O O
uptake NN O O
inhibition NN O O
tended NN O O
to NN O O
have NN O O
higher NN O O
IgG NN O O
titers NN O O
than NN O O
patients NN O O
who NN O O
tested NN O O
negative NN O O
for NN O O
uptake NN O O
inhibition NN O O
. NN O O
Among NN O O
the NN O O
32 NN O O
patients NN O O
with NN O O
evaluable NN O O
pharmacokinetic NN O O
( NN O O
PK NN O O
) NN O O
samples NN O O
, NN O O
5 NN O O
patients NN O O
tested NN O O
positive NN O O
for NN O O
uptake NN O O
inhibition NN O O
. NN O O
The NN O O
clinical NN O O
relevance NN O O
of NN O O
this NN O O
in NN O O
vitro NN O O
inhibition NN O O
is NN O O
not NN O O
fully NN O O
understood NN O O
. NN O O
The NN O O
clearance NN O O
values NN O O
for NN O O
4 NN O O
of NN O O
these NN O O
5 NN O O
patients NN O O
were NN O O
approximately NN O O
1.2- NN O O
to NN O O
1.8-fold NN O O
greater NN O O
in NN O O
the NN O O
presence NN O O
of NN O O
inhibitory NN O O
antibodies NN O O
( NN O O
Week NN O O
52 NN O O
) NN O O
as NN O O
compared NN O O
to NN O O
in NN O O
the NN O O
absence NN O O
of NN O O
inhibitory NN O O
antibodies NN O O
( NN O O
Week NN O O
0 NN O O
) NN O O
[ NN O O
seeClinical NN O O
Pharmacology NN O O
( NN O O
12.3 NN O O
) NN O O
] NN O O
. NN O O
Some NN O O
patients NN O O
in NN O O
the NN O O
clinical NN O O
studies NN O O
or NN O O
in NN O O
the NN O O
postmarketing NN O O
setting NN O O
have NN O O
undergone NN O O
testing NN O O
for NN O O
alglucosidase NN O O
alfa NN O O
- NN O O
specific NN O O
IgE NN O O
antibodies NN O O
. NN O O
Testing NN O O
was NN O O
performed NN O O
in NN O O
patients NN O O
who NN O O
experienced NN O O
moderate NN B-Severity B-Severity
to NN I-Severity I-Severity
severe NN I-Severity I-Severity
or NN O O
recurrent NN B-AdverseReaction B-AdverseReaction
hypersensitivity NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
for NN O O
which NN O O
mast NN O O
- NN O O
cell NN O O
activation NN O O
was NN O O
suspected NN O O
. NN O O
Some NN O O
of NN O O
the NN O O
patients NN O O
who NN O O
tested NN O O
positive NN O O
for NN O O
alglucosidase NN O O
alfa NN O O
- NN O O
specific NN O O
IgE NN O O
antibodies NN O O
experienced NN O O
anaphylactic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
[ NN O O
seeBoxed NN O O
WarningandWarnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
Some NN O O
patients NN O O
who NN O O
tested NN O O
positive NN O O
for NN O O
alglucosidase NN O O
alfa NN O O
- NN O O
specific NN O O
IgE NN O O
antibodies NN O O
and NN O O
experienced NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
were NN O O
able NN O O
to NN O O
be NN O O
rechallenged NN O O
with NN O O
alglucosidase NN O O
alfa NN O O
using NN O O
a NN O O
slower NN O O
infusion NN O O
rate NN O O
at NN O O
lower NN O O
starting NN O O
doses NN O O
and NN O O
have NN O O
continued NN O O
to NN O O
receive NN O O
treatment NN O O
under NN O O
close NN O O
clinical NN O O
supervision NN O O
[ NN O O
seeWarnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
Since NN O O
patients NN O O
who NN O O
develop NN O O
IgE NN O O
antibodies NN O O
to NN O O
alglucosidase NN O O
alfa NN O O
appear NN O O
to NN O O
be NN O O
at NN O O
a NN O O
higher NN O O
risk NN O O
for NN O O
developing NN O O
anaphylaxis NN O O
and NN O O
hypersensitivity NN O O
reactions NN O O
, NN O O
these NN O O
patients NN O O
should NN O O
be NN O O
monitored NN O O
more NN O O
closely NN O O
during NN O O
administration NN O O
of NN O O
alglucosidase NN O O
alfa NN O O
. NN O O
The NN O O
detection NN O O
of NN O O
antibody NN O O
formation NN O O
is NN O O
highly NN O O
dependent NN O O
on NN O O
the NN O O
sensitivity NN O O
and NN O O
specificity NN O O
of NN O O
the NN O O
assay NN O O
. NN O O
Additionally NN O O
, NN O O
the NN O O
observed NN O O
incidence NN O O
of NN O O
antibody NN O O
( NN O O
including NN O O
neutralizing NN O O
antibody NN O O
) NN O O
positivity NN O O
in NN O O
an NN O O
assay NN O O
may NN O O
be NN O O
influenced NN O O
by NN O O
several NN O O
factors NN O O
including NN O O
assay NN O O
methodology NN O O
, NN O O
sample NN O O
handling NN O O
, NN O O
timing NN O O
of NN O O
sample NN O O
collection NN O O
, NN O O
concomitant NN O O
medications NN O O
, NN O O
and NN O O
underlying NN O O
disease NN O O
. NN O O
For NN O O
these NN O O
reasons NN O O
, NN O O
comparison NN O O
of NN O O
the NN O O
incidence NN O O
of NN O O
antibodies NN O O
to NN O O
alglucosidase NN O O
alfa NN O O
with NN O O
the NN O O
incidence NN O O
of NN O O
antibodies NN O O
to NN O O
other NN O O
products NN O O
may NN O O
be NN O O
misleading NN O O
. NN O O
6.3 NN O O
Postmarketing NN O O
Experience NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
identified NN O O
during NN O O
post NN O O
approval NN O O
use NN O O
of NN O O
alglucosidase NN O O
alfa NN O O
. NN O O
Because NN O O
these NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
In NN O O
postmarketing NN O O
experience NN O O
with NN O O
alglucosidase NN O O
alfa NN O O
, NN O O
serious NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
reported NN O O
, NN O O
including NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
[ NN O O
seeBoxed NN O O
WarningandWarnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
Acute NN B-AdverseReaction B-AdverseReaction
cardiorespiratory NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
possibly NN O O
associated NN O O
with NN O O
fluid NN B-AdverseReaction B-AdverseReaction
overload NN I-AdverseReaction I-AdverseReaction
has NN O O
been NN O O
reported NN O O
in NN O O
infantile NN O O
- NN O O
onset NN O O
Pompe NN O O
disease NN O O
patients NN O O
with NN O O
pre NN O O
- NN O O
existing NN O O
hypertrophic NN O O
cardiomyopathy NN O O
[ NN O O
seeBoxed NN O O
WarningandWarning NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
. NN O O
Recurrent NN O O
reactions NN O O
consisting NN O O
of NN O O
flu NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
like NN I-AdverseReaction I-AdverseReaction
illness NN I-AdverseReaction I-AdverseReaction
or NN O O
a NN O O
combination NN O O
of NN O O
events NN O O
such NN O O
as NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
chills NN B-AdverseReaction B-AdverseReaction
myalgia NN B-AdverseReaction B-AdverseReaction
arthralgia NN B-AdverseReaction B-AdverseReaction
pain NN B-AdverseReaction B-AdverseReaction
or NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
occurring NN O O
after NN O O
completion NN O O
of NN O O
infusions NN O O
and NN O O
lasting NN O O
usually NN O O
for NN O O
1 NN O O
- NN O O
3 NN O O
days NN O O
have NN O O
been NN O O
observed NN O O
in NN O O
some NN O O
patients NN O O
treated NN O O
with NN O O
alglucosidase NN O O
alfa NN O O
. NN O O
The NN O O
majority NN O O
of NN O O
patients NN O O
were NN O O
able NN O O
to NN O O
be NN O O
rechallenged NN O O
with NN O O
alglucosidase NN O O
alfa NN O O
using NN O O
lower NN O O
doses NN O O
and/or NN O O
pretreatment NN O O
with NN O O
anti NN O O
- NN O O
inflammatory NN O O
drugs NN O O
and/or NN O O
corticosteroids NN O O
and NN O O
were NN O O
able NN O O
to NN O O
continue NN O O
treatment NN O O
under NN O O
close NN O O
clinical NN O O
supervision NN O O
. NN O O
In NN O O
addition NN O O
to NN O O
the NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
reported NN O O
in NN O O
clinical NN O O
trials NN O O
[ NN O O
seeAdverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
, NN O O
the NN O O
following NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
at NN O O
least NN O O
2 NN O O
patients NN O O
and NN O O
included NN O O
: NN O O
anaphylactic NN B-AdverseReaction B-AdverseReaction
shock NN I-AdverseReaction I-AdverseReaction
respiratory NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
respiratory NN B-AdverseReaction B-AdverseReaction
arrest NN I-AdverseReaction I-AdverseReaction
cardiac NN B-AdverseReaction B-AdverseReaction
arrest NN I-AdverseReaction I-AdverseReaction
hypoxia NN B-AdverseReaction B-AdverseReaction
dyspnea NN B-AdverseReaction B-AdverseReaction
wheezing NN B-AdverseReaction B-AdverseReaction
convulsions NN B-AdverseReaction B-AdverseReaction
peripheral NN B-AdverseReaction B-AdverseReaction
coldness NN I-AdverseReaction I-AdverseReaction
restlessness NN B-AdverseReaction B-AdverseReaction
nervousness NN B-AdverseReaction B-AdverseReaction
back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
stridor NN B-AdverseReaction B-AdverseReaction
pharyngeal NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
apnea NN B-AdverseReaction B-AdverseReaction
muscle NN B-AdverseReaction B-AdverseReaction
spasm NN I-AdverseReaction I-AdverseReaction
and NN O O
conjunctivitis NN B-AdverseReaction B-AdverseReaction
In NN O O
addition NN O O
, NN O O
one NN O O
case NN O O
of NN O O
hyperparathyroidism NN B-AdverseReaction B-AdverseReaction
has NN O O
been NN O O
reported NN O O
. NN O O
Systemic NN O O
and NN O O
cutaneous NN B-AdverseReaction B-AdverseReaction
immune NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
mediated NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
proteinuria NN B-AdverseReaction B-AdverseReaction
and NN O O
nephrotic NN B-AdverseReaction B-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
secondary NN O O
to NN O O
membranous NN B-AdverseReaction B-AdverseReaction
glomerulonephritis NN I-AdverseReaction I-AdverseReaction
and NN O O
necrotizing NN B-AdverseReaction B-AdverseReaction
skin NN I-AdverseReaction I-AdverseReaction
lesions NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
postmarketing NN O O
safety NN O O
experience NN O O
with NN O O
alglucosidase NN O O
alfa NN O O
[ NN O O
seeWarnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
RISK NN B-Factor B-Factor
OF NN O O
ANAPHYLAXIS NN B-AdverseReaction B-AdverseReaction
HYPERSENSITIVITY NN B-AdverseReaction B-AdverseReaction
AND NN O O
IMMUNE NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
MEDIATED NN I-AdverseReaction I-AdverseReaction
REACTIONS NN I-AdverseReaction I-AdverseReaction
AND NN O O
RISK NN B-Factor B-Factor
OF NN O O
CARDIORESPIRATORY NN B-AdverseReaction B-AdverseReaction
FAILURE NN I-AdverseReaction I-AdverseReaction
WARNING NN O O
: NN O O
RISK NN B-Factor B-Factor
OF NN O O
ANAPHYLAXIS NN B-AdverseReaction B-AdverseReaction
HYPERSENSITIVITY NN B-AdverseReaction B-AdverseReaction
AND NN O O
IMMUNE NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
MEDIATED NN I-AdverseReaction I-AdverseReaction
REACTIONS NN I-AdverseReaction I-AdverseReaction
AND NN O O
RISK NN B-Factor B-Factor
OF NN O O
CARDIORESPIRATORY NN B-AdverseReaction B-AdverseReaction
FAILURE NN I-AdverseReaction I-AdverseReaction
Life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
anaphylactic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
and NN O O
severe NN B-Severity B-Severity
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
presenting NN O O
as NN O O
respiratory NN B-AdverseReaction B-AdverseReaction
distress NN I-AdverseReaction I-AdverseReaction
hypoxia NN B-AdverseReaction B-AdverseReaction
apnea NN B-AdverseReaction B-AdverseReaction
dyspnea NN B-AdverseReaction B-AdverseReaction
bradycardia NN B-AdverseReaction B-AdverseReaction
tachycardia NN B-AdverseReaction B-AdverseReaction
bronchospasm NN B-AdverseReaction B-AdverseReaction
throat NN B-AdverseReaction B-AdverseReaction
tightness NN I-AdverseReaction I-AdverseReaction
hypotension NN B-AdverseReaction B-AdverseReaction
angioedema NN B-AdverseReaction B-AdverseReaction
( NN O O
including NN O O
tongue NN O O
or NN O O
lip NN B-AdverseReaction B-AdverseReaction
swelling NN I-AdverseReaction I-AdverseReaction
periorbital NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
and NN O O
face NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
and NN O O
urticaria NN B-AdverseReaction B-AdverseReaction
have NN O O
occurred NN O O
in NN O O
some NN O O
patients NN O O
during NN O O
and NN O O
after NN O O
alglucosidase NN O O
alfa NN O O
infusions NN O O
. NN O O
Immune NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
mediated NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
presenting NN O O
as NN O O
proteinuria NN B-AdverseReaction B-AdverseReaction
nephrotic NN B-AdverseReaction B-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
and NN O O
necrotizing NN B-AdverseReaction B-AdverseReaction
skin NN I-AdverseReaction I-AdverseReaction
lesions NN I-AdverseReaction I-AdverseReaction
have NN O O
occurred NN O O
in NN O O
some NN O O
patients NN O O
following NN O O
alglucosidase NN O O
alfa NN O O
treatment NN O O
. NN O O
Closely NN O O
observe NN O O
patients NN O O
during NN O O
and NN O O
after NN O O
alglucosidase NN O O
alfa NN O O
administration NN O O
and NN O O
be NN O O
prepared NN O O
to NN O O
manage NN O O
anaphylaxis NN O O
and NN O O
hypersensitivity NN O O
reactions NN O O
. NN O O
Inform NN O O
patients NN O O
of NN O O
the NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
anaphylaxis NN O O
, NN O O
hypersensitivity NN O O
reactions NN O O
, NN O O
and NN O O
immune NN O O
- NN O O
mediated NN O O
reactions NN O O
and NN O O
have NN O O
them NN O O
seek NN O O
immediate NN O O
medical NN O O
care NN O O
should NN O O
signs NN O O
and NN O O
symptoms NN O O
occur NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
, NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
Infantile NN O O
- NN O O
onset NN O O
Pompe NN O O
disease NN O O
patients NN O O
with NN O O
compromised NN O O
cardiac NN O O
or NN O O
respiratory NN O O
function NN O O
may NN B-Factor B-Factor
be NN O O
at NN O O
risk NN O O
of NN O O
serious NN B-Severity B-Severity
acute NN O O
exacerbation NN O O
of NN O O
their NN O O
cardiac NN O O
or NN O O
respiratory NN O O
compromise NN O O
due NN O O
to NN O O
fluid NN B-AdverseReaction B-AdverseReaction
overload NN I-AdverseReaction I-AdverseReaction
and NN O O
require NN O O
additional NN O O
monitoring NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
. NN O O
WARNING NN O O
: NN O O
RISK NN B-Factor B-Factor
OF NN O O
ANAPHYLAXIS NN B-AdverseReaction B-AdverseReaction
HYPERSENSITIVITY NN B-AdverseReaction B-AdverseReaction
AND NN O O
IMMUNE NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
MEDIATED NN I-AdverseReaction I-AdverseReaction
REACTIONS NN I-AdverseReaction I-AdverseReaction
and NN O O
RISK NN B-Factor B-Factor
OF NN O O
CARDIORESPIRATORY NN B-AdverseReaction B-AdverseReaction
FAILURE NN I-AdverseReaction I-AdverseReaction
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
. NN O O
* NN O O
Life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
anaphylactic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
and NN O O
severe NN B-Severity B-Severity
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
have NN O O
occurred NN O O
in NN O O
some NN O O
patients NN O O
during NN O O
and NN O O
after NN O O
alglucosidase NN O O
alfa NN O O
infusions NN O O
. NN O O
Immune NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
mediated NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
presenting NN O O
as NN O O
proteinuria NN B-AdverseReaction B-AdverseReaction
nephrotic NN B-AdverseReaction B-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
and NN O O
necrotizing NN B-AdverseReaction B-AdverseReaction
skin NN I-AdverseReaction I-AdverseReaction
lesions NN I-AdverseReaction I-AdverseReaction
have NN O O
occurred NN O O
in NN O O
some NN O O
patients NN O O
following NN O O
alglucosidase NN O O
alfa NN O O
treatment NN O O
. NN O O
Closely NN O O
observe NN O O
patients NN O O
during NN O O
and NN O O
after NN O O
alglucosidase NN O O
alfa NN O O
administration NN O O
and NN O O
be NN O O
prepared NN O O
to NN O O
manage NN O O
anaphylaxis NN O O
and NN O O
hypersensitivity NN O O
reactions NN O O
. NN O O
Inform NN O O
patients NN O O
of NN O O
the NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
anaphylaxis NN O O
, NN O O
hypersensitivity NN O O
reactions NN O O
, NN O O
and NN O O
immune NN O O
- NN O O
mediated NN O O
reactions NN O O
and NN O O
have NN O O
them NN O O
seek NN O O
immediate NN O O
medical NN O O
care NN O O
should NN O O
signs NN O O
and NN O O
symptoms NN O O
occur NN O O
( NN O O
5.1 NN O O
, NN O O
5.2 NN O O
) NN O O
. NN O O
* NN O O
Infantile NN O O
- NN O O
onset NN O O
Pompe NN O O
disease NN O O
patients NN O O
with NN O O
compromised NN O O
cardiac NN O O
or NN O O
respiratory NN O O
function NN O O
may NN B-Factor B-Factor
be NN O O
at NN O O
risk NN O O
of NN O O
serious NN B-Severity B-Severity
acute NN O O
exacerbation NN O O
of NN O O
their NN O O
cardiac NN O O
or NN O O
respiratory NN O O
compromise NN O O
due NN O O
to NN O O
fluid NN B-AdverseReaction B-AdverseReaction
overload NN I-AdverseReaction I-AdverseReaction
and NN O O
require NN O O
additional NN O O
monitoring NN O O
( NN O O
5.3 NN O O
) NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Anaphylaxis NN B-AdverseReaction B-AdverseReaction
and NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
Life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
anaphylaxis NN B-AdverseReaction B-AdverseReaction
and NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
observed NN O O
in NN O O
some NN O O
patients NN O O
during NN O O
and NN O O
after NN O O
treatment NN O O
with NN O O
alglucosidase NN O O
alfa NN O O
. NN O O
Ensure NN O O
that NN O O
appropriate NN O O
medical NN O O
support NN O O
measures NN O O
, NN O O
including NN O O
cardiopulmonary NN O O
resuscitation NN O O
equipment NN O O
, NN O O
are NN O O
readily NN O O
available NN O O
. NN O O
If NN O O
anaphylaxis NN O O
or NN O O
severe NN O O
hypersensitivity NN O O
reactions NN O O
occur NN O O
, NN O O
immediately NN O O
discontinue NN O O
infusion NN O O
and NN O O
initiate NN O O
appropriate NN O O
medical NN O O
treatment NN O O
( NN O O
5.1 NN O O
) NN O O
. NN O O
* NN O O
Immune NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Mediated NN I-AdverseReaction I-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
patients NN O O
for NN O O
the NN O O
development NN O O
of NN O O
systemic NN O O
immune NN O O
- NN O O
mediated NN O O
reactions NN O O
involving NN O O
skin NN O O
and NN O O
other NN O O
organs NN O O
( NN O O
5.2 NN O O
) NN O O
. NN O O
* NN O O
Risk NN B-Factor B-Factor
of NN O O
Acute NN B-AdverseReaction B-AdverseReaction
Cardiorespiratory NN I-AdverseReaction I-AdverseReaction
Failure NN I-AdverseReaction I-AdverseReaction
Patients NN O O
with NN O O
compromised NN O O
cardiac NN O O
or NN O O
respiratory NN O O
function NN O O
may NN B-Factor B-Factor
be NN O O
at NN O O
risk NN O O
of NN O O
acute NN B-AdverseReaction B-AdverseReaction
cardiorespiratory NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
Caution NN O O
should NN O O
be NN O O
exercised NN O O
when NN O O
administering NN O O
alglucosidase NN O O
alfa NN O O
to NN O O
patients NN O O
susceptible NN O O
to NN O O
fluid NN O O
volume NN O O
overload NN O O
. NN O O
Appropriate NN O O
medical NN O O
support NN O O
and NN O O
monitoring NN O O
measures NN O O
should NN O O
be NN O O
available NN O O
during NN O O
infusion NN O O
( NN O O
5.3 NN O O
) NN O O
. NN O O
* NN O O
Risk NN B-Factor B-Factor
of NN O O
Cardiac NN B-AdverseReaction B-AdverseReaction
Arrhythmia NN I-AdverseReaction I-AdverseReaction
and NN O O
Sudden NN B-AdverseReaction B-AdverseReaction
Cardiac NN I-AdverseReaction I-AdverseReaction
Death NN I-AdverseReaction I-AdverseReaction
during NN O O
General NN O O
Anesthesia NN O O
for NN O O
Central NN O O
Venous NN O O
Catheter NN O O
Placement NN O O
: NN O O
Caution NN O O
should NN O O
be NN O O
used NN O O
when NN O O
administering NN O O
general NN O O
anesthesia NN O O
for NN O O
the NN O O
placement NN O O
of NN O O
a NN O O
central NN O O
venous NN O O
catheter NN O O
intended NN O O
for NN O O
alglucosidase NN O O
alfa NN O O
infusion NN O O
( NN O O
5.4 NN O O
) NN O O
. NN O O
5.1 NN O O
Anaphylaxis NN O O
and NN O O
Hypersensitivity NN O O
Reactions NN O O
Anaphylaxis NN B-AdverseReaction B-AdverseReaction
and NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
observed NN O O
in NN O O
patients NN O O
during NN O O
and NN O O
up NN O O
to NN O O
3 NN O O
hours NN O O
after NN O O
alglucosidase NN O O
alfa NN O O
infusion NN O O
. NN O O
Some NN O O
of NN O O
the NN O O
reactions NN O O
were NN O O
life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
and NN O O
included NN O O
anaphylactic NN B-AdverseReaction B-AdverseReaction
shock NN I-AdverseReaction I-AdverseReaction
cardiac NN B-AdverseReaction B-AdverseReaction
arrest NN I-AdverseReaction I-AdverseReaction
respiratory NN B-AdverseReaction B-AdverseReaction
arrest NN I-AdverseReaction I-AdverseReaction
respiratory NN B-AdverseReaction B-AdverseReaction
distress NN I-AdverseReaction I-AdverseReaction
hypoxia NN B-AdverseReaction B-AdverseReaction
apnea NN B-AdverseReaction B-AdverseReaction
dyspnea NN B-AdverseReaction B-AdverseReaction
bradycardia NN B-AdverseReaction B-AdverseReaction
tachycardia NN B-AdverseReaction B-AdverseReaction
bronchospasm NN B-AdverseReaction B-AdverseReaction
throat NN B-AdverseReaction B-AdverseReaction
tightness NN I-AdverseReaction I-AdverseReaction
hypotension NN B-AdverseReaction B-AdverseReaction
angioedema NN B-AdverseReaction B-AdverseReaction
( NN O O
including NN O O
tongue NN O O
or NN O O
lip NN B-AdverseReaction B-AdverseReaction
swelling NN I-AdverseReaction I-AdverseReaction
periorbital NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
and NN O O
face NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
and NN O O
urticaria NN B-AdverseReaction B-AdverseReaction
Other NN O O
accompanying NN O O
reactions NN O O
included NN O O
chest NN B-AdverseReaction B-AdverseReaction
discomfort NN I-AdverseReaction I-AdverseReaction
wheezing NN B-AdverseReaction B-AdverseReaction
tachypnea NN B-AdverseReaction B-AdverseReaction
cyanosis NN B-AdverseReaction B-AdverseReaction
decreased NN B-AdverseReaction B-AdverseReaction
oxygen NN I-AdverseReaction I-AdverseReaction
saturation NN I-AdverseReaction I-AdverseReaction
convulsions NN B-AdverseReaction B-AdverseReaction
pruritus NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
hyperhidrosis NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
dizziness NN B-AdverseReaction B-AdverseReaction
hypertension NN B-AdverseReaction B-AdverseReaction
blood NN O O
pressure NN O O
, NN O O
flushing NN B-AdverseReaction B-AdverseReaction
hot NN O O
, NN O O
erythema NN B-AdverseReaction B-AdverseReaction
pyrexia NN B-AdverseReaction B-AdverseReaction
pallor NN B-AdverseReaction B-AdverseReaction
peripheral NN B-AdverseReaction B-AdverseReaction
coldness NN I-AdverseReaction I-AdverseReaction
restlessness NN B-AdverseReaction B-AdverseReaction
nervousness NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
and NN O O
paresthesia NN B-AdverseReaction B-AdverseReaction
Some NN O O
of NN O O
these NN O O
reactions NN O O
were NN O O
IgE NN O O
- NN O O
mediated NN O O
. NN O O
If NN O O
anaphylaxis NN O O
or NN O O
severe NN O O
hypersensitivity NN O O
reactions NN O O
occur NN O O
, NN O O
immediately NN O O
discontinue NN O O
administration NN O O
of NN O O
alglucosidase NN O O
alfa NN O O
, NN O O
and NN O O
initiate NN O O
appropriate NN O O
medical NN O O
treatment NN O O
. NN O O
Severe NN O O
reactions NN O O
are NN O O
generally NN O O
managed NN O O
with NN O O
infusion NN O O
interruption NN O O
, NN O O
administration NN O O
of NN O O
antihistamines NN O O
, NN O O
corticosteroids NN O O
, NN O O
intravenous NN O O
fluids NN O O
, NN O O
and/or NN O O
oxygen NN O O
, NN O O
when NN O O
clinically NN O O
indicated NN O O
. NN O O
In NN O O
some NN O O
cases NN O O
of NN O O
anaphylaxis NN O O
, NN O O
epinephrine NN O O
has NN O O
been NN O O
administered NN O O
. NN O O
Appropriate NN O O
medical NN O O
support NN O O
, NN O O
including NN O O
cardiopulmonary NN O O
resuscitation NN O O
equipment NN O O
, NN O O
should NN O O
be NN O O
readily NN O O
available NN O O
when NN O O
alglucosidase NN O O
alfa NN O O
is NN O O
administered NN O O
. NN O O
The NN O O
risks NN O O
and NN O O
benefits NN O O
of NN O O
re NN O O
- NN O O
administering NN O O
alglucosidase NN O O
alfa NN O O
following NN O O
an NN O O
anaphylactic NN O O
or NN O O
hypersensitivity NN O O
reaction NN O O
should NN O O
be NN O O
considered NN O O
. NN O O
Some NN O O
patients NN O O
have NN O O
been NN O O
rechallenged NN O O
and NN O O
have NN O O
continued NN O O
to NN O O
receive NN O O
alglucosidase NN O O
alfa NN O O
under NN O O
close NN O O
clinical NN O O
supervision NN O O
. NN O O
Extreme NN O O
care NN O O
should NN O O
be NN O O
exercised NN O O
, NN O O
with NN O O
appropriate NN O O
resuscitation NN O O
measures NN O O
available NN O O
, NN O O
if NN O O
the NN O O
decision NN O O
is NN O O
made NN O O
to NN O O
re NN O O
- NN O O
administer NN O O
the NN O O
product NN O O
[ NN O O
seeAdverse NN O O
Reactions NN O O
( NN O O
6.2 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
Immune NN O O
- NN O O
Mediated NN O O
Reactions NN O O
Immune NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
mediated NN I-AdverseReaction I-AdverseReaction
cutaneous NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
with NN O O
alglucosidase NN O O
alfa NN O O
including NN O O
necrotizing NN B-AdverseReaction B-AdverseReaction
skin NN I-AdverseReaction I-AdverseReaction
lesions NN I-AdverseReaction I-AdverseReaction
[ NN O O
seeAdverse NN O O
Reactions NN O O
( NN O O
6.3 NN O O
) NN O O
] NN O O
. NN O O
Systemic NN B-AdverseReaction B-AdverseReaction
immune NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
mediated NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
possible NN B-Factor B-Factor
type NN B-AdverseReaction B-AdverseReaction
III NN I-AdverseReaction I-AdverseReaction
immune NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
mediated NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
observed NN O O
with NN O O
alglucosidase NN O O
alfa NN O O
. NN O O
These NN O O
reactions NN O O
occurred NN O O
several NN O O
weeks NN O O
to NN O O
3 NN O O
years NN O O
after NN O O
initiation NN O O
of NN O O
alglucosidase NN O O
alfa NN O O
infusions NN O O
. NN O O
Skin NN O O
biopsy NN O O
in NN O O
one NN O O
patient NN O O
demonstrated NN O O
deposition NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
anti NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
rhGAA NN I-AdverseReaction I-AdverseReaction
antibodies NN I-AdverseReaction I-AdverseReaction
in NN O O
the NN O O
lesion NN O O
. NN O O
Another NN O O
patient NN O O
developed NN O O
severe NN B-Severity B-Severity
inflammatory NN B-AdverseReaction B-AdverseReaction
arthropathy NN I-AdverseReaction I-AdverseReaction
in NN O O
association NN O O
with NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
and NN O O
elevated NN B-AdverseReaction B-AdverseReaction
erythrocyte NN I-AdverseReaction I-AdverseReaction
sedimentation NN I-AdverseReaction I-AdverseReaction
rate NN I-AdverseReaction I-AdverseReaction
Nephrotic NN B-AdverseReaction B-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
secondary NN O O
to NN O O
membranous NN B-AdverseReaction B-AdverseReaction
glomerulonephritis NN I-AdverseReaction I-AdverseReaction
was NN O O
observed NN O O
in NN O O
some NN O O
Pompe NN O O
disease NN O O
patients NN O O
treated NN O O
with NN O O
alglucosidase NN O O
alfa NN O O
who NN O O
had NN O O
persistently NN O O
positive NN B-AdverseReaction B-AdverseReaction
anti NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
rhGAA NN I-AdverseReaction I-AdverseReaction
IgG NN I-AdverseReaction I-AdverseReaction
antibody NN I-AdverseReaction I-AdverseReaction
titers NN I-AdverseReaction I-AdverseReaction
In NN O O
these NN O O
patients NN O O
, NN O O
renal NN O O
biopsy NN O O
was NN O O
consistent NN O O
with NN O O
immune NN B-AdverseReaction B-AdverseReaction
complex NN I-AdverseReaction I-AdverseReaction
deposition NN I-AdverseReaction I-AdverseReaction
Patients NN O O
improved NN O O
following NN O O
treatment NN O O
interruption NN O O
. NN O O
Therefore NN O O
, NN O O
patients NN O O
receiving NN O O
alglucosidase NN O O
alfa NN O O
should NN O O
undergo NN O O
periodic NN O O
urinalysis NN O O
[ NN O O
seeAdverse NN O O
Reactions NN O O
( NN O O
6.3 NN O O
) NN O O
] NN O O
. NN O O
Patients NN O O
should NN O O
be NN O O
monitored NN O O
for NN O O
the NN O O
development NN O O
of NN O O
systemic NN O O
immune NN O O
- NN O O
mediated NN O O
reactions NN O O
involving NN O O
skin NN O O
and NN O O
other NN O O
organs NN O O
while NN O O
receiving NN O O
alglucosidase NN O O
alfa NN O O
. NN O O
If NN O O
immune NN O O
- NN O O
mediated NN O O
reactions NN O O
occur NN O O
, NN O O
consider NN O O
discontinuation NN O O
of NN O O
the NN O O
administration NN O O
of NN O O
alglucosidase NN O O
alfa NN O O
, NN O O
and NN O O
initiate NN O O
appropriate NN O O
medical NN O O
treatment NN O O
. NN O O
The NN O O
risks NN O O
and NN O O
benefits NN O O
of NN O O
re NN O O
- NN O O
administering NN O O
alglucosidase NN O O
alfa NN O O
following NN O O
an NN O O
immune NN O O
- NN O O
mediated NN O O
reaction NN O O
should NN O O
be NN O O
considered NN O O
. NN O O
Some NN O O
patients NN O O
have NN O O
been NN O O
able NN O O
to NN O O
be NN O O
rechallenged NN O O
and NN O O
have NN O O
continued NN O O
to NN O O
receive NN O O
alglucosidase NN O O
alfa NN O O
under NN O O
close NN O O
clinical NN O O
supervision NN O O
. NN O O
5.3 NN O O
Risk NN O O
of NN O O
Acute NN O O
Cardiorespiratory NN O O
Failure NN O O
Patients NN O O
with NN O O
acute NN O O
underlying NN O O
respiratory NN O O
illness NN O O
or NN O O
compromised NN O O
cardiac NN O O
and/or NN O O
respiratory NN O O
function NN O O
may NN B-Factor B-Factor
be NN O O
at NN O O
risk NN O O
of NN O O
serious NN B-Severity B-Severity
exacerbation NN O O
of NN O O
their NN O O
cardiac NN O O
or NN O O
respiratory NN O O
compromise NN O O
during NN O O
infusions NN O O
. NN O O
Appropriate NN O O
medical NN O O
support NN O O
and NN O O
monitoring NN O O
measures NN O O
should NN O O
be NN O O
readily NN O O
available NN O O
during NN O O
alglucosidase NN O O
alfa NN O O
infusion NN O O
, NN O O
and NN O O
some NN O O
patients NN O O
may NN O O
require NN O O
prolonged NN O O
observation NN O O
times NN O O
that NN O O
should NN O O
be NN O O
individualized NN O O
based NN O O
on NN O O
the NN O O
needs NN O O
of NN O O
the NN O O
patient NN O O
. NN O O
Acute NN B-AdverseReaction B-AdverseReaction
cardiorespiratory NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
has NN O O
been NN O O
observed NN O O
in NN O O
infantile NN O O
- NN O O
onset NN O O
Pompe NN O O
disease NN O O
patients NN O O
with NN O O
underlying NN O O
cardiac NN O O
hypertrophy NN O O
, NN O O
possibly NN O O
associated NN O O
with NN O O
fluid NN B-AdverseReaction B-AdverseReaction
overload NN I-AdverseReaction I-AdverseReaction
with NN O O
intravenous NN O O
administration NN O O
of NN O O
alglucosidase NN O O
alfa NN O O
[ NN O O
seeDosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
] NN O O
. NN O O
5.4 NN O O
Risk NN O O
of NN O O
Cardiac NN O O
Arrhythmia NN O O
and NN O O
Sudden NN O O
Cardiac NN O O
Death NN O O
During NN O O
General NN O O
Anesthesia NN O O
for NN O O
Central NN O O
Venous NN O O
Catheter NN O O
Placement NN O O
Administration NN O O
of NN O O
general NN O O
anesthesia NN O O
can NN O O
be NN O O
complicated NN O O
by NN O O
the NN O O
presence NN O O
of NN O O
severe NN O O
cardiac NN O O
and NN O O
skeletal NN O O
( NN O O
including NN O O
respiratory NN O O
) NN O O
muscle NN O O
weakness NN O O
. NN O O
Therefore NN O O
, NN O O
caution NN O O
should NN O O
be NN O O
used NN O O
when NN O O
administering NN O O
general NN O O
anesthesia NN O O
. NN O O
Ventricular NN B-AdverseReaction B-AdverseReaction
arrhythmias NN I-AdverseReaction I-AdverseReaction
and NN O O
bradycardia NN B-AdverseReaction B-AdverseReaction
resulting NN O O
in NN O O
cardiac NN B-AdverseReaction B-AdverseReaction
arrest NN I-AdverseReaction I-AdverseReaction
or NN O O
death NN B-AdverseReaction B-AdverseReaction
or NN O O
requiring NN O O
cardiac NN O O
resuscitation NN O O
or NN O O
defibrillation NN O O
have NN O O
been NN O O
observed NN O O
in NN O O
infantile NN O O
- NN O O
onset NN O O
Pompe NN O O
disease NN O O
patients NN O O
with NN O O
cardiac NN O O
hypertrophy NN O O
during NN O O
general NN O O
anesthesia NN O O
for NN O O
central NN O O
venous NN O O
catheter NN O O
placement NN O O
. NN O O
5.5 NN O O
Risk NN O O
of NN O O
Antibody NN O O
Development NN O O
As NN O O
with NN O O
all NN O O
therapeutic NN O O
proteins NN O O
, NN O O
there NN O O
is NN O O
potential NN O O
for NN O O
immunogenicity NN O O
. NN O O
In NN O O
clinical NN O O
studies NN O O
, NN O O
the NN O O
majority NN O O
of NN O O
patients NN O O
developed NN O O
IgG NN O O
antibodies NN O O
to NN O O
alglucosidase NN O O
alfa NN O O
, NN O O
typically NN O O
within NN O O
3 NN O O
months NN O O
of NN O O
treatment NN O O
. NN O O
There NN O O
is NN O O
evidence NN O O
to NN O O
suggest NN O O
that NN O O
some NN O O
patients NN O O
who NN O O
develop NN O O
high NN O O
and NN O O
sustained NN O O
IgG NN O O
antibody NN O O
titers NN O O
may NN B-Factor B-Factor
experience NN O O
reduced NN B-AdverseReaction B-AdverseReaction
clinical NN I-AdverseReaction I-AdverseReaction
efficacy NN I-AdverseReaction I-AdverseReaction
to NN O O
alglucosidase NN O O
alfa NN O O
treatment NN O O
, NN O O
such NN O O
as NN O O
loss NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
motor NN I-AdverseReaction I-AdverseReaction
function NN I-AdverseReaction I-AdverseReaction
ventilator NN O O
dependence NN O O
, NN O O
or NN O O
death NN B-AdverseReaction B-AdverseReaction
The NN O O
effect NN O O
of NN O O
antibody NN O O
development NN O O
on NN O O
the NN O O
long NN O O
term NN O O
efficacy NN O O
of NN O O
alglucosidase NN O O
alfa NN O O
is NN O O
not NN O O
fully NN O O
understood NN O O
. NN O O
Patients NN O O
should NN O O
be NN O O
monitored NN O O
for NN O O
IgG NN O O
antibody NN O O
formation NN O O
every NN O O
3 NN O O
months NN O O
for NN O O
2 NN O O
years NN O O
and NN O O
then NN O O
annually NN O O
thereafter NN O O
. NN O O
Testing NN O O
for NN O O
IgG NN O O
titers NN O O
may NN O O
also NN O O
be NN O O
considered NN O O
if NN O O
patients NN O O
develop NN O O
hypersensitivity NN O O
reactions NN O O
, NN O O
other NN O O
immune NN O O
- NN O O
mediated NN O O
reactions NN O O
, NN O O
or NN O O
lose NN O O
clinical NN O O
response NN O O
. NN O O
Patients NN O O
who NN O O
experience NN O O
reduced NN O O
clinical NN O O
response NN O O
may NN O O
also NN O O
be NN O O
tested NN O O
for NN O O
inhibitory NN O O
antibody NN O O
activity NN O O
. NN O O
Patients NN O O
who NN O O
experience NN O O
anaphylactic NN O O
or NN O O
hypersensitivity NN O O
reactions NN O O
may NN O O
also NN O O
be NN O O
tested NN O O
for NN O O
IgE NN O O
antibodies NN O O
to NN O O
alglucosidase NN O O
alfa NN O O
and NN O O
other NN O O
mediators NN O O
of NN O O
anaphylaxis NN O O
[ NN O O
seeAdverse NN O O
Reactions NN O O
( NN O O
6.2 NN O O
) NN O O
] NN O O
. NN O O
There NN O O
are NN O O
currently NN O O
no NN O O
marketed NN O O
tests NN O O
for NN O O
antibodies NN O O
against NN O O
alglucosidase NN O O
alfa NN O O
; NN O O
however NN O O
, NN O O
a NN O O
testing NN O O
service NN O O
is NN O O
provided NN O O
by NN O O
Genzyme NN O O
. NN O O
Contact NN O O
your NN O O
local NN O O
Genzyme NN O O
representative NN O O
or NN O O
Genzyme NN O O
Corporation NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
745 NN O O
- NN O O
4447 NN O O
for NN O O
information NN O O
on NN O O
testing NN O O
and NN O O
to NN O O
obtain NN O O
a NN O O
sample NN O O
collection NN O O
box NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
EXCERPT NN O O
: NN O O
Commonly NN O O
observed NN O O
adverse NN O O
reactions NN O O
( NN O O
incidence NN O O
>=5 NN O O
% NN O O
and NN O O
2-fold NN O O
greater NN O O
than NN O O
placebo NN O O
) NN O O
were NN O O
: NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
nasal NN B-AdverseReaction B-AdverseReaction
congestion NN I-AdverseReaction I-AdverseReaction
orthostatic NN B-AdverseReaction B-AdverseReaction
hypotension NN I-AdverseReaction I-AdverseReaction
somnolence NN B-AdverseReaction B-AdverseReaction
tachycardia NN B-AdverseReaction B-AdverseReaction
and NN O O
weight NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Novartis NN O O
Pharmaceuticals NN O O
Corporation NN O O
at NN O O
1 NN O O
- NN O O
888 NN O O
- NN O O
669 NN O O
- NN O O
6682 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Studies NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trial NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O
The NN O O
information NN O O
below NN O O
is NN O O
derived NN O O
from NN O O
a NN O O
clinical NN O O
trial NN O O
database NN O O
for NN O O
FANAPT NN O O
consisting NN O O
of NN O O
2070 NN O O
patients NN O O
exposed NN O O
to NN O O
FANAPT NN O O
at NN O O
doses NN O O
of NN O O
10 NN O O
mg/day NN O O
or NN O O
greater NN O O
, NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
schizophrenia NN O O
. NN O O
Of NN O O
these NN O O
, NN O O
806 NN O O
received NN O O
FANAPT NN O O
for NN O O
at NN O O
least NN O O
6 NN O O
months NN O O
, NN O O
with NN O O
463 NN O O
exposed NN O O
to NN O O
FANAPT NN O O
for NN O O
at NN O O
least NN O O
12 NN O O
months NN O O
. NN O O
All NN O O
of NN O O
these NN O O
patients NN O O
who NN O O
received NN O O
FANAPT NN O O
were NN O O
participating NN O O
in NN O O
multiple NN O O
- NN O O
dose NN O O
clinical NN O O
trials NN O O
. NN O O
The NN O O
conditions NN O O
and NN O O
duration NN O O
of NN O O
treatment NN O O
with NN O O
FANAPT NN O O
varied NN O O
greatly NN O O
and NN O O
included NN O O
( NN O O
in NN O O
overlapping NN O O
categories NN O O
) NN O O
, NN O O
open NN O O
- NN O O
label NN O O
and NN O O
double NN O O
- NN O O
blind NN O O
phases NN O O
of NN O O
studies NN O O
, NN O O
inpatients NN O O
and NN O O
outpatients NN O O
, NN O O
fixed NN O O
- NN O O
dose NN O O
and NN O O
flexible NN O O
- NN O O
dose NN O O
studies NN O O
, NN O O
and NN O O
short NN O O
- NN O O
term NN O O
and NN O O
longer NN O O
- NN O O
term NN O O
exposure NN O O
. NN O O
Adverse NN O O
reactions NN O O
during NN O O
exposure NN O O
were NN O O
obtained NN O O
by NN O O
general NN O O
inquiry NN O O
and NN O O
recorded NN O O
by NN O O
clinical NN O O
investigators NN O O
using NN O O
their NN O O
own NN O O
terminology NN O O
. NN O O
Consequently NN O O
, NN O O
to NN O O
provide NN O O
a NN O O
meaningful NN O O
estimate NN O O
of NN O O
the NN O O
proportion NN O O
of NN O O
individuals NN O O
experiencing NN O O
adverse NN O O
reactions NN O O
, NN O O
reactions NN O O
were NN O O
grouped NN O O
in NN O O
standardized NN O O
categories NN O O
using NN O O
MedDRA NN O O
terminology NN O O
. NN O O
The NN O O
stated NN O O
frequencies NN O O
of NN O O
adverse NN O O
reactions NN O O
represent NN O O
the NN O O
proportions NN O O
of NN O O
individuals NN O O
who NN O O
experienced NN O O
a NN O O
treatment NN O O
- NN O O
emergent NN O O
adverse NN O O
reaction NN O O
of NN O O
the NN O O
type NN O O
listed NN O O
. NN O O
A NN O O
reaction NN O O
was NN O O
considered NN O O
treatment NN O O
- NN O O
emergent NN O O
if NN O O
it NN O O
occurred NN O O
for NN O O
the NN O O
first NN O O
time NN O O
or NN O O
worsened NN O O
while NN O O
receiving NN O O
therapy NN O O
following NN O O
baseline NN O O
evaluation NN O O
. NN O O
The NN O O
information NN O O
presented NN O O
in NN O O
these NN O O
sections NN O O
was NN O O
derived NN O O
from NN O O
pooled NN O O
data NN O O
from NN O O
4 NN O O
placebo NN O O
- NN O O
controlled NN O O
, NN O O
4- NN O O
or NN O O
6-week NN O O
, NN O O
fixed- NN O O
or NN O O
flexible NN O O
- NN O O
dose NN O O
studies NN O O
in NN O O
patients NN O O
who NN O O
received NN O O
FANAPT NN O O
at NN O O
daily NN O O
doses NN O O
within NN O O
a NN O O
range NN O O
of NN O O
10 NN O O
to NN O O
24 NN O O
mg NN O O
( NN O O
n=874 NN O O
) NN O O
. NN O O
Adverse NN O O
Reactions NN O O
Occurring NN O O
at NN O O
an NN O O
Incidence NN O O
of NN O O
2 NN O O
% NN O O
or NN O O
More NN O O
among NN O O
FANAPT NN O O
-Treated NN O O
Patients NN O O
and NN O O
More NN O O
Frequent NN O O
than NN O O
Placebo NN O O
Table NN O O
7 NN O O
enumerates NN O O
the NN O O
pooled NN O O
incidences NN O O
of NN O O
treatment NN O O
- NN O O
emergent NN O O
adverse NN O O
reactions NN O O
that NN O O
were NN O O
spontaneously NN O O
reported NN O O
in NN O O
four NN O O
placebo NN O O
- NN O O
controlled NN O O
, NN O O
4- NN O O
or NN O O
6-week NN O O
, NN O O
fixed- NN O O
or NN O O
flexible NN O O
- NN O O
dose NN O O
studies NN O O
, NN O O
listing NN O O
those NN O O
reactions NN O O
that NN O O
occurred NN O O
in NN O O
2 NN O O
% NN O O
or NN O O
more NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
FANAPT NN O O
in NN O O
any NN O O
of NN O O
the NN O O
dose NN O O
groups NN O O
, NN O O
and NN O O
for NN O O
which NN O O
the NN O O
incidence NN O O
in NN O O
FANAPT NN O O
- NN O O
treated NN O O
patients NN O O
in NN O O
any NN O O
dose NN O O
group NN O O
was NN O O
greater NN O O
than NN O O
the NN O O
incidence NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
placebo NN O O
. NN O O
Table NN O O
7 NN O O
: NN O O
Percentage NN O O
of NN O O
Treatment NN O O
- NN O O
Emergent NN O O
Adverse NN O O
Reactions NN O O
in NN O O
Short NN O O
- NN O O
Term NN O O
, NN O O
Fixed- NN O O
or NN O O
Flexible NN O O
- NN O O
Dose NN O O
, NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Trials NN O O
in NN O O
Adult NN O O
Patients NN O O
* NN O O
Body NN O O
System NN O O
or NN O O
Organ NN O O
Class NN O O
Placebo( NN O O
% NN O O
) NN O O
FANAPT NN O O
10 NN O O
- NN O O
16 NN O O
mg/day( NN O O
% NN O O
) NN O O
FANAPT NN O O
20 NN O O
- NN O O
24 NN O O
mg/day( NN O O
% NN O O
) NN O O
Dictionary NN O O
- NN O O
derived NN O O
Term NN O O
( NN O O
N=587 NN O O
) NN O O
( NN O O
N=483 NN O O
) NN O O
( NN O O
N=391 NN O O
) NN O O
Body NN O O
as NN O O
a NN O O
Whole NN O O
Arthralgia NN B-AdverseReaction B-AdverseReaction
2 NN O O
3 NN O O
3 NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
3 NN O O
4 NN O O
6 NN O O
Musculoskeletal NN B-AdverseReaction B-AdverseReaction
Stiffness NN I-AdverseReaction I-AdverseReaction
1 NN O O
1 NN O O
3 NN O O
Weight NN B-AdverseReaction B-AdverseReaction
Increased NN I-AdverseReaction I-AdverseReaction
1 NN O O
1 NN O O
9 NN O O
Cardiac NN O O
Disorders NN O O
Tachycardia NN B-AdverseReaction B-AdverseReaction
1 NN O O
3 NN O O
12 NN O O
Eye NN O O
Disorders NN O O
Vision NN B-AdverseReaction B-AdverseReaction
Blurred NN I-AdverseReaction I-AdverseReaction
2 NN O O
3 NN O O
1 NN O O
Gastrointestinal NN O O
Disorders NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
8 NN O O
7 NN O O
10 NN O O
Dry NN B-AdverseReaction B-AdverseReaction
Mouth NN I-AdverseReaction I-AdverseReaction
1 NN O O
8 NN O O
10 NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
4 NN O O
5 NN O O
7 NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
Discomfort NN I-AdverseReaction I-AdverseReaction
1 NN O O
1 NN O O
3 NN O O
Infections NN O O
Nasopharyngitis NN B-AdverseReaction B-AdverseReaction
3 NN O O
4 NN O O
3 NN O O
Upper NN B-AdverseReaction B-AdverseReaction
Respiratory NN I-AdverseReaction I-AdverseReaction
Tract NN I-AdverseReaction I-AdverseReaction
Infection NN I-AdverseReaction I-AdverseReaction
1 NN O O
2 NN O O
3 NN O O
Nervous NN O O
System NN O O
Disorders NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
7 NN O O
10 NN O O
20 NN O O
Somnolence NN B-AdverseReaction B-AdverseReaction
5 NN O O
9 NN O O
15 NN O O
Extrapyramidal NN B-AdverseReaction B-AdverseReaction
Disorder NN I-AdverseReaction I-AdverseReaction
4 NN O O
5 NN O O
4 NN O O
Tremor NN B-AdverseReaction B-AdverseReaction
2 NN O O
3 NN O O
3 NN O O
Lethargy NN B-AdverseReaction B-AdverseReaction
1 NN O O
3 NN O O
1 NN O O
Reproductive NN O O
System NN O O
Ejaculation NN B-AdverseReaction B-AdverseReaction
Failure NN I-AdverseReaction I-AdverseReaction
< NN O O
1 NN O O
2 NN O O
2 NN O O
Respiratory NN O O
Nasal NN B-AdverseReaction B-AdverseReaction
Congestion NN I-AdverseReaction I-AdverseReaction
2 NN O O
5 NN O O
8 NN O O
Dyspnea NN B-AdverseReaction B-AdverseReaction
< NN O O
1 NN O O
2 NN O O
2 NN O O
Skin NN O O
Rash NN B-AdverseReaction B-AdverseReaction
2 NN O O
3 NN O O
2 NN O O
Vascular NN O O
Disorders NN O O
Orthostatic NN B-AdverseReaction B-AdverseReaction
Hypotension NN I-AdverseReaction I-AdverseReaction
1 NN O O
3 NN O O
5 NN O O
Hypotension NN B-AdverseReaction B-AdverseReaction
< NN O O
1 NN O O
< NN O O
1 NN O O
3 NN O O
* NN O O
Table NN O O
includes NN O O
adverse NN O O
reactions NN O O
that NN O O
were NN O O
reported NN O O
in NN O O
2 NN O O
% NN O O
or NN O O
more NN O O
of NN O O
patients NN O O
in NN O O
any NN O O
of NN O O
the NN O O
FANAPT NN O O
dose NN O O
groups NN O O
and NN O O
which NN O O
occurred NN O O
at NN O O
greater NN O O
incidence NN O O
than NN O O
in NN O O
the NN O O
placebo NN O O
- NN O O
group NN O O
. NN O O
Figures NN O O
rounded NN O O
to NN O O
the NN O O
nearest NN O O
integer NN O O
. NN O O
Dose NN O O
- NN O O
Related NN O O
Adverse NN O O
Reactions NN O O
in NN O O
Clinical NN O O
Trials NN O O
Based NN O O
on NN O O
the NN O O
pooled NN O O
data NN O O
from NN O O
4 NN O O
placebo NN O O
- NN O O
controlled NN O O
, NN O O
4- NN O O
or NN O O
6-week NN O O
, NN O O
fixed- NN O O
or NN O O
flexible NN O O
- NN O O
dose NN O O
studies NN O O
, NN O O
adverse NN O O
reactions NN O O
that NN O O
occurred NN O O
with NN O O
a NN O O
greater NN O O
than NN O O
2 NN O O
% NN O O
incidence NN O O
in NN O O
the NN O O
patients NN O O
treated NN O O
with NN O O
FANAPT NN O O
, NN O O
and NN O O
for NN O O
which NN O O
the NN O O
incidence NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
FANAPT NN O O
20 NN O O
to NN O O
24 NN O O
mg/day NN O O
were NN O O
twice NN O O
than NN O O
the NN O O
incidence NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
FANAPT NN O O
10 NN O O
to NN O O
16 NN O O
mg/day NN O O
were NN O O
: NN O O
abdominal NN B-AdverseReaction B-AdverseReaction
discomfort NN I-AdverseReaction I-AdverseReaction
dizziness NN B-AdverseReaction B-AdverseReaction
hypotension NN B-AdverseReaction B-AdverseReaction
musculoskeletal NN B-AdverseReaction B-AdverseReaction
stiffness NN I-AdverseReaction I-AdverseReaction
tachycardia NN B-AdverseReaction B-AdverseReaction
and NN O O
weight NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
Common NN O O
and NN O O
Drug NN O O
- NN O O
Related NN O O
Adverse NN O O
Reactions NN O O
in NN O O
Clinical NN O O
Trials NN O O
Based NN O O
on NN O O
the NN O O
pooled NN O O
data NN O O
from NN O O
4 NN O O
placebo NN O O
- NN O O
controlled NN O O
, NN O O
4- NN O O
or NN O O
6-week NN O O
, NN O O
fixed- NN O O
or NN O O
flexible NN O O
- NN O O
dose NN O O
studies NN O O
, NN O O
the NN O O
following NN O O
adverse NN O O
reactions NN O O
occurred NN O O
in NN O O
>=5 NN O O
% NN O O
incidence NN O O
in NN O O
the NN O O
patients NN O O
treated NN O O
with NN O O
FANAPT NN O O
and NN O O
at NN O O
least NN O O
twice NN O O
the NN O O
placebo NN O O
rate NN O O
for NN O O
at NN O O
least NN O O
1 NN O O
dose NN O O
: NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
nasal NN B-AdverseReaction B-AdverseReaction
congestion NN I-AdverseReaction I-AdverseReaction
somnolence NN B-AdverseReaction B-AdverseReaction
tachycardia NN B-AdverseReaction B-AdverseReaction
orthostatic NN B-AdverseReaction B-AdverseReaction
hypotension NN I-AdverseReaction I-AdverseReaction
and NN O O
weight NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
Dizziness NN B-AdverseReaction B-AdverseReaction
tachycardia NN B-AdverseReaction B-AdverseReaction
and NN O O
weight NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
were NN O O
at NN O O
least NN O O
twice NN O O
as NN O O
common NN O O
on NN O O
20 NN O O
to NN O O
24 NN O O
mg/day NN O O
as NN O O
on NN O O
10 NN O O
to NN O O
16 NN O O
mg/day NN O O
. NN O O
Extrapyramidal NN O O
Symptoms NN O O
( NN O O
EPS NN O O
) NN O O
in NN O O
Clinical NN O O
Trials NN O O
Pooled NN O O
data NN O O
from NN O O
the NN O O
4 NN O O
placebo NN O O
- NN O O
controlled NN O O
, NN O O
4- NN O O
or NN O O
6-week NN O O
, NN O O
fixed- NN O O
or NN O O
flexible NN O O
- NN O O
dose NN O O
studies NN O O
provided NN O O
information NN O O
regarding NN O O
treatment NN O O
- NN O O
emergent NN O O
EPS NN B-AdverseReaction B-AdverseReaction
Adverse NN O O
event NN O O
data NN O O
collected NN O O
from NN O O
those NN O O
trials NN O O
showed NN O O
the NN O O
following NN O O
rates NN O O
of NN O O
EPS NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
as NN O O
shown NN O O
in NN O O
Table NN O O
8 NN O O
. NN O O
Table NN O O
8 NN O O
: NN O O
Percentage NN O O
of NN O O
EPS NN B-AdverseReaction B-AdverseReaction
Compared NN O O
to NN O O
Placebo NN O O
Placebo( NN O O
% NN O O
) NN O O
FANAPT NN O O
10 NN O O
- NN O O
16 NN O O
mg/day( NN O O
% NN O O
) NN O O
FANAPT NN O O
20 NN O O
- NN O O
24 NN O O
mg/day( NN O O
% NN O O
) NN O O
Adverse NN O O
Event NN O O
Term NN O O
( NN O O
N=587 NN O O
) NN O O
( NN O O
N=483 NN O O
) NN O O
( NN O O
N=391 NN O O
) NN O O
All NN O O
EPS NN O O
events NN O O
11.6 NN O O
13.5 NN O O
15.1 NN O O
Akathisia NN B-AdverseReaction B-AdverseReaction
2.7 NN O O
1.7 NN O O
2.3 NN O O
Bradykinesia NN B-AdverseReaction B-AdverseReaction
0 NN O O
0.6 NN O O
0.5 NN O O
Dyskinesia NN B-AdverseReaction B-AdverseReaction
1.5 NN O O
1.7 NN O O
1.0 NN O O
Dystonia NN B-AdverseReaction B-AdverseReaction
0.7 NN O O
1.0 NN O O
0.8 NN O O
Parkinsonism NN B-AdverseReaction B-AdverseReaction
0 NN O O
0.2 NN O O
0.3 NN O O
Tremor NN B-AdverseReaction B-AdverseReaction
1.9 NN O O
2.5 NN O O
3.1 NN O O
Adverse NN O O
Reactions NN O O
Associated NN O O
with NN O O
Discontinuation NN O O
of NN O O
Treatment NN O O
in NN O O
Clinical NN O O
Trials NN O O
Based NN O O
on NN O O
the NN O O
pooled NN O O
data NN O O
from NN O O
4 NN O O
placebo NN O O
- NN O O
controlled NN O O
, NN O O
4- NN O O
or NN O O
6-week NN O O
, NN O O
fixed- NN O O
or NN O O
flexible NN O O
- NN O O
dose NN O O
studies NN O O
, NN O O
there NN O O
was NN O O
no NN O O
difference NN O O
in NN O O
the NN O O
incidence NN O O
of NN O O
discontinuation NN O O
due NN O O
to NN O O
adverse NN O O
events NN O O
between NN O O
FANAPT NN O O
- NN O O
treated NN O O
( NN O O
5 NN O O
% NN O O
) NN O O
and NN O O
placebo NN O O
- NN O O
treated NN O O
( NN O O
5 NN O O
% NN O O
) NN O O
patients NN O O
. NN O O
The NN O O
types NN O O
of NN O O
adverse NN O O
events NN O O
that NN O O
led NN O O
to NN O O
discontinuation NN O O
were NN O O
similar NN O O
for NN O O
the NN O O
FANAPT- NN O O
and NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Demographic NN O O
Differences NN O O
in NN O O
Adverse NN O O
Reactions NN O O
in NN O O
Clinical NN O O
Trials NN O O
An NN O O
examination NN O O
of NN O O
population NN O O
subgroups NN O O
in NN O O
the NN O O
4 NN O O
placebo NN O O
- NN O O
controlled NN O O
, NN O O
4- NN O O
or NN O O
6-week NN O O
, NN O O
fixed- NN O O
or NN O O
flexible NN O O
- NN O O
dose NN O O
studies NN O O
did NN O O
not NN O O
reveal NN O O
any NN O O
evidence NN O O
of NN O O
differences NN O O
in NN O O
safety NN O O
on NN O O
the NN O O
basis NN O O
of NN O O
age NN O O
, NN O O
gender NN O O
or NN O O
race NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
Laboratory NN O O
Test NN O O
Abnormalities NN O O
in NN O O
Clinical NN O O
Trials NN O O
There NN O O
were NN O O
no NN O O
differences NN O O
between NN O O
FANAPT NN O O
and NN O O
placebo NN O O
in NN O O
the NN O O
incidence NN O O
of NN O O
discontinuation NN O O
due NN O O
to NN O O
changes NN O O
in NN O O
hematology NN O O
, NN O O
urinalysis NN O O
, NN O O
or NN O O
serum NN O O
chemistry NN O O
. NN O O
In NN O O
short NN O O
- NN O O
term NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
( NN O O
4- NN O O
to NN O O
6-weeks NN O O
) NN O O
, NN O O
there NN O O
were NN O O
1.0 NN O O
% NN O O
( NN O O
13/1342 NN O O
) NN O O
iloperidone NN O O
- NN O O
treated NN O O
patients NN O O
with NN O O
hematocrit NN O O
at NN O O
least NN O O
one NN O O
time NN O O
below NN O O
the NN O O
extended NN O O
normal NN O O
range NN O O
during NN O O
post NN O O
- NN O O
randomization NN O O
treatment NN O O
, NN O O
compared NN O O
to NN O O
0.3 NN O O
% NN O O
( NN O O
2/585 NN O O
) NN O O
on NN O O
placebo NN O O
. NN O O
The NN O O
extended NN O O
normal NN O O
range NN O O
for NN O O
lowered NN O O
hematocrit NN O O
was NN O O
defined NN O O
in NN O O
each NN O O
of NN O O
these NN O O
trials NN O O
as NN O O
the NN O O
value NN O O
15 NN O O
% NN O O
below NN O O
the NN O O
normal NN O O
range NN O O
for NN O O
the NN O O
centralized NN O O
laboratory NN O O
that NN O O
was NN O O
used NN O O
in NN O O
the NN O O
trial NN O O
. NN O O
Other NN O O
Reactions NN O O
During NN O O
the NN O O
Premarketing NN O O
Evaluation NN O O
of NN O O
FANAPT NN O O
The NN O O
following NN O O
is NN O O
a NN O O
list NN O O
of NN O O
MedDRA NN O O
terms NN O O
that NN O O
reflect NN O O
treatment NN O O
- NN O O
emergent NN O O
adverse NN O O
reactions NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
FANAPT NN O O
at NN O O
multiple NN O O
doses NN O O
>=4 NN O O
mg/day NN O O
during NN O O
any NN O O
phase NN O O
of NN O O
a NN O O
trial NN O O
with NN O O
the NN O O
database NN O O
of NN O O
3210 NN O O
FANAPT NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
All NN O O
reported NN O O
reactions NN O O
are NN O O
included NN O O
except NN O O
those NN O O
already NN O O
listed NN O O
in NN O O
Table NN O O
7 NN O O
, NN O O
or NN O O
other NN O O
parts NN O O
of NN O O
the NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
section NN O O
, NN O O
those NN O O
considered NN O O
in NN O O
the NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5 NN O O
) NN O O
, NN O O
those NN O O
reaction NN O O
terms NN O O
which NN O O
were NN O O
so NN O O
general NN O O
as NN O O
to NN O O
be NN O O
uninformative NN O O
, NN O O
reactions NN O O
reported NN O O
in NN O O
fewer NN O O
than NN O O
3 NN O O
patients NN O O
and NN O O
which NN O O
were NN O O
neither NN O O
serious NN O O
nor NN O O
life NN O O
- NN O O
threatening NN O O
, NN O O
reactions NN O O
that NN O O
are NN O O
otherwise NN O O
common NN O O
as NN O O
background NN O O
reactions NN O O
, NN O O
and NN O O
reactions NN O O
considered NN O O
unlikely NN O O
to NN O O
be NN O O
drug NN O O
related NN O O
. NN O O
It NN O O
is NN O O
important NN O O
to NN O O
emphasize NN O O
that NN O O
, NN O O
although NN O O
the NN O O
reactions NN O O
reported NN O O
occurred NN O O
during NN O O
treatment NN O O
with NN O O
FANAPT NN O O
, NN O O
they NN O O
were NN O O
not NN O O
necessarily NN O O
caused NN O O
by NN O O
it NN O O
. NN O O
Reactions NN O O
are NN O O
further NN O O
categorized NN O O
by NN O O
MedDRA NN O O
system NN O O
organ NN O O
class NN O O
and NN O O
listed NN O O
in NN O O
order NN O O
of NN O O
decreasing NN O O
frequency NN O O
according NN O O
to NN O O
the NN O O
following NN O O
definitions NN O O
: NN O O
frequent NN O O
adverse NN O O
events NN O O
are NN O O
those NN O O
occurring NN O O
in NN O O
at NN O O
least NN O O
1/100 NN O O
patients NN O O
( NN O O
only NN O O
those NN O O
not NN O O
listed NN O O
in NN O O
Table NN O O
7 NN O O
appear NN O O
in NN O O
this NN O O
listing NN O O
) NN O O
; NN O O
infrequent NN O O
adverse NN O O
reactions NN O O
are NN O O
those NN O O
occurring NN O O
in NN O O
1/100 NN O O
to NN O O
1/1000 NN O O
patients NN O O
; NN O O
rare NN O O
events NN O O
are NN O O
those NN O O
occurring NN O O
in NN O O
fewer NN O O
than NN O O
1/1000 NN O O
patients NN O O
. NN O O
Blood NN O O
and NN O O
Lymphatic NN O O
Disorders NN O O
: NN O O
Infrequent NN O O
- NN O O
anemia NN B-AdverseReaction B-AdverseReaction
iron NN B-AdverseReaction B-AdverseReaction
deficiency NN I-AdverseReaction I-AdverseReaction
anemia NN I-AdverseReaction I-AdverseReaction
Rare NN O O
- NN O O
leukopenia NN B-AdverseReaction B-AdverseReaction
Cardiac NN O O
Disorders NN O O
: NN O O
Frequent NN O O
- NN O O
palpitations NN B-AdverseReaction B-AdverseReaction
Rare NN O O
- NN O O
arrhythmia NN B-AdverseReaction B-AdverseReaction
atrioventricular NN B-AdverseReaction B-AdverseReaction
block NN I-AdverseReaction I-AdverseReaction
first NN B-Severity B-Severity
degree NN I-Severity I-Severity
cardiac NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
( NN O O
including NN O O
congestive NN O O
and NN O O
acute NN O O
) NN O O
Ear NN O O
and NN O O
Labyrinth NN O O
Disorders NN O O
: NN O O
Infrequent NN O O
- NN O O
vertigo NN B-AdverseReaction B-AdverseReaction
tinnitus NN B-AdverseReaction B-AdverseReaction
Endocrine NN O O
Disorders NN O O
: NN O O
Infrequent NN O O
- NN O O
hypothyroidism NN B-AdverseReaction B-AdverseReaction
Eye NN O O
Disorders NN O O
: NN O O
Frequent NN O O
- NN O O
conjunctivitis NN B-AdverseReaction B-AdverseReaction
( NN O O
including NN O O
allergic NN O O
) NN O O
; NN O O
Infrequent NN O O
- NN O O
dry NN B-AdverseReaction B-AdverseReaction
eye NN I-AdverseReaction I-AdverseReaction
blepharitis NN B-AdverseReaction B-AdverseReaction
eyelid NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
eye NN B-AdverseReaction B-AdverseReaction
swelling NN I-AdverseReaction I-AdverseReaction
lenticular NN B-AdverseReaction B-AdverseReaction
opacities NN I-AdverseReaction I-AdverseReaction
cataract NN B-AdverseReaction B-AdverseReaction
hyperemia NN B-AdverseReaction B-AdverseReaction
( NN O O
including NN O O
conjunctival NN O O
) NN O O
Gastrointestinal NN O O
Disorders NN O O
: NN O O
Infrequent NN O O
- NN O O
gastritis NN B-AdverseReaction B-AdverseReaction
salivary NN B-AdverseReaction B-AdverseReaction
hypersecretion NN I-AdverseReaction I-AdverseReaction
fecal NN B-AdverseReaction B-AdverseReaction
incontinence NN I-AdverseReaction I-AdverseReaction
mouth NN B-AdverseReaction B-AdverseReaction
ulceration NN I-AdverseReaction I-AdverseReaction
Rare NN O O
- NN O O
aphthous NN B-AdverseReaction B-AdverseReaction
stomatitis NN I-AdverseReaction I-AdverseReaction
duodenal NN B-AdverseReaction B-AdverseReaction
ulcer NN I-AdverseReaction I-AdverseReaction
hiatus NN B-AdverseReaction B-AdverseReaction
hernia NN I-AdverseReaction I-AdverseReaction
hyperchlorhydria NN B-AdverseReaction B-AdverseReaction
lip NN B-AdverseReaction B-AdverseReaction
ulceration NN I-AdverseReaction I-AdverseReaction
reflux NN B-AdverseReaction B-AdverseReaction
esophagitis NN I-AdverseReaction I-AdverseReaction
stomatitis NN B-AdverseReaction B-AdverseReaction
General NN O O
Disorders NN O O
and NN O O
Administrative NN O O
Site NN O O
Conditions NN O O
: NN O O
Infrequent NN O O
- NN O O
edema NN B-AdverseReaction B-AdverseReaction
( NN O O
general NN O O
, NN O O
pitting NN O O
, NN O O
due NN O O
to NN O O
cardiac NN O O
disease NN O O
) NN O O
, NN O O
difficulty NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
walking NN I-AdverseReaction I-AdverseReaction
thirst NN B-AdverseReaction B-AdverseReaction
Rare NN O O
- NN O O
hyperthermia NN B-AdverseReaction B-AdverseReaction
Hepatobiliary NN O O
Disorders NN O O
: NN O O
Infrequent NN O O
- NN O O
cholelithiasis NN B-AdverseReaction B-AdverseReaction
Investigations NN O O
: NN O O
Frequent NN O O
- NN O O
weight NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
Infrequent NN O O
- NN O O
hemoglobin NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
neutrophil NN B-AdverseReaction B-AdverseReaction
count NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
hematocrit NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
Metabolism NN O O
and NN O O
Nutrition NN O O
Disorders NN O O
: NN O O
Infrequent NN O O
- NN O O
increased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
dehydration NN B-AdverseReaction B-AdverseReaction
hypokalemia NN B-AdverseReaction B-AdverseReaction
fluid NN B-AdverseReaction B-AdverseReaction
retention NN I-AdverseReaction I-AdverseReaction
Musculoskeletal NN O O
and NN O O
Connective NN O O
Tissue NN O O
Disorders NN O O
: NN O O
Frequent NN O O
- NN O O
myalgia NN B-AdverseReaction B-AdverseReaction
muscle NN B-AdverseReaction B-AdverseReaction
spasms NN I-AdverseReaction I-AdverseReaction
Rare NN O O
- NN O O
torticollis NN B-AdverseReaction B-AdverseReaction
Nervous NN O O
System NN O O
Disorders NN O O
: NN O O
Infrequent NN O O
- NN O O
paresthesia NN B-AdverseReaction B-AdverseReaction
psychomotor NN B-AdverseReaction B-AdverseReaction
hyperactivity NN I-AdverseReaction I-AdverseReaction
restlessness NN B-AdverseReaction B-AdverseReaction
amnesia NN B-AdverseReaction B-AdverseReaction
nystagmus NN B-AdverseReaction B-AdverseReaction
Rare NN O O
- NN O O
restless NN B-AdverseReaction B-AdverseReaction
legs NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
Psychiatric NN O O
Disorders NN O O
: NN O O
Frequent NN O O
- NN O O
restlessness NN B-AdverseReaction B-AdverseReaction
aggression NN B-AdverseReaction B-AdverseReaction
delusion NN B-AdverseReaction B-AdverseReaction
Infrequent NN O O
- NN O O
hostility NN B-AdverseReaction B-AdverseReaction
libido NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
paranoia NN B-AdverseReaction B-AdverseReaction
anorgasmia NN B-AdverseReaction B-AdverseReaction
confusional NN B-AdverseReaction B-AdverseReaction
state NN I-AdverseReaction I-AdverseReaction
mania NN B-AdverseReaction B-AdverseReaction
catatonia NN B-AdverseReaction B-AdverseReaction
mood NN B-AdverseReaction B-AdverseReaction
swings NN I-AdverseReaction I-AdverseReaction
panic NN B-AdverseReaction B-AdverseReaction
attack NN I-AdverseReaction I-AdverseReaction
obsessive NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
compulsive NN I-AdverseReaction I-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
bulimia NN B-AdverseReaction B-AdverseReaction
nervosa NN I-AdverseReaction I-AdverseReaction
delirium NN B-AdverseReaction B-AdverseReaction
polydipsia NN B-AdverseReaction B-AdverseReaction
psychogenic NN I-AdverseReaction I-AdverseReaction
impulse NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
control NN I-AdverseReaction I-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
major NN B-AdverseReaction B-AdverseReaction
depression NN I-AdverseReaction I-AdverseReaction
Renal NN O O
and NN O O
Urinary NN O O
Disorders NN O O
: NN O O
Frequent NN O O
- NN O O
urinary NN B-AdverseReaction B-AdverseReaction
incontinence NN I-AdverseReaction I-AdverseReaction
Infrequent NN O O
- NN O O
dysuria NN B-AdverseReaction B-AdverseReaction
pollakiuria NN B-AdverseReaction B-AdverseReaction
enuresis NN B-AdverseReaction B-AdverseReaction
nephrolithiasis NN B-AdverseReaction B-AdverseReaction
Rare NN O O
- NN O O
urinary NN B-AdverseReaction B-AdverseReaction
retention NN I-AdverseReaction I-AdverseReaction
renal NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
acute NN I-AdverseReaction I-AdverseReaction
Reproductive NN O O
System NN O O
and NN O O
Breast NN O O
Disorders NN O O
: NN O O
Frequent NN O O
- NN O O
erectile NN B-AdverseReaction B-AdverseReaction
dysfunction NN I-AdverseReaction I-AdverseReaction
Infrequent NN O O
- NN O O
testicular NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
amenorrhea NN B-AdverseReaction B-AdverseReaction
breast NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
Rare NN O O
- NN O O
menstruation NN B-AdverseReaction B-AdverseReaction
irregular NN I-AdverseReaction I-AdverseReaction
gynecomastia NN B-AdverseReaction B-AdverseReaction
menorrhagia NN B-AdverseReaction B-AdverseReaction
metrorrhagia NN B-AdverseReaction B-AdverseReaction
postmenopausal NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
prostatitis NN B-AdverseReaction B-AdverseReaction
Respiratory NN O O
, NN O O
Thoracic NN O O
and NN O O
Mediastinal NN O O
Disorders NN O O
: NN O O
Infrequent NN O O
- NN O O
epistaxis NN B-AdverseReaction B-AdverseReaction
asthma NN B-AdverseReaction B-AdverseReaction
rhinorrhea NN B-AdverseReaction B-AdverseReaction
sinus NN B-AdverseReaction B-AdverseReaction
congestion NN I-AdverseReaction I-AdverseReaction
nasal NN B-AdverseReaction B-AdverseReaction
dryness NN I-AdverseReaction I-AdverseReaction
Rare NN O O
- NN O O
dry NN B-AdverseReaction B-AdverseReaction
throat NN I-AdverseReaction I-AdverseReaction
sleep NN B-AdverseReaction B-AdverseReaction
apnea NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
dyspnea NN B-AdverseReaction B-AdverseReaction
exertional NN I-AdverseReaction I-AdverseReaction
6.2 NN O O
Postmarketing NN O O
Experience NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
identified NN O O
during NN O O
post NN O O
- NN O O
approval NN O O
use NN O O
of NN O O
FANAPT NN O O
: NN O O
retrograde NN B-AdverseReaction B-AdverseReaction
ejaculation NN I-AdverseReaction I-AdverseReaction
Because NN O O
these NN O O
reactions NN O O
were NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
INCREASED NN O O
MORTALITY NN B-AdverseReaction B-AdverseReaction
IN NN O O
ELDERLY NN O O
PATIENTS NN O O
WITH NN O O
DEMENTIA NN O O
- NN O O
RELATED NN O O
PSYCHOSIS NN O O
WARNING NN O O
: NN O O
INCREASED NN O O
MORTALITY NN B-AdverseReaction B-AdverseReaction
IN NN O O
ELDERLY NN O O
PATIENTS NN O O
WITH NN O O
DEMENTIA NN O O
- NN O O
RELATED NN O O
PSYCHOSIS NN O O
Elderly NN O O
patients NN O O
with NN O O
dementia NN O O
- NN O O
related NN O O
psychosis NN O O
treated NN O O
with NN O O
antipsychotic NN B-DrugClass B-DrugClass
drugs NN I-DrugClass I-DrugClass
are NN O O
at NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
death NN B-AdverseReaction B-AdverseReaction
Analysis NN O O
of NN O O
seventeen NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
( NN O O
modal NN O O
duration NN O O
10 NN O O
weeks NN O O
) NN O O
, NN O O
largely NN O O
in NN O O
patients NN O O
taking NN O O
atypical NN O O
antipsychotic NN O O
drugs NN O O
, NN O O
revealed NN O O
a NN O O
risk NN B-Factor B-Factor
of NN O O
death NN B-AdverseReaction B-AdverseReaction
in NN O O
the NN O O
drug NN O O
- NN O O
treated NN O O
patients NN O O
of NN O O
between NN O O
1.6 NN O O
to NN O O
1.7 NN O O
times NN O O
the NN O O
risk NN O O
of NN O O
death NN O O
in NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Over NN O O
the NN O O
course NN O O
of NN O O
a NN O O
typical NN O O
10-week NN O O
controlled NN O O
trial NN O O
, NN O O
the NN O O
rate NN O O
of NN O O
death NN B-AdverseReaction B-AdverseReaction
in NN O O
drug NN O O
- NN O O
treated NN O O
patients NN O O
was NN O O
about NN O O
4.5 NN O O
% NN O O
, NN O O
compared NN O O
to NN O O
a NN O O
rate NN O O
of NN O O
about NN O O
2.6 NN O O
% NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
. NN O O
Although NN O O
the NN O O
causes NN O O
of NN O O
death NN B-AdverseReaction B-AdverseReaction
were NN O O
varied NN O O
, NN O O
most NN O O
of NN O O
the NN O O
deaths NN B-AdverseReaction B-AdverseReaction
appeared NN O O
to NN O O
be NN O O
either NN O O
cardiovascular NN O O
( NN O O
e.g. NN O O
, NN O O
heart NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
sudden NN B-AdverseReaction B-AdverseReaction
death NN I-AdverseReaction I-AdverseReaction
or NN O O
infectious NN O O
( NN O O
e.g. NN O O
, NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
in NN O O
nature NN O O
. NN O O
Observational NN O O
studies NN O O
suggest NN O O
that NN O O
, NN O O
similar NN O O
to NN O O
atypical NN O O
antipsychotic NN O O
drugs NN O O
, NN O O
treatment NN O O
with NN O O
conventional NN O O
antipsychotic NN O O
drugs NN O O
may NN O O
increase NN O O
mortality NN O O
. NN O O
The NN O O
extent NN O O
to NN O O
which NN O O
the NN O O
findings NN O O
of NN O O
increased NN O O
mortality NN O O
in NN O O
observational NN O O
studies NN O O
may NN O O
be NN O O
attributed NN O O
to NN O O
the NN O O
antipsychotic NN O O
drug NN O O
as NN O O
opposed NN O O
to NN O O
some NN O O
characteristic(s NN O O
) NN O O
of NN O O
the NN O O
patients NN O O
is NN O O
not NN O O
clear NN O O
. NN O O
FANAPT NN O O
is NN O O
not NN O O
approved NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
patients NN O O
with NN O O
Dementia NN O O
- NN O O
Related NN O O
Psychosis NN O O
. NN O O
[ NN O O
See NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
WARNING NN O O
: NN O O
INCREASED NN O O
MORTALITY NN B-AdverseReaction B-AdverseReaction
IN NN O O
ELDERLY NN O O
PATIENTS NN O O
WITH NN O O
DEMENTIA NN O O
- NN O O
RELATED NN O O
PSYCHOSIS NN O O
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
. NN O O
Elderly NN O O
patients NN O O
with NN O O
dementia NN O O
- NN O O
related NN O O
psychosis NN O O
treated NN O O
with NN O O
antipsychotic NN B-DrugClass B-DrugClass
drugs NN I-DrugClass I-DrugClass
are NN O O
at NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
death NN B-AdverseReaction B-AdverseReaction
FANAPT NN O O
is NN O O
not NN O O
approved NN O O
for NN O O
use NN O O
in NN O O
patients NN O O
with NN O O
dementia NN O O
- NN O O
related NN O O
psychosis NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Elderly NN O O
patients NN O O
with NN O O
dementia NN O O
- NN O O
related NN O O
psychosis NN O O
who NN O O
are NN O O
treated NN O O
with NN O O
atypical NN B-DrugClass B-DrugClass
antipsychotic NN I-DrugClass I-DrugClass
drugs NN I-DrugClass I-DrugClass
are NN O O
at NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
death NN B-AdverseReaction B-AdverseReaction
and NN O O
cerebrovascular NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
including NN O O
stroke NN B-AdverseReaction B-AdverseReaction
( NN O O
5.1 NN O O
) NN O O
* NN O O
QT NN B-AdverseReaction B-AdverseReaction
prolongation NN I-AdverseReaction I-AdverseReaction
Prolongs NN B-AdverseReaction B-AdverseReaction
QT NN I-AdverseReaction I-AdverseReaction
interval NN I-AdverseReaction I-AdverseReaction
and NN O O
may NN B-Factor B-Factor
be NN O O
associated NN O O
with NN O O
arrhythmia NN B-AdverseReaction B-AdverseReaction
and NN O O
sudden NN B-AdverseReaction B-AdverseReaction
death NN I-AdverseReaction I-AdverseReaction
using NN O O
other NN O O
antipsychotics NN O O
first NN O O
. NN O O
Avoid NN O O
use NN O O
of NN O O
FANAPT NN O O
in NN O O
combination NN O O
with NN O O
other NN O O
drugs NN O O
that NN O O
are NN O O
known NN O O
to NN O O
prolong NN O O
QTc NN O O
; NN O O
use NN O O
caution NN O O
and NN O O
consider NN O O
dose NN O O
modification NN O O
when NN O O
prescribing NN O O
FANAPT NN O O
with NN O O
other NN O O
drugs NN O O
that NN O O
inhibit NN O O
FANAPT NN O O
metabolism NN O O
. NN O O
Monitor NN O O
serum NN O O
potassium NN O O
and NN O O
magnesium NN O O
in NN O O
patients NN O O
at NN O O
risk NN O O
for NN O O
electrolyte NN O O
disturbances NN O O
. NN O O
( NN O O
1 NN O O
, NN O O
5.2 NN O O
, NN O O
7.1 NN O O
, NN O O
7.3 NN O O
, NN O O
12.3 NN O O
) NN O O
* NN O O
Neuroleptic NN B-AdverseReaction B-AdverseReaction
Malignant NN I-AdverseReaction I-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
Manage NN O O
with NN O O
immediate NN O O
discontinuation NN O O
of NN O O
drug NN O O
and NN O O
close NN O O
monitoring NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Tardive NN B-AdverseReaction B-AdverseReaction
dyskinesia NN I-AdverseReaction I-AdverseReaction
Discontinue NN O O
if NN O O
clinically NN O O
appropriate NN O O
. NN O O
( NN O O
5.4 NN O O
) NN O O
* NN O O
* NN O O
Hyperglycemia NN B-AdverseReaction B-AdverseReaction
and NN O O
diabetes NN B-AdverseReaction B-AdverseReaction
mellitus NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
patients NN O O
for NN O O
symptoms NN O O
of NN O O
hyperglycemia NN O O
including NN O O
polydipsia NN O O
, NN O O
polyuria NN O O
, NN O O
polyphagia NN O O
, NN O O
and NN O O
weakness NN O O
. NN O O
Monitor NN O O
glucose NN O O
regularly NN O O
in NN O O
patients NN O O
at NN O O
risk NN O O
for NN O O
diabetes NN O O
. NN O O
( NN O O
5.5 NN O O
) NN O O
* NN O O
Dyslipidemia NN B-AdverseReaction B-AdverseReaction
Undesirable NN O O
alterations NN O O
have NN O O
been NN O O
observed NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
atypical NN O O
antipsychotics NN O O
. NN O O
( NN O O
5.5 NN O O
) NN O O
* NN O O
Weight NN B-AdverseReaction B-AdverseReaction
Gain NN I-AdverseReaction I-AdverseReaction
Weight NN O O
gain NN O O
has NN O O
been NN O O
reported NN O O
. NN O O
Monitor NN O O
weight NN O O
. NN O O
( NN O O
5.5 NN O O
) NN O O
Metabolic NN B-AdverseReaction B-AdverseReaction
Changes NN I-AdverseReaction I-AdverseReaction
Atypical NN B-DrugClass B-DrugClass
antipsychotic NN I-DrugClass I-DrugClass
drugs NN I-DrugClass I-DrugClass
have NN O O
been NN O O
associated NN O O
with NN O O
metabolic NN O O
changes NN O O
that NN O O
may NN O O
increase NN O O
cardiovascular/cerebrovascular NN O O
risk NN O O
. NN O O
These NN O O
metabolic NN B-AdverseReaction B-AdverseReaction
changes NN I-AdverseReaction I-AdverseReaction
include NN O O
hyperglycemia NN B-AdverseReaction B-AdverseReaction
dyslipidemia NN B-AdverseReaction B-AdverseReaction
and NN O O
weight NN B-AdverseReaction B-AdverseReaction
gain NN I-AdverseReaction I-AdverseReaction
( NN O O
5.5 NN O O
) NN O O
* NN O O
Seizures NN B-AdverseReaction B-AdverseReaction
Use NN O O
cautiously NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
seizures NN O O
or NN O O
with NN O O
conditions NN O O
that NN O O
lower NN O O
seizure NN O O
threshold NN O O
. NN O O
( NN O O
5.6 NN O O
) NN O O
* NN O O
Orthostatic NN B-AdverseReaction B-AdverseReaction
hypotension NN I-AdverseReaction I-AdverseReaction
Dizziness NN B-AdverseReaction B-AdverseReaction
tachycardia NN B-AdverseReaction B-AdverseReaction
and NN O O
syncope NN B-AdverseReaction B-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
with NN O O
standing NN O O
. NN O O
( NN O O
5.7 NN O O
) NN O O
* NN O O
Leukopenia NN B-AdverseReaction B-AdverseReaction
Neutropenia NN B-AdverseReaction B-AdverseReaction
and NN O O
Agranulocytosis NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
with NN O O
antipsychotics NN B-DrugClass B-DrugClass
Patients NN O O
with NN O O
a NN O O
pre NN O O
- NN O O
existing NN O O
low NN O O
white NN O O
blood NN O O
cell NN O O
count NN O O
( NN O O
WBC NN O O
) NN O O
or NN O O
a NN O O
history NN O O
of NN O O
leukopenia/neutropenia NN O O
should NN O O
have NN O O
their NN O O
complete NN O O
blood NN O O
count NN O O
( NN O O
CBC NN O O
) NN O O
monitored NN O O
frequently NN O O
during NN O O
the NN O O
first NN O O
few NN O O
months NN O O
of NN O O
therapy NN O O
and NN O O
should NN O O
discontinue NN O O
FANAPT NN O O
at NN O O
the NN O O
first NN O O
sign NN O O
of NN O O
a NN O O
decline NN O O
in NN O O
WBC NN O O
in NN O O
the NN O O
absence NN O O
of NN O O
other NN O O
causative NN O O
factors NN O O
. NN O O
( NN O O
5.8 NN O O
) NN O O
* NN O O
Suicide NN B-AdverseReaction B-AdverseReaction
Close NN O O
supervision NN O O
of NN O O
high NN O O
risk NN O O
patients NN O O
. NN O O
( NN O O
5.12 NN O O
) NN O O
* NN O O
Priapism NN B-AdverseReaction B-AdverseReaction
Cases NN O O
have NN O O
been NN O O
reported NN O O
in NN O O
association NN O O
with NN O O
FANAPT NN O O
treatment NN O O
. NN O O
( NN O O
5.13 NN O O
) NN O O
* NN O O
Potential NN B-Factor B-Factor
for NN O O
cognitive NN O O
and NN O O
motor NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
Use NN O O
caution NN O O
when NN O O
operating NN O O
machinery NN O O
. NN O O
( NN O O
5.14 NN O O
) NN O O
* NN O O
See NN O O
Full NN O O
Prescribing NN O O
Information NN O O
for NN O O
additional NN O O
WARNINGS NN O O
and NN O O
PRECAUTIONS. NN O O
5.1 NN O O
Increased NN O O
Risks NN O O
in NN O O
Elderly NN O O
Patients NN O O
with NN O O
Dementia NN O O
- NN O O
Related NN O O
Psychosis NN O O
Increased NN O O
Mortality NN O O
Elderly NN O O
patients NN O O
with NN O O
dementia NN O O
- NN O O
related NN O O
psychosis NN O O
treated NN O O
with NN O O
atypical NN B-DrugClass B-DrugClass
antipsychotic NN I-DrugClass I-DrugClass
drugs NN I-DrugClass I-DrugClass
are NN O O
at NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
death NN B-AdverseReaction B-AdverseReaction
compared NN O O
to NN O O
placebo NN O O
. NN O O
FANAPT NN O O
is NN O O
not NN O O
approved NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
patients NN O O
with NN O O
dementia NN O O
- NN O O
related NN O O
psychosis NN O O
[ NN O O
s NN O O
ee NN O O
Boxed NN O O
Warning NN O O
] NN O O
. NN O O
Cerebrovascular NN O O
Adverse NN O O
Events NN O O
, NN O O
Including NN O O
Stroke NN O O
In NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
with NN O O
risperidone NN O O
, NN O O
aripiprazole NN O O
, NN O O
and NN O O
olanzapine NN O O
in NN O O
elderly NN O O
patients NN O O
with NN O O
dementia NN O O
, NN O O
there NN O O
was NN O O
a NN O O
higher NN O O
incidence NN O O
of NN O O
cerebrovascular NN B-AdverseReaction B-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
( NN O O
cerebrovascular NN O O
accidents NN O O
and NN O O
transient NN B-AdverseReaction B-AdverseReaction
ischemic NN I-AdverseReaction I-AdverseReaction
attacks NN I-AdverseReaction I-AdverseReaction
including NN O O
fatalities NN B-AdverseReaction B-AdverseReaction
compared NN O O
to NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
FANAPT NN O O
is NN O O
not NN O O
approved NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
patients NN O O
with NN O O
dementia NN O O
- NN O O
related NN O O
psychosis NN O O
[ NN O O
s NN O O
ee NN O O
Boxed NN O O
Warning NN O O
] NN O O
. NN O O
5.2 NN O O
QT NN O O
Prolongation NN O O
In NN O O
an NN O O
open NN O O
- NN O O
label NN O O
QTc NN O O
study NN O O
in NN O O
patients NN O O
with NN O O
schizophrenia NN O O
or NN O O
schizoaffective NN O O
disorder NN O O
( NN O O
n=160 NN O O
) NN O O
, NN O O
FANAPT NN O O
was NN O O
associated NN O O
with NN O O
QTc NN B-AdverseReaction B-AdverseReaction
prolongation NN I-AdverseReaction I-AdverseReaction
of NN O O
9 NN O O
msec NN O O
at NN O O
an NN O O
iloperidone NN O O
dose NN O O
of NN O O
12 NN O O
mg NN O O
twice NN O O
daily NN O O
. NN O O
The NN O O
effect NN O O
of NN O O
FANAPT NN O O
on NN O O
the NN O O
QT NN O O
interval NN O O
was NN O O
augmented NN O O
by NN O O
the NN O O
presence NN O O
of NN O O
CYP450 NN O O
2D6 NN O O
or NN O O
3A4 NN O O
metabolic NN O O
inhibition NN O O
( NN O O
paroxetine NN O O
20 NN O O
mg NN O O
once NN O O
daily NN O O
and NN O O
ketoconazole NN O O
200 NN O O
mg NN O O
twice NN O O
daily NN O O
, NN O O
respectively NN O O
) NN O O
. NN O O
Under NN O O
conditions NN O O
of NN O O
metabolic NN O O
inhibition NN O O
for NN O O
both NN O O
2D6 NN O O
and NN O O
3A4 NN O O
, NN O O
FANAPT NN O O
12 NN O O
mg NN O O
twice NN O O
daily NN O O
was NN O O
associated NN O O
with NN O O
a NN O O
mean NN O O
QTcF NN B-AdverseReaction B-AdverseReaction
increase NN I-AdverseReaction I-AdverseReaction
from NN O O
baseline NN O O
of NN O O
about NN O O
19 NN O O
msec NN O O
. NN O O
No NN B-Negation B-Negation
cases NN O O
of NN O O
torsade NN B-AdverseReaction B-AdverseReaction
de NN I-AdverseReaction I-AdverseReaction
pointes NN I-AdverseReaction I-AdverseReaction
or NN O O
other NN O O
severe NN B-Severity B-Severity
cardiac NN B-AdverseReaction B-AdverseReaction
arrhythmias NN I-AdverseReaction I-AdverseReaction
were NN O O
observed NN O O
during NN O O
the NN O O
pre NN O O
- NN O O
marketing NN O O
clinical NN O O
program NN O O
. NN O O
The NN O O
use NN O O
of NN O O
FANAPT NN O O
should NN O O
be NN O O
avoided NN O O
in NN O O
combination NN O O
with NN O O
other NN O O
drugs NN O O
that NN O O
are NN O O
known NN O O
to NN O O
prolong NN O O
QTc NN O O
including NN O O
Class NN O O
1A NN O O
( NN O O
e.g. NN O O
, NN O O
quinidine NN O O
, NN O O
procainamide NN O O
) NN O O
or NN O O
Class NN O O
III NN O O
( NN O O
e.g. NN O O
, NN O O
amiodarone NN O O
, NN O O
sotalol NN O O
) NN O O
antiarrhythmic NN O O
medications NN O O
, NN O O
antipsychotic NN O O
medications NN O O
( NN O O
e.g. NN O O
, NN O O
chlorpromazine NN O O
, NN O O
thioridazine NN O O
) NN O O
, NN O O
antibiotics NN O O
( NN O O
e.g. NN O O
, NN O O
gatifloxacin NN O O
, NN O O
moxifloxacin NN O O
) NN O O
, NN O O
or NN O O
any NN O O
other NN O O
class NN O O
of NN O O
medications NN O O
known NN O O
to NN O O
prolong NN O O
the NN O O
QTc NN O O
interval NN O O
( NN O O
e.g. NN O O
, NN O O
pentamidine NN O O
, NN O O
levomethadyl NN O O
acetate NN O O
, NN O O
methadone NN O O
) NN O O
. NN O O
FANAPT NN O O
should NN O O
also NN O O
be NN O O
avoided NN O O
in NN O O
patients NN O O
with NN O O
congenital NN O O
long NN O O
QT NN O O
syndrome NN O O
and NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
cardiac NN O O
arrhythmias NN O O
. NN O O
Certain NN O O
circumstances NN O O
may NN O O
increase NN O O
the NN O O
risk NN O O
of NN O O
torsade NN O O
de NN O O
pointes NN O O
and/or NN O O
sudden NN O O
death NN O O
in NN O O
association NN O O
with NN O O
the NN O O
use NN O O
of NN O O
drugs NN O O
that NN O O
prolong NN O O
the NN O O
QTc NN O O
interval NN O O
, NN O O
including NN O O
( NN O O
1 NN O O
) NN O O
bradycardia NN O O
; NN O O
( NN O O
2 NN O O
) NN O O
hypokalemia NN O O
or NN O O
hypomagnesemia NN O O
; NN O O
( NN O O
3 NN O O
) NN O O
concomitant NN O O
use NN O O
of NN O O
other NN O O
drugs NN O O
that NN O O
prolong NN O O
the NN O O
QTc NN O O
interval NN O O
; NN O O
and NN O O
( NN O O
4 NN O O
) NN O O
presence NN O O
of NN O O
congenital NN O O
prolongation NN O O
of NN O O
the NN O O
QT NN O O
interval NN O O
; NN O O
( NN O O
5 NN O O
) NN O O
recent NN O O
acute NN O O
myocardial NN O O
infarction NN O O
; NN O O
and/or NN O O
( NN O O
6 NN O O
) NN O O
uncompensated NN O O
heart NN O O
failure NN O O
. NN O O
Caution NN O O
is NN O O
warranted NN O O
when NN O O
prescribing NN O O
FANAPT NN O O
with NN O O
drugs NN O O
that NN O O
inhibit NN O O
FANAPT NN O O
metabolism NN O O
[ NN O O
see NN O O
Drug NN O O
Interaction NN O O
s NN O O
( NN O O
7.1 NN O O
) NN O O
] NN O O
, NN O O
and NN O O
in NN O O
patients NN O O
with NN O O
reduced NN O O
activity NN O O
of NN O O
CYP2D6 NN O O
[ NN O O
see NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.3 NN O O
) NN O O
] NN O O
. NN O O
It NN O O
is NN O O
recommended NN O O
that NN O O
patients NN O O
being NN O O
considered NN O O
for NN O O
FANAPT NN O O
treatment NN O O
who NN O O
are NN O O
at NN O O
risk NN O O
for NN O O
significant NN O O
electrolyte NN O O
disturbances NN O O
have NN O O
baseline NN O O
serum NN O O
potassium NN O O
and NN O O
magnesium NN O O
measurements NN O O
with NN O O
periodic NN O O
monitoring NN O O
. NN O O
Hypokalemia NN O O
( NN O O
and/or NN O O
hypomagnesemia NN O O
) NN O O
may NN O O
increase NN O O
the NN O O
risk NN O O
of NN O O
QT NN O O
prolongation NN O O
and NN O O
arrhythmia NN O O
. NN O O
FANAPT NN O O
should NN O O
be NN O O
avoided NN O O
in NN O O
patients NN O O
with NN O O
histories NN O O
of NN O O
significant NN O O
cardiovascular NN O O
illness NN O O
, NN O O
e.g. NN O O
, NN O O
QT NN O O
prolongation NN O O
, NN O O
recent NN O O
acute NN O O
myocardial NN O O
infarction NN O O
, NN O O
uncompensated NN O O
heart NN O O
failure NN O O
, NN O O
or NN O O
cardiac NN O O
arrhythmia NN O O
. NN O O
FANAPT NN O O
should NN O O
be NN O O
discontinued NN O O
in NN O O
patients NN O O
who NN O O
are NN O O
found NN O O
to NN O O
have NN O O
persistent NN O O
QTc NN O O
measurements NN O O
>500 NN O O
msec NN O O
. NN O O
If NN O O
patients NN O O
taking NN O O
FANAPT NN O O
experience NN O O
symptoms NN O O
that NN O O
could NN O O
indicate NN O O
the NN O O
occurrence NN O O
of NN O O
cardiac NN O O
arrhythmias NN O O
, NN O O
e.g. NN O O
, NN O O
dizziness NN O O
, NN O O
palpitations NN O O
, NN O O
or NN O O
syncope NN O O
, NN O O
the NN O O
prescriber NN O O
should NN O O
initiate NN O O
further NN O O
evaluation NN O O
, NN O O
including NN O O
cardiac NN O O
monitoring NN O O
. NN O O
5.3 NN O O
Neuroleptic NN O O
Malignant NN O O
Syndrome NN O O
( NN O O
NMS NN O O
) NN O O
A NN O O
potentially NN O O
fatal NN O O
symptom NN O O
complex NN O O
sometimes NN O O
referred NN O O
to NN O O
as NN O O
Neuroleptic NN B-AdverseReaction B-AdverseReaction
Malignant NN I-AdverseReaction I-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
NMS NN O O
) NN O O
has NN O O
been NN O O
reported NN O O
in NN O O
association NN O O
with NN O O
administration NN O O
of NN O O
antipsychotic NN O O
drugs NN O O
, NN O O
including NN O O
FANAPT. NN O O
Clinical NN O O
manifestations NN O O
include NN O O
hyperpyrexia NN B-AdverseReaction B-AdverseReaction
muscle NN B-AdverseReaction B-AdverseReaction
rigidity NN I-AdverseReaction I-AdverseReaction
altered NN B-AdverseReaction B-AdverseReaction
mental NN I-AdverseReaction I-AdverseReaction
status NN I-AdverseReaction I-AdverseReaction
( NN O O
including NN O O
catatonic NN B-AdverseReaction B-AdverseReaction
signs NN I-AdverseReaction I-AdverseReaction
and NN O O
evidence NN O O
of NN O O
autonomic NN B-AdverseReaction B-AdverseReaction
instability NN I-AdverseReaction I-AdverseReaction
( NN O O
irregular NN O O
pulse NN O O
or NN O O
blood NN O O
pressure NN O O
, NN O O
tachycardia NN B-AdverseReaction B-AdverseReaction
diaphoresis NN B-AdverseReaction B-AdverseReaction
and NN O O
cardiac NN B-AdverseReaction B-AdverseReaction
dysrhythmia NN I-AdverseReaction I-AdverseReaction
Additional NN O O
signs NN O O
may NN B-Factor B-Factor
include NN O O
elevated NN B-AdverseReaction B-AdverseReaction
creatine NN I-AdverseReaction I-AdverseReaction
phosphokinase NN I-AdverseReaction I-AdverseReaction
myoglobinuria NN B-AdverseReaction B-AdverseReaction
( NN O O
rhabdomyolysis NN O O
) NN O O
, NN O O
and NN O O
acute NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
The NN O O
diagnostic NN O O
evaluation NN O O
of NN O O
patients NN O O
with NN O O
this NN O O
syndrome NN O O
is NN O O
complicated NN O O
. NN O O
In NN O O
arriving NN O O
at NN O O
a NN O O
diagnosis NN O O
, NN O O
it NN O O
is NN O O
important NN O O
to NN O O
identify NN O O
cases NN O O
in NN O O
which NN O O
the NN O O
clinical NN O O
presentation NN O O
includes NN O O
both NN O O
serious NN O O
medical NN O O
illness NN O O
( NN O O
e.g. NN O O
, NN O O
pneumonia NN O O
, NN O O
systemic NN O O
infection NN O O
, NN O O
etc NN O O
. NN O O
) NN O O
and NN O O
untreated NN O O
or NN O O
inadequately NN O O
treated NN O O
extrapyramidal NN O O
signs NN O O
and NN O O
symptoms NN O O
( NN O O
EPS NN O O
) NN O O
. NN O O
Other NN O O
important NN O O
considerations NN O O
in NN O O
the NN O O
differential NN O O
diagnosis NN O O
include NN O O
central NN O O
anticholinergic NN O O
toxicity NN O O
, NN O O
heat NN O O
stroke NN O O
, NN O O
drug NN O O
fever NN O O
, NN O O
and NN O O
primary NN O O
central NN O O
nervous NN O O
system NN O O
( NN O O
CNS NN O O
) NN O O
pathology NN O O
. NN O O
The NN O O
management NN O O
of NN O O
this NN O O
syndrome NN O O
should NN O O
include NN O O
: NN O O
( NN O O
1 NN O O
) NN O O
immediate NN O O
discontinuation NN O O
of NN O O
the NN O O
antipsychotic NN O O
drugs NN O O
and NN O O
other NN O O
drugs NN O O
not NN O O
essential NN O O
to NN O O
concurrent NN O O
therapy NN O O
, NN O O
( NN O O
2 NN O O
) NN O O
intensive NN O O
symptomatic NN O O
treatment NN O O
and NN O O
medical NN O O
monitoring NN O O
, NN O O
and NN O O
( NN O O
3 NN O O
) NN O O
treatment NN O O
of NN O O
any NN O O
concomitant NN O O
serious NN O O
medical NN O O
problems NN O O
for NN O O
which NN O O
specific NN O O
treatments NN O O
are NN O O
available NN O O
. NN O O
There NN O O
is NN O O
no NN O O
general NN O O
agreement NN O O
about NN O O
specific NN O O
pharmacological NN O O
treatment NN O O
regimens NN O O
for NN O O
NMS. NN O O
If NN O O
a NN O O
patient NN O O
requires NN O O
antipsychotic NN O O
drug NN O O
treatment NN O O
after NN O O
recovery NN O O
from NN O O
NMS NN O O
, NN O O
the NN O O
potential NN O O
reintroduction NN O O
of NN O O
drug NN O O
therapy NN O O
should NN O O
be NN O O
carefully NN O O
considered NN O O
. NN O O
The NN O O
patient NN O O
should NN O O
be NN O O
carefully NN O O
monitored NN O O
, NN O O
since NN O O
recurrences NN O O
of NN O O
NMS NN O O
have NN O O
been NN O O
reported NN O O
. NN O O
5.4 NN O O
Tardive NN O O
Dyskinesia NN O O
Tardive NN B-AdverseReaction B-AdverseReaction
dyskinesia NN I-AdverseReaction I-AdverseReaction
is NN O O
a NN O O
syndrome NN O O
consisting NN O O
of NN O O
potentially NN O O
irreversible NN O O
, NN O O
involuntary NN B-AdverseReaction B-AdverseReaction
, NN I-AdverseReaction I-AdverseReaction
dyskinetic NN I-AdverseReaction I-AdverseReaction
movements NN I-AdverseReaction I-AdverseReaction
which NN O O
may NN O O
develop NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
antipsychotic NN B-DrugClass B-DrugClass
drugs NN I-DrugClass I-DrugClass
Although NN O O
the NN O O
prevalence NN O O
of NN O O
the NN O O
syndrome NN O O
appears NN O O
to NN O O
be NN O O
highest NN O O
among NN O O
the NN O O
elderly NN O O
, NN O O
especially NN O O
elderly NN O O
women NN O O
, NN O O
it NN O O
is NN O O
impossible NN O O
to NN O O
rely NN O O
on NN O O
prevalence NN O O
estimates NN O O
to NN O O
predict NN O O
, NN O O
at NN O O
the NN O O
inception NN O O
of NN O O
antipsychotic NN O O
treatment NN O O
, NN O O
which NN O O
patients NN O O
are NN O O
likely NN O O
to NN O O
develop NN O O
the NN O O
syndrome NN O O
. NN O O
Whether NN O O
antipsychotic NN O O
drug NN O O
products NN O O
differ NN O O
in NN O O
their NN O O
potential NN O O
to NN O O
cause NN O O
tardive NN O O
dyskinesia NN O O
is NN O O
unknown NN O O
. NN O O
The NN O O
risk NN O O
of NN O O
developing NN O O
tardive NN O O
dyskinesia NN O O
and NN O O
the NN O O
likelihood NN O O
that NN O O
it NN O O
will NN O O
become NN O O
irreversible NN O O
are NN O O
believed NN O O
to NN O O
increase NN O O
as NN O O
the NN O O
duration NN O O
of NN O O
treatment NN O O
and NN O O
the NN O O
total NN O O
cumulative NN O O
dose NN O O
of NN O O
antipsychotic NN O O
administered NN O O
increases NN O O
. NN O O
However NN O O
, NN O O
the NN O O
syndrome NN O O
can NN O O
develop NN O O
, NN O O
although NN O O
much NN O O
less NN O O
commonly NN O O
, NN O O
after NN O O
relatively NN O O
brief NN O O
treatment NN O O
periods NN O O
at NN O O
low NN O O
doses NN O O
. NN O O
There NN O O
is NN O O
no NN O O
known NN O O
treatment NN O O
for NN O O
established NN O O
cases NN O O
of NN O O
tardive NN O O
dyskinesia NN O O
, NN O O
although NN O O
the NN O O
syndrome NN O O
may NN O O
remit NN O O
, NN O O
partially NN O O
or NN O O
completely NN O O
, NN O O
if NN O O
antipsychotic NN O O
treatment NN O O
is NN O O
withdrawn NN O O
. NN O O
Antipsychotic NN O O
treatment NN O O
itself NN O O
, NN O O
however NN O O
, NN O O
may NN O O
suppress NN O O
( NN O O
or NN O O
partially NN O O
suppress NN O O
) NN O O
the NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
the NN O O
syndrome NN O O
and NN O O
thereby NN O O
may NN O O
possibly NN O O
mask NN O O
the NN O O
underlying NN O O
process NN O O
. NN O O
The NN O O
effect NN O O
that NN O O
symptomatic NN O O
suppression NN O O
has NN O O
upon NN O O
the NN O O
long NN O O
- NN O O
term NN O O
course NN O O
of NN O O
the NN O O
syndrome NN O O
is NN O O
unknown NN O O
. NN O O
Given NN O O
these NN O O
considerations NN O O
, NN O O
FANAPT NN O O
should NN O O
be NN O O
prescribed NN O O
in NN O O
a NN O O
manner NN O O
that NN O O
is NN O O
most NN O O
likely NN O O
to NN O O
minimize NN O O
the NN O O
occurrence NN O O
of NN O O
tardive NN O O
dyskinesia NN O O
. NN O O
Chronic NN O O
antipsychotic NN O O
treatment NN O O
should NN O O
generally NN O O
be NN O O
reserved NN O O
for NN O O
patients NN O O
who NN O O
suffer NN O O
from NN O O
a NN O O
chronic NN O O
illness NN O O
that NN O O
( NN O O
1 NN O O
) NN O O
is NN O O
known NN O O
to NN O O
respond NN O O
to NN O O
antipsychotic NN O O
drugs NN O O
, NN O O
and NN O O
( NN O O
2 NN O O
) NN O O
for NN O O
whom NN O O
alternative NN O O
, NN O O
equally NN O O
effective NN O O
, NN O O
but NN O O
potentially NN O O
less NN O O
harmful NN O O
treatments NN O O
are NN O O
not NN O O
available NN O O
or NN O O
appropriate NN O O
. NN O O
In NN O O
patients NN O O
who NN O O
do NN O O
require NN O O
chronic NN O O
treatment NN O O
, NN O O
the NN O O
smallest NN O O
dose NN O O
and NN O O
the NN O O
shortest NN O O
duration NN O O
of NN O O
treatment NN O O
producing NN O O
a NN O O
satisfactory NN O O
clinical NN O O
response NN O O
should NN O O
be NN O O
sought NN O O
. NN O O
The NN O O
need NN O O
for NN O O
continued NN O O
treatment NN O O
should NN O O
be NN O O
reassessed NN O O
periodically NN O O
. NN O O
If NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
tardive NN O O
dyskinesia NN O O
appear NN O O
in NN O O
a NN O O
patient NN O O
on NN O O
FANAPT NN O O
, NN O O
drug NN O O
discontinuation NN O O
should NN O O
be NN O O
considered NN O O
. NN O O
However NN O O
, NN O O
some NN O O
patients NN O O
may NN O O
require NN O O
treatment NN O O
with NN O O
FANAPT NN O O
despite NN O O
the NN O O
presence NN O O
of NN O O
the NN O O
syndrome NN O O
. NN O O
5.5 NN O O
Metabolic NN O O
Changes NN O O
Atypical NN B-DrugClass B-DrugClass
antipsychotic NN I-DrugClass I-DrugClass
drugs NN I-DrugClass I-DrugClass
have NN O O
been NN O O
associated NN O O
with NN O O
metabolic NN O O
changes NN O O
that NN O O
may NN O O
increase NN O O
cardiovascular/cerebrovascular NN O O
risk NN O O
. NN O O
These NN O O
metabolic NN O O
changes NN O O
include NN O O
hyperglycemia NN B-AdverseReaction B-AdverseReaction
dyslipidemia NN B-AdverseReaction B-AdverseReaction
and NN O O
body NN B-AdverseReaction B-AdverseReaction
weight NN I-AdverseReaction I-AdverseReaction
gain NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Patient NN O O
Counseling NN O O
Information NN O O
( NN O O
17.3 NN O O
) NN O O
] NN O O
. NN O O
While NN O O
all NN O O
atypical NN O O
antipsychotic NN O O
drugs NN O O
have NN O O
been NN O O
shown NN O O
to NN O O
produce NN O O
some NN O O
metabolic NN O O
changes NN O O
, NN O O
each NN O O
drug NN O O
in NN O O
the NN O O
class NN O O
has NN O O
its NN O O
own NN O O
specific NN O O
risk NN O O
profile NN O O
. NN O O
Hyperglycemia NN O O
and NN O O
Diabetes NN O O
Mellitus NN O O
Hyperglycemia NN B-AdverseReaction B-AdverseReaction
in NN O O
some NN O O
cases NN O O
extreme NN B-Severity B-Severity
and NN O O
associated NN O O
with NN O O
ketoacidosis NN B-AdverseReaction B-AdverseReaction
or NN O O
hyperosmolar NN B-AdverseReaction B-AdverseReaction
coma NN I-AdverseReaction I-AdverseReaction
or NN O O
death NN B-AdverseReaction B-AdverseReaction
has NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
atypical NN O O
antipsychotics NN O O
including NN O O
FANAPT. NN O O
Assessment NN O O
of NN O O
the NN O O
relationship NN O O
between NN O O
atypical NN O O
antipsychotic NN O O
use NN O O
and NN O O
glucose NN O O
abnormalities NN O O
is NN O O
complicated NN O O
by NN O O
the NN O O
possibility NN O O
of NN O O
an NN O O
increased NN O O
background NN O O
risk NN O O
of NN O O
diabetes NN O O
mellitus NN O O
in NN O O
patients NN O O
with NN O O
schizophrenia NN O O
and NN O O
the NN O O
increasing NN O O
incidence NN O O
of NN O O
diabetes NN O O
mellitus NN O O
in NN O O
the NN O O
general NN O O
population NN O O
. NN O O
Given NN O O
these NN O O
confounders NN O O
, NN O O
the NN O O
relationship NN O O
between NN O O
atypical NN O O
antipsychotic NN O O
use NN O O
and NN O O
hyperglycemia NN O O
- NN O O
related NN O O
adverse NN O O
events NN O O
is NN O O
not NN O O
completely NN O O
understood NN O O
. NN O O
However NN O O
, NN O O
epidemiological NN O O
studies NN O O
suggest NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
treatment NN O O
- NN O O
emergent NN O O
hyperglycemia NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
in NN O O
patients NN O O
treated NN O O
with NN O O
the NN O O
atypical NN B-DrugClass B-DrugClass
antipsychotics NN I-DrugClass I-DrugClass
included NN O O
in NN O O
these NN O O
studies NN O O
. NN O O
Because NN O O
FANAPT NN O O
was NN O O
not NN O O
marketed NN O O
at NN O O
the NN O O
time NN O O
these NN O O
studies NN O O
were NN O O
performed NN O O
, NN O O
it NN O O
is NN O O
not NN O O
known NN O O
if NN O O
FANAPT NN O O
is NN O O
associated NN O O
with NN O O
this NN O O
increased NN O O
risk NN O O
. NN O O
Patients NN O O
with NN O O
an NN O O
established NN O O
diagnosis NN O O
of NN O O
diabetes NN O O
mellitus NN O O
who NN O O
are NN O O
started NN O O
on NN O O
atypical NN O O
antipsychotics NN O O
should NN O O
be NN O O
monitored NN O O
regularly NN O O
for NN O O
worsening NN O O
of NN O O
glucose NN O O
control NN O O
. NN O O
Patients NN O O
with NN O O
risk NN O O
factors NN O O
for NN O O
diabetes NN O O
mellitus NN O O
( NN O O
e.g. NN O O
, NN O O
obesity NN O O
, NN O O
family NN O O
history NN O O
of NN O O
diabetes NN O O
) NN O O
who NN O O
are NN O O
starting NN O O
treatment NN O O
with NN O O
atypical NN O O
antipsychotics NN O O
should NN O O
undergo NN O O
fasting NN O O
blood NN O O
glucose NN O O
testing NN O O
at NN O O
the NN O O
beginning NN O O
of NN O O
treatment NN O O
and NN O O
periodically NN O O
during NN O O
treatment NN O O
. NN O O
Any NN O O
patient NN O O
treated NN O O
with NN O O
atypical NN O O
antipsychotics NN O O
should NN O O
be NN O O
monitored NN O O
for NN O O
symptoms NN O O
of NN O O
hyperglycemia NN O O
including NN O O
polydipsia NN O O
, NN O O
polyuria NN O O
, NN O O
polyphagia NN O O
, NN O O
and NN O O
weakness NN O O
. NN O O
Patients NN O O
who NN O O
develop NN O O
symptoms NN O O
of NN O O
hyperglycemia NN O O
during NN O O
treatment NN O O
with NN O O
atypical NN O O
antipsychotics NN O O
should NN O O
undergo NN O O
fasting NN O O
blood NN O O
glucose NN O O
testing NN O O
. NN O O
In NN O O
some NN O O
cases NN O O
, NN O O
hyperglycemia NN O O
has NN O O
resolved NN O O
when NN O O
the NN O O
atypical NN O O
antipsychotic NN O O
was NN O O
discontinued NN O O
; NN O O
however NN O O
, NN O O
some NN O O
patients NN O O
required NN O O
continuation NN O O
of NN O O
antidiabetic NN O O
treatment NN O O
despite NN O O
discontinuation NN O O
of NN O O
the NN O O
suspect NN O O
drug NN O O
. NN O O
Data NN O O
from NN O O
a NN O O
4-week NN O O
, NN O O
fixed NN O O
- NN O O
dose NN O O
study NN O O
in NN O O
adult NN O O
subjects NN O O
with NN O O
schizophrenia NN O O
, NN O O
in NN O O
which NN O O
fasting NN O O
blood NN O O
samples NN O O
were NN O O
drawn NN O O
, NN O O
are NN O O
presented NN O O
in NN O O
Table NN O O
1 NN O O
. NN O O
Table NN O O
1 NN O O
: NN O O
Change NN O O
in NN O O
Fasting NN O O
Glucose NN O O
FANAPT NN O O
Placebo NN O O
24 NN O O
mg/day NN O O
Mean NN O O
Change NN O O
from NN O O
Baseline(mg/dL NN O O
) NN O O
n=114 NN O O
n=228 NN O O
Serum NN O O
Glucose NN O O
Change NN O O
from NN O O
Baseline NN O O
-0.5 NN O O
6.6 NN O O
Proportion NN O O
of NN O O
Patients NN O O
with NN O O
Shifts NN O O
Serum NN O O
Glucose NN O O
Normal NN O O
to NN O O
High NN O O
2.5 NN O O
% NN O O
10.7 NN O O
% NN O O
( NN O O
< NN O O
100 NN O O
mg/dL NN O O
to NN O O
>=126 NN O O
mg/dL NN O O
) NN O O
( NN O O
2/80 NN O O
) NN O O
( NN O O
18/169 NN O O
) NN O O
Pooled NN O O
analyses NN O O
of NN O O
glucose NN O O
data NN O O
from NN O O
clinical NN O O
studies NN O O
including NN O O
longer NN O O
term NN O O
trials NN O O
are NN O O
shown NN O O
in NN O O
Table NN O O
2 NN O O
. NN O O
Table NN O O
2 NN O O
: NN O O
Change NN O O
in NN O O
Glucose NN O O
Mean NN O O
Change NN O O
from NN O O
Baseline NN O O
( NN O O
mg/dL NN O O
) NN O O
3 NN O O
- NN O O
6 NN O O
months NN O O
6 NN O O
- NN O O
12 NN O O
months NN O O
>12 NN O O
months NN O O
FANAPT NN O O
10 NN O O
- NN O O
16 NN O O
mg/day NN O O
1.8 NN O O
( NN O O
N=773 NN O O
) NN O O
5.4 NN O O
( NN O O
N=723 NN O O
) NN O O
5.4 NN O O
( NN O O
N=425 NN O O
) NN O O
FANAPT NN O O
20 NN O O
- NN O O
24 NN O O
mg/day NN O O
-3.6 NN O O
( NN O O
N=34 NN O O
) NN O O
-9.0 NN O O
( NN O O
N=31 NN O O
) NN O O
-18.0 NN O O
( NN O O
N=20 NN O O
) NN O O
Dyslipidemia NN O O
Undesirable NN B-AdverseReaction B-AdverseReaction
alterations NN I-AdverseReaction I-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
lipids NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
observed NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
atypical NN B-DrugClass B-DrugClass
antipsychotics NN I-DrugClass I-DrugClass
Data NN O O
from NN O O
a NN O O
placebo NN O O
- NN O O
controlled NN O O
, NN O O
4-week NN O O
, NN O O
fixed NN O O
- NN O O
dose NN O O
study NN O O
, NN O O
in NN O O
which NN O O
fasting NN O O
blood NN O O
samples NN O O
were NN O O
drawn NN O O
, NN O O
in NN O O
adult NN O O
subjects NN O O
with NN O O
schizophrenia NN O O
are NN O O
presented NN O O
in NN O O
Table NN O O
3 NN O O
. NN O O
Table NN O O
3 NN O O
: NN O O
Change NN O O
in NN O O
Fasting NN O O
Lipids NN O O
FANAPT NN O O
Placebo NN O O
24 NN O O
mg/day NN O O
Mean NN O O
Change NN O O
from NN O O
Baseline NN O O
( NN O O
mg/dL NN O O
) NN O O
Cholesterol NN O O
n=114 NN O O
n=228 NN O O
Change NN O O
from NN O O
baseline NN O O
-2.17 NN O O
8.18 NN O O
LDL NN O O
n=109 NN O O
n=217 NN O O
Change NN O O
from NN O O
baseline NN O O
-1.41 NN O O
9.03 NN O O
HDL NN O O
n=114 NN O O
n=228 NN O O
Change NN O O
from NN O O
baseline NN O O
-3.35 NN O O
0.55 NN O O
Triglycerides NN O O
n=114 NN O O
n=228 NN O O
Change NN O O
from NN O O
baseline NN O O
16.47 NN O O
-0.83 NN O O
Proportion NN O O
of NN O O
Patients NN O O
with NN O O
Shifts NN O O
Cholesterol NN O O
Normal NN O O
to NN O O
High NN O O
1.4 NN O O
% NN O O
3.6 NN O O
% NN O O
( NN O O
< NN O O
200 NN O O
mg/dL NN O O
to NN O O
>=240 NN O O
mg/dL NN O O
) NN O O
( NN O O
1/72 NN O O
) NN O O
( NN O O
5/141 NN O O
) NN O O
LDL NN O O
Normal NN O O
to NN O O
High NN O O
2.4 NN O O
% NN O O
1.1 NN O O
% NN O O
( NN O O
< NN O O
100 NN O O
mg/dL NN O O
to NN O O
>=160 NN O O
mg/dL NN O O
) NN O O
( NN O O
1/42 NN O O
) NN O O
( NN O O
1/90 NN O O
) NN O O
HDL NN O O
Normal NN O O
to NN O O
Low NN O O
23.8 NN O O
% NN O O
12.1 NN O O
% NN O O
( NN O O
>=40 NN O O
mg/dL NN O O
to NN O O
< NN O O
40 NN O O
mg/dL NN O O
) NN O O
( NN O O
19/80 NN O O
) NN O O
( NN O O
20/166 NN O O
) NN O O
Triglycerides NN O O
Normal NN O O
to NN O O
High NN O O
8.3 NN O O
% NN O O
10.1 NN O O
% NN O O
( NN O O
< NN O O
150 NN O O
mg/dL NN O O
to NN O O
>=200 NN O O
mg/dL NN O O
) NN O O
( NN O O
6/72 NN O O
) NN O O
( NN O O
15/148 NN O O
) NN O O
Pooled NN O O
analyses NN O O
of NN O O
cholesterol NN O O
and NN O O
triglyceride NN O O
data NN O O
from NN O O
clinical NN O O
studies NN O O
including NN O O
longer NN O O
term NN O O
trials NN O O
are NN O O
shown NN O O
in NN O O
Tables NN O O
4 NN O O
and NN O O
5 NN O O
. NN O O
Table NN O O
4 NN O O
: NN O O
Change NN O O
in NN O O
Cholesterol NN O O
Mean NN O O
Change NN O O
from NN O O
Baseline NN O O
( NN O O
mg/dL NN O O
) NN O O
3 NN O O
- NN O O
6 NN O O
months NN O O
6 NN O O
- NN O O
12 NN O O
months NN O O
>12 NN O O
months NN O O
FANAPT NN O O
10 NN O O
- NN O O
16 NN O O
mg/day NN O O
-3.9 NN O O
( NN O O
N=783 NN O O
) NN O O
-3.9 NN O O
( NN O O
N=726 NN O O
) NN O O
-7.7 NN O O
( NN O O
N=428 NN O O
) NN O O
FANAPT NN O O
20 NN O O
- NN O O
24 NN O O
mg/day NN O O
-19.4 NN O O
( NN O O
N=34 NN O O
) NN O O
-23.2 NN O O
( NN O O
N=31 NN O O
) NN O O
-19.4 NN O O
( NN O O
N=20 NN O O
) NN O O
Table NN O O
5 NN O O
: NN O O
Change NN O O
in NN O O
Triglycerides NN O O
Mean NN O O
Change NN O O
from NN O O
Baseline NN O O
( NN O O
mg/dL NN O O
) NN O O
3 NN O O
- NN O O
6 NN O O
months NN O O
6 NN O O
- NN O O
12 NN O O
months NN O O
>12 NN O O
months NN O O
FANAPT NN O O
10 NN O O
- NN O O
16 NN O O
mg/day NN O O
-8.9 NN O O
( NN O O
N=783 NN O O
) NN O O
-8.9 NN O O
( NN O O
N=726 NN O O
) NN O O
-17.7 NN O O
( NN O O
N=428 NN O O
) NN O O
FANAPT NN O O
20 NN O O
- NN O O
24 NN O O
mg/day NN O O
-26.6 NN O O
( NN O O
N=34 NN O O
) NN O O
-35.4 NN O O
( NN O O
N=31 NN O O
) NN O O
-17.7 NN O O
( NN O O
N=20 NN O O
) NN O O
Weight NN O O
Gain NN O O
Weight NN B-AdverseReaction B-AdverseReaction
gain NN I-AdverseReaction I-AdverseReaction
has NN O O
been NN O O
observed NN O O
with NN O O
atypical NN B-DrugClass B-DrugClass
antipsychotic NN I-DrugClass I-DrugClass
use NN O O
. NN O O
Clinical NN O O
monitoring NN O O
of NN O O
weight NN O O
is NN O O
recommended NN O O
. NN O O
Across NN O O
all NN O O
short- NN O O
and NN O O
long NN O O
- NN O O
term NN O O
studies NN O O
, NN O O
the NN O O
overall NN O O
mean NN O O
change NN O O
from NN O O
baseline NN O O
at NN O O
endpoint NN O O
was NN O O
2.1 NN O O
kg NN O O
. NN O O
Changes NN O O
in NN O O
body NN O O
weight NN O O
( NN O O
kg NN O O
) NN O O
and NN O O
the NN O O
proportion NN O O
of NN O O
subjects NN O O
with NN O O
>=7 NN O O
% NN O O
gain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
body NN I-AdverseReaction I-AdverseReaction
weight NN I-AdverseReaction I-AdverseReaction
from NN O O
4 NN O O
placebo NN O O
- NN O O
controlled NN O O
, NN O O
4- NN O O
or NN O O
6-week NN O O
, NN O O
fixed- NN O O
or NN O O
flexible NN O O
- NN O O
dose NN O O
studies NN O O
in NN O O
adult NN O O
subjects NN O O
are NN O O
presented NN O O
in NN O O
Table NN O O
6 NN O O
. NN O O
Table NN O O
6 NN O O
: NN O O
Change NN O O
in NN O O
Body NN O O
Weight NN O O
FANAPT NN O O
FANAPT NN O O
Placebo NN O O
10 NN O O
- NN O O
16 NN O O
mg/day NN O O
20 NN O O
- NN O O
24 NN O O
mg/day NN O O
n=576 NN O O
n=481 NN O O
n=391 NN O O
Weight NN O O
( NN O O
kg NN O O
) NN O O
Change NN O O
from NN O O
Baseline NN O O
-0.1 NN O O
2.0 NN O O
2.7 NN O O
Weight NN O O
Gain NN O O
>=7 NN O O
% NN O O
increase NN O O
from NN O O
Baseline NN O O
4 NN O O
% NN O O
12 NN O O
% NN O O
18 NN O O
% NN O O
5.6 NN O O
Seizures NN O O
In NN O O
short NN O O
- NN O O
term NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
( NN O O
4- NN O O
to NN O O
6-weeks NN O O
) NN O O
, NN O O
seizures NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
0.1 NN O O
% NN O O
( NN O O
1/1344 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
FANAPT NN O O
compared NN O O
to NN O O
0.3 NN O O
% NN O O
( NN O O
2/587 NN O O
) NN O O
on NN O O
placebo NN O O
. NN O O
As NN O O
with NN O O
other NN O O
antipsychotics NN O O
, NN O O
FANAPT NN O O
should NN O O
be NN O O
used NN O O
cautiously NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
seizures NN O O
or NN O O
with NN O O
conditions NN O O
that NN O O
potentially NN O O
lower NN O O
the NN O O
seizure NN O O
threshold NN O O
, NN O O
e.g. NN O O
, NN O O
Alzheimer NN O O
's NN O O
dementia NN O O
. NN O O
Conditions NN O O
that NN O O
lower NN O O
the NN O O
seizure NN O O
threshold NN O O
may NN O O
be NN O O
more NN O O
prevalent NN O O
in NN O O
a NN O O
population NN O O
of NN O O
65 NN O O
years NN O O
or NN O O
older NN O O
. NN O O
5.7 NN O O
Orthostatic NN O O
Hypotension NN O O
and NN O O
Syncope NN O O
FANAPT NN O O
can NN B-Factor B-Factor
induce NN O O
orthostatic NN B-AdverseReaction B-AdverseReaction
hypotension NN I-AdverseReaction I-AdverseReaction
associated NN O O
with NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
tachycardia NN B-AdverseReaction B-AdverseReaction
and NN O O
syncope NN B-AdverseReaction B-AdverseReaction
This NN O O
reflects NN O O
its NN O O
alpha1-adrenergic NN O O
antagonist NN O O
properties NN O O
. NN O O
In NN O O
double NN O O
- NN O O
blind NN O O
placebo NN O O
- NN O O
controlled NN O O
short NN O O
- NN O O
term NN O O
studies NN O O
, NN O O
where NN O O
the NN O O
dose NN O O
was NN O O
increased NN O O
slowly NN O O
, NN O O
as NN O O
recommended NN O O
above NN O O
, NN O O
syncope NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
0.4 NN O O
% NN O O
( NN O O
5/1344 NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
FANAPT NN O O
, NN O O
compared NN O O
with NN O O
0.2 NN O O
% NN O O
( NN O O
1/587 NN O O
) NN O O
on NN O O
placebo NN O O
. NN O O
Orthostatic NN B-AdverseReaction B-AdverseReaction
hypotension NN I-AdverseReaction I-AdverseReaction
was NN O O
reported NN O O
in NN O O
5 NN O O
% NN O O
of NN O O
patients NN O O
given NN O O
20 NN O O
to NN O O
24 NN O O
mg/day NN O O
, NN O O
3 NN O O
% NN O O
of NN O O
patients NN O O
given NN O O
10 NN O O
to NN O O
16 NN O O
mg/day NN O O
, NN O O
and NN O O
1 NN O O
% NN O O
of NN O O
patients NN O O
given NN O O
placebo NN O O
. NN O O
More NN O O
rapid NN O O
titration NN O O
would NN O O
be NN O O
expected NN O O
to NN O O
increase NN O O
the NN O O
rate NN O O
of NN O O
orthostatic NN O O
hypotension NN O O
and NN O O
syncope NN O O
. NN O O
FANAPT NN O O
should NN O O
be NN O O
used NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
with NN O O
known NN O O
cardiovascular NN O O
disease NN O O
( NN O O
e.g. NN O O
, NN O O
heart NN O O
failure NN O O
, NN O O
history NN O O
of NN O O
myocardial NN O O
infarction NN O O
, NN O O
ischemia NN O O
, NN O O
or NN O O
conduction NN O O
abnormalities NN O O
) NN O O
, NN O O
cerebrovascular NN O O
disease NN O O
, NN O O
or NN O O
conditions NN O O
that NN O O
predispose NN O O
the NN O O
patient NN O O
to NN O O
hypotension NN O O
( NN O O
dehydration NN O O
, NN O O
hypovolemia NN O O
, NN O O
and NN O O
treatment NN O O
with NN O O
antihypertensive NN O O
medications NN O O
) NN O O
. NN O O
Monitoring NN O O
of NN O O
orthostatic NN O O
vital NN O O
signs NN O O
should NN O O
be NN O O
considered NN O O
in NN O O
patients NN O O
who NN O O
are NN O O
vulnerable NN O O
to NN O O
hypotension NN O O
. NN O O
5.8 NN O O
Leukopenia NN O O
, NN O O
Neutropenia NN O O
and NN O O
Agranulocytosis NN O O
In NN O O
clinical NN O O
trial NN O O
and NN O O
postmarketing NN O O
experience NN O O
, NN O O
events NN O O
of NN O O
leukopenia NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
temporally NN O O
related NN O O
to NN O O
antipsychotic NN B-DrugClass B-DrugClass
agents NN I-DrugClass I-DrugClass
Agranulocytosis NN B-AdverseReaction B-AdverseReaction
( NN O O
including NN O O
fatal NN B-AdverseReaction B-AdverseReaction
cases NN O O
) NN O O
has NN O O
also NN O O
been NN O O
reported NN O O
. NN O O
Possible NN O O
risk NN O O
factors NN O O
for NN O O
leukopenia NN B-AdverseReaction B-AdverseReaction
include NN O O
preexisting NN O O
low NN O O
white NN O O
blood NN O O
cell NN O O
count NN O O
( NN O O
WBC NN O O
) NN O O
and NN O O
history NN O O
of NN O O
drug NN O O
induced NN O O
leukopenia/neutropenia NN O O
. NN O O
Patients NN O O
with NN O O
a NN O O
pre NN O O
- NN O O
existing NN O O
low NN O O
WBC NN O O
or NN O O
a NN O O
history NN O O
of NN O O
drug NN O O
induced NN O O
leukopenia/neutropenia NN O O
should NN O O
have NN O O
their NN O O
complete NN O O
blood NN O O
count NN O O
( NN O O
CBC NN O O
) NN O O
monitored NN O O
frequently NN O O
during NN O O
the NN O O
first NN O O
few NN O O
months NN O O
of NN O O
therapy NN O O
and NN O O
should NN O O
discontinue NN O O
FANAPT NN O O
at NN O O
the NN O O
first NN O O
sign NN O O
of NN O O
a NN O O
decline NN O O
in NN O O
WBC NN O O
in NN O O
the NN O O
absence NN O O
of NN O O
other NN O O
causative NN O O
factors NN O O
. NN O O
Patients NN O O
with NN O O
neutropenia NN O O
should NN O O
be NN O O
carefully NN O O
monitored NN O O
for NN O O
fever NN O O
or NN O O
other NN O O
symptoms NN O O
or NN O O
signs NN O O
of NN O O
infection NN O O
and NN O O
treated NN O O
promptly NN O O
if NN O O
such NN O O
symptoms NN O O
or NN O O
signs NN O O
occur NN O O
. NN O O
Patients NN O O
with NN O O
severe NN O O
neutropenia NN O O
( NN O O
absolute NN O O
neutrophil NN O O
count NN O O
< NN O O
1000/mm NN O O
3 NN O O
) NN O O
should NN O O
discontinue NN O O
FANAPT NN O O
and NN O O
have NN O O
their NN O O
WBC NN O O
followed NN O O
until NN O O
recovery NN O O
. NN O O
5.9 NN O O
Hyperprolactinemia NN O O
As NN O O
with NN O O
other NN O O
drugs NN O O
that NN O O
antagonize NN O O
dopamine NN O O
D2 NN O O
receptors NN O O
, NN O O
FANAPT NN O O
elevates NN B-AdverseReaction B-AdverseReaction
prolactin NN I-AdverseReaction I-AdverseReaction
levels NN I-AdverseReaction I-AdverseReaction
Hyperprolactinemia NN B-AdverseReaction B-AdverseReaction
may NN B-Factor B-Factor
suppress NN B-AdverseReaction B-AdverseReaction
hypothalamic NN I-AdverseReaction I-AdverseReaction
GnRH NN I-AdverseReaction I-AdverseReaction
resulting NN O O
in NN O O
reduced NN B-AdverseReaction B-AdverseReaction
pituitary NN I-AdverseReaction I-AdverseReaction
gonadotropin NN I-AdverseReaction I-AdverseReaction
secretion NN I-AdverseReaction I-AdverseReaction
This NN O O
, NN O O
in NN O O
turn NN O O
, NN O O
may NN B-Factor B-Factor
inhibit NN B-AdverseReaction B-AdverseReaction
reproductive NN I-AdverseReaction I-AdverseReaction
function NN I-AdverseReaction I-AdverseReaction
by NN O O
impairing NN B-AdverseReaction B-AdverseReaction
gonadalsteroidogenesis NN I-AdverseReaction I-AdverseReaction
in NN O O
both NN O O
female NN O O
and NN O O
male NN O O
patients NN O O
. NN O O
Galactorrhea NN B-AdverseReaction B-AdverseReaction
amenorrhea NN B-AdverseReaction B-AdverseReaction
gynecomastia NN B-AdverseReaction B-AdverseReaction
and NN O O
impotence NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
with NN O O
prolactin NN B-DrugClass B-DrugClass
- NN I-DrugClass I-DrugClass
elevating NN I-DrugClass I-DrugClass
compounds NN I-DrugClass I-DrugClass
Long NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
standing NN I-AdverseReaction I-AdverseReaction
hyperprolactinemia NN I-AdverseReaction I-AdverseReaction
when NN O O
associated NN O O
with NN O O
hypogonadism NN B-AdverseReaction B-AdverseReaction
may NN B-Factor B-Factor
lead NN O O
to NN O O
decreased NN B-AdverseReaction B-AdverseReaction
bone NN I-AdverseReaction I-AdverseReaction
density NN I-AdverseReaction I-AdverseReaction
in NN O O
both NN O O
female NN O O
and NN O O
male NN O O
patients NN O O
. NN O O
Tissue NN O O
culture NN O O
experiments NN O O
indicate NN O O
that NN O O
approximately NN O O
one NN O O
- NN O O
third NN O O
of NN O O
human NN O O
breast NN O O
cancers NN O O
are NN O O
prolactin NN O O
- NN O O
dependent NN O O
in NN O O
vitro NN O O
, NN O O
a NN O O
factor NN O O
of NN O O
potential NN O O
importance NN O O
if NN O O
the NN O O
prescription NN O O
of NN O O
these NN O O
drugs NN O O
is NN O O
contemplated NN O O
in NN O O
a NN O O
patient NN O O
with NN O O
previously NN O O
detected NN O O
breast NN O O
cancer NN O O
. NN O O
Mammary NN B-AdverseReaction B-AdverseReaction
gland NN I-AdverseReaction I-AdverseReaction
proliferative NN I-AdverseReaction I-AdverseReaction
changes NN I-AdverseReaction I-AdverseReaction
and NN O O
increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
prolactin NN I-AdverseReaction I-AdverseReaction
were NN O O
seen NN O O
in NN O O
mice NN B-Animal B-Animal
and NN O O
rats NN B-Animal B-Animal
treated NN O O
with NN O O
FANAPT NN O O
[ NN O O
see NN O O
Nonclinical NN O O
Toxicology NN O O
( NN O O
13.1 NN O O
) NN O O
] NN O O
. NN O O
Neither NN O O
clinical NN O O
studies NN O O
nor NN O O
epidemiologic NN O O
studies NN O O
conducted NN O O
to NN O O
date NN O O
have NN O O
shown NN O O
an NN O O
association NN O O
between NN O O
chronic NN O O
administration NN O O
of NN O O
this NN O O
class NN O O
of NN O O
drugs NN O O
and NN O O
tumorigenesis NN O O
in NN O O
humans NN O O
; NN O O
the NN O O
available NN O O
evidence NN O O
is NN O O
considered NN O O
too NN O O
limited NN O O
to NN O O
be NN O O
conclusive NN O O
at NN O O
this NN O O
time NN O O
. NN O O
In NN O O
a NN O O
short NN O O
- NN O O
term NN O O
placebo NN O O
- NN O O
controlled NN O O
trial NN O O
( NN O O
4-weeks NN O O
) NN O O
, NN O O
the NN O O
mean NN O O
change NN O O
from NN O O
baseline NN O O
to NN O O
endpoint NN O O
in NN O O
plasma NN O O
prolactin NN O O
levels NN O O
for NN O O
the NN O O
FANAPT NN O O
24 NN O O
mg/day NN O O
- NN O O
treated NN O O
group NN O O
was NN O O
an NN O O
increase NN O O
of NN O O
2.6 NN B-Severity B-Severity
ng/mL NN I-Severity I-Severity
compared NN O O
to NN O O
a NN O O
decrease NN O O
of NN O O
6.3 NN O O
ng/mL NN O O
in NN O O
the NN O O
placebo NN O O
- NN O O
group NN O O
. NN O O
In NN O O
this NN O O
trial NN O O
, NN O O
elevated NN B-AdverseReaction B-AdverseReaction
plasma NN I-AdverseReaction I-AdverseReaction
prolactin NN I-AdverseReaction I-AdverseReaction
levels NN I-AdverseReaction I-AdverseReaction
were NN O O
observed NN O O
in NN O O
26 NN O O
% NN O O
of NN O O
adults NN O O
treated NN O O
with NN O O
FANAPT NN O O
compared NN O O
to NN O O
12 NN O O
% NN O O
in NN O O
the NN O O
placebo NN O O
- NN O O
group NN O O
. NN O O
In NN O O
the NN O O
short NN O O
- NN O O
term NN O O
trials NN O O
, NN O O
FANAPT NN O O
was NN O O
associated NN O O
with NN O O
modest NN B-Severity B-Severity
levels NN I-Severity I-Severity
of NN O O
prolactin NN B-AdverseReaction B-AdverseReaction
elevation NN I-AdverseReaction I-AdverseReaction
compared NN O O
to NN O O
greater NN B-Severity B-Severity
prolactin NN B-AdverseReaction B-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
observed NN O O
with NN O O
some NN O O
other NN B-DrugClass B-DrugClass
antipsychotic NN I-DrugClass I-DrugClass
agents NN I-DrugClass I-DrugClass
In NN O O
pooled NN O O
analysis NN O O
from NN O O
clinical NN O O
studies NN O O
including NN O O
longer NN O O
term NN O O
trials NN O O
, NN O O
in NN O O
3210 NN O O
adults NN O O
treated NN O O
with NN O O
iloperidone NN O O
, NN O O
gynecomastia NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
2 NN O O
male NN O O
subjects NN O O
( NN O O
0.1 NN O O
% NN O O
) NN O O
compared NN O O
to NN O O
0 NN O O
% NN O O
in NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
, NN O O
and NN O O
galactorrhea NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
8 NN O O
female NN O O
subjects NN O O
( NN O O
0.2 NN O O
% NN O O
) NN O O
compared NN O O
to NN O O
3 NN O O
female NN O O
subjects NN O O
( NN O O
0.5 NN O O
% NN O O
) NN O O
in NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
5.10 NN O O
Body NN O O
Temperature NN O O
Regulation NN O O
Disruption NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
body NN I-AdverseReaction I-AdverseReaction
's NN I-AdverseReaction I-AdverseReaction
ability NN I-AdverseReaction I-AdverseReaction
to NN I-AdverseReaction I-AdverseReaction
reduce NN I-AdverseReaction I-AdverseReaction
core NN I-AdverseReaction I-AdverseReaction
body NN I-AdverseReaction I-AdverseReaction
temperature NN I-AdverseReaction I-AdverseReaction
has NN O O
been NN O O
attributed NN O O
to NN O O
antipsychotic NN B-DrugClass B-DrugClass
agents NN I-DrugClass I-DrugClass
Appropriate NN O O
care NN O O
is NN O O
advised NN O O
when NN O O
prescribing NN O O
FANAPT NN O O
for NN O O
patients NN O O
who NN O O
will NN O O
be NN O O
experiencing NN O O
conditions NN O O
which NN O O
may NN O O
contribute NN O O
to NN O O
an NN O O
elevation NN O O
in NN O O
core NN O O
body NN O O
temperature NN O O
, NN O O
e.g. NN O O
, NN O O
exercising NN O O
strenuously NN O O
, NN O O
exposure NN O O
to NN O O
extreme NN O O
heat NN O O
, NN O O
receiving NN O O
concomitant NN O O
medication NN O O
with NN O O
anticholinergic NN O O
activity NN O O
, NN O O
or NN O O
being NN O O
subject NN O O
to NN O O
dehydration NN O O
. NN O O
5.11 NN O O
Dysphagia NN O O
Esophageal NN B-AdverseReaction B-AdverseReaction
dysmotility NN I-AdverseReaction I-AdverseReaction
and NN O O
aspiration NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
associated NN O O
with NN O O
antipsychotic NN B-DrugClass B-DrugClass
drug NN I-DrugClass I-DrugClass
use NN O O
. NN O O
Aspiration NN O O
pneumonia NN O O
is NN O O
a NN O O
common NN O O
cause NN O O
of NN O O
morbidity NN O O
and NN O O
mortality NN O O
in NN O O
elderly NN O O
patients NN O O
, NN O O
in NN O O
particular NN O O
those NN O O
with NN O O
advanced NN O O
Alzheimer NN O O
's NN O O
dementia NN O O
. NN O O
FANAPT NN O O
and NN O O
other NN O O
antipsychotic NN O O
drugs NN O O
should NN O O
be NN O O
used NN O O
cautiously NN O O
in NN O O
patients NN O O
at NN O O
risk NN O O
for NN O O
aspiration NN O O
pneumonia NN O O
[ NN O O
see NN O O
Boxed NN O O
Warning NN O O
] NN O O
. NN O O
5.12 NN O O
Suicide NN O O
The NN O O
possibility NN O O
of NN O O
a NN O O
suicide NN O O
attempt NN O O
is NN O O
inherent NN O O
in NN O O
psychotic NN O O
illness NN O O
, NN O O
and NN O O
close NN O O
supervision NN O O
of NN O O
high NN O O
- NN O O
risk NN O O
patients NN O O
should NN O O
accompany NN O O
drug NN O O
therapy NN O O
. NN O O
Prescriptions NN O O
for NN O O
FANAPT NN O O
should NN O O
be NN O O
written NN O O
for NN O O
the NN O O
smallest NN O O
quantity NN O O
of NN O O
tablets NN O O
consistent NN O O
with NN O O
good NN O O
patient NN O O
management NN O O
in NN O O
order NN O O
to NN O O
reduce NN O O
the NN O O
risk NN O O
of NN O O
overdose NN O O
. NN O O
5.13 NN O O
Priapism NN O O
Three NN O O
cases NN O O
of NN O O
priapism NN B-AdverseReaction B-AdverseReaction
were NN O O
reported NN O O
in NN O O
the NN O O
premarketing NN O O
FANAPT NN O O
program NN O O
. NN O O
Drugs NN B-DrugClass B-DrugClass
with NN I-DrugClass I-DrugClass
alpha NN I-DrugClass I-DrugClass
- NN I-DrugClass I-DrugClass
adrenergic NN I-DrugClass I-DrugClass
blocking NN I-DrugClass I-DrugClass
effects NN I-DrugClass I-DrugClass
have NN O O
been NN O O
reported NN O O
to NN O O
induce NN O O
priapism NN B-AdverseReaction B-AdverseReaction
FANAPT NN O O
shares NN O O
this NN O O
pharmacologic NN O O
activity NN O O
. NN O O
Severe NN B-Severity B-Severity
priapism NN B-AdverseReaction B-AdverseReaction
may NN O O
require NN O O
surgical NN O O
intervention NN O O
. NN O O
5.14 NN O O
Potential NN O O
for NN O O
Cognitive NN O O
and NN O O
Motor NN O O
Impairment NN O O
FANAPT NN O O
, NN O O
like NN O O
other NN O O
antipsychotics NN O O
, NN O O
has NN O O
the NN O O
potential NN B-Factor B-Factor
to NN O O
impair NN B-AdverseReaction B-AdverseReaction
judgment NN I-AdverseReaction I-AdverseReaction
thinking NN O O
or NN O O
motor NN O O
skills NN O O
. NN O O
In NN O O
short NN O O
- NN O O
term NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
, NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
( NN O O
including NN O O
sedation NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
11.9 NN O O
% NN O O
( NN O O
104/874 NN O O
) NN O O
of NN O O
adult NN O O
patients NN O O
treated NN O O
with NN O O
FANAPT NN O O
at NN O O
doses NN O O
of NN O O
10 NN O O
mg/day NN O O
or NN O O
greater NN O O
versus NN O O
5.3 NN O O
% NN O O
( NN O O
31/587 NN O O
) NN O O
treated NN O O
with NN O O
placebo NN O O
. NN O O
Patients NN O O
should NN O O
be NN O O
cautioned NN O O
about NN O O
operating NN O O
hazardous NN O O
machinery NN O O
, NN O O
including NN O O
automobiles NN O O
, NN O O
until NN O O
they NN O O
are NN O O
reasonably NN O O
certain NN O O
that NN O O
therapy NN O O
with NN O O
FANAPT NN O O
does NN O O
not NN O O
affect NN O O
them NN O O
adversely NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
are NN O O
discussed NN O O
in NN O O
greater NN O O
detail NN O O
in NN O O
other NN O O
sections NN O O
of NN O O
the NN O O
labeling NN O O
: NN O O
* NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Bullous NN O O
and NN O O
Exfoliative NN B-AdverseReaction B-AdverseReaction
Skin NN I-AdverseReaction I-AdverseReaction
Disorders NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
Interstitial NN B-AdverseReaction B-AdverseReaction
Lung NN I-AdverseReaction I-AdverseReaction
Disease NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
* NN O O
Hepatic NN B-AdverseReaction B-AdverseReaction
Toxicity NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
* NN O O
Keratitis NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
Most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=20 NN O O
% NN O O
) NN O O
are NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
acneiform NN O O
, NN O O
stomatitis NN B-AdverseReaction B-AdverseReaction
paronychia NN B-AdverseReaction B-AdverseReaction
dry NN B-AdverseReaction B-AdverseReaction
skin NN I-AdverseReaction I-AdverseReaction
decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
pruritus NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Boehringer NN O O
Ingelheim NN O O
Pharmaceuticals NN O O
, NN O O
Inc. NN O O
at NN O O
( NN O O
800 NN O O
) NN O O
542 NN O O
- NN O O
6257 NN O O
or NN O O
( NN O O
800 NN O O
) NN O O
459 NN O O
- NN O O
9906 NN O O
TTY NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
orwww.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
The NN O O
safety NN O O
evaluation NN O O
of NN O O
GILOTRIF NN O O
is NN O O
based NN O O
on NN O O
the NN O O
data NN O O
from NN O O
more NN O O
than NN O O
3800 NN O O
patients NN O O
, NN O O
including NN O O
2135 NN O O
NSCLC NN O O
patients NN O O
receiving NN O O
GILOTRIF NN O O
monotherapy NN O O
at NN O O
or NN O O
above NN O O
the NN O O
recommended NN O O
dose NN O O
. NN O O
Controlled NN O O
Study NN O O
The NN O O
data NN O O
in NN O O
Tables NN O O
1 NN O O
and NN O O
2 NN O O
below NN O O
reflect NN O O
exposure NN O O
of NN O O
229 NN O O
EGFR NN O O
- NN O O
TKI NN O O
naive NN O O
GILOTRIF NN O O
- NN O O
treated NN O O
patients NN O O
with NN O O
EGFR NN O O
mutation NN O O
- NN O O
positive NN O O
, NN O O
metastatic NN O O
, NN O O
non NN O O
- NN O O
squamous NN O O
, NN O O
NSCLC NN O O
enrolled NN O O
in NN O O
a NN O O
randomized NN O O
, NN O O
multicenter NN O O
, NN O O
open NN O O
- NN O O
label NN O O
trial NN O O
( NN O O
Study NN O O
1 NN O O
) NN O O
. NN O O
Patients NN O O
received NN O O
GILOTRIF NN O O
40 NN O O
mg NN O O
daily NN O O
until NN O O
documented NN O O
disease NN O O
progression NN O O
or NN O O
intolerance NN O O
to NN O O
the NN O O
therapy NN O O
. NN O O
A NN O O
total NN O O
of NN O O
111 NN O O
patients NN O O
were NN O O
treated NN O O
with NN O O
pemetrexed/cisplatin NN O O
. NN O O
Patients NN O O
were NN O O
treated NN O O
with NN O O
pemetrexed NN O O
500 NN O O
mg/m2 NN O O
followed NN O O
after NN O O
30 NN O O
minutes NN O O
by NN O O
cisplatin NN O O
75 NN O O
mg/m2 NN O O
every NN O O
three NN O O
weeks NN O O
for NN O O
a NN O O
maximum NN O O
of NN O O
six NN O O
treatment NN O O
courses NN O O
. NN O O
The NN O O
median NN O O
exposure NN O O
was NN O O
11.0 NN O O
months NN O O
for NN O O
patients NN O O
treated NN O O
with NN O O
GILOTRIF NN O O
and NN O O
3.4 NN O O
months NN O O
for NN O O
patients NN O O
treated NN O O
with NN O O
pemetrexed/cisplatin NN O O
. NN O O
The NN O O
overall NN O O
trial NN O O
population NN O O
had NN O O
a NN O O
median NN O O
age NN O O
of NN O O
61 NN O O
years NN O O
; NN O O
61 NN O O
% NN O O
of NN O O
patients NN O O
in NN O O
the NN O O
GILOTRIF NN O O
arm NN O O
and NN O O
60 NN O O
% NN O O
of NN O O
patients NN O O
in NN O O
the NN O O
pemetrexed/cisplatin NN O O
arm NN O O
were NN O O
younger NN O O
than NN O O
65 NN O O
years NN O O
. NN O O
A NN O O
total NN O O
of NN O O
64 NN O O
% NN O O
of NN O O
patients NN O O
on NN O O
GILOTRIF NN O O
and NN O O
67 NN O O
% NN O O
of NN O O
pemetrexed/cisplatin NN O O
patients NN O O
were NN O O
female NN O O
. NN O O
More NN O O
than NN O O
two NN O O
- NN O O
thirds NN O O
of NN O O
patients NN O O
were NN O O
from NN O O
Asia NN O O
( NN O O
GILOTRIF NN O O
70 NN O O
% NN O O
; NN O O
pemetrexed/cisplatin NN O O
72 NN O O
% NN O O
) NN O O
. NN O O
Serious NN O O
adverse NN O O
reactions NN O O
were NN O O
reported NN O O
in NN O O
29 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
GILOTRIF. NN O O
The NN O O
most NN O O
frequent NN O O
serious NN O O
adverse NN O O
reactions NN O O
reported NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
GILOTRIF NN O O
were NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
( NN O O
6.6 NN O O
% NN O O
) NN O O
; NN O O
vomiting NN B-AdverseReaction B-AdverseReaction
( NN O O
4.8 NN O O
% NN O O
) NN O O
; NN O O
and NN O O
dyspnea NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
and NN O O
hypokalemia NN B-AdverseReaction B-AdverseReaction
( NN O O
1.7 NN O O
% NN O O
each NN O O
) NN O O
. NN O O
Fatal NN B-AdverseReaction B-AdverseReaction
adverse NN O O
reactions NN O O
in NN O O
GILOTRIF NN O O
- NN O O
treated NN O O
patients NN O O
in NN O O
Study NN O O
1 NN O O
included NN O O
pulmonary NN B-AdverseReaction B-AdverseReaction
toxicity NN I-AdverseReaction I-AdverseReaction
adverse NN O O
reactions NN O O
( NN O O
1.3 NN O O
% NN O O
) NN O O
, NN O O
sepsis NN B-AdverseReaction B-AdverseReaction
( NN O O
0.43 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
( NN O O
0.43 NN O O
% NN O O
) NN O O
. NN O O
Dose NN O O
reductions NN O O
due NN O O
to NN O O
adverse NN O O
reactions NN O O
were NN O O
required NN O O
in NN O O
57 NN O O
% NN O O
of NN O O
GILOTRIF NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
The NN O O
most NN O O
frequent NN O O
adverse NN O O
reactions NN O O
that NN O O
led NN O O
to NN O O
dose NN O O
reduction NN O O
in NN O O
the NN O O
patients NN O O
treated NN O O
with NN O O
GILOTRIF NN O O
were NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
( NN O O
20 NN O O
% NN O O
) NN O O
, NN O O
rash NN B-AdverseReaction B-AdverseReaction
( NN O O
19 NN O O
% NN O O
) NN O O
, NN O O
paronychia NN B-AdverseReaction B-AdverseReaction
( NN O O
14 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
stomatitis NN B-AdverseReaction B-AdverseReaction
( NN O O
10 NN O O
% NN O O
) NN O O
. NN O O
Discontinuation NN O O
of NN O O
therapy NN O O
in NN O O
GILOTRIF NN O O
- NN O O
treated NN O O
patients NN O O
for NN O O
adverse NN O O
reactions NN O O
was NN O O
14.0 NN O O
% NN O O
. NN O O
The NN O O
most NN O O
frequent NN O O
adverse NN O O
reactions NN O O
that NN O O
led NN O O
to NN O O
discontinuation NN O O
in NN O O
GILOTRIF NN O O
- NN O O
treated NN O O
patients NN O O
were NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
( NN O O
1.3 NN O O
% NN O O
) NN O O
, NN O O
ILD NN B-AdverseReaction B-AdverseReaction
( NN O O
0.9 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
paronychia NN B-AdverseReaction B-AdverseReaction
( NN O O
0.9 NN O O
% NN O O
) NN O O
. NN O O
Clinical NN O O
trials NN O O
of NN O O
GILOTRIF NN O O
excluded NN O O
patients NN O O
with NN O O
an NN O O
abnormal NN O O
left NN O O
ventricular NN O O
ejection NN O O
fraction NN O O
( NN O O
LVEF NN O O
) NN O O
, NN O O
i.e. NN O O
, NN O O
below NN O O
the NN O O
institutional NN O O
lower NN O O
limit NN O O
of NN O O
normal NN O O
. NN O O
In NN O O
Study NN O O
1 NN O O
, NN O O
all NN O O
patients NN O O
were NN O O
evaluated NN O O
for NN O O
LVEF NN O O
at NN O O
screening NN O O
and NN O O
every NN O O
9 NN O O
weeks NN O O
thereafter NN O O
in NN O O
the NN O O
GILOTRIF NN O O
- NN O O
treated NN O O
group NN O O
and NN O O
as NN O O
needed NN O O
in NN O O
the NN O O
pemetrexed/cisplatin NN O O
group NN O O
. NN O O
More NN O O
GILOTRIF NN O O
- NN O O
treated NN O O
patients NN O O
( NN O O
2.2 NN O O
% NN O O
; NN O O
n=5 NN O O
) NN O O
experienced NN O O
ventricular NN B-AdverseReaction B-AdverseReaction
dysfunction NN I-AdverseReaction I-AdverseReaction
( NN O O
defined NN O O
as NN O O
diastolic NN B-AdverseReaction B-AdverseReaction
dysfunction NN I-AdverseReaction I-AdverseReaction
left NN B-AdverseReaction B-AdverseReaction
ventricular NN I-AdverseReaction I-AdverseReaction
dysfunction NN I-AdverseReaction I-AdverseReaction
or NN O O
ventricular NN B-AdverseReaction B-AdverseReaction
dilation NN I-AdverseReaction I-AdverseReaction
all NN O O
< NN O O
Grade NN O O
3 NN O O
) NN O O
compared NN O O
to NN O O
chemotherapy NN O O
- NN O O
treated NN O O
patients NN O O
( NN O O
0.9 NN O O
% NN O O
; NN O O
n=1 NN O O
) NN O O
. NN O O
Table NN O O
1 NN O O
Adverse NN O O
Reactions NN O O
Reported NN O O
in NN O O
>=10 NN O O
% NN O O
of NN O O
GILOTRIF NN O O
- NN O O
Treated NN O O
Patients NN O O
in NN O O
Study NN O O
1 NN O O
* NN O O
None NN O O
of NN O O
the NN O O
adverse NN O O
reactions NN O O
in NN O O
this NN O O
table NN O O
except NN O O
stomatitis NN B-AdverseReaction B-AdverseReaction
( NN O O
one NN O O
patient NN O O
on NN O O
GILOTRIF NN O O
[ NN O O
0.4 NN O O
% NN O O
] NN O O
) NN O O
were NN O O
Grade NN B-Severity B-Severity
4 NN I-Severity I-Severity
in NN O O
severity NN O O
1 NN O O
Includes NN O O
stomatitis NN B-AdverseReaction B-AdverseReaction
aphthous NN B-AdverseReaction B-AdverseReaction
stomatitis NN I-AdverseReaction I-AdverseReaction
mucosal NN B-AdverseReaction B-AdverseReaction
inflammation NN I-AdverseReaction I-AdverseReaction
mouth NN B-AdverseReaction B-AdverseReaction
ulceration NN I-AdverseReaction I-AdverseReaction
oral NN B-AdverseReaction B-AdverseReaction
mucosa NN I-AdverseReaction I-AdverseReaction
erosion NN I-AdverseReaction I-AdverseReaction
mucosal NN B-AdverseReaction B-AdverseReaction
erosion NN I-AdverseReaction I-AdverseReaction
mucosal NN B-AdverseReaction B-AdverseReaction
ulceration NN I-AdverseReaction I-AdverseReaction
2 NN O O
Includes NN O O
group NN O O
of NN O O
rash NN B-AdverseReaction B-AdverseReaction
preferred NN O O
terms NN O O
, NN O O
acne NN B-AdverseReaction B-AdverseReaction
acne NN B-AdverseReaction B-AdverseReaction
pustular NN I-AdverseReaction I-AdverseReaction
dermatitis NN B-AdverseReaction B-AdverseReaction
acneiform NN I-AdverseReaction I-AdverseReaction
3 NN O O
Includes NN O O
paronychia NN B-AdverseReaction B-AdverseReaction
nail NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
nail NN B-AdverseReaction B-AdverseReaction
bed NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
GILOTRIFn=229 NN O O
Pemetrexed/Cisplatinn=111 NN O O
Adverse NN O O
Reaction NN O O
All NN O O
Grades( NN O O
% NN O O
) NN O O
Grade NN O O
3*( NN O O
% NN O O
) NN O O
All NN O O
Grades( NN O O
% NN O O
) NN O O
Grade NN O O
3*( NN O O
% NN O O
) NN O O
Gastrointestinal NN O O
disorders NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
96 NN O O
15 NN O O
23 NN O O
2 NN O O
Stomatitis NN B-AdverseReaction B-AdverseReaction
1 NN O O
71 NN O O
9 NN O O
15 NN O O
1 NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
25 NN O O
4 NN O O
68 NN O O
4 NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
23 NN O O
4 NN O O
47 NN O O
3 NN O O
Cheilitis NN B-AdverseReaction B-AdverseReaction
12 NN O O
0 NN O O
1 NN O O
0 NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
Rash NN B-AdverseReaction B-AdverseReaction
acneiform NN O O
2 NN O O
90 NN O O
16 NN O O
11 NN O O
0 NN O O
Pruritus NN B-AdverseReaction B-AdverseReaction
21 NN O O
0 NN O O
1 NN O O
0 NN O O
Dry NN B-AdverseReaction B-AdverseReaction
skin NN I-AdverseReaction I-AdverseReaction
31 NN O O
0 NN O O
2 NN O O
0 NN O O
Infections NN O O
and NN O O
infestations NN O O
Paronychia NN B-AdverseReaction B-AdverseReaction
3 NN O O
58 NN O O
11 NN O O
0 NN O O
0 NN O O
Cystitis NN B-AdverseReaction B-AdverseReaction
13 NN O O
1 NN O O
5 NN O O
0 NN O O
Metabolism NN O O
and NN O O
nutrition NN O O
disorders NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
29 NN O O
4 NN O O
55 NN O O
4 NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
and NN O O
mediastinal NN O O
disorders NN O O
Epistaxis NN B-AdverseReaction B-AdverseReaction
17 NN O O
0 NN O O
2 NN O O
1 NN O O
Rhinorrhea NN B-AdverseReaction B-AdverseReaction
11 NN O O
0 NN O O
6 NN O O
0 NN O O
Investigations NN O O
Weight NN B-AdverseReaction B-AdverseReaction
Decreased NN I-AdverseReaction I-AdverseReaction
17 NN O O
1 NN O O
14 NN O O
1 NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
12 NN O O
0 NN O O
6 NN O O
0 NN O O
Eye NN O O
disorders NN O O
Conjunctivitis NN B-AdverseReaction B-AdverseReaction
11 NN O O
0 NN O O
3 NN O O
0 NN O O
Table NN O O
2 NN O O
Adverse NN O O
Reactions NN O O
of NN O O
Laboratory NN O O
Abnormalities NN O O
from NN O O
the NN O O
Investigations NN O O
SOC NN O O
Reported NN O O
in NN O O
>=5 NN O O
% NN O O
of NN O O
GILOTRIF NN O O
- NN O O
Treated NN O O
Patients NN O O
in NN O O
Study NN O O
1 NN O O
1 NN O O
Includes NN O O
hypokalemia NN B-AdverseReaction B-AdverseReaction
blood NN B-AdverseReaction B-AdverseReaction
potassium NN I-AdverseReaction I-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
organ NN O O
class NN O O
GILOTRIFn=229 NN O O
Pemetrexed/Cisplatinn=111 NN O O
Adverse NN O O
Reaction NN O O
All NN O O
Grades( NN O O
% NN O O
) NN O O
Grades NN O O
3 NN O O
- NN O O
4( NN O O
% NN O O
) NN O O
All NN O O
Grades( NN O O
% NN O O
) NN O O
Grades NN O O
3 NN O O
- NN O O
4( NN O O
% NN O O
) NN O O
Alanine NN B-AdverseReaction B-AdverseReaction
aminotransferase NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
11 NN O O
2 NN O O
4 NN O O
0 NN O O
Hypokalemia NN B-AdverseReaction B-AdverseReaction
1 NN O O
11 NN O O
4 NN O O
5 NN O O
4 NN O O
Aspartate NN B-AdverseReaction B-AdverseReaction
aminotransferase NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
8 NN O O
2 NN O O
2 NN O O
1 NN O O
6.2 NN O O
Postmarketing NN O O
Experience NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
identified NN O O
during NN O O
post NN O O
- NN O O
approval NN O O
use NN O O
of NN O O
GILOTRIF. NN O O
Because NN O O
these NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
* NN O O
Pancreatitis NN B-AdverseReaction B-AdverseReaction
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Diarrhea NN O O
: NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
may NN B-Factor B-Factor
result NN O O
in NN O O
dehydration NN B-AdverseReaction B-AdverseReaction
and NN O O
renal NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
Withhold NN O O
GILOTRIF NN O O
for NN O O
severe NN O O
and NN O O
prolonged NN O O
diarrhea NN O O
not NN O O
responsive NN O O
to NN O O
anti NN O O
- NN O O
diarrheal NN O O
agents NN O O
. NN O O
( NN O O
2.3,5.1 NN O O
) NN O O
* NN O O
Bullous NN O O
and NN O O
Exfoliative NN O O
Skin NN O O
Disorders NN O O
: NN O O
Severe NN B-Severity B-Severity
bullous NN O O
, NN O O
blistering NN O O
, NN O O
and NN O O
exfoliating NN O O
lesions NN O O
occurred NN O O
in NN O O
0.15 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
Discontinue NN O O
for NN O O
life NN O O
- NN O O
threatening NN O O
cutaneous NN O O
reactions NN O O
. NN O O
Withhold NN O O
GILOTRIF NN O O
for NN O O
severe NN O O
and NN O O
prolonged NN O O
cutaneous NN O O
reactions NN O O
. NN O O
( NN O O
2.3,5.2 NN O O
) NN O O
* NN O O
Interstitial NN B-AdverseReaction B-AdverseReaction
lung NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
( NN O O
ILD NN O O
) NN O O
: NN O O
Occurs NN O O
in NN O O
1.5 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
Withhold NN O O
GILOTRIF NN O O
for NN O O
acute NN O O
onset NN O O
or NN O O
worsening NN O O
of NN O O
pulmonary NN O O
symptoms NN O O
. NN O O
Discontinue NN O O
GILOTRIF NN O O
if NN O O
ILD NN O O
is NN O O
diagnosed NN O O
. NN O O
( NN O O
2.3,5.3 NN O O
) NN O O
* NN O O
Hepatic NN B-AdverseReaction B-AdverseReaction
toxicity NN I-AdverseReaction I-AdverseReaction
Fatal NN B-AdverseReaction B-AdverseReaction
hepatic NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
occurs NN O O
in NN O O
0.18 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
Monitor NN O O
with NN O O
periodic NN O O
liver NN O O
testing NN O O
. NN O O
Withhold NN O O
or NN O O
discontinue NN O O
GILOTRIF NN O O
for NN O O
severe NN O O
or NN O O
worsening NN O O
liver NN O O
tests NN O O
. NN O O
( NN O O
2.3,5.4 NN O O
) NN O O
* NN O O
Keratitis NN B-AdverseReaction B-AdverseReaction
Occurs NN O O
in NN O O
0.8 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
Withhold NN O O
GILOTRIF NN O O
for NN O O
keratitis NN O O
evaluation NN O O
. NN O O
Withhold NN O O
or NN O O
discontinue NN O O
GILOTRIF NN O O
for NN O O
confirmed NN O O
ulcerative NN O O
keratitis NN O O
. NN O O
( NN O O
2.3,5.5 NN O O
) NN O O
* NN O O
Embryofetal NN B-AdverseReaction B-AdverseReaction
toxicity NN I-AdverseReaction I-AdverseReaction
Can NN B-Factor B-Factor
cause NN O O
fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
Advise NN O O
females NN O O
of NN O O
the NN O O
potential NN O O
hazard NN O O
to NN O O
the NN O O
fetus NN O O
and NN O O
to NN O O
use NN O O
highly NN O O
effective NN O O
contraception NN O O
. NN O O
( NN O O
5.6 NN O O
) NN O O
5.1 NN O O
Diarrhea NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
has NN O O
resulted NN O O
in NN O O
dehydration NN B-AdverseReaction B-AdverseReaction
with NN O O
or NN O O
without NN O O
renal NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
some NN O O
of NN O O
these NN O O
cases NN O O
were NN O O
fatal NN B-AdverseReaction B-AdverseReaction
In NN O O
Study NN O O
1 NN O O
, NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
96 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
GILOTRIF NN O O
( NN O O
n=229 NN O O
) NN O O
, NN O O
of NN O O
which NN O O
15 NN O O
% NN O O
was NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
in NN O O
severity NN O O
and NN O O
occurred NN O O
within NN O O
the NN O O
first NN O O
6 NN O O
weeks NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Renal NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
as NN O O
a NN O O
consequence NN O O
of NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
6.1 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
GILOTRIF NN O O
, NN O O
out NN O O
of NN O O
which NN O O
3 NN O O
( NN O O
1.3 NN O O
% NN O O
) NN O O
were NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
For NN O O
patients NN O O
who NN O O
develop NN O O
prolonged NN O O
Grade NN O O
2 NN O O
diarrhea NN O O
lasting NN O O
more NN O O
than NN O O
48 NN O O
hours NN O O
or NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
Grade NN O O
3 NN O O
diarrhea NN O O
, NN O O
withhold NN O O
GILOTRIF NN O O
until NN O O
diarrhea NN O O
resolves NN O O
to NN O O
Grade NN O O
1 NN O O
or NN O O
less NN O O
, NN O O
and NN O O
resume NN O O
GILOTRIF NN O O
with NN O O
appropriate NN O O
dose NN O O
reduction NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
] NN O O
. NN O O
Provide NN O O
patients NN O O
with NN O O
an NN O O
anti NN O O
- NN O O
diarrheal NN O O
agent NN O O
( NN O O
e.g. NN O O
, NN O O
loperamide NN O O
) NN O O
for NN O O
self NN O O
- NN O O
administration NN O O
at NN O O
the NN O O
onset NN O O
of NN O O
diarrhea NN O O
and NN O O
instruct NN O O
patients NN O O
to NN O O
continue NN O O
anti NN O O
- NN O O
diarrheal NN O O
therapy NN O O
until NN O O
loose NN O O
bowel NN O O
movements NN O O
cease NN O O
for NN O O
12 NN O O
hours NN O O
. NN O O
5.2 NN O O
Bullous NN O O
and NN O O
Exfoliative NN O O
Skin NN O O
Disorders NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
cutaneous NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
characterized NN O O
by NN O O
bullous NN O O
, NN O O
blistering NN O O
, NN O O
and NN O O
exfoliating NN B-AdverseReaction B-AdverseReaction
lesions NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
6 NN O O
( NN O O
0.15 NN O O
% NN O O
) NN O O
of NN O O
the NN O O
3865 NN O O
patients NN O O
who NN O O
received NN O O
GILOTRIF NN O O
across NN O O
clinical NN O O
trials NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
In NN O O
Study NN O O
1 NN O O
, NN O O
the NN O O
overall NN O O
incidence NN O O
of NN O O
cutaneous NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
consisting NN O O
of NN O O
rash NN B-AdverseReaction B-AdverseReaction
erythema NN B-AdverseReaction B-AdverseReaction
and NN O O
acneiform NN B-AdverseReaction B-AdverseReaction
rash NN I-AdverseReaction I-AdverseReaction
was NN O O
90 NN O O
% NN O O
, NN O O
and NN O O
the NN O O
incidence NN O O
of NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
cutaneous NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
was NN O O
16 NN O O
% NN O O
. NN O O
In NN O O
addition NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
Grade NN B-Severity B-Severity
1 NN I-Severity I-Severity
- NN I-Severity I-Severity
3 NN I-Severity I-Severity
palmar NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
plantar NN I-AdverseReaction I-AdverseReaction
erythrodysesthesia NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
was NN O O
7 NN O O
% NN O O
. NN O O
Discontinue NN O O
GILOTRIF NN O O
in NN O O
patients NN O O
who NN O O
develop NN O O
life NN O O
- NN O O
threatening NN O O
bullous NN O O
, NN O O
blistering NN O O
, NN O O
or NN O O
exfoliating NN O O
lesions NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
] NN O O
. NN O O
For NN O O
patients NN O O
who NN O O
develop NN O O
prolonged NN O O
Grade NN O O
2 NN O O
cutaneous NN O O
adverse NN O O
reactions NN O O
lasting NN O O
more NN O O
than NN O O
7 NN O O
days NN O O
, NN O O
intolerable NN O O
Grade NN O O
2 NN O O
, NN O O
or NN O O
Grade NN O O
3 NN O O
cutaneous NN O O
reactions NN O O
, NN O O
withhold NN O O
GILOTRIF NN O O
until NN O O
the NN O O
adverse NN O O
reaction NN O O
resolves NN O O
to NN O O
Grade NN O O
1 NN O O
or NN O O
less NN O O
, NN O O
and NN O O
resume NN O O
GILOTRIF NN O O
with NN O O
appropriate NN O O
dose NN O O
reduction NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
] NN O O
. NN O O
5.3 NN O O
Interstitial NN O O
Lung NN O O
Disease NN O O
( NN O O
ILD NN O O
) NN O O
ILD NN B-AdverseReaction B-AdverseReaction
or NN O O
ILD NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
like NN I-AdverseReaction I-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
( NN O O
e.g. NN O O
, NN O O
lung NN B-AdverseReaction B-AdverseReaction
infiltration NN I-AdverseReaction I-AdverseReaction
pneumonitis NN B-AdverseReaction B-AdverseReaction
acute NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
distress NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
or NN O O
alveolitis NN B-AdverseReaction B-AdverseReaction
allergic NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
1.5 NN O O
% NN O O
of NN O O
the NN O O
3865 NN O O
patients NN O O
who NN O O
received NN O O
GILOTRIF NN O O
across NN O O
clinical NN O O
trials NN O O
; NN O O
of NN O O
these NN O O
, NN O O
0.4 NN O O
% NN O O
were NN O O
fatal NN B-AdverseReaction B-AdverseReaction
The NN O O
incidence NN O O
of NN O O
ILD NN B-AdverseReaction B-AdverseReaction
appeared NN O O
to NN O O
be NN O O
higher NN O O
in NN O O
patients NN O O
of NN O O
Asian NN O O
ethnicity NN O O
( NN O O
2.1 NN O O
% NN O O
) NN O O
as NN O O
compared NN O O
to NN O O
non NN O O
- NN O O
Asians NN O O
( NN O O
1.2 NN O O
% NN O O
) NN O O
. NN O O
In NN O O
Study NN O O
1 NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
Grade NN O O
>=3 NN O O
ILD NN B-AdverseReaction B-AdverseReaction
was NN O O
1.3 NN O O
% NN O O
and NN O O
resulted NN O O
in NN O O
death NN B-AdverseReaction B-AdverseReaction
in NN O O
1 NN O O
% NN O O
of NN O O
GILOTRIF NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Withhold NN O O
GILOTRIF NN O O
during NN O O
evaluation NN O O
of NN O O
patients NN O O
with NN O O
suspected NN O O
ILD NN O O
, NN O O
and NN O O
discontinue NN O O
GILOTRIF NN O O
in NN O O
patients NN O O
with NN O O
confirmed NN O O
ILD NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
] NN O O
. NN O O
5.4 NN O O
Hepatic NN O O
Toxicity NN O O
In NN O O
3865 NN O O
patients NN O O
who NN O O
received NN O O
GILOTRIF NN O O
across NN O O
clinical NN O O
trials NN O O
, NN O O
10.1 NN O O
% NN O O
had NN O O
liver NN B-AdverseReaction B-AdverseReaction
test NN I-AdverseReaction I-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
of NN O O
which NN O O
7 NN O O
( NN O O
0.18 NN O O
% NN O O
) NN O O
were NN O O
fatal NN B-AdverseReaction B-AdverseReaction
In NN O O
Study NN O O
1 NN O O
, NN O O
liver NN B-AdverseReaction B-AdverseReaction
test NN I-AdverseReaction I-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
of NN O O
any NN O O
grade NN O O
occurred NN O O
in NN O O
17.5 NN O O
% NN O O
of NN O O
the NN O O
patients NN O O
treated NN O O
with NN O O
GILOTRIF. NN O O
Obtain NN O O
periodic NN O O
liver NN O O
testing NN O O
in NN O O
patients NN O O
during NN O O
treatment NN O O
with NN O O
GILOTRIF. NN O O
Withhold NN O O
GILOTRIF NN O O
in NN O O
patients NN O O
who NN O O
develop NN O O
worsening NN O O
of NN O O
liver NN O O
function NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
] NN O O
. NN O O
In NN O O
patients NN O O
who NN O O
develop NN O O
severe NN O O
hepatic NN O O
impairment NN O O
while NN O O
taking NN O O
GILOTRIF NN O O
, NN O O
treatment NN O O
should NN O O
be NN O O
discontinued NN O O
. NN O O
5.5 NN O O
Keratitis NN O O
Keratitis NN B-AdverseReaction B-AdverseReaction
characterized NN O O
as NN O O
acute NN O O
or NN O O
worsening NN B-AdverseReaction B-AdverseReaction
eye NN I-AdverseReaction I-AdverseReaction
inflammation NN I-AdverseReaction I-AdverseReaction
lacrimation NN B-AdverseReaction B-AdverseReaction
light NN B-AdverseReaction B-AdverseReaction
sensitivity NN I-AdverseReaction I-AdverseReaction
blurred NN B-AdverseReaction B-AdverseReaction
vision NN I-AdverseReaction I-AdverseReaction
eye NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
and/or NN O O
red NN B-AdverseReaction B-AdverseReaction
eye NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
0.8 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
GILOTRIF NN O O
among NN O O
3865 NN O O
patients NN O O
across NN O O
clinical NN O O
trials NN O O
. NN O O
Keratitis NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
5 NN O O
( NN O O
2.2 NN O O
% NN O O
) NN O O
patients NN O O
in NN O O
Study NN O O
1 NN O O
, NN O O
with NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
in NN O O
1 NN O O
( NN O O
0.4 NN O O
% NN O O
) NN O O
. NN O O
Withhold NN O O
GILOTRIF NN O O
during NN O O
evaluation NN O O
of NN O O
patients NN O O
with NN O O
suspected NN O O
keratitis NN O O
, NN O O
and NN O O
if NN O O
diagnosis NN O O
of NN O O
ulcerative NN O O
keratitis NN O O
is NN O O
confirmed NN O O
, NN O O
treatment NN O O
with NN O O
GILOTRIF NN O O
should NN O O
be NN O O
interrupted NN O O
or NN O O
discontinued NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
] NN O O
. NN O O
If NN O O
keratitis NN O O
is NN O O
diagnosed NN O O
, NN O O
the NN O O
benefits NN O O
and NN O O
risks NN O O
of NN O O
continuing NN O O
treatment NN O O
should NN O O
be NN O O
carefully NN O O
considered NN O O
. NN O O
GILOTRIF NN O O
should NN O O
be NN O O
used NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
keratitis NN O O
, NN O O
ulcerative NN O O
keratitis NN O O
, NN O O
or NN O O
severe NN O O
dry NN O O
eye NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Contact NN O O
lens NN O O
use NN O O
is NN O O
also NN O O
a NN O O
risk NN O O
factor NN O O
for NN O O
keratitis NN O O
and NN O O
ulceration NN O O
. NN O O
5.6 NN O O
Embryofetal NN O O
Toxicity NN O O
Based NN O O
on NN O O
its NN O O
mechanism NN O O
of NN O O
action NN O O
, NN O O
GILOTRIF NN O O
can NN B-Factor B-Factor
cause NN O O
fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
when NN O O
administered NN O O
to NN O O
a NN O O
pregnant NN O O
woman NN O O
. NN O O
Afatinib NN O O
was NN O O
embryotoxic NN B-AdverseReaction B-AdverseReaction
and NN O O
, NN O O
in NN O O
animals NN O O
with NN O O
maternal NN O O
toxicity NN O O
, NN O O
led NN O O
to NN O O
abortions NN B-AdverseReaction B-AdverseReaction
at NN I-AdverseReaction I-AdverseReaction
late NN I-AdverseReaction I-AdverseReaction
gestational NN I-AdverseReaction I-AdverseReaction
stages NN I-AdverseReaction I-AdverseReaction
in NN O O
rabbits NN B-Animal B-Animal
at NN O O
doses NN O O
of NN O O
5 NN O O
mg/kg NN O O
( NN O O
approximately NN O O
0.2 NN O O
times NN O O
the NN O O
human NN O O
exposure NN O O
at NN O O
the NN O O
recommended NN O O
dose NN O O
of NN O O
40 NN O O
mg NN O O
daily NN O O
) NN O O
or NN O O
greater NN O O
. NN O O
If NN O O
this NN O O
drug NN O O
is NN O O
used NN O O
during NN O O
pregnancy NN O O
, NN O O
or NN O O
if NN O O
the NN O O
patient NN O O
becomes NN O O
pregnant NN O O
while NN O O
taking NN O O
this NN O O
drug NN O O
, NN O O
the NN O O
patient NN O O
should NN O O
be NN O O
apprised NN O O
of NN O O
the NN O O
potential NN O O
hazard NN O O
to NN O O
the NN O O
fetus NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.1 NN O O
) NN O O
] NN O O
. NN O O
Advise NN O O
females NN O O
of NN O O
reproductive NN O O
potential NN O O
to NN O O
use NN O O
highly NN O O
effective NN O O
contraception NN O O
during NN O O
treatment NN O O
, NN O O
and NN O O
for NN O O
at NN O O
least NN O O
2 NN O O
weeks NN O O
after NN O O
the NN O O
last NN O O
dose NN O O
of NN O O
GILOTRIF. NN O O
Advise NN O O
patients NN O O
to NN O O
contact NN O O
their NN O O
healthcare NN O O
provider NN O O
if NN O O
they NN O O
become NN O O
pregnant NN O O
, NN O O
or NN O O
if NN O O
pregnancy NN O O
is NN O O
suspected NN O O
, NN O O
while NN O O
taking NN O O
GILOTRIF NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.1and8.6 NN O O
) NN O O
] NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
is NN O O
discussed NN O O
in NN O O
more NN O O
detail NN O O
in NN O O
other NN O O
sections NN O O
of NN O O
the NN O O
labeling NN O O
: NN O O
* NN O O
Seizure NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>= NN O O
10 NN O O
% NN O O
) NN O O
are NN O O
asthenia NN B-AdverseReaction B-AdverseReaction
back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
constipation NN B-AdverseReaction B-AdverseReaction
arthralgia NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
hot NN B-AdverseReaction B-AdverseReaction
flush NN I-AdverseReaction I-AdverseReaction
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
peripheral NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
dyspnea NN B-AdverseReaction B-AdverseReaction
musculoskeletal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
weight NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
hypertension NN B-AdverseReaction B-AdverseReaction
and NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Astellas NN O O
Pharma NN O O
US NN O O
, NN O O
Inc. NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
727 NN O O
- NN O O
7003 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trial NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
Two NN O O
randomized NN O O
clinical NN O O
trials NN O O
enrolled NN O O
patients NN O O
with NN O O
metastatic NN O O
prostate NN O O
cancer NN O O
that NN O O
has NN O O
progressed NN O O
on NN O O
androgen NN O O
deprivation NN O O
therapy NN O O
( NN O O
GnRH NN O O
therapy NN O O
or NN O O
bilateral NN O O
orchiectomy NN O O
) NN O O
, NN O O
a NN O O
disease NN O O
setting NN O O
that NN O O
is NN O O
also NN O O
defined NN O O
as NN O O
metastatic NN O O
CRPC. NN O O
In NN O O
both NN O O
studies NN O O
, NN O O
patients NN O O
received NN O O
XTANDI NN O O
160 NN O O
mg NN O O
orally NN O O
once NN O O
daily NN O O
in NN O O
the NN O O
active NN O O
treatment NN O O
arm NN O O
or NN O O
placebo NN O O
in NN O O
the NN O O
control NN O O
arm NN O O
. NN O O
All NN O O
patients NN O O
continued NN O O
androgen NN O O
deprivation NN O O
therapy NN O O
. NN O O
Patients NN O O
were NN O O
allowed NN O O
, NN O O
but NN O O
not NN O O
required NN O O
, NN O O
to NN O O
take NN O O
glucocorticoids NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>= NN O O
10 NN O O
% NN O O
) NN O O
that NN O O
occurred NN O O
more NN O O
commonly NN O O
( NN O O
>= NN O O
2 NN O O
% NN O O
over NN O O
placebo NN O O
) NN O O
in NN O O
the NN O O
XTANDI NN O O
- NN O O
treated NN O O
patients NN O O
from NN O O
the NN O O
two NN O O
randomized NN O O
clinical NN O O
trials NN O O
were NN O O
asthenia NN B-AdverseReaction B-AdverseReaction
back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
constipation NN B-AdverseReaction B-AdverseReaction
arthralgia NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
hot NN B-AdverseReaction B-AdverseReaction
flush NN I-AdverseReaction I-AdverseReaction
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
peripheral NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
dyspnea NN B-AdverseReaction B-AdverseReaction
musculoskeletal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
weight NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
hypertension NN B-AdverseReaction B-AdverseReaction
and NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
Study NN O O
1 NN O O
: NN O O
Metastatic NN O O
Castration NN O O
- NN O O
Resistant NN O O
Prostate NN O O
Cancer NN O O
Following NN O O
Chemotherapy NN O O
Study NN O O
1 NN O O
enrolled NN O O
1199 NN O O
patients NN O O
with NN O O
metastatic NN O O
CRPC NN O O
who NN O O
had NN O O
previously NN O O
received NN O O
docetaxel NN O O
. NN O O
The NN O O
median NN O O
duration NN O O
of NN O O
treatment NN O O
was NN O O
8.3 NN O O
months NN O O
with NN O O
XTANDI NN O O
and NN O O
3.0 NN O O
months NN O O
with NN O O
placebo NN O O
. NN O O
During NN O O
the NN O O
trial NN O O
, NN O O
48 NN O O
% NN O O
of NN O O
patients NN O O
on NN O O
the NN O O
XTANDI NN O O
arm NN O O
and NN O O
46 NN O O
% NN O O
of NN O O
patients NN O O
on NN O O
the NN O O
placebo NN O O
arm NN O O
received NN O O
glucocorticoids NN O O
. NN O O
Grade NN O O
3 NN O O
and NN O O
higher NN O O
adverse NN O O
reactions NN O O
were NN O O
reported NN O O
among NN O O
47 NN O O
% NN O O
of NN O O
XTANDI NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
53 NN O O
% NN O O
of NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Discontinuations NN O O
due NN O O
to NN O O
adverse NN O O
events NN O O
were NN O O
reported NN O O
for NN O O
16 NN O O
% NN O O
of NN O O
XTANDI NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
18 NN O O
% NN O O
of NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reaction NN O O
leading NN O O
to NN O O
treatment NN O O
discontinuation NN O O
was NN O O
seizure NN B-AdverseReaction B-AdverseReaction
which NN O O
occurred NN O O
in NN O O
0.9 NN O O
% NN O O
of NN O O
the NN O O
XTANDI NN O O
- NN O O
treated NN O O
patients NN O O
compared NN O O
to NN O O
none NN O O
( NN O O
0 NN O O
% NN O O
) NN O O
of NN O O
the NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Table NN O O
1 NN O O
shows NN O O
adverse NN O O
reactions NN O O
reported NN O O
in NN O O
Study NN O O
1 NN O O
that NN O O
occurred NN O O
at NN O O
a NN O O
>= NN O O
2 NN O O
% NN O O
higher NN O O
frequency NN O O
in NN O O
the NN O O
XTANDI NN O O
arm NN O O
compared NN O O
to NN O O
the NN O O
placebo NN O O
arm NN O O
. NN O O
Table NN O O
1 NN O O
. NN O O
Adverse NN O O
Reactions NN O O
in NN O O
Study NN O O
1 NN O O
XTANDI NN O O
N NN O O
= NN O O
800 NN O O
Placebo NN O O
N NN O O
= NN O O
399 NN O O
Grade NN O O
1 NN O O
- NN O O
4a NN O O
( NN O O
% NN O O
) NN O O
Grade NN O O
3 NN O O
- NN O O
4 NN O O
( NN O O
% NN O O
) NN O O
Grade NN O O
1 NN O O
- NN O O
4 NN O O
( NN O O
% NN O O
) NN O O
Grade NN O O
3 NN O O
- NN O O
4 NN O O
( NN O O
% NN O O
) NN O O
General NN O O
Disorders NN O O
Asthenic NN B-AdverseReaction B-AdverseReaction
Conditions NN I-AdverseReaction I-AdverseReaction
50.6 NN O O
9.0 NN O O
44.4 NN O O
9.3 NN O O
Peripheral NN B-AdverseReaction B-AdverseReaction
Edema NN I-AdverseReaction I-AdverseReaction
15.4 NN O O
1.0 NN O O
13.3 NN O O
0.8 NN O O
Musculoskeletal NN O O
And NN O O
Connective NN O O
Tissue NN O O
Disorders NN O O
Back NN B-AdverseReaction B-AdverseReaction
Pain NN I-AdverseReaction I-AdverseReaction
26.4 NN O O
5.3 NN O O
24.3 NN O O
4.0 NN O O
Arthralgia NN B-AdverseReaction B-AdverseReaction
20.5 NN O O
2.5 NN O O
17.3 NN O O
1.8 NN O O
Musculoskeletal NN B-AdverseReaction B-AdverseReaction
Pain NN I-AdverseReaction I-AdverseReaction
15.0 NN O O
1.3 NN O O
11.5 NN O O
0.3 NN O O
Muscular NN B-AdverseReaction B-AdverseReaction
Weakness NN I-AdverseReaction I-AdverseReaction
9.8 NN O O
1.5 NN O O
6.8 NN O O
1.8 NN O O
Musculoskeletal NN B-AdverseReaction B-AdverseReaction
Stiffness NN I-AdverseReaction I-AdverseReaction
2.6 NN O O
0.3 NN O O
0.3 NN O O
0.0 NN O O
Gastrointestinal NN O O
Disorders NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
21.8 NN O O
1.1 NN O O
17.5 NN O O
0.3 NN O O
Vascular NN O O
Disorders NN O O
Hot NN B-AdverseReaction B-AdverseReaction
Flush NN I-AdverseReaction I-AdverseReaction
20.3 NN O O
0.0 NN O O
10.3 NN O O
0.0 NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
6.4 NN O O
2.1 NN O O
2.8 NN O O
1.3 NN O O
Nervous NN O O
System NN O O
Disorders NN O O
Headache NN B-AdverseReaction B-AdverseReaction
12.1 NN O O
0.9 NN O O
5.5 NN O O
0.0 NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
9.5 NN O O
0.5 NN O O
7.5 NN O O
0.5 NN O O
Spinal NN B-AdverseReaction B-AdverseReaction
Cord NN I-AdverseReaction I-AdverseReaction
Compression NN I-AdverseReaction I-AdverseReaction
and NN O O
Cauda NN B-AdverseReaction B-AdverseReaction
Equina NN I-AdverseReaction I-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
7.4 NN O O
6.6 NN O O
4.5 NN O O
3.8 NN O O
Paresthesia NN B-AdverseReaction B-AdverseReaction
6.6 NN O O
0.0 NN O O
4.5 NN O O
0.0 NN O O
Mental NN B-AdverseReaction B-AdverseReaction
Impairment NN I-AdverseReaction I-AdverseReaction
Disorders NN I-AdverseReaction I-AdverseReaction
4.3 NN O O
0.3 NN O O
1.8 NN O O
0.0 NN O O
Hypoesthesia NN B-AdverseReaction B-AdverseReaction
4.0 NN O O
0.3 NN O O
1.8 NN O O
0.0 NN O O
Infections NN O O
And NN O O
Infestations NN O O
Upper NN B-AdverseReaction B-AdverseReaction
Respiratory NN I-AdverseReaction I-AdverseReaction
Tract NN I-AdverseReaction I-AdverseReaction
Infection NN I-AdverseReaction I-AdverseReaction
10.9 NN O O
0.0 NN O O
6.5 NN O O
0.3 NN O O
Lower NN O O
Respiratory NN O O
Tract NN O O
And NN O O
Lung NN B-AdverseReaction B-AdverseReaction
Infection NN I-AdverseReaction I-AdverseReaction
8.5 NN O O
2.4 NN O O
4.8 NN O O
1.3 NN O O
Psychiatric NN O O
Disorders NN O O
Insomnia NN B-AdverseReaction B-AdverseReaction
8.8 NN O O
0.0 NN O O
6.0 NN O O
0.5 NN O O
Anxiety NN B-AdverseReaction B-AdverseReaction
6.5 NN O O
0.3 NN O O
4.0 NN O O
0.0 NN O O
Renal NN O O
And NN O O
Urinary NN O O
Disorders NN O O
Hematuria NN B-AdverseReaction B-AdverseReaction
6.9 NN O O
1.8 NN O O
4.5 NN O O
1.0 NN O O
Pollakiuria NN B-AdverseReaction B-AdverseReaction
4.8 NN O O
0.0 NN O O
2.5 NN O O
0.0 NN O O
Injury NN O O
, NN O O
Poisoning NN O O
And NN O O
Procedural NN O O
Complications NN O O
Fall NN B-AdverseReaction B-AdverseReaction
4.6 NN O O
0.3 NN O O
1.3 NN O O
0.0 NN O O
Non NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
pathologic NN I-AdverseReaction I-AdverseReaction
Fractures NN I-AdverseReaction I-AdverseReaction
4.0 NN O O
1.4 NN O O
0.8 NN O O
0.3 NN O O
Skin NN O O
And NN O O
Subcutaneous NN O O
Tissue NN O O
Disorders NN O O
Pruritus NN B-AdverseReaction B-AdverseReaction
3.8 NN O O
0.0 NN O O
1.3 NN O O
0.0 NN O O
Dry NN B-AdverseReaction B-AdverseReaction
Skin NN I-AdverseReaction I-AdverseReaction
3.5 NN O O
0.0 NN O O
1.3 NN O O
0.0 NN O O
Respiratory NN O O
Disorders NN O O
Epistaxis NN B-AdverseReaction B-AdverseReaction
3.3 NN O O
0.1 NN O O
1.3 NN O O
0.3 NN O O
a NN O O
CTCAE NN O O
v4b NN O O
Includes NN O O
asthenia NN B-AdverseReaction B-AdverseReaction
and NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
Includes NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
and NN O O
vertigo NN B-AdverseReaction B-AdverseReaction
Includes NN O O
amnesia NN B-AdverseReaction B-AdverseReaction
memory NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
cognitive NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
and NN O O
disturbance NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
attention NN I-AdverseReaction I-AdverseReaction
Includes NN O O
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
sinusitis NN B-AdverseReaction B-AdverseReaction
rhinitis NN B-AdverseReaction B-AdverseReaction
pharyngitis NN B-AdverseReaction B-AdverseReaction
and NN O O
laryngitis NN B-AdverseReaction B-AdverseReaction
Includes NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
lower NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
bronchitis NN B-AdverseReaction B-AdverseReaction
and NN O O
lung NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
Study NN O O
2 NN O O
: NN O O
Chemotherapy NN O O
- NN O O
naive NN O O
Metastatic NN O O
Castration NN O O
- NN O O
Resistant NN O O
Prostate NN O O
Cancer NN O O
Study NN O O
2 NN O O
enrolled NN O O
1717 NN O O
patients NN O O
with NN O O
metastatic NN O O
CRPC NN O O
who NN O O
had NN O O
not NN O O
received NN O O
prior NN O O
cytotoxic NN O O
chemotherapy NN O O
, NN O O
of NN O O
whom NN O O
1715 NN O O
received NN O O
at NN O O
least NN O O
one NN O O
dose NN O O
of NN O O
study NN O O
drug NN O O
. NN O O
The NN O O
median NN O O
duration NN O O
of NN O O
treatment NN O O
was NN O O
17.5 NN O O
months NN O O
with NN O O
XTANDI NN O O
and NN O O
4.6 NN O O
months NN O O
with NN O O
placebo NN O O
. NN O O
Grade NN O O
3 NN O O
- NN O O
4 NN O O
adverse NN O O
reactions NN O O
were NN O O
reported NN O O
in NN O O
44 NN O O
% NN O O
of NN O O
XTANDI NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
37 NN O O
% NN O O
of NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Discontinuations NN O O
due NN O O
to NN O O
adverse NN O O
events NN O O
were NN O O
reported NN O O
for NN O O
6 NN O O
% NN O O
of NN O O
XTANDI NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
6 NN O O
% NN O O
of NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reaction NN O O
leading NN O O
to NN O O
treatment NN O O
discontinuation NN O O
was NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
which NN O O
occurred NN O O
in NN O O
1 NN O O
% NN O O
of NN O O
patients NN O O
on NN O O
each NN O O
treatment NN O O
arm NN O O
. NN O O
Table NN O O
2 NN O O
includes NN O O
adverse NN O O
reactions NN O O
reported NN O O
in NN O O
Study NN O O
2 NN O O
that NN O O
occurred NN O O
at NN O O
a NN O O
>= NN O O
2 NN O O
% NN O O
higher NN O O
frequency NN O O
in NN O O
the NN O O
XTANDI NN O O
arm NN O O
compared NN O O
to NN O O
the NN O O
placebo NN O O
arm NN O O
. NN O O
Table NN O O
2 NN O O
. NN O O
Adverse NN O O
Reactions NN O O
in NN O O
Study NN O O
2 NN O O
XTANDI NN O O
N NN O O
= NN O O
871 NN O O
Placebo NN O O
N NN O O
= NN O O
844 NN O O
Grade NN O O
1 NN O O
- NN O O
4 NN O O
a NN O O
( NN O O
% NN O O
) NN O O
Grade NN O O
3 NN O O
- NN O O
4 NN O O
( NN O O
% NN O O
) NN O O
Grade NN O O
1 NN O O
- NN O O
4 NN O O
( NN O O
% NN O O
) NN O O
Grade NN O O
3 NN O O
- NN O O
4 NN O O
( NN O O
% NN O O
) NN O O
General NN O O
Disorders NN O O
Asthenic NN B-AdverseReaction B-AdverseReaction
Conditions NN I-AdverseReaction I-AdverseReaction
46.9 NN O O
3.4 NN O O
33.0 NN O O
2.8 NN O O
Peripheral NN B-AdverseReaction B-AdverseReaction
Edema NN I-AdverseReaction I-AdverseReaction
11.5 NN O O
0.2 NN O O
8.2 NN O O
0.4 NN O O
Musculoskeletal NN O O
And NN O O
Connective NN O O
Tissue NN O O
Disorders NN O O
Back NN B-AdverseReaction B-AdverseReaction
Pain NN I-AdverseReaction I-AdverseReaction
28.6 NN O O
2.5 NN O O
22.4 NN O O
3.0 NN O O
Arthralgia NN B-AdverseReaction B-AdverseReaction
21.4 NN O O
1.6 NN O O
16.1 NN O O
1.1 NN O O
Gastrointestinal NN O O
Disorders NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
23.2 NN O O
0.7 NN O O
17.3 NN O O
0.4 NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
16.8 NN O O
0.3 NN O O
14.3 NN O O
0.4 NN O O
Vascular NN O O
Disorders NN O O
Hot NN B-AdverseReaction B-AdverseReaction
Flush NN I-AdverseReaction I-AdverseReaction
18.0 NN O O
0.1 NN O O
7.8 NN O O
0.0 NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
14.2 NN O O
7.2 NN O O
4.1 NN O O
2.3 NN O O
Nervous NN O O
System NN O O
Disorders NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
11.3 NN O O
0.3 NN O O
7.1 NN O O
0.0 NN O O
Headache NN B-AdverseReaction B-AdverseReaction
11.0 NN O O
0.2 NN O O
7.0 NN O O
0.4 NN O O
Dysgeusia NN B-AdverseReaction B-AdverseReaction
7.6 NN O O
0.1 NN O O
3.7 NN O O
0.0 NN O O
Mental NN B-AdverseReaction B-AdverseReaction
Impairment NN I-AdverseReaction I-AdverseReaction
Disorders NN I-AdverseReaction I-AdverseReaction
5.7 NN O O
0.0 NN O O
1.3 NN O O
0.1 NN O O
Restless NN B-AdverseReaction B-AdverseReaction
Legs NN I-AdverseReaction I-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
2.1 NN O O
0.1 NN O O
0.4 NN O O
0.0 NN O O
Respiratory NN O O
Disorders NN O O
Dyspneae NN B-AdverseReaction B-AdverseReaction
11.0 NN O O
0.6 NN O O
8.5 NN O O
0.6 NN O O
Infections NN O O
And NN O O
Infestations NN O O
Upper NN B-AdverseReaction B-AdverseReaction
Respiratory NN I-AdverseReaction I-AdverseReaction
Tract NN I-AdverseReaction I-AdverseReaction
Infection NN I-AdverseReaction I-AdverseReaction
16.4 NN O O
0.0 NN O O
10.5 NN O O
0.0 NN O O
Lower NN O O
Respiratory NN O O
Tract NN O O
And NN O O
Lung NN B-AdverseReaction B-AdverseReaction
Infection NN I-AdverseReaction I-AdverseReaction
7.9 NN O O
1.5 NN O O
4.7 NN O O
1.1 NN O O
Psychiatric NN O O
Disorders NN O O
Insomnia NN B-AdverseReaction B-AdverseReaction
8.2 NN O O
0.1 NN O O
5.7 NN O O
0.0 NN O O
Renal NN O O
And NN O O
Urinary NN O O
Disorders NN O O
Hematuria NN B-AdverseReaction B-AdverseReaction
8.8 NN O O
1.3 NN O O
5.8 NN O O
1.3 NN O O
Injury NN O O
, NN O O
Poisoning NN O O
And NN O O
Procedural NN O O
Complications NN O O
Fall NN B-AdverseReaction B-AdverseReaction
12.7 NN O O
1.6 NN O O
5.3 NN O O
0.7 NN O O
Non NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Pathological NN I-AdverseReaction I-AdverseReaction
Fracture NN I-AdverseReaction I-AdverseReaction
8.8 NN O O
2.1 NN O O
3.0 NN O O
1.1 NN O O
Metabolism NN O O
and NN O O
Nutrition NN O O
Disorders NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
Appetite NN I-AdverseReaction I-AdverseReaction
18.9 NN O O
0.3 NN O O
16.4 NN O O
0.7 NN O O
Investigations NN O O
Weight NN B-AdverseReaction B-AdverseReaction
Decreased NN I-AdverseReaction I-AdverseReaction
12.4 NN O O
0.8 NN O O
8.5 NN O O
0.2 NN O O
Reproductive NN O O
System NN O O
and NN O O
Breast NN O O
disorders NN O O
Gynecomastia NN B-AdverseReaction B-AdverseReaction
3.4 NN O O
0.0 NN O O
1.4 NN O O
0.0 NN O O
a NN O O
CTCAE NN O O
v4b NN O O
Includes NN O O
asthenia NN B-AdverseReaction B-AdverseReaction
and NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
Includes NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
and NN O O
vertigo NN B-AdverseReaction B-AdverseReaction
Includes NN O O
amnesia NN B-AdverseReaction B-AdverseReaction
memory NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
cognitive NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
and NN O O
disturbance NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
attention NN I-AdverseReaction I-AdverseReaction
Includes NN O O
dyspnea NN B-AdverseReaction B-AdverseReaction
exertional NN B-AdverseReaction B-AdverseReaction
dyspnea NN I-AdverseReaction I-AdverseReaction
and NN O O
dyspnea NN B-AdverseReaction B-AdverseReaction
at NN I-AdverseReaction I-AdverseReaction
rest NN I-AdverseReaction I-AdverseReaction
Includes NN O O
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
sinusitis NN B-AdverseReaction B-AdverseReaction
rhinitis NN B-AdverseReaction B-AdverseReaction
pharyngitis NN B-AdverseReaction B-AdverseReaction
and NN O O
laryngitis NN B-AdverseReaction B-AdverseReaction
Includes NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
lower NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
bronchitis NN B-AdverseReaction B-AdverseReaction
and NN O O
lung NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
Laboratory NN O O
Abnormalities NN O O
In NN O O
the NN O O
two NN O O
randomized NN O O
clinical NN O O
trials NN O O
, NN O O
Grade NN B-Severity B-Severity
1 NN I-Severity I-Severity
- NN I-Severity I-Severity
4 NN I-Severity I-Severity
neutropenia NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
15 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
XTANDI NN O O
( NN O O
1 NN O O
% NN O O
Grade NN O O
3 NN O O
- NN O O
4 NN O O
) NN O O
and NN O O
in NN O O
6 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
placebo NN O O
( NN O O
0.5 NN O O
% NN O O
Grade NN O O
3 NN O O
- NN O O
4 NN O O
) NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
Grade NN B-Severity B-Severity
1 NN I-Severity I-Severity
- NN I-Severity I-Severity
4 NN I-Severity I-Severity
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
was NN O O
6 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
XTANDI NN O O
( NN O O
0.3 NN O O
% NN O O
Grade NN O O
3 NN O O
- NN O O
4 NN O O
) NN O O
and NN O O
5 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
placebo NN O O
( NN O O
0.5 NN O O
% NN O O
Grade NN O O
3 NN O O
- NN O O
4 NN O O
) NN O O
. NN O O
Grade NN B-Severity B-Severity
1 NN I-Severity I-Severity
- NN I-Severity I-Severity
4 NN I-Severity I-Severity
elevations NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
ALT NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
10 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
XTANDI NN O O
( NN O O
0.2 NN O O
% NN O O
Grade NN O O
3 NN O O
- NN O O
4 NN O O
) NN O O
and NN O O
16 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
placebo NN O O
( NN O O
0.2 NN O O
% NN O O
Grade NN O O
3 NN O O
- NN O O
4 NN O O
) NN O O
. NN O O
Grade NN B-Severity B-Severity
1 NN I-Severity I-Severity
- NN I-Severity I-Severity
4 NN I-Severity I-Severity
elevations NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
bilirubin NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
3 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
XTANDI NN O O
( NN O O
0.1 NN O O
% NN O O
Grade NN O O
3 NN O O
- NN O O
4 NN O O
) NN O O
and NN O O
2 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
placebo NN O O
( NN O O
no NN O O
Grade NN O O
3 NN O O
- NN O O
4 NN O O
) NN O O
. NN O O
Infections NN O O
In NN O O
Study NN O O
1 NN O O
, NN O O
1 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
XTANDI NN O O
compared NN O O
to NN O O
0.3 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
placebo NN O O
died NN B-AdverseReaction B-AdverseReaction
from NN O O
infections NN B-AdverseReaction B-AdverseReaction
or NN O O
sepsis NN B-AdverseReaction B-AdverseReaction
In NN O O
Study NN O O
2 NN O O
, NN O O
1 NN O O
patient NN O O
in NN O O
each NN O O
treatment NN O O
group NN O O
( NN O O
0.1 NN O O
% NN O O
) NN O O
had NN O O
an NN O O
infection NN B-AdverseReaction B-AdverseReaction
resulting NN O O
in NN O O
death NN B-AdverseReaction B-AdverseReaction
Falls NN O O
and NN O O
Fall NN O O
- NN O O
related NN O O
Injuries NN O O
In NN O O
the NN O O
two NN O O
randomized NN O O
clinical NN O O
trials NN O O
, NN O O
falls NN B-AdverseReaction B-AdverseReaction
including NN O O
fall NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
injuries NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
9 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
XTANDI NN O O
compared NN O O
to NN O O
4 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
placebo NN O O
. NN O O
Falls NN B-AdverseReaction B-AdverseReaction
were NN O O
not NN B-Negation B-Negation
associated NN O O
with NN O O
loss NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
consciousness NN I-AdverseReaction I-AdverseReaction
or NN O O
seizure NN B-AdverseReaction B-AdverseReaction
Fall NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
injuries NN I-AdverseReaction I-AdverseReaction
were NN O O
more NN O O
severe NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
XTANDI NN O O
and NN O O
included NN O O
non NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
pathologic NN I-AdverseReaction I-AdverseReaction
fractures NN I-AdverseReaction I-AdverseReaction
joint NN B-AdverseReaction B-AdverseReaction
injuries NN I-AdverseReaction I-AdverseReaction
and NN O O
hematomas NN B-AdverseReaction B-AdverseReaction
Hypertension NN B-AdverseReaction B-AdverseReaction
In NN O O
the NN O O
two NN O O
randomized NN O O
trials NN O O
, NN O O
hypertension NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
11 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
XTANDI NN O O
and NN O O
4 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
placebo NN O O
. NN O O
No NN B-Negation B-Negation
patients NN O O
experienced NN O O
hypertensive NN B-AdverseReaction B-AdverseReaction
crisis NN I-AdverseReaction I-AdverseReaction
Medical NN O O
history NN O O
of NN O O
hypertension NN O O
was NN O O
balanced NN O O
between NN O O
arms NN O O
. NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
led NN O O
to NN O O
study NN O O
discontinuation NN O O
in NN O O
< NN O O
1 NN O O
% NN O O
of NN O O
patients NN O O
in NN O O
each NN O O
arm NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
Seizure NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
0.9 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
XTANDI NN O O
who NN O O
previously NN O O
received NN O O
docetaxel NN O O
and NN O O
in NN O O
0.1 NN O O
% NN O O
of NN O O
patients NN O O
who NN O O
were NN O O
chemotherapy NN O O
- NN O O
naive NN O O
. NN O O
There NN O O
is NN O O
no NN O O
clinical NN O O
trial NN O O
experience NN O O
with NN O O
XTANDI NN O O
in NN O O
patients NN O O
who NN O O
have NN O O
had NN O O
a NN O O
seizure NN O O
. NN O O
Permanently NN O O
discontinue NN O O
XTANDI NN O O
in NN O O
patients NN O O
who NN O O
develop NN O O
a NN O O
seizure NN O O
during NN O O
treatment NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
5.1 NN O O
Seizure NN O O
In NN O O
Study NN O O
1 NN O O
, NN O O
which NN O O
enrolled NN O O
patients NN O O
who NN O O
previously NN O O
received NN O O
docetaxel NN O O
, NN O O
7 NN O O
of NN O O
800 NN O O
( NN O O
0.9 NN O O
% NN O O
) NN O O
patients NN O O
treated NN O O
with NN O O
XTANDI NN O O
experienced NN O O
a NN O O
seizure NN B-AdverseReaction B-AdverseReaction
and NN O O
no NN B-Negation B-Negation
patients NN O O
treated NN O O
with NN O O
placebo NN O O
experienced NN O O
a NN O O
seizure NN B-AdverseReaction B-AdverseReaction
Seizure NN B-AdverseReaction B-AdverseReaction
occurred NN O O
from NN O O
31 NN O O
to NN O O
603 NN O O
days NN O O
after NN O O
initiation NN O O
of NN O O
XTANDI. NN O O
In NN O O
Study NN O O
2 NN O O
, NN O O
1 NN O O
of NN O O
871 NN O O
( NN O O
0.1 NN O O
% NN O O
) NN O O
chemotherapy NN O O
- NN O O
naive NN O O
patients NN O O
treated NN O O
with NN O O
XTANDI NN O O
and NN O O
1 NN O O
of NN O O
844 NN O O
( NN O O
0.1 NN O O
% NN O O
) NN O O
patients NN O O
treated NN O O
with NN O O
placebo NN O O
experienced NN O O
a NN O O
seizure NN B-AdverseReaction B-AdverseReaction
Patients NN O O
experiencing NN O O
seizure NN B-AdverseReaction B-AdverseReaction
were NN O O
permanently NN O O
discontinued NN O O
from NN O O
therapy NN O O
and NN O O
all NN O O
seizure NN O O
events NN O O
resolved NN O O
. NN O O
There NN O O
is NN O O
no NN O O
clinical NN O O
trial NN O O
experience NN O O
re NN O O
- NN O O
administering NN O O
XTANDI NN O O
to NN O O
patients NN O O
who NN O O
experienced NN O O
seizure NN O O
. NN O O
Limited NN O O
safety NN O O
data NN O O
are NN O O
available NN O O
in NN O O
patients NN O O
with NN O O
predisposing NN O O
factors NN O O
for NN O O
seizure NN O O
because NN O O
these NN O O
patients NN O O
were NN O O
generally NN O O
excluded NN O O
from NN O O
the NN O O
trials NN O O
. NN O O
These NN O O
exclusion NN O O
criteria NN O O
included NN O O
a NN O O
history NN O O
of NN O O
seizure NN O O
, NN O O
underlying NN O O
brain NN O O
injury NN O O
with NN O O
loss NN O O
of NN O O
consciousness NN O O
, NN O O
transient NN O O
ischemic NN O O
attack NN O O
within NN O O
the NN O O
past NN O O
12 NN O O
months NN O O
, NN O O
cerebral NN O O
vascular NN O O
accident NN O O
, NN O O
brain NN O O
metastases NN O O
, NN O O
and NN O O
brain NN O O
arteriovenous NN O O
malformation NN O O
. NN O O
Study NN O O
1 NN O O
excluded NN O O
the NN O O
use NN O O
of NN O O
concomitant NN O O
medications NN O O
that NN O O
may NN O O
lower NN O O
the NN O O
seizure NN O O
threshold NN O O
, NN O O
whereas NN O O
Study NN O O
2 NN O O
permitted NN O O
the NN O O
use NN O O
of NN O O
these NN O O
medications NN O O
. NN O O
Because NN O O
of NN O O
the NN O O
risk NN O O
of NN O O
seizure NN O O
associated NN O O
with NN O O
XTANDI NN O O
use NN O O
, NN O O
patients NN O O
should NN O O
be NN O O
advised NN O O
of NN O O
the NN O O
risk NN O O
of NN O O
engaging NN O O
in NN O O
any NN O O
activity NN O O
where NN O O
sudden NN O O
loss NN O O
of NN O O
consciousness NN O O
could NN O O
cause NN O O
serious NN O O
harm NN O O
to NN O O
themselves NN O O
or NN O O
others NN O O
. NN O O
Permanently NN O O
discontinue NN O O
XTANDI NN O O
in NN O O
patients NN O O
who NN O O
develop NN O O
a NN O O
seizure NN O O
during NN O O
treatment NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
serious NN O O
reactions NN O O
are NN O O
described NN O O
in NN O O
greater NN O O
detail NN O O
in NN O O
the NN O O
Warnings NN O O
and NN O O
Precautions NN O O
section NN O O
: NN O O
* NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
Clostridium NN B-AdverseReaction B-AdverseReaction
difficile NN I-AdverseReaction I-AdverseReaction
-associated NN I-AdverseReaction I-AdverseReaction
diarrhea NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=5 NN O O
% NN O O
in NN O O
either NN O O
indication NN O O
) NN O O
are NN O O
nausea NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
and NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Merck NN O O
Sharp NN O O
& NN O O
Dohme NN O O
Corp. NN O O
, NN O O
a NN O O
subsidiary NN O O
of NN O O
Merck NN O O
& NN O O
Co. NN O O
, NN O O
Inc. NN O O
, NN O O
at NN O O
1 NN O O
- NN O O
877 NN O O
- NN O O
888 NN O O
- NN O O
4231 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trial NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
also NN O O
may NN O O
not NN O O
reflect NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
ZERBAXA NN O O
was NN O O
evaluated NN O O
in NN O O
Phase NN O O
3 NN O O
comparator NN O O
- NN O O
controlled NN O O
clinical NN O O
trials NN O O
of NN O O
cIAI NN O O
and NN O O
cUTI NN O O
, NN O O
which NN O O
included NN O O
a NN O O
total NN O O
of NN O O
1015 NN O O
patients NN O O
treated NN O O
with NN O O
ZERBAXA NN O O
and NN O O
1032 NN O O
patients NN O O
treated NN O O
with NN O O
comparator NN O O
( NN O O
levofloxacin NN O O
750 NN O O
mg NN O O
daily NN O O
in NN O O
cUTI NN O O
or NN O O
meropenem NN O O
1 NN O O
g NN O O
every NN O O
8 NN O O
hours NN O O
in NN O O
cIAI NN O O
) NN O O
for NN O O
up NN O O
to NN O O
14 NN O O
days NN O O
. NN O O
The NN O O
mean NN O O
age NN O O
of NN O O
treated NN O O
patients NN O O
was NN O O
48 NN O O
to NN O O
50 NN O O
years NN O O
( NN O O
range NN O O
18 NN O O
to NN O O
92 NN O O
years NN O O
) NN O O
, NN O O
across NN O O
treatment NN O O
arms NN O O
and NN O O
indications NN O O
. NN O O
In NN O O
both NN O O
indications NN O O
, NN O O
about NN O O
25 NN O O
% NN O O
of NN O O
the NN O O
subjects NN O O
were NN O O
65 NN O O
years NN O O
of NN O O
age NN O O
or NN O O
older NN O O
. NN O O
Most NN O O
patients NN O O
( NN O O
75 NN O O
% NN O O
) NN O O
enrolled NN O O
in NN O O
the NN O O
cUTI NN O O
trial NN O O
were NN O O
female NN O O
, NN O O
and NN O O
most NN O O
patients NN O O
( NN O O
58 NN O O
% NN O O
) NN O O
enrolled NN O O
in NN O O
the NN O O
cIAI NN O O
trial NN O O
were NN O O
male NN O O
. NN O O
Most NN O O
patients NN O O
( NN O O
>70 NN O O
% NN O O
) NN O O
in NN O O
both NN O O
trials NN O O
were NN O O
enrolled NN O O
in NN O O
Eastern NN O O
Europe NN O O
and NN O O
were NN O O
White NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
5 NN O O
% NN O O
or NN O O
greater NN O O
in NN O O
either NN O O
indication NN O O
) NN O O
occurring NN O O
in NN O O
patients NN O O
receiving NN O O
ZERBAXA NN O O
were NN O O
nausea NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
and NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
Table NN O O
5 NN O O
lists NN O O
adverse NN O O
reactions NN O O
occurring NN O O
in NN O O
1 NN O O
% NN O O
or NN O O
greater NN O O
of NN O O
patients NN O O
receiving NN O O
ZERBAXA NN O O
in NN O O
Phase NN O O
3 NN O O
clinical NN O O
trials NN O O
. NN O O
Table NN O O
5 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Occurring NN O O
in NN O O
1 NN O O
% NN O O
or NN O O
Greater NN O O
of NN O O
Patients NN O O
Receiving NN O O
ZERBAXA NN O O
in NN O O
Phase NN O O
3 NN O O
Clinical NN O O
Trials NN O O
Preferred NN O O
Term NN O O
Complicated NN O O
Intra NN O O
- NN O O
abdominal NN O O
Infections NN O O
Complicated NN O O
Urinary NN O O
Tract NN O O
Infections NN O O
, NN O O
Including NN O O
Pyelonephritis NN O O
ZERBAXA(N=482 NN O O
) NN O O
Meropenem(N=497 NN O O
) NN O O
ZERBAXA(N=533 NN O O
) NN O O
Levofloxacin(N=535 NN O O
) NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
38 NN O O
( NN O O
7.9 NN O O
) NN O O
29 NN O O
( NN O O
5.8 NN O O
) NN O O
15 NN O O
( NN O O
2.8 NN O O
) NN O O
9 NN O O
( NN O O
1.7 NN O O
) NN O O
Headache NN B-AdverseReaction B-AdverseReaction
12 NN O O
( NN O O
2.5 NN O O
) NN O O
9 NN O O
( NN O O
1.8 NN O O
) NN O O
31 NN O O
( NN O O
5.8 NN O O
) NN O O
26 NN O O
( NN O O
4.9 NN O O
) NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
30 NN O O
( NN O O
6.2 NN O O
) NN O O
25 NN O O
( NN O O
5 NN O O
) NN O O
10 NN O O
( NN O O
1.9 NN O O
) NN O O
23 NN O O
( NN O O
4.3 NN O O
) NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
27 NN O O
( NN O O
5.6 NN O O
) NN O O
20 NN O O
( NN O O
4 NN O O
) NN O O
9 NN O O
( NN O O
1.7 NN O O
) NN O O
5 NN O O
( NN O O
0.9 NN O O
) NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
9 NN O O
( NN O O
1.9 NN O O
) NN O O
6 NN O O
( NN O O
1.2 NN O O
) NN O O
21 NN O O
( NN O O
3.9 NN O O
) NN O O
17 NN O O
( NN O O
3.2 NN O O
) NN O O
Insomnia NN B-AdverseReaction B-AdverseReaction
17 NN O O
( NN O O
3.5 NN O O
) NN O O
11 NN O O
( NN O O
2.2 NN O O
) NN O O
7 NN O O
( NN O O
1.3 NN O O
) NN O O
14 NN O O
( NN O O
2.6 NN O O
) NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
16 NN O O
( NN O O
3.3 NN O O
) NN O O
20 NN O O
( NN O O
4 NN O O
) NN O O
6 NN O O
( NN O O
1.1 NN O O
) NN O O
6 NN O O
( NN O O
1.1 NN O O
) NN O O
Hypokalemia NN B-AdverseReaction B-AdverseReaction
16 NN O O
( NN O O
3.3 NN O O
) NN O O
10 NN O O
( NN O O
2 NN O O
) NN O O
4 NN O O
( NN O O
0.8 NN O O
) NN O O
2 NN O O
( NN O O
0.4 NN O O
) NN O O
ALT NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
7 NN O O
( NN O O
1.5 NN O O
) NN O O
5 NN O O
( NN O O
1 NN O O
) NN O O
9 NN O O
( NN O O
1.7 NN O O
) NN O O
5 NN O O
( NN O O
0.9 NN O O
) NN O O
AST NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
5 NN O O
( NN O O
1 NN O O
) NN O O
3 NN O O
( NN O O
0.6 NN O O
) NN O O
9 NN O O
( NN O O
1.7 NN O O
) NN O O
5 NN O O
( NN O O
0.9 NN O O
) NN O O
Anemia NN B-AdverseReaction B-AdverseReaction
7 NN O O
( NN O O
1.5 NN O O
) NN O O
5 NN O O
( NN O O
1 NN O O
) NN O O
2 NN O O
( NN O O
0.4 NN O O
) NN O O
5 NN O O
( NN O O
0.9 NN O O
) NN O O
Thrombocytosis NN B-AdverseReaction B-AdverseReaction
9 NN O O
( NN O O
1.9 NN O O
) NN O O
5 NN O O
( NN O O
1 NN O O
) NN O O
2 NN O O
( NN O O
0.4 NN O O
) NN O O
2 NN O O
( NN O O
0.4 NN O O
) NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
6 NN O O
( NN O O
1.2 NN O O
) NN O O
2 NN O O
( NN O O
0.4 NN O O
) NN O O
4 NN O O
( NN O O
0.8 NN O O
) NN O O
2 NN O O
( NN O O
0.4 NN O O
) NN O O
Anxiety NN B-AdverseReaction B-AdverseReaction
9 NN O O
( NN O O
1.9 NN O O
) NN O O
7 NN O O
( NN O O
1.4 NN O O
) NN O O
1 NN O O
( NN O O
0.2 NN O O
) NN O O
4 NN O O
( NN O O
0.7 NN O O
) NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
4 NN O O
( NN O O
0.8 NN O O
) NN O O
5 NN O O
( NN O O
1 NN O O
) NN O O
6 NN O O
( NN O O
1.1 NN O O
) NN O O
1 NN O O
( NN O O
0.2 NN O O
) NN O O
Hypotension NN B-AdverseReaction B-AdverseReaction
8 NN O O
( NN O O
1.7 NN O O
) NN O O
4 NN O O
( NN O O
0.8 NN O O
) NN O O
2 NN O O
( NN O O
0.4 NN O O
) NN O O
1 NN O O
( NN O O
0.2 NN O O
) NN O O
Atrial NN B-AdverseReaction B-AdverseReaction
fibrillation NN I-AdverseReaction I-AdverseReaction
6 NN O O
( NN O O
1.2 NN O O
) NN O O
3 NN O O
( NN O O
0.6 NN O O
) NN O O
1 NN O O
( NN O O
0.2 NN O O
) NN O O
0 NN O O
Rash NN B-AdverseReaction B-AdverseReaction
8 NN O O
( NN O O
1.7 NN O O
) NN O O
7 NN O O
( NN O O
1.4 NN O O
) NN O O
5 NN O O
( NN O O
0.9 NN O O
) NN O O
2 NN O O
( NN O O
0.4 NN O O
) NN O O
Treatment NN O O
discontinuation NN O O
due NN O O
to NN O O
adverse NN O O
events NN O O
occurred NN O O
in NN O O
2.0 NN O O
% NN O O
( NN O O
20/1015 NN O O
) NN O O
of NN O O
patients NN O O
receiving NN O O
ZERBAXA NN O O
and NN O O
1.9 NN O O
% NN O O
( NN O O
20/1032 NN O O
) NN O O
of NN O O
patients NN O O
receiving NN O O
comparator NN O O
drugs NN O O
. NN O O
Renal NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
( NN O O
including NN O O
the NN O O
terms NN O O
renal NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
renal NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
and NN O O
renal NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
acute NN I-AdverseReaction I-AdverseReaction
led NN O O
to NN O O
discontinuation NN O O
of NN O O
treatment NN O O
in NN O O
5/1015 NN O O
( NN O O
0.5 NN O O
% NN O O
) NN O O
subjects NN O O
receiving NN O O
ZERBAXA NN O O
and NN O O
none NN O O
in NN O O
the NN O O
comparator NN O O
arms NN O O
. NN O O
Increased NN O O
Mortality NN O O
In NN O O
the NN O O
cIAI NN O O
trials NN O O
( NN O O
Phase NN O O
2 NN O O
and NN O O
3 NN O O
) NN O O
, NN O O
death NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
2.5 NN O O
% NN O O
( NN O O
14/564 NN O O
) NN O O
of NN O O
patients NN O O
receiving NN O O
ZERBAXA NN O O
and NN O O
in NN O O
1.5 NN O O
% NN O O
( NN O O
8/536 NN O O
) NN O O
of NN O O
patients NN O O
receiving NN O O
meropenem NN O O
. NN O O
The NN O O
causes NN O O
of NN O O
death NN B-AdverseReaction B-AdverseReaction
varied NN O O
and NN O O
included NN O O
worsening NN O O
and/or NN O O
complications NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
surgery NN O O
and NN O O
underlying NN O O
conditions NN O O
. NN O O
Less NN O O
Common NN O O
Adverse NN O O
Reactions NN O O
The NN O O
following NN O O
selected NN O O
adverse NN O O
reactions NN O O
were NN O O
reported NN O O
in NN O O
ZERBAXA NN O O
- NN O O
treated NN O O
subjects NN O O
at NN O O
a NN O O
rate NN O O
of NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
: NN O O
* NN O O
Cardiac NN O O
disorders NN O O
: NN O O
tachycardia NN B-AdverseReaction B-AdverseReaction
angina NN B-AdverseReaction B-AdverseReaction
pectoris NN I-AdverseReaction I-AdverseReaction
* NN O O
Gastrointestinal NN O O
disorders NN O O
: NN O O
ileus NN B-AdverseReaction B-AdverseReaction
gastritis NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
distension NN I-AdverseReaction I-AdverseReaction
dyspepsia NN B-AdverseReaction B-AdverseReaction
flatulence NN B-AdverseReaction B-AdverseReaction
ileus NN B-AdverseReaction B-AdverseReaction
paralytic NN I-AdverseReaction I-AdverseReaction
* NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
: NN O O
infusion NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
* NN O O
Infections NN O O
and NN O O
infestations NN O O
: NN O O
candidiasis NN B-AdverseReaction B-AdverseReaction
oropharyngeal NN O O
, NN O O
fungal NN B-AdverseReaction B-AdverseReaction
urinary NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
* NN O O
Investigations NN O O
: NN O O
increased NN B-AdverseReaction B-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
gamma NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
glutamyl NN I-AdverseReaction I-AdverseReaction
transpeptidase NN I-AdverseReaction I-AdverseReaction
( NN O O
GGT NN O O
) NN O O
, NN O O
increased NN B-AdverseReaction B-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
alkaline NN I-AdverseReaction I-AdverseReaction
phosphatase NN I-AdverseReaction I-AdverseReaction
positive NN B-AdverseReaction B-AdverseReaction
Coombs NN I-AdverseReaction I-AdverseReaction
test NN I-AdverseReaction I-AdverseReaction
* NN O O
Metabolism NN O O
and NN O O
nutrition NN O O
disorders NN O O
: NN O O
hyperglycemia NN B-AdverseReaction B-AdverseReaction
hypomagnesemia NN B-AdverseReaction B-AdverseReaction
hypophosphatemia NN B-AdverseReaction B-AdverseReaction
* NN O O
Nervous NN O O
system NN O O
disorders NN O O
: NN O O
ischemic NN B-AdverseReaction B-AdverseReaction
stroke NN I-AdverseReaction I-AdverseReaction
* NN O O
Renal NN O O
and NN O O
urinary NN O O
system NN O O
: NN O O
renal NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
renal NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
* NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
and NN O O
mediastinal NN O O
disorders NN O O
: NN O O
dyspnea NN B-AdverseReaction B-AdverseReaction
* NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
: NN O O
urticaria NN B-AdverseReaction B-AdverseReaction
* NN O O
Vascular NN O O
disorders NN O O
: NN O O
venous NN B-AdverseReaction B-AdverseReaction
thrombosis NN I-AdverseReaction I-AdverseReaction
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Decreased NN O O
efficacy NN O O
in NN O O
patients NN O O
with NN O O
baseline NN O O
CrCl NN O O
of NN O O
30 NN O O
to NN O O
< NN O O
=50 NN O O
mL/min NN O O
. NN O O
Monitor NN O O
CrCl NN O O
at NN O O
least NN O O
daily NN O O
in NN O O
patients NN O O
with NN O O
changing NN O O
renal NN O O
function NN O O
and NN O O
adjust NN O O
the NN O O
dose NN O O
of NN O O
ZERBAXA NN O O
accordingly NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Serious NN B-Severity B-Severity
hypersensitivity NN O O
( NN O O
anaphylactic NN O O
) NN O O
reactions NN O O
have NN O O
been NN O O
reported NN O O
with NN O O
beta NN B-DrugClass B-DrugClass
- NN I-DrugClass I-DrugClass
lactam NN I-DrugClass I-DrugClass
antibacterial NN I-DrugClass I-DrugClass
drugs NN I-DrugClass I-DrugClass
Exercise NN O O
caution NN O O
in NN O O
patients NN O O
with NN O O
known NN O O
hypersensitivity NN O O
to NN O O
beta NN O O
- NN O O
lactam NN O O
antibacterial NN O O
drugs NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Clostridium NN B-AdverseReaction B-AdverseReaction
difficile NN I-AdverseReaction I-AdverseReaction
-associated NN I-AdverseReaction I-AdverseReaction
diarrhea NN I-AdverseReaction I-AdverseReaction
( NN O O
CDAD NN O O
) NN O O
has NN O O
been NN O O
reported NN O O
with NN O O
nearly NN O O
all NN O O
systemic NN O O
antibacterial NN O O
agents NN O O
, NN O O
including NN O O
ZERBAXA. NN O O
Evaluate NN O O
if NN O O
diarrhea NN O O
occurs NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
5.1 NN O O
Decreased NN O O
Efficacy NN O O
in NN O O
Patients NN O O
with NN O O
Baseline NN O O
Creatinine NN O O
Clearance NN O O
of NN O O
30 NN O O
to NN O O
< NN O O
=50 NN O O
mL/min NN O O
In NN O O
a NN O O
subgroup NN O O
analysis NN O O
of NN O O
a NN O O
Phase NN O O
3 NN O O
cIAI NN O O
trial NN O O
, NN O O
clinical NN O O
cure NN O O
rates NN O O
were NN O O
lower NN O O
in NN O O
patients NN O O
with NN O O
baseline NN O O
creatinine NN O O
clearance NN O O
( NN O O
CrCl NN O O
) NN O O
of NN O O
30 NN O O
to NN O O
< NN O O
=50 NN O O
mL/min NN O O
compared NN O O
to NN O O
those NN O O
with NN O O
CrCl NN O O
>=50 NN O O
mL/min NN O O
( NN O O
Table NN O O
4 NN O O
) NN O O
. NN O O
The NN O O
reduction NN O O
in NN O O
clinical NN O O
cure NN O O
rates NN O O
was NN O O
more NN O O
marked NN O O
in NN O O
the NN O O
ZERBAXA NN O O
plus NN O O
metronidazole NN O O
arm NN O O
compared NN O O
to NN O O
the NN O O
meropenem NN O O
arm NN O O
. NN O O
A NN O O
similar NN O O
trend NN O O
was NN O O
also NN O O
seen NN O O
in NN O O
the NN O O
cUTI NN O O
trial NN O O
. NN O O
Monitor NN O O
CrCl NN O O
at NN O O
least NN O O
daily NN O O
in NN O O
patients NN O O
with NN O O
changing NN O O
renal NN O O
function NN O O
and NN O O
adjust NN O O
the NN O O
dosage NN O O
of NN O O
ZERBAXA NN O O
accordingly NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
] NN O O
. NN O O
Table NN O O
4 NN O O
: NN O O
Clinical NN O O
Cure NN O O
Rates NN O O
in NN O O
a NN O O
Phase NN O O
3 NN O O
Trial NN O O
of NN O O
cIAI NN O O
by NN O O
Baseline NN O O
Renal NN O O
Function NN O O
( NN O O
MITT NN O O
Population NN O O
) NN O O
Baseline NN O O
Renal NN O O
Function NN O O
ZERBAXA NN O O
plus NN O O
metronidazolen/N NN O O
( NN O O
% NN O O
) NN O O
Meropenemn/N NN O O
( NN O O
% NN O O
) NN O O
Normal/mild NN O O
impairment(CrCl NN O O
>=50 NN O O
mL/min NN O O
) NN O O
312/366 NN O O
( NN O O
85.2 NN O O
) NN O O
355/404 NN O O
( NN O O
87.9 NN O O
) NN O O
Moderate NN O O
impairment(CrCl NN O O
30 NN O O
to NN O O
< NN O O
=50 NN O O
mL/min NN O O
) NN O O
11/23 NN O O
( NN O O
47.8 NN O O
) NN O O
9/13 NN O O
( NN O O
69.2 NN O O
) NN O O
5.2 NN O O
Hypersensitivity NN O O
Reactions NN O O
Serious NN B-Severity B-Severity
and NN O O
occasionally NN O O
fatal NN B-AdverseReaction B-AdverseReaction
hypersensitivity NN O O
( NN O O
anaphylactic NN O O
) NN O O
reactions NN O O
have NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
receiving NN O O
beta NN B-DrugClass B-DrugClass
- NN I-DrugClass I-DrugClass
lactam NN I-DrugClass I-DrugClass
antibacterial NN I-DrugClass I-DrugClass
drugs NN I-DrugClass I-DrugClass
Before NN O O
initiating NN O O
therapy NN O O
with NN O O
ZERBAXA NN O O
, NN O O
make NN O O
careful NN O O
inquiry NN O O
about NN O O
previous NN O O
hypersensitivity NN O O
reactions NN O O
to NN O O
other NN O O
cephalosporins NN O O
, NN O O
penicillins NN O O
, NN O O
or NN O O
other NN O O
beta NN O O
- NN O O
lactams NN O O
. NN O O
If NN O O
this NN O O
product NN O O
is NN O O
to NN O O
be NN O O
given NN O O
to NN O O
a NN O O
patient NN O O
with NN O O
a NN O O
cephalosporin NN O O
, NN O O
penicillin NN O O
, NN O O
or NN O O
other NN O O
beta NN O O
- NN O O
lactam NN O O
allergy NN O O
, NN O O
exercise NN O O
caution NN O O
because NN O O
cross NN O O
sensitivity NN O O
has NN O O
been NN O O
established NN O O
. NN O O
If NN O O
an NN O O
anaphylactic NN O O
reaction NN O O
to NN O O
ZERBAXA NN O O
occurs NN O O
, NN O O
discontinue NN O O
the NN O O
drug NN O O
and NN O O
institute NN O O
appropriate NN O O
therapy NN O O
. NN O O
5.3 NN O O
Clostridium NN O O
difficile NN O O
-associated NN O O
Diarrhea NN O O
Clostridium NN B-AdverseReaction B-AdverseReaction
difficile NN I-AdverseReaction I-AdverseReaction
-associated NN I-AdverseReaction I-AdverseReaction
diarrhea NN I-AdverseReaction I-AdverseReaction
( NN O O
CDAD NN O O
) NN O O
has NN O O
been NN O O
reported NN O O
for NN O O
nearly NN O O
all NN O O
systemic NN O O
antibacterial NN O O
agents NN O O
, NN O O
including NN O O
ZERBAXA NN O O
, NN O O
and NN O O
may NN O O
range NN O O
in NN O O
severity NN O O
from NN O O
mild NN B-Severity B-Severity
diarrhea NN B-AdverseReaction B-AdverseReaction
to NN O O
fatal NN B-AdverseReaction B-AdverseReaction
colitis NN B-AdverseReaction B-AdverseReaction
Treatment NN O O
with NN O O
antibacterial NN O O
agents NN O O
alters NN O O
the NN O O
normal NN O O
flora NN O O
of NN O O
the NN O O
colon NN O O
and NN O O
may NN O O
permit NN O O
overgrowth NN O O
of NN O O
C NN O O
. NN O O
difficile NN O O
. NN O O
C. NN O O
difficile NN O O
produces NN O O
toxins NN O O
A NN O O
and NN O O
B NN O O
which NN O O
contribute NN O O
to NN O O
the NN O O
development NN O O
of NN O O
CDAD. NN O O
CDAD NN O O
must NN O O
be NN O O
considered NN O O
in NN O O
all NN O O
patients NN O O
who NN O O
present NN O O
with NN O O
diarrhea NN O O
following NN O O
antibacterial NN O O
use NN O O
. NN O O
Careful NN O O
medical NN O O
history NN O O
is NN O O
necessary NN O O
because NN O O
CDAD NN O O
has NN O O
been NN O O
reported NN O O
to NN O O
occur NN O O
more NN O O
than NN O O
2 NN O O
months NN O O
after NN O O
the NN O O
administration NN O O
of NN O O
antibacterial NN O O
agents NN O O
. NN O O
If NN O O
CDAD NN O O
is NN O O
confirmed NN O O
, NN O O
discontinue NN O O
antibacterials NN O O
not NN O O
directed NN O O
against NN O O
C. NN O O
difficile NN O O
, NN O O
if NN O O
possible NN O O
. NN O O
Manage NN O O
fluid NN O O
and NN O O
electrolyte NN O O
levels NN O O
as NN O O
appropriate NN O O
, NN O O
supplement NN O O
protein NN O O
intake NN O O
, NN O O
monitor NN O O
antibacterial NN O O
treatment NN O O
of NN O O
C. NN O O
difficile NN O O
, NN O O
and NN O O
institute NN O O
surgical NN O O
evaluation NN O O
as NN O O
clinically NN O O
indicated NN O O
. NN O O
5.4 NN O O
Development NN O O
of NN O O
Drug NN O O
- NN O O
Resistant NN O O
Bacteria NN O O
Prescribing NN O O
ZERBAXA NN O O
in NN O O
the NN O O
absence NN O O
of NN O O
a NN O O
proven NN O O
or NN O O
strongly NN O O
suspected NN O O
bacterial NN O O
infection NN O O
is NN O O
unlikely NN O O
to NN O O
provide NN O O
benefit NN O O
to NN O O
the NN O O
patient NN O O
and NN O O
risks NN O O
the NN O O
development NN O O
of NN O O
drug NN O O
- NN O O
resistant NN O O
bacteria NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
serious NN O O
adverse NN O O
reactions NN O O
are NN O O
discussed NN O O
in NN O O
greater NN O O
detail NN O O
in NN O O
other NN O O
sections NN O O
of NN O O
the NN O O
label NN O O
: NN O O
* NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Pancreatitis NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
Glucose NN B-AdverseReaction B-AdverseReaction
intolerance NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
* NN O O
Thrombosis NN B-AdverseReaction B-AdverseReaction
and NN O O
hemorrhage NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
incidence NN O O
1 NN O O
% NN O O
or NN O O
greater NN O O
) NN O O
with NN O O
ERWINAZE NN O O
treatment NN O O
are NN O O
systemic NN B-AdverseReaction B-AdverseReaction
hypersensitivity NN I-AdverseReaction I-AdverseReaction
hyperglycemia NN B-AdverseReaction B-AdverseReaction
transaminases NN B-AdverseReaction B-AdverseReaction
abnormal NN I-AdverseReaction I-AdverseReaction
fever NN B-AdverseReaction B-AdverseReaction
pancreatitis NN B-AdverseReaction B-AdverseReaction
local NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
thrombosis NN B-AdverseReaction B-AdverseReaction
hyperbilirubinemia NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
and NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
EXCERPT NN O O
: NN O O
Most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
incidence NN O O
1 NN O O
% NN O O
or NN O O
greater NN O O
) NN O O
are NN O O
: NN O O
systemic NN B-AdverseReaction B-AdverseReaction
hypersensitivity NN I-AdverseReaction I-AdverseReaction
hyperglycemia NN B-AdverseReaction B-AdverseReaction
transaminases NN B-AdverseReaction B-AdverseReaction
abnormal NN I-AdverseReaction I-AdverseReaction
fever NN B-AdverseReaction B-AdverseReaction
pancreatitis NN B-AdverseReaction B-AdverseReaction
local NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
thrombosis NN B-AdverseReaction B-AdverseReaction
hyperbilirubinemia NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
and NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Jazz NN O O
Pharmaceuticals NN O O
, NN O O
Inc. NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
520 NN O O
- NN O O
5568 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
6.1 NN O O
Clinical NN O O
Studies NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
controlled NN O O
, NN O O
but NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
trials NN O O
of NN O O
ERWINAZE NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
other NN O O
drugs NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
The NN O O
data NN O O
presented NN O O
below NN O O
are NN O O
based NN O O
on NN O O
information NN O O
collected NN O O
from NN O O
Study NN O O
1 NN O O
, NN O O
a NN O O
single NN O O
- NN O O
arm NN O O
, NN O O
multi NN O O
- NN O O
center NN O O
, NN O O
open NN O O
- NN O O
label NN O O
, NN O O
safety NN O O
and NN O O
clinical NN O O
pharmacology NN O O
trial NN O O
( NN O O
intramuscular NN O O
administration NN O O
) NN O O
, NN O O
the NN O O
ERWINAZE NN O O
Master NN O O
Treatment NN O O
Protocol NN O O
( NN O O
EMTP NN O O
) NN O O
, NN O O
an NN O O
expanded NN O O
access NN O O
program NN O O
( NN O O
both NN O O
intramuscular NN O O
, NN O O
intravenous NN O O
, NN O O
and NN O O
other NN O O
or NN O O
unknown NN O O
administration NN O O
) NN O O
, NN O O
and NN O O
Study NN O O
2 NN O O
, NN O O
a NN O O
single NN O O
- NN O O
arm NN O O
, NN O O
multi NN O O
- NN O O
center NN O O
, NN O O
open NN O O
- NN O O
label NN O O
, NN O O
pharmacokinetic NN O O
( NN O O
PK NN O O
) NN O O
study NN O O
trial NN O O
of NN O O
intravenous NN O O
administration NN O O
of NN O O
ERWINAZE.Study NN O O
1 NN O O
enrolled NN O O
58 NN O O
patients NN O O
treated NN O O
on NN O O
National NN O O
Cancer NN O O
Institute NN O O
( NN O O
NCI)-sponsored NN O O
cooperative NN O O
group NN O O
ALL NN O O
protocols NN O O
who NN O O
were NN O O
unable NN O O
to NN O O
continue NN O O
to NN O O
receive NN O O
pegaspargase NN O O
due NN O O
to NN O O
hypersensitivity NN O O
reactions NN O O
. NN O O
Patients NN O O
received NN O O
6 NN O O
doses NN O O
of NN O O
ERWINAZE NN O O
25,000 NN O O
International NN O O
Units/m NN O O
2 NN O O
intramuscularly NN O O
on NN O O
a NN O O
Monday NN O O
, NN O O
Wednesday NN O O
, NN O O
and NN O O
Friday NN O O
schedule NN O O
as NN O O
a NN O O
replacement NN O O
for NN O O
each NN O O
scheduled NN O O
dose NN O O
of NN O O
pegaspargase NN O O
remaining NN O O
on NN O O
their NN O O
original NN O O
treatment NN O O
protocol NN O O
. NN O O
The NN O O
Study NN O O
1 NN O O
population NN O O
included NN O O
patients NN O O
with NN O O
a NN O O
median NN O O
age NN O O
of NN O O
11 NN O O
years NN O O
( NN O O
2 NN O O
to NN O O
18 NN O O
years NN O O
) NN O O
; NN O O
59 NN O O
% NN O O
were NN O O
male NN O O
, NN O O
78 NN O O
% NN O O
were NN O O
White NN O O
, NN O O
10 NN O O
% NN O O
were NN O O
Black/African NN O O
American NN O O
, NN O O
5 NN O O
% NN O O
were NN O O
Asian NN O O
, NN O O
and NN O O
7 NN O O
% NN O O
were NN O O
other NN O O
or NN O O
unknown NN O O
. NN O O
A NN O O
total NN O O
of NN O O
35 NN O O
% NN O O
were NN O O
Hispanic NN O O
or NN O O
Latino NN O O
. NN O O
In NN O O
Study NN O O
1 NN O O
, NN O O
the NN O O
number NN O O
of NN O O
ERWINAZE NN O O
courses NN O O
ranged NN O O
from NN O O
1 NN O O
to NN O O
9 NN O O
. NN O O
In NN O O
this NN O O
study NN O O
, NN O O
76 NN O O
% NN O O
( NN O O
44 NN O O
of NN O O
58 NN O O
) NN O O
completed NN O O
all NN O O
planned NN O O
therapy NN O O
. NN O O
Fourteen NN O O
( NN O O
24 NN O O
% NN O O
) NN O O
patients NN O O
stopped NN O O
therapy NN O O
prior NN O O
to NN O O
completion NN O O
; NN O O
seven NN O O
due NN O O
to NN O O
allergic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
five NN O O
due NN O O
to NN O O
physician NN O O
or NN O O
patient NN O O
choice NN O O
, NN O O
one NN O O
due NN O O
to NN O O
disease NN O O
progression NN O O
, NN O O
and NN O O
one NN O O
due NN O O
to NN O O
discontinuation NN O O
during NN O O
frontline NN O O
protocol NN O O
. NN O O
All NN O O
other NN O O
chemotherapy NN O O
was NN O O
continued NN O O
according NN O O
to NN O O
the NN O O
patient NN O O
's NN O O
prescribed NN O O
treatment NN O O
regimen NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
].Study NN O O
2 NN O O
enrolled NN O O
30 NN O O
patients NN O O
[ NN O O
29 NN O O
were NN O O
being NN O O
treated NN O O
for NN O O
ALL NN O O
and NN O O
one NN O O
for NN O O
lymphoblastic NN O O
lymphoma NN O O
( NN O O
LBL NN O O
) NN O O
] NN O O
following NN O O
allergy NN O O
to NN O O
native NN O O
E. NN O O
coli NN O O
asparaginase NN O O
or NN O O
pegaspargase NN O O
. NN O O
Patients NN O O
received NN O O
ERWINAZE NN O O
25,000 NN O O
International NN O O
Unit/m NN O O
2 NN O O
/dose NN O O
, NN O O
administered NN O O
by NN O O
intravenous NN O O
infusion NN O O
on NN O O
a NN O O
Monday NN O O
, NN O O
Wednesday NN O O
, NN O O
and NN O O
Friday NN O O
schedule NN O O
( NN O O
6 NN O O
doses NN O O
) NN O O
as NN O O
a NN O O
replacement NN O O
for NN O O
doses NN O O
remaining NN O O
on NN O O
their NN O O
original NN O O
treatment NN O O
plan NN O O
. NN O O
The NN O O
Study NN O O
2 NN O O
population NN O O
included NN O O
patients NN O O
with NN O O
a NN O O
median NN O O
age NN O O
of NN O O
7 NN O O
years NN O O
( NN O O
1 NN O O
to NN O O
17 NN O O
years NN O O
) NN O O
; NN O O
63 NN O O
% NN O O
were NN O O
male NN O O
, NN O O
27 NN O O
% NN O O
were NN O O
Hispanic NN O O
or NN O O
Latino NN O O
, NN O O
83 NN O O
% NN O O
were NN O O
White NN O O
, NN O O
3 NN O O
% NN O O
were NN O O
Black/African NN O O
American NN O O
, NN O O
7 NN O O
% NN O O
were NN O O
Asian NN O O
, NN O O
and NN O O
7 NN O O
% NN O O
were NN O O
other NN O O
( NN O O
American NN O O
Indian NN O O
, NN O O
Alaska NN O O
Native NN O O
or NN O O
Indian NN O O
) NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
EMTP NN O O
trial NN O O
enrolled NN O O
1368 NN O O
patients NN O O
with NN O O
ALL NN O O
or NN O O
lymphoblastic NN O O
lymphoma NN O O
who NN O O
received NN O O
ERWINAZE NN O O
after NN O O
developing NN O O
systemic NN O O
hypersensitivity NN O O
to NN O O
an NN O O
E. NN O O
coli NN O O
-derived NN O O
asparaginase NN O O
. NN O O
Of NN O O
these NN O O
1368 NN O O
patients NN O O
, NN O O
safety NN O O
data NN O O
were NN O O
received NN O O
for NN O O
940 NN O O
patients NN O O
with NN O O
a NN O O
median NN O O
age NN O O
of NN O O
9 NN O O
years NN O O
( NN O O
0 NN O O
to NN O O
76 NN O O
years NN O O
) NN O O
, NN O O
63 NN O O
% NN O O
were NN O O
male NN O O
, NN O O
91 NN O O
% NN O O
with NN O O
leukemia NN O O
, NN O O
3 NN O O
% NN O O
with NN O O
lymphoma NN O O
, NN O O
and NN O O
6 NN O O
% NN O O
with NN O O
unknown NN O O
disease NN O O
information NN O O
. NN O O
Patients NN O O
received NN O O
ERWINAZE NN O O
according NN O O
to NN O O
several NN O O
schedules NN O O
, NN O O
and NN O O
treatment NN O O
center NN O O
specifications NN O O
with NN O O
doses NN O O
that NN O O
ranged NN O O
from NN O O
20,000 NN O O
to NN O O
25,000 NN O O
International NN O O
Units/m NN O O
2 NN O O
. NN O O
The NN O O
route NN O O
of NN O O
administration NN O O
was NN O O
intramuscular NN O O
n=852 NN O O
, NN O O
intravenous NN O O
n=29 NN O O
, NN O O
other NN O O
or NN O O
unknown NN O O
n=59 NN O O
. NN O O
In NN O O
the NN O O
EMTP NN O O
trial NN O O
, NN O O
the NN O O
planned NN O O
number NN O O
of NN O O
doses NN O O
of NN O O
ERWINAZE NN O O
ranged NN O O
from NN O O
3 NN O O
to NN O O
48 NN O O
doses NN O O
. NN O O
Seventy NN O O
- NN O O
eight NN O O
percent NN O O
of NN O O
patients NN O O
( NN O O
693 NN O O
of NN O O
893 NN O O
) NN O O
were NN O O
able NN O O
to NN O O
receive NN O O
all NN O O
planned NN O O
doses NN O O
to NN O O
complete NN O O
their NN O O
prescribed NN O O
treatment NN O O
regimen NN O O
. NN O O
In NN O O
Study NN O O
1 NN O O
and NN O O
Study NN O O
2 NN O O
, NN O O
safety NN O O
information NN O O
was NN O O
prospectively NN O O
and NN O O
systematically NN O O
collected NN O O
. NN O O
In NN O O
Study NN O O
1 NN O O
, NN O O
all NN O O
Grades NN O O
of NN O O
adverse NN O O
events NN O O
were NN O O
reported NN O O
for NN O O
the NN O O
following NN O O
adverse NN O O
events NN O O
of NN O O
special NN O O
interest NN O O
: NN O O
allergy NN B-AdverseReaction B-AdverseReaction
pancreatitis NN B-AdverseReaction B-AdverseReaction
coagulopathy NN B-AdverseReaction B-AdverseReaction
( NN O O
hemorrhage NN O O
, NN O O
thrombosis NN B-AdverseReaction B-AdverseReaction
or NN O O
infarct NN B-AdverseReaction B-AdverseReaction
hyperbilirubinemia NN B-AdverseReaction B-AdverseReaction
hyperglycemia NN B-AdverseReaction B-AdverseReaction
hyperlipidemia NN B-AdverseReaction B-AdverseReaction
ketoacidosis NN B-AdverseReaction B-AdverseReaction
and NN O O
CNS NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
( NN O O
hemorrhage NN O O
, NN O O
thrombosis NN O O
or NN O O
infarction NN O O
, NN O O
and NN O O
cerebral NN B-AdverseReaction B-AdverseReaction
venous NN I-AdverseReaction I-AdverseReaction
thrombosis NN I-AdverseReaction I-AdverseReaction
and NN O O
only NN O O
Grade NN O O
3 NN O O
and NN O O
4 NN O O
events NN O O
were NN O O
reported NN O O
for NN O O
other NN O O
adverse NN O O
events NN O O
. NN O O
In NN O O
Study NN O O
2 NN O O
all NN O O
adverse NN O O
events NN O O
of NN O O
all NN O O
Grades NN O O
were NN O O
prospectively NN O O
collected NN O O
. NN O O
In NN O O
the NN O O
EMTP NN O O
trial NN O O
, NN O O
safety NN O O
data NN O O
were NN O O
derived NN O O
from NN O O
case NN O O
report NN O O
forms NN O O
that NN O O
collected NN O O
adverse NN O O
event NN O O
information NN O O
. NN O O
The NN O O
forms NN B-Factor B-Factor
specifically NN I-Factor I-Factor
requested NN I-Factor I-Factor
information NN I-Factor I-Factor
on NN O O
occurrence NN O O
of NN O O
allergic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
thrombotic NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
hemorrhagic NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
hepatobiliary NN B-AdverseReaction B-AdverseReaction
disorders NN I-AdverseReaction I-AdverseReaction
pancreatic NN B-AdverseReaction B-AdverseReaction
disorders NN I-AdverseReaction I-AdverseReaction
and NN O O
hyperglycemia NN B-AdverseReaction B-AdverseReaction
The NN O O
incidence NN O O
of NN O O
non NN O O
- NN O O
hematologic NN O O
, NN O O
non NN O O
- NN O O
infectious NN O O
, NN O O
adverse NN O O
events NN O O
( NN O O
all NN O O
Grades NN O O
) NN O O
in NN O O
Study NN O O
1 NN O O
, NN O O
Study NN O O
2 NN O O
, NN O O
and NN O O
the NN O O
EMTP NN O O
trial NN O O
is NN O O
provided NN O O
in NN O O
Table NN O O
1 NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
Grade NN O O
3 NN O O
or NN O O
greater NN O O
non NN O O
- NN O O
hematologic NN O O
, NN O O
non NN O O
- NN O O
infectious NN O O
adverse NN O O
reactions NN O O
occurring NN O O
with NN O O
ERWINAZE NN O O
in NN O O
Study NN O O
1 NN O O
, NN O O
Study NN O O
2 NN O O
and NN O O
EMTP NN O O
trial NN O O
is NN O O
provided NN O O
in NN O O
Table NN O O
2 NN O O
. NN O O
Table NN O O
1 NN O O
Table NN O O
2 NN O O
6.2 NN O O
Immunogenicity NN O O
As NN O O
with NN O O
most NN O O
therapeutic NN O O
proteins NN O O
, NN O O
patients NN O O
may NN O O
develop NN O O
anti NN O O
- NN O O
drug NN O O
antibodies NN O O
( NN O O
ADA NN O O
) NN O O
to NN O O
ERWINAZE.In NN O O
a NN O O
study NN O O
with NN O O
ERWINAZE NN O O
treatment NN O O
by NN O O
intramuscular NN O O
administration NN O O
( NN O O
Study NN O O
1 NN O O
) NN O O
, NN O O
6 NN O O
of NN O O
56 NN O O
( NN O O
11 NN O O
% NN O O
) NN O O
patients NN O O
treated NN O O
with NN O O
ERWINAZE NN O O
developed NN O O
antibodies NN O O
to NN O O
ERWINAZE. NN O O
Of NN O O
these NN O O
6 NN O O
ADA NN O O
positive NN O O
patients NN O O
, NN O O
one NN O O
experienced NN O O
a NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
during NN O O
Study NN O O
1 NN O O
( NN O O
2 NN O O
% NN O O
, NN O O
1 NN O O
of NN O O
56 NN O O
) NN O O
. NN O O
None NN O O
of NN O O
these NN O O
6 NN O O
patients NN O O
had NN O O
neutralizing NN O O
antibodies NN O O
. NN O O
In NN O O
a NN O O
study NN O O
with NN O O
ERWINAZE NN O O
treatment NN O O
by NN O O
intravenous NN O O
administration NN O O
( NN O O
Study NN O O
2 NN O O
) NN O O
, NN O O
4 NN O O
of NN O O
30 NN O O
( NN O O
13.3 NN O O
% NN O O
) NN O O
patients NN O O
treated NN O O
with NN O O
ERWINAZE NN O O
developed NN O O
anti NN O O
- NN O O
ERWINAZE NN O O
antibodies NN O O
. NN O O
Of NN O O
these NN O O
4 NN O O
patients NN O O
who NN O O
developed NN O O
anti NN O O
- NN O O
ERWINAZE NN O O
antibodies NN O O
, NN O O
3 NN O O
experienced NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
( NN O O
10 NN O O
% NN O O
, NN O O
3 NN O O
of NN O O
30 NN O O
) NN O O
during NN O O
the NN O O
study NN O O
. NN O O
None NN O O
of NN O O
these NN O O
4 NN O O
patients NN O O
had NN O O
neutralizing NN O O
antibodies NN O O
. NN O O
The NN O O
presence NN O O
of NN O O
ADA NN O O
to NN O O
ERWINAZE NN O O
is NN O O
associated NN O O
with NN O O
a NN O O
higher NN O O
risk NN B-Factor B-Factor
of NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
in NN O O
patients NN O O
who NN O O
received NN O O
ERWINAZE NN O O
through NN O O
intravenous NN O O
infusion NN O O
compared NN O O
to NN O O
intramuscular NN O O
administration NN O O
of NN O O
ERWINAZE.Immunogenicity NN O O
assay NN O O
are NN O O
highly NN O O
dependent NN O O
on NN O O
the NN O O
sensitivity NN O O
and NN O O
specificity NN O O
of NN O O
the NN O O
assay NN O O
and NN O O
may NN O O
be NN O O
influenced NN O O
by NN O O
several NN O O
factors NN O O
such NN O O
as NN O O
: NN O O
assay NN O O
methodology NN O O
, NN O O
sample NN O O
handling NN O O
, NN O O
timing NN O O
of NN O O
sample NN O O
collection NN O O
, NN O O
concomitant NN O O
medications NN O O
, NN O O
and NN O O
underlying NN O O
disease NN O O
. NN O O
For NN O O
these NN O O
reasons NN O O
, NN O O
comparison NN O O
of NN O O
the NN O O
incidence NN O O
of NN O O
antibodies NN O O
to NN O O
ERWINAZE NN O O
with NN O O
the NN O O
incidence NN O O
of NN O O
antibodies NN O O
to NN O O
other NN O O
products NN O O
may NN O O
be NN O O
misleading NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
If NN O O
the NN O O
following NN O O
occur NN O O
, NN O O
discontinue NN O O
ERWINAZE:Serious NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
( NN O O
5.1)Severe NN O O
or NN O O
hemorrhagic NN B-AdverseReaction B-AdverseReaction
pancreatitis NN I-AdverseReaction I-AdverseReaction
( NN O O
5.2 NN O O
) NN O O
* NN O O
Glucose NN B-AdverseReaction B-AdverseReaction
intolerance NN I-AdverseReaction I-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
and NN O O
, NN O O
in NN O O
some NN O O
cases NN O O
, NN O O
may NN O O
be NN O O
irreversible NN B-Severity B-Severity
Perform NN O O
appropriate NN O O
monitoring NN O O
and NN O O
treat NN O O
hyperglycemia NN O O
with NN O O
insulin NN O O
, NN O O
as NN O O
necessary NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Thrombosis NN B-AdverseReaction B-AdverseReaction
hemorrhage NN B-AdverseReaction B-AdverseReaction
discontinue NN O O
ERWINAZE NN O O
until NN O O
resolved NN O O
( NN O O
5.4 NN O O
) NN O O
5.1 NN O O
Hypersensitivity NN O O
Reactions NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
and NN O O
4 NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
after NN O O
the NN O O
use NN O O
of NN O O
ERWINAZE NN O O
have NN O O
occurred NN O O
in NN O O
5 NN O O
% NN O O
of NN O O
patients NN O O
in NN O O
clinical NN O O
trials NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Administer NN O O
this NN O O
product NN O O
in NN O O
a NN O O
setting NN O O
with NN O O
resuscitation NN O O
equipment NN O O
and NN O O
other NN O O
agents NN O O
necessary NN O O
to NN O O
treat NN O O
anaphylaxis NN O O
. NN O O
If NN O O
a NN O O
serious NN O O
hypersensitivity NN O O
reaction NN O O
occurs NN O O
, NN O O
discontinue NN O O
ERWINAZE NN O O
and NN O O
initiate NN O O
appropriate NN O O
therapy NN O O
. NN O O
5.2 NN O O
Pancreatitis NN O O
Pancreatitis NN B-AdverseReaction B-AdverseReaction
has NN O O
been NN O O
reported NN O O
in NN O O
4 NN O O
% NN O O
of NN O O
patients NN O O
in NN O O
clinical NN O O
trials NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Evaluate NN O O
patients NN O O
with NN O O
symptoms NN O O
compatible NN O O
with NN O O
pancreatitis NN O O
to NN O O
establish NN O O
a NN O O
diagnosis NN O O
. NN O O
Discontinue NN O O
ERWINAZE NN O O
for NN O O
severe NN O O
or NN O O
hemorrhagic NN O O
pancreatitis NN O O
manifested NN O O
by NN O O
abdominal NN O O
pain NN O O
> NN O O
72 NN O O
hours NN O O
and NN O O
amylase NN O O
elevation NN O O
>= NN O O
2.0 NN O O
x NN O O
ULN. NN O O
Severe NN O O
pancreatitis NN O O
is NN O O
a NN O O
contraindication NN O O
to NN O O
additional NN O O
asparaginase NN O O
administration NN O O
. NN O O
In NN O O
the NN O O
case NN O O
of NN O O
mild NN O O
pancreatitis NN O O
, NN O O
hold NN O O
ERWINAZE NN O O
until NN O O
the NN O O
signs NN O O
and NN O O
symptoms NN O O
subside NN O O
and NN O O
amylase NN O O
levels NN O O
return NN O O
to NN O O
normal NN O O
. NN O O
After NN O O
resolution NN O O
, NN O O
treatment NN O O
with NN O O
ERWINAZE NN O O
may NN O O
be NN O O
resumed NN O O
. NN O O
5.3 NN O O
Glucose NN O O
Intolerance NN O O
Glucose NN O O
intolerance NN O O
has NN O O
been NN O O
reported NN O O
in NN O O
5 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
ERWINAZE NN O O
in NN O O
clinical NN O O
trials NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
In NN O O
some NN O O
cases NN O O
glucose NN B-AdverseReaction B-AdverseReaction
intolerance NN I-AdverseReaction I-AdverseReaction
may NN O O
be NN O O
irreversible NN B-Severity B-Severity
Monitor NN O O
glucose NN O O
levels NN O O
in NN O O
patients NN O O
at NN O O
baseline NN O O
and NN O O
periodically NN O O
during NN O O
treatment NN O O
. NN O O
Administer NN O O
insulin NN O O
therapy NN O O
as NN O O
necessary NN O O
in NN O O
patients NN O O
with NN O O
hyperglycemia NN O O
. NN O O
5.4 NN O O
Thrombosis NN O O
and NN O O
Hemorrhage NN O O
Serious NN B-Severity B-Severity
thrombotic NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
including NN O O
sagittal NN B-AdverseReaction B-AdverseReaction
sinus NN I-AdverseReaction I-AdverseReaction
thrombosis NN I-AdverseReaction I-AdverseReaction
and NN O O
pulmonary NN B-AdverseReaction B-AdverseReaction
embolism NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
with NN O O
both NN O O
E. NN O O
coli NN O O
and NN O O
Erwinia NN O O
-derived NN O O
L NN O O
- NN O O
asparaginase NN O O
therapy NN O O
. NN O O
The NN O O
following NN O O
coagulation NN O O
proteins NN O O
were NN O O
decreased NN O O
in NN O O
the NN O O
majority NN O O
of NN O O
patients NN O O
after NN O O
a NN O O
2-week NN O O
course NN O O
of NN O O
ERWINAZE NN O O
by NN O O
intramuscular NN O O
administration NN O O
: NN O O
fibrinogen NN O O
, NN O O
protein NN O O
C NN O O
activity NN O O
, NN O O
protein NN O O
S NN O O
activity NN O O
, NN O O
and NN O O
anti NN O O
- NN O O
thrombin NN O O
III. NN O O
Discontinue NN O O
ERWINAZE NN O O
for NN O O
a NN O O
thrombotic NN O O
or NN O O
hemorrhagic NN O O
event NN O O
until NN O O
symptoms NN O O
resolve NN O O
; NN O O
after NN O O
resolution NN O O
, NN O O
treatment NN O O
with NN O O
ERWINAZE NN O O
may NN O O
be NN O O
resumed NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
EXCERPT NN O O
: NN O O
Most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
2 NN O O
% NN O O
) NN O O
include NN O O
headache NN B-AdverseReaction B-AdverseReaction
flushing NN B-AdverseReaction B-AdverseReaction
nasal NN B-AdverseReaction B-AdverseReaction
congestion NN I-AdverseReaction I-AdverseReaction
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
and NN O O
back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
1 NN O O
- NN O O
877 NN O O
- NN O O
663 NN O O
- NN O O
0412 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
STENDRA NN O O
was NN O O
administered NN O O
to NN O O
2215 NN O O
men NN O O
during NN O O
clinical NN O O
trials NN O O
. NN O O
In NN O O
trials NN O O
of NN O O
STENDRA NN O O
for NN O O
use NN O O
as NN O O
needed NN O O
, NN O O
a NN O O
total NN O O
of NN O O
493 NN O O
patients NN O O
were NN O O
exposed NN O O
for NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
6 NN O O
months NN O O
, NN O O
and NN O O
153 NN O O
patients NN O O
were NN O O
treated NN O O
for NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
12 NN O O
months NN O O
. NN O O
In NN O O
three NN O O
randomized NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
lasting NN O O
up NN O O
to NN O O
3 NN O O
months NN O O
in NN O O
duration NN O O
, NN O O
the NN O O
mean NN O O
age NN O O
of NN O O
patients NN O O
was NN O O
56.4 NN O O
years NN O O
( NN O O
range NN O O
from NN O O
23 NN O O
to NN O O
88 NN O O
years NN O O
) NN O O
. NN O O
83.9 NN O O
% NN O O
of NN O O
patients NN O O
were NN O O
White NN O O
, NN O O
13.8 NN O O
% NN O O
were NN O O
Black NN O O
, NN O O
1.4 NN O O
% NN O O
Asian NN O O
, NN O O
and NN O O
< NN O O
1 NN O O
% NN O O
Hispanic NN O O
. NN O O
41.1 NN O O
% NN O O
were NN O O
current NN O O
or NN O O
previous NN O O
smokers NN O O
. NN O O
30.6 NN O O
% NN O O
had NN O O
diabetes NN O O
mellitus NN O O
. NN O O
The NN O O
discontinuation NN O O
rate NN O O
due NN O O
to NN O O
adverse NN O O
reactions NN O O
for NN O O
patients NN O O
treated NN O O
with NN O O
STENDRA NN O O
50 NN O O
mg NN O O
, NN O O
100 NN O O
mg NN O O
, NN O O
or NN O O
200 NN O O
mg NN O O
was NN O O
1.4 NN O O
% NN O O
, NN O O
2.0 NN O O
% NN O O
, NN O O
and NN O O
2.0 NN O O
% NN O O
, NN O O
respectively NN O O
, NN O O
compared NN O O
to NN O O
1.7 NN O O
% NN O O
for NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Table NN O O
1 NN O O
presents NN O O
the NN O O
adverse NN O O
reactions NN O O
reported NN O O
when NN O O
STENDRA NN O O
was NN O O
taken NN O O
as NN O O
recommended NN O O
( NN O O
on NN O O
an NN O O
as NN O O
- NN O O
needed NN O O
basis NN O O
) NN O O
from NN O O
these NN O O
3 NN O O
clinical NN O O
trials NN O O
. NN O O
Table NN O O
1 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Reported NN O O
by NN O O
Greater NN O O
Than NN O O
or NN O O
Equal NN O O
to NN O O
2 NN O O
% NN O O
of NN O O
Patients NN O O
Treated NN O O
with NN O O
STENDRA NN O O
From NN O O
3 NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Clinical NN O O
Trials NN O O
Lasting NN O O
3 NN O O
Months NN O O
for NN O O
STENDRA NN O O
Use NN O O
as NN O O
Needed NN O O
Adverse NN O O
Reaction NN O O
Placebo(N NN O O
= NN O O
349 NN O O
) NN O O
STENDRA NN O O
50 NN O O
mg(N NN O O
= NN O O
217 NN O O
) NN O O
STENDRA NN O O
100 NN O O
mg(N NN O O
= NN O O
349 NN O O
) NN O O
STENDRA NN O O
200 NN O O
mg(N NN O O
= NN O O
352 NN O O
) NN O O
Headache NN B-AdverseReaction B-AdverseReaction
1.7 NN O O
% NN O O
5.1 NN O O
% NN O O
6.9 NN O O
% NN O O
10.5 NN O O
% NN O O
Flushing NN B-AdverseReaction B-AdverseReaction
0.0 NN O O
% NN O O
3.2 NN O O
% NN O O
4.3 NN O O
% NN O O
4.0 NN O O
% NN O O
Nasal NN B-AdverseReaction B-AdverseReaction
congestion NN I-AdverseReaction I-AdverseReaction
1.1 NN O O
% NN O O
1.8 NN O O
% NN O O
2.9 NN O O
% NN O O
2.0 NN O O
% NN O O
Nasopharyngitis NN B-AdverseReaction B-AdverseReaction
2.9 NN O O
% NN O O
0.9 NN O O
% NN O O
2.6 NN O O
% NN O O
3.4 NN O O
% NN O O
Back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
1.1 NN O O
% NN O O
3.2 NN O O
% NN O O
2.0 NN O O
% NN O O
1.1 NN O O
% NN O O
Adverse NN O O
reactions NN O O
reported NN O O
by NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
1 NN O O
% NN O O
, NN O O
but NN O O
less NN O O
than NN O O
2 NN O O
% NN O O
of NN O O
patients NN O O
in NN O O
any NN O O
STENDRA NN O O
dose NN O O
group NN O O
, NN O O
and NN O O
greater NN O O
than NN O O
placebo NN O O
included NN O O
: NN O O
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
( NN O O
URI NN O O
) NN O O
, NN O O
bronchitis NN B-AdverseReaction B-AdverseReaction
influenza NN B-AdverseReaction B-AdverseReaction
sinusitis NN B-AdverseReaction B-AdverseReaction
sinus NN B-AdverseReaction B-AdverseReaction
congestion NN I-AdverseReaction I-AdverseReaction
hypertension NN B-AdverseReaction B-AdverseReaction
dyspepsia NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
constipation NN B-AdverseReaction B-AdverseReaction
and NN O O
rash NN B-AdverseReaction B-AdverseReaction
In NN O O
an NN O O
open NN O O
- NN O O
label NN O O
, NN O O
long NN O O
- NN O O
term NN O O
extension NN O O
study NN O O
of NN O O
two NN O O
of NN O O
these NN O O
randomized NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
, NN O O
the NN O O
total NN O O
duration NN O O
of NN O O
treatment NN O O
was NN O O
up NN O O
to NN O O
52 NN O O
weeks NN O O
. NN O O
Among NN O O
the NN O O
712 NN O O
patients NN O O
who NN O O
participated NN O O
in NN O O
this NN O O
open NN O O
- NN O O
label NN O O
extension NN O O
study NN O O
, NN O O
the NN O O
mean NN O O
age NN O O
of NN O O
the NN O O
population NN O O
was NN O O
56.4 NN O O
years NN O O
( NN O O
range NN O O
from NN O O
23 NN O O
to NN O O
88 NN O O
years NN O O
) NN O O
. NN O O
The NN O O
discontinuation NN O O
rate NN O O
due NN O O
to NN O O
adverse NN O O
reactions NN O O
for NN O O
patients NN O O
treated NN O O
with NN O O
STENDRA NN O O
( NN O O
50 NN O O
mg NN O O
, NN O O
100 NN O O
mg NN O O
, NN O O
or NN O O
200 NN O O
mg NN O O
) NN O O
was NN O O
2.8 NN O O
% NN O O
. NN O O
In NN O O
this NN O O
extension NN O O
trial NN O O
, NN O O
all NN O O
eligible NN O O
patients NN O O
were NN O O
initially NN O O
assigned NN O O
to NN O O
STENDRA NN O O
100 NN O O
mg NN O O
. NN O O
At NN O O
any NN O O
point NN O O
during NN O O
the NN O O
trial NN O O
, NN O O
patients NN O O
could NN O O
request NN O O
to NN O O
have NN O O
their NN O O
dose NN O O
of NN O O
STENDRA NN O O
increased NN O O
to NN O O
200 NN O O
mg NN O O
or NN O O
decreased NN O O
to NN O O
50 NN O O
mg NN O O
based NN O O
on NN O O
their NN O O
individual NN O O
response NN O O
to NN O O
treatment NN O O
. NN O O
In NN O O
total NN O O
, NN O O
536 NN O O
( NN O O
approximately NN O O
75 NN O O
% NN O O
) NN O O
patients NN O O
increased NN O O
their NN O O
dose NN O O
to NN O O
200 NN O O
mg NN O O
and NN O O
5 NN O O
( NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
) NN O O
patients NN O O
reduced NN O O
their NN O O
dose NN O O
to NN O O
50 NN O O
mg NN O O
. NN O O
Table NN O O
2 NN O O
presents NN O O
the NN O O
adverse NN O O
reactions NN O O
reported NN O O
when NN O O
STENDRA NN O O
was NN O O
taken NN O O
as NN O O
recommended NN O O
( NN O O
on NN O O
an NN O O
as NN O O
- NN O O
needed NN O O
basis NN O O
) NN O O
in NN O O
this NN O O
open NN O O
- NN O O
label NN O O
extension NN O O
trial NN O O
. NN O O
Table NN O O
2 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Reported NN O O
by NN O O
Greater NN O O
Than NN O O
or NN O O
Equal NN O O
to NN O O
2 NN O O
% NN O O
of NN O O
Patients NN O O
Treated NN O O
With NN O O
STENDRA NN O O
in NN O O
an NN O O
Open NN O O
- NN O O
Label NN O O
Extension NN O O
Trial NN O O
Adverse NN O O
Reaction NN O O
STENDRA(N NN O O
= NN O O
711 NN O O
) NN O O
Headache NN B-AdverseReaction B-AdverseReaction
5.6 NN O O
% NN O O
Flushing NN B-AdverseReaction B-AdverseReaction
3.5 NN O O
% NN O O
Nasopharyngitis NN B-AdverseReaction B-AdverseReaction
3.4 NN O O
% NN O O
Nasal NN B-AdverseReaction B-AdverseReaction
congestion NN I-AdverseReaction I-AdverseReaction
2.1 NN O O
% NN O O
Adverse NN O O
reactions NN O O
reported NN O O
by NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
1 NN O O
% NN O O
, NN O O
but NN O O
less NN O O
than NN O O
2 NN O O
% NN O O
of NN O O
patients NN O O
in NN O O
the NN O O
open NN O O
- NN O O
label NN O O
extension NN O O
study NN O O
included NN O O
: NN O O
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
( NN O O
URI NN O O
) NN O O
, NN O O
influenza NN B-AdverseReaction B-AdverseReaction
sinusitis NN B-AdverseReaction B-AdverseReaction
bronchitis NN B-AdverseReaction B-AdverseReaction
dizziness NN B-AdverseReaction B-AdverseReaction
back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
arthralgia NN B-AdverseReaction B-AdverseReaction
hypertension NN B-AdverseReaction B-AdverseReaction
and NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
The NN O O
following NN O O
events NN O O
occurred NN O O
in NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
of NN O O
patients NN O O
in NN O O
the NN O O
three NN O O
placebo NN O O
- NN O O
controlled NN O O
3-month NN O O
clinical NN O O
trials NN O O
and/or NN O O
the NN O O
open NN O O
- NN O O
label NN O O
, NN O O
long NN O O
- NN O O
term NN O O
extension NN O O
study NN O O
lasting NN O O
12 NN O O
months NN O O
. NN O O
A NN O O
causal NN O O
relationship NN O O
to NN O O
STENDRA NN O O
is NN O O
uncertain NN O O
. NN O O
Excluded NN O O
from NN O O
this NN O O
list NN O O
are NN O O
those NN O O
events NN O O
that NN O O
were NN O O
minor NN O O
, NN O O
those NN O O
with NN O O
no NN O O
plausible NN O O
relation NN O O
to NN O O
drug NN O O
use NN O O
, NN O O
and NN O O
reports NN O O
too NN O O
imprecise NN O O
to NN O O
be NN O O
meaningful NN O O
. NN O O
Body NN O O
as NN O O
a NN O O
whole NN O O
- NN O O
edema NN B-AdverseReaction B-AdverseReaction
peripheral NN I-AdverseReaction I-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
Cardiovascular NN O O
- NN O O
angina NN B-AdverseReaction B-AdverseReaction
unstable NN B-AdverseReaction B-AdverseReaction
angina NN I-AdverseReaction I-AdverseReaction
deep NN B-AdverseReaction B-AdverseReaction
vein NN I-AdverseReaction I-AdverseReaction
thrombosis NN I-AdverseReaction I-AdverseReaction
palpitations NN B-AdverseReaction B-AdverseReaction
Digestive NN O O
- NN O O
gastritis NN B-AdverseReaction B-AdverseReaction
gastroesophageal NN B-AdverseReaction B-AdverseReaction
reflux NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
hypoglycemia NN B-AdverseReaction B-AdverseReaction
blood NN B-AdverseReaction B-AdverseReaction
glucose NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
alanine NN B-AdverseReaction B-AdverseReaction
aminotransferase NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
oropharyngeal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
stomach NN B-AdverseReaction B-AdverseReaction
discomfort NN I-AdverseReaction I-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
Musculoskeletal NN O O
- NN O O
muscle NN B-AdverseReaction B-AdverseReaction
spasms NN I-AdverseReaction I-AdverseReaction
musculoskeletal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
myalgia NN B-AdverseReaction B-AdverseReaction
pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
Nervous NN O O
- NN O O
depression NN B-AdverseReaction B-AdverseReaction
insomnia NN B-AdverseReaction B-AdverseReaction
somnolence NN B-AdverseReaction B-AdverseReaction
vertigo NN B-AdverseReaction B-AdverseReaction
Respiratory NN O O
- NN O O
cough NN B-AdverseReaction B-AdverseReaction
dyspnea NN B-AdverseReaction B-AdverseReaction
exertional NN I-AdverseReaction I-AdverseReaction
epistaxis NN B-AdverseReaction B-AdverseReaction
wheezing NN B-AdverseReaction B-AdverseReaction
Skin NN O O
and NN O O
Appendages NN O O
- NN O O
pruritus NN B-AdverseReaction B-AdverseReaction
Urogenital NN O O
- NN O O
balanitis NN B-AdverseReaction B-AdverseReaction
erection NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
hematuria NN B-AdverseReaction B-AdverseReaction
nephrolithiasis NN B-AdverseReaction B-AdverseReaction
pollakiuria NN B-AdverseReaction B-AdverseReaction
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
In NN O O
an NN O O
additional NN O O
randomized NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
study NN O O
lasting NN O O
up NN O O
to NN O O
3 NN O O
months NN O O
in NN O O
298 NN O O
men NN O O
who NN O O
had NN O O
undergone NN O O
bilateral NN O O
nerve NN O O
- NN O O
sparing NN O O
radical NN O O
prostatectomy NN O O
for NN O O
prostate NN O O
cancer NN O O
, NN O O
the NN O O
mean NN O O
age NN O O
of NN O O
patients NN O O
was NN O O
58.4 NN O O
years NN O O
( NN O O
range NN O O
40 NN O O
- NN O O
70 NN O O
) NN O O
. NN O O
Table NN O O
3 NN O O
presents NN O O
the NN O O
adverse NN O O
reactions NN O O
reported NN O O
in NN O O
this NN O O
study NN O O
. NN O O
Table NN O O
3 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Reported NN O O
by NN O O
Greater NN O O
than NN O O
or NN O O
Equal NN O O
to NN O O
2 NN O O
% NN O O
of NN O O
Patients NN O O
Treated NN O O
with NN O O
STENDRA NN O O
in NN O O
a NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Clinical NN O O
Trial NN O O
Lasting NN O O
3 NN O O
Months NN O O
in NN O O
Patients NN O O
Who NN O O
Underwent NN O O
Bilateral NN O O
Nerve NN O O
- NN O O
Sparing NN O O
Radical NN O O
Prostatectomy NN O O
Adverse NN O O
Reaction NN O O
Placebo(N NN O O
= NN O O
100 NN O O
) NN O O
STENDRA NN O O
100 NN O O
mg(N NN O O
= NN O O
99 NN O O
) NN O O
STENDRA NN O O
200 NN O O
mg(N NN O O
= NN O O
99 NN O O
) NN O O
Headache NN B-AdverseReaction B-AdverseReaction
1.0 NN O O
% NN O O
8.1 NN O O
% NN O O
12.1 NN O O
% NN O O
Flushing NN B-AdverseReaction B-AdverseReaction
0.0 NN O O
% NN O O
5.1 NN O O
% NN O O
10.1 NN O O
% NN O O
Nasopharyngitis NN B-AdverseReaction B-AdverseReaction
0.0 NN O O
% NN O O
3.0 NN O O
% NN O O
5.1 NN O O
% NN O O
Upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
0.0 NN O O
% NN O O
2.0 NN O O
% NN O O
3.0 NN O O
% NN O O
Nasal NN B-AdverseReaction B-AdverseReaction
congestion NN I-AdverseReaction I-AdverseReaction
1.0 NN O O
% NN O O
3.0 NN O O
% NN O O
1.0 NN O O
% NN O O
Back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
1.0 NN O O
% NN O O
3.0 NN O O
% NN O O
2.0 NN O O
% NN O O
Electrocardiogram NN B-AdverseReaction B-AdverseReaction
abnormal NN I-AdverseReaction I-AdverseReaction
0.0 NN O O
% NN O O
1.0 NN O O
% NN O O
3.0 NN O O
% NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
0.0 NN O O
% NN O O
1.0 NN O O
% NN O O
2.0 NN O O
% NN O O
A NN O O
randomized NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
2 NN O O
months NN O O
study NN O O
was NN O O
conducted NN O O
in NN O O
435 NN O O
subjects NN O O
with NN O O
a NN O O
mean NN O O
age NN O O
of NN O O
58.2 NN O O
years NN O O
( NN O O
range NN O O
24 NN O O
to NN O O
86 NN O O
years NN O O
) NN O O
to NN O O
determine NN O O
the NN O O
time NN O O
to NN O O
onset NN O O
of NN O O
effect NN O O
of NN O O
STENDRA NN O O
, NN O O
defined NN O O
as NN O O
the NN O O
time NN O O
to NN O O
the NN O O
first NN O O
occurrence NN O O
of NN O O
an NN O O
erection NN O O
sufficient NN O O
for NN O O
sexual NN O O
intercourse NN O O
. NN O O
Table NN O O
4 NN O O
presents NN O O
the NN O O
adverse NN O O
reactions NN O O
occurring NN O O
in NN O O
>= NN O O
2 NN O O
% NN O O
of NN O O
subjects NN O O
treated NN O O
with NN O O
STENDRA. NN O O
Table NN O O
4 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Reported NN O O
by NN O O
>= NN O O
2 NN O O
% NN O O
of NN O O
Patients NN O O
Treated NN O O
with NN O O
STENDRA NN O O
in NN O O
a NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Clinical NN O O
Trial NN O O
Lasting NN O O
2 NN O O
Months NN O O
to NN O O
Determine NN O O
the NN O O
Time NN O O
to NN O O
Onset NN O O
of NN O O
Effect NN O O
( NN O O
Study NN O O
3 NN O O
) NN O O
Adverse NN O O
Reaction NN O O
Placebon=143 NN O O
STENDRA NN O O
100 NN O O
mgn=146 NN O O
STENDRA NN O O
200 NN O O
mgn=146 NN O O
Headache NN B-AdverseReaction B-AdverseReaction
0.7 NN O O
% NN O O
1.4 NN O O
% NN O O
8.9 NN O O
% NN O O
Nasal NN B-AdverseReaction B-AdverseReaction
congestion NN I-AdverseReaction I-AdverseReaction
0.0 NN O O
% NN O O
0.7 NN O O
% NN O O
4.1 NN O O
% NN O O
Gastroenteritis NN B-AdverseReaction B-AdverseReaction
viral NN I-AdverseReaction I-AdverseReaction
0.0 NN O O
% NN O O
0.0 NN O O
% NN O O
2.1 NN O O
% NN O O
Across NN O O
all NN O O
trials NN O O
with NN O O
any NN O O
STENDRA NN O O
dose NN O O
, NN O O
1 NN O O
subject NN O O
reported NN O O
a NN O O
change NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
color NN I-AdverseReaction I-AdverseReaction
vision NN I-AdverseReaction I-AdverseReaction
6.2 NN O O
Postmarketing NN O O
Experience NN O O
Ophthalmologic NN O O
: NN O O
Non NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
arteritic NN I-AdverseReaction I-AdverseReaction
anterior NN I-AdverseReaction I-AdverseReaction
ischemic NN I-AdverseReaction I-AdverseReaction
optic NN I-AdverseReaction I-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
( NN O O
NAION NN O O
) NN O O
, NN O O
a NN O O
cause NN O O
of NN O O
decreased NN B-AdverseReaction B-AdverseReaction
vision NN I-AdverseReaction I-AdverseReaction
including NN O O
permanent NN B-AdverseReaction B-AdverseReaction
loss NN I-AdverseReaction I-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
vision NN I-AdverseReaction I-AdverseReaction
has NN O O
been NN O O
reported NN O O
rarely NN O O
post NN O O
- NN O O
marketing NN O O
in NN O O
temporal NN O O
association NN O O
with NN O O
the NN O O
use NN O O
of NN O O
phosphodiesterase NN B-DrugClass B-DrugClass
type NN I-DrugClass I-DrugClass
5 NN I-DrugClass I-DrugClass
( NN I-DrugClass I-DrugClass
PDE5 NN I-DrugClass I-DrugClass
) NN I-DrugClass I-DrugClass
inhibitors NN I-DrugClass I-DrugClass
Most NN O O
, NN O O
but NN O O
not NN O O
all NN O O
, NN O O
of NN O O
these NN O O
patients NN O O
had NN O O
underlying NN O O
anatomic NN O O
or NN O O
vascular NN O O
risk NN O O
factors NN O O
for NN O O
developing NN O O
NAION NN O O
, NN O O
including NN O O
but NN O O
not NN O O
necessarily NN O O
limited NN O O
to NN O O
: NN O O
low NN O O
cup NN O O
to NN O O
disc NN O O
ratio NN O O
( NN O O
" NN O O
crowded NN O O
disc NN O O
" NN O O
) NN O O
, NN O O
age NN O O
over NN O O
50 NN O O
, NN O O
diabetes NN O O
, NN O O
hypertension NN O O
, NN O O
coronary NN O O
artery NN O O
disease NN O O
, NN O O
hyperlipidemia NN O O
, NN O O
and NN O O
smoking NN O O
. NN O O
It NN O O
is NN O O
not NN O O
possible NN O O
to NN O O
determine NN O O
whether NN O O
these NN O O
events NN O O
are NN O O
related NN O O
directly NN O O
to NN O O
the NN O O
use NN O O
of NN O O
PDE5 NN O O
inhibitors NN O O
, NN O O
to NN O O
the NN O O
patient NN O O
's NN O O
underlying NN O O
vascular NN O O
risk NN O O
factors NN O O
or NN O O
anatomical NN O O
defects NN O O
, NN O O
to NN O O
a NN O O
combination NN O O
of NN O O
these NN O O
factors NN O O
, NN O O
or NN O O
to NN O O
other NN O O
factors NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4)andPatient NN O O
Counseling NN O O
Information NN O O
( NN O O
17.6 NN O O
) NN O O
] NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
Evaluation NN O O
of NN O O
erectile NN O O
dysfunction NN O O
( NN O O
ED NN O O
) NN O O
should NN O O
include NN O O
an NN O O
appropriate NN O O
medical NN O O
assessment NN O O
to NN O O
identify NN O O
potential NN O O
underlying NN O O
causes NN O O
, NN O O
as NN O O
well NN O O
as NN O O
treatment NN O O
options NN O O
. NN O O
Before NN O O
prescribing NN O O
STENDRA NN O O
, NN O O
it NN O O
is NN O O
important NN O O
to NN O O
note NN O O
the NN O O
following NN O O
: NN O O
EXCERPT NN O O
: NN O O
* NN O O
Patients NN O O
should NN O O
not NN O O
use NN O O
STENDRA NN O O
if NN O O
sexual NN O O
activity NN O O
is NN O O
inadvisable NN O O
due NN O O
to NN O O
cardiovascular NN O O
status NN O O
or NN O O
any NN O O
other NN O O
reason NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Use NN O O
of NN O O
STENDRA NN O O
with NN O O
alpha NN O O
- NN O O
blockers NN O O
, NN O O
other NN O O
antihypertensives NN O O
, NN O O
or NN O O
substantial NN O O
amounts NN O O
of NN O O
alcohol NN O O
( NN O O
greater NN O O
than NN O O
3 NN O O
units NN O O
) NN O O
may NN O O
lead NN O O
to NN O O
hypotension NN B-AdverseReaction B-AdverseReaction
( NN O O
2.3,5.6,5.7 NN O O
) NN O O
* NN O O
Patients NN O O
should NN O O
seek NN O O
emergency NN O O
treatment NN O O
if NN O O
an NN O O
erection NN O O
lasts NN O O
greater NN O O
than NN O O
4 NN O O
hours NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Patients NN O O
should NN O O
stop NN O O
STENDRA NN O O
and NN O O
seek NN O O
medical NN O O
care NN O O
if NN O O
a NN O O
sudden NN O O
loss NN O O
of NN O O
vision NN O O
occurs NN O O
in NN O O
one NN O O
or NN O O
both NN O O
eyes NN O O
, NN O O
which NN O O
could NN O O
be NN O O
a NN O O
sign NN O O
of NN O O
Non NN O O
Arteritic NN O O
Ischemic NN O O
Optic NN O O
Neuropathy NN O O
( NN O O
NAION NN O O
) NN O O
. NN O O
STENDRA NN O O
should NN O O
be NN O O
used NN O O
with NN O O
caution NN O O
, NN O O
and NN O O
only NN O O
when NN O O
the NN O O
anticipated NN O O
benefits NN O O
outweigh NN O O
the NN O O
risks NN O O
, NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
NAION. NN O O
Patients NN O O
with NN O O
a NN O O
" NN O O
crowded NN O O
" NN O O
optic NN O O
disc NN O O
may NN O O
also NN O O
be NN O O
at NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
NAION NN O O
( NN O O
5.4,6.2 NN O O
) NN O O
* NN O O
Patients NN O O
should NN O O
stop NN O O
taking NN O O
STENDRA NN O O
and NN O O
seek NN O O
prompt NN O O
medical NN O O
attention NN O O
in NN O O
the NN O O
event NN O O
of NN O O
sudden NN O O
decrease NN O O
or NN O O
loss NN O O
of NN O O
hearing NN O O
( NN O O
5.5 NN O O
) NN O O
5.1 NN O O
Cardiovascular NN O O
Risks NN O O
There NN O O
is NN O O
a NN O O
potential NN B-Factor B-Factor
for NN O O
cardiac NN B-AdverseReaction B-AdverseReaction
risk NN I-AdverseReaction I-AdverseReaction
during NN O O
sexual NN O O
activity NN O O
in NN O O
patients NN O O
with NN O O
pre NN O O
- NN O O
existing NN O O
cardiovascular NN O O
disease NN O O
. NN O O
Therefore NN O O
, NN O O
treatments NN O O
for NN O O
ED NN O O
, NN O O
including NN O O
STENDRA NN O O
, NN O O
should NN O O
not NN O O
be NN O O
used NN O O
in NN O O
men NN O O
for NN O O
whom NN O O
sexual NN O O
activity NN O O
is NN O O
inadvisable NN O O
because NN O O
of NN O O
their NN O O
underlying NN O O
cardiovascular NN O O
status NN O O
. NN O O
Patients NN O O
with NN O O
left NN O O
ventricular NN O O
outflow NN O O
obstruction NN O O
( NN O O
e.g. NN O O
, NN O O
aortic NN O O
stenosis NN O O
, NN O O
idiopathic NN O O
hypertrophic NN O O
subaortic NN O O
stenosis NN O O
) NN O O
and NN O O
those NN O O
with NN O O
severely NN O O
impaired NN O O
autonomic NN O O
control NN O O
of NN O O
blood NN O O
pressure NN O O
can NN O O
be NN O O
particularly NN O O
sensitive NN O O
to NN O O
the NN O O
actions NN O O
of NN O O
vasodilators NN O O
, NN O O
including NN O O
STENDRA. NN O O
The NN O O
following NN O O
groups NN O O
of NN O O
patients NN O O
were NN O O
not NN O O
included NN O O
in NN O O
clinical NN O O
safety NN O O
and NN O O
efficacy NN O O
trials NN O O
for NN O O
STENDRA NN O O
, NN O O
and NN O O
therefore NN O O
until NN O O
further NN O O
information NN O O
is NN O O
available NN O O
, NN O O
STENDRA NN O O
is NN O O
not NN O O
recommended NN O O
for NN O O
the NN O O
following NN O O
groups NN O O
: NN O O
* NN O O
Patients NN O O
who NN O O
have NN O O
suffered NN O O
a NN O O
myocardial NN O O
infarction NN O O
, NN O O
stroke NN O O
, NN O O
life NN O O
- NN O O
threatening NN O O
arrhythmia NN O O
, NN O O
or NN O O
coronary NN O O
revascularization NN O O
within NN O O
the NN O O
last NN O O
6 NN O O
months NN O O
; NN O O
* NN O O
Patients NN O O
with NN O O
resting NN O O
hypotension NN O O
( NN O O
blood NN O O
pressure NN O O
less NN O O
than NN O O
90/50 NN O O
mmHg NN O O
) NN O O
or NN O O
hypertension NN O O
( NN O O
blood NN O O
pressure NN O O
greater NN O O
than NN O O
170/100 NN O O
mmHg NN O O
) NN O O
; NN O O
* NN O O
Patients NN O O
with NN O O
unstable NN O O
angina NN O O
, NN O O
angina NN O O
with NN O O
sexual NN O O
intercourse NN O O
, NN O O
or NN O O
New NN O O
York NN O O
Heart NN O O
Association NN O O
Class NN O O
2 NN O O
or NN O O
greater NN O O
congestive NN O O
heart NN O O
failure NN O O
. NN O O
As NN O O
with NN O O
other NN O O
PDE5 NN O O
inhibitors NN O O
STENDRA NN O O
has NN O O
systemic NN O O
vasodilatory NN O O
properties NN O O
and NN O O
may NN O O
augment NN O O
the NN O O
blood NN O O
pressure NN O O
- NN O O
lowering NN O O
effect NN O O
of NN O O
other NN O O
anti NN O O
- NN O O
hypertensive NN O O
medications NN O O
. NN O O
STENDRA NN O O
200 NN O O
mg NN O O
resulted NN O O
in NN O O
transient NN B-AdverseReaction B-AdverseReaction
decreases NN I-AdverseReaction I-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
sitting NN I-AdverseReaction I-AdverseReaction
blood NN I-AdverseReaction I-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
in NN O O
healthy NN O O
volunteers NN O O
of NN O O
8.0 NN B-Severity B-Severity
mmHg NN I-Severity I-Severity
systolic NN I-Severity I-Severity
and NN I-Severity I-Severity
3.3 NN I-Severity I-Severity
mmHg NN I-Severity I-Severity
diastolic NN I-Severity I-Severity
[ NN O O
seeClinical NN O O
Pharmacology NN O O
( NN O O
12.2 NN O O
) NN O O
] NN O O
, NN O O
with NN O O
the NN O O
maximum NN O O
decrease NN O O
observed NN O O
at NN O O
1 NN O O
hour NN O O
after NN O O
dosing NN O O
. NN O O
While NN O O
this NN O O
normally NN O O
would NN O O
be NN O O
expected NN O O
to NN O O
be NN O O
of NN O O
little NN O O
consequence NN O O
in NN O O
most NN O O
patients NN O O
, NN O O
prior NN O O
to NN O O
prescribing NN O O
STENDRA NN O O
, NN O O
physicians NN O O
should NN O O
carefully NN O O
consider NN O O
whether NN O O
patients NN O O
with NN O O
underlying NN O O
cardiovascular NN O O
disease NN O O
could NN O O
be NN O O
affected NN O O
adversely NN O O
by NN O O
such NN O O
vasodilatory NN O O
effects NN O O
, NN O O
especially NN O O
in NN O O
combination NN O O
with NN O O
sexual NN O O
activity NN O O
. NN O O
5.2 NN O O
Concomitant NN O O
Use NN O O
of NN O O
CYP3A4 NN O O
Inhibitors NN O O
STENDRA NN O O
metabolism NN O O
is NN O O
principally NN O O
mediated NN O O
by NN O O
the NN O O
CYP450 NN O O
isoform NN O O
3A4 NN O O
( NN O O
CYP3A4 NN O O
) NN O O
. NN O O
Inhibitors NN O O
of NN O O
CYP3A4 NN O O
may NN O O
reduce NN O O
STENDRA NN O O
clearance NN O O
and NN O O
increase NN O O
plasma NN O O
concentrations NN O O
of NN O O
avanafil NN O O
. NN O O
For NN O O
patients NN O O
taking NN O O
concomitant NN O O
strong NN O O
CYP3A4 NN O O
inhibitors NN O O
( NN O O
including NN O O
ketoconazole NN O O
, NN O O
ritonavir NN O O
, NN O O
atazanavir NN O O
, NN O O
clarithromycin NN O O
, NN O O
indinavir NN O O
, NN O O
itraconazole NN O O
, NN O O
nefazodone NN O O
, NN O O
nelfinavir NN O O
, NN O O
saquinavir NN O O
, NN O O
and NN O O
telithromycin NN O O
) NN O O
, NN O O
do NN O O
not NN O O
use NN O O
STENDRA NN O O
[ NN O O
seeDrug NN O O
Interactions NN O O
( NN O O
7.2 NN O O
) NN O O
] NN O O
. NN O O
For NN O O
patients NN O O
taking NN O O
concomitant NN O O
moderate NN O O
CYP3A4 NN O O
inhibitors NN O O
( NN O O
including NN O O
erythromycin NN O O
, NN O O
amprenavir NN O O
, NN O O
aprepitant NN O O
, NN O O
diltiazem NN O O
, NN O O
fluconazole NN O O
, NN O O
fosamprenavir NN O O
, NN O O
and NN O O
verapamil NN O O
) NN O O
, NN O O
the NN O O
maximum NN O O
recommended NN O O
dose NN O O
of NN O O
STENDRA NN O O
is NN O O
50 NN O O
mg NN O O
, NN O O
not NN O O
to NN O O
exceed NN O O
once NN O O
every NN O O
24 NN O O
hours NN O O
[ NN O O
seeDrug NN O O
Interactions NN O O
( NN O O
7.2 NN O O
) NN O O
] NN O O
. NN O O
5.3 NN O O
Prolonged NN O O
Erection NN O O
Prolonged NN B-AdverseReaction B-AdverseReaction
erection NN I-AdverseReaction I-AdverseReaction
greater NN O O
than NN O O
4 NN B-Severity B-Severity
hours NN I-Severity I-Severity
and NN O O
priapism NN B-AdverseReaction B-AdverseReaction
( NN O O
painful NN O O
erections NN O O
greater NN O O
than NN O O
6 NN B-Severity B-Severity
hours NN I-Severity I-Severity
in NN O O
duration NN O O
) NN O O
have NN O O
been NN O O
reported NN O O
with NN O O
other NN O O
PDE5 NN B-DrugClass B-DrugClass
inhibitors NN I-DrugClass I-DrugClass
In NN O O
the NN O O
event NN O O
of NN O O
an NN O O
erection NN O O
that NN O O
persists NN O O
longer NN O O
than NN O O
4 NN O O
hours NN O O
, NN O O
the NN O O
patient NN O O
should NN O O
seek NN O O
immediate NN O O
medical NN O O
assistance NN O O
. NN O O
If NN O O
not NN O O
treated NN O O
immediately NN O O
, NN O O
penile NN O O
tissue NN O O
damage NN O O
and NN O O
permanent NN O O
loss NN O O
of NN O O
potency NN O O
could NN O O
result NN O O
. NN O O
STENDRA NN O O
should NN O O
be NN O O
used NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
with NN O O
anatomical NN O O
deformation NN O O
of NN O O
the NN O O
penis NN O O
( NN O O
such NN O O
as NN O O
angulation NN O O
, NN O O
cavernosal NN O O
fibrosis NN O O
, NN O O
or NN O O
Peyronie NN O O
's NN O O
disease NN O O
) NN O O
, NN O O
or NN O O
in NN O O
patients NN O O
who NN O O
have NN O O
conditions NN O O
which NN O O
may NN O O
predispose NN O O
them NN O O
to NN O O
priapism NN O O
( NN O O
such NN O O
as NN O O
sickle NN O O
cell NN O O
anemia NN O O
, NN O O
multiple NN O O
myeloma NN O O
, NN O O
or NN O O
leukemia NN O O
) NN O O
. NN O O
5.4 NN O O
Effects NN O O
on NN O O
Eye NN O O
Physicians NN O O
should NN O O
advise NN O O
patients NN O O
to NN O O
stop NN O O
use NN O O
of NN O O
all NN O O
PDE5 NN O O
inhibitors NN O O
, NN O O
including NN O O
STENDRA NN O O
, NN O O
and NN O O
seek NN O O
medical NN O O
attention NN O O
in NN O O
the NN O O
event NN O O
of NN O O
a NN O O
sudden NN O O
loss NN O O
of NN O O
vision NN O O
in NN O O
one NN O O
or NN O O
both NN O O
eyes NN O O
. NN O O
Such NN O O
an NN O O
event NN O O
may NN O O
be NN O O
a NN O O
sign NN O O
of NN O O
non NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
arteritic NN I-AdverseReaction I-AdverseReaction
anterior NN I-AdverseReaction I-AdverseReaction
ischemic NN I-AdverseReaction I-AdverseReaction
optic NN I-AdverseReaction I-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
( NN O O
NAION NN O O
) NN O O
, NN O O
a NN O O
rare NN O O
condition NN O O
and NN O O
a NN O O
cause NN O O
of NN O O
decreased NN B-AdverseReaction B-AdverseReaction
vision NN I-AdverseReaction I-AdverseReaction
including NN O O
permanent NN B-AdverseReaction B-AdverseReaction
loss NN I-AdverseReaction I-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
vision NN I-AdverseReaction I-AdverseReaction
that NN O O
has NN O O
been NN O O
reported NN O O
rarely NN O O
postmarketing NN O O
in NN O O
temporal NN O O
association NN O O
with NN O O
the NN O O
use NN O O
of NN O O
all NN O O
PDE5 NN B-DrugClass B-DrugClass
inhibitors NN I-DrugClass I-DrugClass
Based NN O O
on NN O O
published NN O O
literature NN O O
, NN O O
the NN O O
annual NN O O
incidence NN O O
of NN O O
NAION NN O O
is NN O O
2.5 NN O O
- NN O O
11.8 NN O O
cases NN O O
per NN O O
100,000 NN O O
in NN O O
males NN O O
aged NN O O
>= NN O O
50 NN O O
. NN O O
An NN O O
observational NN O O
study NN O O
evaluated NN O O
whether NN O O
recent NN O O
use NN O O
of NN O O
PDE5 NN B-DrugClass B-DrugClass
inhibitors NN I-DrugClass I-DrugClass
as NN O O
a NN O O
class NN O O
, NN O O
was NN O O
associated NN O O
with NN O O
acute NN O O
onset NN O O
of NN O O
NAION NN B-AdverseReaction B-AdverseReaction
The NN O O
results NN O O
suggest NN O O
an NN O O
approximate NN O O
2-fold NN O O
increase NN O O
in NN O O
the NN O O
risk NN O O
of NN O O
NAION NN B-AdverseReaction B-AdverseReaction
within NN O O
5 NN O O
half NN O O
- NN O O
lives NN O O
of NN O O
PDE5 NN B-DrugClass B-DrugClass
inhibitor NN I-DrugClass I-DrugClass
use NN O O
. NN O O
From NN O O
this NN O O
information NN O O
, NN O O
it NN O O
is NN O O
not NN O O
possible NN O O
to NN O O
determine NN O O
whether NN O O
these NN O O
events NN O O
are NN O O
related NN O O
directly NN O O
to NN O O
the NN O O
use NN O O
of NN O O
PDE5 NN O O
inhibitors NN O O
or NN O O
to NN O O
other NN O O
factors NN O O
[ NN O O
seeAdverse NN O O
Reactions NN O O
( NN O O
6.2 NN O O
) NN O O
] NN O O
. NN O O
Physicians NN O O
should NN O O
consider NN O O
whether NN O O
their NN O O
patients NN O O
with NN O O
underlying NN O O
NAION NN O O
risk NN O O
factors NN O O
could NN O O
be NN O O
adversely NN O O
affected NN O O
by NN O O
use NN O O
of NN O O
PDE5 NN O O
inhibitors NN O O
. NN O O
Individuals NN O O
who NN O O
have NN O O
already NN O O
experienced NN O O
NAION NN O O
are NN O O
at NN O O
increased NN O O
risk NN O O
of NN O O
NAION NN O O
recurrence NN O O
. NN O O
Therefore NN O O
, NN O O
PDE5 NN O O
inhibitors NN O O
, NN O O
including NN O O
STENDRA NN O O
, NN O O
should NN O O
be NN O O
used NN O O
with NN O O
caution NN O O
in NN O O
these NN O O
patients NN O O
and NN O O
only NN O O
when NN O O
the NN O O
anticipated NN O O
benefits NN O O
outweigh NN O O
the NN O O
risks NN O O
. NN O O
Individuals NN O O
with NN O O
" NN O O
crowded NN O O
" NN O O
optic NN O O
disc NN O O
are NN O O
also NN O O
considered NN O O
at NN O O
greater NN O O
risk NN O O
for NN O O
NAION NN O O
compared NN O O
to NN O O
the NN O O
general NN O O
population NN O O
, NN O O
however NN O O
, NN O O
evidence NN O O
is NN O O
insufficient NN O O
to NN O O
support NN O O
screening NN O O
of NN O O
prospective NN O O
users NN O O
of NN O O
PDE5 NN O O
inhibitors NN O O
, NN O O
including NN O O
STENDRA NN O O
, NN O O
for NN O O
this NN O O
uncommon NN O O
condition NN O O
. NN O O
5.5 NN O O
Sudden NN O O
Hearing NN O O
Loss NN O O
Use NN O O
of NN O O
PDE5 NN B-DrugClass B-DrugClass
inhibitors NN I-DrugClass I-DrugClass
has NN O O
been NN O O
associated NN O O
with NN O O
sudden NN O O
decrease NN O O
or NN O O
loss NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
hearing NN I-AdverseReaction I-AdverseReaction
which NN O O
may NN O O
be NN O O
accompanied NN O O
by NN O O
tinnitus NN B-AdverseReaction B-AdverseReaction
or NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
It NN O O
is NN O O
not NN O O
possible NN O O
to NN O O
determine NN O O
whether NN O O
these NN O O
events NN O O
are NN O O
related NN O O
directly NN O O
to NN O O
the NN O O
use NN O O
of NN O O
PDE5 NN O O
inhibitors NN O O
or NN O O
to NN O O
other NN O O
factors NN O O
[ NN O O
seeAdverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
] NN O O
. NN O O
Patients NN O O
experiencing NN O O
these NN O O
symptoms NN O O
should NN O O
be NN O O
advised NN O O
to NN O O
stop NN O O
taking NN O O
STENDRA NN O O
and NN O O
seek NN O O
prompt NN O O
medical NN O O
attention NN O O
. NN O O
5.6 NN O O
Alpha NN O O
- NN O O
Blockers NN O O
and NN O O
Other NN O O
Antihypertensives NN O O
Physicians NN O O
should NN O O
discuss NN O O
with NN O O
patients NN O O
the NN O O
potential NN O O
for NN O O
STENDRA NN O O
to NN O O
augment NN O O
the NN O O
blood NN O O
pressure NN O O
- NN O O
lowering NN O O
effect NN O O
of NN O O
alpha NN O O
- NN O O
blockers NN O O
and NN O O
other NN O O
antihypertensive NN O O
medications NN O O
[ NN O O
seeDrug NN O O
Interactions NN O O
( NN O O
7.1)andClinical NN O O
Pharmacology NN O O
( NN O O
12.2 NN O O
) NN O O
] NN O O
. NN O O
Caution NN O O
is NN O O
advised NN O O
when NN O O
PDE5 NN O O
inhibitors NN O O
are NN O O
co NN O O
- NN O O
administered NN O O
with NN O O
alpha NN O O
- NN O O
blockers NN O O
. NN O O
Phosphodiesterase NN O O
type NN O O
5 NN O O
inhibitors NN O O
, NN O O
including NN O O
STENDRA NN O O
, NN O O
and NN O O
alpha NN O O
- NN O O
adrenergic NN O O
blocking NN O O
agents NN O O
are NN O O
both NN O O
vasodilators NN O O
with NN O O
blood NN O O
pressure NN O O
- NN O O
lowering NN O O
effects NN O O
. NN O O
When NN O O
vasodilators NN O O
are NN O O
used NN O O
in NN O O
combination NN O O
, NN O O
an NN O O
additive NN O O
effect NN O O
on NN O O
blood NN O O
pressure NN O O
may NN O O
be NN O O
anticipated NN O O
. NN O O
In NN O O
some NN O O
patients NN O O
, NN O O
concomitant NN O O
use NN O O
of NN O O
these NN O O
two NN O O
drug NN O O
classes NN O O
can NN B-Factor B-Factor
lower NN O O
blood NN O O
pressure NN O O
significantly NN O O
leading NN O O
to NN O O
symptomatic NN B-AdverseReaction B-AdverseReaction
hypotension NN I-AdverseReaction I-AdverseReaction
( NN O O
e.g. NN O O
, NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
lightheadedness NN B-AdverseReaction B-AdverseReaction
fainting NN B-AdverseReaction B-AdverseReaction
Consideration NN O O
should NN O O
be NN O O
given NN O O
to NN O O
the NN O O
following NN O O
: NN O O
* NN O O
Patients NN O O
should NN O O
be NN O O
stable NN O O
on NN O O
alpha NN O O
- NN O O
blocker NN O O
therapy NN O O
prior NN O O
to NN O O
initiating NN O O
treatment NN O O
with NN O O
a NN O O
PDE5 NN O O
inhibitor NN O O
. NN O O
Patients NN O O
who NN O O
demonstrate NN O O
hemodynamic NN O O
instability NN O O
on NN O O
alpha NN O O
- NN O O
blocker NN O O
therapy NN O O
alone NN O O
are NN O O
at NN O O
increased NN O O
risk NN O O
of NN O O
symptomatic NN B-AdverseReaction B-AdverseReaction
hypotension NN I-AdverseReaction I-AdverseReaction
with NN O O
concomitant NN O O
use NN O O
of NN O O
PDE5 NN B-DrugClass B-DrugClass
inhibitors NN I-DrugClass I-DrugClass
* NN O O
In NN O O
those NN O O
patients NN O O
who NN O O
are NN O O
stable NN O O
on NN O O
alpha NN O O
- NN O O
blocker NN O O
therapy NN O O
, NN O O
PDE5 NN O O
inhibitors NN O O
should NN O O
be NN O O
initiated NN O O
at NN O O
the NN O O
lowest NN O O
dose NN O O
( NN O O
STENDRA NN O O
50 NN O O
mg NN O O
) NN O O
. NN O O
* NN O O
In NN O O
those NN O O
patients NN O O
already NN O O
taking NN O O
an NN O O
optimized NN O O
dose NN O O
of NN O O
a NN O O
PDE5 NN O O
inhibitor NN O O
, NN O O
alpha NN O O
- NN O O
blocker NN O O
therapy NN O O
should NN O O
be NN O O
initiated NN O O
at NN O O
the NN O O
lowest NN O O
dose NN O O
. NN O O
Stepwise NN O O
increase NN O O
in NN O O
alpha NN O O
- NN O O
blocker NN O O
dose NN O O
may NN O O
be NN O O
associated NN O O
with NN O O
further NN O O
lowering NN O O
of NN O O
blood NN O O
pressure NN O O
when NN O O
taking NN O O
a NN O O
PDE5 NN O O
inhibitor NN O O
. NN O O
Safety NN O O
of NN O O
combined NN O O
use NN O O
of NN O O
PDE5 NN O O
inhibitors NN O O
and NN O O
alpha NN O O
- NN O O
blockers NN O O
may NN O O
be NN O O
affected NN O O
by NN O O
other NN O O
variables NN O O
, NN O O
including NN O O
intravascular NN O O
volume NN O O
depletion NN O O
and NN O O
other NN O O
anti NN O O
- NN O O
hypertensive NN O O
drugs NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2 NN O O
) NN O O
and NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.1 NN O O
) NN O O
] NN O O
. NN O O
5.7 NN O O
Alcohol NN O O
Patients NN O O
should NN O O
be NN O O
made NN O O
aware NN O O
that NN O O
both NN O O
alcohol NN O O
and NN O O
PDE5 NN O O
inhibitors NN O O
including NN O O
STENDRA NN O O
act NN O O
as NN O O
vasodilators NN O O
. NN O O
When NN O O
vasodilators NN O O
are NN O O
taken NN O O
in NN O O
combination NN O O
, NN O O
blood NN O O
- NN O O
pressure NN O O
- NN O O
lowering NN O O
effects NN O O
of NN O O
each NN O O
individual NN O O
compound NN O O
may NN O O
be NN O O
increased NN O O
. NN O O
Therefore NN O O
, NN O O
physicians NN O O
should NN O O
inform NN O O
patients NN O O
that NN O O
substantial NN O O
consumption NN O O
of NN O O
alcohol NN O O
( NN O O
e.g. NN O O
, NN O O
greater NN O O
than NN O O
3 NN O O
units NN O O
) NN O O
in NN O O
combination NN O O
with NN O O
STENDRA NN O O
may NN O O
increase NN O O
the NN O O
potential NN O O
for NN O O
orthostatic NN O O
signs NN O O
and NN O O
symptoms NN O O
, NN O O
including NN O O
increase NN O O
in NN O O
heart NN O O
rate NN O O
, NN O O
decrease NN O O
in NN O O
standing NN O O
blood NN O O
pressure NN O O
, NN O O
dizziness NN O O
, NN O O
and NN O O
headache NN O O
[ NN O O
seeDrug NN O O
Interactions NN O O
( NN O O
7.1)andClinical NN O O
Pharmacology NN O O
( NN O O
12.2 NN O O
) NN O O
] NN O O
. NN O O
5.8 NN O O
Combination NN O O
with NN O O
Other NN O O
PDE5 NN O O
Inhibitors NN O O
or NN O O
Erectile NN O O
Dysfunction NN O O
Therapies NN O O
The NN O O
safety NN O O
and NN O O
efficacy NN O O
of NN O O
combinations NN O O
of NN O O
STENDRA NN O O
with NN O O
other NN O O
treatments NN O O
for NN O O
ED NN O O
has NN O O
not NN O O
been NN O O
studied NN O O
. NN O O
Therefore NN O O
, NN O O
the NN O O
use NN O O
of NN O O
such NN O O
combinations NN O O
is NN O O
not NN O O
recommended NN O O
. NN O O
5.9 NN O O
Effects NN O O
on NN O O
Bleeding NN O O
The NN O O
safety NN O O
of NN O O
STENDRA NN O O
is NN O O
unknown NN O O
in NN O O
patients NN O O
with NN O O
bleeding NN O O
disorders NN O O
and NN O O
patients NN O O
with NN O O
active NN O O
peptic NN O O
ulceration NN O O
. NN O O
In NN B-Factor B-Factor
vitro NN I-Factor I-Factor
studies NN I-Factor I-Factor
with NN O O
human NN O O
platelets NN O O
indicate NN O O
that NN O O
STENDRA NN O O
potentiates NN B-AdverseReaction B-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
anti NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
aggregatory NN I-AdverseReaction I-AdverseReaction
effect NN I-AdverseReaction I-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
sodium NN I-AdverseReaction I-AdverseReaction
nitroprusside NN I-AdverseReaction I-AdverseReaction
( NN O O
a NN O O
nitric NN O O
oxide NN O O
[ NN O O
NO NN O O
] NN O O
donor NN O O
) NN O O
. NN O O
5.10 NN O O
Counseling NN O O
Patients NN O O
about NN O O
Sexually NN O O
Transmitted NN O O
Diseases NN O O
The NN O O
use NN O O
of NN O O
STENDRA NN O O
offers NN O O
no NN O O
protection NN O O
against NN O O
sexually NN O O
transmitted NN O O
diseases NN O O
. NN O O
Counseling NN O O
patients NN O O
about NN O O
the NN O O
protective NN O O
measures NN O O
necessary NN O O
to NN O O
guard NN O O
against NN O O
sexually NN O O
transmitted NN O O
diseases NN O O
, NN O O
including NN O O
Human NN O O
Immunodeficiency NN O O
Virus NN O O
( NN O O
HIV NN O O
) NN O O
, NN O O
should NN O O
be NN O O
considered NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
potential NN O O
serious NN O O
adverse NN O O
reactions NN O O
are NN O O
discussed NN O O
in NN O O
greater NN O O
detail NN O O
in NN O O
other NN O O
sections NN O O
of NN O O
the NN O O
labeling NN O O
: NN O O
Splenic NN B-AdverseReaction B-AdverseReaction
Rupture NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
Acute NN B-AdverseReaction B-AdverseReaction
Respiratory NN I-AdverseReaction I-AdverseReaction
Distress NN I-AdverseReaction I-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
Serious NN B-Severity B-Severity
Allergic NN B-AdverseReaction B-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
Use NN O O
in NN O O
Patients NN O O
with NN O O
Sickle NN O O
Cell NN O O
Disease NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
Capillary NN B-AdverseReaction B-AdverseReaction
Leak NN I-AdverseReaction I-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
Potential NN B-Factor B-Factor
for NN O O
Tumor NN B-AdverseReaction B-AdverseReaction
Growth NN I-AdverseReaction I-AdverseReaction
Stimulatory NN I-AdverseReaction I-AdverseReaction
Effects NN I-AdverseReaction I-AdverseReaction
on NN I-AdverseReaction I-AdverseReaction
Malignant NN I-AdverseReaction I-AdverseReaction
Cells NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.6 NN O O
) NN O O
] NN O O
The NN O O
most NN O O
common NN O O
treatment NN O O
- NN O O
emergent NN O O
adverse NN O O
reaction NN O O
that NN O O
occurred NN O O
at NN O O
an NN O O
incidence NN O O
of NN O O
at NN O O
least NN O O
1 NN O O
% NN O O
or NN O O
greater NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
GRANIX NN O O
at NN O O
the NN O O
recommended NN O O
dose NN O O
and NN O O
was NN O O
numerically NN O O
two NN O O
times NN O O
more NN O O
frequent NN O O
than NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
was NN O O
bone NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
EXCERPT NN O O
: NN O O
* NN O O
Most NN O O
common NN O O
adverse NN O O
reaction NN O O
to NN O O
GRANIX NN O O
is NN O O
bone NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
( NN O O
6 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
TEVA NN O O
at NN O O
1 NN O O
- NN O O
866 NN O O
- NN O O
832 NN O O
- NN O O
8537 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O
GRANIX NN O O
clinical NN O O
trials NN O O
safety NN O O
data NN O O
are NN O O
based NN O O
upon NN O O
the NN O O
results NN O O
of NN O O
three NN O O
randomized NN O O
clinical NN O O
trials NN O O
in NN O O
patients NN O O
receiving NN O O
myeloablative NN O O
chemotherapy NN O O
for NN O O
breast NN O O
cancer NN O O
( NN O O
N=348 NN O O
) NN O O
, NN O O
lung NN O O
cancer NN O O
( NN O O
N=240 NN O O
) NN O O
and NN O O
non NN O O
- NN O O
Hodgkin NN O O
's NN O O
lymphoma NN O O
( NN O O
N=92 NN O O
) NN O O
. NN O O
In NN O O
the NN O O
breast NN O O
cancer NN O O
study NN O O
, NN O O
99 NN O O
% NN O O
of NN O O
patients NN O O
were NN O O
female NN O O
, NN O O
the NN O O
median NN O O
age NN O O
was NN O O
50 NN O O
years NN O O
, NN O O
and NN O O
86 NN O O
% NN O O
of NN O O
patients NN O O
were NN O O
Caucasian NN O O
. NN O O
In NN O O
the NN O O
lung NN O O
cancer NN O O
study NN O O
, NN O O
80 NN O O
% NN O O
of NN O O
patients NN O O
were NN O O
male NN O O
, NN O O
the NN O O
median NN O O
age NN O O
was NN O O
58 NN O O
years NN O O
, NN O O
and NN O O
95 NN O O
% NN O O
of NN O O
patients NN O O
were NN O O
Caucasian NN O O
. NN O O
In NN O O
the NN O O
non NN O O
- NN O O
Hodgkin NN O O
's NN O O
lymphoma NN O O
study NN O O
, NN O O
52 NN O O
% NN O O
of NN O O
patients NN O O
were NN O O
male NN O O
, NN O O
the NN O O
median NN O O
age NN O O
was NN O O
55 NN O O
years NN O O
, NN O O
and NN O O
88 NN O O
% NN O O
of NN O O
patients NN O O
were NN O O
Caucasian NN O O
. NN O O
In NN O O
all NN O O
three NN O O
studies NN O O
a NN O O
placebo NN O O
( NN O O
Cycle NN O O
1 NN O O
of NN O O
the NN O O
breast NN O O
cancer NN O O
study NN O O
only NN O O
) NN O O
or NN O O
a NN O O
non NN O O
- NN O O
US NN O O
- NN O O
approved NN O O
filgrastim NN O O
product NN O O
were NN O O
used NN O O
as NN O O
controls NN O O
. NN O O
Both NN O O
GRANIX NN O O
and NN O O
the NN O O
non NN O O
- NN O O
US NN O O
- NN O O
approved NN O O
filgrastim NN O O
product NN O O
were NN O O
administered NN O O
at NN O O
5 NN O O
mcg/kg NN O O
subcutaneously NN O O
once NN O O
daily NN O O
beginning NN O O
one NN O O
day NN O O
after NN O O
chemotherapy NN O O
for NN O O
at NN O O
least NN O O
five NN O O
days NN O O
and NN O O
continued NN O O
to NN O O
a NN O O
maximum NN O O
of NN O O
14 NN O O
days NN O O
or NN O O
until NN O O
an NN O O
ANC NN O O
of NN O O
>=10,000 NN O O
x NN O O
10 NN O O
6 NN O O
/L NN O O
after NN O O
nadir NN O O
was NN O O
reached NN O O
. NN O O
Bone NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
was NN O O
the NN O O
most NN O O
frequent NN O O
treatment NN O O
- NN O O
emergent NN O O
adverse NN O O
reaction NN O O
that NN O O
occurred NN O O
in NN O O
at NN O O
least NN O O
1 NN O O
% NN O O
or NN O O
greater NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
GRANIX NN O O
at NN O O
the NN O O
recommended NN O O
dose NN O O
and NN O O
was NN O O
numerically NN O O
two NN O O
times NN O O
more NN O O
frequent NN O O
than NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
. NN O O
The NN O O
overall NN O O
incidence NN O O
of NN O O
bone NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
in NN O O
Cycle NN O O
1 NN O O
of NN O O
treatment NN O O
was NN O O
3.4 NN O O
% NN O O
( NN O O
3.4 NN O O
% NN O O
GRANIX NN O O
, NN O O
1.4 NN O O
% NN O O
placebo NN O O
, NN O O
7.5 NN O O
% NN O O
non NN O O
- NN O O
US NN O O
- NN O O
approved NN O O
filgrastim NN O O
product NN O O
) NN O O
. NN O O
Leukocytosis NN O O
In NN O O
clinical NN O O
studies NN O O
, NN O O
leukocytosis NN B-AdverseReaction B-AdverseReaction
( NN O O
WBC NN O O
counts NN O O
> NN O O
100,000 NN O O
x NN O O
10 NN O O
6 NN O O
/L NN O O
) NN O O
was NN O O
observed NN O O
in NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
patients NN O O
with NN O O
non NN O O
- NN O O
myeloid NN O O
malignancies NN O O
receiving NN O O
GRANIX. NN O O
No NN O O
complications NN O O
attributable NN O O
to NN O O
leukocytosis NN B-AdverseReaction B-AdverseReaction
were NN O O
reported NN O O
in NN O O
clinical NN O O
studies NN O O
. NN O O
Additional NN O O
Adverse NN O O
Reactions NN O O
Other NN O O
adverse NN O O
reactions NN O O
known NN O O
to NN O O
occur NN O O
following NN O O
administration NN O O
of NN O O
human NN B-DrugClass B-DrugClass
granulocyte NN I-DrugClass I-DrugClass
colony NN I-DrugClass I-DrugClass
- NN I-DrugClass I-DrugClass
stimulating NN I-DrugClass I-DrugClass
factors NN I-DrugClass I-DrugClass
include NN O O
myalgia NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
Sweet NN B-AdverseReaction B-AdverseReaction
's NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
acute NN O O
febrile NN O O
neutrophilic NN O O
dermatosis NN O O
) NN O O
, NN O O
cutaneous NN B-AdverseReaction B-AdverseReaction
vasculitis NN I-AdverseReaction I-AdverseReaction
and NN O O
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
6.2 NN O O
Immunogenicity NN O O
As NN O O
with NN O O
all NN O O
therapeutic NN O O
proteins NN O O
, NN O O
there NN O O
is NN O O
a NN O O
potential NN O O
for NN O O
immunogenicity NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
antibody NN O O
development NN O O
in NN O O
patients NN O O
receiving NN O O
GRANIX NN O O
has NN O O
not NN O O
been NN O O
adequately NN O O
determined NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Splenic NN B-AdverseReaction B-AdverseReaction
Rupture NN I-AdverseReaction I-AdverseReaction
Discontinue NN O O
GRANIX NN O O
if NN O O
suspected NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Acute NN B-AdverseReaction B-AdverseReaction
Respiratory NN I-AdverseReaction I-AdverseReaction
Distress NN I-AdverseReaction I-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
ARDS NN O O
) NN O O
: NN O O
Monitor NN O O
for NN O O
and NN O O
manage NN O O
immediately NN O O
. NN O O
Discontinue NN O O
GRANIX NN O O
if NN O O
suspected NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Allergic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
( NN O O
angioneurotic NN O O
edema NN O O
, NN O O
dermatitis NN B-AdverseReaction B-AdverseReaction
allergic NN I-AdverseReaction I-AdverseReaction
drug NN B-AdverseReaction B-AdverseReaction
hypersensitivity NN I-AdverseReaction I-AdverseReaction
hypersensitivity NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
pruritic NN B-AdverseReaction B-AdverseReaction
rash NN I-AdverseReaction I-AdverseReaction
and NN O O
urticaria NN B-AdverseReaction B-AdverseReaction
( NN O O
5.3 NN O O
) NN O O
* NN O O
Sickle NN B-AdverseReaction B-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
crisis NN I-AdverseReaction I-AdverseReaction
Severe NN B-Severity B-Severity
and NN O O
sometimes NN O O
fatal NN B-AdverseReaction B-AdverseReaction
crisis NN O O
can NN B-Factor B-Factor
occur NN O O
. NN O O
Discontinue NN O O
GRANIX NN O O
if NN O O
suspected NN O O
( NN O O
5.4 NN O O
) NN O O
* NN O O
Capillary NN B-AdverseReaction B-AdverseReaction
Leak NN I-AdverseReaction I-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
if NN O O
symptoms NN O O
develop NN O O
and NN O O
administer NN O O
standard NN O O
symptomatic NN O O
treatment NN O O
( NN O O
5.5 NN O O
) NN O O
5.1 NN O O
Splenic NN O O
Rupture NN O O
Splenic NN B-AdverseReaction B-AdverseReaction
rupture NN I-AdverseReaction I-AdverseReaction
including NN O O
fatal NN B-AdverseReaction B-AdverseReaction
cases NN O O
, NN O O
can NN B-Factor B-Factor
occur NN O O
following NN O O
administration NN O O
of NN O O
human NN O O
granulocyte NN O O
colony NN O O
- NN O O
stimulating NN O O
factors NN O O
. NN O O
In NN O O
patients NN O O
who NN O O
report NN O O
upper NN O O
abdominal NN O O
or NN O O
shoulder NN O O
pain NN O O
after NN O O
receiving NN O O
GRANIX NN O O
, NN O O
discontinue NN O O
GRANIX NN O O
and NN O O
evaluate NN O O
for NN O O
an NN O O
enlarged NN O O
spleen NN O O
or NN O O
splenic NN O O
rupture NN O O
. NN O O
5.2 NN O O
Acute NN O O
Respiratory NN O O
Distress NN O O
Syndrome NN O O
( NN O O
ARDS NN O O
) NN O O
Acute NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
distress NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
ARDS NN O O
) NN O O
can NN O O
occur NN O O
in NN O O
patients NN O O
receiving NN O O
human NN B-DrugClass B-DrugClass
granulocyte NN I-DrugClass I-DrugClass
colony NN I-DrugClass I-DrugClass
- NN I-DrugClass I-DrugClass
stimulating NN I-DrugClass I-DrugClass
factors NN I-DrugClass I-DrugClass
Evaluate NN O O
patients NN O O
who NN O O
develop NN O O
fever NN O O
and NN O O
lung NN O O
infiltrates NN O O
or NN O O
respiratory NN O O
distress NN O O
after NN O O
receiving NN O O
GRANIX NN O O
, NN O O
for NN O O
ARDS. NN O O
Discontinue NN O O
GRANIX NN O O
in NN O O
patients NN O O
with NN O O
ARDS. NN O O
5.3 NN O O
Allergic NN O O
Reactions NN O O
Serious NN B-Severity B-Severity
allergic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
can NN O O
occur NN O O
in NN O O
patients NN O O
receiving NN O O
human NN B-DrugClass B-DrugClass
granulocyte NN I-DrugClass I-DrugClass
colony NN I-DrugClass I-DrugClass
- NN I-DrugClass I-DrugClass
stimulating NN I-DrugClass I-DrugClass
factors NN I-DrugClass I-DrugClass
Reactions NN O O
can NN O O
occur NN O O
on NN O O
initial NN O O
exposure NN O O
. NN O O
The NN O O
administration NN O O
of NN O O
antihistamines NN O O
, NN O O
steroids NN O O
, NN O O
bronchodilators NN O O
, NN O O
and/or NN O O
epinephrine NN O O
may NN O O
reduce NN O O
the NN O O
severity NN O O
of NN O O
the NN O O
reactions NN O O
. NN O O
Permanently NN O O
discontinue NN O O
GRANIX NN O O
in NN O O
patients NN O O
with NN O O
serious NN O O
allergic NN O O
reactions NN O O
. NN O O
Do NN O O
not NN O O
administer NN O O
GRANIX NN O O
to NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
serious NN O O
allergic NN O O
reactions NN O O
to NN O O
filgrastim NN O O
or NN O O
pegfilgrastim NN O O
. NN O O
5.4 NN O O
Use NN O O
in NN O O
Patients NN O O
with NN O O
Sickle NN O O
Cell NN O O
Disease NN O O
Severe NN O O
and NN O O
sometimes NN O O
fatal NN B-AdverseReaction B-AdverseReaction
sickle NN B-AdverseReaction B-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
crises NN I-AdverseReaction I-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
in NN O O
patients NN O O
with NN O O
sickle NN O O
cell NN O O
disease NN O O
receiving NN O O
human NN O O
granulocyte NN O O
colony NN O O
- NN O O
stimulating NN O O
factors NN O O
. NN O O
Consider NN O O
the NN O O
potential NN O O
risks NN O O
and NN O O
benefits NN O O
prior NN O O
to NN O O
the NN O O
administration NN O O
of NN O O
human NN O O
granulocyte NN O O
colony NN O O
- NN O O
stimulating NN O O
factors NN O O
in NN O O
patients NN O O
with NN O O
sickle NN O O
cell NN O O
disease NN O O
. NN O O
Discontinue NN O O
GRANIX NN O O
in NN O O
patients NN O O
undergoing NN O O
a NN O O
sickle NN O O
cell NN O O
crisis NN O O
. NN O O
5.5 NN O O
Capillary NN O O
Leak NN O O
Syndrome NN O O
Capillary NN B-AdverseReaction B-AdverseReaction
leak NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
CLS NN O O
) NN O O
can NN O O
occur NN O O
in NN O O
patients NN O O
receiving NN O O
human NN B-DrugClass B-DrugClass
granulocyte NN I-DrugClass I-DrugClass
colony NN I-DrugClass I-DrugClass
- NN I-DrugClass I-DrugClass
stimulating NN I-DrugClass I-DrugClass
factors NN I-DrugClass I-DrugClass
and NN O O
is NN O O
characterized NN O O
by NN O O
hypotension NN B-AdverseReaction B-AdverseReaction
hypoalbuminemia NN B-AdverseReaction B-AdverseReaction
edema NN B-AdverseReaction B-AdverseReaction
and NN O O
hemoconcentration NN B-AdverseReaction B-AdverseReaction
Episodes NN O O
vary NN O O
in NN O O
frequency NN O O
, NN O O
severity NN O O
and NN O O
may NN O O
be NN O O
life NN O O
- NN O O
threatening NN O O
if NN O O
treatment NN O O
is NN O O
delayed NN O O
. NN O O
Patients NN O O
who NN O O
develop NN O O
symptoms NN O O
of NN O O
capillary NN O O
leak NN O O
syndrome NN O O
should NN O O
be NN O O
closely NN O O
monitored NN O O
and NN O O
receive NN O O
standard NN O O
symptomatic NN O O
treatment NN O O
, NN O O
which NN O O
may NN O O
include NN O O
a NN O O
need NN O O
for NN O O
intensive NN O O
care NN O O
. NN O O
5.6 NN O O
Potential NN O O
for NN O O
Tumor NN O O
Growth NN O O
Stimulatory NN O O
Effects NN O O
on NN O O
Malignant NN O O
Cells NN O O
The NN O O
granulocyte NN O O
colony NN O O
- NN O O
stimulating NN O O
factor NN O O
( NN O O
G NN O O
- NN O O
CSF NN O O
) NN O O
receptor NN O O
through NN O O
which NN O O
GRANIX NN O O
acts NN O O
has NN O O
been NN O O
found NN O O
on NN O O
tumor NN O O
cell NN O O
lines NN O O
. NN O O
The NN O O
possibility NN B-Factor B-Factor
that NN O O
GRANIX NN O O
acts NN O O
as NN O O
a NN O O
growth NN O O
factor NN O O
for NN O O
any NN O O
tumor NN O O
type NN O O
, NN O O
including NN O O
myeloid NN B-AdverseReaction B-AdverseReaction
malignancies NN I-AdverseReaction I-AdverseReaction
and NN O O
myelodysplasia NN B-AdverseReaction B-AdverseReaction
diseases NN O O
for NN O O
which NN O O
GRANIX NN O O
is NN O O
not NN O O
approved NN O O
, NN O O
can NN O O
not NN O O
be NN O O
excluded NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
Adverse NN O O
reactions NN O O
associated NN O O
with NN O O
ophthalmic NN B-DrugClass B-DrugClass
steroids NN I-DrugClass I-DrugClass
include NN O O
elevated NN B-AdverseReaction B-AdverseReaction
intraocular NN I-AdverseReaction I-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
which NN O O
may NN O O
be NN O O
associated NN O O
with NN O O
optic NN B-AdverseReaction B-AdverseReaction
nerve NN I-AdverseReaction I-AdverseReaction
damage NN I-AdverseReaction I-AdverseReaction
visual NN O O
acuity NN O O
and NN O O
field NN O O
defects NN O O
, NN O O
posterior NN B-AdverseReaction B-AdverseReaction
subcapsular NN I-AdverseReaction I-AdverseReaction
cataract NN I-AdverseReaction I-AdverseReaction
formation NN I-AdverseReaction I-AdverseReaction
secondary NN B-AdverseReaction B-AdverseReaction
ocular NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
from NN O O
pathogens NN O O
including NN O O
herpes NN O O
simplex NN O O
, NN O O
and NN O O
perforation NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
globe NN I-AdverseReaction I-AdverseReaction
where NN O O
there NN O O
is NN O O
thinning NN O O
of NN O O
the NN O O
cornea NN O O
or NN O O
sclera NN O O
. NN O O
6.1 NN O O
Ocular NN O O
Surgery NN O O
Ocular NN B-AdverseReaction B-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
occurring NN O O
in NN O O
5 NN O O
- NN O O
15 NN O O
% NN O O
of NN O O
subjects NN O O
in NN O O
clinical NN O O
studies NN O O
with NN O O
DUREZOL NN O O
included NN O O
corneal NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
ciliary NN O O
and NN O O
conjunctival NN B-AdverseReaction B-AdverseReaction
hyperemia NN I-AdverseReaction I-AdverseReaction
eye NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
photophobia NN B-AdverseReaction B-AdverseReaction
posterior NN B-AdverseReaction B-AdverseReaction
capsule NN I-AdverseReaction I-AdverseReaction
opacification NN I-AdverseReaction I-AdverseReaction
anterior NN B-AdverseReaction B-AdverseReaction
chamber NN I-AdverseReaction I-AdverseReaction
cells NN I-AdverseReaction I-AdverseReaction
anterior NN B-AdverseReaction B-AdverseReaction
chamber NN I-AdverseReaction I-AdverseReaction
flare NN I-AdverseReaction I-AdverseReaction
conjunctival NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
and NN O O
blepharitis NN B-AdverseReaction B-AdverseReaction
Other NN O O
ocular NN O O
adverse NN O O
reactions NN O O
occurring NN O O
in NN O O
1 NN O O
- NN O O
5 NN O O
% NN O O
of NN O O
subjects NN O O
included NN O O
reduced NN B-AdverseReaction B-AdverseReaction
visual NN I-AdverseReaction I-AdverseReaction
acuity NN I-AdverseReaction I-AdverseReaction
punctate NN B-AdverseReaction B-AdverseReaction
keratitis NN I-AdverseReaction I-AdverseReaction
eye NN B-AdverseReaction B-AdverseReaction
inflammation NN I-AdverseReaction I-AdverseReaction
and NN O O
iritis NN B-AdverseReaction B-AdverseReaction
Ocular NN O O
adverse NN O O
reactions NN O O
occurring NN O O
in NN O O
< NN O O
1 NN O O
% NN O O
of NN O O
subjects NN O O
included NN O O
application NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
discomfort NN I-AdverseReaction I-AdverseReaction
or NN O O
irritation NN O O
, NN O O
corneal NN B-AdverseReaction B-AdverseReaction
pigmentation NN I-AdverseReaction I-AdverseReaction
and NN O O
striae NN O O
, NN O O
episcleritis NN B-AdverseReaction B-AdverseReaction
eye NN B-AdverseReaction B-AdverseReaction
pruritis NN I-AdverseReaction I-AdverseReaction
eyelid NN B-AdverseReaction B-AdverseReaction
irritation NN I-AdverseReaction I-AdverseReaction
and NN O O
crusting NN O O
, NN O O
foreign NN B-AdverseReaction B-AdverseReaction
body NN I-AdverseReaction I-AdverseReaction
sensation NN I-AdverseReaction I-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
lacrimation NN I-AdverseReaction I-AdverseReaction
macular NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
sclera NN B-AdverseReaction B-AdverseReaction
hyperemia NN I-AdverseReaction I-AdverseReaction
and NN O O
uveitis NN B-AdverseReaction B-AdverseReaction
Most NN O O
of NN O O
these NN O O
reactions NN O O
may NN O O
have NN O O
been NN O O
the NN O O
consequence NN O O
of NN O O
the NN O O
surgical NN O O
procedure NN O O
. NN O O
6.2 NN O O
Endogenous NN O O
Anterior NN O O
Uveitis NN O O
A NN O O
total NN O O
of NN O O
200 NN O O
subjects NN O O
participated NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
for NN O O
endogenous NN O O
anterior NN O O
uveitis NN O O
, NN O O
of NN O O
which NN O O
106 NN O O
were NN O O
exposed NN O O
to NN O O
DUREZOL. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
of NN O O
those NN O O
exposed NN O O
to NN O O
DUREZOL NN O O
occurring NN O O
in NN O O
5 NN O O
- NN O O
10 NN O O
% NN O O
of NN O O
subjects NN O O
included NN O O
blurred NN B-AdverseReaction B-AdverseReaction
vision NN I-AdverseReaction I-AdverseReaction
eye NN B-AdverseReaction B-AdverseReaction
irritation NN I-AdverseReaction I-AdverseReaction
eye NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
IOP NN I-AdverseReaction I-AdverseReaction
iritis NN B-AdverseReaction B-AdverseReaction
limbal NN O O
and NN O O
conjunctival NN B-AdverseReaction B-AdverseReaction
hyperemia NN I-AdverseReaction I-AdverseReaction
punctate NN B-AdverseReaction B-AdverseReaction
keratitis NN I-AdverseReaction I-AdverseReaction
and NN O O
uveitis NN B-AdverseReaction B-AdverseReaction
Adverse NN O O
reactions NN O O
occurring NN O O
in NN O O
2 NN O O
- NN O O
5 NN O O
% NN O O
of NN O O
subjects NN O O
included NN O O
anterior NN B-AdverseReaction B-AdverseReaction
chamber NN I-AdverseReaction I-AdverseReaction
flare NN I-AdverseReaction I-AdverseReaction
corneal NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
dry NN B-AdverseReaction B-AdverseReaction
eye NN I-AdverseReaction I-AdverseReaction
iridocyclitis NN B-AdverseReaction B-AdverseReaction
photophobia NN B-AdverseReaction B-AdverseReaction
and NN O O
reduced NN B-AdverseReaction B-AdverseReaction
visual NN I-AdverseReaction I-AdverseReaction
acuity NN I-AdverseReaction I-AdverseReaction
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Intraocular NN O O
pressure NN O O
( NN O O
IOP NN O O
) NN O O
increase- NN O O
Prolonged NN O O
use NN O O
of NN O O
corticosteroids NN B-DrugClass B-DrugClass
may NN O O
result NN O O
in NN O O
glaucoma NN B-AdverseReaction B-AdverseReaction
with NN O O
damage NN B-AdverseReaction B-AdverseReaction
to NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
optic NN I-AdverseReaction I-AdverseReaction
nerve NN I-AdverseReaction I-AdverseReaction
defects NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
visual NN I-AdverseReaction I-AdverseReaction
acuity NN I-AdverseReaction I-AdverseReaction
and NN O O
fields NN O O
of NN O O
vision NN O O
. NN O O
If NN O O
this NN O O
product NN O O
is NN O O
used NN O O
for NN O O
10 NN O O
days NN O O
or NN O O
longer NN O O
, NN O O
IOP NN O O
should NN O O
be NN O O
monitored NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
item{ NN O O
Cataracts- NN O O
Use NN O O
of NN O O
corticosteroids NN B-DrugClass B-DrugClass
may NN O O
result NN O O
in NN O O
posterior NN B-AdverseReaction B-AdverseReaction
subcapsular NN I-AdverseReaction I-AdverseReaction
cataract NN I-AdverseReaction I-AdverseReaction
formation NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
item{ NN O O
Delayed NN O O
healing- NN O O
The NN O O
use NN O O
of NN O O
steroids NN B-DrugClass B-DrugClass
after NN O O
cataract NN O O
surgery NN O O
may NN O O
delay NN B-AdverseReaction B-AdverseReaction
healing NN I-AdverseReaction I-AdverseReaction
and NN O O
increase NN O O
the NN O O
incidence NN O O
of NN O O
bleb NN O O
formation NN O O
. NN O O
In NN O O
those NN O O
diseases NN O O
causing NN O O
thinning NN O O
of NN O O
the NN O O
cornea NN O O
or NN O O
sclera NN O O
, NN O O
perforations NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
known NN O O
to NN O O
occur NN O O
with NN O O
the NN O O
use NN O O
of NN O O
topical NN O O
steroids NN B-DrugClass B-DrugClass
The NN O O
initial NN O O
prescription NN O O
and NN O O
renewal NN O O
of NN O O
the NN O O
medication NN O O
order NN O O
beyond NN O O
28 NN O O
days NN O O
should NN O O
be NN O O
made NN O O
by NN O O
a NN O O
physician NN O O
only NN O O
after NN O O
examination NN O O
of NN O O
the NN O O
patient NN O O
with NN O O
the NN O O
aid NN O O
of NN O O
magnification NN O O
such NN O O
as NN O O
slit NN O O
lamp NN O O
biomicroscopy NN O O
and NN O O
, NN O O
where NN O O
appropriate NN O O
, NN O O
fluorescein NN O O
staining NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
item{ NN O O
Bacterial NN O O
infections- NN O O
Prolonged NN O O
use NN O O
of NN O O
corticosteroids NN B-DrugClass B-DrugClass
may NN O O
suppress NN B-AdverseReaction B-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
host NN I-AdverseReaction I-AdverseReaction
response NN I-AdverseReaction I-AdverseReaction
and NN O O
thus NN O O
increase NN O O
the NN O O
hazard NN O O
of NN O O
secondary NN B-AdverseReaction B-AdverseReaction
ocular NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
In NN O O
acute NN O O
purulent NN O O
conditions NN O O
, NN O O
steroids NN O O
may NN O O
mask NN O O
infection NN O O
or NN O O
enhance NN O O
existing NN O O
infection NN O O
. NN O O
If NN O O
signs NN O O
and NN O O
symptoms NN O O
fail NN O O
to NN O O
improve NN O O
after NN O O
2 NN O O
days NN O O
, NN O O
the NN O O
patient NN O O
should NN O O
be NN O O
re NN O O
- NN O O
evaluated NN O O
. NN O O
( NN O O
5.4 NN O O
) NN O O
item{ NN O O
Viral NN O O
infections- NN O O
Employment NN O O
of NN O O
a NN O O
corticosteroid NN O O
medication NN O O
in NN O O
the NN O O
treatment NN O O
of NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
herpes NN O O
simplex NN O O
requires NN O O
great NN O O
caution NN O O
. NN O O
Use NN O O
of NN O O
ocular NN O O
steroids NN B-DrugClass B-DrugClass
may NN O O
prolong NN O O
the NN O O
course NN O O
and NN O O
may NN O O
exacerbate NN O O
the NN O O
severity NN O O
of NN O O
many NN O O
viral NN O O
infections NN O O
of NN O O
the NN O O
eye NN O O
( NN O O
including NN O O
herpes NN O O
simplex NN O O
) NN O O
. NN O O
( NN O O
5.5 NN O O
) NN O O
item{ NN O O
Fungal NN O O
infections- NN O O
Fungal NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
cornea NN I-AdverseReaction I-AdverseReaction
are NN O O
particularly NN O O
prone NN O O
to NN O O
develop NN O O
coincidentally NN O O
with NN O O
long NN O O
- NN O O
term NN O O
local NN O O
steroid NN B-DrugClass B-DrugClass
application NN O O
. NN O O
Fungus NN O O
invasion NN O O
must NN O O
be NN O O
considered NN O O
in NN O O
any NN O O
persistent NN O O
corneal NN O O
ulceration NN O O
where NN O O
a NN O O
steroid NN O O
has NN O O
been NN O O
used NN O O
or NN O O
is NN O O
in NN O O
use NN O O
. NN O O
( NN O O
5.6 NN O O
) NN O O
} NN O O
} NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Alcon NN O O
Laboratories NN O O
, NN O O
Inc. NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
757 NN O O
- NN O O
9195 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
5.1 NN O O
IOP NN O O
Increase NN O O
Prolonged NN O O
use NN O O
of NN O O
corticosteroids NN B-DrugClass B-DrugClass
may NN O O
result NN O O
in NN O O
glaucoma NN B-AdverseReaction B-AdverseReaction
with NN O O
damage NN B-AdverseReaction B-AdverseReaction
to NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
optic NN I-AdverseReaction I-AdverseReaction
nerve NN I-AdverseReaction I-AdverseReaction
defects NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
visual NN I-AdverseReaction I-AdverseReaction
acuity NN I-AdverseReaction I-AdverseReaction
and NN O O
fields NN O O
of NN O O
vision NN O O
. NN O O
Steroids NN O O
should NN O O
be NN O O
used NN O O
with NN O O
caution NN O O
in NN O O
the NN O O
presence NN O O
of NN O O
glaucoma NN O O
. NN O O
If NN O O
this NN O O
product NN O O
is NN O O
used NN O O
for NN O O
10 NN O O
days NN O O
or NN O O
longer NN O O
, NN O O
intraocular NN O O
pressure NN O O
should NN O O
be NN O O
monitored NN O O
. NN O O
5.2 NN O O
Cataracts NN O O
Use NN O O
of NN O O
corticosteroids NN B-DrugClass B-DrugClass
may NN O O
result NN O O
in NN O O
posterior NN B-AdverseReaction B-AdverseReaction
subcapsular NN I-AdverseReaction I-AdverseReaction
cataract NN I-AdverseReaction I-AdverseReaction
formation NN O O
. NN O O
5.3 NN O O
Delayed NN O O
Healing NN O O
The NN O O
use NN O O
of NN O O
steroids NN B-DrugClass B-DrugClass
after NN O O
cataract NN O O
surgery NN O O
may NN O O
delay NN B-AdverseReaction B-AdverseReaction
healing NN I-AdverseReaction I-AdverseReaction
and NN O O
increase NN O O
the NN O O
incidence NN O O
of NN O O
bleb NN O O
formation NN O O
. NN O O
In NN O O
those NN O O
diseases NN O O
causing NN O O
thinning NN O O
of NN O O
the NN O O
cornea NN O O
or NN O O
sclera NN O O
, NN O O
perforations NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
known NN O O
to NN O O
occur NN O O
with NN O O
the NN O O
use NN O O
of NN O O
topical NN O O
steroids NN B-DrugClass B-DrugClass
The NN O O
initial NN O O
prescription NN O O
and NN O O
renewal NN O O
of NN O O
the NN O O
medication NN O O
order NN O O
beyond NN O O
28 NN O O
days NN O O
should NN O O
be NN O O
made NN O O
by NN O O
a NN O O
physician NN O O
only NN O O
after NN O O
examination NN O O
of NN O O
the NN O O
patient NN O O
with NN O O
the NN O O
aid NN O O
of NN O O
magnification NN O O
such NN O O
as NN O O
slit NN O O
lamp NN O O
biomicroscopy NN O O
and NN O O
, NN O O
where NN O O
appropriate NN O O
, NN O O
fluorescein NN O O
staining NN O O
. NN O O
5.4 NN O O
Bacterial NN O O
Infections NN O O
Prolonged NN O O
use NN O O
of NN O O
corticosteroids NN B-DrugClass B-DrugClass
may NN O O
suppress NN B-AdverseReaction B-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
host NN I-AdverseReaction I-AdverseReaction
response NN I-AdverseReaction I-AdverseReaction
and NN O O
thus NN O O
increase NN O O
the NN O O
hazard NN O O
of NN O O
secondary NN B-AdverseReaction B-AdverseReaction
ocular NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
In NN O O
acute NN O O
purulent NN O O
conditions NN O O
, NN O O
steroids NN O O
may NN O O
mask NN O O
infection NN O O
or NN O O
enhance NN O O
existing NN O O
infection NN O O
. NN O O
If NN O O
signs NN O O
and NN O O
symptoms NN O O
fail NN O O
to NN O O
improve NN O O
after NN O O
2 NN O O
days NN O O
, NN O O
the NN O O
patient NN O O
should NN O O
be NN O O
re NN O O
- NN O O
evaluated NN O O
. NN O O
5.5 NN O O
Viral NN O O
Infections NN O O
Employment NN O O
of NN O O
a NN O O
corticosteroid NN O O
medication NN O O
in NN O O
the NN O O
treatment NN O O
of NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
herpes NN O O
simplex NN O O
requires NN O O
great NN O O
caution NN O O
. NN O O
Use NN O O
of NN O O
ocular NN O O
steroids NN B-DrugClass B-DrugClass
may NN O O
prolong NN O O
the NN O O
course NN O O
and NN O O
may NN O O
exacerbate NN O O
the NN O O
severity NN O O
of NN O O
many NN O O
viral NN O O
infections NN O O
of NN O O
the NN O O
eye NN O O
( NN O O
including NN O O
herpes NN O O
simplex NN O O
) NN O O
. NN O O
5.6 NN O O
Fungal NN O O
Infections NN O O
Fungal NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
cornea NN I-AdverseReaction I-AdverseReaction
are NN O O
particularly NN O O
prone NN O O
to NN O O
develop NN O O
coincidentally NN O O
with NN O O
long NN O O
- NN O O
term NN O O
local NN O O
steroid NN B-DrugClass B-DrugClass
application NN O O
. NN O O
Fungus NN O O
invasion NN O O
must NN O O
be NN O O
considered NN O O
in NN O O
any NN O O
persistent NN O O
corneal NN O O
ulceration NN O O
where NN O O
a NN O O
steroid NN O O
has NN O O
been NN O O
used NN O O
or NN O O
is NN O O
in NN O O
use NN O O
. NN O O
Fungal NN O O
culture NN O O
should NN O O
be NN O O
taken NN O O
when NN O O
appropriate NN O O
. NN O O
5.7 NN O O
Topical NN O O
Ophthalmic NN O O
Use NN O O
Only NN O O
DUREZOL NN O O
is NN O O
not NN O O
indicated NN O O
for NN O O
intraocular NN O O
administration NN O O
. NN O O
5.8 NN O O
Contact NN O O
Lens NN O O
Wear NN O O
DUREZOL NN O O
should NN O O
not NN O O
be NN O O
instilled NN O O
while NN O O
wearing NN O O
contact NN O O
lenses NN O O
. NN O O
Remove NN O O
contact NN O O
lenses NN O O
prior NN O O
to NN O O
instillation NN O O
of NN O O
DUREZOL. NN O O
The NN O O
preservative NN O O
in NN O O
DUREZOL NN O O
may NN O O
be NN O O
absorbed NN O O
by NN O O
soft NN O O
contact NN O O
lenses NN O O
. NN O O
Lenses NN O O
may NN O O
be NN O O
reinserted NN O O
after NN O O
10 NN O O
minutes NN O O
following NN O O
administration NN O O
of NN O O
DUREZOL. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
serious NN O O
adverse NN O O
reactions NN O O
are NN O O
described NN O O
in NN O O
more NN O O
detail NN O O
in NN O O
other NN O O
sections NN O O
of NN O O
the NN O O
prescribing NN O O
information NN O O
. NN O O
* NN O O
Hematologic NN B-AdverseReaction B-AdverseReaction
Toxicity NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Infection NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
Hepatotoxicity NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
* NN O O
Tumor NN B-AdverseReaction B-AdverseReaction
Lysis NN I-AdverseReaction I-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
* NN O O
Gastrointestinal NN B-AdverseReaction B-AdverseReaction
Toxicity NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
observed NN O O
in NN O O
the NN O O
trial NN O O
of NN O O
patients NN O O
with NN O O
relapsed NN O O
or NN O O
refractory NN O O
PTCL NN O O
treated NN O O
with NN O O
Beleodaq NN O O
were NN O O
nausea NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
pyrexia NN B-AdverseReaction B-AdverseReaction
anemia NN B-AdverseReaction B-AdverseReaction
and NN O O
vomiting NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
. NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>25 NN O O
% NN O O
) NN O O
are NN O O
nausea NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
pyrexia NN B-AdverseReaction B-AdverseReaction
anemia NN B-AdverseReaction B-AdverseReaction
and NN O O
vomiting NN B-AdverseReaction B-AdverseReaction
( NN O O
6 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Spectrum NN O O
Pharmaceuticals NN O O
, NN O O
Inc. NN O O
at NN O O
1 NN O O
- NN O O
888 NN O O
- NN O O
292 NN O O
- NN O O
9617 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
Beleodaq NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
Adverse NN O O
Reactions NN O O
in NN O O
Patients NN O O
with NN O O
Peripheral NN O O
T NN O O
- NN O O
Cell NN O O
Lymphoma NN O O
The NN O O
safety NN O O
of NN O O
Beleodaq NN O O
was NN O O
evaluated NN O O
in NN O O
129 NN O O
patients NN O O
with NN O O
relapsed NN O O
or NN O O
refractory NN O O
PTCL NN O O
in NN O O
the NN O O
single NN O O
arm NN O O
clinical NN O O
trial NN O O
in NN O O
which NN O O
patients NN O O
were NN O O
administered NN O O
Beleodaq NN O O
at NN O O
a NN O O
dosage NN O O
of NN O O
1,000 NN O O
mg/m2 NN O O
administered NN O O
over NN O O
30 NN O O
minutes NN O O
by NN O O
IV NN O O
infusion NN O O
once NN O O
daily NN O O
on NN O O
Days NN O O
1 NN O O
- NN O O
5 NN O O
of NN O O
a NN O O
21-day NN O O
cycle NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
median NN O O
duration NN O O
of NN O O
treatment NN O O
was NN O O
2 NN O O
cycles NN O O
( NN O O
range NN O O
1 NN O O
- NN O O
33 NN O O
cycles NN O O
) NN O O
. NN O O
Table NN O O
2 NN O O
summarizes NN O O
the NN O O
adverse NN O O
reactions NN O O
regardless NN O O
of NN O O
causality NN O O
from NN O O
the NN O O
trial NN O O
in NN O O
patients NN O O
with NN O O
relapsed NN O O
or NN O O
refractory NN O O
PTCL. NN O O
Table NN O O
2 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Occurring NN O O
in NN O O
>= NN O O
10 NN O O
% NN O O
of NN O O
Patients NN O O
by NN O O
Preferred NN O O
Term NN O O
and NN O O
Severity NN O O
in NN O O
Patients NN O O
with NN O O
Relapsed NN O O
or NN O O
Refractory NN O O
PTCL NN O O
( NN O O
NCI NN O O
- NN O O
CTC NN O O
Grade NN O O
1 NN O O
- NN O O
4 NN O O
) NN O O
MedDRA NN O O
Preferred NN O O
Term NN O O
Percentage NN O O
of NN O O
Patients NN O O
( NN O O
% NN O O
) NN O O
( NN O O
N=129 NN O O
) NN O O
All NN O O
Grades NN O O
Grade NN O O
3 NN O O
or NN O O
4 NN O O
All NN O O
Adverse NN O O
Reactions NN O O
97 NN O O
61 NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
42 NN O O
1 NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
37 NN O O
5 NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
35 NN O O
2 NN O O
Anemia NN B-AdverseReaction B-AdverseReaction
32 NN O O
11 NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
29 NN O O
1 NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
23 NN O O
1 NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
23 NN O O
2 NN O O
Dyspnea NN B-AdverseReaction B-AdverseReaction
22 NN O O
6 NN O O
Rash NN B-AdverseReaction B-AdverseReaction
20 NN O O
1 NN O O
Peripheral NN B-AdverseReaction B-AdverseReaction
Edema NN I-AdverseReaction I-AdverseReaction
20 NN O O
0 NN O O
Cough NN B-AdverseReaction B-AdverseReaction
19 NN O O
0 NN O O
Thrombocytopenia NN B-AdverseReaction B-AdverseReaction
16 NN O O
7 NN O O
Pruritus NN B-AdverseReaction B-AdverseReaction
16 NN O O
3 NN O O
Chills NN B-AdverseReaction B-AdverseReaction
16 NN O O
1 NN O O
Increased NN B-AdverseReaction B-AdverseReaction
Blood NN I-AdverseReaction I-AdverseReaction
Lactate NN I-AdverseReaction I-AdverseReaction
Dehydrogenase NN I-AdverseReaction I-AdverseReaction
16 NN O O
2 NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
Appetite NN I-AdverseReaction I-AdverseReaction
15 NN O O
2 NN O O
Headache NN B-AdverseReaction B-AdverseReaction
15 NN O O
0 NN O O
Infusion NN B-AdverseReaction B-AdverseReaction
Site NN I-AdverseReaction I-AdverseReaction
Pain NN I-AdverseReaction I-AdverseReaction
14 NN O O
0 NN O O
Hypokalemia NN B-AdverseReaction B-AdverseReaction
12 NN O O
4 NN O O
Prolonged NN B-AdverseReaction B-AdverseReaction
QT NN I-AdverseReaction I-AdverseReaction
11 NN O O
4 NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
11 NN O O
1 NN O O
Hypotension NN B-AdverseReaction B-AdverseReaction
10 NN O O
3 NN O O
Phlebitis NN B-AdverseReaction B-AdverseReaction
10 NN O O
1 NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
10 NN O O
0 NN O O
Note NN O O
: NN O O
Adverse NN O O
reactions NN O O
are NN O O
listed NN O O
by NN O O
order NN O O
of NN O O
incidence NN O O
in NN O O
the NN O O
" NN O O
All NN O O
Grades NN O O
" NN O O
category NN O O
first NN O O
, NN O O
then NN O O
by NN O O
incidence NN O O
in NN O O
" NN O O
the NN O O
Grade NN O O
3 NN O O
or NN O O
4 NN O O
" NN O O
category NN O O
; NN O O
MedDRA NN O O
= NN O O
Medical NN O O
Dictionary NN O O
for NN O O
Regulatory NN O O
Activities NN O O
; NN O O
Severity NN O O
measured NN O O
by NN O O
National NN O O
Cancer NN O O
Institute NN O O
Common NN O O
Terminology NN O O
Criteria NN O O
for NN O O
Adverse NN O O
Events NN O O
( NN O O
NCI NN O O
- NN O O
CTCAE NN O O
) NN O O
version NN O O
3.0 NN O O
Serious NN O O
Adverse NN O O
Reactions NN O O
Sixty NN O O
- NN O O
one NN O O
patients NN O O
( NN O O
47.3 NN O O
% NN O O
) NN O O
experienced NN O O
serious NN O O
adverse NN O O
reactions NN O O
while NN O O
taking NN O O
Beleodaq NN O O
or NN O O
within NN O O
30 NN O O
days NN O O
after NN O O
their NN O O
last NN O O
dose NN O O
of NN O O
Beleodaq NN O O
. NN O O
The NN O O
most NN O O
common NN O O
serious NN O O
adverse NN O O
reactions NN O O
( NN O O
> NN O O
2 NN O O
% NN O O
) NN O O
were NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
pyrexia NN B-AdverseReaction B-AdverseReaction
infection NN B-AdverseReaction B-AdverseReaction
anemia NN B-AdverseReaction B-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
and NN O O
multi NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
organ NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
One NN O O
treatment NN O O
- NN O O
related NN O O
death NN B-AdverseReaction B-AdverseReaction
associated NN O O
with NN O O
hepatic NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
was NN O O
reported NN O O
in NN O O
the NN O O
trial NN O O
. NN O O
One NN O O
patient NN O O
with NN O O
baseline NN O O
hyperuricemia NN O O
and NN O O
bulky NN O O
disease NN O O
experienced NN O O
Grade NN B-Severity B-Severity
4 NN I-Severity I-Severity
tumor NN B-AdverseReaction B-AdverseReaction
lysis NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
during NN O O
the NN O O
first NN O O
cycle NN O O
of NN O O
treatment NN O O
and NN O O
died NN B-AdverseReaction B-AdverseReaction
due NN O O
to NN O O
multi NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
organ NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
A NN O O
treatment NN O O
- NN O O
related NN O O
death NN B-AdverseReaction B-AdverseReaction
from NN O O
ventricular NN B-AdverseReaction B-AdverseReaction
fibrillation NN I-AdverseReaction I-AdverseReaction
was NN O O
reported NN O O
in NN O O
another NN O O
monotherapy NN O O
clinical NN O O
trial NN O O
with NN O O
Beleodaq NN O O
. NN O O
ECG NN O O
analysis NN O O
did NN B-Negation B-Negation
not NN I-Negation I-Negation
identify NN I-Negation I-Negation
QTc NN B-AdverseReaction B-AdverseReaction
prolongation NN I-AdverseReaction I-AdverseReaction
Discontinuations NN O O
due NN O O
to NN O O
Adverse NN O O
Reactions NN O O
Twenty NN O O
- NN O O
five NN O O
patients NN O O
( NN O O
19.4 NN O O
% NN O O
) NN O O
discontinued NN O O
treatment NN O O
with NN O O
Beleodaq NN O O
due NN O O
to NN O O
adverse NN O O
reactions NN O O
. NN O O
The NN O O
adverse NN O O
reactions NN O O
reported NN O O
most NN O O
frequently NN O O
as NN O O
the NN O O
reason NN O O
for NN O O
discontinuation NN O O
of NN O O
treatment NN O O
included NN O O
anemia NN B-AdverseReaction B-AdverseReaction
febrile NN B-AdverseReaction B-AdverseReaction
neutropenia NN I-AdverseReaction I-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
and NN O O
multi NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
organ NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
Dosage NN O O
Modifications NN O O
due NN O O
to NN O O
Adverse NN O O
Reactions NN O O
In NN O O
the NN O O
trial NN O O
, NN O O
dosage NN O O
adjustments NN O O
due NN O O
to NN O O
adverse NN O O
reactions NN O O
occurred NN O O
in NN O O
12 NN O O
% NN O O
of NN O O
Beleodaq NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Thrombocytopenia NN B-AdverseReaction B-AdverseReaction
leukopenia NN B-AdverseReaction B-AdverseReaction
( NN O O
neutropenia NN O O
and NN O O
lymphopenia NN B-AdverseReaction B-AdverseReaction
and NN O O
anemia NN B-AdverseReaction B-AdverseReaction
Monitor NN O O
blood NN O O
counts NN O O
and NN O O
modify NN O O
dosage NN O O
for NN O O
hematologic NN O O
toxicities NN O O
. NN O O
( NN O O
2.2 NN O O
, NN O O
5.1 NN O O
) NN O O
* NN O O
Infection NN B-AdverseReaction B-AdverseReaction
Serious NN B-Severity B-Severity
and NN O O
fatal NN B-AdverseReaction B-AdverseReaction
infections NN B-AdverseReaction B-AdverseReaction
( NN O O
e.g. NN O O
, NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
and NN O O
sepsis NN B-AdverseReaction B-AdverseReaction
( NN O O
5.2 NN O O
) NN O O
* NN O O
Hepatotoxicity NN B-AdverseReaction B-AdverseReaction
Beleodaq NN O O
may NN B-Factor B-Factor
cause NN O O
hepatic NN B-AdverseReaction B-AdverseReaction
toxicity NN I-AdverseReaction I-AdverseReaction
and NN O O
liver NN B-AdverseReaction B-AdverseReaction
function NN I-AdverseReaction I-AdverseReaction
test NN I-AdverseReaction I-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
liver NN O O
function NN O O
tests NN O O
and NN O O
omit NN O O
or NN O O
modify NN O O
dosage NN O O
for NN O O
hepatic NN O O
toxicities NN O O
. NN O O
( NN O O
2.2 NN O O
, NN O O
5.3 NN O O
) NN O O
* NN O O
Tumor NN B-AdverseReaction B-AdverseReaction
lysis NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
patients NN O O
with NN O O
advanced NN O O
stage NN O O
disease NN O O
and/or NN O O
high NN O O
tumor NN O O
burden NN O O
and NN O O
take NN O O
appropriate NN O O
precautions NN O O
. NN O O
( NN O O
5.4 NN O O
) NN O O
* NN O O
Embryo NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
fetal NN I-AdverseReaction I-AdverseReaction
toxicity NN I-AdverseReaction I-AdverseReaction
Beleodaq NN O O
may NN B-Factor B-Factor
cause NN O O
fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
when NN O O
administered NN O O
to NN O O
a NN O O
pregnant NN O O
woman NN O O
. NN O O
Advise NN O O
women NN O O
of NN O O
potential NN O O
harm NN O O
to NN O O
the NN O O
fetus NN O O
and NN O O
to NN O O
avoid NN O O
pregnancy NN O O
while NN O O
receiving NN O O
Beleodaq NN O O
. NN O O
( NN O O
5.6 NN O O
) NN O O
5.1 NN O O
Hematologic NN O O
Toxicity NN O O
Beleodaq NN O O
can NN B-Factor B-Factor
cause NN O O
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
leukopenia NN B-AdverseReaction B-AdverseReaction
( NN O O
neutropenia NN O O
and NN O O
lymphopenia NN B-AdverseReaction B-AdverseReaction
and/or NN O O
anemia NN B-AdverseReaction B-AdverseReaction
monitor NN O O
blood NN O O
counts NN O O
weekly NN O O
during NN O O
treatment NN O O
, NN O O
and NN O O
modify NN O O
dosage NN O O
as NN O O
necessary NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
and NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
Infections NN O O
Serious NN B-Severity B-Severity
and NN O O
sometimes NN O O
fatal NN B-AdverseReaction B-AdverseReaction
infections NN B-AdverseReaction B-AdverseReaction
including NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
and NN O O
sepsis NN B-AdverseReaction B-AdverseReaction
have NN O O
occurred NN O O
with NN O O
Beleodaq NN O O
. NN O O
Do NN O O
not NN O O
administer NN O O
Beleodaq NN O O
to NN O O
patients NN O O
with NN O O
an NN O O
active NN O O
infection NN O O
. NN O O
Patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
extensive NN O O
or NN O O
intensive NN O O
chemotherapy NN O O
may NN O O
be NN O O
at NN O O
higher NN O O
risk NN O O
of NN O O
life NN O O
threatening NN O O
infections NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
5.3 NN O O
Hepatotoxicity NN O O
Beleodaq NN O O
can NN B-Factor B-Factor
cause NN O O
fatal NN B-AdverseReaction B-AdverseReaction
hepatotoxicity NN B-AdverseReaction B-AdverseReaction
and NN O O
liver NN B-AdverseReaction B-AdverseReaction
function NN I-AdverseReaction I-AdverseReaction
test NN I-AdverseReaction I-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Monitor NN O O
liver NN O O
function NN O O
tests NN O O
before NN O O
treatment NN O O
and NN O O
before NN O O
the NN O O
start NN O O
of NN O O
each NN O O
cycle NN O O
. NN O O
Interrupt NN O O
or NN O O
adjust NN O O
dosage NN O O
until NN O O
recovery NN O O
, NN O O
or NN O O
permanently NN O O
discontinue NN O O
Beleodaq NN O O
based NN O O
on NN O O
the NN O O
severity NN O O
of NN O O
the NN O O
hepatic NN O O
toxicity NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
] NN O O
. NN O O
5.4 NN O O
Tumor NN O O
Lysis NN O O
Syndrome NN O O
Tumor NN B-AdverseReaction B-AdverseReaction
lysis NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
has NN O O
occurred NN O O
in NN O O
Beleodaq NN O O
- NN O O
treated NN O O
patients NN O O
in NN O O
the NN O O
clinical NN O O
trial NN O O
of NN O O
patients NN O O
with NN O O
relapsed NN O O
or NN O O
refractory NN O O
PTCL NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
. NN O O
Monitor NN O O
patients NN O O
with NN O O
advanced NN O O
stage NN O O
disease NN O O
and/or NN O O
high NN O O
tumor NN O O
burden NN O O
and NN O O
take NN O O
appropriate NN O O
precautions NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
5.5 NN O O
Gastrointestinal NN O O
Toxicity NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
and NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
occur NN O O
with NN O O
Beleodaq NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
and NN O O
may NN O O
require NN O O
the NN O O
use NN O O
of NN O O
antiemetic NN O O
and NN O O
antidiarrheal NN O O
medications NN O O
. NN O O
5.6 NN O O
Embryo NN O O
- NN O O
fetal NN O O
Toxicity NN O O
Beleodaq NN O O
can NN B-Factor B-Factor
cause NN O O
fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
when NN O O
administered NN O O
to NN O O
a NN O O
pregnant NN O O
woman NN O O
. NN O O
Beleodaq NN O O
may NN B-Factor B-Factor
cause NN O O
teratogenicity NN B-AdverseReaction B-AdverseReaction
and/or NN O O
embryo NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
fetal NN I-AdverseReaction I-AdverseReaction
lethality NN I-AdverseReaction I-AdverseReaction
because NN O O
it NN O O
is NN O O
genotoxic NN B-AdverseReaction B-AdverseReaction
and NN O O
targets NN O O
actively NN O O
dividing NN O O
cells NN O O
[ NN O O
see NN O O
Nonclinical NN O O
Toxicology NN O O
( NN O O
13.1 NN O O
) NN O O
] NN O O
. NN O O
Women NN O O
of NN O O
childbearing NN O O
potential NN O O
should NN O O
be NN O O
advised NN O O
to NN O O
avoid NN O O
pregnancy NN O O
while NN O O
receiving NN O O
Beleodaq NN O O
. NN O O
If NN O O
this NN O O
drug NN O O
is NN O O
used NN O O
during NN O O
pregnancy NN O O
, NN O O
or NN O O
if NN O O
the NN O O
patient NN O O
becomes NN O O
pregnant NN O O
while NN O O
taking NN O O
this NN O O
drug NN O O
, NN O O
the NN O O
patient NN O O
should NN O O
be NN O O
apprised NN O O
of NN O O
potential NN O O
hazard NN O O
to NN O O
the NN O O
fetus NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.1 NN O O
) NN O O
] NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
Clinically NN O O
significant NN O O
adverse NN O O
reactions NN O O
that NN O O
appear NN O O
in NN O O
other NN O O
sections NN O O
of NN O O
the NN O O
labeling NN O O
include NN O O
the NN O O
following NN O O
: NN O O
* NN O O
Somnolence NN B-AdverseReaction B-AdverseReaction
or NN O O
Sedation NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Potentiation NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
Sedation NN I-AdverseReaction I-AdverseReaction
from NN O O
Concomitant NN O O
Use NN O O
with NN O O
Central NN O O
Nervous NN O O
System NN O O
Depressants NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
Withdrawal NN O O
Symptoms NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
* NN O O
Serious NN B-Severity B-Severity
Dermatological NN B-AdverseReaction B-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
, NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
* NN O O
Physical NN O O
and NN O O
Psychological NN B-AdverseReaction B-AdverseReaction
Dependence NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
* NN O O
Suicidal NN B-AdverseReaction B-AdverseReaction
Behavior NN I-AdverseReaction I-AdverseReaction
and NN O O
Ideation NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.6 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
Adverse NN O O
reactions NN O O
that NN O O
occurred NN O O
at NN O O
least NN O O
10 NN O O
% NN O O
more NN O O
frequently NN O O
than NN O O
placebo NN O O
in NN O O
any NN O O
ONFI NN O O
dose NN O O
included NN O O
constipation NN B-AdverseReaction B-AdverseReaction
somnolence NN B-AdverseReaction B-AdverseReaction
or NN O O
sedation NN B-AdverseReaction B-AdverseReaction
pyrexia NN B-AdverseReaction B-AdverseReaction
lethargy NN B-AdverseReaction B-AdverseReaction
and NN O O
drooling NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Lundbeck NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
455 NN O O
- NN O O
1141 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
During NN O O
its NN O O
development NN O O
for NN O O
the NN O O
adjunctive NN O O
treatment NN O O
of NN O O
seizures NN O O
associated NN O O
with NN O O
LGS NN O O
, NN O O
ONFI NN O O
was NN O O
administered NN O O
to NN O O
333 NN O O
healthy NN O O
volunteers NN O O
and NN O O
300 NN O O
patients NN O O
with NN O O
a NN O O
current NN O O
or NN O O
prior NN O O
diagnosis NN O O
of NN O O
LGS NN O O
, NN O O
including NN O O
197 NN O O
patients NN O O
treated NN O O
for NN O O
12 NN O O
months NN O O
or NN O O
more NN O O
. NN O O
The NN O O
conditions NN O O
and NN O O
duration NN O O
of NN O O
exposure NN O O
varied NN O O
greatly NN O O
and NN O O
included NN O O
single- NN O O
and NN O O
multiple NN O O
- NN O O
dose NN O O
clinical NN O O
pharmacology NN O O
studies NN O O
in NN O O
healthy NN O O
volunteers NN O O
and NN O O
two NN O O
double NN O O
- NN O O
blind NN O O
studies NN O O
in NN O O
patients NN O O
with NN O O
LGS NN O O
( NN O O
Study NN O O
1 NN O O
and NN O O
2 NN O O
) NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
. NN O O
Only NN O O
Study NN O O
1 NN O O
included NN O O
a NN O O
placebo NN O O
group NN O O
, NN O O
allowing NN O O
comparison NN O O
of NN O O
adverse NN O O
reaction NN O O
rates NN O O
on NN O O
ONFI NN O O
at NN O O
several NN O O
doses NN O O
to NN O O
placebo NN O O
. NN O O
Adverse NN O O
Reactions NN O O
Leading NN O O
to NN O O
Discontinuation NN O O
in NN O O
an NN O O
LGS NN O O
Placebo NN O O
Controlled NN O O
Clinical NN O O
Trial NN O O
( NN O O
Study NN O O
1 NN O O
) NN O O
The NN O O
adverse NN O O
reactions NN O O
associated NN O O
with NN O O
ONFI NN O O
treatment NN O O
discontinuation NN O O
in NN O O
>=1 NN O O
% NN O O
of NN O O
patients NN O O
in NN O O
decreasing NN O O
order NN O O
of NN O O
frequency NN O O
included NN O O
lethargy NN B-AdverseReaction B-AdverseReaction
somnolence NN B-AdverseReaction B-AdverseReaction
ataxia NN B-AdverseReaction B-AdverseReaction
aggression NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
and NN O O
insomnia NN B-AdverseReaction B-AdverseReaction
Most NN O O
Common NN O O
Adverse NN O O
Reactions NN O O
in NN O O
an NN O O
LGS NN O O
Placebo NN O O
Controlled NN O O
Clinical NN O O
Trial NN O O
( NN O O
Study NN O O
1 NN O O
) NN O O
Table NN O O
3 NN O O
lists NN O O
the NN O O
adverse NN O O
reactions NN O O
that NN O O
occurred NN O O
in NN O O
>=5 NN O O
% NN O O
of NN O O
ONFI NN O O
treated NN O O
patients NN O O
( NN O O
at NN O O
any NN O O
dose NN O O
) NN O O
, NN O O
and NN O O
at NN O O
a NN O O
rate NN O O
greater NN O O
than NN O O
placebo NN O O
treated NN O O
patients NN O O
, NN O O
in NN O O
the NN O O
randomized NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
, NN O O
parallel NN O O
group NN O O
clinical NN O O
study NN O O
of NN O O
adjunctive NN O O
AED NN O O
therapy NN O O
for NN O O
15 NN O O
weeks NN O O
( NN O O
Study NN O O
1 NN O O
) NN O O
. NN O O
Table NN O O
3 NN O O
. NN O O
Adverse NN O O
Reactions NN O O
Reported NN O O
for NN O O
>=5 NN O O
% NN O O
of NN O O
Patients NN O O
and NN O O
More NN O O
Frequently NN O O
than NN O O
Placebo NN O O
in NN O O
Any NN O O
Treatment NN O O
Group NN O O
a NN O O
Maximum NN O O
daily NN O O
dose NN O O
of NN O O
5 NN O O
mg NN O O
for NN O O
< NN O O
=30 NN O O
kg NN O O
body NN O O
weight NN O O
; NN O O
10 NN O O
mg NN O O
for NN O O
>30 NN O O
kg NN O O
body NN O O
weight NN O O
b NN O O
Maximum NN O O
daily NN O O
dose NN O O
of NN O O
10 NN O O
mg NN O O
for NN O O
< NN O O
=30 NN O O
kg NN O O
body NN O O
weight NN O O
; NN O O
20 NN O O
mg NN O O
for NN O O
>30 NN O O
kg NN O O
body NN O O
weight NN O O
c NN O O
Maximum NN O O
daily NN O O
dose NN O O
of NN O O
20 NN O O
mg NN O O
for NN O O
< NN O O
=30 NN O O
kg NN O O
body NN O O
weight NN O O
; NN O O
40 NN O O
mg NN O O
for NN O O
>30 NN O O
kg NN O O
body NN O O
weight NN O O
Placebo NN O O
N=59 NN O O
% NN O O
ONFI NN O O
Dose NN O O
Level NN O O
All NN O O
ONFI NN O O
N=179 NN O O
% NN O O
Low NN O O
a NN O O
N=58 NN O O
% NN O O
Medium NN O O
b NN O O
N=62 NN O O
% NN O O
High NN O O
c NN O O
N=59 NN O O
% NN O O
Gastrointestinal NN O O
Disorders NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
5 NN O O
9 NN O O
5 NN O O
7 NN O O
7 NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
0 NN O O
2 NN O O
2 NN O O
10 NN O O
5 NN O O
Dysphagia NN B-AdverseReaction B-AdverseReaction
0 NN O O
0 NN O O
0 NN O O
5 NN O O
2 NN O O
General NN O O
Disorders NN O O
and NN O O
Administration NN O O
Site NN O O
Conditions NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
3 NN O O
17 NN O O
10 NN O O
12 NN O O
13 NN O O
Irritability NN B-AdverseReaction B-AdverseReaction
5 NN O O
3 NN O O
11 NN O O
5 NN O O
7 NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
2 NN O O
5 NN O O
5 NN O O
3 NN O O
5 NN O O
Infections NN O O
and NN O O
Infestations NN O O
Upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
10 NN O O
10 NN O O
13 NN O O
14 NN O O
12 NN O O
Pneumonia NN B-AdverseReaction B-AdverseReaction
2 NN O O
3 NN O O
3 NN O O
7 NN O O
4 NN O O
Urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
0 NN O O
2 NN O O
5 NN O O
5 NN O O
4 NN O O
Bronchitis NN B-AdverseReaction B-AdverseReaction
0 NN O O
2 NN O O
0 NN O O
5 NN O O
2 NN O O
Metabolism NN O O
and NN O O
Nutrition NN O O
Disorders NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
3 NN O O
3 NN O O
0 NN O O
7 NN O O
3 NN O O
Increased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
0 NN O O
2 NN O O
3 NN O O
5 NN O O
3 NN O O
Nervous NN O O
System NN O O
Disorders NN O O
Somnolence NN B-AdverseReaction B-AdverseReaction
or NN O O
Sedation NN B-AdverseReaction B-AdverseReaction
15 NN O O
17 NN O O
27 NN O O
32 NN O O
26 NN O O
Somnolence NN B-AdverseReaction B-AdverseReaction
12 NN O O
16 NN O O
24 NN O O
25 NN O O
22 NN O O
Sedation NN B-AdverseReaction B-AdverseReaction
3 NN O O
2 NN O O
3 NN O O
9 NN O O
5 NN O O
Lethargy NN B-AdverseReaction B-AdverseReaction
5 NN O O
10 NN O O
5 NN O O
15 NN O O
10 NN O O
Drooling NN B-AdverseReaction B-AdverseReaction
3 NN O O
0 NN O O
13 NN O O
14 NN O O
9 NN O O
Ataxia NN B-AdverseReaction B-AdverseReaction
3 NN O O
3 NN O O
2 NN O O
10 NN O O
5 NN O O
Psychomotor NN B-AdverseReaction B-AdverseReaction
hyperactivity NN I-AdverseReaction I-AdverseReaction
3 NN O O
3 NN O O
3 NN O O
5 NN O O
4 NN O O
Dysarthria NN B-AdverseReaction B-AdverseReaction
0 NN O O
2 NN O O
2 NN O O
5 NN O O
3 NN O O
Psychiatric NN O O
Disorders NN O O
Aggression NN B-AdverseReaction B-AdverseReaction
5 NN O O
3 NN O O
8 NN O O
14 NN O O
8 NN O O
Insomnia NN B-AdverseReaction B-AdverseReaction
2 NN O O
2 NN O O
5 NN O O
7 NN O O
5 NN O O
Respiratory NN O O
Disorders NN O O
Cough NN B-AdverseReaction B-AdverseReaction
0 NN O O
3 NN O O
5 NN O O
7 NN O O
5 NN O O
6.2 NN O O
Post NN O O
Marketing NN O O
Experience NN O O
These NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
; NN O O
therefore NN O O
, NN O O
it NN O O
is NN O O
not NN O O
possible NN O O
to NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
Adverse NN O O
reactions NN O O
are NN O O
categorized NN O O
by NN O O
system NN O O
organ NN O O
class NN O O
. NN O O
Blood NN O O
Disorders NN O O
: NN O O
Anemia NN B-AdverseReaction B-AdverseReaction
eosinophilia NN B-AdverseReaction B-AdverseReaction
leukopenia NN B-AdverseReaction B-AdverseReaction
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
Eye NN O O
Disorders NN O O
: NN O O
Diplopia NN B-AdverseReaction B-AdverseReaction
vision NN B-AdverseReaction B-AdverseReaction
blurred NN I-AdverseReaction I-AdverseReaction
Gastrointestinal NN O O
Disorders NN O O
: NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
distention NN I-AdverseReaction I-AdverseReaction
General NN O O
Disorders NN O O
and NN O O
Administration NN O O
Site NN O O
Conditions NN O O
: NN O O
Hypothermia NN B-AdverseReaction B-AdverseReaction
Investigations NN O O
: NN O O
Hepatic NN B-AdverseReaction B-AdverseReaction
enzyme NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
Musculoskeletal NN O O
: NN O O
Muscle NN B-AdverseReaction B-AdverseReaction
spasms NN I-AdverseReaction I-AdverseReaction
Psychiatric NN O O
Disorders NN O O
: NN O O
Agitation NN B-AdverseReaction B-AdverseReaction
anxiety NN B-AdverseReaction B-AdverseReaction
apathy NN B-AdverseReaction B-AdverseReaction
confusional NN B-AdverseReaction B-AdverseReaction
state NN I-AdverseReaction I-AdverseReaction
depression NN B-AdverseReaction B-AdverseReaction
delirium NN B-AdverseReaction B-AdverseReaction
delusion NN B-AdverseReaction B-AdverseReaction
hallucination NN B-AdverseReaction B-AdverseReaction
Renal NN O O
and NN O O
Urinary NN O O
Disorders NN O O
: NN O O
Urinary NN B-AdverseReaction B-AdverseReaction
retention NN I-AdverseReaction I-AdverseReaction
Respiratory NN O O
Disorders NN O O
: NN O O
Aspiration NN B-AdverseReaction B-AdverseReaction
respiratory NN B-AdverseReaction B-AdverseReaction
depression NN I-AdverseReaction I-AdverseReaction
Skin NN O O
and NN O O
Subcutaneous NN O O
Tissue NN O O
Disorders NN O O
: NN O O
Rash NN B-AdverseReaction B-AdverseReaction
urticaria NN B-AdverseReaction B-AdverseReaction
angioedema NN B-AdverseReaction B-AdverseReaction
and NN O O
facial NN O O
and NN O O
lip NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Somnolence NN B-AdverseReaction B-AdverseReaction
or NN O O
Sedation NN B-AdverseReaction B-AdverseReaction
Monitor NN O O
for NN O O
central NN O O
nervous NN O O
system NN O O
( NN O O
CNS NN O O
) NN O O
depression NN O O
. NN O O
Risk NN O O
may NN O O
be NN O O
increased NN O O
with NN O O
concomitant NN O O
use NN O O
of NN O O
other NN O O
CNS NN O O
depressants NN O O
. NN O O
( NN O O
5.1 NN O O
, NN O O
5.2 NN O O
) NN O O
* NN O O
Withdrawal NN O O
: NN O O
Symptoms NN O O
may NN O O
occur NN O O
with NN O O
rapid NN O O
dose NN O O
reduction NN O O
or NN O O
discontinuation NN O O
. NN O O
Discontinue NN O O
ONFI NN O O
gradually NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Serious NN B-Severity B-Severity
Dermatological NN B-AdverseReaction B-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
Stevens NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Johnson NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
and NN O O
toxic NN B-AdverseReaction B-AdverseReaction
epidermal NN I-AdverseReaction I-AdverseReaction
necrolysis NN I-AdverseReaction I-AdverseReaction
ONFI NN O O
at NN O O
first NN O O
sign NN O O
of NN O O
rash NN O O
unless NN O O
the NN O O
rash NN O O
is NN O O
clearly NN O O
not NN O O
drug NN O O
- NN O O
related NN O O
. NN O O
( NN O O
5.4 NN O O
) NN O O
* NN O O
Physical NN O O
and NN O O
Psychological NN B-AdverseReaction B-AdverseReaction
Dependence NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
substance NN O O
abuse NN O O
for NN O O
signs NN O O
of NN O O
habituation NN O O
and NN O O
dependence NN O O
( NN O O
5.5 NN O O
, NN O O
9 NN O O
) NN O O
* NN O O
Suicidal NN B-AdverseReaction B-AdverseReaction
Behavior NN I-AdverseReaction I-AdverseReaction
and NN O O
Ideation NN O O
: NN O O
Monitor NN O O
for NN O O
suicidal NN O O
thoughts NN O O
or NN O O
behaviors NN O O
( NN O O
5.6 NN O O
) NN O O
5.1 NN O O
Somnolence NN O O
or NN O O
Sedation NN O O
ONFI NN O O
causes NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
and NN O O
sedation NN B-AdverseReaction B-AdverseReaction
In NN O O
clinical NN O O
trials NN O O
, NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
or NN O O
sedation NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
at NN O O
all NN O O
effective NN O O
doses NN O O
and NN O O
was NN O O
dose NN O O
- NN O O
related NN O O
. NN O O
In NN O O
general NN O O
, NN O O
somnolence NN B-AdverseReaction B-AdverseReaction
and NN O O
sedation NN B-AdverseReaction B-AdverseReaction
begin NN O O
within NN O O
the NN O O
first NN O O
month NN O O
of NN O O
treatment NN O O
and NN O O
may NN O O
diminish NN O O
with NN O O
continued NN O O
treatment NN O O
. NN O O
Prescribers NN O O
should NN O O
monitor NN O O
patients NN O O
for NN O O
somnolence NN O O
and NN O O
sedation NN O O
, NN O O
particularly NN O O
with NN O O
concomitant NN O O
use NN O O
of NN O O
other NN O O
central NN O O
nervous NN O O
system NN O O
depressants NN O O
. NN O O
Prescribers NN O O
should NN O O
caution NN O O
patients NN O O
against NN O O
engaging NN O O
in NN O O
hazardous NN O O
activities NN O O
requiring NN O O
mental NN O O
alertness NN O O
, NN O O
such NN O O
as NN O O
operating NN O O
dangerous NN O O
machinery NN O O
or NN O O
motor NN O O
vehicles NN O O
, NN O O
until NN O O
the NN O O
effect NN O O
of NN O O
ONFI NN O O
is NN O O
known NN O O
. NN O O
5.2 NN O O
Potentiation NN O O
of NN O O
Sedation NN O O
from NN O O
Concomitant NN O O
Use NN O O
with NN O O
Central NN O O
Nervous NN O O
System NN O O
Depressants NN O O
Since NN O O
ONFI NN O O
has NN O O
a NN O O
central NN O O
nervous NN O O
system NN O O
( NN O O
CNS NN O O
) NN O O
depressant NN O O
effect NN O O
, NN O O
patients NN O O
or NN O O
their NN O O
caregivers NN O O
should NN O O
be NN O O
cautioned NN O O
against NN O O
simultaneous NN O O
use NN O O
with NN O O
other NN O O
CNS NN O O
depressant NN O O
drugs NN O O
or NN O O
alcohol NN O O
, NN O O
and NN O O
cautioned NN O O
that NN O O
the NN O O
effects NN O O
of NN O O
other NN O O
CNS NN O O
depressant NN O O
drugs NN O O
or NN O O
alcohol NN O O
may NN O O
be NN O O
potentiated NN O O
. NN O O
5.3 NN O O
Withdrawal NN O O
Symptoms NN O O
Abrupt NN O O
discontinuation NN O O
of NN O O
ONFI NN O O
should NN O O
be NN O O
avoided NN O O
. NN O O
ONFI NN O O
should NN O O
be NN O O
tapered NN O O
by NN O O
decreasing NN O O
the NN O O
dose NN O O
every NN O O
week NN O O
by NN O O
5 NN O O
- NN O O
10 NN O O
mg/day NN O O
until NN O O
discontinuation NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
] NN O O
. NN O O
Withdrawal NN O O
symptoms NN O O
occurred NN O O
following NN O O
abrupt NN O O
discontinuation NN O O
of NN O O
ONFI NN O O
; NN O O
the NN O O
risk NN O O
of NN O O
withdrawal NN O O
symptoms NN O O
is NN O O
greater NN O O
with NN O O
higher NN O O
doses NN O O
. NN O O
As NN O O
with NN O O
all NN O O
antiepileptic NN O O
drugs NN O O
, NN O O
ONFI NN O O
should NN O O
be NN O O
withdrawn NN O O
gradually NN O O
to NN O O
minimize NN O O
the NN O O
risk NN O O
of NN O O
precipitating NN O O
seizures NN O O
, NN O O
seizure NN O O
exacerbation NN O O
, NN O O
or NN O O
status NN O O
epilepticus NN O O
. NN O O
Withdrawal NN O O
symptoms NN O O
( NN O O
e.g. NN O O
, NN O O
convulsions NN O O
, NN O O
psychosis NN O O
, NN O O
hallucinations NN O O
, NN O O
behavioral NN O O
disorder NN O O
, NN O O
tremor NN O O
, NN O O
and NN O O
anxiety NN O O
) NN O O
have NN O O
been NN O O
reported NN O O
following NN O O
abrupt NN O O
discontinuance NN O O
of NN O O
benzodiazepines NN O O
. NN O O
The NN O O
more NN O O
severe NN O O
withdrawal NN O O
symptoms NN O O
have NN O O
usually NN O O
been NN O O
limited NN O O
to NN O O
patients NN O O
who NN O O
received NN O O
excessive NN O O
doses NN O O
over NN O O
an NN O O
extended NN O O
period NN O O
of NN O O
time NN O O
, NN O O
followed NN O O
by NN O O
an NN O O
abrupt NN O O
discontinuation NN O O
. NN O O
Generally NN O O
milder NN O O
withdrawal NN O O
symptoms NN O O
( NN O O
e.g. NN O O
, NN O O
dysphoria NN O O
, NN O O
anxiety NN O O
, NN O O
and NN O O
insomnia NN O O
) NN O O
have NN O O
been NN O O
reported NN O O
following NN O O
abrupt NN O O
discontinuance NN O O
of NN O O
benzodiazepines NN O O
taken NN O O
continuously NN O O
at NN O O
therapeutic NN O O
doses NN O O
for NN O O
several NN O O
months NN O O
. NN O O
5.4 NN O O
Serious NN O O
Dermatological NN O O
Reactions NN O O
Serious NN B-Severity B-Severity
skin NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
Stevens NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Johnson NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
SJS NN O O
) NN O O
and NN O O
toxic NN B-AdverseReaction B-AdverseReaction
epidermal NN I-AdverseReaction I-AdverseReaction
necrolysis NN I-AdverseReaction I-AdverseReaction
( NN O O
TEN NN O O
) NN O O
, NN O O
have NN O O
been NN O O
reported NN O O
with NN O O
ONFI NN O O
in NN O O
both NN O O
children NN O O
and NN O O
adults NN O O
during NN O O
the NN O O
post NN O O
- NN O O
marketing NN O O
period NN O O
. NN O O
Patients NN O O
should NN O O
be NN O O
closely NN O O
monitored NN O O
for NN O O
signs NN O O
or NN O O
symptoms NN O O
of NN O O
SJS/TEN NN O O
, NN O O
especially NN O O
during NN O O
the NN O O
first NN O O
8 NN O O
weeks NN O O
of NN O O
treatment NN O O
initiation NN O O
or NN O O
when NN O O
re NN O O
- NN O O
introducing NN O O
therapy NN O O
. NN O O
ONFI NN O O
should NN O O
be NN O O
discontinued NN O O
at NN O O
the NN O O
first NN O O
sign NN O O
of NN O O
rash NN O O
, NN O O
unless NN O O
the NN O O
rash NN O O
is NN O O
clearly NN O O
not NN O O
drug NN O O
- NN O O
related NN O O
. NN O O
If NN O O
signs NN O O
or NN O O
symptoms NN O O
suggest NN O O
SJS/TEN NN O O
, NN O O
use NN O O
of NN O O
this NN O O
drug NN O O
should NN O O
not NN O O
be NN O O
resumed NN O O
and NN O O
alternative NN O O
therapy NN O O
should NN O O
be NN O O
considered NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
] NN O O
. NN O O
5.5 NN O O
Physical NN O O
and NN O O
Psychological NN O O
Dependence NN O O
Patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
substance NN O O
abuse NN O O
should NN O O
be NN O O
under NN O O
careful NN O O
surveillance NN O O
when NN O O
receiving NN O O
ONFI NN O O
or NN O O
other NN O O
psychotropic NN O O
agents NN O O
because NN O O
of NN O O
the NN O O
predisposition NN O O
of NN O O
such NN O O
patients NN O O
to NN O O
habituation NN O O
and NN O O
dependence NN O O
[ NN O O
see NN O O
Drug NN O O
Abuse NN O O
and NN O O
Dependence NN O O
( NN O O
9 NN O O
) NN O O
] NN O O
. NN O O
5.6 NN O O
Suicidal NN O O
Behavior NN O O
and NN O O
Ideation NN O O
Antiepileptic NN O O
drugs NN O O
( NN O O
AEDs NN O O
) NN O O
, NN O O
including NN O O
ONFI NN O O
, NN O O
increase NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
thoughts NN I-AdverseReaction I-AdverseReaction
or NN O O
behavior NN O O
in NN O O
patients NN O O
taking NN O O
these NN O O
drugs NN O O
for NN O O
any NN O O
indication NN O O
. NN O O
Patients NN O O
treated NN O O
with NN O O
any NN O O
AED NN O O
for NN O O
any NN O O
indication NN O O
should NN O O
be NN O O
monitored NN O O
for NN O O
the NN O O
emergence NN O O
or NN O O
worsening NN O O
of NN O O
depression NN O O
, NN O O
suicidal NN O O
thoughts NN O O
or NN O O
behavior NN O O
, NN O O
and/or NN O O
any NN O O
unusual NN O O
changes NN O O
in NN O O
mood NN O O
or NN O O
behavior NN O O
. NN O O
Pooled NN O O
analyses NN O O
of NN O O
199 NN O O
placebo NN O O
- NN O O
controlled NN O O
clinical NN O O
trials NN O O
( NN O O
mono- NN O O
and NN O O
adjunctive NN O O
therapy NN O O
) NN O O
of NN O O
11 NN O O
different NN O O
AEDs NN B-DrugClass B-DrugClass
showed NN O O
that NN O O
patients NN O O
randomized NN O O
to NN O O
one NN O O
of NN O O
the NN O O
AEDs NN O O
had NN O O
approximately NN O O
twice NN O O
the NN O O
risk NN O O
( NN O O
adjusted NN O O
relative NN O O
risk NN O O
1.8 NN O O
, NN O O
95 NN O O
% NN O O
confidence NN O O
interval NN O O
[ NN O O
CI NN O O
] NN O O
: NN O O
1.2 NN O O
, NN O O
2.7 NN O O
) NN O O
of NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
thinking NN I-AdverseReaction I-AdverseReaction
or NN O O
behavior NN O O
compared NN O O
to NN O O
patients NN O O
randomized NN O O
to NN O O
placebo NN O O
. NN O O
In NN O O
these NN O O
trials NN O O
, NN O O
which NN O O
had NN O O
a NN O O
median NN O O
treatment NN O O
duration NN O O
of NN O O
12 NN O O
weeks NN O O
, NN O O
the NN O O
estimated NN O O
incidence NN O O
rate NN O O
of NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
behavior NN I-AdverseReaction I-AdverseReaction
or NN O O
ideation NN O O
among NN O O
27,863 NN O O
AED NN B-DrugClass B-DrugClass
treated NN O O
patients NN O O
was NN O O
0.43 NN O O
% NN O O
, NN O O
compared NN O O
to NN O O
0.24 NN O O
% NN O O
among NN O O
16,029 NN O O
placebo NN O O
treated NN O O
patients NN O O
, NN O O
representing NN O O
an NN O O
increase NN O O
of NN O O
approximately NN O O
one NN O O
case NN O O
of NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
thinking NN I-AdverseReaction I-AdverseReaction
or NN O O
behavior NN O O
for NN O O
every NN O O
530 NN O O
patients NN O O
treated NN O O
. NN O O
There NN O O
were NN O O
four NN O O
suicides NN B-AdverseReaction B-AdverseReaction
in NN O O
drug NN O O
treated NN O O
patients NN O O
in NN O O
the NN O O
trials NN O O
and NN O O
none NN O O
in NN O O
placebo NN O O
treated NN O O
patients NN O O
, NN O O
but NN O O
the NN O O
number NN O O
is NN O O
too NN O O
small NN O O
to NN O O
allow NN O O
any NN O O
conclusion NN O O
about NN O O
drug NN O O
effect NN O O
on NN O O
suicide NN B-AdverseReaction B-AdverseReaction
The NN O O
increased NN O O
risk NN O O
of NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
thoughts NN I-AdverseReaction I-AdverseReaction
or NN O O
behavior NN O O
with NN O O
AEDs NN B-DrugClass B-DrugClass
was NN O O
observed NN O O
as NN O O
early NN O O
as NN O O
one NN O O
week NN O O
after NN O O
starting NN O O
drug NN O O
treatment NN O O
with NN O O
AEDs NN O O
and NN O O
persisted NN O O
for NN O O
the NN O O
duration NN O O
of NN O O
treatment NN O O
assessed NN O O
. NN O O
Because NN O O
most NN O O
trials NN O O
included NN O O
in NN O O
the NN O O
analysis NN O O
did NN O O
not NN O O
extend NN O O
beyond NN O O
24 NN O O
weeks NN O O
, NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
thoughts NN I-AdverseReaction I-AdverseReaction
or NN O O
behavior NN O O
beyond NN O O
24 NN O O
weeks NN O O
could NN O O
not NN O O
be NN O O
assessed NN O O
. NN O O
The NN O O
risk NN B-Factor B-Factor
of NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
thoughts NN I-AdverseReaction I-AdverseReaction
or NN O O
behavior NN O O
was NN O O
generally NN O O
consistent NN O O
among NN O O
drugs NN O O
in NN O O
the NN O O
data NN O O
analyzed NN O O
. NN O O
The NN O O
finding NN O O
of NN O O
increased NN O O
risk NN O O
with NN O O
AEDs NN O O
of NN O O
varying NN O O
mechanisms NN O O
of NN O O
action NN O O
and NN O O
across NN O O
a NN O O
range NN O O
of NN O O
indications NN O O
suggests NN O O
that NN O O
the NN O O
risk NN O O
applies NN O O
to NN O O
all NN O O
AEDs NN O O
used NN O O
for NN O O
any NN O O
indication NN O O
. NN O O
The NN O O
risk NN O O
did NN O O
not NN O O
vary NN O O
substantially NN O O
by NN O O
age NN O O
( NN O O
5 NN O O
- NN O O
100 NN O O
years NN O O
) NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
analyzed NN O O
. NN O O
Table NN O O
2 NN O O
shows NN O O
absolute NN O O
and NN O O
relative NN O O
risk NN O O
by NN O O
indication NN O O
for NN O O
all NN O O
evaluated NN O O
AEDs NN O O
. NN O O
Table NN O O
2 NN O O
. NN O O
Risk NN O O
by NN O O
Indication NN O O
for NN O O
Antiepileptic NN O O
Drugs NN O O
in NN O O
the NN O O
Pooled NN O O
Analysis NN O O
Indication NN O O
Placebo NN O O
Patients NN O O
with NN O O
Events NN O O
per NN O O
1000 NN O O
Patients NN O O
Drug NN O O
Patients NN O O
with NN O O
Events NN O O
per NN O O
1000 NN O O
Patients NN O O
Relative NN O O
Risk NN O O
: NN O O
Incidence NN O O
of NN O O
Drug NN O O
Events NN O O
in NN O O
Drug NN O O
Patients/Incidencein NN O O
Placebo NN O O
Patients NN O O
Risk NN O O
Difference NN O O
: NN O O
Additional NN O O
Drug NN O O
Patients NN O O
with NN O O
Events NN O O
per NN O O
1000 NN O O
Patients NN O O
Epilepsy NN O O
1.0 NN O O
3.4 NN O O
3.5 NN O O
2.4 NN O O
Psychiatric NN O O
5.7 NN O O
8.5 NN O O
1.5 NN O O
2.9 NN O O
Other NN O O
1.0 NN O O
1.8 NN O O
1.9 NN O O
0.9 NN O O
Total NN O O
2.4 NN O O
4.3 NN O O
1.8 NN O O
1.9 NN O O
The NN O O
relative NN O O
risk NN B-Factor B-Factor
for NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
thoughts NN I-AdverseReaction I-AdverseReaction
or NN O O
behavior NN O O
was NN O O
higher NN O O
in NN O O
clinical NN O O
trials NN O O
for NN O O
epilepsy NN O O
than NN O O
in NN O O
clinical NN O O
trials NN O O
for NN O O
psychiatric NN O O
or NN O O
other NN O O
conditions NN O O
, NN O O
but NN O O
the NN O O
absolute NN O O
risk NN O O
differences NN O O
were NN O O
similar NN O O
for NN O O
the NN O O
epilepsy NN O O
and NN O O
psychiatric NN O O
indications NN O O
. NN O O
Anyone NN O O
considering NN O O
prescribing NN O O
ONFI NN O O
or NN O O
any NN O O
other NN O O
AED NN O O
must NN O O
balance NN O O
the NN O O
risk NN O O
of NN O O
suicidal NN O O
thoughts NN O O
or NN O O
behavior NN O O
with NN O O
the NN O O
risk NN O O
of NN O O
untreated NN O O
illness NN O O
. NN O O
Epilepsy NN O O
and NN O O
many NN O O
other NN O O
illnesses NN O O
for NN O O
which NN O O
AEDs NN O O
are NN O O
prescribed NN O O
are NN O O
themselves NN O O
associated NN O O
with NN O O
morbidity NN O O
and NN O O
mortality NN O O
and NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
suicidal NN O O
thoughts NN O O
and NN O O
behavior NN O O
. NN O O
Should NN O O
suicidal NN O O
thoughts NN O O
and NN O O
behavior NN O O
emerge NN O O
during NN O O
treatment NN O O
, NN O O
the NN O O
prescriber NN O O
needs NN O O
to NN O O
consider NN O O
whether NN O O
the NN O O
emergence NN O O
of NN O O
these NN O O
symptoms NN O O
in NN O O
any NN O O
given NN O O
patient NN O O
may NN O O
be NN O O
related NN O O
to NN O O
the NN O O
illness NN O O
being NN O O
treated NN O O
. NN O O
Patients NN O O
, NN O O
their NN O O
caregivers NN O O
, NN O O
and NN O O
families NN O O
should NN O O
be NN O O
informed NN O O
that NN O O
AEDs NN O O
increase NN O O
the NN O O
risk NN O O
of NN O O
suicidal NN O O
thoughts NN O O
and NN O O
behavior NN O O
and NN O O
should NN O O
be NN O O
advised NN O O
of NN O O
the NN O O
need NN O O
to NN O O
be NN O O
alert NN O O
for NN O O
the NN O O
emergence NN O O
or NN O O
worsening NN O O
of NN O O
the NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
depression NN O O
, NN O O
any NN O O
unusual NN O O
changes NN O O
in NN O O
mood NN O O
or NN O O
behavior NN O O
, NN O O
or NN O O
the NN O O
emergence NN O O
of NN O O
suicidal NN O O
thoughts NN O O
, NN O O
behavior NN O O
, NN O O
or NN O O
thoughts NN O O
about NN O O
self NN O O
- NN O O
harm NN O O
. NN O O
Behaviors NN O O
of NN O O
concern NN O O
should NN O O
be NN O O
reported NN O O
immediately NN O O
to NN O O
healthcare NN O O
providers NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
are NN O O
discussed NN O O
in NN O O
greater NN O O
detail NN O O
in NN O O
other NN O O
sections NN O O
of NN O O
the NN O O
label NN O O
: NN O O
* NN O O
Cardiovascular NN B-AdverseReaction B-AdverseReaction
Disorders NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
Malignant NN B-AdverseReaction B-AdverseReaction
Neoplasms NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
* NN O O
Gallbladder NN B-AdverseReaction B-AdverseReaction
Disease NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
* NN O O
Hypertriglyceridemia NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.8 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
In NN O O
four NN O O
prospective NN O O
, NN O O
randomized NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
the NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
incidence NN O O
>= NN O O
5 NN O O
% NN O O
) NN O O
were NN O O
muscle NN B-AdverseReaction B-AdverseReaction
spasms NN I-AdverseReaction I-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
dyspepsia NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
upper NN I-AdverseReaction I-AdverseReaction
oropharyngeal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
dizziness NN B-AdverseReaction B-AdverseReaction
and NN O O
neck NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Pfizer NN O O
Inc. NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
438 NN O O
- NN O O
1985 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O
The NN O O
safety NN O O
of NN O O
conjugated NN O O
estrogens/bazedoxifene NN O O
was NN O O
evaluated NN O O
in NN O O
four NN O O
Phase NN O O
3 NN O O
clinical NN O O
trials NN O O
ranging NN O O
from NN O O
12 NN O O
weeks NN O O
to NN O O
24 NN O O
months NN O O
in NN O O
duration NN O O
and NN O O
enrolling NN O O
6,210 NN O O
postmenopausal NN O O
women NN O O
age NN O O
40 NN O O
to NN O O
75 NN O O
years NN O O
( NN O O
mean NN O O
age NN O O
55 NN O O
years NN O O
) NN O O
. NN O O
A NN O O
total NN O O
of NN O O
1,224 NN O O
patients NN O O
were NN O O
treated NN O O
with NN O O
DUAVEE NN O O
and NN O O
1,069 NN O O
patients NN O O
received NN O O
placebo NN O O
. NN O O
Women NN O O
enrolled NN O O
in NN O O
Studies NN O O
1 NN O O
and NN O O
2 NN O O
received NN O O
calcium NN O O
( NN O O
600 NN O O
- NN O O
1200 NN O O
mg NN O O
) NN O O
and NN O O
vitamin NN O O
D NN O O
( NN O O
200 NN O O
- NN O O
400 NN O O
IU NN O O
) NN O O
daily NN O O
, NN O O
while NN O O
women NN O O
in NN O O
Studies NN O O
3 NN O O
and NN O O
4 NN O O
received NN O O
no NN O O
calcium NN O O
and NN O O
vitamin NN O O
D NN O O
supplementation NN O O
as NN O O
part NN O O
of NN O O
the NN O O
protocol NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
all NN O O
- NN O O
cause NN O O
mortality NN B-AdverseReaction B-AdverseReaction
was NN O O
0.0 NN B-Negation B-Negation
% NN I-Negation I-Negation
in NN O O
the NN O O
DUAVEE NN O O
group NN O O
and NN O O
0.2 NN O O
% NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
serious NN O O
adverse NN O O
reactions NN O O
was NN O O
3.5 NN O O
% NN O O
in NN O O
the NN O O
DUAVEE NN O O
group NN O O
and NN O O
4.8 NN O O
% NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
. NN O O
The NN O O
percentage NN O O
of NN O O
patients NN O O
who NN O O
withdrew NN O O
from NN O O
treatment NN O O
due NN O O
to NN O O
adverse NN O O
reactions NN O O
was NN O O
7.5 NN O O
% NN O O
in NN O O
the NN O O
DUAVEE NN O O
group NN O O
and NN O O
10.0 NN O O
% NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
leading NN O O
to NN O O
discontinuation NN O O
were NN O O
hot NN B-AdverseReaction B-AdverseReaction
flush NN I-AdverseReaction I-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
upper NN I-AdverseReaction I-AdverseReaction
and NN O O
nausea NN B-AdverseReaction B-AdverseReaction
The NN O O
most NN O O
commonly NN O O
observed NN O O
adverse NN O O
reactions NN O O
( NN O O
incidence NN O O
>= NN O O
5 NN O O
% NN O O
) NN O O
more NN O O
frequently NN O O
reported NN O O
in NN O O
women NN O O
treated NN O O
with NN O O
DUAVEE NN O O
than NN O O
placebo NN O O
are NN O O
presented NN O O
in NN O O
Table NN O O
1 NN O O
. NN O O
Table NN O O
1 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
( NN O O
Incidence NN O O
>= NN O O
5 NN O O
% NN O O
) NN O O
More NN O O
Common NN O O
in NN O O
the NN O O
DUAVEE NN O O
Treatment NN O O
Group NN O O
in NN O O
Placebo NN O O
- NN O O
controlled NN O O
Trials NN O O
DUAVEE NN O O
( NN O O
N=1224)n NN O O
( NN O O
% NN O O
) NN O O
Placebo NN O O
( NN O O
N=1069)n NN O O
( NN O O
% NN O O
) NN O O
Gastrointestinal NN O O
disorders NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
100 NN O O
( NN O O
8 NN O O
) NN O O
58 NN O O
( NN O O
5 NN O O
) NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
96 NN O O
( NN O O
8 NN O O
) NN O O
57 NN O O
( NN O O
5 NN O O
) NN O O
Dyspepsia NN B-AdverseReaction B-AdverseReaction
84 NN O O
( NN O O
7 NN O O
) NN O O
59 NN O O
( NN O O
6 NN O O
) NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
upper NN I-AdverseReaction I-AdverseReaction
81 NN O O
( NN O O
7 NN O O
) NN O O
58 NN O O
( NN O O
5 NN O O
) NN O O
Musculoskeletal NN O O
and NN O O
connective NN O O
tissue NN O O
disorders NN O O
Muscle NN B-AdverseReaction B-AdverseReaction
spasms NN I-AdverseReaction I-AdverseReaction
110 NN O O
( NN O O
9 NN O O
) NN O O
63 NN O O
( NN O O
6 NN O O
) NN O O
Neck NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
62 NN O O
( NN O O
5 NN O O
) NN O O
46 NN O O
( NN O O
4 NN O O
) NN O O
Nervous NN O O
system NN O O
disorders NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
65 NN O O
( NN O O
5 NN O O
) NN O O
37 NN O O
( NN O O
3 NN O O
) NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
, NN O O
and NN O O
mediastinal NN O O
disorders NN O O
Oropharyngeal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
80 NN O O
( NN O O
7 NN O O
) NN O O
61 NN O O
( NN O O
6 NN O O
) NN O O
Venous NN O O
thromboembolism NN O O
: NN O O
In NN O O
the NN O O
clinical NN O O
studies NN O O
with NN O O
DUAVEE NN O O
, NN O O
the NN O O
reporting NN O O
rates NN O O
for NN O O
venous NN B-AdverseReaction B-AdverseReaction
thromboembolism NN I-AdverseReaction I-AdverseReaction
( NN O O
deep NN O O
venous NN O O
thrombosis NN O O
, NN O O
pulmonary NN B-AdverseReaction B-AdverseReaction
embolism NN I-AdverseReaction I-AdverseReaction
and NN O O
retinal NN B-AdverseReaction B-AdverseReaction
vein NN I-AdverseReaction I-AdverseReaction
thrombosis NN I-AdverseReaction I-AdverseReaction
were NN O O
low NN O O
in NN O O
all NN O O
treatment NN O O
groups NN O O
. NN O O
Adverse NN O O
reactions NN O O
of NN O O
venous NN B-AdverseReaction B-AdverseReaction
thromboembolism NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
in NN O O
0.0 NN B-Negation B-Negation
% NN I-Negation I-Negation
of NN O O
patients NN O O
treated NN O O
with NN O O
DUAVEE NN O O
and NN O O
0.1 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
placebo NN O O
. NN O O
Due NN O O
to NN O O
the NN O O
low NN O O
rate NN O O
of NN O O
events NN O O
in NN O O
both NN O O
groups NN O O
, NN O O
it NN O O
is NN O O
not NN O O
possible NN O O
to NN O O
conclude NN O O
that NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
venous NN B-AdverseReaction B-AdverseReaction
thromboembolism NN I-AdverseReaction I-AdverseReaction
with NN O O
DUAVEE NN O O
is NN O O
different NN O O
from NN O O
that NN O O
seen NN O O
with NN O O
other NN O O
estrogen NN O O
therapies NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
ENDOMETRIAL NN B-AdverseReaction B-AdverseReaction
CANCER NN I-AdverseReaction I-AdverseReaction
CARDIOVASCULAR NN B-AdverseReaction B-AdverseReaction
DISORDERS NN I-AdverseReaction I-AdverseReaction
AND NN O O
PROBABLE NN B-Factor B-Factor
DEMENTIA NN B-AdverseReaction B-AdverseReaction
WARNING NN O O
: NN O O
ENDOMETRIAL NN B-AdverseReaction B-AdverseReaction
CANCER NN I-AdverseReaction I-AdverseReaction
CARDIOVASCULAR NN B-AdverseReaction B-AdverseReaction
DISORDERS NN I-AdverseReaction I-AdverseReaction
AND NN O O
PROBABLE NN B-Factor B-Factor
DEMENTIA NN B-AdverseReaction B-AdverseReaction
* NN O O
Women NN O O
taking NN O O
DUAVEE NN O O
should NN O O
not NN O O
take NN O O
additional NN O O
estrogens NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
There NN O O
is NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
endometrial NN B-AdverseReaction B-AdverseReaction
cancer NN I-AdverseReaction I-AdverseReaction
in NN O O
a NN O O
woman NN O O
with NN O O
a NN O O
uterus NN O O
who NN O O
uses NN O O
unopposed NN O O
estrogens NN B-DrugClass B-DrugClass
DUAVEE NN O O
has NN O O
been NN O O
shown NN O O
to NN O O
reduce NN B-Factor B-Factor
the NN I-Factor I-Factor
risk NN I-Factor I-Factor
of NN O O
endometrial NN B-AdverseReaction B-AdverseReaction
hyperplasia NN I-AdverseReaction I-AdverseReaction
which NN O O
may NN O O
be NN O O
a NN O O
precursor NN O O
to NN O O
endometrial NN O O
cancer NN O O
. NN O O
Adequate NN O O
diagnostic NN O O
measures NN O O
, NN O O
including NN O O
directed NN O O
or NN O O
random NN O O
endometrial NN O O
sampling NN O O
when NN O O
indicated NN O O
, NN O O
should NN O O
be NN O O
undertaken NN O O
to NN O O
rule NN O O
out NN O O
malignancy NN O O
in NN O O
postmenopausal NN O O
women NN O O
with NN O O
undiagnosed NN O O
persistent NN O O
or NN O O
recurring NN O O
abnormal NN O O
genital NN O O
bleeding NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
* NN O O
Estrogen NN O O
therapy NN O O
should NN O O
not NN O O
be NN O O
used NN O O
for NN O O
the NN O O
prevention NN O O
of NN O O
cardiovascular NN O O
disease NN O O
or NN O O
dementia NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
, NN O O
5.4 NN O O
) NN O O
] NN O O
* NN O O
The NN O O
Women NN O O
's NN O O
Health NN O O
Initiative NN O O
( NN O O
WHI NN O O
) NN O O
estrogen NN O O
- NN O O
alone NN O O
substudy NN O O
reported NN O O
increased NN O O
risks NN O O
of NN O O
stroke NN B-AdverseReaction B-AdverseReaction
and NN O O
deep NN B-AdverseReaction B-AdverseReaction
vein NN I-AdverseReaction I-AdverseReaction
thrombosis NN I-AdverseReaction I-AdverseReaction
( NN O O
DVT NN O O
) NN O O
in NN O O
postmenopausal NN O O
women NN O O
( NN O O
50 NN O O
to NN O O
79 NN O O
years NN O O
of NN O O
age NN O O
) NN O O
during NN O O
7.1 NN O O
years NN O O
of NN O O
treatment NN O O
with NN O O
daily NN O O
oral NN B-DrugClass B-DrugClass
conjugated NN I-DrugClass I-DrugClass
estrogens NN I-DrugClass I-DrugClass
( NN O O
0.625 NN O O
mg)-alone NN O O
, NN O O
relative NN O O
to NN O O
placebo NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
The NN O O
WHI NN O O
Memory NN O O
Study NN O O
( NN O O
WHIMS NN O O
) NN O O
estrogen NN O O
- NN O O
alone NN O O
ancillary NN O O
study NN O O
of NN O O
WHI NN O O
reported NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
probable NN O O
dementia NN B-AdverseReaction B-AdverseReaction
in NN O O
postmenopausal NN O O
women NN O O
65 NN O O
years NN O O
of NN O O
age NN O O
and NN O O
older NN O O
during NN O O
5.2 NN O O
years NN O O
of NN O O
treatment NN O O
with NN O O
daily NN O O
conjugated NN B-DrugClass B-DrugClass
estrogens NN I-DrugClass I-DrugClass
( NN O O
0.625 NN O O
mg)-alone NN O O
, NN O O
relative NN O O
to NN O O
placebo NN O O
. NN O O
It NN O O
is NN O O
unknown NN O O
whether NN O O
this NN O O
finding NN O O
applies NN O O
to NN O O
younger NN O O
postmenopausal NN O O
women NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
In NN O O
the NN O O
absence NN O O
of NN O O
comparable NN O O
data NN O O
, NN O O
these NN O O
risks NN O O
should NN O O
be NN O O
assumed NN O O
to NN O O
be NN O O
similar NN O O
for NN O O
other NN O O
doses NN O O
of NN O O
conjugated NN O O
estrogens NN O O
and NN O O
other NN O O
dosage NN O O
forms NN O O
of NN O O
estrogens NN O O
. NN O O
Estrogens NN O O
should NN O O
be NN O O
prescribed NN O O
at NN O O
the NN O O
lowest NN O O
effective NN O O
doses NN O O
and NN O O
for NN O O
the NN O O
shortest NN O O
duration NN O O
consistent NN O O
with NN O O
treatment NN O O
goals NN O O
and NN O O
risks NN O O
for NN O O
the NN O O
individual NN O O
woman NN O O
. NN O O
EXCERPT NN O O
: NN O O
WARNING NN O O
: NN O O
ENDOMETRIAL NN B-AdverseReaction B-AdverseReaction
CANCER NN I-AdverseReaction I-AdverseReaction
CARDIOVASCULAR NN B-AdverseReaction B-AdverseReaction
DISORDERS NN I-AdverseReaction I-AdverseReaction
AND NN O O
PROBABLE NN B-Factor B-Factor
DEMENTIA NN B-AdverseReaction B-AdverseReaction
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
Boxed NN O O
Warning NN O O
. NN O O
* NN O O
Women NN O O
taking NN O O
DUAVEE NN O O
should NN O O
not NN O O
take NN O O
additional NN O O
estrogens NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
There NN O O
is NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
endometrial NN B-AdverseReaction B-AdverseReaction
cancer NN I-AdverseReaction I-AdverseReaction
in NN O O
a NN O O
woman NN O O
with NN O O
a NN O O
uterus NN O O
who NN O O
uses NN O O
unopposed NN O O
estrogens NN B-DrugClass B-DrugClass
( NN O O
5.1 NN O O
, NN O O
5.3 NN O O
) NN O O
* NN O O
Estrogen NN O O
therapy NN O O
should NN O O
not NN O O
be NN O O
used NN O O
for NN O O
the NN O O
prevention NN O O
of NN O O
cardiovascular NN O O
disease NN O O
or NN O O
dementia NN O O
( NN O O
5.2 NN O O
, NN O O
5.4 NN O O
) NN O O
* NN O O
The NN O O
Women NN O O
's NN O O
Health NN O O
Initiative NN O O
( NN O O
WHI NN O O
) NN O O
estrogen NN B-DrugClass B-DrugClass
substudy NN O O
reported NN O O
increased NN O O
risks NN O O
of NN O O
stroke NN B-AdverseReaction B-AdverseReaction
and NN O O
deep NN B-AdverseReaction B-AdverseReaction
vein NN I-AdverseReaction I-AdverseReaction
thrombosis NN I-AdverseReaction I-AdverseReaction
( NN O O
DVT NN O O
) NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
The NN O O
WHI NN O O
Memory NN O O
Study NN O O
( NN O O
WHIMS NN O O
) NN O O
estrogen NN B-DrugClass B-DrugClass
ancillary NN O O
study NN O O
of NN O O
WHI NN O O
reported NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
probable NN O O
dementia NN B-AdverseReaction B-AdverseReaction
in NN O O
postmenopausal NN O O
women NN O O
65 NN O O
years NN O O
of NN O O
age NN O O
and NN O O
older NN O O
( NN O O
5.4 NN O O
) NN O O
BOXED NN O O
WARNING NN O O
: NN O O
Patient NN O O
InformationDUAVEE NN O O
( NN O O
r NN O O
) NN O O
( NN O O
DEW NN O O
' NN O O
ah NN O O
- NN O O
vee)(conjugated NN O O
estrogens/bazedoxifene)Tablets NN O O
Read NN O O
this NN O O
Patient NN O O
Information NN O O
before NN O O
you NN O O
start NN O O
taking NN O O
DUAVEE NN O O
and NN O O
each NN O O
time NN O O
you NN O O
get NN O O
a NN O O
refill NN O O
. NN O O
There NN O O
may NN O O
be NN O O
new NN O O
information NN O O
. NN O O
This NN O O
information NN O O
does NN O O
not NN O O
take NN O O
the NN O O
place NN O O
of NN O O
talking NN O O
to NN O O
your NN O O
healthcare NN O O
provider NN O O
about NN O O
your NN O O
medical NN O O
condition NN O O
or NN O O
your NN O O
treatment NN O O
. NN O O
What NN O O
is NN O O
the NN O O
most NN O O
important NN O O
information NN O O
I NN O O
should NN O O
know NN O O
about NN O O
DUAVEE NN O O
? NN O O
* NN O O
Do NN O O
not NN O O
take NN O O
additional NN O O
estrogen NN O O
products NN O O
while NN O O
you NN O O
are NN O O
taking NN O O
DUAVEE. NN O O
* NN O O
Using NN O O
estrogens NN O O
may NN O O
increase NN O O
your NN O O
chance NN O O
of NN O O
getting NN O O
cancer NN O O
of NN O O
the NN O O
uterus NN O O
( NN O O
womb NN O O
) NN O O
. NN O O
* NN O O
Report NN O O
any NN O O
unusual NN O O
vaginal NN O O
bleeding NN O O
right NN O O
away NN O O
while NN O O
you NN O O
are NN O O
taking NN O O
DUAVEE. NN O O
Vaginal NN O O
bleeding NN O O
after NN O O
menopause NN O O
may NN O O
be NN O O
a NN O O
warning NN O O
sign NN O O
of NN O O
cancer NN O O
of NN O O
the NN O O
uterus NN O O
( NN O O
womb NN O O
) NN O O
. NN O O
Your NN O O
healthcare NN O O
provider NN O O
should NN O O
check NN O O
any NN O O
unusual NN O O
vaginal NN O O
bleeding NN O O
to NN O O
find NN O O
out NN O O
the NN O O
cause NN O O
. NN O O
* NN O O
Do NN O O
not NN O O
use NN O O
estrogens NN O O
to NN O O
prevent NN O O
heart NN O O
disease NN O O
, NN O O
heart NN O O
attacks NN O O
, NN O O
strokes NN O O
or NN O O
dementia NN O O
( NN O O
decline NN O O
in NN O O
brain NN O O
function NN O O
) NN O O
. NN O O
* NN O O
Using NN O O
estrogens NN O O
may NN O O
increase NN O O
your NN O O
chances NN O O
of NN O O
getting NN O O
strokes NN O O
or NN O O
blood NN O O
clots NN O O
. NN O O
* NN O O
Using NN O O
estrogens NN O O
may NN O O
increase NN O O
your NN O O
chance NN O O
of NN O O
getting NN O O
dementia NN O O
, NN O O
based NN O O
on NN O O
a NN O O
study NN O O
of NN O O
women NN O O
65 NN O O
years NN O O
of NN O O
age NN O O
or NN O O
older NN O O
. NN O O
* NN O O
You NN O O
and NN O O
your NN O O
healthcare NN O O
provider NN O O
should NN O O
talk NN O O
regularly NN O O
about NN O O
whether NN O O
you NN O O
still NN O O
need NN O O
treatment NN O O
with NN O O
DUAVEE. NN O O
What NN O O
is NN O O
DUAVEE NN O O
? NN O O
DUAVEE NN O O
is NN O O
a NN O O
prescription NN O O
medicine NN O O
that NN O O
contains NN O O
a NN O O
mixture NN O O
of NN O O
estrogens NN O O
and NN O O
bazedoxifene NN O O
. NN O O
What NN O O
is NN O O
DUAVEE NN O O
used NN O O
for NN O O
? NN O O
DUAVEE NN O O
is NN O O
used NN O O
after NN O O
menopause NN O O
for NN O O
women NN O O
with NN O O
a NN O O
uterus NN O O
to NN O O
: NN O O
* NN O O
reduce NN O O
moderate NN O O
to NN O O
severe NN O O
hot NN O O
flushesEstrogens NN O O
are NN O O
hormones NN O O
made NN O O
by NN O O
a NN O O
woman NN O O
's NN O O
ovaries NN O O
. NN O O
The NN O O
ovaries NN O O
normally NN O O
stop NN O O
making NN O O
estrogens NN O O
when NN O O
a NN O O
woman NN O O
is NN O O
between NN O O
45 NN O O
and NN O O
55 NN O O
years NN O O
old NN O O
. NN O O
This NN O O
drop NN O O
in NN O O
body NN O O
estrogen NN O O
levels NN O O
causes NN O O
the NN O O
" NN O O
change NN O O
of NN O O
life NN O O
" NN O O
or NN O O
menopause NN O O
( NN O O
the NN O O
end NN O O
of NN O O
monthly NN O O
menstrual NN O O
periods NN O O
) NN O O
. NN O O
Sometimes NN O O
both NN O O
ovaries NN O O
are NN O O
removed NN O O
during NN O O
an NN O O
operation NN O O
before NN O O
natural NN O O
menopause NN O O
takes NN O O
place NN O O
. NN O O
The NN O O
sudden NN O O
drop NN O O
in NN O O
estrogen NN O O
levels NN O O
causes NN O O
" NN O O
surgical NN O O
menopause."When NN O O
the NN O O
estrogen NN O O
levels NN O O
begin NN O O
dropping NN O O
, NN O O
some NN O O
women NN O O
get NN O O
very NN O O
uncomfortable NN O O
symptoms NN O O
, NN O O
such NN O O
as NN O O
feelings NN O O
of NN O O
warmth NN O O
in NN O O
the NN O O
face NN O O
, NN O O
neck NN O O
, NN O O
and NN O O
chest NN O O
, NN O O
or NN O O
sudden NN O O
intense NN O O
episodes NN O O
of NN O O
heat NN O O
and NN O O
sweating NN O O
( NN O O
" NN O O
hot NN O O
flashes NN O O
" NN O O
or NN O O
" NN O O
hot NN O O
flushes NN O O
" NN O O
) NN O O
. NN O O
In NN O O
some NN O O
women NN O O
, NN O O
the NN O O
symptoms NN O O
are NN O O
mild NN O O
, NN O O
and NN O O
they NN O O
will NN O O
not NN O O
need NN O O
to NN O O
take NN O O
medicines NN O O
. NN O O
In NN O O
other NN O O
women NN O O
, NN O O
symptoms NN O O
can NN O O
be NN O O
more NN O O
severe NN O O
. NN O O
* NN O O
help NN O O
reduce NN O O
your NN O O
chances NN O O
of NN O O
developing NN O O
osteoporosis NN O O
( NN O O
thin NN O O
, NN O O
weak NN O O
bones)If NN O O
you NN O O
use NN O O
DUAVEE NN O O
only NN O O
to NN O O
prevent NN O O
osteoporosis NN O O
due NN O O
to NN O O
menopause NN O O
, NN O O
talk NN O O
with NN O O
your NN O O
healthcare NN O O
provider NN O O
about NN O O
whether NN O O
a NN O O
different NN O O
treatment NN O O
or NN O O
medicine NN O O
without NN O O
estrogens NN O O
might NN O O
be NN O O
better NN O O
for NN O O
you NN O O
. NN O O
DUAVEE NN O O
should NN O O
be NN O O
taken NN O O
for NN O O
the NN O O
shortest NN O O
time NN O O
possible NN O O
and NN O O
only NN O O
for NN O O
as NN O O
long NN O O
as NN O O
treatment NN O O
is NN O O
needed NN O O
. NN O O
You NN O O
and NN O O
your NN O O
healthcare NN O O
provider NN O O
should NN O O
talk NN O O
regularly NN O O
about NN O O
whether NN O O
you NN O O
still NN O O
need NN O O
treatment NN O O
with NN O O
DUAVEE. NN O O
DUAVEE NN O O
is NN O O
not NN O O
for NN O O
use NN O O
in NN O O
children NN O O
. NN O O
It NN O O
is NN O O
not NN O O
known NN O O
if NN O O
DUAVEE NN O O
is NN O O
safe NN O O
and NN O O
effective NN O O
in NN O O
people NN O O
with NN O O
kidney NN O O
problems NN O O
. NN O O
Who NN O O
should NN O O
not NN O O
take NN O O
DUAVEE NN O O
? NN O O
Do NN O O
not NN O O
take NN O O
DUAVEE NN O O
if NN O O
you NN O O
: NN O O
* NN O O
currently NN O O
have NN O O
or NN O O
have NN O O
had NN O O
blood NN O O
clots NN O O
* NN O O
are NN O O
allergic NN O O
to NN O O
estrogens NN O O
or NN O O
bazedoxifene NN O O
, NN O O
the NN O O
active NN O O
ingredients NN O O
in NN O O
DUAVEE NN O O
, NN O O
or NN O O
any NN O O
of NN O O
its NN O O
ingredients NN O O
. NN O O
See NN O O
the NN O O
list NN O O
of NN O O
ingredients NN O O
in NN O O
DUAVEE NN O O
at NN O O
the NN O O
end NN O O
of NN O O
this NN O O
leaflet NN O O
. NN O O
* NN O O
have NN O O
unusual NN O O
vaginal NN O O
bleeding NN O O
. NN O O
Vaginal NN O O
bleeding NN O O
after NN O O
menopause NN O O
may NN O O
be NN O O
a NN O O
warning NN O O
sign NN O O
of NN O O
cancer NN O O
of NN O O
the NN O O
uterus NN O O
( NN O O
womb NN O O
) NN O O
. NN O O
Your NN O O
healthcare NN O O
provider NN O O
should NN O O
check NN O O
any NN O O
unusual NN O O
vaginal NN O O
bleeding NN O O
to NN O O
find NN O O
out NN O O
the NN O O
cause NN O O
. NN O O
* NN O O
currently NN O O
have NN O O
or NN O O
have NN O O
had NN O O
certain NN O O
cancers NN O O
. NN O O
Estrogens NN O O
may NN O O
increase NN O O
the NN O O
chances NN O O
of NN O O
getting NN O O
certain NN O O
types NN O O
of NN O O
cancers NN O O
, NN O O
including NN O O
cancer NN O O
of NN O O
the NN O O
breast NN O O
or NN O O
uterus NN O O
. NN O O
If NN O O
you NN O O
have NN O O
or NN O O
have NN O O
had NN O O
cancer NN O O
, NN O O
talk NN O O
with NN O O
your NN O O
healthcare NN O O
provider NN O O
about NN O O
whether NN O O
you NN O O
should NN O O
use NN O O
DUAVEE. NN O O
* NN O O
currently NN O O
have NN O O
or NN O O
have NN O O
had NN O O
liver NN O O
problems NN O O
* NN O O
have NN O O
been NN O O
diagnosed NN O O
with NN O O
a NN O O
bleeding NN O O
disorder NN O O
* NN O O
think NN O O
you NN O O
may NN O O
be NN O O
pregnant NN O O
. NN O O
DUAVEE NN O O
is NN O O
not NN O O
for NN O O
pregnant NN O O
women NN O O
. NN O O
If NN O O
you NN O O
think NN O O
you NN O O
may NN O O
be NN O O
pregnant NN O O
, NN O O
you NN O O
should NN O O
have NN O O
a NN O O
pregnancy NN O O
test NN O O
and NN O O
know NN O O
the NN O O
results NN O O
. NN O O
Do NN O O
not NN O O
take NN O O
DUAVEE NN O O
if NN O O
the NN O O
test NN O O
is NN O O
positive NN O O
and NN O O
talk NN O O
to NN O O
your NN O O
healthcare NN O O
provider NN O O
. NN O O
* NN O O
are NN O O
breastfeeding NN O O
or NN O O
plan NN O O
to NN O O
breastfeed NN O O
. NN O O
It NN O O
is NN O O
not NN O O
known NN O O
if NN O O
DUAVEE NN O O
passes NN O O
into NN O O
your NN O O
breast NN O O
milk NN O O
. NN O O
You NN O O
and NN O O
your NN O O
healthcare NN O O
provider NN O O
should NN O O
decide NN O O
if NN O O
you NN O O
will NN O O
take NN O O
DUAVEE NN O O
or NN O O
breastfeed NN O O
. NN O O
You NN O O
should NN O O
not NN O O
do NN O O
both NN O O
. NN O O
What NN O O
should NN O O
I NN O O
tell NN O O
my NN O O
healthcare NN O O
provider NN O O
before NN O O
taking NN O O
DUAVEE NN O O
? NN O O
Before NN O O
you NN O O
take NN O O
DUAVEE NN O O
, NN O O
tell NN O O
your NN O O
healthcare NN O O
provider NN O O
if NN O O
you NN O O
: NN O O
* NN O O
have NN O O
any NN O O
unusual NN O O
vaginal NN O O
bleeding NN O O
. NN O O
* NN O O
have NN O O
any NN O O
other NN O O
medical NN O O
conditions NN O O
. NN O O
Your NN O O
healthcare NN O O
provider NN O O
may NN O O
need NN O O
to NN O O
check NN O O
you NN O O
more NN O O
carefully NN O O
if NN O O
you NN O O
have NN O O
certain NN O O
conditions NN O O
, NN O O
such NN O O
as NN O O
asthma NN O O
( NN O O
wheezing NN O O
) NN O O
, NN O O
epilepsy NN O O
( NN O O
seizures NN O O
) NN O O
, NN O O
diabetes NN O O
, NN O O
migraine NN O O
, NN O O
endometriosis NN O O
, NN O O
lupus NN O O
, NN O O
or NN O O
problems NN O O
with NN O O
your NN O O
heart NN O O
, NN O O
liver NN O O
, NN O O
thyroid NN O O
, NN O O
kidneys NN O O
, NN O O
or NN O O
have NN O O
high NN O O
calcium NN O O
levels NN O O
in NN O O
your NN O O
blood NN O O
. NN O O
* NN O O
are NN O O
going NN O O
to NN O O
have NN O O
surgery NN O O
or NN O O
will NN O O
be NN O O
on NN O O
bed NN O O
rest NN O O
. NN O O
Your NN O O
healthcare NN O O
provider NN O O
will NN O O
let NN O O
you NN O O
know NN O O
if NN O O
you NN O O
need NN O O
to NN O O
stop NN O O
taking NN O O
DUAVEE. NN O O
Tell NN O O
your NN O O
healthcare NN O O
provider NN O O
about NN O O
all NN O O
the NN O O
medicines NN O O
you NN O O
take NN O O
, NN O O
including NN O O
prescription NN O O
and NN O O
over NN O O
- NN O O
the NN O O
- NN O O
counter NN O O
medicines NN O O
, NN O O
vitamins NN O O
, NN O O
and NN O O
herbal NN O O
supplements NN O O
. NN O O
Especially NN O O
tell NN O O
your NN O O
healthcare NN O O
provider NN O O
if NN O O
you NN O O
take NN O O
other NN O O
hormonal NN O O
medicines NN O O
, NN O O
including NN O O
progestins NN O O
or NN O O
other NN O O
medicines NN O O
like NN O O
DUAVEE. NN O O
Ask NN O O
your NN O O
healthcare NN O O
provider NN O O
if NN O O
you NN O O
do NN O O
not NN O O
know NN O O
if NN O O
you NN O O
take NN O O
any NN O O
of NN O O
these NN O O
medicines NN O O
. NN O O
Some NN O O
medicines NN O O
may NN O O
affect NN O O
how NN O O
DUAVEE NN O O
works NN O O
. NN O O
DUAVEE NN O O
may NN O O
also NN O O
affect NN O O
how NN O O
your NN O O
other NN O O
medicines NN O O
work NN O O
. NN O O
Keep NN O O
a NN O O
list NN O O
of NN O O
your NN O O
medicines NN O O
and NN O O
show NN O O
it NN O O
to NN O O
your NN O O
healthcare NN O O
provider NN O O
and NN O O
pharmacist NN O O
when NN O O
you NN O O
get NN O O
a NN O O
new NN O O
medicine NN O O
. NN O O
How NN O O
should NN O O
I NN O O
take NN O O
DUAVEE NN O O
? NN O O
* NN O O
DUAVEE NN O O
comes NN O O
in NN O O
a NN O O
blister NN O O
package NN O O
. NN O O
* NN O O
Record NN O O
the NN O O
date NN O O
you NN O O
open NN O O
the NN O O
foil NN O O
pouch NN O O
in NN O O
the NN O O
space NN O O
provided NN O O
on NN O O
the NN O O
blister NN O O
package NN O O
label NN O O
. NN O O
Do NN O O
not NN O O
use NN O O
if NN O O
the NN O O
blister NN O O
package NN O O
has NN O O
been NN O O
open NN O O
for NN O O
more NN O O
than NN O O
60 NN O O
days NN O O
. NN O O
* NN O O
Take NN O O
DUAVEE NN O O
exactly NN O O
as NN O O
your NN O O
healthcare NN O O
provider NN O O
tells NN O O
you NN O O
to NN O O
take NN O O
it NN O O
. NN O O
* NN O O
Take NN O O
1 NN O O
DUAVEE NN O O
tablet NN O O
at NN O O
the NN O O
same NN O O
time NN O O
each NN O O
day NN O O
. NN O O
* NN O O
DUAVEE NN O O
should NN O O
be NN O O
swallowed NN O O
whole NN O O
. NN O O
* NN O O
Take NN O O
DUAVEE NN O O
with NN O O
or NN O O
without NN O O
food NN O O
. NN O O
* NN O O
You NN O O
should NN O O
not NN O O
remove NN O O
DUAVEE NN O O
from NN O O
the NN O O
blister NN O O
until NN O O
right NN O O
before NN O O
you NN O O
are NN O O
ready NN O O
to NN O O
take NN O O
it NN O O
. NN O O
Remove NN O O
1 NN O O
tablet NN O O
at NN O O
a NN O O
time NN O O
from NN O O
the NN O O
blister NN O O
package NN O O
. NN O O
Do NN O O
not NN O O
place NN O O
DUAVEE NN O O
in NN O O
pill NN O O
boxes NN O O
or NN O O
pill NN O O
organizers NN O O
. NN O O
* NN O O
If NN O O
you NN O O
miss NN O O
a NN O O
dose NN O O
of NN O O
DUAVEE NN O O
, NN O O
take NN O O
it NN O O
as NN O O
soon NN O O
as NN O O
you NN O O
remember NN O O
. NN O O
If NN O O
it NN O O
is NN O O
almost NN O O
time NN O O
for NN O O
your NN O O
next NN O O
dose NN O O
, NN O O
skip NN O O
the NN O O
missed NN O O
dose NN O O
. NN O O
Take NN O O
the NN O O
next NN O O
dose NN O O
at NN O O
your NN O O
regular NN O O
time NN O O
. NN O O
Do NN O O
not NN O O
take NN O O
2 NN O O
doses NN O O
at NN O O
the NN O O
same NN O O
time NN O O
unless NN O O
your NN O O
healthcare NN O O
provider NN O O
tells NN O O
you NN O O
to NN O O
. NN O O
If NN O O
you NN O O
are NN O O
not NN O O
sure NN O O
about NN O O
your NN O O
dosing NN O O
, NN O O
call NN O O
your NN O O
healthcare NN O O
provider NN O O
. NN O O
* NN O O
If NN O O
you NN O O
take NN O O
a NN O O
calcium NN O O
or NN O O
vitamin NN O O
D NN O O
supplement NN O O
, NN O O
you NN O O
may NN O O
take NN O O
it NN O O
at NN O O
the NN O O
same NN O O
time NN O O
you NN O O
take NN O O
DUAVEE. NN O O
* NN O O
If NN O O
you NN O O
take NN O O
too NN O O
much NN O O
DUAVEE NN O O
, NN O O
call NN O O
your NN O O
healthcare NN O O
provider NN O O
. NN O O
Symptoms NN O O
of NN O O
taking NN O O
too NN O O
much NN O O
DUAVEE NN O O
include NN O O
: NN O O
nauseavomitingbreast NN O O
tendernessdizzinessabdominal NN O O
painfeeling NN O O
tiredvaginal NN O O
bleeding NN O O
What NN O O
are NN O O
the NN O O
possible NN O O
side NN O O
effects NN O O
of NN O O
DUAVEE NN O O
? NN O O
Side NN O O
effects NN O O
are NN O O
grouped NN O O
by NN O O
how NN O O
serious NN O O
they NN O O
are NN O O
and NN O O
how NN O O
often NN O O
they NN O O
happen NN O O
when NN O O
you NN O O
are NN O O
treated NN O O
. NN O O
Serious NN O O
side NN O O
effects NN O O
include NN O O
: NN O O
* NN O O
blood NN O O
clots NN O O
* NN O O
stroke NN O O
* NN O O
heart NN O O
attack NN O O
* NN O O
cancer NN O O
of NN O O
the NN O O
lining NN O O
of NN O O
the NN O O
uterus NN O O
* NN O O
breast NN O O
cancer NN O O
* NN O O
cancer NN O O
of NN O O
the NN O O
ovary NN O O
* NN O O
dementia NN O O
* NN O O
gallbladder NN O O
problems NN O O
* NN O O
loss NN O O
of NN O O
vision NN O O
* NN O O
high NN O O
blood NN O O
pressure NN O O
* NN O O
increased NN O O
fats NN O O
in NN O O
your NN O O
blood NN O O
* NN O O
liver NN O O
problems NN O O
* NN O O
thyroid NN O O
problems NN O O
* NN O O
fluid NN O O
retention NN O O
* NN O O
low NN O O
calcium NN O O
* NN O O
swelling NN O O
of NN O O
your NN O O
mouth NN O O
or NN O O
tongue NN O O
* NN O O
worsening NN O O
of NN O O
other NN O O
medical NN O O
problems NN O O
such NN O O
as NN O O
asthma NN O O
, NN O O
diabetes NN O O
, NN O O
epilepsy NN O O
, NN O O
migraines NN O O
, NN O O
a NN O O
genetic NN O O
problem NN O O
called NN O O
porphyria NN O O
, NN O O
lupus NN O O
and NN O O
liver NN O O
problems NN O O
Call NN O O
your NN O O
healthcare NN O O
provider NN O O
right NN O O
away NN O O
if NN O O
you NN O O
get NN O O
any NN O O
of NN O O
the NN O O
following NN O O
warning NN O O
signs NN O O
, NN O O
or NN O O
any NN O O
other NN O O
unusual NN O O
symptoms NN O O
that NN O O
concern NN O O
you NN O O
: NN O O
* NN O O
new NN O O
breast NN O O
lumps NN O O
* NN O O
unusual NN O O
vaginal NN O O
bleeding NN O O
* NN O O
changes NN O O
in NN O O
vision NN O O
or NN O O
speech NN O O
* NN O O
sudden NN O O
new NN O O
severe NN O O
headaches NN O O
* NN O O
severe NN O O
pains NN O O
in NN O O
your NN O O
chest NN O O
or NN O O
legs NN O O
with NN O O
or NN O O
without NN O O
shortness NN O O
of NN O O
breath NN O O
, NN O O
weakness NN O O
and NN O O
fatigue NN O O
Less NN O O
serious NN O O
, NN O O
but NN O O
common NN O O
side NN O O
effects NN O O
include NN O O
: NN O O
* NN O O
muscle NN O O
spasms NN O O
* NN O O
nausea NN O O
* NN O O
diarrhea NN O O
* NN O O
upset NN O O
stomach NN O O
* NN O O
abdominal NN O O
pain NN O O
* NN O O
throat NN O O
pain NN O O
* NN O O
dizziness NN O O
* NN O O
neck NN O O
pain NN O O
These NN O O
are NN O O
not NN O O
all NN O O
the NN O O
possible NN O O
side NN O O
effects NN O O
of NN O O
DUAVEE. NN O O
For NN O O
more NN O O
information NN O O
, NN O O
ask NN O O
your NN O O
healthcare NN O O
provider NN O O
or NN O O
pharmacist NN O O
. NN O O
Tell NN O O
your NN O O
healthcare NN O O
provider NN O O
if NN O O
you NN O O
have NN O O
any NN O O
side NN O O
effects NN O O
that NN O O
bother NN O O
you NN O O
or NN O O
do NN O O
not NN O O
go NN O O
away NN O O
. NN O O
Call NN O O
your NN O O
doctor NN O O
for NN O O
medical NN O O
advice NN O O
about NN O O
side NN O O
effects NN O O
. NN O O
You NN O O
may NN O O
report NN O O
side NN O O
effects NN O O
to NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
. NN O O
What NN O O
can NN O O
I NN O O
do NN O O
to NN O O
lower NN O O
my NN O O
chances NN O O
of NN O O
a NN O O
serious NN O O
side NN O O
effect NN O O
with NN O O
DUAVEE NN O O
? NN O O
* NN O O
Talk NN O O
with NN O O
your NN O O
healthcare NN O O
provider NN O O
regularly NN O O
about NN O O
whether NN O O
you NN O O
should NN O O
continue NN O O
taking NN O O
DUAVEE. NN O O
* NN O O
See NN O O
you NN O O
healthcare NN O O
provider NN O O
right NN O O
away NN O O
if NN O O
you NN O O
get NN O O
vaginal NN O O
bleeding NN O O
while NN O O
taking NN O O
DUAVEE. NN O O
* NN O O
Have NN O O
a NN O O
pelvic NN O O
exam NN O O
, NN O O
breast NN O O
exam NN O O
and NN O O
mammogram NN O O
( NN O O
breast NN O O
X NN O O
- NN O O
ray NN O O
) NN O O
every NN O O
year NN O O
unless NN O O
your NN O O
healthcare NN O O
provider NN O O
tells NN O O
you NN O O
something NN O O
else NN O O
. NN O O
* NN O O
If NN O O
members NN O O
of NN O O
your NN O O
family NN O O
have NN O O
had NN O O
breast NN O O
cancer NN O O
or NN O O
if NN O O
you NN O O
have NN O O
ever NN O O
had NN O O
breast NN O O
lumps NN O O
or NN O O
an NN O O
abnormal NN O O
mammogram NN O O
, NN O O
you NN O O
may NN O O
need NN O O
to NN O O
have NN O O
breast NN O O
exams NN O O
more NN O O
often NN O O
. NN O O
* NN O O
If NN O O
you NN O O
have NN O O
high NN O O
blood NN O O
pressure NN O O
, NN O O
high NN O O
cholesterol NN O O
( NN O O
fat NN O O
in NN O O
the NN O O
blood NN O O
) NN O O
, NN O O
diabetes NN O O
, NN O O
are NN O O
overweight NN O O
, NN O O
or NN O O
if NN O O
you NN O O
use NN O O
tobacco NN O O
, NN O O
you NN O O
may NN O O
have NN O O
higher NN O O
chances NN O O
of NN O O
getting NN O O
heart NN O O
disease NN O O
. NN O O
Ask NN O O
your NN O O
healthcare NN O O
provider NN O O
for NN O O
ways NN O O
to NN O O
lower NN O O
your NN O O
chances NN O O
of NN O O
getting NN O O
heart NN O O
disease NN O O
. NN O O
How NN O O
do NN O O
I NN O O
store NN O O
DUAVEE NN O O
? NN O O
* NN O O
Store NN O O
DUAVEE NN O O
at NN O O
room NN O O
temperature NN O O
between NN O O
68 NN O O
degrees NN O O
F NN O O
to NN O O
77 NN O O
degrees NN O O
F NN O O
( NN O O
20 NN O O
degrees NN O O
C NN O O
to NN O O
25 NN O O
degrees NN O O
C NN O O
) NN O O
. NN O O
* NN O O
Keep NN O O
DUAVEE NN O O
in NN O O
the NN O O
blister NN O O
until NN O O
you NN O O
are NN O O
ready NN O O
to NN O O
take NN O O
it NN O O
to NN O O
protect NN O O
the NN O O
tablet NN O O
from NN O O
moisture NN O O
. NN O O
* NN O O
Do NN O O
not NN O O
place NN O O
DUAVEE NN O O
in NN O O
pill NN O O
boxes NN O O
or NN O O
pill NN O O
organizers NN O O
. NN O O
* NN O O
After NN O O
opening NN O O
the NN O O
foil NN O O
pouch NN O O
the NN O O
DUAVEE NN O O
blisters NN O O
come NN O O
in NN O O
, NN O O
DUAVEE NN O O
must NN O O
be NN O O
used NN O O
within NN O O
60 NN O O
days NN O O
. NN O O
Keep NN O O
DUAVEE NN O O
and NN O O
all NN O O
other NN O O
medicines NN O O
out NN O O
of NN O O
the NN O O
reach NN O O
of NN O O
children NN O O
. NN O O
General NN O O
information NN O O
about NN O O
the NN O O
safe NN O O
and NN O O
effective NN O O
use NN O O
of NN O O
DUAVEE NN O O
Medicines NN O O
are NN O O
sometimes NN O O
prescribed NN O O
for NN O O
purposes NN O O
other NN O O
than NN O O
those NN O O
listed NN O O
in NN O O
a NN O O
Patient NN O O
Information NN O O
leaflet NN O O
. NN O O
Do NN O O
not NN O O
use NN O O
DUAVEE NN O O
for NN O O
a NN O O
condition NN O O
for NN O O
which NN O O
it NN O O
was NN O O
not NN O O
prescribed NN O O
. NN O O
Do NN O O
not NN O O
give NN O O
DUAVEE NN O O
to NN O O
other NN O O
people NN O O
, NN O O
even NN O O
if NN O O
they NN O O
have NN O O
the NN O O
same NN O O
symptoms NN O O
you NN O O
have NN O O
. NN O O
It NN O O
may NN O O
harm NN O O
them NN O O
. NN O O
This NN O O
Patient NN O O
Information NN O O
summarizes NN O O
the NN O O
most NN O O
important NN O O
information NN O O
about NN O O
DUAVEE. NN O O
If NN O O
you NN O O
would NN O O
like NN O O
more NN O O
information NN O O
, NN O O
talk NN O O
with NN O O
your NN O O
healthcare NN O O
provider NN O O
. NN O O
You NN O O
can NN O O
ask NN O O
your NN O O
pharmacist NN O O
or NN O O
healthcare NN O O
provider NN O O
for NN O O
information NN O O
about NN O O
DUAVEE NN O O
that NN O O
is NN O O
written NN O O
for NN O O
health NN O O
professionals NN O O
. NN O O
For NN O O
more NN O O
information NN O O
, NN O O
go NN O O
to NN O O
www NN O O
. NN O O
DUAVEE.com NN O O
, NN O O
or NN O O
call NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
438 NN O O
- NN O O
1985 NN O O
. NN O O
What NN O O
are NN O O
the NN O O
ingredients NN O O
in NN O O
DUAVEE NN O O
? NN O O
Active NN O O
Ingredients NN O O
: NN O O
conjugated NN O O
estrogens NN O O
and NN O O
bazedoxifene NN O O
. NN O O
Conjugated NN O O
estrogens NN O O
are NN O O
a NN O O
mixture NN O O
of NN O O
sodium NN O O
estrone NN O O
sulfate NN O O
and NN O O
sodium NN O O
equilin NN O O
sulfate NN O O
and NN O O
other NN O O
components NN O O
, NN O O
including NN O O
sodium NN O O
sulfate NN O O
conjugates NN O O
, NN O O
17alpha NN O O
- NN O O
dihydroequilin NN O O
, NN O O
17alpha NN O O
- NN O O
estradiol NN O O
, NN O O
and NN O O
17beta NN O O
- NN O O
dihydroequilin NN O O
. NN O O
Inactive NN O O
Ingredients NN O O
: NN O O
calcium NN O O
phosphate NN O O
tribasic NN O O
, NN O O
hydroxypropyl NN O O
cellulose NN O O
, NN O O
microcrystalline NN O O
cellulose NN O O
, NN O O
powdered NN O O
cellulose NN O O
, NN O O
hypromellose NN O O
, NN O O
lactose NN O O
monohydrate NN O O
, NN O O
magnesium NN O O
stearate NN O O
, NN O O
polyethylene NN O O
glycol NN O O
, NN O O
sucrose NN O O
, NN O O
ascorbic NN O O
acid NN O O
, NN O O
sucrose NN O O
palmitic NN O O
acid NN O O
ester NN O O
, NN O O
hydroxyethylcellulose NN O O
, NN O O
titanium NN O O
dioxide NN O O
, NN O O
red NN O O
iron NN O O
oxide NN O O
, NN O O
yellow NN O O
iron NN O O
oxide NN O O
, NN O O
black NN O O
iron NN O O
oxide NN O O
, NN O O
povidone NN O O
, NN O O
polydextrose NN O O
, NN O O
maltitol NN O O
, NN O O
poloxamer NN O O
188 NN O O
, NN O O
propylene NN O O
glycol NN O O
, NN O O
isopropyl NN O O
alcohol NN O O
. NN O O
This NN O O
Patient NN O O
Information NN O O
has NN O O
been NN O O
approved NN O O
by NN O O
the NN O O
U.S. NN O O
Food NN O O
and NN O O
Drug NN O O
Administration NN O O
. NN O O
This NN O O
product NN O O
's NN O O
label NN O O
may NN O O
have NN O O
been NN O O
updated NN O O
. NN O O
For NN O O
current NN O O
full NN O O
prescribing NN O O
information NN O O
, NN O O
please NN O O
visit NN O O
www.pfizer.com NN O O
. NN O O
LAB-0583 NN O O
- NN O O
1.0 NN O O
October NN O O
2013 NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Women NN O O
taking NN O O
DUAVEE NN O O
should NN O O
not NN O O
take NN O O
progestins NN O O
, NN O O
additional NN O O
estrogens NN O O
or NN O O
additional NN O O
estrogen NN O O
agonist/antagonists NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Cardiovascular NN B-AdverseReaction B-AdverseReaction
disorders NN I-AdverseReaction I-AdverseReaction
including NN O O
venous NN B-AdverseReaction B-AdverseReaction
thromboembolism NN I-AdverseReaction I-AdverseReaction
pulmonary NN B-AdverseReaction B-AdverseReaction
embolism NN I-AdverseReaction I-AdverseReaction
stroke NN B-AdverseReaction B-AdverseReaction
and NN O O
retinal NN B-AdverseReaction B-AdverseReaction
vascular NN I-AdverseReaction I-AdverseReaction
thrombosis NN I-AdverseReaction I-AdverseReaction
( NN O O
5.2 NN O O
, NN O O
5.6 NN O O
) NN O O
* NN O O
Malignant NN B-AdverseReaction B-AdverseReaction
neoplasms NN I-AdverseReaction I-AdverseReaction
including NN O O
endometrial NN B-AdverseReaction B-AdverseReaction
cancer NN I-AdverseReaction I-AdverseReaction
breast NN B-AdverseReaction B-AdverseReaction
cancer NN I-AdverseReaction I-AdverseReaction
and NN O O
ovarian NN B-AdverseReaction B-AdverseReaction
cancer NN I-AdverseReaction I-AdverseReaction
( NN O O
5.3 NN O O
) NN O O
* NN O O
Estrogens NN O O
increase NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
gallbladder NN B-AdverseReaction B-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
( NN O O
5.5 NN O O
) NN O O
* NN O O
Discontinue NN O O
estrogen NN O O
if NN O O
loss NN O O
of NN O O
vision NN O O
, NN O O
severe NN O O
hypertriglyceridemia NN O O
or NN O O
cholestatic NN O O
jaundice NN O O
occurs NN O O
( NN O O
5.6 NN O O
, NN O O
5.8 NN O O
, NN O O
5.9 NN O O
) NN O O
* NN O O
Monitor NN O O
thyroid NN O O
function NN O O
in NN O O
women NN O O
on NN O O
thyroid NN O O
replacement NN O O
therapy NN O O
( NN O O
5.10 NN O O
, NN O O
5.17 NN O O
) NN O O
5.1 NN O O
Drugs NN O O
Containing NN O O
Progestins NN O O
, NN O O
Estrogens NN O O
or NN O O
Estrogen NN O O
Agonist/Antagonists NN O O
DUAVEE NN O O
contains NN O O
conjugated NN O O
estrogens NN O O
and NN O O
bazedoxifene NN O O
, NN O O
an NN O O
estrogen NN O O
agonist/antagonist NN O O
. NN O O
Women NN O O
taking NN O O
DUAVEE NN O O
should NN O O
not NN O O
take NN O O
progestins NN O O
, NN O O
additional NN O O
estrogens NN O O
or NN O O
additional NN O O
estrogen NN O O
agonist/antagonists NN O O
. NN O O
5.2 NN O O
Cardiovascular NN O O
Disorders NN O O
Estrogen NN O O
agonist/antagonists NN O O
( NN O O
including NN O O
bazedoxifene NN O O
, NN O O
a NN O O
component NN O O
of NN O O
DUAVEE NN O O
) NN O O
and NN O O
estrogens NN O O
individually NN O O
are NN O O
known NN O O
to NN O O
increase NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
VTE NN B-AdverseReaction B-AdverseReaction
An NN O O
increased NN O O
risk NN O O
of NN O O
stroke NN B-AdverseReaction B-AdverseReaction
and NN O O
DVT NN B-AdverseReaction B-AdverseReaction
has NN O O
been NN O O
reported NN O O
with NN O O
estrogen NN B-DrugClass B-DrugClass
therapy NN O O
. NN O O
Should NN O O
any NN O O
of NN O O
these NN O O
occur NN O O
or NN O O
be NN O O
suspected NN O O
, NN O O
DUAVEE NN O O
should NN O O
be NN O O
discontinued NN O O
immediately NN O O
. NN O O
Risk NN O O
factors NN O O
for NN O O
arterial NN O O
vascular NN O O
disease NN O O
( NN O O
for NN O O
example NN O O
, NN O O
hypertension NN O O
, NN O O
diabetes NN O O
mellitus NN O O
, NN O O
tobacco NN O O
use NN O O
, NN O O
hypercholesterolemia NN O O
, NN O O
and NN O O
obesity NN O O
) NN O O
and/or NN O O
VTE NN O O
( NN O O
for NN O O
example NN O O
, NN O O
personal NN O O
history NN O O
or NN O O
family NN O O
history NN O O
of NN O O
VTE NN O O
, NN O O
obesity NN O O
, NN O O
and NN O O
systemic NN O O
lupus NN O O
erythematosus NN O O
) NN O O
should NN O O
be NN O O
managed NN O O
appropriately NN O O
. NN O O
Stroke NN O O
In NN O O
the NN O O
WHI NN O O
estrogen NN O O
- NN O O
alone NN O O
substudy NN O O
, NN O O
a NN O O
statistically NN O O
significant NN O O
increased NN O O
risk NN O O
of NN O O
stroke NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
women NN O O
50 NN O O
to NN O O
79 NN O O
years NN O O
of NN O O
age NN O O
receiving NN O O
daily NN O O
conjugated NN B-DrugClass B-DrugClass
estrogens NN I-DrugClass I-DrugClass
( NN O O
CE NN O O
) NN O O
( NN O O
0.625 NN O O
mg)-alone NN O O
compared NN O O
to NN O O
women NN O O
in NN O O
the NN O O
same NN O O
age NN O O
group NN O O
receiving NN O O
placebo NN O O
( NN O O
45 NN O O
versus NN O O
33 NN O O
per NN O O
10,000 NN O O
women NN O O
- NN O O
years NN O O
) NN O O
. NN O O
The NN O O
increase NN O O
in NN O O
risk NN O O
was NN O O
demonstrated NN O O
in NN O O
year NN O O
1 NN O O
and NN O O
persisted NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14.5 NN O O
) NN O O
] NN O O
. NN O O
Subgroup NN O O
analyses NN O O
of NN O O
women NN O O
50 NN O O
to NN O O
59 NN O O
years NN O O
of NN O O
age NN O O
suggest NN O O
no NN B-Negation B-Negation
increased NN O O
risk NN O O
of NN O O
stroke NN B-AdverseReaction B-AdverseReaction
for NN O O
those NN O O
women NN O O
receiving NN O O
conjugated NN B-DrugClass B-DrugClass
estrogens NN I-DrugClass I-DrugClass
( NN O O
0.625 NN O O
mg)-alone NN O O
versus NN O O
those NN O O
receiving NN O O
placebo NN O O
( NN O O
18 NN O O
versus NN O O
21 NN O O
per NN O O
10,000 NN O O
women NN O O
- NN O O
years NN O O
) NN O O
. NN O O
Should NN O O
a NN O O
stroke NN O O
occur NN O O
or NN O O
be NN O O
suspected NN O O
, NN O O
DUAVEE NN O O
should NN O O
be NN O O
discontinued NN O O
immediately NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
] NN O O
. NN O O
Coronary NN O O
Heart NN O O
Disease NN O O
In NN O O
the NN O O
WHI NN O O
estrogen NN O O
- NN O O
alone NN O O
substudy NN O O
, NN O O
no NN O O
overall NN O O
effect NN O O
on NN O O
coronary NN B-AdverseReaction B-AdverseReaction
heart NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
( NN O O
CHD NN O O
) NN O O
events NN O O
( NN O O
defined NN O O
as NN O O
nonfatal NN B-Severity B-Severity
myocardial NN B-AdverseReaction B-AdverseReaction
infarction NN I-AdverseReaction I-AdverseReaction
silent NN B-AdverseReaction B-AdverseReaction
myocardial NN I-AdverseReaction I-AdverseReaction
infarction NN I-AdverseReaction I-AdverseReaction
or NN O O
CHD NN B-AdverseReaction B-AdverseReaction
death NN I-AdverseReaction I-AdverseReaction
was NN O O
reported NN O O
in NN O O
women NN O O
receiving NN O O
estrogen NN B-DrugClass B-DrugClass
compared NN O O
to NN O O
placebo NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14.5 NN O O
) NN O O
] NN O O
. NN O O
Subgroup NN O O
analyses NN O O
of NN O O
women NN O O
50 NN O O
to NN O O
59 NN O O
years NN O O
of NN O O
age NN O O
suggest NN O O
a NN O O
statistically NN O O
non NN O O
- NN O O
significant NN O O
reduction NN B-Negation B-Negation
in NN O O
CHD NN B-AdverseReaction B-AdverseReaction
events NN O O
( NN O O
CE NN O O
[ NN O O
0.625 NN O O
mg]-alone NN O O
compared NN O O
to NN O O
placebo NN O O
) NN O O
in NN O O
women NN O O
with NN O O
less NN O O
than NN O O
10 NN O O
years NN O O
since NN O O
menopause NN O O
( NN O O
8 NN O O
versus NN O O
16 NN O O
per NN O O
10,000 NN O O
women NN O O
- NN O O
years NN O O
) NN O O
. NN O O
Venous NN O O
Thromboembolism NN O O
( NN O O
VTE NN O O
) NN O O
In NN O O
the NN O O
WHI NN O O
estrogen NN O O
- NN O O
alone NN O O
substudy NN O O
, NN O O
the NN O O
risk NN O O
of NN O O
VTE NN B-AdverseReaction B-AdverseReaction
[ NN O O
DVT NN O O
and NN O O
pulmonary NN B-AdverseReaction B-AdverseReaction
embolism NN I-AdverseReaction I-AdverseReaction
( NN O O
PE NN O O
) NN O O
] NN O O
was NN O O
increased NN O O
for NN O O
women NN O O
receiving NN O O
daily NN O O
conjugated NN B-DrugClass B-DrugClass
estrogens NN I-DrugClass I-DrugClass
( NN O O
0.625 NN O O
mg)-alone NN O O
compared NN O O
to NN O O
placebo NN O O
( NN O O
30 NN O O
versus NN O O
22 NN O O
per NN O O
10,000 NN O O
women NN O O
- NN O O
years NN O O
) NN O O
, NN O O
although NN O O
only NN O O
the NN O O
increased NN O O
risk NN O O
of NN O O
DVT NN B-AdverseReaction B-AdverseReaction
reached NN O O
statistical NN O O
significance NN O O
( NN O O
23 NN O O
versus NN O O
15 NN O O
per NN O O
10,000 NN O O
women NN O O
- NN O O
years NN O O
) NN O O
. NN O O
The NN O O
increase NN O O
in NN O O
VTE NN B-AdverseReaction B-AdverseReaction
risk NN B-Factor B-Factor
was NN O O
demonstrated NN O O
during NN O O
the NN O O
first NN O O
2 NN O O
years NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14.5 NN O O
) NN O O
] NN O O
. NN O O
If NN O O
feasible NN O O
, NN O O
DUAVEE NN O O
should NN O O
be NN O O
discontinued NN O O
at NN O O
least NN O O
4 NN O O
to NN O O
6 NN O O
weeks NN O O
before NN O O
surgery NN O O
of NN O O
the NN O O
type NN O O
associated NN O O
with NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
thromboembolism NN O O
, NN O O
or NN O O
during NN O O
periods NN O O
of NN O O
prolonged NN O O
immobilization NN O O
. NN O O
Because NN O O
immobilization NN O O
increases NN O O
the NN O O
risk NN O O
for NN O O
venous NN O O
thromboembolic NN O O
events NN O O
independent NN O O
of NN O O
therapy NN O O
, NN O O
DUAVEE NN O O
should NN O O
be NN O O
discontinued NN O O
prior NN O O
to NN O O
and NN O O
during NN O O
prolonged NN O O
immobilization NN O O
( NN O O
e.g. NN O O
, NN O O
post NN O O
- NN O O
surgical NN O O
recovery NN O O
, NN O O
prolonged NN O O
bed NN O O
rest NN O O
) NN O O
and NN O O
DUAVEE NN O O
therapy NN O O
should NN O O
be NN O O
resumed NN O O
only NN O O
after NN O O
the NN O O
patient NN O O
is NN O O
fully NN O O
ambulatory NN O O
. NN O O
In NN O O
addition NN O O
, NN O O
women NN O O
taking NN O O
DUAVEE NN O O
should NN O O
be NN O O
advised NN O O
to NN O O
move NN O O
about NN O O
periodically NN O O
during NN O O
travel NN O O
involving NN O O
prolonged NN O O
immobilization NN O O
. NN O O
5.3 NN O O
Malignant NN O O
Neoplasms NN O O
Endometrial NN O O
Cancer NN O O
An NN O O
increased NN O O
risk NN O O
of NN O O
endometrial NN B-AdverseReaction B-AdverseReaction
cancer NN I-AdverseReaction I-AdverseReaction
has NN O O
been NN O O
reported NN O O
with NN O O
the NN O O
use NN O O
of NN O O
unopposed NN O O
estrogen NN B-DrugClass B-DrugClass
therapy NN O O
in NN O O
women NN O O
with NN O O
a NN O O
uterus NN O O
. NN O O
The NN O O
reported NN O O
endometrial NN B-AdverseReaction B-AdverseReaction
cancer NN I-AdverseReaction I-AdverseReaction
risk NN O O
among NN O O
unopposed NN O O
estrogen NN B-DrugClass B-DrugClass
users NN O O
is NN O O
about NN O O
2 NN O O
to NN O O
12 NN O O
times NN O O
greater NN O O
than NN O O
in NN O O
non NN O O
- NN O O
users NN O O
, NN O O
and NN O O
appears NN O O
dependent NN O O
on NN O O
duration NN O O
of NN O O
treatment NN O O
and NN O O
on NN O O
estrogen NN O O
dose NN O O
. NN O O
Most NN O O
studies NN O O
show NN O O
no NN O O
significant NN O O
increased NN O O
risk NN O O
associated NN O O
with NN O O
use NN O O
of NN O O
estrogens NN O O
for NN O O
less NN O O
than NN O O
1 NN O O
year NN O O
. NN O O
The NN O O
greatest NN O O
risk NN O O
appears NN O O
associated NN O O
with NN O O
prolonged NN O O
use NN O O
, NN O O
with NN O O
increased NN O O
risks NN O O
of NN O O
15- NN O O
to NN O O
24-fold NN O O
for NN O O
5 NN O O
to NN O O
10 NN O O
years NN O O
or NN O O
more NN O O
of NN O O
treatment NN O O
. NN O O
This NN O O
risk NN O O
has NN O O
been NN O O
shown NN O O
to NN O O
persist NN O O
for NN O O
at NN O O
least NN O O
8 NN O O
to NN O O
15 NN O O
years NN O O
after NN O O
estrogen NN O O
therapy NN O O
is NN O O
discontinued NN O O
. NN O O
DUAVEE NN O O
contains NN O O
an NN O O
estrogen NN O O
agonist/antagonist NN O O
. NN O O
This NN O O
component NN O O
reduces NN O O
the NN O O
risk NN O O
of NN O O
endometrial NN O O
hyperplasia NN O O
that NN O O
can NN O O
occur NN O O
with NN O O
the NN O O
conjugated NN O O
estrogens NN O O
component NN O O
. NN O O
Endometrial NN O O
hyperplasia NN O O
may NN O O
be NN O O
a NN O O
precursor NN O O
to NN O O
endometrial NN O O
cancer NN O O
. NN O O
Women NN O O
taking NN O O
DUAVEE NN O O
should NN O O
not NN O O
take NN O O
additional NN O O
estrogens NN O O
as NN O O
this NN O O
may NN O O
increase NN O O
the NN O O
risk NN O O
of NN O O
endometrial NN O O
hyperplasia NN O O
. NN O O
Clinical NN O O
surveillance NN O O
of NN O O
all NN O O
women NN O O
taking NN O O
DUAVEE NN O O
is NN O O
important NN O O
. NN O O
Adequate NN O O
diagnostic NN O O
measures NN O O
, NN O O
including NN O O
directed NN O O
or NN O O
random NN O O
endometrial NN O O
sampling NN O O
when NN O O
indicated NN O O
, NN O O
should NN O O
be NN O O
undertaken NN O O
to NN O O
rule NN O O
out NN O O
malignancy NN O O
in NN O O
postmenopausal NN O O
women NN O O
with NN O O
undiagnosed NN O O
persistent NN O O
or NN O O
recurring NN O O
abnormal NN O O
genital NN O O
bleeding NN O O
. NN O O
Breast NN O O
Cancer NN O O
The NN O O
most NN O O
important NN O O
randomized NN O O
clinical NN O O
study NN O O
providing NN O O
information NN O O
about NN O O
breast NN O O
cancer NN O O
in NN O O
estrogen NN O O
- NN O O
alone NN O O
users NN O O
is NN O O
the NN O O
WHI NN O O
substudy NN O O
of NN O O
daily NN O O
conjugated NN O O
estrogens NN O O
( NN O O
0.625 NN O O
mg)-alone NN O O
. NN O O
In NN O O
the NN O O
WHI NN O O
estrogen NN O O
- NN O O
alone NN O O
substudy NN O O
, NN O O
after NN O O
an NN O O
average NN O O
follow NN O O
- NN O O
up NN O O
of NN O O
7.1 NN O O
years NN O O
, NN O O
daily NN O O
conjugated NN B-DrugClass B-DrugClass
estrogen NN I-DrugClass I-DrugClass
( NN O O
0.625 NN O O
mg)-alone NN O O
was NN O O
not NN O O
associated NN O O
with NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
invasive NN B-AdverseReaction B-AdverseReaction
breast NN I-AdverseReaction I-AdverseReaction
cancer NN I-AdverseReaction I-AdverseReaction
( NN O O
relative NN O O
risk NN O O
[ NN O O
RR NN O O
] NN O O
0.80 NN O O
) NN O O
. NN O O
The NN O O
use NN O O
of NN O O
estrogen NN O O
- NN O O
alone NN O O
has NN O O
been NN O O
reported NN O O
to NN O O
result NN O O
in NN O O
an NN O O
increase NN O O
in NN O O
abnormal NN O O
mammograms NN O O
requiring NN O O
further NN O O
evaluation NN O O
. NN O O
The NN O O
effect NN O O
of NN O O
treatment NN O O
with NN O O
DUAVEE NN O O
on NN O O
the NN O O
risk NN O O
of NN O O
breast NN O O
cancer NN O O
is NN O O
unknown NN O O
. NN O O
All NN O O
women NN O O
should NN O O
receive NN O O
yearly NN O O
breast NN O O
examinations NN O O
by NN O O
a NN O O
healthcare NN O O
provider NN O O
and NN O O
perform NN O O
monthly NN O O
breast NN O O
self NN O O
- NN O O
examinations NN O O
. NN O O
In NN O O
addition NN O O
, NN O O
mammography NN O O
examinations NN O O
should NN O O
be NN O O
scheduled NN O O
based NN O O
on NN O O
patient NN O O
age NN O O
, NN O O
risk NN O O
factors NN O O
, NN O O
and NN O O
prior NN O O
mammogram NN O O
results NN O O
. NN O O
Ovarian NN O O
Cancer NN O O
In NN O O
some NN O O
epidemiological NN O O
studies NN O O
, NN O O
the NN O O
use NN O O
of NN O O
estrogen NN B-DrugClass B-DrugClass
products NN O O
, NN O O
in NN O O
particular NN O O
for NN O O
5 NN O O
or NN O O
more NN O O
years NN O O
, NN O O
has NN O O
been NN O O
associated NN O O
with NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
ovarian NN B-AdverseReaction B-AdverseReaction
cancer NN I-AdverseReaction I-AdverseReaction
However NN O O
, NN O O
the NN O O
duration NN O O
of NN O O
exposure NN O O
associated NN O O
with NN O O
increased NN O O
risk NN O O
is NN O O
not NN O O
consistent NN O O
across NN O O
all NN O O
epidemiologic NN O O
studies NN O O
, NN O O
and NN O O
some NN O O
report NN O O
no NN O O
association NN O O
. NN O O
The NN O O
effect NN O O
of NN O O
treatment NN O O
with NN O O
DUAVEE NN O O
on NN O O
the NN O O
risk NN O O
of NN O O
ovarian NN O O
cancer NN O O
is NN O O
unknown NN O O
. NN O O
5.4 NN O O
Probable NN O O
Dementia NN O O
In NN O O
the NN O O
WHIMS NN O O
estrogen NN O O
- NN O O
alone NN O O
ancillary NN O O
study NN O O
of NN O O
WHI NN O O
, NN O O
a NN O O
population NN O O
of NN O O
2,947 NN O O
hysterectomized NN O O
women NN O O
65 NN O O
to NN O O
79 NN O O
years NN O O
of NN O O
age NN O O
was NN O O
randomized NN O O
to NN O O
daily NN O O
CE NN O O
( NN O O
0.625 NN O O
mg)-alone NN O O
or NN O O
placebo NN O O
. NN O O
After NN O O
an NN O O
average NN O O
follow NN O O
- NN O O
up NN O O
of NN O O
5.2 NN O O
years NN O O
, NN O O
28 NN O O
women NN O O
in NN O O
the NN O O
estrogen NN B-DrugClass B-DrugClass
group NN O O
and NN O O
19 NN O O
women NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
were NN O O
diagnosed NN O O
with NN O O
probable NN O O
dementia NN B-AdverseReaction B-AdverseReaction
The NN O O
relative NN O O
risk NN O O
of NN O O
probable NN O O
dementia NN B-AdverseReaction B-AdverseReaction
for NN O O
CE NN B-DrugClass B-DrugClass
versus NN O O
placebo NN O O
was NN O O
1.49 NN O O
( NN O O
95 NN O O
percent NN O O
CI NN O O
, NN O O
0.83 NN O O
- NN O O
2.66 NN O O
) NN O O
. NN O O
The NN O O
absolute NN O O
risk NN O O
of NN O O
probable NN O O
dementia NN B-AdverseReaction B-AdverseReaction
for NN O O
CE NN B-DrugClass B-DrugClass
versus NN O O
placebo NN O O
was NN O O
37 NN O O
versus NN O O
25 NN O O
cases NN O O
per NN O O
10,000 NN O O
women NN O O
- NN O O
years NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.5 NN O O
) NN O O
and NN O O
Clinical NN O O
Studies NN O O
( NN O O
14.6 NN O O
) NN O O
] NN O O
. NN O O
5.5 NN O O
Gallbladder NN O O
Disease NN O O
A NN O O
2- NN O O
to NN O O
4-fold NN O O
increase NN O O
in NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
gallbladder NN B-AdverseReaction B-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
requiring NN O O
surgery NN O O
in NN O O
postmenopausal NN O O
women NN O O
receiving NN O O
estrogens NN O O
has NN O O
been NN O O
reported NN O O
. NN O O
5.6 NN O O
Visual NN O O
Abnormalities NN O O
Retinal NN B-AdverseReaction B-AdverseReaction
vascular NN I-AdverseReaction I-AdverseReaction
thrombosis NN I-AdverseReaction I-AdverseReaction
has NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
receiving NN O O
estrogens NN O O
. NN O O
Discontinue NN O O
medication NN O O
pending NN O O
examination NN O O
if NN O O
there NN O O
is NN O O
sudden NN O O
partial NN O O
or NN O O
complete NN O O
loss NN O O
of NN O O
vision NN O O
, NN O O
or NN O O
a NN O O
sudden NN O O
onset NN O O
of NN O O
proptosis NN O O
, NN O O
diplopia NN O O
, NN O O
or NN O O
migraine NN O O
. NN O O
If NN O O
examination NN O O
reveals NN O O
papilledema NN O O
or NN O O
retinal NN O O
vascular NN O O
lesions NN O O
, NN O O
DUAVEE NN O O
should NN O O
be NN O O
permanently NN O O
discontinued NN O O
. NN O O
5.7 NN O O
Elevated NN O O
Blood NN O O
Pressure NN O O
In NN O O
a NN O O
small NN O O
number NN O O
of NN O O
case NN O O
reports NN O O
in NN O O
women NN O O
receiving NN O O
estrogens NN O O
, NN O O
substantial NN B-Severity B-Severity
increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
blood NN I-AdverseReaction I-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
attributed NN O O
to NN O O
idiosyncratic NN O O
reactions NN O O
to NN O O
estrogens NN O O
. NN O O
In NN O O
a NN O O
large NN O O
, NN O O
randomized NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
clinical NN O O
study NN O O
, NN O O
a NN O O
generalized NN O O
effect NN O O
of NN O O
estrogens NN O O
on NN O O
blood NN O O
pressure NN O O
was NN O O
not NN B-Negation B-Negation
seen NN O O
. NN O O
5.8 NN O O
Hypertriglyceridemia NN O O
In NN O O
women NN O O
with NN O O
pre NN O O
- NN O O
existing NN O O
hypertriglyceridemia NN O O
, NN O O
treatment NN O O
with NN O O
estrogens NN O O
may NN B-Factor B-Factor
be NN O O
associated NN O O
with NN O O
elevations NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
plasma NN I-AdverseReaction I-AdverseReaction
triglycerides NN I-AdverseReaction I-AdverseReaction
leading NN O O
to NN O O
pancreatitis NN B-AdverseReaction B-AdverseReaction
Consider NN O O
discontinuation NN O O
of NN O O
DUAVEE NN O O
if NN O O
pancreatitis NN O O
occurs NN O O
. NN O O
5.9 NN O O
Hepatic NN O O
Impairment NN O O
and NN O O
Past NN O O
History NN O O
of NN O O
Cholestatic NN O O
Jaundice NN O O
DUAVEE NN O O
has NN O O
not NN O O
been NN O O
studied NN O O
in NN O O
women NN O O
with NN O O
impaired NN O O
liver NN O O
function NN O O
or NN O O
past NN O O
history NN O O
of NN O O
cholestatic NN O O
jaundice NN O O
. NN O O
Estrogens NN O O
may NN O O
be NN O O
poorly NN O O
metabolized NN O O
in NN O O
women NN O O
with NN O O
impaired NN O O
liver NN O O
function NN O O
. NN O O
On NN O O
average NN O O
, NN O O
women NN O O
with NN O O
hepatic NN O O
impairment NN O O
treated NN O O
with NN O O
bazedoxifene NN O O
alone NN O O
showed NN O O
a NN O O
4.3-fold NN O O
increase NN O O
in NN O O
overall NN O O
exposures NN O O
compared NN O O
with NN O O
controls NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.7 NN O O
) NN O O
and NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.3 NN O O
) NN O O
] NN O O
. NN O O
For NN O O
women NN O O
with NN O O
a NN O O
history NN O O
of NN O O
cholestatic NN O O
jaundice NN O O
associated NN O O
with NN O O
past NN O O
estrogen NN O O
use NN O O
or NN O O
with NN O O
pregnancy NN O O
, NN O O
caution NN O O
should NN O O
be NN O O
exercised NN O O
; NN O O
and NN O O
in NN O O
the NN O O
case NN O O
of NN O O
recurrence NN O O
, NN O O
DUAVEE NN O O
should NN O O
be NN O O
discontinued NN O O
. NN O O
Use NN O O
of NN O O
DUAVEE NN O O
in NN O O
patients NN O O
with NN O O
hepatic NN O O
impairment NN O O
is NN O O
contraindicated NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
] NN O O
. NN O O
5.10 NN O O
Hypothyroidism NN O O
Estrogen NN O O
administration NN O O
leads NN O O
to NN O O
increased NN O O
thyroid NN O O
- NN O O
binding NN O O
globulin NN O O
( NN O O
TBG NN O O
) NN O O
levels NN O O
. NN O O
Women NN O O
with NN O O
normal NN O O
thyroid NN O O
function NN O O
can NN O O
compensate NN O O
for NN O O
the NN O O
increased NN B-AdverseReaction B-AdverseReaction
TBG NN I-AdverseReaction I-AdverseReaction
by NN O O
making NN O O
more NN O O
thyroid NN O O
hormone NN O O
, NN O O
thus NN O O
maintaining NN O O
free NN O O
T4 NN O O
and NN O O
T3 NN O O
serum NN O O
concentrations NN O O
in NN O O
the NN O O
normal NN O O
range NN O O
. NN O O
Women NN O O
dependent NN O O
on NN O O
thyroid NN O O
hormone NN O O
replacement NN O O
therapy NN O O
who NN O O
are NN O O
also NN O O
receiving NN O O
estrogens NN O O
may NN O O
require NN O O
increased NN O O
doses NN O O
of NN O O
their NN O O
thyroid NN O O
replacement NN O O
therapy NN O O
. NN O O
These NN O O
women NN O O
should NN O O
have NN O O
their NN O O
thyroid NN O O
function NN O O
monitored NN O O
in NN O O
order NN O O
to NN O O
maintain NN O O
their NN O O
free NN O O
thyroid NN O O
hormone NN O O
levels NN O O
in NN O O
an NN O O
acceptable NN O O
range NN O O
. NN O O
5.11 NN O O
Fluid NN O O
Retention NN O O
Estrogens NN O O
may NN B-Factor B-Factor
cause NN O O
some NN O O
degree NN O O
of NN O O
fluid NN B-AdverseReaction B-AdverseReaction
retention NN I-AdverseReaction I-AdverseReaction
Because NN O O
of NN O O
this NN O O
, NN O O
patients NN O O
who NN O O
have NN O O
conditions NN O O
that NN O O
might NN O O
be NN O O
influenced NN O O
by NN O O
this NN O O
factor NN O O
, NN O O
such NN O O
as NN O O
cardiac NN O O
dysfunction NN O O
or NN O O
renal NN O O
impairment NN O O
, NN O O
warrant NN O O
careful NN O O
observation NN O O
when NN O O
estrogens NN O O
are NN O O
prescribed NN O O
. NN O O
Use NN O O
of NN O O
DUAVEE NN O O
in NN O O
patients NN O O
with NN O O
renal NN O O
impairment NN O O
is NN O O
not NN O O
recommended NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.6 NN O O
) NN O O
] NN O O
. NN O O
5.12 NN O O
Hypocalcemia NN O O
Estrogen NN O O
therapy NN O O
should NN O O
be NN O O
used NN O O
with NN O O
caution NN O O
in NN O O
women NN O O
with NN O O
hypoparathyroidism NN O O
as NN O O
estrogen NN O O
- NN O O
induced NN O O
hypocalcemia NN O O
may NN O O
occur NN O O
. NN O O
5.13 NN O O
Hereditary NN O O
Angioedema NN O O
Exogenous NN O O
estrogens NN O O
may NN B-Factor B-Factor
exacerbate NN O O
symptoms NN O O
of NN O O
angioedema NN O O
in NN O O
women NN O O
with NN O O
hereditary NN O O
angioedema NN O O
. NN O O
5.14 NN O O
Exacerbation NN O O
of NN O O
Other NN O O
Conditions NN O O
Estrogens NN O O
may NN O O
cause NN O O
an NN O O
exacerbation NN O O
of NN O O
asthma NN O O
, NN O O
diabetes NN O O
mellitus NN O O
, NN O O
epilepsy NN O O
, NN O O
migraine NN O O
or NN O O
porphyria NN O O
, NN O O
systemic NN O O
lupus NN O O
erythematosus NN O O
, NN O O
and NN O O
hepatic NN O O
hemangiomas NN O O
and NN O O
should NN O O
be NN O O
used NN O O
with NN O O
caution NN O O
in NN O O
women NN O O
with NN O O
these NN O O
conditions NN O O
. NN O O
5.15 NN O O
Premenopausal NN O O
Women NN O O
There NN O O
is NN O O
no NN O O
indication NN O O
for NN O O
premenopausal NN O O
use NN O O
of NN O O
DUAVEE. NN O O
The NN O O
efficacy NN O O
and NN O O
safety NN O O
of NN O O
DUAVEE NN O O
in NN O O
premenopausal NN O O
women NN O O
have NN O O
not NN O O
been NN O O
established NN O O
, NN O O
and NN O O
its NN O O
use NN O O
is NN O O
not NN O O
recommended NN O O
. NN O O
5.16 NN O O
Laboratory NN O O
Tests NN O O
Serum NN O O
follicle NN O O
stimulating NN O O
hormone NN O O
( NN O O
FSH NN O O
) NN O O
and NN O O
estradiol NN O O
levels NN O O
have NN O O
not NN O O
been NN O O
shown NN O O
to NN O O
be NN O O
useful NN O O
in NN O O
the NN O O
management NN O O
of NN O O
moderate NN O O
to NN O O
severe NN O O
vasomotor NN O O
symptoms NN O O
. NN O O
5.17 NN O O
Drug NN O O
- NN O O
Laboratory NN O O
Test NN O O
Interactions NN O O
Accelerated NN B-AdverseReaction B-AdverseReaction
prothrombin NN I-AdverseReaction I-AdverseReaction
time NN I-AdverseReaction I-AdverseReaction
partial NN O O
thromboplastin NN O O
time NN O O
, NN O O
and NN O O
platelet NN O O
aggregation NN O O
time NN O O
; NN O O
increased NN B-AdverseReaction B-AdverseReaction
platelet NN I-AdverseReaction I-AdverseReaction
count NN I-AdverseReaction I-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
factors NN I-AdverseReaction I-AdverseReaction
II NN I-AdverseReaction I-AdverseReaction
VII NN O O
antigen NN O O
, NN O O
VIII NN O O
antigen NN O O
, NN O O
VIII NN O O
coagulant NN O O
activity NN O O
, NN O O
IX NN O O
, NN O O
X NN O O
, NN O O
XII NN O O
, NN O O
VII NN O O
- NN O O
X NN O O
complex NN O O
, NN O O
II NN O O
- NN O O
VII NN O O
- NN O O
X NN O O
complex NN O O
, NN O O
and NN O O
beta NN O O
- NN O O
thromboglobulin NN O O
; NN O O
decreased NN B-AdverseReaction B-AdverseReaction
levels NN I-AdverseReaction I-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
antifactor NN I-AdverseReaction I-AdverseReaction
Xa NN I-AdverseReaction I-AdverseReaction
and NN O O
antithrombin NN O O
III NN O O
, NN O O
decreased NN B-AdverseReaction B-AdverseReaction
antithrombin NN I-AdverseReaction I-AdverseReaction
III NN I-AdverseReaction I-AdverseReaction
activity NN I-AdverseReaction I-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
levels NN I-AdverseReaction I-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
fibrinogen NN I-AdverseReaction I-AdverseReaction
and NN O O
fibrinogen NN O O
activity NN O O
; NN O O
increased NN B-AdverseReaction B-AdverseReaction
plasminogen NN I-AdverseReaction I-AdverseReaction
antigen NN I-AdverseReaction I-AdverseReaction
and NN O O
activity NN O O
. NN O O
Increased NN B-AdverseReaction B-AdverseReaction
thyroid NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
binding NN I-AdverseReaction I-AdverseReaction
globulin NN I-AdverseReaction I-AdverseReaction
( NN O O
TBG NN O O
) NN O O
leading NN O O
to NN O O
increased NN B-AdverseReaction B-AdverseReaction
circulating NN I-AdverseReaction I-AdverseReaction
total NN I-AdverseReaction I-AdverseReaction
thyroid NN I-AdverseReaction I-AdverseReaction
hormone NN I-AdverseReaction I-AdverseReaction
as NN O O
measured NN O O
by NN O O
protein NN O O
- NN O O
bound NN O O
iodine NN O O
( NN O O
PBI NN O O
) NN O O
, NN O O
T4 NN O O
levels NN O O
( NN O O
by NN O O
column NN O O
or NN O O
by NN O O
radioimmunoassay NN O O
) NN O O
, NN O O
or NN O O
T3 NN O O
levels NN O O
by NN O O
radioimmunoassay NN O O
. NN O O
T3 NN O O
resin NN O O
uptake NN O O
is NN O O
decreased NN O O
, NN O O
reflecting NN O O
the NN O O
elevated NN B-AdverseReaction B-AdverseReaction
TBG NN I-AdverseReaction I-AdverseReaction
Free NN O O
T4 NN O O
and NN O O
free NN O O
T3 NN O O
concentrations NN O O
are NN O O
unaltered NN O O
. NN O O
Women NN O O
on NN O O
thyroid NN O O
replacement NN O O
therapy NN O O
may NN O O
require NN O O
higher NN O O
doses NN O O
of NN O O
thyroid NN O O
hormone NN O O
. NN O O
Other NN O O
binding NN O O
proteins NN O O
may NN B-Factor B-Factor
be NN O O
elevated NN O O
in NN O O
serum NN O O
, NN O O
for NN O O
example NN O O
, NN O O
corticosteroid NN O O
binding NN O O
globulin NN O O
( NN O O
CBG NN O O
) NN O O
, NN O O
sex NN O O
hormone NN O O
- NN O O
binding NN O O
globulin NN O O
( NN O O
SHBG NN O O
) NN O O
, NN O O
leading NN O O
to NN O O
increased NN B-AdverseReaction B-AdverseReaction
total NN I-AdverseReaction I-AdverseReaction
circulating NN I-AdverseReaction I-AdverseReaction
corticosteroids NN I-AdverseReaction I-AdverseReaction
and NN O O
sex NN O O
steroids NN O O
, NN O O
respectively NN O O
. NN O O
Free NN O O
hormone NN O O
concentrations NN O O
, NN O O
such NN O O
as NN O O
testosterone NN O O
and NN O O
estradiol NN O O
, NN O O
may NN B-Factor B-Factor
be NN O O
decreased NN O O
. NN O O
Other NN O O
plasma NN O O
proteins NN O O
may NN B-Factor B-Factor
be NN O O
increased NN O O
( NN O O
angiotensinogen/renin NN O O
substrate NN O O
, NN O O
alpha-1-antitrypsin NN O O
, NN O O
ceruloplasmin NN O O
) NN O O
. NN O O
Increased NN B-AdverseReaction B-AdverseReaction
plasma NN I-AdverseReaction I-AdverseReaction
high NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
density NN I-AdverseReaction I-AdverseReaction
lipoprotein NN I-AdverseReaction I-AdverseReaction
( NN O O
HDL NN O O
) NN O O
and NN O O
HDL2 NN O O
cholesterol NN O O
subfraction NN O O
concentrations NN O O
, NN O O
reduced NN O O
low NN O O
- NN O O
density NN O O
lipoprotein NN O O
( NN O O
LDL NN O O
) NN O O
cholesterol NN O O
concentrations NN O O
, NN O O
increased NN B-AdverseReaction B-AdverseReaction
triglyceride NN I-AdverseReaction I-AdverseReaction
levels NN I-AdverseReaction I-AdverseReaction
Impaired NN B-AdverseReaction B-AdverseReaction
glucose NN I-AdverseReaction I-AdverseReaction
tolerance NN I-AdverseReaction I-AdverseReaction

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
serious NN O O
adverse NN O O
reactions NN O O
with NN O O
the NN O O
use NN O O
of NN O O
COCs NN O O
are NN O O
discussed NN O O
elsewhere NN O O
in NN O O
the NN O O
labeling NN O O
: NN O O
* NN O O
Serious NN B-Severity B-Severity
cardiovascular NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
and NN O O
stroke NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Boxed NN O O
Warning NN O O
and NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Vascular NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Liver NN B-AdverseReaction B-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
Adverse NN O O
reactions NN O O
commonly NN O O
reported NN O O
by NN O O
COC NN O O
users NN O O
are NN O O
: NN O O
* NN O O
Irregular NN B-AdverseReaction B-AdverseReaction
uterine NN I-AdverseReaction I-AdverseReaction
bleeding NN I-AdverseReaction I-AdverseReaction
* NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
* NN O O
Breast NN B-AdverseReaction B-AdverseReaction
tenderness NN I-AdverseReaction I-AdverseReaction
* NN O O
Headache NN B-AdverseReaction B-AdverseReaction
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>= NN O O
2 NN O O
% NN O O
) NN O O
in NN O O
clinical NN O O
trials NN O O
for NN O O
Natazia NN O O
are NN O O
headaches NN B-AdverseReaction B-AdverseReaction
irregular NN B-AdverseReaction B-AdverseReaction
uterine NN I-AdverseReaction I-AdverseReaction
bleeding NN I-AdverseReaction I-AdverseReaction
( NN O O
including NN O O
migraines NN B-AdverseReaction B-AdverseReaction
13 NN O O
% NN O O
, NN O O
breast NN B-AdverseReaction B-AdverseReaction
tenderness NN I-AdverseReaction I-AdverseReaction
7 NN O O
% NN O O
, NN O O
menstrual NN B-AdverseReaction B-AdverseReaction
disorders NN I-AdverseReaction I-AdverseReaction
7 NN O O
% NN O O
, NN O O
nausea NN B-AdverseReaction B-AdverseReaction
or NN O O
vomiting NN B-AdverseReaction B-AdverseReaction
6 NN O O
% NN O O
, NN O O
acne NN B-AdverseReaction B-AdverseReaction
4 NN O O
% NN O O
, NN O O
mood NN B-AdverseReaction B-AdverseReaction
changes NN I-AdverseReaction I-AdverseReaction
( NN O O
3 NN O O
% NN O O
) NN O O
and NN O O
increased NN B-AdverseReaction B-AdverseReaction
weight NN I-AdverseReaction I-AdverseReaction
3 NN O O
% NN O O
. NN O O
( NN O O
6 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Bayer NN O O
HealthCare NN O O
Pharmaceuticals NN O O
Inc. NN O O
at NN O O
1 NN O O
- NN O O
888 NN O O
- NN O O
842 NN O O
- NN O O
2937 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
Contraception NN O O
and NN O O
Heavy NN O O
Menstrual NN O O
Bleeding NN O O
Studies NN O O
A NN O O
total NN O O
of NN O O
2,131 NN O O
women NN O O
, NN O O
18 NN O O
to NN O O
54 NN O O
years NN O O
of NN O O
age NN O O
, NN O O
who NN O O
took NN O O
at NN O O
least NN O O
one NN O O
dose NN O O
of NN O O
Natazia NN O O
were NN O O
enrolled NN O O
in NN O O
four NN O O
clinical NN O O
phase NN O O
3 NN O O
trials NN O O
. NN O O
A NN O O
total NN O O
of NN O O
1,867 NN O O
subjects NN O O
were NN O O
included NN O O
in NN O O
two NN O O
clinical NN O O
phase NN O O
3 NN O O
studies NN O O
with NN O O
a NN O O
treatment NN O O
duration NN O O
up NN O O
to NN O O
28 NN O O
cycles NN O O
with NN O O
Natazia NN O O
as NN O O
an NN O O
oral NN O O
contraceptive NN O O
and NN O O
264 NN O O
subjects NN O O
in NN O O
the NN O O
two NN O O
phase NN O O
3 NN O O
clinical NN O O
trials NN O O
with NN O O
a NN O O
treatment NN O O
duration NN O O
of NN O O
7 NN O O
cycles NN O O
evaluating NN O O
Natazia NN O O
in NN O O
the NN O O
treatment NN O O
of NN O O
heavy NN O O
, NN O O
prolonged NN O O
, NN O O
and/or NN O O
frequent NN O O
menstrual NN O O
bleeding NN O O
in NN O O
women NN O O
without NN O O
organic NN O O
pathology NN O O
. NN O O
[ NN O O
See NN O O
Clinical NN O O
Studies NN O O
( NN O O
14.1 NN O O
, NN O O
14.2 NN O O
. NN O O
) NN O O
] NN O O
Adverse NN O O
Reactions NN O O
Leading NN O O
to NN O O
Study NN O O
Discontinuation NN O O
: NN O O
11.4 NN O O
% NN O O
of NN O O
the NN O O
women NN O O
discontinued NN O O
from NN O O
the NN O O
clinical NN O O
trials NN O O
due NN O O
to NN O O
an NN O O
adverse NN O O
reaction NN O O
; NN O O
the NN O O
most NN O O
frequent NN O O
adverse NN O O
reactions NN O O
leading NN O O
to NN O O
discontinuation NN O O
were NN O O
menstrual NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
( NN O O
metrorrhagia NN O O
, NN O O
menorrhagia NN B-AdverseReaction B-AdverseReaction
menstruation NN B-AdverseReaction B-AdverseReaction
irregular NN I-AdverseReaction I-AdverseReaction
genital NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
vaginal NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
dysfunctional NN B-AdverseReaction B-AdverseReaction
uterine NN I-AdverseReaction I-AdverseReaction
bleeding NN I-AdverseReaction I-AdverseReaction
( NN O O
2.3 NN O O
% NN O O
) NN O O
; NN O O
mood NN B-AdverseReaction B-AdverseReaction
changes NN I-AdverseReaction I-AdverseReaction
( NN O O
depression NN O O
, NN O O
mood NN B-AdverseReaction B-AdverseReaction
swings NN I-AdverseReaction I-AdverseReaction
mood NN B-AdverseReaction B-AdverseReaction
altered NN I-AdverseReaction I-AdverseReaction
depressed NN B-AdverseReaction B-AdverseReaction
mood NN I-AdverseReaction I-AdverseReaction
dysthymic NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
crying NN B-AdverseReaction B-AdverseReaction
( NN O O
1.2 NN O O
% NN O O
) NN O O
; NN O O
acne NN B-AdverseReaction B-AdverseReaction
( NN O O
1.1 NN O O
% NN O O
) NN O O
, NN O O
headache NN B-AdverseReaction B-AdverseReaction
( NN O O
including NN O O
migraines NN B-AdverseReaction B-AdverseReaction
( NN O O
1.1 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
weight NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
( NN O O
0.7 NN O O
% NN O O
) NN O O
. NN O O
Common NN O O
Adverse NN O O
Reactions NN O O
( NN O O
>= NN O O
2 NN O O
% NN O O
) NN O O
: NN O O
headache NN B-AdverseReaction B-AdverseReaction
( NN O O
including NN O O
migraines NN B-AdverseReaction B-AdverseReaction
( NN O O
12.7 NN O O
% NN O O
) NN O O
, NN O O
breast NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
discomfort NN O O
or NN O O
tenderness NN O O
( NN O O
7.0 NN O O
% NN O O
) NN O O
, NN O O
menstrual NN B-AdverseReaction B-AdverseReaction
disorders NN I-AdverseReaction I-AdverseReaction
( NN O O
metrorrhagia NN O O
, NN O O
menstruation NN B-AdverseReaction B-AdverseReaction
irregular NN I-AdverseReaction I-AdverseReaction
menorrhagia NN B-AdverseReaction B-AdverseReaction
vaginal NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
dysfunctional NN B-AdverseReaction B-AdverseReaction
uterine NN I-AdverseReaction I-AdverseReaction
bleeding NN I-AdverseReaction I-AdverseReaction
genital NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
abnormal NN B-AdverseReaction B-AdverseReaction
withdrawal NN I-AdverseReaction I-AdverseReaction
bleeding NN I-AdverseReaction I-AdverseReaction
uterine NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
( NN O O
6.9 NN O O
% NN O O
) NN O O
, NN O O
nausea NN B-AdverseReaction B-AdverseReaction
or NN O O
vomiting NN B-AdverseReaction B-AdverseReaction
( NN O O
6.0 NN O O
% NN O O
) NN O O
, NN O O
acne NN B-AdverseReaction B-AdverseReaction
( NN O O
3.9 NN O O
% NN O O
) NN O O
, NN O O
mood NN B-AdverseReaction B-AdverseReaction
changes NN I-AdverseReaction I-AdverseReaction
( NN O O
depression NN O O
, NN O O
mood NN B-AdverseReaction B-AdverseReaction
swings NN I-AdverseReaction I-AdverseReaction
depressed NN B-AdverseReaction B-AdverseReaction
mood NN I-AdverseReaction I-AdverseReaction
mood NN B-AdverseReaction B-AdverseReaction
altered NN I-AdverseReaction I-AdverseReaction
affect NN B-AdverseReaction B-AdverseReaction
lability NN I-AdverseReaction I-AdverseReaction
dysthymic NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
crying NN B-AdverseReaction B-AdverseReaction
( NN O O
3.0 NN O O
% NN O O
) NN O O
and NN O O
increased NN B-AdverseReaction B-AdverseReaction
weight NN I-AdverseReaction I-AdverseReaction
( NN O O
2.9 NN O O
% NN O O
) NN O O
. NN O O
Serious NN O O
Adverse NN O O
Reactions NN O O
: NN O O
myocardial NN B-AdverseReaction B-AdverseReaction
infarction NN I-AdverseReaction I-AdverseReaction
( NN O O
2 NN O O
cases NN O O
) NN O O
, NN O O
ruptured NN B-AdverseReaction B-AdverseReaction
ovarian NN I-AdverseReaction I-AdverseReaction
cyst NN I-AdverseReaction I-AdverseReaction
( NN O O
2 NN O O
cases NN O O
) NN O O
, NN O O
deep NN B-AdverseReaction B-AdverseReaction
vein NN I-AdverseReaction I-AdverseReaction
thrombosis NN I-AdverseReaction I-AdverseReaction
focal NN B-AdverseReaction B-AdverseReaction
nodular NN I-AdverseReaction I-AdverseReaction
hyperplasia NN I-AdverseReaction I-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
liver NN I-AdverseReaction I-AdverseReaction
uterine NN B-AdverseReaction B-AdverseReaction
leiomyoma NN I-AdverseReaction I-AdverseReaction
acute NN B-AdverseReaction B-AdverseReaction
cholecystitis NN I-AdverseReaction I-AdverseReaction
and NN O O
chronic NN B-AdverseReaction B-AdverseReaction
acalculous NN I-AdverseReaction I-AdverseReaction
cholecystitis NN I-AdverseReaction I-AdverseReaction
6.2 NN O O
Postmarketing NN O O
Experience NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
identified NN O O
during NN O O
post NN O O
- NN O O
approval NN O O
use NN O O
of NN O O
Natazia NN O O
. NN O O
Because NN O O
these NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
Vascular NN O O
disorders NN O O
: NN O O
Venous NN O O
and NN O O
arterial NN B-AdverseReaction B-AdverseReaction
thromboembolic NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
( NN O O
including NN O O
pulmonary NN B-AdverseReaction B-AdverseReaction
emboli NN I-AdverseReaction I-AdverseReaction
deep NN B-AdverseReaction B-AdverseReaction
vein NN I-AdverseReaction I-AdverseReaction
thrombosis NN I-AdverseReaction I-AdverseReaction
cerebral NN B-AdverseReaction B-AdverseReaction
thrombosis NN I-AdverseReaction I-AdverseReaction
myocardial NN B-AdverseReaction B-AdverseReaction
infarction NN I-AdverseReaction I-AdverseReaction
and NN O O
stroke NN B-AdverseReaction B-AdverseReaction
hypertension NN B-AdverseReaction B-AdverseReaction
Hepatobiliary NN O O
disorders NN O O
: NN O O
Gallbladder NN B-AdverseReaction B-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
hepatitis NN B-AdverseReaction B-AdverseReaction
Immune NN O O
system NN O O
disorders NN O O
: NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
Metabolism NN O O
and NN O O
nutrition NN O O
disorders NN O O
: NN O O
Fluid NN B-AdverseReaction B-AdverseReaction
retention NN I-AdverseReaction I-AdverseReaction
hypertriglyceridemia NN B-AdverseReaction B-AdverseReaction
Nervous NN O O
system NN O O
disorders NN O O
: NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
: NN O O
Chloasma NN B-AdverseReaction B-AdverseReaction
angioedema NN B-AdverseReaction B-AdverseReaction
erythema NN B-AdverseReaction B-AdverseReaction
nodosum NN I-AdverseReaction I-AdverseReaction
erythema NN B-AdverseReaction B-AdverseReaction
multiforme NN I-AdverseReaction I-AdverseReaction
Gastrointestinal NN O O
disorders NN O O
: NN O O
Gastrointestinal NN B-AdverseReaction B-AdverseReaction
symptoms NN I-AdverseReaction I-AdverseReaction
( NN O O
for NN O O
example NN O O
, NN O O
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
Infections NN O O
and NN O O
infestations NN O O
: NN O O
Vulvovaginal NN B-AdverseReaction B-AdverseReaction
candidiasis NN I-AdverseReaction I-AdverseReaction
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
CIGARETTE NN O O
SMOKING NN O O
AND NN O O
SERIOUS NN B-Severity B-Severity
CARDIOVASCULAR NN B-AdverseReaction B-AdverseReaction
EVENTS NN I-AdverseReaction I-AdverseReaction
WARNING NN O O
: NN O O
CIGARETTE NN O O
SMOKING NN O O
AND NN O O
SERIOUS NN B-Severity B-Severity
CARDIOVASCULAR NN B-AdverseReaction B-AdverseReaction
EVENTS NN I-AdverseReaction I-AdverseReaction
Cigarette NN O O
smoking NN O O
increases NN O O
the NN O O
risk NN O O
of NN O O
serious NN O O
cardiovascular NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
from NN O O
combination NN B-DrugClass B-DrugClass
oral NN I-DrugClass I-DrugClass
contraceptives NN I-DrugClass I-DrugClass
( NN O O
COC NN O O
) NN O O
use NN O O
. NN O O
This NN O O
risk NN O O
increases NN O O
with NN O O
age NN O O
, NN O O
particularly NN O O
in NN O O
women NN O O
over NN O O
35 NN O O
years NN O O
of NN O O
age NN O O
, NN O O
and NN O O
with NN O O
the NN O O
number NN O O
of NN O O
cigarettes NN O O
smoked NN O O
. NN O O
For NN O O
this NN O O
reason NN O O
, NN O O
COCs NN O O
should NN O O
not NN O O
be NN O O
used NN O O
by NN O O
women NN O O
who NN O O
are NN O O
over NN O O
35 NN O O
years NN O O
of NN O O
age NN O O
and NN O O
smoke NN O O
. NN O O
[ NN O O
See NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
. NN O O
] NN O O
EXCERPT NN O O
: NN O O
WARNING NN O O
: NN O O
CIGARETTE NN O O
SMOKING NN O O
AND NN O O
SERIOUS NN B-Severity B-Severity
CARDIOVASCULAR NN B-AdverseReaction B-AdverseReaction
EVENTS NN I-AdverseReaction I-AdverseReaction
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
. NN O O
* NN O O
Women NN O O
over NN O O
35 NN O O
years NN O O
old NN O O
who NN O O
smoke NN O O
should NN O O
not NN O O
use NN O O
Natazia NN O O
. NN O O
( NN O O
4 NN O O
) NN O O
* NN O O
Cigarette NN O O
smoking NN O O
increases NN O O
the NN O O
risk NN O O
of NN O O
serious NN O O
cardiovascular NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
from NN O O
combination NN B-DrugClass B-DrugClass
oral NN I-DrugClass I-DrugClass
contraceptive NN I-DrugClass I-DrugClass
( NN O O
COC NN O O
) NN O O
use NN O O
. NN O O
( NN O O
4 NN O O
) NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Vascular NN O O
risks NN O O
: NN O O
Stop NN O O
Natazia NN O O
if NN O O
a NN O O
thrombotic NN O O
event NN O O
occurs NN O O
. NN O O
Stop NN O O
Natazia NN O O
at NN O O
least NN O O
4 NN O O
weeks NN O O
before NN O O
and NN O O
through NN O O
2 NN O O
weeks NN O O
after NN O O
major NN O O
surgery NN O O
. NN O O
Start NN O O
Natazia NN O O
no NN O O
earlier NN O O
than NN O O
4 NN O O
weeks NN O O
after NN O O
delivery NN O O
, NN O O
in NN O O
women NN O O
who NN O O
are NN O O
not NN O O
breastfeeding NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Liver NN B-AdverseReaction B-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
: NN O O
Discontinue NN O O
Natazia NN O O
if NN O O
jaundice NN O O
occurs NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
High NN B-AdverseReaction B-AdverseReaction
blood NN I-AdverseReaction I-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
: NN O O
Do NN O O
not NN O O
prescribe NN O O
Natazia NN O O
for NN O O
women NN O O
with NN O O
uncontrolled NN O O
hypertension NN O O
or NN O O
hypertension NN O O
with NN O O
vascular NN O O
disease NN O O
. NN O O
( NN O O
5.4 NN O O
) NN O O
* NN O O
Carbohydrate NN O O
and NN O O
lipid NN B-AdverseReaction B-AdverseReaction
metabolic NN I-AdverseReaction I-AdverseReaction
effects NN I-AdverseReaction I-AdverseReaction
: NN O O
Monitor NN O O
prediabetic NN O O
and NN O O
diabetic NN O O
women NN O O
taking NN O O
Natazia NN O O
. NN O O
Consider NN O O
an NN O O
alternate NN O O
contraceptive NN O O
method NN O O
for NN O O
women NN O O
with NN O O
uncontrolled NN O O
dyslipidemia NN O O
. NN O O
( NN O O
5.6 NN O O
) NN O O
* NN O O
Headache NN B-AdverseReaction B-AdverseReaction
: NN O O
Evaluate NN O O
significant NN O O
change NN O O
in NN O O
headaches NN O O
and NN O O
discontinue NN O O
Natazia NN O O
if NN O O
indicated NN O O
. NN O O
( NN O O
5.7 NN O O
) NN O O
* NN O O
Uterine NN B-AdverseReaction B-AdverseReaction
bleeding NN I-AdverseReaction I-AdverseReaction
: NN O O
Evaluate NN O O
irregular NN O O
bleeding NN O O
or NN O O
amenorrhea NN O O
. NN O O
( NN O O
5.8 NN O O
) NN O O
* NN O O
CYP3A4 NN O O
induction NN O O
: NN O O
Women NN O O
taking NN O O
strong NN O O
CYP3A4 NN O O
inducers NN O O
( NN O O
for NN O O
example NN O O
, NN O O
carbamazepine NN O O
, NN O O
phenytoin NN O O
, NN O O
rifampicin NN O O
, NN O O
and NN O O
St. NN O O
John NN O O
's NN O O
wort NN O O
) NN O O
should NN O O
not NN O O
choose NN O O
Natazia NN O O
as NN O O
their NN O O
oral NN O O
contraceptive NN O O
due NN O O
to NN O O
the NN O O
possibility NN O O
of NN O O
decreased NN O O
contraceptive NN O O
efficacy NN O O
. NN O O
( NN O O
5.13 NN O O
, NN O O
7.1 NN O O
) NN O O
5.1 NN O O
Thromboembolic NN O O
Disorders NN O O
and NN O O
Other NN O O
Vascular NN O O
Problems NN O O
Stop NN O O
Natazia NN O O
if NN O O
an NN O O
arterial NN O O
or NN O O
venous NN O O
thrombotic NN O O
event NN O O
( NN O O
VTE NN O O
) NN O O
occurs NN O O
. NN O O
The NN O O
use NN O O
of NN O O
COCs NN B-DrugClass B-DrugClass
increases NN O O
the NN O O
risk NN O O
of NN O O
venous NN B-AdverseReaction B-AdverseReaction
thromboembolism NN I-AdverseReaction I-AdverseReaction
However NN O O
, NN O O
pregnancy NN B-Factor B-Factor
increases NN O O
the NN O O
risk NN O O
of NN O O
venous NN B-AdverseReaction B-AdverseReaction
thromboembolism NN I-AdverseReaction I-AdverseReaction
as NN O O
much NN O O
or NN O O
more NN O O
than NN O O
the NN O O
use NN O O
of NN O O
COCs NN O O
. NN O O
The NN O O
risk NN O O
of NN O O
VTE NN B-AdverseReaction B-AdverseReaction
in NN O O
women NN O O
using NN O O
COCs NN B-DrugClass B-DrugClass
has NN O O
been NN O O
estimated NN O O
to NN O O
be NN O O
3 NN O O
to NN O O
9 NN O O
per NN O O
10,000 NN O O
woman NN O O
- NN O O
years NN O O
. NN O O
The NN O O
risk NN B-Factor B-Factor
of NN O O
VTE NN B-AdverseReaction B-AdverseReaction
is NN O O
highest NN O O
during NN O O
the NN O O
first NN O O
year NN O O
of NN O O
use NN O O
. NN O O
Data NN O O
from NN O O
a NN O O
large NN O O
, NN O O
prospective NN O O
cohort NN O O
safety NN O O
study NN O O
of NN O O
various NN O O
COCs NN O O
suggest NN O O
that NN O O
this NN O O
increased NN O O
risk NN O O
, NN O O
as NN O O
compared NN O O
to NN O O
that NN O O
in NN O O
non NN O O
- NN O O
COC NN O O
users NN O O
, NN O O
is NN O O
greatest NN O O
during NN O O
the NN O O
first NN O O
6 NN O O
months NN O O
of NN O O
COC NN O O
use NN O O
. NN O O
Data NN O O
from NN O O
this NN O O
safety NN O O
study NN O O
indicate NN O O
that NN O O
the NN O O
greatest NN O O
risk NN O O
of NN O O
VTE NN B-AdverseReaction B-AdverseReaction
is NN O O
present NN O O
after NN O O
initially NN O O
starting NN O O
a NN O O
COC NN B-DrugClass B-DrugClass
or NN O O
restarting NN O O
( NN O O
following NN O O
a NN O O
4 NN O O
week NN O O
or NN O O
greater NN O O
pill NN O O
- NN O O
free NN O O
interval NN O O
) NN O O
the NN O O
same NN O O
or NN O O
a NN O O
different NN O O
COC. NN O O
Use NN O O
of NN O O
COCs NN B-DrugClass B-DrugClass
also NN O O
increases NN O O
the NN O O
risk NN O O
of NN O O
arterial NN B-AdverseReaction B-AdverseReaction
thromboses NN I-AdverseReaction I-AdverseReaction
such NN O O
as NN O O
strokes NN B-AdverseReaction B-AdverseReaction
and NN O O
myocardial NN B-AdverseReaction B-AdverseReaction
infarctions NN I-AdverseReaction I-AdverseReaction
especially NN O O
in NN O O
women NN O O
with NN O O
other NN O O
risk NN O O
factors NN O O
for NN O O
these NN O O
events NN O O
. NN O O
The NN O O
risk NN O O
of NN O O
thromboembolic NN B-AdverseReaction B-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
due NN O O
to NN O O
oral NN B-DrugClass B-DrugClass
contraceptives NN I-DrugClass I-DrugClass
gradually NN O O
disappears NN O O
after NN O O
COC NN O O
use NN O O
is NN O O
discontinued NN O O
. NN O O
If NN O O
feasible NN O O
, NN O O
stop NN O O
Natazia NN O O
at NN O O
least NN O O
4 NN O O
weeks NN O O
before NN O O
and NN O O
through NN O O
2 NN O O
weeks NN O O
after NN O O
major NN O O
surgery NN O O
or NN O O
other NN O O
surgeries NN O O
known NN O O
to NN O O
have NN O O
an NN O O
elevated NN O O
risk NN O O
of NN O O
thromboembolism NN O O
. NN O O
Start NN O O
Natazia NN O O
no NN O O
earlier NN O O
than NN O O
4 NN O O
weeks NN O O
after NN O O
delivery NN O O
, NN O O
in NN O O
women NN O O
who NN O O
are NN O O
not NN O O
breastfeeding NN O O
. NN O O
The NN O O
risk NN O O
of NN O O
postpartum NN O O
thromboembolism NN O O
decreases NN O O
after NN O O
the NN O O
third NN O O
postpartum NN O O
week NN O O
, NN O O
whereas NN O O
the NN O O
risk NN O O
of NN O O
ovulation NN O O
increases NN O O
after NN O O
the NN O O
third NN O O
postpartum NN O O
week NN O O
. NN O O
COCs NN B-DrugClass B-DrugClass
have NN O O
been NN O O
shown NN O O
to NN O O
increase NN O O
both NN O O
the NN O O
relative NN O O
and NN O O
attributable NN O O
risks NN O O
of NN O O
cerebrovascular NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
( NN O O
thrombotic NN O O
and NN O O
hemorrhagic NN B-AdverseReaction B-AdverseReaction
strokes NN I-AdverseReaction I-AdverseReaction
although NN O O
, NN O O
in NN O O
general NN O O
, NN O O
the NN O O
risk NN O O
is NN O O
greatest NN O O
among NN O O
older NN O O
( NN O O
>35 NN O O
years NN O O
of NN O O
age NN O O
) NN O O
, NN O O
hypertensive NN O O
women NN O O
who NN O O
also NN O O
smoke NN O O
. NN O O
COCs NN B-DrugClass B-DrugClass
also NN O O
increase NN O O
the NN O O
risk NN O O
for NN O O
stroke NN B-AdverseReaction B-AdverseReaction
in NN O O
women NN O O
with NN O O
other NN O O
underlying NN O O
risk NN O O
factors NN O O
. NN O O
Oral NN O O
contraceptives NN O O
must NN O O
be NN O O
used NN O O
with NN O O
caution NN O O
in NN O O
women NN O O
with NN O O
cardiovascular NN O O
disease NN O O
risk NN O O
factors NN O O
. NN O O
Stop NN O O
Natazia NN O O
if NN O O
there NN O O
is NN O O
unexplained NN O O
loss NN O O
of NN O O
vision NN O O
, NN O O
proptosis NN O O
, NN O O
diplopia NN O O
, NN O O
papilledema NN O O
, NN O O
or NN O O
retinal NN O O
vascular NN O O
lesions NN O O
. NN O O
Evaluate NN O O
for NN O O
retinal NN O O
vein NN O O
thrombosis NN O O
immediately NN O O
. NN O O
[ NN O O
See NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
. NN O O
] NN O O
5.2 NN O O
Carcinoma NN O O
of NN O O
the NN O O
Breasts NN O O
and NN O O
Reproductive NN O O
Organs NN O O
Women NN O O
who NN O O
currently NN O O
have NN O O
or NN O O
have NN O O
had NN O O
breast NN O O
cancer NN O O
should NN O O
not NN O O
use NN O O
Natazia NN O O
because NN O O
breast NN O O
cancer NN O O
is NN O O
a NN O O
hormonally NN O O
- NN O O
sensitive NN O O
tumor NN O O
. NN O O
There NN O O
is NN O O
substantial NN O O
evidence NN O O
that NN O O
COCs NN O O
do NN O O
not NN B-Negation B-Negation
increase NN O O
the NN O O
incidence NN O O
of NN O O
breast NN B-AdverseReaction B-AdverseReaction
cancer NN I-AdverseReaction I-AdverseReaction
Although NN O O
some NN O O
past NN O O
studies NN O O
have NN O O
suggested NN O O
that NN O O
COCs NN O O
might NN O O
increase NN O O
the NN O O
incidence NN O O
of NN O O
breast NN B-AdverseReaction B-AdverseReaction
cancer NN I-AdverseReaction I-AdverseReaction
more NN O O
recent NN O O
studies NN O O
have NN O O
not NN B-Negation B-Negation
confirmed NN I-Negation I-Negation
such NN O O
findings NN O O
. NN O O
Some NN O O
studies NN O O
suggest NN O O
that NN O O
COCs NN B-DrugClass B-DrugClass
are NN O O
associated NN O O
with NN O O
an NN O O
increase NN O O
in NN O O
the NN O O
risk NN O O
of NN O O
cervical NN B-AdverseReaction B-AdverseReaction
cancer NN I-AdverseReaction I-AdverseReaction
or NN O O
intraepithelial NN O O
neoplasia NN O O
. NN O O
However NN O O
, NN O O
there NN O O
is NN O O
controversy NN O O
about NN O O
the NN O O
extent NN O O
to NN O O
which NN O O
these NN O O
findings NN O O
may NN O O
be NN O O
due NN O O
to NN O O
differences NN O O
in NN O O
sexual NN O O
behavior NN O O
and NN O O
other NN O O
factors NN O O
. NN O O
Endometrial NN O O
biopsies NN O O
performed NN O O
in NN O O
a NN O O
subset NN O O
of NN O O
subjects NN O O
in NN O O
a NN O O
Phase NN O O
3 NN O O
Natazia NN O O
clinical NN O O
trial NN O O
did NN O O
not NN O O
reveal NN O O
any NN O O
unexpected NN O O
or NN O O
concerning NN O O
findings NN O O
for NN O O
subjects NN O O
taking NN O O
COCs NN O O
. NN O O
[ NN O O
See NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
. NN O O
] NN O O
5.3 NN O O
Liver NN O O
Disease NN O O
Discontinue NN O O
Natazia NN O O
if NN O O
jaundice NN O O
develops NN O O
. NN O O
Steroid NN O O
hormones NN O O
may NN O O
be NN O O
poorly NN O O
metabolized NN O O
in NN O O
patients NN O O
with NN O O
impaired NN O O
liver NN O O
function NN O O
. NN O O
Acute NN O O
or NN O O
chronic NN O O
disturbances NN O O
of NN O O
liver NN O O
function NN O O
may NN O O
necessitate NN O O
the NN O O
discontinuation NN O O
of NN O O
COC NN O O
use NN O O
until NN O O
markers NN O O
of NN O O
liver NN O O
function NN O O
return NN O O
to NN O O
normal NN O O
and NN O O
COC NN O O
causation NN O O
has NN O O
been NN O O
excluded NN O O
. NN O O
Hepatic NN B-AdverseReaction B-AdverseReaction
adenomas NN I-AdverseReaction I-AdverseReaction
are NN O O
associated NN O O
with NN O O
COC NN B-DrugClass B-DrugClass
use NN O O
. NN O O
An NN O O
estimate NN O O
of NN O O
the NN O O
attributable NN O O
risk NN O O
is NN O O
3.3 NN O O
cases/100,000 NN O O
COC NN O O
users NN O O
. NN O O
Rupture NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
hepatic NN I-AdverseReaction I-AdverseReaction
adenomas NN I-AdverseReaction I-AdverseReaction
may NN B-Factor B-Factor
cause NN O O
death NN B-AdverseReaction B-AdverseReaction
through NN O O
intra NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
abdominal NN I-AdverseReaction I-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
Studies NN O O
have NN O O
shown NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
developing NN O O
hepatocellular NN B-AdverseReaction B-AdverseReaction
carcinoma NN I-AdverseReaction I-AdverseReaction
in NN O O
long NN O O
- NN O O
term NN O O
( NN O O
> NN O O
8 NN O O
years NN O O
) NN O O
COC NN B-DrugClass B-DrugClass
users NN O O
. NN O O
However NN O O
, NN O O
the NN O O
attributable NN O O
risk NN O O
of NN O O
liver NN B-AdverseReaction B-AdverseReaction
cancers NN I-AdverseReaction I-AdverseReaction
in NN O O
COC NN B-DrugClass B-DrugClass
users NN O O
is NN O O
less NN O O
than NN O O
one NN O O
case NN O O
per NN O O
million NN O O
users NN O O
. NN O O
Oral NN B-DrugClass B-DrugClass
contraceptive NN I-DrugClass I-DrugClass
cholestasis NN B-AdverseReaction B-AdverseReaction
may NN O O
occur NN O O
in NN O O
women NN O O
with NN O O
a NN O O
history NN O O
of NN O O
pregnancy NN O O
- NN O O
related NN O O
cholestasis NN O O
. NN O O
Women NN O O
with NN O O
a NN O O
history NN O O
of NN O O
COC NN B-DrugClass B-DrugClass
cholestasis NN B-AdverseReaction B-AdverseReaction
may NN O O
have NN O O
the NN O O
condition NN O O
recur NN O O
with NN O O
subsequent NN O O
COC NN O O
use NN O O
. NN O O
5.4 NN O O
High NN O O
Blood NN O O
Pressure NN O O
For NN O O
women NN O O
with NN O O
well NN O O
- NN O O
controlled NN O O
hypertension NN O O
, NN O O
monitor NN O O
blood NN O O
pressure NN O O
and NN O O
stop NN O O
Natazia NN O O
if NN O O
blood NN O O
pressure NN O O
rises NN O O
significantly NN O O
. NN O O
Women NN O O
with NN O O
uncontrolled NN O O
hypertension NN O O
or NN O O
hypertension NN O O
with NN O O
vascular NN O O
disease NN O O
should NN O O
not NN O O
use NN O O
COCs NN O O
. NN O O
An NN O O
increase NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
blood NN I-AdverseReaction I-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
has NN O O
been NN O O
reported NN O O
in NN O O
women NN O O
taking NN O O
COCs NN B-DrugClass B-DrugClass
and NN O O
this NN O O
increase NN O O
is NN O O
more NN O O
likely NN O O
in NN O O
older NN O O
women NN O O
and NN O O
with NN O O
extended NN O O
duration NN O O
of NN O O
use NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
hypertension NN B-AdverseReaction B-AdverseReaction
increases NN O O
with NN O O
increasing NN O O
concentration NN O O
of NN O O
progestin NN O O
. NN O O
5.5 NN O O
Gallbladder NN O O
Disease NN O O
Studies NN O O
suggest NN O O
a NN O O
small NN O O
increased NN O O
relative NN O O
risk NN O O
of NN O O
developing NN O O
gallbladder NN B-AdverseReaction B-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
among NN O O
COC NN B-DrugClass B-DrugClass
users NN O O
. NN O O
5.6 NN O O
Carbohydrate NN O O
and NN O O
Lipid NN O O
Metabolic NN O O
Effects NN O O
Carefully NN O O
monitor NN O O
prediabetic NN O O
and NN O O
diabetic NN O O
women NN O O
who NN O O
are NN O O
taking NN O O
Natazia NN O O
. NN O O
COCs NN B-DrugClass B-DrugClass
may NN O O
decrease NN B-AdverseReaction B-AdverseReaction
glucose NN I-AdverseReaction I-AdverseReaction
tolerance NN I-AdverseReaction I-AdverseReaction
in NN O O
a NN O O
dose NN O O
- NN O O
related NN O O
fashion NN O O
. NN O O
Consider NN O O
alternative NN O O
contraception NN O O
for NN O O
women NN O O
with NN O O
uncontrolled NN O O
dyslipidemia NN O O
. NN O O
A NN O O
small NN O O
proportion NN O O
of NN O O
women NN O O
will NN O O
have NN O O
adverse NN B-AdverseReaction B-AdverseReaction
lipid NN I-AdverseReaction I-AdverseReaction
changes NN I-AdverseReaction I-AdverseReaction
while NN O O
on NN O O
COCs NN B-DrugClass B-DrugClass
Women NN O O
with NN O O
hypertriglyceridemia NN O O
, NN O O
or NN O O
a NN O O
family NN O O
history NN O O
thereof NN O O
, NN O O
may NN O O
be NN O O
at NN O O
an NN O O
increased NN O O
risk NN O O
of NN O O
pancreatitis NN B-AdverseReaction B-AdverseReaction
when NN O O
using NN O O
COCs NN B-DrugClass B-DrugClass
5.7 NN O O
Headache NN O O
If NN O O
a NN O O
woman NN O O
taking NN O O
Natazia NN O O
develops NN O O
new NN O O
headaches NN O O
that NN O O
are NN O O
recurrent NN O O
, NN O O
persistent NN O O
, NN O O
or NN O O
severe NN B-Severity B-Severity
evaluate NN O O
the NN O O
cause NN O O
and NN O O
discontinue NN O O
Natazia NN O O
if NN O O
indicated NN O O
. NN O O
An NN O O
increase NN O O
in NN O O
frequency NN O O
or NN O O
severity NN O O
of NN O O
migraine NN B-AdverseReaction B-AdverseReaction
during NN O O
COC NN B-DrugClass B-DrugClass
use NN O O
( NN O O
which NN O O
may NN B-Factor B-Factor
be NN O O
prodromal NN O O
of NN O O
a NN O O
cerebrovascular NN B-AdverseReaction B-AdverseReaction
event NN I-AdverseReaction I-AdverseReaction
may NN O O
be NN O O
a NN O O
reason NN O O
for NN O O
immediate NN O O
discontinuation NN O O
of NN O O
the NN O O
COC. NN O O
5.8 NN O O
Bleeding NN O O
Irregularities NN O O
Breakthrough NN B-AdverseReaction B-AdverseReaction
bleeding NN I-AdverseReaction I-AdverseReaction
and NN O O
spotting NN B-AdverseReaction B-AdverseReaction
sometimes NN O O
occur NN O O
in NN O O
patients NN O O
on NN O O
COCs NN B-DrugClass B-DrugClass
especially NN O O
during NN O O
the NN O O
first NN O O
three NN O O
months NN O O
of NN O O
use NN O O
. NN O O
If NN O O
bleeding NN O O
persists NN O O
or NN O O
occurs NN O O
after NN O O
previously NN O O
regular NN O O
cycles NN O O
, NN O O
check NN O O
for NN O O
causes NN O O
such NN O O
as NN O O
pregnancy NN O O
or NN O O
malignancy NN O O
. NN O O
If NN O O
pathology NN O O
and NN O O
pregnancy NN O O
are NN O O
excluded NN O O
, NN O O
bleeding NN O O
irregularities NN O O
may NN O O
resolve NN O O
over NN O O
time NN O O
or NN O O
with NN O O
a NN O O
change NN O O
to NN O O
a NN O O
different NN O O
COC. NN O O
Women NN O O
who NN O O
are NN O O
not NN O O
pregnant NN O O
and NN O O
use NN O O
Natazia NN O O
, NN O O
may NN B-Factor B-Factor
experience NN O O
amenorrhea NN B-AdverseReaction B-AdverseReaction
Based NN O O
on NN O O
patient NN O O
diaries NN O O
, NN O O
amenorrhea NN O O
occurs NN O O
in NN O O
approximately NN O O
16 NN O O
% NN O O
of NN O O
cycles NN O O
in NN O O
women NN O O
using NN O O
Natazia NN O O
. NN O O
Pregnancy NN O O
should NN O O
be NN O O
ruled NN O O
out NN O O
in NN O O
the NN O O
event NN O O
of NN O O
amenorrhea NN O O
occurring NN O O
in NN O O
two NN O O
or NN O O
more NN O O
consecutive NN O O
cycles NN O O
. NN O O
Some NN O O
women NN O O
may NN B-Factor B-Factor
encounter NN O O
amenorrhea NN B-AdverseReaction B-AdverseReaction
or NN O O
oligomenorrhea NN B-AdverseReaction B-AdverseReaction
after NN O O
stopping NN O O
COCs NN O O
, NN O O
especially NN O O
when NN O O
such NN O O
a NN O O
condition NN O O
was NN O O
pre NN O O
- NN O O
existent NN O O
. NN O O
Based NN O O
on NN O O
patient NN O O
diaries NN O O
from NN O O
three NN O O
clinical NN O O
trials NN O O
evaluating NN O O
the NN O O
safety NN O O
and NN O O
efficacy NN O O
of NN O O
Natazia NN O O
for NN O O
contraception NN O O
, NN O O
10 NN O O
- NN O O
23 NN O O
% NN O O
of NN O O
women NN O O
experienced NN O O
intracyclic NN B-AdverseReaction B-AdverseReaction
bleeding NN I-AdverseReaction I-AdverseReaction
per NN O O
cycle NN O O
. NN O O
5.9 NN O O
COC NN O O
Use NN O O
Before NN O O
or NN O O
During NN O O
Early NN O O
Pregnancy NN O O
Extensive NN O O
epidemiological NN O O
studies NN O O
have NN O O
revealed NN O O
no NN B-Negation B-Negation
increased NN O O
risk NN O O
of NN O O
birth NN B-AdverseReaction B-AdverseReaction
defects NN I-AdverseReaction I-AdverseReaction
in NN O O
women NN O O
who NN O O
have NN O O
used NN O O
oral NN O O
contraceptives NN O O
prior NN O O
to NN O O
pregnancy NN O O
. NN O O
Studies NN O O
also NN O O
do NN O O
not NN B-Negation B-Negation
suggest NN O O
a NN O O
teratogenic NN B-AdverseReaction B-AdverseReaction
effect NN I-AdverseReaction I-AdverseReaction
particularly NN O O
in NN O O
so NN O O
far NN O O
as NN O O
cardiac NN B-AdverseReaction B-AdverseReaction
anomalies NN I-AdverseReaction I-AdverseReaction
and NN O O
limb NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
reduction NN I-AdverseReaction I-AdverseReaction
defects NN I-AdverseReaction I-AdverseReaction
are NN O O
concerned NN O O
, NN O O
when NN O O
taken NN O O
inadvertently NN O O
during NN O O
early NN O O
pregnancy NN O O
. NN O O
Oral NN O O
contraceptive NN O O
use NN O O
should NN O O
be NN O O
discontinued NN O O
if NN O O
pregnancy NN O O
is NN O O
confirmed NN O O
. NN O O
The NN O O
administration NN O O
of NN O O
oral NN O O
contraceptives NN O O
to NN O O
induce NN O O
withdrawal NN O O
bleeding NN O O
should NN O O
not NN O O
be NN O O
used NN O O
as NN O O
a NN O O
test NN O O
for NN O O
pregnancy NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.1 NN O O
) NN O O
] NN O O
. NN O O
5.10 NN O O
Depression NN O O
Women NN O O
with NN O O
a NN O O
history NN O O
of NN O O
depression NN O O
should NN O O
be NN O O
carefully NN O O
observed NN O O
and NN O O
Natazia NN O O
discontinued NN O O
if NN O O
depression NN O O
recurs NN O O
to NN O O
a NN O O
serious NN O O
degree NN O O
. NN O O
5.11 NN O O
Interference NN O O
with NN O O
Laboratory NN O O
Tests NN O O
The NN O O
use NN O O
of NN O O
COCs NN O O
may NN O O
change NN O O
the NN O O
results NN O O
of NN O O
some NN O O
laboratory NN O O
tests NN O O
, NN O O
such NN O O
as NN O O
coagulation NN O O
factors NN O O
, NN O O
lipids NN O O
, NN O O
glucose NN O O
tolerance NN O O
, NN O O
and NN O O
binding NN O O
proteins NN O O
. NN O O
Women NN O O
on NN O O
thyroid NN O O
hormone NN O O
replacement NN O O
therapy NN O O
may NN O O
need NN O O
increased NN O O
doses NN O O
of NN O O
thyroid NN O O
hormone NN O O
because NN O O
serum NN O O
concentrations NN O O
of NN O O
thyroid NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
binding NN I-AdverseReaction I-AdverseReaction
globulin NN I-AdverseReaction I-AdverseReaction
increase NN I-AdverseReaction I-AdverseReaction
with NN O O
use NN O O
of NN O O
COCs NN B-DrugClass B-DrugClass
[ NN O O
see NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.3 NN O O
) NN O O
] NN O O
. NN O O
5.12 NN O O
Monitoring NN O O
A NN O O
woman NN O O
who NN O O
is NN O O
taking NN O O
COCs NN O O
should NN O O
have NN O O
a NN O O
yearly NN O O
visit NN O O
with NN O O
her NN O O
healthcare NN O O
provider NN O O
for NN O O
a NN O O
blood NN O O
pressure NN O O
check NN O O
and NN O O
for NN O O
other NN O O
indicated NN O O
healthcare NN O O
. NN O O
5.13 NN O O
Drug NN O O
Interactions NN O O
Women NN O O
who NN O O
take NN O O
medications NN O O
that NN O O
are NN O O
strong NN O O
cytochrome NN O O
P450 NN O O
3A4 NN O O
( NN O O
CYP3A4 NN O O
) NN O O
inducers NN O O
( NN O O
for NN O O
example NN O O
, NN O O
carbamazepine NN O O
, NN O O
phenytoin NN O O
, NN O O
rifampicin NN O O
, NN O O
and NN O O
St. NN O O
John NN O O
's NN O O
wort NN O O
) NN O O
should NN O O
not NN O O
choose NN O O
Natazia NN O O
as NN O O
their NN O O
oral NN O O
contraceptive NN O O
while NN O O
using NN O O
these NN O O
inducers NN O O
and NN O O
for NN O O
at NN O O
least NN O O
28 NN O O
days NN O O
after NN O O
discontinuation NN O O
of NN O O
these NN O O
inducers NN O O
due NN O O
to NN O O
the NN O O
possibility NN O O
of NN O O
decreased NN O O
contraceptive NN O O
efficacy NN O O
. NN O O
[ NN O O
See NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.1 NN O O
) NN O O
and NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.3 NN O O
) NN O O
. NN O O
] NN O O
5.14 NN O O
Other NN O O
Conditions NN O O
In NN O O
women NN O O
with NN O O
hereditary NN O O
angioedema NN O O
, NN O O
exogenous NN O O
estrogens NN O O
may NN B-Factor B-Factor
induce NN O O
or NN O O
exacerbate NN O O
symptoms NN O O
of NN O O
angioedema NN B-AdverseReaction B-AdverseReaction
Chloasma NN B-AdverseReaction B-AdverseReaction
may NN B-Factor B-Factor
occasionally NN O O
occur NN O O
, NN O O
especially NN O O
in NN O O
women NN O O
with NN O O
a NN O O
history NN O O
of NN O O
chloasma NN O O
gravidarum NN O O
. NN O O
Women NN O O
with NN O O
a NN O O
tendency NN O O
to NN O O
chloasma NN O O
should NN O O
avoid NN O O
exposure NN O O
to NN O O
the NN O O
sun NN O O
or NN O O
ultraviolet NN O O
radiation NN O O
while NN O O
taking NN O O
COCs NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
EXCERPT NN O O
: NN O O
Most NN O O
commonly NN O O
reported NN O O
adverse NN O O
reactions NN O O
were NN O O
flushing NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
, NN O O
headache NN B-AdverseReaction B-AdverseReaction
( NN O O
1 NN O O
% NN O O
) NN O O
, NN O O
increased NN B-AdverseReaction B-AdverseReaction
blood NN I-AdverseReaction I-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
, NN O O
nausea NN B-AdverseReaction B-AdverseReaction
( NN O O
1 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
( NN O O
1 NN O O
% NN O O
) NN O O
. NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
GE NN O O
Healthcare NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
654 NN O O
- NN O O
0118 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
( NN O O
6 NN O O
) NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
and NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
Vizamyl NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O
In NN O O
clinical NN O O
trials NN O O
, NN O O
761 NN O O
adults NN O O
( NN O O
367 NN O O
men NN O O
and NN O O
394 NN O O
women NN O O
, NN O O
91 NN O O
% NN O O
Caucasian NN O O
) NN O O
with NN O O
a NN O O
mean NN O O
age NN O O
of NN O O
62 NN O O
years NN O O
( NN O O
range NN O O
18 NN O O
- NN O O
93 NN O O
years NN O O
) NN O O
received NN O O
Vizamyl NN O O
. NN O O
Most NN O O
subjects NN O O
( NN O O
530 NN O O
, NN O O
70 NN O O
% NN O O
) NN O O
received NN O O
a NN O O
dose NN O O
of NN O O
185 NN O O
MBq NN O O
( NN O O
5 NN O O
mCi NN O O
) NN O O
. NN O O
One NN O O
subject NN O O
out NN O O
of NN O O
761 NN O O
administered NN O O
Vizamyl NN O O
experienced NN O O
a NN O O
serious NN B-Severity B-Severity
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
with NN O O
flushing NN B-AdverseReaction B-AdverseReaction
dyspnea NN B-AdverseReaction B-AdverseReaction
and NN O O
chest NN B-AdverseReaction B-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
within NN O O
minutes NN O O
following NN O O
Vizamyl NN O O
administration NN O O
and NN O O
recovered NN O O
with NN O O
treatment NN O O
. NN O O
Most NN O O
adverse NN O O
reactions NN O O
were NN O O
mild NN O O
to NN O O
moderate NN O O
in NN O O
intensity NN O O
and NN O O
resolved NN O O
spontaneously NN O O
. NN O O
The NN O O
most NN O O
commonly NN O O
reported NN O O
adverse NN O O
reactions NN O O
( NN O O
occurring NN O O
in NN O O
at NN O O
least NN O O
1 NN O O
% NN O O
of NN O O
subjects NN O O
) NN O O
in NN O O
Vizamyl NN O O
- NN O O
treated NN O O
subjects NN O O
are NN O O
shown NN O O
in NN O O
Table NN O O
2 NN O O
. NN O O
Table NN O O
2 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Reported NN O O
in NN O O
Clinical NN O O
Trials NN O O
of NN O O
Vizamyl NN O O
( NN O O
N NN O O
= NN O O
761 NN O O
subjects NN O O
) NN O O
Adverse NN O O
Reaction NN O O
N NN O O
( NN O O
percent NN O O
of NN O O
patients NN O O
) NN O O
Flushing NN B-AdverseReaction B-AdverseReaction
16 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
Increased NN B-AdverseReaction B-AdverseReaction
blood NN I-AdverseReaction I-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
13 NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
Headache NN B-AdverseReaction B-AdverseReaction
10 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
8 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
8 NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
Ask NN O O
patients NN O O
about NN O O
prior NN O O
reactions NN O O
to NN O O
Vizamyl NN O O
. NN O O
Observe NN O O
for NN O O
hypersensitivity NN O O
signs NN O O
and NN O O
symptoms NN O O
following NN O O
Vizamyl NN O O
administration NN O O
. NN O O
Have NN O O
resuscitation NN O O
equipment NN O O
and NN O O
trained NN O O
personnel NN O O
available NN O O
at NN O O
time NN O O
of NN O O
Vizamyl NN O O
administration NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Image NN O O
interpretation NN O O
errors NN O O
( NN O O
especially NN O O
false NN O O
positives NN O O
) NN O O
have NN O O
been NN O O
observed NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Radiation NN B-AdverseReaction B-AdverseReaction
risk NN I-AdverseReaction I-AdverseReaction
Vizamyl NN O O
, NN O O
similar NN O O
to NN O O
all NN O O
radiopharmaceuticals NN O O
, NN O O
contributes NN O O
to NN O O
a NN O O
patient NN O O
's NN O O
long NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
term NN I-AdverseReaction I-AdverseReaction
cumulative NN I-AdverseReaction I-AdverseReaction
radiation NN I-AdverseReaction I-AdverseReaction
exposure NN I-AdverseReaction I-AdverseReaction
Ensure NN O O
safe NN O O
handling NN O O
to NN O O
protect NN O O
patients NN O O
and NN O O
health NN O O
care NN O O
workers NN O O
from NN O O
unintentional NN O O
radiation NN O O
exposure NN O O
( NN O O
2.1 NN O O
, NN O O
5.3 NN O O
) NN O O
5.1 NN O O
Hypersensitivity NN O O
Reactions NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
such NN O O
as NN O O
flushing NN B-AdverseReaction B-AdverseReaction
and NN O O
dyspnea NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
observed NN O O
within NN O O
minutes NN O O
following NN O O
Vizamyl NN O O
administration NN O O
. NN O O
These NN O O
reactions NN O O
may NN O O
occur NN O O
in NN O O
patients NN O O
with NN O O
no NN O O
history NN O O
of NN O O
prior NN O O
exposure NN O O
to NN O O
Vizamyl NN O O
. NN O O
Before NN O O
administering NN O O
Vizamyl NN O O
, NN O O
ask NN O O
patients NN O O
about NN O O
prior NN O O
reactions NN O O
to NN O O
drugs NN O O
, NN O O
especially NN O O
those NN O O
containing NN O O
polysorbate NN O O
80 NN O O
. NN O O
Have NN O O
resuscitation NN O O
equipment NN O O
and NN O O
trained NN O O
personnel NN O O
immediately NN O O
available NN O O
at NN O O
the NN O O
time NN O O
of NN O O
Vizamyl NN O O
administration NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
Risk NN O O
for NN O O
Image NN O O
Misinterpretation NN O O
and NN O O
Other NN O O
Errors NN O O
Errors NN O O
may NN O O
occur NN O O
while NN O O
using NN O O
Vizamyl NN O O
PET NN O O
images NN O O
to NN O O
estimate NN O O
brain NN O O
neuritic NN O O
plaque NN O O
density NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
. NN O O
Image NN O O
interpretation NN O O
is NN O O
performed NN O O
independently NN O O
of NN O O
the NN O O
patient NN O O
's NN O O
clinical NN O O
information NN O O
. NN O O
The NN O O
use NN O O
of NN O O
clinical NN O O
information NN O O
in NN O O
the NN O O
interpretation NN O O
of NN O O
Vizamyl NN O O
images NN O O
has NN O O
not NN O O
been NN O O
evaluated NN O O
and NN O O
may NN O O
lead NN O O
to NN O O
errors NN O O
. NN O O
Extensive NN O O
brain NN O O
atrophy NN O O
may NN O O
limit NN O O
the NN O O
ability NN O O
to NN O O
distinguish NN O O
grey NN O O
and NN O O
white NN O O
matter NN O O
on NN O O
a NN O O
Vizamyl NN O O
scan NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.5 NN O O
) NN O O
] NN O O
. NN O O
Motion NN O O
artifacts NN O O
may NN O O
distort NN O O
the NN O O
image NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
] NN O O
. NN O O
Vizamyl NN O O
scan NN O O
results NN O O
are NN O O
indicative NN O O
of NN O O
the NN O O
brain NN O O
neuritic NN O O
amyloid NN O O
plaque NN O O
content NN O O
only NN O O
at NN O O
the NN O O
time NN O O
of NN O O
image NN O O
acquisition NN O O
and NN O O
a NN O O
negative NN O O
scan NN O O
result NN O O
does NN O O
not NN O O
preclude NN O O
the NN O O
development NN O O
of NN O O
brain NN O O
amyloid NN O O
in NN O O
the NN O O
future NN O O
. NN O O
5.3 NN O O
Radiation NN O O
Risk NN O O
Vizamyl NN O O
, NN O O
similar NN O O
to NN O O
other NN O O
radiopharmaceuticals NN O O
, NN O O
contributes NN O O
to NN O O
a NN O O
patient NN O O
's NN O O
overall NN O O
long NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
term NN I-AdverseReaction I-AdverseReaction
cumulative NN I-AdverseReaction I-AdverseReaction
radiation NN I-AdverseReaction I-AdverseReaction
exposure NN I-AdverseReaction I-AdverseReaction
Long NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
term NN I-AdverseReaction I-AdverseReaction
cumulative NN I-AdverseReaction I-AdverseReaction
radiation NN I-AdverseReaction I-AdverseReaction
exposure NN I-AdverseReaction I-AdverseReaction
is NN O O
associated NN O O
with NN O O
an NN O O
increased NN O O
risk NN B-Factor B-Factor
of NN O O
cancer NN B-AdverseReaction B-AdverseReaction
Ensure NN O O
safe NN O O
handling NN O O
to NN O O
protect NN O O
patients NN O O
and NN O O
health NN O O
care NN O O
workers NN O O
from NN O O
unintentional NN O O
radiation NN O O
exposure NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.1 NN O O
) NN O O
] NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
serious NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
associated NN O O
with NN O O
Zydelig NN O O
in NN O O
clinical NN O O
trials NN O O
and NN O O
are NN O O
discussed NN O O
in NN O O
greater NN O O
detail NN O O
in NN O O
other NN O O
sections NN O O
of NN O O
the NN O O
prescribing NN O O
information NN O O
. NN O O
* NN O O
Hepatotoxicity NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Severe NN B-Severity B-Severity
Diarrhea NN B-AdverseReaction B-AdverseReaction
or NN O O
Colitis NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
Pneumonitis NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
* NN O O
Intestinal NN B-AdverseReaction B-AdverseReaction
Perforation NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
* NN O O
Severe NN B-Severity B-Severity
Cutaneous NN B-AdverseReaction B-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
* NN O O
Anaphylaxis NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.6 NN O O
) NN O O
] NN O O
* NN O O
Neutropenia NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.7 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
incidence NN O O
>=20 NN O O
% NN O O
) NN O O
are NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
pyrexia NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
pneumonia NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
chills NN B-AdverseReaction B-AdverseReaction
and NN O O
rash NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
. NN O O
The NN O O
most NN O O
common NN O O
laboratory NN O O
abnormalities NN O O
( NN O O
incidence NN O O
>=30 NN O O
% NN O O
) NN O O
are NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
hypertriglyceridemia NN B-AdverseReaction B-AdverseReaction
hyperglycemia NN B-AdverseReaction B-AdverseReaction
ALT NN B-AdverseReaction B-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
and NN O O
AST NN B-AdverseReaction B-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
. NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Gilead NN O O
Sciences NN O O
, NN O O
Inc. NN O O
at NN O O
1 NN O O
- NN O O
800-GILEAD-5 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
6.1 NN O O
Clinical NN O O
Trial NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
Summary NN O O
of NN O O
Clinical NN O O
Trials NN O O
in NN O O
Chronic NN O O
Lymphocytic NN O O
Leukemia NN O O
The NN O O
safety NN O O
data NN O O
reflect NN O O
subject NN O O
exposure NN O O
to NN O O
Zydelig NN O O
from NN O O
Study NN O O
1 NN O O
, NN O O
in NN O O
which NN O O
218 NN O O
subjects NN O O
with NN O O
relapsed NN O O
CLL NN O O
received NN O O
up NN O O
to NN O O
8 NN O O
doses NN O O
of NN O O
rituximab NN O O
with NN O O
or NN O O
without NN O O
Zydelig NN O O
150 NN O O
mg NN O O
twice NN O O
daily NN O O
. NN O O
The NN O O
median NN O O
duration NN O O
of NN O O
exposure NN O O
to NN O O
Zydelig NN O O
was NN O O
5 NN O O
months NN O O
. NN O O
Serious NN O O
adverse NN O O
reactions NN O O
were NN O O
reported NN O O
in NN O O
54 NN O O
( NN O O
49 NN O O
% NN O O
) NN O O
subjects NN O O
treated NN O O
with NN O O
Zydelig NN O O
+ NN O O
rituximab NN O O
. NN O O
The NN O O
most NN O O
frequent NN O O
( NN O O
>=2 NN O O
% NN O O
) NN O O
serious NN O O
adverse NN O O
reactions NN O O
reported NN O O
for NN O O
subjects NN O O
treated NN O O
with NN O O
Zydelig NN O O
were NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
( NN O O
17 NN O O
% NN O O
) NN O O
, NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
( NN O O
9 NN O O
% NN O O
) NN O O
, NN O O
sepsis NN B-AdverseReaction B-AdverseReaction
( NN O O
8 NN O O
% NN O O
) NN O O
, NN O O
febrile NN B-AdverseReaction B-AdverseReaction
neutropenia NN I-AdverseReaction I-AdverseReaction
( NN O O
5 NN O O
% NN O O
) NN O O
and NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
( NN O O
5 NN O O
% NN O O
) NN O O
. NN O O
Adverse NN O O
reactions NN O O
that NN O O
led NN O O
to NN O O
discontinuation NN O O
of NN O O
Zydelig NN O O
occurred NN O O
in NN O O
11 NN O O
( NN O O
10 NN O O
% NN O O
) NN O O
subjects NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
that NN O O
led NN O O
to NN O O
treatment NN O O
discontinuations NN O O
were NN O O
hepatotoxicity NN B-AdverseReaction B-AdverseReaction
and NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
Thirty NN O O
- NN O O
nine NN O O
subjects NN O O
( NN O O
35 NN O O
% NN O O
) NN O O
had NN O O
dose NN O O
interruptions NN O O
and NN O O
sixteen NN O O
subjects NN O O
( NN O O
15 NN O O
% NN O O
) NN O O
had NN O O
dose NN O O
reductions NN O O
due NN O O
to NN O O
adverse NN O O
reactions NN O O
or NN O O
laboratory NN O O
abnormalities NN O O
. NN O O
The NN O O
most NN O O
common NN O O
reasons NN O O
for NN O O
dose NN O O
reductions NN O O
were NN O O
elevated NN B-AdverseReaction B-AdverseReaction
transaminases NN I-AdverseReaction I-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
or NN O O
colitis NN B-AdverseReaction B-AdverseReaction
and NN O O
rash NN B-AdverseReaction B-AdverseReaction
Table NN O O
2 NN O O
and NN O O
Table NN O O
3 NN O O
summarize NN O O
common NN O O
adverse NN O O
reactions NN O O
and NN O O
laboratory NN O O
abnormalities NN O O
reported NN O O
for NN O O
Zydelig NN O O
+ NN O O
rituximab NN O O
and NN O O
placebo NN O O
+ NN O O
rituximab NN O O
arms NN O O
. NN O O
Table NN O O
2 NN O O
Adverse NN O O
Reactions NN O O
Reported NN O O
in NN O O
>=5 NN O O
% NN O O
of NN O O
CLL NN O O
Patients NN O O
and NN O O
Occurred NN O O
at NN O O
>=2 NN O O
% NN O O
Higher NN O O
Incidence NN O O
in NN O O
Subjects NN O O
Receiving NN O O
Zydelig NN O O
Zydelig NN O O
+ NN O O
RN=110 NN O O
( NN O O
% NN O O
) NN O O
Placebo NN O O
+ NN O O
RN=108 NN O O
( NN O O
% NN O O
) NN O O
Adverse NN O O
Reaction NN O O
Any NN O O
Grade NN O O
Grade NN O O
>=3 NN O O
Any NN O O
Grade NN O O
Grade NN O O
>=3 NN O O
R NN O O
: NN O O
rituximab NN O O
Gastrointestinal NN O O
disorders NN O O
nausea NN B-AdverseReaction B-AdverseReaction
28 NN O O
( NN O O
25 NN O O
) NN O O
0 NN O O
23 NN O O
( NN O O
21 NN O O
) NN O O
0 NN O O
vomiting NN B-AdverseReaction B-AdverseReaction
14 NN O O
( NN O O
13 NN O O
) NN O O
0 NN O O
9 NN O O
( NN O O
8 NN O O
) NN O O
0 NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
23 NN O O
( NN O O
21 NN O O
) NN O O
6 NN O O
( NN O O
5 NN O O
) NN O O
17 NN O O
( NN O O
16 NN O O
) NN O O
0 NN O O
gastroesophageal NN B-AdverseReaction B-AdverseReaction
reflux NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
7 NN O O
( NN O O
6 NN O O
) NN O O
0 NN O O
1 NN O O
( NN O O
1 NN O O
) NN O O
0 NN O O
stomatitis NN B-AdverseReaction B-AdverseReaction
7 NN O O
( NN O O
6 NN O O
) NN O O
2 NN O O
( NN O O
2 NN O O
) NN O O
2 NN O O
( NN O O
2 NN O O
) NN O O
0 NN O O
Nervous NN O O
system NN O O
disorders NN O O
headache NN B-AdverseReaction B-AdverseReaction
11 NN O O
( NN O O
10 NN O O
) NN O O
1 NN O O
( NN O O
1 NN O O
) NN O O
5 NN O O
( NN O O
5 NN O O
) NN O O
0 NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
38 NN O O
( NN O O
35 NN O O
) NN O O
3 NN O O
( NN O O
3 NN O O
) NN O O
18 NN O O
( NN O O
17 NN O O
) NN O O
1 NN O O
( NN O O
1 NN O O
) NN O O
chills NN B-AdverseReaction B-AdverseReaction
23 NN O O
( NN O O
21 NN O O
) NN O O
2 NN O O
( NN O O
2 NN O O
) NN O O
17 NN O O
( NN O O
16 NN O O
) NN O O
0 NN O O
pain NN B-AdverseReaction B-AdverseReaction
8 NN O O
( NN O O
7 NN O O
) NN O O
0 NN O O
2 NN O O
( NN O O
2 NN O O
) NN O O
0 NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
rash NN B-AdverseReaction B-AdverseReaction
20 NN O O
( NN O O
18 NN O O
) NN O O
4 NN O O
( NN O O
4 NN O O
) NN O O
7 NN O O
( NN O O
6 NN O O
) NN O O
1 NN O O
( NN O O
1 NN O O
) NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
, NN O O
and NN O O
mediastinal NN O O
disorders NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
25 NN O O
( NN O O
23 NN O O
) NN O O
18 NN O O
( NN O O
16 NN O O
) NN O O
19 NN O O
( NN O O
18 NN O O
) NN O O
14 NN O O
( NN O O
13 NN O O
) NN O O
nasal NN B-AdverseReaction B-AdverseReaction
congestion NN I-AdverseReaction I-AdverseReaction
6 NN O O
( NN O O
5 NN O O
) NN O O
0 NN O O
2 NN O O
( NN O O
2 NN O O
) NN O O
0 NN O O
Infections NN O O
and NN O O
infestations NN O O
sepsis NN B-AdverseReaction B-AdverseReaction
9 NN O O
( NN O O
8 NN O O
) NN O O
8 NN O O
( NN O O
7 NN O O
) NN O O
4 NN O O
( NN O O
4 NN O O
) NN O O
4 NN O O
( NN O O
4 NN O O
) NN O O
bronchitis NN B-AdverseReaction B-AdverseReaction
7 NN O O
( NN O O
6 NN O O
) NN O O
1 NN O O
( NN O O
1 NN O O
) NN O O
3 NN O O
( NN O O
3 NN O O
) NN O O
1 NN O O
( NN O O
1 NN O O
) NN O O
sinusitis NN B-AdverseReaction B-AdverseReaction
9 NN O O
( NN O O
8 NN O O
) NN O O
0 NN O O
4 NN O O
( NN O O
4 NN O O
) NN O O
0 NN O O
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
6 NN O O
( NN O O
5 NN O O
) NN O O
0 NN O O
3 NN O O
( NN O O
3 NN O O
) NN O O
2 NN O O
( NN O O
2 NN O O
) NN O O
Musculoskeletal NN O O
and NN O O
connective NN O O
tissue NN O O
disorders NN O O
arthralgia NN B-AdverseReaction B-AdverseReaction
8 NN O O
( NN O O
7 NN O O
) NN O O
1 NN O O
( NN O O
1 NN O O
) NN O O
4 NN O O
( NN O O
4 NN O O
) NN O O
1 NN O O
( NN O O
1 NN O O
) NN O O
Table NN O O
3 NN O O
Treatment NN O O
- NN O O
emergent NN O O
Laboratory NN O O
Abnormalities NN O O
Reported NN O O
in NN O O
>=10 NN O O
% NN O O
of NN O O
CLL NN O O
Patients NN O O
Occurring NN O O
at NN O O
a NN O O
>=5 NN O O
% NN O O
Higher NN O O
Incidence NN O O
in NN O O
Subjects NN O O
Receiving NN O O
Zydelig NN O O
Zydelig NN O O
+ NN O O
RN=110 NN O O
( NN O O
% NN O O
) NN O O
Placebo NN O O
+ NN O O
RN=108 NN O O
( NN O O
% NN O O
) NN O O
Laboratory NN O O
Parameter NN O O
Any NN O O
Grade NN O O
Grade NN O O
3 NN O O
- NN O O
4 NN O O
Any NN O O
Grade NN O O
Grade NN O O
3 NN O O
- NN O O
4 NN O O
Grades NN O O
were NN O O
obtained NN O O
per NN O O
CTCAE NN O O
version NN O O
4.03.R NN O O
: NN O O
rituximab NN O O
Hematology NN O O
abnormalities NN O O
neutrophil NN B-AdverseReaction B-AdverseReaction
count NN I-AdverseReaction I-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
66 NN O O
( NN O O
60 NN O O
) NN O O
41 NN O O
( NN O O
37 NN O O
) NN O O
55 NN O O
( NN O O
51 NN O O
) NN O O
29 NN O O
( NN O O
27 NN O O
) NN O O
lymphocyte NN B-AdverseReaction B-AdverseReaction
count NN I-AdverseReaction I-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
22 NN O O
( NN O O
20 NN O O
) NN O O
10 NN O O
( NN O O
9 NN O O
) NN O O
13 NN O O
( NN O O
12 NN O O
) NN O O
4 NN O O
( NN O O
4 NN O O
) NN O O
lymphocyte NN B-AdverseReaction B-AdverseReaction
count NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
27 NN O O
( NN O O
25 NN O O
) NN O O
20 NN O O
( NN O O
18 NN O O
) NN O O
10 NN O O
( NN O O
9 NN O O
) NN O O
5 NN O O
( NN O O
5 NN O O
) NN O O
Serum NN O O
chemistry NN O O
abnormalities NN O O
ALT NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
38 NN O O
( NN O O
35 NN O O
) NN O O
9 NN O O
( NN O O
8 NN O O
) NN O O
11 NN O O
( NN O O
10 NN O O
) NN O O
1 NN O O
( NN O O
1 NN O O
) NN O O
AST NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
27 NN O O
( NN O O
25 NN O O
) NN O O
6 NN O O
( NN O O
5 NN O O
) NN O O
15 NN O O
( NN O O
14 NN O O
) NN O O
0 NN O O
GGT NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
29 NN O O
( NN O O
26 NN O O
) NN O O
2 NN O O
( NN O O
2 NN O O
) NN O O
15 NN O O
( NN O O
14 NN O O
) NN O O
3 NN O O
( NN O O
3 NN O O
) NN O O
triglycerides NN O O
( NN O O
hypertriglyceridemia NN O O
) NN O O
62 NN O O
( NN O O
56 NN O O
) NN O O
3 NN O O
( NN O O
3 NN O O
) NN O O
37 NN O O
( NN O O
34 NN O O
) NN O O
0 NN O O
hyperglycemia NN B-AdverseReaction B-AdverseReaction
59 NN O O
( NN O O
54 NN O O
) NN O O
8 NN O O
( NN O O
7 NN O O
) NN O O
50 NN O O
( NN O O
46 NN O O
) NN O O
2 NN O O
( NN O O
2 NN O O
) NN O O
hypoglycemia NN B-AdverseReaction B-AdverseReaction
12 NN O O
( NN O O
11 NN O O
) NN O O
0 NN O O
5 NN O O
( NN O O
5 NN O O
) NN O O
0 NN O O
hyponatremia NN B-AdverseReaction B-AdverseReaction
22 NN O O
( NN O O
20 NN O O
) NN O O
2 NN O O
( NN O O
2 NN O O
) NN O O
16 NN O O
( NN O O
15 NN O O
) NN O O
7 NN O O
( NN O O
6 NN O O
) NN O O
Summary NN O O
of NN O O
Clinical NN O O
Trials NN O O
in NN O O
Indolent NN O O
Non NN O O
- NN O O
Hodgkin NN O O
Lymphoma NN O O
The NN O O
safety NN O O
data NN O O
reflect NN O O
exposure NN O O
to NN O O
Zydelig NN O O
in NN O O
146 NN O O
adults NN O O
with NN O O
indolent NN O O
non NN O O
- NN O O
Hodgkin NN O O
lymphoma NN O O
treated NN O O
with NN O O
Zydelig NN O O
150 NN O O
mg NN O O
twice NN O O
daily NN O O
in NN O O
clinical NN O O
trials NN O O
. NN O O
The NN O O
median NN O O
duration NN O O
of NN O O
exposure NN O O
was NN O O
6.1 NN O O
months NN O O
( NN O O
range NN O O
0.3 NN O O
to NN O O
26.4 NN O O
months NN O O
) NN O O
. NN O O
Serious NN O O
adverse NN O O
reactions NN O O
were NN O O
reported NN O O
in NN O O
73 NN O O
( NN O O
50 NN O O
% NN O O
) NN O O
subjects NN O O
. NN O O
The NN O O
most NN O O
frequent NN O O
serious NN O O
adverse NN O O
reactions NN O O
that NN O O
occurred NN O O
were NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
( NN O O
15 NN O O
% NN O O
) NN O O
, NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
( NN O O
11 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
( NN O O
9 NN O O
% NN O O
) NN O O
. NN O O
Adverse NN O O
reactions NN O O
resulted NN O O
in NN O O
interruption NN O O
or NN O O
discontinuation NN O O
for NN O O
78 NN O O
( NN O O
53 NN O O
% NN O O
) NN O O
subjects NN O O
. NN O O
The NN O O
most NN O O
common NN O O
reasons NN O O
for NN O O
interruption NN O O
or NN O O
discontinuations NN O O
were NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
( NN O O
11 NN O O
% NN O O
) NN O O
, NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
( NN O O
11 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
elevated NN B-AdverseReaction B-AdverseReaction
transaminases NN I-AdverseReaction I-AdverseReaction
( NN O O
10 NN O O
% NN O O
) NN O O
. NN O O
Table NN O O
4 NN O O
provides NN O O
the NN O O
adverse NN O O
reactions NN O O
occurring NN O O
in NN O O
at NN O O
least NN O O
10 NN O O
% NN O O
of NN O O
subjects NN O O
receiving NN O O
Zydelig NN O O
monotherapy NN O O
, NN O O
and NN O O
Table NN O O
5 NN O O
provides NN O O
the NN O O
treatment NN O O
- NN O O
emergent NN O O
laboratory NN O O
abnormalities NN O O
. NN O O
Table NN O O
4 NN O O
Adverse NN O O
Reactions NN O O
( NN O O
>= NN O O
10 NN O O
% NN O O
of NN O O
Subjects NN O O
) NN O O
in NN O O
Patients NN O O
with NN O O
Indolent NN O O
non NN O O
- NN O O
Hodgkin NN O O
Lymphoma NN O O
Treated NN O O
with NN O O
Zydelig NN O O
150 NN O O
mg NN O O
BID NN O O
Zydelig NN O O
MonotherapyN=146 NN O O
( NN O O
% NN O O
) NN O O
Adverse NN O O
Reaction NN O O
Any NN O O
Grade NN O O
Grade NN O O
>=3 NN O O
Gastrointestinal NN O O
disorders NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
68 NN O O
( NN O O
47 NN O O
) NN O O
20 NN O O
( NN O O
14 NN O O
) NN O O
nausea NN B-AdverseReaction B-AdverseReaction
42 NN O O
( NN O O
29 NN O O
) NN O O
2 NN O O
( NN O O
1 NN O O
) NN O O
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
38 NN O O
( NN O O
26 NN O O
) NN O O
3 NN O O
( NN O O
2 NN O O
) NN O O
vomiting NN B-AdverseReaction B-AdverseReaction
22 NN O O
( NN O O
15 NN O O
) NN O O
2 NN O O
( NN O O
1 NN O O
) NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
44 NN O O
( NN O O
30 NN O O
) NN O O
2 NN O O
( NN O O
1 NN O O
) NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
41 NN O O
( NN O O
28 NN O O
) NN O O
3 NN O O
( NN O O
2 NN O O
) NN O O
asthenia NN B-AdverseReaction B-AdverseReaction
17 NN O O
( NN O O
12 NN O O
) NN O O
3 NN O O
( NN O O
2 NN O O
) NN O O
peripheral NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
15 NN O O
( NN O O
10 NN O O
) NN O O
3 NN O O
( NN O O
2 NN O O
) NN O O
Infections NN O O
and NN O O
infestations NN O O
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
18 NN O O
( NN O O
12 NN O O
) NN O O
0 NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
, NN O O
and NN O O
mediastinal NN O O
disorders NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
37 NN O O
( NN O O
25 NN O O
) NN O O
23 NN O O
( NN O O
16 NN O O
) NN O O
cough NN B-AdverseReaction B-AdverseReaction
42 NN O O
( NN O O
29 NN O O
) NN O O
1 NN O O
( NN O O
1 NN O O
) NN O O
dyspnea NN B-AdverseReaction B-AdverseReaction
25 NN O O
( NN O O
17 NN O O
) NN O O
6 NN O O
( NN O O
4 NN O O
) NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
disorders NN O O
rash NN B-AdverseReaction B-AdverseReaction
31 NN O O
( NN O O
21 NN O O
) NN O O
4 NN O O
( NN O O
3 NN O O
) NN O O
night NN B-AdverseReaction B-AdverseReaction
sweats NN I-AdverseReaction I-AdverseReaction
18 NN O O
( NN O O
12 NN O O
) NN O O
0 NN O O
Nervous NN O O
system NN O O
disorders NN O O
headache NN B-AdverseReaction B-AdverseReaction
16 NN O O
( NN O O
11 NN O O
) NN O O
1 NN O O
( NN O O
1 NN O O
) NN O O
Metabolism NN O O
and NN O O
nutrition NN O O
disorders NN O O
decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
24 NN O O
( NN O O
16 NN O O
) NN O O
1 NN O O
( NN O O
1 NN O O
) NN O O
Psychiatric NN O O
disorders NN O O
insomnia NN B-AdverseReaction B-AdverseReaction
17 NN O O
( NN O O
12 NN O O
) NN O O
0 NN O O
Table NN O O
5 NN O O
Treatment NN O O
- NN O O
emergent NN O O
Laboratory NN O O
Abnormalities NN O O
in NN O O
Patients NN O O
with NN O O
Indolent NN O O
non NN O O
- NN O O
Hodgkin NN O O
Lymphoma NN O O
Treated NN O O
with NN O O
Zydelig NN O O
150 NN O O
mg NN O O
BID NN O O
Zydelig NN O O
MonotherapyN=146 NN O O
( NN O O
% NN O O
) NN O O
Laboratory NN O O
Abnormality NN O O
Any NN O O
Grade NN O O
Grade NN O O
3 NN O O
Grade NN O O
4 NN O O
Grades NN O O
were NN O O
obtained NN O O
per NN O O
CTCAE NN O O
version NN O O
4.03 NN O O
. NN O O
Serum NN O O
chemistry NN O O
abnormalities NN O O
ALT NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
73 NN O O
( NN O O
50 NN O O
) NN O O
20 NN O O
( NN O O
14 NN O O
) NN O O
7 NN O O
( NN O O
5 NN O O
) NN O O
AST NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
60 NN O O
( NN O O
41 NN O O
) NN O O
12 NN O O
( NN O O
8 NN O O
) NN O O
6 NN O O
( NN O O
4 NN O O
) NN O O
Hematology NN O O
abnormalities NN O O
neutrophils NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
78 NN O O
( NN O O
53 NN O O
) NN O O
20 NN O O
( NN O O
14 NN O O
) NN O O
16 NN O O
( NN O O
11 NN O O
) NN O O
hemoglobin NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
41 NN O O
( NN O O
28 NN O O
) NN O O
3 NN O O
( NN O O
2 NN O O
) NN O O
0 NN O O
platelets NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
38 NN O O
( NN O O
26 NN O O
) NN O O
4 NN O O
( NN O O
3 NN O O
) NN O O
5 NN O O
( NN O O
3 NN O O
) NN O O
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
FATAL NN B-AdverseReaction B-AdverseReaction
AND NN O O
SERIOUS NN B-Severity B-Severity
TOXICITIES NN B-AdverseReaction B-AdverseReaction
HEPATIC NN O O
, NN O O
SEVERE NN B-Severity B-Severity
DIARRHEA NN B-AdverseReaction B-AdverseReaction
COLITIS NN B-AdverseReaction B-AdverseReaction
PNEUMONITIS NN B-AdverseReaction B-AdverseReaction
and NN O O
INTESTINAL NN B-AdverseReaction B-AdverseReaction
PERFORATION NN I-AdverseReaction I-AdverseReaction
WARNING NN O O
: NN O O
FATAL NN B-AdverseReaction B-AdverseReaction
AND NN O O
SERIOUS NN B-Severity B-Severity
TOXICITIES NN B-AdverseReaction B-AdverseReaction
HEPATIC NN O O
, NN O O
SEVERE NN B-Severity B-Severity
DIARRHEA NN B-AdverseReaction B-AdverseReaction
COLITIS NN B-AdverseReaction B-AdverseReaction
PNEUMONITIS NN B-AdverseReaction B-AdverseReaction
and NN O O
INTESTINAL NN B-AdverseReaction B-AdverseReaction
PERFORATION NN I-AdverseReaction I-AdverseReaction
* NN O O
Fatal NN B-AdverseReaction B-AdverseReaction
and/or NN O O
serious NN B-Severity B-Severity
hepatotoxicity NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
14 NN O O
% NN O O
of NN O O
Zydelig NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Monitor NN O O
hepatic NN O O
function NN O O
prior NN O O
to NN O O
and NN O O
during NN O O
treatment NN O O
. NN O O
Interrupt NN O O
and NN O O
then NN O O
reduce NN O O
or NN O O
discontinue NN O O
Zydelig NN O O
as NN O O
recommended NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
, NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Fatal NN B-AdverseReaction B-AdverseReaction
and/or NN O O
serious NN B-Severity B-Severity
and NN O O
severe NN B-Severity B-Severity
diarrhea NN B-AdverseReaction B-AdverseReaction
or NN O O
colitis NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
14 NN O O
% NN O O
of NN O O
Zydelig NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Monitor NN O O
for NN O O
the NN O O
development NN O O
of NN O O
severe NN O O
diarrhea NN O O
or NN O O
colitis NN O O
. NN O O
Interrupt NN O O
and NN O O
then NN O O
reduce NN O O
or NN O O
discontinue NN O O
Zydelig NN O O
as NN O O
recommended NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
, NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Fatal NN B-AdverseReaction B-AdverseReaction
and NN O O
serious NN B-Severity B-Severity
pneumonitis NN B-AdverseReaction B-AdverseReaction
can NN O O
occur NN O O
in NN O O
Zydelig NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Monitor NN O O
for NN O O
pulmonary NN O O
symptoms NN O O
and NN O O
bilateral NN O O
interstitial NN O O
infiltrates NN O O
. NN O O
Interrupt NN O O
or NN O O
discontinue NN O O
Zydelig NN O O
as NN O O
recommended NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
, NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Fatal NN B-AdverseReaction B-AdverseReaction
and NN O O
serious NN B-Severity B-Severity
intestinal NN B-AdverseReaction B-AdverseReaction
perforation NN I-AdverseReaction I-AdverseReaction
can NN O O
occur NN O O
in NN O O
Zydelig NN O O
- NN O O
treated NN O O
patients NN O O
across NN O O
clinical NN O O
trials NN O O
. NN O O
Discontinue NN O O
Zydelig NN O O
for NN O O
intestinal NN O O
perforation NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
. NN O O
EXCERPT NN O O
: NN O O
WARNING NN O O
: NN O O
FATAL NN B-AdverseReaction B-AdverseReaction
AND NN O O
SERIOUS NN B-Severity B-Severity
TOXICITIES NN B-AdverseReaction B-AdverseReaction
HEPATIC NN O O
, NN O O
SEVERE NN B-Severity B-Severity
DIARRHEA NN B-AdverseReaction B-AdverseReaction
COLITIS NN B-AdverseReaction B-AdverseReaction
PNEUMONITIS NN B-AdverseReaction B-AdverseReaction
and NN O O
INTESTINAL NN B-AdverseReaction B-AdverseReaction
PERFORATION NN I-AdverseReaction I-AdverseReaction
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
. NN O O
* NN O O
Fatal NN B-AdverseReaction B-AdverseReaction
and/or NN O O
serious NN B-Severity B-Severity
hepatotoxicity NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
14 NN O O
% NN O O
of NN O O
Zydelig NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Monitor NN O O
hepatic NN O O
function NN O O
prior NN O O
to NN O O
and NN O O
during NN O O
treatment NN O O
. NN O O
Interrupt NN O O
and NN O O
then NN O O
reduce NN O O
or NN O O
discontinue NN O O
Zydelig NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Fatal NN B-AdverseReaction B-AdverseReaction
and/or NN O O
serious NN B-Severity B-Severity
and NN O O
severe NN B-Severity B-Severity
diarrhea NN B-AdverseReaction B-AdverseReaction
or NN O O
colitis NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
14 NN O O
% NN O O
of NN O O
Zydelig NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Monitor NN O O
for NN O O
the NN O O
development NN O O
of NN O O
severe NN O O
diarrhea NN O O
or NN O O
colitis NN O O
. NN O O
Interrupt NN O O
and NN O O
then NN O O
reduce NN O O
or NN O O
discontinue NN O O
Zydelig NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Fatal NN B-AdverseReaction B-AdverseReaction
and NN O O
serious NN B-Severity B-Severity
pneumonitis NN B-AdverseReaction B-AdverseReaction
can NN O O
occur NN O O
in NN O O
Zydelig NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Monitor NN O O
for NN O O
pulmonary NN O O
symptoms NN O O
and NN O O
bilateral NN O O
interstitial NN O O
infiltrates NN O O
. NN O O
Interrupt NN O O
or NN O O
discontinue NN O O
Zydelig NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Fatal NN B-AdverseReaction B-AdverseReaction
and NN O O
serious NN B-Severity B-Severity
intestinal NN B-AdverseReaction B-AdverseReaction
perforation NN I-AdverseReaction I-AdverseReaction
can NN O O
occur NN O O
in NN O O
Zydelig NN O O
- NN O O
treated NN O O
patients NN O O
across NN O O
clinical NN O O
trials NN O O
. NN O O
Discontinue NN O O
Zydelig NN O O
if NN O O
intestinal NN O O
perforation NN O O
is NN O O
suspected NN O O
. NN O O
( NN O O
5.4 NN O O
) NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Severe NN B-Severity B-Severity
cutaneous NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
patients NN O O
for NN O O
the NN O O
development NN O O
of NN O O
severe NN O O
cutaneous NN O O
reactions NN O O
and NN O O
discontinue NN O O
Zydelig NN O O
. NN O O
( NN O O
5.5 NN O O
) NN O O
* NN O O
Anaphylaxis NN B-AdverseReaction B-AdverseReaction
Monitor NN O O
patients NN O O
for NN O O
anaphylaxis NN O O
and NN O O
discontinue NN O O
Zydelig NN O O
. NN O O
( NN O O
5.6 NN O O
) NN O O
* NN O O
Neutropenia NN B-AdverseReaction B-AdverseReaction
monitor NN O O
blood NN O O
counts NN O O
. NN O O
( NN O O
5.7 NN O O
) NN O O
* NN O O
Embryo NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
fetal NN I-AdverseReaction I-AdverseReaction
toxicity NN I-AdverseReaction I-AdverseReaction
may NN B-Factor B-Factor
cause NN O O
fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
Advise NN O O
women NN O O
of NN O O
potential NN O O
risk NN O O
to NN O O
a NN O O
fetus NN O O
and NN O O
to NN O O
avoid NN O O
pregnancy NN O O
while NN O O
taking NN O O
Zydelig NN O O
. NN O O
( NN O O
5.8 NN O O
) NN O O
5.1 NN O O
Hepatotoxicity NN O O
Fatal NN B-AdverseReaction B-AdverseReaction
and/or NN O O
serious NN B-Severity B-Severity
hepatotoxicity NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
14 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
Zydelig NN O O
. NN O O
Elevations NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
ALT NN I-AdverseReaction I-AdverseReaction
or NN O O
AST NN O O
greater NN O O
than NN O O
5 NN B-Severity B-Severity
times NN I-Severity I-Severity
the NN I-Severity I-Severity
upper NN I-Severity I-Severity
limit NN I-Severity I-Severity
of NN I-Severity I-Severity
normal NN I-Severity I-Severity
have NN O O
occurred NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
These NN O O
findings NN O O
were NN O O
generally NN O O
observed NN O O
within NN O O
the NN O O
first NN O O
12 NN O O
weeks NN O O
of NN O O
treatment NN O O
and NN O O
were NN O O
reversible NN O O
with NN O O
dose NN O O
interruption NN O O
. NN O O
After NN O O
resumption NN O O
of NN O O
treatment NN O O
at NN O O
a NN O O
lower NN O O
dose NN O O
, NN O O
26 NN O O
% NN O O
of NN O O
patients NN O O
had NN O O
recurrence NN O O
of NN O O
ALT NN O O
and NN O O
AST NN O O
elevations NN O O
. NN O O
Discontinue NN O O
Zydelig NN O O
for NN O O
recurrent NN O O
hepatotoxicity NN O O
. NN O O
Avoid NN O O
concurrent NN O O
use NN O O
of NN O O
Zydelig NN O O
with NN O O
other NN O O
drugs NN O O
that NN O O
may NN O O
cause NN O O
liver NN O O
toxicity NN O O
. NN O O
Monitor NN O O
ALT NN O O
and NN O O
AST NN O O
in NN O O
all NN O O
patients NN O O
every NN O O
2 NN O O
weeks NN O O
for NN O O
the NN O O
first NN O O
3 NN O O
months NN O O
of NN O O
treatment NN O O
, NN O O
every NN O O
4 NN O O
weeks NN O O
for NN O O
the NN O O
next NN O O
3 NN O O
months NN O O
, NN O O
then NN O O
every NN O O
1 NN O O
to NN O O
3 NN O O
months NN O O
thereafter NN O O
. NN O O
Monitor NN O O
weekly NN O O
for NN O O
liver NN O O
toxicity NN O O
if NN O O
the NN O O
ALT NN O O
or NN O O
AST NN O O
rises NN O O
above NN O O
3 NN O O
times NN O O
the NN O O
upper NN O O
limit NN O O
of NN O O
normal NN O O
until NN O O
resolved NN O O
. NN O O
Withhold NN O O
Zydelig NN O O
if NN O O
the NN O O
ALT NN O O
or NN O O
AST NN O O
is NN O O
greater NN O O
than NN O O
5 NN O O
times NN O O
the NN O O
upper NN O O
limit NN O O
of NN O O
normal NN O O
, NN O O
and NN O O
continue NN O O
to NN O O
monitor NN O O
AST NN O O
, NN O O
ALT NN O O
and NN O O
total NN O O
bilirubin NN O O
weekly NN O O
until NN O O
the NN O O
abnormality NN O O
is NN O O
resolved NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
Severe NN O O
Diarrhea NN O O
or NN O O
Colitis NN O O
Severe NN B-Severity B-Severity
diarrhea NN B-AdverseReaction B-AdverseReaction
or NN O O
colitis NN B-AdverseReaction B-AdverseReaction
( NN O O
Grade NN O O
3 NN O O
or NN O O
higher NN O O
) NN O O
occurred NN O O
in NN O O
14 NN O O
% NN O O
of NN O O
Zydelig NN O O
- NN O O
treated NN O O
patients NN O O
across NN O O
clinical NN O O
trials NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
at NN O O
any NN O O
time NN O O
. NN O O
Avoid NN O O
concurrent NN O O
use NN O O
of NN O O
Zydelig NN O O
and NN O O
other NN O O
drugs NN O O
that NN O O
cause NN O O
diarrhea NN O O
. NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
due NN O O
to NN O O
Zydelig NN O O
responds NN O O
poorly NN O O
to NN O O
antimotility NN O O
agents NN O O
. NN O O
Median NN O O
time NN O O
to NN O O
resolution NN O O
ranged NN O O
between NN O O
1 NN O O
week NN O O
and NN O O
1 NN O O
month NN O O
across NN O O
trials NN O O
, NN O O
following NN O O
interruption NN O O
of NN O O
Zydelig NN O O
therapy NN O O
and NN O O
in NN O O
some NN O O
instances NN O O
, NN O O
use NN O O
of NN O O
corticosteroids NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
] NN O O
. NN O O
5.3 NN O O
Pneumonitis NN O O
Fatal NN B-AdverseReaction B-AdverseReaction
and NN O O
serious NN B-Severity B-Severity
pneumonitis NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
Zydelig NN O O
. NN O O
Patients NN O O
taking NN O O
Zydelig NN O O
who NN O O
present NN O O
with NN O O
pulmonary NN O O
symptoms NN O O
such NN O O
as NN O O
cough NN O O
, NN O O
dyspnea NN O O
, NN O O
hypoxia NN O O
, NN O O
interstitial NN O O
infiltrates NN O O
on NN O O
a NN O O
radiologic NN O O
exam NN O O
, NN O O
or NN O O
a NN O O
decline NN O O
by NN O O
more NN O O
than NN O O
5 NN O O
% NN O O
in NN O O
oxygen NN O O
saturation NN O O
should NN O O
be NN O O
evaluated NN O O
for NN O O
pneumonitis NN O O
. NN O O
If NN O O
pneumonitis NN O O
is NN O O
suspected NN O O
, NN O O
interrupt NN O O
Zydelig NN O O
until NN O O
the NN O O
etiology NN O O
of NN O O
the NN O O
pulmonary NN O O
symptoms NN O O
has NN O O
been NN O O
determined NN O O
. NN O O
Patients NN O O
with NN O O
pneumonitis NN O O
thought NN O O
to NN O O
be NN O O
caused NN O O
by NN O O
Zydelig NN O O
have NN O O
been NN O O
treated NN O O
with NN O O
discontinuation NN O O
of NN O O
Zydelig NN O O
and NN O O
administration NN O O
of NN O O
corticosteroids NN O O
. NN O O
5.4 NN O O
Intestinal NN O O
Perforation NN O O
Fatal NN B-AdverseReaction B-AdverseReaction
and NN O O
serious NN B-Severity B-Severity
intestinal NN B-AdverseReaction B-AdverseReaction
perforation NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
Zydelig NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
At NN O O
the NN O O
time NN O O
of NN O O
perforation NN O O
, NN O O
some NN O O
patients NN O O
had NN O O
moderate NN B-Severity B-Severity
to NN O O
severe NN B-Severity B-Severity
diarrhea NN B-AdverseReaction B-AdverseReaction
Advise NN O O
patients NN O O
to NN O O
promptly NN O O
report NN O O
any NN O O
new NN O O
or NN O O
worsening NN O O
abdominal NN O O
pain NN O O
, NN O O
chills NN O O
, NN O O
fever NN O O
, NN O O
nausea NN O O
, NN O O
or NN O O
vomiting NN O O
. NN O O
Discontinue NN O O
Zydelig NN O O
permanently NN O O
in NN O O
patients NN O O
who NN O O
experience NN O O
intestinal NN O O
perforation NN O O
. NN O O
5.5 NN O O
Severe NN O O
Cutaneous NN O O
Reactions NN O O
One NN O O
case NN O O
of NN O O
toxic NN B-AdverseReaction B-AdverseReaction
epidermal NN I-AdverseReaction I-AdverseReaction
necrolysis NN I-AdverseReaction I-AdverseReaction
( NN O O
TEN NN O O
) NN O O
occurred NN O O
in NN O O
a NN O O
study NN O O
of NN O O
Zydelig NN O O
in NN O O
combination NN O O
with NN O O
rituximab NN O O
and NN O O
bendamustine NN O O
. NN O O
Other NN O O
severe NN B-Severity B-Severity
or NN O O
life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
( NN O O
Grade NN O O
>=3 NN O O
) NN O O
cutaneous NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
dermatitis NN B-AdverseReaction B-AdverseReaction
exfoliative NN I-AdverseReaction I-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
erythematous NN I-AdverseReaction I-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
generalized NN I-AdverseReaction I-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
macular NN I-AdverseReaction I-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
maculo NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
papular NN I-AdverseReaction I-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
papular NN I-AdverseReaction I-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
pruritic NN I-AdverseReaction I-AdverseReaction
exfoliative NN B-AdverseReaction B-AdverseReaction
rash NN I-AdverseReaction I-AdverseReaction
and NN O O
skin NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
Zydelig NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Monitor NN O O
patients NN O O
for NN O O
the NN O O
development NN O O
of NN O O
severe NN O O
cutaneous NN O O
reactions NN O O
and NN O O
discontinue NN O O
Zydelig NN O O
. NN O O
5.6 NN O O
Anaphylaxis NN O O
Serious NN B-Severity B-Severity
allergic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
on NN O O
Zydelig NN O O
. NN O O
In NN O O
patients NN O O
who NN O O
develop NN O O
serious NN O O
allergic NN O O
reactions NN O O
, NN O O
discontinue NN O O
Zydelig NN O O
permanently NN O O
and NN O O
institute NN O O
appropriate NN O O
supportive NN O O
measures NN O O
. NN O O
5.7 NN O O
Neutropenia NN O O
Treatment NN O O
- NN O O
emergent NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
or NN O O
4 NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
31 NN O O
% NN O O
of NN O O
Zydelig NN O O
- NN O O
treated NN O O
patients NN O O
across NN O O
clinical NN O O
trials NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Monitor NN O O
blood NN O O
counts NN O O
at NN O O
least NN O O
every NN O O
two NN O O
weeks NN O O
for NN O O
the NN O O
first NN O O
3 NN O O
months NN O O
of NN O O
therapy NN O O
, NN O O
and NN O O
at NN O O
least NN O O
weekly NN O O
in NN O O
patients NN O O
while NN O O
neutrophil NN O O
counts NN O O
are NN O O
less NN O O
than NN O O
1.0 NN O O
Gi/L NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
] NN O O
. NN O O
5.8 NN O O
Embryo NN O O
- NN O O
fetal NN O O
Toxicity NN O O
Based NN O O
on NN O O
findings NN O O
in NN O O
animals NN B-Animal B-Animal
Zydelig NN O O
may NN O O
cause NN O O
fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
when NN O O
administered NN O O
to NN O O
a NN O O
pregnant NN O O
woman NN O O
. NN O O
Idelalisib NN O O
is NN O O
teratogenic NN B-AdverseReaction B-AdverseReaction
in NN O O
rats NN B-Animal B-Animal
at NN O O
systemic NN O O
exposures NN O O
12 NN O O
times NN O O
those NN O O
reported NN O O
in NN O O
patients NN O O
at NN O O
the NN O O
recommended NN O O
dose NN O O
of NN O O
150 NN O O
mg NN O O
twice NN O O
daily NN O O
. NN O O
If NN O O
this NN O O
drug NN O O
is NN O O
used NN O O
during NN O O
pregnancy NN O O
, NN O O
or NN O O
if NN O O
the NN O O
patient NN O O
becomes NN O O
pregnant NN O O
while NN O O
taking NN O O
this NN O O
drug NN O O
, NN O O
the NN O O
patient NN O O
should NN O O
be NN O O
apprised NN O O
of NN O O
the NN O O
potential NN O O
hazard NN O O
to NN O O
a NN O O
fetus NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.1 NN O O
) NN O O
] NN O O
. NN O O
Advise NN O O
females NN O O
of NN O O
reproductive NN O O
potential NN O O
to NN O O
avoid NN O O
becoming NN O O
pregnant NN O O
while NN O O
taking NN O O
Zydelig NN O O
. NN O O
If NN O O
contraceptive NN O O
methods NN O O
are NN O O
being NN O O
considered NN O O
, NN O O
use NN O O
effective NN O O
contraception NN O O
during NN O O
treatment NN O O
, NN O O
and NN O O
for NN O O
at NN O O
least NN O O
1 NN O O
month NN O O
after NN O O
the NN O O
last NN O O
dose NN O O
of NN O O
Zydelig NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.6 NN O O
) NN O O
] NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Psoriatic NN O O
Arthritis NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=5 NN O O
% NN O O
) NN O O
are NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
and NN O O
headache NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
* NN O O
Psoriasis NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=5 NN O O
% NN O O
) NN O O
are NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
and NN O O
headache NN B-AdverseReaction B-AdverseReaction
including NN O O
tension NN B-AdverseReaction B-AdverseReaction
headache NN I-AdverseReaction I-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Celgene NN O O
Corporation NN O O
at NN O O
1 NN O O
- NN O O
888 NN O O
- NN O O
423 NN O O
- NN O O
5436 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trial NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O
Psoriatic NN O O
Arthritis NN O O
Clinical NN O O
Trials NN O O
OTEZLA NN O O
was NN O O
evaluated NN O O
in NN O O
3 NN O O
multicenter NN O O
, NN O O
randomized NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
[ NN O O
Studies NN O O
PsA-1 NN O O
, NN O O
PsA-2 NN O O
, NN O O
and NN O O
PsA-3 NN O O
] NN O O
of NN O O
similar NN O O
design NN O O
in NN O O
adult NN O O
patients NN O O
with NN O O
active NN O O
psoriatic NN O O
arthritis NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14.1 NN O O
) NN O O
] NN O O
. NN O O
Across NN O O
the NN O O
3 NN O O
studies NN O O
, NN O O
there NN O O
were NN O O
1493 NN O O
patients NN O O
randomized NN O O
equally NN O O
to NN O O
placebo NN O O
, NN O O
OTEZLA NN O O
20 NN O O
mg NN O O
twice NN O O
daily NN O O
or NN O O
OTEZLA NN O O
30 NN O O
mg NN O O
twice NN O O
daily NN O O
. NN O O
Titration NN O O
was NN O O
used NN O O
over NN O O
the NN O O
first NN O O
5 NN O O
days NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.1 NN O O
) NN O O
] NN O O
. NN O O
Placebo NN O O
patients NN O O
whose NN O O
tender NN O O
and NN O O
swollen NN O O
joint NN O O
counts NN O O
had NN O O
not NN O O
improved NN O O
by NN O O
at NN O O
least NN O O
20 NN O O
% NN O O
were NN O O
re NN O O
- NN O O
randomized NN O O
1:1 NN O O
in NN O O
a NN O O
blinded NN O O
fashion NN O O
to NN O O
either NN O O
OTEZLA NN O O
20 NN O O
mg NN O O
twice NN O O
daily NN O O
or NN O O
30 NN O O
mg NN O O
twice NN O O
daily NN O O
at NN O O
week NN O O
16 NN O O
while NN O O
OTEZLA NN O O
patients NN O O
remained NN O O
on NN O O
their NN O O
initial NN O O
treatment NN O O
. NN O O
Patients NN O O
ranged NN O O
in NN O O
age NN O O
from NN O O
18 NN O O
to NN O O
83 NN O O
years NN O O
, NN O O
with NN O O
an NN O O
overall NN O O
median NN O O
age NN O O
of NN O O
51 NN O O
years NN O O
. NN O O
The NN O O
majority NN O O
of NN O O
the NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
presented NN O O
inTable NN O O
2occurred NN O O
within NN O O
the NN O O
first NN O O
2 NN O O
weeks NN O O
of NN O O
treatment NN O O
and NN O O
tended NN O O
to NN O O
resolve NN O O
over NN O O
time NN O O
with NN O O
continued NN O O
dosing NN O O
. NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
and NN O O
nausea NN B-AdverseReaction B-AdverseReaction
were NN O O
the NN O O
most NN O O
commonly NN O O
reported NN O O
adverse NN O O
reactions NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
leading NN O O
to NN O O
discontinuation NN O O
for NN O O
patients NN O O
taking NN O O
OTEZLA NN O O
were NN O O
nausea NN B-AdverseReaction B-AdverseReaction
( NN O O
1.8 NN O O
% NN O O
) NN O O
, NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
( NN O O
1.8 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
headache NN B-AdverseReaction B-AdverseReaction
( NN O O
1.2 NN O O
% NN O O
) NN O O
. NN O O
The NN O O
proportion NN O O
of NN O O
patients NN O O
with NN O O
psoriatic NN O O
arthritis NN O O
who NN O O
discontinued NN O O
treatment NN O O
due NN O O
to NN O O
any NN O O
adverse NN O O
reaction NN O O
was NN O O
4.6 NN O O
% NN O O
for NN O O
patients NN O O
taking NN O O
OTEZLA NN O O
30 NN O O
mg NN O O
twice NN O O
daily NN O O
and NN O O
1.2 NN O O
% NN O O
for NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Table NN O O
2 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Reported NN O O
in NN O O
>=2 NN O O
% NN O O
of NN O O
Patients NN O O
on NN O O
OTEZLA NN O O
30 NN O O
mg NN O O
Twice NN O O
Daily NN O O
and NN O O
>=1 NN O O
% NN O O
Than NN O O
That NN O O
Observed NN O O
in NN O O
Patients NN O O
on NN O O
Placebo NN O O
for NN O O
up NN O O
to NN O O
Day NN O O
112 NN O O
( NN O O
Week NN O O
16 NN O O
) NN O O
a NN O O
Of NN O O
the NN O O
reported NN O O
gastrointestinal NN B-AdverseReaction B-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
1 NN O O
subject NN O O
experienced NN O O
a NN O O
serious NN B-Severity B-Severity
adverse NN O O
reaction NN O O
of NN O O
nausea NN B-AdverseReaction B-AdverseReaction
and NN O O
vomiting NN B-AdverseReaction B-AdverseReaction
in NN O O
OTEZLA NN O O
30 NN O O
mg NN O O
twice NN O O
daily NN O O
; NN O O
1 NN O O
subject NN O O
treated NN O O
with NN O O
OTEZLA NN O O
20 NN O O
mg NN O O
twice NN O O
daily NN O O
experienced NN O O
a NN O O
serious NN B-Severity B-Severity
adverse NN O O
reaction NN O O
of NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
1 NN O O
patient NN O O
treated NN O O
with NN O O
OTEZLA NN O O
30 NN O O
mg NN O O
twice NN O O
daily NN O O
experienced NN O O
a NN O O
serious NN B-Severity B-Severity
adverse NN O O
reaction NN O O
of NN O O
headache NN B-AdverseReaction B-AdverseReaction
b NN O O
Of NN O O
the NN O O
reported NN O O
adverse NN O O
drug NN O O
reactions NN O O
none NN O O
were NN O O
serious NN O O
. NN O O
c NN O O
n NN O O
( NN O O
% NN O O
) NN O O
indicates NN O O
number NN O O
of NN O O
patients NN O O
and NN O O
percent NN O O
. NN O O
Placebo NN O O
OTEZLA NN O O
30 NN O O
mg NN O O
BID NN O O
Preferred NN O O
Term NN O O
Day NN O O
1 NN O O
to NN O O
5(N=495)n NN O O
( NN O O
% NN O O
) NN O O
c NN O O
Day NN O O
6 NN O O
to NN O O
Day NN O O
112(N=490)n NN O O
( NN O O
% NN O O
) NN O O
Day NN O O
1 NN O O
to NN O O
5(N=497)n NN O O
( NN O O
% NN O O
) NN O O
Day NN O O
6 NN O O
to NN O O
Day NN O O
112(N=493)n NN O O
( NN O O
% NN O O
) NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
a NN O O
6 NN O O
( NN O O
1.2 NN O O
) NN O O
8 NN O O
( NN O O
1.6 NN O O
) NN O O
46 NN O O
( NN O O
9.3 NN O O
) NN O O
38 NN O O
( NN O O
7.7 NN O O
) NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
a NN O O
7 NN O O
( NN O O
1.4 NN O O
) NN O O
15 NN O O
( NN O O
3.1 NN O O
) NN O O
37 NN O O
( NN O O
7.4 NN O O
) NN O O
44 NN O O
( NN O O
8.9 NN O O
) NN O O
Headache NN B-AdverseReaction B-AdverseReaction
a NN O O
9 NN O O
( NN O O
1.8 NN O O
) NN O O
11 NN O O
( NN O O
2.2 NN O O
) NN O O
24 NN O O
( NN O O
4.8 NN O O
) NN O O
29 NN O O
( NN O O
5.9 NN O O
) NN O O
Upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tractinfection NN I-AdverseReaction I-AdverseReaction
b NN O O
3 NN O O
( NN O O
0.6 NN O O
) NN O O
9 NN O O
( NN O O
1.8 NN O O
) NN O O
3 NN O O
( NN O O
0.6 NN O O
) NN O O
19 NN O O
( NN O O
3.9 NN O O
) NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
a NN O O
2 NN O O
( NN O O
0.4 NN O O
) NN O O
2 NN O O
( NN O O
0.4 NN O O
) NN O O
4 NN O O
( NN O O
0.8 NN O O
) NN O O
16 NN O O
( NN O O
3.2 NN O O
) NN O O
Nasopharyngitis NN B-AdverseReaction B-AdverseReaction
b NN O O
1 NN O O
( NN O O
0.2 NN O O
) NN O O
8 NN O O
( NN O O
1.6 NN O O
) NN O O
1 NN O O
( NN O O
0.2 NN O O
) NN O O
13 NN O O
( NN O O
2.6 NN O O
) NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
upper NN I-AdverseReaction I-AdverseReaction
b NN O O
0 NN O O
( NN O O
0.0 NN O O
) NN O O
1 NN O O
( NN O O
0.2 NN O O
) NN O O
3 NN O O
( NN O O
0.6 NN O O
) NN O O
10 NN O O
( NN O O
2.0 NN O O
) NN O O
Other NN O O
adverse NN O O
reactions NN O O
reported NN O O
in NN O O
patients NN O O
on NN O O
OTEZLA NN O O
in NN O O
clinical NN O O
studies NN O O
including NN O O
extension NN O O
studies NN O O
: NN O O
Immune NN O O
system NN O O
disorders NN O O
: NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
Investigations NN O O
: NN O O
Weight NN B-AdverseReaction B-AdverseReaction
decrease NN I-AdverseReaction I-AdverseReaction
Gastrointestinal NN O O
Disorders NN O O
: NN O O
Frequent NN B-AdverseReaction B-AdverseReaction
bowel NN I-AdverseReaction I-AdverseReaction
movement NN I-AdverseReaction I-AdverseReaction
gastroesophageal NN B-AdverseReaction B-AdverseReaction
reflux NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
dyspepsia NN B-AdverseReaction B-AdverseReaction
Metabolism NN O O
and NN O O
Nutrition NN O O
Disorders NN O O
: NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
Nervous NN O O
System NN O O
Disorders NN O O
: NN O O
Migraine NN B-AdverseReaction B-AdverseReaction
Respiratory NN O O
, NN O O
Thoracic NN O O
, NN O O
and NN O O
Mediastinal NN O O
Disorders NN O O
: NN O O
Cough NN B-AdverseReaction B-AdverseReaction
Skin NN O O
and NN O O
Subcutaneous NN O O
Tissue NN O O
Disorders NN O O
: NN O O
Rash NN B-AdverseReaction B-AdverseReaction
patient NN O O
treated NN O O
with NN O O
OTEZLA NN O O
30 NN O O
mg NN O O
twice NN O O
daily NN O O
experienced NN O O
a NN O O
serious NN O O
adverse NN O O
reaction NN O O
. NN O O
Psoriasis NN O O
Clinical NN O O
Trials NN O O
The NN O O
safety NN O O
of NN O O
OTEZLA NN O O
( NN O O
r NN O O
) NN O O
was NN O O
assessed NN O O
in NN O O
1426 NN O O
subjects NN O O
in NN O O
3 NN O O
randomized NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
in NN O O
adult NN O O
subjects NN O O
with NN O O
moderate NN O O
to NN O O
severe NN O O
plaque NN O O
psoriasis NN O O
who NN O O
were NN O O
candidates NN O O
for NN O O
phototherapy NN O O
or NN O O
systemic NN O O
therapy NN O O
. NN O O
Subjects NN O O
were NN O O
randomized NN O O
to NN O O
receive NN O O
OTEZLA NN O O
30 NN O O
mg NN O O
twice NN O O
daily NN O O
or NN O O
placebo NN O O
twice NN O O
daily NN O O
. NN O O
Titration NN O O
was NN O O
used NN O O
over NN O O
the NN O O
first NN O O
5 NN O O
days NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.1 NN O O
) NN O O
] NN O O
. NN O O
Subjects NN O O
ranged NN O O
in NN O O
age NN O O
from NN O O
18 NN O O
to NN O O
83 NN O O
years NN O O
, NN O O
with NN O O
an NN O O
overall NN O O
median NN O O
age NN O O
of NN O O
46 NN O O
years NN O O
. NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
and NN O O
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
were NN O O
the NN O O
most NN O O
commonly NN O O
reported NN O O
adverse NN O O
reactions NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
leading NN O O
to NN O O
discontinuation NN O O
for NN O O
subjects NN O O
taking NN O O
OTEZLA NN O O
were NN O O
nausea NN B-AdverseReaction B-AdverseReaction
( NN O O
1.6 NN O O
% NN O O
) NN O O
, NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
( NN O O
1.0 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
headache NN B-AdverseReaction B-AdverseReaction
( NN O O
0.8 NN O O
% NN O O
) NN O O
. NN O O
The NN O O
proportion NN O O
of NN O O
subjects NN O O
with NN O O
psoriasis NN O O
who NN O O
discontinued NN O O
treatment NN O O
due NN O O
to NN O O
any NN O O
adverse NN O O
reaction NN O O
was NN O O
6.1 NN O O
% NN O O
for NN O O
subjects NN O O
treated NN O O
with NN O O
OTEZLA NN O O
30 NN O O
mg NN O O
twice NN O O
daily NN O O
and NN O O
4.1 NN O O
% NN O O
for NN O O
placebo NN O O
- NN O O
treated NN O O
subjects NN O O
. NN O O
Table NN O O
3 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Reported NN O O
in NN O O
>=1 NN O O
% NN O O
of NN O O
Subjects NN O O
on NN O O
OTEZLA NN O O
and NN O O
With NN O O
Greater NN O O
Frequency NN O O
Than NN O O
in NN O O
Subjects NN O O
on NN O O
Placebo NN O O
; NN O O
up NN O O
to NN O O
Day NN O O
112 NN O O
( NN O O
Week NN O O
16 NN O O
) NN O O
* NN O O
Two NN O O
subjects NN O O
treated NN O O
with NN O O
OTEZLA NN O O
experienced NN O O
serious NN B-Severity B-Severity
adverse NN O O
reaction NN O O
of NN O O
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
Preferred NN O O
Term NN O O
Placebo NN O O
( NN O O
N=506)n NN O O
( NN O O
% NN O O
) NN O O
OTEZLA NN O O
30 NN O O
mg NN O O
BID NN O O
( NN O O
N=920)n NN O O
( NN O O
% NN O O
) NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
32 NN O O
( NN O O
6 NN O O
) NN O O
160 NN O O
( NN O O
17 NN O O
) NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
35 NN O O
( NN O O
7 NN O O
) NN O O
155 NN O O
( NN O O
17 NN O O
) NN O O
Upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
31 NN O O
( NN O O
6 NN O O
) NN O O
84 NN O O
( NN O O
9 NN O O
) NN O O
Tension NN B-AdverseReaction B-AdverseReaction
headache NN I-AdverseReaction I-AdverseReaction
21 NN O O
( NN O O
4 NN O O
) NN O O
75 NN O O
( NN O O
8 NN O O
) NN O O
Headache NN B-AdverseReaction B-AdverseReaction
19 NN O O
( NN O O
4 NN O O
) NN O O
55 NN O O
( NN O O
6 NN O O
) NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
11 NN O O
( NN O O
2 NN O O
) NN O O
39 NN O O
( NN O O
4 NN O O
) NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
8 NN O O
( NN O O
2 NN O O
) NN O O
35 NN O O
( NN O O
4 NN O O
) NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
9 NN O O
( NN O O
2 NN O O
) NN O O
29 NN O O
( NN O O
3 NN O O
) NN O O
Dyspepsia NN B-AdverseReaction B-AdverseReaction
6 NN O O
( NN O O
1 NN O O
) NN O O
29 NN O O
( NN O O
3 NN O O
) NN O O
Decrease NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
5 NN O O
( NN O O
1 NN O O
) NN O O
26 NN O O
( NN O O
3 NN O O
) NN O O
Insomnia NN B-AdverseReaction B-AdverseReaction
4 NN O O
( NN O O
1 NN O O
) NN O O
21 NN O O
( NN O O
2 NN O O
) NN O O
Back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
4 NN O O
( NN O O
1 NN O O
) NN O O
20 NN O O
( NN O O
2 NN O O
) NN O O
Migraine NN B-AdverseReaction B-AdverseReaction
5 NN O O
( NN O O
1 NN O O
) NN O O
19 NN O O
( NN O O
2 NN O O
) NN O O
Frequent NN B-AdverseReaction B-AdverseReaction
bowel NN I-AdverseReaction I-AdverseReaction
movements NN I-AdverseReaction I-AdverseReaction
1 NN O O
( NN O O
0 NN O O
) NN O O
17 NN O O
( NN O O
2 NN O O
) NN O O
Depression NN B-AdverseReaction B-AdverseReaction
2 NN O O
( NN O O
0 NN O O
) NN O O
12 NN O O
( NN O O
1 NN O O
) NN O O
Bronchitis NN B-AdverseReaction B-AdverseReaction
2 NN O O
( NN O O
0 NN O O
) NN O O
12 NN O O
( NN O O
1 NN O O
) NN O O
Tooth NN B-AdverseReaction B-AdverseReaction
abscess NN I-AdverseReaction I-AdverseReaction
0 NN O O
( NN O O
0 NN O O
) NN O O
10 NN O O
( NN O O
1 NN O O
) NN O O
Folliculitis NN B-AdverseReaction B-AdverseReaction
0 NN O O
( NN O O
0 NN O O
) NN O O
9 NN O O
( NN O O
1 NN O O
) NN O O
Sinus NN B-AdverseReaction B-AdverseReaction
headache NN I-AdverseReaction I-AdverseReaction
0 NN O O
( NN O O
0 NN O O
) NN O O
9 NN O O
( NN O O
1 NN O O
) NN O O
Severe NN O O
worsening NN O O
of NN O O
psoriasis NN O O
( NN O O
rebound NN O O
) NN O O
occurred NN O O
in NN O O
0.3 NN O O
% NN O O
( NN O O
4/1184 NN O O
) NN O O
subjects NN O O
following NN O O
discontinuation NN O O
of NN O O
treatment NN O O
with NN O O
OTEZLA. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Depression NN B-AdverseReaction B-AdverseReaction
: NN O O
Advise NN O O
patients NN O O
, NN O O
their NN O O
caregivers NN O O
, NN O O
and NN O O
families NN O O
to NN O O
be NN O O
alert NN O O
for NN O O
the NN O O
emergence NN O O
or NN O O
worsening NN O O
of NN O O
depression NN O O
, NN O O
suicidal NN O O
thoughts NN O O
or NN O O
other NN O O
mood NN O O
changes NN O O
and NN O O
if NN O O
such NN O O
changes NN O O
occur NN O O
to NN O O
contact NN O O
their NN O O
healthcare NN O O
provider NN O O
. NN O O
Carefully NN O O
weigh NN O O
risks NN O O
and NN O O
benefits NN O O
of NN O O
treatment NN O O
with NN O O
OTEZLA NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
depression NN O O
and/or NN O O
suicidal NN O O
thoughts NN O O
or NN O O
behavior NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Weight NN B-AdverseReaction B-AdverseReaction
Decrease NN I-AdverseReaction I-AdverseReaction
: NN O O
Monitor NN O O
weight NN O O
regularly NN O O
. NN O O
If NN O O
unexplained NN O O
or NN O O
clinically NN O O
significant NN O O
weight NN O O
loss NN O O
occurs NN O O
, NN O O
evaluate NN O O
weight NN O O
loss NN O O
and NN O O
consider NN O O
discontinuation NN O O
of NN O O
OTEZLA NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Drug NN O O
Interactions NN O O
: NN O O
Use NN O O
with NN O O
strong NN O O
cytochrome NN O O
P450 NN O O
enzyme NN O O
inducers NN O O
( NN O O
e.g. NN O O
, NN O O
rifampin NN O O
, NN O O
phenobarbital NN O O
, NN O O
carbamazepine NN O O
, NN O O
phenytoin NN O O
) NN O O
is NN O O
not NN O O
recommended NN O O
because NN O O
loss NN O O
of NN O O
efficacy NN O O
may NN O O
occur NN O O
( NN O O
5.3,7.1 NN O O
) NN O O
5.1 NN O O
Depression NN O O
Treatment NN O O
with NN O O
OTEZLA NN O O
is NN O O
associated NN O O
with NN O O
an NN O O
increase NN O O
in NN O O
adverse NN O O
reactions NN O O
of NN O O
depression NN B-AdverseReaction B-AdverseReaction
Before NN O O
using NN O O
OTEZLA NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
depression NN O O
and/or NN O O
suicidal NN O O
thoughts NN O O
or NN O O
behavior NN O O
prescribers NN O O
should NN O O
carefully NN O O
weigh NN O O
the NN O O
risks NN O O
and NN O O
benefits NN O O
of NN O O
treatment NN O O
with NN O O
OTEZLA NN O O
in NN O O
such NN O O
patients NN O O
. NN O O
Patients NN O O
, NN O O
their NN O O
caregivers NN O O
, NN O O
and NN O O
families NN O O
should NN O O
be NN O O
advised NN O O
of NN O O
the NN O O
need NN O O
to NN O O
be NN O O
alert NN O O
for NN O O
the NN O O
emergence NN O O
or NN O O
worsening NN O O
of NN O O
depression NN O O
, NN O O
suicidal NN O O
thoughts NN O O
or NN O O
other NN O O
mood NN O O
changes NN O O
, NN O O
and NN O O
if NN O O
such NN O O
changes NN O O
occur NN O O
to NN O O
contact NN O O
their NN O O
healthcare NN O O
provider NN O O
. NN O O
Prescribers NN O O
should NN O O
carefully NN O O
evaluate NN O O
the NN O O
risks NN O O
and NN O O
benefits NN O O
of NN O O
continuing NN O O
treatment NN O O
with NN O O
OTEZLA NN O O
if NN O O
such NN O O
events NN O O
occur NN O O
. NN O O
Psoriatic NN O O
arthritis NN O O
: NN O O
During NN O O
the NN O O
0 NN O O
to NN O O
16 NN O O
week NN O O
placebo NN O O
- NN O O
controlled NN O O
period NN O O
of NN O O
the NN O O
3 NN O O
controlled NN O O
clinical NN O O
trials NN O O
, NN O O
1.0 NN O O
% NN O O
( NN O O
10/998 NN O O
) NN O O
of NN O O
subjects NN O O
treated NN O O
with NN O O
OTEZLA NN O O
reported NN O O
depression NN B-AdverseReaction B-AdverseReaction
or NN O O
depressed NN B-AdverseReaction B-AdverseReaction
mood NN I-AdverseReaction I-AdverseReaction
compared NN O O
to NN O O
0.8 NN O O
% NN O O
( NN O O
4/495 NN O O
) NN O O
treated NN O O
with NN O O
placebo NN O O
. NN O O
During NN O O
the NN O O
clinical NN O O
trials NN O O
, NN O O
0.3 NN O O
% NN O O
( NN O O
4/1441 NN O O
) NN O O
of NN O O
subjects NN O O
treated NN O O
with NN O O
OTEZLA NN O O
discontinued NN O O
treatment NN O O
due NN O O
to NN O O
depression NN B-AdverseReaction B-AdverseReaction
or NN O O
depressed NN B-AdverseReaction B-AdverseReaction
mood NN I-AdverseReaction I-AdverseReaction
compared NN O O
with NN O O
none NN O O
in NN O O
placebo NN O O
treated NN O O
subjects NN O O
( NN O O
0/495 NN O O
) NN O O
. NN O O
Depression NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
as NN O O
serious NN B-Severity B-Severity
in NN O O
0.2 NN O O
% NN O O
( NN O O
3/1441 NN O O
) NN O O
of NN O O
subjects NN O O
exposed NN O O
to NN O O
OTEZLA NN O O
, NN O O
compared NN O O
to NN O O
none NN O O
in NN O O
placebo NN O O
- NN O O
treated NN O O
subjects NN O O
( NN O O
0/495 NN O O
) NN O O
. NN O O
Instances NN O O
of NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
ideation NN I-AdverseReaction I-AdverseReaction
and NN O O
behavior NN O O
have NN O O
been NN O O
observed NN O O
in NN O O
0.2 NN O O
% NN O O
( NN O O
3/1441 NN O O
) NN O O
of NN O O
subjects NN O O
while NN O O
receiving NN O O
OTEZLA NN O O
, NN O O
compared NN O O
to NN O O
none NN O O
in NN O O
placebo NN O O
treated NN O O
subjects NN O O
( NN O O
0/495 NN O O
) NN O O
. NN O O
In NN O O
the NN O O
clinical NN O O
trials NN O O
, NN O O
2 NN O O
subjects NN O O
who NN O O
received NN O O
placebo NN O O
committed NN O O
suicide NN B-AdverseReaction B-AdverseReaction
compared NN O O
to NN O O
none NN B-Negation B-Negation
in NN O O
OTEZLA NN O O
- NN O O
treated NN O O
subjects NN O O
. NN O O
Psoriasis NN O O
: NN O O
During NN O O
the NN O O
0 NN O O
to NN O O
16 NN O O
week NN O O
placebo NN O O
- NN O O
controlled NN O O
period NN O O
of NN O O
the NN O O
3 NN O O
controlled NN O O
clinical NN O O
trials NN O O
, NN O O
1.3 NN O O
% NN O O
( NN O O
12/920 NN O O
) NN O O
of NN O O
subjects NN O O
treated NN O O
with NN O O
OTEZLA NN O O
reported NN O O
depression NN B-AdverseReaction B-AdverseReaction
compared NN O O
to NN O O
0.4 NN O O
% NN O O
( NN O O
2/506 NN O O
) NN O O
treated NN O O
with NN O O
placebo NN O O
. NN O O
During NN O O
the NN O O
clinical NN O O
trials NN O O
, NN O O
0.1 NN O O
% NN O O
( NN O O
1/1308 NN O O
) NN O O
of NN O O
subjects NN O O
treated NN O O
with NN O O
OTEZLA NN O O
discontinued NN O O
treatment NN O O
due NN O O
to NN O O
depression NN B-AdverseReaction B-AdverseReaction
compared NN O O
with NN O O
none NN O O
in NN O O
placebo NN O O
- NN O O
treated NN O O
subjects(0/506 NN O O
) NN O O
. NN O O
Depression NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
as NN O O
serious NN B-Severity B-Severity
in NN O O
0.1 NN O O
% NN O O
( NN O O
1/1308 NN O O
) NN O O
of NN O O
subjects NN O O
exposed NN O O
to NN O O
OTEZLA NN O O
, NN O O
compared NN O O
to NN O O
none NN O O
in NN O O
placebo NN O O
- NN O O
treated NN O O
subjects NN O O
( NN O O
0/506 NN O O
) NN O O
. NN O O
Instances NN O O
of NN O O
suicidal NN B-AdverseReaction B-AdverseReaction
behavior NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
observed NN O O
in NN O O
0.1 NN O O
% NN O O
( NN O O
1/1308 NN O O
) NN O O
of NN O O
subjects NN O O
while NN O O
receiving NN O O
OTEZLA NN O O
, NN O O
compared NN O O
to NN O O
0.2 NN O O
% NN O O
( NN O O
1/506 NN O O
) NN O O
in NN O O
placebo NN O O
- NN O O
treated NN O O
subjects NN O O
. NN O O
In NN O O
the NN O O
clinical NN O O
trials NN O O
, NN O O
one NN O O
subject NN O O
treated NN O O
with NN O O
OTEZLA NN O O
attempted NN B-AdverseReaction B-AdverseReaction
suicide NN I-AdverseReaction I-AdverseReaction
while NN O O
one NN O O
who NN O O
received NN O O
placebo NN B-Factor B-Factor
committed NN O O
suicide NN B-AdverseReaction B-AdverseReaction
5.2 NN O O
Weight NN O O
Decrease NN O O
During NN O O
the NN O O
controlled NN O O
period NN O O
of NN O O
the NN O O
studies NN O O
in NN O O
psoriatic NN O O
arthritis NN O O
( NN O O
PsA NN O O
) NN O O
, NN O O
weight NN B-AdverseReaction B-AdverseReaction
decrease NN I-AdverseReaction I-AdverseReaction
between NN O O
5%-10 NN O O
% NN O O
of NN O O
body NN O O
weight NN O O
was NN O O
reported NN O O
in NN O O
10 NN O O
% NN O O
( NN O O
49/497 NN O O
) NN O O
of NN O O
subjects NN O O
treated NN O O
with NN O O
OTEZLA NN O O
30 NN O O
mg NN O O
twice NN O O
daily NN O O
compared NN O O
to NN O O
3.3 NN O O
% NN O O
( NN O O
16/495 NN O O
) NN O O
treated NN O O
with NN O O
placebo NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
During NN O O
the NN O O
controlled NN O O
period NN O O
of NN O O
the NN O O
trials NN O O
in NN O O
psoriasis NN O O
, NN O O
weight NN B-AdverseReaction B-AdverseReaction
decrease NN I-AdverseReaction I-AdverseReaction
between NN B-Severity B-Severity
5%-10 NN I-Severity I-Severity
% NN I-Severity I-Severity
of NN I-Severity I-Severity
body NN I-Severity I-Severity
weight NN I-Severity I-Severity
occurred NN O O
in NN O O
12 NN O O
% NN O O
( NN O O
96/784 NN O O
) NN O O
of NN O O
subjects NN O O
treated NN O O
with NN O O
OTEZLA NN O O
compared NN O O
to NN O O
5 NN O O
% NN O O
( NN O O
19/382 NN O O
) NN O O
treated NN O O
with NN O O
placebo NN O O
. NN O O
Weight NN B-AdverseReaction B-AdverseReaction
decrease NN I-AdverseReaction I-AdverseReaction
of NN O O
>=10 NN O O
% NN O O
of NN O O
body NN O O
weight NN O O
occurred NN O O
in NN O O
2 NN O O
% NN O O
( NN O O
16/784 NN O O
) NN O O
of NN O O
subjects NN O O
treated NN O O
with NN O O
OTEZLA NN O O
30 NN O O
mg NN O O
twice NN O O
daily NN O O
compared NN O O
to NN O O
1 NN O O
% NN O O
( NN O O
3/382 NN O O
) NN O O
subjects NN O O
treated NN O O
with NN O O
placebo NN O O
. NN O O
Patients NN O O
treated NN O O
with NN O O
OTEZLA NN O O
should NN O O
have NN O O
their NN O O
weight NN O O
monitored NN O O
regularly NN O O
. NN O O
If NN O O
unexplained NN O O
or NN O O
clinically NN O O
significant NN O O
weight NN O O
loss NN O O
occurs NN O O
, NN O O
weight NN O O
loss NN O O
should NN O O
be NN O O
evaluated NN O O
, NN O O
and NN O O
discontinuation NN O O
of NN O O
OTEZLA NN O O
should NN O O
be NN O O
considered NN O O
. NN O O
5.3 NN O O
Drug NN O O
Interactions NN O O
Co NN O O
- NN O O
administration NN O O
of NN O O
strong NN O O
cytochrome NN O O
P450 NN O O
enzyme NN O O
inducer NN O O
, NN O O
rifampin NN O O
, NN O O
resulted NN O O
in NN O O
a NN O O
reduction NN O O
of NN O O
systemic NN O O
exposure NN O O
of NN O O
apremilast NN O O
, NN O O
which NN O O
may NN O O
result NN O O
in NN O O
a NN O O
loss NN O O
of NN O O
efficacy NN O O
of NN O O
OTEZLA. NN O O
Therefore NN O O
, NN O O
the NN O O
use NN O O
of NN O O
cytochrome NN O O
P450 NN O O
enzyme NN O O
inducers NN O O
( NN O O
e.g. NN O O
, NN O O
rifampin NN O O
, NN O O
phenobarbital NN O O
, NN O O
carbamazepine NN O O
, NN O O
phenytoin NN O O
) NN O O
with NN O O
OTEZLA NN O O
is NN O O
not NN O O
recommended NN O O
[ NN O O
see NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.1 NN O O
) NN O O
and NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.3 NN O O
) NN O O
] NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
most NN O O
serious NN O O
adverse NN O O
reactions NN O O
reported NN O O
with NN O O
PRADAXA NN O O
were NN O O
related NN O O
to NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
EXCERPT NN O O
: NN O O
Most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>15 NN O O
% NN O O
) NN O O
are NN O O
gastritis NN B-AdverseReaction B-AdverseReaction
symptoms NN O O
and NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Boehringer NN O O
Ingelheim NN O O
Pharmaceuticals NN O O
, NN O O
Inc. NN O O
at NN O O
( NN O O
800 NN O O
) NN O O
542 NN O O
- NN O O
6257 NN O O
or NN O O
( NN O O
800 NN O O
) NN O O
459 NN O O
- NN O O
9906 NN O O
TTY NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reactions NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
Reduction NN O O
of NN O O
Risk NN O O
of NN O O
Stroke NN O O
and NN O O
Systemic NN O O
Embolism NN O O
in NN O O
Non NN O O
- NN O O
valvular NN O O
Atrial NN O O
Fibrillation NN O O
The NN O O
RE NN O O
- NN O O
LY NN O O
( NN O O
Randomized NN O O
Evaluation NN O O
of NN O O
Long NN O O
- NN O O
term NN O O
Anticoagulant NN O O
Therapy NN O O
) NN O O
study NN O O
provided NN O O
safety NN O O
information NN O O
on NN O O
the NN O O
use NN O O
of NN O O
two NN O O
doses NN O O
of NN O O
PRADAXA NN O O
and NN O O
warfarin NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14.1 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
numbers NN O O
of NN O O
patients NN O O
and NN O O
their NN O O
exposures NN O O
are NN O O
described NN O O
in NN O O
Table NN O O
1 NN O O
. NN O O
Limited NN O O
information NN O O
is NN O O
presented NN O O
on NN O O
the NN O O
110 NN O O
mg NN O O
dosing NN O O
arm NN O O
because NN O O
this NN O O
dose NN O O
is NN O O
not NN O O
approved NN O O
. NN O O
Table NN O O
1 NN O O
Summary NN O O
of NN O O
Treatment NN O O
Exposure NN O O
in NN O O
RE NN O O
- NN O O
LY NN O O
PRADAXA NN O O
110 NN O O
mg NN O O
twice NN O O
daily NN O O
PRADAXA NN O O
150 NN O O
mg NN O O
twice NN O O
daily NN O O
Warfarin NN O O
Total NN O O
number NN O O
treated NN O O
5983 NN O O
6059 NN O O
5998 NN O O
Exposure NN O O
> NN O O
12 NN O O
months NN O O
4936 NN O O
4939 NN O O
5193 NN O O
> NN O O
24 NN O O
months NN O O
2387 NN O O
2405 NN O O
2470 NN O O
Mean NN O O
exposure NN O O
( NN O O
months NN O O
) NN O O
20.5 NN O O
20.3 NN O O
21.3 NN O O
Total NN O O
patient NN O O
- NN O O
years NN O O
10,242 NN O O
10,261 NN O O
10,659 NN O O
Drug NN O O
Discontinuation NN O O
in NN O O
RE NN O O
- NN O O
LY NN O O
The NN O O
rates NN O O
of NN O O
adverse NN O O
reactions NN O O
leading NN O O
to NN O O
treatment NN O O
discontinuation NN O O
were NN O O
21 NN O O
% NN O O
for NN O O
PRADAXA NN O O
150 NN O O
mg NN O O
and NN O O
16 NN O O
% NN O O
for NN O O
warfarin NN O O
. NN O O
The NN O O
most NN O O
frequent NN O O
adverse NN O O
reactions NN O O
leading NN O O
to NN O O
discontinuation NN O O
of NN O O
PRADAXA NN O O
were NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
and NN O O
gastrointestinal NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
( NN O O
i.e. NN O O
, NN O O
dyspepsia NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
upper NN B-AdverseReaction B-AdverseReaction
abdominal NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
gastrointestinal NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
and NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
Bleeding NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
Table NN O O
2 NN O O
shows NN O O
the NN O O
number NN O O
of NN O O
adjudicated NN O O
major NN B-Severity B-Severity
bleeding NN B-AdverseReaction B-AdverseReaction
events NN O O
during NN O O
the NN O O
treatment NN O O
period NN O O
in NN O O
the NN O O
RE NN O O
- NN O O
LY NN O O
study NN O O
, NN O O
with NN O O
the NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
rate NN O O
per NN O O
100 NN O O
subject NN O O
- NN O O
years NN O O
( NN O O
% NN O O
) NN O O
. NN O O
Major NN B-Severity B-Severity
bleeding NN B-AdverseReaction B-AdverseReaction
is NN O O
defined NN O O
as NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
accompanied NN O O
by NN O O
one NN O O
or NN O O
more NN O O
of NN O O
the NN O O
following NN O O
: NN O O
a NN O O
decrease NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
hemoglobin NN I-AdverseReaction I-AdverseReaction
of NN O O
>=2 NN O O
g/dL NN O O
, NN O O
a NN O O
transfusion NN O O
of NN O O
>=2 NN O O
units NN O O
of NN O O
packed NN O O
red NN O O
blood NN O O
cells NN O O
, NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
at NN I-AdverseReaction I-AdverseReaction
a NN I-AdverseReaction I-AdverseReaction
critical NN I-AdverseReaction I-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
or NN O O
with NN O O
a NN O O
fatal NN B-AdverseReaction B-AdverseReaction
outcome NN O O
. NN O O
Intracranial NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
included NN O O
intracerebral NN O O
( NN O O
hemorrhagic NN O O
stroke NN O O
) NN O O
, NN O O
subarachnoid NN O O
, NN O O
and NN O O
subdural NN B-AdverseReaction B-AdverseReaction
bleeds NN I-AdverseReaction I-AdverseReaction
Table NN O O
2 NN O O
Adjudicated NN O O
Major NN B-Severity B-Severity
Bleeding NN B-AdverseReaction B-AdverseReaction
Events NN O O
in NN O O
Treated NN O O
Patientsa NN O O
aPatients NN O O
during NN O O
treatment NN O O
or NN O O
within NN O O
2 NN O O
days NN O O
of NN O O
stopping NN O O
study NN O O
treatment NN O O
. NN O O
Major NN B-Severity B-Severity
bleeding NN B-AdverseReaction B-AdverseReaction
events NN O O
within NN O O
each NN O O
subcategory NN O O
were NN O O
counted NN O O
once NN O O
per NN O O
patient NN O O
, NN O O
but NN O O
patients NN O O
may NN O O
have NN O O
contributed NN O O
events NN O O
to NN O O
multiple NN O O
subcategories NN O O
. NN O O
bAnnual NN O O
event NN O O
rate NN O O
per NN O O
100 NN O O
pt NN O O
- NN O O
years NN O O
= NN O O
100 NN O O
* NN O O
number NN O O
of NN O O
subjects NN O O
with NN O O
event/subject NN O O
- NN O O
years NN O O
. NN O O
Subject NN O O
- NN O O
years NN O O
is NN O O
defined NN O O
as NN O O
cumulative NN O O
number NN O O
of NN O O
days NN O O
from NN O O
first NN O O
drug NN O O
intake NN O O
to NN O O
event NN O O
date NN O O
, NN O O
date NN O O
of NN O O
last NN O O
drug NN O O
intake NN O O
+ NN O O
2 NN O O
, NN O O
death NN O O
date NN O O
( NN O O
whatever NN O O
occurred NN O O
first NN O O
) NN O O
across NN O O
all NN O O
treated NN O O
subjects NN O O
divided NN O O
by NN O O
365.25 NN O O
. NN O O
In NN O O
case NN O O
of NN O O
recurrent NN O O
events NN O O
of NN O O
the NN O O
same NN O O
category NN O O
, NN O O
the NN O O
first NN O O
event NN O O
was NN O O
considered NN O O
. NN O O
cDefined NN O O
as NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
accompanied NN O O
by NN O O
one NN O O
or NN O O
more NN O O
of NN O O
the NN O O
following NN O O
: NN O O
a NN O O
decrease NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
hemoglobin NN I-AdverseReaction I-AdverseReaction
of NN O O
>=2 NN O O
g/dL NN O O
, NN O O
a NN O O
transfusion NN O O
of NN O O
2 NN O O
or NN O O
more NN O O
units NN O O
of NN O O
packed NN O O
red NN O O
blood NN O O
cells NN O O
, NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
at NN I-AdverseReaction I-AdverseReaction
a NN I-AdverseReaction I-AdverseReaction
critical NN I-AdverseReaction I-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
or NN O O
with NN O O
fatal NN B-AdverseReaction B-AdverseReaction
outcome NN O O
. NN O O
dIntracranial NN O O
bleed NN O O
included NN O O
intracerebral NN O O
( NN O O
hemorrhagic NN O O
stroke NN O O
) NN O O
, NN O O
subarachnoid NN O O
, NN O O
and NN O O
subdural NN B-AdverseReaction B-AdverseReaction
bleeds NN I-AdverseReaction I-AdverseReaction
eOn NN O O
- NN O O
treatment NN O O
analysis NN O O
based NN O O
on NN O O
the NN O O
safety NN O O
population NN O O
, NN O O
compared NN O O
to NN O O
ITT NN O O
analysis NN O O
presented NN O O
in NN O O
Section NN O O
14 NN O O
Clinical NN O O
Studies NN O O
. NN O O
fFatal NN O O
bleed NN B-AdverseReaction B-AdverseReaction
Adjudicated NN O O
major NN B-Severity B-Severity
bleed NN B-AdverseReaction B-AdverseReaction
as NN O O
defined NN O O
above NN O O
with NN O O
investigator NN O O
reported NN O O
fatal NN B-AdverseReaction B-AdverseReaction
outcome NN O O
and NN O O
adjudicated NN O O
death NN B-AdverseReaction B-AdverseReaction
with NN O O
primary NN O O
cause NN O O
from NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
gNon NN O O
- NN O O
intracranial NN O O
fatal NN B-AdverseReaction B-AdverseReaction
bleed NN O O
: NN O O
Adjudicated NN O O
major NN B-Severity B-Severity
bleed NN B-AdverseReaction B-AdverseReaction
as NN O O
defined NN O O
above NN O O
and NN O O
adjudicated NN O O
death NN B-AdverseReaction B-AdverseReaction
with NN O O
primary NN O O
cause NN O O
from NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
but NN O O
without NN B-Negation B-Negation
symptomatic NN B-AdverseReaction B-AdverseReaction
intracranial NN I-AdverseReaction I-AdverseReaction
bleed NN I-AdverseReaction I-AdverseReaction
based NN O O
on NN O O
investigator NN O O
's NN O O
clinical NN O O
assessment NN O O
. NN O O
Event NN O O
PRADAXA NN O O
150 NN O O
mgN NN O O
= NN O O
6059n NN O O
( NN O O
%/year NN O O
b NN O O
) NN O O
WarfarinN NN O O
= NN O O
5998n NN O O
( NN O O
%/year NN O O
b NN O O
) NN O O
PRADAXA NN O O
150 NN O O
mgvs NN O O
. NN O O
WarfarinHR NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
) NN O O
Major NN B-Severity B-Severity
Bleeding NN B-AdverseReaction B-AdverseReaction
c NN O O
350 NN O O
( NN O O
3.47 NN O O
) NN O O
374 NN O O
( NN O O
3.58 NN O O
) NN O O
0.97 NN O O
( NN O O
0.84 NN O O
, NN O O
1.12 NN O O
) NN O O
Intracranial NN B-AdverseReaction B-AdverseReaction
Hemorrhage NN I-AdverseReaction I-AdverseReaction
( NN O O
ICH NN O O
) NN O O
d NN O O
23 NN O O
( NN O O
0.22 NN O O
) NN O O
82 NN O O
( NN O O
0.77 NN O O
) NN O O
0.29 NN O O
( NN O O
0.18 NN O O
, NN O O
0.46 NN O O
) NN O O
Hemorrhagic NN B-AdverseReaction B-AdverseReaction
Stroke NN I-AdverseReaction I-AdverseReaction
e NN O O
6 NN O O
( NN O O
0.06 NN O O
) NN O O
40 NN O O
( NN O O
0.37 NN O O
) NN O O
0.16 NN O O
( NN O O
0.07 NN O O
, NN O O
0.37 NN O O
) NN O O
Other NN O O
ICH NN B-AdverseReaction B-AdverseReaction
17 NN O O
( NN O O
0.17 NN O O
) NN O O
46 NN O O
( NN O O
0.43 NN O O
) NN O O
0.38 NN O O
( NN O O
0.22 NN O O
, NN O O
0.67 NN O O
) NN O O
Gastrointestinal NN O O
162 NN O O
( NN O O
1.59 NN O O
) NN O O
111 NN O O
( NN O O
1.05 NN O O
) NN O O
1.51 NN O O
( NN O O
1.19 NN O O
, NN O O
1.92 NN O O
) NN O O
Fatal NN B-AdverseReaction B-AdverseReaction
Bleeding NN B-AdverseReaction B-AdverseReaction
f NN O O
7 NN O O
( NN O O
0.07 NN O O
) NN O O
16 NN O O
( NN O O
0.15 NN O O
) NN O O
0.45 NN O O
( NN O O
0.19 NN O O
, NN O O
1.10 NN O O
) NN O O
ICH NN B-AdverseReaction B-AdverseReaction
3 NN O O
( NN O O
0.03 NN O O
) NN O O
9 NN O O
( NN O O
0.08 NN O O
) NN O O
0.35 NN O O
( NN O O
0.09 NN O O
, NN O O
1.28 NN O O
) NN O O
Non NN O O
- NN O O
intracranial NN O O
g NN O O
4 NN O O
( NN O O
0.04 NN O O
) NN O O
7 NN O O
( NN O O
0.07 NN O O
) NN O O
0.59 NN O O
( NN O O
0.17 NN O O
, NN O O
2.02 NN O O
) NN O O
There NN O O
was NN O O
a NN O O
higher NN O O
rate NN O O
of NN O O
any NN O O
gastrointestinal NN B-AdverseReaction B-AdverseReaction
bleeds NN I-AdverseReaction I-AdverseReaction
in NN O O
patients NN O O
receiving NN O O
PRADAXA NN O O
150 NN O O
mg NN O O
than NN O O
in NN O O
patients NN O O
receiving NN O O
warfarin NN O O
( NN O O
6.6 NN O O
% NN O O
vs. NN O O
4.2 NN O O
% NN O O
, NN O O
respectively NN O O
) NN O O
. NN O O
The NN O O
risk NN B-Factor B-Factor
of NN O O
major NN B-Severity B-Severity
bleeds NN B-AdverseReaction B-AdverseReaction
was NN O O
similar NN O O
with NN O O
PRADAXA NN O O
150 NN O O
mg NN O O
and NN O O
warfarin NN O O
across NN O O
major NN O O
subgroups NN O O
defined NN O O
by NN O O
baseline NN O O
characteristics NN O O
( NN O O
see NN O O
Figure NN O O
1 NN O O
) NN O O
, NN O O
with NN O O
the NN O O
exception NN O O
of NN O O
age NN O O
, NN O O
where NN O O
there NN O O
was NN O O
a NN O O
trend NN O O
towards NN O O
a NN O O
higher NN O O
incidence NN O O
of NN O O
major NN B-Severity B-Severity
bleeding NN B-AdverseReaction B-AdverseReaction
on NN O O
PRADAXA NN O O
( NN O O
hazard NN O O
ratio NN O O
1.2 NN O O
, NN O O
95 NN O O
% NN O O
CI NN O O
: NN O O
1.0 NN O O
to NN O O
1.5 NN O O
) NN O O
for NN O O
patients NN O O
>=75 NN O O
years NN O O
of NN O O
age NN O O
. NN O O
Figure NN O O
1 NN O O
Adjudicated NN O O
Major NN B-Severity B-Severity
Bleeding NN B-AdverseReaction B-AdverseReaction
by NN O O
Baseline NN O O
Characteristics NN O O
Including NN O O
Hemorrhagic NN O O
Stroke NN O O
Treated NN O O
Patients NN O O
Note NN O O
: NN O O
The NN O O
figure NN O O
above NN O O
presents NN O O
effects NN O O
in NN O O
various NN O O
subgroups NN O O
all NN O O
of NN O O
which NN O O
are NN O O
baseline NN O O
characteristics NN O O
and NN O O
all NN O O
of NN O O
which NN O O
were NN O O
pre NN O O
- NN O O
specified NN O O
. NN O O
The NN O O
95 NN O O
% NN O O
confidence NN O O
limits NN O O
that NN O O
are NN O O
shown NN O O
do NN O O
not NN O O
take NN O O
into NN O O
account NN O O
how NN O O
many NN O O
comparisons NN O O
were NN O O
made NN O O
, NN O O
nor NN O O
do NN O O
they NN O O
reflect NN O O
the NN O O
effect NN O O
of NN O O
a NN O O
particular NN O O
factor NN O O
after NN O O
adjustment NN O O
for NN O O
all NN O O
other NN O O
factors NN O O
. NN O O
Apparent NN O O
homogeneity NN O O
or NN O O
heterogeneity NN O O
among NN O O
groups NN O O
should NN O O
not NN O O
be NN O O
over NN O O
- NN O O
interpreted NN O O
. NN O O
Figure NN O O
1 NN O O
Gastrointestinal NN O O
Adverse NN O O
Reactions NN O O
Patients NN O O
on NN O O
PRADAXA NN O O
150 NN O O
mg NN O O
had NN O O
an NN O O
increased NN O O
incidence NN O O
of NN O O
gastrointestinal NN B-AdverseReaction B-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
( NN O O
35 NN O O
% NN O O
vs. NN O O
24 NN O O
% NN O O
on NN O O
warfarin NN O O
) NN O O
. NN O O
These NN O O
were NN O O
commonly NN O O
dyspepsia NN B-AdverseReaction B-AdverseReaction
( NN O O
including NN O O
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
upper NN I-AdverseReaction I-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
discomfort NN I-AdverseReaction I-AdverseReaction
and NN O O
epigastric NN B-AdverseReaction B-AdverseReaction
discomfort NN I-AdverseReaction I-AdverseReaction
and NN O O
gastritis NN B-AdverseReaction B-AdverseReaction
symptoms NN O O
( NN O O
including NN O O
GERD NN B-AdverseReaction B-AdverseReaction
esophagitis NN B-AdverseReaction B-AdverseReaction
erosive NN B-AdverseReaction B-AdverseReaction
gastritis NN I-AdverseReaction I-AdverseReaction
gastric NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
hemorrhagic NN B-AdverseReaction B-AdverseReaction
gastritis NN I-AdverseReaction I-AdverseReaction
hemorrhagic NN B-AdverseReaction B-AdverseReaction
erosive NN I-AdverseReaction I-AdverseReaction
gastritis NN I-AdverseReaction I-AdverseReaction
and NN O O
gastrointestinal NN B-AdverseReaction B-AdverseReaction
ulcer NN I-AdverseReaction I-AdverseReaction
Hypersensitivity NN O O
Reactions NN O O
In NN O O
the NN O O
RE NN O O
- NN O O
LY NN O O
study NN O O
, NN O O
drug NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
( NN O O
including NN O O
urticaria NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
and NN O O
pruritus NN B-AdverseReaction B-AdverseReaction
allergic NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
anaphylactic NN B-AdverseReaction B-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
and NN O O
anaphylactic NN B-AdverseReaction B-AdverseReaction
shock NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
in NN O O
< NN O O
0.1 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
PRADAXA. NN O O
Treatment NN O O
and NN O O
Reduction NN O O
in NN O O
the NN O O
Risk NN O O
of NN O O
Recurrence NN O O
of NN O O
Deep NN O O
Venous NN O O
Thrombosis NN O O
and NN O O
Pulmonary NN O O
Embolism NN O O
PRADAXA NN O O
was NN O O
studied NN O O
in NN O O
4387 NN O O
patients NN O O
in NN O O
4 NN O O
pivotal NN O O
, NN O O
parallel NN O O
, NN O O
randomized NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
trials NN O O
. NN O O
Three NN O O
of NN O O
these NN O O
trials NN O O
were NN O O
active NN O O
- NN O O
controlled NN O O
( NN O O
warfarin NN O O
) NN O O
( NN O O
RE NN O O
- NN O O
COVER NN O O
, NN O O
RE NN O O
- NN O O
COVER NN O O
II NN O O
, NN O O
and NN O O
RE NN O O
- NN O O
MEDY NN O O
) NN O O
, NN O O
and NN O O
one NN O O
study NN O O
( NN O O
RE NN O O
- NN O O
SONATE NN O O
) NN O O
was NN O O
placebo NN O O
- NN O O
controlled NN O O
. NN O O
The NN O O
demographic NN O O
characteristics NN O O
were NN O O
similar NN O O
among NN O O
the NN O O
4 NN O O
pivotal NN O O
studies NN O O
and NN O O
between NN O O
the NN O O
treatment NN O O
groups NN O O
within NN O O
these NN O O
studies NN O O
. NN O O
Approximately NN O O
60 NN O O
% NN O O
of NN O O
the NN O O
treated NN O O
patients NN O O
were NN O O
male NN O O
, NN O O
with NN O O
a NN O O
mean NN O O
age NN O O
of NN O O
55.1 NN O O
years NN O O
. NN O O
The NN O O
majority NN O O
of NN O O
the NN O O
patients NN O O
were NN O O
white NN O O
( NN O O
87.7 NN O O
% NN O O
) NN O O
, NN O O
10.3 NN O O
% NN O O
were NN O O
Asian NN O O
, NN O O
and NN O O
1.9 NN O O
% NN O O
were NN O O
black NN O O
with NN O O
a NN O O
mean NN O O
CrCl NN O O
of NN O O
105.6 NN O O
mL/min NN O O
. NN O O
Bleeding NN B-AdverseReaction B-AdverseReaction
events NN O O
for NN O O
the NN O O
4 NN O O
pivotal NN O O
studies NN O O
were NN O O
classified NN O O
as NN O O
major NN B-Severity B-Severity
bleeding NN B-AdverseReaction B-AdverseReaction
events NN O O
if NN O O
at NN O O
least NN O O
one NN O O
of NN O O
the NN O O
following NN O O
criteria NN O O
applied NN O O
: NN O O
fatal NN B-AdverseReaction B-AdverseReaction
bleeding NN B-AdverseReaction B-AdverseReaction
symptomatic NN B-AdverseReaction B-AdverseReaction
bleeding NN I-AdverseReaction I-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
a NN I-AdverseReaction I-AdverseReaction
critical NN I-AdverseReaction I-AdverseReaction
area NN I-AdverseReaction I-AdverseReaction
or NN O O
organ NN O O
( NN O O
intraocular NN O O
, NN O O
intracranial NN O O
, NN O O
intraspinal NN O O
or NN O O
intramuscular NN O O
with NN O O
compartment NN B-AdverseReaction B-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
retroperitoneal NN B-AdverseReaction B-AdverseReaction
bleeding NN I-AdverseReaction I-AdverseReaction
intra NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
articular NN I-AdverseReaction I-AdverseReaction
bleeding NN I-AdverseReaction I-AdverseReaction
or NN O O
pericardial NN B-AdverseReaction B-AdverseReaction
bleeding NN I-AdverseReaction I-AdverseReaction
bleeding NN B-AdverseReaction B-AdverseReaction
causing NN O O
a NN O O
fall NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
hemoglobin NN I-AdverseReaction I-AdverseReaction
level NN I-AdverseReaction I-AdverseReaction
of NN O O
2.0 NN B-Severity B-Severity
g/dL NN I-Severity I-Severity
( NN O O
1.24 NN O O
mmol/L NN O O
or NN O O
more NN O O
, NN O O
or NN O O
leading NN O O
to NN O O
transfusion NN O O
of NN O O
2 NN O O
or NN O O
more NN O O
units NN O O
of NN O O
whole NN O O
blood NN O O
or NN O O
red NN O O
cells NN O O
) NN O O
. NN O O
RE NN O O
- NN O O
COVER NN O O
and NN O O
RE NN O O
- NN O O
COVER NN O O
II NN O O
studies NN O O
compared NN O O
PRADAXA NN O O
150 NN O O
mg NN O O
twice NN O O
daily NN O O
and NN O O
warfarin NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
deep NN O O
vein NN O O
thrombosis NN O O
and NN O O
pulmonary NN O O
embolism NN O O
. NN O O
Patients NN O O
received NN O O
5 NN O O
- NN O O
10 NN O O
days NN O O
of NN O O
an NN O O
approved NN O O
parenteral NN O O
anticoagulant NN O O
therapy NN O O
followed NN O O
by NN O O
6 NN O O
months NN O O
, NN O O
with NN O O
mean NN O O
exposure NN O O
of NN O O
164 NN O O
days NN O O
, NN O O
of NN O O
oral NN O O
only NN O O
treatment NN O O
; NN O O
warfarin NN O O
was NN O O
overlapped NN O O
with NN O O
parenteral NN O O
therapy NN O O
. NN O O
Table NN O O
3 NN O O
shows NN O O
the NN O O
number NN O O
of NN O O
patients NN O O
experiencing NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
events NN O O
in NN O O
the NN O O
pooled NN O O
analysis NN O O
of NN O O
RE NN O O
- NN O O
COVER NN O O
and NN O O
RE NN O O
- NN O O
COVER NN O O
II NN O O
studies NN O O
during NN O O
the NN O O
full NN O O
treatment NN O O
including NN O O
parenteral NN O O
and NN O O
oral NN O O
only NN O O
treatment NN O O
periods NN O O
after NN O O
randomization NN O O
. NN O O
Table NN O O
3 NN O O
Bleeding NN B-AdverseReaction B-AdverseReaction
Events NN O O
in NN O O
RE NN O O
- NN O O
COVER NN O O
and NN O O
RE NN O O
- NN O O
COVER NN O O
II NN O O
Treated NN O O
Patients NN O O
Note NN O O
: NN O O
MBE NN B-AdverseReaction B-AdverseReaction
can NN O O
belong NN O O
to NN O O
more NN O O
than NN O O
one NN O O
criterion NN O O
. NN O O
a NN O O
Patients NN O O
with NN O O
at NN O O
least NN O O
one NN O O
MBE NN B-AdverseReaction B-AdverseReaction
b NN O O
Bleeding NN B-AdverseReaction B-AdverseReaction
site NN O O
based NN O O
on NN O O
investigator NN O O
assessment NN O O
. NN O O
Patients NN O O
can NN O O
have NN O O
more NN O O
than NN O O
one NN O O
site NN O O
of NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
c NN O O
Confidence NN O O
interval NN O O
Patients NN O O
Major NN B-Severity B-Severity
bleeding NN B-AdverseReaction B-AdverseReaction
event NN O O
a NN O O
Bleeding NN B-AdverseReaction B-AdverseReaction
sites NN O O
for NN O O
MBE NN B-AdverseReaction B-AdverseReaction
b NN O O
Clinically NN O O
relevant NN O O
non NN B-Severity B-Severity
- NN I-Severity I-Severity
major NN I-Severity I-Severity
bleeding NN B-AdverseReaction B-AdverseReaction
Any NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
The NN O O
rate NN O O
of NN O O
any NN O O
gastrointestinal NN B-AdverseReaction B-AdverseReaction
bleeds NN I-AdverseReaction I-AdverseReaction
in NN O O
patients NN O O
receiving NN O O
PRADAXA NN O O
150 NN O O
mg NN O O
in NN O O
the NN O O
full NN O O
treatment NN O O
period NN O O
was NN O O
3.1 NN O O
% NN O O
( NN O O
2.4 NN O O
% NN O O
on NN O O
warfarin NN O O
) NN O O
. NN O O
The NN O O
RE NN O O
- NN O O
MEDY NN O O
and NN O O
RE NN O O
- NN O O
SONATE NN O O
studies NN O O
provided NN O O
safety NN O O
information NN O O
on NN O O
the NN O O
use NN O O
of NN O O
PRADAXA NN O O
for NN O O
the NN O O
reduction NN O O
in NN O O
the NN O O
risk NN O O
of NN O O
recurrence NN O O
of NN O O
deep NN O O
vein NN O O
thrombosis NN O O
and NN O O
pulmonary NN O O
embolism NN O O
. NN O O
RE NN O O
- NN O O
MEDY NN O O
was NN O O
an NN O O
active NN O O
- NN O O
controlled NN O O
study NN O O
( NN O O
warfarin NN O O
) NN O O
in NN O O
which NN O O
1430 NN O O
patients NN O O
received NN O O
PRADAXA NN O O
150 NN O O
mg NN O O
twice NN O O
daily NN O O
following NN O O
3 NN O O
to NN O O
12 NN O O
months NN O O
of NN O O
oral NN O O
anticoagulant NN O O
regimen NN O O
. NN O O
Patients NN O O
in NN O O
the NN O O
treatment NN O O
studies NN O O
who NN O O
rolled NN O O
over NN O O
into NN O O
the NN O O
RE NN O O
- NN O O
MEDY NN O O
study NN O O
had NN O O
a NN O O
combined NN O O
treatment NN O O
duration NN O O
of NN O O
up NN O O
to NN O O
more NN O O
than NN O O
3 NN O O
years NN O O
, NN O O
with NN O O
mean NN O O
exposure NN O O
of NN O O
473 NN O O
days NN O O
. NN O O
Table NN O O
4 NN O O
shows NN O O
the NN O O
number NN O O
of NN O O
patients NN O O
experiencing NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
events NN O O
in NN O O
the NN O O
study NN O O
. NN O O
Table NN O O
4 NN O O
Bleeding NN B-AdverseReaction B-AdverseReaction
Events NN O O
in NN O O
RE NN O O
- NN O O
MEDY NN O O
Treated NN O O
Patients NN O O
Note NN O O
: NN O O
MBE NN B-AdverseReaction B-AdverseReaction
can NN O O
belong NN O O
to NN O O
more NN O O
than NN O O
one NN O O
criterion NN O O
. NN O O
a NN O O
Patients NN O O
with NN O O
at NN O O
least NN O O
one NN O O
MBE NN B-AdverseReaction B-AdverseReaction
b NN O O
Bleeding NN B-AdverseReaction B-AdverseReaction
site NN O O
based NN O O
on NN O O
investigator NN O O
assessment NN O O
. NN O O
Patients NN O O
can NN O O
have NN O O
more NN O O
than NN O O
one NN O O
site NN O O
of NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
c NN O O
Confidence NN O O
interval NN O O
Patients NN O O
Major NN B-Severity B-Severity
bleeding NN B-AdverseReaction B-AdverseReaction
event NN O O
a NN O O
Bleeding NN B-AdverseReaction B-AdverseReaction
sites NN O O
for NN O O
MBE NN B-AdverseReaction B-AdverseReaction
b NN O O
Clinically NN O O
relevant NN O O
non NN B-Severity B-Severity
- NN I-Severity I-Severity
major NN I-Severity I-Severity
bleeding NN B-AdverseReaction B-AdverseReaction
Any NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
In NN O O
the NN O O
RE NN O O
- NN O O
MEDY NN O O
study NN O O
, NN O O
the NN O O
rate NN O O
of NN O O
any NN O O
gastrointestinal NN B-AdverseReaction B-AdverseReaction
bleeds NN I-AdverseReaction I-AdverseReaction
in NN O O
patients NN O O
receiving NN O O
PRADAXA NN O O
150 NN O O
mg NN O O
was NN O O
3.1 NN O O
% NN O O
( NN O O
2.2 NN O O
% NN O O
on NN O O
warfarin NN O O
) NN O O
. NN O O
RE NN O O
- NN O O
SONATE NN O O
was NN O O
a NN O O
placebo NN O O
- NN O O
controlled NN O O
study NN O O
in NN O O
which NN O O
684 NN O O
patients NN O O
received NN O O
PRADAXA NN O O
150 NN O O
mg NN O O
twice NN O O
daily NN O O
following NN O O
6 NN O O
to NN O O
18 NN O O
months NN O O
of NN O O
oral NN O O
anticoagulant NN O O
regimen NN O O
. NN O O
Patients NN O O
in NN O O
the NN O O
treatment NN O O
studies NN O O
who NN O O
rolled NN O O
over NN O O
into NN O O
the NN O O
RE NN O O
- NN O O
SONATE NN O O
study NN O O
had NN O O
combined NN O O
treatment NN O O
duration NN O O
up NN O O
to NN O O
9 NN O O
months NN O O
, NN O O
with NN O O
mean NN O O
exposure NN O O
of NN O O
165 NN O O
days NN O O
. NN O O
Table NN O O
5 NN O O
shows NN O O
the NN O O
number NN O O
of NN O O
patients NN O O
experiencing NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
events NN O O
in NN O O
the NN O O
study NN O O
. NN O O
Table NN O O
5 NN O O
Bleeding NN B-AdverseReaction B-AdverseReaction
Events NN O O
in NN O O
RE NN O O
- NN O O
SONATE NN O O
Treated NN O O
Patients NN O O
Note NN O O
: NN O O
MBE NN B-AdverseReaction B-AdverseReaction
can NN O O
belong NN O O
to NN O O
more NN O O
than NN O O
one NN O O
criterion NN O O
. NN O O
a NN O O
Patients NN O O
with NN O O
at NN O O
least NN O O
one NN O O
MBE NN B-AdverseReaction B-AdverseReaction
b NN O O
Bleeding NN B-AdverseReaction B-AdverseReaction
site NN O O
based NN O O
on NN O O
investigator NN O O
assessment NN O O
. NN O O
Patients NN O O
can NN O O
have NN O O
more NN O O
than NN O O
one NN O O
site NN O O
of NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
c NN O O
Confidence NN O O
interval NN O O
Patients NN O O
Major NN B-Severity B-Severity
bleeding NN B-AdverseReaction B-AdverseReaction
event NN O O
a NN O O
Clinically NN O O
relevant NN O O
non NN B-Severity B-Severity
- NN I-Severity I-Severity
major NN I-Severity I-Severity
bleeding NN B-AdverseReaction B-AdverseReaction
Any NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
In NN O O
the NN O O
RE NN O O
- NN O O
SONATE NN O O
study NN O O
, NN O O
the NN O O
rate NN O O
of NN O O
any NN O O
gastrointestinal NN B-AdverseReaction B-AdverseReaction
bleeds NN I-AdverseReaction I-AdverseReaction
in NN O O
patients NN O O
receiving NN O O
PRADAXA NN O O
150 NN O O
mg NN O O
was NN O O
0.7 NN O O
% NN O O
( NN O O
0.3 NN O O
% NN O O
on NN O O
placebo NN O O
) NN O O
. NN O O
Clinical NN O O
Myocardial NN O O
Infarction NN O O
Events NN O O
In NN O O
the NN O O
active NN O O
- NN O O
controlled NN O O
VTE NN O O
studies NN O O
, NN O O
a NN O O
higher NN O O
rate NN O O
of NN O O
clinical NN O O
myocardial NN B-AdverseReaction B-AdverseReaction
infarction NN I-AdverseReaction I-AdverseReaction
was NN O O
reported NN O O
in NN O O
patients NN O O
who NN O O
received NN O O
PRADAXA NN O O
[ NN O O
20 NN O O
( NN O O
0.66 NN O O
per NN O O
100 NN O O
patient NN O O
- NN O O
years NN O O
) NN O O
] NN O O
than NN O O
in NN O O
those NN O O
who NN O O
received NN O O
warfarin NN O O
[ NN O O
5 NN O O
( NN O O
0.17 NN O O
per NN O O
100 NN O O
patient NN O O
- NN O O
years NN O O
) NN O O
] NN O O
. NN O O
In NN O O
the NN O O
placebo NN O O
- NN O O
controlled NN O O
study NN O O
, NN O O
a NN O O
similar NN O O
rate NN O O
of NN O O
non NN B-Severity B-Severity
- NN I-Severity I-Severity
fatal NN I-Severity I-Severity
and NN O O
fatal NN B-AdverseReaction B-AdverseReaction
clinical NN O O
myocardial NN B-AdverseReaction B-AdverseReaction
infarction NN I-AdverseReaction I-AdverseReaction
was NN O O
reported NN O O
in NN O O
patients NN O O
who NN O O
received NN O O
PRADAXA NN O O
[ NN O O
1 NN O O
( NN O O
0.32 NN O O
per NN O O
100 NN O O
patient NN O O
- NN O O
years NN O O
) NN O O
] NN O O
and NN O O
in NN O O
those NN O O
who NN O O
received NN O O
placebo NN O O
[ NN O O
1 NN O O
( NN O O
0.34 NN O O
per NN O O
100 NN O O
patient NN O O
- NN O O
years NN O O
) NN O O
] NN O O
. NN O O
Gastrointestinal NN O O
Adverse NN O O
Reactions NN O O
In NN O O
the NN O O
four NN O O
pivotal NN O O
studies NN O O
, NN O O
patients NN O O
on NN O O
PRADAXA NN O O
150 NN O O
mg NN O O
had NN O O
a NN O O
similar NN O O
incidence NN O O
of NN O O
gastrointestinal NN B-AdverseReaction B-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
( NN O O
24.7 NN O O
% NN O O
vs. NN O O
22.7 NN O O
% NN O O
on NN O O
warfarin NN O O
) NN O O
. NN O O
Dyspepsia NN B-AdverseReaction B-AdverseReaction
( NN O O
including NN O O
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
upper NN I-AdverseReaction I-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
discomfort NN I-AdverseReaction I-AdverseReaction
and NN O O
epigastric NN B-AdverseReaction B-AdverseReaction
discomfort NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
patients NN O O
on NN O O
PRADAXA NN O O
in NN O O
7.5 NN O O
% NN O O
vs. NN O O
5.5 NN O O
% NN O O
on NN O O
warfarin NN O O
, NN O O
and NN O O
gastritis NN B-AdverseReaction B-AdverseReaction
symptoms NN O O
( NN O O
including NN O O
gastritis NN B-AdverseReaction B-AdverseReaction
GERD NN B-AdverseReaction B-AdverseReaction
esophagitis NN B-AdverseReaction B-AdverseReaction
erosive NN B-AdverseReaction B-AdverseReaction
gastritis NN I-AdverseReaction I-AdverseReaction
and NN O O
gastric NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
occurred NN O O
at NN O O
3.0 NN O O
% NN O O
vs. NN O O
1.7 NN O O
% NN O O
, NN O O
respectively NN O O
. NN O O
Hypersensitivity NN O O
Reactions NN O O
In NN O O
the NN O O
4 NN O O
pivotal NN O O
studies NN O O
, NN O O
drug NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
( NN O O
including NN O O
urticaria NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
and NN O O
pruritus NN B-AdverseReaction B-AdverseReaction
allergic NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
anaphylactic NN B-AdverseReaction B-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
and NN O O
anaphylactic NN B-AdverseReaction B-AdverseReaction
shock NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
in NN O O
0.1 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
PRADAXA. NN O O
6.2 NN O O
Postmarketing NN O O
Experience NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
identified NN O O
during NN O O
post NN O O
approval NN O O
use NN O O
of NN O O
PRADAXA. NN O O
Because NN O O
these NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
identified NN O O
during NN O O
post NN O O
approval NN O O
use NN O O
of NN O O
PRADAXA NN O O
: NN O O
angioedema NN B-AdverseReaction B-AdverseReaction
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
esophageal NN B-AdverseReaction B-AdverseReaction
ulcer NN I-AdverseReaction I-AdverseReaction
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
( NN O O
A NN O O
) NN O O
PREMATURE NN O O
DISCONTINUATION NN O O
OF NN O O
PRADAXA NN O O
INCREASES NN O O
THE NN O O
RISK NN O O
OF NN O O
THROMBOTIC NN O O
EVENTS NN O O
, NN O O
( NN O O
B NN O O
) NN O O
SPINAL/EPIDURAL NN O O
HEMATOMA NN O O
WARNING NN O O
: NN O O
( NN O O
A NN O O
) NN O O
PREMATURE NN O O
DISCONTINUATION NN O O
OF NN O O
PRADAXA NN O O
INCREASES NN O O
THE NN O O
RISK NN O O
OF NN O O
THROMBOTIC NN O O
EVENTS NN O O
, NN O O
( NN O O
B NN O O
) NN O O
SPINAL/EPIDURAL NN O O
HEMATOMA NN O O
( NN O O
A NN O O
) NN O O
PREMATURE NN O O
DISCONTINUATION NN O O
OF NN O O
PRADAXA NN O O
INCREASES NN O O
THE NN O O
RISK NN O O
OF NN O O
THROMBOTIC NN O O
EVENTSPremature NN O O
discontinuation NN O O
of NN O O
any NN O O
oral NN O O
anticoagulant NN O O
, NN O O
including NN O O
PRADAXA NN O O
, NN O O
increases NN O O
the NN O O
risk NN O O
of NN O O
thrombotic NN O O
events NN O O
. NN O O
If NN O O
anticoagulation NN O O
with NN O O
PRADAXA NN O O
is NN O O
discontinued NN O O
for NN O O
a NN O O
reason NN O O
other NN O O
than NN O O
pathological NN O O
bleeding NN O O
or NN O O
completion NN O O
of NN O O
a NN O O
course NN O O
of NN O O
therapy NN O O
, NN O O
consider NN O O
coverage NN O O
with NN O O
another NN O O
anticoagulant NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.4 NN O O
, NN O O
2.5 NN O O
, NN O O
2.6 NN O O
) NN O O
and NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
( NN O O
B NN O O
) NN O O
SPINAL/EPIDURAL NN O O
HEMATOMAEpidural NN O O
or NN O O
spinal NN B-AdverseReaction B-AdverseReaction
hematomas NN I-AdverseReaction I-AdverseReaction
may NN B-Factor B-Factor
occur NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
PRADAXA NN O O
who NN O O
are NN O O
receiving NN O O
neuraxial NN O O
anesthesia NN O O
or NN O O
undergoing NN O O
spinal NN O O
puncture NN O O
. NN O O
These NN O O
hematomas NN B-AdverseReaction B-AdverseReaction
may NN B-Factor B-Factor
result NN O O
in NN O O
long NN O O
- NN O O
term NN O O
or NN O O
permanent NN B-AdverseReaction B-AdverseReaction
paralysis NN I-AdverseReaction I-AdverseReaction
Consider NN O O
these NN O O
risks NN O O
when NN O O
scheduling NN O O
patients NN O O
for NN O O
spinal NN O O
procedures NN O O
. NN O O
Factors NN O O
that NN O O
can NN O O
increase NN O O
the NN O O
risk NN O O
of NN O O
developing NN O O
epidural NN O O
or NN O O
spinal NN O O
hematomas NN O O
in NN O O
these NN O O
patients NN O O
include NN O O
: NN O O
use NN O O
of NN O O
indwelling NN O O
epidural NN O O
catheters NN O O
concomitant NN O O
use NN O O
of NN O O
other NN O O
drugs NN O O
that NN O O
affect NN O O
hemostasis NN O O
, NN O O
such NN O O
as NN O O
non NN O O
- NN O O
steroidal NN O O
anti NN O O
- NN O O
inflammatory NN O O
drugs NN O O
( NN O O
NSAIDs NN O O
) NN O O
, NN O O
platelet NN O O
inhibitors NN O O
, NN O O
other NN O O
anticoagulants NN O O
a NN O O
history NN O O
of NN O O
traumatic NN O O
or NN O O
repeated NN O O
epidural NN O O
or NN O O
spinal NN O O
punctures NN O O
a NN O O
history NN O O
of NN O O
spinal NN O O
deformity NN O O
or NN O O
spinal NN O O
surgery NN O O
optimal NN O O
timing NN O O
between NN O O
the NN O O
administration NN O O
of NN O O
PRADAXA NN O O
and NN O O
neuraxial NN O O
procedures NN O O
is NN O O
not NN O O
known NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
. NN O O
Monitor NN O O
patients NN O O
frequently NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
neurological NN O O
impairment NN O O
. NN O O
If NN O O
neurological NN O O
compromise NN O O
is NN O O
noted NN O O
, NN O O
urgent NN O O
treatment NN O O
is NN O O
necessary NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
.Consider NN O O
the NN O O
benefits NN O O
and NN O O
risks NN O O
before NN O O
neuraxial NN O O
intervention NN O O
in NN O O
patients NN O O
anticoagulated NN O O
or NN O O
to NN O O
be NN O O
anticoagulated NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
. NN O O
EXCERPT NN O O
: NN O O
WARNING NN O O
: NN O O
( NN O O
A NN O O
) NN O O
PREMATURE NN O O
DISCONTINUATION NN O O
OF NN O O
PRADAXA NN O O
INCREASES NN O O
THE NN O O
RISK NN O O
OF NN O O
THROMBOTIC NN O O
EVENTS NN O O
, NN O O
and NN O O
( NN O O
B NN O O
) NN O O
SPINAL/EPIDURAL NN O O
HEMATOMA NN O O
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
( NN O O
A NN O O
) NN O O
PREMATURE NN O O
DISCONTINUATION NN O O
OF NN O O
PRADAXA NN O O
INCREASES NN O O
THE NN O O
RISK NN O O
OF NN O O
THROMBOTIC NN O O
EVENTS NN O O
: NN O O
Premature NN O O
discontinuation NN O O
of NN O O
any NN O O
oral NN O O
anticoagulant NN O O
, NN O O
including NN O O
PRADAXA NN O O
, NN O O
increases NN O O
the NN O O
risk NN O O
of NN O O
thrombotic NN O O
events NN O O
. NN O O
To NN O O
reduce NN O O
this NN O O
risk NN O O
, NN O O
consider NN O O
coverage NN O O
with NN O O
another NN O O
anticoagulant NN O O
if NN O O
PRADAXA NN O O
is NN O O
discontinued NN O O
for NN O O
a NN O O
reason NN O O
other NN O O
than NN O O
pathological NN O O
bleeding NN O O
or NN O O
completion NN O O
of NN O O
a NN O O
course NN O O
of NN O O
therapy NN O O
( NN O O
2.4 NN O O
, NN O O
2.5 NN O O
, NN O O
2.6 NN O O
, NN O O
5.1 NN O O
) NN O O
. NN O O
( NN O O
B NN O O
) NN O O
SPINAL/EPIDURAL NN O O
HEMATOMA NN O O
: NN O O
Epidural NN O O
or NN O O
spinal NN B-AdverseReaction B-AdverseReaction
hematomas NN I-AdverseReaction I-AdverseReaction
may NN B-Factor B-Factor
occur NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
PRADAXA NN O O
who NN O O
are NN O O
receiving NN O O
neuraxial NN O O
anesthesia NN O O
or NN O O
undergoing NN O O
spinal NN O O
puncture NN O O
. NN O O
These NN O O
hematomas NN B-AdverseReaction B-AdverseReaction
may NN B-Factor B-Factor
result NN O O
in NN O O
long NN O O
- NN O O
term NN O O
or NN O O
permanent NN B-AdverseReaction B-AdverseReaction
paralysis NN I-AdverseReaction I-AdverseReaction
( NN O O
5.3 NN O O
) NN O O
. NN O O
Monitor NN O O
patients NN O O
frequently NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
neurological NN O O
impairment NN O O
and NN O O
if NN O O
observed NN O O
, NN O O
treat NN O O
urgently NN O O
. NN O O
Consider NN O O
the NN O O
benefits NN O O
and NN O O
risks NN O O
before NN O O
neuraxial NN O O
intervention NN O O
in NN O O
patients NN O O
who NN O O
are NN O O
or NN O O
who NN O O
need NN O O
to NN O O
be NN O O
anticoagulated NN O O
( NN O O
5.3 NN O O
) NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Bleeding NN B-AdverseReaction B-AdverseReaction
PRADAXA NN O O
can NN B-Factor B-Factor
cause NN O O
serious NN B-Severity B-Severity
and NN O O
fatal NN B-AdverseReaction B-AdverseReaction
bleeding NN B-AdverseReaction B-AdverseReaction
( NN O O
5.2 NN O O
) NN O O
* NN O O
Bioprosthetic NN O O
heart NN O O
valves NN O O
: NN O O
PRADAXA NN O O
use NN O O
not NN O O
recommended NN O O
( NN O O
5.4 NN O O
) NN O O
5.1 NN O O
Increased NN O O
Risk NN O O
of NN O O
Thrombotic NN O O
Events NN O O
after NN O O
Premature NN O O
Discontinuation NN O O
Premature NN O O
discontinuation NN O O
of NN O O
any NN O O
oral NN O O
anticoagulant NN O O
, NN O O
including NN O O
PRADAXA NN O O
, NN O O
in NN O O
the NN O O
absence NN O O
of NN O O
adequate NN O O
alternative NN O O
anticoagulation NN O O
increases NN O O
the NN O O
risk NN O O
of NN O O
thrombotic NN O O
events NN O O
. NN O O
If NN O O
PRADAXA NN O O
is NN O O
discontinued NN O O
for NN O O
a NN O O
reason NN O O
other NN O O
than NN O O
pathological NN O O
bleeding NN O O
or NN O O
completion NN O O
of NN O O
a NN O O
course NN O O
of NN O O
therapy NN O O
, NN O O
consider NN O O
coverage NN O O
with NN O O
another NN O O
anticoagulant NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.4 NN O O
, NN O O
2.5 NN O O
, NN O O
2.6 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
Risk NN O O
of NN O O
Bleeding NN O O
PRADAXA NN O O
increases NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
and NN O O
can NN B-Factor B-Factor
cause NN O O
significant NN B-Severity B-Severity
and NN O O
, NN O O
sometimes NN O O
, NN O O
fatal NN B-AdverseReaction B-AdverseReaction
bleeding NN B-AdverseReaction B-AdverseReaction
Promptly NN O O
evaluate NN O O
any NN O O
signs NN O O
or NN O O
symptoms NN O O
of NN O O
blood NN O O
loss NN O O
( NN O O
e.g. NN O O
, NN O O
a NN O O
drop NN O O
in NN O O
hemoglobin NN O O
and/or NN O O
hematocrit NN O O
or NN O O
hypotension NN O O
) NN O O
. NN O O
Discontinue NN O O
PRADAXA NN O O
in NN O O
patients NN O O
with NN O O
active NN O O
pathological NN O O
bleeding NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
] NN O O
. NN O O
Risk NN O O
factors NN O O
for NN O O
bleeding NN O O
include NN O O
the NN O O
concomitant NN O O
use NN O O
of NN O O
other NN O O
drugs NN O O
that NN O O
increase NN O O
the NN O O
risk NN O O
of NN O O
bleeding NN O O
( NN O O
e.g. NN O O
, NN O O
anti NN O O
- NN O O
platelet NN O O
agents NN O O
, NN O O
heparin NN O O
, NN O O
fibrinolytic NN O O
therapy NN O O
, NN O O
and NN O O
chronic NN O O
use NN O O
of NN O O
NSAIDs NN O O
) NN O O
. NN O O
PRADAXA NN O O
's NN O O
anticoagulant NN O O
activity NN O O
and NN O O
half NN O O
- NN O O
life NN O O
are NN O O
increased NN O O
in NN O O
patients NN O O
with NN O O
renal NN O O
impairment NN O O
[ NN O O
see NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.2 NN O O
) NN O O
] NN O O
. NN O O
Reversal NN O O
of NN O O
Anticoagulant NN O O
Effect NN O O
: NN O O
A NN O O
specific NN O O
reversal NN O O
agent NN O O
for NN O O
dabigatran NN O O
is NN O O
not NN O O
available NN O O
. NN O O
Hemodialysis NN O O
can NN O O
remove NN O O
dabigatran NN O O
; NN O O
however NN O O
the NN O O
clinical NN O O
experience NN O O
supporting NN O O
the NN O O
use NN O O
of NN O O
hemodialysis NN O O
as NN O O
a NN O O
treatment NN O O
for NN O O
bleeding NN O O
is NN O O
limited NN O O
[ NN O O
see NN O O
Overdosage NN O O
( NN O O
10 NN O O
) NN O O
] NN O O
. NN O O
Activated NN O O
prothrombin NN O O
complex NN O O
concentrates NN O O
( NN O O
aPCCs NN O O
, NN O O
e.g. NN O O
, NN O O
FEIBA NN O O
) NN O O
, NN O O
or NN O O
recombinant NN O O
Factor NN O O
VIIa NN O O
, NN O O
or NN O O
concentrates NN O O
of NN O O
coagulation NN O O
factors NN O O
II NN O O
, NN O O
IX NN O O
or NN O O
X NN O O
may NN O O
be NN O O
considered NN O O
but NN O O
their NN O O
use NN O O
has NN O O
not NN O O
been NN O O
evaluated NN O O
in NN O O
clinical NN O O
trials NN O O
. NN O O
Protamine NN O O
sulfate NN O O
and NN O O
vitamin NN O O
K NN O O
are NN O O
not NN O O
expected NN O O
to NN O O
affect NN O O
the NN O O
anticoagulant NN O O
activity NN O O
of NN O O
dabigatran NN O O
. NN O O
Consider NN O O
administration NN O O
of NN O O
platelet NN O O
concentrates NN O O
in NN O O
cases NN O O
where NN O O
thrombocytopenia NN O O
is NN O O
present NN O O
or NN O O
long NN O O
- NN O O
acting NN O O
antiplatelet NN O O
drugs NN O O
have NN O O
been NN O O
used NN O O
. NN O O
5.3 NN O O
Spinal/Epidural NN O O
Anesthesia NN O O
or NN O O
Puncture NN O O
When NN O O
neuraxial NN O O
anesthesia NN O O
( NN O O
spinal/epidural NN O O
anesthesia NN O O
) NN O O
or NN O O
spinal NN O O
puncture NN O O
is NN O O
employed NN O O
, NN O O
patients NN O O
treated NN O O
with NN O O
anticoagulant NN B-DrugClass B-DrugClass
agents NN I-DrugClass I-DrugClass
are NN O O
at NN O O
risk NN O O
of NN O O
developing NN O O
an NN O O
epidural NN O O
or NN O O
spinal NN B-AdverseReaction B-AdverseReaction
hematoma NN I-AdverseReaction I-AdverseReaction
which NN O O
can NN O O
result NN O O
in NN O O
long NN O O
- NN O O
term NN O O
or NN O O
permanent NN B-AdverseReaction B-AdverseReaction
paralysis NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Boxed NN O O
Warning NN O O
] NN O O
. NN O O
To NN O O
reduce NN O O
the NN O O
potential NN O O
risk NN O O
of NN O O
bleeding NN O O
associated NN O O
with NN O O
the NN O O
concurrent NN O O
use NN O O
of NN O O
dabigatran NN O O
and NN O O
epidural NN O O
or NN O O
spinal NN O O
anesthesia/analgesia NN O O
or NN O O
spinal NN O O
puncture NN O O
, NN O O
consider NN O O
the NN O O
pharmacokinetic NN O O
profile NN O O
of NN O O
dabigatran NN O O
[ NN O O
see NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.3 NN O O
) NN O O
] NN O O
. NN O O
Placement NN O O
or NN O O
removal NN O O
of NN O O
an NN O O
epidural NN O O
catheter NN O O
or NN O O
lumbar NN O O
puncture NN O O
is NN O O
best NN O O
performed NN O O
when NN O O
the NN O O
anticoagulant NN O O
effect NN O O
of NN O O
dabigatran NN O O
is NN O O
low NN O O
; NN O O
however NN O O
, NN O O
the NN O O
exact NN O O
timing NN O O
to NN O O
reach NN O O
a NN O O
sufficiently NN O O
low NN O O
anticoagulant NN O O
effect NN O O
in NN O O
each NN O O
patient NN O O
is NN O O
not NN O O
known NN O O
. NN O O
Should NN O O
the NN O O
physician NN O O
decide NN O O
to NN O O
administer NN O O
anticoagulation NN O O
in NN O O
the NN O O
context NN O O
of NN O O
epidural NN O O
or NN O O
spinal NN O O
anesthesia/analgesia NN O O
or NN O O
lumbar NN O O
puncture NN O O
, NN O O
monitor NN O O
frequently NN O O
to NN O O
detect NN O O
any NN O O
signs NN O O
or NN O O
symptoms NN O O
of NN O O
neurological NN O O
impairment NN O O
, NN O O
such NN O O
as NN O O
midline NN O O
back NN O O
pain NN O O
, NN O O
sensory NN O O
and NN O O
motor NN O O
deficits NN O O
( NN O O
numbness NN O O
, NN O O
tingling NN O O
, NN O O
or NN O O
weakness NN O O
in NN O O
lower NN O O
limbs NN O O
) NN O O
, NN O O
bowel NN O O
and/or NN O O
bladder NN O O
dysfunction NN O O
. NN O O
Instruct NN O O
patients NN O O
to NN O O
immediately NN O O
report NN O O
if NN O O
they NN O O
experience NN O O
any NN O O
of NN O O
the NN O O
above NN O O
signs NN O O
or NN O O
symptoms NN O O
. NN O O
If NN O O
signs NN O O
or NN O O
symptoms NN O O
of NN O O
spinal NN O O
hematoma NN O O
are NN O O
suspected NN O O
, NN O O
initiate NN O O
urgent NN O O
diagnosis NN O O
and NN O O
treatment NN O O
including NN O O
consideration NN O O
for NN O O
spinal NN O O
cord NN O O
decompression NN O O
even NN O O
though NN O O
such NN O O
treatment NN O O
may NN O O
not NN O O
prevent NN O O
or NN O O
reverse NN O O
neurological NN O O
sequelae NN O O
. NN O O
5.4 NN O O
Thromboembolic NN O O
and NN O O
Bleeding NN O O
Events NN O O
in NN O O
Patients NN O O
with NN O O
Prosthetic NN O O
Heart NN O O
Valves NN O O
The NN O O
safety NN O O
and NN O O
efficacy NN O O
of NN O O
PRADAXA NN O O
in NN O O
patients NN O O
with NN O O
bileaflet NN O O
mechanical NN O O
prosthetic NN O O
heart NN O O
valves NN O O
was NN O O
evaluated NN O O
in NN O O
the NN O O
RE NN O O
- NN O O
ALIGN NN O O
trial NN O O
, NN O O
in NN O O
which NN O O
patients NN O O
with NN O O
bileaflet NN O O
mechanical NN O O
prosthetic NN O O
heart NN O O
valves NN O O
( NN O O
recently NN O O
implanted NN O O
or NN O O
implanted NN O O
more NN O O
than NN O O
three NN O O
months NN O O
prior NN O O
to NN O O
enrollment NN O O
) NN O O
were NN O O
randomized NN O O
to NN O O
dose NN O O
adjusted NN O O
warfarin NN O O
or NN O O
150 NN O O
, NN O O
220 NN O O
, NN O O
or NN O O
300 NN O O
mg NN O O
of NN O O
PRADAXA NN O O
twice NN O O
a NN O O
day NN O O
. NN O O
RE NN O O
- NN O O
ALIGN NN O O
was NN O O
terminated NN O O
early NN O O
due NN O O
to NN O O
the NN O O
occurrence NN O O
of NN O O
significantly NN O O
more NN O O
thromboembolic NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
( NN O O
valve NN O O
thrombosis NN O O
, NN O O
stroke NN O O
, NN O O
transient NN B-AdverseReaction B-AdverseReaction
ischemic NN I-AdverseReaction I-AdverseReaction
attack NN I-AdverseReaction I-AdverseReaction
and NN O O
myocardial NN B-AdverseReaction B-AdverseReaction
infarction NN I-AdverseReaction I-AdverseReaction
and NN O O
an NN O O
excess NN O O
of NN O O
major NN B-Severity B-Severity
bleeding NN B-AdverseReaction B-AdverseReaction
( NN O O
predominantly NN O O
post NN O O
- NN O O
operative NN O O
pericardial NN B-AdverseReaction B-AdverseReaction
effusions NN I-AdverseReaction I-AdverseReaction
requiring NN O O
intervention NN O O
for NN O O
hemodynamic NN O O
compromise NN O O
) NN O O
in NN O O
the NN O O
PRADAXA NN O O
treatment NN O O
arm NN O O
as NN O O
compared NN O O
to NN O O
the NN O O
warfarin NN O O
treatment NN O O
arm NN O O
. NN O O
These NN O O
bleeding NN B-AdverseReaction B-AdverseReaction
and NN O O
thromboembolic NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
were NN O O
seen NN O O
both NN O O
in NN O O
patients NN O O
who NN O O
were NN O O
initiated NN O O
on NN O O
PRADAXA NN O O
post NN O O
- NN O O
operatively NN O O
within NN O O
three NN O O
days NN O O
of NN O O
mechanical NN O O
bileaflet NN O O
valve NN O O
implantation NN O O
, NN O O
as NN O O
well NN O O
as NN O O
in NN O O
patients NN O O
whose NN O O
valves NN O O
had NN O O
been NN O O
implanted NN O O
more NN O O
than NN O O
three NN O O
months NN O O
prior NN O O
to NN O O
enrollment NN O O
. NN O O
Therefore NN O O
, NN O O
the NN O O
use NN O O
of NN O O
PRADAXA NN O O
is NN O O
contraindicated NN O O
in NN O O
patients NN O O
with NN O O
mechanical NN O O
prosthetic NN O O
valves NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
use NN O O
of NN O O
PRADAXA NN O O
for NN O O
the NN O O
prophylaxis NN O O
of NN O O
thromboembolic NN O O
events NN O O
in NN O O
patients NN O O
with NN O O
atrial NN O O
fibrillation NN O O
in NN O O
the NN O O
setting NN O O
of NN O O
other NN O O
forms NN O O
of NN O O
valvular NN O O
heart NN O O
disease NN O O
, NN O O
including NN O O
the NN O O
presence NN O O
of NN O O
a NN O O
bioprosthetic NN O O
heart NN O O
valve NN O O
, NN O O
has NN O O
not NN O O
been NN O O
studied NN O O
and NN O O
is NN O O
not NN O O
recommended NN O O
. NN O O
5.5 NN O O
Effect NN O O
of NN O O
P NN O O
- NN O O
gp NN O O
Inducers NN O O
and NN O O
Inhibitors NN O O
on NN O O
Dabigatran NN O O
Exposure NN O O
The NN O O
concomitant NN O O
use NN O O
of NN O O
PRADAXA NN O O
with NN O O
P NN O O
- NN O O
gp NN O O
inducers NN O O
( NN O O
e.g. NN O O
, NN O O
rifampin NN O O
) NN O O
reduces NN O O
exposure NN O O
to NN O O
dabigatran NN O O
and NN O O
should NN O O
generally NN O O
be NN O O
avoided NN O O
[ NN O O
see NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.3 NN O O
) NN O O
] NN O O
. NN O O
P NN O O
- NN O O
gp NN O O
inhibition NN O O
and NN O O
impaired NN O O
renal NN O O
function NN O O
are NN O O
the NN O O
major NN O O
independent NN O O
factors NN O O
that NN O O
result NN O O
in NN O O
increased NN O O
exposure NN O O
to NN O O
dabigatran NN O O
[ NN O O
see NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.3 NN O O
) NN O O
] NN O O
. NN O O
Concomitant NN O O
use NN O O
of NN O O
P NN O O
- NN O O
gp NN O O
inhibitors NN O O
in NN O O
patients NN O O
with NN O O
renal NN O O
impairment NN O O
is NN O O
expected NN O O
to NN O O
produce NN O O
increased NN O O
exposure NN O O
of NN O O
dabigatran NN O O
compared NN O O
to NN O O
that NN O O
seen NN O O
with NN O O
either NN O O
factor NN O O
alone NN O O
. NN O O
Reduction NN O O
of NN O O
Risk NN O O
of NN O O
Stroke NN O O
and NN O O
Systemic NN O O
Embolism NN O O
in NN O O
Non NN O O
- NN O O
valvular NN O O
Atrial NN O O
Fibrillation NN O O
Reduce NN O O
the NN O O
dose NN O O
of NN O O
PRADAXA NN O O
to NN O O
75 NN O O
mg NN O O
twice NN O O
daily NN O O
when NN O O
dronedarone NN O O
or NN O O
systemic NN O O
ketoconazole NN O O
is NN O O
coadministered NN O O
with NN O O
PRADAXA NN O O
in NN O O
patients NN O O
with NN O O
moderate NN O O
renal NN O O
impairment NN O O
( NN O O
CrCl NN O O
30 NN O O
- NN O O
50 NN O O
mL/min NN O O
) NN O O
. NN O O
Avoid NN O O
use NN O O
of NN O O
PRADAXA NN O O
and NN O O
P NN O O
- NN O O
gp NN O O
inhibitors NN O O
in NN O O
patients NN O O
with NN O O
severe NN O O
renal NN O O
impairment NN O O
( NN O O
CrCl NN O O
15 NN O O
- NN O O
30 NN O O
mL/min NN O O
) NN O O
[ NN O O
see NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.1 NN O O
) NN O O
and NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.6 NN O O
) NN O O
] NN O O
. NN O O
Treatment NN O O
and NN O O
Reduction NN O O
in NN O O
the NN O O
Risk NN O O
of NN O O
Recurrence NN O O
of NN O O
Deep NN O O
Venous NN O O
Thrombosis NN O O
and NN O O
Pulmonary NN O O
Embolism NN O O
Avoid NN O O
use NN O O
of NN O O
PRADAXA NN O O
and NN O O
concomitant NN O O
P NN O O
- NN O O
gp NN O O
inhibitors NN O O
in NN O O
patients NN O O
with NN O O
CrCl NN O O
< NN O O
50 NN O O
mL/min NN O O
[ NN O O
see NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.2 NN O O
) NN O O
and NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.6 NN O O
) NN O O
] NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
important NN O O
adverse NN O O
reactions NN O O
are NN O O
described NN O O
below NN O O
and NN O O
elsewhere NN O O
in NN O O
the NN O O
labeling NN O O
: NN O O
* NN O O
Hypotension NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Impairment NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
Renal NN I-AdverseReaction I-AdverseReaction
Function NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
Hyperkalemia NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
* NN O O
Hypoglycemia NN B-AdverseReaction B-AdverseReaction
with NN O O
Concomitant NN O O
Use NN O O
with NN O O
Insulin NN O O
and NN O O
Insulin NN O O
Secretagogues NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
* NN O O
Genital NN B-AdverseReaction B-AdverseReaction
Mycotic NN I-AdverseReaction I-AdverseReaction
Infections NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
* NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.6 NN O O
) NN O O
] NN O O
* NN O O
Bone NN B-AdverseReaction B-AdverseReaction
Fracture NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.7 NN O O
) NN O O
] NN O O
* NN O O
Increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
Low NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Density NN I-AdverseReaction I-AdverseReaction
Lipoprotein NN I-AdverseReaction I-AdverseReaction
( NN O O
LDL NN O O
- NN O O
C NN O O
) NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.8 NN O O
) NN O O
] NN O O
* NN O O
Most NN O O
common NN O O
adverse NN O O
reactions NN O O
associated NN O O
with NN O O
INVOKANA NN O O
( NN O O
5 NN O O
% NN O O
or NN O O
greater NN O O
incidence NN O O
) NN O O
: NN O O
female NN B-AdverseReaction B-AdverseReaction
genital NN I-AdverseReaction I-AdverseReaction
mycotic NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
and NN O O
increased NN B-AdverseReaction B-AdverseReaction
urination NN I-AdverseReaction I-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
EXCERPT NN O O
: NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Janssen NN O O
Pharmaceuticals NN O O
, NN O O
Inc. NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
526 NN O O
- NN O O
7736 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Studies NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
the NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O
Pool NN O O
of NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Trials NN O O
The NN O O
data NN O O
in NN O O
Table NN O O
1 NN O O
is NN O O
derived NN O O
from NN O O
four NN O O
26-week NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
. NN O O
In NN O O
one NN O O
trial NN O O
INVOKANA NN O O
was NN O O
used NN O O
as NN O O
monotherapy NN O O
and NN O O
in NN O O
three NN O O
trials NN O O
INVOKANA NN O O
was NN O O
used NN O O
as NN O O
add NN O O
- NN O O
on NN O O
therapy NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
. NN O O
These NN O O
data NN O O
reflect NN O O
exposure NN O O
of NN O O
1667 NN O O
patients NN O O
to NN O O
INVOKANA NN O O
and NN O O
a NN O O
mean NN O O
duration NN O O
of NN O O
exposure NN O O
to NN O O
INVOKANA NN O O
of NN O O
24 NN O O
weeks NN O O
. NN O O
Patients NN O O
received NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
( NN O O
N=833 NN O O
) NN O O
, NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
( NN O O
N=834 NN O O
) NN O O
or NN O O
placebo NN O O
( NN O O
N=646 NN O O
) NN O O
once NN O O
daily NN O O
. NN O O
The NN O O
mean NN O O
age NN O O
of NN O O
the NN O O
population NN O O
was NN O O
56 NN O O
years NN O O
and NN O O
2 NN O O
% NN O O
were NN O O
older NN O O
than NN O O
75 NN O O
years NN O O
of NN O O
age NN O O
. NN O O
Fifty NN O O
percent NN O O
( NN O O
50 NN O O
% NN O O
) NN O O
of NN O O
the NN O O
population NN O O
was NN O O
male NN O O
and NN O O
72 NN O O
% NN O O
were NN O O
Caucasian NN O O
, NN O O
12 NN O O
% NN O O
were NN O O
Asian NN O O
, NN O O
and NN O O
5 NN O O
% NN O O
were NN O O
Black NN O O
or NN O O
African NN O O
American NN O O
. NN O O
At NN O O
baseline NN O O
the NN O O
population NN O O
had NN O O
diabetes NN O O
for NN O O
an NN O O
average NN O O
of NN O O
7.3 NN O O
years NN O O
, NN O O
had NN O O
a NN O O
mean NN O O
HbA1C NN O O
of NN O O
8.0 NN O O
% NN O O
and NN O O
20 NN O O
% NN O O
had NN O O
established NN O O
microvascular NN O O
complications NN O O
of NN O O
diabetes NN O O
. NN O O
Baseline NN O O
renal NN O O
function NN O O
was NN O O
normal NN O O
or NN O O
mildly NN O O
impaired NN O O
( NN O O
mean NN O O
eGFR NN O O
88 NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
) NN O O
. NN O O
Table NN O O
1 NN O O
shows NN O O
common NN O O
adverse NN O O
reactions NN O O
associated NN O O
with NN O O
the NN O O
use NN O O
of NN O O
INVOKANA. NN O O
These NN O O
adverse NN O O
reactions NN O O
were NN O O
not NN O O
present NN O O
at NN O O
baseline NN O O
, NN O O
occurred NN O O
more NN O O
commonly NN O O
on NN O O
INVOKANA NN O O
than NN O O
on NN O O
placebo NN O O
, NN O O
and NN O O
occurred NN O O
in NN O O
at NN O O
least NN O O
2 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
either NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
or NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
. NN O O
Table NN O O
1 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
From NN O O
Pool NN O O
of NN O O
Four NN O O
26-Week NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Studies NN O O
Reported NN O O
in NN O O
>= NN O O
2 NN O O
% NN O O
of NN O O
INVOKANA NN O O
- NN O O
Treated NN O O
PatientsThe NN O O
four NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
included NN O O
one NN O O
monotherapy NN O O
trial NN O O
and NN O O
three NN O O
add NN O O
- NN O O
on NN O O
combination NN O O
trials NN O O
with NN O O
metformin NN O O
, NN O O
metformin NN O O
and NN O O
sulfonylurea NN O O
, NN O O
or NN O O
metformin NN O O
and NN O O
pioglitazone NN O O
. NN O O
Adverse NN O O
Reaction NN O O
PlaceboN=646 NN O O
INVOKANA NN O O
100 NN O O
mgN=833 NN O O
INVOKANA NN O O
300 NN O O
mgN=834 NN O O
Female NN B-AdverseReaction B-AdverseReaction
genital NN I-AdverseReaction I-AdverseReaction
mycotic NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
3.2 NN O O
% NN O O
10.4 NN O O
% NN O O
11.4 NN O O
% NN O O
Urinary NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
4.0 NN O O
% NN O O
5.9 NN O O
% NN O O
4.3 NN O O
% NN O O
Increased NN B-AdverseReaction B-AdverseReaction
urination NN I-AdverseReaction I-AdverseReaction
0.8 NN O O
% NN O O
5.3 NN O O
% NN O O
4.6 NN O O
% NN O O
Male NN B-AdverseReaction B-AdverseReaction
genital NN I-AdverseReaction I-AdverseReaction
mycotic NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
0.6 NN O O
% NN O O
4.2 NN O O
% NN O O
3.7 NN O O
% NN O O
Vulvovaginal NN B-AdverseReaction B-AdverseReaction
pruritus NN I-AdverseReaction I-AdverseReaction
0.0 NN O O
% NN O O
1.6 NN O O
% NN O O
3.0 NN O O
% NN O O
Thirst NN B-AdverseReaction B-AdverseReaction
0.2 NN O O
% NN O O
2.8 NN O O
% NN O O
2.3 NN O O
% NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
0.9 NN O O
% NN O O
1.8 NN O O
% NN O O
2.3 NN O O
% NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
1.5 NN O O
% NN O O
2.2 NN O O
% NN O O
2.3 NN O O
% NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
was NN O O
also NN O O
more NN O O
commonly NN O O
reported NN O O
in NN O O
patients NN O O
taking NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
( NN O O
1.8 NN O O
% NN O O
) NN O O
, NN O O
300 NN O O
mg NN O O
( NN O O
1.7 NN O O
% NN O O
) NN O O
than NN O O
in NN O O
patients NN O O
taking NN O O
placebo NN O O
( NN O O
0.8 NN O O
% NN O O
) NN O O
. NN O O
Pool NN O O
of NN O O
Placebo- NN O O
and NN O O
Active NN O O
- NN O O
Controlled NN O O
Trials NN O O
The NN O O
occurrence NN O O
of NN O O
adverse NN O O
reactions NN O O
for NN O O
canagliflozin NN O O
was NN O O
evaluated NN O O
in NN O O
a NN O O
larger NN O O
pool NN O O
of NN O O
patients NN O O
participating NN O O
in NN O O
placebo- NN O O
and NN O O
active NN O O
- NN O O
controlled NN O O
trials NN O O
. NN O O
The NN O O
data NN O O
combined NN O O
eight NN O O
clinical NN O O
trials NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
and NN O O
reflect NN O O
exposure NN O O
of NN O O
6177 NN O O
patients NN O O
to NN O O
INVOKANA. NN O O
The NN O O
mean NN O O
duration NN O O
of NN O O
exposure NN O O
to NN O O
INVOKANA NN O O
was NN O O
38 NN O O
weeks NN O O
with NN O O
1832 NN O O
individuals NN O O
exposed NN O O
to NN O O
INVOKANA NN O O
for NN O O
greater NN O O
than NN O O
50 NN O O
weeks NN O O
. NN O O
Patients NN O O
received NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
( NN O O
N=3092 NN O O
) NN O O
, NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
( NN O O
N=3085 NN O O
) NN O O
or NN O O
comparator NN O O
( NN O O
N=3262 NN O O
) NN O O
once NN O O
daily NN O O
. NN O O
The NN O O
mean NN O O
age NN O O
of NN O O
the NN O O
population NN O O
was NN O O
60 NN O O
years NN O O
and NN O O
5 NN O O
% NN O O
were NN O O
older NN O O
than NN O O
75 NN O O
years NN O O
of NN O O
age NN O O
. NN O O
Fifty NN O O
- NN O O
eight NN O O
percent NN O O
( NN O O
58 NN O O
% NN O O
) NN O O
of NN O O
the NN O O
population NN O O
was NN O O
male NN O O
and NN O O
73 NN O O
% NN O O
were NN O O
Caucasian NN O O
, NN O O
16 NN O O
% NN O O
were NN O O
Asian NN O O
, NN O O
and NN O O
4 NN O O
% NN O O
were NN O O
Black NN O O
or NN O O
African NN O O
American NN O O
. NN O O
At NN O O
baseline NN O O
, NN O O
the NN O O
population NN O O
had NN O O
diabetes NN O O
for NN O O
an NN O O
average NN O O
of NN O O
11 NN O O
years NN O O
, NN O O
had NN O O
a NN O O
mean NN O O
HbA1C NN O O
of NN O O
8.0 NN O O
% NN O O
and NN O O
33 NN O O
% NN O O
had NN O O
established NN O O
microvascular NN O O
complications NN O O
of NN O O
diabetes NN O O
. NN O O
Baseline NN O O
renal NN O O
function NN O O
was NN O O
normal NN O O
or NN O O
mildly NN O O
impaired NN O O
( NN O O
mean NN O O
eGFR NN O O
81 NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
) NN O O
. NN O O
The NN O O
types NN O O
and NN O O
frequency NN O O
of NN O O
common NN O O
adverse NN O O
reactions NN O O
observed NN O O
in NN O O
the NN O O
pool NN O O
of NN O O
eight NN O O
clinical NN O O
trials NN O O
were NN O O
consistent NN O O
with NN O O
those NN O O
listed NN O O
in NN O O
Table NN O O
1 NN O O
. NN O O
In NN O O
this NN O O
pool NN O O
, NN O O
INVOKANA NN O O
was NN O O
also NN O O
associated NN O O
with NN O O
the NN O O
adverse NN O O
reactions NN O O
of NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
( NN O O
1.7 NN O O
% NN O O
with NN O O
comparator NN O O
, NN O O
2.2 NN O O
% NN O O
with NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
, NN O O
and NN O O
2.0 NN O O
% NN O O
with NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
) NN O O
and NN O O
loss NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
strength NN I-AdverseReaction I-AdverseReaction
or NN O O
energy NN O O
( NN O O
i.e. NN O O
, NN O O
asthenia NN B-AdverseReaction B-AdverseReaction
( NN O O
0.6 NN O O
% NN O O
with NN O O
comparator NN O O
, NN O O
0.7 NN O O
% NN O O
with NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
, NN O O
and NN O O
1.1 NN O O
% NN O O
with NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
) NN O O
. NN O O
In NN O O
the NN O O
pool NN O O
of NN O O
eight NN O O
clinical NN O O
trials NN O O
, NN O O
the NN O O
incidence NN O O
rate NN O O
of NN O O
pancreatitis NN O O
( NN O O
acute NN O O
or NN O O
chronic NN O O
) NN O O
was NN O O
0.9 NN O O
, NN O O
2.7 NN O O
, NN O O
and NN O O
0.9 NN O O
per NN O O
1000 NN O O
patient NN O O
- NN O O
years NN O O
of NN O O
exposure NN O O
to NN O O
comparator NN O O
, NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
, NN O O
and NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
, NN O O
respectively NN O O
. NN O O
In NN O O
the NN O O
pool NN O O
of NN O O
eight NN O O
clinical NN O O
trials NN O O
, NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
( NN O O
including NN O O
erythema NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
pruritus NN B-AdverseReaction B-AdverseReaction
urticaria NN B-AdverseReaction B-AdverseReaction
and NN O O
angioedema NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
3.0 NN O O
% NN O O
, NN O O
3.8 NN O O
% NN O O
, NN O O
and NN O O
4.2 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
comparator NN O O
, NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
, NN O O
and NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
, NN O O
respectively NN O O
. NN O O
Five NN O O
patients NN O O
experienced NN O O
serious NN B-Severity B-Severity
adverse NN O O
reactions NN O O
of NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
with NN O O
INVOKANA NN O O
, NN O O
which NN O O
included NN O O
4 NN O O
patients NN O O
with NN O O
urticaria NN B-AdverseReaction B-AdverseReaction
and NN O O
1 NN O O
patient NN O O
with NN O O
a NN O O
diffuse NN B-AdverseReaction B-AdverseReaction
rash NN I-AdverseReaction I-AdverseReaction
and NN O O
urticaria NN B-AdverseReaction B-AdverseReaction
occurring NN O O
within NN O O
hours NN O O
of NN O O
exposure NN O O
to NN O O
INVOKANA. NN O O
Among NN O O
these NN O O
patients NN O O
, NN O O
2 NN O O
patients NN O O
discontinued NN O O
INVOKANA. NN O O
One NN O O
patient NN O O
with NN O O
urticaria NN B-AdverseReaction B-AdverseReaction
had NN O O
recurrence NN O O
when NN O O
INVOKANA NN O O
was NN O O
re NN O O
- NN O O
initiated NN O O
. NN O O
Photosensitivity NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
( NN O O
including NN O O
photosensitivity NN B-AdverseReaction B-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
polymorphic NN B-AdverseReaction B-AdverseReaction
light NN I-AdverseReaction I-AdverseReaction
eruption NN I-AdverseReaction I-AdverseReaction
and NN O O
sunburn NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
0.1 NN O O
% NN O O
, NN O O
0.2 NN O O
% NN O O
, NN O O
and NN O O
0.2 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
comparator NN O O
, NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
, NN O O
and NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
, NN O O
respectively NN O O
. NN O O
Other NN O O
adverse NN O O
reactions NN O O
occurring NN O O
more NN O O
frequently NN O O
on NN O O
INVOKANA NN O O
than NN O O
on NN O O
comparator NN O O
were NN O O
: NN O O
Volume NN O O
Depletion NN O O
- NN O O
Related NN O O
Adverse NN O O
Reactions NN O O
INVOKANA NN O O
results NN O O
in NN O O
an NN O O
osmotic NN B-AdverseReaction B-AdverseReaction
diuresis NN I-AdverseReaction I-AdverseReaction
which NN O O
may NN B-Factor B-Factor
lead NN O O
to NN O O
reductions NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
intravascular NN I-AdverseReaction I-AdverseReaction
volume NN I-AdverseReaction I-AdverseReaction
In NN O O
clinical NN O O
studies NN O O
, NN O O
treatment NN O O
with NN O O
INVOKANA NN O O
was NN O O
associated NN O O
with NN O O
a NN O O
dose NN O O
- NN O O
dependent NN O O
increase NN O O
in NN O O
the NN O O
incidence NN O O
of NN O O
volume NN B-AdverseReaction B-AdverseReaction
depletion NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
( NN O O
e.g. NN O O
, NN O O
hypotension NN B-AdverseReaction B-AdverseReaction
postural NN B-AdverseReaction B-AdverseReaction
dizziness NN I-AdverseReaction I-AdverseReaction
orthostatic NN B-AdverseReaction B-AdverseReaction
hypotension NN I-AdverseReaction I-AdverseReaction
syncope NN B-AdverseReaction B-AdverseReaction
and NN O O
dehydration NN B-AdverseReaction B-AdverseReaction
An NN O O
increased NN O O
incidence NN O O
was NN O O
observed NN O O
in NN O O
patients NN O O
on NN O O
the NN O O
300 NN O O
mg NN O O
dose NN O O
. NN O O
The NN O O
three NN O O
factors NN O O
associated NN O O
with NN O O
the NN O O
largest NN O O
increase NN O O
in NN O O
volume NN B-AdverseReaction B-AdverseReaction
depletion NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
were NN O O
the NN O O
use NN O O
of NN O O
loop NN O O
diuretics NN O O
, NN O O
moderate NN O O
renal NN O O
impairment NN O O
( NN O O
eGFR NN O O
30 NN O O
to NN O O
less NN O O
than NN O O
60 NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
) NN O O
, NN O O
and NN O O
age NN O O
75 NN O O
years NN O O
and NN O O
older NN O O
( NN O O
Table NN O O
2 NN O O
) NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
, NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
, NN O O
and NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.5 NN O O
and NN O O
8.6 NN O O
) NN O O
] NN O O
. NN O O
Table NN O O
2 NN O O
: NN O O
Proportion NN O O
of NN O O
Patients NN O O
With NN O O
at NN O O
Least NN O O
One NN O O
Volume NN B-AdverseReaction B-AdverseReaction
Depletion NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Related NN I-AdverseReaction I-AdverseReaction
Adverse NN I-AdverseReaction I-AdverseReaction
Reaction NN I-AdverseReaction I-AdverseReaction
( NN O O
Pooled NN O O
Results NN O O
from NN O O
8 NN O O
Clinical NN O O
Trials NN O O
) NN O O
Baseline NN O O
Characteristic NN O O
Comparator NN O O
Group NN O O
% NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
% NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
% NN O O
Overall NN O O
population NN O O
1.5 NN O O
% NN O O
2.3 NN O O
% NN O O
3.4 NN O O
% NN O O
75 NN O O
years NN O O
of NN O O
age NN O O
and NN O O
older NN O O
2.6 NN O O
% NN O O
4.9 NN O O
% NN O O
8.7 NN O O
% NN O O
eGFR NN B-AdverseReaction B-AdverseReaction
less NN I-AdverseReaction I-AdverseReaction
than NN I-AdverseReaction I-AdverseReaction
60 NN I-AdverseReaction I-AdverseReaction
mL/min/1.73 NN I-AdverseReaction I-AdverseReaction
m NN I-AdverseReaction I-AdverseReaction
2 NN I-AdverseReaction I-AdverseReaction
2.5 NN O O
% NN O O
4.7 NN O O
% NN O O
8.1 NN O O
% NN O O
Use NN O O
of NN O O
loop NN O O
diuretic NN O O
4.7 NN O O
% NN O O
3.2 NN O O
% NN O O
8.8 NN O O
% NN O O
Falls NN O O
In NN O O
a NN O O
pool NN O O
of NN O O
nine NN O O
clinical NN O O
trials NN O O
with NN O O
mean NN O O
duration NN O O
of NN O O
exposure NN O O
to NN O O
INVOKANA NN O O
of NN O O
85 NN O O
weeks NN O O
, NN O O
the NN O O
proportion NN O O
of NN O O
patients NN O O
who NN O O
experienced NN O O
falls NN B-AdverseReaction B-AdverseReaction
was NN O O
1.3 NN O O
% NN O O
, NN O O
1.5 NN O O
% NN O O
, NN O O
and NN O O
2.1 NN O O
% NN O O
with NN O O
comparator NN O O
, NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
, NN O O
and NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
, NN O O
respectively NN O O
. NN O O
The NN O O
higher NN O O
risk NN B-Factor B-Factor
of NN O O
falls NN B-AdverseReaction B-AdverseReaction
for NN O O
patients NN O O
treated NN O O
with NN O O
INVOKANA NN O O
was NN O O
observed NN O O
within NN O O
the NN O O
first NN O O
few NN O O
weeks NN O O
of NN O O
treatment NN O O
. NN O O
Impairment NN O O
in NN O O
Renal NN O O
Function NN O O
INVOKANA NN O O
is NN O O
associated NN O O
with NN O O
a NN O O
dose NN O O
- NN O O
dependent NN O O
increase NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
and NN O O
a NN O O
concomitant NN O O
fall NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
estimated NN I-AdverseReaction I-AdverseReaction
GFR NN I-AdverseReaction I-AdverseReaction
( NN O O
Table NN O O
3 NN O O
) NN O O
. NN O O
Patients NN O O
with NN O O
moderate NN O O
renal NN O O
impairment NN O O
at NN O O
baseline NN O O
had NN O O
larger NN O O
mean NN O O
changes NN O O
. NN O O
Table NN O O
3 NN O O
: NN O O
Changes NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
Serum NN I-AdverseReaction I-AdverseReaction
Creatinine NN I-AdverseReaction I-AdverseReaction
and NN O O
eGFR NN O O
Associated NN O O
with NN O O
INVOKANA NN O O
in NN O O
the NN O O
Pool NN O O
of NN O O
Four NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Trials NN O O
and NN O O
Moderate NN O O
Renal NN O O
Impairment NN O O
Trial NN O O
PlaceboN=646 NN O O
INVOKANA NN O O
100 NN O O
mgN=833 NN O O
INVOKANA NN O O
300 NN O O
mgN=834 NN O O
Pool NN O O
of NN O O
Four NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Trials NN O O
Baseline NN O O
Creatinine NN O O
( NN O O
mg/dL NN O O
) NN O O
0.84 NN O O
0.82 NN O O
0.82 NN O O
eGFR NN O O
( NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
) NN O O
87.0 NN O O
88.3 NN O O
88.8 NN O O
Week NN O O
6 NN O O
Change NN O O
Creatinine NN O O
( NN O O
mg/dL NN O O
) NN O O
0.01 NN O O
0.03 NN O O
0.05 NN O O
eGFR NN O O
( NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
) NN O O
-1.6 NN O O
-3.8 NN O O
-5.0 NN O O
End NN O O
of NN O O
Treatment NN O O
Change NN O O
Creatinine NN O O
( NN O O
mg/dL NN O O
) NN O O
0.01 NN O O
0.02 NN O O
0.03 NN O O
eGFR NN O O
( NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
) NN O O
-1.6 NN O O
-2.3 NN O O
-3.4 NN O O
PlaceboN=90 NN O O
INVOKANA NN O O
100 NN O O
mgN=90 NN O O
INVOKANA NN O O
300 NN O O
mgN=89 NN O O
Moderate NN O O
Renal NN O O
Impairment NN O O
Trial NN O O
Baseline NN O O
Creatinine NN O O
( NN O O
mg/dL NN O O
) NN O O
1.61 NN O O
1.62 NN O O
1.63 NN O O
eGFR NN O O
( NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
) NN O O
40.1 NN O O
39.7 NN O O
38.5 NN O O
Week NN O O
3 NN O O
Change NN O O
Creatinine NN O O
( NN O O
mg/dL NN O O
) NN O O
0.03 NN O O
0.18 NN O O
0.28 NN O O
eGFR NN O O
( NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
) NN O O
-0.7 NN O O
-4.6 NN O O
-6.2 NN O O
End NN O O
of NN O O
Treatment NN O O
Change NN O O
Creatinine NN O O
( NN O O
mg/dL NN O O
) NN O O
0.07 NN O O
0.16 NN O O
0.18 NN O O
eGFR NN O O
( NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
) NN O O
-1.5 NN O O
-3.6 NN O O
-4.0 NN O O
In NN O O
the NN O O
pool NN O O
of NN O O
four NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
where NN O O
patients NN O O
had NN O O
normal NN O O
or NN O O
mildly NN O O
impaired NN O O
baseline NN O O
renal NN O O
function NN O O
, NN O O
the NN O O
proportion NN O O
of NN O O
patients NN O O
who NN O O
experienced NN O O
at NN O O
least NN O O
one NN O O
event NN O O
of NN O O
significant NN B-Severity B-Severity
renal NN B-AdverseReaction B-AdverseReaction
function NN I-AdverseReaction I-AdverseReaction
decline NN I-AdverseReaction I-AdverseReaction
defined NN O O
as NN O O
an NN O O
eGFR NN B-AdverseReaction B-AdverseReaction
below NN I-AdverseReaction I-AdverseReaction
80 NN I-AdverseReaction I-AdverseReaction
mL/min/1.73 NN I-AdverseReaction I-AdverseReaction
m NN I-AdverseReaction I-AdverseReaction
2 NN I-AdverseReaction I-AdverseReaction
and NN O O
30 NN O O
% NN O O
lower NN O O
than NN O O
baseline NN O O
, NN O O
was NN O O
2.1 NN O O
% NN O O
with NN O O
placebo NN O O
, NN O O
2.0 NN O O
% NN O O
with NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
, NN O O
and NN O O
4.1 NN O O
% NN O O
with NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
. NN O O
At NN O O
the NN O O
end NN O O
of NN O O
treatment NN O O
, NN O O
0.5 NN O O
% NN O O
with NN O O
placebo NN O O
, NN O O
0.7 NN O O
% NN O O
with NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
, NN O O
and NN O O
1.4 NN O O
% NN O O
with NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
had NN O O
a NN O O
significant NN B-Severity B-Severity
renal NN B-AdverseReaction B-AdverseReaction
function NN I-AdverseReaction I-AdverseReaction
decline NN I-AdverseReaction I-AdverseReaction
In NN O O
a NN O O
trial NN O O
carried NN O O
out NN O O
in NN O O
patients NN O O
with NN O O
moderate NN O O
renal NN O O
impairment NN O O
with NN O O
a NN O O
baseline NN O O
eGFR NN O O
of NN O O
30 NN O O
to NN O O
less NN O O
than NN O O
50 NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
( NN O O
mean NN O O
baseline NN O O
eGFR NN O O
39 NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
) NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14.3 NN O O
) NN O O
] NN O O
, NN O O
the NN O O
proportion NN O O
of NN O O
patients NN O O
who NN O O
experienced NN O O
at NN O O
least NN O O
one NN O O
event NN O O
of NN O O
significant NN B-Severity B-Severity
renal NN B-AdverseReaction B-AdverseReaction
function NN I-AdverseReaction I-AdverseReaction
decline NN I-AdverseReaction I-AdverseReaction
defined NN O O
as NN O O
an NN O O
eGFR NN B-AdverseReaction B-AdverseReaction
30 NN I-AdverseReaction I-AdverseReaction
% NN I-AdverseReaction I-AdverseReaction
lower NN I-AdverseReaction I-AdverseReaction
than NN I-AdverseReaction I-AdverseReaction
baseline NN I-AdverseReaction I-AdverseReaction
was NN O O
6.9 NN O O
% NN O O
with NN O O
placebo NN O O
, NN O O
18 NN O O
% NN O O
with NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
, NN O O
and NN O O
22.5 NN O O
% NN O O
with NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
. NN O O
At NN O O
the NN O O
end NN O O
of NN O O
treatment NN O O
, NN O O
4.6 NN O O
% NN O O
with NN O O
placebo NN O O
, NN O O
3.4 NN O O
% NN O O
with NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
, NN O O
and NN O O
2.2 NN O O
% NN O O
with NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
had NN O O
a NN O O
significant NN B-Severity B-Severity
renal NN B-AdverseReaction B-AdverseReaction
function NN I-AdverseReaction I-AdverseReaction
decline NN I-AdverseReaction I-AdverseReaction
In NN O O
a NN O O
pooled NN O O
population NN O O
of NN O O
patients NN O O
with NN O O
moderate NN O O
renal NN O O
impairment NN O O
( NN O O
N=1085 NN O O
) NN O O
with NN O O
baseline NN O O
eGFR NN O O
of NN O O
30 NN O O
to NN O O
less NN O O
than NN O O
60 NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
( NN O O
mean NN O O
baseline NN O O
eGFR NN O O
48 NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
) NN O O
, NN O O
the NN O O
overall NN O O
incidence NN O O
of NN O O
these NN O O
events NN O O
was NN O O
lower NN O O
than NN O O
in NN O O
the NN O O
dedicated NN O O
trial NN O O
but NN O O
a NN O O
dose NN O O
- NN O O
dependent NN O O
increase NN O O
in NN O O
incident NN O O
episodes NN O O
of NN O O
significant NN B-Severity B-Severity
renal NN B-AdverseReaction B-AdverseReaction
function NN I-AdverseReaction I-AdverseReaction
decline NN I-AdverseReaction I-AdverseReaction
compared NN O O
to NN O O
placebo NN O O
was NN O O
still NN O O
observed NN O O
. NN O O
Use NN O O
of NN O O
INVOKANA NN O O
has NN O O
been NN O O
associated NN O O
with NN O O
an NN O O
increased NN O O
incidence NN O O
of NN O O
renal NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
( NN O O
e.g. NN O O
, NN O O
increased NN B-AdverseReaction B-AdverseReaction
blood NN I-AdverseReaction I-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
decreased NN B-AdverseReaction B-AdverseReaction
glomerular NN I-AdverseReaction I-AdverseReaction
filtration NN I-AdverseReaction I-AdverseReaction
rate NN I-AdverseReaction I-AdverseReaction
renal NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
and NN O O
acute NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
particularly NN O O
in NN O O
patients NN O O
with NN O O
moderate NN O O
renal NN O O
impairment NN O O
. NN O O
In NN O O
the NN O O
pooled NN O O
analysis NN O O
of NN O O
patients NN O O
with NN O O
moderate NN O O
renal NN O O
impairment NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
renal NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
was NN O O
3.7 NN O O
% NN O O
with NN O O
placebo NN O O
, NN O O
8.9 NN O O
% NN O O
with NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
, NN O O
and NN O O
9.3 NN O O
% NN O O
with NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
. NN O O
Discontinuations NN O O
due NN O O
to NN O O
renal NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
related NN I-AdverseReaction I-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
1.0 NN O O
% NN O O
with NN O O
placebo NN O O
, NN O O
1.2 NN O O
% NN O O
with NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
, NN O O
and NN O O
1.6 NN O O
% NN O O
with NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
Genital NN O O
Mycotic NN O O
Infections NN O O
In NN O O
the NN O O
pool NN O O
of NN O O
four NN O O
placebo NN O O
- NN O O
controlled NN O O
clinical NN O O
trials NN O O
, NN O O
female NN B-AdverseReaction B-AdverseReaction
genital NN I-AdverseReaction I-AdverseReaction
mycotic NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
( NN O O
e.g. NN O O
, NN O O
vulvovaginal NN B-AdverseReaction B-AdverseReaction
mycotic NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
vulvovaginal NN B-AdverseReaction B-AdverseReaction
candidiasis NN I-AdverseReaction I-AdverseReaction
and NN O O
vulvovaginitis NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
3.2 NN O O
% NN O O
, NN O O
10.4 NN O O
% NN O O
, NN O O
and NN O O
11.4 NN O O
% NN O O
of NN O O
females NN O O
treated NN O O
with NN O O
placebo NN O O
, NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
, NN O O
and NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
, NN O O
respectively NN O O
. NN O O
Patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
genital NN O O
mycotic NN O O
infections NN O O
were NN O O
more NN O O
likely NN O O
to NN O O
develop NN O O
genital NN B-AdverseReaction B-AdverseReaction
mycotic NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
on NN O O
INVOKANA. NN O O
Female NN O O
patients NN O O
who NN O O
developed NN O O
genital NN O O
mycotic NN O O
infections NN O O
on NN O O
INVOKANA NN O O
were NN O O
more NN O O
likely NN O O
to NN O O
experience NN O O
recurrence NN O O
and NN O O
require NN O O
treatment NN O O
with NN O O
oral NN O O
or NN O O
topical NN O O
antifungal NN O O
agents NN O O
and NN O O
anti NN O O
- NN O O
microbial NN O O
agents NN O O
. NN O O
In NN O O
females NN O O
, NN O O
discontinuation NN O O
due NN O O
to NN O O
genital NN O O
mycotic NN O O
infections NN O O
occurred NN O O
in NN O O
0 NN O O
% NN O O
and NN O O
0.7 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
placebo NN O O
and NN O O
INVOKANA NN O O
, NN O O
respectively NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
. NN O O
In NN O O
the NN O O
pool NN O O
of NN O O
four NN O O
placebo NN O O
- NN O O
controlled NN O O
clinical NN O O
trials NN O O
, NN O O
male NN B-AdverseReaction B-AdverseReaction
genital NN I-AdverseReaction I-AdverseReaction
mycotic NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
( NN O O
e.g. NN O O
, NN O O
candidal NN B-AdverseReaction B-AdverseReaction
balanitis NN I-AdverseReaction I-AdverseReaction
balanoposthitis NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
0.6 NN O O
% NN O O
, NN O O
4.2 NN O O
% NN O O
, NN O O
and NN O O
3.7 NN O O
% NN O O
of NN O O
males NN O O
treated NN O O
with NN O O
placebo NN O O
, NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
, NN O O
and NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
, NN O O
respectively NN O O
. NN O O
Male NN B-AdverseReaction B-AdverseReaction
genital NN I-AdverseReaction I-AdverseReaction
mycotic NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
occurred NN O O
more NN O O
commonly NN O O
in NN O O
uncircumcised NN O O
males NN O O
and NN O O
in NN O O
males NN O O
with NN O O
a NN O O
prior NN O O
history NN O O
of NN O O
balanitis NN O O
or NN O O
balanoposthitis NN O O
. NN O O
Male NN O O
patients NN O O
who NN O O
developed NN O O
genital NN O O
mycotic NN O O
infections NN O O
on NN O O
INVOKANA NN O O
were NN O O
more NN O O
likely NN O O
to NN O O
experience NN O O
recurrent NN O O
infections NN O O
( NN O O
22 NN O O
% NN O O
on NN O O
INVOKANA NN O O
versus NN O O
none NN O O
on NN O O
placebo NN O O
) NN O O
, NN O O
and NN O O
require NN O O
treatment NN O O
with NN O O
oral NN O O
or NN O O
topical NN O O
antifungal NN O O
agents NN O O
and NN O O
anti NN O O
- NN O O
microbial NN O O
agents NN O O
than NN O O
patients NN O O
on NN O O
comparators NN O O
. NN O O
In NN O O
males NN O O
, NN O O
discontinuations NN O O
due NN O O
to NN O O
genital NN O O
mycotic NN O O
infections NN O O
occurred NN O O
in NN O O
0 NN O O
% NN O O
and NN O O
0.5 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
placebo NN O O
and NN O O
INVOKANA NN O O
, NN O O
respectively NN O O
. NN O O
In NN O O
the NN O O
pooled NN O O
analysis NN O O
of NN O O
8 NN O O
controlled NN O O
trials NN O O
, NN O O
phimosis NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
0.3 NN O O
% NN O O
of NN O O
uncircumcised NN O O
male NN O O
patients NN O O
treated NN O O
with NN O O
INVOKANA NN O O
and NN O O
0.2 NN O O
% NN O O
required NN O O
circumcision NN O O
to NN O O
treat NN O O
the NN O O
phimosis NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
. NN O O
Hypoglycemia NN O O
In NN O O
all NN O O
clinical NN O O
trials NN O O
, NN O O
hypoglycemia NN O O
was NN O O
defined NN O O
as NN O O
any NN O O
event NN O O
regardless NN O O
of NN O O
symptoms NN O O
, NN O O
where NN O O
biochemical NN O O
hypoglycemia NN O O
was NN O O
documented NN O O
( NN O O
any NN O O
glucose NN O O
value NN O O
below NN O O
or NN O O
equal NN O O
to NN O O
70 NN O O
mg/dL NN O O
) NN O O
. NN O O
Severe NN O O
hypoglycemia NN O O
was NN O O
defined NN O O
as NN O O
an NN O O
event NN O O
consistent NN O O
with NN O O
hypoglycemia NN O O
where NN O O
the NN O O
patient NN O O
required NN O O
the NN O O
assistance NN O O
of NN O O
another NN O O
person NN O O
to NN O O
recover NN O O
, NN O O
lost NN O O
consciousness NN O O
, NN O O
or NN O O
experienced NN O O
a NN O O
seizure NN O O
( NN O O
regardless NN O O
of NN O O
whether NN O O
biochemical NN O O
documentation NN O O
of NN O O
a NN O O
low NN O O
glucose NN O O
value NN O O
was NN O O
obtained NN O O
) NN O O
. NN O O
In NN O O
individual NN O O
clinical NN O O
trials NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
, NN O O
episodes NN O O
of NN O O
hypoglycemia NN B-AdverseReaction B-AdverseReaction
occurred NN O O
at NN O O
a NN O O
higher NN O O
rate NN O O
when NN O O
INVOKANA NN O O
was NN O O
co NN O O
- NN O O
administered NN O O
with NN O O
insulin NN O O
or NN O O
sulfonylureas NN O O
( NN O O
Table NN O O
4 NN O O
) NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
. NN O O
Table NN O O
4 NN O O
: NN O O
Incidence NN O O
of NN O O
Hypoglycemia NN B-AdverseReaction B-AdverseReaction
of NN O O
patients NN O O
experiencing NN O O
at NN O O
least NN O O
one NN O O
event NN O O
of NN O O
hypoglycemia NN B-AdverseReaction B-AdverseReaction
based NN O O
on NN O O
either NN O O
biochemically NN O O
documented NN O O
episodes NN O O
or NN O O
severe NN B-Severity B-Severity
hypoglycemic NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
in NN O O
the NN O O
intent NN O O
- NN O O
to NN O O
- NN O O
treat NN O O
population NN O O
in NN O O
Controlled NN O O
Clinical NN O O
Studies NN O O
Monotherapy(26 NN O O
weeks NN O O
) NN O O
Placebo(N=192 NN O O
) NN O O
INVOKANA NN O O
100 NN O O
mg(N=195 NN O O
) NN O O
INVOKANA NN O O
300 NN O O
mg(N=197 NN O O
) NN O O
Overall NN O O
[ NN O O
N NN O O
( NN O O
% NN O O
) NN O O
] NN O O
5 NN O O
( NN O O
2.6 NN O O
) NN O O
7 NN O O
( NN O O
3.6 NN O O
) NN O O
6 NN O O
( NN O O
3.0 NN O O
) NN O O
In NN O O
Combination NN O O
with NN O O
Metformin(26 NN O O
weeks NN O O
) NN O O
Placebo NN O O
+ NN O O
Metformin(N=183 NN O O
) NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
+ NN O O
Metformin(N=368 NN O O
) NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
+ NN O O
Metformin(N=367 NN O O
) NN O O
Overall NN O O
[ NN O O
N NN O O
( NN O O
% NN O O
) NN O O
] NN O O
3 NN O O
( NN O O
1.6 NN O O
) NN O O
16 NN O O
( NN O O
4.3 NN O O
) NN O O
17 NN O O
( NN O O
4.6 NN O O
) NN O O
Severe NN O O
[ NN O O
N NN O O
( NN O O
% NN O O
) NN O O
] NN O O
0 NN O O
( NN O O
0 NN O O
) NN O O
1 NN O O
( NN O O
0.3 NN O O
) NN O O
1 NN O O
( NN O O
0.3 NN O O
) NN O O
In NN O O
Combination NN O O
with NN O O
Metformin(52 NN O O
weeks NN O O
) NN O O
Glimepiride NN O O
+ NN O O
Metformin(N=482 NN O O
) NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
+ NN O O
Metformin(N=483 NN O O
) NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
+ NN O O
Metformin(N=485 NN O O
) NN O O
Overall NN O O
[ NN O O
N NN O O
( NN O O
% NN O O
) NN O O
] NN O O
165 NN O O
( NN O O
34.2 NN O O
) NN O O
27 NN O O
( NN O O
5.6 NN O O
) NN O O
24 NN O O
( NN O O
4.9 NN O O
) NN O O
Severe NN O O
[ NN O O
N NN O O
( NN O O
% NN O O
) NN O O
] NN O O
15 NN O O
( NN O O
3.1 NN O O
) NN O O
2 NN O O
( NN O O
0.4 NN O O
) NN O O
3 NN O O
( NN O O
0.6 NN O O
) NN O O
In NN O O
Combination NN O O
with NN O O
Sulfonylurea(18 NN O O
weeks NN O O
) NN O O
Placebo NN O O
+ NN O O
Sulfonylurea(N=69 NN O O
) NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
+ NN O O
Sulfonylurea(N=74 NN O O
) NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
+ NN O O
Sulfonylurea(N=72 NN O O
) NN O O
Overall NN O O
[ NN O O
N NN O O
( NN O O
% NN O O
) NN O O
] NN O O
4 NN O O
( NN O O
5.8 NN O O
) NN O O
3 NN O O
( NN O O
4.1 NN O O
) NN O O
9 NN O O
( NN O O
12.5 NN O O
) NN O O
In NN O O
Combination NN O O
with NN O O
Metformin NN O O
+ NN O O
Sulfonylurea(26 NN O O
weeks NN O O
) NN O O
Placebo NN O O
+ NN O O
Metformin NN O O
+ NN O O
Sulfonylurea(N=156 NN O O
) NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
+ NN O O
Metformin NN O O
+ NN O O
Sulfonylurea(N=157 NN O O
) NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
+ NN O O
Metformin NN O O
+ NN O O
Sulfonylurea(N=156 NN O O
) NN O O
Overall NN O O
[ NN O O
N NN O O
( NN O O
% NN O O
) NN O O
] NN O O
24 NN O O
( NN O O
15.4 NN O O
) NN O O
43 NN O O
( NN O O
27.4 NN O O
) NN O O
47 NN O O
( NN O O
30.1 NN O O
) NN O O
Severe NN O O
[ NN O O
N NN O O
( NN O O
% NN O O
) NN O O
] NN O O
1 NN O O
( NN O O
0.6 NN O O
) NN O O
1 NN O O
( NN O O
0.6 NN O O
) NN O O
0 NN O O
In NN O O
Combination NN O O
with NN O O
Metformin NN O O
+ NN O O
Sulfonylurea(52 NN O O
weeks NN O O
) NN O O
Sitagliptin NN O O
+ NN O O
Metformin NN O O
+ NN O O
Sulfonylurea(N=378 NN O O
) NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
+ NN O O
Metformin NN O O
+ NN O O
Sulfonylurea(N=377 NN O O
) NN O O
Overall NN O O
[ NN O O
N NN O O
( NN O O
% NN O O
) NN O O
] NN O O
154 NN O O
( NN O O
40.7 NN O O
) NN O O
163 NN O O
( NN O O
43.2 NN O O
) NN O O
Severe NN O O
[ NN O O
N NN O O
( NN O O
% NN O O
) NN O O
] NN O O
13 NN O O
( NN O O
3.4 NN O O
) NN O O
15 NN O O
( NN O O
4.0 NN O O
) NN O O
In NN O O
Combination NN O O
with NN O O
Metformin NN O O
+ NN O O
Pioglitazone(26 NN O O
weeks NN O O
) NN O O
Placebo NN O O
+ NN O O
Metformin NN O O
+ NN O O
Pioglitazone(N=115 NN O O
) NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
+ NN O O
Metformin NN O O
+ NN O O
Pioglitazone(N=113 NN O O
) NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
+ NN O O
Metformin NN O O
+ NN O O
Pioglitazone(N=114 NN O O
) NN O O
Overall NN O O
[ NN O O
N NN O O
( NN O O
% NN O O
) NN O O
] NN O O
3 NN O O
( NN O O
2.6 NN O O
) NN O O
3 NN O O
( NN O O
2.7 NN O O
) NN O O
6 NN O O
( NN O O
5.3 NN O O
) NN O O
In NN O O
Combination NN O O
with NN O O
Insulin(18 NN O O
weeks NN O O
) NN O O
Placebo(N=565 NN O O
) NN O O
INVOKANA NN O O
100 NN O O
mg(N=566 NN O O
) NN O O
INVOKANA NN O O
300 NN O O
mg(N=587 NN O O
) NN O O
Overall NN O O
[ NN O O
N NN O O
( NN O O
% NN O O
) NN O O
] NN O O
208 NN O O
( NN O O
36.8 NN O O
) NN O O
279 NN O O
( NN O O
49.3 NN O O
) NN O O
285 NN O O
( NN O O
48.6 NN O O
) NN O O
Severe NN O O
[ NN O O
N NN O O
( NN O O
% NN O O
) NN O O
] NN O O
14 NN O O
( NN O O
2.5 NN O O
) NN O O
10 NN O O
( NN O O
1.8 NN O O
) NN O O
16 NN O O
( NN O O
2.7 NN O O
) NN O O
Bone NN O O
Fracture NN O O
The NN O O
occurrence NN O O
of NN O O
bone NN B-AdverseReaction B-AdverseReaction
fractures NN I-AdverseReaction I-AdverseReaction
was NN O O
evaluated NN O O
in NN O O
a NN O O
pool NN O O
of NN O O
nine NN O O
clinical NN O O
trials NN O O
with NN O O
a NN O O
mean NN O O
duration NN O O
of NN O O
exposure NN O O
to NN O O
INVOKANA NN O O
of NN O O
85 NN O O
weeks NN O O
. NN O O
The NN O O
incidence NN O O
rates NN O O
of NN O O
adjudicated NN O O
bone NN B-AdverseReaction B-AdverseReaction
fractures NN I-AdverseReaction I-AdverseReaction
were NN O O
1.1 NN O O
, NN O O
1.4 NN O O
, NN O O
and NN O O
1.5 NN O O
per NN O O
100 NN O O
patient NN O O
- NN O O
years NN O O
of NN O O
exposure NN O O
in NN O O
the NN O O
comparator NN O O
, NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
, NN O O
and NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
groups NN O O
, NN O O
respectively NN O O
. NN O O
Fractures NN B-AdverseReaction B-AdverseReaction
were NN O O
observed NN O O
as NN O O
early NN O O
as NN O O
12 NN O O
weeks NN O O
after NN O O
treatment NN O O
initiation NN O O
and NN O O
were NN O O
more NN O O
likely NN O O
to NN O O
be NN O O
low NN B-Severity B-Severity
trauma NN I-Severity I-Severity
( NN O O
e.g. NN O O
, NN O O
fall NN O O
from NN O O
no NN O O
more NN O O
than NN O O
standing NN O O
height NN O O
) NN O O
, NN O O
and NN O O
affect NN O O
the NN O O
upper NN O O
extremities NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.7 NN O O
) NN O O
] NN O O
. NN O O
Laboratory NN O O
and NN O O
Imaging NN O O
Tests NN O O
Increases NN O O
in NN O O
Serum NN O O
Potassium NN O O
In NN O O
a NN O O
pooled NN O O
population NN O O
of NN O O
patients NN O O
( NN O O
N=723 NN O O
) NN O O
with NN O O
moderate NN O O
renal NN O O
impairment NN O O
( NN O O
eGFR NN O O
45 NN O O
to NN O O
less NN O O
than NN O O
60 NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
) NN O O
, NN O O
increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
potassium NN I-AdverseReaction I-AdverseReaction
to NN O O
greater NN O O
than NN O O
5.4 NN B-Severity B-Severity
mEq/L NN I-Severity I-Severity
and NN O O
15 NN B-Severity B-Severity
% NN I-Severity I-Severity
above NN I-Severity I-Severity
baseline NN I-Severity I-Severity
occurred NN O O
in NN O O
5.3 NN O O
% NN O O
, NN O O
5.0 NN O O
% NN O O
, NN O O
and NN O O
8.8 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
placebo NN O O
, NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
, NN O O
and NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
, NN O O
respectively NN O O
. NN O O
Severe NN O O
elevations NN O O
( NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
6.5 NN O O
mEq/L NN O O
) NN O O
occurred NN O O
in NN O O
0.4 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
placebo NN O O
, NN O O
no NN O O
patients NN O O
treated NN O O
with NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
, NN O O
and NN O O
1.3 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
. NN O O
In NN O O
these NN O O
patients NN O O
, NN O O
increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
potassium NN I-AdverseReaction I-AdverseReaction
were NN O O
more NN O O
commonly NN O O
seen NN O O
in NN O O
those NN O O
with NN O O
elevated NN O O
potassium NN O O
at NN O O
baseline NN O O
. NN O O
Among NN O O
patients NN O O
with NN O O
moderate NN O O
renal NN O O
impairment NN O O
, NN O O
approximately NN O O
84 NN O O
% NN O O
were NN O O
taking NN O O
medications NN O O
that NN O O
interfere NN O O
with NN O O
potassium NN O O
excretion NN O O
, NN O O
such NN O O
as NN O O
potassium NN O O
- NN O O
sparing NN O O
diuretics NN O O
, NN O O
angiotensin NN O O
- NN O O
converting NN O O
- NN O O
enzyme NN O O
inhibitors NN O O
, NN O O
and NN O O
angiotensin NN O O
- NN O O
receptor NN O O
blockers NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
and NN O O
5.3 NN O O
) NN O O
and NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.6 NN O O
) NN O O
] NN O O
. NN O O
Increases NN O O
in NN O O
Serum NN O O
Magnesium NN O O
Dose NN O O
- NN O O
related NN O O
increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
magnesium NN I-AdverseReaction I-AdverseReaction
were NN O O
observed NN O O
early NN O O
after NN O O
initiation NN O O
of NN O O
INVOKANA NN O O
( NN O O
within NN O O
6 NN O O
weeks NN O O
) NN O O
and NN O O
remained NN O O
elevated NN O O
throughout NN O O
treatment NN O O
. NN O O
In NN O O
the NN O O
pool NN O O
of NN O O
four NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
, NN O O
the NN O O
mean NN O O
percent NN O O
change NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
magnesium NN I-AdverseReaction I-AdverseReaction
levels NN I-AdverseReaction I-AdverseReaction
was NN O O
8.1 NN O O
% NN O O
and NN O O
9.3 NN O O
% NN O O
with NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
and NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
, NN O O
respectively NN O O
, NN O O
compared NN O O
to NN O O
-0.6 NN O O
% NN O O
with NN O O
placebo NN O O
. NN O O
In NN O O
a NN O O
trial NN O O
of NN O O
patients NN O O
with NN O O
moderate NN O O
renal NN O O
impairment NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14.3 NN O O
) NN O O
] NN O O
, NN O O
serum NN B-AdverseReaction B-AdverseReaction
magnesium NN I-AdverseReaction I-AdverseReaction
levels NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
by NN O O
0.2 NN O O
% NN O O
, NN O O
9.2 NN O O
% NN O O
, NN O O
and NN O O
14.8 NN O O
% NN O O
with NN O O
placebo NN O O
, NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
, NN O O
and NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
, NN O O
respectively NN O O
. NN O O
Increases NN O O
in NN O O
Serum NN O O
Phosphate NN O O
Dose NN O O
- NN O O
related NN O O
increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
phosphate NN I-AdverseReaction I-AdverseReaction
levels NN O O
were NN O O
observed NN O O
with NN O O
INVOKANA. NN O O
In NN O O
the NN O O
pool NN O O
of NN O O
four NN O O
placebo NN O O
controlled NN O O
trials NN O O
, NN O O
the NN O O
mean NN O O
percent NN O O
change NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
phosphate NN I-AdverseReaction I-AdverseReaction
levels NN I-AdverseReaction I-AdverseReaction
were NN O O
3.6 NN O O
% NN O O
and NN O O
5.1 NN O O
% NN O O
with NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
and NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
, NN O O
respectively NN O O
, NN O O
compared NN O O
to NN O O
1.5 NN O O
% NN O O
with NN O O
placebo NN O O
. NN O O
In NN O O
a NN O O
trial NN O O
of NN O O
patients NN O O
with NN O O
moderate NN O O
renal NN O O
impairment NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14.3 NN O O
) NN O O
] NN O O
, NN O O
the NN O O
mean NN O O
serum NN B-AdverseReaction B-AdverseReaction
phosphate NN I-AdverseReaction I-AdverseReaction
levels NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
by NN O O
1.2 NN O O
% NN O O
, NN O O
5.0 NN O O
% NN O O
, NN O O
and NN O O
9.3 NN O O
% NN O O
with NN O O
placebo NN O O
, NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
, NN O O
and NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
, NN O O
respectively NN O O
. NN O O
Increases NN O O
in NN O O
Low NN O O
- NN O O
Density NN O O
Lipoprotein NN O O
Cholesterol NN O O
( NN O O
LDL NN O O
- NN O O
C NN O O
) NN O O
and NN O O
non NN O O
- NN O O
High NN O O
- NN O O
Density NN O O
Lipoprotein NN O O
Cholesterol NN O O
( NN O O
non NN O O
- NN O O
HDL NN O O
- NN O O
C NN O O
) NN O O
In NN O O
the NN O O
pool NN O O
of NN O O
four NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
, NN O O
dose NN O O
- NN O O
related NN O O
increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
LDL NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
with NN O O
INVOKANA NN O O
were NN O O
observed NN O O
. NN O O
Mean NN O O
changes NN O O
( NN O O
percent NN O O
changes NN O O
) NN O O
from NN O O
baseline NN O O
in NN O O
LDL NN O O
- NN O O
C NN O O
relative NN O O
to NN O O
placebo NN O O
were NN O O
4.4 NN B-Severity B-Severity
mg/dL NN I-Severity I-Severity
( NN O O
4.5 NN O O
% NN O O
) NN O O
and NN O O
8.2 NN B-Severity B-Severity
mg/dL NN I-Severity I-Severity
( NN O O
8.0 NN O O
% NN O O
) NN O O
with NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
and NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
, NN O O
respectively NN O O
. NN O O
The NN O O
mean NN O O
baseline NN O O
LDL NN O O
- NN O O
C NN O O
levels NN O O
were NN O O
104 NN O O
to NN O O
110 NN O O
mg/dL NN O O
across NN O O
treatment NN O O
groups NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.8 NN O O
) NN O O
] NN O O
. NN O O
Dose NN O O
- NN O O
related NN O O
increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
non NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
HDL NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
with NN O O
INVOKANA NN O O
were NN O O
observed NN O O
. NN O O
Mean NN O O
changes NN O O
( NN O O
percent NN O O
changes NN O O
) NN O O
from NN O O
baseline NN O O
in NN O O
non NN O O
- NN O O
HDL NN O O
- NN O O
C NN O O
relative NN O O
to NN O O
placebo NN O O
were NN O O
2.1 NN B-Severity B-Severity
mg/dL NN I-Severity I-Severity
( NN O O
1.5 NN O O
% NN O O
) NN O O
and NN O O
5.1 NN B-Severity B-Severity
mg/dL NN I-Severity I-Severity
( NN O O
3.6 NN O O
% NN O O
) NN O O
with NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
and NN O O
300 NN O O
mg NN O O
, NN O O
respectively NN O O
. NN O O
The NN O O
mean NN O O
baseline NN O O
non NN O O
- NN O O
HDL NN O O
- NN O O
C NN O O
levels NN O O
were NN O O
140 NN O O
to NN O O
147 NN O O
mg/dL NN O O
across NN O O
treatment NN O O
groups NN O O
. NN O O
Increases NN O O
in NN O O
Hemoglobin NN O O
In NN O O
the NN O O
pool NN O O
of NN O O
four NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
, NN O O
mean NN O O
changes NN O O
( NN O O
percent NN O O
changes NN O O
) NN O O
from NN O O
baseline NN O O
in NN O O
hemoglobin NN O O
were NN O O
-0.18 NN O O
g/dL NN O O
( NN O O
-1.1 NN O O
% NN O O
) NN O O
with NN O O
placebo NN O O
, NN O O
0.47 NN B-Severity B-Severity
g/dL NN I-Severity I-Severity
( NN O O
3.5 NN O O
% NN O O
) NN O O
with NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
, NN O O
and NN O O
0.51 NN B-Severity B-Severity
g/dL NN I-Severity I-Severity
( NN O O
3.8 NN O O
% NN O O
) NN O O
with NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
. NN O O
The NN O O
mean NN O O
baseline NN O O
hemoglobin NN O O
value NN O O
was NN O O
approximately NN O O
14.1 NN O O
g/dL NN O O
across NN O O
treatment NN O O
groups NN O O
. NN O O
At NN O O
the NN O O
end NN O O
of NN O O
treatment NN O O
, NN O O
0.8 NN O O
% NN O O
, NN O O
4.0 NN O O
% NN O O
, NN O O
and NN O O
2.7 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
placebo NN O O
, NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
, NN O O
and NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
, NN O O
respectively NN O O
, NN O O
had NN O O
hemoglobin NN B-AdverseReaction B-AdverseReaction
above NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
upper NN I-AdverseReaction I-AdverseReaction
limit NN I-AdverseReaction I-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
normal NN I-AdverseReaction I-AdverseReaction
Decreases NN O O
in NN O O
Bone NN O O
Mineral NN O O
Density NN O O
Bone NN O O
mineral NN O O
density NN O O
( NN O O
BMD NN O O
) NN O O
was NN O O
measured NN O O
by NN O O
dual NN O O
- NN O O
energy NN O O
X NN O O
- NN O O
ray NN O O
absorptiometry NN O O
in NN O O
a NN O O
clinical NN O O
trial NN O O
of NN O O
714 NN O O
older NN O O
adults NN O O
( NN O O
mean NN O O
age NN O O
64 NN O O
years NN O O
) NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14.3 NN O O
) NN O O
] NN O O
. NN O O
At NN O O
2 NN O O
years NN O O
, NN O O
patients NN O O
randomized NN O O
to NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
and NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
had NN O O
placebo NN O O
- NN O O
corrected NN O O
declines NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
BMD NN I-AdverseReaction I-AdverseReaction
at NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
total NN I-AdverseReaction I-AdverseReaction
hip NN I-AdverseReaction I-AdverseReaction
of NN O O
0.9 NN B-Severity B-Severity
% NN I-Severity I-Severity
and NN O O
1.2 NN B-Severity B-Severity
% NN I-Severity I-Severity
respectively NN O O
, NN O O
and NN O O
at NN O O
the NN O O
lumbar NN O O
spine NN O O
of NN O O
0.3 NN B-Severity B-Severity
% NN I-Severity I-Severity
and NN O O
0.7 NN B-Severity B-Severity
% NN I-Severity I-Severity
respectively NN O O
. NN O O
Additionally NN O O
, NN O O
placebo NN O O
- NN O O
adjusted NN O O
BMD NN O O
declines NN O O
were NN O O
0.1 NN B-Severity B-Severity
% NN I-Severity I-Severity
at NN O O
the NN O O
femoral NN O O
neck NN O O
for NN O O
both NN O O
INVOKANA NN O O
doses NN O O
and NN O O
0.4 NN B-Severity B-Severity
% NN I-Severity I-Severity
at NN O O
the NN O O
distal NN O O
forearm NN O O
for NN O O
patients NN O O
randomized NN O O
to NN O O
INVOKANA NN O O
300 NN O O
mg NN O O
. NN O O
The NN O O
placebo NN O O
- NN O O
adjusted NN O O
change NN O O
at NN O O
the NN O O
distal NN O O
forearm NN O O
for NN O O
patients NN O O
randomized NN O O
to NN O O
INVOKANA NN O O
100 NN O O
mg NN O O
was NN O O
0 NN O O
% NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Hypotension NN B-AdverseReaction B-AdverseReaction
Before NN O O
initiating NN O O
INVOKANA NN O O
, NN O O
assess NN O O
volume NN O O
status NN O O
and NN O O
correct NN O O
hypovolemia NN O O
in NN O O
patients NN O O
with NN O O
renal NN O O
impairment NN O O
, NN O O
the NN O O
elderly NN O O
, NN O O
in NN O O
patients NN O O
with NN O O
low NN O O
systolic NN O O
blood NN O O
pressure NN O O
, NN O O
or NN O O
if NN O O
on NN O O
diuretics NN O O
, NN O O
ACEi NN O O
, NN O O
or NN O O
ARB. NN O O
Monitor NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
during NN O O
therapy NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Impairment NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
Renal NN I-AdverseReaction I-AdverseReaction
Function NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
renal NN O O
function NN O O
during NN O O
therapy NN O O
. NN O O
More NN O O
frequent NN O O
monitoring NN O O
is NN O O
recommended NN O O
in NN O O
patients NN O O
with NN O O
eGFR NN O O
below NN O O
60 NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Hyperkalemia NN B-AdverseReaction B-AdverseReaction
Monitor NN O O
potassium NN O O
levels NN O O
in NN O O
patients NN O O
with NN O O
impaired NN O O
renal NN O O
function NN O O
and NN O O
in NN O O
patients NN O O
predisposed NN O O
to NN O O
hyperkalemia NN O O
( NN O O
2.2 NN O O
, NN O O
5.3 NN O O
, NN O O
6.1 NN O O
, NN O O
8.6 NN O O
) NN O O
* NN O O
Hypoglycemia NN B-AdverseReaction B-AdverseReaction
Consider NN O O
a NN O O
lower NN O O
dose NN O O
of NN O O
insulin NN O O
or NN O O
the NN O O
insulin NN O O
secretagogue NN O O
to NN O O
reduce NN O O
the NN O O
risk NN O O
of NN O O
hypoglycemia NN O O
when NN O O
used NN O O
in NN O O
combination NN O O
with NN O O
INVOKANA NN O O
( NN O O
5.4 NN O O
) NN O O
* NN O O
Genital NN B-AdverseReaction B-AdverseReaction
mycotic NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
and NN O O
treat NN O O
if NN O O
indicated NN O O
( NN O O
5.5 NN O O
) NN O O
* NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
Discontinue NN O O
INVOKANA NN O O
and NN O O
monitor NN O O
until NN O O
signs NN O O
and NN O O
symptoms NN O O
resolve NN O O
( NN O O
5.6 NN O O
) NN O O
* NN O O
Bone NN B-AdverseReaction B-AdverseReaction
fracture NN I-AdverseReaction I-AdverseReaction
Consider NN O O
factors NN O O
that NN O O
contribute NN O O
to NN O O
fracture NN O O
risk NN O O
before NN O O
initiating NN O O
INVOKANA NN O O
( NN O O
5.7 NN O O
) NN O O
* NN O O
Increased NN B-AdverseReaction B-AdverseReaction
LDL NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
LDL NN O O
- NN O O
C NN O O
and NN O O
treat NN O O
if NN O O
appropriate NN O O
( NN O O
5.8 NN O O
) NN O O
5.1 NN O O
Hypotension NN O O
INVOKANA NN O O
causes NN O O
intravascular NN B-AdverseReaction B-AdverseReaction
volume NN I-AdverseReaction I-AdverseReaction
contraction NN I-AdverseReaction I-AdverseReaction
Symptomatic NN B-AdverseReaction B-AdverseReaction
hypotension NN I-AdverseReaction I-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
after NN O O
initiating NN O O
INVOKANA NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
particularly NN O O
in NN O O
patients NN O O
with NN O O
impaired NN O O
renal NN O O
function NN O O
( NN O O
eGFR NN O O
less NN O O
than NN O O
60 NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
) NN O O
, NN O O
elderly NN O O
patients NN O O
, NN O O
patients NN O O
on NN O O
either NN O O
diuretics NN O O
or NN O O
medications NN O O
that NN O O
interfere NN O O
with NN O O
the NN O O
renin NN O O
- NN O O
angiotensin NN O O
- NN O O
aldosterone NN O O
system NN O O
( NN O O
e.g. NN O O
, NN O O
angiotensin NN O O
- NN O O
converting NN O O
- NN O O
enzyme NN O O
[ NN O O
ACE NN O O
] NN O O
inhibitors NN O O
, NN O O
angiotensin NN O O
receptor NN O O
blockers NN O O
[ NN O O
ARBs NN O O
] NN O O
) NN O O
, NN O O
or NN O O
patients NN O O
with NN O O
low NN O O
systolic NN O O
blood NN O O
pressure NN O O
. NN O O
Before NN O O
initiating NN O O
INVOKANA NN O O
in NN O O
patients NN O O
with NN O O
one NN O O
or NN O O
more NN O O
of NN O O
these NN O O
characteristics NN O O
, NN O O
volume NN O O
status NN O O
should NN O O
be NN O O
assessed NN O O
and NN O O
corrected NN O O
. NN O O
Monitor NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
after NN O O
initiating NN O O
therapy NN O O
. NN O O
5.2 NN O O
Impairment NN O O
in NN O O
Renal NN O O
Function NN O O
INVOKANA NN O O
increases NN B-AdverseReaction B-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
and NN O O
decreases NN B-AdverseReaction B-AdverseReaction
eGFR NN I-AdverseReaction I-AdverseReaction
Patients NN O O
with NN O O
hypovolemia NN O O
may NN O O
be NN O O
more NN O O
susceptible NN O O
to NN O O
these NN O O
changes NN O O
. NN O O
Renal NN B-AdverseReaction B-AdverseReaction
function NN I-AdverseReaction I-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
after NN O O
initiating NN O O
INVOKANA NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
More NN O O
frequent NN O O
renal NN O O
function NN O O
monitoring NN O O
is NN O O
recommended NN O O
in NN O O
patients NN O O
with NN O O
an NN O O
eGFR NN O O
below NN O O
60 NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
. NN O O
5.3 NN O O
Hyperkalemia NN O O
INVOKANA NN O O
can NN B-Factor B-Factor
lead NN O O
to NN O O
hyperkalemia NN B-AdverseReaction B-AdverseReaction
Patients NN O O
with NN O O
moderate NN O O
renal NN O O
impairment NN O O
who NN O O
are NN O O
taking NN O O
medications NN O O
that NN O O
interfere NN O O
with NN O O
potassium NN O O
excretion NN O O
, NN O O
such NN O O
as NN O O
potassium NN O O
- NN O O
sparing NN O O
diuretics NN O O
, NN O O
or NN O O
medications NN O O
that NN O O
interfere NN O O
with NN O O
the NN O O
renin NN O O
- NN O O
angiotensin NN O O
- NN O O
aldosterone NN O O
system NN O O
are NN O O
at NN O O
an NN O O
increased NN O O
risk NN B-Factor B-Factor
of NN O O
developing NN O O
hyperkalemia NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
and NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Monitor NN O O
serum NN O O
potassium NN O O
levels NN O O
periodically NN O O
after NN O O
initiating NN O O
INVOKANA NN O O
in NN O O
patients NN O O
with NN O O
impaired NN O O
renal NN O O
function NN O O
and NN O O
in NN O O
patients NN O O
predisposed NN O O
to NN O O
hyperkalemia NN O O
due NN O O
to NN O O
medications NN O O
or NN O O
other NN O O
medical NN O O
conditions NN O O
. NN O O
5.4 NN O O
Hypoglycemia NN O O
with NN O O
Concomitant NN O O
Use NN O O
with NN O O
Insulin NN O O
and NN O O
Insulin NN O O
Secretagogues NN O O
Insulin NN O O
and NN O O
insulin NN O O
secretagogues NN O O
are NN O O
known NN O O
to NN O O
cause NN O O
hypoglycemia NN O O
. NN O O
INVOKANA NN O O
can NN O O
increase NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
hypoglycemia NN B-AdverseReaction B-AdverseReaction
when NN O O
combined NN O O
with NN O O
insulin NN O O
or NN O O
an NN O O
insulin NN O O
secretagogue NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Therefore NN O O
, NN O O
a NN O O
lower NN O O
dose NN O O
of NN O O
insulin NN O O
or NN O O
insulin NN O O
secretagogue NN O O
may NN O O
be NN O O
required NN O O
to NN O O
minimize NN O O
the NN O O
risk NN O O
of NN O O
hypoglycemia NN O O
when NN O O
used NN O O
in NN O O
combination NN O O
with NN O O
INVOKANA. NN O O
5.5 NN O O
Genital NN O O
Mycotic NN O O
Infections NN O O
INVOKANA NN O O
increases NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
genital NN B-AdverseReaction B-AdverseReaction
mycotic NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
Patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
genital NN O O
mycotic NN O O
infections NN O O
and NN O O
uncircumcised NN O O
males NN O O
were NN O O
more NN O O
likely NN O O
to NN O O
develop NN O O
genital NN B-AdverseReaction B-AdverseReaction
mycotic NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Monitor NN O O
and NN O O
treat NN O O
appropriately NN O O
. NN O O
5.6 NN O O
Hypersensitivity NN O O
Reactions NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
( NN O O
e.g. NN O O
, NN O O
generalized NN B-AdverseReaction B-AdverseReaction
urticaria NN I-AdverseReaction I-AdverseReaction
some NN O O
serious NN B-Severity B-Severity
were NN O O
reported NN O O
with NN O O
INVOKANA NN O O
treatment NN O O
; NN O O
these NN O O
reactions NN O O
generally NN O O
occurred NN O O
within NN O O
hours NN O O
to NN O O
days NN O O
after NN O O
initiating NN O O
INVOKANA. NN O O
If NN O O
hypersensitivity NN O O
reactions NN O O
occur NN O O
, NN O O
discontinue NN O O
use NN O O
of NN O O
INVOKANA NN O O
; NN O O
treat NN O O
and NN O O
monitor NN O O
until NN O O
signs NN O O
and NN O O
symptoms NN O O
resolve NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
and NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
5.7 NN O O
Bone NN O O
Fracture NN O O
An NN O O
increased NN O O
risk NN B-Factor B-Factor
of NN O O
bone NN B-AdverseReaction B-AdverseReaction
fracture NN I-AdverseReaction I-AdverseReaction
occurring NN O O
as NN O O
early NN O O
as NN O O
12 NN O O
weeks NN O O
after NN O O
treatment NN O O
initiation NN O O
, NN O O
was NN O O
observed NN O O
in NN O O
patients NN O O
using NN O O
INVOKANA. NN O O
Consider NN O O
factors NN O O
that NN O O
contribute NN O O
to NN O O
fracture NN O O
risk NN O O
prior NN O O
to NN O O
initiating NN O O
INVOKANA NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
5.8 NN O O
Increases NN O O
in NN O O
Low NN O O
- NN O O
Density NN O O
Lipoprotein NN O O
( NN O O
LDL NN O O
- NN O O
C NN O O
) NN O O
Dose NN O O
- NN O O
related NN O O
increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
LDL NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
occur NN O O
with NN O O
INVOKANA NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
Monitor NN O O
LDL NN O O
- NN O O
C NN O O
and NN O O
treat NN O O
if NN O O
appropriate NN O O
after NN O O
initiating NN O O
INVOKANA. NN O O
5.9 NN O O
Macrovascular NN O O
Outcomes NN O O
There NN O O
have NN O O
been NN O O
no NN O O
clinical NN O O
studies NN O O
establishing NN O O
conclusive NN O O
evidence NN O O
of NN O O
macrovascular NN O O
risk NN O O
reduction NN O O
with NN O O
INVOKANA NN O O
or NN O O
any NN O O
other NN O O
antidiabetic NN O O
drug NN O O
. NN O O

-DOCSTART- -X- -X- O

EXCERPT NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
in NN O O
>=13 NN O O
% NN O O
of NN O O
patients NN O O
are NN O O
: NN O O
Infections NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
pyrexia NN B-AdverseReaction B-AdverseReaction
tonsilitis NN B-AdverseReaction B-AdverseReaction
anemia NN B-AdverseReaction B-AdverseReaction
ear NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
and NN O O
headache NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Accredo NN O O
Health NN O O
Group NN O O
Inc. NN O O
at NN O O
1 NN O O
- NN O O
888 NN O O
- NN O O
454 NN O O
- NN O O
8860,or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6 NN O O
ADVERSE NN O O
REACTIONS NN O O
6.1 NN O O
Retrospective NN O O
Case NN O O
Series NN O O
Experience NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
occurring NN O O
in NN O O
>= NN O O
13 NN O O
% NN O O
of NN O O
patients NN O O
) NN O O
, NN O O
regardless NN O O
of NN O O
causality NN O O
, NN O O
are NN O O
: NN O O
Infections NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
pyrexia NN B-AdverseReaction B-AdverseReaction
tonsilitis NN B-AdverseReaction B-AdverseReaction
anemia NN B-AdverseReaction B-AdverseReaction
ear NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
and NN O O
headache NN B-AdverseReaction B-AdverseReaction
Table NN O O
1 NN O O
summarizes NN O O
adverse NN O O
reactions NN O O
occurring NN O O
in NN O O
2 NN O O
or NN O O
more NN O O
patients NN O O
treated NN O O
with NN O O
Carbaglu NN O O
in NN O O
the NN O O
retrospective NN O O
case NN O O
series NN O O
. NN O O
Because NN O O
these NN O O
reactions NN O O
were NN O O
reported NN O O
retrospectively NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
Table NN O O
1 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
Reported NN O O
in NN O O
> NN O O
2 NN O O
Patients NN O O
in NN O O
the NN O O
Retrospective NN O O
Case NN O O
Series NN O O
treated NN O O
with NN O O
Carbaglu NN O O
System NN O O
Organ NN O O
Class NN O O
Preferred NN O O
Term NN O O
Number NN O O
of NN O O
Patients NN O O
( NN O O
N)( NN O O
% NN O O
) NN O O
TOTAL NN O O
23 NN O O
( NN O O
100 NN O O
) NN O O
Blood NN O O
and NN O O
lymphatic NN O O
system NN O O
disorders NN O O
Anemia NN B-AdverseReaction B-AdverseReaction
3 NN O O
( NN O O
13 NN O O
) NN O O
Ear NN O O
and NN O O
labyrinth NN O O
disorders NN O O
Ear NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
3 NN O O
( NN O O
13 NN O O
) NN O O
Gastrointestinal NN O O
disorders NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
4 NN O O
( NN O O
17 NN O O
) NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
3 NN O O
( NN O O
13 NN O O
) NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
6 NN O O
( NN O O
26 NN O O
) NN O O
Dysgeusia NN B-AdverseReaction B-AdverseReaction
2 NN O O
( NN O O
9 NN O O
) NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
Asthenia NN B-AdverseReaction B-AdverseReaction
2 NN O O
( NN O O
9 NN O O
) NN O O
Hyperhidrosis NN B-AdverseReaction B-AdverseReaction
2 NN O O
( NN O O
9 NN O O
) NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
4 NN O O
( NN O O
17 NN O O
) NN O O
Infections NN O O
and NN O O
infestations NN O O
Infection NN B-AdverseReaction B-AdverseReaction
3 NN O O
( NN O O
13 NN O O
) NN O O
Influenza NN B-AdverseReaction B-AdverseReaction
2 NN O O
( NN O O
9 NN O O
) NN O O
Nasopharyngitis NN B-AdverseReaction B-AdverseReaction
3 NN O O
( NN O O
13 NN O O
) NN O O
Pneumonia NN B-AdverseReaction B-AdverseReaction
2 NN O O
( NN O O
9 NN O O
) NN O O
Tonsillitis NN B-AdverseReaction B-AdverseReaction
4 NN O O
( NN O O
17 NN O O
) NN O O
Investigations NN O O
Hemoglobin NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
3 NN O O
( NN O O
13 NN O O
) NN O O
Weight NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
2 NN O O
( NN O O
9 NN O O
) NN O O
Metabolism NN O O
and NN O O
nutrition NN O O
disorders NN O O
Anorexia NN B-AdverseReaction B-AdverseReaction
2 NN O O
( NN O O
9 NN O O
) NN O O
Nervous NN O O
system NN O O
disorders NN O O
Headache NN B-AdverseReaction B-AdverseReaction
3 NN O O
( NN O O
13 NN O O
) NN O O
Somnolence NN B-AdverseReaction B-AdverseReaction
2 NN O O
( NN O O
9 NN O O
) NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
Rash NN B-AdverseReaction B-AdverseReaction
2 NN O O
( NN O O
9 NN O O
) NN O O
EXCERPT NN O O
: NN O O
Hyperammonemia NN B-AdverseReaction B-AdverseReaction
: NN O O
Monitor NN O O
plasma NN O O
ammonia NN O O
levels NN O O
during NN O O
treatment NN O O
. NN O O
Prolonged NN O O
exposure NN O O
to NN O O
elevated NN O O
plasma NN O O
ammonia NN O O
levels NN O O
can NN O O
rapidly NN O O
result NN O O
in NN O O
injury NN O O
to NN O O
the NN O O
brain NN O O
or NN O O
death NN O O
. NN O O
Prompt NN O O
use NN O O
of NN O O
all NN O O
therapies NN O O
necessary NN O O
to NN O O
reduce NN O O
plasma NN O O
ammonia NN O O
levels NN O O
is NN O O
essential NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
Therapeutic NN O O
Monitoring NN O O
: NN O O
Plasma NN O O
ammonia NN O O
levels NN O O
should NN O O
be NN O O
maintained NN O O
within NN O O
normal NN O O
range NN O O
for NN O O
age NN O O
via NN O O
individual NN O O
dose NN O O
adjustment NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
Nutritional NN O O
Management NN O O
: NN O O
In NN O O
the NN O O
initial NN O O
treatment NN O O
of NN O O
NAGS NN O O
deficiency NN O O
, NN O O
protein NN O O
restriction NN O O
is NN O O
recommended NN O O
. NN O O
When NN O O
plasma NN O O
ammonia NN O O
level NN O O
is NN O O
normalized NN O O
, NN O O
dietary NN O O
protein NN O O
intake NN O O
can NN O O
usually NN O O
be NN O O
reintroduced.( NN O O
5.3 NN O O
) NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
5.1 NN O O
Hyperammonemia NN O O
Any NN O O
episode NN O O
of NN O O
acute NN O O
symptomatic NN O O
hyperammonemia NN O O
should NN O O
be NN O O
treated NN O O
as NN O O
a NN O O
life NN O O
- NN O O
threatening NN O O
emergency NN O O
. NN O O
Treatment NN O O
of NN O O
hyperammonemia NN O O
may NN O O
require NN O O
dialysis NN O O
, NN O O
preferably NN O O
hemodialysis NN O O
, NN O O
to NN O O
remove NN O O
a NN O O
large NN O O
burden NN O O
of NN O O
ammonia NN O O
. NN O O
Uncontrolled NN O O
hyperammonemia NN O O
can NN O O
rapidly NN O O
result NN O O
in NN O O
brain NN O O
injury/damage NN O O
or NN O O
death NN O O
, NN O O
and NN O O
prompt NN O O
use NN O O
of NN O O
all NN O O
therapies NN O O
necessary NN O O
to NN O O
reduce NN O O
plasma NN O O
ammonia NN O O
levels NN O O
is NN O O
essential NN O O
. NN O O
Management NN O O
of NN O O
hyperammonemia NN O O
due NN O O
to NN O O
NAGS NN O O
deficiency NN O O
should NN O O
be NN O O
done NN O O
in NN O O
coordination NN O O
with NN O O
medical NN O O
personnel NN O O
experienced NN O O
in NN O O
metabolic NN O O
disorders NN O O
. NN O O
Ongoing NN O O
monitoring NN O O
of NN O O
plasma NN O O
ammonia NN O O
levels NN O O
, NN O O
neurological NN O O
status NN O O
, NN O O
laboratory NN O O
tests NN O O
and NN O O
clinical NN O O
responses NN O O
in NN O O
patients NN O O
receiving NN O O
Carbaglu NN O O
is NN O O
crucial NN O O
to NN O O
assess NN O O
patient NN O O
response NN O O
to NN O O
treatment NN O O
. NN O O
5.2 NN O O
Therapeutic NN O O
Monitoring NN O O
Plasma NN O O
ammonia NN O O
levels NN O O
should NN O O
be NN O O
maintained NN O O
within NN O O
normal NN O O
range NN O O
for NN O O
age NN O O
via NN O O
individual NN O O
dose NN O O
adjustment NN O O
. NN O O
5.3 NN O O
Nutritional NN O O
Management NN O O
Since NN O O
hyperammonemia NN O O
is NN O O
the NN O O
result NN O O
of NN O O
protein NN O O
catabolism NN O O
, NN O O
complete NN O O
protein NN O O
restriction NN O O
is NN O O
recommended NN O O
to NN O O
be NN O O
maintained NN O O
for NN O O
24 NN O O
to NN O O
48 NN O O
hours NN O O
and NN O O
caloric NN O O
supplementation NN O O
should NN O O
be NN O O
maximized NN O O
to NN O O
reverse NN O O
catabolism NN O O
and NN O O
nitrogen NN O O
turnover NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
serious NN O O
adverse NN O O
reactions NN O O
are NN O O
described NN O O
elsewhere NN O O
in NN O O
labeling NN O O
: NN O O
* NN O O
Bradyarrhythmia NN B-AdverseReaction B-AdverseReaction
and NN O O
Atrioventricular NN B-AdverseReaction B-AdverseReaction
Blocks NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Infections NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
Progressive NN B-AdverseReaction B-AdverseReaction
multifocal NN I-AdverseReaction I-AdverseReaction
leukoencephalopathy NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
* NN O O
Macular NN B-AdverseReaction B-AdverseReaction
Edema NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
* NN O O
Posterior NN B-AdverseReaction B-AdverseReaction
Reversible NN I-AdverseReaction I-AdverseReaction
Encephalopathy NN I-AdverseReaction I-AdverseReaction
Syndrome NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
* NN O O
Respiratory NN B-AdverseReaction B-AdverseReaction
Effects NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.6 NN O O
) NN O O
] NN O O
* NN O O
Liver NN B-AdverseReaction B-AdverseReaction
Injury NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.7 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
Most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
incidence NN O O
>=10 NN O O
% NN O O
and NN O O
> NN O O
placebo NN O O
) NN O O
: NN O O
Headache NN B-AdverseReaction B-AdverseReaction
liver NN B-AdverseReaction B-AdverseReaction
transaminase NN I-AdverseReaction I-AdverseReaction
elevation NN I-AdverseReaction I-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
influenza NN B-AdverseReaction B-AdverseReaction
sinusitis NN B-AdverseReaction B-AdverseReaction
back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
and NN O O
pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Novartis NN O O
Pharmaceuticals NN O O
Corporation NN O O
at NN O O
1 NN O O
- NN O O
888 NN O O
- NN O O
669 NN O O
- NN O O
6682 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
In NN O O
clinical NN O O
trials NN O O
( NN O O
Studies NN O O
1 NN O O
, NN O O
2 NN O O
, NN O O
and NN O O
3 NN O O
) NN O O
, NN O O
a NN O O
total NN O O
of NN O O
1212 NN O O
patients NN O O
with NN O O
relapsing NN O O
forms NN O O
of NN O O
multiple NN O O
sclerosis NN O O
received NN O O
GILENYA NN O O
0.5 NN O O
mg NN O O
. NN O O
This NN O O
included NN O O
783 NN O O
patients NN O O
who NN O O
received NN O O
GILENYA NN O O
0.5 NN O O
mg NN O O
in NN O O
the NN O O
2-year NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
( NN O O
Studies NN O O
1 NN O O
and NN O O
3 NN O O
) NN O O
and NN O O
429 NN O O
patients NN O O
who NN O O
received NN O O
GILENYA NN O O
0.5 NN O O
mg NN O O
in NN O O
the NN O O
1 NN O O
year NN O O
active NN O O
- NN O O
controlled NN O O
trial NN O O
( NN O O
Study NN O O
2 NN O O
) NN O O
. NN O O
The NN O O
overall NN O O
exposure NN O O
in NN O O
the NN O O
controlled NN O O
trials NN O O
was NN O O
equivalent NN O O
to NN O O
1716 NN O O
person NN O O
- NN O O
years NN O O
. NN O O
Approximately NN O O
1000 NN O O
patients NN O O
received NN O O
at NN O O
least NN O O
2 NN O O
years NN O O
of NN O O
treatment NN O O
with NN O O
GILENYA NN O O
0.5 NN O O
mg NN O O
. NN O O
In NN O O
all NN O O
clinical NN O O
studies NN O O
, NN O O
including NN O O
uncontrolled NN O O
extension NN O O
studies NN O O
, NN O O
the NN O O
exposure NN O O
to NN O O
GILENYA NN O O
0.5 NN O O
mg NN O O
was NN O O
approximately NN O O
4119 NN O O
person NN O O
- NN O O
years NN O O
. NN O O
In NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
, NN O O
the NN O O
most NN O O
frequent NN O O
adverse NN O O
reactions NN O O
( NN O O
incidence NN O O
>=10 NN O O
% NN O O
and NN O O
>placebo NN O O
) NN O O
for NN O O
GILENYA NN O O
0.5 NN O O
mg NN O O
were NN O O
headache NN B-AdverseReaction B-AdverseReaction
liver NN B-AdverseReaction B-AdverseReaction
transaminase NN I-AdverseReaction I-AdverseReaction
elevation NN I-AdverseReaction I-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
influenza NN B-AdverseReaction B-AdverseReaction
sinusitis NN B-AdverseReaction B-AdverseReaction
back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
and NN O O
pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
Adverse NN O O
events NN O O
that NN O O
led NN O O
to NN O O
treatment NN O O
discontinuation NN O O
and NN O O
occurred NN O O
in NN O O
more NN O O
than NN O O
1 NN O O
% NN O O
of NN O O
patients NN O O
taking NN O O
GILENYA NN O O
0.5 NN O O
mg NN O O
were NN O O
serum NN B-AdverseReaction B-AdverseReaction
transaminase NN I-AdverseReaction I-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
( NN O O
4.7 NN O O
% NN O O
compared NN O O
to NN O O
1 NN O O
% NN O O
on NN O O
placebo NN O O
) NN O O
and NN O O
basal NN B-AdverseReaction B-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
carcinoma NN I-AdverseReaction I-AdverseReaction
( NN O O
1 NN O O
% NN O O
compared NN O O
to NN O O
0.5 NN O O
% NN O O
on NN O O
placebo NN O O
) NN O O
. NN O O
Table NN O O
1 NN O O
lists NN O O
adverse NN O O
reactions NN O O
that NN O O
occurred NN O O
in NN O O
>= NN O O
1 NN O O
% NN O O
of NN O O
GILENYA NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
>= NN O O
1 NN O O
% NN O O
higher NN O O
rate NN O O
than NN O O
for NN O O
placebo NN O O
. NN O O
Table NN O O
1 NN O O
Adverse NN O O
Reactions NN O O
Reported NN O O
in NN O O
Studies NN O O
1 NN O O
and NN O O
3 NN O O
( NN O O
Occurring NN O O
in NN O O
>=1 NN O O
% NN O O
of NN O O
Patients NN O O
and NN O O
Reported NN O O
for NN O O
GILENYA NN O O
0.5 NN O O
mg NN O O
at NN O O
>=1 NN O O
% NN O O
Higher NN O O
Rate NN O O
than NN O O
for NN O O
Placebo NN O O
) NN O O
Primary NN O O
System NN O O
Organ NN O O
Class NN O O
Preferred NN O O
Term NN O O
GILENYA NN O O
0.5 NN O O
mg NN O O
N=783 NN O O
% NN O O
Placebo NN O O
N=773 NN O O
% NN O O
Infections NN O O
Influenza NN B-AdverseReaction B-AdverseReaction
11 NN O O
8 NN O O
Sinusitis NN B-AdverseReaction B-AdverseReaction
11 NN O O
8 NN O O
Bronchitis NN B-AdverseReaction B-AdverseReaction
8 NN O O
5 NN O O
Herpes NN B-AdverseReaction B-AdverseReaction
zoster NN I-AdverseReaction I-AdverseReaction
2 NN O O
1 NN O O
Tinea NN B-AdverseReaction B-AdverseReaction
versicolor NN I-AdverseReaction I-AdverseReaction
2 NN O O
< NN O O
1 NN O O
Cardiac NN O O
Disorders NN O O
Bradycardia NN B-AdverseReaction B-AdverseReaction
3 NN O O
1 NN O O
Nervous NN O O
system NN O O
disorders NN O O
Headache NN B-AdverseReaction B-AdverseReaction
25 NN O O
24 NN O O
Migraine NN B-AdverseReaction B-AdverseReaction
6 NN O O
4 NN O O
Gastrointestinal NN O O
disorders NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
13 NN O O
12 NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
13 NN O O
10 NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
11 NN O O
10 NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
Asthenia NN B-AdverseReaction B-AdverseReaction
2 NN O O
1 NN O O
Musculoskeletal NN O O
and NN O O
connective NN O O
tissue NN O O
disorders NN O O
Back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
10 NN O O
9 NN O O
Pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
10 NN O O
7 NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
Alopecia NN B-AdverseReaction B-AdverseReaction
3 NN O O
2 NN O O
Actinic NN B-AdverseReaction B-AdverseReaction
keratosis NN I-AdverseReaction I-AdverseReaction
2 NN O O
1 NN O O
Investigations NN O O
Liver NN B-AdverseReaction B-AdverseReaction
transaminase NN I-AdverseReaction I-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
( NN O O
ALT/GGT/AST NN O O
) NN O O
15 NN O O
4 NN O O
Blood NN B-AdverseReaction B-AdverseReaction
triglycerides NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
3 NN O O
1 NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
, NN O O
and NN O O
mediastinal NN O O
disorders NN O O
Cough NN B-AdverseReaction B-AdverseReaction
12 NN O O
11 NN O O
Dyspnea NN B-AdverseReaction B-AdverseReaction
9 NN O O
7 NN O O
Eye NN O O
disorders NN O O
Vision NN B-AdverseReaction B-AdverseReaction
blurred NN I-AdverseReaction I-AdverseReaction
4 NN O O
2 NN O O
Vascular NN O O
disorders NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
8 NN O O
4 NN O O
Blood NN O O
and NN O O
lymphatic NN O O
system NN O O
disorders NN O O
Lymphopenia NN B-AdverseReaction B-AdverseReaction
7 NN O O
< NN O O
1 NN O O
Leukopenia NN B-AdverseReaction B-AdverseReaction
2 NN O O
< NN O O
1 NN O O
Neoplasms NN O O
benign NN O O
, NN O O
malignant NN O O
and NN O O
unspecified(including NN O O
cysts NN O O
and NN O O
polyps NN O O
) NN O O
Skin NN B-AdverseReaction B-AdverseReaction
papilloma NN I-AdverseReaction I-AdverseReaction
3 NN O O
2 NN O O
Basal NN B-AdverseReaction B-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
carcinoma NN I-AdverseReaction I-AdverseReaction
2 NN O O
1 NN O O
Adverse NN O O
reactions NN O O
of NN O O
dizziness NN B-AdverseReaction B-AdverseReaction
pneumonia NN B-AdverseReaction B-AdverseReaction
eczema NN B-AdverseReaction B-AdverseReaction
and NN O O
pruritus NN B-AdverseReaction B-AdverseReaction
were NN O O
also NN O O
reported NN O O
in NN O O
Studies NN O O
1 NN O O
and NN O O
3 NN O O
but NN O O
did NN O O
not NN O O
meet NN O O
the NN O O
reporting NN O O
rate NN O O
criteria NN O O
for NN O O
inclusion NN O O
in NN O O
Table NN O O
1 NN O O
( NN O O
difference NN O O
was NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
) NN O O
. NN O O
Adverse NN O O
reactions NN O O
with NN O O
GILENYA NN O O
0.5 NN O O
mg NN O O
in NN O O
Study NN O O
2 NN O O
, NN O O
the NN O O
1-year NN O O
active NN O O
- NN O O
controlled NN O O
( NN O O
versus NN O O
interferon NN O O
beta-1a NN O O
) NN O O
study NN O O
were NN O O
generally NN O O
similar NN O O
to NN O O
those NN O O
in NN O O
Studies NN O O
1 NN O O
and NN O O
3 NN O O
. NN O O
Vascular NN O O
Events NN O O
Vascular NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
including NN O O
ischemic NN O O
and NN O O
hemorrhagic NN B-AdverseReaction B-AdverseReaction
strokes NN I-AdverseReaction I-AdverseReaction
and NN O O
peripheral NN B-AdverseReaction B-AdverseReaction
arterial NN I-AdverseReaction I-AdverseReaction
occlusive NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
in NN O O
premarketing NN O O
clinical NN O O
trials NN O O
in NN O O
patients NN O O
who NN O O
received NN O O
GILENYA NN O O
doses NN O O
( NN O O
1.25 NN O O
- NN O O
5 NN O O
mg NN O O
) NN O O
higher NN O O
than NN O O
recommended NN O O
for NN O O
use NN O O
in NN O O
MS. NN O O
Similar NN O O
events NN O O
have NN O O
been NN O O
reported NN O O
with NN O O
GILENYA NN O O
0.5 NN O O
mg NN O O
in NN O O
the NN O O
postmarketing NN O O
setting NN O O
although NN O O
a NN O O
causal NN O O
relationship NN O O
has NN O O
not NN O O
been NN O O
established NN O O
. NN O O
Lymphomas NN O O
Cases NN O O
of NN O O
lymphoma NN B-AdverseReaction B-AdverseReaction
have NN O O
occurred NN O O
in NN O O
premarketing NN O O
clinical NN O O
trials NN O O
and NN O O
in NN O O
the NN O O
postmarketing NN O O
setting NN O O
. NN O O
The NN O O
relationship NN O O
to NN O O
GILENYA NN O O
remains NN O O
uncertain NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Bradycardia NN B-AdverseReaction B-AdverseReaction
and/or NN O O
atrioventricular NN B-AdverseReaction B-AdverseReaction
conduction NN I-AdverseReaction I-AdverseReaction
after NN O O
first NN O O
dose NN O O
: NN O O
Monitor NN O O
patients NN O O
. NN O O
( NN O O
2 NN O O
, NN O O
5.1 NN O O
) NN O O
* NN O O
Infections NN B-AdverseReaction B-AdverseReaction
GILENYA NN O O
may NN O O
increase NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
infections NN B-AdverseReaction B-AdverseReaction
A NN O O
recent NN O O
CBC NN O O
should NN O O
be NN O O
available NN O O
before NN O O
initiating NN O O
treatment NN O O
. NN O O
Monitor NN O O
for NN O O
infection NN O O
during NN O O
treatment NN O O
and NN O O
for NN O O
2 NN O O
months NN O O
after NN O O
discontinuation NN O O
. NN O O
Do NN O O
not NN O O
start NN O O
in NN O O
patients NN O O
with NN O O
active NN O O
infections NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Progressive NN B-AdverseReaction B-AdverseReaction
multifocal NN I-AdverseReaction I-AdverseReaction
leukoencephalopathy NN I-AdverseReaction I-AdverseReaction
( NN O O
PML NN O O
) NN O O
; NN O O
Withhold NN O O
GILENYA NN O O
at NN O O
the NN O O
first NN O O
sign NN O O
or NN O O
symptom NN O O
suggestive NN O O
of NN O O
PML. NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Macular NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
Perform NN O O
an NN O O
examination NN O O
of NN O O
the NN O O
fundus NN O O
including NN O O
the NN O O
macula NN O O
before NN O O
and NN O O
3 NN O O
- NN O O
4 NN O O
months NN O O
after NN O O
treatment NN O O
initiation NN O O
. NN O O
Patients NN O O
with NN O O
diabetes NN O O
mellitus NN O O
or NN O O
a NN O O
history NN O O
of NN O O
uveitis NN O O
are NN O O
at NN O O
increased NN O O
risk NN O O
. NN O O
( NN O O
5.4 NN O O
) NN O O
* NN O O
Posterior NN B-AdverseReaction B-AdverseReaction
reversible NN I-AdverseReaction I-AdverseReaction
encephalopathy NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
PRES NN O O
) NN O O
: NN O O
If NN O O
suspected NN O O
, NN O O
discontinue NN O O
GILENYA. NN O O
( NN O O
5.5 NN O O
) NN O O
* NN O O
Decrease NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
pulmonary NN I-AdverseReaction I-AdverseReaction
function NN I-AdverseReaction I-AdverseReaction
tests NN I-AdverseReaction I-AdverseReaction
( NN O O
PFT NN O O
) NN O O
: NN O O
Obtain NN O O
PFT NN O O
when NN O O
clinically NN O O
indicated NN O O
. NN O O
( NN O O
5.6 NN O O
) NN O O
* NN O O
Liver NN B-AdverseReaction B-AdverseReaction
injury NN I-AdverseReaction I-AdverseReaction
liver NN O O
enzyme NN O O
results NN O O
should NN O O
be NN O O
available NN O O
before NN O O
initiation NN O O
. NN O O
Discontinue NN O O
if NN O O
significant NN O O
liver NN O O
injury NN O O
occurs NN O O
. NN O O
( NN O O
5.7 NN O O
) NN O O
* NN O O
Women NN O O
of NN O O
childbearing NN O O
potential NN O O
should NN O O
use NN O O
effective NN O O
contraception NN O O
during NN O O
and NN O O
for NN O O
2 NN O O
months NN O O
after NN O O
stopping NN O O
GILENYA. NN O O
( NN O O
5.8 NN O O
) NN O O
* NN O O
Blood NN O O
pressure NN O O
( NN O O
BP NN O O
) NN O O
: NN O O
Monitor NN O O
BP NN O O
during NN O O
treatment NN O O
. NN O O
( NN O O
5.9 NN O O
) NN O O
5.1 NN O O
Bradyarrhythmia NN O O
and NN O O
Atrioventricular NN O O
Blocks NN O O
Because NN O O
of NN O O
a NN O O
risk NN O O
for NN O O
bradyarrhythmia NN O O
and NN O O
atrioventricular NN O O
( NN O O
AV NN O O
) NN O O
blocks NN O O
, NN O O
patients NN O O
should NN O O
be NN O O
monitored NN O O
during NN O O
GILENYA NN O O
treatment NN O O
initiation NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2 NN O O
) NN O O
] NN O O
. NN O O
Reduction NN O O
in NN O O
Heart NN O O
Rate NN O O
After NN O O
the NN O O
first NN O O
dose NN O O
of NN O O
GILENYA NN O O
, NN O O
the NN O O
heart NN B-AdverseReaction B-AdverseReaction
rate NN I-AdverseReaction I-AdverseReaction
decrease NN I-AdverseReaction I-AdverseReaction
starts NN O O
within NN O O
an NN O O
hour NN O O
. NN O O
On NN O O
Day NN O O
1 NN O O
, NN O O
the NN O O
maximum NN O O
decline NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
heart NN I-AdverseReaction I-AdverseReaction
rate NN I-AdverseReaction I-AdverseReaction
generally NN O O
occurs NN O O
within NN O O
6 NN O O
hours NN O O
and NN O O
recovers NN O O
, NN O O
although NN O O
not NN O O
to NN O O
baseline NN O O
levels NN O O
, NN O O
by NN O O
8 NN O O
to NN O O
10 NN O O
hours NN O O
postdose NN O O
. NN O O
Because NN O O
of NN O O
physiological NN O O
diurnal NN O O
variation NN O O
, NN O O
there NN O O
is NN O O
a NN O O
second NN O O
period NN O O
of NN O O
heart NN B-AdverseReaction B-AdverseReaction
rate NN I-AdverseReaction I-AdverseReaction
decrease NN I-AdverseReaction I-AdverseReaction
within NN O O
24 NN O O
hours NN O O
after NN O O
the NN O O
first NN O O
dose NN O O
. NN O O
In NN O O
some NN O O
patients NN O O
, NN O O
heart NN B-AdverseReaction B-AdverseReaction
rate NN I-AdverseReaction I-AdverseReaction
decrease NN I-AdverseReaction I-AdverseReaction
during NN O O
the NN O O
second NN O O
period NN O O
is NN O O
more NN O O
pronounced NN O O
than NN O O
the NN O O
decrease NN O O
observed NN O O
in NN O O
the NN O O
first NN O O
6 NN O O
hours NN O O
. NN O O
Heart NN B-AdverseReaction B-AdverseReaction
rates NN I-AdverseReaction I-AdverseReaction
below NN I-AdverseReaction I-AdverseReaction
40 NN I-AdverseReaction I-AdverseReaction
beats NN I-AdverseReaction I-AdverseReaction
per NN I-AdverseReaction I-AdverseReaction
minute NN I-AdverseReaction I-AdverseReaction
were NN O O
rarely NN O O
observed NN O O
. NN O O
In NN O O
controlled NN O O
clinical NN O O
trials NN O O
, NN O O
adverse NN O O
reactions NN O O
of NN O O
symptomatic NN B-AdverseReaction B-AdverseReaction
bradycardia NN I-AdverseReaction I-AdverseReaction
following NN O O
the NN O O
first NN O O
dose NN O O
were NN O O
reported NN O O
in NN O O
0.6 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
GILENYA NN O O
0.5 NN O O
mg NN O O
and NN O O
in NN O O
0.1 NN O O
% NN O O
of NN O O
patients NN O O
on NN O O
placebo NN O O
. NN O O
Patients NN O O
who NN O O
experienced NN O O
bradycardia NN B-AdverseReaction B-AdverseReaction
were NN O O
generally NN O O
asymptomatic NN O O
, NN O O
but NN O O
some NN O O
patients NN O O
experienced NN O O
hypotension NN B-AdverseReaction B-AdverseReaction
dizziness NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
palpitations NN B-AdverseReaction B-AdverseReaction
and/or NN O O
chest NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
that NN O O
usually NN O O
resolved NN O O
within NN O O
the NN O O
first NN O O
24 NN O O
hours NN O O
on NN O O
treatment NN O O
. NN O O
Following NN O O
the NN O O
second NN O O
dose NN O O
, NN O O
a NN O O
further NN O O
decrease NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
heart NN I-AdverseReaction I-AdverseReaction
rate NN I-AdverseReaction I-AdverseReaction
may NN O O
occur NN O O
when NN O O
compared NN O O
to NN O O
the NN O O
heart NN O O
rate NN O O
prior NN O O
to NN O O
the NN O O
second NN O O
dose NN O O
, NN O O
but NN O O
this NN O O
change NN O O
is NN O O
of NN O O
a NN O O
smaller NN O O
magnitude NN O O
than NN O O
that NN O O
observed NN O O
following NN O O
the NN O O
first NN O O
dose NN O O
. NN O O
With NN O O
continued NN O O
dosing NN O O
, NN O O
the NN O O
heart NN O O
rate NN O O
returns NN O O
to NN O O
baseline NN O O
within NN O O
1 NN O O
month NN O O
of NN O O
chronic NN O O
treatment NN O O
. NN O O
Atrioventricular NN O O
Blocks NN O O
Initiation NN O O
of NN O O
GILENYA NN O O
treatment NN O O
has NN O O
resulted NN O O
in NN O O
transient NN B-Severity B-Severity
AV NN B-AdverseReaction B-AdverseReaction
conduction NN I-AdverseReaction I-AdverseReaction
delays NN I-AdverseReaction I-AdverseReaction
In NN O O
controlled NN O O
clinical NN O O
trials NN O O
, NN O O
first NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
degree NN I-AdverseReaction I-AdverseReaction
AV NN I-AdverseReaction I-AdverseReaction
block NN I-AdverseReaction I-AdverseReaction
after NN O O
the NN O O
first NN O O
dose NN O O
occurred NN O O
in NN O O
4.7 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
GILENYA NN O O
and NN O O
1.6 NN O O
% NN O O
of NN O O
patients NN O O
on NN O O
placebo NN O O
. NN O O
In NN O O
a NN O O
study NN O O
of NN O O
697 NN O O
patients NN O O
with NN O O
available NN O O
24-hour NN O O
Holter NN O O
monitoring NN O O
data NN O O
after NN O O
their NN O O
first NN O O
dose NN O O
( NN O O
N=351 NN O O
receiving NN O O
GILENYA NN O O
and NN O O
N=346 NN O O
on NN O O
placebo NN O O
) NN O O
, NN O O
second NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
degree NN I-AdverseReaction I-AdverseReaction
AV NN I-AdverseReaction I-AdverseReaction
blocks NN I-AdverseReaction I-AdverseReaction
( NN O O
Mobitz NN O O
Types NN O O
I NN O O
[ NN O O
Wenckebach NN O O
] NN O O
or NN O O
2:1 NN B-AdverseReaction B-AdverseReaction
AV NN I-AdverseReaction I-AdverseReaction
blocks NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
4 NN O O
% NN O O
( NN O O
N=14 NN O O
) NN O O
of NN O O
patients NN O O
receiving NN O O
GILENYA NN O O
and NN O O
2 NN O O
% NN O O
( NN O O
N=7 NN O O
) NN O O
of NN O O
patients NN O O
on NN O O
placebo NN O O
. NN O O
Of NN O O
the NN O O
14 NN O O
patients NN O O
receiving NN O O
GILENYA NN O O
, NN O O
7 NN O O
patients NN O O
had NN O O
2:1 NN B-AdverseReaction B-AdverseReaction
AV NN I-AdverseReaction I-AdverseReaction
block NN I-AdverseReaction I-AdverseReaction
( NN O O
5 NN O O
patients NN O O
within NN O O
the NN O O
first NN O O
6 NN O O
hours NN O O
postdose NN O O
and NN O O
2 NN O O
patients NN O O
after NN O O
6 NN O O
hours NN O O
postdose NN O O
) NN O O
. NN O O
All NN O O
second NN O O
degree NN O O
AV NN O O
blocks NN O O
on NN O O
placebo NN B-Factor B-Factor
were NN O O
Mobitz NN O O
Type NN O O
I NN O O
and NN O O
occurred NN O O
after NN O O
the NN O O
first NN O O
12 NN O O
hours NN O O
postdose NN O O
. NN O O
The NN O O
conduction NN B-AdverseReaction B-AdverseReaction
abnormalities NN I-AdverseReaction I-AdverseReaction
were NN O O
usually NN O O
transient NN B-Severity B-Severity
and NN O O
asymptomatic NN O O
, NN O O
and NN O O
resolved NN O O
within NN O O
the NN O O
first NN O O
24 NN O O
hours NN O O
on NN O O
treatment NN O O
, NN O O
but NN O O
they NN O O
occasionally NN O O
required NN O O
treatment NN O O
with NN O O
atropine NN O O
or NN O O
isoproterenol NN O O
. NN O O
Postmarketing NN O O
Experience NN O O
In NN O O
the NN O O
postmarketing NN O O
setting NN O O
, NN O O
third NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
degree NN I-AdverseReaction I-AdverseReaction
AV NN I-AdverseReaction I-AdverseReaction
block NN I-AdverseReaction I-AdverseReaction
and NN O O
AV NN B-AdverseReaction B-AdverseReaction
block NN I-AdverseReaction I-AdverseReaction
with NN O O
junctional NN B-AdverseReaction B-AdverseReaction
escape NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
observed NN O O
during NN O O
the NN O O
first NN O O
- NN O O
dose NN O O
6-hour NN O O
observation NN O O
period NN O O
with NN O O
GILENYA. NN O O
Isolated NN O O
delayed NN O O
onset NN O O
events NN O O
, NN O O
including NN O O
transient NN B-Severity B-Severity
asystole NN B-AdverseReaction B-AdverseReaction
and NN O O
unexplained NN O O
death NN B-AdverseReaction B-AdverseReaction
have NN O O
occurred NN O O
within NN O O
24 NN O O
hours NN O O
of NN O O
the NN O O
first NN O O
dose NN O O
. NN O O
These NN O O
events NN O O
were NN O O
confounded NN O O
by NN O O
concomitant NN O O
medications NN O O
and/or NN O O
preexisting NN O O
disease NN O O
, NN O O
and NN O O
the NN O O
relationship NN O O
to NN O O
GILENYA NN O O
is NN O O
uncertain NN O O
. NN O O
Cases NN O O
of NN O O
syncope NN B-AdverseReaction B-AdverseReaction
were NN O O
also NN O O
reported NN O O
after NN O O
the NN O O
first NN O O
dose NN O O
of NN O O
GILENYA. NN O O
5.2 NN O O
Infections NN O O
Risk NN O O
of NN O O
Infections NN O O
GILENYA NN O O
causes NN O O
a NN O O
dose NN O O
- NN O O
dependent NN O O
reduction NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
peripheral NN I-AdverseReaction I-AdverseReaction
lymphocyte NN I-AdverseReaction I-AdverseReaction
count NN I-AdverseReaction I-AdverseReaction
to NN O O
20%-30 NN B-Severity B-Severity
% NN I-Severity I-Severity
of NN I-Severity I-Severity
baseline NN I-Severity I-Severity
values NN O O
because NN O O
of NN O O
reversible NN B-Severity B-Severity
sequestration NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
lymphocytes NN I-AdverseReaction I-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
lymphoid NN I-AdverseReaction I-AdverseReaction
tissues NN I-AdverseReaction I-AdverseReaction
GILENYA NN O O
may NN O O
therefore NN O O
increase NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
infections NN B-AdverseReaction B-AdverseReaction
some NN O O
serious NN B-Severity B-Severity
in NN O O
nature NN O O
[ NN O O
see NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.2 NN O O
) NN O O
] NN O O
. NN O O
Before NN O O
initiating NN O O
treatment NN O O
with NN O O
GILENYA NN O O
, NN O O
a NN O O
recent NN O O
CBC NN O O
( NN O O
i.e. NN O O
, NN O O
within NN O O
6 NN O O
months NN O O
or NN O O
after NN O O
discontinuation NN O O
of NN O O
prior NN O O
therapy NN O O
) NN O O
should NN O O
be NN O O
available NN O O
. NN O O
Consider NN O O
suspending NN O O
treatment NN O O
with NN O O
GILENYA NN O O
if NN O O
a NN O O
patient NN O O
develops NN O O
a NN O O
serious NN O O
infection NN O O
, NN O O
and NN O O
reassess NN O O
the NN O O
benefits NN O O
and NN O O
risks NN O O
prior NN O O
to NN O O
reinitiation NN O O
of NN O O
therapy NN O O
. NN O O
Because NN O O
the NN O O
elimination NN O O
of NN O O
fingolimod NN O O
after NN O O
discontinuation NN O O
may NN O O
take NN O O
up NN O O
to NN O O
2 NN O O
months NN O O
, NN O O
continue NN O O
monitoring NN O O
for NN O O
infections NN O O
throughout NN O O
this NN O O
period NN O O
. NN O O
Instruct NN O O
patients NN O O
receiving NN O O
GILENYA NN O O
to NN O O
report NN O O
symptoms NN O O
of NN O O
infections NN O O
to NN O O
a NN O O
physician NN O O
. NN O O
Patients NN O O
with NN O O
active NN O O
acute NN O O
or NN O O
chronic NN O O
infections NN O O
should NN O O
not NN O O
start NN O O
treatment NN O O
until NN O O
the NN O O
infection(s NN O O
) NN O O
is NN O O
resolved NN O O
. NN O O
In NN O O
MS NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
, NN O O
the NN O O
overall NN O O
rate NN O O
of NN O O
infections NN B-AdverseReaction B-AdverseReaction
( NN O O
72 NN O O
% NN O O
) NN O O
with NN O O
GILENYA NN O O
was NN O O
similar NN O O
to NN O O
placebo NN O O
. NN O O
However NN O O
, NN O O
bronchitis NN B-AdverseReaction B-AdverseReaction
herpes NN B-AdverseReaction B-AdverseReaction
zoster NN I-AdverseReaction I-AdverseReaction
influenza NN B-AdverseReaction B-AdverseReaction
sinusitis NN B-AdverseReaction B-AdverseReaction
and NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
were NN O O
more NN O O
common NN O O
in NN O O
GILENYA NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
occurred NN O O
at NN O O
a NN O O
rate NN O O
of NN O O
2.3 NN O O
% NN O O
in NN O O
the NN O O
GILENYA NN O O
group NN O O
versus NN O O
1.6 NN O O
% NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
. NN O O
Herpes NN O O
Viral NN O O
Infections NN O O
In NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
, NN O O
the NN O O
rate NN O O
of NN O O
herpetic NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
was NN O O
9 NN O O
% NN O O
in NN O O
patients NN O O
receiving NN O O
GILENYA NN O O
0.5 NN O O
mg NN O O
and NN O O
7 NN O O
% NN O O
on NN O O
placebo NN O O
. NN O O
Two NN O O
patients NN O O
died NN B-AdverseReaction B-AdverseReaction
of NN O O
herpetic NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
during NN O O
controlled NN O O
trials NN O O
. NN O O
One NN O O
death NN B-AdverseReaction B-AdverseReaction
was NN O O
due NN O O
to NN O O
disseminated NN B-AdverseReaction B-AdverseReaction
primary NN I-AdverseReaction I-AdverseReaction
herpes NN I-AdverseReaction I-AdverseReaction
zoster NN I-AdverseReaction I-AdverseReaction
and NN O O
the NN O O
other NN O O
to NN O O
herpes NN B-AdverseReaction B-AdverseReaction
simplex NN I-AdverseReaction I-AdverseReaction
encephalitis NN I-AdverseReaction I-AdverseReaction
In NN O O
both NN O O
cases NN O O
, NN O O
the NN O O
patients NN O O
were NN O O
taking NN O O
a NN O O
1.25 NN O O
mg NN O O
dose NN O O
of NN O O
fingolimod NN O O
( NN O O
higher NN O O
than NN O O
the NN O O
recommended NN O O
0.5 NN O O
mg NN O O
dose NN O O
) NN O O
and NN O O
had NN O O
received NN O O
high NN O O
- NN O O
dose NN O O
corticosteroid NN O O
therapy NN O O
to NN O O
treat NN O O
suspected NN O O
MS NN O O
relapses NN O O
. NN O O
Serious NN B-Severity B-Severity
life NN B-Severity B-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
events NN O O
of NN O O
disseminated NN O O
varicella NN O O
zoster NN O O
and NN O O
herpes NN B-AdverseReaction B-AdverseReaction
simplex NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
including NN O O
cases NN O O
of NN O O
encephalitis NN B-AdverseReaction B-AdverseReaction
and NN O O
multiorgan NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
have NN O O
occurred NN O O
with NN O O
GILENYA NN O O
0.5 NN O O
mg NN O O
in NN O O
the NN O O
postmarketing NN O O
setting NN O O
. NN O O
One NN O O
of NN O O
these NN O O
events NN O O
was NN O O
fatal NN B-AdverseReaction B-AdverseReaction
Include NN O O
disseminated NN O O
herpetic NN O O
infections NN O O
in NN O O
the NN O O
differential NN O O
diagnosis NN O O
of NN O O
patients NN O O
who NN O O
are NN O O
receiving NN O O
GILENYA NN O O
and NN O O
present NN O O
with NN O O
an NN O O
atypical NN O O
MS NN O O
relapse NN O O
or NN O O
multiorgan NN O O
failure NN O O
. NN O O
Cryptococcal NN O O
infections NN O O
Cryptococcal NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
including NN O O
cases NN O O
of NN O O
cryptococcal NN B-AdverseReaction B-AdverseReaction
meningitis NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
with NN O O
GILENYA NN O O
in NN O O
the NN O O
postmarketing NN O O
setting NN O O
. NN O O
Patients NN O O
with NN O O
symptoms NN O O
and NN O O
signs NN O O
consistent NN O O
with NN O O
cryptococcal NN O O
meningitis NN O O
should NN O O
undergo NN O O
prompt NN O O
diagnostic NN O O
evaluation NN O O
and NN O O
treatment NN O O
. NN O O
Prior NN O O
and NN O O
Concomitant NN O O
Treatment NN O O
with NN O O
Antineoplastic NN O O
, NN O O
Immunosuppressive NN O O
, NN O O
or NN O O
Immune NN O O
- NN O O
Modulating NN O O
Therapies NN O O
In NN O O
clinical NN O O
studies NN O O
, NN O O
patients NN O O
who NN O O
received NN O O
GILENYA NN O O
did NN O O
not NN O O
receive NN O O
concomitant NN O O
treatment NN O O
with NN O O
antineoplastic NN O O
, NN O O
non NN O O
- NN O O
corticosteroid NN O O
immunosuppressive NN O O
, NN O O
or NN O O
immune NN O O
- NN O O
modulating NN O O
therapies NN O O
used NN O O
for NN O O
treatment NN O O
of NN O O
MS. NN O O
Concomitant NN O O
use NN O O
of NN O O
GILENYA NN O O
with NN O O
any NN O O
of NN O O
these NN O O
therapies NN O O
, NN O O
and NN O O
also NN O O
with NN O O
corticosteroids NN O O
, NN O O
would NN O O
be NN O O
expected NN O O
to NN O O
increase NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
immunosuppression NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Drug NN O O
Interactions NN O O
( NN O O
7 NN O O
) NN O O
] NN O O
. NN O O
When NN O O
switching NN O O
to NN O O
GILENYA NN O O
from NN O O
immune NN O O
- NN O O
modulating NN O O
or NN O O
immunosuppressive NN O O
medications NN O O
, NN O O
consider NN O O
the NN O O
duration NN O O
of NN O O
their NN O O
effects NN O O
and NN O O
their NN O O
mode NN O O
of NN O O
action NN O O
to NN O O
avoid NN O O
unintended NN O O
additive NN O O
immunosuppressive NN O O
effects NN O O
. NN O O
Varicella NN O O
Zoster NN O O
Virus NN O O
Antibody NN O O
Testing/Vaccination NN O O
Patients NN O O
without NN O O
a NN O O
healthcare NN O O
professional NN O O
confirmed NN O O
history NN O O
of NN O O
chickenpox NN O O
or NN O O
without NN O O
documentation NN O O
of NN O O
a NN O O
full NN O O
course NN O O
of NN O O
vaccination NN O O
against NN O O
varicella NN O O
zoster NN O O
virus NN O O
( NN O O
VZV NN O O
) NN O O
should NN O O
be NN O O
tested NN O O
for NN O O
antibodies NN O O
to NN O O
VZV NN O O
before NN O O
initiating NN O O
GILENYA. NN O O
VZV NN O O
vaccination NN O O
of NN O O
antibody NN O O
- NN O O
negative NN O O
patients NN O O
is NN O O
recommended NN O O
prior NN O O
to NN O O
commencing NN O O
treatment NN O O
with NN O O
GILENYA NN O O
, NN O O
following NN O O
which NN O O
initiation NN O O
of NN O O
treatment NN O O
with NN O O
GILENYA NN O O
should NN O O
be NN O O
postponed NN O O
for NN O O
1 NN O O
month NN O O
to NN O O
allow NN O O
the NN O O
full NN O O
effect NN O O
of NN O O
vaccination NN O O
to NN O O
occur NN O O
. NN O O
5.3 NN O O
Progressive NN O O
Multifocal NN O O
Leukoencephalopathy NN O O
A NN O O
case NN O O
of NN O O
progressive NN B-AdverseReaction B-AdverseReaction
multifocal NN I-AdverseReaction I-AdverseReaction
leukoencephalopathy NN I-AdverseReaction I-AdverseReaction
( NN O O
PML NN O O
) NN O O
and NN O O
a NN O O
case NN O O
of NN O O
probable NN B-Factor B-Factor
PML NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
patients NN O O
with NN O O
MS NN O O
who NN O O
received NN O O
GILENYA NN O O
in NN O O
the NN O O
post NN O O
marketing NN O O
setting NN O O
. NN O O
PML NN B-AdverseReaction B-AdverseReaction
is NN O O
an NN O O
opportunistic NN B-AdverseReaction B-AdverseReaction
viral NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
brain NN I-AdverseReaction I-AdverseReaction
caused NN O O
by NN O O
the NN O O
JC NN B-AdverseReaction B-AdverseReaction
virus NN I-AdverseReaction I-AdverseReaction
( NN O O
JCV NN O O
) NN O O
that NN O O
typically NN B-Factor B-Factor
only NN O O
occurs NN O O
in NN O O
patients NN O O
who NN O O
are NN O O
immunocompromised NN O O
, NN O O
and NN O O
that NN O O
usually NN B-Factor B-Factor
leads NN O O
to NN O O
death NN B-AdverseReaction B-AdverseReaction
or NN O O
severe NN B-Severity B-Severity
disability NN B-AdverseReaction B-AdverseReaction
One NN O O
patient NN O O
developed NN O O
PML NN B-AdverseReaction B-AdverseReaction
after NN O O
taking NN O O
GILENYA NN O O
for NN O O
approximately NN O O
2.5 NN O O
years NN O O
. NN O O
The NN O O
other NN O O
patient NN O O
developed NN O O
probable NN B-Factor B-Factor
PML NN B-AdverseReaction B-AdverseReaction
after NN O O
taking NN O O
GILENYA NN O O
for NN O O
approximately NN O O
4 NN O O
years NN O O
. NN O O
The NN O O
diagnosis NN O O
of NN O O
probable NN B-Factor B-Factor
PML NN B-AdverseReaction B-AdverseReaction
was NN O O
based NN O O
on NN O O
MRI NN O O
findings NN O O
and NN O O
the NN O O
detection NN O O
of NN O O
JCV NN O O
DNA NN O O
in NN O O
the NN O O
CSF NN O O
in NN O O
the NN O O
absence NN B-Negation B-Negation
of NN O O
clinical NN O O
signs NN O O
or NN O O
symptoms NN O O
specific NN O O
to NN O O
PML NN B-AdverseReaction B-AdverseReaction
The NN O O
patients NN O O
had NN O O
no NN O O
other NN O O
identified NN O O
systemic NN O O
medical NN O O
conditions NN O O
resulting NN O O
in NN O O
compromised NN B-AdverseReaction B-AdverseReaction
immune NN I-AdverseReaction I-AdverseReaction
system NN I-AdverseReaction I-AdverseReaction
function NN O O
and NN O O
had NN O O
not NN O O
previously NN O O
been NN O O
treated NN O O
with NN O O
natalizumab NN B-Negation B-Negation
which NN O O
has NN O O
a NN O O
known NN O O
association NN O O
with NN O O
PML NN B-AdverseReaction B-AdverseReaction
The NN O O
patients NN O O
were NN O O
also NN O O
not NN O O
taking NN O O
any NN O O
immunosuppressive NN O O
or NN O O
immunomodulatory NN O O
medications NN O O
concomitantly NN O O
. NN O O
At NN O O
the NN O O
first NN O O
sign NN O O
or NN O O
symptom NN O O
suggestive NN O O
of NN O O
PML NN O O
, NN O O
withhold NN O O
GILENYA NN O O
and NN O O
perform NN O O
an NN O O
appropriate NN O O
diagnostic NN O O
evaluation NN O O
. NN O O
MRI NN O O
signs NN O O
may NN O O
be NN O O
apparent NN O O
before NN O O
clinical NN O O
symptoms NN O O
. NN O O
Typical NN B-Factor B-Factor
symptoms NN O O
associated NN O O
with NN O O
PML NN B-AdverseReaction B-AdverseReaction
are NN O O
diverse NN O O
, NN O O
progress NN O O
over NN O O
days NN O O
to NN O O
weeks NN O O
, NN O O
and NN O O
include NN O O
progressive NN B-AdverseReaction B-AdverseReaction
weakness NN I-AdverseReaction I-AdverseReaction
on NN I-AdverseReaction I-AdverseReaction
one NN I-AdverseReaction I-AdverseReaction
side NN I-AdverseReaction I-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
body NN I-AdverseReaction I-AdverseReaction
or NN O O
clumsiness NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
limbs NN I-AdverseReaction I-AdverseReaction
disturbance NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
vision NN I-AdverseReaction I-AdverseReaction
and NN O O
changes NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
thinking NN I-AdverseReaction I-AdverseReaction
memory NN O O
, NN O O
and NN O O
orientation NN O O
leading NN O O
to NN O O
confusion NN B-AdverseReaction B-AdverseReaction
and NN O O
personality NN B-AdverseReaction B-AdverseReaction
changes NN I-AdverseReaction I-AdverseReaction
5.4 NN O O
Macular NN O O
Edema NN O O
Fingolimod NN O O
increases NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
macular NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
Perform NN O O
an NN O O
examination NN O O
of NN O O
the NN O O
fundus NN O O
including NN O O
the NN O O
macula NN O O
in NN O O
all NN O O
patients NN O O
before NN O O
starting NN O O
treatment NN O O
, NN O O
again NN O O
3 NN O O
- NN O O
4 NN O O
months NN O O
after NN O O
starting NN O O
treatment NN O O
, NN O O
and NN O O
again NN O O
at NN O O
any NN O O
time NN O O
after NN O O
a NN O O
patient NN O O
reports NN O O
visual NN O O
disturbances NN O O
while NN O O
on NN O O
GILENYA NN O O
therapy NN O O
. NN O O
A NN O O
dose NN O O
- NN O O
dependent NN O O
increase NN O O
in NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
macular NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
the NN O O
GILENYA NN O O
clinical NN O O
development NN O O
program NN O O
. NN O O
In NN O O
2-year NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
studies NN O O
in NN O O
patients NN O O
with NN O O
multiple NN O O
sclerosis NN O O
, NN O O
macular NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
with NN O O
or NN O O
without NN O O
visual NN B-AdverseReaction B-AdverseReaction
symptoms NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
1.5 NN O O
% NN O O
of NN O O
patients NN O O
( NN O O
11/799 NN O O
) NN O O
treated NN O O
with NN O O
fingolimod NN O O
1.25 NN O O
mg NN O O
, NN O O
0.5 NN O O
% NN O O
of NN O O
patients NN O O
( NN O O
4/783 NN O O
) NN O O
treated NN O O
with NN O O
GILENYA NN O O
0.5 NN O O
mg NN O O
and NN O O
0.4 NN O O
% NN O O
of NN O O
patients NN O O
( NN O O
3/773 NN O O
) NN O O
treated NN O O
with NN O O
placebo NN O O
. NN O O
Macular NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
occurred NN O O
predominantly NN O O
during NN O O
the NN O O
first NN O O
3 NN O O
to NN O O
4 NN O O
months NN O O
of NN O O
therapy NN O O
. NN O O
These NN O O
clinical NN O O
trials NN O O
excluded NN O O
patients NN O O
with NN O O
diabetes NN O O
mellitus NN O O
, NN O O
a NN O O
known NN O O
risk NN O O
factor NN O O
for NN O O
macular NN O O
edema NN O O
( NN O O
see NN O O
below NN O O
Macular NN O O
Edema NN O O
in NN O O
Patients NN O O
with NN O O
History NN O O
of NN O O
Uveitis NN O O
or NN O O
Diabetes NN O O
Mellitus NN O O
) NN O O
. NN O O
Symptoms NN O O
of NN O O
macular NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
included NN O O
blurred NN B-AdverseReaction B-AdverseReaction
vision NN I-AdverseReaction I-AdverseReaction
and NN O O
decreased NN B-AdverseReaction B-AdverseReaction
visual NN I-AdverseReaction I-AdverseReaction
acuity NN I-AdverseReaction I-AdverseReaction
Routine NN O O
ophthalmological NN O O
examination NN O O
detected NN O O
macular NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
in NN O O
some NN O O
patients NN O O
with NN O O
no NN B-Negation B-Negation
visual NN B-AdverseReaction B-AdverseReaction
symptoms NN I-AdverseReaction I-AdverseReaction
Macular NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
generally NN O O
partially NN O O
or NN O O
completely NN O O
resolved NN O O
with NN O O
or NN O O
without NN O O
treatment NN O O
after NN O O
drug NN O O
discontinuation NN O O
. NN O O
Some NN O O
patients NN O O
had NN O O
residual NN O O
visual NN B-AdverseReaction B-AdverseReaction
acuity NN I-AdverseReaction I-AdverseReaction
loss NN I-AdverseReaction I-AdverseReaction
even NN O O
after NN O O
resolution NN O O
of NN O O
macular NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
Macular NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
has NN O O
also NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
taking NN O O
GILENYA NN O O
0.5 NN O O
mg NN O O
in NN O O
the NN O O
postmarketing NN O O
setting NN O O
, NN O O
usually NN O O
within NN O O
the NN O O
first NN O O
6 NN O O
months NN O O
of NN O O
treatment NN O O
. NN O O
Continuation NN O O
of NN O O
GILENYA NN O O
in NN O O
patients NN O O
who NN O O
develop NN O O
macular NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
has NN O O
not NN O O
been NN O O
evaluated NN O O
. NN O O
A NN O O
decision NN O O
on NN O O
whether NN O O
or NN O O
not NN O O
to NN O O
discontinue NN O O
GILENYA NN O O
therapy NN O O
should NN O O
include NN O O
an NN O O
assessment NN O O
of NN O O
the NN O O
potential NN O O
benefits NN O O
and NN O O
risks NN O O
for NN O O
the NN O O
individual NN O O
patient NN O O
. NN O O
The NN O O
risk NN O O
of NN O O
recurrence NN O O
after NN O O
rechallenge NN O O
has NN O O
not NN O O
been NN O O
evaluated NN O O
. NN O O
Macular NN O O
Edema NN O O
in NN O O
Patients NN O O
with NN O O
History NN O O
of NN O O
Uveitis NN O O
or NN O O
Diabetes NN O O
Mellitus NN O O
Patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
uveitis NN O O
and NN O O
patients NN O O
with NN O O
diabetes NN O O
mellitus NN O O
are NN O O
at NN O O
increased NN O O
risk NN B-Factor B-Factor
of NN O O
macular NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
during NN O O
GILENYA NN O O
therapy NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
macular NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
is NN O O
also NN O O
increased NN O O
in NN O O
MS NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
uveitis NN O O
. NN O O
In NN O O
the NN O O
combined NN O O
clinical NN O O
trial NN O O
experience NN O O
with NN O O
all NN O O
doses NN O O
of NN O O
fingolimod NN O O
, NN O O
the NN O O
rate NN O O
of NN O O
macular NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
was NN O O
approximately NN O O
20 NN O O
% NN O O
in NN O O
MS NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
uveitis NN O O
versus NN O O
0.6 NN O O
% NN O O
in NN O O
those NN O O
without NN O O
a NN O O
history NN O O
of NN O O
uveitis NN O O
. NN O O
GILENYA NN O O
has NN O O
not NN O O
been NN O O
tested NN O O
in NN O O
MS NN O O
patients NN O O
with NN O O
diabetes NN O O
mellitus NN O O
. NN O O
In NN O O
addition NN O O
to NN O O
the NN O O
examination NN O O
of NN O O
the NN O O
fundus NN O O
including NN O O
the NN O O
macula NN O O
prior NN O O
to NN O O
treatment NN O O
and NN O O
at NN O O
3 NN O O
- NN O O
4 NN O O
months NN O O
after NN O O
starting NN O O
treatment NN O O
, NN O O
MS NN O O
patients NN O O
with NN O O
diabetes NN O O
mellitus NN O O
or NN O O
a NN O O
history NN O O
of NN O O
uveitis NN O O
should NN O O
have NN O O
regular NN O O
follow NN O O
- NN O O
up NN O O
examinations NN O O
. NN O O
5.5 NN O O
Posterior NN O O
Reversible NN O O
Encephalopathy NN O O
Syndrome NN O O
There NN O O
have NN O O
been NN O O
rare NN O O
cases NN O O
of NN O O
posterior NN B-AdverseReaction B-AdverseReaction
reversible NN I-AdverseReaction I-AdverseReaction
encephalopathy NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
( NN O O
PRES NN O O
) NN O O
reported NN O O
in NN O O
patients NN O O
receiving NN O O
GILENYA. NN O O
Symptoms NN O O
reported NN O O
included NN O O
sudden NN O O
onset NN O O
of NN O O
severe NN B-Severity B-Severity
headache NN B-AdverseReaction B-AdverseReaction
altered NN B-AdverseReaction B-AdverseReaction
mental NN I-AdverseReaction I-AdverseReaction
status NN I-AdverseReaction I-AdverseReaction
visual NN B-AdverseReaction B-AdverseReaction
disturbances NN I-AdverseReaction I-AdverseReaction
and NN O O
seizure NN B-AdverseReaction B-AdverseReaction
Symptoms NN O O
of NN O O
PRES NN B-AdverseReaction B-AdverseReaction
are NN O O
usually NN O O
reversible NN O O
but NN O O
may NN B-Factor B-Factor
evolve NN O O
into NN O O
ischemic NN B-AdverseReaction B-AdverseReaction
stroke NN I-AdverseReaction I-AdverseReaction
or NN O O
cerebral NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
Delay NN O O
in NN O O
diagnosis NN O O
and NN O O
treatment NN O O
may NN O O
lead NN O O
to NN O O
permanent NN O O
neurological NN O O
sequelae NN O O
. NN O O
If NN O O
PRES NN O O
is NN O O
suspected NN O O
, NN O O
GILENYA NN O O
should NN O O
be NN O O
discontinued NN O O
. NN O O
5.6 NN O O
Respiratory NN O O
Effects NN O O
Dose NN O O
- NN O O
dependent NN O O
reductions NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
forced NN I-AdverseReaction I-AdverseReaction
expiratory NN I-AdverseReaction I-AdverseReaction
volume NN I-AdverseReaction I-AdverseReaction
over NN I-AdverseReaction I-AdverseReaction
1 NN I-AdverseReaction I-AdverseReaction
second NN I-AdverseReaction I-AdverseReaction
( NN O O
FEV1 NN O O
) NN O O
and NN O O
diffusion NN O O
lung NN O O
capacity NN O O
for NN O O
carbon NN O O
monoxide NN O O
( NN O O
DLCO NN O O
) NN O O
were NN O O
observed NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
GILENYA NN O O
as NN O O
early NN O O
as NN O O
1 NN O O
month NN O O
after NN O O
treatment NN O O
initiation NN O O
. NN O O
In NN O O
2-year NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
, NN O O
the NN O O
reduction NN O O
from NN O O
baseline NN O O
in NN O O
the NN O O
percent NN O O
of NN O O
predicted NN O O
values NN O O
for NN O O
FEV1 NN O O
at NN O O
the NN O O
time NN O O
of NN O O
last NN O O
assessment NN O O
on NN O O
drug NN O O
was NN O O
2.8 NN B-Severity B-Severity
% NN I-Severity I-Severity
for NN O O
GILENYA NN O O
0.5 NN O O
mg NN O O
and NN O O
1.0 NN O O
% NN O O
for NN O O
placebo NN O O
. NN O O
For NN O O
DLCO NN O O
, NN O O
the NN O O
reduction NN O O
from NN O O
baseline NN O O
in NN O O
percent NN O O
of NN O O
predicted NN O O
values NN O O
at NN O O
the NN O O
time NN O O
of NN O O
last NN O O
assessment NN O O
on NN O O
drug NN O O
was NN O O
3.3 NN B-Severity B-Severity
% NN I-Severity I-Severity
for NN O O
GILENYA NN O O
0.5 NN O O
mg NN O O
and NN O O
0.5 NN O O
% NN O O
for NN O O
placebo NN O O
. NN O O
The NN O O
changes NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
FEV1 NN I-AdverseReaction I-AdverseReaction
appear NN O O
to NN O O
be NN O O
reversible NN B-Severity B-Severity
after NN O O
treatment NN O O
discontinuation NN O O
. NN O O
There NN O O
is NN O O
insufficient NN O O
information NN O O
to NN O O
determine NN O O
the NN O O
reversibility NN O O
of NN O O
the NN O O
decrease NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
DLCO NN I-AdverseReaction I-AdverseReaction
after NN O O
drug NN O O
discontinuation NN O O
. NN O O
In NN O O
MS NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
, NN O O
dyspnea NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
in NN O O
9 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
GILENYA NN O O
0.5 NN O O
mg NN O O
and NN O O
7 NN O O
% NN O O
of NN O O
patients NN O O
receiving NN O O
placebo NN O O
. NN O O
Several NN O O
patients NN O O
discontinued NN O O
GILENYA NN O O
because NN O O
of NN O O
unexplained NN O O
dyspnea NN B-AdverseReaction B-AdverseReaction
during NN O O
the NN O O
extension NN O O
( NN O O
uncontrolled NN O O
) NN O O
studies NN O O
. NN O O
GILENYA NN O O
has NN O O
not NN O O
been NN O O
tested NN O O
in NN O O
MS NN O O
patients NN O O
with NN O O
compromised NN O O
respiratory NN O O
function NN O O
. NN O O
Spirometric NN O O
evaluation NN O O
of NN O O
respiratory NN O O
function NN O O
and NN O O
evaluation NN O O
of NN O O
DLCO NN O O
should NN O O
be NN O O
performed NN O O
during NN O O
therapy NN O O
with NN O O
GILENYA NN O O
if NN O O
clinically NN O O
indicated NN O O
. NN O O
5.7 NN O O
Liver NN O O
Injury NN O O
Elevations NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
liver NN I-AdverseReaction I-AdverseReaction
enzymes NN I-AdverseReaction I-AdverseReaction
may NN B-Factor B-Factor
occur NN O O
in NN O O
patients NN O O
receiving NN O O
GILENYA. NN O O
Recent NN O O
( NN O O
i.e. NN O O
, NN O O
within NN O O
last NN O O
6 NN O O
months NN O O
) NN O O
transaminase NN O O
and NN O O
bilirubin NN O O
levels NN O O
should NN O O
be NN O O
available NN O O
before NN O O
initiation NN O O
of NN O O
GILENYA NN O O
therapy NN O O
. NN O O
In NN O O
2-year NN O O
placebo NN O O
- NN O O
controlled NN O O
clinical NN O O
trials NN O O
, NN O O
elevation NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
liver NN I-AdverseReaction I-AdverseReaction
transaminases NN I-AdverseReaction I-AdverseReaction
to NN O O
3-fold NN B-Severity B-Severity
the NN I-Severity I-Severity
upper NN I-Severity I-Severity
limit NN I-Severity I-Severity
of NN I-Severity I-Severity
normal NN I-Severity I-Severity
( NN I-Severity I-Severity
ULN NN I-Severity I-Severity
) NN I-Severity I-Severity
or NN O O
greater NN O O
occurred NN O O
in NN O O
14 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
GILENYA NN O O
0.5 NN O O
mg NN O O
and NN O O
3 NN O O
% NN O O
of NN O O
patients NN O O
on NN O O
placebo NN O O
. NN O O
Elevations NN O O
5-fold NN O O
the NN O O
ULN NN O O
or NN O O
greater NN O O
occurred NN O O
in NN O O
4.5 NN O O
% NN O O
of NN O O
patients NN O O
on NN O O
GILENYA NN O O
and NN O O
1 NN O O
% NN O O
of NN O O
patients NN O O
on NN O O
placebo NN O O
. NN O O
The NN O O
majority NN O O
of NN O O
elevations NN O O
occurred NN O O
within NN O O
6 NN O O
to NN O O
9 NN O O
months NN O O
. NN O O
In NN O O
clinical NN O O
trials NN O O
, NN O O
GILENYA NN O O
was NN O O
discontinued NN O O
if NN O O
the NN O O
elevation NN O O
exceeded NN O O
5 NN O O
times NN O O
the NN O O
ULN. NN O O
Serum NN O O
transaminase NN O O
levels NN O O
returned NN O O
to NN O O
normal NN O O
within NN O O
approximately NN O O
2 NN O O
months NN O O
after NN O O
discontinuation NN O O
of NN O O
GILENYA. NN O O
Recurrence NN O O
of NN O O
liver NN B-AdverseReaction B-AdverseReaction
transaminase NN I-AdverseReaction I-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
occurred NN O O
with NN O O
rechallenge NN O O
in NN O O
some NN O O
patients NN O O
. NN O O
Liver NN O O
enzymes NN O O
should NN O O
be NN O O
monitored NN O O
in NN O O
patients NN O O
who NN O O
develop NN O O
symptoms NN O O
suggestive NN O O
of NN O O
hepatic NN O O
dysfunction NN O O
, NN O O
such NN O O
as NN O O
unexplained NN O O
nausea NN O O
, NN O O
vomiting NN O O
, NN O O
abdominal NN O O
pain NN O O
, NN O O
fatigue NN O O
, NN O O
anorexia NN O O
, NN O O
or NN O O
jaundice NN O O
and/or NN O O
dark NN O O
urine NN O O
. NN O O
GILENYA NN O O
should NN O O
be NN O O
discontinued NN O O
if NN O O
significant NN O O
liver NN O O
injury NN O O
is NN O O
confirmed NN O O
. NN O O
Patients NN O O
with NN O O
preexisting NN O O
liver NN O O
disease NN O O
may NN O O
be NN O O
at NN O O
increased NN O O
risk NN B-Factor B-Factor
of NN O O
developing NN O O
elevated NN B-AdverseReaction B-AdverseReaction
liver NN I-AdverseReaction I-AdverseReaction
enzymes NN I-AdverseReaction I-AdverseReaction
when NN O O
taking NN O O
GILENYA. NN O O
Because NN O O
GILENYA NN O O
exposure NN O O
is NN O O
doubled NN O O
in NN O O
patients NN O O
with NN O O
severe NN O O
hepatic NN O O
impairment NN O O
, NN O O
these NN O O
patients NN O O
should NN O O
be NN O O
closely NN O O
monitored NN O O
, NN O O
as NN O O
the NN O O
risk NN O O
of NN O O
adverse NN O O
reactions NN O O
is NN O O
greater NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.6 NN O O
) NN O O
, NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.3 NN O O
) NN O O
] NN O O
. NN O O
5.8 NN O O
Fetal NN O O
Risk NN O O
Based NN O O
on NN O O
animal NN B-Animal B-Animal
studies NN O O
, NN O O
GILENYA NN O O
may NN O O
cause NN O O
fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
Because NN O O
it NN O O
takes NN O O
approximately NN O O
2 NN O O
months NN O O
to NN O O
eliminate NN O O
GILENYA NN O O
from NN O O
the NN O O
body NN O O
, NN O O
women NN O O
of NN O O
childbearing NN O O
potential NN O O
should NN O O
use NN O O
effective NN O O
contraception NN O O
to NN O O
avoid NN O O
pregnancy NN O O
during NN O O
and NN O O
for NN O O
2 NN O O
months NN O O
after NN O O
stopping NN O O
GILENYA NN O O
treatment NN O O
. NN O O
5.9 NN O O
Blood NN O O
Pressure NN O O
Effects NN O O
In NN O O
MS NN O O
controlled NN O O
clinical NN O O
trials NN O O
, NN O O
patients NN O O
treated NN O O
with NN O O
GILENYA NN O O
0.5 NN O O
mg NN O O
had NN O O
an NN O O
average NN O O
increase NN O O
over NN O O
placebo NN O O
of NN O O
approximately NN O O
3 NN B-Severity B-Severity
mmHg NN I-Severity I-Severity
in NN O O
systolic NN O O
pressure NN O O
, NN O O
and NN O O
approximately NN O O
2 NN B-Severity B-Severity
mmHg NN I-Severity I-Severity
in NN O O
diastolic NN O O
pressure NN O O
, NN O O
first NN O O
detected NN O O
after NN O O
approximately NN O O
1 NN O O
month NN O O
of NN O O
treatment NN O O
initiation NN O O
, NN O O
and NN O O
persisting NN O O
with NN O O
continued NN O O
treatment NN O O
. NN O O
Hypertension NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
as NN O O
an NN O O
adverse NN O O
reaction NN O O
in NN O O
8 NN O O
% NN O O
of NN O O
patients NN O O
on NN O O
GILENYA NN O O
0.5 NN O O
mg NN O O
and NN O O
in NN O O
4 NN O O
% NN O O
of NN O O
patients NN O O
on NN O O
placebo NN O O
. NN O O
Blood NN O O
pressure NN O O
should NN O O
be NN O O
monitored NN O O
during NN O O
treatment NN O O
with NN O O
GILENYA. NN O O
5.10 NN O O
Immune NN O O
System NN O O
Effects NN O O
Following NN O O
GILENYA NN O O
Discontinuation NN O O
Fingolimod NN O O
remains NN O O
in NN O O
the NN O O
blood NN O O
and NN O O
has NN O O
pharmacodynamic NN O O
effects NN O O
, NN O O
including NN O O
decreased NN B-AdverseReaction B-AdverseReaction
lymphocyte NN I-AdverseReaction I-AdverseReaction
counts NN I-AdverseReaction I-AdverseReaction
for NN O O
up NN O O
to NN O O
2 NN O O
months NN O O
following NN O O
the NN O O
last NN O O
dose NN O O
of NN O O
GILENYA. NN O O
Lymphocyte NN O O
counts NN O O
generally NN O O
return NN O O
to NN O O
the NN O O
normal NN O O
range NN O O
within NN O O
1 NN O O
- NN O O
2 NN O O
months NN O O
of NN O O
stopping NN O O
therapy NN O O
[ NN O O
see NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.2 NN O O
) NN O O
] NN O O
. NN O O
Because NN O O
of NN O O
the NN O O
continuing NN O O
pharmacodynamic NN O O
effects NN O O
of NN O O
fingolimod NN O O
, NN O O
initiating NN O O
other NN O O
drugs NN O O
during NN O O
this NN O O
period NN O O
warrants NN O O
the NN O O
same NN O O
considerations NN O O
needed NN O O
for NN O O
concomitant NN O O
administration NN O O
( NN O O
e.g. NN O O
, NN O O
risk NN B-Factor B-Factor
of NN O O
additive NN O O
immunosuppressant NN B-AdverseReaction B-AdverseReaction
effects NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Drug NN O O
Interactions NN O O
( NN O O
7 NN O O
) NN O O
] NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
serious NN O O
adverse NN O O
reactionsare NN O O
discussed NN O O
elsewhere NN O O
in NN O O
the NN O O
labeling NN O O
: NN O O
* NN O O
Nephrogenic NN B-AdverseReaction B-AdverseReaction
systemic NN I-AdverseReaction I-AdverseReaction
fibrosis NN I-AdverseReaction I-AdverseReaction
( NN O O
NSF NN O O
) NN O O
[ NN O O
see NN O O
Boxed NN O O
Warning NN O O
and NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
and NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
Most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
incidence NN O O
>= NN O O
0.5 NN O O
% NN O O
) NN O O
are NN O O
nausea NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
feeling NN B-AdverseReaction B-AdverseReaction
hot NN I-AdverseReaction I-AdverseReaction
dizziness NN B-AdverseReaction B-AdverseReaction
and NN O O
back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
( NN O O
6 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Bayer NN O O
HealthCare NN O O
Pharmaceuticals NN O O
Inc. NN O O
at NN O O
1 NN O O
- NN O O
888 NN O O
- NN O O
84-BAYER NN O O
( NN O O
1 NN O O
- NN O O
888 NN O O
- NN O O
842 NN O O
- NN O O
2937 NN O O
) NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O
The NN O O
adverse NN O O
reactions NN O O
described NN O O
in NN O O
this NN O O
section NN O O
reflect NN O O
EOVIST NN O O
exposure NN O O
in NN O O
1,989 NN O O
subjects NN O O
with NN O O
the NN O O
majority NN O O
( NN O O
1,581 NN O O
subjects NN O O
) NN O O
receiving NN O O
the NN O O
recommended NN O O
dose NN O O
. NN O O
Overall NN O O
, NN O O
59 NN O O
% NN O O
of NN O O
the NN O O
subjects NN O O
were NN O O
men NN O O
and NN O O
the NN O O
ethnic NN O O
distribution NN O O
was NN O O
64 NN O O
% NN O O
Caucasian NN O O
, NN O O
22 NN O O
% NN O O
Asian NN O O
, NN O O
3 NN O O
% NN O O
Hispanic NN O O
, NN O O
2 NN O O
% NN O O
Black NN O O
, NN O O
and NN O O
0.5 NN O O
% NN O O
of NN O O
subjects NN O O
consisted NN O O
of NN O O
other NN O O
ethnic NN O O
groups NN O O
. NN O O
The NN O O
average NN O O
age NN O O
was NN O O
57 NN O O
years NN O O
( NN O O
age NN O O
range NN O O
from NN O O
19 NN O O
to NN O O
84 NN O O
years NN O O
) NN O O
. NN O O
Overall NN O O
, NN O O
4 NN O O
% NN O O
of NN O O
subjects NN O O
reported NN O O
one NN O O
or NN O O
more NN O O
adverse NN O O
reactions NN O O
following NN O O
EOVIST NN O O
administration NN O O
. NN O O
The NN O O
most NN O O
frequent NN O O
( NN O O
>= NN O O
0.5 NN O O
% NN O O
) NN O O
adverse NN O O
reactions NN O O
associated NN O O
with NN O O
the NN O O
use NN O O
of NN O O
EOVIST NN O O
were NN O O
nausea NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
feeling NN B-AdverseReaction B-AdverseReaction
hot NN I-AdverseReaction I-AdverseReaction
dizziness NN B-AdverseReaction B-AdverseReaction
and NN O O
back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
Adverse NN O O
reactions NN O O
were NN O O
predominantly NN O O
of NN O O
mild NN O O
to NN O O
moderate NN O O
severity NN O O
. NN O O
Table NN O O
1 NN O O
lists NN O O
adverse NN O O
reactions NN O O
that NN O O
occurred NN O O
in NN O O
>= NN O O
0.1 NN O O
% NN O O
of NN O O
subjects NN O O
treated NN O O
with NN O O
EOVIST. NN O O
Table NN O O
1 NN O O
Adverse NN O O
Reactions NN O O
Reaction NN O O
Rate NN O O
( NN O O
%)n NN O O
= NN O O
1581 NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
1.1 NN O O
Headache NN B-AdverseReaction B-AdverseReaction
1.1 NN O O
Feeling NN B-AdverseReaction B-AdverseReaction
hot NN I-AdverseReaction I-AdverseReaction
0.8 NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
0.6 NN O O
Back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
0.6 NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
0.4 NN O O
Blood NN B-AdverseReaction B-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
0.4 NN O O
Injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
( NN O O
pain NN O O
, NN O O
burning NN O O
, NN O O
coldness NN O O
, NN O O
extravasation NN O O
, NN O O
irritation NN O O
) NN O O
0.4 NN O O
Dysgeusia NN B-AdverseReaction B-AdverseReaction
0.4 NN O O
Paresthesia NN B-AdverseReaction B-AdverseReaction
0.3 NN O O
Flushing NN B-AdverseReaction B-AdverseReaction
0.3 NN O O
Parosmia NN B-AdverseReaction B-AdverseReaction
0.3 NN O O
Pruritus NN O O
( NN O O
generalized NN O O
, NN O O
eye NN O O
) NN O O
0.3 NN O O
Rash NN B-AdverseReaction B-AdverseReaction
0.3 NN O O
Respiratory NN B-AdverseReaction B-AdverseReaction
disorders NN I-AdverseReaction I-AdverseReaction
( NN O O
dyspnea NN O O
, NN O O
respiratory NN B-AdverseReaction B-AdverseReaction
distress NN I-AdverseReaction I-AdverseReaction
0.2 NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
0.2 NN O O
Chest NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
0.1 NN O O
Vertigo NN B-AdverseReaction B-AdverseReaction
0.1 NN O O
Dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
0.1 NN O O
Chills NN B-AdverseReaction B-AdverseReaction
0.1 NN O O
Feeling NN B-AdverseReaction B-AdverseReaction
abnormal NN I-AdverseReaction I-AdverseReaction
0.1 NN O O
Adverse NN O O
reactions NN O O
that NN O O
occurred NN O O
with NN O O
a NN O O
frequency NN O O
of NN O O
< NN O O
0.1 NN O O
% NN O O
in NN O O
subjects NN O O
who NN O O
received NN O O
EOVIST NN O O
include NN O O
: NN O O
tremor NN B-AdverseReaction B-AdverseReaction
akathisia NN B-AdverseReaction B-AdverseReaction
bundle NN B-AdverseReaction B-AdverseReaction
branch NN I-AdverseReaction I-AdverseReaction
block NN I-AdverseReaction I-AdverseReaction
palpitation NN B-AdverseReaction B-AdverseReaction
oral NN B-AdverseReaction B-AdverseReaction
discomfort NN I-AdverseReaction I-AdverseReaction
salivary NN B-AdverseReaction B-AdverseReaction
hypersecretion NN I-AdverseReaction I-AdverseReaction
maculopapular NN B-AdverseReaction B-AdverseReaction
rash NN I-AdverseReaction I-AdverseReaction
hyperhidrosis NN B-AdverseReaction B-AdverseReaction
discomfort NN B-AdverseReaction B-AdverseReaction
and NN O O
malaise NN B-AdverseReaction B-AdverseReaction
Elevation NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
iron NN I-AdverseReaction I-AdverseReaction
values NN O O
and NN O O
serum NN O O
bilirubin NN O O
laboratory NN O O
values NN O O
were NN O O
reported NN O O
in NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
of NN O O
patients NN O O
after NN O O
administration NN O O
of NN O O
EOVIST. NN O O
The NN O O
values NN O O
did NN O O
not NN O O
exceed NN O O
more NN O O
than NN O O
3 NN O O
times NN O O
the NN O O
baseline NN O O
values NN O O
and NN O O
returned NN O O
to NN O O
baseline NN O O
within NN O O
1 NN O O
to NN O O
4 NN O O
days NN O O
. NN O O
6.2 NN O O
Postmarketing NN O O
Experience NN O O
The NN O O
following NN O O
additional NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
reported NN O O
during NN O O
the NN O O
postmarketing NN O O
use NN O O
of NN O O
EOVIST. NN O O
Because NN O O
these NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
* NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
( NN O O
anaphylacticshock NN O O
, NN O O
hypotension NN B-AdverseReaction B-AdverseReaction
pharyngolaryngeal NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
urticaria NN B-AdverseReaction B-AdverseReaction
face NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
rhinitis NN B-AdverseReaction B-AdverseReaction
conjunctivitis NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
hypoesthesia NN B-AdverseReaction B-AdverseReaction
sneezing NN B-AdverseReaction B-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
and NN O O
pallor NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
Tachycardia NN B-AdverseReaction B-AdverseReaction
* NN O O
Restlessness NN B-AdverseReaction B-AdverseReaction
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
NEPHROGENIC NN B-AdverseReaction B-AdverseReaction
SYSTEMIC NN I-AdverseReaction I-AdverseReaction
FIBROSIS NN I-AdverseReaction I-AdverseReaction
( NN O O
NSF NN O O
) NN O O
WARNING NN O O
: NN O O
NEPHROGENIC NN B-AdverseReaction B-AdverseReaction
SYSTEMIC NN I-AdverseReaction I-AdverseReaction
FIBROSIS NN I-AdverseReaction I-AdverseReaction
( NN O O
NSF NN O O
) NN O O
Gadolinium NN B-DrugClass B-DrugClass
- NN I-DrugClass I-DrugClass
based NN I-DrugClass I-DrugClass
contrast NN I-DrugClass I-DrugClass
agents NN I-DrugClass I-DrugClass
( NN O O
GBCAs NN O O
) NN O O
increase NN O O
the NN O O
risk NN O O
for NN O O
NSF NN B-AdverseReaction B-AdverseReaction
among NN O O
patients NN O O
with NN O O
impaired NN O O
elimination NN O O
of NN O O
the NN O O
drugs NN O O
. NN O O
Avoid NN O O
use NN O O
of NN O O
GBCAs NN O O
in NN O O
these NN O O
patients NN O O
unless NN O O
the NN O O
diagnostic NN O O
information NN O O
is NN O O
essential NN O O
and NN O O
not NN O O
available NN O O
with NN O O
non NN O O
- NN O O
contrasted NN O O
MRI NN O O
or NN O O
other NN O O
modalities NN O O
. NN O O
NSF NN B-AdverseReaction B-AdverseReaction
may NN B-Factor B-Factor
result NN O O
in NN O O
fatal NN B-AdverseReaction B-AdverseReaction
or NN O O
debilitating NN B-Severity B-Severity
fibrosis NN B-AdverseReaction B-AdverseReaction
affecting NN O O
the NN O O
skin NN O O
, NN O O
muscle NN O O
and NN O O
internal NN O O
organs NN O O
. NN O O
* NN O O
The NN O O
risk NN B-Factor B-Factor
for NN O O
NSF NN B-AdverseReaction B-AdverseReaction
appears NN O O
highest NN O O
among NN O O
patients NN O O
with:oChronic NN O O
, NN O O
severe NN O O
kidney NN O O
disease NN O O
( NN O O
GFR NN O O
< NN O O
30 NN O O
mL/min/1.73m2 NN O O
) NN O O
, NN O O
oroAcute NN O O
kidney NN O O
injury NN O O
. NN O O
* NN O O
Screen NN O O
patients NN O O
for NN O O
acute NN O O
kidney NN O O
injury NN O O
and NN O O
other NN O O
conditions NN O O
that NN O O
may NN O O
reduce NN O O
renal NN O O
function NN O O
. NN O O
For NN O O
patients NN O O
at NN O O
risk NN O O
for NN O O
chronically NN O O
reduced NN O O
renal NN O O
function NN O O
( NN O O
for NN O O
example NN O O
, NN O O
age NN O O
> NN O O
60 NN O O
years NN O O
, NN O O
hypertension NN O O
or NN O O
diabetes NN O O
) NN O O
, NN O O
estimate NN O O
the NN O O
glomerular NN O O
filtration NN O O
rate NN O O
( NN O O
GFR NN O O
) NN O O
through NN O O
laboratory NN O O
testing NN O O
. NN O O
For NN O O
patients NN O O
at NN O O
highest NN O O
risk NN O O
for NN O O
NSF NN O O
, NN O O
do NN O O
not NN O O
exceed NN O O
the NN O O
recommended NN O O
EOVIST NN O O
dose NN O O
and NN O O
allow NN O O
a NN O O
sufficient NN O O
period NN O O
of NN O O
time NN O O
for NN O O
elimination NN O O
of NN O O
the NN O O
drug NN O O
from NN O O
the NN O O
body NN O O
prior NN O O
to NN O O
any NN O O
re NN O O
- NN O O
administration NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
EXCERPT NN O O
: NN O O
WARNING NN O O
: NN O O
NEPHROGENIC NN B-AdverseReaction B-AdverseReaction
SYSTEMIC NN I-AdverseReaction I-AdverseReaction
FIBROSIS NN I-AdverseReaction I-AdverseReaction
( NN O O
NSF NN O O
) NN O O
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
. NN O O
Gadolinium NN B-DrugClass B-DrugClass
- NN I-DrugClass I-DrugClass
based NN I-DrugClass I-DrugClass
contrast NN I-DrugClass I-DrugClass
agents NN I-DrugClass I-DrugClass
( NN O O
GBCAs NN O O
) NN O O
increase NN O O
the NN O O
risk NN O O
for NN O O
NSF NN B-AdverseReaction B-AdverseReaction
among NN O O
patients NN O O
with NN O O
impaired NN O O
elimination NN O O
of NN O O
the NN O O
drugs NN O O
. NN O O
Avoid NN O O
use NN O O
of NN O O
GBCAs NN O O
in NN O O
these NN O O
patients NN O O
unless NN O O
the NN O O
diagnostic NN O O
information NN O O
is NN O O
essential NN O O
and NN O O
not NN O O
available NN O O
with NN O O
non NN O O
- NN O O
contrasted NN O O
MRI NN O O
or NN O O
other NN O O
modalities NN O O
. NN O O
* NN O O
The NN O O
risk NN B-Factor B-Factor
for NN O O
NSF NN B-AdverseReaction B-AdverseReaction
appears NN O O
highest NN O O
among NN O O
patients NN O O
with:oChronic NN O O
, NN O O
severe NN O O
kidney NN O O
disease NN O O
( NN O O
GFR NN O O
< NN O O
30 NN O O
mL/min/1.73m2 NN O O
) NN O O
, NN O O
oroAcute NN O O
kidney NN O O
injury NN O O
. NN O O
* NN O O
Screen NN O O
patients NN O O
for NN O O
acute NN O O
kidney NN O O
injury NN O O
and NN O O
other NN O O
conditions NN O O
that NN O O
may NN O O
reduce NN O O
renal NN O O
function NN O O
. NN O O
For NN O O
patients NN O O
at NN O O
risk NN O O
for NN O O
chronically NN O O
reduced NN O O
renal NN O O
function NN O O
( NN O O
for NN O O
example NN O O
, NN O O
age NN O O
>60 NN O O
years NN O O
, NN O O
hypertension NN O O
or NN O O
diabetes NN O O
) NN O O
, NN O O
estimate NN O O
the NN O O
glomerular NN O O
filtration NN O O
rate NN O O
( NN O O
GFR NN O O
) NN O O
through NN O O
laboratory NN O O
testing NN O O
( NN O O
5.1 NN O O
) NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Nephrogenic NN B-AdverseReaction B-AdverseReaction
Systemic NN I-AdverseReaction I-AdverseReaction
Fibrosis NN I-AdverseReaction I-AdverseReaction
has NN O O
occurred NN O O
in NN O O
patients NN O O
with NN O O
impaired NN O O
elimination NN O O
of NN O O
GBCAs NN O O
. NN O O
Higher NN O O
than NN O O
recommended NN O O
dosing NN O O
or NN O O
repeated NN O O
dosing NN O O
appears NN O O
to NN O O
increase NN O O
the NN O O
risk NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Hypersensitivity NN O O
: NN O O
anaphylactoid/hypersensitivity NN O O
reactions NN O O
with NN O O
cardiovascular NN O O
, NN O O
respiratory NN O O
and NN O O
cutaneous NN B-AdverseReaction B-AdverseReaction
manifestations NN I-AdverseReaction I-AdverseReaction
ranging NN O O
from NN O O
mild NN B-Severity B-Severity
to NN O O
severe NN B-Severity B-Severity
reactions NN O O
including NN O O
shock NN B-AdverseReaction B-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
. NN O O
Monitor NN O O
patients NN O O
closely NN O O
for NN O O
need NN O O
of NN O O
emergency NN O O
cardiorespiratory NN O O
support NN O O
( NN O O
5.2 NN O O
) NN O O
5.1 NN O O
Nephrogenic NN O O
Systemic NN O O
Fibrosis NN O O
( NN O O
NSF NN O O
) NN O O
Gadolinium NN B-DrugClass B-DrugClass
- NN I-DrugClass I-DrugClass
based NN I-DrugClass I-DrugClass
contrast NN I-DrugClass I-DrugClass
agents NN I-DrugClass I-DrugClass
( NN O O
GBCAs NN O O
) NN O O
increase NN O O
the NN O O
risk NN B-Factor B-Factor
for NN O O
nephrogenic NN B-AdverseReaction B-AdverseReaction
systemic NN I-AdverseReaction I-AdverseReaction
fibrosis NN I-AdverseReaction I-AdverseReaction
( NN O O
NSF NN O O
) NN O O
among NN O O
patients NN O O
with NN O O
impaired NN O O
elimination NN O O
of NN O O
the NN O O
drugs NN O O
. NN O O
Avoid NN O O
use NN O O
of NN O O
GBCAs NN O O
among NN O O
these NN O O
patients NN O O
unless NN O O
the NN O O
diagnostic NN O O
information NN O O
is NN O O
essential NN O O
and NN O O
not NN O O
available NN O O
with NN O O
non NN O O
- NN O O
contrast NN O O
enhanced NN O O
MRI NN O O
or NN O O
other NN O O
modalities NN O O
. NN O O
The NN O O
GBCA NN B-DrugClass B-DrugClass
NSF NN B-AdverseReaction B-AdverseReaction
risk NN O O
appears NN O O
highest NN O O
for NN O O
patients NN O O
with NN O O
chronic NN O O
, NN O O
severe NN O O
kidney NN O O
disease NN O O
( NN O O
GFR NN O O
< NN O O
30 NN O O
mL/min/1.73m NN O O
2 NN O O
) NN O O
as NN O O
well NN O O
as NN O O
patients NN O O
with NN O O
acute NN O O
kidney NN O O
injury NN O O
. NN O O
The NN O O
risk NN O O
appears NN O O
lower NN O O
for NN O O
patients NN O O
with NN O O
chronic NN O O
, NN O O
moderate NN O O
kidney NN O O
disease NN O O
( NN O O
GFR NN O O
30 NN O O
to NN O O
59 NN O O
mL/min/1.73m NN O O
2 NN O O
) NN O O
and NN O O
little NN O O
, NN O O
if NN O O
any NN O O
, NN O O
for NN O O
patients NN O O
with NN O O
chronic NN O O
, NN O O
mild NN O O
kidney NN O O
disease NN O O
( NN O O
GFR NN O O
60 NN O O
to NN O O
89 NN O O
mL/min/1.73m NN O O
2 NN O O
) NN O O
. NN O O
NSF NN B-AdverseReaction B-AdverseReaction
may NN B-Factor B-Factor
result NN O O
in NN O O
fatal NN B-AdverseReaction B-AdverseReaction
or NN O O
debilitating NN B-Severity B-Severity
fibrosis NN B-AdverseReaction B-AdverseReaction
affecting NN O O
the NN O O
skin NN O O
, NN O O
muscle NN O O
and NN O O
internal NN O O
organs NN O O
. NN O O
Report NN O O
any NN O O
diagnosis NN O O
of NN O O
NSF NN O O
following NN O O
EOVIST NN O O
administration NN O O
to NN O O
Bayer NN O O
HealthCare NN O O
( NN O O
1 NN O O
- NN O O
888 NN O O
- NN O O
842 NN O O
- NN O O
2937 NN O O
) NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
) NN O O
. NN O O
Screen NN O O
patients NN O O
for NN O O
acute NN O O
kidney NN O O
injury NN O O
and NN O O
other NN O O
conditions NN O O
that NN O O
may NN O O
reduce NN O O
renal NN O O
function NN O O
. NN O O
Features NN O O
of NN O O
acute NN O O
kidney NN O O
injury NN O O
consist NN O O
of NN O O
rapid NN O O
( NN O O
over NN O O
hours NN O O
to NN O O
days NN O O
) NN O O
and NN O O
usually NN O O
reversible NN O O
decrease NN O O
in NN O O
kidney NN O O
function NN O O
, NN O O
commonly NN O O
in NN O O
the NN O O
setting NN O O
of NN O O
surgery NN O O
, NN O O
severe NN O O
infection NN O O
, NN O O
injury NN O O
or NN O O
drug NN O O
- NN O O
induced NN O O
kidney NN O O
toxicity NN O O
. NN O O
Serum NN O O
creatinine NN O O
levels NN O O
and NN O O
estimated NN O O
GFR NN O O
may NN O O
not NN O O
reliably NN O O
assess NN O O
renal NN O O
function NN O O
in NN O O
the NN O O
setting NN O O
of NN O O
acute NN O O
kidney NN O O
injury NN O O
. NN O O
For NN O O
patients NN O O
at NN O O
risk NN O O
for NN O O
chronically NN O O
reduced NN O O
renal NN O O
function NN O O
( NN O O
for NN O O
example NN O O
, NN O O
age NN O O
> NN O O
60 NN O O
years NN O O
, NN O O
diabetes NN O O
mellitus NN O O
or NN O O
chronic NN O O
hypertension NN O O
) NN O O
, NN O O
estimate NN O O
the NN O O
GFR NN O O
through NN O O
laboratory NN O O
testing NN O O
. NN O O
Among NN O O
the NN O O
factors NN O O
that NN O O
may NN O O
increase NN O O
the NN O O
risk NN B-Factor B-Factor
for NN O O
NSF NN B-AdverseReaction B-AdverseReaction
are NN O O
repeated NN O O
or NN O O
higher NN O O
than NN O O
recommended NN O O
doses NN O O
of NN O O
a NN O O
GBCA NN O O
and NN O O
degree NN O O
of NN O O
renal NN O O
impairment NN O O
at NN O O
the NN O O
time NN O O
of NN O O
exposure NN O O
. NN O O
Record NN O O
the NN O O
specific NN O O
GBCA NN O O
and NN O O
the NN O O
dose NN O O
administrated NN O O
to NN O O
a NN O O
patient NN O O
. NN O O
For NN O O
patients NN O O
at NN O O
highest NN O O
risk NN O O
for NN O O
NSF NN O O
, NN O O
do NN O O
not NN O O
exceed NN O O
the NN O O
recommended NN O O
EOVIST NN O O
dose NN O O
and NN O O
allow NN O O
a NN O O
sufficient NN O O
period NN O O
of NN O O
time NN O O
for NN O O
elimination NN O O
of NN O O
the NN O O
drug NN O O
prior NN O O
to NN O O
any NN O O
re NN O O
- NN O O
administration NN O O
. NN O O
For NN O O
patients NN O O
receiving NN O O
hemodialysis NN O O
, NN O O
physicians NN O O
may NN O O
consider NN O O
the NN O O
prompt NN O O
initiation NN O O
of NN O O
hemodialysis NN O O
following NN O O
the NN O O
administration NN O O
of NN O O
a NN O O
GBCA NN O O
in NN O O
order NN O O
to NN O O
enhance NN O O
the NN O O
contrast NN O O
agent NN O O
's NN O O
elimination NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.6 NN O O
) NN O O
and NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.3 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
usefulness NN O O
of NN O O
hemodialysis NN O O
in NN O O
the NN O O
prevention NN O O
of NN O O
NSF NN O O
is NN O O
unknown NN O O
. NN O O
5.2 NN O O
Hypersensitivity NN O O
Reactions NN O O
Anaphylactic NN O O
and NN O O
other NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
with NN O O
cardiovascular NN O O
, NN O O
respiratory NN O O
and NN O O
cutaneous NN B-AdverseReaction B-AdverseReaction
manifestations NN I-AdverseReaction I-AdverseReaction
ranging NN O O
from NN O O
mild NN B-Severity B-Severity
to NN O O
severe NN B-Severity B-Severity
including NN O O
shock NN B-AdverseReaction B-AdverseReaction
have NN O O
uncommonly NN O O
occurred NN O O
following NN O O
EOVIST NN O O
administration NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Before NN O O
EOVIST NN O O
administration NN O O
, NN O O
assess NN O O
all NN O O
patients NN O O
for NN O O
any NN O O
history NN O O
of NN O O
a NN O O
reaction NN O O
to NN O O
contrast NN O O
media NN O O
, NN O O
bronchial NN O O
asthma NN O O
and NN O O
allergic NN O O
disorders NN O O
. NN O O
These NN O O
patients NN O O
may NN O O
have NN O O
an NN O O
increased NN O O
risk NN B-Factor B-Factor
for NN O O
a NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
to NN O O
EOVIST. NN O O
* NN O O
Administer NN O O
EOVIST NN O O
only NN O O
in NN O O
situations NN O O
where NN O O
trained NN O O
personnel NN O O
and NN O O
therapies NN O O
are NN O O
promptly NN O O
available NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
hypersensitivity NN O O
reactions NN O O
, NN O O
including NN O O
personnel NN O O
trained NN O O
in NN O O
resuscitation NN O O
. NN O O
Most NN O O
hypersensitivity NN O O
reactions NN O O
to NN O O
EOVIST NN O O
have NN O O
occurred NN O O
within NN O O
half NN O O
an NN O O
hour NN O O
after NN O O
administration NN O O
. NN O O
Delayed NN O O
reactions NN O O
can NN B-Factor B-Factor
occur NN O O
up NN O O
to NN O O
several NN O O
days NN O O
after NN O O
EOVIST NN O O
administration NN O O
. NN O O
Observe NN O O
patients NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
hypersensitivity NN O O
reactions NN O O
during NN O O
and NN O O
following NN O O
EOVIST NN O O
administration NN O O
. NN O O
5.3 NN O O
Acute NN O O
Kidney NN O O
Injury NN O O
In NN O O
patients NN O O
with NN O O
chronic NN O O
renal NN O O
impairment NN O O
, NN O O
acute NN B-AdverseReaction B-AdverseReaction
kidney NN I-AdverseReaction I-AdverseReaction
injury NN I-AdverseReaction I-AdverseReaction
sometimes NN O O
requiring NN O O
dialysis NN O O
has NN O O
been NN O O
observed NN O O
with NN O O
the NN O O
use NN O O
of NN O O
some NN O O
GBCAs NN B-DrugClass B-DrugClass
The NN O O
risk NN B-Factor B-Factor
of NN O O
acute NN B-AdverseReaction B-AdverseReaction
kidney NN I-AdverseReaction I-AdverseReaction
injury NN I-AdverseReaction I-AdverseReaction
might NN O O
be NN O O
lower NN O O
with NN O O
EOVIST NN O O
due NN O O
to NN O O
its NN O O
dual NN O O
excretory NN O O
pathways NN O O
. NN O O
Do NN O O
not NN O O
exceed NN O O
the NN O O
recommended NN O O
dose NN O O
; NN O O
the NN O O
risk NN O O
of NN O O
acute NN O O
kidney NN O O
injury NN O O
may NN O O
increase NN O O
with NN O O
higher NN O O
than NN O O
recommended NN O O
doses NN O O
. NN O O
5.4 NN O O
Extravasation NN O O
and NN O O
Injection NN O O
Site NN O O
Reactions NN O O
Ensure NN O O
catheter NN O O
and NN O O
venous NN O O
patency NN O O
before NN O O
the NN O O
injection NN O O
of NN O O
EOVIST. NN O O
Extravasation NN O O
into NN O O
tissues NN O O
during NN O O
EOVIST NN O O
administration NN O O
may NN B-Factor B-Factor
result NN O O
in NN O O
local NN O O
tissue NN O O
reactions NN O O
. NN O O
Strictly NN O O
avoid NN O O
intramuscular NN O O
administration NN O O
of NN O O
EOVIST NN O O
because NN O O
it NN O O
may NN O O
cause NN O O
myocyte NN O O
necrosis NN O O
and NN O O
inflammation NN O O
[ NN O O
see NN O O
Nonclinical NN O O
Toxicology NN O O
( NN O O
13.2 NN O O
) NN O O
] NN O O
. NN O O
5.5 NN O O
Interference NN O O
with NN O O
Laboratory NN O O
Tests NN O O
Serum NN O O
iron NN O O
determination NN O O
using NN O O
complexometric NN O O
methods NN O O
( NN O O
for NN O O
example NN O O
, NN O O
ferrocene NN O O
complexation NN O O
method NN O O
) NN O O
may NN O O
result NN O O
in NN O O
falsely NN O O
high NN O O
or NN O O
low NN O O
values NN O O
for NN O O
up NN O O
to NN O O
24 NN O O
hours NN O O
after NN O O
the NN O O
examination NN O O
with NN O O
EOVIST NN O O
because NN O O
of NN O O
the NN O O
caloxetate NN O O
trisodium NN O O
excipients NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
5.6 NN O O
Interference NN O O
with NN O O
Visualization NN O O
of NN O O
Liver NN O O
Lesions NN O O
Severe NN O O
renal NN O O
or NN O O
hepatic NN O O
failure NN O O
may NN O O
impair NN O O
EOVIST NN O O
imaging NN O O
performance NN O O
. NN O O
In NN O O
patients NN O O
with NN O O
end NN O O
- NN O O
stage NN O O
renal NN O O
failure NN O O
, NN O O
hepatic NN O O
contrast NN O O
was NN O O
markedly NN O O
reduced NN O O
and NN O O
was NN O O
attributed NN O O
to NN O O
elevated NN O O
serum NN O O
ferritin NN O O
levels NN O O
. NN O O
In NN O O
patients NN O O
with NN O O
abnormally NN O O
high NN O O
( NN O O
>3 NN O O
mg/dL NN O O
) NN O O
serum NN O O
bilirubin NN O O
, NN O O
reduced NN O O
hepatic NN O O
contrast NN O O
was NN O O
observed NN O O
. NN O O
If NN O O
EOVIST NN O O
is NN O O
used NN O O
in NN O O
these NN O O
patients NN O O
, NN O O
complete NN O O
MRI NN O O
no NN O O
later NN O O
than NN O O
60 NN O O
minutes NN O O
after NN O O
EOVIST NN O O
administration NN O O
and NN O O
use NN O O
a NN O O
paired NN O O
non NN O O
- NN O O
contrast NN O O
and NN O O
contrast NN O O
MRI NN O O
set NN O O
for NN O O
diagnosis NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
serious NN O O
reactions NN O O
are NN O O
described NN O O
below NN O O
or NN O O
elsewhere NN O O
in NN O O
the NN O O
prescribing NN O O
information NN O O
: NN O O
* NN O O
Risk NN B-Factor B-Factor
of NN O O
Thyroid NN B-AdverseReaction B-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
Tumors NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Acute NN B-AdverseReaction B-AdverseReaction
Pancreatitis NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
* NN O O
Hypoglycemia NN B-AdverseReaction B-AdverseReaction
with NN O O
Concomitant NN O O
Use NN O O
of NN O O
Insulin NN O O
Secretagogues NN O O
or NN O O
Insulin NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
* NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
* NN O O
Renal NN B-AdverseReaction B-AdverseReaction
Impairment NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
Adverse NN O O
reactions NN O O
, NN O O
reported NN O O
in NN O O
>=5 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
TANZEUM NN O O
and NN O O
more NN O O
frequently NN O O
than NN O O
in NN O O
patients NN O O
on NN O O
placebo NN O O
, NN O O
were NN O O
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
arthralgia NN B-AdverseReaction B-AdverseReaction
sinusitis NN B-AdverseReaction B-AdverseReaction
and NN O O
influenza NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
GlaxoSmithKline NN O O
at NN O O
1 NN O O
- NN O O
888 NN O O
- NN O O
825 NN O O
- NN O O
5249 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
with NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
Pool NN O O
of NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Trials NN O O
The NN O O
data NN O O
in NN O O
Table NN O O
1 NN O O
are NN O O
derived NN O O
from NN O O
4 NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
. NN O O
TANZEUM NN O O
was NN O O
used NN O O
as NN O O
monotherapy NN O O
in NN O O
1 NN O O
trial NN O O
and NN O O
as NN O O
add NN O O
- NN O O
on NN O O
therapy NN O O
in NN O O
3 NN O O
trials NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
. NN O O
These NN O O
data NN O O
reflect NN O O
exposure NN O O
of NN O O
923 NN O O
patients NN O O
to NN O O
TANZEUM NN O O
and NN O O
a NN O O
mean NN O O
duration NN O O
of NN O O
exposure NN O O
to NN O O
TANZEUM NN O O
of NN O O
93 NN O O
weeks NN O O
. NN O O
The NN O O
mean NN O O
age NN O O
of NN O O
participants NN O O
was NN O O
55 NN O O
years NN O O
, NN O O
1 NN O O
% NN O O
of NN O O
participants NN O O
were NN O O
75 NN O O
years NN O O
or NN O O
older NN O O
and NN O O
53 NN O O
% NN O O
of NN O O
participants NN O O
were NN O O
male NN O O
. NN O O
The NN O O
population NN O O
in NN O O
these NN O O
studies NN O O
was NN O O
48 NN O O
% NN O O
white NN O O
, NN O O
13 NN O O
% NN O O
African/African NN O O
American NN O O
, NN O O
7 NN O O
% NN O O
Asian NN O O
, NN O O
and NN O O
29 NN O O
% NN O O
Hispanic/Latino NN O O
. NN O O
At NN O O
baseline NN O O
, NN O O
the NN O O
population NN O O
had NN O O
type NN O O
2 NN O O
diabetes NN O O
for NN O O
an NN O O
average NN O O
of NN O O
7 NN O O
years NN O O
and NN O O
had NN O O
a NN O O
mean NN O O
HbA1c NN O O
of NN O O
8.1 NN O O
% NN O O
. NN O O
At NN O O
baseline NN O O
, NN O O
17 NN O O
% NN O O
of NN O O
the NN O O
population NN O O
in NN O O
these NN O O
studies NN O O
reported NN O O
peripheral NN O O
neuropathy NN O O
and NN O O
4 NN O O
% NN O O
reported NN O O
retinopathy NN O O
. NN O O
Baseline NN O O
estimated NN O O
renal NN O O
function NN O O
was NN O O
normal NN O O
or NN O O
mildly NN O O
impaired NN O O
( NN O O
eGFR NN O O
>60 NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
) NN O O
in NN O O
91 NN O O
% NN O O
of NN O O
the NN O O
study NN O O
population NN O O
and NN O O
moderately NN O O
impaired NN O O
( NN O O
eGFR NN O O
30 NN O O
to NN O O
60 NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
) NN O O
in NN O O
9 NN O O
% NN O O
. NN O O
Table NN O O
1 NN O O
shows NN O O
common NN O O
adverse NN O O
reactions NN O O
excluding NN O O
hypoglycemia NN B-AdverseReaction B-AdverseReaction
associated NN O O
with NN O O
the NN O O
use NN O O
of NN O O
TANZEUM NN O O
in NN O O
the NN O O
pool NN O O
of NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
. NN O O
These NN O O
adverse NN O O
reactions NN O O
were NN O O
not NN O O
present NN O O
at NN O O
baseline NN O O
, NN O O
occurred NN O O
more NN O O
commonly NN O O
on NN O O
TANZEUM NN O O
than NN O O
on NN O O
placebo NN O O
, NN O O
and NN O O
occurred NN O O
in NN O O
at NN O O
least NN O O
5 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
TANZEUM. NN O O
Table NN O O
1 NN O O
. NN O O
Adverse NN O O
Reactions NN O O
in NN O O
Placebo NN O O
- NN O O
controlled NN O O
Trials NN O O
Reported NN O O
in NN O O
>=5 NN O O
% NN O O
of NN O O
Patients NN O O
Treated NN O O
with NN O O
TANZEUM NN O O
a NN O O
Adverse NN O O
Reaction NN O O
Placebo NN O O
( NN O O
N NN O O
= NN O O
468 NN O O
) NN O O
% NN O O
TANZEUM NN O O
( NN O O
N NN O O
= NN O O
923 NN O O
) NN O O
% NN O O
Upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
13.0 NN O O
14.2 NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
10.5 NN O O
13.1 NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
9.6 NN O O
11.1 NN O O
Injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
2.1 NN O O
10.5 NN O O
Cough NN B-AdverseReaction B-AdverseReaction
6.2 NN O O
6.9 NN O O
Back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
5.8 NN O O
6.7 NN O O
Arthralgia NN B-AdverseReaction B-AdverseReaction
6.4 NN O O
6.6 NN O O
Sinusitis NN B-AdverseReaction B-AdverseReaction
5.8 NN O O
6.2 NN O O
Influenza NN B-AdverseReaction B-AdverseReaction
3.2 NN O O
5.2 NN O O
* NN O O
a NN O O
Adverse NN O O
reactions NN O O
reported NN O O
includes NN O O
adverse NN O O
reactions NN O O
occurring NN O O
with NN O O
the NN O O
use NN O O
of NN O O
glycemic NN O O
rescue NN O O
medications NN O O
which NN O O
included NN O O
metformin NN O O
( NN O O
17 NN O O
% NN O O
for NN O O
placebo NN O O
and NN O O
10 NN O O
% NN O O
for NN O O
TANZEUM NN O O
) NN O O
and NN O O
insulin NN O O
( NN O O
24 NN O O
% NN O O
for NN O O
placebo NN O O
and NN O O
14 NN O O
% NN O O
for NN O O
TANZEUM NN O O
) NN O O
. NN O O
* NN O O
b NN O O
See NN O O
below NN O O
for NN O O
other NN O O
events NN O O
of NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
reported NN O O
. NN O O
Gastrointestinal NN O O
Adverse NN O O
Reactions NN O O
In NN O O
the NN O O
pool NN O O
of NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
, NN O O
gastrointestinal NN B-AdverseReaction B-AdverseReaction
complaints NN I-AdverseReaction I-AdverseReaction
occurred NN O O
more NN O O
frequently NN O O
among NN O O
patients NN O O
receiving NN O O
TANZEUM NN O O
( NN O O
39 NN O O
% NN O O
) NN O O
than NN O O
patients NN O O
receiving NN O O
placebo NN O O
( NN O O
33 NN O O
% NN O O
) NN O O
. NN O O
In NN O O
addition NN O O
to NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
and NN O O
nausea NN B-AdverseReaction B-AdverseReaction
( NN O O
see NN O O
Table NN O O
1 NN O O
) NN O O
, NN O O
the NN O O
following NN O O
gastrointestinal NN B-AdverseReaction B-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
also NN O O
occurred NN O O
more NN O O
frequently NN O O
in NN O O
patients NN O O
receiving NN O O
TANZEUM NN O O
: NN O O
vomiting NN B-AdverseReaction B-AdverseReaction
( NN O O
2.6 NN O O
% NN O O
versus NN O O
4.2 NN O O
% NN O O
for NN O O
placebo NN O O
versus NN O O
TANZEUM NN O O
) NN O O
, NN O O
gastroesophageal NN B-AdverseReaction B-AdverseReaction
reflux NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
( NN O O
1.9 NN O O
% NN O O
versus NN O O
3.5 NN O O
% NN O O
for NN O O
placebo NN O O
versus NN O O
TANZEUM NN O O
) NN O O
, NN O O
and NN O O
dyspepsia NN B-AdverseReaction B-AdverseReaction
( NN O O
2.8 NN O O
% NN O O
versus NN O O
3.4 NN O O
% NN O O
for NN O O
placebo NN O O
versus NN O O
TANZEUM NN O O
) NN O O
. NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
also NN O O
contributed NN O O
to NN O O
the NN O O
frequently NN O O
reported NN O O
reactions NN O O
. NN O O
In NN O O
the NN O O
group NN O O
treated NN O O
with NN O O
TANZEUM NN O O
, NN O O
investigators NN O O
graded NN O O
the NN O O
severity NN O O
of NN O O
GI NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
as NN O O
" NN O O
mild NN O O
" NN O O
in NN O O
56 NN O O
% NN O O
of NN O O
cases NN O O
, NN O O
" NN O O
moderate NN O O
" NN O O
in NN O O
37 NN O O
% NN O O
of NN O O
cases NN O O
, NN O O
and NN O O
" NN O O
severe NN O O
" NN O O
in NN O O
7 NN O O
% NN O O
of NN O O
cases NN O O
. NN O O
Discontinuation NN O O
due NN O O
to NN O O
GI NN B-AdverseReaction B-AdverseReaction
adverse NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
2 NN O O
% NN O O
of NN O O
individuals NN O O
on NN O O
TANZEUM NN O O
or NN O O
placebo NN O O
. NN O O
Injection NN O O
Site NN O O
Reactions NN O O
In NN O O
the NN O O
pool NN O O
of NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
, NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
occurred NN O O
more NN O O
frequently NN O O
on NN O O
TANZEUM NN O O
( NN O O
18 NN O O
% NN O O
) NN O O
than NN O O
on NN O O
placebo NN O O
( NN O O
8 NN O O
% NN O O
) NN O O
. NN O O
In NN O O
addition NN O O
to NN O O
the NN O O
term NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
( NN O O
see NN O O
Table NN O O
1 NN O O
) NN O O
, NN O O
the NN O O
following NN O O
other NN O O
types NN O O
of NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
also NN O O
occurred NN O O
more NN O O
frequently NN O O
on NN O O
TANZEUM NN O O
: NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
hematoma NN I-AdverseReaction I-AdverseReaction
( NN O O
1.9 NN O O
% NN O O
versus NN O O
2.1 NN O O
% NN O O
for NN O O
placebo NN O O
versus NN O O
TANZEUM NN O O
) NN O O
, NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
erythema NN I-AdverseReaction I-AdverseReaction
( NN O O
0.4 NN O O
% NN O O
versus NN O O
1.7 NN O O
% NN O O
for NN O O
placebo NN O O
versus NN O O
TANZEUM NN O O
) NN O O
, NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
rash NN I-AdverseReaction I-AdverseReaction
( NN O O
0 NN O O
% NN O O
versus NN O O
1.4 NN O O
% NN O O
for NN O O
placebo NN O O
versus NN O O
TANZEUM NN O O
) NN O O
, NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
hypersensitivity NN I-AdverseReaction I-AdverseReaction
( NN O O
0 NN O O
% NN O O
versus NN O O
0.8 NN O O
% NN O O
for NN O O
placebo NN O O
versus NN O O
TANZEUM NN O O
) NN O O
, NN O O
and NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
( NN O O
0.6 NN O O
% NN O O
versus NN O O
0.7 NN O O
% NN O O
for NN O O
placebo NN O O
versus NN O O
TANZEUM NN O O
) NN O O
. NN O O
Injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pruritus NN I-AdverseReaction I-AdverseReaction
also NN O O
contributed NN O O
to NN O O
the NN O O
frequently NN O O
reported NN O O
reactions NN O O
. NN O O
The NN O O
majority NN O O
of NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
were NN O O
judged NN O O
as NN O O
" NN O O
mild NN O O
" NN O O
by NN O O
investigators NN O O
in NN O O
both NN O O
groups NN O O
( NN O O
73 NN O O
% NN O O
for NN O O
TANZEUM NN O O
versus NN O O
94 NN O O
% NN O O
for NN O O
placebo NN O O
) NN O O
. NN O O
More NN O O
patients NN O O
on NN O O
TANZEUM NN O O
than NN O O
on NN O O
placebo NN O O
: NN O O
discontinued NN O O
due NN O O
to NN O O
an NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
( NN O O
2 NN O O
% NN O O
versus NN O O
0.2 NN O O
% NN O O
) NN O O
, NN O O
experienced NN O O
more NN O O
than NN O O
2 NN O O
reactions NN O O
( NN O O
38 NN O O
% NN O O
versus NN O O
20 NN O O
% NN O O
) NN O O
, NN O O
had NN O O
a NN O O
reaction NN O O
judged NN O O
by NN O O
investigators NN O O
to NN O O
be NN O O
" NN O O
moderate NN O O
" NN O O
or NN O O
" NN O O
severe NN O O
" NN O O
( NN O O
27 NN O O
% NN O O
versus NN O O
6 NN O O
% NN O O
) NN O O
and NN O O
required NN O O
local NN O O
or NN O O
systemic NN O O
treatment NN O O
for NN O O
the NN O O
reactions NN O O
( NN O O
36 NN O O
% NN O O
versus NN O O
11 NN O O
% NN O O
) NN O O
. NN O O
Pool NN O O
of NN O O
Placebo- NN O O
and NN O O
Active NN O O
- NN O O
controlled NN O O
Trials NN O O
The NN O O
occurrence NN O O
of NN O O
adverse NN O O
reactions NN O O
was NN O O
also NN O O
evaluated NN O O
in NN O O
a NN O O
larger NN O O
pool NN O O
of NN O O
patients NN O O
with NN O O
type NN O O
2 NN O O
diabetes NN O O
participating NN O O
in NN O O
7 NN O O
placebo- NN O O
and NN O O
active NN O O
- NN O O
controlled NN O O
trials NN O O
. NN O O
These NN O O
trials NN O O
evaluated NN O O
the NN O O
use NN O O
of NN O O
TANZEUM NN O O
as NN O O
monotherapy NN O O
, NN O O
and NN O O
as NN O O
add NN O O
- NN O O
on NN O O
therapy NN O O
to NN O O
oral NN O O
antidiabetic NN O O
agents NN O O
, NN O O
and NN O O
as NN O O
add NN O O
- NN O O
on NN O O
therapy NN O O
to NN O O
basal NN O O
insulin NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
. NN O O
In NN O O
this NN O O
pool NN O O
, NN O O
a NN O O
total NN O O
of NN O O
2,116 NN O O
patients NN O O
with NN O O
type NN O O
2 NN O O
diabetes NN O O
were NN O O
treated NN O O
with NN O O
TANZEUM NN O O
for NN O O
a NN O O
mean NN O O
duration NN O O
of NN O O
75 NN O O
weeks NN O O
. NN O O
The NN O O
mean NN O O
age NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
TANZEUM NN O O
was NN O O
55 NN O O
years NN O O
, NN O O
1.5 NN O O
% NN O O
of NN O O
the NN O O
population NN O O
in NN O O
these NN O O
studies NN O O
was NN O O
75 NN O O
years NN O O
or NN O O
older NN O O
and NN O O
51 NN O O
% NN O O
of NN O O
participants NN O O
were NN O O
male NN O O
. NN O O
Forty NN O O
- NN O O
eight NN O O
percent NN O O
of NN O O
patients NN O O
were NN O O
white NN O O
, NN O O
15 NN O O
% NN O O
African/African NN O O
American NN O O
, NN O O
9 NN O O
% NN O O
Asian NN O O
, NN O O
and NN O O
26 NN O O
% NN O O
were NN O O
Hispanic/Latino NN O O
. NN O O
At NN O O
baseline NN O O
, NN O O
the NN O O
population NN O O
had NN O O
diabetes NN O O
for NN O O
an NN O O
average NN O O
of NN O O
8 NN O O
years NN O O
and NN O O
had NN O O
a NN O O
mean NN O O
HbA1c NN O O
of NN O O
8.2 NN O O
% NN O O
. NN O O
At NN O O
baseline NN O O
, NN O O
21 NN O O
% NN O O
of NN O O
the NN O O
population NN O O
reported NN O O
peripheral NN O O
neuropathy NN O O
and NN O O
5 NN O O
% NN O O
reported NN O O
retinopathy NN O O
. NN O O
Baseline NN O O
estimated NN O O
renal NN O O
function NN O O
was NN O O
normal NN O O
or NN O O
mildly NN O O
impaired NN O O
( NN O O
eGFR NN O O
>60 NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
) NN O O
in NN O O
92 NN O O
% NN O O
of NN O O
the NN O O
population NN O O
and NN O O
moderately NN O O
impaired NN O O
( NN O O
eGFR NN O O
30 NN O O
to NN O O
60 NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
) NN O O
in NN O O
8 NN O O
% NN O O
of NN O O
the NN O O
population NN O O
. NN O O
In NN O O
the NN O O
pool NN O O
of NN O O
placebo- NN O O
and NN O O
active NN O O
- NN O O
controlled NN O O
trials NN O O
, NN O O
the NN O O
types NN O O
and NN O O
frequency NN O O
of NN O O
common NN O O
adverse NN O O
reactions NN O O
excluding NN O O
hypoglycemia NN B-AdverseReaction B-AdverseReaction
were NN O O
similar NN O O
to NN O O
those NN O O
listed NN O O
in NN O O
Table NN O O
1 NN O O
. NN O O
Other NN O O
Adverse NN O O
Reactions NN O O
Hypoglycemia NN O O
The NN O O
proportion NN O O
of NN O O
patients NN O O
experiencing NN O O
at NN O O
least NN O O
one NN O O
documented NN O O
symptomatic NN B-Severity B-Severity
hypoglycemic NN B-AdverseReaction B-AdverseReaction
episode NN I-AdverseReaction I-AdverseReaction
on NN O O
TANZEUM NN O O
and NN O O
the NN O O
proportion NN O O
of NN O O
patients NN O O
experiencing NN O O
at NN O O
least NN O O
one NN O O
severe NN B-Severity B-Severity
hypoglycemic NN B-AdverseReaction B-AdverseReaction
episode NN I-AdverseReaction I-AdverseReaction
on NN O O
TANZEUM NN O O
in NN O O
clinical NN O O
trials NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
is NN O O
shown NN O O
in NN O O
Table NN O O
2 NN O O
. NN O O
Hypoglycemia NN B-AdverseReaction B-AdverseReaction
was NN O O
more NN O O
frequent NN O O
when NN O O
TANZEUM NN O O
was NN O O
added NN O O
to NN O O
sulfonylurea NN O O
or NN O O
insulin NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
. NN O O
Table NN O O
2 NN O O
. NN O O
Incidence NN O O
( NN O O
% NN O O
) NN O O
of NN O O
Hypoglycemia NN O O
in NN O O
Clinical NN O O
Trials NN O O
of NN O O
TANZEUM NN O O
a NN O O
TANZEUM NN O O
Monotherapyb NN O O
Placebo NN O O
30 NN O O
mg NN O O
Weekly NN O O
( NN O O
52 NN O O
Weeks NN O O
) NN O O
N NN O O
= NN O O
101 NN O O
N NN O O
= NN O O
101 NN O O
Documented NN O O
symptomaticc NN O O
2 NN O O
% NN O O
2 NN O O
% NN O O
Severed NN O O
- NN O O
- NN O O
In NN O O
Combination NN O O
with NN O O
Metformin NN O O
Trial NN O O
Placebo NN O O
TANZEUM NN O O
( NN O O
104 NN O O
Weeks)e NN O O
N NN O O
= NN O O
101 NN O O
N NN O O
= NN O O
302 NN O O
Documented NN O O
symptomatic NN O O
4 NN O O
% NN O O
3 NN O O
% NN O O
Severe NN O O
- NN O O
- NN O O
In NN O O
Combination NN O O
with NN O O
Pioglitazone NN O O
+/- NN O O
Placebo NN O O
TANZEUM NN O O
Metformin NN O O
( NN O O
52 NN O O
Weeks NN O O
) NN O O
N NN O O
= NN O O
151 NN O O
N NN O O
= NN O O
150 NN O O
Documented NN O O
symptomatic NN O O
1 NN O O
% NN O O
3 NN O O
% NN O O
Severe NN O O
- NN O O
1 NN O O
% NN O O
In NN O O
Combination NN O O
with NN O O
Metformin NN O O
and NN O O
Placebo NN O O
TANZEUM NN O O
Sulfonylurea NN O O
( NN O O
52 NN O O
Weeks NN O O
) NN O O
N NN O O
= NN O O
115 NN O O
N NN O O
= NN O O
271 NN O O
Documented NN O O
symptomatic NN O O
7 NN O O
% NN O O
13 NN O O
% NN O O
Severe NN O O
- NN O O
0.4 NN O O
% NN O O
In NN O O
Combination NN O O
with NN O O
Insulin NN O O
Lispro NN O O
TANZEUM NN O O
Insulin NN O O
Glargine NN O O
( NN O O
26 NN O O
Weeks NN O O
) NN O O
N NN O O
= NN O O
281 NN O O
N NN O O
= NN O O
285 NN O O
Documented NN O O
symptomatic NN O O
30 NN O O
% NN O O
16 NN O O
% NN O O
Severe NN O O
0.7 NN O O
% NN O O
- NN O O
In NN O O
Combination NN O O
with NN O O
Insulin NN O O
Glargine NN O O
TANZEUM NN O O
Metformin NN O O
+/- NN O O
Sulfonylurea NN O O
( NN O O
52 NN O O
Weeks NN O O
) NN O O
N NN O O
= NN O O
241 NN O O
N NN O O
= NN O O
504 NN O O
Documented NN O O
symptomatic NN O O
27 NN O O
% NN O O
17 NN O O
% NN O O
Severe NN O O
0.4 NN O O
% NN O O
0.4 NN O O
% NN O O
In NN O O
Combination NN O O
with NN O O
OADs NN O O
in NN O O
Renal NN O O
Sitagliptin NN O O
TANZEUM NN O O
Impairment NN O O
( NN O O
26 NN O O
Weeks NN O O
) NN O O
N NN O O
= NN O O
246 NN O O
N NN O O
= NN O O
249 NN O O
Documented NN O O
symptomatic NN O O
6 NN O O
% NN O O
10 NN O O
% NN O O
Severe NN O O
0.8 NN O O
% NN O O
- NN O O
* NN O O
OAD NN O O
= NN O O
Oral NN O O
antidiabetic NN O O
agents NN O O
. NN O O
* NN O O
a NN O O
Data NN O O
presented NN O O
are NN O O
to NN O O
the NN O O
primary NN O O
endpoint NN O O
and NN O O
include NN O O
only NN O O
events NN O O
occurring NN O O
on NN O O
- NN O O
therapy NN O O
with NN O O
randomized NN O O
medications NN O O
and NN O O
excludes NN O O
events NN O O
occurring NN O O
after NN O O
use NN O O
of NN O O
glycemic NN O O
rescue NN O O
medications NN O O
( NN O O
i.e. NN O O
, NN O O
primarily NN O O
metformin NN O O
or NN O O
insulin NN O O
) NN O O
. NN O O
* NN O O
b NN O O
In NN O O
this NN O O
trial NN O O
, NN O O
no NN B-Negation B-Negation
documented NN O O
symptomatic NN B-Severity B-Severity
or NN O O
severe NN B-Severity B-Severity
hypoglycemia NN B-AdverseReaction B-AdverseReaction
were NN O O
reported NN O O
for NN O O
TANZEUM NN O O
50 NN O O
mg NN O O
and NN O O
these NN O O
data NN O O
are NN O O
omitted NN O O
from NN O O
the NN O O
table NN O O
. NN O O
* NN O O
c NN O O
Plasma NN B-AdverseReaction B-AdverseReaction
glucose NN I-AdverseReaction I-AdverseReaction
concentration NN I-AdverseReaction I-AdverseReaction
< NN I-AdverseReaction I-AdverseReaction
=70 NN I-AdverseReaction I-AdverseReaction
mg/dL NN I-AdverseReaction I-AdverseReaction
and NN O O
presence NN O O
of NN O O
hypoglycemic NN B-AdverseReaction B-AdverseReaction
symptoms NN I-AdverseReaction I-AdverseReaction
* NN O O
d NN O O
Event NN O O
requiring NN O O
another NN O O
person NN O O
to NN O O
administer NN O O
a NN O O
resuscitative NN O O
action NN O O
. NN O O
* NN O O
e NN O O
Rate NN O O
of NN O O
documented NN O O
symptomatic NN B-Severity B-Severity
hypoglycemia NN B-AdverseReaction B-AdverseReaction
for NN O O
active NN O O
controls NN O O
18 NN O O
% NN O O
( NN O O
glimepiride NN O O
) NN O O
and NN O O
2 NN O O
% NN O O
( NN O O
sitagliptin NN O O
) NN O O
. NN O O
Pneumonia NN O O
In NN O O
the NN O O
pool NN O O
of NN O O
7 NN O O
placebo- NN O O
and NN O O
active NN O O
- NN O O
controlled NN O O
trials NN O O
, NN O O
the NN O O
adverse NN O O
reaction NN O O
of NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
was NN O O
reported NN O O
more NN O O
frequently NN O O
in NN O O
patients NN O O
receiving NN O O
TANZEUM NN O O
( NN O O
1.8 NN O O
% NN O O
) NN O O
than NN O O
in NN O O
patients NN O O
in NN O O
the NN O O
all NN O O
- NN O O
comparators NN O O
group NN O O
( NN O O
0.8 NN O O
% NN O O
) NN O O
. NN O O
More NN O O
cases NN O O
of NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
in NN O O
the NN O O
group NN O O
receiving NN O O
TANZEUM NN O O
were NN O O
serious NN B-Severity B-Severity
( NN O O
0.4 NN O O
% NN O O
for NN O O
TANZEUM NN O O
versus NN O O
0.1 NN O O
% NN O O
for NN O O
all NN O O
comparators NN O O
) NN O O
. NN O O
Atrial NN O O
Fibrillation/Flutte NN O O
r NN O O
In NN O O
the NN O O
pool NN O O
of NN O O
7 NN O O
placebo- NN O O
and NN O O
active NN O O
- NN O O
controlled NN O O
trials NN O O
, NN O O
adverse NN O O
reactions NN O O
of NN O O
atrial NN B-AdverseReaction B-AdverseReaction
fibrillation NN I-AdverseReaction I-AdverseReaction
( NN O O
1.0 NN O O
% NN O O
) NN O O
and NN O O
atrial NN B-AdverseReaction B-AdverseReaction
flutter NN I-AdverseReaction I-AdverseReaction
( NN O O
0.2 NN O O
% NN O O
) NN O O
were NN O O
reported NN O O
more NN O O
frequently NN O O
for NN O O
TANZEUM NN O O
than NN O O
for NN O O
all NN O O
comparators NN O O
( NN O O
0.5 NN O O
% NN O O
and NN O O
0 NN O O
% NN O O
, NN O O
respectively NN O O
) NN O O
. NN O O
In NN O O
both NN O O
groups NN O O
, NN O O
patients NN O O
with NN O O
events NN O O
were NN O O
generally NN O O
male NN O O
, NN O O
older NN O O
, NN O O
and NN O O
had NN O O
underlying NN O O
renal NN O O
impairment NN O O
or NN O O
cardiac NN O O
disease NN O O
( NN O O
e.g. NN O O
, NN O O
history NN O O
of NN O O
arrhythmia NN O O
, NN O O
palpitations NN O O
, NN O O
congestive NN O O
heart NN O O
failure NN O O
, NN O O
cardiomyopathy NN O O
, NN O O
etc NN O O
. NN O O
) NN O O
. NN O O
Appendicitis NN O O
In NN O O
the NN O O
pool NN O O
of NN O O
placebo- NN O O
and NN O O
active NN O O
- NN O O
controlled NN O O
trials NN O O
, NN O O
serious NN B-Severity B-Severity
events NN O O
of NN O O
appendicitis NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
0.3 NN O O
% NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
TANZEUM NN O O
compared NN O O
with NN O O
0 NN O O
% NN O O
among NN O O
all NN O O
comparators NN O O
. NN O O
Immunogenicity NN O O
In NN O O
the NN O O
pool NN O O
of NN O O
7 NN O O
placebo- NN O O
and NN O O
active NN O O
- NN O O
controlled NN O O
trials NN O O
, NN O O
116 NN O O
( NN O O
5.5 NN O O
% NN O O
) NN O O
of NN O O
2,098 NN O O
patients NN O O
exposed NN O O
to NN O O
TANZEUM NN O O
tested NN O O
positive NN O O
for NN O O
anti NN O O
- NN O O
albiglutide NN O O
antibodies NN O O
at NN O O
any NN O O
time NN O O
during NN O O
the NN O O
trials NN O O
. NN O O
None NN O O
of NN O O
these NN O O
antibodies NN O O
were NN O O
shown NN O O
to NN O O
neutralize NN O O
the NN O O
activity NN O O
of NN O O
albiglutide NN O O
in NN O O
an NN O O
in NN O O
vitro NN O O
bioassay NN O O
. NN O O
Presence NN O O
of NN O O
antibody NN O O
did NN O O
not NN O O
correlate NN O O
with NN O O
reduced NN O O
efficacy NN O O
as NN O O
measured NN O O
by NN O O
HbA1c NN O O
and NN O O
fasting NN O O
plasma NN O O
glucose NN O O
or NN O O
specific NN O O
adverse NN O O
reactions NN O O
. NN O O
Consistent NN O O
with NN O O
the NN O O
high NN O O
homology NN O O
of NN O O
albiglutide NN O O
with NN O O
human NN O O
GLP-1 NN O O
, NN O O
the NN O O
majority NN O O
of NN O O
patients NN O O
( NN O O
approximately NN O O
79 NN O O
% NN O O
) NN O O
with NN O O
anti NN O O
- NN O O
albiglutide NN O O
antibodies NN O O
also NN O O
tested NN O O
positive NN O O
for NN O O
anti NN O O
- NN O O
GLP-1 NN O O
antibodies NN O O
; NN O O
none NN O O
were NN O O
neutralizing NN O O
. NN O O
A NN O O
minority NN O O
of NN O O
patients NN O O
( NN O O
approximately NN O O
17 NN O O
% NN O O
) NN O O
who NN O O
tested NN O O
positive NN O O
for NN O O
anti NN O O
- NN O O
albiglutide NN O O
antibodies NN O O
also NN O O
transiently NN O O
tested NN O O
positive NN O O
for NN O O
antibodies NN O O
to NN O O
human NN O O
albumin NN O O
. NN O O
The NN O O
detection NN O O
of NN O O
antibody NN O O
formation NN O O
is NN O O
highly NN O O
dependent NN O O
on NN O O
the NN O O
sensitivity NN O O
and NN O O
specificity NN O O
of NN O O
the NN O O
assay NN O O
. NN O O
Additionally NN O O
, NN O O
the NN O O
observed NN O O
incidence NN O O
of NN O O
antibody NN O O
( NN O O
including NN O O
neutralizing NN O O
antibody NN O O
) NN O O
positivity NN O O
in NN O O
an NN O O
assay NN O O
may NN O O
be NN O O
influenced NN O O
by NN O O
several NN O O
factors NN O O
including NN O O
assay NN O O
methodology NN O O
, NN O O
sample NN O O
handling NN O O
, NN O O
timing NN O O
of NN O O
sample NN O O
collection NN O O
, NN O O
concomitant NN O O
medications NN O O
, NN O O
and NN O O
underlying NN O O
disease NN O O
. NN O O
For NN O O
these NN O O
reasons NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
antibodies NN O O
to NN O O
albiglutide NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
with NN O O
the NN O O
incidence NN O O
of NN O O
antibodies NN O O
of NN O O
other NN O O
products NN O O
. NN O O
Liver NN O O
Enzyme NN O O
Abnormalities NN O O
In NN O O
the NN O O
pool NN O O
of NN O O
placebo- NN O O
and NN O O
active NN O O
- NN O O
controlled NN O O
trials NN O O
, NN O O
a NN O O
similar NN O O
proportion NN O O
of NN O O
patients NN O O
experienced NN O O
at NN O O
least NN O O
one NN O O
event NN O O
of NN O O
alanine NN O O
aminotransferase NN O O
( NN O O
ALT NN O O
) NN O O
increase NN O O
of NN O O
3-fold NN O O
or NN O O
greater NN O O
above NN O O
the NN O O
upper NN O O
limit NN O O
of NN O O
normal NN O O
( NN O O
0.9 NN O O
% NN O O
and NN O O
0.9 NN O O
% NN O O
for NN O O
all NN O O
comparators NN O O
versus NN O O
TANZEUM NN O O
) NN O O
. NN O O
Three NN O O
subjects NN O O
on NN O O
TANZEUM NN O O
and NN O O
one NN O O
subject NN O O
in NN O O
the NN O O
all NN O O
- NN O O
comparator NN O O
group NN O O
experienced NN O O
at NN O O
least NN O O
one NN O O
event NN O O
of NN O O
ALT NN B-AdverseReaction B-AdverseReaction
increase NN I-AdverseReaction I-AdverseReaction
of NN O O
10-fold NN O O
or NN O O
greater NN O O
above NN O O
the NN O O
upper NN O O
limit NN O O
of NN O O
normal NN O O
. NN O O
In NN O O
one NN O O
of NN O O
the NN O O
3 NN O O
cases NN O O
an NN O O
alternate NN B-Negation B-Negation
etiology NN I-Negation I-Negation
was NN O O
identified NN O O
to NN O O
explain NN O O
the NN O O
rise NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
liver NN I-AdverseReaction I-AdverseReaction
enzyme NN I-AdverseReaction I-AdverseReaction
( NN O O
acute NN O O
viral NN O O
hepatitis NN O O
) NN O O
. NN O O
In NN O O
one NN O O
case NN O O
, NN O O
insufficient NN O O
information NN O O
was NN O O
obtained NN O O
to NN O O
establish NN O O
or NN O O
refute NN O O
a NN O O
drug NN O O
- NN O O
related NN O O
causality NN O O
. NN O O
In NN O O
the NN O O
third NN O O
case NN O O
, NN O O
elevation NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
ALT NN I-AdverseReaction I-AdverseReaction
( NN O O
10 NN O O
times NN O O
the NN O O
upper NN O O
limit NN O O
of NN O O
normal NN O O
) NN O O
was NN O O
accompanied NN O O
by NN O O
an NN O O
increase NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
total NN I-AdverseReaction I-AdverseReaction
bilirubin NN I-AdverseReaction I-AdverseReaction
( NN O O
4 NN O O
times NN O O
the NN O O
upper NN O O
limit NN O O
of NN O O
normal NN O O
) NN O O
and NN O O
occurred NN O O
8 NN O O
days NN O O
after NN O O
the NN O O
first NN O O
dose NN O O
of NN O O
TANZEUM. NN O O
The NN O O
etiology NN O O
of NN O O
hepatocellular NN B-AdverseReaction B-AdverseReaction
injury NN I-AdverseReaction I-AdverseReaction
was NN O O
possibly NN O O
related NN O O
to NN O O
TANZEUM NN O O
but NN O O
direct NN O O
attribution NN O O
to NN O O
TANZEUM NN O O
was NN O O
confounded NN O O
by NN O O
the NN O O
presence NN O O
of NN O O
gallstone NN O O
disease NN O O
diagnosed NN O O
on NN O O
ultrasound NN O O
3 NN O O
weeks NN O O
after NN O O
the NN O O
event NN O O
. NN O O
Gamma NN O O
Glutamyltransferase NN O O
( NN O O
GGT NN O O
) NN O O
Increase NN O O
In NN O O
the NN O O
pool NN O O
of NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
, NN O O
the NN O O
adverse NN O O
event NN O O
of NN O O
increased NN B-AdverseReaction B-AdverseReaction
GGT NN I-AdverseReaction I-AdverseReaction
occurred NN O O
more NN O O
frequently NN O O
in NN O O
the NN O O
group NN O O
treated NN O O
with NN O O
TANZEUM NN O O
( NN O O
0.9 NN O O
% NN O O
and NN O O
1.5 NN O O
% NN O O
for NN O O
placebo NN O O
versus NN O O
TANZEUM NN O O
) NN O O
. NN O O
Heart NN O O
Rate NN O O
Increase NN O O
In NN O O
the NN O O
pool NN O O
of NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
, NN O O
mean NN O O
heart NN O O
rate NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
TANZEUM NN O O
was NN O O
higher NN O O
by NN O O
an NN O O
average NN O O
of NN O O
1 NN O O
to NN O O
2 NN O O
bpm NN O O
compared NN O O
with NN O O
mean NN O O
heart NN O O
rate NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
placebo NN O O
across NN O O
study NN O O
visits NN O O
. NN O O
The NN O O
long NN O O
- NN O O
term NN O O
clinical NN O O
effects NN O O
of NN O O
the NN O O
increase NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
heart NN I-AdverseReaction I-AdverseReaction
rate NN I-AdverseReaction I-AdverseReaction
have NN O O
not NN O O
been NN O O
established NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.6 NN O O
) NN O O
] NN O O
. NN O O
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
RISK NN B-Factor B-Factor
OF NN O O
THYROID NN B-AdverseReaction B-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
CELL NN I-AdverseReaction I-AdverseReaction
TUMORS NN I-AdverseReaction I-AdverseReaction
WARNING NN O O
: NN O O
RISK NN B-Factor B-Factor
OF NN O O
THYROID NN B-AdverseReaction B-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
CELL NN I-AdverseReaction I-AdverseReaction
TUMORS NN I-AdverseReaction I-AdverseReaction
* NN O O
Carcinogenicity NN O O
of NN O O
albiglutide NN O O
could NN O O
not NN O O
be NN O O
assessed NN O O
in NN O O
rodents NN O O
, NN O O
but NN O O
other NN O O
glucagon NN B-DrugClass B-DrugClass
- NN I-DrugClass I-DrugClass
like NN I-DrugClass I-DrugClass
peptide-1 NN I-DrugClass I-DrugClass
( NN I-DrugClass I-DrugClass
GLP-1 NN I-DrugClass I-DrugClass
) NN I-DrugClass I-DrugClass
receptor NN I-DrugClass I-DrugClass
agonists NN I-DrugClass I-DrugClass
have NN O O
caused NN O O
thyroid NN B-AdverseReaction B-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
tumors NN I-AdverseReaction I-AdverseReaction
in NN O O
rodents NN B-Animal B-Animal
at NN O O
clinically NN O O
relevant NN O O
exposures NN O O
. NN O O
Human NN O O
relevance NN O O
of NN O O
GLP-1 NN B-DrugClass B-DrugClass
receptor NN I-DrugClass I-DrugClass
agonist NN I-DrugClass I-DrugClass
induced NN O O
C NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
tumors NN I-AdverseReaction I-AdverseReaction
in NN O O
rodents NN B-Animal B-Animal
has NN O O
not NN O O
been NN O O
determined NN O O
. NN O O
It NN O O
is NN O O
unknown NN B-Factor B-Factor
whether NN O O
TANZEUM(r NN O O
) NN O O
causes NN O O
thyroid NN B-AdverseReaction B-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
tumors NN I-AdverseReaction I-AdverseReaction
including NN O O
medullary NN B-AdverseReaction B-AdverseReaction
thyroid NN I-AdverseReaction I-AdverseReaction
carcinoma NN I-AdverseReaction I-AdverseReaction
( NN O O
MTC NN O O
) NN O O
, NN O O
in NN O O
humans NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
, NN O O
Nonclinical NN O O
Toxicology NN O O
( NN O O
13.1 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
TANZEUM NN O O
is NN O O
contraindicated NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
personal NN O O
or NN O O
family NN O O
history NN O O
of NN O O
MTC NN O O
or NN O O
in NN O O
patients NN O O
with NN O O
Multiple NN O O
Endocrine NN O O
Neoplasia NN O O
syndrome NN O O
type NN O O
2 NN O O
( NN O O
MEN NN O O
2 NN O O
) NN O O
. NN O O
Counsel NN O O
patients NN O O
regarding NN O O
the NN O O
potential NN O O
risk NN O O
of NN O O
MTC NN O O
with NN O O
the NN O O
use NN O O
of NN O O
TANZEUM NN O O
and NN O O
inform NN O O
them NN O O
of NN O O
the NN O O
symptoms NN O O
of NN O O
thyroid NN O O
tumors NN O O
( NN O O
e.g. NN O O
, NN O O
mass NN O O
in NN O O
the NN O O
neck NN O O
, NN O O
dysphagia NN O O
, NN O O
dyspnea NN O O
, NN O O
persistent NN O O
hoarseness NN O O
) NN O O
. NN O O
Routine NN O O
monitoring NN O O
of NN O O
serum NN O O
calcitonin NN O O
or NN O O
using NN O O
thyroid NN O O
ultrasound NN O O
monitoring NN O O
is NN O O
of NN O O
uncertain NN O O
value NN O O
for NN O O
early NN O O
detection NN O O
of NN O O
MTC NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
TANZEUM NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4.1 NN O O
) NN O O
, NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
WARNING NN O O
: NN O O
RISK NN B-Factor B-Factor
OF NN O O
THYROID NN B-AdverseReaction B-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
CELL NN I-AdverseReaction I-AdverseReaction
TUMORS NN I-AdverseReaction I-AdverseReaction
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
. NN O O
* NN O O
Carcinogenicity NN O O
of NN O O
albiglutide NN O O
could NN O O
not NN O O
be NN O O
assessed NN O O
in NN O O
rodents NN O O
, NN O O
but NN O O
other NN O O
glucagon NN B-DrugClass B-DrugClass
- NN I-DrugClass I-DrugClass
like NN I-DrugClass I-DrugClass
peptide-1 NN I-DrugClass I-DrugClass
( NN I-DrugClass I-DrugClass
GLP-1 NN I-DrugClass I-DrugClass
) NN I-DrugClass I-DrugClass
receptor NN I-DrugClass I-DrugClass
agonists NN I-DrugClass I-DrugClass
have NN O O
caused NN O O
thyroid NN B-AdverseReaction B-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
tumors NN I-AdverseReaction I-AdverseReaction
in NN O O
rodents NN B-Animal B-Animal
at NN O O
clinically NN O O
relevant NN O O
exposures NN O O
. NN O O
Human NN O O
relevance NN O O
of NN O O
GLP-1 NN B-DrugClass B-DrugClass
receptor NN I-DrugClass I-DrugClass
agonist NN I-DrugClass I-DrugClass
induced NN O O
C NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
tumors NN I-AdverseReaction I-AdverseReaction
in NN O O
rodents NN B-Animal B-Animal
has NN O O
not NN O O
been NN O O
determined NN O O
. NN O O
It NN O O
is NN O O
unknown NN B-Factor B-Factor
whether NN O O
TANZEUM NN O O
causes NN O O
thyroid NN B-AdverseReaction B-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
tumors NN I-AdverseReaction I-AdverseReaction
including NN O O
medullary NN B-AdverseReaction B-AdverseReaction
thyroid NN I-AdverseReaction I-AdverseReaction
carcinoma NN I-AdverseReaction I-AdverseReaction
( NN O O
MTC NN O O
) NN O O
, NN O O
in NN O O
humans NN O O
. NN O O
( NN O O
5.1 NN O O
, NN O O
13.1 NN O O
) NN O O
* NN O O
TANZEUM NN O O
is NN O O
contraindicated NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
personal NN O O
or NN O O
family NN O O
history NN O O
of NN O O
MTC NN O O
or NN O O
in NN O O
patients NN O O
with NN O O
Multiple NN O O
Endocrine NN O O
Neoplasia NN O O
syndrome NN O O
type NN O O
2 NN O O
( NN O O
MEN NN O O
2 NN O O
) NN O O
. NN O O
Counsel NN O O
patients NN O O
regarding NN O O
the NN O O
potential NN O O
risk NN O O
of NN O O
MTC NN O O
and NN O O
symptoms NN O O
of NN O O
thyroid NN O O
tumors NN O O
( NN O O
4.1 NN O O
, NN O O
5.1 NN O O
) NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Thyroid NN B-AdverseReaction B-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
Tumors NN I-AdverseReaction I-AdverseReaction
See NN O O
Boxed NN O O
Warning NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Pancreatitis NN B-AdverseReaction B-AdverseReaction
Discontinue NN O O
promptly NN O O
if NN O O
suspected NN O O
. NN O O
Do NN O O
not NN O O
restart NN O O
if NN O O
confirmed NN O O
. NN O O
Consider NN O O
other NN O O
antidiabetic NN O O
therapies NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
pancreatitis NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Hypoglycemia NN B-AdverseReaction B-AdverseReaction
Can NN O O
occur NN O O
when NN O O
used NN O O
in NN O O
combination NN O O
with NN O O
insulin NN O O
secretagogues NN O O
( NN O O
e.g. NN O O
, NN O O
sulfonylureas NN O O
) NN O O
or NN O O
insulin NN O O
. NN O O
Consider NN O O
lowering NN O O
sulfonylurea NN O O
or NN O O
insulin NN O O
dosage NN O O
when NN O O
starting NN O O
TANZEUM. NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
Reactions NN I-AdverseReaction I-AdverseReaction
Discontinue NN O O
TANZEUM NN O O
if NN O O
suspected NN O O
. NN O O
Monitor NN O O
and NN O O
treat NN O O
promptly NN O O
per NN O O
standard NN O O
of NN O O
care NN O O
until NN O O
signs NN O O
and NN O O
symptoms NN O O
resolve NN O O
. NN O O
( NN O O
5.4 NN O O
) NN O O
* NN O O
Renal NN B-AdverseReaction B-AdverseReaction
Impairment NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
renal NN O O
function NN O O
in NN O O
patients NN O O
with NN O O
renal NN O O
impairment NN O O
reporting NN O O
severe NN O O
adverse NN O O
gastrointestinal NN O O
reactions NN O O
. NN O O
( NN O O
5.5 NN O O
) NN O O
* NN O O
Macrovascular NN O O
Outcomes NN O O
: NN O O
There NN O O
have NN O O
been NN O O
no NN O O
clinical NN O O
trials NN O O
establishing NN O O
conclusive NN O O
evidence NN O O
of NN O O
macrovascular NN O O
risk NN O O
reduction NN O O
with NN O O
TANZEUM NN O O
or NN O O
any NN O O
other NN O O
antidiabetic NN O O
drug NN O O
. NN O O
( NN O O
5.6 NN O O
) NN O O
5.1 NN O O
Risk NN O O
of NN O O
Thyroid NN O O
C NN O O
- NN O O
cell NN O O
Tumors NN O O
Carcinogenicity NN O O
of NN O O
albiglutide NN O O
could NN O O
not NN O O
be NN O O
assessed NN O O
in NN O O
rodents NN O O
due NN O O
to NN O O
the NN O O
rapid NN O O
development NN O O
of NN O O
drug NN O O
- NN O O
clearing NN O O
, NN O O
anti NN O O
- NN O O
drug NN O O
antibodies NN O O
[ NN O O
see NN O O
Nonclinical NN O O
Toxicology NN O O
( NN O O
13.1 NN O O
) NN O O
] NN O O
. NN O O
Other NN O O
GLP-1 NN B-DrugClass B-DrugClass
receptor NN I-DrugClass I-DrugClass
agonists NN I-DrugClass I-DrugClass
have NN O O
caused NN O O
dose NN O O
- NN O O
related NN O O
and NN O O
treatment NN O O
- NN O O
duration NN O O
- NN O O
dependent NN O O
thyroid NN B-AdverseReaction B-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
tumors NN I-AdverseReaction I-AdverseReaction
( NN O O
adenomas NN O O
or NN O O
carcinomas NN O O
) NN O O
in NN O O
rodents NN B-Animal B-Animal
Human NN O O
relevance NN O O
of NN O O
GLP-1 NN B-DrugClass B-DrugClass
receptor NN I-DrugClass I-DrugClass
agonist NN I-DrugClass I-DrugClass
induced NN O O
C NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
tumors NN I-AdverseReaction I-AdverseReaction
in NN O O
rodents NN B-Animal B-Animal
has NN O O
not NN O O
been NN O O
determined NN O O
. NN O O
It NN O O
is NN O O
unknown NN B-Factor B-Factor
whether NN O O
TANZEUM NN O O
causes NN O O
thyroid NN B-AdverseReaction B-AdverseReaction
C NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
tumors NN I-AdverseReaction I-AdverseReaction
including NN O O
MTC NN B-AdverseReaction B-AdverseReaction
in NN O O
humans NN O O
[ NN O O
see NN O O
Boxed NN O O
Warning NN O O
, NN O O
Contraindications NN O O
( NN O O
4.1 NN O O
) NN O O
] NN O O
. NN O O
Across NN O O
8 NN O O
Phase NN O O
III NN O O
clinical NN O O
trials NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
, NN O O
MTC NN B-AdverseReaction B-AdverseReaction
was NN O O
diagnosed NN O O
in NN O O
1 NN O O
patient NN O O
receiving NN O O
TANZEUM NN O O
and NN O O
1 NN O O
patient NN O O
receiving NN O O
placebo NN O O
. NN O O
Both NN O O
patients NN O O
had NN O O
markedly NN O O
elevated NN O O
serum NN O O
calcitonin NN O O
levels NN O O
at NN O O
baseline NN O O
. NN O O
Cases NN O O
of NN O O
MTC NN B-AdverseReaction B-AdverseReaction
in NN O O
patients NN O O
treated NN O O
with NN O O
liraglutide NN B-DrugClass B-DrugClass
another NN O O
GLP-1 NN O O
receptor NN O O
agonist NN O O
, NN O O
have NN O O
been NN O O
reported NN O O
in NN O O
the NN O O
postmarketing NN O O
period NN O O
; NN O O
the NN O O
data NN O O
in NN O O
these NN O O
reports NN O O
are NN O O
insufficient NN O O
to NN O O
establish NN O O
or NN O O
exclude NN O O
a NN O O
causal NN O O
relationship NN O O
between NN O O
MTC NN B-AdverseReaction B-AdverseReaction
and NN O O
GLP-1 NN B-DrugClass B-DrugClass
receptor NN I-DrugClass I-DrugClass
agonist NN I-DrugClass I-DrugClass
use NN O O
in NN O O
humans NN O O
. NN O O
TANZEUM NN O O
is NN O O
contraindicated NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
personal NN O O
or NN O O
family NN O O
history NN O O
of NN O O
MTC NN O O
or NN O O
in NN O O
patients NN O O
with NN O O
MEN NN O O
2 NN O O
. NN O O
Counsel NN O O
patients NN O O
regarding NN O O
the NN O O
potential NN O O
risk NN O O
for NN O O
MTC NN O O
with NN O O
the NN O O
use NN O O
of NN O O
TANZEUM NN O O
and NN O O
inform NN O O
them NN O O
of NN O O
symptoms NN O O
of NN O O
thyroid NN O O
tumors NN O O
( NN O O
e.g. NN O O
, NN O O
a NN O O
mass NN O O
in NN O O
the NN O O
neck NN O O
, NN O O
dysphagia NN O O
, NN O O
dyspnea NN O O
, NN O O
or NN O O
persistent NN O O
hoarseness NN O O
) NN O O
. NN O O
Routine NN O O
monitoring NN O O
of NN O O
serum NN O O
calcitonin NN O O
or NN O O
using NN O O
thyroid NN O O
ultrasound NN O O
is NN O O
of NN O O
uncertain NN O O
value NN O O
for NN O O
early NN O O
detection NN O O
of NN O O
MTC NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
TANZEUM. NN O O
Such NN O O
monitoring NN O O
may NN O O
increase NN O O
the NN O O
risk NN O O
of NN O O
unnecessary NN O O
procedures NN O O
, NN O O
due NN O O
to NN O O
the NN O O
low NN O O
specificity NN O O
of NN O O
serum NN O O
calcitonin NN O O
testing NN O O
for NN O O
MTC NN O O
and NN O O
a NN O O
high NN O O
background NN O O
incidence NN O O
of NN O O
thyroid NN O O
disease NN O O
. NN O O
Significantly NN O O
elevated NN O O
serum NN O O
calcitonin NN O O
may NN O O
indicate NN O O
MTC NN O O
and NN O O
patients NN O O
with NN O O
MTC NN O O
usually NN O O
have NN O O
calcitonin NN O O
values NN O O
>50 NN O O
ng/L. NN O O
If NN O O
serum NN O O
calcitonin NN O O
is NN O O
measured NN O O
and NN O O
found NN O O
to NN O O
be NN O O
elevated NN O O
, NN O O
the NN O O
patient NN O O
should NN O O
be NN O O
further NN O O
evaluated NN O O
. NN O O
Patients NN O O
with NN O O
thyroid NN O O
nodules NN O O
noted NN O O
on NN O O
physical NN O O
examination NN O O
or NN O O
neck NN O O
imaging NN O O
should NN O O
also NN O O
be NN O O
further NN O O
evaluated NN O O
. NN O O
5.2 NN O O
Acute NN O O
Pancreatitis NN O O
In NN O O
clinical NN O O
trials NN O O
, NN O O
acute NN B-AdverseReaction B-AdverseReaction
pancreatitis NN I-AdverseReaction I-AdverseReaction
has NN O O
been NN O O
reported NN O O
in NN O O
association NN O O
with NN O O
TANZEUM. NN O O
Across NN O O
8 NN O O
Phase NN O O
III NN O O
clinical NN O O
trials NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
, NN O O
pancreatitis NN B-AdverseReaction B-AdverseReaction
adjudicated NN O O
as NN O O
likely NN O O
related NN O O
to NN O O
therapy NN O O
occurred NN O O
more NN O O
frequently NN O O
in NN O O
patients NN O O
receiving NN O O
TANZEUM NN O O
( NN O O
6 NN O O
of NN O O
2,365 NN O O
[ NN O O
0.3 NN O O
% NN O O
] NN O O
) NN O O
than NN O O
in NN O O
patients NN O O
receiving NN O O
placebo NN O O
( NN O O
0 NN O O
of NN O O
468 NN O O
[ NN O O
0 NN O O
% NN O O
] NN O O
) NN O O
or NN O O
active NN O O
comparators NN O O
( NN O O
2 NN O O
of NN O O
2,065 NN O O
[ NN O O
0.1 NN O O
% NN O O
] NN O O
) NN O O
. NN O O
After NN O O
initiation NN O O
of NN O O
TANZEUM NN O O
, NN O O
observe NN O O
patients NN O O
carefully NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
pancreatitis NN O O
( NN O O
including NN O O
persistent NN O O
severe NN O O
abdominal NN O O
pain NN O O
, NN O O
sometimes NN O O
radiating NN O O
to NN O O
the NN O O
back NN O O
and NN O O
which NN O O
may NN O O
or NN O O
may NN O O
not NN O O
be NN O O
accompanied NN O O
by NN O O
vomiting NN O O
) NN O O
. NN O O
If NN O O
pancreatitis NN O O
is NN O O
suspected NN O O
, NN O O
promptly NN O O
discontinue NN O O
TANZEUM. NN O O
If NN O O
pancreatitis NN O O
is NN O O
confirmed NN O O
, NN O O
TANZEUM NN O O
should NN O O
not NN O O
be NN O O
restarted NN O O
. NN O O
TANZEUM NN O O
has NN O O
not NN O O
been NN O O
studied NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
pancreatitis NN O O
to NN O O
determine NN O O
whether NN O O
these NN O O
patients NN O O
are NN O O
at NN O O
increased NN O O
risk NN O O
for NN O O
pancreatitis NN O O
. NN O O
Consider NN O O
other NN O O
antidiabetic NN O O
therapies NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
pancreatitis NN O O
. NN O O
5.3 NN O O
Hypoglycemia NN O O
with NN O O
Concomitant NN O O
Use NN O O
of NN O O
Insulin NN O O
Secretagogues NN O O
or NN O O
Insulin NN O O
The NN O O
risk NN B-Factor B-Factor
of NN O O
hypoglycemia NN B-AdverseReaction B-AdverseReaction
is NN O O
increased NN O O
when NN O O
TANZEUM NN O O
is NN O O
used NN O O
in NN O O
combination NN O O
with NN O O
insulin NN O O
secretagogues NN O O
( NN O O
e.g. NN O O
, NN O O
sulfonylureas NN O O
) NN O O
or NN O O
insulin NN O O
. NN O O
Therefore NN O O
, NN O O
patients NN O O
may NN O O
require NN O O
a NN O O
lower NN O O
dose NN O O
of NN O O
sulfonylurea NN O O
or NN O O
insulin NN O O
to NN O O
reduce NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
hypoglycemia NN B-AdverseReaction B-AdverseReaction
in NN O O
this NN O O
setting NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
, NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
5.4 NN O O
Hypersensitivity NN O O
Reactions NN O O
Across NN O O
8 NN O O
Phase NN O O
III NN O O
clinical NN O O
trials NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
, NN O O
a NN O O
serious NN B-Severity B-Severity
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
with NN O O
pruritus NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
and NN O O
dyspnea NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
a NN O O
patient NN O O
treated NN O O
with NN O O
TANZEUM. NN O O
If NN O O
hypersensitivity NN O O
reactions NN O O
occur NN O O
, NN O O
discontinue NN O O
use NN O O
of NN O O
TANZEUM NN O O
; NN O O
treat NN O O
promptly NN O O
per NN O O
standard NN O O
of NN O O
care NN O O
and NN O O
monitor NN O O
until NN O O
signs NN O O
and NN O O
symptoms NN O O
resolve NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4.2 NN O O
) NN O O
] NN O O
. NN O O
5.5 NN O O
Renal NN O O
Impairment NN O O
In NN O O
patients NN O O
treated NN O O
with NN O O
GLP-1 NN B-DrugClass B-DrugClass
receptor NN I-DrugClass I-DrugClass
agonists NN I-DrugClass I-DrugClass
there NN O O
have NN O O
been NN O O
postmarketing NN O O
reports NN O O
of NN O O
acute NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
and NN O O
worsening NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
chronic NN I-AdverseReaction I-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
which NN O O
may NN O O
sometimes NN O O
require NN O O
hemodialysis NN O O
. NN O O
Some NN O O
of NN O O
these NN O O
events NN O O
were NN O O
reported NN O O
in NN O O
patients NN O O
without NN O O
known NN O O
underlying NN O O
renal NN O O
disease NN O O
. NN O O
A NN O O
majority NN O O
of NN O O
reported NN O O
events NN O O
occurred NN O O
in NN O O
patients NN O O
who NN O O
had NN O O
experienced NN O O
nausea NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
or NN O O
dehydration NN B-AdverseReaction B-AdverseReaction
In NN O O
a NN O O
trial NN O O
of NN O O
TANZEUM NN O O
in NN O O
patients NN O O
with NN O O
renal NN O O
impairment NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14.3 NN O O
) NN O O
] NN O O
, NN O O
the NN O O
frequency NN O O
of NN O O
such NN O O
gastrointestinal NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
increased NN O O
as NN O O
renal NN B-AdverseReaction B-AdverseReaction
function NN I-AdverseReaction I-AdverseReaction
declined NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.6 NN O O
) NN O O
] NN O O
. NN O O
Because NN O O
these NN O O
reactions NN O O
may NN O O
worsen NN O O
renal NN O O
function NN O O
, NN O O
use NN O O
caution NN O O
when NN O O
initiating NN O O
or NN O O
escalating NN O O
doses NN O O
of NN O O
TANZEUM NN O O
in NN O O
patients NN O O
with NN O O
renal NN O O
impairment NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
, NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.6 NN O O
) NN O O
] NN O O
. NN O O
5.6 NN O O
Macrovascular NN O O
Outcomes NN O O
There NN O O
have NN O O
been NN O O
no NN O O
clinical NN O O
trials NN O O
establishing NN O O
conclusive NN O O
evidence NN O O
of NN O O
macrovascular NN O O
risk NN O O
reduction NN O O
with NN O O
TANZEUM NN O O
or NN O O
any NN O O
other NN O O
antidiabetic NN O O
drug NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
are NN O O
discussed NN O O
in NN O O
greater NN O O
detail NN O O
in NN O O
other NN O O
sections NN O O
of NN O O
the NN O O
labeling NN O O
: NN O O
* NN O O
Gastrointestinal NN B-AdverseReaction B-AdverseReaction
toxicity NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
and NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Myelosuppression NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.4 NN O O
) NN O O
and NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Hepatic NN B-AdverseReaction B-AdverseReaction
toxicity NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.5 NN O O
) NN O O
and NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Fluid NN B-AdverseReaction B-AdverseReaction
retention NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Renal NN B-AdverseReaction B-AdverseReaction
toxicity NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
. NN O O
EXCERPT NN O O
: NN O O
Most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
incidence NN O O
greater NN O O
than NN O O
20 NN O O
% NN O O
) NN O O
are NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
anemia NN B-AdverseReaction B-AdverseReaction
pyrexia NN B-AdverseReaction B-AdverseReaction
and NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
( NN O O
6 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Pfizer NN O O
Inc. NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
438 NN O O
- NN O O
1985 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
Serious NN O O
adverse NN O O
reactions NN O O
reported NN O O
include NN O O
anaphylactic NN B-AdverseReaction B-AdverseReaction
shock NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
] NN O O
, NN O O
myelosuppression NN B-AdverseReaction B-AdverseReaction
gastrointestinal NN B-AdverseReaction B-AdverseReaction
toxicity NN I-AdverseReaction I-AdverseReaction
( NN O O
diarrhea NN O O
) NN O O
, NN O O
fluid NN B-AdverseReaction B-AdverseReaction
retention NN I-AdverseReaction I-AdverseReaction
hepatotoxicity NN B-AdverseReaction B-AdverseReaction
and NN O O
rash NN B-AdverseReaction B-AdverseReaction
Adverse NN O O
reactions NN O O
of NN O O
any NN O O
toxicity NN O O
grade NN O O
reported NN O O
for NN O O
greater NN O O
than NN O O
20 NN O O
% NN O O
of NN O O
patients NN O O
in NN O O
the NN O O
Phase NN O O
1/2 NN O O
safety NN O O
population NN O O
( NN O O
n=546 NN O O
) NN O O
were NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
( NN O O
82 NN O O
% NN O O
) NN O O
, NN O O
nausea NN B-AdverseReaction B-AdverseReaction
( NN O O
46 NN O O
% NN O O
) NN O O
, NN O O
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
( NN O O
41 NN O O
% NN O O
) NN O O
, NN O O
vomiting NN B-AdverseReaction B-AdverseReaction
( NN O O
39 NN O O
% NN O O
) NN O O
, NN O O
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
( NN O O
37 NN O O
% NN O O
) NN O O
, NN O O
rash NN B-AdverseReaction B-AdverseReaction
( NN O O
35 NN O O
% NN O O
) NN O O
, NN O O
anemia NN B-AdverseReaction B-AdverseReaction
( NN O O
27 NN O O
% NN O O
) NN O O
, NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
( NN O O
26 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
fatigue NN B-AdverseReaction B-AdverseReaction
( NN O O
24 NN O O
% NN O O
) NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
. NN O O
Adverse NN O O
Reactions NN O O
in NN O O
Patients NN O O
with NN O O
Imatinib NN O O
- NN O O
Resistant NN O O
or NN O O
-Intolerant NN O O
Ph+ NN O O
Chronic NN O O
Phase NN O O
( NN O O
CP NN O O
) NN O O
, NN O O
Accelerated NN O O
Phase NN O O
( NN O O
AP NN O O
) NN O O
, NN O O
and NN O O
Blast NN O O
Phase NN O O
( NN O O
BP NN O O
) NN O O
CML NN O O
The NN O O
single NN O O
- NN O O
arm NN O O
Phase NN O O
1/2 NN O O
clinical NN O O
trial NN O O
( NN O O
Study NN O O
1 NN O O
) NN O O
enrolled NN O O
patients NN O O
with NN O O
Ph+ NN O O
chronic NN O O
, NN O O
accelerated NN O O
, NN O O
or NN O O
blast NN O O
phase NN O O
chronic NN O O
myelogenous NN O O
leukemia NN O O
( NN O O
CML NN O O
) NN O O
and NN O O
with NN O O
resistance NN O O
or NN O O
intolerance NN O O
to NN O O
prior NN O O
therapy NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
safety NN O O
population NN O O
( NN O O
received NN O O
at NN O O
least NN O O
1 NN O O
dose NN O O
of NN O O
BOSULIF NN O O
) NN O O
included NN O O
546 NN O O
CML NN O O
patients NN O O
: NN O O
* NN O O
287 NN O O
patients NN O O
with NN O O
CP NN O O
CML NN O O
previously NN O O
treated NN O O
with NN O O
imatinib NN O O
only NN O O
who NN O O
had NN O O
a NN O O
median NN O O
duration NN O O
of NN O O
BOSULIF NN O O
treatment NN O O
of NN O O
24 NN O O
months NN O O
, NN O O
and NN O O
a NN O O
median NN O O
dose NN O O
intensity NN O O
of NN O O
484 NN O O
mg/day NN O O
. NN O O
* NN O O
119 NN O O
patients NN O O
with NN O O
CP NN O O
CML NN O O
previously NN O O
treated NN O O
with NN O O
both NN O O
imatinib NN O O
and NN O O
at NN O O
least NN O O
1 NN O O
additional NN O O
TKI NN O O
who NN O O
had NN O O
a NN O O
median NN O O
duration NN O O
of NN O O
BOSULIF NN O O
treatment NN O O
of NN O O
9 NN O O
months NN O O
and NN O O
a NN O O
median NN O O
dose NN O O
intensity NN O O
of NN O O
475 NN O O
mg/day NN O O
. NN O O
* NN O O
140 NN O O
patients NN O O
with NN O O
advanced NN O O
phase NN O O
CML NN O O
including NN O O
76 NN O O
patients NN O O
with NN O O
AP NN O O
CML NN O O
and NN O O
64 NN O O
patients NN O O
with NN O O
BP NN O O
CML. NN O O
In NN O O
the NN O O
patients NN O O
with NN O O
AP NN O O
CML NN O O
and NN O O
BP NN O O
CML NN O O
, NN O O
the NN O O
median NN O O
duration NN O O
of NN O O
BOSULIF NN O O
treatment NN O O
was NN O O
10 NN O O
months NN O O
and NN O O
3 NN O O
months NN O O
, NN O O
respectively NN O O
. NN O O
The NN O O
median NN O O
dose NN O O
intensity NN O O
was NN O O
483 NN O O
mg/day NN O O
, NN O O
and NN O O
500 NN O O
mg/day NN O O
, NN O O
in NN O O
the NN O O
AP NN O O
CML NN O O
and NN O O
BP NN O O
CML NN O O
cohorts NN O O
, NN O O
respectively NN O O
. NN O O
Table NN O O
3 NN O O
identifies NN O O
adverse NN O O
reactions NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
10 NN O O
% NN O O
for NN O O
all NN O O
grades NN O O
and NN O O
grades NN O O
3 NN O O
or NN O O
4 NN O O
for NN O O
the NN O O
Phase NN O O
1/2 NN O O
CML NN O O
safety NN O O
population NN O O
. NN O O
Table NN O O
3 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
( NN O O
10 NN O O
% NN O O
or NN O O
Greater NN O O
) NN O O
in NN O O
Patients NN O O
with NN O O
CML NN O O
in NN O O
Study NN O O
1 NN O O
Chronic NN O O
Phase NN O O
CMLN=406 NN O O
Advanced NN O O
Phase NN O O
CMLN=140 NN O O
All NN O O
Grades( NN O O
% NN O O
) NN O O
Grade NN O O
3/4( NN O O
% NN O O
) NN O O
All NN O O
Grades( NN O O
% NN O O
) NN O O
Grade NN O O
3/4( NN O O
% NN O O
) NN O O
Advanced NN O O
Phase NN O O
CML NN O O
includes NN O O
patients NN O O
with NN O O
Accelerated NN O O
Phase NN O O
and NN O O
Blast NN O O
Phase NN O O
CML NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
84 NN O O
9 NN O O
76 NN O O
5 NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
46 NN O O
1 NN O O
47 NN O O
2 NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
Pain NN I-AdverseReaction I-AdverseReaction
40 NN O O
1 NN O O
29 NN O O
5 NN O O
Thrombocytopenia NN B-AdverseReaction B-AdverseReaction
40 NN O O
26 NN O O
42 NN O O
37 NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
37 NN O O
3 NN O O
42 NN O O
4 NN O O
Rash NN B-AdverseReaction B-AdverseReaction
34 NN O O
8 NN O O
35 NN O O
4 NN O O
Fatigue NN B-AdverseReaction B-AdverseReaction
26 NN O O
1 NN O O
20 NN O O
4 NN O O
Anemia NN B-AdverseReaction B-AdverseReaction
23 NN O O
9 NN O O
37 NN O O
26 NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
22 NN O O
< NN O O
1 NN O O
36 NN O O
3 NN O O
Increased NN B-AdverseReaction B-AdverseReaction
alanine NN I-AdverseReaction I-AdverseReaction
aminotransferase NN I-AdverseReaction I-AdverseReaction
20 NN O O
7 NN O O
10 NN O O
5 NN O O
Headache NN B-AdverseReaction B-AdverseReaction
20 NN O O
1 NN O O
18 NN O O
4 NN O O
Cough NN B-AdverseReaction B-AdverseReaction
20 NN O O
0 NN O O
21 NN O O
0 NN O O
Increased NN B-AdverseReaction B-AdverseReaction
aspartate NN I-AdverseReaction I-AdverseReaction
aminotransferase NN I-AdverseReaction I-AdverseReaction
16 NN O O
4 NN O O
11 NN O O
3 NN O O
Neutropenia NN B-AdverseReaction B-AdverseReaction
16 NN O O
11 NN O O
19 NN O O
18 NN O O
Edema NN B-AdverseReaction B-AdverseReaction
14 NN O O
< NN O O
1 NN O O
14 NN O O
1 NN O O
Arthralgia NN B-AdverseReaction B-AdverseReaction
14 NN O O
< NN O O
1 NN O O
13 NN O O
0 NN O O
Decreased NN B-AdverseReaction B-AdverseReaction
appetite NN I-AdverseReaction I-AdverseReaction
13 NN O O
1 NN O O
14 NN O O
0 NN O O
Respiratory NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
12 NN O O
< NN O O
1 NN O O
10 NN O O
0 NN O O
Nasopharyngitis NN B-AdverseReaction B-AdverseReaction
12 NN O O
0 NN O O
5 NN O O
0 NN O O
Back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
12 NN O O
1 NN O O
7 NN O O
1 NN O O
Asthenia NN B-AdverseReaction B-AdverseReaction
11 NN O O
1 NN O O
10 NN O O
1 NN O O
Pruritus NN B-AdverseReaction B-AdverseReaction
11 NN O O
1 NN O O
8 NN O O
0 NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
10 NN O O
0 NN O O
13 NN O O
1 NN O O
Dyspnea NN B-AdverseReaction B-AdverseReaction
10 NN O O
1 NN O O
19 NN O O
6 NN O O
In NN O O
the NN O O
single NN O O
- NN O O
arm NN O O
Phase NN O O
1/2 NN O O
clinical NN O O
trial NN O O
, NN O O
one NN O O
patient NN O O
( NN O O
0.2 NN O O
% NN O O
) NN O O
experienced NN O O
QTcF NN B-AdverseReaction B-AdverseReaction
interval NN I-AdverseReaction I-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
greater NN I-AdverseReaction I-AdverseReaction
than NN I-AdverseReaction I-AdverseReaction
500 NN I-AdverseReaction I-AdverseReaction
milliseconds NN I-AdverseReaction I-AdverseReaction
Patients NN O O
with NN O O
uncontrolled NN O O
or NN O O
significant NN O O
cardiovascular NN O O
disease NN O O
including NN O O
QT NN O O
interval NN O O
prolongation NN O O
were NN O O
excluded NN O O
by NN O O
protocol NN O O
. NN O O
Table NN O O
4 NN O O
identifies NN O O
the NN O O
clinically NN O O
relevant NN O O
or NN O O
severe NN O O
Grade NN O O
3/4 NN O O
laboratory NN O O
test NN O O
abnormalities NN O O
for NN O O
the NN O O
Phase NN O O
1/2 NN O O
CML NN O O
safety NN O O
population NN O O
. NN O O
Table NN O O
4 NN O O
: NN O O
Number NN O O
( NN O O
% NN O O
) NN O O
of NN O O
Patients NN O O
with NN O O
Clinically NN O O
Relevant NN O O
or NN O O
Severe NN O O
Grade NN O O
3/4 NN O O
Laboratory NN O O
Test NN O O
Abnormalities NN O O
in NN O O
Patients NN O O
with NN O O
CML NN O O
in NN O O
Study NN O O
1 NN O O
, NN O O
Safety NN O O
Population NN O O
Chronic NN O O
Phase NN O O
CML NN O O
Advanced NN O O
Phase NN O O
CML NN O O
All NN O O
CP NN O O
and NN O O
AdvP NN O O
CML NN O O
N=406 NN O O
N=140 NN O O
N=546 NN O O
n NN O O
( NN O O
% NN O O
) NN O O
n NN O O
( NN O O
% NN O O
) NN O O
n NN O O
( NN O O
% NN O O
) NN O O
Hematology NN O O
Parameters NN O O
Platelet NN O O
Count NN O O
( NN O O
Low NN O O
) NN O O
less NN O O
than NN O O
50*10 NN B-Severity B-Severity
9 NN I-Severity I-Severity
/L NN I-Severity I-Severity
102 NN O O
( NN O O
25 NN O O
) NN O O
80 NN O O
( NN O O
57 NN O O
) NN O O
182 NN O O
( NN O O
33 NN O O
) NN O O
Absolute NN B-AdverseReaction B-AdverseReaction
Neutrophil NN I-AdverseReaction I-AdverseReaction
Count NN I-AdverseReaction I-AdverseReaction
less NN I-AdverseReaction I-AdverseReaction
than NN I-AdverseReaction I-AdverseReaction
1*10 NN I-AdverseReaction I-AdverseReaction
9 NN I-AdverseReaction I-AdverseReaction
/L NN I-AdverseReaction I-AdverseReaction
74 NN O O
( NN O O
18 NN O O
) NN O O
52 NN O O
( NN O O
37 NN O O
) NN O O
126 NN O O
( NN O O
23 NN O O
) NN O O
Hemoglobin NN O O
( NN O O
Low NN O O
) NN O O
less NN O O
than NN O O
80 NN B-Severity B-Severity
g/L NN I-Severity I-Severity
53 NN O O
( NN O O
13 NN O O
) NN O O
49 NN O O
( NN O O
35 NN O O
) NN O O
102 NN O O
( NN O O
19 NN O O
) NN O O
Biochemistry NN O O
Parameters NN O O
SGPT/ALT NN O O
greater NN O O
than NN O O
5.0*ULN NN O O
39 NN O O
( NN O O
10 NN O O
) NN O O
8 NN O O
( NN O O
6 NN O O
) NN O O
47 NN O O
( NN O O
9 NN O O
) NN O O
SGOT/AST NN O O
greater NN O O
than NN O O
5.0*ULN NN O O
17 NN O O
( NN O O
4 NN O O
) NN O O
4 NN O O
( NN O O
3 NN O O
) NN O O
21 NN O O
( NN O O
4 NN O O
) NN O O
Lipase NN B-AdverseReaction B-AdverseReaction
greater NN I-AdverseReaction I-AdverseReaction
than NN I-AdverseReaction I-AdverseReaction
2*ULN NN I-AdverseReaction I-AdverseReaction
33 NN O O
( NN O O
8 NN O O
) NN O O
4 NN O O
( NN O O
3 NN O O
) NN O O
37 NN O O
( NN O O
7 NN O O
) NN O O
Phosphorus NN O O
( NN O O
Low NN O O
) NN O O
less NN O O
than NN O O
0.6 NN B-Severity B-Severity
mmol/L NN I-Severity I-Severity
30 NN O O
( NN O O
7 NN O O
) NN O O
10 NN O O
( NN O O
7 NN O O
) NN O O
40 NN O O
( NN O O
7 NN O O
) NN O O
Total NN B-AdverseReaction B-AdverseReaction
Bilirubin NN I-AdverseReaction I-AdverseReaction
greater NN I-AdverseReaction I-AdverseReaction
than NN I-AdverseReaction I-AdverseReaction
3.0*ULN NN I-AdverseReaction I-AdverseReaction
3 NN O O
( NN O O
1 NN O O
) NN O O
2 NN O O
( NN O O
1 NN O O
) NN O O
5 NN O O
( NN O O
1 NN O O
) NN O O
Additional NN O O
Adverse NN O O
Reactions NN O O
from NN O O
Multiple NN O O
Clinical NN O O
Trials NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
were NN O O
reported NN O O
in NN O O
patients NN O O
in NN O O
clinical NN O O
trials NN O O
with NN O O
BOSULIF NN O O
( NN O O
less NN O O
than NN O O
10 NN O O
% NN O O
of NN O O
BOSULIF NN O O
- NN O O
treated NN O O
patients NN O O
) NN O O
. NN O O
They NN O O
represent NN O O
an NN O O
evaluation NN O O
of NN O O
the NN O O
adverse NN O O
reaction NN O O
data NN O O
from NN O O
870 NN O O
patients NN O O
with NN O O
Ph+ NN O O
leukemia NN O O
who NN O O
received NN O O
at NN O O
least NN O O
1 NN O O
dose NN O O
of NN O O
single NN O O
- NN O O
agent NN O O
BOSULIF. NN O O
These NN O O
adverse NN O O
reactions NN O O
are NN O O
presented NN O O
by NN O O
system NN O O
organ NN O O
class NN O O
and NN O O
are NN O O
ranked NN O O
by NN O O
frequency NN O O
. NN O O
These NN O O
adverse NN O O
reactions NN O O
are NN O O
included NN O O
based NN O O
on NN O O
clinical NN O O
relevance NN O O
and NN O O
ranked NN O O
in NN O O
order NN O O
of NN O O
decreasing NN O O
seriousness NN O O
within NN O O
each NN O O
category NN O O
. NN O O
Blood NN O O
and NN O O
Lymphatic NN O O
System NN O O
Disorders NN O O
: NN O O
1 NN O O
% NN O O
and NN O O
less NN O O
than NN O O
10 NN O O
% NN O O
- NN O O
febrile NN B-AdverseReaction B-AdverseReaction
neutropenia NN I-AdverseReaction I-AdverseReaction
Cardiac NN O O
Disorders NN O O
: NN O O
1 NN O O
% NN O O
and NN O O
less NN O O
than NN O O
10 NN O O
% NN O O
- NN O O
pericardial NN B-AdverseReaction B-AdverseReaction
effusion NN I-AdverseReaction I-AdverseReaction
0.1 NN O O
% NN O O
and NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
- NN O O
pericarditis NN B-AdverseReaction B-AdverseReaction
Ear NN O O
and NN O O
Labyrinth NN O O
Disorders NN O O
: NN O O
1 NN O O
% NN O O
and NN O O
less NN O O
than NN O O
10 NN O O
% NN O O
- NN O O
tinnitus NN B-AdverseReaction B-AdverseReaction
Gastrointestinal NN O O
Disorders NN O O
: NN O O
1 NN O O
% NN O O
and NN O O
less NN O O
than NN O O
10 NN O O
% NN O O
- NN O O
gastritis NN B-AdverseReaction B-AdverseReaction
0.1 NN O O
% NN O O
and NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
- NN O O
acute NN B-AdverseReaction B-AdverseReaction
pancreatitis NN I-AdverseReaction I-AdverseReaction
gastrointestinal NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
( NN O O
includes NN O O
gastrointestinal NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
gastric NN B-AdverseReaction B-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
upper NN B-AdverseReaction B-AdverseReaction
gastrointestinal NN I-AdverseReaction I-AdverseReaction
hemorrhage NN I-AdverseReaction I-AdverseReaction
General NN O O
Disorders NN O O
and NN O O
Administrative NN O O
Site NN O O
Conditions NN O O
: NN O O
1 NN O O
% NN O O
and NN O O
less NN O O
than NN O O
10 NN O O
% NN O O
- NN O O
chest NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
( NN O O
includes NN O O
chest NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
and NN O O
chest NN B-AdverseReaction B-AdverseReaction
discomfort NN I-AdverseReaction I-AdverseReaction
pain NN B-AdverseReaction B-AdverseReaction
Hepatobiliary NN O O
Disorders NN O O
: NN O O
1 NN O O
% NN O O
and NN O O
less NN O O
than NN O O
10 NN O O
% NN O O
- NN O O
hepatotoxicity NN B-AdverseReaction B-AdverseReaction
( NN O O
includes NN O O
hepatotoxicity NN B-AdverseReaction B-AdverseReaction
toxic NN B-AdverseReaction B-AdverseReaction
hepatitis NN I-AdverseReaction I-AdverseReaction
and NN O O
cytolytic NN B-AdverseReaction B-AdverseReaction
hepatitis NN I-AdverseReaction I-AdverseReaction
abnormal NN B-AdverseReaction B-AdverseReaction
hepatic NN I-AdverseReaction I-AdverseReaction
function NN I-AdverseReaction I-AdverseReaction
( NN O O
includes NN O O
abnormal NN B-AdverseReaction B-AdverseReaction
hepatic NN I-AdverseReaction I-AdverseReaction
function NN I-AdverseReaction I-AdverseReaction
liver NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
0.1 NN O O
% NN O O
and NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
- NN O O
liver NN B-AdverseReaction B-AdverseReaction
injury NN I-AdverseReaction I-AdverseReaction
Immune NN O O
System NN O O
Disorders NN O O
: NN O O
1 NN O O
% NN O O
and NN O O
less NN O O
than NN O O
10 NN O O
% NN O O
- NN O O
drug NN B-AdverseReaction B-AdverseReaction
hypersensitivity NN I-AdverseReaction I-AdverseReaction
0.1 NN O O
% NN O O
and NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
- NN O O
anaphylactic NN B-AdverseReaction B-AdverseReaction
shock NN I-AdverseReaction I-AdverseReaction
Infections NN O O
and NN O O
Infestations NN O O
: NN O O
1 NN O O
% NN O O
and NN O O
less NN O O
than NN O O
10 NN O O
% NN O O
- NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
( NN O O
includes NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
bronchopneumonia NN B-AdverseReaction B-AdverseReaction
lobar NN B-AdverseReaction B-AdverseReaction
pneumonia NN I-AdverseReaction I-AdverseReaction
primary NN B-AdverseReaction B-AdverseReaction
atypical NN I-AdverseReaction I-AdverseReaction
pneumonia NN I-AdverseReaction I-AdverseReaction
influenza NN B-AdverseReaction B-AdverseReaction
bronchitis NN B-AdverseReaction B-AdverseReaction
Investigations NN O O
: NN O O
1 NN O O
% NN O O
and NN O O
less NN O O
than NN O O
10 NN O O
% NN O O
- NN O O
electrocardiogram NN B-AdverseReaction B-AdverseReaction
QT NN I-AdverseReaction I-AdverseReaction
prolonged NN I-AdverseReaction I-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
blood NN I-AdverseReaction I-AdverseReaction
creatine NN I-AdverseReaction I-AdverseReaction
phosphokinase NN I-AdverseReaction I-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
blood NN I-AdverseReaction I-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
Metabolism NN O O
and NN O O
Nutrition NN O O
Disorder NN O O
: NN O O
1 NN O O
% NN O O
and NN O O
less NN O O
than NN O O
10 NN O O
% NN O O
- NN O O
hyperkalemia NN B-AdverseReaction B-AdverseReaction
dehydration NN B-AdverseReaction B-AdverseReaction
Musculoskeletal NN O O
and NN O O
Connective NN O O
Tissue NN O O
Disorder NN O O
: NN O O
1 NN O O
% NN O O
and NN O O
less NN O O
than NN O O
10 NN O O
% NN O O
- NN O O
myalgia NN B-AdverseReaction B-AdverseReaction
Nervous NN O O
System NN O O
Disorders NN O O
: NN O O
1 NN O O
% NN O O
and NN O O
less NN O O
than NN O O
10 NN O O
% NN O O
- NN O O
dysgeusia NN B-AdverseReaction B-AdverseReaction
Renal NN O O
and NN O O
Urinary NN O O
Disorders NN O O
: NN O O
1 NN O O
% NN O O
and NN O O
less NN O O
than NN O O
10 NN O O
% NN O O
- NN O O
acute NN B-AdverseReaction B-AdverseReaction
renal NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
renal NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
Respiratory NN O O
, NN O O
Thoracic NN O O
and NN O O
Mediastinal NN O O
Disorders NN O O
: NN O O
1 NN O O
% NN O O
and NN O O
less NN O O
than NN O O
10 NN O O
% NN O O
- NN O O
pleural NN B-AdverseReaction B-AdverseReaction
effusion NN I-AdverseReaction I-AdverseReaction
0.1 NN O O
% NN O O
and NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
- NN O O
acute NN B-AdverseReaction B-AdverseReaction
pulmonary NN I-AdverseReaction I-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
respiratory NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
pulmonary NN B-AdverseReaction B-AdverseReaction
hypertension NN I-AdverseReaction I-AdverseReaction
Skin NN O O
and NN O O
Subcutaneous NN O O
Disorders NN O O
: NN O O
1 NN O O
% NN O O
and NN O O
less NN O O
than NN O O
10 NN O O
% NN O O
- NN O O
urticaria NN B-AdverseReaction B-AdverseReaction
pruritus NN B-AdverseReaction B-AdverseReaction
acne NN B-AdverseReaction B-AdverseReaction
0.1 NN O O
% NN O O
and NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
- NN O O
erythema NN B-AdverseReaction B-AdverseReaction
multiforme NN I-AdverseReaction I-AdverseReaction
exfoliative NN B-AdverseReaction B-AdverseReaction
rash NN I-AdverseReaction I-AdverseReaction
drug NN B-AdverseReaction B-AdverseReaction
eruption NN I-AdverseReaction I-AdverseReaction
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Gastrointestinal NN B-AdverseReaction B-AdverseReaction
Toxicity NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
and NN O O
manage NN O O
as NN O O
necessary NN O O
. NN O O
Withhold NN O O
, NN O O
dose NN O O
reduce NN O O
, NN O O
or NN O O
discontinue NN O O
BOSULIF. NN O O
( NN O O
2.3 NN O O
, NN O O
5.1 NN O O
) NN O O
* NN O O
Myelosuppression NN B-AdverseReaction B-AdverseReaction
Monitor NN O O
blood NN O O
counts NN O O
and NN O O
manage NN O O
as NN O O
necessary NN O O
. NN O O
( NN O O
2.4 NN O O
, NN O O
5.2 NN O O
) NN O O
* NN O O
Hepatic NN B-AdverseReaction B-AdverseReaction
Toxicity NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
liver NN O O
enzymes NN O O
at NN O O
least NN O O
monthly NN O O
for NN O O
the NN O O
first NN O O
three NN O O
months NN O O
and NN O O
as NN O O
needed NN O O
. NN O O
Withhold NN O O
, NN O O
dose NN O O
reduce NN O O
, NN O O
or NN O O
discontinue NN O O
BOSULIF. NN O O
( NN O O
2.3 NN O O
, NN O O
5.3 NN O O
) NN O O
* NN O O
Fluid NN B-AdverseReaction B-AdverseReaction
Retention NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
patients NN O O
and NN O O
manage NN O O
using NN O O
standard NN O O
of NN O O
care NN O O
treatment NN O O
. NN O O
Withhold NN O O
, NN O O
dose NN O O
reduce NN O O
, NN O O
or NN O O
discontinue NN O O
BOSULIF. NN O O
( NN O O
2.3 NN O O
, NN O O
5.4 NN O O
) NN O O
* NN O O
Renal NN B-AdverseReaction B-AdverseReaction
Toxicity NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
patients NN O O
for NN O O
renal NN O O
function NN O O
at NN O O
baseline NN O O
and NN O O
during NN O O
therapy NN O O
with NN O O
BOSULIF NN O O
( NN O O
5.5 NN O O
) NN O O
* NN O O
Embryofetal NN B-AdverseReaction B-AdverseReaction
Toxicity NN I-AdverseReaction I-AdverseReaction
May NN B-Factor B-Factor
cause NN O O
fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
Females NN O O
of NN O O
reproductive NN O O
potential NN O O
should NN O O
avoid NN O O
becoming NN O O
pregnant NN O O
while NN O O
being NN O O
treated NN O O
with NN O O
BOSULIF. NN O O
( NN O O
5.6 NN O O
) NN O O
5.1 NN O O
Gastrointestinal NN O O
Toxicity NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
and NN O O
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
occur NN O O
with NN O O
BOSULIF NN O O
treatment NN O O
. NN O O
Monitor NN O O
and NN O O
manage NN O O
patients NN O O
using NN O O
standards NN O O
of NN O O
care NN O O
, NN O O
including NN O O
antidiarrheals NN O O
, NN O O
antiemetics NN O O
, NN O O
and NN O O
fluid NN O O
replacement NN O O
. NN O O
In NN O O
the NN O O
single NN O O
- NN O O
arm NN O O
Phase NN O O
1/2 NN O O
clinical NN O O
trial NN O O
, NN O O
the NN O O
median NN O O
time NN O O
to NN O O
onset NN O O
for NN O O
diarrhea NN O O
( NN O O
all NN O O
grades NN O O
) NN O O
was NN O O
2 NN O O
days NN O O
and NN O O
the NN O O
median NN O O
duration NN O O
per NN O O
event NN O O
was NN O O
1 NN O O
day NN O O
. NN O O
Among NN O O
the NN O O
patients NN O O
who NN O O
experienced NN O O
diarrhea NN O O
, NN O O
the NN O O
median NN O O
number NN O O
of NN O O
episodes NN O O
of NN O O
diarrhea NN O O
per NN O O
patient NN O O
during NN O O
treatment NN O O
with NN O O
BOSULIF NN O O
was NN O O
3 NN O O
( NN O O
range NN O O
1 NN O O
- NN O O
221 NN O O
) NN O O
. NN O O
To NN O O
manage NN O O
gastrointestinal NN O O
toxicity NN O O
, NN O O
withhold NN O O
, NN O O
dose NN O O
reduce NN O O
, NN O O
or NN O O
discontinue NN O O
BOSULIF NN O O
as NN O O
necessary NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
and NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
Myelosuppression NN O O
Thrombocytopenia NN B-AdverseReaction B-AdverseReaction
anemia NN B-AdverseReaction B-AdverseReaction
and NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
occur NN O O
with NN O O
BOSULIF NN O O
treatment NN O O
. NN O O
Perform NN O O
complete NN O O
blood NN O O
counts NN O O
weekly NN O O
for NN O O
the NN O O
first NN O O
month NN O O
of NN O O
therapy NN O O
and NN O O
then NN O O
monthly NN O O
thereafter NN O O
, NN O O
or NN O O
as NN O O
clinically NN O O
indicated NN O O
. NN O O
To NN O O
manage NN O O
myelosuppression NN O O
, NN O O
withhold NN O O
, NN O O
dose NN O O
reduce NN O O
, NN O O
or NN O O
discontinue NN O O
BOSULIF NN O O
as NN O O
necessary NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.4 NN O O
) NN O O
and NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
] NN O O
. NN O O
5.3 NN O O
Hepatic NN O O
Toxicity NN O O
One NN O O
case NN O O
consistent NN O O
with NN O O
drug NN B-AdverseReaction B-AdverseReaction
induced NN I-AdverseReaction I-AdverseReaction
liver NN I-AdverseReaction I-AdverseReaction
injury NN I-AdverseReaction I-AdverseReaction
( NN O O
defined NN O O
as NN O O
concurrent NN O O
elevations NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
ALT NN I-AdverseReaction I-AdverseReaction
or NN O O
AST NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
3*ULN NN B-Severity B-Severity
with NN O O
total NN B-AdverseReaction B-AdverseReaction
bilirubin NN I-AdverseReaction I-AdverseReaction
greater NN I-AdverseReaction I-AdverseReaction
than NN I-AdverseReaction I-AdverseReaction
2*ULN NN I-AdverseReaction I-AdverseReaction
and NN O O
alkaline NN B-AdverseReaction B-AdverseReaction
phosphatase NN I-AdverseReaction I-AdverseReaction
less NN I-AdverseReaction I-AdverseReaction
than NN I-AdverseReaction I-AdverseReaction
2*ULN NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
a NN O O
trial NN O O
of NN O O
BOSULIF NN O O
in NN O O
combination NN O O
with NN O O
letrozole NN O O
. NN O O
The NN O O
patient NN O O
recovered NN O O
fully NN O O
following NN O O
discontinuation NN O O
of NN O O
BOSULIF. NN O O
This NN O O
case NN O O
represented NN O O
1 NN O O
out NN O O
of NN O O
1209 NN O O
patients NN O O
in NN O O
BOSULIF NN O O
clinical NN O O
trials NN O O
. NN O O
In NN O O
the NN O O
546 NN O O
patients NN O O
from NN O O
the NN O O
safety NN O O
population NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
ALT NN B-AdverseReaction B-AdverseReaction
elevation NN I-AdverseReaction I-AdverseReaction
was NN O O
17 NN O O
% NN O O
and NN O O
AST NN B-AdverseReaction B-AdverseReaction
elevation NN I-AdverseReaction I-AdverseReaction
was NN O O
14 NN O O
% NN O O
. NN O O
Twenty NN O O
percent NN O O
of NN O O
the NN O O
patients NN O O
experienced NN O O
an NN O O
increase NN O O
in NN O O
either NN O O
ALT NN O O
or NN O O
AST. NN O O
Most NN O O
cases NN O O
of NN O O
transaminase NN B-AdverseReaction B-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
occurred NN O O
early NN O O
in NN O O
treatment NN O O
; NN O O
of NN O O
patients NN O O
who NN O O
experienced NN O O
transaminase NN B-AdverseReaction B-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
of NN O O
any NN O O
grade NN O O
, NN O O
more NN O O
than NN O O
80 NN O O
% NN O O
experienced NN O O
their NN O O
first NN O O
event NN O O
within NN O O
the NN O O
first NN O O
3 NN O O
months NN O O
. NN O O
The NN O O
median NN O O
time NN O O
to NN O O
onset NN O O
of NN O O
increased NN B-AdverseReaction B-AdverseReaction
ALT NN I-AdverseReaction I-AdverseReaction
and NN O O
AST NN O O
was NN O O
30 NN O O
and NN O O
33 NN O O
days NN O O
, NN O O
respectively NN O O
, NN O O
and NN O O
the NN O O
median NN O O
duration NN O O
for NN O O
each NN O O
was NN O O
21 NN O O
days NN O O
. NN O O
Perform NN O O
hepatic NN O O
enzyme NN O O
tests NN O O
monthly NN O O
for NN O O
the NN O O
first NN O O
three NN O O
months NN O O
of NN O O
BOSULIF NN O O
treatment NN O O
and NN O O
as NN O O
clinically NN O O
indicated NN O O
. NN O O
In NN O O
patients NN O O
with NN O O
transaminase NN O O
elevations NN O O
, NN O O
monitor NN O O
liver NN O O
enzymes NN O O
more NN O O
frequently NN O O
. NN O O
Withhold NN O O
, NN O O
dose NN O O
reduce NN O O
, NN O O
or NN O O
discontinue NN O O
BOSULIF NN O O
as NN O O
necessary NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
and NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
] NN O O
. NN O O
5.4 NN O O
Fluid NN O O
Retention NN O O
Fluid NN B-AdverseReaction B-AdverseReaction
retention NN I-AdverseReaction I-AdverseReaction
occurs NN O O
with NN O O
BOSULIF NN O O
and NN O O
may NN B-Factor B-Factor
manifest NN O O
as NN O O
pericardial NN B-AdverseReaction B-AdverseReaction
effusion NN I-AdverseReaction I-AdverseReaction
pleural NN B-AdverseReaction B-AdverseReaction
effusion NN I-AdverseReaction I-AdverseReaction
pulmonary NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
and/or NN O O
peripheral NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
In NN O O
the NN O O
single NN O O
- NN O O
arm NN O O
Phase NN O O
1/2 NN O O
clinical NN O O
trial NN O O
in NN O O
546 NN O O
patients NN O O
with NN O O
CML NN O O
treated NN O O
with NN O O
prior NN O O
therapy NN O O
, NN O O
severe NN B-Severity B-Severity
fluid NN B-AdverseReaction B-AdverseReaction
retention NN I-AdverseReaction I-AdverseReaction
was NN O O
reported NN O O
in NN O O
14 NN O O
patients NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
. NN O O
Specifically NN O O
, NN O O
9 NN O O
patients NN O O
had NN O O
a NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
or NN O O
4 NN O O
pleural NN B-AdverseReaction B-AdverseReaction
effusion NN I-AdverseReaction I-AdverseReaction
3 NN O O
patients NN O O
experienced NN O O
both NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
or NN O O
Grade NN B-Severity B-Severity
4 NN I-Severity I-Severity
pleural NN O O
and NN O O
pericardial NN B-AdverseReaction B-AdverseReaction
effusions NN I-AdverseReaction I-AdverseReaction
1 NN O O
patient NN O O
experienced NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
peripheral NN O O
and NN O O
pulmonary NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
and NN O O
1 NN O O
patient NN O O
had NN O O
a NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
edema NN B-AdverseReaction B-AdverseReaction
Monitor NN O O
and NN O O
manage NN O O
patients NN O O
using NN O O
standards NN O O
of NN O O
care NN O O
. NN O O
Interrupt NN O O
, NN O O
dose NN O O
reduce NN O O
or NN O O
discontinue NN O O
BOSULIF NN O O
as NN O O
necessary NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.3 NN O O
) NN O O
and NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
] NN O O
. NN O O
5.5 NN O O
Renal NN O O
Toxicity NN O O
An NN O O
on NN O O
- NN O O
treatment NN O O
decline NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
estimated NN I-AdverseReaction I-AdverseReaction
glomerular NN I-AdverseReaction I-AdverseReaction
filtration NN I-AdverseReaction I-AdverseReaction
rate NN I-AdverseReaction I-AdverseReaction
( NN O O
eGFR NN O O
) NN O O
has NN O O
occurred NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
BOSULIF. NN O O
Table NN O O
2 NN O O
identifies NN O O
the NN O O
shift NN O O
from NN O O
baseline NN O O
to NN O O
lowest NN O O
observed NN O O
estimated NN O O
glomerular NN O O
filtration NN O O
rate NN O O
( NN O O
eGFR NN O O
) NN O O
during NN O O
BOSULIF NN O O
therapy NN O O
for NN O O
patients NN O O
in NN O O
the NN O O
global NN O O
Ph+ NN O O
Leukemia NN O O
studies NN O O
. NN O O
The NN O O
median NN O O
duration NN O O
of NN O O
therapy NN O O
with NN O O
BOSULIF NN O O
was NN O O
approximately NN O O
17 NN O O
months NN O O
( NN O O
range NN O O
, NN O O
0.03 NN O O
to NN O O
95 NN O O
) NN O O
for NN O O
patients NN O O
in NN O O
these NN O O
studies NN O O
. NN O O
Table NN O O
2 NN O O
: NN O O
Shift NN O O
from NN O O
Baseline NN O O
to NN O O
Lowest NN O O
Observed NN O O
eGFR NN O O
Group NN O O
During NN O O
Treatment NN O O
Safety NN O O
Population NN O O
in NN O O
Clinical NN O O
Studies NN O O
( NN O O
n=818)Among NN O O
the NN O O
818 NN O O
patients NN O O
, NN O O
eGFR NN O O
was NN O O
missing NN O O
in NN O O
5 NN O O
patients NN O O
at NN O O
baseline NN O O
or NN O O
on NN O O
- NN O O
therapy NN O O
. NN O O
There NN O O
were NN O O
no NN O O
patients NN O O
with NN O O
kidney NN O O
failure NN O O
at NN O O
baseline NN O O
. NN O O
Baseline NN O O
Follow NN O O
Up NN O O
Renal NN O O
Function NN O O
Status NN O O
n NN O O
Normaln NN O O
( NN O O
% NN O O
) NN O O
Mildn NN O O
( NN O O
% NN O O
) NN O O
Mild NN O O
to NN O O
Moderaten NN O O
( NN O O
% NN O O
) NN O O
Moderate NN O O
to NN O O
Severen NN O O
( NN O O
% NN O O
) NN O O
Severen NN O O
( NN O O
% NN O O
) NN O O
Kidney NN B-AdverseReaction B-AdverseReaction
Failure NN I-AdverseReaction I-AdverseReaction
( NN O O
% NN O O
) NN O O
Notes NN O O
: NN O O
Grading NN O O
is NN O O
based NN O O
on NN O O
Modification NN O O
in NN O O
Diet NN O O
in NN O O
Renal NN O O
Disease NN O O
method NN O O
( NN O O
MDRD).KDIGO NN O O
Classification NN O O
by NN O O
eGFR NN O O
: NN O O
Normal NN O O
: NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
90 NN O O
, NN O O
Mild NN O O
: NN O O
60 NN O O
to NN O O
less NN O O
than NN O O
90 NN O O
, NN O O
Mild NN O O
to NN O O
Moderate NN O O
: NN O O
45 NN O O
to NN O O
less NN O O
than NN O O
60 NN O O
, NN O O
Moderate NN O O
to NN O O
Severe NN O O
: NN O O
30 NN O O
to NN O O
less NN O O
than NN O O
45 NN O O
, NN O O
Severe NN O O
: NN O O
15 NN O O
to NN O O
less NN O O
than NN O O
30 NN O O
, NN O O
Kidney NN O O
Failure NN O O
: NN O O
less NN O O
than NN O O
15 NN O O
ml/min/1.73 NN O O
m NN O O
2 NN O O
. NN O O
Normal NN O O
274 NN O O
53 NN O O
( NN O O
19 NN O O
) NN O O
174 NN O O
( NN O O
64 NN O O
) NN O O
30 NN O O
( NN O O
11 NN O O
) NN O O
14 NN O O
( NN O O
5 NN O O
) NN O O
1 NN O O
( NN O O
< NN O O
1 NN O O
) NN O O
1 NN O O
( NN O O
< NN O O
1 NN O O
) NN O O
Mild NN O O
438 NN O O
10 NN O O
( NN O O
2 NN O O
) NN O O
170 NN O O
( NN O O
39 NN O O
) NN O O
177 NN O O
( NN O O
40 NN O O
) NN O O
63 NN O O
( NN O O
14 NN O O
) NN O O
14 NN O O
( NN O O
3 NN O O
) NN O O
2 NN O O
( NN O O
1 NN O O
) NN O O
Mild NN O O
to NN O O
Moderate NN O O
79 NN O O
0 NN O O
4 NN O O
( NN O O
5 NN O O
) NN O O
28 NN O O
( NN O O
35 NN O O
) NN O O
37 NN O O
( NN O O
47 NN O O
) NN O O
10 NN O O
( NN O O
13 NN O O
) NN O O
0 NN O O
Moderate NN O O
to NN O O
Severe NN O O
24 NN O O
0 NN O O
1 NN O O
( NN O O
4 NN O O
) NN O O
1 NN O O
( NN O O
4 NN O O
) NN O O
6 NN O O
( NN O O
25 NN O O
) NN O O
15 NN O O
( NN O O
63 NN O O
) NN O O
1 NN O O
( NN O O
4 NN O O
) NN O O
Severe NN O O
1 NN O O
0 NN O O
0 NN O O
0 NN O O
0 NN O O
0 NN O O
1 NN O O
( NN O O
100 NN O O
) NN O O
Total NN O O
816 NN O O
63 NN O O
( NN O O
8 NN O O
) NN O O
349 NN O O
( NN O O
43 NN O O
) NN O O
236 NN O O
( NN O O
29 NN O O
) NN O O
120 NN O O
( NN O O
15 NN O O
) NN O O
40 NN O O
( NN O O
5 NN O O
) NN O O
5 NN O O
( NN O O
1 NN O O
) NN O O
Monitor NN O O
renal NN O O
function NN O O
at NN O O
baseline NN O O
and NN O O
during NN O O
therapy NN O O
with NN O O
BOSULIF NN O O
, NN O O
with NN O O
particular NN O O
attention NN O O
to NN O O
those NN O O
patients NN O O
who NN O O
have NN O O
preexisting NN O O
renal NN O O
impairment NN O O
or NN O O
risk NN O O
factors NN O O
for NN O O
renal NN O O
dysfunction NN O O
. NN O O
Consider NN O O
dose NN O O
adjustment NN O O
in NN O O
patients NN O O
with NN O O
baseline NN O O
and NN O O
treatment NN O O
emergent NN O O
renal NN O O
impairment NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.7 NN O O
) NN O O
] NN O O
. NN O O
5.6 NN O O
Embryofetal NN O O
Toxicity NN O O
There NN O O
are NN O O
no NN O O
adequate NN O O
and NN O O
well NN O O
controlled NN O O
studies NN O O
of NN O O
BOSULIF NN O O
in NN O O
pregnant NN O O
women NN O O
. NN O O
BOSULIF NN O O
can NN B-Factor B-Factor
cause NN O O
fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
when NN O O
administered NN O O
to NN O O
a NN O O
pregnant NN O O
woman NN O O
. NN O O
Bosutinib NN O O
caused NN O O
embryofetal NN B-AdverseReaction B-AdverseReaction
toxicities NN I-AdverseReaction I-AdverseReaction
in NN O O
rabbits NN B-Animal B-Animal
at NN O O
maternal NN O O
exposures NN O O
that NN O O
were NN O O
greater NN O O
than NN O O
the NN O O
clinical NN O O
exposure NN O O
at NN O O
the NN O O
recommended NN O O
bosutinib NN O O
dose NN O O
of NN O O
500 NN O O
mg/day NN O O
. NN O O
Females NN O O
of NN O O
reproductive NN O O
potential NN O O
should NN O O
be NN O O
advised NN O O
to NN O O
avoid NN O O
pregnancy NN O O
while NN O O
being NN O O
treated NN O O
with NN O O
BOSULIF. NN O O
If NN O O
this NN O O
drug NN O O
is NN O O
used NN O O
during NN O O
pregnancy NN O O
, NN O O
or NN O O
if NN O O
the NN O O
patient NN O O
becomes NN O O
pregnant NN O O
while NN O O
taking NN O O
this NN O O
drug NN O O
, NN O O
the NN O O
patient NN O O
should NN O O
be NN O O
apprised NN O O
of NN O O
the NN O O
potential NN O O
hazard NN O O
to NN O O
the NN O O
fetus NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.1 NN O O
) NN O O
] NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
incidence NN O O
>=25 NN O O
% NN O O
) NN O O
were NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
anemia NN B-AdverseReaction B-AdverseReaction
asthenia NN B-AdverseReaction B-AdverseReaction
alopecia NN B-AdverseReaction B-AdverseReaction
peripheral NN B-AdverseReaction B-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
and NN O O
constipation NN B-AdverseReaction B-AdverseReaction
( NN O O
6 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Eisai NN O O
Inc. NN O O
at NN O O
( NN O O
1 NN O O
- NN O O
877 NN O O
- NN O O
873 NN O O
- NN O O
4724 NN O O
) NN O O
or NN O O
contact NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
the NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
other NN O O
clinical NN O O
trials NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
are NN O O
discussed NN O O
in NN O O
detail NN O O
in NN O O
other NN O O
sections NN O O
of NN O O
the NN O O
labeling NN O O
: NN O O
* NN O O
Neutropenia NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Peripheral NN B-AdverseReaction B-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
QT NN B-AdverseReaction B-AdverseReaction
interval NN I-AdverseReaction I-AdverseReaction
prolongation NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
>=25 NN O O
% NN O O
) NN O O
reported NN O O
in NN O O
patients NN O O
receiving NN O O
HALAVEN NN O O
were NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
anemia NN B-AdverseReaction B-AdverseReaction
asthenia NN B-AdverseReaction B-AdverseReaction
alopecia NN B-AdverseReaction B-AdverseReaction
peripheral NN B-AdverseReaction B-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
and NN O O
constipation NN B-AdverseReaction B-AdverseReaction
The NN O O
most NN O O
common NN O O
serious NN O O
adverse NN O O
reactions NN O O
reported NN O O
in NN O O
patients NN O O
receiving NN O O
HALAVEN NN O O
were NN O O
febrile NN B-AdverseReaction B-AdverseReaction
neutropenia NN I-AdverseReaction I-AdverseReaction
( NN O O
4 NN O O
% NN O O
) NN O O
and NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
) NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reaction NN O O
resulting NN O O
in NN O O
discontinuation NN O O
of NN O O
HALAVEN NN O O
was NN O O
peripheral NN B-AdverseReaction B-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
( NN O O
5 NN O O
% NN O O
) NN O O
. NN O O
In NN O O
clinical NN O O
trials NN O O
, NN O O
HALAVEN NN O O
has NN O O
been NN O O
administered NN O O
to NN O O
1,222 NN O O
patients NN O O
with NN O O
multiple NN O O
tumor NN O O
types NN O O
, NN O O
including NN O O
240 NN O O
patients NN O O
exposed NN O O
to NN O O
HALAVEN NN O O
for NN O O
6 NN O O
months NN O O
or NN O O
longer NN O O
. NN O O
The NN O O
majority NN O O
of NN O O
the NN O O
1,222 NN O O
patients NN O O
were NN O O
women NN O O
( NN O O
82 NN O O
% NN O O
) NN O O
with NN O O
a NN O O
median NN O O
age NN O O
of NN O O
58 NN O O
years NN O O
( NN O O
range NN O O
: NN O O
26 NN O O
to NN O O
91 NN O O
years NN O O
) NN O O
. NN O O
The NN O O
racial NN O O
and NN O O
ethnic NN O O
distribution NN O O
was NN O O
Caucasian NN O O
( NN O O
83 NN O O
% NN O O
) NN O O
, NN O O
Black NN O O
( NN O O
5 NN O O
% NN O O
) NN O O
, NN O O
Asian NN O O
( NN O O
2 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
other NN O O
( NN O O
5 NN O O
% NN O O
) NN O O
. NN O O
The NN O O
adverse NN O O
reactions NN O O
described NN O O
in NN O O
Table NN O O
2 NN O O
were NN O O
identified NN O O
in NN O O
750 NN O O
patients NN O O
treated NN O O
in NN O O
Study NN O O
1 NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
. NN O O
In NN O O
Study NN O O
1 NN O O
, NN O O
patients NN O O
were NN O O
randomized NN O O
( NN O O
2:1 NN O O
) NN O O
to NN O O
receive NN O O
either NN O O
HALAVEN NN O O
( NN O O
1.4 NN O O
mg/m NN O O
2 NN O O
on NN O O
Days NN O O
1 NN O O
and NN O O
8 NN O O
of NN O O
a NN O O
21-day NN O O
cycle NN O O
) NN O O
or NN O O
single NN O O
agent NN O O
treatment NN O O
chosen NN O O
by NN O O
their NN O O
physician NN O O
( NN O O
control NN O O
group NN O O
) NN O O
. NN O O
A NN O O
total NN O O
of NN O O
503 NN O O
patients NN O O
received NN O O
HALAVEN NN O O
, NN O O
and NN O O
247 NN O O
patients NN O O
in NN O O
the NN O O
control NN O O
group NN O O
received NN O O
therapy NN O O
consisting NN O O
of NN O O
chemotherapy NN O O
[ NN O O
total NN O O
97 NN O O
% NN O O
( NN O O
anthracyclines NN O O
10 NN O O
% NN O O
, NN O O
capecitabine NN O O
18 NN O O
% NN O O
, NN O O
gemcitabine NN O O
19 NN O O
% NN O O
, NN O O
taxanes NN O O
15 NN O O
% NN O O
, NN O O
vinorelbine NN O O
25 NN O O
% NN O O
, NN O O
other NN O O
chemotherapies NN O O
10 NN O O
% NN O O
) NN O O
] NN O O
or NN O O
hormonal NN O O
therapy NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
. NN O O
The NN O O
median NN O O
duration NN O O
of NN O O
exposure NN O O
was NN O O
118 NN O O
days NN O O
for NN O O
patients NN O O
receiving NN O O
HALAVEN NN O O
and NN O O
63 NN O O
days NN O O
for NN O O
patients NN O O
receiving NN O O
control NN O O
therapy NN O O
. NN O O
Table NN O O
2 NN O O
reports NN O O
the NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
occurring NN O O
in NN O O
at NN O O
least NN O O
10 NN O O
% NN O O
of NN O O
patients NN O O
in NN O O
either NN O O
group NN O O
. NN O O
Table NN O O
2 NN O O
Adverse NN O O
Reactions NN O O
with NN O O
a NN O O
Per NN O O
- NN O O
Patient NN O O
Incidence NN O O
of NN O O
at NN O O
Least NN O O
10 NN O O
% NN O O
in NN O O
Study NN O O
1 NN O O
MedDRA NN O O
ver NN O O
10.0 NN O O
HALAVEN NN O O
n=503 NN O O
Control NN O O
Group NN O O
n=247 NN O O
All NN O O
Grades NN O O
>= NN O O
Grade NN O O
3 NN O O
All NN O O
Grades NN O O
>= NN O O
Grade NN O O
3 NN O O
Blood NN O O
and NN O O
Lymphatic NN O O
System NN O O
Disorders NN O O
a NN O O
Neutropenia NN B-AdverseReaction B-AdverseReaction
82 NN O O
% NN O O
57 NN O O
% NN O O
53 NN O O
% NN O O
23 NN O O
% NN O O
Anemia NN B-AdverseReaction B-AdverseReaction
58 NN O O
% NN O O
2 NN O O
% NN O O
55 NN O O
% NN O O
4 NN O O
% NN O O
Nervous NN O O
system NN O O
disorders NN O O
Peripheral NN B-AdverseReaction B-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
b NN O O
35 NN O O
% NN O O
8 NN O O
% NN O O
16 NN O O
% NN O O
2 NN O O
% NN O O
Headache NN B-AdverseReaction B-AdverseReaction
19 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
12 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
General NN O O
disorders NN O O
and NN O O
administrative NN O O
site NN O O
conditions NN O O
Asthenia NN B-AdverseReaction B-AdverseReaction
54 NN O O
% NN O O
10 NN O O
% NN O O
40 NN O O
% NN O O
11 NN O O
% NN O O
Mucosal NN B-AdverseReaction B-AdverseReaction
inflammation NN I-AdverseReaction I-AdverseReaction
9 NN O O
% NN O O
1 NN O O
% NN O O
10 NN O O
% NN O O
2 NN O O
% NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
21 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
13 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
Gastrointestinal NN O O
disorders NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
25 NN O O
% NN O O
1 NN O O
% NN O O
21 NN O O
% NN O O
1 NN O O
% NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
18 NN O O
% NN O O
0 NN O O
18 NN O O
% NN O O
0 NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
35 NN O O
% NN O O
1 NN O O
% NN O O
28 NN O O
% NN O O
3 NN O O
% NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
18 NN O O
% NN O O
1 NN O O
% NN O O
18 NN O O
% NN O O
1 NN O O
% NN O O
Musculoskeletal NN O O
and NN O O
connective NN O O
tissue NN O O
disorders NN O O
Arthralgia NN B-AdverseReaction B-AdverseReaction
22 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
12 NN O O
% NN O O
1 NN O O
% NN O O
Back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
16 NN O O
% NN O O
1 NN O O
% NN O O
7 NN O O
% NN O O
2 NN O O
% NN O O
Bone NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
12 NN O O
% NN O O
2 NN O O
% NN O O
9 NN O O
% NN O O
2 NN O O
% NN O O
Pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
11 NN O O
% NN O O
1 NN O O
% NN O O
10 NN O O
% NN O O
1 NN O O
% NN O O
Investigations NN O O
Weight NN B-AdverseReaction B-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
21 NN O O
% NN O O
1 NN O O
% NN O O
14 NN O O
% NN O O
< NN O O
1 NN O O
% NN O O
Metabolism NN O O
and NN O O
nutrition NN O O
disorders NN O O
Anorexia NN B-AdverseReaction B-AdverseReaction
20 NN O O
% NN O O
1 NN O O
% NN O O
13 NN O O
% NN O O
1 NN O O
% NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
, NN O O
and NN O O
mediastinal NN O O
disorders NN O O
Cough NN B-AdverseReaction B-AdverseReaction
14 NN O O
% NN O O
0 NN O O
9 NN O O
% NN O O
0 NN O O
Dyspnea NN B-AdverseReaction B-AdverseReaction
16 NN O O
% NN O O
4 NN O O
% NN O O
13 NN O O
% NN O O
4 NN O O
% NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
Alopecia NN B-AdverseReaction B-AdverseReaction
45 NN O O
% NN O O
NA NN O O
c NN O O
10 NN O O
% NN O O
NA NN O O
c NN O O
Infections NN O O
and NN O O
Infestations NN O O
Urinary NN B-AdverseReaction B-AdverseReaction
Tract NN I-AdverseReaction I-AdverseReaction
Infection NN I-AdverseReaction I-AdverseReaction
10 NN O O
% NN O O
1 NN O O
% NN O O
5 NN O O
% NN O O
0 NN O O
a. NN O O
based NN O O
upon NN O O
laboratory NN O O
data NN O O
. NN O O
b NN O O
includes NN O O
neuropathy NN B-AdverseReaction B-AdverseReaction
peripheral NN I-AdverseReaction I-AdverseReaction
neuropathy NN B-AdverseReaction B-AdverseReaction
peripheral NN B-AdverseReaction B-AdverseReaction
motor NN I-AdverseReaction I-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
polyneuropathy NN B-AdverseReaction B-AdverseReaction
peripheral NN B-AdverseReaction B-AdverseReaction
sensoryneuropathy NN I-AdverseReaction I-AdverseReaction
and NN O O
paraesthesia NN B-AdverseReaction B-AdverseReaction
c NN O O
not NN O O
applicable NN O O
; NN O O
( NN O O
grading NN O O
system NN O O
does NN O O
not NN O O
specify NN O O
> NN O O
Grade NN O O
2 NN O O
for NN O O
alopecia NN B-AdverseReaction B-AdverseReaction
Cytopenias NN O O
: NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
neutropenia NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
28 NN O O
% NN O O
( NN O O
143/503 NN O O
) NN O O
of NN O O
patients NN O O
who NN O O
received NN O O
HALAVEN NN O O
in NN O O
Study NN O O
1 NN O O
, NN O O
and NN O O
29 NN O O
% NN O O
( NN O O
144/503 NN O O
) NN O O
of NN O O
patients NN O O
experienced NN O O
Grade NN B-Severity B-Severity
4 NN I-Severity I-Severity
neutropenia NN B-AdverseReaction B-AdverseReaction
Febrile NN B-AdverseReaction B-AdverseReaction
neutropenia NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
5 NN O O
% NN O O
( NN O O
23/503 NN O O
) NN O O
of NN O O
patients NN O O
; NN O O
two NN O O
patients NN O O
( NN O O
0.4 NN O O
% NN O O
) NN O O
died NN B-AdverseReaction B-AdverseReaction
from NN O O
complications NN O O
of NN O O
febrile NN B-AdverseReaction B-AdverseReaction
neutropenia NN I-AdverseReaction I-AdverseReaction
Dose NN O O
reduction NN O O
due NN O O
to NN O O
neutropenia NN B-AdverseReaction B-AdverseReaction
was NN O O
required NN O O
in NN O O
12 NN O O
% NN O O
( NN O O
62/503 NN O O
) NN O O
of NN O O
patients NN O O
and NN O O
discontinuation NN O O
was NN O O
required NN O O
in NN O O
< NN O O
1 NN O O
% NN O O
of NN O O
patients NN O O
. NN O O
The NN O O
mean NN O O
time NN O O
to NN O O
nadir NN O O
was NN O O
13 NN O O
days NN O O
and NN O O
the NN O O
mean NN O O
time NN O O
to NN O O
recovery NN O O
from NN O O
severe NN B-Severity B-Severity
neutropenia NN B-AdverseReaction B-AdverseReaction
( NN O O
< NN O O
500/mm NN O O
3 NN O O
) NN O O
was NN O O
8 NN O O
days NN O O
. NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
or NN O O
greater NN O O
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
1 NN O O
% NN O O
( NN O O
7/503 NN O O
) NN O O
of NN O O
patients NN O O
. NN O O
G NN O O
- NN O O
CSF NN O O
( NN O O
granulocyte NN O O
colony NN O O
- NN O O
stimulating NN O O
factor NN O O
) NN O O
or NN O O
GM NN O O
- NN O O
CSF NN O O
( NN O O
granulocyte NN O O
- NN O O
macrophage NN O O
colony NN O O
- NN O O
stimulating NN O O
factor NN O O
) NN O O
was NN O O
used NN O O
in NN O O
19 NN O O
% NN O O
of NN O O
patients NN O O
who NN O O
received NN O O
HALAVEN. NN O O
Peripheral NN O O
Neuropathy NN O O
: NN O O
In NN O O
Study NN O O
1 NN O O
, NN O O
17 NN O O
% NN O O
of NN O O
enrolled NN O O
patients NN O O
had NN O O
Grade NN B-Severity B-Severity
1 NN I-Severity I-Severity
peripheral NN B-AdverseReaction B-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
and NN O O
3 NN O O
% NN O O
of NN O O
patients NN O O
had NN O O
Grade NN B-Severity B-Severity
2 NN I-Severity I-Severity
peripheral NN B-AdverseReaction B-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
at NN O O
baseline NN O O
. NN O O
Dose NN O O
reduction NN O O
due NN O O
to NN O O
peripheral NN B-AdverseReaction B-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
was NN O O
required NN O O
by NN O O
3 NN O O
% NN O O
( NN O O
14/503 NN O O
) NN O O
of NN O O
patients NN O O
who NN O O
received NN O O
HALAVEN. NN O O
Four NN O O
percent NN O O
( NN O O
20/503 NN O O
) NN O O
of NN O O
patients NN O O
experienced NN O O
peripheral NN B-AdverseReaction B-AdverseReaction
motor NN I-AdverseReaction I-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
of NN O O
any NN O O
grade NN O O
and NN O O
2 NN O O
% NN O O
( NN O O
8/503 NN O O
) NN O O
of NN O O
patients NN O O
developed NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
peripheral NN B-AdverseReaction B-AdverseReaction
motor NN I-AdverseReaction I-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
Liver NN O O
Function NN O O
Test NN O O
Abnormalities NN O O
: NN O O
Among NN O O
patients NN O O
with NN O O
Grade NN O O
0 NN O O
or NN O O
1 NN O O
ALT NN O O
levels NN O O
at NN O O
baseline NN O O
, NN O O
18 NN O O
% NN O O
of NN O O
HALAVEN NN O O
- NN O O
treated NN O O
patients NN O O
experienced NN O O
Grade NN B-Severity B-Severity
2 NN I-Severity I-Severity
or NN O O
greater NN O O
ALT NN B-AdverseReaction B-AdverseReaction
elevation NN I-AdverseReaction I-AdverseReaction
One NN O O
HALAVEN NN O O
- NN O O
treated NN O O
patient NN O O
without NN O O
documented NN O O
liver NN O O
metastases NN O O
had NN O O
concomitant NN O O
Grade NN B-Severity B-Severity
2 NN I-Severity I-Severity
elevations NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
bilirubin NN I-AdverseReaction I-AdverseReaction
and NN O O
ALT NN O O
; NN O O
these NN O O
abnormalities NN O O
resolved NN O O
and NN O O
did NN O O
not NN O O
recur NN O O
with NN O O
re NN O O
- NN O O
exposure NN O O
to NN O O
HALAVEN. NN O O
Less NN O O
Common NN O O
Adverse NN O O
Reactions NN O O
: NN O O
The NN O O
following NN O O
additional NN O O
adverse NN O O
reactions NN O O
were NN O O
reported NN O O
in NN O O
>=5 NN O O
% NN O O
to NN O O
< NN O O
10 NN O O
% NN O O
of NN O O
the NN O O
HALAVEN NN O O
- NN O O
treated NN O O
group NN O O
: NN O O
* NN O O
Eye NN O O
Disorders NN O O
: NN O O
increased NN B-AdverseReaction B-AdverseReaction
lacrimation NN I-AdverseReaction I-AdverseReaction
* NN O O
Gastrointestinal NN O O
Disorders NN O O
: NN O O
dyspepsia NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
stomatitis NN B-AdverseReaction B-AdverseReaction
dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
* NN O O
General NN O O
Disorders NN O O
and NN O O
Administration NN O O
Site NN O O
Conditions NN O O
: NN O O
peripheral NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
* NN O O
Infections NN O O
and NN O O
Infestations NN O O
: NN O O
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
* NN O O
Metabolism NN O O
and NN O O
Nutrition NN O O
Disorders NN O O
: NN O O
hypokalemia NN B-AdverseReaction B-AdverseReaction
* NN O O
Musculoskeletal NN O O
and NN O O
Connective NN O O
Tissue NN O O
Disorders NN O O
: NN O O
muscle NN B-AdverseReaction B-AdverseReaction
spasms NN I-AdverseReaction I-AdverseReaction
muscular NN B-AdverseReaction B-AdverseReaction
weakness NN I-AdverseReaction I-AdverseReaction
* NN O O
Nervous NN O O
System NN O O
Disorders NN O O
: NN O O
dysgeusia NN B-AdverseReaction B-AdverseReaction
dizziness NN B-AdverseReaction B-AdverseReaction
* NN O O
Psychiatric NN O O
Disorders NN O O
: NN O O
insomnia NN B-AdverseReaction B-AdverseReaction
depression NN B-AdverseReaction B-AdverseReaction
* NN O O
Skin NN O O
and NN O O
Subcutaneous NN O O
Tissue NN O O
Disorders NN O O
: NN O O
rash NN B-AdverseReaction B-AdverseReaction
6 NN O O
. NN O O
2 NN O O
Postmarketing NN O O
Experience NN O O
The NN O O
following NN O O
adverse NN O O
drug NN O O
reactions NN O O
have NN O O
been NN O O
identified NN O O
during NN O O
post NN O O
- NN O O
approval NN O O
of NN O O
HALAVEN. NN O O
Because NN O O
these NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
* NN O O
Blood NN O O
and NN O O
Lymphatic NN O O
System NN O O
Disorders NN O O
: NN O O
lymphopenia NN B-AdverseReaction B-AdverseReaction
* NN O O
Gastrointestinal NN O O
Disorders NN O O
: NN O O
pancreatitis NN B-AdverseReaction B-AdverseReaction
* NN O O
Hepatobiliary NN O O
Disorders NN O O
: NN O O
hepatotoxicity NN B-AdverseReaction B-AdverseReaction
* NN O O
Immune NN O O
System NN O O
Disorders NN O O
: NN O O
drug NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
* NN O O
Infections NN O O
and NN O O
Infestations NN O O
: NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
sepsis NN B-AdverseReaction B-AdverseReaction
sepsis NN O O
* NN O O
Metabolism NN O O
and NN O O
Nutrition NN O O
Disorders NN O O
: NN O O
hypomagnesemia NN B-AdverseReaction B-AdverseReaction
dehydration NN B-AdverseReaction B-AdverseReaction
* NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
and NN O O
mediastinal NN O O
disorders NN O O
: NN O O
interstitial NN B-AdverseReaction B-AdverseReaction
lung NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
* NN O O
Skin NN O O
and NN O O
Subcutaneous NN O O
Tissue NN O O
Disorders NN O O
: NN O O
pruritus NN B-AdverseReaction B-AdverseReaction
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Neutropenia NN B-AdverseReaction B-AdverseReaction
: NN O O
Monitor NN O O
peripheral NN O O
blood NN O O
cell NN O O
counts NN O O
and NN O O
adjust NN O O
dose NN O O
as NN O O
appropriate NN O O
( NN O O
2.2 NN O O
, NN O O
5.1 NN O O
, NN O O
6 NN O O
) NN O O
* NN O O
Peripheral NN B-AdverseReaction B-AdverseReaction
Neuropathy NN I-AdverseReaction I-AdverseReaction
: NN O O
Monitor NN O O
for NN O O
signs NN O O
of NN O O
neuropathy NN O O
. NN O O
Manage NN O O
with NN O O
dose NN O O
delay NN O O
and NN O O
adjustment NN O O
( NN O O
2.2 NN O O
, NN O O
5.2 NN O O
, NN O O
6 NN O O
) NN O O
* NN O O
Embryo NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Fetal NN I-AdverseReaction I-AdverseReaction
Toxicity NN I-AdverseReaction I-AdverseReaction
: NN O O
Fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
when NN O O
administered NN O O
to NN O O
a NN O O
pregnant NN O O
woman NN O O
( NN O O
5.3 NN O O
) NN O O
( NN O O
8.1 NN O O
) NN O O
* NN O O
QT NN B-AdverseReaction B-AdverseReaction
Prolongation NN I-AdverseReaction I-AdverseReaction
: NN O O
Monitor NN O O
for NN O O
prolonged NN O O
QT NN O O
intervals NN O O
in NN O O
patients NN O O
with NN O O
congestive NN O O
heart NN O O
failure NN O O
, NN O O
bradyarrhythmias NN O O
, NN O O
drugs NN O O
known NN O O
to NN O O
prolong NN O O
the NN O O
QT NN O O
interval NN O O
, NN O O
and NN O O
electrolyte NN O O
abnormalities NN O O
. NN O O
Avoid NN O O
in NN O O
patients NN O O
with NN O O
congenital NN O O
long NN O O
QT NN O O
syndrome NN O O
( NN O O
5.4 NN O O
) NN O O
5.1 NN O O
Neutropenia NN O O
Severe NN B-Severity B-Severity
neutropenia NN B-AdverseReaction B-AdverseReaction
( NN O O
ANC NN O O
< NN O O
500/mm NN O O
3 NN O O
) NN O O
lasting NN O O
more NN O O
than NN O O
one NN O O
week NN O O
occurred NN O O
in NN O O
12 NN O O
% NN O O
( NN O O
62/503 NN O O
) NN O O
of NN O O
patients NN O O
in NN O O
Study NN O O
1 NN O O
, NN O O
leading NN O O
to NN O O
discontinuation NN O O
in NN O O
< NN O O
1 NN O O
% NN O O
of NN O O
patients NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
] NN O O
. NN O O
Patients NN O O
with NN O O
alanine NN O O
aminotransferase NN O O
or NN O O
aspartate NN O O
aminotransferase NN O O
> NN O O
3 NN O O
* NN O O
ULN NN O O
( NN O O
upper NN O O
limit NN O O
of NN O O
normal NN O O
) NN O O
experienced NN O O
a NN O O
higher NN O O
incidence NN O O
of NN O O
Grade NN B-Severity B-Severity
4 NN I-Severity I-Severity
neutropenia NN B-AdverseReaction B-AdverseReaction
and NN O O
febrile NN B-AdverseReaction B-AdverseReaction
neutropenia NN I-AdverseReaction I-AdverseReaction
than NN O O
patients NN O O
with NN O O
normal NN O O
aminotransferase NN O O
levels NN O O
. NN O O
Patients NN O O
with NN O O
bilirubin NN O O
> NN O O
1.5 NN O O
* NN O O
ULN NN O O
also NN O O
had NN O O
a NN O O
higher NN O O
incidence NN O O
of NN O O
Grade NN B-Severity B-Severity
4 NN I-Severity I-Severity
neutropenia NN B-AdverseReaction B-AdverseReaction
and NN O O
febrile NN B-AdverseReaction B-AdverseReaction
neutropenia NN I-AdverseReaction I-AdverseReaction
Monitor NN O O
complete NN O O
blood NN O O
counts NN O O
prior NN O O
to NN O O
each NN O O
dose NN O O
; NN O O
increase NN O O
the NN O O
frequency NN O O
of NN O O
monitoring NN O O
in NN O O
patients NN O O
who NN O O
develop NN O O
Grade NN O O
3 NN O O
or NN O O
4 NN O O
cytopenias NN O O
. NN O O
Delay NN O O
administration NN O O
of NN O O
HALAVEN NN O O
and NN O O
reduce NN O O
subsequent NN O O
doses NN O O
in NN O O
patients NN O O
who NN O O
experience NN O O
febrile NN O O
neutropenia NN O O
or NN O O
Grade NN O O
4 NN O O
neutropenia NN O O
lasting NN O O
longer NN O O
than NN O O
7 NN O O
days NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
] NN O O
. NN O O
Clinical NN O O
studies NN O O
of NN O O
HALAVEN NN O O
did NN O O
not NN O O
include NN O O
patients NN O O
with NN O O
baseline NN O O
neutrophil NN O O
counts NN O O
below NN O O
1,500/mm NN O O
3 NN O O
. NN O O
5.2 NN O O
Peripheral NN O O
Neuropathy NN O O
Grade NN B-Severity B-Severity
3 NN I-Severity I-Severity
peripheral NN B-AdverseReaction B-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
occurred NN O O
in NN O O
8 NN O O
% NN O O
( NN O O
40/503 NN O O
) NN O O
of NN O O
patients NN O O
, NN O O
and NN O O
Grade NN B-Severity B-Severity
4 NN I-Severity I-Severity
in NN O O
0.4 NN O O
% NN O O
( NN O O
2/503 NN O O
) NN O O
of NN O O
patients NN O O
in NN O O
Study NN O O
1 NN O O
. NN O O
Peripheral NN B-AdverseReaction B-AdverseReaction
neuropathy NN I-AdverseReaction I-AdverseReaction
was NN O O
the NN O O
most NN O O
common NN O O
toxicity NN O O
leading NN O O
to NN O O
discontinuation NN O O
of NN O O
HALAVEN NN O O
( NN O O
5 NN O O
% NN O O
of NN O O
patients NN O O
; NN O O
24/503 NN O O
) NN O O
. NN O O
Neuropathy NN B-AdverseReaction B-AdverseReaction
lasting NN O O
more NN O O
than NN O O
one NN O O
year NN O O
occurred NN O O
in NN O O
5 NN O O
% NN O O
( NN O O
26/503 NN O O
) NN O O
of NN O O
patients NN O O
. NN O O
Twenty NN O O
- NN O O
two NN O O
percent NN O O
( NN O O
109/503 NN O O
) NN O O
of NN O O
patients NN O O
developed NN O O
a NN O O
new NN O O
or NN O O
worsening NN O O
neuropathy NN B-AdverseReaction B-AdverseReaction
that NN O O
had NN O O
not NN O O
recovered NN O O
within NN O O
a NN O O
median NN O O
follow NN O O
- NN O O
up NN O O
duration NN O O
of NN O O
269 NN O O
days NN O O
( NN O O
range NN O O
25 NN O O
- NN O O
662 NN O O
days NN O O
) NN O O
. NN O O
Monitor NN O O
patients NN O O
closely NN O O
for NN O O
signs NN O O
of NN O O
peripheral NN O O
motor NN O O
and NN O O
sensory NN O O
neuropathy NN O O
. NN O O
Withhold NN O O
HALAVEN NN O O
in NN O O
patients NN O O
who NN O O
experience NN O O
Grade NN O O
3 NN O O
or NN O O
4 NN O O
peripheral NN O O
neuropathy NN O O
until NN O O
resolution NN O O
to NN O O
Grade NN O O
2 NN O O
or NN O O
less NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2.2 NN O O
) NN O O
] NN O O
. NN O O
5.3 NN O O
Embryo NN O O
- NN O O
Fetal NN O O
Toxicity NN O O
There NN O O
are NN O O
no NN O O
adequate NN O O
and NN O O
well NN O O
- NN O O
controlled NN O O
studies NN O O
of NN O O
HALAVEN NN O O
in NN O O
pregnant NN O O
women NN O O
. NN O O
HALAVEN NN O O
is NN O O
a NN O O
microtubule NN B-DrugClass B-DrugClass
inhibitor NN I-DrugClass I-DrugClass
therefore NN O O
, NN O O
it NN O O
is NN O O
expected NN O O
to NN O O
cause NN O O
fetal NN B-AdverseReaction B-AdverseReaction
harm NN I-AdverseReaction I-AdverseReaction
when NN O O
administered NN O O
to NN O O
a NN O O
pregnant NN O O
woman NN O O
. NN O O
Embryo NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
fetal NN I-AdverseReaction I-AdverseReaction
toxicity NN I-AdverseReaction I-AdverseReaction
and NN O O
teratogenicity NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
rats NN B-Animal B-Animal
that NN O O
received NN O O
eribulin NN O O
mesylate NN O O
at NN O O
approximately NN O O
half NN O O
of NN O O
the NN O O
recommended NN O O
human NN O O
dose NN O O
based NN O O
on NN O O
body NN O O
surface NN O O
area NN O O
. NN O O
If NN B-Factor B-Factor
this NN O O
drug NN O O
is NN O O
used NN O O
during NN O O
pregnancy NN O O
, NN O O
or NN O O
if NN O O
a NN O O
patient NN O O
becomes NN O O
pregnant NN O O
while NN O O
taking NN O O
this NN O O
drug NN O O
, NN O O
she NN O O
should NN O O
be NN O O
apprised NN O O
of NN O O
the NN O O
potential NN O O
hazard NN O O
to NN O O
the NN O O
fetus NN B-Factor B-Factor
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.1 NN O O
) NN O O
] NN O O
. NN O O
5.4 NN O O
QT NN O O
Prolongation NN O O
In NN O O
an NN O O
uncontrolled NN O O
open NN O O
- NN O O
label NN O O
ECG NN O O
study NN O O
in NN O O
26 NN O O
patients NN O O
, NN O O
QT NN B-AdverseReaction B-AdverseReaction
prolongation NN I-AdverseReaction I-AdverseReaction
was NN O O
observed NN O O
on NN O O
Day NN O O
8 NN O O
, NN O O
independent NN O O
of NN O O
eribulin NN O O
concentration NN O O
, NN O O
with NN O O
no NN B-Negation B-Negation
QT NN B-AdverseReaction B-AdverseReaction
prolongation NN I-AdverseReaction I-AdverseReaction
observed NN O O
on NN O O
Day NN O O
1 NN O O
. NN O O
ECG NN O O
monitoring NN O O
is NN O O
recommended NN O O
if NN O O
therapy NN O O
is NN O O
initiated NN O O
in NN O O
patients NN O O
with NN O O
congestive NN O O
heart NN O O
failure NN O O
, NN O O
bradyarrhythmias NN O O
, NN O O
drugs NN O O
known NN O O
to NN O O
prolong NN O O
the NN O O
QT NN O O
interval NN O O
, NN O O
including NN O O
Class NN O O
Ia NN O O
and NN O O
III NN O O
antiarrhythmics NN O O
, NN O O
and NN O O
electrolyte NN O O
abnormalities NN O O
. NN O O
Correct NN O O
hypokalemia NN O O
or NN O O
hypomagnesemia NN O O
prior NN O O
to NN O O
initiating NN O O
HALAVEN NN O O
and NN O O
monitor NN O O
these NN O O
electrolytes NN O O
periodically NN O O
during NN O O
therapy NN O O
. NN O O
Avoid NN O O
HALAVEN NN O O
in NN O O
patients NN O O
with NN O O
congenital NN O O
long NN O O
QT NN O O
syndrome NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reaction NN O O
occurring NN O O
in NN O O
approximately NN O O
25 NN O O
% NN O O
of NN O O
patients NN O O
was NN O O
a NN O O
mild NN B-Severity B-Severity
taste NN B-AdverseReaction B-AdverseReaction
following NN I-AdverseReaction I-AdverseReaction
instillation NN I-AdverseReaction I-AdverseReaction
Other NN O O
adverse NN O O
reactions NN O O
which NN O O
occurred NN O O
in NN O O
2 NN O O
- NN O O
5 NN O O
% NN O O
of NN O O
subjects NN O O
were NN O O
eye NN B-AdverseReaction B-AdverseReaction
irritation NN I-AdverseReaction I-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
and NN O O
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
( NN O O
6 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Bausch NN O O
& NN O O
Lomb NN O O
Incorporated NN O O
. NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
323 NN O O
- NN O O
0000 NN O O
, NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O
The NN O O
most NN O O
common NN O O
reported NN O O
adverse NN O O
reaction NN O O
occurring NN O O
in NN O O
approximately NN O O
25 NN O O
% NN O O
of NN O O
subjects NN O O
was NN O O
a NN O O
mild NN B-Severity B-Severity
taste NN B-AdverseReaction B-AdverseReaction
following NN I-AdverseReaction I-AdverseReaction
instillation NN I-AdverseReaction I-AdverseReaction
Other NN O O
adverse NN O O
reactions NN O O
occurring NN O O
in NN O O
2 NN O O
- NN O O
5 NN O O
% NN O O
of NN O O
subjects NN O O
were NN O O
eye NN B-AdverseReaction B-AdverseReaction
irritation NN I-AdverseReaction I-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
and NN O O
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
6.2 NN O O
Post NN O O
Marketing NN O O
Experience NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
rarely NN O O
during NN O O
the NN O O
post NN O O
- NN O O
marketing NN O O
use NN O O
of NN O O
BEPREVE. NN O O
Because NN O O
these NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
unknown NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
casual NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
The NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
include NN O O
itching NN B-AdverseReaction B-AdverseReaction
body NN B-AdverseReaction B-AdverseReaction
rash NN I-AdverseReaction I-AdverseReaction
and NN O O
swelling NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
lips NN I-AdverseReaction I-AdverseReaction
tongue NN O O
and/or NN O O
throat NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
To NN O O
minimize NN O O
the NN O O
risk NN O O
of NN O O
contamination NN O O
, NN O O
do NN O O
not NN O O
touch NN O O
dropper NN O O
tip NN O O
to NN O O
any NN O O
surface NN O O
. NN O O
Keep NN O O
bottle NN O O
tightly NN O O
closed NN O O
when NN O O
not NN O O
in NN O O
use NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
BEPREVE NN O O
should NN O O
not NN O O
be NN O O
used NN O O
to NN O O
treat NN O O
contact NN O O
lens NN O O
- NN O O
related NN O O
irritation NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Remove NN O O
contact NN O O
lenses NN O O
prior NN O O
to NN O O
instillation NN O O
of NN O O
BEPREVE. NN O O
( NN O O
5.2 NN O O
) NN O O
5.1 NN O O
Contamination NN O O
of NN O O
Tip NN O O
and NN O O
Solution NN O O
To NN O O
minimize NN O O
contaminating NN O O
the NN O O
dropper NN O O
tip NN O O
and NN O O
solution NN O O
, NN O O
care NN O O
should NN O O
be NN O O
taken NN O O
not NN O O
to NN O O
touch NN O O
the NN O O
eyelids NN O O
or NN O O
surrounding NN O O
areas NN O O
with NN O O
the NN O O
dropper NN O O
tip NN O O
of NN O O
the NN O O
bottle NN O O
. NN O O
Keep NN O O
bottle NN O O
tightly NN O O
closed NN O O
when NN O O
not NN O O
in NN O O
use NN O O
. NN O O
5.2 NN O O
Contact NN O O
Lens NN O O
Use NN O O
Patients NN O O
should NN O O
be NN O O
advised NN O O
not NN O O
to NN O O
wear NN O O
a NN O O
contact NN O O
lens NN O O
if NN O O
their NN O O
eye NN O O
is NN O O
red NN O O
. NN O O
BEPREVE NN O O
should NN O O
not NN O O
be NN O O
used NN O O
to NN O O
treat NN O O
contact NN O O
lens NN O O
- NN O O
related NN O O
irritation NN O O
. NN O O
BEPREVE NN O O
should NN O O
not NN O O
be NN O O
instilled NN O O
while NN O O
wearing NN O O
contact NN O O
lenses NN O O
. NN O O
Remove NN O O
contact NN O O
lenses NN O O
prior NN O O
to NN O O
instillation NN O O
of NN O O
BEPREVE. NN O O
The NN O O
preservative NN O O
in NN O O
BEPREVE NN O O
, NN O O
benzalkonium NN O O
chloride NN O O
, NN O O
may NN O O
be NN O O
absorbed NN O O
by NN O O
soft NN O O
contact NN O O
lenses NN O O
. NN O O
Lenses NN O O
may NN O O
be NN O O
reinserted NN O O
after NN O O
10 NN O O
minutes NN O O
following NN O O
administration NN O O
of NN O O
BEPREVE. NN O O
5.3 NN O O
Topical NN O O
Ophthalmic NN O O
Use NN O O
Only NN O O
BEPREVE NN O O
is NN O O
for NN O O
topical NN O O
ophthalmic NN O O
use NN O O
only NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
most NN O O
serious NN O O
adverse NN O O
reactions NN O O
were NN O O
: NN O O
* NN O O
Serious NN B-Severity B-Severity
Infections NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
* NN O O
Malignancies NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
Most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
incidence NN O O
>=3 NN O O
% NN O O
) NN O O
are NN O O
: NN O O
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
viral NN B-AdverseReaction B-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
bronchitis NN B-AdverseReaction B-AdverseReaction
hypertension NN B-AdverseReaction B-AdverseReaction
and NN O O
rash NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
. NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contactJanssen NN O O
Biotech NN O O
, NN O O
Inc. NN O O
at NN O O
1 NN O O
- NN O O
800-JANSSEN NN O O
( NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
526 NN O O
- NN O O
7736 NN O O
) NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O
The NN O O
safety NN O O
data NN O O
described NN O O
below NN O O
are NN O O
based NN O O
on NN O O
one NN O O
, NN O O
randomized NN O O
, NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
controlled NN O O
Phase NN O O
3 NN O O
trial NN O O
in NN O O
patients NN O O
with NN O O
RA NN O O
receiving NN O O
SIMPONI NN O O
ARIA NN O O
by NN O O
intravenous NN O O
infusion NN O O
( NN O O
Trial NN O O
1 NN O O
) NN O O
. NN O O
The NN O O
protocol NN O O
included NN O O
provisions NN O O
for NN O O
patients NN O O
taking NN O O
placebo NN O O
to NN O O
receive NN O O
treatment NN O O
with NN O O
SIMPONI NN O O
ARIA NN O O
at NN O O
Week NN O O
16 NN O O
or NN O O
Week NN O O
24 NN O O
either NN O O
by NN O O
patient NN O O
response NN O O
( NN O O
based NN O O
on NN O O
uncontrolled NN O O
disease NN O O
activity NN O O
) NN O O
or NN O O
by NN O O
design NN O O
, NN O O
so NN O O
that NN O O
adverse NN O O
events NN O O
can NN O O
not NN O O
always NN O O
be NN O O
unambiguously NN O O
attributed NN O O
to NN O O
a NN O O
given NN O O
treatment NN O O
. NN O O
Comparisons NN O O
between NN O O
placebo NN O O
and NN O O
SIMPONI NN O O
ARIA NN O O
were NN O O
based NN O O
on NN O O
the NN O O
first NN O O
24 NN O O
weeks NN O O
of NN O O
exposure NN O O
. NN O O
Trial NN O O
1 NN O O
included NN O O
197 NN O O
control NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
463 NN O O
SIMPONI NN O O
ARIA NN O O
- NN O O
treated NN O O
patients NN O O
( NN O O
which NN O O
includes NN O O
control NN O O
- NN O O
treated NN O O
patients NN O O
who NN O O
switched NN O O
to NN O O
SIMPONI NN O O
ARIA NN O O
at NN O O
Week NN O O
16 NN O O
) NN O O
. NN O O
The NN O O
proportion NN O O
of NN O O
patients NN O O
who NN O O
discontinued NN O O
treatment NN O O
due NN O O
to NN O O
adverse NN O O
reactions NN O O
in NN O O
the NN O O
controlled NN O O
phase NN O O
of NN O O
Trial NN O O
1 NN O O
through NN O O
Week NN O O
24 NN O O
was NN O O
3.5 NN O O
% NN O O
for NN O O
SIMPONI NN O O
ARIA NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
0.5 NN O O
% NN O O
for NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
was NN O O
the NN O O
most NN O O
common NN O O
adverse NN O O
reaction NN O O
reported NN O O
in NN O O
the NN O O
trial NN O O
through NN O O
Week NN O O
24 NN O O
occurring NN O O
in NN O O
6.5 NN O O
% NN O O
of NN O O
SIMPONI NN O O
ARIA NN O O
- NN O O
treated NN O O
patients NN O O
as NN O O
compared NN O O
with NN O O
7.6 NN O O
% NN O O
of NN O O
control NN O O
- NN O O
treated NN O O
patients NN O O
, NN O O
respectively NN O O
. NN O O
Infections NN O O
Serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
observed NN O O
in NN O O
SIMPONI NN O O
ARIA NN O O
- NN O O
treated NN O O
patients NN O O
included NN O O
sepsis NN B-AdverseReaction B-AdverseReaction
pneumonia NN B-AdverseReaction B-AdverseReaction
cellulitis NN B-AdverseReaction B-AdverseReaction
abscess NN B-AdverseReaction B-AdverseReaction
opportunistic NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
tuberculosis NN B-AdverseReaction B-AdverseReaction
( NN O O
TB NN O O
) NN O O
, NN O O
and NN O O
invasive NN B-AdverseReaction B-AdverseReaction
fungal NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
Cases NN O O
of NN O O
TB NN B-AdverseReaction B-AdverseReaction
included NN O O
pulmonary NN O O
and NN O O
extrapulmonary NN B-AdverseReaction B-AdverseReaction
TB NN I-AdverseReaction I-AdverseReaction
The NN O O
majority NN O O
of NN O O
the NN O O
TB NN B-AdverseReaction B-AdverseReaction
cases NN O O
occurred NN O O
in NN O O
countries NN O O
with NN O O
a NN O O
high NN O O
incidence NN O O
rate NN O O
of NN O O
TB NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
In NN O O
the NN O O
controlled NN O O
phase NN O O
of NN O O
Trial NN O O
1 NN O O
through NN O O
Week NN O O
24 NN O O
, NN O O
infections NN B-AdverseReaction B-AdverseReaction
were NN O O
observed NN O O
in NN O O
27 NN O O
% NN O O
of NN O O
SIMPONI NN O O
ARIA NN O O
- NN O O
treated NN O O
patients NN O O
compared NN O O
with NN O O
24 NN O O
% NN O O
of NN O O
control NN O O
- NN O O
treated NN O O
patients NN O O
, NN O O
and NN O O
serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
were NN O O
observed NN O O
in NN O O
0.9 NN O O
% NN O O
of NN O O
SIMPONI NN O O
ARIA NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
0.0 NN O O
% NN O O
of NN O O
control NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Through NN O O
Week NN O O
24 NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
per NN O O
100 NN O O
patient NN O O
- NN O O
years NN O O
of NN O O
follow NN O O
- NN O O
up NN O O
was NN O O
2.2 NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
0.61 NN O O
, NN O O
5.71 NN O O
) NN O O
for NN O O
the NN O O
SIMPONI NN O O
ARIA NN O O
group NN O O
, NN O O
and NN O O
0 NN O O
( NN O O
0.00 NN O O
, NN O O
3.79 NN O O
) NN O O
for NN O O
the NN O O
placebo NN O O
group NN O O
. NN O O
In NN O O
the NN O O
controlled NN O O
and NN O O
uncontrolled NN O O
portions NN O O
of NN O O
Trial NN O O
1 NN O O
, NN O O
958 NN O O
total NN O O
patient NN O O
- NN O O
years NN O O
of NN O O
follow NN O O
- NN O O
up NN O O
with NN O O
a NN O O
median NN O O
follow NN O O
- NN O O
up NN O O
of NN O O
approximately NN O O
92 NN O O
weeks NN O O
, NN O O
the NN O O
incidence NN O O
per NN O O
100 NN O O
patient NN O O
- NN O O
years NN O O
of NN O O
all NN O O
serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
was NN O O
4.07 NN O O
( NN O O
CI NN O O
: NN O O
2.90 NN O O
, NN O O
5.57 NN O O
) NN O O
in NN O O
patients NN O O
receiving NN O O
SIMPONI NN O O
ARIA NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
In NN O O
the NN O O
controlled NN O O
and NN O O
uncontrolled NN O O
portions NN O O
of NN O O
Trial NN O O
1 NN O O
, NN O O
in NN O O
SIMPONI NN O O
ARIA NN O O
treated NN O O
patients NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
active NN B-AdverseReaction B-AdverseReaction
TB NN I-AdverseReaction I-AdverseReaction
per NN O O
100 NN O O
patient NN O O
- NN O O
years NN O O
was NN O O
0.31 NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
: NN O O
0.06 NN O O
; NN O O
0.92 NN O O
) NN O O
and NN O O
the NN O O
incidence NN O O
of NN O O
other NN O O
opportunistic NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
per NN O O
100 NN O O
patient NN O O
- NN O O
years NN O O
was NN O O
0.42 NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
: NN O O
0.11 NN O O
, NN O O
1.07 NN O O
) NN O O
. NN O O
Malignancies NN O O
One NN O O
case NN O O
of NN O O
malignancy NN B-AdverseReaction B-AdverseReaction
other NN O O
than NN O O
lymphoma NN B-AdverseReaction B-AdverseReaction
and NN O O
NMSC NN B-AdverseReaction B-AdverseReaction
with NN O O
SIMPONI NN O O
ARIA NN O O
was NN O O
reported NN O O
through NN O O
Week NN O O
24 NN O O
during NN O O
the NN O O
controlled NN O O
phase NN O O
of NN O O
Trial NN O O
1 NN O O
. NN O O
In NN O O
the NN O O
controlled NN O O
and NN O O
uncontrolled NN O O
portions NN O O
through NN O O
approximately NN O O
92 NN O O
weeks NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
malignancies NN B-AdverseReaction B-AdverseReaction
per NN O O
100 NN O O
patient NN O O
- NN O O
years NN O O
, NN O O
other NN O O
than NN O O
lymphoma NN B-AdverseReaction B-AdverseReaction
and NN O O
NMSC NN B-AdverseReaction B-AdverseReaction
in NN O O
SIMPONI NN O O
ARIA NN O O
- NN O O
treated NN O O
patients NN O O
was NN O O
0.31 NN O O
( NN O O
CI NN O O
: NN O O
0.06 NN O O
, NN O O
0.92 NN O O
) NN O O
and NN O O
the NN O O
incidence NN O O
of NN O O
NMSC NN B-AdverseReaction B-AdverseReaction
was NN O O
0.1 NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
: NN O O
0.00 NN O O
, NN O O
0.58 NN O O
) NN O O
. NN O O
Liver NN O O
Enzyme NN O O
Elevations NN O O
There NN O O
have NN O O
been NN O O
reports NN O O
of NN O O
severe NN B-Severity B-Severity
hepatic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
acute NN B-AdverseReaction B-AdverseReaction
liver NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
in NN O O
patients NN O O
receiving NN O O
TNF NN B-DrugClass B-DrugClass
- NN I-DrugClass I-DrugClass
blockers NN I-DrugClass I-DrugClass
In NN O O
the NN O O
controlled NN O O
phase NN O O
of NN O O
Trial NN O O
1 NN O O
, NN O O
through NN O O
Week NN O O
24 NN O O
, NN O O
ALT NN B-AdverseReaction B-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
>= NN O O
5 NN B-Severity B-Severity
* NN I-Severity I-Severity
ULN NN I-Severity I-Severity
occurred NN O O
in NN O O
0.8 NN O O
% NN O O
of NN O O
SIMPONI NN O O
ARIA NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
0 NN O O
% NN O O
of NN O O
control NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
ALT NN B-AdverseReaction B-AdverseReaction
elevations NN I-AdverseReaction I-AdverseReaction
>= NN O O
3 NN B-Severity B-Severity
* NN I-Severity I-Severity
ULN NN I-Severity I-Severity
occurred NN O O
in NN O O
2.3 NN O O
% NN O O
of NN O O
SIMPONI NN O O
ARIA NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
2.5 NN O O
% NN O O
of NN O O
control NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Since NN O O
many NN O O
of NN O O
the NN O O
patients NN O O
in NN O O
the NN O O
Phase NN O O
3 NN O O
trial NN O O
were NN O O
also NN O O
taking NN O O
medications NN O O
that NN O O
cause NN O O
liver NN O O
enzyme NN O O
elevations NN O O
( NN O O
e.g. NN O O
, NN O O
nonsteroidal NN O O
anti NN O O
- NN O O
inflammatory NN O O
drugs NN O O
[ NN O O
NSAIDs NN O O
] NN O O
, NN O O
methotrexate NN O O
[ NN O O
MTX NN O O
] NN O O
, NN O O
or NN O O
isoniazid NN O O
prophylaxis NN O O
) NN O O
, NN O O
the NN O O
relationship NN O O
between NN O O
SIMPONI NN O O
ARIA NN O O
and NN O O
liver NN O O
enzyme NN O O
elevation NN O O
is NN O O
not NN O O
clear NN O O
. NN O O
Autoimmune NN O O
Disorders NN O O
and NN O O
Autoantibodies NN O O
The NN O O
use NN O O
of NN O O
TNF NN B-DrugClass B-DrugClass
- NN I-DrugClass I-DrugClass
blockers NN I-DrugClass I-DrugClass
of NN O O
which NN O O
SIMPONI NN O O
ARIA NN O O
is NN O O
a NN O O
member NN O O
, NN O O
has NN O O
been NN O O
associated NN O O
with NN O O
the NN O O
formation NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
autoantibodies NN I-AdverseReaction I-AdverseReaction
and NN O O
, NN O O
rarely NN O O
, NN O O
with NN O O
the NN O O
development NN O O
of NN O O
a NN O O
lupus NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
like NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
At NN O O
Week NN O O
20 NN O O
in NN O O
Trial NN O O
1 NN O O
, NN O O
17 NN O O
% NN O O
of NN O O
SIMPONI NN O O
ARIA NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
13 NN O O
% NN O O
of NN O O
control NN O O
patients NN O O
were NN O O
newly NN B-AdverseReaction B-AdverseReaction
ANA NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
positive NN I-AdverseReaction I-AdverseReaction
( NN O O
at NN O O
titers NN O O
of NN O O
1:160 NN O O
or NN O O
greater NN O O
) NN O O
. NN O O
Of NN O O
these NN O O
patients NN O O
, NN O O
one NN O O
SIMPONI NN O O
ARIA NN O O
- NN O O
treated NN O O
patient NN O O
and NN O O
no NN B-Negation B-Negation
control NN O O
- NN O O
treated NN O O
patients NN O O
had NN O O
newly NN B-AdverseReaction B-AdverseReaction
positive NN I-AdverseReaction I-AdverseReaction
anti NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
dsDNA NN I-AdverseReaction I-AdverseReaction
antibodies NN I-AdverseReaction I-AdverseReaction
Administration NN O O
Reactions NN O O
In NN O O
the NN O O
controlled NN O O
phase NN O O
of NN O O
Trial NN O O
1 NN O O
through NN O O
Week NN O O
24 NN O O
, NN O O
1.1 NN O O
% NN O O
of NN O O
SIMPONI NN O O
ARIA NN O O
infusions NN O O
were NN O O
associated NN O O
with NN O O
an NN O O
infusion NN B-AdverseReaction B-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
compared NN O O
with NN O O
0.2 NN O O
% NN O O
of NN O O
infusions NN O O
in NN O O
the NN O O
control NN O O
group NN O O
. NN O O
The NN O O
most NN O O
common NN O O
infusion NN O O
reaction NN O O
in NN O O
SIMPONI NN O O
ARIA NN O O
treated NN O O
patients NN O O
was NN O O
rash NN B-AdverseReaction B-AdverseReaction
No NN B-Negation B-Negation
serious NN B-Severity B-Severity
infusion NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
were NN O O
reported NN O O
. NN O O
Immunogenicity NN O O
Antibodies NN O O
to NN O O
SIMPONI NN O O
ARIA NN O O
were NN O O
detected NN O O
in NN O O
13 NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
golimumab NN O O
- NN O O
treated NN O O
patients NN O O
following NN O O
IV NN O O
administration NN O O
of NN O O
SIMPONI NN O O
ARIA NN O O
in NN O O
combination NN O O
with NN O O
MTX NN O O
through NN O O
Week NN O O
24 NN O O
of NN O O
Trial NN O O
1 NN O O
. NN O O
All NN O O
patients NN O O
who NN O O
were NN O O
positive NN O O
for NN O O
antibodies NN O O
to NN O O
golimumab NN O O
had NN O O
neutralizing NN O O
antibodies NN O O
based NN O O
on NN O O
an NN O O
in NN O O
vitro NN O O
cell NN O O
- NN O O
based NN O O
assay NN O O
. NN O O
The NN O O
small NN O O
number NN O O
of NN O O
patients NN O O
positive NN O O
for NN O O
antibodies NN O O
to NN O O
SIMPONI NN O O
ARIA NN O O
limits NN O O
the NN O O
ability NN O O
to NN O O
draw NN O O
definitive NN O O
conclusions NN O O
regarding NN O O
the NN O O
relationship NN O O
between NN O O
antibodies NN O O
to NN O O
golimumab NN O O
and NN O O
clinical NN O O
efficacy NN O O
or NN O O
safety NN O O
measures NN O O
. NN O O
The NN O O
data NN O O
above NN O O
reflect NN O O
the NN O O
percentage NN O O
of NN O O
patients NN O O
whose NN O O
test NN O O
results NN O O
were NN O O
considered NN O O
positive NN O O
for NN O O
antibodies NN O O
to NN O O
SIMPONI NN O O
ARIA NN O O
in NN O O
an NN O O
ELISA NN O O
assay NN O O
. NN O O
The NN O O
ELISA NN O O
assay NN O O
is NN O O
subject NN O O
to NN O O
interference NN O O
by NN O O
co NN O O
- NN O O
present NN O O
golimumab NN O O
and NN O O
thus NN O O
the NN O O
results NN O O
are NN O O
an NN O O
underestimate NN O O
of NN O O
the NN O O
rate NN O O
of NN O O
product NN O O
immunogenicity NN O O
and NN O O
are NN O O
in NN O O
addition NN O O
highly NN O O
dependent NN O O
on NN O O
the NN O O
sensitivity NN O O
and NN O O
specificity NN O O
of NN O O
the NN O O
assay NN O O
. NN O O
Additionally NN O O
, NN O O
the NN O O
observed NN O O
incidence NN O O
of NN O O
antibody NN O O
positivity NN O O
in NN O O
an NN O O
assay NN O O
may NN O O
be NN O O
influenced NN O O
by NN O O
several NN O O
factors NN O O
including NN O O
sample NN O O
handling NN O O
, NN O O
timing NN O O
of NN O O
sample NN O O
collection NN O O
, NN O O
concomitant NN O O
medications NN O O
, NN O O
and NN O O
underlying NN O O
disease NN O O
. NN O O
For NN O O
these NN O O
reasons NN O O
, NN O O
comparison NN O O
of NN O O
the NN O O
incidence NN O O
of NN O O
antibodies NN O O
to NN O O
SIMPONI NN O O
ARIA NN O O
with NN O O
the NN O O
incidence NN O O
of NN O O
antibodies NN O O
to NN O O
other NN O O
products NN O O
may NN O O
be NN O O
misleading NN O O
. NN O O
Other NN O O
Adverse NN O O
Reactions NN O O
Table NN O O
1 NN O O
summarizes NN O O
the NN O O
adverse NN O O
drug NN O O
reactions NN O O
that NN O O
occurred NN O O
at NN O O
a NN O O
rate NN O O
of NN O O
at NN O O
least NN O O
1 NN O O
% NN O O
in NN O O
the NN O O
SIMPONI NN O O
ARIA NN O O
+ NN O O
MTX NN O O
group NN O O
with NN O O
a NN O O
higher NN O O
incidence NN O O
than NN O O
in NN O O
the NN O O
placebo NN O O
+ NN O O
MTX NN O O
group NN O O
during NN O O
the NN O O
controlled NN O O
period NN O O
of NN O O
Trial NN O O
1 NN O O
through NN O O
Week NN O O
24 NN O O
. NN O O
Table NN O O
1 NN O O
: NN O O
Adverse NN O O
Drug NN O O
Reactions NN O O
Reported NN O O
by NN O O
>= NN O O
1 NN O O
% NN O O
of NN O O
SIMPONI NN O O
ARIA NN O O
- NN O O
Treated NN O O
Patients NN O O
and NN O O
with NN O O
a NN O O
Higher NN O O
Incidence NN O O
than NN O O
Placebo NN O O
- NN O O
Treated NN O O
Patients NN O O
in NN O O
Trial NN O O
1 NN O O
through NN O O
Week NN O O
24 NN O O
Placebo NN O O
+ NN O O
MTX NN O O
SIMPONI NN O O
ARIA NN O O
+ NN O O
MTX NN O O
Patients NN O O
treated NN O O
197 NN O O
463 NN O O
Adverse NN O O
Reaction NN O O
Infections NN O O
and NN O O
Infestations NN O O
Upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
( NN O O
such NN O O
as NN O O
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
pharyngitis NN B-AdverseReaction B-AdverseReaction
laryngitis NN B-AdverseReaction B-AdverseReaction
and NN O O
rhinitis NN B-AdverseReaction B-AdverseReaction
12 NN O O
% NN O O
13 NN O O
% NN O O
Viral NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
( NN O O
such NN O O
as NN O O
influenza NN B-AdverseReaction B-AdverseReaction
and NN O O
herpes NN B-AdverseReaction B-AdverseReaction
3 NN O O
% NN O O
4 NN O O
% NN O O
Bacterial NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
0 NN O O
% NN O O
1 NN O O
% NN O O
Bronchitis NN B-AdverseReaction B-AdverseReaction
1 NN O O
% NN O O
3 NN O O
% NN O O
Vascular NN B-AdverseReaction B-AdverseReaction
disorders NN I-AdverseReaction I-AdverseReaction
Hypertension NN B-AdverseReaction B-AdverseReaction
2 NN O O
% NN O O
3 NN O O
% NN O O
Skin NN O O
and NN O O
subcutaneous NN O O
disorders NN O O
Rash NN B-AdverseReaction B-AdverseReaction
1 NN O O
% NN O O
3 NN O O
% NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
Pyrexia NN B-AdverseReaction B-AdverseReaction
1 NN O O
% NN O O
2 NN O O
% NN O O
Blood NN O O
and NN O O
lymphatic NN B-AdverseReaction B-AdverseReaction
disorders NN I-AdverseReaction I-AdverseReaction
Leukopenia NN B-AdverseReaction B-AdverseReaction
0 NN O O
% NN O O
1 NN O O
% NN O O
Other NN O O
and NN O O
less NN O O
common NN O O
clinical NN O O
trial NN O O
adverse NN O O
drug NN O O
reactions NN O O
Adverse NN O O
drug NN O O
reactions NN O O
that NN O O
do NN O O
not NN O O
appear NN O O
in NN O O
Table NN O O
1 NN O O
or NN O O
that NN O O
occurred NN O O
< NN O O
1 NN O O
% NN O O
in NN O O
SIMPONI NN O O
ARIA NN O O
- NN O O
treated NN O O
patients NN O O
during NN O O
Trial NN O O
1 NN O O
through NN O O
Week NN O O
24 NN O O
that NN O O
do NN O O
not NN O O
appear NN O O
in NN O O
the NN O O
Warnings NN O O
and NN O O
Precautions NN O O
section NN O O
included NN O O
the NN O O
following NN O O
events NN O O
listed NN O O
by NN O O
system NN O O
organ NN O O
class NN O O
: NN O O
Infections NN O O
and NN O O
Infestations NN O O
: NN O O
Superficial NN B-AdverseReaction B-AdverseReaction
fungal NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
sinusitis NN B-AdverseReaction B-AdverseReaction
abscess NN B-AdverseReaction B-AdverseReaction
lower NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
( NN O O
pneumonia NN O O
) NN O O
, NN O O
pyelonephritis NN B-AdverseReaction B-AdverseReaction
Investigations NN O O
: NN O O
Alanine NN B-AdverseReaction B-AdverseReaction
aminotransferase NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
aspartate NN B-AdverseReaction B-AdverseReaction
aminotransferase NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
neutrophil NN B-AdverseReaction B-AdverseReaction
count NN I-AdverseReaction I-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
Nervous NN O O
system NN O O
disorders NN O O
: NN O O
Dizziness NN B-AdverseReaction B-AdverseReaction
paresthesia NN B-AdverseReaction B-AdverseReaction
Gastrointestinal NN O O
disorders NN O O
: NN O O
Constipation NN B-AdverseReaction B-AdverseReaction
6.2 NN O O
Post NN O O
- NN O O
marketing NN O O
Experience NN O O
There NN O O
is NN O O
no NN O O
post NN O O
- NN O O
marketing NN O O
experience NN O O
available NN O O
for NN O O
SIMPONI NN O O
ARIA. NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
identified NN O O
during NN O O
post NN O O
- NN O O
approval NN O O
use NN O O
of NN O O
the NN O O
subcutaneous NN O O
formulation NN O O
of NN O O
golimumab NN O O
. NN O O
Because NN O O
these NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
golimumab NN O O
exposure NN O O
. NN O O
Neoplasm NN O O
Benign NN O O
and NN O O
Malignant NN O O
: NN O O
Melanoma NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
Immune NN O O
System NN O O
Disorders NN O O
: NN O O
Serious NN B-Severity B-Severity
systemic NN B-AdverseReaction B-AdverseReaction
hypersensitivity NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
( NN O O
including NN O O
anaphylactic NN B-AdverseReaction B-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.10 NN O O
) NN O O
] NN O O
, NN O O
sarcoidosis NN B-AdverseReaction B-AdverseReaction
Respiratory NN O O
, NN O O
thoracic NN O O
and NN O O
mediastinal NN O O
disorders NN O O
: NN O O
Interstitial NN B-AdverseReaction B-AdverseReaction
lung NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
Skin NN O O
and NN O O
subcutaneous NN O O
tissue NN O O
disorders NN O O
: NN O O
Skin NN B-AdverseReaction B-AdverseReaction
exfoliation NN I-AdverseReaction I-AdverseReaction
bullous NN B-AdverseReaction B-AdverseReaction
skin NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
SERIOUS NN B-Severity B-Severity
INFECTIONS NN B-AdverseReaction B-AdverseReaction
AND NN O O
MALIGNANCY NN B-AdverseReaction B-AdverseReaction
WARNING NN O O
: NN O O
SERIOUS NN B-Severity B-Severity
INFECTIONS NN B-AdverseReaction B-AdverseReaction
AND NN O O
MALIGNANCY NN B-AdverseReaction B-AdverseReaction
EXCERPT NN O O
: NN O O
WARNING NN O O
: NN O O
SERIOUS NN B-Severity B-Severity
INFECTIONS NN B-AdverseReaction B-AdverseReaction
AND NN O O
MALIGNANCY NN B-AdverseReaction B-AdverseReaction
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
. NN O O
* NN O O
Serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
leading NN O O
to NN O O
hospitalization NN O O
or NN O O
death NN B-AdverseReaction B-AdverseReaction
including NN O O
tuberculosis NN B-AdverseReaction B-AdverseReaction
( NN O O
TB NN O O
) NN O O
, NN O O
bacterial NN B-AdverseReaction B-AdverseReaction
sepsis NN I-AdverseReaction I-AdverseReaction
invasive NN O O
fungal NN O O
( NN O O
such NN O O
as NN O O
histoplasmosis NN B-AdverseReaction B-AdverseReaction
and NN O O
other NN O O
opportunistic NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
have NN O O
occurred NN O O
in NN O O
patients NN O O
receiving NN O O
SIMPONI NN O O
ARIA NN O O
( NN O O
5.1 NN O O
) NN O O
. NN O O
* NN O O
Discontinue NN O O
SIMPONI NN O O
ARIA NN O O
if NN O O
a NN O O
patient NN O O
develops NN O O
a NN O O
serious NN O O
infection NN O O
or NN O O
sepsis NN O O
( NN O O
5.1 NN O O
) NN O O
. NN O O
* NN O O
Perform NN O O
test NN O O
for NN O O
latent NN O O
TB NN O O
; NN O O
if NN O O
positive NN O O
, NN O O
start NN O O
treatment NN O O
for NN O O
TB NN O O
prior NN O O
to NN O O
starting NN O O
SIMPONI NN O O
ARIA NN O O
( NN O O
5.1 NN O O
) NN O O
. NN O O
* NN O O
Monitor NN O O
all NN O O
patients NN O O
for NN O O
active NN O O
TB NN O O
during NN O O
treatment NN O O
, NN O O
even NN O O
if NN O O
initial NN O O
latent NN O O
TB NN O O
test NN O O
is NN O O
negative NN O O
( NN O O
5.1 NN O O
) NN O O
. NN O O
* NN O O
Lymphoma NN B-AdverseReaction B-AdverseReaction
and NN O O
other NN O O
malignancies NN B-AdverseReaction B-AdverseReaction
some NN O O
fatal NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
children NN O O
and NN O O
adolescent NN O O
patients NN O O
treated NN O O
with NN O O
TNF NN O O
blockers NN O O
, NN O O
of NN O O
which NN O O
SIMPONI NN O O
ARIA NN O O
is NN O O
a NN O O
member NN O O
( NN O O
5.2 NN O O
) NN O O
. NN O O
SERIOUS NN O O
INFECTIONS NN O O
Patients NN O O
treated NN O O
with NN O O
SIMPONI NN O O
ARIA NN O O
are NN O O
at NN O O
increased NN O O
risk NN B-Factor B-Factor
for NN O O
developing NN O O
serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
that NN O O
may NN B-Factor B-Factor
lead NN O O
to NN O O
hospitalization NN O O
or NN O O
death NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
Most NN O O
patients NN O O
who NN O O
developed NN O O
these NN O O
infections NN B-AdverseReaction B-AdverseReaction
were NN O O
taking NN O O
concomitant NN O O
immunosuppressants NN O O
such NN O O
as NN O O
methotrexate NN O O
or NN O O
corticosteroids NN O O
. NN O O
Discontinue NN O O
SIMPONI NN O O
ARIA NN O O
if NN O O
a NN O O
patient NN O O
develops NN O O
a NN O O
serious NN O O
infection NN O O
. NN O O
Reported NN O O
infections NN O O
with NN O O
TNF NN O O
- NN O O
blockers NN O O
, NN O O
of NN O O
which NN O O
SIMPONI NN O O
ARIA NN O O
is NN O O
a NN O O
member NN O O
, NN O O
include NN O O
: NN O O
* NN O O
Active NN B-AdverseReaction B-AdverseReaction
tuberculosis NN I-AdverseReaction I-AdverseReaction
including NN O O
reactivation NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
latent NN I-AdverseReaction I-AdverseReaction
tuberculosis NN I-AdverseReaction I-AdverseReaction
Patients NN O O
with NN O O
tuberculosis NN B-AdverseReaction B-AdverseReaction
have NN O O
frequently NN O O
presented NN O O
with NN O O
disseminated NN O O
or NN O O
extrapulmonary NN O O
disease NN O O
. NN O O
Test NN O O
patients NN O O
for NN O O
latent NN O O
tuberculosis NN O O
before NN O O
SIMPONI NN O O
ARIA NN O O
use NN O O
and NN O O
during NN O O
therapy NN O O
. NN O O
Initiate NN O O
treatment NN O O
for NN O O
latent NN O O
tuberculosis NN O O
prior NN O O
to NN O O
SIMPONI NN O O
ARIA NN O O
use NN O O
. NN O O
* NN O O
Invasive NN B-AdverseReaction B-AdverseReaction
fungal NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
including NN O O
histoplasmosis NN B-AdverseReaction B-AdverseReaction
coccidioidomycosis NN B-AdverseReaction B-AdverseReaction
candidiasis NN B-AdverseReaction B-AdverseReaction
aspergillosis NN B-AdverseReaction B-AdverseReaction
blastomycosis NN B-AdverseReaction B-AdverseReaction
and NN O O
pneumocystosis NN B-AdverseReaction B-AdverseReaction
Patients NN O O
with NN O O
histoplasmosis NN O O
or NN O O
other NN O O
invasive NN O O
fungal NN O O
infections NN O O
may NN O O
present NN O O
with NN O O
disseminated NN O O
, NN O O
rather NN O O
than NN O O
localized NN O O
, NN O O
disease NN O O
. NN O O
Antigen NN O O
and NN O O
antibody NN O O
testing NN O O
for NN O O
histoplasmosis NN O O
may NN O O
be NN O O
negative NN O O
in NN O O
some NN O O
patients NN O O
with NN O O
active NN O O
infection NN O O
. NN O O
Consider NN O O
empiric NN O O
anti NN O O
- NN O O
fungal NN O O
therapy NN O O
in NN O O
patients NN O O
at NN O O
risk NN O O
for NN O O
invasive NN O O
fungal NN O O
infections NN O O
who NN O O
develop NN O O
severe NN O O
systemic NN O O
illness NN O O
. NN O O
* NN O O
Bacterial NN O O
, NN O O
viral NN O O
, NN O O
and NN O O
other NN O O
infections NN B-AdverseReaction B-AdverseReaction
due NN I-AdverseReaction I-AdverseReaction
to NN I-AdverseReaction I-AdverseReaction
opportunistic NN I-AdverseReaction I-AdverseReaction
pathogens NN I-AdverseReaction I-AdverseReaction
including NN O O
Legionella NN O O
and NN O O
Listeria NN O O
. NN O O
Consider NN O O
the NN O O
risks NN O O
and NN O O
benefits NN O O
of NN O O
treatment NN O O
with NN O O
SIMPONI NN O O
ARIA NN O O
prior NN O O
to NN O O
initiating NN O O
therapy NN O O
in NN O O
patients NN O O
with NN O O
chronic NN O O
or NN O O
recurrent NN O O
infection NN O O
. NN O O
Monitor NN O O
patients NN O O
closely NN O O
for NN O O
the NN O O
development NN O O
of NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
infection NN O O
during NN O O
and NN O O
after NN O O
treatment NN O O
with NN O O
SIMPONI NN O O
ARIA NN O O
, NN O O
including NN O O
the NN O O
possible NN O O
development NN O O
of NN O O
tuberculosis NN O O
in NN O O
patients NN O O
who NN O O
tested NN O O
negative NN O O
for NN O O
latent NN O O
tuberculosis NN O O
infection NN O O
prior NN O O
to NN O O
initiating NN O O
therapy NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
MALIGNANCY NN O O
Lymphoma NN B-AdverseReaction B-AdverseReaction
and NN O O
other NN O O
malignancies NN B-AdverseReaction B-AdverseReaction
some NN O O
fatal NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
children NN O O
and NN O O
adolescent NN O O
patients NN O O
treated NN O O
with NN O O
TNF NN O O
blockers NN O O
, NN O O
of NN O O
which NN O O
SIMPONI NN O O
ARIA NN O O
is NN O O
a NN O O
member NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
- NN O O
Do NN O O
not NN O O
start NN O O
SIMPONI NN O O
ARIA NN O O
during NN O O
an NN O O
active NN O O
infection NN O O
. NN O O
If NN O O
an NN O O
infection NN O O
develops NN O O
, NN O O
monitor NN O O
carefully NN O O
, NN O O
and NN O O
stop NN O O
SIMPONI NN O O
ARIA NN O O
if NN O O
infection NN O O
becomes NN O O
serious NN O O
( NN O O
5.1 NN O O
) NN O O
. NN O O
* NN O O
Invasive NN B-AdverseReaction B-AdverseReaction
fungal NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
- NN O O
For NN O O
patients NN O O
who NN O O
develop NN O O
a NN O O
systemic NN O O
illness NN O O
on NN O O
SIMPONI NN O O
ARIA NN O O
, NN O O
consider NN O O
empiric NN O O
antifungal NN O O
therapy NN O O
for NN O O
those NN O O
who NN O O
reside NN O O
in NN O O
or NN O O
travel NN O O
to NN O O
regions NN O O
where NN O O
mycoses NN O O
are NN O O
endemic NN O O
( NN O O
5.1 NN O O
) NN O O
. NN O O
* NN O O
Hepatitis NN B-AdverseReaction B-AdverseReaction
B NN I-AdverseReaction I-AdverseReaction
reactivation NN I-AdverseReaction I-AdverseReaction
- NN O O
Monitor NN O O
HBV NN O O
carriers NN O O
during NN O O
and NN O O
several NN O O
months NN O O
after NN O O
therapy NN O O
. NN O O
If NN O O
reactivation NN O O
occurs NN O O
, NN O O
stop NN O O
SIMPONI NN O O
ARIA NN O O
and NN O O
begin NN O O
anti NN O O
- NN O O
viral NN O O
therapy NN O O
( NN O O
5.1 NN O O
) NN O O
. NN O O
* NN O O
Malignancies NN B-AdverseReaction B-AdverseReaction
- NN O O
More NN O O
cases NN O O
of NN O O
lymphoma NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
observed NN O O
among NN O O
patients NN O O
receiving NN O O
TNF NN O O
- NN O O
blockers NN O O
compared NN O O
with NN O O
patients NN O O
in NN O O
the NN O O
control NN O O
groups NN O O
. NN O O
Cases NN O O
of NN O O
other NN O O
malignancies NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
observed NN O O
among NN O O
patients NN O O
receiving NN O O
TNF NN O O
- NN O O
blockers NN O O
( NN O O
5.2 NN O O
) NN O O
. NN O O
* NN O O
Heart NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
- NN O O
Worsening NN O O
, NN O O
or NN O O
new NN O O
onset NN O O
, NN O O
may NN B-Factor B-Factor
occur NN O O
. NN O O
Stop NN O O
SIMPONI NN O O
ARIA NN O O
if NN O O
new NN O O
or NN O O
worsening NN O O
symptoms NN O O
occur NN O O
( NN O O
5.3 NN O O
) NN O O
. NN O O
* NN O O
Demyelinating NN B-AdverseReaction B-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
exacerbation NN O O
or NN O O
new NN O O
onset NN O O
, NN O O
may NN B-Factor B-Factor
occur NN O O
( NN O O
5.4 NN O O
) NN O O
. NN O O
* NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
Serious NN B-Severity B-Severity
systemic NN B-AdverseReaction B-AdverseReaction
hypersensitivity NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
may NN B-Factor B-Factor
occur NN O O
( NN O O
5.10 NN O O
) NN O O
. NN O O
5.1 NN O O
Serious NN O O
Infections NN O O
Patients NN O O
treated NN O O
with NN O O
SIMPONI NN O O
ARIA NN O O
are NN O O
at NN O O
increased NN O O
risk NN B-Factor B-Factor
for NN O O
developing NN O O
serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
involving NN O O
various NN O O
organ NN O O
systems NN O O
and NN O O
sites NN O O
that NN O O
may NN B-Factor B-Factor
lead NN O O
to NN O O
hospitalization NN O O
or NN O O
death NN B-AdverseReaction B-AdverseReaction
Opportunistic NN B-AdverseReaction B-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
due NN O O
to NN O O
bacterial NN O O
, NN O O
mycobacterial NN O O
, NN O O
invasive NN O O
fungal NN O O
, NN O O
viral NN O O
, NN O O
or NN O O
parasitic NN O O
organisms NN O O
including NN O O
aspergillosis NN B-AdverseReaction B-AdverseReaction
blastomycosis NN B-AdverseReaction B-AdverseReaction
candidiasis NN B-AdverseReaction B-AdverseReaction
coccidioidomycosis NN B-AdverseReaction B-AdverseReaction
histoplasmosis NN B-AdverseReaction B-AdverseReaction
legionellosis NN B-AdverseReaction B-AdverseReaction
listeriosis NN B-AdverseReaction B-AdverseReaction
pneumocystosis NN B-AdverseReaction B-AdverseReaction
and NN O O
tuberculosis NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
with NN O O
TNF NN B-DrugClass B-DrugClass
- NN I-DrugClass I-DrugClass
blockers NN I-DrugClass I-DrugClass
Patients NN O O
have NN O O
frequently NN O O
presented NN O O
with NN O O
disseminated NN O O
rather NN O O
than NN O O
localized NN O O
disease NN O O
. NN O O
The NN O O
concomitant NN O O
use NN O O
of NN O O
a NN O O
TNF NN O O
- NN O O
blocker NN O O
and NN O O
abatacept NN O O
or NN O O
anakinra NN O O
was NN O O
associated NN O O
with NN O O
a NN O O
higher NN O O
risk NN O O
of NN O O
serious NN O O
infections NN O O
; NN O O
therefore NN O O
, NN O O
the NN O O
concomitant NN O O
use NN O O
of NN O O
SIMPONI NN O O
ARIA NN O O
and NN O O
these NN O O
biologic NN O O
products NN O O
is NN O O
not NN O O
recommended NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
, NN O O
5.6 NN O O
) NN O O
and NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.2 NN O O
) NN O O
] NN O O
. NN O O
Treatment NN O O
with NN O O
SIMPONI NN O O
ARIA NN O O
should NN O O
not NN O O
be NN O O
initiated NN O O
in NN O O
patients NN O O
with NN O O
an NN O O
active NN O O
infection NN O O
, NN O O
including NN O O
clinically NN O O
important NN O O
localized NN O O
infections NN O O
. NN O O
Patients NN O O
greater NN O O
than NN O O
65 NN O O
years NN O O
of NN O O
age NN O O
, NN O O
patients NN O O
with NN O O
co NN O O
- NN O O
morbid NN O O
conditions NN O O
and/or NN O O
patients NN O O
taking NN O O
concomitant NN O O
immunosuppressants NN O O
such NN O O
as NN O O
corticosteroids NN O O
or NN O O
methotrexate NN O O
may NN O O
be NN O O
at NN O O
greater NN O O
risk NN O O
of NN O O
infection NN O O
. NN O O
Consider NN O O
the NN O O
risks NN O O
and NN O O
benefits NN O O
of NN O O
treatment NN O O
prior NN O O
to NN O O
initiating NN O O
SIMPONI NN O O
ARIA NN O O
in NN O O
patients NN O O
: NN O O
* NN O O
with NN O O
chronic NN O O
or NN O O
recurrent NN O O
infection NN O O
; NN O O
* NN O O
who NN O O
have NN O O
been NN O O
exposed NN O O
to NN O O
tuberculosis NN O O
; NN O O
* NN O O
with NN O O
a NN O O
history NN O O
of NN O O
an NN O O
opportunistic NN O O
infection NN O O
; NN O O
* NN O O
who NN O O
have NN O O
resided NN O O
or NN O O
traveled NN O O
in NN O O
areas NN O O
of NN O O
endemic NN O O
tuberculosis NN O O
or NN O O
endemic NN O O
mycoses NN O O
, NN O O
such NN O O
as NN O O
histoplasmosis NN O O
, NN O O
coccidioidomycosis NN O O
, NN O O
or NN O O
blastomycosis NN O O
; NN O O
or NN O O
* NN O O
with NN O O
underlying NN O O
conditions NN O O
that NN O O
may NN O O
predispose NN O O
them NN O O
to NN O O
infection NN O O
. NN O O
Monitoring NN O O
Closely NN O O
monitor NN O O
patients NN O O
for NN O O
the NN O O
development NN O O
of NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
infection NN O O
during NN O O
and NN O O
after NN O O
treatment NN O O
with NN O O
SIMPONI NN O O
ARIA. NN O O
Discontinue NN O O
SIMPONI NN O O
ARIA NN O O
if NN O O
a NN O O
patient NN O O
develops NN O O
a NN O O
serious NN O O
infection NN O O
, NN O O
an NN O O
opportunistic NN O O
infection NN O O
, NN O O
or NN O O
sepsis NN O O
. NN O O
For NN O O
patients NN O O
who NN O O
develop NN O O
a NN O O
new NN O O
infection NN O O
during NN O O
treatment NN O O
with NN O O
SIMPONI NN O O
ARIA NN O O
, NN O O
perform NN O O
a NN O O
prompt NN O O
and NN O O
complete NN O O
diagnostic NN O O
workup NN O O
appropriate NN O O
for NN O O
an NN O O
immunocompromised NN O O
patient NN O O
and NN O O
initiate NN O O
appropriate NN O O
antimicrobial NN O O
therapy NN O O
and NN O O
closely NN O O
monitor NN O O
them NN O O
. NN O O
Tuberculosis NN O O
Cases NN O O
of NN O O
reactivation NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
tuberculosis NN I-AdverseReaction I-AdverseReaction
or NN O O
new NN B-AdverseReaction B-AdverseReaction
tuberculosis NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
observed NN O O
in NN O O
patients NN O O
receiving NN O O
TNF NN O O
- NN O O
blockers NN O O
, NN O O
including NN O O
patients NN O O
who NN O O
have NN O O
previously NN O O
received NN O O
treatment NN O O
for NN O O
latent NN O O
or NN O O
active NN O O
tuberculosis NN O O
. NN O O
Evaluate NN O O
patients NN O O
for NN O O
tuberculosis NN O O
risk NN O O
factors NN O O
and NN O O
test NN O O
for NN O O
latent NN O O
infection NN O O
prior NN O O
to NN O O
initiating NN O O
SIMPONI NN O O
ARIA NN O O
and NN O O
periodically NN O O
during NN O O
therapy NN O O
. NN O O
Treatment NN O O
of NN O O
latent NN O O
tuberculosis NN O O
infection NN O O
prior NN O O
to NN O O
therapy NN O O
with NN O O
TNF NN O O
- NN O O
blockers NN O O
has NN O O
been NN O O
shown NN O O
to NN O O
reduce NN O O
the NN O O
risk NN O O
of NN O O
tuberculosis NN O O
reactivation NN O O
during NN O O
therapy NN O O
. NN O O
Prior NN O O
to NN O O
initiating NN O O
SIMPONI NN O O
ARIA NN O O
, NN O O
assess NN O O
if NN O O
treatment NN O O
for NN O O
latent NN O O
tuberculosis NN O O
is NN O O
needed NN O O
; NN O O
An NN O O
induration NN O O
of NN O O
5 NN O O
mm NN O O
or NN O O
greater NN O O
is NN O O
a NN O O
positive NN O O
tuberculin NN O O
skin NN O O
test NN O O
, NN O O
even NN O O
for NN O O
patients NN O O
previously NN O O
vaccinated NN O O
with NN O O
Bacille NN O O
Calmette NN O O
- NN O O
Guerin NN O O
( NN O O
BCG NN O O
) NN O O
. NN O O
Consider NN O O
anti NN O O
- NN O O
tuberculosis NN O O
therapy NN O O
prior NN O O
to NN O O
initiation NN O O
of NN O O
SIMPONI NN O O
ARIA NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
past NN O O
history NN O O
of NN O O
latent NN O O
or NN O O
active NN O O
tuberculosis NN O O
in NN O O
whom NN O O
an NN O O
adequate NN O O
course NN O O
of NN O O
treatment NN O O
can NN O O
not NN O O
be NN O O
confirmed NN O O
, NN O O
and NN O O
for NN O O
patients NN O O
with NN O O
a NN O O
negative NN O O
test NN O O
for NN O O
latent NN O O
tuberculosis NN O O
but NN O O
having NN O O
risk NN O O
factors NN O O
for NN O O
tuberculosis NN O O
infection NN O O
. NN O O
Consultation NN O O
with NN O O
a NN O O
physician NN O O
with NN O O
expertise NN O O
in NN O O
the NN O O
treatment NN O O
of NN O O
tuberculosis NN O O
is NN O O
recommended NN O O
to NN O O
aid NN O O
in NN O O
the NN O O
decision NN O O
whether NN O O
initiating NN O O
anti NN O O
- NN O O
tuberculosis NN O O
therapy NN O O
is NN O O
appropriate NN O O
for NN O O
an NN O O
individual NN O O
patient NN O O
. NN O O
Cases NN O O
of NN O O
active NN O O
tuberculosis NN O O
have NN O O
occurred NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
the NN O O
subcutaneous NN O O
formulation NN O O
of NN O O
golimumab NN O O
during NN O O
and NN O O
after NN O O
treatment NN O O
for NN O O
latent NN O O
tuberculosis NN O O
. NN O O
Monitor NN O O
patients NN O O
for NN O O
the NN O O
development NN O O
of NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
tuberculosis NN O O
including NN O O
patients NN O O
who NN O O
tested NN O O
negative NN O O
for NN O O
latent NN O O
tuberculosis NN O O
infection NN O O
prior NN O O
to NN O O
initiating NN O O
therapy NN O O
, NN O O
patients NN O O
who NN O O
are NN O O
on NN O O
treatment NN O O
for NN O O
latent NN O O
tuberculosis NN O O
, NN O O
or NN O O
patients NN O O
who NN O O
were NN O O
previously NN O O
treated NN O O
for NN O O
tuberculosis NN O O
infection NN O O
. NN O O
Consider NN O O
tuberculosis NN O O
in NN O O
the NN O O
differential NN O O
diagnosis NN O O
in NN O O
patients NN O O
who NN O O
develop NN O O
a NN O O
new NN O O
infection NN O O
during NN O O
SIMPONI NN O O
ARIA NN O O
treatment NN O O
, NN O O
especially NN O O
in NN O O
patients NN O O
who NN O O
have NN O O
previously NN O O
or NN O O
recently NN O O
traveled NN O O
to NN O O
countries NN O O
with NN O O
a NN O O
high NN O O
prevalence NN O O
of NN O O
tuberculosis NN O O
, NN O O
or NN O O
who NN O O
have NN O O
had NN O O
close NN O O
contact NN O O
with NN O O
a NN O O
person NN O O
with NN O O
active NN O O
tuberculosis NN O O
. NN O O
Invasive NN O O
Fungal NN O O
Infections NN O O
If NN O O
patients NN O O
develop NN O O
a NN O O
serious NN O O
systemic NN O O
illness NN O O
and NN O O
they NN O O
reside NN O O
or NN O O
travel NN O O
in NN O O
regions NN O O
where NN O O
mycoses NN O O
are NN O O
endemic NN O O
, NN O O
consider NN O O
invasive NN O O
fungal NN O O
infection NN O O
in NN O O
the NN O O
differential NN O O
diagnosis NN O O
. NN O O
Consider NN O O
appropriate NN O O
empiric NN O O
antifungal NN O O
therapy NN O O
and NN O O
take NN O O
into NN O O
account NN O O
both NN O O
the NN O O
risk NN O O
for NN O O
severe NN O O
fungal NN O O
infection NN O O
and NN O O
the NN O O
risks NN O O
of NN O O
antifungal NN O O
therapy NN O O
while NN O O
a NN O O
diagnostic NN O O
workup NN O O
is NN O O
being NN O O
performed NN O O
. NN O O
Antigen NN O O
and NN O O
antibody NN O O
testing NN O O
for NN O O
histoplasmosis NN O O
may NN O O
be NN O O
negative NN O O
in NN O O
some NN O O
patients NN O O
with NN O O
active NN O O
infection NN O O
. NN O O
To NN O O
aid NN O O
in NN O O
the NN O O
management NN O O
of NN O O
such NN O O
patients NN O O
, NN O O
consider NN O O
consultation NN O O
with NN O O
a NN O O
physician NN O O
with NN O O
expertise NN O O
in NN O O
the NN O O
diagnosis NN O O
and NN O O
treatment NN O O
of NN O O
invasive NN O O
fungal NN O O
infections NN O O
. NN O O
Hepatitis NN O O
B NN O O
Virus NN O O
Reactivation NN O O
The NN O O
use NN O O
of NN O O
TNF NN O O
- NN O O
blockers NN O O
, NN O O
of NN O O
which NN O O
SIMPONI NN O O
ARIA NN O O
is NN O O
a NN O O
member NN O O
, NN O O
has NN O O
been NN O O
associated NN O O
with NN O O
reactivation NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
hepatitis NN I-AdverseReaction I-AdverseReaction
B NN I-AdverseReaction I-AdverseReaction
virus NN I-AdverseReaction I-AdverseReaction
( NN O O
HBV NN O O
) NN O O
in NN O O
patients NN O O
who NN O O
are NN O O
chronic NN O O
hepatitis NN O O
B NN O O
carriers NN O O
( NN O O
i.e. NN O O
, NN O O
surface NN O O
antigen NN O O
positive NN O O
) NN O O
. NN O O
In NN O O
some NN O O
instances NN O O
, NN O O
HBV NN B-AdverseReaction B-AdverseReaction
reactivation NN I-AdverseReaction I-AdverseReaction
occurring NN O O
in NN O O
conjunction NN O O
with NN O O
TNF NN O O
- NN O O
blocker NN O O
therapy NN O O
has NN O O
been NN O O
fatal NN B-AdverseReaction B-AdverseReaction
The NN O O
majority NN O O
of NN O O
these NN O O
reports NN O O
have NN O O
occurred NN O O
in NN O O
patients NN O O
who NN O O
received NN O O
concomitant NN O O
immunosuppressants NN O O
. NN O O
All NN O O
patients NN O O
should NN O O
be NN O O
tested NN O O
for NN O O
HBV NN O O
infection NN O O
before NN O O
initiating NN O O
TNF NN O O
- NN O O
blocker NN O O
therapy NN O O
. NN O O
For NN O O
patients NN O O
who NN O O
test NN O O
positive NN O O
for NN O O
hepatitis NN O O
B NN O O
surface NN O O
antigen NN O O
, NN O O
consultation NN O O
with NN O O
a NN O O
physician NN O O
with NN O O
expertise NN O O
in NN O O
the NN O O
treatment NN O O
of NN O O
hepatitis NN O O
B NN O O
is NN O O
recommended NN O O
before NN O O
initiating NN O O
TNF NN O O
- NN O O
blocker NN O O
therapy NN O O
. NN O O
The NN O O
risks NN O O
and NN O O
benefits NN O O
of NN O O
treatment NN O O
should NN O O
be NN O O
considered NN O O
prior NN O O
to NN O O
prescribing NN O O
TNF NN O O
- NN O O
blockers NN O O
, NN O O
including NN O O
SIMPONI NN O O
ARIA NN O O
, NN O O
to NN O O
patients NN O O
who NN O O
are NN O O
carriers NN O O
of NN O O
HBV. NN O O
Adequate NN O O
data NN O O
are NN O O
not NN O O
available NN O O
on NN O O
whether NN O O
anti NN O O
- NN O O
viral NN O O
therapy NN O O
can NN O O
reduce NN O O
the NN O O
risk NN O O
of NN O O
HBV NN O O
reactivation NN O O
in NN O O
HBV NN O O
carriers NN O O
who NN O O
are NN O O
treated NN O O
with NN O O
TNF NN O O
- NN O O
blockers NN O O
. NN O O
Patients NN O O
who NN O O
are NN O O
carriers NN O O
of NN O O
HBV NN O O
and NN O O
require NN O O
treatment NN O O
with NN O O
TNF NN O O
- NN O O
blockers NN O O
should NN O O
be NN O O
closely NN O O
monitored NN O O
for NN O O
clinical NN O O
and NN O O
laboratory NN O O
signs NN O O
of NN O O
active NN O O
HBV NN O O
infection NN O O
throughout NN O O
therapy NN O O
and NN O O
for NN O O
several NN O O
months NN O O
following NN O O
termination NN O O
of NN O O
therapy NN O O
. NN O O
In NN O O
patients NN O O
who NN O O
develop NN O O
HBV NN O O
reactivation NN O O
, NN O O
TNF NN O O
- NN O O
blockers NN O O
should NN O O
be NN O O
stopped NN O O
and NN O O
antiviral NN O O
therapy NN O O
with NN O O
appropriate NN O O
supportive NN O O
treatment NN O O
should NN O O
be NN O O
initiated NN O O
. NN O O
The NN O O
safety NN O O
of NN O O
resuming NN O O
TNF NN O O
- NN O O
blockers NN O O
after NN O O
HBV NN O O
reactivation NN O O
has NN O O
been NN O O
controlled NN O O
is NN O O
not NN O O
known NN O O
. NN O O
Therefore NN O O
, NN O O
prescribers NN O O
should NN O O
exercise NN O O
caution NN O O
when NN O O
considering NN O O
resumption NN O O
of NN O O
TNF NN O O
- NN O O
blockers NN O O
in NN O O
this NN O O
situation NN O O
and NN O O
monitor NN O O
patients NN O O
closely NN O O
. NN O O
5.2 NN O O
Malignancies NN O O
Malignancies NN O O
in NN O O
Pediatric NN O O
Patients NN O O
Malignancies NN B-AdverseReaction B-AdverseReaction
some NN O O
fatal NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
among NN O O
children NN O O
, NN O O
adolescents NN O O
, NN O O
and NN O O
young NN O O
adults NN O O
who NN O O
received NN O O
treatment NN O O
with NN O O
TNF NN O O
- NN O O
blocking NN O O
agents NN O O
( NN O O
initiation NN O O
of NN O O
therapy NN O O
< NN O O
= NN O O
18 NN O O
years NN O O
of NN O O
age NN O O
) NN O O
, NN O O
of NN O O
which NN O O
SIMPONI NN O O
ARIA NN O O
is NN O O
a NN O O
member NN O O
. NN O O
Approximately NN O O
half NN O O
the NN O O
cases NN O O
were NN O O
lymphomas NN B-AdverseReaction B-AdverseReaction
including NN O O
Hodgkin NN O O
's NN O O
and NN O O
non NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Hodgkin NN I-AdverseReaction I-AdverseReaction
's NN I-AdverseReaction I-AdverseReaction
lymphoma NN I-AdverseReaction I-AdverseReaction
The NN O O
other NN O O
cases NN O O
represented NN O O
a NN O O
variety NN O O
of NN O O
malignancies NN B-AdverseReaction B-AdverseReaction
including NN O O
rare NN B-AdverseReaction B-AdverseReaction
malignancies NN I-AdverseReaction I-AdverseReaction
that NN O O
are NN O O
usually NN O O
associated NN O O
with NN O O
immunosuppression NN B-AdverseReaction B-AdverseReaction
and NN O O
malignancies NN O O
that NN O O
are NN O O
not NN O O
usually NN O O
observed NN O O
in NN O O
children NN O O
and NN O O
adolescents NN O O
. NN O O
The NN O O
malignancies NN O O
occurred NN O O
after NN O O
a NN O O
median NN O O
of NN O O
30 NN O O
months NN O O
( NN O O
range NN O O
1 NN O O
to NN O O
84 NN O O
months NN O O
) NN O O
after NN O O
the NN O O
first NN O O
dose NN O O
of NN O O
TNF NN O O
- NN O O
blocker NN O O
therapy NN O O
. NN O O
Most NN O O
of NN O O
the NN O O
patients NN O O
were NN O O
receiving NN O O
concomitant NN O O
immunosuppressants NN O O
. NN O O
These NN O O
cases NN O O
were NN O O
reported NN O O
post NN O O
- NN O O
marketing NN O O
and NN O O
are NN O O
derived NN O O
from NN O O
a NN O O
variety NN O O
of NN O O
sources NN O O
, NN O O
including NN O O
registries NN O O
and NN O O
spontaneous NN O O
post NN O O
- NN O O
marketing NN O O
reports NN O O
. NN O O
Use NN O O
of NN O O
SIMPONI NN O O
ARIA NN O O
in NN O O
patients NN O O
under NN O O
18 NN O O
years NN O O
of NN O O
age NN O O
has NN O O
not NN O O
been NN O O
established NN O O
. NN O O
Malignancies NN O O
in NN O O
Adult NN O O
Patients NN O O
The NN O O
risks NN O O
and NN O O
benefits NN O O
of NN O O
TNF NN O O
- NN O O
blocker NN O O
treatment NN O O
including NN O O
SIMPONI NN O O
ARIA NN O O
should NN O O
be NN O O
considered NN O O
prior NN O O
to NN O O
initiating NN O O
therapy NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
known NN O O
malignancy NN O O
other NN O O
than NN O O
a NN O O
successfully NN O O
treated NN O O
non NN O O
- NN O O
melanoma NN O O
skin NN O O
cancer NN O O
( NN O O
NMSC NN O O
) NN O O
or NN O O
when NN O O
considering NN O O
continuing NN O O
a NN O O
TNF NN O O
- NN O O
blocker NN O O
in NN O O
patients NN O O
who NN O O
develop NN O O
a NN O O
malignancy NN O O
. NN O O
In NN O O
the NN O O
controlled NN O O
portions NN O O
of NN O O
clinical NN O O
trials NN O O
of NN O O
TNF NN O O
- NN O O
blockers NN O O
including NN O O
the NN O O
subcutaneous NN O O
formulation NN O O
of NN O O
golimumab NN O O
more NN O O
cases NN O O
of NN O O
lymphoma NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
observed NN O O
among NN O O
patients NN O O
receiving NN O O
anti NN O O
- NN O O
TNF NN O O
treatment NN O O
compared NN O O
with NN O O
patients NN O O
in NN O O
the NN O O
control NN O O
groups NN O O
. NN O O
Patients NN O O
with NN O O
RA NN O O
and NN O O
other NN O O
chronic NN O O
inflammatory NN O O
diseases NN O O
, NN O O
particularly NN O O
patients NN O O
with NN O O
highly NN O O
active NN O O
disease NN O O
and/or NN O O
chronic NN O O
exposure NN O O
to NN O O
immunosuppressant NN O O
therapies NN O O
, NN O O
may NN O O
be NN O O
at NN O O
higher NN O O
risk NN B-Factor B-Factor
( NN O O
up NN O O
to NN O O
several NN O O
fold NN O O
) NN O O
than NN O O
the NN O O
general NN O O
population NN O O
for NN O O
the NN O O
development NN O O
of NN O O
lymphoma NN B-AdverseReaction B-AdverseReaction
even NN O O
in NN O O
the NN O O
absence NN O O
of NN O O
TNF NN O O
- NN O O
blocking NN O O
therapy NN O O
. NN O O
Cases NN O O
of NN O O
acute NN O O
and NN O O
chronic NN B-AdverseReaction B-AdverseReaction
leukemia NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
with NN O O
post NN O O
- NN O O
marketing NN O O
TNF NN O O
- NN O O
blocker NN O O
use NN O O
in NN O O
rheumatoid NN O O
arthritis NN O O
and NN O O
other NN O O
indications NN O O
. NN O O
Even NN O O
in NN O O
the NN O O
absence NN O O
of NN O O
TNF NN O O
- NN O O
blocker NN O O
therapy NN O O
, NN O O
patients NN O O
with NN O O
rheumatoid NN O O
arthritis NN O O
may NN O O
be NN O O
at NN O O
a NN O O
higher NN O O
risk NN O O
( NN O O
approximately NN O O
2-fold NN O O
) NN O O
than NN O O
the NN O O
general NN O O
population NN O O
for NN O O
the NN O O
development NN O O
of NN O O
leukemia NN O O
. NN O O
Rare NN O O
post NN O O
- NN O O
marketing NN O O
cases NN O O
of NN O O
hepatosplenic NN B-AdverseReaction B-AdverseReaction
T NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
lymphoma NN I-AdverseReaction I-AdverseReaction
( NN O O
HSTCL NN O O
) NN O O
have NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
TNF NN O O
- NN O O
blocking NN O O
agents NN O O
. NN O O
This NN O O
rare NN B-AdverseReaction B-AdverseReaction
type NN I-AdverseReaction I-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
T NN I-AdverseReaction I-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
lymphoma NN I-AdverseReaction I-AdverseReaction
has NN O O
a NN O O
very NN O O
aggressive NN O O
disease NN O O
course NN O O
and NN O O
is NN O O
usually NN O O
fatal NN B-AdverseReaction B-AdverseReaction
Nearly NN O O
all NN O O
of NN O O
the NN O O
reported NN O O
TNF NN O O
- NN O O
blocker NN O O
associated NN O O
cases NN O O
have NN O O
occurred NN O O
in NN O O
patients NN O O
with NN O O
Crohn NN O O
's NN O O
disease NN O O
or NN O O
ulcerative NN O O
colitis NN O O
. NN O O
The NN O O
majority NN O O
were NN O O
in NN O O
adolescent NN O O
and NN O O
young NN O O
adult NN O O
males NN O O
. NN O O
Almost NN O O
all NN O O
these NN O O
patients NN O O
had NN O O
received NN O O
treatment NN O O
with NN O O
azathioprine NN O O
( NN O O
AZA NN O O
) NN O O
or NN O O
6-mercaptopurine NN O O
( NN O O
6-MP NN O O
) NN O O
concomitantly NN O O
with NN O O
a NN O O
TNF NN O O
- NN O O
blocker NN O O
at NN O O
or NN O O
prior NN O O
to NN O O
diagnosis NN O O
. NN O O
A NN O O
risk NN O O
for NN O O
the NN O O
development NN O O
for NN O O
hepatosplenic NN O O
T NN O O
- NN O O
cell NN O O
lymphoma NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
TNF NN O O
- NN O O
blockers NN O O
can NN O O
not NN O O
be NN O O
excluded NN O O
. NN O O
Melanoma NN B-AdverseReaction B-AdverseReaction
has NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
TNF NN O O
- NN O O
blocking NN O O
agents NN O O
, NN O O
including NN O O
the NN O O
subcutaneous NN O O
formulation NN O O
of NN O O
golimumab NN O O
. NN O O
Merkel NN B-AdverseReaction B-AdverseReaction
cell NN I-AdverseReaction I-AdverseReaction
carcinoma NN I-AdverseReaction I-AdverseReaction
has NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
TNF NN O O
- NN O O
blocking NN O O
agents NN O O
. NN O O
Periodic NN O O
skin NN O O
examination NN O O
is NN O O
recommended NN O O
for NN O O
all NN O O
patients NN O O
, NN O O
particularly NN O O
those NN O O
with NN O O
risk NN O O
factors NN O O
for NN O O
skin NN O O
cancer NN O O
. NN O O
In NN O O
controlled NN O O
trials NN O O
of NN O O
other NN O O
TNF NN O O
- NN O O
blockers NN O O
in NN O O
patients NN O O
at NN O O
higher NN O O
risk NN O O
for NN O O
malignancies NN O O
( NN O O
e.g. NN O O
, NN O O
patients NN O O
with NN O O
COPD NN O O
, NN O O
patients NN O O
with NN O O
Wegener NN O O
's NN O O
granulomatosis NN O O
treated NN O O
with NN O O
concomitant NN O O
cyclophosphamide NN O O
) NN O O
a NN O O
greater NN O O
portion NN O O
of NN O O
malignancies NN B-AdverseReaction B-AdverseReaction
occurred NN O O
in NN O O
the NN O O
TNF NN O O
- NN O O
blocker NN O O
group NN O O
compared NN O O
to NN O O
the NN O O
controlled NN O O
group NN O O
. NN O O
In NN O O
an NN O O
exploratory NN O O
clinical NN O O
trial NN O O
evaluating NN O O
the NN O O
use NN O O
of NN O O
the NN O O
subcutaneous NN O O
formulation NN O O
of NN O O
golimumab NN O O
in NN O O
patients NN O O
with NN O O
severe NN O O
persistent NN O O
asthma NN O O
, NN O O
more NN O O
patients NN O O
treated NN O O
with NN O O
golimumab NN O O
reported NN O O
malignancies NN B-AdverseReaction B-AdverseReaction
compared NN O O
with NN O O
control NN O O
patients NN O O
. NN O O
The NN O O
significance NN O O
of NN O O
this NN O O
finding NN O O
is NN O O
unknown NN O O
. NN O O
During NN O O
the NN O O
controlled NN O O
portion NN O O
of NN O O
the NN O O
Phase NN O O
3 NN O O
trial NN O O
in NN O O
RA NN O O
for NN O O
SIMPONI NN O O
ARIA NN O O
, NN O O
the NN O O
incidence NN O O
of NN O O
malignancies NN B-AdverseReaction B-AdverseReaction
other NN O O
than NN O O
lymphoma NN O O
and NN O O
NMSC NN O O
per NN O O
100-patient NN O O
- NN O O
years NN O O
of NN O O
follow NN O O
- NN O O
up NN O O
was NN O O
0.56 NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
: NN O O
0.01 NN O O
, NN O O
3.11 NN O O
) NN O O
in NN O O
the NN O O
SIMPONI NN O O
ARIA NN O O
group NN O O
compared NN O O
with NN O O
an NN O O
incidence NN O O
of NN O O
0 NN O O
( NN O O
95 NN O O
% NN O O
CI NN O O
: NN O O
0.00 NN O O
, NN O O
3.79 NN O O
) NN O O
in NN O O
the NN O O
placebo NN O O
group NN O O
. NN O O
5.3 NN O O
Congestive NN O O
Heart NN O O
Failure NN O O
Cases NN O O
of NN O O
worsening NN B-AdverseReaction B-AdverseReaction
congestive NN I-AdverseReaction I-AdverseReaction
heart NN I-AdverseReaction I-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
( NN O O
CHF NN O O
) NN O O
and NN O O
new NN B-AdverseReaction B-AdverseReaction
onset NN I-AdverseReaction I-AdverseReaction
CHF NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
with NN O O
TNF NN O O
- NN O O
blockers NN O O
, NN O O
including NN O O
SIMPONI NN O O
ARIA. NN O O
In NN O O
several NN O O
exploratory NN O O
trials NN O O
of NN O O
other NN O O
TNF NN O O
- NN O O
blockers NN O O
in NN O O
the NN O O
treatment NN O O
of NN O O
CHF NN O O
, NN O O
there NN O O
were NN O O
greater NN O O
proportions NN O O
of NN O O
TNF NN O O
- NN O O
blocker NN O O
treated NN O O
patients NN O O
who NN O O
had NN O O
CHF NN B-AdverseReaction B-AdverseReaction
exacerbations NN I-AdverseReaction I-AdverseReaction
requiring NN O O
hospitalization NN O O
or NN O O
increased NN B-AdverseReaction B-AdverseReaction
mortality NN I-AdverseReaction I-AdverseReaction
SIMPONI NN O O
ARIA NN O O
has NN O O
not NN O O
been NN O O
studied NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
CHF NN O O
and NN O O
SIMPONI NN O O
ARIA NN O O
should NN O O
be NN O O
used NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
with NN O O
CHF. NN O O
If NN O O
a NN O O
decision NN O O
is NN O O
made NN O O
to NN O O
administer NN O O
SIMPONI NN O O
ARIA NN O O
to NN O O
RA NN O O
patients NN O O
with NN O O
CHF NN O O
, NN O O
these NN O O
patients NN O O
should NN O O
be NN O O
closely NN O O
monitored NN O O
during NN O O
therapy NN O O
, NN O O
and NN O O
SIMPONI NN O O
ARIA NN O O
should NN O O
be NN O O
discontinued NN O O
if NN O O
new NN O O
or NN O O
worsening NN O O
symptoms NN O O
of NN O O
CHF NN O O
appear NN O O
. NN O O
5.4 NN O O
Demyelinating NN O O
Disorders NN O O
Use NN O O
of NN O O
TNF NN O O
- NN O O
blockers NN O O
, NN O O
of NN O O
which NN O O
SIMPONI NN O O
ARIA NN O O
is NN O O
a NN O O
member NN O O
, NN O O
has NN O O
been NN O O
associated NN O O
with NN O O
rare NN O O
cases NN O O
of NN O O
new NN O O
onset NN O O
or NN O O
exacerbation NN O O
of NN O O
central NN O O
nervous NN O O
system NN O O
( NN O O
CNS NN O O
) NN O O
demyelinating NN O O
disorders NN O O
, NN O O
including NN O O
multiple NN B-AdverseReaction B-AdverseReaction
sclerosis NN I-AdverseReaction I-AdverseReaction
( NN O O
MS NN O O
) NN O O
and NN O O
peripheral NN B-AdverseReaction B-AdverseReaction
demyelinating NN I-AdverseReaction I-AdverseReaction
disorders NN I-AdverseReaction I-AdverseReaction
including NN O O
Guillain NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Barre NN I-AdverseReaction I-AdverseReaction
syndrome NN I-AdverseReaction I-AdverseReaction
Cases NN O O
of NN O O
central NN B-AdverseReaction B-AdverseReaction
demyelination NN I-AdverseReaction I-AdverseReaction
MS NN B-AdverseReaction B-AdverseReaction
optic NN B-AdverseReaction B-AdverseReaction
neuritis NN I-AdverseReaction I-AdverseReaction
and NN O O
peripheral NN B-AdverseReaction B-AdverseReaction
demyelinating NN I-AdverseReaction I-AdverseReaction
polyneuropathy NN I-AdverseReaction I-AdverseReaction
have NN O O
rarely NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
the NN O O
subcutaneous NN O O
formulation NN O O
of NN O O
golimumab NN O O
. NN O O
Prescribers NN O O
should NN O O
exercise NN O O
caution NN O O
in NN O O
considering NN O O
the NN O O
use NN O O
of NN O O
TNF NN O O
- NN O O
blockers NN O O
, NN O O
including NN O O
SIMPONI NN O O
ARIA NN O O
, NN O O
in NN O O
patients NN O O
with NN O O
central NN O O
or NN O O
peripheral NN O O
nervous NN O O
system NN O O
demyelinating NN O O
disorders NN O O
. NN O O
Discontinuation NN O O
of NN O O
SIMPONI NN O O
ARIA NN O O
should NN O O
be NN O O
considered NN O O
if NN O O
these NN O O
disorders NN O O
develop NN O O
. NN O O
5.5 NN O O
Use NN O O
with NN O O
Abatacept NN O O
In NN O O
controlled NN O O
trials NN O O
, NN O O
the NN O O
concurrent NN O O
administration NN O O
of NN O O
another NN O O
TNF NN O O
- NN O O
blocker NN O O
and NN O O
abatacept NN O O
was NN O O
associated NN O O
with NN O O
a NN O O
greater NN O O
proportion NN O O
of NN O O
serious NN O O
infections NN O O
than NN O O
the NN O O
use NN O O
of NN O O
a NN O O
TNF NN O O
- NN O O
blocker NN O O
alone NN O O
; NN O O
and NN O O
the NN O O
combination NN O O
therapy NN O O
, NN O O
compared NN O O
to NN O O
the NN O O
use NN O O
of NN O O
a NN O O
TNF NN O O
- NN O O
blocker NN O O
alone NN O O
, NN O O
has NN O O
not NN O O
demonstrated NN O O
improved NN O O
clinical NN O O
benefit NN O O
in NN O O
the NN O O
treatment NN O O
of NN O O
RA. NN O O
Therefore NN O O
, NN O O
the NN O O
combination NN O O
of NN O O
TNF NN O O
- NN O O
blockers NN O O
including NN O O
SIMPONI NN O O
ARIA NN O O
and NN O O
abatacept NN O O
is NN O O
not NN O O
recommended NN O O
[ NN O O
see NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.2 NN O O
) NN O O
] NN O O
. NN O O
5.6 NN O O
Use NN O O
with NN O O
Anakinra NN O O
Concurrent NN O O
administration NN O O
of NN O O
anakinra NN O O
( NN O O
an NN O O
interleukin-1 NN O O
antagonist NN O O
) NN O O
and NN O O
another NN O O
TNF NN O O
- NN O O
blocker NN O O
, NN O O
was NN O O
associated NN O O
with NN O O
a NN O O
greater NN O O
portion NN O O
of NN O O
serious NN O O
infections NN O O
and NN O O
neutropenia NN O O
and NN O O
no NN O O
additional NN O O
benefits NN O O
compared NN O O
with NN O O
the NN O O
TNF NN O O
- NN O O
blocker NN O O
alone NN O O
. NN O O
Therefore NN O O
, NN O O
the NN O O
combination NN O O
of NN O O
anakinra NN O O
with NN O O
TNF NN O O
- NN O O
blockers NN O O
, NN O O
including NN O O
SIMPONI NN O O
ARIA NN O O
, NN O O
is NN O O
not NN O O
recommended NN O O
[ NN O O
see NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.2 NN O O
) NN O O
] NN O O
. NN O O
5.7 NN O O
Switching NN O O
Between NN O O
Biological NN O O
Disease NN O O
Modifying NN O O
Antirheumatic NN O O
Drugs NN O O
( NN O O
DMARDs NN O O
) NN O O
Care NN O O
should NN O O
be NN O O
taken NN O O
when NN O O
switching NN O O
from NN O O
one NN O O
biologic NN O O
product NN O O
to NN O O
another NN O O
biologic NN O O
product NN O O
since NN O O
overlapping NN O O
biological NN O O
activity NN O O
may NN O O
further NN O O
increase NN O O
the NN O O
risk NN O O
of NN O O
infection NN O O
. NN O O
5.8 NN O O
Hematologic NN O O
Cytopenias NN O O
There NN O O
have NN O O
been NN O O
post NN O O
- NN O O
marketing NN O O
reports NN O O
of NN O O
pancytopenia NN B-AdverseReaction B-AdverseReaction
leukopenia NN B-AdverseReaction B-AdverseReaction
neutropenia NN B-AdverseReaction B-AdverseReaction
aplastic NN B-AdverseReaction B-AdverseReaction
anemia NN I-AdverseReaction I-AdverseReaction
and NN O O
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
in NN O O
patients NN O O
receiving NN O O
TNF NN O O
- NN O O
blockers NN O O
. NN O O
In NN O O
clinical NN O O
studies NN O O
, NN O O
cases NN O O
of NN O O
pancytopenia NN B-AdverseReaction B-AdverseReaction
leukopenia NN B-AdverseReaction B-AdverseReaction
neutropenia NN B-AdverseReaction B-AdverseReaction
and NN O O
thrombocytopenia NN B-AdverseReaction B-AdverseReaction
have NN O O
also NN O O
occurred NN O O
in NN O O
SIMPONI NN O O
ARIA NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Caution NN O O
should NN O O
be NN O O
exercised NN O O
when NN O O
using NN O O
TNF NN O O
- NN O O
blockers NN O O
, NN O O
including NN O O
SIMPONI NN O O
ARIA NN O O
, NN O O
in NN O O
patients NN O O
who NN O O
have NN O O
or NN O O
have NN O O
had NN O O
significant NN O O
cytopenias NN O O
. NN O O
5.9 NN O O
Vaccinations/Therapeutic NN O O
Infectious NN O O
Agents NN O O
Live NN O O
Vaccines NN O O
Patients NN O O
treated NN O O
with NN O O
SIMPONI NN O O
ARIA NN O O
may NN O O
receive NN O O
vaccinations NN O O
, NN O O
except NN O O
for NN O O
live NN O O
vaccines NN O O
. NN O O
In NN O O
patients NN O O
receiving NN O O
anti NN O O
- NN O O
TNF NN O O
therapy NN O O
, NN O O
limited NN O O
data NN O O
are NN O O
available NN O O
on NN O O
the NN O O
response NN O O
to NN O O
live NN O O
vaccination NN O O
, NN O O
or NN O O
on NN O O
the NN O O
secondary NN O O
transmission NN O O
of NN O O
infection NN O O
by NN O O
live NN O O
vaccines NN O O
. NN O O
Use NN O O
of NN O O
live NN O O
vaccines NN O O
could NN O O
result NN O O
in NN O O
clinical NN O O
infections NN O O
, NN O O
including NN O O
disseminated NN O O
infections NN O O
. NN O O
Therapeutic NN O O
Infectious NN O O
Agents NN O O
Other NN O O
uses NN O O
of NN O O
therapeutic NN O O
infectious NN O O
agents NN O O
such NN O O
as NN O O
live NN O O
attenuated NN O O
bacteria NN O O
( NN O O
e.g. NN O O
, NN O O
BCG NN O O
bladder NN O O
instillation NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
cancer NN O O
) NN O O
could NN O O
result NN O O
in NN O O
clinical NN O O
infections NN O O
, NN O O
including NN O O
disseminated NN O O
infections NN O O
. NN O O
It NN O O
is NN O O
recommended NN O O
that NN O O
therapeutic NN O O
infectious NN O O
agents NN O O
not NN O O
be NN O O
given NN O O
concurrently NN O O
with NN O O
SIMPONI NN O O
ARIA. NN O O
5.10 NN O O
Hypersensitivity NN O O
Reactions NN O O
In NN O O
post NN O O
- NN O O
marketing NN O O
experience NN O O
, NN O O
serious NN B-Severity B-Severity
systemic NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
( NN O O
including NN O O
anaphylactic NN B-AdverseReaction B-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
following NN O O
administration NN O O
of NN O O
the NN O O
subcutaneous NN O O
formulation NN O O
of NN O O
golimumab NN O O
. NN O O
Some NN O O
of NN O O
these NN O O
reactions NN O O
occurred NN O O
after NN O O
the NN O O
first NN O O
administration NN O O
of NN O O
golimumab NN O O
. NN O O
If NN O O
an NN O O
anaphylactic NN O O
or NN O O
other NN O O
serious NN O O
allergic NN O O
reaction NN O O
occurs NN O O
, NN O O
administration NN O O
of NN O O
SIMPONI NN O O
ARIA NN O O
should NN O O
be NN O O
discontinued NN O O
immediately NN O O
and NN O O
appropriate NN O O
therapy NN O O
instituted NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
GBCAs NN B-DrugClass B-DrugClass
have NN O O
been NN O O
associated NN O O
with NN O O
a NN O O
risk NN O O
for NN O O
NSF NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
NSF NN B-AdverseReaction B-AdverseReaction
has NN O O
not NN B-Negation B-Negation
been NN O O
reported NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
clear NN O O
history NN O O
of NN O O
exposure NN O O
to NN O O
DOTAREM NN O O
alone NN O O
. NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
and NN O O
acute NN B-AdverseReaction B-AdverseReaction
kidney NN I-AdverseReaction I-AdverseReaction
injury NN I-AdverseReaction I-AdverseReaction
are NN O O
described NN O O
in NN O O
other NN O O
sections NN O O
of NN O O
the NN O O
labeling NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
and NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
. NN O O
EXCERPT NN O O
: NN O O
The NN O O
most NN O O
frequent NN O O
( NN O O
>= NN O O
0.2 NN O O
% NN O O
) NN O O
adverse NN O O
reactions NN O O
in NN O O
clinical NN O O
studies NN O O
were NN O O
nausea NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
coldness NN I-AdverseReaction I-AdverseReaction
and NN O O
burning NN B-AdverseReaction B-AdverseReaction
sensation NN I-AdverseReaction I-AdverseReaction
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
GUERBET NN O O
LLC NN O O
at NN O O
1 NN O O
- NN O O
877 NN O O
- NN O O
729 NN O O
- NN O O
6679 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
6.1 NN O O
Clinical NN O O
Studies NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O
The NN O O
data NN O O
described NN O O
below NN O O
reflect NN O O
DOTAREM NN O O
exposure NN O O
in NN O O
2813 NN O O
patients NN O O
, NN O O
representing NN O O
2672 NN O O
adults NN O O
and NN O O
141 NN O O
pediatric NN O O
patients NN O O
. NN O O
Overall NN O O
, NN O O
55 NN O O
% NN O O
of NN O O
the NN O O
patients NN O O
were NN O O
men NN O O
. NN O O
In NN O O
clinical NN O O
trials NN O O
where NN O O
ethnicity NN O O
was NN O O
recorded NN O O
the NN O O
ethnic NN O O
distribution NN O O
was NN O O
74 NN O O
% NN O O
Caucasian NN O O
, NN O O
12 NN O O
% NN O O
Asian NN O O
, NN O O
4 NN O O
% NN O O
Black NN O O
, NN O O
and NN O O
10 NN O O
% NN O O
others NN O O
. NN O O
The NN O O
average NN O O
age NN O O
was NN O O
53 NN O O
years NN O O
( NN O O
range NN O O
from NN O O
0.1 NN O O
to NN O O
97 NN O O
years NN O O
) NN O O
. NN O O
Overall NN O O
, NN O O
3.9 NN O O
% NN O O
of NN O O
patients NN O O
reported NN O O
at NN O O
least NN O O
one NN O O
adverse NN O O
reaction NN O O
, NN O O
primarily NN O O
occurring NN O O
immediately NN O O
or NN O O
several NN O O
days NN O O
following NN O O
DOTAREM NN O O
administration NN O O
. NN O O
Most NN O O
adverse NN O O
reactions NN O O
were NN O O
mild NN O O
or NN O O
moderate NN O O
in NN O O
severity NN O O
and NN O O
transient NN O O
in NN O O
nature NN O O
. NN O O
Table NN O O
2 NN O O
lists NN O O
adverse NN O O
reactions NN O O
that NN O O
occurred NN O O
in NN O O
>= NN O O
0.2 NN O O
% NN O O
patients NN O O
who NN O O
received NN O O
DOTAREM. NN O O
Table NN O O
2 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
in NN O O
Clinical NN O O
Trials NN O O
Reaction NN O O
Rate NN O O
( NN O O
% NN O O
) NN O O
n=2813 NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
0.6 NN O O
% NN O O
Headache NN B-AdverseReaction B-AdverseReaction
0.5 NN O O
% NN O O
Injection NN B-AdverseReaction B-AdverseReaction
Site NN I-AdverseReaction I-AdverseReaction
Pain NN I-AdverseReaction I-AdverseReaction
0.4 NN O O
% NN O O
Injection NN B-AdverseReaction B-AdverseReaction
Site NN I-AdverseReaction I-AdverseReaction
Coldness NN I-AdverseReaction I-AdverseReaction
0.2 NN O O
% NN O O
Burning NN B-AdverseReaction B-AdverseReaction
Sensation NN I-AdverseReaction I-AdverseReaction
0.2 NN O O
% NN O O
Adverse NN O O
reactions NN O O
that NN O O
occurred NN O O
with NN O O
a NN O O
frequency NN O O
< NN O O
0.2 NN O O
% NN O O
in NN O O
patients NN O O
who NN O O
received NN O O
DOTAREM NN O O
include NN O O
: NN O O
feeling NN B-AdverseReaction B-AdverseReaction
cold NN I-AdverseReaction I-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
somnolence NN B-AdverseReaction B-AdverseReaction
fatigue NN B-AdverseReaction B-AdverseReaction
dizziness NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
pruritus NN B-AdverseReaction B-AdverseReaction
paresthesia NN B-AdverseReaction B-AdverseReaction
dysgeusia NN B-AdverseReaction B-AdverseReaction
pain NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
extremity NN I-AdverseReaction I-AdverseReaction
anxiety NN B-AdverseReaction B-AdverseReaction
hypertension NN B-AdverseReaction B-AdverseReaction
palpitations NN B-AdverseReaction B-AdverseReaction
oropharyngeal NN B-AdverseReaction B-AdverseReaction
discomfort NN I-AdverseReaction I-AdverseReaction
serum NN B-AdverseReaction B-AdverseReaction
creatinine NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
and NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
site NN O O
inflammation NN O O
, NN O O
extravasation NN O O
, NN O O
pruritus NN O O
, NN O O
and NN O O
warmth NN O O
. NN O O
Adverse NN O O
Reactions NN O O
in NN O O
Pediatric NN O O
Patients NN O O
During NN O O
clinical NN O O
trials NN O O
, NN O O
141 NN O O
pediatric NN O O
patients NN O O
( NN O O
7 NN O O
aged NN O O
< NN O O
24 NN O O
months NN O O
, NN O O
33 NN O O
aged NN O O
2 NN O O
- NN O O
5 NN O O
years NN O O
, NN O O
58 NN O O
aged NN O O
6 NN O O
- NN O O
11 NN O O
years NN O O
and NN O O
43 NN O O
aged NN O O
12 NN O O
- NN O O
17 NN O O
) NN O O
received NN O O
DOTAREM. NN O O
Overall NN O O
, NN O O
6 NN O O
pediatric NN O O
patients NN O O
( NN O O
4.3 NN O O
% NN O O
) NN O O
reported NN O O
at NN O O
least NN O O
one NN O O
adverse NN O O
reaction NN O O
following NN O O
DOTAREM NN O O
administration NN O O
. NN O O
The NN O O
most NN O O
frequently NN O O
reported NN O O
adverse NN O O
reaction NN O O
was NN O O
headache NN B-AdverseReaction B-AdverseReaction
( NN O O
1.5 NN O O
% NN O O
) NN O O
. NN O O
Most NN O O
adverse NN O O
events NN O O
were NN O O
mild NN O O
in NN O O
severity NN O O
and NN O O
transient NN O O
in NN O O
nature NN O O
, NN O O
and NN O O
all NN O O
patients NN O O
recovered NN O O
without NN O O
treatment NN O O
. NN O O
6.2 NN O O
Postmarketing NN O O
Experience NN O O
The NN O O
following NN O O
additional NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
identified NN O O
during NN O O
postmarketing NN O O
use NN O O
of NN O O
DOTAREM. NN O O
Because NN O O
these NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
Table NN O O
3 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
in NN O O
the NN O O
Postmarketing NN O O
Experience NN O O
System NN O O
Organ NN O O
Class NN O O
Adverse NN O O
Reaction NN O O
Cardiac NN O O
Disorders NN O O
bradycardia NN B-AdverseReaction B-AdverseReaction
tachycardia NN B-AdverseReaction B-AdverseReaction
arrhythmia NN B-AdverseReaction B-AdverseReaction
Immune NN O O
System NN O O
Disorders NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
/anaphylactoid NN O O
reactions NN O O
including NN O O
cardiac NN B-AdverseReaction B-AdverseReaction
arrest NN I-AdverseReaction I-AdverseReaction
respiratory NN B-AdverseReaction B-AdverseReaction
arrest NN I-AdverseReaction I-AdverseReaction
cyanosis NN B-AdverseReaction B-AdverseReaction
pharyngeal NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
laryngospasm NN B-AdverseReaction B-AdverseReaction
bronchospasm NN B-AdverseReaction B-AdverseReaction
angioedema NN B-AdverseReaction B-AdverseReaction
conjunctivitis NN B-AdverseReaction B-AdverseReaction
ocular NN B-AdverseReaction B-AdverseReaction
hyperemia NN I-AdverseReaction I-AdverseReaction
eyelid NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
lacrimation NN B-AdverseReaction B-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
hyperhidrosis NN B-AdverseReaction B-AdverseReaction
urticaria NN B-AdverseReaction B-AdverseReaction
Nervous NN O O
System NN O O
Disorders NN O O
coma NN B-AdverseReaction B-AdverseReaction
convulsion NN B-AdverseReaction B-AdverseReaction
syncope NN B-AdverseReaction B-AdverseReaction
presyncope NN B-AdverseReaction B-AdverseReaction
parosmia NN B-AdverseReaction B-AdverseReaction
tremor NN B-AdverseReaction B-AdverseReaction
Musculoskeletal NN O O
and NN O O
Connective NN O O
Tissue NN O O
Disorders NN O O
muscle NN B-AdverseReaction B-AdverseReaction
contracture NN I-AdverseReaction I-AdverseReaction
muscle NN B-AdverseReaction B-AdverseReaction
weakness NN I-AdverseReaction I-AdverseReaction
Gastrointestinal NN O O
Disorders NN O O
diarrhea NN B-AdverseReaction B-AdverseReaction
salivary NN B-AdverseReaction B-AdverseReaction
hypersecretion NN I-AdverseReaction I-AdverseReaction
General NN O O
Disorders NN O O
and NN O O
Administration NN O O
Site NN O O
Conditions NN O O
malaise NN B-AdverseReaction B-AdverseReaction
fever NN B-AdverseReaction B-AdverseReaction
Skin NN O O
and NN O O
Subcutaneous NN O O
Tissue NN O O
Disorders NN O O
NSF NN B-AdverseReaction B-AdverseReaction
in NN O O
patients NN O O
whose NN O O
reports NN O O
were NN O O
confounded NN O O
by NN O O
the NN O O
receipt NN O O
of NN O O
other NN O O
GBCAs NN B-DrugClass B-DrugClass
or NN O O
in NN O O
situations NN O O
where NN O O
receipt NN O O
of NN O O
other NN O O
GBCAs NN O O
could NN O O
not NN O O
be NN O O
ruled NN O O
out NN O O
. NN O O
No NN B-Negation B-Negation
unconfounded NN O O
cases NN O O
of NN O O
NSF NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
with NN O O
DOTAREM. NN O O
Vascular NN O O
Disorders NN O O
superficial NN B-AdverseReaction B-AdverseReaction
phlebitis NN I-AdverseReaction I-AdverseReaction
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
NEPHROGENIC NN B-AdverseReaction B-AdverseReaction
SYSTEMIC NN I-AdverseReaction I-AdverseReaction
FIBROSIS NN I-AdverseReaction I-AdverseReaction
( NN O O
NSF NN O O
) NN O O
WARNING NN O O
: NN O O
NEPHROGENIC NN B-AdverseReaction B-AdverseReaction
SYSTEMIC NN I-AdverseReaction I-AdverseReaction
FIBROSIS NN I-AdverseReaction I-AdverseReaction
( NN O O
NSF NN O O
) NN O O
Gadolinium NN B-DrugClass B-DrugClass
- NN I-DrugClass I-DrugClass
based NN I-DrugClass I-DrugClass
contrast NN I-DrugClass I-DrugClass
agents NN I-DrugClass I-DrugClass
( NN O O
GBCAs NN O O
) NN O O
increase NN O O
the NN O O
risk NN O O
for NN O O
NSF NN B-AdverseReaction B-AdverseReaction
among NN O O
patients NN O O
with NN O O
impaired NN O O
elimination NN O O
of NN O O
the NN O O
drugs NN O O
. NN O O
Avoid NN O O
use NN O O
of NN O O
GBCAs NN O O
in NN O O
these NN O O
patients NN O O
unless NN O O
the NN O O
diagnostic NN O O
information NN O O
is NN O O
essential NN O O
and NN O O
not NN O O
available NN O O
with NN O O
non NN O O
- NN O O
contrasted NN O O
MRI NN O O
or NN O O
other NN O O
modalities NN O O
. NN O O
NSF NN B-AdverseReaction B-AdverseReaction
may NN B-Factor B-Factor
result NN O O
in NN O O
fatal NN B-AdverseReaction B-AdverseReaction
or NN O O
debilitating NN B-Severity B-Severity
fibrosis NN B-AdverseReaction B-AdverseReaction
affecting NN O O
the NN O O
skin NN O O
, NN O O
muscle NN O O
and NN O O
internal NN O O
organs NN O O
. NN O O
* NN O O
The NN O O
risk NN B-Factor B-Factor
for NN O O
NSF NN B-AdverseReaction B-AdverseReaction
appears NN O O
highest NN O O
among NN O O
patients NN O O
with:Chronic NN O O
, NN O O
severe NN O O
kidney NN O O
disease NN O O
( NN O O
GFR NN O O
< NN O O
30 NN O O
mL/min/1.73 NN O O
m2 NN O O
) NN O O
, NN O O
orAcute NN O O
kidney NN O O
injury NN O O
. NN O O
* NN O O
Screen NN O O
patients NN O O
for NN O O
acute NN O O
kidney NN O O
injury NN O O
and NN O O
other NN O O
conditions NN O O
that NN O O
may NN O O
reduce NN O O
renal NN O O
function NN O O
. NN O O
For NN O O
patients NN O O
at NN O O
risk NN O O
for NN O O
chronically NN O O
reduced NN O O
renal NN O O
function NN O O
( NN O O
e.g. NN O O
age NN O O
> NN O O
60 NN O O
years NN O O
, NN O O
hypertension NN O O
, NN O O
diabetes NN O O
) NN O O
, NN O O
estimate NN O O
the NN O O
glomerular NN O O
filtration NN O O
rate NN O O
( NN O O
GFR NN O O
) NN O O
through NN O O
laboratory NN O O
testing NN O O
( NN O O
5.1 NN O O
) NN O O
. NN O O
* NN O O
For NN O O
patients NN O O
at NN O O
highest NN O O
risk NN O O
for NN O O
NSF NN O O
, NN O O
do NN O O
not NN O O
exceed NN O O
the NN O O
recommended NN O O
DOTAREM NN O O
dose NN O O
and NN O O
allow NN O O
a NN O O
sufficient NN O O
period NN O O
of NN O O
time NN O O
for NN O O
elimination NN O O
of NN O O
the NN O O
drug NN O O
from NN O O
the NN O O
body NN O O
prior NN O O
to NN O O
any NN O O
re NN O O
- NN O O
administration NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
EXCERPT NN O O
: NN O O
WARNING NN O O
: NN O O
NEPHROGENIC NN B-AdverseReaction B-AdverseReaction
SYSTEMIC NN I-AdverseReaction I-AdverseReaction
FIBROSIS NN I-AdverseReaction I-AdverseReaction
( NN O O
NSF NN O O
) NN O O
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
Gadolinium NN B-DrugClass B-DrugClass
- NN I-DrugClass I-DrugClass
based NN I-DrugClass I-DrugClass
contrast NN I-DrugClass I-DrugClass
agents NN I-DrugClass I-DrugClass
( NN O O
GBCAs NN O O
) NN O O
increase NN O O
the NN O O
risk NN O O
for NN O O
NSF NN B-AdverseReaction B-AdverseReaction
among NN O O
patients NN O O
with NN O O
impaired NN O O
elimination NN O O
of NN O O
the NN O O
drugs NN O O
. NN O O
Avoid NN O O
use NN O O
of NN O O
GBCAs NN O O
in NN O O
these NN O O
patients NN O O
unless NN O O
the NN O O
diagnostic NN O O
information NN O O
is NN O O
essential NN O O
and NN O O
not NN O O
available NN O O
with NN O O
non NN O O
- NN O O
contrasted NN O O
MRI NN O O
or NN O O
other NN O O
modalities NN O O
. NN O O
* NN O O
The NN O O
risk NN B-Factor B-Factor
for NN O O
NSF NN B-AdverseReaction B-AdverseReaction
appears NN O O
highest NN O O
among NN O O
patients NN O O
with:Chronic NN O O
, NN O O
severe NN O O
kidney NN O O
disease NN O O
( NN O O
GFR NN O O
< NN O O
30 NN O O
mL/min/1.73 NN O O
m2 NN O O
) NN O O
, NN O O
orAcute NN O O
kidney NN O O
injury NN O O
. NN O O
* NN O O
Screen NN O O
patients NN O O
for NN O O
acute NN O O
kidney NN O O
injury NN O O
and NN O O
other NN O O
conditions NN O O
that NN O O
may NN O O
reduce NN O O
renal NN O O
function NN O O
. NN O O
For NN O O
patients NN O O
at NN O O
risk NN O O
for NN O O
chronically NN O O
reduced NN O O
renal NN O O
function NN O O
( NN O O
for NN O O
example NN O O
age NN O O
> NN O O
60 NN O O
years NN O O
, NN O O
hypertension NN O O
or NN O O
diabetes NN O O
) NN O O
, NN O O
estimate NN O O
the NN O O
glomerular NN O O
filtration NN O O
rate NN O O
( NN O O
GFR NN O O
) NN O O
through NN O O
laboratory NN O O
testing NN O O
( NN O O
5.1 NN O O
) NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Nephrogenic NN B-AdverseReaction B-AdverseReaction
Systemic NN I-AdverseReaction I-AdverseReaction
Fibrosis NN I-AdverseReaction I-AdverseReaction
has NN O O
occurred NN O O
in NN O O
patients NN O O
with NN O O
impaired NN O O
elimination NN O O
of NN O O
GBCAs NN O O
. NN O O
Higher NN O O
than NN O O
recommended NN O O
dosing NN O O
or NN O O
repeat NN O O
dosing NN O O
appear NN O O
to NN O O
increase NN O O
the NN O O
risk NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
Anaphylactoid/anaphylactic NN O O
reactions NN O O
with NN O O
cardiovascular NN O O
, NN O O
respiratory NN O O
or NN O O
cutaneous NN B-AdverseReaction B-AdverseReaction
manifestations NN I-AdverseReaction I-AdverseReaction
ranging NN O O
from NN O O
mild NN B-Severity B-Severity
to NN O O
severe NN B-Severity B-Severity
including NN O O
death NN B-AdverseReaction B-AdverseReaction
have NN O O
uncommonly NN O O
occurred NN O O
. NN O O
Monitor NN O O
patients NN O O
closely NN O O
for NN O O
need NN O O
of NN O O
emergency NN O O
cardiorespiratory NN O O
support NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
5.1 NN O O
Nephrogenic NN O O
Systemic NN O O
Fibrosis NN O O
Gadolinium NN B-DrugClass B-DrugClass
- NN I-DrugClass I-DrugClass
based NN I-DrugClass I-DrugClass
contrast NN I-DrugClass I-DrugClass
agents NN I-DrugClass I-DrugClass
( NN O O
GBCAs NN O O
) NN O O
increase NN O O
the NN O O
risk NN O O
for NN O O
nephrogenic NN B-AdverseReaction B-AdverseReaction
systemic NN I-AdverseReaction I-AdverseReaction
fibrosis NN I-AdverseReaction I-AdverseReaction
( NN O O
NSF NN O O
) NN O O
among NN O O
patients NN O O
with NN O O
impaired NN O O
elimination NN O O
of NN O O
the NN O O
drugs NN O O
. NN O O
Avoid NN O O
use NN O O
of NN O O
GBCAs NN O O
among NN O O
these NN O O
patients NN O O
unless NN O O
the NN O O
diagnostic NN O O
information NN O O
is NN O O
essential NN O O
and NN O O
not NN O O
available NN O O
with NN O O
non NN O O
- NN O O
contrast NN O O
MRI NN O O
or NN O O
other NN O O
modalities NN O O
. NN O O
The NN O O
GBCA NN B-DrugClass B-DrugClass
NSF NN B-AdverseReaction B-AdverseReaction
risk NN O O
appears NN O O
highest NN O O
for NN O O
patients NN O O
with NN O O
chronic NN O O
, NN O O
severe NN O O
kidney NN O O
disease NN O O
( NN O O
GFR NN O O
< NN O O
30 NN O O
mL/min/1.73m NN O O
2 NN O O
) NN O O
as NN O O
well NN O O
as NN O O
patients NN O O
with NN O O
acute NN O O
kidney NN O O
injury NN O O
. NN O O
The NN O O
risk NN O O
appears NN O O
lower NN O O
for NN O O
patients NN O O
with NN O O
chronic NN O O
, NN O O
moderate NN O O
kidney NN O O
disease NN O O
( NN O O
GFR NN O O
30 NN O O
- NN O O
59 NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
) NN O O
and NN O O
little NN O O
, NN O O
if NN O O
any NN O O
, NN O O
for NN O O
patients NN O O
with NN O O
chronic NN O O
, NN O O
mild NN O O
kidney NN O O
disease NN O O
( NN O O
GFR NN O O
60 NN O O
- NN O O
89 NN O O
mL/min/1.73 NN O O
m NN O O
2 NN O O
) NN O O
. NN O O
NSF NN B-AdverseReaction B-AdverseReaction
may NN B-Factor B-Factor
result NN O O
in NN O O
fatal NN B-AdverseReaction B-AdverseReaction
or NN O O
debilitating NN B-Severity B-Severity
fibrosis NN B-AdverseReaction B-AdverseReaction
affecting NN O O
the NN O O
skin NN O O
, NN O O
muscle NN O O
and NN O O
internal NN O O
organs NN O O
. NN O O
Report NN O O
any NN O O
diagnosis NN O O
of NN O O
NSF NN O O
following NN O O
DOTAREM NN O O
administration NN O O
to NN O O
Guerbet NN O O
LLC NN O O
( NN O O
1 NN O O
- NN O O
877 NN O O
- NN O O
729 NN O O
- NN O O
6679 NN O O
) NN O O
or NN O O
FDA NN O O
( NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
) NN O O
. NN O O
Screen NN O O
patients NN O O
for NN O O
acute NN O O
kidney NN O O
injury NN O O
and NN O O
other NN O O
conditions NN O O
that NN O O
may NN O O
reduce NN O O
renal NN O O
function NN O O
. NN O O
Features NN O O
of NN O O
acute NN O O
kidney NN O O
injury NN O O
consist NN O O
of NN O O
rapid NN O O
( NN O O
over NN O O
hours NN O O
to NN O O
days NN O O
) NN O O
and NN O O
usually NN O O
reversible NN O O
decrease NN O O
in NN O O
kidney NN O O
function NN O O
, NN O O
commonly NN O O
in NN O O
the NN O O
setting NN O O
of NN O O
surgery NN O O
, NN O O
severe NN O O
infection NN O O
, NN O O
injury NN O O
or NN O O
drug NN O O
- NN O O
induced NN O O
kidney NN O O
toxicity NN O O
. NN O O
Serum NN O O
creatinine NN O O
levels NN O O
and NN O O
estimated NN O O
GFR NN O O
may NN O O
not NN O O
reliably NN O O
assess NN O O
renal NN O O
function NN O O
in NN O O
the NN O O
setting NN O O
of NN O O
acute NN O O
kidney NN O O
injury NN O O
. NN O O
For NN O O
patients NN O O
at NN O O
risk NN O O
for NN O O
chronically NN O O
reduced NN O O
renal NN O O
function NN O O
( NN O O
e.g. NN O O
, NN O O
age NN O O
> NN O O
60 NN O O
years NN O O
, NN O O
diabetes NN O O
mellitus NN O O
or NN O O
chronic NN O O
hypertension NN O O
) NN O O
, NN O O
estimate NN O O
the NN O O
GFR NN O O
through NN O O
laboratory NN O O
testing NN O O
. NN O O
Among NN O O
the NN O O
factors NN O O
that NN O O
may NN O O
increase NN O O
the NN O O
risk NN O O
for NN O O
NSF NN O O
are NN O O
repeated NN O O
or NN O O
higher NN O O
than NN O O
recommended NN O O
doses NN O O
of NN O O
a NN O O
GBCA NN O O
and NN O O
the NN O O
degree NN O O
of NN O O
renal NN O O
impairment NN O O
at NN O O
the NN O O
time NN O O
of NN O O
exposure NN O O
. NN O O
Record NN O O
the NN O O
specific NN O O
GBCA NN O O
and NN O O
the NN O O
dose NN O O
administered NN O O
to NN O O
a NN O O
patient NN O O
. NN O O
For NN O O
patients NN O O
at NN O O
highest NN O O
risk NN O O
for NN O O
NSF NN O O
, NN O O
do NN O O
not NN O O
exceed NN O O
the NN O O
recommended NN O O
DOTAREM NN O O
dose NN O O
and NN O O
allow NN O O
a NN O O
sufficient NN O O
period NN O O
of NN O O
time NN O O
for NN O O
elimination NN O O
of NN O O
the NN O O
drug NN O O
prior NN O O
to NN O O
re NN O O
- NN O O
administration NN O O
. NN O O
For NN O O
patients NN O O
receiving NN O O
hemodialysis NN O O
, NN O O
physicians NN O O
may NN O O
consider NN O O
the NN O O
prompt NN O O
initiation NN O O
of NN O O
hemodialysis NN O O
following NN O O
the NN O O
administration NN O O
of NN O O
a NN O O
GBCA NN O O
in NN O O
order NN O O
to NN O O
enhance NN O O
the NN O O
contrast NN O O
agent NN O O
's NN O O
elimination NN O O
. NN O O
The NN O O
usefulness NN O O
of NN O O
hemodialysis NN O O
in NN O O
the NN O O
prevention NN O O
of NN O O
NSF NN O O
is NN O O
unknown NN O O
[ NN O O
see NN O O
Dosage NN O O
and NN O O
Administration NN O O
( NN O O
2 NN O O
) NN O O
and NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12 NN O O
) NN O O
] NN O O
. NN O O
5.2 NN O O
Hypersensitivity NN O O
Reactions NN O O
Anaphylactic NN O O
and NN O O
anaphylactoid NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
with NN O O
DOTAREM NN O O
, NN O O
involving NN O O
cardiovascular NN O O
, NN O O
respiratory NN O O
, NN O O
and/or NN O O
cutaneous NN O O
manifestations NN O O
. NN O O
Some NN O O
patients NN O O
experienced NN O O
circulatory NN B-AdverseReaction B-AdverseReaction
collapse NN I-AdverseReaction I-AdverseReaction
and NN O O
died NN B-AdverseReaction B-AdverseReaction
In NN O O
most NN O O
cases NN O O
, NN O O
initial NN O O
symptoms NN O O
occurred NN O O
within NN O O
minutes NN O O
of NN O O
DOTAREM NN O O
administration NN O O
and NN O O
resolved NN O O
with NN O O
prompt NN O O
emergency NN O O
treatment NN O O
[ NN O O
see NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Before NN O O
DOTAREM NN O O
administration NN O O
, NN O O
assess NN O O
all NN O O
patients NN O O
for NN O O
any NN O O
history NN O O
of NN O O
a NN O O
reaction NN O O
to NN O O
contrast NN O O
media NN O O
, NN O O
bronchial NN O O
asthma NN O O
and/or NN O O
allergic NN O O
disorders NN O O
. NN O O
These NN O O
patients NN O O
may NN B-Factor B-Factor
have NN O O
an NN O O
increased NN O O
risk NN O O
for NN O O
a NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
to NN O O
DOTAREM. NN O O
* NN O O
Administer NN O O
DOTAREM NN O O
only NN O O
in NN O O
situations NN O O
where NN O O
trained NN O O
personnel NN O O
and NN O O
therapies NN O O
are NN O O
promptly NN O O
available NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
hypersensitivity NN O O
reactions NN O O
, NN O O
including NN O O
personnel NN O O
trained NN O O
in NN O O
resuscitation NN O O
. NN O O
* NN O O
During NN O O
and NN O O
following NN O O
DOTAREM NN O O
administration NN O O
, NN O O
observe NN O O
patients NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
hypersensitivity NN O O
reactions NN O O
. NN O O
5.3 NN O O
Acute NN O O
Kidney NN O O
Injury NN O O
In NN O O
patients NN O O
with NN O O
chronically NN O O
reduced NN O O
renal NN O O
function NN O O
, NN O O
acute NN B-AdverseReaction B-AdverseReaction
kidney NN I-AdverseReaction I-AdverseReaction
injury NN I-AdverseReaction I-AdverseReaction
requiring NN O O
dialysis NN O O
has NN O O
occurred NN O O
with NN O O
the NN O O
use NN O O
of NN O O
GBCAs NN B-DrugClass B-DrugClass
The NN O O
risk NN O O
of NN O O
acute NN O O
kidney NN O O
injury NN O O
may NN O O
increase NN O O
with NN O O
increasing NN O O
dose NN O O
of NN O O
the NN O O
contrast NN O O
agent NN O O
; NN O O
administer NN O O
the NN O O
lowest NN O O
dose NN O O
necessary NN O O
for NN O O
adequate NN O O
imaging NN O O
. NN O O
Screen NN O O
all NN O O
patients NN O O
for NN O O
renal NN O O
impairment NN O O
by NN O O
obtaining NN O O
a NN O O
history NN O O
and/or NN O O
laboratory NN O O
tests NN O O
. NN O O
Consider NN O O
follow NN O O
- NN O O
up NN O O
renal NN O O
function NN O O
assessments NN O O
for NN O O
patients NN O O
with NN O O
a NN O O
history NN O O
of NN O O
renal NN O O
dysfunction NN O O
. NN O O
5.4 NN O O
Extravasation NN O O
and NN O O
Injection NN O O
Site NN O O
Reactions NN O O
Ensure NN O O
catheter NN O O
and NN O O
venous NN O O
patency NN O O
before NN O O
the NN O O
injection NN O O
of NN O O
DOTAREM. NN O O
Extravasation NN O O
into NN O O
tissues NN O O
during NN O O
DOTAREM NN O O
administration NN O O
may NN B-Factor B-Factor
result NN O O
in NN O O
tissue NN O O
irritation NN O O
[ NN O O
see NN O O
Nonclinical NN O O
Toxicology NN O O
( NN O O
13.2 NN O O
) NN O O
] NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
to NN O O
XEOMIN NN O O
are NN O O
discussed NN O O
in NN O O
greater NN O O
detail NN O O
in NN O O
other NN O O
sections NN O O
of NN O O
the NN O O
labeling NN O O
: NN O O
* NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
and NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
* NN O O
Dysphagia NN B-AdverseReaction B-AdverseReaction
and NN O O
Breathing NN B-AdverseReaction B-AdverseReaction
Difficulties NN I-AdverseReaction I-AdverseReaction
in NN O O
Treatment NN O O
of NN O O
cervical NN O O
dystonia NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
* NN O O
Spread NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
Effects NN I-AdverseReaction I-AdverseReaction
from NN I-AdverseReaction I-AdverseReaction
Toxin NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
EXCERPT NN O O
: NN O O
Cervical NN O O
Dystonia NN O O
: NN O O
The NN O O
most NN O O
commonly NN O O
observed NN O O
adverse NN O O
reactions NN O O
( NN O O
>=5 NN O O
% NN O O
of NN O O
patients NN O O
and NN O O
> NN O O
placebo NN O O
) NN O O
are NN O O
dysphagia NN B-AdverseReaction B-AdverseReaction
neck NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
muscle NN B-AdverseReaction B-AdverseReaction
weakness NN I-AdverseReaction I-AdverseReaction
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
and NN O O
musculoskeletal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
. NN O O
Blepharospasm NN O O
: NN O O
The NN O O
most NN O O
commonly NN O O
observed NN O O
adverse NN O O
reactions NN O O
( NN O O
>=5 NN O O
% NN O O
of NN O O
patients NN O O
and NN O O
> NN O O
placebo NN O O
) NN O O
are NN O O
eyelid NN B-AdverseReaction B-AdverseReaction
ptosis NN I-AdverseReaction I-AdverseReaction
dry NN B-AdverseReaction B-AdverseReaction
eye NN I-AdverseReaction I-AdverseReaction
dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
visual NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
dyspnea NN B-AdverseReaction B-AdverseReaction
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
and NN O O
respiratory NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
. NN O O
Glabellar NN O O
Lines NN O O
: NN O O
The NN O O
most NN O O
commonly NN O O
observed NN O O
adverse NN O O
reaction NN O O
( NN O O
>1 NN O O
% NN O O
of NN O O
patients NN O O
and NN O O
> NN O O
placebo NN O O
) NN O O
is NN O O
headache NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
. NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Merz NN O O
Pharmaceuticals NN O O
, NN O O
LLC NN O O
at NN O O
888 NN O O
- NN O O
493 NN O O
- NN O O
6646 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
, NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
Cervical NN O O
Dystonia NN O O
The NN O O
data NN O O
described NN O O
below NN O O
reflect NN O O
exposure NN O O
to NN O O
a NN O O
single NN O O
intramuscular NN O O
dose NN O O
of NN O O
XEOMIN NN O O
in NN O O
a NN O O
placebo NN O O
- NN O O
controlled NN O O
, NN O O
Phase NN O O
3 NN O O
trial NN O O
in NN O O
patients NN O O
with NN O O
cervical NN O O
dystonia NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14.1 NN O O
) NN O O
] NN O O
. NN O O
In NN O O
this NN O O
study NN O O
, NN O O
159 NN O O
patients NN O O
received NN O O
XEOMIN NN O O
( NN O O
78 NN O O
were NN O O
randomized NN O O
to NN O O
receive NN O O
a NN O O
total NN O O
dose NN O O
of NN O O
120 NN O O
Units NN O O
, NN O O
and NN O O
81 NN O O
were NN O O
randomized NN O O
to NN O O
receive NN O O
a NN O O
total NN O O
dose NN O O
of NN O O
240 NN O O
Units NN O O
) NN O O
. NN O O
XEOMIN NN O O
- NN O O
treated NN O O
patients NN O O
were NN O O
18 NN O O
to NN O O
79 NN O O
years NN O O
old NN O O
( NN O O
mean NN O O
53 NN O O
years NN O O
) NN O O
, NN O O
and NN O O
were NN O O
predominantly NN O O
female NN O O
( NN O O
66 NN O O
% NN O O
) NN O O
and NN O O
Caucasian NN O O
( NN O O
91 NN O O
% NN O O
) NN O O
. NN O O
At NN O O
study NN O O
baseline NN O O
, NN O O
approximately NN O O
25 NN O O
% NN O O
had NN O O
mild NN O O
, NN O O
50 NN O O
% NN O O
had NN O O
moderate NN O O
, NN O O
and NN O O
25 NN O O
% NN O O
had NN O O
severe NN O O
cervical NN O O
dystonia NN O O
. NN O O
Approximately NN O O
61 NN O O
% NN O O
of NN O O
XEOMIN NN O O
- NN O O
treated NN O O
patients NN O O
had NN O O
previously NN O O
received NN O O
another NN O O
botulinum NN O O
toxin NN O O
type NN O O
A NN O O
product NN O O
. NN O O
Common NN O O
adverse NN O O
events NN O O
( NN O O
>=5 NN O O
% NN O O
in NN O O
any NN O O
XEOMIN NN O O
treatment NN O O
group NN O O
) NN O O
observed NN O O
in NN O O
patients NN O O
who NN O O
received NN O O
XEOMIN NN O O
( NN O O
120 NN O O
Units NN O O
or NN O O
240 NN O O
Units NN O O
) NN O O
included NN O O
dysphagia NN B-AdverseReaction B-AdverseReaction
neck NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
muscle NN B-AdverseReaction B-AdverseReaction
weakness NN I-AdverseReaction I-AdverseReaction
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
and NN O O
musculoskeletal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
Table NN O O
2 NN O O
: NN O O
Most NN O O
Common NN O O
TEAEs NN O O
( NN O O
>=5 NN O O
% NN O O
) NN O O
and NN O O
Greater NN O O
than NN O O
Placebo NN O O
: NN O O
Double NN O O
- NN O O
Blind NN O O
Phase NN O O
of NN O O
Clinical NN O O
Trial NN O O
Double NN O O
- NN O O
Blind NN O O
Phase NN O O
System NN O O
Organ NN O O
ClassPreferred NN O O
Term NN O O
XEOMIN NN O O
120 NN O O
Units(N=77 NN O O
) NN O O
XEOMIN NN O O
240 NN O O
Units(N=82 NN O O
) NN O O
Placebo(N=74 NN O O
) NN O O
Any NN O O
TEAEs NN O O
57 NN O O
% NN O O
55 NN O O
% NN O O
42 NN O O
% NN O O
Musculoskeletal NN O O
and NN O O
connective NN O O
tissue NN O O
disorders NN O O
23 NN O O
% NN O O
32 NN O O
% NN O O
11 NN O O
% NN O O
Neck NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
7 NN O O
% NN O O
15 NN O O
% NN O O
4 NN O O
% NN O O
Muscular NN B-AdverseReaction B-AdverseReaction
weakness NN I-AdverseReaction I-AdverseReaction
7 NN O O
% NN O O
11 NN O O
% NN O O
1 NN O O
% NN O O
Musculoskeletal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
7 NN O O
% NN O O
4 NN O O
% NN O O
1 NN O O
% NN O O
Gastrointestinal NN O O
disorders NN O O
18 NN O O
% NN O O
24 NN O O
% NN O O
4 NN O O
% NN O O
Dysphagia NN B-AdverseReaction B-AdverseReaction
13 NN O O
% NN O O
18 NN O O
% NN O O
3 NN O O
% NN O O
Nervous NN O O
system NN O O
disorders NN O O
16 NN O O
% NN O O
17 NN O O
% NN O O
7 NN O O
% NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
16 NN O O
% NN O O
11 NN O O
% NN O O
11 NN O O
% NN O O
Injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
9 NN O O
% NN O O
4 NN O O
% NN O O
7 NN O O
% NN O O
Infections NN O O
and NN O O
infestations NN O O
14 NN O O
% NN O O
13 NN O O
% NN O O
11 NN O O
% NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
and NN O O
mediastinal NN O O
disorders NN O O
13 NN O O
% NN O O
10 NN O O
% NN O O
3 NN O O
% NN O O
Blepharospasm NN O O
In NN O O
the NN O O
placebo NN O O
- NN O O
controlled NN O O
Phase NN O O
3 NN O O
trial NN O O
in NN O O
patients NN O O
with NN O O
blepharospasm NN B-AdverseReaction B-AdverseReaction
previously NN O O
treated NN O O
with NN O O
onabotulinumtoxinA NN O O
( NN O O
Botox NN O O
) NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14.2 NN O O
) NN O O
] NN O O
, NN O O
74 NN O O
patients NN O O
received NN O O
XEOMIN NN O O
at NN O O
a NN O O
mean NN O O
dose NN O O
of NN O O
approximately NN O O
33 NN O O
Units NN O O
per NN O O
eye NN O O
( NN O O
minimum NN O O
10 NN O O
Units NN O O
, NN O O
maximum NN O O
50 NN O O
Units NN O O
) NN O O
. NN O O
XEOMIN NN O O
- NN O O
treated NN O O
patients NN O O
were NN O O
22 NN O O
to NN O O
79 NN O O
years NN O O
of NN O O
age NN O O
( NN O O
mean NN O O
62 NN O O
years NN O O
) NN O O
, NN O O
predominantly NN O O
female NN O O
( NN O O
65 NN O O
% NN O O
) NN O O
, NN O O
Caucasian NN O O
( NN O O
79 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
had NN O O
a NN O O
mean NN O O
time NN O O
since NN O O
diagnosis NN O O
of NN O O
approximately NN O O
5 NN O O
years NN O O
. NN O O
The NN O O
adverse NN O O
events NN O O
occurring NN O O
in NN O O
>=5 NN O O
% NN O O
of NN O O
XEOMIN NN O O
- NN O O
treated NN O O
patients NN O O
and NN O O
greater NN O O
than NN O O
placebo NN O O
in NN O O
the NN O O
Phase NN O O
3 NN O O
study NN O O
were NN O O
eyelid NN B-AdverseReaction B-AdverseReaction
ptosis NN I-AdverseReaction I-AdverseReaction
dry NN B-AdverseReaction B-AdverseReaction
eye NN I-AdverseReaction I-AdverseReaction
dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
visual NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
dyspnea NN B-AdverseReaction B-AdverseReaction
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
and NN O O
respiratory NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
No NN O O
serious NN O O
adverse NN O O
events NN O O
occurred NN O O
in NN O O
patients NN O O
who NN O O
received NN O O
XEOMIN NN O O
; NN O O
one NN O O
placebo NN B-Factor B-Factor
patient NN O O
experienced NN O O
a NN O O
serious NN B-Severity B-Severity
adverse NN O O
event NN O O
( NN O O
dyspnea NN O O
) NN O O
. NN O O
Table NN O O
3 NN O O
: NN O O
Most NN O O
Common NN O O
TEAEs NN O O
( NN O O
>=5 NN O O
% NN O O
) NN O O
and NN O O
Greater NN O O
than NN O O
Placebo NN O O
: NN O O
Double NN O O
- NN O O
Blind NN O O
Phase NN O O
of NN O O
Clinical NN O O
Trial NN O O
Double NN O O
- NN O O
Blind NN O O
Phase NN O O
System NN O O
Organ NN O O
Class NN O O
Preferred NN O O
Term NN O O
XEOMIN(N=74 NN O O
) NN O O
Placebo(N=34 NN O O
) NN O O
Subjects NN O O
with NN O O
TEAEs NN O O
70 NN O O
% NN O O
62 NN O O
% NN O O
Eye NN O O
disorders NN O O
38 NN O O
% NN O O
21 NN O O
% NN O O
Eyelid NN B-AdverseReaction B-AdverseReaction
ptosis NN I-AdverseReaction I-AdverseReaction
19 NN O O
% NN O O
9 NN O O
% NN O O
Dry NN B-AdverseReaction B-AdverseReaction
eye NN I-AdverseReaction I-AdverseReaction
16 NN O O
% NN O O
12 NN O O
% NN O O
Visual NN B-AdverseReaction B-AdverseReaction
impairment NN I-AdverseReaction I-AdverseReaction
12 NN O O
% NN O O
6 NN O O
% NN O O
Gastrointestinal NN O O
disorders NN O O
30 NN O O
% NN O O
15 NN O O
% NN O O
Dry NN B-AdverseReaction B-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
16 NN O O
% NN O O
3 NN O O
% NN O O
Diarrhoea NN B-AdverseReaction B-AdverseReaction
8 NN O O
% NN O O
- NN O O
Infections NN O O
and NN O O
infestations NN O O
20 NN O O
% NN O O
15 NN O O
% NN O O
Nasopharyngitis NN B-AdverseReaction B-AdverseReaction
5 NN O O
% NN O O
3 NN O O
% NN O O
Respiratory NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
5 NN O O
% NN O O
3 NN O O
% NN O O
Nervous NN O O
system NN O O
disorders NN O O
14 NN O O
% NN O O
9 NN O O
% NN O O
Headache NN B-AdverseReaction B-AdverseReaction
7 NN O O
% NN O O
3 NN O O
% NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
11 NN O O
% NN O O
9 NN O O
% NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
and NN O O
mediastinal NN O O
disorders NN O O
11 NN O O
% NN O O
3 NN O O
% NN O O
Dyspnoea NN B-AdverseReaction B-AdverseReaction
5 NN O O
% NN O O
3 NN O O
% NN O O
Glabellar NN O O
Lines NN O O
In NN O O
three NN O O
placebo NN O O
- NN O O
controlled NN O O
trials NN O O
in NN O O
803 NN O O
subjects NN O O
with NN O O
glabellar NN O O
lines NN O O
, NN O O
535 NN O O
subjects NN O O
received NN O O
a NN O O
single NN O O
dose NN O O
of NN O O
20 NN O O
Units NN O O
XEOMIN NN O O
and NN O O
268 NN O O
subjects NN O O
received NN O O
placebo NN O O
. NN O O
XEOMIN NN O O
treated NN O O
subjects NN O O
were NN O O
24 NN O O
to NN O O
74 NN O O
years NN O O
old NN O O
, NN O O
and NN O O
were NN O O
predominantly NN O O
female NN O O
( NN O O
88 NN O O
% NN O O
) NN O O
. NN O O
The NN O O
most NN O O
frequent NN O O
adverse NN O O
reactions NN O O
in NN O O
XEOMIN NN O O
treated NN O O
subjects NN O O
were NN O O
: NN O O
headache NN B-AdverseReaction B-AdverseReaction
29 NN O O
( NN O O
5.4 NN O O
% NN O O
) NN O O
, NN O O
facial NN B-AdverseReaction B-AdverseReaction
paresis NN I-AdverseReaction I-AdverseReaction
4 NN O O
( NN O O
0.7 NN O O
% NN O O
) NN O O
, NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
hematoma NN I-AdverseReaction I-AdverseReaction
3 NN O O
( NN O O
0.6 NN O O
% NN O O
) NN O O
and NN O O
eyelid NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
2 NN O O
( NN O O
0.4 NN O O
% NN O O
) NN O O
. NN O O
Four NN O O
serious NN O O
adverse NN O O
events NN O O
occurred NN O O
in NN O O
two NN O O
placebo NN O O
- NN O O
treated NN O O
subjects NN O O
. NN O O
Six NN O O
XEOMIN NN O O
treated NN O O
subjects NN O O
experienced NN O O
six NN O O
serious NN O O
adverse NN O O
events NN O O
. NN O O
All NN O O
serious NN O O
adverse NN O O
events NN O O
were NN O O
assessed NN O O
as NN O O
unrelated NN O O
to NN O O
study NN O O
drug NN O O
. NN O O
The NN O O
adverse NN O O
reactions NN O O
below NN O O
reflect NN O O
exposure NN O O
to NN O O
XEOMIN NN O O
with NN O O
glabellar NN O O
lines NN O O
in NN O O
placebo NN O O
- NN O O
controlled NN O O
studies NN O O
. NN O O
Adverse NN O O
reactions NN O O
are NN O O
adverse NN O O
events NN O O
in NN O O
which NN O O
there NN O O
is NN O O
some NN O O
basis NN O O
to NN O O
believe NN O O
there NN O O
is NN O O
a NN O O
causal NN O O
relationship NN O O
between NN O O
the NN O O
drug NN O O
and NN O O
the NN O O
occurrence NN O O
of NN O O
the NN O O
adverse NN O O
event NN O O
. NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
Table NN O O
4 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
in NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Trials NN O O
Adverse NN O O
reactions NN O O
XEOMIN(N=535 NN O O
) NN O O
( NN O O
% NN O O
) NN O O
Placebo(N=268 NN O O
) NN O O
( NN O O
% NN O O
) NN O O
Nervous NN O O
system NN O O
disorders NN O O
33 NN O O
( NN O O
6.1 NN O O
) NN O O
6 NN O O
( NN O O
2.2 NN O O
) NN O O
Headache NN B-AdverseReaction B-AdverseReaction
1 NN O O
29 NN O O
( NN O O
5.4 NN O O
) NN O O
6 NN O O
( NN O O
2.2 NN O O
) NN O O
Facial NN B-AdverseReaction B-AdverseReaction
paresis NN I-AdverseReaction I-AdverseReaction
( NN O O
brow NN O O
ptosis NN O O
) NN O O
4 NN O O
( NN O O
0.7 NN O O
) NN O O
0 NN O O
General NN O O
disorders NN O O
and NN O O
administration NN O O
site NN O O
conditions NN O O
5 NN O O
( NN O O
0.9 NN O O
) NN O O
2 NN O O
( NN O O
0.7 NN O O
) NN O O
Injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
hematoma NN I-AdverseReaction I-AdverseReaction
3 NN O O
( NN O O
0.6 NN O O
) NN O O
0 NN O O
Injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
1 NN O O
( NN O O
0.2 NN O O
) NN O O
0 NN O O
Facial NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
1 NN O O
( NN O O
0.2 NN O O
) NN O O
0 NN O O
Injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
swelling NN I-AdverseReaction I-AdverseReaction
0 NN O O
1 NN O O
( NN O O
0.4 NN O O
) NN O O
Sensation NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
0 NN O O
1 NN O O
( NN O O
0.4 NN O O
) NN O O
Eye NN O O
disorders NN O O
5 NN O O
( NN O O
0.9 NN O O
) NN O O
0 NN O O
Eyelid NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
2 NN O O
( NN O O
0.4 NN O O
) NN O O
0 NN O O
Blepharospasm NN B-AdverseReaction B-AdverseReaction
1 NN O O
( NN O O
0.2 NN O O
) NN O O
0 NN O O
Eye NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
1(0.2 NN O O
) NN O O
0 NN O O
Eyelid NN B-AdverseReaction B-AdverseReaction
ptosis NN I-AdverseReaction I-AdverseReaction
1(0.2 NN O O
) NN O O
0 NN O O
In NN O O
open NN O O
label NN O O
, NN O O
multiple NN O O
dose NN O O
trials NN O O
, NN O O
adverse NN O O
reactions NN O O
were NN O O
reported NN O O
for NN O O
105 NN O O
of NN O O
the NN O O
800 NN O O
subjects NN O O
( NN O O
13.1 NN O O
% NN O O
) NN O O
. NN O O
Headache NN B-AdverseReaction B-AdverseReaction
was NN O O
the NN O O
most NN O O
common NN O O
adverse NN O O
reaction NN O O
, NN O O
reported NN O O
for NN O O
57 NN O O
subjects NN O O
( NN O O
7.1 NN O O
% NN O O
) NN O O
, NN O O
followed NN O O
by NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
hematoma NN I-AdverseReaction I-AdverseReaction
in NN O O
8 NN O O
subjects NN O O
( NN O O
1.0 NN O O
% NN O O
) NN O O
. NN O O
Adverse NN O O
reactions NN O O
reported NN O O
in NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
of NN O O
subjects NN O O
were NN O O
: NN O O
facial NN B-AdverseReaction B-AdverseReaction
paresis NN I-AdverseReaction I-AdverseReaction
( NN O O
brow NN O O
ptosis NN O O
) NN O O
, NN O O
muscle NN B-AdverseReaction B-AdverseReaction
disorder NN I-AdverseReaction I-AdverseReaction
( NN O O
elevation NN O O
of NN O O
eyebrow NN O O
) NN O O
, NN O O
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
and NN O O
eyelid NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
6.2 NN O O
Immunogenicity NN O O
As NN O O
with NN O O
all NN O O
therapeutic NN O O
proteins NN O O
, NN O O
there NN O O
is NN O O
a NN O O
potential NN O O
for NN O O
immunogenicity NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
antibody NN O O
formation NN O O
is NN O O
highly NN O O
dependent NN O O
on NN O O
the NN O O
sensitivity NN O O
and NN O O
specificity NN O O
of NN O O
the NN O O
assay NN O O
. NN O O
In NN O O
addition NN O O
, NN O O
the NN O O
observed NN O O
incidence NN O O
of NN O O
antibody NN O O
positivity NN O O
in NN O O
an NN O O
assay NN O O
may NN O O
be NN O O
influenced NN O O
by NN O O
several NN O O
factors NN O O
including NN O O
assay NN O O
methodology NN O O
, NN O O
sample NN O O
handling NN O O
, NN O O
timing NN O O
of NN O O
sample NN O O
collection NN O O
, NN O O
concomitant NN O O
medications NN O O
, NN O O
and NN O O
underlying NN O O
disease NN O O
. NN O O
For NN O O
these NN O O
reasons NN O O
, NN O O
comparison NN O O
of NN O O
the NN O O
incidence NN O O
of NN O O
antibodies NN O O
across NN O O
products NN O O
in NN O O
this NN O O
class NN O O
may NN O O
be NN O O
misleading NN O O
. NN O O
6.3 NN O O
Postmarketing NN O O
Experience NN O O
The NN O O
following NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
reported NN O O
during NN O O
post NN O O
- NN O O
approval NN O O
use NN O O
with NN O O
XEOMIN. NN O O
Because NN O O
these NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
: NN O O
eye NN B-AdverseReaction B-AdverseReaction
swelling NN I-AdverseReaction I-AdverseReaction
eyelid NN B-AdverseReaction B-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
dysphagia NN B-AdverseReaction B-AdverseReaction
nausea NN B-AdverseReaction B-AdverseReaction
flu NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
like NN I-AdverseReaction I-AdverseReaction
symptoms NN I-AdverseReaction I-AdverseReaction
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
injection NN B-AdverseReaction B-AdverseReaction
site NN I-AdverseReaction I-AdverseReaction
reaction NN I-AdverseReaction I-AdverseReaction
allergic NN B-AdverseReaction B-AdverseReaction
dermatitis NN I-AdverseReaction I-AdverseReaction
localized NN B-AdverseReaction B-AdverseReaction
allergic NN I-AdverseReaction I-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
like NN O O
swelling NN O O
, NN O O
edema NN O O
, NN O O
erythema NN O O
, NN O O
pruritus NN O O
or NN O O
rash NN O O
, NN O O
herpes NN B-AdverseReaction B-AdverseReaction
zoster NN I-AdverseReaction I-AdverseReaction
muscular NN B-AdverseReaction B-AdverseReaction
weakness NN I-AdverseReaction I-AdverseReaction
muscle NN B-AdverseReaction B-AdverseReaction
spasm NN I-AdverseReaction I-AdverseReaction
dysarthria NN B-AdverseReaction B-AdverseReaction
myalgia NN B-AdverseReaction B-AdverseReaction
and NN O O
hypersensitivity NN B-AdverseReaction B-AdverseReaction
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
DISTANT NN B-AdverseReaction B-AdverseReaction
SPREAD NN I-AdverseReaction I-AdverseReaction
OF NN I-AdverseReaction I-AdverseReaction
TOXIN NN I-AdverseReaction I-AdverseReaction
EFFECT NN I-AdverseReaction I-AdverseReaction
WARNING NN O O
: NN O O
DISTANT NN B-AdverseReaction B-AdverseReaction
SPREAD NN I-AdverseReaction I-AdverseReaction
OF NN I-AdverseReaction I-AdverseReaction
TOXIN NN I-AdverseReaction I-AdverseReaction
EFFECT NN I-AdverseReaction I-AdverseReaction
Postmarketing NN O O
reports NN O O
indicate NN O O
that NN O O
the NN O O
effects NN O O
of NN O O
XEOMIN NN O O
and NN O O
all NN O O
botulinum NN O O
toxin NN O O
products NN O O
may NN B-Factor B-Factor
spread NN B-AdverseReaction B-AdverseReaction
from NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
area NN I-AdverseReaction I-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
injection NN I-AdverseReaction I-AdverseReaction
to NN O O
produce NN O O
symptoms NN O O
consistent NN O O
with NN O O
botulinum NN O O
toxin NN B-AdverseReaction B-AdverseReaction
effects NN I-AdverseReaction I-AdverseReaction
These NN O O
may NN B-Factor B-Factor
include NN O O
asthenia NN B-AdverseReaction B-AdverseReaction
generalized NN B-AdverseReaction B-AdverseReaction
muscle NN I-AdverseReaction I-AdverseReaction
weakness NN I-AdverseReaction I-AdverseReaction
diplopia NN B-AdverseReaction B-AdverseReaction
blurred NN B-AdverseReaction B-AdverseReaction
vision NN I-AdverseReaction I-AdverseReaction
ptosis NN B-AdverseReaction B-AdverseReaction
dysphagia NN B-AdverseReaction B-AdverseReaction
dysphonia NN B-AdverseReaction B-AdverseReaction
dysarthria NN B-AdverseReaction B-AdverseReaction
urinary NN B-AdverseReaction B-AdverseReaction
incontinence NN I-AdverseReaction I-AdverseReaction
and NN O O
breathing NN B-AdverseReaction B-AdverseReaction
difficulties NN I-AdverseReaction I-AdverseReaction
These NN O O
symptoms NN O O
have NN O O
been NN O O
reported NN O O
hours NN O O
to NN O O
weeks NN O O
after NN O O
injection NN O O
. NN O O
Swallowing NN O O
and NN O O
breathing NN B-AdverseReaction B-AdverseReaction
difficulties NN I-AdverseReaction I-AdverseReaction
can NN O O
be NN O O
life NN B-Severity B-Severity
threatening NN I-Severity I-Severity
and NN O O
there NN O O
have NN O O
been NN O O
reports NN O O
of NN O O
death NN B-AdverseReaction B-AdverseReaction
The NN O O
risk NN O O
of NN O O
symptoms NN O O
is NN O O
probably NN O O
greatest NN O O
in NN O O
children NN O O
treated NN O O
for NN O O
spasticity NN O O
but NN O O
symptoms NN O O
can NN O O
also NN O O
occur NN O O
in NN O O
adults NN O O
treated NN O O
for NN O O
spasticity NN O O
and NN O O
other NN O O
conditions NN O O
, NN O O
particularly NN O O
in NN O O
those NN O O
patients NN O O
who NN O O
have NN O O
underlying NN O O
conditions NN O O
that NN O O
would NN O O
predispose NN O O
them NN O O
to NN O O
these NN O O
symptoms NN O O
. NN O O
In NN O O
unapproved NN O O
uses NN O O
, NN O O
including NN O O
spasticity NN O O
in NN O O
children NN O O
and NN O O
adults NN O O
, NN O O
and NN O O
in NN O O
approved NN O O
indications NN O O
, NN O O
cases NN O O
of NN O O
spread NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
effect NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
at NN O O
doses NN O O
comparable NN O O
to NN O O
those NN O O
used NN O O
to NN O O
treat NN O O
cervical NN O O
dystonia NN O O
and NN O O
at NN O O
lower NN O O
doses NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
EXCERPT NN O O
: NN O O
WARNING NN O O
: NN O O
DISTANT NN B-AdverseReaction B-AdverseReaction
SPREAD NN I-AdverseReaction I-AdverseReaction
OF NN I-AdverseReaction I-AdverseReaction
TOXIN NN I-AdverseReaction I-AdverseReaction
EFFECT NN I-AdverseReaction I-AdverseReaction
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
. NN O O
The NN O O
effects NN O O
of NN O O
XEOMIN NN O O
and NN O O
all NN O O
botulinum NN O O
toxin NN O O
products NN O O
may NN B-Factor B-Factor
spread NN B-AdverseReaction B-AdverseReaction
from NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
area NN I-AdverseReaction I-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
injection NN I-AdverseReaction I-AdverseReaction
to NN O O
produce NN O O
symptoms NN O O
consistent NN O O
with NN O O
botulinum NN O O
toxin NN B-AdverseReaction B-AdverseReaction
effects NN I-AdverseReaction I-AdverseReaction
These NN O O
symptoms NN O O
have NN O O
been NN O O
reported NN O O
hours NN O O
to NN O O
weeks NN O O
after NN O O
injection NN O O
. NN O O
Swallowing NN O O
and NN O O
breathing NN B-AdverseReaction B-AdverseReaction
difficulties NN I-AdverseReaction I-AdverseReaction
can NN B-Factor B-Factor
be NN O O
life NN B-Severity B-Severity
threatening NN I-Severity I-Severity
and NN O O
there NN O O
have NN O O
been NN O O
reports NN O O
of NN O O
death NN B-AdverseReaction B-AdverseReaction
The NN O O
risk NN O O
of NN O O
symptoms NN O O
is NN O O
probably NN O O
greatest NN O O
in NN O O
children NN O O
treated NN O O
for NN O O
spasticity NN O O
but NN O O
symptoms NN O O
can NN O O
also NN O O
occur NN O O
in NN O O
adults NN O O
, NN O O
particularly NN O O
in NN O O
those NN O O
patients NN O O
who NN O O
have NN O O
underlying NN O O
conditions NN O O
that NN O O
would NN O O
predispose NN O O
them NN O O
to NN O O
these NN O O
symptoms NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
For NN O O
All NN O O
Indications NN O O
: NN O O
* NN O O
The NN O O
potency NN O O
Units NN O O
of NN O O
XEOMIN NN O O
are NN O O
not NN O O
interchangeable NN O O
with NN O O
other NN O O
preparations NN O O
of NN O O
botulinum NN O O
toxin NN O O
products NN O O
. NN O O
Therefore NN O O
, NN O O
Units NN O O
of NN O O
biological NN O O
activity NN O O
of NN O O
XEOMIN NN O O
can NN O O
not NN O O
be NN O O
compared NN O O
to NN O O
or NN O O
converted NN O O
into NN O O
Units NN O O
of NN O O
any NN O O
other NN O O
botulinum NN O O
toxin NN O O
products NN O O
( NN O O
5.2 NN O O
) NN O O
. NN O O
* NN O O
Immediate NN O O
medical NN O O
attention NN O O
may NN O O
be NN O O
required NN O O
in NN O O
cases NN O O
of NN O O
respiratory NN O O
, NN O O
speech NN O O
or NN O O
swallowing NN O O
difficulties NN O O
( NN O O
5.1 NN O O
, NN O O
5.4 NN O O
) NN O O
. NN O O
* NN O O
Use NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
with NN O O
compromised NN O O
respiratory NN O O
function NN O O
or NN O O
dysphagia NN O O
( NN O O
5.4 NN O O
) NN O O
. NN O O
* NN O O
Concomitant NN O O
neuromuscular NN O O
disorders NN O O
may NN O O
exacerbate NN O O
clinical NN O O
effects NN O O
of NN O O
treatment NN O O
( NN O O
5.5 NN O O
) NN O O
. NN O O
Cervical NN O O
Dystonia NN O O
( NN O O
5.4 NN O O
) NN O O
: NN O O
* NN O O
Patients NN O O
with NN O O
smaller NN O O
neck NN O O
muscle NN O O
mass NN O O
and NN O O
patients NN O O
who NN O O
require NN O O
bilateral NN O O
injections NN O O
into NN O O
the NN O O
sternocleidomastoid NN O O
muscles NN O O
are NN O O
at NN O O
greater NN O O
risk NN B-Factor B-Factor
of NN O O
dysphagia NN B-AdverseReaction B-AdverseReaction
* NN O O
Limiting NN O O
the NN O O
dose NN O O
injected NN O O
into NN O O
the NN O O
sternocleidomastoid NN O O
muscle NN O O
may NN O O
decrease NN O O
the NN O O
occurrence NN O O
of NN O O
dysphagia NN O O
. NN O O
Blepharospasm NN O O
( NN O O
5.6 NN O O
) NN O O
: NN O O
* NN O O
Corneal NN B-AdverseReaction B-AdverseReaction
exposure NN I-AdverseReaction I-AdverseReaction
and NN O O
ulceration NN O O
* NN O O
Injection NN O O
of NN O O
XEOMIN NN O O
into NN O O
the NN O O
orbicularis NN O O
oculi NN O O
muscle NN O O
may NN B-Factor B-Factor
lead NN O O
to NN O O
reduced NN B-AdverseReaction B-AdverseReaction
blinking NN I-AdverseReaction I-AdverseReaction
and NN O O
corneal NN B-AdverseReaction B-AdverseReaction
exposure NN I-AdverseReaction I-AdverseReaction
with NN O O
possible NN B-Factor B-Factor
ulceration NN O O
or NN O O
perforation NN O O
. NN O O
* NN O O
Lower NN O O
lid NN O O
injections NN O O
should NN O O
not NN O O
be NN O O
repeated NN O O
if NN O O
diplopia NN O O
occurred NN O O
with NN O O
previous NN O O
botulinum NN O O
toxin NN O O
injections NN O O
. NN O O
Glabellar NN O O
Lines NN O O
( NN O O
5.7 NN O O
) NN O O
: NN O O
* NN O O
Risk NN B-Factor B-Factor
of NN O O
ptosis NN B-AdverseReaction B-AdverseReaction
( NN O O
5.7 NN O O
) NN O O
. NN O O
5.1 NN O O
Spread NN O O
of NN O O
Toxin NN O O
Effect NN O O
Postmarketing NN O O
safety NN O O
data NN O O
from NN O O
XEOMIN NN O O
and NN O O
other NN O O
approved NN O O
botulinum NN O O
toxins NN O O
suggest NN O O
that NN O O
botulinum NN O O
toxin NN O O
effects NN O O
may NN B-Factor B-Factor
in NN O O
some NN O O
cases NN O O
, NN O O
be NN O O
observed NN O O
beyond NN O O
the NN O O
site NN O O
of NN O O
local NN O O
injection NN O O
. NN O O
The NN O O
symptoms NN O O
are NN O O
consistent NN O O
with NN O O
the NN O O
mechanism NN O O
of NN O O
action NN O O
of NN O O
botulinum NN O O
toxin NN O O
and NN O O
may NN O O
include NN O O
asthenia NN B-AdverseReaction B-AdverseReaction
generalized NN B-AdverseReaction B-AdverseReaction
muscle NN I-AdverseReaction I-AdverseReaction
weakness NN I-AdverseReaction I-AdverseReaction
diplopia NN B-AdverseReaction B-AdverseReaction
blurred NN B-AdverseReaction B-AdverseReaction
vision NN I-AdverseReaction I-AdverseReaction
ptosis NN B-AdverseReaction B-AdverseReaction
dysphagia NN B-AdverseReaction B-AdverseReaction
dysphonia NN B-AdverseReaction B-AdverseReaction
dysarthria NN B-AdverseReaction B-AdverseReaction
urinary NN B-AdverseReaction B-AdverseReaction
incontinence NN I-AdverseReaction I-AdverseReaction
and NN O O
breathing NN B-AdverseReaction B-AdverseReaction
difficulties NN I-AdverseReaction I-AdverseReaction
These NN O O
symptoms NN O O
have NN O O
been NN O O
reported NN O O
hours NN O O
to NN O O
weeks NN O O
after NN O O
injection NN O O
. NN O O
Swallowing NN O O
and NN O O
breathing NN B-AdverseReaction B-AdverseReaction
difficulties NN I-AdverseReaction I-AdverseReaction
can NN B-Factor B-Factor
be NN O O
life NN B-Severity B-Severity
threatening NN I-Severity I-Severity
and NN O O
there NN O O
have NN O O
been NN O O
reports NN O O
of NN O O
death NN B-AdverseReaction B-AdverseReaction
related NN O O
to NN O O
the NN O O
spread NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
toxin NN I-AdverseReaction I-AdverseReaction
effects NN I-AdverseReaction I-AdverseReaction
The NN O O
risk NN O O
of NN O O
symptoms NN O O
is NN O O
probably NN O O
greatest NN O O
in NN O O
children NN O O
treated NN O O
for NN O O
spasticity NN O O
but NN O O
symptoms NN O O
can NN O O
occur NN O O
in NN O O
adults NN O O
treated NN O O
for NN O O
spasticity NN O O
and NN O O
other NN O O
conditions NN O O
, NN O O
and NN O O
particularly NN O O
in NN O O
those NN O O
patients NN O O
who NN O O
have NN O O
underlying NN O O
conditions NN O O
that NN O O
would NN O O
predispose NN O O
them NN O O
to NN O O
these NN O O
symptoms NN O O
. NN O O
In NN O O
unapproved NN O O
uses NN O O
, NN O O
including NN O O
spasticity NN O O
in NN O O
children NN O O
and NN O O
adults NN O O
, NN O O
and NN O O
in NN O O
approved NN O O
indications NN O O
, NN O O
symptoms NN O O
consistent NN O O
with NN O O
spread NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
toxin NN I-AdverseReaction I-AdverseReaction
effect NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
at NN O O
doses NN O O
comparable NN O O
to NN O O
or NN O O
lower NN O O
than NN O O
doses NN O O
used NN O O
to NN O O
treat NN O O
cervical NN O O
dystonia NN O O
. NN O O
Patients NN O O
or NN O O
caregivers NN O O
should NN O O
be NN O O
advised NN O O
to NN O O
seek NN O O
immediate NN O O
medical NN O O
care NN O O
if NN O O
swallowing NN O O
, NN O O
speech NN O O
, NN O O
or NN O O
respiratory NN O O
disorders NN O O
occur NN O O
. NN O O
5.2 NN O O
Lack NN O O
of NN O O
Interchangeability NN O O
between NN O O
Botulinum NN O O
Toxin NN O O
Products NN O O
The NN O O
potency NN O O
Units NN O O
of NN O O
XEOMIN NN O O
are NN O O
specific NN O O
to NN O O
the NN O O
preparation NN O O
and NN O O
assay NN O O
method NN O O
utilized NN O O
. NN O O
They NN O O
are NN O O
not NN O O
interchangeable NN O O
with NN O O
the NN O O
other NN O O
preparations NN O O
of NN O O
botulinum NN O O
toxin NN O O
products NN O O
and NN O O
, NN O O
therefore NN O O
, NN O O
Units NN O O
of NN O O
biological NN O O
activity NN O O
of NN O O
XEOMIN NN O O
can NN O O
not NN O O
be NN O O
compared NN O O
to NN O O
or NN O O
converted NN O O
into NN O O
Units NN O O
of NN O O
any NN O O
other NN O O
botulinum NN O O
toxin NN O O
products NN O O
assessed NN O O
with NN O O
any NN O O
other NN O O
specific NN O O
assay NN O O
method NN O O
[ NN O O
see NN O O
Description NN O O
( NN O O
11 NN O O
) NN O O
] NN O O
. NN O O
5.3 NN O O
Hypersensitivity NN O O
Reactions NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
have NN O O
been NN O O
reported NN O O
with NN O O
botulinum NN B-DrugClass B-DrugClass
toxin NN I-DrugClass I-DrugClass
products NN I-DrugClass I-DrugClass
( NN O O
anaphylaxis NN O O
, NN O O
serum NN B-AdverseReaction B-AdverseReaction
sickness NN I-AdverseReaction I-AdverseReaction
urticaria NN B-AdverseReaction B-AdverseReaction
soft NN B-AdverseReaction B-AdverseReaction
tissue NN I-AdverseReaction I-AdverseReaction
edema NN I-AdverseReaction I-AdverseReaction
and NN O O
dyspnea NN B-AdverseReaction B-AdverseReaction
If NN O O
serious NN O O
and/or NN O O
immediate NN O O
hypersensitivity NN O O
reactions NN O O
occur NN O O
further NN O O
injection NN O O
of NN O O
XEOMIN NN O O
should NN O O
be NN O O
discontinued NN O O
and NN O O
appropriate NN O O
medical NN O O
therapy NN O O
immediately NN O O
instituted NN O O
. NN O O
5.4 NN O O
Dysphagia NN O O
and NN O O
Breathing NN O O
Difficulties NN O O
in NN O O
Treatment NN O O
of NN O O
Cervical NN O O
Dystonia NN O O
Treatment NN O O
with NN O O
XEOMIN NN O O
and NN O O
other NN O O
botulinum NN O O
toxin NN O O
products NN O O
can NN B-Factor B-Factor
result NN O O
in NN O O
swallowing NN O O
or NN O O
breathing NN B-AdverseReaction B-AdverseReaction
difficulties NN I-AdverseReaction I-AdverseReaction
Patients NN O O
with NN O O
pre NN O O
- NN O O
existing NN O O
swallowing NN O O
or NN O O
breathing NN O O
difficulties NN O O
may NN O O
be NN O O
more NN O O
susceptible NN O O
to NN O O
these NN O O
complications NN O O
. NN O O
In NN O O
most NN O O
cases NN O O
, NN O O
this NN O O
is NN O O
a NN O O
consequence NN O O
of NN O O
weakening NN O O
of NN O O
muscles NN O O
in NN O O
the NN O O
area NN O O
of NN O O
injection NN O O
that NN O O
are NN O O
involved NN O O
in NN O O
breathing NN O O
or NN O O
swallowing NN O O
. NN O O
When NN O O
distant NN O O
effects NN O O
occur NN O O
, NN O O
additional NN O O
respiratory NN O O
muscles NN O O
may NN O O
be NN O O
involved NN O O
[ NN O O
See NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
Deaths NN B-AdverseReaction B-AdverseReaction
as NN O O
a NN O O
complication NN O O
of NN O O
severe NN B-Severity B-Severity
dysphagia NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
after NN O O
treatment NN O O
with NN O O
botulinum NN B-DrugClass B-DrugClass
toxin NN I-DrugClass I-DrugClass
Dysphagia NN B-AdverseReaction B-AdverseReaction
may NN O O
persist NN O O
for NN O O
several NN O O
months NN O O
, NN O O
and NN O O
require NN O O
use NN O O
of NN O O
a NN O O
feeding NN O O
tube NN O O
to NN O O
maintain NN O O
adequate NN O O
nutrition NN O O
and NN O O
hydration NN O O
. NN O O
Aspiration NN B-AdverseReaction B-AdverseReaction
may NN B-Factor B-Factor
result NN O O
from NN O O
severe NN B-Severity B-Severity
dysphagia NN B-AdverseReaction B-AdverseReaction
and NN O O
is NN O O
a NN O O
particular NN O O
risk NN O O
when NN O O
treating NN O O
patients NN O O
in NN O O
whom NN O O
swallowing NN O O
or NN O O
respiratory NN O O
function NN O O
is NN O O
already NN O O
compromised NN O O
. NN O O
Treatment NN O O
of NN O O
cervical NN O O
dystonia NN O O
with NN O O
botulinum NN B-DrugClass B-DrugClass
toxins NN I-DrugClass I-DrugClass
may NN O O
weaken NN B-AdverseReaction B-AdverseReaction
neck NN I-AdverseReaction I-AdverseReaction
muscles NN I-AdverseReaction I-AdverseReaction
that NN O O
serve NN O O
as NN O O
accessory NN O O
muscles NN O O
of NN O O
ventilation NN O O
. NN O O
This NN O O
may NN B-Factor B-Factor
result NN O O
in NN O O
critical NN B-Severity B-Severity
loss NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
breathing NN I-AdverseReaction I-AdverseReaction
capacity NN I-AdverseReaction I-AdverseReaction
in NN O O
patients NN O O
with NN O O
respiratory NN O O
disorders NN O O
who NN O O
may NN O O
have NN O O
become NN O O
dependent NN O O
upon NN O O
these NN O O
accessory NN O O
muscles NN O O
. NN O O
There NN O O
have NN O O
been NN O O
post NN O O
- NN O O
marketing NN O O
reports NN O O
of NN O O
serious NN B-Severity B-Severity
breathing NN B-AdverseReaction B-AdverseReaction
difficulties NN I-AdverseReaction I-AdverseReaction
including NN O O
respiratory NN B-AdverseReaction B-AdverseReaction
failure NN I-AdverseReaction I-AdverseReaction
in NN O O
patients NN O O
with NN O O
cervical NN O O
dystonia NN O O
treated NN O O
with NN O O
botulinum NN B-DrugClass B-DrugClass
toxin NN I-DrugClass I-DrugClass
products NN I-DrugClass I-DrugClass
Patients NN O O
with NN O O
smaller NN O O
neck NN O O
muscle NN O O
mass NN O O
and NN O O
patients NN O O
who NN O O
require NN O O
bilateral NN O O
injections NN O O
into NN O O
the NN O O
sternocleidomastoid NN O O
muscles NN O O
have NN O O
been NN O O
reported NN O O
to NN O O
be NN O O
at NN O O
greater NN O O
risk NN B-Factor B-Factor
of NN O O
dysphagia NN B-AdverseReaction B-AdverseReaction
In NN O O
general NN O O
, NN O O
limiting NN O O
the NN O O
dose NN O O
injected NN O O
into NN O O
the NN O O
sternocleidomastoid NN O O
muscle NN O O
may NN O O
decrease NN O O
the NN O O
occurrence NN O O
of NN O O
dysphagia NN O O
. NN O O
Patients NN O O
treated NN O O
with NN O O
botulinum NN O O
toxin NN O O
may NN O O
require NN O O
immediate NN O O
medical NN O O
attention NN O O
should NN O O
they NN O O
develop NN O O
problems NN O O
with NN O O
swallowing NN O O
, NN O O
speech NN O O
or NN O O
respiratory NN O O
disorders NN O O
. NN O O
These NN O O
reactions NN O O
can NN O O
occur NN O O
within NN O O
hours NN O O
to NN O O
weeks NN O O
after NN O O
injection NN O O
with NN O O
botulinum NN O O
toxin NN O O
[ NN O O
See NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
and NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
5.5 NN O O
Pre NN O O
- NN O O
existing NN O O
Neuromuscular NN O O
Disorders NN O O
and NN O O
other NN O O
Special NN O O
Populations NN O O
Individuals NN O O
with NN O O
peripheral NN O O
motor NN O O
neuropathic NN O O
diseases NN O O
, NN O O
amyotrophic NN O O
lateral NN O O
sclerosis NN O O
, NN O O
or NN O O
neuromuscular NN O O
junctional NN O O
disorders NN O O
( NN O O
e.g. NN O O
, NN O O
myasthenia NN O O
gravis NN O O
or NN O O
Lambert NN O O
- NN O O
Eaton NN O O
syndrome NN O O
) NN O O
should NN O O
be NN O O
monitored NN O O
particularly NN O O
closely NN O O
when NN O O
given NN O O
botulinum NN O O
toxin NN O O
. NN O O
Patients NN O O
with NN O O
neuromuscular NN O O
disorders NN O O
may NN O O
be NN O O
at NN O O
increased NN O O
risk NN B-Factor B-Factor
of NN O O
clinically NN O O
significant NN O O
effects NN O O
including NN O O
severe NN B-Severity B-Severity
dysphagia NN B-AdverseReaction B-AdverseReaction
and NN O O
respiratory NN B-AdverseReaction B-AdverseReaction
compromise NN I-AdverseReaction I-AdverseReaction
from NN O O
typical NN O O
doses NN O O
of NN O O
XEOMIN NN O O
[ NN O O
See NN O O
Adverse NN O O
Reactions NN O O
( NN O O
6.1 NN O O
) NN O O
] NN O O
. NN O O
5.6 NN O O
Corneal NN O O
Exposure NN O O
, NN O O
Corneal NN O O
Ulceration NN O O
, NN O O
and NN O O
Ectropion NN O O
in NN O O
Patients NN O O
Treated NN O O
with NN O O
XEOMIN NN O O
for NN O O
Blepharospasm NN O O
Reduced NN B-AdverseReaction B-AdverseReaction
blinking NN I-AdverseReaction I-AdverseReaction
from NN O O
injection NN O O
of NN O O
botulinum NN B-DrugClass B-DrugClass
toxin NN I-DrugClass I-DrugClass
products NN I-DrugClass I-DrugClass
in NN O O
the NN O O
orbicularis NN O O
muscle NN O O
can NN O O
lead NN O O
to NN O O
corneal NN B-AdverseReaction B-AdverseReaction
exposure NN I-AdverseReaction I-AdverseReaction
persistent NN O O
epithelial NN O O
defect NN O O
and NN O O
corneal NN B-AdverseReaction B-AdverseReaction
ulceration NN I-AdverseReaction I-AdverseReaction
especially NN O O
in NN O O
patients NN O O
with NN O O
VII NN O O
nerve NN O O
disorders NN O O
. NN O O
Careful NN O O
testing NN O O
of NN O O
corneal NN O O
sensation NN O O
in NN O O
eyes NN O O
previously NN O O
operated NN O O
upon NN O O
, NN O O
avoidance NN O O
of NN O O
injection NN O O
into NN O O
the NN O O
lower NN O O
lid NN O O
area NN O O
to NN O O
avoid NN O O
ectropion NN O O
, NN O O
and NN O O
vigorous NN O O
treatment NN O O
of NN O O
any NN O O
epithelial NN O O
defect NN O O
should NN O O
be NN O O
employed NN O O
. NN O O
This NN O O
may NN O O
require NN O O
protective NN O O
drops NN O O
, NN O O
ointment NN O O
, NN O O
therapeutic NN O O
soft NN O O
contact NN O O
lenses NN O O
, NN O O
or NN O O
closure NN O O
of NN O O
the NN O O
eye NN O O
by NN O O
patching NN O O
or NN O O
other NN O O
means NN O O
. NN O O
Because NN O O
of NN O O
its NN O O
anticholinergic NN O O
effects NN O O
, NN O O
XEOMIN NN O O
should NN O O
be NN O O
used NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
at NN O O
risk NN O O
of NN O O
developing NN O O
narrow NN O O
angle NN O O
glaucoma NN O O
. NN O O
To NN O O
prevent NN O O
ectropion NN O O
, NN O O
botulinum NN O O
toxin NN O O
products NN O O
should NN O O
not NN O O
be NN O O
injected NN O O
into NN O O
the NN O O
medial NN O O
lower NN O O
eyelid NN O O
area NN O O
. NN O O
Ecchymosis NN O O
easily NN O O
occurs NN O O
in NN O O
the NN O O
soft NN O O
tissues NN O O
of NN O O
the NN O O
eyelid NN O O
. NN O O
Immediate NN O O
gentle NN O O
pressure NN O O
at NN O O
the NN O O
injection NN O O
site NN O O
can NN O O
limit NN O O
that NN O O
risk NN O O
. NN O O
5.7 NN O O
Risk NN O O
of NN O O
Ptosis NN O O
in NN O O
Patients NN O O
Treated NN O O
with NN O O
XEOMIN NN O O
for NN O O
Glabellar NN O O
Lines NN O O
Do NN O O
not NN O O
exceed NN O O
the NN O O
recommended NN O O
dosage NN O O
and NN O O
frequency NN O O
of NN O O
administration NN O O
of NN O O
XEOMIN. NN O O
In NN O O
order NN O O
to NN O O
reduce NN O O
the NN O O
complication NN O O
of NN O O
ptosis NN O O
the NN O O
following NN O O
steps NN O O
should NN O O
be NN O O
taken NN O O
: NN O O
* NN O O
Avoid NN O O
injection NN O O
near NN O O
the NN O O
levator NN O O
palpebrae NN O O
superioris NN O O
, NN O O
particularly NN O O
in NN O O
patients NN O O
with NN O O
larger NN O O
brow NN O O
depressor NN O O
complexes NN O O
. NN O O
* NN O O
Corrugator NN O O
injections NN O O
should NN O O
be NN O O
placed NN O O
at NN O O
least NN O O
1 NN O O
cm NN O O
above NN O O
the NN O O
bony NN O O
supraorbital NN O O
ridge NN O O
. NN O O
5.8 NN O O
Human NN O O
Albumin NN O O
and NN O O
Transmission NN O O
of NN O O
Viral NN O O
Diseases NN O O
This NN O O
product NN O O
contains NN O O
albumin NN O O
, NN O O
a NN O O
derivative NN O O
of NN O O
human NN O O
blood NN O O
. NN O O
Based NN O O
on NN O O
effective NN O O
donor NN O O
screening NN O O
and NN O O
product NN O O
manufacturing NN O O
processes NN O O
, NN O O
it NN O O
carries NN O O
an NN O O
extremely NN O O
remote NN O O
risk NN B-Factor B-Factor
for NN O O
transmission NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
viral NN I-AdverseReaction I-AdverseReaction
diseases NN I-AdverseReaction I-AdverseReaction
A NN O O
theoretical NN O O
risk NN B-Factor B-Factor
for NN O O
transmission NN O O
of NN O O
Creutzfeldt NN B-AdverseReaction B-AdverseReaction
- NN I-AdverseReaction I-AdverseReaction
Jakob NN I-AdverseReaction I-AdverseReaction
disease NN I-AdverseReaction I-AdverseReaction
( NN O O
CJD NN O O
) NN O O
is NN O O
also NN O O
considered NN O O
extremely NN O O
remote NN O O
. NN O O
No NN O O
cases NN O O
of NN O O
transmission NN O O
of NN O O
viral NN O O
diseases NN O O
or NN O O
CJD NN O O
have NN O O
ever NN O O
been NN O O
reported NN O O
for NN O O
albumin NN O O
. NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
LABA NN O O
, NN O O
such NN O O
as NN O O
vilanterol NN O O
, NN O O
one NN O O
of NN O O
the NN O O
active NN O O
ingredients NN O O
in NN O O
BREO NN O O
ELLIPTA NN O O
, NN O O
increase NN O O
the NN O O
risk NN B-Factor B-Factor
of NN O O
asthma NN O O
- NN O O
related NN O O
death NN B-AdverseReaction B-AdverseReaction
Currently NN O O
available NN O O
data NN O O
are NN O O
inadequate NN O O
to NN O O
determine NN O O
whether NN O O
concurrent NN O O
use NN O O
of NN O O
inhaled NN O O
corticosteroids NN O O
or NN O O
other NN O O
long NN O O
- NN O O
term NN O O
asthma NN O O
control NN O O
drugs NN O O
mitigates NN O O
the NN O O
increased NN O O
risk NN O O
of NN O O
asthma NN O O
- NN O O
related NN O O
death NN B-AdverseReaction B-AdverseReaction
from NN O O
LABA NN B-DrugClass B-DrugClass
Available NN O O
data NN O O
from NN O O
controlled NN O O
clinical NN O O
trials NN O O
suggest NN O O
that NN O O
LABA NN O O
increase NN O O
the NN O O
risk NN O O
of NN O O
asthma NN O O
- NN O O
related NN O O
hospitalization NN O O
in NN O O
pediatric NN O O
and NN O O
adolescent NN O O
patients NN O O
. NN O O
Data NN O O
from NN O O
a NN O O
large NN O O
placebo NN O O
- NN O O
controlled NN O O
US NN O O
trial NN O O
that NN O O
compared NN O O
the NN O O
safety NN O O
of NN O O
another NN O O
LABA NN B-DrugClass B-DrugClass
( NN O O
salmeterol NN O O
) NN O O
or NN O O
placebo NN O O
added NN O O
to NN O O
usual NN O O
asthma NN O O
therapy NN O O
showed NN O O
an NN O O
increase NN O O
in NN O O
asthma NN O O
- NN O O
related NN O O
deaths NN B-AdverseReaction B-AdverseReaction
in NN O O
subjects NN O O
receiving NN O O
salmeterol NN O O
. NN O O
[ NN O O
See NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
. NN O O
] NN O O
Systemic NN O O
and NN O O
local NN O O
corticosteroid NN O O
use NN O O
may NN O O
result NN O O
in NN O O
the NN O O
following NN O O
: NN O O
* NN O O
Candida NN B-AdverseReaction B-AdverseReaction
albicans NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
* NN O O
Increased NN O O
risk NN B-Factor B-Factor
of NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
in NN O O
COPD NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
* NN O O
Immunosuppression NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.6 NN O O
) NN O O
] NN O O
* NN O O
Hypercorticism NN B-AdverseReaction B-AdverseReaction
and NN O O
adrenal NN B-AdverseReaction B-AdverseReaction
suppression NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.8 NN O O
) NN O O
] NN O O
* NN O O
Reduction NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
bone NN I-AdverseReaction I-AdverseReaction
mineral NN I-AdverseReaction I-AdverseReaction
density NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.13 NN O O
) NN O O
] NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
with NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
practice NN O O
. NN O O
EXCERPT NN O O
: NN O O
* NN O O
COPD NN O O
: NN O O
Most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
incidence NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
3 NN O O
% NN O O
) NN O O
are NN O O
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
and NN O O
oral NN B-AdverseReaction B-AdverseReaction
candidiasis NN I-AdverseReaction I-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
* NN O O
Asthma NN O O
: NN O O
Most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
incidence NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
2 NN O O
% NN O O
) NN O O
are NN O O
nasopharyngitis NN B-AdverseReaction B-AdverseReaction
oral NN B-AdverseReaction B-AdverseReaction
candidiasis NN I-AdverseReaction I-AdverseReaction
headache NN B-AdverseReaction B-AdverseReaction
influenza NN B-AdverseReaction B-AdverseReaction
upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
bronchitis NN B-AdverseReaction B-AdverseReaction
sinusitis NN B-AdverseReaction B-AdverseReaction
oropharyngeal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
dysphonia NN B-AdverseReaction B-AdverseReaction
and NN O O
cough NN B-AdverseReaction B-AdverseReaction
( NN O O
6.2 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
GlaxoSmithKline NN O O
at NN O O
1 NN O O
- NN O O
888 NN O O
- NN O O
825 NN O O
- NN O O
5249 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
in NN O O
Chronic NN O O
Obstructive NN O O
Pulmonary NN O O
Disease NN O O
The NN O O
clinical NN O O
program NN O O
for NN O O
BREO NN O O
ELLIPTA NN O O
included NN O O
7,700 NN O O
subjects NN O O
with NN O O
COPD NN O O
in NN O O
two NN O O
6-month NN O O
lung NN O O
function NN O O
trials NN O O
, NN O O
two NN O O
12-month NN O O
exacerbation NN O O
trials NN O O
, NN O O
and NN O O
6 NN O O
other NN O O
trials NN O O
of NN O O
shorter NN O O
duration NN O O
. NN O O
A NN O O
total NN O O
of NN O O
2,034 NN O O
subjects NN O O
with NN O O
COPD NN O O
received NN O O
at NN O O
least NN O O
1 NN O O
dose NN O O
of NN O O
BREO NN O O
ELLIPTA NN O O
100/25 NN O O
, NN O O
and NN O O
1,087 NN O O
subjects NN O O
received NN O O
a NN O O
higher NN O O
strength NN O O
of NN O O
fluticasone NN O O
furoate/vilanterol NN O O
. NN O O
The NN O O
safety NN O O
data NN O O
described NN O O
below NN O O
are NN O O
based NN O O
on NN O O
the NN O O
confirmatory NN O O
6- NN O O
and NN O O
12-month NN O O
trials NN O O
. NN O O
Adverse NN O O
reactions NN O O
observed NN O O
in NN O O
the NN O O
other NN O O
trials NN O O
were NN O O
similar NN O O
to NN O O
those NN O O
observed NN O O
in NN O O
the NN O O
confirmatory NN O O
trials NN O O
. NN O O
6-Month NN O O
Trials NN O O
The NN O O
incidence NN O O
of NN O O
adverse NN O O
reactions NN O O
associated NN O O
with NN O O
BREO NN O O
ELLIPTA NN O O
100/25 NN O O
in NN O O
Table NN O O
1 NN O O
is NN O O
based NN O O
on NN O O
2 NN O O
placebo NN O O
- NN O O
controlled NN O O
, NN O O
6-month NN O O
clinical NN O O
trials NN O O
( NN O O
Trials NN O O
1 NN O O
and NN O O
2 NN O O
; NN O O
n NN O O
= NN O O
1,224 NN O O
and NN O O
n NN O O
= NN O O
1,030 NN O O
, NN O O
respectively NN O O
) NN O O
. NN O O
Of NN O O
the NN O O
2,254 NN O O
subjects NN O O
, NN O O
70 NN O O
% NN O O
were NN O O
male NN O O
and NN O O
84 NN O O
% NN O O
were NN O O
white NN O O
. NN O O
They NN O O
had NN O O
a NN O O
mean NN O O
age NN O O
of NN O O
62 NN O O
years NN O O
and NN O O
an NN O O
average NN O O
smoking NN O O
history NN O O
of NN O O
44 NN O O
pack NN O O
- NN O O
years NN O O
, NN O O
with NN O O
54 NN O O
% NN O O
identified NN O O
as NN O O
current NN O O
smokers NN O O
. NN O O
At NN O O
screening NN O O
, NN O O
the NN O O
mean NN O O
postbronchodilator NN O O
percent NN O O
predicted NN O O
FEV1was NN O O
48 NN O O
% NN O O
( NN O O
range NN O O
: NN O O
14 NN O O
% NN O O
to NN O O
87 NN O O
% NN O O
) NN O O
, NN O O
the NN O O
mean NN O O
postbronchodilator NN O O
FEV1/forced NN O O
vital NN O O
capacity NN O O
( NN O O
FVC NN O O
) NN O O
ratio NN O O
was NN O O
47 NN O O
% NN O O
( NN O O
range NN O O
: NN O O
17 NN O O
% NN O O
to NN O O
88 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
the NN O O
mean NN O O
percent NN O O
reversibility NN O O
was NN O O
14 NN O O
% NN O O
( NN O O
range NN O O
: NN O O
-41 NN O O
% NN O O
to NN O O
152 NN O O
% NN O O
) NN O O
. NN O O
Subjects NN O O
received NN O O
1 NN O O
inhalation NN O O
once NN O O
daily NN O O
of NN O O
the NN O O
following NN O O
: NN O O
BREO NN O O
ELLIPTA NN O O
100/25 NN O O
, NN O O
BREO NN O O
ELLIPTA NN O O
200/25 NN O O
, NN O O
fluticasone NN O O
furoate/vilanterol NN O O
50 NN O O
mcg/25 NN O O
mcg NN O O
, NN O O
fluticasone NN O O
furoate NN O O
100 NN O O
mcg NN O O
, NN O O
fluticasone NN O O
furoate NN O O
200 NN O O
mcg NN O O
, NN O O
vilanterol NN O O
25 NN O O
mcg NN O O
, NN O O
or NN O O
placebo NN O O
. NN O O
Table NN O O
1 NN O O
. NN O O
Adverse NN O O
Reactions NN O O
with NN O O
BREO NN O O
ELLIPTA NN O O
100/25 NN O O
with NN O O
>=3 NN O O
% NN O O
Incidence NN O O
and NN O O
More NN O O
Common NN O O
than NN O O
Placebo NN O O
in NN O O
Subjects NN O O
with NN O O
Chronic NN O O
Obstructive NN O O
Pulmonary NN O O
Disease NN O O
Adverse NN O O
Reaction NN O O
BREO NN O O
ELLIPTA NN O O
100/25 NN O O
( NN O O
n NN O O
= NN O O
410 NN O O
) NN O O
% NN O O
Vilanterol NN O O
25 NN O O
mcg NN O O
( NN O O
n NN O O
= NN O O
408 NN O O
) NN O O
% NN O O
Fluticasone NN O O
Furoate NN O O
100 NN O O
mcg NN O O
( NN O O
n NN O O
= NN O O
410 NN O O
) NN O O
% NN O O
Placebo NN O O
( NN O O
n NN O O
= NN O O
412 NN O O
) NN O O
% NN O O
Infections NN O O
and NN O O
infestations NN O O
Nasopharyngitis NN B-AdverseReaction B-AdverseReaction
9 NN O O
10 NN O O
8 NN O O
8 NN O O
Upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
7 NN O O
5 NN O O
4 NN O O
3 NN O O
Oropharyngeal NN B-AdverseReaction B-AdverseReaction
candidiasis NN I-AdverseReaction I-AdverseReaction
a NN O O
5 NN O O
2 NN O O
3 NN O O
2 NN O O
Nervous NN O O
system NN O O
disorders NN O O
Headache NN B-AdverseReaction B-AdverseReaction
7 NN O O
9 NN O O
7 NN O O
5 NN O O
a NN O O
Includes NN O O
oral NN B-AdverseReaction B-AdverseReaction
candidiasis NN I-AdverseReaction I-AdverseReaction
oropharyngeal NN B-AdverseReaction B-AdverseReaction
candidiasis NN I-AdverseReaction I-AdverseReaction
candidiasis NN B-AdverseReaction B-AdverseReaction
and NN O O
fungal NN B-AdverseReaction B-AdverseReaction
oropharyngitis NN I-AdverseReaction I-AdverseReaction
12-Month NN O O
Trials NN O O
Long NN O O
- NN O O
term NN O O
safety NN O O
data NN O O
is NN O O
based NN O O
on NN O O
two NN O O
12-month NN O O
trials NN O O
( NN O O
Trials NN O O
3 NN O O
and NN O O
4 NN O O
; NN O O
n NN O O
= NN O O
1,633 NN O O
and NN O O
n NN O O
= NN O O
1,622 NN O O
, NN O O
respectively NN O O
) NN O O
. NN O O
Trials NN O O
3 NN O O
and NN O O
4 NN O O
included NN O O
3,255 NN O O
subjects NN O O
, NN O O
of NN O O
which NN O O
57 NN O O
% NN O O
were NN O O
male NN O O
and NN O O
85 NN O O
% NN O O
were NN O O
white NN O O
. NN O O
They NN O O
had NN O O
a NN O O
mean NN O O
age NN O O
of NN O O
64 NN O O
years NN O O
and NN O O
an NN O O
average NN O O
smoking NN O O
history NN O O
of NN O O
46 NN O O
pack NN O O
- NN O O
years NN O O
, NN O O
with NN O O
44 NN O O
% NN O O
identified NN O O
as NN O O
current NN O O
smokers NN O O
. NN O O
At NN O O
screening NN O O
, NN O O
the NN O O
mean NN O O
postbronchodilator NN O O
percent NN O O
predicted NN O O
FEV1was NN O O
45 NN O O
% NN O O
( NN O O
range NN O O
: NN O O
12 NN O O
% NN O O
to NN O O
91 NN O O
% NN O O
) NN O O
, NN O O
and NN O O
the NN O O
mean NN O O
postbronchodilator NN O O
FEV1/FVC NN O O
ratio NN O O
was NN O O
46 NN O O
% NN O O
( NN O O
range NN O O
: NN O O
17 NN O O
% NN O O
to NN O O
81 NN O O
% NN O O
) NN O O
, NN O O
indicating NN O O
that NN O O
the NN O O
subject NN O O
population NN O O
had NN O O
moderate NN O O
to NN O O
very NN O O
severely NN O O
impaired NN O O
airflow NN O O
obstruction NN O O
. NN O O
Subjects NN O O
received NN O O
1 NN O O
inhalation NN O O
once NN O O
daily NN O O
of NN O O
the NN O O
following NN O O
: NN O O
BREO NN O O
ELLIPTA NN O O
100/25 NN O O
, NN O O
BREO NN O O
ELLIPTA NN O O
200/25 NN O O
, NN O O
fluticasone NN O O
furoate/vilanterol NN O O
50 NN O O
mcg/25 NN O O
mcg NN O O
, NN O O
or NN O O
vilanterol NN O O
25 NN O O
mcg NN O O
. NN O O
In NN O O
addition NN O O
to NN O O
the NN O O
reactions NN O O
shown NN O O
in NN O O
Table NN O O
1 NN O O
, NN O O
adverse NN O O
reactions NN O O
occurring NN O O
in NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
3 NN O O
% NN O O
of NN O O
the NN O O
subjects NN O O
treated NN O O
with NN O O
BREO NN O O
ELLIPTA NN O O
100/25 NN O O
( NN O O
n NN O O
= NN O O
806 NN O O
) NN O O
for NN O O
12 NN O O
months NN O O
included NN O O
back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
pneumonia NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.5 NN O O
) NN O O
] NN O O
, NN O O
bronchitis NN B-AdverseReaction B-AdverseReaction
sinusitis NN B-AdverseReaction B-AdverseReaction
cough NN B-AdverseReaction B-AdverseReaction
oropharyngeal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
arthralgia NN B-AdverseReaction B-AdverseReaction
influenza NN B-AdverseReaction B-AdverseReaction
pharyngitis NN B-AdverseReaction B-AdverseReaction
and NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
6.2 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
in NN O O
Asthma NN O O
BREO NN O O
ELLIPTA NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
asthma NN O O
was NN O O
studied NN O O
in NN O O
18 NN O O
double NN O O
- NN O O
blind NN O O
, NN O O
parallel NN O O
- NN O O
group NN O O
, NN O O
controlled NN O O
trials NN O O
( NN O O
11 NN O O
with NN O O
placebo NN O O
) NN O O
of NN O O
4 NN O O
to NN O O
76 NN O O
weeks NN O O
' NN O O
duration NN O O
, NN O O
which NN O O
enrolled NN O O
9,969 NN O O
subjects NN O O
with NN O O
asthma NN O O
. NN O O
BREO NN O O
ELLIPTA NN O O
100/25 NN O O
was NN O O
studied NN O O
in NN O O
2,369 NN O O
subjects NN O O
and NN O O
BREO NN O O
ELLIPTA NN O O
200/25 NN O O
was NN O O
studied NN O O
in NN O O
956 NN O O
subjects NN O O
. NN O O
While NN O O
subjects NN O O
aged NN O O
12 NN O O
to NN O O
17 NN O O
years NN O O
were NN O O
included NN O O
in NN O O
these NN O O
trials NN O O
, NN O O
BREO NN O O
ELLIPTA NN O O
is NN O O
not NN O O
approved NN O O
for NN O O
use NN O O
in NN O O
this NN O O
age NN O O
- NN O O
group NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.4 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
safety NN O O
data NN O O
described NN O O
below NN O O
are NN O O
based NN O O
on NN O O
two NN O O
12-week NN O O
efficacy NN O O
trials NN O O
, NN O O
one NN O O
24-week NN O O
efficacy NN O O
trial NN O O
, NN O O
and NN O O
two NN O O
long NN O O
- NN O O
term NN O O
trials NN O O
. NN O O
12-Week NN O O
Trials NN O O
Trial NN O O
1 NN O O
was NN O O
a NN O O
12-week NN O O
trial NN O O
that NN O O
evaluated NN O O
the NN O O
efficacy NN O O
of NN O O
BREO NN O O
ELLIPTA NN O O
100/25 NN O O
in NN O O
adolescent NN O O
and NN O O
adult NN O O
subjects NN O O
with NN O O
asthma NN O O
compared NN O O
with NN O O
fluticasone NN O O
furoate NN O O
100 NN O O
mcg NN O O
and NN O O
placebo NN O O
. NN O O
Of NN O O
the NN O O
609 NN O O
subjects NN O O
, NN O O
58 NN O O
% NN O O
were NN O O
female NN O O
and NN O O
84 NN O O
% NN O O
were NN O O
white NN O O
; NN O O
the NN O O
mean NN O O
age NN O O
was NN O O
40 NN O O
years NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
adverse NN O O
reactions NN O O
associated NN O O
with NN O O
BREO NN O O
ELLIPTA NN O O
100/25 NN O O
is NN O O
shown NN O O
in NN O O
Table NN O O
2 NN O O
. NN O O
Table NN O O
2 NN O O
. NN O O
Adverse NN O O
Reactions NN O O
with NN O O
BREO NN O O
ELLIPTA NN O O
100/25 NN O O
with NN O O
>=2 NN O O
% NN O O
Incidence NN O O
and NN O O
More NN O O
Common NN O O
than NN O O
Placebo NN O O
in NN O O
Subjects NN O O
with NN O O
Asthma NN O O
( NN O O
Trial NN O O
1 NN O O
) NN O O
Adverse NN O O
Reaction NN O O
BREO NN O O
ELLIPTA NN O O
100/25 NN O O
( NN O O
n NN O O
= NN O O
201 NN O O
) NN O O
% NN O O
Fluticasone NN O O
Furoate NN O O
100 NN O O
mcg NN O O
( NN O O
n NN O O
= NN O O
205 NN O O
) NN O O
% NN O O
Placebo NN O O
( NN O O
n NN O O
= NN O O
203 NN O O
) NN O O
% NN O O
Infections NN O O
and NN O O
infestations NN O O
Nasopharyngitis NN B-AdverseReaction B-AdverseReaction
10 NN O O
7 NN O O
7 NN O O
Oral NN B-AdverseReaction B-AdverseReaction
candidiasis NN I-AdverseReaction I-AdverseReaction
a NN O O
2 NN O O
2 NN O O
0 NN O O
Nervous NN O O
system NN O O
disorders NN O O
Headache NN B-AdverseReaction B-AdverseReaction
5 NN O O
4 NN O O
4 NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
, NN O O
and NN O O
mediastinal NN O O
disorders NN O O
Oropharyngeal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
2 NN O O
2 NN O O
1 NN O O
Dysphonia NN B-AdverseReaction B-AdverseReaction
2 NN O O
1 NN O O
0 NN O O
a NN O O
Includes NN O O
oral NN B-AdverseReaction B-AdverseReaction
candidiasis NN I-AdverseReaction I-AdverseReaction
and NN O O
oropharyngeal NN B-AdverseReaction B-AdverseReaction
candidiasis NN I-AdverseReaction I-AdverseReaction
Trial NN O O
2 NN O O
was NN O O
a NN O O
12-week NN O O
trial NN O O
that NN O O
evaluated NN O O
the NN O O
efficacy NN O O
of NN O O
BREO NN O O
ELLIPTA NN O O
100/25 NN O O
, NN O O
BREO NN O O
ELLIPTA NN O O
200/25 NN O O
, NN O O
and NN O O
fluticasone NN O O
furoate NN O O
100 NN O O
mcg NN O O
in NN O O
adolescent NN O O
and NN O O
adult NN O O
subjects NN O O
with NN O O
asthma NN O O
. NN O O
This NN O O
trial NN O O
did NN O O
not NN O O
have NN O O
a NN O O
placebo NN O O
arm NN O O
. NN O O
Of NN O O
the NN O O
1,039 NN O O
subjects NN O O
, NN O O
60 NN O O
% NN O O
were NN O O
female NN O O
and NN O O
88 NN O O
% NN O O
were NN O O
white NN O O
; NN O O
the NN O O
mean NN O O
age NN O O
was NN O O
46 NN O O
years NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
adverse NN O O
reactions NN O O
associated NN O O
with NN O O
BREO NN O O
ELLIPTA NN O O
100/25 NN O O
and NN O O
BREO NN O O
ELLIPTA NN O O
200/25 NN O O
is NN O O
shown NN O O
in NN O O
Table NN O O
3 NN O O
. NN O O
Table NN O O
3 NN O O
. NN O O
Adverse NN O O
Reactions NN O O
with NN O O
BREO NN O O
ELLIPTA NN O O
100/25 NN O O
and NN O O
BREO NN O O
ELLIPTA NN O O
200/25 NN O O
with NN O O
>=2 NN O O
% NN O O
Incidence NN O O
in NN O O
Subjects NN O O
with NN O O
Asthma NN O O
( NN O O
Trial NN O O
2 NN O O
) NN O O
Adverse NN O O
Reaction NN O O
BREO NN O O
ELLIPTA NN O O
200/25 NN O O
( NN O O
n NN O O
= NN O O
346 NN O O
) NN O O
% NN O O
BREO NN O O
ELLIPTA NN O O
100/25 NN O O
( NN O O
n NN O O
= NN O O
346 NN O O
) NN O O
% NN O O
Fluticasone NN O O
Furoate NN O O
100 NN O O
mcg NN O O
( NN O O
n NN O O
= NN O O
347 NN O O
) NN O O
% NN O O
Nervous NN O O
system NN O O
disorders NN O O
Headache NN B-AdverseReaction B-AdverseReaction
8 NN O O
8 NN O O
9 NN O O
Infections NN O O
and NN O O
infestations NN O O
Nasopharyngitis NN B-AdverseReaction B-AdverseReaction
7 NN O O
6 NN O O
7 NN O O
Influenza NN B-AdverseReaction B-AdverseReaction
3 NN O O
3 NN O O
1 NN O O
Upper NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
2 NN O O
2 NN O O
3 NN O O
Sinusitis NN B-AdverseReaction B-AdverseReaction
2 NN O O
1 NN O O
< NN O O
1 NN O O
Bronchitis NN B-AdverseReaction B-AdverseReaction
2 NN O O
< NN O O
1 NN O O
2 NN O O
Respiratory NN O O
, NN O O
thoracic NN O O
and NN O O
mediastinal NN O O
disorders NN O O
Oropharyngeal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
2 NN O O
2 NN O O
1 NN O O
Cough NN B-AdverseReaction B-AdverseReaction
1 NN O O
2 NN O O
1 NN O O
24-Week NN O O
Trial NN O O
Trial NN O O
3 NN O O
was NN O O
a NN O O
24-week NN O O
trial NN O O
that NN O O
evaluated NN O O
the NN O O
efficacy NN O O
of NN O O
BREO NN O O
ELLIPTA NN O O
200/25 NN O O
once NN O O
daily NN O O
, NN O O
fluticasone NN O O
furoate NN O O
200 NN O O
mcg NN O O
once NN O O
daily NN O O
, NN O O
and NN O O
fluticasone NN O O
propionate NN O O
500 NN O O
mcg NN O O
twice NN O O
daily NN O O
in NN O O
adolescent NN O O
and NN O O
adult NN O O
subjects NN O O
with NN O O
asthma NN O O
. NN O O
Of NN O O
the NN O O
586 NN O O
subjects NN O O
, NN O O
59 NN O O
% NN O O
were NN O O
female NN O O
and NN O O
84 NN O O
% NN O O
were NN O O
white NN O O
; NN O O
the NN O O
mean NN O O
age NN O O
was NN O O
46 NN O O
years NN O O
. NN O O
This NN O O
trial NN O O
did NN O O
not NN O O
have NN O O
a NN O O
placebo NN O O
arm NN O O
. NN O O
In NN O O
addition NN O O
to NN O O
the NN O O
reactions NN O O
shown NN O O
in NN O O
Tables NN O O
2 NN O O
and NN O O
3 NN O O
, NN O O
adverse NN O O
reactions NN O O
occurring NN O O
in NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
2 NN O O
% NN O O
of NN O O
subjects NN O O
treated NN O O
with NN O O
BREO NN O O
ELLIPTA NN O O
200/25 NN O O
included NN O O
viral NN B-AdverseReaction B-AdverseReaction
respiratory NN I-AdverseReaction I-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
pharyngitis NN B-AdverseReaction B-AdverseReaction
pyrexia NN B-AdverseReaction B-AdverseReaction
and NN O O
arthralgia NN B-AdverseReaction B-AdverseReaction
12-Month NN O O
Trial NN O O
Long NN O O
- NN O O
term NN O O
safety NN O O
data NN O O
is NN O O
based NN O O
on NN O O
a NN O O
12-month NN O O
trial NN O O
that NN O O
evaluated NN O O
the NN O O
safety NN O O
of NN O O
BREO NN O O
ELLIPTA NN O O
100/25 NN O O
once NN O O
daily NN O O
( NN O O
n NN O O
= NN O O
201 NN O O
) NN O O
, NN O O
BREO NN O O
ELLIPTA NN O O
200/25 NN O O
once NN O O
daily NN O O
( NN O O
n NN O O
= NN O O
202 NN O O
) NN O O
, NN O O
and NN O O
fluticasone NN O O
propionate NN O O
500 NN O O
mcg NN O O
twice NN O O
daily NN O O
( NN O O
n NN O O
= NN O O
100 NN O O
) NN O O
in NN O O
adolescent NN O O
and NN O O
adult NN O O
subjects NN O O
with NN O O
asthma NN O O
( NN O O
Trial NN O O
4 NN O O
) NN O O
. NN O O
Overall NN O O
, NN O O
63 NN O O
% NN O O
were NN O O
female NN O O
and NN O O
67 NN O O
% NN O O
were NN O O
white NN O O
. NN O O
The NN O O
mean NN O O
age NN O O
was NN O O
39 NN O O
years NN O O
; NN O O
adolescents NN O O
( NN O O
aged NN O O
12 NN O O
to NN O O
17 NN O O
years NN O O
) NN O O
made NN O O
up NN O O
16 NN O O
% NN O O
of NN O O
the NN O O
population NN O O
. NN O O
In NN O O
addition NN O O
to NN O O
the NN O O
reactions NN O O
shown NN O O
in NN O O
Tables NN O O
2 NN O O
and NN O O
3 NN O O
, NN O O
adverse NN O O
reactions NN O O
occurring NN O O
in NN O O
greater NN O O
than NN O O
or NN O O
equal NN O O
to NN O O
2 NN O O
% NN O O
of NN O O
the NN O O
subjects NN O O
treated NN O O
with NN O O
BREO NN O O
ELLIPTA NN O O
100/25 NN O O
or NN O O
BREO NN O O
ELLIPTA NN O O
200/25 NN O O
for NN O O
12 NN O O
months NN O O
included NN O O
pyrexia NN B-AdverseReaction B-AdverseReaction
back NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
extrasystoles NN B-AdverseReaction B-AdverseReaction
upper NN B-AdverseReaction B-AdverseReaction
abdominal NN I-AdverseReaction I-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
respiratory NN B-AdverseReaction B-AdverseReaction
tract NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
allergic NN B-AdverseReaction B-AdverseReaction
rhinitis NN I-AdverseReaction I-AdverseReaction
pharyngitis NN B-AdverseReaction B-AdverseReaction
rhinitis NN B-AdverseReaction B-AdverseReaction
arthralgia NN B-AdverseReaction B-AdverseReaction
supraventricular NN B-AdverseReaction B-AdverseReaction
extrasystoles NN I-AdverseReaction I-AdverseReaction
ventricular NN B-AdverseReaction B-AdverseReaction
extrasystoles NN I-AdverseReaction I-AdverseReaction
acute NN B-AdverseReaction B-AdverseReaction
sinusitis NN I-AdverseReaction I-AdverseReaction
and NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
Exacerbation NN O O
Trial NN O O
In NN O O
a NN O O
24- NN O O
to NN O O
76-week NN O O
trial NN O O
, NN O O
subjects NN O O
received NN O O
BREO NN O O
ELLIPTA NN O O
100/25 NN O O
( NN O O
n NN O O
= NN O O
1,009 NN O O
) NN O O
or NN O O
fluticasone NN O O
furoate NN O O
100 NN O O
mcg NN O O
( NN O O
n NN O O
= NN O O
1,010 NN O O
) NN O O
( NN O O
Trial NN O O
5 NN O O
) NN O O
. NN O O
Subjects NN O O
participating NN O O
in NN O O
this NN O O
trial NN O O
had NN O O
a NN O O
history NN O O
of NN O O
one NN O O
or NN O O
more NN O O
asthma NN O O
exacerbations NN O O
that NN O O
required NN O O
treatment NN O O
with NN O O
oral/systemic NN O O
corticosteroids NN O O
or NN O O
emergency NN O O
department NN O O
visit NN O O
or NN O O
in NN O O
- NN O O
patient NN O O
hospitalization NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
asthma NN O O
in NN O O
the NN O O
year NN O O
prior NN O O
to NN O O
trial NN O O
entry NN O O
. NN O O
Overall NN O O
, NN O O
67 NN O O
% NN O O
were NN O O
female NN O O
and NN O O
73 NN O O
% NN O O
were NN O O
white NN O O
; NN O O
the NN O O
mean NN O O
age NN O O
was NN O O
42 NN O O
years NN O O
( NN O O
adolescents NN O O
aged NN O O
12 NN O O
to NN O O
17 NN O O
years NN O O
made NN O O
up NN O O
14 NN O O
% NN O O
of NN O O
the NN O O
population NN O O
) NN O O
. NN O O
While NN O O
subjects NN O O
aged NN O O
12 NN O O
to NN O O
17 NN O O
years NN O O
were NN O O
included NN O O
in NN O O
this NN O O
trial NN O O
, NN O O
BREO NN O O
ELLIPTA NN O O
is NN O O
not NN O O
approved NN O O
for NN O O
use NN O O
in NN O O
this NN O O
age NN O O
- NN O O
group NN O O
[ NN O O
see NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.4 NN O O
) NN O O
] NN O O
. NN O O
Asthma NN O O
- NN O O
related NN O O
hospitalizations NN O O
occurred NN O O
in NN O O
10 NN O O
subjects NN O O
( NN O O
1 NN O O
% NN O O
) NN O O
treated NN O O
with NN O O
BREO NN O O
ELLIPTA NN O O
100/25 NN O O
compared NN O O
with NN O O
7 NN O O
subjects NN O O
( NN O O
0.7 NN O O
% NN O O
) NN O O
treated NN O O
with NN O O
fluticasone NN O O
furoate NN O O
100 NN O O
mcg NN O O
. NN O O
Among NN O O
subjects NN O O
aged NN O O
12 NN O O
to NN O O
17 NN O O
years NN O O
, NN O O
asthma NN O O
- NN O O
related NN O O
hospitalizations NN O O
occurred NN O O
in NN O O
4 NN O O
subjects NN O O
( NN O O
2.6 NN O O
% NN O O
) NN O O
treated NN O O
with NN O O
BREO NN O O
ELLIPTA NN O O
100/25 NN O O
( NN O O
n NN O O
= NN O O
151 NN O O
) NN O O
compared NN O O
with NN O O
0 NN O O
subjects NN O O
treated NN O O
with NN O O
fluticasone NN O O
furoate NN O O
100 NN O O
mcg NN O O
( NN O O
n NN O O
= NN O O
130 NN O O
) NN O O
. NN O O
There NN O O
were NN O O
no NN B-Negation B-Negation
asthma NN O O
- NN O O
related NN O O
deaths NN B-AdverseReaction B-AdverseReaction
or NN O O
asthma NN O O
- NN O O
related NN O O
intubations NN O O
observed NN O O
in NN O O
this NN O O
trial NN O O
. NN O O
6.3 NN O O
Postmarketing NN O O
Experience NN O O
In NN O O
addition NN O O
to NN O O
adverse NN O O
reactions NN O O
reported NN O O
from NN O O
clinical NN O O
trials NN O O
, NN O O
the NN O O
following NN O O
adverse NN O O
reactions NN O O
have NN O O
been NN O O
identified NN O O
during NN O O
postapproval NN O O
use NN O O
of NN O O
BREO NN O O
ELLIPTA. NN O O
Because NN O O
these NN O O
reactions NN O O
are NN O O
reported NN O O
voluntarily NN O O
from NN O O
a NN O O
population NN O O
of NN O O
uncertain NN O O
size NN O O
, NN O O
it NN O O
is NN O O
not NN O O
always NN O O
possible NN O O
to NN O O
reliably NN O O
estimate NN O O
their NN O O
frequency NN O O
or NN O O
establish NN O O
a NN O O
causal NN O O
relationship NN O O
to NN O O
drug NN O O
exposure NN O O
. NN O O
These NN O O
events NN O O
have NN O O
been NN O O
chosen NN O O
for NN O O
inclusion NN O O
due NN O O
to NN O O
either NN O O
their NN O O
seriousness NN O O
, NN O O
frequency NN O O
of NN O O
reporting NN O O
, NN O O
or NN O O
causal NN O O
connection NN O O
to NN O O
BREO NN O O
ELLIPTA NN O O
or NN O O
a NN O O
combination NN O O
of NN O O
these NN O O
factors NN O O
. NN O O
Cardiac NN O O
Disorders NN O O
Palpitations NN B-AdverseReaction B-AdverseReaction
tachycardia NN B-AdverseReaction B-AdverseReaction
Immune NN O O
System NN O O
Disorders NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
including NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
angioedema NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
and NN O O
urticaria NN B-AdverseReaction B-AdverseReaction
Musculoskeletal NN O O
and NN O O
Connective NN O O
Tissue NN O O
Disorders NN O O
Muscle NN B-AdverseReaction B-AdverseReaction
spasms NN I-AdverseReaction I-AdverseReaction
Nervous NN O O
System NN O O
Disorders NN O O
Tremor NN B-AdverseReaction B-AdverseReaction
Psychiatric NN O O
Disorders NN O O
Nervousness NN B-AdverseReaction B-AdverseReaction
BOXED NN O O
WARNING NN O O
: NN O O
WARNING NN O O
: NN O O
ASTHMA NN O O
- NN O O
RELATED NN O O
DEATH NN B-AdverseReaction B-AdverseReaction
WARNING NN O O
: NN O O
ASTHMA NN O O
- NN O O
RELATED NN O O
DEATH NN B-AdverseReaction B-AdverseReaction
Long NN O O
- NN O O
acting NN O O
beta2-adrenergic NN O O
agonists NN O O
( NN O O
LABA NN O O
) NN O O
, NN O O
such NN O O
as NN O O
vilanterol NN O O
, NN O O
one NN O O
of NN O O
the NN O O
active NN O O
ingredients NN O O
in NN O O
BREO NN O O
ELLIPTA NN O O
, NN O O
increase NN O O
the NN O O
risk NN O O
of NN O O
asthma NN O O
- NN O O
related NN O O
death NN B-AdverseReaction B-AdverseReaction
Data NN O O
from NN O O
a NN O O
large NN O O
placebo NN O O
- NN O O
controlled NN O O
US NN O O
trial NN O O
that NN O O
compared NN O O
the NN O O
safety NN O O
of NN O O
another NN O O
LABA NN B-DrugClass B-DrugClass
( NN O O
salmeterol NN O O
) NN O O
with NN O O
placebo NN O O
added NN O O
to NN O O
usual NN O O
asthma NN O O
therapy NN O O
showed NN O O
an NN O O
increase NN O O
in NN O O
asthma NN O O
- NN O O
related NN O O
deaths NN B-AdverseReaction B-AdverseReaction
in NN O O
subjects NN O O
receiving NN O O
salmeterol NN O O
. NN O O
This NN O O
finding NN O O
with NN O O
salmeterol NN O O
is NN O O
considered NN O O
a NN O O
class NN O O
effect NN O O
of NN O O
LABA. NN O O
Currently NN O O
available NN O O
data NN O O
are NN O O
inadequate NN O O
to NN O O
determine NN O O
whether NN O O
concurrent NN O O
use NN O O
of NN O O
inhaled NN O O
corticosteroids NN O O
( NN O O
ICS NN O O
) NN O O
or NN O O
other NN O O
long NN O O
- NN O O
term NN O O
asthma NN O O
control NN O O
drugs NN O O
mitigates NN O O
the NN O O
increased NN O O
risk NN O O
of NN O O
asthma NN O O
- NN O O
related NN O O
death NN B-AdverseReaction B-AdverseReaction
from NN O O
LABA NN B-DrugClass B-DrugClass
Available NN O O
data NN O O
from NN O O
controlled NN O O
clinical NN O O
trials NN O O
suggest NN O O
that NN O O
LABA NN O O
increase NN O O
the NN O O
risk NN O O
of NN O O
asthma NN O O
- NN O O
related NN O O
hospitalization NN O O
in NN O O
pediatric NN O O
and NN O O
adolescent NN O O
patients NN O O
. NN O O
Therefore NN O O
, NN O O
when NN O O
treating NN O O
patients NN O O
with NN O O
asthma NN O O
, NN O O
physicians NN O O
should NN O O
only NN O O
prescribe NN O O
BREO NN O O
ELLIPTA NN O O
for NN O O
patients NN O O
not NN O O
adequately NN O O
controlled NN O O
on NN O O
a NN O O
long NN O O
- NN O O
term NN O O
asthma NN O O
control NN O O
medication NN O O
, NN O O
such NN O O
as NN O O
an NN O O
inhaled NN O O
corticosteroid NN O O
, NN O O
or NN O O
whose NN O O
disease NN O O
severity NN O O
clearly NN O O
warrants NN O O
initiation NN O O
of NN O O
treatment NN O O
with NN O O
both NN O O
an NN O O
inhaled NN O O
corticosteroid NN O O
and NN O O
a NN O O
LABA. NN O O
Once NN O O
asthma NN O O
control NN O O
is NN O O
achieved NN O O
and NN O O
maintained NN O O
, NN O O
assess NN O O
the NN O O
patient NN O O
at NN O O
regular NN O O
intervals NN O O
and NN O O
step NN O O
down NN O O
therapy NN O O
( NN O O
e.g. NN O O
, NN O O
discontinue NN O O
BREO NN O O
ELLIPTA NN O O
) NN O O
if NN O O
possible NN O O
without NN O O
loss NN O O
of NN O O
asthma NN O O
control NN O O
and NN O O
maintain NN O O
the NN O O
patient NN O O
on NN O O
a NN O O
long NN O O
- NN O O
term NN O O
asthma NN O O
control NN O O
medication NN O O
, NN O O
such NN O O
as NN O O
an NN O O
inhaled NN O O
corticosteroid NN O O
. NN O O
Do NN O O
not NN O O
use NN O O
BREO NN O O
ELLIPTA NN O O
for NN O O
patients NN O O
whose NN O O
asthma NN O O
is NN O O
adequately NN O O
controlled NN O O
on NN O O
low- NN O O
or NN O O
medium NN O O
- NN O O
dose NN O O
inhaled NN O O
corticosteroids NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
EXCERPT NN O O
: NN O O
WARNING NN O O
: NN O O
ASTHMA NN O O
- NN O O
RELATED NN O O
DEATH NN B-AdverseReaction B-AdverseReaction
See NN O O
full NN O O
prescribing NN O O
information NN O O
for NN O O
complete NN O O
boxed NN O O
warning NN O O
. NN O O
* NN O O
Long NN O O
- NN O O
acting NN O O
beta2-adrenergic NN O O
agonists NN O O
( NN O O
LABA NN O O
) NN O O
, NN O O
such NN O O
as NN O O
vilanterol NN O O
, NN O O
increase NN O O
the NN O O
risk NN O O
of NN O O
asthma NN O O
- NN O O
related NN O O
death NN B-AdverseReaction B-AdverseReaction
A NN O O
placebo NN O O
- NN O O
controlled NN O O
trial NN O O
with NN O O
another NN O O
LABA NN B-DrugClass B-DrugClass
( NN O O
salmeterol NN O O
) NN O O
showed NN O O
an NN O O
increase NN O O
in NN O O
asthma NN O O
- NN O O
related NN O O
deaths NN B-AdverseReaction B-AdverseReaction
This NN O O
finding NN O O
with NN O O
salmeterol NN O O
is NN O O
considered NN O O
a NN O O
class NN O O
effect NN O O
of NN O O
all NN O O
LABA. NN O O
Currently NN O O
available NN O O
data NN O O
are NN O O
inadequate NN O O
to NN O O
determine NN O O
whether NN O O
concurrent NN O O
use NN O O
of NN O O
inhaled NN O O
corticosteroids NN O O
( NN O O
ICS NN O O
) NN O O
or NN O O
other NN O O
long NN O O
- NN O O
term NN O O
asthma NN O O
control NN O O
drugs NN O O
mitigates NN O O
the NN O O
increased NN O O
risk NN O O
of NN O O
asthma NN O O
- NN O O
related NN O O
death NN B-AdverseReaction B-AdverseReaction
from NN O O
LABA NN B-DrugClass B-DrugClass
Available NN O O
data NN O O
from NN O O
controlled NN O O
clinical NN O O
trials NN O O
suggest NN O O
that NN O O
LABA NN O O
increase NN O O
the NN O O
risk NN O O
of NN O O
asthma NN O O
- NN O O
related NN O O
hospitalization NN O O
in NN O O
pediatric NN O O
and NN O O
adolescent NN O O
patients NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
When NN O O
treating NN O O
patients NN O O
with NN O O
asthma NN O O
, NN O O
only NN O O
prescribe NN O O
BREO NN O O
ELLIPTA NN O O
for NN O O
patients NN O O
not NN O O
adequately NN O O
controlled NN O O
on NN O O
a NN O O
long NN O O
- NN O O
term NN O O
asthma NN O O
control NN O O
medication NN O O
, NN O O
such NN O O
as NN O O
an NN O O
ICS NN O O
, NN O O
or NN O O
whose NN O O
disease NN O O
severity NN O O
clearly NN O O
warrants NN O O
initiation NN O O
of NN O O
treatment NN O O
with NN O O
both NN O O
an NN O O
ICS NN O O
and NN O O
a NN O O
LABA. NN O O
Once NN O O
asthma NN O O
control NN O O
is NN O O
achieved NN O O
and NN O O
maintained NN O O
, NN O O
assess NN O O
the NN O O
patient NN O O
at NN O O
regular NN O O
intervals NN O O
and NN O O
step NN O O
down NN O O
therapy NN O O
( NN O O
e.g. NN O O
, NN O O
discontinue NN O O
BREO NN O O
ELLIPTA NN O O
) NN O O
if NN O O
possible NN O O
without NN O O
loss NN O O
of NN O O
asthma NN O O
control NN O O
and NN O O
maintain NN O O
the NN O O
patient NN O O
on NN O O
a NN O O
long NN O O
- NN O O
term NN O O
asthma NN O O
control NN O O
medication NN O O
, NN O O
such NN O O
as NN O O
an NN O O
ICS. NN O O
Do NN O O
not NN O O
use NN O O
BREO NN O O
ELLIPTA NN O O
for NN O O
patients NN O O
whose NN O O
asthma NN O O
is NN O O
adequately NN O O
controlled NN O O
on NN O O
low- NN O O
or NN O O
medium NN O O
- NN O O
dose NN O O
ICS.(1.2 NN O O
, NN O O
5.1 NN O O
) NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
LABA NN B-DrugClass B-DrugClass
increase NN O O
the NN O O
risk NN O O
of NN O O
asthma NN O O
- NN O O
related NN O O
death NN B-AdverseReaction B-AdverseReaction
and NN O O
asthma NN O O
- NN O O
related NN O O
hospitalizations NN O O
. NN O O
Prescribe NN O O
only NN O O
for NN O O
recommended NN O O
patient NN O O
populations NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Do NN O O
not NN O O
initiate NN O O
in NN O O
acutely NN O O
deteriorating NN O O
COPD NN O O
or NN O O
asthma NN O O
. NN O O
Do NN O O
not NN O O
use NN O O
to NN O O
treat NN O O
acute NN O O
symptoms NN O O
. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Do NN O O
not NN O O
use NN O O
in NN O O
combination NN O O
with NN O O
an NN O O
additional NN O O
medicine NN O O
containing NN O O
a NN O O
LABA NN O O
because NN O O
of NN O O
risk NN O O
of NN O O
overdose NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
* NN O O
Candida NN B-AdverseReaction B-AdverseReaction
albicans NN I-AdverseReaction I-AdverseReaction
infection NN I-AdverseReaction I-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
mouth NN I-AdverseReaction I-AdverseReaction
and NN O O
pharynx NN O O
may NN B-Factor B-Factor
occur NN O O
. NN O O
Monitor NN O O
patients NN O O
periodically NN O O
. NN O O
Advise NN O O
the NN O O
patient NN O O
to NN O O
rinse NN O O
his/her NN O O
mouth NN O O
with NN O O
water NN O O
without NN O O
swallowing NN O O
after NN O O
inhalation NN O O
to NN O O
help NN O O
reduce NN O O
the NN O O
risk NN O O
. NN O O
( NN O O
5.4 NN O O
) NN O O
* NN O O
Increased NN O O
risk NN B-Factor B-Factor
of NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
in NN O O
patients NN O O
with NN O O
COPD. NN O O
Monitor NN O O
patients NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
pneumonia NN O O
. NN O O
( NN O O
5.5 NN O O
) NN O O
* NN O O
Potential NN B-Factor B-Factor
worsening NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
infections NN I-AdverseReaction I-AdverseReaction
( NN O O
e.g. NN O O
, NN O O
existing NN O O
tuberculosis NN O O
; NN O O
fungal NN O O
, NN O O
bacterial NN O O
, NN O O
viral NN O O
, NN O O
or NN O O
parasitic NN O O
infections NN O O
; NN O O
ocular NN O O
herpes NN O O
simplex NN O O
) NN O O
. NN O O
Use NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
with NN O O
these NN O O
infections NN O O
. NN O O
More NN O O
serious NN B-Severity B-Severity
or NN O O
even NN O O
fatal NN B-AdverseReaction B-AdverseReaction
course NN O O
of NN O O
chickenpox NN B-AdverseReaction B-AdverseReaction
or NN O O
measles NN B-AdverseReaction B-AdverseReaction
can NN B-Factor B-Factor
occur NN O O
in NN O O
susceptible NN O O
patients NN O O
. NN O O
( NN O O
5.6 NN O O
) NN O O
* NN O O
Risk NN B-Factor B-Factor
of NN O O
impaired NN B-AdverseReaction B-AdverseReaction
adrenal NN I-AdverseReaction I-AdverseReaction
function NN I-AdverseReaction I-AdverseReaction
when NN O O
transferring NN O O
from NN O O
systemic NN O O
corticosteroids NN O O
. NN O O
Taper NN O O
patients NN O O
slowly NN O O
from NN O O
systemic NN O O
corticosteroids NN O O
if NN O O
transferring NN O O
to NN O O
BREO NN O O
ELLIPTA. NN O O
( NN O O
5.7 NN O O
) NN O O
* NN O O
Hypercorticism NN B-AdverseReaction B-AdverseReaction
and NN O O
adrenal NN B-AdverseReaction B-AdverseReaction
suppression NN I-AdverseReaction I-AdverseReaction
may NN B-Factor B-Factor
occur NN O O
with NN O O
very NN O O
high NN O O
dosages NN O O
or NN O O
at NN O O
the NN O O
regular NN O O
dosage NN O O
in NN O O
susceptible NN O O
individuals NN O O
. NN O O
If NN O O
such NN O O
changes NN O O
occur NN O O
, NN O O
discontinue NN O O
BREO NN O O
ELLIPTA NN O O
slowly NN O O
. NN O O
( NN O O
5.8 NN O O
) NN O O
* NN O O
If NN O O
paradoxical NN O O
bronchospasm NN O O
occurs NN O O
, NN O O
discontinue NN O O
BREO NN O O
ELLIPTA NN O O
and NN O O
institute NN O O
alternative NN O O
therapy NN O O
. NN O O
( NN O O
5.10 NN O O
) NN O O
* NN O O
Use NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
with NN O O
cardiovascular NN O O
disorders NN O O
because NN O O
of NN O O
beta NN O O
- NN O O
adrenergic NN O O
stimulation NN O O
. NN O O
( NN O O
5.12 NN O O
) NN O O
* NN O O
Assess NN O O
for NN O O
decrease NN O O
in NN O O
bone NN O O
mineral NN O O
density NN O O
initially NN O O
and NN O O
periodically NN O O
thereafter NN O O
. NN O O
( NN O O
5.13 NN O O
) NN O O
* NN O O
Close NN O O
monitoring NN O O
for NN O O
glaucoma NN O O
and NN O O
cataracts NN O O
is NN O O
warranted NN O O
. NN O O
( NN O O
5.14 NN O O
) NN O O
* NN O O
Use NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
with NN O O
convulsive NN O O
disorders NN O O
, NN O O
thyrotoxicosis NN O O
, NN O O
diabetes NN O O
mellitus NN O O
, NN O O
and NN O O
ketoacidosis NN O O
. NN O O
( NN O O
5.15 NN O O
) NN O O
* NN O O
Be NN O O
alert NN O O
to NN O O
hypokalemia NN O O
and NN O O
hyperglycemia NN O O
. NN O O
( NN O O
5.16 NN O O
) NN O O
5.1 NN O O
Asthma NN O O
- NN O O
Related NN O O
Death NN O O
LABA NN B-DrugClass B-DrugClass
such NN O O
as NN O O
vilanterol NN O O
, NN O O
one NN O O
of NN O O
the NN O O
active NN O O
ingredients NN O O
in NN O O
BREO NN O O
ELLIPTA NN O O
, NN O O
increase NN O O
the NN O O
risk NN O O
of NN O O
asthma NN O O
- NN O O
related NN O O
death NN B-AdverseReaction B-AdverseReaction
Currently NN O O
available NN O O
data NN O O
are NN O O
inadequate NN O O
to NN O O
determine NN O O
whether NN O O
concurrent NN O O
use NN O O
of NN O O
inhaled NN O O
corticosteroids NN O O
or NN O O
other NN O O
long NN O O
- NN O O
term NN O O
asthma NN O O
control NN O O
drugs NN O O
mitigates NN O O
the NN O O
increased NN O O
risk NN O O
of NN O O
asthma NN O O
- NN O O
related NN O O
death NN B-AdverseReaction B-AdverseReaction
from NN O O
LABA NN B-DrugClass B-DrugClass
Available NN O O
data NN O O
from NN O O
controlled NN O O
clinical NN O O
trials NN O O
suggest NN O O
that NN O O
LABA NN O O
increase NN O O
the NN O O
risk NN O O
of NN O O
asthma NN O O
- NN O O
related NN O O
hospitalization NN O O
in NN O O
pediatric NN O O
and NN O O
adolescent NN O O
patients NN O O
. NN O O
Therefore NN O O
, NN O O
when NN O O
treating NN O O
patients NN O O
with NN O O
asthma NN O O
, NN O O
physicians NN O O
should NN O O
only NN O O
prescribe NN O O
BREO NN O O
ELLIPTA NN O O
for NN O O
patients NN O O
not NN O O
adequately NN O O
controlled NN O O
on NN O O
a NN O O
long NN O O
- NN O O
term NN O O
asthma NN O O
control NN O O
medication NN O O
, NN O O
such NN O O
as NN O O
an NN O O
inhaled NN O O
corticosteroid NN O O
, NN O O
or NN O O
whose NN O O
disease NN O O
severity NN O O
clearly NN O O
warrants NN O O
initiation NN O O
of NN O O
treatment NN O O
with NN O O
both NN O O
an NN O O
inhaled NN O O
corticosteroid NN O O
and NN O O
a NN O O
LABA. NN O O
Once NN O O
asthma NN O O
control NN O O
is NN O O
achieved NN O O
and NN O O
maintained NN O O
, NN O O
assess NN O O
the NN O O
patient NN O O
at NN O O
regular NN O O
intervals NN O O
and NN O O
step NN O O
down NN O O
therapy NN O O
( NN O O
e.g. NN O O
, NN O O
discontinue NN O O
BREO NN O O
ELLIPTA NN O O
) NN O O
if NN O O
possible NN O O
without NN O O
loss NN O O
of NN O O
asthma NN O O
control NN O O
and NN O O
maintain NN O O
the NN O O
patient NN O O
on NN O O
a NN O O
long NN O O
- NN O O
term NN O O
asthma NN O O
control NN O O
medication NN O O
, NN O O
such NN O O
as NN O O
an NN O O
inhaled NN O O
corticosteroid NN O O
. NN O O
Do NN O O
not NN O O
use NN O O
BREO NN O O
ELLIPTA NN O O
for NN O O
patients NN O O
whose NN O O
asthma NN O O
is NN O O
adequately NN O O
controlled NN O O
on NN O O
low- NN O O
or NN O O
medium NN O O
- NN O O
dose NN O O
inhaled NN O O
corticosteroids NN O O
. NN O O
A NN O O
28-week NN O O
, NN O O
placebo NN O O
- NN O O
controlled NN O O
, NN O O
US NN O O
trial NN O O
that NN O O
compared NN O O
the NN O O
safety NN O O
of NN O O
another NN O O
LABA NN B-DrugClass B-DrugClass
( NN O O
salmeterol NN O O
) NN O O
with NN O O
placebo NN O O
, NN O O
each NN O O
added NN O O
to NN O O
usual NN O O
asthma NN O O
therapy NN O O
, NN O O
showed NN O O
an NN O O
increase NN O O
in NN O O
asthma NN O O
- NN O O
related NN O O
deaths NN B-AdverseReaction B-AdverseReaction
in NN O O
subjects NN O O
receiving NN O O
salmeterol NN O O
( NN O O
13/13,176 NN O O
in NN O O
subjects NN O O
treated NN O O
with NN O O
salmeterol NN O O
vs. NN O O
3/13,179 NN O O
in NN O O
subjects NN O O
treated NN O O
with NN O O
placebo NN O O
; NN O O
relative NN O O
risk NN O O
: NN O O
4.37 NN O O
[ NN O O
95 NN O O
% NN O O
CI NN O O
: NN O O
1.25 NN O O
, NN O O
15.34 NN O O
] NN O O
) NN O O
. NN O O
The NN O O
increased NN O O
risk NN O O
of NN O O
asthma NN O O
- NN O O
related NN O O
death NN B-AdverseReaction B-AdverseReaction
is NN O O
considered NN O O
a NN O O
class NN O O
effect NN O O
of NN O O
LABA NN B-DrugClass B-DrugClass
including NN O O
vilanterol NN O O
, NN O O
one NN O O
of NN O O
the NN O O
active NN O O
ingredients NN O O
in NN O O
BREO NN O O
ELLIPTA. NN O O
No NN B-Factor B-Factor
trial NN I-Factor I-Factor
adequate NN I-Factor I-Factor
to NN O O
determine NN O O
whether NN O O
the NN O O
rate NN O O
of NN O O
asthma NN O O
- NN O O
related NN O O
death NN B-AdverseReaction B-AdverseReaction
is NN O O
increased NN O O
in NN O O
subjects NN O O
treated NN O O
with NN O O
BREO NN O O
ELLIPTA NN O O
has NN O O
been NN O O
conducted NN O O
. NN O O
Data NN O O
are NN O O
not NN B-Factor B-Factor
available NN I-Factor I-Factor
to NN O O
determine NN O O
whether NN O O
the NN O O
rate NN O O
of NN O O
death NN B-AdverseReaction B-AdverseReaction
in NN O O
patients NN O O
with NN O O
COPD NN O O
is NN O O
increased NN O O
by NN O O
LABA. NN O O
5.2 NN O O
Deterioration NN O O
of NN O O
Disease NN O O
and NN O O
Acute NN O O
Episodes NN O O
BREO NN O O
ELLIPTA NN O O
should NN O O
not NN O O
be NN O O
initiated NN O O
in NN O O
patients NN O O
during NN O O
rapidly NN O O
deteriorating NN O O
or NN O O
potentially NN O O
life NN O O
- NN O O
threatening NN O O
episodes NN O O
of NN O O
COPD NN O O
or NN O O
asthma NN O O
. NN O O
BREO NN O O
ELLIPTA NN O O
has NN O O
not NN O O
been NN O O
studied NN O O
in NN O O
subjects NN O O
with NN O O
acutely NN O O
deteriorating NN O O
COPD NN O O
or NN O O
asthma NN O O
. NN O O
The NN O O
initiation NN O O
of NN O O
BREO NN O O
ELLIPTA NN O O
in NN O O
this NN O O
setting NN O O
is NN O O
not NN O O
appropriate NN O O
. NN O O
COPD NN O O
may NN O O
deteriorate NN O O
acutely NN O O
over NN O O
a NN O O
period NN O O
of NN O O
hours NN O O
or NN O O
chronically NN O O
over NN O O
several NN O O
days NN O O
or NN O O
longer NN O O
. NN O O
If NN O O
BREO NN O O
ELLIPTA NN O O
100/25 NN O O
no NN O O
longer NN O O
controls NN O O
symptoms NN O O
of NN O O
bronchoconstriction NN O O
; NN O O
the NN O O
patient NN O O
's NN O O
inhaled NN O O
, NN O O
short NN O O
- NN O O
acting NN O O
, NN O O
beta2-agonist NN O O
becomes NN O O
less NN O O
effective NN O O
; NN O O
or NN O O
the NN O O
patient NN O O
needs NN O O
more NN O O
short NN O O
- NN O O
acting NN O O
beta2-agonist NN O O
than NN O O
usual NN O O
, NN O O
these NN O O
may NN O O
be NN O O
markers NN O O
of NN O O
deterioration NN O O
of NN O O
disease NN O O
. NN O O
In NN O O
this NN O O
setting NN O O
a NN O O
reevaluation NN O O
of NN O O
the NN O O
patient NN O O
and NN O O
the NN O O
COPD NN O O
treatment NN O O
regimen NN O O
should NN O O
be NN O O
undertaken NN O O
at NN O O
once NN O O
. NN O O
For NN O O
COPD NN O O
, NN O O
increasing NN O O
the NN O O
daily NN O O
dose NN O O
of NN O O
BREO NN O O
ELLIPTA NN O O
100/25 NN O O
is NN O O
not NN O O
appropriate NN O O
in NN O O
this NN O O
situation NN O O
. NN O O
Increasing NN O O
use NN O O
of NN O O
inhaled NN O O
, NN O O
short NN O O
- NN O O
acting NN O O
beta2-agonists NN O O
is NN O O
a NN O O
marker NN O O
of NN O O
deteriorating NN O O
asthma NN O O
. NN O O
In NN O O
this NN O O
situation NN O O
, NN O O
the NN O O
patient NN O O
requires NN O O
immediate NN O O
reevaluation NN O O
with NN O O
reassessment NN O O
of NN O O
the NN O O
treatment NN O O
regimen NN O O
, NN O O
giving NN O O
special NN O O
consideration NN O O
to NN O O
the NN O O
possible NN O O
need NN O O
for NN O O
replacing NN O O
the NN O O
current NN O O
strength NN O O
of NN O O
BREO NN O O
ELLIPTA NN O O
with NN O O
a NN O O
higher NN O O
strength NN O O
, NN O O
adding NN O O
additional NN O O
inhaled NN O O
corticosteroid NN O O
, NN O O
or NN O O
initiating NN O O
systemic NN O O
corticosteroids NN O O
. NN O O
Patients NN O O
should NN O O
not NN O O
use NN O O
more NN O O
than NN O O
1 NN O O
inhalation NN O O
once NN O O
daily NN O O
of NN O O
BREO NN O O
ELLIPTA. NN O O
BREO NN O O
ELLIPTA NN O O
should NN O O
not NN O O
be NN O O
used NN O O
for NN O O
the NN O O
relief NN O O
of NN O O
acute NN O O
symptoms NN O O
, NN O O
i.e. NN O O
, NN O O
as NN O O
rescue NN O O
therapy NN O O
for NN O O
the NN O O
treatment NN O O
of NN O O
acute NN O O
episodes NN O O
of NN O O
bronchospasm NN O O
. NN O O
BREO NN O O
ELLIPTA NN O O
has NN O O
not NN O O
been NN O O
studied NN O O
in NN O O
the NN O O
relief NN O O
of NN O O
acute NN O O
symptoms NN O O
and NN O O
extra NN O O
doses NN O O
should NN O O
not NN O O
be NN O O
used NN O O
for NN O O
that NN O O
purpose NN O O
. NN O O
Acute NN O O
symptoms NN O O
should NN O O
be NN O O
treated NN O O
with NN O O
an NN O O
inhaled NN O O
, NN O O
short NN O O
- NN O O
acting NN O O
beta2-agonist NN O O
. NN O O
When NN O O
beginning NN O O
treatment NN O O
with NN O O
BREO NN O O
ELLIPTA NN O O
, NN O O
patients NN O O
who NN O O
have NN O O
been NN O O
taking NN O O
oral NN O O
or NN O O
inhaled NN O O
, NN O O
short NN O O
- NN O O
acting NN O O
beta2-agonists NN O O
on NN O O
a NN O O
regular NN O O
basis NN O O
( NN O O
e.g. NN O O
, NN O O
4 NN O O
times NN O O
a NN O O
day NN O O
) NN O O
should NN O O
be NN O O
instructed NN O O
to NN O O
discontinue NN O O
the NN O O
regular NN O O
use NN O O
of NN O O
these NN O O
drugs NN O O
and NN O O
to NN O O
use NN O O
them NN O O
only NN O O
for NN O O
symptomatic NN O O
relief NN O O
of NN O O
acute NN O O
respiratory NN O O
symptoms NN O O
. NN O O
When NN O O
prescribing NN O O
BREO NN O O
ELLIPTA NN O O
, NN O O
the NN O O
healthcare NN O O
provider NN O O
should NN O O
also NN O O
prescribe NN O O
an NN O O
inhaled NN O O
, NN O O
short NN O O
- NN O O
acting NN O O
beta2-agonist NN O O
and NN O O
instruct NN O O
the NN O O
patient NN O O
on NN O O
how NN O O
it NN O O
should NN O O
be NN O O
used NN O O
. NN O O
5.3 NN O O
Excessive NN O O
Use NN O O
of NN O O
BREO NN O O
ELLIPTA NN O O
and NN O O
Use NN O O
with NN O O
Other NN O O
Long NN O O
- NN O O
Acting NN O O
Beta2-Agonists NN O O
BREO NN O O
ELLIPTA NN O O
should NN O O
not NN O O
be NN O O
used NN O O
more NN O O
often NN O O
than NN O O
recommended NN O O
, NN O O
at NN O O
higher NN O O
doses NN O O
than NN O O
recommended NN O O
, NN O O
or NN O O
in NN O O
conjunction NN O O
with NN O O
other NN O O
medicines NN O O
containing NN O O
LABA NN O O
, NN O O
as NN O O
an NN O O
overdose NN O O
may NN O O
result NN O O
. NN O O
Clinically NN O O
significant NN O O
cardiovascular NN O O
effects NN O O
and NN O O
fatalities NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
association NN O O
with NN O O
excessive NN O O
use NN O O
of NN O O
inhaled NN B-DrugClass B-DrugClass
sympathomimetic NN I-DrugClass I-DrugClass
drugs NN I-DrugClass I-DrugClass
Patients NN O O
using NN O O
BREO NN O O
ELLIPTA NN O O
should NN O O
not NN O O
use NN O O
another NN O O
medicine NN O O
containing NN O O
a NN O O
LABA NN O O
( NN O O
e.g. NN O O
, NN O O
salmeterol NN O O
, NN O O
formoterol NN O O
fumarate NN O O
, NN O O
arformoterol NN O O
tartrate NN O O
, NN O O
indacaterol NN O O
) NN O O
for NN O O
any NN O O
reason NN O O
. NN O O
5.4 NN O O
Local NN O O
Effects NN O O
of NN O O
Inhaled NN O O
Corticosteroids NN O O
In NN O O
clinical NN O O
trials NN O O
, NN O O
the NN O O
development NN O O
of NN O O
localized NN O O
infections NN O O
of NN O O
the NN O O
mouth NN O O
and NN O O
pharynx NN O O
with NN O O
Candida NN O O
albicans NN O O
has NN O O
occurred NN O O
in NN O O
subjects NN O O
treated NN O O
with NN O O
BREO NN O O
ELLIPTA. NN O O
When NN O O
such NN O O
an NN O O
infection NN O O
develops NN O O
, NN O O
it NN O O
should NN O O
be NN O O
treated NN O O
with NN O O
appropriate NN O O
local NN O O
or NN O O
systemic NN O O
( NN O O
i.e. NN O O
, NN O O
oral NN O O
) NN O O
antifungal NN O O
therapy NN O O
while NN O O
treatment NN O O
with NN O O
BREO NN O O
ELLIPTA NN O O
continues NN O O
, NN O O
but NN O O
at NN O O
times NN O O
therapy NN O O
with NN O O
BREO NN O O
ELLIPTA NN O O
may NN O O
need NN O O
to NN O O
be NN O O
interrupted NN O O
. NN O O
Advise NN O O
the NN O O
patient NN O O
to NN O O
rinse NN O O
his/her NN O O
mouth NN O O
with NN O O
water NN O O
without NN O O
swallowing NN O O
following NN O O
inhalation NN O O
to NN O O
help NN O O
reduce NN O O
the NN O O
risk NN O O
of NN O O
oropharyngeal NN O O
candidiasis NN O O
. NN O O
5.5 NN O O
Pneumonia NN O O
An NN O O
increase NN O O
in NN O O
the NN O O
incidence NN O O
of NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
has NN O O
been NN O O
observed NN O O
in NN O O
subjects NN O O
with NN O O
COPD NN O O
receiving NN O O
BREO NN O O
ELLIPTA NN O O
100/25 NN O O
in NN O O
clinical NN O O
trials NN O O
. NN O O
There NN O O
was NN O O
also NN O O
an NN O O
increased NN O O
incidence NN O O
of NN O O
pneumonias NN B-AdverseReaction B-AdverseReaction
resulting NN O O
in NN O O
hospitalization NN O O
. NN O O
In NN O O
some NN O O
incidences NN O O
these NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
events NN O O
were NN O O
fatal NN B-AdverseReaction B-AdverseReaction
Physicians NN O O
should NN O O
remain NN O O
vigilant NN O O
for NN O O
the NN O O
possible NN O O
development NN O O
of NN O O
pneumonia NN O O
in NN O O
patients NN O O
with NN O O
COPD NN O O
as NN O O
the NN O O
clinical NN O O
features NN O O
of NN O O
such NN O O
infections NN O O
overlap NN O O
with NN O O
the NN O O
symptoms NN O O
of NN O O
COPD NN O O
exacerbations NN O O
. NN O O
In NN O O
replicate NN O O
12-month NN O O
trials NN O O
in NN O O
3,255 NN O O
subjects NN O O
with NN O O
COPD NN O O
who NN O O
had NN O O
experienced NN O O
a NN O O
COPD NN O O
exacerbation NN O O
in NN O O
the NN O O
previous NN O O
year NN O O
, NN O O
there NN O O
was NN O O
a NN O O
higher NN O O
incidence NN O O
of NN O O
pneumonia NN B-AdverseReaction B-AdverseReaction
reported NN O O
in NN O O
subjects NN O O
receiving NN O O
fluticasone NN O O
furoate/vilanterol NN O O
50 NN O O
mcg/25 NN O O
mcg NN O O
: NN O O
6 NN O O
% NN O O
( NN O O
48 NN O O
of NN O O
820 NN O O
subjects NN O O
) NN O O
; NN O O
BREO NN O O
ELLIPTA NN O O
100/25 NN O O
: NN O O
6 NN O O
% NN O O
( NN O O
51 NN O O
of NN O O
806 NN O O
subjects NN O O
) NN O O
; NN O O
or NN O O
BREO NN O O
ELLIPTA NN O O
200/25 NN O O
: NN O O
7 NN O O
% NN O O
( NN O O
55 NN O O
of NN O O
811 NN O O
subjects NN O O
) NN O O
than NN O O
in NN O O
subjects NN O O
receiving NN O O
vilanterol NN O O
25 NN O O
mcg NN O O
: NN O O
3 NN O O
% NN O O
( NN O O
27 NN O O
of NN O O
818 NN O O
subjects NN O O
) NN O O
. NN O O
There NN O O
was NN O O
no NN B-Negation B-Negation
fatal NN B-AdverseReaction B-AdverseReaction
pneumonia NN B-AdverseReaction B-AdverseReaction
in NN O O
subjects NN O O
receiving NN O O
vilanterol NN O O
or NN O O
fluticasone NN O O
furoate/vilanterol NN O O
50 NN O O
mcg/25 NN O O
mcg NN O O
. NN O O
There NN O O
was NN O O
fatal NN B-AdverseReaction B-AdverseReaction
pneumonia NN B-AdverseReaction B-AdverseReaction
in NN O O
1 NN O O
subject NN O O
receiving NN O O
BREO NN O O
ELLIPTA NN O O
100/25 NN O O
and NN O O
in NN O O
7 NN O O
subjects NN O O
receiving NN O O
BREO NN O O
ELLIPTA NN O O
200/25 NN O O
( NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
for NN O O
each NN O O
treatment NN O O
group NN O O
) NN O O
. NN O O
5.6 NN O O
Immunosuppression NN O O
Persons NN O O
who NN O O
are NN O O
using NN O O
drugs NN B-DrugClass B-DrugClass
that NN I-DrugClass I-DrugClass
suppress NN I-DrugClass I-DrugClass
the NN I-DrugClass I-DrugClass
immune NN I-DrugClass I-DrugClass
system NN I-DrugClass I-DrugClass
are NN O O
more NN O O
susceptible NN O O
to NN O O
infections NN B-AdverseReaction B-AdverseReaction
than NN O O
healthy NN O O
individuals NN O O
. NN O O
Chickenpox NN B-AdverseReaction B-AdverseReaction
and NN O O
measles NN B-AdverseReaction B-AdverseReaction
for NN O O
example NN O O
, NN O O
can NN O O
have NN O O
a NN O O
more NN O O
serious NN B-Severity B-Severity
or NN O O
even NN O O
fatal NN B-AdverseReaction B-AdverseReaction
course NN O O
in NN O O
susceptible NN O O
children NN O O
or NN O O
adults NN O O
using NN O O
corticosteroids NN B-DrugClass B-DrugClass
In NN O O
such NN O O
children NN O O
or NN O O
adults NN O O
who NN O O
have NN O O
not NN O O
had NN O O
these NN O O
diseases NN O O
or NN O O
been NN O O
properly NN O O
immunized NN O O
, NN O O
particular NN O O
care NN O O
should NN O O
be NN O O
taken NN O O
to NN O O
avoid NN O O
exposure NN O O
. NN O O
How NN O O
the NN O O
dose NN O O
, NN O O
route NN O O
, NN O O
and NN O O
duration NN O O
of NN O O
corticosteroid NN O O
administration NN O O
affect NN O O
the NN O O
risk NN O O
of NN O O
developing NN O O
a NN O O
disseminated NN O O
infection NN O O
is NN O O
not NN O O
known NN O O
. NN O O
The NN O O
contribution NN O O
of NN O O
the NN O O
underlying NN O O
disease NN O O
and/or NN O O
prior NN O O
corticosteroid NN O O
treatment NN O O
to NN O O
the NN O O
risk NN O O
is NN O O
also NN O O
not NN O O
known NN O O
. NN O O
If NN O O
a NN O O
patient NN O O
is NN O O
exposed NN O O
to NN O O
chickenpox NN O O
, NN O O
prophylaxis NN O O
with NN O O
varicella NN O O
zoster NN O O
immune NN O O
globulin NN O O
( NN O O
VZIG NN O O
) NN O O
may NN O O
be NN O O
indicated NN O O
. NN O O
If NN O O
a NN O O
patient NN O O
is NN O O
exposed NN O O
to NN O O
measles NN O O
, NN O O
prophylaxis NN O O
with NN O O
pooled NN O O
intramuscular NN O O
immunoglobulin NN O O
( NN O O
IG NN O O
) NN O O
may NN O O
be NN O O
indicated NN O O
. NN O O
( NN O O
See NN O O
the NN O O
respective NN O O
package NN O O
inserts NN O O
for NN O O
complete NN O O
VZIG NN O O
and NN O O
IG NN O O
prescribing NN O O
information NN O O
. NN O O
) NN O O
If NN O O
chickenpox NN O O
develops NN O O
, NN O O
treatment NN O O
with NN O O
antiviral NN O O
agents NN O O
may NN O O
be NN O O
considered NN O O
. NN O O
Inhaled NN O O
corticosteroids NN O O
should NN O O
be NN O O
used NN O O
with NN O O
caution NN O O
, NN O O
if NN O O
at NN O O
all NN O O
, NN O O
in NN O O
patients NN O O
with NN O O
active NN O O
or NN O O
quiescent NN O O
tuberculosis NN O O
infections NN O O
of NN O O
the NN O O
respiratory NN O O
tract NN O O
; NN O O
systemic NN O O
fungal NN O O
, NN O O
bacterial NN O O
, NN O O
viral NN O O
, NN O O
or NN O O
parasitic NN O O
infections NN O O
; NN O O
or NN O O
ocular NN O O
herpes NN O O
simplex NN O O
. NN O O
5.7 NN O O
Transferring NN O O
Patients NN O O
from NN O O
Systemic NN O O
Corticosteroid NN O O
Therapy NN O O
Particular NN O O
care NN O O
is NN O O
needed NN O O
for NN O O
patients NN O O
who NN O O
have NN O O
been NN O O
transferred NN O O
from NN O O
systemically NN O O
active NN O O
corticosteroids NN O O
to NN O O
inhaled NN O O
corticosteroids NN O O
because NN O O
deaths NN O O
due NN O O
to NN O O
adrenal NN O O
insufficiency NN O O
have NN O O
occurred NN O O
in NN O O
patients NN O O
with NN O O
asthma NN O O
during NN O O
and NN O O
after NN O O
transfer NN O O
from NN O O
systemic NN O O
corticosteroids NN O O
to NN O O
less NN O O
systemically NN O O
available NN O O
inhaled NN O O
corticosteroids NN O O
. NN O O
After NN O O
withdrawal NN O O
from NN O O
systemic NN O O
corticosteroids NN O O
, NN O O
a NN O O
number NN O O
of NN O O
months NN O O
are NN O O
required NN O O
for NN O O
recovery NN O O
of NN O O
hypothalamic NN O O
- NN O O
pituitary NN O O
- NN O O
adrenal NN O O
( NN O O
HPA NN O O
) NN O O
function NN O O
. NN O O
Patients NN O O
who NN O O
have NN O O
been NN O O
previously NN O O
maintained NN O O
on NN O O
20 NN O O
mg NN O O
or NN O O
more NN O O
of NN O O
prednisone NN O O
( NN O O
or NN O O
its NN O O
equivalent NN O O
) NN O O
may NN O O
be NN O O
most NN O O
susceptible NN O O
, NN O O
particularly NN O O
when NN O O
their NN O O
systemic NN O O
corticosteroids NN O O
have NN O O
been NN O O
almost NN O O
completely NN O O
withdrawn NN O O
. NN O O
During NN O O
this NN O O
period NN O O
of NN O O
HPA NN O O
suppression NN O O
, NN O O
patients NN O O
may NN O O
exhibit NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
adrenal NN O O
insufficiency NN O O
when NN O O
exposed NN O O
to NN O O
trauma NN O O
, NN O O
surgery NN O O
, NN O O
or NN O O
infection NN O O
( NN O O
particularly NN O O
gastroenteritis NN O O
) NN O O
or NN O O
other NN O O
conditions NN O O
associated NN O O
with NN O O
severe NN O O
electrolyte NN O O
loss NN O O
. NN O O
Although NN O O
BREO NN O O
ELLIPTA NN O O
may NN O O
control NN O O
COPD NN O O
or NN O O
asthma NN O O
symptoms NN O O
during NN O O
these NN O O
episodes NN O O
, NN O O
in NN O O
recommended NN O O
doses NN O O
it NN O O
supplies NN O O
less NN O O
than NN O O
normal NN O O
physiological NN O O
amounts NN O O
of NN O O
glucocorticoid NN O O
systemically NN O O
and NN O O
does NN O O
NOT NN O O
provide NN O O
the NN O O
mineralocorticoid NN O O
activity NN O O
that NN O O
is NN O O
necessary NN O O
for NN O O
coping NN O O
with NN O O
these NN O O
emergencies NN O O
. NN O O
During NN O O
periods NN O O
of NN O O
stress NN O O
, NN O O
a NN O O
severe NN O O
COPD NN O O
exacerbation NN O O
, NN O O
or NN O O
a NN O O
severe NN O O
asthma NN O O
attack NN O O
, NN O O
patients NN O O
who NN O O
have NN O O
been NN O O
withdrawn NN O O
from NN O O
systemic NN O O
corticosteroids NN O O
should NN O O
be NN O O
instructed NN O O
to NN O O
resume NN O O
oral NN O O
corticosteroids NN O O
( NN O O
in NN O O
large NN O O
doses NN O O
) NN O O
immediately NN O O
and NN O O
to NN O O
contact NN O O
their NN O O
physicians NN O O
for NN O O
further NN O O
instruction NN O O
. NN O O
These NN O O
patients NN O O
should NN O O
also NN O O
be NN O O
instructed NN O O
to NN O O
carry NN O O
a NN O O
warning NN O O
card NN O O
indicating NN O O
that NN O O
they NN O O
may NN O O
need NN O O
supplementary NN O O
systemic NN O O
corticosteroids NN O O
during NN O O
periods NN O O
of NN O O
stress NN O O
, NN O O
a NN O O
severe NN O O
COPD NN O O
exacerbation NN O O
, NN O O
or NN O O
a NN O O
severe NN O O
asthma NN O O
attack NN O O
. NN O O
Patients NN O O
requiring NN O O
oral NN O O
corticosteroids NN O O
should NN O O
be NN O O
weaned NN O O
slowly NN O O
from NN O O
systemic NN O O
corticosteroid NN O O
use NN O O
after NN O O
transferring NN O O
to NN O O
BREO NN O O
ELLIPTA. NN O O
Prednisone NN O O
reduction NN O O
can NN O O
be NN O O
accomplished NN O O
by NN O O
reducing NN O O
the NN O O
daily NN O O
prednisone NN O O
dose NN O O
by NN O O
2.5 NN O O
mg NN O O
on NN O O
a NN O O
weekly NN O O
basis NN O O
during NN O O
therapy NN O O
with NN O O
BREO NN O O
ELLIPTA. NN O O
Lung NN O O
function NN O O
( NN O O
FEV1or NN O O
peak NN O O
expiratory NN O O
flow NN O O
) NN O O
, NN O O
beta NN O O
- NN O O
agonist NN O O
use NN O O
, NN O O
and NN O O
COPD NN O O
or NN O O
asthma NN O O
symptoms NN O O
should NN O O
be NN O O
carefully NN O O
monitored NN O O
during NN O O
withdrawal NN O O
of NN O O
oral NN O O
corticosteroids NN O O
. NN O O
In NN O O
addition NN O O
, NN O O
patients NN O O
should NN O O
be NN O O
observed NN O O
for NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
adrenal NN O O
insufficiency NN O O
, NN O O
such NN O O
as NN O O
fatigue NN O O
, NN O O
lassitude NN O O
, NN O O
weakness NN O O
, NN O O
nausea NN O O
and NN O O
vomiting NN O O
, NN O O
and NN O O
hypotension NN O O
. NN O O
Transfer NN O O
of NN O O
patients NN O O
from NN O O
systemic NN O O
corticosteroid NN O O
therapy NN O O
to NN O O
BREO NN O O
ELLIPTA NN O O
may NN O O
unmask NN O O
allergic NN O O
conditions NN O O
previously NN O O
suppressed NN O O
by NN O O
the NN O O
systemic NN O O
corticosteroid NN O O
therapy NN O O
( NN O O
e.g. NN O O
, NN O O
rhinitis NN O O
, NN O O
conjunctivitis NN O O
, NN O O
eczema NN O O
, NN O O
arthritis NN O O
, NN O O
eosinophilic NN O O
conditions NN O O
) NN O O
. NN O O
During NN O O
withdrawal NN O O
from NN O O
oral NN O O
corticosteroids NN O O
, NN O O
some NN O O
patients NN O O
may NN O O
experience NN O O
symptoms NN O O
of NN O O
systemically NN O O
active NN O O
corticosteroid NN O O
withdrawal NN O O
( NN O O
e.g. NN O O
, NN O O
joint NN O O
and/or NN O O
muscular NN O O
pain NN O O
, NN O O
lassitude NN O O
, NN O O
depression NN O O
) NN O O
despite NN O O
maintenance NN O O
or NN O O
even NN O O
improvement NN O O
of NN O O
respiratory NN O O
function NN O O
. NN O O
5.8 NN O O
Hypercorticism NN O O
and NN O O
Adrenal NN O O
Suppression NN O O
Inhaled NN O O
fluticasone NN O O
furoate NN O O
is NN O O
absorbed NN O O
into NN O O
the NN O O
circulation NN O O
and NN O O
can NN O O
be NN O O
systemically NN O O
active NN O O
. NN O O
Effects NN O O
of NN O O
fluticasone NN O O
furoate NN O O
on NN O O
the NN O O
HPA NN O O
axis NN O O
are NN O O
not NN O O
observed NN O O
with NN O O
the NN O O
therapeutic NN O O
doses NN O O
of NN O O
BREO NN O O
ELLIPTA. NN O O
However NN O O
, NN O O
exceeding NN O O
the NN O O
recommended NN O O
dosage NN O O
or NN O O
coadministration NN O O
with NN O O
a NN O O
strong NN O O
cytochrome NN O O
P450 NN O O
3A4 NN O O
( NN O O
CYP3A4 NN O O
) NN O O
inhibitor NN O O
may NN B-Factor B-Factor
result NN O O
in NN O O
HPA NN B-AdverseReaction B-AdverseReaction
dysfunction NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.9 NN O O
) NN O O
, NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.1 NN O O
) NN O O
] NN O O
. NN O O
Because NN O O
of NN O O
the NN O O
possibility NN O O
of NN O O
significant NN O O
systemic NN O O
absorption NN O O
of NN O O
inhaled NN O O
corticosteroids NN O O
in NN O O
sensitive NN O O
patients NN O O
, NN O O
patients NN O O
treated NN O O
with NN O O
BREO NN O O
ELLIPTA NN O O
should NN O O
be NN O O
observed NN O O
carefully NN O O
for NN O O
any NN O O
evidence NN O O
of NN O O
systemic NN O O
corticosteroid NN O O
effects NN O O
. NN O O
Particular NN O O
care NN O O
should NN O O
be NN O O
taken NN O O
in NN O O
observing NN O O
patients NN O O
postoperatively NN O O
or NN O O
during NN O O
periods NN O O
of NN O O
stress NN O O
for NN O O
evidence NN O O
of NN O O
inadequate NN O O
adrenal NN O O
response NN O O
. NN O O
It NN O O
is NN O O
possible NN O O
that NN O O
systemic NN O O
corticosteroid NN O O
effects NN O O
such NN O O
as NN O O
hypercorticism NN B-AdverseReaction B-AdverseReaction
and NN O O
adrenal NN B-AdverseReaction B-AdverseReaction
suppression NN I-AdverseReaction I-AdverseReaction
( NN O O
including NN O O
adrenal NN B-AdverseReaction B-AdverseReaction
crisis NN I-AdverseReaction I-AdverseReaction
may NN B-Factor B-Factor
appear NN O O
in NN O O
a NN O O
small NN O O
number NN O O
of NN O O
patients NN O O
who NN O O
are NN O O
sensitive NN O O
to NN O O
these NN O O
effects NN O O
. NN O O
If NN O O
such NN O O
effects NN O O
occur NN O O
, NN O O
BREO NN O O
ELLIPTA NN O O
should NN O O
be NN O O
reduced NN O O
slowly NN O O
, NN O O
consistent NN O O
with NN O O
accepted NN O O
procedures NN O O
for NN O O
reducing NN O O
systemic NN O O
corticosteroids NN O O
, NN O O
and NN O O
other NN O O
treatments NN O O
for NN O O
management NN O O
of NN O O
COPD NN O O
or NN O O
asthma NN O O
symptoms NN O O
should NN O O
be NN O O
considered NN O O
. NN O O
5.9 NN O O
Drug NN O O
Interactions NN O O
with NN O O
Strong NN O O
Cytochrome NN O O
P450 NN O O
3A4 NN O O
Inhibitors NN O O
Caution NN O O
should NN O O
be NN O O
exercised NN O O
when NN O O
considering NN O O
the NN O O
coadministration NN O O
of NN O O
BREO NN O O
ELLIPTA NN O O
with NN O O
long NN O O
- NN O O
term NN O O
ketoconazole NN O O
and NN O O
other NN O O
known NN O O
strong NN O O
CYP3A4 NN O O
inhibitors NN O O
( NN O O
e.g. NN O O
, NN O O
ritonavir NN O O
, NN O O
clarithromycin NN O O
, NN O O
conivaptan NN O O
, NN O O
indinavir NN O O
, NN O O
itraconazole NN O O
, NN O O
lopinavir NN O O
, NN O O
nefazodone NN O O
, NN O O
nelfinavir NN O O
, NN O O
saquinavir NN O O
, NN O O
telithromycin NN O O
, NN O O
troleandomycin NN O O
, NN O O
voriconazole NN O O
) NN O O
because NN O O
increased NN O O
systemic NN O O
corticosteroid NN O O
and NN O O
increased NN O O
cardiovascular NN O O
adverse NN O O
effects NN O O
may NN O O
occur NN O O
[ NN O O
see NN O O
Drug NN O O
Interactions NN O O
( NN O O
7.1 NN O O
) NN O O
, NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.3 NN O O
) NN O O
] NN O O
. NN O O
5.10 NN O O
Paradoxical NN O O
Bronchospasm NN O O
As NN O O
with NN O O
other NN O O
inhaled NN O O
medicines NN O O
, NN O O
BREO NN O O
ELLIPTA NN O O
can NN B-Factor B-Factor
produce NN O O
paradoxical NN B-AdverseReaction B-AdverseReaction
bronchospasm NN I-AdverseReaction I-AdverseReaction
which NN O O
may NN B-Factor B-Factor
be NN O O
life NN B-Severity B-Severity
threatening NN I-Severity I-Severity
If NN O O
paradoxical NN O O
bronchospasm NN O O
occurs NN O O
following NN O O
dosing NN O O
with NN O O
BREO NN O O
ELLIPTA NN O O
, NN O O
it NN O O
should NN O O
be NN O O
treated NN O O
immediately NN O O
with NN O O
an NN O O
inhaled NN O O
, NN O O
short NN O O
- NN O O
acting NN O O
bronchodilator NN O O
; NN O O
BREO NN O O
ELLIPTA NN O O
should NN O O
be NN O O
discontinued NN O O
immediately NN O O
; NN O O
and NN O O
alternative NN O O
therapy NN O O
should NN O O
be NN O O
instituted NN O O
. NN O O
5.11 NN O O
Hypersensitivity NN O O
Reactions NN O O
, NN O O
Including NN O O
Anaphylaxis NN O O
Hypersensitivity NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
such NN O O
as NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
angioedema NN B-AdverseReaction B-AdverseReaction
rash NN B-AdverseReaction B-AdverseReaction
and NN O O
urticaria NN B-AdverseReaction B-AdverseReaction
may NN B-Factor B-Factor
occur NN O O
after NN O O
administration NN O O
of NN O O
BREO NN O O
ELLIPTA. NN O O
Discontinue NN O O
BREO NN O O
ELLIPTA NN O O
if NN O O
such NN O O
reactions NN O O
occur NN O O
. NN O O
There NN O O
have NN O O
been NN O O
reports NN O O
of NN O O
anaphylactic NN B-AdverseReaction B-AdverseReaction
reactions NN I-AdverseReaction I-AdverseReaction
in NN O O
patients NN O O
with NN O O
severe NN O O
milk NN O O
protein NN O O
allergy NN O O
after NN O O
inhalation NN O O
of NN O O
other NN O O
powder NN B-DrugClass B-DrugClass
medications NN I-DrugClass I-DrugClass
containing NN I-DrugClass I-DrugClass
lactose NN I-DrugClass I-DrugClass
therefore NN O O
, NN O O
patients NN O O
with NN O O
severe NN O O
milk NN O O
protein NN O O
allergy NN O O
should NN O O
not NN O O
use NN O O
BREO NN O O
ELLIPTA NN O O
[ NN O O
see NN O O
Contraindications NN O O
( NN O O
4 NN O O
) NN O O
] NN O O
. NN O O
5.12 NN O O
Cardiovascular NN O O
Effects NN O O
Vilanterol NN O O
, NN O O
like NN O O
other NN O O
beta2-agonists NN O O
, NN O O
can NN B-Factor B-Factor
produce NN O O
a NN O O
clinically NN O O
significant NN O O
cardiovascular NN O O
effect NN O O
in NN O O
some NN O O
patients NN O O
as NN O O
measured NN O O
by NN O O
increases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
pulse NN I-AdverseReaction I-AdverseReaction
rate NN I-AdverseReaction I-AdverseReaction
systolic NN O O
or NN O O
diastolic NN O O
blood NN O O
pressure NN O O
, NN O O
and NN O O
also NN O O
cardiac NN B-AdverseReaction B-AdverseReaction
arrhythmias NN I-AdverseReaction I-AdverseReaction
such NN O O
as NN O O
supraventricular NN B-AdverseReaction B-AdverseReaction
tachycardia NN I-AdverseReaction I-AdverseReaction
and NN O O
extrasystoles NN B-AdverseReaction B-AdverseReaction
If NN O O
such NN O O
effects NN O O
occur NN O O
, NN O O
BREO NN O O
ELLIPTA NN O O
may NN O O
need NN O O
to NN O O
be NN O O
discontinued NN O O
. NN O O
In NN O O
addition NN O O
, NN O O
beta NN B-DrugClass B-DrugClass
- NN I-DrugClass I-DrugClass
agonists NN I-DrugClass I-DrugClass
have NN O O
been NN O O
reported NN O O
to NN O O
produce NN O O
electrocardiographic NN B-AdverseReaction B-AdverseReaction
changes NN I-AdverseReaction I-AdverseReaction
such NN O O
as NN O O
flattening NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
T NN I-AdverseReaction I-AdverseReaction
wave NN I-AdverseReaction I-AdverseReaction
prolongation NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
QTc NN I-AdverseReaction I-AdverseReaction
interval NN I-AdverseReaction I-AdverseReaction
and NN O O
ST NN B-AdverseReaction B-AdverseReaction
segment NN I-AdverseReaction I-AdverseReaction
depression NN I-AdverseReaction I-AdverseReaction
although NN O O
the NN O O
clinical NN O O
significance NN O O
of NN O O
these NN O O
findings NN O O
is NN O O
unknown NN O O
. NN O O
Fatalities NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
association NN O O
with NN O O
excessive NN O O
use NN O O
of NN O O
inhaled NN O O
sympathomimetic NN O O
drugs NN O O
. NN O O
In NN O O
healthy NN O O
subjects NN O O
, NN O O
large NN O O
doses NN O O
of NN O O
inhaled NN O O
fluticasone NN O O
furoate/vilanterol NN O O
( NN O O
4 NN O O
times NN O O
the NN O O
recommended NN O O
dose NN O O
of NN O O
vilanterol NN O O
, NN O O
representing NN O O
a NN O O
12- NN O O
or NN O O
10-fold NN O O
higher NN O O
systemic NN O O
exposure NN O O
than NN O O
seen NN O O
in NN O O
subjects NN O O
with NN O O
COPD NN O O
or NN O O
asthma NN O O
, NN O O
respectively NN O O
) NN O O
have NN O O
been NN O O
associated NN O O
with NN O O
clinically NN B-Severity B-Severity
significant NN I-Severity I-Severity
prolongation NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
QTc NN I-AdverseReaction I-AdverseReaction
interval NN I-AdverseReaction I-AdverseReaction
which NN O O
has NN O O
the NN O O
potential NN B-Factor B-Factor
for NN O O
producing NN O O
ventricular NN B-AdverseReaction B-AdverseReaction
arrhythmias NN I-AdverseReaction I-AdverseReaction
Therefore NN O O
, NN O O
BREO NN O O
ELLIPTA NN O O
, NN O O
like NN O O
other NN O O
sympathomimetic NN O O
amines NN O O
, NN O O
should NN O O
be NN O O
used NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
with NN O O
cardiovascular NN O O
disorders NN O O
, NN O O
especially NN O O
coronary NN O O
insufficiency NN O O
, NN O O
cardiac NN O O
arrhythmias NN O O
, NN O O
and NN O O
hypertension NN O O
. NN O O
5.13 NN O O
Reduction NN O O
in NN O O
Bone NN O O
Mineral NN O O
Density NN O O
Decreases NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
bone NN I-AdverseReaction I-AdverseReaction
mineral NN I-AdverseReaction I-AdverseReaction
density NN I-AdverseReaction I-AdverseReaction
( NN O O
BMD NN O O
) NN O O
have NN O O
been NN O O
observed NN O O
with NN O O
long NN O O
- NN O O
term NN O O
administration NN O O
of NN O O
products NN O O
containing NN O O
inhaled NN O O
corticosteroids NN B-DrugClass B-DrugClass
The NN O O
clinical NN O O
significance NN O O
of NN O O
small NN O O
changes NN O O
in NN O O
BMD NN O O
with NN O O
regard NN O O
to NN O O
long NN O O
- NN O O
term NN O O
consequences NN O O
such NN O O
as NN O O
fracture NN O O
is NN O O
unknown NN O O
. NN O O
Patients NN O O
with NN O O
major NN O O
risk NN O O
factors NN O O
for NN O O
decreased NN O O
bone NN O O
mineral NN O O
content NN O O
, NN O O
such NN O O
as NN O O
prolonged NN O O
immobilization NN O O
, NN O O
family NN O O
history NN O O
of NN O O
osteoporosis NN O O
, NN O O
postmenopausal NN O O
status NN O O
, NN O O
tobacco NN O O
use NN O O
, NN O O
advanced NN O O
age NN O O
, NN O O
poor NN O O
nutrition NN O O
, NN O O
or NN O O
chronic NN O O
use NN O O
of NN O O
drugs NN O O
that NN O O
can NN O O
reduce NN O O
bone NN O O
mass NN O O
( NN O O
e.g. NN O O
, NN O O
anticonvulsants NN O O
, NN O O
oral NN O O
corticosteroids NN O O
) NN O O
should NN O O
be NN O O
monitored NN O O
and NN O O
treated NN O O
with NN O O
established NN O O
standards NN O O
of NN O O
care NN O O
. NN O O
Since NN O O
patients NN O O
with NN O O
COPD NN O O
often NN O O
have NN O O
multiple NN O O
risk NN O O
factors NN O O
for NN O O
reduced NN O O
BMD NN O O
, NN O O
assessment NN O O
of NN O O
BMD NN O O
is NN O O
recommended NN O O
prior NN O O
to NN O O
initiating NN O O
BREO NN O O
ELLIPTA NN O O
and NN O O
periodically NN O O
thereafter NN O O
. NN O O
If NN O O
significant NN O O
reductions NN O O
in NN O O
BMD NN O O
are NN O O
seen NN O O
and NN O O
BREO NN O O
ELLIPTA NN O O
is NN O O
still NN O O
considered NN O O
medically NN O O
important NN O O
for NN O O
that NN O O
patient NN O O
's NN O O
COPD NN O O
therapy NN O O
, NN O O
use NN O O
of NN O O
medicine NN O O
to NN O O
treat NN O O
or NN O O
prevent NN O O
osteoporosis NN O O
should NN O O
be NN O O
strongly NN O O
considered NN O O
. NN O O
5.14 NN O O
Glaucoma NN O O
and NN O O
Cataracts NN O O
Glaucoma NN B-AdverseReaction B-AdverseReaction
increased NN B-AdverseReaction B-AdverseReaction
intraocular NN I-AdverseReaction I-AdverseReaction
pressure NN I-AdverseReaction I-AdverseReaction
and NN O O
cataracts NN B-AdverseReaction B-AdverseReaction
have NN O O
been NN O O
reported NN O O
in NN O O
patients NN O O
with NN O O
COPD NN O O
or NN O O
asthma NN O O
following NN O O
the NN O O
long NN O O
- NN O O
term NN O O
administration NN O O
of NN O O
inhaled NN O O
corticosteroids NN B-DrugClass B-DrugClass
Therefore NN O O
, NN O O
close NN O O
monitoring NN O O
is NN O O
warranted NN O O
in NN O O
patients NN O O
with NN O O
a NN O O
change NN O O
in NN O O
vision NN O O
or NN O O
with NN O O
a NN O O
history NN O O
of NN O O
increased NN O O
intraocular NN O O
pressure NN O O
, NN O O
glaucoma NN O O
, NN O O
and/or NN O O
cataracts NN O O
. NN O O
5.15 NN O O
Coexisting NN O O
Conditions NN O O
BREO NN O O
ELLIPTA NN O O
, NN O O
like NN O O
all NN O O
medicines NN O O
containing NN O O
sympathomimetic NN O O
amines NN O O
, NN O O
should NN O O
be NN O O
used NN O O
with NN O O
caution NN O O
in NN O O
patients NN O O
with NN O O
convulsive NN O O
disorders NN O O
or NN O O
thyrotoxicosis NN O O
and NN O O
in NN O O
those NN O O
who NN O O
are NN O O
unusually NN O O
responsive NN O O
to NN O O
sympathomimetic NN O O
amines NN O O
. NN O O
Doses NN O O
of NN O O
the NN O O
related NN O O
beta2-adrenoceptor NN B-DrugClass B-DrugClass
agonist NN I-DrugClass I-DrugClass
albuterol NN O O
, NN O O
when NN O O
administered NN O O
intravenously NN O O
, NN O O
have NN O O
been NN O O
reported NN O O
to NN O O
aggravate NN B-AdverseReaction B-AdverseReaction
preexisting NN I-AdverseReaction I-AdverseReaction
diabetes NN I-AdverseReaction I-AdverseReaction
mellitus NN I-AdverseReaction I-AdverseReaction
and NN O O
ketoacidosis NN O O
. NN O O
5.16 NN O O
Hypokalemia NN O O
and NN O O
Hyperglycemia NN O O
Beta NN O O
- NN O O
adrenergic NN O O
agonist NN O O
medicines NN O O
may NN B-Factor B-Factor
produce NN O O
significant NN B-Severity B-Severity
hypokalemia NN B-AdverseReaction B-AdverseReaction
in NN O O
some NN O O
patients NN O O
, NN O O
possibly NN O O
through NN O O
intracellular NN O O
shunting NN O O
, NN O O
which NN O O
has NN O O
the NN O O
potential NN O O
to NN O O
produce NN O O
adverse NN O O
cardiovascular NN O O
effects NN O O
. NN O O
The NN O O
decrease NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
serum NN I-AdverseReaction I-AdverseReaction
potassium NN I-AdverseReaction I-AdverseReaction
is NN O O
usually NN O O
transient NN O O
, NN O O
not NN O O
requiring NN O O
supplementation NN O O
. NN O O
Beta NN B-DrugClass B-DrugClass
- NN I-DrugClass I-DrugClass
agonist NN I-DrugClass I-DrugClass
medications NN I-DrugClass I-DrugClass
may NN O O
produce NN O O
transient NN B-Severity B-Severity
hyperglycemia NN B-AdverseReaction B-AdverseReaction
in NN O O
some NN O O
patients NN O O
. NN O O
In NN O O
clinical NN O O
trials NN O O
evaluating NN O O
BREO NN O O
ELLIPTA NN O O
in NN O O
subjects NN O O
with NN O O
COPD NN O O
or NN O O
asthma NN O O
, NN O O
there NN O O
was NN O O
no NN O O
evidence NN O O
of NN O O
a NN O O
treatment NN O O
effect NN O O
on NN O O
serum NN O O
glucose NN O O
or NN O O
potassium NN O O
. NN O O
5.17 NN O O
Effect NN O O
on NN O O
Growth NN O O
Orally NN B-DrugClass B-DrugClass
inhaled NN I-DrugClass I-DrugClass
corticosteroids NN I-DrugClass I-DrugClass
may NN O O
cause NN O O
a NN O O
reduction NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
growth NN I-AdverseReaction I-AdverseReaction
velocity NN I-AdverseReaction I-AdverseReaction
when NN O O
administered NN O O
to NN O O
children NN O O
and NN O O
adolescents NN O O
. NN O O
[ NN O O
See NN O O
Use NN O O
in NN O O
Specific NN O O
Populations NN O O
( NN O O
8.4 NN O O
) NN O O
. NN O O
] NN O O

-DOCSTART- -X- -X- O

6 NN O O
ADVERSE NN O O
REACTIONS NN O O
The NN O O
following NN O O
important NN O O
adverse NN O O
reactions NN O O
are NN O O
described NN O O
elsewhere NN O O
in NN O O
labeling NN O O
: NN O O
* NN O O
Anaphylaxis NN B-AdverseReaction B-AdverseReaction
and NN O O
Angioedema NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.1 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Progressive NN B-AdverseReaction B-AdverseReaction
multifocal NN I-AdverseReaction I-AdverseReaction
leukoencephalopathy NN I-AdverseReaction I-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Lymphopenia NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
. NN O O
* NN O O
Flushing NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.4 NN O O
) NN O O
] NN O O
. NN O O
EXCERPT NN O O
: NN O O
Most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
incidence NN O O
>=10 NN O O
% NN O O
and NN O O
>=2 NN O O
% NN O O
placebo NN O O
) NN O O
were NN O O
flushing NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
and NN O O
nausea NN B-AdverseReaction B-AdverseReaction
( NN O O
6.1 NN O O
) NN O O
To NN O O
report NN O O
SUSPECTED NN O O
ADVERSE NN O O
REACTIONS NN O O
, NN O O
contact NN O O
Biogen NN O O
at NN O O
1 NN O O
- NN O O
800 NN O O
- NN O O
456 NN O O
- NN O O
2255 NN O O
or NN O O
FDA NN O O
at NN O O
1 NN O O
- NN O O
800-FDA-1088 NN O O
or NN O O
www.fda.gov/medwatch NN O O
. NN O O
6.1 NN O O
Clinical NN O O
Trials NN O O
Experience NN O O
Because NN O O
clinical NN O O
trials NN O O
are NN O O
conducted NN O O
under NN O O
widely NN O O
varying NN O O
conditions NN O O
, NN O O
adverse NN O O
reaction NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
trials NN O O
of NN O O
a NN O O
drug NN O O
can NN O O
not NN O O
be NN O O
directly NN O O
compared NN O O
to NN O O
rates NN O O
in NN O O
the NN O O
clinical NN O O
trials NN O O
of NN O O
another NN O O
drug NN O O
and NN O O
may NN O O
not NN O O
reflect NN O O
the NN O O
rates NN O O
observed NN O O
in NN O O
clinical NN O O
practice NN O O
. NN O O
The NN O O
most NN O O
common NN O O
adverse NN O O
reactions NN O O
( NN O O
incidence NN O O
>=10 NN O O
% NN O O
and NN O O
>=2 NN O O
% NN O O
more NN O O
than NN O O
placebo NN O O
) NN O O
for NN O O
TECFIDERA NN O O
were NN O O
flushing NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
and NN O O
nausea NN B-AdverseReaction B-AdverseReaction
Adverse NN O O
Reactions NN O O
in NN O O
Placebo NN O O
- NN O O
Controlled NN O O
Trials NN O O
In NN O O
the NN O O
two NN O O
well NN O O
- NN O O
controlled NN O O
studies NN O O
demonstrating NN O O
effectiveness NN O O
, NN O O
1529 NN O O
patients NN O O
received NN O O
TECFIDERA NN O O
with NN O O
an NN O O
overall NN O O
exposure NN O O
of NN O O
2244 NN O O
person NN O O
- NN O O
years NN O O
[ NN O O
see NN O O
Clinical NN O O
Studies NN O O
( NN O O
14 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
adverse NN O O
reactions NN O O
presented NN O O
in NN O O
the NN O O
table NN O O
below NN O O
are NN O O
based NN O O
on NN O O
safety NN O O
information NN O O
from NN O O
769 NN O O
patients NN O O
treated NN O O
with NN O O
TECFIDERA NN O O
240 NN O O
mg NN O O
twice NN O O
a NN O O
day NN O O
and NN O O
771 NN O O
placebo NN O O
- NN O O
treated NN O O
patients NN O O
. NN O O
Table NN O O
1 NN O O
: NN O O
Adverse NN O O
Reactions NN O O
in NN O O
Study NN O O
1 NN O O
and NN O O
2 NN O O
reported NN O O
for NN O O
TECFIDERA NN O O
240 NN O O
mg NN O O
BID NN O O
at NN O O
>= NN O O
2 NN O O
% NN O O
higher NN O O
incidence NN O O
than NN O O
placebo NN O O
TECFIDERA NN O O
N=769 NN O O
% NN O O
Placebo NN O O
N=771 NN O O
% NN O O
Flushing NN B-AdverseReaction B-AdverseReaction
40 NN O O
6 NN O O
Abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
18 NN O O
10 NN O O
Diarrhea NN B-AdverseReaction B-AdverseReaction
14 NN O O
11 NN O O
Nausea NN B-AdverseReaction B-AdverseReaction
12 NN O O
9 NN O O
Vomiting NN B-AdverseReaction B-AdverseReaction
9 NN O O
5 NN O O
Pruritus NN B-AdverseReaction B-AdverseReaction
8 NN O O
4 NN O O
Rash NN B-AdverseReaction B-AdverseReaction
8 NN O O
3 NN O O
Albumin NN B-AdverseReaction B-AdverseReaction
urine NN I-AdverseReaction I-AdverseReaction
present NN I-AdverseReaction I-AdverseReaction
6 NN O O
4 NN O O
Erythema NN B-AdverseReaction B-AdverseReaction
5 NN O O
1 NN O O
Dyspepsia NN B-AdverseReaction B-AdverseReaction
5 NN O O
3 NN O O
Aspartate NN B-AdverseReaction B-AdverseReaction
aminotransferase NN I-AdverseReaction I-AdverseReaction
increased NN I-AdverseReaction I-AdverseReaction
4 NN O O
2 NN O O
Lymphopenia NN B-AdverseReaction B-AdverseReaction
2 NN O O
< NN O O
1 NN O O
Gastrointestinal NN O O
TECFIDERA NN O O
caused NN O O
GI NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
( NN O O
e.g. NN O O
, NN O O
nausea NN B-AdverseReaction B-AdverseReaction
vomiting NN B-AdverseReaction B-AdverseReaction
diarrhea NN B-AdverseReaction B-AdverseReaction
abdominal NN B-AdverseReaction B-AdverseReaction
pain NN I-AdverseReaction I-AdverseReaction
and NN O O
dyspepsia NN B-AdverseReaction B-AdverseReaction
The NN O O
incidence NN O O
of NN O O
GI NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
was NN O O
higher NN O O
early NN O O
in NN O O
the NN O O
course NN O O
of NN O O
treatment NN O O
( NN O O
primarily NN O O
in NN O O
month NN O O
1 NN O O
) NN O O
and NN O O
usually NN O O
decreased NN O O
over NN O O
time NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
TECFIDERA NN O O
compared NN O O
with NN O O
placebo NN O O
. NN O O
Four NN O O
percent NN O O
( NN O O
4 NN O O
% NN O O
) NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
TECFIDERA NN O O
and NN O O
less NN O O
than NN O O
1 NN O O
% NN O O
of NN O O
placebo NN O O
patients NN O O
discontinued NN O O
due NN O O
to NN O O
gastrointestinal NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
The NN O O
incidence NN O O
of NN O O
serious NN B-Severity B-Severity
GI NN B-AdverseReaction B-AdverseReaction
events NN I-AdverseReaction I-AdverseReaction
was NN O O
1 NN O O
% NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
TECFIDERA. NN O O
Hepatic NN O O
Transaminases NN O O
An NN O O
increased NN O O
incidence NN O O
of NN O O
elevations NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
hepatic NN I-AdverseReaction I-AdverseReaction
transaminases NN I-AdverseReaction I-AdverseReaction
in NN O O
patients NN O O
treated NN O O
with NN O O
TECFIDERA NN O O
was NN O O
seen NN O O
primarily NN O O
during NN O O
the NN O O
first NN O O
six NN O O
months NN O O
of NN O O
treatment NN O O
, NN O O
and NN O O
most NN O O
patients NN O O
with NN O O
elevations NN O O
had NN O O
levels NN O O
< NN O O
3 NN O O
times NN O O
the NN O O
upper NN O O
limit NN O O
of NN O O
normal NN O O
( NN O O
ULN NN O O
) NN O O
. NN O O
Elevations NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
alanine NN I-AdverseReaction I-AdverseReaction
aminotransferase NN I-AdverseReaction I-AdverseReaction
and NN O O
aspartate NN O O
aminotransferase NN O O
to NN O O
>= NN O O
3 NN O O
times NN O O
the NN O O
ULN NN O O
occurred NN O O
in NN O O
a NN O O
small NN O O
number NN O O
of NN O O
patients NN O O
treated NN O O
with NN O O
both NN O O
TECFIDERA NN O O
and NN O O
placebo NN O O
and NN O O
were NN O O
balanced NN O O
between NN O O
groups NN O O
. NN O O
There NN O O
were NN O O
no NN B-Negation B-Negation
elevations NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
transaminases NN I-AdverseReaction I-AdverseReaction
>= NN O O
3 NN B-Severity B-Severity
times NN I-Severity I-Severity
the NN I-Severity I-Severity
ULN NN I-Severity I-Severity
with NN O O
concomitant NN O O
elevations NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
total NN I-AdverseReaction I-AdverseReaction
bilirubin NN I-AdverseReaction I-AdverseReaction
> NN O O
2 NN B-Severity B-Severity
times NN I-Severity I-Severity
the NN I-Severity I-Severity
ULN NN I-Severity I-Severity
Discontinuations NN O O
due NN O O
to NN O O
elevated NN B-AdverseReaction B-AdverseReaction
hepatic NN I-AdverseReaction I-AdverseReaction
transaminases NN I-AdverseReaction I-AdverseReaction
were NN O O
< NN O O
1 NN O O
% NN O O
and NN O O
were NN O O
similar NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
TECFIDERA NN O O
or NN O O
placebo NN O O
. NN O O
Eosinophilia NN O O
A NN O O
transient NN B-Severity B-Severity
increase NN B-AdverseReaction B-AdverseReaction
in NN I-AdverseReaction I-AdverseReaction
mean NN I-AdverseReaction I-AdverseReaction
eosinophil NN I-AdverseReaction I-AdverseReaction
counts NN I-AdverseReaction I-AdverseReaction
was NN O O
seen NN O O
during NN O O
the NN O O
first NN O O
2 NN O O
months NN O O
of NN O O
therapy NN O O
. NN O O
Adverse NN O O
Reactions NN O O
in NN O O
Placebo NN O O
- NN O O
Controlled NN O O
and NN O O
Uncontrolled NN O O
Studies NN O O
In NN O O
placebo NN O O
- NN O O
controlled NN O O
and NN O O
uncontrolled NN O O
clinical NN O O
studies NN O O
, NN O O
a NN O O
total NN O O
of NN O O
2513 NN O O
patients NN O O
have NN O O
received NN O O
TECFIDERA NN O O
and NN O O
been NN O O
followed NN O O
for NN O O
periods NN O O
up NN O O
to NN O O
4 NN O O
years NN O O
with NN O O
an NN O O
overall NN O O
exposure NN O O
of NN O O
4603 NN O O
person NN O O
- NN O O
years NN O O
. NN O O
Approximately NN O O
1162 NN O O
patients NN O O
have NN O O
received NN O O
more NN O O
than NN O O
2 NN O O
years NN O O
of NN O O
treatment NN O O
with NN O O
TECFIDERA. NN O O
The NN O O
adverse NN O O
reaction NN O O
profile NN O O
of NN O O
TECFIDERA NN O O
in NN O O
the NN O O
uncontrolled NN O O
clinical NN O O
studies NN O O
was NN O O
consistent NN O O
with NN O O
the NN O O
experience NN O O
in NN O O
the NN O O
placebo NN O O
- NN O O
controlled NN O O
clinical NN O O
trials NN O O
. NN O O
5 NN O O
WARNINGS NN O O
AND NN O O
PRECAUTIONS NN O O
EXCERPT NN O O
: NN O O
* NN O O
Anaphylaxis NN B-AdverseReaction B-AdverseReaction
and NN O O
angioedema NN B-AdverseReaction B-AdverseReaction
Discontinue NN O O
and NN O O
do NN O O
not NN O O
restart NN O O
TECFIDERA NN O O
if NN O O
these NN O O
occur NN O O
. NN O O
( NN O O
5.1 NN O O
) NN O O
* NN O O
Progressive NN B-AdverseReaction B-AdverseReaction
multifocal NN I-AdverseReaction I-AdverseReaction
leukoencephalopathy NN I-AdverseReaction I-AdverseReaction
( NN O O
PML NN O O
) NN O O
: NN O O
Withhold NN O O
TECFIDERA NN O O
at NN O O
the NN O O
first NN O O
sign NN O O
or NN O O
symptom NN O O
suggestive NN O O
of NN O O
PML. NN O O
( NN O O
5.2 NN O O
) NN O O
* NN O O
Lymphopenia NN B-AdverseReaction B-AdverseReaction
Obtain NN O O
a NN O O
CBC NN O O
including NN O O
lymphocyte NN O O
count NN O O
before NN O O
initiating NN O O
TECFIDERA NN O O
, NN O O
after NN O O
6 NN O O
months NN O O
, NN O O
and NN O O
every NN O O
6 NN O O
to NN O O
12 NN O O
months NN O O
thereafter NN O O
. NN O O
Consider NN O O
interruption NN O O
of NN O O
TECFIDERA NN O O
if NN O O
lymphocyte NN O O
counts NN O O
< NN O O
0.5 NN O O
x NN O O
10 NN O O
9 NN O O
/L NN O O
persist NN O O
for NN O O
more NN O O
than NN O O
six NN O O
months NN O O
. NN O O
( NN O O
5.3 NN O O
) NN O O
5.1 NN O O
Anaphylaxis NN O O
and NN O O
Angioedema NN O O
TECFIDERA NN O O
can NN B-Factor B-Factor
cause NN O O
anaphylaxis NN B-AdverseReaction B-AdverseReaction
and NN O O
angioedema NN B-AdverseReaction B-AdverseReaction
after NN O O
the NN O O
first NN O O
dose NN O O
or NN O O
at NN O O
any NN O O
time NN O O
during NN O O
treatment NN O O
. NN O O
Signs NN O O
and NN O O
symptoms NN O O
have NN O O
included NN O O
difficulty NN B-AdverseReaction B-AdverseReaction
breathing NN I-AdverseReaction I-AdverseReaction
urticaria NN B-AdverseReaction B-AdverseReaction
and NN O O
swelling NN B-AdverseReaction B-AdverseReaction
of NN I-AdverseReaction I-AdverseReaction
the NN I-AdverseReaction I-AdverseReaction
throat NN I-AdverseReaction I-AdverseReaction
and NN O O
tongue NN O O
. NN O O
Patients NN O O
should NN O O
be NN O O
instructed NN O O
to NN O O
discontinue NN O O
TECFIDERA NN O O
and NN O O
seek NN O O
immediate NN O O
medical NN O O
care NN O O
should NN O O
they NN O O
experience NN O O
signs NN O O
and NN O O
symptoms NN O O
of NN O O
anaphylaxis NN O O
or NN O O
angioedema NN O O
. NN O O
5.2 NN O O
Progressive NN O O
Multifocal NN O O
Leukoencephalopathy NN O O
A NN O O
fatal NN B-AdverseReaction B-AdverseReaction
case NN O O
of NN O O
progressive NN B-AdverseReaction B-AdverseReaction
multifocal NN I-AdverseReaction I-AdverseReaction
leukoencephalopathy NN I-AdverseReaction I-AdverseReaction
( NN O O
PML NN O O
) NN O O
occurred NN O O
in NN O O
a NN O O
patient NN O O
with NN O O
MS NN O O
who NN O O
received NN O O
TECFIDERA NN O O
for NN O O
4 NN O O
years NN O O
while NN O O
enrolled NN O O
in NN O O
a NN O O
clinical NN O O
trial NN O O
. NN O O
PML NN O O
is NN O O
an NN O O
opportunistic NN O O
viral NN O O
infection NN O O
of NN O O
the NN O O
brain NN O O
caused NN O O
by NN O O
the NN O O
JC NN O O
virus NN O O
( NN O O
JCV NN O O
) NN O O
that NN O O
typically NN O O
only NN O O
occurs NN O O
in NN O O
patients NN O O
who NN O O
are NN O O
immunocompromised NN O O
, NN O O
and NN O O
that NN O O
usually NN O O
leads NN O O
to NN O O
death NN O O
or NN O O
severe NN O O
disability NN O O
. NN O O
During NN O O
the NN O O
clinical NN O O
trial NN O O
, NN O O
the NN O O
patient NN O O
experienced NN O O
prolonged NN B-Severity B-Severity
lymphopenia NN B-AdverseReaction B-AdverseReaction
( NN O O
lymphocyte NN O O
counts NN O O
predominantly NN O O
< NN O O
0.5x10 NN O O
9 NN O O
/L NN O O
for NN O O
3.5 NN O O
years NN O O
) NN O O
while NN O O
taking NN O O
TECFIDERA NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.3 NN O O
) NN O O
] NN O O
. NN O O
The NN O O
role NN O O
of NN O O
lymphopenia NN B-AdverseReaction B-AdverseReaction
in NN O O
this NN O O
case NN O O
is NN O O
unknown NN O O
. NN O O
The NN O O
patient NN O O
had NN O O
no NN O O
other NN O O
identified NN O O
systemic NN O O
medical NN O O
conditions NN O O
resulting NN O O
in NN O O
compromised NN O O
immune NN O O
system NN O O
function NN O O
and NN O O
had NN O O
not NN O O
previously NN O O
been NN O O
treated NN O O
with NN O O
natalizumab NN O O
, NN O O
which NN O O
has NN O O
a NN O O
known NN O O
association NN O O
with NN O O
PML. NN O O
The NN O O
patient NN O O
was NN O O
also NN O O
not NN O O
taking NN O O
any NN O O
immunosuppressive NN O O
or NN O O
immunomodulatory NN O O
medications NN O O
concomitantly NN O O
. NN O O
At NN O O
the NN O O
first NN O O
sign NN O O
or NN O O
symptom NN O O
suggestive NN O O
of NN O O
PML NN O O
, NN O O
withhold NN O O
TECFIDERA NN O O
and NN O O
perform NN O O
an NN O O
appropriate NN O O
diagnostic NN O O
evaluation NN O O
. NN O O
Typical NN O O
symptoms NN O O
associated NN O O
with NN O O
PML NN O O
are NN O O
diverse NN O O
, NN O O
progress NN O O
over NN O O
days NN O O
to NN O O
weeks NN O O
, NN O O
and NN O O
include NN O O
progressive NN O O
weakness NN O O
on NN O O
one NN O O
side NN O O
of NN O O
the NN O O
body NN O O
or NN O O
clumsiness NN O O
of NN O O
limbs NN O O
, NN O O
disturbance NN O O
of NN O O
vision NN O O
, NN O O
and NN O O
changes NN O O
in NN O O
thinking NN O O
, NN O O
memory NN O O
, NN O O
and NN O O
orientation NN O O
leading NN O O
to NN O O
confusion NN O O
and NN O O
personality NN O O
changes NN O O
. NN O O
5.3 NN O O
Lymphopenia NN O O
TECFIDERA NN O O
may NN B-Factor B-Factor
decrease NN B-AdverseReaction B-AdverseReaction
lymphocyte NN I-AdverseReaction I-AdverseReaction
counts NN I-AdverseReaction I-AdverseReaction
In NN O O
the NN O O
MS NN O O
placebo NN O O
controlled NN O O
trials NN O O
, NN O O
mean NN O O
lymphocyte NN B-AdverseReaction B-AdverseReaction
counts NN I-AdverseReaction I-AdverseReaction
decreased NN I-AdverseReaction I-AdverseReaction
by NN O O
approximately NN O O
30 NN O O
% NN O O
during NN O O
the NN O O
first NN O O
year NN O O
of NN O O
treatment NN O O
with NN O O
TECFIDERA NN O O
and NN O O
then NN O O
remained NN O O
stable NN O O
. NN O O
Four NN O O
weeks NN O O
after NN O O
stopping NN O O
TECFIDERA NN O O
, NN O O
mean NN O O
lymphocyte NN O O
counts NN O O
increased NN O O
but NN O O
did NN O O
not NN O O
return NN O O
to NN O O
baseline NN O O
. NN O O
Six NN O O
percent NN O O
( NN O O
6 NN O O
% NN O O
) NN O O
of NN O O
TECFIDERA NN O O
patients NN O O
and NN O O
< NN O O
1 NN O O
% NN O O
of NN O O
placebo NN O O
patients NN O O
experienced NN O O
lymphocyte NN B-AdverseReaction B-AdverseReaction
counts NN I-AdverseReaction I-AdverseReaction
< NN I-AdverseReaction I-AdverseReaction
0.5x10 NN I-AdverseReaction I-AdverseReaction
9 NN I-AdverseReaction I-AdverseReaction
/L NN I-AdverseReaction I-AdverseReaction
( NN O O
lower NN O O
limit NN O O
of NN O O
normal NN O O
0.91x10 NN O O
9 NN O O
/L NN O O
) NN O O
. NN O O
The NN O O
incidence NN O O
of NN O O
infections NN B-AdverseReaction B-AdverseReaction
( NN O O
60 NN O O
% NN O O
vs NN O O
58 NN O O
% NN O O
) NN O O
and NN O O
serious NN B-Severity B-Severity
infections NN B-AdverseReaction B-AdverseReaction
( NN O O
2 NN O O
% NN O O
vs NN O O
2 NN O O
% NN O O
) NN O O
was NN O O
similar NN O O
in NN O O
patients NN O O
treated NN O O
with NN O O
TECFIDERA NN O O
or NN O O
placebo NN O O
, NN O O
respectively NN O O
. NN O O
There NN O O
was NN O O
no NN B-Negation B-Negation
increased NN O O
incidence NN O O
of NN O O
serious NN B-Severity B-Severity
infections NN O O
observed NN O O
in NN O O
patients NN O O
with NN O O
lymphocyte NN O O
counts NN O O
< NN O O
0.8x10 NN O O
9 NN O O
/L NN O O
or NN O O
0.5x10 NN O O
9 NN O O
/L NN O O
in NN O O
controlled NN O O
trials NN O O
, NN O O
although NN O O
one NN O O
patient NN O O
in NN O O
an NN O O
extension NN O O
study NN O O
developed NN O O
PML NN B-AdverseReaction B-AdverseReaction
in NN O O
the NN O O
setting NN O O
of NN O O
prolonged NN B-AdverseReaction B-AdverseReaction
lymphopenia NN I-AdverseReaction I-AdverseReaction
( NN O O
lymphocyte NN O O
counts NN O O
predominantly NN O O
< NN O O
0.5x10 NN O O
9 NN O O
/L NN O O
for NN O O
3.5 NN O O
years NN O O
) NN O O
[ NN O O
see NN O O
Warnings NN O O
and NN O O
Precautions NN O O
( NN O O
5.2 NN O O
) NN O O
] NN O O
. NN O O
In NN O O
controlled NN O O
and NN O O
uncontrolled NN O O
clinical NN O O
trials NN O O
, NN O O
2 NN O O
% NN O O
of NN O O
patients NN O O
experienced NN O O
lymphocyte NN B-AdverseReaction B-AdverseReaction
counts NN I-AdverseReaction I-AdverseReaction
< NN I-AdverseReaction I-AdverseReaction
0.5 NN I-AdverseReaction I-AdverseReaction
x NN I-AdverseReaction I-AdverseReaction
10 NN I-AdverseReaction I-AdverseReaction
9 NN I-AdverseReaction I-AdverseReaction
/L NN I-AdverseReaction I-AdverseReaction
for NN O O
at NN O O
least NN O O
six NN O O
months NN O O
. NN O O
In NN O O
these NN O O
patients NN O O
, NN O O
the NN O O
majority NN O O
of NN O O
lymphocyte NN O O
counts NN O O
remained NN O O
< NN O O
0.5x10 NN O O
9 NN O O
/L NN O O
with NN O O
continued NN O O
therapy NN O O
. NN O O
TECFIDERA NN O O
has NN O O
not NN O O
been NN O O
studied NN O O
in NN O O
patients NN O O
with NN O O
pre NN O O
- NN O O
existing NN O O
low NN O O
lymphocyte NN O O
counts NN O O
. NN O O
Before NN O O
initiating NN O O
treatment NN O O
with NN O O
TECFIDERA NN O O
, NN O O
a NN O O
CBC NN O O
including NN O O
lymphocyte NN O O
count NN O O
should NN O O
be NN O O
obtained NN O O
. NN O O
A NN O O
CBC NN O O
including NN O O
lymphocyte NN O O
count NN O O
should NN O O
also NN O O
be NN O O
obtained NN O O
after NN O O
6 NN O O
months NN O O
of NN O O
treatment NN O O
, NN O O
every NN O O
6 NN O O
to NN O O
12 NN O O
months NN O O
thereafter NN O O
, NN O O
and NN O O
as NN O O
clinically NN O O
indicated NN O O
. NN O O
Consider NN O O
interruption NN O O
of NN O O
TECFIDERA NN O O
in NN O O
patients NN O O
with NN O O
lymphocyte NN O O
counts NN O O
< NN O O
0.5 NN O O
x NN O O
10 NN O O
9 NN O O
/L NN O O
persisting NN O O
for NN O O
more NN O O
than NN O O
six NN O O
months NN O O
. NN O O
Given NN O O
the NN O O
potential NN O O
for NN O O
delay NN O O
in NN O O
lymphocyte NN O O
recovery NN O O
after NN O O
discontinuation NN O O
of NN O O
TECFIDERA NN O O
, NN O O
consider NN O O
following NN O O
lymphocyte NN O O
counts NN O O
until NN O O
lymphopenia NN O O
is NN O O
resolved NN O O
. NN O O
Withholding NN O O
treatment NN O O
should NN O O
be NN O O
considered NN O O
in NN O O
patients NN O O
with NN O O
serious NN O O
infections NN O O
until NN O O
the NN O O
infection(s NN O O
) NN O O
is NN O O
resolved NN O O
. NN O O
Decisions NN O O
about NN O O
whether NN O O
or NN O O
not NN O O
to NN O O
restart NN O O
TECFIDERA NN O O
should NN O O
be NN O O
individualized NN O O
based NN O O
on NN O O
clinical NN O O
circumstances NN O O
. NN O O
5.4 NN O O
Flushing NN O O
TECFIDERA NN O O
may NN O O
cause NN O O
flushing NN B-AdverseReaction B-AdverseReaction
( NN O O
e.g. NN O O
, NN O O
warmth NN B-AdverseReaction B-AdverseReaction
redness NN B-AdverseReaction B-AdverseReaction
itching NN B-AdverseReaction B-AdverseReaction
and/or NN O O
burning NN B-AdverseReaction B-AdverseReaction
sensation NN I-AdverseReaction I-AdverseReaction
In NN O O
clinical NN O O
trials NN O O
, NN O O
40 NN O O
% NN O O
of NN O O
TECFIDERA NN O O
treated NN O O
patients NN O O
experienced NN O O
flushing NN B-AdverseReaction B-AdverseReaction
Flushing NN B-AdverseReaction B-AdverseReaction
symptoms NN O O
generally NN O O
began NN O O
soon NN O O
after NN O O
initiating NN O O
TECFIDERA NN O O
and NN O O
usually NN O O
improved NN O O
or NN O O
resolved NN O O
over NN O O
time NN O O
. NN O O
In NN O O
the NN O O
majority NN O O
of NN O O
patients NN O O
who NN O O
experienced NN O O
flushing NN B-AdverseReaction B-AdverseReaction
it NN O O
was NN O O
mild NN B-Severity B-Severity
or NN O O
moderate NN B-Severity B-Severity
in NN O O
severity NN O O
. NN O O
Three NN O O
percent NN O O
( NN O O
3 NN O O
% NN O O
) NN O O
of NN O O
patients NN O O
discontinued NN O O
TECFIDERA NN O O
for NN O O
flushing NN B-AdverseReaction B-AdverseReaction
and NN O O
< NN O O
1 NN O O
% NN O O
had NN O O
serious NN B-Severity B-Severity
flushing NN B-AdverseReaction B-AdverseReaction
symptoms NN O O
that NN O O
were NN O O
not NN B-Severity B-Severity
life NN I-Severity I-Severity
- NN I-Severity I-Severity
threatening NN I-Severity I-Severity
but NN O O
led NN O O
to NN O O
hospitalization NN O O
. NN O O
Administration NN O O
of NN O O
TECFIDERA NN O O
with NN O O
food NN O O
may NN O O
reduce NN O O
the NN O O
incidence NN O O
of NN O O
flushing NN B-AdverseReaction B-AdverseReaction
Alternatively NN O O
, NN O O
administration NN O O
of NN O O
non NN O O
- NN O O
enteric NN O O
coated NN O O
aspirin NN O O
( NN O O
up NN O O
to NN O O
a NN O O
dose NN O O
of NN O O
325 NN O O
mg NN O O
) NN O O
30 NN O O
minutes NN O O
prior NN O O
to NN O O
TECFIDERA NN O O
dosing NN O O
may NN O O
reduce NN O O
the NN O O
incidence NN O O
or NN O O
severity NN O O
of NN O O
flushing NN B-AdverseReaction B-AdverseReaction
[ NN O O
see NN O O
Dosing NN O O
and NN O O
Administration NN O O
( NN O O
2.1 NN O O
) NN O O
and NN O O
Clinical NN O O
Pharmacology NN O O
( NN O O
12.3 NN O O
) NN O O
] NN O O
. NN O O

